PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	VANLAAR, T; STEEGENGA, WT; JOCHEMSEN, AG; TERLETH, C; VANDEREB, AJ				VANLAAR, T; STEEGENGA, WT; JOCHEMSEN, AG; TERLETH, C; VANDEREB, AJ			BLOOMS SYNDROME CELLS GM1492 LACK DETECTABLE P53 PROTEIN BUT EXHIBIT NORMAL G1 CELL-CYCLE ARREST AFTER UV IRRADIATION	ONCOGENE			English	Note							WILD-TYPE P53	The tumor suppressor gene p53 is thought to be a key factor in the onset of G1 cell-cycle arrest following DNA damage. However, here we describe cells derived from a patient with Bloom's syndrome, lacking any detectable p53 protein, that still shows a functional G1 cell-cycle checkpoint after irradiation with UV-C. Comparison with cells from other Bloom's patients showed that the absence of p53 protein is not a specific characteristic of Bloom's syndrome.	LEIDEN UNIV,SYLVIUS LAB,MOLEC CARCINOGENESIS LAB,2300 RA LEIDEN,NETHERLANDS	Leiden University; Leiden University - Excl LUMC								DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FRIEDBERG EC, 1985, DNA REPAIR, P532; FRITSCHE M, 1993, ONCOGENE, V8, P307; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lane David P., 1992, Current Biology, V2, P581, DOI 10.1016/0960-9822(92)90154-3; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LU X, 1992, CELL, V70, P153, DOI 10.1016/0092-8674(92)90541-J; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; TISHLER RB, 1993, CANCER RES, V53, P2212; VANDENHEUVEL SJL, 1990, EMBO J, V9, P2621, DOI 10.1002/j.1460-2075.1990.tb07444.x; WILLIS AE, 1987, NATURE, V325, P355, DOI 10.1038/325355a0; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	21	18	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					981	983						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108144				2022-12-17	WOS:A1994MW55100038
J	YAN, XQ; BRADY, G; ISCOVE, NN				YAN, XQ; BRADY, G; ISCOVE, NN			OVEREXPRESSION OF PDGF-B IN MURINE HEMATOPOIETIC-CELLS INDUCES A LETHAL MYELOPROLIFERATIVE SYNDROME IN-VIVO	ONCOGENE			English	Article							V-SIS GENE; COLONY-STIMULATING FACTOR; TUMOR-NECROSIS-FACTOR; GROWTH-FACTOR; RETROVIRUS VECTORS; GM-CSF; EXPRESSION; INTERLEUKIN-1; INVIVO; MICE	Although PDGF is not a primary hematopoietic cytokine, effects in hematopoietic cell cultures have been reported. We recently described responses of multilineage hematopoietic precursors to PDGF. The effects were shown to be neutralized by antibody to LL-1 beta and mediated by marrow macrophages that expressed PDGF receptor RNA and responded to PDGF by upregulation of IL-1 RNA. The present study was performed to determine whether constitutive expression of PDGF by hematopoietic cells would have hematopoetic consequences in vivo. Retroviral vectors containing a PDGF-B gene were constructed and infected into normal marrow cells. Irradiated mice reconstituted with infected cells consistently developed a lethal myeloproliferative syndrome with anemia, neutrophilia and monocytosis, declining hematopoiesis in marrow with shift to the spleen, and extensive infiltration of immature hematopoietic cells into the parenchymal organs and connective tissues. In addition to PDGF, the retroviral constructs expressed a nea resistance marker. Phenotypic expression patterns in fibroblasts and in hematopoietic colony-forming cells in vitro were consistent with a significant degree of interaction between the two expressed inserts. Moreover, selection of infected cells for G418 resistance significantly reduced not only the number of infected reconstituting cells but also the intensity of the evoked syndrome in vivo. The observations have important implications for projected gene therapy protocols, and identify a novel potential pathway to myeloproliferative disease.	UNIV TORONTO, ONTARIO CANC INST, DEPT MED BIOPHYS, TORONTO M4X 1K9, ON, CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto								BANCROFT JD, 1984, MANUAL HISTOLOGICAL, P52; BOULTER CA, 1987, NUCLEIC ACIDS RES, V15, P7194, DOI 10.1093/nar/15.17.7194; BOWENPOPE DF, 1984, BLOOD, V64, P458; BOWTELL DDL, 1988, J VIROL, V62, P2464, DOI 10.1128/JVI.62.7.2464-2473.1988; BRACH MA, 1990, BLOOD, V76, P1972; BRADY G, 1988, ONCOGENE, V3, P687; BRANDT SJ, 1990, J CLIN INVEST, V86, P592, DOI 10.1172/JCI114749; CHANG JM, 1989, J CLIN INVEST, V84, P1488, DOI 10.1172/JCI114324; CHANG JM, 1989, BLOOD, V73, P1487; DAINIAK N, 1983, J CLIN INVEST, V71, P1206, DOI 10.1172/JCI110869; DELWICHE F, 1985, J CLIN INVEST, V76, P137, DOI 10.1172/JCI111936; DICK JE, 1991, BLOOD, V78, P624, DOI 10.1182/blood.V78.3.624.bloodjournal783624; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; ELIAS JA, 1990, J IMMUNOL, V145, P161; EMERMAN M, 1986, NUCLEIC ACIDS RES, V14, P9381, DOI 10.1093/nar/14.23.9381; EMERMAN M, 1984, CELL, V39, P459, DOI 10.1016/0092-8674(84)90453-7; FIBBE WE, 1988, BLOOD, V72, P860; HALL DJ, 1989, MOL CELL BIOL, V9, P1705, DOI 10.1128/MCB.9.4.1705; HANNINK M, 1986, MOL CELL BIOL, V6, P1304, DOI 10.1128/MCB.6.4.1304; HARIHARAN IK, 1989, CURR TOP MICROBIOL, V149, P99; HARRISON DE, 1991, BLOOD, V78, P1237; HAWLEY RG, 1992, J EXP MED, V176, P1149, DOI 10.1084/jem.176.4.1149; HAWLEY TS, 1991, LEUKEMIA RES, V15, P659, DOI 10.1016/0145-2126(91)90068-5; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; ISCOVE NN, 1989, J IMMUNOL, V142, P2332; ISCOVE NN, 1990, J IMMUNOL, V145, P190; JOHNSON GR, 1989, EMBO J, V8, P441, DOI 10.1002/j.1460-2075.1989.tb03396.x; JOHNSSON A, 1986, EMBO J, V5, P1535, DOI 10.1002/j.1460-2075.1986.tb04394.x; JOHNSSON A, 1985, P NATL ACAD SCI USA, V82, P1721, DOI 10.1073/pnas.82.6.1721; KOHASE M, 1987, MOL CELL BIOL, V7, P273, DOI 10.1128/MCB.7.1.273; LEAL F, 1985, SCIENCE, V230, P327, DOI 10.1126/science.2996133; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; METCALF D, 1989, LEUKEMIA, V3, P847; MICHALEVICZ R, 1986, BRIT J HAEMATOL, V63, P591, DOI 10.1111/j.1365-2141.1986.tb07537.x; PAIGE CJ, 1986, J IMMUNOL METHODS, V93, P37, DOI 10.1016/0022-1759(86)90430-8; PANTAZIS P, 1990, EUR J HAEMATOL, V45, P127; QUESNIAUX VFJ, 1993, BLOOD, V81, P1497; RAINES EW, 1990, HDB EXPT PHARM 1, V95, P173; ROLLINS BJ, 1988, P NATL ACAD SCI USA, V85, P3738, DOI 10.1073/pnas.85.11.3738; Sambrook J., 1989, MOL CLONING; SIEFF CA, 1987, J CLIN INVEST, V79, P48, DOI 10.1172/JCI112806; VAUX DL, 1990, INT IMMUNOL, V2, P965, DOI 10.1093/intimm/2.10.965; WONG PMC, 1989, MOL CELL BIOL, V9, P798, DOI 10.1128/MCB.9.2.798; YAN XQ, 1993, J IMMUNOL, V150, P2440; ZSEBO KM, 1988, BLOOD, V71, P99; [No title captured]	46	18	18	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1994	9	1					163	173						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302575				2022-12-17	WOS:A1994MW24700020
J	BASELGA, J; MAERZ, WJ; MOY, D; MILLER, WH; CASTRO, L; REUTER, VE; YAO, TJ; MASUI, H; DMITROVSKY, E				BASELGA, J; MAERZ, WJ; MOY, D; MILLER, WH; CASTRO, L; REUTER, VE; YAO, TJ; MASUI, H; DMITROVSKY, E			OVER-EXPRESSION OF TRANSFORMING GROWTH-FACTOR-ALPHA ANTAGONIZES THE ANTI-TUMORIGENIC BUT NOT THE DIFFERENTIATION ACTIONS OF RETINOIC ACID IN A HUMAN TERATOCARCINOMA CELL	ONCOGENE			English	Article							EMBRYONAL CARCINOMA-CELLS; RIBONUCLEIC-ACID; LINE TERA-2; RECEPTOR; INVITRO; CANCER; ANTIBODIES; INDUCTION; CLONING	All-trans retinoic acid (RA) treatment of the multipotent human teratocarcinoma (TC) cell line NTERA-2 clone D1 (abbreviated NT2/D1) induces a neuronal phenotype and other cell lineages. NT2/D1 cells basally express transforming growth factor alpha (TGF-alpha) mRNA and secreted protein. After RA-treatment TGF-alpha expression is markedly reduced. This decline in TGF-alpha expression accompanies the induction of the neuronal phenotype and a marked reduction of tumorigenicity in athymic mice. This suggested a causal link between reduced TGF-alpha expression and the induced differentiation or loss of tumorigenicity of these RA-treated TC cells. To evaluate this possibility, an RA-refractory NT2/D1 subclone was analysed. This subclone, designated NT2/D1-R1, failed to induce differentiation or to decrease TGF-alpha expression despite RA treatment. To further explore the relationship between TGF-alpha expression and RA actions in this human TC cell, a TGF-alpha cDNA was stably transfected and expressed in NT2/D1 cells. RA-treatment of independently obtained TGF-alpha over-expressing clones and a representative control transfectant only expressing the neomycin resistance gene produced a neuronal phenotype similar to parental NT2/D1 cells as assessed by morphologic, immunophenotypic, and gene expression markers of differentiation. RA-treatment of these clones also induced a G1 arrest similar to parental cells. However, only the TGF-alpha over-expressing clones that secreted high levels of TGF-alpha protein into the conditioned media before and after RA treatment still developed tumors in athymic mice despite prior exposure of these cells to RA. This finding demonstrates that TGF-alpha can inhibit the anti-tumorigenic effects of RA in human TCs. Thus, over-expression of a single growth factor that normally declines with RA treatment antagonizes the antitumorigenic but not the differentiation actions of RA in this human tumor cell.	CORNELL UNIV,MED CTR,MEM SLOAN KETTERING CANC CTR,DEPT MED,DIV SOLID TUMOR ONCOL,MOLEC MED LAB,NEW YORK,NY 10021; CORNELL UNIV,MED CTR,MEM SLOAN KETTERING CANC CTR,DEPT MED,DIV SOLID TUMOR ONCOL,RECEPT BIOL LAB,NEW YORK,NY 10021; CORNELL UNIV,MED CTR,MEM SLOAN KETTERING CANC CTR,DEPT PATHOL,NEW YORK,NY 10021; CORNELL UNIV,MED CTR,MEM SLOAN KETTERING CANC CTR,DEPT BIOSTAT,NEW YORK,NY 10021	Cornell University; Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center					NCI NIH HHS [1R01-CA54494-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054494] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; ANDREWS PW, 1986, DIFFERENTIATION, V31, P119, DOI 10.1111/j.1432-0436.1986.tb00392.x; ANDREWS PW, 1984, LAB INVEST, V50, P147; ANDREWS PW, 1990, DIFFERENTIATION, V43, P131, DOI 10.1111/j.1432-0436.1990.tb00439.x; BADER SA, 1991, CELL GROWTH DIFFER, V2, P245; BRAND N, 1988, NATURE, V332, P851; BROOKES S, 1989, ONCOGENE, V4, P429; CARLIN CR, 1985, EXP CELL RES, V159, P17, DOI 10.1016/S0014-4827(85)80033-1; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; DAVIS LG, 1986, BASIC METHODS MOL BI, P286; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; DIPPOLD WG, 1980, P NATL ACAD SCI-BIOL, V77, P6114, DOI 10.1073/pnas.77.10.6114; DMITROVSKY E, 1990, ONCOGENE RES, V5, P233; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; ENGSTROM W, 1985, J CELL SCI, V73, P361; FENDERSON BA, 1987, DEV BIOL, V122, P21, DOI 10.1016/0012-1606(87)90328-9; FOGH J, 1978, NUDE MOUSE EXPT CLIN, P215; GILL GN, 1984, J BIOL CHEM, V259, P7755; GROUCH GD, 1991, CANCER RES, V51, P4882; GUDAS LJ, 1992, CELL GROWTH DIFFER, V3, P655; KURIE JM, IN PRESS DIFFERENTIA; MASSAGUE J, 1983, J BIOL CHEM, V258, P3614; MIETTINEN OS, 1985, THEORETICAL EPIDEMIO, P135; MILLER WH, 1990, ONCOGENE, V5, P511; MILLER WH, 1993, IN PRESS DIFFERENTIA; ROSENTHAL A, 1986, CELL, V46, P301, DOI 10.1016/0092-8674(86)90747-6; SCHOFIELD PN, 1987, J CELL SCI, V88, P57; SCHREIBER AB, 1986, SCIENCE, V232, P1250, DOI 10.1126/science.2422759; SHEVINSKY LH, 1982, CELL, V30, P697, DOI 10.1016/0092-8674(82)90274-4; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; WEIMA SM, 1989, DIFFERENTIATION, V41, P245, DOI 10.1111/j.1432-0436.1989.tb00753.x; YOSHIDA T, 1988, BIOCHEM BIOPH RES CO, V155, P1324, DOI 10.1016/S0006-291X(88)81286-5; ZELEN M, 1971, BIOMETRIKA, V58, P129, DOI 10.1093/biomet/58.1.129	34	18	18	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1993	8	12					3257	3263						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247529				2022-12-17	WOS:A1993MG78200008
J	BHATTACHARYA, G; LEE, L; REDDY, ESP; RAO, VN				BHATTACHARYA, G; LEE, L; REDDY, ESP; RAO, VN			TRANSCRIPTIONAL ACTIVATION DOMAINS OF ELK-1, DELTA-ELK-1 AND SAP-1 PROTEINS	ONCOGENE			English	Note							ETS-RELATED PROTEIN; LONG TERMINAL REPEAT; DNA-BINDING; C-FOS; C-ETS-1 PROTOONCOGENE; FACTOR P62TCF; SEQUENCES; ONCOGENE; GENE; COOPERATE	elk-1, an ets related gene codes for a sequence specific DNA binding transcriptional activator which in association with serum response factor (SRF) forms a ternary complex at the c-fos serum response element (SRE). Recently the C-terminal region of both elk-1 and Delta elk-1 proteins was shown to undergo phosphorylation by MAP kinases and function as an activator of MAP kinases. Here we show that Delta elk-1 and two other elk-1 related proteins SAP-1a and SAP-1b, like elk-1, can function as transcriptional activators. In this report we have localized the transcriptional activation domain of the SAP-I proteins (STA) to a large portion of the carboxy terminal region and have identified two autonomous transcriptional activation domains in the elk-1 protein, one at the amino (ETA-1) and the other at the carboxy terminal region (ETA-2). Delta elk-1 protein contains only the ETA-2 domain indicating differential usage of activation domains as a result of alternative splicing. We can speculate that the ETA-1 domain can function in vivo independent of ETA-2, but the ETA-2 domain can function either in the absence of ETA-1 (as seen in Delta elk-1) or in the presence of accessory proteins like SRF. The role of SRF in the activation of the ternary complex might be to bind to the ETA-1 domain, somehow conceal it's activation domain and in the process unmask the ETA-2 domain (for phosphorylation by MAP kinases) and activate transcription. The ETA-1 domain may be functioning as a negative regulatory transcriptional activation domain for ETA-2 These observations suggest that the elk-1 family of proteins may not only regulate fos and MAP kinases but also other elk-1 target genes that are essential for cellular growth control.	JEFFERSON CANC INST,PHILADELPHIA,PA 19107; PROGRAMME RESOURCES INC,FREDERICK,MD 21702	Jefferson University								BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; JANKNECHT R, 1992, NUCLEIC ACIDS RES, V20, P3317, DOI 10.1093/nar/20.13.3317; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LEUTHER KK, 1992, SCIENCE, V256, P1333, DOI 10.1126/science.1598579; MA J, 1987, CELL, V50, P137, DOI 10.1016/0092-8674(87)90670-2; MAKI RA, 1993, SCIENCE, V259, P1622; MARIAS R, 1993, CELL, V73, P381; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; RAO VN, 1992, ONCOGENE, V7, P65; RAO VN, 1993, ONCOGENE, V8, P2167; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; RAO VN, 1993, CANCER RES, V53, P215; RAO VN, 1993, CANCER RES, V53, P3449; RAO VN, 1992, ONCOGENE, V11, P2335; RAY D, 1992, MOL CELL BIOL, V12, P4297, DOI 10.1128/MCB.12.10.4297; REDDY ESP, 1991, ONCOGENE, V6, P2285; SCHNEIKERT J, 1992, ONCOGENE, V7, P249; SIDDIQUE HR, 1993, ONCOGENE, V8, P1751; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; [No title captured]	36	18	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1993	8	12					3459	3464						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247551				2022-12-17	WOS:A1993MG78200033
J	ZU, YL; MAEKAWA, T; NOMURA, N; NAKATA, T; ISHII, S				ZU, YL; MAEKAWA, T; NOMURA, N; NAKATA, T; ISHII, S			REGULATION OF TRANSACTIVATING CAPACITY OF CRE-BPA BY PHORBOL ESTER TUMOR PROMOTER TPA	ONCOGENE			English	Article							PROTEIN-KINASE-C; LEUCINE ZIPPER PROTEINS; ELEMENT-BINDING PROTEIN; AMP RESPONSE ELEMENT; ATF CDNA CLONES; CYCLIC-AMP; SOMATOSTATIN GENE; JUN ENCODES; TRANSCRIPTION; CRE-BP1	CRE-BPa, here designated as CRE-BPaalpha, is a novel member of the CRE (cAMP response element)-binding protein CRE-BP1 family. CRE-BPaalpha has four regions highly homologous to CRE-BP1, including a putative metal finger structure and a DNA-binding domain consisting of a basic amino acid cluster and a leucine zipper. CRE-BPa specifically binds to CRE as a homodimer or heterodimer with c-Jun or CRE-BP1. Here we report three alternative splicing forms of CRE-BPaalpha: two of them, CRE-BPabeta and CRE-BPagamma, lack the N-terminal 7 and 33 amino acids of CRE-BPaalpha, and the third one CRE-BPadelta, has 16 additional amino acids in the N-terminus and amino acids 156-508 of CRE-BPaalpha. In CAT cotransfection experiments using CV-1 cells, transient expression of each of four CRE-BPa proteins caused a 1.6- to 3.4-fold increase of CRE-dependent transcription, respectively. Interestingly, these weak trans-activating capacities of CRE-BPa proteins were enhanced 2.7- to 3.6-fold by treatment of cells with 12-0-tetradecanoyl-phorbol 13-acetate (TPA). However, CRE-BPa did not affect the TPA-induced and TRE (TPA response element)-dependent transcription. These results indicate that CRE-BPa is a CRE-dependent trans-activator, and that CRE-BPa can confer TPA inducibility on CRE. Thus, CRE-BPa has an unique characteristic of cross-talk between cAMP pathway and TPA pathway.	TSUKUBA LIFE SCI CTR,INST PHYS & CHEM RES,MOLEC GENET LAB,TSUKUBA,IBARAKI 305,JAPAN; NIPPON MED COLL,INST GERONTOL,MOLEC BIOL LAB,NAKAHARA KU,KANAGAWA 211,JAPAN	RIKEN; Nippon Medical School			Ishii, Shunsuke/A-5271-2016	Ishii, Shunsuke/0000-0002-6530-2478				ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CHUNG B, 1986, P NATL ACAD SCI USA, V83, P8962, DOI 10.1073/pnas.83.23.8962; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; DEUTSCH PJ, 1988, P NATL ACAD SCI USA, V85, P7922, DOI 10.1073/pnas.85.21.7922; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GAIRE M, 1990, NUCLEIC ACIDS RES, V18, P3467, DOI 10.1093/nar/18.12.3467; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; KANEHISA M, 1984, NUCLEIC ACIDS RES, V12, P203, DOI 10.1093/nar/12.1Part1.203; KARPINSKI BA, 1992, P NATL ACAD SCI USA, V89, P4820, DOI 10.1073/pnas.89.11.4820; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MAEKAWA T, 1991, ONCOGENE, V6, P627; MATSUDA S, 1991, J BIOL CHEM, V266, P18188; METZ R, 1991, GENE DEV, V5, P174; MIZUSAWA S, 1986, NUCLEIC ACIDS RES, V14, P1319, DOI 10.1093/nar/14.3.1319; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; NOMURA N, 1993, J BIOL CHEM, V268, P4259; NOMURA N, 1989, NUCLEIC ACIDS RES, V17, P5489, DOI 10.1093/nar/17.14.5489; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; SAKURAI A, 1991, BIOCHEM BIOPH RES CO, V181, P629, DOI 10.1016/0006-291X(91)91237-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; YOSHIMURA T, 1990, EMBO J, V9, P2535; YU Y, 1991, J BIOL CHEM, V266, P24134	44	18	22	1	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1993	8	10					2749	2758						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8378084				2022-12-17	WOS:A1993LX34300016
J	VINCENT, S; MARTY, L; LEGALLIC, L; JEANTEUR, P; FORT, P				VINCENT, S; MARTY, L; LEGALLIC, L; JEANTEUR, P; FORT, P			CHARACTERIZATION OF LATE RESPONSE GENES SEQUENTIALLY EXPRESSED DURING RENEWED GROWTH OF FIBROBLASTIC CELLS	ONCOGENE			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR; CULTURED MOUSE CELLS; MESSENGER-RNA LEVELS; RAT FIBROBLASTS; 3T3 CELLS; C-FOS; MONOCLONAL-ANTIBODY; HAMSTER FIBROBLASTS; MOLECULAR-CLONING; MAMMALIAN-CELLS	Many proto-oncogenes are rapidly and transiently activated during the early stages of the cellular transition from a resting G0 state to the DNA synthesis (S) phase. To get better understanding of the gene complexity involved at later stages, we isolated, by cDNA cloning, and identified 17 genes that are activated sequentially during the period of time from proto-oncogene expression to the onset of DNA synthesis in the hamster CCL39 fibroblastic cell line. When protein synthesis is inhibited, induced expression of these genes is unaffected for 10 of them, enhanced for four, in a fashion similar to the immediate-early response genes, and inhibited for three, as observed for delayed early-response genes. In addition to rhoG, a new member of the ras homolog gene family (Vincent et al., 1992), cDNA sequencing indicated that six of them correspond to cytoskeletal proteins (alpha-tubulin, vascular alpha-actin and skeletal gamma-actin), extracellular matrix protein (thrombospondin), secreted protease (plasminogen activator inhibitor-1) and energy-linked transporter (mitochondrial proton/phosphate symporter). This overall survey shows that numerous differentially regulated gene activations are associated with the cell cycle progression, and suggests that proteins involved in cellular reshaping participate actively in the control of cellular growth.	INST GENET MOLEC MONTPELLIER,BP 5051,ROUTE MENDE,F-34033 MONTPELLIER 1,FRANCE				Fort, Philippe/M-9498-2015	Fort, Philippe/0000-0001-5997-8722; Le Gallic, Lionel/0000-0001-7147-9846				ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; ANDREASEN PA, 1990, MOL CELL ENDOCRINOL, V68, P1, DOI 10.1016/0303-7207(90)90164-4; BATTINI R, 1987, J BIOL CHEM, V262, P4355; BELYAVSKY A, 1989, NUCLEIC ACIDS RES, V17, P2919, DOI 10.1093/nar/17.8.2919; BRAVO R, 1988, COLD SPRING HARB SYM, V53, P901, DOI 10.1101/SQB.1988.053.01.103; CAMPISI J, 1982, P NATL ACAD SCI-BIOL, V79, P436, DOI 10.1073/pnas.79.2.436; CICCARELLI P, 1989, SCIENCE, V10, P1525; DESSEN P, 1990, COMPUT APPL BIOSCI, V6, P355; DIECKMANN D, 1991, NATURE, V351, P400; DIXIT VM, 1985, P NATL ACAD SCI USA, V82, P3472, DOI 10.1073/pnas.82.10.3472; DONOVIEL DB, 1990, J CELL PHYSIOL, V145, P16, DOI 10.1002/jcp.1041450104; ELLIOTT EM, 1986, MOL CELL BIOL, V6, P906, DOI 10.1128/MCB.6.3.906; FERREIRA GC, 1989, J BIOL CHEM, V264, P15628; FORT P, 1987, NUCLEIC ACIDS RES, V15, P5657, DOI 10.1093/nar/15.14.5657; GLAICHENHAUS N, 1987, CELL, V50, P1081, DOI 10.1016/0092-8674(87)90174-7; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HENNESSY SW, 1989, J CELL BIOL, V108, P729, DOI 10.1083/jcb.108.2.729; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HIRSCHHORN RR, 1984, P NATL ACAD SCI-BIOL, V81, P6004, DOI 10.1073/pnas.81.19.6004; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; KEUTZER JC, 1990, EXP CELL RES, V188, P153, DOI 10.1016/0014-4827(90)90291-H; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; LARSON RA, 1984, AM J MED, V76, P827, DOI 10.1016/0002-9343(84)90994-X; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; MAJACK RA, 1988, J CELL BIOL, V106, P415, DOI 10.1083/jcb.106.2.415; MAJACK RA, 1987, J BIOL CHEM, V262, P8821; MATRISIAN LM, 1985, NUCLEIC ACIDS RES, V13, P711, DOI 10.1093/nar/13.3.711; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; MIN BH, 1990, J BIOL CHEM, V265, P16667; NIKAIDO T, 1991, EXP CELL RES, V192, P102, DOI 10.1016/0014-4827(91)90163-O; NY T, 1986, P NATL ACAD SCI USA, V83, P6776, DOI 10.1073/pnas.83.18.6776; PRENDERGAST GC, 1990, MOL CELL BIOL, V10, P1265, DOI 10.1128/MCB.10.3.1265; REIBEL L, 1991, BIOCHEM BIOPH RES CO, V175, P451, DOI 10.1016/0006-291X(91)91585-Z; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SAWDEY M, 1989, J BIOL CHEM, V264, P10396; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; SEUWEN K, 1990, J BIOL CHEM, V265, P22292; TARABOLETTI G, 1990, J CELL BIOL, V111, P765, DOI 10.1083/jcb.111.2.765; TOKUNAGA K, 1988, MOL CELL BIOL, V8, P3929, DOI 10.1128/MCB.8.9.3929; VANOBBERGHEMSCH.E, 1983, EMBO J, V4, P2927; VINCENT S, 1992, MOL CELL BIOL, V12, P3138, DOI 10.1128/MCB.12.7.3138; YANG HC, 1986, J CELL PHYSIOL, V127, P410, DOI 10.1002/jcp.1041270309; YEN TJ, 1988, NATURE, V334, P580, DOI 10.1038/334580a0	50	18	18	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1603	1610						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	7684829				2022-12-17	WOS:A1993LE06400024
J	ESCOT, C; SIMONYLAFONTAINE, J; MAUDELONDE, T; PUECH, C; PUJOL, H; ROCHEFORT, H				ESCOT, C; SIMONYLAFONTAINE, J; MAUDELONDE, T; PUECH, C; PUJOL, H; ROCHEFORT, H			POTENTIAL VALUE OF INCREASED MYC BUT NOT ERBB2 RNA LEVELS AS A MARKER OF HIGH-RISK MASTOPATHIES	ONCOGENE			English	Article							HUMAN-BREAST-CANCER; C-MYC; ONCOGENE EXPRESSION; ESTROGEN-RECEPTOR; DIFFERENTIAL EXPRESSION; CARCINOMA INSITU; BENIGN; CELLS; LESIONS; TISSUE	MYC and ERBB2 levels were measured in 38 benign breast diseases using a semiquantitative in situ hybridization technique. Mean levels of MYC and ERBB2 gene expression in benign tissues were similar to those measured in 15 breast cancers with no amplification at the loci concerned. Interestingly, MYC but not ERBB2 RNA levels were increased (t-test, P = 0.03) in benign mastopathies of patients with a first-degree (mother/sister) family history (FH) of breast cancer. Among patients without a first-degree FH, MYC RNA levels were significantly higher (t-test, P = 0.02) during the follicular (preovulatory) than the luteal (post-ovulatory) phase and also significantly higher than levels observed in patients with no menstrual cycle (peri- or postmenopausal) (P = 0.004), indicating an in vivo hormonal regulation of MYC. After exclusion of the first-degree FH patients a higher MYC expression was detected in atypia than in other histological types at the follicular but not at the luteal phase, suggesting an increased sensitivity of these high-risk lesions to estrogens. We propose that in addition to a family history and proliferative atypia, elevated MYC RNA levels during the post-ovulatory phase could potentially be used as a marker of the risk of developing breast cancer. The increase in MYC RNA in high-risk breast diseases also suggests that MYC deregulation might be involved in the early stages of mammary carcinogenesis.	INSERM,U148,UNITE HORMONE & CANC,F-34090 MONTPELLIER,FRANCE; CTR VAL AURELLE,F-34094 MONTPELLIER 5,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; UNICANCER; Universite de Montpellier; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM)								ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; ARRUSHDI A, 1983, SCIENCE, V222, P390, DOI 10.1126/science.6414084; BARNES DM, 1992, EUR J CANCER, V28A, P644, DOI 10.1016/S0959-8049(05)80117-0; BENZ CC, 1989, JNCI-J NATL CANCER I, V81, P1704, DOI 10.1093/jnci/81.22.1704; BURCK KB, 1988, ONCOGENES INTRO CONC; CALLAHAN R, 1989, JNCI-J NATL CANCER I, V81, P1780, DOI 10.1093/jnci/81.23.1780; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; CHALBOS D, 1990, JNCI-J NATL CANCER I, V82, P602, DOI 10.1093/jnci/82.7.602; DATI C, 1990, ONCOGENE, V5, P1001; DUBIK D, 1987, CANCER RES, V47, P6517; ESCOT C, 1991, ANAL CELL PATHOL, V3, P215; GARCIA M, 1986, CANCER RES, V46, P3734; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; HAAGENSEN CD, 1978, CANCER, V42, P737, DOI 10.1002/1097-0142(197808)42:2<737::AID-CNCR2820420247>3.0.CO;2-T; HUTCHINSON WB, 1980, J NATL CANCER I, V65, P13; JACQUEMIER JD, 1990, BREAST CANCER RES TR, V15, P109, DOI 10.1007/BF01810783; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; LEROY X, 1991, ONCOGENE, V6, P431; LIU E, 1992, ONCOGENE, V7, P1027; LONDON SJ, 1992, JAMA-J AM MED ASSOC, V267, P941, DOI 10.1001/jama.267.7.941; MARIANICOSTANTINI R, 1988, CANCER RES, V48, P199; PAGE DL, 1985, CANCER, V55, P2698, DOI 10.1002/1097-0142(19850601)55:11<2698::AID-CNCR2820551127>3.0.CO;2-A; PAGE DL, 1992, BREAST, V1, P3; PARKER CL, 1988, AM J EPIDEMIOL, V128, P467; PAVELIC SP, 1992, CANCER RES, V52, P2597; PETERSEN OW, 1987, CANCER RES, V47, P5748; PIKE MC, 1981, 8 BANB REP; SANTOS GF, 1988, J BIOL CHEM, V263, P9565; SIERRA F, 1982, P NATL ACAD SCI-BIOL, V79, P1795, DOI 10.1073/pnas.79.6.1795; TAUCHI K, 1989, VIRCHOWS ARCH A, V416, P65, DOI 10.1007/BF01606471; THEILLET C, 1989, ONCOGENE, V4, P915; VANDEVIJVER MJ, 1988, NEW ENGL J MED, V319, P1239, DOI 10.1056/NEJM198811103191902; WALKER KJ, 1992, EUR J CANCER, V28A, P34, DOI 10.1016/0959-8049(92)90379-G; WELLINGS SR, 1975, J NATL CANCER I, V55, P231; WHITTAKER JL, 1986, INT J CANCER, V38, P651, DOI 10.1002/ijc.2910380506	35	18	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					969	974						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8455947				2022-12-17	WOS:A1993KT22000019
J	MODAK, SP; PRINCIPAUD, E; SPOHR, G				MODAK, SP; PRINCIPAUD, E; SPOHR, G			REGULATION OF XENOPUS C-MYC PROMOTER ACTIVITY IN OOCYTES AND EMBRYOS	ONCOGENE			English	Article							E2F TRANSCRIPTION FACTOR; TRANS-ACTIVATION; BINDING PROTEIN; CELL-DIVISION; MESSENGER-RNA; EXPRESSION; GENE; ELEMENT; ONCOGENE; LAEVIS	We have studied the regulation of transcription of the Xenopus c-myc I gene in oocytes and embryos. Various 5' and internal deletions of a 1310-bp-long c-myc I promoter fragment have been ligated upstream of the chloramphenicol acetyl transferase (CAT) reporter gene and microinjected into oocytes and fertilized eggs. Activity was determined by CAT assay and primer extension. The c-myc promoter drives transcription very efficiently, and a truncated promoter - 158/+ 46 essentially retains full activity. This region contains an overlapping E2F/SP1 site and two tandem Sp1 sites homologous to those found in the c-myc gene of mouse. Internal deletions show that both elements are equally active in oocytes in driving the expression of CAT. A germinal vesicle extract contains a DNA-binding activity specific for an Sp1 consensus sequence but not the E2F site. The data suggest that the high transcription level of the endogenous c-myc gene in Xenopus oocytes is mediated by Spl or a related transcription factor. In embryos a different mechanism emerges and the functional role of the Spl binding sites appears to be less important.	UNIV GENEVA,DEPT BIOL CELLULAIRE,30 QUAI ERNEST ANSERMET,CH-1211 GENEVA 4,SWITZERLAND	University of Geneva								ANDERSON GM, 1991, MOL CELL BIOL, V11, P1935, DOI 10.1128/MCB.11.4.1935; BENHATTAR J, 1989, NUCLEIC ACIDS RES, V17, P10179, DOI 10.1093/nar/17.24.10179; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; DANG CV, 1991, BIOCHIM BIOPHYS ACTA, V337, P664; DAVIS TL, 1989, P NATL ACAD SCI USA, V86, P9682, DOI 10.1073/pnas.86.24.9682; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; FALCONE G, 1985, P NATL ACAD SCI USA, V82, P426, DOI 10.1073/pnas.82.2.426; GODEAU F, 1986, EMBO J, V5, P3571, DOI 10.1002/j.1460-2075.1986.tb04684.x; Gurdon J. B., 1986, MICROINJECTION ORGAN, P269; GURDON JB, 1983, METHOD ENZYMOL, V101, P370; GUSSE M, 1989, MOL CELL BIOL, V9, P5395, DOI 10.1128/MCB.9.12.5395; HAY N, 1989, GENE DEV, V3, P293, DOI 10.1101/gad.3.3.293; HAY N, 1987, GENE DEV, V1, P659, DOI 10.1101/gad.1.7.659; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KING MW, 1986, MOL CELL BIOL, V6, P4499, DOI 10.1128/MCB.6.12.4499; KINNIBURGH AJ, 1989, NUCLEIC ACIDS RES, V17, P7771, DOI 10.1093/nar/17.19.7771; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LOBO SM, 1989, CELL, V58, P55, DOI 10.1016/0092-8674(89)90402-9; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MCKNIGHT SL, 1984, CELL, V37, P253, DOI 10.1016/0092-8674(84)90321-0; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; NISHIKURA K, 1986, MOL CELL BIOL, V6, P4093, DOI 10.1128/MCB.6.11.4093; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; POSTEL EH, 1989, MOL CELL BIOL, V9, P5123, DOI 10.1128/MCB.9.11.5123; PRINCIPAUD E, 1991, NUCLEIC ACIDS RES, V19, P3081, DOI 10.1093/nar/19.11.3081; RAYCHAUDHURI P, 1990, J VIROL, V64, P2702, DOI 10.1128/JVI.64.6.2702-2710.1990; SAMBROOK I, 1989, MOL CLONING LABORATO; SCHNEIDER R, 1986, NUCLEIC ACIDS RES, V14, P1303, DOI 10.1093/nar/14.3.1303; SPENCER CA, 1990, ADV CANCER RES, V56, P1; SU W, 1991, GENE DEV, V5, P820, DOI 10.1101/gad.5.5.820; TAKIMOTO M, 1989, J BIOL CHEM, V264, P8992; TAYLOR MV, 1986, EMBO J, V5, P3563, DOI 10.1002/j.1460-2075.1986.tb04683.x; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; THOMPSON CB, 1985, NATURE, V314, P363, DOI 10.1038/314363a0; VRIZ S, 1989, EMBO J, V8, P4091, DOI 10.1002/j.1460-2075.1989.tb08593.x; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578	41	18	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					645	654						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437848				2022-12-17	WOS:A1993KN00800015
J	PAULES, RS; RESNICK, J; KASENALLY, AB; ERNST, MK; DONOVAN, P; VANDEWOUDE, GF				PAULES, RS; RESNICK, J; KASENALLY, AB; ERNST, MK; DONOVAN, P; VANDEWOUDE, GF			CHARACTERIZATION OF ACTIVATED AND NORMAL MOUSE MOS GENE IN MURINE 3T3 CELLS	ONCOGENE			English	Article							PROTO-ONCOGENE PRODUCT; MEIOTIC MATURATION; SARCOMA-VIRUS; M-PHASE; DEVELOPMENTAL REGULATION; OOCYTE MATURATION; XENOPUS OOCYTES; CDC2 PROTEIN; GERM-CELLS; MEIOSIS-II	We have characterized the mouse Mos proto-oncogene product, pp39Mos in murine fibroblasts. When expressed in NIH3T3 cells under the influence of the long terminal repeat regulatory element from Moloney murine sarcoma virus [NIH(pTS-1) cells], the Mos protein was present in low levels and had a half-life of about 30 min. In extracts from NIH(pTS-1) cells, we detected additional forms of Mos protein that apparently arose from internal initiation codons (p24Mos and p29Mos) or from upstream non-AUG initiation codons (p42Mos and p44Mos). The Mos protein was found to exist in these cells as a phosphoprotein, pp39Mos, and, when immunoprecipitated with an antiserum specific for the Mos N-terminus [anti-Mos(6-24)], had autophosphorylating kinase activity. We found that anti-Mos(6-24) also detected non-Mos protein kinase activity and non-Mos phosphoproteins in addition to p39Mos. We present evidence, on both the RNA and protein levels, that non-transformed mouse 3T3 cells do not express endogenous Mos.	ST MARYS HOSP,SCH MED,LUDWIG INST CANC RES,LONDON W2 1PG,ENGLAND; NCI,FREDERICK CANC RES & DEV CTR,BASIC RES PROGRAM,ABL,FREDERICK,MD 21702	Imperial College London; Ludwig Institute for Cancer Research; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	PAULES, RS (corresponding author), NIEHS,MAMMALIAN MOLEC GENET GRP,POB 12233,RES TRIANGLE PK,NC 27709, USA.			Paules, Richard S/0000-0001-9106-7486	OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLAIR DG, 1986, CELL, V46, P785, DOI 10.1016/0092-8674(86)90354-5; BLAIR DG, 1981, SCIENCE, V212, P941, DOI 10.1126/science.7233190; DAAR I, 1991, SCIENCE, V253, P74, DOI 10.1126/science.1829549; DAAR I, 1991, J CELL BIOL, V114, P329, DOI 10.1083/jcb.114.2.329; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; FRANKEL AE, 1976, P NATL ACAD SCI USA, V73, P3705, DOI 10.1073/pnas.73.10.3705; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GOLDMAN DS, 1987, P NATL ACAD SCI USA, V84, P4509, DOI 10.1073/pnas.84.13.4509; HERZOG NK, 1989, ONCOGENE, V4, P1307; HERZOG NK, 1988, ONCOGENE, V3, P225; JONES M, 1980, P NATL ACAD SCI-BIOL, V77, P2651, DOI 10.1073/pnas.77.5.2651; KANKI JP, 1991, P NATL ACAD SCI USA, V88, P5794, DOI 10.1073/pnas.88.13.5794; KESHET E, 1988, ONCOGENE, V2, P235; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIBOVITCH SA, 1990, ONCOGENE, V5, P1149; LEIBOVITCH SA, 1991, ONCOGENE, V6, P1617; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MAXWELL SA, 1985, J VIROL, V55, P874, DOI 10.1128/JVI.55.3.874-876.1985; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; MELCHERS F, 1985, P NATL ACAD SCI USA, V82, P7681, DOI 10.1073/pnas.82.22.7681; MUTTER GL, 1987, P NATL ACAD SCI USA, V84, P5301, DOI 10.1073/pnas.84.15.5301; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OKEEFE SJ, 1989, P NATL ACAD SCI USA, V86, P7038, DOI 10.1073/pnas.86.18.7038; OSKARSSON M, 1980, SCIENCE, V207, P1222, DOI 10.1126/science.6243788; PAPKOFF J, 1982, CELL, V29, P417, DOI 10.1016/0092-8674(82)90158-1; PAPKOFF J, 1981, CELL, V27, P109, DOI 10.1016/0092-8674(81)90365-2; PAULES RS, 1989, P NATL ACAD SCI USA, V86, P5395, DOI 10.1073/pnas.86.14.5395; PAULES RS, 1988, ONCOGENE, V3, P59; PLATT EJ, 1986, ANAL BIOCHEM, V156, P126, DOI 10.1016/0003-2697(86)90163-6; PROPST F, 1985, NATURE, V315, P516, DOI 10.1038/315516a0; PROPST F, 1987, MOL CELL BIOL, V7, P1629, DOI 10.1128/MCB.7.5.1629; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SCHMIDT M, 1988, MOL CELL BIOL, V8, P923, DOI 10.1128/MCB.8.2.923; SCHULZ N, 1992, CANCER RES, V52, P450; SINGH B, 1987, J VIROL, V61, P3625, DOI 10.1128/JVI.61.11.3625-3629.1987; Stein Gary S., 1989, P133; TOBEY RA, 1988, EXP CELL RES, V179, P400, DOI 10.1016/0014-4827(88)90279-0; VANDEWOUDE GF, 1980, COLD SPRING HARB SYM, V44, P735, DOI 10.1101/SQB.1980.044.01.079; WASSERMAN WJ, 1978, J CELL BIOL, V78, P15; WATANABE N, 1989, NATURE, V342, P505, DOI 10.1038/342505a0; YEW N, 1991, MOL CELL BIOL, V11, P604, DOI 10.1128/MCB.11.2.604; YEW N, 1992, NATURE, V355, P649, DOI 10.1038/355649a0; ZHAO X, 1990, ONCOGENE, V5, P1727; ZHAO X, 1991, ONCOGENE, V6, P43; ZHOU R, 1991, CELL GROWTH DIFFER, V2, P257; ZHOU RP, 1991, SCIENCE, V251, P671, DOI 10.1126/science.1825142; ZINN K, 1983, CELL, V34, P856	51	18	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1992	7	12					2489	2498						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KA856	1461652				2022-12-17	WOS:A1992KA85600014
J	WANG, YS; SUGIYAMA, H; AXELSON, H; PANDA, CK; BABONITS, M; MA, A; STEINBERG, JM; ALT, FW; KLEIN, G; WIENER, F				WANG, YS; SUGIYAMA, H; AXELSON, H; PANDA, CK; BABONITS, M; MA, A; STEINBERG, JM; ALT, FW; KLEIN, G; WIENER, F			FUNCTIONAL HOMOLOGY BETWEEN N-MYC AND C-MYC IN MURINE PLASMACYTOMAGENESIS - PLASMACYTOMA DEVELOPMENT IN N-MYC TRANSGENIC MICE	ONCOGENE			English	Article							LEUKEMIA-VIRUS; V-ABL; CHROMOSOMAL TRANSLOCATIONS; CELLULAR ONCOGENES; KINASE-ACTIVITY; BALB/C MICE; B-CELLS; GENE; EXPRESSION; AMPLIFICATION	Mouse plasmacytomas induced by pristane oil alone, or in combination with Abelson murine leukemia virus (A-MuLV), regularly carry one of three alternative chromosomal translocations that juxtapose c-myc to immunoglobulin heavy- or light-chain loci. E-mu-c-myc transgenic mice develop translocation-free plasmacytomas after induction by pristane oil and/or A-MuLV [Sugiyama, H., Silva, S., Wang, Y., Weber, G., Babonits, M., Rosen, A., Wiener, F. & Klein, G. (1990). Int. J. Cancer, 46, 845-8521. In order to test whether another member of the myc family, N-myc, could play a similar role as c-myc, we treated E-mu- N -myc transgenic mice with pristane and helper-free A-MuLV. Of 20 mice that received a single pristane injection followed by A-MuLV, 17 developed plasmacytomas with a mean latency period of 54 +/- 20 days. In a corresponding group that only received a single pristane injection, five out of six transgenic mice developed plasmacytomas with a mean latency period of 142 +/- 32 days. However, after three monthly injections of pristane, all 15 transgenic mice developed plasmacytomas with a mean latency period of 128 +/- 20 days. All plasmacytomas expressed the N-myc transgene, while none of them expressed either c-myc or endogenous N-myc. None of the tumors carried the usual plasmacytoma-associated translocations.	COLUMBIA UNIV COLL PHYS & SURG,HOWARD HUGHES MED INST,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT BIOCHEM,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT MICROBIOL,NEW YORK,NY 10032; NCI,GENET LAB,BETHESDA,MD 20892	Columbia University; Howard Hughes Medical Institute; Columbia University; Columbia University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	WANG, YS (corresponding author), KAROLINSKA INST,DEPT TUMOR BIOL,BOX 60400,S-10401 STOCKHOLM 60,SWEDEN.				NATIONAL CANCER INSTITUTE [R01CA014054] Funding Source: NIH RePORTER; NCI NIH HHS [5 RO1 CA 14054-15] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ADAMS JM, 1991, BIOCHIM BIOPHYS ACTA, V1072, P9, DOI 10.1016/0304-419X(91)90004-5; ALEXANDER WS, 1989, MOL CELL BIOL, V9, P67, DOI 10.1128/MCB.9.1.67; ALT FW, 1986, COLD SPRING HARB SYM, V1, P931; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BROOKS BJ, 1987, ADV VIRAL ONCOL, V7, P155; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; DEPINHO R, 1987, J CELL BIOCHEM, V33, P257, DOI 10.1002/jcb.240330404; DEPINHO RA, 1986, P NATL ACAD SCI USA, V83, P1827, DOI 10.1073/pnas.83.6.1827; DILDROP R, 1989, EMBO J, V8, P1121, DOI 10.1002/j.1460-2075.1989.tb03482.x; GERONDAKIS S, 1984, CELL, V36, P973, DOI 10.1016/0092-8674(84)90047-3; GOUGH NM, 1981, P NATL ACAD SCI-BIOL, V78, P509, DOI 10.1073/pnas.78.1.509; GREEN PL, 1987, P NATL ACAD SCI USA, V84, P5932, DOI 10.1073/pnas.84.16.5932; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; KLEIN G, 1985, IMMUNOL TODAY, V6, P208, DOI 10.1016/0167-5699(85)90036-2; KONOPKA JB, 1984, J VIROL, V51, P223, DOI 10.1128/JVI.51.1.223-232.1984; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; LEE WH, 1984, NATURE, V309, P458, DOI 10.1038/309458a0; MA A, 1991, MOL CELL BIOL, V11, P440, DOI 10.1128/MCB.11.1.440; MINTY AJ, 1981, J BIOL CHEM, V256, P1008; OHNO S, 1984, J EXP MED, V159, P1762, DOI 10.1084/jem.159.6.1762; PEAR WS, 1988, MOL CELL BIOL, V8, P441, DOI 10.1128/MCB.8.1.441; POTTER M, 1973, SCIENCE, V182, P592, DOI 10.1126/science.182.4112.592; POTTER M, 1987, SCIENCE, V235, P787, DOI 10.1126/science.3810165; POTTER M, 1984, ADV VIRAL ONCOL, V4, P139; REDDY EP, 1983, P NATL ACAD SCI-BIOL, V80, P3623, DOI 10.1073/pnas.80.12.3623; ROSEN A, 1979, J IMMUNOL METHODS, V28, P1, DOI 10.1016/0022-1759(79)90322-3; ROSENBAUM H, 1989, EMBO J, V8, P749, DOI 10.1002/j.1460-2075.1989.tb03435.x; ROSENBAUM H, 1990, EMBO J, V9, P897, DOI 10.1002/j.1460-2075.1990.tb08187.x; Sambrook J., 1989, MOL CLONING LAB MANU; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; SUGIYAMA H, 1990, INT J CANCER, V46, P845, DOI 10.1002/ijc.2910460516; SUGIYAMA H, 1989, INT J CANCER, V44, P348, DOI 10.1002/ijc.2910440227; VANLOHUIZEN M, 1989, EMBO J, V8, P133, DOI 10.1002/j.1460-2075.1989.tb03357.x; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; WIENER F, 1984, J EXP MED, V159, P276, DOI 10.1084/jem.159.1.276; WONG AJ, 1986, SCIENCE, V233, P461, DOI 10.1126/science.3014659; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	38	18	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1992	7	6					1241	1247						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU642	1375720				2022-12-17	WOS:A1992HU64200023
J	KYPRIANOU, N; TAYLORPAPADIMITRIOU, J				KYPRIANOU, N; TAYLORPAPADIMITRIOU, J			ISOLATION OF AZATYROSINE-INDUCED REVERTANTS FROM RAS-TRANSFORMED HUMAN MAMMARY EPITHELIAL-CELLS	ONCOGENE			English	Article								Non-transformed revertant clones were isolated from the ras-transformed MTSV1-7 (ras) cell line, after treatment with the antibiotic azatyrosine. Azatyrosine significantly inhibited the growth of the ras-transformed cells but not of the normal MTSV1-7. After 7 days of azatyrosine treatment, approximately 30% of MTSV1-7 (ras) cells survived, and revertant cell lines were selected by random cloning. The azatyrosine-induced revertants (six clones) were considered non-transformed on the basis of (a) their substantially reduced ability to form colonies in soft agar, and (b) their inability to produce tumours in nude mice. Molecular analysis of the revertants revealed that each contains multiple copies of the v-H-ras gene and expresses high levels of v-H-ras mRNA, and all revertants sustain elevated levels of p21ras protein. Thus, the revertant phenotype induced by azatyrosine does not result from inactivation of v-H-ras oncogene or inhibition of its expression. In vivo guanine nucleotide binding to p21ras in the revertant cell lines demonstrated binding of both GTP and GDP, indicating that reversion to the non-transformed phenotype was not due to inability of p21ras to bind GTP. The expression of the human K-rev-1 gene, a known tumour-suppressor gene in ras-transformed NIH3T3 cells, was studied in the isolated azatyrosine revertants. All six revertants showed a significant increase in the K-rev-1 transcript levels compared with the ras-transformed MTSVI-7 cells. These results suggest that tumorigenic transformation of human mammary epithelial cells by v-H-ras may be influenced by the level of expression of the tumour-suppressor gene, K-rev-1.	IMPERIAL CANC RES FUND, POB 123, LINCOLNS INN FIELDS, LONDON WC2A 3PX, ENGLAND	Cancer Research UK								ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARTEK J, 1991, P NATL ACAD SCI USA, V88, P3520, DOI 10.1073/pnas.88.9.3520; BOS JL, 1989, CANCER RES, V49, P4682; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CONTENTE S, 1990, SCIENCE, V249, P796, DOI 10.1126/science.1697103; DOERFLER W, 1983, ANNU REV BIOCHEM, V52, P93, DOI 10.1146/annurev.bi.52.070183.000521; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; HSIAO WLW, 1985, MOL CELL BIOL, V5, P1800, DOI 10.1128/MCB.5.7.1800; KITAYAMA H, 1990, P NATL ACAD SCI USA, V87, P4284, DOI 10.1073/pnas.87.11.4284; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maniatis T., 1982, MOL CLONING; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; NAKAYASU M, 1988, P NATL ACAD SCI USA, V85, P9066, DOI 10.1073/pnas.85.23.9066; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; NODA M, 1989, P NATL ACAD SCI USA, V86, P162, DOI 10.1073/pnas.86.1.162; PATERSON H, 1989, CIBA F SYMP, V142, P134; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; SAMID D, 1987, MOL CELL BIOL, V7, P2196, DOI 10.1128/MCB.7.6.2196; SAMID D, 1984, BIOCHEM BIOPH RES CO, V119, P21, DOI 10.1016/0006-291X(84)91612-7; SHINDOOKADA N, 1989, MOL CARCINOGEN, V2, P159, DOI 10.1002/mc.2940020309; TAYLORPAPADIMITRIOU J, 1989, J CELL SCI, V94, P403; TAYLORPAPADIMITRIOU J, 1977, J NATL CANCER I, V58, P1563, DOI 10.1093/jnci/58.6.1563; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; YANAGIHARA K, 1990, ONCOGENE, V5, P1179	30	18	18	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1992	7	1					57	63						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC227	1741165				2022-12-17	WOS:A1992HC22700008
J	MARSHALL, J; SMITH, AE; CHENG, SH				MARSHALL, J; SMITH, AE; CHENG, SH			MONOCLONAL-ANTIBODY SPECIFIC FOR BK VIRUS LARGE-T ANTIGEN ALLOWS DISCRIMINATION AMONG THE DIFFERENT PAPOVAVIRAL LARGE-T ANTIGENS	ONCOGENE			English	Note							PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; DEFICIENCY SYNDROME AIDS; JC VIRUS; SIMIAN VIRUS-40; TRANSGENIC MICE; POLYOMAVIRUS-BK; BRAIN-TUMORS; DNA; IDENTIFICATION; TRANSFORMATION	The human papovaviruses BK virus (BKV) and JC virus (JCV) both encode a large-tumor (T) antigen which are highly homologous to each other as well as to simian virus 40 (SV40) large-T antigen. This high conservation of amino acid sequence has resulted in overlapping antigenicity such that immunological differentiation of the large-T antigens from the three different viruses has been difficult. Here we describe the generation and characterization of a new monoclonal antibody (BK-T.1) which is specific for BKV large-T antigen and which does not cross-react with the other papovaviral T antigens. We show that when BK-T.1 is used in conjunction with preexisting monoclonal antibodies against SV40 large-T antigen, it is possible to identify the origin of papovavirus T antigens.	GENZYME CORP,CELLULAR REGULAT LAB,1 MT RD,FRAMINGHAM,MA 01701	Sanofi-Aventis; Genzyme Corporation			Cheng, Seng H/AAC-6564-2022	Marshall, John/0000-0003-1361-2869	DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS [N44CP085655] Funding Source: NIH RePORTER; NCI NIH HHS [N44-CP-85655] Funding Source: Medline	DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BETH E, 1977, INT J CANCER, V20, P551, DOI 10.1002/ijc.2910200412; BOLLAG B, 1989, J VIROL, V63, P863, DOI 10.1128/JVI.63.2.863-872.1989; BRINSTER RL, 1984, CELL, V37, P367, DOI 10.1016/0092-8674(84)90367-2; Carrol SB, 1987, DNA CLONING PRACTICA, V3, P89; CHENG SH, 1986, EMBO J, V5, P325, DOI 10.1002/j.1460-2075.1986.tb04216.x; COLEMAN DV, 1980, J INFECT DIS, V142, P1, DOI 10.1093/infdis/142.1.1; COLEMAN DV, 1978, J CLIN PATHOL, V31, P338, DOI 10.1136/jcp.31.4.338; COLEMAN DV, 1980, RECENT ADV CLIN VIRO, V2, P89; DORRIES K, 1987, VIROLOGY, V160, P268, DOI 10.1016/0042-6822(87)90071-7; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; GARDNER SD, 1971, LANCET, V1, P1253; GARDNER SD, 1973, BRIT MED J, V1, P74; GARDNER SD, 1977, RECENT ADV CLINICAL, V1, P93; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; KITAMURA T, 1990, J INFECT DIS, V161, P1128, DOI 10.1093/infdis/161.6.1128; KRUPP LB, 1985, ANN NEUROL, V17, P344, DOI 10.1002/ana.410170407; LAI CJ, 1979, J VIROL, V30, P141, DOI 10.1128/JVI.30.1.141-147.1979; MESSING J, 1977, P NATL ACAD SCI USA, V74, P3642, DOI 10.1073/pnas.74.9.3642; MOLE SE, 1987, DNA CLONING, V3, P113; MULLER WJ, 1984, MOL CELL BIOL, V4, P2406, DOI 10.1128/MCB.4.11.2406; PADGETT B, 1981, DNA TUMOR VIRUSES MO, P334; PADGETT BL, 1971, LANCET, V1, P1257; PATER MM, 1982, MOL CELL BIOL, V2, P837, DOI 10.1128/MCB.2.7.837; PATER MM, 1980, VIRUSES NATURALLY OC, P329; RUTHER U, 1983, EMBO J, V2, P1791, DOI 10.1002/j.1460-2075.1983.tb01659.x; RYDER K, 1983, VIROLOGY, V129, P239, DOI 10.1016/0042-6822(83)90412-9; SCHREIRER AA, 1986, J NATL CANCER I, V76, P1255; SHAH K, 1976, AM J EPIDEMIOL, V103, P1; SMALL JA, 1986, P NATL ACAD SCI USA, V83, P8288, DOI 10.1073/pnas.83.21.8288; STONER GL, 1986, P NATL ACAD SCI USA, V83, P2271, DOI 10.1073/pnas.83.7.2271; TAKEMOTO KK, 1973, J VIROL, V12, P625, DOI 10.1128/JVI.12.3.625-631.1973; WALKER DL, 1978, HDB CLIN NEUROLOGY 2, V34, P207; WALKER DL, 1973, SLOW VIRUS DISEASE, P45; WILEY CA, 1988, ACTA NEUROPATHOL, V76, P338, DOI 10.1007/BF00686970	34	18	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1991	6	9					1673	1676						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1656370				2022-12-17	WOS:A1991GX27400024
J	DEMILIA, JC; MATHEYPREVOT, B; JAROS, K; WOLF, B; STEELE, G; SUMMERHAYES, IC				DEMILIA, JC; MATHEYPREVOT, B; JAROS, K; WOLF, B; STEELE, G; SUMMERHAYES, IC			PRENEOPLASTIC LESIONS INDUCED BY MYC AND SRC ONCOGENES IN A HETEROTOPIC RAT COLON	ONCOGENE			English	Article							PROTEIN-KINASE ACTIVITY; TRANSGENIC MICE; CELL-LINES; COLORECTAL CANCERS; GENE-MUTATIONS; HA-RAS; TRANSFORMATION; CARCINOMA; DEREGULATION; VIRUS	With the use of viral vectors harboring myc and src oncogenes, we have assessed the potential contribution of these different elements to colonic neoplasia using a transplantation technique resulting in the formation of a heterotopic colon in Wistar Furth rats. While myc alone induced atypia and some dysplasia, src induced focal dysplastic lesions throughout the colon mucosa with evidence of metaplasia. In contrast, lesions induced by myc and src acting cooperatively, were highly dysplastic with evidence of tumor formation after protracted periods. These results indicated the formation of histologically distinct preneoplastic lesions elicited by the action of a single oncogene in colon implants with the production of adenocarcinomas when such oncogenic elements act cooperatively. This model provides an opportunity for studies of the action of different oncogenes, acting singly or in combination, in the multi-step progression to colon tumor formation.	NEW ENGLAND DEACONESS HOSP, CANC BIOL LAB, 50 BINNEY ST, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DEPT PEDIAT ONCOL, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School					NATIONAL CANCER INSTITUTE [P01CA044704] Funding Source: NIH RePORTER; NCI NIH HHS [CA44704] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; DOTTO GP, 1988, P NATL ACAD SCI USA, V85, P6389, DOI 10.1073/pnas.85.17.6389; EDWARDS PAW, 1988, ONCOGENE, V2, P407; ERISMAN MD, 1988, ONCOGENE, V2, P367; ERISMAN MD, 1985, MOL CELL BIOL, V5, P1969, DOI 10.1128/MCB.5.8.1969; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; JOYCE AD, 1988, J UROLOGY, V140, P1067, DOI 10.1016/S0022-5347(17)41928-8; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; NEWBOLD RF, 1983, NATURE, V304, P648, DOI 10.1038/304648a0; RASSOULZADEGAN M, 1982, NATURE, V300, P713, DOI 10.1038/300713a0; ROOP DR, 1986, NATURE, V323, P822, DOI 10.1038/323822a0; ROSEN N, 1986, J BIOL CHEM, V261, P3754; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; STRICKLAND JE, 1988, CANCER RES, V48, P165; THOMPSON TC, 1989, CELL, V56, P917, DOI 10.1016/0092-8674(89)90625-9; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WAGNER HE, 1990, ONCOGENE, V5, P557	23	18	18	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1991	6	2					303	309						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ134	2000223				2022-12-17	WOS:A1991FZ13400017
J	REY, I; SCHWEIGHOFFER, F; BARLAT, I; CAMONIS, J; BOYMARCOTTE, E; GUILBAUD, R; JACQUET, M; TOCQUE, B				REY, I; SCHWEIGHOFFER, F; BARLAT, I; CAMONIS, J; BOYMARCOTTE, E; GUILBAUD, R; JACQUET, M; TOCQUE, B			THE COOH-DOMAIN OF THE PRODUCT OF THE SACCHAROMYCES-CEREVISIAE SCD25 GENE ELICITS ACTIVATION OF P21-RAS PROTEINS IN MAMMALIAN-CELLS	ONCOGENE			English	Note							CDC25 GENE; CYCLASE PATHWAY; TUMOR-PROMOTER; RAS; GAP; SUPPRESSES; MUTATION; CLONING; MUTANTS; GTPASE	The evidence presented here indicates that the domain containing the COOH-terminal part of the Saccharomyces cerevisiae SCD25 gene product (C-domain), which is homologous to the COOH-terminal part of CDC25 protein, can elicit activation of mammalian ras proteins in CHO cells. Transfection of expression vectors carrying the C-domain of SCD25, but not of CDC25, promotes the GTP-bound form of ras proteins as determined by analysis of the guanine nucleotides bound to ras proteins immunoprecipitated by Y13-259 mAb, and enhances transcription of a HIV-LTR-CAT construct. This is the first demonstration of the activation of ras proteins by transfection of a single heterologous gene.	RHONE POULENC SANTE,CRV AIBV,F-94403 VITRY,FRANCE; UNIV PARIS 11,CNRS,URA 1354,INFORMAT GENET & DEV GRP,F-91405 ORSAY,FRANCE	Sanofi-Aventis; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay								ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; ARANZANASEISDED.F, 1989, ONCOGENE, V4, P1359; BOYMARCOTTE E, 1989, GENE, V77, P21, DOI 10.1016/0378-1119(89)90355-7; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CAMONIS JH, 1988, MOL CELL BIOL, V8, P2980, DOI 10.1128/MCB.8.7.2980; CAMONIS JH, 1986, EMBO J, V5, P375, DOI 10.1002/j.1460-2075.1986.tb04222.x; CAMONIS JH, 1990, IN PRESS GENE; CRECHET JB, 1990, SCIENCE, V248, P866, DOI 10.1126/science.2188363; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GIBBS JB, 1987, J BIOL CHEM, V262, P10426; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; IMLER JL, 1988, NATURE, V332, P275, DOI 10.1038/332275a0; JACQUET M, 1989, GUANINE NUCLEOTIDE B, V165, P241; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; ROBINSON LC, 1987, SCIENCE, V235, P1218, DOI 10.1126/science.3547648; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; SCHWEIGHOFFER F, 1989, ADV 2ND MESSENGER PH, V53, P329; SODROSKI J, 1985, SCIENCE, V229, P74, DOI 10.1126/science.2990041; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WASYLYK C, 1987, CELL, V48, P525, DOI 10.1016/0092-8674(87)90203-0	23	18	19	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1991	6	2					347	349						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ134	2000228				2022-12-17	WOS:A1991FZ13400024
J	RYSECK, RP; KOVARY, K; BRAVO, R				RYSECK, RP; KOVARY, K; BRAVO, R			INTEGRITY OF FOS B-LEUCINE ZIPPER IS ESSENTIAL FOR ITS INTERACTION WITH JUN PROTEINS	ONCOGENE			English	Note											RYSECK, RP (corresponding author), SQUIBB INST MED RES,DEPT MOLEC BIOL,POB 4000,PRINCETON,NJ 08543, USA.		Kovary, Karla/E-3979-2013					ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BRAVO R, 1989, GROWTH FACTORS DIFFE; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; PAYRE F, 1988, FEBS LETT, V234, P245, DOI 10.1016/0014-5793(88)80091-7; RANSONE LJ, 1989, GENE DEV, V3, P770, DOI 10.1101/gad.3.6.770; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VOGT PK, 1989, TRENDS BIOCHEM SCI, V14, P172, DOI 10.1016/0968-0004(89)90268-5; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	19	18	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1990	5	7					1091	1093						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP415	2115643				2022-12-17	WOS:A1990DP41500023
J	KELLER, JR; RUSCETTI, SK; RUSCETTI, FW				KELLER, JR; RUSCETTI, SK; RUSCETTI, FW			INTRODUCTION OF V-ABL ONCOGENE INDUCES MONOCYTIC DIFFERENTIATION OF AN IL-3-DEPENDENT MYELOID PROGENITOR-CELL LINE	ONCOGENE			English	Article									NCI,GENET LAB,BETHESDA,MD 20892; NCI,FREDERICK CANC RES FACIL,DIV CANC TREATMENT,BIOL RESPONSE MODIFIERS PROGRAM,FREDERICK,MD 21701	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	KELLER, JR (corresponding author), NCI,FREDERICK CANC RES FACIL,BIOL CARCINOGENESIS DEV PROGRAM,FREDERICK,MD 21701, USA.		Keller, Jonathan R./O-6677-2018		OFFICE OF THE DIRECTOR, NCI [N01CO074102] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74102] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAUMBACH WR, 1986, J VIROL, V59, P276, DOI 10.1128/JVI.59.2.276-283.1986; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; CARACCIOLO D, 1989, SCIENCE, V245, P1107, DOI 10.1126/science.2672339; CHAMPLIN RE, 1985, BLOOD, V65, P1039; CONSCIENCE JF, 1986, EMBO J, V5, P317, DOI 10.1002/j.1460-2075.1986.tb04215.x; COOK WD, 1985, CELL, V41, P677, DOI 10.1016/S0092-8674(85)80048-9; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; GONDA TJ, 1985, EMBO J, V4, P2003, DOI 10.1002/j.1460-2075.1985.tb03884.x; GREENBERGER JS, 1983, FED PROC, V42, P2762; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; HOLMES KL, 1986, J EXP MED, V164, P443, DOI 10.1084/jem.164.2.443; IHLE JN, 1984, CURR TOP MICROBIOL I, V113, P85; METCALF D, 1984, HEMOPOIETIC COLONIES; NOWELL PC, 1960, SCIENCE, V132, P1497; OLIFF A, 1985, P NATL ACAD SCI USA, V81, P5464; PIERCE JH, 1985, CELL, V41, P685, DOI 10.1016/S0092-8674(85)80049-0; PIERCE JH, 1984, P NATL ACAD SCI-BIOL, V81, P2374, DOI 10.1073/pnas.81.8.2374; RAPP UR, 1985, NATURE, V317, P434, DOI 10.1038/317434a0; RIGBY PN, 1977, J MOL BIOL, V113, P236; ROVERA G, 1987, ONCOGENE, V1, P29; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; WANECK GL, 1986, CELL, V44, P337, DOI 10.1016/0092-8674(86)90768-3; WANG JYJ, 1983, MOL CELL BIOL, V3, P773, DOI 10.1128/MCB.3.5.773; WEINSTEIN Y, 1986, P NATL ACAD SCI USA, V83, P5010, DOI 10.1073/pnas.83.14.5010; WHITLOCK CA, 1983, CELL, V32, P903, DOI 10.1016/0092-8674(83)90075-2; WITTE ON, 1978, P NATL ACAD SCI USA, V75, P2488, DOI 10.1073/pnas.75.5.2488; WOLGEMUTH DJ, 1985, MOL CELL BIOL, V5, P1791; WONG PMC, 1987, EXP HEMATOL, V15, P280	31	18	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1990	5	4					549	555						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DB853	2158039				2022-12-17	WOS:A1990DB85300014
J	ASKER, C; STEINITZ, M; ANDERSSON, K; SUMEGI, J; KLEIN, G; INGVARSSON, S				ASKER, C; STEINITZ, M; ANDERSSON, K; SUMEGI, J; KLEIN, G; INGVARSSON, S			NUCLEOTIDE-SEQUENCE OF THE RAT BMYC GENE	ONCOGENE			English	Note									KAROLINSKA INST,DEPT TUMOR BIOL,S-10401 STOCKHOLM 60,SWEDEN	Karolinska Institutet			Ingvarsson, Sigurdur/E-7448-2011	Ingvarsson, Sigurdur/0000-0003-4125-1714	NCI NIH HHS [3R01CA14054] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA014054] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BIRRER MJ, 1988, MOL CELL BIOL, V8, P2668, DOI 10.1128/MCB.8.6.2668; BLANCHARD JM, 1985, NATURE, V317, P443, DOI 10.1038/317443a0; BONNIEU A, 1988, ONCOGENE RES, V3, P155; BROOKS BJ, 1987, ADV VIRAL ONCOL, V7, P155; CAVALIERI F, 1988, ONCOGENE, V2, P289; CLASSON M, 1987, NATURE, V330, P272, DOI 10.1038/330272a0; DANG CV, 1988, MOL CELL BIOL, V8, P4048, DOI 10.1128/MCB.8.10.4048; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; DEGREVE J, 1988, MOL CELL BIOL, V8, P4381, DOI 10.1128/MCB.8.10.4381; DEPINHO RA, 1986, P NATL ACAD SCI USA, V83, P1827, DOI 10.1073/pnas.83.6.1827; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EVAN GI, 1989, IN PRESS MOL CELL BI, V9; FIGGE J, 1988, J VIROL, V62, P1814, DOI 10.1128/JVI.62.5.1814-1818.1988; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; HALLEWELL RA, 1980, GENE, V9, P27, DOI 10.1016/0378-1119(80)90165-1; HATHAWAY GM, 1982, CURR TOP CELL REGUL, V21, P101; HAYASHI K, 1987, NUCLEIC ACIDS RES, V15, P6419, DOI 10.1093/nar/15.16.6419; HENRIKSSON M, 1988, ONCOGENE, V3, P587; HOPPE J, 1981, EUR J BIOCHEM, V17, P585; IGUCHIARIGA SMM, 1987, EMBO J, V6, P2365, DOI 10.1002/j.1460-2075.1987.tb02513.x; IGUCHIARIGA SMM, 1988, EMBO J, V7, P3135, DOI 10.1002/j.1460-2075.1988.tb03180.x; IKEGAKI N, 1989, EMBO J, V8, P1793, DOI 10.1002/j.1460-2075.1989.tb03573.x; INGVARSSON S, 1988, ONCOGENE, V3, P679; INGVARSSON S, 1988, MOL CELL BIOL, V8, P3168, DOI 10.1128/MCB.8.8.3168; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; KAYE F, 1988, MOL CELL BIOL, V8, P186, DOI 10.1128/MCB.8.1.186; KINGSTON RE, 1984, NATURE, V312, P280, DOI 10.1038/312280a0; LEGOUY E, 1987, EMBO J, V6, P3359, DOI 10.1002/j.1460-2075.1987.tb02657.x; NORRANDER J, 1983, GENE, V26, P101, DOI 10.1016/0378-1119(83)90040-9; ONCLERCQ R, 1988, J VIROL, V62, P4533, DOI 10.1128/JVI.62.12.4533-4537.1988; PRENDERGAST GC, 1989, MOL CELL BIOL, V9, P124, DOI 10.1128/MCB.9.1.124; RAMSAY G, 1986, MOL CELL BIOL, V6, P4450, DOI 10.1128/MCB.6.12.4450; RECHSTEINER M, 1987, TRENDS BIOCHEM SCI, V12, P390; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARID J, 1987, P NATL ACAD SCI USA, V84, P170, DOI 10.1073/pnas.84.1.170; SCHMID P, 1989, SCIENCE, V243, P226, DOI 10.1126/science.2911736; SEJERSEN T, 1987, EXP CELL RES, V172, P304, DOI 10.1016/0014-4827(87)90389-2; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SMALL D, 1977, BIOCHEM BIOPH RES CO, V79, P341, DOI 10.1016/0006-291X(77)90101-2; STADEN R, 1980, NUCLEIC ACIDS RES, V8, P3673, DOI 10.1093/nar/8.16.3673; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANLOHUIZEN M, 1989, EMBO J, V8, P133, DOI 10.1002/j.1460-2075.1989.tb03357.x; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; YANCOPOULOS GD, 1985, P NATL ACAD SCI USA, V82, P5455, DOI 10.1073/pnas.82.16.5455; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	47	18	20	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1989	4	12					1523	1527						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB659	2687773				2022-12-17	WOS:A1989CB65900017
J	ARENZANASEISDEDOS, F; ISRAEL, N; BACHELERIE, F; HAZAN, U; ALCAMI, J; DAUTRY, F; VIRELIZIER, JL				ARENZANASEISDEDOS, F; ISRAEL, N; BACHELERIE, F; HAZAN, U; ALCAMI, J; DAUTRY, F; VIRELIZIER, JL			C-HA-RAS TRANSFECTION INDUCES HUMAN IMMUNODEFICIENCY VIRUS (HIV) TRANSCRIPTION THROUGH THE HIV-ENHANCER IN HUMAN-FIBROBLASTS AND ASTROCYTES	ONCOGENE			English	Article									INST PASTEUR,IMMUNOL VIRALE LAB,F-75724 PARIS 15,FRANCE; INST GUSTAVE ROUSSY,ONCOL MOLEC LAB,F-94805 VILLEJUIF,FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UNICANCER; Gustave Roussy			BACHELERIE, FRANCOISE/F-8823-2013; Arenzana-Seisdedos, Fernando/E-5835-2016; Alcami, Pepe/T-2242-2018	BACHELERIE, FRANCOISE/0000-0002-0399-3277; Alcami, Pepe/0000-0003-0023-7377				ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; CHANG EH, 1982, P NATL ACAD SCI-BIOL, V79, P4848, DOI 10.1073/pnas.79.16.4848; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; FOLKS TM, 1989, P NATL ACAD SCI USA, V86, P2365, DOI 10.1073/pnas.86.7.2365; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; FRANZA BR, 1987, NATURE, V330, P391, DOI 10.1038/330391a0; HARADA S, 1986, VIROLOGY, V154, P249, DOI 10.1016/0042-6822(86)90451-4; IMLER JL, 1988, NATURE, V332, P275, DOI 10.1038/332275a0; KAUFMAN JD, 1987, MOL CELL BIOL, V7, P3759, DOI 10.1128/MCB.7.10.3759; LANGLADEDEMOYEN P, 1988, J IMMUNOL, V141, P1949; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MORRIS JDH, 1989, ONCOGENE, V4, P27; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; REED JC, 1986, P NATL ACAD SCI USA, V83, P3982, DOI 10.1073/pnas.83.11.3982; ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; STACEY DW, 1987, MOL CELL BIOL, V7, P523, DOI 10.1128/MCB.7.1.523; TONGSTARKSEN SE, 1987, P NATL ACAD SCI USA, V84, P6845, DOI 10.1073/pnas.84.19.6845; TONGSTARKSEN SE, 1989, J IMMUNOL, V142, P702; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4	29	18	18	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1989	4	11					1359	1362						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AX659	2682462				2022-12-17	WOS:A1989AX65900013
J	MAHADEVAN, LC; TARGETT, K; HEATH, JK				MAHADEVAN, LC; TARGETT, K; HEATH, JK			2-AMINOPURINE ABOLISHES EPIDERMAL GROWTH FACTOR-STIMULATED PHOSPHORYLATION OF COMPLEXED AND CHROMATIN-ASSOCIATED FORMS OF A 33KDA PHOSPHOPROTEIN	ONCOGENE			English	Article											MAHADEVAN, LC (corresponding author), UNIV OXFORD,DEPT BIOCHEM,OXFORD OX1 3QU,ENGLAND.							BERRIDGE MJ, 1986, ONCOGENES GROWTH CON, P147; BRAVO R, 1987, CELL, V48, P251, DOI 10.1016/0092-8674(87)90428-4; BRAVO R, 1986, ONCOGENES GROWTH CON, P253; CHAN YL, 1988, J BIOL CHEM, V263, P2891; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COUGHLIN SR, 1985, CELL, V43, P243, DOI 10.1016/0092-8674(85)90029-7; DOWNES CP, 1985, MOL ASPECTS CELLULAR, V4, P3; FARRELL PJ, 1977, CELL, V11, P187, DOI 10.1016/0092-8674(77)90330-0; GARRELS JI, 1983, METHOD ENZYMOL, V100, P411; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HERRLICH P, 1987, ENERGETICS CELL; HUNTER T, 1986, ONCOGENES GROWTH CON, P138; KAIBUCHI K, 1986, J BIOL CHEM, V261, P1187; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; MAHADEVAN LC, 1988, ONCOGENE, V2, P249; MAHADEVAN LC, 1989, RECEPTOR PRACTICAL A; MARTINPEREZ J, 1983, P NATL ACAD SCI-BIOL, V80, P926, DOI 10.1073/pnas.80.4.926; MOOLENAAR WH, 1986, ONCOGENES GROWTH CON, P160; NILSENHAMILTON M, 1981, ANAL BIOCHEM, V115, P438, DOI 10.1016/0003-2697(81)90030-0; NILSENHAMILTON M, 1979, NATURE, V279, P444, DOI 10.1038/279444a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OLIVIER AR, 1988, P NATL ACAD SCI USA, V85, P4720, DOI 10.1073/pnas.85.13.4720; PARKER PJ, 1986, ONCOGENES GROWTH CON, P154; PEPINSKY RB, 1986, NATURE, V321, P81, DOI 10.1038/321081a0; POUYSSEGUR J, 1985, CANCER CELL, V3, P409; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; RAMJOUE HPR, 1977, J BIOL CHEM, V252, P9065; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SAVAGE CR, 1972, J BIOL CHEM, V247, P7609; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SHIBANUMA M, 1987, EUR J BIOCHEM, V164, P15, DOI 10.1111/j.1432-1033.1987.tb10985.x; THOMAS G, 1980, CELL, V19, P1015, DOI 10.1016/0092-8674(80)90092-6; THOMAS G, 1979, P NATL ACAD SCI USA, V76, P3952, DOI 10.1073/pnas.76.8.3952; WETTENHALL REH, 1988, BIOCHEMISTRY-US, V27, P170, DOI 10.1021/bi00401a026; ZINN K, 1988, SCIENCE, V240, P210, DOI 10.1126/science.3281258	40	18	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1989	4	6					699	706						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA660	2786618				2022-12-17	WOS:A1989AA66000005
J	ROMERO, P; BERAN, M; SHTALRID, M; ANDERSSON, B; TALPAZ, M; BLICK, M				ROMERO, P; BERAN, M; SHTALRID, M; ANDERSSON, B; TALPAZ, M; BLICK, M			ALTERNATIVE 5' END OF THE BCR-ABL TRANSCRIPT IN CHRONIC MYELOGENOUS LEUKEMIA	ONCOGENE			English	Article									UNIV TEXAS,MD ANDERSON HOSP & TUMOR INST,CTR CANC,DEPT CLIN IMMUNOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON HOSP & TUMOR INST,CTR CANC,DEPT BIOL THERAPY,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON HOSP & TUMOR INST,CTR CANC,DEPT HEMATOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center				Talpaz, Moshe/0000-0003-3361-3981				ARRUSHDI A, 1988, ONCOGENE, V2, P353; BERSTEIN R, 1988, SEMIN HEMATOL, V25, P20; BLICK M, 1987, CANCER GENET CYTOGEN, V27, P349, DOI 10.1016/0165-4608(87)90018-5; BLICK MB, 1986, LEUKEMIA RES, V10, P1401, DOI 10.1016/0145-2126(86)90006-8; CATOVSKY D, 1979, AM J CLIN PATHOL, V72, P736; CHAMPLIN RE, 1985, BLOOD, V65, P1039; CHAN LC, 1987, NATURE, V325, P635, DOI 10.1038/325635a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARK SS, 1987, SCIENCE, V235, P85, DOI 10.1126/science.3541203; CLARK SS, 1988, SCIENCE, V239, P775, DOI 10.1126/science.3422516; COLLINS S, 1987, MOL CELL BIOL, V7, P2870, DOI 10.1128/MCB.7.8.2870; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; DREAZEN O, 1988, SEMIN HEMATOL, V25, P35; FAINSTEIN E, 1987, NATURE, V330, P386, DOI 10.1038/330386a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; GROSVELD G, 1986, MOL CELL BIOL, V6, P607, DOI 10.1128/MCB.6.2.607; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HARIHARAN IK, 1987, EMBO J, V6, P115, DOI 10.1002/j.1460-2075.1987.tb04727.x; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; HERMANS A, 1987, CELL, V51, P33, DOI 10.1016/0092-8674(87)90007-9; KLOETZER W, 1985, VIROLOGY, V140, P230, DOI 10.1016/0042-6822(85)90361-7; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KURZROCK R, 1987, BLOOD, V70, P233; KURZROCK R, 1987, NATURE, V325, P631, DOI 10.1038/325631a0; LIFSHITZ B, 1988, ONCOGENE, V2, P113; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MAXWELL SA, 1987, CANCER RES, V47, P1731; MESMASSON AM, 1986, P NATL ACAD SCI USA, V83, P9768, DOI 10.1073/pnas.83.24.9768; MESSING J, 1983, METHOD ENZYMOL, V101, P20; NOWELL PC, 1960, SCIENCE, V132, P1497; PRYWES R, 1983, CELL, V34, P569, DOI 10.1016/0092-8674(83)90389-6; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; RUBIN CM, 1988, P NATL ACAD SCI USA, V85, P2795, DOI 10.1073/pnas.85.8.2795; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; SHTIVELMAN E, 1987, BLOOD, V69, P971; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; 1978, BRIT J HAEMATOL, V39, P311	40	18	19	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1989	4	1					93	98						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5674	2915904				2022-12-17	WOS:A1989U567400014
J	LAZARUS, P; PARKIN, N; SONENBERG, N				LAZARUS, P; PARKIN, N; SONENBERG, N			DEVELOPMENTAL REGULATION OF TRANSLATION BY THE 5' NONCODING REGION OF MURINE C-MYC MESSENGER-RNA IN XENOPUS-LAEVIS	ONCOGENE			English	Article									MCGILL UNIV,DEPT BIOCHEM,3655 DRUMMOND ST,MONTREAL H3G 1Y6,QUEBEC,CANADA; MCGILL UNIV,CTR CANC,MONTREAL H3G 1Y6,QUEBEC,CANADA	McGill University; McGill University			Parkin, Neil/P-2724-2019					BAIM SB, 1985, MOL CELL BIOL, V5, P1839, DOI 10.1128/MCB.5.8.1839; BASS BL, 1987, CELL, V48, P607, DOI 10.1016/0092-8674(87)90239-X; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; Colman A., 1984, TRANSCRIPTION TRANSL, P49; CORCORAN LM, 1985, CELL, V40, P71, DOI 10.1016/0092-8674(85)90310-1; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; DARVEAU A, 1985, P NATL ACAD SCI USA, V82, P2315, DOI 10.1073/pnas.82.8.2315; EISENMAN RN, 1985, MOL CELL BIOL, V5, P114, DOI 10.1128/MCB.5.1.114; GODEAU F, 1986, EMBO J, V5, P3571, DOI 10.1002/j.1460-2075.1986.tb04684.x; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KING MW, 1986, MOL CELL BIOL, V6, P4499, DOI 10.1128/MCB.6.12.4499; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LEDER P, 1983, SCIENCE, V222, P765, DOI 10.1126/science.6356357; Maxam A.M., 1980, METHODS ENZYMOL, V65, P449; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MUESING MA, 1987, CELL, V48, P691, DOI 10.1016/0092-8674(87)90247-9; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; PARKIN N, 1988, MOL CELL BIOL, V8, P2875, DOI 10.1128/MCB.8.7.2875; PARKIN NT, 1988, EMBO J, V7, P2831, DOI 10.1002/j.1460-2075.1988.tb03139.x; PELLETIER J, 1985, CELL, V40, P515, DOI 10.1016/0092-8674(85)90200-4; PELLETIER J, 1988, J VIROL, V62, P2219, DOI 10.1128/JVI.62.7.2219-2227.1988; PERSSON H, 1984, SCIENCE, V225, P718, DOI 10.1126/science.6463648; RAMSAY G, 1984, P NATL ACAD SCI-BIOL, V81, P7742, DOI 10.1073/pnas.81.24.7742; REBAGLIATI MR, 1987, CELL, V48, P599, DOI 10.1016/0092-8674(87)90238-8; RICHTER JD, 1982, DEV BIOL, V89, P152; RIVERA VM, 1988, IN PRESS VIROLOGY; ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3; TAYLOR MV, 1986, EMBO J, V5, P3563, DOI 10.1002/j.1460-2075.1986.tb04683.x; WAGNER RW, 1988, MOL CELL BIOL, V8, P770, DOI 10.1128/MCB.8.2.770; WASSERMAN WJ, 1986, GAMETOGENESIS EARLY, P111; WATT R, 1983, NATURE, V303, P725, DOI 10.1038/303725a0; WATT RA, 1985, MOL CELL BIOL, V5, P448, DOI 10.1128/MCB.5.3.448; ZOLLER MJ, 1982, NUCLEIC ACIDS RES, V10, P6487, DOI 10.1093/nar/10.20.6487	38	18	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1988	3	5					517	521						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	R5163	3078957				2022-12-17	WOS:A1988R516300005
J	KING, HWS; TEMPEST, PR; MERRIFIELD, KR; RANCE, AJ				KING, HWS; TEMPEST, PR; MERRIFIELD, KR; RANCE, AJ			TPR HOMOLOGS ACTIVATE MET AND RAF	ONCOGENE			English	Article									UNIV ABERDEEN,SCOTGEN LTD,DEPT GENET,ABERDEEN AB9 2TN,SCOTLAND	University of Aberdeen	KING, HWS (corresponding author), INST CANC RES,CHESTER BEATTY LABS,FULHAM RD,LONDON SW3 6JB,ENGLAND.							BISHOP M, 1984, NUCLEIC ACIDS RES, V12, P5471, DOI 10.1093/nar/12.13.5471; Chan A. H. Y., UNPUB; CHAN AML, 1987, ONCOGENE, V1, P229; COOPER CS, 1984, CANCER RES, V44, P1; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; DEAN M, 1987, MOL CELL BIOL, V7, P921, DOI 10.1128/MCB.7.2.921; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HARRINGTON WF, 1984, ANNU REV BIOCHEM, V53, P35, DOI 10.1146/annurev.bi.53.070184.000343; ISHIKAWA F, 1985, BIOCHEM BIOPH RES CO, V132, P186, DOI 10.1016/0006-291X(85)91005-8; ISHIKAWA F, 1986, P NATL ACAD SCI USA, V83, P3209, DOI 10.1073/pnas.83.10.3209; ISHIKAWA F, 1987, MOL CELL BIOL, V7, P1226, DOI 10.1128/MCB.7.3.1226; KIENY MP, 1983, GENE, V26, P91, DOI 10.1016/0378-1119(83)90039-2; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; NAHARRO G, 1984, SCIENCE, V223, P63, DOI 10.1126/science.6318314; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI M, 1987, P NATL ACAD SCI USA, V84, P935, DOI 10.1073/pnas.84.4.935; TEMPEST PR, 1986, CARCINOGENESIS, V7, P2051, DOI 10.1093/carcin/7.12.2051; TEMPEST PR, 1986, FEBS LETT, V209, P357, DOI 10.1016/0014-5793(86)81142-5	21	18	19	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1988	2	6					617	619						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	N8415	3387099				2022-12-17	WOS:A1988N841500014
J	Chen, XY; Xu, RS; He, D; Zhang, Y; Chen, HT; Zhu, YX; Cheng, YX; Liu, R; Zhu, RR; Gong, L; Xiao, MQ; Wang, ZW; Deng, LP; Cao, K				Chen, Xingyu; Xu, Runshi; He, Dong; Zhang, Yao; Chen, Haotian; Zhu, Yuxing; Cheng, YaXin; Liu, Rui; Zhu, Rongrong; Gong, Lian; Xiao, Mengqing; Wang, Zhanwang; Deng, Liping; Cao, Ke			CD8(+) T effector and immune checkpoint signatures predict prognosis and responsiveness to immunotherapy in bladder cancer	ONCOGENE			English	Article							MORTALITY; CXCL13	Immune-checkpoint blockade (ICB) has been routinely implemented to treat bladder cancer; however, most patients have little or no clinical benefit. In this study, 348 pretreated metastatic urothelial cancer samples from the IMvigor210 cohort were used to identify important genes significantly associated with CD8+ T effector and immune checkpoint signatures. The immune checkpoint inhibitor score (IMS) scoring system was constructed to predict the immunotherapy responsiveness. Transcriptome analysis confirmed that the high IMS score group had significant immune activation with better prognosis and higher immunotherapy responsiveness, which was a powerful biomarker for predicting the prognosis and responsiveness of ICB. Tumor immune dysfunction and exclusion (TIDE) scores were calculated using 2031 external bladder cancer samples for further validation. We selected the important Hub genes as potential therapeutic targets, and validated the genes using genomic, transcriptomic, immunomic, and other multi-omics methods. In addition, we construct a risk prediction model which could stratify patients with bladder cancer and predict patient prognosis and ICB treatment responsiveness. In conclusion, this study identified effective biomarkers for the prediction of immune checkpoint inhibitor treatment responsiveness in bladder cancer patients and provided new immunotherapeutic targets.	[Chen, Xingyu; Zhang, Yao; Chen, Haotian; Zhu, Yuxing; Cheng, YaXin; Liu, Rui; Zhu, Rongrong; Gong, Lian; Xiao, Mengqing; Wang, Zhanwang; Deng, Liping; Cao, Ke] Cent South Univ, Xiangya Hosp 3, Dept Oncol, 283 Tongzipo Rd, Changsha 410013, Peoples R China; [Xu, Runshi] Hunan Univ Chinese Med, Med Sch, 300 Xueshi Rd,Hanpu Kejiao Pk, Changsha 410208, Peoples R China; [He, Dong] Hunan Univ Chinese Med, Peoples Hosp Hunan Prov 2, Dept Resp, Changsha 410000, Peoples R China	Central South University; Hunan University of Chinese Medicine; Hunan University of Chinese Medicine	Cao, K (corresponding author), Cent South Univ, Xiangya Hosp 3, Dept Oncol, 283 Tongzipo Rd, Changsha 410013, Peoples R China.	csucaoke@163.com	Xu, Runshi/AEI-9782-2022		National Natural Science Foundation of China [81874137]; science and technology innovation Program of Hunan Province [2020RC4011]; Outstanding Youth Foundation of Hunan Province [2018JJ1047]; Hunan Province Science and Technology Talent Promotion Project [2019TJ-Q10]; Young Scholars of "Furong Scholar Program" in Hunan Province [206030106]; Wisdom Accumulation and Talent Cultivation Project of the Third Xiangya Hospital of Central South University [BJ202001]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); science and technology innovation Program of Hunan Province; Outstanding Youth Foundation of Hunan Province; Hunan Province Science and Technology Talent Promotion Project; Young Scholars of "Furong Scholar Program" in Hunan Province; Wisdom Accumulation and Talent Cultivation Project of the Third Xiangya Hospital of Central South University	We would like to thank the TCGA, GEO, and TIMER databases for the availability of the data. We would like to thank TissueGnostics Aisa Pacific limited for their technical support, And the help of hongzhe Sun and Xiaojing Liu, the technical engineer. This work was supported by the National Natural Science Foundation of China (81874137), the science and technology innovation Program of Hunan Province (2020RC4011), the Outstanding Youth Foundation of Hunan Province (2018JJ1047), the Hunan Province Science and Technology Talent Promotion Project (2019TJ-Q10), Young Scholars of "Furong Scholar Program" in Hunan Province(206030106), and the Wisdom Accumulation and Talent Cultivation Project of the Third Xiangya Hospital of Central South University (BJ202001).	Ai LY, 2020, ADV EXP MED BIOL, V1248, P33, DOI 10.1007/978-981-15-3266-5_3; Ammirante M, 2014, P NATL ACAD SCI USA, V111, P14776, DOI 10.1073/pnas.1416498111; Ansell SM, 2015, NEW ENGL J MED, V372, P311, DOI 10.1056/NEJMoa1411087; Antoni S, 2017, EUR UROL, V71, P96, DOI 10.1016/j.eururo.2016.06.010; Biswas S, 2014, BREAST CANCER RES TR, V143, P265, DOI 10.1007/s10549-013-2811-8; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chen LP, 2015, J CLIN INVEST, V125, P3384, DOI 10.1172/JCI80011; Chen XY, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.672158; Choucair K, 2020, CANCER GENE THER, V27, P841, DOI 10.1038/s41417-020-0174-y; Darvin P, 2018, EXP MOL MED, V50, DOI 10.1038/s12276-018-0191-1; Das M, 2017, IMMUNOL REV, V276, P97, DOI 10.1111/imr.12520; Diskin B, 2020, NAT IMMUNOL, V21, P442, DOI 10.1038/s41590-020-0620-x; Garon EB, 2015, NEW ENGL J MED, V372, P2018, DOI 10.1056/NEJMoa1501824; Groeneveld CS, 2021, EUR J CANCER, V148, P181, DOI 10.1016/j.ejca.2021.01.036; Hasan S, 2020, ANN SURG, V271, P716, DOI 10.1097/SLA.0000000000003051; Hu J, 2021, THERANOSTICS, V11, P3089, DOI 10.7150/thno.53649; Jiang P, 2018, NAT MED, V24, P1550, DOI 10.1038/s41591-018-0136-1; Jimenez-Sanchez A, 2020, NAT GENET, V52, P582, DOI 10.1038/s41588-020-0630-5; Joseph A, 2020, ANN INTENSIVE CARE, V10, DOI 10.1186/s13613-020-00761-w; Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559; Lees JR, 2020, CELL IMMUNOL, V357, DOI 10.1016/j.cellimm.2020.104212; Lino AC, 2018, IMMUNITY, V49, P120, DOI 10.1016/j.immuni.2018.06.007; Marin-Acevedo JA, 2019, MAYO CLIN PROC, V94, P1321, DOI 10.1016/j.mayocp.2019.03.012; Middha S, 2019, JCO PRECIS ONCOL, V3, DOI 10.1200/PO.18.00321; Powles T, 2014, NATURE, V515, P558, DOI 10.1038/nature13904; Prokunina L, 2002, NAT GENET, V32, P666, DOI 10.1038/ng1020; Robert C, 2019, LANCET ONCOL, V20, P1239, DOI 10.1016/S1470-2045(19)30388-2; Roh W, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aah3560; Saginala Kalyan, 2020, Med Sci (Basel), V8, DOI 10.3390/medsci8010015; Sell V, 2020, WORLD J UROL, V38, P1001, DOI 10.1007/s00345-019-02841-4; Spangler JB, 2015, ANNU REV IMMUNOL, V33, P139, DOI 10.1146/annurev-immunol-032713-120211; Sunshine J, 2015, CURR OPIN PHARMACOL, V23, P32, DOI 10.1016/j.coph.2015.05.011	33	17	17	10	29	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	2021	40	43					6223	6234		10.1038/s41388-021-02019-6	http://dx.doi.org/10.1038/s41388-021-02019-6		SEP 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WO5HW	34552192				2022-12-17	WOS:000698327300001
J	Li, DD; She, JJ; Hu, XH; Zhang, MX; Sun, RN; Qin, SS				Li, Dandan; She, Jiajun; Hu, Xinhui; Zhang, Meixin; Sun, Ruonan; Qin, Shanshan			The ELF3-regulated lncRNA UBE2CP3 is over-stabilized by RNA-RNA interactions and drives gastric cancer metastasis via miR-138-5p/ITGA2 axis	ONCOGENE			English	Article							CROSSTALK; CELLS	LncRNAs play essential roles in tumorigenesis and tumor progression. Pseudogene UBE2CP3 is an antisense intronic lncRNA. However, the biological function of UBE2CP3 in gastric cancer (GC) remains unknown. In this study, we revealed that lncRNA UBE2CP3 was aberrantly upregulated in multiple independent gastric cancer cohorts, and its overexpression was clinically associated with poor prognosis in GC. UBE2CP3 was mainly located in cytoplasm and promoted migratory and invasive capacities of GC cells in vitro and in vivo. Mechanismly, a novel dysregulated ceRNA network UB2CP3/miR-138-5p/ITGA2 was identified in GC by transcriptome sequencing. Furthermore, rescue assay further confirmed that UBE2CP3 mainly promoted GC progression through miR-138-5p/ITGA2 axis. More importantly, our data proved that UBE2CP3/IGFBP7 could form an RNA duplex, thereby directly interacting with the ILF3 protein. In turn, this RNA-RNA interaction between IGFBP7 mRNA and UBE2CP3 mediated by ILF3 protein plays an essential role in protecting the mRNA stability of UBE2CP3. In addition, transcription factor ELF3 was identified to be a direct repressor of lncRNA UBE2CP3 in GC. Taken together, overexpression of UBE2CP3 promotes tumor progression via cascade amplification of ITGA2 upregulation in GC. Our finding has revealed that the dysregulation of UBE2CP3 is probably due to the downregulation of ELF3 and/or the overexpression of IGFBP7 mRNA in GC. Our findings reveal, for the first time, that UBE2CP3 plays crucial a role in GC progression by modulating miR-138-5p/ITGA2 axis, suggesting that UBE2CP3 may serve as a potential therapeutic target in GC.	[Li, Dandan; Qin, Shanshan] Hubei Univ Med, Sch Basic Med Sci, Hubei Key Lab Embryon Stem Cell Res, Shiyan, Hubei, Peoples R China; [Li, Dandan; She, Jiajun; Hu, Xinhui; Zhang, Meixin; Sun, Ruonan; Qin, Shanshan] Hubei Univ Med, Acad Biomed Res, Lab Tumor Biol, Shiyan, Hubei, Peoples R China	Hubei University of Medicine; Hubei University of Medicine	Qin, SS (corresponding author), Hubei Univ Med, Sch Basic Med Sci, Hubei Key Lab Embryon Stem Cell Res, Shiyan, Hubei, Peoples R China.; Qin, SS (corresponding author), Hubei Univ Med, Acad Biomed Res, Lab Tumor Biol, Shiyan, Hubei, Peoples R China.	qinss77@163.com	Qin, Shanshan/HGU-6157-2022	Qin, Shanshan/0000-0002-8527-5278; Li, Dandan/0000-0002-6224-8867	National Natural Science Foundation of China [81802375]; Hubei University of Medicine [2016QDJZR07, 2017QDJZR05]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Hubei University of Medicine	This study was supported by grants from the National Natural Science Foundation of China (grant no. 81802375); the Faculty Development Grants from Hubei University of Medicine (grant nos. 2016QDJZR07 and 2017QDJZR05).	Bala P, 2021, ONCOGENE, V40, P863, DOI 10.1038/s41388-020-01537-z; Canel M, 2013, J CELL SCI, V126, P393, DOI 10.1242/jcs.100115; Chan JJ, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19051310; Chuang YC, 2018, BIOL PROCED ONLINE, V10, DOI 10.1186/s12575-018-0073-x; Dong JQ, 2017, CLIN CANCER RES, V23, P3461, DOI 10.1158/1078-0432.CCR-16-2180; Gaballa R, 2020, CANCERS, V12, DOI 10.3390/cancers12082300; Hayashi H, 2015, ONCOGENE, V34, P199, DOI 10.1038/onc.2013.547; He D, 2021, ONCOGENE, V40, P355, DOI 10.1038/s41388-020-01528-0; Huang L, 2020, CLIN TRANSL MED, V10, DOI 10.1002/ctm2.203; Karreth FA, 2013, CANCER DISCOV, V3, P1113, DOI 10.1158/2159-8290.CD-13-0202; Li DD, 2020, MOL THER-NUCL ACIDS, V19, P109, DOI 10.1016/j.omtn.2019.11.003; Li DD, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00220; Liu Q, 2016, MOL THER, V24, P1726, DOI 10.1038/mt.2016.151; Liu XS, 2016, TUMOR BIOL, V37, P7951, DOI 10.1007/s13277-015-4696-0; Lou WY, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00085; Lv Y, 2021, ONCOGENE, V40, P3826, DOI 10.1038/s41388-021-01812-7; Ma HW, 2017, ONCOTARGET, V8, P52211, DOI 10.18632/oncotarget.11075; Pandolfi P, 2012, EUR J CANCER, V48, pS16, DOI 10.1016/S0959-8049(12)70773-6; Pang L, 2017, ONCOL REP, V38, P1295, DOI 10.3892/or.2017.5745; Ren DY, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1496-1; Salemi Z, 2021, J CELL PHYSIOL, V236, P4954, DOI 10.1002/jcp.30202; Shi XF, 2013, CANCER LETT, V339, P159, DOI 10.1016/j.canlet.2013.06.013; Tay Y, 2014, NATURE, V505, P344, DOI 10.1038/nature12986; Wang JJ, 2021, FEBS OPEN BIO, V11, P1814, DOI 10.1002/2211-5463.13125; Wang Q, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00308; Wang X., 2021, CLIN TRANSL MED, V11; Wu LF, 2021, CLIN TRANSL MED, V11, DOI 10.1002/ctm2.325; Xu YC, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0684-8; Yan LT, 2021, CLIN TRANSL MED, V11, DOI 10.1002/ctm2.255; Yang Y, 2020, CLIN TRANSL MED, V10, DOI 10.1002/ctm2.155; Yeh M, 2019, AM J CANCER RES, V9, P1118; Zhang W, 2020, CANCER MANAG RES, V12, P8137, DOI 10.2147/CMAR.S253777; Zhao SL, 2021, ONCOGENE, V40, P4709, DOI 10.1038/s41388-021-01859-6; Zheng J, 2019, ONCOGENE, V38, P7073, DOI 10.1038/s41388-019-0934-z	34	17	17	2	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	2021	40	35					5403	5415		10.1038/s41388-021-01948-6	http://dx.doi.org/10.1038/s41388-021-01948-6		JUL 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UO0SJ	34274947	hybrid, Green Published			2022-12-17	WOS:000673748200002
J	Pal, A; Barrett, TF; Paolini, R; Parikh, A; Puram, SV				Pal, Ananya; Barrett, Thomas F.; Paolini, Rachel; Parikh, Anuraag; Puram, Sidharth V.			Partial EMT in head and neck cancer biology: a spectrum instead of a switch	ONCOGENE			English	Review							EPITHELIAL-MESENCHYMAL TRANSITION; CIRCULATING TUMOR-CELLS; E-CADHERIN; EXTRACAPSULAR SPREAD; MALIGNANT BEHAVIOR; CARCINOMA; EXPRESSION; PLASTICITY; PATHWAY; TRANSCRIPTION	Our understanding of epithelial-to-mesenchymal transition (EMT) has slowly evolved from a simple two state, binary model to a multi-step, dynamic continuum of epithelial-to-mesenchymal plasticity, with metastable intermediate transition states that may drive cancer metastasis. Head and neck cancer is no exception, and in this review, we use head and neck as a case study for how partial-EMT (p-EMT) cell states may play an important role in cancer progression. In particular, we summarize recent in vitro and in vivo studies that uncover these intermediate transition states, which exhibit both epithelial and mesenchymal properties and appear to have distinct advantages in migration, survival in the bloodstream, and seeding and propagation within secondary metastatic sites. We then summarize the common and distinct regulators of p-EMT as well as methodologies for identifying this unique cellular subpopulation, with a specific emphasis on the role of cutting-edge technologies, such as single cell approaches. Finally, we propose strategies to target p-EMT cells, highlighting potential opportunities for therapeutic intervention to specifically target the process of metastasis. Thus, although significant challenges remain, including numerous gaps in current knowledge, a deeper understanding of EMT plasticity and a genuine identification of EMT as spectrum rather than a switch will be critical for improving patient diagnosis and treatment across oncology.	[Pal, Ananya; Barrett, Thomas F.; Paolini, Rachel; Puram, Sidharth V.] Washington Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, St Louis, MO 63110 USA; [Parikh, Anuraag] Columbia Univ, Vagelos Coll Phys & Surg, Dept Otolaryngol Head & Neck Surg, New York, NY USA; [Puram, Sidharth V.] Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA	Washington University (WUSTL); Columbia University; Washington University (WUSTL)	Puram, SV (corresponding author), Washington Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, St Louis, MO 63110 USA.; Puram, SV (corresponding author), Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA.	sidpuram@wustl.edu		Puram, Sidharth/0000-0003-3543-889X	NIH/NCI [K08CA237732]; Cancer Research Foundation [P20-0563]; Doris Duke Foundation; American Cancer Society; V Foundation [V2019-005]; Washington University Dean's Scholars Program; National Institute of Deafness and Other Communication Disorders [T32DC000022]	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cancer Research Foundation; Doris Duke Foundation(Doris Duke Charitable Foundation (DDCF)); American Cancer Society(American Cancer Society); V Foundation; Washington University Dean's Scholars Program; National Institute of Deafness and Other Communication Disorders(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	This work was graciously supported by an NIH/NCI K08CA237732 as well as the Cancer Research Foundation: P20-0563, Doris Duke Foundation, American Cancer Society, V Foundation: V2019-005, and the Washington University Dean's Scholars Program (SVP). This work was also supported by the National Institute of Deafness and Other Communication Disorders (T32DC000022) (TFB).	Aceto N, 2014, CELL, V158, P1110, DOI 10.1016/j.cell.2014.07.013; Aiello NM, 2018, DEV CELL, V45, P681, DOI 10.1016/j.devcel.2018.05.027; Amintas S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072653; Armstrong AJ, 2011, MOL CANCER RES, V9, P997, DOI 10.1158/1541-7786.MCR-10-0490; Bhatia S, 2020, FRONT MOL BIOSCI, V7, DOI 10.3389/fmolb.2020.00071; Bhatia S, 2017, BIOCHEM J, V474, P3269, DOI 10.1042/BCJ20160782; Biddle A, 2016, EBIOMEDICINE, V4, P138, DOI 10.1016/j.ebiom.2016.01.007; Birchmeier C, 1996, ACTA ANAT, V156, P217; Bocci F, 2019, INTEGR BIOL-UK, V11, P251, DOI 10.1093/intbio/zyz021; Brabletz T, 2012, NAT REV CANCER, V12, P425, DOI 10.1038/nrc3265; Burger GA, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00162; Cai JH, 2019, CANCER RES TREAT, V51, P252, DOI 10.4143/crt.2017.613; Campbell K, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10269-y; Celia-Terrassa T, 2012, J CLIN INVEST, V122, P1849, DOI 10.1172/JCI59218; Chen S, 2018, ONCOL LETT, V15, P7144, DOI 10.3892/ol.2018.8219; Cho SJ, 2018, ARCH PATHOL LAB MED, V142, P952, DOI 10.5858/arpa.2018-0082-RA; Chui MH, 2013, INT J CANCER, V132, P1487, DOI 10.1002/ijc.27745; Ciftci R, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.e11526; De Cecco L, 2015, ONCOTARGET, V6, P9627, DOI 10.18632/oncotarget.3301; De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447; Deng SJ, 2018, ONCOGENE, V37, P5811, DOI 10.1038/s41388-018-0382-1; Devarajan E, 2012, INT J CANCER, V131, P1023, DOI 10.1002/ijc.26493; Dhasarathy A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026514; Dohadwala M, 2010, OTOLARYNG HEAD NECK, V142, P753, DOI 10.1016/j.otohns.2010.01.034; Espinoza I, 2013, PHARMACOL THERAPEUT, V139, P95, DOI 10.1016/j.pharmthera.2013.02.003; Evans AJ, 2007, MOL CELL BIOL, V27, P157, DOI 10.1128/MCB.00892-06; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; Fustaino V, 2017, ONCOTARGET, V8, P103340, DOI 10.18632/oncotarget.21132; George JT, 2017, CANCER RES, V77, P6415, DOI 10.1158/0008-5472.CAN-16-3521; Giampieri S, 2009, NAT CELL BIOL, V11, P1287, DOI 10.1038/ncb1973; Godin L, 2020, CANCERS, V12, DOI 10.3390/cancers12040906; Gonzalez VD, 2018, CELL REP, V22, P1875, DOI 10.1016/j.celrep.2018.01.053; GREENBURG G, 1982, J CELL BIOL, V95, P333, DOI 10.1083/jcb.95.1.333; Grosse-Wilde A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126522; Harb J, 2019, CURR ONCOL REP, V21, DOI 10.1007/s11912-019-0763-9; He P, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32737-z; Horiguchi K, 2009, J BIOL CHEM, V284, P245, DOI 10.1074/jbc.M804777200; Hou JM, 2012, J CLIN ONCOL, V30, P525, DOI 10.1200/JCO.2010.33.3716; Hou JM, 2011, AM J PATHOL, V178, P989, DOI 10.1016/j.ajpath.2010.12.003; Huang RYJ, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.442; Hugo HJ, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-235; Ivanovic V, 2006, CLIN CHIM ACTA, V371, P191, DOI 10.1016/j.cca.2006.02.027; Ji AL, 2020, CELL, V182, P497, DOI 10.1016/j.cell.2020.05.039; Jolly MK, 2019, J CLIN MED, V8, DOI 10.3390/jcm8101542; Jolly MK, 2018, BBA-REV CANCER, V1870, P151, DOI 10.1016/j.bbcan.2018.07.001; Jolly MK, 2017, MOL ONCOL, V11, P739, DOI 10.1002/1878-0261.12084; Jolly MK, 2017, NPJ BREAST CANCER, V3, DOI 10.1038/s41523-017-0023-9; Jolly MK, 2014, J R SOC INTERFACE, V11, DOI 10.1098/rsif.2014.0962; Joosse SA, 2015, EMBO MOL MED, V7, P1, DOI 10.15252/emmm.201303698; Jung AR, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-60707-x; Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009; Karacosta LG, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13441-6; Karaosmanoglu O, 2018, CELL ONCOL, V41, P439, DOI 10.1007/s13402-018-0384-6; Kim JM, 2013, EUR ARCH OTO-RHINO-L, V270, P1137, DOI 10.1007/s00405-012-2161-x; Kinker GS, 2020, NAT GENET, V52, P1208, DOI 10.1038/s41588-020-00726-6; Kisoda S, 2020, ORAL DIS, V26, P1149, DOI 10.1111/odi.13351; Kohler I, 2015, J GASTROEN HEPATOL, V30, P78, DOI 10.1111/jgh.12752; Kojc N, 2009, VIRCHOWS ARCH, V454, P549, DOI 10.1007/s00428-009-0771-5; Kroger C, 2019, P NATL ACAD SCI USA, V116, P7353, DOI 10.1073/pnas.1812876116; Kurimoto R, 2016, INT J ONCOL, V48, P1825, DOI 10.3892/ijo.2016.3419; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Langley RR, 2011, INT J CANCER, V128, P2527, DOI 10.1002/ijc.26031; Latil M, 2017, CELL STEM CELL, V20, P191, DOI 10.1016/j.stem.2016.10.018; Lawrence MS, 2015, NATURE, V517, P576, DOI 10.1038/nature14129; Lecharpentier A, 2011, BRIT J CANCER, V105, P1338, DOI 10.1038/bjc.2011.405; Lee WY, 2014, ANN SURG ONCOL, V21, P1904, DOI 10.1245/s10434-014-3567-z; Li J, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5917-5; Liang FL, 2013, PATHOL RES PRACT, V209, P269, DOI 10.1016/j.prp.2013.01.009; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; McMahon S, 2006, J BIOL CHEM, V281, P24171, DOI 10.1074/jbc.M604507200; Medici D, 2008, MOL BIOL CELL, V19, P4875, DOI 10.1091/mbc.E08-05-0506; Miao JW, 2014, INT J ONCOL, V45, P165, DOI 10.3892/ijo.2014.2422; Newman AM, 2019, NAT BIOTECHNOL, V37, P773, DOI 10.1038/s41587-019-0114-2; Nguyen PT, 2011, HISTOL HISTOPATHOL, V26, P147, DOI 10.14670/HH-26.147; Nijkamp MM, 2011, RADIOTHER ONCOL, V99, P344, DOI 10.1016/j.radonc.2011.05.066; Ocana OH, 2012, CANCER CELL, V22, P709, DOI 10.1016/j.ccr.2012.10.012; Panchy N, 2020, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01479; Papadaki MA, 2019, MOL CANCER THER, V18, P437, DOI 10.1158/1535-7163.MCT-18-0584; Parikh AS, 2019, ORAL ONCOL, V99, DOI 10.1016/j.oraloncology.2019.104458; Pastushenko I, 2019, TRENDS CELL BIOL, V29, P212, DOI 10.1016/j.tcb.2018.12.001; Pastushenko I, 2018, NATURE, V556, P463, DOI 10.1038/s41586-018-0040-3; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Plaks V, 2015, CELL STEM CELL, V16, P225, DOI 10.1016/j.stem.2015.02.015; Polioudaki H, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1386-7; Puram SV, 2018, MOL CELL ONCOL, V5, DOI 10.1080/23723556.2018.1448244; Puram SV, 2017, CELL, V171, P1611, DOI 10.1016/j.cell.2017.10.044; Qi ZT, 2021, CANCERS, V13, DOI 10.3390/cancers13061230; Qi ZT, 2019, ORAL ONCOL, V99, DOI 10.1016/j.oraloncology.2019.104441; Rhim AD, 2012, CELL, V148, P349, DOI 10.1016/j.cell.2011.11.025; Ruscetti M, 2015, CANCER RES, V75, P2749, DOI 10.1158/0008-5472.CAN-14-3476; Saitoh M, 2018, J BIOCHEM, V164, P257, DOI 10.1093/jb/mvy047; Sanchez-Tillo E, 2012, CELL MOL LIFE SCI, V69, P3429, DOI 10.1007/s00018-012-1122-2; Scheel C, 2012, SEMIN CANCER BIOL, V22, P396, DOI 10.1016/j.semcancer.2012.04.001; Seshacharyulu P, 2012, EXPERT OPIN THER TAR, V16, P15, DOI 10.1517/14728222.2011.648617; Sha YT, 2020, NUCLEIC ACIDS RES, V48, P9505, DOI 10.1093/nar/gkaa725; Simpson A, 2017, TARGET ONCOL, V12, P571, DOI 10.1007/s11523-017-0514-5; Sirin AH, 2019, TECH COLOPROCTOL, V23, P333, DOI 10.1007/s10151-019-01959-2; Stepan KO, 2020, ORAL ONCOL, V110, DOI 10.1016/j.oraloncology.2020.104893; Storci G, 2010, J CELL PHYSIOL, V225, P682, DOI 10.1002/jcp.22264; Strauss R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016186; Suarez-Causado A, 2015, BBA-MOL CELL RES, V1853, P2453, DOI 10.1016/j.bbamcr.2015.05.017; Subbalakshmi AR, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.553342; Tada H, 2020, ANTICANCER RES, V40, P3559, DOI 10.21873/anticanres.14345; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Tomson AM, 1996, CLIN EXP METASTAS, V14, P501, DOI 10.1007/BF00115110; Tretbar Sandy, 2019, Oncotarget, V10, P1507, DOI 10.18632/oncotarget.26682; Tsai JH, 2012, CANCER CELL, V22, P725, DOI 10.1016/j.ccr.2012.09.022; TUCKER G C, 1988, Development (Cambridge), V103, P81; van Dijk D, 2018, CELL, V174, P716, DOI 10.1016/j.cell.2018.05.061; Viebahn C, 1995, ACTA ANAT, V154, P79; Visvader JE, 2012, CELL STEM CELL, V10, P717, DOI 10.1016/j.stem.2012.05.007; Wan YH, 2020, HEAD NECK-J SCI SPEC, V42, P1067, DOI 10.1002/hed.26104; Wang RY, 2016, ONCOL RES, V24, P225, DOI 10.3727/096504016X14648701447931; Williams ED, 2019, NAT REV CANCER, V19, P716, DOI 10.1038/s41568-019-0213-x; Wu SY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123976; Xiong HG, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1254-4; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5; Xu WT, 2015, CELL ADHES MIGR, V9, P317, DOI 10.1080/19336918.2015.1016686; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; Yang J, 2020, NAT REV MOL CELL BIO, V21, P341, DOI 10.1038/s41580-020-0237-9; Yu M, 2013, SCIENCE, V339, P580, DOI 10.1126/science.1228522; Zaravinos A., 2015, J ONCOL, V2015, DOI DOI 10.1155/2015/865816; Zhang H, 2003, BLOOD, V101, P2253, DOI 10.1182/blood-2002-02-0629; Zhang JY, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005304; Zhang L, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-108; Zidar N, 2011, HUM PATHOL, V42, P482, DOI 10.1016/j.humpath.2010.07.020	128	17	17	1	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2021	40	32					5049	5065		10.1038/s41388-021-01868-5	http://dx.doi.org/10.1038/s41388-021-01868-5		JUL 2021	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA7OD	34239045	Green Accepted			2022-12-17	WOS:000670851600003
J	Goydel, RS; Rader, C				Goydel, Rebecca S.; Rader, Christoph			Antibody-based cancer therapy	ONCOGENE			English	Review							IMMUNOGENIC CELL-DEATH; IMMUNOTHERAPY; STRATEGIES; MOLECULES; ANTIGEN; SITE	Over the past 25 years, antibody therapeutics have emerged as clinically and commercially successful pharmaceuticals, rapidly approaching 100 Food and Drug Administration approvals with combined annual global sales exceeding $100 billion. Nearly half of the marketed antibody therapeutics are used in oncology. These antibody-based cancer therapies can be broken down into three categories based on their different mechanisms of action, i.e., (i) natural properties, (ii) engagement of cytotoxic T cells, and (iii) delivery of cytotoxic payloads. Both natural and engineered properties of the antibody molecule are founded on its highly stable and modular architecture. In this review we provide an overview and outlook of the rapidly evolving landscape of antibody-based cancer therapy.	[Goydel, Rebecca S.; Rader, Christoph] Scripps Res Inst, Dept Immunol & Microbiol, Jupiter, FL 92037 USA	Scripps Research Institute	Rader, C (corresponding author), Scripps Res Inst, Dept Immunol & Microbiol, Jupiter, FL 92037 USA.	crader@scripps.edu		Rader, Christoph/0000-0001-9955-3454	Klorfine Foundation; Frenchman's Creek Women for Cancer Research; National Institutes of Health [R01 CA174844, R01 CA181258, R01 CA204484, R21 CA229961]	Klorfine Foundation; Frenchman's Creek Women for Cancer Research; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We acknowledge support by predoctoral stipends from the Klorfine Foundation and the Frenchman's Creek Women for Cancer Research (to R.S.G.) and National Institutes of Health Grants R01 CA174844, R01 CA181258, R01 CA204484, and R21 CA229961 (to C.R.). We thank Dr. HaJeung Park from the X-Ray Crystallography Core of The Scripps Research Institute (Jupiter, FL) for contributing Fig. 1C.	Alfaleh MA, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01986; Beck A, 2017, NAT REV DRUG DISCOV, V16, P315, DOI 10.1038/nrd.2016.268; Beerli RR, 2010, MABS-AUSTIN, V2, P365, DOI 10.4161/mabs.12187; Brerski RJ, 2016, CURR OPIN IMMUNOL, V40, P62, DOI 10.1016/j.coi.2016.03.002; Briney B, 2019, NATURE, V566, P393, DOI 10.1038/s41586-019-0879-y; Brinkmann U, 2017, MABS-AUSTIN, V9, P182, DOI 10.1080/19420862.2016.1268307; Clynes RA, 2019, ANNU REV MED, V70, P437, DOI 10.1146/annurev-med-062617-035821; Cotton AD, 2021, J AM CHEM SOC, V143, P593, DOI 10.1021/jacs.0c10008; Daher M, 2021, CANCER DISCOV, V11, P45, DOI 10.1158/2159-8290.CD-20-0556; Denkberg G, 2002, P NATL ACAD SCI USA, V99, P9421, DOI 10.1073/pnas.132285699; Desnoyers LR, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006682; Dougan M, 2020, J CLIN INVEST, V130, P51, DOI 10.1172/JCI131194; Ellerman D, 2019, METHODS, V154, P102, DOI 10.1016/j.ymeth.2018.10.026; Feng MY, 2019, NAT REV CANCER, V19, P568, DOI 10.1038/s41568-019-0183-z; Galluzzi L, 2017, NAT REV IMMUNOL, V17, P97, DOI 10.1038/nri.2016.107; Goydel RS, 2020, J BIOL CHEM, V295, P5995, DOI 10.1074/jbc.RA120.012791; Green DJ, 2017, CANCER RES, V77, P2191, DOI 10.1158/0008-5472.CAN-16-2523; GROSS G, 1989, P NATL ACAD SCI USA, V86, P10024, DOI 10.1073/pnas.86.24.10024; Hodgins JJ, 2019, J CLIN INVEST, V129, P3499, DOI 10.1172/JCI129338; Hong MH, 2020, CANCER CELL, V38, P473, DOI 10.1016/j.ccell.2020.07.005; Hsiue EHC, 2021, SCIENCE, V371, P1009, DOI 10.1126/science.abc8697; Johnston RJ, 2019, NATURE, V574, P565, DOI 10.1038/s41586-019-1674-5; June CH, 2018, SCIENCE, V359, P1361, DOI 10.1126/science.aar6711; Kamata-Sakurai M, 2021, CANCER DISCOV, V11, P158, DOI 10.1158/2159-8290.CD-20-0328; Kaplon H, 2021, MABS-AUSTIN, V13, DOI 10.1080/19420862.2020.1860476; Kobayashi H, 2019, ACCOUNTS CHEM RES, V52, P2332, DOI 10.1021/acs.accounts.9b00273; Kraeber-Bodere F, 2003, CLIN CANCER RES, V9, p3973S; Kreitman RJ, 2011, CLIN CANCER RES, V17, P6398, DOI 10.1158/1078-0432.CCR-11-0487; Kroemer G, 2013, ANNU REV IMMUNOL, V31, P51, DOI 10.1146/annurev-immunol-032712-100008; Labrijn AF, 2019, NAT REV DRUG DISCOV, V18, P585, DOI 10.1038/s41573-019-0028-1; Larkin J, 2019, NEW ENGL J MED, V381, P1535, DOI 10.1056/NEJMoa1910836; Lemery S, 2017, NEW ENGL J MED, V377, P1409, DOI 10.1056/NEJMp1709968; Liu RN, 2020, ANTIBODIES, V9, DOI 10.3390/antib9040064; Maude SL, 2018, NEW ENGL J MED, V378, P439, DOI 10.1056/NEJMoa1709866; Mayes PA, 2018, NAT REV DRUG DISCOV, V17, P509, DOI 10.1038/nrd.2018.75; Mazor R, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01261; Mitsunaga M, 2011, NAT MED, V17, P1685, DOI 10.1038/nm.2554; Muller P, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac4925; Neri D, 2016, CURR OPIN IMMUNOL, V40, P96, DOI 10.1016/j.coi.2016.03.006; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Rader C, 2020, CURR OPIN BIOTECH, V65, P9, DOI 10.1016/j.copbio.2019.11.020; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; Rosenberg SA, 2014, J IMMUNOL, V192, P5451, DOI 10.4049/jimmunol.1490019; Sadelain M, 2017, NATURE, V545, P423, DOI 10.1038/nature22395; Schreiber RD, 2011, SCIENCE, V331, P1565, DOI 10.1126/science.1203486; Scott DE, 2016, NAT REV DRUG DISCOV, V15, P533, DOI 10.1038/nrd.2016.29; Srivastava S, 2021, CANCER CELL, V39, P193, DOI 10.1016/j.ccell.2020.11.005; Stadtmauer EA, 2020, SCIENCE, V367, P1001, DOI 10.1126/science.aba7365; Walsh SJ, 2021, CHEM SOC REV, V50, P1305, DOI 10.1039/d0cs00310g; Wang LX, 2019, ANNU REV BIOCHEM, V88, P433, DOI 10.1146/annurev-biochem-062917-012911; Wolchok JD, 2017, NEW ENGL J MED, V377, P1345, DOI 10.1056/NEJMoa1709684; Wu XF, 2019, METHODS, V154, P3, DOI 10.1016/j.ymeth.2018.08.010; Zheng SM, 2016, MABS-AUSTIN, V8, P551, DOI 10.1080/19420862.2015.1136762	53	17	17	2	16	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2021	40	21					3655	3664		10.1038/s41388-021-01811-8	http://dx.doi.org/10.1038/s41388-021-01811-8		MAY 2021	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SI8ZW	33947958	Green Accepted			2022-12-17	WOS:000647099200002
J	Wilson, K; Shiuan, E; Brantley-Sieders, DM				Wilson, Kalin; Shiuan, Eileen; Brantley-Sieders, Dana M.			Oncogenic functions and therapeutic targeting of EphA2 in cancer	ONCOGENE			English	Review								More than 25 years of research and preclinical validation have defined EphA2 receptor tyrosine kinase as a promising molecular target for clinical translation in cancer treatment. Molecular, genetic, biochemical, and pharmacological targeting strategies have been extensively tested in vitro and in vivo, and drugs like dasatinib, initially designed to target SRC family kinases, have been found to also target EphA2 activity. Other small molecules, therapeutic targeting antibodies, and peptide-drug conjugates are being tested, and more recently, approaches harnessing antitumor immunity against EphA2-expressing cancer cells have emerged as a promising strategy. This review will summarize preclinical studies supporting the oncogenic role of EphA2 in breast cancer, lung cancer, glioblastoma, and melanoma, while delineating the differing roles of canonical and noncanonical EphA2 signaling in each setting. This review also summarizes completed and ongoing clinical trials, highlighting the promise and challenges of targeting EphA2 in cancer.	[Wilson, Kalin; Shiuan, Eileen] Vanderbilt Univ, Sch Med, Nashville, TN 37232 USA; [Brantley-Sieders, Dana M.] Vanderbilt Univ, Med Ctr, Dept Med, Div Rheumatol & Immunol, Nashville, TN 37232 USA; [Brantley-Sieders, Dana M.] Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Brantley-Sieders, DM (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med, Div Rheumatol & Immunol, Nashville, TN 37232 USA.; Brantley-Sieders, DM (corresponding author), Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA.	dana.brantley@vumc.org		Brantley-Sieders, Dana/0000-0002-2751-6547	NCI NIH HHS [R01 CA177681, F30 CA216891] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Affinito A, 2020, MOL THER-NUCL ACIDS, V20, P176, DOI 10.1016/j.omtn.2020.02.005; Affinito A, 2019, MOL THER-NUCL ACIDS, V18, P99, DOI 10.1016/j.omtn.2019.08.015; Amato KR, 2016, CANCER RES, V76, P305, DOI 10.1158/0008-5472.CAN-15-0717; American Cancer Society,, 2020, COL CANC; Annunziata Christina M, 2013, Invest New Drugs, V31, P77, DOI 10.1007/s10637-012-9801-2; Arnato KR, 2014, J CLIN INVEST, V124, P2037, DOI 10.1172/JCI72522; Azimi A, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.406; Barquilla A, 2016, MOL BIOL CELL, V27, P2757, DOI 10.1091/mbc.E16-01-0048; Bennett G, 2020, MOL CANCER THER, V19, P1385, DOI 10.1158/1535-7163.MCT-19-1092; Bielamowicz K, 2018, NEURO-ONCOLOGY, V20, P506, DOI 10.1093/neuonc/nox182; Bin Fang W, 2005, ONCOGENE, V24, P7859, DOI 10.1038/sj.onc.1208937; Binda E, 2012, CANCER CELL, V22, P765, DOI 10.1016/j.ccr.2012.11.005; Brannan JM, 2009, CANCER PREV RES, V2, P1039, DOI 10.1158/1940-6207.CAPR-09-0212; Brantley-Sieders DM, 2008, J CLIN INVEST, V118, P64, DOI 10.1172/JCI33154; Brantley-Sieders DM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024426; Canon J, 2019, NATURE, V575, P217, DOI 10.1038/s41586-019-1694-1; Chan BA, 2015, TRANSL LUNG CANCER R, V4, P36, DOI 10.3978/j.issn.2218-6751.2014.05.01; Chee CE, 2013, ONCOLOGIST, V18, P1091, DOI 10.1634/theoncologist.2013-0255; Chen J, 2012, NATURE, V488, P522, DOI 10.1038/nature11287; Chen J, 2015, CYTOKINE GROWTH F R, V26, P1, DOI 10.1016/j.cytogfr.2014.05.001; Choi K, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001226; Chow KKH, 2013, MOL THER, V21, P629, DOI 10.1038/mt.2012.210; Conover JC, 2000, NAT NEUROSCI, V3, P1091, DOI 10.1038/80606; EASTY DJ, 1993, J INVEST DERMATOL, V101, P679, DOI 10.1111/1523-1747.ep12371675; EASTY DJ, 1995, INT J CANCER, V60, P129, DOI 10.1002/ijc.2910600119; EASTY DJ, 1995, CANCER RES, V55, P2528; Easty DJ, 1999, INT J CANCER, V84, P494, DOI 10.1002/(SICI)1097-0215(19991022)84:5<494::AID-IJC8>3.3.CO;2-F; Faoro L, 2010, J BIOL CHEM, V285, P18575, DOI 10.1074/jbc.M109.075085; Fattet L, 2020, DEV CELL, V54, P302, DOI 10.1016/j.devcel.2020.05.031; Ferluga S, 2016, ONCOTARGET, V7, P59860, DOI 10.18632/oncotarget.10978; Finn RS, 2011, CLIN CANCER RES, V17, P6905, DOI 10.1158/1078-0432.CCR-11-0288; Gambini L, 2018, ACS CHEM BIOL, V13, P2633, DOI 10.1021/acschembio.8b00556; Gokmen-Polar Y, 2011, BREAST CANCER RES TR, V127, P375, DOI 10.1007/s10549-010-1004-y; Gravina GL, 2019, CANCERS, V11, DOI 10.3390/cancers11030359; Guo CC, 2013, J THORAC ONCOL, V8, P301, DOI 10.1097/JTO.0b013e318282def7; Hamaoka Y, 2016, CELL SIGNAL, V28, P937, DOI 10.1016/j.cellsig.2016.04.009; Hasegawa J, 2016, CANCER BIOL THER, V17, P1158, DOI 10.1080/15384047.2016.1235663; Hatano M, 2005, NEOPLASIA, V7, P717, DOI 10.1593/neo.05277; Heinzlmeir S, 2016, ACS CHEM BIOL, V11, P3400, DOI 10.1021/acschembio.6b00709; Hess AR, 2001, CANCER RES, V61, P3250; Himanen JP, 2001, NATURE, V414, P933, DOI 10.1038/414933a; Himanen JP, 2009, EMBO REP, V10, P722, DOI 10.1038/embor.2009.91; Holmberg J, 2005, GENE DEV, V19, P462, DOI 10.1101/gad.326905; Ishikawa M, 2012, LUNG CANCER, V76, P431, DOI 10.1016/j.lungcan.2011.12.004; Jackson D, 2008, CANCER RES, V68, P9367, DOI 10.1158/0008-5472.CAN-08-1933; Kikawa KD, 2002, J BIOL CHEM, V277, P39274, DOI 10.1074/jbc.M207127200; Kim C, 2019, J THORAC ONCOL, V14, pS281, DOI 10.1016/j.jtho.2019.08.565; Kinch MS, 2003, CLIN CANCER RES, V9, P613; Kluger HM, 2011, CANCER-AM CANCER SOC, V117, P2202, DOI 10.1002/cncr.25766; Koch H, 2015, J PROTEOME RES, V14, P2617, DOI 10.1021/acs.jproteome.5b00161; Koshikawa N, 2015, CANCER RES, V75, P3327, DOI 10.1158/0008-5472.CAN-14-2798; Kullander K, 2002, NAT REV MOL CELL BIO, V3, P475, DOI 10.1038/nrm856; Larsen AB, 2007, MOL CANCER RES, V5, P283, DOI 10.1158/1541-7786.MCR-06-0321; Larsen AB, 2010, CELL SIGNAL, V22, P636, DOI 10.1016/j.cellsig.2009.11.018; Lathia JD, 2015, GENE DEV, V29, P1203, DOI 10.1101/gad.261982.115; Liang LY, 2019, ONCOGENE, V38, P6567, DOI 10.1038/s41388-019-0931-2; Lim DA, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a018820; Lisabeth EM, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a009159; Liu FH, 2006, CANCER RES, V66, P10815, DOI 10.1158/0008-5472.CAN-06-1408; Lombardo LJ, 2004, J MED CHEM, V47, P6658, DOI 10.1021/jm049486a; Margaryan NV, 2009, CANCER BIOL THER, V8, P275, DOI 10.4161/cbt.8.3.7485; Miao BC, 2015, CANCER DISCOV, V5, P274, DOI 10.1158/2159-8290.CD-14-0295; Miao H, 2015, ONCOGENE, V34, P558, DOI 10.1038/onc.2013.590; Miao H, 2000, NAT CELL BIOL, V2, P62, DOI 10.1038/35000008; Miao H, 2009, CANCER CELL, V16, P9, DOI 10.1016/j.ccr.2009.04.009; Mitri Z, 2016, CLIN CANCER RES, V22, P5706, DOI 10.1158/1078-0432.CCR-15-2845; Mo J, 2020, CELL ONCOL, V43, P655, DOI 10.1007/s13402-020-00511-x; Noblitt LW, 2004, CANCER GENE THER, V11, P757, DOI 10.1038/sj.cgt.7700761; North HA, 2013, CEREB CORTEX, V23, P1765, DOI 10.1093/cercor/bhs183; Okada H, 2008, J NEURO-ONCOL, V88, P245, DOI 10.1007/s11060-008-9566-9; Paraiso KHT, 2015, CANCER DISCOV, V5, P264, DOI 10.1158/2159-8290.CD-14-0293; Park JE, 2013, GENES-BASEL, V4, P334, DOI 10.3390/genes4030334; Parri M, 2009, CANCER RES, V69, P2072, DOI 10.1158/0008-5472.CAN-08-1845; Pollack IF, 2016, J NEURO-ONCOL, V130, P517, DOI 10.1007/s11060-016-2245-3; Prat A, 2011, MOL ONCOL, V5, P5, DOI 10.1016/j.molonc.2010.11.003; Ramnarain DB, 2006, CANCER RES, V66, P867, DOI 10.1158/0008-5472.CAN-05-2753; Sakamoto A, 2018, ANTICANCER RES, V38, P3273, DOI 10.21873/anticanres.12592; Shen WS, 2014, GROWTH FACTORS, V32, P247, DOI 10.3109/08977194.2014.984806; Shitara K, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0679-9; Skoulidis F, 2019, NAT REV CANCER, V19, P495, DOI 10.1038/s41568-019-0179-8; Song W, 2017, ONCOGENE, V36, P5620, DOI 10.1038/onc.2017.170; Song WQ, 2020, MOL CANCER RES, V18, P1735, DOI 10.1158/1541-7786.MCR-20-0075; Song WQ, 2014, CANCER RES, V74, P2444, DOI 10.1158/0008-5472.CAN-13-2136; Sugiyama N, 2013, J CELL BIOL, V201, P467, DOI 10.1083/jcb.201205176; Tan YHC, 2019, ONCOGENESIS, V8, DOI 10.1038/s41389-019-0159-6; Tarhini AA, 2016, MELANOMA MANAG, V3, P251, DOI 10.2217/mmt-2016-0016; Travis WD, 2015, J THORAC ONCOL, V10, P1243, DOI 10.1097/JTO.0000000000000630; Udayakumar D, 2011, ONCOGENE, V30, P4921, DOI 10.1038/onc.2011.210; Vaught D, 2009, MOL BIOL CELL, V20, P2572, DOI 10.1091/mbc.E08-04-0378; Volz C, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107568; Wang LF, 2008, ONCOL REP, V19, P151; Weigelt B, 2010, MOL ONCOL, V4, P192, DOI 10.1016/j.molonc.2010.04.004; Weinstein IB, 2006, NAT CLIN PRACT ONCOL, V3, P448, DOI 10.1038/ncponc0558; White BEP, 2014, CELL ADHES MIGR, V8, P327, DOI 10.4161/19336918.2014.970012; Wybenga-Groot LE, 2001, CELL, V106, P745, DOI 10.1016/S0092-8674(01)00496-2; Wykosky J, 2005, MOL CANCER RES, V3, P541, DOI 10.1158/1541-7786.MCR-05-0056; Yeddula N, 2015, P NATL ACAD SCI USA, V112, pE6476, DOI 10.1073/pnas.1520110112; Youngblood VM, 2016, CANCER RES, V76, P1825, DOI 10.1158/0008-5472.CAN-15-0847; Zantek ND, 1999, CELL GROWTH DIFFER, V10, P629; Zelinski DP, 2001, CANCER RES, V61, P2301; Zhang GQ, 2008, CANCER RES, V68, P1691, DOI 10.1158/0008-5472.CAN-07-2372; Zhou Y, 2017, BIOL PHARM BULL, V40, P1616, DOI 10.1248/bpb.b17-00446; Zhou Y, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8679; Zhuang GL, 2010, CANCER RES, V70, P299, DOI 10.1158/0008-5472.CAN-09-1845; Zisch AH, 2000, ONCOGENE, V19, P177, DOI 10.1038/sj.onc.1203304	105	17	18	6	26	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2021	40	14					2483	2495		10.1038/s41388-021-01714-8	http://dx.doi.org/10.1038/s41388-021-01714-8		MAR 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK3YE	33686241	Green Accepted			2022-12-17	WOS:000626396000001
J	Yan, QX; Zeng, P; Zhou, XQ; Zhao, XY; Chen, RQ; Qiao, J; Feng, L; Zhu, ZJ; Zhang, GZ; Chen, CR				Yan, Qiuxia; Zeng, Peng; Zhou, Xiuqin; Zhao, Xiaoying; Chen, Runqiang; Qiao, Jing; Feng, Ling; Zhu, Zhenjie; Zhang, Guozhi; Chen, Cairong			RBMX suppresses tumorigenicity and progression of bladder cancer by interacting with the hnRNP A1 protein to regulate PKM alternative splicing	ONCOGENE			English	Article								The prognosis for patients with metastatic bladder cancer (BCa) is poor, and it is not improved by current treatments. RNA-binding motif protein X-linked (RBMX) are involved in the regulation of the malignant progression of various tumors. However, the role of RBMX in BCa tumorigenicity and progression remains unclear. In this study, we found that RBMX was significantly downregulated in BCa tissues, especially in muscle-invasive BCa tissues. RBMX expression was negatively correlated with tumor stage, histological grade and poor patient prognosis. Functional assays demonstrated that RBMX inhibited BCa cell proliferation, colony formation, migration, and invasion in vitro and suppressed tumor growth and metastasis in vivo. Mechanistic investigations revealed that hnRNP A1 was an RBMX-binding protein. RBMX competitively inhibited the combination of the RGG motif in hnRNP A1 and the sequences flanking PKM exon 9, leading to the formation of lower PKM2 and higher PKM1 levels, which attenuated the tumorigenicity and progression of BCa. Moreover, RBMX inhibited aerobic glycolysis through hnRNP A1-dependent PKM alternative splicing and counteracted the PKM2 overexpression-induced aggressive phenotype of the BCa cells. In conclusion, our findings indicate that RBMX suppresses BCa tumorigenicity and progression via an hnRNP A1-mediated PKM alternative splicing mechanism. RBMX may serve as a novel prognostic biomarker for clinical intervention in BCa.	[Yan, Qiuxia; Zhou, Xiuqin; Zhao, Xiaoying; Chen, Runqiang; Qiao, Jing; Feng, Ling; Zhu, Zhenjie; Zhang, Guozhi; Chen, Cairong] Guangzhou Med Univ, Ctr Reprod Med, Qingyuan Peoples Hosp, Affiliated Hosp 6, Qingyuan, Guangdong, Peoples R China; [Zeng, Peng] Guangzhou Med Univ, Dept Urol, Qingyuan Peoples Hosp, Affiliated Hosp 6, Qingyuan, Guangdong, Peoples R China	Guangzhou Medical University; Guangzhou Medical University	Yan, QX; Chen, CR (corresponding author), Guangzhou Med Univ, Ctr Reprod Med, Qingyuan Peoples Hosp, Affiliated Hosp 6, Qingyuan, Guangdong, Peoples R China.	yanqiuxia1982@163.com; cairong1222@163.com		Yan, Qiuxia/0000-0002-7701-5126	National Natural Science Foundation of China [82002671]; Guangdong Basic and Applied Basic Research Foundation [2019A1515010249]; Qingyuan Science and Technology Project [2020KJJH023]; China Postdoctoral Science Foundation [2019M663398]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Basic and Applied Basic Research Foundation; Qingyuan Science and Technology Project; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	This work was supported by the National Natural Science Foundation of China (No. 82002671), Guangdong Basic and Applied Basic Research Foundation (No. 2019A1515010249), The Qingyuan Science and Technology Project (No. 2020KJJH023), and China Postdoctoral Science Foundation (No. 2019M663398). We thank Prof. Guojun Zhao and Prof. Lin Qi for providing scientific advices. We would like to thank Laboratory Animal Center, The Sixth Affiliated Hospital of Guangzhou Medical University for support in all animal experiments. Finally, we thank American Journal Experts for the English language editing.	Adamson B, 2012, NAT CELL BIOL, V14, P318, DOI 10.1038/ncb2426; Babjuk M, 2019, EUR UROL, V76, P639, DOI 10.1016/j.eururo.2019.08.016; Barboro P, 2014, CANCER LETT, V352, P152, DOI 10.1016/j.canlet.2014.06.019; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cambier S, 2016, EUR UROL, V69, P60, DOI 10.1016/j.eururo.2015.06.045; Chen M, 2012, NAT STRUCT MOL BIOL, V19, P346, DOI 10.1038/nsmb.2219; Chen M, 2010, CANCER RES, V70, P8977, DOI 10.1158/0008-5472.CAN-10-2513; Chen X, 2017, J CELL MOL MED, V21, P1266, DOI 10.1111/jcmm.12999; Chen ZY, 2019, MOL THER, V27, P326, DOI 10.1016/j.ymthe.2018.12.015; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; Cirak S, 2011, LANCET, V378, P595, DOI 10.1016/S0140-6736(11)60756-3; Climente-Gonzalez H, 2017, CELL REP, V20, P2215, DOI 10.1016/j.celrep.2017.08.012; Clower CV, 2010, P NATL ACAD SCI USA, V107, P1894, DOI 10.1073/pnas.0914845107; David CJ, 2010, NATURE, V463, P364, DOI 10.1038/nature08697; Elliott DJ, 2019, INT J BIOCHEM CELL B, V108, P1, DOI 10.1016/j.biocel.2018.12.014; Funt SA, 2017, NAT REV CLIN ONCOL, V14, P221, DOI 10.1038/nrclinonc.2016.188; Ganapathy-Kanniappan S, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-152; Georgilis A, 2018, CANCER CELL, V34, P85, DOI 10.1016/j.ccell.2018.06.007; Ghosh M, 2020, NUCLEIC ACIDS RES, V48, P4492, DOI 10.1093/nar/gkaa134; Gu ZM, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0392-4; Han N, 2013, J CANCER RES THER, V9, pS129, DOI 10.4103/0973-1482.122506; Heinrich B, 2009, J BIOL CHEM, V284, P14303, DOI 10.1074/jbc.M901026200; Huang JZ, 2017, MOL CELL, V68, P171, DOI 10.1016/j.molcel.2017.09.015; Israelsen WJ, 2015, SEMIN CELL DEV BIOL, V43, P43, DOI 10.1016/j.semcdb.2015.08.004; Jean-Philippe J, 2013, INT J MOL SCI, V14, P18999, DOI 10.3390/ijms140918999; Kanhoush R, 2010, NUCLEUS-PHILA, V1, P109, DOI 10.4161/nucl.1.1.10857; Kashima T, 2007, HUM MOL GENET, V16, P3149, DOI 10.1093/hmg/ddm276; Ko CC, 2014, J BIOL CHEM, V289, P22078, DOI 10.1074/jbc.M114.553248; Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038; Lee SCW, 2016, NAT MED, V22, P976, DOI 10.1038/nm.4165; Lee SCW, 2016, NAT MED, V22, P672, DOI 10.1038/nm.4097; Lew CR, 2015, NAT REV UROL, V12, P383, DOI 10.1038/nrurol.2015.111; Li XB, 2015, THORAC CANCER, V6, P17, DOI 10.1111/1759-7714.12148; Lu JR, 2015, CANCER LETT, V356, P156, DOI 10.1016/j.canlet.2014.04.001; Munschauer M, 2018, NATURE, V561, P132, DOI 10.1038/s41586-018-0453-z; Ouyang YQ, 2011, INT J CANCER, V128, P2010, DOI 10.1002/ijc.25544; Ploussard G, 2014, EUR UROL, V66, P361, DOI 10.1016/j.eururo.2013.09.050; Qian SX, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0360-4; Rajeshkumar NV, 2015, CANCER RES, V75, P3355, DOI 10.1158/0008-5472.CAN-15-0108; Renieri A, 2014, LUNG CANCER, V85, P168, DOI 10.1016/j.lungcan.2014.05.020; Roy R, 2017, WIRES RNA, V8, DOI 10.1002/wrna.1431; Shen SH, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gkr1291; Shi YJ, 2008, CANCER RES, V68, P10215, DOI 10.1158/0008-5472.CAN-08-1066; Shin KH, 2008, NITRIC OXIDE-BIOL CH, V19, P125, DOI 10.1016/j.niox.2008.04.012; Shin KH, 2008, BIOCHEM BIOPH RES CO, V372, P880, DOI 10.1016/j.bbrc.2008.05.175; Shirai T, 2016, J EXP MED, V213, P337, DOI 10.1084/jem.20150900; Song HJ, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00857-7; Sun QA, 2011, P NATL ACAD SCI USA, V108, P4129, DOI 10.1073/pnas.1014769108; Szklarczyk D, 2015, NUCLEIC ACIDS RES, V43, pD447, DOI 10.1093/nar/gku1003; Tamada M, 2012, CLIN CANCER RES, V18, P5554, DOI 10.1158/1078-0432.CCR-12-0859; Tennant DA, 2010, NAT REV CANCER, V10, P267, DOI 10.1038/nrc2817; Thandapani P, 2013, MOL CELL, V50, P613, DOI 10.1016/j.molcel.2013.05.021; Vishnu P, 2011, ONCOTARGETS THER, V4, P97, DOI 10.2147/OTT.S22875; Wang Y, 2014, CANCER CELL, V26, P374, DOI 10.1016/j.ccr.2014.07.010; Wen ZL, 2020, RNA BIOL, V17, P381, DOI 10.1080/15476286.2019.1708547; Xie RH, 2019, CANCER LETT, V449, P31, DOI 10.1016/j.canlet.2019.01.041; Yang H, 2019, ONCOGENE, V38, P4915, DOI 10.1038/s41388-019-0764-z; Yang WW, 2012, CELL, V150, P685, DOI 10.1016/j.cell.2012.07.018; Zhang DL, 2018, FRONT MED-PRC, V12, P280, DOI 10.1007/s11684-017-0580-1; Zhang LF, 2015, EMBO J, V34, P2671, DOI 10.15252/embj.201591803; Zhu LY, 2019, MOL THER, V27, P1621, DOI 10.1016/j.ymthe.2019.05.023	61	17	17	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2021	40	15					2635	2650		10.1038/s41388-021-01666-z	http://dx.doi.org/10.1038/s41388-021-01666-z		FEB 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN8NW	33564070	Green Published, hybrid			2022-12-17	WOS:000616489100011
J	Cui, CH; Liu, Y; Gerloff, D; Rohde, C; Pauli, C; Kohn, M; Misiak, D; Oellerich, T; Schwartz, S; Schmidt, LH; Wiewrodt, R; Marra, A; Hillejan, L; Bartel, F; Wickenhauser, C; Huttelmaier, S; Gollner, S; Zhou, FB; Edemir, B; Muller-Tidow, C				Cui, Chunhong; Liu, Yi; Gerloff, Dennis; Rohde, Christian; Pauli, Cornelius; Koehn, Marcel; Misiak, Danny; Oellerich, Thomas; Schwartz, Schraga; Schmidt, Lars-Henning; Wiewrodt, Rainer; Marra, Alessandro; Hillejan, Ludger; Bartel, Frank; Wickenhauser, Claudia; Huettelmaier, Stefan; Goellner, Stefanie; Zhou, Fengbiao; Edemir, Bayram; Mueller-Tidow, Carsten			NOP10 predicts lung cancer prognosis and its associated small nucleolar RNAs drive proliferation and migration	ONCOGENE			English	Article							NONCODING RNA; DYSKERATOSIS-CONGENITA; SELF-RENEWAL; SNORNA U50; MUTATIONS; PSEUDOURIDYLATION; RECOGNITION; MICRORNAS; PROMOTES; MODOMICS	Non-small cell lung cancer (NSCLC) is the leading cause of cancer death worldwide underlining the urgent need for new biomarkers and therapeutic targets for this disease. Long noncoding RNAs are critical players in NSCLC but the role of small RNA species is not well understood. In the present study, we investigated the role of H/ACA box small nucleolar RNAs (snoRNAs) and snoRNA-bound ribonucleoproteins (snoRNPs) in the tumorigenesis of NSCLC. H/ACA box snoRNPs including the NOP10 core protein were highly expressed in NSCLC. High levels of either NOP10 mRNA or protein were associated with poor prognosis in NSCLC patients. Loss of NOP10 and subsequent reduction of H/ACA box snoRNAs and rRNA pseudouridylation inhibited lung cancer cell growth, colony formation, migration, and invasion. A focused CRISPR/Cas9 snoRNA knockout screen revealed that genomic deletion of SNORA65, SNORA7A, and SNORA7B reduced proliferation of lung cancer cells. In line, high levels of SNORA65, SNORA7A, and SNORA7B were observed in primary lung cancer specimens with associated changes in rRNA pseudouridylation. Knockdown of either SNORA65 or SNORA7A/B inhibited growth and colony formation of NSCLC cell lines. Our data indicate that specific H/ACA box snoRNAs and snoRNA-associated proteins such as NOP10 have an oncogenic role in NSCLC providing new potential biomarkers and therapeutic targets for the disease.	[Cui, Chunhong; Liu, Yi; Rohde, Christian; Goellner, Stefanie; Zhou, Fengbiao; Mueller-Tidow, Carsten] Heidelberg Univ, Dept Med Hematol Oncol & Rheumatol 5, D-69120 Heidelberg, Germany; [Gerloff, Dennis; Pauli, Cornelius; Edemir, Bayram] Martin Luther Univ Halle Wittenberg, Dept Hematol & Oncol, D-06120 Halle, Saale, Germany; [Koehn, Marcel; Misiak, Danny; Huettelmaier, Stefan; Goellner, Stefanie] Martin Luther Univ Halle Wittenberg, Inst Mol Med, D-06120 Halle, Saale, Germany; [Oellerich, Thomas] Goethe Univ, Dept Med 2, Hematol Oncol, D-60590 Frankfurt, Germany; [Oellerich, Thomas] German Canc Res Ctr, German Canc Consortium, D-69120 Heidelberg, Germany; [Oellerich, Thomas] Frankfurt Canc Inst, Dept Mol Diagnost Translat Prote, D-60596 Frankfurt, Germany; [Schwartz, Schraga] Weizmann Inst Sci, Rehovot, Israel; [Schmidt, Lars-Henning; Wiewrodt, Rainer] Univ Munster, Dept Med A, D-48149 Munster, Germany; [Marra, Alessandro] Rems Murr Kliniken, Dept Surg, Thorac Surg, D-71364 Winnenden, Germany; [Hillejan, Ludger] Niels Stensen Kliniken, Dept Thorac Surg, D-49179 Ostercappeln, Germany; [Bartel, Frank; Wickenhauser, Claudia] Martin Luther Univ Halle Wittenberg, Inst Pathol, D-06097 Halle, Saale, Germany; [Mueller-Tidow, Carsten] Natl Ctr Tumor Dis NCT, D-69120 Heidelberg, Germany; [Cui, Chunhong] Shanghai Univ Med & Hlth Sci, Shanghai 201318, Peoples R China; [Gerloff, Dennis] Martin Luther Univ Halle Wittenberg, Dept Dermatol & Venereol, D-06120 Halle, Saale, Germany; [Schmidt, Lars-Henning] Klinikum Ingolstadt, Klin Pneumol Beatmungsmed & Thorakale Onkol, D-85049 Ingolstadt, Germany	Ruprecht Karls University Heidelberg; Martin Luther University Halle Wittenberg; Martin Luther University Halle Wittenberg; Goethe University Frankfurt; Helmholtz Association; German Cancer Research Center (DKFZ); Weizmann Institute of Science; University of Munster; Martin Luther University Halle Wittenberg; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Shanghai University of Medicine & Health Sciences; Martin Luther University Halle Wittenberg	Muller-Tidow, C (corresponding author), Heidelberg Univ, Dept Med Hematol Oncol & Rheumatol 5, D-69120 Heidelberg, Germany.; Muller-Tidow, C (corresponding author), Natl Ctr Tumor Dis NCT, D-69120 Heidelberg, Germany.	Carsten.Mueller-Tidow@med.uni-heidelberg.de	Misiak, Danny/AAV-9317-2020; Zhou, Fengbiao/AAL-3221-2021; Hüttelmaier, Stefan/AAQ-1203-2021	Misiak, Danny/0000-0001-5931-8425; Cui, Chunhong/0000-0002-7705-204X; Zhou, Fengbiao/0000-0002-9221-1096	German Research Foundation (DFG) [ZH831/1-1, MU1328/15-1, MU1328/18-1]; German Cancer Aid (DKH) [70112974, 70113908]; German Jose-Carreras Leukemia Foundation (DJCLS) [22R/2017]	German Research Foundation (DFG)(German Research Foundation (DFG)); German Cancer Aid (DKH)(Deutsche Krebshilfe); German Jose-Carreras Leukemia Foundation (DJCLS)	We thank Katrin Nerger for excellent technical assistance and Dr. sc. agr. Volker Eckstein and Stefanie Hofmann for cell sorting. We are grateful to Annette Becker, M.A., for help with project organization. Research reported in this publication was (in part) supported by funds from the German Research Foundation (DFG; ZH831/1-1 to F. Z., MU1328/15-1 and MU1328/18-1 to C.M-T.), the German Cancer Aid (DKH; Projects 70112974 and 70113908 to C.M-T.) and the German Jose-Carreras Leukemia Foundation (DJCLS; 22R/2017 to C.M-T).	Alter BP, 2009, BLOOD, V113, P6549, DOI 10.1182/blood-2008-12-192880; Aubrey BJ, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026062; Bakin AV, 1998, METH MOL B, V77, P297; Bankhead P, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17204-5; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bellodi C, 2013, CELL REP, V3, P1493, DOI 10.1016/j.celrep.2013.04.030; Bellodi C, 2010, CANCER RES, V70, P6026, DOI 10.1158/0008-5472.CAN-09-4730; Boccaletto P, 2018, NUCLEIC ACIDS RES, V46, pD303, DOI 10.1093/nar/gkx1030; Cancer Genome Atlas Research Network, 2018, Nature, V559, pE12, DOI [10.1038/nature13385, 10.1038/s41586-018-0228-6]; Chang LS, 2002, BIOCHEM BIOPH RES CO, V299, P196, DOI 10.1016/S0006-291X(02)02623-2; Chen JB, 2018, J CANCER, V9, P4774, DOI 10.7150/jca.25811; Chen LY, 2015, SCI REP-UK, V5, DOI 10.1038/srep08588; Dong XY, 2008, HUM MOL GENET, V17, P1031, DOI 10.1093/hmg/ddm375; Dong XY, 2009, J GENET GENOMICS, V36, P447, DOI 10.1016/S1673-8527(08)60134-4; Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074; Fernandez-Marcelo T, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0195-9; Gainor JF, 2013, CLIN CANCER RES, V19, P4273, DOI 10.1158/1078-0432.CCR-13-0318; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Heiss NS, 1998, NAT GENET, V19, P32, DOI 10.1038/ng0598-32; Ji P, 2003, ONCOGENE, V22, P8031, DOI 10.1038/sj.onc.1206928; Jordan EJ, 2017, CANCER DISCOV, V7, P596, DOI 10.1158/2159-8290.CD-16-1337; Kiss AM, 2002, NUCLEIC ACIDS RES, V30, P4643, DOI 10.1093/nar/gkf592; Kiss T, 2001, EMBO J, V20, P3617, DOI 10.1093/emboj/20.14.3617; de Sousa VML, 2018, PATHOBIOLOGY, V85, P96, DOI 10.1159/000487440; Lekka E, 2018, FEBS LETT, V592, P2884, DOI 10.1002/1873-3468.13182; Li W, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0554-4; Lu QC, 2018, FASEB J, V32, P3957, DOI 10.1096/fj.201701237RR; Machnicka Magdalena A, 2013, Nucleic Acids Res, V41, pD262, DOI 10.1093/nar/gks1007; Mannoor K, 2012, BBA-REV CANCER, V1826, P121, DOI 10.1016/j.bbcan.2012.03.005; Massenet S, 2017, RNA BIOL, V14, P680, DOI 10.1080/15476286.2016.1243646; McMahon M, 2015, WIRES RNA, V6, P173, DOI 10.1002/wrna.1266; Mei YP, 2012, ONCOGENE, V31, P2794, DOI 10.1038/onc.2011.449; Meier UT, 2005, CHROMOSOMA, V114, P1, DOI 10.1007/s00412-005-0333-9; Nagy A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27521-y; Okugawa Y, 2017, GUT, V66, P107, DOI 10.1136/gutjnl-2015-309359; Pao W, 2004, SEMIN CANCER BIOL, V14, P33, DOI 10.1016/j.semcancer.2003.11.005; Pasquinelli AE, 2012, NAT REV GENET, V13, P271, DOI 10.1038/nrg3162; Penzo M, 2018, BIOMOLECULES, V8, DOI 10.3390/biom8020038; Polacek N, 2005, CRIT REV BIOCHEM MOL, V40, P285, DOI 10.1080/10409230500326334; Riely Gregory J, 2009, Proc Am Thorac Soc, V6, P201, DOI 10.1513/pats.200809-107LC; Schmidt LH, 2011, J THORAC ONCOL, V6, P1984, DOI 10.1097/JTO.0b013e3182307eac; Schwartz S, 2014, CELL, V159, P148, DOI 10.1016/j.cell.2014.08.028; Shalem O, 2014, SCIENCE, V343, P84, DOI 10.1126/science.1247005; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Taft RJ, 2010, J PATHOL, V220, P126, DOI 10.1002/path.2638; Torre LA, 2016, ADV EXP MED BIOL, V893, P1, DOI 10.1007/978-3-319-24223-1_1; TYC K, 1989, EMBO J, V8, P3113, DOI 10.1002/j.1460-2075.1989.tb08463.x; Walne AJ, 2007, HUM MOL GENET, V16, P1619, DOI 10.1093/hmg/ddm111; Yoshihama Maki, 2013, BMC Res Notes, V6, P426, DOI 10.1186/1756-0500-6-426; Zaringhalam M, 2016, METHODS, V107, P63, DOI 10.1016/j.ymeth.2016.03.001; Zhang Y, 2017, STEM CELLS, V35, P222, DOI 10.1002/stem.2490; Zhou FB, 2017, NAT CELL BIOL, V19, P844, DOI 10.1038/ncb3563	53	17	17	2	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2021	40	5					909	921		10.1038/s41388-020-01570-y	http://dx.doi.org/10.1038/s41388-020-01570-y		DEC 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC5NB	33288886	hybrid, Green Published			2022-12-17	WOS:000599015000001
J	Ma, JF; Weng, L; Bastian, BC; Chen, X				Ma, Jiafang; Weng, Li; Bastian, Boris C.; Chen, Xu			Functional characterization of uveal melanoma oncogenes	ONCOGENE			English	Article							ACTIVATING MUTATIONS; SOMATIC MUTATIONS; GNA11 MUTATIONS; ALPHA-SUBUNIT; SF3B1; PHOSPHORYLATION; EXPRESSION; PLATFORM; RASGRP3; PATHWAY	Uveal melanoma (UM) is a currently untreatable form of melanoma with a 50% mortality rate. Characterization of the essential signaling pathways driving this cancer is critical to develop target therapies. Activating mutations in the G alpha q signaling pathway at the level of GNAQ, GNA11, or rarely CYSLTR2 or PLC beta 4 are considered alterations driving proliferation in UM and several other neoplastic disorders. Here, we systematically examined the oncogenic signaling output of various mutations recurrently identified in human tumors. We demonstrate that CYSLTR2 -> GNAQ/11 -> PLC beta act in a linear signaling cascade that, via protein kinase C (PKC), activates in parallel the MAP-kinase and FAK/Yes-associated protein pathways. Using genetic ablation and pharmacological inhibition, we show that the PKC/RasGRP3/MAPK signaling branch is the essential component that drives the proliferation of UM. Only inhibition of the MAPK branch but not the FAK branch synergizes with inhibition of the proximal cascade, providing a blueprint for combination therapy. All oncogenic signaling could be extinguished by the novel GNAQ/11 inhibitor YM-254890, in all UM cells with driver mutation in the G alpha q subunit or the upstream receptor. Our findings highlight the GNAQ/11 -> PLC beta -> PKC -> MAPK pathway as the central signaling axis to be suppressed pharmacologically to treat for neoplastic disorders with G alpha q pathway mutations.	[Ma, Jiafang; Weng, Li; Bastian, Boris C.; Chen, Xu] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA; [Ma, Jiafang; Weng, Li; Bastian, Boris C.; Chen, Xu] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA; [Ma, Jiafang; Weng, Li; Bastian, Boris C.; Chen, Xu] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center	Bastian, BC; Chen, X (corresponding author), Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA.; Bastian, BC; Chen, X (corresponding author), Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA.; Bastian, BC; Chen, X (corresponding author), Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA.	Boris.Bastian@ucsf.edu; Xu.Chen@ucsf.edu		chen, xu/0000-0003-2524-4979	National Cancer Institute [CA220481, CA142873]; Gerson and Barbara Baker Distinguished Professorship	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Gerson and Barbara Baker Distinguished Professorship	This work was supported by R35 grant CA220481 and R01 grant CA142873 from the National Cancer Institute and the Gerson and Barbara Baker Distinguished Professorship (all to BCB). We thank Han Yue for providing help for IP1 assay. We thank the Preclinical Therapeutics, Laboratory for Cell Analysis of University of California, San Francisco for technical support and analyses.	Amirouchene-Angelozzi N, 2014, MOL ONCOL, V8, P1508, DOI 10.1016/j.molonc.2014.06.004; Annala S, 2019, SCI SIGNAL, V12, DOI 10.1126/scisignal.aau5948; ARNESEN K, 1985, INT OPHTHALMOL, V7, P143, DOI 10.1007/BF00128360; Ayturk UM, 2016, AM J HUM GENET, V98, P789, DOI 10.1016/j.ajhg.2016.03.009; Bean GR, 2017, MODERN PATHOL, V30, P722, DOI 10.1038/modpathol.2016.234; Cao J, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkw660; Carvajal RD, 2018, J CLIN ONCOL, V36, P1232, DOI 10.1200/JCO.2017.74.1090; Carvajal RD, 2014, JAMA-J AM MED ASSOC, V311, P2397, DOI 10.1001/jama.2014.6096; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen X, 2014, ONCOGENE, V33, P4724, DOI 10.1038/onc.2013.418; Chen X, 2017, CANCER CELL, V31, P685, DOI 10.1016/j.ccell.2017.04.002; Couto JA, 2017, ANGIOGENESIS, V20, P303, DOI 10.1007/s10456-016-9538-1; Couto JA, 2016, PLAST RECONSTR SURG, V137, p77E, DOI 10.1097/PRS.0000000000001868; Di Veroli GY, 2016, BIOINFORMATICS, V32, P2866, DOI 10.1093/bioinformatics/btw230; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; Feng XD, 2019, CANCER CELL, V35, P457, DOI 10.1016/j.ccell.2019.01.009; Feng XD, 2014, CANCER CELL, V25, P831, DOI 10.1016/j.ccr.2014.04.016; Furney SJ, 2013, CANCER DISCOV, V3, P1122, DOI 10.1158/2159-8290.CD-13-0330; Goldsmith ZG, 2007, ONCOGENE, V26, P3122, DOI 10.1038/sj.onc.1210407; Griewank KG, 2012, PIGM CELL MELANOMA R, V25, DOI 10.1111/j.1755-148X.2012.00971.x; Hao YW, 2008, J BIOL CHEM, V283, P5496, DOI 10.1074/jbc.M709037200; Harbour JW, 2013, NAT GENET, V45, P133, DOI 10.1038/ng.2523; Harbour JW, 2010, SCIENCE, V330, P1410, DOI 10.1126/science.1194472; Heasley LE, 1996, MOL CELL BIOL, V16, P648; JHON DY, 1993, J BIOL CHEM, V268, P6654; Johansson P, 2016, ONCOTARGET, V7, P4624, DOI 10.18632/oncotarget.6614; Joseph NM, 2018, AM J SURG PATHOL, V42, P1201, DOI 10.1097/PAS.0000000000001110; Kamato D., 2015, FRONTIERS CARDIOVASC, V2, P1, DOI [10.3389/FCVM.2015.00014/BIBTEX, DOI 10.3389/FCVM.2015.00014/BIBTEX]; Kapiteijn E, 2019, CANCER RES, V79, DOI 10.1158/1538-7445.AM2019-CT068; Kim YJ, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-63391-z; Kostenis E, 2020, J BIOL CHEM, V295, P5206, DOI 10.1074/jbc.REV119.007061; Kuschak M, 2020, BRIT J PHARMACOL, V177, P1898, DOI 10.1111/bph.14960; Lapadula D, 2019, MOL CANCER RES, V17, P963, DOI 10.1158/1541-7786.MCR-18-0574; LEE CH, 1992, J BIOL CHEM, V267, P16044; LEE CW, 1994, J BIOL CHEM, V269, P25335; Levy D, 2008, MOL CELL, V29, P350, DOI 10.1016/j.molcel.2007.12.022; Li BC, 2019, J CLIN INVEST, V129, P1167, DOI 10.1172/JCI122440; Lim YH, 2016, AM J HUM GENET, V99, P443, DOI 10.1016/j.ajhg.2016.06.010; Malfacini D, 2019, J BIOL CHEM, V294, P5747, DOI 10.1074/jbc.RA118.007250; Martin M, 2013, NAT GENET, V45, P933, DOI 10.1038/ng.2674; Martins L, 2017, J MOL GRAPH MODEL, V76, P429, DOI 10.1016/j.jmgm.2017.07.011; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; Maziarz M, 2018, J BIOL CHEM, V293, P19586, DOI 10.1074/jbc.RA118.005291; Moore AR, 2018, CELL REP, V22, P2455, DOI 10.1016/j.celrep.2018.01.081; Moore AR, 2016, NAT GENET, V48, P675, DOI 10.1038/ng.3549; Murali R, 2012, ACTA NEUROPATHOL, V123, P457, DOI 10.1007/s00401-012-0948-x; Nakashima M, 2014, J HUM GENET, V59, P691, DOI 10.1038/jhg.2014.95; Onken MD, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aao6852; Piperno-Neumann S, 2020, MOL CANCER THER, V19, P1031, DOI 10.1158/1535-7163.MCT-19-0098; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Robertson AG, 2017, CANCER CELL, V32, P204, DOI 10.1016/j.ccell.2017.07.003; Rozengurt E, 2005, J BIOL CHEM, V280, P13205, DOI 10.1074/jbc.R500002200; Sanjana NE, 2014, NAT METHODS, V11, P783, DOI 10.1038/nmeth.3047; Schank TE, 2019, CANCERS, V11, DOI 10.3390/cancers11081048; Schneider B, 2019, PATHOL ONCOL RES, V25, P1319, DOI 10.1007/s12253-017-0371-7; Schrage R, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10156; Shain AH, 2019, NAT GENET, V51, P1123, DOI 10.1038/s41588-019-0440-9; Sheng XA, 2016, EUR J CANCER, V65, P156, DOI 10.1016/j.ejca.2016.06.019; Shirley MD, 2013, NEW ENGL J MED, V368, P1971, DOI 10.1056/NEJMoa1213507; Singh Arun D, 2005, Ophthalmol Clin North Am, V18, P75, DOI 10.1016/j.ohc.2004.07.002; Sugihara T, 2018, MOL CANCER RES, V16, P1556, DOI 10.1158/1541-7786.MCR-18-0158; Takasaki J, 2004, J BIOL CHEM, V279, P47438, DOI 10.1074/jbc.M408846200; Tanjoni I, 2010, CANCER BIOL THER, V9, P764, DOI 10.4161/cbt.9.10.11434; Teixeira C, 2003, BLOOD, V102, P1414, DOI 10.1182/blood-2002-11-3621; Thomas AC, 2016, J INVEST DERMATOL, V136, P770, DOI 10.1016/j.jid.2015.11.027; Tietze D, 2019, J CHEM INF MODEL, V59, P4361, DOI 10.1021/acs.jcim.9b00433; Trinquet E, 2006, ANAL BIOCHEM, V358, P126, DOI 10.1016/j.ab.2006.08.002; van Dinten LC, 2005, INVEST OPHTH VIS SCI, V46, P24, DOI 10.1167/iovs.04-0961; Van Raamsdonk CD, 2010, NEW ENGL J MED, V363, P2191, DOI 10.1056/NEJMoa1000584; Van Raamsdonk CD, 2009, NATURE, V457, P599, DOI 10.1038/nature07586; WILKIE TM, 1991, P NATL ACAD SCI USA, V88, P10049, DOI 10.1073/pnas.88.22.10049; Yu FX, 2014, CANCER CELL, V25, P822, DOI 10.1016/j.ccr.2014.04.017; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907	73	17	17	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	2021	40	4					806	820		10.1038/s41388-020-01569-5	http://dx.doi.org/10.1038/s41388-020-01569-5		DEC 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA4GO	33262460	Green Accepted, Green Submitted			2022-12-17	WOS:000595928700005
J	Song, Y; Zeng, SS; Zheng, GP; Chen, DY; Li, P; Yang, MQ; Luo, K; Yin, J; Gu, YX; Zhang, ZJ; Jia, XT; Qiu, N; He, ZM; Li, HS; Liu, H				Song, Ying; Zeng, Shanshan; Zheng, Guopei; Chen, Danyang; Li, Pan; Yang, Mingqiang; Luo, Kai; Yin, Jiang; Gu, Yixue; Zhang, Zhijie; Jia, Xiaoting; Qiu, Ni; He, Zhimin; Li, Hongsheng; Liu, Hao			FOXO3a-driven miRNA signatures suppresses VEGF-A/NRP1 signaling and breast cancer metastasis	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; ENDOTHELIAL GROWTH-FACTOR; TUMOR PROGRESSION; FOXO3A; VEGF; MICROENVIRONMENT; NEUROPILIN-1; ACTIVATION; EXPRESSION; KNOCKDOWN	Metastasis remains the major obstacle to improved survival for breast cancer patients. Downregulation of FOXO3a transcription factor in breast cancer is causally associated with the development of metastasis through poorly understood mechanisms. Here, we report that FOXO3a is functionally related to the inhibition of VEGF-A/NRP1 signaling and to the consequent suppression of breast cancer metastasis. We show that FOXO3a directly induces miR-29b-2 and miR-338 expression. Ectopic expression of miR-29b-2/miR-338 significantly suppresses EMT, migration/invasion, and in vivo metastasis of breast cancer. Moreover, we demonstrate that miR-29b-2 directly targets VEGF-A while miR-338 directly targets NRP1, and show that regulation of miR-29b-2 and miR-338 mediates the ability of FOXO3a to suppress VEGF-A/NRP1 signaling and breast cancer metastasis. Clinically, our results show that the FOXO3a-miR-29b-2/miR-338-VEGF-A/NRP1 axis is dysregulated and plays a critical role in disease progression in breast cancer. Collectively, our findings propose that FOXO3a functions as a metastasis suppressor, and define a novel signaling axis of FOXO3a-miRNA-VEGF-A/NRP1 in breast cancer, which might be potential therapeutic targets for breast cancer.	[Song, Ying; Zeng, Shanshan; Zheng, Guopei; Chen, Danyang; Li, Pan; Yang, Mingqiang; Luo, Kai; Yin, Jiang; Gu, Yixue; Zhang, Zhijie; Jia, Xiaoting; Qiu, Ni; He, Zhimin; Li, Hongsheng; Liu, Hao] Canc Hosp, Guangzhou 510095, Peoples R China; [Song, Ying; Zeng, Shanshan; Zheng, Guopei; Chen, Danyang; Li, Pan; Yang, Mingqiang; Luo, Kai; Yin, Jiang; Gu, Yixue; Zhang, Zhijie; Jia, Xiaoting; Qiu, Ni; He, Zhimin; Li, Hongsheng; Liu, Hao] Inst Guangzhou Med Univ, Guangzhou Key Lab Translat Med Malignant Tumor Tr, Guangzhou 510095, Peoples R China		He, ZM; Li, HS; Liu, H (corresponding author), Canc Hosp, Guangzhou 510095, Peoples R China.; He, ZM; Li, HS; Liu, H (corresponding author), Inst Guangzhou Med Univ, Guangzhou Key Lab Translat Med Malignant Tumor Tr, Guangzhou 510095, Peoples R China.	hezhimin2005@yahoo.com; lihongsheng@gzhmu.edu.cn; haoliu2020@163.com		Liu, Hao/0000-0001-6338-4003; SONG, YING/0000-0002-5781-0317	National Natural Science Foundation of China [81772825, 81402497, 81672616, 81272450]; Guangdong Natural Science Funds for Distinguished Young Scholars [2016A030306003]; Guangdong Special Support Program [2017TQ04R809]; Guangdong Natural Science Funds [2017A030313500, 2017A030313867]; Science and Technology Program of Guangzhou [201707010381, 201707010354]; Clinical Key Specialty Project of Guangzhou Medical University [2020-05]; Guangzhou key medical discipline construction project fund	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Natural Science Funds for Distinguished Young Scholars; Guangdong Special Support Program; Guangdong Natural Science Funds; Science and Technology Program of Guangzhou; Clinical Key Specialty Project of Guangzhou Medical University; Guangzhou key medical discipline construction project fund	This work was supported by the National Natural Science Foundation of China (81772825, 81402497, 81672616, and 81272450), supported by grants from Guangdong Natural Science Funds for Distinguished Young Scholars (No.2016A030306003), Supported by Guangdong Special Support Program (2017TQ04R809), grants from Guangdong Natural Science Funds (2017A030313500 and 2017A030313867), the Science and Technology Program of Guangzhou (201707010381 and 201707010354), Clinical Key Specialty Project of Guangzhou Medical University (No. 2020-05), and Guangzhou key medical discipline construction project fund.	Allen JE, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004828; Bando H, 2005, BRIT J CANCER, V92, P553, DOI 10.1038/sj.bjc.6602374; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Cheng CW, 2015, ONCOTARGET, V6, P44222, DOI 10.18632/oncotarget.5826; Chou CC, 2014, CANCER RES, V74, P4783, DOI 10.1158/0008-5472.CAN-14-0135; Chou J, 2013, NAT CELL BIOL, V15, P201, DOI 10.1038/ncb2672; Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Ghosh S, 2008, HUM PATHOL, V39, P1835, DOI 10.1016/j.humpath.2008.06.004; Harbeck N, 2019, NAT REV DIS PRIMERS, V5, DOI [10.1038/s41572-019-0111-2, 10.1038/s41572-019-0122-z]; Herzog B, 2011, MOL BIOL CELL, V22, P2766, DOI 10.1091/mbc.E09-12-1061; Hornsveld M, 2018, CANCER RES, V78, P2356, DOI 10.1158/0008-5472.CAN-17-2511; Jin Y, 2015, INT J ONCOL, V47, P1594, DOI 10.3892/ijo.2015.3114; Jubb AM, 2012, J PATHOL, V226, P50, DOI 10.1002/path.2989; Karadedou CT, 2012, ONCOGENE, V31, P1845, DOI 10.1038/onc.2011.368; Karaman S, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.151019; Lam EWF, 2013, NAT REV CANCER, V13, P482, DOI 10.1038/nrc3539; Li J, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1046-x; Liu H, 2020, CELL DEATH DIFFER, V27, P966, DOI 10.1038/s41418-019-0389-3; Liu H, 2015, CELL SIGNAL, V27, P510, DOI 10.1016/j.cellsig.2015.01.001; Liu YQ, 2018, MOL CANCER, V17, DOI 10.1186/s12943-017-0751-3; Lu Jing, 2009, Cancer Res, V69, P4951, DOI 10.1158/0008-5472.CAN-09-0099; Luo M, 2019, CANCER LETT, V455, P26, DOI 10.1016/j.canlet.2019.04.019; Luo MN, 2016, CANCER LETT, V373, P1, DOI 10.1016/j.canlet.2016.01.010; Ma ZQ, 2018, SEMIN CANCER BIOL, V50, P21, DOI 10.1016/j.semcancer.2018.02.004; Ni D, 2014, CLIN CANCER RES, V20, P1779, DOI 10.1158/1078-0432.CCR-13-1687; Peng Y, 2016, SIGNAL TRANSDUCT TAR, V1, DOI 10.1038/sigtrans.2015.4; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Ru P, 2012, MOL CANCER THER, V11, P1166, DOI 10.1158/1535-7163.MCT-12-0100; Saharinen P, 2011, TRENDS MOL MED, V17, P347, DOI 10.1016/j.molmed.2011.01.015; Shiota M, 2010, CLIN CANCER RES, V16, P5654, DOI 10.1158/1078-0432.CCR-10-0376; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Spill F, 2016, CURR OPIN BIOTECH, V40, P41, DOI 10.1016/j.copbio.2016.02.007; Stafford LJ, 2008, INT J BIOCHEM CELL B, V40, P874, DOI 10.1016/j.biocel.2007.12.016; Storz P, 2009, MOL CELL BIOL, V29, P4906, DOI 10.1128/MCB.00077-09; Su JC, 2016, SCI REP-UK, V6, DOI 10.1038/srep28888; Sun F, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0611-0; Sunters A, 2003, J BIOL CHEM, V278, P49795, DOI 10.1074/jbc.M309523200; Tenbaum SP, 2012, NAT MED, V18, P892, DOI 10.1038/nm.2772; Wang K, 2010, J BIOL CHEM, V285, P16958, DOI 10.1074/jbc.M109.093005; Weigelt B, 2005, NAT REV CANCER, V5, P591, DOI 10.1038/nrc1670; Yang JY, 2008, NAT CELL BIOL, V10, P138, DOI 10.1038/ncb1676; Yang JY, 2009, CLIN CANCER RES, V15, P752, DOI 10.1158/1078-0432.CCR-08-0124; Yeung KT, 2017, MOL ONCOL, V11, P28, DOI 10.1002/1878-0261.12017; Zou YY, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1872	45	17	18	4	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	2021	40	4					777	790		10.1038/s41388-020-01562-y	http://dx.doi.org/10.1038/s41388-020-01562-y		DEC 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA4GO	33262463	Green Published, hybrid			2022-12-17	WOS:000595928700008
J	Angel, I; Kerman, OP; Rousso-Noori, L; Friedmann-Morvinski, D				Angel, Inbar; Pilo Kerman, Ori; Rousso-Noori, Liat; Friedmann-Morvinski, Dinorah			Tenascin C promotes cancer cell plasticity in mesenchymal glioblastoma	ONCOGENE			English	Article							NF-KAPPA-B; STEM-CELLS; GLIOMA; ACTIVATION; DIFFERENTIATION; TRANSFORMATION; ANGIOGENESIS; INHIBITION; PROGNOSIS; RAS	Interconversion of transformed non-stem cells to cancer stem cells, termed cancer cell plasticity, contributes to intra-tumor heterogeneity and its molecular mechanisms are currently unknown. Here, we have identified Tenascin C (TNC) to be upregulated and secreted in mesenchymal glioblastoma (MES GBM) subtype with high NF-kappa B signaling activity. Silencing TNC decreases proliferation, migration and suppresses self-renewal of glioma stem cells. Loss of TNC in MES GBM compromises de-differentiation of transformed astrocytes and blocks the ability of glioma stem cells to differentiate into tumor derived endothelial cells (TDEC). Inhibition of NF-kappa B activity or TNC knockdown in tumor cells decreased their tumorigenic potential in vivo. Our results uncover a link between NF-kappa B activation in MES GBM and high levels of TNC in GBM extracellular matrix. We suggest that TNC plays an important role in the autocrine regulation of glioma cell plasticity and hence can be a potential molecular target for MES GBM.	[Angel, Inbar; Pilo Kerman, Ori; Rousso-Noori, Liat; Friedmann-Morvinski, Dinorah] Tel Aviv Univ, Sch Neurobiol Biochem & Biophys, George S Wise Fac Life Sci, Tel Aviv, Israel; [Friedmann-Morvinski, Dinorah] Tel Aviv Univ, Sagol Sch Neurosci, Tel Aviv, Israel	Tel Aviv University; Tel Aviv University	Friedmann-Morvinski, D (corresponding author), Tel Aviv Univ, Sch Neurobiol Biochem & Biophys, George S Wise Fac Life Sci, Tel Aviv, Israel.; Friedmann-Morvinski, D (corresponding author), Tel Aviv Univ, Sagol Sch Neurosci, Tel Aviv, Israel.	dino@tauex.tau.ac.il		Friedmann-Morvinski, Dinorah/0000-0002-6394-9876; Rousso Noori, Liat/0000-0001-7582-3165	Israel Science Foundation [1310/15]; Israel Cancer Research Fund (Research Career Development Award); EU-FP7 Marie Curie Actions (Career Integration Grant)	Israel Science Foundation(Israel Science Foundation); Israel Cancer Research Fund (Research Career Development Award); EU-FP7 Marie Curie Actions (Career Integration Grant)	We thank Yifeng Xia and Eugene Ke for assistance in bioinformatic analysis, and Prof. Michal Baniyash for critically reading the manuscript. This research was supported by grants to DF-M from the Israel Science Foundation (Grant no. 1310/15), the Israel Cancer Research Fund (Research Career Development Award), and the EU-FP7 Marie Curie Actions (Career Integration Grant).	Androutsellis-Theotokis A, 2006, NATURE, V442, P823, DOI 10.1038/nature04940; Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028; Bhat KPL, 2013, CANCER CELL, V24, P331, DOI 10.1016/j.ccr.2013.08.001; Bottero V, 2006, CELL DEATH DIFFER, V13, P785, DOI 10.1038/sj.cdd.4401888; Bowman RL, 2017, NEURO-ONCOLOGY, V19, P139, DOI 10.1093/neuonc/now247; Brosicke N, 2015, CELL ADHES MIGR, V9, P131, DOI 10.1080/19336918.2014.1000071; Cabrera MC, 2015, WORLD J STEM CELLS, V7, P27, DOI 10.4252/wjsc.v7.i1.27; Carro MS, 2010, NATURE, V463, P318, DOI 10.1038/nature08712; Chaffer CL, 2013, CELL, V154, P61, DOI 10.1016/j.cell.2013.06.005; Chiquet-Ehrismann R, 2014, MATRIX BIOL, V37, P112, DOI 10.1016/j.matbio.2014.01.007; Dufraine J, 2008, ONCOGENE, V27, P5132, DOI 10.1038/onc.2008.227; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; Friedmann-Morvinski D, 2016, ONCOGENE, V35, P608, DOI 10.1038/onc.2015.119; Friedmann-Morvinski D, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1501292; Friedmann-Morvinski Dinorah, 2014, Critical Reviews in Oncogenesis, V19, P327; Friedmann-Morvinski D, 2014, EMBO REP, V15, P244, DOI 10.1002/embr.201338254; Friedmann-Morvinski D, 2012, SCIENCE, V338, P1080, DOI 10.1126/science.1226929; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; Garcion E, 2004, DEVELOPMENT, V131, P3423, DOI 10.1242/dev.01202; Gridley T, 2007, DEVELOPMENT, V134, P2709, DOI 10.1242/dev.004184; Hovinga KE, 2010, STEM CELLS, V28, P1019, DOI 10.1002/stem.429; Huse JT, 2011, GLIA, V59, P1190, DOI 10.1002/glia.21165; Ischenko I, 2013, P NATL ACAD SCI USA, V110, P3937, DOI 10.1073/pnas.1219592110; Langlois B, 2014, ONCOTARGET, V5, P10529, DOI 10.18632/oncotarget.2470; Lowy CM, 2015, CELL ADHES MIGR, V9, P112, DOI 10.1080/19336918.2015.1008331; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Martiny-Baron G, 2010, ANGIOGENESIS, V13, P259, DOI 10.1007/s10456-010-9183-z; Marumoto T, 2009, NAT MED, V15, P110, DOI 10.1038/nm.1863; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Mettouchi A, 1997, MOL CELL BIOL, V17, P3202, DOI 10.1128/MCB.17.6.3202; Midwood KS, 2016, J CELL SCI, V129, P4321, DOI 10.1242/jcs.190546; Midwood KS, 2011, CELL MOL LIFE SCI, V68, P3175, DOI 10.1007/s00018-011-0783-6; Miroshnikova YA, 2016, NAT CELL BIOL, V18, P1336, DOI 10.1038/ncb3429; Nie S, 2015, J PROTEOME RES, V14, P814, DOI 10.1021/pr5008653; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Poltavets V, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00431; Ricci-Vitiani L, 2010, NATURE, V468, P824, DOI 10.1038/nature09557; Rupp T, 2016, CELL REP, V17, P2607, DOI 10.1016/j.celrep.2016.11.012; Saito N, 2014, STEM CELLS, V32, P301, DOI 10.1002/stem.1528; Sarkar S, 2017, CANCER RES, V77, P3231, DOI 10.1158/0008-5472.CAN-16-2171; Schwitalla S, 2013, CELL, V152, P25, DOI 10.1016/j.cell.2012.12.012; Shen Q, 2004, SCIENCE, V304, P1338, DOI 10.1126/science.1095505; Soda Y, 2011, P NATL ACAD SCI USA, V108, P4274, DOI 10.1073/pnas.1016030108; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Xia SL, 2016, NEURO-ONCOLOGY, V18, P507, DOI 10.1093/neuonc/nov171; Yamini B, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7090125; Yoshida T, 2015, CELL ADHES MIGR, V9, P96, DOI 10.1080/19336918.2015.1008332; Zuber J, 2011, NAT BIOTECHNOL, V29, P79, DOI 10.1038/nbt.1720	51	17	18	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 12	2020	39	46					6990	7004		10.1038/s41388-020-01506-6	http://dx.doi.org/10.1038/s41388-020-01506-6		OCT 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OQ9FF	33077835				2022-12-17	WOS:000579741400001
J	Ray, U; Raghavan, SC				Ray, Ujjayinee; Raghavan, Sathees C.			Modulation of DNA double-strand break repair as a strategy to improve precise genome editing	ONCOGENE			English	Review							HOMOLOGY-DIRECTED REPAIR; ONE-STEP GENERATION; KNOCK-IN; EFFICIENT GENERATION; RESTRICTION ENZYMES; ENCAPSULATED SCR7; HUMAN-CELLS; CRISPR-CAS9; PROTEIN; MICE	In the present day, it is possible to incorporate targeted mutations or replace a gene using genome editing techniques such as customisable CRISPR/Cas9 system. Although induction of DNA double-strand breaks (DSBs) by genome editing tools can be repaired by both non-homologous end joining (NHEJ) and homologous recombination (HR), the skewness of the former pathway in human and other mammals normally result in imprecise repair. Scientists working at the crossroads of DNA repair and genome editing have devised new strategies for using a specific pathway to their advantage. Refinement in the efficiency of precise gene editing was witnessed upon downregulation of NHEJ by knockdown or using small molecule inhibitors on one hand, and upregulation of HR proteins and addition of HR stimulators, other hand. The exploitation of cell cycle phase differences together with appropriate donor DNA length/sequence and small molecules has provided further improvement in precise genome editing. The present article reviews the mechanisms of improving the efficiency of precise genome editing in several model organisms and in clinics.	[Ray, Ujjayinee; Raghavan, Sathees C.] Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore	Raghavan, SC (corresponding author), Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India.	sathees@iisc.ac.in			CEFIPRA [IFC/52034/2015/131]; DAE [21/01/2016-BRNS/35074]; DBT Glue-Grant [BT/PR23078/MED/29/1253/2017]; IISc-DBT partnership programme [BT/PR27952-INF/22/212/2018]; CSIR, India	CEFIPRA; DAE(Department of Atomic Energy (DAE)); DBT Glue-Grant; IISc-DBT partnership programme(Indian Institute of Science (IISC) - Bangalore); CSIR, India(Council of Scientific & Industrial Research (CSIR) - India)	We thank Urbi Roy, Dipayan Ghosh and other members of SCR laboratory for critical reading and comments on the paper. This work was supported by grants from CEFIPRA (IFC/52034/2015/131), DAE (21/01/2016-BRNS/35074), DBT Glue-Grant (BT/PR23078/MED/29/1253/2017), IISc-DBT partnership programme (BT/PR27952-INF/22/212/2018) to SCR. UR is supported by Senior Research Fellowship (SRF) from CSIR, India.	Aird EJ, 2018, COMMUN BIOL, V1, DOI 10.1038/s42003-018-0054-2; Allen AG, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02940; Aslan Y, 2017, DEVELOPMENT, V144, P2852, DOI 10.1242/dev.152967; Auer TO, 2014, GENOME RES, V24, P142, DOI 10.1101/gr.161638.113; Barrangou R, 2016, NAT BIOTECHNOL, V34, P933, DOI 10.1038/nbt.3659; Beumer KJ, 2008, P NATL ACAD SCI USA, V105, P19821, DOI 10.1073/pnas.0810475105; Bhargava R, 2016, TRENDS GENET, V32, P566, DOI 10.1016/j.tig.2016.06.007; Boboila C, 2010, P NATL ACAD SCI USA, V107, P3034, DOI 10.1073/pnas.0915067107; Boch J, 2009, SCIENCE, V326, P1509, DOI 10.1126/science.1178811; Boel A, 2018, DIS MODEL MECH, V11, DOI 10.1242/dmm.035352; Brinkman EK, 2018, MOL CELL, V70, P801, DOI 10.1016/j.molcel.2018.04.016; Canny MD, 2018, NAT BIOTECHNOL, V36, P95, DOI 10.1038/nbt.4021; Carlson-Stevermer J, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01875-9; Ceccaldi R, 2016, TRENDS CELL BIOL, V26, P52, DOI 10.1016/j.tcb.2015.07.009; Chandrasegaran S, 2016, J MOL BIOL, V428, P963, DOI 10.1016/j.jmb.2015.10.014; Charpentier M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03475-7; Chen SA, 2019, CELL REP, V27, P3780, DOI 10.1016/j.celrep.2019.05.103; Christian M, 2010, GENETICS, V186, P757, DOI 10.1534/genetics.110.120717; Davis AJ, 2013, TRANSL CANCER RES, V2, P130, DOI 10.3978/j.issn.2218-676X.2013.04.02; Davis KM, 2015, NAT CHEM BIOL, V11, P316, DOI [10.1038/nchembio.1793, 10.1038/NCHEMBIO.1793]; Davis L, 2016, CELL REP, V17, P1872, DOI 10.1016/j.celrep.2016.10.049; Di Primio C, 2005, NUCLEIC ACIDS RES, V33, P4639, DOI 10.1093/nar/gki778; Du J, 2018, MOL CANCER THER, V17, P419, DOI 10.1158/1535-7163.MCT-17-0090; Dungl DA, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00240; Frank KM, 1998, NATURE, V396, P173, DOI 10.1038/24172; Gaj T, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a023754; Greco GE, 2016, DNA REPAIR, V43, P18, DOI 10.1016/j.dnarep.2016.04.004; Grundy GJ, 2013, EMBO J, V32, P112, DOI 10.1038/emboj.2012.304; Gutschner T, 2016, CELL REP, V14, P1555, DOI 10.1016/j.celrep.2016.01.019; Haber JE, 2016, ANNU REV GENET, V50, P1, DOI 10.1146/annurev-genet-120215-035043; Harper JW, 2007, MOL CELL, V28, P739, DOI 10.1016/j.molcel.2007.11.015; Hart T, 2015, CELL, V163, DOI 10.1016/j.cell.2015.11.015; Heyer WD, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a016501; Holt N, 2010, NAT BIOTECHNOL, V28, P839, DOI 10.1038/nbt.1663; Hsu PD, 2014, CELL, V157, P1262, DOI 10.1016/j.cell.2014.05.010; Hu Z, 2018, CELL BIOSCI, V8, DOI 10.1186/s13578-018-0200-z; Huang XS, 2015, STEM CELLS, V33, P1470, DOI 10.1002/stem.1969; Hung PJ, 2018, MOL CELL, V71, P332, DOI 10.1016/j.molcel.2018.06.018; Hyodo T, 2020, CELL REP, V30, P1195, DOI 10.1016/j.celrep.2019.12.064; Jasin M, 2016, DNA REPAIR, V44, P6, DOI 10.1016/j.dnarep.2016.05.001; Javadekar SM, 2015, FEBS J, V282, P2627, DOI 10.1111/febs.13311; Jayavaradhan R, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10735-7; Jinek M, 2012, SCIENCE, V337, P816, DOI 10.1126/science.1225829; John F, 2015, FARADAY DISCUSS, V177, P155, DOI 10.1039/c4fd00176a; John F, 2015, MACROMOL BIOSCI, V15, P521, DOI 10.1002/mabi.201400480; Kent T, 2015, NAT STRUCT MOL BIOL, V22, P230, DOI 10.1038/nsmb.2961; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Killian T, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15206-x; Kim YG, 1996, P NATL ACAD SCI USA, V93, P1156, DOI 10.1073/pnas.93.3.1156; Kostyushev D, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-38526-6; Kulashreshtha M, 2016, NUCLEIC ACIDS RES, V44, P8272, DOI 10.1093/nar/gkw573; Lackner DH, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10237; Leahy JJJ, 2004, BIOORG MED CHEM LETT, V14, P6083, DOI 10.1016/j.bmcl.2004.09.060; Li GL, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09306-x; Li HY, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-019-0089-y; Lieber MR, 2010, ANNU REV BIOCHEM, V79, P181, DOI 10.1146/annurev.biochem.052308.093131; Lin S, 2014, ELIFE, V3, DOI 10.7554/eLife.04766; Liu YF, 2016, SCI REP-UK, V6, DOI 10.1038/srep24014; Lok BH, 2013, ONCOGENE, V32, P3552, DOI 10.1038/onc.2012.391; Ma M, 2017, CELL RES, V27, P578, DOI 10.1038/cr.2017.29; Ma YW, 2016, RNA BIOL, V13, P605, DOI 10.1080/15476286.2016.1185591; Mali P, 2013, SCIENCE, V339, P823, DOI 10.1126/science.1232033; Mao ZY, 2008, DNA REPAIR, V7, P1765, DOI 10.1016/j.dnarep.2008.06.018; Maruyama T, 2015, NAT BIOTECHNOL, V33, P538, DOI 10.1038/nbt.3190; Mikuni T, 2016, CELL, V165, P1803, DOI 10.1016/j.cell.2016.04.044; Miura H, 2018, NAT PROTOC, V13, P195, DOI 10.1038/nprot.2017.153; Moreno-Mateos MA, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01836-2; Moscou MJ, 2009, SCIENCE, V326, P1501, DOI 10.1126/science.1178817; Nambiar M, 2011, NUCLEIC ACIDS RES, V39, P5813, DOI 10.1093/nar/gkr223; Nambiar TS, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11105-z; Tran NT, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00365; Ochi T, 2015, SCIENCE, V347, P185, DOI 10.1126/science.1261971; Ochs F, 2016, NAT STRUCT MOL BIOL, V23, P714, DOI 10.1038/nsmb.3251; Orthwein A, 2015, NATURE, V528, P422, DOI 10.1038/nature16142; Pandey M., 2019, J RAD CANC RES, V10, P27, DOI 10.4103/jrcr.jrcr_24_18; Pandey M., 2017, J RADIAT CANCER RES, V8, P93, DOI [10.4103/jrcr.jrcr_18_17, DOI 10.4103/JRCR.JRCR_18_17]; Paulsen BS, 2017, NAT BIOMED ENG, V1, P878, DOI 10.1038/s41551-017-0145-2; Pawelczak KS, 2018, ACS CHEM BIOL, V13, P389, DOI 10.1021/acschembio.7b00777; Pinder J, 2015, NUCLEIC ACIDS RES, V43, P9379, DOI 10.1093/nar/gkv993; Ran FA, 2013, CELL, V154, P1380, DOI 10.1016/j.cell.2013.08.021; Ray U., 2020, CLIN ONCOL RES, V3, P2; Ray U, 2020, MOL CARCINOGEN, V59, P618, DOI 10.1002/mc.23186; Reid DA, 2017, NUCLEIC ACIDS RES, V45, P1872, DOI 10.1093/nar/gkw1221; Reid DA, 2015, P NATL ACAD SCI USA, V112, pE2575, DOI 10.1073/pnas.1420115112; Reyes AP, 2018, CELL STEM CELL, V23, P155, DOI 10.1016/j.stem.2018.07.008; Richardson CD, 2018, NAT GENET, V50, P1132, DOI 10.1038/s41588-018-0174-0; Riesenberg S, 2019, NUCLEIC ACIDS RES, V47, pE116, DOI 10.1093/nar/gkz669; Riesenberg S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04609-7; Robert F, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0215-6; Saito S, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms16112; Savic N, 2018, ELIFE, V7, DOI 10.7554/eLife.33761; Savic N, 2016, TRANSL RES, V168, P15, DOI 10.1016/j.trsl.2015.09.008; Shao SM, 2017, INT J BIOCHEM CELL B, V92, P43, DOI 10.1016/j.biocel.2017.09.012; Sharma S, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.58; Shen B, 2014, NAT METHODS, V11, P399, DOI [10.1038/NMETH.2857, 10.1038/nmeth.2857]; Shim G, 2017, ACTA PHARMACOL SIN, V38, P738, DOI 10.1038/aps.2017.2; Singh P, 2015, GENETICS, V199, P1, DOI 10.1534/genetics.114.169771; Smith CE, 2007, NATURE, V447, P102, DOI 10.1038/nature05723; Smith C, 2015, MOL THER, V23, P570, DOI 10.1038/mt.2014.226; Smith J, 2000, NUCLEIC ACIDS RES, V28, P3361, DOI 10.1093/nar/28.17.3361; Song B, 2015, STEM CELLS DEV, V24, P1053, DOI 10.1089/scd.2014.0347; Song F, 2017, MOL THER-NUCL ACIDS, V7, P53, DOI 10.1016/j.omtn.2017.02.006; Song J, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10548; Srivastava M, 2015, CHEM BIOL, V22, P17, DOI 10.1016/j.chembiol.2014.11.013; Srivastava M, 2012, CELL, V151, P1474, DOI 10.1016/j.cell.2012.11.054; Suzuki K, 2016, NATURE, V540, P144, DOI 10.1038/nature20565; Tanenbaum ME, 2014, CELL, V159, P635, DOI 10.1016/j.cell.2014.09.039; Tomimatsu N, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4561; Tripathi V, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03393-8; Chu VT, 2015, NAT BIOTECHNOL, V33, P543, DOI 10.1038/nbt.3198; Vartak SV, 2018, FEBS J, V285, P3959, DOI 10.1111/febs.14661; Wang HY, 2013, CELL, V153, P910, DOI 10.1016/j.cell.2013.04.025; Wienert B, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15845-1; Wu Y, 2008, J BIOL CHEM, V283, P14883, DOI 10.1074/jbc.M801097200; Wyman C, 2006, ANNU REV GENET, V40, P363, DOI 10.1146/annurev.genet.40.110405.090451; Xu SX, 2020, PROTEIN CELL, V11, P352, DOI 10.1007/s13238-020-00699-6; Yang D, 2016, SCI REP-UK, V6, DOI 10.1038/srep21264; Yang H, 2013, CELL, V154, P1370, DOI 10.1016/j.cell.2013.08.022; Ye LP, 2018, CELL DISCOV, V4, DOI 10.1038/s41421-018-0049-7; Yu C, 2015, CELL STEM CELL, V16, P142, DOI 10.1016/j.stem.2015.01.003; Yu SL, 2011, J BIOTECHNOL, V154, P21, DOI 10.1016/j.jbiotec.2011.03.023; Zelensky AN, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00124-3	122	17	17	1	22	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 8	2020	39	41					6393	6405		10.1038/s41388-020-01445-2	http://dx.doi.org/10.1038/s41388-020-01445-2		SEP 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OA1JL	32884115				2022-12-17	WOS:000565829600002
J	Liang, ER; Lu, YS; Shi, YQ; Zhou, Q; Zhi, FC				Liang, Erbo; Lu, Yishi; Shi, Yanqiang; Zhou, Qian; Zhi, Fachao			MYEOV increases HES1 expression and promotes pancreatic cancer progression by enhancing SOX9 transactivity	ONCOGENE			English	Article							DNA METHYLATION; GENE-EXPRESSION; CELL; METASTASIS; EPIDEMIOLOGY; ACTIVATION; SUBSET; 11Q13; KRAS; SRY	Emerging evidence indicates that myeloma overexpressed (MYEOV) is an oncogene and plays crucial roles in multiple human cancers. However, its roles in the development of pancreatic ductal adenocarcinoma (PDAC) remain elusive. Here, we provide evidence of essential roles of MYEOV in the development and progression of PDAC. In tumor specimens derived from pancreatic cancer patients, MYEOV was overexpressed and associated with poor prognosis. In addition, MYEOV expression in PDAC was upregulated through promoter hypomethylation. MYEOV depletion impaired metastatic ability and proliferation of PDAC cells both in vitro and in vivo, whereas its overexpression had the opposite effect. Mechanistic investigations revealed that MYEOV interacted with SRY-Box Transcription Factor 9 (SOX9), a well-known oncogenic transcription factor in PDAC. This interaction occurred mainly in the nuclei of PDAC cells and increased transcriptional activity of SOX9. Furthermore, MYEOV promoted the expression ofHairy and enhancer of split homolog-1 (HES1), a SOX9 target gene, by enhancing SOX9 DNA-binding ability to theHES1enhancer without affecting the protein level and subcellular localization of SOX9. HES1 knockdown partly abrogated the oncogenic effect of MYEOV. Our findings suggest that MYEOV could be a potential prognostic biomarker and therapeutic target for PDAC.	[Liang, Erbo; Lu, Yishi; Shi, Yanqiang; Zhou, Qian; Zhi, Fachao] Guangdong Prov Key Lab Gastroenterol, Guangzhou 510515, Peoples R China; [Liang, Erbo; Lu, Yishi; Shi, Yanqiang; Zhou, Qian; Zhi, Fachao] Inst Gastroenterol Guangdong Prov, Guangzhou 510515, Peoples R China; [Liang, Erbo; Lu, Yishi; Shi, Yanqiang; Zhou, Qian; Zhi, Fachao] Southern Med Univ, Nanfang Hosp, Dept Gastroenterol, Guangzhou 510515, Peoples R China	Southern Medical University - China	Zhi, FC (corresponding author), Guangdong Prov Key Lab Gastroenterol, Guangzhou 510515, Peoples R China.; Zhi, FC (corresponding author), Inst Gastroenterol Guangdong Prov, Guangzhou 510515, Peoples R China.; Zhi, FC (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Gastroenterol, Guangzhou 510515, Peoples R China.	zhifc41532@163.com		Zhi, Fachao/0000-0001-8674-4737; Shi, Yanqiang/0000-0003-0814-6322				Abel EV, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091983; Coccaro N, 2016, ONCOL LETT, V12, P1460, DOI 10.3892/ol.2016.4759; Deng FH, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0244-8; Fang LS, 2019, ONCOGENE, V38, P896, DOI 10.1038/s41388-018-0484-9; Fukuda Akihisa, 2013, Gastroenterology, V145, P904, DOI 10.1053/j.gastro.2013.08.028; Grimm D, 2020, SEMIN CANCER BIOL, V67, P122, DOI 10.1016/j.semcancer.2019.03.004; Grimont A, 2015, GUT, V64, P1790, DOI 10.1136/gutjnl-2014-307075; Harley VR, 2003, ENDOCR REV, V24, P466, DOI 10.1210/er.2002-0025; Horie M, 2017, MOL CANCER RES, V15, P1354, DOI 10.1158/1541-7786.MCR-17-0191; Huang L, 2015, NAT MED, V21, P1364, DOI 10.1038/nm.3973; Huang WY, 2015, NUCLEIC ACIDS RES, V43, pD856, DOI 10.1093/nar/gku1151; Ilic M, 2016, WORLD J GASTROENTERO, V22, P9694, DOI 10.3748/wjg.v22.i44.9694; Janssen JWG, 2000, BLOOD, V95, P2691; Janssen JWG, 2002, J HUM GENET, V47, P460, DOI 10.1007/s100380200065; Janssen JWG, 2002, INT J CANCER, V102, P608, DOI 10.1002/ijc.10765; Kawaguchi Y, 2013, J CLIN INVEST, V123, P1881, DOI 10.1172/JCI66022; Kopp JL, 2012, CANCER CELL, V22, P737, DOI 10.1016/j.ccr.2012.10.025; Lawlor G, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-81; Lee JY, 2014, PANCREATOLOGY, V14, P48, DOI 10.1016/j.pan.2013.11.011; Leung CON, 2016, ONCOTARGET, V7, P29371, DOI 10.18632/oncotarget.8835; Leyden J, 2006, BRIT J CANCER, V94, P1204, DOI 10.1038/sj.bjc.6603054; Li TT, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0877-2; Liu ZH, 2015, CANCER BIOL THER, V16, P353, DOI 10.1080/15384047.2015.1016662; McGuigan A, 2018, WORLD J GASTROENTERO, V24, P4846, DOI 10.3748/wjg.v24.i43.4846; Mertin S, 1999, NUCLEIC ACIDS RES, V27, P1359, DOI 10.1093/nar/27.5.1359; Mishra NK, 2017, ONCOTARGET, V8, P28990, DOI 10.18632/oncotarget.15993; Moreaux J, 2010, EXP HEMATOL, V38, P1189, DOI 10.1016/j.exphem.2010.09.002; Moss AC, 2006, BIOCHEM BIOPH RES CO, V345, P216, DOI 10.1016/j.bbrc.2006.04.094; Muller P, 2010, BREAST CANCER RES TR, V120, P317, DOI 10.1007/s10549-009-0381-6; Nevala-Plagemann C, 2020, NAT REV CLIN ONCOL, V17, P108, DOI 10.1038/s41571-019-0281-6; Nishikawa Y, 2019, ONCOGENE, V38, P4283, DOI 10.1038/s41388-019-0718-5; Rani A, 2016, CYTOKINE GROWTH F R, V30, P113, DOI 10.1016/j.cytogfr.2016.03.010; Royo JL, 2007, NAT PROTOC, V2, P1734, DOI 10.1038/nprot.2007.244; Ruan HH, 2017, ONCOTARGET, V8, P113163, DOI 10.18632/oncotarget.22635; Sato N, 2003, CANCER RES, V63, P4158; Seymour PA, 2007, P NATL ACAD SCI USA, V104, P1865, DOI 10.1073/pnas.0609217104; Shen ZY, 2015, ONCOTARGET, V6, P20672, DOI 10.18632/oncotarget.3967; Shi JG, 2018, INT J ONCOL, V52, P179, DOI 10.3892/ijo.2017.4201; Sim H, 2008, TRENDS ENDOCRIN MET, V19, P213, DOI 10.1016/j.tem.2008.04.002; Sun L, 2013, STEM CELLS, V31, P1454, DOI 10.1002/stem.1394; Takita J, 2011, CANCER SCI, V102, P1645, DOI 10.1111/j.1349-7006.2011.01995.x; Xie VK, 2017, CLIN CANCER RES, V23, P5585, DOI 10.1158/1078-0432.CCR-17-0387; Yen WC, 2015, CLIN CANCER RES, V21, P2084, DOI 10.1158/1078-0432.CCR-14-2808; Zhao TS, 2017, CANCER RES, V77, P874, DOI 10.1158/0008-5472.CAN-16-2170; Zhou H, 2018, ONCOGENE, V37, P912, DOI 10.1038/onc.2017.393	45	17	17	4	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 8	2020	39	41					6437	6450		10.1038/s41388-020-01443-4	http://dx.doi.org/10.1038/s41388-020-01443-4		SEP 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OA1JL	32879444				2022-12-17	WOS:000565482600002
J	He, SW; Xu, C; Li, YQ; Li, YQ; Zhao, Y; Zhang, PP; Lei, Y; Liang, YL; Li, JY; Li, Q; Chen, Y; Huang, SY; Ma, J; Liu, N				He, Shi-Wei; Xu, Cheng; Li, Ying-Qing; Li, Ying-Qin; Zhao, Yin; Zhang, Pan-Pan; Lei, Yuan; Liang, Ye-Lin; Li, Jun-Yan; Li, Qian; Chen, Yang; Huang, Sheng-Yan; Ma, Jun; Liu, Na			AR-induced long non-coding RNA LINC01503 facilitates proliferation and metastasis via the SFPQ-FOSL1 axis in nasopharyngeal carcinoma	ONCOGENE			English	Article							SFPQ; PROGNOSIS; INVASION; LNCRNA	Increasing evidence indicates that long non-coding RNAs (lncRNAs) play vital roles in the tumorigenesis and progression of cancers. However, the functions and regulatory mechanisms of lncRNAs in nasopharyngeal carcinoma (NPC) are still largely unknown. Our previous lncRNA expression profiles identified that LINC01503 was overexpressed in NPC. Here, we verified that LINC01503 was highly expressed in NPC and correlated with poor prognosis. LINC01503 promoted NPC cell proliferation, migration, and invasion in vitro, and facilitated tumor growth and metastasis in vivo. Mechanistically, LINC01503 recruited splicing factor proline-and glutamine-rich (SFPQ) to activate Fos like 1 (FOSL1) transcription, and ectopic expression of FOSL1 reversed the suppressive effect of LINC01503 knockdown on NPC progression. Moreover, androgen receptor (AR)-mediated transcription activation was responsible for the overexpression of LINC01503, and AR ligand-dependent cell growth, migration, and invasion in NPC cells. Taken together, our findings reveal that AR-induced LINC01503 can promote NPC progression through the SFPQ-FOSL1 axis, which represents a novel prognostic biomarker and therapeutic target for NPC patients.	[He, Shi-Wei; Xu, Cheng; Li, Ying-Qing; Li, Ying-Qin; Zhao, Yin; Zhang, Pan-Pan; Lei, Yuan; Liang, Ye-Lin; Li, Jun-Yan; Li, Qian; Chen, Yang; Huang, Sheng-Yan; Ma, Jun; Liu, Na] Sun Yat Sen Univ, Guangdong Key Lab Nasopharyngeal Carcinoma Diag &, Collaborat Innovat Ctr Canc Med, Canc Ctr,State Key Lab Oncol South China, 651 Dongfeng Rd East, Guangzhou 510060, Guangdong, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University	Liu, N (corresponding author), Sun Yat Sen Univ, Guangdong Key Lab Nasopharyngeal Carcinoma Diag &, Collaborat Innovat Ctr Canc Med, Canc Ctr,State Key Lab Oncol South China, 651 Dongfeng Rd East, Guangzhou 510060, Guangdong, Peoples R China.	liun1@sysucc.org.cn	lei, yuan/GXW-0547-2022	Zhao, Yin/0000-0001-7007-2999; Ma, Jun/0000-0002-1137-9349	Key-Area Research and Development Program of Guangdong Province [2019B020230002]; Natural Science Foundation of Guangdong Province [2017A030312003]; Health and Medical Collaborative Innovation Project of Guangzhou City, China [201803040003]; Innovation Team Development Plan of the Ministry of Education [IRT_17R110]; Overseas Expertise Introduction Project for Discipline Innovation (111 Project) [B14035]; National Natural Science Foundation of China [8200110172, 81773229]	Key-Area Research and Development Program of Guangdong Province; Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Health and Medical Collaborative Innovation Project of Guangzhou City, China; Innovation Team Development Plan of the Ministry of Education; Overseas Expertise Introduction Project for Discipline Innovation (111 Project); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We thank all the patients from the Sun Yat-sen University Cancer Center, who were involved in this study. This study was supported by grants from the National Natural Science Foundation of China (8200110172, CX; 81773229, NL), Key-Area Research and Development Program of Guangdong Province (2019B020230002, JM), Natural Science Foundation of Guangdong Province (2017A030312003, JM), Health and Medical Collaborative Innovation Project of Guangzhou City, China (201803040003, JM), Innovation Team Development Plan of the Ministry of Education (IRT_17R110, JM), and Overseas Expertise Introduction Project for Discipline Innovation (111 Project, B14035, JM). The raw data of this paper have been uploaded onto the Research Data Deposit (RDD) with an RDD number of RDDB2020000912.	Au KH, 2018, ORAL ONCOL, V77, P16, DOI 10.1016/j.oraloncology.2017.12.004; Bai SS, 2019, ONCOGENE, V38, P4977, DOI 10.1038/s41388-019-0768-8; Batista PJ, 2013, CELL, V152, P1298, DOI 10.1016/j.cell.2013.02.012; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chen XW, 2018, J CELL BIOCHEM, V119, P4945, DOI 10.1002/jcb.26739; Chen YG, 2017, NAT IMMUNOL, V18, P962, DOI 10.1038/ni.3771; Chen YP, 2019, LANCET, V394, P64, DOI 10.1016/S0140-6736(19)30956-0; Chen YP, 2018, CLIN CANCER RES, V24, P1824, DOI 10.1158/1078-0432.CCR-17-2656; Fatica A, 2014, NAT REV GENET, V15, P7, DOI 10.1038/nrg3606; Geisler S, 2013, NAT REV MOL CELL BIO, V14, P699, DOI 10.1038/nrm3679; Han Y, 2019, J CELL PHYSIOL, V234, P3598, DOI 10.1002/jcp.27048; He SW, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0175-4; He Y, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0265-y; Hirose T, 2014, MOL BIOL CELL, V25, P169, DOI 10.1091/mbc.E13-09-0558; Huang WH, 2018, PROSTATE, V78, P1248, DOI 10.1002/pros.23700; Hui EP, 2018, CLIN CANCER RES, V24, P1030, DOI 10.1158/1078-0432.CCR-17-1667; Imamura K, 2014, MOL CELL, V53, P393, DOI 10.1016/j.molcel.2014.01.009; Jain AK, 2016, MOL CELL, V64, P967, DOI 10.1016/j.molcel.2016.10.039; Jiang XM, 2020, AGING-US, V12, P1237, DOI 10.18632/aging.102680; Knott GJ, 2016, NUCLEIC ACIDS RES, V44, P3989, DOI 10.1093/nar/gkw271; Lee AWM, 2015, J CLIN ONCOL, V33, P3356, DOI 10.1200/JCO.2015.60.9347; Lee MW, 2015, NUCLEIC ACIDS RES, V43, P3826, DOI 10.1093/nar/gkv156; Li G, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2755-6; Liu TY, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0873-2; Liu YW, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0588-9; Lu SR, 2018, EXP THER MED, V16, P4879, DOI 10.3892/etm.2018.6775; Misawa A, 2016, J BIOL CHEM, V291, P17861, DOI 10.1074/jbc.M116.718536; Mitani Y, 2020, CLIN CANCER RES, V26, P1175, DOI 10.1158/1078-0432.CCR-19-1603; Parolia A, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0314-4; Peng H, 2019, CLIN CANCER RES, V25, P4271, DOI 10.1158/1078-0432.CCR-18-3065; Qu YK, 2019, EUR REV MED PHARMACO, V23, P6445, DOI 10.26355/eurrev_201908_18526; Ransohoff JD, 2018, NAT REV MOL CELL BIO, V19, P143, DOI 10.1038/nrm.2017.104; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Tan BS, 2019, ONCOGENE, V38, P5612, DOI 10.1038/s41388-019-0812-8; Tosetti V, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180579; Wang FW, 2019, J CLIN INVEST, V129, P727, DOI 10.1172/JCI122478; Wang H, 2019, EUR REV MED PHARMACO, V23, P1600, DOI 10.26355/eurrev_201902_17119; Wang YY, 2015, CELL STEM CELL, V16, P413, DOI 10.1016/j.stem.2015.03.003; Wen X, 2018, THERANOSTICS, V8, P5676, DOI 10.7150/thno.28538; Wen X, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17111956; Xie JJ, 2018, GASTROENTEROLOGY, V154, P2137, DOI 10.1053/j.gastro.2018.02.018; Yao RW, 2019, NAT CELL BIOL, V21, P542, DOI 10.1038/s41556-019-0311-8; Yu WW, 2019, ONCOGENE, V38, P1225, DOI 10.1038/s41388-018-0463-1; Zhang W, 2019, PLOS GENET, V15, DOI 10.1371/journal.pgen.1008325; Zhang YJ, 2018, NAT GENET, V50, P814, DOI 10.1038/s41588-018-0120-1; Zhang Y, 2019, NEW ENGL J MED, V381, P1124, DOI 10.1056/NEJMoa1905287; Zheng ZQ, 2019, CANCER RES, V79, P4612, DOI 10.1158/0008-5472.CAN-19-0799	47	17	17	2	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 20	2020	39	34					5616	5632		10.1038/s41388-020-01388-8	http://dx.doi.org/10.1038/s41388-020-01388-8		JUL 2020	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NE9FK	32661324	Green Published, hybrid			2022-12-17	WOS:000548100200002
J	Meng, DF; Sun, R; Liu, GY; Peng, LX; Zheng, LS; Xie, P; Lin, ST; Mei, Y; Qiang, YY; Li, CZ; Xu, L; Peng, XS; Hu, H; Lang, YH; Liu, ZJ; Wang, MD; Guo, LL; Xie, DH; Shu, DT; Li, HF; Luo, FF; Niu, XT; Huang, BJ; Qian, CN				Meng, Dong-Fang; Sun, Rui; Liu, Guo-Ying; Peng, Li-Xia; Zheng, Li-Sheng; Xie, Ping; Lin, Si-Ting; Mei, Yan; Qiang, Yuan-Yuan; Li, Chang-Zhi; Xu, Liang; Peng, Xing-Si; Hu, Hao; Lang, Yan-Hong; Liu, Zhi-Jie; Wang, Ming-Dian; Guo, Ling-Ling; Xie, De-Huan; Shu, Di-Tian; Li, Hai-Feng; Luo, Fei-Fei; Niu, Xing-Tang; Huang, Bi-Jun; Qian, Chao-Nan			S100A14 suppresses metastasis of nasopharyngeal carcinoma by inhibition of NF-kB signaling through degradation of IRAK1	ONCOGENE			English	Article							KAPPA-B; BREAST-CANCER; PROMOTES METASTASIS; ACTIVATION; EXPRESSION; PROTEINS; KINASE; PELLINO; BINDING; CELLS	Nasopharyngeal carcinoma (NPC) is a unique head and neck cancer with highly aggressive and metastatic potential in which distant metastasis is the main reason for treatment failure. Till present, the underlying molecular mechanisms of NPC metastasis remains poorly understood. Here, we identified S100 calcium-binding protein A14 (S100A14) as a functional regulator suppressing NPC metastasis by inhibiting the NF-kB signaling pathway and reversing the epithelial-mesenchymal transition (EMT). S100A14 was found to be downregulated in highly metastatic NPC cells and tissues. Immunohistochemical staining of 202 NPC samples revealed that lower S100A14 expression was significantly correlated with shorter patient overall survival (OS) and distant metastasis-free survival (DMFS). S100A14 was also found as an independent prognostic factor for favorable survival. Gain- and loss-of-function studies confirmed that S100A14 suppressed the in vitro and in vivo motility of NPC cells. Mechanistically, S100A14 promoted the ubiquitin-proteasome-mediated degradation of interleukin-1 receptor-associated kinase 1 (IRAK1) to suppress NPC cellular migration. Moreover, S100A14 and IRAK1 established a feedback loop that could be disrupted by the IRAK1 inhibitor T2457. Overall, our findings showed that the S100A14-IRAK1 feedback loop could be a promising therapeutic target for NPC metastasis.	[Meng, Dong-Fang; Sun, Rui; Liu, Guo-Ying; Peng, Li-Xia; Zheng, Li-Sheng; Lin, Si-Ting; Mei, Yan; Li, Chang-Zhi; Peng, Xing-Si; Lang, Yan-Hong; Liu, Zhi-Jie; Wang, Ming-Dian; Guo, Ling-Ling; Xie, De-Huan; Shu, Di-Tian; Luo, Fei-Fei; Huang, Bi-Jun; Qian, Chao-Nan] Sun Yat Sen Univ, Canc Ctr, State Key Lab Oncol South China, Guangzhou 510060, Peoples R China; [Meng, Dong-Fang; Sun, Rui; Liu, Guo-Ying; Peng, Li-Xia; Zheng, Li-Sheng; Lin, Si-Ting; Mei, Yan; Li, Chang-Zhi; Peng, Xing-Si; Lang, Yan-Hong; Liu, Zhi-Jie; Wang, Ming-Dian; Guo, Ling-Ling; Xie, De-Huan; Shu, Di-Tian; Luo, Fei-Fei; Huang, Bi-Jun; Qian, Chao-Nan] Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, Guangzhou 510060, Peoples R China; [Meng, Dong-Fang; Sun, Rui; Liu, Guo-Ying; Peng, Li-Xia; Zheng, Li-Sheng; Lin, Si-Ting; Mei, Yan; Li, Chang-Zhi; Peng, Xing-Si; Lang, Yan-Hong; Liu, Zhi-Jie; Wang, Ming-Dian; Guo, Ling-Ling; Xie, De-Huan; Shu, Di-Tian; Luo, Fei-Fei; Huang, Bi-Jun; Qian, Chao-Nan] Sun Yat Sen Univ, Canc Ctr, Guangdong Key Lab Nasopharyngeal Carcinoma Diag &, Guangzhou 510060, Peoples R China; [Meng, Dong-Fang; Sun, Rui; Liu, Guo-Ying; Peng, Li-Xia; Zheng, Li-Sheng; Lin, Si-Ting; Mei, Yan; Li, Chang-Zhi; Peng, Xing-Si; Lang, Yan-Hong; Liu, Zhi-Jie; Wang, Ming-Dian; Guo, Ling-Ling; Xie, De-Huan; Shu, Di-Tian; Luo, Fei-Fei; Huang, Bi-Jun; Qian, Chao-Nan] Sun Yat Sen Univ, Canc Ctr, Dept Nasopharyngeal Carcinoma, Guangzhou 510060, Peoples R China; [Meng, Dong-Fang] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Radiat Oncol, Jinan 250117, Peoples R China; [Xie, Ping] Xiamen Univ, Xiangan Hosp, Sch Med, Dept Radiat Oncol, Xiamen, Peoples R China; [Qiang, Yuan-Yuan] Ningxia Med Univ, Ningxia Key Lab Cerebrocran Dis, Yinchuan 750001, Ningxia, Peoples R China; [Xu, Liang] Sun Yat Sen Univ, Inst Gastroenterol, Affiliated Hosp 6, Guangzhou 510655, Guangdong, Peoples R China; [Hu, Hao] Sun Yat Sen Univ, Dept Tradit Chinese Med, Affiliated Hosp 1, Guangzhou 510080, Guangdong, Peoples R China; [Li, Hai-Feng] Sun Yat Sen Univ, Dept Med Oncol, Canc Ctr, Guangzhou 510060, Peoples R China; [Niu, Xing-Tang] Sun Yat Sen Univ, Dept Plast Surg, Affiliated Hosp 1, Guangzhou 510080, Guangdong, Peoples R China; [Qian, Chao-Nan] Guangzhou Concord Canc Ctr, Guangzhou, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Shandong First Medical University & Shandong Academy of Medical Sciences; Xiamen University; Ningxia Medical University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Qian, CN (corresponding author), Sun Yat Sen Univ, Canc Ctr, State Key Lab Oncol South China, Guangzhou 510060, Peoples R China.; Qian, CN (corresponding author), Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, Guangzhou 510060, Peoples R China.; Qian, CN (corresponding author), Sun Yat Sen Univ, Canc Ctr, Guangdong Key Lab Nasopharyngeal Carcinoma Diag &, Guangzhou 510060, Peoples R China.; Qian, CN (corresponding author), Sun Yat Sen Univ, Canc Ctr, Dept Nasopharyngeal Carcinoma, Guangzhou 510060, Peoples R China.; Qian, CN (corresponding author), Guangzhou Concord Canc Ctr, Guangzhou, Peoples R China.	qianchn@sysucc.org.cn	HU, HAO/ABF-6803-2020; peng, li/GQH-5153-2022; Huang, Bi-Jun/GSD-2430-2022	HU, HAO/0000-0002-4319-2706; 	National Natural Science Foundation of China [81872384, 81672872, 81472386, 81972785, 81773162, 81572901, 81902974]; Science and Technology Planning Project of Guangdong Province, China [2013B021800065]; Provincial Natural Science Foundation of Guangdong, China [2016A030311011, 2017A030313866]; Provincial Natural Science Foundation of Fujian, China [2019J05008]; Sun Yat-sen University [84000-18843409]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Planning Project of Guangdong Province, China; Provincial Natural Science Foundation of Guangdong, China; Provincial Natural Science Foundation of Fujian, China(Natural Science Foundation of Fujian Province); Sun Yat-sen University	This work was supported by grants from the National Natural Science Foundation of China (Nos. 81872384, 81672872, and 81472386 to C.Q., Nos. 81972785, 81773162, and 81572901 to B.H., No. 81902974 to P.X.), the Science and Technology Planning Project of Guangdong Province, China (No. 2013B021800065 to R.S.), the Provincial Natural Science Foundation of Guangdong, China (No. 2016A030311011 to C.Q., No. 2017A030313866 to B.H.), the Provincial Natural Science Foundation of Fujian, China (No. 2019J05008 to P.X.), and a research program from Sun Yat-sen University (No. 84000-18843409 to C.Q.).	Basnet Suyog, 2019, Oncotarget, V10, P2996, DOI 10.18632/oncotarget.26861; Bigelow RLH, 2009, BREAST CANCER RES TR, V117, P31, DOI 10.1007/s10549-008-0170-7; Blanchard P, 2015, LANCET ONCOL, V16, P645, DOI 10.1016/S1470-2045(15)70126-9; Brabletz T, 2018, NAT REV CANCER, V18, P128, DOI 10.1038/nrc.2017.118; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Bresnick AR, 2015, NAT REV CANCER, V15, P96, DOI 10.1038/nrc3893; Bulk E, 2009, CLIN CANCER RES, V15, P22, DOI 10.1158/1078-0432.CCR-08-0953; Cao Su-Mei, 2011, Chin J Cancer, V30, P114; Chen HY, 2013, MOL CANCER RES, V11, P1542, DOI 10.1158/1541-7786.MCR-13-0317; Chen HY, 2009, CANCER RES, V69, P3451, DOI 10.1158/0008-5472.CAN-08-4231; Chen YP, 2019, LANCET, V394, P64, DOI 10.1016/S0140-6736(19)30956-0; Chou J, 2008, HEAD NECK-J SCI SPEC, V30, P946, DOI 10.1002/hed.20833; Colevas AD, 2018, J NATL COMPR CANC NE, V16, P479, DOI 10.6004/jnccn.2018.0026; DiDonato JA, 2012, IMMUNOL REV, V246, P379, DOI 10.1111/j.1600-065X.2012.01099.x; Donato R, 2013, CURR MOL MED, V13, P24, DOI 10.2174/156652413804486214; Dumbrepatil AB, 2019, J BIOL CHEM, V294, P6888, DOI 10.1074/jbc.RA119.007719; Feng RM, 2019, CANCER COMMUN, V39, DOI 10.1186/s40880-019-0368-6; Feng SS, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192208; Filipek A, 2006, CHEMOTHERAPY, V52, P32, DOI 10.1159/000090240; Gallo LH, 2017, CELL CYCLE, V16, P634, DOI 10.1080/15384101.2017.1288326; Goh JY, 2017, NAT MED, V23, P1319, DOI 10.1038/nm.4405; Gottipati S, 2008, CELL SIGNAL, V20, P269, DOI 10.1016/j.cellsig.2007.08.009; Graczyk A, 2014, INT J BIOCHEM CELL B, V57, P135, DOI 10.1016/j.biocel.2014.10.007; Ichikawa M, 2011, MOL CANCER RES, V9, P133, DOI 10.1158/1541-7786.MCR-10-0394; Jin QE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019375; Knop J, 1999, FEBS LETT, V448, P81, DOI 10.1016/S0014-5793(99)00322-1; Kwon CH, 2013, MOL CELLS, V35, P226, DOI 10.1007/s10059-013-2269-x; Lesniak W, 2007, J INVEST DERMATOL, V127, P2307, DOI 10.1038/sj.jid.5700879; Lesniak W, 2011, CLIN EPIGENETICS, V2, P77, DOI 10.1007/s13148-011-0023-9; Li XJ, 2011, CANCER RES, V71, P3162, DOI 10.1158/0008-5472.CAN-10-3557; Li XX, 2001, P NATL ACAD SCI USA, V98, P4461, DOI 10.1073/pnas.071054198; Li YY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14121; Li ZY, 2015, J CLIN INVEST, V125, P1081, DOI 10.1172/JCI75821; Lindsey JC, 2007, BRIT J CANCER, V97, P267, DOI 10.1038/sj.bjc.6603852; Meng DF, 2018, J CANCER, V9, P92, DOI 10.7150/jca.21357; Meng DF, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-016-0483-z; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Ordureau A, 2008, BIOCHEM J, V409, P43, DOI 10.1042/BJ20071365; Qian CN, 2017, CHIN J CANCER, V36, DOI 10.1186/s40880-017-0206-7; Rhyasen GW, 2013, CANCER CELL, V24, P90, DOI 10.1016/j.ccr.2013.05.006; Sapkota D, 2012, ORAL ONCOL, V48, P219, DOI 10.1016/j.oraloncology.2011.10.001; Sapkota D, 2011, EUR J CANCER, V47, P600, DOI 10.1016/j.ejca.2010.10.012; Schauvliege R, 2006, FEBS LETT, V580, P4697, DOI 10.1016/j.febslet.2006.07.046; Schneider G, 2011, AMINO ACIDS, V41, P773, DOI 10.1007/s00726-010-0498-2; Smith H, 2009, P NATL ACAD SCI USA, V106, P4584, DOI 10.1073/pnas.0900774106; Srivastava R, 2012, CANCER RES, V72, P6209, DOI 10.1158/0008-5472.CAN-12-0337; Taniguchi K, 2018, NAT REV IMMUNOL, V18, P309, DOI 10.1038/nri.2017.142; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tsai WC, 2006, MOL CANCER RES, V4, P539, DOI 10.1158/1541-7786.MCR-05-0266; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wang XH, 2010, AM J PATHOL, V177, P586, DOI 10.2353/ajpath.2010.091217; Wee ZN, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9746; Windheim M, 2008, MOL CELL BIOL, V28, P1783, DOI 10.1128/MCB.02380-06; Xiong TF, 2019, MELANOMA RES, V29, P23, DOI 10.1097/CMR.0000000000000512; Xu CS, 2014, J BIOL CHEM, V289, P827, DOI 10.1074/jbc.M113.469718; Xu L, 2018, CANCER LETT, V431, P230, DOI 10.1016/j.canlet.2017.10.016; Yi M, 2018, J CELL PHYSIOL, V233, P5537, DOI 10.1002/jcp.26410; Zhang W, 2020, CANCER COMMUN, V40, P69, DOI 10.1002/cac2.12010; Zheng LS, 2017, CANCER RES, V77, P579, DOI 10.1158/0008-5472.CAN-16-1281; Zhu M, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.297	60	17	20	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 23	2020	39	30					5307	5322		10.1038/s41388-020-1363-8	http://dx.doi.org/10.1038/s41388-020-1363-8		JUN 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MO5BV	32555330				2022-12-17	WOS:000545371000001
J	Lu, YF; Xu, XP; Lu, XP; Zhu, Q; Liu, G; Bao, YT; Wen, H; Li, YL; Gu, W; Zhu, WG				Lu, Ya-Fei; Xu, Xiao-Peng; Lu, Xiao-Peng; Zhu, Qian; Liu, Ge; Bao, Yan-Tao; Wen, He; Li, Ying-Lu; Gu, Wei; Zhu, Wei-Guo			SIRT7 activates p53 by enhancing PCAF-mediated MDM2 degradation to arrest the cell cycle	ONCOGENE			English	Article							PROMOTES; ACETYLATION; INHIBITION; STRESS; PHOSPHORYLATION; UBIQUITINATION; METABOLISM; PATHWAY; DIFFERENTIATION; BIOSYNTHESIS	Sirtuin 7 (SIRT7), an NAD(+)-dependent deacetylase, plays vital roles in energy sensing, but the underlying mechanisms of action remain less clear. Here, we report that SIRT7 is required for p53-dependent cell-cycle arrest during glucose deprivation. We show that SIRT7 directly interacts with p300/CBP-associated factor (PCAF) and the affinity for this interaction increases during glucose deprivation. Upon binding, SIRT7 deacetylates PCAF at lysine 720 (K720), which augments PCAF binding to murine double minute (MDM2), the p53 E3 ubiquitin ligase, leading to accelerated MDM2 degradation. This effect results in upregulated expression of the cell-cycle inhibitor, p21(Waf1/Cip1), which further leads to cell-cycle arrest and decreased cell viability. These data highlight the importance of the SIRT7-PCAF interaction in regulating p53 activity and cell-cycle progression during conditions of glucose deprivation. This axis may represent a new avenue to design effective therapeutics based on tumor starvation.	[Lu, Ya-Fei; Xu, Xiao-Peng; Lu, Xiao-Peng; Zhu, Qian; Liu, Ge; Bao, Yan-Tao; Wen, He; Zhu, Wei-Guo] Shenzhen Univ, Dept Biochem & Mol Biol, Guangdong Key Lab Genome Instabil & Human Dis, Int Canc Ctr,Sch Med, Shenzhen 518055, Peoples R China; [Li, Ying-Lu; Gu, Wei] Columbia Univ, Coll Phys & Surg, Inst Canc Genet, New York, NY 10032 USA; [Zhu, Wei-Guo] Peking Univ, Beijing Key Lab Prot Posttranslat Modificat & Cel, Key Lab Carcinogenesis & Translat Res,Minist Educ, Dept Biochem & Mol Biol,Sch Basic Med Sci,Hlth Sc, Beijing 100191, Peoples R China; [Zhu, Wei-Guo] Peking Univ Tsinghua Univ Ctr Life Sci, Beijing 100871, Peoples R China	Shenzhen University; Columbia University; Peking University; Peking University	Zhu, WG (corresponding author), Shenzhen Univ, Dept Biochem & Mol Biol, Guangdong Key Lab Genome Instabil & Human Dis, Int Canc Ctr,Sch Med, Shenzhen 518055, Peoples R China.; Li, YL (corresponding author), Columbia Univ, Coll Phys & Surg, Inst Canc Genet, New York, NY 10032 USA.; Zhu, WG (corresponding author), Peking Univ, Beijing Key Lab Prot Posttranslat Modificat & Cel, Key Lab Carcinogenesis & Translat Res,Minist Educ, Dept Biochem & Mol Biol,Sch Basic Med Sci,Hlth Sc, Beijing 100191, Peoples R China.; Zhu, WG (corresponding author), Peking Univ Tsinghua Univ Ctr Life Sci, Beijing 100871, Peoples R China.	yl4187@cumc.columbia.edu; zhuweiguo@szu.edu.cn	Wen, He/GZL-8825-2022; Bao, Yantao/AAK-6146-2021; Li, Yinglu/GWC-7573-2022	Gu, Wei/0000-0002-1480-2368	National Key R&D Program of China [2017YFA0503900]; NFSC [81720108027, 81530074]; Science and Technology Program of Guangdong Province in China [2017B030301016]; Shenzhen Municipal Commission of Science and Technology Innovation [JCYJ20170818092450901]; Discipline Construction of Shenzhen [(2016)1452]	National Key R&D Program of China; NFSC(National Natural Science Foundation of China (NSFC)); Science and Technology Program of Guangdong Province in China; Shenzhen Municipal Commission of Science and Technology Innovation; Discipline Construction of Shenzhen	The authors thank K. F. Chua for providing SIRT7 plasmids. The authors also appreciate Ye Zhang for sharing PCAF plasmids. Finally, the authors are grateful to Dr Jessica Tamanini (Shenzhen University) for proofreading the manuscript. This work was supported by National Key R&D Program of China [2017YFA0503900]; NFSC [81720108027, 81530074]; Science and Technology Program of Guangdong Province in China [2017B030301016]; Shenzhen Municipal Commission of Science and Technology Innovation [JCYJ20170818092450901]; and Discipline Construction Funding of Shenzhen [(2016)1452].	Barber MF, 2012, NATURE, V487, P114, DOI 10.1038/nature11043; Ben Sahra I, 2010, CANCER RES, V70, P2465, DOI 10.1158/0008-5472.CAN-09-2782; Brooks CL, 2006, MOL CELL, V21, P307, DOI 10.1016/j.molcel.2006.01.020; Canto C, 2009, NATURE, V458, P1056, DOI 10.1038/nature07813; Chalkiadaki A, 2012, NAT REV ENDOCRINOL, V8, P287, DOI 10.1038/nrendo.2011.225; Chen SF, 2013, MOL CELL, V52, P303, DOI 10.1016/j.molcel.2013.10.010; Dornan D, 2004, NATURE, V429, P86, DOI 10.1038/nature02514; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Finkel T, 2009, NATURE, V460, P587, DOI 10.1038/nature08197; Gai X, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.76; Gannon HS, 2012, CANCER CELL, V21, P668, DOI 10.1016/j.ccr.2012.04.011; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Gregoire S, 2007, MOL CELL BIOL, V27, P1280, DOI 10.1128/MCB.00882-06; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Han JA, 2002, EMBO J, V21, P5635, DOI 10.1093/emboj/cdf591; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; He HQ, 2017, CELL REP, V20, P2010, DOI 10.1016/j.celrep.2017.08.016; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hu HG, 2017, HEPATOLOGY, V65, P515, DOI 10.1002/hep.28887; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Jiang L, 2017, J BIOL CHEM, V292, P13296, DOI 10.1074/jbc.M117.780130; Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027; Kopeina GS, 2017, BBA-REV CANCER, V1867, P29, DOI 10.1016/j.bbcan.2016.11.002; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Lee IH, 2012, SCIENCE, V336, P225, DOI 10.1126/science.1218395; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; Li L, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12235; Li TT, 2014, J BIOL CHEM, V289, P3775, DOI 10.1074/jbc.M113.531640; Li YL, 2018, NUCLEIC ACIDS RES, V46, P7716, DOI 10.1093/nar/gky568; Lin RT, 2013, MOL CELL, V51, P506, DOI 10.1016/j.molcel.2013.07.002; Linares LK, 2007, NAT CELL BIOL, V9, P331, DOI 10.1038/ncb1545; Linares LK, 2003, P NATL ACAD SCI USA, V100, P12009, DOI 10.1073/pnas.2030930100; Liu L, 1999, MOL CELL BIOL, V19, P1202; Michishita E, 2005, MOL BIOL CELL, V16, P4623, DOI 10.1091/mbc.E05-01-0033; Mohrin M, 2015, SCIENCE, V347, P1374, DOI 10.1126/science.aaa2361; Nihira NT, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aai8026; Pediconi N, 2009, MOL CELL BIOL, V29, P1989, DOI 10.1128/MCB.00552-08; Pelicano H, 2006, ONCOGENE, V25, P4633, DOI 10.1038/sj.onc.1209597; Qi H, 2018, J BIOL CHEM, V293, P17769, DOI 10.1074/jbc.RA118.003629; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Revollo JR, 2004, J BIOL CHEM, V279, P50754, DOI 10.1074/jbc.M408388200; Santos-Rosa H, 2003, NUCLEIC ACIDS RES, V31, P4285, DOI 10.1093/nar/gkg655; Sen N, 2011, MOL CELL, V44, P621, DOI 10.1016/j.molcel.2011.08.044; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shin JY, 2013, CELL REP, V5, P654, DOI 10.1016/j.celrep.2013.10.007; Stommel JM, 2004, EMBO J, V23, P1547, DOI 10.1038/sj.emboj.7600145; Sun C, 2014, CELL REP, V9, P2250, DOI 10.1016/j.celrep.2014.11.029; Sun LH, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12497; Sunami Y, 2017, J BIOL CHEM, V292, P2815, DOI 10.1074/jbc.M116.745398; Tang M, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav1118; Tang XL, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00396-9; Vakhrusheva O, 2008, CIRC RES, V102, P703, DOI 10.1161/CIRCRESAHA.107.164558; Vazquez BN, 2016, EMBO J, V35, P1488, DOI 10.15252/embj.201593499; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang XJ, 2004, FEBS LETT, V561, P195, DOI 10.1016/S0014-5793(04)00168-1; Wu D, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00652; Yan WW, 2018, EMBO REP, V19, DOI 10.15252/embr.201846377; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yoshizawa T, 2014, CELL METAB, V19, P712, DOI 10.1016/j.cmet.2014.03.006; Yu J, 2017, CELL REP, V18, P1229, DOI 10.1016/j.celrep.2017.01.009; Zhang P, 2016, STEM CELLS, V34, P2332, DOI 10.1002/stem.2424; Zheng X, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-96; Zhu WG, 2004, J BIOL CHEM, V279, P15161, DOI 10.1074/jbc.M311703200	64	17	17	5	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2020	39	24					4650	4665		10.1038/s41388-020-1305-5	http://dx.doi.org/10.1038/s41388-020-1305-5		MAY 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LY0HO	32404984	Green Published, hybrid			2022-12-17	WOS:000532808000002
J	Tsai, CN; Yu, SC; Lee, CW; Pang, JHS; Wu, CH; Lin, SE; Chung, YH; Tsai, CL; Hsieh, SY; Yu, MC				Tsai, Chi-Neu; Yu, Shu-Chuan; Lee, Chao-Wei; Pang, Jong-Hwei Su; Wu, Chun-Hsin; Lin, Sey-En; Chung, Yi-Hsiu; Tsai, Chia-Lung; Hsieh, Sen-Yung; Yu, Ming-Chin			SOX4 activates CXCL12 in hepatocellular carcinoma cells to modulate endothelial cell migration and angiogenesis in vivo	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; EXPRESSION; HCC; CXCR4; LIVER; GENE; METASTASIS; MANAGEMENT; CHEMOKINES; SORAFENIB	The overexpression of SOX4 in various kinds of cancer cells was associated with poor prognosis for patients. The role of SOX4 in angiogenesis and tumor microenvironment modulation was recently documented in breast cancer but remains unclear in hepatocellular carcinoma (HCC). In our study, the clinical relevance of SOX4 overexpression in HCC and its role in the tumor microenvironment were investigated. The overexpression of SOX4 (SOX4(high)) in tumor lesions was associated with higher microvessel density (P = 0.012), tumor thrombosis formation (P = 0.012), distant metastasis (P < 0.001), and an independent prognostic factor for disease-free survival in HCC patients (P = 0.048). Endogenous SOX4 knockout in Hep3B cells by the CRISPR/cas9 system reduced the expression of CXCL12, which, in turn, attenuated chemotaxis in human umbilical vein endothelial cells, tube formation in vitro, reduced tumor growth, reticular fiber production, and angiogenesis in vivo in a xenograft mouse model. Treatment with an antagonist targeting CXCR4 (AMD3100), a receptor of CXCL12, inhibited chemotaxis and tube formation in endothelial cells in vitro. The CXCL12 promoter was activated by ectopic expression of a Flag-tagged SOX4 plasmid, endogenous SOX4 knockdown abolished promoter activity of CXCL12 as shown by luciferase assays, and an association with the CXCL12 promoter was identified via chromatin immunoprecipitation in HCC cells. In conclusion, SOX4 modulates the CXCL12 promoter in HCC cells. The secretory CXCL12, in turn, modulates CXCR4 in endothelial cells, reticular fibers to regulate the tumor microenvironment and modulate neovascularization, which might contribute to the distant metastasis of tumors.	[Tsai, Chi-Neu; Lee, Chao-Wei; Pang, Jong-Hwei Su] Chang Gung Univ, Grad Inst Clin Med Sci, Taoyuan 33302, Taiwan; [Tsai, Chi-Neu; Yu, Shu-Chuan; Lee, Chao-Wei; Wu, Chun-Hsin; Yu, Ming-Chin] Chang Gung Mem Hosp, Dept Surg, Linkou Branch, Taoyuan 33305, Taiwan; [Lin, Sey-En] Wan Fang Hosp, Dept Pathol, Taipei 11696, Taiwan; [Lin, Sey-En] Taipei Med Univ, Coll Med, Sch Med, Dept Pathol, Taipei 11031, Taiwan; [Chung, Yi-Hsiu] Chang Gung Mem Hosp, Ctr Adv Mol Imaging & Translat CAMIT, Taoyuan 33305, Taiwan; [Tsai, Chia-Lung] Chang Gung Mem Hosp, Linkou Branch, Genom Med Core Lab, Taoyuan 33305, Taiwan; [Hsieh, Sen-Yung] Chang Gung Mem Hosp, Dept Gastroenterol & Hepatol, Linkou Branch, Taoyuan 33305, Taiwan; [Yu, Ming-Chin] Xiamen Chang Gung Hosp, Dept Surg, Xiamen 361028, Peoples R China	Chang Gung University; Chang Gung Memorial Hospital; Taipei Municipal WanFang Hospital; Taipei Medical University; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital	Yu, MC (corresponding author), Chang Gung Mem Hosp, Dept Surg, Linkou Branch, Taoyuan 33305, Taiwan.; Yu, MC (corresponding author), Xiamen Chang Gung Hosp, Dept Surg, Xiamen 361028, Peoples R China.	mingchin2000@gmail.com	Tsai, Chi-Neu/AAZ-2558-2020; Tsai, Chi neu/C-3373-2011; Yu, Ming-Chin/D-4464-2018	Tsai, Chi-Neu/0000-0002-5940-0696; Tsai, Chi neu/0000-0002-5940-0696; Yu, Ming-Chin/0000-0002-6980-7123; Lin, Sey-En/0000-0002-8994-9452	Chang Gung Medical Foundation in Taiwan [CMRPD1G0611, CMRPD1H0661, CORPG1G0021, CMRPG1J0061]; Ministry of Science and Technology [MOST 103-2314-B-182A-082-MY1-3, MOST 106-2314-B-182A-113]	Chang Gung Medical Foundation in Taiwan; Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea)	Financial support by Chang Gung Medical Foundation in Taiwan: CMRPD1G0611 and CMRPD1H0661 for Dr CN Tsai, CORPG1G0021 and CMRPG1J0061 for Dr MC Yu and Ministry of Science and Technology: MOST 103-2314-B-182A-082-MY1-3 and MOST 106-2314-B-182A-113 for Dr MC Yu.	Boogerd CJJ, 2011, CELL MOL LIFE SCI, V68, P3949, DOI 10.1007/s00018-011-0693-7; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Cheng AL, 2009, LANCET ONCOL, V10, P25, DOI 10.1016/S1470-2045(08)70285-7; Cheung M, 2000, MOL BRAIN RES, V79, P180, DOI 10.1016/S0169-328X(00)00109-1; Choi C, 2014, LIVER CANCER, V3, P405, DOI 10.1159/000343861; Chun YS, 2018, ANN SURG ONCOL, V25, P845, DOI 10.1245/s10434-017-6025-x; Chung YH, 2017, MOLECULES, V22, DOI 10.3390/molecules22111946; Cong L, 2013, SCIENCE, V339, P819, DOI 10.1126/science.1231143; Dong YY, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0795-5; Fang CL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052804; Fang JH, 2019, HEPATOLOGY, V70, P824, DOI 10.1002/hep.30366; Fong ZV, 2014, CANCER-AM CANCER SOC, V120, P2824, DOI 10.1002/cncr.28730; Foronda M, 2014, CELL REP, V8, P486, DOI 10.1016/j.celrep.2014.06.031; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Ghanem I, 2014, AM J TRANSL RES, V6, P340; Gores GJ, 2014, NAT REV GASTRO HEPAT, V11, P645, DOI 10.1038/nrgastro.2014.157; Griffith JW, 2014, ANNU REV IMMUNOL, V32, P659, DOI 10.1146/annurev-immunol-032713-120145; Guo F, 2016, ONCOGENE, V35, P816, DOI 10.1038/onc.2015.139; Hanley KL, 2015, HEPATOLOGY, V62, P343, DOI 10.1002/hep.27860; Hasegawa S, 2016, INT J ONCOL, V48, P145, DOI 10.3892/ijo.2015.3258; Huang DW, 2007, NUCLEIC ACIDS RES, V35, pW169, DOI 10.1093/nar/gkm415; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Inoue H, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2090-y; Janssens R, 2018, CELL MOL IMMUNOL, V15, P299, DOI 10.1038/cmi.2017.107; Jin PP, 2018, JPN J CLIN ONCOL, V48, P1058, DOI 10.1093/jjco/hyy138; Kasagi Y, 2016, CANCER RES, V76, P347, DOI 10.1158/0008-5472.CAN-15-1563; Keating GM, 2017, TARGET ONCOL, V12, P243, DOI 10.1007/s11523-017-0484-7; Kee BL, 2014, BLOOD, V123, P4009, DOI 10.1182/blood-2014-05-574178; Koumangoye RB, 2015, MOL CANCER, V14, DOI 10.1186/s12943-014-0284-y; Kow AWC, 2012, ANN SURG ONCOL, V19, P2246, DOI 10.1245/s10434-012-2260-3; Lai YH, 2011, BMC CELL BIOL, V12, DOI 10.1186/1471-2121-12-50; Liao YL, 2008, ONCOGENE, V27, P5578, DOI 10.1038/onc.2008.168; Liu H, 2008, CELL MOL IMMUNOL, V5, P373, DOI 10.1038/cmi.2008.46; Mantovani A, 2010, CYTOKINE GROWTH F R, V21, P27, DOI 10.1016/j.cytogfr.2009.11.007; Medina PP, 2009, HUM MOL GENET, V18, P1343, DOI 10.1093/hmg/ddp034; Nagarsheth N, 2017, NAT REV IMMUNOL, V17, P559, DOI 10.1038/nri.2017.49; Pan X, 2006, BIOCHEM BIOPH RES CO, V344, P727, DOI 10.1016/j.bbrc.2006.03.194; Parvani JG, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3466; Polimeno MN, 2015, CELL MOL IMMUNOL, V12, P474, DOI 10.1038/cmi.2014.102; Sartorius K, 2015, CANCER EPIDEMIOL, V39, P284, DOI 10.1016/j.canep.2015.04.006; Schrader J, 2011, HEPATOLOGY, V53, P1192, DOI 10.1002/hep.24108; Semaan A, 2017, VIRCHOWS ARCH, V470, P185, DOI 10.1007/s00428-016-2051-5; Sethi A, 2011, INVEST OPHTH VIS SCI, V52, P5240, DOI 10.1167/iovs.11-7287; Shah AD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142337; Shibuta K, 2002, JPN J CANCER RES, V93, P789, DOI 10.1111/j.1349-7006.2002.tb01321.x; Sinner D, 2007, MOL CELL BIOL, V27, P7802, DOI 10.1128/MCB.02179-06; Sun XQ, 2010, CANCER METAST REV, V29, P709, DOI 10.1007/s10555-010-9256-x; Tadeo I, 2016, BRIT J CANCER, V115, P480, DOI 10.1038/bjc.2016.210; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Vervoort SJ, 2018, ELIFE, V7, DOI 10.7554/eLife.27706; Wang BC, 2016, TUMOR BIOL, V37, P9131, DOI 10.1007/s13277-015-4756-5; Wang L, 2014, PROSTATE, V74, P647, DOI 10.1002/pros.22783; Xu J, 2017, CLIN CANCER RES, V23, P4482, DOI 10.1158/1078-0432.CCR-16-2131; You Y, 2016, ONCOTARGET, V7, P32221, DOI 10.18632/oncotarget.8515; Zhang JC, 2012, CANCER RES, V72, P4597, DOI 10.1158/0008-5472.CAN-12-1045	55	17	17	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2020	39	24					4695	4710		10.1038/s41388-020-1319-z	http://dx.doi.org/10.1038/s41388-020-1319-z		MAY 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LY0HO	32404985				2022-12-17	WOS:000532808000001
J	Kwon, OS; Lee, H; Kong, HJ; Kwon, EJ; Park, JE; Lee, W; Kang, S; Kim, M; Kim, W; Cha, HJ				Kwon, Ok-Seon; Lee, Haeseung; Kong, Hyeon-Joon; Kwon, Eun-Ji; Park, Ji Eun; Lee, Wooin; Kang, Seungmin; Kim, Mirang; Kim, Wankyu; Cha, Hyuk-Jin			Connectivity map-based drug repositioning of bortezomib to reverse the metastatic effect of GALNT14 in lung cancer	ONCOGENE			English	Article							TGF-BETA; EXPRESSION; INHIBITORS; GENE; GLYCOSYLATION; CANDIDATES; PROTEASOME; DULANERMIN; GALNAC-T14; MIGRATION	Despite the continual discovery of promising new cancer targets, drug discovery is often hampered by the poor druggability of these targets. As such, repurposing FDA-approved drugs based on cancer signatures is a useful alternative to cancer precision medicine. Here, we adopted an in silico approach based on large-scale gene expression signatures to identify drug candidates for lung cancer metastasis. Our clinicogenomic analysis identified GALNT14 as a putative driver of lung cancer metastasis, leading to poor survival. To overcome the poor druggability of GALNT14 in the control of metastasis, we utilized the Connectivity Map and identified bortezomib (BTZ) as a potent metastatic inhibitor, bypassing the direct inhibition of the enzymatic activity of GALNT14. The antimetastatic effect of BTZ was verified both in vitro and in vivo. Notably, both BTZ treatment and GALNT14 knockdown attenuated TGF beta-mediated gene expression and suppressed TGF beta-dependent metastatic genes. These results demonstrate that our in silico approach is a viable strategy for the use of undruggable targets in cancer therapies and for revealing the underlying mechanisms of these targets.	[Kwon, Ok-Seon; Kwon, Eun-Ji; Park, Ji Eun; Lee, Wooin; Cha, Hyuk-Jin] Seoul Natl Univ, Coll Pharm, Seoul 08826, South Korea; [Kwon, Ok-Seon; Cha, Hyuk-Jin] Seoul Natl Univ, Pharmaceut Sci Res Inst, Seoul 08826, South Korea; [Lee, Haeseung; Kim, Wankyu] Ewha Womans Univ, Dept Life Sci, Coll Nat Sci, Seoul 03760, South Korea; [Kong, Hyeon-Joon] Sogang Univ, Dept Life Sci, Coll Nat Sci, Seoul 04107, South Korea; [Kang, Seungmin] Ewha Womans Univ, KaiPharm, Seoul 03760, South Korea; [Kim, Mirang] Korea Res Inst Biosci & Biotechnol KRIBB, Personalized Genom Med Res Ctr, Daejeon 34141, South Korea; [Kwon, Ok-Seon] Korea Res Inst Biosci & Biotechnol KRIBB, Stem Cell Convergence Res Ctr, Daejeon 34141, South Korea; [Lee, Haeseung] Korea Inst Oriental Med, Future Med Div, Intellectual Informat Team, Daejeon 34054, South Korea	Seoul National University (SNU); Seoul National University (SNU); Ewha Womans University; Sogang University; Ewha Womans University; Korea Research Institute of Bioscience & Biotechnology (KRIBB); Korea Research Institute of Bioscience & Biotechnology (KRIBB); Korea Institute of Oriental Medicine (KIOM)	Cha, HJ (corresponding author), Seoul Natl Univ, Coll Pharm, Seoul 08826, South Korea.; Cha, HJ (corresponding author), Seoul Natl Univ, Pharmaceut Sci Res Inst, Seoul 08826, South Korea.; Kim, W (corresponding author), Ewha Womans Univ, Dept Life Sci, Coll Nat Sci, Seoul 03760, South Korea.	wkim@ewha.ac.kr; hjcha93@snu.ac.kr	; Lee, Wooin/K-7789-2012	Cha, Hyuk-Jin/0000-0001-9277-2662; Lee, Haeseung/0000-0002-9947-4032; Lee, Wooin/0000-0001-7805-869X	National Research Foundation of Korea [NRF-2017M3C9A5028691, NRF-2019R1C1C1008710, NRF-2017M3A9B3061843]	National Research Foundation of Korea(National Research Foundation of Korea)	We appreciate Jeong-Hwan Kim, Seon-Young Kim and Dong-Uk Kim at Korea Research Institute of Bioscience and Biotechnology (KRIBB) for helpful discussions. This work was supported by a grant from the National Research Foundation of Korea (NRF-2017M3C9A5028691 from HJ.C, NRF-2019R1C1C1008710 from OS.K and NRF-2017M3A9B3061843 from W.K).	Argyriou AA, 2008, BLOOD, V112, P1593, DOI 10.1182/blood-2008-04-149385; Ashburn TT, 2004, NAT REV DRUG DISCOV, V3, P673, DOI 10.1038/nrd1468; Bertolini F, 2015, NAT REV CLIN ONCOL, V12, P732, DOI 10.1038/nrclinonc.2015.169; Chang TP, 2015, J IMMUNOL, V194, P2942, DOI 10.4049/jimmunol.1402610; Chen B, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms16022; Dang CV, 2017, NAT REV CANCER, V17, P502, DOI 10.1038/nrc.2017.36; De Mariano M, 2015, ONCOTARGET, V6, P26335, DOI 10.18632/oncotarget.4501; Gandolfi S, 2017, CANCER METAST REV, V36, P561, DOI 10.1007/s10555-017-9707-8; Gayvert KM, 2016, CELL REP, V15, P2348, DOI 10.1016/j.celrep.2016.05.037; Groll M, 2006, STRUCTURE, V14, P451, DOI 10.1016/j.str.2005.11.019; Gross BJ, 2008, J AM CHEM SOC, V130, P440, DOI 10.1021/ja078125s; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Hang HC, 2004, CHEM BIOL, V11, P337, DOI 10.1016/j.chembiol.2004.02.023; Huang DD, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317705849; Iorio F, 2013, DRUG DISCOV TODAY, V18, P350, DOI 10.1016/j.drudis.2012.07.014; Jahchan NS, 2013, CANCER DISCOV, V3, P1364, DOI 10.1158/2159-8290.CD-13-0183; Kim ES, 2011, CANCER DISCOV, V1, P44, DOI 10.1158/2159-8274.CD-10-0010; Kwon OS, 2019, ARCH PHARM RES, V42, P879, DOI 10.1007/s12272-019-01176-3; Kwon OS, 2015, ONCOTARGET, V6, P41916, DOI 10.18632/oncotarget.6019; Lazo JS, 2016, ANNU REV PHARMACOL, V56, P23, DOI 10.1146/annurev-pharmtox-010715-103440; Lee H, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150460; Lee JS, 2015, NEURO-ONCOLOGY, V17, P95, DOI 10.1093/neuonc/nou145; Levy L, 2005, MOL CELL BIOL, V25, P8108, DOI 10.1128/MCB.25.18.8108-8125.2005; Li AM, 2013, BIOCHEM BIOPH RES CO, V436, P486, DOI 10.1016/j.bbrc.2013.05.131; Liang KH, 2016, PHARMACOGENOMICS, V17, P353, DOI 10.2217/pgs.15.179; Maggiora G, 2014, J MED CHEM, V57, P3186, DOI 10.1021/jm401411z; Marquart J, 2018, JAMA ONCOL, V4, P1093, DOI 10.1001/jamaoncol.2018.1660; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Moon YW, 2015, CELL DEATH DIFFER, V22, P1341, DOI 10.1038/cdd.2014.228; Nagaraj AB, 2018, ONCOGENE, V37, P403, DOI 10.1038/onc.2017.328; Olsen D, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00105; Oprea TI, 2015, ASSAY DRUG DEV TECHN, V13, P299, DOI 10.1089/adt.2015.29011.tiodrrr; Padua D, 2008, CELL, V133, P66, DOI 10.1016/j.cell.2008.01.046; Padua D, 2009, CELL RES, V19, P89, DOI 10.1038/cr.2008.316; Shan JS, 2018, TRANSL ONCOL, V11, P786, DOI 10.1016/j.tranon.2018.04.003; Sleire L, 2017, PHARMACOL RES, V124, P74, DOI 10.1016/j.phrs.2017.07.013; Song KH, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13796; Soria JC, 2011, J CLIN ONCOL, V29, P4442, DOI 10.1200/JCO.2011.37.2623; Spear BB, 2001, TRENDS MOL MED, V7, P201, DOI 10.1016/S1471-4914(01)01986-4; Stern HM, 2010, CLIN CANCER RES, V16, P1587, DOI 10.1158/1078-0432.CCR-09-3108; Subramanian A, 2017, CELL, V171, P1437, DOI 10.1016/j.cell.2017.10.049; Ten Hagen KG, 2003, GLYCOBIOLOGY, V13, p1R, DOI 10.1093/glycob/cwg007; Tian HN, 2015, MOL CARCINOGEN, V54, P1159, DOI 10.1002/mc.22186; Tsherniak A, 2017, CELL, V170, P564, DOI 10.1016/j.cell.2017.06.010; van Noort V, 2014, CANCER RES, V74, P5690, DOI 10.1158/0008-5472.CAN-13-3540; van 't Veer LJ, 2008, NATURE, V452, P564, DOI 10.1038/nature06915; Wagle MC, 2018, NPJ PRECIS ONCOL, V2, DOI 10.1038/s41698-018-0051-4; Wagner KW, 2007, NAT MED, V13, P1070, DOI 10.1038/nm1627; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wang ZQ, 2014, ONCOTARGET, V5, P544, DOI 10.18632/oncotarget.1652; Wu C, 2009, J BIOSCIENCES, V34, P389, DOI 10.1007/s12038-009-0045-z; Yeh CT, 2014, INT J CANCER, V134, P1214, DOI 10.1002/ijc.28439; Zeniya M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13486-x; Zhou X, 2017, J THORAC ONCOL, V12, pS1542, DOI 10.1016/j.jtho.2017.06.044	54	17	17	2	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2020	39	23					4567	4580		10.1038/s41388-020-1316-2	http://dx.doi.org/10.1038/s41388-020-1316-2		MAY 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LU5ZF	32388539				2022-12-17	WOS:000531196000001
J	Zhang, X; Zegar, T; Lucas, A; Morrison-Smith, C; Knox, T; French, CA; Knapp, S; Muller, S; Siveke, JT				Zhang, Xin; Zegar, Tim; Lucas, Anais; Morrison-Smith, Chevaun; Knox, Tatiana; French, Christopher A.; Knapp, Stefan; Muller, Susanne; Siveke, Jens T.			Therapeutic targeting of p300/CBP HAT domain for the treatment of NUT midline carcinoma	ONCOGENE			English	Article							BROMODOMAIN INHIBITOR; CBP/P300 BROMODOMAIN; THYMIC CARCINOMA; BET; REARRANGEMENT	Nuclear protein of the testis (NUT) midline carcinoma (NMC), is a rare and highly aggressive form of undifferentiated squamous cell carcinoma. NMC is molecularly characterized by chromosomal rearrangement of the NUT gene to another gene, most commonly the bromodomain and extraterminal domain (BET) gene BRD4, forming the BRD4-NUT fusion oncogene. Therefore, inhibiting BRD4-NUT oncogenic function directly by BET inhibitors represents an attractive therapeutic approach but toxicity may limit the use of pan-BET inhibitors treating this cancer. We thus performed a drug screening approach using a library consisting of epigenetic compounds and 'Donated Chemical Probes' collated by the Structural Genomics Consortium (SGC) and identified the p300/CBP HAT inhibitor A-485, in addition to the well-known BET inhibitor JQ1, to be the most active candidate for NMC treatment. In contrast to JQ1, A-485 was selectively potent in NMC compared to other cell lines tested. Mechanistically, A-485 inhibited p300-mediated histone acetylation, leading to disruption of BRD4-NUT binding to hyperacetylated megadomains. Consistently, BRD4-NUT megadomain-associated genes MYC, CCAT1 and TP63 were downregulated by A-485. A-485 strongly induced squamous differentiation, cell cycle arrest and apoptosis. Combined inhibition of p300/CBP and BET showed synergistic effects. In summary, we identified the p300/CBP HAT domain as a putative therapeutic target in highly therapy-resistant NMC.	[Zhang, Xin; Zegar, Tim; Siveke, Jens T.] Univ Hosp Essen, West German Canc Ctr, Inst Dev Canc Therapeut, Essen, Germany; [Zhang, Xin; Zegar, Tim; Siveke, Jens T.] German Canc Consortium DKTK, Partner Site Essen, Div Solid Tumor Translat Oncol, Heidelberg, Germany; [Zhang, Xin; Zegar, Tim; Siveke, Jens T.] DKFZ, German Canc Res Ctr, Heidelberg, Germany; [Lucas, Anais; Knapp, Stefan; Muller, Susanne] Goethe Univ Frankfurt, Buchmann Inst Life Sci, Struct Genom Consortium, D-60438 Frankfurt, Germany; [Lucas, Anais; Knapp, Stefan; Muller, Susanne] Goethe Univ Frankfurt, Inst Pharmaceut Chem, D-60438 Frankfurt, Germany; [Lucas, Anais; Knapp, Stefan] German Canc Consortium DKTK, Partner Site Frankfurt Mainz, D-60438 Frankfurt, Germany; [Lucas, Anais; Knapp, Stefan] Frankfurt Canc Inst FCI, D-60438 Frankfurt, Germany; [Morrison-Smith, Chevaun; Knox, Tatiana; French, Christopher A.] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA 02115 USA	University of Duisburg Essen; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Goethe University Frankfurt; Goethe University Frankfurt; Helmholtz Association; German Cancer Research Center (DKFZ); Harvard University; Brigham & Women's Hospital; Harvard Medical School	Siveke, JT (corresponding author), Univ Hosp Essen, West German Canc Ctr, Inst Dev Canc Therapeut, Essen, Germany.; Siveke, JT (corresponding author), German Canc Consortium DKTK, Partner Site Essen, Div Solid Tumor Translat Oncol, Heidelberg, Germany.; Siveke, JT (corresponding author), DKFZ, German Canc Res Ctr, Heidelberg, Germany.	jens.siveke@uk-essen.de	Knapp, Stefan/AAG-2347-2019; Siveke, Jens/AAQ-6170-2021	Knapp, Stefan/0000-0001-5995-6494; Siveke, Jens/0000-0002-8772-4778; Muller-Knapp, Susanne/0000-0003-2402-4157	AbbVie; Bayer Pharma AG; SGC [1097737]; Boehringer Ingelheim; Canada Foundation for Innovation; Eshelman Institute for Innovation; Genome Canada through Ontario Genomics Institute [OGI-055]; Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant] [115766]; Janssen; Merck KGaA; MSD; Novartis Pharma AG; Ontario Ministry of Research, Innovation and Science (MRIS); Pfizer; Sao Paulo Research Foundation-FAPESP; Takeda; Wellcome Trust; German Cancer Aid (PIPAC consortium) [70112505]; German Cancer Consortium (DKTK); Deutsche Forschungsgemeinschaft (DFG) [SI1549/3-1]; Deutsche Forschungsgemeinschaft (DFG) through Collaborative Research Center SFB824; Projekt DEAL	AbbVie(AbbVie); Bayer Pharma AG; SGC; Boehringer Ingelheim(Boehringer Ingelheim); Canada Foundation for Innovation(Canada Foundation for InnovationCGIAR); Eshelman Institute for Innovation; Genome Canada through Ontario Genomics Institute(Genome Canada); Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant]; Janssen(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Merck KGaA; MSD; Novartis Pharma AG; Ontario Ministry of Research, Innovation and Science (MRIS); Pfizer(Pfizer); Sao Paulo Research Foundation-FAPESP(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Takeda(Takeda Pharmaceutical Company Ltd); Wellcome Trust(Wellcome TrustEuropean Commission); German Cancer Aid (PIPAC consortium); German Cancer Consortium (DKTK); Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Deutsche Forschungsgemeinschaft (DFG) through Collaborative Research Center SFB824(German Research Foundation (DFG)); Projekt DEAL	We are grateful for support by the SGC, a registered charity (no. 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada through Ontario Genomics Institute [OGI-055], Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA, MSD, Novartis Pharma AG, Ontario Ministry of Research, Innovation and Science (MRIS), Pfizer, Sao Paulo Research Foundation-FAPESP, Takeda, and the Wellcome Trust. JTS and SK are supported by the German Cancer Aid (grant no. 70112505; PIPAC consortium). JTS is supported by the German Cancer Consortium (DKTK) and the Deutsche Forschungsgemeinschaft (DFG) through grant SI1549/3-1 (Clinical Research Unit KFO337) and Collaborative Research Center SFB824 (project C4). Open access funding provided by Projekt DEAL.	Alekseyenko AA, 2015, GENE DEV, V29, P1507, DOI 10.1101/gad.267583.115; Bauer DE, 2012, CLIN CANCER RES, V18, P5773, DOI 10.1158/1078-0432.CCR-12-1153; Brooks N, 2019, CANCER RES, V79, DOI 10.1158/1538-7445.SABCS18-3826; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; Fong CY, 2015, NATURE, V525, P538, DOI 10.1038/nature14888; French CA, 2003, CANCER RES, V63, P304; French CA, 2001, AM J PATHOL, V159, P1987, DOI 10.1016/S0002-9440(10)63049-0; GILES F, 2018, ANN ONCOL S8, V29, P279, DOI DOI 10.1093/annonc/mdy279.416; Hammitzsch A, 2015, P NATL ACAD SCI USA, V112, P10768, DOI 10.1073/pnas.1501956112; Haruki N, 2005, J MED GENET, V42, P558, DOI 10.1136/jmg.2004.029686; Ianevski A, 2017, BIOINFORMATICS, V33, P2413, DOI 10.1093/bioinformatics/btx162; IGUCHI H, 1990, CANCER RES, V50, P3691; KEES UR, 1991, AM J PEDIAT HEMATOL, V13, P459; Kimura H, 2010, CHEM BIOL, V17, P1282, DOI 10.1016/j.chembiol.2010.10.011; KUZUME T, 1992, INT J CANCER, V50, P259, DOI 10.1002/ijc.2910500216; Lasko LM, 2017, NATURE, V550, P128, DOI 10.1038/nature24028; Lewin J, 2018, J CLIN ONCOL, V36, P3007, DOI 10.1200/JCO.2018.78.2292; Matzuk MM, 2012, CELL, V150, P673, DOI 10.1016/j.cell.2012.06.045; Muller S, 2018, ELIFE, V7, DOI 10.7554/eLife.34311; O'Dwyer PJ, 2016, CANCER RES, V76, DOI 10.1158/1538-7445.AM2016-CT014; Picaud S, 2015, CANCER RES, V75, P5106, DOI 10.1158/0008-5472.CAN-15-0236; Reynoird N, 2010, EMBO J, V29, P2943, DOI 10.1038/emboj.2010.176; Scheer S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-07905-4; Stathis A, 2018, CANCER DISCOV, V8, P24, DOI 10.1158/2159-8290.CD-17-0605; Stathis A, 2016, CANCER DISCOV, V6, P492, DOI 10.1158/2159-8290.CD-15-1335; Syntichaki P, 2000, NATURE, V404, P414, DOI 10.1038/35006136; Toretsky JA, 2003, AM J CLIN ONCOL-CANC, V26, P300, DOI 10.1097/00000421-200306000-00019; Wu Q, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09672-2; Xiang JF, 2014, CELL RES, V24, P513, DOI 10.1038/cr.2014.35; Yan JP, 2011, J BIOL CHEM, V286, P27663, DOI 10.1074/jbc.M111.246975; Yan YQ, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.7_suppl.62	32	17	19	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2020	39	24					4770	4779		10.1038/s41388-020-1301-9	http://dx.doi.org/10.1038/s41388-020-1301-9		MAY 2020	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LY0HO	32366905	Green Published, hybrid			2022-12-17	WOS:000530271400001
J	Wang, Y; Ma, RN; Liu, B; Kong, JY; Lin, HY; Yu, X; Wang, RY; Li, L; Gao, M; Zhou, BS; Mohan, M; Yu, H; Hou, ZY; Shen, HB; Qian, BY				Wang, Yu; Ma, Rongna; Liu, Ben; Kong, Jinyu; Lin, Hongyan; Yu, Xiao; Wang, Ruoyang; Li, Lei; Gao, Ming; Zhou, Baosen; Mohan, Man; Yu, Herbert; Hou, Zhaoyuan; Shen, Hongbin; Qian, Biyun			SNP rs17079281 decreases lung cancer risk through creating an YY1-binding site to suppress DCBLD1 expression	ONCOGENE			English	Article							GENOME-WIDE ASSOCIATION; SUSCEPTIBILITY LOCI; GENETIC SUSCEPTIBILITY; IDENTIFICATION; TUMORS	Genome-wide association studies (GWAS) have identified numerous genetic variants that are associated with lung cancer risk, but the biological mechanisms underlying these associations remain largely unknown. Here we investigated the functional relevance of a genetic region in 6q22.2 which was identified to be associated with lung cancer risk in our previous GWAS. We performed linkage disequilibrium (LD) analysis and bioinformatic prediction to screen functional SNPs linked to a tagSNP in 6q22.2 loci, followed by two case-control studies and a meta-analysis with 4403 cases and 5336 controls to identify if these functional SNPs were associated with lung cancer risk. A novel SNP rs17079281 in the DCBLD1 promoter was identified to be associated with lung cancer risk in Chinese populations. Compared with those with C allele, patients with T allele had lower risk of adenocarcinoma (adjusted OR = 0.86; 95% CI: 0.80-0.92), but not squamous cell carcinoma (adjusted OR = 0.99; 95% CI: 0.91-1.10), and patients with the C/T or T/T genotype had lower levels of DCBLD1 expression than those with C/C genotype in lung adenocarcinoma tissues. We performed functional assays to characterize its biological relevance. The results showed that the T allele of rs17079281 had higher binding affinity to transcription factor YY1 than the C allele, which suppressed DCBLD1 expression. DCBLD1 behaved like an oncogene, promoting tumor growth by influencing cell cycle progression. These findings suggest that the functional variant rs17079281C>T decreased lung adenocarcinoma risk by creating an YY1-binding site to suppress DCBLD1 expression, which may serve as a biomarker for assessing lung cancer susceptibility.	[Wang, Yu; Ma, Rongna; Lin, Hongyan; Yu, Xiao; Wang, Ruoyang; Li, Lei; Qian, Biyun] Shanghai Jiao Tong Univ, Sch Med, Shanghai Tongren Hosp, Hongqiao Int Inst Med, Shanghai 200025, Peoples R China; [Wang, Yu; Ma, Rongna; Lin, Hongyan; Yu, Xiao; Wang, Ruoyang; Li, Lei; Qian, Biyun] Shanghai Jiao Tong Univ, Sch Med, Fac Publ Hlth, Shanghai 200025, Peoples R China; [Liu, Ben; Kong, Jinyu; Gao, Ming] Tianjin Med Univ, Dept Canc Epidemiol & Biostat, Canc Inst & Hosp, Natl Clin Res Ctr Canc, Tianjin 300060, Peoples R China; [Zhou, Baosen] China Med Univ, Sch Publ Hlth, Dept Epidemiol, Shenyang 110001, Liaoning, Peoples R China; [Mohan, Man] Shanghai Jiao Tong Univ, Shanghai Key Lab Tumor Microenvironm & Inflammat, Sch Med, Dept Biochem & Mol Cell Biol, Shanghai 200025, Peoples R China; [Yu, Herbert] Univ Hawaii, Canc Epidemiol Program, Canc Ctr, Honolulu, HI 96813 USA; [Hou, Zhaoyuan] Shanghai Jiao Tong Univ, Fac Basic Med, Sch Med, Hongqiao Inst Med,Shanghai Tongren Hosp, Shanghai 200025, Peoples R China; [Shen, Hongbin] Nanjing Med Univ, Canc Ctr, Sect Clin Epidemiol, Jiangsu Key Lab Canc Biomarkers Prevent & Treatme, Nanjing 211166, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Tianjin Medical University; China Medical University; Shanghai Jiao Tong University; Cancer Research Center of Hawaii; University of Hawaii System; Shanghai Jiao Tong University; Nanjing Medical University	Qian, BY (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Shanghai Tongren Hosp, Hongqiao Int Inst Med, Shanghai 200025, Peoples R China.; Qian, BY (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Fac Publ Hlth, Shanghai 200025, Peoples R China.	qianbiyun@sjtu.edu.cn	Liu, Ben/AAZ-4649-2021	Liu, Ben/0000-0001-8452-5397; Mohan, Man/0000-0002-8811-8542	National Natural Science Foundation of China [81573231]; Natural Science Foundation of Shanghai [15ZR1424400]; National Human Genetic Resources Sharing Service Platform [2005DKA21300]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Shanghai(Natural Science Foundation of Shanghai); National Human Genetic Resources Sharing Service Platform	This work was supported by the National Natural Science Foundation of China (Grant no. 81573231), Natural Science Foundation of Shanghai (Grant no.15ZR1424400), National Human Genetic Resources Sharing Service Platform(2005DKA21300). We thank Cancer Biobank of Tianjin Medical University Cancer Institute and Hospital for providing the biological samples. We thank Cancer Biobank of Tianjin Medical University Cancer Institute and Hospital for providing the biological samples.	Boyle AP, 2012, GENOME RES, V22, P1790, DOI 10.1101/gr.137323.112; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Donnelly P, 2008, NATURE, V456, P728, DOI 10.1038/nature07631; Fu JY, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002431; Galvin KM, 1997, MOL CELL BIOL, V17, P3723, DOI 10.1128/MCB.17.7.3723; Han JY, 2014, PHARMACOGENOMICS J, V14, P20, DOI 10.1038/tpj.2013.7; Hirschhorn JN, 2005, NAT REV GENET, V6, P95, DOI 10.1038/nrg1521; Hong QY, 2015, CANCER-AM CANCER SOC, V121, P3080, DOI 10.1002/cncr.29584; Hu ZB, 2011, NAT GENET, V43, P792, DOI 10.1038/ng.875; Koshikawa K, 2002, ONCOGENE, V21, P2822, DOI 10.1038/sj.onc.1205405; Lan Q, 2012, NAT GENET, V44, P1330, DOI 10.1038/ng.2456; Liu B, 2015, ONCOTARGET, V6, P9445, DOI 10.18632/oncotarget.3255; Liu SG, 2015, GENET MOL RES, V14, P4469, DOI 10.4238/2015.May.4.4; Maurano MT, 2012, SCIENCE, V337, P1190, DOI 10.1126/science.1222794; McCarthy MI, 2008, NAT REV GENET, V9, P356, DOI 10.1038/nrg2344; McKay JD, 2017, NAT GENET, V49, P1126, DOI 10.1038/ng.3892; Pashos EE, 2017, CELL STEM CELL, V20, P558, DOI 10.1016/j.stem.2017.03.017; Peters U, 2013, GASTROENTEROLOGY, V144, P799, DOI 10.1053/j.gastro.2012.12.020; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Rimkunas VM, 2012, CLIN CANCER RES, V18, P4449, DOI 10.1158/1078-0432.CCR-11-3351; Ryan BM, 2015, CANCER RES, V75, P566, DOI 10.1158/0008-5472.CAN-14-2101; Wang K, 2010, AM J HUM GENET, V86, P730, DOI 10.1016/j.ajhg.2010.04.003; Xie D, 2013, CELL, V155, P713, DOI 10.1016/j.cell.2013.09.043; YANT SR, 1995, NUCLEIC ACIDS RES, V23, P4353, DOI 10.1093/nar/23.21.4353; Zhang XL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041930	25	17	18	2	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	20					4092	4102		10.1038/s41388-020-1278-4	http://dx.doi.org/10.1038/s41388-020-1278-4		MAR 2020	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LN3GC	32231272	Green Published, hybrid			2022-12-17	WOS:000522380700001
J	Ripani, P; Delp, J; Bode, K; Delgado, ME; Dietrich, L; Betzler, VM; Yan, N; von Scheven, G; Mayer, TU; Leist, M; Brunner, T				Ripani, P.; Delp, J.; Bode, K.; Delgado, M. E.; Dietrich, L.; Betzler, V. M.; Yan, N.; von Scheven, G.; Mayer, T. U.; Leist, M.; Brunner, T.			Thiazolides promote G1 cell cycle arrest in colorectal cancer cells by targeting the mitochondrial respiratory chain	ONCOGENE			English	Article							HELICOBACTER-PYLORI; DRUG NITAZOXANIDE; VIRUS-REPLICATION; INDUCED APOPTOSIS; INHIBITION; PRAZIQUANTEL; TIZOXANIDE; CHILDREN; CULTURE	Systemic toxicity and tumor cell resistance still limit the efficacy of chemotherapy in colorectal cancer. Therefore, alternative treatments are desperately needed. The thiazolide Nitazoxanide (NTZ) is an FDA-approved drug for the treatment of parasite-mediated infectious diarrhea with a favorable safety profile. Interestingly, NTZ and the thiazolide RM4819-its bromo-derivative lacking antibiotic activity-are also promising candidates for cancer treatment. Yet the exact anticancer mechanism(s) of these compounds still remains unclear. In this study, we systematically investigated RM4819 and NTZ in 2D and 3D colorectal cancer culture systems. Both compounds strongly inhibited proliferation of colon carcinoma cell lines by promoting G1 phase cell cycle arrest. Thiazolide-induced cell cycle arrest was independent of the p53/p21 axis, but was mediated by inhibition of protein translation via the mTOR/c-Myc/p27 pathway, likely caused by inhibition of mitochondrial respiration. While both thiazolides demonstrated mitochondrial uncoupling activity, only RM4819 inhibited the mitochondrial respiratory chain complex III. Interestingly, thiazolides also potently inhibited the growth of murine colonic tumoroids in a comparable manner with cisplatin, while in contrast to cisplatin thiazolides did not affect the growth of primary intestinal organoids. Thus, thiazolides appear to have a tumor-selective antiproliferative activity, which offers new perspectives in the treatment of colorectal cancer.	[Ripani, P.; Bode, K.; Delgado, M. E.; Dietrich, L.; Betzler, V. M.; Brunner, T.] Univ Konstanz, Dept Biol Biochem Pharmacol, Constance, Germany; [Ripani, P.; Delp, J.; Mayer, T. U.; Leist, M.; Brunner, T.] Univ Konstanz, Konstanz Res Sch Chem Biol KORS CB, Constance, Germany; [Delp, J.; Leist, M.] Univ Konstanz, Chair Vitro Toxicol & Biomed, Doerenkamp Zbinden Fdn, Constance, Germany; [Betzler, V. M.] Univ Konstanz, Biotechnol Inst Thurgau, Constance, Germany; [Yan, N.] Peking Univ, Dept Med Chem, Hlth Sci Ctr, Beijing, Peoples R China; [von Scheven, G.] Univ Konstanz, Dept Biol, Mol Toxicol Grp, Constance, Germany; [Mayer, T. U.] Univ Konstanz, Dept Biol, Mol Genet, Constance, Germany	University of Konstanz; University of Konstanz; University of Konstanz; University of Konstanz; Peking University; University of Konstanz; University of Konstanz	Brunner, T (corresponding author), Univ Konstanz, Dept Biol Biochem Pharmacol, Constance, Germany.; Brunner, T (corresponding author), Univ Konstanz, Konstanz Res Sch Chem Biol KORS CB, Constance, Germany.	thomas.brunner@uni-konstanz.de	Leist, Marcel/D-2133-2010; Delgado, M.Eugenia/ABH-3795-2020	Leist, Marcel/0000-0002-3778-8693; Delgado, M.Eugenia/0000-0002-8653-1819; Niu, Yan/0000-0001-9193-8659; Delp, Johannes/0000-0003-3224-0677; Mayer, Thomas/0000-0001-6954-2287				Angelucci F, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1494-4; Ashour DS, 2016, EXP PARASITOL, V170, P28, DOI 10.1016/j.exppara.2016.08.009; Aslam S, 2007, FUTURE MICROBIOL, V2, P583, DOI 10.2217/17460913.2.6.583; Bode KJ, 2019, BIOTECHNIQUES, V67, P23, DOI 10.2144/btn-2019-0023; Brockmann A, 2014, ACS CHEM BIOL, V9, P1520, DOI 10.1021/cb500209a; Castell A, 2015, CANCER DISCOV, V5, P701, DOI 10.1158/2159-8290.CD-15-0660; Chu IM, 2008, NAT REV CANCER, V8, P253, DOI 10.1038/nrc2347; Ciardiello D, 2019, CANCER TREAT REV, V76, P22, DOI 10.1016/j.ctrv.2019.04.003; de Carvalho LPS, 2009, J MED CHEM, V52, P5789, DOI 10.1021/jm9010719; de Caryalho LPS, 2011, ACS MED CHEM LETT, V2, P849, DOI 10.1021/ml200157f; Delp J, 2019, ARCH TOXICOL, V93, P1585, DOI 10.1007/s00204-019-02473-y; Delp J, 2018, TOXICOL APPL PHARM, V354, P64, DOI 10.1016/j.taap.2017.12.013; Di Santo N, 2014, MUTAT RES-FUND MOL M, V768, P16, DOI 10.1016/j.mrfmmm.2014.05.005; El-Deiry WS, 2016, CANCER RES, V76, P5189, DOI 10.1158/0008-5472.CAN-16-2055; Fan-Minogue H, 2013, MOL CANCER THER, V12, P1896, DOI 10.1158/1535-7163.MCT-12-1243; Favennec L, 2003, ALIMENT PHARM THER, V17, P265, DOI 10.1046/j.1365-2036.2003.01419.x; Fontaine E, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00753; Fox LM, 2005, CLIN INFECT DIS, V40, P1173, DOI 10.1086/428839; Grabinger T, 2016, METHODS MOL BIOL, V1491, P83, DOI 10.1007/978-1-4939-3581-9_7; Guttner Y, 2003, ANTIMICROB AGENTS CH, V47, P3780, DOI 10.1128/AAC.47.12.3780-3783.2003; Hauck Ludger, 2004, V296, P239; Hickson SE, 2018, VIROLOGY, V518, P398, DOI 10.1016/j.virol.2018.03.023; Hu YJ, 2017, PHARMACOL RES, V119, P219, DOI 10.1016/j.phrs.2017.01.034; Hydbring P, 2017, GENES-BASEL, V8, DOI 10.3390/genes8070174; Kozovska Z, 2014, BIOMED PHARMACOTHER, V68, P911, DOI 10.1016/j.biopha.2014.10.019; Kuipers EJ, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.65; La Frazia S, 2018, ANTIVIR RES, V157, P159, DOI 10.1016/j.antiviral.2018.06.008; Lam KKY, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002691; Lateef M, 2008, INT J INFECT DIS, V12, P80, DOI 10.1016/j.ijid.2007.04.017; Liu Y, 2006, P NATL ACAD SCI USA, V103, P976, DOI 10.1073/pnas.0510146103; Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074; McVay CS, 2000, ANTIMICROB AGENTS CH, V44, P2254, DOI 10.1128/AAC.44.9.2254-2258.2000; Muller J, 2008, INT J CANCER, V123, P1797, DOI 10.1002/ijc.23755; Neufert C, 2007, NAT PROTOC, V2, P1998, DOI 10.1038/nprot.2007.279; Ortiz JJ, 2002, T ROY SOC TROP MED H, V96, P193, DOI 10.1016/S0035-9203(02)90301-9; Pankuch GA, 2006, ANTIMICROB AGENTS CH, V50, P1112, DOI 10.1128/AAC.50.3.1112-1117.2006; Perelygina L, 2017, ANTIVIR RES, V147, P58, DOI 10.1016/j.antiviral.2017.09.019; Piacentini S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28172-9; Pushpakom S, 2019, NAT REV DRUG DISCOV, V18, P41, DOI 10.1038/nrd.2018.168; Qu Y, 2018, NAT CHEM BIOL, V14, P94, DOI [10.1038/NCHEMBIO.2510, 10.1038/nchembio.2510]; Rossignol JF, 2014, ANTIVIR RES, V110, P94, DOI 10.1016/j.antiviral.2014.07.014; ROSSIGNOL JF, 1984, AM J TROP MED HYG, V33, P511, DOI 10.4269/ajtmh.1984.33.511; Rossingol JF, 2016, J INFECT PUBLIC HEAL, V9, P227, DOI 10.1016/j.jiph.2016.04.001; Senkowski W, 2015, MOL CANCER THER, V14, P1504, DOI 10.1158/1535-7163.MCT-14-0792; Shakya Anshul, 2018, Curr Drug Discov Technol, V15, P201, DOI 10.2174/1570163814666170727130003; Sidler D, 2012, ONCOGENE, V31, P4095, DOI 10.1038/onc.2011.575; Stachulski AV, 2018, FUTURE MED CHEM, V10, P851, DOI 10.4155/fmc-2017-0217; Stachulski AV, 2017, EUR J MED CHEM, V126, P154, DOI 10.1016/j.ejmech.2016.09.080; Tilmanis D, 2017, ANTIVIR RES, V147, P142, DOI 10.1016/j.antiviral.2017.10.002; Tsou L, 2011, CELL METAB, V13, P476, DOI 10.1016/j.cmet.2011.03.006; Wang X, 2018, SPR GEOL, P9, DOI 10.1007/978-3-319-58325-9_2; Webster PC, 2010, CAN MED ASSOC J, V182, pE141, DOI 10.1503/cmaj.109-3109; Weinberg SE, 2015, NAT CHEM BIOL, V11, P9, DOI 10.1038/nchembio.1712; Xue X, 2013, JOVE-J VIS EXP, DOI 10.3791/50210; Yamamoto Y, 1999, CHEMOTHERAPY, V45, P303, DOI 10.1159/000007200; Yan B, 2016, MITOCHONDRION, V26, P86, DOI 10.1016/j.mito.2015.12.007; Zaman SB, 2017, CUREUS, V9, pe1352; Zhu YM, 2018, J CLIN INVEST, V128, P3682, DOI 10.1172/JCI120844	58	17	17	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	11					2345	2357		10.1038/s41388-019-1142-6	http://dx.doi.org/10.1038/s41388-019-1142-6			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KU0ZS	31844249	Green Submitted			2022-12-17	WOS:000519440400008
J	Voringer, S; Schreyer, L; Nadolni, W; Meier, MA; Woerther, K; Mittermeier, C; Ferioli, S; Singer, S; Holzer, K; Zierler, S; Chubanov, V; Liebl, B; Gudermann, T; Muehlich, S				Voringer, Sandra; Schreyer, Laura; Nadolni, Wiebke; Meier, Melanie A.; Woerther, Katharina; Mittermeier, Constanze; Ferioli, Silvia; Singer, Stephan; Holzer, Kerstin; Zierler, Susanna; Chubanov, Vladimir; Liebl, Bernhard; Gudermann, Thomas; Muehlich, Susanne			Inhibition of TRPM7 blocks MRTF/SRF-dependent transcriptional and tumorigenic activity	ONCOGENE			English	Article							SERUM RESPONSE FACTOR; KINASE-ACTIVITY; ACTIN DYNAMICS; CELL; RHOA; PHOSPHORYLATION; GROWTH	Myocardin-related transcription factors A and B (MRTFs) are coactivators of Serum Response Factor (SRF) that mediates the expression of genes involved in cell proliferation, migration and differentiation. There is mounting evidence that MRTFs and SRF represent promising targets for hepatocellular carcinoma (HCC) growth. Since MRTF-A nuclear localization is a prerequisite for its transcriptional activity and oncogenic properties, we searched for pharmacologically active compounds able to redistribute MRTF-A to the cytoplasm. We identified NS8593, a negative gating modulator of the transient receptor potential cation channel TRPM7, as a novel inhibitor of MRTF-A nuclear localization and transcriptional activity. Using a pharmacological approach and targeted genome editing, we investigated the functional contribution of TRPM7, a unique ion channel containing a serine-threonine kinase domain, to MRTF transcriptional and tumorigenic activity. We found that TRPM7 function regulates RhoA activity and subsequently actin polymerization, MRTF-A-Filamin A complex formation and MRTF-A/SRF target gene expression. Mechanistically, TRPM7 signaling relies on TRPM7 channel-mediated Mg2+ influx and phosphorylation of RhoA by TRPM7 kinase. Pharmacological blockade of TRPM7 results in oncogene-induced senescence of hepatocellular carcinoma (HCC) cells in vitro and in vivo in HCC xenografts. Hence, inhibition of the TRPM7/MRTF axis emerges as a promising strategy to curb HCC growth.	[Voringer, Sandra; Schreyer, Laura; Nadolni, Wiebke; Meier, Melanie A.; Woerther, Katharina; Mittermeier, Constanze; Ferioli, Silvia; Zierler, Susanna; Chubanov, Vladimir; Gudermann, Thomas; Muehlich, Susanne] Ludwig Maximilians Univ Munchen, Walther Straub Inst Pharmacol & Toxicol, Munich, Germany; [Singer, Stephan; Holzer, Kerstin] Univ Med Greifswald, Inst Pathol, Greifswald, Germany; [Liebl, Bernhard] LGL Bayer Landesamt Gesundheit & Lebensmittelsich, Oberschleissheim, Germany; [Schreyer, Laura; Meier, Melanie A.; Muehlich, Susanne] Friedrich Alexander Univ Erlangen Nurnberg, Dept Chem & Pharm Mol & Clin Pharm, Erlangen, Germany	University of Munich; Greifswald Medical School; Bavarian Health & Food Safety Authority; University of Erlangen Nuremberg	Muehlich, S (corresponding author), Ludwig Maximilians Univ Munchen, Walther Straub Inst Pharmacol & Toxicol, Munich, Germany.; Muehlich, S (corresponding author), Friedrich Alexander Univ Erlangen Nurnberg, Dept Chem & Pharm Mol & Clin Pharm, Erlangen, Germany.	susanne.muehlich@fau.de	Zierler, Susanna/E-2070-2012	Zierler, Susanna/0000-0002-4684-0385				Baarlink C, 2013, SCIENCE, V340, P864, DOI 10.1126/science.1235038; Bae JS, 2014, INT J ONCOL, V44, P129, DOI 10.3892/ijo.2013.2154; Blomen VA, 2015, SCIENCE, V350, P1092, DOI 10.1126/science.aac7557; Chen WL, 2015, ONCOTARGET, V6, P16321, DOI 10.18632/oncotarget.3872; Chubanov V, 2012, BRIT J PHARMACOL, V166, P1357, DOI 10.1111/j.1476-5381.2012.01855.x; Chubanov V, 2007, J BIOL CHEM, V282, P7656, DOI 10.1074/jbc.M611117200; Chubanov V, 2017, CELL CALCIUM, V67, P166, DOI 10.1016/j.ceca.2017.03.004; Chubanov V, 2016, ELIFE, V5, DOI 10.7554/eLife.20914; Clark K, 2006, EMBO J, V25, P290, DOI 10.1038/sj.emboj.7600931; Clark K, 2008, J MOL BIOL, V378, P790, DOI 10.1016/j.jmb.2008.02.057; Deason-Towne F, 2012, CELL SIGNAL, V24, P2070, DOI 10.1016/j.cellsig.2012.06.015; Dorovkov MV, 2011, BIOCHEMISTRY-US, V50, P2187, DOI 10.1021/bi101963h; Ellerbroek SM, 2003, J BIOL CHEM, V278, P19023, DOI 10.1074/jbc.M213066200; Essletzbichler P, 2014, GENOME RES, V24, P2059, DOI 10.1101/gr.177220.114; Evelyn CR, 2007, MOL CANCER THER, V6, P2249, DOI 10.1158/1535-7163.MCT-06-0782; Fleig A, 2014, HANDB EXP PHARMACOL, V222, P521, DOI 10.1007/978-3-642-54215-2_21; Hampl V, 2013, EMBO MOL MED, V5, P1367, DOI 10.1002/emmm.201202406; Hayashi K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089016; Hermanns C, 2017, ONCOGENE, V36, P3464, DOI 10.1038/onc.2016.496; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; Huang JH, 2017, CELL COMMUN SIGNAL, V15, DOI 10.1186/s12964-017-0187-9; Jin J, 2012, P NATL ACAD SCI USA, V109, pE225, DOI 10.1073/pnas.1120033109; Kaitsuka T, 2014, SCI REP-UK, V4, DOI 10.1038/srep05718; Kim BJ, 2008, CANCER SCI, V99, P2502, DOI 10.1111/j.1349-7006.2008.00982.x; Kircher P, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aad2959; Krapivinsky G, 2014, CELL, V157, P1061, DOI 10.1016/j.cell.2014.03.046; Krishnamoorthy M, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aah6692; Kwon CY, 2010, INT J ONCOL, V37, P837, DOI 10.3892/ijo_00000734; Londono MC, 2015, J HEPATOL, V62, P1196, DOI 10.1016/j.jhep.2015.01.028; Lundquist MR, 2014, CELL, V156, P563, DOI 10.1016/j.cell.2013.12.035; Matsushita M, 2005, J BIOL CHEM, V280, P20793, DOI 10.1074/jbc.M413671200; Miralles F, 2003, CELL, V113, P329, DOI 10.1016/S0092-8674(03)00278-2; Mittermeier L, 2019, P NATL ACAD SCI USA, V116, P4706, DOI 10.1073/pnas.1810633116; Muehlich S, 2012, ONCOGENE, V31, P3913, DOI 10.1038/onc.2011.560; Nadler MJS, 2001, NATURE, V411, P590, DOI 10.1038/35079092; Ohrnberger S, 2015, HEPATOLOGY, V61, P979, DOI 10.1002/hep.27539; Olson EN, 2010, NAT REV MOL CELL BIO, V11, P353, DOI 10.1038/nrm2890; Perraud AL, 2011, CELL SIGNAL, V23, P586, DOI 10.1016/j.cellsig.2010.11.011; Prevarskaya N, 2010, TRENDS MOL MED, V16, P107, DOI 10.1016/j.molmed.2010.01.005; Rolli-Derkinderen M, 2005, CIRC RES, V96, P1152, DOI 10.1161/01.RES.0000170084.88780.ea; Romagnani A, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01960-z; Ryazanova LV, 2004, J BIOL CHEM, V279, P3708, DOI 10.1074/jbc.M308820200; Rybarczyk P, 2017, NEOPLASIA, V19, P288, DOI 10.1016/j.neo.2017.01.004; Schmitz C, 2003, CELL, V114, P191, DOI 10.1016/S0092-8674(03)00556-7; Su LT, 2011, BIOCHEM J, V434, P513, DOI 10.1042/BJ20101678; Thompson AI, 2015, BMC GASTROENTEROL, V15, DOI 10.1186/s12876-015-0291-5; Tong JF, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147103; Wang ZY, 2015, HISTOCHEM CELL BIOL, V144, P39, DOI 10.1007/s00418-015-1311-9; Winkles JA, 1998, PROG NUCLEIC ACID RE, V58, P41; Yee NS, 2017, PHARMACEUTICALS-BASE, V10, DOI 10.3390/ph10020039; Yee Nelson S, 2014, Cells, V3, P751, DOI 10.3390/cells3030751; Yee NS, 2012, SCIENTIFICA, V2012, DOI 10.6064/2012/415158; Yu-Wai-Man C, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00212-w	53	17	17	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	11					2328	2344		10.1038/s41388-019-1140-8	http://dx.doi.org/10.1038/s41388-019-1140-8			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KU0ZS	31844251				2022-12-17	WOS:000519440400007
J	Zhuo, MH; Chen, WB; Shang, SH; Guo, P; Peng, KS; Li, M; Mo, PL; Zhang, YY; Qiu, XF; Li, WG; Yu, CD				Zhuo, Minghui; Chen, Wenbo; Shang, Shaohui; Guo, Peng; Peng, Kesong; Li, Ming; Mo, Pingli; Zhang, Yongyou; Qiu, Xingfeng; Li, Wengang; Yu, Chundong			Inflammation-induced JMJD2D promotes colitis recovery and colon tumorigenesis by activating Hedgehog signaling	ONCOGENE			English	Article							INTESTINAL INFLAMMATION; KAPPA-B; EPITHELIAL-CELLS; RANDOMIZED-TRIAL; ASPIRIN; METASTASIS; INHIBITION; SALICYLATE; VISMODEGIB; DEFICIENT	Histone demethylase JMJD2D can promote gene expression by specifically demethylating H3K9me2/3. The role of JMJD2D in colitis and colitis-associated colorectal cancer (CRC) progression remains unclear. Here, we show that colonic JMJD2D is induced by TNF alpha during dextran sulfate sodium-induced colitis. JMJD2D-deficient mice exhibit more severe colon damage and defective colon regeneration due to impaired Hedgehog signaling activation after colitis. JMJD2D knockdown in CRC cells suppresses Hedgehog signaling, resulting in reduced CRC growth and metastasis. Mechanistically, JMJD2D promotes Hedgehog target gene expression through interacting with Gli2 to reduce H3K9me3 levels at the promoter. Clinically, JMJD2D expression is upregulated and positively correlated with Gli2 expression in human inflammatory bowel disease specimens and CRC specimens. The JMJD2D inhibitor 5-c-8HQ or aspirin synergizes with Hedgehog inhibitor vismodegib to inhibit CRC cell proliferation and tumorigenesis. Collectively, our findings unveil an essential role of JMJD2D in activating the processes of colonic protection, regeneration, and tumorigenesis.	[Zhuo, Minghui; Shang, Shaohui; Guo, Peng; Peng, Kesong; Mo, Pingli; Zhang, Yongyou; Yu, Chundong] Xiamen Univ, Sch Life Sci, Innovat Ctr Cell Biol, State Key Lab Cellular Stress Biol, Xiamen, Peoples R China; [Chen, Wenbo] Xiamen Univ, Dept Cardiol, Affiliated Hosp 1, Xiamen, Peoples R China; [Peng, Kesong] Fudan Univ, Sch Basic Med Sci, Dept Cellular & Genet Med, Shanghai, Peoples R China; [Li, Ming; Li, Wengang] Xiamen Univ, Sch Med, Xiangan Hosp, Dept Hepatobiliary & Pancreat & Organ Transplanta, Xiamen, Peoples R China; [Qiu, Xingfeng] Xiamen Univ, Zhongshan Hosp, Dept Gastrointestinal Surg, Xiamen, Peoples R China	Xiamen University; Xiamen University; Fudan University; Xiamen University; Xiamen University	Yu, CD (corresponding author), Xiamen Univ, Sch Life Sci, Innovat Ctr Cell Biol, State Key Lab Cellular Stress Biol, Xiamen, Peoples R China.; Li, WG (corresponding author), Xiamen Univ, Sch Med, Xiangan Hosp, Dept Hepatobiliary & Pancreat & Organ Transplanta, Xiamen, Peoples R China.; Qiu, XF (corresponding author), Xiamen Univ, Zhongshan Hosp, Dept Gastrointestinal Surg, Xiamen, Peoples R China.	dr.qxf@xmu.edu.cn; lwg11861@163.com; cdyu@xmu.edu.cn		zhang, yongyou/0000-0003-2413-9106	National Natural Science Foundation of China [81970485, 81772942, 81901597]; National Basic Research Program of China (973 Program) [2015CB553800]; National Science and Technology Major Project of China [2017ZX10203206]; Scientific Research Foundation for Advanced Talents, Xiang'an Hospital of Xiamen University [PM20180917008]; Natural Science Foundation of Fujian Province [2017J01268]; National Health and Family Planning Commission's Scientific Research Foundation-Health and Education cooperation foundation [WKJ2016-2-17]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Basic Research Program of China (973 Program)(National Basic Research Program of China); National Science and Technology Major Project of China; Scientific Research Foundation for Advanced Talents, Xiang'an Hospital of Xiamen University; Natural Science Foundation of Fujian Province(Natural Science Foundation of Fujian Province); National Health and Family Planning Commission's Scientific Research Foundation-Health and Education cooperation foundation	We thank Shiwen Luo (Nanchang University) for providing Gli2 expression plasmid and Hedgehog signaling reporter 8xGBS, Chenglin Bian for TCGA data analysis, and Lei Huang for technical support. This study was supported by grants from the National Natural Science Foundation of China (no. 81970485 to CY), the National Natural Science Foundation of China (no. 81772942 to CY), the National Basic Research Program of China (973 Program, no. 2015CB553800 to CY), the National Natural Science Foundation of China (no. 81901597 to WC), the National Science and Technology Major Project of China (2017ZX10203206 to WL), the Scientific Research Foundation for Advanced Talents, Xiang'an Hospital of Xiamen University (no. PM20180917008 to WL), the Natural Science Foundation of Fujian Province (2017J01268 to XQ), and the National Health and Family Planning Commission's Scientific Research Foundation-Health and Education cooperation foundation (WKJ2016-2-17 to XQ).	Accari SL, 2015, INT REV CEL MOL BIO, V319, P165, DOI 10.1016/bs.ircmb.2015.07.003; Baron JA, 2003, NEW ENGL J MED, V348, P891, DOI 10.1056/NEJMoa021735; Berlin J, 2013, CLIN CANCER RES, V19, P258, DOI 10.1158/1078-0432.CCR-12-1800; Berry WL, 2013, CANCER RES, V73, P2936, DOI 10.1158/0008-5472.CAN-12-4300; Buller NVJA, 2012, PHYSIOLOGY, V27, P148, DOI 10.1152/physiol.00003.2012; Catenacci DVT, 2015, J CLIN ONCOL, V33, P4284, DOI 10.1200/JCO.2015.62.8719; Chen WB, 2018, INT J BIOL SCI, V14, P2051, DOI 10.7150/ijbs.28576; Dai P, 1999, J BIOL CHEM, V274, P8143, DOI 10.1074/jbc.274.12.8143; Das S, 2016, ONCOGENE, V35, P2645, DOI 10.1038/onc.2015.327; Elinav E, 2013, NAT REV CANCER, V13, P759, DOI 10.1038/nrc3611; Fattahi S, 2018, J CELL PHYSIOL, V233, P5726, DOI 10.1002/jcp.26506; Feagins LA, 2009, NAT REV GASTRO HEPAT, V6, P297, DOI 10.1038/nrgastro.2009.44; Geng H, 2018, GASTROENTEROLOGY, V155, P144, DOI 10.1053/j.gastro.2018.03.058; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Ikram MS, 2004, J INVEST DERMATOL, V122, P1503, DOI 10.1111/j.0022-202X.2004.22612.x; Jiang J, 2008, DEV CELL, V15, P801, DOI 10.1016/j.devcel.2008.11.010; Kasper M, 2006, EUR J CANCER, V42, P437, DOI 10.1016/j.ejca.2005.08.039; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Lees CW, 2008, PLOS MED, V5, P1761, DOI 10.1371/journal.pmed.0050239; Markowitz SD, 2009, NEW ENGL J MED, V361, P2449, DOI 10.1056/NEJMra0804588; Mizushima T, 2013, AM J PATHOL, V183, P1936, DOI 10.1016/j.ajpath.2013.08.012; Naito Y, 2003, J GASTROEN HEPATOL, V18, P560, DOI 10.1046/j.1440-1746.2003.03034.x; Onizawa M, 2009, AM J PHYSIOL-GASTR L, V296, pG850, DOI 10.1152/ajpgi.00071.2008; Peng KS, 2019, GASTROENTEROLOGY, V156, P1112, DOI 10.1053/j.gastro.2018.11.036; Pugliese D, 2017, EXPERT REV CLIN IMMU, V13, P223, DOI 10.1080/1744666X.2017.1243468; Ranganathan P, 2013, AM J PHYSIOL-RENAL, V305, pF1422, DOI 10.1152/ajprenal.00319.2013; Regl G, 2004, CANCER RES, V64, P7724, DOI 10.1158/0008-5472.CAN-04-1085; Rominger CM, 2009, J PHARMACOL EXP THER, V329, P995, DOI 10.1124/jpet.109.152090; Sandler RS, 2003, NEW ENGL J MED, V348, P883, DOI 10.1056/NEJMoa021633; Schwitalla S, 2013, CANCER CELL, V23, P93, DOI 10.1016/j.ccr.2012.11.014; Sekulic A, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3286-5; Sekulic A, 2012, NEW ENGL J MED, V366, P2171, DOI 10.1056/NEJMoa1113713; Sipos Ferenc, 2002, Orv Hetil, V143, P2485; Terzic J, 2010, GASTROENTEROLOGY, V138, P2101, DOI 10.1053/j.gastro.2010.01.058; Tong ZW, 2015, J BIOL CHEM, V290, P18596, DOI 10.1074/jbc.M115.640490; Ullman TA, 2011, GASTROENTEROLOGY, V140, P1807, DOI 10.1053/j.gastro.2011.01.057; Varnat F, 2009, EMBO MOL MED, V1, P338, DOI 10.1002/emmm.200900039; Wang Y, 2013, LAB INVEST, V93, P1024, DOI 10.1038/labinvest.2013.89; Whetstine JR, 2006, CELL, V125, P467, DOI 10.1016/j.cell.2006.03.028; Wirtz S, 2017, NAT PROTOC, V12, P1295, DOI 10.1038/nprot.2017.044; Xiao YT, 2016, CYTOKINE, V83, P189, DOI 10.1016/j.cyto.2016.04.012; Xu YH, 2007, IMMUNOL CELL BIOL, V85, P633, DOI 10.1038/sj.icb.7100112; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; Zhao B, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8166	44	17	17	9	23	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	2020	39	16					3336	3353		10.1038/s41388-020-1219-2	http://dx.doi.org/10.1038/s41388-020-1219-2		FEB 2020	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF9OJ	32094404				2022-12-17	WOS:000515475800001
J	Viallard, C; Audiger, C; Popovic, N; Akla, N; Lanthier, K; Legault-Navarrete, I; Melichar, H; Costantino, S; Lesage, S; Larrivee, B				Viallard, Claire; Audiger, Cindy; Popovic, Natalija; Akla, Naoufal; Lanthier, Kevin; Legault-Navarrete, Isaac; Melichar, Heather; Costantino, Santiago; Lesage, Sylvie; Larrivee, Bruno			BMP9 signaling promotes the normalization of tumor blood vessels	ONCOGENE			English	Article							BONE MORPHOGENETIC PROTEIN-9; ENDOTHELIAL-CELL-ADHESION; RECEPTOR-LIKE KINASE-1; VASCULAR NORMALIZATION; ANTIANGIOGENIC THERAPY; INHIBITS ANGIOGENESIS; IN-VIVO; CANCER; HYPOXIA; GROWTH	The presence of an immature tumor vascular network contributes to cancer dissemination and the development of resistance to therapies. Strategies to normalize the tumor vasculature are therefore of significant therapeutic interest for cancer treatments. VEGF inhibitors are used clinically to normalize tumor blood vessels. However, the time frame and dosage of these inhibitors required to achieve normalization is rather narrow, and there is a need to identify additional signaling targets to attain vascular normalization. In addition to VEGF, the endothelial-specific receptor Alk1 plays a critical role in vascular development and promotes vascular remodeling and maturation. Therefore, we sought to evaluate the effects of the Alk1 ligand BMP9 on tumor vascular formation. BMP9 overexpression in Lewis Lung Carcinoma (LLC) tumors significantly delayed tumor growth. Blood vessels in BMP9-overexpressing LLC tumors displayed markers of vascular maturation and were characterized by increased perivascular cell coverage. Tumor vasculature normalization was associated with decreased permeability and increased perfusion. These changes in vascular function in BMP9-overexpressing LLC tumors resulted in significant alterations of the tumor microenvironment, characterized by a decrease in hypoxia and an increase in immune infiltration. In conclusion, we show that BMP9 promotes vascular normalization in LLC tumors that leads to changes in the microenvironment.	[Viallard, Claire; Audiger, Cindy; Popovic, Natalija; Akla, Naoufal; Lanthier, Kevin; Legault-Navarrete, Isaac; Melichar, Heather; Costantino, Santiago; Lesage, Sylvie; Larrivee, Bruno] Ctr Rech Hop Maisonneuve Rosemt, Montreal, PQ, Canada; [Viallard, Claire; Popovic, Natalija; Lanthier, Kevin; Larrivee, Bruno] Univ Montreal, Dept Biol Mol, Montreal, PQ, Canada; [Audiger, Cindy; Lesage, Sylvie] Univ Montreal, Dept Microbiol Infectiol & Immunol, Montreal, PQ, Canada; [Akla, Naoufal] Univ Montreal, Dept Biochim, Montreal, PQ, Canada; [Melichar, Heather] Univ Montreal, Dept Med, Montreal, PQ, Canada; [Costantino, Santiago; Larrivee, Bruno] Univ Montreal, Dept Ophtalmol, Montreal, PQ, Canada	Universite de Montreal; Universite de Montreal; Universite de Montreal; Universite de Montreal; Universite de Montreal	Larrivee, B (corresponding author), Ctr Rech Hop Maisonneuve Rosemt, Montreal, PQ, Canada.; Larrivee, B (corresponding author), Univ Montreal, Dept Biol Mol, Montreal, PQ, Canada.; Larrivee, B (corresponding author), Univ Montreal, Dept Ophtalmol, Montreal, PQ, Canada.	bruno.larrivee@umontreal.ca	Costantino, Santiago/ABD-5472-2020	Costantino, Santiago/0000-0002-2454-2635; Popovic, Natalija/0000-0002-8324-4099; Larrivee, Bruno/0000-0003-1388-3108; Lesage, Sylvie/0000-0002-0968-2795	Cancer Research Society; Canadian Institutes of Health Research [363450]; Fonds de recherche -Sante (FRQS); Department of Ophthalmology of Universite de Montreal Research Fund Award (FROUM); Suzanne-Veronneau-Troutmann Award (SVT); FRQS scholarship; Montreal Diabetes Research Center PhD Award; Heart and Stroke Foundation of Canada	Cancer Research Society; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Fonds de recherche -Sante (FRQS); Department of Ophthalmology of Universite de Montreal Research Fund Award (FROUM); Suzanne-Veronneau-Troutmann Award (SVT); FRQS scholarship; Montreal Diabetes Research Center PhD Award; Heart and Stroke Foundation of Canada(Heart & Stroke Foundation of Canada)	We thank Dr. Paul S. Oh for kindly providing the Alk1.EC mice and Manuel Buscarlet for assistance with data analysis. This work was supported by an operating grant from the Cancer Research Society, and an operating grant from the Canadian Institutes of Health Research (363450). CV was supported by a post-doctoral research award from Fonds de recherche -Sante (FRQS). NA was supported by the Department of Ophthalmology of Universite de Montreal Research Fund Award (FROUM), Suzanne-Veronneau-Troutmann Award (SVT) and a FRQS scholarship. CA is recipient of a Montreal Diabetes Research Center PhD Award. SL is an FRQS Research Scholar Emeritus. BL is recipient of a New Investigator Award from the Heart and Stroke Foundation of Canada.	Abou-Alfa GK, 2019, ONCOLOGIST, V24, P161, DOI 10.1634/theoncologist.2018-0654; Akla N, 2018, ARTERIOSCL THROM VAS, V38, P1821, DOI 10.1161/ATVBAHA.118.310733; Appleby SL, 2016, J IMMUNOL, V197, P3302, DOI 10.4049/jimmunol.1601219; Arndt H, 1996, GUT, V38, P911, DOI 10.1136/gut.38.6.911; Azzi S, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00211; Baeyens N, 2016, J CELL BIOL, V214, P807, DOI 10.1083/jcb.201603106; Batchelor TT, 2007, CANCER CELL, V11, P83, DOI 10.1016/j.ccr.2006.11.021; Benn A, 2016, J CELL SCI, V129, P206, DOI 10.1242/jcs.179960; Berman ME, 1996, J IMMUNOL, V156, P1515; Brand V, 2016, MOL ONCOL, V10, P1603, DOI 10.1016/j.molonc.2016.10.002; Carmeliet P, 2011, NAT REV DRUG DISCOV, V10, P417, DOI 10.1038/nrd3455; Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144; Cerani A, 2013, CELL METAB, V18, P505, DOI 10.1016/j.cmet.2013.09.003; Chabot C, 2009, MOL CELL BIOL, V29, P241, DOI 10.1128/MCB.01374-08; David L, 2008, CIRC RES, V102, P914, DOI 10.1161/CIRCRESAHA.107.165530; David L, 2007, BLOOD, V109, P1953, DOI 10.1182/blood-2006-07-034124; de Vinuesa AG, 2016, BIOCHEM SOC T, V44, P1142, DOI 10.1042/BST20160093; del Toro R, 2010, BLOOD, V116, P4025, DOI 10.1182/blood-2010-02-270819; Douaisi M, 2017, J IMMUNOL, V198, P2310, DOI 10.4049/jimmunol.1500350; Duriez PJ, 2000, J BIOL CHEM, V275, P18099, DOI 10.1074/jbc.M908925199; Eales KL, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2015.50; Ebos JML, 2011, NAT REV CLIN ONCOL, V8, P210, DOI 10.1038/nrclinonc.2011.21; Friedl J, 2002, BLOOD, V100, P1334, DOI 10.1182/blood.V100.4.1334.h81602001334_1334_1339; Goel S, 2011, PHYSIOL REV, V91, P1071, DOI 10.1152/physrev.00038.2010; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Greenberg JI, 2009, EXPERT OPIN BIOL TH, V9, P1347, DOI 10.1517/14712590903208883; Gupta S, 2015, CURR ONCOL REP, V17, DOI 10.1007/s11912-015-0441-5; Hawinkels LJAC, 2016, CLIN CANCER RES, V22, P96, DOI 10.1158/1078-0432.CCR-15-0743; Hawinkels LJAC, 2013, EXPERT OPIN INV DRUG, V22, P1371, DOI 10.1517/13543784.2013.837884; Hu-Lowe DD, 2011, CANCER RES, V71, P1362, DOI 10.1158/0008-5472.CAN-10-1451; Huang YH, 2013, CANCER RES, V73, P2943, DOI 10.1158/0008-5472.CAN-12-4354; Huang YH, 2012, P NATL ACAD SCI USA, V109, P17561, DOI 10.1073/pnas.1215397109; Inai T, 2004, AM J PATHOL, V165, P35, DOI 10.1016/S0002-9440(10)63273-7; Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819; Jayson GC, 2016, LANCET, V388, P518, DOI 10.1016/S0140-6736(15)01088-0; Jerkic M, 2015, FASEB J, V29, P3678, DOI 10.1096/fj.14-269258; Keane MP, 2004, J IMMUNOL, V172, P2853, DOI 10.4049/jimmunol.172.5.2853; Kim JH, 2012, ANGIOGENESIS, V15, P497, DOI 10.1007/s10456-012-9277-x; Kim R, 2007, IMMUNOLOGY, V121, P1, DOI 10.1111/j.1365-2567.2007.02587.x; Koch AW, 2011, DEV CELL, V20, P33, DOI 10.1016/j.devcel.2010.12.001; Kumar V, 2014, IMMUNOLOGY, V143, P512, DOI 10.1111/imm.12380; Lamouille S, 2002, BLOOD, V100, P4495, DOI 10.1182/blood.V100.13.4495; Larrivee B, 2012, DEV CELL, V22, P489, DOI 10.1016/j.devcel.2012.02.005; Lechner MG, 2013, J IMMUNOTHER, V36, P477, DOI 10.1097/01.cji.0000436722.46675.4a; Liu T, 2014, SCI REP-UK, V4, DOI 10.1038/srep04833; Long L, 2015, NAT MED, V21, P777, DOI 10.1038/nm.3877; Lu TY, 2011, J CLIN INVEST, V121, P4015, DOI 10.1172/JCI45862; McKenney JK, 2001, AM J SURG PATHOL, V25, P1167, DOI 10.1097/00000478-200109000-00007; Mitchell D, 2010, MOL CANCER THER, V9, P379, DOI 10.1158/1535-7163.MCT-09-0650; Mitrofan CG, 2017, J BIOL CHEM, V292, P13714, DOI 10.1074/jbc.M117.778506; Moya IM, 2012, DEV CELL, V22, P501, DOI 10.1016/j.devcel.2012.01.007; Murakami T, 2009, J BIOL CHEM, V284, P21036, DOI 10.1074/jbc.M109.016766; Nakahara T, 2006, CANCER RES, V66, P1434, DOI 10.1158/0008-5472.CAN-05-0923; Noman MZ, 2015, AM J PHYSIOL-CELL PH, V309, pC569, DOI 10.1152/ajpcell.00207.2015; Nouvion AL, 2010, J CELL SCI, V123, P4221, DOI 10.1242/jcs.073635; Ntumba K, 2016, ONCOTARGET, V7, P55957, DOI 10.18632/oncotarget.11182; Ochoa-Callejero L, 2016, SCI REP-UK, V6, DOI 10.1038/srep33495; Ola R, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13650; Oladipupo SS, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33037-2; Ouarne M, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0885-1; Oubaha M, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf9440; Park JS, 2016, CANCER CELL, V30, P953, DOI 10.1016/j.ccell.2016.10.018; Qin RS, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4738-2; Renier N, 2016, CELL, V165, P1789, DOI 10.1016/j.cell.2016.05.007; Ricard N, 2012, BLOOD, V119, P6162, DOI 10.1182/blood-2012-01-407593; Rostama B, 2015, ARTERIOSCL THROM VAS, V35, P2626, DOI 10.1161/ATVBAHA.115.306541; Sceneay J, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.22355; Scharpfenecker M, 2007, J CELL SCI, V120, P964, DOI 10.1242/jcs.002949; Shrimali RK, 2010, CANCER RES, V70, P6171, DOI 10.1158/0008-5472.CAN-10-0153; Sitkovsky MV, 2008, CLIN CANCER RES, V14, P5947, DOI 10.1158/1078-0432.CCR-08-0229; Stacchini A, 2003, J BIOL REG HOMEOS AG, V17, P308; Sun ZY, 2012, J EXP MED, V209, P1363, DOI 10.1084/jem.20111343; Taguchi K, 2019, J IMMUNOL METHODS, V464, P105, DOI 10.1016/j.jim.2018.11.005; Tian HY, 2018, FASEB J, V32, P2934, DOI 10.1096/fj.201700867RR; Tolaney SM, 2015, P NATL ACAD SCI USA, V112, P14325, DOI 10.1073/pnas.1518808112; Upton PD, 2009, J BIOL CHEM, V284, P15794, DOI 10.1074/jbc.M109.002881; Varadaraj A, 2015, NEOPLASIA, V17, P826, DOI 10.1016/j.neo.2015.11.003; Vaupel P, 2004, ONCOLOGIST, V9, P10, DOI 10.1634/theoncologist.9-90005-10; Viallard C, 2017, ANGIOGENESIS, V20, P409, DOI 10.1007/s10456-017-9562-9; Voss MH, 2019, CANCER-AM CANCER SOC, V125, P2400, DOI 10.1002/cncr.32061; Wang XE, 2016, ONCOTARGET, V7, P41857, DOI 10.18632/oncotarget.9621; Ye L, 2008, MOL CANCER RES, V6, P1594, DOI 10.1158/1541-7786.MCR-08-0171; Yi M, 2009, P NATL ACAD SCI USA, V106, P17886, DOI 10.1073/pnas.0901324106; Yoong KF, 1998, J IMMUNOL, V160, P3978	84	17	18	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	14					2996	3014		10.1038/s41388-020-1200-0	http://dx.doi.org/10.1038/s41388-020-1200-0		FEB 2020	19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KZ2VB	32042114				2022-12-17	WOS:000512528200004
J	Chen, PZ; Duan, XH; Li, XG; Li, JQ; Ba, Q; Wang, H				Chen, Peizhan; Duan, Xiaohua; Li, Xiaoguang; Li, Jingquan; Ba, Qian; Wang, Hui			HIPK2 suppresses tumor growth and progression of hepatocellular carcinoma through promoting the degradation of HIF-1 alpha	ONCOGENE			English	Article							PROTEIN; APOPTOSIS; GENE; P53; PHOSPHORYLATION; IDENTIFICATION; EPIDEMIOLOGY; CONTRIBUTES; METASTASIS; STABILITY	Aberrant angiogenesis of hepatocellular carcinoma (HCC) leads to tumor growth and local or distant metastasis. Uncovering the underlying mechanisms for the neoangiogenesis of HCC can provide novel potential therapeutic targets in the clinic. Here, we reported that serine/threonine homeodomain-interacting protein kinase 2 (HIPK2) was frequently downregulated in HCC tissues compared with the adjacent normal tissues, and patients with lower HIPK2 protein expression were associated with worse overall survival. Both in vitro and in vivo, HIPK2 inhibited the migration of HCC cells, as well as tumor growth and metastasis in xenograft and orthotopic syngeneic HCC mouse models. Furthermore, HIPK2 inhibited the angiogenesis in HCC tumors. Under the hypoxic condition, HIPK2 knockdown enhanced the angiogenesis and the key regulator, HIF-1 alpha signaling pathway; however, HIPK2 overexpression downregulated the tumoral angiogenesis and HIF-1 alpha signaling. In HCC cells, HIPK2 could directly bind to HIF-1 alpha and stimulate the ubiquitination of HIF-1 alpha for proteasomal degradation. HIF-1 alpha knockout partially rescued the promoting effect of HIPK2 depletion on angiogenesis and tumor growth. In conclusion, the downregulation of HIPK2 could enhance the angiogenesis in HCC through inducing the HIF-1 alpha pathway, and further contribute to tumor growth and metastasis, which may provide a novel therapeutic strategy for HCC.	[Chen, Peizhan; Li, Xiaoguang; Li, Jingquan; Ba, Qian; Wang, Hui] Shanghai Jiao Tong Univ, Sch Med, Sch Publ Hlth, State Key Lab Oncogenes & Related Genes,Ctr Singl, Shanghai 200025, Peoples R China; [Chen, Peizhan; Duan, Xiaohua; Wang, Hui] Chinese Acad Sci, Shanghai Inst Biol Sci, Shanghai Inst Nutr & Hlth, CAS Key Lab Nutr Metab & Food Safety, Shanghai 200031, Peoples R China	Shanghai Jiao Tong University; Chinese Academy of Sciences; Shanghai Institute of Nutrition & Health, CAS; Shanghai Institutes for Biological Sciences, CAS	Ba, Q; Wang, H (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Sch Publ Hlth, State Key Lab Oncogenes & Related Genes,Ctr Singl, Shanghai 200025, Peoples R China.; Wang, H (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Shanghai Inst Nutr & Hlth, CAS Key Lab Nutr Metab & Food Safety, Shanghai 200031, Peoples R China.	qba@shsmu.edu.cn; huiwang@shsmu.edu.cn	Ba, Qian/AAZ-2623-2021	Ba, Qian/0000-0002-7253-7566	National Key R&D Program of China [2018YFC2000700, 2018ZX10302205, 2017YFC0907001]; National Natural Science Foundation of China [81630086, 81573161, 81973078, 81427805]; Science and Technology Commission of Shanghai Municipality [16391903700]; Shanghai Municipality Health Commission [20164Y0250, 2017YQ0059]; Major Science and Technology Innovation Program of Shanghai Municipal Education Commission [2019-01-07-00-01-E00059]; Chinese Academy of Sciences [ZDRW-ZS-2017-1]; Science and Technology Commission of Jiading Distinct [JDKW-2017-W09]; Shanghai Jiao Tong University [YG2017MS85]; Shanghai Municipal Human Resources and Social Security Bureau [2018060]	National Key R&D Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Commission of Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM)); Shanghai Municipality Health Commission; Major Science and Technology Innovation Program of Shanghai Municipal Education Commission; Chinese Academy of Sciences(Chinese Academy of Sciences); Science and Technology Commission of Jiading Distinct; Shanghai Jiao Tong University; Shanghai Municipal Human Resources and Social Security Bureau	This work was supported by grants from the National Key R&D Program of China (2018YFC2000700, 2018ZX10302205, and 2017YFC0907001), the National Natural Science Foundation of China (81630086, 81573161, 81973078, and 81427805), the Science and Technology Commission of Shanghai Municipality (16391903700), the Shanghai Municipality Health Commission (20164Y0250 and 2017YQ0059), the Major Science and Technology Innovation Program of Shanghai Municipal Education Commission (2019-01-07-00-01-E00059), the Key Research Program (ZDRW-ZS-2017-1) of the Chinese Academy of Sciences, Shanghai Municipal Human Resources and Social Security Bureau (2018060), Science and Technology Commission of Jiading Distinct (JDKW-2017-W09), and Shanghai Jiao Tong University (YG2017MS85).	Ba Q, 2017, J MOL CELL BIOL, V9, P209, DOI 10.1093/jmcb/mjx019; Bitomsky N, 2009, FEBS J, V276, P6074, DOI 10.1111/j.1742-4658.2009.07331.x; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cai JL, 2017, EBIOMEDICINE, V19, P18, DOI 10.1016/j.ebiom.2017.04.014; Calzado MA, 2009, NAT CELL BIOL, V11, P85, DOI 10.1038/ncb1816; Choi JR, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16489-w; Clark T, 2015, CURR PROBL DIAGN RAD, V44, P479, DOI 10.1067/j.cpradiol.2015.04.004; Di Stefana V, 2005, FEBS LETT, V579, P5473, DOI 10.1016/j.febslet.2005.09.008; Di Stefano V, 2004, ONCOGENE, V23, P5185, DOI 10.1038/sj.onc.1207656; Fang JM, 2001, CANCER RES, V61, P5731; Feng YY, 2017, ONCOTARGET, V8, P20452, DOI 10.18632/oncotarget.14723; Garufi A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048342; Guan Yong-Song, 2012, ISRN Gastroenterol, V2012, P480650, DOI 10.5402/2012/480650; Hofmann TG, 2000, BIOCHIMIE, V82, P1123, DOI 10.1016/S0300-9084(00)01196-2; Hu HY, 2019, INT J BIOL MACROMOL, V132, P470, DOI 10.1016/j.ijbiomac.2019.03.221; Kim CJ, 2004, ONCOGENE, V23, P8591, DOI 10.1038/sj.onc.1208113; Kim EJ, 2002, J BIOL CHEM, V277, P32020, DOI 10.1074/jbc.M200153200; Lazzari C, 2011, ONCOGENE, V30, P4802, DOI 10.1038/onc.2011.182; Lee Ji-Won, 2004, Experimental & Molecular Medicine, V36, P1; Li QX, 2007, CANCER RES, V67, P66, DOI 10.1158/0008-5472.CAN-06-1671; Li XG, 2017, GUT, V66, P157, DOI 10.1136/gutjnl-2015-310514; Lin JW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094040; Liu SP, 2012, J HEPATOL, V56, P389, DOI 10.1016/j.jhep.2011.08.008; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; McGlynn KA, 2011, CLIN LIVER DIS, V15, P223, DOI 10.1016/j.cld.2011.03.006; Moehlenbrink J, 2010, CANCER LETT, V292, P119, DOI 10.1016/j.canlet.2009.11.016; Morse MA, 2019, CLIN CANCER RES, V25, P912, DOI 10.1158/1078-0432.CCR-18-1254; Nardinocchi L, 2011, AGING-US, V3, P33, DOI 10.18632/aging.100254; Nardinocchi L, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-1; Nardinocchi L, 2009, BBA-MOL CELL RES, V1793, P368, DOI 10.1016/j.bbamcr.2008.10.013; Puca R, 2008, GYNECOL ONCOL, V109, P403, DOI 10.1016/j.ygyno.2008.02.018; Qin Y, 2019, CELL PROLIFERAT, V52, DOI 10.1111/cpr.12603; Rinaldo C, 2007, MOL CELL, V25, P739, DOI 10.1016/j.molcel.2007.02.008; Tan MY, 2014, J CELL BIOCHEM, V115, P1762, DOI 10.1002/jcb.24842; Tan XY, 2018, J CELL BIOCHEM, V119, P5153, DOI 10.1002/jcb.26542; Upadhyay M, 2016, BIOCHEM BIOPH RES CO, V472, P580, DOI 10.1016/j.bbrc.2016.03.035; Wang SY, 2012, CLIN CANCER RES, V18, P2987, DOI 10.1158/1078-0432.CCR-11-2863; Wang Y, 2001, BMC Mol Biol, V2, P8, DOI 10.1186/1471-2199-2-8; Zhang N, 2018, J GENET, V97, P47, DOI 10.1007/s12041-018-0881-4; Zhang OH, 2003, CELL, V115, P177, DOI 10.1016/S0092-8674(03)00802-X; Zhang QH, 2005, P NATL ACAD SCI USA, V102, P2802, DOI 10.1073/pnas.0409373102; Zhang Z, 2018, EXP THER MED, V15, P1113, DOI 10.3892/etm.2017.5468; Zhou LH, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-747; Zhu AX, 2011, NAT REV CLIN ONCOL, V8, P292, DOI 10.1038/nrclinonc.2011.30	44	17	17	2	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	14					2863	2876		10.1038/s41388-020-1190-y	http://dx.doi.org/10.1038/s41388-020-1190-y		FEB 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KZ2VB	32034309				2022-12-17	WOS:000511752600002
J	Ray, A; Song, Y; Du, T; Chauhan, D; Anderson, KC				Ray, Arghya; Song, Yan; Du, Ting; Chauhan, Dharminder; Anderson, Kenneth C.			Preclinical validation of Alpha-Enolase (ENO1) as a novel immunometabolic target in multiple myeloma	ONCOGENE			English	Article							DRUG-RESISTANCE; IMMUNE; INHIBITOR; THERAPIES; HYPOXIA; CELLS; CYTOTOXICITY; GROWTH; OXYGEN; MODEL	Bone marrow plasmacytoid dendritic cells (pDCs) in patients with multiple myeloma (MM) promote tumor growth, survival, drug resistance, and immune suppression. Understanding the molecular signaling crosstalk among the tumor cells, pDCs and immune cells will identify novel therapeutic approaches to enhance anti-MM immunity. Using oligonucleotide arrays, we found that pDC-MM interactions induce metabolic enzyme Alpha-Enolase (ENO1) in both pDCs and MM cells. Analysis of MM patient gene expression profiling database showed that ENO1 expression inversely correlates with overall survival. Protein expression analysis showed that ENO1 is expressed in pDC and MM cells; and importantly, that pDC-MM coculture further increases ENO1 expression in both MM cells and pDCs. Using our coculture models of patient autologous pDC-T-NK-MM cells, we examined whether targeting ENO1 can enhance anti-MM immunity. Biochemical inhibition of ENO1 with ENO1 inhibitor (ENO1i) activates pDCs, as well as increases pDC-induced MM-specific CD8(+) CTL and NK cell activity against autologous tumor cells. Combination of ENO1i and anti-PD-L1 Ab or HDAC6i ACY-241 enhances autologous MM-specific CD8(+) CTL activity. Our preclinical data therefore provide the basis for novel immune-based therapeutic approaches targeting ENO1, alone or in combination with anti-PD-L1 Ab or ACY241, to restore anti-MM immunity, enhance MM cytotoxicity, and improve patient outcome.	[Ray, Arghya; Song, Yan; Du, Ting; Chauhan, Dharminder; Anderson, Kenneth C.] Harvard Med Sch, Dept Med Oncol, LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA; [Ray, Arghya; Song, Yan; Du, Ting; Chauhan, Dharminder; Anderson, Kenneth C.] Harvard Med Sch, Jerome Lipper Myeloma Ctr, Dana Farber Canc Inst, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Chauhan, D; Anderson, KC (corresponding author), Harvard Med Sch, Dept Med Oncol, LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA.; Chauhan, D; Anderson, KC (corresponding author), Harvard Med Sch, Jerome Lipper Myeloma Ctr, Dana Farber Canc Inst, Boston, MA 02115 USA.	Dharminder_Chauhan@dfci.harvard.edu; Kenneth_Anderson@dfci.harvard.edu			Dr. Miriam and Sheldon Adelson Medical Research Foundation; National Institutes of Health Specialized Programs of Research Excellence (SPORE) grant [P50100707, R01CA207237, R01 CA050947]	Dr. Miriam and Sheldon Adelson Medical Research Foundation; National Institutes of Health Specialized Programs of Research Excellence (SPORE) grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The grant supports for this investigation were provided by "Dr. Miriam and Sheldon Adelson Medical Research Foundation", and by the National Institutes of Health Specialized Programs of Research Excellence (SPORE) grant P50100707, R01CA207237, and R01 CA050947. KCA is an American Cancer Society Clinical Research Professor.	Ader I, 2008, CANCER RES, V68, P8635, DOI 10.1158/0008-5472.CAN-08-0917; Anderson KC, 2018, J ONCOL PRACT, V14, P411, DOI 10.1200/JOP.18.00311; Anderson KC, 2013, J NATL COMPR CANC NE, V11, P676, DOI 10.6004/jnccn.2013.0199; Anderson KC, 2012, J CLIN ONCOL, V30, P445, DOI 10.1200/JCO.2011.37.8919; Bae J, 2018, LEUKEMIA, V32, P1932, DOI 10.1038/s41375-018-0062-8; Barlogie B, 2006, NEW ENGL J MED, V354, P1021, DOI 10.1056/NEJMoa053583; Bi EG, 2018, J CLIN INVEST, V128, P4821, DOI 10.1172/JCI121421; Cappello P, 2017, FRONT BIOSCI-LANDMRK, V22, P944, DOI 10.2741/4526; Cappello P, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1112940; Chauhan D, 2003, BLOOD, V101, P3606, DOI 10.1182/blood-2002-10-3146; Chauhan D, 2009, CANCER CELL, V16, P309, DOI 10.1016/j.ccr.2009.08.019; Colegio OR, 2014, NATURE, V513, P559, DOI 10.1038/nature13490; de Broek IV, 2006, HAEMATOL-HEMATOL J, V91, P200; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Granchi C, 2014, BIOORG MED CHEM LETT, V24, P4915, DOI 10.1016/j.bmcl.2014.09.041; Gu ZM, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0392-4; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Heuck CJ, 2014, LEUKEMIA, V28, P2410, DOI 10.1038/leu.2014.232; Ikeda S, 2018, BLOOD ADV, V2, P323, DOI 10.1182/bloodadvances.2017008847; Jung DW, 2013, ACS CHEM BIOL, V8, P1271, DOI 10.1021/cb300687k; Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009; Li WB, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071616; Liberti MV, 2016, NAT CHEM BIOL, V12, P577, DOI 10.1038/nchembio.2133; Lu CC, 2014, J CHROMATOGR A, V1372, P34, DOI 10.1016/j.chroma.2014.10.098; Maiso P, 2015, CANCER RES, V75, P2071, DOI 10.1158/0008-5472.CAN-14-3400; Manasanch EE, 2019, BLOOD ADV, V3, P2400, DOI 10.1182/bloodadvances.2019000300; Milosevic A, 2004, SEMIN RADIAT ONCOL, V14, P249, DOI 10.1016/j.semradonc.2004.04.006; Muller FL, 2012, NATURE, V488, P337, DOI 10.1038/nature11331; Pacella I, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01889; Qorraj M, 2017, LEUKEMIA, V31, P470, DOI 10.1038/leu.2016.214; Ray A, 2018, LEUKEMIA, V32, P843, DOI 10.1038/leu.2017.322; Ray A, 2015, LEUKEMIA, V29, P1441, DOI 10.1038/leu.2015.11; Ray A, 2014, LEUKEMIA, V28, P1716, DOI 10.1038/leu.2014.46; Ray A, 2020, LEUKEMIA, V34, P567, DOI 10.1038/s41375-019-0558-x; Ryans K, 2017, BMC IMMUNOL, V18, DOI 10.1186/s12865-017-0212-1; Shaughnessy JD, 2007, BLOOD, V109, P2276, DOI 10.1182/blood-2006-07-038430; Shin YC, 2008, CANCER RES, V68, P1751, DOI 10.1158/0008-5472.CAN-07-2766; Stessman HAF, 2013, MOL CANCER THER, V12, P1140, DOI 10.1158/1535-7163.MCT-12-1151; Warburg O, 1927, J GEN PHYSIOL, V8, P519, DOI 10.1085/jgp.8.6.519; Zhao MY, 2015, ONCOTARGET, V6, P15610, DOI 10.18632/oncotarget.3639; Zhu XH, 2015, EXP CELL RES, V335, P216, DOI 10.1016/j.yexcr.2015.05.020	41	17	19	2	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	13					2786	2796		10.1038/s41388-020-1172-0	http://dx.doi.org/10.1038/s41388-020-1172-0		FEB 2020	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KX4EF	32024967	Green Accepted			2022-12-17	WOS:000511273600001
J	Chen, LP; De Menna, M; Groenewoud, A; Thalmann, GN; Kruithof-de Julio, M; Snaar-Jagalska, BE				Chen, Lanpeng; De Menna, Marta; Groenewoud, Arwin; Thalmann, George N.; Kruithof-de Julio, Marianna; Snaar-Jagalska, B. Ewa			A NF-kappa B-Activin A signaling axis enhances prostate cancer metastasis	ONCOGENE			English	Article							TGF-BETA; BONE METASTASIS; GROWTH-FACTOR; SELF-RENEWAL; STEM-CELLS; ZEBRAFISH; MODEL; PROGRESSION; INHIBITION; BREAST	Metastasis is a main cause of death in prostate cancer (PCa). To dissect the molecular cues from cancer cell-microenvironment interaction that drive metastatic cascade, bone metastatic PCa cells were intravenously implanted into zebrafish embryos and mice tibia forming metastatic lesions. Transcriptomic analysis showed an elevated expression of stemness genes, pro-inflammatory cytokines and TGF-beta family member Activin A in the cancer cells at metastatic onset in both animal models. Consistently, analysis of clinical datasets revealed that the expression of Activin A is specifically elevated in metastases and correlates with poor prognosis in stratified high-risk PCa patients. It is further unveiled that the microenvironment induced Activin A expression by NF-kappa B activation. The elevated level of Activin A enhanced the invasive ALDH(hi) CSC-like phenotypes and PCa proliferation by activation of Smad and ERK1/2 signaling driving metastasis. Suppression of Activin A or Activin receptor significantly reduced the CSC-like subpopulation, invasion, metastatic growth, and bone lesion formation in zebrafish and mice xenografts, suggesting a functional role of NF-kappa B-dependent Activin A in PCa metastasis. Overall, our study demonstrates that human PCa cells can display a comparable response with the microenvironment in zebrafish and mice xenografts. Combining both animal models, we uncovered the microenvironment-dependent activin signaling as an essential driver in PCa metastasis with therapeutic potential.	[Chen, Lanpeng; Groenewoud, Arwin; Snaar-Jagalska, B. Ewa] Leiden Univ, Inst Biol, Leiden, Netherlands; [De Menna, Marta; Kruithof-de Julio, Marianna] Univ Bern, Dept BioMed Res, Urol Res Lab, Bern, Switzerland; [Thalmann, George N.] Inselspital Bern, Dept Urol, Bern, Switzerland	Leiden University; Leiden University - Excl LUMC; University of Bern; University of Bern; University Hospital of Bern	Snaar-Jagalska, BE (corresponding author), Leiden Univ, Inst Biol, Leiden, Netherlands.; Kruithof-de Julio, M (corresponding author), Univ Bern, Dept BioMed Res, Urol Res Lab, Bern, Switzerland.	marianna.kruithofdejulio@dbmr.unibe.ch; b.e.snaar-jagalska@biology.leidenuniv.nl		Kruithof-de Julio, Marianna/0000-0002-6085-7706; De Menna, Marta/0000-0002-6306-3485	Alpe D'HuZes (AdH)/KWF PROPER entitled "Near-patient prostate cancer models for the assessment of disease prognosis and therapy" [UL2014-7058]; SNF [31003A_169352]	Alpe D'HuZes (AdH)/KWF PROPER entitled "Near-patient prostate cancer models for the assessment of disease prognosis and therapy"; SNF	We thank Dr Gabriel van der Pluijm (Deportment of Urology, LUMC) for providing experimental material, Prof. Peter ten Dijke (Department of Molecular Cell Biology) for providing experimental material and critical scientific discussion and Guido de Roo from the Flow cytometry facility (Department of Hematology, LUMC) for technical support, Prof. Rob Hoeben and Martijn Rabelink (Department of Cell Biology, LUMC) for providing lentiviral shRNA vectors (Sigma-Aldrich). The present work was supported by a personalized medicine grant from Alpe D'HuZes (AdH)/KWF PROPER entitled "Near-patient prostate cancer models for the assessment of disease prognosis and therapy" (UL2014-7058) and SNF 31003A_169352.	Aguirre-Gamboa R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074250; Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Anders S, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-10-r106; Bashir M, 2015, NPJ BREAST CANCER, V1, DOI 10.1038/npjbcancer.2015.7; Brown CW, 2003, MOL ENDOCRINOL, V17, P2404, DOI 10.1210/me.2003-0051; Byfield SD, 2004, MOL PHARMACOL, V65, P744, DOI 10.1124/mol.65.3.744; Chen L, 2017, METHOD CELL BIOL, V138, P471, DOI 10.1016/bs.mcb.2016.10.009; Clements M, 2011, CURR BIOL, V21, P1289, DOI 10.1016/j.cub.2011.06.048; Collins AT, 2005, CANCER RES, V65, P10946, DOI 10.1158/0008-5472.CAN-05-2018; Cui C, 2011, METHOD CELL BIOL, V105, P273, DOI 10.1016/B978-0-12-381320-6.00012-6; Dai JL, 2016, BONEKEY REP, V5, DOI 10.1038/bonekey.2016.4; Dalkin AC, 1996, ENDOCRINOLOGY, V137, P5230, DOI 10.1210/en.137.12.5230; Dooley K, 2000, CURR OPIN GENET DEV, V10, P252, DOI 10.1016/S0959-437X(00)00074-5; Drabsch Y, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3573; Ellett F, 2011, BLOOD, V117, pE49, DOI 10.1182/blood-2010-10-314120; Fior R, 2017, P NATL ACAD SCI USA, V114, pE8234, DOI 10.1073/pnas.1618389114; Gold E, 2012, MOL CELL ENDOCRINOL, V359, P107, DOI 10.1016/j.mce.2011.07.005; Gray PC, 2012, FEBS LETT, V586, P1836, DOI 10.1016/j.febslet.2012.01.051; He SN, 2012, J PATHOL, V227, P431, DOI 10.1002/path.4013; HEMMATIBRIVANLOU A, 1994, CELL, V77, P283, DOI 10.1016/0092-8674(94)90320-4; Hofland J, 2012, ENDOCRINOLOGY, V153, P5726, DOI 10.1210/en.2011-2065; Hsu WK, 2008, J NUCL MED, V49, P414, DOI 10.2967/jnumed.107.045666; James D, 2005, DEVELOPMENT, V132, P1273, DOI 10.1242/dev.01706; Jemal A, 2010, CANC EPIDEMIOLOGY PR, P1055; Jin H, 2007, BLOOD, V109, P5208, DOI 10.1182/blood-2007-01-069005; Karkampouna S, 2018, J PATHOL, V245, P297, DOI 10.1002/path.5083; Lawson ND, 2002, DEV BIOL, V248, P307, DOI 10.1006/dbio.2002.0711; Leto G, 2006, CLIN EXP METASTAS, V23, P117, DOI 10.1007/s10585-006-9010-5; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Liu TL, 2018, SCIENCE, V360, DOI 10.1126/science.aaq1392; Lonardo E, 2011, CELL STEM CELL, V9, P433, DOI 10.1016/j.stem.2011.10.001; Loomans HA, 2015, CANCERS, V7, P70, DOI 10.3390/cancers7010070; Lu HH, 2014, NAT CELL BIOL, V16, P1105, DOI 10.1038/ncb3041; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; McKenzie S, 2006, J CELL BIOCHEM, V97, P18, DOI 10.1002/jcb.20634; Nomura M, 1998, NATURE, V393, P786, DOI 10.1038/31693; Postlethwait JH, 1998, NAT GENET, V18, P345, DOI 10.1038/ng0498-345; Quail DF, 2014, ONCOGENE, V33, P461, DOI 10.1038/onc.2012.608; Sacco A, 2016, CANCER RES, V76, P463, DOI 10.1158/0008-5472.CAN-15-1926; Schier AF, 2000, NATURE, V403, P385, DOI 10.1038/35000126; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shiozawa Y, 2016, ONCOTARGET, V7, P41217, DOI 10.18632/oncotarget.9251; Shiozawa Y, 2011, J CLIN INVEST, V121, P1298, DOI 10.1172/JCI43414; Singh S, 2013, FREE RADICAL BIO MED, V56, P89, DOI 10.1016/j.freeradbiomed.2012.11.010; Strizzi L, 2005, ONCOGENE, V24, P5731, DOI 10.1038/sj.onc.1208918; Tamplin OJ, 2015, CELL, V160, P241, DOI 10.1016/j.cell.2014.12.032; THALMANN GN, 1994, CANCER RES, V54, P2577; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; Tulotta C, 2016, DIS MODEL MECH, V9, P141, DOI 10.1242/dmm.023275; van den Hoogen C, 2010, CANCER RES, V70, P5163, DOI 10.1158/0008-5472.CAN-09-3806; Wamsley JJ, 2015, CANCER RES, V75, P426, DOI 10.1158/0008-5472.CAN-13-2702; Wang Q, 2012, MED ONCOL, V29, P77, DOI 10.1007/s12032-010-9766-y; White R, 2013, NAT REV CANCER, V13, P624, DOI 10.1038/nrc3589; Xiao L, 2006, STEM CELLS, V24, P1476, DOI 10.1634/stemcells.2005-0299; Zon LI, 2005, NAT REV DRUG DISCOV, V4, P35, DOI 10.1038/nrd1606; Zoni E, 2017, ONCOGENE, V36, P4739, DOI 10.1038/onc.2017.87	56	17	20	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	8					1634	1651		10.1038/s41388-019-1103-0	http://dx.doi.org/10.1038/s41388-019-1103-0			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN6CG	31740783				2022-12-17	WOS:000514923000002
J	Chen, XY; Xiong, XF; Cui, DR; Yang, F; Wei, DP; Li, HM; Shu, JF; Bi, YL; Dai, XQ; Gong, LY; Sun, Y; Zhao, YC				Chen, Xiaoyu; Xiong, Xiufang; Cui, Danrui; Yang, Fei; Wei, Dongping; Li, Haomin; Shu, Jianfeng; Bi, Yanli; Dai, Xiaoqing; Gong, Longyuan; Sun, Yi; Zhao, Yongchao			DEPTOR is an in vivo tumor suppressor that inhibits prostate tumorigenesis via the inactivation of mTORC1/2 signals	ONCOGENE			English	Article							BETA-TRCP; CANCER; PTEN; PROGRESSION; ACTIVATION; GROWTH; RADIOTHERAPY; DEGRADATION; METABOLISM; TRANSITION	The DEPTOR-mTORC1/2 axis has been shown to play an important, but a context dependent role in the regulation of proliferation and the survival of various cancer cells in cell culture settings. The in vivo role of DEPTOR in tumorigenesis remains elusive. Here we showed that the levels of both DEPTOR protein and mRNA were substantially decreased in human prostate cancer tissues, which positively correlated with disease progression. DEPTOR depletion accelerated proliferation and survival, migration, and invasion in human prostate cancer cells. Mechanistically, DEPTOR depletion not only activated both mTORC1 and mTORC2 signals to promote cell proliferation and survival, but also induced an AKT-dependent epithelial-mesenchymal transition (EMT) and beta-catenin nuclear translocation to promote cell migration and invasion. Abrogation of mTOR or AKT activation rescued the biological consequences of DEPTOR depletion. Importantly, in a Deptor-KO mouse model, Deptor knockout accelerated prostate tumorigenesis triggered by Pten loss via the activation of mTOR signaling. Collectively, our study demonstrates that DEPTOR is a tumor suppressor in the prostate, and its depletion promotes tumorigenesis via the activation of mTORC1 and mTORC2 signals. Thus, DEPTOR reactivation via a variety of means would have therapeutic potential for the treatment of prostate cancer.	[Chen, Xiaoyu; Cui, Danrui; Shu, Jianfeng; Bi, Yanli; Dai, Xiaoqing; Gong, Longyuan; Zhao, Yongchao] Zhejiang Univ, Affiliated Hosp 1, Key Lab Combined Multiorgan Transplantat, Minist Publ Hlth,Sch Med, Hangzhou, Peoples R China; [Chen, Xiaoyu; Xiong, Xiufang; Cui, Danrui; Yang, Fei; Li, Haomin; Shu, Jianfeng; Bi, Yanli; Dai, Xiaoqing; Gong, Longyuan; Sun, Yi; Zhao, Yongchao] Zhejiang Univ, Inst Translat Med, Sch Med, Hangzhou, Peoples R China; [Xiong, Xiufang; Sun, Yi] Zhejiang Univ, Affiliated Hosp 2, Canc Inst, Sch Med, Hangzhou, Peoples R China; [Wei, Dongping] Nanjing Med Univ, Nanjing Hosp 1, Dept Oncol, Nanjing, Peoples R China; [Li, Haomin] Zhejiang Univ, Childrens Hosp, Sch Med, Hangzhou, Zhejiang, Peoples R China; [Sun, Yi] Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA	Zhejiang University; Zhejiang University; Zhejiang University; Nanjing Medical University; Zhejiang University; University of Michigan System; University of Michigan	Zhao, YC (corresponding author), Zhejiang Univ, Affiliated Hosp 1, Key Lab Combined Multiorgan Transplantat, Minist Publ Hlth,Sch Med, Hangzhou, Peoples R China.; Zhao, YC (corresponding author), Zhejiang Univ, Inst Translat Med, Sch Med, Hangzhou, Peoples R China.	yongchao@zju.edu.cn	Li, Haomin/AAY-5044-2021; Sun, Yi/K-1025-2014	Li, Haomin/0000-0002-6420-7719; Sun, Yi/0000-0002-5841-4287; Xiong, Xiufang/0000-0001-6842-3673	National Key R&D Program of China [2016YFA0501800]; National Natural Science Foundation of China [81672728, 81972591, 81721091, 81572708, 31501129, 81974429, 81572718, 81630076, 81672895]; Natural Science Foundation of Zhejiang Province [LR16C050001]	National Key R&D Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Zhejiang Province(Natural Science Foundation of Zhejiang Province)	This work was supported by the National Key R&D Program of China (2016YFA0501800 to YZ, XX, and YS), the National Natural Science Foundation of China (81672728, 81972591, and 81721091 to YZ, 81572708, 31501129, and 81974429 to XX, 81572718 and 81630076 to YS, and 81672895 to DW), and the Natural Science Foundation of Zhejiang Province (LR16C050001 to YZ).	Beer TM, 2017, EUR UROL, V71, P151, DOI 10.1016/j.eururo.2016.07.032; Blando J, 2009, AM J PATHOL, V174, P1869, DOI 10.2353/ajpath.2009.080055; Brand D, 2018, EUR UROL, V73, P521, DOI 10.1016/j.eururo.2017.12.021; Caron A, 2018, PHYSIOL REV, V98, P1765, DOI 10.1152/physrev.00064.2017; Caron A, 2017, MOL METAB, V6, P447, DOI 10.1016/j.molmet.2017.02.005; Chiarini F, 2015, TRENDS PHARMACOL SCI, V36, P124, DOI 10.1016/j.tips.2014.11.004; Crabb SJ, 2017, INVEST NEW DRUG, V35, P599, DOI 10.1007/s10637-017-0433-4; Duan SS, 2011, MOL CELL, V44, P317, DOI 10.1016/j.molcel.2011.09.005; Edlind MP, 2014, ASIAN J ANDROL, V16, P378, DOI 10.4103/1008-682X.122876; El Sheikh SS, 2008, NEOPLASIA, V10, P949, DOI 10.1593/neo.08582; Ferraldeschi R, 2015, EUR UROL, V67, P795, DOI 10.1016/j.eururo.2014.10.027; Fraser M, 2012, CLIN CANCER RES, V18, P1015, DOI 10.1158/1078-0432.CCR-11-2189; Gao DM, 2011, MOL CELL, V44, P290, DOI 10.1016/j.molcel.2011.08.030; Gonzalez DM, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005189; Goodall J, 2017, CANCER DISCOV, V7, P1006, DOI 10.1158/2159-8290.CD-17-0261; Henderson V, 2015, CELL ADHES MIGR, V9, P255, DOI 10.1080/19336918.2015.1013383; Huang W, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-1; Jamaspishvili T, 2018, NAT REV UROL, V15, P222, DOI 10.1038/nrurol.2018.9; Janku F, 2018, NAT REV CLIN ONCOL, V15, P273, DOI 10.1038/nrclinonc.2018.28; Ji YM, 2016, ONCOTARGET, V7, P14188, DOI 10.18632/oncotarget.7420; Julien S, 2007, ONCOGENE, V26, P7445, DOI 10.1038/sj.onc.1210546; Khamis ZI, 2012, MED RES REV, V32, P1026, DOI 10.1002/med.20232; Lai EY, 2014, ASIAN PAC J CANCER P, V15, P4589, DOI 10.7314/APJCP.2014.15.11.4589; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Lamouille S, 2012, J CELL SCI, V125, P1259, DOI 10.1242/jcs.095299; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Lee YR, 2018, NAT REV MOL CELL BIO, V19, P547, DOI 10.1038/s41580-018-0015-0; Li H, 2014, ONCOTARGET, V5, P12811, DOI 10.18632/oncotarget.2659; Liu QS, 2010, J MED CHEM, V53, P7146, DOI 10.1021/jm101144f; Lynch JT, 2018, MOL CANCER THER, V17, P2309, DOI 10.1158/1535-7163.MCT-18-0183; Mahal BA, 2018, EUR UROL, V74, P146, DOI 10.1016/j.eururo.2018.01.043; Obara A, 2015, BIOCHEM BIOPH RES CO, V460, P1047, DOI 10.1016/j.bbrc.2015.03.148; Pei L, 2011, MOL MED REP, V4, P817, DOI 10.3892/mmr.2011.503; Peterson TR, 2009, CELL, V137, P873, DOI 10.1016/j.cell.2009.03.046; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Reid AHM, 2010, BRIT J CANCER, V102, P678, DOI 10.1038/sj.bjc.6605554; Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.02.004, 10.1016/j.cell.2017.03.035]; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Sole CV, 2013, EUR J NUCL MED MOL I, V40, P1635, DOI 10.1007/s00259-013-2479-7; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Thoreen CC, 2009, J BIOL CHEM, V284, P8023, DOI 10.1074/jbc.M900301200; Wang H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056664; Wang JC, 2018, BBA-MOL CELL RES, V1865, P1105, DOI 10.1016/j.bbamcr.2018.05.007; Yen CH, 2012, MOL MED, V18, P546, DOI 10.2119/molmed.2012.00003.erratum; Zhang S, 2019, CANCER RES, V79, P3725, DOI 10.1158/0008-5472.CAN-19-0180; Zhao Y, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.125; Zhao YC, 2012, NEOPLASIA, V14, P360, DOI 10.1593/neo.12532; Zhao YC, 2011, MOL CELL, V44, P304, DOI 10.1016/j.molcel.2011.08.029; Zhou XF, 2016, MOL CANCER RES, V14, P448, DOI 10.1158/1541-7786.MCR-15-0480; Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025	50	17	17	2	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	7					1557	1571		10.1038/s41388-019-1085-y	http://dx.doi.org/10.1038/s41388-019-1085-y			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KL2WP	31685947	Green Published, hybrid			2022-12-17	WOS:000513289600012
J	Huang, J; Lan, XW; Wang, T; Lu, HL; Cao, MR; Yan, S; Cui, Y; Jia, DX; Cai, L; Xing, Y				Huang, Jian; Lan, Xiuwen; Wang, Ting; Lu, Hailing; Cao, Mengru; Yan, Shi; Cui, Yue; Jia, Dexin; Cai, Li; Xing, Ying			Targeting the IL-1 beta/EHD1/TUBB3 axis overcomes resistance to EGFR-TKI in NSCLC	ONCOGENE			English	Article							CELL LUNG-CANCER; DOMAIN 1 PROMOTES; III BETA-TUBULIN; BINDING PROTEIN; FOCAL ADHESIONS; STRESS FIBERS; KAPPA-B; INHIBITORS; SENSITIVITY; MICROTUBULES	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) significantly prolong the survival time of non-small-cell lung cancer (NSCLC) patients with EGFR-activating mutations, but resistance develops universally. Activation of the phosphatidyl inositol-3 kinase (PI3K)/AKT signaling pathway and phenotypic alterations in epithelial-mesenchymal transition (EMT) are both mechanisms of acquired resistance to EGFR-TKIs. However, the mechanisms underlying this resistance remain unclear. In this study, EHD1 depletion significantly increased NSCLC cell sensitivity to EGFR-TKI, which was accompanied by EMT reversal. Microarray analysis showed that the PTEN/PI3K/AKT signaling pathway is a crucial pathway regulated by EHD1. Moreover, a PTEN inhibitor abolished EHD1 shRNA regulation of EGFR-TKI sensitivity, EMT, and cancer progression. Mass spectrometry showed that TUBB3 is a novel EHD1-interacting protein. EHD1 modulated microtubule stability by interacting with TUBB3. Furthermore, TUBB3 depletion significantly attenuated EHD1-induced EGFR-TKI resistance and EMT. Bioinformatics analysis revealed that EHD1 is significantly associated with the gene set, "Cellular Response to Interleukin-1 beta (IL-1 beta)". As expected, treatment with IL-1 beta led to increased expression of EHD1, activation of PTEN/PI3K/AKT signaling, and induction of EMT in NSCLC cells. In patient specimens, EHD1 was highly expressed in EGFR-TKI-refractory specimens. EHD1 was positively associated with TUBB3 and IL-1R1 but negatively associated with PTEN. In addition, targeting the IL-1 beta/EHD1/TUBB3 axis mitigated cancer progression by inhibiting cell proliferation and metastasis and promoting apoptosis. Our study demonstrates the involvement of the IL-1 beta/EHD1/TUBB3 axis in EGFR-TKI resistance and provides a potential therapeutic approach for treating patients with NSCLC that has acquired EGFR-TKI resistance.	[Huang, Jian; Wang, Ting; Lu, Hailing; Cao, Mengru; Yan, Shi; Cui, Yue; Jia, Dexin; Cai, Li; Xing, Ying] Harbin Med Univ, Dept Med Oncol 4, Canc Hosp, 150 Haping Rd, Harbin 150040, Peoples R China; [Lan, Xiuwen] Harbin Med Univ, Dept Crit Care Med, Canc Hosp, 150 Haping Rd, Harbin 150040, Peoples R China	Harbin Medical University; Harbin Medical University	Cai, L; Xing, Y (corresponding author), Harbin Med Univ, Dept Med Oncol 4, Canc Hosp, 150 Haping Rd, Harbin 150040, Peoples R China.	caili@ems.hrbmu.edu.cn; xingying0618@163.com		Huang, Jian/0000-0002-2409-0878	Certificate of China Postdoctoral Science Foundation [2015M581477, 2017M621307]; Hei Long Jiang Postdoctoral Foundation [LBH-Z15145, LBH-Z17182]; Natural Science and Technology Foundation of Heilongjiang Province [LC2016037]; Fundamental Research Funds for the Provincial Universities; Hai Yan Youth Fund from Harbin Medical University Cancer Hospital [JJQN2018-11, JJQN2018-02, BJQN2019-07]; Top-Notch Youth Fund from Harbin Medical University Cancer Hospital [JJQN2018-11, JJQN2018-02, BJQN2019-07]; NSFC [81772474, 81572276, 81803023, 81602717]	Certificate of China Postdoctoral Science Foundation; Hei Long Jiang Postdoctoral Foundation; Natural Science and Technology Foundation of Heilongjiang Province; Fundamental Research Funds for the Provincial Universities; Hai Yan Youth Fund from Harbin Medical University Cancer Hospital; Top-Notch Youth Fund from Harbin Medical University Cancer Hospital; NSFC(National Natural Science Foundation of China (NSFC))	This study was supported in part by grants from the Certificate of China Postdoctoral Science Foundation Grant (2015M581477, 2017M621307), the Hei Long Jiang Postdoctoral Foundation (LBH-Z15145, LBH-Z17182), the Natural Science and Technology Foundation of Heilongjiang Province (LC2016037), the Fundamental Research Funds for the Provincial Universities, the Hai Yan Youth Fund and Top-Notch Youth Fund from Harbin Medical University Cancer Hospital (JJQN2018-11, JJQN2018-02 and BJQN2019-07), and the NSFC (Grant Nos. 81772474, 81572276, 81803023 and 81602717).	Amann J, 2005, CANCER RES, V65, P226; Apte RN, 2006, EUR J CANCER, V42, P751, DOI 10.1016/j.ejca.2006.01.010; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Burke SJ, 2015, AM J PHYSIOL-ENDOC M, V309, pE715, DOI 10.1152/ajpendo.00153.2015; Chan JK, 2014, GYNECOL ONCOL, V133, P568, DOI 10.1016/j.ygyno.2014.03.564; Daumke O, 2007, NATURE, V449, P923, DOI 10.1038/nature06173; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; Du JT, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1553-x; Duran GE, 2017, BRIT J CANCER, V116, P1318, DOI 10.1038/bjc.2017.102; Edgar KA, 2010, CANCER RES, V70, P1164, DOI 10.1158/0008-5472.CAN-09-2525; Engelman JA, 2005, P NATL ACAD SCI USA, V102, P3788, DOI 10.1073/pnas.0409773102; Enomoto T, 1996, CELL STRUCT FUNCT, V21, P317, DOI 10.1247/csf.21.317; Etienne-Manneville S, 2004, TRAFFIC, V5, P470, DOI 10.1111/j.1600-0854.2004.00196.x; Fernando RI, 2016, ONCOTARGET, V7, P42031, DOI 10.18632/oncotarget.9662; Franco-Barraza J, 2010, ARCH MED RES, V41, P170, DOI 10.1016/j.arcmed.2010.04.010; Gan PP, 2007, CANCER RES, V67, P9356, DOI 10.1158/0008-5472.CAN-07-0509; Gelfo V, 2018, CANCERS, V10, DOI 10.3390/cancers10100355; George M, 2007, BMC CELL BIOL, V8, DOI 10.1186/1471-2121-8-3; Hehnly H, 2014, DEV CELL, V28, P497, DOI 10.1016/j.devcel.2014.01.014; Hinsch A, 2017, HUM PATHOL, V61, P210, DOI 10.1016/j.humpath.2016.11.005; Hyman DM, 2015, CANCER CHEMOTH PHARM, V75, P747, DOI 10.1007/s00280-015-2693-z; Jackman D, 2010, J CLIN ONCOL, V28, P357, DOI 10.1200/JCO.2009.24.7049; Jacobsen K, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00450-6; Jean A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172358; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; Juric D, 2015, NATURE, V518, P240, DOI 10.1038/nature13948; Kavallaris M, 2010, NAT REV CANCER, V10, P194, DOI 10.1038/nrc2803; Kim SM, 2012, MOL CANCER THER, V11, P2254, DOI 10.1158/1535-7163.MCT-12-0311; Kim SB, 2017, LANCET ONCOL, V18, P1360, DOI 10.1016/S1470-2045(17)30450-3; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Lebok P, 2016, ONCOL LETT, V11, P1987, DOI 10.3892/ol.2016.4206; Lee DH, 2017, PHARMACOL THERAPEUT, V174, P1, DOI 10.1016/j.pharmthera.2017.02.001; Li YJ, 2005, WORLD J GASTROENTERO, V11, P2117, DOI 10.3748/wjg.v11.i14.2117; Liu BP, 1998, CELL ADHES COMMUN, V5, P249, DOI 10.3109/15419069809040295; Liu Y, 2018, ONCOL LETT, V16, P4263, DOI 10.3892/ol.2018.9200; LUDUENA RF, 1993, MOL BIOL CELL, V4, P445, DOI 10.1091/mbc.4.5.445; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001; Mantovani A, 2018, IMMUNOL REV, V281, P57, DOI 10.1111/imr.12614; Mariani M, 2012, CLIN CANCER RES, V18, P2964, DOI 10.1158/1078-0432.CCR-11-2318; McCarroll JA, 2015, CANCER RES, V75, P415, DOI 10.1158/0008-5472.CAN-14-2740; Meng QW, 2017, ONCOTARGET, V8, P22433, DOI 10.18632/oncotarget.11220; Nakaya Y, 2008, NAT CELL BIOL, V10, P765, DOI 10.1038/ncb1739; Nickoloff BJ, 2005, J INVEST DERMATOL, V124, pX, DOI 10.1111/j.0022-202X.2005.23724.x; Ono M, 2004, MOL CANCER THER, V3, P465; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Parker AL, 2016, CARCINOGENESIS, V37, P787, DOI 10.1093/carcin/bgw058; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Powell S, 2014, ONCOL LETT, V7, P405, DOI 10.3892/ol.2013.1734; Reiman T, 2012, ANN ONCOL, V23, P86, DOI 10.1093/annonc/mdr033; Reinecke JB, 2015, TRAFFIC, V16, P48, DOI 10.1111/tra.12234; Riihimaki M, 2014, LUNG CANCER, V86, P78, DOI 10.1016/j.lungcan.2014.07.020; SATIR P, 1990, CANCER INVEST, V8, P685, DOI 10.3109/07357909009018945; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Sobierajska K, 2016, BBA-MOL CELL RES, V1863, P2221, DOI 10.1016/j.bbamcr.2016.05.008; Solinas G, 2010, CANCER METAST REV, V29, P243, DOI 10.1007/s10555-010-9227-2; Soucheray M, 2015, CANCER RES, V75, P4372, DOI 10.1158/0008-5472.CAN-15-0377; Steel JL, 2018, PSYCHOSOM MED, V80, P483, DOI 10.1097/PSY.0000000000000579; Suda K, 2018, MOL CANCER THER, V17, P2257, DOI 10.1158/1535-7163.MCT-17-1279; Sullivan I, 2016, THER ADV RESPIR DIS, V10, P549, DOI 10.1177/1753465816670498; Sun XO, 2011, CELL CYCLE, V10, P3929, DOI 10.4161/cc.10.22.18106; Tong DD, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317691010; Walczak CE, 2010, NAT REV MOL CELL BIO, V11, P91, DOI 10.1038/nrm2832; Wang DY, 2015, INFLAMMATION, V38, P2235, DOI 10.1007/s10753-015-0206-1; Wang XF, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0208-z; Weng CH, 2019, ONCOGENE, V38, P455, DOI 10.1038/s41388-018-0454-2; Yao Z, 2010, P NATL ACAD SCI USA, V107, P15535, DOI 10.1073/pnas.1009472107; Yuan TL, 2008, ONCOGENE, V27, P5497, DOI 10.1038/onc.2008.245	68	17	19	1	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	8					1739	1755		10.1038/s41388-019-1099-5	http://dx.doi.org/10.1038/s41388-019-1099-5			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN6CG	31740781				2022-12-17	WOS:000514923000009
J	Osei-Amponsa, V; Buckwalter, JM; Shuman, L; Zheng, ZY; Yamashita, H; Walter, V; Wildermuth, T; Ellis-Mohl, J; Liu, C; Warrick, JI; Shantz, LM; Feehan, RP; AI-Ahmadie, H; Mendelsohn, C; Raman, JD; Kaestner, KH; Wu, XR; DeGraff, DJ				Osei-Amponsa, Vasty; Buckwalter, Jenna M.; Shuman, Lauren; Zheng, Zongyu; Yamashita, Hironobu; Walter, Vonn; Wildermuth, Thomas; Ellis-Mohl, Justine; Liu, Chang; Warrick, Joshua, I; Shantz, Lisa M.; Feehan, Robert P.; AI-Ahmadie, Hikmat; Mendelsohn, Cathy; Raman, Jay D.; Kaestner, Klaus H.; Wu, Xue-Ru; DeGraff, David J.			Hypermethylation of FOXA1 and allelic loss of PTEN drive squamous differentiation and promote heterogeneity in bladder cancer	ONCOGENE			English	Article							BREAST-CANCER; CARCINOMAS; EXPRESSION; BASAL; N-BUTYL-N-(4-HYDROXYBUTYL)NITROSAMINE; HETEROZYGOSITY; INACTIVATION; METHYLATION; UROTHELIUM; PHYSIOLOGY	Intratumoral heterogeneity in bladder cancer is a barrier to accurate molecular sub-classification and treatment efficacy. However, individual cellular and mechanistic contributions to tumor heterogeneity are controversial. We examined potential mechanisms of FOXA1 and PTEN inactivation in bladder cancer and their contribution to tumor heterogeneity. These analyses were complemented with inactivation of FOXA1 and PTEN in intermediate and luminal mouse urothelium. We show inactivation and reduced expression of FOXA1 and PTEN is prevalent in human disease, where PTEN and FOXA1 are downregulated by allelic loss and site-specific DNA hypermethylation, respectively. Conditional inactivation of both Foxa1 and Pten in intermediate/luminal cells in mice results in development of bladder cancer exhibiting squamous features as well as enhanced sensitivity to a bladder-specific carcinogen. In addition, FOXA1 is hypermethylated in basal bladder cancer cell lines, and this is reversed by treatment with DNA methyltransferase inhibitors. By integrating human correlative and in vivo studies, we define a critical role for PTEN loss and epigenetic silencing of FOXA1 in heterogeneous human disease and show genetic targeting of luminal/intermediate cells in mice drives squamous differentiation.	[Osei-Amponsa, Vasty; Buckwalter, Jenna M.; Shuman, Lauren; Zheng, Zongyu; Yamashita, Hironobu; Wildermuth, Thomas; Ellis-Mohl, Justine; Warrick, Joshua, I; Raman, Jay D.; DeGraff, David J.] Penn State Univ, Coll Med, Dept Pathol & Lab Med, Hershey, PA 17033 USA; [Buckwalter, Jenna M.; Shuman, Lauren; Yamashita, Hironobu; Wildermuth, Thomas; Ellis-Mohl, Justine; Warrick, Joshua, I; Raman, Jay D.; DeGraff, David J.] Penn State Univ, Coll Med, Dept Surg, Div Urol, Hershey, PA USA; [Walter, Vonn] Penn State Univ, Coll Med, Dept Publ Hlth Sci, Hershey, PA USA; [Liu, Chang; Mendelsohn, Cathy] Columbia Univ, Dept Urol, New York, NY USA; [Shantz, Lisa M.; Feehan, Robert P.] Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA USA; [AI-Ahmadie, Hikmat] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA; [Kaestner, Klaus H.] Univ Penn, Dept Genet, Philadelphia, PA 19104 USA; [Wu, Xue-Ru] NYU, Sch Med, Dept Urol, New York, NY 10003 USA; [Wu, Xue-Ru] NYU, Sch Med, Dept Pathol, New York, NY USA; [Wu, Xue-Ru] Vet Affairs New York Harbor Healthcare Syst, Manhattan Campus, New York, NY USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Columbia University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Memorial Sloan Kettering Cancer Center; University of Pennsylvania; New York University; New York University	DeGraff, DJ (corresponding author), Penn State Univ, Coll Med, Dept Pathol & Lab Med, Hershey, PA 17033 USA.	ddegraff@pennstatehealth.psu.edu		Yamashita, Hironobu/0000-0003-2587-7100; Shuman, Lauren/0000-0003-2383-2240; Wu, Xue-Ru/0000-0001-6058-6291	Departments of Pathology and Surgery at Pennsylvania State University College of Medicine [K99CA172122, R00CA172122]; Ken and Bonnie Shockey Fund for Urologic Research [K99CA172122, R00CA172122]; Bladder Cancer Support Group at Penn State Health [K99CA172122, R00CA172122]	Departments of Pathology and Surgery at Pennsylvania State University College of Medicine; Ken and Bonnie Shockey Fund for Urologic Research; Bladder Cancer Support Group at Penn State Health	Supported by K99CA172122 (DJD), R00CA172122 (DJD), startup funding from the Departments of Pathology and Surgery at Pennsylvania State University College of Medicine (DJD), the Ken and Bonnie Shockey Fund for Urologic Research and the Bladder Cancer Support Group at Penn State Health. The authors wish to additionally acknowledge the expert administrative assistance of Kimberly Walker, and valuable discussions with Gordon Robertson, Mauro Castro and Clarice Groeneveld.	Al-Ahmadie HA, 2016, NAT GENET, V48, P356, DOI 10.1038/ng.3503; Aveyard JS, 1999, BRIT J CANCER, V80, P904, DOI 10.1038/sj.bjc.6690439; BERTRAM JS, 1972, EUR J CANCER, V8, P587, DOI 10.1016/0014-2964(72)90137-5; Bertucci F, 2012, CURR MOL MED, V12, P96, DOI 10.2174/156652412798376134; Cairns P, 1998, ONCOGENE, V16, P3215, DOI 10.1038/sj.onc.1201855; Cappellen D, 1997, ONCOGENE, V14, P3059, DOI 10.1038/sj.onc.1201154; Cheng JC, 2004, MOL CELL BIOL, V24, P1270, DOI 10.1128/MCB.24.3.1270-1278.2004; Choi W, 2014, CANCER CELL, V25, P152, DOI 10.1016/j.ccr.2014.01.009; Damrauer JS, 2014, P NATL ACAD SCI USA, V111, P3110, DOI 10.1073/pnas.1318376111; DeGraff DJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036669; Drayton RM, 2014, ONCOTARGET, V5, P6375, DOI 10.18632/oncotarget.2221; Espinal AC, 2017, BREAST CANCER RES TR, V166, P559, DOI 10.1007/s10549-017-4418-y; Gao N, 2008, GENE DEV, V22, P3435, DOI 10.1101/gad.1752608; Ghosh S, 2014, BREAST CANCER RES TR, V147, P653, DOI 10.1007/s10549-014-3132-2; Gong C, 2015, ONCOGENE, V34, P5012, DOI 10.1038/onc.2014.421; Gross K, 2016, J DEV BIOL, V4, DOI 10.3390/jdb4010004; Guo CC, 2016, EUR UROL, V70, P611, DOI 10.1016/j.eururo.2016.02.056; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; He F, 2015, CANCER RES, V75, P2017, DOI 10.1158/0008-5472.CAN-14-3067; He ZM, 2012, MUTAT RES-GEN TOX EN, V742, P92, DOI 10.1016/j.mrgentox.2011.11.015; Hedegaard J, 2016, CANCER CELL, V30, P27, DOI 10.1016/j.ccell.2016.05.004; Hoadley KA, 2014, CELL, V158, P929, DOI 10.1016/j.cell.2014.06.049; Hovelson DH, 2018, EUR UROL, V74, P741, DOI 10.1016/j.eururo.2018.06.047; JOST SP, 1989, J ANAT, V167, P103; Karoui M, 2004, BRIT J CANCER, V90, P1230, DOI 10.1038/sj.bjc.6601687; Khandelwal P, 2009, AM J PHYSIOL-RENAL, V297, pF1477, DOI 10.1152/ajprenal.00327.2009; Knobbe CB, 2008, ONCOGENE, V27, P5398, DOI 10.1038/onc.2008.238; Lesche R, 2002, GENESIS, V32, P148, DOI 10.1002/gene.10036; Li Z, 2012, CELL, V148, P72, DOI 10.1016/j.cell.2011.11.026; Mermel CH, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-4-r41; Miyamoto H, 2007, J NATL CANCER I, V99, P558, DOI 10.1093/jnci/djk113; Mo L, 2005, AM J PHYSIOL-RENAL, V289, pF562, DOI 10.1152/ajprenal.00368.2004; Moch H, 2016, WHO CLASSIFICATION T; NAGAO M, 1977, CANCER RES, V37, P399; OHTANI M, 1986, CANCER RES, V46, P2001; Oliveira PA, 2005, J EXP CLIN CANC RES, V24, P609; Puzio-Kuter AM, 2009, GENE DEV, V23, P675, DOI 10.1101/gad.1772909; R Core Team, 2019, R LANG ENV STAT COMP; Reddy OL, 2015, AM J PATHOL, V185, P1385, DOI 10.1016/j.ajpath.2015.01.014; Robertson AG, 2017, CELL, V171, P540, DOI 10.1016/j.cell.2017.09.007; Staack A, 2005, DIFFERENTIATION, V73, P121, DOI 10.1111/j.1432-0436.2005.00014.x; Thomsen MBH, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11291-0; Thorat MA, 2008, J CLIN PATHOL, V61, P327, DOI 10.1136/jcp.2007.052431; Tsuruta H, 2006, CANCER RES, V66, P8389, DOI 10.1158/0008-5472.CAN-05-4627; Van Batavia J, 2014, NAT CELL BIOL, V16, P982, DOI 10.1038/ncb3038; Varley CL, 2009, CELL DEATH DIFFER, V16, P103, DOI 10.1038/cdd.2008.116; Vasconcelos-Nobrega C, 2012, IN VIVO, V26, P727; Walter V, 2018, CANCER RES, V78, P337533; Warrick JI, 2019, EUR UROL, V75, P18, DOI 10.1016/j.eururo.2018.09.003; Warrick JI, 2016, SCI REP-UK, V6, DOI 10.1038/srep38531; Warrick JI, 2016, INT J SURG PATHOL, V24, P306, DOI 10.1177/1066896916629783; Yoo LI, 2006, CANCER RES, V66, P1929, DOI 10.1158/0008-5472.CAN-05-1986	52	17	17	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	6					1302	1317		10.1038/s41388-019-1063-4	http://dx.doi.org/10.1038/s41388-019-1063-4			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE4UH	31636388				2022-12-17	WOS:000526714600010
J	Wang, Z; Li, YJ; Wu, DL; Yu, S; Wang, YL; Chan, FL				Wang, Zhu; Li, Youjia; Wu, Dinglan; Yu, Shan; Wang, Yuliang; Chan, Franky Leung			Nuclear receptor HNF4 alpha performs a tumor suppressor function in prostate cancer via its induction of p21-driven cellular senescence	ONCOGENE			English	Article							TRANSCRIPTION FACTOR; FACTOR 4-ALPHA; GENE-EXPRESSION; EPITHELIAL-CELLS; THERAPEUTIC TARGET; ANDROGEN RECEPTOR; FACTOR-4-ALPHA; PROLIFERATION; PROMOTES; GROWTH	Hepatocyte nuclear factor 4 alpha (HNF4 alpha, NR2A1) is a highly conserved member of the nuclear receptor superfamily. Recent advances reveal that it is a key transcriptional regulator of genes, broadly involved in xenobiotic and drug metabolism and also cancers of gastrointestinal tract. However, the exact functional roles of HNF4 alpha in prostate cancer progression are still not fully understood. In this study, we determined the functional significance of HNF4 alpha in prostate cancer. Our results showed that HNF4 alpha exhibited a reduced expression pattern in clinical prostate cancer tissues, prostate cancer cell lines and xenograft model of castration-relapse prostate cancer. Stable HNF4 alpha knockdown not only could promote cell proliferation and suppress doxorubicin (Dox)-induced cellular senescence in prostate cancer cells, but also confer resistance to paclitaxel treatment and enhance colony formation capacity and in vivo tumorigenicity of prostate cancer cells. On the contrary, ectopic overexpression of HNF4 alpha could significantly inhibit the cell proliferation of prostate cancer cells, induce cell-cycle arrest at G(2)/M phase and trigger the cellular senescence in prostate cancer cells by activation of p21 signal pathway in a p53-independent manner via its direct transactivation of CDKN1A. Together, our results show that HNF4 alpha performs a tumor suppressor function in prostate cancer via a mechanism of p21-driven cellular senescence.	[Wang, Zhu] Southern Med Univ, Peoples Hosp Longhua, Dept Urol, Shenzhen 518109, Guangdong, Peoples R China; [Wang, Zhu; Li, Youjia; Wu, Dinglan; Yu, Shan; Wang, Yuliang; Chan, Franky Leung] Chinese Univ Hong Kong, Sch Biomed Sci, Hong Kong, Peoples R China	Southern Medical University - China; Chinese University of Hong Kong	Wang, YL; Chan, FL (corresponding author), Chinese Univ Hong Kong, Sch Biomed Sci, Hong Kong, Peoples R China.	yuliang.wang816@gmail.com; franky-chan@cuhk.edu.hk		Wang, Zhu/0000-0002-5457-3731; Wu, Dinglan/0000-0002-5057-9626	CUHK [2015.1.064]; Research Grants Council of Hong Kong [461012]; Shenzhen Science and Technology Program (Basic Research Project) [JCYJ20180228163919346]	CUHK(Chinese University of Hong Kong); Research Grants Council of Hong Kong(Hong Kong Research Grants Council); Shenzhen Science and Technology Program (Basic Research Project)	This work was supported by a Direct Grant for Research 2015-2016 from CUHK (grant no. 2015.1.064), a General Research Fund (project number 461012) from the Research Grants Council of Hong Kong (to Chan FL), and Shenzhen Science and Technology Program (Basic Research Project; project number JCYJ20180228163919346 to ZW)	Ahn SH, 2008, INFLAMM BOWEL DIS, V14, P908, DOI 10.1002/ibd.20413; Alimonti A, 2010, J CLIN INVEST, V120, P681, DOI 10.1172/JCI40535; Attard G, 2016, LANCET, V387, P70, DOI 10.1016/S0140-6736(14)61947-4; Barrett JC, 2009, NAT GENET, V41, P1330, DOI 10.1038/ng.483; Bonzo JA, 2012, J BIOL CHEM, V287, P7345, DOI 10.1074/jbc.M111.334599; Cairns P, 1997, CANCER RES, V57, P4997; CHARTIER FL, 1994, GENE, V147, P269, DOI 10.1016/0378-1119(94)90079-5; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Cheung CP, 2005, J CLIN ENDOCR METAB, V90, P1830, DOI 10.1210/jc.2004-1421; Chiba H, 2005, EXP CELL RES, V302, P11, DOI 10.1016/j.yexcr.2004.08.014; Chu JH, 2009, PROSTATE, V69, P428, DOI 10.1002/pros.20897; Collado M, 2010, NAT REV CANCER, V10, P51, DOI 10.1038/nrc2772; Darsigny M, 2010, CANCER RES, V70, P9423, DOI 10.1158/0008-5472.CAN-10-1697; Darsigny M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007609; Dhe-Paganon S, 2002, J BIOL CHEM, V277, P37973, DOI 10.1074/jbc.C200420200; Drewa T., 2010, Experimental Oncology, V32, P228; Duncan SA, 1997, DEVELOPMENT, V124, P279; Erdmann S, 2007, BIOL CHEM, V388, P91, DOI 10.1515/BC.2007.011; Grigo K, 2008, BIOL CHEM, V389, P179, DOI 10.1515/BC.2008.011; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; Hertz R, 1998, NATURE, V392, P512, DOI 10.1038/33185; Hwang-Verslues WW, 2010, CURR OPIN PHARMACOL, V10, P698, DOI 10.1016/j.coph.2010.08.010; Lazarevich N, 2004, HEPATOLOGY, V39, P1038, DOI 10.1002/hep.20155; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li JX, 2000, GENE DEV, V14, P464; Loaiza N, 2016, BBA-REV CANCER, V1865, P155, DOI 10.1016/j.bbcan.2016.01.007; Lucas B, 2005, ONCOGENE, V24, P6418, DOI 10.1038/sj.onc.1208794; Marcil V, 2012, GENES IMMUN, V13, P556, DOI 10.1038/gene.2012.37; MIQUEROL L, 1994, J BIOL CHEM, V269, P8944; Moschini M, 2017, EUR UROL, V72, P238, DOI 10.1016/j.eururo.2017.03.009; Muller M, 2009, ANTIOXID REDOX SIGN, V11, P59, DOI 10.1089/ars.2008.2104; Nanni S, 2006, MOL CANCER RES, V4, P79, DOI 10.1158/1541-7786.MCR-05-0098; Ning BF, 2010, CANCER RES, V70, P7640, DOI 10.1158/0008-5472.CAN-10-0824; Olsen CL, 2002, ONCOGENE, V21, P6328, DOI 10.1038/sj.onc.1205780; Oshima T, 2007, PATHOL INT, V57, P82, DOI 10.1111/j.1440-1827.2006.02061.x; Parviz F, 2003, NAT GENET, V34, P292, DOI 10.1038/ng1175; Pihlajamaa P, 2014, EMBO J, V33, P312, DOI 10.1002/embj.201385895; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Rieck S, 2012, MOL ENDOCRINOL, V26, P1590, DOI 10.1210/me.2012-1019; Sel S, 1996, CANCER LETT, V101, P205, DOI 10.1016/0304-3835(96)04136-5; Sharma S, 2010, PATHOLOGY, V42, P507, DOI 10.3109/00313025.2010.508791; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; STEPHENSON RA, 1992, J NATL CANCER I, V84, P951, DOI 10.1093/jnci/84.12.951; Sugai M, 2008, PATHOL INT, V58, P681, DOI 10.1111/j.1440-1827.2008.02293.x; Sugano M, 2013, AM J SURG PATHOL, V37, P211, DOI 10.1097/PAS.0b013e31826be303; Tanaka T, 2006, J PATHOL, V208, P662, DOI 10.1002/path.1928; Tang DG, 2001, SCIENCE, V291, P868, DOI 10.1126/science.1056780; THALMANN GN, 1994, CANCER RES, V54, P2577; Walesky C, 2013, HEPATOLOGY, V57, P2480, DOI 10.1002/hep.26251; Walesky C, 2013, AM J PHYSIOL-GASTR L, V304, pG26, DOI 10.1152/ajpgi.00064.2012; Wallace TA, 2008, CANCER RES, V68, P927, DOI 10.1158/0008-5472.CAN-07-2608; Wang Z, 2018, ENDOCR-RELAT CANCER, V25, P35, DOI 10.1530/ERC-17-0280; Wisely GB, 2002, STRUCTURE, V10, P1225, DOI 10.1016/S0969-2126(02)00829-8; Wu DL, 2015, J PATHOL, V236, P103, DOI 10.1002/path.4505; Xiang X, 2015, CANCER LETT, V359, P187, DOI 10.1016/j.canlet.2015.01.008; Xiao LJ, 2018, CANCER RES, V78, P2205, DOI 10.1158/0008-5472.CAN-17-2341; Xu L, 2001, CANCER RES, V61, P3176; Yamagata K, 2014, VITAM HORM, V95, P407, DOI 10.1016/B978-0-12-800174-5.00016-8; Yu S, 2008, ONCOGENE, V27, P3313, DOI 10.1038/sj.onc.1210986; Yu SA, 2007, CANCER RES, V67, P4904, DOI 10.1158/0008-5472.CAN-06-3855; Yu S, 2014, J PATHOL, V234, P514, DOI 10.1002/path.4413; Yu S, 2013, CANCER LETT, V328, P83, DOI 10.1016/j.canlet.2012.09.006; Yu S, 2009, BIOCHEM BIOPH RES CO, V382, P756, DOI 10.1016/j.bbrc.2009.03.110; Yusuf D, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-3-r24; Zou C, 2014, J PATHOL, V233, P61, DOI 10.1002/path.4329	66	17	17	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	7					1572	1589		10.1038/s41388-019-1080-3	http://dx.doi.org/10.1038/s41388-019-1080-3			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KL2WP	31695151	Green Published, hybrid			2022-12-17	WOS:000513289600013
J	He, J; Zhou, MX; Li, XY; Gu, SW; Cao, Y; Xing, TF; Chen, W; Chu, CY; Gu, F; Zhou, J; Jin, YT; Ma, J; Ma, D; Zou, Q				He, Jing; Zhou, Mingxia; Li, Xiaoyan; Gu, Siwen; Cao, Yun; Xing, Tengfei; Chen, Wei; Chu, Chengyu; Gu, Fei; Zhou, Jian; Jin, Yiting; Ma, Jing; Ma, Duan; Zou, Qiang			SLC34A2 simultaneously promotes papillary thyroid carcinoma growth and invasion through distinct mechanisms	ONCOGENE			English	Article							NONSMALL CELL LUNG; COLORECTAL-CANCER; PROTEIN-KINASE; PROLIFERATION; PROGRESSION; METASTASIS; FAMILY	Thyroid cancer is the fastest growing cancer among all solid tumors in recent decades. Papillary thyroid carcinoma (PTC) is the most predominant type of thyroid cancer. Around 30% of PTC patients with distant metastases and local invasion receive poor prognosis. Thus, the identification of new druggable biological targets is of great importance. Accumulating evidence indicates that solute carrier family numbers have emerged as obligate effectors during the progression of multiple malignancies. Here, we uncovered the functional significance, molecular mechanisms, and clinical impact of solute carrier family 34 member A2 (SLC34A2) in PTC. SLC34A2 was markedly overexpressed in PTC tissues at both mRNA and protein levels compared with matched adjacent normal tissues due to promoter hypomethylation mediated by the DNA methyltransferase 3 beta (DNMT3B). Furthermore, a series of in vivo and in vitro gain- or loss-of-functional assays elucidated the role of SLC34A2 in boosting cell proliferation, cell cycle progression, migration, invasion, and adhesion of PTC cells. Using immunoprecipitation and mass spectrometry, we discovered that SLC34A2 bound to the actin-binding repeats domain of Cortactin (CTTN), thereby inducing the invadopodia formation of PTC cells to promote the metastasis potential of PTC cells. Besides, our mechanistic studies, as well as gene set enrichment analysis (GSEA), have pinpointed the PTEN/AKT/FOXO3a pathway as a major signaling functioning downstream of SLC34A2 regulated cell growth. Taken together, our results highlighted that SLC34A2 plays a pivotal oncogenic role during carcinogenesis and metastasis through distinct mechanisms in PTC.	[He, Jing; Li, Xiaoyan; Gu, Siwen; Cao, Yun; Xing, Tengfei; Chen, Wei; Chu, Chengyu; Gu, Fei; Zhou, Jian; Jin, Yiting; Zou, Qiang] Fudan Univ, Huashan Hosp, Dept Gen Surg, 12 Urumqi Middle Rd, Shanghai 200040, Peoples R China; [Zhou, Mingxia] Shanghai Jiao Tong Univ, Xinhua Hosp, Sch Med, Dept Gastroenterol, 1665 Kongjiang Rd, Shanghai 200092, Peoples R China; [Ma, Jing; Ma, Duan] Fudan Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Key Lab Metab & Mol Med,Minist Educ, 130 Dongan Rd, Shanghai 200032, Peoples R China; [Ma, Jing; Ma, Duan] Fudan Univ, Inst Biomed Sci, 130 Dongan Rd, Shanghai 200032, Peoples R China	Fudan University; Shanghai Jiao Tong University; Fudan University; Fudan University	Zou, Q (corresponding author), Fudan Univ, Huashan Hosp, Dept Gen Surg, 12 Urumqi Middle Rd, Shanghai 200040, Peoples R China.; Ma, D (corresponding author), Fudan Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Key Lab Metab & Mol Med,Minist Educ, 130 Dongan Rd, Shanghai 200032, Peoples R China.; Ma, D (corresponding author), Fudan Univ, Inst Biomed Sci, 130 Dongan Rd, Shanghai 200032, Peoples R China.	duanma@fudan.edu.cn; zouqiang_hs@163.com		Li, Xiaoyan/0000-0002-1243-3845	Science and Technology Commission of Shanghai Municipality [15411952503]; National Nature Science Foundation of China [81602326, 81741078, 81801501]	Science and Technology Commission of Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM)); National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by Science and Technology Commission of Shanghai Municipality (No. 15411952503) and National Nature Science Foundation of China (Nos. 81602326, 81741078, and 81801501).	Lacerda-Abreu MA, 2018, BBA-REV CANCER, V1870, P291, DOI 10.1016/j.bbcan.2018.05.001; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cabanillas ME, 2016, LANCET, V388, P2783, DOI 10.1016/S0140-6736(16)30172-6; Calnan DR, 2008, ONCOGENE, V27, P2276, DOI 10.1038/onc.2008.21; Cesar-Razquin A, 2015, CELL, V162, P478, DOI 10.1016/j.cell.2015.07.022; Chen DR, 2010, ANTICANCER RES, V30, P4135; Crowell JA, 2007, MOL CANCER THER, V6, P2139, DOI 10.1158/1535-7163.MCT-07-0120; Davies KD, 2012, CLIN CANCER RES, V18, P4570, DOI 10.1158/1078-0432.CCR-12-0550; Eddy RJ, 2017, TRENDS CELL BIOL, V27, P595, DOI 10.1016/j.tcb.2017.03.003; Fisher KE, 2014, MODERN PATHOL, V27, P222, DOI 10.1038/modpathol.2013.140; Gamble LD, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aau1099; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; He J, 2018, CANCER SCI, V109, P642, DOI 10.1111/cas.13478; He J, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0378-z; Hernando N, 2018, COMPR PHYSIOL, V8, P1065, DOI 10.1002/cphy.c170024; Hirai H, 2010, MOL CANCER THER, V9, P1956, DOI 10.1158/1535-7163.MCT-09-1012; Jarzab B, 2005, CANCER RES, V65, P1587, DOI 10.1158/0008-5472.CAN-04-3078; Jeannot Pauline, 2020, Small GTPases, V11, P256, DOI 10.1080/21541248.2017.1405773; Jin H, 2009, AM J RESP CRIT CARE, V179, P59, DOI 10.1164/rccm.200802-306OC; Kareva I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0051844; Kim S, 2018, ONCOGENE, V37, P2982, DOI 10.1038/s41388-018-0124-4; Li YH, 2016, ONCOL RES, V24, P511, DOI 10.3727/096504016X14719078133483; Li YJ, 2018, CANCER RES, V78, P5216, DOI 10.1158/0008-5472.CAN-18-0003; Lin KD, 2015, CLIN CANCER RES, V21, P5139, DOI 10.1158/1078-0432.CCR-14-3383; Liu XZ, 2017, DNA CELL BIOL, V36, P775, DOI 10.1089/dna.2017.3750; Lv P, 2014, INT J MOL SCI, V15, P5774, DOI 10.3390/ijms15045774; Lv SD, 2018, ONCOGENE, V37, P1354, DOI 10.1038/s41388-017-0026-x; Mader CC, 2011, CANCER RES, V71, P1730, DOI 10.1158/0008-5472.CAN-10-1432; Neel DS, 2019, CANCER RES, V79, P546, DOI 10.1158/0008-5472.CAN-18-1492; Ramirez-Moya J, 2018, ONCOGENE, V37, P3369, DOI 10.1038/s41388-017-0088-9; Rangel LBA, 2003, ONCOGENE, V22, P7225, DOI 10.1038/sj.onc.1207008; Ricketts CJ, 2012, EPIGENETICS-US, V7, P278, DOI 10.4161/epi.7.3.19103; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Spina A, 2013, J CELL PHYSIOL, V228, P198, DOI 10.1002/jcp.24124; Wagner CA, 2014, PFLUG ARCH EUR J PHY, V466, P139, DOI 10.1007/s00424-013-1418-6; Wang Y, 2015, J BIOMED SCI, V22, DOI 10.1186/s12929-015-0158-7; Watkins RJ, 2016, J CLIN ENDOCR METAB, V101, P4551, DOI 10.1210/jc.2016-1932; Weisenberger DJ, 2018, ONCOGENE, V37, P566, DOI 10.1038/onc.2017.374; Wong CC, 2017, ONCOGENE, V36, P3359, DOI 10.1038/onc.2016.485; Wong CC, 2016, GASTROENTEROLOGY, V151, P945, DOI 10.1053/j.gastro.2016.07.011; Yousefi M, 2018, CELL ONCOL, V41, P123, DOI 10.1007/s13402-018-0376-6	41	17	17	1	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	13					2658	2675		10.1038/s41388-020-1181-z	http://dx.doi.org/10.1038/s41388-020-1181-z		JAN 2020	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KX4EF	32005974				2022-12-17	WOS:000510346700004
J	Lee, PC; Chen, ST; Kuo, TC; Lino, TC; Lin, MC; Huang, J; Hung, JS; Hsu, CL; Juan, HF; Lee, PH; Huang, MC				Lee, Po-Chu; Chen, Syue-Ting; Kuo, Ting-Chun; Lino, Tzu-Chi; Lin, Mei-Chun; Huang, John; Hung, Ji-Shiang; Hsu, Chia-Lang; Juan, Hsueh-Fen; Lee, Po-Huang; Huang, Min-Chuan			C1GALT1 is associated with poor survival and promotes soluble Ephrin A1-mediated cell migration through activation of EPHA2 in gastric cancer	ONCOGENE			English	Article							HEPATOCELLULAR-CARCINOMA; O-GLYCOSYLATION; RECEPTORS; MET; BIOMARKERS; LIGANDS; TARGETS; GROWTH	C1GALT1 controls the crucial step of GalNAc-type O-glycosylation and is associated with both physiologic and pathologic conditions, including cancers. EPH receptors comprise the largest family of receptor tyrosine kinases (RTKs) and modulate a diverse range of developmental processes and human diseases. However, the role of C1GALT1 in the signaling of EPH receptors remains largely overlooked. Here, we showed that C1GALT1 high expression in gastric adenocarcinomas correlated with adverse clinicopathologic features and is an independent prognostic factor for poor overall survival. Silencing or loss of C1GALT1 inhibited cell viability, migration, invasion, tumor growth and metastasis, as well as increased apoptosis and cytotoxicity of 5-fluorouracil in AGS and MKN45 cells. Phospho-RTK array and western blot analysis showed that C1GALT1 depletion suppressed tyrosine phosphorylation of EPHA2 induced by soluble Ephrin A1-Fc. O-glycans on EPHA2 were modified by C1GALT1 and both S277A and T429A mutants, which are O-glycosites on EPHA2, dramatically enhanced phosphorylation of Y588, suggesting that not only overall O-glycan structures but also site-specific O-glycosylation can regulate EPHA2 activity. Furthermore, depletion of C1GALT1 decreased Ephrin A1-Fc induced migration and reduced Ephrin A1 binding to cell surfaces. The effects of C1GALT1 knockdown or knockout on cell invasiveness in vitro and in vivo were phenocopied by EPHA2 knockdown in gastric cancer cells. These results suggest that C1GALT1 promotes phosphorylation of EPHA2 and enhances soluble Ephrin A1-mediated migration primarily by modifying EPHA2 O-glycosylation. Our study highlights the importance of GalNAc-type O-glycosylation in EPH receptor-regulated diseases and identifies C1GALT1 as a potential therapeutic target for gastric cancer.	[Lee, Po-Chu; Kuo, Ting-Chun; Huang, John; Hung, Ji-Shiang; Lee, Po-Huang] Natl Taiwan Univ Hosp, Dept Surg, Taipei, Taiwan; [Lee, Po-Chu; Kuo, Ting-Chun] Natl Taiwan Univ Hosp, Dept Traumatol, Taipei, Taiwan; [Lee, Po-Chu] Natl Taiwan Univ, Coll Med, Grad Inst Clin Med, Taipei, Taiwan; [Chen, Syue-Ting; Kuo, Ting-Chun; Lino, Tzu-Chi; Huang, Min-Chuan] Natl Taiwan Univ, Coll Med, Grad Inst Anat & Cell Biol, Taipei, Taiwan; [Lin, Mei-Chun] Natl Taiwan Univ Hosp, Dept Otolaryngol, Taipei, Taiwan; [Hsu, Chia-Lang] Natl Taiwan Univ Hosp, Dept Med Res, Taipei, Taiwan; [Juan, Hsueh-Fen] Natl Taiwan Univ, Dept Life Sci, Taipei, Taiwan; [Lee, Po-Huang] E DA Hosp, Dept Surg, Kaohsiung, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; E-Da Hospital	Huang, MC (corresponding author), Natl Taiwan Univ, Coll Med, Grad Inst Anat & Cell Biol, Taipei, Taiwan.	mchuang@ntu.edu.tw	; Hsu, Chia-Lang/O-1458-2013	Hung, Ji-Shiang/0000-0001-7392-5694; JUAN, HSUEH-FEN/0000-0003-4876-3309; KUO, TING-CHUN/0000-0003-1960-1423; LEE, PO-HUANG/0000-0001-5831-035X; LEE, PO-CHU/0000-0001-5053-1895; Hsu, Chia-Lang/0000-0002-7447-8045; HUANG, MIN-CHUAN/0000-0002-0704-3447	National Taiwan University Hospital [109-049]; Ministry of Science and Technology, Taiwan [108-2320-B-002-064-MY3]	National Taiwan University Hospital(National Taiwan University); Ministry of Science and Technology, Taiwan(Ministry of Science and Technology, TaiwanMinistry of Science, ICT & Future Planning, Republic of Korea)	The authors thank Dr Shu-Yun Tung (Academia Sinica, Taiwan) for performing global gene expression analysis and Dr Chiung-Nien Chen and Dr I-Rue Lai (National Taiwan University Hospital, Taiwan) for providing gastric cancer cell lines. This study was supported by National Taiwan University Hospital (109-049) to PCL, and Ministry of Science and Technology, Taiwan (108-2320-B-002-064-MY3) to MCH.	Alford S, 2010, CANCER CELL INT, V10, DOI 10.1186/1475-2867-10-41; Beauchamp A, 2012, SEMIN CELL DEV BIOL, V23, P109, DOI 10.1016/j.semcdb.2011.10.019; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Boyd AW, 2014, NAT REV DRUG DISCOV, V13, P39, DOI 10.1038/nrd4175; Bradley CA, 2017, NAT REV CLIN ONCOL, V14, P562, DOI 10.1038/nrclinonc.2017.40; Campos D, 2015, MOL CELL PROTEOMICS, V14, P1616, DOI 10.1074/mcp.M114.046862; Chou CH, 2015, ONCOTARGET, V6, P6123, DOI 10.18632/oncotarget.3045; Chu ML, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19788-y; Cui XD, 2010, INT J CANCER, V126, P940, DOI 10.1002/ijc.24798; Deng NT, 2012, GUT, V61, P673, DOI 10.1136/gutjnl-2011-301839; Duarte HO, 2016, BIOMOLECULES, V6, DOI 10.3390/biom6030033; Fife CM, 2014, BRIT J PHARMACOL, V171, P5507, DOI 10.1111/bph.12704; Fuster MM, 2005, NAT REV CANCER, V5, P526, DOI 10.1038/nrc1649; Gill DJ, 2013, P NATL ACAD SCI USA, V110, pE3152, DOI 10.1073/pnas.1305269110; GOSEKI N, 1992, GUT, V33, P606, DOI 10.1136/gut.33.5.606; Gravalos C, 2008, ANN ONCOL, V19, P1523, DOI 10.1093/annonc/mdn169; Herath NI, 2010, INT J CANCER, V126, P2003, DOI 10.1002/ijc.25147; Ho WL, 2014, ONCOTARGET, V5, P12247, DOI 10.18632/oncotarget.2627; Huang J, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3875-3; Huang MJ, 2015, ONCOTARGET, V6, P5650, DOI 10.18632/oncotarget.3117; Hung JS, 2014, ONCOTARGET, V5, P2096, DOI 10.18632/oncotarget.1815; Ieguchi K, 2014, ONCOGENE, V33, P2179, DOI 10.1038/onc.2013.180; Ju TZ, 2002, P NATL ACAD SCI USA, V99, P16613, DOI 10.1073/pnas.262438199; Kania A, 2016, NAT REV MOL CELL BIO, V17, P240, DOI 10.1038/nrm.2015.16; Kudo T, 2013, BLOOD, V122, P1649, DOI 10.1182/blood-2012-12-471102; Lin MC, 2018, ONCOGENE, V37, P5780, DOI 10.1038/s41388-018-0375-0; Lisle JE, 2013, BBA-REV CANCER, V1835, P243, DOI 10.1016/j.bbcan.2013.01.003; Liu SY, 2016, ONCOTARGET, V7, P11251, DOI 10.18632/oncotarget.7081; Nakamura R, 2005, CANCER SCI, V96, P42, DOI 10.1111/j.1349-7006.2005.00007.x; Neill T, 2016, J CELL BIOL, V215, P687, DOI 10.1083/jcb.201603079; Ohtsu A, 2003, J CLIN ONCOL, V21, P54, DOI 10.1200/JCO.2003.04.130; Pasquale EB, 2010, NAT REV CANCER, V10, P165, DOI 10.1038/nrc2806; Peng Z, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0092924, 10.1371/journal.pone.0084502, 10.1371/journal.pone.0085663]; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Sierra JC, 2018, GUT, V67, P1247, DOI 10.1136/gutjnl-2016-312888; Ten Hagen KG, 2003, GLYCOBIOLOGY, V13, p1R, DOI 10.1093/glycob/cwg007; Tian E, 2009, GLYCOCONJUGATE J, V26, P325, DOI 10.1007/s10719-008-9162-4; Tran DT, 2013, J BIOL CHEM, V288, P6921, DOI 10.1074/jbc.R112.418558; Tran Phu N, 2017, Gastrointest Cancer, V7, P1, DOI 10.2147/GICTT.S113525; Uchida Y, 2013, CANCER BIOL THER, V14, P127, DOI 10.4161/cbt.22634; Vaught D, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2207; Washington K, 2010, ANN SURG ONCOL, V17, P3077, DOI 10.1245/s10434-010-1362-z; Wen QC, 2017, ONCOTARGET, V8, P47998, DOI 10.18632/oncotarget.18208; Wu J, 2016, ONCOTARGET, V7, P25315, DOI 10.18632/oncotarget.8287; Wu YM, 2013, CANCER RES, V73, P5580, DOI 10.1158/0008-5472.CAN-13-0869; Wu YM, 2011, CANCER RES, V71, P7270, DOI 10.1158/0008-5472.CAN-11-1161; Wykosky J, 2008, MOL CANCER RES, V6, P1795, DOI 10.1158/1541-7786.MCR-08-0244; Xi HQ, 2012, J CELL MOL MED, V16, P2894, DOI 10.1111/j.1582-4934.2012.01612.x; Yao HP, 2013, NAT REV CANCER, V13, P466, DOI 10.1038/nrc3545; Yuan W, 2012, NEOPLASMA, V59, P105, DOI 10.4149/neo_2012_014; Yuan WJ, 2009, DIGEST DIS SCI, V54, P2410, DOI 10.1007/s10620-008-0649-4	51	17	17	1	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	13					2724	2740		10.1038/s41388-020-1178-7	http://dx.doi.org/10.1038/s41388-020-1178-7		JAN 2020	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KX4EF	32005975	Green Published, hybrid			2022-12-17	WOS:000510346700005
J	Salcher, S; Spoden, G; Hagenbuchner, J; Fuhrer, S; Kaserer, T; Tollinger, M; Huber-Cantonati, P; Gruber, T; Schuster, D; Gust, R; Zwierzina, H; Muller, T; Kiechl-Kohlendorfer, U; Ausserlechner, MJ; Obexer, P				Salcher, Stefan; Spoden, Gilles; Hagenbuchner, Judith; Fuehrer, Sebastian; Kaserer, Teresa; Tollinger, Martin; Huber-Cantonati, Petra; Gruber, Thomas; Schuster, Daniela; Gust, Ronald; Zwierzina, Heinz; Mueller, Thomas; Kiechl-Kohlendorfer, Ursula; Ausserlechner, Michael J.; Obexer, Petra			A drug library screen identifies Carbenoxolone as novel FOXO inhibitor that overcomes FOXO3-mediated chemoprotection in high-stage neuroblastoma	ONCOGENE			English	Article							TRANSCRIPTION FACTOR; NEURONAL APOPTOSIS; CELLS; CANCER; EXPRESSION; RESISTANCE; AXIS; DIFFERENTIATION; INDUCTION; REPRESSION	The transcription factor FOXO3 has been associated in different tumor entities with hallmarks of cancer, including metastasis, tumor angiogenesis, maintenance of tumor-initiating stem cells, and drug resistance. In neuroblastoma (NB), we recently demonstrated that nuclear FOXO3 promotes tumor angiogenesis in vivo and chemoresistance in vitro. Hence, inhibiting the transcriptional activity of FOXO3 is a promising therapeutic strategy. However, as no FOXO3 inhibitor is clinically available to date, we used a medium-throughput fluorescence polarization assay (FPA) screening in a drug-repositioning approach to identify compounds that bind to the FOXO3-DNA-binding-domain (DBD). Carbenoxolone (CBX), a glycyrrhetinic acid derivative, was identified as a potential FOXO3-inhibitory compound that binds to the FOXO3-DBD with a binding affinity of 19 mu M. Specific interaction of CBX with the FOXO3-DBD was validated by fluorescence-based electrophoretic mobility shift assay (FAM-EMSA). CBX inhibits the transcriptional activity of FOXO3 target genes, as determined by chromatin immunoprecipitation (ChIP), DEPP-, and BIM promoter reporter assays, and real-time RT-PCR analyses. In high-stage NB cells with functional TP53, FOXO3 triggers the expression of SESN3, which increases chemoprotection and cell survival. Importantly, FOXO3 inhibition by CBX treatment at pharmacologically relevant concentrations efficiently repressed FOXO3-mediated SESN3 expression and clonogenic survival and sensitized high-stage NB cells to chemotherapy in a 2D and 3D culture model. Thus, CBX might be a promising novel candidate for the treatment of therapy-resistant high-stage NB and other "FOXO-resistant" cancers.	[Salcher, Stefan; Hagenbuchner, Judith; Kiechl-Kohlendorfer, Ursula; Obexer, Petra] Med Univ Innsbruck, Dept Pediat 2, Innsbruck, Austria; [Salcher, Stefan; Spoden, Gilles; Huber-Cantonati, Petra; Obexer, Petra] Tyrolean Canc Res Inst, Innsbruck, Austria; [Fuehrer, Sebastian; Tollinger, Martin] Univ Innsbruck, CMBI, Inst Organ Chem, Innsbruck, Austria; [Kaserer, Teresa; Schuster, Daniela; Gust, Ronald] Univ Innsbruck, CMBI, Inst Pharm Pharmaceut Chem, Innsbruck, Austria; [Gruber, Thomas] Med Univ Innsbruck, Div Translat Cell Genet, Innsbruck, Austria; [Schuster, Daniela] Paracelsus Med Univ Salzburg, Inst Pharm, Dept Pharmaceut & Med Chem, Salzburg, Austria; [Zwierzina, Heinz] Med Univ Innsbruck, Dept Internal Med 5, Innsbruck, Austria; [Mueller, Thomas; Ausserlechner, Michael J.] Med Univ Innsbruck, Dept Pediat 1, Innsbruck, Austria	Medical University of Innsbruck; University of Innsbruck; University of Innsbruck; Medical University of Innsbruck; Paracelsus Private Medical University; Medical University of Innsbruck; Medical University of Innsbruck	Obexer, P (corresponding author), Med Univ Innsbruck, Dept Pediat 2, Innsbruck, Austria.; Obexer, P (corresponding author), Tyrolean Canc Res Inst, Innsbruck, Austria.; Ausserlechner, MJ (corresponding author), Med Univ Innsbruck, Dept Pediat 1, Innsbruck, Austria.	Michael.J.Ausserlechner@i-med.ac.at; Petra.Obexer@i-med.ac.at	Tollinger, Martin/E-5896-2011; Führer, Sebastian/AAG-2389-2021; Schuster, Daniela/C-1024-2014	Tollinger, Martin/0000-0002-2177-983X; Führer, Sebastian/0000-0002-6523-1307; Schuster, Daniela/0000-0002-9933-8938; Gruber, Thomas/0000-0002-5796-7090; Ausserlechner, Michael/0000-0002-1015-2302; Kaserer, Teresa/0000-0003-0372-1885; Salcher, Stefan/0000-0003-2391-6954; Hagenbuchner, Judith/0000-0003-1396-3407	COMET center of excellence ONCOTYROL; Kinderkrebshilfe fur Tirol und Vorarlberg; Sudtiroler Krebshilfe; Kinderkrebshilfe Sudtirol-Regenbogen; SVP-Frauen-Initiative; MFF-Tirol [296, 208]; Tirol-Kliniken GmbH; Tyrolean Cancer Society;  [FWF-I3089-B28]	COMET center of excellence ONCOTYROL; Kinderkrebshilfe fur Tirol und Vorarlberg; Sudtiroler Krebshilfe; Kinderkrebshilfe Sudtirol-Regenbogen; SVP-Frauen-Initiative; MFF-Tirol; Tirol-Kliniken GmbH; Tyrolean Cancer Society; 	We thank Andreas Villunger, Domenico Accili, and Joan Massague for providing plasmids. This work was supported by grants by the COMET center of excellence ONCOTYROL, by the "Kinderkrebshilfe fur Tirol und Vorarlberg", the "Sudtiroler Krebshilfe", the "Kinderkrebshilfe Sudtirol-Regenbogen", the "SVP-Frauen-Initiative", the "MFF-Tirol (Project Nr. 296 and 208)", and the FWF-I3089-B28. The Tyrolean Cancer Research Institute and this study are supported by the "Tirol-Kliniken GmbH" and the "Tyrolean Cancer Society".	Arrozi AP, 2017, APPL BIOCHEM BIOTECH, V183, P853, DOI 10.1007/s12010-017-2468-6; Ausserlechner MJ, 2012, NEUROBLASTOMA PRESEN, P325; Baar MP, 2017, CELL, V169, P132, DOI 10.1016/j.cell.2017.02.031; BARON JH, 1978, GUT, V19, P330, DOI 10.1136/gut.19.4.330; BERTACCINI G, 1985, DIGEST DIS SCI, V30, pS43, DOI 10.1007/BF01309384; Bingel C, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.398; Bouillet P, 2001, MAMM GENOME, V12, P163, DOI 10.1007/s003350010242; Boura E, 2007, J BIOL CHEM, V282, P8265, DOI 10.1074/jbc.M605682200; Chen JR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013704; de Brachene AC, 2016, CELL MOL LIFE SCI, V73, P1159, DOI 10.1007/s00018-015-2112-y; Diep CH, 2013, CELL CYCLE, V12, P1433, DOI 10.4161/cc.24550; Du YH, 2006, J BIOMOL SCREEN, V11, P269, DOI 10.1177/1087057105284862; Du Yuhong, 2008, Curr Chem Genomics, V2, P40, DOI 10.2174/1875397300802010040; Grignani F, 1998, CANCER RES, V58, P14; GROSS N, 1992, INT J CANCER, V52, P85, DOI 10.1002/ijc.2910520116; Hagenbuchner Judith, 2016, Oncotarget, V7, P77591, DOI 10.18632/oncotarget.12728; Hagenbuchner J, 2012, J CELL SCI, V125, P1191, DOI 10.1242/jcs.092098; Harada Y, 2010, J EXP MED, V207, P1381, DOI 10.1084/jem.20100004; Hou J, 2015, LUMINESCENCE, V30, P780, DOI 10.1002/bio.2820; Hui RCY, 2008, MOL CELL BIOL, V28, P5886, DOI 10.1128/MCB.01265-07; Hui RCY, 2008, MOL CANCER THER, V7, P670, DOI 10.1158/1535-7163.MCT-07-0397; Hurtz C, 2011, J EXP MED, V208, P2163, DOI 10.1084/jem.20110304; Jiang JX, 2016, BMC CELL BIOL, V17, DOI 10.1186/s12860-016-0094-8; Jones G, 1997, J MOL BIOL, V267, P727, DOI 10.1006/jmbi.1996.0897; Karki S, 2015, ARTERIOSCL THROM VAS, V35, P1498, DOI 10.1161/ATVBAHA.114.305139; Komatsu N, 2003, J BIOL CHEM, V278, P6411, DOI 10.1074/jbc.M211562200; Kumazoe M, 2017, ONCOGENE, V36, P2643, DOI 10.1038/onc.2016.426; Kumazoe M, 2017, J BIOL CHEM, V292, P10813, DOI 10.1074/jbc.M116.772111; Li DY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132998; Li DY, 2009, J CEREBR BLOOD F MET, V29, P1903, DOI 10.1038/jcbfm.2009.102; Maiese Kenneth, 2016, J Transl Sci, V2, P241; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; Matkar S, 2015, CANCER CELL, V28, P472, DOI 10.1016/j.ccell.2015.09.005; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Moosavi MA, 2011, DARU, V19, P455; Nagashima T, 2010, MOL PHARMACOL, V78, P961, DOI 10.1124/mol.110.065714; Naka K, 2010, CANCER SCI, V101, P1577, DOI 10.1111/j.1349-7006.2010.01584.x; Naka K, 2010, NATURE, V463, P676, DOI 10.1038/nature08734; Narath R, 2005, CYTOM PART A, V68A, P113, DOI 10.1002/cyto.a.20190; Nikolovska-Coleska Z, 2004, ANAL BIOCHEM, V332, P261, DOI 10.1016/j.ab.2004.05.055; O'Carroll SJ, 2013, METHODS MOL BIOL, V1037, P519, DOI 10.1007/978-1-62703-505-7_31; Obexer P, 2007, CELL DEATH DIFFER, V14, P534, DOI 10.1038/sj.cdd.4402017; Obsil T, 2008, ONCOGENE, V27, P2263, DOI 10.1038/onc.2008.20; Obsil T, 2011, BBA-MOL CELL RES, V1813, P1946, DOI 10.1016/j.bbamcr.2010.11.025; Opel D, 2007, CANCER RES, V67, P735, DOI 10.1158/0008-5472.CAN-06-2201; Osuka S, 2013, STEM CELLS, V31, P627, DOI 10.1002/stem.1328; Ouyang W, 2010, NAT IMMUNOL, V11, P618, DOI 10.1038/ni.1884; Pan CW, 2017, EMBO J, V36, P995, DOI 10.15252/embj.201695534; Pellicano F, 2014, STEM CELLS, V32, P2324, DOI 10.1002/stem.1748; Qian ZR, 2017, INT J CANCER, V140, P2792, DOI 10.1002/ijc.30690; Qin WP, 2008, ANN NY ACAD SCI, V1147, P335, DOI 10.1196/annals.1427.024; Rupp M, 2017, ONCOGENE, V36, P6190, DOI 10.1038/onc.2017.288; Saha P, 2015, MOL CELL NEUROSCI, V68, P203, DOI 10.1016/j.mcn.2015.08.002; Salcher S, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0661-4; Salcher S, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-224; Sandeep TC, 2004, P NATL ACAD SCI USA, V101, P6734, DOI 10.1073/pnas.0306996101; Sanna PP, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/tp.2016.13; Santamaria CM, 2009, LEUKEMIA RES, V33, P1706, DOI 10.1016/j.leukres.2009.04.024; Savai R, 2014, NAT MED, V20, P1289, DOI 10.1038/nm.3695; Shi C, 2016, J BIOENERG BIOMEMBR, V48, P189, DOI 10.1007/s10863-016-9645-0; Shi C, 2016, J CELL SCI, V129, P1815, DOI 10.1242/jcs.185009; Storz P, 2009, MOL CELL BIOL, V29, P4906, DOI 10.1128/MCB.00077-09; Sun LQ, 2018, BEHAV BRAIN RES, V337, P271, DOI 10.1016/j.bbr.2017.08.042; Sykes SM, 2011, CELL, V146, P697, DOI 10.1016/j.cell.2011.07.032; Takeuchi H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021050; Tan P, 2015, SCI REP, V5; Tenbaum SP, 2012, NAT MED, V18, P892, DOI 10.1038/nm.2772; Tsai KL, 2007, NUCLEIC ACIDS RES, V35, P6984, DOI 10.1093/nar/gkm703; van Boxtel R, 2013, CELL DEATH DIFFER, V20, P1219, DOI 10.1038/cdd.2013.81; Wilson MSC, 2011, CURR DRUG TARGETS, V12, P1256; Wolber G, 2005, J CHEM INF MODEL, V45, P160, DOI 10.1021/ci049885e; Wong HKA, 2013, HUM MOL GENET, V22, P3077, DOI 10.1093/hmg/ddt164; Xu K, 2017, ONCOL REP, V37, P2391, DOI 10.3892/or.2017.5459; Yoo KY, 2012, NEUROCHEM RES, V37, P588, DOI 10.1007/s11064-011-0648-2; Yu YY, 2016, ONCOTARGET, V7, P80888, DOI 10.18632/oncotarget.13105; Yulyana Y, 2013, STEM CELLS DEV, V22, P1870, DOI 10.1089/scd.2012.0529; Zeldich E, 2014, J BIOL CHEM, V289, P24700, DOI 10.1074/jbc.M114.567321; Zhou LQ, 2018, MOL MED REP, V17, P5684, DOI 10.3892/mmr.2018.8624; Zhou YP, 2018, IUBMB LIFE, V70, P276, DOI 10.1002/iub.1699; Zou P, 2014, CELL CYCLE, V13, P3759, DOI 10.4161/15384101.2014.965977	80	17	19	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	5					1080	1097		10.1038/s41388-019-1044-7	http://dx.doi.org/10.1038/s41388-019-1044-7			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KI2VY	31591479	Green Published, hybrid			2022-12-17	WOS:000511209700010
J	Li, MY; Peng, WH; Wu, CH; Chang, YM; Lin, YL; Chang, GD; Wu, HC; Chen, GC				Li, Meng-Yen; Peng, Wen-Hsin; Wu, Chien-Hsun; Chang, Ya-Min; Lin, Yu-Ling; Chang, Geen-Dong; Wu, Han-Chung; Chen, Guang-Chao			PTPN3 suppresses lung cancer cell invasiveness by counteracting Src-mediated DAAM1 activation and actin polymerization	ONCOGENE			English	Article							PROTEIN-TYROSINE PHOSPHATASES; FAMILY KINASES; MIGRATION; INVASION; ADHESION; METASTASIS; GROWTH; MORPHOGENESIS; PROLIFERATION; EXPRESSION	Cancer cell migration plays a crucial role during the metastatic process. Reversible tyrosine phosphorylation by protein tyrosine kinases (PTKs) and protein tyrosine phosphatases (PTPs) have been implicated in the regulation of cancer cell migration and invasion. However, the underlying mechanisms have not been fully elucidated. Here, we show that depletion of the FERM and PDZ domain-containing protein tyrosine phosphatase PTPN3 enhances lung cancer cell migration/invasion and metastasis by promoting actin filament assembly and focal adhesion dynamics. We further identified Src and DAAM1 (dishevelled associated activator of morphogenesis 1) as interactors of PTPN3. DAAM1 is a formin-like protein involved in the regulation of actin cytoskeletal remodeling. PTPN3 inhibits Src activity and Src-mediated phosphorylation of Tyr652 on DAAM1. The tyrosine phosphorylation of DAAM1 is essential for DAAM1 homodimer formation and actin polymerization. Ectopic expression of a DAAM1 phosphodeficient mutant inhibited F-actin assembly and suppressed lung cancer cell migration and invasion. Our findings reveal a novel mechanism by which reversible tyrosine phosphorylation of DAAM1 by Src and PTPN3 regulates actin dynamics and lung cancer invasiveness.	[Li, Meng-Yen; Peng, Wen-Hsin; Lin, Yu-Ling; Chen, Guang-Chao] Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan; [Chang, Ya-Min; Chang, Geen-Dong; Chen, Guang-Chao] Natl Taiwan Univ, Coll Life Sci, Inst Biochem Sci, Taipei 106, Taiwan; [Wu, Chien-Hsun; Wu, Han-Chung] Acad Sinica, Inst Cellular & Organism Biol, Taipei 115, Taiwan	Academia Sinica - Taiwan; National Taiwan University; Academia Sinica - Taiwan	Chen, GC (corresponding author), Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan.; Chen, GC (corresponding author), Natl Taiwan Univ, Coll Life Sci, Inst Biochem Sci, Taipei 106, Taiwan.	gcchen@gate.sinica.edu.tw	Wu, Han-Chung/B-1209-2011	Wu, Han-Chung/0000-0002-5185-1169; Chen, Guang-Chao/0000-0002-4980-4718	Ministry of Science and Technology of Taiwan [NSC102-2311-B-001-027-MY3]; Academia Sinica	Ministry of Science and Technology of Taiwan(Ministry of Science and Technology, Taiwan); Academia Sinica(Academia Sinica - Taiwan)	We thank Ruey-Hwa Chen, Raymond Habas, Jean-Cheng Kuo, Jai Prakash Singh, and Tzu-Ching Meng for helpful discussion and reagents. We thank Chin-Chun Hung for confocal and cell imaging assistance; Suh-Yuen Liang for the bioinformatic support; Min-Feng Hsu for structural assistance; the National RNAi Core Facility for shRNAs; Academia Sinica Common Mass Spectrometry Facilities for mass spectrometric assistance; IBC Histopathology Core Facility for tissue processing and histology. We are grateful to Cindy Lee for English editing. This work was supported by the Ministry of Science and Technology of Taiwan (NSC102-2311-B-001-027-MY3) and Academia Sinica.	Alonso A, 2004, CELL, V117, P699, DOI 10.1016/j.cell.2004.05.018; Aspenstrom P, 2006, EXP CELL RES, V312, P2180, DOI 10.1016/j.yexcr.2006.03.013; Bollu LR, 2017, CLIN CANCER RES, V23, P2136, DOI 10.1158/1078-0432.CCR-16-0934; Bromann PA, 2004, ONCOGENE, V23, P7957, DOI 10.1038/sj.onc.1208079; Campellone KG, 2010, NAT REV MOL CELL BIO, V11, P237, DOI 10.1038/nrm2867; Chen DY, 2012, J CELL SCI, V125, P4841, DOI 10.1242/jcs.108597; Devreotes P, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a005959; Disanza A, 2005, CELL MOL LIFE SCI, V62, P955, DOI 10.1007/s00018-004-4472-6; Dong L, 2018, MOL CELL BIOCHEM, V438, P183, DOI 10.1007/s11010-017-3125-7; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Friedl P, 2010, J CELL BIOL, V188, P11, DOI 10.1083/jcb.200909003; Gao Q, 2014, GASTROENTEROLOGY, V146, P1397, DOI 10.1053/j.gastro.2014.01.062; Gardberg M, 2016, J PATHOL CLIN RES, V2, P41, DOI 10.1002/cjp2.34; Gardel ML, 2010, ANNU REV CELL DEV BI, V26, P315, DOI 10.1146/annurev.cellbio.011209.122036; Glondu-Lassis M, 2010, CANCER RES, V70, P5116, DOI 10.1158/0008-5472.CAN-09-4368; Guarino M, 2010, J CELL PHYSIOL, V223, P14, DOI 10.1002/jcp.22011; Hou SW, 2010, CANCER RES, V70, P2901, DOI 10.1158/0008-5472.CAN-09-3229; Huveneers S, 2009, J CELL SCI, V122, P1059, DOI 10.1242/jcs.039446; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Jung Y, 2012, GENE CHROMOSOME CANC, V51, P590, DOI 10.1002/gcc.21945; Kan-o M, 2012, BIOL OPEN, V1, P889, DOI 10.1242/bio.20121370; Kedrin D, 2007, J MAMMARY GLAND BIOL, V12, P143, DOI 10.1007/s10911-007-9046-4; Kim D, 2016, ONCOTARGET, V7, P17829, DOI 10.18632/oncotarget.7429; Kim LC, 2009, NAT REV CLIN ONCOL, V6, P587, DOI 10.1038/nrclinonc.2009.129; Labbe DP, 2012, PROG MOL BIOL TRANSL, V106, P253, DOI 10.1016/B978-0-12-396456-4.00009-2; Li DQ, 2011, DEVELOPMENT, V138, P303, DOI 10.1242/dev.055566; Li MY, 2015, ONCOGENE, V34, P3791, DOI 10.1038/onc.2014.312; Li SQ, 2016, SCI REP-UK, V6, DOI 10.1038/srep36873; Lin G, 2011, GENE DEV, V25, P1412, DOI 10.1101/gad.2018911; Liu GY, 2018, ONCOL REP, V39, P465, DOI 10.3892/or.2017.6124; Lizarraga F, 2009, CANCER RES, V69, P2792, DOI 10.1158/0008-5472.CAN-08-3709; Lu CL, 2015, ONCOTARGET, V6, P24912, DOI 10.18632/oncotarget.4701; Lu J, 2007, J MOL BIOL, V369, P1258, DOI 10.1016/j.jmb.2007.04.002; Martin GS, 2001, NAT REV MOL CELL BIO, V2, P467, DOI 10.1038/35073094; Mendoza MC, 2013, SEMIN CELL DEV BIOL, V24, P272, DOI 10.1016/j.semcdb.2013.01.007; Nelson KS, 2012, NAT CELL BIOL, V14, P518, DOI 10.1038/ncb2467; Parsons SJ, 2004, ONCOGENE, V23, P7906, DOI 10.1038/sj.onc.1208160; Patel A, 2016, LIFE SCI, V157, P52, DOI 10.1016/j.lfs.2016.05.036; Prokop Andreas, 2011, Commun Integr Biol, V4, P538, DOI 10.4161/cib.4.5.16511; Randall TS, 2014, EUR J CELL BIOL, V93, P205, DOI 10.1016/j.ejcb.2013.11.004; Reig G, 2014, DEVELOPMENT, V141, P1999, DOI 10.1242/dev.101451; Reynolds AB, 2014, ONCOGENE, V33, P4537, DOI 10.1038/onc.2013.416; Ridley AJ, 2015, CURR OPIN CELL BIOL, V36, P103, DOI 10.1016/j.ceb.2015.08.005; SEN B, 2011, J SIGNAL TRANSDUCT, DOI DOI 10.1063/1.3603036; Shojima K, 2015, SCI REP-UK, V5, DOI 10.1038/srep08042; Stehbens SJ, 2014, METHOD CELL BIOL, V123, P335, DOI 10.1016/B978-0-12-420138-5.00018-5; Svitkina Tatyana, 2018, Cold Spring Harb Perspect Biol, V10, DOI 10.1101/cshperspect.a018267; Tepass U, 2009, CURR OPIN GENET DEV, V19, P357, DOI 10.1016/j.gde.2009.05.006; van Vliet C, 2005, NAT IMMUNOL, V6, P253, DOI 10.1038/ni1169; Wang SE, 2005, MOL CELL BIOL, V25, P4703, DOI 10.1128/MCB.25.11.4703-4715.2005; Wang XW, 2018, CELL BIOL INT, V42, P598, DOI 10.1002/cbin.10936; Wang ZH, 2004, SCIENCE, V304, P1164, DOI 10.1126/science.1096096; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Xiong HP, 2018, CELL SIGNAL, V44, P33, DOI 10.1016/j.cellsig.2018.01.013; Yamashita M, 2007, GENES CELLS, V12, P1255, DOI 10.1111/j.1365-2443.2007.01132.x; Yan T, 2018, J BIOL CHEM, V293, P10172, DOI 10.1074/jbc.RA117.000327; Yin M, 2017, ONCOTARGET, V8, P88232, DOI 10.18632/oncotarget.21088; Young KG, 2010, BBA-MOL CELL RES, V1803, P183, DOI 10.1016/j.bbamcr.2008.09.017; Zeng YF, 2015, EXP MOL PATHOL, V98, P260, DOI 10.1016/j.yexmp.2015.03.008; Zheng YH, 2013, CHIN J CANCER, V32, P75, DOI [10.5732/cjc.012.10084, 10.5732/cjc.012.1008]; Zhou F, 2009, HUM MOL GENET, V18, P2472, DOI 10.1093/hmg/ddp185; Zhu XL, 2008, INT J COLORECTAL DIS, V23, P1041, DOI 10.1007/s00384-008-0520-2; Zhu YC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037823	63	17	17	2	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 31	2019	38	44					7002	7016		10.1038/s41388-019-0948-6	http://dx.doi.org/10.1038/s41388-019-0948-6			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ1AO	31406243				2022-12-17	WOS:000493892900004
J	Bhoopathi, P; Pradhan, AK; Bacolod, MD; Emdad, L; Sarkar, D; Das, SK; Fisher, PB				Bhoopathi, Praveen; Pradhan, Anjan K.; Bacolod, Manny D.; Emdad, Luni; Sarkar, Devanand; Das, Swadesh K.; Fisher, Paul B.			Regulation of neuroblastoma migration, invasion, and in vivo metastasis by genetic and pharmacological manipulation of MDA-9/Syntenin	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; ALPHA-6-BETA-4 INTEGRIN; TUMOR INVASION; CANCER; EXPRESSION; PROLIFERATION; GLYCOPROTEIN; INHIBITION; GTPASES; TARGET	Despite multi-modality treatments, prognosis for advanced stage neuroblastoma (NB) remains challenging with residual long-term disabilities in survivors. Advanced stage NB is metastatic, which is a principal cause of cancer-related deaths. We presently document a primary role of MDA-9 in NB progression and define the molecular mechanisms by which MDA-9 promotes transformed phenotypes. NB cell lines and clinical samples display elevated MDA-9 expression and bioinformatic analysis supports an association between elevated MDA-9 and bone metastasis and poor prognosis. Genetic (shmda-9, mda9 siRNA) or pharmacological (small molecule inhibitor of protein-protein interactions; PDZ1i) blockade of MDA-9 decreases NB migration, invasion, and metastasis. Blocking mda-9 expression or disrupting MDA-9 partner protein interactions downregulates integrin alpha 6 and beta 4, diminishing Src activity and suppressing Rho-Rac-Cdc42 activity. These signaling changes inhibit cofilin and matrix metalloproteinases reducing in vitro and in vivo NB cell migration. Overexpression of integrin a6 and beta 4 rescues the invasion phenotype and increases Src activity, supporting integrins as essential regulators of MDA-9-mediated NB migration and invasion. We identify MDA-9 as a key contributor to NB pathogenesis and show that genetic or pharmacological inhibition suppresses NB pathogenesis by an integrin-mediated Src-disruption pathway.	[Bhoopathi, Praveen; Pradhan, Anjan K.; Emdad, Luni; Sarkar, Devanand; Das, Swadesh K.; Fisher, Paul B.] Virginia Commonwealth Univ, Dept Human & Mol Genet, Sch Med, Richmond, VA 23284 USA; [Bhoopathi, Praveen; Pradhan, Anjan K.; Emdad, Luni; Sarkar, Devanand; Das, Swadesh K.; Fisher, Paul B.] Virginia Commonwealth Univ, Sch Med, VCU Inst Mol Med, Richmond, VA 23284 USA; [Bacolod, Manny D.] Weill Cornell Med Coll, New York, NY USA; [Emdad, Luni; Sarkar, Devanand; Das, Swadesh K.; Fisher, Paul B.] Virginia Commonwealth Univ, VCU Massey Canc Ctr, Sch Med, Richmond, VA 23284 USA	Virginia Commonwealth University; Virginia Commonwealth University; Cornell University; Virginia Commonwealth University	Fisher, PB (corresponding author), Virginia Commonwealth Univ, Dept Human & Mol Genet, Sch Med, Richmond, VA 23284 USA.; Fisher, PB (corresponding author), Virginia Commonwealth Univ, Sch Med, VCU Inst Mol Med, Richmond, VA 23284 USA.; Fisher, PB (corresponding author), Virginia Commonwealth Univ, VCU Massey Canc Ctr, Sch Med, Richmond, VA 23284 USA.	paul.fisher@vcuhealth.org	Pradhan, Anjan K/O-2555-2014	Bacolod, Manny/0000-0002-2085-4877	National Foundation for Cancer Research (NFCR); NCI Cancer Center Support Grant [P30 CA016059]; VCU Institute of Molecular Medicine (VIMM); Genetics Enhancement Fund; InVaMet Therapeutics, Inc. (IVMT); NATIONAL CANCER INSTITUTE [P30CA016059] Funding Source: NIH RePORTER	National Foundation for Cancer Research (NFCR); NCI Cancer Center Support Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); VCU Institute of Molecular Medicine (VIMM); Genetics Enhancement Fund; InVaMet Therapeutics, Inc. (IVMT); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The present study was supported in part by the National Foundation for Cancer Research (NFCR) (to PBF), NCI Cancer Center Support Grant to VCU Massey Cancer Center (MCC) P30 CA016059 (to PBF and DS), the VCU Institute of Molecular Medicine (VIMM) (PBF) and the Genetics Enhancement Fund (PBF, SKD, and LE). Support was also provided by a Sponsored Research Agreement from InVaMet Therapeutics, Inc. (IVMT) (SKD). PBF holds the Thelma Newmeyer Corman Chair in Cancer Research at the MCC.	Bacolod MD, 2015, ADV CANCER RES, V127, P49, DOI 10.1016/bs.acr.2015.04.006; Bhoopathi P, 2016, CANCER RES, V76, P3572, DOI 10.1158/0008-5472.CAN-15-2959; Bhoopathi P, 2011, CELL SIGNAL, V23, P1978, DOI 10.1016/j.cellsig.2011.07.008; Bolos V, 2010, ONCOTARGETS THER, V3, P83; Boukerche H, 2005, CANCER RES, V65, P10901, DOI 10.1158/0008-5472.CAN-05-1614; Boukerche H, 2008, P NATL ACAD SCI USA, V105, P15914, DOI 10.1073/pnas.0808171105; Chaturvedi NK, 2016, ONCOTARGET, V7, P15215, DOI 10.18632/oncotarget.7714; Colburn ZT, 2018, J CELL SCI, V131, DOI 10.1242/jcs.214593; Das SK, 2019, MOL CANCER THER, V18, P1997, DOI 10.1158/1535-7163.MCT-18-1019; Das SK, 2019, ADV CANCER RES, V144, P137, DOI 10.1016/bs.acr.2019.03.011; Das SK, 2019, ACS CHEM NEUROSCI, V10, P1121, DOI 10.1021/acschemneuro.9b00016; Das SK, 2018, CANCER RES, V78, P2852, DOI 10.1158/0008-5472.CAN-17-2992; Das SK, 2016, ONCOTARGET, V7, P46848, DOI 10.18632/oncotarget.10040; Das SK, 2013, CANCER RES, V73, P844, DOI 10.1158/0008-5472.CAN-12-1681; Das SK, 2012, CANCER RES, V72, P6217, DOI 10.1158/0008-5472.CAN-12-0402; Das SK, 2012, FRONT BIOSCI-LANDMRK, V17, P1, DOI 10.2741/3911; Dasgupta S, 2013, CLIN CANCER RES, V19, P4621, DOI 10.1158/1078-0432.CCR-13-0585; Dominguez-Gimenez P, 2007, J CELL SCI, V120, P1061, DOI 10.1242/jcs.03404; Guan XM, 2015, ACTA PHARM SIN B, V5, P402, DOI 10.1016/j.apsb.2015.07.005; Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727; Kaminska K, 2015, J CELL MOL MED, V19, P283, DOI 10.1111/jcmm.12408; Kegelman TP, 2017, P NATL ACAD SCI USA, V114, P370, DOI 10.1073/pnas.1616100114; Kegelman TP, 2015, EXPERT OPIN THER TAR, V19, P97, DOI 10.1517/14728222.2014.959495; Kegelman TP, 2014, NEURO-ONCOLOGY, V16, P50, DOI 10.1093/neuonc/not157; Kramer M, 2016, J NEUROSCI, V36, P10425, DOI 10.1523/JNEUROSCI.0183-16.2016; Lee SH, 2010, MOL CELLS, V29, P311, DOI 10.1007/s10059-010-0053-8; Lin JJ, 1996, MOL CELL DIFFER, V4, P317; Lin JJ, 1998, GENE, V207, P105, DOI 10.1016/S0378-1119(97)00562-3; Melzer C, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/8534371; Menezes ME, 2016, ONCOTARGET, V7, P80175, DOI 10.18632/oncotarget.13373; Mercurio AM, 2001, CURR OPIN CELL BIOL, V13, P541, DOI 10.1016/S0955-0674(00)00249-0; Meyer A, 2004, NEOPLASIA, V6, P332, DOI 10.1593/neo.03445; Miao H, 2002, J CELL SCI, V115, P2199; Morandi F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029922; Nakajima S, 2004, CLIN CANCER RES, V10, P4125, DOI 10.1158/1078-0432.CCR-0578-03; O'Connor KL, 2012, AM J PHYSIOL-CELL PH, V302, pC605, DOI 10.1152/ajpcell.00095.2011; Rastogi P, 2015, INDIAN J HEMATOL BLO, V31, P57, DOI 10.1007/s12288-014-0405-1; Russell AJ, 2003, J CELL SCI, V116, P3543, DOI 10.1242/jcs.00663; Sarkar D, 2008, CANCER RES, V68, P3087, DOI 10.1158/0008-5472.CAN-07-6210; Schwartz MA, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a005066; Seong BKA, 2017, CANCER RES, V77, P696, DOI 10.1158/0008-5472.CAN-16-1502; Shohet J, 2017, BMJ-BRIT MED J, V357, DOI 10.1136/bmj.j1863; Son H, 2010, TOX RESEARCH, V26, P245, DOI 10.5487/TR.2010.26.4.245; Stivarou T, 2015, CANCERS, V7, P238, DOI 10.3390/cancers7010238; Su ZZ, 2002, ONCOGENE, V21, P3592, DOI 10.1038/sj.onc.1205445; Takahashi C, 1998, P NATL ACAD SCI USA, V95, P13221, DOI 10.1073/pnas.95.22.13221; Talukdar S, 2018, AUTOPHAGY, V14, P1845, DOI 10.1080/15548627.2018.1502564; Talukdar S, 2018, P NATL ACAD SCI USA, V115, P5768, DOI 10.1073/pnas.1721650115; Talukdar S, 2016, ONCOTARGET, V7, P54102, DOI 10.18632/oncotarget.10851; Webb AH, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3418-y; Welch DR, 2016, ADV CANCER RES, V132, P1	51	17	17	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 10	2019	38	41					6781	6793		10.1038/s41388-019-0920-5	http://dx.doi.org/10.1038/s41388-019-0920-5			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JC8UZ	31406249	Green Accepted			2022-12-17	WOS:000489552900006
J	Khoshchehreh, R; Totonchi, M; Ramirez, JC; Torres, R; Baharvand, H; Aicher, A; Ebrahimi, M; Heeschen, C				Khoshchehreh, Reyhaneh; Totonchi, Mehdi; Carlos Ramirez, Juan; Torres, Raul; Baharvand, Hossein; Aicher, Alexandra; Ebrahimi, Marzieh; Heeschen, Christopher			Epigenetic reprogramming of primary pancreatic cancer cells counteracts their in vivo tumourigenicity	ONCOGENE			English	Article							STEM-CELLS; INHIBITION; DEDIFFERENTIATION; PLURIPOTENCY; TECHNOLOGY; DOT1L	Pancreatic ductal adenocarcinoma (PDAC) arises through accumulation of multiple genetic alterations. However, cancer cells also acquire and depend on cancer-specific epigenetic changes. To conclusively demonstrate the crucial relevance of the epigenetic programme for the tumourigenicity of the cancer cells, we used cellular reprogramming technology to reverse these epigenetic changes. We reprogrammed human PDAC cultures using three different techniques - (1) lentivirally via induction of Yamanaka Factors (OSKM), (2) the pluripotency-associated gene OCT4 and the microRNA mir-302, or (3) using episomal vectors as a safer alternative without genomic integration. We found that induction with episomal vectors was the most efficient method to reprogram primary human PDAC cultures as well as primary human fibroblasts that served as positive controls. Successful reprogramming was evidenced by immunostaining, alkaline phosphatase staining, and real-time PCR. Intriguingly, reprogramming of primary human PDAC cultures drastically reduced their in vivo tumourigenicity, which appeared to be driven by the cells' enhanced differentiation and loss of stemness upon transplantation. Our study demonstrates that reprogrammed primary PDAC cultures are functionally distinct from parental PDAC cells resulting in drastically reduced tumourigenicity in vitro and in vivo. Thus, epigenetic alterations account at least in part for the tumourigenicity and aggressiveness of pancreatic cancer, supporting the notion that epigenetic modulators could be a suitable approach to improve the dismal outcome of patients with pancreatic cancer.	[Khoshchehreh, Reyhaneh; Totonchi, Mehdi; Baharvand, Hossein; Ebrahimi, Marzieh] ACECR, Royan Inst Stern Cell Biol & Technol, Cell Sci Res Ctr, Dept Stern Cells & Dev Biol, Tehran, Iran; [Khoshchehreh, Reyhaneh; Baharvand, Hossein; Ebrahimi, Marzieh] Univ Sci & Culture, Dept Dev Biol, Tehran, Iran; [Totonchi, Mehdi] ACECR, Royan Inst Reprod Biomed, Reprod Biomed Res Ctr, Dept Genet, Tehran, Iran; [Carlos Ramirez, Juan] VIVEBioTECH, San Sebastian 20009, Spain; [Torres, Raul] CNIO, Human Canc Genet Program, Mol Cytogenet & Genome Editing Unit, Madrid 28029, Spain; [Torres, Raul] Univ Barcelona, Sch Med, Josep Carreras Leukemia Res Inst, Barcelona 08036, Spain; [Torres, Raul] Univ Barcelona, Sch Med, Dept Biomed, Barcelona 08036, Spain; [Aicher, Alexandra] Univ Sydney, Centenary Inst, Gene & Stem Cell Therapy Program, Camperdown, NSW 2050, Australia; [Aicher, Alexandra; Heeschen, Christopher] Spanish Natl Canc Res Ctr CNIO, Mol Pathol Programme, Madrid 28029, Spain	Academic Center for Education, Culture & Research (ACECR); Academic Center for Education, Culture & Research (ACECR); Centro Nacional de Investigaciones Oncologicas (CNIO); Institut de Recerca Contra la Leucemia Josep Carreras (IJC); University of Barcelona; University of Barcelona; University of Sydney; Centenary Institute; Centro Nacional de Investigaciones Oncologicas (CNIO)	Ebrahimi, M (corresponding author), ACECR, Royan Inst Stern Cell Biol & Technol, Cell Sci Res Ctr, Dept Stern Cells & Dev Biol, Tehran, Iran.; Ebrahimi, M (corresponding author), Univ Sci & Culture, Dept Dev Biol, Tehran, Iran.; Aicher, A (corresponding author), Univ Sydney, Centenary Inst, Gene & Stem Cell Therapy Program, Camperdown, NSW 2050, Australia.; Aicher, A; Heeschen, C (corresponding author), Spanish Natl Canc Res Ctr CNIO, Mol Pathol Programme, Madrid 28029, Spain.	aicher_a@yahoo.com; Mebrahimi@royaninstitute.org; christopher.heeschen@icloud.com	Ruiz, Raul Torres/J-1649-2018; ebrahimi, marzieh/AAO-2659-2020; Aicher, Alexandra/GZK-8031-2022	Ruiz, Raul Torres/0000-0001-9606-0398; ebrahimi, marzieh/0000-0003-1140-0379; Aicher, Alexandra/0000-0002-8920-9577	ERC [Pa-CSC 233460]; European Community [602783]; Royan Institute [91000413]	ERC(European Research Council (ERC)European Commission); European Community(European Commission); Royan Institute	The research was supported by the ERC Advanced Investigator Grant (Pa-CSC 233460, to C.H.), the European Community's Seventh Framework Programme (FP7/2007-2013) under grant agreement no 602783 (CAM-PaC, to CH) and funding provided by the Royan Institute (#91000413 to ME).	Blelloch RH, 2004, P NATL ACAD SCI USA, V101, P13985, DOI 10.1073/pnas.0405015101; Carette JE, 2010, BLOOD, V115, P4039, DOI 10.1182/blood-2009-07-231845; Carey BW, 2009, P NATL ACAD SCI USA, V106, P157, DOI 10.1073/pnas.0811426106; Chen CW, 2015, NAT MED, V21, P335, DOI 10.1038/nm.3832; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Cioffi M, 2015, CLIN CANCER RES, V21, P2325, DOI 10.1158/1078-0432.CCR-14-1399; Daigle SR, 2013, BLOOD, V122, P1017, DOI 10.1182/blood-2013-04-497644; Duan HY, 2017, GYNECOL ONCOL, V147, P408, DOI 10.1016/j.ygyno.2017.08.010; Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005; Friedlander SYG, 2009, CANCER CELL, V16, P379, DOI 10.1016/j.ccr.2009.09.027; Hermann PC, 2014, GASTROENTEROLOGY, V147, P1119, DOI 10.1053/j.gastro.2014.08.002; Hochedlinger K, 2004, GENE DEV, V18, P1875, DOI 10.1101/gad.1213504; Kim J, 2015, EMBO J, V34, P739, DOI 10.15252/embj.201490736; Krstic M, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2697-z; Kumano K, 2012, BLOOD, V119, P6234, DOI 10.1182/blood-2011-07-367441; Lee JJ, 2014, LAB INVEST, V94, P822, DOI 10.1038/labinvest.2014.87; Li L, 2003, CANCER RES, V63, P2733; Lonardo E, 2011, CELL STEM CELL, V9, P433, DOI 10.1016/j.stem.2011.10.001; De Bonis ML, 2014, STEM CELL REP, V2, P690, DOI 10.1016/j.stemcr.2014.03.002; Matsuda Y, 2014, PATHOL INT, V64, P299, DOI 10.1111/pin.12180; Matsui T, 2012, STEM CELLS, V30, P1109, DOI 10.1002/stem.1091; MCKINNELL RG, 1969, SCIENCE, V165, P394, DOI 10.1126/science.165.3891.394; Miyoshi N, 2010, P NATL ACAD SCI USA, V107, P40, DOI 10.1073/pnas.0912407107; Morandi A, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00040; Rahib L, 2014, CANCER RES, V74, P2913, DOI 10.1158/0008-5472.CAN-14-0155; Rubio-Viqueira B, 2006, CLIN CANCER RES, V12, P4652, DOI 10.1158/1078-0432.CCR-06-0113; Sainz B, 2014, CANCER RES, V74, P7309, DOI 10.1158/0008-5472.CAN-14-1354; Schlaeger TM, 2015, NAT BIOTECHNOL, V33, P58, DOI 10.1038/nbt.3070; Semi K, 2015, CANCER SCI, V106, P1251, DOI 10.1111/cas.12758; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Waddell N, 2015, NATURE, V518, P495, DOI 10.1038/nature14169; Wang H, 2017, ONCOTARGET, V8; Yamada Y, 2014, STEM CELL TRANSL MED, V3, P1182, DOI 10.5966/sctm.2014-0090; Zagorac S, 2016, CANCER RES, V76, P4546, DOI 10.1158/0008-5472.CAN-15-3268; Zhang X, 2013, ONCOGENE, V32, P2249, DOI 10.1038/onc.2012.237; Zhou Z, 2018, J CELL PHYSIOL, V233, P1359, DOI 10.1002/jcp.26012	37	17	17	1	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 22	2019	38	34					6226	6239		10.1038/s41388-019-0871-x	http://dx.doi.org/10.1038/s41388-019-0871-x			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IS5RM	31308488	Green Published, hybrid			2022-12-17	WOS:000482210100006
J	Hardy, LR; Pergande, MR; Esparza, K; Heath, KN; Onyuksel, H; Cologna, SM; Burdette, JE				Hardy, Laura R.; Pergande, Melissa R.; Esparza, Karina; Heath, Kimberly N.; Onyuksel, Hayat; Cologna, Stephanie M.; Burdette, Joanna E.			Proteomic analysis reveals a role for PAX8 in peritoneal colonization of high grade serous ovarian cancer that can be targeted with micelle encapsulated thiostrepton	ONCOGENE			English	Article							GROWTH; FOXM1; EXPRESSION; CELLS; TRANSITION; TISSUES	High grade serous ovarian cancer (HGSOC) is the fifth leading cause of cancer deaths among women yet effective targeted therapies against this disease are limited. The heterogeneity of HGSOC, including few shared oncogenic drivers and origination from both the fallopian tube epithelium (FTE) and ovarian surface epithelium (OSE), has hampered development of targeted drug therapies. PAX8 is a lineage-specific transcription factor expressed in the FTE that is also ubiquitously expressed in HGSOC where it is an important driver of proliferation, migration, and cell survival. PAX8 is not normally expressed in the OSE, but it is turned on after malignant transformation. In this study, we use proteomic and transcriptomic analysis to examine the role of PAX8 leading to increased migratory capabilities in a human ovarian cancer model, as well as in tumor models derived from the OSE and FTE. We find that PAX8 is a master regulator of migration with unique downstream transcriptional targets that are dependent on the cell's site of origin. Importantly, we show that targeting PAX8, either through CRISPR genomic alteration or through drug treatment with micelle encapsulated thiostrepton, leads to a reduction in tumor burden. These findings suggest PAX8 is a unifying protein driving metastasis in ovarian tumors that could be developed as an effective drug target to treat HGSOC derived from both the OSE and FTE.	[Hardy, Laura R.; Heath, Kimberly N.; Burdette, Joanna E.] Univ Illinois, Dept Pharmaceut Sci, Chicago, IL 60607 USA; [Pergande, Melissa R.; Cologna, Stephanie M.] Univ Illinois, Dept Chem, Chicago, IL USA; [Esparza, Karina; Onyuksel, Hayat] Univ Illinois, Dept Biopharmaceut Sci, Chicago, IL USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Burdette, JE (corresponding author), Univ Illinois, Dept Pharmaceut Sci, Chicago, IL 60607 USA.	joannab@uic.edu		Pergande, Melissa/0000-0003-1197-4057	Department of Defense Ovarian Cancer Fund [160076]; National Cancer Institute [F30CA224986]; National Cancer Center for Research Resources Facilities Improvement Program [C06RR15482]; University of Illinois-Chicago Department of Chemistry; Ara Parsegian Medical Research Foundation; Abraham Lincoln Fellowship; NATIONAL CANCER INSTITUTE [F30CA224986] Funding Source: NIH RePORTER	Department of Defense Ovarian Cancer Fund(United States Department of Defense); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Cancer Center for Research Resources Facilities Improvement Program; University of Illinois-Chicago Department of Chemistry; Ara Parsegian Medical Research Foundation; Abraham Lincoln Fellowship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the Department of Defense Ovarian Cancer Fund 160076, the National Cancer Institute F30CA224986, the National Cancer Center for Research Resources Facilities Improvement Program C06RR15482, the University of Illinois-Chicago Department of Chemistry, the Ara Parsegian Medical Research Foundation, and the Abraham Lincoln Fellowship.	Adler EK, 2017, ONCOTARGET, V8, P108316, DOI 10.18632/oncotarget.22718; Adusumilli R, 2017, METHODS MOL BIOL, V1550, P339, DOI 10.1007/978-1-4939-6747-6_23; Ashok B, 2004, J PHARM SCI-US, V93, P2476, DOI 10.1002/jps.20150; Batth TS, 2014, J PROTEOME RES, V13, P6176, DOI 10.1021/pr500893m; Cancer Genome Atlas Research Network, 2011, Nature, V474, P609, DOI 10.1038/nature10166; Cheung HW, 2011, P NATL ACAD SCI USA, V108, P12372, DOI 10.1073/pnas.1109363108; de Cristofaro T, 2016, ONCOTARGET, V7, P41929, DOI 10.18632/oncotarget.9740; de Cristofaro T, 2009, J MOL ENDOCRINOL, V42, P35, DOI 10.1677/JME-08-0100; Di Palma T, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-292; Eddie SL, 2015, ONCOTARGET, V6, P20500, DOI 10.18632/oncotarget.3985; Elias KM, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.87988; Endsley MP, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00154; Esparza K, 2019, INT J PHARMACEUT, V556, P21, DOI 10.1016/j.ijpharm.2018.12.001; Ghannam-Shahbari D, 2018, ONCOGENE, V37, P2213, DOI 10.1038/s41388-017-0040-z; Gokce E, 2011, J CHROMATOGR B, V879, P610, DOI 10.1016/j.jchromb.2011.01.032; Grassi ML, 2017, J PROTEOMICS, V151, P2, DOI 10.1016/j.jprot.2016.06.009; Haley J, 2016, ONCOTARGET, V7, P32810, DOI 10.18632/oncotarget.9053; Harms JM, 2008, MOL CELL, V30, P26, DOI 10.1016/j.molcel.2008.01.009; Hegde NS, 2011, NAT CHEM, V3, P725, DOI [10.1038/nchem.1114, 10.1038/NCHEM.1114]; Jiang LZ, 2015, J CANCER RES CLIN, V141, P971, DOI 10.1007/s00432-014-1872-3; Ke N, 2011, METHODS MOL BIOL, V740, P33, DOI 10.1007/978-1-61779-108-6_6; King SM, 2013, CARCINOGENESIS, V34, P1125, DOI 10.1093/carcin/bgt003; King SM, 2011, ENDOCR-RELAT CANCER, V18, P627, DOI 10.1530/ERC-11-0107; Kurman RJ, 2011, HUM PATHOL, V42, P918, DOI 10.1016/j.humpath.2011.03.003; Labidi-Galy SI, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00962-1; Laury AR, 2010, AM J SURG PATHOL, V34, P627, DOI 10.1097/PAS.0b013e3181da7687; Li CG, 2011, ONCOGENE, V30, P4824, DOI 10.1038/onc.2011.190; Lim SB, 2012, J CONTROL RELEASE, V163, P34, DOI 10.1016/j.jconrel.2012.06.002; Mansouri A, 1998, NAT GENET, V19, P87, DOI 10.1038/ng0598-87; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; McCloskey CW, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00053; Musrap N, 2015, J BIOL CHEM, V290, P17218, DOI 10.1074/jbc.M115.639773; Ong SE, 2006, NAT PROTOC, V1, P2650, DOI 10.1038/nprot.2006.427; Ozcan A, 2011, MODERN PATHOL, V24, P751, DOI 10.1038/modpathol.2011.3; Piek JMJ, 2001, J PATHOL, V195, P451, DOI 10.1002/path.1000; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Rodgers LH, 2016, ONCOTARGET, V7, P32785, DOI 10.18632/oncotarget.9051; Russo A, 2018, ONCOGENE, V37, P1976, DOI 10.1038/s41388-017-0097-8; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Tanwar PS, 2014, CARCINOGENESIS, V35, P546, DOI 10.1093/carcin/bgt357; Waldemarson S, 2012, J PROTEOME RES, V11, P2876, DOI 10.1021/pr201258q; Wang LN, 2012, J CELL BIOCHEM, V113, P3762, DOI 10.1002/jcb.24250; Wang M, 2011, MOL CANCER THER, V10, P2287, DOI 10.1158/1535-7163.MCT-11-0536; Wisniewski JR, 2009, NAT METHODS, V6, P359, DOI [10.1038/nmeth.1322, 10.1038/NMETH.1322]; Zhang X, 2014, ONCOTARGET, V5, P11365, DOI 10.18632/oncotarget.2497	45	17	17	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 8	2019	38	32					6003	6016		10.1038/s41388-019-0842-2	http://dx.doi.org/10.1038/s41388-019-0842-2			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IP8XH	31296958	Green Accepted			2022-12-17	WOS:000480329900001
J	Clarke, PA; Roe, T; Swabey, K; Hobbs, SM; McAndrew, C; Tomlin, K; Westwood, I; Burke, R; van Montfort, R; Workman, P				Clarke, Paul A.; Roe, Toby; Swabey, Kate; Hobbs, Steve M.; McAndrew, Craig; Tomlin, Kathy; Westwood, Isaac; Burke, Rosemary; van Montfort, Robert; Workman, Paul			Dissecting mechanisms of resistance to targeted drug combination therapy in human colorectal cancer	ONCOGENE			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE INHIBITION; MUTATIONS CONFER RESISTANCE; MEK INHIBITION; ACQUIRED-RESISTANCE; ERK1/2 INHIBITOR; COMBINED BRAF; CLINICAL DEVELOPMENT; APOPTOTIC RESPONSE; TUMOR-GROWTH; PI3 KINASE	Genomic alterations in cancer cells result in vulnerabilities that clinicians can exploit using molecularly targeted drugs, guided by knowledge of the tumour genotype. However, the selective activity of these drugs exerts an evolutionary pressure on cancers that can result in the outgrowth of resistant clones. Use of rational drug combinations can overcome resistance to targeted drugs, but resistance may eventually develop to combinatorial therapies. We selected MAPK- and PI3K-pathway inhibition in colorectal cancer as a model system to dissect out mechanisms of resistance. We focused on these signalling pathways because they are frequently activated in colorectal tumours, have well-characterised mutations and are clinically relevant. By treating a panel of 47 human colorectal cancer cell lines with a combination of MEK- and PI3K-inhibitors, we observe a synergistic inhibition of growth in almost all cell lines. Cells with KRAS mutations are less sensitive to PI3K inhibition, but are particularly sensitive to the combined treatment. Colorectal cancer cell lines with inherent or acquired resistance to monotherapy do not show a synergistic response to the combination treatment. Cells that acquire resistance to an MEK-PI3K inhibitor combination treatment still respond to an ERK-PI3K inhibitor regimen, but subsequently also acquire resistance to this combination treatment. Importantly, the mechanisms of resistance to MEK and PI3K inhibitors observed, MEK1/2 mutation or loss of PTEN, are similar to those detected in the clinic. ERK inhibitors may have clinical utility in overcoming resistance to MEK inhibitor regimes; however, we find a recurrent active site mutation of ERK2 that drives resistance to ERK inhibitors in mono- or combined regimens, suggesting that resistance will remain a hurdle. Importantly, we find that the addition of low concentrations of the BCL2-family inhibitor navitoclax to the MEK-PI3K inhibitor regimen improves the synergistic interaction and blocks the acquisition of resistance.	[Clarke, Paul A.; Roe, Toby; Swabey, Kate; Hobbs, Steve M.; McAndrew, Craig; Tomlin, Kathy; Westwood, Isaac; Burke, Rosemary; van Montfort, Robert; Workman, Paul] Inst Canc Res, Canc Res UK Canc Therapeut Unit, London SM2 5NG, England	Cancer Research UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Clarke, PA (corresponding author), Inst Canc Res, Canc Res UK Canc Therapeut Unit, London SM2 5NG, England.	paul.clarke@icr.ac.uk		Clarke, Paul/0000-0001-9342-1290	Cancer Research UK [C309/A11566, C368/A6743, A368/A7990]; Cancer Research UK; Kidani Memorial fund	Cancer Research UK(Cancer Research UK); Cancer Research UK(Cancer Research UK); Kidani Memorial fund	This work was supported by Cancer Research UK (grant numbers C309/A11566, C368/A6743, and A368/A7990). We acknowledge Cancer Research UK funding to the Cancer Research UK Unit at The Institute of Cancer Research. Paul Workman is a Cancer Research UK Life Fellow. We thank the Kidani Memorial fund for supporting KS. We thank Julian Blagg and Peter Sheldrake for synthesis of CCT245731, and Nicky Evans for editorial assistance.	Aronov AM, 2007, J MED CHEM, V50, P1280, DOI 10.1021/jm061381f; Bean GR, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003483; Blake JF, 2016, J MED CHEM, V59, P5650, DOI 10.1021/acs.jmedchem.6b00389; Chaikuad A, 2014, NAT CHEM BIOL, V10, P853, DOI [10.1038/NCHEMBIO.1629, 10.1038/nchembio.1629]; CHOU TC, 1983, TRENDS PHARMACOL SCI, V4, P450, DOI 10.1016/0165-6147(83)90490-X; Corcoran RB, 2015, J CLIN ONCOL, V33, P4023, DOI 10.1200/JCO.2015.63.2471; Corcoran RB, 2013, CANCER CELL, V23, P121, DOI 10.1016/j.ccr.2012.11.007; de Castro DG, 2013, CLIN PHARMACOL THER, V93, P252, DOI 10.1038/clpt.2012.237; Dreyling M, 2017, J CLIN ONCOL, V35, P3898, DOI 10.1200/JCO.2017.75.4648; Emery CM, 2009, P NATL ACAD SCI USA, V106, P20411, DOI 10.1073/pnas.0905833106; Faber AC, 2014, CANCER DISCOV, V4, P42, DOI 10.1158/2159-8290.CD-13-0315; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Folkes AJ, 2008, J MED CHEM, V51, P5522, DOI 10.1021/jm800295d; Garcia-Garcia C, 2015, CLIN CANCER RES, V21, P5499, DOI 10.1158/1078-0432.CCR-14-3091; Garraway LA, 2012, CANCER DISCOV, V2, P214, DOI 10.1158/2159-8290.CD-12-0012; Garrison Erik, 12073907 ARXIV; Germann UA, 2017, MOL CANCER THER, V16, P2351, DOI 10.1158/1535-7163.MCT-17-0456; Goetz EM, 2014, CANCER RES, V74, P7079, DOI 10.1158/0008-5472.CAN-14-2073; Guillard S, 2009, CELL CYCLE, V8, P443, DOI 10.4161/cc.8.3.7643; Haagensen EJ, 2012, BRIT J CANCER, V106, P1386, DOI 10.1038/bjc.2012.70; Hatzivassiliou G, 2012, MOL CANCER THER, V11, P1143, DOI 10.1158/1535-7163.MCT-11-1010; Hayakawa M, 2006, BIOORGAN MED CHEM, V14, P6847, DOI 10.1016/j.bmc.2006.06.046; Herrero A, 2015, CANCER CELL, V28, P170, DOI 10.1016/j.ccell.2015.07.001; Hobbs S, 1998, BIOCHEM BIOPH RES CO, V252, P368, DOI 10.1006/bbrc.1998.9646; Hoeflich KP, 2012, CANCER RES, V72, P210, DOI 10.1158/0008-5472.CAN-11-1515; Holford J, 1998, BRIT J CANCER, V77, P366, DOI 10.1038/bjc.1998.59; Jaiswal BS, 2018, CLIN CANCER RES, V24, P4044, DOI 10.1158/1078-0432.CCR-17-3674; Jha S, 2016, MOL CANCER THER, V15, P548, DOI 10.1158/1535-7163.MCT-15-0172; Johnson DB, 2014, J CLIN ONCOL, V32, P3697, DOI 10.1200/JCO.2014.57.3535; Jokinen E, 2015, THER ADV MED ONCOL, V7, P170, DOI 10.1177/1758834015571111; Juric D, 2015, NATURE, V518, P240, DOI 10.1038/nature13948; Kaserer T, 2018, CELL CHEM BIOL, V25, P1359, DOI 10.1016/j.chembiol.2018.07.013; Konieczkowski DJ, 2018, CANCER CELL, V33, P801, DOI 10.1016/j.ccell.2018.03.025; Kumar R, 2016, J PHARMACEUT BIOMED, V125, P140, DOI 10.1016/j.jpba.2016.03.036; Larkin J, 2014, NEW ENGL J MED, V371, P1867, DOI 10.1056/NEJMoa1408868; Li H, 2010, BIOINFORMATICS, V26, P589, DOI 10.1093/bioinformatics/btp698; Long GV, 2014, NEW ENGL J MED, V371, P1877, DOI 10.1056/NEJMoa1406037; Mancini M, 2016, SEMIN CELL DEV BIOL, V50, P164, DOI 10.1016/j.semcdb.2015.09.018; Martinelli E, 2013, INT J CANCER, V133, P2089, DOI 10.1002/ijc.28236; Migliardi G, 2012, CLIN CANCER RES, V18, P2515, DOI 10.1158/1078-0432.CCR-11-2683; Morris EJ, 2013, CANCER DISCOV, V3, P742, DOI 10.1158/2159-8290.CD-13-0070; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Oddo D, 2016, CANCER RES, V76, P4504, DOI 10.1158/0008-5472.CAN-16-0396; Petigny-Lechartier C, 2017, MOL CANCER THER, V16, P102, DOI 10.1158/1535-7163.MCT-16-0342; Raynaud FI, 2007, CANCER RES, V67, P5840, DOI 10.1158/0008-5472.CAN-06-4615; Raynaud FI, 2009, MOL CANCER THER, V8, P1725, DOI 10.1158/1535-7163.MCT-08-1200; Ren DC, 2010, SCIENCE, V330, P1390, DOI 10.1126/science.1190217; ROY S, 2010, J MOL SIGNAL, V5, DOI DOI 10.1186/1750-2187-5-10; Sale MJ, 2013, BIOCHEM J, V450, P285, DOI 10.1042/BJ20121212; Samatar AA, 2014, NAT REV DRUG DISCOV, V13, P928, DOI 10.1038/nrd4281; Solit DB, 2006, NATURE, V439, P358, DOI 10.1038/nature04304; Su YW, 2018, BIOCHEM PHARMACOL, V148, P13, DOI 10.1016/j.bcp.2017.11.022; Sullivan RJ, 2018, CANCER DISCOV, V8, P184, DOI 10.1158/2159-8290.CD-17-1119; Wagle N, 2014, CANCER DISCOV, V4, P61, DOI 10.1158/2159-8290.CD-13-0631; Workman P, 2013, CURR OPIN PHARMACOL, V13, P486, DOI 10.1016/j.coph.2013.06.004; Yang JY, 2008, NAT CELL BIOL, V10, P138, DOI 10.1038/ncb1676; Yang WS, 2008, NAT CELL BIOL, V10, P125, DOI 10.1038/ncb0208-125; Yap TA, 2012, ANNU REV PHARMACOL, V52, P549, DOI 10.1146/annurev-pharmtox-010611-134532; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zhao YJ, 2014, NAT REV CLIN ONCOL, V11, P385, DOI 10.1038/nrclinonc.2014.83; Zunder ER, 2008, CANCER CELL, V14, P180, DOI 10.1016/j.ccr.2008.06.014	62	17	17	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2019	38	25					5076	5090		10.1038/s41388-019-0780-z	http://dx.doi.org/10.1038/s41388-019-0780-z			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IE1KY	30905967	hybrid, Green Published			2022-12-17	WOS:000472145900014
J	Zhao, GX; Xu, YY; Weng, SQ; Zhang, S; Chen, Y; Shen, XZ; Dong, L; Chen, S				Zhao, Guang-Xi; Xu, Ying-Ying; Weng, Shu-Qiang; Zhang, Si; Chen, Ying; Shen, Xi-Zhong; Dong, Ling; Chen, She			CAPS1 promotes colorectal cancer metastasis via Snail mediated epithelial mesenchymal transformation	ONCOGENE			English	Article							CA2+-DEPENDENT ACTIVATOR PROTEIN; E-CADHERIN; CELLS REVEALS; TUMOR-CELLS; SECRETION; TRANSITION; EXPRESSION; INVASION; SYSTEM; EMT	Colorectal cancer (CRC) is a common gastrointestinal cancer with high mortality rate mostly due to metastasis. Ca2+-dependent activator protein for secretion 1 (CAPS1) was originally identified as a soluble factor that reconstitutes Ca2+-dependent secretion. In this study, we discovered a novel role of CAPS1 in CRC metastasis. CAPS1 is frequently up-regulated in CRC tissues. Increased CAPS1 expression is associated with frequent metastasis and poor prognosis of CRC patients. Overexpression of CAPS1 promotes CRC cell migration and invasion in vitro, as well as liver metastasis in vivo, without affecting cell proliferation. CAPS1 induces epithelial-mesenchymal transition (EMT), including decreased E-cadherin and ZO-1, epithelial marker expression, and increased N-cadherin and Snail, mesenchymal marker expression. Snail knockdown reversed CAPS1-induced EMT, cell migration and invasion. This result indicates that Snail is required for CAPS1-mediated EMT process and metastasis in CRC. Furthermore, CAPS1 can bind with Septin2 and p85 (subunit of PI3K). LY294002 and wortmanin, PI3K/Akt inhibitors, can abolish CAPS1-induced increase of Akt/GSK3 beta activity, as well as increase of Snail protein level. Taken together, CAPS1 promotes colorectal cancer metastasis through PI3K/Akt/GSK3 beta/Snail signal pathway-mediated EMT process.	[Zhao, Guang-Xi; Weng, Shu-Qiang; Shen, Xi-Zhong; Dong, Ling] Fudan Univ, Zhongshan Hosp, Shanghai Inst Liver Dis, Dept Gastroenterol & Hepatol, Shanghai 200032, Peoples R China; [Zhao, Guang-Xi; Xu, Ying-Ying; Zhang, Si; Chen, She] Fudan Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Key Lab Glycoconjugate Res,Minist Publ Hlth, Shanghai 200032, Peoples R China; [Chen, Ying] Fudan Univ, Sch Basic Med Sci, Dept Physiol & Pathophysiol, Shanghai 200032, Peoples R China	Fudan University; Fudan University; Fudan University	Shen, XZ; Dong, L (corresponding author), Fudan Univ, Zhongshan Hosp, Shanghai Inst Liver Dis, Dept Gastroenterol & Hepatol, Shanghai 200032, Peoples R China.; Chen, S (corresponding author), Fudan Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Key Lab Glycoconjugate Res,Minist Publ Hlth, Shanghai 200032, Peoples R China.	shen.xizhong@zs-hospital.sh.cn; dong.ling@zs-hospital.sh.cn; shechen@fudan.edu.cn	zhang, si/AAG-9094-2021	zhang, Si/0000-0002-5682-4995	National Natural Science Foundation of China (NSFC) [81672334, 81772615, 81572686, 81772968, 81573423, 81770137, 81672720]; Shanghai Science and Technology Commission [15410710100, 16ZR1406100]	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Shanghai Science and Technology Commission(Shanghai Science & Technology CommitteeScience & Technology Commission of Shanghai Municipality (STCSM))	This work was supported by the National Natural Science Foundation of China (NSFC) (81672334, 81772615, 81572686, 81772968, 81573423, 81770137, 81672720) and Shanghai Science and Technology Commission (15410710100, 16ZR1406100).	Abbey M, 2016, SCI REP-UK, V6, DOI 10.1038/srep20007; Agarwal E, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-145; Angelis D, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00122; Ann K, 1997, J BIOL CHEM, V272, P19637, DOI 10.1074/jbc.272.32.19637; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Tang BL, 2015, MOL MEMBR BIOL, V32, P120, DOI 10.3109/09687688.2015.1079934; Cao H, 2015, PATHOL RES PRACT, V211, P557, DOI 10.1016/j.prp.2015.05.010; Cao LQ, 2015, CANCER LETT, V359, P127, DOI 10.1016/j.canlet.2015.01.004; Chen L, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0534-9; Chen T, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01024-2; Chen XF, 2012, MOL BIOL REP, V39, P3549, DOI 10.1007/s11033-011-1128-0; Garcia Z, 2006, EMBO J, V25, P4740, DOI 10.1038/sj.emboj.7601324; Guaita S, 2002, J BIOL CHEM, V277, P39209, DOI 10.1074/jbc.M206400200; Hahn S, 2013, EMBO J, V32, P3079, DOI 10.1038/emboj.2013.236; Hawk ET, 2005, J CLIN ONCOL, V23, P378, DOI 10.1200/JCO.2005.08.097; HAY JC, 1992, J CELL BIOL, V119, P139, DOI 10.1083/jcb.119.1.139; Hosono M, 2016, NEUROSCI LETT, V617, P232, DOI 10.1016/j.neulet.2016.02.035; Huang XT, 2018, CELL PHYSIOL BIOCHEM, V47, P590, DOI 10.1159/000490015; Huang YW, 2006, FEBS J, V273, P3248, DOI 10.1111/j.1742-4658.2006.05333.x; Im HJ, 2016, CANCER RES, V76, P1698, DOI 10.1158/0008-5472.CAN-15-2114; James DJ, 2009, P NATL ACAD SCI USA, V106, P17308, DOI 10.1073/pnas.0900755106; Do K, 2015, INVEST NEW DRUG, V33, P720, DOI 10.1007/s10637-015-0212-z; Koch H, 2000, BIOCHEM J, V349, P247, DOI 10.1042/0264-6021:3490247; Leipe DD, 2002, J MOL BIOL, V317, P41, DOI 10.1006/jmbi.2001.5378; Liu TT, 2011, ACTA BIOCH BIOPH SIN, V43, P542, DOI 10.1093/abbs/gmr044; Lu LL, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/5874127; Luo W, 2018, PHYTOTHER RES, V32, P2009, DOI 10.1002/ptr.6132; Mali AV, 2018, CANCER BIOL MED, V15, P137, DOI 10.20892/j.issn.2095-3941.2018.0012; Mathias RA, 2009, J PROTEOME RES, V8, P2827, DOI 10.1021/pr8010974; Miller S, 2011, NEURO-ONCOLOGY, V13, P866, DOI 10.1093/neuonc/nor070; Mundade Rasika, 2014, Oncoscience, V1, P400; Nagano K, 2015, INT J BIOCHEM CELL B, V62, P62, DOI 10.1016/j.biocel.2015.02.013; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Pemberton JG, 2014, GEN COMP ENDOCR, V205, P268, DOI 10.1016/j.ygcen.2014.03.011; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Price TJ, 2014, LANCET ONCOL, V15, P569, DOI 10.1016/S1470-2045(14)70118-4; Rettig J, 2002, SCIENCE, V298, P781, DOI 10.1126/science.1075375; Rokavec M, 2014, J CLIN INVEST, V124, P1853, DOI 10.1172/JCI73531; Sadakata T, 2007, J HISTOCHEM CYTOCHEM, V55, P301, DOI 10.1369/jhc.6A7033.2006; Sanchez-Tillo E, 2012, CELL MOL LIFE SCI, V69, P3429, DOI 10.1007/s00018-012-1122-2; Shiozaki H, 1996, CANCER, V77, P1605, DOI 10.1002/(SICI)1097-0142(19960415)77:8+<1605::AID-CNCR4>3.3.CO;2-R; Smit MA, 2009, MOL CELL BIOL, V29, P3722, DOI 10.1128/MCB.01164-08; Tanaka T, 2017, J CELL PHYSIOL, V232, P939, DOI 10.1002/jcp.25619; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thuault S, 2008, J BIOL CHEM, V283, P33437, DOI 10.1074/jbc.M802016200; Vu T, 2017, CANCERS, V9, DOI 10.3390/cancers9120171; VanSaun MN, 2009, AM J PATHOL, V175, P355, DOI 10.2353/ajpath.2009.080703; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; WALENT JH, 1992, CELL, V70, P765, DOI 10.1016/0092-8674(92)90310-9; Wang JM, 2015, ONCOTARGET, V6, P27427, DOI 10.18632/oncotarget.4861; Wang YD, 2018, EUR J PHARMACOL, V834, P45, DOI 10.1016/j.ejphar.2018.07.006; Wu LG, 2014, ANNU REV PHYSIOL, V76, P301, DOI 10.1146/annurev-physiol-021113-170305; Xu DC, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0547-4; Xue RY, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17101626; Zhang Y, 2017, MOL CARCINOGEN, V56, P272, DOI 10.1002/mc.22491; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	57	17	19	0	16	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	2019	38	23					4574	4589		10.1038/s41388-019-0740-7	http://dx.doi.org/10.1038/s41388-019-0740-7			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IB4KM	30742066				2022-12-17	WOS:000470240300010
J	Marchand, B; Pitarresi, JR; Reichert, M; Suzuki, K; Laczko, D; Rustgi, AK				Marchand, Benoit; Pitarresi, Jason R.; Reichert, Maximilian; Suzuki, Kensuke; Laczko, Dorottya; Rustgi, Anil K.			PRRX1 isoforms cooperate with FOXM1 to regulate the DNA damage response in pancreatic cancer cells	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; HOMEOBOX GENE; TRANSCRIPTION FACTORS; METASTATIC COLONIZATION; BREAST-CANCER; COMET ASSAY; EXPRESSION; PRX2; INHIBITION; REPAIR	PRRX1 is a homeodomain transcriptional factor, which has two isoforms, PRXX1A and PRRX1B. The PRRX1 isoforms have been demonstrated to be important in pancreatic cancer, especially in the regulation of epithelial-to-mesenchymal transition (EMT) in Pancreatic Ductal Adenocarcinoma (PDAC) and of mesenchymal-to-epithelial transition (MET) in liver metastasis. In order to determine the functional underpinnings of PRRX1 and its isoforms, we have unraveled a new interplay between PRRX1 and the FOXM1 transcriptional factors. Our detailed biochemical analysis reveals the direct physical interaction between PRRX1 and FOXM1 proteins that requires the PRRX1A/B 200-222/217 amino acid (aa) region and the FOXM1 Forkhead domain. Additionally, we demonstrate the cooperation between PRRX1 and FOXM1 in the regulation of FOXM1-dependent transcriptional activity. Moreover, we establish FOXM1 as a critical downstream target of PRRX1 in pancreatic cancer cells. We demonstrate a novel role for PRRX1 in the regulation of genes involved in DNA repair pathways. Indeed, we show that expression of PRRX1 isoforms may limit the induction of DNA damage in pancreatic cancer cells. Finally, we demonstrate that targeting FOXM1 with the small molecule inhibitor FDI6 suppress pancreatic cancer cell proliferation and induces their apoptotic cell death. FDI6 sensitizes pancreatic cancer cells to Etoposide and Gemcitabine induced apoptosis. Our data provide new insights into PRRX1's involvement in regulating DNA damage and provide evidence of a possible PRRX1-FOXM1 axis that is critical for PDAC cells.	[Marchand, Benoit; Pitarresi, Jason R.; Reichert, Maximilian; Suzuki, Kensuke; Laczko, Dorottya; Rustgi, Anil K.] Univ Penn, Perelman Sch Med, Dept Med, Div Gastroenterol, Philadelphia, PA 19104 USA; [Marchand, Benoit; Pitarresi, Jason R.; Suzuki, Kensuke; Laczko, Dorottya; Rustgi, Anil K.] Univ Penn, Abramson Canc Ctr, Perelman Sch Med, Philadelphia, PA 19104 USA; [Reichert, Maximilian] Tech Univ Munich, Med Klin 2, D-81675 Munich, Germany; [Reichert, Maximilian; Rustgi, Anil K.] Univ Penn, Perelman Sch Med, Dept Genet, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Technical University of Munich; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munich; University of Pennsylvania; Pennsylvania Medicine	Rustgi, AK (corresponding author), Univ Penn, Perelman Sch Med, Dept Med, Div Gastroenterol, Philadelphia, PA 19104 USA.; Rustgi, AK (corresponding author), Univ Penn, Abramson Canc Ctr, Perelman Sch Med, Philadelphia, PA 19104 USA.; Rustgi, AK (corresponding author), Univ Penn, Perelman Sch Med, Dept Genet, Philadelphia, PA 19104 USA.	anil2@pennmedicine.upenn.edu	Reichert, Maximilian/GOH-1246-2022	Marchand, Benoit/0000-0001-9302-6688	NIH/NIDDK [R01 DK060694]; Center for Molecular Studies in Digestive and Liver Diseases [NIH P30 DK050306]; American Cancer Society; Fonds de recherche en sante du Quebec [P-Marchand-35978]; National Pancreas Foundation; German Cancer Aid Foundation (Max Eder Program, Deutsche Krebshilfe) [111273]; AGA-Actavis Research Award in Pancreatic Disorders; NIH loan repayment program; NCI [F32 CA221094]; NATIONAL CANCER INSTITUTE [F32CA221094] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007066, R01DK060694, P30DK050306] Funding Source: NIH RePORTER	NIH/NIDDK(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Center for Molecular Studies in Digestive and Liver Diseases; American Cancer Society(American Cancer Society); Fonds de recherche en sante du Quebec(Fonds de la Recherche en Sante du Quebec); National Pancreas Foundation; German Cancer Aid Foundation (Max Eder Program, Deutsche Krebshilfe); AGA-Actavis Research Award in Pancreatic Disorders; NIH loan repayment program(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We are grateful to Dr. Zheng Fu (Virginia Commonwealth University) for providing the 6xFOXM1 luciferase reporter construct. We thank Dr. Kaori Ihida-Stansbury (University of Pennsylvania) for the PRRX1 wild type and Knockout mouse embryonic fibroblasts (MEFs). The Tenascin-C (TN7) luciferase construct was kindly provided by Dr. Edward E. Morrisey (University of Pennsylvania). We are thankful to the Molecular Pathology and Imaging Core, the Cell Culture and iPS Core and the HumanMicrobial Analytic and Repository Core Facilities. This work was supported by the NIH/NIDDK R01 DK060694 (BM, MR, JRP, AKR), the Center for Molecular Studies in Digestive and Liver Diseases (NIH P30 DK050306), the American Cancer Society, Fonds de recherche en sante du Quebec P-Marchand-35978 (BM), National Pancreas Foundation (MR), German Cancer Aid Foundation (Max Eder Program, Deutsche Krebshilfe 111273 to MR), AGA-Actavis Research Award in Pancreatic Disorders (MR), NCI F32 CA221094 (JRP) and the NIH loan repayment program (JRP).	American Cancer Society, 2018, CANC FACTS FIG 2018; Bailey P, 2016, NATURE, V531, P47, DOI 10.1038/nature16965; Baranski OA, 2015, CELL PROLIFERAT, V48, P105, DOI 10.1111/cpr.12153; Bergwerff M, 2000, VIRCHOWS ARCH, V436, P12, DOI 10.1007/PL00008193; Berry FB, 2006, HUM MOL GENET, V15, P905, DOI 10.1093/hmg/ddl008; Bhat UG, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006593; Bhat UG, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005592; Copertino DW, 1997, P NATL ACAD SCI USA, V94, P1846, DOI 10.1073/pnas.94.5.1846; Ewald B, 2007, MOL CANCER THER, V6, P1239, DOI 10.1158/1535-7163.MCT-06-0633; Foucher I, 2003, DEVELOPMENT, V130, P1867, DOI 10.1242/dev.00414; Gartel AL, 2017, CANCER RES, V77, P3135, DOI 10.1158/0008-5472.CAN-16-3566; Golson ML, 2016, DEVELOPMENT, V143, P4558, DOI 10.1242/dev.112672; Gormally MV, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6165; Guo JB, 2015, MED ONCOL, V32, DOI 10.1007/s12032-014-0393-x; Guo Y, 2002, P NATL ACAD SCI USA, V99, P3663, DOI 10.1073/pnas.062041099; Gyori BM, 2014, REDOX BIOL, V2, P457, DOI 10.1016/j.redox.2013.12.020; Halasi M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031761; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Huang C, 2014, CLIN CANCER RES, V20, P1477, DOI 10.1158/1078-0432.CCR-13-2311; Huang C, 2012, CANCER RES, V72, P655, DOI 10.1158/0008-5472.CAN-11-3102; Ihida-Stansbury K, 2004, CIRC RES, V94, P1507, DOI 10.1161/01.RES.0000130656.72424.20; Jones FS, 2001, CIRC RES, V89, P131, DOI 10.1161/hh1401.093582; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; KERN MJ, 1992, NUCLEIC ACIDS RES, V20, P5189, DOI 10.1093/nar/20.19.5189; KERN MJ, 1994, GENOMICS, V19, P334, DOI 10.1006/geno.1994.1066; Khongkow P, 2014, ONCOGENE, V33, P4144, DOI 10.1038/onc.2013.457; Kong XY, 2013, CANCER RES, V73, P3987, DOI 10.1158/0008-5472.CAN-12-3859; Kwok JMM, 2010, MOL CANCER RES, V8, P24, DOI 10.1158/1541-7786.MCR-09-0432; Laczko D, 2017, AM J PATHOL, V187, P1787, DOI 10.1016/j.ajpath.2017.04.013; Lu MF, 1999, DEV BIOL, V205, P145, DOI 10.1006/dbio.1998.9116; Lu MF, 1999, DEVELOPMENT, V126, P495; Major ML, 2004, MOL CELL BIOL, V24, P2649, DOI 10.1128/MCB.24.7.2649-2661.2004; Marchand B, 2015, J BIOL CHEM, V290, P5592, DOI 10.1074/jbc.M114.616714; Marchand B, 2012, CARCINOGENESIS, V33, P529, DOI 10.1093/carcin/bgr309; Marshak S, 2000, MOL CELL BIOL, V20, P7583, DOI 10.1128/MCB.20.20.7583-7590.2000; MARTIN JF, 1995, GENE DEV, V9, P1237, DOI 10.1101/gad.9.10.1237; Monteiro LJ, 2013, ONCOGENE, V32, P4634, DOI 10.1038/onc.2012.491; Norris RA, 2001, DNA CELL BIOL, V20, P89, DOI 10.1089/104454901750070292; Norris RA, 2001, J BIOL CHEM, V276, P26829, DOI 10.1074/jbc.M100239200; Ocana OH, 2012, CANCER CELL, V22, P709, DOI 10.1016/j.ccr.2012.10.012; Olive PL, 2006, NAT PROTOC, V1, P23, DOI 10.1038/nprot.2006.5; Park YY, 2012, CARCINOGENESIS, V33, P1843, DOI 10.1093/carcin/bgs167; Qu SM, 1999, DEVELOPMENT, V126, P359; Radhakrishnan SK, 2006, CANCER RES, V66, P9731, DOI 10.1158/0008-5472.CAN-06-1576; Rahib L, 2014, CANCER RES, V74, P2913, DOI 10.1158/0008-5472.CAN-14-0155; Reichert M, 2013, GENE DEV, V27, P288, DOI 10.1101/gad.204453.112; Rhim AD, 2012, CELL, V148, P349, DOI 10.1016/j.cell.2011.11.025; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Takahashi Y, 2013, BRIT J CANCER, V109, P307, DOI 10.1038/bjc.2013.339; Takano S, 2016, GENE DEV, V30, P233, DOI 10.1101/gad.263327.115; Tan YJ, 2007, MOL CELL BIOL, V27, P1007, DOI 10.1128/MCB.01068-06; ten Berge D, 1998, DEVELOPMENT, V125, P3831; Tucker SC, 1999, J BIOL CHEM, V274, P32325, DOI 10.1074/jbc.274.45.32325; Waddell N, 2015, NATURE, V518, P495, DOI 10.1038/nature14169; Zhang N, 2012, CLIN CANCER RES, V18, P5961, DOI 10.1158/1078-0432.CCR-12-0039; Zhang N, 2011, CANCER CELL, V20, P427, DOI 10.1016/j.ccr.2011.08.016; Zhang YH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023069; Zheng L, 2015, INT J CLIN EXP PATHO, V8, P10534; Zona S, 2014, BBA-GENE REGUL MECH, V1839, P1316, DOI 10.1016/j.bbagrm.2014.09.016	60	17	17	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 30	2019	38	22					4325	4339		10.1038/s41388-019-0725-6	http://dx.doi.org/10.1038/s41388-019-0725-6			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IA1RB	30705403	Green Accepted			2022-12-17	WOS:000469339100009
J	Carrero, I; Liu, HC; Sikora, AG; Milosavljevic, A				Carrero, Ivenise; Liu, Hsuan-Chen; Sikora, Andrew G.; Milosavljevic, Aleksandar			Histoepigenetic analysis of HPV- and tobacco-associated head and neck cancer identifies both subtype-specific and common therapeutic targets despite divergent microenvironments	ONCOGENE			English	Article							SQUAMOUS-CELL CARCINOMA; DNA METHYLATION DATA; HUMAN-PAPILLOMAVIRUS; GENE-EXPRESSION; POSITIVE HEAD; SURVIVAL; GENOME; EPIDEMIOLOGY; SIGNATURE; MUTATION	Although head and neck squamous cell carcinoma (HNSCC) has in the past been largely associated with tobacco use, human papillomavirus (HPV+) oropharynx cancer has in recent years emerged as the fastest growing type of HNSCC. Patients with HPV+ HNSCC have a better prognosis; however, the 5-year survival for both HPV+ and HPV- subtypes with recurrent or metastatic disease is poor. To gain insights into the tumor microenvironments of both HNSCC subtypes and identify potential therapeutic targets, we performed epigenomic deconvolution on 580 HNSCC samples from the TCGA dataset. Deconvolution revealed distinct molecular and histoepigenetic profiles of the two tumor subtypes, including their cellular composition, epigenomic profiles and gene expression for constituent cell types, and potential cancer cell-specific targets. Our analyses show that high abundance of both CD8 T-cells and B-cells explains better prognosis in HPV+ HNSCC. Deconvolution of gene expression profiles revealed higher expression of the immunotherapy target PD-1 in HPV+ immune cells compared to HPV- cells, suggesting that HPV+ tumors may preferentially benefit from PD-1 targeted therapy. Further analyses identified HPV+ and HPV- cancer cell surface proteins that can also serve as potential targets for therapy. Specifically, Wnt pathway receptor ROR2 is preferentially overexpressed in HPV+ subtypes, suggesting opportunities for development of targeted therapy based on HPV status. In summary, the comprehensive molecular and histoepigenetic analysis of tumor microenvironments by epigenomic deconvolution reveals potential novel biomarkers and targets for precision therapy of HNSCC.	[Carrero, Ivenise; Milosavljevic, Aleksandar] Baylor Coll Med, Mol & Human Genet Dept, Houston, TX 77030 USA; [Carrero, Ivenise; Milosavljevic, Aleksandar] Baylor Coll Med, Epigenome Ctr, Houston, TX 77030 USA; [Liu, Hsuan-Chen] Baylor Coll Med, Translat Biol & Mol Med Program, Houston, TX 77030 USA; [Liu, Hsuan-Chen; Sikora, Andrew G.] Baylor Coll Med, Dept Otolaryngol Head & Neck Surg, Houston, TX 77030 USA; [Milosavljevic, Aleksandar] Baylor Coll Med, Program Quantitat & Computat Biosci, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Milosavljevic, A (corresponding author), Baylor Coll Med, Mol & Human Genet Dept, Houston, TX 77030 USA.; Milosavljevic, A (corresponding author), Baylor Coll Med, Epigenome Ctr, Houston, TX 77030 USA.; Sikora, AG (corresponding author), Baylor Coll Med, Dept Otolaryngol Head & Neck Surg, Houston, TX 77030 USA.; Milosavljevic, A (corresponding author), Baylor Coll Med, Program Quantitat & Computat Biosci, Houston, TX 77030 USA.	Andrew.Sikora@bcm.edu; amilosav@bcm.edu		Liu, Hsuan-Chen/0000-0001-7857-0204	Common Fund of the National Institutes of Health (NIH) [5U54 DA036134]; Carolyn Weiss Law Foundation for Academic Excellence; Baylor College of Medicine Dan L. Duncan Cancer Center Pilot Grant; NATIONAL INSTITUTE ON DRUG ABUSE [U54DA036134] Funding Source: NIH RePORTER	Common Fund of the National Institutes of Health (NIH); Carolyn Weiss Law Foundation for Academic Excellence; Baylor College of Medicine Dan L. Duncan Cancer Center Pilot Grant; NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This work was supported by a grant from the Common Fund of the National Institutes of Health (NIH) (5U54 DA036134) (to A. M.), the Carolyn Weiss Law Foundation for Academic Excellence (to AS), and the Baylor College of Medicine Dan L. Duncan Cancer Center Pilot Grant (to AS).	Afghahi A, 2015, CANCER J, V21, P294, DOI 10.1097/PPO.0000000000000135; Ahmed S, 2015, BREAST CANCER-TOKYO, V22, P101, DOI 10.1007/s12282-015-0587-x; Ang KK, 2010, NEW ENGL J MED, V363, P24, DOI 10.1056/NEJMoa0912217; Aran D, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9971; Argiris A, 2009, CANCER-AM CANCER SOC, V115, P4504, DOI 10.1002/cncr.24528; Assenov Y, 2014, NAT METHODS, V11, P1138, DOI [10.1038/NMETH.3115, 10.1038/nmeth.3115]; Bausch-Fluck D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121314; Becht E, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1070-5; Becht E, 2016, ADV IMMUNOL, V130, P95, DOI 10.1016/bs.ai.2015.12.002; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Castiglioni P, 2005, EUR J IMMUNOL, V35, P1360, DOI 10.1002/eji.200425530; Chaturvedi AK, 2011, J CLIN ONCOL, V29, P4294, DOI 10.1200/JCO.2011.36.4596; Chen AX, 2016, INT J CLIN EXP PATHO, V9, P10981; Clements WM, 2002, CANCER RES, V62, P3503; Dalen AGD, 2003, INT J CANCER, V103, P768, DOI 10.1002/ijc.10903; Debey S, 2004, PHARMACOGENOMICS J, V4, P193, DOI 10.1038/sj.tpj.6500240; Esposti DD, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0419-z; Fakhry C, 2008, JNCI-J NATL CANCER I, V100, P261, DOI 10.1093/jnci/djn011; Ford CE, 2013, INT J CANCER, V133, P779, DOI 10.1002/ijc.27984; Forster MD, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00310; Ganguly KK, 2013, CELL ADHES MIGR, V7, P251, DOI 10.4161/cam.23840; Gentles AJ, 2015, NAT MED, V21, P938, DOI 10.1038/nm.3909; Gutman DA, 2013, J AM MED INFORM ASSN, V20, P1091, DOI 10.1136/amiajnl-2012-001469; Houseman EA, 2014, CANCER INFORM, V13, P53, DOI 10.4137/CIN.S13980; Houseman EA, 2014, BIOINFORMATICS, V30, P1431, DOI 10.1093/bioinformatics/btu029; Ishikawa N, 2007, CANCER RES, V67, P11601, DOI 10.1158/0008-5472.CAN-07-3243; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Kamburov A, 2011, NUCLEIC ACIDS RES, V39, pD712, DOI 10.1093/nar/gkq1156; Knights Alexander J, 2012, Trends Cancer Res, V8, P61; Kong HK, 2012, J BIOL CHEM, V287, P38889, DOI 10.1074/jbc.M112.394270; Koshizuka K, 2018, ONCOTARGET, V9, P3663, DOI 10.18632/oncotarget.23194; Lawrence MS, 2015, NATURE, V517, P576, DOI 10.1038/nature14129; Li Y, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-S5-S11; Litwin TR, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9080206; Lleras RA, 2013, CLIN CANCER RES, V19, P5444, DOI 10.1158/1078-0432.CCR-12-3280; Lonsdale J, 2013, NAT GENET, V45, P580, DOI 10.1038/ng.2653; Mandal R, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.89829; McCormack PL, 2008, DRUGS, V68, P487, DOI 10.2165/00003495-200868040-00009; McKaig RG, 1998, HEAD NECK-J SCI SPEC, V20, P250, DOI 10.1002/(SICI)1097-0347(199805)20:3<250::AID-HED11>3.3.CO;2-2; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Mroz Edmund A, 2016, World J Otorhinolaryngol Head Neck Surg, V2, P60, DOI 10.1016/j.wjorl.2016.05.007; Nulton TJ, 2017, ONCOTARGET, V8, P17684, DOI 10.18632/oncotarget.15179; Onuchic V, 2016, CELL REP, V17, P2075, DOI 10.1016/j.celrep.2016.10.057; Orentas RJ, 2012, FRONT ONCOL, V2, DOI [10.3389/FONC.2012.00194/ABSTRACT, DOI 10.3389/FONC.2012.00194/ABSTRACT]; Organization WH, 2014, REV CANC MED WHO LIS, P1; Ragin CCR, 2007, J DENT RES, V86, P104, DOI 10.1177/154405910708600202; Riaz N, 2014, GENES DIS, V1, P75, DOI 10.1016/j.gendis.2014.07.002; Rieke DT, 2016, ONCOL RES TREAT, V39, P780, DOI 10.1159/000452432; Sakamoto T, 2017, ORAL ONCOL, V69, P15, DOI 10.1016/j.oraloncology.2017.03.019; Seguin L, 2015, TRENDS CELL BIOL, V25, P234, DOI 10.1016/j.tcb.2014.12.006; Seiwert TY, 2015, CLIN CANCER RES, V21, P632, DOI 10.1158/1078-0432.CCR-13-3310; Smith EM, 2008, ORAL ONCOL, V44, P133, DOI 10.1016/j.oraloncology.2007.01.010; Snell LM, 2017, TRENDS IMMUNOL, V38, P542, DOI 10.1016/j.it.2017.05.005; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tagliamonte M, 2014, HUM VACC IMMUNOTHER, V10, P3332, DOI 10.4161/21645515.2014.973317; Tong CCL, 2012, IMMUNOL RES, V54, P266, DOI 10.1007/s12026-012-8306-6; Voloshanenko O, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20641-5; Wang B, 2015, GENET MOL RES, V14, P17406, DOI 10.4238/2015.December.21.10; Wang JP, 2015, ONCOTARGET, V6, P18162, DOI 10.18632/oncotarget.4216; Yearley JH, 2017, CLIN CANCER RES, V23, P3158, DOI 10.1158/1078-0432.CCR-16-1761; Zhan T, 2017, ONCOGENE, V36, P1461, DOI 10.1038/onc.2016.304; Zhang YX, 2016, CLIN CANCER RES, V22, P4735, DOI 10.1158/1078-0432.CCR-16-0323	62	17	17	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 9	2019	38	19					3551	3568		10.1038/s41388-018-0659-4	http://dx.doi.org/10.1038/s41388-018-0659-4			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HX4OU	30655605	Green Published, hybrid			2022-12-17	WOS:000467379600001
J	Velez, MVL; Verhaegh, GW; Smit, F; Sedelaar, JPM; Schalken, JA				Velez, Maria V. Luna; Verhaegh, Gerald W.; Smit, Frank; Sedelaar, J. P. Michiel; Schalken, Jack A.			Suppression of prostate tumor cell survival by antisense oligonucleotide-mediated inhibition of AR-V7 mRNA synthesis	ONCOGENE			English	Article							ANDROGEN-RECEPTOR; SPLICE VARIANTS; POLY(ADP-RIBOSE) POLYMERASE; RESISTANT; CANCER; ENZALUTAMIDE; PREDICTION; THERAPY; FUSION; IDENTIFICATION	One of the mechanisms by which advanced prostate cancer develops resistance to androgen deprivation therapy is the elevated expression of C-terminally truncated androgen receptor (AR) variants. These variants, such as AR-V7, originate from aberrant splicing of the AR pre-mRNA and the inclusion of a cryptic exon containing a premature stop codon in the mRNA. The resulting loss of the ligand-binding domain allows AR-V7 to act as a constitutively active transcription factor. Here, we designed two antisense oligonucleotides (AONs) directed against cryptic splicing signals within the AR pre-mRNA. These two AONs, AON-ISE and AON-ESE, demonstrated high efficiency in silencing AR-V7 splicing without affecting full-length AR expression. The subsequent downregulation of AR-V7-target gene UBE2C was accompanied by inhibition of androgen-independent cell proliferation and induction of apoptosis in castration-resistant prostate cancer (CRPC)-derived cell line models 22Rv1, DuCaP, and VCaP. Our results show that splicing-directed AONs can efficiently prevent expression of AR-V7, providing an attractive new therapeutic option for the treatment of CRPC.	[Velez, Maria V. Luna; Verhaegh, Gerald W.; Sedelaar, J. P. Michiel; Schalken, Jack A.] Radboud Univ Nijmegen, Med Ctr, Radboud Inst Mol Life Sci, Dept Urol, Nijmegen, Netherlands; [Smit, Frank] MDxHealth, Nijmegen, Netherlands	Radboud University Nijmegen	Schalken, JA (corresponding author), Radboud Univ Nijmegen, Med Ctr, Radboud Inst Mol Life Sci, Dept Urol, Nijmegen, Netherlands.	Jack.Schalken@radboudumc.nl	Sedelaar, Michiel/L-4643-2015; Schalken, Jack A/B-1277-2014	Sedelaar, Michiel/0000-0002-3768-7374; Schalken, Jack A/0000-0001-8274-7797	NWO [022.003.007]	NWO(Netherlands Organization for Scientific Research (NWO))	The authors would like to thank Sophie Cools, Cornelius Jansen, and Mirjam de Weijert for their excellent technical assistance. We also would like to thank Dr. Kenneth J. Pienta M.D. from Johns Hopkins for kindly providing us with the DuCaP and VCaP cell lines. This work was sponsored by an NWO grant (Project number: 022.003.007).	Antonarakis ES, 2014, NEW ENGL J MED, V371, P1028, DOI 10.1056/NEJMoa1315815; Armstrong AJ, 2010, CLIN CANCER RES, V16, P203, DOI 10.1158/1078-0432.CCR-09-2514; Beer TM, 2017, LANCET ONCOL, V18, P1532, DOI 10.1016/S1470-2045(17)30605-8; Bianchini D, 2013, BRIT J CANCER, V109, P2579, DOI 10.1038/bjc.2013.619; Cai CM, 2011, CANCER CELL, V20, P457, DOI 10.1016/j.ccr.2011.09.001; Cao B, 2014, ONCOTARGET, V5, P1646, DOI 10.18632/oncotarget.1802; Cartegni L, 2003, NUCLEIC ACIDS RES, V31, P3568, DOI 10.1093/nar/gkg616; Chiriboga CA, 2016, NEUROLOGY, V86, P890, DOI 10.1212/WNL.0000000000002445; Chou CP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093934; Cornford P, 2017, EUR UROL, V71, P630, DOI 10.1016/j.eururo.2016.08.002; D'Amours D, 1998, RADIAT RES, V150, P3, DOI 10.2307/3579638; De Clercq E, 1969, Antimicrob Agents Chemother (Bethesda), V9, P187; Dehm SM, 2008, CANCER RES, V68, P5469, DOI 10.1158/0008-5472.CAN-08-0594; Ding Y, 2004, NUCLEIC ACIDS RES, V32, pW135, DOI 10.1093/nar/gkh449; Geary RS, 2015, ADV DRUG DELIVER REV, V87, P46, DOI 10.1016/j.addr.2015.01.008; Germain M, 1999, J BIOL CHEM, V274, P28379, DOI 10.1074/jbc.274.40.28379; Guo ZY, 2009, CANCER RES, V69, P2305, DOI 10.1158/0008-5472.CAN-08-3795; Hache M, 2016, J CHILD NEUROL, V31, P899, DOI 10.1177/0883073815627882; Havens MA, 2016, NUCLEIC ACIDS RES, V44, P6549, DOI 10.1093/nar/gkw533; Hebsgaard SM, 1996, NUCLEIC ACIDS RES, V24, P3439, DOI 10.1093/nar/24.17.3439; Hessels D, 2007, CLIN CANCER RES, V13, P5103, DOI 10.1158/1078-0432.CCR-07-0700; Hornberg E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019059; Hu R, 2012, CANCER RES, V72, P3457, DOI 10.1158/0008-5472.CAN-11-3892; Hu R, 2009, CANCER RES, V69, P16, DOI 10.1158/0008-5472.CAN-08-2764; KRONGRAD A, 1991, MOL CELL ENDOCRINOL, V76, P79, DOI 10.1016/0303-7207(91)90262-Q; Leyten GHJM, 2015, CLIN CANCER RES, V21, P3061, DOI 10.1158/1078-0432.CCR-14-3334; Li YM, 2013, CANCER RES, V73, P483, DOI 10.1158/0008-5472.CAN-12-3630; Liu LL, 2014, ONCOGENE, V33, P3140, DOI 10.1038/onc.2013.284; Manoharan M, 1999, BBA-GENE STRUCT EXPR, V1489, P117, DOI 10.1016/S0167-4781(99)00138-4; Mendell JR, 2016, ANN NEUROL, V79, P257, DOI 10.1002/ana.24555; Mostaghel EA, 2011, CLIN CANCER RES, V17, P5913, DOI 10.1158/1078-0432.CCR-11-0728; Moulder SL, 2008, CLIN CANCER RES, V14, P7909, DOI 10.1158/1078-0432.CCR-08-1104; Mounir Z, 2015, ONCOGENE, V34, P3815, DOI 10.1038/onc.2014.308; Nadiminty N, 2013, MOL CANCER THER, V12, P1629, DOI 10.1158/1535-7163.MCT-13-0027; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Sazani P, 2003, J CLIN INVEST, V112, P481, DOI 10.1172/JCI200319547; Scher HI, 2005, J CLIN ONCOL, V23, P8253, DOI 10.1200/JCO.2005.03.4777; Scoles DR, 2017, NATURE, V544, P362, DOI 10.1038/nature22044; Sedelaar JPM, 2009, PROSTATE, V69, P1724, DOI 10.1002/pros.21028; Smith PJ, 2006, HUM MOL GENET, V15, P2490, DOI 10.1093/hmg/ddl171; SPROAT BS, 1989, NUCLEIC ACIDS RES, V17, P3373, DOI 10.1093/nar/17.9.3373; Swayampakula AK, 2008, J CLIN ONCOL, V26, DOI 10.1200/jco.2008.26.15_suppl.11550; Tasfaout H, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15661; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Verhaart IEC, 2013, NUCLEIC ACID THER, V23, P228, DOI 10.1089/nat.2012.0398; Voit T, 2014, LANCET NEUROL, V13, P987, DOI 10.1016/S1474-4422(14)70195-4; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0; Wang JH, 2008, CANCER RES, V68, P8516, DOI 10.1158/0008-5472.CAN-08-1147; Wheeler TM, 2012, NATURE, V488, P111, DOI 10.1038/nature11362; Wraight CJ, 2000, NAT BIOTECHNOL, V18, P521, DOI 10.1038/75382; Yamamoto Y, 2015, CLIN CANCER RES, V21, P1675, DOI 10.1158/1078-0432.CCR-14-1108; Yeo GW, 2005, P NATL ACAD SCI USA, V102, P2850, DOI 10.1073/pnas.0409742102; Zhang XT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027970	53	17	17	2	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 9	2019	38	19					3696	3709		10.1038/s41388-019-0696-7	http://dx.doi.org/10.1038/s41388-019-0696-7			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HX4OU	30664691	Green Published, hybrid			2022-12-17	WOS:000467379600010
J	Huang, JF; Jiang, HY; Cai, H; Liu, Y; Zhu, YQ; Lin, SS; Hu, TT; Wang, TT; Yang, WJ; Xiao, B; Sun, SH; Ma, LY; Yin, HR; Wang, F				Huang, Jin-Feng; Jiang, Hong-Yue; Cai, Hui; Liu, Yan; Zhu, Yi-Qing; Lin, Sha-Sha; Hu, Ting-Ting; Wang, Tian-Tian; Yang, Wen-Jun; Xiao, Bang; Sun, Shu-Han; Ma, Li-Ye; Yin, Hui-Rong; Wang, Fang			Genome-wide screening identifies oncofetal lncRNA Ptn-dt promoting the proliferation of hepatocellular carcinoma cells by regulating the Ptn receptor	ONCOGENE			English	Article							LONG NONCODING RNA; ANAPLASTIC LYMPHOMA KINASE; MESSENGER-RNA; FETAL LIVER; PROTEIN HUR; CANCER; PLEIOTROPHIN; EXPRESSION; GROWTH; BETA	Oncofetal genes are genes that express abundantly in both fetal and tumor tissues yet downregulated or undetected in adult tissues, and can be used as tumor markers for cancer diagnosis and treatment. Meanwhile, long noncoding RNAs (lncRNAs) are known to play crucial roles in the pathogenesis of hepatocellular carcinoma (HCC), including tumor growth, proliferation, metastasis, invasion, and recurrence. We performed a genome-wide screening using microarrays to detect the lncRNA expression profiles in fetal livers, adult livers, and liver cancer tissues from mice to identify oncofetal lncRNAs in HCC. From the microarray data analysis, we identified lncRNA Ptn-dt as a possible oncofetal gene. Both in vitro and in vivo experiments results confirmed that overexpression of Ptn-dt significantly promoted the proliferation of mouse HCC cells. RNA pulldown assay showed that Ptn-dt could interact with the HuR protein. Interestingly, miR-96 binds with HuR to maintain its stability as well. Overexpression of lncRNA Ptn-dt led to the downregulation of miR-96, which might be due to the interaction between Ptn-dt and HuR. Meanwhile, previous studies have reported that Ptn can promote tumor growth and vascular abnormalization via anaplastic lymphoma kinase (Alk) signaling. In our study, we found that overexpression of Ptn-dt could promote the expression of Alk through repressing miR-96 via interacting with HuR, thus enhancing the biologic function of Ptn. In summary, a new oncofetal lncRNA Ptn-dt is identified, and it can promote the proliferation of HCC cells by regulating the HuR/miR-96/Alk pathway and Ptn-Alk axis.	[Huang, Jin-Feng; Liu, Yan; Zhu, Yi-Qing; Wang, Tian-Tian; Yang, Wen-Jun; Xiao, Bang; Sun, Shu-Han; Wang, Fang] Second Mil Med Univ, Dept Med Genet, Shanghai 200433, Peoples R China; [Huang, Jin-Feng; Wang, Tian-Tian; Sun, Shu-Han; Wang, Fang] Second Mil Med Univ, Changhai Hosp, Dept Clin Genet, Shanghai 200433, Peoples R China; [Jiang, Hong-Yue] Fudan Univ, Zhongshan Hosp, Dept Gastroenterol, Shanghai 200032, Peoples R China; [Cai, Hui; Ma, Li-Ye] Second Mil Med Univ, Changhai Hosp, Dept Gen Surg, Shanghai 200433, Peoples R China; [Lin, Sha-Sha; Hu, Ting-Ting; Yin, Hui-Rong] Second Mil Med Univ, Changhai Hosp, Ctr Reprod Med, Shanghai 200433, Peoples R China	Naval Medical University; Naval Medical University; Fudan University; Naval Medical University; Naval Medical University	Wang, F (corresponding author), Second Mil Med Univ, Dept Med Genet, Shanghai 200433, Peoples R China.; Wang, F (corresponding author), Second Mil Med Univ, Changhai Hosp, Dept Clin Genet, Shanghai 200433, Peoples R China.; Ma, LY (corresponding author), Second Mil Med Univ, Changhai Hosp, Dept Gen Surg, Shanghai 200433, Peoples R China.; Yin, HR (corresponding author), Second Mil Med Univ, Changhai Hosp, Ctr Reprod Med, Shanghai 200433, Peoples R China.	malydr@163.com; topyin@126.com; wfsjz@163.com		, Jin-Feng/0000-0002-4757-3418; Jiang, Hongyue/0000-0001-8783-7759	National Key Basic Research Program (973 project) from the Ministry of Science and Technology of China [2015CB554004]; National Natural Science Foundation of China [81672775, 81330037]; Natural Science Foundation of Shanghai [15XD1504500]	National Key Basic Research Program (973 project) from the Ministry of Science and Technology of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Shanghai(Natural Science Foundation of Shanghai)	We thank Dr. Li Su for the help in flow cytometry technique, and the Institutional Animal Care and Use Committee (the Second Military Medical University, Shanghai, China) for the ethics approval of animal studies. Some elements of Fig. 6 are from LES LABORATOIRES SERVIER. This work was supported by grants from the National Key Basic Research Program (973 project) (2015CB554004) from the Ministry of Science and Technology of China, the National Natural Science Foundation of China (81672775 and 81330037) and the Natural Science Foundation of Shanghai (15XD1504500).	BECKER D, 2012, MOL CANCER, V11; BERGSTRAND CG, 1956, SCAND J CLIN LAB INV, V8, P174, DOI 10.3109/00365515609049266; Boyerinas B, 2008, CANCER RES, V68, P2587, DOI 10.1158/0008-5472.CAN-08-0264; Brennan CM, 2001, CELL MOL LIFE SCI, V58, P266, DOI 10.1007/PL00000854; Cao CH, 2015, GASTROENTEROLOGY, V148, P415, DOI 10.1053/j.gastro.2014.10.012; Cooper C, 2009, NUCLEIC ACIDS RES, V37, P4518, DOI 10.1093/nar/gkp441; Coulouarn C, 2005, J HEPATOL, V42, P860, DOI 10.1016/j.jhep.2005.01.027; Filipowicz W, 2011, PROG DRUG RES, V67, P221, DOI 10.1007/978-3-7643-8989-5_11; Grzelinski M, 2009, NEOPLASIA, V11, P145, DOI 10.1593/neo.81040; Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975; Hashiguchi Y, 2012, INT J ONCOL, V40, P1477, DOI 10.3892/ijo.2012.1363; Hu M, 2005, CANCER RES, V65, P8715, DOI 10.1158/0008-5472.CAN-05-0700; Huang JF, 2013, HEPATOLOGY, V57, P1882, DOI 10.1002/hep.26195; Iavarone M, 2015, HEPATOLOGY, V62, P784, DOI 10.1002/hep.27729; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Kaur K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175471; Kong DS, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm121; Kotake Y, 2011, ONCOGENE, V30, P1956, DOI 10.1038/onc.2010.568; Koutsioumpa M, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0287-3; Liu HY, 2006, PLOS MED, V3, P1090, DOI 10.1371/journal.pmed.0030232; Ma YL, 2010, J CELL MOL MED, V14, P2697, DOI 10.1111/j.1582-4934.2010.01191.x; Majumdar A, 2012, NAT REV GASTRO HEPAT, V9, P530, DOI 10.1038/nrgastro.2012.114; Martens-Uzunova ES, 2014, EUR UROL, V65, P1140, DOI 10.1016/j.eururo.2013.12.003; Michelotti GA, 2016, GUT, V65, P683, DOI 10.1136/gutjnl-2014-308176; Papadimitriou E, 2009, EUR CYTOKINE NETW, V20, P180, DOI 10.1684/ecn.2009.0172; Park TJ, 2008, MOL CARCINOGEN, V47, P784, DOI 10.1002/mc.20438; Perez-Pinera P, 2008, CURR OPIN HEMATOL, V15, P210, DOI 10.1097/MOH.0b013e3282fdc69e; Powers C, 2002, J BIOL CHEM, V277, P14153, DOI 10.1074/jbc.M112354200; Prensner JR, 2011, NAT BIOTECHNOL, V29, P742, DOI 10.1038/nbt.1914; Quinn JJ, 2016, NAT REV GENET, V17, P47, DOI 10.1038/nrg.2015.10; Raveh E, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0458-2; Rosenfield SM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047876; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Srikantan S, 2012, CURR PROTEIN PEPT SC, V13, P372, DOI 10.2174/138920312801619394; Ulitsky I, 2013, CELL, V154, P26, DOI 10.1016/j.cell.2013.06.020; Venook AP, 2010, ONCOLOGIST, V15, P5, DOI 10.1634/theoncologist.2010-S4-05; Vishwamitra D, 2012, AM J PATHOL, V180, P1772, DOI 10.1016/j.ajpath.2012.01.008; Wang F, 2014, HEPATOLOGY, V60, P1278, DOI 10.1002/hep.27239; Wang L, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt006; Wang SB, 2016, FEBS LETT, V590, P559, DOI 10.1002/1873-3468.12078; Wilusz CJ, 2012, MOL CELL, V47, P495, DOI 10.1016/j.molcel.2012.08.005; Xu D, 2013, HEPATOLOGY, V58, P739, DOI 10.1002/hep.26361; Xu F, 2010, J CELL BIOCHEM, V111, P727, DOI 10.1002/jcb.22762; Yamauchi N, 2005, MODERN PATHOL, V18, P1591, DOI 10.1038/modpathol.3800436; Yong KJ, 2013, NEW ENGL J MED, V368, P2266, DOI 10.1056/NEJMoa1300297; Yoon JH, 2012, MOL CELL, V47, P648, DOI 10.1016/j.molcel.2012.06.027; Yuan JH, 2014, CANCER CELL, V25, P666, DOI 10.1016/j.ccr.2014.03.010; Zhang L, 2016, MOL CELL ONCOL, V3, DOI 10.1080/23723556.2016.1141087; Zhang YM, 2015, INT J CLIN EXP MED, V8, P11683; Zheng L, 2014, TUMOR BIOL, V35, P4095, DOI 10.1007/s13277-013-1535-z	51	17	17	0	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2019	38	18					3428	3445		10.1038/s41388-018-0643-z	http://dx.doi.org/10.1038/s41388-018-0643-z			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HW3RI	30643194				2022-12-17	WOS:000466610000008
J	Sepult, C; Bellefroid, M; Rocks, N; Donati, K; Gerard, C; Gilles, C; Ludwig, A; Duysinx, B; Noel, A; Cataldo, D				Sepult, Christelle; Bellefroid, Marine; Rocks, Natacha; Donati, Kim; Gerard, Catherine; Gilles, Christine; Ludwig, Andreas; Duysinx, Bernard; Noel, Agnes; Cataldo, Didier			ADAM10 mediates malignant pleural mesothelioma invasiveness	ONCOGENE			English	Article							ALPHA-SECRETASE ADAM10; N-CADHERIN; CLEAVAGE; GROWTH; MIGRATION; METALLOPROTEINASES; DISINTEGRIN; INVASION	Malignant pleural mesothelioma (MPM) is an aggressive cancer with limited therapeutic options and treatment efficiency. Even if the latency period between asbestos exposure, the main risk factor, and mesothelioma development is very long, the local invasion of mesothelioma is very rapid leading to a mean survival of one year after diagnosis. ADAM10 (A Disintegrin And Metalloprotease) sheddase targets membrane-bound substrates and its overexpression is associated with progression in several cancers. However, nothing is known about ADAM10 implication in MPM. In this study, we demonstrated higher ADAM10 expression levels in human MPM as compared to control pleural samples and in human MPM cell line. This ADAM10 overexpression was also observed in murine MPM samples. Two mouse mesothelioma cell lines were used in this study including one primary cell line obtained by repeated asbestos fibre injections. We show, in vitro, that ADAM10 targeting through shRNA and pharmacological (GI254023X) approaches reduced drastically mesothelioma cell migration and invasion, as well as for human mesothelioma cells treated with siRNA targeting ADAM10. Moreover, ADAM10 downregulation in murine mesothelioma cells significantly impairs MPM progression in vivo after intrapleural cell injection. We also demonstrate that ADAM10 sheddase downregulation decreases the production of a soluble N-cadherin fragment through membrane N-cadherin, which stimulated mesothelioma cell migration. Taken together, we demonstrate that ADAM10 is overexpressed in MPM and takes part to MPM progression through the generation of N-cadherin fragment that stimulates mesothelioma cell migration. ADAM10 inhibition is worth considering as a therapeutic perspective in mesothelioma context.	[Sepult, Christelle; Bellefroid, Marine; Rocks, Natacha; Donati, Kim; Gerard, Catherine; Gilles, Christine; Noel, Agnes; Cataldo, Didier] Univ Liege, Lab Tumour & Dev Biol, GIGA Canc, Ave Hippocrate 13, B-4000 Liege, Belgium; [Ludwig, Andreas] Rhein Westfal TH Aachen, Inst Pharmacol & Toxicol, Aachen, Germany; [Duysinx, Bernard; Cataldo, Didier] CHU Liege, Dept Resp Dis, Ave Hippocrate 13, B-4000 Liege, Belgium; [Duysinx, Bernard; Cataldo, Didier] Univ Liege, Ave Hippocrate 13, B-4000 Liege, Belgium	University of Liege; RWTH Aachen University; University of Liege; University of Liege	Cataldo, D (corresponding author), Univ Liege, Lab Tumour & Dev Biol, GIGA Canc, Ave Hippocrate 13, B-4000 Liege, Belgium.; Cataldo, D (corresponding author), CHU Liege, Dept Resp Dis, Ave Hippocrate 13, B-4000 Liege, Belgium.; Cataldo, D (corresponding author), Univ Liege, Ave Hippocrate 13, B-4000 Liege, Belgium.	didier.cataldo@uliege.be	Ludwig, Andreas/I-5685-2012; Cataldo, Didier/GPG-3453-2022	Ludwig, Andreas/0000-0001-8536-4986; Noel, Agnes/0000-0002-7670-6179	Fonds National pour la Recherche Scientifique (FRS-FNRS Televie) [7463213 F, 7457116 F]; Centre AntiCancereux (University of Liege); foundation Leon Fredericq (University of Liege); Foundation against Cancer, Belgium [FA/2014/314]; Interuniversity Attraction Poles Program-Belgian State-Belgian Science Policy [P7/30]	Fonds National pour la Recherche Scientifique (FRS-FNRS Televie)(Fonds de la Recherche Scientifique - FNRS); Centre AntiCancereux (University of Liege)(University of Liege); foundation Leon Fredericq (University of Liege); Foundation against Cancer, Belgium; Interuniversity Attraction Poles Program-Belgian State-Belgian Science Policy(Belgian Federal Science Policy Office)	The authors acknowledge the contribution of the GIGA Viral Vectors Platform, of Silvia Blacher for the statistical analysis, and Vincent Heinen for his contribution to human sample collection. The authors thank Pascale Heneaux, Fabienne Perin and especially Christine Fink and Celine Vanwinge for technical support. This study was financially supported by grants from the Fonds National pour la Recherche Scientifique (FRS-FNRS Televie, Grants no 7463213 F and no 7457116 F), the Centre AntiCancereux (University of Liege), The foundation Leon Fredericq (University of Liege), the Foundation against Cancer (FA/2014/314), Belgium, Interuniversity Attraction Poles Program-Belgian State-Belgian Science Policyproject P7/30.	Altomare DA, 2005, ONCOGENE, V24, P6080, DOI 10.1038/sj.onc.1208744; Altomare DA, 2005, CANCER RES, V65, P8090, DOI 10.1158/0008-5472.CAN-05-2312; Andreini C, 2005, J PROTEOME RES, V4, P881, DOI 10.1021/pr0500096; Bononi A, 2015, EXPERT REV RESP MED, V9, P633, DOI 10.1586/17476348.2015.1081066; Bot J, 2003, PATHOL RES PRACT, V199, P341, DOI 10.1078/0344-0338-00427; Brooks AN, 2012, CLIN CANCER RES, V18, P1855, DOI 10.1158/1078-0432.CCR-11-0699; Carnet O, 2015, NEOPLASIA, V17, P552, DOI 10.1016/j.neo.2015.07.002; Chae YK, 2017, ONCOTARGET, V8, P16052, DOI 10.18632/oncotarget.14109; Derycke L, 2006, CLIN EXP METASTAS, V23, P187, DOI 10.1007/s10585-006-9029-7; Donaldson K, 2013, ADV DRUG DELIVER REV, V65, P2078, DOI 10.1016/j.addr.2013.07.014; Donati K, 2017, CANCER GROWTH METAST, V10, DOI 10.1177/1179064417738513; Dreymueller D, 2017, PLATELETS, V28, P354, DOI 10.1080/09537104.2016.1203396; Dreymueller D, 2015, AM J PHYSIOL-LUNG C, V308, pL325, DOI 10.1152/ajplung.00294.2014; Fu L, 2014, TUMOR BIOL, V35, P9263, DOI 10.1007/s13277-014-2201-9; Guo JL, 2012, ONCOL REP, V28, P1709, DOI 10.3892/or.2012.2003; Huang YH, 2017, J ADOLESCENT HEALTH, V61, P527, DOI 10.1016/j.jadohealth.2017.05.003; Hundhausen C, 2003, BLOOD, V102, P1186, DOI 10.1182/blood-2002-12-3775; Kern A, 2006, J BIOL CHEM, V281, P2405, DOI 10.1074/jbc.M505625200; Kim JB, 2000, J CELL BIOL, V151, P1193, DOI 10.1083/jcb.151.6.1193; Kohutek ZA, 2009, J NEUROSCI, V29, P4605, DOI 10.1523/JNEUROSCI.5126-08.2009; Liu SY, 2015, MOL MED REP, V11, P597, DOI 10.3892/mmr.2014.2652; Madoux F, 2016, SCI REP-UK, V6, DOI 10.1038/s41598-016-0013-4; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; Mezzapelle R, 2016, SCI REP, V6, P1; Moss ML, 2008, CURR PHARM BIOTECHNO, V9, P2, DOI 10.2174/138920108783497613; Moss ML, 2007, J BIOL CHEM, V282, P35712, DOI 10.1074/jbc.M703231200; Mullooly M, 2015, BRIT J CANCER, V113, P945, DOI 10.1038/bjc.2015.288; Otjacques E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062818; PARADIES NE, 1993, J NEUROSCI RES, V36, P33, DOI 10.1002/jnr.490360105; Paulissen G, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-127; Pruessmeyer J, 2014, BLOOD, V123, P4077, DOI 10.1182/blood-2013-09-511543; Quispel-Janssen JM, 2018, CLIN CANCER RES, V24, P84, DOI 10.1158/1078-0432.CCR-17-1172; Ray M, 2009, CHEST, V136, P888, DOI 10.1378/chest.08-2665; Reiss K, 2005, EMBO J, V24, P742, DOI 10.1038/sj.emboj.7600548; Rocks N, 2008, BIOCHIMIE, V90, P369, DOI 10.1016/j.biochi.2007.08.008; Rocks N, 2006, BRIT J CANCER, V94, P724, DOI 10.1038/sj.bjc.6602990; Schnell J, 2017, DTSCH ARZTEBL INT, V114, P739, DOI 10.3238/arztebl.2017.0739; Schuck F, 2016, J ALZHEIMERS DIS, V50, P817, DOI 10.3233/JAD-150737; Shackleton B, 2016, FLUIDS BARRIERS CNS, V13, DOI 10.1186/s12987-016-0038-x; Sun YZ, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317712592; Suyama K, 2002, CANCER CELL, V2, P301, DOI 10.1016/S1535-6108(02)00150-2; Nguyen T, 2016, EUR J CELL BIOL, V95, P415, DOI 10.1016/j.ejcb.2016.05.002; Utton MA, 2001, J NEUROCHEM, V76, P1421, DOI 10.1046/j.1471-4159.2001.00140.x; Vincent B, 2016, BRAIN RES BULL, V126, P154, DOI 10.1016/j.brainresbull.2016.03.020; Yap TA, 2017, NAT REV CANCER, V17, P475, DOI 10.1038/nrc.2017.42; Yaziji H, 2006, MODERN PATHOL, V19, P514, DOI 10.1038/modpathol.3800534; Yilmaz M, 2010, MOL CANCER RES, V8, P629, DOI 10.1158/1541-7786.MCR-10-0139; You B, 2015, CANCER SCI, V106, P1506, DOI 10.1111/cas.12800; Zhang WQ, 2015, ANN TRANSL MED, V3, DOI 10.3978/j.issn.2305-5839.2015.07.03	49	17	18	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2019	38	18					3521	3534		10.1038/s41388-018-0669-2	http://dx.doi.org/10.1038/s41388-018-0669-2			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HW3RI	30651596	hybrid, Green Published			2022-12-17	WOS:000466610000014
J	Ubby, I; Krueger, C; Rosato, R; Qian, W; Chang, J; Sabapathy, K				Ubby, Ifeoma; Krueger, Christian; Rosato, Roberto; Qian, Wei; Chang, Jenny; Sabapathy, Kanaga			Cancer therapeutic targeting using mutant-p53-specific siRNAs	ONCOGENE			English	Article							MUTANT P53; RNA INTERFERENCE; WILD-TYPE; GENE; MUTATIONS; TP53; GAIN; EXPRESSION; ABROGATION; GEFITINIB	Mutations in Tp53 compromise therapeutic response, due either to the dominant-negative effect over the functional wild-type allele; or as a result of the survival advantage conferred by mutant p53 to which cancer cells become addicted. Thus, targeting mutant p53 represents an effective therapeutic strategy to treat over half of all cancers. We have therefore generated a series of small-interfering-RNAs, capable of targeting four p53 hot-spot mutants which represent similar to 20% of all p53 mutations. These mutant-p53-specific siRNAs (MupSi) are highly specific in silencing the expression of the intended mutants without affecting wild-type p53. Functionally, these MupSis induce cell death by abrogating both the addiction to mutant p53 and the dominant-negative effect; and retard tumor growth in xenografts when administered in a therapeutic setting. These data together demonstrate the possibility of targeting mutant p53 specifically to improve clinical outcome.	[Ubby, Ifeoma; Krueger, Christian; Sabapathy, Kanaga] Natl Canc Ctr Singapore, Humphrey Oei Inst Canc Res, Div Cellular & Mol Res, Singapore 169610, Singapore; [Rosato, Roberto; Qian, Wei; Chang, Jenny] Houston Methodist Canc Ctr, 6445 Main St, Houston, TX 77030 USA; [Sabapathy, Kanaga] Duke NUS Med Sch, Canc & Stem Cell Biol Program, Singapore 169857, Singapore; [Sabapathy, Kanaga] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Biochem, Singapore 119228, Singapore; [Sabapathy, Kanaga] Inst Mol & Cellular Biol, Singapore 138673, Singapore	National Cancer Centre Singapore (NCCS); The Methodist Hospital System; The Methodist Hospital - Houston; National University of Singapore; National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Sabapathy, K (corresponding author), Natl Canc Ctr Singapore, Humphrey Oei Inst Canc Res, Div Cellular & Mol Res, Singapore 169610, Singapore.; Sabapathy, K (corresponding author), Duke NUS Med Sch, Canc & Stem Cell Biol Program, Singapore 169857, Singapore.; Sabapathy, K (corresponding author), Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Biochem, Singapore 119228, Singapore.; Sabapathy, K (corresponding author), Inst Mol & Cellular Biol, Singapore 138673, Singapore.	cmrksb@nccs.com.sg			National Medical Research Council of Singapore	National Medical Research Council of Singapore(National Medical Research Council, Singapore)	We thank the National Medical Research Council of Singapore for funding support to KS.	Alexandrova EM, 2015, NATURE, V523, P352, DOI 10.1038/nature14430; Allen EHA, 2013, INVEST OPHTH VIS SCI, V54, P494, DOI 10.1167/iovs.12-10528; Barata P, 2016, CANCER TREAT REV, V50, P35, DOI 10.1016/j.ctrv.2016.08.004; Berghmans S, 2005, P NATL ACAD SCI USA, V102, P407, DOI 10.1073/pnas.0406252102; Bieging KT, 2014, NAT REV CANCER, V14, P359, DOI 10.1038/nrc3711; Blagosklonny MV, 2005, CANCER RES, V65, P7386, DOI 10.1158/0008-5472.CAN-04-3433; Bossi G, 2006, ONCOGENE, V25, P304, DOI 10.1038/sj.onc.1209026; Bouaoun L, 2016, HUM MUTAT, V37, P865, DOI 10.1002/humu.23035; Capdeville R, 2002, NAT REV DRUG DISCOV, V1, P493, DOI 10.1038/nrd839; Dave B, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw292; Dave B, 2014, P NATL ACAD SCI USA, V111, P8838, DOI 10.1073/pnas.1320769111; Dearth LR, 2007, CARCINOGENESIS, V28, P289, DOI 10.1093/carcin/bgl132; Donehower LA, 2014, HUM MUTAT, V35, P715, DOI 10.1002/humu.22507; Eiden AM, 2016, CLIN CANCER RES, V22, P277, DOI 10.1158/1078-0432.CCR-14-3239; Evans EK, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aao1690; Forbes SA, 2015, NUCLEIC ACIDS RES, V43, pD805, DOI 10.1093/nar/gku1075; Freed-Pastor WA, 2012, CELL, V148, P244, DOI 10.1016/j.cell.2011.12.017; Giles FJ, 2009, LEUKEMIA, V23, P1698, DOI 10.1038/leu.2009.111; Hanel W, 2013, CELL DEATH DIFFER, V20, P898, DOI 10.1038/cdd.2013.17; Hansen SA, 2016, DIS MODEL MECH, V9, P1139, DOI 10.1242/dmm.025767; Herbst RS, 2004, NAT REV CANCER, V4, P956, DOI 10.1038/nrc1506; Hickerson RP, 2008, J INVEST DERMATOL, V128, P594, DOI 10.1038/sj.jid.5701060; Hwang LA, 2018, CELL REP, V22, P299, DOI 10.1016/j.celrep.2017.11.112; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kim A, 2016, EXPERT OPIN DRUG DIS, V11, P907, DOI 10.1080/17460441.2016.1201057; Klaeger S, 2017, SCIENCE, V358, DOI 10.1126/science.aan4368; Lawrence MS, 2014, NATURE, V505, P495, DOI 10.1038/nature12912; Leachman SA, 2010, MOL THER, V18, P442, DOI 10.1038/mt.2009.273; Lee MK, 2008, J CELL SCI, V121, P1899, DOI 10.1242/jcs.022822; Lee MK, 2012, CANCER CELL, V22, P751, DOI 10.1016/j.ccr.2012.10.022; Liu Y, 2016, J INVEST DERMATOL, V136, P45, DOI 10.1038/JID.2015.375; Martinez LA, 2002, P NATL ACAD SCI USA, V99, P14849, DOI 10.1073/pnas.222406899; Merino Diana, 2014, Subcell Biochem, V85, P1, DOI 10.1007/978-94-017-9211-0_1; Montgomery Mary K, 2004, Methods Mol Biol, V265, P3; Muller PAJ, 2009, CELL, V139, P1327, DOI 10.1016/j.cell.2009.11.026; Novelli F, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.118; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Phang BH, 2015, P NATL ACAD SCI USA, V112, pE6349, DOI 10.1073/pnas.1510043112; Rasheed SAK, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0337-x; Sabapathy K, 2018, NAT REV CLIN ONCOL, V15, P13, DOI 10.1038/nrclinonc.2017.151; Sabapathy K, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00276; Schrama D, 2006, NAT REV DRUG DISCOV, V5, P147, DOI 10.1038/nrd1957; Semczuk A, 2010, ONCOLOGY-BASEL, V78, P220, DOI 10.1159/000314353; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; Shrivastava Neeta, 2008, Biotechnol J, V3, P339, DOI 10.1002/biot.200700215; Solomon BJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144559; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; Sur S, 2009, P NATL ACAD SCI USA, V106, P3964, DOI 10.1073/pnas.0813333106; Trochet D, 2018, EMBO MOL MED, V10, P239, DOI 10.15252/emmm.201707988; Trochet D, 2015, CURR GENE THER, V15, P503, DOI 10.2174/1566523215666150812115730; Vikhanskaya F, 2007, NUCLEIC ACIDS RES, V35, P2093, DOI 10.1093/nar/gkm099; Voorhoeve PM, 2003, CANCER CELL, V4, P311, DOI 10.1016/S1535-6108(03)00223-X; Wang YX, 2011, J CLIN INVEST, V121, P893, DOI 10.1172/JCI44504; Zilfou JT, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001883	54	17	18	2	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2019	38	18					3415	3427		10.1038/s41388-018-0652-y	http://dx.doi.org/10.1038/s41388-018-0652-y			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HW3RI	30643191	Green Published, hybrid			2022-12-17	WOS:000466610000007
J	Gold, A; Eini, L; Nissim-Rafinia, M; Viner, R; Ezer, S; Erez, K; Aqaqe, N; Hanania, R; Milyavsky, M; Meshorer, E; Goldberg, M				Gold, Ayala; Eini, Lital; Nissim-Rafinia, Malka; Viner, Ruth; Ezer, Shlomit; Erez, Keren; Aqaqe, Nasma; Hanania, Rotem; Milyavsky, Michael; Meshorer, Eran; Goldberg, Michal			Spironolactone inhibits the growth of cancer stem cells by impairing DNA damage response	ONCOGENE			English	Article							TRICHOSTATIN-A; APOPTOSIS; THERAPY; INDUCTION; SURVIVAL; SCREEN; AGENTS	The cancer stem cell (CSC) model suggests that a subpopulation of cells within the tumor, the CSCs, is responsible for cancer relapse and metastasis formation. CSCs hold unique characteristics, such as self-renewal, differentiation abilities, and resistance to chemotherapy, raising the need for discovering drugs that target CSCs. Previously we have found that the antihypertensive drug spironolactone impairs DNA damage response in cancer cells. Here we show that spironolactone, apart from inhibiting cancerous cell growth, is also highly toxic to CSCs. Notably, we demonstrate that CSCs have high basal levels of DNA double-strand breaks (DSBs). Mechanistically, we reveal that spironolactone does not damage the DNA but impairs DSB repair and induces apoptosis in cancer cells and CSCs while sparing healthy cells. In vivo, spironolactone treatment reduced the size and CSC content of tumors. Overall, we suggest spironolactone as an anticancer reagent, toxic to both cancer cells and, particularly to, CSCs.	[Gold, Ayala; Eini, Lital; Nissim-Rafinia, Malka; Viner, Ruth; Ezer, Shlomit; Erez, Keren; Hanania, Rotem; Meshorer, Eran; Goldberg, Michal] Hebrew Univ Jerusalem, Dept Genet, Inst Life Sci, Edmond J Safra Campus, IL-9190401 Jerusalem, Israel; [Nissim-Rafinia, Malka; Meshorer, Eran] Hebrew Univ Jerusalem, Edmond & Lily Safra Ctr Brain Sci ELSC, Edmond J Safra Campus, IL-9190401 Jerusalem, Israel; [Aqaqe, Nasma; Milyavsky, Michael] Tel Aviv Univ, Sackler Fac Med, Dept Pathol, IL-69978 Tel Aviv, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Tel Aviv University; Sackler Faculty of Medicine	Meshorer, E; Goldberg, M (corresponding author), Hebrew Univ Jerusalem, Dept Genet, Inst Life Sci, Edmond J Safra Campus, IL-9190401 Jerusalem, Israel.; Meshorer, E (corresponding author), Hebrew Univ Jerusalem, Edmond & Lily Safra Ctr Brain Sci ELSC, Edmond J Safra Campus, IL-9190401 Jerusalem, Israel.	eran.meshorer@mail.huji.ac.il; goldbergm@mail.huji.ac.il		Meshorer, Eran/0000-0003-4777-986X; Goldberg, Michal/0000-0001-9397-2383	Israel Science Foundation [1353/12, 1140/17]; Israel Cancer Association [20171152]; DKFZ-MOST Collaboration [CA180]	Israel Science Foundation(Israel Science Foundation); Israel Cancer Association; DKFZ-MOST Collaboration	This work was supported by grant 1353/12 from the Israel Science Foundation and grant 20171152 from the Israel Cancer Association, with the generous assistance of Nancy and Peter Brown through the ICA USA to MG, and by grant 1140/17 from the Israel Science Foundation and CA180 from the DKFZ-MOST Collaboration to EM.	Alekseev S, 2014, CHEM BIOL, V21, P398, DOI 10.1016/j.chembiol.2013.12.014; Bake M., 2008, NAT REP STEM CELLS, DOI [10.1038/stemcells.2008.153, DOI 10.1038/STEMCELLS.2008.153]; Bandhavkar S, 2016, CANCER MED-US, V5, P649, DOI 10.1002/cam4.629; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Belmokhtar CA, 2001, ONCOGENE, V20, P3354, DOI 10.1038/sj.onc.1204436; Biechonski S, 2017, CARCINOGENESIS, V38, P367, DOI 10.1093/carcin/bgx002; Campos B, 2010, CLIN CANCER RES, V16, P2715, DOI 10.1158/1078-0432.CCR-09-1800; Chadwick JA, 2015, FASEB J, V29, P4544, DOI 10.1096/fj.15-276782; Chang CH, 2015, STEM CELL REP, V5, P378, DOI 10.1016/j.stemcr.2015.07.009; Chen YL, 2012, J CELL BIOCHEM, V113, P3643, DOI 10.1002/jcb.24228; Cheung-Ong K, 2013, CHEM BIOL, V20, P648, DOI 10.1016/j.chembiol.2013.04.007; Choi YH, 2005, INT J ONCOL, V27, P473; Chuang YW, 2017, J HYPERTENS, V35, P170, DOI 10.1097/HJH.0000000000001130; Clarke MF, 2005, BIOL BLOOD MARROW TR, V11, P14, DOI 10.1016/j.bbmt.2004.11.011; Dictus C, 2007, J NEUROSCI METH, V161, P250, DOI 10.1016/j.jneumeth.2006.11.012; Ferguson LR, 2015, SEMIN CANCER BIOL, V35, pS5, DOI 10.1016/j.semcancer.2015.03.005; Funder JW, 2013, INTEGR BLOOD PRESS C, V6, P129, DOI 10.2147/IBPC.S13783; GARDINER P, 1989, J CLIN PHARMACOL, V29, P342, DOI 10.1002/j.1552-4604.1989.tb03339.x; Gavande NS, 2016, PHARMACOL THERAPEUT, V160, P65, DOI 10.1016/j.pharmthera.2016.02.003; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harper JW, 2007, MOL CELL, V28, P739, DOI 10.1016/j.molcel.2007.11.015; Helleday T, 2008, NAT REV CANCER, V8, P193, DOI 10.1038/nrc2342; Kotsantis P, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13087; Lamb J, 2007, NAT REV CANCER, V7, P54, DOI 10.1038/nrc2044; Leung WH, 2013, J EXP MED, V210, P2675, DOI 10.1084/jem.20122292; Louka M, 2015, ADVANCES IN DNA REPAIR, P415, DOI 10.5772/61355; LUMB G, 1978, J ENVIRON PATHOL TOX, V1, P641; Ferreira JRO, 2013, TOXICOL IN VITRO, V27, P1458, DOI 10.1016/j.tiv.2013.03.010; Oliver FJ, 1998, J BIOL CHEM, V273, P33533, DOI 10.1074/jbc.273.50.33533; Peitzsch C, 2017, SEMIN CANCER BIOL, V44, P10, DOI 10.1016/j.semcancer.2017.02.011; Rajanna A, 2016, MED HYPOTHESES, V88, P83, DOI 10.1016/j.mehy.2015.11.009; Scaffidi P, 2011, NAT CELL BIOL, V13, P1051, DOI 10.1038/ncb2308; Shahar OD, 2014, NUCLEIC ACIDS RES, V42, P5689, DOI 10.1093/nar/gku217; Shaked Y, 2016, NAT REV CLIN ONCOL, V13, P611, DOI 10.1038/nrclinonc.2016.57; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Struthers A, 2008, CLIN CARDIOL, V31, P153, DOI 10.1002/clc.20324; Taghiyev AF, 2005, CANCER BIOL THER, V4, P382; Torres CM, 2016, SCIENCE, V353, DOI 10.1126/science.aaf1644; Yao X, 2007, AM J MED SCI, V334, P115, DOI 10.1097/MAJ.0b013e31812dfe1e	39	17	20	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2019	38	17					3103	3118		10.1038/s41388-018-0654-9	http://dx.doi.org/10.1038/s41388-018-0654-9			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU8RI	30622338				2022-12-17	WOS:000465557200001
J	Tang, H; Jiang, LX; Zhu, CL; Liu, R; Wu, YF; Yan, Q; Liu, M; Jia, YX; Chen, J; Qin, YR; Lee, VHF; Luo, SX; Wang, QM; Guan, XY				Tang, Hong; Jiang, Lingxi; Zhu, Cailei; Liu, Raymond; Wu, Yufeng; Yan, Qian; Liu, Ming; Jia, Yongxu; Chen, Juan; Qin, Yanru; Lee, Victor Ho-Fun; Luo, Suxia; Wang, Qiming; Guan, Xin-Yuan			Loss of cell adhesion molecule L1 like promotes tumor growth and metastasis in esophageal squamous cell carcinomay	ONCOGENE			English	Article							CHROMOSOME 3P; GENETIC ALTERATIONS; HIGH-FREQUENCY; BETA-CATENIN; CANCER; SUPPRESSOR; LUNG; NEUROPILIN-1; METHYLATION; ABERRATIONS	Esophageal squamous cells carcinoma (ESCC) is a major common thoracic tumor characterized by distinctly high incidences and mortality rates. Despite advances in multimodality therapy, the mortality rate of ESCC remains high and understanding of molecular alterations leading to the development and progression of ESCC is still very limited. In this study, a new tumor suppressor candidate, cell adhesion molecule with homology to L1CAM (CHL1), located at 3p26 which was frequently deleted in ESCC was identified. Reduced expression of CHL1 correlated with poor differentiation, increased invasion, and lymph-node metastasis, advanced tumor stage, and decreased overall survival. Methylation-specific PCR and FISH assays revealed that down-regulation of CHL1 in both ESCC cell lines and clinical samples were associated with promoter hypermethylation and loss of heterozygosity. Functional studies using lentiviral-based overexpression and knockdown systems provided direct support of CHL1 to function as an important tumor suppressor with both anti-proliferation and anti-metastasis abilities, through Merlin and SEMA3B-Np1-mediated inhibition of AKT signaling pathway. Further characterization of CHL1 may provide a novel therapeutic target in ESCC treatment.	[Tang, Hong; Wu, Yufeng; Luo, Suxia; Wang, Qiming] Zhengzhou Univ, Henan Canc Hosp, Affiliated Canc Hosp, Dept Internal Med, Zhengzhou, Henan, Peoples R China; [Tang, Hong; Jiang, Lingxi; Zhu, Cailei; Liu, Raymond; Yan, Qian; Chen, Juan; Lee, Victor Ho-Fun; Guan, Xin-Yuan] Univ Hong Kong, Dept Clin Oncol, Li Ka Shing Fac Med, Hong Kong, Peoples R China; [Jiang, Lingxi] Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, Shanghai Key Lab Gastr Neoplasms, Shanghai, Peoples R China; [Liu, Ming] Guangzhou Med Univ, Sch Basic Med Sci, Key Lab Prot Modificat & Degradat, Guangzhou, Guangdong, Peoples R China; [Jia, Yongxu; Qin, Yanru] Zhengzhou Univ, Dept Clin Oncol, Affiliated Hosp 1, Zhengzhou, Henan, Peoples R China	Zhengzhou University; University of Hong Kong; Shanghai Jiao Tong University; Guangzhou Medical University; Zhengzhou University	Luo, SX; Wang, QM (corresponding author), Zhengzhou Univ, Henan Canc Hosp, Affiliated Canc Hosp, Dept Internal Med, Zhengzhou, Henan, Peoples R China.; Guan, XY (corresponding author), Univ Hong Kong, Dept Clin Oncol, Li Ka Shing Fac Med, Hong Kong, Peoples R China.	luosxrm@163.com; qimingwang1006@126.com; xyguan@hku.hk	; /A-3639-2009	Wu, Yufeng/0000-0003-0510-0388; Lee, Victor/0000-0002-6283-978X; LIU, MING/0000-0003-3222-8715; /0000-0003-1874-9805	National Key R&D Program of China [2017YFC1309000]; Shenzhen Peacock Team Project [KQTD2015033117210153]; National Natural Science Foundation of China [81472250, 81602061, 81772554]; Hong Kong Research Grant Council [HKU/7668/11 M, 767313, C7038-14G, C7027-14G]; Health and Medical Research Fund [04150826]; Natural Science Foundation of Henan Province [182300410376, 182300410297, 162300410300]	National Key R&D Program of China; Shenzhen Peacock Team Project; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Hong Kong Research Grant Council(Hong Kong Research Grants Council); Health and Medical Research Fund; Natural Science Foundation of Henan Province	This work was supported by grants from National Key R&D Program of China (2017YFC1309000), Shenzhen Peacock Team Project (KQTD2015033117210153), National Natural Science Foundation of China (81472250, 81602061, and 81772554), the Hong Kong Research Grant Council grants including GRF (HKU/7668/11 M and 767313), CRF (C7038-14G and C7027-14G), Health and Medical Research Fund (04150826), and Natural Science Foundation of Henan Province (182300410376, 182300410297, and 162300410300). Professor XY Guan is Sophie YM Chan Professor in cancer research.	Ackermann S, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-840; Castro-Rivera E, 2008, CANCER RES, V68, P8295, DOI 10.1158/0008-5472.CAN-07-6601; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chan ASC, 2000, CANCER RES, V60, P5365; Chen J, 2012, CHIN J CANCER, V31, P215, DOI 10.5732/cjc.011.10364; DALBAGNI G, 1993, LANCET, V342, P469, DOI 10.1016/0140-6736(93)91595-D; Fu L, 2007, CANCER RES, V67, P10720, DOI 10.1158/0008-5472.CAN-07-2411; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Guan XY, 2001, CANCER RES, V61, P3806; Knosel T, 2005, CLIN EXP METASTAS, V22, P533, DOI 10.1007/s10585-005-5239-7; Kou CH, 2015, BIOCHEM BIOPH RES CO, V464, P519, DOI 10.1016/j.bbrc.2015.06.173; Kwong D, 2004, HUM PATHOL, V35, P309, DOI 10.1016/j.humpath.2003.10.020; Li J Y, 1982, Natl Cancer Inst Monogr, V62, P113; Li K, 2002, INT J CANCER, V102, P271, DOI [10.1002/ijc.10706, 10.1002/jhc.10706]; Li Y, 2002, J BIOL CHEM, V277, P11352, DOI 10.1074/jbc.M109062200; Loginov VI, 2009, MOL BIOL+, V43, P1014, DOI 10.1134/S0026893309060156; Ming XY, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13568; Miyoshi Y, 1998, CANCER RES, V58, P2524; OGASAWARA S, 1995, CANCER RES, V55, P891; Ogawara Y, 2002, J BIOL CHEM, V277, P21843, DOI 10.1074/jbc.M109745200; Ognibene Marzia, 2018, Oncotarget, V9, P25903, DOI 10.18632/oncotarget.25403; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Portale G, 2006, J AM COLL SURGEONS, V202, P588, DOI 10.1016/j.jamcollsurg.2005.12.022; PRESTI JC, 1991, CANCER RES, V51, P5405; Qian CN, 2006, CANCER RES, V66, P10365, DOI 10.1158/0008-5472.CAN-06-2977; Qin YR, 2008, INT J CANCER, V123, P826, DOI 10.1002/ijc.23577; Raju SC, 2015, ORAL ONCOL, V51, P470, DOI 10.1016/j.oraloncology.2015.01.014; Rong R, 2004, P NATL ACAD SCI USA, V101, P18200, DOI 10.1073/pnas.0405971102; Schlatter MC, 2008, J NEUROCHEM, V104, P731, DOI 10.1111/j.1471-4159.2007.05013.x; Senchenko VN, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015612; SHIMADA Y, 1992, CANCER, V69, P277, DOI 10.1002/1097-0142(19920115)69:2<277::AID-CNCR2820690202>3.0.CO;2-C; Tao Q, 2002, HUM MOL GENET, V11, P2091, DOI 10.1093/hmg/11.18.2091; Uchida K, 2011, ONCOL REP, V26, P463, DOI 10.3892/or.2011.1327; Wright AG, 2007, J NEUROSCI, V27, P13667, DOI 10.1523/JNEUROSCI.2888-07.2007; Xie D, 2003, INT J CANCER, V107, P896, DOI 10.1002/ijc.11514; Yamaguchi H, 2007, BBA-MOL CELL RES, V1773, P642, DOI 10.1016/j.bbamcr.2006.07.001; Yen CC, 2007, LUNG CANCER, V57, P292, DOI 10.1016/j.lungcan.2007.04.007; Zhang YJ, 2002, MOL CARCINOGEN, V35, P85, DOI 10.1002/mc.10076; Zhu C, 2009, ONCOGENE, V28, P2821, DOI 10.1038/onc.2009.137; 2001, CANCER, V92, P2769; 2010, INT J CANCER, V127, P2893, DOI DOI 10.1002/IJC.25516	41	17	18	4	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2019	38	17					3119	3133		10.1038/s41388-018-0648-7	http://dx.doi.org/10.1038/s41388-018-0648-7			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU8RI	30622339				2022-12-17	WOS:000465557200002
J	Chen, J; Zhang, WM; Wang, Y; Zhao, D; Wu, MJ; Fan, JW; Li, JT; Gong, Y; Dan, NN; Yang, D; Liu, R; Zhan, QM				Chen, Jie; Zhang, Weimin; Wang, Yan; Zhao, Di; Wu, Mengjiao; Fan, Jiawen; Li, Jinting; Gong, Ying; Dan, Nana; Yang, Di; Liu, Rui; Zhan, Qimin			The diacylglycerol kinase alpha (DGK alpha)/Akt/NF-kappa B feedforward loop promotes esophageal squamous cell carcinoma (ESCC) progression via FAK-dependent and FAK-independent manner	ONCOGENE			English	Article							FOCAL ADHESION KINASE; NF-KAPPA-B; EPIDERMAL-GROWTH-FACTOR; ACTIVATION; INFLAMMATION; AKT; PROLIFERATION; INHIBITION; MIGRATION; SUBUNIT	Many reports have described DGK alpha as an oncogene, hence, we investigated its function and the underlying mechanisms in esophageal squamous cell carcinoma (ESCC) progression. This study demonstrated that DGK alpha was upregulated by inflammatory stimulants and formed feedforward loop with Akt/NF-kappa B signaling in ESCC cells. Mechanistically, DGK alpha-activated Akt/NF-kappa B signaling via stimulating PA production to reduce cAMP level and PTEN activity, and specifically, independently of its kinase function, through direct interaction with the FERM domain of FAK to relieve the auto-inhibitory effect of FERM domain on FAK. Overexpression of DGK alpha promoted cancer malignant progression both in vitro and in vivo, whereas depletion of DGK alpha suppressed these effects. Importantly, DGK alpha expression was tightly correlated with the malignancy of various inflammation-related squamous carcinomas and the oncogenic Akt/NF-kappa B activity. Therefore, DGK alpha is critically involved in inflammation-mediated ESCC progression, supporting DGK alpha as a potential target for ESCC therapy.	[Chen, Jie; Zhang, Weimin; Wang, Yan; Zhao, Di; Wu, Mengjiao; Fan, Jiawen; Li, Jinting; Gong, Ying; Dan, Nana; Yang, Di; Liu, Rui; Zhan, Qimin] Peking Univ, Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing,Lab Mol Oncol, Beijing 100142, Peoples R China; [Zhan, Qimin] Chinese Acad Med Sci, State Key Lab Mol Oncol, Canc Inst, Beijing 100021, Peoples R China; [Zhan, Qimin] Chinese Acad Med Sci, Canc Hosp, Beijing 100021, Peoples R China; [Zhan, Qimin] Peking Union Med Coll, Beijing 100021, Peoples R China	Peking University; Chinese Academy of Medical Sciences - Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College	Zhan, QM (corresponding author), Peking Univ, Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing,Lab Mol Oncol, Beijing 100142, Peoples R China.; Zhan, QM (corresponding author), Chinese Acad Med Sci, State Key Lab Mol Oncol, Canc Inst, Beijing 100021, Peoples R China.; Zhan, QM (corresponding author), Chinese Acad Med Sci, Canc Hosp, Beijing 100021, Peoples R China.; Zhan, QM (corresponding author), Peking Union Med Coll, Beijing 100021, Peoples R China.	zhanqimin@bjmu.edu.en			National 973 Program [2015CB553904]; National Natural Fund of China [81830086, 81490753, 81502110, 81772504]; Beijing Municipal Administration of Hospitals's Youth Program [QML20171105]	National 973 Program(National Basic Research Program of China); National Natural Fund of China; Beijing Municipal Administration of Hospitals's Youth Program	This work is supported by the National 973 Program (2015CB553904) and National Natural Fund of China (81830086, 81490753, 81502110, and 81772504). Beijing Municipal Administration of Hospitals's Youth Program, code: QML20171105.	Andl CD, 2003, J BIOL CHEM, V278, P1824, DOI 10.1074/jbc.M209148200; Balkwill F, 2006, CANCER METAST REV, V25, P409, DOI 10.1007/s10555-006-9005-3; Castellano E, 2013, CANCER CELL, V24, P617, DOI 10.1016/j.ccr.2013.09.012; Chechlinska M, 2010, NAT REV CANCER, V10, P2, DOI 10.1038/nrc2782; Chen J, 2015, ONCOGENE, V34, P5114, DOI 10.1038/onc.2014.434; Chen J, 2015, CANCER RES, V75, P4198, DOI 10.1158/0008-5472.CAN-15-1062; Chen MF, 2012, J MOL MED, V90, P89, DOI 10.1007/s00109-011-0809-4; Dan HC, 2008, GENE DEV, V22, P1490, DOI 10.1101/gad.1662308; Dominguez CL, 2013, CANCER DISCOV, V3, P782, DOI 10.1158/2159-8290.CD-12-0215; Elinav E, 2013, NAT REV CANCER, V13, P759, DOI 10.1038/nrc3611; Guo ST, 2016, ONCOGENE, V35, P3049, DOI 10.1038/onc.2015.361; Guo W, 2005, CHINESE MED J-PEKING, V118, P1870; Hellyer NJ, 1998, BIOCHEM J, V333, P757, DOI 10.1042/bj3330757; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; Ito T, 2008, CANCER RES, V68, P3214, DOI 10.1158/0008-5472.CAN-07-3043; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Li Y, 2018, CANCER LETT, V430, P57, DOI 10.1016/j.canlet.2018.05.013; Lin CY, 2013, CANCER RES, V73, P3638, DOI 10.1158/0008-5472.CAN-12-4028; Lou LG, 2002, J BIOL CHEM, V277, P32799, DOI 10.1074/jbc.M201491200; Luzzatto L, 2015, NEW ENGL J MED, V373, P84, DOI 10.1056/NEJMsb1502456; Martinez K, 2013, J LIPID RES, V54, P662, DOI 10.1194/jlr.M031211; Merida I, 2008, BIOCHEM J, V409, P1, DOI 10.1042/BJ20071040; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; Nemoz G, 1997, MOL PHARMACOL, V51, P242, DOI 10.1124/mol.51.2.242; Okada M, 2012, BIOCHEM BIOPH RES CO, V420, P479, DOI 10.1016/j.bbrc.2012.03.057; Poullet P, 2001, J BIOL CHEM, V276, P37686, DOI 10.1074/jbc.M106175200; Rainero E, 2012, J CELL BIOL, V196, P277, DOI 10.1083/jcb.201109112; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Song LB, 2012, GASTROENTEROLOGY, V143, P995, DOI 10.1053/j.gastro.2012.06.033; Streblow DN, 2003, J BIOL CHEM, V278, P50456, DOI 10.1074/jbc.M307936200; Sugimoto N, 2011, NEUROSCI LETT, V497, P55, DOI 10.1016/j.neulet.2011.04.028; Takeishi K, 2012, J HEPATOL, V57, P77, DOI 10.1016/j.jhep.2012.02.026; Torres-Ayuso P, 2014, ONCOTARGET, V5, P9710, DOI 10.18632/oncotarget.2344; van Blitterswijk WJ, 2000, CELL SIGNAL, V12, P595, DOI 10.1016/S0898-6568(00)00113-3; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Voronov E, 2003, P NATL ACAD SCI USA, V100, P2645, DOI 10.1073/pnas.0437939100; Wang F, 2009, CURR OPIN PHARMACOL, V9, P389, DOI 10.1016/j.coph.2009.06.005; Wu DW, 2015, ONCOGENE, V34, P3882, DOI 10.1038/onc.2015.203; Xia H, 2004, J BIOL CHEM, V279, P33024, DOI 10.1074/jbc.M313265200; Zhang B, 2017, DNA CELL BIOL, V36, P237, DOI 10.1089/dna.2016.3535; Zhou H, 2010, CANCER CELL, V17, P560, DOI 10.1016/j.ccr.2010.04.023	41	17	19	2	16	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2019	38	14					2533	2550		10.1038/s41388-018-0604-6	http://dx.doi.org/10.1038/s41388-018-0604-6			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HR7LI	30532074				2022-12-17	WOS:000463335200007
J	Chong, YC; Lim, TE; Fu, YY; Shin, EM; Tergaonkar, V; Han, WP				Chong, Yong Chun; Lim, Tau En; Fu, Yanyun; Shin, Eun Myoung; Tergaonkar, Vinay; Han, Weiping			Indian Hedgehog links obesity to development of hepatocellular carcinoma	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; HEPATIC STELLATE CELLS; PATHWAY ACTIVATION; WNT/BETA-CATENIN; C-MYC; LIVER; CANCER; FIBROSIS; ROLES; SHH	Obesity increases the risk of hepatocellular carcinoma (HCC), but precise identification and characterization of druggable oncogenic pathways that contribute to the progression of NAFLD to HCC, and hence to the increased incidence and aggressiveness of HCC in obese individuals is lacking. In this regard, we demonstrate that the Indian Hedgehog (Ihh) signaling pathway is upregulated in the fatty livers of mice consuming a high fat diet, and furthermore sustained in HCC tumors specifically within the context of a NAFLD microenvironment. Using a diet-induced mouse model of HCC wherein only obese mice develop HCC, targeted ablation of hepatocyte-secreted Ihh results in a decreased tumor burden and lower grade tumors. Ihh activation regulates the transdifferentiation of ciliated stellate cells and proliferation of Epcam(+) ductal cells to promote fibrosis. Mechanistically, increased expression of hitherto uncharacterized effectors of Hh pathway, namely Myc and Tgf-beta 2 is critical to the observed physiology. This pro-tumorigenic response is driven by increased expression of Wnt5a to effect a poorly-differentiated and invasive tumor phenotype. Wnt5a secreted from activated stellate cells act on Ror2-expressing hepatocytes. We further demonstrate that Wnt5a expression is also elevated in poorly-differentiated HCC cells, suggesting that these ligands are also able to function in an autocrine positive feedback manner to sustain poorly-differentiated tumors. Taken together, our study provides a mechanistic understanding for how Ihh signaling promotes HCC tumorigenesis specifically in obese mice. We propose that therapeutic targeting of the Hh pathway offers benefit for patients with dietary / NAFLD-driven steatotic HCC.	[Chong, Yong Chun; Lim, Tau En; Fu, Yanyun; Han, Weiping] ASTAR, Singapore Bioimaging Consortium, Lab Metab Med, Singapore, Singapore; [Shin, Eun Myoung] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore, Singapore; [Shin, Eun Myoung; Tergaonkar, Vinay; Han, Weiping] ASTAR, Inst Mol & Cell Biol, Singapore, Singapore; [Tergaonkar, Vinay; Han, Weiping] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Biochem, Singapore, Singapore; [Tergaonkar, Vinay] Univ South Australia, Ctr Canc Biol, Adelaide, SA, Australia; [Tergaonkar, Vinay] SA Pathol, Adelaide, SA, Australia	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Bioengineering & Bioimaging (IBB); A*STAR - Singapore Bioimaging Consortium (SBIC); National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; Centre for Cancer Biology; University of South Australia; SA Pathology	Han, WP (corresponding author), ASTAR, Singapore Bioimaging Consortium, Lab Metab Med, Singapore, Singapore.; Han, WP (corresponding author), ASTAR, Inst Mol & Cell Biol, Singapore, Singapore.; Han, WP (corresponding author), Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Biochem, Singapore, Singapore.	Weiping_Han@sbic.a-star.edu.sg		Chong, Yong Chun/0000-0001-9664-1715	A*STAR Biomedical Research Council [OFYIRG17may044]; National Medical Research Council, Singapore	A*STAR Biomedical Research Council(Agency for Science Technology & Research (A*STAR)); National Medical Research Council, Singapore(National Medical Research Council, SingaporeUK Research & Innovation (UKRI)Medical Research Council UK (MRC))	WH is supported by intramural funding from the A*STAR Biomedical Research Council. YCC is supported by a Young Individual Research Grant (OFYIRG17may044) from the National Medical Research Council, Singapore.	Ahn S, 2004, CELL, V118, P505, DOI 10.1016/j.cell.2004.07.023; Akinyemiju T, 2017, JAMA ONCOL, V3, P1683, DOI 10.1001/jamaoncol.2017.3055; Axelson M, 2013, CLIN CANCER RES, V19, P2289, DOI 10.1158/1078-0432.CCR-12-1956; Bafico A, 2004, CANCER CELL, V6, P497, DOI 10.1016/j.ccr.2004.09.032; Bai CB, 2002, DEVELOPMENT, V129, P4753; Bajenaru ML, 2002, MOL CELL BIOL, V22, P5100, DOI 10.1128/MCB.22.14.5100-5113.2002; Bijlsma MF, 2008, EXP BIOL MED, V233, P989, DOI 10.3181/0711-RM-307; Bitgood MJ, 1996, CURR BIOL, V6, P298, DOI 10.1016/S0960-9822(02)00480-3; Blaner WS, 2009, BBA-MOL CELL BIOL L, V1791, P467, DOI 10.1016/j.bbalip.2008.11.001; Cairo S, 2008, CANCER CELL, V14, P471, DOI 10.1016/j.ccr.2008.11.002; Calle EE, 2003, NEW ENGL J MED, V348, P1625, DOI 10.1056/NEJMoa021423; Calle EE, 2004, NAT REV CANCER, V4, P579, DOI 10.1038/nrc1408; Casey D, 2017, CLIN CANCER RES, V23, P2377, DOI 10.1158/1078-0432.CCR-16-2051; Choi SS, 2011, INT J BIOCHEM CELL B, V43, P238, DOI 10.1016/j.biocel.2010.10.015; Choi SS, 2009, AM J PHYSIOL-GASTR L, V297, pG1093, DOI 10.1152/ajpgi.00292.2009; Corbit KC, 2005, NATURE, V437, P1018, DOI 10.1038/nature04117; Czech MP, 2017, NAT MED, V23, P804, DOI 10.1038/nm.4350; Debebe A, 2017, ONCOGENE, V36, P6020, DOI 10.1038/onc.2017.207; Dohi T, 2012, J LEUKOCYTE BIOL, V92, P265, DOI 10.1189/jlb.0112042; Fabian SL, 2012, AM J PATHOL, V180, P1441, DOI 10.1016/j.ajpath.2011.12.039; Fabregat I, 2016, FEBS J, V283, P2219, DOI 10.1111/febs.13665; Fendrich V, 2008, GASTROENTEROLOGY, V135, P621, DOI 10.1053/j.gastro.2008.04.011; Feng L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038400; Font-Burgada J, 2016, CELL METAB, V23, P48, DOI 10.1016/j.cmet.2015.12.015; Friedman SL, 2008, PHYSIOL REV, V88, P125, DOI 10.1152/physrev.00013.2007; Gujral TS, 2014, CELL, V159, P844, DOI 10.1016/j.cell.2014.10.032; Hassan MM, 2015, GASTROENTEROLOGY, V149, P119, DOI 10.1053/j.gastro.2015.03.044; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Jung IH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027941; Kaposi-Novak P, 2009, CANCER RES, V69, P2775, DOI 10.1158/0008-5472.CAN-08-3357; Kim J, 2009, P NATL ACAD SCI USA, V106, P21666, DOI 10.1073/pnas.0912180106; Lodato F, 2006, WORLD J GASTROENTERO, V12, P7239, DOI 10.3748/wjg.v12.i45.7239; Long FX, 2001, DEVELOPMENT, V128, P5099; Loo TM, 2017, CANCER DISCOV, V7, P522, DOI 10.1158/2159-8290.CD-16-0932; Luga V, 2012, CELL, V151, P1542, DOI 10.1016/j.cell.2012.11.024; Mehlem A, 2013, NAT PROTOC, V8, P1149, DOI 10.1038/nprot.2013.055; Monga SP, 2015, GASTROENTEROLOGY, V148, P1294, DOI 10.1053/j.gastro.2015.02.056; Novoyatleva T, 2013, BASIC RES CARDIOL, V108, DOI 10.1007/s00395-012-0325-x; Omenetti A, 2008, J CLIN INVEST, V118, P3331, DOI 10.1172/JCI35875; Park EJ, 2010, CELL, V140, P197, DOI 10.1016/j.cell.2009.12.052; Peng T, 2015, NATURE, V526, P578, DOI 10.1038/nature14984; Postic C, 1999, J BIOL CHEM, V274, P305, DOI 10.1074/jbc.274.1.305; Potter JJ, 1999, LIVER, V19, P135, DOI 10.1111/j.1478-3231.1999.tb00023.x; Razzaque MS, 2005, J PATHOL, V207, P453, DOI 10.1002/path.1870; Rohatgi R, 2007, SCIENCE, V317, P372, DOI 10.1126/science.1139740; Schlange T, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1769; Schuppan D, 2008, LANCET, V371, P838, DOI 10.1016/S0140-6736(08)60383-9; Shin K, 2011, NATURE, V472, P110, DOI 10.1038/nature09851; Stewart GA, 2003, J PATHOL, V199, P488, DOI 10.1002/path.1295; Swiderska-Syn M, 2014, GUT, V63, P1333, DOI 10.1136/gutjnl-2013-305962; Szczepny A, 2017, ONCOGENE, V36, P5544, DOI 10.1038/onc.2017.173; Teglund S, 2010, BBA-REV CANCER, V1805, P181, DOI 10.1016/j.bbcan.2010.01.003; Tirnitz-Parker JEE, 2007, INT J BIOCHEM CELL B, V39, P2226, DOI 10.1016/j.biocel.2007.06.008; Velazquez RF, 2003, HEPATOLOGY, V37, P520, DOI 10.1053/jhep.2003.50093; VESSELINOVITCH SD, 1983, CANCER RES, V43, P4253; Wang XB, 2016, CELL METAB, V24, P848, DOI 10.1016/j.cmet.2016.09.016; Watkins DN, 2003, NATURE, V422, P313, DOI 10.1038/nature01493; Williams MJ, 2014, GASTROENTEROLOGY, V146, P349, DOI 10.1053/j.gastro.2013.11.034; Yuzugullu H, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-90; Zhang XM, 2001, CELL, V105, P781, DOI 10.1016/S0092-8674(01)00385-3	60	17	17	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2019	38	12					2206	2222		10.1038/s41388-018-0585-5	http://dx.doi.org/10.1038/s41388-018-0585-5			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP6UR	30470823				2022-12-17	WOS:000461822600015
J	Bakhshinyan, D; Venugopal, C; Adile, AA; Garg, N; Manoranjan, B; Hallett, R; Wang, X; Mahendram, S; Vora, P; Vijayakumar, T; Subapanditha, M; Singh, M; Kameda-Smith, MM; Qazi, M; McFarlane, N; Mann, A; Ajani, OA; Yarascavitch, B; Ramaswamy, V; Farooq, H; Morrissy, S; Cao, LX; Sydorenko, N; Baiazitov, R; Du, W; Sheedy, J; Weetall, M; Moon, YC; Lee, CS; Kwiecien, JM; Delaney, KH; Doble, B; Cho, YJ; Mitra, S; Kaplan, D; Taylor, MD; Davis, TW; Singh, SK				Bakhshinyan, David; Venugopal, Chitra; Adile, Ashley A.; Garg, Neha; Manoranjan, Branavan; Hallett, Robin; Wang, Xin; Mahendram, Sujeivan; Vora, Parvez; Vijayakumar, Thusyanth; Subapanditha, Minomi; Singh, Mohini; Kameda-Smith, Michelle Masayo; Qazi, Maleeha; McFarlane, Nicole; Mann, Aneet; Ajani, Olufemi A.; Yarascavitch, Blake; Ramaswamy, Vijay; Farooq, Hamza; Morrissy, Sorana; Cao, Liangxian; Sydorenko, Nadiya; Baiazitov, Ramil; Du, Wu; Sheedy, Josephine; Weetall, Marla; Moon, Young-Choon; Lee, Chang-Sun; Kwiecien, Jacek M.; Delaney, Kathleen H.; Doble, Brad; Cho, Yoon-Jae; Mitra, Siddhartha; Kaplan, David; Taylor, Michael D.; Davis, Thomas W.; Singh, Sheila K.			BMI1 is a therapeutic target in recurrent medulloblastoma	ONCOGENE			English	Article							NEURAL STEM-CELLS; CHILDHOOD MEDULLOBLASTOMA; MOLECULAR SUBGROUPS; MALIGNANT GLIOMA; CANCER; CLASSIFICATION; PREDICTION; REGULATORS; MODEL	Medulloblastoma (MB) is the most frequent malignant pediatric brain tumor, representing 20% of newly diagnosed childhood central nervous system malignancies. Although advances in multimodal therapy yielded a 5-year survivorship of 80%, MB still accounts for the leading cause of childhood cancer mortality. In this work, we describe the epigenetic regulator BMI1 as a novel therapeutic target for the treatment of recurrent human Group 3 MB, a childhood brain tumor for which there is virtually no treatment option beyond palliation. Current clinical trials for recurrent MB patients based on genomic profiles of primary, treatment-naive tumors will provide limited clinical benefit since recurrent metastatic MBs are highly genetically divergent from their primary tumor. Using a small molecule inhibitor against BMI1, PTC-028, we were able to demonstrate complete ablation of self-renewal of MB stem cells in vitro. When administered to mice xenografted with patient tumors, we observed significant reduction in tumor burden in both local and metastatic compartments and subsequent increased survival, without neurotoxicity. Strikingly, serial in vivo re-transplantation assays demonstrated a marked reduction in tumor initiation ability of recurrent MB cells upon re-transplantation of PTC-028-treated cells into secondary recipient mouse brains. As Group 3 MB is often metastatic and uniformly fatal at recurrence, with no current or planned trials of targeted therapy, an efficacious targeted agent would be rapidly transitioned to clinical trials.	[Bakhshinyan, David; Venugopal, Chitra; Adile, Ashley A.; Garg, Neha; Manoranjan, Branavan; Mahendram, Sujeivan; Vora, Parvez; Vijayakumar, Thusyanth; Subapanditha, Minomi; Singh, Mohini; Kameda-Smith, Michelle Masayo; Qazi, Maleeha; McFarlane, Nicole; Mann, Aneet; Doble, Brad; Singh, Sheila K.] McMaster Univ, McMaster Stem Cell & Canc Res Inst, Hamilton, ON L8S 4L8, Canada; [Bakhshinyan, David; Adile, Ashley A.; Manoranjan, Branavan; Vijayakumar, Thusyanth; Singh, Mohini; Kameda-Smith, Michelle Masayo; Qazi, Maleeha; Doble, Brad; Singh, Sheila K.] McMaster Univ, Dept Biochem, Hamilton, ON L8S 4L8, Canada; [Bakhshinyan, David; Adile, Ashley A.; Manoranjan, Branavan; Vijayakumar, Thusyanth; Singh, Mohini; Kameda-Smith, Michelle Masayo; Qazi, Maleeha; Doble, Brad; Singh, Sheila K.] McMaster Univ, Dept Biomed Sci, Hamilton, ON L8S 4L8, Canada; [Venugopal, Chitra; Garg, Neha; Mahendram, Sujeivan; Vora, Parvez; Subapanditha, Minomi; Kameda-Smith, Michelle Masayo; McFarlane, Nicole; Ajani, Olufemi A.; Yarascavitch, Blake; Singh, Sheila K.] McMaster Univ, Surg, Fac Hlth Sci, Hamilton, ON L8S 4L8, Canada; [Manoranjan, Branavan; Singh, Sheila K.] McMaster Univ, Michael G DeGroote Sch Med, Hamilton, ON L8S 4L8, Canada; [Hallett, Robin] Univ Toronto, Hosp Sick Children, Cell Biol Program, Toronto, ON M5S 1A1, Canada; [Wang, Xin; Ramaswamy, Vijay; Farooq, Hamza] Univ Toronto, Hosp Sick Children, Dev Stem Cell Biol Program, Toronto, ON M5S 1A1, Canada; [Wang, Xin; Farooq, Hamza; Taylor, Michael D.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5S 1A1, Canada; [Ramaswamy, Vijay; Morrissy, Sorana] Hosp Sick Children, Div Haematol Oncol, Toronto, ON M5G 1X8, Canada; [Cao, Liangxian; Sydorenko, Nadiya; Baiazitov, Ramil; Du, Wu; Sheedy, Josephine; Weetall, Marla; Moon, Young-Choon; Lee, Chang-Sun; Davis, Thomas W.] PTC Therapeut, 100 Corp Court, South Plainfield, NJ 07080 USA; [Kwiecien, Jacek M.; Delaney, Kathleen H.] McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON L8S 4L8, Canada; [Kwiecien, Jacek M.] Med Univ Lublin, Dept Clin Pathomorphol, Lublin, Poland; [Cho, Yoon-Jae; Mitra, Siddhartha] Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA; [Cho, Yoon-Jae; Mitra, Siddhartha] Stanford Univ, Sch Med, Dept Neurosurg, Stanford, CA 94305 USA; [Kaplan, David] Univ Toronto, Dept Mol Genet, Toronto, ON M5G 1X8, Canada; [Taylor, Michael D.] Hosp Sick Children, Div Neurosurg, Toronto, ON M5G 1X8, Canada	McMaster University; McMaster University; McMaster University; McMaster University; McMaster University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); McMaster University; Medical University of Lublin; Stanford University; Stanford University; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Singh, SK (corresponding author), McMaster Univ, McMaster Stem Cell & Canc Res Inst, Hamilton, ON L8S 4L8, Canada.; Singh, SK (corresponding author), McMaster Univ, Dept Biochem, Hamilton, ON L8S 4L8, Canada.; Singh, SK (corresponding author), McMaster Univ, Dept Biomed Sci, Hamilton, ON L8S 4L8, Canada.; Singh, SK (corresponding author), McMaster Univ, Surg, Fac Hlth Sci, Hamilton, ON L8S 4L8, Canada.; Singh, SK (corresponding author), McMaster Univ, Michael G DeGroote Sch Med, Hamilton, ON L8S 4L8, Canada.	ssingh@mcmaster.ca	Doble, Bradley/V-7848-2019; Garg, Neha/AAG-5180-2020; Yarascavitch, Blake/AAR-8800-2021; Singh, Sheila K/W-2799-2018; Wang, Xin/O-8779-2019	Doble, Bradley/0000-0002-0260-2983; Garg, Neha/0000-0003-2227-8292; Yarascavitch, Blake/0000-0003-1810-1267; Singh, Sheila K/0000-0003-1272-5300; Wang, Xin/0000-0001-6292-3087; Taylor, Michael/0000-0001-7009-3466; Morrissy, Sorana/0000-0001-8526-562X; Adile, Ashley/0000-0002-3700-7527; Ramaswamy, Vijay/0000-0002-6557-895X	Canada Research Chair award; Canadian Institutes of Health Research (CIHR); Stem Cell Network; Ontario Institute for Cancer Research Cancer Stem Cell Program; Canadian Cancer Society Research Institute; Cancer Research Society; Brain Tumor Foundation of Canada	Canada Research Chair award(Natural Resources CanadaCanadian Forest ServiceCanada Research Chairs); Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Stem Cell Network; Ontario Institute for Cancer Research Cancer Stem Cell Program; Canadian Cancer Society Research Institute(Canadian Cancer Society (CCS)); Cancer Research Society; Brain Tumor Foundation of Canada	SKS is supported by Canada Research Chair award, and operating grants from Canadian Institutes of Health Research (CIHR), Stem Cell Network, the Ontario Institute for Cancer Research Cancer Stem Cell Program, the Canadian Cancer Society Research Institute, the Cancer Research Society, the Brain Tumor Foundation of Canada, and generous donations from the Box Run Foundation, Team Kelsey, and patients and their families.	ALKEMA MJ, 1993, HUM MOL GENET, V2, P1597, DOI 10.1093/hmg/2.10.1597; Bandopadhayay P, 2014, CLIN CANCER RES, V20, P912, DOI 10.1158/1078-0432.CCR-13-2281; Bruggeman SWM, 2007, CANCER CELL, V12, P328, DOI 10.1016/j.ccr.2007.08.032; Cavalli FMG, 2017, CANCER CELL, V31, P737, DOI 10.1016/j.ccell.2017.05.005; Chen J, 2012, NATURE, V488, P522, DOI 10.1038/nature11287; Cho JH, 2011, BMC SYST BIOL, V5, DOI 10.1186/1752-0509-5-117; Cho YJ, 2011, J CLIN ONCOL, V29, P1424, DOI 10.1200/JCO.2010.28.5148; Ellison DW, 2010, ACTA NEUROPATHOL, V120, P305, DOI 10.1007/s00401-010-0726-6; Facchino S, 2010, J NEUROSCI, V30, P10096, DOI 10.1523/JNEUROSCI.1634-10.2010; Gargiulo G, 2013, CANCER CELL, V23, P660, DOI 10.1016/j.ccr.2013.03.030; Glinsky GV, 2005, J CLIN INVEST, V115, P1503, DOI 10.1172/JCI23412; Hallett RM, 2012, BMC MED GENOMICS, V5, DOI 10.1186/1755-8794-5-16; Hallett RM, 2012, SCI REP-UK, V2, DOI 10.1038/srep00227; HE XM, 1991, LAB INVEST, V64, P833; Huse JT, 2010, NAT REV CANCER, V10, P319, DOI 10.1038/nrc2818; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Ismail IH, 2010, J CELL BIOL, V191, P45, DOI 10.1083/jcb.201003034; Kool M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003088; Kreso A, 2014, NAT MED, V20, P29, DOI 10.1038/nm.3418; Leung C, 2004, NATURE, V428, P337, DOI 10.1038/nature02385; Northcott PA, 2011, J CLIN ONCOL, V29, P1408, DOI 10.1200/JCO.2009.27.4324; Pei YX, 2012, CANCER CELL, V21, P155, DOI 10.1016/j.ccr.2011.12.021; Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a; Ramaswamy V, 2013, LANCET ONCOL, V14, P1200, DOI 10.1016/S1470-2045(13)70449-2; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Sauvageau M, 2010, CELL STEM CELL, V7, P299, DOI 10.1016/j.stem.2010.08.002; Schwalbe EC, 2017, LANCET ONCOL, V18, P958, DOI 10.1016/S1470-2045(17)30243-7; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Taylor MD, 2012, ACTA NEUROPATHOL, V123, P465, DOI 10.1007/s00401-011-0922-z; Thompson MC, 2006, J CLIN ONCOL, V24, P1924, DOI 10.1200/JCO.2005.04.4974; Tropepe V, 1999, DEV BIOL, V208, P166, DOI 10.1006/dbio.1998.9192; Venugopal C, 2015, CLIN CANCER RES, V21, P5324, DOI 10.1158/1078-0432.CCR-14-3147; Venugopal C, 2012, J NEURO-ONCOL, V109, P457, DOI 10.1007/s11060-012-0917-1; Wang HB, 2004, NATURE, V431, P873, DOI 10.1038/nature02985; Wang X, 2012, ONCOGENE, V31, P187, DOI 10.1038/onc.2011.232; Wang X, 2015, ACTA NEUROPATHOL, V129, P449, DOI 10.1007/s00401-015-1389-0; Wu X, 2012, NATURE, V482, P529, DOI 10.1038/nature10825; Yong KJ, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad6066	40	17	18	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2019	38	10					1702	1716		10.1038/s41388-018-0549-9	http://dx.doi.org/10.1038/s41388-018-0549-9			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HN8DD	30348991				2022-12-17	WOS:000460423800010
J	Hsu, FF; Chou, YT; Chiang, MT; Li, FA; Yeh, CT; Lee, WH; Chau, LY				Hsu, Fu-Fei; Chou, Yi-Tai; Chiang, Ming-Tsai; Li, Fu-An; Yeh, Chi-Tai; Lee, Wei-Hwa; Chau, Lee-Young			Signal peptide peptidase promotes tumor progression via facilitating FKBP8 degradation	ONCOGENE			English	Article							INTRAMEMBRANE PROTEOLYSIS; HEME OXYGENASE-1; CLEAVAGE; PROTEIN; IDENTIFICATION; INHIBITOR; MECHANISM; BCL-2	Signal peptide peptidase (SPP) is an endoplasmic reticulum (ER)-resident aspartyl protease mediating intramembrane cleavage of type II transmembrane proteins. Increasing evidence has supported the role of SPP in ER-associated protein degradation. In the present study, we show that SPP expression is highly induced in human lung and breast cancers and correlated with disease outcome. Stable depletion of SPP expression in lung and breast cancer cell lines significantly reduced cell growth and migration/invasion abilities. Quantitative analysis of the proteomic changes of microsomal proteins in lung cancer cells by the stable isotope labeling with amino acids in cell culture (SILAC) approach revealed that the level of FKBP8, an endogenous inhibitor of mTOR, was significantly increased following SPP depletion. Co-immunoprecipitation assay and confocal immunofluorescence demonstrated that SPP interacted and colocalized with FKBP8 in ER, supporting that FKBP8 is a protein substrate of SPP. Cycloheximide chase and proteasome inhibition experiments revealed that SPP-mediated proteolysis facilitated FKBP8 protein degradation in cytosol. Further experiment demonstrated that the levels of phosphorylation in mTOR and its downstream effectors, S6K and 4E-BP1, were significantly lower in SPP-depleted cells. The reduced mTOR signaling and decreases of growth and migration/invasion abilities induced by SPP depletion in cancer cells could be reversed by FKBP8 downregulation. The implication of FKBP8 in SPP-mediated tumorigenicity was also observed in the xenograft model. Together, these findings disclose that SPP promotes tumor progression, at least in part, via facilitating the degradation of FKBP8 to enhance mTOR signaling.	[Hsu, Fu-Fei; Chou, Yi-Tai; Chiang, Ming-Tsai; Li, Fu-An; Chau, Lee-Young] Acad Sinica, Inst Biomed Sci, Taipei, Taiwan; [Yeh, Chi-Tai; Lee, Wei-Hwa] Taipei Med Univ, Shuang Ho Hosp, Canc Ctr, Taipei, Taiwan	Academia Sinica - Taiwan; Taipei Medical University; Shuang Ho Hospital	Chau, LY (corresponding author), Acad Sinica, Inst Biomed Sci, Taipei, Taiwan.	lyc@ibms.sinica.edu.tw	Chau, Lee-Young/N-7659-2018; Li, Fu-An/M-8506-2019	Chau, Lee-Young/0000-0002-6316-2328; Li, Fu-An/0000-0002-0580-7765	Ministry of Science and Technology Taiwan [MOST 103-2320-B-001-013-MY3]; Institute of Biomedical Sciences, Academia Sinica	Ministry of Science and Technology Taiwan(Ministry of Science and Technology, Taiwan); Institute of Biomedical Sciences, Academia Sinica(Academia Sinica - Taiwan)	This work was supported by the Ministry of Science and Technology Taiwan (MOST 103-2320-B-001-013-MY3) and Institute of Biomedical Sciences, Academia Sinica.	Avci D, 2015, TRENDS CELL BIOL, V25, P611, DOI 10.1016/j.tcb.2015.07.003; Avci D, 2014, MOL CELL, V56, P630, DOI 10.1016/j.molcel.2014.10.012; Bai XC, 2007, SCIENCE, V318, P977, DOI 10.1126/science.1147379; Barth S, 2009, J BIOL CHEM, V284, P23046, DOI 10.1074/jbc.M109.032631; Boname JM, 2014, J CELL BIOL, V205, P847, DOI 10.1083/jcb.201312009; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Chen CY, 2014, EMBO J, V33, P2492, DOI 10.15252/embj.201488208; Chen XL, 2015, PROTEOMICS, V15, P3175, DOI 10.1002/pmic.201500108; Choi MS, 2011, BIOCHEM BIOPH RES CO, V406, P305, DOI 10.1016/j.bbrc.2011.02.037; Das I, 2004, J BIOL CHEM, V279, P30771, DOI 10.1074/jbc.M309252200; Edlich F, 2005, EMBO J, V24, P2688, DOI 10.1038/sj.emboj.7600739; Fong S, 2003, P NATL ACAD SCI USA, V100, P14253, DOI 10.1073/pnas.2332307100; Guan M, 2015, SCI REP-UK, V5, DOI 10.1038/srep09698; Hsu FF, 2015, ONCOGENE, V34, P2360, DOI 10.1038/onc.2014.166; Hwang HW, 2009, J BIOL CHEM, V284, P22672, DOI 10.1074/jbc.M109.028001; LAM E, 1995, GENE, V160, P297, DOI 10.1016/0378-1119(95)00216-S; Lemberg MK, 2002, MOL CELL, V10, P735, DOI 10.1016/S1097-2765(02)00655-X; Loureiro J, 2006, NATURE, V441, P894, DOI 10.1038/nature04830; Mentrup T, 2017, EUR J CELL BIOL, V96, P372, DOI 10.1016/j.ejcb.2017.03.002; Murakami D, 2003, ONCOGENE, V22, P1511, DOI 10.1038/sj.onc.1206298; Okamoto K, 2004, J VIROL, V78, P6370, DOI 10.1128/JVI.78.12.6370-6380.2004; Shi XH, 2016, P NATL ACAD SCI USA, V113, P8825, DOI 10.1073/pnas.1603364113; Shirane M, 2003, NAT CELL BIOL, V5, P28, DOI 10.1038/ncb894; Song W, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9022; Targett-Adams P, 2006, J BIOL CHEM, V281, P29221, DOI 10.1074/jbc.M605373200; Urban S, 2002, CURR OPIN GENET DEV, V12, P512, DOI 10.1016/S0959-437X(02)00334-9; Cespedes MV, 2010, AM J PATHOL, V177, P2067, DOI 10.2353/ajpath.2010.100079; Voss M, 2013, BBA-BIOMEMBRANES, V1828, P2828, DOI 10.1016/j.bbamem.2013.03.033; Wahlstrom AM, 2007, BLOOD, V109, P763, DOI 10.1182/blood-2006-05-024752; Wei JW, 2017, CNS NEUROSCI THER, V23, P257, DOI 10.1111/cns.12672; Weihofen A, 2002, SCIENCE, V296, P2215, DOI 10.1126/science.1070925; Wolfe MS, 2009, J BIOL CHEM, V284, P13969, DOI 10.1074/jbc.R800039200	32	17	18	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2019	38	10					1688	1701		10.1038/s41388-018-0539-y	http://dx.doi.org/10.1038/s41388-018-0539-y			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HN8DD	30348988				2022-12-17	WOS:000460423800009
J	Zhang, DD; Li, Y; Xu, Y; Kim, J; Huang, S				Zhang, Dan-Dan; Li, Yue; Xu, Yuan; Kim, Jaejik; Huang, Shuang			Phosphodiesterase 7B/microRNA-200c relationship regulates triple-negative breast cancer cell growth	ONCOGENE			English	Article							7B MESSENGER-RNA; NUCLEOTIDE PHOSPHODIESTERASE; MIR-200 FAMILY; ENHANCES RADIOSENSITIVITY; MESENCHYMAL TRANSITION; INCREASED EXPRESSION; DOWN-REGULATION; CYCLIC-AMP; PROTEIN; APOPTOSIS	Members of microRNA-200 (miRNA-200) family have a regulatory role in epithelial to mesenchymal transition (EMT) by suppressing Zeb1 and Zeb2 expression. Consistent with its role in suppressing EMT, Hsa-miR-200c-3p (miR-200c), a member of miR-200 family is poorly expressed in mesenchymal-like triple-negative breast cancer (TNBC) cells and ectopic miR-200c expression suppresses cell migration. In this study, we demonstrated that miR-200c potently inhibited TNBC cell growth and tumor development in a mechanism distinct from its ability to downregulate Zeb1 and Zeb2 expression, because silencing them only marginally affected TNBC cell growth. We identified phosphodiesterase 7B (PDE7B) as a bona fide miR-200c target. Importantly, miR-200c-led inhibition in cell growth and tumor development was prevented by forcing PDE7B transgene expression, while knockdown of PDE7B effectively inhibited cell growth. These results suggest that miR-200c inhibits cell growth by targeting PDE7B mRNA. To elucidate mechanism underlying miR-200c/PDE7B regulation of TNBC cell growth, we showed that cAMP concentration was lower in TNBC cells compared with estrogen receptor-positive (ER +) cells, and that both miR-200c and PDE7B siRNAs were able to increase cAMP concentration in TNBC cells. High level of cellular cAMP has been shown to induce cell cycle arrest and apoptosis in TNBC cells. Our observation that ectopic expression of miR-200c triggered apoptosis indicates that it does so by elevating level of cellular cAMP. Analysis of breast tumor gene expression datasets revealed an inverse association between miR-200c and PDE7B expression. Especially, both low miR-200c and high PDE7B expression were correlated with poor survival of breast cancer patients. Our study supports a critical role of miR-200c/PDE7B relationship in TNBC tumorigenesis.	[Zhang, Dan-Dan; Xu, Yuan; Huang, Shuang] Shanghai Univ Tradit Chinese Med, Inst Interdisciplinary Integrat Med Res, Shanghai 201203, Peoples R China; [Li, Yue; Huang, Shuang] Univ Florida, Coll Med, Dept Anat & Cell Biol, Gainesville, FL 32608 USA; [Kim, Jaejik] Sungkyunkwan Univ, Dept Stat, Seoul 03063, South Korea	Shanghai University of Traditional Chinese Medicine; State University System of Florida; University of Florida; Sungkyunkwan University (SKKU)	Zhang, DD; Huang, S (corresponding author), Shanghai Univ Tradit Chinese Med, Inst Interdisciplinary Integrat Med Res, Shanghai 201203, Peoples R China.; Huang, S (corresponding author), Univ Florida, Coll Med, Dept Anat & Cell Biol, Gainesville, FL 32608 USA.	izhangdd@126.com; shuanghuang@ufl.edu	zhang, dan-dan/AAR-5085-2020	zhang, dan-dan/0000-0003-0591-2167	NSF of China [81773946, 81573673, 81001666]; NIH [CA187152]; Florida Breast Cancer Foundation; NATIONAL CANCER INSTITUTE [R01CA187152] Funding Source: NIH RePORTER	NSF of China(National Natural Science Foundation of China (NSFC)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Florida Breast Cancer Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by funding from NSF of China 81773946, 81573673, 81001666 (DZ), NIH CA187152 (SH), and Florida Breast Cancer Foundation (SH).	Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bender AT, 2006, PHARMACOL REV, V58, P488, DOI 10.1124/pr.58.3.5; Brooks MD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107397; Budczies J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051862; Chen HM, 2009, CANCER RES, V69, P9228, DOI 10.1158/0008-5472.CAN-09-1950; Cho-Chung YS, 2005, ANN NY ACAD SCI, V1058, P76, DOI 10.1196/annals.1359.014; CHOCHUNG YS, 1981, SCIENCE, V214, P77, DOI 10.1126/science.6269181; Cochrane DR, 2009, MOL CANCER THER, V8, P1055, DOI 10.1158/1535-7163.MCT-08-1046; Damiano V, 2017, GENE CHROMOSOME CANC, V56, P147, DOI 10.1002/gcc.22422; Dicitore A, 2016, ENDOCRINE, V51, P101, DOI 10.1007/s12020-015-0597-7; DREES M, 1993, CANCER RES, V53, P3058; Fang C, 2013, LEUKEMIA RES, V37, P536, DOI 10.1016/j.leukres.2013.02.006; Feng ZM, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1655-5; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Hong S, 2014, NEOPLASIA, V16, P279, DOI 10.1016/j.neo.2014.03.010; Hong SG, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003706; Howe EN, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2867; Hu Q, 2013, ONCOGENE, V32, P3933, DOI 10.1038/onc.2012.414; Hurteau GJ, 2007, CANCER RES, V67, P7972, DOI 10.1158/0008-5472.CAN-07-1058; Jones R, 2017, ONCOTARGET, V8, P23727, DOI 10.18632/oncotarget.15829; Karagkouni D, 2018, NUCLEIC ACIDS RES, V46, pD239, DOI 10.1093/nar/gkx1141; Kim SN, 2001, INT J CANCER, V93, P33, DOI 10.1002/ijc.1308; Knezevic J, 2015, ONCOGENE, V34, P5997, DOI 10.1038/onc.2015.48; Korner C, 2013, J BIOL CHEM, V288, P8750, DOI 10.1074/jbc.M112.414128; Kopp F, 2014, ONCOTARGET, V5, P185, DOI 10.18632/oncotarget.1427; Kopp F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050469; Levy I, 2011, CURR OPIN PHARMACOL, V11, P689, DOI 10.1016/j.coph.2011.10.003; Li JH, 2014, NUCLEIC ACIDS RES, V42, pD92, DOI 10.1093/nar/gkt1248; Li Y, 2010, CANCER RES, V70, P7894, DOI 10.1158/0008-5472.CAN-10-1675; Lim YY, 2013, J CELL SCI, V126, P2256, DOI 10.1242/jcs.122275; Lin J, 2013, J CELL BIOCHEM, V114, P606, DOI 10.1002/jcb.24398; Liu JW, 2016, INT J NANOMED, V11, P6713, DOI 10.2147/IJN.S111647; Luo DY, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-57; Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174; Maurice DH, 2014, NAT REV DRUG DISCOV, V13, P290, DOI 10.1038/nrd4228; McEwan DG, 2007, CANCER RES, V67, P5248, DOI 10.1158/0008-5472.CAN-07-0097; Naviglio S, 2010, J CELL PHYSIOL, V225, P801, DOI 10.1002/jcp.22288; Naviglio S, 2009, CANCER BIOL THER, V8, P1183, DOI 10.4161/cbt.8.12.8562; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Pattabiraman DR, 2016, SCIENCE, V351, P1042, DOI 10.1126/science.aad3680; Radisky DC, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2885; Savai R, 2010, EXPERT OPIN INV DRUG, V19, P117, DOI 10.1517/13543780903485642; Shimizu K, 2009, ANTICANCER RES, V29, P1119; Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011; Song CL, 2015, ONCOTARGET, V6, P34968, DOI 10.18632/oncotarget.5198; Sossey-Alaoui K, 2011, INT J CANCER, V129, P1331, DOI 10.1002/ijc.25793; Sun QQ, 2015, INT J CANCER, V136, P1003, DOI 10.1002/ijc.29065; Tamura M, 2015, CANCER SCI, V106, P1033, DOI 10.1111/cas.12713; Wang W, 2016, ONCOTARGET, V7, P87232, DOI 10.18632/oncotarget.13601; Wolfrum C, 2007, NAT BIOTECHNOL, V25, P1149, DOI 10.1038/nbt1339; Yang L, 2015, ONCOTARGET, V6, P20801, DOI 10.18632/oncotarget.4600; Yi Y, 2017, NUCLEIC ACIDS RES, V45, pD115, DOI 10.1093/nar/gkw1052; Zhang LZ, 2011, INT J CANCER, V129, P1162, DOI 10.1002/ijc.25785; Zhang LZ, 2008, P NATL ACAD SCI USA, V105, P19532, DOI 10.1073/pnas.0806152105; Zheng Q, 2017, CELL DEATH DIFFER, V24, P2161, DOI 10.1038/cdd.2017.136	55	17	21	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2019	38	7					1106	1120		10.1038/s41388-018-0499-2	http://dx.doi.org/10.1038/s41388-018-0499-2			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HL3OH	30209363	Green Accepted			2022-12-17	WOS:000458624900013
J	Chen, WH; Cai, MY; Zhang, JX; Wang, FW; Tang, LQ; Liao, YJ; Jin, XH; Wang, CY; Guo, L; Jiang, YG; Ren, CP; Mai, HQ; Zeng, MS; Kung, HF; Qian, CN; Xie, D				Chen, Wen-Hui; Cai, Mu-Yan; Zhang, Jia-Xing; Wang, Feng-Wei; Tang, Lin-Quan; Liao, Yi-Ji; Jin, Xiao-Han; Wang, Chen-Yuan; Guo, Ling; Jiang, Yi-Guo; Ren, Cai-Ping; Mai, Hai-Qiang; Zeng, Mu-Sheng; Kung, Hsiang-Fu; Qian, Chao-Nan; Xie, Dan			FMNL1 mediates nasopharyngeal carcinoma cell aggressiveness by epigenetically upregulating MTA1	ONCOGENE			English	Article							LEUKOCYTE FORMIN; CANCER; METASTASIS; REORGANIZATION; CYTOSKELETON; INVADOPODIA; EXPRESSION; MICRORNAS; MECHANISM; CORTACTIN	It has been suggested that formin-like protein 1 (FMNL1) plays an important role in the pathogenic process of several hematopoietic malignancies. In this study, we performed a series of in vivo and in vitro assays to elucidate the biological functions of FMNL1 and underlying mechanisms in human nasopharyngeal carcinoma (NPC) pathogenesis. Herein, we report that high expression of FMNL1 in NPC is positively associated with an aggressive disease and/or poor patient survival. Ectopic overexpression of FMNL1 in NPC cells substantially promoted cell invadopodia formation, epithelial-mesenchymal transition (EMT) and invasiveness, whereas depletion of FMNL1 potently suppressed NPC cells invadopodia formation, EMT, and invasive/metastatic capacities. We further show that FMNL1 could enhance NPC cell aggressiveness by increasing a key downstream target, the metastasis-associated protein 1 (MTA1) gene. Importantly, ectopic overexpression of FMNL1 in NPC cells markedly improved the binding of HDAC1 with Profilin2 in the cytoplasm and suppressed the enrichment of HDAC1 on the promoter of MTA1 and thereby, leading to an increased MTA1 transcription and expression. Furthermore, in addition to the amplification of FMNL1 gene, decreased level of miR-16 in NPCs is another critical mechanism to upregulate FMNL1 expression. These results, collectively, provide first-line of evidences that high expression of FMNL1, resulted from decreased miR-16 and/or MTA1 amplification, has a potent oncogenic role to drive the development and aggressive process of NPC by upregulating MTA1, and FMNL1 might be employed as a new prognostic biomarker and therapeutic target for human NPC.	[Chen, Wen-Hui; Cai, Mu-Yan; Zhang, Jia-Xing; Wang, Feng-Wei; Tang, Lin-Quan; Liao, Yi-Ji; Jin, Xiao-Han; Wang, Chen-Yuan; Guo, Ling; Mai, Hai-Qiang; Zeng, Mu-Sheng; Kung, Hsiang-Fu; Qian, Chao-Nan; Xie, Dan] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China; [Chen, Wen-Hui; Cai, Mu-Yan; Zhang, Jia-Xing; Wang, Feng-Wei; Tang, Lin-Quan; Liao, Yi-Ji; Jin, Xiao-Han; Wang, Chen-Yuan; Guo, Ling; Mai, Hai-Qiang; Zeng, Mu-Sheng; Kung, Hsiang-Fu; Qian, Chao-Nan; Xie, Dan] Sun Yat Sen Univ, Ctr Canc, Collaborat Innovat Ctr Canc Med, Guangzhou, Guangdong, Peoples R China; [Chen, Wen-Hui] Jinan Univ, Dept Oncol, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China; [Cai, Mu-Yan; Xie, Dan] Sun Yat Sen Univ, Ctr Canc, Dept Pathol, Guangzhou, Guangdong, Peoples R China; [Zhang, Jia-Xing] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Oncol, Guangzhou, Guangdong, Peoples R China; [Tang, Lin-Quan; Guo, Ling; Mai, Hai-Qiang; Qian, Chao-Nan] Sun Yat Sen Univ, Ctr Canc, Dept Nasopharyngeal Canc, Guangzhou, Guangdong, Peoples R China; [Jiang, Yi-Guo] Guangzhou Med Univ, State Key Lab Resp Dis, Guangzhou, Guangdong, Peoples R China; [Ren, Cai-Ping] Cent South Univ, Sch Basic Med Sci, Collaborat Innovat Ctr Canc Med, Canc Res Inst, Changsha, Hunan, Peoples R China; [Ren, Cai-Ping] Cent South Univ, Sch Basic Med Sci, Chinese Minist Hlth, Key Lab Carcinogenesis, Changsha, Hunan, Peoples R China; [Kung, Hsiang-Fu] Chinese Univ Hong Kong, State Key Lab Oncol South China, Hong Kong, Hong Kong, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; Jinan University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Guangzhou Medical University; State Key Laboratory of Respiratory Disease; Central South University; Central South University; Chinese University of Hong Kong; State Key Lab Oncology South China	Xie, D (corresponding author), Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China.; Xie, D (corresponding author), Sun Yat Sen Univ, Ctr Canc, Collaborat Innovat Ctr Canc Med, Guangzhou, Guangdong, Peoples R China.; Xie, D (corresponding author), Sun Yat Sen Univ, Ctr Canc, Dept Pathol, Guangzhou, Guangdong, Peoples R China.	xiedan@sysucc.org.cn	LIAO, YIJI/Z-4902-2019	LIAO, YIJI/0000-0002-0849-4573; zeng, musheng/0000-0003-3509-5591; Jiang, Yiguo/0000-0002-9499-2594	National Key R&D Program of China [2017YFC1309001]; Nature Science Foundation of China [81572359, 81572848, 81702681, 81730072]; Open Project of State Key Laboratory of Respiratory Disease of China [SKLRD2016OP004]	National Key R&D Program of China; Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); Open Project of State Key Laboratory of Respiratory Disease of China	This work was supported by grants from the National Key R&D Program of China (No. 2017YFC1309001), the Nature Science Foundation of China (No. 81572359, 81572848, 81702681, and 81730072) and Open Project of State Key Laboratory of Respiratory Disease of China (No. SKLRD2016OP004).	Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bowden ET, 2006, EXP CELL RES, V312, P1240, DOI 10.1016/j.yexcr.2005.12.012; Chesarone MA, 2010, NAT REV MOL CELL BIO, V11, P62, DOI 10.1038/nrm2816; FANDI A, 1994, SEMIN ONCOL, V21, P382; Favaro P, 2013, J LEUKOCYTE BIOL, V94, P503, DOI 10.1189/jlb.0113057; Favaro PMB, 2006, LEUKEMIA RES, V30, P735, DOI 10.1016/j.leukres.2005.10.003; Favaro PMB, 2003, BIOCHEM BIOPH RES CO, V311, P365, DOI 10.1016/j.bbrc.2003.10.012; Gardberg M, 2014, J HISTOCHEM CYTOCHEM, V62, P460, DOI 10.1369/0022155414532293; Gomez TS, 2007, IMMUNITY, V26, P177, DOI 10.1016/j.immuni.2007.01.008; Goode BL, 2007, ANNU REV BIOCHEM, V76, P593, DOI 10.1146/annurev.biochem.75.103004.142647; He SH, 2013, J CELL PHYSIOL, V228, P1525, DOI 10.1002/jcp.24311; Higgs HN, 2005, TRENDS BIOCHEM SCI, V30, P342, DOI 10.1016/j.tibs.2005.04.014; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Jones-Rhoades MW, 2004, MOL CELL, V14, P787, DOI 10.1016/j.molcel.2004.05.027; Kuhn Sonja, 2014, Small GTPases, V5, pe29513, DOI 10.4161/sgtp.29513; Kumar R, 2003, SEMIN ONCOL, V30, P30, DOI 10.1053/j.seminoncol.2003.08.005; Li JS, 2013, CHIN J CANCER, V32, P3, DOI 10.5732/cjc.011.10381; Liu LL, 2014, HEPATOLOGY, V59, P531, DOI 10.1002/hep.26677; Liu N, 2012, LANCET ONCOL, V13, DOI 10.1016/S1470-2045(12)70102-X; Luger K, 1998, CURR OPIN GENET DEV, V8, P140, DOI 10.1016/S0959-437X(98)80134-2; Marzook H, 2014, CANCER METAST REV, V33, P953, DOI 10.1007/s10555-014-9521-5; Mersich AT, 2010, CYTOSKELETON, V67, P573, DOI 10.1002/cm.20468; Pakala SB, 2011, ONCOGENE, V30, P2230, DOI 10.1038/onc.2010.608; Qian CN, 2006, CANCER RES, V66, P10365, DOI 10.1158/0008-5472.CAN-06-2977; Schuster IG, 2007, BLOOD, V110, P2931, DOI 10.1182/blood-2006-11-058750; Song QC, 2013, J EXP CLIN CANC RES, V32, DOI 10.1186/1756-9966-32-54; Song QC, 2013, INT J BIOCHEM CELL B, V45, P1439, DOI 10.1016/j.biocel.2013.04.017; STARK GR, 1989, CELL, V57, P901, DOI 10.1016/0092-8674(89)90328-0; Tang YN, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9230; Toh Y, 2009, CLIN EXP METASTAS, V26, P215, DOI 10.1007/s10585-008-9233-8; Tong ZT, 2012, ONCOGENE, V31, P583, DOI 10.1038/onc.2011.254; Wang ZB, 2009, CELL, V138, P1019, DOI 10.1016/j.cell.2009.06.049; Webb BA, 2007, EUR J CELL BIOL, V86, P189, DOI 10.1016/j.ejcb.2007.01.003; Wee Joseph Tien Seng, 2010, Chin J Cancer, V29, P517; Wei William I, 2007, Curr Opin Otolaryngol Head Neck Surg, V15, P99, DOI 10.1097/MOO.0b013e3280148a06; West AC, 2014, J CLIN INVEST, V124, P30, DOI 10.1172/JCI69738; Winter M, 2013, EMBO J, V32, P3176, DOI 10.1038/emboj.2013.243; Yilmaz M, 2009, CANCER METAST REV, V28, P15, DOI 10.1007/s10555-008-9169-0; Young KG, 2010, BBA-MOL CELL RES, V1803, P183, DOI 10.1016/j.bbamcr.2008.09.017; Zhang LF, 2015, CHIN J CANCER, V34, DOI 10.1186/s40880-015-0018-6; Zheng F, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1004873; Zheng F, 2012, GUT, V61, P278, DOI 10.1136/gut.2011.239145; Zhu W, 2012, GUT, V61, P562, DOI 10.1136/gutjnl-2011-300207	43	17	17	2	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 29	2018	37	48					6243	6258		10.1038/s41388-018-0351-8	http://dx.doi.org/10.1038/s41388-018-0351-8			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC2HE	30013189				2022-12-17	WOS:000451622100004
J	Lee, E; Collazo-Lorduy, A; Castillo-Martin, M; Gong, YX; Wang, L; Oh, WK; Galsky, MD; Cordon-Cardo, C; Zhu, J				Lee, Eunjee; Collazo-Lorduy, Ana; Castillo-Martin, Mireia; Gong, Yixuan; Wang, Li; Oh, William K.; Galsky, Matthew D.; Cordon-Cardo, Carlos; Zhu, Jun			Identification of microR-106b as a prognostic biomarker of p53-like bladder cancers by ActMiR	ONCOGENE			English	Article							GENE-EXPRESSION SIGNATURE; ALKALOID EMETINE; DOWN-REGULATION; MICRORNA; CISPLATIN; TARGETS; CELLS	Bladder cancers can be categorized into subtypes according to gene expression patterns. P53-like muscle-invasive bladder cancers are generally resistant to cisplatin-based chemotherapy, but exhibit heterogeneous clinical outcomes with a prognosis intermediate to that of the luminal and basal subtypes. The optimal approach to p53-like tumors remains poorly defined and better means to risk-stratify such tumors and identification of novel therapeutic targets is urgently needed. MicroRNAs (miRNAs) play a key role in cancer, both in tumorigenesis and tumor progression. In the past few years, miRNA expression signatures have been reported as prognostic biomarkers in different tumor types including bladder cancer. However, miRNA's expression does not always correlate well with its activity. We previously developed ActMiR, a computational method for explicitly inferring miRNA activities. We applied ActMiR to The Cancer Genome Atlas (TCGA) bladder cancer data set and identified the activities of miR-106b-5p and miR-532-3p as potential prognostic markers of the p53-like subtype, and validated them in three independent bladder cancer data sets. Especially, higher miR-106b-5p activity was consistently associated with better survival in these data sets. Furthermore, we experimentally validated causal relationships between miR-106-5p and its predicted target genes in p53-like cell line HT1197. HT1197 cells treated with the miR-106b-5p-specific inhibitor were more invasive while cells treated with the miR-106b-5p-specific mimic were less invasive than corresponding controls. Altogether, our results suggest that miR-106b-5p activity can categorize p53-like bladder tumors into more and less-favorable prognostic groups, which provides critical information for personalizing treatment option for p53-like bladder cancers.	[Lee, Eunjee; Wang, Li; Zhu, Jun] Dept Genet & Genom Sci, New York, NY 10029 USA; [Lee, Eunjee; Wang, Li; Zhu, Jun] Icahn Sch Med Mt Sinai, Icahn Inst Genom & Multiscale Biol, New York, NY 10029 USA; [Lee, Eunjee; Wang, Li; Zhu, Jun] Sema4, Stamford, CT 06902 USA; [Collazo-Lorduy, Ana; Castillo-Martin, Mireia; Cordon-Cardo, Carlos] Icahn Sch Med Mt Sinai, Dept Pathol, New York, NY 10029 USA; [Castillo-Martin, Mireia] Champalimaud Ctr Unknown, Dept Pathol, Lisbon, Portugal; [Gong, Yixuan; Oh, William K.; Galsky, Matthew D.; Zhu, Jun] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Fundacao Champalimaud; Icahn School of Medicine at Mount Sinai	Zhu, J (corresponding author), Dept Genet & Genom Sci, New York, NY 10029 USA.; Zhu, J (corresponding author), Icahn Sch Med Mt Sinai, Icahn Inst Genom & Multiscale Biol, New York, NY 10029 USA.; Zhu, J (corresponding author), Sema4, Stamford, CT 06902 USA.; Zhu, J (corresponding author), Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA.	jun.zhu@mssm.edu	; Oh, William/B-9163-2012	Zhu, Jun/0000-0003-0834-8178; Oh, William/0000-0001-5113-8147; Cordon-Cardo, Carlos/0000-0003-0858-5624	National Institutes of Health [R01-AG046170, U01-HG008451]; Spanish Society of Medical Oncology; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [U01HG008451] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [U01AG046170] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Spanish Society of Medical Oncology; NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank members of Zhu laboratory for discussions. This work was partially supported by National Institutes of Health (grant numbers R01-AG046170, U01-HG008451); and the Spanish Society of Medical Oncology to ACL.	Arvey A, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.24; Aushev VN, 2018, CLIN CANCER RES, V24, P581, DOI 10.1158/1078-0432.CCR-17-0996; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Ching CB, 2010, LAB INVEST, V90, P1406, DOI 10.1038/labinvest.2010.133; Choi W, 2014, CANCER CELL, V25, P152, DOI 10.1016/j.ccr.2014.01.009; Ebert MS, 2007, NAT METHODS, V4, P721, DOI 10.1038/NMETH1079; Ebert MS, 2010, CURR BIOL, V20, pR858, DOI 10.1016/j.cub.2010.08.052; Enokida H, 2016, INVESTIG CLIN UROL, V57, pS60, DOI 10.4111/icu.2016.57.S1.S60; Esposti DD, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16226-3; Farazi TA, 2013, ADV EXP MED BIOL, V774, P1, DOI 10.1007/978-94-007-5590-1_1; Foreman KE, 2014, J UROLOGY, V191, P502, DOI 10.1016/j.juro.2013.09.014; Garnett MJ, 2012, NATURE, V483, P570, DOI 10.1038/nature11005; Gregory PA, 2008, CELL CYCLE, V7, P3112, DOI 10.4161/cc.7.20.6851; Grimson A, 2007, MOL CELL, V27, P91, DOI 10.1016/j.molcel.2007.06.017; Guancial EA, 2014, UROL ONCOL-SEMIN ORI, V32, DOI 10.1016/j.urolonc.2013.04.014; Harrell F, 2013, NON TRADITIONAL REF, V3; Jansson MD, 2012, MOL ONCOL, V6, P590, DOI 10.1016/j.molonc.2012.09.006; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Knowles MA, 2015, NAT REV CANCER, V15, P25, DOI 10.1038/nrc3817; Krol J, 2010, NAT REV GENET, V11, P597, DOI 10.1038/nrg2843; Kuzaka B, 2015, ARCH MED SCI, V11, P378, DOI 10.5114/aoms.2014.46796; Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939; Lee E, 2016, BIOINFORMATICS, V32, P96, DOI 10.1093/bioinformatics/btv531; Lee YS, 2005, J BIOL CHEM, V280, P16635, DOI 10.1074/jbc.M412247200; Lindgren D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038863; Mariathasan S, 2018, NATURE, V554, P544, DOI 10.1038/nature25501; McConkey DJ, 2016, EUR UROL, V69, P855, DOI 10.1016/j.eururo.2015.08.034; Moller M, 2007, ONCOL REP, V18, P737; Mullokandov G, 2012, NAT METHODS, V9, P840, DOI [10.1038/NMETH.2078, 10.1038/nmeth.2078]; Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/nmeth.3337, 10.1038/NMETH.3337]; Ochoa AE, 2016, ONCOTARGET, V7, P80164, DOI 10.18632/oncotarget.13284; Riester M, 2012, CLIN CANCER RES, V18, P1323, DOI 10.1158/1078-0432.CCR-11-2271; Robertson AG, 2017, CELL, V171, P540, DOI 10.1016/j.cell.2017.09.007; Seiler R, 2017, EUR UROL, V72, P142, DOI 10.1016/j.eururo.2017.03.021; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sun Q, 2015, INT J ONCOL, V46, P389, DOI 10.3892/ijo.2014.2703; Weinstein JN, 2014, NATURE, V507, P315, DOI 10.1038/nature12965; Wu LJ, 2015, ONCOL LETT, V9, P213, DOI 10.3892/ol.2014.2706; Yoshihara K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3612; Zhao W, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-419	41	17	17	0	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2018	37	44					5858	5872		10.1038/s41388-018-0367-0	http://dx.doi.org/10.1038/s41388-018-0367-0			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GY9EX	29970902	hybrid, Green Published, Green Accepted			2022-12-17	WOS:000448943100004
J	Chen, J; Li, WJ; Cui, K; Ji, KY; Xu, SX; Xu, Y				Chen, Jian; Li, Wenjuan; Cui, Ke; Ji, Kaiyuan; Xu, Shuxiang; Xu, Yang			Artemisitene suppresses tumorigenesis by inducing DNA damage through deregulating c-Myc-topoisomerase pathway	ONCOGENE			English	Article							II-BETA; COLORECTAL-CANCER; STRAND BREAKS; CELLS; ANTICANCER; INHIBITION; DOXORUBICIN; PROTECTS; TARGET	Cancer chemotherapeutic agents such as doxorubicin are DNA damage inducers that also kill normal cells, making them highly toxic to cancer patients. To improve the efficacy and safety of chemotherapy, it is important to develop new chemotherapeutic agents that selectively kill cancer cells. Here we demonstrate that artemisitene (ATT), a natural derivative of the antimalarial drug artemisinin, selectively induces DNA double-stranded breaks (DSBs) and apoptosis in various human cancer cells by suppressing the expression of topoisomerases in human cancer cells. ATT effectively kills human cancer cells without apparent cytotoxicity on normal human cells or mouse liver and kidney. We discovered that c-Myc induces the expression of topoisomerases to prevent accumulation of DNA damage in human cancer cells. ATT selectively destabilizes c-Myc in human cancer cells by promoting the ubiquitination of c-Myc through the specific induction of the c-Myc E3 ligase NEDD4. Therefore, ATT represents a promising new chemotherapeutic drug candidate that can eliminate human cancer cells with minimized cytotoxic effects on normal cells.	[Chen, Jian; Ji, Kaiyuan; Xu, Shuxiang; Xu, Yang] Southern Med Univ, Sch Basic Med Sci, Canc Res Inst, Guangdong Prov Key Lab Tumor Immunotherapy, Guangzhou 510515, Guangdong, Peoples R China; [Li, Wenjuan; Cui, Ke; Xu, Yang] Guangzhou Univ Chinese Med, Affiliated Hosp 2, Guangdong Prov Acad Chinese Med Sci, Ctr Regenerat & Translat Med, Guangzhou 510632, Guangdong, Peoples R China; [Xu, Yang] Univ Calif San Diego, Div Biol Sci, 9500 Gilman Dr, La Jolla, CA 92093 USA	Southern Medical University - China; Guangzhou University of Chinese Medicine; University of California System; University of California San Diego	Xu, Y (corresponding author), Southern Med Univ, Sch Basic Med Sci, Canc Res Inst, Guangdong Prov Key Lab Tumor Immunotherapy, Guangzhou 510515, Guangdong, Peoples R China.; Xu, Y (corresponding author), Guangzhou Univ Chinese Med, Affiliated Hosp 2, Guangdong Prov Acad Chinese Med Sci, Ctr Regenerat & Translat Med, Guangzhou 510632, Guangdong, Peoples R China.; Xu, Y (corresponding author), Univ Calif San Diego, Div Biol Sci, 9500 Gilman Dr, La Jolla, CA 92093 USA.	yangxu@ucsd.edu		Xu, Yang/0000-0001-5574-921X; Chen, Jian/0000-0001-7535-6499	Postdoctoral Science Foundation of China [2015M582371]; NSFC [81430032, U1601222, 81502595]; Guangdong Provincial Key Laboratory of Cancer Immunotherapy; Guangzhou Key Laboratory of Tumor Immunology Research; Guangdong Provincial Key Special Science and Technology Project [2015B020225004]; Guangdong NSF Major basic research developmental project; California Institute for Regenerative Medicine	Postdoctoral Science Foundation of China(China Postdoctoral Science Foundation); NSFC(National Natural Science Foundation of China (NSFC)); Guangdong Provincial Key Laboratory of Cancer Immunotherapy; Guangzhou Key Laboratory of Tumor Immunology Research; Guangdong Provincial Key Special Science and Technology Project; Guangdong NSF Major basic research developmental project; California Institute for Regenerative Medicine(California Institute for Regenerative Medicine)	Wenjuan Li was supported by a fellowship from Postdoctoral Science Foundation of China (2015M582371). This study was supported by NSFC (nos. 81430032, U1601222, 81502595), Guangdong Provincial Key Laboratory of Cancer Immunotherapy, Guangzhou Key Laboratory of Tumor Immunology Research, Guangdong Provincial Key Special Science and Technology Project (2015B020225004), Guangdong NSF Major basic research developmental project, and grants from California Institute for Regenerative Medicine.	Azarova AM, 2007, P NATL ACAD SCI USA, V104, P11014, DOI 10.1073/pnas.0704002104; Bandi S, 2011, AM J PATHOL, V178, P161, DOI 10.1016/j.ajpath.2010.11.001; Bhandari A, 2017, J INVEST MED, V65, P311, DOI 10.1136/jim-2016-000229; Bollimpelli VS, 2017, ARCH BIOCHEM BIOPHYS, V633, P78, DOI 10.1016/j.abb.2017.06.021; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Chen WM, 2016, FASEB J, V30, P2500, DOI 10.1096/fj.201500109R; Chen Y, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11057; Choi WH, 2017, J CLIN MED, V6, DOI 10.3390/jcm6030030; Chong CM, 2016, REDOX BIOL, V9, P50, DOI 10.1016/j.redox.2016.06.002; Chumduri C, 2013, CELL HOST MICROBE, V13, P746, DOI 10.1016/j.chom.2013.05.010; Cowell IG, 2012, P NATL ACAD SCI USA, V109, P8989, DOI 10.1073/pnas.1204406109; Cuya SM, 2017, CANCER CHEMOTH PHARM, V80, P1, DOI 10.1007/s00280-017-3334-5; Damiani RM, 2016, ARCH TOXICOL, V90, P2063, DOI 10.1007/s00204-016-1759-y; Efferth T, 2011, PHYTOMEDICINE, V18, P959, DOI 10.1016/j.phymed.2011.06.008; Ezoe S, 2012, INT J ENV RES PUB HE, V9, P2444, DOI 10.3390/ijerph9072444; Farrell AS, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a014365; Gilbert DC, 2012, BRIT J CANCER, V106, P18, DOI 10.1038/bjc.2011.498; Hoffman B, 1998, ONCOGENE, V17, P3351, DOI 10.1038/sj.onc.1202592; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; Hsu E, 2006, T ROY SOC TROP MED H, V100, P505, DOI 10.1016/j.trstmh.2005.09.020; Jadaun A, 2017, J PHOTOCH PHOTOBIO B, V167, P299, DOI 10.1016/j.jphotobiol.2017.01.010; Jiang JH, 2011, CANCER RES, V71, P5546, DOI 10.1158/0008-5472.CAN-10-3423; Kim EJ, 2017, TOXICOL APPL PHARM, V330, P84, DOI 10.1016/j.taap.2017.07.007; Kim J, 2017, ONCOGENE, V36, P6472, DOI 10.1038/onc.2017.265; King B, 2013, CELL, V153, P1552, DOI 10.1016/j.cell.2013.05.041; Lake BB, 2012, STEM CELLS, V30, P888, DOI 10.1002/stem.1054; Li T, 2012, INT IMMUNOPHARMACOL, V12, P144, DOI 10.1016/j.intimp.2011.11.004; Liu Q, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0654-3; Lyu YL, 2007, CANCER RES, V67, P8839, DOI 10.1158/0008-5472.CAN-07-1649; Matsumoto Y, 2005, J MED INVESTIG, V52, P41, DOI 10.2152/jmi.52.41; Nitiss JL, 2009, NAT REV CANCER, V9, P338, DOI 10.1038/nrc2607; Ooko E, 2015, PHYTOMEDICINE, V22, P1045, DOI 10.1016/j.phymed.2015.08.002; Polager S, 2009, NAT REV CANCER, V9, P738, DOI 10.1038/nrc2718; Pommier Y, 2010, CHEM BIOL, V17, P421, DOI 10.1016/j.chembiol.2010.04.012; Posner GH, 2002, BIOORGAN MED CHEM, V10, P227, DOI 10.1016/S0968-0896(01)00270-X; ROCA J, 1994, P NATL ACAD SCI USA, V91, P1781, DOI 10.1073/pnas.91.5.1781; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rubin EH, 2000, HUM PATHOL, V31, P631, DOI 10.1053/hupa.2000.8629; Singh A, 2012, CELL, V148, P639, DOI 10.1016/j.cell.2011.12.033; Singh S, 2012, FREE RADICAL BIO MED, V53, P1782, DOI 10.1016/j.freeradbiomed.2012.07.025; Slezakova S, 2017, ANTICANCER RES, V37, P5995, DOI 10.21873/anticanres.12046; Thomas LR, 2011, ADV CANCER RES, V110, P77, DOI 10.1016/B978-0-12-386469-7.00004-9; Xu SM, 2016, PROTEIN CELL, V7, P684, DOI 10.1007/s13238-016-0297-y; Zhang P, 2010, BRIT J CANCER, V102, P862, DOI 10.1038/sj.bjc.6605572	44	17	18	2	21	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 13	2018	37	37					5079	5087		10.1038/s41388-018-0331-z	http://dx.doi.org/10.1038/s41388-018-0331-z			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GT3LT	29795406				2022-12-17	WOS:000444405300004
J	Kota, S; Hou, SR; Guerrant, W; Madoux, F; Troutman, S; Fernandez-Vega, V; Alekseeva, N; Madala, N; Scampavia, L; Kissil, J; Spicer, TP				Kota, Smitha; Hou, Shurong; Guerrant, William; Madoux, Franck; Troutman, Scott; Fernandez-Vega, Virneliz; Alekseeva, Nina; Madala, Neeharika; Scampavia, Louis; Kissil, Joseph; Spicer, Timothy P.			A novel three-dimensional high-throughput screening approach identifies inducers of a mutant KRAS selective lethal phenotype	ONCOGENE			English	Article							HUMAN CANCER-CELLS; SYNTHETIC LETHALITY; K-RAS; DRUG DISCOVERY; SMALL-MOLECULE; IN-VITRO; CULTURE; 3D; 3RD-DIMENSION; SPHEROIDS	The RAS proteins are the most frequently mutated oncogenes in cancer, with highest frequency found in pancreatic, lung, and colon tumors. Moreover, the activity of RAS is required for the proliferation and/or survival of these tumor cells and thus represents a high-value target for therapeutic development. Direct targeting of RAS has proven challenging for multiple reasons stemming from the biology of the protein, the complexity of downstream effector pathways and upstream regulatory networks. Thus, significant efforts have been directed at identifying downstream targets on which RAS is dependent. These efforts have proven challenging, in part due to confounding factors such as reliance on two-dimensional adherent monolayer cell cultures that inadequately recapitulate the physiologic context to which cells are exposed in vivo. To overcome these issues, we implemented a high-throughput screening (HTS) approach using a spheroid-based 3-dimensional culture format, thought to more closely reflect conditions experienced by cells in vivo. Using isogenic cell pairs, differing in the status of KRAS, we identified Proscillaridin A as a selective inhibitor of cells harboring the oncogenic KRas(G12v) allele. Significantly, the identification of Proscillaridin A was facilitated by the 3D screening platform and would not have been discovered employing standard 2D culturing methods.	[Kota, Smitha; Hou, Shurong; Guerrant, William; Madoux, Franck; Troutman, Scott; Fernandez-Vega, Virneliz; Alekseeva, Nina; Madala, Neeharika; Scampavia, Louis; Kissil, Joseph; Spicer, Timothy P.] Scripps Res Inst, Dept Mol Med, Jupiter, FL 33458 USA; [Madoux, Franck] Amgen Inc, Thousand Oaks, CA 91320 USA	Scripps Research Institute; Amgen	Kissil, J; Spicer, TP (corresponding author), Scripps Res Inst, Dept Mol Med, Jupiter, FL 33458 USA.	jkissil@scripps.edu; spicert@scripps.edu			National Cancer Institute of the National Institutes of Health [R33CA206949, CA124495]; NATIONAL CANCER INSTITUTE [R01CA124495, R33CA206949] Funding Source: NIH RePORTER	National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Pierre Baillargeon and Lina Deluca at Scripps for their help with compound management. This work was supported in part by the National Cancer Institute of the National Institutes of Health under Award Number R33CA206949 (TPS) and CA124495 (JK).	Alevizopoulos K, 2014, CURR DRUG TARGETS, V15, P988, DOI 10.2174/1389450115666140908125025; Antoni D, 2015, INT J MOL SCI, V16, P5517, DOI 10.3390/ijms16035517; Babij C, 2011, CANCER RES, V71, P5818, DOI 10.1158/0008-5472.CAN-11-0778; Barbie DA, 2009, NATURE, V462, P108, DOI 10.1038/nature08460; Bittker JA., 2010, SCREEN RAS SELECTIVE; Chan DA, 2011, NAT REV DRUG DISCOV, V10, P351, DOI 10.1038/nrd3374; Clevers H, 2016, CELL, V165, P1586, DOI 10.1016/j.cell.2016.05.082; Cukierman E, 2001, SCIENCE, V294, P1708, DOI 10.1126/science.1064829; Delebinski CI, 2015, CELL PROLIFERAT, V48, P600, DOI 10.1111/cpr.12208; Denicolai E, 2014, ONCOTARGET, V5, P10934, DOI 10.18632/oncotarget.2541; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Felth J, 2009, J NAT PROD, V72, P1969, DOI 10.1021/np900210m; Fennema E, 2013, TRENDS BIOTECHNOL, V31, P108, DOI 10.1016/j.tibtech.2012.12.003; Foster SA, 2016, CANCER CELL, V29, P477, DOI 10.1016/j.ccell.2016.02.010; Guo W, 2008, CANCER RES, V68, P7403, DOI 10.1158/0008-5472.CAN-08-1449; Gysin Stephan, 2011, Genes Cancer, V2, P359, DOI 10.1177/1947601911412376; Kim N, 2016, SCI REP-UK, V6, DOI 10.1038/srep29721; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; Longati P, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-95; Luo J, 2009, CELL, V137, P835, DOI 10.1016/j.cell.2009.05.006; Luo TP, 2012, P NATL ACAD SCI USA, V109, P2860, DOI 10.1073/pnas.1120589109; Madoux F, 2017, SLAS DISCOV, V22, P516, DOI 10.1177/2472555216686308; Pampaloni F, 2007, NAT REV MOL CELL BIO, V8, P839, DOI 10.1038/nrm2236; Powell K, 2017, SCIENCE, V356, P96, DOI 10.1126/science.356.6333.96; Prior IA, 2012, CANCER RES, V72, P2457, DOI 10.1158/0008-5472.CAN-11-2612; Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106; Ramaiahgari SC, 2014, ARCH TOXICOL, V88, P1083, DOI 10.1007/s00204-014-1215-9; Scholl C, 2009, CELL, V137, P821, DOI 10.1016/j.cell.2009.03.017; Shaw AT, 2011, P NATL ACAD SCI USA, V108, P8773, DOI 10.1073/pnas.1105941108; Singh A, 2009, CELL CYCLE, V8, P2676, DOI 10.4161/cc.8.17.9336; Torrance CJ, 2001, NAT BIOTECHNOL, V19, P940, DOI 10.1038/nbt1001-940; Tung YC, 2011, ANALYST, V136, P473, DOI 10.1039/c0an00609b; Verjans ET, 2018, J CELL PHYSIOL, V233, P2993, DOI 10.1002/jcp.26052; Vicent S, 2010, J CLIN INVEST, V120, P3940, DOI 10.1172/JCI44165; Wang Y, 2010, ONCOGENE, V29, P4658, DOI 10.1038/onc.2010.218; Weiwer M, 2012, ACS MED CHEM LETT, V3, P1034, DOI 10.1021/ml300246r; Yamada KM, 2007, CELL, V130, P601, DOI 10.1016/j.cell.2007.08.006; Zanoni M, 2016, SCI REP-UK, V6, DOI 10.1038/srep19103; Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206	39	17	17	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 9	2018	37	32					4372	4384		10.1038/s41388-018-0257-5	http://dx.doi.org/10.1038/s41388-018-0257-5			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GP8FA	29743592	Green Accepted			2022-12-17	WOS:000441144300003
J	Klose, R; Adam, MG; Weis, EM; Moll, I; Wustehube-Lausch, J; Tetzlaff, F; Oka, C; Ehrmann, M; Fischer, A				Klose, Ralph; Adam, M. Gordian; Weis, Eva-Maria; Moll, Iris; Wustehube-Lausch, Joycelyn; Tetzlaff, Fabian; Oka, Chio; Ehrmann, Michael; Fischer, Andreas			Inactivation of the serine protease HTRA1 inhibits tumor growth by deregulating angiogenesis	ONCOGENE			English	Article							SMALL-VESSEL DISEASE; NOTCH LIGAND; DLL4; SUSCEPTIBILITY; DEFICIENCY; EXPRESSION; REPRESSION; MUTATIONS	The serine protease HTRA1 is involved in several vascular diseases and its expression is often deregulated in cancer. We aimed at identifying how HTRA1 in the vasculature affects tumor growth. Here we report that silencing of HTRA1 in cultured endothelial cells increased migration rate and tube formation, whereas forced HTRA1 expression impaired sprouting angiogenesis. Mechanistically, endothelial HTRA1 expression enhanced Delta/Notch signaling by reducing the amount of the weak Notch ligand JAG1. HTRA1 physically interacted with JAG1 and cleaved it within the intracellular domain, leading to protein degradation. Expression of a constitutive active Notch1 prevented the hypersprouting phenotype upon silencing of HTRA1. In HtrA1-deficient mice, endothelial Notch signaling was diminished and isolated endothelial cells had increased expression of VEGF receptor-2. Growth of syngeneic tumors was strongly impaired in HtrA1(-/-) mice. The tumor vasculature was much denser in HtrA1(-/-) mice and less covered with mural cells. This chaotic and immature vascular network was poorly functional as indicated by large hypoxic tumor areas and low tumor cell proliferation rates. In summary, inhibition of HTRA1 in the tumor stroma impaired tumor progression by deregulating angiogenesis.	[Klose, Ralph; Adam, M. Gordian; Weis, Eva-Maria; Moll, Iris; Wustehube-Lausch, Joycelyn; Tetzlaff, Fabian; Fischer, Andreas] German Canc Res Ctr, Div Vasc Signaling & Canc A270, D-69120 Heidelberg, Germany; [Wustehube-Lausch, Joycelyn; Fischer, Andreas] Heidelberg Univ, Med Fac Mannheim, European Ctr Angiosci, D-68167 Mannheim, Germany; [Oka, Chio] Nara Inst Sci & Technol, Lab Gene Funct Anim, 8916-5 Takayama, Ikoma, Nara 6300192, Japan; [Ehrmann, Michael] Univ Duisburg Essen, Ctr Med Biotechnol, Fac Biol, D-45117 Essen, Germany; [Fischer, Andreas] Heidelberg Univ Hosp, Med Clin 1, Endocrinol & Clin Chem, D-69120 Heidelberg, Germany; [Adam, M. Gordian] Metan Hlth GmbH, Berlin, Germany; [Wustehube-Lausch, Joycelyn] BioNTech AG, Mainz, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Nara Institute of Science & Technology; University of Duisburg Essen; Ruprecht Karls University Heidelberg; BioNTech SE	Fischer, A (corresponding author), German Canc Res Ctr, Div Vasc Signaling & Canc A270, D-69120 Heidelberg, Germany.; Fischer, A (corresponding author), Heidelberg Univ, Med Fac Mannheim, European Ctr Angiosci, D-68167 Mannheim, Germany.; Fischer, A (corresponding author), Heidelberg Univ Hosp, Med Clin 1, Endocrinol & Clin Chem, D-69120 Heidelberg, Germany.	a.fischer@dkfz.de	Ehrmann, Michael/A-7307-2012	Ehrmann, Michael/0000-0002-1927-260X; Fischer, Andreas/0000-0002-4889-0909	Fritz-Thyssen Foundation [10.13.1.160]; Deutsche Forschungsgemeinschaft [SFB-TR23]; Deutsche Krebshilfe [110638]; Helmholtz Society	Fritz-Thyssen Foundation; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Deutsche Krebshilfe(Deutsche Krebshilfe); Helmholtz Society(Helmholtz Association)	This work was supported by the Fritz-Thyssen Foundation (10.13.1.160), the Deutsche Forschungsgemeinschaft (SFB-TR23, project A7), the Deutsche Krebshilfe (110638), and the Helmholtz Society to AF.	Altobelli E, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4041-2; Beaufort N, 2014, P NATL ACAD SCI USA, V111, P16496, DOI 10.1073/pnas.1418087111; Benedito R, 2009, CELL, V137, P1124, DOI 10.1016/j.cell.2009.03.025; Brutsch R, 2010, CIRC RES, V107, P592, DOI 10.1161/CIRCRESAHA.110.217257; Catrein I, 2005, FEBS J, V272, P2892, DOI 10.1111/j.1742-4658.2005.04710.x; De Luca A, 2003, J HISTOCHEM CYTOCHEM, V51, P1279, DOI 10.1177/002215540305101004; Fischer A, 2007, NUCLEIC ACIDS RES, V35, P4583, DOI 10.1093/nar/gkm477; Friedrich U, 2015, HUM MOL GENET, V24, P6361, DOI 10.1093/hmg/ddv346; Grau S, 2006, J BIOL CHEM, V281, P6124, DOI 10.1074/jbc.M500361200; Hara K, 2009, NEW ENGL J MED, V360, P1729, DOI 10.1056/NEJMoa0801560; Hasan MZ, 2015, DEV BIOL, V397, P89, DOI 10.1016/j.ydbio.2014.10.015; He XP, 2010, CANCER RES, V70, P3109, DOI 10.1158/0008-5472.CAN-09-3557; Jabs M, 2018, CIRCULATION, V137, P2592, DOI 10.1161/CIRCULATIONAHA.117.029733; Keller A, 2002, ANAL CHEM, V74, P5383, DOI 10.1021/ac025747h; Klose R, 2015, CARDIOVASC RES, V107, P153, DOI 10.1093/cvr/cvv151; Kofler NM, 2015, SCI REP-UK, V5, DOI 10.1038/srep16449; Limbourg A, 2007, CIRC RES, V100, P363, DOI 10.1161/01.RES.0000258174.77370.2c; Noguera-Troise I, 2006, NATURE, V444, P1032, DOI 10.1038/nature05355; Noseda M, 2004, MOL CELL BIOL, V24, P8813, DOI 10.1128/MCB.24.20.8813-8822.2004; Oka C, 2004, DEVELOPMENT, V131, P1041, DOI 10.1242/dev.00999; Outtz HH, 2010, J IMMUNOL, V185, P4363, DOI 10.4049/jimmunol.1000720; Poepsel S, 2015, NAT CHEM BIOL, V11, P862, DOI [10.1038/NCHEMBIO.1931, 10.1038/nchembio.1931]; Potente M, 2011, CELL, V146, P873, DOI 10.1016/j.cell.2011.08.039; Ridgway J, 2006, NATURE, V444, P1083, DOI 10.1038/nature05313; Shiga A, 2011, HUM MOL GENET, V20, P1800, DOI 10.1093/hmg/ddr063; Takeshita K, 2007, CIRC RES, V100, P70, DOI 10.1161/01.RES.0000254788.47304.6e; Teoh SSY, 2015, PLACENTA, V36, P990, DOI 10.1016/j.placenta.2015.07.001; Tsuchiya A, 2005, BONE, V37, P323, DOI 10.1016/j.bone.2005.03.015; Verdura E, 2015, BRAIN, V138, P2347, DOI 10.1093/brain/awv155; Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811; Zhang L, 2012, J BIOL CHEM, V287, P1520, DOI 10.1074/jbc.M111.275990	31	17	17	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 2	2018	37	31					4260	4272		10.1038/s41388-018-0258-4	http://dx.doi.org/10.1038/s41388-018-0258-4			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GP1HN	29713059				2022-12-17	WOS:000440566100005
J	Li, X; Ma, HG; Li, L; Chen, YF; Sun, X; Dong, ZZ; Liu, JY; Zhu, WM; Zhang, JT				Li, Xia; Ma, Hongguang; Li, Lin; Chen, Yifan; Sun, Xiao; Dong, Zizheng; Liu, Jing-Yuan; Zhu, Weiming; Zhang, Jian-Ting			Novel synthetic bisindolylmaleimide alkaloids inhibit STAT3 activation by binding to the SH2 domain and suppress breast xenograft tumor growth	ONCOGENE			English	Article							EPITHELIAL-CELLS; CANCER; PHOSPHORYLATION; PATHOGENESIS; EXPRESSION; PATHWAY	Signal transducer and activator of transcription 3 (STAT3) is constitutively activated in malignant tumors and plays important roles in multiple aspects of cancer aggressiveness. Thus, targeting STAT3 promises to be an attractive strategy for the treatment of advanced metastatic tumors. Bisindolylmaleimide alkaloid (BMA) has been shown to have anticancer activities and was thought to suppress tumor cell growth by inhibiting protein kinase C. In this study, we show that a newly synthesized BMA analog, BMA097, is effective in suppressing tumor cell and xenograft growth and in inducing spontaneous apoptosis. We also provide evidence that BMA097 binds directly to the SH2 domain of STAT3 and inhibits STAT3 phosphorylation and activation, leading to reduced expression of STAT3 downstream target genes. Structure activity relationship analysis revealed that the hydroxymethyl group in the 2,5-dihydropyrrole-2,5-dione prohibits STAT3 inhibitory activity of BMA analogs. Altogether, we conclude that the synthetic BMA analogs may be developed as anti-cancer drugs by targeting and binding to the SH2 domain of STAT3 and inhibiting the STAT3 signaling pathway.	[Li, Xia; Chen, Yifan; Dong, Zizheng; Liu, Jing-Yuan; Zhang, Jian-Ting] Indiana Univ Sch Med, Dept Pharmacol & Toxicol, Indianapolis, IN 46202 USA; [Li, Xia; Li, Lin; Sun, Xiao] Shandong Univ, Sch Ocean, Weihai, Peoples R China; [Ma, Hongguang; Zhu, Weiming] Ocean Univ China, Sch Med & Pharm, Key Lab Marine Drugs, Minist Educ China, Qingdao, Peoples R China; [Liu, Jing-Yuan] Indiana Univ Purdue Univ, Dept Comp & Informat Sci, Indianapolis, IN 46202 USA; [Zhang, Jian-Ting] Indiana Univ Sch Med, IU Simon Canc Ctr, Indianapolis, IN 46202 USA	Indiana University System; Indiana University Bloomington; Shandong University; Ministry of Education, China; Ocean University of China; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University Bloomington	Li, X; Liu, JY; Zhang, JT (corresponding author), Indiana Univ Sch Med, Dept Pharmacol & Toxicol, Indianapolis, IN 46202 USA.; Zhu, WM (corresponding author), Ocean Univ China, Sch Med & Pharm, Key Lab Marine Drugs, Minist Educ China, Qingdao, Peoples R China.; Liu, JY (corresponding author), Indiana Univ Purdue Univ, Dept Comp & Informat Sci, Indianapolis, IN 46202 USA.; Zhang, JT (corresponding author), Indiana Univ Sch Med, IU Simon Canc Ctr, Indianapolis, IN 46202 USA.	xiali@sdu.edu.cn; jliu2@iu.edu; weimingzhu@ouc.edu.cn; jianzhan@iu.edu		Zhang, Jian-Ting/0000-0002-2803-9914	Program for Changjiang Scholars and Innovative Research Team in University (PCSIRT) [IRT_17R68]; National Natural Science Foundation of China [81273532, U1501221]; National Institute of Health [R01 CA211904]; NATIONAL CANCER INSTITUTE [R01CA211904] Funding Source: NIH RePORTER	Program for Changjiang Scholars and Innovative Research Team in University (PCSIRT)(Program for Changjiang Scholars & Innovative Research Team in University (PCSIRT)); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank IU Big Red supercomputers for the CPU time. This work was supported in part by grants from the Program for Changjiang Scholars and Innovative Research Team in University (PCSIRT, No IRT_17R68), the National Natural Science Foundation of China (Nos. 81273532 & U1501221) and by National Institute of Health Grant R01 CA211904.	Bhatnagar I, 2010, MAR DRUGS, V8, P2673, DOI 10.3390/md8102673; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Chen Q, 2006, J BIOL CHEM, V281, P31152, DOI 10.1074/jbc.M603529200; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Dechow TN, 2004, P NATL ACAD SCI USA, V101, P10602, DOI 10.1073/pnas.0404100101; Fiser A, 2003, BIOINFORMATICS, V19, P2500, DOI 10.1093/bioinformatics/btg362; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; Gartsbein M, 2006, J CELL SCI, V119, P470, DOI 10.1242/jcs.02744; Huang W, 2016, ONCOGENE, V35, P783, DOI 10.1038/onc.2015.215; Huang W, 2014, ACS CHEM BIOL, V9, P1188, DOI 10.1021/cb500071v; Li Y, 2007, CANCER RES, V67, P8494, DOI 10.1158/0008-5472.CAN-07-0647; Liu JY, 2011, J CHEM INF MODEL, V51, P2612, DOI 10.1021/ci200212y; Liu SS, 2013, ACTA PHARMACOL SIN, V34, P271, DOI 10.1038/aps.2012.137; Ma HG, 2016, CHINESE J ORG CHEM, V36, P1839, DOI 10.6023/cjoc201602035; Mantel C, 2012, BLOOD, V120, P2589, DOI 10.1182/blood-2012-01-404004; Marotta LLC, 2011, J CLIN INVEST, V121, P2723, DOI 10.1172/JCI44745; MENG EC, 1992, J COMPUT CHEM, V13, P505, DOI 10.1002/jcc.540130412; Mukohara T, 2003, LUNG CANCER, V41, P123, DOI 10.1016/S0169-5002(03)00225-3; Pajak B, 2008, ADV MED SCI-POLAND, V53, P21, DOI 10.2478/v10039-008-0028-6; Pereira ER, 1996, J MED CHEM, V39, P4471; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Pfeiffer M, 2009, BRIT J CANCER, V100, P1949, DOI 10.1038/sj.bjc.6605068; Qian L, 2006, BIOCHEM BIOPH RES CO, V345, P660, DOI 10.1016/j.bbrc.2006.04.153; Welte T, 2003, P NATL ACAD SCI USA, V100, P1879, DOI 10.1073/PNAS.0237137100; Yeh HH, 2006, ONCOGENE, V25, P4300, DOI 10.1038/sj.onc.1209464; Yu H, 2014, NAT REV CANCER, V14, P736, DOI 10.1038/nrc3818; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	28	17	18	3	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	18					2469	2480		10.1038/s41388-017-0076-0	http://dx.doi.org/10.1038/s41388-017-0076-0			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GE7BW	29456240	Green Submitted, Green Accepted			2022-12-17	WOS:000431386000010
J	Roudnicky, F; Yoon, SY; Poghosyan, S; Schwager, S; Poyet, C; Vella, G; Bachmann, SB; Karaman, S; Shin, JW; Otto, VI; Detmar, M				Roudnicky, Filip; Yoon, Sun Young; Poghosyan, Susanna; Schwager, Simon; Poyet, Cedric; Vella, Giorgia; Bachmann, Samia B.; Karaman, Sinem; Shin, Jay W.; Otto, Vivianne I.; Detmar, Michael			Alternative transcription of a shorter, non-anti-angiogenic thrombospondin-2 variant in cancer-associated blood vessels	ONCOGENE			English	Article							ENDOTHELIAL-CELL PROLIFERATION; INVASIVE BLADDER-CANCER; TUMOR-GROWTH; VEGF-A; ENDOGENOUS INHIBITOR; EXPRESSION DATA; TYPE-1 REPEATS; MICE; IDENTIFICATION; SKIN	Thrombospondin-2 (TSP2) is an anti-angiogenic matricellular protein that inhibits tumor growth and angiogenesis. Tumor-associated blood vascular endothelial cells (BECs) were isolated from human invasive bladder cancers and from matched normal bladder tissue by immuno-laser capture microdissection. Exon expression profiling analyses revealed a particularly high expression of a short TSP2 transcript containing only the last 9 (3') exons of the full-length TSP2 transcript. Using 5' and 3' RACE (rapid amplification of cDNA ends) and Sanger sequencing, we confirmed the existence of the shorter transcript of TSP2 (sTSP2) and determined its sequence which completely lacked the anti-angiogenic thrombospondin type 1 repeats domain. The largest open reading frame predicted within the transcript comprises 209 amino acids and matches almost completely the C-terminal lectin domain of full-length TSP2. We produced recombinant sTSP2 and found that unlike the full-length TSP2, sTSP2 did not inhibit vascular endothelial growth factor-A-induced proliferation of cultured human BECs, but in contrast when combined with TSP2 blocked the inhibitory effects of TSP2 on BEC proliferation. In vivo studies with stably transfected A431 squamous cell carcinoma cells revealed that full-length TSP2, but not sTSP2, inhibited tumor growth and angiogenesis. This study reveals that the transcriptional program of tumor stromal cells can change to transcribe a new version of an endogenous angiogenesis inhibitor that has lost its anti-angiogenic activity.	[Roudnicky, Filip; Yoon, Sun Young; Poghosyan, Susanna; Schwager, Simon; Vella, Giorgia; Bachmann, Samia B.; Karaman, Sinem; Otto, Vivianne I.; Detmar, Michael] ETH, Inst Pharmaceut Sci, Zurich, Switzerland; [Poyet, Cedric] Univ Zurich Hosp, Dept Urol, Zurich, Switzerland; [Shin, Jay W.] RIKEN Ctr Life Sci Technol, Div Genom Technol, Yokohama, Kanagawa, Japan	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Zurich; University Zurich Hospital; RIKEN	Detmar, M (corresponding author), ETH, Inst Pharmaceut Sci, Zurich, Switzerland.	michael.detmar@pharma.ethz.ch	Karaman, Sinem/C-4428-2017	Karaman, Sinem/0000-0002-0719-1773; Otto, Vivianne/0000-0002-1157-0186; Roudnicky, Filip/0000-0001-7156-2383	Swiss National Science Foundation [310030B_147087]; Advanced European Research Council Grant LYVICAM; Krebsliga Schweiz; Krebsliga Zurich	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Advanced European Research Council Grant LYVICAM; Krebsliga Schweiz; Krebsliga Zurich	This work was supported by Swiss National Science Foundation grant 310030B_147087, Advanced European Research Council Grant LYVICAM, Krebsliga Schweiz and Krebsliga Zurich (to MD).	Armstrong LC, 2002, MOL BIOL CELL, V13, P1893, DOI 10.1091/mbc.E01-09-0066; Balar AV, 2013, J CLIN ONCOL, V31, P724, DOI 10.1200/JCO.2012.42.5215; Bengtsson M, 2008, AROMA AFFYMETRIX GEN; Borgia B, 2010, CANCER RES, V70, P309, DOI 10.1158/0008-5472.CAN-09-2939; Buckanovich RJ, 2007, J CLIN ONCOL, V25, P852, DOI 10.1200/JCO.2006.08.8583; Carlson CB, 2008, CELL MOL LIFE SCI, V65, P672, DOI 10.1007/s00018-007-7484-1; Carnemolla B, 2002, BLOOD, V99, P1659, DOI 10.1182/blood.V99.5.1659; Castronovo V, 2006, MOL CELL PROTEOMICS, V5, P2083, DOI 10.1074/mcp.M600164-MCP200; Cline MS, 2005, BIOINFORMATICS, V21, pI107, DOI 10.1093/bioinformatics/bti1010; Dawson DW, 1999, MOL PHARMACOL, V55, P332, DOI 10.1124/mol.55.2.332; DETMAR M, 1990, J INVEST DERMATOL, V95, pS219, DOI 10.1111/1523-1747.ep12875807; Detmar M, 2000, J DERMATOL SCI, V24, pS78, DOI 10.1016/S0923-1811(00)00145-6; Dieterich LC, 2012, J PATHOL, V228, P378, DOI 10.1002/path.4072; Djebali S, 2012, NATURE, V489, P101, DOI 10.1038/nature11233; Emig D, 2010, NUCLEIC ACIDS RES, V38, pW755, DOI 10.1093/nar/gkq405; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Forrest ARR, 2014, NATURE, V507, P462, DOI 10.1038/nature13182; Francois P, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3246; Freeman LA, 2013, METHODS MOL BIOL, V1027, P3, DOI 10.1007/978-1-60327-369-5_1; Gardina PJ, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-325; Geback T, 2009, BIOTECHNIQUES, V46, P265, DOI 10.2144/000113083; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Hanahan D, 1996, EUR J CANCER, V32A, P2386, DOI 10.1016/S0959-8049(96)00401-7; Hawighorst T, 2001, EMBO J, V20, P2631, DOI 10.1093/emboj/20.11.2631; Hirakawa S, 2003, AM J PATHOL, V162, P575, DOI 10.1016/S0002-9440(10)63851-5; Huggenberger R, 2010, J EXP MED, V207, P2255, DOI 10.1084/jem.20100559; Huwiler KG, 2002, BIOCHEMISTRY-US, V41, P14329, DOI 10.1021/bi026463u; Iruela-Arispe ML, 1999, CIRCULATION, V100, P1423, DOI 10.1161/01.CIR.100.13.1423; Kunstfeld R, 2014, J DERMATOL SCI, V74, P106, DOI 10.1016/j.jdermsci.2014.01.002; Kyriakides TR, 1999, J INVEST DERMATOL, V113, P782, DOI 10.1046/j.1523-1747.1999.00755.x; Kyriakides TR, 1998, J CELL BIOL, V140, P419, DOI 10.1083/jcb.140.2.419; Kyriakides TR, 1999, P NATL ACAD SCI USA, V96, P4449, DOI 10.1073/pnas.96.8.4449; Laajala E, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-7-r77; Lawler J, 2004, INT J BIOCHEM CELL B, V36, P1038, DOI 10.1016/j.biocel.2004.01.008; Lawler PR, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006627; Neri D, 2005, NAT REV CANCER, V5, P436, DOI 10.1038/nrc1627; Noh YH, 2003, J INVEST DERMATOL, V121, P1536, DOI 10.1046/j.1523-1747.2003.12643.x; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Pan Q, 2008, NAT GENET, V40, P1413, DOI 10.1038/ng.259; Panetti TS, 1997, J LAB CLIN MED, V129, P208, DOI 10.1016/S0022-2143(97)90141-4; Purdom E, 2008, BIOINFORMATICS, V24, P1707, DOI 10.1093/bioinformatics/btn284; Ren B, 2009, CANCER RES, V69, P3856, DOI 10.1158/0008-5472.CAN-08-2940; Rodrigo-Domingo M, 2014, BRIEF BIOINFORM, V15, P519, DOI 10.1093/bib/bbt011; Roudnicky F, 2017, J PATHOL, V242, P193, DOI 10.1002/path.4892; Roudnicky F, 2013, CANCER RES, V73, P1097, DOI 10.1158/0008-5472.CAN-12-1855; Rybak JN, 2007, CANCER RES, V67, P10948, DOI 10.1158/0008-5472.CAN-07-1436; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Smyth G. K., 2004, STAT APPL GENET MOL, V3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027, 10.2202/1544-6115.1027/MACHINEREADABLECITATION/RIS]; Srinivasan K, 2005, METHODS, V37, P345, DOI 10.1016/j.ymeth.2005.09.007; Streit M, 1999, AM J PATHOL, V155, P441, DOI 10.1016/S0002-9440(10)65140-1; Streit M, 1999, P NATL ACAD SCI USA, V96, P14888, DOI 10.1073/pnas.96.26.14888; Streit M, 2002, CANCER RES, V62, P2004; Sun JF, 2009, AM J PHYSIOL-HEART C, V296, pH1344, DOI 10.1152/ajpheart.01246.2008; VOGEL T, 1993, J CELL BIOCHEM, V53, P74, DOI 10.1002/jcb.240530109; VOLPERT OV, 1995, BIOCHEM BIOPH RES CO, V217, P326, DOI 10.1006/bbrc.1995.2780; Wang ET, 2008, NATURE, V456, P470, DOI 10.1038/nature07509; Wiemann S, 2001, GENOME RES, V11, P422, DOI 10.1101/gr.GR1547R; Yang XP, 2016, CELL, V164, P805, DOI 10.1016/j.cell.2016.01.029; Yee KO, 2004, AM J PATHOL, V165, P541, DOI 10.1016/S0002-9440(10)63319-6	60	17	17	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	19					2573	2585		10.1038/s41388-018-0129-z	http://dx.doi.org/10.1038/s41388-018-0129-z			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GF3RN	29467494	hybrid, Green Published			2022-12-17	WOS:000431873400009
J	Logue, JS; Cartagena-Rivera, AX; Chadwick, RS				Logue, Jeremy S.; Cartagena-Rivera, Alexander X.; Chadwick, Richard S.			c-Src activity is differentially required by cancer cell motility modes	ONCOGENE			English	Article							FOCAL ADHESION KINASE; PHASE-II TRIAL; SARACATINIB AZD0530; INHIBITOR SARACATINIB; BREAST-CANCER; MIGRATION; FAK; PROTEOLYSIS; BMS-354825; DASATINIB	Cancer cell migration requires that cells respond and adapt to their surroundings. In the absence of extracellular matrix cues, cancer cells will undergo a mesenchymal to ameboid transition, whereas a highly confining space will trigger a switch to "leader bleb-based" migration. To identify oncogenic signaling pathways mediating these transitions, we undertook a targeted screen using clinically useful inhibitors. Elevated Src activity was found to change actin and focal adhesion dynamics, whereas inhibiting Src triggered focal adhesion disassembly and blebbing. On non-adherent substrates and in collagen matrices, amoeboid-like, blebbing cells having high Src activity formed protrusions of the plasma membrane. To evaluate the role of Src in confined cells, we use a novel approach that places cells under a slab of polydimethylsiloxane (PDMS), which is held at a defined height. Using this method, we find that leader bleb-based migration is resistant to Src inhibition. High Src activity was found to markedly change the architecture of cortical actomyosin, reduce cell mechanical properties, and the percentage of cells that undergo leader bleb-based migration. Thus, Src is a signal transducer that can potently influence transitions between migration modes with implications for the rational development of metastasis inhibitors.	[Logue, Jeremy S.] NHLBI, NIH, Bldg 10, Bethesda, MD 20892 USA; [Logue, Jeremy S.; Cartagena-Rivera, Alexander X.; Chadwick, Richard S.] NIDCD, NIH, Bethesda, MD 20892 USA; [Logue, Jeremy S.] Albany Med Coll, Dept Regenerat & Canc Cell Biol, Albany, NY 12208 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); Albany Medical College	Logue, JS (corresponding author), NHLBI, NIH, Bldg 10, Bethesda, MD 20892 USA.; Logue, JS (corresponding author), NIDCD, NIH, Bethesda, MD 20892 USA.; Logue, JS (corresponding author), Albany Med Coll, Dept Regenerat & Canc Cell Biol, Albany, NY 12208 USA.	loguej@mail.amc.edu	Cartagena-Rivera, Alexander X./I-6101-2016	Cartagena-Rivera, Alexander X./0000-0001-6227-2499	intramural research program at the NIH; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [ZIADC000033] Funding Source: NIH RePORTER	intramural research program at the NIH; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	We thank Clare Waterman (NHLBI) and members of the Waterman Lab for insightful discussions and for the use of spinning disk confocal microscopes. We thank the NHLBI Light Microscopy Core Facility for use of the Zeiss LSM 880 Airyscan. This work was supported by funds from the intramural research program at the NIH.	Artym Vira V, 2010, Curr Protoc Cell Biol, VChapter 10, DOI 10.1002/0471143030.cb1018s48; Benink HA, 2005, J CELL BIOL, V168, P429, DOI 10.1083/jcb.200411109; Bergert M, 2015, NAT CELL BIOL, V17, P524, DOI 10.1038/ncb3134; Cartagena-Rivera AX, 2016, BIOPHYS J, V110, P2528, DOI 10.1016/j.bpj.2016.04.034; Case LB, 2015, NAT CELL BIOL, V17, P955, DOI 10.1038/ncb3191; Chan KT, 2010, J BIOL CHEM, V285, P11418, DOI 10.1074/jbc.M109.090746; Charras GT, 2005, NATURE, V435, P365, DOI 10.1038/nature03550; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; Ezratty EJ, 2005, NAT CELL BIOL, V7, P581, DOI 10.1038/ncb1262; Ferrando IM, 2012, MOL CELL PROTEOMICS, V11, P355, DOI 10.1074/mcp.M111.015750; Finn RS, 2011, CLIN CANCER RES, V17, P6905, DOI 10.1158/1078-0432.CCR-11-0288; Fury MG, 2011, ANTICANCER RES, V31, P249; Gangadhar TC, 2013, INVEST NEW DRUG, V31, P769, DOI 10.1007/s10637-012-9897-4; Gorelik R, 2014, NAT PROTOC, V9, P1931, DOI 10.1038/nprot.2014.131; Green TP, 2009, MOL ONCOL, V3, P248, DOI 10.1016/j.molonc.2009.01.002; Gucalp A, 2011, CLIN BREAST CANCER, V11, P306, DOI 10.1016/j.clbc.2011.03.021; Horton ER, 2016, J CELL BIOL, V212, P349, DOI 10.1083/jcb.201508080; ILLC D, 1995, NATURE, V377, P539; Kanchanawong P, 2010, NATURE, V468, P580, DOI 10.1038/nature09621; Kim LC, 2009, NAT REV CLIN ONCOL, V6, P587, DOI 10.1038/nrclinonc.2009.129; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Kluger HM, 2011, CANCER-AM CANCER SOC, V117, P2202, DOI 10.1002/cncr.25766; Liu YJ, 2015, CELL, V160, P659, DOI 10.1016/j.cell.2015.01.007; Logue JS, 2015, ELIFE, V4, DOI 10.7554/eLife.08314; Lombardo LJ, 2004, J MED CHEM, V47, P6658, DOI 10.1021/jm049486a; Mackay HJ, 2012, INVEST NEW DRUG, V30, P1158, DOI 10.1007/s10637-011-9650-4; Mayer EL, 2011, CLIN CANCER RES, V17, P6897, DOI 10.1158/1078-0432.CCR-11-0070; Meijering E, 2012, METHOD ENZYMOL, V504, P183, DOI 10.1016/B978-0-12-391857-4.00009-4; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; Molina JR, 2014, LUNG CANCER, V85, P245, DOI 10.1016/j.lungcan.2014.03.004; O'Hare T, 2005, CANCER RES, V65, P4500, DOI 10.1158/0008-5472.CAN-05-0259; Plotnikov SV, 2012, CELL, V151, P1513, DOI 10.1016/j.cell.2012.11.034; Ruprecht V, 2015, CELL, V160, P673, DOI 10.1016/j.cell.2015.01.008; Sahai E, 2003, NAT CELL BIOL, V5, P711, DOI 10.1038/ncb1019; Schaller MD, 2010, J CELL SCI, V123, P1007, DOI 10.1242/jcs.045112; Schell MJ, 2001, J BIOL CHEM, V276, P37537, DOI 10.1074/jbc.M104101200; Schilder RJ, 2012, GYNECOL ONCOL, V127, P70, DOI 10.1016/j.ygyno.2012.06.009; Schmid B, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-274; Sharma MR, 2012, INVEST NEW DRUG, V30, P1211, DOI 10.1007/s10637-011-9681-x; Shin W., 2010, LIVE CELL IMAGING LA, P119; Tozluoglu M, 2013, NAT CELL BIOL, V15, P751, DOI 10.1038/ncb2775; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Wolf K, 2003, J CELL BIOL, V160, P267, DOI 10.1083/jcb.200209006; Wong SY, 2006, CELL CYCLE, V5, P812, DOI 10.4161/cc.5.8.2646; Zhang SY, 2012, TRENDS PHARMACOL SCI, V33, P122, DOI 10.1016/j.tips.2011.11.002	45	17	17	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	16					2104	2121		10.1038/s41388-017-0071-5	http://dx.doi.org/10.1038/s41388-017-0071-5			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GD5ZV	29379163	Green Published, hybrid			2022-12-17	WOS:000430589000003
J	Song, SH; Jeon, MS; Nam, JW; Kang, JK; Lee, YJ; Kang, JY; Kim, HP; Han, SW; Kang, GH; Kim, TY				Song, S. H.; Jeon, M. S.; Nam, J. W.; Kang, J. K.; Lee, Y. J.; Kang, J. Y.; Kim, H. P.; Han, S. W.; Kang, G. H.; Kim, T. Y.			Aberrant GATA2 epigenetic dysregulation induces a GATA2/GATA6 switch in human gastric cancer	ONCOGENE			English	Article							BETA-GLOBIN LOCUS; ACUTE MYELOID-LEUKEMIA; DNA METHYLATION; HELICOBACTER-PYLORI; EMBRYONIC-DEVELOPMENT; LINEAGE-SURVIVAL; POLYCOMB; RISK; DIFFERENTIATION; EXPRESSION	Six GATA transcription factors play important roles in eukaryotic development. Among these, GATA2, an essential factor for the hematopoietic cell lineage, exhibits low expression in human gastric tissues, whereas GATA6, which is crucial for gastrointestinal development and differentiation, is frequently amplified and/or overexpressed in human gastric cancer. Interestingly, we found that GATA6 was overexpressed in human gastric cancer cells only when GATA2 expression was completely absent, thereby showing an inverse correlation between GATA2 and GATA6. In gastric cancer cells that express high GATA6 levels, a GATA2 CpG island is hypermethylated, repressing expression in these cells. In contrast, GATA6 expression is undetectable in GATA2-overexpressing gastric cancer cells, which lack GATA2 DNA methylation. Furthermore, PRC2 complex-mediated transcriptional silencing of GATA6 was observed in the GATA2-overexpressing cells. We also show that the GATA2 and PRC2 complexes are enriched within the GATA6 locus, and that the recruitment of the PRC2 complex is impaired by disrupting GATA2 expression, resulting in GATA6 upregulation. In addition, ectopic GATA2 expression significantly downregulates GATA6 expression, suggesting GATA2 directly represses GATA6. Furthermore, GATA6 downregulation showed antitumor activity by inducing growth arrest. Finally, we show that aberrant GATA2 methylation occurs early during the multistep process of gastric carcinogenesis regardless of Helicobacter pylori infection. Taken together, GATA2 dysregulation by epigenetic modification is associated with unfavorable phenotypes in human gastric cancer cells by allowing GATA6 expression.	[Song, S. H.; Jeon, M. S.; Nam, J. W.; Kang, J. K.; Lee, Y. J.; Kang, J. Y.; Kim, H. P.; Han, S. W.; Kim, T. Y.] Seoul Natl Univ, Canc Res Inst, Canc Genom Res Lab, Seoul, South Korea; [Jeon, M. S.; Nam, J. W.; Kang, J. K.; Lee, Y. J.; Kang, J. Y.; Kim, H. P.; Kim, T. Y.] Seoul Natl Univ, Grad Sch Convergence Sci & Technol, Dept Mol Med & Biopharmaceut Sci, Seoul, South Korea; [Han, S. W.; Kim, T. Y.] Seoul Natl Univ Hosp, Dept Internal Med, Seoul 110744, South Korea; [Kang, G. H.] Seoul Natl Univ, Canc Res Inst, Lab Epigenet, Seoul, South Korea; [Kang, G. H.] Seoul Natl Univ, Dept Pathol, Coll Med, Seoul, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Seoul National University Hospital; Seoul National University (SNU); Seoul National University (SNU)	Kim, TY (corresponding author), Seoul Natl Univ Hosp, Dept Internal Med, Seoul 110744, South Korea.	kimty@snu.ac.kr	/Y-5959-2019; Kang, Gyeong Hoon/F-1051-2010	Kang, Gyeong Hoon/0000-0003-2380-6675	Korea Health Technology R&D Project through the Korea Health Industry Development Institute; Ministry of Health & Welfare, Republic of Korea [HI14C1277]; Bio & Medical Technology Development Program of the National Research Foundation (NRF) - Ministry of Science, ICT & Future Planning, Republic of Korea [NRF-2016M3A9B6026918, NRF-2016M3A9B6026921, 2011-0030049]; NRF - Ministry of Education, Republic of Korea [NRF-2016R1D1A1B03930736]	Korea Health Technology R&D Project through the Korea Health Industry Development Institute; Ministry of Health & Welfare, Republic of Korea(Ministry of Health & Welfare (MOHW), Republic of Korea); Bio & Medical Technology Development Program of the National Research Foundation (NRF) - Ministry of Science, ICT & Future Planning, Republic of Korea(National Research Foundation of KoreaMinistry of Science, ICT & Future Planning, Republic of Korea); NRF - Ministry of Education, Republic of Korea(Ministry of Education (MOE), Republic of KoreaNational Research Foundation of Korea)	This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute, funded by the Ministry of Health & Welfare, Republic of Korea (HI14C1277), by the Bio & Medical Technology Development Program of the National Research Foundation (NRF) funded by the Ministry of Science, ICT & Future Planning, Republic of Korea (NRF-2016M3A9B6026918, NRF-2016M3A9B6026921 and 2011-0030049) and by Basic Science Research Program through the NRF funded by the Ministry of Education, Republic of Korea (NRF-2016R1D1A1B03930736).	Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130; Beuling E, 2011, GASTROENTEROLOGY, V140, P1219, DOI 10.1053/j.gastro.2011.01.033; Bresnick EH, 2012, NUCLEIC ACIDS RES, V40, P5819, DOI 10.1093/nar/gks281; Bresnick EH, 2010, J BIOL CHEM, V285, P31087, DOI 10.1074/jbc.R110.159079; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Capo-Chichi CD, 2009, MOL CELL BIOL, V29, P4766, DOI 10.1128/MCB.00087-09; Cheung WKC, 2013, CANCER CELL, V23, P725, DOI 10.1016/j.ccr.2013.04.009; Chia NY, 2015, GUT, V64, P707, DOI 10.1136/gutjnl-2013-306596; Deng DJ, 2010, ADV GENET, V71, P125, DOI [10.1016/S0065-2660(10)71005-1, 10.1016/B978-0-12-380864-6.00005-5]; Deng NT, 2012, GUT, V61, P673, DOI 10.1136/gutjnl-2011-301839; Dyson MT, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004158; Endoh M, 2008, DEVELOPMENT, V135, P1513, DOI 10.1242/dev.014340; Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113; Grass JA, 2003, P NATL ACAD SCI USA, V100, P8811, DOI 10.1073/pnas.1432147100; Hattori N, 2014, BIOCHEM BIOPH RES CO, V455, P3, DOI 10.1016/j.bbrc.2014.08.140; Haveri H, 2008, BMC GASTROENTEROL, V8, DOI 10.1186/1471-230X-8-9; Johnson KD, 2012, J CLIN INVEST, V122, P3692, DOI 10.1172/JCI61623; Kang JY, 2015, ONCOGENE, V34, P5677, DOI 10.1038/onc.2015.17; Kang JY, 2015, AM J PATHOL, V185, P666, DOI 10.1016/j.ajpath.2014.11.022; Kang XL, 2010, MOL CELL, V38, P191, DOI 10.1016/j.molcel.2010.03.005; Kang Y, 2017, BBA-GENE REGUL MECH, V1860, P416, DOI 10.1016/j.bbagrm.2017.01.013; Kang Y, 2015, BBA-GENE REGUL MECH, V1849, P282, DOI 10.1016/j.bbagrm.2014.12.010; Karimi P, 2014, CANCER EPIDEM BIOMAR, V23, P700, DOI 10.1158/1055-9965.EPI-13-1057; Katsumura KR, 2016, CELL REP, V16, P2428, DOI 10.1016/j.celrep.2016.07.058; Kim HP, 2014, ONCOGENE, V33, P5434, DOI 10.1038/onc.2013.490; Ku Ja-Lok, 2005, Cancer Res Treat, V37, P1, DOI 10.4143/crt.2005.37.1.1; Lin L, 2012, P NATL ACAD SCI USA, V109, P4251, DOI 10.1073/pnas.1011989109; Liu ZJ, 2014, CLIN CANCER RES, V20, P4598, DOI 10.1158/1078-0432.CCR-13-3380; Liu-Chittenden Y, 2017, ONCOGENE, V36, P3541, DOI 10.1038/onc.2016.497; Lu R, 2011, J BIOL CHEM, V286, P8425, DOI 10.1074/jbc.M110.202150; Maekita T, 2006, CLIN CANCER RES, V12, P989, DOI 10.1158/1078-0432.CCR-05-2096; Matsusaka K, 2014, WORLD J GASTROENTERO, V20, P3916, DOI 10.3748/wjg.v20.i14.3916; Molkentin JD, 2000, J BIOL CHEM, V275, P38949, DOI 10.1074/jbc.R000029200; Moriguchi T, 2014, INT J HEMATOL, V100, P417, DOI 10.1007/s12185-014-1568-0; Morrisey EE, 1998, GENE DEV, V12, P3579, DOI 10.1101/gad.12.22.3579; Morrisey EE, 1997, DEV BIOL, V183, P21, DOI 10.1006/dbio.1996.8485; Nakajima T, 2006, CANCER EPIDEM BIOMAR, V15, P2317, DOI 10.1158/1055-9965.EPI-06-0436; Pan XQ, 2000, J BIOCHEM, V127, P105, DOI 10.1093/oxfordjournals.jbchem.a022570; Park SY, 2009, J PATHOL, V219, P410, DOI 10.1002/path.2596; Ping N, 2017, LEUKEMIA, V31, P195, DOI 10.1038/leu.2016.162; Rodriguez-Paredes M, 2011, NAT MED, V17, P330, DOI 10.1038/nm.2305; Schuettengruber B, 2007, CELL, V128, P735, DOI 10.1016/j.cell.2007.02.009; Shalem O, 2014, SCIENCE, V343, P84, DOI 10.1126/science.1247005; Shih AH, 2015, CANCER CELL, V27, P502, DOI 10.1016/j.ccell.2015.03.009; Song SH, 2007, MOL CELL, V28, P810, DOI 10.1016/j.molcel.2007.09.025; Song SH, 2011, DRUGS, V71, P2391, DOI 10.2165/11596690-000000000-00000; Sulahian R, 2014, ONCOGENE, V33, P5637, DOI 10.1038/onc.2013.517; Tahara T, 2015, EPIGENOMICS-UK, V7, P475, DOI 10.2217/epi.15.4; Ushijima T, 2012, CLIN CANCER RES, V18, P923, DOI 10.1158/1078-0432.CCR-11-2011; Yu M, 2009, MOL CELL, V36, P682, DOI 10.1016/j.molcel.2009.11.002; Yun J, 2016, NUCLEIC ACIDS RES, V44, P558, DOI 10.1093/nar/gkv933	51	17	18	1	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 22	2018	37	8					993	1004		10.1038/onc.2017.397	http://dx.doi.org/10.1038/onc.2017.397			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FX2QD	29106391				2022-12-17	WOS:000425905700003
J	Debruyne, DN; Turchi, L; Burel-Vandenbos, F; Fareh, M; Almairac, F; Virolle, V; Figarella-Branger, D; Baeza-Kallee, N; Lagadec, P; Kubiniek, V; Paquis, P; Fontaine, D; Junier, MP; Chneiweiss, H; Virolle, T				Debruyne, D. N.; Turchi, L.; Burel-Vandenbos, F.; Fareh, M.; Almairac, F.; Virolle, V.; Figarella-Branger, D.; Baeza-Kallee, N.; Lagadec, P.; Kubiniek, V.; Paquis, P.; Fontaine, D.; Junier, M-P; Chneiweiss, H.; Virolle, T.			DOCK4 promotes loss of proliferation in glioblastoma progenitor cells through nuclear beta-catenin accumulation and subsequent miR-302-367 cluster expression	ONCOGENE			English	Article							CANCER STEM-CELL; GLIOMA-INITIATING CELLS; NANOG; TUMORS	Glioblastomas (GBM) are lethal primitive brain tumours characterized by a strong intra-tumour heterogeneity. We observed in GBM tissues the coexistence of functionally divergent micro-territories either enriched in more differentiated and non-mitotic cells or in mitotic undifferentiated OLIG2 positive cells while sharing similar genomic abnormalities. Understanding the formation of such functionally divergent micro-territories in glioblastomas (GBM) is essential to comprehend GBM biogenesis, plasticity and to develop therapies. Here we report an unexpected anti-proliferative role of beta-catenin in non-mitotic differentiated GBM cells. By cell type specific stimulation of miR-302, which directly represses cyclin D1 and stemness features, beta-catenin is capable to change its known proliferative function. Nuclear beta-catenin accumulation in non-mitotic cells is due to a feed forward mechanism between DOCK4 and beta-catenin, allowed by increased GSK3-beta activity. DOCK4 over expression suppresses selfrenewal and tumorigenicity of GBM stem-like cells. Accordingly in the frame of GBM median of survival, increased level of DOCK4 predicts improved patient survival.	[Debruyne, D. N.; Turchi, L.; Burel-Vandenbos, F.; Fareh, M.; Almairac, F.; Virolle, V.; Lagadec, P.; Paquis, P.; Virolle, T.] Univ Cote dAzur, Nice, France; [Debruyne, D. N.; Turchi, L.; Burel-Vandenbos, F.; Fareh, M.; Almairac, F.; Virolle, V.; Lagadec, P.; Paquis, P.; Virolle, T.] CNRS, UMR7277, Nice, France; [Debruyne, D. N.; Turchi, L.; Burel-Vandenbos, F.; Fareh, M.; Almairac, F.; Virolle, V.; Lagadec, P.; Paquis, P.; Virolle, T.] INSERM, U1091, Nice, France; [Turchi, L.; Almairac, F.; Paquis, P.; Fontaine, D.] CHU Nice, Hop Pasteur, Serv Neurchirurg, Nice, France; [Burel-Vandenbos, F.] CHU Nice, Hop Pasteur, Serv Anatomopathol, Nice, France; [Figarella-Branger, D.; Baeza-Kallee, N.] Aix Marseille Univ, Fac Med Timone, Marseille, France; [Figarella-Branger, D.; Baeza-Kallee, N.] INSERM, UMR 911, CRO2, Marseille, France; [Figarella-Branger, D.] CHU Timone, Dept Pathol, Marseille 5, France; [Kubiniek, V.] Univ Hosp Nice, Lab Solid Tumors Genet, Nice, France; [Junier, M-P; Chneiweiss, H.] CNRS, Neurosci Paris Seine IBPS UMR8246, 7 Quai St Bernard, Paris, France; [Junier, M-P; Chneiweiss, H.] Team Glial Plast, 7 Quai St Bernard, Paris, France; [Junier, M-P; Chneiweiss, H.] INSERM, U1130, Neurosci Paris Seine IBPS, 7 Quai St Bernard, Paris, France; [Junier, M-P; Chneiweiss, H.] Univ Paris 06, UMCR18, Neurosci Paris Seine IBPS, 7 Quai St Bernard, Paris, France	UDICE-French Research Universities; Universite Cote d'Azur; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice; CHU Nice; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; CHU Nice; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Virolle, T (corresponding author), Univ Nice Sophia Antipolis, Inst Biol, iBV, UFR Sci, Batiment Sci Nat,Parc Valrose,28 Ave Valrose, F-06108 Nice 2, France.	Virolle@unice.fr	herve, chneiweiss/Q-6818-2019; LAGADEC, Patricia/P-4538-2016; Virolle, Thierry/E-5838-2016	herve, chneiweiss/0000-0001-7675-5061; LAGADEC, Patricia/0000-0002-5105-782X; Fareh, Mohamed/0000-0001-9551-8213; Fontaine, Denys/0000-0001-5012-6769; Turchi, Laurent/0000-0003-2020-5831	Association pour la Recherche sur le Cancer [3161]; Association Sauvons Laura; ADerTU; Association Dimitri Bessiere; Agence Nationale pour la Recherche (ANR Jeunes Chercheurs, Jeunes Chercheuses, "GLIOMIRSTEM project"); Fondation de France; ARC projet [SFI20111203773]; INCA PLBIO; ITMO CANCER plan cancer; INSERM; UNSA	Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Association Sauvons Laura; ADerTU; Association Dimitri Bessiere; Agence Nationale pour la Recherche (ANR Jeunes Chercheurs, Jeunes Chercheuses, "GLIOMIRSTEM project")(French National Research Agency (ANR)); Fondation de France(Fondation de France); ARC projet; INCA PLBIO; ITMO CANCER plan cancer; INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); UNSA	This work was supported by grants from the Association pour la Recherche sur le Cancer (subvention 3161), Association Sauvons Laura, ADerTU, Association Dimitri Bessiere, Agence Nationale pour la Recherche (ANR Jeunes Chercheurs, Jeunes Chercheuses, "GLIOMIRSTEM project"), Fondation de France, ARC projet (SFI20111203773), INCA PLBIO2012, ITMO CANCER plan cancer, INSERM, UNSA. We thank A Borderie, S Bestree, C Hagnere, F Frassinetti, S Rekima, AC Peyron and F Keslair for their technical assistance and C. Colin for the statistical analysis. We thank Doctor Enzo Lalli for providing the PKF115-584 inhibitor and Doctor Andreas Schedl for the mYhBCATf and the TopFlash reporter plasmid. We thank Doctor Ellen Van Obberghen-Schilling for grammatical corrections.	Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Dahan P, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.509; Fan X, 2010, STEM CELLS, V28, P5, DOI 10.1002/stem.254; Fareh M, 2012, CELL DEATH DIFFER, V19, P232, DOI 10.1038/cdd.2011.89; Farhana L, 2012, J ONCOL, V2012, DOI 10.1155/2012/796729; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Germano I, 2010, NEUROPHARMACOLOGY, V58, P903, DOI 10.1016/j.neuropharm.2009.12.019; Gong AH, 2012, CANCER RES, V72, P5658, DOI 10.1158/0008-5472.CAN-12-0953; Hallett RM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033976; Johannessen TCA, 2012, EXPERT REV ANTICANC, V12, P635, DOI [10.1586/ERA.12.37, 10.1586/era.12.37]; Kleppe M, 2012, CELL STEM CELL, V10, P351, DOI 10.1016/j.stem.2012.03.006; Korur S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007443; Kotliarova S, 2008, CANCER RES, V68, P6643, DOI 10.1158/0008-5472.CAN-08-0850; LaFramboise T, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001086; Lee M, 2012, INT J GYNECOL CANCER, V22, P1489, DOI 10.1097/IGJ.0b013e3182738307; Ligon KL, 2007, NEURON, V53, P503, DOI 10.1016/j.neuron.2007.01.009; Meng HM, 2010, CANCER BIOL THER, V9, P295, DOI 10.4161/cbt.9.4.10666; Mills CN, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00047; Nagata T, 2014, BREAST CANCER-TOKYO, V21, P96, DOI 10.1007/s12282-012-0357-y; Patru C, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-66; Piccirillo SGM, 2007, ERNST SCHERING FOUND, V5, P59, DOI 10.1007/2789_2007_044; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Singh SK, 2003, CANCER RES, V63, P5821; Snuderl M, 2011, CANCER CELL, V20, P810, DOI 10.1016/j.ccr.2011.11.005; Sottoriva A, 2013, P NATL ACAD SCI USA, V110, P4009, DOI 10.1073/pnas.1219747110; Sottoriva A, 2013, CANCER RES, V73, P41, DOI 10.1158/0008-5472.CAN-12-2273; Turchi L, 2013, STEM CELLS, V31, P1252, DOI 10.1002/stem.1373; Upadhyay G, 2008, ONCOGENE, V27, P5845, DOI 10.1038/onc.2008.202; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126; Yuan XP, 2004, ONCOGENE, V23, P9392, DOI 10.1038/sj.onc.1208311	32	17	18	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 11	2018	37	2					241	254		10.1038/onc.2017.323	http://dx.doi.org/10.1038/onc.2017.323			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS8AN	28925399				2022-12-17	WOS:000422631700010
J	Fettig, LM; McGinn, O; Finlay-Schultz, J; LaBarbera, DV; Nordeen, SK; Sartorius, CA				Fettig, L. M.; McGinn, O.; Finlay-Schultz, J.; LaBarbera, D. V.; Nordeen, S. K.; Sartorius, C. A.			Cross talk between progesterone receptors and retinoic acid receptors in regulation of cytokeratin 5-positive breast cancer cells	ONCOGENE			English	Article							NEGATIVE RESPONSE ELEMENTS; STEM-CELL; ESTROGEN-RECEPTOR; NUCLEAR RECEPTORS; LINE T-47D; EXPRESSION; POPULATION; ALPHA; RESPONSIVENESS; MODULATORS	Half of estrogen receptor-positive breast cancers contain a subpopulation of cytokeratin 5 (CK5)-expressing cells that are therapy resistant and exhibit increased cancer stem cell (CSC) properties. We and others have demonstrated that progesterone (P4) increases CK5+ breast cancer cells. We previously discovered that retinoids block P4 induction of CK5+ cells. Here we investigated the mechanisms by which progesterone receptors (PR) and retinoic acid receptors (RAR) regulate CK5 expression and breast CSC activity. After P4 treatment, sorted CK5+ compared to CK5 - cells were more tumorigenic in vivo. In vitro, P4-treated breast cancer cells formed larger mammospheres and silencing of CK5 using small hairpin RNA abolished this P4-dependent increase in mammosphere size. Retinoic acid (RA) treatment blocked the P4 increase in CK5+ cells and prevented the P4 increase in mammosphere size. Dual small interfering RNA (siRNA) silencing of RAR alpha and RAR gamma reversed RA blockade of P4-induced CK5. Using promoter deletion analysis, we identified a region 1.1 kb upstream of the CK5 transcriptional start site that is necessary for P4 activation and contains a putative progesterone response element (PRE). We confirmed by chromatin immunoprecipitation that P4 recruits PR to the CK5 promoter near the - 1.1 kb essential PRE, and also to a proximal region near - 130 bp that contains PRE half-sites and a RA response element (RARE). RA induced loss of PR binding only at the proximal site. Interestingly, RARa was recruited to the - 1.1 kb PRE and the - 130 bp PRE/RARE regions with P4, but not RA alone or RA plus P4. Treatment of breast cancer xenografts in vivo with the retinoid fenretinide reduced the accumulation of CK5+ cells during estrogen depletion. This reduction, together with the inhibition of CK5+ cell expansion through RAR/PR cross talk, may explain the efficacy of retinoids in prevention of some breast cancer recurrences.	[Fettig, L. M.; McGinn, O.; Finlay-Schultz, J.; Nordeen, S. K.; Sartorius, C. A.] Univ Colorado, Dept Pathol, Anschutz Med Campus,12801 E 17th Ave MS8104, Aurora, CO 80045 USA; [LaBarbera, D. V.] Univ Colorado, Skaggs Sch Pharm & Pharmaceut Sci, Dept Pharmaceut Sci, Anschutz Med Campus, Aurora, CO 80045 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	Sartorius, CA (corresponding author), Univ Colorado, Dept Pathol, Anschutz Med Campus,12801 E 17th Ave MS8104, Aurora, CO 80045 USA.	Carol.Sartorius@ucdenver.edu	McGinn, Olivia/J-8337-2015	McGinn, Olivia/0000-0003-0769-5581; Finlay-Schultz, Jessica/0000-0002-7855-9870	University of Colorado Cancer Center Flow Cytometry, Biorepository Core, and Tissue Culture Cores [P30CA046934]; Colorado Clinical and Translational Sciences Institute NIH [TL1 TR001081]; National Institutes of Health [NIH F31 CA210519, NIH 2R01 CA140985]; Breast Cancer Research Foundation [16-072]; Breast Cancer Research Foundation (CAS); Breast Cancer Research Foundation (co-PI); NATIONAL CANCER INSTITUTE [F31CA210519, R01CA140985, P30CA046934] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [TL1TR001081] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK048520] Funding Source: NIH RePORTER	University of Colorado Cancer Center Flow Cytometry, Biorepository Core, and Tissue Culture Cores; Colorado Clinical and Translational Sciences Institute NIH; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Breast Cancer Research Foundation; Breast Cancer Research Foundation (CAS); Breast Cancer Research Foundation (co-PI); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank the University of Colorado Cancer Center Flow Cytometry, Biorepository Core, and Tissue Culture Cores supported by P30CA046934 and the University of Colorado Department of Pathology Sequencing Core for their technical assistance and services. We thank Andrea Osypuk and Story Wilson for their assistance with Aperio imaging and analysis. This work was supported by grants from the Colorado Clinical and Translational Sciences Institute NIH TL1 TR001081 (LMF), National Institutes of Health grants NIH F31 CA210519 (LMF), NIH 2R01 CA140985 (CAS) and Breast Cancer Research Foundation (16-072, CAS, co-PI).	Allan Alison L, 2006, Breast Dis, V26, P87; Asselin-Labat ML, 2010, NATURE, V465, P798, DOI 10.1038/nature09027; Axlund SD, 2013, HORM CANCER-US, V4, P36, DOI 10.1007/s12672-012-0127-5; Boudreau A, 2013, P NATL ACAD SCI USA, V110, pE3937, DOI 10.1073/pnas.1315022110; Chaffer CL, 2011, P NATL ACAD SCI USA, V108, P7950, DOI 10.1073/pnas.1102454108; Cheang MCU, 2008, CLIN CANCER RES, V14, P1368, DOI 10.1158/1078-0432.CCR-07-1658; Cheung KJ, 2013, CELL, V155, P1639, DOI 10.1016/j.cell.2013.11.029; Chung BM, 2013, CURR OPIN CELL BIOL, V25, P600, DOI 10.1016/j.ceb.2013.06.008; Cittelly DM, 2013, ONCOGENE, V32, P2555, DOI 10.1038/onc.2012.275; Clarke CL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035859; CLARKE CL, 1991, J BIOL CHEM, V266, P18969; CLARKE CL, 1990, J BIOL CHEM, V265, P12694; Daniel AR, 2015, ONCOGENE, V34, P506, DOI 10.1038/onc.2013.579; Finlay-Schultz J, 2015, ONCOGENE, V34, P3676, DOI 10.1038/onc.2014.298; Frasor J, 2003, ENDOCRINOLOGY, V144, P4562, DOI 10.1210/en.2003-0567; Garattini E, 2014, CANCER TREAT REV, V40, P739, DOI 10.1016/j.ctrv.2014.01.001; Gianni' M, 2001, BLOOD, V97, P3234, DOI 10.1182/blood.V97.10.3234; Goodman CR, 2016, ONCOGENE, V35, P1373, DOI 10.1038/onc.2015.193; Graham JD, 2009, ENDOCRINOLOGY, V150, P3318, DOI 10.1210/en.2008-1630; Gudas LJ, 2011, J CELL PHYSIOL, V226, P322, DOI 10.1002/jcp.22417; Guedj M, 2012, ONCOGENE, V31, P1196, DOI 10.1038/onc.2011.301; Horwitz KB, 2008, J CLIN ENDOCR METAB, V93, P3295, DOI 10.1210/jc.2008-0938; Horwitzt KB, 2008, P NATL ACAD SCI USA, V105, P5774, DOI 10.1073/pnas.0706216105; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Hua SJ, 2009, CELL, V137, P1259, DOI 10.1016/j.cell.2009.04.043; Iliopoulos D, 2011, P NATL ACAD SCI USA, V108, P1397, DOI 10.1073/pnas.1018898108; Jho SH, 2001, J BIOL CHEM, V276, P45914, DOI 10.1074/jbc.M103144200; Joshi PA, 2010, NATURE, V465, P803, DOI 10.1038/nature09091; Kabos P, 2012, BREAST CANCER RES TR, V135, P415, DOI 10.1007/s10549-012-2164-8; Kabos P, 2011, BREAST CANCER RES TR, V128, P45, DOI 10.1007/s10549-010-1078-6; Kim S, 2006, NATURE, V441, P362, DOI 10.1038/nature04659; Knox AJ, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0418-6; Knutson TP, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3211; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; le Maire A, 2012, CURR TOP MED CHEM, V12, P505, DOI 10.2174/156802612799436687; LIEBERMAN BA, 1993, MOL ENDOCRINOL, V7, P515, DOI 10.1210/me.7.4.515; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Mohammed H, 2015, NATURE, V523, P313, DOI 10.1038/nature14583; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; Osborne CK, 2011, ANNU REV MED, V62, P233, DOI 10.1146/annurev-med-070909-182917; Osborne CK, 2005, BREAST, V14, P458, DOI 10.1016/j.breast.2005.08.024; Perissi V, 2005, NAT REV MOL CELL BIO, V6, P542, DOI 10.1038/nrm1680; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Radoja N, 1997, J INVEST DERMATOL, V109, P566, DOI 10.1111/1523-1747.ep12337483; Radoja N, 2000, MOL CELL BIOL, V20, P4328, DOI 10.1128/MCB.20.12.4328-4339.2000; Reid Brian G, 2014, Curr Chem Genom Transl Med, V8, P27, DOI 10.2174/2213988501408010027; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; ROMAN SD, 1992, CANCER RES, V52, P2236; Ross-Innes CS, 2010, GENE DEV, V24, P171, DOI 10.1101/gad.552910; Sato T, 2014, ONCOGENE, V33, P2215, DOI 10.1038/onc.2013.172; Seltmann K, 2013, P NATL ACAD SCI USA, V110, P18507, DOI 10.1073/pnas.1310493110; Singhal H, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1501924; Tang XH, 2011, ANNU REV PATHOL-MECH, V6, P345, DOI 10.1146/annurev-pathol-011110-130303; Toivola DM, 2010, TRENDS CELL BIOL, V20, P79, DOI 10.1016/j.tcb.2009.11.004; Veronesi U, 2006, ANN ONCOL, V17, P1065, DOI 10.1093/annonc/mdl047; Widschwendter M, 1997, CANCER RES, V57, P4158; Yoo BH, 2012, J BIOMOL SCREEN, V17, P1211, DOI 10.1177/1087057112452138	58	17	17	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 2	2017	36	44					6074	6084		10.1038/onc.2017.204	http://dx.doi.org/10.1038/onc.2017.204			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FL5CU	28692043	Green Accepted			2022-12-17	WOS:000414249800002
J	Kumar, R; Deivendran, S; Santhoshkumar, TR; Pillai, MR				Kumar, R.; Deivendran, S.; Santhoshkumar, T. R.; Pillai, M. R.			Signaling coupled epigenomic regulation of gene expression	ONCOGENE			English	Review							PHOSPHORYLATES HISTONE H3; DNA-DAMAGE RESPONSE; KINASE AURORA B; TYROSINE KINASE; BREAST-CANCER; MYELOPROLIFERATIVE DISORDERS; TRANSCRIPTIONAL REGULATION; METHYLTRANSFERASE ACTIVITY; PAK1 PHOSPHORYLATION; CELL-TRANSFORMATION	Inheritance of genomic information independent of the DNA sequence, the epigenetics, as well as gene transcription are profoundly shaped by serine/threonine and tyrosine signaling kinases and components of the chromatin remodeling complexes. To precisely respond to a changing external milieu, human cells efficiently translate upstream signals into post-translational modifications (PTMs) on histones and coregulators such as corepressors, coactivators, DNA-binding factors and PTM modifying enzymes. Because a protein with multiple residues for putative PTMs is expected to undergo more than one PTM in cells stimulated with growth factors, the outcome of combinational PTM codes on histones and coregulators is profoundly shaped by regulatory interplays between PTMs. The genomic functions of signaling kinases in cancer cells are manifested by the downstream effectors of cytoplasmic signaling cascades as well as translocation of the cytoplasmic signaling kinases to the nucleus. Signaling-mediated phosphorylation of histones serves as a regulatory switch for other PTMs, and connects chromatin remodeling complexes into gene transcription and gene activity. Here, we will discuss the recent advances in signaling-dependent epigenomic regulation of gene transcription using a few representative cancer-relevant serine/threonine and tyrosine kinases and their interplay with chromatin remodeling factors in cancer cells.	[Kumar, R.] George Washington Univ, Sch Med & Hlth Sci, Dept Biochem & Mol Med, Washington, DC 20052 USA; [Kumar, R.; Deivendran, S.; Santhoshkumar, T. R.; Pillai, M. R.] Rajiv Gandhi Ctr Biotechnol, Canc Res Program, Thiruvananthapuram 695014, Kerala, India	George Washington University; Department of Biotechnology (DBT) India; Rajiv Gandhi Centre for Biotechnology (RGCB)	Kumar, R (corresponding author), Rajiv Gandhi Ctr Biotechnol, Canc Res Program, Thiruvananthapuram 695014, Kerala, India.	rakeshkumar@rgcb.res.in	Sankaran, Deivendran/X-8009-2019; Kumar, Rakesh/ABD-1065-2020	Kumar, Rakesh/0000-0001-7664-0803	National Institutes of Health [CA090970, CA088023]; Department of Biotechnology, Government of India; Indian Council of Medical Research [3/1/3/JRF-2010/MPD]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Biotechnology, Government of India(Department of Biotechnology (DBT) India); Indian Council of Medical Research(Indian Council of Medical Research (ICMR))	We regret for not discussing the deserving work from many of our colleagues due to space limitations. Over the years, signaling and chromatin remodeling studies in Rakesh Kumar laboratory have been supported by the National Institutes of Health grants CA090970 and CA088023. M. Radhakrishna Pillai laboratory is supported by the Department of Biotechnology, Government of India. S. Deivendran is supported by a Senior Research Fellowship from the Indian Council of Medical Research (No. 3/1/3/JRF-2010/MPD).	Aihara H, 2016, MOL CELL, V64, P176, DOI 10.1016/j.molcel.2016.09.012; Baek SH, 2011, MOL CELL, V42, P274, DOI 10.1016/j.molcel.2011.03.022; Barnes CJ, 2003, NAT STRUCT BIOL, V10, P622, DOI 10.1038/nsb957; Barnes CJ, 2003, CANCER METAST REV, V22, P301, DOI 10.1023/A:1023726827771; Barros P, 2012, NUCLEIC ACIDS RES, V40, P7776, DOI 10.1093/nar/gks571; Basnet H, 2014, NATURE, V516, P267, DOI 10.1038/nature13736; Baxter EJ, 2005, LANCET, V365, P1054, DOI 10.1016/S0140-6736(05)71142-9; Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001; Briscoe J, 1996, PHILOS T ROY SOC B, V351, P167, DOI 10.1098/rstb.1996.0013; Bungard D, 2010, SCIENCE, V329, P1201, DOI 10.1126/science.1191241; Cha TL, 2005, SCIENCE, V310, P306, DOI 10.1126/science.1118947; Chatterjee A, 2014, CELL REP, V9, P1333, DOI 10.1016/j.celrep.2014.10.039; Chen E, 2014, HEMATOL-AM SOC HEMAT, P268, DOI 10.1182/asheducation-2014.1.268; Cheng MB, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1002026; Cheung WL, 2005, CURR BIOL, V15, P656, DOI 10.1016/j.cub.2005.02.049; Cheung WL, 2003, CELL, V113, P507, DOI 10.1016/S0092-8674(03)00355-6; Choi HS, 2008, FASEB J, V22, P113, DOI 10.1096/fj.07-9078com; Choi HS, 2005, J BIOL CHEM, V280, P13545, DOI 10.1074/jbc.M410521200; Chou RH, 2014, DEV CELL, V30, P224, DOI 10.1016/j.devcel.2014.06.008; Christova R, 2007, J CELL SCI, V120, P3262, DOI 10.1242/jcs.012328; Chu CS, 2011, J BIOL CHEM, V286, P35843, DOI 10.1074/jbc.M111.228064; Dai J, 2005, GENE DEV, V19, P472, DOI 10.1101/gad.1267105; Darieva Z, 2015, ELIFE, V4, DOI 10.7554/eLife.09886; Dawson MA, 2012, CELL REP, V2, P470, DOI 10.1016/j.celrep.2012.08.016; Dawson MR, 2009, NATURE, V461, pE4, DOI 10.1038/nature08254; Duan Q, 2008, J BIOL CHEM, V283, P33585, DOI 10.1074/jbc.M803312200; Dyson MH, 2005, J CELL SCI, V118, P2247, DOI 10.1242/jcs.02373; Eswaran J, 2012, CLIN CANCER RES, V18, P3743, DOI 10.1158/1078-0432.CCR-11-1952; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; Frangini A, 2013, MOL CELL, V51, P647, DOI 10.1016/j.molcel.2013.08.022; Garg R, 2014, ONCOGENE, V33, P5225, DOI 10.1038/onc.2013.524; Gatchalian J, 2016, NUCLEIC ACIDS RES, V44, P6102, DOI 10.1093/nar/gkw193; Ge Z, 2006, MOL CELL BIOL, V26, P230, DOI 10.1128/MCB.26.1.230-237.2006; Ghanta KS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017135; Goto H, 2002, GENES CELLS, V7, P11, DOI 10.1046/j.1356-9597.2001.00498.x; Griffiths DS, 2011, NAT CELL BIOL, V13, P13, DOI 10.1038/ncb2135; Hammer A, 2015, FASEB J, V29, P943, DOI 10.1096/fj.14-259366; Happel N, 2009, J MOL BIOL, V386, P339, DOI 10.1016/j.jmb.2008.12.047; Harrison BC, 2010, FEBS LETT, V584, P1103, DOI 10.1016/j.febslet.2010.02.057; Heintzman ND, 2007, NAT GENET, V39, P311, DOI 10.1038/ng1966; Hergeth SP, 2011, J CELL SCI, V124, P1623, DOI 10.1242/jcs.084947; Hofmann J, 2004, CURR CANCER DRUG TAR, V4, P125, DOI 10.2174/1568009043481579; Hossain MB, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1501290; Hurd PJ, 2009, J BIOL CHEM, V284, P16575, DOI 10.1074/jbc.M109.005421; Ishibashi K, 2013, J CELL SCI, V126, P625, DOI 10.1242/jcs.116277; Jagadeeshan S, 2015, ONCOGENE, V34, P455, DOI 10.1038/onc.2013.576; Josefowicz SZ, 2016, MOL CELL, V64, P347, DOI 10.1016/j.molcel.2016.09.026; Kang B, 2011, GENE DEV, V25, P1359, DOI 10.1101/gad.2055511; Kang TH, 2007, MOL CELL BIOL, V27, P8533, DOI 10.1128/MCB.00018-07; Kelly AE, 2010, SCIENCE, V330, P235, DOI 10.1126/science.1189505; Kim K, 2012, ONCOGENE, V31, P4290, DOI 10.1038/onc.2011.605; Kohler J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034973; Krishnamoorthy T, 2006, GENE DEV, V20, P2580, DOI 10.1101/gad.1457006; Kumar R, 2016, ONCOGENE, V35, P4423, DOI 10.1038/onc.2015.513; Kumar R, 2016, ADV CANCER RES, V130, P137, DOI 10.1016/bs.acr.2016.01.002; Kumar R, 2006, NAT REV CANCER, V6, P459, DOI 10.1038/nrc1892; Kumar R, 2017, GENE, V605, P20, DOI 10.1016/j.gene.2016.12.014; Kumar R, 2016, GENE, V582, P112, DOI 10.1016/j.gene.2016.02.012; Kurat CF, 2011, GENE DEV, V25, P2489, DOI 10.1101/gad.173427.111; Lau ATY, 2011, J BIOL CHEM, V286, P26628, DOI 10.1074/jbc.M110.215590; Lau PNI, 2011, P NATL ACAD SCI USA, V108, P2801, DOI 10.1073/pnas.1012798108; Lee JH, 2015, NUCLEIC ACIDS RES, V43, P4505, DOI 10.1093/nar/gkv176; Lee JS, 2010, CELL, V142, P682, DOI 10.1016/j.cell.2010.08.011; Li DQ, 2015, ADV CANCER RES, V127, P1, DOI 10.1016/bs.acr.2015.04.005; Li DQ, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3545; Li DQ, 2012, CELL REP, V2, P1657, DOI 10.1016/j.celrep.2012.11.018; Li DQ, 2011, P NATL ACAD SCI USA, V108, P8791, DOI 10.1073/pnas.1018389108; Li F, 2002, EMBO REP, V3, P767, DOI 10.1093/embo-reports/kvf157; Li J, 2016, J CELL SCI, V129, P2448, DOI 10.1242/jcs.181248; Liu F, 2011, CANCER CELL, V19, P283, DOI 10.1016/j.ccr.2010.12.020; Liu Y, 2016, FEBS J, V283, P4462, DOI 10.1111/febs.13951; Liu Y, 2013, FEBS LETT, V587, P847, DOI 10.1016/j.febslet.2013.02.023; Liu Y, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003199; Mahajan K, 2013, TRENDS GENET, V29, P394, DOI 10.1016/j.tig.2013.02.003; Mahajan K, 2012, NAT STRUCT MOL BIOL, V19, P930, DOI 10.1038/nsmb.2356; Manavathi B, 2007, J BIOL CHEM, V282, P1529, DOI 10.1074/jbc.R600029200; Martelli AM, 2012, BBA-MOL CELL RES, V1823, P2168, DOI 10.1016/j.bbamcr.2012.08.017; Martiny-Baron G, 2007, PHARMACOL RES, V55, P477, DOI 10.1016/j.phrs.2007.04.001; McCuaig RD, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00562; Meng Q, 2007, P NATL ACAD SCI USA, V104, P5866, DOI 10.1073/pnas.0701065104; Metzger E, 2008, NAT CELL BIOL, V10, P53, DOI 10.1038/ncb1668; Metzger E, 2010, NATURE, V464, P792, DOI 10.1038/nature08839; Molli PR, 2010, J CELL BIOL, V190, P101, DOI 10.1083/jcb.200908050; Motwani M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066585; Musselman CA, 2012, NAT STRUCT MOL BIOL, V19, P1218, DOI 10.1038/nsmb.2436; Nair SS, 2013, MOL CELL, V49, P704, DOI 10.1016/j.molcel.2012.12.016; Nikonova AS, 2013, CELL MOL LIFE SCI, V70, P661, DOI 10.1007/s00018-012-1073-7; North JA, 2011, NUCLEIC ACIDS RES, V39, P6465, DOI 10.1093/nar/gkr304; O'Sullivan AG, 2015, ONCOTARGET, V6, P26437, DOI 10.18632/oncotarget.4664; Ostrovskyi D, 2016, FUTURE MED CHEM, V8, P1537, DOI 10.4155/fmc-2016-0132; Pakala SB, 2013, CANCER RES, V73, P3761, DOI 10.1158/0008-5472.CAN-12-3998; Park CH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044307; Pascreau Gaetan, 2003, Prog Cell Cycle Res, V5, P369; Pollack BP, 1999, J BIOL CHEM, V274, P31531, DOI 10.1074/jbc.274.44.31531; Preuss U, 2003, NUCLEIC ACIDS RES, V31, P878, DOI 10.1093/nar/gkg176; Prigent C, 2003, J CELL SCI, V116, P3677, DOI 10.1242/jcs.00735; Reddy SDN, 2011, P NATL ACAD SCI USA, V108, P4200, DOI 10.1073/pnas.1101193108; Rider L, 2007, J BIOL CHEM, V282, P30985, DOI 10.1074/jbc.M701794200; Rinaldo C, 2012, MOL CELL, V47, P87, DOI 10.1016/j.molcel.2012.04.029; Ringrose L, 2004, ANNU REV GENET, V38, P413, DOI 10.1146/annurev.genet.38.072902.091907; Rokudai S, 2013, P NATL ACAD SCI USA, V110, P3895, DOI 10.1073/pnas.1300490110; Rosenthal A, 2014, EXPERT OPIN PHARMACO, V15, P1265, DOI 10.1517/14656566.2014.913024; Rothbart SB, 2014, BBA-GENE REGUL MECH, V1839, P627, DOI 10.1016/j.bbagrm.2014.03.001; Sabbattini P, 2014, MOL BIOL CELL, V25, P904, DOI 10.1091/mbc.E13-10-0628; Sanchez-Solana B, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.404061; Sanidas I, 2014, MOL CELL, V53, P577, DOI 10.1016/j.molcel.2013.12.018; Sawa C, 2004, MOL CELL BIOL, V24, P4734, DOI 10.1128/MCB.24.11.4734-4742.2004; Sawicka A, 2014, GENOME RES, V24, P1808, DOI 10.1101/gr.176255.114; Selvi BR, 2010, BBA-GENE REGUL MECH, V1799, P810, DOI 10.1016/j.bbagrm.2010.09.005; Shimada M, 2008, CELL, V132, P221, DOI 10.1016/j.cell.2007.12.013; Singh RR, 2005, J BIOL CHEM, V280, P18130, DOI 10.1074/jbc.M412607200; Spangle JM, 2016, CELL REP, V15, P2692, DOI 10.1016/j.celrep.2016.05.046; Stojic L, 2011, EPIGENET CHROMATIN, V4, DOI 10.1186/1756-8935-4-16; Sutcliffe EL, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00260; Sutcliffe EL, 2011, MOL CELL, V41, P704, DOI 10.1016/j.molcel.2011.02.030; Swinstead EE, 2016, BIOESSAYS, V38, P1150, DOI 10.1002/bies.201600137; Tessarz P, 2014, NAT REV MOL CELL BIO, V15, P703, DOI 10.1038/nrm3890; Thomas JL, 2015, MOL CELL BIOL, V35, P4110, DOI 10.1128/MCB.00354-15; Toker Alex, 2014, Advances in Biological Regulation, V55, P28, DOI 10.1016/j.jbior.2014.04.001; Vadlamudi RK, 2005, ONCOGENE, V24, P4591, DOI 10.1038/sj.onc.1208672; Varier RA, 2010, EMBO J, V29, P3967, DOI 10.1038/emboj.2010.261; Wang FW, 2011, CURR BIOL, V21, P1061, DOI 10.1016/j.cub.2011.05.016; Wang RA, 2003, J CELL BIOL, V161, P583, DOI 10.1083/JCB.200212066; Wang SC, 2009, CLIN CANCER RES, V15, P6484, DOI 10.1158/1078-0432.CCR-08-2813; Wang YN, 2012, CELL BIOSCI, V2, DOI 10.1186/2045-3701-2-13; Wang YH, 2013, MOL CELL, V49, P283, DOI 10.1016/j.molcel.2012.10.028; Wang Z, 2015, P NATL ACAD SCI USA, V112, P8487, DOI 10.1073/pnas.1423325112; Warsito D, 2016, ONCOTARGET, V7, P42288, DOI 10.18632/oncotarget.9785; Wike CL, 2016, ELIFE, V5, DOI 10.7554/eLife.11402; Wu SY, 2013, MOL CELL, V49, P843, DOI 10.1016/j.molcel.2012.12.006; Xiao A, 2009, NATURE, V457, P57, DOI 10.1038/nature07668; Xing S, 2008, BLOOD, V111, P5109, DOI 10.1182/blood-2007-05-091579; Xu KX, 2012, SCIENCE, V338, P1465, DOI 10.1126/science.1227604; Yang WW, 2012, CELL, V150, P685, DOI 10.1016/j.cell.2012.07.018; Yang ZB, 2005, CANCER RES, V65, P3179, DOI 10.1158/0008-5472.CAN-04-3480; Yi SA, 2016, MOL CELL, V62, P443, DOI 10.1016/j.molcel.2016.03.011; Zhang Y, 2004, J BIOL CHEM, V279, P21866, DOI 10.1074/jbc.M400099200; Zhao ZS, 2005, MOL CELL, V20, P237, DOI 10.1016/j.molcel.2005.08.035; Zhu F, 2011, CANCER RES, V71, P393, DOI 10.1158/0008-5472.CAN-10-2012	139	17	17	2	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 26	2017	36	43					5917	5926		10.1038/onc.2017.201	http://dx.doi.org/10.1038/onc.2017.201			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FK9OT	28650470				2022-12-17	WOS:000413841400001
J	Kato, T; Sato, T; Yokoi, K; Sekido, Y				Kato, T.; Sato, T.; Yokoi, K.; Sekido, Y.			E-cadherin expression is correlated with focal adhesion kinase inhibitor resistance in Merlin-negative malignant mesothelioma cells	ONCOGENE			English	Article							NF2 TUMOR-SUPPRESSOR; PLEURAL MESOTHELIOMA; OVARIAN-CANCER; SIGNALING PATHWAYS; GROWTH-FACTOR; LUNG-CANCER; GENE NF2; PROLIFERATION; FAK; PROMOTES	Malignant mesothelioma (MM) is an aggressive tumor commonly caused by asbestos exposure after a long latency. Focal adhesion kinase (FAK) inhibitors inhibit the cell growth of Merlin-deficient MM cells; however, their clinical efficacy has not been clearly determined. The aim of this study was to evaluate the growth inhibitory effect of the FAK inhibitor VS-4718 on MM cell lines and identify biomarkers for its efficacy. Although most Merlin-deficient cell lines were sensitive to VS-4718 compared with control MeT-5A cells, a subset of these cell lines exhibited resistance to this drug. Microarray and qRT-PCR analyses using RNA isolated from Merlin-deficient MM cell lines revealed a significant correlation between E-cadherin mRNA levels and VS-4718 resistance. Merlin-and E-cadherin-negative Y-MESO-22 cells underwent apoptosis upon treatment with a low concentration of VS-4718, whereas Merlin-negative, E-cadherin-positive Y-MESO-9 cells did not undergo VS-4718-induced apoptosis. Furthermore, E-cadherin knockdown in Merlin-negative MM cells significantly sensitized cells to VS-4718 and induced apoptotic cell death upon VS-4718 treatment. Together, our results suggest that E-cadherin serves as a predictive biomarker for molecular target therapy with FAK inhibitors for patients with mesothelioma and that its expression endows MM cells with resistance to FAK inhibitors.	[Kato, T.; Sato, T.; Sekido, Y.] Aichi Canc Ctr, Div Mol Oncol, Res Inst, Nagoya, Aichi, Japan; [Kato, T.; Yokoi, K.] Nagoya Univ, Dept Thorac Surg, Grad Sch Med, Nagoya, Aichi, Japan; [Sekido, Y.] Dept Canc Genet, Program Funct Construct Med, Nagoya, Aichi, Japan	Aichi Cancer Center; Nagoya University	Sekido, Y (corresponding author), Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.	ysekido@aichi-cc.jp		Kato, Taketo/0000-0003-2568-6603; Sekido, Yoshitaka/0000-0002-2428-3848	JSPS KAKENHI [JP25290053, JP16H04706]; Takeda Science Foundation; Princess Takamatsu Cancer Research Fund [14-24617]; Project Mirai Cancer Research Grants; P-DIRECT; Grants-in-Aid for Scientific Research [16H04706] Funding Source: KAKEN	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Takeda Science Foundation(Takeda Science Foundation (TSF)); Princess Takamatsu Cancer Research Fund; Project Mirai Cancer Research Grants; P-DIRECT; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by JSPS KAKENHI (Grant Numbers JP25290053 and JP16H04706), the Takeda Science Foundation, a Research Grant from the Princess Takamatsu Cancer Research Fund (14-24617), Project Mirai Cancer Research Grants, and P-DIRECT. We thank Dr Adi F Gazdar for the cell lines, Dr Hideki Murakami for his technical support during gene expression profiling, and Miwako Nishizawa for her excellent technical assistance. We gratefully thank Dr Hirotaka Osada for the study design and his careful supervision of the data (Dr Osada was a member of our lab and passed away on 23 August 2016).	Addis B, 2009, HISTOPATHOLOGY, V54, P55, DOI 10.1111/j.1365-2559.2008.03178.x; Altomare DA, 2005, CANCER RES, V65, P8090, DOI 10.1158/0008-5472.CAN-05-2312; BIANCHI AB, 1995, P NATL ACAD SCI USA, V92, P10854, DOI 10.1073/pnas.92.24.10854; Breitling R, 2004, FEBS LETT, V573, P83, DOI 10.1016/j.febslet.2004.07.055; Bueno R, 2016, NAT GENET, V48, P407, DOI 10.1038/ng.3520; Canel M, 2013, J CELL SCI, V126, P393, DOI 10.1242/jcs.100115; Cole BK, 2008, MOL CELL BIOL, V28, P1274, DOI 10.1128/MCB.01139-07; Dong LL, 2012, ACTA PHARMACOL SIN, V33, P817, DOI 10.1038/aps.2012.30; Frank AL, 2014, ANN GLOB HEALTH, V80, P257, DOI 10.1016/j.aogh.2014.09.016; Gabarra-Niecko V, 2003, CANCER METAST REV, V22, P359, DOI 10.1023/A:1023725029589; Gladden AB, 2010, DEV CELL, V19, P727, DOI 10.1016/j.devcel.2010.10.008; Guo GW, 2015, CANCER RES, V75, P264, DOI 10.1158/0008-5472.CAN-14-1008; Houshmandi SS, 2009, MOL CELL BIOL, V29, P1472, DOI 10.1128/MCB.01392-08; Ishiguro F, 2012, J THORAC ONCOL, V7, P890, DOI 10.1097/JTO.0b013e31824af2db; James MF, 2009, MOL CELL BIOL, V29, P4250, DOI 10.1128/MCB.01581-08; Japan Ministry of Health, 2015, TRENDS DEATHS DUE MA; Jiang H, 2016, NAT MED, V22, P851, DOI 10.1038/nm.4123; Kakiuchi T, 2016, CARCINOGENESIS, V37, P1098, DOI 10.1093/carcin/bgw084; Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244; Kawaguchi K, 2009, CARCINOGENESIS, V30, P1097, DOI 10.1093/carcin/bgp097; Kenny PA, 2007, MOL ONCOL, V1, P84, DOI 10.1016/j.molonc.2007.02.004; Lallemand D, 2009, J CELL SCI, V122, P4141, DOI 10.1242/jcs.045914; Li W, 2012, EMBO REP, V13, P204, DOI 10.1038/embor.2012.11; Lim STS, 2013, MOL CELLS, V36, P1, DOI 10.1007/s10059-013-0139-1; Lopez-Lago MA, 2009, MOL CELL BIOL, V29, P4235, DOI 10.1128/MCB.01578-08; Luo M, 2009, CANCER RES, V69, P466, DOI 10.1158/0008-5472.CAN-08-3078; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Marlowe TA, 2016, MOL CANCER THER, V15, P3028, DOI 10.1158/1535-7163.MCT-16-0366; McLean GW, 2005, NAT REV CANCER, V5, P505, DOI 10.1038/nrc1647; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; Mizuno T, 2012, ONCOGENE, V31, P5117, DOI 10.1038/onc.2012.5; Muller AM, 2002, VIRCHOWS ARCH, V441, P41, DOI 10.1007/s00428-001-0563-z; Murakami H, 2011, CANCER RES, V71, P873, DOI 10.1158/0008-5472.CAN-10-2164; Nelson WJ, 2008, BIOCHEM SOC T, V36, P149, DOI 10.1042/BST0360149; Ordonez NG, 2003, AM J SURG PATHOL, V27, P1031, DOI 10.1097/00000478-200308000-00001; Poulikakos PI, 2006, ONCOGENE, V25, P5960, DOI 10.1038/sj.onc.1209587; Robinson BWS, 2005, LANCET, V366, P397, DOI 10.1016/S0140-6736(05)67025-0; Robinson BWS, 2005, NEW ENGL J MED, V353, P1591, DOI 10.1056/NEJMra050152; Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01; Sawada K, 2008, CANCER RES, V68, P2329, DOI 10.1158/0008-5472.CAN-07-5167; SEKIDO Y, 1995, CANCER RES, V55, P1227; Sekido Y, 2010, CANCER SCI, V101, P1, DOI 10.1111/j.1349-7006.2009.01336.x; Shah NR, 2014, GYNECOL ONCOL, V134, P104, DOI 10.1016/j.ygyno.2014.04.044; Shapiro IM, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008639; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Stamenkovic I, 2010, CURR PROTEIN PEPT SC, V11, P471, DOI 10.2174/138920310791824011; Tanaka I, 2015, ONCOGENE, V34, P73, DOI 10.1038/onc.2013.528; Tang KJ, 2016, CLIN CANCER RES, V22, P5851, DOI 10.1158/1078-0432.CCR-15-2603; Taniguchi T, 2007, CANCER SCI, V98, P438, DOI 10.1111/j.1349-7006.2006.00386.x; Tanjoni I, 2010, CANCER BIOL THER, V9, P764, DOI 10.4161/cbt.9.10.11434; Usami N, 2006, CANCER SCI, V97, P387, DOI 10.1111/j.1349-7006.2006.00184.x; Vogelzang NJ, 2003, J CLIN ONCOL, V21, P2636, DOI 10.1200/JCO.2003.11.136; Xiao GH, 2005, MOL CELL BIOL, V25, P2384, DOI 10.1128/MCB.25.6.2384-2394.2005; Xu LH, 2000, J BIOL CHEM, V275, P30597, DOI 10.1074/jbc.M910027199; Zhang WT, 2006, J CELL SCI, V119, P283, DOI 10.1242/jcs.02738	55	17	17	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 28	2017	36	39					5522	5531		10.1038/onc.2017.147	http://dx.doi.org/10.1038/onc.2017.147			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FI4RG	28553954				2022-12-17	WOS:000411960500008
J	Zhang, Y; Hu, Y; Wang, JL; Yao, H; Wang, H; Liang, L; Li, C; Shi, H; Chen, Y; Fang, JY; Xu, J				Zhang, Y.; Hu, Y.; Wang, J-L; Yao, H.; Wang, H.; Liang, L.; Li, C.; Shi, H.; Chen, Y.; Fang, J-Y; Xu, J.			Proteomic identification of ERP29 as a key chemoresistant factor activated by the aggregating p53 mutant Arg282Trp	ONCOGENE			English	Article							GAIN-OF-FUNCTION; PROTEIN 29 ERP29; CANCER CELLS; UNFOLDED PROTEIN; EXPRESSION; APOPTOSIS; GENE; DNA; CHEMOTHERAPY; PROGRESSION	Mutation of the TP53 gene represents a prevalent genetic alteration in human cancers, and a subset of p53 mutants may form amyloid-like aggregates that contribute to the gain of oncogenic functions (GOFs) and chemoresistance. Here we identify the pathways that may mediate the aggregation-associated GOF by using combined proteomic analysis and genome-wide recruitment profiling. Mass spectrometry revealed activation of unfolded protein response (UPR) pathway and upregulation of endoplasmic reticulum protein 29 (ERp29) in (R282W)TP53-expressing cells that were exposed to cisplatin stress. Chromatin immunoprecipitation sequencing identified a significant 'CCCASS' binding motif of Arg282Trp, which is present in the promoter region of ERP29 gene. The mutant p53 upregulated ERP29 mRNA and protein expression levels, whereas targeting ERP29 by specific small interfering RNAs suppressed the chemoresistant effect of Arg282Trp. The anti-aggregation peptide ReACp53 significantly decreased ERP29 expression and suppressed the chemoresistant effect. These findings highlight a role of ERP29 in the acquired chemoresistance of cancer cells expressing the aggregating p53 mutant Arg282Trp. Our results also suggest that ERP29-mediated GOF can be targeted by the anti-aggregation peptide ReACp53.	[Zhang, Y.; Hu, Y.; Wang, J-L; Yao, H.; Wang, H.; Liang, L.; Li, C.; Chen, Y.; Fang, J-Y; Xu, J.] Shanghai Jiao Tong Univ, Key Lab Gastroenterol & Hepatol,Renji Hosp, State Key Lab Oncogenes & Related Genes,Sch Med, Div Gastroenterol & Hepatol,Minist Hlth, Shanghai, Peoples R China; [Zhang, Y.; Hu, Y.; Wang, J-L; Yao, H.; Wang, H.; Liang, L.; Li, C.; Chen, Y.; Fang, J-Y; Xu, J.] Shanghai Inst Digest Dis, Shanghai, Peoples R China; [Hu, Y.] Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Dept Gastroenterol, Shanghai, Peoples R China; [Shi, H.] Sichuan Univ, West China Hosp, Div Canc Biotherapy, State Key Lab Biotherapy, Chengdu, Sichuan, Peoples R China; [Shi, H.] Sichuan Univ, West China Hosp, Ctr Canc, Chengdu, Sichuan, Peoples R China; [Shi, H.] Collaborat Innovat Ctr Biotherapy, Chengdu, Sichuan, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Sichuan University; Sichuan University	Xu, J (corresponding author), Shanghai Jiao Tong Univ, State Key Lab Oncogenes & Related Genes, Renji Hosp, Sch Med, Shanghai 200001, Peoples R China.	jiexu@sjtu.edu.cn	Xu, Jie/K-3712-2019; li, chu/GPS-7224-2022	Xu, Jie/0000-0001-9163-3898; zhang, yao/0000-0003-1174-7049; Li, Chushu/0000-0001-6658-2208	National Natural Science Foundation of China [81572326, 81322036, 81272383, 81421001, 81320108024, 81530072, 81602518, 81502015, 81572303]; Top-Notch Young Talents Program of China [ZTZ2015-48]; Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support [20152514]; National Key Research & Development (RD) Plan [2016YFC0906000, 2016YFC0906002]; National Key Technology Support Program [2015BAI13B07]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Top-Notch Young Talents Program of China; Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support; National Key Research & Development (RD) Plan; National Key Technology Support Program(National Key Technology R&D Program)	This project was supported by grants from National Natural Science Foundation of China (81572326, 81322036, 81272383, 81421001, 81320108024, 81530072, 81602518, 81502015 and 81572303); Top-Notch Young Talents Program of China (ZTZ2015-48); Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support (20152514); National Key Research & Development (R&D) Plan (2016YFC0906000 and 2016YFC0906002); and National Key Technology Support Program (2015BAI13B07). The sponsors of this study had no role in the collection of the data, the analysis and interpretation of the data, the decision to submit the manuscript for publication or the writing of the manuscript.	Acin S, 2011, J PATHOL, V225, P479, DOI 10.1002/path.2971; Al-Rawashdeh FY, 2010, EUR J GASTROEN HEPAT, V22, P1099, DOI 10.1097/MEG.0b013e3283378405; Ali A, 2014, CANCER LETT, V354, P87, DOI 10.1016/j.canlet.2014.07.045; Bailey TL, 2011, BIOINFORMATICS, V27, P1653, DOI 10.1093/bioinformatics/btr261; Bom APDA, 2012, J BIOL CHEM, V287, P28152, DOI 10.1074/jbc.M112.340638; Brosh R, 2009, NAT REV CANCER, V9, P701, DOI 10.1038/nrc2693; Chen SH, 2015, SCI REP-UK, V5, DOI 10.1038/srep14723; Chen SH, 2015, FEBS OPEN BIO, V5, P91, DOI 10.1016/j.fob.2015.01.004; Cheung EC, 2010, CURR OPIN CELL BIOL, V22, P186, DOI 10.1016/j.ceb.2009.12.006; Chiang MF, 2012, BIOMED PHARMACOTHER, V66, P433, DOI 10.1016/j.biopha.2012.03.003; Cino EA, 2016, SCI REP-UK, V6, DOI 10.1038/srep32535; Coffill CR, 2012, EMBO REP, V13, P638, DOI 10.1038/embor.2012.74; Das S, 2009, MOL BIOL CELL, V20, P2593, DOI 10.1091/mbc.E08-07-0790; Datta A, 2016, GENOM DATA, V8, P47, DOI 10.1016/j.gdata.2016.03.003; Di Fiore R, 2014, BONE, V60, P198, DOI 10.1016/j.bone.2013.12.021; Do PM, 2012, GENE DEV, V26, P830, DOI 10.1101/gad.181685.111; Dudgeon C, 2014, GENE DEV, V28, P2613, DOI 10.1101/gad.252148.114; Epple LM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073267; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Freed-Pastor WA, 2012, GENE DEV, V26, P1268, DOI 10.1101/gad.190678.112; Gifford JB, 2016, MOL CANCER THER, V15, P1043, DOI 10.1158/1535-7163.MCT-15-0774; Guan Z, 2007, CANCER RES, V67, P10436, DOI 10.1158/0008-5472.CAN-07-1379; He C, 2017, CHEMOTHERAPY, V62, P43, DOI 10.1159/000446361; Hirsch I, 2014, APOPTOSIS, V19, P801, DOI 10.1007/s10495-013-0961-0; Hume MA, 2015, NUCLEIC ACIDS RES, V43, pD117, DOI 10.1093/nar/gku1045; Humpton TJ, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026146; Kim E, 2007, ONCOGENE, V26, P2185, DOI 10.1038/sj.onc.1210312; Kim MK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120536; Kiprijanovska S., 2014, INT J PROTEOMICS, V2014, DOI DOI 10.1155/2014/594761; Krishnan SR, 2015, BREAST CANCER RES TR, V150, P487, DOI 10.1007/s10549-015-3339-x; Lasagna-Reeves CA, 2013, BIOCHEM BIOPH RES CO, V430, P963, DOI 10.1016/j.bbrc.2012.11.130; Lavra L, 2009, J PATHOL, V218, P66, DOI 10.1002/path.2510; Lee E, 2006, CANCER RES, V66, P7849, DOI 10.1158/0008-5472.CAN-06-1660; Levy CB, 2011, INT J BIOCHEM CELL B, V43, P60, DOI 10.1016/j.biocel.2010.10.017; Li D, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.158; Lu Jin-Jian, 2015, Chin J Nat Med, V13, P673, DOI 10.1016/S1875-5364(15)30065-0; Maere S, 2005, BIOINFORMATICS, V21, P3448, DOI 10.1093/bioinformatics/bti551; Magdeldin S, 2014, CLIN PROTEOM, V11, DOI 10.1186/1559-0275-11-16; Mantovani F, 2017, FEBS J, V284, P837, DOI 10.1111/febs.13948; Mathelier A, 2016, NUCLEIC ACIDS RES, V44, pD110, DOI 10.1093/nar/gkv1176; May Caroline, 2012, Methods Mol Biol, V893, P37, DOI 10.1007/978-1-61779-885-6_3; Mori-Iwamoto S, 2007, INT J ONCOL, V31, P1345; Muller PAJ, 2013, NAT CELL BIOL, V15, P2, DOI 10.1038/ncb2641; Neilsen PM, 2011, ONCOTARGET, V2, P1203; Nesslinger NJ, 2003, CANCER RES, V63, P2228; Oren M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001107; Pi LH, 2014, ONCOL LETT, V7, P685, DOI 10.3892/ol.2013.1753; Polotskaia A, 2015, P NATL ACAD SCI USA, V112, pE1220, DOI 10.1073/pnas.1416318112; Qi L, 2012, MED ONCOL, V29, P721, DOI 10.1007/s12032-011-9929-5; Schwartz M, 2016, J IMMUNOTHER CANCER, V4, DOI 10.1186/s40425-016-0145-x; Silva JL, 2014, TRENDS BIOCHEM SCI, V39, P260, DOI 10.1016/j.tibs.2014.04.001; Song IK, 2016, SCI REP-UK, V6, DOI 10.1038/srep34432; Soragni A, 2016, CANCER CELL, V29, P90, DOI 10.1016/j.ccell.2015.12.002; Vaughan CA, 2012, BIOCHEM BIOPH RES CO, V428, P6, DOI 10.1016/j.bbrc.2012.09.029; Vousden KH, 2009, NAT REV CANCER, V9, P691, DOI 10.1038/nrc2715; Walerych D, 2016, CELL CYCLE, V15, P3009, DOI 10.1080/15384101.2016.1215703; Walerych D, 2016, NAT CELL BIOL, V18, P897, DOI 10.1038/ncb3380; Walerych D, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00289; Wang X, 2014, ANN SURG ONCOL, V21, P1337, DOI 10.1245/s10434-013-3380-0; Xu J, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.75; Xu J, 2014, SCI REP-UK, V4, DOI 10.1038/srep04223; Xu J, 2011, NAT CHEM BIOL, V7, P285, DOI 10.1038/nchembio.546; Yang-Hartwich Y, 2015, ONCOGENE, V34, P3605, DOI 10.1038/onc.2014.296; Zhang DH, 2010, EXP CELL RES, V316, P3522, DOI 10.1016/j.yexcr.2010.08.014; Zhang Y, 2016, ONCOTARGET, V7, P11056, DOI 10.18632/oncotarget.7090; Zhou G, 2014, MOL CELL, V54, P960, DOI 10.1016/j.molcel.2014.04.024	66	17	19	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 28	2017	36	39					5473	5483		10.1038/onc.2017.152	http://dx.doi.org/10.1038/onc.2017.152			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FI4RG	28534505				2022-12-17	WOS:000411960500004
J	Ueno, N; Nishimura, N; Ueno, S; Endo, S; Tatetsu, H; Hirata, S; Hata, H; Matsuoka, M; Mitsuya, H; Okuno, Y				Ueno, N.; Nishimura, N.; Ueno, S.; Endo, S.; Tatetsu, H.; Hirata, S.; Hata, H.; Matsuoka, M.; Mitsuya, H.; Okuno, Y.			PU.1 acts as tumor suppressor for myeloma cells through direct transcriptional repression of IRF4	ONCOGENE			English	Article							REGULATORY FACTOR FAMILY; MULTIPLE-MYELOMA; DISTAL ELEMENTS; GENE; PROTEINS; EXPRESSION; SURVIVAL; IDENTIFICATION; THALIDOMIDE; MECHANISM	We previously reported that PU.1 is downregulated in the majority of myeloma cell lines and primary myeloma cells of certain myeloma patients, and conditional expression of PU.1 in such myeloma cell lines induced cell cycle arrest and apoptosis. We found downregulation of IRF4 protein in the U266 myeloma cell line following induction of PU.1. Previous studies reported that knockdown of IRF4 in myeloma cell lines induces apoptosis, prompting us to further investigate the role of IRF4 downregulation in PU.1-induced cell cycle arrest and apoptosis in myeloma cells. PU. 1 induced downregulation of IRF4 at the protein level, cell cycle arrest and apoptosis in six myeloma cell lines. Chromatin immunoprecipitation (ChIP) revealed that PU.1 directly binds to the IRF4 promoter, whereas a reporter assay showed that PU.1 may suppress IRF4 promoter activity. Stable expression of IRF4 in myeloma cells expressing PU.1 partially rescued the cells from apoptosis induced by PU.1. As it was reported that IRF4 directly binds to the IRF7 promoter and downregulates its expression in activated B cell-like subtype of diffuse large B cell lymphoma cells, we performed ChIP assays and found that IRF4 directly binds the IRF7 promoter in myeloma cells. It is known that IRF7 positively upregulates interferon-beta (IFN beta) and induces apoptosis in many cell types. Binding of IRF4 to the IRF7 promoter decreased following PU.1 induction, accompanied by downregulation of IRF4 protein expression. Knockdown of IRF7 protected PU.1-expressing myeloma cells from apoptosis. Furthermore, IFN beta, which is a downstream target of IRF7, was upregulated in myeloma cells along with IRF7 after PU.1 induction. Finally, we evaluated the mRNA expression levels of PU.1, IRF4 and IRF7 in primary myeloma cells from patients and found that PU.1 and IRF7 were strongly downregulated in contrast to the high expression levels of IRF4. These data strongly suggest that PU.1-induced apoptosis in myeloma cells is associated with IRF4 downregulation and subsequent IRF7 upregulation.	[Ueno, N.; Nishimura, N.; Ueno, S.; Endo, S.; Tatetsu, H.; Hirata, S.; Hata, H.; Matsuoka, M.; Mitsuya, H.; Okuno, Y.] Kumamoto Univ, Grad Sch Med, Dept Hematol, Chuo Ku, 1-1-1 Honjo, Kumamoto 8608556, Japan; [Ueno, N.; Nishimura, N.; Ueno, S.; Endo, S.; Tatetsu, H.; Hirata, S.; Hata, H.; Matsuoka, M.; Mitsuya, H.; Okuno, Y.] Kumamoto Univ, Grad Sch Med, Dept Rheumatol & Infect Dis, Chuo Ku, 1-1-1 Honjo, Kumamoto 8608556, Japan	Kumamoto University; Kumamoto University	Okuno, Y (corresponding author), Kumamoto Univ, Grad Sch Med, Dept Hematol, Chuo Ku, 1-1-1 Honjo, Kumamoto 8608556, Japan.; Okuno, Y (corresponding author), Kumamoto Univ, Grad Sch Med, Dept Rheumatol & Infect Dis, Chuo Ku, 1-1-1 Honjo, Kumamoto 8608556, Japan.	yokuno@gpo.kumamoto-u.ac.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan (JSPS KAKENHI) [26461427]	Ministry of Education, Culture, Sports, Science and Technology of Japan (JSPS KAKENHI)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This study was supported by grants from the Ministry of Education, Culture, Sports, Science and Technology of Japan (JSPS KAKENHI grant number 26461427).	Brugnoli F, 2010, EXP CELL RES, V316, P38, DOI 10.1016/j.yexcr.2009.09.004; Chapman MA, 2011, NATURE, V471, P467, DOI 10.1038/nature09837; Chen Q, 2001, BLOOD, V98, P2183, DOI 10.1182/blood.V98.7.2183; Desai S, 2009, J IMMUNOL, V183, P5778, DOI 10.4049/jimmunol.0901120; DOLBEARE F, 1983, P NATL ACAD SCI-BIOL, V80, P5573, DOI 10.1073/pnas.80.18.5573; Endo S, 2016, BIOCHEM BIOPH RES CO, V469, P236, DOI 10.1016/j.bbrc.2015.11.116; Honda K, 2005, NATURE, V434, P772, DOI 10.1038/nature03464; Ito T, 2010, SCIENCE, V327, P1345, DOI 10.1126/science.1177319; Kaufman RM, 1999, BLOOD, V94, P3178, DOI 10.1182/blood.V94.9.3178.421k23_3178_3184; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; Kronke J, 2014, SCIENCE, V343, P301, DOI 10.1126/science.1244851; Krysinska H, 2007, MOL CELL BIOL, V27, P878, DOI 10.1128/MCB.01915-06; Kyle RA, 2008, BLOOD, V111, P2962, DOI 10.1182/blood-2007-10-078022; Lehtonen A, 2005, J IMMUNOL, V175, P6570, DOI 10.4049/jimmunol.175.10.6570; Li YL, 2001, BLOOD, V98, P2958, DOI 10.1182/blood.V98.10.2958; Lopez-Girona A, 2011, BRIT J HAEMATOL, V154, P325, DOI 10.1111/j.1365-2141.2011.08689.x; Lu G, 2014, SCIENCE, V343, P305, DOI 10.1126/science.1244917; Mamane Y, 1999, GENE, V237, P1, DOI 10.1016/S0378-1119(99)00262-0; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; Miyoshi H, 1998, J VIROL, V72, P8150, DOI 10.1128/JVI.72.10.8150-8157.1998; Miyoshi H, 1997, P NATL ACAD SCI USA, V94, P10319, DOI 10.1073/pnas.94.19.10319; Moreau P, 2012, BLOOD, V120, P947, DOI 10.1182/blood-2012-04-403733; Morgan GJ, 2012, NAT REV CANCER, V12, P335, DOI 10.1038/nrc3257; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; Nikolajczyk BS, 1999, IMMUNITY, V11, P11, DOI 10.1016/S1074-7613(00)80077-1; Ochiai K, 2013, IMMUNITY, V38, P918, DOI 10.1016/j.immuni.2013.04.009; Ocio EM, 2008, LANCET ONCOL, V9, P1157, DOI 10.1016/S1470-2045(08)70304-8; Ohguchi H, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10258; Okuno Y, 2005, MOL CELL BIOL, V25, P2832, DOI 10.1128/MCB.25.7.2832-2845.2005; Okuno Y, 2002, BLOOD, V100, P4420, DOI 10.1182/blood-2002-03-0788; Okuno Y, 2002, P NATL ACAD SCI USA, V99, P6246, DOI 10.1073/pnas.092027799; Ozato K, 2007, J BIOL CHEM, V282, P20065, DOI 10.1074/jbc.R700003200; Palumbo A, 2008, BLOOD, V111, P3968, DOI 10.1182/blood-2007-10-117457; Palumbo A, 2014, J CLIN ONCOL, V32, P587, DOI 10.1200/JCO.2013.48.7934; Piya S, 2011, MOL CANCER RES, V9, P1356, DOI 10.1158/1541-7786.MCR-11-0185; Rosenbauer F, 2006, NAT GENET, V38, P27, DOI 10.1038/ng1679; Rosenbauer F, 2004, NAT GENET, V36, P624, DOI 10.1038/ng1361; Savickiene J, 2011, DIFFERENTIATION, V81, P57, DOI 10.1016/j.diff.2010.08.003; Schonheit J, 2013, CELL REP, V3, P1617, DOI 10.1016/j.celrep.2013.04.007; Shaffer AL, 2008, NATURE, V454, P226, DOI 10.1038/nature07064; Takaoka A, 2008, CANCER SCI, V99, P467, DOI 10.1111/j.1349-7006.2007.00720.x; Tatetsu H, 2007, CANCER RES, V67, P5328, DOI 10.1158/0008-5472.CAN-06-4265; Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847; Ueno S, 2009, ONCOGENE, V28, P4116, DOI 10.1038/onc.2009.263; Yang YB, 2012, CANCER CELL, V21, P723, DOI 10.1016/j.ccr.2012.05.024; Yuki H, 2013, BLOOD, V121, P962, DOI 10.1182/blood-2012-05-431429; Zhu YX, 2014, BLOOD, V124, P536, DOI 10.1182/blood-2014-02-557819	47	17	18	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	2017	36	31					4481	4497		10.1038/onc.2017.79	http://dx.doi.org/10.1038/onc.2017.79			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FC4JL	28368411				2022-12-17	WOS:000406806000010
J	He, DM; Ren, BG; Liu, S; Tan, LZ; Cieply, K; Tseng, G; Yu, YP; Luo, JH				He, D-M; Ren, B-G; Liu, S.; Tan, L-Z; Cieply, K.; Tseng, G.; Yu, Y. P.; Luo, J-H			Oncogenic activity of amplified miniature chromosome maintenance 8 in human malignancies	ONCOGENE			English	Article							GENE-EXPRESSION ALTERATIONS; PROSTATE-CANCER; DNA-REPLICATION; PROTEIN MCM7; HEPATOCELLULAR-CARCINOMA; CELL-CYCLE; CDK4; INHIBITOR; CHROMATIN; KINASES	Miniature chromosome maintenance (MCM) proteins play critical roles in DNA replication licensing, initiation and elongation. MCM8, one of the MCM proteins playing a critical role in DNA repairing and recombination, was found to have overexpression and increased DNA copy number in a variety of human malignancies. The gain of MCM8 is associated with aggressive clinical features of several human cancers. Increased expression of MCM8 in prostate cancer is associated with cancer recurrence. Forced expression of MCM8 in RWPE1 cells, the immortalized but non-transformed prostate epithelial cell line, exhibited fast cell growth and transformation, while knock down of MCM8 in PC3, DU145 and LNCaP cells induced cell growth arrest, and decreased tumour volumes and mortality of severe combined immunodeficiency mice xenografted with PC3 and DU145 cells. MCM8 bound cyclin D1 and activated Rb protein phosphorylation by cyclin-dependent kinase 4 in vitro and in vivo. The cyclin D1/MCM8 interaction is required for Rb phosphorylation and S-phase entry in cancer cells. As a result, our study showed that copy number increase and overexpression of MCM8 may play critical roles in human cancer development.	[He, D-M; Ren, B-G; Tan, L-Z; Cieply, K.; Yu, Y. P.; Luo, J-H] Univ Pittsburgh, Sch Med, Dept Pathol, 3550 Terrace St,Scaife S-728, Pittsburgh, PA 15261 USA; [Liu, S.; Tseng, G.] Univ Pittsburgh, Dept Biostat, Sch Med, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Luo, JH (corresponding author), Univ Pittsburgh, Sch Med, Dept Pathol, 3550 Terrace St,Scaife S-728, Pittsburgh, PA 15261 USA.	luoj@msx.upmc.edu			National Cancer Institute [RO1 CA098249]; University of Pittsburgh Cancer Institute; NATIONAL CANCER INSTITUTE [R01CA098249] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); University of Pittsburgh Cancer Institute; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants from National Cancer Institute (RO1 CA098249) to JHL and a grant from University of Pittsburgh Cancer Institute.	Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; AlAsiri S, 2015, J CLIN INVEST, V125, P258, DOI 10.1172/JCI78473; Blow JJ, 2002, TRENDS CELL BIOL, V12, P72, DOI 10.1016/S0962-8924(01)02203-6; Ciriello G, 2013, NAT GENET, V45, P1127, DOI 10.1038/ng.2762; Dai K, 1996, J BIOL CHEM, V271, P22030, DOI 10.1074/jbc.271.36.22030; Edwards MC, 2002, J BIOL CHEM, V277, P33049, DOI 10.1074/jbc.M204438200; Facoetti A, 2006, ANTICANCER RES, V26, P1071; Feber A, 2011, GENOME RES, V21, P515, DOI 10.1101/gr.109678.110; Feng CJ, 2008, ANTICANCER RES, V28, P3763; Freeman A, 1999, CLIN CANCER RES, V5, P2121; Fristrup N, 2013, AM J PATHOL, V182, P339, DOI 10.1016/j.ajpath.2012.10.017; Fujioka S, 2009, LUNG CANCER, V65, P223, DOI 10.1016/j.lungcan.2008.11.007; Gozuacik D, 2003, NUCLEIC ACIDS RES, V31, P570, DOI 10.1093/nar/gkg136; Han YC, 2010, CANCER RES, V70, P4375, DOI 10.1158/0008-5472.CAN-09-4403; Hansen KD, 2011, NAT GENET, V43, P768, DOI 10.1038/ng.865; Honeycutt KA, 2006, ONCOGENE, V25, P4027, DOI 10.1038/sj.onc.1209435; Iizuka N, 2006, J CANCER RES CLIN, V132, P473, DOI 10.1007/s00432-006-0094-8; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Jing L, 2004, AM J PATHOL, V164, P1799, DOI 10.1016/S0002-9440(10)63738-8; Kang W, 2014, ONCOL REP, V31, P2071, DOI 10.3892/or.2014.3094; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Kearsey SE, 1996, BIOESSAYS, V18, P183, DOI 10.1002/bies.950180305; Labib K, 2001, MOL BIOL CELL, V12, P3658, DOI 10.1091/mbc.12.11.3658; Laitinen S, 2008, INT J CANCER, V122, P595, DOI 10.1002/ijc.23145; Lee KY, NAT COMMUN, V6, P7744; Lu ZH, 1999, MOL BIOL CELL, V10, P4091, DOI 10.1091/mbc.10.12.4091; Luo JH, 2002, DRUG TODAY, V38, P713, DOI 10.1358/dot.2002.38.10.704653; Luo JH, 2002, MOL CARCINOGEN, V33, P25, DOI 10.1002/mc.10018; Luo JH, 2013, AM J PATHOL, V182, P2028, DOI 10.1016/j.ajpath.2013.02.040; Luo JH, 2011, WORLD J CLIN ONCOL, V2, P120, DOI 10.5306/wjco.v2.i2.120; Lutzmann M, 2012, MOL CELL, V47, P523, DOI 10.1016/j.molcel.2012.05.048; Maiorano D, 2005, CELL, V120, P315, DOI 10.1016/j.cell.2004.12.010; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; Nishihara K, 2008, INT J ONCOL, V33, P245, DOI 10.3892/ijo_00000003; Ota T, 2011, MODERN PATHOL, V24, P277, DOI 10.1038/modpathol.2010.202; Padmanabhan V, 2004, J CLIN PATHOL, V57, P1057, DOI 10.1136/jcp.2004.016436; Park J, 2013, MOL CELL BIOL, V33, P1632, DOI 10.1128/MCB.01503-12; Ren B, 2006, ONCOGENE, V25, P1090, DOI 10.1038/sj.onc.1209134; Ren BG, 2007, J NATL CANCER I, V99, P868, DOI 10.1093/jnci/djk199; Shi YK, 2008, AM J PATHOL, V173, P1758, DOI 10.2353/ajpath.2008.080363; Shohet JM, 2002, CANCER RES, V62, P1123; Siegel RL, 2017, CA CANC J CLIN 2017; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Vallot C, 2011, JNCI-J NATL CANCER I, V103, P47, DOI 10.1093/jnci/djq470; van Dekken H, 2009, CANCER GENET CYTOGEN, V189, P37, DOI 10.1016/j.cancergencyto.2008.08.018; Volkening M, 2005, MOL CELL BIOL, V25, P1560, DOI 10.1128/MCB.25.4.1560-1568.2005; Wang H, 2012, J BIOL CHEM, V287, P16890, DOI 10.1074/jbc.M111.322636; Wang LQ, 2013, J NANOMATER, V2013, DOI 10.1155/2013/321459; Weinstein JN, 2013, NAT GENET, V45, P1113, DOI 10.1038/ng.2764; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yu YP, 2013, AM J PATHOL, V183, P1960, DOI 10.1016/j.ajpath.2013.08.018; Yu YP, 2012, AM J PATHOL, V180, P2240, DOI 10.1016/j.ajpath.2012.03.008; Yu YP, 2006, UROLOGY, V68, P578, DOI 10.1016/j.urology.2006.03.027; Yu YP, 2006, CANCER RES, V66, P7414, DOI 10.1158/0008-5472.CAN-06-0227; Yu YP, 2005, CARCINOGENESIS, V26, P471, DOI 10.1093/carcin/bgh310; Yu YP, 2004, J CLIN ONCOL, V22, P2790, DOI 10.1200/JCO.2004.05.158; Zack TI, 2013, NAT GENET, V45, P1134, DOI 10.1038/ng.2760; Zhang JM, 1999, EMBO J, V18, P926, DOI 10.1093/emboj/18.4.926; Zhou YM, 2012, LIVER INT, V32, P1505, DOI 10.1111/j.1478-3231.2012.02846.x	64	17	18	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2017	36	25					3629	3639		10.1038/onc.2017.123	http://dx.doi.org/10.1038/onc.2017.123			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY3NL	28481876	Green Accepted			2022-12-17	WOS:000403878600012
J	Sarkar, M; Khare, V; Ghosh, MK				Sarkar, M.; Khare, V.; Ghosh, M. K.			The DEAD box protein p68: a novel coactivator of Stat3 in mediating oncogenesis	ONCOGENE			English	Article							COLORECTAL-CANCER; BETA-CATENIN; RNA HELICASE; EXPRESSION; ACTIVATION; APOPTOSIS; TARGET; CELLS; TRANSFORMATION; PATHWAY	DEAD box RNA helicase p68 acts as a transcriptional coactivator of several oncogenic transcription factors apart from being a vital player of RNA metabolism. Signal transducer and activator of transcription 3 (Stat3) is a major oncogenic contributor of diverse cancers, including that of colon. Deciphering the mechanistic insights of coactivation of Stat3 transcriptional activity may aid in improved therapeutic strategies. Here we report for the first time a novel mechanism of alliance between p68 and Stat3 in stimulating transcriptional activity of Stat3. Interestingly, we observed that the expression of p68 and Stat3 bears strong positive correlation and significant colocalization in normal and colon carcinoma patient samples. We demonstrated that p68 directly interacts with Stat3 in HEK293 cells as well as multiple colon cancer cell lines. Additionally, p68 positively modulated both mRNA and protein expression levels of Stat3 target genes; promoter activity of Stat3 target gene Mcl-1 in multiple colon cancer cell lines. Also, p68 occupied the promoters of multiple Stat3 target genes in enhancing Stat3-dependent transcription. Moreover, the strong positive correlation between the abundance of p68 and Stat3 target genes in the same set of colon carcinoma samples further supported our observations. Enhanced expression levels of Stat3 target genes observed in primary tumors and metastatic lung nodules, generated in mice colorectal allograft model using syngeneic cells stably expressing p68, further reinforced our in vitro findings. Hence, this study unravels novel modes of p68-mediated oncogenesis through coactivation of Stat3 and enhancing Stat3 signaling.	[Sarkar, M.; Khare, V.; Ghosh, M. K.] IICB, CSIR, Canc Biol & Inflammatory Disorder Div, Signal Transduct Canc & Stem Cells Lab, Kolkata, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Biology (IICB)	Ghosh, MK (corresponding author), IICB, CSIR, Canc Biol & Inflammatory Disorder, Signal Transduct Canc & Stem Cells Lab, 4 Raja SC Mullick Rd, Kolkata 700032, W Bengal, India.	mrinal.res@gmail.com		Sarkar, Dr Moumita/0000-0002-7437-5353	CSIR, India [EMPOWER-OLP-002, MEDCHEM-BSC0108]; DST Nano Mission programme [SR/NM/NS-1058/2015]; CSIR-MAYO Clinic programme [MLP-0017]	CSIR, India(Council of Scientific & Industrial Research (CSIR) - India); DST Nano Mission programme; CSIR-MAYO Clinic programme	We thank Dr Frances V Fuller-Pace and Dr Kenneth M Yamada for gifting the pGS5-p68 construct and pGZ21dx vector, respectively. We also thank Dr Uttara Chatterjee (Park Clinic, India) for providing human normal colon and colon carcinoma samples, related pathological reports and helping in the data analysis. This work is supported by grants from CSIR, India (EMPOWER-OLP-002, MEDCHEM-BSC0108 and CSIR-MAYO Clinic programme: MLP-0017) and DST Nano Mission programme (SR/NM/NS-1058/2015) to Dr Mrinal K Ghosh.	Ahmed SF, 2015, MOL THER, V23, P255, DOI 10.1038/mt.2014.202; Akgul C, 2000, CELL MOL LIFE SCI, V57, P684, DOI 10.1007/PL00000728; Bendardaf R, 2008, ANTICANCER RES, V28, P3865; Bhattacharya S, 2015, CELL ONCOL, V38, P265, DOI 10.1007/s13402-015-0228-6; Bhattacharya S, 2014, FEBS J, V281, P3061, DOI 10.1111/febs.12843; Cai BH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041742; Cao D, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-432; Carpenter RL, 2014, CANCERS, V6, P897, DOI 10.3390/cancers6020897; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chatterjee A, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.63; Dai TY, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/s13046-014-0064-y; Dechow TN, 2004, P NATL ACAD SCI USA, V101, P10602, DOI 10.1073/pnas.0404100101; Fuller-Pace FV, 2011, FUTURE ONCOL, V7, P239, DOI 10.2217/FON.11.1; Ghosh MK, 2005, ONCOGENE, V24, P7290, DOI 10.1038/sj.onc.1208894; Gordziel C, 2013, BRIT J CANCER, V109, P138, DOI 10.1038/bjc.2013.274; Guturi KKN, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0496-5; Henderson-Jackson EB, 2010, INT J CLIN EXP PATHO, V3, P768; Isomoto H, 2005, HEPATOLOGY, V42, P1329, DOI 10.1002/hep.20966; Iwamoto M, 2000, CARCINOGENESIS, V21, P1935, DOI 10.1093/carcin/21.11.1935; Janknecht R, 2010, AM J TRANSL RES, V2, P223; Kamran MZ, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/421821; Langers AMJ, 2012, BRIT J CANCER, V106, P1495, DOI 10.1038/bjc.2012.80; Lassmann S, 2007, J CLIN PATHOL, V60, P173, DOI 10.1136/jcp.2005.035113; Lee WS, 2015, AM J CANCER RES, V5, P101; Leslie K, 2006, CANCER RES, V66, P2544, DOI 10.1158/0008-5472.CAN-05-2203; Mandal T, 2014, CELL SIGNAL, V26, P1725, DOI 10.1016/j.cellsig.2014.04.003; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Sagawa M, 2008, CANCER SCI, V99, P1820, DOI 10.1111/j.1349-7006.2008.00872.x; Said AH, 2014, CANCERS, V6, P366, DOI 10.3390/cancers6010366; Sarkar M, 2015, ONCOGENE, V34, P5843, DOI 10.1038/onc.2015.42; Sarkar M, 2016, FRONT BIOSCI-LANDMRK, V21, P225, DOI 10.2741/4386; Sha JF, 2010, J VIROL, V84, P4050, DOI 10.1128/JVI.02131-09; Shin S, 2007, CANCER RES, V67, P7572, DOI 10.1158/0008-5472.CAN-06-4652; Siddiquee KAZ, 2008, CELL RES, V18, P254, DOI 10.1038/cr.2008.18; Song YH, 2008, MOL IMMUNOL, V45, P137, DOI 10.1016/j.molimm.2007.04.031; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Thakur R, 2013, J CELL MOL MED, V17, P449, DOI 10.1111/jcmm.12033; Wang SW, 2014, INT J ONCOL, V44, P1032, DOI 10.3892/ijo.2014.2259; Xie TX, 2004, ONCOGENE, V23, P3550, DOI 10.1038/sj.onc.1207383; Yang JS, 2011, ACTA HISTOCHEM, V113, P810, DOI 10.1016/j.acthis.2011.01.002; Yu H, 2014, NAT REV CANCER, V14, P736, DOI 10.1038/nrc3818; Yue P, 2009, EXPERT OPIN INV DRUG, V18, P45, DOI [10.1517/13543780802565791, 10.1517/13543780802565791 ]; Zhang YL, 2008, WORLD J GASTROENTERO, V14, P3069, DOI 10.3748/wjg.14.3069	43	17	18	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	2017	36	22					3080	3093		10.1038/onc.2016.449	http://dx.doi.org/10.1038/onc.2016.449			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EW6KA	27941883				2022-12-17	WOS:000402617900002
J	Choi, YM; Kim, KB; Lee, JH; Chun, YK; An, IS; An, S; Bae, S				Choi, Y. M.; Kim, K. B.; Lee, J. H.; Chun, Y. K.; An, I. S.; An, S.; Bae, S.			DBC2/RhoBTB2 functions as a tumor suppressor protein via Musashi-2 ubiquitination in breast cancer	ONCOGENE			English	Article							RNA-BINDING PROTEIN; PROMOTER METHYLATION; MYELOID-LEUKEMIA; RHOBTB2 DBC2; HEPATOCELLULAR-CARCINOMA; LIGASE COMPLEXES; DNA METHYLATION; BLADDER-CANCER; BTB PROTEINS; E3 LIGASE	The gene encoding 'deleted in breast cancer 2' (DBC2), also referred to as RHOBTB2 (Rho-related BTB domain-containing protein 2), is classified as a tumor suppressor gene. DBC2 is a substrate-specific adaptor protein for a novel class of Cullin-3 (CUL3)-based E3 ubiquitin ligases; however, it is unclear if the substrate adaptor function of DBC2 is required for its tumor suppressor activity. Furthermore, the key substrates of DBC2-mediated ubiquitination have yet to be identified. In the present study, we established a genome-wide human cDNA library-based in vitro ubiquitination target screening assay and identified Musashi-2 (MSI2) as a novel ubiquitination target protein of DBC2. MSI2 directly interacted with DBC2, and this interaction promoted MSI2 polyubiquitination and proteasomal degradation in breast cancer cells. Overexpression and knockdown experiments demonstrated that DBC2 suppressed MSI2-associated oncogenic functions and induced apoptosis. Immunohistochemistry analysis of a breast cancer tissue microarray revealed that DBC2 and MSI2 protein levels are inversely correlated in both normal breast tissues and breast cancer tissues. Taken together, these findings provide evidence that DBC2 suppresses tumorigenesis in breast cancer by ubiquitinating MSI2.	[Choi, Y. M.; An, S.; Bae, S.] Konkuk Univ, KU Ctr Integrated Sci & Technol, 120 Neungdong Ro, Seoul 05029, South Korea; [Choi, Y. M.; Kim, K. B.; An, I. S.] Korea Inst Dermatol Sci, 2nd Enterprise Res Bldg, Seoul, Chungcheongbuk, South Korea; [Lee, J. H.] Dankook Univ, Lab Mol Oncol, Coll Med, Cheil Gen Hosp, Seoul, South Korea; [Lee, J. H.; Chun, Y. K.] Dankook Univ, Womens Healthcare Ctr, Coll Med, Seoul, South Korea; [Chun, Y. K.] Dankook Univ, Coll Med, Cheil Gen Hosp, Dept Pathol, Seoul, South Korea	Konkuk University; Dankook University; Dankook University; Dankook University	Bae, S (corresponding author), Konkuk Univ, KU Ctr Integrated Sci & Technol, 120 Neungdong Ro, Seoul 05029, South Korea.	sbae@konkuk.ac.kr			KU Research Professor Program of Konkuk University; National Research Foundation of Korea (NRF) from the Ministry of Science, ICT and Future Planning [20110028646, 2013R1A1A1012205]	KU Research Professor Program of Konkuk University; National Research Foundation of Korea (NRF) from the Ministry of Science, ICT and Future Planning	We thank all the members of our research group for their support and advice during this study. This work was supported by the KU Research Professor Program of Konkuk University (to SB) and National Research Foundation of Korea (NRF) grants from the Ministry of Science, ICT and Future Planning (Grant 20110028646 to SA and Grant 2013R1A1A1012205 to SB).	Bae S, 2008, INT J MOL MED, V21, P381; Bae SH, 2012, CELL RES, V22, P873, DOI 10.1038/cr.2012.38; Barbouti A, 2003, CANCER RES, V63, P1202; Bedford L, 2011, NAT REV DRUG DISCOV, V10, P29, DOI 10.1038/nrd3321; Berthold J, 2008, EXP CELL RES, V314, P3453, DOI 10.1016/j.yexcr.2008.09.005; Byers RJ, 2011, BLOOD, V118, P2857, DOI 10.1182/blood-2011-04-346767; Chen YZ, 2009, MOL CELL, V35, P841, DOI 10.1016/j.molcel.2009.09.004; Cho YG, 2008, ACTA ONCOL, V47, P366, DOI 10.1080/02841860701644094; Cox JL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062857; Dong W, 2012, ASIAN PAC J CANCER P, V13, P2021, DOI 10.7314/APJCP.2012.13.5.2021; Figueroa P, 2005, PLANT CELL, V17, P1180, DOI 10.1105/tpc.105.031989; Freeman SN, 2010, CANCER BIOL THER, V10, P1123, DOI 10.4161/cbt.10.11.13786; Furukawa M, 2003, NAT CELL BIOL, V5, P1001, DOI 10.1038/ncb1056; Fushman D, 2010, J MOL BIOL, V395, P803, DOI 10.1016/j.jmb.2009.10.039; Gao C, 2015, INT J ONCOL, V46, P732, DOI 10.3892/ijo.2014.2749; Geyer R, 2003, MOL CELL, V12, P783, DOI 10.1016/S1097-2765(03)00341-1; Hamaguchi M, 2002, P NATL ACAD SCI USA, V99, P13647, DOI 10.1073/pnas.212516099; Han LL, 2013, BIOTECHNOL LETT, V35, P1175, DOI 10.1007/s10529-013-1190-x; Han YX, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136484; He L, 2014, J CELL MOL MED, V18, P49, DOI 10.1111/jcmm.12158; Jin ZY, 2009, CELL, V137, P721, DOI 10.1016/j.cell.2009.03.015; Jin Z, 2013, CANCER BIOTHER RADIO, V28, P709, DOI 10.1089/cbr.2012.1386; Jung JH, 2011, CELL DEATH DIFFER, V18, P1865, DOI 10.1038/cdd.2011.57; Kagara N, 2012, AM J PATHOL, V181, P257, DOI 10.1016/j.ajpath.2012.03.019; Katz Y, 2014, ELIFE, V3, DOI 10.7554/eLife.03915; Kharas MG, 2010, NAT MED, V16, P903, DOI 10.1038/nm.2187; Knowles MA, 2005, CANCER LETT, V225, P121, DOI 10.1016/j.canlet.2004.10.047; Kobayashi A, 2004, MOL CELL BIOL, V24, P7130, DOI 10.1128/MCB.24.16.7130-7139.2004; Li N, 2015, CELL REP, V13, P2440, DOI 10.1016/j.celrep.2015.11.022; Maerki S, 2009, J CELL BIOL, V187, P791, DOI 10.1083/jcb.200906117; Manjarrez JR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090054; Mao HT, 2011, GENE, V486, P74, DOI 10.1016/j.gene.2011.07.018; Mao HT, 2010, MOL CARCINOGEN, V49, P283, DOI 10.1002/mc.20598; Nikpour P, 2011, J CELL MOL MED, V15, P1210, DOI 10.1111/j.1582-4934.2010.01090.x; Pintard L, 2004, EMBO J, V23, P1681, DOI 10.1038/sj.emboj.7600186; Pintard L, 2003, NATURE, V425, P311, DOI 10.1038/nature01959; Sakakibara S, 2001, J NEUROSCI, V21, P8091, DOI 10.1523/JNEUROSCI.21-20-08091.2001; Shi Y, 2008, UROL ONCOL-SEMIN ORI, V26, P465, DOI 10.1016/j.urolonc.2007.08.009; Shilpa V, 2014, INDIAN J MED RES, V140, P616; Taggart J, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10739; Tang WW, 2014, INT J MOL MED, V33, P722, DOI 10.3892/ijmm.2013.1593; Thol F, 2013, ANN HEMATOL, V92, P315, DOI 10.1007/s00277-012-1637-5; van den Heuvel S, 2004, CURR BIOL, V14, pR59, DOI 10.1016/j.cub.2003.12.044; Wang MH, 2015, AM J CANCER RES, V5, P1089; Wang S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7517; Wilkins A, 2004, GENE DEV, V18, P856, DOI 10.1101/gad.1177904; Xu L, 2003, NATURE, V425, P316, DOI 10.1038/nature01985; Zhang HG, 2004, ONCOGENE, V23, P2009, DOI 10.1038/sj.onc.1207373; Zhang HJ, 2014, EXP CELL RES, V320, P119, DOI 10.1016/j.yexcr.2013.09.009; Zhang Q, 2006, DEV CELL, V10, P719, DOI 10.1016/j.devcel.2006.05.004; Zmetakova I, 2013, NEOPLASMA, V60, P635, DOI 10.4149/neo_2013_082; ZOLLMAN S, 1994, P NATL ACAD SCI USA, V91, P10717, DOI 10.1073/pnas.91.22.10717	52	17	20	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2017	36	20					2802	2812		10.1038/onc.2016.441	http://dx.doi.org/10.1038/onc.2016.441			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EV3ZM	27941885	hybrid, Green Published			2022-12-17	WOS:000401697800003
J	Martin, EE; Huang, W; Anwar, T; Arellano-Garcia, C; Burman, B; Guan, JL; Gonzalez, ME; Kleer, CG				Martin, E. E.; Huang, W.; Anwar, T.; Arellano-Garcia, C.; Burman, B.; Guan, J-L; Gonzalez, M. E.; Kleer, C. G.			MMTV-cre; Ccn6 knockout mice develop tumors recapitulating human metaplastic breast carcinomas	ONCOGENE			English	Article							TO-MESENCHYMAL TRANSITION; P63 EXPRESSION; MAMMARY-TUMORS; CANCER; WISP3; CELLS; INVASION; GENE; METASTASIS; INVOLUTION	Metaplastic breast carcinoma is an aggressive form of invasive breast cancer with histological evidence of epithelial to mesenchymal transition (EMT). However, the defining molecular events are unknown. Here we show that CCN6 (WISP3), a secreted matricellular protein of the CCN (CYR61/CTGF/NOV) family, is significantly downregulated in clinical samples of human spindle cell metaplastic breast carcinoma. We generated a mouse model of mammary epithelial-specific Ccn6 deletion by developing a floxed Ccn6 mouse which was bred with an MMTV-Cre mouse. Ccn6(fl/fl); MMTV-Cre mice displayed severe defects in ductal branching and abnormal age-related involution compared to littermate controls. Ccn6(fl/fl); MMTV-Cre mice developed invasive high grade mammary carcinomas with bona fide EMT, histologically similar to human metaplastic breast carcinomas. Global gene expression profiling of Ccn6(fl/fl) mammary carcinomas and comparison of orthologous genes with a human metaplastic carcinoma signature revealed a significant overlap of 87 genes (P = 5x10(-11)). Among the shared deregulated genes between mouse and human are important regulators of epithelial morphogenesis including Cdh1, Ck19, Cldn3 and 4, Ddr1, and Wnt10a. These results document a causal role for Ccn6 deletion in the pathogenesis of metaplastic carcinomas with histological and molecular similarities with human disease. We provide a platform to study new targets in the diagnosis and treatment of human metaplastic carcinomas, and a new disease relevant model in which to test new treatment strategies.	[Martin, E. E.; Huang, W.; Anwar, T.; Arellano-Garcia, C.; Burman, B.; Gonzalez, M. E.; Kleer, C. G.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; [Martin, E. E.; Huang, W.; Anwar, T.; Arellano-Garcia, C.; Burman, B.; Gonzalez, M. E.; Kleer, C. G.] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; [Anwar, T.] Univ Michigan, Med Scientist Training Program, Ann Arbor, MI 48109 USA; [Anwar, T.] Univ Michigan, Mol & Cellular Pathol Grad Program, Ann Arbor, MI 48109 USA; [Arellano-Garcia, C.] Univ Michigan, Postbaccalaureate Res Educ Program, Ann Arbor, MI 48109 USA; [Guan, J-L] Univ Cincinnati, Dept Canc Biol, Cincinnati, OH USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University System of Ohio; University of Cincinnati	Kleer, CG (corresponding author), Univ Michigan, Dept Pathol, Comprehens Canc Ctr 4217, 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	kleer@umich.edu		Arellano-Garcia, Caroline/0000-0002-4103-4042	National Institutes of Health (NIH) grant [R01CA125577, R01CA107469, F30CA196084, R25GM086262]; University of Michigan's Cancer Center [5 P30 CA46592]; NATIONAL CANCER INSTITUTE [R01CA125577, K08CA090876, P30CA046592, F30CA196084, R01CA107469] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R25GM086262] Funding Source: NIH RePORTER	National Institutes of Health (NIH) grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Michigan's Cancer Center(University of Michigan System); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by the National Institutes of Health (NIH) grant R01CA125577 and R01CA107469 (C.G.K), F30CA196084 (T.A), R25GM086262 (PREP program, C.A-G), and the University of Michigan's Cancer Center Support grant 5 P30 CA46592. We thank Dr Stephen Weiss for the MMTV-Cre line A mice in FVB background, and members of the Kleer lab for critical review of the manuscript.	Anwar TE, 2013, HUM PATHOL, V44, P1457, DOI 10.1016/j.humpath.2013.01.005; Bae SY, 2011, BREAST CANCER RES TR, V126, P471, DOI 10.1007/s10549-011-1359-8; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bernardo GM, 2012, BIOSCIENCE REP, V32, P113, DOI 10.1042/BSR20110046; Blackburn AC, 2007, AM J PATHOL, V170, P2030, DOI 10.2353/ajpath.2007.060512; Burstein MD, 2015, CLIN CANCER RES, V21, P1688, DOI 10.1158/1078-0432.CCR-14-0432; Ferguson BW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036618; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Hayes MJ, 2008, CLIN CANCER RES, V14, P4038, DOI 10.1158/1078-0432.CCR-07-4379; Hennessy BT, 2009, CANCER RES, V69, P4116, DOI 10.1158/0008-5472.CAN-08-3441; Hennessy BT, 2006, ANN ONCOL, V17, P605, DOI 10.1093/annonc/mdl006; Huang W, 2008, AM J PATHOL, V172, P893, DOI 10.2353/ajpath.2008.070899; Huang W, 2016, ONCOTARGET, V7, P25180, DOI 10.18632/oncotarget.7734; Huang W, 2010, CANCER RES, V70, P3340, DOI 10.1158/0008-5472.CAN-09-4225; Hugo H, 2007, J CELL PHYSIOL, V213, P374, DOI 10.1002/jcp.21223; Hurvitz JR, 1999, NAT GENET, V23, P94, DOI 10.1038/12699; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; JONES L P, 2011, J CANC SCI THER S, V2, P1, DOI [DOI 10.4172/1948-5956.S2-004, 10.4172/1948-5956]; Jun JI, 2011, NAT REV DRUG DISCOV, V10, P945, DOI 10.1038/nrd3599; Kleer CG, 2004, NEOPLASIA, V6, P179, DOI 10.1593/neo.03316; Kleer CG, 2002, ONCOGENE, V21, P3172, DOI 10.1038/sj.onc.1205462; Koker MM, 2004, AM J SURG PATHOL, V28, P1506, DOI 10.1097/01.pas.0000138183.97366.fd; Kutz WE, 2005, MOL CELL BIOL, V25, P414, DOI 10.1128/MCB.25.1.414-421.2005; Lau LF, 2011, CELL MOL LIFE SCI, V68, P3149, DOI 10.1007/s00018-011-0778-3; Li Y, 2015, ONCOTARGET, V6, P32656, DOI 10.18632/oncotarget.5328; Lorenzatti G, 2011, J CELL SCI, V124, P1752, DOI 10.1242/jcs.084194; Luini A, 2007, BREAST CANCER RES TR, V101, P349, DOI 10.1007/s10549-006-9301-1; McAllister KA, 2002, CANCER RES, V62, P990; Milanese TR, 2006, J NATL CANCER I, V98, P1600, DOI 10.1093/jnci/djj439; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; Morishita A, 2013, CANCER RES, V73, P4289, DOI 10.1158/0008-5472.CAN-12-3848; OBERMAN HA, 1987, AM J SURG PATHOL, V11, P918, DOI 10.1097/00000478-198712000-00002; Pal A, 2012, NEOPLASIA, V14, P1067, DOI 10.1593/neo.121322; Pal A, 2012, CANCER RES, V72, P4818, DOI 10.1158/0008-5472.CAN-12-0154; Parr C, 2006, INT J CANCER, V119, P1176, DOI 10.1002/ijc.21881; Pennica D, 1998, P NATL ACAD SCI USA, V95, P14717, DOI 10.1073/pnas.95.25.14717; Radisky DC, 2009, J MAMMARY GLAND BIOL, V14, P181, DOI 10.1007/s10911-009-9123-y; Rakha EA, 2015, BRIT J CANCER, V112, P283, DOI 10.1038/bjc.2014.592; Reis JS, 2005, BREAST CANCER RES, V7, pR1028, DOI 10.1186/bcr1341; Reis JS, 2003, APPL IMMUNOHISTO M M, V11, P1, DOI 10.1097/00022744-200303000-00001; Reis JS, 2003, HISTOPATHOLOGY, V42, P94, DOI 10.1046/j.1365-2559.2003.01513_2.x; Ritchie ME, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-261; Rungta S, 2012, ARCH PATHOL LAB MED, V136, P896, DOI 10.5858/arpa.2012-0166-CR; Smyth G. K., 2004, STAT APPL GENET MOL, V3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027, 10.2202/1544-6115.1027/MACHINEREADABLECITATION/RIS]; Tchatchou S, 2010, HUM MUTAT, V31, P60, DOI 10.1002/humu.21134; Toy KA, 2015, BREAST CANCER RES TR, V150, P9, DOI 10.1007/s10549-015-3285-7; van Golen KL, 1999, CLIN CANCER RES, V5, P2511; Weigelt B, 2015, MODERN PATHOL, V28, P340, DOI 10.1038/modpathol.2014.142; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Zhang YH, 2012, MODERN PATHOL, V25, P178, DOI 10.1038/modpathol.2011.167; Zhang YH, 2005, BREAST CANCER RES, V7, pR1080, DOI 10.1186/bcr1351; Zhou ZN, 2014, ONCOGENE, V33, P3784, DOI 10.1038/onc.2013.363	52	17	17	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 20	2017	36	16					2275	2285		10.1038/onc.2016.381	http://dx.doi.org/10.1038/onc.2016.381			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ES8DM	27819674	Green Accepted			2022-12-17	WOS:000399782700008
J	Wang, J; Zhang, B; Wu, H; Cai, J; Sui, X; Wang, Y; Li, H; Qiu, Y; Wang, T; Chen, Z; Zhu, Q; Xia, H; Song, W; Xiang, AP				Wang, J.; Zhang, B.; Wu, H.; Cai, J.; Sui, X.; Wang, Y.; Li, H.; Qiu, Y.; Wang, T.; Chen, Z.; Zhu, Q.; Xia, H.; Song, W.; Xiang, A. P.			CD51 correlates with the TGF-beta pathway and is a functional marker for colorectal cancer stem cells	ONCOGENE			English	Article							INITIATING CELLS; PHENOTYPIC CHARACTERIZATION; METASTATIC CAPACITY; POOR-PROGNOSIS; COLON; ALPHA; MOUSE; TARGET; TUMORS; OVEREXPRESSION	Colorectal cancer (CRC) is one of the top three most prevalent and deadly cancers. A cancer stem cell (CSC) sub-population that is characterized by the abilities of tumor initiation, self-renewal, metastasis and resistance to chemotherapy can suggest new therapeutic targets. However, no such sub-population has been conclusively identified for CRC, and we lack any marker to identify cells with all of the above characteristics. Here, we report that CD51(+) CRC cells displayed greater sphere-forming and tumorigenic capacities, increased migratory and invasive potentials, and enhanced chemoresistance compared with CD51(-) CRC cells. CD51 knockdown reduced the side population, sphere formation, cell motility and inhibited tumor incidence and metastasis in an in vivo tumor model. Furthermore, CD51 could bind transforming growth factor beta (TGF-beta) receptors, and that it upregulated TGF-beta/Smad signaling. These results indicate that CD51 is a novel functional marker for colorectal CSCs which may provide an therapeutic target for the efficient elimination of colorectal CSCs.	[Wang, J.; Zhang, B.; Wu, H.; Xia, H.; Xiang, A. P.] Sun Yat Sen Univ, Zhongshan Sch Med, Affiliated Guangzhou Women & Childrens Hosp, Program Stem Cells & Regenerat Med, Guangzhou, Guangdong, Peoples R China; [Wang, J.; Zhang, B.; Wu, H.; Cai, J.; Wang, Y.; Li, H.; Qiu, Y.; Wang, T.; Xiang, A. P.] Sun Yat Sen Univ, Key Lab Stem Cells & Tissue Engn, Ctr Stem Cell Biol & Tissue Engn, Minist Educ, 74,Zhongshan 2nd Rd, Guangzhou 510080, Guangdong, Peoples R China; [Cai, J.; Xiang, A. P.] Sun Yat Sen Univ, Zhongshan Sch Med, Affiliated Hosp 3, Biotherapy Ctr, Guangzhou, Guangdong, Peoples R China; [Sui, X.; Zhu, Q.] Xi An Jiao Tong Univ, Coll Med, Affiliated Hosp 1, Dept Oncol, Xian, Peoples R China; [Chen, Z.; Song, W.] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Gastrointestinal Pancreat Surg, Guangzhou, Guangdong, Peoples R China; [Xiang, A. P.] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Biochem, Guangzhou, Guangdong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Xi'an Jiaotong University; Sun Yat Sen University; Sun Yat Sen University	Xiang, AP (corresponding author), Sun Yat Sen Univ, Key Lab Stem Cells & Tissue Engn, Ctr Stem Cell Biol & Tissue Engn, Minist Educ, 74,Zhongshan 2nd Rd, Guangzhou 510080, Guangdong, Peoples R China.; Song, W (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Dept Gastrointestinal Surg, 58 Zhongshan 2nd Rd, Guangzhou 510080, Guangdong, Peoples R China.	songwu@mail.sysu.edu.cn; xiangp@mail.sysu.edu.cn	Cai, Jianye/GOK-2676-2022	Wu, Hao-Xiang/0000-0001-6719-7133	National Basic Research Program of China [2012CBA01302]; National Natural Science Foundation of China [81425016, 81270646]; Natural Science Foundation of Guangdong Province [S2013030013305, S20120011190, 2015A030312013]; Key Scientific and Technological Projects of Guangdong Province [2014B020226002, 2015B020226004, 2014B020228003, 2015B020228001]; Key Scientific and Technological Program of Guangzhou City [201400000003-3, 201508020262, 201300000089]; Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme (GDUPS)	National Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Key Scientific and Technological Projects of Guangdong Province; Key Scientific and Technological Program of Guangzhou City; Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme (GDUPS)	This work was supported by the National Basic Research Program of China (2012CBA01302); the National Natural Science Foundation of China (81425016, 81270646); the Natural Science Foundation of Guangdong Province (S2013030013305, S20120011190, 2015A030312013); the Key Scientific and Technological Projects of Guangdong Province (2014B020226002, 2015B020226004, 2014B020228003, 2015B020228001); Key Scientific and Technological Program of Guangzhou City (201400000003-3, 201508020262, 201300000089); Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme (GDUPS, 2013).	Abetov D, 2015, TUMOR BIOL, V36, P1339, DOI 10.1007/s13277-015-3198-4; Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Callahan JF, 2002, J MED CHEM, V45, P999, DOI 10.1021/jm010493y; Chu P, 2009, INT J CANCER, V124, P1312, DOI 10.1002/ijc.24061; Clevers H, 2011, NAT MED, V17, P313, DOI 10.1038/nm.2304; Colak S, 2014, CELL DEATH DIFFER, V21, P1170, DOI 10.1038/cdd.2014.37; Dalerba P, 2007, P NATL ACAD SCI USA, V104, P10158, DOI 10.1073/pnas.0703478104; Derynck R, 2014, CURR OPIN CELL BIOL, V31, P56, DOI 10.1016/j.ceb.2014.09.001; Du L, 2008, CLIN CANCER RES, V14, P6751, DOI 10.1158/1078-0432.CCR-08-1034; Emmink BL, 2011, GASTROENTEROLOGY, V141, P269, DOI 10.1053/j.gastro.2011.03.052; Fang DD, 2010, BRIT J CANCER, V102, P1265, DOI 10.1038/sj.bjc.6605610; Gao WC, 2013, GASTROENTEROLOGY, V145, P636, DOI 10.1053/j.gastro.2013.05.049; Gemei M, 2013, CANCER-AM CANCER SOC, V119, P729, DOI 10.1002/cncr.27794; Ha SY, 2014, J CLIN PATHOL, V67, P576, DOI 10.1136/jclinpath-2013-202163; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Haraguchi N, 2010, J CLIN INVEST, V120, P3326, DOI 10.1172/JCI42550; Henderson NC, 2013, NAT MED, V19, P1617, DOI 10.1038/nm.3282; Ho MM, 2007, CANCER RES, V67, P4827, DOI 10.1158/0008-5472.CAN-06-3557; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Ikushima H, 2009, CELL STEM CELL, V5, P504, DOI 10.1016/j.stem.2009.08.018; Ito M, 2002, BLOOD, V100, P3175, DOI 10.1182/blood-2001-12-0207; Jiang MH, 2014, CELL RES, V24, P1466, DOI 10.1038/cr.2014.149; Ke Q, 2013, HUM MOL GENET, V22, P2221, DOI 10.1093/hmg/ddt074; Lathia JD, 2010, CELL STEM CELL, V6, P421, DOI 10.1016/j.stem.2010.02.018; Levin TG, 2010, GASTROENTEROLOGY, V139, P2072, DOI 10.1053/j.gastro.2010.08.053; Li WQ, 2015, BIOMATERIALS, V39, P75, DOI 10.1016/j.biomaterials.2014.10.056; Liu SP, 2013, GASTROENTEROLOGY, V144, P1031, DOI 10.1053/j.gastro.2013.01.046; Lotti F, 2013, J EXP MED, V210, P2851, DOI 10.1084/jem.20131195; Lu HH, 2014, NAT CELL BIOL, V16, P1105, DOI 10.1038/ncb3041; Lu XJ, 2008, PERSPECT MED CHEM, V2, P57; Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Oskarsson T, 2014, CELL STEM CELL, V14, P306, DOI 10.1016/j.stem.2014.02.002; Pan QZ, 2015, STEM CELLS, V33, P354, DOI 10.1002/stem.1850; Pang R, 2010, CELL STEM CELL, V6, P603, DOI 10.1016/j.stem.2010.04.001; Park CY, 2009, MOL THER, V17, P219, DOI 10.1038/mt.2008.254; Pinho S, 2013, J EXP MED, V210, P1351, DOI 10.1084/jem.20122252; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Savagner P, 2001, BIOESSAYS, V23, P912, DOI 10.1002/bies.1132; Seguin L, 2015, TRENDS CELL BIOL, V25, P234, DOI 10.1016/j.tcb.2014.12.006; Seguin L, 2014, NAT CELL BIOL, V16, P457, DOI 10.1038/ncb2953; Song LB, 2012, GASTROENTEROLOGY, V143, P995, DOI 10.1053/j.gastro.2012.06.033; Su YJ, 2011, EMBO J, V30, P3186, DOI 10.1038/emboj.2011.211; Tang KH, 2013, CANCER RES, V73, P2322, DOI 10.1158/0008-5472.CAN-12-2991; Thien A, 2015, DEV CELL, V32, P617, DOI 10.1016/j.devcel.2015.01.026; Tirino V, 2013, FASEB J, V27, P13, DOI 10.1096/fj.12-218222; Todaro M, 2008, CELL CYCLE, V7, P309, DOI 10.4161/cc.7.3.5389; Todaro M, 2014, CELL STEM CELL, V14, P342, DOI 10.1016/j.stem.2014.01.009; Todaro M, 2010, GASTROENTEROLOGY, V138, P2151, DOI 10.1053/j.gastro.2009.12.063; Tsai JH, 2013, GENE DEV, V27, P2192, DOI 10.1101/gad.225334.113; Vaillant F, 2008, CANCER RES, V68, P7711, DOI 10.1158/0008-5472.CAN-08-1949; Vaiopoulos AG, 2012, STEM CELLS, V30, P363, DOI 10.1002/stem.1031; Vermeulen L, 2008, P NATL ACAD SCI USA, V105, P13427, DOI 10.1073/pnas.0805706105; Vogetseder A, 2013, INT J CANCER, V133, P2362, DOI 10.1002/ijc.28267; Waisberg J, 2014, ANTICANCER RES, V34, P5599; Wang J, 2016, ONCOGENE, V35, P3139, DOI 10.1038/onc.2015.370; WERSTO RP, 1991, CANCER, V67, P106, DOI 10.1002/1097-0142(19910101)67:1<106::AID-CNCR2820670120>3.0.CO;2-I; Wilson BJ, 2011, CURR COLORECT CANC R, V7, P128, DOI 10.1007/s11888-011-0093-2; Wu ZM, 2015, CELL STEM CELL, V17, P47, DOI 10.1016/j.stem.2015.05.016; Xu S, 2015, ONCOGENE, V34, P1520, DOI 10.1038/onc.2014.95; Yan M, 2013, MOL CELL PROTEOMICS, V12, P3271, DOI 10.1074/mcp.M112.025460; Yang CP, 2015, ONCOTARGET, V6, P27714, DOI 10.18632/oncotarget.4663; Yang L, 2014, MODERN PATHOL, V27, P775, DOI 10.1038/modpathol.2013.189; Ye X, 2015, NATURE, V525, P256, DOI 10.1038/nature14897; Yuan JH, 2014, CANCER CELL, V25, P666, DOI 10.1016/j.ccr.2014.03.010; Zeuner A, 2014, CELL STEM CELL, V15, P692, DOI 10.1016/j.stem.2014.11.012	67	17	18	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 9	2017	36	10					1351	1363		10.1038/onc.2016.299	http://dx.doi.org/10.1038/onc.2016.299			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EN2TG	27593923				2022-12-17	WOS:000395862500004
J	Liu, T; Xiong, J; Yi, S; Zhang, H; Zhou, S; Gu, L; Zhou, M				Liu, T.; Xiong, J.; Yi, S.; Zhang, H.; Zhou, S.; Gu, L.; Zhou, M.			FKBP12 enhances sensitivity to chemotherapy-induced cancer cell apoptosis by inhibiting MDM2	ONCOGENE			English	Article							UBIQUITIN-PROTEIN LIGASE; P53 TUMOR-SUPPRESSOR; FK506-BINDING PROTEINS; PROLYL ISOMERASE; DEGRADATION; PROMOTES; TRANSACTIVATION; STABILIZATION; IMMUNOPHILIN; EXPRESSION	The FK506-binding protein 12 (FKBP12) is a cytoplasmic protein and has been reported to possess multiple functions in signaling transduction based on its interaction with different cellular targets. Here, we report that FKBP12 interacts with oncoprotein MDM2 and induces MDM2 degradation. We demonstrate that FKBP12 degrades MDM2 through binding to MDM2 protein, disrupting MDM2/MDM4 interaction and inducing MDM2 self-ubiquitination. The FKBP12-mediated MDM2 degradation was significantly enhanced when the transfected MDM2 was localized in the cytoplasm. The endogenous MDM2, when it was induced by p53 subjecting to DNA-damaging stimuli such as treatment with doxorubicin, was also significantly inhibited by FKBP12. This is due to translocation of p53-induced MDM2 from the nucleus to the cytoplasm, which facilitates interaction with cytoplasmic FKBP12. Furthermore, the enhanced level of MDM2 following p53 activation in nutlin-3 treated cells was also inhibited by FKBP12. The FKBP12-mediated downregulation of MDM2 in response to doxorubicin or nutlin-3 results in continuing and constitutive activation of p53, inhibition of XIAP and sensitization of cancer cells to apoptosis. These results identify a novel function for FKBP12 in downregulating MDM2, which directly enhances sensitivity of cancer cells to chemotherapy and nutlin-3 treatment.	[Liu, T.; Yi, S.; Zhang, H.; Gu, L.; Zhou, M.] Emory Univ, Sch Med, Dept Pediat, Div Hematol Oncol,Aflac Canc Ctr & Blood Disorder, 1760 Haygood Dr, Atlanta, GA 30322 USA; [Xiong, J.; Zhou, S.] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Inst Pathol, Wuhan, Peoples R China	Emory University; Huazhong University of Science & Technology	Gu, L; Zhou, M (corresponding author), Emory Univ, Sch Med, Dept Pediat, Div Hematol Oncol,Aflac Canc Ctr & Blood Disorder, 1760 Haygood Dr, Atlanta, GA 30322 USA.	lbgu@emory.edu; mzhou@emory.edu			R01 grants [CA180519, CA123490, CA143107]; Hyundai Hope on Wheels [79387GA]; CURE; National Natural Science Foundation of China [81472488]; NATIONAL CANCER INSTITUTE [R01CA180519, R01CA123490, R01CA143107] Funding Source: NIH RePORTER	R01 grants; Hyundai Hope on Wheels; CURE; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by R01 grants (CA180519, CA123490 and CA143107) to MZ; the Scholar award (79387GA) from Hyundai Hope on Wheels to MZ; research grants from CURE to MZ and LG; and a National Natural Science Foundation of China grant (No. 81472488) to SZ.	BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; Blattner C, 2002, MOL CELL BIOL, V22, P6170, DOI 10.1128/MCB.22.17.6170-6182.2002; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; BUESORAMOS CE, 1993, BLOOD, V82, P2617; Cheng QA, 2011, CELL CYCLE, V10, P1162, DOI 10.4161/cc.10.7.15249; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Gu LB, 2009, CANCER CELL, V15, P363, DOI 10.1016/j.ccr.2009.03.002; Gudavicius G, 2014, RNA, V20, P1014, DOI 10.1261/rna.042648.113; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Jiang BH, 2008, DRUG RESIST UPDATE, V11, P63, DOI 10.1016/j.drup.2008.03.001; JUVEN T, 1993, ONCOGENE, V8, P3411; Kang CB, 2008, NEUROSIGNALS, V16, P318, DOI 10.1159/000123041; Linares LK, 2003, FEBS LETT, V554, P73, DOI 10.1016/S0014-5793(03)01108-6; Linke K, 2008, CELL DEATH DIFFER, V15, P841, DOI 10.1038/sj.cdd.4402309; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Liu T, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0334-0; Mathea S, 2011, BIOCHEMISTRY-US, V50, P10844, DOI 10.1021/bi2013855; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Meek DW, 2003, MOL CANCER RES, V1, P1017; Mendrysa SM, 2000, MOL CELL BIOL, V20, P2023, DOI 10.1128/MCB.20.6.2023-2030.2000; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; Ochocka AM, 2009, FEBS LETT, V583, P621, DOI 10.1016/j.febslet.2009.01.009; Okamoto K, 2002, MOL CELL, V9, P761, DOI 10.1016/S1097-2765(02)00504-X; Pan Y, 2003, MOL CELL BIOL, V23, P5113, DOI 10.1128/MCB.23.15.5113-5121.2003; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Schreiber KH, 2015, AGING CELL, V14, P265, DOI 10.1111/acel.12313; Sharp DA, 1999, J BIOL CHEM, V274, P38189, DOI 10.1074/jbc.274.53.38189; Somarelli JA, 2008, PROTEINS, V72, P197, DOI 10.1002/prot.21908; Stad R, 2001, EMBO REP, V2, P1029, DOI 10.1093/embo-reports/kve227; Wang TW, 1996, CELL, V86, P435, DOI 10.1016/S0092-8674(00)80116-6; Wawrzynow B, 2007, J BIOL CHEM, V282, P32603, DOI 10.1074/jbc.M702767200; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016	36	17	17	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	12					1678	1686		10.1038/onc.2016.331	http://dx.doi.org/10.1038/onc.2016.331			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EP6AP	27617579	Green Published, hybrid			2022-12-17	WOS:000397460600007
J	Takiar, V; Ip, CKM; Gao, M; Mills, GB; Cheung, LWT				Takiar, V.; Ip, C. K. M.; Gao, M.; Mills, G. B.; Cheung, L. W. T.			Neomorphic mutations create therapeutic challenges in cancer	ONCOGENE			English	Review							YIN-YANG 1; TRANSCRIPTION FACTOR YIN-YANG-1; PROTEIN PHOSPHATASE-ACTIVITY; ISOCITRATE-DEHYDROGENASE 1; P53 TUMOR-SUPPRESSOR; WILD-TYPE P53; MUTANT P53; GENE-EXPRESSION; ONCOMETABOLITE 2-HYDROXYGLUTARATE; PIK3CA MUTATIONS	Oncogenesis is a pathologic process driven by genomic aberrations, including changes in nucleotide sequences. The majority of these mutational events fall into two broad categories: inactivation of tumor suppressor genes (hypomorph, antimorph or amorph) or activation of oncogenes (hypermorph). The recent surge in genome sequence data and functional genomics research has ushered in the discovery of aberrations in a third category: gain-of-novel-function mutation (neomorph). These neomorphic mutations, which can be found in both tumor suppressor genes and oncogenes, produce proteins with entirely different functions from their respective wild-type (WT) proteins and the other morphs. The unanticipated phenotypic outcomes elicited by neomorphic mutations imply that tumors with the neomorphic mutations may not respond to therapies designed to target the WT protein. Therefore, understanding the functional activities of each genomic aberration to be targeted is crucial in devising effective treatment strategies that will benefit specific cancer patients.	[Takiar, V.] Univ Cincinnati, Coll Med, UC Barrett Canc Ctr, Dept Radiat Oncol, Cincinnati, OH 45221 USA; [Takiar, V.] Univ Cincinnati, Coll Med, UC Barrett Canc Ctr, Dept Canc Biol, Cincinnati, OH 45221 USA; [Ip, C. K. M.; Gao, M.; Mills, G. B.; Cheung, L. W. T.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA; [Mills, G. B.; Cheung, L. W. T.] Univ Hong Kong, LKS Fac Med, Sch Biomed Sci, 21 Sassoon Rd, Pokfulam, Hong Kong, Peoples R China	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University of Texas System; UTMD Anderson Cancer Center; University of Hong Kong	Mills, GB; Cheung, LWT (corresponding author), Univ Hong Kong, LKS Fac Med, Sch Biomed Sci, 21 Sassoon Rd, Pokfulam, Hong Kong, Peoples R China.	gmills@mdanderson.org; lydiacwt@hku.hk		Ip, Carman K.M./0000-0002-6672-5982; Cheung, Lydia Wai Ting/0000-0003-1137-3200; Mills, Gordon/0000-0002-0144-9614; Takiar, Vinita/0000-0002-2499-3516	Adelson Medical Research Foundation; HKU Seed Funding Programme for Basic Research [201606159001];  [U54HG008100];  [U01CA168394];  [P50 CA098258];  [P50CA083639]; NATIONAL CANCER INSTITUTE [U01CA217842, P50CA098258] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [U54HG008100] Funding Source: NIH RePORTER	Adelson Medical Research Foundation; HKU Seed Funding Programme for Basic Research; ; ; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	We apologize to colleagues whose work was not cited owing to space constraints or our oversight. This work was supported by U54HG008100, U01CA168394, P50 CA098258, P50CA083639, the Adelson Medical Research Foundation and HKU Seed Funding Programme for Basic Research (201606159001).	Adorno M, 2009, CELL, V137, P87, DOI 10.1016/j.cell.2009.01.039; Alagesan B, 2015, CLIN CANCER RES, V21, P396, DOI 10.1158/1078-0432.CCR-14-1591; Allouche A, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1851; Andronesi OC, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3002693; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; Bader AG, 2006, P NATL ACAD SCI USA, V103, P1475, DOI 10.1073/pnas.0510857103; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; Baritaki S, 2007, INT J ONCOL, V31, P69; Begon DY, 2005, J BIOL CHEM, V280, P24428, DOI 10.1074/jbc.M503790200; Boulahbel H, 2009, BIOCHEM SOC T, V37, P291, DOI 10.1042/BST0370291; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Britten CD, 2013, CANCER CHEMOTH PHARM, V71, P1395, DOI 10.1007/s00280-013-2121-1; Brosh R, 2009, NAT REV CANCER, V9, P701, DOI 10.1038/nrc2693; Cai XM, 2005, INT J CANCER, V117, P905, DOI 10.1002/ijc.21251; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Cao YN, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3810; Castellano G, 2010, CELL CYCLE, V9, P557, DOI 10.4161/cc.9.3.10554; Castellano G, 2009, CELL CYCLE, V8, P1367, DOI 10.4161/cc.8.9.8314; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chan WM, 2004, MOL CELL BIOL, V24, P3536, DOI 10.1128/MCB.24.8.3536-3551.2004; Cheung LWT, 2015, ELIFE, V4, DOI 10.7554/eLife.06866; Cheung LWT, 2014, CANCER CELL, V26, P479, DOI 10.1016/j.ccell.2014.08.017; Cheung LWT, 2011, CANCER DISCOV, V1, P170, DOI 10.1158/2159-8290.CD-11-0039; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Choi C, 2012, NAT MED, V18, P624, DOI 10.1038/nm.2682; Chou WC, 2010, BLOOD, V115, P2749, DOI 10.1182/blood-2009-11-253070; Chowdhury R, 2011, EMBO REP, V12, P463, DOI 10.1038/embor.2011.43; Clark O, 2016, CLIN CANCER RES, V22, P1837, DOI 10.1158/1078-0432.CCR-13-1333; Costa HA, 2015, P NATL ACAD SCI USA, V112, P13976, DOI 10.1073/pnas.1422504112; Creixell P, 2015, CELL, V163, P187, DOI 10.1016/j.cell.2015.08.057; Creixell P, 2015, CELL, V163, P202, DOI 10.1016/j.cell.2015.08.056; Cromer MK, 2015, P NATL ACAD SCI USA, V112, P4062, DOI 10.1073/pnas.1503696112; Crunkhorn S, 2015, NAT REV DRUG DISCOV, V14, P15, DOI 10.1038/nrd4523; Cuevas BD, 2001, J BIOL CHEM, V276, P27455, DOI 10.1074/jbc.M100556200; DALZIEL K, 1980, FEBS LETT, V117, pK45, DOI 10.1016/0014-5793(80)80569-2; Dang L, 2009, NATURE, V462, P739, DOI 10.1038/nature08617; Davison TS, 1999, J BIOL CHEM, V274, P18709, DOI 10.1074/jbc.274.26.18709; de Nigris F, 2006, EUR J CANCER, V42, P2420, DOI 10.1016/j.ejca.2006.06.008; deGraffenried LA, 2004, ANN ONCOL, V15, P1510, DOI 10.1093/annonc/mdh388; DELEO AB, 1979, P NATL ACAD SCI USA, V76, P2420, DOI 10.1073/pnas.76.5.2420; Deng Z, 2009, ONCOGENE, V28, P3746, DOI 10.1038/onc.2009.231; Di Agostino S, 2006, CANCER CELL, V10, P191, DOI 10.1016/j.ccr.2006.08.013; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; Dogruluk T, 2015, CANCER RES, V75, P5341, DOI 10.1158/0008-5472.CAN-15-1654; Eiriksdottir G, 1998, ONCOGENE, V16, P21, DOI 10.1038/sj.onc.1201509; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Figueroa ME, 2010, CANCER CELL, V18, P553, DOI 10.1016/j.ccr.2010.11.015; Filipp FV, 2012, PIGM CELL MELANOMA R, V25, P375, DOI 10.1111/j.1755-148X.2012.00989.x; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; Freed-Pastor WA, 2012, GENE DEV, V26, P1268, DOI 10.1101/gad.190678.112; Freeman DJ, 2003, CANCER CELL, V3, P117, DOI 10.1016/S1535-6108(03)00021-7; Frum Rebecca A, 2014, Subcell Biochem, V85, P187, DOI 10.1007/978-94-017-9211-0_10; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Garban HJ, 2001, J IMMUNOL, V167, P75, DOI 10.4049/jimmunol.167.1.75; Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113; Gong LL, 2015, CELL CYCLE, V14, P2323, DOI 10.1080/15384101.2015.1044174; Gordon S, 2006, ONCOGENE, V25, P1125, DOI 10.1038/sj.onc.1209080; Gronroos E, 2004, P NATL ACAD SCI USA, V101, P12165, DOI 10.1073/pnas.0402283101; Gross S, 2010, J EXP MED, V207, P339, DOI 10.1084/jem.20092506; Grubach L, 2008, EUR J HAEMATOL, V81, P112, DOI 10.1111/j.1600-0609.2008.01083.x; Guo JU, 2011, CELL, V145, P423, DOI 10.1016/j.cell.2011.03.022; Hao YJ, 2013, CANCER CELL, V23, P583, DOI 10.1016/j.ccr.2013.03.021; Harpur AG, 1999, J BIOL CHEM, V274, P12323, DOI 10.1074/jbc.274.18.12323; Hartmann C, 2009, ACTA NEUROPATHOL, V118, P469, DOI 10.1007/s00401-009-0561-9; Hausinger RP, 2004, CRIT REV BIOCHEM MOL, V39, P21, DOI 10.1080/10409230490440541; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; Huang CH, 2007, SCIENCE, V318, P1744, DOI 10.1126/science.1150799; Ihle NT, 2009, CANCER RES, V69, P143, DOI 10.1158/0008-5472.CAN-07-6656; Imbriano C, 2005, MOL CELL BIOL, V25, P3737, DOI 10.1128/MCB.25.9.3737-3751.2005; Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3; Isakoff SJ, 2005, CANCER RES, V65, P10992, DOI 10.1158/0008-5472.CAN-05-2612; Janku F, 2014, CELL REP, V6, P377, DOI 10.1016/j.celrep.2013.12.035; Jiao YC, 2011, SCIENCE, V331, P1199, DOI 10.1126/science.1200609; Jo SH, 2001, J BIOL CHEM, V276, P16168, DOI 10.1074/jbc.M010120200; Joerger AC, 2009, P NATL ACAD SCI USA, V106, P17705, DOI 10.1073/pnas.0905867106; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Kalinina J, 2012, J MOL MED, V90, P1161, DOI 10.1007/s00109-012-0888-x; Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634; Kang MR, 2009, INT J CANCER, V125, P353, DOI 10.1002/ijc.24379; Kim SY, 2007, MOL CELL BIOCHEM, V302, P27, DOI 10.1007/s11010-007-9421-x; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Kohsaka S, 2014, NAT GENET, V46, P595, DOI 10.1038/ng.2969; Kramer OH, 2014, TRENDS PHARMACOL SCI, V35, P501, DOI 10.1016/j.tips.2014.08.001; Kravchenko JE, 2008, P NATL ACAD SCI USA, V105, P6302, DOI 10.1073/pnas.0802091105; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; Lee JH, 2005, SCIENCE, V308, P551, DOI 10.1126/science.1108297; Lee SM, 2002, FREE RADICAL BIO MED, V32, P1185, DOI 10.1016/S0891-5849(02)00815-8; Levine AJ, 2009, NAT REV CANCER, V9, P749, DOI 10.1038/nrc2723; Li D, 2011, CELL DEATH DIFFER, V18, P1904, DOI 10.1038/cdd.2011.71; Ligresti G, 2009, CELL CYCLE, V8, P1352, DOI 10.4161/cc.8.9.8255; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; Liu JL, 2011, MODERN PATHOL, V24, P1327, DOI 10.1038/modpathol.2011.98; Lokshin M, 2007, NUCLEIC ACIDS RES, V35, P340, DOI 10.1093/nar/gkl1047; Losman JA, 2013, SCIENCE, V339, P1621, DOI 10.1126/science.1231677; Lu C, 2012, NATURE, V483, P474, DOI 10.1038/nature10860; Luo J, 2005, CELL CYCLE, V4, P1309, DOI 10.4161/cc.4.10.2062; Lv S, 2011, ANTICANCER RES, V31, P4457; Ma K, 2008, CELL SIGNAL, V20, P684, DOI 10.1016/j.cellsig.2007.12.004; Mardis ER, 2009, NEW ENGL J MED, V361, P1058, DOI 10.1056/NEJMoa0903840; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; Matsumura N, 2009, MOL CANCER RES, V7, P210, DOI 10.1158/1541-7786.MCR-08-0255; Metallo CM, 2012, NATURE, V481, P380, DOI 10.1038/nature10602; Miled N, 2007, SCIENCE, V317, P239, DOI 10.1126/science.1135394; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; Moll UM, 2004, MOL CANCER RES, V2, P371; MULLER H. J., 1932, Proceedings. 6th Int. Congr. Genet., V1, P213; Muller PAJ, 2009, CELL, V139, P1327, DOI 10.1016/j.cell.2009.11.026; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Okoye-Okafor UC, 2015, NAT CHEM BIOL, V11, P878, DOI 10.1038/nchembio.1930; Papa A, 2014, CELL, V157, P595, DOI 10.1016/j.cell.2014.03.027; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Peng YH, 2001, J BIOL CHEM, V276, P40583, DOI 10.1074/jbc.M102817200; Perez CA, 2007, ONCOGENE, V26, P7363, DOI 10.1038/sj.onc.1210561; Perez RE, 2010, J CELL PHYSIOL, V225, P394, DOI 10.1002/jcp.22285; Petitjean A, 2007, ONCOGENE, V26, P2157, DOI 10.1038/sj.onc.1210302; Pitts TM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113037; Pope WB, 2012, J NEURO-ONCOL, V107, P197, DOI 10.1007/s11060-011-0737-8; Popovici-Muller J, 2012, ACS MED CHEM LETT, V3, P850, DOI 10.1021/ml300225h; Quayle SN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049466; RIGGS KJ, 1993, MOL CELL BIOL, V13, P7487, DOI 10.1128/MCB.13.12.7487; Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395; Rodriguez-Escudero I, 2011, HUM MOL GENET, V20, P4132, DOI 10.1093/hmg/ddr337; Rohle D, 2013, SCIENCE, V340, P626, DOI 10.1126/science.1236062; ROTTER V, 1983, P NATL ACAD SCI-BIOL, V80, P2613, DOI 10.1073/pnas.80.9.2613; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Seligson D, 2005, INT J ONCOL, V27, P131; Selivanova G, 2007, ONCOGENE, V26, P2243, DOI 10.1038/sj.onc.1210295; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Shimizu T, 2012, CLIN CANCER RES, V18, P2316, DOI 10.1158/1078-0432.CCR-11-2381; Shrivastava A, 1996, P NATL ACAD SCI USA, V93, P10638, DOI 10.1073/pnas.93.20.10638; Shukla N, 2012, CLIN CANCER RES, V18, P748, DOI 10.1158/1078-0432.CCR-11-2056; Simpson L, 2001, EXP CELL RES, V264, P29, DOI 10.1006/excr.2000.5130; Song H, 2007, NAT CELL BIOL, V9, P573, DOI 10.1038/ncb1571; Sorensen PHB, 2002, J CLIN ONCOL, V20, P2672, DOI 10.1200/JCO.2002.03.137; Stemke-Hale K, 2008, CANCER RES, V68, P6084, DOI 10.1158/0008-5472.CAN-07-6854; Strano S, 2001, J BIOL CHEM, V276, P15164, DOI 10.1074/jbc.M010484200; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; Sui GC, 2004, CELL, V117, P859, DOI 10.1016/j.cell.2004.06.004; TAPSCOTT SJ, 1991, J CLIN INVEST, V87, P1133, DOI 10.1172/JCI115109; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; Temraz S, 2015, INT J MOL SCI, V16, P22976, DOI 10.3390/ijms160922976; Tibarewal P, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002138; Trotman LC, 2007, CELL, V128, P141, DOI 10.1016/j.cell.2006.11.040; VANANTWERP ME, 1992, P NATL ACAD SCI USA, V89, P9010, DOI 10.1073/pnas.89.19.9010; Vasudevan KM, 2009, CANCER CELL, V16, P21, DOI 10.1016/j.ccr.2009.04.012; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2009, NAT REV CANCER, V9, P691, DOI 10.1038/nrc2715; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang F, 2013, SCIENCE, V340, P622, DOI 10.1126/science.1234769; Wang W, 2015, J BIOMOL SCREEN, V20, P821, DOI 10.1177/1087057115579637; Ward PS, 2010, CANCER CELL, V17, P225, DOI 10.1016/j.ccr.2010.01.020; Wee S, 2008, P NATL ACAD SCI USA, V105, P13057, DOI 10.1073/pnas.0802655105; Wee S, 2009, CANCER RES, V69, P4286, DOI 10.1158/0008-5472.CAN-08-4765; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; Wiech M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051426; Williams SC, 2011, ACTA NEUROPATHOL, V121, P279, DOI 10.1007/s00401-010-0790-y; Wu HY, 2009, P NATL ACAD SCI USA, V106, P20258, DOI 10.1073/pnas.0902369106; Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014; Xu X, 2004, J BIOL CHEM, V279, P33946, DOI 10.1074/jbc.M404298200; Yakovleva T, 2004, BIOCHEM BIOPH RES CO, V318, P615, DOI 10.1016/j.bbrc.2004.04.065; Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710; Yan W, 2013, ONCOGENE, V32, P599, DOI 10.1038/onc.2012.81; Yi YW, 2013, ONCOTARGET, V4, P984, DOI 10.18632/oncotarget.1070; Yu JH, 1998, MOL CELL BIOL, V18, P1379, DOI 10.1128/MCB.18.3.1379; Yu X, 2012, CANCER CELL, V21, P614, DOI 10.1016/j.ccr.2012.03.042; Zack TI, 2013, NAT GENET, V45, P1134, DOI 10.1038/ng.2760; Zhao JJ, 2005, P NATL ACAD SCI USA, V102, P18443, DOI 10.1073/pnas.0508988102; Zhao SM, 2009, SCIENCE, V324, P261, DOI 10.1126/science.1170944	178	17	18	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	12					1607	1618		10.1038/onc.2016.312	http://dx.doi.org/10.1038/onc.2016.312			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EP6AP	27841866	Green Accepted			2022-12-17	WOS:000397460600001
J	Sauer, M; Schuldner, M; Hoffmann, N; Cetintas, A; Reiners, KS; Shatnyeva, O; Hallek, M; Hansen, HP; Gasser, S; von Strandmann, EP				Sauer, M.; Schuldner, M.; Hoffmann, N.; Cetintas, A.; Reiners, K. S.; Shatnyeva, O.; Hallek, M.; Hansen, H. P.; Gasser, S.; von Strandmann, E. P.			CBP/p300 acetyltransferases regulate the expression of NKG2D ligands on tumor cells	ONCOGENE			English	Article							B-ASSOCIATED TRANSCRIPT-3; DNA-DAMAGE RESPONSE; UP-REGULATION; NK CELLS; LEUKEMIA-CELLS; NF-KB; RECEPTOR; ACTIVATION; MUTATIONS; INDUCTION	Tumor surveillance of natural killer (NK) cells is mediated by the cytotoxicity receptor natural-killer group 2 member D (NKG2D). Ligands for NKG2D are generally not expressed on healthy cells, but induced on the surface of malignant cells. To date, NKG2D ligand (NKG2D-L) induction was mainly described to depend on the activation of the DNA damage response, although the molecular mechanisms that regulate NKG2D-L expression remain largely unknown. Here, we show that the acetyltransferases CBP (CREB-binding protein) and p300 play a crucial role in the regulation of NKG2D-L on tumor cells. Loss of CBP/p300 decreased the basal cell surface expression of human ligands and reduced the upregulation of MICA/B and ULBP2 in response to histone deacetylase inhibitors or DNA damage. Furthermore, CBP/P300 deficiency abrogated the sensitivity of stressed cells to NK cell-mediated killing. CBP/p300 were also identified as major regulators of mouse NKG2D ligand RAE-1 in vitro and in vivo using the E mu-Myc lymphoma model. Mechanistically, we observed an enhanced activation of the CBP/p300 binding transcription factor CREB (cAMP response element-binding protein) correlating to the NKG2D-L upregulation. Moreover, increased binding of CREB and CBP/p300 to NKG2D-L promoters and elevated histone acetylation were detectable. This study provides strong evidence for a major role of CBP and p300 in orchestrating NKG2D-L induction and consequently immunosurveillance of tumors in mice and humans. These findings might help to develop novel immunotherapeutic approaches against cancer.	[Sauer, M.; Schuldner, M.; Hoffmann, N.; Cetintas, A.; Reiners, K. S.; Shatnyeva, O.; Hallek, M.; Hansen, H. P.; von Strandmann, E. P.] Univ Hosp Cologne, Dept Internal Med 1, Kerpener Str 62, D-50937 Cologne, Germany; [Hallek, M.] Univ Cologne, Cologne Excellence Cluster Cellular Stress Respon, Cologne, Germany; [Gasser, S.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Microbiol, Immunol Programme, Singapore 117548, Singapore; [von Strandmann, E. P.] Philipps Univ, Ctr Tumor Biol & Immunol, Expt Tumor Res, Clin Hematol Oncol & Immunol, Marburg, Germany	University of Cologne; University of Cologne; National University of Singapore; Philipps University Marburg	von Strandmann, EP (corresponding author), Univ Hosp Cologne, Dept Internal Med 1, Kerpener Str 62, D-50937 Cologne, Germany.	elke.pogge@uk-koeln.de	Hallek, Michael/Y-3191-2019	Hallek, Michael/0000-0002-7425-4455; Reiners, Katrin/0000-0002-5908-8823	Deutsche Forschungsgemeinschaft [KFO286]; Jose Carreras-Leukamie Stiftung [DJCLS R 14/08]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Jose Carreras-Leukamie Stiftung	This study was supported by the Deutsche Forschungsgemeinschaft (KFO286, RP4; to EPvS) and the Jose Carreras-Leukamie Stiftung (DJCLS R 14/08; to EPvS). This study contains parts of the PhD thesis from MS.	Andresen L, 2007, J IMMUNOL, V179, P8235, DOI 10.4049/jimmunol.179.12.8235; Armeanu S, 2005, CANCER RES, V65, P6321, DOI 10.1158/0008-5472.CAN-04-4252; Arrighetti Noemi, 2015, Critical Reviews in Oncogenesis, V20, P83; Ashburner BP, 2001, MOL CELL BIOL, V21, P7065, DOI 10.1128/MCB.21.20.7065-7077.2001; Bauer S, 1999, SCIENCE, V285, P727, DOI 10.1126/science.285.5428.727; Behera J, 2015, MINI-REV MED CHEM, V15, P731, DOI 10.2174/1389557515666150521162237; Belting L, 2015, EUR J IMMUNOL, V45, P2593, DOI 10.1002/eji.201445375; Besse B, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1071008; Boll B, 2009, CLIN CANCER RES, V15, P5108, DOI 10.1158/1078-0432.CCR-09-0213; Bowers EM, 2010, CHEM BIOL, V17, P471, DOI 10.1016/j.chembiol.2010.03.006; Carayannopoulos LN, 2002, J IMMUNOL, V169, P4079, DOI 10.4049/jimmunol.169.8.4079; Cerboni C, 2007, BLOOD, V110, P606, DOI 10.1182/blood-2006-10-052720; Cerwenka A, 2000, IMMUNITY, V12, P721, DOI 10.1016/S1074-7613(00)80222-8; Champsaur M, 2010, IMMUNOL REV, V235, P267, DOI 10.1111/j.0105-2896.2010.00893.x; Dai Y, 2005, MOL CELL BIOL, V25, P5429, DOI 10.1128/MCB.25.13.5429-5444.2005; Deng WW, 2015, SCIENCE, V348, P136, DOI 10.1126/science.1258867; Diefenbach A, 2000, NAT IMMUNOL, V1, P119, DOI 10.1038/77793; Gasser S, 2005, NATURE, V436, P1186, DOI 10.1038/nature03884; Gayther SA, 2000, NAT GENET, V24, P300, DOI 10.1038/73536; Guerra N, 2008, IMMUNITY, V28, P571, DOI 10.1016/j.immuni.2008.02.016; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; Heinemann A, 2012, CANCER RES, V72, P460, DOI 10.1158/0008-5472.CAN-11-1977; Iannello A, 2013, J EXP MED, V210, P2057, DOI 10.1084/jem.20130783; Klein JM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079502; Kovalchuk AL, 2000, J EXP MED, V192, P1183, DOI 10.1084/jem.192.8.1183; Kung AL, 2000, GENE DEV, V14, P272; Lam AR, 2014, CANCER RES, V74, P2193, DOI 10.1158/0008-5472.CAN-13-1703; Lanier LL, 2015, CANCER IMMUNOL RES, V3, P575, DOI 10.1158/2326-6066.CIR-15-0098; Le Gallo M, 2012, NAT GENET, V44, P1310, DOI 10.1038/ng.2455; Lee Jong-Soo, 2007, Cancer Res Treat, V39, P125, DOI 10.4143/crt.2007.39.3.125; Li H, 2011, CELL CYCLE, V10, P3346, DOI 10.4161/cc.10.19.17630; Lin D, 2012, J BIOL CHEM, V287, P4299, DOI 10.1074/jbc.M111.282152; Molinero LL, 2004, J IMMUNOL, V173, P5583, DOI 10.4049/jimmunol.173.9.5583; Mullighan CG, 2011, NATURE, V471, P235, DOI 10.1038/nature09727; Pasqualucci L, 2011, NATURE, V471, P189, DOI 10.1038/nature09730; Raulet DH, 2013, ANNU REV IMMUNOL, V31, P413, DOI 10.1146/annurev-immunol-032712-095951; Reiners KS, 2013, BLOOD, V121, P3658, DOI 10.1182/blood-2013-01-476606; Routes JM, 2005, J EXP MED, V202, P1477, DOI 10.1084/jem.20050240; Sato T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059702; Sauer M, 2013, BIOL CHEM, V394, P1325, DOI 10.1515/hsz-2013-0161; Schoetterl Sonja, 2015, Critical Reviews in Oncogenesis, V20, P139; Simhadri VR, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003377; Soriani A, 2014, J IMMUNOL, V193, P950, DOI 10.4049/jimmunol.1400271; Textor S, 2011, CANCER RES, V71, P5998, DOI 10.1158/0008-5472.CAN-10-3211; von Strandmann EP, 2007, IMMUNITY, V27, P965, DOI 10.1016/j.immuni.2007.10.010; Xu W, 2006, BLOOD, V107, P4407, DOI 10.1182/blood-2005-08-3263	46	17	19	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 16	2017	36	7					933	941		10.1038/onc.2016.259	http://dx.doi.org/10.1038/onc.2016.259			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8JG	27477692	Green Published, hybrid			2022-12-17	WOS:000394169100006
J	Berens, EB; Sharif, GM; Schmidt, MO; Yan, G; Shuptrine, CW; Weiner, LM; Glasgow, E; Riegel, AT; Wellstein, A				Berens, E. B.; Sharif, G. M.; Schmidt, M. O.; Yan, G.; Shuptrine, C. W.; Weiner, L. M.; Glasgow, E.; Riegel, A. T.; Wellstein, A.			Keratin-associated protein 5-5 controls cytoskeletal function and cancer cell vascular invasion	ONCOGENE			English	Article							INTERMEDIATE-FILAMENTS; EXPRESSION; MICROENVIRONMENT; DISSEMINATION; PROGRESSION; METASTASIS; MOTILITY; ADHESION	Cancer cell vascular invasion is a crucial step in the malignant progression toward metastasis. Here we used a genome-wide RNA interference screen with E0771 mammary cancer cells to uncover drivers of endothelial monolayer invasion. We identified keratin-associated protein 5-5 (Krtap5-5) as a candidate. Krtap5-5 belongs to a large protein family that is implicated in crosslinking keratin intermediate filaments during hair formation, yet these Krtaps have no reported role in cancer. Depletion of Krtap5-5 from cancer cells led to cell blebbing and a loss of keratins 14 and 18, in addition to the upregulation of vimentin intermediate filaments. This intermediate filament subtype switching induced dysregulation of the actin cytoskeleton and reduced the expression of hemidesmosomal a6/beta 4-integrins. We further demonstrate that knockdown of keratin 18 phenocopies the loss of Krtap5-5, suggesting that Krtap5-5 crosstalks with keratin 18 in E0771 cells. Disruption of the keratin cytoskeleton by perturbing Krtap5-5 function broadly altered the expression of cytoskeleton regulators and the localization of cell surface markers. Krtap5-5 depletion did not impact cell viability but reduced cell motility and extracellular matrix invasion, as well as extravasation of cancer cells into tissues in zebrafish and mice. We conclude that Krtap5-5 is a previously unknown regulator of cytoskeletal function in cancer cells that modulates motility and vascular invasion. Thus, in addition to its physiologic function, a Krtap can serve as a switch toward malignant progression.	[Berens, E. B.; Sharif, G. M.; Schmidt, M. O.; Yan, G.; Shuptrine, C. W.; Weiner, L. M.; Glasgow, E.; Riegel, A. T.; Wellstein, A.] Georgetown Univ, Dept Oncol, Lombardi Comprehens Canc Ctr, Washington, DC USA	Georgetown University	Wellstein, A (corresponding author), Georgetown Univ, Dept Oncol, Lombardi Canc Ctr, 3970 Reservoir Rd, Washington, DC 20007 USA.	wellstea@georgetown.edu	Schmidt, Marcel/AAV-8054-2021	Schmidt, Marcel/0000-0002-3991-2766; Sharif, Ghada/0000-0001-5344-3575; Glasgow, Eric/0000-0001-7729-3954	NIH/NCI [CA71508, CA51008, CA177466, CA113477]; NATIONAL CANCER INSTITUTE [R01CA050633, P30CA051008, R01CA071508, R01CA113477, R33CA177466, T32CA009686] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Peter Johnson of the Georgetown University Microscopy Core for assistance with immunofluorescence, Dr Karen Creswell and Alex Joseph of the Georgetown University Flow Cytometry Core for running our FACS samples, and Idalia Cruz for assistance with the tail vein injections. We extend our gratitude to Dr Rudolf Leube and Dr Nicole Schwarz for generously providing the KRT18 expression vector used in this study, as well as to Dr Anne Cress for the HYD1 hemidesmosomal integrin blocker. Finally, we thank Dr Ian Gallicano for critical evaluation of the manuscript and for providing constructive feedback. This study was supported by NIH/NCI grants CA71508, CA51008, CA177466 (AW) and CA113477 (ATR).	ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Berens EB, 2015, JOVE-J VIS EXP, DOI 10.3791/53409; Bornschlogl T, 2016, P NATL ACAD SCI USA, V113, P5940, DOI 10.1073/pnas.1520302113; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Cline MS, 2013, SCI REP-UK, V3, DOI 10.1038/srep02652; Cobb JP, 1996, BRIT J ANAESTH, V77, P3, DOI 10.1093/bja/77.1.3; Coulombe PA, 2002, CURR OPIN CELL BIOL, V14, P110, DOI 10.1016/S0955-0674(01)00301-5; Cross LM, 2003, ARTERIOSCL THROM VAS, V23, P911, DOI 10.1161/01.ATV.0000068685.72914.7E; Cummings MC, 2014, J PATHOL, V232, P23, DOI 10.1002/path.4288; de Pereda JM, 2009, CELL ADHES MIGR, V3, P361, DOI 10.4161/cam.3.4.9525; Deb-Choudhury S, 2015, PROTEINS, V83, P224, DOI 10.1002/prot.24727; DeRoock IB, 2001, CANCER RES, V61, P3308; Dong Y, 2013, NAT BIOTECHNOL, V31, P135, DOI 10.1038/nbt.2478; Ewens A, 2005, ANTICANCER RES, V25, P3905; Fletcher DA, 2010, NATURE, V463, P485, DOI 10.1038/nature08908; Friedl P, 2011, CELL, V147, P992, DOI 10.1016/j.cell.2011.11.016; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; Fujikawa H, 2013, J INVEST DERMATOL, V133, P2780, DOI 10.1038/jid.2013.233; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hendrix MJC, 1997, AM J PATHOL, V150, P483; Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727; Jamora C, 2002, NAT CELL BIOL, V4, pE101, DOI 10.1038/ncb0402-e101; Karantza V, 2011, ONCOGENE, V30, P127, DOI 10.1038/onc.2010.456; Kedrin D, 2007, J MAMMARY GLAND BIOL, V12, P143, DOI 10.1007/s10911-007-9046-4; Khan I, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-779; Kolsch A, 2010, J CELL SCI, V123, P2266, DOI 10.1242/jcs.068080; Lefkowitz GK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027603; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Machesky LM, 2008, FEBS LETT, V582, P2102, DOI 10.1016/j.febslet.2008.03.039; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; Moller B, 2016, J OPEN RES STW, V4, P17, DOI [10.5334/jors.103, DOI 10.5334/JORS.103]; Ramms L, 2013, P NATL ACAD SCI USA, V110, P18513, DOI 10.1073/pnas.1313491110; Reymond N, 2013, NAT REV CANCER, V13, P858, DOI 10.1038/nrc3628; Rogers MA, 2006, INT REV CYTOL, V251, P209, DOI 10.1016/S0074-7696(06)51006-X; Schaller G, 1996, CLIN CANCER RES, V2, P1879; Seltmann K, 2015, J INVEST DERMATOL, V135, P1609, DOI 10.1038/jid.2015.46; Seltmann K, 2013, P NATL ACAD SCI USA, V110, P18507, DOI 10.1073/pnas.1310493110; Sharif GM, 2015, ONCOGENE, V34, P5879, DOI 10.1038/onc.2015.44; Shimomura Y, 2015, J INVEST DERMATOL, V10, P230; Sroka TC, 2006, CARCINOGENESIS, V27, P1748, DOI 10.1093/carcin/bgl005; TAYLORPAPADIMITRIOU J, 1989, J CELL SCI, V94, P403; Wu DD, 2008, BMC EVOL BIOL, V8, DOI 10.1186/1471-2148-8-241; Yahagi S, 2004, BIOCHEM BIOPH RES CO, V318, P655, DOI 10.1016/j.bbrc.2004.04.074; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; Zhang WY, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005049	45	17	17	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 2	2017	36	5					593	605		10.1038/onc.2016.234	http://dx.doi.org/10.1038/onc.2016.234			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IS	27375028	Green Accepted			2022-12-17	WOS:000394167700002
J	Tournillon, AS; Lopez, I; Malbert-Colas, L; Findakly, S; Naski, N; Olivares-Illana, V; Karakostis, K; Vojtesek, B; Nylander, K; Fahraeus, R				Tournillon, A-S; Lopez, I.; Malbert-Colas, L.; Findakly, S.; Naski, N.; Olivares-Illana, V.; Karakostis, K.; Vojtesek, B.; Nylander, K.; Fahraeus, R.			p53 binds the mdmx mRNA and controls its translation	ONCOGENE			English	Article							ENDOPLASMIC-RETICULUM STRESS; DNA-DAMAGE; EMBRYONIC LETHALITY; FEEDBACK LOOP; ACTIVATION; PROTEIN; GENE; DOMAIN; AMPLIFICATION; RECOGNITION	MDMX and MDM2 are two nonredundant essential regulators of p53 tumor suppressor activity. MDM2 controls p53 expression levels, whereas MDMX is predominantly a negative regulator of p53 trans-activity. The feedback loops between MDM2 and p53 are well studied and involve both negative and positive regulation on transcriptional, translational and post-translational levels but little is known on the regulatory pathways between p53 and MDMX. Here we show that overexpression of p53 suppresses mdmx mRNA translation in vitro and in cell-based assays. The core domain of p53 binds the 5' untranslated region (UTR) of the mdmx mRNA in a zinc-dependent manner that together with a trans-suppression domain located in p53 N-terminus controls MDMX synthesis. This interaction can be visualized in the nuclear and cytoplasmic compartment. Fusion of the mdmx 5' UTR to the ovalbumin open reading frame leads to suppression of ovalbumin synthesis. Interestingly, the transcription inactive p53 mutant R273H has a different RNA-binding profile compared with the wild-type p53 and differentiates the synthesis of MDMX isoforms. This study describes p53 as a trans-suppressor of the mdmx mRNA and adds a further level to the intricate feedback system that exist between p53 and its key regulatory factors and emphasizes the important role of mRNA translation control in regulating protein expression in the p53 pathway.	[Tournillon, A-S; Lopez, I.; Malbert-Colas, L.; Findakly, S.; Naski, N.; Karakostis, K.; Fahraeus, R.] Univ Paris 07, Hop St Louis, Inst Natl Sante & Rech Med, Inst Genet Mol,Equipe Labellisee Ligue Canc,UMR11, 27 Rue Juliette Dodu, F-75010 Paris, France; [Olivares-Illana, V.] Univ Auonoma San Luis Potosi, Inst Fis, San Luis Potosi, Mexico; [Vojtesek, B.; Fahraeus, R.] Masaryk Mem Canc Inst, RECAMO, Brno, Czech Republic; [Nylander, K.; Fahraeus, R.] Umea Univ, Dept Med Biosci, Umea, Sweden	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Masaryk Memorial Cancer Institute; Umea University	Fahraeus, R (corresponding author), Univ Paris 07, Hop St Louis, Inst Natl Sante & Rech Med, Inst Genet Mol,Equipe Labellisee Ligue Canc,UMR11, 27 Rue Juliette Dodu, F-75010 Paris, France.	robin.fahraeus@inserm.fr	Karakostis, Konstantinos/ABC-9700-2020; Olivares-Illana, Vanesa/AAF-9710-2021; Karakostis, Konstantinos/AGJ-3251-2022; fahraeus, robin/K-8726-2014; Karakostis, Konstantinos/GNW-4090-2022	Karakostis, Konstantinos/0000-0003-1122-7860; Olivares-Illana, Vanesa/0000-0001-6949-5986; Lopez, Ignacio/0000-0001-9669-8906	la Ligue Contre le Cancer; PACRI; AXA Research Fund; Fondation pour la Recherche Medicale [FDT20150532276]; GACR [16-07321S]; MH CZ-DRO (MMCI) [00209805]; Inserm;  [MEYS-NPS I-L01413]	la Ligue Contre le Cancer(Ligue nationale contre le cancer); PACRI; AXA Research Fund(AXA Research Fund); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); GACR(Grant Agency of the Czech Republic); MH CZ-DRO (MMCI); Inserm(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); 	This work was supported by la Ligue Contre le Cancer and Inserm. A-ST is supported by PACRI. IL is supported by AXA Research Fund and Fondation pour la Recherche Medicale (FDT20150532276). BV was supported by GACR 16-07321S and BV and RF were supported by MEYS-NPS I-L01413 and MH CZ-DRO (MMCI, 00209805). We thank the IUH platform for technical assistance.	Cassiday LA, 2002, NUCLEIC ACIDS RES, V30, P4118, DOI 10.1093/nar/gkf512; Danovi D, 2004, MOL CELL BIOL, V24, P5835, DOI 10.1128/MCB.24.13.5835-5843.2004; Gajjar M, 2012, CANCER CELL, V21, P25, DOI 10.1016/j.ccr.2011.11.016; Galy B, 2001, ONCOGENE, V20, P4613, DOI 10.1038/sj.onc.1204630; Galy B, 2001, ONCOGENE, V20, P1669, DOI 10.1038/sj.onc.1204271; Gembarska A, 2012, NAT MED, V18, P1239, DOI 10.1038/nm.2863; Grover R, 2009, ONCOGENE, V28, P2766, DOI 10.1038/onc.2009.138; Gu JJ, 2002, J BIOL CHEM, V277, P19251, DOI 10.1074/jbc.C200150200; Hudson WH, 2014, NAT REV MOL CELL BIO, V15, P749, DOI 10.1038/nrm3884; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kaustov L, 2006, CELL CYCLE, V5, P489, DOI 10.4161/cc.5.5.2489; Kitayner M, 2006, MOL CELL, V22, P741, DOI 10.1016/j.molcel.2006.05.015; Lopez I, 2015, CELL CYCLE, V14, P3373, DOI 10.1080/15384101.2015.1090066; Lunde BM, 2007, NAT REV MOL CELL BIO, V8, P479, DOI 10.1038/nrm2178; Malbert-Colas L, 2014, MOL CELL, V54, P500, DOI 10.1016/j.molcel.2014.02.035; Mandke P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042034; Miller SJ, 2000, MOL CELL BIOL, V20, P8420, DOI 10.1128/MCB.20.22.8420-8431.2000; Mlynarczyk C, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6067; Montes de Oca LR, 1995, NATURE, V378, P203; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; Naski N, 2009, CELL CYCLE, V8, P31, DOI 10.4161/cc.8.1.7326; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Oren M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001107; Pant V, 2013, GENE DEV, V27, P1857, DOI 10.1101/gad.227249.113; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; Perry ME, 2000, J BIOL CHEM, V275, P5733, DOI 10.1074/jbc.275.8.5733; Phillips A, 2010, J BIOL CHEM, V285, P29111, DOI 10.1074/jbc.M110.129726; Riley KJL, 2007, RNA, V13, P1825, DOI 10.1261/rna.673407; Riley KJL, 2006, RNA, V12, P620, DOI 10.1261/rna.2286706; Saucedo LJ, 1999, J BIOL CHEM, V274, P8161, DOI 10.1074/jbc.274.12.8161; Scrable H, 2005, INT J BIOCHEM CELL B, V37, P913, DOI 10.1016/j.biocel.2004.11.014; Suswam EA, 2005, NUCLEIC ACIDS RES, V33, P4507, DOI 10.1093/nar/gki763; Tournillon AS, 2015, CELL CYCLE, V14, P449, DOI 10.4161/15384101.2014.977081; Vise PD, 2005, NUCLEIC ACIDS RES, V33, P2061, DOI 10.1093/nar/gki336; Wade M, 2006, J BIOL CHEM, V281, P33036, DOI 10.1074/jbc.M605405200; Yin YL, 2002, NAT CELL BIOL, V4, P462, DOI 10.1038/ncb801	37	17	17	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 2	2017	36	5					723	730		10.1038/onc.2016.236	http://dx.doi.org/10.1038/onc.2016.236			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IS	27375027				2022-12-17	WOS:000394167700013
J	Chowdhury, AR; Long, A; Fuchs, SY; Rustgi, A; Avadhani, NG				Chowdhury, A. Roy; Long, A.; Fuchs, S. Y.; Rustgi, A.; Avadhani, N. G.			Mitochondrial stress-induced p53 attenuates HIF-1 alpha activity by physical association and enhanced ubiquitination	ONCOGENE			English	Article							HYPOXIA-INDUCIBLE FACTOR; COLON-CANCER CELLS; TUMOR-SUPPRESSOR P53; FACTOR 1-ALPHA; FACTOR-I; PROLYL HYDROXYLATION; GENE-TRANSCRIPTION; MESSENGER-RNA; ACTIVATION; APOPTOSIS	Retrograde signaling is a mechanism by which mitochondrial dysfunction is communicated to the nucleus for inducing a metabolic shift essential for cell survival. Previously, we showed that partial mitochondrial DNA (mtDNA) depletion in different cell types induced mitochondrial retrograde signaling pathway (MtRS) involving Ca+2-sensitive Calcineurin (Cn) activation as an immediate upstream event of stress response. In multiple cell types, this stress signaling was shown to induce tumorigenic phenotypes in immortalized cells. In this study we show that MtRS also induces p53 expression, which was abrogated by Ca2+ chelators and short hairpin RNA-mediated knockdown of CnA beta mRNA. Mitochondrial dysfunction induced by mitochondrial ionophore, carbonyl cyanide m-chlorophenyl hydrazone and other respiratory inhibitors, which perturb the transmembrane potential, were equally efficient in inducing the expression of p53 and downregulation of MDM2. Stress-induced p53 physically interacted with hypoxiainducible factor-1 alpha (HIF-1 alpha) and attenuated the latter's binding to promoter DNA motifs. In addition, p53 promoted ubiquitination and degradation of HIF-1 alpha in partial mtDNA-depleted cells. The mtDNA depleted cells, with inhibited HIF-1 alpha, showed upregulation of glycolytic pathway genes, glucose transporter 1-4 (Glut1-4), phosphoglycerate kinase 1 and Glucokinase but not of prolyl hydroxylase isoforms. For the first time we show that p53 is induced as part of MtRS and it renders HIF-1 alpha inactive by physical interaction. In this respect, our results show that MtRS induces tumor growth independent of the HIF-1 alpha pathway.	[Chowdhury, A. Roy; Fuchs, S. Y.; Avadhani, N. G.] Univ Penn, Sch Vet Med, Dept Biomed Sci, 189E Old Vet Bldg, Philadelphia, PA 19104 USA; [Chowdhury, A. Roy; Fuchs, S. Y.; Avadhani, N. G.] Univ Penn, Sch Vet Med, Mari Lowe Ctr Comparat Oncol, 189E Old Vet Bldg, Philadelphia, PA 19104 USA; [Long, A.; Rustgi, A.] Univ Penn, Perelman Sch Med, Abramson Canc Ctr, Div Gastroenterol,Dept Med & Genet, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine	Avadhani, NG (corresponding author), Univ Penn, Sch Vet Med, Dept Biomed Sci, 189E Old Vet Bldg, Philadelphia, PA 19104 USA.; Avadhani, NG (corresponding author), Univ Penn, Sch Vet Med, Mari Lowe Ctr Comparat Oncol, 189E Old Vet Bldg, Philadelphia, PA 19104 USA.	narayan@vet.upenn.edu			NIH grant [CA-22762, AR-067066]; Harriet Ellison Woodward trust (NGA); NIH MSTP training grant AL; NATIONAL CANCER INSTITUTE [R01CA092900, R01CA022762, R37CA022762] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR067066] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK050306] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA022986] Funding Source: NIH RePORTER	NIH grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Harriet Ellison Woodward trust (NGA); NIH MSTP training grant AL; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))	We thank Drs Craig Thompson, Gregg Semenza and Bert Vogelstein for generously providing the promoter constructs and cell lines used in this study. This work was supported by NIH grant CA-22762, AR-067066 and an endowment from the Harriet Ellison Woodward trust (NGA) and NIH MSTP training grant AL. We also acknowledge the help of the Imaging Core facility at the School of Veterinary Medicine and the NIH/NIDDK Center for Molecular Studies in Digestive and Liver Diseases (P30DK050306) and its Cell collection core.	Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; Amuthan G, 2001, EMBO J, V20, P1910, DOI 10.1093/emboj/20.8.1910; An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Appelhoff RJ, 2004, J BIOL CHEM, V279, P38458, DOI 10.1074/jbc.M406026200; Arnuthan G, 2002, ONCOGENE, V21, P7839, DOI 10.1038/sj.onc.1205983; Barliya T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022849; Bell EL, 2007, J CELL BIOL, V177, P1029, DOI 10.1083/jcb.200609074; Bensaad K, 2007, TRENDS CELL BIOL, V17, P286, DOI 10.1016/j.tcb.2007.04.004; Berglind H, 2008, CANCER BIOL THER, V7, P699, DOI 10.4161/cbt.7.5.5712; Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; Biswas G, 1999, EMBO J, V18, P522, DOI 10.1093/emboj/18.3.522; Biswas G, 2003, J CELL BIOL, V161, P507, DOI 10.1083/jcb.200211104; Biswas G, 2005, CELL DEATH DIFFER, V12, P266, DOI 10.1038/sj.cdd.4401553; Blagosklonny MV, 1998, J BIOL CHEM, V273, P11995, DOI 10.1074/jbc.273.20.11995; Boland ML, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00292; Brar SS, 2012, AM J PHYSIOL-LUNG C, V303, pL413, DOI 10.1152/ajplung.00343.2011; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Butow RA, 2004, MOL CELL, V14, P1, DOI 10.1016/S1097-2765(04)00179-0; Camenisch Gieri, 2002, Methods Mol Biol, V196, P117; Cao YT, 2005, CANCER RES, V65, P5498, DOI 10.1158/0008-5472.CAN-04-4553; Chae S, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003266; Chatterjee A, 2006, ONCOGENE, V25, P4663, DOI 10.1038/sj.onc.1209604; Chen CH, 2001, J BIOL CHEM, V276, P9519, DOI 10.1074/jbc.M010144200; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Dang DT, 2006, CANCER RES, V66, P1684, DOI 10.1158/0008-5472.CAN-05-2887; Dhanasekaran A, 2005, FREE RADICAL BIO MED, V39, P567, DOI 10.1016/j.freeradbiomed.2005.04.016; Formentini L, 2012, MOL CELL, V45, P731, DOI 10.1016/j.molcel.2012.01.008; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Green DR, 2009, NATURE, V458, P1127, DOI 10.1038/nature07986; Gu J, 2001, J BIOL CHEM, V276, P3550, DOI 10.1074/jbc.M009522200; Guha M, 2014, ONCOGENE, V33, P5238, DOI 10.1038/onc.2013.467; Guha M, 2007, J BIOL CHEM, V282, P14536, DOI 10.1074/jbc.M611693200; Guha M, 2013, MITOCHONDRION, V13, P577, DOI 10.1016/j.mito.2013.08.007; Hamanaka RB, 2010, TRENDS BIOCHEM SCI, V35, P505, DOI 10.1016/j.tibs.2010.04.002; Haynes CM, 2010, MOL CELL, V37, P529, DOI 10.1016/j.molcel.2010.01.015; Hon WC, 2002, NATURE, V417, P975, DOI 10.1038/nature00767; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Iommarini L, 2014, HUM MOL GENET, V23, P1453, DOI 10.1093/hmg/ddt533; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jiang P, 2011, NAT CELL BIOL, V13, P310, DOI 10.1038/ncb2172; Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027; King M P, 1996, Methods Enzymol, V264, P304, DOI 10.1016/S0076-6879(96)64029-4; Kojima K, 2011, BLOOD, V118, P4431, DOI 10.1182/blood-2011-02-334136; Liu G, 2006, J CELL BIOCHEM, V97, P448, DOI 10.1002/jcb.20700; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Matoba S, 2006, SCIENCE, V312, P1650, DOI 10.1126/science.1126863; Menendez D, 2007, MOL CELL BIOL, V27, P2590, DOI 10.1128/MCB.01742-06; Minet E, 1999, BIOCHEM BIOPH RES CO, V261, P534, DOI 10.1006/bbrc.1999.0995; Moll UM, 2006, ONCOGENE, V25, P4725, DOI 10.1038/sj.onc.1209601; Obacz J, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-93; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Puzio-Kuter Anna M, 2011, Genes Cancer, V2, P385, DOI 10.1177/1947601911409738; Ravi R, 2000, GENE DEV, V14, P34; Roger L, 2010, J CELL SCI, V123, P1295, DOI 10.1242/jcs.061002; Sermeus A, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.48; Sun Y, 1999, MOL CARCINOGEN, V24, P25, DOI 10.1002/(SICI)1098-2744(199901)24:1<25::AID-MC4>3.3.CO;2-J; Tang WG, 2012, CARCINOGENESIS, V33, P1762, DOI 10.1093/carcin/bgs190; Wallace DC, 2005, COLD SH Q B, V70, P363, DOI 10.1101/sqb.2005.70.035; Wallace DC, 2013, J CLIN INVEST, V123, P1405, DOI 10.1172/JCI61398; Wallace DC, 2012, NAT REV CANCER, V12, P685, DOI 10.1038/nrc3365; Wang G L, 1996, Curr Opin Hematol, V3, P156; Wanka C, 2012, ONCOGENE, V31, P3764, DOI 10.1038/onc.2011.530; Xu HB, 2006, BIOCHEM BIOPH RES CO, V341, P938, DOI 10.1016/j.bbrc.2005.12.227	64	17	18	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 19	2017	36	3					397	409		10.1038/onc.2016.211	http://dx.doi.org/10.1038/onc.2016.211			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IB	27345397	Green Accepted			2022-12-17	WOS:000394166000009
J	Rohrig, F; Vorlova, S; Hoffmann, H; Wartenberg, M; Escorcia, FE; Keller, S; Tenspoldel, M; Weigand, I; Gatzner, S; Manova, K; Penack, O; Scheinberg, DA; Rosenwald, A; Ergun, S; Granot, Z; Henke, E				Roehrig, F.; Vorlova, S.; Hoffmann, H.; Wartenberg, M.; Escorcia, F. E.; Keller, S.; Tenspoldel, M.; Weigand, I.; Gaetzner, S.; Manova, K.; Penack, O.; Scheinberg, D. A.; Rosenwald, A.; Erguen, S.; Granot, Z.; Henke, E.			VEGF-ablation therapy reduces drug delivery and therapeutic response in ECM-dense tumors	ONCOGENE			English	Article							FACTOR RECEPTOR-2 BLOCKADE; LYSYL OXIDASE; GROWTH-FACTOR; ANTITUMOR-ACTIVITY; VASCULAR NORMALIZATION; BLOOD-VESSELS; IN-VIVO; BEVACIZUMAB; IMPROVES; BIODISTRIBUTION	The inadequate transport of drugs into the tumor tissue caused by its abnormal vasculature is a major obstacle to the treatment of cancer. Anti-vascular endothelial growth factor (anti-VEGF) drugs can cause phenotypic alteration and maturation of the tumor's vasculature. However, whether this consistently improves delivery and subsequent response to therapy is still controversial. Clinical results indicate that not all patients benefit from antiangiogenic treatment, necessitating the development of criteria to predict the effect of these agents in individual tumors. We demonstrate that, in anti-VEGF-refractory murine tumors, vascular changes after VEGF ablation result in reduced delivery leading to therapeutic failure. In these tumors, the impaired response after anti-VEGF treatment is directly linked to strong deposition of fibrillar extracellular matrix (ECM) components and high expression of lysyl oxidases. The resulting condensed, highly crosslinked ECM impeded drug permeation, protecting tumor cells from exposure to small-molecule drugs. The reduced vascular density after anti-VEGF treatment further decreased delivery in these tumors, an effect not compensated by the improved vessel quality. Pharmacological inhibition of lysyl oxidases improved drug delivery in various tumor models and reversed the negative effect of VEGF ablation on drug delivery and therapeutic response in anti-VEGF-resistant tumors. In conclusion, the vascular changes after anti-VEGF therapy can have a context-dependent negative impact on overall therapeutic efficacy. A determining factor is the tumor ECM, which strongly influences the effect of anti-VEGF therapy. Our results reveal the prospect to revert a possible negative effect and to potentiate responsiveness to antiangiogenic therapy by concomitantly targeting ECM-modifying enzymes.	[Roehrig, F.; Hoffmann, H.; Keller, S.; Tenspoldel, M.; Weigand, I.; Erguen, S.; Henke, E.] Univ Wurzburg, Inst Anat & Cell Biol, Koellikerstr 6, D-97070 Wurzburg, Germany; [Roehrig, F.; Vorlova, S.; Hoffmann, H.; Gaetzner, S.; Henke, E.] Univ Klinikum Wurzburg, Inst Expt Biomed, Wurzburg, Germany; [Roehrig, F.; Hoffmann, H.; Henke, E.] Univ Wurzburg, Grad Sch Life Sci, Wurzburg, Germany; [Wartenberg, M.; Rosenwald, A.] Univ Wurzburg, Inst Pathol, Wurzburg, Germany; [Wartenberg, M.; Rosenwald, A.] CCCMF, Wurzburg, Germany; [Escorcia, F. E.; Scheinberg, D. A.] Mem Sloan Kettering Canc Ctr, Mol Pharmacol & Chem Program, 1275 York Ave, New York, NY 10021 USA; [Manova, K.] Mem Sloan Kettering Canc Ctr, Mol Cytol Core Facil, 1275 York Ave, New York, NY 10021 USA; [Penack, O.] Univ Klinikum Charite, Med Klin Schwerpunkt Hamatol Onkol & Tumorimmunol, Berlin, Germany; [Granot, Z.] Inst Med Res Israel Canada, Dept Dev Biol & Canc Res, Jerusalem, Israel; [Granot, Z.] Hebrew Univ Jerusalem, Hadassah Med Sch, Jerusalem, Israel	University of Wurzburg; University of Wurzburg; University of Wurzburg; University of Wurzburg; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Hebrew University of Jerusalem	Henke, E (corresponding author), Univ Wurzburg, Inst Anat & Cell Biol, Koellikerstr 6, D-97070 Wurzburg, Germany.	erik.henke@uni-wuerzburg.de	Escorcia, Freddy E/GVS-4521-2022; Henke, Erik/AAG-7053-2020; Penack, Olaf/L-1068-2016	Henke, Erik/0000-0003-2380-2682; Escorcia, Freddy E/0000-0002-0727-3242; Rohrig, Florian/0000-0002-6879-7883; Wartenberg, Martin/0000-0002-5378-3825; Penack, Olaf/0000-0003-4876-802X	Deutsche Forschungsgemeinschaft (DFG) [HE3565/1-1, HE3565/2-1, HE3565/3-1]	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG))	We thank Robert Benezra (Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center) for helpful discussion; Thomas Jarchau (Institute for clinical Biochemistry and Pathobiochemistry, Univeritatsklinikum Wurzburg) for a thorough correction of the manuscript; and Afshar Barlas, Mesruh Turkekul (Molecular Cytology Core facility, Memorial Sloan-Kettering Cancer Center) and Oliver Reinhardt (Biology Master Course, Universitat Wurzburg) for help with experiments. Funding was provided by the Deutsche Forschungsgemeinschaft (DFG Grant Nos. HE3565/1-1, HE3565/2-1 and HE3565/3-1 to EH).	Arjaans M, 2013, CANCER RES, V73, P3347, DOI 10.1158/0008-5472.CAN-12-3518; Baker AM, 2013, CANCER RES, V73, P583, DOI 10.1158/0008-5472.CAN-12-2447; Barry-Hamilton V, 2010, NAT MED, V16, P1009, DOI 10.1038/nm.2208; Bondareva A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005620; Cesca M, 2009, NEOPLASIA, V11, P1155, DOI 10.1593/neo.09866; Chung AS, 2013, NAT MED, V19, P1114, DOI 10.1038/nm.3291; Constantinidou A, 2013, EXPERT REV ANTICANC, V13, P211, DOI [10.1586/ERA.12.161, 10.1586/era.12.161]; Diop-Frimpong B, 2011, P NATL ACAD SCI USA, V108, P2909, DOI 10.1073/pnas.1018892108; Du R, 2008, CANCER CELL, V13, P206, DOI 10.1016/j.ccr.2008.01.034; DUNN JF, 1995, MAGN RESON MED, V34, P515, DOI 10.1002/mrm.1910340405; Eisinger-Mathason TSK, 2013, CANCER DISCOV, V3, P1190, DOI 10.1158/2159-8290.CD-13-0118; Erler JT, 2006, CANCER RES, V66, P10238, DOI 10.1158/0008-5472.CAN-06-3197; Erler JT, 2006, NATURE, V440, P1222, DOI 10.1038/nature04695; Escorcia FE, 2010, CANCER RES, V70, P9277, DOI 10.1158/0008-5472.CAN-10-2029; Feres EJ, 1995, J BIOL CHEM, V270, P30797, DOI 10.1074/jbc.270.51.30797; Fogelgren B, 2005, J BIOL CHEM, V280, P24690, DOI 10.1074/jbc.M412979200; Gangloff A, 2005, J NUCL MED, V46, P1866; Hansen-Algenstaedt N, 2000, CANCER RES, V60, P4556; Heskamp S, 2013, INT J CANCER, V133, P307, DOI 10.1002/ijc.28046; Hobbs SK, 1998, P NATL ACAD SCI USA, V95, P4607, DOI 10.1073/pnas.95.8.4607; Jacobetz MA, 2013, GUT, V62, P112, DOI 10.1136/gutjnl-2012-302529; Jain RK, 2014, CANCER CELL, V26, P605, DOI 10.1016/j.ccell.2014.10.006; Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819; Kato Y, 2006, MAGN RESON MED, V55, P755, DOI 10.1002/mrm.20831; Kesner AL, 2007, J NUCL MED, V48, P2021, DOI 10.2967/jnumed.107.045716; Kim S, 2012, MOL VIS, V18, P265; Kratz F., 2011, DRUG DELIVERY ONCOLO, V1, pLIX; Krishnamachary B, 2003, CANCER RES, V63, P1138; Liang WC, 2006, J BIOL CHEM, V281, P951, DOI 10.1074/jbc.M508199200; Lin KY, 2008, TRANSL ONCOL, V1, P84, DOI 10.1593/tlo.08118; Liu JQ, 2012, P NATL ACAD SCI USA, V109, P16618, DOI 10.1073/pnas.1117610109; Lorenzo E, 2002, J BIOL CHEM, V277, P10883, DOI 10.1074/jbc.M107442200; McKee TD, 2006, CANCER RES, V66, P2509, DOI 10.1158/0008-5472.CAN-05-2242; Memon AA, 2009, CANCER RES, V69, P873, DOI 10.1158/0008-5472.CAN-08-3118; Mendenhall WM, 2009, AM J CLIN ONCOL-CANC, V32, P436, DOI 10.1097/COC.0b013e318173a54f; Minko T, 2000, PHARMACEUT RES, V17, P505, DOI 10.1023/A:1007500412442; Phillips PG, 2011, ANTICANCER RES, V31, P411; Primeau AJ, 2005, CLIN CANCER RES, V11, P8782, DOI 10.1158/1078-0432.CCR-05-1664; Provenzano PP, 2012, CANCER CELL, V21, P418, DOI 10.1016/j.ccr.2012.01.007; Rapisarda A, 2009, MOL CANCER THER, V8, P1867, DOI 10.1158/1535-7163.MCT-09-0274; Rodriguez HM, 2010, J BIOL CHEM, V285, P20964, DOI 10.1074/jbc.M109.094136; Sandhu JK, 2000, J NATL CANCER I, V92, P1429, DOI 10.1093/jnci/92.17.1429; Singh M, 2010, NAT BIOTECHNOL, V28, P585, DOI 10.1038/nbt.1640; Staffhorst RWHM, 2008, ANTI-CANCER DRUG, V19, P721, DOI 10.1097/CAD.0b013e328304355f; Stylianopoulos T, 2013, P NATL ACAD SCI USA, V110, P18632, DOI 10.1073/pnas.1318415110; TEICHER BA, 1990, SCIENCE, V247, P1457, DOI 10.1126/science.2108497; Tong RT, 2004, CANCER RES, V64, P3731, DOI 10.1158/0008-5472.CAN-04-0074; Turley RS, 2012, CLIN CANCER RES, V18, P3328, DOI 10.1158/1078-0432.CCR-11-3000; Van der Veldt AAM, 2012, CANCER CELL, V21, P82, DOI 10.1016/j.ccr.2011.11.023; Wilgus ML, 2011, CANCER-AM CANCER SOC, V117, P2186, DOI 10.1002/cncr.25768; Willett CG, 2004, NAT MED, V10, P145, DOI 10.1038/nm988; WILMARTH KR, 1992, J TOXICOL ENV HEALTH, V37, P411, DOI 10.1080/15287399209531680; Winkler F, 2004, CANCER CELL, V6, P553, DOI 10.1016/S1535-6108(04)00305-8; Wong CCL, 2011, P NATL ACAD SCI USA, V108, P16369, DOI 10.1073/pnas.1113483108; Xie J, 2012, INT ORTHOP, V36, P207, DOI 10.1007/s00264-011-1261-3	55	17	20	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	2017	36	1					1	12		10.1038/onc.2016.182	http://dx.doi.org/10.1038/onc.2016.182			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK6XJ	27270432	Green Published, hybrid			2022-12-17	WOS:000394069100001
J	Chen, CH; Chang, WH; Su, KY; Ku, WH; Chang, GC; Hong, QS; Hsiao, YJ; Chen, HC; Chen, HY; Wu, R; Yang, PC; Chen, JJW; Yu, SL				Chen, C-H; Chang, W-H; Su, K-Y; Ku, W-H; Chang, G-C; Hong, Q-S; Hsiao, Y-J; Chen, H-C; Chen, H-Y; Wu, R.; Yang, P-C; Chen, J. J. W.; Yu, S-L			HLJ1 is an endogenous Src inhibitor suppressing cancer progression through dual mechanisms	ONCOGENE			English	Article							CELL LUNG-CANCER; FAMILY KINASES; G-PROTEINS; PHASE-II; C-SRC; TYROSINE PHOSPHORYLATION; ACTIN CYTOSKELETON; TARGETING SRC; BETA-CATENIN; SH2 DOMAIN	HLJ1 (DNAJB4), a DNAJ/Hsp40 chaperone, has emerged as a novel prognostic marker in lung cancers; however, the molecular contribution and functionality in neoplastic diseases remain to be established. This study demonstrated that HLJ1 inhibits epithelial-mesenchymal transition in vitro and reduces lung cancer metastasis in vivo. Using shRNA silencing and ectopic expression of HLJ1, we found that HLJ1 not only suppresses catalytic activity of Src but also downregulates the formation of oncogenic complexes associated with the EGFR, FAK and STAT3 signaling pathways. A screen of specimens from HLJ1-knockout mice and lung cancer patients validated that HLJ1 expression is inversely correlated with Src activity. Mechanistically, HLJ1 protein directly bound to catalytic and protein-binding domains of Src through its amino acid Y172 and the P301/P304 motif. Following Src-induced HLJ1 phosphorylation at Y172, HLJ1-Src interaction was elevated, resulting in Src inhibition and malignancy suppression. Interestingly, both Src-binding regions also occurred in other DNAJB family members and contributed to anti-invasive activities of DNAJB proteins. We conclude that HLJ1 is an endogenous Src inhibitor that can suppress cancer metastasis through complex interacting mechanisms. This HLJ1-Src complex might provide a promising molecular model for developing new anticancer strategies.	[Chen, C-H; Wu, R.] Univ Calif Davis, Dept Internal Med, Davis, CA 95616 USA; [Chen, C-H; Wu, R.] Univ Calif Davis, Ctr Comparat Resp Biol & Med, Davis, CA 95616 USA; [Chen, C-H] Univ Calif Davis, Dept Internal Med, Div Nephrol, Davis, CA 95616 USA; [Chang, W-H; Yang, P-C] Natl Taiwan Univ, Coll Med, Inst Mol Med, Taipei, Taiwan; [Su, K-Y; Hong, Q-S; Hsiao, Y-J; Yu, S-L] Natl Taiwan Univ, Coll Med, Dept Clin Lab Sci & Med Biotechnol, Taipei 100, Taiwan; [Su, K-Y; Yu, S-L] Natl Taiwan Univ Hosp, Dept Lab Med, Taipei, Taiwan; [Ku, W-H] Taipei Inst Pathol, Taipei, Taiwan; [Chang, G-C] Taichung Vet Gen Hosp, Div Chest Med, Taichung, Taiwan; [Chen, H-C] Natl Chung Hsing Univ, Dept Life Sci, Taichung, Taiwan; [Chen, H-Y] Acad Sinica, Inst Stat Sci, Taipei, Taiwan; [Yang, P-C] Natl Taiwan Univ, Coll Med, Dept Internal Med, Taipei, Taiwan; [Chen, J. J. W.] Natl Chung Hsing Univ, Inst Biomed Sci, Taichung, Taiwan; [Chen, J. J. W.] Natl Chung Hsing Univ, Agr Biotechnol Ctr, Taichung, Taiwan; [Yu, S-L] Natl Taiwan Univ, Coll Med, Dept Pathol, Taipei, Taiwan; [Yu, S-L] Natl Taiwan Univ, Coll Med, Grad Inst Pathol, Taipei, Taiwan; [Yu, S-L] Natl Taiwan Univ, Coll Med, Ctr Optoclect Biomed, Taipei, Taiwan	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis; National Taiwan University; National Taiwan University; National Taiwan University; National Taiwan University Hospital; Taichung Veterans General Hospital; National Chung Hsing University; Academia Sinica - Taiwan; National Taiwan University; National Chung Hsing University; National Chung Hsing University; National Taiwan University; National Taiwan University; National Taiwan University	Yu, SL (corresponding author), Natl Taiwan Univ, Coll Med, Dept Clin Lab Sci & Med Biotechnol, Taipei 100, Taiwan.; Chen, JJW (corresponding author), Natl Chung Hsing Univ, Inst Biomed Sci, Taichung, Taiwan.	jwchen@dragon.nchu.cdu.tw; slyu@ntu.edu.tw	SU, KANG-YI/GNM-5753-2022; Chen, Hsuan-Yu/AAE-8428-2019	SU, KANG-YI/0000-0002-6538-9526; YU, SUNG-LIANG/0000-0003-4535-9036; Hsiao, Yi-Jing/0000-0001-8780-8800; Chang, Wen-Hsin/0000-0002-8027-302X; Chen, Jeremy J.W./0000-0003-1049-3825	Ministry of Science and Technology, Taiwan, ROC [NSC 98-2314-B-005-001-MY3, NSC 102-2911-I-002-303, NSC 103-2911-I-002-303]; National Taiwan University [102R7557, 103R7557]; Tobacco-Related Disease Research Program (TRDRP) [23FT-0104]; Ministry of Education, Taiwan, ROC	Ministry of Science and Technology, Taiwan, ROC(Ministry of Science and Technology, Taiwan); National Taiwan University(National Taiwan University); Tobacco-Related Disease Research Program (TRDRP)(University of California System); Ministry of Education, Taiwan, ROC(Ministry of Education, Taiwan)	We thank Dr Po-Chao Chan (Department of Life Science, National Chung Hsing University, Taichung, Taiwan) and Dr Samuel Chung (Department of Internal Medicine, University of California Davis, Davis, CA, USA) for useful discussion; Dr Yung-Hao Wong (Institute of Biomedical Sciences, National Chung Hsing University, Taichung, Taiwan) for the advice regarding protein docking; Dr Yu-Ching Lin (UNIMED Healthcare Inc., Taiwan) and the Center for Innovative Therapeutics Discovery of National Taiwan University for technological support in ForteBio system; and the Integrated Core Facility for Functional Genomics of the National Core Facility Program for Biotechnology (NCFPB) for technological support. This work was supported by grants from the Ministry of Science and Technology, Taiwan, ROC (NSC 98-2314-B-005-001-MY3, NSC 102-2911-I-002-303 and NSC 103-2911-I-002-303) and National Taiwan University (102R7557 and 103R7557), as well as in part by the Tobacco-Related Disease Research Program (TRDRP; 23FT-0104 to C-H Chen) and by the Ministry of Education, Taiwan, ROC under the ATU plan.	Ahn BY, 2010, ONCOGENE, V29, P1155, DOI 10.1038/onc.2009.413; Armaiz-Pena GN, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2413; BIBBINS KB, 1993, MOL CELL BIOL, V13, P7278, DOI 10.1128/MCB.13.12.7278; Boggon TJ, 2004, ONCOGENE, V23, P7918, DOI 10.1038/sj.onc.1208081; Bolos V, 2010, ONCOTARGETS THER, V3, P83; Brunner AM, 2013, J THORAC ONCOL, V8, P1434, DOI 10.1097/JTO.0b013e3182a47162; Chang BY, 1998, MOL CELL BIOL, V18, P3245, DOI 10.1128/MCB.18.6.3245; Chang TP, 2010, CANCER RES, V70, P1656, DOI 10.1158/0008-5472.CAN-09-2453; Chee CE, 2013, ONCOLOGIST, V18, P1091, DOI 10.1634/theoncologist.2013-0255; Chen CY, 2013, CANCER RES, V73, P4009, DOI 10.1158/0008-5472.CAN-12-4066; Chen CH, 2014, AM J RESP CRIT CARE, V190, P1127, DOI 10.1164/rccm.201408-1505OC; Chen CH, 2010, EXP CELL RES, V316, P2910, DOI 10.1016/j.yexcr.2010.06.027; Chen JJW, 2001, CANCER RES, V61, P5223; DeSantis CE, 2014, CA-CANCER J CLIN, V64, P252, DOI 10.3322/caac.21235; ERPEL T, 1995, EMBO J, V14, P963, DOI 10.1002/j.1460-2075.1995.tb07077.x; Fincham VJ, 1996, J CELL BIOL, V135, P1551, DOI 10.1083/jcb.135.6.1551; Frame MC, 2004, J CELL SCI, V117, P989, DOI 10.1242/jcs.01111; Frame MC, 2002, BBA-REV CANCER, V1602, P114, DOI 10.1016/S0304-419X(02)00040-9; Gonfloni S, 1999, NAT STRUCT BIOL, V6, P760; Guarino M, 2010, J CELL PHYSIOL, V223, P14, DOI 10.1002/jcp.22011; Ishizawar R, 2004, CANCER CELL, V6, P209, DOI 10.1016/j.ccr.2004.09.001; Johnson FM, 2010, J CLIN ONCOL, V28, P4609, DOI 10.1200/JCO.2010.30.5474; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Kim LC, 2009, NAT REV CLIN ONCOL, V6, P587, DOI 10.1038/nrclinonc.2009.129; Kraskouskaya D, 2013, CHEM SOC REV, V42, P3337, DOI 10.1039/c3cs35449k; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Liu Y, 2014, INT J CLIN EXP PATHO, V7, P969; Masaki T, 2003, EUR J CANCER, V39, P1447, DOI 10.1016/S0959-8049(03)00276-4; Mitra A, 2012, ONCOGENE, V31, P4472, DOI 10.1038/onc.2011.623; Mitra A, 2010, J BIOL CHEM, V285, P24686, DOI 10.1074/jbc.M109.094847; Mitra A, 2009, CLIN EXP METASTAS, V26, P559, DOI 10.1007/s10585-009-9255-x; Oneyama C, 2008, MOL CELL, V30, P426, DOI 10.1016/j.molcel.2008.03.026; Pawson T, 2004, CELL, V116, P191, DOI 10.1016/S0092-8674(03)01077-8; Rahmani Z, 2006, J CELL SCI, V119, P646, DOI 10.1242/jcs.02778; Rothschild SI, 2010, CLIN LUNG CANCER, V11, P238, DOI 10.3816/CLC.2010.n.030; Rush J, 2005, NAT BIOTECHNOL, V23, P94, DOI 10.1038/nbt1046; Saibil H, 2013, NAT REV MOL CELL BIO, V14, P630, DOI 10.1038/nrm3658; Seibel NM, 2007, ANAL BIOCHEM, V368, P95, DOI 10.1016/j.ab.2007.05.025; Sterrenberg JN, 2011, CANCER LETT, V312, P129, DOI 10.1016/j.canlet.2011.08.019; Tsai MF, 2006, JNCI-J NATL CANCER I, V98, P825, DOI 10.1093/jnci/djj229; Wang CC, 2005, ONCOGENE, V24, P4081, DOI 10.1038/sj.onc.1208573; Zhang J, 2007, AM J PATHOL, V170, P366, DOI 10.2353/ajpath.2007.060706; Zhang SY, 2012, TRENDS PHARMACOL SCI, V33, P122, DOI 10.1016/j.tips.2011.11.002; Zhang SY, 2011, NAT MED, V17, P461, DOI 10.1038/nm.2309; Zhang XHF, 2009, CANCER CELL, V16, P67, DOI 10.1016/j.ccr.2009.05.017; Zhou J, 2003, J BIOL CHEM, V278, P6936, DOI 10.1074/jbc.M210628200	46	17	17	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 27	2016	35	43					5674	5685		10.1038/onc.2016.106	http://dx.doi.org/10.1038/onc.2016.106			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA9XP	27065329				2022-12-17	WOS:000386998300010
J	Zhang, W; Hong, S; Maniar, KP; Cheng, S; Jie, C; Rademaker, AW; Krensky, AM; Clayberger, C				Zhang, W.; Hong, S.; Maniar, K. P.; Cheng, S.; Jie, C.; Rademaker, A. W.; Krensky, A. M.; Clayberger, C.			KLF13 regulates the differentiation-dependent human papillomavirus life cycle in keratinocytes through STAT5 and IL-8	ONCOGENE			English	Article							KRUPPEL-LIKE FACTORS; TUMOR-SUPPRESSOR; CLINICAL-IMPLICATIONS; CHEMOKINE RANTES; CERVICAL-CANCER; INTERLEUKIN-8; EXPRESSION; ANGIOGENESIS; GROWTH; TRANSFORMATION	High-risk strains of human papillomavirus (HPV) are the causative agents of cervical and anogenital cancers and are associated with 5% of all human cancers. Although prophylactic vaccines targeting a subset of HPV types are available, they are ineffective in HPV-infected individuals. Elucidation of the mechanisms controlling HPV replication may allow development of novel anti-HPV therapeutics. Infectious HPV virions are produced during terminal differentiation of host cells. The process of viral maturation requires synergistic interactions between viral and cellular proteins that leads to amplification of the viral genome and expression of late viral genes. Here we show that the transcription factor Kruppel-like factor 13 (KLF13) has a critical role in the HPV life cycle. KLF13 is overexpressed in HPV-positive keratinocytes and cervical cancer cell lines. Expression of KLF13 in normal cervical epithelium is low but increases significantly in cervical intraepithelial neoplasia and invasive squamous cervical cancer. After HPV infection, the E7 protein suppresses ubiquitin ligase FBW7 expression leading to an increase in KLF13 expression. Reduction of KLF13 with short hairpin RNA in differentiating HPV-positive cells resulted in diminished levels of viral gene expression and genome amplification. Knockdown of KLF13 also reduced the level of the transcription factor signal transducer and activator of transcription 5, which led to the downregulation of the ataxia-telangiectasia mutated DNA damage pathway and the chemokine interleukin-8 (IL-8). In addition, neutralization of IL-8 diminished viral genome amplification in differentiating HPV-positive cells. Thus, KLF13 is critical for the activation of the HPV productive life cycle and is likely involved in initiation and progression of cervical cancer.	[Zhang, W.; Hong, S.; Cheng, S.; Krensky, A. M.; Clayberger, C.] Northwestern Univ, Feinberg Sch Med, Dept Microbiol Immunol, 300 East Super St, Chicago, IL 60611 USA; [Maniar, K. P.] Northwestern Univ, Dept Pathol, Feinberg Sch Med, Chicago, IL 60611 USA; [Jie, C.] Des Moines Univ, Dept Res Biostat, Des Moines, IA USA; [Rademaker, A. W.] Northwestern Univ, Dept Prevent Med, Feinberg Sch Med, Chicago, IL 60611 USA; [Rademaker, A. W.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Feinberg Sch Med, Chicago, IL 60611 USA; [Krensky, A. M.] Northwestern Univ, Dept Pediat, Feinberg Sch Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center; Northwestern University; Feinberg School of Medicine	Clayberger, C (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Microbiol Immunol, 300 East Super St, Chicago, IL 60611 USA.	Clayberger@northwestern.edu	zhang, wei/A-7015-2011		H Foundation Cancer Research Fund; Robert H Lurie Comprehensive Cancer Center	H Foundation Cancer Research Fund; Robert H Lurie Comprehensive Cancer Center	This work was supported in part by the H Foundation Cancer Research Fund and Robert H Lurie Comprehensive Cancer Center (to W Zhang). We thank Dr Laimonis A Laimins for helpful discussions.	Ahn YT, 2007, MOL CELL BIOL, V27, P253, DOI 10.1128/MCB.01071-06; Ai WD, 2000, J VIROL, V74, P5198, DOI 10.1128/JVI.74.11.5198-5205.2000; Aldinucci D, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/292376; ANTTILA HSI, 1992, CLIN EXP IMMUNOL, V89, P509; Apt D, 1996, VIROLOGY, V224, P281, DOI 10.1006/viro.1996.0530; Arbyn M, 2011, ANN ONCOL, V22, P2675, DOI 10.1093/annonc/mdr015; Britschgi A, 2012, CANCER CELL, V22, P419; Cao ZX, 2010, BLOOD, V116, P4404, DOI 10.1182/blood-2010-05-285353; Chen JJW, 2003, CLIN CANCER RES, V9, P729; De Larco JE, 2004, CLIN CANCER RES, V10, P4895, DOI 10.1158/1078-0432.CCR-03-0760; Desaintes C, 1996, SEMIN CANCER BIOL, V7, P339, DOI 10.1006/scbi.1996.0043; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Fehrmann Frauke, 2005, Methods Mol Biol, V292, P317; Forte E, 2015, J VIROL, V89, P2333, DOI 10.1128/JVI.03317-14; Fujimoto J, 2000, CANCER RES, V60, P2632; Grone A, 2002, VET IMMUNOL IMMUNOP, V88, P1, DOI 10.1016/S0165-2427(02)00136-8; Harper DM, 2006, LANCET, V367, P1247, DOI 10.1016/S0140-6736(06)68439-0; Harry BL, 2012, EXPERT OPIN INV DRUG, V21, P637, DOI 10.1517/13543784.2012.677432; Henson B J, 2010, Cytogenet Genome Res, V128, P192, DOI 10.1159/000308303; Hong SM, 2013, J NANOMATER, V2013, DOI [10.1155/2013/246328, 10.1155/2013/790323]; Hong SY, 2013, FUTURE MICROBIOL, V8, P1547, DOI 10.2217/fmb.13.127; Kajitani N, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00152; Kim DS, 2012, BLOOD, V120, P1658, DOI 10.1182/blood-2012-03-415968; Liao W, 2008, NAT IMMUNOL, V9, P1288, DOI 10.1038/ni.1656; Limame R, 2014, ONCOTARGET, V5, P29, DOI 10.18632/oncotarget.1456; Marrero-Rodriguez D, 2014, TUMOR BIOL, V35, P11399, DOI 10.1007/s13277-014-2380-4; Masuya D, 2001, CANCER, V92, P2628, DOI 10.1002/1097-0142(20011115)92:10<2628::AID-CNCR1616>3.0.CO;2-F; McConnell BB, 2010, PHYSIOL REV, V90, P1337, DOI 10.1152/physrev.00058.2009; MEYERS C, 1992, SCIENCE, V257, P971, DOI 10.1126/science.1323879; Moody CA, 2010, NAT REV CANCER, V10, P550, DOI 10.1038/nrc2886; Moody CA, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000605; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; Nelson EA, 2011, BLOOD, V117, P3421, DOI 10.1182/blood-2009-11-255232; Ojesina AI, 2014, NATURE, V506, P371, DOI 10.1038/nature12881; Ooi AGL, 2010, P NATL ACAD SCI USA, V107, P21505, DOI 10.1073/pnas.1016218107; Parkin DM, 2006, VACCINE, V24, P11, DOI 10.1016/j.vaccine.2006.05.111; Sakakibara N, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003321; Simard JC, 2014, FEBS LETT, V588, P2141, DOI 10.1016/j.febslet.2014.04.027; Steenbergen RDM, 2014, NAT REV CANCER, V14, P395, DOI 10.1038/nrc3728; Thierry F, 2009, VIROLOGY, V384, P375, DOI 10.1016/j.virol.2008.11.014; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; Walker J, 2011, VIROLOGY, V410, P283, DOI 10.1016/j.virol.2010.11.010; Waugh DJJ, 2008, CLIN CANCER RES, V14, P6735, DOI 10.1158/1078-0432.CCR-07-4843; Welcker M, 2008, NAT REV CANCER, V8, P83, DOI 10.1038/nrc2290; Wu SH, 2013, MOL CELL BIOCHEM, V375, P69, DOI 10.1007/s11010-012-1529-y; Xie KP, 2001, CYTOKINE GROWTH F R, V12, P375, DOI 10.1016/S1359-6101(01)00016-8; Zhang W, 2010, ONCOGENE, V29, P2467, DOI 10.1038/onc.2010.12; Zhao X, 2010, ARTHRITIS RHEUM-US, V62, P3425, DOI 10.1002/art.27632	48	17	20	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2016	35	42					5565	5575		10.1038/onc.2016.97	http://dx.doi.org/10.1038/onc.2016.97			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA9XO	27041562				2022-12-17	WOS:000386998200010
J	Alesi, GN; Jin, L; Li, D; Magliocca, K; Kang, Y; Chen, ZG; Shin, DM; Khuri, FR; Kang, S				Alesi, G. N.; Jin, L.; Li, D.; Magliocca, K. R.; Kang, Y.; Chen, Z. G.; Shin, D. M.; Khuri, F. R.; Kang, S.			RSK2 signals through stathmin to promote microtubule dynamics and tumor metastasis	ONCOGENE			English	Article							CANCER METASTASIS; MAP KINASE; TYROSINE PHOSPHORYLATION; PROTEOMIC ANALYSIS; POTENTIAL TARGET; CELL-MIGRATION; PROTEIN; IDENTIFICATION; PATHWAY; EXPRESSION	Metastasis is responsible for 490% of cancer-related deaths. Complex signaling in cancer cells orchestrates the progression from a primary to a metastatic cancer. However, the mechanisms of these cellular changes remain elusive. We previously demonstrated that p90 ribosomal S6 kinase 2 (RSK2) promotes tumor metastasis. Here we investigated the role of RSK2 in the regulation of microtubule dynamics and its potential implication in cancer cell invasion and tumor metastasis. Stable knockdown of RSK2 disrupted microtubule stability and decreased phosphorylation of stathmin, a microtubule-destabilizing protein, at serine 16 in metastatic human cancer cells. We found that RSK2 directly binds and phosphorylates stathmin at the leading edge of cancer cells. Phosphorylation of stathmin by RSK2 reduced stathmin-mediated microtubule depolymerization. Moreover, overexpression of phospho-mimetic mutant stathmin S16D significantly rescued the decreased invasive and metastatic potential mediated by RSK2 knockdown in vitro and in vivo. Furthermore, stathmin phosphorylation positively correlated with RSK2 expression and metastatic cancer progression in primary patient tumor samples. Our finding demonstrates that RSK2 directly phosphorylates stathmin and regulates microtubule polymerization to provide a pro-invasive and pro-metastatic advantage to cancer cells. Therefore, the RSK2-stathmin pathway represents a promising therapeutic target and a prognostic marker for metastatic human cancers.	[Alesi, G. N.; Jin, L.; Li, D.; Chen, Z. G.; Shin, D. M.; Khuri, F. R.; Kang, S.] Emory Univ, Sch Med, Winship Canc Inst, Dept Hematol & Med Oncol, 1365-C Clifton Rd NE,Suite C3006, Atlanta, GA 30322 USA; [Magliocca, K. R.] Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA; [Kang, Y.] Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Emory University; Emory University; Princeton University	Kang, S (corresponding author), Emory Univ, Sch Med, Winship Canc Inst, Dept Hematol & Med Oncol, 1365-C Clifton Rd NE,Suite C3006, Atlanta, GA 30322 USA.	smkang@emory.edu	Khuri, Fadlo R./AAU-4942-2020	Khuri, Fadlo R./0000-0002-8638-7618; Kang, Yibin/0000-0002-1626-6730	NIH [R01 CA175316, F31 CA183365]; ACS grant [RSG-11-081-01]; NATIONAL CANCER INSTITUTE [R01CA175316, F31CA183365] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ACS grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We acknowledge Dr Anthea Hammond for editorial assistance. We thank the shared resources facilities of the Winship Cancer Institute and the Integrated Cellular Imaging Core of Emory University. We also acknowledge and thank Dr Shi-Yong Sun for his insightful scientific input in the development of this work. This work was supported in part by NIH grants R01 CA175316 (to SK), F31 CA183365 (to GNA) and ACS grant RSG-11-081-01 (to SK). GNA is an NIH predoctoral fellow. FRK and SK are Georgia Cancer Coalition Scholars. SK is a Robbins Scholar and an American Cancer Society Basic Research Scholar.	Anjum R, 2008, NAT REV MOL CELL BIO, V9, P747, DOI 10.1038/nrm2509; Belletti B, 2008, MOL BIOL CELL, V19, P2003, DOI 10.1091/mbc.E07-09-0894; Belletti B, 2011, EXPERT OPIN THER TAR, V15, P1249, DOI 10.1517/14728222.2011.620951; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; BERETTA L, 1993, J BIOL CHEM, V268, P20076; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; Buck M, 2001, MOL CELL, V8, P807, DOI 10.1016/S1097-2765(01)00374-4; Carr JR, 2010, CANCER RES, V70, P5054, DOI 10.1158/0008-5472.CAN-10-0545; Cassimeris L, 2002, CURR OPIN CELL BIOL, V14, P18, DOI 10.1016/S0955-0674(01)00289-7; Cheng AL, 2008, CLIN CANCER RES, V14, P435, DOI 10.1158/1078-0432.CCR-07-1215; Clarkl DE, 2001, EMBO J, V20, P3484, DOI 10.1093/emboj/20.13.3484; Daub H, 2001, J BIOL CHEM, V276, P1677, DOI 10.1074/jbc.C000635200; Dehan E, 2009, MOL CELL, V33, P109, DOI 10.1016/j.molcel.2008.12.020; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Hitosugi T, 2011, MOL CELL, V44, P864, DOI 10.1016/j.molcel.2011.10.015; Holmfeldt P, 2006, MOL BIOL CELL, V17, P2921, DOI 10.1091/mbc.e06-02-0165; Hsieh SY, 2010, MOL CARCINOGEN, V49, P476, DOI 10.1002/mc.20627; Jeon TY, 2010, BRIT J CANCER, V102, P710, DOI 10.1038/sj.bjc.6605537; Jin LT, 2015, CANCER CELL, V27, P257, DOI 10.1016/j.ccell.2014.12.006; Jin LT, 2013, MOL CELL BIOL, V33, P2574, DOI 10.1128/MCB.01677-12; Kang SM, 2007, CANCER CELL, V12, P201, DOI 10.1016/j.ccr.2007.08.003; Kang SM, 2010, J CLIN INVEST, V120, P1165, DOI 10.1172/JCI40582; Kang YB, 2005, P NATL ACAD SCI USA, V102, P13909, DOI 10.1073/pnas.0506517102; Kinoshita I, 2003, ONCOGENE, V22, P2710, DOI 10.1038/sj.onc.1206371; Li D, 2013, J BIOL CHEM, V288, P32528, DOI 10.1074/jbc.M113.500561; Li N, 2011, P NATL ACAD SCI USA, V108, P12851, DOI 10.1073/pnas.1017372108; Li Y, 2010, ENDOCRINOLOGY, V151, P5146, DOI 10.1210/en.2009-1506; MARKLUND U, 1994, EUR J BIOCHEM, V225, P53, DOI 10.1111/j.1432-1033.1994.00053.x; Misek DE, 2002, CANCER CELL, V2, P217, DOI 10.1016/S1535-6108(02)00124-1; Mistry SJ, 1998, BIOCHEM J, V334, P23, DOI 10.1042/bj3340023; Mizumura K, 2006, J CELL PHYSIOL, V206, P363, DOI 10.1002/jcp.20465; Morrison KC, 2012, ANAL BIOCHEM, V420, P26, DOI 10.1016/j.ab.2011.08.020; Ng DCH, 2006, J CELL BIOL, V172, P245, DOI 10.1083/jcb.200503021; Nguyen DX, 2007, NAT REV GENET, V8, P341, DOI 10.1038/nrg2101; Palmer A, 1998, EMBO J, V17, P5037, DOI 10.1093/emboj/17.17.5037; Persad S, 2003, CANCER METAST REV, V22, P375, DOI 10.1023/A:1023777013659; Polzin RG, 2004, GENE, V341, P209, DOI 10.1016/j.gene.2004.06.052; Sahai E, 2005, CURR OPIN GENET DEV, V15, P87, DOI 10.1016/j.gde.2004.12.002; San-Marina S, 2012, BBA-GENE REGUL MECH, V1819, P1164, DOI 10.1016/j.bbagrm.2012.09.004; Schoumacher M, 2010, J CELL BIOL, V189, P541, DOI 10.1083/jcb.200909113; Shimamura A, 2000, CURR BIOL, V10, P127, DOI 10.1016/S0960-9822(00)00310-9; Tan HT, 2012, J PROTEOME RES, V11, P1433, DOI 10.1021/pr2010956; Tournebize R, 1997, EMBO J, V16, P5537, DOI 10.1093/emboj/16.18.5537	46	17	19	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 13	2016	35	41					5412	5421		10.1038/onc.2016.79	http://dx.doi.org/10.1038/onc.2016.79			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA5QU	27041561	Green Accepted			2022-12-17	WOS:000386677800007
J	Urtasun, R; Elizalde, M; Azkona, M; Latasa, MU; Garcia-Irigoyen, O; Uriarte, I; Fernandez-Barrena, MG; Vicent, S; Alonso, MM; Muntane, J; Prieto, J; Avila, MA; Berasain, C				Urtasun, R.; Elizalde, M.; Azkona, M.; Latasa, M. U.; Garcia-Irigoyen, O.; Uriarte, I.; Fernandez-Barrena, M. G.; Vicent, S.; Alonso, M. M.; Muntane, J.; Prieto, J.; Avila, M. A.; Berasain, C.			Splicing regulator SLU7 preserves survival of hepatocellular carcinoma cells and other solid tumors via oncogenic miR-17-92 cluster expression	ONCOGENE			English	Article							MICRORNA CLUSTER; CYCLE ARREST; AUTOPHAGY; MYC; APOPTOSIS; GROWTH; ROLES; AMPHIREGULIN; INHIBITION; METABOLISM	Resisting death is a central hallmark of cancer cells. Tumors rely on a number of genetic mechanisms to avoid apoptosis, and alterations in mRNA alternative splicing are increasingly recognized to have a role in tumorigenesis. In this study, we identify the splicing regulator SLU7 as an essential factor for the preservation of hepatocellular carcinoma (HCC) cells viability. Compared with hepatocytes, SLU7 expression is reduced in HCC cells; however, further SLU7 depletion triggered autophagy-related cellular apoptosis in association with the overproduction of reactive oxygen species. Remarkably, these responses were not observed in primary human hepatocytes or in the well-differentiated HepaRG cell line. Mechanistically, we demonstrate that SLU7 binds the C13orf25 primary transcript in which the polycistronic oncomir miR-17-92 cluster is encompassed, and is necessary for its processing and expression. SLU7 knockdown altered the splicing of the C13orf25 primary transcript, and markedly reduced the expression of its miR-17, miR-20 and miR-92a constituents. This led to the upregulation of CDKN1A (P21) and BCL2L11 (BIM) expression, two bona fide targets of the miR-17-92 cluster and recognized mediators of its pro-survival and tumorigenic activity. Interestingly, altered splicing of miR-17-92 and downregulation of miR-17 and miR-20 were not observed upon SLU7 knockdown in non-transformed hepatocytes, but was found in other (HeLa, H358) but not in all (Caco2) non-hepatic tumor cells. The functional relevance of miR-17-92 dysregulation upon SLU7 knockdown was established when oxidative stress, autophagy and apoptosis were reversed by co-transfection of HCC cells with a miR-17 mimic. Together, these findings indicate that SLU7 is co-opted by HCC cells and other tumor cell types to maintain survival, and identify this splicing regulator as a new determinant for the expression of the oncogenic miR-17-92 cluster. This novel mechanism may be exploited for the development of antitumoral strategies in cancers displaying such SLU7-miR-17-92 crosstalk.	[Urtasun, R.; Elizalde, M.; Azkona, M.; Latasa, M. U.; Garcia-Irigoyen, O.; Fernandez-Barrena, M. G.; Prieto, J.; Avila, M. A.; Berasain, C.] Univ Navarra, CIMA, Div Hepatol, Avda Pio 12,N55, Pamplona 31008, Spain; [Urtasun, R.; Latasa, M. U.; Fernandez-Barrena, M. G.; Vicent, S.; Alonso, M. M.; Avila, M. A.; Berasain, C.] Navarra Inst Hlth Res, IDISNA, Pamplona, Spain; [Uriarte, I.; Muntane, J.; Prieto, J.; Avila, M. A.; Berasain, C.] Inst Salud Carlos III, CIBERehd, Madrid, Spain; [Vicent, S.; Alonso, M. M.] Univ Navarra, CIMA, Div Oncol, Pamplona, Spain; [Alonso, M. M.] Univ Navarra Clin, Div Oncol, Pamplona, Spain; [Muntane, J.] Univ Seville, Dept Gen Surg, Virgen del Rocio Virgen Macarena Univ Hosp, IBiS,CSIC, Seville, Spain	University of Navarra; CIBER - Centro de Investigacion Biomedica en Red; CIBEREHD; Instituto de Salud Carlos III; University of Navarra; University of Navarra; Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC-JA-USE - Instituto de Biomedicina de Sevilla (IBIS)	Avila, MA; Berasain, C (corresponding author), Univ Navarra, CIMA, Div Hepatol, Avda Pio 12,N55, Pamplona 31008, Spain.	maavila@unav.es; cberasain@unav.es	Alonso, Marta M/AAI-9457-2020; Garcia-Irigoyen, Oihane/HDM-3461-2022; Sharma, Ashwani/AAK-3879-2020; URIARTE, IKER/Z-2161-2019; Vicent, Silvestre/K-4261-2017; URTASUN, RAQUEL/AAD-1590-2021; Uriarte, Iker/AFP-1513-2022; Avila, Matias A/Y-6342-2019; Azkona, Maria/Z-2273-2019; Fernandez-Barrena, Maite G/J-8040-2014; Latasa, Maria Ujue/Z-2178-2019; Uriarte, Iker/AFP-1514-2022; Berasain, Carmen/E-4139-2016; M., Elizalde/Z-2691-2019	Alonso, Marta M/0000-0002-7520-7351; Garcia-Irigoyen, Oihane/0000-0002-9964-3940; Sharma, Ashwani/0000-0001-9835-1973; URIARTE, IKER/0000-0001-5237-7799; Vicent, Silvestre/0000-0002-9457-6881; Avila, Matias A/0000-0001-6570-3557; Azkona, Maria/0000-0003-4044-8427; Fernandez-Barrena, Maite G/0000-0003-0375-6236; Latasa, Maria Ujue/0000-0002-0878-1337; Berasain, Carmen/0000-0001-7075-2476; M., Elizalde/0000-0002-7636-1836; Prieto, Jesus/0000-0002-1091-9593; URTASUN, RAQUEL/0000-0003-2332-5361	Instituto de Salud Carlos III (ISCIII) - 'Fondo Europeo de Desarrollo Regional' (FEDER) 'Una manera de hacer Europa' [FIS PI10/02642, PI13/00359, PI10/00038, PI13/00385]; PFIS fellowship from ISCIII; FPU fellowship from Ministerio de Educacion, Cultura y Deporte; Gobierno de Navarra; Ministerio de Educacion; Fundaciones Mario Losantos, MTorres, Eugenio Rodriguez Pascual; Agustina Damboriena Support	Instituto de Salud Carlos III (ISCIII) - 'Fondo Europeo de Desarrollo Regional' (FEDER) 'Una manera de hacer Europa'; PFIS fellowship from ISCIII; FPU fellowship from Ministerio de Educacion, Cultura y Deporte; Gobierno de Navarra; Ministerio de Educacion; Fundaciones Mario Losantos, MTorres, Eugenio Rodriguez Pascual; Agustina Damboriena Support	FIMA and the 'UTE project CIMA'; RTICC-RD06 00200061; CIBERehd; Grant numbers: FIS PI10/02642, PI13/00359, PI10/00038, PI13/00385 from Instituto de Salud Carlos III (ISCIII) co-financed by 'Fondo Europeo de Desarrollo Regional' (FEDER) 'Una manera de hacer Europa'; Gobierno de Navarra; 'Torres Quevedo' and 'Ramon y Cajal' contracts from Ministerio de Educacion; PFIS fellowship from ISCIII; FPU fellowship from Ministerio de Educacion, Cultura y Deporte; Fundaciones Mario Losantos, MTorres, Eugenio Rodriguez Pascual; Agustina Damboriena Support.	Alberstein M, 2007, RNA, V13, P1988, DOI 10.1261/rna.492907; Bellot GL, 2013, MITOCHONDRION, V13, P155, DOI 10.1016/j.mito.2012.06.007; Berasain C, 2005, J BIOL CHEM, V280, P19012, DOI 10.1074/jbc.M413344200; Berasain C, 2014, HEPAT ONCOL, V1, P241, DOI [10.2217/hep.13.17, 10.2217/HEP.13.17]; Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005; Castillo J, 2006, CANCER RES, V66, P6129, DOI 10.1158/0008-5472.CAN-06-0404; Castillo J, 2009, GASTROENTEROLOGY, V137, P1805, DOI 10.1053/j.gastro.2009.07.065; Chen J, 2015, ONCOGENE, V34, P1, DOI 10.1038/onc.2013.570; Chettouh H, 2013, CANCER RES, V73, P3974, DOI 10.1158/0008-5472.CAN-12-3824; Comincini S, 2013, CANCER BIOL THER, V14, P574, DOI 10.4161/cbt.24597; Concepcion CP, 2012, CANCER J, V18, P262, DOI 10.1097/PPO.0b013e318258b60a; Czaja MJ, 2013, AUTOPHAGY, V9, P1131, DOI 10.4161/auto.25063; Das S, 2014, MOL CANCER RES, V12, P1195, DOI 10.1158/1541-7786.MCR-14-0131; David CJ, 2010, GENE DEV, V24, P2343, DOI 10.1101/gad.1973010; David CJ, 2010, NATURE, V463, P364, DOI 10.1038/nature08697; Ebi H, 2009, ONCOGENE, V28, P3371, DOI 10.1038/onc.2009.201; Elizalde M, 2014, J CLIN INVEST, V124, P2909, DOI 10.1172/JCI74382; Faustino NA, 2003, GENE DEV, V17, P419, DOI 10.1101/gad.1048803; Filomeni G, 2015, CELL DEATH DIFFER, V22, P377, DOI 10.1038/cdd.2014.150; Fontana L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002236; Ghigna C, 1998, CANCER RES, V58, P5818; Guil S, 2007, NAT STRUCT MOL BIOL, V14, P591, DOI 10.1038/nsmb1250; Hayashita Y, 2005, CANCER RES, V65, P9628, DOI 10.1158/0008-5472.CAN-05-2352; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Hsu TYT, 2015, NATURE, V525, P384, DOI 10.1038/nature14985; Inomata M, 2009, BLOOD, V113, P396, DOI 10.1182/blood-2008-07-163907; Janas MM, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002330; Ji M, 2011, AM J PATHOL, V179, P1645, DOI 10.1016/j.ajpath.2011.06.008; Jiang XJ, 2015, J CLIN INVEST, V125, P47, DOI 10.1172/JCI73942; Kiyono K, 2009, CANCER RES, V69, P8844, DOI 10.1158/0008-5472.CAN-08-4401; Koh CM, 2015, NATURE, V523, P96, DOI 10.1038/nature14351; Kurokawa K, 2014, ONCOGENE, V33, P1407, DOI 10.1038/onc.2013.86; Lee Y, 2015, ANNU REV BIOCHEM, V84, P291, DOI 10.1146/annurev-biochem-060614-034316; Li YL, 2014, CANCER CELL, V26, P262, DOI 10.1016/j.ccr.2014.06.014; Macip S, 2002, EMBO J, V21, P2180, DOI 10.1093/emboj/21.9.2180; Mendell JT, 2008, CELL, V133, P217, DOI 10.1016/j.cell.2008.04.001; Mogilyansky E, 2013, CELL DEATH DIFFER, V20, P1603, DOI 10.1038/cdd.2013.125; Nikoletopoulou V, 2013, BBA-MOL CELL RES, V1833, P3448, DOI 10.1016/j.bbamcr.2013.06.001; Olive V, 2013, IMMUNOL REV, V253, P158, DOI 10.1111/imr.12054; Olive V, 2010, INT J BIOCHEM CELL B, V42, P1348, DOI 10.1016/j.biocel.2010.03.004; Oltean S, 2014, ONCOGENE, V33, P5311, DOI 10.1038/onc.2013.533; Osada H, 2011, CANCER SCI, V102, P9, DOI 10.1111/j.1349-7006.2010.01707.x; Ota A, 2004, CANCER RES, V64, P3087, DOI 10.1158/0008-5472.CAN-03-3773; Paglin S, 2001, CANCER RES, V61, P439; Perugorria MJ, 2009, CANCER RES, V69, P1358, DOI 10.1158/0008-5472.CAN-08-2545; Petrocca F, 2008, CANCER CELL, V13, P272, DOI 10.1016/j.ccr.2008.02.013; Shomron N, 2009, J BIOMED BIOTECHNOL, DOI 10.1155/2009/594678; Singh RK, 2012, TRENDS MOL MED, V18, P472, DOI 10.1016/j.molmed.2012.06.006; Tan WQ, 2014, WORLD J GASTROENTERO, V20, P5962, DOI 10.3748/wjg.v20.i20.5962; Thomas M, 2013, INT J MOL SCI, V14, P12273, DOI 10.3390/ijms140612273; Urtasun R, 2011, HEPATOLOGY, V54, P2149, DOI 10.1002/hep.24587; Yang H, 2015, BRIT J CANCER, V112, P112, DOI 10.1038/bjc.2014.547; Ying SY, 2006, J BIOMED SCI, V13, P5, DOI 10.1007/s11373-005-9036-8; Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645; Zhu HQ, 2014, AM J PATHOL, V184, P2828, DOI 10.1016/j.ajpath.2014.06.024	56	17	18	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 8	2016	35	36					4719	4729		10.1038/onc.2015.517	http://dx.doi.org/10.1038/onc.2015.517			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW0IS	26804174				2022-12-17	WOS:000383324700005
J	Ande, SR; Nguyen, KH; Padilla-Meier, GP; Nyomba, BLG; Mishra, S				Ande, S. R.; Nguyen, K. H.; Padilla-Meier, G. P.; Nyomba, B. L. G.; Mishra, S.			Expression of a mutant prohibitin from the aP2 gene promoter leads to obesity-linked tumor development in insulin resistance-dependent manner	ONCOGENE			English	Article							DENDRITIC CELLS; BREAST-CANCER; MOUSE MODEL; IGF-AXIS; GHRELIN; INFLAMMATION; IMMUNITY; PROTEIN; DRIVEN; IMMUNOMETABOLISM	A critical unmet need for the study of obesity-linked cancer is the lack of preclinical models that spontaneously develop obesity and cancer sequentially. Prohibitin (PHB) is a pleiotropic protein that has a role in adipose and immune functions. We capitalized on this attribute of PHB to develop a mouse model for obesity-linked tumor. We achieved this by expressing Y114F-PHB (m-PHB) from the aP2 gene promoter for simultaneous manipulation of adipogenic and immune signaling functions. The m-PHB mice develop obesity in a sex-neutral manner, but only male mice develop impaired glucose homeostasis and hyperinsulinemia similar to transgenic mice expressing PHB. Interestingly, only male m-PHB mice develop histiocytosis with lymphadenopathy, suggesting that metabolic dysregulation or m-PHB alone is not sufficient for the tumor development and that both are required for tumorigenesis. Moreover, ovariectomy in female m-PHB mice resulted in impaired glucose homeostasis, hyperinsulinemia and consequently tumor development similar to male m-PHB mice. These changes were not observed in sham-operated control m-Mito-Ob mice, further confirming the role of obesity-related metabolic dysregulation in tumor development in m-PHB mice. Our data provide a proof-of-concept that obesity-associated hyperinsulinemia promotes tumor development by facilitating dormant mutant to manifest and reveals a sex-dimorphic role of PHB in adipose-immune interaction or immunometabolism. Targeting PHB may provide a unique opportunity for the modulation of immunometabolism in obesity, cancer and in immune diseases.	[Ande, S. R.; Nguyen, K. H.; Padilla-Meier, G. P.; Nyomba, B. L. G.; Mishra, S.] Univ Manitoba, Dept Internal Med, Winnipeg, MB, Canada; [Mishra, S.] Univ Manitoba, Dept Physiol & Pathophysiol, Winnipeg, MB, Canada	University of Manitoba; University of Manitoba	Mishra, S (corresponding author), Univ Manitoba, Dept Internal Med, John Buhler Res Ctr, Room 843,715 McDermot Ave, Winnipeg, MB R3E 3P4, Canada.	suresh.mishra@umanitoba.ca	Ande, Sudharsana Rao/AAU-6950-2021; Mishra, Suresh/W-1633-2019	Ande, Sudharsana Rao/0000-0001-8194-2902; Nyomba, B. L. Gregoire/0000-0001-9472-607X	Natural Sciences and Engineering Research Council of Canada; Canadian Breast Cancer Foundation; Manitoba Health Research Council (MHRC); Canada Foundation for Innovation; MHRC Postdoctoral Fellowship Award	Natural Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)CGIAR); Canadian Breast Cancer Foundation(Canadian Cancer Society (CCS)); Manitoba Health Research Council (MHRC); Canada Foundation for Innovation(Canada Foundation for InnovationCGIAR); MHRC Postdoctoral Fellowship Award	We thank Anamarija Perry, Department of Pathology, University of Manitoba, Canada for help with tumor characterization and Nivida Mishra for proofreading the manuscript. We were supported by the Natural Sciences and Engineering Research Council of Canada, Canadian Breast Cancer Foundation, Manitoba Health Research Council (MHRC) and Canada Foundation for Innovation. GPP-M is a recipient of an MHRC Postdoctoral Fellowship Award.	Ande SR, 2014, DIABETES, V63, P3734, DOI 10.2337/db13-1807; Ande SR, 2009, BIOCHEM BIOPH RES CO, V390, P1023, DOI 10.1016/j.bbrc.2009.10.101; Ande SR, 2009, BBA-MOL CELL RES, V1793, P1372, DOI 10.1016/j.bbamcr.2009.05.008; Artal-Sanz M, 2009, NATURE, V461, P793, DOI 10.1038/nature08466; de Gruijl TD, 2006, J IMMUNOL, V176, P7232, DOI 10.4049/jimmunol.176.12.7232; DeCensi A, 2014, BREAST CANCER RES TR, V148, P81, DOI 10.1007/s10549-014-3141-1; Dixit VD, 2004, J CLIN INVEST, V114, P57, DOI 10.1172/JCI200421134; DIXIT VD, 2006, BRAIN BEHAV IMMUN, V20, P14; Dixit VD, 2008, J LEUKOCYTE BIOL, V84, P882, DOI 10.1189/jlb.0108028; Fu YC, 2006, ATHEROSCLEROSIS, V188, P102, DOI 10.1016/j.atherosclerosis.2005.10.041; Gahete MD, 2014, CARCINOGENESIS, V35, P2467, DOI 10.1093/carcin/bgu161; Gallagher EJ, 2013, DIABETES, V62, P3553, DOI 10.2337/db13-0249; Gonzalez-Rey E, 2006, GASTROENTEROLOGY, V130, P1707, DOI 10.1053/j.gastro.2006.01.041; Haabeth OAW, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1239; Hernandez BY, 2015, CANCER MED-US, V4, P354, DOI 10.1002/cam4.375; Hvid H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079710; Kim DK, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004098; Kusminski CM, 2012, NAT MED, V18, P1539, DOI 10.1038/nm.2899; Leenen PJM, 2010, J LEUKOCYTE BIOL, V87, P949, DOI 10.1189/jlb.0609432; Li WG, 2004, CIRCULATION, V109, P2221, DOI 10.1161/01.CIR.0000127956.43874.F2; Madeddu C, 2014, J CELL MOL MED, V18, P2519, DOI 10.1111/jcmm.12413; Makarem N, 2008, CANCER CAUSE CONTROL, V26, P277; Markle JG, 2014, TRENDS IMMUNOL, V35, P97, DOI 10.1016/j.it.2013.10.006; Mathis D, 2011, NAT REV IMMUNOL, V11, P81, DOI 10.1038/nri2922; Nakagawa H, 2014, CANCER CELL, V26, P331, DOI 10.1016/j.ccr.2014.07.001; Ng M, 2014, LANCET, V384, P766, DOI 10.1016/S0140-6736(14)60460-8; Nijtmans LGJ, 2002, CELL MOL LIFE SCI, V59, P143, DOI 10.1007/s00018-002-8411-0; Nikolic T, 2005, HISTIOCYTIC DISORDERS OF CHILDREN AND ADULTS, P40; Pileri SA, 2002, HISTOPATHOLOGY, V41, P1, DOI 10.1046/j.1365-2559.2002.01418.x; Rajalingam K, 2005, NAT CELL BIOL, V7, P837, DOI 10.1038/ncb1283; Renehan AG, 2008, LANCET, V371, P569, DOI 10.1016/S0140-6736(08)60269-X; Renehan AG, 2006, TRENDS ENDOCRIN MET, V17, P328, DOI 10.1016/j.tem.2006.08.006; Richter-Dennerlein R, 2014, CELL METAB, V20, P158, DOI 10.1016/j.cmet.2014.04.016; Roding S, 2013, DIAGNOSTIC HISTOPATH; Rose D P, 2004, Obes Rev, V5, P153, DOI 10.1111/j.1467-789X.2004.00142.x; Rutkowski MR, 2015, CANCER CELL, V27, P27, DOI 10.1016/j.ccell.2014.11.009; Schipper HS, 2012, TRENDS ENDOCRIN MET, V23, P407, DOI 10.1016/j.tem.2012.05.011; Sell H, 2012, NAT REV ENDOCRINOL, V8, P709, DOI 10.1038/nrendo.2012.114; Sharma A, 2004, P NATL ACAD SCI USA, V101, P17492, DOI 10.1073/pnas.0407536101; Takahashi S, 2011, BIOCHEM BIOPH RES CO, V405, P462, DOI 10.1016/j.bbrc.2011.01.054; TERASHIMA M, 1994, EMBO J, V13, P3782, DOI 10.1002/j.1460-2075.1994.tb06689.x; Venkan K, 2013, J HEPATOL, V60, P175; Wiedmer P, 2007, NAT CLIN PRACT ENDOC, V3, P705, DOI 10.1038/ncpendmet0625; Wolin KY, 2010, ONCOLOGIST, V15, P556, DOI 10.1634/theoncologist.2009-0285; Zhang Y, 2009, CANCER RES, V69, P5259, DOI 10.1158/0008-5472.CAN-08-3444; Zhao M, 2014, WORLD J CLIN ONCOL, V5, P248, DOI 10.5306/wjco.v5.i3.248	46	17	17	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	34					4459	4470		10.1038/onc.2015.501	http://dx.doi.org/10.1038/onc.2015.501			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU4AC	26751773				2022-12-17	WOS:000382153100004
J	Hiratsuka, T; Takei, Y; Ohmori, R; Imai, Y; Ozeki, M; Tamaki, K; Haga, H; Nakamura, T; Tsuruyama, T				Hiratsuka, T.; Takei, Y.; Ohmori, R.; Imai, Y.; Ozeki, M.; Tamaki, K.; Haga, H.; Nakamura, T.; Tsuruyama, T.			ZFP521 contributes to pre-B-cell lymphomagenesis through modulation of the pre-B-cell receptor signaling pathway	ONCOGENE			English	Article							ZINC-FINGER PROTEIN; ACUTE LYMPHOBLASTIC-LEUKEMIA; NF-KAPPA-B; RETROVIRUS INTEGRATION; BONE-MARROW; BCR CHECKPOINT; HEAVY-CHAINS; GENE; BTK; LOCUS	ZFP521 was previously identified as a putative gene involved in induction of B-cell lymphomagenesis. However, the contribution of ZFP521 to lymphomagenesis has not been confirmed. In this study, we sought to elucidate the role of ZFP521 in B-cell lymphomagenesis. To this end, we used a retroviral insertion method to show that ZFP521 was a target of mutagenesis in pre-B-lymphoblastic lymphoma cells. The pre-B-cell receptor (pre-BCR) signaling molecules BLNK, BTK and BANK1 were positively regulated by the ZFP521 gene, leading to enhancement of the pre-BCR signaling pathway. In addition, c-myc and c-jun were upregulated following activation of ZFP521. Stimulation of pre-BCR signaling using anti-Vpreb antibodies caused aberrant upregulation of c-myc and c-jun and of Ccnd3, which encodes cyclin D3, thereby inducing the growth of pre-B cells. Stimulation with Vpreb affected the growth of pre-B cells, and addition of interleukin (IL)-7 receptor exerted competitive effects on pre-B-cell growth. Knockdown of BTK and BANK1, targets of ZFP521, suppressed the effects of Vpreb stimulation on cell growth. Furthermore, in human lymphoblastic lymphoma, analogous to pre-B-cell lymphoma in mice, the expression of ZNF521, the homolog of ZFP521 in humans, was upregulated. In conclusion, our data showed that the ZFP521 gene comprehensively induced pre-B-cell lymphomagenesis by modulating the pre-B-cell receptor signaling pathway.	[Hiratsuka, T.] Kyoto Univ, Grad Sch Med, Dept Pathol & Biol Dis, Kyoto, Japan; [Takei, Y.; Haga, H.; Tsuruyama, T.] Kyoto Univ Hosp, Dept Diagnost Pathol, Kyoto 606, Japan; [Ohmori, R.; Tsuruyama, T.] Kyoto Univ, Grad Sch Med, Ctr Anat Pathol & Forens Med Res, Kyoto, Japan; [Imai, Y.; Ozeki, M.; Tamaki, K.] Kyoto Univ, Grad Sch Med, Dept Forens Med, Kyoto, Japan; [Nakamura, T.] Carcinogenesis Lab, Inst Canc, Tokyo, Japan	Kyoto University; Kyoto University; Kyoto University; Kyoto University	Tsuruyama, T (corresponding author), Kyoto Univ Hosp, Dept Diagnost Pathol, Sakyo Ku, 54 Shogoin Kawaharacho, Kyoto 6068506, Japan.	tsuruyam@kuhp.kyoto-u.ac.jp		Haga, Hironori/0000-0003-4322-9561				Addison WN, 2014, MOL CELL BIOL, V34, P3076, DOI 10.1128/MCB.00185-14; Akinleye A, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-59; Bernal-Quiros M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059842; Bond HM, 2008, INT J BIOCHEM CELL B, V40, P848, DOI 10.1016/j.biocel.2007.04.006; Bond HM, 2004, BLOOD, V103, P2062, DOI 10.1182/blood-2003-07-2388; Clark MR, 2014, NAT REV IMMUNOL, V14, P69, DOI 10.1038/nri3570; Corcoran AE, 1998, NATURE, V391, P904, DOI 10.1038/36122; Dai XZ, 2007, J IMMUNOL, V179, P1068, DOI 10.4049/jimmunol.179.2.1068; DAVIDSON WF, 1984, J IMMUNOL, V133, P744; Fernandez-Vega I, 2015, VIRCHOWS ARCH, V466, P229, DOI 10.1007/s00428-014-1698-z; Flemming A, 2003, NAT IMMUNOL, V4, P38, DOI 10.1038/ni862; Geier JK, 2006, SEMIN IMMUNOL, V18, P31, DOI 10.1016/j.smim.2005.11.001; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; Hendriks RW, 2004, TRENDS IMMUNOL, V25, P249, DOI 10.1016/j.it.2004.02.011; Hiai H, 2003, CANCER SCI, V94, P847, DOI 10.1111/j.1349-7006.2003.tb01365.x; Hiratsuka T, 2008, LEUKEMIA RES, V32, P309, DOI 10.1016/j.leukres.2007.05.013; Imai C, 2004, LEUKEMIA, V18, P922, DOI 10.1038/sj.leu.2403349; Imamura Y, 2009, J BIOL CHEM, V284, P9804, DOI 10.1074/jbc.M809051200; Jin G, 2003, CANCER SCI, V94, P791, DOI 10.1111/j.1349-7006.2003.tb01520.x; Kamiya D, 2011, NATURE, V470, P503, DOI 10.1038/nature09726; Kaszynski RH, 2010, CANCER SCI, V101, P800, DOI 10.1111/j.1349-7006.2009.01437.x; Kiviranta R, 2013, J EXP MED, V210, P969, DOI 10.1084/jem.20121187; Li LX, 2010, J IMMUNOL, V184, P1728, DOI 10.4049/jimmunol.0903023; Lu LM, 1999, CANCER RES, V59, P2593; Malin S, 2010, NAT IMMUNOL, V11, P171, DOI 10.1038/ni.1827; Mandal M, 2009, NAT IMMUNOL, V10, P1110, DOI 10.1038/ni.1785; Mega T, 2011, CELL CYCLE, V10, P2129, DOI 10.4161/cc.10.13.16045; Melchers F, 2005, NAT REV IMMUNOL, V5, P578, DOI 10.1038/nri1649; Minegishi Y, 2001, IMMUNITY, V14, P631, DOI 10.1016/S1074-7613(01)00131-5; Muschen M, 2015, BLOOD, V125, P3688, DOI 10.1182/blood-2015-01-567842; Mullighan CG, 2007, NATURE, V446, P758, DOI 10.1038/nature05690; Murray MY, 2015, CELL CYCLE, V14, P2367, DOI 10.1080/15384101.2014.998067; Nakayama J, 2009, BLOOD, V113, P1483, DOI 10.1182/blood-2008-07-166355; Nutt SL, 1997, GENE DEV, V11, P476, DOI 10.1101/gad.11.4.476; Rickert RC, 2013, NAT REV IMMUNOL, V13, P578, DOI 10.1038/nri3487; Rushworth SA, 2013, CELL SIGNAL, V25, P106, DOI 10.1016/j.cellsig.2012.09.008; Stadhouders R, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001791; Tsuruyama T, 2002, P NATL ACAD SCI USA, V99, P8253, DOI 10.1073/pnas.112202899; Tsuruyama T, 2011, AM J PATHOL, V178, P1374, DOI 10.1016/j.ajpath.2010.12.012; Tsuruyama T, 2010, J LEUKOCYTE BIOL, V88, P107, DOI 10.1189/jlb.1109748; Warming S, 2003, BLOOD, V101, P1934, DOI 10.1182/blood-2002-08-2652; Wei CJ, 2000, J IMMUNOL, V164, P1961, DOI 10.4049/jimmunol.164.4.1961; Wollscheid B, 1999, CURR TOP MICROBIOL, V246, P283; Yamasaki N, 2010, ONCOGENE, V29, P1963, DOI 10.1038/onc.2009.475; Yasuda T, 2002, J EXP MED, V196, P51, DOI 10.1084/jem.20020068; Yokoyama K, 2002, EMBO J, V21, P83, DOI 10.1093/emboj/21.1.83	46	17	18	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 23	2016	35	25					3227	3238		10.1038/onc.2015.385	http://dx.doi.org/10.1038/onc.2015.385			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP2GN	26522721				2022-12-17	WOS:000378306400002
J	Wang, J; Cai, J; Huang, Y; Ke, Q; Wu, B; Wang, S; Han, X; Wang, T; Wang, Y; Li, W; Lao, C; Song, W; Xiang, AP				Wang, J.; Cai, J.; Huang, Y.; Ke, Q.; Wu, B.; Wang, S.; Han, X.; Wang, T.; Wang, Y.; Li, W.; Lao, C.; Song, W.; Xiang, A. P.			Nestin regulates proliferation and invasion of gastrointestinal stromal tumor cells by altering mitochondrial dynamics	ONCOGENE			English	Article							INTERMEDIATE-FILAMENT NESTIN; PLURIPOTENT STEM-CELLS; OXIDATIVE STRESS; TARGETING MITOCHONDRIA; CANCER-THERAPY; MORPHOLOGY; EXPRESSION; ROS; PHOSPHORYLATION; VIMENTIN	Nestin is widely expressed in numerous tumors and has become a diagnostic and prognostic indicator. However, the exact mechanism by which nestin contributes to tumor malignancy remains poorly understood. Here, we found marked upregulation of nestin expression in highly proliferative and invasive gastrointestinal stromal tumor (GIST) specimens. Nestin knockdown in GIST cells reduced the proliferative and invasive activity owing to a decrease of mitochondrial intracellular reactive oxygen species (ROS) generation. Furthermore, nestin was co-localized with mitochondria, and knockdown of nestin increased mitochondrial elongation and influenced the mitochondrial function, including oxygen consumption rates, ATP generation and mitochondrial membrane potential and so on. In exploring the underlying mechanism, we demonstrated nestin knockdown inhibited the mitochondrial recruitment of Dynamin-related protein1 and induced the change of mitochondrial dynamics. Thus, nestin may have an important role in GIST malignancy by regulating mitochondrial dynamics and altering intracellular ROS levels. The findings provide new clues to reveal mechanisms by which nestin mediates the proliferation and invasion of GISTs.	[Wang, J.; Cai, J.; Li, W.; Xiang, A. P.] Sun Yat Sen Univ, Zhongshan Sch Med, Affiliated Guangzhou Women & Childrens Hosp, Program Stem Cells & Regenerat Med, Guangzhou 510275, Guangdong, Peoples R China; [Wang, J.; Cai, J.; Huang, Y.; Ke, Q.; Wang, T.; Wang, Y.; Li, W.; Lao, C.; Xiang, A. P.] Sun Yat Sen Univ, Minist Educ, Key Lab Stem Cells & Tissue Engn, Ctr Stem Cell Biol & Tissue Engn, 74 Zhongshan 2nd Rd, Guangzhou 510275, Guangdong, Peoples R China; [Cai, J.; Xiang, A. P.] Sun Yat Sen Univ, Zhongshan Sch Med, Affiliated Hosp 3, Biotherapy Ctr, Guangzhou 510275, Guangdong, Peoples R China; [Ke, Q.] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Cell Biol, Guangzhou 510275, Guangdong, Peoples R China; [Wu, B.] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Cardiol, Guangzhou 510275, Guangdong, Peoples R China; [Wang, S.; Song, W.] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Gastrointestinal Pancreat Surg, Guangzhou 510275, Guangdong, Peoples R China; [Han, X.] Peking Union Med Coll, Fuwai Hosp, Dept Populat Genet & Prevent, Beijing 100021, Peoples R China; [Li, W.; Xiang, A. P.] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Biochem, Guangzhou 510275, Guangdong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Chinese Academy of Medical Sciences - Peking Union Medical College; Fu Wai Hospital - CAMS; Peking Union Medical College; Sun Yat Sen University	Xiang, AP (corresponding author), Sun Yat Sen Univ, Minist Educ, Key Lab Stem Cells & Tissue Engn, Ctr Stem Cell Biol & Tissue Engn, 74 Zhongshan 2nd Rd, Guangzhou 510275, Guangdong, Peoples R China.	xiangp@mail.sysu.edu.cn	Cai, Jianye/GOK-2676-2022	Huang, Yinong/0000-0002-7364-2894	National Basic Research Program of China [2012CBA01302]; National Natural Science Foundation of China [81425016, 81270646, 31171398]; Natural Science Foundation of Guangdong Province [S2013030013305, 2015A030312013]; Key Scientific and Technological Projects of Guangdong Province [2014B020226002, 2015B020226004, 2014B020228003, 2007A032100003]; Key Scientific and Technological Program of Guangzhou City [201400000003-3, 201508020262, 201300000089, 2010U1-E00551]; Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme (GDUPS)	National Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Key Scientific and Technological Projects of Guangdong Province; Key Scientific and Technological Program of Guangzhou City; Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme (GDUPS)	This work was supported by the National Basic Research Program of China (2012CBA01302); the National Natural Science Foundation of China (81425016, 81270646, 31171398); the Natural Science Foundation of Guangdong Province (S2013030013305, 2015A030312013); the Key Scientific and Technological Projects of Guangdong Province (2014B020226002, 2015B020226004, 2014B020228003, 2007A032100003); Key Scientific and Technological Program of Guangzhou City (201400000003-3, 201508020262, 201300000089, 2010U1-E00551); Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme (GDUPS, 2013).	Anesti V, 2006, BBA-BIOENERGETICS, V1757, P692, DOI 10.1016/j.bbabio.2006.04.013; Chan DC, 2012, ANNU REV GENET, V46, P265, DOI 10.1146/annurev-genet-110410-132529; Chappell NP, 2012, J PROTEOME RES, V11, P4605, DOI 10.1021/pr300403d; Chen ZG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085584; Cheng FY, 2012, BIOMATERIALS, V33, P3195, DOI 10.1016/j.biomaterials.2012.01.023; D'Autreaux B, 2007, NAT REV MOL CELL BIO, V8, P813, DOI 10.1038/nrm2256; DAHLSTRAND J, 1992, CANCER RES, V52, P5334; De Vos KJ, 2005, CURR BIOL, V15, P678, DOI 10.1016/j.cub.2005.02.064; FRISEN J, 1995, J CELL BIOL, V131, P453, DOI 10.1083/jcb.131.2.453; Fulda S, 2010, NAT REV DRUG DISCOV, V9, P447, DOI 10.1038/nrd3137; Gilyarov A V, 2008, Neurosci Behav Physiol, V38, P165, DOI 10.1007/s11055-008-0025-z; Holmstrom KM, 2014, NAT REV MOL CELL BIO, V15, P411, DOI 10.1038/nrm3801; Huang YL, 2009, J BIOCHEM, V146, P307, DOI 10.1093/jb/mvp070; Jiang MH, 2014, CELL RES, V24, P1466, DOI 10.1038/cr.2014.149; Karbowski M, 2003, CELL DEATH DIFFER, V10, P870, DOI 10.1038/sj.cdd.4401260; Kashatus JA, 2015, MOL CELL, V57, P537, DOI 10.1016/j.molcel.2015.01.002; Ke Q, 2013, HUM MOL GENET, V22, P2221, DOI 10.1093/hmg/ddt074; Kleeberger W, 2007, CANCER RES, V67, P9199, DOI 10.1158/0008-5472.CAN-07-0806; Koopman WJH, 2005, AM J PHYSIOL-CELL PH, V289, pC881, DOI 10.1152/ajpcell.00104.2005; Le Belle JE, 2011, CELL STEM CELL, V8, P59, DOI 10.1016/j.stem.2010.11.028; LeBleu VS, 2014, NAT CELL BIOL, V16, P992, DOI 10.1038/ncb3039; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Li P, 2013, NAT NEUROSCI, V16, P1737, DOI 10.1038/nn.3553; Liesa M, 2009, PHYSIOL REV, V89, P799, DOI 10.1152/physrev.00030.2008; Lim SO, 2008, GASTROENTEROLOGY, V135, P2128, DOI 10.1053/j.gastro.2008.07.027; Liu J, 2014, STEM CELLS, V32, P1843, DOI 10.1002/stem.1682; Malhas AN, 2009, J CELL BIOL, V184, P45, DOI 10.1083/jcb.200804155; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; Matsuda Y., 2014, CANCER BIOL THER, V11, P512; Milner DJ, 2000, J CELL BIOL, V150, P1283, DOI 10.1083/jcb.150.6.1283; Ngan CY, 2007, BRIT J CANCER, V96, P986, DOI 10.1038/sj.bjc.6603651; Rubin BP, 2007, LANCET, V369, P1731, DOI 10.1016/S0140-6736(07)60780-6; Sabharwal SS, 2014, NAT REV CANCER, V14, P709, DOI 10.1038/nrc3803; Sahlgren CM, 2006, EMBO J, V25, P4808, DOI 10.1038/sj.emboj.7601366; Serasinghe Madhavika N, 2015, MOL CELL, V57, P521; StoneO MR, 2007, J CELL SCI, V120, P3999, DOI 10.1242/jcs.009241; Su HT, 2013, MOL CANCER RES, V11, P768, DOI 10.1158/1541-7786.MCR-12-0511; Tang HL, 2008, BIOCHEM J, V410, P141, DOI 10.1042/BJ20071072; Tao GZ, 2009, J CELL SCI, V122, P3851, DOI 10.1242/jcs.051862; Tao GZ, 2005, J BIOL CHEM, V280, P12162, DOI 10.1074/jbc.M412505200; Toivola DM, 2010, TRENDS CELL BIOL, V20, P79, DOI 10.1016/j.tcb.2009.11.004; Toivola DM, 2005, TRENDS CELL BIOL, V15, P608, DOI 10.1016/j.tcb.2005.09.004; Tormos KV, 2011, CELL METAB, V14, P537, DOI 10.1016/j.cmet.2011.08.007; Tsujimura T, 2001, AM J PATHOL, V158, P817, DOI 10.1016/S0002-9440(10)64029-1; Vanderwinden JM, 2002, CELL TISSUE RES, V309, P261, DOI 10.1007/s00441-002-0590-3; Verstraeten VLRM, 2009, J CELL MOL MED, V13, P959, DOI 10.1111/j.1582-4934.2009.00690.x; Wallace DC, 2012, NAT REV CANCER, V12, P685, DOI 10.1038/nrc3365; Wang YD, 1998, SCIENCE, V279, P537, DOI 10.1126/science.279.5350.537; Weinberg SE, 2015, NAT CHEM BIOL, V11, P9, DOI 10.1038/nchembio.1712; Wikstrom JD, 2013, MOL ENDOCRINOL, V27, P1706, DOI 10.1210/me.2013-1109; Winter L, 2008, J CELL BIOL, V181, P903, DOI 10.1083/jcb.200710151; Yang XH, 2008, J CLIN PATHOL, V61, P467, DOI 10.1136/jcp.2007.047605; Yu TZ, 2006, P NATL ACAD SCI USA, V103, P2653, DOI 10.1073/pnas.0511154103; Zhu QS, 2011, ONCOGENE, V30, P457, DOI 10.1038/onc.2010.421	54	17	19	2	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 16	2016	35	24					3139	3150		10.1038/onc.2015.370	http://dx.doi.org/10.1038/onc.2015.370			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO9GI	26434586				2022-12-17	WOS:000378092700006
J	Schnerch, D; Nigg, EA				Schnerch, D.; Nigg, E. A.			Structural centrosome aberrations favor proliferation by abrogating microtubule-dependent tissue integrity of breast epithelial mammospheres	ONCOGENE			English	Article							PROMOTES MAMMARY TUMORIGENESIS; NINEIN-LIKE PROTEIN; CELL POLARITY; CENTRIOLE BIOGENESIS; CANCER; NLP; ORGANIZATION; DUPLICATION; EXPRESSION; CARCINOMA	Structural centrosome aberrations are frequently observed in early stage carcinomas, but their role in malignant transformation is poorly understood. Here, we examined the impact of overexpression of Ninein-like protein (Nlp) on the architecture of polarized epithelia in three-dimensional mammospheres. When Nlp was overexpressed to levels resembling those seen in human tumors, it formed striking centrosome-related bodies (CRBs), which sequestered Ninein and affected the kinetics of microtubule (MT) nucleation and release. In turn, the profound reorganization of the MT cytoskeleton resulted in mislocalization of several adhesion and junction proteins as well as the tumor suppressor Scribble, resulting in the disruption of epithelial polarity, cell-cell interactions and mammosphere architecture. Remarkably, cells harboring Nlp-CRBs displayed an enhanced proliferative response to epidermal growth factor. These results demonstrate that structural centrosome aberrations cause not only the disruption of epithelial polarity but also favor overproliferation, two phenotypes typically associated with human carcinomas.	[Schnerch, D.; Nigg, E. A.] Univ Basel, Biozentrum, Klingelbergstr 50-70, CH-4056 Basel, Switzerland	University of Basel	Nigg, EA (corresponding author), Univ Basel, Biozentrum, Klingelbergstr 50-70, CH-4056 Basel, Switzerland.	erich.nigg@unibas.ch		nigg, erich/0000-0003-4835-5719	University of Basel; Swiss National Science Foundation [310030B_149641]; Friedrich-Alexander-Universitat Erlangen-Nurnberg (FAU)	University of Basel; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Friedrich-Alexander-Universitat Erlangen-Nurnberg (FAU)	We thank Tilman Brummer (University of Freiburg), Stefan Zimmermann and Ralph Wasch (University Medical Center Freiburg) as well as Heike Brinkhaus and Mohamed Bentires-Alj (FMI Basel) for cell lines and technical advice, and Cheuk Leung (University of Minnesota) as well as Yi-Ren Hong (Kaohsiung Medical University, Taiwan) for viral vectors. We also thank Alexia Loynton-Ferrand and other members of the Imaging Core Facility (IMCF) for help and Elena Nigg-Martignoni for technical assistance. Finally, we are grateful to Felix B. Engel and the 'Emerging fields Initiative' (EFI) for 'Cell Cycle in Disease and Regeneration (CYDER)' from the Friedrich-Alexander-Universitat Erlangen-Nurnberg (FAU) for constructive comments and support, as well as to all members of the Nigg lab for helpful discussions. This work was supported by the University of Basel and the Swiss National Science Foundation (310030B_149641).	Abal M, 2002, J CELL BIOL, V159, P731, DOI 10.1083/jcb.200207076; Andersen JS, 2003, NATURE, V426, P570, DOI 10.1038/nature02166; Azimzadeh J, 2007, J CELL SCI, V120, P2139, DOI 10.1242/jcs.005231; Bartolini F, 2006, J CELL SCI, V119, P4155, DOI 10.1242/jcs.03227; Basto R, 2008, CELL, V133, P1032, DOI 10.1016/j.cell.2008.05.039; Bettencourt-Dias M, 2005, CURR BIOL, V15, P2199, DOI 10.1016/j.cub.2005.11.042; Bettencourt-Dias M, 2011, TRENDS GENET, V27, P307, DOI 10.1016/j.tig.2011.05.004; Brito DA, 2012, CURR OPIN CELL BIOL, V24, P4, DOI 10.1016/j.ceb.2012.01.003; Carraway Coralie A Carothers, 2007, Sci STKE, V2007, pre3, DOI 10.1126/stke.3812007re3; Casenghi M, 2005, J CELL SCI, V118, P5101, DOI 10.1242/jcs.02622; Casenghi M, 2003, DEV CELL, V5, P113, DOI 10.1016/S1534-5807(03)00193-X; D'Assoro AB, 2002, BREAST CANCER RES TR, V75, P25, DOI 10.1023/A:1016550619925; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Delgehyr N, 2005, J CELL SCI, V118, P1565, DOI 10.1242/jcs.02302; Dow LE, 2008, ONCOGENE, V27, P5988, DOI 10.1038/onc.2008.219; Feigin ME, 2014, CANCER RES, V74, P3180, DOI 10.1158/0008-5472.CAN-13-3415; Fogeron ML, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2517; Fry AM, 1998, EMBO J, V17, P470, DOI 10.1093/emboj/17.2.470; Fujita Y, 2011, CANCER SCI, V102, P1749, DOI 10.1111/j.1349-7006.2011.02011.x; Ganem NJ, 2009, NATURE, V460, P278, DOI 10.1038/nature08136; Godinho SA, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0467; Godinho SA, 2014, NATURE, V510, P167, DOI 10.1038/nature13277; Gonczy P, 2012, NAT REV MOL CELL BIO, V13, P425, DOI 10.1038/nrm3373; Guo HQ, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1752; Guo WJ, 2006, CELL, V126, P489, DOI 10.1016/j.cell.2006.05.047; Habedanck R, 2005, NAT CELL BIOL, V7, P1140, DOI 10.1038/ncb1320; Harris H, 2008, J CELL SCI, V121, P3, DOI [10.1242/jcs.017483, 10.1242/jcs.025742]; Hernandez P, 2010, DIS MODEL MECH, V3, P304, DOI 10.1242/dmm.004507; Hogan C, 2012, CELL MOL LIFE SCI, V69, P203, DOI 10.1007/s00018-011-0806-3; Hotta A, 2010, J CELL BIOL, V189, P901, DOI 10.1083/jcb.200910095; Jakobsen L, 2011, EMBO J, V30, P1520, DOI 10.1038/emboj.2011.63; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Jiang F, 2003, INT J CANCER, V106, P661, DOI 10.1002/ijc.11251; Kayser G, 2005, VIRCHOWS ARCH, V447, P61, DOI 10.1007/s00428-004-1191-1; Kleylein-Sohn J, 2007, DEV CELL, V13, P190, DOI 10.1016/j.devcel.2007.07.002; Kollman JM, 2011, NAT REV MOL CELL BIO, V12, P709, DOI 10.1038/nrm3209; Kronenwett U, 2005, BRIT J CANCER, V92, P389, DOI 10.1038/sj.bjc.6602246; Lechler T, 2007, J CELL BIOL, V176, P147, DOI 10.1083/jcb.200609109; Lee MH, 2008, J CELL SCI, V121, P1141, DOI 10.1242/jcs.016634; Leung CT, 2012, NATURE, V482, P410, DOI 10.1038/nature10826; Li J, 2011, BRIT J CANCER, V104, P1523, DOI 10.1038/bjc.2011.130; Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30; Lingle WL, 1999, AM J PATHOL, V155, P1941, DOI 10.1016/S0002-9440(10)65513-7; Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999; Lingle WL, 1998, P NATL ACAD SCI USA, V95, P2950, DOI 10.1073/pnas.95.6.2950; Luders J, 2007, NAT REV MOL CELL BIO, V8, P161, DOI 10.1038/nrm2100; Meng W, 2008, CELL, V135, P948, DOI 10.1016/j.cell.2008.09.040; Mogensen MM, 2000, J CELL SCI, V113, P3013; MOGENSEN MM, 2004, CENTROSOMES DEV DIS, P299; Moss DK, 2007, J CELL SCI, V120, P3064, DOI 10.1242/jcs.010322; Musch A, 2004, TRAFFIC, V5, P1, DOI 10.1046/j.1600-0854.2003.00149.x; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Nagasaka K, 2010, ONCOGENE, V29, P5311, DOI 10.1038/onc.2010.265; NATALI PG, 1992, BRIT J CANCER, V66, P318, DOI 10.1038/bjc.1992.263; Navarro C, 2005, ONCOGENE, V24, P4330, DOI 10.1038/sj.onc.1208632; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Nigg EA, 2006, INT J CANCER, V119, P2717, DOI 10.1002/ijc.22245; Nigg EA, 2011, NAT CELL BIOL, V13, P1154, DOI 10.1038/ncb2345; Partanen JI, 2007, P NATL ACAD SCI USA, V104, P14694, DOI 10.1073/pnas.0704677104; PETERSEN OW, 1992, P NATL ACAD SCI USA, V89, P9064, DOI 10.1073/pnas.89.19.9064; Pihan GA, 2003, CANCER RES, V63, P1398; Qu D, 2008, GYNECOL ONCOL, V110, P230, DOI 10.1016/j.ygyno.2008.04.015; Rapley J, 2005, MOL CELL BIOL, V25, P1309, DOI 10.1128/MCB.25.4.1309-1324.2005; Rodriguez-Boulan E, 2014, NAT REV MOL CELL BIO, V15, P225, DOI 10.1038/nrm3775; Royer C, 2011, CELL DEATH DIFFER, V18, P1470, DOI 10.1038/cdd.2011.60; Salisbury JL, 1999, J HISTOCHEM CYTOCHEM, V47, P1265, DOI 10.1177/002215549904701006; Sato N, 1999, CLIN CANCER RES, V5, P963; Schmidt TI, 2009, CURR BIOL, V19, P1005, DOI 10.1016/j.cub.2009.05.016; Segat D, 2010, HISTOL HISTOPATHOL, V25, P551, DOI 10.14670/HH-25.551; Shao SJ, 2010, J CLIN INVEST, V120, P498, DOI 10.1172/JCI39447; Simpson DR, 2011, CANCER RES, V71, P3822, DOI 10.1158/0008-5472.CAN-10-3782; Thein KH, 2007, J CELL BIOL, V178, P345, DOI 10.1083/jcb.200701163; Wang Y, 2007, J BIOL CHEM, V282, P17712, DOI 10.1074/jbc.M701350200; Weber K, 2008, MOL THER, V16, P698, DOI 10.1038/mt.2008.6; Xiang B, 2006, METHOD ENZYMOL, V406, P692, DOI 10.1016/S0076-6879(06)06054-X; Yamauchi H, 2012, CELL RES, V22, P1527, DOI 10.1038/cr.2012.69; Yan J, 2010, J BIOL CHEM, V285, P40230, DOI 10.1074/jbc.M110.140541; Yan XM, 2006, MOL BIOL CELL, V17, P634, DOI 10.1091/mbc.E05-08-0810; Yu LL, 2009, ONCOL REP, V22, P789, DOI 10.3892/or_00000501; Yvon AMC, 2002, MOL BIOL CELL, V13, P1871, DOI 10.1091/mbc.01-11-0539; Zhan LX, 2008, CELL, V135, P865, DOI 10.1016/j.cell.2008.09.045; Zhao WH, 2012, CANCER BIOL THER, V13, P156, DOI 10.4161/cbt.13.3.18697; Zhao XL, 2010, CANCER BIOL THER, V10, P949, DOI 10.4161/cbt.10.9.13368; Zufferey R, 1997, NAT BIOTECHNOL, V15, P871, DOI 10.1038/nbt0997-871; Zyss D, 2009, TRENDS CELL BIOL, V19, P334, DOI 10.1016/j.tcb.2009.04.001	85	17	18	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2016	35	21					2711	2722		10.1038/onc.2015.332	http://dx.doi.org/10.1038/onc.2015.332			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0MJ	26364601	Green Published, hybrid			2022-12-17	WOS:000377472700005
J	Oneyama, C; Yoshikawa, Y; Ninomiya, Y; Iino, T; Tsukita, S; Okada, M				Oneyama, C.; Yoshikawa, Y.; Ninomiya, Y.; Iino, T.; Tsukita, S.; Okada, M.			Fer tyrosine kinase oligomer mediates and amplifies Src-induced tumor progression	ONCOGENE			English	Article							C-SRC; CORTACTIN PHOSPHORYLATION; CARCINOMA CELLS; FAMILY KINASES; SARCOMA VIRUS; HUMAN CANCER; EXPRESSION; ACTIVATION; EZRIN; TRANSFORMATION	c-Src is upregulated in various human cancers, suggesting its role in malignant progression. However, the molecular circuits of c-Src oncogenic signaling remain elusive. Here we show that Fer tyrosine kinase oligomer mediates and amplifies Src-induced tumor progression. Previously, we showed that transformation of fibroblasts is promoted by the relocation of c-Src to non-raft membranes. In this study, we identified Fer and ezrin as non-raft c-Src targets. c-Src directly activated Fer by initiating its autophosphorylation, which was further amplified by Fer oligomerization. Fer interacted with active c-Src at focal adhesion membranes and activated Fer-phosphorylated ezrin to induce cell transformation. Fer was also crucial for cell transformation induced by v-Src or epidermal growth-factor receptor activation. Furthermore, Fer activation was required for tumorigenesis and invasiveness in some cancer cells in which c-Src is upregulated. We propose that the Src-Fer axis represents a new therapeutic target for treatment of a subset of human cancers.	[Oneyama, C.; Yoshikawa, Y.; Ninomiya, Y.; Iino, T.; Okada, M.] Osaka Univ, Dept Oncogene Res, Microbial Dis Res Inst, 3-1 Yamadaoka, Suita, Osaka 5650871, Japan; [Tsukita, S.] Osaka Univ, Grad Sch Frontier Biosci, Lab Biol Sci, Osaka, Japan; [Tsukita, S.] Osaka Univ, Grad Sch Med, Osaka, Japan	Osaka University; Osaka University; Osaka University	Oneyama, C (corresponding author), Osaka Univ, Dept Oncogene Res, Microbial Dis Res Inst, 3-1 Yamadaoka, Suita, Osaka 5650871, Japan.	coneyama@biken.osaka-u.ac.jp			Exciting Leading-Edge Research Project; MEET Project at Osaka University; Ministry of Education, Culture, Sports, Science and Technology of Japan for Young Scientists; Yasuda Medical Foundation; Grants-in-Aid for Scientific Research [25117716, 26640078] Funding Source: KAKEN	Exciting Leading-Edge Research Project; MEET Project at Osaka University; Ministry of Education, Culture, Sports, Science and Technology of Japan for Young Scientists(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Yasuda Medical Foundation; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank T Akagi for pCX4 vector, N Mochizuki for a series of Fer expression vectors, A Imamoto for SFC - cells, K Saito for technical assistance with the LC-MS/MS analysis and JA Cooper for critical reading and editing of the manuscript. LC-MS/MS analysis was performed in the DNA-chip Development Centre for Infectious Diseases (RIMD, Osaka University). This work was supported by the Exciting Leading-Edge Research Project and the MEET Project at Osaka University; grants-in-aid from the Ministry of Education, Culture, Sports, Science and Technology of Japan for Young Scientists (A); and The Yasuda Medical Foundation.	Akagi T, 2003, P NATL ACAD SCI USA, V100, P13567, DOI 10.1073/pnas.1834876100; Allard P, 2000, MOL CELL ENDOCRINOL, V159, P63, DOI 10.1016/S0303-7207(99)00205-1; Anastassiadis T, 2011, NAT BIOTECHNOL, V29, P1039, DOI 10.1038/nbt.2017; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Craig AWB, 1999, J BIOL CHEM, V274, P19934, DOI 10.1074/jbc.274.28.19934; Craig AWB, 2001, MOL CELL BIOL, V21, P603, DOI 10.1128/MCB.21.2.603-613.2001; Elliott BE, 2004, J CELL BIOCHEM, V92, P16, DOI 10.1002/jcb.20033; Frame MC, 2002, BBA-REV CANCER, V1602, P114, DOI 10.1016/S0304-419X(02)00040-9; Greer P, 2002, NAT REV MOL CELL BIO, V3, P278, DOI 10.1038/nrm783; Guo CH, 2011, P NATL ACAD SCI USA, V108, P7968, DOI 10.1073/pnas.1105369108; Hakak Y, 1999, CURR BIOL, V9, P1039, DOI 10.1016/S0960-9822(99)80453-9; Heiska L, 2011, ONCOGENE, V30, P4953, DOI 10.1038/onc.2011.207; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; Inoue K, 2009, GENE THER, V16, P1383, DOI 10.1038/gt.2009.105; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; Ishizawar R, 2004, CANCER CELL, V6, P209, DOI 10.1016/j.ccr.2004.09.001; Itoh T, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000393; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; Kawabuchi M, 2000, NATURE, V404, P999, DOI 10.1038/35010121; Kawakami M, 2013, INT J CLIN EXP PATHO, V6, P598; Kim L, 1998, J BIOL CHEM, V273, P23542, DOI 10.1074/jbc.273.36.23542; KIM L, 1995, MOL CELL BIOL, V15, P4553; Kogata N, 2003, MOL BIOL CELL, V14, P3553, DOI 10.1091/mbc.E03-02-0080; Laszlo GS, 2009, CURR BIOL, V19, P157, DOI 10.1016/j.cub.2008.12.007; Lennartsson J, 2013, J BIOL CHEM, V288, P15736, DOI 10.1074/jbc.M113.476424; Li HY, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-366; Lingwood D, 2007, NAT PROTOC, V2, P2159, DOI 10.1038/nprot.2007.294; Mak H, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-82; Menges Craig W, 2010, Genes Cancer, V1, P493; Miyata Y, 2013, CANCER SCI, V104, P681, DOI 10.1111/cas.12140; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; Okada M, 2012, INT J BIOL SCI, V8, P1385, DOI 10.7150/ijbs.5141; Oneyama C, 2012, ONCOGENE, V31, P1623, DOI 10.1038/onc.2011.367; Oneyama C, 2008, MOL CELL, V30, P426, DOI 10.1016/j.molcel.2008.03.026; Oneyama C, 2008, GENES CELLS, V13, P1, DOI 10.1111/j.1365-2443.2007.01145.x; Oneyama C, 2009, MOL CELL BIOL, V29, P6462, DOI 10.1128/MCB.00941-09; Rous P, 1911, J EXP MED, V13, P397, DOI 10.1084/jem.13.4.397; Sangrar W, 2007, MOL CELL BIOL, V27, P6140, DOI 10.1128/MCB.01744-06; Senis YA, 2003, J THROMB HAEMOST, V1, P1062, DOI 10.1046/j.1538-7836.2003.t01-1-00124.x; STEHELIN D, 1976, NATURE, V260, P170, DOI 10.1038/260170a0; TAKEYA T, 1982, J VIROL, V44, P1; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; Tsukita S, 1999, J BIOL CHEM, V274, P34507, DOI 10.1074/jbc.274.49.34507; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366; Yu YL, 2004, NAT MED, V10, P175, DOI 10.1038/nm966	47	17	17	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	2016	35	4					501	512		10.1038/onc.2015.110	http://dx.doi.org/10.1038/onc.2015.110			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC2OT	25867068				2022-12-17	WOS:000369056700010
J	Zhang, M; Xu, E; Zhang, J; Chen, X				Zhang, M.; Xu, E.; Zhang, J.; Chen, X.			PPM1D phosphatase, a target of p53 and RBM38 RNA-binding protein, inhibits p53 mRNA translation via dephosphorylation of RBM38	ONCOGENE			English	Article							CHK2 KINASE; WIP1; RNPC1; BREAST; EXPRESSION; FAMILY; ACTIVATION; MUTATIONS; HUR	PPM1D phosphatase, also called wild-type p53-induced phosphatase 1, promotes tumor development by inactivating the p53 tumor suppressor pathway. RBM38 RNA-binding protein, also called RNPC1 and a target of p53, inhibits p53 messenger RNA (mRNA) translation, which can be reversed by GSK3 protein kinase via phosphorylation of RBM38 at serine 195. Here we showed that ectopic expression of RBM38 increases, whereas knockdown of RBM38 inhibits, PPM1D mRNA translation. Consistent with this, we found that RBM38 directly binds to PPM1D 3'-untranslated region (3'-UTR) and promotes expression of a heterologous reporter gene that carries PPM1D 3'-UTR in a dose-dependent manner. Interestingly, we showed that PPM1D directly interacts with and dephosphorylates RBM38 at serine 195. Furthermore, we showed that PPM1D modulates p53 mRNA translation and p53-dependent growth suppression through dephosphorylation of RBM38. These findings provide evidence that the crosstalk between PPM1D and RBM38, both of which are targets and modulators of p53, has a critical role in p53 expression and activity.	[Zhang, M.; Xu, E.; Zhang, J.; Chen, X.] Univ Calif Davis, Sch Vet Med, Comparat Oncol Lab, Dept Surg & Radiol Sci, Davis, CA 95616 USA	University of California System; University of California Davis	Chen, X (corresponding author), Univ Calif Davis, Sch Vet Med, Comparat Oncol Lab, 2128A Tupper Hall, Davis, CA 95616 USA.	xbchen@ucdavis.edu			NIH [CA076069, CA081237, CA121137]; NATIONAL CANCER INSTITUTE [R01CA076069, R01CA081237, R01CA121137, R29CA076069] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work is supported in part by NIH grants CA076069, CA081237 and CA121137.	Bonifacino J S, 2001, Curr Protoc Protein Sci, VChapter 3, DOI 10.1002/0471140864.ps0307s17; Cho SJ, 2010, NUCLEIC ACIDS RES, V38, P2256, DOI 10.1093/nar/gkp1229; Cho SJ, 2012, J BIOL CHEM, V287, P14535, DOI 10.1074/jbc.M111.326827; Feldstein O, 2012, MOL CANCER RES, V10, P1169, DOI 10.1158/1541-7786.MCR-12-0331; Fiscella M, 1997, P NATL ACAD SCI USA, V94, P6048, DOI 10.1073/pnas.94.12.6048; Fujimoto H, 2006, CELL DEATH DIFFER, V13, P1170, DOI 10.1038/sj.cdd.4401801; Gilmartin AG, 2014, NAT CHEM BIOL, V10, P181, DOI [10.1038/NCHEMBIO.1427, 10.1038/nchembio.1427]; Heinicke LA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078031; Kleiblova P, 2013, J CELL BIOL, V201, P511, DOI 10.1083/jcb.201210031; Leveille N, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1519; Li J, 2002, NAT GENET, V31, P133, DOI 10.1038/ng888; Lu XB, 2005, GENE DEV, V19, P1162, DOI 10.1101/gad.1291305; Lu XB, 2007, CANCER CELL, V12, P342, DOI 10.1016/j.ccr.2007.08.033; Nannenga B, 2006, MOL CARCINOGEN, V45, P594, DOI 10.1002/mc.20195; Natrajan R, 2009, CLIN CANCER RES, V15, P2711, DOI 10.1158/1078-0432.CCR-08-1878; Oliva-Trastoy M, 2007, ONCOGENE, V26, P1449, DOI 10.1038/sj.onc.1209927; Pandolfi S, 2013, ONCOGENE, V32, P4737, DOI 10.1038/onc.2012.502; Parssinen J, 2008, CANCER GENET CYTOGEN, V182, P33, DOI 10.1016/j.cancergencyto.2007.12.013; Peritz T, 2006, NAT PROTOC, V1, P577, DOI 10.1038/nprot.2006.82; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Rayter S, 2008, ONCOGENE, V27, P1036, DOI 10.1038/sj.onc.1210729; Ruark E, 2013, NATURE, V493, P406, DOI 10.1038/nature11725; Shreeram S, 2006, MOL CELL, V23, P757, DOI 10.1016/j.molcel.2006.07.010; Shu LM, 2006, GENE DEV, V20, P2961, DOI 10.1101/gad.1463306; Takekawa M, 2000, EMBO J, V19, P6517, DOI 10.1093/emboj/19.23.6517; Tan DSP, 2009, CLIN CANCER RES, V15, P2269, DOI 10.1158/1078-0432.CCR-08-2403; Wang W, 2014, BRAZ J MED BIOL RES, V47, P1044, DOI 10.1590/1414-431X20143645; Warzecha CC, 2009, MOL CELL, V33, P591, DOI 10.1016/j.molcel.2009.01.025; Xu E, 2013, ONCOGENE, V32, P2169, DOI 10.1038/onc.2012.238; Yan WS, 2012, MOL CELL BIOL, V32, P2336, DOI 10.1128/MCB.00215-12; Yin T, 2013, J BIOL CHEM, V288, P23680, DOI 10.1074/jbc.M113.480186; Yoda A, 2006, J BIOL CHEM, V281, P24847, DOI 10.1074/jbc.M600403200; Zhang J, 2007, MOL CELL BIOL, V27, P3868, DOI 10.1128/MCB.02112-06; Zhang J, 2011, GENE DEV, V25, P1528, DOI 10.1101/gad.2069311; Zhang J, 2010, P NATL ACAD SCI USA, V107, P9614, DOI 10.1073/pnas.0912594107; Zhang M, 2013, GENE DEV, V27, P2246, DOI 10.1101/gad.221739.113; ZHANG W, 1994, CANCER RES, V54, P4448	37	17	18	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2015	34	48					5900	5911		10.1038/onc.2015.31	http://dx.doi.org/10.1038/onc.2015.31			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CX1CO	25823026	Green Accepted, Green Submitted			2022-12-17	WOS:000365434000004
J	Liang, Y; Gao, H; Lin, SY; Goss, JA; Du, C; Li, K				Liang, Y.; Gao, H.; Lin, S-Y; Goss, J. A.; Du, C.; Li, K.			Mcph1/Brit1 deficiency promotes genomic instability and tumor formation in a mouse model	ONCOGENE			English	Article							DNA-DAMAGE RESPONSE; LI-FRAUMENI-SYNDROME; INDUCED CELL-DEATH; BREAST-CANCER; MITOTIC ENTRY; CENTROSOME AMPLIFICATION; MCPH1 PROTEIN; BRCT DOMAIN; P53; MICROCEPHALIN	MCPH1, also known as BRIT1, has recently been identified as a novel key regulatory gene of the DNA damage response pathway. MCPH1 is located on human chromosome 8p23.1, where human cancers frequently show loss of heterozygosity. As such, MCPH1 is aberrantly expressed in many malignancies, including breast and ovarian cancers, and the function of MCPH1 has been implicated in tumor suppression. However, it remains poorly understood whether MCPH1 deficiency leads to tumorigenesis. Here we generated and studied both Mcph1(-/-) and Mcph1(-/-)p53(-/-) mice; we showed that Mcph1(-/-) mice developed tumors with long latency, and that primary lymphoma developed significantly earlier in Mcph1(-/-)p53(-/-) mice than in Mcph11(+/+)p53(-/-) and Mcph1(+/-)p53(-/-) mice. The Mcph1(-/-)p53(-/-) lymphomas and derived murine embryonic fibroblasts (MEFs) were both more sensitive to irradiation. Mcph1 deficiency resulted in remarkably increased chromosome and chromatid breaks in Mcph1(-/-)p53(-/-) lymphomas and MEFs, as determined by metaphase spread assay and spectral karyotyping analysis. In addition, Mcph1 deficiency significantly enhanced aneuploidy as well as abnormal centrosome multiplication in Mcph1(-/-)p53(-/-) cells. Meanwhile, Mcph1 deficiency impaired double strand break (DSB) repair in Mcph1(-/-)p53(-/-) MEFs as demonstrated by neutral Comet assay. Compared with Mcph1(+/+)p53(-/-) MEFs, homologous recombination and non-homologous end-joining activities were significantly decreased in Mcph1(-/-)p53(-/-) MEFs. Notably, reconstituted MCPH1 rescued the defects of DSB repair and alleviated chromosomal aberrations in Mcph1(-/-)p53(-/-) MEFs. Taken together, our data demonstrate MCPH1 deficiency promotes genomic instability and increases cancer susceptibility. Our study using knockout mouse models provides convincing genetic evidence that MCPH1 is a bona fide tumor suppressor gene. Its deficiency leading to defective DNA repair in tumors can be used to develop novel targeted cancer therapies in the future.	[Liang, Y.; Gao, H.; Goss, J. A.; Li, K.] Baylor Coll Med, Michael E DeBakey Dept Surg, Houston, TX 77030 USA; [Liang, Y.] Taishan Med Univ, Sch Pharmaceut Sci, Tai An, Shandong, Peoples R China; [Lin, S-Y] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA; [Du, C.] Univ Cincinnati, Coll Med, Dept Canc Biol, Cincinnati, OH USA; [Du, C.] Univ Cincinnati, Coll Med, Dept Cell Biol, Cincinnati, OH USA	Baylor College of Medicine; Shandong First Medical University & Shandong Academy of Medical Sciences; University of Texas System; UTMD Anderson Cancer Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Li, K (corresponding author), Baylor Coll Med, Michael E DeBakey Dept Surg, ABBR, R417,MC BCM390,One Baylor Plaza, Houston, TX 77030 USA.	kli@bcm.edu	Liang, Yulong/A-2171-2013	Liang, Yulong/0000-0001-8219-9575	National Institutes of Health [R01-CA155151, R21-CA161513]; St Luke's Episcopal Hospital McDonald Research Foundation; National Natural Science Foundation of China [81372589]; NATIONAL CANCER INSTITUTE [P30CA125123, R01CA155151, R21CA161513] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR024574] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI036211] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056338] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); St Luke's Episcopal Hospital McDonald Research Foundation; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by grants from the National Institutes of Health to KL (R01-CA155151 and R21-CA161513), a grant from the St Luke's Episcopal Hospital McDonald Research Foundation to KL and a grant from National Natural Science Foundation of China (to YL, 81372589). We thank BCM Cytometry and Cell Sorting Core (NCRR S10RR024574, NIAID AI036211 and NCI P30CA125123) and Molecular Morphology Core Laboratory (PHS DK56338) for technical assistance. We also thank Drs Zhijie Li, Han Lin, Ana Rodriguez (all from Baylor College of Medicine, Houston, TX, USA) and Guang Peng (UT MD Anderson Cancer Center, Houston, TX, USA) for providing anti-CD4/CD8 antibodies (ZL), assisting in NHEJ analysis (HL), editing of this manuscript (AR) and providing HR-related plasmids (GP).	Alderton GK, 2006, NAT CELL BIOL, V8, P725, DOI 10.1038/ncb1431; Bachelier R, 2003, ONCOGENE, V22, P528, DOI 10.1038/sj.onc.1206208; Bhattacharya N, 2013, ANN SURG ONCOL, V20, pS424, DOI 10.1245/s10434-012-2715-6; Bonner WM, 2008, NAT REV CANCER, V8, P957, DOI 10.1038/nrc2523; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Brown JAL, 2010, ONCOGENE, V29, P5537, DOI 10.1038/onc.2010.302; Bruning-Richardson A, 2011, BRIT J CANCER, V104, P1602, DOI 10.1038/bjc.2011.117; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Celeste A, 2003, CELL, V114, P371, DOI 10.1016/S0092-8674(03)00567-1; Clapperton JA, 2004, NAT STRUCT MOL BIOL, V11, P512, DOI 10.1038/nsmb775; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Duesberg P, 2004, IUBMB LIFE, V56, P65, DOI 10.1080/15216540410001667902; Efeyan A, 2007, CELL CYCLE, V6, P1006, DOI 10.4161/cc.6.9.4211; Gordon DJ, 2012, NAT REV GENET, V13, P189, DOI 10.1038/nrg3123; Gruber R, 2011, NAT CELL BIOL, V13, P1325, DOI 10.1038/ncb2342; Grundy S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071629; Guidos CJ, 1996, GENE DEV, V10, P2038, DOI 10.1101/gad.10.16.2038; Gurley KE, 1998, CANCER RES, V58, P3111; Hiramoto T, 1999, ONCOGENE, V18, P3422, DOI 10.1038/sj.onc.1202691; Kang J, 2005, MOL CELL BIOL, V25, P661, DOI 10.1128/MCB.25.2.661-670.2005; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Leung JW, 2011, J BIOL CHEM, V286, P21393, DOI 10.1074/jbc.M110.208793; Liang YL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000826; Lieber MR, 2003, NAT REV MOL CELL BIO, V4, P712, DOI 10.1038/nrm1202; Lin SY, 2010, YONSEI MED J, V51, P295, DOI 10.3349/ymj.2010.51.3.295; Mailloux AW, 2009, J IMMUNOL, V182, P2753, DOI 10.4049/jimmunol.0801124; Manke IA, 2003, SCIENCE, V302, P636, DOI 10.1126/science.1088877; MATSUMOTO K, 1991, IMMUNOLOGY, V72, P20; Mei JJ, 2001, CURR BIOL, V11, P1197, DOI 10.1016/S0960-9822(01)00325-6; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Milliken EL, 2008, ONCOGENE, V27, P1759, DOI 10.1038/sj.onc.1210815; Mohaghegh P, 2001, HUM MOL GENET, V10, P741, DOI 10.1093/hmg/10.7.741; Mohammad DH, 2009, DNA REPAIR, V8, P1009, DOI 10.1016/j.dnarep.2009.04.004; Nacht M, 1996, GENE DEV, V10, P2055, DOI 10.1101/gad.10.16.2055; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Olive PL, 2006, NAT PROTOC, V1, P23, DOI 10.1038/nprot.2006.5; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Peng G, 2009, NAT CELL BIOL, V11, P865, DOI 10.1038/ncb1895; Rai R, 2008, CELL CYCLE, V7, P2225, DOI 10.4161/cc.7.14.6303; Rai R, 2006, CANCER CELL, V10, P145, DOI 10.1016/j.ccr.2006.07.002; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013; Richardson J, 2011, BREAST CANCER RES TR, V127, P639, DOI 10.1007/s10549-010-1019-4; Roos WP, 2006, TRENDS MOL MED, V12, P440, DOI 10.1016/j.molmed.2006.07.007; Rothenberg EV, 2005, ANNU REV IMMUNOL, V23, P601, DOI 10.1146/annurev.immunol.23.021704.115737; Schoenmakers EFPM, 1999, CANCER RES, V59, P19; Shi L, 2012, GENE, V495, P1, DOI 10.1016/j.gene.2011.12.053; Singh B, 2002, AM J PATHOL, V161, P365, DOI 10.1016/S0002-9440(10)64191-0; Singh N, 2012, J BIOL CHEM, V287, P2854, DOI 10.1074/jbc.M111.307868; Sotiropoulou PA, 2010, NAT CELL BIOL, V12, P572, DOI 10.1038/ncb2059; Sung P, 2006, NAT REV MOL CELL BIO, V7, P739, DOI 10.1038/nrm2008; Tarapore P, 2002, ONCOGENE, V21, P6234, DOI 10.1038/sj.onc.1205707; Tibelius A, 2009, J CELL BIOL, V185, P1149, DOI 10.1083/jcb.200810159; Venkatesh T, 2014, EUR J CELL BIOL, V93, P98, DOI 10.1016/j.ejcb.2014.01.005; Venkatesh T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054643; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; Ward IM, 2005, MOL CELL BIOL, V25, P10079, DOI 10.1128/MCB.25.22.10079-10086.2005; Wong AKC, 1998, ONCOGENE, V17, P2279, DOI 10.1038/sj.onc.1202150; Wood JL, 2007, J BIOL CHEM, V282, P35416, DOI 10.1074/jbc.M705245200; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Wu XL, 2009, CANCER RES, V69, P5531, DOI 10.1158/0008-5472.CAN-08-4834; Wurmbach E, 2007, HEPATOLOGY, V45, P938, DOI 10.1002/hep.21622; Yang SZ, 2008, EMBO REP, V9, P907, DOI 10.1038/embor.2008.128; Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753; Zhang B, 2013, CARCINOGENESIS, V34, P2271, DOI 10.1093/carcin/bgt190; Zhang J, 2013, ASIAN PAC J CANCER P, V14, P7295, DOI 10.7314/APJCP.2013.14.12.7295	66	17	17	2	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2015	34	33					4368	4378		10.1038/onc.2014.367	http://dx.doi.org/10.1038/onc.2014.367			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CO9KK	25362854	Green Accepted			2022-12-17	WOS:000359494400008
J	Schwarzer, A; Holtmann, H; Brugman, M; Meyer, J; Schauerte, C; Zuber, J; Steinemann, D; Schlegelberger, B; Li, Z; Baum, C				Schwarzer, A.; Holtmann, H.; Brugman, M.; Meyer, J.; Schauerte, C.; Zuber, J.; Steinemann, D.; Schlegelberger, B.; Li, Z.; Baum, C.			Hyperactivation of mTORC1 and mTORC2 by multiple oncogenic events causes addiction to eIF4E-dependent mRNA translation in T-cell leukemia	ONCOGENE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; GLUCOCORTICOID RESISTANCE; STEM-CELLS; COMPLEX 2; C-MYC; PTEN; ACTIVATION; PATHWAY; AKT; INHIBITION	High activation of the PI3K-AKT-mTOR pathway is characteristic for T-cell acute lymphoblastic leukemia (T-ALL). The activity of the master regulator of this pathway, PTEN, is often impaired in T-ALL. However, experimental evidence suggests that input from receptor tyrosine kinases (RTKs) is required for sustained mTOR activation, even in the absence of PTEN. We previously reported the expression of Neurotrophin receptor tyrosine kinases (TRKs) and their respective ligands in primary human leukemia samples. In the present study we aimed to dissect the downstream signaling cascades of TRK-induced T-ALL in a murine model and show that T-ALLs induced by deregulated receptor tyrosine kinase signaling acquire activating mutations in Notch1 and lose PTEN during clonal evolution. Some clones additionally lost one allele of the homeodomain transcription factor Cux1. All events independently led to a gradual hyperactivation of both mTORC1 and mTORC2 signaling. We dissected the role of the individual mTOR complexes by shRNA knockdown and found that the separate depletion of mTORC1 or mTORC2 reduced the growth of T-ALL blasts, but was not sufficient to induce apoptosis. In contrast, knockdown of the mTOR downstream effector eIF4E caused a striking cytotoxic effect, demonstrating a critical addiction to cap-dependent mRNA-translation. Although high mTORC2-AKT activation is commonly associated with drug-resistance, we demonstrate that T-ALL displaying a strong mTORC2-AKT activation were specifically susceptible to 4EGI-1, an inhibitor of the eIF4E-eIF4G interaction. To decipher the mechanism of 4EGI-1, we performed a genome-wide analysis of mRNAs that are translationally regulated by 4EGI-1 in T-ALL. 4EGI-1 effectively reduced the ribosomal occupancy of mRNAs that were strongly upregulated in T-ALL blasts compared with normal thymocytes including transcripts important for translation, mitochondria and cell cycle progression, such as cyclins and ribosomal proteins. These data suggest that disrupting the eIF4E-eIF4G interaction constitutes a promising therapy strategy in mTOR-deregulated T-cell leukemia.	[Schwarzer, A.; Brugman, M.; Meyer, J.; Li, Z.; Baum, C.] Hannover Med Sch, Inst Expt Hematol, D-30625 Hannover, Germany; [Holtmann, H.; Schauerte, C.] Hannover Med Sch, Inst Biochem, D-30625 Hannover, Germany; [Zuber, J.] Res Inst Mol Pathol IMP, Vienna, Austria; [Steinemann, D.; Schlegelberger, B.] Hannover Med Sch, Inst Cell & Mol Pathol, D-30625 Hannover, Germany	Hannover Medical School; Hannover Medical School; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Hannover Medical School	Schwarzer, A (corresponding author), Hannover Med Sch, Inst Expt Hematol, OE6960,Carl Neuberg Str 1, D-30625 Hannover, Germany.	schwarzer.adrian@mh-hannover.de	Brugman, Martijn/F-3389-2011; Zuber, Johannes/E-7517-2011; Schwarzer, Adrian/AAA-2571-2022	Brugman, Martijn/0000-0003-2675-2705; Zuber, Johannes/0000-0001-8810-6835; Schwarzer, Adrian/0000-0001-5684-2280	Hannover Biomedical Research School (HBRS); MD-PhD program 'Molecular Medicine'; Deutsche Krebshilfe [108245, 109800]; Deutsche Jose Carreras Leukamie-Stiftung [DJCLS F10/06]; Deutsche Forschungsgemeinschaft [Li 1608/2-1, SFB738]; DFG-Cluster of Excellence REBIRTH	Hannover Biomedical Research School (HBRS); MD-PhD program 'Molecular Medicine'; Deutsche Krebshilfe(Deutsche Krebshilfe); Deutsche Jose Carreras Leukamie-Stiftung; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); DFG-Cluster of Excellence REBIRTH	AS was supported by the Hannover Biomedical Research School (HBRS) and the MD-PhD program 'Molecular Medicine'. We thank Dr Jan Cools, Center for Human Genetics, KULeuven, Leuven for the MOHITO cell line. We thank Dr Phillip Ivanyi and Professor Anke Franzke, Department of Hematology, MHH for providing human T-ALL cell lines. We thank Rena-Mareike Struss, Institute of Experimental Hematology, Hannover Medical School for help with mouse experiments and Anneke Doerrie, Institute of Biochemistry, for assistance in polysome profiling experiments. We thank Axel Schambach, Institute of Experimental Hematology, for providing pRSF91. IRES. dTomato and pRRL.PPT.SF.IRES.EGFP. WPRE vectors. We thank Thomas Neumann and Maike Stahlhut for performing the microarray experiments. We thank the Cell Sorting Unit of Hannover Medical School for performing sorting experiments and Michael Morgan for proofreading the manuscript. This work was supported by the Deutsche Krebshilfe (grants: 108245 and 109800), the Deutsche Jose Carreras Leukamie-Stiftung (grant: DJCLS F10/06), the Deutsche Forschungsgemeinschaft (grants: Li 1608/2-1 and SFB738) and the DFG-Cluster of Excellence REBIRTH.	Ashworth TD, 2010, BLOOD, V116, P5455, DOI 10.1182/blood-2010-05-286328; Aster JC, 2008, ANNU REV PATHOL-MECH, V3, P587, DOI 10.1146/annurev.pathmechdis.3.121806.154300; Birsoy K, 2014, NATURE, V508, P108, DOI 10.1038/nature13110; Blackburn JS, 2014, CANCER CELL, V25, P366, DOI 10.1016/j.ccr.2014.01.032; Bonnet M, 2011, BLOOD, V117, P6650, DOI 10.1182/blood-2011-02-336842; Chan SM, 2007, BLOOD, V110, P278, DOI 10.1182/blood-2006-08-039883; Chen LM, 2012, ONCOTARGET, V3, P869, DOI 10.18632/oncotarget.598; Chiang MY, 2008, J CLIN INVEST, V118, P3181, DOI 10.1172/JCI35090; Clappier E, 2011, J EXP MED, V208, P653, DOI 10.1084/jem.20110105; Curry NL, 2013, CANCER DISCOV, V3, P908, DOI 10.1158/2159-8290.CD-12-0507; De Benedetti A, 2004, ONCOGENE, V23, P3189, DOI 10.1038/sj.onc.1207545; Dello Sbarba P, 2014, HYPOXIA, V2, P1; Fellmann C, 2013, CELL REP, V5, P1704, DOI 10.1016/j.celrep.2013.11.020; Fu Z, 2008, ONCOGENE, V27, P2312, DOI 10.1038/onc.2008.24; Gokbuget N, 2012, BLOOD, V120, P2032, DOI 10.1182/blood-2011-12-399287; Graeber TG, 2001, NAT GENET, V29, P295, DOI 10.1038/ng755; Gutierrez A, 2011, J EXP MED, V208, P1595, DOI 10.1084/jem.20101691; Gutierrez A, 2009, BLOOD, V114, P647, DOI 10.1182/blood-2009-02-206722; Homminga I, 2011, CANCER CELL, V19, P484, DOI 10.1016/j.ccr.2011.02.008; Hsieh AC, 2012, NATURE, V485, P55, DOI 10.1038/nature10912; Hsieh AC, 2010, CANCER CELL, V17, P249, DOI 10.1016/j.ccr.2010.01.021; Jo OD, 2008, J BIOL CHEM, V283, P23274, DOI 10.1074/jbc.M801185200; Kleppe M, 2011, HAEMATOL-HEMATOL J, V96, P779, DOI 10.3324/haematol.2010.035931; Lagadinou ED, 2013, CELL STEM CELL, V12, P329, DOI 10.1016/j.stem.2012.12.013; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Larsson O, 2011, BIOINFORMATICS, V27, P1440, DOI 10.1093/bioinformatics/btr146; Lee JY, 2010, CELL STEM CELL, V7, P593, DOI 10.1016/j.stem.2010.09.015; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Lee K, 2012, J EXP MED, V209, P713, DOI 10.1084/jem.20111470; Li ZX, 2009, BLOOD, V113, P2028, DOI 10.1182/blood-2008-05-155200; Lin CJ, 2012, CELL REPORTS, V1, P325, DOI 10.1016/j.celrep.2012.02.010; Meyer J, 2007, LEUKEMIA, V21, P2171, DOI 10.1038/sj.leu.2404882; Moerke NJ, 2007, CELL, V128, P257, DOI 10.1016/j.cell.2006.11.046; Mulloy JC, 2005, P NATL ACAD SCI USA, V102, P4016, DOI 10.1073/pnas.0404701102; Ntziachristos P, 2012, NAT MED, V18, P298, DOI 10.1038/nm.2651; Palomero T, 2007, NAT MED, V13, P1203, DOI 10.1038/nm1636; Pearse RN, 2005, BLOOD, V105, P4429, DOI 10.1182/blood-2004-08-3096; Piovan E, 2013, CANCER CELL, V24, P766, DOI 10.1016/j.ccr.2013.10.022; RAMSAY G, 1984, P NATL ACAD SCI-BIOL, V81, P7742, DOI 10.1073/pnas.81.24.7742; Ren MQ, 2009, BLOOD, V114, P1576, DOI 10.1182/blood-2009-03-212704; Renne C, 2008, LEUKEMIA RES, V32, P163, DOI 10.1016/j.leukres.2007.05.019; Rhein M, 2011, ANN HEMATOL, V90, P283, DOI 10.1007/s00277-010-1065-3; Schatz JH, 2011, J EXP MED, V208, P1799, DOI 10.1084/jem.20110846; Segal RA, 2003, ANNU REV NEUROSCI, V26, P299, DOI 10.1146/annurev.neuro.26.041002.131421; Silva A, 2008, J CLIN INVEST, V118, P3762, DOI 10.1172/JCI34616; Soulier J, 2005, BLOOD, V106, P274, DOI 10.1182/blood-2004-10-3900; Subramaniam PS, 2012, CANCER CELL, V21, P459, DOI 10.1016/j.ccr.2012.02.029; Tamburini J, 2009, BLOOD, V114, P1618, DOI 10.1182/blood-2008-10-184515; Thoreen CC, 2012, NATURE, V485, P109, DOI 10.1038/nature11083; Trinquand A, 2013, J CLIN ONCOL, V31, P4333, DOI 10.1200/JCO.2012.48.5292; van Vlierberghe P, 2008, BRIT J HAEMATOL, V143, P153, DOI 10.1111/j.1365-2141.2008.07314.x; Wasag B, 2011, HAEMATOL-HEMATOL J, V96, P922, DOI 10.3324/haematol.2010.036558; Wei G, 2006, CANCER CELL, V10, P331, DOI 10.1016/j.ccr.2006.09.006; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Wong CC, 2014, NAT GENET, V46, P33, DOI 10.1038/ng.2846	55	17	18	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	27					3593	3604		10.1038/onc.2014.290	http://dx.doi.org/10.1038/onc.2014.290			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM1IQ	25241901				2022-12-17	WOS:000357434900011
J	Morris, SM; Carter, KT; Baek, JY; Koszarek, A; Yeh, MM; Knoblaugh, SE; Grady, WM				Morris, S. M.; Carter, K. T.; Baek, J. Y.; Koszarek, A.; Yeh, M. M.; Knoblaugh, S. E.; Grady, W. M.			TGF-beta signaling alters the pattern of liver tumorigenesis induced by Pten inactivation	ONCOGENE			English	Article							GROWTH-FACTOR-BETA; EMBRYONIC STEM-CELLS; RECEPTOR C-KIT; CYCLIN D1; CARCINOMA; EXPRESSION; CANCER; DIFFERENTIATION; ROLES; MOUSE	Hepatocarcinogenesis results from the accumulation of genetic and epigenetic changes in liver cells. A common mechanism through which these alterations induce liver cancer is by deregulating signaling pathways. A number of signaling pathways, including the PI3K/PTEN/AKT and transforming growth factor beta (TGF-beta) pathways have been implicated in normal liver development as well as in cancer formation. In this study, we assessed the effect of the TGF-beta signaling pathway on liver tumors induced by phosphatase and tensin homolog (Pten) loss. Inactivation of only the TGF-beta receptor type II, Tgfbr2, in the mouse liver (Tgfbr2(LKO)) had no overt phenotype, while inactivation of Pten alone (Pten(LKO)), resulted in the formation of both hepatocellular carcinomas and cholangiocarcinomas (CC). Interestingly, deletion of both Pten and Tgfbr2 (Pten(LKO); Tgfbr2(LKO)) in the mouse liver resulted in a dramatic shift in tumor type to predominantly CC. Assessment of the PI3K/PTEN/AKT pathway revealed increased phosphorylation of AKT and glycogen synthase kinase 3 beta (GSK-3 beta) in both the Pten(LKO) and Pten(LKO); Tgfbr2(LKO) mice, suggesting that this pathway is constitutively active regardless of the status of the TGF-beta signaling pathway. However, phosphorylation of p70 S6 kinase was observed in the liver of all three phenotypes (Tgfbr2(LKO), Pten(LKO), Pten(LKO); Tgfbr2(LKO)) indicating that the loss of Tgfbr2 and/or Pten leads to an increase in this signaling pathway. Analysis of markers of liver progenitor/stem cells revealed that the loss of TGF-beta signaling resulted in increased expression of c-Kit and CD133. Furthermore, in addition to increased c-Kit and CD133, Scf and EpCam expression were also increased in the double knock-out mice. These results suggest that the alteration in tumor types between the Pten(LKO) mice and Pten(LKO); Tgfbr2(LKO) mice is secondary to the altered regulation of stem-cell features induced by the loss of TGF-beta signaling.	[Morris, S. M.; Carter, K. T.; Koszarek, A.; Grady, W. M.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA; [Baek, J. Y.] Natl Canc Ctr, Res Inst & Hosp, Ctr Colorectal Canc, Goyang, South Korea; [Yeh, M. M.] Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA; [Knoblaugh, S. E.] Fred Hutchinson Canc Res Ctr, Comparat Med, Seattle, WA 98109 USA; [Grady, W. M.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; National Cancer Center - Korea (NCC); University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle	Grady, WM (corresponding author), Fred Hutchinson Canc Res Ctr, Div Clin Res, 1100 Fairview Ave N,Mailstop D4-100, Seattle, WA 98109 USA.	wgrady@fhcrc.org			Burroughs Wellcome Fund; National Institutes of Health [RO1 DK60669-01, P30 CA015704]; National Institutes of Health Interdisciplinary Training Grant [T32 CA080416]; Experimental Histopathology, Scientific Imaging and Comparative Medicine Cores at the Fred Hutchinson Cancer Research Center; NATIONAL CANCER INSTITUTE [T32CA080416, P30CA015704] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060669] Funding Source: NIH RePORTER	Burroughs Wellcome Fund(Burroughs Wellcome Fund); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institutes of Health Interdisciplinary Training Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Experimental Histopathology, Scientific Imaging and Comparative Medicine Cores at the Fred Hutchinson Cancer Research Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work is supported in part by funding from Burroughs Wellcome Fund, the National Institutes of Health (RO1 DK60669-01 and P30 CA015704, WMG) and by the National Institutes of Health Interdisciplinary Training Grant (T32 CA080416, SMM). The authors thank Jean Campbell and members of the Grady laboratory for helpful suggestions. We also wish to acknowledge support from the Experimental Histopathology, Scientific Imaging and Comparative Medicine Cores at the Fred Hutchinson Cancer Research Center.	Amin Rupen, 2008, Gastrointest Cancer Res, V2, pS27; Attisano Liliana, 2013, F1000Prime Rep, V5, P17, DOI 10.12703/P5-17; Bierie B, 2006, CYTOKINE GROWTH F R, V17, P29, DOI 10.1016/j.cytogfr.2005.09.006; Breuhahn K, 2006, ONCOGENE, V25, P3787, DOI 10.1038/sj.onc.1209556; Cai J, 2007, HEPATOLOGY, V45, P1229, DOI 10.1002/hep.21582; Carracedo A, 2008, ONCOGENE, V27, P5527, DOI 10.1038/onc.2008.247; Chalhoub N, 2009, ANNU REV PATHOL-MECH, V4, P127, DOI 10.1146/annurev.pathol.4.110807.092311; Chen CL, 2013, J CLIN INVEST, V123, P2832, DOI 10.1172/JCI65859; Chytil A, 2002, GENESIS, V32, P73, DOI 10.1002/gene.10046; Clotman F, 2005, GENE DEV, V19, P1849, DOI 10.1101/gad.340305; Deschl U, 2001, INT CLASSIFICATION R, P59; Fabregat I, 2009, WORLD J GASTROENTERO, V15, P513, DOI 10.3748/wjg.15.513; Forbes S A, 2008, Curr Protoc Hum Genet, VChapter 10, DOI 10.1002/0471142905.hg1011s57; Galicia VA, 2010, GASTROENTEROLOGY, V139, P2170, DOI 10.1053/j.gastro.2010.09.002; Herrera B, 2012, CURR PHARM DESIGN, V18, P4114, DOI 10.2174/138161212802430503; Hollander MC, 2011, NAT REV CANCER, V11, P289, DOI 10.1038/nrc3037; Horie Y, 2004, J CLIN INVEST, V113, P1774, DOI 10.1172/JCI200420513; Hu TH, 2003, CANCER, V97, P1929, DOI 10.1002/cncr.11266; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Kim H, 2004, J HEPATOL, V40, P298, DOI 10.1016/j.jhep.2003.10.023; Kitisin K, 2007, ONCOGENE, V26, P7103, DOI 10.1038/sj.onc.1210513; Knobbe CB, 2008, ONCOGENE, V27, P5398, DOI 10.1038/onc.2008.238; Lesche R, 2002, GENESIS, V32, P148, DOI 10.1002/gene.10036; Luo SM, 2005, WORLD J GASTROENTERO, V11, P4272; Majumdar A, 2012, NAT REV GASTRO HEPAT, V9, P530, DOI 10.1038/nrgastro.2012.114; Mansuroglu T, 2009, EUR J GASTROEN HEPAT, V21, P1206, DOI 10.1097/MEG.0b013e328317f4ef; Mansuroglu T, 2009, LAB INVEST, V89, P562, DOI 10.1038/labinvest.2009.15; Mittal S, 2013, J CLIN GASTROENTEROL, V47, pS2, DOI 10.1097/MCG.0b013e3182872f29; Morris SM, 2012, HEPATOLOGY, V55, P121, DOI 10.1002/hep.24653; Petritsch C, 2000, GENE DEV, V14, P3093, DOI 10.1101/gad.854200; Peyrou M, 2010, WORLD J GASTROENTERO, V16, P4627, DOI 10.3748/wjg.v16.i37.4627; Postic C, 2000, GENESIS, V26, P149, DOI 10.1002/(SICI)1526-968X(200002)26:2<149::AID-GENE16>3.0.CO;2-V; Postic C, 1999, J BIOL CHEM, V274, P305, DOI 10.1074/jbc.274.1.305; Romero-Gallo J, 2005, ONCOGENE, V24, P3028, DOI 10.1038/sj.onc.1208475; Rountree CB, 2009, STEM CELLS, V27, P290, DOI 10.1634/stemcells.2008-0332; Shi YJ, 2012, J CELL SCI, V125, P4687, DOI 10.1242/jcs.093765; Shiraki N, 2008, GENES CELLS, V13, P731, DOI 10.1111/j.1365-2443.2008.01201.x; Singal AK, 2011, J CANCER RES CLIN, V137, P1071, DOI 10.1007/s00432-010-0971-z; Stiles B, 2004, P NATL ACAD SCI USA, V101, P2082, DOI 10.1073/pnas.0308617100; Sugimachi K, 2001, J HEPATOL, V35, P74, DOI 10.1016/S0168-8278(01)00079-4; Thoolen B, 2010, TOXICOL PATHOL, V38, p5S, DOI 10.1177/0192623310386499; Wakefield LM, 2013, NAT REV CANCER, V13, P328, DOI 10.1038/nrc3500; WENNERBERG AE, 1993, AM J PATHOL, V143, P1050; Whittaker S, 2010, ONCOGENE, V29, P4989, DOI 10.1038/onc.2010.236; Wu K, 2012, HEPATOLOGY, V56, P2255, DOI 10.1002/hep.26007; Wu X, 2012, LIVER TUMORS, P37; Xu XL, 2006, J CLIN INVEST, V116, P1843, DOI 10.1172/JCI27282; Yamashita T, 2013, J CLIN INVEST, V123, P1911, DOI 10.1172/JCI66024; Yao YJ, 1999, ONCOGENE, V18, P3181, DOI 10.1038/sj.onc.1202659; Yeh MM, 2010, J GASTROEN HEPATOL, V25, P1485, DOI 10.1111/j.1440-1746.2010.06430.x; Zaret KS, 2001, CURR OPIN GENET DEV, V11, P568, DOI 10.1016/S0959-437X(00)00234-3; Zhou L, 2006, WORLD J GASTROENTERO, V12, P1175, DOI 10.3748/wjg.v12.i8.1175	52	17	18	0	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2015	34	25					3273	3282		10.1038/onc.2014.258	http://dx.doi.org/10.1038/onc.2014.258			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK9XH	25132272	Green Accepted			2022-12-17	WOS:000356592300006
J	Kurklu, B; Whitehead, RH; Ong, EK; Minamoto, T; Fox, JG; Mann, JR; Judd, LM; Giraud, AS; Menheniott, TR				Kurklu, B.; Whitehead, R. H.; Ong, E. K.; Minamoto, T.; Fox, J. G.; Mann, J. R.; Judd, L. M.; Giraud, A. S.; Menheniott, T. R.			Lineage-specific RUNX3 hypomethylation marks the preneoplastic immune component of gastric cancer	ONCOGENE			English	Article							DNA METHYLATION; TUMOR-SUPPRESSOR; T-CELLS; EXPRESSION; GENES; HYPERMETHYLATION; PROTEINS; ENHANCER; COLITIS; ABSENCE	Runt domain transcription factor 3 (RUNX3) is widely regarded as a tumour-suppressor gene inactivated by DNA hypermethylation of its canonical CpG (cytidine-phosphate-guanidine) island (CGI) promoter in gastric cancer (GC). Absence of RUNX3 expression from normal gastric epithelial cells (GECs), the progenitors to GC, coupled with frequent RUNX3 overexpression in GC progression, challenge this longstanding paradigm. However, epigenetic models to better describe RUNX3 deregulation in GC have not emerged. Here, we identify lineage-specific DNA methylation at an alternate, non-CGI promoter (P1) as a new mechanism of RUNX3 epigenetic control. In normal GECs, P1 was hypermethylated and repressed, whereas in immune lineages P1 was hypomethylated and widely expressed. In human GC development, we detected aberrant P1 hypomethylation signatures associated with the early inflammatory, preneoplastic and tumour stages. Aberrant P1 hypomethylation was fully recapitulated in mouse models of gastric inflammation and tumorigenesis. Cell sorting showed that P1 hypomethylation reflects altered cell-type composition of the gastric epithelium/tumour microenvironment caused by immune cell recruitment, not methylation loss. Finally, via long-term culture of gastric tumour epithelium, we revealed that de novo methylation of the RUNX3 canonical CGI promoter is a bystander effect of oncogenic immortalization and not likely causal in GC pathogenesis as previously argued. We propose a new model of RUNX3 epigenetic control in cancer, based on immune-specific, non-CGI promoter hypomethylation. This novel epigenetic signature may have utility in early detection of GC and possibly other epithelial cancers with premalignant immune involvement.	[Kurklu, B.; Ong, E. K.; Mann, J. R.; Judd, L. M.; Giraud, A. S.; Menheniott, T. R.] Royal Childrens Hosp, Murdoch Childrens Res Inst, Infect & Immun, Parkville, Vic 3052, Australia; [Kurklu, B.; Whitehead, R. H.; Judd, L. M.; Giraud, A. S.; Menheniott, T. R.] Univ Melbourne, Dept Paediat, Melbourne, Vic, Australia; [Minamoto, T.] Kanazawa Univ, Canc Res Inst, Div Translat & Clin Oncol, Kanazawa, Ishikawa 920, Japan; [Fox, J. G.] MIT, Div Comparat Med, Dept Biol Engn, Cambridge, MA 02139 USA; [Mann, J. R.] Univ Melbourne, Dept Zool, Melbourne, Vic, Australia	Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; University of Melbourne; Kanazawa University; Massachusetts Institute of Technology (MIT); University of Melbourne	Menheniott, TR (corresponding author), Royal Childrens Hosp, Murdoch Childrens Res Inst, Infect & Immun, Flemington Rd, Parkville, Vic 3052, Australia.	treve.menheniott@mcri.edu.au	Menheniott, Treve/D-7964-2015	Menheniott, Treve/0000-0003-2349-8238; Judd, Louise/0000-0003-3613-4839	National Health and Medical Research Council (NH&MRC) of Australia [1006542]; Victorian Government's Medical Research Operational Infrastructure Program; Grants-in-Aid for Scientific Research [25670572] Funding Source: KAKEN; NATIONAL CANCER INSTITUTE [P01CA028842] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES002109] Funding Source: NIH RePORTER	National Health and Medical Research Council (NH&MRC) of Australia(National Health and Medical Research Council (NHMRC) of Australia); Victorian Government's Medical Research Operational Infrastructure Program; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank Professor Y Groner and Dr D Levanon (The Weizmann Institute of Science, Rehovot, Israel) for their gift of anti-Runx3 antiserum and critical reviews of the manuscript. We thank Professor I van Driel (University of Melbourne, Australia) for providing H+/K+ ATPase-gmcsf transgenic mice and Professor M Ernst (Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia) for providing gp130<SUP>F/F</SUP> mice. We thank Dr J Dabritz (Murdoch Children's Research Institute) for critically reviewing the manuscript. This work was supported by a project grant (1006542) awarded to TRM by the National Health and Medical Research Council (NH&MRC) of Australia and by the Victorian Government's Medical Research Operational Infrastructure Program.	Biondo M, 2001, J IMMUNOL, V166, P2090, DOI 10.4049/jimmunol.166.3.2090; Brenner O, 2004, P NATL ACAD SCI USA, V101, P16016, DOI 10.1073/pnas.0407180101; Clark SJ, 2002, ONCOGENE, V21, P5380, DOI 10.1038/sj.onc.1205598; Coolen MW, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm662; CORREA P, 1975, LANCET, V2, P58; Dedeurwaerder S, 2012, ONCOIMMUNOLOGY, V1, P962, DOI 10.4161/onci.19996; Dedeurwaerder S, 2011, EMBO MOL MED, V3, P726, DOI 10.1002/emmm.201100801; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; Esteller M, 2001, CANCER RES, V61, P3225; Fainaru O, 2004, EMBO J, V23, P969, DOI 10.1038/sj.emboj.7600085; Fan XY, 2011, BMC GASTROENTEROL, V11, DOI 10.1186/1471-230X-11-92; Ferlay J, 2013, IARC CANCERBASE; Fujii S, 2008, J BIOL CHEM, V283, P17324, DOI 10.1074/jbc.M800224200; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Han H, 2011, HUM MOL GENET, V20, P4299, DOI 10.1093/hmg/ddr356; Hoffmann Werner, 2013, Front Biosci (Schol Ed), V5, P720; Hu M, 2005, NAT GENET, V37, P899, DOI 10.1038/ng1596; Hu SL, 2011, MED ONCOL, V28, P447, DOI 10.1007/s12032-010-9467-6; Huber M, 1998, P NATL ACAD SCI USA, V95, P11330, DOI 10.1073/pnas.95.19.11330; Jackson CB, 2007, J PATHOL, V213, P140, DOI 10.1002/path.2218; Judd LM, 2004, GASTROENTEROLOGY, V126, P196, DOI 10.1053/j.gastro.2003.10.066; Kalesnikoff J, 2011, METHODS MOL BIOL, V677, P207, DOI 10.1007/978-1-60761-869-0_15; Keshet I, 2006, NAT GENET, V38, P149, DOI 10.1038/ng1719; Kudo Y, 2011, J CELL BIOCHEM, V112, P387, DOI 10.1002/jcb.22967; Lai CB, 2012, J BIOL CHEM, V287, P7324, DOI 10.1074/jbc.M111.306936; Landan G, 2012, NAT GENET, V44, P1207, DOI 10.1038/ng.2442; Lee KS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030786; Levanon D, 2001, MECH DEVELOP, V109, P413, DOI 10.1016/S0925-4773(01)00537-8; Levanon D, 2002, EMBO J, V21, P3454, DOI 10.1093/emboj/cdf370; Levanon D, 2014, MOL CELL BIOL, V34, P1158, DOI 10.1128/MCB.01202-13; Levanon D, 2011, EMBO MOL MED, V3, P593, DOI 10.1002/emmm.201100168; Li J, 2004, J CLIN PATHOL, V57, P294, DOI 10.1136/jcp.2003.013011; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Lian JB, 2004, CRIT REV EUKAR GENE, V14, P1; Menheniott TR, 2010, GASTROENTEROLOGY, V138, P1823, DOI 10.1053/j.gastro.2010.01.050; Peterson AJ, 2010, GASTROENTEROLOGY, V139, P2005, DOI 10.1053/j.gastro.2010.08.043; Salto-Tellez M, 2006, ONCOGENE, V25, P7646, DOI 10.1038/sj.onc.1209739; Schier S, 2005, ONCOLOGY-BASEL, V69, P9, DOI 10.1159/000086625; Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950; Schmid CA, 2013, GASTROENTEROLOGY, V144, P22, DOI 10.1053/j.gastro.2012.11.014; Schmidl C, 2009, GENOME RES, V19, P1165, DOI 10.1101/gr.091470.109; Smiraglia DJ, 2001, HUM MOL GENET, V10, P1413, DOI 10.1093/hmg/10.13.1413; So K, 2006, PATHOL INT, V56, P571, DOI 10.1111/j.1440-1827.2006.02010.x; Sproul D, 2011, P NATL ACAD SCI USA, V108, P4364, DOI 10.1073/pnas.1013224108; Subramaniam MM, 2009, BBA-REV CANCER, V1796, P315, DOI 10.1016/j.bbcan.2009.07.004; Sugai M, 2011, J IMMUNOL, V186, P6515, DOI 10.4049/jimmunol.1001671; Taniuchi I, 2002, CELL, V111, P621, DOI 10.1016/S0092-8674(02)01111-X; Weber M, 2005, NAT GENET, V37, P853, DOI 10.1038/ng1598; Weber M, 2007, NAT GENET, V39, P457, DOI 10.1038/ng1990; Westendorf JJ, 1999, J CELL BIOCHEM, P51; Whitehead RH, 2003, CULTURE HUMAN TUMOR, P68; Woolf E, 2003, P NATL ACAD SCI USA, V100, P7731, DOI 10.1073/pnas.1232420100; Yeoh KG, 2007, J GASTROEN HEPATOL, V22, P970, DOI 10.1111/j.1440-1746.2007.04956.x	53	17	18	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 28	2015	34	22					2856	2866		10.1038/onc.2014.233	http://dx.doi.org/10.1038/onc.2014.233			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CJ2OM	25088199	Green Published, Green Accepted			2022-12-17	WOS:000355324300005
J	Gelb, T; Pshenichkin, S; Rodriguez, OC; Hathaway, HA; Grajkowska, E; DiRaddo, JO; Wroblewska, B; Yasuda, RP; Albanese, C; Wolfe, BB; Wroblewski, JT				Gelb, T.; Pshenichkin, S.; Rodriguez, O. C.; Hathaway, H. A.; Grajkowska, E.; DiRaddo, J. O.; Wroblewska, B.; Yasuda, R. P.; Albanese, C.; Wolfe, B. B.; Wroblewski, J. T.			Metabotropic glutamate receptor 1 acts as a dependence receptor creating a requirement for glutamate to sustain the viability and growth of human melanomas	ONCOGENE			English	Article							HUMAN MELANOCYTES; EXPRESSION; GRM1; GLUTAMATE-RECEPTOR-1; BLOCKADE; NETRIN-1; EXCITOTOXICITY; PROLIFERATION; SUPPRESSION; INHIBITION	Metabotropic glutamate 1 (mGlu) receptor has been proposed as a target for the treatment of metastatic melanoma. Studies have demonstrated that inhibiting the release of glutamate (the natural ligand of mGlu1 receptors), results in a decrease of melanoma tumor growth in mGlu1 receptor-expressing melanomas. Here we demonstrate that mGlu1 receptors, which have been previously characterized as oncogenes, also behave like dependence receptors by creating a dependence on glutamate for sustained cell viability. In the mGlu1 receptor-expressing melanoma cell lines SK-MEL-2 (SK2) and SK-MEL-5 (SK5), we show that glutamate is both necessary and sufficient to maintain cell viability, regardless of underlying genetic mutations. Addition of glutamate increased DNA synthesis, whereas removal of glutamate not only suppressed DNA synthesis but also promoted cell death in SK2 and SK5 melanoma cells. Using genetic and pharmacological inhibitors, we established that this effect of glutamate is mediated by the activation of mGlu1 receptors. The stimulatory potential of mGlu1 receptors was further confirmed in vivo in a melanoma cell xenograft model. In this model, subcutaneous injection of SK5 cells with short hairpin RNA-targeted downregulation of mGlu1 receptors resulted in a decrease in the rate of tumor growth relative to control. We also demonstrate for the first time that a selective mGlu1 receptor antagonist JNJ16259685 ((3,4-Dihydro-2H-pyrano[2,3-b]quinolin-7-yl)-(cis-4-methoxycyclohexyl)-methanone) slows SK2 and SK5 melanoma tumor growth in vivo. Taken together, these data suggest that pharmacological inhibition of mGlu1 receptors may be a novel approach for the treatment of metastatic melanoma.	[Gelb, T.; Pshenichkin, S.; Hathaway, H. A.; Grajkowska, E.; DiRaddo, J. O.; Wroblewska, B.; Yasuda, R. P.; Wolfe, B. B.; Wroblewski, J. T.] Georgetown Univ, Med Ctr, Dept Physiol & Pharmacol, Washington, DC 20057 USA; [Rodriguez, O. C.; Albanese, C.] Georgetown Univ, Dept Lombardi Comprehens Canc Ctr, Washington, DC USA	Georgetown University; Georgetown University	Wroblewski, JT (corresponding author), Georgetown Univ, Med Ctr, Dept Physiol & Pharmacol, 3900 Reservoir Rd,NW, Washington, DC 20057 USA.	wroblewj@georgetown.edu		Hathaway, Hannah/0000-0003-0906-1726	NIH/NCI grant [P30-CA051008]; Pharmaceutical Research and Manufacturers of America Foundation Pre Doctoral Fellowship in Pharmacology/Toxicology; National Institutes of Health grant [NS37436, CA129003]; NATIONAL CANCER INSTITUTE [R01CA129003, P30CA051008] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037436] Funding Source: NIH RePORTER	NIH/NCI grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Pharmaceutical Research and Manufacturers of America Foundation Pre Doctoral Fellowship in Pharmacology/Toxicology; National Institutes of Health grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank the Flow Cytometry and Cell Sorting Shared Resource (partially supported by the NIH/NCI grant P30-CA051008), particularly Karen Creswell, and the Histopathology and Tissue Shared Resource (partially supported by the NIH/NCI grant P30-CA051008) at The Georgetown-Lombardi Comprehensive Cancer Center (Georgetown University, Washington, DC, USA) for their expertise. Also, we thank Dr Suzie Chen from Rutgers University for her guidance and generosity and Maria Salinas (Georgetown) for her technical expertise. This work was partially supported by the Pharmaceutical Research and Manufacturers of America Foundation Pre Doctoral Fellowship in Pharmacology/Toxicology to TG, The National Institutes of Health grant NS37436 to JTW and CA129003 to CA.	American Cancer Society, 2013, CANC FACTS FIG 2013; Banda M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0081126; Blaabjerg M, 2003, EXP NEUROL, V183, P573, DOI 10.1016/S0014-4886(03)00204-8; Brocke KS, 2010, CANCER BIOL THER, V9; Chang HJ, 2005, CLIN CANCER RES, V11, P3288, DOI 10.1158/1078-0432.CCR-04-1912; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; de Groot J, 2011, GLIA, V59, P1181, DOI 10.1002/glia.21113; Delloye-Bourgeois C, 2009, J EXP MED, V206, P833, DOI 10.1084/jem.20082299; Delloye-Bourgeois C, 2009, JNCI-J NATL CANCER I, V101, P237, DOI 10.1093/jnci/djn491; Deng WB, 2006, J NEUROCHEM, V98, P213, DOI 10.1111/j.1471-4159.2006.03861.x; DiRaddo JO, 2013, GENE, V519, P367, DOI 10.1016/j.gene.2013.02.009; Emery AC, 2010, J BIOL CHEM, V285, P26041, DOI 10.1074/jbc.M110.139899; Fitamant J, 2008, P NATL ACAD SCI USA, V105, P4850, DOI 10.1073/pnas.0709810105; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Frati C, 2000, J CELL PHYSIOL, V183, P364, DOI 10.1002/(SICI)1097-4652(200006)183:3<364::AID-JCP9>3.3.CO;2-O; Goldschneider D, 2010, ONCOGENE, V29, P1865, DOI 10.1038/onc.2010.13; Hartsough EJ, 2014, MOL CANCER RES, V12, P795, DOI 10.1158/1541-7786.MCR-13-0581; Hoogduijn MJ, 2006, PIGM CELL RES, V19, P58, DOI 10.1111/j.1600-0749.2005.00284.x; Johannessen CM, 2010, NATURE, V468, P968, DOI 10.1038/nature09627; Khan AJ, 2011, CLIN CANCER RES, V17, P1807, DOI 10.1158/1078-0432.CCR-10-1276; Koochekpour S, 2012, CLIN CANCER RES, V18, P5888, DOI 10.1158/1078-0432.CCR-12-1308; Lavreysen H, 2004, NEUROPHARMACOLOGY, V47, P961, DOI 10.1016/j.neuropharm.2004.08.007; Le MN, 2010, J INVEST DERMATOL, V130, P2240, DOI 10.1038/jid.2010.126; Lee HJ, 2012, BBA-GENE REGUL MECH, V1819, P1123, DOI 10.1016/j.bbagrm.2012.06.005; Lee HJ, 2011, CLIN CANCER RES, V17, P7080, DOI 10.1158/1078-0432.CCR-11-0098; Lyons SA, 2007, CANCER RES, V67, P9463, DOI 10.1158/0008-5472.CAN-07-2034; Maira F, 2012, CURR DRUG DELIV, V9, P17, DOI 10.2174/156720112798376032; Martino JJ, 2013, ONCOGENE, V32, P4366, DOI 10.1038/onc.2012.471; Namkoong J, 2007, CANCER RES, V67, P2298, DOI 10.1158/0008-5472.CAN-06-3665; Ohtani Y, 2008, ONCOGENE, V27, P7162, DOI 10.1038/onc.2008.329; Ortiz P, 2007, EUR J HUM GENET, V15, P1176, DOI 10.1038/sj.ejhg.5201887; Park SY, 2007, ONCOL REP, V17, P81; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; Pollock PM, 2003, NAT GENET, V34, P108, DOI 10.1038/ng1148; Prickett TD, 2012, CLIN CANCER RES, V18, P4240, DOI 10.1158/1078-0432.CCR-11-1217; Pshenichkin S, 2008, NEUROPHARMACOLOGY, V55, P500, DOI 10.1016/j.neuropharm.2008.06.039; Ringer L, 2011, CANCER BIOL THER, V12, P818, DOI 10.4161/cbt.12.9.17682; Rzeski W, 2002, BIOCHEM PHARMACOL, V64, P1195, DOI 10.1016/S0006-2952(02)01218-2; Seidlitz EP, 2009, CLIN EXP METASTAS, V26, P781, DOI 10.1007/s10585-009-9277-4; Shin SS, 2008, NEUROPHARMACOLOGY, V55, P396, DOI 10.1016/j.neuropharm.2008.04.021; Shin SS, 2008, PIGM CELL MELANOMA R, V21, P368, DOI 10.1111/j.1755-148X.2008.00452.x; Speyer CL, 2012, BREAST CANCER RES TR, V132, P565, DOI 10.1007/s10549-011-1624-x; Steckler T, 2005, BEHAV BRAIN RES, V164, P52, DOI 10.1016/j.bbr.2005.05.010; Steckler T, 2005, PSYCHOPHARMACOLOGY, V179, P198, DOI 10.1007/s00213-004-2056-7; Teh Jessica, 2012, Wiley Interdiscip Rev Membr Transp Signal, V1, P211; Wangari-Talbot J, 2012, MOL CANCER RES, V10, P1440, DOI 10.1158/1541-7786.MCR-12-0158; Wei XM, 2011, NAT GENET, V43, P442, DOI 10.1038/ng.810; Wen Y, 2014, CANCER RES, V74, P2499, DOI 10.1158/0008-5472.CAN-13-1531; Willard SS, 2013, INT J BIOL SCI, V9, P948, DOI 10.7150/ijbs.6426; Yajima I, 2012, DERMAT RES PRACT, V2012, DOI 10.1155/2012/354191; Ye ZC, 1999, CANCER RES, V59, P4383	52	17	17	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 21	2015	34	21					2711	2720		10.1038/onc.2014.231	http://dx.doi.org/10.1038/onc.2014.231			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CI7XN	25065592	Green Accepted			2022-12-17	WOS:000354979500004
J	Voce, DJ; Schmitt, AM; Uppal, A; McNerney, ME; Bernal, GM; Cahill, KE; Wahlstrom, JS; Nassiri, A; Yu, X; Crawley, CD; White, KP; Onel, K; Weichselbaum, RR; Yamini, B				Voce, D. J.; Schmitt, A. M.; Uppal, A.; McNerney, M. E.; Bernal, G. M.; Cahill, K. E.; Wahlstrom, J. S.; Nassiri, A.; Yu, X.; Crawley, C. D.; White, K. P.; Onel, K.; Weichselbaum, R. R.; Yamini, B.			Nfkb1 is a haploinsufficient DNA damage-specific tumor suppressor	ONCOGENE			English	Article							NF-KAPPA-B; CHRONIC LYMPHOCYTIC-LEUKEMIA; MYELOID-LEUKEMIA; CELL LYMPHOMA; P50 SUBUNIT; EXPRESSION; GENE; TEMOZOLOMIDE; MICROARRAY; MICE	NF-kappa B proteins play a central and subunit-specific role in the response to DNA damage. Previous work identified p50/NF-kappa B1 as being necessary for cytotoxicity in response to DNA alkylation damage. Given the importance of damage-induced cell death for the maintenance of genomic stability, we examined whether Nfkb1 acts as a tumor suppressor in the setting of alkylation damage. Hprt mutation analysis demonstrates that Nfkb1(-/-) cells accumulate more alkylator-induced, but not ionizing radiation (IR)-induced, mutations than similarly treated wild-type cells. Subsequent in vivo tumor induction studies reveal that following alkylator treatment, but not IR, Nfkb1(-/-) mice develop more lymphomas than similarly treated Nfkb1(+/+) animals. Heterozygous mice develop lymphomas at an intermediate rate and retain functional p50 in their tumors, indicating that Nfkb1 acts in a haploinsufficient manner. Analysis of human cancers, including therapy-related myeloid neoplasms, demonstrates that NFKB1 mRNA expression is downregulated compared with control samples in multiple hematological malignancies. These data indicate that Nfkb1 is a haploinsufficient, pathway-specific tumor suppressor that prevents the development of hematologic malignancy in the setting of alkylation damage.	[Voce, D. J.; Schmitt, A. M.; Bernal, G. M.; Cahill, K. E.; Wahlstrom, J. S.; Nassiri, A.; Yu, X.; Crawley, C. D.; Yamini, B.] Univ Chicago, Neurosurg Sect, Chicago, IL 60637 USA; [Uppal, A.] Univ Chicago, Dept Surg, Sect Gen Surg, Chicago, IL 60637 USA; [McNerney, M. E.] Univ Chicago, Dept Pathol, Inst Genom & Syst Biol, Chicago, IL 60637 USA; [White, K. P.] Univ Chicago, Dept Human Genet, Inst Genom & Syst Biol, Chicago, IL 60637 USA; [Onel, K.] Univ Chicago, Dept Pediat, Chicago, IL 60637 USA; [Weichselbaum, R. R.] Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA; [Weichselbaum, R. R.] Univ Chicago, Ludwig Ctr Metastasis Res, Chicago, IL 60637 USA	University of Chicago; University of Chicago; University of Chicago; University of Chicago; University of Chicago; University of Chicago; University of Chicago	Yamini, B (corresponding author), Univ Chicago, Neurosurg Sect, MC3026,5841S Maryland Ave, Chicago, IL 60637 USA.	byamini@surgery.bsd.uchicago.edu		McNerney, Megan/0000-0002-8260-3598	NIH [1R01CA136937]; Ludwig Center for Metastasis Research; Leukemia & Lymphoma Society; Chicago Cancer Genomes Project; NATIONAL CANCER INSTITUTE [R01CA136937, K08CA181254] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ludwig Center for Metastasis Research; Leukemia & Lymphoma Society(Leukemia and Lymphoma Society); Chicago Cancer Genomes Project; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to RF de Pooter and B Kee for helpful contributions. This work was supported by NIH grant 1R01CA136937 (to BY), The Ludwig Center for Metastasis Research; Leukemia & Lymphoma Society Fellow award (M.E.M) and the Chicago Cancer Genomes Project.	Allan JM, 2005, NAT REV CANCER, V5, P943, DOI 10.1038/nrc1749; Andersson A, 2007, LEUKEMIA, V21, P1198, DOI 10.1038/sj.leu.2404688; Barrett T, 2011, NUCLEIC ACIDS RES, V39, pD1005, DOI 10.1093/nar/gkq1184; Chang PY, 2006, CANCER RES, V66, P6008, DOI 10.1158/0008-5472.CAN-06-0194; Dajee M, 2003, NATURE, V421, P639, DOI 10.1038/nature01283; Du P, 2008, BIOINFORMATICS, V24, P1547, DOI 10.1093/bioinformatics/btn224; DUMENCO LL, 1993, SCIENCE, V259, P219, DOI 10.1126/science.8421782; Gerondakis S, 2006, ONCOGENE, V25, P6781, DOI 10.1038/sj.onc.1209944; Glauert HP, 2006, TOXICOL SCI, V90, P331, DOI 10.1093/toxsci/kfj116; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Haslinger C, 2004, J CLIN ONCOL, V22, P3937, DOI 10.1200/JCO.2004.12.133; Hoffmann A, 2003, EMBO J, V22, P5530, DOI 10.1093/emboj/cdg534; JOSHI VV, 1970, J NATL CANCER I, V45, P335; Karban AS, 2004, HUM MOL GENET, V13, P35, DOI 10.1093/hmg/ddh008; Keller U, 2005, ONCOGENE, V24, P6231, DOI 10.1038/sj.onc.1208779; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; Li ZP, 2005, J IMMUNOL, V174, P205, DOI 10.4049/jimmunol.174.1.205; Margison GP, 2002, MUTAGENESIS, V17, P483, DOI 10.1093/mutage/17.6.483; Massoumi R, 2006, CELL, V125, P665, DOI 10.1016/j.cell.2006.03.041; McNerney ME, 2013, BLOOD, V121, P975, DOI 10.1182/blood-2012-04-426965; Newlands ES, 1997, CANCER TREAT REV, V23, P35, DOI 10.1016/S0305-7372(97)90019-0; Neyns B, 2008, J CLIN ONCOL, V26, P4518, DOI 10.1200/JCO.2008.18.8177; Olive PL, 2006, NAT PROTOC, V1, P23, DOI 10.1038/nprot.2006.5; Perkins ND, 2004, TRENDS CELL BIOL, V14, P64, DOI 10.1016/j.tcb.2003.12.004; Piccaluga PP, 2007, J CLIN INVEST, V117, P823, DOI 10.1172/JCI26833; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Rocha S, 2005, EMBO J, V24, P1157, DOI 10.1038/sj.emboj.7600608; Rosenwald A, 2001, J EXP MED, V194, P1639, DOI 10.1084/jem.194.11.1639; Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Schmitt AM, 2011, MOL CELL, V44, P785, DOI 10.1016/j.molcel.2011.09.026; Sean D, 2007, BIOINFORMATICS, V23, P1846, DOI 10.1093/bioinformatics/btm254; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; Smith SM, 2003, BLOOD, V102, P43, DOI 10.1182/blood-2002-11-3343; Wolff B, 1999, ONCOGENE, V18, P2663, DOI 10.1038/sj.onc.1202617; Wood ME, 2012, J CLIN ONCOL, V30, P3734, DOI 10.1200/JCO.2012.41.8681; Yamini B, 2007, CANCER RES, V67, P6889, DOI 10.1158/0008-5472.CAN-06-4496	38	17	18	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 21	2015	34	21					2807	2813		10.1038/onc.2014.211	http://dx.doi.org/10.1038/onc.2014.211			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CI7XN	25043302	Green Accepted			2022-12-17	WOS:000354979500013
J	Chakraborty, AA; Scuoppo, C; Dey, S; Thomas, LR; Lorey, SL; Lowe, SW; Tansey, WP				Chakraborty, A. A.; Scuoppo, C.; Dey, S.; Thomas, L. R.; Lorey, S. L.; Lowe, S. W.; Tansey, W. P.			A common functional consequence of tumor-derived mutations within c-MYC	ONCOGENE			English	Article							BURKITT-LYMPHOMA; MOUSE PLASMACYTOMAS; CODING REGION; ONCOGENE; PROGRESSION; SUPPRESSOR; TARGETS; BIM	The relevance of changes to the coding sequence of the c-MYC oncogene to malignancy is controversial. Overexpression of a pristine form of MYC is observed in many cancers and is sufficient to drive tumorigenesis in most contexts. Yet missense changes to MYC are found in similar to 50% of Burkitt's lymphomas, aggregate within an amino-terminal degron important for proteasomal destruction of MYC, and where examined profoundly enhance the tumorigenic properties of MYC in vitro and in vivo. Much of the controversy surrounding these mutants stems from the limited number of mutations that have been evaluated and their clustering within a single region of the MYC protein; the highly-conserved Myc box I (MbI) element. Here, by analysis of extant genomic data sets, we identify a previously unrecognized hotspot for tumor-associated MYC mutations, located in a conserved central portion of the protein. We show that, despite their distal location in MYC, mutations in this region precisely phenocopy those in MbI in terms of stability, in vitro transformation, growth-promoting properties, in vivo tumorigenesis and ability to escape p53-dependent tumor surveillance mechanisms. The striking parallels between the behavior of tumor-derived mutations in disparate regions of the MYC protein reveals that a common molecular process is disrupted by these mutations, implying an active role for these mutations in tumorigenesis and suggesting that different therapeutic strategies may be needed for treatment of lymphomas expressing wild type versus mutant forms of MYC protein.	[Chakraborty, A. A.; Scuoppo, C.; Lowe, S. W.; Tansey, W. P.] Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; [Chakraborty, A. A.; Dey, S.; Thomas, L. R.; Lorey, S. L.; Tansey, W. P.] Vanderbilt Univ, Dept Cell & Dev Biol, Sch Med, Nashville, TN 37232 USA; [Lowe, S. W.] Howard Hughes Med Inst, New York, NY USA	Cold Spring Harbor Laboratory; Vanderbilt University; Howard Hughes Medical Institute	Tansey, WP (corresponding author), Vanderbilt Univ, Dept Cell & Dev Biol, Sch Med, 465 21st Ave South, Nashville, TN 37232 USA.	william.p.tansey@vanderbilt.edu		Tansey, William/0000-0002-3900-0978	CSHL Cancer Center [CA45508]; Vanderbilt Ingram Cancer Center [CA68485]; US Public Health Service from the NCI [CA-13106]; Howard Hughes Medical Institute; NATIONAL CANCER INSTITUTE [P01CA013106, P01CA087497, P30CA068485, P30CA045508] Funding Source: NIH RePORTER	CSHL Cancer Center; Vanderbilt Ingram Cancer Center; US Public Health Service from the NCI; Howard Hughes Medical Institute(Howard Hughes Medical Institute); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	For reagents, we thank the CSHL Antibody Shared Resource and the Vanderbilt Antibody and Protein Shared Resource. We thank Simone Salghetti for technical assistance. This work was supported by the CSHL Cancer Center Support Grant CA45508, the Vanderbilt Ingram Cancer Center Support grant CA68485 and by US Public Health Service grant CA-13106 from the NCI (WPT/SWL) and Howard Hughes Medical Institute (SWL). SWL is an investigator in the Howard Hughes Medical Institute.	Axelson H, 1995, EUR J CANCER, V31A, P2099, DOI 10.1016/0959-8049(95)00449-1; BHATIA K, 1994, BLOOD, V84, P883; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; CLARK HM, 1994, CANCER RES, V54, P3383; Conzen SD, 2000, MOL CELL BIOL, V20, P6008, DOI 10.1128/MCB.20.16.6008-6018.2000; Egle A, 2004, P NATL ACAD SCI USA, V101, P6164, DOI 10.1073/pnas.0401471101; Faber AC, 2011, CANCER DISCOV, V1, P352, DOI 10.1158/2159-8290.CD-11-0106; Giulino-Roth L, 2012, BLOOD, V120, P5181, DOI 10.1182/blood-2012-06-437624; Hemann MT, 2005, NATURE, V436, P807, DOI 10.1038/nature03845; Herbst A, 2005, EMBO REP, V6, P177, DOI 10.1038/sj.embor.7400333; Love C, 2012, NAT GENET, V44, P1321, DOI 10.1038/ng.2468; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; Murphy DJ, 2008, CANCER CELL, V14, P447, DOI 10.1016/j.ccr.2008.10.018; MURPHY W, 1986, P NATL ACAD SCI USA, V83, P2939, DOI 10.1073/pnas.83.9.2939; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; RABBITTS TH, 1983, NATURE, V306, P760, DOI 10.1038/306760a0; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Schmitz R, 2012, NATURE, V490, P116, DOI 10.1038/nature11378; SHOWE LC, 1985, MOL CELL BIOL, V5, P501, DOI 10.1128/MCB.5.3.501; Tworkowski KA, 2008, P NATL ACAD SCI USA, V105, P6103, DOI 10.1073/pnas.0802095105; Wang XY, 2011, CANCER RES, V71, P925, DOI 10.1158/0008-5472.CAN-10-1032; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; WESTAWAY D, 1984, P NATL ACAD SCI-BIOL, V81, P843, DOI 10.1073/pnas.81.3.843	23	17	17	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 30	2015	34	18					2406	2409		10.1038/onc.2014.186	http://dx.doi.org/10.1038/onc.2014.186			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CH2AH	24998853	Green Accepted			2022-12-17	WOS:000353824800013
J	Chen, X; Paranjape, T; Stahlhut, C; McVeigh, T; Keane, F; Nallur, S; Miller, N; Kerin, M; Deng, Y; Yao, X; Zhao, H; Weidhaas, JB; Slack, FJ				Chen, X.; Paranjape, T.; Stahlhut, C.; McVeigh, T.; Keane, F.; Nallur, S.; Miller, N.; Kerin, M.; Deng, Y.; Yao, X.; Zhao, H.; Weidhaas, J. B.; Slack, F. J.			Targeted resequencing of the microRNAome and 3 ' UTRome reveals functional germline DNA variants with altered prevalence in epithelial ovarian cancer	ONCOGENE			English	Article							SINGLE NUCLEOTIDE POLYMORPHISMS; ACUTE MYELOID-LEUKEMIA; LARGE GENE LISTS; SOMATIC MUTATIONS; PCM1-JAK2 FUSION; BINDING-SITES; BREAST-CANCER; KRAS-VARIANT; RISK; GENOME	Ovarian cancer is a major cause of cancer deaths, yet there have been few known genetic risk factors identified, the best known of which are disruptions in protein coding sequences (BRCA1 and 2). Recent findings indicate that there are powerful genetic markers of cancer risk outside of these regions, in the noncoding mRNA control regions. To identify additional cancer-associated, functional non-protein-coding sequence germline variants associated with ovarian cancer risk, we captured DNA regions corresponding to all validated human microRNAs and the 3' untranslated regions (UTRs) of similar to 6000 cancer-associated genes from 31 ovarian cancer patients. Multiple single-nucleotide polymorphisms in the 3'UTR of the vascular endothelial growth factor receptor/FLT1, E2F2 and PCM1 oncogenes were highly enriched in ovarian cancer patients compared with the 1000 Genome Project. Sequenom validation in a case-control study (267 cases and 89 controls) confirmed a novel variant in the PCM1 3'UTR is significantly associated with ovarian cancer (P = 0.0086). This work identifies a potential new ovarian cancer locus and further confirms that cancer resequencing efforts should not ignore the study of noncoding regions of cancer patients.	[Chen, X.; Stahlhut, C.; Slack, F. J.] Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA; [Chen, X.; Zhao, H.] Yale Univ, Sch Med, Program Computat Biol & Bioinformat, New Haven, CT 06520 USA; [Paranjape, T.; Nallur, S.; Weidhaas, J. B.] Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06520 USA; [McVeigh, T.; Miller, N.; Kerin, M.] Natl Univ Ireland Galway, Discipline Surg, Galway, Ireland; [McVeigh, T.; Miller, N.; Kerin, M.] Galway Univ, Hosp, Galway, Ireland; [Keane, F.] Yale Univ, Sch Med, New Haven, CT 06520 USA; [Deng, Y.; Yao, X.] Yale Univ, Sch Med, Yale Ctr Analyt Sci, New Haven, CT 06520 USA; [Zhao, H.] Yale Univ, Sch Med, Dept Genet, New Haven, CT 06520 USA; [Zhao, H.] Yale Univ, Sch Publ Hlth, Dept Biostat, New Haven, CT 06520 USA	Yale University; Yale University; Yale University; Ollscoil na Gaillimhe-University of Galway; Ollscoil na Gaillimhe-University of Galway; Yale University; Yale University; Yale University; Yale University	Slack, FJ (corresponding author), Yale Univ, Dept Mol Cellular & Dev Biol, 266 Whitney Ave,POB 208103, New Haven, CT 06520 USA.	joanne.weidhaas@yale.edu; frank.slack@yale.edu	Miller, Nicola/F-4009-2018; McVeigh, Terri/AAX-8075-2021	Miller, Nicola/0000-0002-5416-7047; McVeigh, Terri/0000-0001-9201-9216; Stahlhut, Carlos/0000-0002-8472-7156; Slack, Frank/0000-0001-8263-0409; Weidhaas, Joanne/0000-0002-5096-3281; Kerin, Michael/0000-0003-4164-5561	Lo Graduate Fellowship for Excellence in Stem Cell Research; China Scholars Council; NATIONAL CANCER INSTITUTE [P30CA016359, R01CA157749] Funding Source: NIH RePORTER	Lo Graduate Fellowship for Excellence in Stem Cell Research; China Scholars Council; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	XC was supported by Lo Graduate Fellowship for Excellence in Stem Cell Research and a fellowship from the China Scholars Council. TP was supported by a donation from William Hyman, Yale College Class of 1980, in memory of Barbara Skydel. We thank I Tikhonova, M Mahajan and S Mane at the YCGA for performing the Nimblegen enrichment and Sequenom arrays. We thank M State for critical reading of this manuscript. This work was supported by a grant from an anonymous foundation.	Adelaide J, 2006, LEUKEMIA, V20, P536, DOI 10.1038/sj.leu.2404104; Agarwal R, 2003, NAT REV CANCER, V3, P502, DOI 10.1038/nrc1123; Albert TJ, 2007, NAT METHODS, V4, P903, DOI 10.1038/NMETH1111; Altshuler D, 2010, NATURE, V467, P1061, DOI 10.1038/nature09534; Armes JE, 2004, ONCOGENE, V23, P5697, DOI 10.1038/sj.onc.1207740; BALCZON R, 1994, J CELL BIOL, V124, P783, DOI 10.1083/jcb.124.5.783; Bamford S, 2004, BRIT J CANCER, V91, P355, DOI 10.1038/sj.bjc.6601894; Batra J, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-119; Blitzblau RC, 2010, MOL DIAGN THER, V14, P335, DOI 10.2165/11587600-000000000-00000; Bousquet M, 2005, ONCOGENE, V24, P7248, DOI 10.1038/sj.onc.1208850; Bowen NJ, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-71; Calin GA, 2005, NEW ENGL J MED, V353, P1793, DOI 10.1056/NEJMoa050995; Chien J, 2009, GYNECOL ONCOL, V114, P3, DOI 10.1016/j.ygyno.2009.04.002; Chin LJ, 2008, CANCER RES, V68, P8535, DOI 10.1158/0008-5472.CAN-08-2129; Choi M, 2009, P NATL ACAD SCI USA, V106, P19096, DOI 10.1073/pnas.0910672106; Collins FS, 2007, SCI AM, V296, P50, DOI 10.1038/scientificamerican0307-50; Corvi R, 2000, ONCOGENE, V19, P4236, DOI 10.1038/sj.onc.1203772; Cromer MK, 2012, J CLIN ENDOCR METAB, V97, pE1774, DOI 10.1210/jc.2012-1743; Despierre E, 2010, GYNECOL ONCOL, V117, P358, DOI 10.1016/j.ygyno.2010.02.012; Doherty JA, 2010, CANCER EPIDEM BIOMAR, V19, P245, DOI 10.1158/1055-9965.EPI-09-0729; Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112; Hindorff LA, 2009, P NATL ACAD SCI USA, V106, P9362, DOI 10.1073/pnas.0903103106; Hodges E, 2007, NAT GENET, V39, P1522, DOI 10.1038/ng.2007.42; Hoffman AE, 2009, CANCER RES, V69, P5970, DOI 10.1158/0008-5472.CAN-09-0236; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Iorio MV, 2007, CANCER RES, V67, P8699, DOI 10.1158/0008-5472.CAN-07-1936; John B, 2004, PLOS BIOL, V2, P1862, DOI 10.1371/journal.pbio.0020363; Jones S, 2009, SCIENCE, V324, P217, DOI 10.1126/science.1171202; Kato M, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-5-r54; Kontorovich T, 2010, INT J CANCER, V127, P589, DOI 10.1002/ijc.25065; Kumaran GC, 2009, BRIT J CANCER, V100, P1, DOI 10.1038/sj.bjc.6604767; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Li H, 2008, GENOME RES, V18, P1851, DOI 10.1101/gr.078212.108; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Li Y, 2008, GYNECOL ONCOL, V108, P409, DOI 10.1016/j.ygyno.2007.10.024; Liang D, 2010, CANCER RES, V70, P9765, DOI 10.1158/0008-5472.CAN-10-0130; Liu PY, 2012, CARCINOGENESIS, V33, P1270, DOI 10.1093/carcin/bgs148; Lurie G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020703; Manolio TA, 2009, NATURE, V461, P747, DOI 10.1038/nature08494; Mardis ER, 2009, NEW ENGL J MED, V361, P1058, DOI 10.1056/NEJMoa0903840; Markman M, 2009, EXPERT OPIN PHARMACO, V10, P2269, DOI 10.1517/14656560903120907; Masciullo V, 2003, CARCINOGENESIS, V24, P1191, DOI 10.1093/carcin/bgg075; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Okou DT, 2007, NAT METHODS, V4, P907, DOI 10.1038/NMETH1109; Paranjape T, 2011, LANCET ONCOL, V12, P377, DOI 10.1016/S1470-2045(11)70044-4; Parsons DW, 2011, SCIENCE, V331, P435, DOI 10.1126/science.1198056; Pastrello C, 2010, CARCINOGENESIS, V31, P2124, DOI 10.1093/carcin/bgq184; Pearce CL, 2011, HUM MOL GENET, V20, P2263, DOI 10.1093/hmg/ddr087; Peethambaram P, 2011, INT J MOL EPIDEMIOL, V2, P185; Permuth-Wey J, 2011, CANCER RES, V71, P3896, DOI 10.1158/0008-5472.CAN-10-4167; Pils D, 2005, CANCER-AM CANCER SOC, V104, P2417, DOI 10.1002/cncr.21538; Pongsavee M, 2009, GENET TEST MOL BIOMA, V13, P307, DOI 10.1089/gtmb.2008.0127; Ramakrishna M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009983; Ramsingh G, 2010, BLOOD, V116, P5316, DOI 10.1182/blood-2010-05-285395; Ratner ES, 2012, ONCOGENE, V31, P4559, DOI 10.1038/onc.2011.539; Ratner E, 2010, CANCER RES, V70, P6509, DOI 10.1158/0008-5472.CAN-10-0689; Ryan BM, 2010, NAT REV CANCER, V10, P389, DOI 10.1038/nrc2867; Saunders MA, 2007, P NATL ACAD SCI USA, V104, P3300, DOI 10.1073/pnas.0611347104; Shen J, 2008, CARCINOGENESIS, V29, P1963, DOI 10.1093/carcin/bgn172; Shen J, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-47; Smigielski EM, 2000, NUCLEIC ACIDS RES, V28, P352, DOI 10.1093/nar/28.1.352; Terry KL, 2010, INT J MOL EPIDEMIOL, V1, P272; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Wang LH, 2012, GENOME RES, V22, P208, DOI 10.1101/gr.123109.111; Wynendaele J, 2010, CANCER RES, V70, P9641, DOI 10.1158/0008-5472.CAN-10-0527; Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710	67	17	17	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	2015	34	16					2125	2137		10.1038/onc.2014.117	http://dx.doi.org/10.1038/onc.2014.117			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CG3IL	24909162	Green Accepted, Green Published			2022-12-17	WOS:000353173400012
J	Greenall, SA; Donoghue, JF; Gottardo, NG; Johns, TG; Adams, TE				Greenall, S. A.; Donoghue, J. F.; Gottardo, N. G.; Johns, T. G.; Adams, T. E.			Glioma-specific Domain IV EGFR cysteine mutations promote ligand-induced covalent receptor dimerization and display enhanced sensitivity to dacomitinib in vivo	ONCOGENE			English	Article							GROWTH-FACTOR-RECEPTOR; EXTRACELLULAR DOMAIN; TARGETED THERAPIES; TYROSINE KINASES; ERYTHROPOIETIN RECEPTOR; DISULFIDE BOND; ACTIVATION; GLIOBLASTOMA; CELLS; CANCER	A feature of many gliomas is the amplification of the epidermal growth factor receptor (EGFR), resulting in its overexpression. Missense mutations or deletions within the extracellular domain are associated with this amplification and can lead to constitutive activation of the receptor, with the Domain I/II deletion, EGFRvIII, being the most common. These changes have also been associated with increased sensitivity to EGFR inhibition using small molecule inhibitors. We have expressed, in human glioma cells, EGFR containing four glioma-specific EGFR missense mutations within Domain IV (C620Y, C624F, C628Y and C636Y) to analyze their biological properties and sensitivity to EGFR inhibition. One of these mutants, C620Y, exhibited an enhanced basal phosphorylation, which was partially dependent on an EGFR-ligand autocrine loop. All Domain IV mutants responded equally as well as wildtype EGFR (wtEGFR) to ligand stimulation. Biochemical analysis revealed that a pre-formed, disulfide-bonded dimer associated with these mutations was underglycosylated, inactive and cytoplasmically retained. Ligand stimulation resulted in the formation of a tyrosine-phosphorylated, disulfide-bonded dimer for all Domain IV mutants but not for wtEGFR. Following treatment with the next-generation, irreversible pan-ErbB inhibitor dacomitinib, the C620Y, C624F and EGFRvIII mutants were inactivated, covalently dimerized and were retained in the cytoplasm, resulting in cell-surface receptor loss and, for C620Y and C624F, decreased binding of EGF. Dacomitinib treatment significantly reduced the in vivo growth of human glioma xenografts bearing C620Y, but not wtEGFR. Collectively, these data indicate that the unique biochemical traits of Domain IV EGFR cysteine mutants can be exploited for enhanced sensitivity to EGFR small molecule inhibitors, with potential clinical applications.	[Greenall, S. A.; Adams, T. E.] CSIRO, Div Mat Sci & Engn, Parkville, Vic 3052, Australia; [Donoghue, J. F.; Johns, T. G.] Monash Inst Med Res, Oncogen Signaling Lab & Brain Canc Discovery Coll, Clayton, Vic, Australia; [Gottardo, N. G.] Telethon Inst Child Hlth Res & Brain Canc Discove, Ctr Child Hlth Res, Subiaco, WA, Australia	Commonwealth Scientific & Industrial Research Organisation (CSIRO); Monash University; University of Western Australia	Greenall, SA (corresponding author), CSIRO, Div Mat Sci & Engn, 343 Royal Parade, Parkville, Vic 3052, Australia.	sameer.greenall@csiro.au	Adams, Timothy E/I-6231-2012; Johns, Terrance/C-2441-2008	Adams, Timothy E/0000-0003-3436-0066; Johns, Terrance/0000-0002-8874-4543; Donoghue, Jacqueline/0000-0003-1370-2469; Gottardo, Nicholas/0000-0002-1082-6776; Greenall, Sameer/0000-0002-1461-7111	CSIRO OCE Postdoctoral Fellowship; Cure Cancer Australia Foundation Postdoctoral Fellowship; NHMRC project [1028552, 1012020]; Victorian Government's Operational Infrastructure Support Program; Cure for Life Foundation	CSIRO OCE Postdoctoral Fellowship; Cure Cancer Australia Foundation Postdoctoral Fellowship; NHMRC project(National Health and Medical Research Council (NHMRC) of Australia); Victorian Government's Operational Infrastructure Support Program; Cure for Life Foundation	We would like to thank Professor Antony Burgess from the Walter and Eliza Hall Institute, Melbourne, Victoria for his critical review of the manuscript. SAG is supported by a CSIRO OCE Postdoctoral Fellowship. JFD is funded by a Cure Cancer Australia Foundation Postdoctoral Fellowship. TGJ was supported by NH&MRC project grants (1028552 and 1012020), the Victorian Government's Operational Infrastructure Support Program and Cure for Life Foundation.	Abe Y, 1998, J BIOL CHEM, V273, P11150, DOI 10.1074/jbc.273.18.11150; Adams TE, 2009, GROWTH FACTORS, V27, P141, DOI 10.1080/08977190902843565; Arkhipov A, 2013, CELL, V152, P557, DOI 10.1016/j.cell.2012.12.030; Arteaga CL, 1997, J BIOL CHEM, V272, P23247, DOI 10.1074/jbc.272.37.23247; Bae JH, 2010, MOL CELLS, V29, P443, DOI 10.1007/s10059-010-0080-5; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Bublil EM, 2010, FASEB J, V24, P4744, DOI 10.1096/fj.10-166199; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Chong CR, 2013, NAT MED, V19, P1389, DOI 10.1038/nm.3388; Cvrljevic AN, 2011, J CELL SCI, V124, P2938, DOI 10.1242/jcs.083295; Dawson JP, 2005, MOL CELL BIOL, V25, P7734, DOI 10.1128/MCB.25.17.7734-7742.2005; Fan QW, 2013, CANCER CELL, V24, P438, DOI 10.1016/j.ccr.2013.09.004; Ferguson KM, 2003, MOL CELL, V11, P507, DOI 10.1016/S1097-2765(03)00047-9; Frederick L, 2000, CANCER RES, V60, P1383; Gan HK, 2007, J BIOL CHEM, V282, P2840, DOI 10.1074/jbc.M605136200; Greenall SA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034658; He LJ, 2012, SCI REP-UK, V2, DOI 10.1038/srep00854; Idbaih A, 2009, NEUROPATH APPL NEURO, V35, P208, DOI 10.1111/j.1365-2990.2008.00977.x; Johns TG, 2005, FASEB J, V19, P780, DOI 10.1096/fj.04-1766fje; Johns TG, 2002, INT J CANCER, V98, P398, DOI 10.1002/ijc.10189; Laisney JAGC, 2013, ONCOGENE, V32, P2403, DOI 10.1038/onc.2012.267; Lee JC, 2006, PLOS MED, V3, P2264, DOI 10.1371/journal.pmed.0030485; Li L, 2014, ONCOGENE, V33, P4253, DOI 10.1038/onc.2013.400; Lichtner RB, 2001, CANCER RES, V61, P5790; Macdonald J, 2006, BBA-MOL CELL RES, V1763, P870, DOI 10.1016/j.bbamcr.2006.05.002; Mangasarian K, 1997, J CELL PHYSIOL, V172, P117, DOI 10.1002/(SICI)1097-4652(199707)172:1<117::AID-JCP13>3.3.CO;2-S; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Pillay V, 2009, NEOPLASIA, V11, P448, DOI 10.1593/neo.09230; Ramnarain DB, 2006, CANCER RES, V66, P867, DOI 10.1158/0008-5472.CAN-05-2753; Robertson SC, 1998, P NATL ACAD SCI USA, V95, P4567, DOI 10.1073/pnas.95.8.4567; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; Sharma SV, 2007, NAT REV CANCER, V7, P169, DOI 10.1038/nrc2088; Stommel JM, 2007, SCIENCE, V318, P287, DOI 10.1126/science.1142946; Sturm D, 2012, CANCER CELL, V22, P425, DOI 10.1016/j.ccr.2012.08.024; Tebbutt N, 2013, NAT REV CANCER, V13, P663, DOI 10.1038/nrc3559; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; Ymer Susie I, 2011, Cancers (Basel), V3, P2032, DOI 10.3390/cancers3022032; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0; Yu XC, 2002, MOL BIOL CELL, V13, P2547, DOI 10.1091/mbc.01-08-0411	39	17	18	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 26	2015	34	13					1658	1666		10.1038/onc.2014.106	http://dx.doi.org/10.1038/onc.2014.106			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CE5CS	24747966				2022-12-17	WOS:000351848400006
J	Ha, GH; Kim, JL; Petersson, A; Oh, S; Denning, MF; Patel, T; Breuer, EK				Ha, G-H; Kim, J-L; Petersson, A.; Oh, S.; Denning, M. F.; Patel, T.; Breuer, E-K			TACC3 deregulates the DNA damage response and confers sensitivity to radiation and PARP inhibition	ONCOGENE			English	Article							DOUBLE-STRAND BREAKS; ACIDIC COILED-COIL; HOMOLOGOUS RECOMBINATION REPAIR; GENE-EXPRESSION PROFILES; HISTONE H2AX; S-PHASE; IONIZING-RADIATION; HUMAN-CELLS; CHROMOSOMAL-ABERRATIONS; GENOME INSTABILITY	Deregulation of the transforming acidic coiled-coil protein 3 (TACC3), an important factor in the centrosome-microtubule system, has been linked to a variety of human cancer types. We have recently reported on the oncogenic potential of TACC3; however, the molecular mechanisms by which TACC3 mediates oncogenic function remain to be elucidated. In this study, we show that high levels of TACC3 lead to the accumulation of DNA double-strand breaks (DSBs) and disrupt the normal cellular response to DNA damage, at least in part, by negatively regulating the expression of ataxia telangiectasia mutated (ATM) and the subsequent DNA damage response (DDR) signaling cascade. Cells expressing high levels of TACC3 display defective checkpoints and DSB-mediated homologous recombination (HR) and non-homologous end joining (NHEJ) repair systems, leading to genomic instability. Importantly, high levels of TACC3 confer cellular sensitization to radiation and poly(ADP-ribose) polymerase (PARP) inhibition. Overall, our findings provide critical information regarding the mechanisms by which TACC3 contributes to genomic instability, potentially leading to cancer development, and suggest a novel prognostic, diagnostic and therapeutic strategy for the treatment of cancer types expressing high levels of TACC3.	[Ha, G-H; Kim, J-L; Petersson, A.; Denning, M. F.; Breuer, E-K] Loyola Univ, Stritch Sch Med, Cardinal Bernardin Canc Ctr, Inst Oncol, Maywood, IL 60153 USA; [Ha, G-H; Kim, J-L; Petersson, A.; Oh, S.; Breuer, E-K] Loyola Univ, Stritch Sch Med, Dept Radiat Oncol, Maywood, IL 60153 USA; [Denning, M. F.] Loyola Univ, Stritch Sch Med, Dept Pathol, Maywood, IL 60153 USA; [Patel, T.] Loyola Univ, Stritch Sch Med, Dept Mol Pharmacol & Therapeut, Maywood, IL 60153 USA	Loyola University Chicago; Loyola University Chicago; Loyola University Chicago; Loyola University Chicago	Breuer, EK (corresponding author), Loyola Univ, Stritch Sch Med, Dept Radiat Oncol, 2160 South First Ave, Maywood, IL 60153 USA.	eubreuer@luc.edu		Denning, Mitchell/0000-0001-6165-6925; Ha, Geun-Hyoung/0000-0002-9125-1934	Program Development Startup from Loyola University Chicago	Program Development Startup from Loyola University Chicago	This study was supported by the Program Development Startup from Loyola University Chicago.	Aguilera A, 2008, NAT REV GENET, V9, P204, DOI 10.1038/nrg2268; Albee AJ, 2008, MOL BIOL CELL, V19, P3347, DOI 10.1091/mbc.E07-11-1204; Antoni L, 2007, NAT REV CANCER, V7, P925, DOI 10.1038/nrc2251; Asaithamby A, 2009, NUCLEIC ACIDS RES, V37, P3912, DOI 10.1093/nar/gkp237; Ashworth A, 2008, J CLIN ONCOL, V26, P3785, DOI 10.1200/JCO.2008.16.0812; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bargo S, 2010, BIOCHEM BIOPH RES CO, V400, P606, DOI 10.1016/j.bbrc.2010.08.111; Bartek J, 2007, CURR OPIN CELL BIOL, V19, P238, DOI 10.1016/j.ceb.2007.02.009; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Beck H, 2010, J CELL BIOL, V188, P629, DOI 10.1083/jcb.200905059; Berkovich E, 2003, ONCOGENE, V22, P161, DOI 10.1038/sj.onc.1206144; Beucher A, 2009, EMBO J, V28, P3413, DOI 10.1038/emboj.2009.276; Bignold LP, 2006, EXP SUPPL, V96, P1; Bonome T, 2008, CANCER RES, V68, P5478, DOI 10.1158/0008-5472.CAN-07-6595; Bugler B, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-29; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Chanoux RA, 2009, J BIOL CHEM, V284, P5994, DOI 10.1074/jbc.M806739200; Craig AL, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-195; D'Errico M, 2009, EUR J CANCER, V45, P461, DOI 10.1016/j.ejca.2008.10.032; Deckbar D, 2007, J CELL BIOL, V176, P749, DOI 10.1083/jcb.200612047; Dell H, 1999, J BIOL CHEM, V274, P9013, DOI 10.1074/jbc.274.13.9013; Deng CX, 2006, NUCLEIC ACIDS RES, V34, P1416, DOI 10.1093/nar/gkl010; di Fagagna FD, 2004, GENE DEV, V18, P1781, DOI 10.1101/gad.1214504; Dodson GE, 2004, J BIOL CHEM, V279, P34010, DOI 10.1074/jbc.C400242200; Downs JA, 2007, NATURE, V447, P951, DOI 10.1038/nature05980; FAIRBAIRN DW, 1995, MUTAT RES-REV GENET, V339, P37, DOI 10.1016/0165-1110(94)00013-3; Fernet M, 2010, DNA REPAIR, V9, P48, DOI 10.1016/j.dnarep.2009.10.006; FRANKENBERG D, 1981, RADIAT RES, V88, P524, DOI 10.2307/3575641; Gangisetty O, 2004, ONCOGENE, V23, P2559, DOI 10.1038/sj.onc.1207424; Garriga-Canut M, 2004, J BIOL CHEM, V279, P23597, DOI 10.1074/jbc.M313987200; Goldberg M, 2003, NATURE, V421, P952, DOI 10.1038/nature01445; Goodarzi AA, 2008, MOL CELL, V31, P167, DOI 10.1016/j.molcel.2008.05.017; Grutzmann R, 2004, NEOPLASIA, V6, P611, DOI 10.1593/neo.04295; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Ha GH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070353; Ha GH, 2013, CANCER LETT, V336, P24, DOI 10.1016/j.canlet.2013.04.022; Ha GH, 2013, CANCER LETT, V332, P63, DOI 10.1016/j.canlet.2013.01.013; Harper JW, 2007, MOL CELL, V28, P739, DOI 10.1016/j.molcel.2007.11.015; Hong Y, 2010, CLIN EXP METASTAS, V27, P83, DOI 10.1007/s10585-010-9305-4; Hou J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010312; Hu N, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-576; Hurov KE, 2010, GENE DEV, V24, P1939, DOI 10.1101/gad.1934210; Ismail IH, 2010, J CELL BIOL, V191, P45, DOI 10.1083/jcb.201003034; Jackson SP, 2002, CARCINOGENESIS, V23, P687, DOI 10.1093/carcin/23.5.687; Jeggo P, 2007, ONCOGENE, V26, P7717, DOI 10.1038/sj.onc.1210868; Jung CK, 2006, PATHOL INT, V56, P503, DOI 10.1111/j.1440-1827.2006.01998.x; Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188; Kiemeney LA, 2010, NAT GENET, V42, P415, DOI 10.1038/ng.558; Kinoshita K, 2005, J CELL BIOL, V170, P1047, DOI 10.1083/jcb.200503023; Kobayashi J, 2009, BIOCHEM BIOPH RES CO, V380, P752, DOI 10.1016/j.bbrc.2009.01.109; Kocher S, 2012, NUCLEIC ACIDS RES, V40, P8336, DOI 10.1093/nar/gks604; Lauffart B, 2003, GENOMICS, V81, P192, DOI 10.1016/S0888-7543(02)00039-3; Lauffart B, 2002, BIOCHEM J, V363, P195, DOI 10.1042/0264-6021:3630195; Lauffart B., 2007, CANC THERAPY, V5, P409; Lauffart Brenda, 2005, BMC Womens Health, V5, P8, DOI 10.1186/1472-6874-5-8; Lauffart B, 2007, J CELL COMMUN SIGNAL, V1, P5, DOI 10.1007/s12079-007-0001-3; Li WR, 2011, CANCER RES, V71, P4130, DOI 10.1158/0008-5472.CAN-10-2540; Lin SY, 2005, P NATL ACAD SCI USA, V102, P15105, DOI 10.1073/pnas.0507722102; Lio YC, 2004, J BIOL CHEM, V279, P42313, DOI 10.1074/jbc.M405212200; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lowndes NF, 2005, CURR BIOL, V15, pR99, DOI 10.1016/j.cub.2005.01.029; Ma WJ, 2012, P NATL ACAD SCI USA, V109, P6590, DOI 10.1073/pnas.1118078109; Ma XJ, 2003, P NATL ACAD SCI USA, V100, P5974, DOI 10.1073/pnas.0931261100; McKeveney PJ, 2001, BRIT J HAEMATOL, V112, P1016, DOI 10.1046/j.1365-2141.2001.02644.x; McKinnon PJ, 2004, EMBO REP, V5, P772, DOI 10.1038/sj.embor.7400210; Mistrik M, 2009, CELL CYCLE, V8, P2592, DOI 10.4161/cc.8.16.9331; Morton JP, 2010, P NATL ACAD SCI USA, V107, P246, DOI 10.1073/pnas.0908428107; Mostoslavsky R, 2006, CELL, V124, P315, DOI [10.1016/j.cell.2005.11.044, 10.1016/J.CEL.2005.11.044]; Nakada S, 2006, J CLIN INVEST, V116, P80, DOI 10.1172/JCI25716; Nakanishi K, 2005, P NATL ACAD SCI USA, V102, P1110, DOI 10.1073/pnas.0407796102; OBE G, 1992, MUTAGENESIS, V7, P3, DOI 10.1093/mutage/7.1.3; Pan MR, 2011, J BIOL CHEM, V286, P28599, DOI 10.1074/jbc.M111.256297; Partch CL, 2011, P NATL ACAD SCI USA, V108, P7739, DOI 10.1073/pnas.1101357108; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Peng G, 2009, NAT CELL BIOL, V11, P865, DOI 10.1038/ncb1895; Piekorz RP, 2002, EMBO J, V21, P653, DOI 10.1093/emboj/21.4.653; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Rai R, 2006, CANCER CELL, V10, P145, DOI 10.1016/j.ccr.2006.07.002; Rappold I, 2001, J CELL BIOL, V153, P613, DOI 10.1083/jcb.153.3.613; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Riballo E, 2004, MOL CELL, V16, P715, DOI 10.1016/j.molcel.2004.10.029; Roessler S, 2010, CANCER RES, V70, P10202, DOI 10.1158/0008-5472.CAN-10-2607; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Sadek CM, 2000, MECH DEVELOP, V97, P13, DOI 10.1016/S0925-4773(00)00415-9; Sadek CM, 2003, GENE EXPR PATTERNS, V3, P203, DOI 10.1016/S1567-133X(02)00066-2; Sanchez-Carbayo M, 2006, J CLIN ONCOL, V24, P778, DOI 10.1200/JCO.2005.03.2375; Schneider L, 2007, J BIOL CHEM, V282, P29273, DOI 10.1074/jbc.M704151200; Schuendeln MM, 2004, MOL CELL BIOL, V24, P6403, DOI 10.1128/MCB.24.14.6403-6409.2004; Shanware NP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012173; Shibata A, 2011, EMBO J, V30, P1079, DOI 10.1038/emboj.2011.27; Shrivastav M, 2008, CELL RES, V18, P134, DOI 10.1038/cr.2007.111; Singh D, 2012, SCIENCE, V337, P1231, DOI 10.1126/science.1220834; Sourisseau T, 2010, EMBO MOL MED, V2, P130, DOI 10.1002/emmm.201000068; Stewart GS, 2003, NATURE, V421, P961, DOI 10.1038/nature01446; Stewart JP, 2004, BRIT J HAEMATOL, V126, P72, DOI 10.1111/j.1365-2141.2004.04996.x; Still IH, 2004, BMC EVOL BIOL, V4, DOI 10.1186/1471-2148-4-16; Stroup D, 2000, J LIPID RES, V41, P1; Sun LX, 2006, CANCER CELL, V9, P287, DOI 10.1016/j.ccr.2006.03.003; Talantov D, 2005, CLIN CANCER RES, V11, P7234, DOI 10.1158/1078-0432.CCR-05-0683; Ulisse S, 2007, ENDOCR-RELAT CANCER, V14, P827, DOI 10.1677/ERC-07-0053; van den Bosch M, 2003, EMBO REP, V4, P844, DOI 10.1038/sj.embor.embor925; Vettaikkorumakankauv A., 2008, CANC THERAPY, V6, P805; Wang HY, 2005, J CELL PHYSIOL, V202, P492, DOI 10.1002/jcp.20141; Wang HY, 2004, CANCER RES, V64, P7139, DOI 10.1158/0008-5472.CAN-04-1289; Wang RH, 2008, CANCER CELL, V14, P312, DOI 10.1016/j.ccr.2008.09.001; Ward IM, 2003, J BIOL CHEM, V278, P19579, DOI 10.1074/jbc.C300117200; Wu J, 2012, MOL CELL, V46, P351, DOI 10.1016/j.molcel.2012.02.018; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Yim EK, 2009, ONCOL REP, V21, P549, DOI 10.3892/or_00000256; Yochum GS, 2007, BMC MOL BIOL, V8, DOI 10.1186/1471-2199-8-102; Zhai Y, 2007, CANCER RES, V67, P10163, DOI 10.1158/0008-5472.CAN-07-2056; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747; Ziv Y, 2006, NAT CELL BIOL, V8, P870, DOI 10.1038/ncb1446	114	17	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 26	2015	34	13					1667	1678		10.1038/onc.2014.105	http://dx.doi.org/10.1038/onc.2014.105			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CE5CS	24769898				2022-12-17	WOS:000351848400007
J	Im, YK; La Selva, R; Gandin, V; Ha, JR; Sabourin, V; Sonenberg, N; Pawson, T; Topisirovic, I; Ursini-Siegel, J				Im, Y. K.; La Selva, R.; Gandin, V.; Ha, J. R.; Sabourin, V.; Sonenberg, N.; Pawson, T.; Topisirovic, I.; Ursini-Siegel, J.			The ShcA adaptor activates AKT signaling to potentiate breast tumor angiogenesis by stimulating VEGF mRNA translation in a 4E-BP-dependent manner	ONCOGENE			English	Article							ENDOTHELIAL GROWTH-FACTOR; CANCER CELLS; PROTEIN-SYNTHESIS; MAMMALIAN TARGET; FACTOR EIF-4E; INITIATION; EXPRESSION; RECEPTOR; DISTINCT; MTOR	The ShcA adaptor protein is engaged by numerous receptor tyrosine kinases (RTKs) in breast cancer cells. Once activated, RTKs phosphorylate three key tyrosine phosphorylation sites (Y239, Y240 and Y317) within ShcA that creates a docking site for Grb2/SOS and Grb2/Gab-containing complexes to activate the MAPK and AKT signaling pathways, respectively. We previously demonstrated that a tyrosine to phenylalanine substitution of the ShcA tyrosine phosphorylation sites (Shc3F-Y239/240/313F) significantly impairs breast tumor growth and angiogenesis in transgenic mouse models, in part, through the regulation of vascular endothelial growth factor (VEGF) production. Despite this fact, the underlying molecular mechanisms by which ShcA transduces pro-tumorigenic signals in breast cancer cells remain poorly defined. In this study, we demonstrate that ShcA-dependent activation of AKT, but not the RAS/MAPK pathway, induces VEGF production by bolstering VEGF mRNA translation. Accordingly, ShcA drives breast tumor growth and angiogenesis in vivo in a 4E-BP-dependent manner. These findings establish ShcA as a biological bridge that links AKT activation downstream of RTKs to cap-dependent VEGF mRNA translation in order to promote mammary tumorigenesis.	[Im, Y. K.; La Selva, R.; Gandin, V.; Ha, J. R.; Sabourin, V.; Topisirovic, I.; Ursini-Siegel, J.] McGill Univ, Lady Davis Inst Med Res, Dept Oncol, Montreal, PQ H3T 1E2, Canada; [Sonenberg, N.] Goodman Canc Res Ctr, Montreal, PQ, Canada; [Pawson, T.] Univ Toronto, Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada	Lady Davis Institute; McGill University; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Ursini-Siegel, J (corresponding author), McGill Univ, Lady Davis Inst Med Res, Dept Oncol, 3999 Cote St Catherine Rd,Room F528-1, Montreal, PQ H3T 1E2, Canada.	giuseppina.ursini-siegel@mcgill.ca	Pawson, Tony J/E-4578-2013; Topisirovic, Ivan/A-9426-2008	Topisirovic, Ivan/0000-0002-5510-9762; Gandin, Valentina/0000-0003-2627-1303	Canadian Institutes of Health Research (CIHR) grant [MOP-111143]; TD/LDI; McGill Integrated Research Training Program; CIHR	Canadian Institutes of Health Research (CIHR) grant(Canadian Institutes of Health Research (CIHR)); TD/LDI; McGill Integrated Research Training Program; CIHR(Canadian Institutes of Health Research (CIHR))	We thank Dr Peter Siegel for critical reading of the manuscript and Dr Sonia del Rincon for the VEGF antibody. This work was supported by a Canadian Institutes of Health Research (CIHR) grant (MOP-111143) to JU-S. YKI is the recipient of a TD/LDI studentship. JRH is the recipient of a McGill Integrated Research Training Program studentship. JU-S and IT are recipients of a CIHR New Investigator Salary Support award.	Alain T, 2012, CANCER RES, V72, P6468, DOI 10.1158/0008-5472.CAN-12-2395; Avdulov S, 2004, CANCER CELL, V5, P553, DOI 10.1016/j.ccr.2004.05.024; Braunstein S, 2007, MOL CELL, V28, P501, DOI 10.1016/j.molcel.2007.10.019; Casanova ML, 2002, CANCER RES, V62, P3402; Christoffersson G, 2012, BLOOD, V120, P4653, DOI 10.1182/blood-2012-04-421040; Coleman LJ, 2009, BRIT J CANCER, V100, P1393, DOI 10.1038/sj.bjc.6605044; Dankort D, 2001, J BIOL CHEM, V276, P38921, DOI 10.1074/jbc.M106239200; Davol PA, 2003, CANCER RES, V63, P6772; Dowling RJO, 2010, BBA-PROTEINS PROTEOM, V1804, P433, DOI 10.1016/j.bbapap.2009.12.001; Flowers A, 2009, SURGERY, V146, P220, DOI 10.1016/j.surg.2009.05.010; Garcia-Garcia C, 2012, CLIN CANCER RES, V18, P2603, DOI 10.1158/1078-0432.CCR-11-2750; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Gu HH, 2000, MOL CELL BIOL, V20, P7109, DOI 10.1128/MCB.20.19.7109-7120.2000; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Hardy WR, 2007, SCIENCE, V317, P251, DOI 10.1126/science.1140114; Hsieh AC, 2012, NATURE, V485, P55, DOI 10.1038/nature10912; Kevil CG, 1996, INT J CANCER, V65, P785, DOI 10.1002/(SICI)1097-0215(19960315)65:6<785::AID-IJC14>3.0.CO;2-3; Klos KS, 2006, CANCER RES, V66, P2028, DOI 10.1158/0008-5472.CAN-04-4559; Larsson O, 2012, P NATL ACAD SCI USA, V109, P8977, DOI 10.1073/pnas.1201689109; Li CH, 2011, CANCER BIOL THER, V12, P872, DOI 10.4161/cbt.12.10.17672; Liang YY, 2006, ENDOCR-RELAT CANCER, V13, P905, DOI 10.1677/erc.1.01221; Maity A, 2000, CANCER RES, V60, P5879; Miller TW, 2009, CLIN CANCER RES, V15, P7266, DOI 10.1158/1078-0432.CCR-09-1665; Nasr Z, 2013, ONCOGENE, V32, P861, DOI 10.1038/onc.2012.105; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Petroulakis E, 2009, CANCER CELL, V16, P439, DOI 10.1016/j.ccr.2009.09.025; Pettersson F, 2011, CLIN CANCER RES, V17, P2874, DOI 10.1158/1078-0432.CCR-10-2334; Rojo F, 2007, CLIN CANCER RES, V13, P81, DOI 10.1158/1078-0432.CCR-06-1560; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Ruggero D, 2004, NAT MED, V10, P484, DOI 10.1038/nm1042; SALCINI AE, 1994, ONCOGENE, V9, P2827; Salnikov AV, 2006, INT J CANCER, V119, P2795, DOI 10.1002/ijc.22217; Shama Silvian, 1995, Gene Expression, V4, P241; Tcherkezian JCM, 2014, GENES DEV, V28; Thoreen CC, 2012, NATURE, V485, P109, DOI 10.1038/nature11083; Ursini-Siegel J, 2008, EMBO J, V27, P910, DOI 10.1038/emboj.2008.22; Ursini-Siegel J, 2007, MOL CELL BIOL, V27, P6361, DOI 10.1128/MCB.00686-07; Ursini-Siegel J, 2010, CANCER RES, V70, P7776, DOI 10.1158/0008-5472.CAN-10-2229; Vander Haar E, 2007, NAT CELL BIOL, V9, P316, DOI 10.1038/ncb1547; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; WARNER JR, 1963, P NATL ACAD SCI USA, V49, P122, DOI 10.1073/pnas.49.1.122; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; Xiong SB, 2001, CANCER RES, V61, P1727; Yanagiya A, 2012, MOL CELL, V46, P847, DOI 10.1016/j.molcel.2012.04.004; Zindy P, 2011, CANCER RES, V71, P4068, DOI 10.1158/0008-5472.CAN-11-0420; Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025	48	17	18	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 26	2015	34	13					1729	1735		10.1038/onc.2014.110	http://dx.doi.org/10.1038/onc.2014.110			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CE5CS	24837366				2022-12-17	WOS:000351848400013
J	Li, H; Jiang, X; Yu, Y; Huang, W; Xing, H; Agar, NY; Yang, HW; Yang, B; Carroll, RS; Johnson, MD				Li, H.; Jiang, X.; Yu, Y.; Huang, W.; Xing, H.; Agar, N. Y.; Yang, H. W.; Yang, B.; Carroll, R. S.; Johnson, M. D.			KAP regulates ROCK2 and Cdk2 in an RNA-activated glioblastoma invasion pathway	ONCOGENE			English	Article							CYCLIN-DEPENDENT KINASES; RHO-KINASE; HEPATOCELLULAR-CARCINOMA; PROTEIN PHOSPHATASE; CENTROSOME DUPLICATION; CELL INVASION; TUMOR-GROWTH; LIGHT-CHAIN; IN-VIVO; METASTASIS	Aberrant splicing of the cyclin-dependent kinase-associated phosphatase, KAP, promotes glioblastoma invasion in a Cdc2-dependent manner. However, the mechanism by which this occurs is unknown. Here we show that miR-26a, which is often amplified in glioblastoma, promotes invasion in phosphatase and tensin homolog (PTEN)-competent and PTEN-deficient glioblastoma cells by directly downregulating KAP expression. Mechanistically, we find that KAP binds and activates ROCK2. Thus, RNA-mediated downregulation of KAP leads to decreased ROCK2 activity and this, in turn, increases Rac1-mediated invasion. In addition, the decrease in KAP expression activates the cyclin-dependent kinase, Cdk2, and this directly promotes invasion by increasing retinoblastoma phosphorylation, E2F-dependent Cdc2 expression and Cdc2-mediated inactivation of the actomyosin inhibitor, caldesmon. Importantly, glioblastoma cell invasion mediated by this pathway can be antagonized by Cdk2/Cdc2 inhibitors in vitro and in vivo. Thus, two distinct RNA-based mechanisms activate this novel KAP/ROCK2/Cdk2-dependent invasion pathway in glioblastoma.	[Li, H.; Jiang, X.; Yu, Y.; Huang, W.; Xing, H.; Agar, N. Y.; Yang, H. W.; Yang, B.; Carroll, R. S.; Johnson, M. D.] Brigham & Womens Hosp, Dept Neurosurg, Boston, MA 02446 USA; [Li, H.; Jiang, X.; Yu, Y.; Huang, W.; Xing, H.; Agar, N. Y.; Yang, H. W.; Yang, B.; Carroll, R. S.; Johnson, M. D.] Harvard Univ, Sch Med, Boston, MA 02115 USA; [Li, H.; Yang, B.] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou 450052, Peoples R China; [Johnson, M. D.] Program Neuro Oncol, Dana Farber Brigham, Boston, MA USA; [Johnson, M. D.] Womens Canc Ctr, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Zhengzhou University	Johnson, MD (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Neurosurg, 75 Francis St, Boston, MA 02138 USA.	mjohnson27@partners.org			National Institute of Neurological Disorders and Stroke [R01 NS062219]; National Institutes of Health Director's New Innovator Award [DP2OD002319]; Brain Science Foundation Research Award; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS062219] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP2OD002319] Funding Source: NIH RePORTER	National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); National Institutes of Health Director's New Innovator Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Brain Science Foundation Research Award; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by R01 NS062219 from the National Institute of Neurological Disorders and Stroke, a National Institutes of Health Director's New Innovator Award (DP2OD002319) and a Brain Science Foundation Research Award to MDJ.	Amano M, 1999, J BIOL CHEM, V274, P32418, DOI 10.1074/jbc.274.45.32418; Bales E, 2005, CANCER RES, V65, P692; Berthet C, 2006, CELL DIV, V1, DOI 10.1186/1747-1028-1-10; Corsino PE, 2008, NEOPLASIA, V10, P1240, DOI 10.1593/neo.08710; Ferretti R, 2010, DEV CELL, V18, P486, DOI 10.1016/j.devcel.2009.12.020; Han IS, 2007, J CELL SCI, V120, P246, DOI 10.1242/jcs.03322; HANNON GJ, 1994, P NATL ACAD SCI USA, V91, P1731, DOI 10.1073/pnas.91.5.1731; Huse JT, 2009, GENE DEV, V23, P1327, DOI 10.1101/gad.1777409; Jacobs M, 2006, J BIOL CHEM, V281, P260, DOI 10.1074/jbc.M508847200; Joyce D, 1999, J BIOL CHEM, V274, P25245, DOI 10.1074/jbc.274.36.25245; Kim H, 2010, P NATL ACAD SCI USA, V107, P2183, DOI 10.1073/pnas.0909896107; Kim TM, 2011, CANCER RES, V71, P3387, DOI 10.1158/0008-5472.CAN-10-4117; Knights MJ, 2012, BRAIN PATHOL, V22, P592, DOI 10.1111/j.1750-3639.2012.00573.x; Kwiatkowska A, 2013, ADV EXP MED BIOL, V986, P121, DOI 10.1007/978-94-007-4719-7_7; Lee SW, 2000, MOL CELL BIOL, V20, P1723, DOI 10.1128/MCB.20.5.1723-1732.2000; Li JQ, 2002, HUM PATHOL, V33, P1006, DOI 10.1053/hupa.2002.125774; Li JQ, 2001, HUM PATHOL, V32, P945, DOI 10.1053/hupa.2001.27116; Lin WR, 2013, ONCOL REP, V29, P903, DOI 10.3892/or.2012.2208; Liu BN, 2012, BBA-MOL BASIS DIS, V1822, P1692, DOI 10.1016/j.bbadis.2012.07.019; Lowery DM, 2007, EMBO J, V26, P2262, DOI 10.1038/sj.emboj.7601683; Ma Z, 2006, MOL CELL BIOL, V26, P9016, DOI 10.1128/MCB.01383-06; Morrison DL, 1996, BIOCHEM CELL BIOL, V74, P549, DOI 10.1139/o96-459; Mrugala MM, 2013, DISCOV MED, V15, P221; Nalepa G, 2013, J CELL BIOL, V201, P997, DOI 10.1083/jcb.201205125; Pandithage R, 2008, J CELL BIOL, V180, P915, DOI 10.1083/jcb.200707126; Salhia B, 2005, CANCER RES, V65, P8792, DOI 10.1158/0008-5472.CAN-05-0160; SATTERWHITE LL, 1992, J CELL BIOL, V118, P595, DOI 10.1083/jcb.118.3.595; Tawara S, 2007, J CARDIOVASC PHARM, V50, P195, DOI 10.1097/FJC.0b013e31806befe6; Wang HF, 2011, CANCER RES, V71, P68, DOI 10.1158/0008-5472.CAN-10-0030; Wilkinson S, 2005, NAT CELL BIOL, V7, P255, DOI 10.1038/ncb1230; Yamaguchi H, 2006, STRUCTURE, V14, P589, DOI 10.1016/j.str.2005.11.024; Yang HW, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-301; Yang X, 2013, HEPATOLOGY, V58, P158, DOI 10.1002/hep.26305; Yeh CT, 2000, CANCER RES, V60, P4697; Yoneda A, 2005, J CELL BIOL, V170, P443, DOI 10.1083/jcb.200412043; Yu L, 2013, ONCOL LETT, V5, P1223, DOI 10.3892/ol.2013.1173; Yu Y, 2007, CANCER RES, V67, P130, DOI 10.1158/0008-5472.CAN-06-2478	37	17	18	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 12	2015	34	11					1432	1441		10.1038/onc.2014.49	http://dx.doi.org/10.1038/onc.2014.49			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CD1AR	24704824				2022-12-17	WOS:000350806500009
J	Camacho, CV; Todorova, PK; Hardebeck, MC; Tomimatsu, N; del Alcazar, CRG; Ilcheva, M; Mukherjee, B; McEllin, B; Vemireddy, V; Hatanpaa, K; Story, MD; Habib, AA; Murty, VV; Bachoo, R; Burma, S				Camacho, C. V.; Todorova, P. K.; Hardebeck, M. C.; Tomimatsu, N.; del Alcazar, C. R. Gil; Ilcheva, M.; Mukherjee, B.; McEllin, B.; Vemireddy, V.; Hatanpaa, K.; Story, M. D.; Habib, A. A.; Murty, V. V.; Bachoo, R.; Burma, S.			DNA double-strand breaks cooperate with loss of Ink4 and Arf tumor suppressors to generate glioblastomas with frequent Met amplification	ONCOGENE			English	Article							CENTRAL-NERVOUS-SYSTEM; IONIZING-RADIATION; GROWTH-FACTOR; LET RADIATION; BRAIN-TUMORS; STEM-CELLS; CANCER; GLIOMAS; REPAIR; EXPRESSION	Glioblastomas (GBM) are highly radioresistant and lethal brain tumors. Ionizing radiation (IR)-induced DNA double-strand breaks (DSBs) are a risk factor for the development of GBM. In this study, we systematically examined the contribution of IR-induced DSBs to GBM development using transgenic mouse models harboring brain-targeted deletions of key tumor suppressors frequently lost in GBM, namely Ink4a, Ink4b, Arf and/or PTEN. Using low linear energy transfer (LET) X-rays to generate simple breaks or high LET HZE particles (Fe ions) to generate complex breaks, we found that DSBs induce high-grade gliomas in these mice which, otherwise, do not develop gliomas spontaneously. Loss of Ink4a and Arf was sufficient to trigger IR-induced glioma development but additional loss of Ink4b significantly increased tumor incidence. We analyzed IR-induced tumors for copy number alterations to identify oncogenic changes that were generated and selected for as a consequence of stochastic DSB events. We found Met amplification to be the most significant oncogenic event in these radiation-induced gliomas. Importantly, Met activation resulted in the expression of Sox2, a GBM cancer stem cell marker, and was obligatory for tumor formation. In sum, these results indicate that radiation-induced DSBs cooperate with loss of Ink4 and Arf tumor suppressors to generate high-grade gliomas that are commonly driven by Met amplification and activation.	[Camacho, C. V.; Todorova, P. K.; Hardebeck, M. C.; Tomimatsu, N.; del Alcazar, C. R. Gil; Ilcheva, M.; Mukherjee, B.; Story, M. D.; Burma, S.] Univ Texas SW Med Ctr Dallas, Dept Radiat Oncol, Dallas, TX 75390 USA; [McEllin, B.; Vemireddy, V.; Habib, A. A.; Bachoo, R.] Univ Texas SW Med Ctr Dallas, Dept Neurol & Neurotherapeut, Dallas, TX 75390 USA; [Hatanpaa, K.] Univ Texas SW Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA; [Habib, A. A.] VA North Texas Hlth Care Syst, Dallas, TX USA; [Murty, V. V.] Columbia Univ, Med Ctr, Dept Pathol & Cell Biol, New York, NY USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA North Texas Health Care System; Columbia University	Burma, S (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Radiat Oncol, Div Mol Radiat Biol, 2201 Inwood Rd,NC7-214E, Dallas, TX 75390 USA.	sandeep.burma@utsouthwestern.edu	Story, Michael/AAX-2864-2021; Camacho, Cristel/Q-6197-2017	Story, Michael/0000-0001-6522-4169; Camacho, Cristel/0000-0003-1723-579X; vemireddy, vamsidhara/0000-0001-7068-6640	National Aeronautics and Space Administration [NNX13AI13G]; National Institutes of Health [RO1 CA149461, R01 NS062080]; Cancer Prevention and Research Institute of Texas [RP100644]; National Institute of General Medical Sciences [5T32GM008203]; NCI training [T32CA124334]; NATIONAL CANCER INSTITUTE [R01CA149461, T32CA124334] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008203] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS062080] Funding Source: NIH RePORTER	National Aeronautics and Space Administration(National Aeronautics & Space Administration (NASA)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Prevention and Research Institute of Texas; National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI training(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	SB is supported by grants from the National Aeronautics and Space Administration (NNX13AI13G), National Institutes of Health (RO1 CA149461) and the Cancer Prevention and Research Institute of Texas(RP100644). AAH is supported by a National Institutes of Health grant (R01 NS062080). MCH is supported by a National Institute of General Medical Sciences training grant 5T32GM008203 in cellular and molecular biology. CVC was supported by a NCI training grant (T32CA124334). CVC completed this work in partial fulfillment of the requirements for her PhD degree. We thank Dr Chaitanya Nirodi for valuable advice on cloning and lentivirus production strategies. We also thank the support staff at the NASA Space Radiation Research Laboratory, Brookhaven National Laboratory, Upton, NY, USA, for facilitating particle radiation experiments.	Attolini CSO, 2010, P NATL ACAD SCI USA, V107, P17604, DOI 10.1073/pnas.1009117107; Beroukhim R, 2007, P NATL ACAD SCI USA, V104, P20007, DOI 10.1073/pnas.0710052104; BIGNER SH, 1990, CANCER RES, V50, P8017; Bondy ML, 2008, CANCER-AM CANCER SOC, V113, P1953, DOI 10.1002/cncr.23741; Camacho CV, 2010, CARCINOGENESIS, V31, P1889, DOI 10.1093/carcin/bgq153; Chef T, 2008, RADIAT RES, V170, P553, DOI 10.1667/RR1393.1; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Costes SV, 2006, RADIAT RES, V165, P505, DOI 10.1667/RR3538.1; De Bacco F, 2012, CANCER RES, V72, P4537, DOI 10.1158/0008-5472.CAN-11-3490; De Bacco F, 2011, J NATL CANCER I, V103, P645, DOI 10.1093/jnci/djr093; Durante M, 2008, NAT REV CANCER, V8, P465, DOI 10.1038/nrc2391; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; FISCHER U, 1995, GENE CHROMOSOME CANC, V12, P63, DOI 10.1002/gcc.2870120111; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; Gherardi E, 2012, NAT REV CANCER, V12, P89, DOI 10.1038/nrc3205; Hambardzumyan D, 2011, GLIA, V59, P1155, DOI 10.1002/glia.21142; Hellman A, 2002, CANCER CELL, V1, P89, DOI 10.1016/S1535-6108(02)00017-X; Isaka F, 1999, EUR J NEUROSCI, V11, P2582, DOI 10.1046/j.1460-9568.1999.00699.x; Joo KM, 2012, CANCER RES, V72, P3828, DOI 10.1158/0008-5472.CAN-11-3760; Jun HJ, 2012, ONCOGENE, V31, P3039, DOI 10.1038/onc.2011.474; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Krimpenfort P, 2007, NATURE, V448, P943, DOI 10.1038/nature06084; Laterra J, 1997, BIOCHEM BIOPH RES CO, V235, P743, DOI 10.1006/bbrc.1997.6853; Li YQ, 2005, CANCER RES, V65, P9355, DOI 10.1158/0008-5472.CAN-05-1946; Li YQ, 2011, P NATL ACAD SCI USA, V108, P9951, DOI 10.1073/pnas.1016912108; Liu W, 2011, J CLIN NEUROSCI, V18, P119, DOI 10.1016/j.jocn.2010.05.010; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Mukherjee B, 2008, DNA REPAIR, V7, P1717, DOI 10.1016/j.dnarep.2008.06.016; Mukherjee B, 2009, CANCER RES, V69, P4252, DOI 10.1158/0008-5472.CAN-08-4853; NEGLIA JP, 1991, NEW ENGL J MED, V325, P1330, DOI 10.1056/NEJM199111073251902; Okayasu R, 2012, INT J CANCER, V130, P991, DOI 10.1002/ijc.26445; Paulino AC, 2008, INT J RADIAT ONCOL, V71, P1381, DOI 10.1016/j.ijrobp.2007.12.018; Pearce MS, 2012, LANCET, V380, P499, DOI 10.1016/S0140-6736(12)60815-0; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Purow B, 2009, NAT REV NEUROL, V5, P419, DOI 10.1038/nrneurol.2009.96; Ron E, 2002, PEDIATR RADIOL, V32, P232, DOI 10.1007/s00247-002-0672-0; Sage E, 2011, MUTAT RES-FUND MOL M, V711, P123, DOI 10.1016/j.mrfmmm.2010.12.010; Saha J, 2013, DNA REPAIR, V12, P1143, DOI 10.1016/j.dnarep.2013.10.004; Salvati M, 2003, SURG NEUROL, V60, P60, DOI 10.1016/S0090-3019(03)00137-X; Scotto L, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-58; Smolen GA, 2006, CANCER RES, V66, P3452, DOI 10.1158/0008-5472.CAN-05-4181; Sottoriva A, 2013, P NATL ACAD SCI USA, V110, P4009, DOI 10.1073/pnas.1219747110; Stommel JM, 2007, SCIENCE, V318, P287, DOI 10.1126/science.1142946; Sutter R, 2007, BBA-REV CANCER, V1776, P125, DOI 10.1016/j.bbcan.2007.07.006; Trusolino L, 2010, NAT REV MOL CELL BIO, V11, P834, DOI 10.1038/nrm3012; Turke AB, 2010, CANCER CELL, V17, P77, DOI 10.1016/j.ccr.2009.11.022; Wang HY, 2008, DNA REPAIR, V7, P725, DOI 10.1016/j.dnarep.2008.01.010; Westphal M, 2011, NAT REV NEUROSCI, V12, P495, DOI 10.1038/nrn3060; Yajima H, 2013, DNA REPAIR, V12, P936, DOI 10.1016/j.dnarep.2013.08.009	50	17	17	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2015	34	8					1064	1072		10.1038/onc.2014.29	http://dx.doi.org/10.1038/onc.2014.29			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC1RT	24632607	Green Accepted, Green Submitted			2022-12-17	WOS:000350121300013
J	Kumagai, Y; Naoki, H; Nakasyo, E; Kamioka, Y; Kiyokawa, E; Matsuda, M				Kumagai, Y.; Naoki, H.; Nakasyo, E.; Kamioka, Y.; Kiyokawa, E.; Matsuda, M.			Heterogeneity in ERK activity as visualized by in vivo FRET imaging of mammary tumor cells developed in MMTV-Neu mice	ONCOGENE			English	Article							CANCER STEM-CELLS; BREAST-CANCER; INITIATING CELLS; SELF-RENEWAL; KINASE-ACTIVITY; MOUSE MODELS; MORPHOGENESIS; TUMORIGENESIS; EXPRESSION; TAMOXIFEN	Human epidermal growth factor receptor2/Neu, which is overexpressed in about 30% of human breast cancers, transduces growth signals in large part via the Ras-Raf-MEK-ERK pathway. Nevertheless, it is a matter of controversy whether high ERK activity in breast cancer tissues correlates with better or worse prognosis, leaving the role of ERK activity in the progression of breast cancers unresolved. To address this issue, we live-imaged ERK activity in mammary tumors developed in mouse mammary tumor virus-Neu transgenic mice, which had been crossed with transgenic mice expressing a Forster resonance energy transfer biosensor for ERK. Observation of the tumor by two-photon microscopy revealed significant heterogeneity in ERK activity among the mammary tumor cells. The level of ERK activity in each cell was stable up to several hours, implying a robust mechanism that maintained the ERK activity within a limited range. By sorting the mammary tumor cells on the basis of their ERK activity, we found that ERKhigh cells less efficiently generated tumorspheres in vitro and tumors in vivo than did ERKlow cells. In agreement with this finding, the expressions of the cancer stem cell markers CD49f, CD24 and CD61 were decreased in ERKhigh cells. These observations suggest that high ERK activity may suppress the self-renewal of mammary cancer stem cells.	[Kumagai, Y.; Matsuda, M.] Kyoto Univ, Grad Sch Biostudies, Dept Bioimaging & Cell Signaling, Kyoto 6068501, Japan; [Naoki, H.] Kyoto Univ, Kyoto 6068501, Japan; [Nakasyo, E.] Olympus Corp, R&D Div, Life & Ind Prod Dev Dept 1, Hachioji, Tokyo, Japan; [Kamioka, Y.; Matsuda, M.] Kyoto Univ, Grad Sch Med, Dept Pathol & Biol Dis, Kyoto 6068501, Japan; [Kamioka, Y.] Kyoto Univ, Grad Sch Med, Kyoto 6068501, Japan; [Kiyokawa, E.] Kanazawa Med Univ, Dept Oncol Pathol, Uchinada, Ishikawa 92002, Japan	Kyoto University; Kyoto University; Olympus Corporation; Kyoto University; Kyoto University; Kanazawa Medical University	Matsuda, M (corresponding author), Kyoto Univ, Grad Sch Biostudies, Sakyo Ku, Yoshida Konoe Cho, Kyoto 6068501, Japan.	matsuda.michiyuki.2c@kyoto-u.ac.jp	Naoki, Honda/AAW-6284-2020; Naoki, Honda/N-5674-2017	Naoki, Honda/0000-0001-6816-9126; Naoki, Honda/0000-0001-6816-9126; Matsuda, Michiyuki/0000-0002-5876-9969	Ministry of Education, Culture, Sports, Science and Technology (MEXT) [22113002]; Innovative Techno-Hub for the Integrated Medical Bio-imaging Project of the Special Coordination Funds for Promoting Science and Technology by MEXT, Japan; MEXT, Japan; Animal Care and Use Committee of Kyoto University Graduate School of Medicine [10584]; Grants-in-Aid for Scientific Research [15H05949, 22113001] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology (MEXT)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Innovative Techno-Hub for the Integrated Medical Bio-imaging Project of the Special Coordination Funds for Promoting Science and Technology by MEXT, Japan; MEXT, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Animal Care and Use Committee of Kyoto University Graduate School of Medicine; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	J3B1 cells were kindly provided by Roberto Montesano. We thank Y Inaoka, K Hirano, K Takakura, R Tabata, Y Kitagawa and A Kawagishi for their technical assistance. We are grateful to the members of the Matsuda Laboratory for their helpful discussions. MM was supported by a Grant-in-Aid for Scientific Research on the Innovative Area of 'Fluorescence Live imaging' (No. 22113002) of the Ministry of Education, Culture, Sports, Science and Technology (MEXT), and by an Innovative Techno-Hub for the Integrated Medical Bio-imaging Project of the Special Coordination Funds for Promoting Science and Technology by MEXT, Japan. YK was supported by a Grant-in-Aid for JSPS Fellows from MEXT, Japan. The animal protocols were reviewed and approved by the Animal Care and Use Committee of Kyoto University Graduate School of Medicine (No. 10584).	Aoki K, 2009, NAT PROTOC, V4, P1623, DOI 10.1038/nprot.2009.175; Asselin-Labat ML, 2007, NAT CELL BIOL, V9, P201, DOI 10.1038/ncb1530; Bergqvist J, 2006, EUR J CANCER, V42, P1104, DOI 10.1016/j.ejca.2006.01.028; Brown AP, 2007, CANCER CHEMOTH PHARM, V59, P671, DOI 10.1007/s00280-006-0323-5; Chang CJ, 2011, CANCER CELL, V19, P86, DOI 10.1016/j.ccr.2010.10.035; Chappell J, 2013, GENE DEV, V27, P725, DOI 10.1101/gad.211300.112; Ewald AJ, 2008, DEV CELL, V14, P570, DOI 10.1016/j.devcel.2008.03.003; Goto A, 2013, J NEUROSCI, V33, P4901, DOI 10.1523/JNEUROSCI.4828-12.2013; Greber B, 2010, CELL STEM CELL, V6, P215, DOI 10.1016/j.stem.2010.01.003; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Izrailit J, 2013, P NATL ACAD SCI USA, V110, P1714, DOI 10.1073/pnas.1214014110; Jeselsohn R, 2010, CANCER CELL, V17, P65, DOI 10.1016/j.ccr.2009.11.024; Kamioka Y, 2012, CELL STRUCT FUNCT, V37, P65, DOI 10.1247/csf.11045; Korkaya H, 2008, ONCOGENE, V27, P6120, DOI 10.1038/onc.2008.207; Kunath T, 2007, DEVELOPMENT, V134, P2895, DOI 10.1242/dev.02880; Liu JC, 2012, P NATL ACAD SCI USA, V109, P5832, DOI 10.1073/pnas.1201105109; Liu L, 2009, CANCER RES, V69, P6871, DOI 10.1158/0008-5472.CAN-08-4490; Lo PK, 2012, ONCOGENE, V31, P2614, DOI [10.1038/onc.2012.147, 10.1038/onc.2011.439]; Magnifico A, 2009, CLIN CANCER RES, V15, P2010, DOI 10.1158/1078-0432.CCR-08-1327; McGlynn LM, 2009, CLIN CANCER RES, V15, P1487, DOI 10.1158/1078-0432.CCR-07-4967; Milde-Langosch K, 2005, BRIT J CANCER, V92, P2206, DOI 10.1038/sj.bjc.6602655; Montesano R, 2002, J CELL SCI, V115, P4419, DOI 10.1242/jcs.00164; Mueller H, 2000, INT J CANCER, V89, P384, DOI 10.1002/1097-0215(20000720)89:4<384::AID-IJC11>3.0.CO;2-R; Nobis M, 2013, CANCER RES, V73, P4674, DOI 10.1158/0008-5472.CAN-12-4545; Parashurama N, 2012, STEM CELLS, V30, P2114, DOI 10.1002/stem.1205; Pece S, 2010, CELL, V140, P62, DOI 10.1016/j.cell.2009.12.007; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; Svensson S, 2005, ONCOGENE, V24, P4370, DOI 10.1038/sj.onc.1208626; Ursini-Siegel J, 2007, NAT REV CANCER, V7, P389, DOI 10.1038/nrc2127; Vaillant F, 2008, CANCER RES, V68, P7711, DOI 10.1158/0008-5472.CAN-08-1949; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Whyte J, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2361; Ying QL, 2008, NATURE, V453, P519, DOI 10.1038/nature06968; Zhou BBS, 2009, NAT REV DRUG DISCOV, V8, P806, DOI 10.1038/nrd2137	36	17	17	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2015	34	8					1051	1057		10.1038/onc.2014.28	http://dx.doi.org/10.1038/onc.2014.28			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC1RT	24632612	Green Published			2022-12-17	WOS:000350121300011
J	Bojovic, B; Booth, RE; Jin, Y; Zhou, X; Crowe, DL				Bojovic, B.; Booth, R. E.; Jin, Y.; Zhou, X.; Crowe, D. L.			Alternative lengthening of telomeres in cancer stem cells in vivo	ONCOGENE			English	Article						DNA damage; metastasis; squamous cell carcinoma; basal cells; keratin 15	HUMAN ORAL KERATINOCYTES; CATALYTIC SUBUNIT; MAMMALIAN TELOMERES; MOUSE CELLS; MAINTENANCE; SKIN; GENE; IMMORTALIZATION; TRANSFORMATION; PROLIFERATION	Chromosome ends are protected by telomeres that prevent DNA damage response and degradation. Telomerase expression extends telomeres and inhibits DNA damage response. Telomeres are also maintained by the recombination-based alternative lengthening pathway. Telomerase is believed to be the sole mechanism for telomere maintenance in the epidermis. We show that basal cells in the epidermis maintain telomeres both by telomerase and alternative lengthening of telomere (ALT) mechanisms in vivo. ALT was detected in epidermal stem cells in Terc(-/-) mice, and normal human epidermal keratinocytes are also ALT-positive. The ALT pathway is suppressed in primary, but not metastatic, epidermal squamous cell carcinomas (SCC) in Terc(+/+) mice. The ALT pathway is expressed in stem cells and basal cells in epidermal SCC in Terc(-/-) mice, and in some telomerase-positive human SCC lines. Telomeres shorten markedly in stem cells and basal cells in epidermal SCC in vivo. Telomere shortening is associated with telomeric DNA damage response and apoptosis in stem cells and basal cells. Stem cells were transformed in both primary and metastatic epidermal SCC. Genetic ablation of this small cell population resulted in significant tumor regression in vivo. We concluded that alternative lengthening of telomeres is important in epidermal homeostasis and tumorigenesis in vivo.	[Bojovic, B.; Booth, R. E.; Jin, Y.; Zhou, X.; Crowe, D. L.] Univ Illinois, Ctr Canc, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Crowe, DL (corresponding author), Univ Illinois, Ctr Canc, 801 S Paulina St,Room 530C, Chicago, IL 60612 USA.	dlcrowe@uic.edu			National Institutes of Health [DE14283]; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R03DE014283] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	We thank Dr Chiayeng Wang (University of Illinois, Chicago, IL, USA) for U2OS cells. This research was supported by National Institutes of Health grant DE14283.	Belair CD, 1997, P NATL ACAD SCI USA, V94, P13677, DOI 10.1073/pnas.94.25.13677; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Callicott RJ, 2006, COMPARATIVE MED, V56, P17; Celli GB, 2006, NAT CELL BIOL, V8, P885, DOI 10.1038/ncb1444; Cotsarelis G, 2006, J INVEST DERMATOL, V126, P1459, DOI 10.1038/sj.jid.5700376; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Crowe DL, 2001, NUCLEIC ACIDS RES, V29, P2789, DOI 10.1093/nar/29.13.2789; Flores I, 2005, SCIENCE, V309, P1253, DOI 10.1126/science.1115025; Flores I, 2008, GENE DEV, V22, P654, DOI 10.1101/gad.451008; Ford LP, 2001, J BIOL CHEM, V276, P32198, DOI 10.1074/jbc.M104469200; Fuchs E, 2008, J CELL BIOL, V180, P273, DOI 10.1083/jcb.200708185; Fuchs E, 2007, NATURE, V445, P834, DOI 10.1038/nature05659; Fuchs E, 2009, CELL, V137, P811, DOI 10.1016/j.cell.2009.05.002; Gonzalez-Suarez E, 2001, EMBO J, V20, P2619, DOI 10.1093/emboj/20.11.2619; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Grobelny JV, 2001, HUM MOL GENET, V10, P1953, DOI 10.1093/hmg/10.18.1953; HarleBachor C, 1996, P NATL ACAD SCI USA, V93, P6476, DOI 10.1073/pnas.93.13.6476; Harrington L, 1997, GENE DEV, V11, P3109, DOI 10.1101/gad.11.23.3109; Heaphy CM, 2011, AM J PATHOL, V179, P1608, DOI 10.1016/j.ajpath.2011.06.018; Hemann MT, 1999, NUCLEIC ACIDS RES, V27, P3964, DOI 10.1093/nar/27.20.3964; Henderson S, 1996, J CELL BIOL, V134, P1, DOI 10.1083/jcb.134.1.1; Henson JD, 2010, FEBS LETT, V584, P3800, DOI 10.1016/j.febslet.2010.06.009; Henson JD, 2009, NAT BIOTECHNOL, V27, P1181, DOI 10.1038/nbt.1587; Kang MK, 2004, J CELL PHYSIOL, V199, P364, DOI 10.1002/jcp.10410; Kang MK, 1998, CELL GROWTH DIFFER, V9, P85; Liu YP, 2003, J INVEST DERMATOL, V121, P963, DOI 10.1046/j.1523-1747.2003.12600.x; Malanchi I, 2008, NATURE, V452, P650, DOI 10.1038/nature06835; Martinez P, 2010, AGING CELL, V9, P653, DOI 10.1111/j.1474-9726.2010.00596.x; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Morris RJ, 2004, NAT BIOTECHNOL, V22, P411, DOI 10.1038/nbt950; Nabetani A, 2009, MOL CELL BIOL, V29, P703, DOI 10.1128/MCB.00603-08; Palm W, 2008, ANNU REV GENET, V42, P301, DOI 10.1146/annurev.genet.41.110306.130350; Rajaraman S, 2007, P NATL ACAD SCI USA, V104, P17747, DOI 10.1073/pnas.0706485104; Ramakrishnan S, 1998, CANCER RES, V58, P622; Rossi DJ, 2008, CELL, V132, P681, DOI 10.1016/j.cell.2008.01.036; Sarin KY, 2005, NATURE, V436, P1048, DOI 10.1038/nature03836; Siegl-Cachedenier I, 2007, J CELL BIOL, V179, P277, DOI 10.1083/jcb.200704141; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; Wu GK, 2003, CANCER RES, V63, P2589; Wu YL, 2007, DNA REPAIR, V6, P157, DOI 10.1016/j.dnarep.2006.09.005	42	17	18	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2015	34	5					611	620		10.1038/onc.2013.603	http://dx.doi.org/10.1038/onc.2013.603			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CA4DD	24531712	Green Accepted			2022-12-17	WOS:000348853500008
J	Kershaw, RM; Siddiqui, YH; Roberts, D; Jayaraman, PS; Gaston, K				Kershaw, R. M.; Siddiqui, Y. H.; Roberts, D.; Jayaraman, P-S; Gaston, K.			PRH/HHex inhibits the migration of breast and prostate epithelial cells through direct transcriptional regulation of Endoglin	ONCOGENE			English	Article						HHex; PRH; cell migration; invasion; breast cancer; prostate cancer	MOUSE SKIN CARCINOGENESIS; RICH HOMEODOMAIN PROTEIN; MESSENGER-RNA TRANSPORT; VEGF-SIGNALING GENES; HEMATOPOIETIC-CELLS; ENDOTHELIAL-CELLS; EXPRESSION; HEX; CANCER; DIFFERENTIATION	PRH/HHex (proline-rich homeodomain protein) is a transcription factor that controls cell proliferation and cell differentiation in a variety of tissues. Aberrant subcellular localisation of PRH is associated with breast cancer and thyroid cancer. Further, in blast crisis chronic myeloid leukaemia, and a subset of acute myeloid leukaemias, PRH is aberrantly localised and its activity is downregulated. Here we show that PRH is involved in the regulation of cell migration and cancer cell invasion. We show for the first time that PRH is expressed in prostate cells and that a decrease in PRH protein levels increases the migration of normal prostate epithelial cells. We show that a decrease in PRH protein levels also increases the migration of normal breast epithelial cells. Conversely, PRH overexpression inhibits cell migration and cell invasion by PC3 and DU145 prostate cancer cells and MDA-MB-231 breast cancer cells. Previous work has shown that the transforming growth factor-b co-receptor Endoglin inhibits the migration of prostate and breast cancer cells. Here we show that PRH can bind to the Endoglin promoter in immortalised prostate and breast cells. PRH overexpression in these cells results in increased Endoglin protein expression, whereas PRH knockdown results in decreased Endoglin protein expression. Moreover, we demonstrate that Endoglin overexpression abrogates the increased migration shown by PRH knockdown cells. Our data suggest that PRH controls the migration of multiple epithelial cell lineages in part at least through the direct transcriptional regulation of Endoglin. We discuss these results in terms of the functions of PRH in normal cells and the mislocalisation of PRH seen in multiple cancer cell types.	[Kershaw, R. M.; Roberts, D.; Jayaraman, P-S] Univ Birmingham, Sch Med, Div Immun & Infect, Birmingham, W Midlands, England; [Siddiqui, Y. H.; Gaston, K.] Univ Bristol, Sch Biochem, Bristol B17 8QB, Avon, England	University of Birmingham; University of Bristol	Gaston, K (corresponding author), Univ Bristol, Sch Biochem, Univ Walk, Bristol B17 8QB, Avon, England.	kevin.gaston@bristol.ac.uk	Gaston, Kevin/K-9237-2019	Gaston, Kevin/0000-0002-7349-5513; SIDDIQUI, YUSRA/0000-0001-7231-4736; /0000-0002-6500-9095	Breast Cancer Campaign project grant; University of Bristol; Charles Wallace Pakistan Trust; MRC	Breast Cancer Campaign project grant; University of Bristol; Charles Wallace Pakistan Trust; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We are grateful to Professor Norman J Maitland (University of York) for PNT2-C2 cells and useful discussions, Professor Kate Nobes (University of Bristol) for access to live cell imaging, Professor Clare Isacke (Institute of Cancer Research) for the Endoglin expression vector, Professor Harry Mellor (University of Bristol) and Professor Roy Bicknell (University of Birmingham) for HUVECs and useful discussions, and Professor Carmelo Bernabeu (Centro de Investigaciones Biologicas, Madrid) for Endoglin-luciferase reporter constructs. We are grateful to Laura A V Rodriguez and Xin Yang for technical assistance. This work was funded by a Breast Cancer Campaign project grant to PSJ and KG. YHS is grateful to the University of Bristol for a PhD Scholarship and to the Charles Wallace Pakistan Trust for additional support. DR is grateful to the MRC for a PhD studentship.	Bernabeu C, 2007, J CELL BIOCHEM, V102, P1375, DOI 10.1002/jcb.21594; BERTHON P, 1995, INT J ONCOL, V6, P333; Botella LM, 2001, J BIOL CHEM, V276, P34486, DOI 10.1074/jbc.M011611200; Botella LM, 2002, BLOOD, V100, P4001, DOI 10.1182/blood.V100.12.4001; Craft CS, 2007, ONCOGENE, V26, P7240, DOI 10.1038/sj.onc.1210533; D'Elia AV, 2002, J CLIN ENDOCR METAB, V87, P1376, DOI 10.1210/jc.87.3.1376; Denson LA, 2000, AM J PHYSIOL-GASTR L, V279, pG347, DOI 10.1152/ajpgi.2000.279.2.G347; Desjobert C, 2009, BIOCHEM J, V417, P121, DOI 10.1042/BJ20080872; George A, 2003, ONCOGENE, V22, P6764, DOI 10.1038/sj.onc.1206822; Guerrero-Esteo M, 1999, EUR J CELL BIOL, V78, P614, DOI 10.1016/S0171-9335(99)80046-6; Guiral M, 2001, J BIOL CHEM, V276, P2961, DOI 10.1074/jbc.M004948200; Guo Y, 2003, BLOOD, V102, P2428, DOI 10.1182/blood-2003-02-0634; Henry LA, 2011, ONCOGENE, V30, P1046, DOI 10.1038/onc.2010.488; Jankovic D, 2008, BLOOD, V111, P5672, DOI 10.1182/blood-2007-09-108175; Kassouf W, 2004, PROSTATE CANCER P D, V7, P105, DOI 10.1038/sj.pcan.4500716; Lakshman M, 2011, CLIN EXP METASTAS, V28, P39, DOI 10.1007/s10585-010-9356-6; Lang SH, 2001, BRIT J CANCER, V85, P590, DOI 10.1054/bjoc.2001.1967; Liu YQ, 2002, ONCOGENE, V21, P8272, DOI 10.1038/sj.onc.1206117; Ma C, 2008, CSH PROTOCOLS; McCormack MP, 2010, SCIENCE, V327, P879, DOI 10.1126/science.1182378; Nakagawa T, 2003, ARTERIOSCL THROM VAS, V23, P231, DOI 10.1161/01.ATV.0000052670.55321.87; Noy P, 2012, NUCLEIC ACIDS RES, V40, P9008, DOI 10.1093/nar/gks687; Noy P, 2012, LEUKEMIA RES, V36, P1434, DOI 10.1016/j.leukres.2012.07.013; Noy P, 2010, MOL CELL BIOL, V30, P2120, DOI 10.1128/MCB.01511-09; Oram SH, 2010, ONCOGENE, V29, P5796, DOI 10.1038/onc.2010.320; Oxmann D, 2008, ONCOGENE, V27, P3567, DOI 10.1038/sj.onc.1211025; Perez-Gomez E, 2007, CANCER RES, V67, P10268, DOI 10.1158/0008-5472.CAN-07-1348; Pimanda JE, 2006, BLOOD, V107, P4737, DOI 10.1182/blood-2005-12-4929; Pimanda JE, 2008, BLOOD, V112, P4512, DOI 10.1182/blood-2008-05-157560; Puppin C, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-192; Quintanilla M, 2003, ONCOGENE, V22, P5976, DOI 10.1038/sj.onc.1206841; Romero D, 2010, CARCINOGENESIS, V31, P359, DOI 10.1093/carcin/bgp217; Sanchez-Elsner T, 2002, J BIOL CHEM, V277, P43799, DOI 10.1074/jbc.M207160200; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Soufi A, 2008, BIOCHEM J, V412, P399, DOI 10.1042/BJ20080035; Soufi A, 2006, J MOL BIOL, V358, P943, DOI 10.1016/j.jmb.2006.02.020; Soufi A, 2009, NUCLEIC ACIDS RES, V37, P3288, DOI 10.1093/nar/gkp197; Swingler TE, 2004, J BIOL CHEM, V279, P34938, DOI 10.1074/jbc.M404488200; Topisirovic I, 2003, MOL CELL BIOL, V23, P8992, DOI 10.1128/MCB.23.24.8992-9002.2003; Topisirovic I, 2003, EMBO J, V22, P689, DOI 10.1093/emboj/cdg069; Williams H, 2008, J MOL BIOL, V383, P10, DOI 10.1016/j.jmb.2008.08.004; Wong VCL, 2008, INT J CANCER, V123, P2816, DOI 10.1002/ijc.23882	42	17	17	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 4	2014	33	49					5592	5600		10.1038/onc.2013.496	http://dx.doi.org/10.1038/onc.2013.496			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AW1ZW	24240683	Green Accepted			2022-12-17	WOS:000346088700003
J	Demajo, S; Uribesalgo, I; Gutierrez, A; Ballare, C; Capdevila, S; Roth, M; Zuber, J; Martin-Caballero, J; Di Croce, L				Demajo, S.; Uribesalgo, I.; Gutierrez, A.; Ballare, C.; Capdevila, S.; Roth, M.; Zuber, J.; Martin-Caballero, J.; Di Croce, L.			ZRF1 controls the retinoic acid pathway and regulates leukemogenic potential in acute myeloid leukemia	ONCOGENE			English	Article						acute myeloid leukemia; ZRF1; retinoic acid; transcription; differentiation	ACUTE PROMYELOCYTIC LEUKEMIA; TUMOR-ASSOCIATED ANTIGENS; RAR-ALPHA; DIFFERENTIATION; CANCER; CELLS; TRANSCRIPTION; EXPRESSION; RESPONSES; CHROMATIN	Acute myeloid leukemia (AML) is frequently linked to epigenetic abnormalities and deregulation of gene transcription, which lead to aberrant cell proliferation and accumulation of undifferentiated precursors. ZRF1, a recently characterized epigenetic factor involved in transcriptional regulation, is highly overexpressed in human AML, but it is not known whether it plays a role in leukemia progression. Here, we demonstrate that ZRF1 depletion decreases cell proliferation, induces apoptosis and enhances cell differentiation in human AML cells. Treatment with retinoic acid (RA), a differentiating agent currently used to treat certain AMLs, leads to a functional switch of ZRF1 from a negative regulator to an activator of differentiation. At the molecular level, ZRF1 controls the RA-regulated gene network through its interaction with the RA receptor alpha (RAR alpha) and its binding to RA target genes. Our genome-wide expression study reveals that ZRF1 regulates the transcription of nearly half of RA target genes. Consistent with our in vitro observations that ZRF1 regulates proliferation, apoptosis, and differentiation, ZRF1 depletion strongly inhibits leukemia progression in a xenograft mouse model. Finally, ZRF1 knockdown cooperates with RA treatment in leukemia suppression in vivo. Taken together, our data reveal that ZRF1 is a key transcriptional regulator in leukemia progression and suggest that ZRF1 inhibition could be a novel strategy to be explored for AML treatment.	[Demajo, S.; Uribesalgo, I.; Gutierrez, A.; Ballare, C.; Di Croce, L.] CRG, Barcelona, Spain; [Demajo, S.; Uribesalgo, I.; Gutierrez, A.; Ballare, C.; Di Croce, L.] UPF, Barcelona, Spain; [Capdevila, S.; Martin-Caballero, J.] PRBB, Unidad Anim Lab, Barcelona, Spain; [Roth, M.; Zuber, J.] Inst Mol Pathol, A-1030 Vienna, Austria; [Di Croce, L.] ICREA, Barcelona 08003, Spain	Barcelona Institute of Science & Technology; Pompeu Fabra University; Centre de Regulacio Genomica (CRG); Pompeu Fabra University; Pompeu Fabra University; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); ICREA	Di Croce, L (corresponding author), ICREA, C Dr Aiguader 88, Barcelona 08003, Spain.	luciano.dicroce@crg.eu	Zuber, Johannes/E-7517-2011; Di Croce, Luciano/E-7759-2015; Gutierrez, Arantxa/K-8213-2015; Demajo, Santiago/AAB-1999-2021; Ballare, Cecilia/F-2593-2016	Zuber, Johannes/0000-0001-8810-6835; Di Croce, Luciano/0000-0003-3488-6228; Gutierrez, Arantxa/0000-0001-9033-3834; Ballare, Cecilia/0000-0002-9442-807X; Demajo Meseguer, Santiago/0000-0003-3998-8784; Uribesalgo, Iris/0000-0001-9492-1000	Spanish 'Ministerio de Educacion y Ciencia' [BFU2010-18692]; AGAUR; 'Fundacio La Marato and from by European Commission's 7th Framework Program 4DCellFate [277899]; PFIS fellowship of the 'Instituto de Salud Carlos III'; Worldwide Cancer Research [10-0177] Funding Source: researchfish; ICREA Funding Source: Custom	Spanish 'Ministerio de Educacion y Ciencia'(Spanish Government); AGAUR(Agencia de Gestio D'Ajuts Universitaris de Recerca Agaur (AGAUR)); 'Fundacio La Marato and from by European Commission's 7th Framework Program 4DCellFate; PFIS fellowship of the 'Instituto de Salud Carlos III'; Worldwide Cancer Research; ICREA(ICREA)	We thank the members of the LDC laboratory for discussions, the CRG Genomic Unit, and VA Raker for help in preparing the manuscript. This work was supported by grants from the Spanish 'Ministerio de Educacion y Ciencia' (BFU2010-18692), from AGAUR, from 'Fundacio La Marato and from by European Commission's 7th Framework Program 4DCellFate grant number 277899 to LDC; SD was supported by a PFIS fellowship of the 'Instituto de Salud Carlos III'.	Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036; Anguille S, 2012, LEUKEMIA, V26, P2186, DOI 10.1038/leu.2012.145; Berge T, 2007, BLOOD CELL MOL DIS, V39, P278, DOI 10.1016/j.bcmd.2007.05.007; Campos EI, 2009, ANNU REV GENET, V43, P559, DOI 10.1146/annurev.genet.032608.103928; Chanda B, 2013, CELL, V155, P215, DOI 10.1016/j.cell.2013.08.055; DERMIME S, 1995, LEUKEMIA LYMPHOMA, V16, P289, DOI 10.3109/10428199509049768; Deschler B, 2006, CANCER-AM CANCER SOC, V107, P2099, DOI 10.1002/cncr.22233; Duester G, 2008, CELL, V134, P921, DOI 10.1016/j.cell.2008.09.002; Friedman AD, 2007, ONCOGENE, V26, P6816, DOI 10.1038/sj.onc.1210764; Frith MC, 2004, NUCLEIC ACIDS RES, V32, P1372, DOI 10.1093/nar/gkh299; Giannopoulos K, 2006, INT J ONCOL, V29, P95; Greiner J, 2003, INT J CANCER, V106, P224, DOI 10.1002/ijc.11200; Greiner J, 2004, INT J CANCER, V108, P704, DOI 10.1002/ijc.11623; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Jaiswal H, 2011, MOL CELL BIOL, V31, P1160, DOI 10.1128/MCB.00986-10; Jolma A, 2013, CELL, V152, P327, DOI 10.1016/j.cell.2012.12.009; Kastner P, 2001, ONCOGENE, V20, P7178, DOI 10.1038/sj.onc.1204757; Lehmann S, 2001, CLIN CANCER RES, V7, P367; Minucci S, 2001, ONCOGENE, V20, P3110, DOI 10.1038/sj.onc.1204336; Nowak D, 2009, BLOOD, V113, P3655, DOI 10.1182/blood-2009-01-198911; Oren T, 2003, LEUKEMIA LYMPHOMA, V44, P1881, DOI 10.1080/1042819031000116661; Resto VA, 2000, CANCER RES, V60, P5529; Ribeiro JD, 2013, ONCOGENE, V32, P2161, DOI 10.1038/onc.2012.241; Richly H, 2010, NATURE, V468, P1124, DOI 10.1038/nature09574; Schmitt M, 2006, EXP HEMATOL, V34, P1709, DOI 10.1016/j.exphem.2006.07.009; SHOJI W, 1995, J BIOL CHEM, V270, P24818, DOI 10.1074/jbc.270.42.24818; Siegel S, 2012, ACTA HAEMATOL-BASEL, V127, P193, DOI 10.1159/000335133; Smith JC, 2007, J PROTEOME RES, V6, P3174, DOI 10.1021/pr070122r; Tang XH, 2011, ANNU REV PATHOL-MECH, V6, P345, DOI 10.1146/annurev-pathol-011110-130303; Tenen DG, 2003, NAT REV CANCER, V3, P89, DOI 10.1038/nrc989; Uckun FM, 1996, BLOOD, V88, P1135, DOI 10.1182/blood.V88.4.1135.bloodjournal8841135; Uribesalgo I, 2011, NAT CELL BIOL, V13, P1443, DOI 10.1038/ncb2355; Uribesalgo I, 2011, BRIEF FUNCT GENOMICS, V10, P18, DOI 10.1093/bfgp/elr002; Villa R, 2007, CANCER CELL, V11, P513, DOI 10.1016/j.ccr.2007.04.009; Wang ZY, 2008, BLOOD, V111, P2505, DOI 10.1182/blood-2007-07-102798; Zuber J, 2011, GENE DEV, V25, P1628, DOI 10.1101/gad.17269211	36	17	18	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 27	2014	33	48					5501	5510		10.1038/onc.2013.501	http://dx.doi.org/10.1038/onc.2013.501			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AW1ZO	24292673				2022-12-17	WOS:000346087900003
J	Barras, D; Lorusso, G; Ruegg, C; Widmann, C				Barras, D.; Lorusso, G.; Rueegg, C.; Widmann, C.			Inhibition of cell migration and invasion mediated by the TAT-RasGAP(317-326) peptide requires the DLC1 tumor suppressor	ONCOGENE			English	Article						RasGAP; DLC1; adhesion; migration; invasion; peptide	FOCAL ADHESION KINASE; RAS-GAP; CANCER; RHO; BINDING; PROTEIN; APOPTOSIS; CYTOSKELETON; INTEGRINS; GTPASE	TAT-RasGAP(317-326), a peptide corresponding to the 317-326 sequence of p120 RasGAP coupled with a cell-permeable TAT-derived peptide, sensitizes the death response of various tumor cells to several anticancer treatments. We now report that this peptide is also able to increase cell adherence, prevent cell migration and inhibit matrix invasion. This is accompanied by a marked modification of the actin cytoskeleton and focal adhesion redistribution. Interestingly, integrins and the small Rho GTP-binding protein, which are well-characterized proteins modulating actin fibers, adhesion and migration, do not appear to be required for the pro-adhesive properties of TAT-RasGAP(317-326). In contrast, deleted in liver cancer-1, a tumor suppressor protein, the expression of which is often deregulated in cancer cells, was found to be required for TAT-RasGAP(317-326) to promote cell adherence and inhibit migration. These results show that TAT-RasGAP(317-326), besides its ability to favor tumor cell death, hampers cell migration and invasion.	[Barras, D.; Widmann, C.] Univ Lausanne, Dept Physiol, CH-1005 Lausanne, Vaud, Switzerland; [Lorusso, G.; Rueegg, C.] Univ Fribourg, Dept Med, CH-1700 Fribourg, Switzerland	University of Lausanne; University of Fribourg	Widmann, C (corresponding author), Univ Lausanne, Dept Physiol, Bugnon 7, CH-1005 Lausanne, Vaud, Switzerland.	Christian.Widmann@unil.ch	Widmann, Christian/N-9851-2013	Widmann, Christian/0000-0002-6881-0363; Lorusso, Girieca/0000-0002-2807-3207	Oncosuisse [KFS-02543-02-2010]	Oncosuisse	This work was supported by a grant from Oncosuisse (KFS-02543-02-2010). We thank Professor Nicholas C. Popescu (National Cancer Institute, Bethesda) for the DLC1-null MEFs and Professor David Schlaepfer (Moores UCSD Cancer Center, La Jolla) for the FAK-null MEFs.	Aoki K, 2007, J CELL SCI, V120, P3327, DOI 10.1242/jcs.03485; Barras D, 2011, CURR PHARM BIOTECHNO, V12, P1153, DOI 10.2174/138920111796117337; Beck M, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.82; Bravo-Cordero JJ, 2012, CURR OPIN CELL BIOL, V24, P277, DOI 10.1016/j.ceb.2011.12.004; Bulat N, 2009, J LIPID RES, V50, P81, DOI 10.1194/jlr.M800119-JLR200; Byron A, 2010, CURR BIOL, V20, pR1063, DOI 10.1016/j.cub.2010.10.059; Chiang AC, 2008, NEW ENGL J MED, V359, P2814, DOI 10.1056/NEJMra0805239; Durkin ME, 2007, J CELL MOL MED, V11, P1185, DOI 10.1111/j.1582-4934.2007.00098.x; FELDINGHABERMANN B, 1992, J CLIN INVEST, V89, P2018, DOI 10.1172/JCI115811; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; Hamadi A, 2005, J CELL SCI, V118, P4415, DOI 10.1242/jcs.02565; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hu KQ, 1997, EMBO J, V16, P473, DOI 10.1093/emboj/16.3.473; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; Karaman MW, 2008, NAT BIOTECHNOL, V26, P127, DOI 10.1038/nbt1358; Kawai K, 2004, BIOCHEM SOC T, V32, P1107, DOI 10.1042/BST0321107; Kulkarni SV, 2000, J CELL BIOL, V149, P457, DOI 10.1083/jcb.149.2.457; Lahoz A, 2008, GENE DEV, V22, P1724, DOI 10.1101/gad.1691408; Leblanc V, 1998, MOL CELL BIOL, V18, P5567, DOI 10.1128/MCB.18.9.5567; Li GR, 2011, P NATL ACAD SCI USA, V108, P17129, DOI 10.1073/pnas.1112122108; Mai A, 2011, J CELL BIOL, V194, P291, DOI 10.1083/jcb.201012126; McClatchey AI, 2005, GENE DEV, V19, P2265, DOI 10.1101/gad.1335605; MCGLADE J, 1993, EMBO J, V12, P3073, DOI 10.1002/j.1460-2075.1993.tb05976.x; Michod D, 2004, ONCOGENE, V23, P8971, DOI 10.1038/sj.onc.1207999; Michod D, 2009, JNCI-J NATL CANCER I, V101, P828, DOI 10.1093/jnci/djp100; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; Pamonsinlapatham P, 2009, BIOCHIMIE, V91, P320, DOI 10.1016/j.biochi.2008.10.010; Pittet O, 2007, J PHOTOCH PHOTOBIO B, V88, P29, DOI 10.1016/j.jphotobiol.2007.04.009; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Ross B, 2007, BIOCHEM BIOPH RES CO, V353, P463, DOI 10.1016/j.bbrc.2006.12.044; Sethi N, 2011, NAT REV CANCER, V11, P735, DOI 10.1038/nrc3125; Sheppard D, 2000, MATRIX BIOL, V19, P203, DOI 10.1016/S0945-053X(00)00065-2; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Yang JY, 2005, MOL BIOL CELL, V16, P3511, DOI 10.1091/mbc.E05-01-0080; Yang JY, 2001, MOL CELL BIOL, V21, P5346, DOI 10.1128/MCB.21.16.5346-5358.2001; Yang XY, 2009, ONCOGENE, V28, P1401, DOI 10.1038/onc.2008.498; Yang XY, 2011, CANCER RES, V71, P2916, DOI 10.1158/0008-5472.CAN-10-2158; Yilmaz M, 2009, CANCER METAST REV, V28, P15, DOI 10.1007/s10555-008-9169-0; Yin HL, 2003, ANNU REV PHYSIOL, V65, P761, DOI 10.1146/annurev.physiol.65.092101.142517	45	17	18	1	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	2014	33	44					5163	5172		10.1038/onc.2013.465	http://dx.doi.org/10.1038/onc.2013.465			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR9RZ	24213569	Green Accepted			2022-12-17	WOS:000343914900003
J	Nehil, M; Paquette, J; Tokuyasu, T; McCormick, F				Nehil, M.; Paquette, J.; Tokuyasu, T.; McCormick, F.			High mobility group box 1 promotes tumor cell migration through epigenetic silencing of semaphorin 3A	ONCOGENE			English	Article						HMGB1; SEMA3A; migration; chromatin; metastasis	END-PRODUCTS RAGE; INCREASED EXPRESSION; MURINE COLITIS; HMGB1; CANCER; BINDING; PROTEIN; CARCINOMA; RECEPTOR; GROWTH	High mobility group box 1 (HMGB1) is a 25-kDa chromatin-associated protein that aids in transcription and DNA repair by directly binding to DNA and altering its conformation. Additionally, HMGB1 can act as an extracellular ligand. When released from dying or stressed cells, HMGB1 binds to the RAGE receptor and activates the p42/44 MAP kinase (MAPK) cascade. HMGB1 is overexpressed in many types of cancer and frequently associated with tumor stage and metastasis. This has predominantly been attributed to an autocrine function that drives MAPK pathway activity. However, by using tumor cells with activating MAPK pathway mutations, we have identified a role for HMGB1 in promoting metastasis and tumor growth that is independent of this pathway. In the absence of HMGB1, these tumor cells show defective in vitro migration as well as reduced metastasis and tumor growth in vivo despite high p42/44 phosphorylation. We found that semaphorin 3A (SEMA3A), previously shown to act as a suppressor of angiogenesis and migration, was highly increased during expression in the absence of HMGB1. SEMA3A/HMGB1 double knockdown rescued the migration defect in HMGB1 single knockdown cells. HMGB1 bound at the semaphorin 3A genomic locus, promoted hetrochromatin formation, and decreased occupancy of acetylated histones. Based on human tumor gene expression databases, HMGB1 was significantly inversely correlated with SEMA3A, suggesting that this mechanism may be more widely relevant in different cancer types.	[Nehil, M.] Harvard Univ, Med Scool, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Paquette, J.; Tokuyasu, T.; McCormick, F.] Univ Calif San Francisco, Helen Diller Comprehens Canc Ctr, Program Biomed Sci, San Francisco, CA 94158 USA; [Paquette, J.; Tokuyasu, T.; McCormick, F.] Univ Calif San Francisco, Helen Diller Comprehens Canc Ctr, Bioinformat Program, San Francisco, CA 94158 USA	Harvard University; Dana-Farber Cancer Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center	McCormick, F (corresponding author), Univ Calif San Francisco, Helen Diller Comprehens Canc Ctr, 1450 3rd St,Rm HD-371 UCSF Box 0128, San Francisco, CA 94158 USA.	mccormick@cc.ucsf.edu		Tokuyasu, Taku/0000-0003-3401-3195	UCSF Tetrad program	UCSF Tetrad program	We thank the UCSF Tetrad program for providing funding. We thank Dr Lewis Lanier for all of his advice. We thank Dr Byron Hann, Dr Paul Phojanakong and the UCSF Clinical Therapeutics core for all of their help with mouse xenograft experiments and the UCSF Genome core for their help with gene expression studies.	Agresti A, 2003, BIOCHEM BIOPH RES CO, V302, P421, DOI 10.1016/S0006-291X(03)00184-0; Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021; Brezniceanu ML, 2003, FASEB J, V17, P1295, DOI 10.1096/fj.02-0621fje; Calogero S, 1999, NAT GENET, V22, P276, DOI 10.1038/10338; Casazza A, 2011, ARTERIOSCL THROM VAS, V31, P741, DOI 10.1161/ATVBAHA.110.211920; Cheng BQ, 2008, DIGEST LIVER DIS, V40, P446, DOI 10.1016/j.dld.2007.11.024; Dave SH, 2009, J LEUKOCYTE BIOL, V86, P633, DOI 10.1189/jlb.1008662; El Gazzar M, 2009, MOL CELL BIOL, V29, P1959, DOI 10.1128/MCB.01862-08; Ellerman JE, 2007, CLIN CANCER RES, V13, P2836, DOI 10.1158/1078-0432.CCR-06-1953; GE H, 1994, J BIOL CHEM, V269, P17136; Gebhardt C, 2008, J EXP MED, V205, P275, DOI 10.1084/jem.20070679; Ikediobi ON, 2006, MOL CANCER THER, V5, P2606, DOI 10.1158/1535-7163.MCT-06-0433; Ishiguro H, 2005, PROSTATE, V64, P92, DOI 10.1002/pros.20219; Jayaraman L, 1998, GENE DEV, V12, P462, DOI 10.1101/gad.12.4.462; Joshi SR, 2012, NUCLEIC ACIDS RES, V40, P10161, DOI 10.1093/nar/gks815; Liang XY, 2009, J LEUKOCYTE BIOL, V86, P599, DOI 10.1189/jlb.0908578; Lin Q, 2011, ARTERIOSCL THROM VAS, V31, P1024, DOI 10.1161/ATVBAHA.111.224048; Maeda S, 2007, BIOCHEM BIOPH RES CO, V360, P394, DOI 10.1016/j.bbrc.2007.06.065; Malarkey CS, 2012, TRENDS BIOCHEM SCI, V37, P553, DOI 10.1016/j.tibs.2012.09.003; McCauley MJ, 2007, J MOL BIOL, V374, P993, DOI 10.1016/j.jmb.2007.09.073; Neufeld G, 2008, NAT REV CANCER, V8, P632, DOI 10.1038/nrc2404; Paquette J, 2010, BIOINFORMATICS, V26, P285, DOI 10.1093/bioinformatics/btp656; Poser I, 2003, MOL CELL BIOL, V23, P2991, DOI 10.1128/MCB.23.8.2991-2998.2003; Ranzato E, 2010, CELL BIOCHEM BIOPHYS, V57, P9, DOI 10.1007/s12013-010-9077-0; Sapojnikova N, 2005, BBA-GENE STRUCT EXPR, V1729, P57, DOI 10.1016/j.bbaexp.2005.03.002; Schmidt EF, 2008, J NEUROSCI, V28, P2287, DOI 10.1523/JNEUROSCI.5646-07.2008; Schmidt EF, 2007, ADV EXP MED BIOL, V600, P1; Staton CA, 2011, HISTOPATHOLOGY, V59, P274, DOI 10.1111/j.1365-2559.2011.03922.x; Szak ST, 2001, MOL CELL BIOL, V21, P3375, DOI 10.1128/MCB.21.10.3375-3386.2001; Taguchi A, 2000, NATURE, V405, P354, DOI 10.1038/35012626; van Beijnum JR, 2008, ANGIOGENESIS, V11, P91, DOI 10.1007/s10456-008-9093-5; Volp K, 2006, GUT, V55, P234, DOI 10.1136/gut.2004.062729; Wu D, 2008, J PATHOL, V216, P167, DOI 10.1002/path.2391; Yao XJ, 2010, J CANCER RES CLIN, V136, P677, DOI 10.1007/s00432-009-0706-1	34	17	18	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	2014	33	44					5151	5162		10.1038/onc.2013.459	http://dx.doi.org/10.1038/onc.2013.459			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR9RZ	24213571				2022-12-17	WOS:000343914900002
J	Tien, SC; Chang, ZF				Tien, S-C; Chang, Z-F			Oncogenic Shp2 disturbs microtubule regulation to cause HDAC6-dependent ERK hyperactivation	ONCOGENE			English	Article						ERK; HDAC6; microtubule acetylation; Shp2	TYROSINE-PHOSPHATASE SHP-2; SMALL-MOLECULE INHIBITOR; SIGNALING PATHWAY; DEACETYLASE HDAC6; PTPN11 MUTATIONS; NOONAN-SYNDROME; BREAST-CANCER; ACTIVATION; RECEPTOR; KINASE	Deregulation of Shp2, a non-receptor tyrosine phosphatase, causes hyperactivation of extracellular signal-regulated kinase (ERK), leading to growth abnormality. Here, we show that inhibition of RhoA-Dia is sufficient to upregulate ERK activation in epithelial cells. Oncogenic Shp2 expression attenuates RhoA-Dia signaling, by which microtubule (MT) is destabilized with reduced level of acetylation. Either MT stabilization, silencing of histone deacetylase 6 (HDAC6) or enforcing RhoA-Dia signal prevents oncogenic Shp2-induced ERK hyperactivation. We provide evidence that downregulation of RhoA-Dia-EB1 pathway by oncogenic Shp2 leads to HDAC6-mediated reduction in MT acetylation, in turn affecting ERK regulation. In response to serum stimulation, cells expressing wild-type Shp2 display transient ERK activation. In contrast, cells expressing oncogenic Shp2 have prolonged ERK activation. HDAC6 inhibition diminishes sustained activation of ERK and slows down the growth of these cells. Likewise, in human cancer cells, blocking Shp2 increases MT acetylation and decreases ERK phosphorylation, which are reversed by inhibition of Dia. As such, HDAC6 inhibition in these cells also reduces ERK activity. Our findings link MT regulation by HDAC6 to oncogenic Shp2 and ERK regulation, implicating the therapeutic potential of HDAC6 inhibitor in diseases involving Shp2 deregulation.	[Tien, S-C; Chang, Z-F] Natl Taiwan Univ, Inst Biochem & Mol Biol, Coll Med, Taipei 10764, Taiwan; [Chang, Z-F] Natl Yang Ming Univ, Inst Biochem & Mol Biol, Taipei 112, Taiwan	National Taiwan University; National Yang Ming Chiao Tung University	Chang, ZF (corresponding author), Natl Yang Ming Univ, Inst Biochem & Mol Biol, 155,Sect 2,Linong St, Taipei 112, Taiwan.	zfchang@ym.edu.tw			National Science Council, Taiwan [NSC98-3112-B-010-021]; UST-UCSD International Center of Excellence in Advanced Bio-Engineering; National Science Council I-RiCE Program, Taiwan [NSC101-2911-I-009-101]; Ministry of Education, Taiwan	National Science Council, Taiwan(Ministry of Science and Technology, Taiwan); UST-UCSD International Center of Excellence in Advanced Bio-Engineering; National Science Council I-RiCE Program, Taiwan; Ministry of Education, Taiwan(Ministry of Education, Taiwan)	We thank TS Jou (Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University) for providing MDCK cells and GP135 antibody, TP Yao (Department of Pharmacology and Cancer Bioloby, Duke University, Durham, North Carolina) for providing pCDNA-HDAC6-Flag and EGFP-tubulin-K40R plasmids and JC Kuo (Institute of Biochemistry and Molecular Biology, National Yang Ming University) for detyrosinated (Glu) tubulin antibody, the technical supports from the second core laboratory, Department of Medical Research, National Taiwan University Hospital and the Instrumentation Resource Center of National Yang-Ming University. This research is supported by grants from National Science Council, Taiwan (NSC98-3112-B-010-021), the UST-UCSD International Center of Excellence in Advanced Bio-Engineering sponsored by National Science Council I-RiCE Program, Taiwan (NSC101-2911-I-009-101), and Aim for Top University Plan in National Yang-Ming University sponsored by the Ministry of Education, Taiwan.	Agazie YM, 2003, MOL CELL BIOL, V23, P7875, DOI 10.1128/MCB.23.21.7875-7886.2003; Bard-Chapeau EA, 2011, CANCER CELL, V19, P629, DOI 10.1016/j.ccr.2011.03.023; Chang YC, 2006, CELL DEATH DIFFER, V13, P2023, DOI 10.1038/sj.cdd.4401901; Cleghon V, 1998, MOL CELL, V2, P719, DOI 10.1016/S1097-2765(00)80287-7; Gao YS, 2010, J BIOL CHEM, V285, P11219, DOI 10.1074/jbc.M109.042754; Gelb BD, 2006, HUM MOL GENET, V15, pR220, DOI 10.1093/hmg/ddl197; Gross I, 2001, J BIOL CHEM, V276, P46460, DOI 10.1074/jbc.M108234200; Haggarty SJ, 2003, P NATL ACAD SCI USA, V100, P4389, DOI 10.1073/pnas.0430973100; Hanafusa H, 2002, NAT CELL BIOL, V4, P850, DOI 10.1038/ncb867; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; Kawaguchi Y, 2003, CELL, V115, P727, DOI 10.1016/S0092-8674(03)00939-5; Kodama A, 2000, MOL BIOL CELL, V11, P2565, DOI 10.1091/mbc.11.8.2565; Kontaridis MI, 2004, MOL CELL BIOL, V24, P5340, DOI 10.1128/MCB.24.12.5340-5352.2004; Kovacs JJ, 2005, MOL CELL, V18, P601, DOI 10.1016/j.molcel.2005.04.021; Lee HH, 2008, J CELL BIOL, V181, P999, DOI 10.1083/jcb.200710187; Lee HH, 2010, J CELL SCI, V123, P3368, DOI 10.1242/jcs.071555; Lee YS, 2008, CANCER RES, V68, P7561, DOI 10.1158/0008-5472.CAN-08-0188; Loh ML, 2004, BLOOD, V103, P2325, DOI 10.1182/blood-2003-09-3287; Maroun CR, 2000, MOL CELL BIOL, V20, P8513, DOI 10.1128/MCB.20.22.8513-8525.2000; Mohi MG, 2007, CURR OPIN GENET DEV, V17, P23, DOI 10.1016/j.gde.2006.12.011; Mohi MG, 2005, CANCER CELL, V7, P179, DOI 10.1016/j.ccr.2005.01.010; Rizvi SA, 2009, CHEM BIOL, V16, P1158, DOI 10.1016/j.chembiol.2009.10.006; Sahai E, 2002, NAT CELL BIOL, V4, P408, DOI 10.1038/ncb796; Sattler M, 2002, CANCER CELL, V1, P479, DOI 10.1016/S1535-6108(02)00074-0; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; Tartaglia M, 2006, AM J HUM GENET, V78, P279, DOI 10.1086/499925; Tartaglia M, 2004, CURR OPIN HEMATOL, V11, P44, DOI 10.1097/00062752-200401000-00007; Tartaglia M, 2001, NAT GENET, V29, P465, DOI 10.1038/ng772; Tsutsumi R, 2006, MOL CELL BIOL, V26, P261, DOI 10.1128/MCB.26.1.261-276.2006; Ukropec JA, 2000, J BIOL CHEM, V275, P5983, DOI 10.1074/jbc.275.8.5983; Valenzuela-Fernandez A, 2008, TRENDS CELL BIOL, V18, P291, DOI 10.1016/j.tcb.2008.04.003; Wen Y, 2004, NAT CELL BIOL, V6, P820, DOI 10.1038/ncb1160; Yoshida N, 2004, CANCER SCI, V95, P496, DOI 10.1111/j.1349-7006.2004.tb03239.x; Zhang SQ, 2004, MOL CELL, V13, P341, DOI 10.1016/S1097-2765(04)00050-4; Zhang XH, 2007, MOL CELL, V27, P197, DOI 10.1016/j.molcel.2007.05.033; Zhang Y, 2008, MOL CELL BIOL, V28, P1688, DOI 10.1128/MCB.01154-06; Zhou XD, 2008, CELL DEATH DIFFER, V15, P988, DOI 10.1038/cdd.2008.54	38	17	19	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 29	2014	33	22					2938	2946		10.1038/onc.2013.241	http://dx.doi.org/10.1038/onc.2013.241			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EI	23770849				2022-12-17	WOS:000337231800013
J	Kim, H; Claps, G; Moller, A; Bowtell, D; Lu, X; Ronai, ZA				Kim, H.; Claps, G.; Moeller, A.; Bowtell, D.; Lu, X.; Ronai, Z. A.			Siah2 regulates tight junction integrity and cell polarity through control of ASPP2 stability	ONCOGENE			English	Article						ASPP2; Siah2; epithelial polarity; tight junction; hypoxia	APOPTOSIS-STIMULATING PROTEIN; UBIQUITIN LIGASE; P53; ASPP2/(53BP2L); TUMORIGENESIS; INHIBITION; HOMOLOG; HYPOXIA; GROWTH; HIF	Changes in cell adhesion and polarity are closely associated with epithelial cell transformation and metastatic capacity. The tumor suppressor protein ASPP (Apoptosis-Stimulating Proteins of p53) 2 has been implicated in control of cell adhesion and polarity through its effect on the PAR complex. Here we demonstrate that under hypoxic conditions, the ubiquitin ligase Siah (seven in absentia homolog) 2 controls ASPP2 availability, with concomitant effect on epithelial cell polarity. LC-MS/MS analysis identified ASPP2 and ASPP1 as Siah2-interacting proteins. Biochemical analysis confirmed this interaction and mapped degron motifs within ASPP2, which are required for Siah2-mediated ubiquitination and proteasomal-dependent degradation. Inhibition of Siah2 expression increases ASPP2 levels and enhances ASPP2-dependent maintenance of tight junction (TJ) integrity, and polarized architecture in three dimensional (3D) organotypic culture. Conversely, increase of Siah2 expression under hypoxia decreases ASPP2 levels and the formation of apical polarity in 3D culture. In all, our studies demonstrate the role of Siah2 in regulation of TJ integrity and cell polarity under hypoxia, through its regulation of ASPP2 stability.	[Kim, H.; Claps, G.; Ronai, Z. A.] Sanford Burnham Med Res Inst, Ctr Canc, Signal Transduct Program, La Jolla, CA 92037 USA; [Moeller, A.; Bowtell, D.] Peter MacCallum Canc Ctr, Div Res, Melbourne, Vic, Australia; [Bowtell, D.] Univ Melbourne, Dept Biochem, Parkville, Vic 3052, Australia; [Lu, X.] Ludwig Inst Canc Res, Nuffield Dept Med, Oxford, England	Sanford Burnham Prebys Medical Discovery Institute; Peter Maccallum Cancer Center; University of Melbourne; Ludwig Institute for Cancer Research; University of Oxford	Ronai, ZA (corresponding author), Sanford Burnham Med Res Inst, Ctr Canc, Signal Transduct Program, La Jolla, CA 92037 USA.	ronai@sbmri.org	Möller, Andreas/O-1063-2015; Bowtell, David/H-1007-2016; Claps, Giuseppina/G-6180-2018	Möller, Andreas/0000-0002-8618-6998; Bowtell, David/0000-0001-9089-7525; Lu, Xin/0000-0002-6587-1152; Kim, Hyungsoo/0000-0002-8189-5939; Claps, Giuseppina/0000-0002-3064-0063; RONAI, ZEEV/0000-0002-3859-0400	NCI [CA111515, CA128814]; NATIONAL CANCER INSTITUTE [P01CA128814, R01CA111515, P30CA030199] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Laurence M Brill of the SBMRI Proteomics Facility for mass spectrometric analysis of the Siah2-binding proteins. Support by NCI grants CA111515 and CA128814 (to ZR) is gratefully acknowledged.	Ahmed AU, 2008, JNCI-J NATL CANCER I, V100, P1606, DOI 10.1093/jnci/djn365; Bergamaschi D, 2003, NAT GENET, V33, P162, DOI 10.1038/ng1070; Bryant DM, 2010, NAT CELL BIOL, V12, P1035, DOI 10.1038/ncb2106; Calzado MA, 2009, BIOL CHEM, V390, P1079, DOI 10.1515/BC.2009.112; Chen D, 2005, CELL DEATH DIFFER, V12, P358, DOI 10.1038/sj.cdd.4401536; Chen MF, 2011, P NATL ACAD SCI USA, V108, P9119, DOI 10.1073/pnas.1100028108; Cong WL, 2010, CURR BIOL, V20, P1408, DOI 10.1016/j.cub.2010.06.024; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Feigin ME, 2009, CURR OPIN CELL BIOL, V21, P694, DOI 10.1016/j.ceb.2009.07.003; Fogal V, 2005, CELL DEATH DIFFER, V12, P369, DOI 10.1038/sj.cdd.4401562; Habelhah H, 2004, J BIOL CHEM, V279, P53782, DOI 10.1074/jbc.M410315200; House CM, 2003, P NATL ACAD SCI USA, V100, P3101, DOI 10.1073/pnas.0534783100; House CM, 2009, CANCER RES, V69, P8835, DOI 10.1158/0008-5472.CAN-09-1676; Kampa KM, 2009, P NATL ACAD SCI USA, V106, P4390, DOI 10.1073/pnas.0809080106; Kim H, 2011, MOL CELL, V44, P532, DOI 10.1016/j.molcel.2011.08.045; Langton PF, 2009, CURR BIOL, V19, P1969, DOI 10.1016/j.cub.2009.10.027; Li SH, 1997, CELL, V90, P469, DOI 10.1016/S0092-8674(00)80507-3; Liu ZJ, 2005, FEBS LETT, V579, P1587, DOI 10.1016/j.febslet.2005.01.069; Moller A, 2009, ONCOGENE, V28, P289, DOI 10.1038/onc.2008.382; Nakayama K, 2004, CELL, V117, P941, DOI 10.1016/j.cell.2004.06.001; Ozdamar B, 2005, SCIENCE, V307, P1603, DOI 10.1126/science.1105718; Qi JF, 2008, P NATL ACAD SCI USA, V105, P16713, DOI 10.1073/pnas.0804063105; Qi JF, 2010, CANCER CELL, V18, P23, DOI 10.1016/j.ccr.2010.05.024; Samuels-Lev Y, 2001, MOL CELL, V8, P781, DOI 10.1016/S1097-2765(01)00367-7; Schmidt RL, 2007, CANCER RES, V67, P11798, DOI 10.1158/0008-5472.CAN-06-4471; Sen N, 2008, NAT CELL BIOL, V10, P866, DOI 10.1038/ncb1747; Sottocornola R, 2010, DEV CELL, V19, P126, DOI 10.1016/j.devcel.2010.06.003; Szczepanowski M, 2007, BIOCHEM BIOPH RES CO, V362, P485, DOI 10.1016/j.bbrc.2007.08.042; Viloria-Petit AM, 2009, P NATL ACAD SCI USA, V106, P14028, DOI 10.1073/pnas.0906796106; Vives V, 2006, GENE DEV, V20, P1262, DOI 10.1101/gad.374006; Zhu ZY, 2005, J BIOL CHEM, V280, P34473, DOI 10.1074/jbc.M503736200	31	17	17	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2014	33	15					2004	2010		10.1038/onc.2013.149	http://dx.doi.org/10.1038/onc.2013.149			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9RK	23644657	Green Accepted			2022-12-17	WOS:000334346300013
J	Chaix, A; Arcangeli, ML; Lopez, S; Voisset, E; Yang, Y; Vita, M; Letard, S; Audebert, S; Finetti, P; Birnbaum, D; Bertucci, F; Aurrand-Lions, M; Dubreuil, P; De Sepulveda, P				Chaix, A.; Arcangeli, M-L; Lopez, S.; Voisset, E.; Yang, Y.; Vita, M.; Letard, S.; Audebert, S.; Finetti, P.; Birnbaum, D.; Bertucci, F.; Aurrand-Lions, M.; Dubreuil, P.; De Sepulveda, P.			KIT-D816V oncogenic activity is controlled by the juxtamembrane docking site Y568-Y570	ONCOGENE			English	Article						receptor; tyrosine kinase; mastocytosis; oncogene; leukemia; mast cell	STEM-CELL FACTOR; RECEPTOR TYROSINE KINASE; C-KIT MUTATIONS; GASTROINTESTINAL STROMAL TUMORS; ACUTE MYELOID-LEUKEMIA; SRC FAMILY KINASES; DOMAIN MUTATIONS; PEDIATRIC MASTOCYTOSIS; ACTIVATING MUTATIONS; SIGNALING PATHWAYS	Mutation of KIT receptor tyrosine kinase at residue D816 results in ligand-independent constitutive kinase activity. This mutation occurs in most patients with mastocytosis, a myeloproliferative neoplasm, and is detected at lower frequencies in acute myeloid leukemia and in germ cell tumors. Other KIT mutations occur in gastrointestinal stromal tumors (GIST) and mucosal melanoma. KIT is considered as a bona fide therapeutic target as c-kit mutations are driving oncogenes in these pathologies. However, several evidences suggest that KIT-D816V mutant is not as aggressive as other KIT mutants. Here, we show that an intracellular docking site in the juxtamembrane region of KIT maintains a negative regulation on KIT-D816V transforming potential. Sixteen signaling proteins were shown to interact with this motif. We further demonstrate that mutation of this site results in signaling modifications, altered gene expression profile and increased transforming activity of KIT-D816V mutant. This result was unexpected as mutations of the homologous sites on wild-type (WT) KIT, or on the related oncogenic FLT3-ITD receptor, impair their function. Our results support the hypothesis that, KIT-D816V mutation is a mild oncogenic event that is sufficient to confer partial transforming properties, but requires additional mutations to acquire its full transforming potential.	[Chaix, A.; Arcangeli, M-L; Lopez, S.; Voisset, E.; Yang, Y.; Vita, M.; Letard, S.; Audebert, S.; Finetti, P.; Birnbaum, D.; Bertucci, F.; Aurrand-Lions, M.; Dubreuil, P.; De Sepulveda, P.] Ctr Rech Cancerol Marseille, INSERM, U1068, F-13009 Marseille, France; [Chaix, A.; Arcangeli, M-L; Lopez, S.; Voisset, E.; Yang, Y.; Vita, M.; Letard, S.; Audebert, S.; Finetti, P.; Birnbaum, D.; Bertucci, F.; Aurrand-Lions, M.; Dubreuil, P.; De Sepulveda, P.] Inst J Paoli I Calmettes, F-13009 Marseille, France; [Chaix, A.; Arcangeli, M-L; Lopez, S.; Voisset, E.; Yang, Y.; Vita, M.; Letard, S.; Audebert, S.; Finetti, P.; Birnbaum, D.; Bertucci, F.; Aurrand-Lions, M.; Dubreuil, P.; De Sepulveda, P.] Aix Marseille Univ, Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UNICANCER; Institut Paoli-Calmette (IPC); UDICE-French Research Universities; Aix-Marseille Universite	De Sepulveda, P (corresponding author), Ctr Rech Cancerol Marseille, INSERM, U1068, 27 Blvd Lei Roure, F-13009 Marseille, France.	paulo.de-sepulveda@inserm.fr	De sepulveda, paulo/K-6043-2015; Voisset, Edwige/AAM-3503-2021; LOPEZ, SOPHIE/R-1917-2016; Aurrand-Lions, Michel/O-9953-2016; Arcangeli, Marie-Laure/L-5991-2017; Dubreuil, Patrice/V-4816-2019; Voisset, Edwige/GSE-5113-2022; dubreuil, patrice/F-5346-2011; Finetti, Pascal/O-8669-2017	De sepulveda, paulo/0000-0001-8295-5414; Voisset, Edwige/0000-0002-0943-4847; LOPEZ, SOPHIE/0000-0002-5009-5533; Aurrand-Lions, Michel/0000-0002-8361-3034; Arcangeli, Marie-Laure/0000-0002-1726-1472; Dubreuil, Patrice/0000-0003-1155-1150; Voisset, Edwige/0000-0002-0943-4847; dubreuil, patrice/0000-0003-1155-1150; Audebert, Stephane/0000-0002-9409-2588; LETARD, Sebastien/0000-0002-6508-7376; Finetti, Pascal/0000-0002-2674-3123	Ministere de la Recherche-ENS; ARC; French Society of Hematology; FRM; Institut Lilly; INCa; OSEO; la Ligue Contre le Cancer	Ministere de la Recherche-ENS; ARC(Australian Research Council); French Society of Hematology; FRM(Fondation pour la Recherche Medicale); Institut Lilly; INCa(Institut National du Cancer (INCA) France); OSEO; la Ligue Contre le Cancer(Ligue nationale contre le cancer)	We thank Cyndie Mosca, F Bardin and K Hanssens for technical assistance. AC is a recipient of PhD fellowships from Ministere de la Recherche-ENS, ARC and a financial support from the French Society of Hematology. We acknowledge postdoctoral fellowships from FRM and Institut Lilly to MLA, from INCa and OSEO to SL and from FRM to MV. This project was supported by grants from la Ligue Contre le Cancer and INCa.	Agosti V, 2004, J EXP MED, V199, P867, DOI 10.1084/jem.20031983; Agosti V, 2009, EXP HEMATOL, V37, P159, DOI 10.1016/j.exphem.2008.10.009; Bayle J, 2004, J BIOL CHEM, V279, P12249, DOI 10.1074/jbc.M313381200; Beghini A, 2004, HAEMATOLOGICA, V89, P920; Bodemer C, 2010, J INVEST DERMATOL, V130, P804, DOI 10.1038/jid.2009.281; Bougherara H, 2009, MOL CANCER RES, V7, P1525, DOI 10.1158/1541-7786.MCR-09-0138; Buettner R, 2008, MOL CANCER RES, V6, P1766, DOI 10.1158/1541-7786.MCR-08-0169; Cairoli R, 2006, BLOOD, V107, P3463, DOI 10.1182/blood-2005-09-3640; Casteran N, 2003, ONCOGENE, V22, P4710, DOI 10.1038/sj.onc.1206587; Chaix A, 2011, J BIOL CHEM, V286, P5956, DOI 10.1074/jbc.M110.182642; Chang PM, 2003, MOL CELL BIOL, V23, P3067, DOI 10.1128/MCB.23.9.3067-3078.2003; Curtin JA, 2006, J CLIN ONCOL, V24, P4340, DOI 10.1200/JCO.2006.06.2984; DeBerry C, 1997, BIOCHEM J, V327, P73, DOI 10.1042/bj3270073; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; GLOVER HR, 1995, ONCOGENE, V11, P1347; Goemans BF, 2005, LEUKEMIA, V19, P1536, DOI 10.1038/sj.leu.2403870; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Hong L, 2004, MOL CELL BIOL, V24, P1401, DOI 10.1128/MCB.24.3.1401-1410.2004; Hongyo T, 2000, CANCER RES, V60, P2345; Kemmer K, 2004, AM J PATHOL, V164, P305, DOI 10.1016/S0002-9440(10)63120-3; Kimura Y, 2004, P NATL ACAD SCI USA, V101, P6015, DOI 10.1073/pnas.0305363101; Kozlowski M, 1998, MOL CELL BIOL, V18, P2089, DOI 10.1128/MCB.18.4.2089; Lennartsson J, 1999, ONCOGENE, V18, P5546, DOI 10.1038/sj.onc.1202929; Lievens PMJ, 2004, J BIOL CHEM, V279, P43254, DOI 10.1074/jbc.M405247200; Lim KH, 2009, BLOOD, V113, P5727, DOI 10.1182/blood-2009-02-205237; Longley BJ, 1999, P NATL ACAD SCI USA, V96, P1609, DOI 10.1073/pnas.96.4.1609; Looijenga LHJ, 2003, CANCER RES, V63, P7674; Masson K, 2009, CELL SIGNAL, V21, P1717, DOI 10.1016/j.cellsig.2009.06.002; Mayerhofer M, 2008, J IMMUNOL, V180, P5466, DOI 10.4049/jimmunol.180.8.5466; Price DJ, 1997, J BIOL CHEM, V272, P5915, DOI 10.1074/jbc.272.9.5915; Rocnik JL, 2006, BLOOD, V108, P1339, DOI 10.1182/blood-2005-11-011429; Rubin BP, 2005, CANCER RES, V65, P6631, DOI 10.1158/0008-5472.CAN-05-0891; Sattler M, 1997, J BIOL CHEM, V272, P10248; Schmidt-Arras DE, 2005, MOL CELL BIOL, V25, P3690, DOI 10.1128/MCB.25.9.3690-3703.2005; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Simon C, 2008, BLOOD, V112, P1039, DOI 10.1182/blood-2008-05-154849; Sommer G, 2003, P NATL ACAD SCI USA, V100, P6706, DOI 10.1073/pnas.1037763100; Sun JM, 2009, J BIOL CHEM, V284, P11039, DOI 10.1074/jbc.M808058200; Tan BL, 2003, J BIOL CHEM, V278, P11686, DOI 10.1074/jbc.M207068200; Tian QS, 1999, AM J PATHOL, V154, P1643, DOI 10.1016/S0002-9440(10)65419-3; Timokhina I, 1998, EMBO J, V17, P6250, DOI 10.1093/emboj/17.21.6250; Ueda S, 2002, BLOOD, V99, P3342, DOI 10.1182/blood.V99.9.3342; Valent P, 2005, LEUKEMIA LYMPHOMA, V46, P35, DOI 10.1080/10428190400010775; Vempati S, 2008, CLIN CANCER RES, V14, P4437, DOI 10.1158/1078-0432.CCR-07-1873; Voisset E, 2007, BLOOD, V110, P2593, DOI 10.1182/blood-2007-02-076471; Voisset E, 2010, BIOCHEM BIOPH RES CO, V393, P174, DOI 10.1016/j.bbrc.2010.01.116; Xiang ZF, 2007, MOL CELL BIOL, V27, P267, DOI 10.1128/MCB.01153-06; Yang Y, 2010, BLOOD, V116, P1114, DOI 10.1182/blood-2009-06-226027; Yuzawa S, 2007, CELL, V130, P323, DOI 10.1016/j.cell.2007.05.055; Zappulla JP, 2005, J EXP MED, V202, P1635, DOI 10.1084/jem.20050807	50	17	17	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 13	2014	33	7					872	881		10.1038/onc.2013.12	http://dx.doi.org/10.1038/onc.2013.12			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB2MN	23416972				2022-12-17	WOS:000331626900008
J	Marcos-Villar, L; Gallego, P; Munoz-Fontela, C; de la Cruz-Herrera, CF; Campagna, M; Gonzalez, D; Lopitz-Otsoa, F; Rodriguez, MS; Rivas, C				Marcos-Villar, L.; Gallego, P.; Munoz-Fontela, C.; de la Cruz-Herrera, C. F.; Campagna, M.; Gonzalez, D.; Lopitz-Otsoa, F.; Rodriguez, M. S.; Rivas, C.			Kaposi's sarcoma-associated herpesvirus lana2 protein interacts with the pocket proteins and inhibits their sumoylation	ONCOGENE			English	Article						pocket proteins; KSHV; LANA2; pocket proteins; sumoylation; LXCXE domain	RETINOBLASTOMA TUMOR-SUPPRESSOR; LARGE T-ANTIGEN; INTERFERON-REGULATORY FACTOR-3; PRIMARY EFFUSION LYMPHOMA; C-MYC; CELL-CYCLE; TRANSCRIPTIONAL REPRESSION; DISTINCT MECHANISMS; FAMILY-MEMBERS; GENE RB2/P130	The pocket proteins retinoblastoma protein (pRb), p107 and p130 are the key targets of oncoproteins expressed by DNA tumor viruses. Some of these viral proteins contain an LXCXE motif that mediates the interaction with the three pocket proteins and the inhibition of the pRb SUMOylation. Kaposi's sarcoma herpesvirus (KSHV) contains at least two proteins that can regulate pRb function but, so far, a KSHV-encoded protein targeting p107 and p130 has not been identified. Here, we show that the KSHV latent protein LANA2 binds to pRb, p107 and p130. LANA2 contains an LXCXE motif that is required for bypassing pRb-mediated cell-cycle arrest and for inhibiting pRb SUMOylation. Finally, we demonstrate that, in addition to pRb, both p107 and p130 can be SUMOylated, and this modification is also inhibited by LANA2 in an LXCXE-dependent manner. These results demonstrate, for the first time, the SUMOylation of p107 or p130 and, so far, they represent the first example of a KSHV protein able to interact with the three pocket proteins and to inhibit their conjugation to SUMO.	[Marcos-Villar, L.; Gallego, P.; de la Cruz-Herrera, C. F.; Campagna, M.; Gonzalez, D.; Rivas, C.] CSIC, Ctr Nacl Biotecnol, Madrid 28049, Spain; [Munoz-Fontela, C.] Heinrich Pette Inst, Leibniz Inst Expt Virol, Hamburg, Germany; [Lopitz-Otsoa, F.; Rodriguez, M. S.] CIBERehd, CIC BioGUNE, Prote Unit, Buildin Derio, Spain; [Rodriguez, M. S.] Inbiomed, Ubiquitylat & Canc Mol Biol Lab, San Sebastian, Gipuzkoa, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Heinrich Pette Institute; CIBER - Centro de Investigacion Biomedica en Red; CIBEREHD; CIC bioGUNE	Rivas, C (corresponding author), CSIC, Ctr Nacl Biotecnol, Campus Univ Autonoma Madrid, Madrid 28049, Spain.	crivas@cnb.csic.es	Rivas, Carmen/AAB-6278-2019; MARCOS-VILLAR, LAURA/L-8444-2014; de Llano, Dolores González/F-2219-2013; Lopitz-Otsoa, Fernando/A-1966-2017; Rivas, Carmen/L-3162-2017	Rivas, Carmen/0000-0002-0518-7199; MARCOS-VILLAR, LAURA/0000-0002-8635-6432; de Llano, Dolores González/0000-0001-8140-7045; Lopitz-Otsoa, Fernando/0000-0001-8452-6939; Rivas, Carmen/0000-0002-0518-7199; de la Cruz-Herrera, Carlos/0000-0002-7493-5154; Munoz-Fontela, Cesar/0000-0002-7725-2586	Juan de la Cierva Program; JAE predoctoral fellowship from CSIC; La Caixa fellowship;  [BFU-2008-03784];  [BFU-2011-27064]	Juan de la Cierva Program; JAE predoctoral fellowship from CSIC; La Caixa fellowship(La Caixa Foundation); ; 	This project has been possible thanks to the generous support from Patrick Moore and Yuan Chang (Pittsburg University, USA) in the initial experiments and to the reagents they provided. This work was supported by BFU-2008-03784 and BFU-2011-27064. MC and LM-V are supported by Juan de la Cierva Program. PG is supported by JAE predoctoral fellowship from CSIC. CFC-H is supported by La Caixa fellowship.	Araki K, 2008, CLIN CANCER RES, V14, P3514, DOI 10.1158/1078-0432.CCR-07-4538; BARBEAU D, 1994, ONCOGENE, V9, P359; Baresova P, 2012, J BIOL CHEM, V287, P16199, DOI 10.1074/jbc.M111.335216; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; Benetti R, 2008, NAT STRUCT MOL BIOL, V15, P268, DOI 10.1038/nsmb.1399; Bowen C, 1998, CANCER RES, V58, P3275; Burkhart DL, 2008, NAT REV CANCER, V8, P671, DOI 10.1038/nrc2399; Campagna M, 2011, CELL DEATH DIFFER, V18, P72, DOI 10.1038/cdd.2010.77; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; Chang Y, 1996, NATURE, V382, P410, DOI 10.1038/382410a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHRISTENSEN JB, 1995, J VIROL, V69, P3945, DOI 10.1128/JVI.69.6.3945-3948.1995; Claudio PP, 2000, CANCER RES, V60, P372; Claudio PP, 2000, CANCER RES, V60, P8; Claudio PP, 1996, CANCER RES, V56, P2003; CLAUDIO PP, 1994, CANCER RES, V54, P5556; DeGregori J, 2006, CURR MOL MED, V6, P739; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; DYSON N, 1992, J VIROL, V66, P4606, DOI 10.1128/JVI.66.7.4606-4611.1992; DYSON N, 1992, CANCER SURV, V12, P161; Esteban M, 2003, J GEN VIROL, V84, P1463, DOI 10.1099/vir.0.19014-0; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; Fan SJ, 2001, ONCOGENE, V20, P4827, DOI 10.1038/sj.onc.1204666; GoddenKent D, 1997, J VIROL, V71, P4193, DOI 10.1128/JVI.71.6.4193-4198.1997; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; Howard CM, 2000, CANCER RES, V60, P2737; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; Joo CH, 2007, J VIROL, V81, P8282, DOI 10.1128/JVI.00235-07; JUNG JU, 1994, MOL CELL BIOL, V14, P7235, DOI 10.1128/MCB.14.11.7235; Kim HY, 2001, EMBO J, V20, P295, DOI 10.1093/emboj/20.1.295; Knudsen KE, 1999, ONCOGENE, V18, P5239, DOI 10.1038/sj.onc.1202910; Ledl A, 2005, ONCOGENE, V24, P3810, DOI 10.1038/sj.onc.1208539; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; Lemaire C, 2005, ONCOGENE, V24, P3297, DOI 10.1038/sj.onc.1208493; Li MT, 1997, J VIROL, V71, P1984, DOI 10.1128/JVI.71.3.1984-1991.1997; Li TW, 2006, J BIOL CHEM, V281, P36221, DOI 10.1074/jbc.M608236200; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; Lu F, 2010, J VIROL, V84, P2697, DOI 10.1128/JVI.01997-09; Lubyova B, 2004, J BIOL CHEM, V279, P7643, DOI 10.1074/jbc.M309485200; Lubyova B, 2007, J BIOL CHEM, V282, P31944, DOI 10.1074/jbc.M706430200; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Marcos-Villar L, J GEN VIROL 1, V92, P188; Marcos-Villar L, 2009, J VIROL, V83, P8849, DOI 10.1128/JVI.00339-09; MAYOL X, 1993, ONCOGENE, V8, P2561; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Miller G, 2007, ADV CANCER RES, V97, P81, DOI 10.1016/S0065-230X(06)97004-3; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; Pantry SN, 2009, SEMIN CANCER BIOL, V19, P153, DOI 10.1016/j.semcancer.2009.02.010; Platt G, 2002, ONCOGENE, V21, P1823, DOI 10.1038/sj.onc.1205360; Radkov SA, 2000, NAT MED, V6, P1121, DOI 10.1038/80459; Rivas C, 2001, J VIROL, V75, P429, DOI 10.1128/JVI.75.1.429-438.2001; Scambia G, 2006, ONCOGENE, V25, P5302, DOI 10.1038/sj.onc.1209620; Schwarze F, 2010, ONCOGENE, V29, P5755, DOI 10.1038/onc.2010.311; Seo T, 2004, ONCOGENE, V23, P6146, DOI 10.1038/sj.onc.1207807; Shin YC, 2008, CANCER RES, V68, P1751, DOI 10.1158/0008-5472.CAN-07-2766; Smith EJ, 1998, CELL GROWTH DIFFER, V9, P297; Starostik P, 1996, MOL CELL BIOL, V16, P3606; Sullivan CS, 2000, MOL CELL BIOL, V20, P6233, DOI 10.1128/MCB.20.17.6233-6243.2000; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Vertegaal ACO, 2006, MOL CELL PROTEOMICS, V5, P2298, DOI 10.1074/mcp.M600212-MCP200; WEINBERG RA, 1995, ANN NY ACAD SCI, V758, P331, DOI 10.1111/j.1749-6632.1995.tb24838.x; Wies E, 2008, BLOOD, V111, P320, DOI 10.1182/blood-2007-05-092288; Wies E, 2009, J BIOL CHEM, V284, P8525, DOI 10.1074/jbc.M809252200; Wirt SE, 2010, CELL DIV, V5, DOI 10.1186/1747-1028-5-9; Xiao ZX, 1996, P NATL ACAD SCI USA, V93, P4633, DOI 10.1073/pnas.93.10.4633; YEUNG RS, 1993, ONCOGENE, V8, P3465; Zalvide J, 1998, MOL CELL BIOL, V18, P1408, DOI 10.1128/MCB.18.3.1408; Zhang BY, 2006, P NATL ACAD SCI USA, V103, P437, DOI 10.1073/pnas.0510012103; Zhao X, 2001, UROLOGY, V57, P860, DOI 10.1016/S0090-4295(01)00946-3; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	73	17	17	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 23	2014	33	4					495	503		10.1038/onc.2012.603	http://dx.doi.org/10.1038/onc.2012.603			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	296VX	23318443				2022-12-17	WOS:000330214600010
J	Lobo, VJSA; Doni, M; Verrecchia, A; Sanulli, S; Faga, G; Piontini, A; Bianchi, M; Conacci-Sorrell, M; Mazzarol, G; Peg, V; Losa, JH; Ronchi, P; Ponzoni, M; Eisenman, RN; Doglioni, C; Amati, B				Lobo, V. J. Sanchez-Arevalo; Doni, M.; Verrecchia, A.; Sanulli, S.; Faga, G.; Piontini, A.; Bianchi, M.; Conacci-Sorrell, M.; Mazzarol, G.; Peg, V.; Losa, J. H.; Ronchi, P.; Ponzoni, M.; Eisenman, R. N.; Doglioni, C.; Amati, B.			Dual regulation of Myc by Abl	ONCOGENE			English	Article						c-Myc; c-Abl; Pin1; CML; Breast Cancer	KINASE C-ABL; TRANSCRIPTIONAL ACTIVITY; TYROSINE KINASE; BREAST-CANCER; APOPTOTIC RESPONSE; ONCOGENE PRODUCT; PHOSPHORYLATION; ACETYLATION; PIN1; ACTIVATION	The tyrosine kinase c-Abl (or Abl) and the prolyl-isomerase Pin1 cooperatively activate the transcription factor p73 by enhancing recruitment of the acetyltransferase p300. As the transcription factor c-Myc (or Myc) is a known target of Pin1 and p300, we hypothesized that it might be regulated in a similar manner. Consistent with this hypothesis, overexpression of Pin1 augmented the interaction of Myc with p300 and transcriptional activity. The action of Abl, however, was more complex than predicted. On one hand, Abl indirectly enhanced phosphorylation of Myc on Ser 62 and Thr 58, its association with Pin1 and p300 and its acetylation by p300. These effects of Abl were exerted through phosphorylation of substrate(s) other than Myc itself. On the other hand, Abl interacted with the C-terminal domain of Myc and phosphorylated up to five tyrosine residues in its N-terminus, the principal of which was Y74. Indirect immunofluorescence or immunohistochemical staining suggested that the Y74-phosphorylated form of Myc (Myc-pY74) localized to the cytoplasm and coexisted either with active Abl in a subset of mammary carcinomas or with Bcr-Abl in chronic myeloid leukemia. In all instances, Myc-pY74 constituted a minor fraction of the cellular Myc protein. Thus, our data unravel two potential effects of Abl on Myc: first, Abl signaling can indirectly augment acetylation of Myc by p300, and most likely also its transcriptional activity in the nucleus; second, Abl can directly phosphorylate Myc on tyrosine: the resulting form of Myc appears to be cytoplasmic, and its presence correlates with Abl activation in cancer.	[Lobo, V. J. Sanchez-Arevalo; Doni, M.; Verrecchia, A.; Sanulli, S.; Faga, G.; Piontini, A.; Mazzarol, G.; Amati, B.] European Inst Oncol IEO, Dept Expt Oncol, Milan, Italy; [Bianchi, M.] FIRC Inst Mol Oncol IFOM, Milan, Italy; [Conacci-Sorrell, M.; Eisenman, R. N.] Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98104 USA; [Peg, V.; Losa, J. H.] Hospital Vall de Hebron, Barcelona, Spain; [Ronchi, P.] Ist Sci San Raffaele, Immunohematol & Transfus Med Serv, I-20132 Milan, Italy; [Ronchi, P.; Ponzoni, M.] Ist Sci San Raffaele, Leukemia Unit, I-20132 Milan, Italy; [Ponzoni, M.; Doglioni, C.] Ist Sci San Raffaele, Pathol Unit, I-20132 Milan, Italy; [Amati, B.] Fdn Ist Italiano Tecnol IIT, Ctr Genom Sci IIT SEMM, Milan, Italy	IRCCS European Institute of Oncology (IEO); IFOM - FIRC Institute of Molecular Oncology; Fred Hutchinson Cancer Center; Hospital Universitari Vall d'Hebron; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Istituto Italiano di Tecnologia - IIT	Amati, B (corresponding author), IIT, Via Adamello 16, I-20139 Milan, Italy.	bruno.amati@iit.it	Lobo, Victor Javier vjsal Sanchez-Arevalo/H-1069-2011; Verrecchia, Alessandro/AAQ-6454-2020; Amati, Bruno/AAM-3418-2020; Peg, Vicente/E-9160-2018; Doni, Mirko/AAN-6027-2020; Doni, Mirko/ABA-9174-2021; Lobo, Victor Javier Sanchez-Arevalo/N-8641-2019; Faga, Giovanni/AAB-5540-2021; Peg., Vicente/AAC-9447-2020; Sorrell, Maralice/ABD-6764-2021	Lobo, Victor Javier vjsal Sanchez-Arevalo/0000-0002-4561-1505; Verrecchia, Alessandro/0000-0002-8596-6650; Peg, Vicente/0000-0002-5203-6166; Doni, Mirko/0000-0001-7099-2701; Lobo, Victor Javier Sanchez-Arevalo/0000-0002-4561-1505; Peg., Vicente/0000-0002-5203-6166; Amati, Bruno/0000-0002-2958-1799; DOGLIONI, Claudio/0000-0002-4969-5216	Ministerio de Ciencia e Inovacion; European Commission FP7 Program (EuroSyStem); European Commission FP7 Program (MODHEP); European Research Council; Association for International Cancer Research (AICR); Cariplo Foundation; Italian Health Ministry; Italian Association for Cancer Research (AIRC); NATIONAL CANCER INSTITUTE [R01CA020525] Funding Source: NIH RePORTER	Ministerio de Ciencia e Inovacion(Spanish Government); European Commission FP7 Program (EuroSyStem); European Commission FP7 Program (MODHEP); European Research Council(European Research Council (ERC)European Commission); Association for International Cancer Research (AICR); Cariplo Foundation(Fondazione Cariplo); Italian Health Ministry(Ministry of Health, Italy); Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Theresia Kress, Stefano Campaner and Giorgio Scita for critical reading of the manuscript, Gianni Del Sal for scientific discussion and reagents, Warren Pear, Ricardo Sanchez-Prieto, Silvio Gutkind, Michael Cole and Pier-Giuseppe Pelicci for reagents, Celine Ngouenet, Arianna Vino, Lorenzo Spagnuolo and Teresa Moline for technical assistance, and the Antibody facility at the IFOM-IEO Campus. STI571 was supplied by Novartis. VJSAL was supported by a post-doctoral fellowship from the Ministerio de Ciencia e Inovacion. Work in the Amati lab was supported by grants from the European Commission FP7 Program (EuroSyStem and MODHEP), the European Research Council, the Association for International Cancer Research (AICR), the Cariplo Foundation, the Italian Health Ministry and the Italian Association for Cancer Research (AIRC).	Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703; Adhikary S, 2005, CELL, V123, P409, DOI 10.1016/j.cell.2005.08.016; Agami R, 1999, NATURE, V399, P809; Barila D, 2000, EMBO J, V19, P273, DOI 10.1093/emboj/19.2.273; Bitomsky N, 2004, ONCOGENE, V23, P7484, DOI 10.1038/sj.onc.1208064; BLACKWOOD EM, 1994, MOL BIOL CELL, V5, P597, DOI 10.1091/mbc.5.5.597; Conacci-Sorrell M, 2010, CELL, V142, P480, DOI 10.1016/j.cell.2010.06.037; CRAIG RW, 1993, CELL GROWTH DIFFER, V4, P349; Deininger MWN, 2000, BLOOD, V96, P3343, DOI 10.1182/blood.V96.10.3343; Faiola F, 2005, MOL CELL BIOL, V25, P10220, DOI 10.1128/MCB.25.23.10220-10234.2005; Frank SR, 2003, EMBO REP, V4, P575, DOI 10.1038/sj.embor.embor861; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Ganguly SS, 2012, ONCOGENE, V31, P1804, DOI 10.1038/onc.2011.361; Gomez-Casares MT, 2013, ONCOGENE, V32, P2239, DOI 10.1038/onc.2012.246; Gong JG, 1999, NATURE, V399, P806; Greasley PJ, 2000, NUCLEIC ACIDS RES, V28, P446, DOI 10.1093/nar/28.2.446; Gregory MA, 2003, J BIOL CHEM, V278, P51606, DOI 10.1074/jbc.M310722200; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; Huang CC, 2008, INT J BIOCHEM CELL B, V40, P423, DOI 10.1016/j.biocel.2007.08.002; Kharbanda S, 2000, MOL CELL BIOL, V20, P4979, DOI 10.1128/MCB.20.14.4979-4989.2000; Levy D, 2008, MOL CELL, V29, P350, DOI 10.1016/j.molcel.2007.12.022; Lu KP, 2007, NAT CHEM BIOL, V3, P619, DOI 10.1038/nchembio.2007.35; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Lufei C, 2007, ONCOGENE, V26, P7656, DOI 10.1038/sj.onc.1210567; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; Mantovani F, 2004, MOL CELL, V14, P625, DOI 10.1016/j.molcel.2004.05.007; Mantovani F, 2007, NAT STRUCT MOL BIOL, V14, P912, DOI 10.1038/nsmb1306; Monje P, 2005, J BIOL CHEM, V280, P35081, DOI 10.1074/jbc.C500353200; Oh AS, 2008, MOL CELL BIOL, V28, P6580, DOI 10.1128/MCB.00118-08; Pandey P, 1996, J BIOL CHEM, V271, P23775, DOI 10.1074/jbc.271.39.23775; Patel JH, 2004, MOL CELL BIOL, V24, P10826, DOI 10.1128/MCB.24.24.10826-10834.2004; Sanchez-Prieto R, 2002, ONCOGENE, V21, P974, DOI 10.1038/sj.onc.1205134; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; Srinivasan D, 2008, ONCOGENE, V27, P1095, DOI 10.1038/sj.onc.1210714; Srinivasan D, 2006, CANCER RES, V66, P5648, DOI 10.1158/0008-5472.CAN-06-0734; SUNDARESAN V, 1987, J CLIN PATHOL, V40, P1274, DOI 10.1136/jcp.40.11.1274; Vervoorts J, 2003, EMBO REP, V4, P484, DOI 10.1038/sj.embor.embor821; WILLIAMS ARW, 1990, J PATHOL, V160, P287, DOI 10.1002/path.1711600404; Wulf GM, 2001, EMBO J, V20, P3459, DOI 10.1093/emboj/20.13.3459; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110; Yi P, 2005, MOL CELL BIOL, V25, P9687, DOI 10.1128/MCB.25.21.9687-9699.2005; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zacchi P, 2002, NATURE, V419, P853, DOI 10.1038/nature01120; Zhang KL, 2005, BIOCHEM BIOPH RES CO, V336, P274, DOI 10.1016/j.bbrc.2005.08.075	44	17	17	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 7	2013	32	45					5261	5271		10.1038/onc.2012.621	http://dx.doi.org/10.1038/onc.2012.621			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	251IS	23318434	Green Accepted, hybrid			2022-12-17	WOS:000326922100002
J	Yang, Y; Wu, J; Demir, A; Castillo-Martin, M; Melamed, RD; Zhang, G; Fukunaga-Kanabis, M; Perez-Lorenzo, R; Zheng, B; Silvers, DN; Brunner, G; Wang, S; Rabadan, R; Cordon-Cardo, C; Celebi, JT				Yang, Y.; Wu, J.; Demir, A.; Castillo-Martin, M.; Melamed, R. D.; Zhang, G.; Fukunaga-Kanabis, M.; Perez-Lorenzo, R.; Zheng, B.; Silvers, D. N.; Brunner, G.; Wang, S.; Rabadan, R.; Cordon-Cardo, C.; Celebi, J. T.			GAB2 induces tumor angiogenesis in NRAS-driven melanoma	ONCOGENE			English	Article						melanoma; angiogenesis; scaffold; adaptor	ADAPTER PROTEINS; CELLS; RAS; AMPLIFICATION; SUSCEPTIBILITY; STIMULATION; BRAF(V600E); ACTIVATION; MIGRATION; ONCOGENE	GAB2 is a scaffold protein with diverse upstream and downstream effectors. MAPK and PI3K signaling pathways are known effectors of GAB2. It is amplified and overexpressed in a variety of human tumors including melanoma. Here we show a previously undescribed role for GAB2 in NRAS-driven melanoma. Specifically, we found that GAB2 is co-expressed with mutant NRAS in melanoma cell lines and tumor samples and its expression correlated with metastatic potential. Co-expression of GAB2(WT) and NRAS(G12D) in melanocytes and in melanoma cells increased anchorage-independent growth by providing GAB2-expressing cells a survival advantage through upregulation of BCL-2 family of anti-apoptotic factors. Of note, collaboration of GAB2 with mutant NRAS enhanced tumorigenesis in vivo and led to an increased vessel density with strong CD34 and VEGFR2 activity. We found that GAB2 facilitiated an angiogenic switch by upregulating HIF-1 alpha and VEGF levels. This angiogenic response was significantly suppressed with the MEK inhibitor PD325901. These data suggest that GAB2-mediated signaling cascades collaborate with NRAS-driven downstream activation for conferring an aggressive phenotype in melanoma. Second, we show that GAB2/NRAS signaling axis is non-linear and non-redundant in melanocytes and melanoma, and thus are acting independent of each other. Finally, we establish a link between GAB2 and angiogenesis in melanoma for the first time. In conclusion, our findings provide evidence that GAB2 is a novel regulator of tumor angiogenesis in NRAS-driven melanoma through regulation of HIF-1 alpha and VEGF expressions mediated by RAS-RAF-MEK-ERK signaling.	[Yang, Y.; Wu, J.; Demir, A.; Perez-Lorenzo, R.; Zheng, B.; Silvers, D. N.; Celebi, J. T.] Columbia Univ, Dept Dermatol, New York, NY 10032 USA; [Castillo-Martin, M.; Cordon-Cardo, C.] Mt Sinai Sch Med, Dept Pathol, New York, NY USA; [Melamed, R. D.; Rabadan, R.] Columbia Univ, Dept Bioinformat, New York, NY 10032 USA; [Zhang, G.; Fukunaga-Kanabis, M.] Wistar Inst Anat & Biol, Melanoma Res Ctr, Philadelphia, PA 19104 USA; [Perez-Lorenzo, R.; Zheng, B.; Silvers, D. N.] Columbia Univ, Dept Pathol, New York, NY 10032 USA; [Brunner, G.] Fachklin Hornheide, Dept Canc Res, Munster, Germany; [Wang, S.] Columbia Univ, Dept Biostat, New York, NY 10032 USA	Columbia University; Icahn School of Medicine at Mount Sinai; Columbia University; The Wistar Institute; Columbia University; Columbia University	Celebi, JT (corresponding author), Columbia Univ, Dept Dermatol, 1150 St,St Nicholas Ave,Room 318, New York, NY 10032 USA.	jt165@columbia.edu	Zhang, Gao/D-3471-2017; DEMIR, AHU/A-5650-2015; Castillo-Martin, Mireia/H-6152-2013; Rabadan, Raul/AAZ-7367-2020	DEMIR, AHU/0000-0001-9276-6318; Zheng, Bin/0000-0002-0998-7177; Perez-Lorenzo, Rolando/0000-0002-9355-9617; Melamed, Rachel/0000-0003-3089-9806; Rabadan, Raul/0000-0001-7946-9255	NIH/NCI [RO1 CA138678]; Dow Foundation; Neuberger Dorothy Rodbell Cohen Foundation; NATIONAL CANCER INSTITUTE [R01CA138678, U54CA121852] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Dow Foundation; Neuberger Dorothy Rodbell Cohen Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work has been supported by grants from the NIH/NCI RO1 CA138678 to JTC, the Dow Foundation to JTC and the Neuberger Dorothy Rodbell Cohen Foundation to JTC. We appreciate the technical assistance of Ruzhen Chen, Tasneem Fatima, Yan Lu, Rong Du and Tingting Wu. We are grateful to the following Shared Resources of the Herbert Irving Comprehensive Cancer Center, Pathology Shared Resource, Flow Cytometry Shared Resource, and Confocal & Microscopy Shared Resource, as well as to the Department of Dermatology's Skin Diseases Research Center Cell Culture Core and Division of Dermatopathology.	Ackermann J, 2005, CANCER RES, V65, P4005, DOI 10.1158/0008-5472.CAN-04-2970; Arbiser JL, 1997, P NATL ACAD SCI USA, V94, P861, DOI 10.1073/pnas.94.3.861; Bardeesy N, 2001, MOL CELL BIOL, V21, P2144, DOI 10.1128/MCB.21.6.2144-2153.2001; BENNETT DC, 1987, INT J CANCER, V39, P414, DOI 10.1002/ijc.2910390324; Bennett HL, 2008, ONCOGENE, V27, P2693, DOI 10.1038/sj.onc.1210928; Bentires-Alj M, 2006, NAT MED, V12, P114, DOI 10.1038/nm1341; Berking C, 2004, CANCER RES, V64, P807, DOI 10.1158/0008-5472.CAN-03-3438; Bocanegra M, 2010, ONCOGENE, V29, P774, DOI 10.1038/onc.2009.364; Brown LA, 2008, GENE CHROMOSOME CANC, V47, P481, DOI 10.1002/gcc.20549; Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144; Caron C, 2009, CELL SIGNAL, V21, P943, DOI 10.1016/j.cellsig.2009.02.004; Chernoff KA, 2009, CLIN CANCER RES, V15, P4288, DOI 10.1158/1078-0432.CCR-09-0280; Chin L, 1997, GENE DEV, V11, P2822, DOI 10.1101/gad.11.21.2822; Chudnovsky Y, 2005, NAT GENET, V37, P745, DOI 10.1038/ng1586; D'Alessio A, 2007, CELL SIGNAL, V19, P1193, DOI 10.1016/j.cellsig.2006.12.011; Dance M, 2006, J BIOL CHEM, V281, P23285, DOI 10.1074/jbc.M600987200; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dickson PV, 2011, SURG ONCOL CLIN N AM, V20, P1, DOI 10.1016/j.soc.2010.09.007; Dufraine J, 2008, ONCOGENE, V27, P5132, DOI 10.1038/onc.2008.227; Gerhardt Holger, 2008, P68, DOI 10.1007/978-0-387-78632-2_6; Gershenwald JE, 2010, ANN SURG ONCOL, V17, P1475, DOI 10.1245/s10434-010-0986-3; Ghosh Papia, 2009, Expert Rev Dermatol, V4, P131, DOI 10.1586/edm.09.2; Gray-Schopfer V, 2007, NATURE, V445, P851, DOI 10.1038/nature05661; Gu HH, 2003, TRENDS CELL BIOL, V13, P122, DOI 10.1016/S0962-8924(03)00002-3; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Gysin Stephan, 2011, Genes Cancer, V2, P359, DOI 10.1177/1947601911412376; Ha L, 2007, P NATL ACAD SCI USA, V104, P10968, DOI 10.1073/pnas.0611638104; Hendrix MJC, 2003, NAT REV CANCER, V3, P411, DOI 10.1038/nrc1092; Horst B, 2009, AM J PATHOL, V174, P1524, DOI 10.2353/ajpath.2009.080543; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; Kameda H, 2006, CLIN EXP IMMUNOL, V144, P335, DOI 10.1111/j.1365-2249.2006.03067.x; Ke Y, 2007, ONCOGENE, V26, P4951, DOI 10.1038/sj.onc.1210315; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Kranenburg O, 2004, BBA-REV CANCER, V1654, P23, DOI 10.1016/j.bbcan.2003.09.004; Laramee M, 2007, J BIOL CHEM, V282, P7758, DOI 10.1074/jbc.M611327200; Lock LS, 2002, MOL BIOL CELL, V13, P2132, DOI 10.1091/mbc.02-02-0031; Lu Y, 2011, P NATL ACAD SCI USA, V108, P2957, DOI 10.1073/pnas.1009395108; Mao YW, 2005, J CELL BIOL, V170, P305, DOI 10.1083/jcb.200505061; Meng SS, 2005, BIOCHEM J, V391, P143, DOI 10.1042/BJ20050229; Milagre C, 2010, CANCER RES, V70, P5549, DOI 10.1158/0008-5472.CAN-09-4254; Mishra PJ, 2010, ONCOGENE, V29, P2449, DOI 10.1038/onc.2009.521; Monsel G, 2010, ONCOGENE, V29, P227, DOI 10.1038/onc.2009.320; Nishida K, 2003, CANCER SCI, V94, P1029, DOI 10.1111/j.1349-7006.2003.tb01396.x; Petti C, 2006, CANCER RES, V66, P6503, DOI 10.1158/0008-5472.CAN-05-4671; Sattler M, 2002, CANCER CELL, V1, P479, DOI 10.1016/S1535-6108(02)00074-0; Sun JM, 2008, J BIOL CHEM, V283, P27444, DOI 10.1074/jbc.M709703200; Tsatsanis C, 2004, ANN NY ACAD SCI, V1028, P168, DOI 10.1196/annals.1322.019; Wang R, 2010, NATURE, V468, P829, DOI 10.1038/nature09624; Wellbrock C, 2004, CANCER RES, V64, P2338, DOI 10.1158/0008-5472.CAN-03-3433; Wozniak A, 2012, CRIT REV ONCOL HEMAT, V82, P200, DOI 10.1016/j.critrevonc.2011.05.003; Zatkova A, 2006, GENE CHROMOSOME CANC, V45, P798, DOI 10.1002/gcc.20344	53	17	18	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 1	2013	32	31					3627	3637		10.1038/onc.2012.367	http://dx.doi.org/10.1038/onc.2012.367			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	194MW	22926523	hybrid, Green Accepted			2022-12-17	WOS:000322638400007
J	Manchanda, PK; Jones, GN; Lee, AA; Pringle, DR; Zhang, M; Yu, L; La Perle, KMD; Kirschner, LS				Manchanda, P. K.; Jones, G. N.; Lee, A. A.; Pringle, D. R.; Zhang, M.; Yu, L.; La Perle, K. M. D.; Kirschner, L. S.			Rac1 is required for Prkar1a-mediated Nf2 suppression in Schwann cell tumors	ONCOGENE			English	Article						PKA; PRKAR1A; Schwann cell tumor; Rac1; Merlin	PROTEIN-KINASE-A; NEUROFIBROMATOSIS TYPE-2 GENE; MEDIATES CONTACT INHIBITION; P21-ACTIVATED KINASE; CYCLIC-AMP; NEURAL CREST; MERLIN; GROWTH; PHOSPHORYLATION; PRODUCT	Schwannomas are peripheral nerve sheath tumors that often occur in the setting of an inherited tumor predisposition syndrome, including neurofibromatosis types 1 (NF1) and 2 (NF2), familial schwannomatosis and Carney complex. Loss of the NF2 tumor suppressor (encoding NF2, or Merlin) is associated with upregulation of the Rac1 small GTPase, which is thought to have a key role in mediating tumor formation. In prior studies, we generated a mouse model of schwannomas by performing tissue-specific knockout (KO) of the Carney complex gene Prkar1a, which encodes the type 1A regulatory subunit of protein kinase A. These tumors exhibited down-regulation of Nf2 protein and an increase in activated Rac1. To assess the requirement for Rac1 in schwannoma formation, we generated a double KO (DKO) of Prkar1a and Rac1 in Schwann cells and monitored tumor formation. Loss of Rac1 reduced tumor formation by reducing proliferation and enhancing apoptosis. Surprisingly, the reduction of tumor formation was accompanied by re-expression of the Nf2 protein. Furthermore, activated Rac1 was able to downregulate Nf2 in vitro in a Pak-dependent manner. These in vivo data indicate that activation of Rac1 is responsible for suppression of Nf2 protein production; deficiency of Nf2 in Schwann cells leads to loss of cellular growth control and tumor formation. Further, PKA activation through mutation in Prkar1a is sufficient to initiate Rac1 signaling, with subsequent reduction of Nf2 and schwannomagenesis. Although in vitro evidence has shown that loss of Nf2 activates Rac1, our data indicate that signaling between Nf2 and Rac1 occurs in a bidirectional fashion, and these interactions are modulated by PKA.	[Manchanda, P. K.; Jones, G. N.; Lee, A. A.; Pringle, D. R.; Zhang, M.; Kirschner, L. S.] Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA; [Yu, L.] Ohio State Univ, Ctr Biostat, Columbus, OH 43210 USA; [La Perle, K. M. D.] Ohio State Univ, Dept Vet Biosci, Columbus, OH 43210 USA; [Kirschner, L. S.] Ohio State Univ, Div Endocrinol Diabet & Metab, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Kirschner, LS (corresponding author), Ohio State Univ, Dept Mol Virol Immunol & Med Genet, 420 West 12th Ave,Tzagournis Res Facil 544, Columbus, OH 43210 USA.	Lawrence.Kirschner@osumc.edu	La Perle, Krista Marie DuBray/B-3099-2015; yu, lianbo/B-3472-2010		Department of Defense (DOD) Neurofibromatosis program; NATIONAL CANCER INSTITUTE [R01CA112268, P01CA124570, P30CA016058] Funding Source: NIH RePORTER	Department of Defense (DOD) Neurofibromatosis program; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grant from the Department of Defense (DOD) Neurofibromatosis program. We thank Dr Matthew D Ringel and Dr Motoyasu Saji for insightful discussions.	Alfthan K, 2004, J BIOL CHEM, V279, P18559, DOI 10.1074/jbc.M313916200; Bashour AM, 2002, MOL CELL BIOL, V22, P1150, DOI 10.1128/MCB.22.4.1150-1157.2002; Beeser A, 2005, J BIOL CHEM, V280, P36609, DOI 10.1074/jbc.M502306200; Benninger Y, 2007, J CELL BIOL, V177, P1051, DOI 10.1083/jcb.200610108; BROCKES JP, 1979, BRAIN RES, V165, P105, DOI 10.1016/0006-8993(79)90048-9; Chan JR, 2007, J CELL BIOL, V177, P953, DOI 10.1083/jcb.200705105; Cotteret S, 2002, GENOME BIOL, V3; Crabtree JS, 2003, MOL CELL BIOL, V23, P6075, DOI 10.1128/MCB.23.17.6075-6085.2003; Feltri ML, 2008, GLIA, V56, P1508, DOI 10.1002/glia.20752; Flaiz C, 2009, EXP NEUROL, V218, P137, DOI 10.1016/j.expneurol.2009.04.019; Gautreau A, 2002, J BIOL CHEM, V277, P31279, DOI 10.1074/jbc.C200125200; Glogauer M, 2003, J IMMUNOL, V170, P5652, DOI 10.4049/jimmunol.170.11.5652; Herrlich P, 2000, ANN NY ACAD SCI, V910, P106; Howe DG, 2000, J NEUROSCI, V20, P3513, DOI 10.1523/JNEUROSCI.20-10-03513.2000; Hulsebos TJM, 2007, AM J HUM GENET, V80, P805, DOI 10.1086/513207; Izawa I, 1996, FEBS LETT, V382, P53, DOI 10.1016/0014-5793(96)00137-8; Jones GN, 2008, NEOPLASIA, V10, P1213, DOI 10.1593/neo.08652; Jones GN, 2010, MOL ENDOCRINOL, V24, P1559, DOI 10.1210/me.2009-0439; Kaempchen K, 2003, HUM MOL GENET, V12, P1211, DOI 10.1093/hmg/ddg146; Kim HA, 1997, J NEUROSCI RES, V49, P236; Kim HA, 2001, J NEUROSCI, V21, P1110; Kirschner LS, 2000, HUM MOL GENET, V9, P3037, DOI 10.1093/hmg/9.20.3037; Kirschner LS, 2000, NAT GENET, V26, P89, DOI 10.1038/79238; Kirschner LS, 2005, CANCER RES, V65, P4506, DOI 10.1158/0008-5472.CAN-05-0580; Kissil JL, 2003, MOL CELL, V12, P841, DOI 10.1016/S1097-2765(03)00382-4; Kissil JL, 2002, J BIOL CHEM, V277, P10394, DOI 10.1074/jbc.M200083200; Kissil Joseph L, 2010, Am J Med Genet A, V152A, P269, DOI 10.1002/ajmg.a.33189; Krause S, 2008, J PERIPHER NERV SYST, V13, P188, DOI 10.1111/j.1529-8027.2008.00177.x; Lang P, 1996, EMBO J, V15, P510, DOI 10.1002/j.1460-2075.1996.tb00383.x; Laulajainen M, 2008, ONCOGENE, V27, P3233, DOI 10.1038/sj.onc.1210988; Meng FY, 2007, J BIOL CHEM, V282, P8256, DOI 10.1074/jbc.M607712200; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; O'Connor KL, 2001, J BIOL CHEM, V276, P47895, DOI 10.1074/jbc.M107235200; Okada T, 2005, J CELL BIOL, V171, P361, DOI 10.1083/jcb.200503165; Okada T, 2007, TRENDS CELL BIOL, V17, P222, DOI 10.1016/j.tcb.2007.03.006; Pankov R, 2005, J CELL BIOL, V170, P793, DOI 10.1083/jcb.200503152; Pelton PD, 1998, ONCOGENE, V17, P2195, DOI 10.1038/sj.onc.1202141; SAINZ J, 1994, HUM MOL GENET, V3, P885, DOI 10.1093/hmg/3.6.885; Schulze KMM, 2002, HUM MOL GENET, V11, P69, DOI 10.1093/hmg/11.1.69; Shaw RJ, 2001, DEV CELL, V1, P63, DOI 10.1016/S1534-5807(01)00009-0; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Stemmer-Rachamimov AO, 2004, CANCER RES, V64, P3718, DOI 10.1158/0008-5472.CAN-03-4079; Thaxton C, 2008, ONCOGENE, V27, P2705, DOI 10.1038/sj.onc.1210923; Thaxton C, 2007, MOL CELL NEUROSCI, V34, P231, DOI 10.1016/j.mcn.2006.11.003; Thurnherr T, 2006, J NEUROSCI, V26, P10110, DOI 10.1523/JNEUROSCI.2158-06.2006; Tonks ID, 2003, GENESIS, V37, P131, DOI 10.1002/gene.10242; Xiao GH, 2005, MOL CELL BIOL, V25, P2384, DOI 10.1128/MCB.25.6.2384-2394.2005; Xiao GH, 2002, J BIOL CHEM, V277, P883, DOI 10.1074/jbc.C100553200; Yin Z, 2008, GENESIS, V46, P37, DOI 10.1002/dvg.20362; Zhang M, 2010, PROSTATE, V70, P807, DOI 10.1002/pros.21114	50	17	20	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 25	2013	32	30					3491	3499		10.1038/onc.2012.374	http://dx.doi.org/10.1038/onc.2012.374			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	188UQ	23045281	Green Accepted			2022-12-17	WOS:000322220800002
J	Costa, C; Santos, M; Martinez-Fernandez, M; Duenas, M; Lorz, C; Garcia-Escudero, R; Paramio, JM				Costa, C.; Santos, M.; Martinez-Fernandez, M.; Duenas, M.; Lorz, C.; Garcia-Escudero, R.; Paramio, J. M.			E2F1 loss induces spontaneous tumour development in Rb-deficient epidermis	ONCOGENE			English	Article						skin; pRb; E2F1; p53; hair follicle; Wnt signalling	HAIR FOLLICLE MORPHOGENESIS; MOUSE SKIN CARCINOGENESIS; BETA-CATENIN ACTIVATION; EPITHELIAL STEM-CELLS; BLADDER-CANCER; RETINOBLASTOMA FAMILY; EXPRESSION PROFILES; TRANSGENIC MODEL; S-PHASE; PROLIFERATION	The specific ablation of Rb1 gene in epidermis (Rb-F/F; K14cre) promotes proliferation and altered differentiation but does not produce spontaneous tumour development. These phenotypic changes are associated with increased expression of E2F members and E2F-dependent transcriptional activity. Here, we have focused on the possible dependence on E2F1 gene function. We have generated mice that lack Rb1 in epidermis in an inducible manner (RbF/F; K14creER(TM)). These mice are indistinguishable from those lacking pRb in this tissue in a constitutive manner (Rb-F/F; K14cre). In an E2F1-null background (Rb-F/F; K14creER(TM); and E2F1(-/-) mice), the phenotype due to acute Rb1 loss is not ameliorated by E2F1 loss, but rather exacerbated, indicating that pRb functions in epidermis do not rely solely on E2F1. On the other hand, Rb-F/F; K14creER(TM); E2F1(-/-) mice develop spontaneous epidermal tumours of hair follicle origin with high incidence. These tumours, which retain a functional p19(arf)/p53 axis, also show aberrant activation of beta-catenin/Wnt pathway. Gene expression studies revealed that these tumours display relevant similarities with specific human tumours. These data demonstrate that the Rb/E2F1 axis exerts essential functions not only in maintaining epidermal homoeostasis, but also in suppressing tumour development in epidermis, and that the disruption of this pathway may induce tumour progression through specific alteration of developmental programs.	[Costa, C.; Santos, M.; Martinez-Fernandez, M.; Duenas, M.; Lorz, C.; Garcia-Escudero, R.; Paramio, J. M.] CIEMAT, Mol Oncol Unit, Dept Basic Res, E-28040 Madrid, Spain	Centro de Investigaciones Energeticas, Medioambientales Tecnologicas	Paramio, JM (corresponding author), CIEMAT, Mol Oncol Unit, Dept Basic Res, Ed 70A,Ave Complutense 40, E-28040 Madrid, Spain.	jesusm.paramio@ciemat.es	Costa, Clotilde/L-6850-2015; Lorz, Corina/E-3651-2016; Paramio, Jesus M/M-8482-2014; Santos, Mirentxu/AAA-1727-2020; Garcia-Escudero, Ramon/A-2735-2012	Lorz, Corina/0000-0001-8214-9076; Paramio, Jesus M/0000-0001-7520-3177; Garcia-Escudero, Ramon/0000-0001-5640-6542; Costa, Clotilde/0000-0001-7327-2259; Duenas, Marta/0000-0003-0857-9726	Ministerio de Ciencia e Innovacion (MICINN) [SAF2006-0121, SAF2011-26122C02-01, JCI-2010-06167]; Comunidad Autonoma de Madrid Oncocycle Program Grant [S2006/BIO-0232, CAM P2010/BMD-2470]; Ministerio de Sanidad y Consumo grant [SCIII-RETIC RD06/0020/0029]; Fundacion Sandra Ibarra	Ministerio de Ciencia e Innovacion (MICINN)(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Comunidad Autonoma de Madrid Oncocycle Program Grant; Ministerio de Sanidad y Consumo grant; Fundacion Sandra Ibarra	Ministerio de Ciencia e Innovacion (MICINN) grants SAF2006-0121, SAF2011-26122C02-01 and JCI-2010-06167, Comunidad Autonoma de Madrid Oncocycle Program Grant S2006/BIO-0232 and: CAM P2010/BMD-2470, Ministerio de Sanidad y Consumo grant ISCIII-RETIC RD06/0020/0029 and from Fundacion Sandra Ibarra to JMP. The excellent technical support by Pilar Hernandez in histology and the personnel of the CIEMAT Animal Facility are specially acknowledged.	Ahmad I, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.7; Ahmad I, 2011, ONCOGENE, V30, P178, DOI 10.1038/onc.2010.399; Ahmad I, 2012, DIS MODEL MECH, V5, P323, DOI 10.1242/dmm.008888; Alonso L, 2003, GENE DEV, V17, P1189, DOI 10.1101/gad.1086903; Brandt WD, 2009, CANCER METAST REV, V28, P291, DOI 10.1007/s10555-009-9187-6; Chan EF, 1999, NAT GENET, V21, P410, DOI 10.1038/7747; Chen R, 2007, NAT METHODS, V4, P879, DOI 10.1038/nmeth1107-879; Chong JL, 2009, NATURE, V462, P930, DOI 10.1038/nature08677; Chong JL, 2009, MOL CELL BIOL, V29, P414, DOI 10.1128/MCB.01161-08; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; D'Souza SJA, 2002, J BIOL CHEM, V277, P10626, DOI 10.1074/jbc.M111956200; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Doglioni C, 2003, AM J PATHOL, V163, P2277, DOI 10.1016/S0002-9440(10)63585-7; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Gandarillas A, 1997, GENE DEV, V11, P2869, DOI 10.1101/gad.11.21.2869; Gat U, 1998, CELL, V95, P605, DOI 10.1016/S0092-8674(00)81631-1; Haegebarth A, 2009, AM J PATHOL, V174, P715, DOI 10.2353/ajpath.2009.080758; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; Huelsken J, 2001, CELL, V105, P533, DOI 10.1016/S0092-8674(01)00336-1; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Lachmann A, 2010, BIOINFORMATICS, V26, P2438, DOI 10.1093/bioinformatics/btq466; Lara MF, 2008, MOL CARCINOGEN, V47, P209, DOI 10.1002/mc.20376; Lara MF, 2008, MOL CARCINOGEN, V47, P105, DOI 10.1002/mc.20367; Lee JS, 2010, J CLIN ONCOL, V28, P2660, DOI 10.1200/JCO.2009.25.0977; Li MM, 2012, MOL CELL, V46, P30, DOI 10.1016/j.molcel.2012.01.020; Lo Celso C, 2004, DEVELOPMENT, V131, P1787, DOI 10.1242/dev.01052; Lobo NA, 2007, ANNU REV CELL DEV BI, V23, P675, DOI 10.1146/annurev.cellbio.22.010305.104154; Lopez RG, 2009, NAT CELL BIOL, V11, P1181, DOI 10.1038/ncb1960; Lorz C, 2010, STEM CELL REV REP, V6, P162, DOI 10.1007/s12015-010-9139-0; Lorz C, 2010, METHODS MOL BIOL, V585, P1, DOI 10.1007/978-1-60761-380-0_1; Lorz C, 2009, CURR MOL MED, V9, P355, DOI 10.2174/156652409787847227; Lowry WE, 2005, GENE DEV, V19, P1596, DOI 10.1101/gad.1324905; Martinez-Cruz AB, 2008, CANCER RES, V68, P683, DOI 10.1158/0008-5472.CAN-07-3049; Morris EJ, 2008, NATURE, V455, P552, DOI 10.1038/nature07310; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; OGUIN WM, 1992, J INVEST DERMATOL, V98, P24, DOI 10.1111/1523-1747.ep12494172; Paramio JM, 1999, MOL CELL BIOL, V19, P3086; Paramio JM, 2000, J BIOL CHEM, V275, P41219, DOI 10.1074/jbc.M004973200; Paulson QX, 2006, CELL CYCLE, V5, P184, DOI 10.4161/cc.5.2.2307; Pierce AM, 1998, ONCOGENE, V16, P1267, DOI 10.1038/sj.onc.1201666; Pierce AM, 1999, MOL CELL BIOL, V19, P6408; Pierce AM, 1998, P NATL ACAD SCI USA, V95, P8858, DOI 10.1073/pnas.95.15.8858; Rabbani F, 1999, J NATL CANCER I, V91, P874, DOI 10.1093/jnci/91.10.874; Rabbani F, 2000, UROL CLIN N AM, V27, P83, DOI 10.1016/S0094-0143(05)70237-8; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Rounbehler RJ, 2002, CANCER RES, V62, P3276; Ruiz S, 2005, CANCER RES, V65, P9678, DOI 10.1158/0008-5472.CAN-05-1853; Ruiz S, 2004, DEVELOPMENT, V131, P2737, DOI 10.1242/dev.01148; Ruiz S, 2004, DEV DYNAM, V230, P410, DOI 10.1002/dvdy.20065; Ruiz S, 2006, CELL CYCLE, V5, P625, DOI 10.4161/cc.5.6.2580; Russell JL, 2006, ONCOGENE, V25, P867, DOI 10.1038/sj.onc.1209120; Saavedra HI, 2002, CELL GROWTH DIFFER, V13, P215; Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; Santos M, 2008, MOL CARCINOGEN, V47, P815, DOI 10.1002/mc.20426; Segrelles C, 2008, MOL BIOL CELL, V19, P137, DOI 10.1091/mbc.E07-08-0764; Segrelles C, 2007, CANCER RES, V67, P10879, DOI 10.1158/0008-5472.CAN-07-2564; Shin K, 2011, NATURE, V472, P110, DOI 10.1038/nature09851; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Takebe N, 2011, NAT REV CLIN ONCOL, V8, P97, DOI 10.1038/nrclinonc.2010.196; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; Wikonkal NM, 2003, NAT CELL BIOL, V5, P655, DOI 10.1038/ncb1001; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Yamasaki L, 1998, NAT GENET, V18, P360, DOI 10.1038/ng0498-360; Ziebold U, 2001, GENE DEV, V15, P386, DOI 10.1101/gad.858801	67	17	17	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 13	2013	32	24					2937	2951		10.1038/onc.2012.316	http://dx.doi.org/10.1038/onc.2012.316			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163WV	22890321				2022-12-17	WOS:000320369700004
J	Hollern, DP; Yuwanita, I; Andrechek, ER				Hollern, D. P.; Yuwanita, I.; Andrechek, E. R.			A mouse model with T58A mutations in Myc reduces the dependence on KRas mutations and has similarities to claudin- low human breast cancer	ONCOGENE			English	Article						Myc; Ras; breast cancer; mammary gland; mutation	TRANSGENIC MICE; GENE; RAS; AMPLIFICATION; PROTEIN; OVEREXPRESSION; CLASSIFICATION; TUMORIGENESIS; HETEROGENEITY; ACTIVATION	Expression of c-Myc is highly prevalent in human breast cancer and stability of the oncoprotein is regulated through Ras-regulated phosphorylation at serine 62 and threonine 58. Previous studies have illustrated the importance of accumulation of KRas mutations in Myc-mediated tumor formation. To examine Myc dependence upon Ras mutations we have generated MMTV regulated Myc and Myc T58A transgenic mice. Expression of the more stable T58A Myc allele resulted in a reduction in KRas-activating mutations. However, in a low-level expression T58A Myc transgenic, the majority of the tumors were squamous or epithelial-to-mesenchymal in nature and accumulated KRas mutations at a higher frequency. Interestingly, we show that these mice develop similar gene expression patterns and signaling pathway utilization as a subtype of human claudin-low breast cancer. Indeed, our results demonstrate a clear division in human claudin-low tumors based on Myc pathway activation and target genes. Together, our results demonstrate that Myc expression and stability has critical effects on molecular heterogeneity in mouse mammary tumors that parallel subtypes of human breast cancer. Oncogene (2013) 32, 1296-1304; doi:10.1038/onc.2012.142; published online 23 April 2012	[Hollern, D. P.; Yuwanita, I.; Andrechek, E. R.] Michigan State Univ, Dept Physiol, E Lansing, MI 48824 USA	Michigan State University	Andrechek, ER (corresponding author), Michigan State Univ, Dept Physiol, 2194 BPS Bldg, E Lansing, MI 48824 USA.	andrech1@msu.edu		Andrechek, Eran/0000-0002-8680-3423	Elsa U Pardee foundation	Elsa U Pardee foundation	A portion of this project was funded by a grant from the Elsa U Pardee foundation to ERA.	AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; Andrechek ER, 2008, DEVELOPMENT, V135, P2403, DOI 10.1242/dev.019018; Andrechek ER, 2010, J MOL MED, V88, P1095, DOI 10.1007/s00109-010-0644-z; Andrechek ER, 2009, P NATL ACAD SCI USA, V106, P16387, DOI 10.1073/pnas.0901250106; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Blancato J, 2004, BRIT J CANCER, V90, P1612, DOI 10.1038/sj.bjc.6601703; Carvalho CM, 2008, J AM STAT ASSOC, V103, P1438, DOI 10.1198/016214508000000869; Chrzan P, 2001, CLIN BIOCHEM, V34, P557, DOI 10.1016/S0009-9120(01)00260-0; D'Cruz CM, 2001, NAT MED, V7, P235, DOI 10.1038/84691; Deming SL, 2000, BRIT J CANCER, V83, P1688, DOI 10.1054/bjoc.2000.1522; Gatza ML, 2010, P NATL ACAD SCI USA, V107, P6994, DOI 10.1073/pnas.0912708107; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Herschkowitz JI, 2012, P NATL ACAD SCI USA, V109, P2778, DOI 10.1073/pnas.1018862108; Kim J, 2010, CELL, V143, P313, DOI 10.1016/j.cell.2010.09.010; Lim E, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2560; McCormack SJ, 1998, ONCOGENE, V16, P2755, DOI 10.1038/sj.onc.1201804; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Podsypanina K, 2008, P NATL ACAD SCI USA, V105, P5242, DOI 10.1073/pnas.0801197105; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; Singh A, 2009, CANCER CELL, V15, P489, DOI 10.1016/j.ccr.2009.03.022; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Sotiriou C, 2003, P NATL ACAD SCI USA, V100, P10393, DOI 10.1073/pnas.1732912100; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Wang XY, 2011, CANCER RES, V71, P925, DOI 10.1158/0008-5472.CAN-10-1032	30	17	19	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2013	32	10					1296	1304		10.1038/onc.2012.142	http://dx.doi.org/10.1038/onc.2012.142			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110OP	22525269				2022-12-17	WOS:000316454500010
J	Griner, EM; Churchill, MEA; Brautigan, DL; Theodorescu, D				Griner, E. M.; Churchill, M. E. A.; Brautigan, D. L.; Theodorescu, D.			PKC alpha phosphorylation of RhoGDI2 at Ser31 disrupts interactions with Rac1 and decreases GDI activity	ONCOGENE			English	Article						RhoGDI2; phosphorylation; GTPase; PKC alpha	RHO-GTPASES; DISSOCIATION INHIBITOR; CARCINOMA-CELLS; BLADDER-CANCER; PROTEIN; METASTASIS; EXPRESSION; INVASION; IDENTIFICATION; ASSOCIATION	Rho family GTPases control a diverse range of cellular processes, and their deregulation has been implicated in human cancer. Guanine nucleotide dissociation inhibitors (GDIs) bind and sequester GTPases in the cytosol, restricting their actions. RhoGDI2 is a member of the GDI family that acts as a metastasis suppressor in a variety of cancer types; however, very little is known about the regulation of this protein. Here, we present a mechanism for inactivation of RhoGDI2 via protein kinase C (PKC) phosphorylation of Ser31 in a region that contacts GTPases. In cells, RhoGDI2 becomes rapidly phosphorylated at Ser31 in response to phorbol 12-myristate 13-acetate stimulation. Based on the effects of pharmacological inhibitors and knockdown by siRNA, we determine that conventional type PKC alpha is responsible for this phosphorylation. Phospho-mimetic S31E-RhoGDI2 exhibits reduced binding to Rac1 relative to wild type, with a concomitant failure to reduce levels of activated endogenous Rac1 or remove Rac1 from membranes. These results reveal a mechanism of downregulation of RhoGDI2 activity through PKC-mediated phosphorylation of Ser31. We hypothesize that this mechanism may serve to neutralize RhoGDI2 function in tumors that express RhoGDI2 and active PKCa. Oncogene (2013) 32, 1010-1017; doi:10.1038/onc.2012.124; published online 2 April 2012	[Griner, E. M.; Brautigan, D. L.] Univ Virginia, Dept Microbiol Immunol & Canc Biol, Ctr Cell Signaling, Charlottesville, VA USA; [Churchill, M. E. A.; Theodorescu, D.] Univ Colorado, Dept Pharmacol, Aurora, CO 80045 USA; [Churchill, M. E. A.; Theodorescu, D.] Univ Colorado, Ctr Comprehens Canc, Aurora, CO 80045 USA	University of Virginia; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	Theodorescu, D (corresponding author), Univ Colorado, Ctr Comprehens Canc, Dept Surg & Pharmacol, 13001 E 17th Pl MS F-434, Aurora, CO 80045 USA.	dantheodorescu@ucdenver.edu	Churchill, Mair E. A./C-5549-2014	Churchill, Mair E. A./0000-0003-0862-235X	National Institutes of Health [CA143971]; Paul Mellon Urologic Cancer Institute (Charlottesville, VA); NATIONAL CANCER INSTITUTE [R01CA143971, P30CA046934] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM079154] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Paul Mellon Urologic Cancer Institute (Charlottesville, VA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Myr-PKC alpha was a generous gift of Dr Marcelo G Kazanietz (University of Pennsylvania). This work was supported by National Institutes of Health grant CA143971 to DT. EMG was supported by the Paul Mellon Urologic Cancer Institute (Charlottesville, VA).	Aaltonen V, 2010, ANTICANCER RES, V30, P3995; Aaltonen V, 2006, J HISTOCHEM CYTOCHEM, V54, P795, DOI 10.1369/jhc.5A6839.2006; Abiatari I, 2009, MOL CANCER THER, V8, P1494, DOI 10.1158/1535-7163.MCT-08-0755; Boulter E, 2010, NAT CELL BIOL, V12, P477, DOI 10.1038/ncb2049; Cho HJ, 2009, CLIN CANCER RES, V15, P2612, DOI 10.1158/1078-0432.CCR-08-2192; DerMardirossian C, 2005, TRENDS CELL BIOL, V15, P356, DOI 10.1016/j.tcb.2005.05.001; Dovas A, 2010, J BIOL CHEM, V285, P23294, DOI 10.1074/jbc.M109.098129; Gildea JJ, 2002, CANCER RES, V62, P6418; Golovanov AP, 2001, J MOL BIOL, V305, P121, DOI 10.1006/jmbi.2000.4262; Gorvel JP, 1998, FEBS LETT, V422, P269, DOI 10.1016/S0014-5793(98)00020-9; Griner EM, 2010, J BIOL CHEM, V285, P16931, DOI 10.1074/jbc.M109.099036; Harding MA, 2010, EUR J CANCER, V46, P1252, DOI 10.1016/j.ejca.2010.02.025; Heasman SJ, 2008, NAT REV MOL CELL BIO, V9, P690, DOI 10.1038/nrm2476; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Kamai T, 2003, CLIN CANCER RES, V9, P2632; Keep NH, 1997, STRUCTURE, V5, P623, DOI 10.1016/S0969-2126(97)00218-9; Koivunen J, 2004, CANCER RES, V64, P5693, DOI 10.1158/0008-5472.CAN-03-3511; Koren R, 2000, APPL IMMUNOHISTO M M, V8, P166, DOI 10.1097/00022744-200006000-00013; Lopez-Pedrera C, 2006, PROTEOMICS, V6, pS293, DOI 10.1002/pmic.200500384; Ma L, 2007, BRIT J HAEMATOL, V139, P217, DOI 10.1111/j.1365-2141.2007.06782.x; Moissoglu K, 2009, CANCER RES, V69, P2838, DOI 10.1158/0008-5472.CAN-08-1397; Niu HY, 2010, ONCOL REP, V24, P465, DOI 10.3892/or_00000880; Pervaiz S, 2001, ONCOGENE, V20, P6263, DOI 10.1038/sj.onc.1204840; Rabinovitz I, 1999, J CELL BIOL, V146, P1147, DOI 10.1083/jcb.146.5.1147; Rex EB, 2010, MOL PHARMACOL, V78, P69, DOI 10.1124/mol.110.063727; Saito N, 2002, J BIOCHEM, V132, P683, DOI 10.1093/oxfordjournals.jbchem.a003274; Scheffzek K, 2000, NAT STRUCT BIOL, V7, P122, DOI 10.1038/72392; SCHERLE P, 1993, P NATL ACAD SCI USA, V90, P7568, DOI 10.1073/pnas.90.16.7568; Siliceo M, 2006, J CELL SCI, V119, P141, DOI 10.1242/jcs.02722; Theodorescu D, 2004, CLIN CANCER RES, V10, P3800, DOI 10.1158/1078-0432.CCR-03-0653; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Vega FM, 2008, FEBS LETT, V582, P2093, DOI 10.1016/j.febslet.2008.04.039; Wu YM, 2009, P NATL ACAD SCI USA, V106, P5807, DOI 10.1073/pnas.0810094106	33	17	20	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 21	2013	32	8					1010	1017		10.1038/onc.2012.124	http://dx.doi.org/10.1038/onc.2012.124			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111LQ	22469974	Green Accepted			2022-12-17	WOS:000316523200008
J	Rieckmann, T; Kriegs, M; Nitsch, L; Hoffer, K; Rohaly, G; Kocher, S; Petersen, C; Dikomey, E; Dornreiter, I; Dahm-Daphi, J				Rieckmann, T.; Kriegs, M.; Nitsch, L.; Hoffer, K.; Rohaly, G.; Kocher, S.; Petersen, C.; Dikomey, E.; Dornreiter, I.; Dahm-Daphi, J.			p53 modulates homologous recombination at I-SceI-induced double-strand breaks through cell-cycle regulation	ONCOGENE			English	Article						p53; homologous recombination; cell cycle	DNA END RESECTION; MUTANT P53; MAMMALIAN-CELLS; HUMAN RAD51; REPAIR; CTIP; PHOSPHORYLATION; INACTIVATION; DISSOCIATION; SUPPRESSION	Inhibition of homologous recombination (HR) is believed to be a transactivation-independent function of p53 that protects from genetic instability. Misrepair by HR can lead to genetic alterations such as translocations, duplications, insertions and loss of heterozygosity, which all bear the risk of driving oncogenic transformation. Regulation of HR by wild-type p53 (wtp53) should prevent these genomic rearrangements. Mutation of p53 is a frequent event during carcinogenesis. In particular, dominant-negative mutants inhibiting wtp53 expressed from the unperturbed allel can drive oncogenic transformation by disrupting the p53-dependent anticancer barrier. Here, we asked whether the hot spot mutants R175H and R273H relax HR control in p53-proficient cells. Utilizing an I-SceI-based reporter assay, we observed a moderate (1.5 x) stimulation of HR upon expression of the mutant proteins in p53-proficient CV-1, but not in p53-deficient H1299 cells. Importantly, the stimulatory effect was exactly paralleled by an increase in the number of HR competent S- and G2-phase cells, which can well explain the enhanced recombination frequencies. Furthermore, the impact on HR exerted by the transactivation domain double-mutant L22Q/W23S and mutant R273P, both of which were reported to regulate HR independently of G1-arrest execution, is also exactly mirrored by cell-cycle behavior. These results are in contrast to previous concepts stating that the transactivation-independent impact of p53 on HR is a general phenomenon valid for replication-associated and also for directly induced double-strand break. Our data strongly suggest that the latter is largely mediated by cell-cycle regulation, a classical transactivation-dependent function of p53. Oncogene (2013) 32, 968-975; doi:10.1038/onc.2012.123; published online 9 April 2012	[Rieckmann, T.; Kriegs, M.; Nitsch, L.; Hoffer, K.; Kocher, S.; Dikomey, E.; Dahm-Daphi, J.] Univ Med Ctr Hamburg Eppendorf, Lab Radiobiol & Expt Radiooncol, Hamburg, Germany; [Rohaly, G.; Dornreiter, I.] Leibniz Inst Expt Virol, Heinrich Pette Inst, Hamburg, Germany; [Kocher, S.; Dahm-Daphi, J.] Univ Marburg, Particle Therapy Ctr, Inst Radiobiol & Mol Radiat Oncol, D-35043 Marburg, Hessen, Germany; [Petersen, C.] Univ Med Ctr Hamburg Eppendorf, Dept Radiotherapy & Radiooncol, Hamburg, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf; Heinrich Pette Institute; Philipps University Marburg; University of Hamburg; University Medical Center Hamburg-Eppendorf	Dahm-Daphi, J (corresponding author), Univ Marburg, Particle Therapy Ctr, Inst Radiobiol & Mol Radiat Oncol, D-35043 Marburg, Hessen, Germany.	jochen.dahmdaphi@staff.uni-marburg.de	Hoffer, Kenneth J/P-6431-2019; Petersen, Cordula/AAW-9789-2020	Rieckmann, Thorsten/0000-0001-8426-107X	German Cancer Aid (Deutsche Krebshilfe) [107889, 107980]	German Cancer Aid (Deutsche Krebshilfe)(Deutsche Krebshilfe)	We thank Dr Tom Misteli for the pDsRed-/-Scel-GR vector. This work was supported by a grant from the German Cancer Aid (Deutsche Krebshilfe No. 107889 to JDD and No. 107980 to ID).	Akyuz N, 2002, MOL CELL BIOL, V22, P6306, DOI 10.1128/MCB.22.17.6306-6317.2002; Albertson DG, 2003, NAT GENET, V34, P369, DOI 10.1038/ng1215; Bertrand P, 2004, TRENDS GENET, V20, P235, DOI 10.1016/j.tig.2004.04.003; Bertrand P, 1997, ONCOGENE, V14, P1117, DOI 10.1038/sj.onc.1200931; Boehden GS, 2003, ONCOGENE, V22, P4111, DOI 10.1038/sj.onc.1206632; Bunz F, 2002, CANCER RES, V62, P1129; Dudenhoffer C, 1999, ONCOGENE, V18, P5773, DOI 10.1038/sj.onc.1202964; Dudenhoffer C, 1998, MOL CELL BIOL, V18, P5332, DOI 10.1128/MCB.18.9.5332; Eid W, 2010, EMBO REP, V11, P962, DOI 10.1038/embor.2010.157; Gatz SA, 2006, CELL DEATH DIFFER, V13, P1003, DOI 10.1038/sj.cdd.4401903; Huertas P, 2009, J BIOL CHEM, V284, P9558, DOI 10.1074/jbc.M808906200; Joerger AC, 2008, ANNU REV BIOCHEM, V77, P557, DOI 10.1146/annurev.biochem.77.060806.091238; Johnson TM, 2005, NAT GENET, V37, P145, DOI 10.1038/ng1498; Kaidi A, 2010, SCIENCE, V329, P1348, DOI 10.1126/science.1192049; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kriegs M, 2010, DNA REPAIR, V9, P889, DOI 10.1016/j.dnarep.2010.05.005; Lee SM, 1997, J BIOL CHEM, V272, P7532, DOI 10.1074/jbc.272.11.7532; Linke SP, 2003, CANCER RES, V63, P2596; Mansour WY, 2008, NUCLEIC ACIDS RES, V36, P4088, DOI 10.1093/nar/gkn347; Mekeel KL, 1997, ONCOGENE, V14, P1847, DOI 10.1038/sj.onc.1201143; Restle A, 2008, NUCLEIC ACIDS RES, V36, P5362, DOI 10.1093/nar/gkn503; Roemer K, 1996, ONCOGENE, V12, P2069; Romanova LY, 2004, ONCOGENE, V23, P9025, DOI 10.1038/sj.onc.1207982; Saintigny Y, 1999, ONCOGENE, V18, P3553, DOI 10.1038/sj.onc.1202941; Saintigny Y, 2002, ONCOGENE, V21, P488, DOI 10.1038/sj.onc.1205040; Sartori AA, 2007, NATURE, V450, P509, DOI 10.1038/nature06337; Sengupta S, 2003, EMBO J, V22, P1210, DOI 10.1093/emboj/cdg114; Soutoglou E, 2007, NAT CELL BIOL, V9, P675, DOI 10.1038/ncb1591; Sturzbecher NW, 1996, EMBO J, V15, P1992; Susse S, 2000, ONCOGENE, V19, P4500, DOI 10.1038/sj.onc.1203809; Tang M, 2006, NAT GENET, V38, P395, DOI 10.1038/ng0406-395; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; Wiesmuller L, 1996, J VIROL, V70, P737; Willers H, 2000, ONCOGENE, V19, P632, DOI 10.1038/sj.onc.1203142; Yoon D, 2004, J MOL BIOL, V336, P639, DOI 10.1016/j.jmb.2003.12.050; You ZS, 2009, MOL CELL, V36, P954, DOI 10.1016/j.molcel.2009.12.002; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637	37	17	17	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 21	2013	32	8					968	975		10.1038/onc.2012.123	http://dx.doi.org/10.1038/onc.2012.123			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111LQ	22484423				2022-12-17	WOS:000316523200004
J	Mao, L; Ding, J; Perdue, A; Yang, L; Zha, Y; Ren, M; Huang, S; Cui, H; Ding, HF				Mao, L.; Ding, J.; Perdue, A.; Yang, L.; Zha, Y.; Ren, M.; Huang, S.; Cui, H.; Ding, H-F			Cyclin E1 is a common target of BMI1 and MYCN and a prognostic marker for neuroblastoma progression	ONCOGENE			English	Article						BMI1; cyclin E1; FBXW7; MYCN; neuroblastoma	CELL SELF-RENEWAL; GENE-EXPRESSION; STEM-CELLS; N-MYC; SENESCENCE; DIFFERENTIATION; INHIBITION; APOPTOSIS; GROWTH; IDENTIFICATION	The Polycomb transcription repressor BMI1 is highly expressed in human neuroblastomas and is required for the clonogenic self-renewal and tumorigenicity of human neuroblastoma cell lines. The molecular basis of BMI1 action in neuroblastoma cells is not well understood. Here we report that BMI1 has a critical role in stabilizing cyclin E1 by repressing the expression of FBXW7, a substrate-recognition subunit of the SCF E3 ubiquitin ligase that targets cyclin E1 for degradation. BMI1 binds to the FBXW7 locus in vivo and represses its mRNA expression. Overexpression of cyclin E1 or abrogation of FBXW7 induction rescues the cell-death phenotype of BMI1 knockdown. Moreover, MYCN, an oncoprotein in the pathogenesis of high-risk neuroblastomas, is able to counteract the death-inducing effect of BMI1 knockdown by activating CCNE1 transcription. We further show that high cyclin E1 expression is associated with Stage 4 neuroblastomas and poor prognosis in patients. These findings suggest a molecular mechanism for the oncogenic activity of BMI1 and MYCN in neuroblastoma pathogenesis and progression by maintaining cyclin E1 levels. Oncogene (2012) 31, 3785-3795; doi:10.1038/onc.2011.536; published online 28 November 2011	[Cui, H.] Southwest Univ, State Key Lab Silkworm Funct Genome Biol, Inst Sericulture & Syst Biol, Chongqing 400716, Peoples R China; [Mao, L.; Ding, J.; Perdue, A.; Yang, L.; Zha, Y.; Ren, M.; Ding, H-F] Georgia Hlth Sci Univ, Ctr Canc, Dept Pathol, Augusta, GA 30912 USA; [Mao, L.] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Neurol, Wuhan 430074, Peoples R China; [Zha, Y.] Three Gorges Univ, Coll Med, Hosp Yichang 1, Dept Neurol, Yichang, Peoples R China; [Huang, S.] Georgia Hlth Sci Univ, Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA	Southwest University - China; University System of Georgia; Augusta University; Huazhong University of Science & Technology; China Three Gorges University; University System of Georgia; Augusta University	Cui, H (corresponding author), Southwest Univ, State Key Lab Silkworm Genome Biol, Inst Sericulture & Syst Biol, 2 Tianshenqiao, Chongqing 400716, Peoples R China.	hcui@swu.edu.cn; hding@georgiahealth.edu		Ding, Han-Fei/0000-0001-5702-3439	NIH [CA124982]; Georgia Cancer Coalition Distinguished Scholar Award [H-FD]; National Basic Research Program of China [2012cb114603]; National Science Foundation of China [NSFC 81101905]; NATIONAL CANCER INSTITUTE [R01CA124982] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Georgia Cancer Coalition Distinguished Scholar Award; National Basic Research Program of China(National Basic Research Program of China); National Science Foundation of China(National Natural Science Foundation of China (NSFC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Q Du for pKMyc-cyclinE1, G Hannon and J Silva for shRNAmir Tet-Off, R Mulligan for pHDM-G and pMD.MLVogp, W Wei for pBabe-puro-p14<SUP>ARF</SUP> and J Khan for gene expression data sets from the Oncogenomics Database. This work was supported by the NIH grant CA124982 and a Georgia Cancer Coalition Distinguished Scholar Award (H-FD), and a grant from the National Basic Research Program of China (No. 2012cb114603) to HC. LM was supported in part by a grant from the National Science Foundation of China (NSFC 81101905).	Asgharzadeh S, 2006, JNCI-J NATL CANCER I, V98, P1193, DOI 10.1093/jnci/djj330; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Bruggeman SWM, 2005, GENE DEV, V19, P1438, DOI 10.1101/gad.1299305; Chang HH, 2010, CLIN CANCER RES, V16, P4411, DOI 10.1158/1078-0432.CCR-09-3360; Chen QR, 2008, GENOMICS, V92, P195, DOI 10.1016/j.ygeno.2008.05.014; Crusio KM, 2010, ONCOGENE, V29, P4865, DOI 10.1038/onc.2010.222; Cui HJ, 2005, J BIOL CHEM, V280, P9474, DOI 10.1074/jbc.M410450200; Cui HJ, 2007, AM J PATHOL, V170, P1370, DOI 10.2353/ajpath.2007.060754; Cui HJ, 2006, J BIOL CHEM, V281, P34696, DOI 10.1074/jbc.M604009200; Ferrari-Toninelli G, 2010, NEURO-ONCOLOGY, V12, P1231, DOI 10.1093/neuonc/noq101; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; Hwang HC, 2005, ONCOGENE, V24, P2776, DOI 10.1038/sj.onc.1208613; Iwama A, 2004, IMMUNITY, V21, P843, DOI 10.1016/j.immuni.2004.11.004; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Ma CX, 2011, TRENDS MOL MED, V17, P88, DOI 10.1016/j.molmed.2010.10.009; Mao L, 2011, CANCER RES, V71, P4314, DOI 10.1158/0008-5472.CAN-11-0051; Maris JM, 1999, J CLIN ONCOL, V17, P2264, DOI 10.1200/JCO.1999.17.7.2264; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Minella AC, 2002, CURR BIOL, V12, P1817, DOI 10.1016/S0960-9822(02)01225-3; Molofsky AV, 2005, GENE DEV, V19, P1432, DOI 10.1101/gad.1299505; Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060; Nakayama KI, 2006, NAT REV CANCER, V6, P369, DOI 10.1038/nrc1881; Nowak K, 2006, NUCLEIC ACIDS RES, V34, P1745, DOI 10.1093/nar/gkl119; Oberthuer A, 2006, J CLIN ONCOL, V24, P5070, DOI 10.1200/JCO.2006.06.1879; Ochiai H, 2010, ONCOGENE, V29, P2681, DOI 10.1038/onc.2010.22; Onoyama I, 2008, CELL CYCLE, V7, P3307, DOI 10.4161/cc.7.21.6931; Otto T, 2009, CANCER CELL, V15, P67, DOI 10.1016/j.ccr.2008.12.005; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Park IK, 2004, J CLIN INVEST, V113, P175, DOI 10.1172/JCI200420800; PerezRoger I, 1997, ONCOGENE, V14, P2373, DOI 10.1038/sj.onc.1201197; Riccardi C, 2006, NAT PROTOC, V1, P1458, DOI 10.1038/nprot.2006.238; Satyanarayana A, 2009, ONCOGENE, V28, P2925, DOI 10.1038/onc.2009.170; Sauvageau M, 2010, CELL STEM CELL, V7, P299, DOI 10.1016/j.stem.2010.08.002; Schwab M, 2004, CANCER LETT, V204, P179, DOI 10.1016/S0304-3835(03)00454-3; Schwartz YB, 2007, NAT REV GENET, V8, P9, DOI 10.1038/nrg1981; Silva JM, 2008, SCIENCE, V319, P617, DOI 10.1126/science.1149185; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; Thompson SL, 2010, CURR BIOL, V20, pR285, DOI 10.1016/j.cub.2010.01.034; Valk-Lingbeek ME, 2004, CELL, V118, P409, DOI 10.1016/j.cell.2004.08.005; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; Wei JS, 2004, CANCER RES, V64, P6883, DOI 10.1158/0008-5472.CAN-04-0695; Wei WY, 2001, MOL CELL BIOL, V21, P6748, DOI 10.1128/MCB.21.20.6748-6757.2001; Welcker M, 2008, NAT REV CANCER, V8, P83, DOI 10.1038/nrc2290; Yamashita M, 2008, J EXP MED, V205, P1109, DOI 10.1084/jem.20072000	51	17	18	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2012	31	33					3785	3795		10.1038/onc.2011.536	http://dx.doi.org/10.1038/onc.2011.536			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	994IU	22120721	Green Accepted			2022-12-17	WOS:000307924900005
J	Franks, SE; Campbell, CI; Barnett, EF; Siwicky, MD; Livingstone, J; Cory, S; Moorehead, RA				Franks, S. E.; Campbell, C. I.; Barnett, E. F.; Siwicky, M. D.; Livingstone, J.; Cory, S.; Moorehead, R. A.			Transgenic IGF-IR overexpression induces mammary tumors with basal-like characteristics, whereas IGF-IR-independent mammary tumors express a claudin-low gene signature	ONCOGENE			English	Article						IGF-IR; mammary tumor; DNA microarray; EMT; claudin	ESTROGEN-RECEPTOR-ALPHA; HUMAN-BREAST-CANCER; PROGESTERONE-RECEPTORS; MOLECULAR PORTRAITS; PROFILES; CARCINOMAS; PATTERNS	Molecular profiling has allowed a more precise classification of human cancers. With respect to breast cancer, this approach has been used to identify five subtypes; luminal A, luminal B, HER2-enriched, basal-like and claudin-low. In addition, this approach can be used to determine the type of tumor represented by particular cell lines or transgenic animal models. Therefore, this approach was utilized to classify the mammary tumors that develop in MTB-IGFIR transgenic mice. It was determined that the primary mammary tumors, which develop due to elevated expression of the type I insulin-like growth factor receptor (IGF-IR) in mammary epithelial cells, most closely resemble murine tumors with basal-like or mixed gene expression profiles and with human basal-like breast cancers. Downregulation of IGF-IR transgene in MTB-IGFIR tumor-bearing mice leads to the regression of most of the tumors, followed by tumor reappearance in some of the mice. These tumors that reappear following IGF-IR transgene downregulation do not express the IGF-IR transgene and cluster with murine mammary tumors that express a mesenchymal gene expression profile and with human claudin-low breast cancers. Therefore, IGF-IR overexpression in murine mammary epithelial cells induces mammary tumors with primarily basal-like characteristics, whereas tumors that develop following IGF-IR downregulation express a gene signature that most closely resembles human claudin-low breast tumors. Oncogene (2012) 31, 3298-3309; doi:10.1038/onc.2011.486; published online 24 October 2011	[Franks, S. E.; Campbell, C. I.; Barnett, E. F.; Siwicky, M. D.; Moorehead, R. A.] Univ Guelph, Ontario Vet Coll, Dept Biomed Sci, Guelph, ON N5A 7Z1, Canada; [Livingstone, J.; Cory, S.] McGill Univ, Rosalind & Morris Goodman Canc Res Ctr, Dept Biochem Oncol, Montreal, PQ, Canada; [Livingstone, J.; Cory, S.] McGill Univ, Rosalind & Morris Goodman Canc Res Ctr, Dept Med, Montreal, PQ, Canada	University of Guelph; McGill University; McGill University	Moorehead, RA (corresponding author), Univ Guelph, Ontario Vet Coll, Dept Biomed Sci, 50 Stone Rd E, Guelph, ON N5A 7Z1, Canada.	rmoorehe@uoguelph.ca		, Roger/0000-0001-9539-6295; Livingstone, Julie/0000-0002-8424-3768	Cancer Research Society; Canadian Institutes of Health Research	Cancer Research Society; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	This work was funded by operating grants from the Cancer Research Society and the Canadian Institutes of Health Research awarded to RAM.	Adelaide J, 2007, CANCER RES, V67, P11565, DOI 10.1158/0008-5472.CAN-07-2536; Fagan D, 2008, J MAMMARY GLAND BIOL, V13, P423, DOI 10.1007/s10911-008-9098-0; Fan C, 2006, NEW ENGL J MED, V355, P560, DOI 10.1056/NEJMoa052933; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Gruvberger S, 2001, CANCER RES, V61, P5979; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Hu ZY, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-96; Huang F, 2009, CANCER RES, V69, P161, DOI 10.1158/0008-5472.CAN-08-0835; Jones RA, 2007, ONCOGENE, V26, P1636, DOI 10.1038/sj.onc.1209955; Jones RA, 2009, ONCOGENE, V13, P407; Klinakis A, 2009, P NATL ACAD SCI USA, V106, P2359, DOI 10.1073/pnas.0810221106; Koda M, 2003, HORM METAB RES, V35, P794; Koda M, 2005, ONCOL REP, V14, P93; Lanzino M, 2008, CURR CANCER DRUG TAR, V8, P597, DOI 10.2174/156800908786241104; Lerma E, 2007, MODERN PATHOL, V20, P1200, DOI 10.1038/modpathol.3800961; Maki RG, 2010, J CLIN ONCOL, V28, P4985, DOI 10.1200/JCO.2009.27.5040; Molyneux G, 2010, CELL STEM CELL, V7, P403, DOI 10.1016/j.stem.2010.07.010; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; PEYRAT JP, 1988, CANCER RES, V48, P6429; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Sarfstein R, 2006, MOL CELL ENDOCRINOL, V252, P241, DOI 10.1016/j.mce.2006.03.018; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Sotiriou C, 2003, P NATL ACAD SCI USA, V100, P10393, DOI 10.1073/pnas.1732912100; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Werner H, 1996, P NATL ACAD SCI USA, V93, P8318, DOI 10.1073/pnas.93.16.8318; West M, 2001, P NATL ACAD SCI USA, V98, P11462, DOI 10.1073/pnas.201162998; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009	29	17	17	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2012	31	27					3298	3309		10.1038/onc.2011.486	http://dx.doi.org/10.1038/onc.2011.486			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	970FL	22020329	Green Published, hybrid			2022-12-17	WOS:000306113400009
J	Merino, D; Strasser, A; Bouillet, P				Merino, D.; Strasser, A.; Bouillet, P.			Bim must be able to engage all pro-survival Bcl-2 family members for efficient tumor suppression	ONCOGENE			English	Article						Myc; bim; tumor suppression; lymphoma; apoptosis	B-CELL LYMPHOMAGENESIS; TRANSGENIC MICE; C-MYC; MEMBRANE PERMEABILIZATION; PROTEINS; DEATH; PUMA; EXPRESSION; LEUKEMIA; DRIVEN	Overexpression of the transcriptional regulator Myc is thought to be the cause or a contributing factor in the development of a large number of human lymphomas and certain other cancers. Apoptotic cell death constitutes a tumor suppressive mechanism, particularly in the context of Myc overexpression. Accordingly, lymphoma development in El-Myc transgenic mice, which mimic the Myc/ IgH chromosomal translocation that causes Burkitt lymphoma, is accelerated by concomitant overexpression of anti-apoptotic Bcl-2 family members or loss of proapoptotic BH3-only proteins, such as Bim. Bim binds with high affinity to all pro-survival Bcl-2-like proteins and can also interact with Bax/ Bak, but it remains unclear which of these interactions are critical for its tumor suppressive function. We have previously generated knock-in mutant mice in which the BH3 region of Bim has been exchanged with that for Bad, Noxa or Puma so that it can only bind to select pro-survival Bcl-2-like proteins: Bim(Bad) binding to Bcl-2, Bcl-xL and Bcl-w, but not Mcl-1 or A1; Bim(Noxa) binding only to Mcl-1 and A1 and as a control, Bim(Puma), which can still bind all pro-survival Bcl-2-like proteins. We have now inter-crossed these Bim mutant mice with El-Myc transgenic mice, and found that both the Bim(Bad) and the Bim(Noxa) mutations but not the Bim(Puma) mutation greatly accelerate Myc-induced lymphoma development and increase leukemic burden. These results demonstrate that for optimal tumor suppressive activity, Bim must be able to interact with all and not just select pro-survival Bcl-2 family members. Oncogene (2012) 31, 3392-3396; doi: 10.1038/onc.2011.508; published online 14 November 2011	[Merino, D.; Strasser, A.; Bouillet, P.] Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3010, Australia; [Merino, D.; Strasser, A.; Bouillet, P.] Univ Melbourne, Dept Med Biol, Melbourne, Vic, Australia	Walter & Eliza Hall Institute; University of Melbourne	Bouillet, P (corresponding author), Walter & Eliza Hall Inst Med Res, 1G Royal Parade, Melbourne, Vic 3010, Australia.	bouillet@wehi.edu.au	Strasser, Andreas/C-7581-2013; Merino, Delphine/L-9159-2017; Bouillet, Philippe/E-1241-2013	Strasser, Andreas/0000-0002-5020-4891; Merino, Delphine/0000-0002-8075-6275; Bouillet, Philippe/0000-0002-9012-6058	Australian National Health and Medical Research Council [461221]; National Cancer Institute [CA43540]; Australian Research Council; Leukemia and Lymphoma Society [7015]; Australian Government (IRISS); Victorian State Government (OIS); NATIONAL CANCER INSTITUTE [R01CA043540] Funding Source: NIH RePORTER	Australian National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Australian Research Council(Australian Research Council); Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); Australian Government (IRISS)(National Health and Medical Research Council (NHMRC) of Australia); Victorian State Government (OIS); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Mikara Robati and Owen Siggs for help with experiments; Jerry Adams, Suzanne Cory, Clare Scott and Cyril Clybouw for insightful discussions; and Em-Myc mice, Bruno Helbert and Carley Young for mouse genotyping; Emily Sutherland and Giovanni Siciliano for mouse husbandry; and Jason Corbin for blood sample analysis. This work was supported by the Australian National Health and Medical Research Council (program grant 461221, Australia Fellowship (AS) and Career Development Award (PB)), the National Cancer Institute (CA43540), the Australian Research Council (DM), the Leukemia and Lymphoma Society (LLS Specialized Center of Research grant 7015) and operational infrastructure grants through the Australian Government (IRISS) and the Victorian State Government (OIS).	ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Anderton E, 2008, ONCOGENE, V27, P421, DOI 10.1038/sj.onc.1210668; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Chipuk JE, 2008, TRENDS CELL BIOL, V18, P157, DOI 10.1016/j.tcb.2008.01.007; Egle A, 2004, P NATL ACAD SCI USA, V101, P6164, DOI 10.1073/pnas.0401471101; Frenzel A, 2010, BLOOD, V115, P995, DOI 10.1182/blood-2009-03-212670; Garrison SP, 2008, MOL CELL BIOL, V28, P5391, DOI 10.1128/MCB.00907-07; Hemann MT, 2004, P NATL ACAD SCI USA, V101, P9333, DOI 10.1073/pnas.0403286101; Kelly PN, 2007, BLOOD, V109, P4907, DOI 10.1182/blood-2006-10-051847; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; Letai A, 2004, CANCER CELL, V6, P241, DOI 10.1016/j.ccr.2004.07.011; Merino D, 2009, J CELL BIOL, V186, P355, DOI 10.1083/jcb.200905153; Michalak EM, 2009, CELL DEATH DIFFER, V16, P684, DOI 10.1038/cdd.2008.195; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Strasser A, 1996, EMBO J, V15, P3823, DOI 10.1002/j.1460-2075.1996.tb00756.x; Strasser A, 2011, EMBO J, V30, P3667, DOI 10.1038/emboj.2011.307; Tagawa H, 2005, ONCOGENE, V24, P1348, DOI 10.1038/sj.onc.1208300; Xiang ZF, 2010, J CLIN INVEST, V120, P2109, DOI 10.1172/JCI39964; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308	22	17	17	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2012	31	28					3392	3396		10.1038/onc.2011.508	http://dx.doi.org/10.1038/onc.2011.508			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	973NT	22081075	Green Accepted			2022-12-17	WOS:000306367600008
J	Darini, CY; Pisani, DF; Hofman, P; Pedeutour, F; Sudaka, I; Chomienne, C; Dani, C; Ladoux, A				Darini, C. Y.; Pisani, D. F.; Hofman, P.; Pedeutour, F.; Sudaka, I.; Chomienne, C.; Dani, C.; Ladoux, A.			Self-renewal gene tracking to identify tumour-initiating cells associated with metastatic potential	ONCOGENE			English	Article						tumour-initiating cells; Oct-4; metastasis; gene tracking	CANCER STEM-CELLS; MYELOID-LEUKEMIA; BONE-MARROW; EXPRESSION; GROWTH; DIFFERENTIATION; IDENTIFICATION; OCT-3/4; CXCR4; HETEROGENEITY	Tumour-initiating cells (TICs) are rare cancer cells isolated from tumours of different origins including high-grade tumours that sustain neoplasic progression and development of metastatic disease. They harbour deregulated stem cells pathways and exhibit an unchecked ability to self-renew, a property essential for tumour progression. Among the essential factors maintaining embryonic stem (ES) cells properties, OCT-4 (also known as POU5F1) has been detected in tumours of different origins. Although ectopic expression results in dysplasic growth restricted to epithelial tissues, overexpression expands the proportion of immature cells in teratomas. However, OCT-4-expressing cells have not been purified from spontaneously occurring tumours, thus information concerning their properties is rather scant. Here, using p53-/- mice expressing green fluorescent protein and the puromycin resistance gene under the control of the Oct-4 promoter, we show that OCT-4 is expressed in 5% onwards of the undifferentiated tumour cell populations derived from different organs. OCT-4 expression was low as compared with ES cells, but was associated with a 'stemness' signature and expression of the chemokine receptor CXCR4. These cells displayed cancer stem cell features, including increased self-renewal and differentiation ability in vitro and in vivo. They not only formed allografts containing immature bone regions but also disseminated into different organs, including lung, liver and bone. Experiments based on RNA interference revealed that Oct-4 expression drives both their engraftment and metastasis formation. This work points out the crucial contribution of Oct-4-expressing TICs in the hierarchical organization of the malignant potential, leading to metastasis formation. Consequently, it provides an appropriate model to develop novel therapies aiming to strike down TICs by targeting self-renewal genes, therefore efficient to reduce tumour growth and metastatic disease. Oncogene (2012) 31, 2438-2449; doi: 10.1038/onc.2011.421; published online 19 September 2011	[Darini, C. Y.; Pisani, D. F.; Pedeutour, F.; Dani, C.; Ladoux, A.] Univ Nice Sophia Antipolis, CNRS, Inst Biol Dev & Canc, F-06107 Nice 2, France; [Hofman, P.] Univ Nice Sophia Antipolis, Fac Med, INSERM, ERI 21,EA 4319, F-06107 Nice 2, France; [Hofman, P.] Univ Nice Sophia Antipolis, Fac Med, Human Biobank, F-06107 Nice 2, France; [Hofman, P.] Univ Nice Sophia Antipolis, CHU Nice, Pasteur Hosp, F-06107 Nice 2, France; [Pedeutour, F.] Univ Nice Sophia Antipolis, Nice Univ Hosp, Fac Med, F-06107 Nice 2, France; [Sudaka, I.] Cimiez Hosp, CHU Nice, Haematol Lab, Nice, France; [Chomienne, C.] Paris Diderot Univ, Hop St Louis, INSERM, UMRS 940, Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice; UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice; UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Ladoux, A (corresponding author), Univ Nice Sophia Antipolis, CNRS, Inst Biol Dev & Canc, 28 Ave Valombrose, F-06107 Nice 2, France.	ladoux@unice.fr	LADOUX, ANNIE/S-2077-2019; LADOUX, ANNIE/O-4267-2016; DANI, Christian/G-3639-2014; Hofman, Paul/P-7654-2018; Pisani, Didier/AAC-2997-2019	LADOUX, ANNIE/0000-0003-3857-2621; LADOUX, ANNIE/0000-0003-3857-2621; DANI, Christian/0000-0003-3228-0230; Hofman, Paul/0000-0003-0431-9353; Pisani, Didier/0000-0001-5879-8527; CHOMIENNE, Christine/0000-0001-5513-5752	Association pour la Recherche contre le Cancer; Institut National du Cancer [CT 30008187, PL-96-007]; Conseil General des Alpes-Maritimes	Association pour la Recherche contre le Cancer(Fondation ARC pour la Recherche sur le Cancer); Institut National du Cancer(Institut National du Cancer (INCA) France); Conseil General des Alpes-Maritimes(Region Provence-Alpes-Cote d'Azur)	We are grateful to Professor Austin Smith and Dr Jenny Nichols for generously providing Oct-4-GiP mice and for useful comments. The contributions of Drs Ez-Zoubir Amri and Gilles Pages for in vivo imaging analyses are appreciated. We thank our colleagues, Dr Katrina Podsypanina and Dr Alain Aurias, for helpful suggestions and discussions. We are indebted to Drs Pascal Peraldi, Nathalie Mazure, Jean-Francois Peyron, Marie-Christine De Vernejoul and Minoo Rassoulzadegan for a careful reading of this manuscript, and to Drs Amanda Patel and Eric Lingueglia for valuable help in editing this manuscript. We acknowledge expert technical assistance of Katia Havet with histology; Agnes Loubat with flow cytometry; Mansour Djedaini with in vivo imaging; Thibault Fabas and Annie-Claude Peyron with genetic analysis; and Franck Paput, Cendrine Dubaud and Jacky Paput with animal care. Our lab receives financial support from Association pour la Recherche contre le Cancer and Institut National du Cancer (grant numbers: CT 30008187 and PL-96-007). We thank Conseil General des Alpes-Maritimes for financial support for the animal imaging equipment (SkyScan).	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Altaba ARI, 2009, EMBO REP, V10, P832, DOI 10.1038/embor.2009.169; Beier D, 2007, CANCER RES, V67, P4010, DOI 10.1158/0008-5472.CAN-06-4180; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Carlisle AJ, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-126; Chambers I, 2007, NATURE, V450, P1230, DOI 10.1038/nature06403; Charafe-Jauffret E, 2009, CANCER RES, V69, P1302, DOI 10.1158/0008-5472.CAN-08-2741; Charrad RS, 1999, NAT MED, V5, P669, DOI 10.1038/9518; Chiou SH, 2010, CANCER RES, V70, P10433, DOI 10.1158/0008-5472.CAN-10-2638; Clement V, 2007, CURR BIOL, V17, P165, DOI 10.1016/j.cub.2006.11.033; Diehn M, 2009, SEMIN RADIAT ONCOL, V19, P78, DOI 10.1016/j.semradonc.2008.11.002; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Felsher DW, 2004, CURR OPIN GENET DEV, V14, P37, DOI 10.1016/j.gde.2003.12.008; Gassmann P, 2009, NEOPLASIA, V11, P651, DOI 10.1593/neo.09272; Gidekel S, 2003, CANCER CELL, V4, P361, DOI 10.1016/S1535-6108(03)00270-8; Harris MA, 2008, CANCER RES, V68, P10051, DOI 10.1158/0008-5472.CAN-08-0786; Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002; Hochedlinger K, 2005, CELL, V121, P465, DOI 10.1016/j.cell.2005.02.018; Hochedlinger K, 2009, DEVELOPMENT, V136, P509, DOI 10.1242/dev.020867; Huang CY, 2009, J CELL PHYSIOL, V221, P204, DOI 10.1002/jcp.21846; Hutchin ME, 2005, GENE DEV, V19, P214, DOI 10.1101/gad.1258705; Kaufman DS, 2006, ANN ONCOL, V17, pV106, DOI 10.1093/annonc/mdj963; Kucia M, 2005, BIOL CELL, V97, P133, DOI 10.1042/BC20040069; le Viseur C, 2008, CANCER CELL, V14, P47, DOI 10.1016/j.ccr.2008.05.015; Lee J, 2007, BIOCHEM J, V406, P519, DOI 10.1042/BJ20070243; Lengner CJ, 2007, CELL STEM CELL, V1, P403, DOI 10.1016/j.stem.2007.07.020; Levings PP, 2009, CANCER RES, V69, P5648, DOI 10.1158/0008-5472.CAN-08-3580; Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030; Marangoni E, 2009, BRIT J CANCER, V100, P918, DOI 10.1038/sj.bjc.6604953; Masui S, 2007, NAT CELL BIOL, V9, P625, DOI 10.1038/ncb1589; Monteiro J, 2010, EUR J CANCER, V46, P1198, DOI 10.1016/j.ejca.2010.02.030; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; O'Brien CA, 2009, SEMIN RADIAT ONCOL, V19, P71, DOI 10.1016/j.semradonc.2008.11.001; Prince ME, 2007, P NATL ACAD SCI USA, V104, P973, DOI 10.1073/pnas.0610117104; Rajagopalan V, 2005, J NEURO-ONCOL, V72, P157, DOI 10.1007/s11060-004-3346-y; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Rodriguez AM, 2005, J EXP MED, V201, P1397, DOI 10.1084/jem.20042224; Santagata S, 2007, AM J SURG PATHOL, V31, P836, DOI 10.1097/PAS.0b013e31802e708a; Shachaf CM, 2004, NATURE, V431, P1112, DOI 10.1038/nature03043; Shackleton M, 2009, CELL, V138, P822, DOI 10.1016/j.cell.2009.08.017; Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Somervaille TCP, 2009, CELL STEM CELL, V4, P129, DOI 10.1016/j.stem.2008.11.015; Wang JL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003769; Ying QL, 2002, NATURE, V416, P545, DOI 10.1038/nature729; Zeelenberg IS, 2001, J CLIN INVEST, V108, P269, DOI 10.1172/JCI200111330; Zeineddine D, 2006, DEV CELL, V11, P535, DOI 10.1016/j.devcel.2006.07.013; Zhang YF, 2010, CANCER LETT, V292, P1, DOI 10.1016/j.canlet.2009.11.003	53	17	18	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2012	31	19					2438	2449		10.1038/onc.2011.421	http://dx.doi.org/10.1038/onc.2011.421			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	941SP	21927026				2022-12-17	WOS:000303985300006
J	Shola, DTN; Wang, H; Wahdan-Alaswad, R; Danielpour, D				Shola, D. T. N.; Wang, H.; Wahdan-Alaswad, R.; Danielpour, D.			Hic-5 controls BMP4 responses in prostate cancer cells through interacting with Smads 1, 5 and 8	ONCOGENE			English	Article						Hic-5; BMP; Smad1; Smad; apoptosis; prostate	BONE MORPHOGENETIC PROTEINS; ANDROGEN RECEPTOR; OXIDATIVE STRESS; METASTATIC PROSTATE; UP-REGULATION; LIM PROTEIN; EXPRESSION; IDENTIFICATION; GROWTH; DEATH	Hydrogen peroxide-inducible clone-5 (Hic-5, or androgen receptor-associated protein 55) is a transforming growth factor-beta-inducible LIM protein whose deregulation is implicated in the progression of prostate cancer. Here, we report that Hic-5 binds to Smads 1, 5 and 8, and represses bone morphogenetic protein (BMP) signaling responses. Myc-Hic-5 but not Myc-paxillin was specifically immunoprecipitated with anti-FLAG IgG1 from lysates of HEK293 co-transfected with either Myc-Hic-5 or Myc-paxillin and FLAG-tagged Smads 1, 5 or 8. We showed that such interactions require the LIM3 domain of Hic-5 and the MH2 domain of those Smads. Anti-Hic-5 antibody specifically pulled down endogenous Smad1 in both the PC3 human prostate cell line and primary cultures of rat prostate fibroblasts, supporting that Hic-5 binds to Smad1 at the endogenous level. Bacterially expressed glutathione S-transferase (GST)-Smads 1, 5 or 8, but not GST alone, pulled down in vitro transcribed and translated Hic-5, implicating that Hic-5 binds directly to Smads 1, 5 and 8. Significantly, using Hic-5 small hairpin RNA silencing and overexpression systems, we show that Hic-5 (at both the endogenous and exogenous levels) represses the ability of BMP4 to induce expression of the inhibitor of differentiation-1 (Id1; a downstream target gene of BMP), activate the Id1 gene promoter and induce apoptosis in human and rat prostate epithelial cells. Moreover, silencing of Hic-5 in PC3 cells as well as in the WPMY-1 human prostate stroma cell line greatly enhances the levels of endogenous phospho-Smad1/5/8. Finally, we provide fluorescent microscopic imaging to support that Smad1 and Hic-5 mutually interact also at the level of their nuclear export mechanisms. Collectively, these results provide the first evidence for a physical and mutual functional interaction between Hic-5 and the BMP signaling pathway. Oncogene (2012) 31, 2480-2490; doi: 10.1038/onc.2011.422; published online 26 September 2011	[Danielpour, D.] Case Western Reserve Univ, Sch Med, Div Gen Med Sci Oncol, Case Comprehens Canc Ctr Res Labs, Cleveland, OH 44106 USA; [Shola, D. T. N.] Case Western Reserve Univ, Dept Mol Biol & Microbiol, Cleveland, OH 44106 USA; [Wang, H.; Wahdan-Alaswad, R.; Danielpour, D.] Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA; [Danielpour, D.] Univ Hosp Cleveland, Dept Urol, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland	Danielpour, D (corresponding author), Case Western Reserve Univ, Sch Med, Div Gen Med Sci Oncol, Case Comprehens Canc Ctr Res Labs, Wolstein Res Bldg,Room 3-532V,2103 Cornell Rd, Cleveland, OH 44106 USA.	dxd49@case.edu	Shola, Dorjee/AAE-1443-2019; Wahdan-alaswad, Reema/AAA-5604-2021	Shola, Dorjee/0000-0001-7236-5912; 	NIH [R01CA102074, R01CA134878]; Case Comprehensive Cancer Center [5T32CA059366-15, P30CA43703]; National Research Service [1F31CA142311]; NATIONAL CANCER INSTITUTE [R01CA102074, F31CA142311, P30CA043703, R01CA134878, T32CA059366] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Case Comprehensive Cancer Center; National Research Service; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NIH Grants R01CA102074 and R01CA134878 (D Danielpour), a pre-doctoral fellowship (R Wahdan-Alaswad) from Case Comprehensive Cancer Center's Research Oncology Training Grant 5T32CA059366-15 and National Research Service Award Individual Fellowship Application 1F31CA142311, and the Case Comprehensive Cancer Center P30CA43703 (for the Cytometry Core facility).	Alarmo EL, 2010, ENDOCR-RELAT CANCER, V17, pR123, DOI 10.1677/ERC-09-0273; Barnes J, 1995, WORLD J UROL, V13, P337; Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922; Bobinac D, 2005, CROAT MED J, V46, P389; Chipuk JE, 2002, J BIOL CHEM, V277, P26412, DOI 10.1074/jbc.M201244200; Corey E, 2007, J UROLOGY, V178, P750, DOI 10.1016/j.juro.2007.06.007; Csiszar A, 2008, AM J PHYSIOL-HEART C, V295, pH569, DOI 10.1152/ajpheart.00180.2008; Cuny GD, 2008, BIOORG MED CHEM LETT, V18, P4388, DOI 10.1016/j.bmcl.2008.06.052; Dabiri G, 2008, J INVEST DERMATOL, V128, P2518, DOI 10.1038/jid.2008.90; DANIELPOUR D, 1994, CANCER RES, V54, P3413; Drori S, 2005, GENE DEV, V19, P362, DOI 10.1101/gad.1240705; Federico A, 2007, INT J CANCER, V121, P2381, DOI 10.1002/ijc.23192; Gambaro K, 2006, CELL DEATH DIFFER, V13, P1075, DOI 10.1038/sj.cdd.4401799; Gao ZL, 2007, EXP CELL RES, V313, P4000, DOI 10.1016/j.yexcr.2007.05.023; Gao ZL, 2005, FEBS LETT, V579, P5651, DOI 10.1016/j.febslet.2005.08.086; Ghogomu SM, 2006, J BIOL CHEM, V281, P1755, DOI 10.1074/jbc.M505869200; Heitzer MD, 2007, STEROIDS, V72, P218, DOI 10.1016/j.steroids.2006.11.010; Heitzer MD, 2006, MOL ENDOCRINOL, V20, P56, DOI 10.1210/me.2005-0065; Hornigold N, 2010, KIDNEY INT, V77, P329, DOI 10.1038/ki.2009.417; Howe JR, 2001, NAT GENET, V28, P184, DOI 10.1038/88919; Hsu MY, 2005, CANCER METAST REV, V24, P251, DOI 10.1007/s10555-005-1575-y; Katagiri T, 2002, GENES CELLS, V7, P949, DOI 10.1046/j.1365-2443.2002.00573.x; Li X, 2011, ONCOGENE, V30, P167, DOI 10.1038/onc.2010.400; Li Z. L, 2006, ZHONGHUA NAN KE XUE, V12, P132; Li Ze-Liang, 2006, Zhonghua Nan Ke Xue, V12, P126; Masuda H, 2003, PROSTATE, V54, P268, DOI 10.1002/pros.10193; Miyazono K, 2010, J BIOCHEM, V147, P35, DOI 10.1093/jb/mvp148; Miyoshi Y, 2003, PROSTATE, V56, P280, DOI 10.1002/pros.10262; Mori K, 2009, MOL BIOL CELL, V20, P218, DOI 10.1091/mbc.E08-04-0428; Przybyszewski WM, 2009, POSTEP HIG MED DOSW, V63, P340; Rahman MM, 2003, P NATL ACAD SCI USA, V100, P5124, DOI 10.1073/pnas.0530097100; SCHIMENTI KJ, 1992, CYTOMETRY, V13, P48, DOI 10.1002/cyto.990130109; Shibanuma M, 2004, J CELL BIOCHEM, V91, P633, DOI 10.1002/jcb.10754; Shibanuma M, 2003, MOL BIOL CELL, V14, P1158, DOI 10.1091/mbc.02-06-0099; Shibanuma M, 1997, MOL CELL BIOL, V17, P1224, DOI 10.1128/MCB.17.3.1224; Song K, 2003, CANCER RES, V63, P4358; Terada N, 2010, CANCER RES, V70, P1606, DOI 10.1158/0008-5472.CAN-09-2984; Thomas SM, 1999, J CELL SCI, V112, P181; Trousse F, 2001, J NEUROSCI, V21, P1292; Tumbarello DA, 2007, J CELL PHYSIOL, V211, P736, DOI 10.1002/jcp.20991; Wahdan-Alaswad RS, 2010, CANCER RES, V70, P9106, DOI 10.1158/0008-5472.CAN-10-1119; Wang H, 2005, J BIOL CHEM, V280, P5154, DOI 10.1074/jbc.M411575200; Wang H, 2008, ONCOGENE, V27, P6791, DOI 10.1038/onc.2008.291; Wong WT, 2010, CIRC RES, V107, P984, DOI 10.1161/CIRCRESAHA.110.222794; Yang J, 2008, ONCOGENE, V27, P5326, DOI 10.1038/onc.2008.165; Ye L, 2007, J UROLOGY, V178, P1086, DOI 10.1016/j.juro.2007.05.003; Yeh Shuyuan, 1999, Keio Journal of Medicine, V48, P87; Yoshida T, 2005, CANCER RES, V65, P9611, DOI 10.1158/0008-5472.CAN-05-0817	48	17	17	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2012	31	19					2480	2490		10.1038/onc.2011.422	http://dx.doi.org/10.1038/onc.2011.422			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	941SP	21996749	Green Accepted			2022-12-17	WOS:000303985300010
J	Levav-Cohen, Y; Wolyniec, K; Alsheich-Bartok, O; Chan, AL; Woods, SJ; Jiang, YH; Haupt, S; Haupt, Y				Levav-Cohen, Y.; Wolyniec, K.; Alsheich-Bartok, O.; Chan, A-L; Woods, S. J.; Jiang, Y-H; Haupt, S.; Haupt, Y.			E6AP is required for replicative and oncogene-induced senescence in mouse embryo fibroblasts	ONCOGENE			English	Article						E6AP; cellular senescence; stress; p53; Ras	UBIQUITIN-PROTEIN LIGASE; HUMAN-PAPILLOMAVIRUS TYPE-16; CELLULAR SENESCENCE; TUMOR SUPPRESSION; G(1) CONTROL; P53; GROWTH; CELLS; ANGELMAN; E6-AP	Cellular senescence is important for the maintenance of tissue homeostasis, and has recently been shown to pose a natural barrier to tumorigenesis. The E3 ubiquitin ligase, E6AP, has been linked to a number of protein regulators of the cell cycle as well as the cellular stress response. We therefore explored the role of E6AP in the cellular response to stress. We found that mouse embryo fibroblasts (MEFs) lacking E6AP escape replicative senescence, as well as Ras-induced senescence associated with impaired markers. E6AP-deficient MEFs exhibit a range of transformed phenotypes: these include the ability to grow under stress conditions (such as low serum and DNA damage), enhanced proliferation, anchorage independent growth and enhanced growth of xenografts in mice. The transformed phenotype of E6AP-deficient MEFs is associated with lower basal and stress-induced accumulation of p53. Overall, our study implicates E6AP as an important regulator of the cellular response to stress, in particular through the regulation of replicative and oncogene-induced senescence. Oncogene (2012) 31, 2199-2209; doi:10.1038/onc.2011.402; published online 19 September 2011	[Wolyniec, K.; Chan, A-L; Woods, S. J.; Haupt, S.; Haupt, Y.] Peter MacCallum Canc Ctr, Div Res, Melbourne, Vic 3002, Australia; [Levav-Cohen, Y.; Alsheich-Bartok, O.] Hebrew Univ Jerusalem, Hadassah Med Sch, Lautenberg Ctr Gen & Tumor Immunol, IL-91010 Jerusalem, Israel; [Jiang, Y-H] Duke Univ, Sch Med, Dept Pediat & Neurobiol, Div Med Genet, Durham, NC USA	Peter Maccallum Cancer Center; Hebrew University of Jerusalem; Duke University	Haupt, Y (corresponding author), Peter MacCallum Canc Ctr, Div Res, St Andrews Pl, Melbourne, Vic 3002, Australia.	ygal.haupt@petermac.org		Haupt, Ygal/0000-0001-5925-0096; Chan, Ai-Leen/0000-0003-3553-7249	NHMRC [509196]; Cancer Council Victoria; VESKI; European commission [503576]	NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Cancer Council Victoria(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria); VESKI; European commission(European CommissionEuropean Commission Joint Research Centre)	We express our thanks to Scott Lowe and Martin Scheffner for the generous gifts of expression plasmids, and to Mariam Mansour for critical comments on the manuscript. Work in the authors laboratory is supported by an NHMRC project grant (grant No. 509196), by a grant from the Cancer Council Victoria, by the VESKI award and by the EC FP6 funding of the European commission (contract 503576). This publication reflects only the authors' views. The European commission is not liable for any use that may be made of the information herein.	Bar-Or RL, 2000, P NATL ACAD SCI USA, V97, P11250, DOI 10.1073/pnas.210171597; Bardeesy N, 2002, NATURE, V419, P162, DOI 10.1038/nature01045; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Beaudenon S, 2008, BMC BIOCHEM, V9, DOI 10.1186/1471-2091-9-S1-S4; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Campisi J, 2005, CELL, V120, P513, DOI 10.1016/j.cell.2005.02.003; Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233; Ciechanover A, 2006, NEUROLOGY, V66, pS7, DOI 10.1212/01.wnl.0000192261.02023.b8; Collado M, 2006, NAT REV CANCER, V6, P472, DOI 10.1038/nrc1884; Collado M, 2010, NAT REV CANCER, V10, P51, DOI 10.1038/nrc2772; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; Di Micco R, 2008, CELL CYCLE, V7, P3601, DOI 10.4161/cc.7.22.7152; Di Micco R, 2007, TRENDS CELL BIOL, V17, P529, DOI 10.1016/j.tcb.2007.07.012; Dimri GP, 2005, CANCER CELL, V7, P505, DOI 10.1016/j.ccr.2005.05.025; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Ferbeyre G, 2002, MOL CELL BIOL, V22, P3497, DOI 10.1128/MCB.22.10.3497-3508.2002; Frank KM, 2000, MOL CELL, V5, P993, DOI 10.1016/S1097-2765(00)80264-6; Gil J, 2006, NAT REV MOL CELL BIO, V7, P667, DOI 10.1038/nrm1987; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; HARVEY M, 1993, FASEB J, V7, P938, DOI 10.1096/fasebj.7.10.8344491; Haupt S, 2009, CANCER RES, V69, P4818, DOI 10.1158/0008-5472.CAN-08-4010; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; Howley Peter M, 2006, Trans Am Clin Climatol Assoc, V117, P113; Howley PM., 2006, T AM CLIN CLIMAT ASS, V117, P126; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; Jiang YH, 1998, NEURON, V21, P799, DOI 10.1016/S0896-6273(00)80596-6; Jiang YH, 1998, CURR OPIN GENET DEV, V8, P334, DOI 10.1016/S0959-437X(98)80091-9; Khan OY, 2006, MOL ENDOCRINOL, V20, P544, DOI 10.1210/me.2005-0110; Kortlever RM, 2006, NAT CELL BIOL, V8, P877, DOI 10.1038/ncb1448; Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610; Lahav G, 2004, NAT GENET, V36, P147, DOI 10.1038/ng1293; Longworth MS, 2004, MICROBIOL MOL BIOL R, V68, P362, DOI 10.1128/MMBR.68.2.362-372.2004; Louria-Hayon I, 2009, CELL DEATH DIFFER, V16, P1156, DOI 10.1038/cdd.2009.31; Maezawa Y, 2006, DIABETES-METAB RES, V22, P313, DOI 10.1002/dmrr.612; Matentzoglu K, 2008, BIOCHEM SOC T, V36, P797, DOI 10.1042/BST0360797; Matsuura T, 1997, NAT GENET, V15, P74, DOI 10.1038/ng0197-74; Mishra A, 2008, CELL MOL LIFE SCI, V65, P656, DOI 10.1007/s00018-007-7476-1; Mishra A, 2009, NEUROBIOL DIS, V36, P26, DOI 10.1016/j.nbd.2009.06.010; MU XC, 1995, J CELL PHYSIOL, V165, P647, DOI 10.1002/jcp.1041650324; Papazoglu C, 2007, J PATHOL, V211, P124, DOI 10.1002/path.2086; Parrinello S, 2003, NAT CELL BIOL, V5, P741, DOI 10.1038/ncb1024; Rodier F, 2007, NUCLEIC ACIDS RES, V35, P7475, DOI 10.1093/nar/gkm744; Rodier F, 2009, NAT CELL BIOL, V11, P973, DOI 10.1038/ncb1909; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sherman M, 2007, FEBS LETT, V581, P3711, DOI 10.1016/j.febslet.2007.05.036; Sherr CJ, 2000, CELL, V102, P407, DOI 10.1016/S0092-8674(00)00046-5; SMITH JR, 1984, INT REV CYTOL, V89, P151, DOI 10.1016/S0074-7696(08)61303-0; Talis AL, 1998, J BIOL CHEM, V273, P6439, DOI 10.1074/jbc.273.11.6439; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; Wolyniec K, 2009, ONCOGENE, V28, P2502, DOI 10.1038/onc.2009.101; Zuckerman V, 2009, J PATHOL, V219, P3, DOI 10.1002/path.2584; Zufferey R, 1998, J VIROL, V72, P9873, DOI 10.1128/JVI.72.12.9873-9880.1998	57	17	17	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2012	31	17					2199	2209		10.1038/onc.2011.402	http://dx.doi.org/10.1038/onc.2011.402			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	934BS	21927031				2022-12-17	WOS:000303415900008
J	Damiano, L; Le Devedec, SE; Di Stefano, P; Repetto, D; Lalai, R; Truong, H; Xiong, JL; Danen, EH; Yan, K; Verbeek, FJ; De Luca, E; Attanasio, F; Buccione, R; Turco, E; van de Water, B; Defilippi, P				Damiano, L.; Le Devedec, S. E.; Di Stefano, P.; Repetto, D.; Lalai, R.; Truong, H.; Xiong, J. L.; Danen, E. H.; Yan, K.; Verbeek, F. J.; De Luca, E.; Attanasio, F.; Buccione, R.; Turco, E.; van de Water, B.; Defilippi, P.			p140Cap suppresses the invasive properties of highly metastatic MTLn3-EGFR cells via impaired cortactin phosphorylation	ONCOGENE			English	Article						p140Cap; cortactin; tumor invasion; metastasis; breast cancer	ACTIN; DYNAMICS; INVADOPODIA; DEGRADATION; MOTILITY; SITES	We have recently shown that the adaptor protein p140Cap regulates tumor properties in terms of cell motility and growth. Here, by using the highly metastatic rat adenocarcinoma cell line MTLn3-epidermal growth factor receptor (EGFR), we assess the role of p140Cap in metastasis formation. Orthotopic transplantation of MTLn3-EGFR cells over-expressing p140Cap in Rag2(-/-)gamma(-/-)(c) mice resulted in normal primary tumor growth compared with the controls. Strikingly, p140Cap over-expression causes an 80% inhibition in the number of lung metastases. p140Cap over-expressing cells display a 50% reduction in directional cell migration, an increased number and size of focal adhesions, and a strong impairment in the ability to invade in a 3D matrix. p140Cap overexpression affects EGFR signaling and tyrosine phosphorylation of cortactin in response to EGF stimulation. Intriguingly, p140Cap associates with cortactin via interaction with its second proline-rich domain to the cortactin SH3 domain. The phosphomimetic cortactin tyrosine 421 mutant rescues migration and invasive properties in p140Cap over-expressing cells. Taken together, these data demonstrate that p140Cap suppresses the invasive properties of highly metastatic breast carcinoma cells by inhibiting cortactin-dependent cell motility. Oncogene (2012) 31, 624-633; doi:10.1038/onc.2011.257; published online 4 July 2011	[Le Devedec, S. E.; Lalai, R.; Truong, H.; Xiong, J. L.; Danen, E. H.; van de Water, B.] Leiden Univ, LACDR, Div Toxicol, Leiden, Netherlands; [Damiano, L.; Di Stefano, P.; Repetto, D.; De Luca, E.; Turco, E.; Defilippi, P.] Univ Turin, Dept Genet Biol & Biochem, Mol Biotechnol Ctr, I-10126 Turin, Italy; [Yan, K.; Verbeek, F. J.] Leiden Univ, Leiden Inst Adv Comp Sci, Leiden, Netherlands; [Attanasio, F.; Buccione, R.] Consorzio Mario Negri Sud, Tumour Cell Invas Lab, Chieti, Italy	Leiden University; Leiden University - Excl LUMC; University of Turin; Leiden University; Leiden University - Excl LUMC; Consorzio Mario Negri Sud	van de Water, B (corresponding author), Leiden Univ, LACDR, Div Toxicol, Leiden, Netherlands.	paola.defilippi@unito.it	DEFILIPPI, Paola/L-2232-2014; De Luca, Elisa/L-2491-2017	De Luca, Elisa/0000-0001-9849-0703; Le Devedec, Sylvia/0000-0002-0615-9616; Yan, Kuan/0000-0003-4143-3569; Defilippi, Paola/0000-0001-6427-4906; danen, erik/0000-0002-0491-6345; Buccione, Roberto/0000-0001-9210-5261	EU; AIRC; MUR (PRIN); Regione Piemonte - Progetti Sanita; Oncoprot; PiSTEM; Druidi; CIPE, Compagnia San Paolo, Torino; Dutch Cancer Society [UL 2006-3521, UL 2007-3860, UL 2010-4670]; Netherlands Genomics Initiative	EU; AIRC; MUR (PRIN); Regione Piemonte - Progetti Sanita; Oncoprot; PiSTEM; Druidi; CIPE, Compagnia San Paolo, Torino; Dutch Cancer Society; Netherlands Genomics Initiative	We thank Stefan Huveneers for help with the in vitro angiogenesis assay. This work was supported by EU FP7 Metafight project, AIRC, MUR (PRIN), Regione Piemonte - Progetti Sanita, Oncoprot, PiSTEM, Druidi and CIPE, Compagnia San Paolo, Torino, the Dutch Cancer Society (UL 2006-3521, UL 2007-3860 and UL 2010-4670) and the Netherlands Genomics Initiative grant to the Netherlands Toxicogenomics Center grant.	Ayala I, 2008, J CELL SCI, V121, P369, DOI 10.1242/jcs.008037; Baldassarre M, 2006, EUR J CELL BIOL, V85, P1217, DOI 10.1016/j.ejcb.2006.08.003; Bowden ET, 2001, METHOD CELL BIOL, V63, P613; Buccione R, 2009, CANCER METAST REV, V28, P137, DOI 10.1007/s10555-008-9176-1; Cabodi S, 2010, NAT REV CANCER, V10, P858, DOI 10.1038/nrc2967; Chin LS, 2000, J BIOL CHEM, V275, P1191, DOI 10.1074/jbc.275.2.1191; Citri A, 2006, NAT REV MOL CELL BIO, V7, P505, DOI 10.1038/nrm1962; Condeelis J, 2003, NAT REV CANCER, V3, P921, DOI 10.1038/nrc1231; Damiano L, 2010, ONCOGENE, V29, P3677, DOI 10.1038/onc.2010.128; Di Stefano P, 2004, MOL BIOL CELL, V15, P787, DOI 10.1091/mbc.E03-09-0689; Di Stefano P, 2007, EMBO J, V26, P2843, DOI 10.1038/sj.emboj.7601724; Gardel ML, 2010, ANNU REV CELL DEV BI, V26, P315, DOI 10.1146/annurev.cellbio.011209.122036; Head JA, 2003, MOL BIOL CELL, V14, P3216, DOI 10.1091/mbc.e02-11-0753; ILLC D, 1995, NATURE, V377, P539; Jaworski J, 2009, NEURON, V61, P85, DOI 10.1016/j.neuron.2008.11.013; Le Devedec SE, 2009, CLIN EXP METASTAS, V26, P673, DOI 10.1007/s10585-009-9267-6; Li YS, 2001, CANCER RES, V61, P6906; Lim ST, 2008, CELL CYCLE, V7, P2306, DOI 10.4161/cc.6367; Lorenz M, 2004, CELL MOTIL CYTOSKEL, V57, P207, DOI 10.1002/cm.10171; Lua BL, 2005, FEBS LETT, V579, P577, DOI 10.1016/j.febslet.2004.12.055; Mader CC, 2011, CANCER RES, V71, P1730, DOI 10.1158/0008-5472.CAN-10-1432; Marxfeld H, 2006, EXP TOXICOL PATHOL, V58, P133, DOI 10.1016/j.etp.2006.05.003; Mori S, 2009, ONCOGENE, V28, P2796, DOI 10.1038/onc.2009.139; NERI A, 1981, INT J CANCER, V28, P731, DOI 10.1002/ijc.2910280612; Normanno N, 2006, GENE, V366, P2, DOI 10.1016/j.gene.2005.10.018; Oser M, 2009, J CELL BIOL, V186, P571, DOI 10.1083/jcb.200812176; Sahai E, 2007, NAT REV CANCER, V7, P737, DOI 10.1038/nrc2229; Vicente-Manzanares M, 2005, J CELL SCI, V118, DOI 10.1242/jcs.02662; Weaver AM, 2008, CANCER LETT, V265, P157, DOI 10.1016/j.canlet.2008.02.066; Webb Donna J., 2004, V294, P3; Weed SA, 2000, J CELL BIOL, V151, P29, DOI 10.1083/jcb.151.1.29; Wolfenson H, 2009, CELL MOTIL CYTOSKEL, V66, P1017, DOI 10.1002/cm.20410; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; Xue CS, 2006, CANCER RES, V66, P192, DOI 10.1158/0008-5472.CAN-05-1242	35	17	17	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2012	31	5					624	633		10.1038/onc.2011.257	http://dx.doi.org/10.1038/onc.2011.257			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891MS	21725361				2022-12-17	WOS:000300221800008
J	Thobe, MN; Gray, JK; Gurusamy, D; Paluch, AM; Wagh, PK; Pathrose, P; Lentsch, AB; Waltz, SE				Thobe, M. N.; Gray, J. K.; Gurusamy, D.; Paluch, A. M.; Wagh, P. K.; Pathrose, P.; Lentsch, A. B.; Waltz, S. E.			The Ron receptor promotes prostate tumor growth in the TRAMP mouse model	ONCOGENE			English	Article						Ron receptor; hepatoctye growth factor-like protein; prostate cancer; MST1R; receptor tyrosine kinase	TYROSINE KINASE RON; NF-KAPPA-B; TRANSGENIC MOUSE; CANCER CELLS; MURINE MODEL; BETA-CATENIN; MET FAMILY; FACTOR-I; OVEREXPRESSION; ACTIVATION	The Ron receptor tyrosine kinase (TK) is overexpressed in many cancers, including prostate cancer. To examine the significance of Ron in prostate cancer in vivo, we utilized a genetically engineered mouse model, referred to as TRAMP mice, that is predisposed to develop prostate tumors. In this model, we show that prostate tumors from 30-week-old TRAMP mice have increased Ron expression compared with age-matched wild-type prostates. Based on the upregulation of Ron in human prostate cancers and in this murine model of prostate tumorigenesis, we hypothesized that this receptor has a functional role in the development of prostate tumors. To test this hypothesis, we crossed TRAMP mice with mice that are deficient in Ron signaling (TK-/-). Interestingly, TK-/- TRAMP+ mice show a significant decrease in prostate tumor mass relative to TRAMP mice containing functional Ron. Moreover, TK-/- TRAMP+ prostate tumors exhibited decreased tumor vascularization relative to TK+/+ TRAMP+ prostate tumors, which correlated with reduced levels of the angiogenic molecules vascular endothelial growth factor and CXCL2. Although Ron loss did not alter tumor cell proliferation, a significant decrease in cell survival was observed. Similarly, murine prostate cancer cell lines containing a Ron deficiency exhibited decreased levels of active nuclear factor-kappa B, suggesting that Ron may be important in regulating prostate cell survival at least partly through this pathway. In total, our data show for the first time that Ron promotes prostate tumor growth, prostate tumor angiogenesis and prostate cancer cell survival in vivo. Oncogene (2011) 30, 4990-4998; doi:10.1038/onc.2011.205; published online 30 May 2011	[Thobe, M. N.; Gray, J. K.; Gurusamy, D.; Paluch, A. M.; Wagh, P. K.; Pathrose, P.; Waltz, S. E.] Univ Cincinnati, Coll Med, Dept Canc & Cell Biol, Cincinnati, OH 45267 USA; [Lentsch, A. B.] Univ Cincinnati, Coll Med, Dept Surg, Cincinnati, OH 45267 USA; [Waltz, S. E.] Cincinnati Vet Affairs Med Ctr, Cincinnati, OH USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; US Department of Veterans Affairs; Veterans Health Administration (VHA); Cincinnati VA Medical Center	Waltz, SE (corresponding author), Univ Cincinnati, Coll Med, Dept Canc & Cell Biol, Vontz Bldg Mol Studies,3125 Eden Ave, Cincinnati, OH 45267 USA.	susan.waltz@uc.edu	Gurusamy, Devikala/T-3410-2019	Gurusamy, Devikala/0000-0002-1727-8653; Waltz, Susan/0000-0003-3572-4642	National Institutes of Health [CA-125379]; Department of Defense [PC060821]; NATIONAL CANCER INSTITUTE [R01CA125379] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Sandy Schwemberger for her assistance with the flow cytometry experiments as well as Gina Ciovacco for her technical contributions. This work was supported by Public Health Services Grant CA-125379 (SEW) from the National Institutes of Health, and by Grant Project No. PC060821 (MNT) from the Department of Defense Congressionally Directed Medical Research Program.	Agus DB, 1999, CANCER RES, V59, P4761; Becker CM, 2002, CANCER BIOL THER, V1, P548, DOI 10.4161/cbt.1.5.176; Chan EL, 2005, ONCOGENE, V24, P479, DOI 10.1038/sj.onc.1208231; Chen YQ, 2000, EXP CELL RES, V261, P229, DOI 10.1006/excr.2000.5012; Chen YQ, 2002, ONCOGENE, V21, P6382, DOI 10.1038/sj.onc.1205783; de Bono JS, 2007, CLIN CANCER RES, V13, P3611, DOI 10.1158/1078-0432.CCR-07-0268; Dhanasekaran SM, 2004, FASEB J, V18, P243, DOI 10.1096/fj.04-2415fje; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; Gingrich JR, 1996, CANCER RES, V56, P4096; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; Iwama A, 1996, EMBO J, V15, P5866, DOI 10.1002/j.1460-2075.1996.tb00973.x; Kassis J, 1999, CLIN CANCER RES, V5, P2251; Kojima S, 2009, INT J UROL, V16, P161, DOI 10.1111/j.1442-2042.2008.02224.x; Lapointe J, 2007, CANCER RES, V67, P8504, DOI 10.1158/0008-5472.CAN-07-0673; Leonis NA, 2002, HEPATOLOGY, V36, P1053, DOI 10.1053/jhep.2002.36822; Logan-Collins J, 2010, CANCER RES, V70, P1130, DOI 10.1158/0008-5472.CAN-09-0761; Maggiora P, 1998, ONCOGENE, V16, P2927, DOI 10.1038/sj.onc.1201812; Mallakin A, 2006, AM J RESP CELL MOL, V34, P15, DOI 10.1165/rcmb.2005-0093OC; Meyer SE, 2009, DEV BIOL, V333, P173, DOI 10.1016/j.ydbio.2009.06.028; Meyer SE, 2009, MOL CARCINOGEN, V48, P995, DOI 10.1002/mc.20551; O'Toole JM, 2006, CANCER RES, V66, P9162, DOI 10.1158/0008-5472.CAN-06-0283; Peace BE, 2005, CANCER RES, V65, P1285, DOI 10.1158/0008-5472.CAN-03-3580; RONSIN C, 1993, ONCOGENE, V8, P1195; Shen H, 2004, AM J PHYSIOL-CELL PH, V286, pC840, DOI 10.1152/ajpcell.00335.2003; Shen H, 2006, PROSTATE, V66, P1721, DOI 10.1002/pros.20476; Shukla S, 2005, PROSTATE, V64, P224, DOI 10.1002/pros.20217; Thobe MN, 2010, ONCOGENE, V29, P214, DOI 10.1038/onc.2009.331; Thomas RM, 2007, CANCER RES, V67, P6075, DOI 10.1158/0008-5472.CAN-06-4128; Vicentini C, 2003, J CANCER RES CLIN, V129, P165, DOI 10.1007/s00432-003-0420-3; Wagh PK, 2011, ONCOGENE, V30, P3694, DOI 10.1038/onc.2011.86; Wagh PK, 2008, ADV CANCER RES, V100, P1, DOI 10.1016/S0065-230X(08)00001-8; Waltz SE, 2001, J CLIN INVEST, V108, P567, DOI 10.1172/JCI200111881; Wang Jun, 2007, J Carcinog, V6, P3, DOI 10.1186/1477-3163-6-3; Wilson CB, 2008, J IMMUNOL, V181, P2303, DOI 10.4049/jimmunol.181.4.2303; Zinser GM, 2006, CANCER RES, V66, P11967, DOI 10.1158/0008-5472.CAN-06-2473	35	17	17	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2011	30	50					4990	4998		10.1038/onc.2011.205	http://dx.doi.org/10.1038/onc.2011.205			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865YJ	21625214	Green Accepted			2022-12-17	WOS:000298346500007
J	Nishikata, I; Nakahata, S; Saito, Y; Kaneda, K; Ichihara, E; Yamakawa, N; Morishita, K				Nishikata, I.; Nakahata, S.; Saito, Y.; Kaneda, K.; Ichihara, E.; Yamakawa, N.; Morishita, K.			Sumoylation of MEL1S at lysine 568 and its interaction with CtBP facilitates its repressor activity and the blockade of G-CSF-induced myeloid differentiation	ONCOGENE			English	Article						MEL1; sumoylation; CtBP; G-CSF	TERMINAL BINDING-PROTEINS; CELL-LINE 32D; TRANSCRIPTIONAL REPRESSION; SUMO MODIFICATION; GENE FAMILY; LEUKEMOGENESIS; COMPLEX; BROWN; T(1-3)(P36-Q21); DISORDERS	MEL1 (MDS1/EVI1-like gene 1/PRDM16), which was identified as a gene near the chromosomal breakpoint in t(1;3)(p36;q21)-positive human acute myeloid leukemia cells, belongs to the (P) under bar RDI-BF1-(R) under bar IZ1 homologous (PR) domain (PRDM) family of transcription repressors. The short form of MEL1 (MEL1S), which lacks the PR-domain at the N-terminus, is the main form expressed in t(1; 3)(p36; q21)-positive acute myeloid leukemia cells. The overexpression of MEL1S blocks granulocyte colony-stimulating factor (G-CSF)-induced myeloid differentiation in interleukin-3-dependent murine myeloid L-G3 cells. In this study, we show that treatment with the histone deacetylase inhibitor trichostatin A abolished the blockade of myeloid differentiation in L-G3 cells over-expressing MEL1S. The expression of MEL1S containing mutated CtBP-interacting motif (CIM) in L-G3 cells still blocked the myeloid differentiation induced by G-CSF. We found that the small ubiquitin-related modifier (SUMO) motif (SM) at lysine 568 (V (K) under bar AE) adjacent to the CIM was necessary to obtain the maximum transcriptional repressor activity of MEL1S. L-G3 cells expressing MEL1S, and bearing mutated CIM and SM differentiated into granulocytes in response to G-CSF; this indicated that both the SUMO modification at lysine 568 and CtBP binding were required for MEL1S-mediated transcriptional repression and blockade of differentiation, which might be relevant for the process of leukemogenesis. Oncogene (2011) 30, 4194-4207; doi:10.1038/onc.2011.132; published online 25 April 2011	[Nishikata, I.; Nakahata, S.; Saito, Y.; Kaneda, K.; Ichihara, E.; Yamakawa, N.; Morishita, K.] Miyazaki Univ, Fac Med, Dept Med Sci, Div Tumor & Cellular Biochem, Miyazaki 8891692, Japan	University of Miyazaki	Morishita, K (corresponding author), Miyazaki Univ, Fac Med, Dept Med Sci, Div Tumor & Cellular Biochem, 5200 Kihara, Miyazaki 8891692, Japan.	kmorishi@med.miyazaki-u.ac.jp	Kaneda-Nakashima, Kazuko/GZM-6591-2022	Kaneda-Nakashima, Kazuko/0000-0001-6657-5059	Ministry of Education, Culture, Sports, Science and Technology in Japan	Ministry of Education, Culture, Sports, Science and Technology in Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This work was supported in part by Grants-in-Aid for Scientific Research of Priority Area from the Ministry of Education, Culture, Sports, Science and Technology in Japan.	BLOOMFIELD CD, 1985, BLOOD, V66, P1409; Chinnadurai G, 2007, INT J BIOCHEM CELL B, V39, P1593, DOI 10.1016/j.biocel.2007.01.025; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; FRIEDMAN AD, 1991, BLOOD, V78, P2426; Giorgino F, 2000, P NATL ACAD SCI USA, V97, P1125, DOI 10.1073/pnas.97.3.1125; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; Izutsu K, 2001, BLOOD, V97, P2815, DOI 10.1182/blood.V97.9.2815; Kagey MH, 2003, CELL, V113, P127, DOI 10.1016/S0092-8674(03)00159-4; Kajimura S, 2008, GENE DEV, V22, P1397, DOI 10.1101/gad.1666108; Kajimura S, 2009, NATURE, V460, P1154, DOI 10.1038/nature08262; KINASHI T, 1991, J EXP MED, V173, P1267, DOI 10.1084/jem.173.5.1267; Kuppuswamy M, 2008, MOL CELL BIOL, V28, P269, DOI 10.1128/MCB.01077-07; Long JY, 2005, J BIOL CHEM, V280, P35477, DOI 10.1074/jbc.M504477200; Maki K, 2008, CANCER SCI, V99, P1878, DOI 10.1111/j.1349-7006.2008.00956.x; MIGLIACCIO G, 1989, J CELL BIOL, V109, P833, DOI 10.1083/jcb.109.2.833; Mitani K, 2004, ONCOGENE, V23, P4263, DOI 10.1038/sj.onc.1207777; Mochizuki N, 2000, BLOOD, V96, P3209, DOI 10.1182/blood.V96.9.3209.h8003209_3209_3214; MOIR DJ, 1984, BLOOD, V64, P553; Morishita K, 2007, INT J HEMATOL, V85, P279, DOI 10.1532/IJH97.06174; Morita Y, 2005, MOL BIOL CELL, V16, P5433, DOI 10.1091/mbc.E05-08-0731; Nishikata I, 2003, BLOOD, V102, P3323, DOI 10.1182/blood-2002-12-3944; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Perdomo J, 2005, MOL CELL BIOL, V25, P1549, DOI 10.1128/MCB.25.4.1549-1559.2005; Quinlan KGR, 2006, MOL CELL BIOL, V26, P8159, DOI 10.1128/MCB.00680-06; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; Seale P, 2008, NATURE, V454, P961, DOI 10.1038/nature07182; Shimahara A, 2010, J BIOL CHEM, V285, P16967, DOI 10.1074/jbc.M110.102046; Shimizu S, 2000, GENE CHROMOSOME CANC, V27, P229, DOI 10.1002/(SICI)1098-2264(200003)27:3<229::AID-GCC2>3.0.CO;2-0; Tillmanns S, 2007, MOL CELL BIOL, V27, P5554, DOI 10.1128/MCB.01811-06; Turner J, 1998, EMBO J, V17, P5129, DOI 10.1093/emboj/17.17.5129; WELBORN JL, 1987, CANCER GENET CYTOGEN, V28, P277, DOI 10.1016/0165-4608(87)90214-7	33	17	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2011	30	40					4194	4207		10.1038/onc.2011.132	http://dx.doi.org/10.1038/onc.2011.132			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	833ZK	21516122				2022-12-17	WOS:000295924600006
J	Ketchart, W; Ogba, N; Kresak, A; Albert, JM; Pink, JJ; Montano, MM				Ketchart, W.; Ogba, N.; Kresak, A.; Albert, J. M.; Pink, J. J.; Montano, M. M.			HEXIM1 is a critical determinant of the response to tamoxifen	ONCOGENE			English	Article						estrogen receptor; tamoxifen; HEXIM1; breast cancer	BREAST CELL-GROWTH; CYCLIN D1; P-TEFB; RESISTANCE; MECHANISMS; CANCER; DISEASE; EXPRESSION; INHIBITOR; RECEPTORS	Tamoxifen resistance is a major problem in the treatment of estrogen receptor (ER)-positive patients. We have previously reported that hexamethylene bis-acetamide-inducible protein 1 (HEXIM1) inhibits ER alpha activity by competing with ER alpha for binding to cyclin T1, a subunit of positive transcription elongation b (P-TEFb). This results in the inhibition of the phosphorylation of RNA polymerase II (RNAPII) at serine 2 and the inhibition of transcription elongation of ER alpha target genes. As HEXIM1 can inhibit ER activity, we examined whether it has a critical role in the inhibitory effects of tamoxifen on ER. We observed that tamoxifen-induced HEXIM1 recruitment to the promoter region of ER target genes and decreased the recruitment of cyclin T1 and serine 2 phosphorylated RNAPII to the coding regions of these genes. Conversely, in cells wherein HEXIM1 expression has been downregulated we observed attenuation of the inhibitory effects of tamoxifen on estrogen-induced cyclin T1 recruitment to coding regions of ER target genes. As a consequence, downregulation of HEXIM1 resulted in the attenuation of the repressive effects of tamoxifen on estrogen-induced gene expression and proliferation. Conferring clinical relevance to our studies is our analysis of human breast cancer tissue samples that indicated association of lower expression of HEXIM1 with tumor recurrence in patients who received tamoxifen. Our studies provide a better understanding of the mechanistic basis for the inhibitory effect of tamoxifen on ER activity and may suggest new therapeutic targets for the treatment of tamoxifen-resistant breast cancer. Oncogene (2011) 30, 3563-3569; doi:10.1038/onc.2011.76; published online 21 March 2011	[Montano, M. M.] Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA; [Kresak, A.] Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA; [Albert, J. M.] Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA; [Pink, J. J.] Case Western Reserve Univ, Div Gen Med Sci Oncol Case Comprehens Canc Ctr, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Montano, MM (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pharmacol, HG Wood Bldg W305,2109 Adelbert Rd, Cleveland, OH 44106 USA.	mxm126@case.edu	Albert, Jeffrey/P-7273-2019; Ogba, Ndiya/K-8429-2014	Albert, Jeffrey/0000-0003-2245-1745; Ogba, Ndiya/0000-0003-0453-3763	National Institute of Health [CA92440]; American Cancer Society [RSG CCE-110689]; NATIONAL CANCER INSTITUTE [R01CA092440] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Wei Wang (CWRU Department of Epidemiology and Biostatistics) for help with construction of graphs representing the relationship between disease recurrence and expressions levels of HEXIM1 in breast tissue. This work was supported by National Institute of Health grant CA92440 to MMM and American Cancer Society grant RSG CCE-110689 to J.J.P.	Anderson H, 2007, J STEROID BIOCHEM, V106, P49, DOI 10.1016/j.jsbmb.2007.05.024; Cleator SJ, 2009, CLIN BREAST CANCER, V9, pS6, DOI 10.3816/CBC.2009.s.001; Deroo BJ, 2006, J CLIN INVEST, V116, P561, DOI 10.1172/JCI27987; Gruber CJ, 2002, NEW ENGL J MED, V346, P340, DOI 10.1056/NEJMra000471; HURVITZ SA, 2008, CANCER, V9, P2385; Kusuhara M, 1999, BIOMED RES-TOKYO, V20, P273, DOI 10.2220/biomedres.20.273; Lahusen T, 2009, BREAST CANCER RES TR, V116, P225, DOI 10.1007/s10549-009-0405-2; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; Lewis JS, 2005, MUTAT RES-FUND MOL M, V591, P247, DOI 10.1016/j.mrfmmm.2005.02.028; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MUSGROVE EA, 1994, SEMIN CANCER BIOL, V5, P381; Ogba N, 2008, CANCER RES, V68, P7015, DOI 10.1158/0008-5472.CAN-08-0814; Osborne CK, 1998, NEW ENGL J MED, V339, P1609, DOI 10.1056/NEJM199811263392207; Riggins RB, 2007, CANCER LETT, V256, P1, DOI 10.1016/j.canlet.2007.03.016; Ring A, 2004, ENDOCR-RELAT CANCER, V11, P643, DOI 10.1677/erc.1.00776; Scott DJ, 2007, INT J ONCOL, V31, P557; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Webb P, 2003, J BIOL CHEM, V278, P6912, DOI 10.1074/jbc.M208501200; Wittmann BM, 2005, ONCOGENE, V24, P5576, DOI 10.1038/sj.onc.1208728; Wittmann BM, 2003, CANCER RES, V63, P5151; Yager JD, 2006, NEW ENGL J MED, V354, P270, DOI 10.1056/NEJMra050776; Yik JHN, 2003, MOL CELL, V12, P971, DOI 10.1016/S1097-2765(03)00388-5; Zwart W, 2009, MOL ENDOCRINOL, V23, P1335, DOI 10.1210/me.2008-0268	23	17	17	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2011	30	33					3563	3569		10.1038/onc.2011.76	http://dx.doi.org/10.1038/onc.2011.76			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	808UL	21423213	Green Accepted			2022-12-17	WOS:000294005100001
J	Suo, J; Snider, SJ; Mills, GB; Creighton, CJ; Chen, AC; Schiff, R; Lloyd, RE; Chang, EC				Suo, J.; Snider, S. J.; Mills, G. B.; Creighton, C. J.; Chen, A. C.; Schiff, R.; Lloyd, R. E.; Chang, E. C.			Int6 regulates both proteasomal degradation and translation initiation and is critical for proper formation of acini by human mammary epithelium	ONCOGENE			English	Article						eIF3; translation; ubiquitin; proteasomes; tumor suppressor	FISSION YEAST HOMOLOG; BREAST-CANCER; TUMOR VIRUS; STEM-CELLS; PROTEIN; GENE; RESISTANCE; EXPRESSION; COMPLEXES; SUBUNIT	INT6/EIF3E has been implicated in breast tumorigenesis, but its functional activities remain poorly defined. We found that, repressing INT6 expression induced transformed properties in normal human mammary epithelium (MCF10A); in contrast, Int6 silencing induced apoptosis in HeLa cells. As in fission yeast, Int6 in human cells was required for assembly of active proteasomes. A reverse-phase protein array screen identified SRC3/AIB1 as one oncoprotein the level and stability of which increased when Int6 was silenced in MCF10A cells. Our data further show that Int6 binds SRC3 and its ubiquitin ligase Fbw7, thus perhaps mediating the interaction between SRC3-Fbw7 and proteasomes. Consistent with this, Int6 silencing did not increase SRC3 levels in HeLa cells, which have low Fbw7 levels. It is surprising that, however, polyubiquitylated proteins do not accumulate or may even decrease in Int6-silenced cells that contain defective proteasomes. Considering that decreased ubiquitin might explain this observation and that Int6 might control ubiquitin levels in its role as a subunit of eIF3 ((e) under bar ukaryote translation (i) under bar nitiation (f) under bar actor 3), we found that silencing Int6 reduced monoubiquitin protein levels, which correlated with a shift of ubiquitin mRNAs from larger polysomes to non-translating ribosomes. In contrast, levels of many housekeeping proteins did not change. This apparent reduction in the translation of ubiquitin genes correlated with a modest reduction in protein synthesis rate and formation of large polysomes. To further determine whether Int6 can selectively control translation, we analyzed translation of different 5'-untranslated region reporters and found that indeed, loss of Int6 had differential effects on these reporters. Together the data suggest that Int6 depletion blocks ubiquitin-dependent proteolysis by decreasing both ubiquitin levels and the assembly of functional proteasome machinery, leading to accumulation of oncoproteins, such as SRC3 that can transform mammary epithelium. Our data also raise the possibility that Int6 can further fine-tune protein levels by selectively controlling translation of specific mRNAs. Oncogene (2011) 30, 724-736; doi:10.1038/onc.2010.445; published online 4 October 2010	[Suo, J.; Chang, E. C.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Suo, J.; Creighton, C. J.; Chen, A. C.; Schiff, R.; Chang, E. C.] Baylor Coll Med, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA; [Snider, S. J.; Lloyd, R. E.] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA; [Mills, G. B.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA; [Creighton, C. J.] Baylor Coll Med, Div Biostat, Houston, TX 77030 USA; [Chen, A. C.; Schiff, R.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; Baylor College of Medicine	Chang, EC (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza, Houston, TX 77030 USA.	echang1@bcm.edu			NIH [CA90464, CA107187, P50CA58183, P50CA058183, AI50237, GM59803]; Susan G. Komen Foundation [PDF0402733]; Expedition Inspiration Fund for Breast Cancer Research; NATIONAL CANCER INSTITUTE [P50CA058183, R01CA107187, R01CA090464] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI050237, R01AI050237] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059803] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Susan G. Komen Foundation(Susan G. Komen Breast Cancer Foundation); Expedition Inspiration Fund for Breast Cancer Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank John Hershey for providing eIF3 antibodies, and members of the Adrian Lee and Steffi Oesterreich labs for the help with tissue culture. We thank Carlos Rivera for technical assistance in the translation study and Steen Pedersen for assistance in the use of the fluorometer, Chris Threetor, Mike Cubbage and Xinrong Fu for the use of a flow cytometer in the Flow Cytometry core lab at Texas Children's Cancer Center, Michael Lewis for confocal microscopy, Gary Chamness for reading the manuscript, Anna Tsimelzon and Susan Hilsenbeck for database analyses, Jan Sap for assistance in Int6 expression studies, Yiling Lu for assistance in the RRPA screen, members of Robert Callahan's group for discussion and David Lonard and Bert O'Malley in the help of SRC3 study. We are particularly grateful to Sizhen Gao, Joan Brugge and Sean McGuire for sharing unpublished results and comments for the paper. ECC is supported by grants from the NIH (CA90464, CA107187 and P50CA58183), JS by fellowships from the Susan G. Komen Foundation (PDF0402733) and Expedition Inspiration Fund for Breast Cancer Research, RS by grants from NIH, P50CA058183 and SU2C (Stand Up 2 Cancer) and REL by NIH grants (AI50237 and GM59803).	Akiyoshi Y, 2001, J BIOL CHEM, V276, P10056, DOI 10.1074/jbc.M010188200; Aravind L, 1998, PROTEIN SCI, V7, P1250, DOI 10.1002/pro.5560070521; Asano K, 1997, J BIOL CHEM, V272, P23477, DOI 10.1074/jbc.272.38.23477; Bandyopadhyay A, 2000, MOL BIOL CELL, V11, P4005, DOI 10.1091/mbc.11.11.4005; Braunstein S, 2007, MOL CELL, V28, P501, DOI 10.1016/j.molcel.2007.10.019; Byrd MP, 2005, J BIOL CHEM, V280, P18610, DOI 10.1074/jbc.M414014200; Crane R, 2000, MOL BIOL CELL, V11, P3993, DOI 10.1091/mbc.11.11.3993; Dawson PJ, 1996, AM J PATHOL, V148, P313; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Diella F, 1997, DNA CELL BIOL, V16, P839, DOI 10.1089/dna.1997.16.839; Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764; Grzmil M, 2010, ONCOGENE, V29, P4080, DOI 10.1038/onc.2010.152; Gunawardane RN, 2005, CANCER RES, V65, P11572, DOI 10.1158/0008-5472.CAN-05-1196; Hanna J, 2003, MOL CELL BIOL, V23, P9251, DOI 10.1128/MCB.23.24.9251-9261.2003; HOAREAU AK, 2002, FEBS LETT, V527, P15, DOI 10.1016/S0014-5793(02)03147-2; Hofmann K, 1998, TRENDS BIOCHEM SCI, V23, P204, DOI 10.1016/S0968-0004(98)01217-1; Li C, 2008, MOL CELL, V31, P835, DOI 10.1016/j.molcel.2008.07.019; Lonard DM, 2008, SCI SIGNAL, V1, DOI 10.1126/stke.113pe16; Mack DL, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1742; MARCHETTI A, 1995, J VIROL, V69, P1932, DOI 10.1128/JVI.69.3.1932-1938.1995; Marchetti A, 2001, INT J ONCOL, V18, P175; Massarweh S, 2006, CANCER RES, V66, P8266, DOI 10.1158/0008-5472.CAN-05-4045; Masutani M, 2007, EMBO J, V26, P3373, DOI 10.1038/sj.emboj.7601765; Mayeur GL, 2002, FEBS LETT, V514, P49, DOI 10.1016/S0014-5793(02)02307-4; Morris C, 2005, ONCOGENE, V24, P1203, DOI 10.1038/sj.onc.1208268; Osborne CK, 2003, J NATL CANCER I, V95, P353, DOI 10.1093/jnci/95.5.353; Rasmussen SB, 2001, ONCOGENE, V20, P5291, DOI 10.1038/sj.onc.1204624; Rivera CI, 2008, VIROLOGY, V375, P59, DOI 10.1016/j.virol.2008.02.002; Rubinson DA, 2003, NAT GENET, V33, P401, DOI 10.1038/ng1117; Sha Z, 2009, MOL CELL, V36, P141, DOI 10.1016/j.molcel.2009.09.026; Tibes R, 2006, MOL CANCER THER, V5, P2512, DOI 10.1158/1535-7163.MCT-06-0334; Umar A, 2009, MOL CELL PROTEOMICS, V8, P1278, DOI 10.1074/mcp.M800493-MCP200; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; WOODS A, 1989, J CELL SCI, V93, P491; Wu RC, 2007, CELL, V129, P1125, DOI 10.1016/j.cell.2007.04.039; Xu JM, 2009, NAT REV CANCER, V9, P615, DOI 10.1038/nrc2695; Yen HCS, 2003, CELL, V112, P207, DOI 10.1016/S0092-8674(03)00043-6; Yen HCS, 2000, P NATL ACAD SCI USA, V97, P14370, DOI 10.1073/pnas.97.26.14370; Yen HCS, 2003, CELL CYCLE, V2, P81, DOI 10.4161/cc.2.2.340; Zhou CS, 2005, BMC BIOL, V3, DOI 10.1186/1741-7007-3-14	40	17	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2011	30	6					724	736		10.1038/onc.2010.445	http://dx.doi.org/10.1038/onc.2010.445			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	719GY	20890303	Green Accepted			2022-12-17	WOS:000287192000009
J	Sauzeau, V; Berenjeno, IM; Citterio, C; Bustelo, XR				Sauzeau, V.; Berenjeno, I. M.; Citterio, C.; Bustelo, X. R.			A transcriptional cross-talk between RhoA and c-Myc inhibits the RhoA/Rock-dependent cytoskeleton	ONCOGENE			English	Article						RhoA; c-Myc; Pak; integrin; stress fibers; gene expression	GTP-BINDING PROTEINS; ROCK-I; KINASE; ACTIVATION; GTPASES; DEGRADATION; DISTINCT; MYOSIN; FAMILY; TARGET	The GTPase RhoA participates in a number of cellular processes, including cytoskeletal organization, mitogenesis and tumorigenesis. We have previously shown that the transforming activity of an oncogenic version of RhoA (Q63L mutant) was highly dependent on the transcriptional factor c-Myc. In contrast to these positive effects in the RhoA route, we show here that c-Myc affects negatively the F-actin cytoskeleton induced by RhoA(Q63L) and its downstream effector, the serine/threonine kinase Rock. This effect entails the activation of a transcriptional program that requires synergistic interactions with RhoA-derived signals and that includes the upregulation of the GTPase Cdc42 and its downstream element Pak1 as well as the repression of specific integrin subunits. The negative effects of c-Myc in the F-actin cytoskeleton are eliminated by the establishment of cell-to-cell contacts, an effect associated with the rescue of Pak1 and integrin levels at the post-transcriptional and transcriptional levels, respectively. These results reveal the presence of a hitherto unknown signaling feed-back loop between RhoA and c-Myc oncogenes that can contribute to maintain fluid cytoskeletal dynamics in cancer cells. Oncogene (2010) 29, 3781-3792; doi: 10.1038/onc.2010.134; published online 10 May 2010	[Sauzeau, V.; Berenjeno, I. M.; Citterio, C.; Bustelo, X. R.] Univ Salamanca, CSIC, Ctr Invest Canc, E-37007 Salamanca, Spain; [Sauzeau, V.; Berenjeno, I. M.; Citterio, C.; Bustelo, X. R.] Univ Salamanca, CSIC, IBMCC, E-37007 Salamanca, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca	Bustelo, XR (corresponding author), Univ Salamanca, CSIC, Ctr Invest Canc, Campus Unamuno, E-37007 Salamanca, Spain.	xbustelo@usal.es	Bustelo, Xose R./AAD-2081-2022; Bustelo, Xose R./A-9526-2010; Sauzeau, Vincent/D-3548-2015	Bustelo, Xose R./0000-0001-9398-6072; Bustelo, Xose R./0000-0001-9398-6072; Sauzeau, Vincent/0000-0002-6187-0312	NIH [5R01CA73735]; Spanish Ministry of Science and Innovation [SAF2006-01789, GEN2003-20239-C06-01]; Red Tematica de Investigacion Cooperativa en Cancer [RD06/0020/0001]; Castilla y Leon Autonomous Government [GR97]; European Union [FP7-HEALTH-2007-A-201862]; NATIONAL CANCER INSTITUTE [R01CA073735] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Spanish Ministry of Science and Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Red Tematica de Investigacion Cooperativa en Cancer; Castilla y Leon Autonomous Government; European Union(European Commission); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank M Blazquez for technical help. XRB work is supported by grants from the NIH (5R01CA73735), the Spanish Ministry of Science and Innovation (SAF2006-01789, GEN2003-20239-C06-01), the Red Tematica de Investigacion Cooperativa en Cancer (RD06/0020/0001), the Castilla y Leon Autonomous Government (GR97), and the 7th Framework European Union Program (FP7-HEALTH-2007-A-201862).	Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Berenjeno IM, 2007, ONCOGENE, V26, P4295, DOI 10.1038/sj.onc.1210194; Bos JL, 2007, CELL, V129, P865, DOI 10.1016/j.cell.2007.05.018; Bustelo XR, 2007, BIOESSAYS, V29, P356, DOI 10.1002/bies.20558; Croft DR, 2004, CANCER RES, V64, P8994, DOI 10.1158/0008-5472.CAN-04-2052; Dransart E, 2005, TRAFFIC, V6, P957, DOI 10.1111/j.1600-0854.2005.00335.x; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Guo FK, 2004, ONCOGENE, V23, P5577, DOI 10.1038/sj.onc.1207752; Hatzoglou A, 2007, MOL BIOL CELL, V18, P1242, DOI 10.1091/mbc.E06-06-0510; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Lee HH, 2008, J CELL BIOL, V181, P999, DOI 10.1083/jcb.200710187; Lee S, 2004, J BIOL CHEM, V279, P1885, DOI 10.1074/jbc.M306968200; Lin R, 1997, CURR BIOL, V7, P794, DOI 10.1016/S0960-9822(06)00338-1; Mueller BK, 2005, NAT REV DRUG DISCOV, V4, P387, DOI 10.1038/nrd1719; Nakano K, 1999, MOL BIOL CELL, V10, P2481, DOI 10.1091/mbc.10.8.2481; Olofsson B, 1999, CELL SIGNAL, V11, P545, DOI 10.1016/S0898-6568(98)00063-1; Ongusaha PP, 2006, CURR BIOL, V16, P2466, DOI 10.1016/j.cub.2006.10.056; Park SY, 2009, NAT STRUCT MOL BIOL, V16, P23, DOI 10.1038/nsmb.1533; Riento K, 2003, MOL CELL BIOL, V23, P4219, DOI 10.1128/MCB.23.12.4219-4229.2003; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; Sahai E, 1999, CURR BIOL, V9, P136, DOI 10.1016/S0960-9822(99)80067-0; Sahai E, 2007, J CELL BIOL, V176, P35, DOI 10.1083/jcb.200605135; Shiio Y, 2002, EMBO J, V21, P5088, DOI 10.1093/emboj/cdf525; Wang HR, 2006, METHOD ENZYMOL, V406, P437, DOI 10.1016/S0076-6879(06)06032-0; Wang HR, 2003, SCIENCE, V302, P1775, DOI 10.1126/science.1090772; Ward Y, 2002, J CELL BIOL, V157, P291, DOI 10.1083/jcb.200111026; Watnick RS, 2003, CANCER CELL, V3, P219, DOI 10.1016/S1535-6108(03)00030-8	30	17	18	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2010	29	26					3781	3792		10.1038/onc.2010.134	http://dx.doi.org/10.1038/onc.2010.134			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	618VW	20453885	Green Accepted, Green Submitted			2022-12-17	WOS:000279385200006
J	Albero, MP; Vaquer, JM; Andreu, EJ; Villanueva, JJ; Franch, L; Ivorra, C; Poch, E; Agirre, X; Prosper, F; Perez-Roger, I				Albero, M. P.; Vaquer, J. M.; Andreu, E. J.; Villanueva, J. J.; Franch, L.; Ivorra, C.; Poch, E.; Agirre, X.; Prosper, F.; Perez-Roger, I.			Bortezomib decreases Rb phosphorylation and induces caspase-dependent apoptosis in Imatinib-sensitive and -resistant Bcr-Abl1-expressing cells	ONCOGENE			English	Article						Bortezomib; CML; Bcr-Abl1; Imatinib resistance; Rb; apoptosis	PHILADELPHIA-CHROMOSOME; PROTEASOME INHIBITION; PROLIFERATION; LYMPHOMA; THERAPY; CYCLINS; DRUGS; DEATH; TRANSFORMATION; DEGRADATION	The use of c-abl-specific inhibitors such as Imatinib (IM) or Dasatinib has revolutionized the treatment of chronic myeloid leukemia (CML). However, a significant percentage of patients become resistant to IM. In this report, we have analyzed the possibility of using the proteasome as a molecular target in CML. Our results show that cells that express Bcr-Abl1 are more sensitive to the inhibition of the proteasome with Bortezomib (Btz) than control cells. This treatment reduces the proliferation of Bcr-Abl1-expressing cells, by inactivating NF-kappa B2 and decreasing the phosphorylation of Rb, eventually leading to an increase in caspase-dependent apoptosis. Furthermore, we show that Btz also induces cell-cycle arrest and apoptosis in cells expressing Bcr-Abl1 mutants that are resistant to IM. These results unravel a new molecular target of Btz, that is the Rb pathway, and open new possibilities in the treatment of CML especially for patients that become resistant to IM because of the presence of the T315I mutation. Oncogene (2010) 29, 3276-3286; doi: 10.1038/onc.2010.81; published online 22 March 2010	[Albero, M. P.; Vaquer, J. M.; Villanueva, J. J.; Franch, L.; Ivorra, C.; Poch, E.; Perez-Roger, I.] Cardenal Herrera CEU Univ, Dept Chem Biochem & Mol Biol, Moncada, Spain; [Andreu, E. J.; Agirre, X.; Prosper, F.] Univ Navarra, Fdn Appl Med Res, Univ Navarra Clin, Dept Hematol, E-31080 Pamplona, Spain; [Andreu, E. J.; Agirre, X.; Prosper, F.] Univ Navarra, Fdn Appl Med Res, Univ Navarra Clin, Area Cell Therapy, E-31080 Pamplona, Spain	Universidad CEU Cardenal Herrera; University of Navarra; University of Navarra	Perez-Roger, I (corresponding author), Cardenal Herrera CEU Univ, Dept Chem Biochem & Mol Biol, Edif Seminario,Av Seminario, Valencia 46113, Spain.	iperez@uch.ceu.es	Poch, Enric/C-5258-2013; Agirre, Xabier/ABE-4110-2020; Pérez Roger, Ignacio/K-1346-2014; Andreu, Enrique J/F-9813-2016; Prosper, Felipe/H-6859-2017	Pérez Roger, Ignacio/0000-0002-5564-6912; Andreu, Enrique J/0000-0001-5317-9989; Prosper, Felipe/0000-0001-6115-8790; Vaquer Santamaria, Juana Maria/0000-0002-4070-602X; Ivorra, Carmen/0000-0002-4699-6689	Instituto de Salud Carlos III [PI060285, PI070602, RD06/0020]; Conselleria de Sanitat; Cardenal Herrera-CEU University; 'UTE project CIMA'; Generalitat Valenciana; Ramon y Cajal; Ministerio de Ciencia e Innovacion	Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); Conselleria de Sanitat; Cardenal Herrera-CEU University; 'UTE project CIMA'; Generalitat Valenciana(Center for Forestry Research & Experimentation (CIEF)European Commission); Ramon y Cajal(Spanish Government); Ministerio de Ciencia e Innovacion(Ministry of Science and Innovation, Spain (MICINN)Instituto de Salud Carlos IIISpanish Government)	We thank Dr Elisabeth Buchdunger at Novartis for providing us with Imatinib and Millenium Pharmaceuticals for the kind gift of Bortezomib. We also thank Dr BJ Druker for the mutant Bcr-Abl1-expressing BaF/3 cells. The study was supported by grants from the Instituto de Salud Carlos III PI060285, PI070602 and RD06/0020 to IPR, FP and EJA; from the Conselleria de Sanitat to IPR; from the Cardenal Herrera-CEU University (PRUCH and Santander-Copernicus) to IPR and 'UTE project CIMA'. Fellowships were from the Cardenal Herrera-CEU University to MPA and JJV and from the Generalitat Valenciana to JMV. EJA is supported by the program Ramon y Cajal from the Ministerio de Ciencia e Innovacion.	Adams J, 2001, SEMIN ONCOL, V28, P613, DOI 10.1053/sonc.2001.28609; Andreu EJ, 2005, CANCER RES, V65, P3264, DOI 10.1158/0008-5472.CAN-04-1357; Barre B, 2007, EMBO J, V26, P4841, DOI 10.1038/sj.emboj.7601899; Brignole C, 2006, J NATL CANCER I, V98, P1142, DOI 10.1093/jnci/djj309; Chauhan D, 2008, BMC BIOCHEM, V9, DOI 10.1186/1471-2091-9-S1-S1; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Crawford LJ, 2009, EXP HEMATOL, V37, P357, DOI 10.1016/j.exphem.2008.11.004; Dai Y, 2004, BLOOD, V104, P509, DOI 10.1182/blood-2003-12-4121; Dasmahapatra G, 2006, LEUKEMIA RES, V30, P1263, DOI 10.1016/j.leukres.2006.01.005; Druker BJ, 2008, BLOOD, V112, P4808, DOI 10.1182/blood-2008-07-077958; Galimberti S, 2008, LEUKEMIA RES, V32, P103, DOI 10.1016/j.leukres.2007.05.023; Gatto S, 2003, HAEMATOLOGICA, V88, P853; Griswold IJ, 2006, MOL CELL BIOL, V26, P6082, DOI 10.1128/MCB.02202-05; Heaney NB, 2010, BLOOD, V115, P2241, DOI 10.1182/blood-2008-06-164582; Heusch M, 1999, ONCOGENE, V18, P6201, DOI 10.1038/sj.onc.1203022; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; Joazeiro CAP, 2006, CANCER RES, V66, P7840, DOI 10.1158/0008-5472.CAN-06-2033; Kano Y, 2007, INVEST NEW DRUG, V25, P31, DOI 10.1007/s10637-006-9000-0; Khidr L, 2006, ONCOGENE, V25, P5210, DOI 10.1038/sj.onc.1209612; Kossatz U, 2004, GENE DEV, V18, P2602, DOI 10.1101/gad.321004; Markovina S, 2008, MOL CANCER RES, V6, P1356, DOI 10.1158/1541-7786.MCR-08-0108; Murray AW, 2004, CELL, V116, P221, DOI 10.1016/S0092-8674(03)01080-8; Ocio EM, 2008, LANCET ONCOL, V9, P1157, DOI 10.1016/S1470-2045(08)70304-8; Perez-Galan P, 2006, BLOOD, V107, P257, DOI 10.1182/blood-2005-05-2091; Perez-Roger I, 1999, EMBO J, V18, P5310, DOI 10.1093/emboj/18.19.5310; Poch E, 2007, EXP CELL RES, V313, P719, DOI 10.1016/j.yexcr.2006.11.006; Pomerantz JL, 2002, MOL CELL, V10, P693, DOI 10.1016/S1097-2765(02)00697-4; Ramirez P, 2008, ONCOLOGIST, V13, P424, DOI 10.1634/theoncologist.2007-0170; Roman-Gomez J, 2007, HAEMATOLOGICA, V92, P153, DOI 10.3324/haematol.10782; Sartore-Bianchi A, 2007, CLIN CANCER RES, V13, P5942, DOI 10.1158/1078-0432.CCR-07-0536; SAWYERS CL, 1993, LEUKEMIA LYMPHOMA, V11, P45, DOI 10.3109/10428199309047862; Shah NP, 2003, ONCOGENE, V22, P7389, DOI 10.1038/sj.onc.1206942; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; Stapnes C, 2007, BRIT J HAEMATOL, V136, P814, DOI 10.1111/j.1365-2141.2007.06504.x; Strauss SJ, 2007, CANCER RES, V67, P2783, DOI 10.1158/0008-5472.CAN-06-3254; Van Phan Nguyen Thanh, 2005, Hum Cell, V18, P25; Vink J, 2006, BRIT J HAEMATOL, V134, P253, DOI 10.1111/j.1365-2141.2006.06170.x; Wei AH, 2008, LEUKEMIA LYMPHOMA, V49, P657, DOI 10.1080/10428190801942378; Yan H, 2007, LEUKEMIA, V21, P1488, DOI 10.1038/sj.leu.2404735; Yang DT, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-40; Yu CR, 2003, BLOOD, V102, P3765, DOI 10.1182/blood-2003-03-0737; Zhao XX, 2008, LEUKEMIA RES, V32, P275, DOI 10.1016/j.leukres.2007.05.024	42	17	19	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2010	29	22					3276	3286		10.1038/onc.2010.81	http://dx.doi.org/10.1038/onc.2010.81			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	605BA	20305692	Green Published			2022-12-17	WOS:000278321100010
J	Chan, PC; Sudhakar, JN; Lai, CC; Chen, HC				Chan, P-C; Sudhakar, J. N.; Lai, C-C; Chen, H-C			Differential phosphorylation of the docking protein Gab1 by c-Src and the hepatocyte growth factor receptor regulates different aspects of cell functions	ONCOGENE			English	Article						Gab1; phosphorylation; Src; Met; Crk; HGF	FACTOR-MEDIATED INTERACTION; KINASE IN-VITRO; PHOSPHATIDYLINOSITOL 3-KINASE; EPITHELIAL MORPHOGENESIS; FACTOR STIMULATION; TYROSINE KINASE; MET; ACTIVATION; IDENTIFICATION; CYTOKINE	The docking protein Grb2-associated binder1 (Gab1) has a central role in the integration of the growth-factor signaling. In this study, we aimed to examine the significance of Src-mediated Gab1 phosphorylation in the hepatocyte growth factor (HGF) signaling. Using both mutagenesis and mass spectrometry approaches, Y242, Y259, Y317, Y373 and Y627 of Gab1 were identified to be phosphorylated by c-Src. It is interesting to note that the binding of the tyrosine phosphatase SHP2 to the Y627 antagonized the effect of c-Src on the phosphorylation of the other four tyrosine residues. Moreover, the tyrosine residues predominantly phosphorylated by c-Src were different from those predominantly phosphorylated by the HGF receptor. Gab1 overexpression potentiated both mitogenic and motogenic activities of HGF. However, a Gab1 mutant with substitutions of the Src phosphorylation sites (Y242, Y259, Y317 and Y373) failed to promote HGF-induced DNA synthesis, but retained its ability to facilitate HGF-induced chemotaxis. Taken together, our results not only suggest that the phosphorylation of Gab1 by c-Src is important for HGF-induced DNA synthesis, but also provide an example to illustrate how a docking protein (for example, Gab1) is differentially phosphorylated by c-Src and a receptor tyrosine kinase to emanate full spectrum of signals to the downstream. Oncogene (2010) 29, 698-710; doi: 10.1038/onc.2009.363; published online 2 November 2009	[Chan, P-C; Chen, H-C] Natl Chung Hsing Univ, Dept Life Sci, Taichung 40227, Taiwan; [Sudhakar, J. N.; Chen, H-C] Natl Chung Hsing Univ, Inst Biomed Sci, Taichung 40227, Taiwan; [Lai, C-C] Natl Chung Hsing Univ, Inst Mol Biol, Taichung 40227, Taiwan	National Chung Hsing University; National Chung Hsing University; National Chung Hsing University	Chen, HC (corresponding author), Natl Chung Hsing Univ, Dept Life Sci, 250 Kuo Kuang Rd, Taichung 40227, Taiwan.	hcchen@nchu.edu.tw	/AGZ-4617-2022	/0000-0002-7133-8266	National Science Council, Taiwan [NSC97-3112-B-005-001, NSC97-2628-B-005-001-MY3]; National Health Research Institutes, Taiwan [NHRI-EX97-9730BI]	National Science Council, Taiwan(Ministry of Science and Technology, Taiwan); National Health Research Institutes, Taiwan(National Health Research Institutes - Taiwan)	We are indebted to Dr T Hirano (Osaka University, Osaka, Japan) for Gab1 cDNA and Gab1-null MEFs and Dr DL Wang (Academia Sinica, Taipei, Taiwan) for Flag-tagged SHP2 and its CS mutant. This work is supported by grants NSC97-3112-B-005-001 and NSC97-2628-B-005-001-MY3 from the National Science Council, Taiwan and NHRI-EX97-9730BI from the National Health Research Institutes, Taiwan.	Chan PC, 2003, J BIOL CHEM, V278, P44075, DOI 10.1074/jbc.M305745200; Chen SY, 2006, MOL CELL BIOL, V26, P5155, DOI 10.1128/MCB.02186-05; Cunnick JM, 2001, J BIOL CHEM, V276, P24380, DOI 10.1074/jbc.M010275200; DERMAN MP, 1995, AM J PHYSIOL-RENAL, V268, pF1211, DOI 10.1152/ajprenal.1995.268.6.F1211; Eulenfeld R, 2009, J CELL SCI, V122, P55, DOI 10.1242/jcs.037226; Gharahdaghi F, 1999, ELECTROPHORESIS, V20, P601, DOI 10.1002/(SICI)1522-2683(19990301)20:3<601::AID-ELPS601>3.3.CO;2-Y; Gu HH, 2003, TRENDS CELL BIOL, V13, P122, DOI 10.1016/S0962-8924(03)00002-3; Gual P, 2000, ONCOGENE, V19, P1509, DOI 10.1038/sj.onc.1203514; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Itoh M, 2000, MOL CELL BIOL, V20, P3695, DOI 10.1128/MCB.20.10.3695-3704.2000; Kallin A, 2004, J BIOL CHEM, V279, P17897, DOI 10.1074/jbc.M312996200; Lamorte L, 2000, ONCOGENE, V19, P5973, DOI 10.1038/sj.onc.1203977; Lehr S, 2004, BIOCHEMISTRY-US, V43, P12133, DOI 10.1021/bi049753e; Lehr S, 1999, BIOCHEMISTRY-US, V38, P151, DOI 10.1021/bi9818265; Lehr S, 2000, BIOCHEMISTRY-US, V39, P10898, DOI 10.1021/bi000982k; Machide M, 2000, J BIOL CHEM, V275, P31392, DOI 10.1074/jbc.M002817200; Maroun CR, 2000, MOL CELL BIOL, V20, P8513, DOI 10.1128/MCB.20.22.8513-8525.2000; Montagner A, 2005, J BIOL CHEM, V280, P5350, DOI 10.1074/jbc.M410012200; Nishida K, 1999, BLOOD, V93, P1809, DOI 10.1182/blood.V93.6.1809.406k35_1809_1816; Podar K, 2004, J BIOL CHEM, V279, P21658, DOI 10.1074/jbc.M305783200; Riordan SM, 2000, BIOCHEM J, V350, P925, DOI 10.1042/0264-6021:3500925; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; Sachs M, 2000, J CELL BIOL, V150, P1375, DOI 10.1083/jcb.150.6.1375; Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419; Schaeper U, 2007, P NATL ACAD SCI USA, V104, P15376, DOI 10.1073/pnas.0702555104; Shi ZQ, 2000, MOL CELL BIOL, V20, P1526, DOI 10.1128/MCB.20.5.1526-1536.2000; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; Terry DE, 2004, J AM SOC MASS SPECTR, V15, P784, DOI 10.1016/j.jasms.2004.02.005; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; Yu CF, 2002, J BIOL CHEM, V277, P19382, DOI 10.1074/jbc.M200732200; Yu CF, 2001, J BIOL CHEM, V276, P32552, DOI 10.1074/jbc.M104493200	31	17	17	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2010	29	5					698	710		10.1038/onc.2009.363	http://dx.doi.org/10.1038/onc.2009.363			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	551QI	19881549				2022-12-17	WOS:000274223700007
J	Ueno, S; Tatetsu, H; Hata, H; Iino, T; Niiro, H; Akashi, K; Tenen, DG; Mitsuya, H; Okuno, Y				Ueno, S.; Tatetsu, H.; Hata, H.; Iino, T.; Niiro, H.; Akashi, K.; Tenen, D. G.; Mitsuya, H.; Okuno, Y.			PU.1 induces apoptosis in myeloma cells through direct transactivation of TRAIL	ONCOGENE			English	Article						myeloma; PU.1; TRAIL; apoptosis; p21	OVERCOMES DRUG-RESISTANCE; TRANSCRIPTION FACTOR PU.1; HEMATOPOIETIC STEM-CELLS; MULTIPLE-MYELOMA; REGULATORY ELEMENTS; DISTAL ELEMENTS; LEUKEMIA-CELLS; GENE; EXPRESSION; GROWTH	We earlier reported that PU.1 was downregulated in myeloma cell lines and myeloma cells in a subset of myeloma patients, and that conditional PU.1 expression in PU.1-negative myeloma cell lines, U266 and KMS12PE, induced growth arrest and apoptosis. To elucidate the molecular mechanisms of the growth arrest and apoptosis, we performed DNA microarray analyses to compare the difference in gene expression before and after PU.1 induction in U266 cells. Among cell cycle-related genes, cyclin A2, cyclin B1, CDK2 and CDK4 were downregulated and p21 was upregulated, although among apoptosis-related genes, tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL) was found highly upregulated. When TRAIL was knocked down by small interference RNAs, apoptosis of PU-1-expressing cells was inhibited, suggesting that TRAIL has a critical role in PU.1-induced apoptosis in both U266 and KMS12PE myeloma cells. In both U266 and KMS12PE cells expressing PU.1, PU.1 directly bound to a region 30 bp downstream of the transcription start site of the TRAIL gene. Upregulation of PU.1-induced transactivation of the TRAIL promoter in reporter assays, and disruption of the PU.1-binding site in the TRAIL promoter eliminated this transactivation. Therefore, we conclude that PU.1 is capable of inducing apoptosis in certain myeloma cells by direct transactivation of TRAIL. Oncogene (2009) 28, 4116-4125; doi:10.1038/onc.2009.263; published online 14 September 2009	[Ueno, S.; Tatetsu, H.; Hata, H.; Mitsuya, H.; Okuno, Y.] Kumamoto Univ Med, Dept Hematol, Kumamoto 8608556, Japan; [Iino, T.; Niiro, H.; Akashi, K.] Kyushu Univ, Grad Sch Med Sci, Fukuoka 812, Japan; [Iino, T.; Akashi, K.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; [Tenen, D. G.] Harvard Univ, Sch Med, Ctr Life Sci, Boston, MA USA; [Tenen, D. G.] Natl Univ Singapore, Canc Sci Inst, Singapore 117548, Singapore	Kumamoto University; Kyushu University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; National University of Singapore	Okuno, Y (corresponding author), Kumamoto Univ Med, Dept Hematol, 1-1-1 Honjo, Kumamoto 8608556, Japan.	yokuno@gpo.kumamoto-u.ac.jp		Tenen, Daniel/0000-0002-6423-3888	International Myeloma Foundation Japan; Ministry of Education, Culture, Sports, Science and Technology of Japan; NATIONAL CANCER INSTITUTE [R01CA041456] Funding Source: NIH RePORTER	International Myeloma Foundation Japan; Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by The Award in Aki's Memory from The International Myeloma Foundation Japan (YO) and grants from the Ministry of Education, Culture, Sports, Science and Technology of Japan.	Amaravadi L, 1999, DNA CELL BIOL, V18, P875, DOI 10.1089/104454999314737; Attal M, 2003, NEW ENGL J MED, V349, P2495, DOI 10.1056/NEJMoa032290; Coccia EM, 1999, ONCOGENE, V18, P2129, DOI 10.1038/sj.onc.1202536; de Veer MJ, 1998, GENOMICS, V54, P267, DOI 10.1006/geno.1998.5555; Gazitt Y, 1999, LEUKEMIA, V13, P1817, DOI 10.1038/sj.leu.2401501; Hideshima T, 2001, CANCER RES, V61, P3071; Hideshima T, 2003, IMMUNOL REV, V194, P164, DOI 10.1034/j.1600-065X.2003.00053.x; Huang G, 2008, NAT GENET, V40, P51, DOI 10.1038/ng.2007.7; Iida S, 1997, NAT GENET, V17, P226, DOI 10.1038/ng1097-226; Insinga A, 2005, NAT MED, V11, P71, DOI 10.1038/nm1160; Kirshner JR, 2005, J VIROL, V79, P9320, DOI 10.1128/JVI.79.14.9320-9324.2005; Klein U, 2006, NAT IMMUNOL, V7, P773, DOI 10.1038/ni1357; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; Li YL, 2001, BLOOD, V98, P2958, DOI 10.1182/blood.V98.10.2958; Loots GG, 2000, SCIENCE, V288, P136, DOI 10.1126/science.288.5463.136; Mariani SM, 1997, J CELL BIOL, V137, P221, DOI 10.1083/jcb.137.1.221; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; Mitsiades CS, 2001, BLOOD, V98, P795, DOI 10.1182/blood.V98.3.795; Mitsiades N, 2002, BLOOD, V99, P2162, DOI 10.1182/blood.V99.6.2162; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; Nebbioso A, 2005, NAT MED, V11, P77, DOI 10.1038/nm1161; Okuno Y, 2005, MOL CELL BIOL, V25, P2832, DOI 10.1128/MCB.25.7.2832-2845.2005; Okuno Y, 2002, BLOOD, V100, P4420, DOI 10.1182/blood-2002-03-0788; Okuno Y, 2002, P NATL ACAD SCI USA, V99, P6246, DOI 10.1073/pnas.092027799; PAHL HL, 1993, J BIOL CHEM, V268, P5014; Radomska HS, 2002, BLOOD, V100, P4410, DOI 10.1182/blood-2002-02-0355; Rosenbauer F, 2006, NAT GENET, V38, P27, DOI 10.1038/ng1679; Rosenbauer F, 2004, NAT GENET, V36, P624, DOI 10.1038/ng1361; Shaffer AL, 2008, NATURE, V454, P226, DOI 10.1038/nature07064; Singhal S, 1999, NEW ENGL J MED, V341, P1565, DOI 10.1056/NEJM199911183412102; Tatetsu H, 2007, CANCER RES, V67, P5328, DOI 10.1158/0008-5472.CAN-06-4265; Tenen DG, 2003, NAT REV CANCER, V3, P89, DOI 10.1038/nrc989; Yu W, 1999, SCIENCE, V285, P1080, DOI 10.1126/science.285.5430.1080	33	17	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 19	2009	28	46					4116	4125		10.1038/onc.2009.263	http://dx.doi.org/10.1038/onc.2009.263			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	530AE	19749795	Green Accepted			2022-12-17	WOS:000272560500007
J	Novosyadlyy, R; Vijayakumar, A; Lann, D; Fierz, Y; Kurshan, N; LeRoith, D				Novosyadlyy, R.; Vijayakumar, A.; Lann, D.; Fierz, Y.; Kurshan, N.; LeRoith, D.			Physical and functional interaction between polyoma virus middle T antigen and insulin and IGF-I receptors is required for oncogene activation and tumour initiation	ONCOGENE			English	Article						oncogenes; polyoma virus middle T oncogene; insulin receptor; IGF-I receptor; crosstalk	MERKEL CELL POLYOMAVIRUS; EPIDERMAL GROWTH-FACTOR; BREAST-CANCER; TRANSFORMED PHENOTYPE; KAPOSIS-SARCOMA; MAMMARY-TUMORS; SRC KINASE; OVEREXPRESSION; TUMORIGENESIS; PROGRESSION	Polyoma virus middle T antigen (PyVmT) is a powerful viral oncogene; however, the mechanisms of PyVmT activation are poorly understood. The insulin-like growth factor I receptor (IGF-IR) and the insulin receptor (IR) are known to be implicated in the development of many cancers. Furthermore, PyVmT-overexpressing mouse mammary carcinoma Met-1 cells are highly responsive to IGF-I and insulin. Herein, we demonstrate that PyVmT physically interacts with IGF-IR and IR in Met-1 cells. Insulin and IGF-I increase association of the IR and IGF-IR with PyVmT, enhance tyrosine phosphorylation of PyVmT and augment the recruitment of Src and PLC gamma(1) to PyVmT. This is accompanied by robust and sustained phosphorylation of Akt and ERK1/2, which are implicated in both PyVmT and IGF-IR/IR signalling. Both ligands significantly increase proliferation, survival, migration and invasion of Met-1 cells. Furthermore, orthotopic inoculation of Met-1 cells with shRNAmir-mediated knockdown of IR or IGF-IR fails to initiate tumour growth in recipient mice. In conclusion, our data indicate that the physical and functional interaction between PyVmT and cellular receptor tyrosine kinases, including IR and IGF-IR, is critical for PyVmT activation and tumour initiation. These results also provide a novel mechanism for oncogene activation in the host cell. Oncogene (2009) 28, 3477-3486; doi: 10.1038/onc.2009.209; published online 20 July 2009	[Novosyadlyy, R.; Vijayakumar, A.; Lann, D.; Fierz, Y.; Kurshan, N.; LeRoith, D.] Mt Sinai Sch Med, Samuel Bronfman Dept Med, Div Endocrinol Diabet & Bone Dis, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	LeRoith, D (corresponding author), Mt Sinai Sch Med, Samuel Bronfman Dept Med, Div Endocrinol Diabet & Bone Dis, 1 Gustave L Levy Pl,Box 1055, New York, NY 10029 USA.	derek.leroith@mssm.edu			National Institutes of Health/National Cancer Institute [1RO1CA128799-O1A1, T32 DK007792]; Swiss National Science Foundation [PBBSB-120851]; Novartis Foundation; NATIONAL CANCER INSTITUTE [R01CA128799] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007792] Funding Source: NIH RePORTER	National Institutes of Health/National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Novartis Foundation(Novartis); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank SD Hurstings (Department of Nutritional Sciences, University of Texas, Austin, TX, USA and Department of Carcinogenesis, University of Texas-MD Anderson Cancer Center, Smithville, TX, USA) and NP Nunez (Department of Nutritional Sciences, University of Texas, Austin, TX, USA) for donating Met-1 cells. This work was funded by National Institutes of Health/National Cancer Institute grant 1RO1CA128799-O1A1. D Lann was supported by National Institutes of Health grant T32 DK007792. Y Fierz was funded by Swiss National Science Foundation grant PBBSB-120851 and Novartis Foundation grant.	Arbet-Engels C, 1999, J BIOL CHEM, V274, P5422, DOI 10.1074/jbc.274.9.5422; Bartucci M, 2001, CANCER RES, V61, P6747; Baserga R, 1999, EXP CELL RES, V253, P1, DOI 10.1006/excr.1999.4667; Belfiore A, 2008, J MAMMARY GLAND BIOL, V13, P381, DOI 10.1007/s10911-008-9099-z; Catrina SB, 2005, BRIT J CANCER, V92, P1467, DOI 10.1038/sj.bjc.6602408; Clemmons DR, 2007, NAT REV DRUG DISCOV, V6, P821, DOI 10.1038/nrd2359; Dilworth SM, 2002, NAT REV CANCER, V2, P951, DOI 10.1038/nrc946; DiMaio D, 1998, ANNU REV MICROBIOL, V52, P397, DOI 10.1146/annurev.micro.52.1.397; Feng HC, 2008, SCIENCE, V319, P1096, DOI 10.1126/science.1152586; Foulongne V, 2008, EMERG INFECT DIS, V14, P1491, DOI 10.3201/eid1409.080651; FRITTITTA L, 1995, J CELL BIOCHEM, V57, P666, DOI 10.1002/jcb.240570411; GIORGINO F, 1991, MOL ENDOCRINOL, V5, P452, DOI 10.1210/mend-5-3-452; GROSS L, 1953, P SOC EXP BIOL MED, V83, P414; GROSS L, 1951, P SOC EXP BIOL MED, V76, P27; GUY CT, 1994, GENE DEV, V8, P23, DOI 10.1101/gad.8.1.23; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Javier RT, 2008, CANCER RES, V68, P7693, DOI 10.1158/0008-5472.CAN-08-3301; Kassem A, 2008, CANCER RES, V68, P5009, DOI 10.1158/0008-5472.CAN-08-0949; Lebrun P, 1998, J BIOL CHEM, V273, P32244, DOI 10.1074/jbc.273.48.32244; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; Lieskovska J, 2006, J BIOL CHEM, V281, P25041, DOI 10.1074/jbc.M602866200; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; MORRIS JDH, 1995, LANCET, V346, P754, DOI 10.1016/S0140-6736(95)91510-9; ONO M, 1991, CELL GROWTH DIFFER, V2, P317; Pisani Paola, 2008, Archives of Physiology and Biochemistry, V114, P63, DOI [10.1080/13813450801954451, 10.1080/13813450801954451 ]; Pollak M, 2008, NAT REV CANCER, V8, P915, DOI 10.1038/nrc2536; Renehan AG, 2004, LANCET, V363, P1346, DOI 10.1016/S0140-6736(04)16044-3; Rose PP, 2007, ONCOGENE, V26, P1995, DOI 10.1038/sj.onc.1210006; SEGAWA K, 1983, NATURE, V304, P742, DOI 10.1038/304742a0; Shepard CR, 2007, ONCOGENE, V26, P3020, DOI 10.1038/sj.onc.1210115; SOEDA E, 1980, NATURE, V285, P165, DOI 10.1038/285165a0; White MK, 2004, VIROLOGY, V324, P1, DOI 10.1016/j.virol.2004.03.025; Yakar S, 2005, CYTOKINE GROWTH F R, V16, P407, DOI 10.1016/j.cytogfr.2005.01.010; zur Hausen H, 2008, INT J CANCER, V123, P247, DOI 10.1002/ijc.23620	35	17	18	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2009	28	39					3477	3486		10.1038/onc.2009.209	http://dx.doi.org/10.1038/onc.2009.209			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	502RR	19617901	Green Accepted			2022-12-17	WOS:000270478300005
J	Plo, I; Lopez, B				Plo, I.; Lopez, B.			AKT1 represses gene conversion induced by different genotoxic stresses and induces supernumerary centrosomes and aneuploidy in hamster ovary cells	ONCOGENE			English	Article						AKT1; BRCA1; homologous recombination; aneuploidy; centrosome; breast and ovary cancer	STRAND BREAK REPAIR; HOMOLOGOUS RECOMBINATION; MAMMALIAN RAD51; DNA-DAMAGE; PHOSPHATIDYLINOSITOL 3-KINASE/AKT; CANCER SUSCEPTIBILITY; G1 CHECKPOINT; BRCA1; PHOSPHORYLATION; INSTABILITY	The oncogenic kinase AKT1 is frequently overexpressed or activated in sporadic breast and ovarian cancers. In human breast tumors, we have previously shown that AKT1 represses homologous recombination (HR) induced by one double-strand break (DSB). To further analyze the impact of AKT1 on HR, we ectopically expressed wildtype or mutant forms of AKT1 in a hamster ovary cell line containing an intrachromosomal substrate for monitoring HR. In this cell line, AKT1 repressed HR induced by different genotoxic stresses including ionizing radiation, UV-C and one single DSB introduced into the intrachromosomal substrate. Consistently, AKT1 disrupted RAD51 foci formation, showing that AKT1 specifically affects gene conversion. Concomitantly, AKT1 represses both BRCA1 foci formation and HR stimulation resulting from BRCA1 overexpression, showing that AKT1 affects BRCA1-mediated HR functions, also in another species (hamster) and in another type of cell tissue (ovary cells). Finally, consistent with the HR defects, active AKT1 expression induces supernumerary centrosomes and aneuploidy. In addition to its impact on cell proliferation and apoptosis, the present data propose a novel oncogenic function for AKT1, by producing genomic instability as a consequence of HR repression. Oncogene (2009) 28, 2231-2237; doi: 10.1038/onc.2009.85; published online 27 April 2009	[Plo, I.; Lopez, B.] CEA, CNRS, Inst Radiobiol Cellulaire & Mol, UMR 217, F-92265 Fontenay Aux Roses, France	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Lopez, B (corresponding author), CEA, CNRS, Inst Radiobiol Cellulaire & Mol, UMR, 18 Route Panorama,BAT 05, F-92265 Fontenay Aux Roses, France.	bernard.lopez@cea.fr	Lopez, Bernard S/O-7308-2017; Plo, Isabelle/C-9056-2017; Plo, Isabelle/AAT-6742-2021	Lopez, Bernard S/0000-0001-5088-0155; Plo, Isabelle/0000-0002-5915-6910; 	La Ligue Nationale contre le Cancer 'Equipes labellisees, La Ligue; l'Agence Nationale de la Recherche; ARC fellowship	La Ligue Nationale contre le Cancer 'Equipes labellisees, La Ligue; l'Agence Nationale de la Recherche(French National Research Agency (ANR)); ARC fellowship(Australian Research Council)	We thank Dr Hemmings (Friedrich Miescher Institute, Basel, Switzerland) for providing us the wtAKT1, myrAKT1 and kdAKT1 expression vectors, and Dr Jasin (Sloan-Kettering Institute, NYC, USA) for providing us with the CHO-DRA10 cell line and the I-SceI expression plasmid. This work was supported by La Ligue Nationale contre le Cancer 'Equipes labellisees, La Ligue 2005 and 2008' and by l'Agence Nationale de la Recherche. IP was a recipient of an ARC fellowship.	Altiok S, 1999, J BIOL CHEM, V274, P32274, DOI 10.1074/jbc.274.45.32274; Aten JA, 2004, SCIENCE, V303, P92, DOI 10.1126/science.1088845; Bertrand P, 2003, ONCOGENE, V22, P7587, DOI 10.1038/sj.onc.1206998; Daboussi F, 2005, ONCOGENE, V24, P3691, DOI 10.1038/sj.onc.1208438; Deans B, 2003, CANCER RES, V63, P8181; Deng CX, 2002, ONCOGENE, V21, P6222, DOI 10.1038/sj.onc.1205713; Griffin CS, 2000, NAT CELL BIOL, V2, P757, DOI 10.1038/35036399; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; Hinton CV, 2007, EXP CELL RES, V313, P1735, DOI 10.1016/j.yexcr.2007.03.008; Hut HMJ, 2003, MOL BIOL CELL, V14, P1993, DOI 10.1091/mbc.E02-08-0510; Ivanov EL, 1996, GENETICS, V142, P693; Kraakman-van der Zwet M, 2002, MOL CELL BIOL, V22, P669, DOI 10.1128/MCB.22.2.669-679.2002; Lambert S, 2000, EMBO J, V19, P3090, DOI 10.1093/emboj/19.12.3090; Lambert S, 2002, ONCOGENE, V21, P4065, DOI 10.1038/sj.onc.1205535; Lee H, 1999, MOL CELL, V4, P1, DOI 10.1016/S1097-2765(00)80182-3; Lee SE, 1998, CELL, V94, P399, DOI 10.1016/S0092-8674(00)81482-8; Liang F, 1998, P NATL ACAD SCI USA, V95, P5172, DOI 10.1073/pnas.95.9.5172; Liu N, 1998, MOL CELL, V1, P783, DOI 10.1016/S1097-2765(00)80078-7; Miralem T, 2003, MOL CELL BIOL, V23, P579, DOI 10.1128/MCB.23.2.579-593.2003; Narod SA, 2004, NAT REV CANCER, V4, P665, DOI 10.1038/nrc1431; Plo I, 2008, CANCER RES, V68, P9404, DOI 10.1158/0008-5472.CAN-08-0861; Saintigny Y, 2007, ONCOGENE, V26, P2769, DOI 10.1038/sj.onc.1210075; Saintigny Y, 1999, ONCOGENE, V18, P3553, DOI 10.1038/sj.onc.1202941; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Sun M, 2001, AM J PATHOL, V159, P431, DOI 10.1016/S0002-9440(10)61714-2; Takata M, 2001, MOL CELL BIOL, V21, P2858, DOI 10.1128/MCB.21.8.2858-2866.2001; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; WANG YY, 1988, MOL CELL BIOL, V8, P196, DOI 10.1128/MCB.8.1.196; Xiang T, 2008, CANCER RES, V68, P10040, DOI 10.1158/0008-5472.CAN-08-3009; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yang HL, 2006, CANCER RES, V66, P3096, DOI 10.1158/0008-5472.CAN-05-3620; Zhang JR, 2004, MOL CELL BIOL, V24, P708, DOI 10.1128/MCB.24.2.708-718.2004	32	17	17	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2009	28	22					2231	2237		10.1038/onc.2009.85	http://dx.doi.org/10.1038/onc.2009.85			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	453VF	19398948				2022-12-17	WOS:000266640300005
J	Sun, P; Nallar, SC; Kalakonda, S; Lindner, DJ; Martin, SS; Kalvakolanu, DV				Sun, P.; Nallar, S. C.; Kalakonda, S.; Lindner, D. J.; Martin, S. S.; Kalvakolanu, D. V.			GRIM-19 inhibits v-Src-induced cell motility by interfering with cytoskeletal restructuring	ONCOGENE			English	Article						interferon; cytoskeleton; oncogenes; metastasis; growth suppression	REGULATORY GENE-PRODUCT; RETINOIC ACID; MATRIX-METALLOPROTEINASE; TYROSINE PHOSPHORYLATION; SIGNAL TRANSDUCER; STAT3 ACTIVATION; DEATH; ACTIN; CORTACTIN; PROTEIN	GRIM-19 (Gene associated with Retinoid-Interferon-induced Mortality 19) is a novel tumor suppressor regulated by interferon/retinoid combination. We have recently shown that GRIM-19 inhibits v-Src-induced oncogenic transformation and metastatic behavior of cells. Oncogenic v-Src induces cell motility by cytoskeletal remodeling, especially the formation of podosomes and. Here, we show that GRIM-19 inhibited the v-Src-induced cell motility by inhibiting cytoskeletal remodeling, that is, podosome formation. We also show that the N terminus of GRIM-19 played a major role in this process and identified critical residues in this region. More importantly, we show that tumor-associated GRIM-19 mutations disrupted its ability to inhibit v-Src-induced cell motility. These actions appear to occur independently of STAT3, a known target of GRIM-19-mediated inhibition. Lastly, tumor-associated GRIM-19 mutants significantly lost their ability to control v-Src-induced metastases in vivo, indicating the biological and pathological significance of these observations.	[Sun, P.; Nallar, S. C.; Kalakonda, S.; Martin, S. S.; Kalvakolanu, D. V.] Univ Maryland, Sch Med, Greenebaum Canc Ctr, Baltimore, MD 21201 USA; [Sun, P.; Kalvakolanu, D. V.] Univ Maryland, Grad Program Life Sci, Baltimore, MD 21201 USA; [Lindner, D. J.] Cleveland Clin, Lerner Res Inst, Taussig Canc Ctr, Cleveland, OH 44106 USA; [Lindner, D. J.] Cleveland Clin, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44106 USA; [Sun, P.; Nallar, S. C.; Kalakonda, S.; Kalvakolanu, D. V.] Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Cleveland Clinic Foundation; Cleveland Clinic Foundation; University System of Maryland; University of Maryland Baltimore	Kalvakolanu, DV (corresponding author), Univ Maryland, Sch Med, Greenebaum Canc Ctr, 660 W Redwood St,Howard Hall Room 324, Baltimore, MD 21201 USA.	dkalvako@umaryland.edu	Lindner, Daniel/ABB-5440-2020		National Cancer Institute [CA105005]; NATIONAL CANCER INSTITUTE [R01CA105005] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	DVK thanks National Cancer Institute (CA105005) for the grant support.	Alchanati I, 2006, ONCOGENE, V25, P7138, DOI 10.1038/sj.onc.1209708; Angell JE, 2000, J BIOL CHEM, V275, P33416, DOI 10.1074/jbc.M003929200; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; Fearnley IM, 2001, J BIOL CHEM, V276, P38345, DOI 10.1074/jbc.C100444200; Frame MC, 2002, NAT REV MOL CELL BIO, V3, P233, DOI 10.1038/nrm779; Hakak Y, 2000, ONCOGENE, V19, P3164, DOI 10.1038/sj.onc.1203655; Head JA, 2003, MOL BIOL CELL, V14, P3216, DOI 10.1091/mbc.e02-11-0753; Huang C, 1997, J BIOL CHEM, V272, P13911, DOI 10.1074/jbc.272.21.13911; Itoh M, 2006, ONCOGENE, V25, P1195, DOI 10.1038/sj.onc.1209149; Jonasch E, 2001, ONCOLOGIST, V6, P34, DOI 10.1634/theoncologist.6-1-34; Kalakonda S, 2007, AM J PATHOL, V171, P1352, DOI 10.2353/ajpath.2007.070241; Kalakonda S, 2007, CANCER RES, V67, P6212, DOI 10.1158/0008-5472.CAN-07-0031; Kolla V, 1996, J BIOL CHEM, V271, P10508, DOI 10.1074/jbc.271.18.10508; Lindner DJ, 1997, CLIN CANCER RES, V3, P931; Lufei CC, 2003, EMBO J, V22, P1325, DOI 10.1093/emboj/cdg135; Ma XR, 2001, J BIOL CHEM, V276, P24843, DOI 10.1074/jbc.M100380200; Martin GS, 2001, NAT REV MOL CELL BIO, V2, P467, DOI 10.1038/35073094; Maximo V, 2005, BRIT J CANCER, V92, P1892, DOI 10.1038/sj.bjc.6602547; Mizutani K, 2002, CANCER RES, V62, P669; MONSKY WL, 1993, CANCER RES, V53, P3159; Ng DCH, 2006, J CELL BIOL, V172, P245, DOI 10.1083/jcb.200503021; Rodriguez OC, 2003, NAT CELL BIOL, V5, P599, DOI 10.1038/ncb0703-599; Scott LA, 2004, MOL CELL BIOL, V24, P1540, DOI 10.1128/MCB.24.4.1540-1559.2004; Seo T, 2002, J VIROL, V76, P8797, DOI 10.1128/JVI.76.17.8797-8807.2002; Tehrani S, 2007, P NATL ACAD SCI USA, V104, P11933, DOI 10.1073/pnas.0701077104; Tehrani S, 2006, MOL BIOL CELL, V17, P2882, DOI 10.1091/mbc.e06-03-0187; Wittmann T, 2001, J CELL SCI, V114, P3795; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; Zhang J, 2003, P NATL ACAD SCI USA, V100, P9342, DOI 10.1073/pnas.1633516100; Zhang L, 2008, CLIN CANCER RES, V14, P559, DOI 10.1158/1078-0432.CCR-07-1176	33	17	22	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2009	28	10					1339	1347		10.1038/onc.2008.480	http://dx.doi.org/10.1038/onc.2008.480			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	417ZC	19151760	Green Accepted			2022-12-17	WOS:000264116000006
J	Shimwell, NJ; Martin, A; Bruton, RK; Blackford, AN; Sedgwick, GG; Gallimore, PH; Turnell, AS; Grand, RJA				Shimwell, N. J.; Martin, A.; Bruton, R. K.; Blackford, A. N.; Sedgwick, G. G.; Gallimore, P. H.; Turnell, A. S.; Grand, R. J. A.			Adenovirus 5 E1A is responsible for increased expression of insulin receptor substrate 4 in established adenovirus 5-transformed cell lines and interacts with IRS components activating the PI3 kinase/Akt signalling pathway	ONCOGENE			English	Article						Ad5E1A; IRS-1; IRS-2; IRS-4; Akt	GROWTH-FACTOR-I; LARGE T-ANTIGEN; GENE-EXPRESSION; BINDING PROTEIN; DNA-REPAIR; TRANSCRIPTIONAL ADAPTER; SIMIAN ADENOVIRUSES; GLUCOSE-HOMEOSTASIS; SEQUENCE-ANALYSIS; MEDIATOR COMPLEX	Using mass spectrometric analysis insulin receptor substrate 4 (IRS-4) has been identified as a novel adenovirus 5 early region 1A (Ad5E1A)-binding protein. IRS-4 interacts with both the transcriptional activation domain (conserved region 3) and the N-terminal region of Ad5E1A13S. Prolonged expression of Ad5E1A13S is required for the observed dramatic increase in the levels of IRS-4 mRNA and protein in Ad5E1-transformed human cell lines. Once expressed, as well as binding to E1A and the insulin receptor, IRS-4 remains tyrosine phosphorylated and constitutively associates with the regulatory p85 subunit of phosphoinositide 3 kinase, resulting in the phosphorylation of Akt (causing activation) and GSK-3 beta (causing inhibition). Reducing IRS-4 expression using small interfering RNA (siRNA) in established Ad5E1A-expressing cell lines decreases the activation of Akt and cellular proliferation. During Ad5 infection, IRS-4 is not expressed. However, Ad5E1A associates with IRS-1, increasing Akt and GSK-3 beta phosphorylation and tyrosine phosphorylation of IRS-1 itself. We conclude that the association and altered regulation of IRS proteins by Ad5E1A contribute to the adenovirus-transformed phenotype and modulates viral infection in an Akt-dependent manner.	[Grand, R. J. A.] Univ Birmingham, Inst Canc Studies, Sch Canc Sci, Canc Res UK, Birmingham B15 2TT, W Midlands, England	Cancer Research UK; University of Birmingham	Grand, RJA (corresponding author), Univ Birmingham, Inst Canc Studies, Sch Canc Sci, Canc Res UK, Birmingham B15 2TT, W Midlands, England.	R.J.A.Grand@bham.ac.uk	Blackford, Andrew N/H-6575-2019	Blackford, Andrew N/0000-0003-1979-021X	Cancer Research UK	Cancer Research UK(Cancer Research UK)	We are most grateful to Dr Joe Mymryk (University of Western Ontario) for the gift of various AdE1A constructs, Professor Thomas Dobner (University of Hamburg) for a gift of the Ad5-transformed rat cell lines, Professor Derek Leroith (Mount Sinai School of Medicine) for IRS-4 cDNA and Cancer Research UK for their financial support.	ARAKI E, 1995, MOL ENDOCRINOL, V9, P1367, DOI 10.1210/me.9.10.1367; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Avvakumov N, 2004, VIROLOGY, V329, P477, DOI 10.1016/j.virol.2004.08.007; Avvakumov N, 2002, J VIROL, V76, P7968, DOI 10.1128/JVI.76.16.7968-7975.2002; Barral PM, 2005, FEBS LETT, V579, P2752, DOI 10.1016/j.febslet.2005.03.095; Bartholomeusz C, 2006, ONCOGENE, V25, P79, DOI 10.1038/sj.onc.1209014; BAYLEY ST, 1994, INT J ONCOL, V5, P425; Berk AJ, 2005, ONCOGENE, V24, P7673, DOI 10.1038/sj.onc.1209040; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; Boyer TG, 1999, NATURE, V399, P276, DOI 10.1038/20466; Bruton RK, 2007, ONCOGENE, V26, P7467, DOI 10.1038/sj.onc.1210551; Cai DS, 2003, J BIOL CHEM, V278, P25323, DOI 10.1074/jbc.M212430200; Cuevas EP, 2007, J HEPATOL, V46, P1089, DOI 10.1016/j.jhep.2007.01.031; DeAngelis T, 2006, ONCOGENE, V25, P32, DOI 10.1038/sj.onc.1209013; Dearth RK, 2007, CELL CYCLE, V6, P705, DOI 10.4161/cc.6.6.4035; Dillon RL, 2007, ONCOGENE, V26, P1338, DOI 10.1038/sj.onc.1210202; DYSON N, 1992, J VIROL, V66, P6893, DOI 10.1128/JVI.66.12.6893-6902.1992; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Endter C, 2004, CURR TOP MICROBIOL, V273, P163; Fantin VR, 1998, J BIOL CHEM, V273, P10726, DOI 10.1074/jbc.273.17.10726; Fantin VR, 2000, AM J PHYSIOL-ENDOC M, V278, pE127, DOI 10.1152/ajpendo.2000.278.1.E127; Fantin VR, 1999, BIOCHEM BIOPH RES CO, V260, P718, DOI 10.1006/bbrc.1999.0967; FEI ZL, 1995, MOL CELL BIOL, V15, P4232; Flaherty DM, 2004, AM J PHYSIOL-LUNG C, V287, pL393, DOI 10.1152/ajplung.00359.2003; Frisch SM, 2002, NAT REV MOL CELL BIO, V3, P441, DOI 10.1038/nrm827; Gallimore PH, 2001, ONCOGENE, V20, P7824, DOI 10.1038/sj.onc.1204913; GEISBERG JV, 1995, MOL CELL BIOL, V15, P6283; GEISBERG JV, 1994, P NATL ACAD SCI USA, V91, P2488, DOI 10.1073/pnas.91.7.2488; Giovannone B, 2000, DIABETES-METAB RES, V16, P434, DOI 10.1002/1520-7560(2000)9999:9999<::AID-DMRR159>3.0.CO;2-8; Honma M, 2006, GENES CELLS, V11, P143, DOI 10.1111/j.1365-2443.2006.00926.x; KELEKAR A, 1987, MOL CELL BIOL, V7, P3899, DOI 10.1128/MCB.7.11.3899; KIM HS, 1995, MOL ENDOCRINOL, V9, P178, DOI 10.1210/me.9.2.178; Lavan BE, 1997, J BIOL CHEM, V272, P21403, DOI 10.1074/jbc.272.34.21403; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; Liu SCH, 1999, J BIOL CHEM, V274, P18093, DOI 10.1074/jbc.274.25.18093; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Qiu HQ, 2005, ONCOGENE, V24, P5656, DOI 10.1038/sj.onc.1208721; Qu BH, 1999, J BIOL CHEM, V274, P31179, DOI 10.1074/jbc.274.44.31179; Rasti M, 2005, J VIROL, V79, P5594, DOI 10.1128/JVI.79.9.5594-5605.2005; Rasti M, 2006, EMBO J, V25, P2710, DOI 10.1038/sj.emboj.7601169; Reiss K, 2006, J CELL PHYSIOL, V206, P295, DOI 10.1002/jcp.20455; STEIN RW, 1987, MOL CELL BIOL, V7, P1164, DOI 10.1128/MCB.7.3.1164; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; Taniguchi CM, 2006, NAT REV MOL CELL BIO, V7, P85, DOI 10.1038/nrm1837; TIMMERS HTM, 1988, J BIOL CHEM, V263, P1329; Trojanek J, 2006, J CELL PHYSIOL, V206, P35, DOI 10.1002/jcp.20425; Trojanek J, 2003, MOL CELL BIOL, V23, P7510, DOI 10.1128/MCB.23.21.7510-7524.2003; Tseng YH, 2004, MOL CELL BIOL, V24, P1918, DOI 10.1128/MCB.24.5.1918-1929.2004; Tsuruzoe K, 2001, MOL CELL BIOL, V21, P26, DOI 10.1128/MCB.21.1.26-38.2001; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609; Wang G, 2002, J VIROL, V76, P9186, DOI 10.1128/JVI.76.18.9186-9193.2002; Ward DG, 2006, BRIT J CANCER, V94, P1898, DOI 10.1038/sj.bjc.6603188; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; White MF, 2006, CAN J PHYSIOL PHARM, V84, P725, DOI 10.1139/Y06-008; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Zhou-Li Fei, 1995, Molecular and Cellular Biology, V15, P4232	60	17	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2009	28	5					686	697		10.1038/onc.2008.417	http://dx.doi.org/10.1038/onc.2008.417			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	403IN	19029952				2022-12-17	WOS:000263076400006
J	Snijders, AM; Huey, B; Connelly, ST; Roy, R; Jordan, RCK; Schmidt, BL; Albertson, DG				Snijders, A. M.; Huey, B.; Connelly, S. T.; Roy, R.; Jordan, R. C. K.; Schmidt, B. L.; Albertson, D. G.			Stromal control of oncogenic traits expressed in response to the overexpression of GLI2, a pleiotropic oncogene	ONCOGENE			English	Article						GLI2; organotypic culture; transdifferentiation; invasion	GENE AMPLIFICATION; GENOMIC INSTABILITY; D1 OVEREXPRESSION; CARCINOMA-CELLS; TUMOR; DIFFERENTIATION; GROWTH; TISSUE; TRANSCRIPTION; INHIBITION	Hedgehog signaling is often activated in tumors, yet it remains unclear how GLI2, a transcription factor activated by this pathway, acts as an oncogene. We show that GLI2 is a pleiotropic oncogene. The overexpression induces genomic instability and blocks differentiation, likely mediated in part by enhanced expression of the stem cell gene SOX2. GLI2 also induces transforming growth factor (TGF) B1-dependent transdifferentiation of foreskin and tongue, but not gingival. broblasts into myofibroblasts, creating an environment permissive for invasion by keratinocytes, which are in various stages of differentiation having downregulated GLI2. Thus, upregulated GLI2 expression is sufficient to induce a number of the acquired characteristics of tumor cells; however, the stroma, in a tissue-specific manner, determines whether certain GLI2 oncogenic traits are expressed.	[Albertson, D. G.] Univ Calif San Francisco, Canc Res Inst, Ctr Comprehens Canc, San Francisco, CA 94143 USA; [Snijders, A. M.; Huey, B.; Roy, R.; Jordan, R. C. K.; Schmidt, B. L.; Albertson, D. G.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA; [Huey, B.; Albertson, D. G.] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA; [Connelly, S. T.; Jordan, R. C. K.] Univ Calif San Francisco, Dept Orofacial Sci, San Francisco, CA 94143 USA; [Schmidt, B. L.] Univ Calif San Francisco, Dept Oral & Maxillofacial Surg, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Albertson, DG (corresponding author), Univ Calif San Francisco, Canc Res Inst, Ctr Comprehens Canc, 2340 Sutter St,Box 0808, San Francisco, CA 94143 USA.	albertson@cc.ucsf.edu		Schmidt, Brian/0000-0002-2409-8984	NIH [CA118323]; California Tobacco-Related Disease Research [14FT-0011]; NCI-sponsored Tumor Microenvironment Training Program; Western Oral Research Consortium (NIH) [K12 DE14609]; NATIONAL CANCER INSTITUTE [R01CA118323] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [K12DE014609] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); California Tobacco-Related Disease Research; NCI-sponsored Tumor Microenvironment Training Program; Western Oral Research Consortium (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	We thank Drs Gillian Hall and Richard Shaw, University of Liverpool for providing oral SCC 1300C2, Dr Fritz Aberger, University of Salzburg for providing the HaCaT Tet cells, HaCaT GLI2 cells and the 6xHis-GLI2DN pcDNA4/TO vector construct and Dr Rosemary Akhurst, UCSF Helen Diller Family Comprehensive Cancer Center (HDFCCC) and Dr J Yingling (Eli Lilly and Company, Indianapolis, IN) for providing the transforming growth factor beta receptor kinase inhibitor, LY2109761. The UCSF HDFCCC Microarray, Tissue, Immunohistochemistry/Molecular Pathology and Genome Analysis Shared Resources provided assistance. This work was supported by NIH Grant CA118323. AMS was the recipient of a postdoctoral fellowship from the California Tobacco-Related Disease Research Program (14FT-0011) and a trainee of the NCI-sponsored Tumor Microenvironment Training Program: Techniques in the Establishment and Manipulation of Organotypic Model Systems. BLS is an appointee of the Western Oral Research Consortium (NIH K12 DE14609).	Albertson DG, 2003, NAT GENET, V34, P369, DOI 10.1038/ng1215; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; BELL E, 1981, SCIENCE, V211, P1052, DOI 10.1126/science.7008197; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Bigelow RLH, 2005, J INVEST DERMATOL, V124, P457, DOI 10.1111/j.0022-202X.2004.23590.x; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Burnworth B, 2006, ONCOGENE, V25, P4399, DOI 10.1038/sj.onc.1209474; Cerezo A, 2003, J INVEST DERMATOL, V121, P110, DOI 10.1046/j.1523-1747.2003.12304.x; Chang HY, 2002, P NATL ACAD SCI USA, V99, P12877, DOI 10.1073/pnas.162488599; Chen YP, 2008, J BIOL CHEM, V283, P17969, DOI 10.1074/jbc.M802917200; Clement V, 2007, CURR BIOL, V17, P165, DOI 10.1016/j.cub.2006.11.033; De Wever O, 2003, J PATHOL, V200, P429, DOI 10.1002/path.1398; Delehedde M, 2001, J INVEST DERMATOL, V116, P366, DOI 10.1046/j.1523-1747.2001.01260.x; Fridlyand J, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-96; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Grachtchouk V, 2003, EMBO J, V22, P2741, DOI 10.1093/emboj/cdg271; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hooper JE, 2005, NAT REV MOL CELL BIO, V6, P306, DOI 10.1038/nrm1622; Izzo JG, 1998, ONCOGENE, V17, P2313, DOI 10.1038/sj.onc.1202153; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Kellermann MG, 2008, ORAL ONCOL, V44, P509, DOI 10.1016/j.oraloncology.2007.07.001; Kendall J, 2007, P NATL ACAD SCI USA, V104, P16663, DOI 10.1073/pnas.0708286104; Kwei KA, 2008, ONCOGENE, V27, P3635, DOI 10.1038/sj.onc.1211012; Lacher MD, 2006, CANCER RES, V66, P1648, DOI 10.1158/0008-5472.CAN-05-2328; Lauth M, 2007, CELL CYCLE, V6, P2458, DOI 10.4161/cc.6.20.4808; Lauth M, 2007, P NATL ACAD SCI USA, V104, P8455, DOI 10.1073/pnas.0609699104; Lewis MP, 2004, BRIT J CANCER, V90, P822, DOI 10.1038/sj.bjc.6601611; Marsh D, 2008, CANCER RES, V68, P3295, DOI 10.1158/0008-5472.CAN-08-0174; MIELE M, 1989, MUTAT RES, V219, P171, DOI 10.1016/0921-8734(89)90012-X; Mueller MM, 2004, NAT REV CANCER, V4, P839, DOI 10.1038/nrc1477; Murnane JP, 2004, BIOESSAYS, V26, P1164, DOI 10.1002/bies.20125; Neill GW, 2008, CARCINOGENESIS, V29, P738, DOI 10.1093/carcin/bgn037; Nelsen CJ, 2005, J BIOL CHEM, V280, P768, DOI 10.1074/jbc.M407105200; Okubo T, 2006, GENE DEV, V20, P2654, DOI 10.1101/gad.1457106; Paulson TG, 1998, MOL CELL BIOL, V18, P3089, DOI 10.1128/MCB.18.5.3089; Que J, 2007, DEVELOPMENT, V134, P2521, DOI 10.1242/dev.003855; Regl G, 2004, ONCOGENE, V23, P1263, DOI 10.1038/sj.onc.1207240; Riobo NA, 2006, CELL CYCLE, V5, P1612, DOI 10.4161/cc.5.15.3130; Roh HJ, 2000, CANCER RES, V60, P6496; Roth JR, 2004, RES MICROBIOL, V155, P342, DOI 10.1016/j.resmic.2004.01.016; Schmidt BL, 2004, J ORAL MAXIL SURG, V62, P1055, DOI 10.1016/j.joms.2004.03.010; Schoop VM, 1999, J INVEST DERMATOL, V112, P343, DOI 10.1046/j.1523-1747.1999.00524.x; Shimizu N, 2005, EXP CELL RES, V302, P233, DOI 10.1016/j.yexcr.2004.09.001; Snijders AM, 2003, ONCOGENE, V22, P4370, DOI 10.1038/sj.onc.1206482; Snijders AM, 2005, ONCOGENE, V24, P4232, DOI 10.1038/sj.onc.1208601; Snijders AM, 2008, GENE CHROMOSOME CANC, V47, P71, DOI 10.1002/gcc.20509; Svensson S, 2003, CANCER RES, V63, P1737; Tuxhorn JA, 2001, J UROLOGY, V166, P2472, DOI 10.1016/S0022-5347(05)65620-0; Verona EV, 2007, CANCER RES, V67, P5737, DOI 10.1158/0008-5472.CAN-07-0444; Weir BA, 2007, NATURE, V450, P893, DOI 10.1038/nature06358; Zeisberg EM, 2007, CANCER RES, V67, P10123, DOI 10.1158/0008-5472.CAN-07-3127; Zhou P, 1996, CANCER RES, V56, P36	52	17	17	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2009	28	5					625	637		10.1038/onc.2008.421	http://dx.doi.org/10.1038/onc.2008.421			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	403IN	19015636	Green Accepted, Green Submitted			2022-12-17	WOS:000263076400001
J	Hoyos, JM; Ferraro, A; Sacchetti, S; Keller, S; De Martino, I; Borbone, E; Pallante, P; Fedele, M; Montanaro, D; Esposito, F; Cserjesi, P; Chiariotti, L; Troncone, G; Fusco, A				Hoyos, J. Martinez; Ferraro, A.; Sacchetti, S.; Keller, S.; De Martino, I.; Borbone, E.; Pallante, P.; Fedele, M.; Montanaro, D.; Esposito, F.; Cserjesi, P.; Chiariotti, L.; Troncone, G.; Fusco, A.			HAND1 gene expression is negatively regulated by the High Mobility Group A1 proteins and is drastically reduced in human thyroid carcinomas	ONCOGENE			English	Article						HMGA1; HAND1; knockout mice; ES cells; thyroid carcinomas	TRANSCRIPTION FACTOR; HMGA1 PROTEINS; IDENTIFICATION; CANCERS; REQUIRES; MICE	HMGA1 proteins exert their major physiological function during embryonic development and play a critical role in neoplastic transformation. Here, we show that Hand1 gene, which codes for a transcription factor crucial for differentiation of trophoblast giant cells and heart development, is upregulated in hmga1 minus embryonic stem cells. We demonstrate that HMGA1 proteins bind directly to Hand1 promoter both in vitro and in vivo and inhibit Hand1 promoter activity. We have also investigated HAND1 expression in human thyroid carcinoma cell lines and tissues, in which HMGA proteins are overexpressed, with respect to normal thyroid; an inverse correlation between HMGA1 and HAND1 expression was found in all thyroid tumor histotypes. A correlation between HAND1 gene repression and promoter hypermethylation was found in anaplastic carcinomas but not in other thyroid tumor histotypes. Therefore, we can hypothesize that HMGA1 overexpression plays a key role on HAND1 silencing in differentiated thyroid carcinomas and that promoter hypermethylation occurs in later stages of thyroid tumor progression. Finally, the restoration of the HAND1 gene expression reduces the clonogenic ability of two human thyroid carcinoma-derived cell lines, suggesting that HAND1 downregulation may have a role in the process of thyroid carcinogenesis.	[Hoyos, J. Martinez; Keller, S.; De Martino, I.; Fedele, M.; Esposito, F.; Chiariotti, L.; Fusco, A.] Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, Ist Endocrinol & Oncol Sperimentale, CNR,Fac Med & Chirurg Napoli, I-80131 Naples, Italy; [Hoyos, J. Martinez; Ferraro, A.; Sacchetti, S.; Keller, S.; De Martino, I.; Borbone, E.; Pallante, P.; Montanaro, D.; Chiariotti, L.; Fusco, A.] CEINGE Biotecn Avanzate, NOGEC, Naples, Italy; [Cserjesi, P.] Tulane Univ, Dept Cell & Mol Biol, New Orleans, LA 70118 USA; [Troncone, G.] Univ Naples Federico II, Dipartimento Anat Patol & Citopatol, Fac Med & Chirurg, I-80131 Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II; CEINGE Biotecnologie Avanzate; Tulane University; University of Naples Federico II	Fusco, A (corresponding author), Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, Ist Endocrinol & Oncol Sperimentale, CNR,Fac Med & Chirurg Napoli, Via Pansini 5, I-80131 Naples, Italy.	afusco@napoli.com	Fedele, Monica/C-1417-2015; Ferraro, Angelo/A-4172-2014; ESPOSITO, FRANCESCO/AAX-2044-2020; Pallante, Pierlorenzo/AAX-8758-2020; Esposito, Francesco/J-9136-2016; Chiariotti, Lorenzo/AAC-5262-2022; Ferraro, Angelo/H-3193-2019	Fedele, Monica/0000-0002-9171-1312; Ferraro, Angelo/0000-0002-2044-7569; Esposito, Francesco/0000-0002-7709-5736; Ferraro, Angelo/0000-0002-2044-7569; Fusco, Alfredo/0000-0003-3332-5197; Martinez Hoyos, Josefina/0000-0002-6909-8259; CHIARIOTTI, Lorenzo/0000-0001-6097-4171	Associazione Italiana Ricerca sul Cancro (AIRC); Ministero dell'Universita e della Ricerca Scientifica e Tecnologica (MIUR); NOGEC-Naples Oncogenomic Center; Associazione Partenopea per le Ricerche Oncologiche (APRO)	Associazione Italiana Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Ministero dell'Universita e della Ricerca Scientifica e Tecnologica (MIUR)(Ministry of Education, Universities and Research (MIUR)); NOGEC-Naples Oncogenomic Center; Associazione Partenopea per le Ricerche Oncologiche (APRO)	This work was supported by grants from the Associazione Italiana Ricerca sul Cancro (AIRC), and the Ministero dell'Universita e della Ricerca Scientifica e Tecnologica (MIUR). This work was supported from NOGEC-Naples Oncogenomic Center. We thank the Associazione Partenopea per le Ricerche Oncologiche (APRO) for its support. We thank Gabriella Sole, INN-CNR of Cagliari, for statistical analysis.	Baldassarre G, 2001, P NATL ACAD SCI USA, V98, P7970, DOI 10.1073/pnas.141224998; Battista S, 2003, FASEB J, V17, P1496, DOI 10.1096/fj.02-0977fje; Berlingieri MT, 2002, ONCOGENE, V21, P2971, DOI 10.1038/sj.onc.1205368; Chiappetta G, 1996, ONCOGENE, V13, P2439; CROSS JC, 1995, DEVELOPMENT, V121, P2513; CSERJESI P, 1995, DEV BIOL, V170, P664, DOI 10.1006/dbio.1995.1245; Donato G, 2004, ONCOL REP, V11, P1209; Fedele M, 2006, CANCER RES, V66, P2536, DOI 10.1158/0008-5472.CAN-05-1889; Fedele M, 2001, CARCINOGENESIS, V22, P1583, DOI 10.1093/carcin/22.10.1583; Fusco A, 2007, NAT REV CANCER, V7, P899, DOI 10.1038/nrc2271; Hagihara A, 2004, ONCOGENE, V23, P8705, DOI 10.1038/sj.onc.1207783; Hoyos JM, 2004, CANCER RES, V64, P5728, DOI 10.1158/0008-5472.CAN-04-1410; Kaneda A, 2002, CANCER RES, V62, P6645; Knofler M, 2002, BIOCHEM J, V361, P641, DOI 10.1042/0264-6021:3610641; Kondo T, 2006, NAT REV CANCER, V6, P292, DOI 10.1038/nrc1836; Pallante P, 2005, BRIT J CANCER, V93, P464, DOI 10.1038/sj.bjc.6602721; Reeves R, 2001, GENE, V277, P63, DOI 10.1016/S0378-1119(01)00689-8; Riley P, 1998, NAT GENET, V18, P271, DOI 10.1038/ng0398-271; Ritter O, 1999, J CELL BIOCHEM, V74, P551, DOI 10.1002/(SICI)1097-4644(19990915)74:4<551::AID-JCB5>3.3.CO;2-0; Takada T, 2004, CANCER SCI, V95, P741, DOI 10.1111/j.1349-7006.2004.tb03255.x; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1	21	17	17	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2009	28	6					876	885		10.1038/onc.2008.438	http://dx.doi.org/10.1038/onc.2008.438			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	406UI	19060921				2022-12-17	WOS:000263320000010
J	Salah, Z; Haupt, S; Maoz, M; Baraz, L; Rotter, V; Peretz, T; Haupt, Y; Bar-Shavit, R				Salah, Z.; Haupt, S.; Maoz, M.; Baraz, L.; Rotter, V.; Peretz, T.; Haupt, Y.; Bar-Shavit, R.			p53 controls hPar1 function and expression	ONCOGENE			English	Article						PAR1; p53; protease; promoter activity; transcription factor	PROTEASE-ACTIVATED RECEPTOR-1; WILD-TYPE P53; HUMAN ENDOTHELIAL-CELLS; GAIN-OF-FUNCTION; MUTANT P53; THROMBIN RECEPTOR; TUMOR-SUPPRESSOR; PROSTATE-CANCER; TRANSCRIPTIONAL REGULATION; MUTATION ANALYSIS	Human protease-activated receptor 1(hPar1) is a bonafide receptor of the hemostatic protease thrombin, and has a central function in tumor progression. Inactivation of the tumor suppressor gene p53 is one of the most common genomic alterations occurring in cancer. Here, we address the interrelations between p53 and hPar1 in cancer. We demonstrate an inverse correlation between hPar1 gene expression and wild-type (wt) p53 levels, and a direct correlation with levels of the mutant (mt) p53. Bioinformatic search revealed the presence of at least two p53 motifs in the hPar1 promoter. Indeed, temperature-sensitive (ts) p53 forms reduced hPar1 promoter activity on wt p53 expression. Ectopic introduction of the p53R175H mutant into cells lacking p53 caused a moderate two-fold induction of hPar1 promoter activity. Chromatin immunoprecipitation (ChIP) analyses confirmed a physical association between the p53 protein and hPar1 chromatin fragments. In parallel, PAR1 function is attenuated by p53, as shown by inhibition of pFAK levels and a Matrigel invasion assay. Ectopic reinforcement of hPar1 rescued the inhibition conferred by p53, confirming that p53 directly affects hPar1 expression and function. Altogether, we provide evidence for a direct binding between p53 and hPar1 chromatin, and assign hPar1 as a target of p53. Oncogene (2008) 27, 6866-6874; doi: 10.1038/onc.2008.324; published online 29 September 2008	[Salah, Z.; Maoz, M.; Baraz, L.; Peretz, T.; Bar-Shavit, R.] Hadassah Univ, Med Ctr, Dept Oncol, Jerusalem, Israel; [Haupt, S.; Haupt, Y.] Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Immunol, Lautenberg Ctr, IL-91010 Jerusalem, Israel; [Rotter, V.] Weizmann Inst Sci, Dept Mol Cell Biol, Rehovot, Israel	Hebrew University of Jerusalem; Hadassah University Medical Center; Hebrew University of Jerusalem; Weizmann Institute of Science	Bar-Shavit, R (corresponding author), Hadassah Hebrew Univ Hosp, Dept Oncol, POB 12000, IL-91120 Jerusalem, Israel.	rachel.bar-shavit@ekmd.huji.ac.il		Haupt, Ygal/0000-0001-5925-0096	Israel Science Foundation by the Israel Academy of Science and Humanities; The Israel Cancer Association; MECC (Middle East Cancer Consortium)	Israel Science Foundation by the Israel Academy of Science and Humanities(Israel Science Foundation); The Israel Cancer Association; MECC (Middle East Cancer Consortium)	Grant support: Israel Science Foundation by the Israel Academy of Science and Humanities, The Israel Cancer Association and MECC (Middle East Cancer Consortium) Small Grant Program (R Bar-Shavit).	Ahn J, 1999, ONCOGENE, V18, P5954, DOI 10.1038/sj.onc.1202986; ALBINI A, 1987, CANCER RES, V47, P3239; Aylon Y, 2007, CELL, V130, P597, DOI 10.1016/j.cell.2007.08.005; Blagosklonny MV, 2000, FASEB J, V14, P1901, DOI 10.1096/fj.99-1078rev; Booden MA, 2004, MOL CELL BIOL, V24, P1990, DOI 10.1128/MCB.24.5.1990-1999.2004; Cadwell C, 2001, GENE, V277, P15, DOI 10.1016/S0378-1119(01)00696-5; Caunt M, 2006, CANCER RES, V66, P4125, DOI 10.1158/0008-5472.CAN-05-2570; Chay CH, 2002, UROLOGY, V60, P760, DOI 10.1016/S0090-4295(02)01969-6; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Darmoul D, 2003, AM J PATHOL, V162, P1503, DOI 10.1016/S0002-9440(10)64283-6; Dearth LR, 2007, CARCINOGENESIS, V28, P289, DOI 10.1093/carcin/bgl132; Di Agostino S, 2006, CANCER CELL, V10, P191, DOI 10.1016/j.ccr.2006.08.013; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Even-Ram S, 1998, NAT MED, V4, P909, DOI 10.1038/nm0898-909; Even-Ram SC, 2001, J BIOL CHEM, V276, P10952, DOI 10.1074/jbc.M007027200; Farmer G, 1996, MOL CELL BIOL, V16, P4295; Hamroun D, 2006, HUM MUTAT, V27, P14, DOI 10.1002/humu.20269; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Ho J, 2003, CELL DEATH DIFFER, V10, P404, DOI 10.1038/sj.cdd.4401191; ISAACS WB, 1991, CANCER RES, V51, P4716; Joerger AC, 2007, ONCOGENE, V26, P2226, DOI 10.1038/sj.onc.1210291; Kastan MB, 2007, CELL, V128, P837, DOI 10.1016/j.cell.2007.02.022; Kato S, 2003, P NATL ACAD SCI USA, V100, P8424, DOI 10.1073/pnas.1431692100; Laptenko O, 2006, CELL DEATH DIFFER, V13, P951, DOI 10.1038/sj.cdd.4401916; Levine AJ, 2006, CELL DEATH DIFFER, V13, P1027, DOI 10.1038/sj.cdd.4401910; Li FZ, 1996, J BIOL CHEM, V271, P26320, DOI 10.1074/jbc.271.42.26320; Martins CP, 2006, CELL, V127, P1323, DOI 10.1016/j.cell.2006.12.007; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Menendez D, 2006, P NATL ACAD SCI USA, V103, P1406, DOI 10.1073/pnas.0508103103; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; Nystedt S, 1996, J BIOL CHEM, V271, P14910, DOI 10.1074/jbc.271.25.14910; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; Prowald A, 2007, PROSTATE, V67, P1751, DOI 10.1002/pros.20660; Resnick MA, 2003, P NATL ACAD SCI USA, V100, P9934, DOI 10.1073/pnas.1633803100; Riewald M, 2005, J BIOL CHEM, V280, P19808, DOI 10.1074/jbc.M500747200; Salah Z, 2005, FASEB J, V19, P62, DOI 10.1096/fj.04-2386com; Salah Z, 2007, CANCER RES, V67, P9835, DOI 10.1158/0008-5472.CAN-07-1886; Salah Z, 2007, MOL CANCER RES, V5, P229, DOI 10.1158/1541-7786.MCR-06-0261; Schmidt VA, 1996, J BIOL CHEM, V271, P9307, DOI 10.1074/jbc.271.16.9307; Sharpless NE, 2007, NATURE, V445, P606, DOI 10.1038/nature05567; Sigal A, 2000, CANCER RES, V60, P6788; Soussi T, 2007, ONCOGENE, V26, P2145, DOI 10.1038/sj.onc.1210280; Strano S, 2007, ONCOGENE, V26, P2212, DOI 10.1038/sj.onc.1210296; Tellez C, 2003, J BIOL CHEM, V278, P46632, DOI 10.1074/jbc.M309159200; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Weinberg RL, 2005, J MOL BIOL, V348, P589, DOI 10.1016/j.jmb.2005.03.014; Weisz L, 2004, CANCER RES, V64, P8318, DOI 10.1158/0008-5472.CAN-04-1145; Willis A, 2004, ONCOGENE, V23, P2330, DOI 10.1038/sj.onc.1207396; Wu SQ, 2002, BLOOD, V100, P4454, DOI 10.1182/blood-2002-02-0415; Yin YJ, 2003, FASEB J, V17, P163, DOI 10.1096/fj.02-0316com	53	17	17	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	2008	27	54					6866	6874		10.1038/onc.2008.324	http://dx.doi.org/10.1038/onc.2008.324			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375IS	18820708				2022-12-17	WOS:000261108000007
J	Sirvent, A; Leroy, C; Boureux, A; Simon, V; Roche, S				Sirvent, A.; Leroy, C.; Boureux, A.; Simon, V.; Roche, S.			The Src-like adaptor protein regulates PDGF-induced actin dorsal ruffles in a c-Cbl-dependent manner	ONCOGENE			English	Article						SLAP; Src; PDGF; Cbl; DNA synthesis; F-actin assembly	RECEPTOR TYROSINE KINASES; DNA-SYNTHESIS; NEGATIVE REGULATION; FIBROBLASTS; MITOGENESIS; EXPRESSION; THYMOCYTES; MIGRATION; BINDING; SLAP	The Src-like adaptor protein (SLAP) belongs to the subfamily of adapter proteins that negatively regulate cellular signalling initiated by tyrosine kinases. SLAP has a unique, myristylated N-terminus, followed by SH3 and SH2 domains with high homology to Src family tyrosine kinases (SFK) and a unique C-terminal tail, which is important for c-Cbl binding. We have previously shown that SLAP negatively regulates platelet-derived growth factor (PDGF)-induced mitogenesis in fibroblasts and we now report that it regulates F-actin assembly for dorsal ruffles formation. c-Cbl mediated SLAP inhibition towards actin remodelling. Moreover, SLAP enhanced PDGF-induced c-Cbl phosphorylation by SFK. In contrast, SLAP mitogenic inhibition was not mediated by c-Cbl, but it rather involved a competitive mechanism with SFK for PDGF-receptor (PDGFR) association and mitogenic signalling. Accordingly, phosphorylation of the Src mitogenic substrates Stat3 and Shc were reduced by SLAP. Thus, we concluded that SLAP regulates PDGFR signalling by two independent mechanisms: a competitive mechanism for PDGF-induced Src mitogenic signalling and a non-competitive mechanism for dorsal ruffles formation mediated by c-Cbl.	[Roche, S.] Univ Montpellier 1, CNRS, CRBM, UMR5237, F-34293 Montpellier 05, France; Univ Montpellier 2, Montpellier, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Universite de Montpellier	Roche, S (corresponding author), Univ Montpellier 1, CNRS, CRBM, UMR5237, 1919 Route Mende, F-34293 Montpellier 05, France.	serge.roche@crbm.cnrs.fr		roche, serge/0000-0003-3413-3859				Boureux A, 2005, J CELL SCI, V118, P3717, DOI 10.1242/jcs.02491; Bromann PA, 2004, ONCOGENE, V23, P7957, DOI 10.1038/sj.onc.1208079; Broome MA, 1999, ONCOGENE, V18, P2908, DOI 10.1038/sj.onc.1202873; Ishizawar R, 2004, CANCER CELL, V6, P209, DOI 10.1016/j.ccr.2004.09.001; Lanzetti L, 2004, NATURE, V429, P309, DOI 10.1038/nature02542; Manes G, 2000, MOL CELL BIOL, V20, P3396, DOI 10.1128/MCB.20.10.3396-3406.2000; Miyake S, 1999, J BIOL CHEM, V274, P16619, DOI 10.1074/jbc.274.23.16619; Myers MD, 2006, NAT IMMUNOL, V7, P57, DOI 10.1038/ni1291; PANDEY A, 1995, J BIOL CHEM, V270, P19201, DOI 10.1074/jbc.270.33.19201; Reddi AL, 2007, J BIOL CHEM, V282, P29336, DOI 10.1074/jbc.M701797200; Roche S, 1998, CURR BIOL, V8, P975, DOI 10.1016/S0960-9822(98)70400-2; Roche S, 1998, MOL CELL BIOL, V18, P7119, DOI 10.1128/MCB.18.12.7119; Scaife RM, 2003, J CELL SCI, V116, P463, DOI 10.1242/jcs.00244; Schmidt MHH, 2005, NAT REV MOL CELL BIO, V6, P907, DOI 10.1038/nrm1762; Sosinowski T, 2001, IMMUNITY, V15, P457, DOI 10.1016/S1074-7613(01)00195-9; Suetsugu S, 2003, DEV CELL, V5, P595, DOI 10.1016/S1534-5807(03)00297-1; Swaminathan G, 2007, ONCOGENE, V26, P4095, DOI 10.1038/sj.onc.1210184; Teckchandani AM, 2005, EXP CELL RES, V307, P247, DOI 10.1016/j.yexcr.2005.03.010; Veracini L, 2006, J CELL SCI, V119, P2921, DOI 10.1242/jcs.03015	19	17	17	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2008	27	24					3494	3500		10.1038/sj.onc.1211011	http://dx.doi.org/10.1038/sj.onc.1211011			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	307HL	18193084	Green Submitted, Bronze			2022-12-17	WOS:000256309900015
J	Wierod, L; Rosseland, CM; Lindeman, B; Oksvold, MP; Grosvik, H; Skarpen, E; Huitfeldt, HS				Wierod, L.; Rosseland, C. M.; Lindeman, B.; Oksvold, M. P.; Grosvik, H.; Skarpen, E.; Huitfeldt, H. S.			Activation of the p53-p21(Cip1) pathway is required for CDK2 activation and S-phase entry in primary rat hepatocytes	ONCOGENE			English	Article						cyclin; nuclear translocation; PI3 kinase; DNA synthesis; primary liver cells	CYCLIN-DEPENDENT KINASE; WILD-TYPE P53; RETINOBLASTOMA PROTEIN; NUCLEAR ACCUMULATION; LIVER-REGENERATION; RESTRICTION POINT; DNA-DAMAGE; GROWTH; TUMOR; PHOSPHORYLATION	p53 plays a major role in the prevention of tumor development. It responds to a range of potentially oncogenic stresses by activating protective mechanisms, most notably cell-cycle arrest and apoptosis. The p53 gene is also induced during normal liver regeneration, and it has been hypothesized that p53 serve as a proliferative 'brake' to control excessive proliferation. However, it has lately been shown that p53 inhibition reduces hepatocyte growth factor-induced DNA synthesis of primary hepatocytes. Here we show that epidermal growth factor (EGF) activated p53 in a phosphatidylinositol-3 kinase-dependent way, and thus induced the cyclin-dependent kinase inhibitor p21(Cip1) in primary rat hepatocytes. p53 inactivation with a dominant-negative mutant (p53(V143A)) attenuated EGF-induced DNA synthesis and was associated with reduced CDK2 phosphorylation and retinoblastoma protein hyperphosphorylation. When p21(Cip1) was ectopically expressed in p53-inactivated cells, these effects were neutralized. In conclusion, our results demonstrate that in normal hepatocytes, EGF-induced expression of p53 is involved in regulating CDK2- and CDK4 activity, through p21(Cip1) expression.	[Wierod, L.; Rosseland, C. M.; Oksvold, M. P.; Grosvik, H.; Skarpen, E.; Huitfeldt, H. S.] Univ Oslo, Lab Toxicol Inst Pathol, Rikshosp Radiumhosp Med Ctr, Rikshosp Univ Hosp, N-0027 Oslo, Norway; [Wierod, L.; Rosseland, C. M.; Oksvold, M. P.; Grosvik, H.; Skarpen, E.; Huitfeldt, H. S.] Univ Oslo, Ctr Cellulare Stress Responses, Oslo, Norway; [Lindeman, B.] Norwegian Inst Publ Hlth, Oslo, Norway	University of Oslo; National Hospital Norway; University of Oslo; Norwegian Institute of Public Health (NIPH)	Wierod, L (corresponding author), Univ Oslo, Lab Toxicol Inst Pathol, Rikshosp Radiumhosp Med Ctr, Rikshosp Univ Hosp, N-0027 Oslo, Norway.	lene.wierod@medisin.uio.no						Alt JR, 2002, J BIOL CHEM, V277, P8517, DOI 10.1074/jbc.M108867200; Arora V, 2000, DRUG METAB DISPOS, V28, P131; Bar J, 2005, CELL DEATH DIFFER, V12, P1578, DOI 10.1038/sj.cdd.4401677; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Coutant A, 2002, HEPATOLOGY, V36, P1079, DOI 10.1053/jhep.2002.36160; da Costa CA, 2002, P NATL ACAD SCI USA, V99, P4043, DOI 10.1073/pnas.062059899; Diehl JA, 1997, MOL CELL BIOL, V17, P7362, DOI 10.1128/MCB.17.12.7362; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fang WA, 2001, ACTA CRYSTALLOGR D, V57, P1162, DOI 10.1107/S090744490100926X; Fausto N, 1986, Symp Fundam Cancer Res, V39, P69; Friedlander P, 1996, J BIOL CHEM, V271, P25468, DOI 10.1074/jbc.271.41.25468; Fujiwara Y, 2006, BIOCHEM BIOPH RES CO, V340, P560, DOI 10.1016/j.bbrc.2005.12.039; Gallant P, 1995, J CELL SCI, P21; Geisen C, 2002, J BIOL CHEM, V277, P39909, DOI 10.1074/jbc.M205919200; Ghosh AK, 2004, J BIOL CHEM, V279, P47455, DOI 10.1074/jbc.M403477200; HARPER JW, 1993, CELL, V75, P805; Hirota Y, 1996, JPN J CANCER RES, V87, P735, DOI 10.1111/j.1349-7006.1996.tb00286.x; Hofseth LJ, 2004, TRENDS PHARMACOL SCI, V25, P177, DOI 10.1016/j.tips.2004.02.009; Ilyin GP, 2003, AM J PHYSIOL-GASTR L, V285, pG115, DOI 10.1152/ajpgi.00309.2002; Inoue Y, 2002, HEPATOLOGY, V36, P336, DOI 10.1053/jhep.2002.34942; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kelly BL, 1998, P NATL ACAD SCI USA, V95, P2535, DOI 10.1073/pnas.95.5.2535; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Latonen L, 2003, CELL SIGNAL, V15, P95, DOI 10.1016/S0898-6568(02)00044-X; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; Loyer P, 1996, J BIOL CHEM, V271, P11484, DOI 10.1074/jbc.271.19.11484; LudesMeyers JH, 1996, MOL CELL BIOL, V16, P6009; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; MATSUOKA M, 1994, MOL CELL BIOL, V14, P7265, DOI 10.1128/MCB.14.11.7265; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Mayo LD, 1997, CANCER RES, V57, P5013; Metcalfe AMJ, 1997, NUCLEIC ACIDS RES, V25, P983, DOI 10.1093/nar/25.5.983; Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8; Monti P, 2002, ONCOGENE, V21, P1641, DOI 10.1038/sj.onc.1205250; Naderi S, 2005, MOL BIOL CELL, V16, P1527, DOI 10.1091/mbc.E04-06-0501; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Rosseland CM, 2005, HEPATOLOGY, V42, P200, DOI 10.1002/hep.20762; Saito A, 2005, J CEREBR BLOOD F MET, V25, P267, DOI 10.1038/sj.jcbfm.9600028; Sheikh MS, 1997, ONCOGENE, V15, P1095, DOI 10.1038/sj.onc.1201264; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; SHIN TH, 1995, MOL CELL BIOL, V15, P4694; Skarpen E, 2000, MOL CARCINOGEN, V28, P84, DOI 10.1002/1098-2744(200006)28:2<84::AID-MC4>3.0.CO;2-X; Tang H, 1998, J BIOL CHEM, V273, P29156, DOI 10.1074/jbc.273.44.29156; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; THOMPSON NL, 1986, CANCER RES, V46, P3111; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wong KB, 1999, P NATL ACAD SCI USA, V96, P8438, DOI 10.1073/pnas.96.15.8438; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973	53	17	19	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	2008	27	19					2763	2771		10.1038/sj.onc.1210937	http://dx.doi.org/10.1038/sj.onc.1210937			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	292IK	18026139	Bronze			2022-12-17	WOS:000255259500011
J	Kadaja-Saarepuu, L; Laos, S; Jaeaeger, K; Viil, J; Balikova, A; Looke, M; Hansson, GC; Maimets, T				Kadaja-Saarepuu, L.; Laos, S.; Jaeaeger, K.; Viil, J.; Balikova, A.; Looke, M.; Hansson, G. C.; Maimets, T.			CD43 promotes cell growth and helps to evade FAS-mediated apoptosis in non-hematopoietic cancer cells lacking the tumor suppressors p53 or ARF	ONCOGENE			English	Article						leukosialin; sialophorin; FAS; colony formation; epithelial cell	NF-KAPPA-B; LYMPHOCYTE SURFACE SIALOGLYCOPROTEIN; ANTIBODY RECOGNIZING CD43; WISKOTT-ALDRICH SYNDROME; MONOCLONAL-ANTIBODY; COLON-CANCER; SIGNALING PATHWAYS; BETA-CATENIN; TF-1 CELLS; STEM-CELLS	CD43 is a highly glycosylated transmembrane protein expressed on the surface of most hematopoietic cells. Expression of CD43 has also been demonstrated in many human tumor tissues, including colon adenomas and carcinomas, but not in normal colon epithelium. The potential contribution of CD43 to tumor development is still not understood. Here, we show that overexpression of CD43 increases cell growth and colony formation in mouse and human cells lacking expression of either p53 or ARF (alternative reading frame) tumor-suppressor proteins. In addition, CD43 overexpression also lowers the detection of the FAS death receptor on the cell surface of human cancer cells, and thereby helps to evade FAS-mediated apoptosis. However, when both p53 and ARF proteins are present, CD43 overexpression activates p53 and suppresses colony formation due to induction of apoptosis. These observations suggest CD43 as a potential contributor to tumor development and the functional ARF-p53 pathway is required for the elimination of cells with aberrant CD43 expression.	[Kadaja-Saarepuu, L.; Jaeaeger, K.; Viil, J.; Balikova, A.; Looke, M.; Maimets, T.] Univ Tartu, Inst Mol & Cell Biol, Dept Cell Biol, EE-51010 Tartu, Estonia; [Laos, S.; Hansson, G. C.] Gothenburg Univ, Dept Med Biochem, Gothenburg, Sweden	University of Tartu; University of Gothenburg	Kadaja-Saarepuu, L (corresponding author), Univ Tartu, Inst Mol & Cell Biol, Dept Cell Biol, 23 Riia St, EE-51010 Tartu, Estonia.	lkadaja@ebc.ee	Hansson, Gunnar C./AAF-7324-2019; Hansson, Gunnar C/A-1236-2009; Maimets, Toivo/E-9268-2017; Jaager, Kersti/G-2786-2017	Hansson, Gunnar C./0000-0002-1900-1869; Hansson, Gunnar C/0000-0002-1900-1869; Maimets, Toivo/0000-0001-6461-3365; Jaager, Kersti/0000-0002-0503-9292				ABARZUA P, 1995, CANCER RES, V55, P3490; Andersson CX, 2004, BIOCHEM BIOPH RES CO, V316, P12, DOI 10.1016/j.bbrc.2004.02.011; ARDMAN B, 1992, P NATL ACAD SCI USA, V89, P5001, DOI 10.1073/pnas.89.11.5001; BAECKSTROM D, 1995, J BIOL CHEM, V270, P13688, DOI 10.1074/jbc.270.23.13688; Bazil V, 1996, BLOOD, V87, P1272, DOI 10.1182/blood.V87.4.1272.bloodjournal8741272; Bazil V, 1997, STEM CELLS, V15, P13, DOI 10.1002/stem.5530150804; BAZIL V, 1997, STEM CELLS, V15, P18; Brown TJ, 1996, J BIOL CHEM, V271, P27686, DOI 10.1074/jbc.271.44.27686; CARLSSON SR, 1986, J BIOL CHEM, V261, P2779; Cermak L, 2002, J BIOL CHEM, V277, P7955, DOI 10.1074/jbc.M108048200; Deng JO, 2002, CANCER CELL, V2, P323, DOI 10.1016/S1535-6108(02)00154-X; DRAGONE LL, 1995, P NATL ACAD SCI USA, V92, P626, DOI 10.1073/pnas.92.2.626; Esteller M, 2000, CANCER RES, V60, P129; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fernandez-Rodriguez J, 2002, TUMOR BIOL, V23, P193, DOI 10.1159/000067252; He YW, 1999, J EXP MED, V190, P1903, DOI 10.1084/jem.190.12.1903; Hewitt RE, 2000, J PATHOL, V192, P446; Ivanov VN, 2003, MOL CELL BIOL, V23, P3623, DOI 10.1128/MCB.23.10.3623-3635.2003; Kadaja L, 2004, ONCOGENE, V23, P2523, DOI 10.1038/sj.onc.1207359; Kyoizumi S, 2004, J IMMUNOL, V172, P7246, DOI 10.4049/jimmunol.172.12.7246; Laos S, 2006, INT J ONCOL, V28, P695; Layseca-Espinosa E, 2003, J LEUKOCYTE BIOL, V74, P1083, DOI 10.1189/jlb.0303095; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Mattioli I, 2004, BLOOD, V104, P3302, DOI 10.1182/blood-2004-04-1536; MAZARS R, 1991, ONCOGENE, V6, P1685; Misawa Y, 1996, EUR J IMMUNOL, V26, P2573, DOI 10.1002/eji.1830261106; Miura Y, 2001, BIOCHEM BIOPH RES CO, V288, P80, DOI 10.1006/bbrc.2001.5729; MOLLER P, 1994, INT J CANCER, V57, P371, DOI 10.1002/ijc.2910570314; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; O'Connell J, 2000, ANN NY ACAD SCI, V910, P178; Onami TM, 2002, J IMMUNOL, V168, P6022, DOI 10.4049/jimmunol.168.12.6022; Ostberg JR, 1998, IMMUNOL TODAY, V19, P546, DOI 10.1016/S0167-5699(98)01343-7; Ouaaz F, 1999, J EXP MED, V189, P999, DOI 10.1084/jem.189.6.999; PALLANT A, 1989, P NATL ACAD SCI USA, V86, P1328, DOI 10.1073/pnas.86.4.1328; Pimenidou A, 2004, ONCOL REP, V11, P327; REMOLDODONNELL E, 1984, J EXP MED, V159, P1705, DOI 10.1084/jem.159.6.1705; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; Santamaria M, 1996, CANCER RES, V56, P3526; Santana MA, 2000, J BIOL CHEM, V275, P31460, DOI 10.1074/jbc.M005231200; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; SHELLEY CS, 1989, P NATL ACAD SCI USA, V86, P2819, DOI 10.1073/pnas.86.8.2819; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Sikut R, 1999, INT J CANCER, V82, P52, DOI 10.1002/(SICI)1097-0215(19990702)82:1<52::AID-IJC10>3.0.CO;2-C; Sikut R, 1997, BIOCHEM BIOPH RES CO, V238, P612, DOI 10.1006/bbrc.1997.7334; von Reyher U, 1998, CANCER RES, V58, P526; Woodman RC, 1998, J EXP MED, V188, P2181, DOI 10.1084/jem.188.11.2181; Zhang K, 1997, CELL IMMUNOL, V176, P158, DOI 10.1006/cimm.1997.1085; Zheng Y, 2001, J IMMUNOL, V166, P4949, DOI 10.4049/jimmunol.166.8.4949; Ziprin P, 2004, BIOL CHEM, V385, P755, DOI 10.1515/BC.2004.092	51	17	20	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	2008	27	12					1705	1715		10.1038/sj.onc.1210802	http://dx.doi.org/10.1038/sj.onc.1210802			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	273WF	17891181				2022-12-17	WOS:000253962100006
J	Siddiqui, K; Del Valle, L; Morellet, N; Cui, J; Ghafouri, M; Mukerjee, R; Urbanska, K; Fan, S; Pattillo, CB; Deshmane, SL; Kiani, MF; Ansari, R; Khalili, K; Roques, BP; Reiss, K; Bouaziz, S; Amini, S; Srinivasan, A; Sawaya, BE				Siddiqui, K.; Del Valle, L.; Morellet, N.; Cui, J.; Ghafouri, M.; Mukerjee, R.; Urbanska, K.; Fan, S.; Pattillo, C. B.; Deshmane, S. L.; Kiani, M. F.; Ansari, R.; Khalili, K.; Roques, B. P.; Reiss, K.; Bouaziz, S.; Amini, S.; Srinivasan, A.; Sawaya, B. E.			Molecular mimicry in inducing DNA damage between HIV-1Vpr and the anticancer agent, cisplatin	ONCOGENE			English	Article						HIV-1; Vpr; DNA damage; chromosomal aberrations; cisplatin; necrosis	IMMUNODEFICIENCY-VIRUS TYPE-1; HISTONE H3 PHOSPHORYLATION; REGULATORY PROTEIN VPR; CELL-CYCLE; NMR STRUCTURE; TERMINAL DOMAIN; MICRONUCLEI FORMATION; VIRION INCORPORATION; GENE-EXPRESSION; ACCESSORY GENE	The human immunodeficiency virus type 1(HIV-1) viral protein R (vpr) gene is an evolutionarily conserved gene among the primate lentiviruses. Several functions are attributed to Vpr including the ability to cause cell death, cell cycle arrest, apoptosis and DNA damage. The Vpr domain responsible for DNA damage as well as the mechanism(s) through which Vpr induces this damage is unknown. Using site-directed mutagenesis, we identified the helical domain II within Vpr (aa 37-50) as the region responsible for causing DNA damage. Interestingly, Vpr D(37-50) failed to cause cell cycle arrest or apoptosis, to induce Ku70 or Ku80 and to suppress tumor growth, but maintained its capability to activate the HIV-1 LTR, to localize to the nucleus and to promote nonhomologous end-joining. In addition, our cytogenetic data indicated that helical domain II induced chromosomal aberrations, which mimicked those induced by cisplatin, an anticancer agent. This novel molecular mimicry function of Vpr might lead to its potential therapeutic use as a tumor suppressor.	[Del Valle, L.; Cui, J.; Ghafouri, M.; Mukerjee, R.; Urbanska, K.; Fan, S.; Deshmane, S. L.; Khalili, K.; Reiss, K.; Sawaya, B. E.] Temple Univ, Sch Med, Dept Neurosci, Philadelphia, PA 19122 USA; [Del Valle, L.; Cui, J.; Ghafouri, M.; Mukerjee, R.; Urbanska, K.; Fan, S.; Deshmane, S. L.; Khalili, K.; Reiss, K.; Sawaya, B. E.] Temple Univ, Sch Med, Ctr Neurovirol, Philadelphia, PA 19122 USA; [Siddiqui, K.; Amini, S.] Temple Univ, Coll Sci & Technol, Dept Biol, Philadelphia, PA 19122 USA; [Morellet, N.; Roques, B. P.; Bouaziz, S.] INSERM, Unite Pharmacol Chim & Genet, Paris 06, France; [Urbanska, K.] Jagiellonian Univ, Fac Biotechnol, Dept Cell Biol, Krakow, Poland; [Pattillo, C. B.; Kiani, M. F.; Ansari, R.] Temple Univ, Dept Mech Engn, Philadelphia, PA 19122 USA; [Srinivasan, A.] Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Institut National de la Sante et de la Recherche Medicale (Inserm); Jagiellonian University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Jefferson University	Sawaya, BE (corresponding author), Temple Univ, Sch Med, Dept Neurosci, 1900 N 12th St, Philadelphia, PA 19122 USA.	sawaya@temple.edu	Pattillo, Christopher/J-9517-2012; Del Valle, Luis/J-4085-2015	Pattillo, Christopher/0000-0002-8017-067X; Del Valle, Luis/0000-0003-3894-9206; morellet, nelly/0000-0001-5076-8884; bouaziz, serge/0000-0001-7792-8307	NATIONAL CANCER INSTITUTE [R01CA095518] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS036466, R01NS040673] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA095518] Funding Source: Medline; NINDS NIH HHS [P01 NS036466, R01 NS040673-05] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Amini S, 2005, MOL CELL BIOL, V25, P8126, DOI 10.1128/MCB.25.18.8126-8138.2005; Amini S, 2004, J BIOL CHEM, V279, P46046, DOI 10.1074/jbc.M403792200; Ayyavoo V, 1997, NAT MED, V3, P1117, DOI 10.1038/nm1097-1117; Baumgartner BL, 2005, GENE DEV, V19, P2522, DOI 10.1101/gad.1373205; Claudio PP, 2006, J CELL PHYSIOL, V208, P602, DOI 10.1002/jcp.20698; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; Gaynor EM, 2001, EXP CELL RES, V267, P243, DOI 10.1006/excr.2001.5247; Goh WC, 1998, NAT MED, V4, P65, DOI 10.1038/nm0198-065; Gougeon ML, 2003, NAT REV IMMUNOL, V3, P392, DOI 10.1038/nri1087; Gragerov A, 1998, VIROLOGY, V245, P323, DOI 10.1006/viro.1998.9138; Guirouilh-Barbat J, 2004, MOL CELL, V14, P611, DOI 10.1016/j.molcel.2004.05.008; Hans F, 2001, ONCOGENE, V20, P3021, DOI 10.1038/sj.onc.1204326; Henklein P, 2000, J BIOL CHEM, V275, P32016, DOI 10.1074/jbc.M004044200; Hiyama H, 1999, J BIOL CHEM, V274, P28019, DOI 10.1074/jbc.274.39.28019; Huang MB, 2000, J NEUROVIROL, V6, P202, DOI 10.3109/13550280009015823; Jacotot E, 2000, J EXP MED, V191, P33, DOI 10.1084/jem.191.1.33; Juan G, 1998, CYTOMETRY, V32, P71, DOI 10.1002/(SICI)1097-0320(19980601)32:2<71::AID-CYTO1>3.0.CO;2-H; Kino T, 2002, J VIROL, V76, P9724, DOI 10.1128/JVI.76.19.9724-9734.2002; Labhart P, 1999, EUR J BIOCHEM, V265, P849, DOI 10.1046/j.1432-1327.1999.00805.x; Le Rouzic E, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-11; Mahalingam S, 1995, VIROLOGY, V214, P647, DOI 10.1006/viro.1995.0079; Mahalingam S, 1997, DNA CELL BIOL, V16, P137, DOI 10.1089/dna.1997.16.137; Mahalingam S, 1997, J VIROL, V71, P6339, DOI 10.1128/JVI.71.9.6339-6347.1997; Majone F, 2000, J BIOL CHEM, V275, P32906, DOI 10.1074/jbc.C000538200; Majone F, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-45; Mameli G, 2007, J GEN VIROL, V88, P631, DOI 10.1099/vir.0.82487-0; McCray AN, 2006, MOL THER, V14, P647, DOI 10.1016/j.ymthe.2006.06.010; Morellet N, 2003, J MOL BIOL, V327, P215, DOI 10.1016/S0022-2836(03)00060-3; Muller C, 2005, CELL CYCLE, V4, P438, DOI 10.4161/cc.4.3.1565; Nakamura T, 2002, VIRUS RES, V90, P263, DOI 10.1016/S0168-1702(02)00230-7; Nishizawa M, 1999, VIROLOGY, V263, P313, DOI 10.1006/viro.1999.9905; Nowak SJ, 2004, TRENDS GENET, V20, P214, DOI 10.1016/j.tig.2004.02.007; Pang S, 2001, CLIN CANCER RES, V7, P3567; Patel CA, 2000, J VIROL, V74, P9717, DOI 10.1128/JVI.74.20.9717-9726.2000; Sawaya BE, 2000, J BIOL CHEM, V275, P35209, DOI 10.1074/jbc.M005197200; Sawaya BE, 1999, GENE THER, V6, P947, DOI 10.1038/sj.gt.3300907; Sawaya BE, 1998, J BIOL CHEM, V273, P20052, DOI 10.1074/jbc.273.32.20052; Schuler W, 1999, J MOL BIOL, V285, P2105, DOI 10.1006/jmbi.1998.2381; Sherman MP, 2002, VIROLOGY, V302, P95, DOI 10.1006/viro.2002.1576; Sherman MP, 2001, J VIROL, V75, P1522, DOI 10.1128/JVI.75.3.1522-1532.2001; Shimura M, 1999, CANCER RES, V59, P2259; Shimura M, 1999, FASEB J, V13, P621, DOI 10.1096/fasebj.13.6.621; SIDDIQUI KM, 1988, MUTAT RES, V207, P179; Stewart SA, 2000, J VIROL, V74, P3105, DOI 10.1128/JVI.74.7.3105-3111.2000; Tachiwana H, 2006, CANCER RES, V66, P627, DOI 10.1158/0008-5472.CAN-05-3144; Trojanek J, 2003, MOL CELL BIOL, V23, P7510, DOI 10.1128/MCB.23.21.7510-7524.2003; WANG LL, 1995, J BIOL CHEM, V270, P25564, DOI 10.1074/jbc.270.43.25564; Wecker K, 1999, EUR J BIOCHEM, V266, P359, DOI 10.1046/j.1432-1327.1999.00858.x; Wecker K, 2002, EUR J BIOCHEM, V269, P3779, DOI 10.1046/j.1432-1033.2002.03067.x; Zhou Y, 2000, J VIROL, V74, P6520, DOI 10.1128/JVI.74.14.6520-6527.2000; Zhou Y, 1998, VIROLOGY, V242, P414, DOI 10.1006/viro.1998.9028; Zhu QZ, 2001, CANCER RES, V61, P64; [No title captured]	53	17	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2008	27	1					32	43		10.1038/sj.onc.1210632	http://dx.doi.org/10.1038/sj.onc.1210632			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	247YO	17653096				2022-12-17	WOS:000252118700004
J	Oxford, G; Smith, SC; Hampton, G; Theodorescu, D				Oxford, G.; Smith, S. C.; Hampton, G.; Theodorescu, D.			Expression profiling of Ral-depleted bladder cancer cells identifies RREB-1 as a novel transcriptional Ral effector	ONCOGENE			English	Article						GTPases; bladder neoplasms; biomarker; metastasis	GTPASES; CARCINOMA; ACTIVATION; PROTEIN; KINASE; GROWTH; RLIP76; PROLIFERATION; METASTASIS; CONTRIBUTE	Although the monomeric GTPases RalA and RalB have been shown to regulate a variety of transcription factors, little is known regarding the differences or similarities in transcriptional programs regulated by RalA compared to RalB. Further, the association of these transcriptional pathways to human carcinogenesis and progression remains unclear. Here, we studied the role of RalA and/or RalB in transcriptional regulation by combining short interfering RNA depletion of Ral with gene expression pro. ling via microarray in the human bladder cancer cell line, UMUC-3. A large number of genes were found to be similarly modulated in cells with RalA and RalB depletion, suggesting that RalA and RalB impinge on overlapping transcriptional signaling pathways. However, smaller sets of genes were modulated by depletion of RalA or RalB, indicating that these closely related proteins also regulate nonoverlapping transcriptional pathways. Computational analysis of upstream sequences of genes modulated by Ral depletion identified Ras-responsive element-binding protein ( RREB)-1, as a putative Ral transcriptional target, which we verified experimentally. Importantly, as a group, Ral-regulated probe sets identified here were disproportionally represented among those differentially expressed as a function of human bladder transformation. Taken together, these data strongly suggest that Ral family members mediate both common and specific transcriptional programs that are associated with human cancer and identify RREB-1 as a novel transcriptional effector of Ral.	Univ Virginia, Hlth Sci Ctr, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA; Genom Inst Novartis Res Fdn, San Diego, CA USA	University of Virginia; Novartis	Theodorescu, D (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Mol Physiol & Biol Phys, Box 422, Charlottesville, VA 22908 USA.	dt9d@virginia.edu	Smith, Steven Christopher/S-9375-2019; Smith, Steven/HDM-9496-2022	Smith, Steven Christopher/0000-0003-0982-4607; 	NCI NIH HHS [R01 CA075115, P01CA104106, CA075115, CA009109-29] Funding Source: Medline; NIGMS NIH HHS [T32GM007267] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075115, R29CA075115, P01CA104106] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007267] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Awasthi S, 2000, BIOCHEMISTRY-US, V39, P9327, DOI 10.1021/bi992964c; Awasthi S, 2003, INT J CANCER, V106, P635, DOI 10.1002/ijc.11260; Bigler D, 2003, ONCOGENE, V22, P1261, DOI 10.1038/sj.onc.1206242; Camonis JH, 2005, TRENDS CELL BIOL, V15, P327, DOI 10.1016/j.tcb.2005.04.002; Carmeliet P, 2005, ONCOLOGY-BASEL, V69, P4, DOI 10.1159/000088478; Chien YC, 2003, EMBO REP, V4, P800, DOI 10.1038/sj.embor.embor899; Dyrskjot L, 2004, CANCER RES, V64, P4040, DOI 10.1158/0008-5472.CAN-03-3620; Feig LA, 2003, TRENDS CELL BIOL, V13, P419, DOI 10.1016/S0962-8924(03)00152-1; Gildea JJ, 2002, CANCER RES, V62, P982; GROSSMAN HB, 1986, J UROLOGY, V136, P953, DOI 10.1016/S0022-5347(17)45139-1; Hamad NM, 2002, GENE DEV, V16, P2045, DOI 10.1101/gad.993902; Haverty PM, 2004, NUCLEIC ACIDS RES, V32, pW213, DOI 10.1093/nar/gkh402; Henry DO, 2000, MOL CELL BIOL, V20, P8084, DOI 10.1128/MCB.20.21.8084-8092.2000; Jebar AH, 2005, ONCOGENE, V24, P5218, DOI 10.1038/sj.onc.1208705; JULLIENFLORES V, 1995, J BIOL CHEM, V270, P22473, DOI 10.1074/jbc.270.38.22473; Lebreton S, 2004, MECH DEVELOP, V121, P1481, DOI 10.1016/j.mod.2004.07.008; Lim KH, 2005, CANCER CELL, V7, P533, DOI 10.1016/j.ccr.2005.04.030; Lim KH, 2006, CURR BIOL, V16, P2385, DOI 10.1016/j.cub.2006.10.023; Moskalenko S, 2003, J BIOL CHEM, V278, P51743, DOI 10.1074/jbc.M308702200; Nicholson BE, 2004, CANCER RES, V64, P7813, DOI 10.1158/0008-5472.CAN-04-0826; Ohta Y, 1999, P NATL ACAD SCI USA, V96, P2122, DOI 10.1073/pnas.96.5.2122; Oxford G, 2005, CANCER RES, V65, P7111, DOI 10.1158/0008-5472.CAN-04-1957; Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550; Shipitsin M, 2004, MOL CELL BIOL, V24, P5746, DOI 10.1128/MCB.24.13.5746-5756.2004; Smith SC, 2006, CANCER RES, V66, P1917, DOI 10.1158/0008-5472.CAN-05-3855; Thiagalingam A, 1996, MOL CELL BIOL, V16, P5335; Ward Y, 2001, MOL CELL BIOL, V21, P5958, DOI 10.1128/MCB.21.17.5958-5969.2001; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Wolthuis RMF, 1998, CURR BIOL, V8, P471, DOI 10.1016/S0960-9822(98)70183-6; Wu X, 2004, BJU INT, V93, P143, DOI 10.1111/j.1464-410X.2004.04574.x; Zhang SL, 2003, ONCOGENE, V22, P2285, DOI 10.1038/sj.onc.1206257	31	17	19	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2007	26	50					7143	7152		10.1038/sj.onc.1210521	http://dx.doi.org/10.1038/sj.onc.1210521			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	228GF	17496927				2022-12-17	WOS:000250715000008
J	Zhou, H; Hou, Q; Hansen, JL; Hsu, YT				Zhou, H.; Hou, Q.; Hansen, J. L.; Hsu, Y-T			Complete activation of Bax by a single site mutation	ONCOGENE			English	Article						bax; mitochondria; apoptosis; Bcl-X-L	CYTOCHROME-C RELEASE; MITOCHONDRIAL-MEMBRANE; BH3-ONLY PROTEINS; CELL-SURVIVAL; APOPTOSIS; BCL-2; OLIGOMERIZATION; DIMERIZATION; DOMAIN; TRANSLOCATION	Bax translocation from the cytosol to mitochondria culminates a key step by which this protein mediates cell death. Here, we identified two amino acids, L70 and D71, within the BH3 domain of Bax that play a critical role in regulating Bax's cytosolic vs mitochondrial distribution. Individual substitution of these amino acids with alanine resulted in Bax conformational change, oligomerization, localization to mitochondria and cell death. Further mutational analysis indicated that L70 interacts with T174, V177 and A178 of Bax's C-terminal hydrophobic segment, while the negative charge of D71 is required for maintaining Bax in its soluble monomeric state. In summary, we have identified a new regulatory site that controls Bax's subcellular distribution and activation.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Peking Union Med Coll, Dept Pharmacol, Inst Mat Med, Beijing, Peoples R China; Chinese Acad Med Sci, Beijing 100037, Peoples R China	Medical University of South Carolina; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Materia Medica - CAMS; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College	Hsu, YT (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave,POB 250509, Charleston, SC 29425 USA.	hsuy@musc.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR015455] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040932] Funding Source: NIH RePORTER; NCRR NIH HHS [COG RR01 5455] Funding Source: Medline; NINDS NIH HHS [R01 NS40932] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; Cartron PF, 2003, J BIOL CHEM, V278, P11633, DOI 10.1074/jbc.M208955200; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Manon S, 1997, FEBS LETT, V415, P29, DOI 10.1016/S0014-5793(97)01087-9; Mateu MG, 1999, P NATL ACAD SCI USA, V96, P3595, DOI 10.1073/pnas.96.7.3595; Meijerink JPP, 1998, BLOOD, V91, P2991, DOI 10.1182/blood.V91.8.2991.2991_2991_2997; Mikhailov V, 2001, J BIOL CHEM, V276, P18361, DOI 10.1074/jbc.M100655200; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Nechushtan A, 2001, J CELL BIOL, V153, P1265, DOI 10.1083/jcb.153.6.1265; OLTVAI ZN, 1993, CELL, V74, P619; Pagliari LJ, 2005, P NATL ACAD SCI USA, V102, P17975, DOI 10.1073/pnas.0506712102; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Smaili SS, 2001, CELL DEATH DIFFER, V8, P909, DOI 10.1038/sj.cdd.4400889; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Wang K, 1998, MOL CELL BIOL, V18, P6083, DOI 10.1128/MCB.18.10.6083; Willis SN, 2005, GENE DEV, V19, P1294, DOI 10.1101/gad.1304105; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440	31	17	17	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 1	2007	26	50					7092	7102		10.1038/sj.onc.1210517	http://dx.doi.org/10.1038/sj.onc.1210517			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	228GF	17486058				2022-12-17	WOS:000250715000003
J	Depaux, A; Regnier-Ricard, F; Germani, A; Varin-Blank, N				Depaux, A.; Regnier-Ricard, F.; Germani, A.; Varin-Blank, N.			A crosstalk between hSiah2 and Pias E3-ligases modulates Pias-dependent activation	ONCOGENE			English	Article						Siah; Pias; ubiquitination; proteasome	C-JUN; PROTEIN INHIBITOR; SIAH-1 INTERACTS; GENE-ACTIVATION; P53 ACTIVITY; RECEPTOR; SUMO; DEGRADATION; HOMOLOGS; DEGRADES	Protein inhibitor of activated STAT ( Pias) and human homologues of seven in absentia ( hSiah) proteins both exhibit properties of ubiquitin- family peptides conjugating enzymes. Pias present E3- ligase activity for small ubiquitin-related modifiers ( Sumo) covalent attachment to their targets. This post- translational modi. cation is responsible for the activation of different transcription factors such as AP1. HSiah proteins possess ubiquitin- E3-ligase activity that triggers their partners to proteasomal-dependent degradation. The present study identifies Pias as a new hSiah2- interacting protein. We demonstrate that hSiah2 regulates specifically the proteasome-dependent degradation of Pias proteins. On reverse, Pias does not prevent hSiah2 degradation. We provide evidences for hSiah2- dependent degradation of Pias as being a mechanism in the regulation of c- jun N- terminal kinase- activating pathways. This report describes a new interconnection between sumoylation and ubiquitination pathways by regulating the levels of the E3-ligases available for these processes.	Univ Paris 05, Inst Cochin, Dept Hematol, CNRS, F-75014 Paris, France; Inserm, U567, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Varin-Blank, N (corresponding author), Univ Paris 05, Inst Cochin, Dept Hematol, CNRS, Bat G Roussy ,7eme etage,27 Rue Fg St Jacques, F-75014 Paris, France.	varin@cochin.inserm.fr		VARIN-BLANK, Nadine/0000-0003-2769-018X				Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; DELLA NG, 1993, DEVELOPMENT, V117, P1333; Depaux A, 2006, BIOCHEM BIOPH RES CO, V348, P857, DOI 10.1016/j.bbrc.2006.07.092; Desterro JMP, 1997, FEBS LETT, V417, P297, DOI 10.1016/S0014-5793(97)01305-7; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; DRISCOLL J, 1990, J BIOL CHEM, V265, P4789; Duval D, 2003, FEBS LETT, V554, P111, DOI 10.1016/S0014-5793(03)01116-5; Floyd ZE, 2001, J BIOL CHEM, V276, P22468, DOI 10.1074/jbc.M009388200; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Freemont PS, 2000, CURR BIOL, V10, pR84, DOI 10.1016/S0960-9822(00)00287-6; Germani A, 2003, ONCOGENE, V22, P8845, DOI 10.1038/sj.onc.1206994; Germani A, 1999, MOL CELL BIOL, V19, P3798; Germani A, 2000, ONCOGENE, V19, P5997, DOI 10.1038/sj.onc.1204002; Gross M, 2001, ONCOGENE, V20, P3880, DOI 10.1038/sj.onc.1204489; Habelhah H, 2002, EMBO J, V21, P5756, DOI 10.1093/emboj/cdf576; House CM, 2003, P NATL ACAD SCI USA, V100, P3101, DOI 10.1073/pnas.0534783100; Hu G, 1997, GENOMICS, V46, P103, DOI 10.1006/geno.1997.4997; Hu G, 1997, GENE DEV, V11, P2701, DOI 10.1101/gad.11.20.2701; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kotaja N, 2002, J BIOL CHEM, V277, P17781, DOI 10.1074/jbc.M106354200; Lallemand-Breitenbach V, 2001, J EXP MED, V193, P1361, DOI 10.1084/jem.193.12.1361; Liu B, 2001, J BIOL CHEM, V276, P36624, DOI 10.1074/jbc.M101085200; Liu B, 2001, P NATL ACAD SCI USA, V98, P3203, DOI 10.1073/pnas.051489598; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Liu YC, 2004, ANNU REV IMMUNOL, V22, P81, DOI 10.1146/annurev.immunol.22.012703.104813; Liu ZH, 1998, ACTA POLYM SIN, P1; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Megidish T, 2002, J BIOL CHEM, V277, P8255, DOI 10.1074/jbc.C200001200; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Millot GA, 2002, EXP HEMATOL, V30, P166, DOI 10.1016/S0301-472X(01)00776-7; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Nakayama K, 2004, CELL CYCLE, V3, P1345, DOI 10.4161/cc.3.11.1207; Polekhina G, 2002, NAT STRUCT BIOL, V9, P68, DOI 10.1038/nsb743; Reed JC, 2002, NAT STRUCT BIOL, V9, P8, DOI 10.1038/nsb0102-8; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Shuai K, 2005, NAT REV IMMUNOL, V5, P593, DOI 10.1038/nri1667; Simon MC, 2004, CELL, V117, P851, DOI 10.1016/j.cell.2004.06.010; Sun LJ, 2004, CURR OPIN CELL BIOL, V16, P119, DOI 10.1016/j.ceb.2004.02.005; Susini L, 2001, P NATL ACAD SCI USA, V98, P15067, DOI 10.1073/pnas.261571998; Tan JA, 2002, J BIOL CHEM, V277, P16993, DOI 10.1074/jbc.M109217200; Tang AH, 1997, CELL, V90, P459, DOI 10.1016/S0092-8674(00)80506-1; Tanikawa J, 2000, J BIOL CHEM, V275, P15578, DOI 10.1074/jbc.M000372200; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Yaron A, 1997, EMBO J, V16, P6486, DOI 10.1093/emboj/16.21.6486; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Zhang JS, 1998, GENE DEV, V12, P1775, DOI 10.1101/gad.12.12.1775	50	17	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 11	2007	26	46					6665	6676		10.1038/sj.onc.1210486	http://dx.doi.org/10.1038/sj.onc.1210486			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	219JT	17533377				2022-12-17	WOS:000250081500008
J	Pina, C; Enver, T				Pina, C.; Enver, T.			Differential contributions of haematopoietic stem cells to foetal and adult haematopoiesis: insights from functional analysis of transcriptional regulators	ONCOGENE			English	Review						cell fate; self-renewal; foetal liver; bone marrow	ACUTE LYMPHOBLASTIC-LEUKEMIA; GONAD-MESONEPHROS REGION; YOLK-SAC HEMATOPOIESIS; ACUTE MYELOID-LEUKEMIA; CORE-BINDING FACTORS; SELF-RENEWAL; BONE-MARROW; MOUSE EMBRYO; DEFINITIVE HEMATOPOIESIS; MICE LACKING	An increasing number of molecules have been identified as candidate regulators of stem cell fates through their involvement in leukaemia or via post- genomic gene discovery approaches. A full understanding of the function of these molecules requires ( 1) detailed knowledge of the gene networks in which they participate and ( 2) an appreciation of how these networks vary as cells progress through the haematopoietic cell hierarchy. An additional layer of complexity is added by the occurrence of different haematopoietic cell hierarchies at different stages of ontogeny. Beyond these issues of cell context dependence, it is important from a mechanistic point of view to define the particular cell fate pathway impacted by any given regulator. Herein, we advance the notion that haematopoietic stem cells ( HSC), which sustain haematopoiesis throughout adult life and are specified in foetal life, have a minimal or late contribution to foetal haematopoiesis but instead largely proliferate during the foetal period. In light of this notion, we revisit published data on mouse knockouts of haematopoietically- affiliated transcription factors highlighting novel insights that may be gained from taking such a view.	Univ Oxford, MRC Mol Haematol Unit, Weatherall Inst Mol Med, Oxford OX3 9DS, England	University of Oxford	Pina, C (corresponding author), Univ Oxford, MRC Mol Haematol Unit, Weatherall Inst Mol Med, Oxford OX3 9DS, England.	cpina@gwmail.jr2.ox.ac.uk		Pina, Cristina/0000-0002-2575-6301	MRC [MC_U137973817] Funding Source: UKRI; Medical Research Council [MC_U137973817] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Adams GB, 2006, NATURE, V439, P599, DOI 10.1038/nature04247; Adolfsson J, 2001, IMMUNITY, V15, P659, DOI 10.1016/S1074-7613(01)00220-5; Adolfsson J, 2005, CELL, V121, P295, DOI 10.1016/j.cell.2005.02.013; Akashi K, 2003, BLOOD, V101, P383, DOI 10.1182/blood-2002-06-1780; Anguita E, 2004, EMBO J, V23, P2841, DOI 10.1038/sj.emboj.7600274; Arai S, 2005, EMBO J, V24, P1863, DOI 10.1038/sj.emboj.7600654; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P2031, DOI 10.1073/pnas.86.6.2031; Betschinger J, 2004, CURR BIOL, V14, pR674, DOI 10.1016/j.cub.2004.08.017; Bhardwaj G, 2001, NAT IMMUNOL, V2, P172, DOI 10.1038/84282; BOEHM T, 1988, EMBO J, V7, P385, DOI 10.1002/j.1460-2075.1988.tb02825.x; Bowie MB, 2007, P NATL ACAD SCI USA, V104, P5878, DOI 10.1073/pnas.0700460104; Bowie MB, 2006, J CLIN INVEST, V116, P2808, DOI 10.1172/JCI28310; Bruno L, 2004, MOL CELL BIOL, V24, P741, DOI 10.1128/MCB.24.2.741-756.2004; Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040; Christensen JL, 2001, P NATL ACAD SCI USA, V98, P14541, DOI 10.1073/pnas.261562798; Collins EC, 2002, TRENDS MOL MED, V8, P436, DOI 10.1016/S1471-4914(02)02397-3; Cumano A, 2001, IMMUNITY, V15, P477, DOI 10.1016/S1074-7613(01)00190-X; Curtis DJ, 2004, BLOOD, V103, P3342, DOI 10.1182/blood-2003-09-3202; de Bruijn MFTR, 2000, EMBO J, V19, P2465, DOI 10.1093/emboj/19.11.2465; de Bruijn MFTR, 2004, ONCOGENE, V23, P4238, DOI 10.1038/sj.onc.1207763; de Bruijn MFTR, 2002, IMMUNITY, V16, P673, DOI 10.1016/S1074-7613(02)00313-8; de la Grange PB, 2006, BLOOD, V108, P2998, DOI 10.1182/blood-2006-05-022988; Delassus S, 1999, BLOOD, V94, P1495, DOI 10.1182/blood.V94.5.1495.417a08_1495_1503; Delassus S, 1996, IMMUNITY, V4, P97, DOI 10.1016/S1074-7613(00)80302-7; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Erfurth F, 2004, LEUKEMIA, V18, P92, DOI 10.1038/sj.leu.2403200; Ernst P, 2004, CURR BIOL, V14, P2063, DOI 10.1016/j.cub.2004.11.012; Ernst P, 2004, DEV CELL, V6, P437, DOI 10.1016/S1534-5807(04)00061-9; Forsberg EC, 2006, CELL, V126, P415, DOI 10.1016/j.cell.2006.06.037; Forsberg EC, 2005, PLOS GENET, V1, P281, DOI 10.1371/journal.pgen.0010028; Galan-Caridad JM, 2007, CELL, V129, P345, DOI 10.1016/j.cell.2007.03.014; Gekas C, 2005, DEV CELL, V8, P365, DOI 10.1016/j.devcel.2004.12.016; Godin I, 1999, J EXP MED, V190, P43, DOI 10.1084/jem.190.1.43; Godin I, 2002, NAT REV IMMUNOL, V2, P593, DOI 10.1038/nri857; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Gothot A, 1997, BLOOD, V90, P4384, DOI 10.1182/blood.V90.11.4384.4384_4384_4393; Hess JL, 2004, TRENDS MOL MED, V10, P500, DOI 10.1016/j.molmed.2004.08.005; Hess JL, 1997, BLOOD, V90, P1799, DOI 10.1182/blood.V90.5.1799; Heyworth C, 1999, GENE DEV, V13, P1847, DOI 10.1101/gad.13.14.1847; Hock H, 2006, CURR OPIN HEMATOL, V13, P1, DOI 10.1097/01.moh.0000190111.85284.8f; Hock H, 2004, GENE DEV, V18, P2336, DOI 10.1101/gad.1239604; Hock H, 2004, NATURE, V431, P1002, DOI 10.1038/nature02994; Hu M, 1997, GENE DEV, V11, P774, DOI 10.1101/gad.11.6.774; Ichikawa M, 2004, NAT MED, V10, P299, DOI 10.1038/nm997; Ivanova NB, 2002, SCIENCE, V298, P601, DOI 10.1126/science.1073823; Iwama A, 2004, IMMUNITY, V21, P843, DOI 10.1016/j.immuni.2004.11.004; Iwasaki H, 2006, GENE DEV, V20, P3010, DOI 10.1101/gad.1493506; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Kikuchi K, 2006, P NATL ACAD SCI USA, V103, P17852, DOI 10.1073/pnas.0603368103; Kingsley PD, 2004, BLOOD, V104, P19, DOI 10.1182/blood-2003-12-4162; Knoblich JA, 1997, CURR OPIN CELL BIOL, V9, P833, DOI 10.1016/S0955-0674(97)80085-3; Kondo M, 2003, ANNU REV IMMUNOL, V21, P759, DOI 10.1146/annurev.immunol.21.120601.141007; Kumaravelu P, 2002, DEVELOPMENT, V129, P4891; Lacorazza HD, 2006, CANCER CELL, V9, P175, DOI 10.1016/j.ccr.2006.02.017; Laslo P, 2006, CELL, V126, P755, DOI 10.1016/j.cell.2006.06.052; Leroy H, 2005, LEUKEMIA, V19, P329, DOI 10.1038/sj.leu.2403614; Lessard J, 1999, GENE DEV, V13, P2691, DOI 10.1101/gad.13.20.2691; Lessard J, 2004, ONCOGENE, V23, P7199, DOI 10.1038/sj.onc.1207940; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Ling KW, 2004, J EXP MED, V200, P871, DOI 10.1084/jem.20031556; Mansson R, 2007, IMMUNITY, V26, P407, DOI 10.1016/j.immuni.2007.02.013; Medvinsky A, 1996, CELL, V86, P897, DOI 10.1016/S0092-8674(00)80165-8; Medvinsky A, 1999, BLOOD, V94, P3613; Medvinsky AL, 1998, DEV COMP IMMUNOL, V22, P289, DOI 10.1016/S0145-305X(98)00007-X; MEDVINSKY AL, 1993, NATURE, V364, P64, DOI 10.1038/364064a0; Mikkola HKA, 2003, NATURE, V421, P547, DOI 10.1038/nature01345; Miller J, 2002, NAT GENET, V32, P645, DOI 10.1038/ng1049; Miyamoto T, 2002, DEV CELL, V3, P137, DOI 10.1016/S1534-5807(02)00201-0; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MORRISON SJ, 1994, IMMUNITY, V1, P661, DOI 10.1016/1074-7613(94)90037-X; Mueller BU, 2006, CURR OPIN HEMATOL, V13, P7, DOI 10.1097/01.moh.0000190110.08156.96; Mukouyama Y, 2000, DEV BIOL, V220, P27, DOI 10.1006/dbio.2000.9617; MULLER AM, 1994, IMMUNITY, V1, P291, DOI 10.1016/1074-7613(94)90081-7; Naito M, 1996, J LEUKOCYTE BIOL, V59, P133, DOI 10.1002/jlb.59.2.133; Niki M, 1997, P NATL ACAD SCI USA, V94, P5697, DOI 10.1073/pnas.94.11.5697; North T, 1999, DEVELOPMENT, V126, P2563; North TE, 2004, STEM CELLS, V22, P158, DOI 10.1634/stemcells.22-2-158; North TE, 2002, IMMUNITY, V16, P661, DOI 10.1016/S1074-7613(02)00296-0; Oguro H, 2006, J EXP MED, V203, P2247, DOI 10.1084/jem.20052477; Ohta H, 2002, J EXP MED, V195, P759, DOI 10.1084/jem.20011911; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Osada H., 1997, Leukemia (Basingstoke), V11, P307; Ottersbach K, 2005, DEV CELL, V8, P377, DOI 10.1016/j.devcel.2005.02.001; Palis J, 2001, P NATL ACAD SCI USA, V98, P4528, DOI 10.1073/pnas.071002398; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Park IK, 2002, BLOOD, V99, P488, DOI 10.1182/blood.V99.2.488; Persons DA, 1999, BLOOD, V93, P488, DOI 10.1182/blood.V93.2.488.402k17_488_499; Porcher C, 1996, CELL, V86, P47, DOI 10.1016/S0092-8674(00)80076-8; Porse BT, 2005, J EXP MED, V202, P85, DOI 10.1084/jem.20050067; Porse BT, 2001, CELL, V107, P247, DOI 10.1016/S0092-8674(01)00516-5; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Reynaud D, 2005, BLOOD, V106, P2318, DOI 10.1182/blood-2005-02-0557; Ringrose L, 2004, ANNU REV GENET, V38, P413, DOI 10.1146/annurev.genet.38.072902.091907; ROBB L, 1995, P NATL ACAD SCI USA, V92, P7075, DOI 10.1073/pnas.92.15.7075; Robb L, 1996, EMBO J, V15, P4123, DOI 10.1002/j.1460-2075.1996.tb00787.x; Rodrigues NP, 2005, BLOOD, V106, P477, DOI 10.1182/blood-2004-08-2989; Rodriguez P, 2005, EMBO J, V24, P2354, DOI 10.1038/sj.emboj.7600702; Rosenbauer F, 2005, BLOOD, V106, P1519, DOI 10.1182/blood-2005-02-0717; Samokhvalov IM, 2007, NATURE, V446, P1056, DOI 10.1038/nature05725; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; Shojaei F, 2005, DEV CELL, V8, P651, DOI 10.1016/j.devcel.2005.03.004; So CW, 2003, CANCER CELL, V3, P161, DOI 10.1016/S1535-6108(03)00019-9; Soneji S, 2007, ANN NY ACAD SCI, V1106, P30, DOI 10.1196/annals.1392.018; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991; Speck NA, 2002, NAT REV CANCER, V2, P502, DOI 10.1038/nrc840; Stier S, 2005, J EXP MED, V201, P1781, DOI 10.1084/jem.20041992; Sugiyama T, 2006, IMMUNITY, V25, P977, DOI 10.1016/j.immuni.2006.10.016; Taoudi S, 2005, DEVELOPMENT, V132, P4179, DOI 10.1242/dev.01974; Tober J, 2007, BLOOD, V109, P1433, DOI 10.1182/blood-2006-06-031898; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; Vander Lugt NM, 1994, GENE DEV, V8, P757; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; Wang LC, 1997, EMBO J, V16, P4374, DOI 10.1093/emboj/16.14.4374; Wang LC, 1998, GENE DEV, V12, P2392, DOI 10.1101/gad.12.15.2392; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; Wilpshaar J, 2000, BLOOD, V96, P2100; Wilpshaar J, 2002, BLOOD, V100, P120, DOI 10.1182/blood.V100.1.120; Wilson A, 2006, NAT REV IMMUNOL, V6, P93, DOI 10.1038/nri1779; Yagi H, 1998, BLOOD, V92, P108, DOI 10.1182/blood.V92.1.108.413k11_108_117; Yamada Y, 1998, P NATL ACAD SCI USA, V95, P3890, DOI 10.1073/pnas.95.7.3890; Yoder MC, 1997, BLOOD, V89, P2176, DOI 10.1182/blood.V89.6.2176; Yu BD, 1998, P NATL ACAD SCI USA, V95, P10632, DOI 10.1073/pnas.95.18.10632; Zelent A, 2004, ONCOGENE, V23, P4275, DOI 10.1038/sj.onc.1207672; Zeng H, 2004, EMBO J, V23, P4116, DOI 10.1038/sj.emboj.7600419; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569; Zhang P, 2004, IMMUNITY, V21, P853, DOI 10.1016/j.immuni.2004.11.006	129	17	18	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2007	26	47					6750	6765		10.1038/sj.onc.1210759	http://dx.doi.org/10.1038/sj.onc.1210759			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	220HE	17934483				2022-12-17	WOS:000250147000007
J	Lau, WM; Ho, TH; Hui, KM				Lau, W. M.; Ho, T. H.; Hui, K. M.			p16(INK4A)-silencing augments DNA damage-induced apoptosis in cervical cancer cells	ONCOGENE			English	Article						p16; RNAi; cervical cancer; DNA damage; apoptosis	HUMAN-PAPILLOMAVIRUS TYPE-16; G(1) ARREST; POSTTRANSLATIONAL MODIFICATION; GROWTH ARREST; P53 PROTEIN; EXPRESSION; DEGRADATION; GENE; RNA; E6	p16(INK4A) ( p16) has been suggested to be an early biomarker for the detection of cervical cancer. However, its functional role in cervical cancer is not well characterized. In this study, we reported the consistent and significant upregulation of p16 in cervical cancer tissues when compared to both matched non-tumourous tissues of the same patient and normal cervical tissues from non- cancer patients. We have employed p16 small interfering RNA ( siRNA) to dissect the role of p16 in cervical carcinogenesis. Although the silencing of p16 was accompanied by the upregulation of p53, p21 and RB in the p16 siRNA- transfected cells, no significant effect on cell cycle progression was observed. When the p16 siRNA-silenced cells were subjected to DNA damage stress including ultraviolet-irradiation and cisplatin treatments, a significantly higher percentage of apoptotic cells could be observed in the p16- siRNA silenced cells compared to control siRNA- treated cells. Moreover, induction of apoptosis was associated with the activation of p53 through phosphorylation, and this process, when studied by gene pro. ling experiments, involved both the intrinsic and extrinsic apoptotic pathways. The observation that silencing of p16 expression augments DNA damage-induced apoptosis in cervical cancer cells offers alternative strategies for anti-cancer therapies for human cervical cancer.	Natl Canc Ctr, Div Cellular & Mol Res, Singapore 169610, Singapore; Singapore Gen Hosp, Singapore, Singapore; KK Womens & Childrens Hosp, Gynaecol Oncol Unit, Singapore, Singapore	National Cancer Centre Singapore (NCCS); Singapore General Hospital; KK Women's & Children's Hospital	Hui, KM (corresponding author), Natl Canc Ctr, Div Cellular & Mol Res, 11 Hosp Dr, Singapore 169610, Singapore.	cmrhkm@nccs.com.sg	Hui, Kam/C-6186-2011	Hui, Kam/0000-0003-1820-1399				Andersson S, 2006, INT J ONCOL, V29, P705; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; BUTZ K, 1995, ONCOGENE, V10, P927; Cheng Q, 2002, INT J CANCER, V98, P419, DOI 10.1002/ijc.10177; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Giarre M, 2001, J VIROL, V75, P4705, DOI 10.1128/JVI.75.10.4705-4712.2001; Goodwin EC, 2000, P NATL ACAD SCI USA, V97, P12513, DOI 10.1073/pnas.97.23.12513; Goodwin EC, 2000, P NATL ACAD SCI USA, V97, P10978, DOI 10.1073/pnas.97.20.10978; Gu W, 2006, CANCER GENE THER, V13, P1023, DOI 10.1038/sj.cgt.7700971; Haapajarvi T, 1999, EXP CELL RES, V248, P272, DOI 10.1006/excr.1999.4403; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; Ishikawa M, 2006, INT J GYNECOL CANCER, V16, P347, DOI 10.1111/j.1525-1438.2006.00355.x; Jiang M, 2002, ONCOGENE, V21, P6041, DOI 10.1038/sj.onc.1205878; Jimenez GS, 1999, ONCOGENE, V18, P7656, DOI 10.1038/sj.onc.1203013; Jones DL, 1997, J VIROL, V71, P2905, DOI 10.1128/JVI.71.4.2905-2912.1997; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kanao H, 2004, CANCER LETT, V213, P31, DOI 10.1016/j.canlet.2004.03.030; Klaes R, 2001, INT J CANCER, V92, P276, DOI 10.1002/ijc.1174; Lee YS, 2006, J PHARMACOL EXP THER, V317, P202, DOI 10.1124/jpet.105.096719; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; MUNGER K, 1992, CANCER SURV, V12, P197; NEVINS JR, 1992, SCIENCE, V258, P424; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Parkin DM, 2001, EUR J CANCER, V37, pS4, DOI 10.1016/S0959-8049(01)00267-2; Putral LN, 2005, MOL PHARMACOL, V68, P1311, DOI 10.1124/mol.105.014191; Queiroz C, 2006, PATHOL RES PRACT, V202, P77, DOI 10.1016/j.prp.2005.08.012; Sano T, 1998, AM J PATHOL, V153, P1741, DOI 10.1016/S0002-9440(10)65689-1; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; Shapiro GI, 1998, MOL CELL BIOL, V18, P378, DOI 10.1128/MCB.18.1.378; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; Yamamoto A, 2003, INT J CANCER, V106, P301, DOI 10.1002/ijc.11219; Zhang JM, 2006, CANCER RES, V66, P10325, DOI 10.1158/0008-5472.CAN-06-1594; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	43	17	18	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2007	26	41					6050	6060		10.1038/sj.onc.1210405	http://dx.doi.org/10.1038/sj.onc.1210405			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	207US	17369842				2022-12-17	WOS:000249277200008
J	Law, FBF; Chen, YW; Wong, KY; Ying, J; Tao, Q; Langford, C; Lee, PY; Law, S; Cheung, RWL; Chui, CH; Tsao, SW; Lam, KY; Wong, J; Srivastava, G; Tang, JCO				Law, F. B. F.; Chen, Y. W.; Wong, K. Y.; Ying, J.; Tao, Q.; Langford, C.; Lee, P. Y.; Law, S.; Cheung, R. W. L.; Chui, C. H.; Tsao, S. W.; Lam, K. Y.; Wong, J.; Srivastava, G.; Tang, J. C. O.			Identifcation of a novel tumor transforming gene GAEC1 at 7q22 which encodes a nuclear protein and is frequently amplified and overexpressed in esophageal squamous cell carcinoma	ONCOGENE			English	Article						gene amplifcation; overexpression; transforming gene; esophageal cancer; 7q22	COMPARATIVE GENOMIC HYBRIDIZATION; CHROMOSOMAL IMBALANCES; KINASE-C; LINES; AMPLIFICATION; ABERRATIONS; MULTIPLE; SEQUENCE; CANCER; PCR	By comparative DNA. fingerprinting, we identified a 357-bp DNA fragment frequently amplified in esophageal squamous cell carcinomas ( ESCC). This fragment overlaps with an expressed sequence tag mapped to 7q22. Further 5' and 3'-rapid amplification of cDNA ends revealed that it is part of a novel, single-exon gene with full-length mRNA of 2052 bp and encodes a nuclear protein of 109 amino acids ( similar to 15 kDa). This gene, designated as gene amplified in esophageal cancer 1 ( GAEC1), was located within a 1-2 Mb amplicon at 7q22.1 identified by high-resolution 1 Mb array-comparative genomic hybridization in 6/10 ESCC cell lines. GAEC1 was ubiquitously expressed in normal tissues including esophageal and gastrointestinal organs; with amplification and overexpression in 6/10 ( 60%) ESCC cell lines and 34/99 ( 34%) primary tumors. Overexpression of GAEC1 in 3T3 mouse. broblasts caused foci formation and colony formation in soft agar, comparable to H-ras and injection of GAEC1-transfected 3T3 cells into athymic nude mice formed undifferentiated sarcoma in vivo, indicating that GAEC1 is a transforming oncogene. Although no significant correlation was observed between GAEC1 amplification and clinicopathological parameters and prognosis, our study demonstrated that overexpressed GAEC1 has tumorigenic potential and suggest that overexpressed GAEC1 may play an important role in ESCC pathogenesis.	Hong Kong Polytech Univ, Dept Appl Biol & Chem Technol, Kowloon, Hong Kong, Peoples R China; State Key Lab Chinese Med & Mol Pharmacol, Shenzhen, Peoples R China; Griffith Univ, Dept Pathol, Nathan, Qld 4111, Australia; Univ Hong Kong, Li Ka Shing Fac Med, Dept Anat, Hong Kong, Hong Kong, Peoples R China; Hong Kong Polytech Univ, Lo Ka Chung Ctr Nat Anti Canc Drug Dev, Kowloon, Hong Kong, Peoples R China; Univ Hong Kong, Li Ka Shing Fac Med, Dept Surg, Hong Kong, Hong Kong, Peoples R China; Wellcome Trust Sanger Inst, Microarray Facil, Cambridge, England; Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Hong Kong, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Hong Kong Canc Inst, Sir YK Pao Ctr Canc, Dept Clin Oncol,State Key Lab Oncol S China,Canc, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Li Ka Shing Fac Med, Dept Pathol, Hong Kong, Hong Kong, Peoples R China	Hong Kong Polytechnic University; Griffith University; University of Hong Kong; Hong Kong Polytechnic University; University of Hong Kong; Wellcome Trust Sanger Institute; Chinese University of Hong Kong; Chinese University of Hong Kong; University of Hong Kong	Tang, JCO (corresponding author), Hong Kong Polytech Univ, Dept Appl Biol & Chem Technol, Kowloon, Hong Kong, Peoples R China.	gopesh@pathology.hku.hk; bccotang@polyu.edu.hk	Tao, Qian/T-4743-2018; Tang, Johnny C. O./M-9639-2014; Tsao, George/C-4422-2009; Tang, Johnny Cheuk-on/W-7214-2019; Law, Simon/C-4324-2009; Law, Fian/C-4692-2009; Lam, Alfred/C-1652-2008	Tao, Qian/0000-0001-5383-4808; Tang, Johnny C. O./0000-0002-4261-3206; Tang, Johnny Cheuk-on/0000-0002-4261-3206; Law, Simon/0000-0002-6518-5806; Lam, Alfred/0000-0003-2771-564X	Wellcome Trust [079643] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Ahmed MN, 2000, CANCER GENET CYTOGEN, V116, P10, DOI 10.1016/S0165-4608(99)00103-X; Ariyama Y, 1999, J HUM GENET, V44, P357, DOI 10.1007/s100380050178; Beaudoing E, 2000, GENOME RES, V10, P1001, DOI 10.1101/gr.10.7.1001; Deng W, 2004, ONCOGENE, V23, P9090, DOI 10.1038/sj.onc.1208119; Forozan F, 2000, CANCER RES, V60, P4519; Fujibe T, 2006, BIOSCI BIOTECH BIOCH, V70, P1827, DOI 10.1271/bbb.50673; Glockner G, 1998, GENOME RES, V8, P1060; GREER CE, 1991, AM J CLIN PATHOL, V95, P117, DOI 10.1093/ajcp/95.2.117; Hu YC, 2001, CLIN CANCER RES, V7, P2213; Hurst CD, 2004, ONCOGENE, V23, P2250, DOI 10.1038/sj.onc.1207260; Ince N, 2000, CANCER RES, V60, P1261; Kang KF, 1996, J IMMUNOL, V156, P1402; Keenan C, 1998, CELL SIGNAL, V10, P225, DOI 10.1016/S0898-6568(97)00121-6; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kwong D, 2004, HUM PATHOL, V35, P309, DOI 10.1016/j.humpath.2003.10.020; Lam AKY, 2000, CRIT REV ONCOL HEMAT, V33, P71, DOI 10.1016/S1040-8428(99)00054-2; LITCHFIELD DW, 1993, MOL CELL BIOCHEM, V128, P187, DOI 10.1007/BF01076770; NOWELL PC, 1989, SEMIN ONCOL, V16, P116; SolinasToldo S, 1996, CANCER RES, V56, P3803; Tang JCO, 2001, CLIN CANCER RES, V7, P1539; Watters DJ, 1999, BIOCHEM PHARMACOL, V58, P383, DOI 10.1016/S0006-2952(99)00063-5; YANG DY, 2000, J KOREAN SOC PRECISI, V17, P5; Ying J, 2006, ONCOGENE, V25, P1070, DOI 10.1038/sj.onc.1209154	23	17	17	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 30	2007	26	40					5877	5888		10.1038/sj.onc.1210390	http://dx.doi.org/10.1038/sj.onc.1210390			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205OH	17384685	Green Accepted			2022-12-17	WOS:000249123100005
J	Pollice, A; Sepe, M; Villella, V; Tolino, F; Vivo, M; Calabro, V; La Mantia, G				Pollice, A.; Sepe, M.; Villella, V. R.; Tolino, F.; Vivo, M.; Calabro, V.; La Mantia, G.			TBP-1 protects the human oncosuppressor p14ARF from proteasomal degradation	ONCOGENE			English	Article						p14ARF; TBP-1; proteasome; N-terminal ubiquitination	ARF TUMOR-SUPPRESSOR; TAT-BINDING PROTEIN-1; 26S PROTEASOME; PROTEOLYSIS; NUCLEOLAR; INK4A/ARF; NUCLEOPHOSMIN; STABILITY; P14(ARF); SUBUNIT	The p14ARF tumor suppressor is a key regulator of cellular proliferation, frequently inactivated in human cancer. The mechanisms that regulate alternative reading frame (ARF) turnover have been obscure for longtime, being ARF a relatively stable protein. Recently, it has been described that its degradation depends, at least in part, on the proteasome and that it can be subjected to N- terminal ubiquitination. We have previously reported that ARF protein levels are regulated by TBP- 1 (Tat- Binding Protein 1), a multifunctional protein, component of the regulatory subunit of the proteasome, involved in different cellular processes. Here we demonstrate that the stabilization effect exerted by TBP- 1 requires an intact N- terminal 39 amino acids in ARF and occurs independently from N- terminal ubiquitination of the protein. Furthermore, we observed that ARF can be degraded in vitro by the 20S proteasome, in the absence of ubiquitination and this effect can be counteracted by TBP- 1. These observations seem relevant in the comprehension of the regulation of ARF metabolism as, among the plethora of cellular ARF's interactors already identifi. ed, only NPM/B23 and TBP- 1 appear to be involved in the control of ARF intracellular levels.	Univ Naples Federico 2, Dipartimento Biol Strutturale & Funz, I-80126 Naples, Italy	University of Naples Federico II	La Mantia, G (corresponding author), Univ Naples Federico 2, Dipartimento Biol Strutturale & Funz, I-80126 Naples, Italy.	lamantia@unina.it	Vivo, Maria/S-3390-2017; Calabro, Viola/H-6156-2013	Vivo, Maria/0000-0003-2458-4226; Calabro, Viola/0000-0002-6508-8889	Telethon [GGP030326] Funding Source: Medline	Telethon(Fondazione Telethon)		Bertwistle D, 2004, MOL CELL BIOL, V24, P985, DOI 10.1128/MCB.24.3.985-996.2004; Bothner B, 2001, J MOL BIOL, V314, P263, DOI 10.1006/jmbi.2001.5110; Chen Y, 1997, J BIOL CHEM, V272, P24081, DOI 10.1074/jbc.272.38.24081; Colombo E, 2005, MOL CELL BIOL, V25, P8874, DOI 10.1128/MCB.25.20.8874-8886.2005; Colucci-D'Amato GL, 2000, J BIOL CHEM, V275, P19306, DOI 10.1074/jbc.275.25.19306; Corn PG, 2003, NAT GENET, V35, P229, DOI 10.1038/ng1254; Gallagher SJ, 2006, INT J BIOCHEM CELL B, V38, P1637, DOI 10.1016/j.biocel.2006.02.008; Gonzalez F, 2002, SCIENCE, V296, P548, DOI 10.1126/science.1069490; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; Kong XG, 2006, MOL CELL BIOL, V26, P2019, DOI 10.1128/MCB.26.6.2019-2028.2006; Korgaonkar C, 2005, MOL CELL BIOL, V25, P1258, DOI 10.1128/MCB.25.4.1258-1271.2005; Kuo ML, 2004, GENE DEV, V18, P1862, DOI 10.1101/gad.1213904; Lam YA, 2002, NATURE, V416, P763, DOI 10.1038/416763a; Liu CW, 2003, SCIENCE, V299, P408, DOI 10.1126/science.1079293; Lohrum MAE, 2000, CURR BIOL, V10, P539, DOI 10.1016/S0960-9822(00)00472-3; Paliwal S, 2006, MOL CELL BIOL, V26, P2360, DOI 10.1128/MCB.26.6.2360-2372.2006; Park BW, 1999, P NATL ACAD SCI USA, V96, P6434, DOI 10.1073/pnas.96.11.6434; Pollice A, 2004, J BIOL CHEM, V279, P6345, DOI 10.1074/jbc.M310957200; Reef S, 2006, MOL CELL, V22, P463, DOI 10.1016/j.molcel.2006.04.014; Rodway H, 2004, ONCOGENE, V23, P6186, DOI 10.1038/sj.onc.1207854; Russell SJ, 1999, MOL CELL, V3, P687, DOI 10.1016/S1097-2765(01)80001-0; Sdek P, 2005, MOL CELL, V20, P699, DOI 10.1016/j.molcel.2005.10.017; Sharpless NE, 2004, EXP GERONTOL, V39, P1751, DOI 10.1016/j.exger.2004.06.025; Sharpless NE, 2005, MUTAT RES-FUND MOL M, V576, P22, DOI 10.1016/j.mrfmmm.2004.08.021; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000	27	17	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 2	2007	26	35					5154	5162		10.1038/sj.onc.1210313	http://dx.doi.org/10.1038/sj.onc.1210313			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	196MT	17334400				2022-12-17	WOS:000248487400014
J	Waha, A; Koch, A; Hartmann, W; Milde, U; Felsberg, J; Hubner, A; Mikeska, T; Goodyer, CG; Sorensen, N; Lindberg, I; Wiestler, OD; Pietsch, T; Waha, A				Waha, A.; Koch, A.; Hartmann, W.; Milde, U.; Felsberg, J.; Huebner, A.; Mikeska, T.; Goodyer, C. G.; Soerensen, N.; Lindberg, I.; Wiestler, O. D.; Pietsch, T.; Waha, A.			SGNE1/7B2 is epigenetically altered and transcriptionally downregulated in human medulloblastomas	ONCOGENE			English	Article						medulloblastoma; SGNE1/7B2; methylation; DMH; cRT-PCR	PRIMITIVE NEUROECTODERMAL TUMORS; CENTRAL-NERVOUS-SYSTEM; COMPARATIVE GENOMIC HYBRIDIZATION; NEUROENDOCRINE PROTEIN 7B2; NH2-TERMINAL SEQUENCE; PITUITARY POLYPEPTIDE; CONVERTASE PC2; CELL-GROWTH; IN-VIVO; EXPRESSION	In a genome-wide screen using differential methylation hybridization (DMH), we have identified a CpG island within the 50 region and untranslated first exon of the secretory granule neuroendocrine protein 1 gene (SGNE1/7B2) that showed hypermethylation in medulloblastomas compared to fetal cerebellum. Bisulfite sequencing and combined bisulfite restriction assay were performed to confirm the methylation status of this CpG island in primary medulloblastomas and medulloblastoma cell lines. Hypermethylation was detected in 16/23 (70%) biopsies and 7/8 (87%) medulloblastoma cell lines, but not in nonneoplastic fetal (n=8) cerebellum. Expression of SGNE1 was investigated by semi-quantitative competitive reverse transcription-polymerase chain reaction and found to be significantly downregulated or absent in all, but one primary medulloblastomas and all cell lines compared to fetal cerebellum. After treatment of medulloblastoma cell lines with 5-aza-2'-deoxycytidine, transcription of SGNE1 was restored. No mutation was found in the coding region of SGNE1 by single-strand conformation polymorphism analysis. Reintroduction of SGNE1 into the medulloblastoma cell line D283Med led to a significant growth suppression and reduced colony formation. In summary, we have identified SGNE1 as a novel epigenetically silenced gene in medulloblastomas. Its frequent inactivation, as well as its inhibitory effect on tumor cell proliferation and focus formation strongly argues for a significant role in medulloblastoma development.	Univ Bonn, Med Ctr, Dept Neuropathol, D-53105 Bonn, Germany; McGill Univ, Montreal Childrens Hosp, Res Inst, Montreal, PQ H3H 1P3, Canada; Univ Wurzburg, Dept Pediat Neurosurg, D-97070 Wurzburg, Germany; Louisiana State Univ, Med Ctr, Dept Biochem & Mol Biol, New Orleans, LA USA; German Canc Res Ctr, D-6900 Heidelberg, Germany	University of Bonn; McGill University; University of Wurzburg; Louisiana State University System; Helmholtz Association; German Cancer Research Center (DKFZ)	Waha, A (corresponding author), Univ Bonn, Med Ctr, Dept Neuropathol, Sigmund Freud Str 25, D-53105 Bonn, Germany.	awaha1@uni-bonn.de	Lindberg, Iris/Q-3825-2019; Hartmann, Wolfgang/G-1893-2017; Mikeska, Thomas/B-4876-2008	Hartmann, Wolfgang/0000-0002-7609-5021; Mikeska, Thomas/0000-0003-1318-0859	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049703] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK049703] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIEGEL JA, 1989, GENE CHROMOSOME CANC, V1, P139, DOI 10.1002/gcc.2870010206; BIGNER SH, 1990, CANCER RES, V50, P2347; Bock C, 2005, BIOINFORMATICS, V21, P4067, DOI 10.1093/bioinformatics/bti652; BRAKS JAM, 1994, CELL, V78, P263, DOI 10.1016/0092-8674(94)90296-8; Braks JAM, 1996, EUR J BIOCHEM, V236, P60, DOI 10.1111/j.1432-1033.1996.00060.x; Cassidy SB, 1997, J MED GENET, V34, P917, DOI 10.1136/jmg.34.11.917; Collini P, 1998, VIRCHOWS ARCH, V432, P505, DOI 10.1007/s004280050198; Fruhwald MC, 2001, ONCOGENE, V20, P5033, DOI 10.1038/sj.onc.1204613; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Hartmann W, 2006, CLIN CANCER RES, V12, P3019, DOI 10.1158/1078-0432.CCR-05-2187; HSI KL, 1982, FEBS LETT, V147, P261, DOI 10.1016/0014-5793(82)81055-7; IGUCHI H, 1984, NEUROENDOCRINOLOGY, V39, P453, DOI 10.1159/000124020; Jeannotte R, 1997, DNA CELL BIOL, V16, P1175, DOI 10.1089/dna.1997.16.1175; Kleihues P, 2002, J NEUROPATH EXP NEUR, V61, P215, DOI 10.1093/jnen/61.3.215; Kobayashi I, 2003, ENDOCRINE, V22, P285, DOI 10.1385/ENDO:22:3:285; KOCH KR, 1996, ALLG VERMESS NACHR, V1, P1; Krause RM, 2001, ASM NEWS, V67, P15; Lindsey Janet C, 2005, Neurosurg Focus, V19, pE10, DOI 10.3171/foc.2005.19.5.11; MATTEI MG, 1990, GENOMICS, V6, P436, DOI 10.1016/0888-7543(90)90473-8; Mbikay M, 2001, BIOCHEM J, V357, P329, DOI 10.1042/0264-6021:3570329; Mercapide J, 2002, CLIN CANCER RES, V8, P1740; PIETSCH T, 1994, CANCER RES, V54, P3278; Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a; Reardon DA, 1997, CANCER RES, V57, P4042; ROEBROEK AJM, 1989, CANCER RES, V49, P4154; Russo C, 1999, CANCER, V86, P331, DOI 10.1002/(SICI)1097-0142(19990715)86:2<331::AID-CNCR18>3.0.CO;2-#; Schmidt G, 2006, DIABETES, V55, P452, DOI 10.2337/diabetes.55.02.06.db05-0733; SEIDAH NG, 1983, ARCH BIOCHEM BIOPHYS, V225, P525, DOI 10.1016/0003-9861(83)90063-2; Seidel B, 1998, DNA CELL BIOL, V17, P1017, DOI 10.1089/dna.1998.17.1017; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; Uziel T, 2006, CELL CYCLE, V5, P363, DOI 10.4161/cc.5.4.2475; Waha A, 2005, NEOPLASIA, V7, P193, DOI 10.1593/neo.04490; Waha A, 2003, J NEUROPATH EXP NEUR, V62, P1192, DOI 10.1093/jnen/62.11.1192; Waha A, 1998, BRAIN PATHOL, V8, P13; WALDBIESER GC, 1991, ENDOCRINOLOGY, V128, P3228, DOI 10.1210/endo-128-6-3228; Westphal CH, 1999, CELL, V96, P689, DOI 10.1016/S0092-8674(00)80579-6; Yan PS, 2001, CANCER RES, V61, P8375; ZHU XR, 1995, J CELL BIOL, V129, P1641, DOI 10.1083/jcb.129.6.1641	38	17	17	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2007	26	38					5662	5668		10.1038/sj.onc.1210338	http://dx.doi.org/10.1038/sj.onc.1210338			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200ZS	17334394				2022-12-17	WOS:000248801900012
J	Fleisig, HB; Orazio, N; Liang, H; Tyler, AF; Adams, HP; Weitzman, MD; Nagarajan, L				Fleisig, H. B.; Orazio, N. I.; Liang, H.; Tyler, A. F.; Adams, H. P.; Weitzman, M. D.; Nagarajan, L.			Adenoviral E1B55K oncoprotein sequesters candidate leukemia suppressor sequence-specific single-stranded DNA-binding protein 2 into aggresomes	ONCOGENE			English	Article						SSBP2; E1B55K; direct interaction; colocalization; aggresomes	TRANSCRIPTIONAL REPRESSION; 55-KILODALTON PROTEIN; CELL-TRANSFORMATION; E1B-55K ONCOPROTEIN; E4ORF6 PROTEINS; NUCLEAR EXPORT; INFECTED CELLS; MRE11 COMPLEX; P53; GENE	Sequence-specific single-stranded DNA-binding protein 2 (SSBP2) is a candidate tumor suppressor for human acute myelogenous leukemia (AML). Inducible expression of SSBP2 causes growth arrest and partial differentiation in AML cells. Here, we report that the adenoviral oncoprotein E1B55K directly binds to endogenous SSBP2 protein and sequesters it into juxtanuclear bodies in adenovirally transformed human embryonic kidney (HEK) 293 cells. Similarly, transient expression of E1B55K in IMR90 fibroblasts and HeLa cells result in the formation of juxtanuclear bodies containing SSBP2. When nuclear export of E1B55K is prevented, SSBP2 remains associated with E1B55K in nuclear foci. A requirement for intact microtubules to retain the integrity of the juxtanuclear bodies suggests them to be E1B55K containing aggresomes. The adenoviral E1B55K protein has been shown to localize to the Mre11 complex and p53 to aggresome structures; together with the viral E4orf6 protein, E1B55K recruits a cellular E3 ubiquitin ligase that induces degradation of Mre11 and p53. However, our present studies reveal that E1B55K does not degrade SSBP2. These data demonstrate that E1B55K targets the candidate leukemia suppressor SSBP2 and suggest that subverting its function may contribute to cell transformation by viral oncoproteins.	MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA; Salk Inst Biol Studies, Genet Lab, La Jolla, CA 92037 USA; Univ Calif San Diego, Div Biol, Grad Program, San Diego, CA 92103 USA	University of Texas System; UTMD Anderson Cancer Center; Salk Institute; University of California System; University of California San Diego	Nagarajan, L (corresponding author), MD Anderson Canc Ctr, Dept Mol Genet, Box 1006,1515 Holcombe Blvd, Houston, TX 77030 USA.	lnagaraj@mdanderson.org			NCI NIH HHS [T32 CA064041, CA16672, CA97093] Funding Source: Medline; NHLBI NIH HHS [HL074449] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, T32CA064041, R01CA097093] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL074449] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahuja D, 2005, ONCOGENE, V24, P7729, DOI 10.1038/sj.onc.1209046; Araujo FD, 2005, J VIROL, V79, P11382, DOI 10.1128/JVI.79.17.11382-11391.2005; Bayarsaihan D, 1996, BIOCHEM J, V314, P293, DOI 10.1042/bj3140293; BROWN CR, 1994, J CELL PHYSIOL, V160, P47, DOI 10.1002/jcp.1041600107; Carson CT, 2003, EMBO J, V22, P6610, DOI 10.1093/emboj/cdg630; Castro P, 2002, GENOMICS, V80, P78, DOI 10.1006/geno.2002.6805; Cathomen T, 2000, J VIROL, V74, P11407, DOI 10.1128/JVI.74.23.11407-11412.2000; Chen L, 2002, P NATL ACAD SCI USA, V99, P14320, DOI 10.1073/pnas.212532399; Dobner T, 2001, CURR TOP MICROBIOL, V259, P25; Dosch T, 2001, J VIROL, V75, P5677, DOI 10.1128/JVI.75.12.5677-5683.2001; Endter C, 2005, ONCOGENE, V24, P55, DOI 10.1038/sj.onc.1208170; Endter C, 2004, CURR TOP MICROBIOL, V273, P163; Felsani A, 2006, ONCOGENE, V25, P5277, DOI 10.1038/sj.onc.1209621; Flint SJ, 2003, CURR TOP MICROBIOL, V272, P287; Goardon N, 2006, EMBO J, V25, P357, DOI 10.1038/sj.emboj.7600934; Harada JN, 2002, J VIROL, V76, P9194, DOI 10.1128/JVI.76.18.9194-9206.2002; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Kratzer F, 2000, ONCOGENE, V19, P850, DOI 10.1038/sj.onc.1203395; Liang H, 2005, ONCOGENE, V24, P2625, DOI 10.1038/sj.onc.1208167; Liu Y, 2005, J VIROL, V79, P14004, DOI 10.1128/JVI.79.22.14004-14016.2005; Martin MED, 1998, J VIROL, V72, P3146, DOI 10.1128/JVI.72.4.3146-3154.1998; Nishioka N, 2005, DEVELOPMENT, V132, P2535, DOI 10.1242/dev.01844; O'Shea CC, 2005, CURR OPIN GENET DEV, V15, P18, DOI 10.1016/j.gde.2004.12.010; ORNELLES DA, 1991, J VIROL, V65, P424, DOI 10.1128/JVI.65.1.424-429.1991; Querido E, 2001, GENE DEV, V15, P3104, DOI 10.1101/gad.926401; Querido E, 1997, J VIROL, V71, P3788, DOI 10.1128/JVI.71.5.3788-3798.1997; Querido E, 2001, J VIROL, V75, P699, DOI 10.1128/JVI.75.2.699-709.2001; SARNOW P, 1982, VIROLOGY, V120, P510, DOI 10.1016/0042-6822(82)90054-X; Schuh AH, 2005, MOL CELL BIOL, V25, P10235, DOI 10.1128/MCB.25.23.10235-10250.2005; STEEGE MW, 1998, PROVEN PRACTICE PREV, V1, P4; Steegenga WT, 1999, MOL CELL BIOL, V19, P3885; Stracker TH, 2002, NATURE, V418, P348, DOI 10.1038/nature00863; Teodoro JG, 1997, J VIROL, V71, P3620, DOI 10.1128/JVI.71.5.3620-3627.1997; van Meyel DJ, 2003, DEVELOPMENT, V130, P1915, DOI 10.1242/dev.00389; Weitzman MD, 2005, ONCOGENE, V24, P7686, DOI 10.1038/sj.onc.1209063; Wienzek S, 2000, J VIROL, V74, P193, DOI 10.1128/JVI.74.1.193-202.2000; Wu LT, 2006, BIOCHEM BIOPH RES CO, V339, P977, DOI 10.1016/j.bbrc.2005.11.098; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; ZANTEMA A, 1985, VIROLOGY, V142, P44, DOI 10.1016/0042-6822(85)90421-0; Zhao LY, 2003, J VIROL, V77, P11809, DOI 10.1128/JVI.77.21.11809-11821.2003	41	17	17	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 19	2007	26	33					4797	4805		10.1038/sj.onc.1210281	http://dx.doi.org/10.1038/sj.onc.1210281			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	191ZL	17311003				2022-12-17	WOS:000248170400004
J	Ott, RG; Simma, O; Kollmann, K; Weisz, E; Zebedin, EM; Schorpp-Kistner, M; Heller, G; Zochbauer, S; Wagner, EF; Freissmuth, M; Sexl, V				Ott, R. G.; Simma, O.; Kollmann, K.; Weisz, E.; Zebedin, E. M.; Schorpp-Kistner, M.; Heller, G.; Zoechbauer, S.; Wagner, E. F.; Freissmuth, M.; Sexl, V.			JunB is a gatekeeper for B-lymphoid leukemia	ONCOGENE			English	Article						JunB; bcr/abl; AP-1; leukemia	CHRONIC MYELOID-LEUKEMIA; CYCLIN-DEPENDENT KINASE; MICE LACKING JUNB; C-JUN; TUMOR-DEVELOPMENT; CELL LYMPHOMAS; EXPRESSION; PHOSPHORYLATION; METHYLATION; GAMMA	Loss of JunB has been observed in human leukemia and lymphoma, but it remains unknown, whether this loss is relevant to disease progression. Here, we investigated the consequences of JunB de. ciency using Abelson-induced B- lymphoid leukemia as a model system. Mice de. cient in JunB expression succumbed to Abelson-induced leukemia with increased incidence and significantly reduced latency. Similarly, bcr/abl p185-transformed JunB-deficient (junBD/D) cells induced leukemia in RAG2(-/-) mice displaying a more malignant phenotype. These observations indicated that cell intrinsic effects within the junBD/D tumor cells accounted for the accelerated leukemia development. Indeed, explantated bcr/abl p185 transformed junBD/D cells proliferated faster than the control cells. The proliferative advantage emerged slowly after the initial transformation process and was associated with increased expression levels of the cell cycle kinase cdk6 and with decreased levels of the cell cycle inhibitor p16INK4a. These alterations were due to irreversible reprogramming of the cell, because - once established - accelerated disease induced by junBD/D cells was not reverted by re-introducing JunB. Consistent with this observation, we found that the p16 promoter was methylated. Thus, JunB functions as a gatekeeper during tumor evolution. In its absence, transformed leukemic cells acquire an enhanced proliferative capacity, which presages a more malignant disease.	MUV, Inst Pharmacol, Vienna, Austria; MUV, Dept Oncol, Vienna, Austria; DKFZ, German Canc Res Ctr, Vienna, Austria; IMP, Vienna, Austria	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Sexl, V (corresponding author), Dept Pharmacol, Waehringerstr 13A, A-1090 Vienna, Austria.	sexl@meduniwien.ac.at	heller, gerwin/E-6521-2011; Zöchbauer-Müller, Sabine/B-8399-2012; Sexl, Veronika/B-8657-2016	heller, gerwin/0000-0001-8742-5631; Zöchbauer-Müller, Sabine/0000-0002-6777-1729; Kollmann, Karoline/0000-0002-7937-4245; Wagner, Erwin F/0000-0001-7872-0196; Sexl, Veronika/0000-0001-9363-0412; Freissmuth, Michael/0000-0001-9398-1765				BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Corcoran MM, 1999, ONCOGENE, V18, P6271, DOI 10.1038/sj.onc.1203033; Deininger M, 2005, BLOOD, V105, P2640, DOI 10.1182/blood-2004-08-3097; Diehl JA, 1997, MOL CELL BIOL, V17, P7362, DOI 10.1128/MCB.17.12.7362; Eferl R, 2003, CELL, V112, P181, DOI 10.1016/S0092-8674(03)00042-4; Ezhevsky SA, 1997, P NATL ACAD SCI USA, V94, P10699, DOI 10.1073/pnas.94.20.10699; GRAWUNDER U, 1993, EUR J IMMUNOL, V23, P544, DOI 10.1002/eji.1830230237; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Kenner L, 2004, J CELL BIOL, V164, P613, DOI 10.1083/jcb.200308155; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Mao X, 2002, GENE CHROMOSOME CANC, V35, P144, DOI 10.1002/gcc.10104; Mao X, 2003, BLOOD, V101, P1513, DOI 10.1182/blood-2002-08-2434; Marique T, 2001, J THEOR BIOL, V209, P3, DOI 10.1006/jtbi.2000.2237; Markevich NI, 2004, J CELL BIOL, V164, P353, DOI 10.1083/jcb.200308060; Mechta-Grigoriou F, 2001, ONCOGENE, V20, P2378, DOI 10.1038/sj.onc.1204381; Passegue E, 2001, CELL, V104, P21, DOI 10.1016/S0092-8674(01)00188-X; Passegue E, 2004, CELL, V119, P431, DOI 10.1016/j.cell.2004.10.010; Rassidakis GZ, 2005, MODERN PATHOL, V18, P1365, DOI 10.1038/modpathol.3800419; Schorpp-Kistner M, 1999, EMBO J, V18, P934, DOI 10.1093/emboj/18.4.934; Sexl V, 2000, BLOOD, V96, P2277, DOI 10.1182/blood.V96.6.2277; Sexl V, 1999, ONCOGENE, V18, P573, DOI 10.1038/sj.onc.1202362; Shankaran V, 2001, NATURE, V410, P1107, DOI 10.1038/35074122; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; Szabowski A, 2000, CELL, V103, P745, DOI 10.1016/S0092-8674(00)00178-1; Szremska AP, 2003, BLOOD, V102, P4159, DOI 10.1182/blood-2003-03-0915; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Wolff L, 2003, ONCOGENE, V22, P9265, DOI 10.1038/sj.onc.1207092; WU JX, 1990, ONCOGENE, V5, P989; Yang MY, 2003, BLOOD, V101, P3205, DOI 10.1182/blood-2002-05-1598	35	17	17	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 19	2007	26	33					4863	4871		10.1038/sj.onc.1210285	http://dx.doi.org/10.1038/sj.onc.1210285			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	191ZL	17297445				2022-12-17	WOS:000248170400011
J	Qian, J; Steigerwald, K; Combs, KA; CBarton, M; Groden, J				Qian, J.; Steigerwald, K.; Combs, K. A.; CBarton, M.; Groden, J.			Caspase cleavage of the APC tumor suppressor and release of an amino-terminal domain is required for the transcription-independent function of APC in apoptosis	ONCOGENE			English	Article						APC; apoptosis; transcription; independent-caspase; colon cancer	ADENOMATOUS POLYPOSIS; PROTEIN	The adenomatous polyposis coli (APC) tumor suppressor is inactivated by mutation in most colorectal tumors. APC is a component of the Wnt signaling pathway and is best known for its ability to downregulate beta-catenin and consequent effects on transcriptional regulation. Previous work demonstrated that APC accelerates apoptosis-associated caspase activity independently of transcription, and suggested novel tumor suppressor functions of APC. In this work, we have mapped the APC apoptosis-accelerating region to amino acids (aa) 1-760 by testing a series of nonoverlapping APC segments. Interestingly, this segment corresponds to a stable group II caspase cleavage product of APC released during apoptosis that includes the aminoterminal aa1-777. Mutation of the APC aspartic acid residue at position 777 to an alanine completely abolished in vitro cleavage of APC by a recombinant group II caspase and rendered the full-length protein unable to accelerate apoptosis in vitro. A truncated APC protein associated with familial and sporadic colorectal cancer, also unable to accelerate apoptosis in vitro and in vivo, is resistant to group II caspase cleavage. These results demonstrate that cleavage of APC and the subsequent release of an aminoterminal segment are necessary for the transcriptionindependent mechanism of APC-mediated apoptosis.	Ohio State Univ, Coll Med, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA; Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA	University System of Ohio; Ohio State University; University System of Ohio; University of Cincinnati; University of Texas System; UTMD Anderson Cancer Center	Groden, J (corresponding author), Ohio State Univ, Coll Med, Dept Mol Virol Immunol & Med Genet, 400 W 12th St, Columbus, OH 43210 USA.	joanna.groden@osumc.edu	Zhang, Spring/K-2787-2013	Barton, Michelle/0000-0002-4042-1374	NATIONAL CANCER INSTITUTE [R15CA063517] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053683] Funding Source: NIH RePORTER; NCI NIH HHS [CA 63517] Funding Source: Medline; NIGMS NIH HHS [R01 GM053683, R01 GM053683-07A2] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTON MC, 1993, GENE DEV, V7, P1796, DOI 10.1101/gad.7.9.1796; Browne SJ, 1998, CELL DEATH DIFFER, V5, P206, DOI 10.1038/sj.cdd.4400331; FASSCHON DM, 1997, J CELL BIOL, V137, P1117; Goss KH, 2000, J CLIN ONCOL, V18, P1967, DOI 10.1200/JCO.2000.18.9.1967; GRODEN J, 1993, AM J HUM GENET, V52, P263; Kim K, 2000, MOL BIOL CELL, V11, P3509, DOI 10.1091/mbc.11.10.3509; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Lillard-Wetherell K, 2004, HUM MOL GENET, V13, P1919, DOI 10.1093/hmg/ddh193; NEWMEYER DD, 1994, CELL, V79, P453; Steigerwald K, 2005, MOL CANCER RES, V3, P78, DOI 10.1158/1541-7786.MCR-03-0189; Webb SJ, 1999, FASEB J, V13, P339, DOI 10.1096/fasebj.13.2.339	11	17	17	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 19	2007	26	33					4872	4876		10.1038/sj.onc.1210265	http://dx.doi.org/10.1038/sj.onc.1210265			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	191ZL	17297457				2022-12-17	WOS:000248170400012
J	Nunoda, K; Tauchi, T; Takaku, T; Okabe, S; Akahane, D; Sashida, G; Ohyashiki, JH; Ohyashiki, K				Nunoda, K.; Tauchi, T.; Takaku, T.; Okabe, S.; Akahane, D.; Sashida, G.; Ohyashiki, J. H.; Ohyashiki, K.			Identification and functional signature of genes regulated by structurally different ABL kinase inhibitors	ONCOGENE			English	Article						BCR-ABL; tyrosine kinase inhibitor; imatinib; dasatinib	BCR-ABL; CELL-PROLIFERATION; LEUKEMIA-CELLS; IMATINIB; RESISTANCE; EXPRESSION; INDEPENDENCE; P27(KIP1); MECHANISM; BINDING	Dasatinib is an ATP-competitive, multi-targeted SRC and ABL kinase inhibitor that can bind BCR-ABL in both the active and inactive conformations. From a clinical standpoint, dasatinib is particularly attractive because it has been shown to induce hematologic and cytogenetic responses in imatinib-resistant chronic myeloid leukemia patients. The fact because the combination of imatinib and dasatinib shows the additive/synergistic growth inhibition on wild-type p210 BCR-ABL-expressing cells, we reasoned that these ABL kinase inhibitors might induce the different molecular pathways. To address this question, we used DNA microarrays to identify genes whose transcription was altered by imatinib and dasatinib. K562 cells were cultured with imatinib or dasatinib for 16 h, and gene expression data were obtained from three independent microarray hybridizations. Almost all of the imatinib-and dasatinib-responsive genes appeared to be similarly increased or decreased in K562 cells; however, small subsets of genes were identified as selectively altered expression by either imatinib or dasatinib. The distinct genes that are selectively modulated by dasatinib are cyclin-dependent kinase 2 (CDK2) and CDK8, which had a maximal reduction of <5-fold in microarray screen. To assess the functional importance of dasatinib regulated genes, we used RNA interference to determine whether reduction of CDK2 and CDK8 affected the growth inhibition. K562 and TF-1BCR-ABL cells, pretreated with CDK2 or CDK8 small interfering RNA, showed additive growth inhibition with imatinib, but not with dasatinib. These findings demonstrate that the additive/ synergistic growth inhibition by imatinib and dasatinib may be mediated in part by CDK2 and CDK8.	Tokyo Med Univ, Dept Internal Med 1, Shinjuku Ku, Tokyo 1600023, Japan; Tokyo Med Univ, Intractable Dis Res Ctr, Shinjuku Ku, Tokyo, Japan	Tokyo Medical University; Tokyo Medical University	Tauchi, T (corresponding author), Tokyo Med Univ, Dept Internal Med 1, Shinjuku Ku, 6-7-1 Nishinhijuku, Tokyo 1600023, Japan.	tauchi@tokyo-med.ac.jp	Sashida, Goro/N-5259-2014	Sashida, Goro/0000-0003-2318-5987				Burgess MR, 2005, P NATL ACAD SCI USA, V102, P3395, DOI 10.1073/pnas.0409770102; Dai Y, 2004, J BIOL CHEM, V279, P34227, DOI 10.1074/jbc.M402290200; Donato NJ, 2003, BLOOD, V101, P690, DOI 10.1182/blood.V101.2.690; Gambacorti-Passerini C, 2005, LEUKEMIA, V19, P1267, DOI 10.1038/sj.leu.2403775; Gesbert F, 2000, J BIOL CHEM, V275, P39223, DOI 10.1074/jbc.M007291200; Hofmann WK, 2002, LANCET, V359, P481, DOI 10.1016/S0140-6736(02)07678-X; Jiang YH, 2000, P NATL ACAD SCI USA, V97, P10538, DOI 10.1073/pnas.190104497; Komatsu N, 2003, J BIOL CHEM, V278, P6411, DOI 10.1074/jbc.M211562200; Lionberger JM, 2000, J BIOL CHEM, V275, P18581, DOI 10.1074/jbc.C000126200; Nakajima A, 2003, MOL CANCER THER, V2, P219; O'Hare T, 2005, CANCER RES, V65, P4500, DOI 10.1158/0008-5472.CAN-05-0259; Ohyashiki JH, 2005, BIOCHEM BIOPH RES CO, V329, P11, DOI 10.1016/j.bbrc.2005.01.090; Parada Y, 2001, J BIOL CHEM, V276, P23572, DOI 10.1074/jbc.M101885200; Prathapam T, 2006, P NATL ACAD SCI USA, V103, P2695, DOI 10.1073/pnas.0511186103; Ptasznik A, 2004, NAT MED, V10, P1187, DOI 10.1038/nm1127; Riley D, 2001, ONCOGENE, V20, P5941, DOI 10.1038/sj.onc.1204826; Samanta AK, 2006, CANCER RES, V66, P6468, DOI 10.1158/0008-5472.CAN-06-0025; Shah NP, 2004, SCIENCE, V305, P399, DOI 10.1126/science.1099480; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Stanglmaier M, 2003, LEUKEMIA, V17, P283, DOI 10.1038/sj.leu.2402778; Takaku T, 2005, BIOCHEM BIOPH RES CO, V336, P469, DOI 10.1016/j.bbrc.2005.08.104; Talpaz M, 2006, NEW ENGL J MED, V354, P2531, DOI 10.1056/NEJMoa055229; TAUCHI T, 1994, J BIOL CHEM, V269, P15381; Tetsu O, 2003, CANCER CELL, V3, P233, DOI 10.1016/S1535-6108(03)00053-9; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Warmuth M, 1997, J BIOL CHEM, V272, P33260, DOI 10.1074/jbc.272.52.33260; Zhang Y, 2006, BRIT J CANCER, V94, P599, DOI 10.1038/sj.bjc.6602968	27	17	17	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 14	2007	26	28					4179	4188		10.1038/sj.onc.1210179	http://dx.doi.org/10.1038/sj.onc.1210179			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	178XD	17213809				2022-12-17	WOS:000247252700013
J	Riz, I; Akimov, SS; Eaker, SS; Baxter, KK; Lee, HJ; Marino-Ramirez, L; Landsman, D; Hawley, TS; Hawley, RG				Riz, I.; Akimov, S. S.; Eaker, S. S.; Baxter, K. K.; Lee, H. J.; Marino-Ramirez, L.; Landsman, D.; Hawley, T. S.; Hawley, R. G.			TLX1/HOX11-induced hematopoietic differentiation blockade	ONCOGENE			English	Article						TLX1/HOX11 oncogene; erythropoiesis; conditional differentiation block; CBP; GATA-1; repressive chromatin domains	TRANSCRIPTION FACTOR GATA-1; CREB-BINDING PROTEIN; T-CELL LEUKEMIA; THYMOCYTE DIFFERENTIATION; ERYTHROID-CELLS; HOX11 INTERACTS; HOMEOBOX GENES; CBP; ACETYLATION; ONCOPROTEIN	Aberrant expression of the human homeobox-containing proto-oncogene TLX1/HOX11 inhibits hematopoietic differentiation programs in a number of murine model systems. Here, we report the establishment of a murine erythroid progenitor cell line, iEBHX1S-4, developmentally arrested by regulatable TLX1 expression. Extinction of TLX1 expression released the iEBHX1S-4 differentiation block, allowing erythropoietin-dependent acquisition of erythroid markers and hemoglobin synthesis. Coordinated activation of erythroid transcriptional networks integrated by the acetyltransferase co-activator CREB-binding protein (CBP) was suggested by bioinformatic analysis of the upstream regulatory regions of several conditionally induced iEBHX1S-4 gene sets. In accord with this notion, CBP-associated acetylation of GATA-1, an essential regulator of erythroid differentiation, increased concomitantly with TLX1 downregulation. Coimmunoprecipitation experiments and glutathione-S-transferase pull-down assays revealed that TLX1 directly binds to CBP, and confocal laser microscopy demonstrated that the two proteins partially colocalize at intranuclear sites in iEBHX1S-4 cells. Notably, the distribution of CBP in conditionally blocked iEBHX1S-4 cells partially overlapped with chromatin marked by a repressive histone methylation pattern, and downregulation of TLX1 coincided with exit of CBP from these heterochromatic regions. Thus, we propose that TLX1-mediated differentiation arrest may be achieved in part through a mechanism that involves redirection of CBP and/or its sequestration in repressive chromatin domains.	George Washington Univ, Dept Anat & Cell Biol, Med Ctr, Washington, DC 20037 USA; NanoDetect Technol, Knoxville, TN USA; George Washington Univ, Mol Med Program, Med Ctr, Washington, DC 20037 USA; George Washington Univ, Genom & Bioinformat Program, Med Ctr, Washington, DC 20037 USA; Natl Ctr Biotechnol Informat, Computat Biol Branch, Natl Lib Med, NIH, Bethesda, MD USA; George Washington Univ, Flow Cytometry Core Facil, Med Ctr, Washington, DC 20037 USA	George Washington University; George Washington University; George Washington University; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM); George Washington University	Hawley, TS (corresponding author), George Washington Univ, Dept Anat & Cell Biol, Med Ctr, 2300 I St NW, Washington, DC 20037 USA.	rghawley@gwu.edu	Mariño-Ramírez, Leonardo/N-5395-2019; Landsman, David/GZK-5496-2022; Landsman, David/C-5923-2009; Mariño-Ramírez, Leonardo/I-5759-2013	Mariño-Ramírez, Leonardo/0000-0002-5716-8512; Landsman, David/0000-0002-9819-6675; Mariño-Ramírez, Leonardo/0000-0002-5716-8512; Hawley, Robert/0000-0003-3512-5818	Intramural NIH HHS [Z99 LM999999] Funding Source: Medline; NHLBI NIH HHS [R01 HL066305-05, R01 HL065519-04, R01 HL066305-02, R01 HL065519-01A1, R01 HL065519-02, R01 HL065519, R01 HL065519-06, R01 HL065519-03, R01 HL066305-04, R01 HL066305-03, R01 HL065519-05, R01 HL066305, R01 HL066305-01A1] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065519, R01HL066305] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [Z01LM000084] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		Ait-Si-Ali S, 2000, ONCOGENE, V19, P2430, DOI 10.1038/sj.onc.1203562; Akimov SS, 2005, STEM CELLS, V23, P1423, DOI 10.1634/stemcells.2005-0390; Allen TD, 2000, LEUKEMIA LYMPHOMA, V39, P241, DOI 10.3109/10428190009065824; Bayly R, 2004, J BIOL CHEM, V279, P55362, DOI 10.1074/jbc.M408654200; Berger LC, 1997, BLOOD, V89, P261, DOI 10.1182/blood.V89.1.261.261_261_271; Blobel GA, 2000, BLOOD, V95, P745, DOI 10.1182/blood.V95.3.745.003k05_745_755; Blobel GA, 1998, P NATL ACAD SCI USA, V95, P2061, DOI 10.1073/pnas.95.5.2061; Choi YJ, 2006, CANCER RES, V66, P2990, DOI 10.1158/0008-5472.CAN-05-2944; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DEAR TN, 1993, P NATL ACAD SCI USA, V90, P4431, DOI 10.1073/pnas.90.10.4431; Deguchi K, 2003, CANCER CELL, V3, P259, DOI 10.1016/S1535-6108(03)00051-5; Greer L, 1998, INT J NON-EQUILIB PR, V11, P1; Guenatri M, 2004, J CELL BIOL, V166, P493, DOI 10.1083/jcb.200403109; HAWLEY RG, 1994, ONCOGENE, V9, P1; Hawley RG, 1997, CANCER RES, V57, P337; Heidari M, 2006, LEUKEMIA, V20, P304, DOI 10.1038/sj.leu.2404071; Helt AM, 2003, CARCINOGENESIS, V24, P159, DOI 10.1093/carcin/24.2.159; Herblot S, 2000, NAT IMMUNOL, V1, P138, DOI 10.1038/77819; Hernandez-Hernandez A, 2006, EMBO J, V25, P3264, DOI 10.1038/sj.emboj.7601228; Hong W, 2002, MOL CELL BIOL, V22, P3729, DOI 10.1128/MCB.22.11.3729-3743.2002; Huang SM, 1999, ONCOGENE, V18, P4958, DOI 10.1038/sj.onc.1202889; Hung HL, 1999, MOL CELL BIOL, V19, P3496; Iyer NG, 2004, ONCOGENE, V23, P4225, DOI 10.1038/sj.onc.1207118; KAMPS MP, 1994, ONCOGENE, V9, P3159; Kang-Decker N, 2004, CANCER CELL, V5, P177, DOI 10.1016/S1535-6108(04)00022-4; Karuppayil SM, 1998, J BIOL CHEM, V273, P17303, DOI 10.1074/jbc.273.28.17303; Kasper LH, 2006, MOL CELL BIOL, V26, P789, DOI 10.1128/MCB.26.3.789-809.2006; Kawabe T, 1997, NATURE, V385, P454, DOI 10.1038/385454a0; Keller G, 1998, BLOOD, V92, P877, DOI 10.1182/blood.V92.3.877.415k11_877_887; Kostic C, 2000, ONCOGENE, V19, P3978, DOI 10.1038/sj.onc.1203747; Krasnoselskaya-Riz I, 2002, AIDS RES HUM RETROV, V18, P591, DOI 10.1089/088922202753747941; Kung AL, 2000, GENE DEV, V14, P272; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Kyba M, 2002, CELL, V109, P29, DOI 10.1016/S0092-8674(02)00680-3; Lahlil R, 2004, MOL CELL BIOL, V24, P1439, DOI 10.1128/MCB.24.4.1439-1452.2004; LARSON RC, 1995, ONCOGENE, V11, P853; Owens BM, 2006, BRIT J HAEMATOL, V132, P216, DOI 10.1111/j.1365-2141.2005.05850.x; Owens BM, 2003, BLOOD, V101, P4966, DOI 10.1182/blood-2002-09-2857; Owens BM, 2002, STEM CELLS, V20, P364, DOI 10.1634/stemcells.20-5-364; Popratiloff A, 2003, J COMP NEUROL, V461, P466, DOI 10.1002/cne.10702; Riz I, 2005, ONCOGENE, V24, P5561, DOI 10.1038/sj.onc.1208727; Rodriguez P, 2005, EMBO J, V24, P2354, DOI 10.1038/sj.emboj.7600702; Schaufele F, 2001, MOL ENDOCRINOL, V15, P1665, DOI 10.1210/me.15.10.1665; Schuh AH, 2005, MOL CELL BIOL, V25, P10235, DOI 10.1128/MCB.25.23.10235-10250.2005; Shen WF, 2001, MOL CELL BIOL, V21, P7509, DOI 10.1128/MCB.21.21.7509-7522.2001; Soulier J, 2005, BLOOD, V106, P274, DOI 10.1182/blood-2004-10-3900; Sykes DB, 2001, BLOOD, V98, P2308, DOI 10.1182/blood.V98.8.2308; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; Watabiki Y, 2003, J HIGH ENERGY PHYS; Wen J, 2005, J BIOL CHEM, V280, P12956, DOI 10.1074/jbc.M412721200; Wu R, 2005, MOL BIOL CELL, V16, P2872, DOI 10.1091/mbc.e04-11-0997; Yang LV, 2001, MECH DEVELOP, V104, P105, DOI 10.1016/S0925-4773(01)00376-8; Yang XJ, 2004, BIOESSAYS, V26, P1076, DOI 10.1002/bies.20104; YOSHIDA M, 1987, CANCER RES, V47, P3688; Zhang N, 1999, ONCOGENE, V18, P2273, DOI 10.1038/sj.onc.1202545	55	17	17	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 14	2007	26	28					4115	4123		10.1038/sj.onc.1210185	http://dx.doi.org/10.1038/sj.onc.1210185			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	178XD	17213805	Green Accepted			2022-12-17	WOS:000247252700007
J	Nandi, S; Reinert, LS; Hachem, A; Mazan-Mamczarz, K; Hagner, P; He, H; Gartenhaus, RB				Nandi, S.; Reinert, L. S.; Hachem, A.; Mazan-Mamczarz, K.; Hagner, P.; He, H.; Gartenhaus, R. B.			Phosphorylation of MCT-1 by p44/42 MAPK is required for its stabilization in response to DNA damage	ONCOGENE			English	Article						lymphoma; stability; phosphorylation	KINASE SIGNALING PATHWAYS; CELL-CYCLE PROGRESSION; B-CELL; CANDIDATE ONCOGENE; PROTEIN STABILITY; APOPTOSIS; PROLIFERATION; INHIBITION; ACTIVATION; EXPRESSION	We discovered a novel oncogene in a T-cell lymphoma cell line, multiple copies in T-cell lymphoma-1 (MCT-1), that has been shown to decrease cell-doubling time, shorten the duration of G(1) transit time and/or G(1)-S transition, and transform NIH3T3 fibroblasts. We subsequently demonstrated that there were significantly increased levels of MCT-1 protein in a subset of primary diffuse large B-cell lymphomas. Levels of MCT-1 protein were shown to be increased after exposure to DNA damaging agents. This increase did not require new protein synthesis, suggesting that post-translational mechanisms were involved. Phosphorylation is one potential mechanism by which the activity of molecules involved in cell cycle/survival is rapidly modulated. The RAS/mitogen-activated/extracellular-regulated kinase (MEK)/extracellular signal-regulated kinases (ERK) pathway plays a prominent role in the regulation of cell growth and proliferation through phosphorylation-dependent regulation of several substrates. The MCT-1 protein is predicted to have numerous putative phosphorylation sites. Using a combination of genetic and pharmacological approaches, we established that phosphorylation of MCT-1 protein by p44/p42 mitogen-activated protein kinases is critical for stabilization of MCT-1 protein and for its ability to promote cell proliferation. Our data suggests that targeting the RAS/MEK/ERK signal transduction cascade may provide a potential therapeutic approach in lymphomas and related malignancies that exhibit high levels of MCT-1 protein.	Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA; Univ Calif San Diego, Dept Med, La Jolla, CA USA	University System of Maryland; University of Maryland Baltimore; University of California System; University of California San Diego	Gartenhaus, RB (corresponding author), Univ Maryland, Greenebaum Canc Ctr, 9-011 BRB,655 W Baltimore St, Baltimore, MD 21201 USA.	rgartenhaus@som.umaryland.edu		Reinert, Line/0000-0002-8317-0886				Chang FM, 2003, INT J ONCOL, V22, P469; Chen SY, 2002, J VIROL, V76, P9556, DOI 10.1128/JVI.76.18.9556-9561.2002; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; Dent P, 2003, ONCOGENE, V22, P5885, DOI 10.1038/sj.onc.1206701; Dierov J, 1999, J CELL BIOCHEM, V74, P544, DOI 10.1002/(SICI)1097-4644(19990915)74:4<544::AID-JCB4>3.3.CO;2-W; Herbert GB, 2001, ONCOGENE, V20, P6777, DOI 10.1038/sj.onc.1204881; Hsu HL, 2005, ONCOGENE, V24, P4956, DOI 10.1038/sj.onc.1208680; Jazirehi AR, 2004, CANCER RES, V64, P7117, DOI 10.1158/0008-5472.CAN-03-3500; Levenson AS, 2005, CANCER RES, V65, P10651, DOI 10.1158/0008-5472.CAN-05-0845; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Prosniak M, 1998, CANCER RES, V58, P4233; Scarpa A, 1999, GENE CHROMOSOME CANC, V26, P203, DOI 10.1002/(SICI)1098-2264(199911)26:3<203::AID-GCC3>3.0.CO;2-E; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Shapiro P, 2002, CRIT REV CL LAB SCI, V39, P285, DOI 10.1080/10408360290795538; Shi B, 2003, BLOOD, V102, P297, DOI 10.1182/blood-2002-11-3486; Tang DM, 2002, J BIOL CHEM, V277, P12710, DOI 10.1074/jbc.M111598200; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Werner CA, 1997, AM J PATHOL, V151, P335; Wilkinson MG, 2000, FASEB J, V14, P2147, DOI 10.1096/fj.00-0102rev; Yang CM, 2003, J BIOMED SCI, V10, P208, DOI 10.1159/000068713	21	17	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 5	2007	26	16					2283	2289		10.1038/sj.onc.1210030	http://dx.doi.org/10.1038/sj.onc.1210030			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	153WC	17016429	Bronze			2022-12-17	WOS:000245466000004
J	Karp, CM; Shukla, MN; Buckley, DJ; Buckley, AR				Karp, C. M.; Shukla, M. N.; Buckley, D. J.; Buckley, A. R.			HRPAP20: a novel calmodulin-binding protein that increases breast cancer cell invasion	ONCOGENE			English	Article						HRPAP20; calmodulin; MMP-9; tumor invasion; metastasis; breast cancer	MMP-9 IMMUNOREACTIVE PROTEIN; LIGHT-CHAIN KINASE; IN-VITRO; TARGET RECOGNITION; PROGNOSTIC VALUE; TUMOR-CELLS; MATRIX; EXPRESSION; GROWTH; IDENTIFICATION	We previously reported the identification of HRPAP20 (hormone-regulated proliferation-associated protein 20), a novel hormone-regulated, proliferation-associated protein. In tumor cell lines, constitutive HRPAP20 expression enhanced proliferation and suppressed apoptosis, characteristics frequently associated with malignant progression. Here, we report that highly invasive breast cancer cell lines and human breast tumor specimens express elevated HRPAP20, which in transfection experiments in MCF-7 and MDA-MB-231 cells, increased invasion. Results from mechanistic studies revealed that HRPAP20 bound to calmodulin (CaM) via a conserved CaM-binding motif. Transfection of MCF-7 breast cancer cells with HRPAP20 harboring a mutated CaM-binding motif (HRPAP20K73A) inhibited its interaction with CaM and failed to increase invasion. Other experiments revealed that transfection with HRPAP20, but not HRPAP20K73A, increased secretion of matrix metallo-proteinase-9 (MMP-9). Moreover, knockdown of HRPAP20 with small interfering RNA in MCF-7/HRPAP20 transfectants and wild-type MDA-MB-231 cells reduced invasion and inhibited secretion of MMP-9. Together these observations suggest that HRPAP20 may be an important regulator of breast tumor cell invasion by a CaM-mediated mechanism that leads to increased MMP-9 secretion. We conclude that dysregulation of HRPAP20 expression in tumor cells may contribute to the observed phenotypic changes associated with breast cancer progression.	Univ Cincinnati, Acad Hlth Ctr, Coll Pharm, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Buckley, AR (corresponding author), Univ Cincinnati, Acad Hlth Ctr, Coll Pharm, 3223 Eden Ave, Cincinnati, OH 45267 USA.	arthur.buckley@uc.edu						Agell N, 2002, CELL SIGNAL, V14, P649, DOI 10.1016/S0898-6568(02)00007-4; ALBINI A, 1987, CANCER RES, V47, P3239; ARAFAH BM, 1986, CANCER RES, V46, P3268; BAGCHI IC, 1992, J BIOL CHEM, V267, P3024; Bartsch JE, 2003, J SURG RES, V110, P383, DOI 10.1016/S0022-4804(03)00007-6; Boehning D, 2004, J BIOL CHEM, V279, P30927, DOI 10.1074/jbc.C400222200; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; Di Carlo A, 2005, INT J ONCOL, V26, P1363; Dumitrescu RG, 2005, J CELL MOL MED, V9, P208, DOI 10.1111/j.1582-4934.2005.tb00350.x; Ellis MJ, 2003, ADV EXP MED BIOL, V532, P223; Enslen H, 1996, P NATL ACAD SCI USA, V93, P10803, DOI 10.1073/pnas.93.20.10803; Fernandez CA, 2005, CLIN CANCER RES, V11, P5390, DOI 10.1158/1078-0432.CCR-04-2391; FITZSIMONS DP, 1992, J BIOL CHEM, V267, P23903; Garbett EA, 2000, J CLIN PATHOL-MOL PA, V53, P99, DOI 10.1136/mp.53.2.99; Glinsky GV, 1997, CANCER LETT, V115, P185, DOI 10.1016/S0304-3835(97)04738-1; Haupt LM, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-18; Hoeflich KP, 2002, CELL, V108, P739, DOI 10.1016/S0092-8674(02)00682-7; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; Karp CM, 2004, CANCER RES, V64, P1016, DOI 10.1158/0008-5472.CAN-03-0023; La Rocca G, 2004, BRIT J CANCER, V90, P1414, DOI 10.1038/sj.bjc.6601725; LEONESSA F, 1992, ACTA ONCOL, V31, P115, DOI 10.3109/02841869209088890; Li HC, 2004, BREAST CANCER RES TR, V88, P75, DOI 10.1007/s10549-004-1200-8; Mariani G, 2005, ANN ONCOL, V16, P191, DOI 10.1093/annonc/mdi719; Mendes O, 2005, CLIN EXP METASTAS, V22, P237, DOI 10.1007/s10585-005-8115-6; MIYAZAKI K, 1994, NATURE, V368, P695, DOI 10.1038/368695b0; MURPHY G, 1989, INT J CANCER, V44, P757, DOI 10.1002/ijc.2910440434; NAKAJIMA M, 1987, CANCER RES, V47, P4869; Paquette B, 2005, INT J CANCER, V113, P706, DOI 10.1002/ijc.20647; Pellikainen JM, 2004, CLIN CANCER RES, V10, P7621, DOI 10.1158/1078-0432.CCR-04-1061; PRZYBLOWSKA K, BREAST CANC RES TREA, V95, P65; Rahko E, 2004, ANTICANCER RES, V24, P4247; Ranuncolo SM, 2003, INT J CANCER, V106, P745, DOI 10.1002/ijc.11288; REICH R, 1988, CANCER RES, V48, P3307; REPESH LA, 1989, INVAS METAST, V9, P192; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; SANJOSE E, 1992, J BIOL CHEM, V267, P15237; Schmitt M, 1990, Blood Coagul Fibrinolysis, V1, P695; Sliva D, 2004, CURR CANCER DRUG TAR, V4, P327, DOI 10.2174/1568009043332961; Strobl JS, 1995, GEN PHARMACOL, V26, P1643, DOI 10.1016/0306-3623(95)00062-3; Stuelten CH, 2005, J CELL SCI, V118, P2143, DOI 10.1242/jcs.02334; Subramaniam Deepa S, 2005, Curr Treat Options Oncol, V6, P147, DOI 10.1007/s11864-005-0022-1; Suzuki M, 1997, J BIOL CHEM, V272, P31730, DOI 10.1074/jbc.272.50.31730; Talvensaari-Mattila A, 2005, CANCER LETT, V217, P237, DOI 10.1016/j.canlet.2004.06.056; Weigelt B, 2004, BRIT J CANCER, V90, P1531, DOI 10.1038/sj.bjc.6601659; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2	45	17	19	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2007	26	12					1780	1788		10.1038/sj.onc.1209980	http://dx.doi.org/10.1038/sj.onc.1209980			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146SS	17001319				2022-12-17	WOS:000244955600012
J	Inamoto, S; Iwata, S; Inamoto, T; Nomura, S; Sasaki, T; Urasaki, Y; Hosono, O; Kawasaki, H; Tanaka, H; Dang, NH; Morimoto, C				Inamoto, S.; Iwata, S.; Inamoto, T.; Nomura, S.; Sasaki, T.; Urasaki, Y.; Hosono, O.; Kawasaki, H.; Tanaka, H.; Dang, N. H.; Morimoto, C.			Crk-associated substrate lymphocyte type regulates transforming growth factor-beta signaling by inhibiting Smad6 and Smad7	ONCOGENE			English	Article						Cas-L; Smad6; Smad7; TGF-beta; cancer	FOCAL ADHESION KINASE; MEDIATED TYROSINE PHOSPHORYLATION; CAS-L; DOCKING PROTEIN; INTEGRIN; HEF1; CELLS; EXPRESSION; RECEPTOR; IDENTIFICATION	Crk-associated substrate lymphocyte type (Cas-L) is a 105 kDa docking protein with diverse functional properties, including regulation of cell division, proliferation, migration and adhesion. Cas-L is also involved in beta 1 integrin- or antigen receptor-mediated signaling in B and T cells. In the present study, we demonstrate that Cas-L potentiates transforming growth factor-beta (TGF-beta) signaling pathway by interacting with Smad6 and Smad7. Immunoprecipitation experiments reveal that single domain deletion of full-length Cas-L completely abolishes its docking function with Smad6 and Smad7, suggesting that the natural structure of Cas-L is necessary for its association with Smad6 and Smad7. On the other hand, both N-terminal and C-terminal deletion mutants of Smad6 and Smad7 still retain their docking ability to Cas-L, suggesting that Smad6 and Smad7 possess several binding motifs to Cas-L. Moreover, Cas-L interaction with Mad-homology (MH)2 domain, but not with MH1 domain of Smad6 or Smad7, ameliorates TGF-beta-induced signaling pathway. Finally, depletion of Cas-L by small-interfering RNA oligo attenuates TGF-beta-induced growth inhibition of Huh-7 cells, with a concomitant reduction in phosphorylation of Smad2 and Smad3. These results strongly suggest that Cas-L is a potential regulator of TGF-beta signaling pathway.	Univ Tokyo, Inst Med Sci, Adv Clin Res Ctr, Div Clin Immunol,Minato Ku, Tokyo 1088639, Japan; Osaka Med Coll, Dept Med, Osaka, Japan; Nevada Canc Inst, Dept Hematol Malignancies, Las Vegas, NV USA	University of Tokyo; Osaka Medical College; University of California System; University of California San Diego	Morimoto, C (corresponding author), Univ Tokyo, Inst Med Sci, Adv Clin Res Ctr, Div Clin Immunol,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	morimoto@ims.u-tokyo.ac.jp	Iwata, Satoshi/A-8819-2011					Astier A, 1997, LEUKEMIA LYMPHOMA, V28, P65, DOI 10.3109/10428199709058332; BARTEL P, 1993, BIOTECHNIQUES, V14, P920; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; Chacko BM, 2004, MOL CELL, V15, P813, DOI 10.1016/j.molcel.2004.07.016; Datta PK, 2000, MOL CELL BIOL, V20, P3157, DOI 10.1128/MCB.20.9.3157-3167.2000; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Fashena SJ, 2002, J CELL SCI, V115, P99; Gronroos E, 2002, MOL CELL, V10, P483, DOI 10.1016/S1097-2765(02)00639-1; Hanyu A, 2001, J CELL BIOL, V155, P1017, DOI 10.1083/jcb.200106023; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Ito Y, 2001, J BIOL CHEM, V276, P44163, DOI 10.1074/jbc.M011424200; Iwata S, 2005, ONCOGENE, V24, P1262, DOI 10.1038/sj.onc.1208261; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; Kamiguchi K, 1999, J IMMUNOL, V163, P563; Kato Y, 2002, NATURE, V418, P641, DOI 10.1038/nature00969; Krishnan P, 2001, DEV GROWTH DIFFER, V43, P115; Law SF, 1996, MOL CELL BIOL, V16, P3327; Law SF, 2000, MOL CELL BIOL, V20, P5184, DOI 10.1128/MCB.20.14.5184-5195.2000; Lee HY, 2002, CANCER RES, V62, P3530; LI L, 1994, P NATL ACAD SCI USA, V91, P5012, DOI 10.1073/pnas.91.11.5012; Liu XH, 2000, EMBO J, V19, P6759, DOI 10.1093/emboj/19.24.6759; Minegishi M, 1996, J EXP MED, V184, P1365, DOI 10.1084/jem.184.4.1365; Miyake-Nishijima R, 2003, ARTHRITIS RHEUM, V48, P1890, DOI 10.1002/art.11047; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Ohashi Y, 1999, J IMMUNOL, V163, P3727; Ohashi Y, 1998, J BIOL CHEM, V273, P6446, DOI 10.1074/jbc.273.11.6446; Ohnuma K, 2004, P NATL ACAD SCI USA, V101, P14186, DOI 10.1073/pnas.0405266101; Pugacheva EN, 2005, NAT CELL BIOL, V7, P937, DOI 10.1038/ncb1309; Sasaki T, 2005, STROKE, V36, P2457, DOI 10.1161/01.STR.0000185672.10390.30; Seo S, 2005, J IMMUNOL, V175, P3492, DOI 10.4049/jimmunol.175.6.3492; Sugano Y, 2003, ONCOGENE, V22, P2309, DOI 10.1038/sj.onc.1206305; Tachibana K, 1997, J BIOL CHEM, V272, P29083, DOI 10.1074/jbc.272.46.29083; Tanaka J, 1999, BIOCHEM BIOPH RES CO, V264, P938, DOI 10.1006/bbrc.1999.1617; van Seventer GA, 2001, EUR J IMMUNOL, V31, P1417, DOI 10.1002/1521-4141(200105)31:5<1417::AID-IMMU1417>3.0.CO;2-C; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Xu L, 2000, NAT CELL BIOL, V2, P559, DOI 10.1038/35019649; Xu WD, 2000, P NATL ACAD SCI USA, V97, P5924, DOI 10.1073/pnas.090097797; Yagil C, 2005, CIRC RES, V96, P617, DOI 10.1161/01.RES.0000160556.52369.61; Zhang ZY, 2000, J BIOL CHEM, V275, P37219, DOI 10.1074/jbc.M001818200	42	17	21	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 8	2007	26	6					893	904		10.1038/sj.onc.1209848	http://dx.doi.org/10.1038/sj.onc.1209848			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134DT	16909115				2022-12-17	WOS:000244063800010
J	Duensing, A; Liu, Y; Spardy, N; Bartoli, K; Tseng, M; Kwon, JA; Teng, X; Duensing, S				Duensing, A.; Liu, Y.; Spardy, N.; Bartoli, K.; Tseng, M.; Kwon, J-A; Teng, X.; Duensing, S.			RNA polymerase II transcription is required for human papillomavirus type 16 E7-and hydroxyurea-induced centriole overduplication	ONCOGENE			English	Article						HPV-16 E7; hydroxyurea; centrioles; RNA polymerase II; cyclin A	CENTROSOME DUPLICATION; GENOMIC INSTABILITY; CELLS; CYCLE; AMPLIFICATION; TRANSFORMATION; DISSOCIATION; REPRODUCTION; REPLICATION; PROTEINS	Aberrant centrosome numbers are detected in virtually all human cancers where they can contribute to chromosomal instability by promoting mitotic spindle abnormalities. Despite their widespread occurrence, the molecular mechanisms that underlie centrosome amplification are only beginning to emerge. Here, we present evidence for a novel regulatory circuit involved in centrosome overduplication that centers on RNA polymerase II (pol II). We found that human papillomavirus type 16 E7(HPV-16 E7)- and hydroxyurea (HU)-induced centriole overduplication are abrogated by alpha-amanitin, a potent and specific RNA pol II inhibitor. In contrast, normal centriole duplication proceeded undisturbed in alpha-amanitin-treated cells. Centriole overduplication was significantly reduced by siRNA-mediated knock down of CREB-binding protein (CBP), a transcriptional co-activator. We identifi ed cyclin A2 as a key transcriptional target of RNA pol II during HU-induced centriole overduplication. Collectively, our results show that ongoing RNA pol II transcription is required for centriole overduplication whereas it may be dispensable for normal centriole duplication. Given that many chemotherapeutic agents function through inhibition of transcription, our results may help to develop strategies to target centrosome-mediated chromosomal instability for cancer therapy and prevention.	Univ Pittsburgh, Inst Canc, Hillman Canc Ctr, Mol Virol Program, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Biochem & Mol Genet Grad Program, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Duensing, S (corresponding author), Univ Pittsburgh, Inst Canc, Hillman Canc Ctr, Mol Virol Program, Res Pavil Suite 1-8,5117 Ctr Ave, Pittsburgh, PA 15213 USA.	duensing@pitt.edu		Duensing, Anette/0000-0002-0168-4067	NATIONAL CANCER INSTITUTE [R01CA112598] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA112598-03, R01 CA112598] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bai VU, 2005, J CELL PHYSIOL, V204, P381, DOI 10.1002/jcp.20422; BALCZON R, 1995, J CELL BIOL, V130, P105, DOI 10.1083/jcb.130.1.105; Bornens M, 2002, CURR OPIN CELL BIOL, V14, P25, DOI 10.1016/S0955-0674(01)00290-3; BRAUDE PR, 1979, DEV BIOL, V68, P440, DOI 10.1016/0012-1606(79)90216-1; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Bushnell DA, 2002, P NATL ACAD SCI USA, V99, P1218, DOI 10.1073/pnas.251664698; Caldeira S, 2000, ONCOGENE, V19, P821, DOI 10.1038/sj.onc.1203375; D'Assoro AB, 2004, ONCOGENE, V23, P4068, DOI 10.1038/sj.onc.1207568; Derheimer FA, 2005, EUR J CANCER, V41, P2569, DOI 10.1016/j.ejca.2005.08.012; Dodson H, 2004, EMBO J, V23, P3864, DOI 10.1038/sj.emboj.7600393; Doxsey S, 2002, MOL CELL, V10, P439, DOI 10.1016/S1097-2765(02)00654-8; Duensing A, 2006, ONCOGENE, V25, P2943, DOI 10.1038/sj.onc.1209310; Duensing S, 2000, P NATL ACAD SCI USA, V97, P10002, DOI 10.1073/pnas.170093297; Duensing S, 2005, CELL BIOL INT, V29, P352, DOI 10.1016/j.cellbi.2005.03.005; Duensing S, 2004, ONCOGENE, V23, P8206, DOI 10.1038/sj.onc.1208012; Duensing S, 2001, BBA-REV CANCER, V1471, pM81, DOI 10.1016/S0304-419X(00)00025-1; Duensing S, 2001, CANCER RES, V61, P2356; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Faivre J, 2002, ONCOGENE, V21, P1493, DOI 10.1038/sj.onc.1205215; Fukasawa K, 2005, CANCER LETT, V230, P6, DOI 10.1016/j.canlet.2004.12.028; GIRDHAM CH, 1991, GENE DEV, V5, P1786, DOI 10.1101/gad.5.10.1786; Gong XQ, 2004, J BIOL CHEM, V279, P27422, DOI 10.1074/jbc.M402163200; Guarguaglini G, 2005, MOL BIOL CELL, V16, P1095, DOI 10.1091/mbc.E04-10-0939; Hahn S, 2004, NAT STRUCT MOL BIOL, V11, P394, DOI 10.1038/nsmb763; Hinchcliffe EH, 2001, GENE DEV, V15, P1167, DOI 10.1101/gad.894001; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Hoffelder DR, 2004, CHROMOSOMA, V112, P389, DOI 10.1007/s00412-004-0284-6; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; Jiang Y, 2004, MOL CELL, V14, P375, DOI 10.1016/S1097-2765(04)00234-5; KURIYAMA R, 1981, J CELL BIOL, V91, P814, DOI 10.1083/jcb.91.3.814; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Mantel C, 1999, BLOOD, V93, P1390, DOI 10.1182/blood.V93.4.1390.404k25_1390_1398; Martin LG, 1998, J VIROL, V72, P975, DOI 10.1128/JVI.72.2.975-985.1998; Matsumoto Y, 1999, CURR BIOL, V9, P429, DOI 10.1016/S0960-9822(99)80191-2; McDermott KM, 2006, PLOS BIOL, V4, P350, DOI 10.1371/journal.pbio.0040051; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Mihaylov IS, 2002, MOL CELL BIOL, V22, P1868, DOI 10.1128/MCB.22.6.1868-1880.2002; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; Munger K, 2002, VIRUS RES, V89, P213, DOI 10.1016/S0168-1702(02)00190-9; Mussman JG, 2000, ONCOGENE, V19, P1635, DOI 10.1038/sj.onc.1203460; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Parvin JD, 1998, CURR OPIN GENET DEV, V8, P565, DOI 10.1016/S0959-437X(98)80012-9; PHILLIPS SG, 1976, J CELL BIOL, V70, P9, DOI 10.1083/jcb.70.1.9; Salisbury JL, 1999, BIOL CELL, V91, P451, DOI 10.1016/S0248-4900(99)80086-0; SLUDER G, 1986, J CELL BIOL, V103, P1873, DOI 10.1083/jcb.103.5.1873; TOMMASINO M, 1993, ONCOGENE, V8, P195; Urbani L, 1999, CURR BIOL, V9, pR315, DOI 10.1016/S0960-9822(99)80201-2; UZAWA M, 1995, DEV BIOL, V171, P51, DOI 10.1006/dbio.1995.1259; Wong C, 2003, NAT CELL BIOL, V5, P539, DOI 10.1038/ncb993; Yam CH, 2002, CELL MOL LIFE SCI, V59, P1317, DOI 10.1007/s00018-002-8510-y	50	17	20	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2007	26	2					215	223		10.1038/sj.onc.1209782	http://dx.doi.org/10.1038/sj.onc.1209782			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124VM	16819507	Green Accepted			2022-12-17	WOS:000243398300005
J	Nguyen-Khac, F; Della Valle, V; Lopez, RG; Ravet, E; Mauchauffe, M; Friedman, AD; Huang, LE; Fichelson, S; Ghysdael, J; Bernard, OA				Nguyen-Khac, F.; Della Valle, V.; Lopez, R. G.; Ravet, E.; Mauchauffe, M.; Friedman, A. D.; Huang, L. E.; Fichelson, S.; Ghysdael, J.; Bernard, O. A.			Functional analyses of the TEL-ARNT fusion protein underscores a role for oxygen tension in hematopoietic cellular differentiation	ONCOGENE			English	Article						TEL/ETV6; ARNT; transcription factor; leukemia; differentiation block	HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; ACUTE MYELOID-LEUKEMIA; ENDOTHELIAL-CELLS; TUMOR-SUPPRESSOR; FACTOR 1-ALPHA; TRANSCRIPTION; GROWTH; TRANSLOCATION; METABOLISM; ACTIVATION	The transcription factor hypoxia inducible factor 1 (HIF1), an HIF1 alpha-aryl hydrocarbon receptor nuclear translocator ( ARNT) dimeric factor, is essential to the cellular response to hypoxia. We described a t(1;12)(q21;p13) chromosomal translocation in human acute myeloblastic leukemia that involves the translocated Ets leukemia (TEL/ETV6) and the ARNT genes and results in the expression of a TEL-ARNT fusion protein. Functional studies show that TEL-ARNT interacts with HIF1 alpha and the complex binds to consensus hypoxia response element. In low oxygen tension conditions, the HIF1 alpha/TEL-ARNT complex does not activate transcription but exerts a dominant-negative effect on normal HIF1 activity. Differentiation of normal human CD34+ progenitors cells along all the erythrocytic, megakaryocytic and granulocytic pathways was accelerated in low versus high oxygen tension conditions. Murine 32Dcl3 myeloid cells also show accelerated granulocytic differentiation in low oxygen tension in response to granulocyte colony-stimulating factor. Interestingly, stable expression of the TEL-ARNT in 32Dcl3 subclones resulted in impaired HIF1-mediated transcriptional response and inhibition of differentiation enhancement in hypoxic conditions. Taken together, our results underscore the role of oxygen tension in the modulation of normal hematopoietic differentiation, whose targeting can participate in human malignancies.	Grp Hosp Pitie Salpetriere, Serv Hematol Biol, F-75013 Paris, France; Univ Paris 05, INSERM, Hop Necker Enfants Malad, IRNEM, Paris, France; CNRS, Inst Curie, UMR 146, F-91405 Orsay, France; CNRS, Inst Cochin Genet Mol, Dept Hematol, INSERM,U567,UMR 8104, Paris, France; INSERM, U674, Paris, France; Johns Hopkins Oncol Ctr, Div Pediat Oncol, Baltimore, MD USA; NCI, Human Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Johns Hopkins University; Johns Hopkins Medicine; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Nguyen-Khac, F (corresponding author), Grp Hosp Pitie Salpetriere, Serv Hematol Biol, Pavillon Laveran 47-83 Bd Hop, F-75013 Paris, France.	florence.nguyen@psl.aphp.fr	Bernard, Olivier A./E-5721-2016; GHYSDAEL, Jacques/F-3377-2013	Bernard, Olivier/0000-0002-0463-9747; Nguyen-Khac, Florence/0000-0003-3107-6668; Huang, Eric/0000-0002-6444-1708				Acker T, 2005, CANCER CELL, V8, P131, DOI 10.1016/j.ccr.2005.07.003; Adelman DM, 1999, GENE DEV, V13, P2478, DOI 10.1101/gad.13.19.2478; An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Baudino TA, 2002, GENE DEV, V16, P2530, DOI 10.1101/gad.1024602; Ciofani M, 2005, NAT IMMUNOL, V6, P881, DOI 10.1038/ni1234; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; Fenrick R, 1999, MOL CELL BIOL, V19, P6566; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Fukuda R, 2002, J BIOL CHEM, V277, P38205, DOI 10.1074/jbc.M203781200; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Golub TR, 1996, MOL CELL BIOL, V16, P4107; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Gustafsson MV, 2005, DEV CELL, V9, P617, DOI 10.1016/j.devcel.2005.09.010; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hiebert SW, 1996, MOL CELL BIOL, V16, P1349; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jiang Y, 2005, LEUKEMIA, V19, P1239, DOI 10.1038/sj.leu.2403734; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; Kim CA, 2001, EMBO J, V20, P4173, DOI 10.1093/emboj/20.15.4173; Kline DD, 2002, P NATL ACAD SCI USA, V99, P821, DOI 10.1073/pnas.022634199; Kojima H, 2002, P NATL ACAD SCI USA, V99, P2170, DOI 10.1073/pnas.052706699; Kotch LE, 1999, DEV BIOL, V209, P254, DOI 10.1006/dbio.1999.9253; Kroon ME, 2001, J CELL SCI, V114, P825; Lacaud G, 2002, BLOOD, V100, P458, DOI 10.1182/blood-2001-12-0321; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; Li J, 2002, J CELL SCI, V115, P1951; Linggi B, 2002, NAT MED, V8, P743, DOI 10.1038/nm726; Liu W, 2006, BLOOD, V107, P698, DOI 10.1182/blood-2005-03-1278; Lopez R, 1999, J BIOL CHEM, V274, P30132, DOI 10.1074/jbc.274.42.30132; Maltepe E, 1997, NATURE, V386, P403, DOI 10.1038/386403a0; Maxwell PH, 2001, CURR OPIN GENET DEV, V11, P293, DOI 10.1016/S0959-437X(00)00193-3; Poirel H, 1997, ONCOGENE, V14, P349, DOI 10.1038/sj.onc.1200829; Ramirez-Bergeron DL, 2004, DEVELOPMENT, V131, P4623, DOI 10.1242/dev.01310; Rubnitz JE, 1999, LEUKEMIA, V13, P6, DOI 10.1038/sj.leu.2401258; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Safran M, 2003, J CLIN INVEST, V111, P779, DOI 10.1172/JCI200318181; Salomon-Nguyen F, 2000, P NATL ACAD SCI USA, V97, P6757, DOI 10.1073/pnas.120162297; Semenza GL, 2000, GENE DEV, V14, P1983; Speck NA, 2001, CURR OPIN HEMATOL, V8, P192, DOI 10.1097/00062752-200107000-00002; Vander Heiden MG, 2001, MOL CELL BIOL, V21, P5899, DOI 10.1128/MCB.21.17.5899-5912.2001; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085; Zelzer E, 2001, MECH DEVELOP, V106, P97, DOI 10.1016/S0925-4773(01)00428-2	45	17	18	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 10	2006	25	35					4840	4847		10.1038/sj.onc.1209503	http://dx.doi.org/10.1038/sj.onc.1209503			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	072QE	16547490				2022-12-17	WOS:000239687100002
J	Hooi, CSF; Blancher, C; Qiu, W; Revet, IM; Williams, LH; Ciavarella, ML; Anderson, RL; Thompson, EW; Connor, A; Phillips, WA; Campbell, IG				Hooi, C. S-F; Blancher, C.; Qiu, W.; Revet, I. M.; Williams, L. H.; Ciavarella, M. L.; Anderson, R. L.; Thompson, E. W.; Connor, A.; Phillips, W. A.; Campbell, I. G.			ST7-mediated suppression of tumorigenicity of prostate cancer cells is characterized by remodeling of the extracellular matrix	ONCOGENE			English	Article						ST7; tumor suppressor; prostate cancer; breast cancer; microarray analysis	SPARC-NULL MICE; FREQUENT LOSS; FUNCTIONAL EVIDENCE; CHROMOSOME 7Q31; ENHANCED GROWTH; POOR-PROGNOSIS; SQUAMOUS-CELL; ST7 GENE; HETEROZYGOSITY; EXPRESSION	Multiple lines of evidence have provided compelling evidence for the existence of a tumor suppressor gene (TSG) on chromosome 7q31.1. ST7 may be the target of this genetic instability but its designation as a TSG is controversial. In this study, we show that, functionally, ST7 behaves as a tumor suppressor in human cancer. ST7 suppressed growth of PC-3 prostate cancer cells inoculated subcutaneously into severe combined immunodeficient mice, and increased the latency of tumor detection from 13 days in control tumors to 23 days. Re-expression of ST7 was also associated with suppression of colony formation under anchorage-independent conditions in MDA-MB-231 breast cancer cells and ST7 mRNA expression was downregulated in 44% of primary breast cancers. Expression pro. ling of PC-3 cells revealed that ST7 predominantly induces changes in genes involved in re-modeling the extracellular matrix such as SPARC, IGFBP5 and several matrix metalloproteinases. These data indicate that ST7 may mediate tumor suppression through modi. cation of the tumor microenvironment.	Peter MacCallum Canc Ctr, Div Res, VBCRC Canc Genet Lab, Melbourne, Vic 8006, Australia; Peter MacCallum Canc Ctr, Surg Oncol Res Lab, Melbourne, Vic, Australia; Peter MacCallum Canc Ctr, Canc Biol Lab, Melbourne, Vic, Australia; St Vincents Inst Med Res, VBCRC Invas & Metastasis Grp, Fitzroy, Vic 3065, Australia; Univ Melbourne, Dept Pathol, Melbourne, Vic, Australia; Univ Melbourne, Dept Surg, St Vincents Hosp, Melbourne, Vic, Australia	Peter Maccallum Cancer Center; Peter Maccallum Cancer Center; Peter Maccallum Cancer Center; St. Vincent's Institute of Medical Research; University of Melbourne; St Vincent's Hospital Melbourne; University of Melbourne	Campbell, IG (corresponding author), Peter MacCallum Canc Ctr, Div Res, VBCRC Canc Genet Lab, Level 2,Locked Bag 1 A Beckett St, Melbourne, Vic 8006, Australia.	ian.campbell@petermac.org	Anderson, Robin/I-2306-2013; Thompson, Erik/GPK-2067-2022; Revet, Ingrid/C-7256-2009; Thompson, Erik W/A-1425-2009; Anderson, Robin/K-6966-2019; Phillips, Wayne A/H-8070-2013; Anderson, Robin/S-1005-2017	Thompson, Erik/0000-0002-9723-4924; Thompson, Erik W/0000-0002-9723-4924; Phillips, Wayne A/0000-0002-7961-638X; Campbell, Ian/0000-0002-7773-4155; Anderson, Robin/0000-0002-6841-7422				Achille A, 1996, CANCER RES, V56, P3808; Barker TH, 2005, J BIOL CHEM, V280, P36483, DOI 10.1074/jbc.M504663200; Barker TH, 2005, AM J PATHOL, V166, P923, DOI 10.1016/S0002-9440(10)62312-7; BIECHE I, 1992, LANCET, V339, P139, DOI 10.1016/0140-6736(92)90208-K; Brekken RA, 2003, J CLIN INVEST, V111, P487, DOI 10.1172/JCI200316804; Brown VL, 2002, BRIT J CANCER, V87, P208, DOI 10.1038/sj.bjc.6600418; Chin D, 2005, INT J CANCER, V113, P789, DOI 10.1002/ijc.20608; Chlenski A, 2004, CANCER RES, V64, P7420, DOI 10.1158/0008-5472.CAN-04-2141; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Dong SM, 2002, CLIN CANCER RES, V8, P2939; Hughes KA, 2001, NAT GENET, V29, P380, DOI 10.1038/ng783; Jones C, 2004, CANCER RES, V64, P3037, DOI 10.1158/0008-5472.CAN-03-2028; Kato Y, 2005, INT J ONCOL, V27, P759; Katoh M, 2002, INT J ONCOL, V20, P1247; Koike M, 1997, GENE CHROMOSOME CANC, V19, P1, DOI 10.1002/(SICI)1098-2264(199705)19:1<1::AID-GCC1>3.0.CO;2-3; Koukourakis MI, 2003, CANCER RES, V63, P5376; Kruzelock RP, 2000, ONCOGENE, V19, P6277, DOI 10.1038/sj.onc.1204013; Latil A, 1995, CLIN CANCER RES, V1, P1385; Le Bail B, 1999, J PATHOL, V189, P46; Lu C, 2003, WORLD J GASTROENTERO, V9, P2662; Lussier C, 2001, J CELL BIOCHEM, V81, P463, DOI 10.1002/1097-4644(20010601)81:3<463::AID-JCB1060>3.3.CO;2-C; Moschos SJ, 2002, ONCOLOGY-BASEL, V63, P317, DOI 10.1159/000066230; OGATA T, 1993, MOL CELL BIOL, V13, P6036, DOI 10.1128/MCB.13.10.6036; Pal S, 2004, MOL CELL BIOL, V24, P9630, DOI 10.1128/MCB.24.21.9630-9645.2004; Palmer RE, 2001, CURR BIOL, V11, P1805, DOI 10.1016/S0960-9822(01)00560-7; Paoni NF, 2003, PHYSIOL GENOMICS, V15, P228, DOI 10.1152/physiolgenomics.00078.2003; Puolakkainen PA, 2004, MOL CANCER RES, V2, P215; Rosenblatt S, 1997, BIOCHEM J, V324, P311, DOI 10.1042/bj3240311; Sassetti C, 1998, J EXP MED, V187, P1965, DOI 10.1084/jem.187.12.1965; Shih SC, 2002, AM J PATHOL, V161, P35, DOI 10.1016/S0002-9440(10)64154-5; Shridhar V, 1997, ONCOGENE, V15, P2727, DOI 10.1038/sj.onc.1201448; Stanhope-Baker P, 2004, J BIOL CHEM, V279, P33575, DOI 10.1074/jbc.M404787200; TAKAHASHI S, 1995, CANCER RES, V55, P4114; Thomas NA, 2001, NAT GENET, V29, P379, DOI 10.1038/ng784; Thomas R, 2000, CLIN CANCER RES, V6, P1140; Vincent JB, 2002, GENOMICS, V80, P283, DOI 10.1006/geno.2002.6835; Vincent JB, 2000, AM J HUM GENET, V67, P510, DOI 10.1086/303005; Yiu GK, 2001, AM J PATHOL, V159, P609, DOI 10.1016/S0002-9440(10)61732-4; ZENKLUSEN JC, 1994, ONCOGENE, V9, P2817; ZENKLUSEN JC, 1995, ONCOGENE, V11, P359; ZENKLUSEN JC, 1994, CANCER RES, V54, P6370; ZENKLUSEN JC, 1994, P NATL ACAD SCI USA, V91, P12155, DOI 10.1073/pnas.91.25.12155; Zenklusen JC, 2001, NAT GENET, V27, P392, DOI 10.1038/86891; ZENKLUSEN JC, 1995, CANCER RES, V55, P1347; Zenklusen JC, 2000, ONCOGENE, V19, P1729, DOI 10.1038/sj.onc.1203488; Zhang JS, 1998, ONCOGENE, V17, P789, DOI 10.1038/sj.onc.1201996	46	17	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2006	25	28					3924	3933		10.1038/sj.onc.1209418	http://dx.doi.org/10.1038/sj.onc.1209418			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	058MJ	16474848				2022-12-17	WOS:000238668800005
J	Grande, SM; Katz, E; Crowley, JE; Bernardini, MS; Ross, SR; Monroe, JG				Grande, SM; Katz, E; Crowley, JE; Bernardini, MS; Ross, SR; Monroe, JG			Cellular ITAM-containing proteins are oncoproteins in nonhematopoietic cells	ONCOGENE			English	Article						oncogene proteins; cell transformation; neoplastic; mammary glands; animal; fibroblasts; signal transduction	EPSTEIN-BARR-VIRUS; SARCOMA-ASSOCIATED HERPESVIRUS; LYMPHOCYTE ANTIGEN RECEPTOR; EPITHELIAL-CELLS; K1 GENE; LATENT MEMBRANE-PROTEIN-2A; 3-DIMENSIONAL CULTURE; CD22-DEFICIENT MICE; SIGNAL-TRANSDUCTION; NEGATIVE REGULATOR	Immunoreceptor tyrosine-based activation motifs (ITAMs) are involved in the transduction of signals necessary for activation, differentiation, and survival in hematopoietic cells. Several viruses have been shown to encode ITAM-containing transmembrane proteins. Although expression of these viral proteins has in some cases been shown to transform nonhematopoietic cells, a causal role for a functional ITAM in this process has not been elucidated. To examine the potential transforming properties of ITAM-containing proteins, a recombinant protein consisting of ITAM-containing cytoplasmic regions of the B-cell antigen receptor was expressed in immortalized murine mammary epithelial and fibroblast cells. Mammary epithelial cells expressing this construct exhibited depolarized morphology in three-dimensional cultures. This transformed phenotype was characterized by a loss of anchorage dependence and hallmarks of epithelial to mesenchymal transition. Fibroblasts expressing this ITAM construct also lost contact inhibition and anchorage dependence. The transformed phenotype seen in both cell types was abrogated upon tyrosine to phenylalanine substitutions of the ITAMs. Inhibition of Syk tyrosine kinase, which associates with the ITAM, also prevented cell transformation. Our results indicate that expression of a nonviral ITAM-containing protein is sufficient for cell transformation. Despite lacking intrinsic enzymatic activity, ITAM-containing proteins can function as potent oncoproteins by scaffolding downstream mediators.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Microbiol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Monroe, JG (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, Room 311 BRBII,421 Curie Blvd, Philadelphia, PA 19104 USA.	monroej@mail.med.upenn.edu		Ross, Susan R/0000-0002-3094-3769	NATIONAL CANCER INSTITUTE [T32CA009140, P01CA093615] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032592] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA093615, CA09140] Funding Source: Medline; NIAID NIH HHS [R01-AI43620, R01-AI32592] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bannish G, 2001, J EXP MED, V194, P1583, DOI 10.1084/jem.194.11.1583; Caldwell RG, 1998, IMMUNITY, V9, P405, DOI 10.1016/S1074-7613(00)80623-8; Callahan R, 2000, ONCOGENE, V19, P992, DOI 10.1038/sj.onc.1203276; Cannons JL, 2004, CURR OPIN IMMUNOL, V16, P296, DOI 10.1016/j.coi.2004.03.011; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Harder T, 2004, TRAFFIC, V5, P265, DOI 10.1111/j.1600-0854.2003.00163.x; HOMBACH J, 1990, NATURE, V343, P760, DOI 10.1038/343760a0; Ikeda M, 2000, VIROLOGY, V268, P178, DOI 10.1006/viro.1999.0166; Ikeda M, 2001, J VIROL, V75, P5711, DOI 10.1128/JVI.75.12.5711-5718.2001; Jacks T, 2002, CELL, V111, P923, DOI 10.1016/S0092-8674(02)01229-1; Katz E, 2005, J EXP MED, V201, P431, DOI 10.1084/jem.20041471; Keshvara LM, 1997, J BIOL CHEM, V272, P10377; Lagunoff M, 1999, P NATL ACAD SCI USA, V96, P5704, DOI 10.1073/pnas.96.10.5704; Lai JYQ, 2003, BIOORG MED CHEM LETT, V13, P3111, DOI 10.1016/S0960-894X(03)00658-9; Lee H, 1998, NAT MED, V4, P435, DOI 10.1038/nm0498-435; Lee H, 1998, MOL CELL BIOL, V18, P5219, DOI 10.1128/MCB.18.9.5219; LONGNECKER R, 1991, J VIROL, V65, P3681, DOI 10.1128/JVI.65.7.3681-3692.1991; Mainiero F, 1996, J CELL BIOL, V134, P241, DOI 10.1083/jcb.134.1.241; Mina-Osorio P, 2004, TRENDS IMMUNOL, V25, P529, DOI 10.1016/j.it.2004.08.008; MONROE JG, 2006, IN PRESS NAT REV IMM; Morrison JA, 2005, J VIROL, V79, P2375, DOI 10.1128/JVI.79.4.2375-2382.2005; Morrison JA, 2003, J VIROL, V77, P12276, DOI 10.1128/JVI.77.22.12276-12284.2003; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Niiro H, 2002, NAT REV IMMUNOL, V2, P945, DOI 10.1038/nri955; Nitschke L, 1997, CURR BIOL, V7, P133, DOI 10.1016/S0960-9822(06)00057-1; OKeefe TL, 1996, SCIENCE, V274, P798, DOI 10.1126/science.274.5288.798; Portis T, 2004, ONCOGENE, V23, P8619, DOI 10.1038/sj.onc.1207905; Prakash O, 2002, JNCI-J NATL CANCER I, V94, P926; Pui JC, 1999, IMMUNITY, V11, P299, DOI 10.1016/S1074-7613(00)80105-3; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; Roose JP, 2003, PLOS BIOL, V1, P271, DOI 10.1371/journal.pbio.0000053; Sato S, 1996, IMMUNITY, V5, P551, DOI 10.1016/S1074-7613(00)80270-8; Scholle F, 2000, J VIROL, V74, P10681, DOI 10.1128/JVI.74.22.10681-10689.2000; Scholle F, 1999, J VIROL, V73, P4767, DOI 10.1128/JVI.73.6.4767-4775.1999; Staub E, 2004, CELL SIGNAL, V16, P435, DOI 10.1016/j.cellsig.2003.08.013; Swart R, 2000, J VIROL, V74, P10838, DOI 10.1128/JVI.74.22.10838-10845.2000; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thorley-Lawson DA, 2001, NAT REV IMMUNOL, V1, P75, DOI 10.1038/35095584; Veillette A, 2002, ANNU REV IMMUNOL, V20, P669, DOI 10.1146/annurev.immunol.20.081501.130710; Vivier E, 2004, SCIENCE, V306, P1517, DOI 10.1126/science.1103478; Weaver VM, 2002, CANCER CELL, V2, P205, DOI 10.1016/S1535-6108(02)00125-3; Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284; Zahir N, 2003, J CELL BIOL, V163, P1397, DOI 10.1083/jcb.200302023	44	17	18	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 4	2006	25	19					2748	2757		10.1038/sj.onc.1209296	http://dx.doi.org/10.1038/sj.onc.1209296			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	039AW	16369490				2022-12-17	WOS:000237272900006
J	Louhelainen, JP; Hurst, CD; Pitt, E; Nishiyama, H; Pickett, HA; Knowles, MA				Louhelainen, JP; Hurst, CD; Pitt, E; Nishiyama, H; Pickett, HA; Knowles, MA			DBC1 re-expression alters the expression of multiple components of the plasminogen pathway	ONCOGENE			English	Article						DBC1; bladder cancer; tumour suppressor gene; expression microarray	TUMOR-SUPPRESSOR REGION; BLADDER-CANCER; HOMOZYGOUS DELETION; IN-VITRO; CELL; METALLOTHIONEIN; ACTIVATOR; UROKINASE; IDENTIFICATION; RECEPTOR	Deleted in bladder cancer 1 (DBC1) is a candidate gene for the bladder tumour suppressor locus at 9q33.1. The function of the gene is currently unknown but a cross-species sequence comparison suggests an important role, as it is highly evolutionarily conserved. Here, we transfected a nonexpressing human bladder cancer cell line with a set of human DBC1 cDNA constructs. The effect on global expression patterns was assessed using cDNA microarrays. The cell clone with the lowest level of DBC1 expression showed induced expression of 26 genes including plasminogen activator inhibitor 2 (SERPINB5; 4.6-fold), heparin-binding EGF-like growth factor precursor ( DTR; 4.2-fold), small proline-rich protein 2B (SPRR2B; 3.6-fold), metallothionein 1 isoforms (MT1B/ MT1A/MT-1F; from 2.9- to 3.2-fold), tissue-type plasminogen activator precursor ( PLAT; 2.8-fold) and urokinasetype plasminogen activator precursor (PLAU; 2.7fold). In clustering analysis, both PLAT and PLAU clustered with the functionally related urokinase plasminogen activator surface receptor (PLAUR; 1.9-fold). Furthermore, 14 human bladder tumours were analysed by real-time quantitative PCR using gene-specific primers for selected (n = 20) genes. The expression levels of SERPINB5, PLAU, PLAUR and MT1 correlated with the DBC1 levels, suggesting previously unknown involvement of DBC1 in the urokinase-plasminogen pathway.	St James Univ Hosp, Canc Res UK, Ctr Clin, Leeds LS9 7TF, W Yorkshire, England	Cancer Research UK; Saint James's University Hospital	Knowles, MA (corresponding author), St James Univ Hosp, Canc Res UK, Ctr Clin, Beckett St, Leeds LS9 7TF, W Yorkshire, England.	margaret.knowles@cancer.org.uk		Knowles, Margaret/0000-0002-9363-8657; Louhelainen, Jari/0000-0001-8680-8614	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BACHMANN F, 1995, THROMB HAEMOSTASIS, V74, P172; Barradas M, 2002, EXP CELL RES, V273, P127, DOI 10.1006/excr.2001.5434; Champelovier P, 2002, UROL RES, V30, P301, DOI 10.1007/s00240-002-0270-5; COHEN RL, 1989, J BIOL CHEM, V264, P8375; ELLER MS, 1995, J CELL SCI, V108, P2741; FOUCRE D, 1991, BRIT J CANCER, V64, P926, DOI 10.1038/bjc.1991.428; Fujiwara H, 2001, J HUM GENET, V46, P372, DOI 10.1007/s100380170056; Fujiyama C, 2001, BRIT J CANCER, V84, P558, DOI 10.1054/bjoc.2000.1641; Habuchi T, 1998, GENOMICS, V48, P277, DOI 10.1006/geno.1997.5165; Habuchi T, 1997, HUM MOL GENET, V6, P913, DOI 10.1093/hmg/6.6.913; Habuchi T, 2001, ONCOGENE, V20, P531, DOI 10.1038/sj.onc.1204122; Hamada T, 1996, BIOCHEM BIOPH RES CO, V219, P829, DOI 10.1006/bbrc.1996.0318; Hasui Y, 1997, J NATL CANCER I, V89, P678, DOI 10.1093/jnci/89.10.678; Hudson MA, 1997, J NATL CANCER I, V89, P709, DOI 10.1093/jnci/89.10.709; Hurst CD, 2004, ONCOGENE, V23, P2250, DOI 10.1038/sj.onc.1207260; Hurst RE, 1999, ADV EXP MED BIOL, V462, P449; Ioachim EE, 2001, ANTICANCER RES, V21, P1757; JENSEN PH, 1994, BRIT J CANCER, V70, P834, DOI 10.1038/bjc.1994.407; Kawano H, 2004, MOL BRAIN RES, V125, P60, DOI 10.1016/j.molbrainres.2004.04.001; Knowles MA, 1999, ELECTROPHORESIS, V20, P269, DOI 10.1002/(SICI)1522-2683(19990201)20:2<269::AID-ELPS269>3.3.CO;2-Z; KONDO Y, 1994, J PHARMACOL EXP THER, V270, P1313; MARVIN KW, 1992, P NATL ACAD SCI USA, V89, P11026, DOI 10.1073/pnas.89.22.11026; Mouton RE, 2000, MECH AGEING DEV, V113, P169, DOI 10.1016/S0047-6374(99)00105-0; Nishiyama H, 1999, GENE CHROMOSOME CANC, V26, P171, DOI 10.1002/(SICI)1098-2264(199910)26:2<171::AID-GCC10>3.3.CO;2-2; Nishiyama H, 2001, ONCOGENE, V20, P2956, DOI 10.1038/sj.onc.1204432; Sens MA, 2000, ENVIRON HEALTH PERSP, V108, P413; Serakinci N, 2004, ONCOGENE, V23, P5095, DOI 10.1038/sj.onc.1207651; Shelton DN, 1999, CURR BIOL, V9, P939, DOI 10.1016/S0960-9822(99)80420-5; Simpkins CO, 2000, CELL MOL BIOL, V46, P465; Stadler WM, 2001, CLIN CANCER RES, V7, P1676; Toshiyuki N, 2004, MOL BRAIN RES, V125, P47, DOI 10.1016/j.molbrainres.2004.03.017; Tsangaris GT, 1998, ANTICANCER RES, V18, P2423; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Williams SV, 2002, GENE CHROMOSOME CANC, V34, P86, DOI 10.1002/gcc.10050; Wright KO, 2004, ONCOGENE, V23, P82, DOI 10.1038/sj.onc.1206642; Wright KO, 2002, J UROLOGY, V168, P2645, DOI 10.1016/S0022-5347(05)64236-X; Yu J, 2003, CELL RES, V13, P319, DOI 10.1038/sj.cr.7290177	37	17	18	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 13	2006	25	16					2409	2419		10.1038/sj.onc.1209228	http://dx.doi.org/10.1038/sj.onc.1209228			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	032HC	16369496				2022-12-17	WOS:000236764300012
J	Sanchez-Aguilera, A; Garcia, JF; Sanchez-Beato, M; Piris, MA				Sanchez-Aguilera, A; Garcia, JF; Sanchez-Beato, M; Piris, MA			Hodgkin's lymphoma cells express alternatively spliced forms of HDM2 with multiple effects on cell cycle control	ONCOGENE			English	Article						HDM2; MDM2; splicing; cell cycle; Hodgkin's lymphoma	MDM2 GENE AMPLIFICATION; MESSENGER-RNA; P53 PROTEIN; TRANSCRIPTS; OVEREXPRESSION; ONCOGENE; BREAST; VARIANTS; GROWTH; DOMAIN	The HDM2 oncoprotein is a cellular inhibitor of p53 and is frequently deregulated in human cancer. However, the HDM2 gene encodes alternatively spliced variants whose functional significance is poorly understood. We had previously reported the detection of alternative HDM2 forms in Hodgkin's lymphoma ( HL)-derived cell lines. Here, we have cloned several of these transcripts, including the previously described HDM2-A, -B and -C ( which encode the COOH terminus of HDM2), and two novel variants ( HDM2-HL1 and -HL2) containing a complete p53 interaction domain. Real-time PCR assays demonstrated that HDM2-A and -B were selectively expressed by HL cell lines and primary tumors, compared with their non-neoplastic counterparts. In transient transfection experiments, alternatively spliced HDM2 isoforms were partially or totally localized within the cytoplasm. HDM2-HL2 was able to inhibit transactivation of a p53-inducible reporter construct and induced a partial relocalization of p53 to the cytoplasm. Expression of HDM2-A and -B caused the activation of p53/p21 and induced growth arrest in primary cells, but also increased the expression levels of cyclins D1 and E. Other possible genes regulated by HDM2-A and -B were identified using cDNA microarray technology. These results imply that HDM2 isoforms may have multiple effects on cell cycle control, and provide insight into the mechanisms through which these molecules contribute to tumorigenesis.	Ctr Nacl Invest Oncol, Mol Pathol Programme, Lymphoma Grp, E-28029 Madrid, Spain		Sanchez-Aguilera, A (corresponding author), Ctr Nacl Invest Oncol, Mol Pathol Programme, Lymphoma Grp, Melchor Fernandez Almagro,3, E-28029 Madrid, Spain.	asanchez@cnio.es	Piris, Miguel A/AAP-1445-2020; Sanchez-Beato, Margarita/G-8753-2012; Piris, Miguel A/B-7067-2008	Piris, Miguel A/0000-0001-5839-3634; Sanchez-Beato, Margarita/0000-0002-0058-7599; Piris, Miguel A/0000-0001-5839-3634				BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; Bartel F, 2002, CANCER CELL, V2, P9, DOI 10.1016/S1535-6108(02)00091-0; Bartel F, 2001, ONCOL RES, V12, P451, DOI 10.3727/096504001108747459; Bartel F, 2001, INT J CANCER, V95, P168, DOI 10.1002/1097-0215(20010520)95:3<168::AID-IJC1029>3.0.CO;2-A; Brown DR, 1998, EMBO J, V17, P2513, DOI 10.1093/emboj/17.9.2513; Dang JJ, 2002, CANCER RES, V62, P1222; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Evans SC, 2001, ONCOGENE, V20, P4041, DOI 10.1038/sj.onc.1204533; Evdokiou A, 2001, INT J ONCOL, V19, P625; Fridman JS, 2003, CANCER RES, V63, P5703; Garcia JF, 2003, BLOOD, V101, P681, DOI 10.1182/blood-2002-04-1128; Garcia JF, 2002, AM J PATHOL, V160, P569, DOI 10.1016/S0002-9440(10)64876-6; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hori M, 2000, PATHOL INT, V50, P786, DOI 10.1046/j.1440-1827.2000.01119.x; Jones SN, 1998, P NATL ACAD SCI USA, V95, P15608, DOI 10.1073/pnas.95.26.15608; Kapp U, 1999, J EXP MED, V189, P1939, DOI 10.1084/jem.189.12.1939; Kraus A, 1999, INT J CANCER, V80, P930, DOI 10.1002/(SICI)1097-0215(19990315)80:6<930::AID-IJC20>3.3.CO;2-D; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lukas J, 2001, CANCER RES, V61, P3212; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; Matsumoto R, 1998, CANCER RES, V58, P609; MAXWELL SA, 1994, ANTICANCER RES, V14, P2541; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; Nelsen CJ, 2005, J BIOL CHEM, V280, P768, DOI 10.1074/jbc.M407105200; Oelmann E, 2002, BLOOD, V99, P258, DOI 10.1182/blood.V99.1.258; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Ongkeko WM, 1999, CURR BIOL, V9, P829, DOI 10.1016/S0960-9822(99)80367-4; Pinkas J, 1999, INT J CANCER, V81, P292, DOI 10.1002/(SICI)1097-0215(19990412)81:2<292::AID-IJC20>3.3.CO;2-9; Rajagopalan H, 2004, NATURE, V428, P77, DOI 10.1038/nature02313; Sanchez-Aguilera A, 2002, BLOOD, V99, P1411, DOI 10.1182/blood.V99.4.1411; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sigalas I, 1996, NAT MED, V2, P912, DOI 10.1038/nm0896-912; Smith CWJ, 2000, TRENDS BIOCHEM SCI, V25, P381, DOI 10.1016/S0968-0004(00)01604-2; Soussi T, 2001, NAT REV CANCER, V1, P233, DOI 10.1038/35106009; Steinman HA, 2004, J BIOL CHEM, V279, P4877, DOI 10.1074/jbc.M305966200; Tamborini E, 2001, INT J CANCER, V92, P790, DOI 10.1002/ijc.1271; Tracey L, 2002, AM J PATHOL, V161, P1825, DOI 10.1016/S0002-9440(10)64459-8; Tzankov A, 2003, J PATHOL, V199, P201, DOI 10.1002/path.1279; WATANABE T, 1994, BLOOD, V84, P3158; Weiss RH, 2003, CANCER CELL, V4, P425, DOI 10.1016/S1535-6108(03)00308-8; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126	43	17	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	18					2565	2574		10.1038/sj.onc.1209282	http://dx.doi.org/10.1038/sj.onc.1209282			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	036TU	16331255				2022-12-17	WOS:000237099400001
J	Worrillow, LJ; Allan, JM				Worrillow, LJ; Allan, JM			Deregulation of homologous recombination DNA repair in alkylating agent-treated stem cell clones: a possible role in the aetiology of chemotherapy-induced leukaemia	ONCOGENE			English	Article						therapy-related AML; DNA mismatch repair; homologous recombination repair; alkylating agents; embryonic stem cells; clones	ACUTE MYELOID-LEUKEMIA; MISMATCH REPAIR; MICROSATELLITE INSTABILITY; MUTATOR PHENOTYPE; P53 MUTATIONS; HUMAN RAD51; MSH2 GENE; MECHANISMS; RESISTANCE; EXPRESSION	Chemotherapeutic regimes involving alkylating agents, such as methylators and cross linking nitrogen mustards, represent a major risk factor for acute myeloid leukaemia. A high frequency of microsatellite instability and evidence of MSH2 loss in alkylating chemotherapy-related acute myeloid leukaemia (t-AML) suggests that DNA mismatch repair (MMR) dysfunction may be an initiating event in disease evolution. Subsequent accumulation of secondary genetic changes as a result of DNA MMR loss may ultimately lead to the gross chromosomal abnormalities seen in t-AML. Homologous recombination repair (HRR) maintains chromosomal stability by the repair of DNA double-strand breaks, and is therefore a possible target for deregulation in MMR dysfunctional t-AML. In order to test this hypothesis Msh2-proficient and -defficient murine embryonic stem (ES) cells were used to examine the effects of MMR status and methylating agent treatment on cellular expression of DNA double-strand break repair genes. HRR gene expression was significantly deregulated in Msh2 null ES cell clones compared to wild-type clones. Furthermore, some Msh2 null clones expressed high levels of Rad51 specifically, a critical component of HRR. Such Rad51 superexpressing clones were also observed when expression was determined in monocytic myeloid cells differentiated from ES cells. A deregulated HRR phenotype could be partially recapitulated in MMR-competent wild-type cells by treatment with the methylating agent, N-methyl-N-nitrosourea. Furthermore, treatment with melphalan, a leukaemogenic DNA crosslinking chemotherapy nitrogen mustard predicted to elicit HRR, selected against cells with deregulated HRR. These data suggest a t-AML mechanism whereby DNA MMR loss promotes the emergence of HRR gene superexpressing clones, with concomitant chromosomal instability. However, melphalan selection against clones with deregulated HRR suggests that persistence and expansion of unstable clones may require additional genetic alterations that promote cell survival.	Univ York, Dept Biol Epidemiol & Genet, York YO10 5DD, N Yorkshire, England	University of York - UK	Allan, JM (corresponding author), Univ York, Dept Biol Epidemiol & Genet, York YO10 5DD, N Yorkshire, England.	jim.allan@egu.york.ac.uk	Allan, James/B-4448-2009	Allan, James/0000-0002-7580-5087				Baumann P, 1997, EMBO J, V16, P5198, DOI 10.1093/emboj/16.17.5198; BenYehuda D, 1996, BLOOD, V88, P4296; BERANEK DT, 1980, CARCINOGENESIS, V1, P595, DOI 10.1093/carcin/1.7.595; Bignami M, 2000, MUTAT RES-REV MUTAT, V462, P71, DOI 10.1016/S1383-5742(00)00016-8; Boulton E, 2003, BLOOD, V101, P2349, DOI 10.1182/blood-2002-08-2394; Casorelli I, 2003, DNA REPAIR, V2, P547, DOI 10.1016/S1568-7864(03)00020-X; Chaney SG, 1996, JNCI-J NATL CANCER I, V88, P1346, DOI 10.1093/jnci/88.19.1346; Clark DJ, 1996, GENE CHROMOSOME CANC, V16, P238, DOI 10.1002/(SICI)1098-2264(199608)16:4<238::AID-GCC3>3.3.CO;2-L; Clarke D, 2000, ONCOGENE, V19, P3343, DOI 10.1038/sj.onc.1203661; Davies SM, 2001, MED PEDIATR ONCOL, V36, P536, DOI 10.1002/mpo.1126; Delwail V, 2002, BRIT J HAEMATOL, V118, P189, DOI 10.1046/j.1365-2141.2002.03564.x; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; Duckett DR, 1996, P NATL ACAD SCI USA, V93, P6443, DOI 10.1073/pnas.93.13.6443; Engelward BP, 1998, J BIOL CHEM, V273, P5412, DOI 10.1074/jbc.273.9.5412; Gaymes TJ, 2002, CANCER RES, V62, P2791; Giot L, 1997, GENETICS, V146, P1239; Glassner BJ, 1998, P NATL ACAD SCI USA, V95, P9997, DOI 10.1073/pnas.95.17.9997; Hampson R, 1997, J BIOL CHEM, V272, P28596, DOI 10.1074/jbc.272.45.28596; Hatch SB, 2005, CLIN CANCER RES, V11, P2180, DOI 10.1158/1078-0432.CCR-04-0234; Hofseth LJ, 2003, J CLIN INVEST, V112, P1887, DOI 10.1172/JCI200319757; Humbert O, 1999, CARCINOGENESIS, V20, P205, DOI 10.1093/carcin/20.2.205; Karran P, 2001, CARCINOGENESIS, V22, P1931, DOI 10.1093/carcin/22.12.1931; Karran P, 2003, BIOCHIMIE, V85, P1149, DOI 10.1016/j.biochi.2003.10.007; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; Kawate H, 1998, P NATL ACAD SCI USA, V95, P5116, DOI 10.1073/pnas.95.9.5116; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; Kim PM, 2001, NUCLEIC ACIDS RES, V29, P4352, DOI 10.1093/nar/29.21.4352; Lee JH, 2005, SCIENCE, V308, P551, DOI 10.1126/science.1108297; Liss B, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf088; Loeb LA, 2001, CANCER RES, V61, P3230; Lowsky R, 2000, BLOOD, V95, P1767, DOI 10.1182/blood.V95.5.1767.005k07_1767_1772; Marmorstein LY, 1998, P NATL ACAD SCI USA, V95, P13869, DOI 10.1073/pnas.95.23.13869; Marra G, 2001, P NATL ACAD SCI USA, V98, P7164, DOI 10.1073/pnas.121136498; Mohammad H, 2002, BRIT J HAEMATOL, V117, P359, DOI 10.1046/j.1365-2141.2002.03458.x; Paull TT, 1999, GENE DEV, V13, P1276, DOI 10.1101/gad.13.10.1276; Pedersen-Bjergaard J, 2002, BLOOD, V99, P1909, DOI 10.1182/blood.V99.6.1909; Posnick LM, 1999, J BACTERIOL, V181, P6763, DOI 10.1128/JB.181.21.6763-6771.1999; Qin XS, 2000, CARCINOGENESIS, V21, P833, DOI 10.1093/carcin/21.4.833; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; Richardson C, 2004, ONCOGENE, V23, P546, DOI 10.1038/sj.onc.1207098; Thirman MJ, 1996, HEMATOL ONCOL CLIN N, V10, P293, DOI 10.1016/S0889-8588(05)70340-3; Trujillo KM, 1998, J BIOL CHEM, V273, P21447, DOI 10.1074/jbc.273.34.21447; Valerie K, 2003, ONCOGENE, V22, P5792, DOI 10.1038/sj.onc.1206679; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; Wang ZM, 2001, J NATL CANCER I, V93, P1473, DOI 10.1093/jnci/93.19.1473; Worrillow LJ, 2003, CLIN CANCER RES, V9, P3012; Zhu YM, 1999, BLOOD, V94, P733, DOI 10.1182/blood.V94.2.733.414k03_733_740	47	17	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	12					1709	1720		10.1038/sj.onc.1209208	http://dx.doi.org/10.1038/sj.onc.1209208			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	021VJ	16278672				2022-12-17	WOS:000236013700003
J	Wisdom, R; Huynh, L; Hsia, D; Kim, S				Wisdom, R; Huynh, L; Hsia, D; Kim, S			RAS and TGF-beta exert antagonistic effects on extracellular matrix gene expression and fibroblast transformation	ONCOGENE			English	Article						transformation; matrix; TGF-beta	INDEPENDENT PATHWAYS; CELLS; JUN; INVASION; CANCER; FOS; IDENTIFICATION; SUPPRESSION; REPRESSION; MUTATIONS	Ras, Raf, and Fos function as components in a signal transduction pathway that is constitutively active in many cancers. Many of the changes that underlie cell transformation arise through changes in gene expression. We have used gene expression pro. ling of 3T3 cells transformed by Ras, Raf, and Fos to de. ne the common and distinct targets of transcriptional control by each of these oncogenes. In this analysis, the most strongly conserved feature of cell transformation at the transcriptional level is the transcriptional repression of genes that encode components of the extracellular matrix (ECM). TGF-beta treatment of fibroblasts is known to increase production of ECM, suggesting that TGF-beta might selectively reverse some of the gene expression changes that occur during cell transformation. Using gene expression pro. ling of the TGF-beta response, we show that the ability of TGF-beta to reverse the changes in gene expression brought about by cellular transformation is essentially confined to genes that encode components of the ECM and the cytoskeleton. This selective reversal of transformation-induced changes in gene expression is associated with partial reversal of many parameters of cell transformation. The results demonstrate a correlation between gene repression by the Ras/Raf/ERK signaling pathway, gene activation by the TGF-beta signaling pathway, and the transformed phenotype in fibroblasts.	Univ Calif Davis, Sch Med, Ctr Canc, Sacramento, CA 95817 USA; Univ Calif Davis, Sch Med, Div Hematol & Oncol, Sacramento, CA 95817 USA	University of California System; University of California Davis; University of California System; University of California Davis	Wisdom, R (corresponding author), Univ Calif Davis, Sch Med, Ctr Canc, Res Bldg 3,Room 1100,4645 2nd Ave, Sacramento, CA 95817 USA.	ronald.wisdom@ucdmc.ucdavis.edu			NATIONAL CANCER INSTITUTE [R01CA064118] Funding Source: NIH RePORTER; NCI NIH HHS [CA64118] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe N, 2000, CANCER RES, V60, P3117; Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Bakin AV, 2004, MOL BIOL CELL, V15, P4682, DOI 10.1091/mbc.E04-04-0353; Bakin AV, 1999, SCIENCE, V283, P387, DOI 10.1126/science.283.5400.387; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hess JL, 1998, AM J CLIN PATHOL, V109, P251, DOI 10.1093/ajcp/109.3.251; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; Johnston IMP, 2000, ONCOGENE, V19, P5348, DOI 10.1038/sj.onc.1203927; Kazmierczak B, 1999, GENE CHROMOSOME CANC, V26, P125; KEETON MR, 1991, J BIOL CHEM, V266, P23048; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Lehmann K, 2000, GENE DEV, V14, P2610, DOI 10.1101/gad.181700; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; McGarry LC, 2004, ONCOGENE, V23, P5284, DOI 10.1038/sj.onc.1207687; Mechta-Grigoriou F, 2001, ONCOGENE, V20, P2378, DOI 10.1038/sj.onc.1204381; Moustakas A, 1999, J CELL SCI, V112, P1169; Ordway JM, 2004, ONCOGENE, V23, P3737, DOI 10.1038/sj.onc.1207483; PARSONS R, 1995, CANCER RES, V55, P5548; Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a; Rangarajan A, 2004, CANCER CELL, V6, P171, DOI 10.1016/j.ccr.2004.07.009; Scott LA, 2004, MOL CELL BIOL, V24, P1540, DOI 10.1128/MCB.24.4.1540-1559.2004; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Sirard C, 2000, J BIOL CHEM, V275, P2063, DOI 10.1074/jbc.275.3.2063; Sprowles A, 2003, ONCOGENE, V22, P498, DOI 10.1038/sj.onc.1206165; Takagi Y, 1998, BRIT J CANCER, V78, P1152, DOI 10.1038/bjc.1998.645; VAN AL, 1993, P NATL ACAD SCI USA, V90, P6213; Verrecchia F, 2001, J BIOL CHEM, V276, P17058, DOI 10.1074/jbc.M100754200; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Wisdom R, 1999, EXP CELL RES, V253, P180, DOI 10.1006/excr.1999.4685; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Wood LJ, 2000, CANCER RES, V60, P4256; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	39	17	17	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 27	2005	24	47					7043	7054		10.1038/sj.onc.1208870	http://dx.doi.org/10.1038/sj.onc.1208870			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	977WC	16007133				2022-12-17	WOS:000232833200006
J	Scully, R; Xie, AY				Scully, R; Xie, AY			In my end is my beginning: control of end resection and DSBR pathway 'choice' by cyclin-dependent kinases	ONCOGENE			English	Review						DSB; recombination; checkpoint; CDK	DNA-DAMAGE RESPONSE; HOMOLOGOUS RECOMBINATION; REPLICATION FORKS; FACTOR-C; CHECKPOINT; ATR; PROTEIN; ACTIVATION; CLASPIN; COMPLEX	The genome is constantly subjected to chemical alterations that have the potential to cause genetic mutation, chromosomal rearrangements and, in the case of multicellular organisms, cancer. Particular vulnerability exists during DNA replication, when the two DNA strands of a chromosome separate to form templates for the synthesis of sister chromatids. Attempted replication across a damaged or nicked DNA template can result in the formation of a double- strand break ( DSB), arguably the most dangerous of DNA lesions. DSBs can also arise directly at any cell cycle stage following exposure to ionizing radiation or radiomimetic agents. To combat these recurrent threats of genomic instability, numerous distinct enzyme systems have evolved that sense DNA damage and coordinate its repair. Part of this coordination involves the activation of signal transduction cascades that target repair proteins, trigger DNA damage- dependent cell cycle checkpoints and profoundly affect chromatin neighboring a DSB. Here, we discuss current models of how lesion processing itself helps to coordinate these signals in dividing cells. Recent evidence in yeast of a role for cyclin- dependent kinases in DNA end resection suggests a possible solution to the long- standing puzzle of how DSBR pathway ` choice' is regulated through the cell cycle.	Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	Scully, R (corresponding author), Harvard Univ, Sch Med, Dept Med, 330 Brookline Ave, Boston, MA 02115 USA.	rscully@bidmc.harvard.edu	Scully, Ralph/F-5008-2013		NATIONAL CANCER INSTITUTE [R01CA095175] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA95175, R01 CA095175-03, R01 CA095175] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham RT, 2004, DNA REPAIR, V3, P883, DOI 10.1016/j.dnarep.2004.04.002; Anderson DG, 1997, GENE DEV, V11, P571, DOI 10.1101/gad.11.5.571; Bassing CH, 2002, CELL, V109, pS45, DOI 10.1016/S0092-8674(02)00675-X; Bermudez VP, 2003, P NATL ACAD SCI USA, V100, P1633, DOI 10.1073/pnas.0437927100; Bessho T, 2000, J BIOL CHEM, V275, P7451, DOI 10.1074/jbc.275.11.7451; Chen YH, 2004, DNA REPAIR, V3, P1025, DOI 10.1016/j.dnarep.2004.03.003; Cox MM, 2000, NATURE, V404, P37, DOI 10.1038/35003501; Critchlow SE, 1998, TRENDS BIOCHEM SCI, V23, P394, DOI 10.1016/S0968-0004(98)01284-5; de Jager M, 2001, MOL CELL, V8, P1129, DOI 10.1016/S1097-2765(01)00381-1; Griffith JD, 2002, J BIOL CHEM, V277, P15233, DOI 10.1074/jbc.C200129200; Haber JE, 1999, NATURE, V398, P665, DOI 10.1038/19423; Hekmat-Nejad M, 2000, CURR BIOL, V10, P1565, DOI 10.1016/S0960-9822(00)00855-1; Ira G, 2004, NATURE, V431, P1011, DOI 10.1038/nature02964; Kowalczykowski SC, 2000, TRENDS BIOCHEM SCI, V25, P156, DOI 10.1016/S0968-0004(00)01569-3; Krogh BO, 2004, ANNU REV GENET, V38, P233, DOI 10.1146/annurev.genet.38.072902.091500; Kumagai A, 2004, J BIOL CHEM, V279, P49599, DOI 10.1074/jbc.M408353200; Lee GS, 2004, CELL, V117, P171, DOI 10.1016/S0092-8674(04)00301-0; Lee J, 2003, MOL CELL, V11, P329, DOI 10.1016/S1097-2765(03)00045-5; Lin SY, 2004, P NATL ACAD SCI USA, V101, P6484, DOI 10.1073/pnas.0401847101; Lisby M, 2004, CELL, V118, P699, DOI 10.1016/j.cell.2004.08.015; LISKAY RM, 1987, GENETICS, V115, P161; Llorente B, 2004, MOL CELL BIOL, V24, P9682, DOI 10.1128/MCB.24.21.9682-9694.2004; Lomonosov M, 2003, GENE DEV, V17, P3017, DOI 10.1101/gad.279003; Mirzoeva OK, 2003, MOL CANCER RES, V1, P207; Osborn AJ, 2002, TRENDS CELL BIOL, V12, P509, DOI 10.1016/S0962-8924(02)02380-2; Parrilla-Castellar E, 2003, J BIOL CHEM, V278, P45507, DOI 10.1074/jbc.C300418200; Parrilla-Castellar ER, 2004, DNA REPAIR, V3, P1009, DOI 10.1016/j.dnarep.2004.03.032; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; Ristic D, 2003, NUCLEIC ACIDS RES, V31, P5229, DOI 10.1093/nar/gkg729; Roos-Mattjus P, 2003, J BIOL CHEM, V278, P24428, DOI 10.1074/jbc.M301544200; RUBNITZ J, 1984, MOL CELL BIOL, V4, P2253, DOI 10.1128/MCB.4.11.2253; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Seigneur M, 1998, CELL, V95, P419, DOI 10.1016/S0092-8674(00)81772-9; Shechter D, 2004, DNA REPAIR, V3, P901, DOI 10.1016/j.dnarep.2004.03.020; Shroff R, 2004, CURR BIOL, V14, P1703, DOI 10.1016/j.cub.2004.09.047; Sogo JM, 2002, SCIENCE, V297, P599, DOI 10.1126/science.1074023; Stracker TH, 2004, DNA REPAIR, V3, P845, DOI 10.1016/j.dnarep.2004.03.014; Van Dyck E, 2001, EMBO REP, V2, P905, DOI 10.1093/embo-reports/kve201; Wyman C, 2004, DNA REPAIR, V3, P827, DOI 10.1016/j.dnarep.2004.03.037; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302; Zou L, 2003, P NATL ACAD SCI USA, V100, P13827, DOI 10.1073/pnas.2336100100; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	42	17	17	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2005	24	17					2871	2876		10.1038/sj.onc.1208609	http://dx.doi.org/10.1038/sj.onc.1208609			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	917MI	15838521	Green Accepted			2022-12-17	WOS:000228465800011
J	Bu, X; Avraham, HK; Li, XY; Lim, B; Jiang, SX; Fu, YG; Pestell, RG; Avraham, S				Bu, X; Avraham, HK; Li, XY; Lim, B; Jiang, SX; Fu, YG; Pestell, RG; Avraham, S			Mayven induces c-Jun expression and cyclin D1 activation in breast cancer cells	ONCOGENE			English	Article						BTB/POZ domain; c-Jun; AP-1; Kelch domain; Mayven; breast cancer	ACUTE PROMYELOCYTIC LEUKEMIA; PROTEIN-PROTEIN-INTERACTION; RECEPTOR-ALPHA; ACROSOMAL PROCESS; KINASE-ACTIVITY; BTB/POZ DOMAIN; DNA-BINDING; CAENORHABDITIS-ELEGANS; HISTONE DEACETYLASE; FINGER PROTEINS	Mayven is a member of the kelch-related superfamily of proteins, characterized by a series of 'kelch' repeats at their carboxyl terminus and a BTB/POZ domain at their NH2-terminus. Little is known about the role of Mayven in cancer. Here, we report that Mayven expression was abundant and diffuse in primary human epithelial breast tumor cells as compared to normal breast epithelial cells, where Mayven was detected in the normal breast layer of the mammary ducts. Overexpression of Mayven resulted in an induction of c-Jun protein levels, as well as increased AP-1 (activating protein 1) transcriptional activity in MCF-7 and T47D breast cancer cells through its BTB/POZ domain. Furthermore, Mayven activated c-Jun N-terminal kinase in breast cancer cells. Mayven, through its BTB/POZ domain, induced cyclin D1 expression and cyclin DI promoter activity and promoted cell cycle progression from the G1 to Sphase. MCF-7 cells transduced with the recombinant retroviral sense Mayven (pMIG-W-Mayven) showed significant induction of c-Jun and cyclin DI mRNA expression and activities as compared to the retroviral vector alone, while MCF-7 cells transduced by the recombinant retroviral antisense Mayven (pMIG-W-Mayven-AS) demonstrated a significant decrease in c-Jun and cyclin D1 expression and activities. Given the crucial functions of cyclin D1 and AP-1 signaling in oncogenesis, our results strongly suggest that overexpression of Mayven may promote tumor growth through c-Jun and cyclin D1.	Beth Israel Deaconess Med Ctr, Div Expt Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Georgetown Univ, Ctr Med, Lombardi Comprehens Canc Ctr, Washington, DC 20057 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Georgetown University	Avraham, S (corresponding author), Beth Israel Deaconess Med Ctr, Div Expt Med, 4 Blackfan Circle, Boston, MA 02115 USA.	savraham@bidmc.harvard.edu		Avraham, Hava/0000-0002-7545-3640	NCI NIH HHS [1R01 CA096805] Funding Source: Medline; NHLBI NIH HHS [1R01 HL080699] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA096805] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL080699] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams J, 2000, TRENDS CELL BIOL, V10, P17, DOI 10.1016/S0962-8924(99)01673-6; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; AVRAHAM S, 2002, RECENT RES DEV BIOL, V1, P231; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; Bomont P, 2000, NAT GENET, V26, P370, DOI 10.1038/81701; BORK P, 1994, J MOL BIOL, V236, P1277, DOI 10.1016/0022-2836(94)90056-6; Brown JR, 1998, MOL CELL BIOL, V18, P5609, DOI 10.1128/MCB.18.9.5609; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; Chen WY, 1998, BLOOD, V91, P603, DOI 10.1182/blood.V91.2.603.603_603_607; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; Daschner PJ, 1999, BREAST CANCER RES TR, V53, P229, DOI 10.1023/A:1006138803392; DEWEINDT C, 1995, CELL GROWTH DIFFER, V6, P1495; Dhordain P, 2000, ONCOGENE, V19, P6240, DOI 10.1038/sj.onc.1203976; DIBELLO PR, 1991, GENETICS, V129, P385; Dinkova-Kostova AT, 2002, P NATL ACAD SCI USA, V99, P11908, DOI 10.1073/pnas.172398899; Dong S, 1996, P NATL ACAD SCI USA, V93, P3624, DOI 10.1073/pnas.93.8.3624; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Eichinger L, 1996, EMBO J, V15, P5547, DOI 10.1002/j.1460-2075.1996.tb00939.x; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; Fu Maofu, 2004, Methods Mol Biol, V284, P15; Fu MF, 2004, ENDOCRINOLOGY, V145, P5439, DOI 10.1210/en.2004-0959; GERASIMOVA TI, 1995, CELL, V82, P587, DOI 10.1016/0092-8674(95)90031-4; GINIGER E, 1994, DEVELOPMENT, V120, P1385; GODT D, 1993, DEVELOPMENT, V119, P799; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HU S, 1995, GENE DEV, V9, P2936, DOI 10.1101/gad.9.23.2936; ITO N, 1994, J MOL BIOL, V238, P794, DOI 10.1006/jmbi.1994.1335; Johnston SRD, 1999, CLIN CANCER RES, V5, P251; Kaplan J, 1997, NUCLEIC ACIDS RES, V25, P1108, DOI 10.1093/nar/25.6.1108; Kim TA, 1998, J CELL BIOL, V141, P553, DOI 10.1083/jcb.141.3.553; Kobayashi A, 2000, MOL CELL BIOL, V20, P1733, DOI 10.1128/MCB.20.5.1733-1746.2000; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; Li XM, 1997, J BIOL CHEM, V272, P27324, DOI 10.1074/jbc.272.43.27324; Liang XQ, 2004, ONCOGENE, V23, P5890, DOI 10.1038/sj.onc.1207776; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Liu MM, 2002, J BIOL CHEM, V277, P24353, DOI 10.1074/jbc.M201829200; Liu YM, 2004, ONCOGENE, V23, P8238, DOI 10.1038/sj.onc.1207889; Mai A, 2004, EXP CELL RES, V300, P72, DOI 10.1016/j.yexcr.2004.06.023; Milde-Langosch K, 2000, INT J CANCER, V87, P468, DOI 10.1002/1097-0215(20000815)87:4<468::AID-IJC2>3.0.CO;2-R; Milde-Langosch K, 2004, BREAST CANCER RES TR, V86, P139, DOI 10.1023/B:BREA.0000032982.49024.71; Ohmachi M, 1999, GENES CELLS, V4, P325, DOI 10.1046/j.1365-2443.1999.00264.x; OWEN C, 1993, J CELL BIOL, V123, P337, DOI 10.1083/jcb.123.2.337; Reuter S, 1998, EMBO J, V17, P215, DOI 10.1093/emboj/17.1.215; RITKE MK, 1994, BIOCHEM PHARMACOL, V48, P525, DOI 10.1016/0006-2952(94)90282-8; ROBINSON DN, 1994, DEVELOPMENT, V120, P2015; Sanders MC, 1996, J BIOL CHEM, V271, P2651, DOI 10.1074/jbc.271.5.2651; SCHMID MF, 1994, J CELL BIOL, V124, P341, DOI 10.1083/jcb.124.3.341; Schrump DS, 1996, CANCER GENE THER, V3, P131; Seyfert VL, 1996, ONCOGENE, V12, P2331; Shah S, 2002, J BIOL CHEM, V277, P25313, DOI 10.1074/jbc.M203158200; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Smith LM, 1999, ONCOGENE, V18, P6063, DOI 10.1038/sj.onc.1202989; Soltysik-Espanola M, 1999, MOL BIOL CELL, V10, P2361, DOI 10.1091/mbc.10.7.2361; Spence HJ, 2000, ONCOGENE, V19, P1266, DOI 10.1038/sj.onc.1203433; Szabo E, 1996, CANCER RES, V56, P305; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; VARKEY JP, 1995, GENE DEV, V9, P1074, DOI 10.1101/gad.9.9.1074; VONBULOW M, 1995, EXP CELL RES, V219, P407, DOI 10.1006/excr.1995.1246; Wang Chenguang, 2004, Cancer Treat Res, V119, P217; WAY M, 1995, J CELL BIOL, V128, P51, DOI 10.1083/jcb.128.1.51; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Xu L, 2003, NATURE, V425, P316, DOI 10.1038/nature01985; XUE FY, 1993, CELL, V72, P681, DOI 10.1016/0092-8674(93)90397-9; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; ZOLLMAN S, 1994, P NATL ACAD SCI USA, V91, P10717, DOI 10.1073/pnas.91.22.10717; Zwijsen RML, 1996, MOL CELL BIOL, V16, P2554	71	17	19	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 31	2005	24	14					2398	2409		10.1038/sj.onc.1208466	http://dx.doi.org/10.1038/sj.onc.1208466			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909RC	15735724				2022-12-17	WOS:000227877400012
J	Guo, XC; Schrader, KA; Xu, YX; Schrader, JW				Guo, XC; Schrader, KA; Xu, YX; Schrader, JW			Expression of a constitutively active mutant of M-Ras in normal bone marrow is sufficient for induction of a malignant mastocytosis/mast cell leukemia, distinct from the histiocytosis/monocytic leukemia induced by expression of activated	ONCOGENE			English	Article						M-Ras; leukemia; mastocytosis; H-Ras dendritic cell	HEMATOPOIETIC GROWTH-FACTORS; COLONY-STIMULATING FACTOR; PROTEIN-KINASE PATHWAY; MESSENGER-RNA TURNOVER; ABL-INDUCED ACTIVATION; N-TERMINAL KINASE; H-RAS; PHOSPHATIDYLINOSITOL 3-KINASE; MAST-CELLS; V-ABL	Expression of constitutively activated M-Ras in normal murine bone-marrow cells was sufficient to induce the factor-independent, in vitro growth and differentiation of colonies of macrophages and neutrophils, and the generation of immortal lines of factor-independent mast cells, and, upon in vivo injection of the transduced cells, a fatal mastocytosis/mast-cell leukemia. In contrast, expression of constitutively activated H-Ras in bone-marrow cells resulted in the in vitro growth, in the absence of exogenous factors, of colonies that contained only macrophages and of lines of cells resembling dendritic cells, and, upon in vivo injection of the transduced cells, a fatal histiocytosis/monocytic leukemia. Macrophages generated by bone-marrow cells expressing activated M-Ras or activated H-Ras differed morphologically, the latter appearing more activated, a difference abrogated by an inhibitor of Erk activation. Inhibition of either Erk or PI3 kinase blocked the capacity of both activated M-Ras and activated H-Ras to support proliferation and viability. However, inhibition of p38 MAPK activity suppressed proliferation of bone-marrow cells expressing activated H-Ras, but enhanced that of bone-marrow cells expressing activated M-Ras. Thus, expression of either activated M-Ras or H-Ras in normal hematopoietic cells was sufficient for transformation but each resulted in the generation of distinct lineages of cells.	Univ British Columbia, Biomed Res Ctr, Vancouver, BC V6T 1Z3, Canada	University of British Columbia	Schrader, JW (corresponding author), Univ British Columbia, Biomed Res Ctr, 2222 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	john@brc.ubc.ca		Schrader, Kasmintan/0000-0002-7413-4314				ANDREJAUSKAS E, 1989, EMBO J, V8, P2575, DOI 10.1002/j.1460-2075.1989.tb08396.x; BASHEY A, 1992, BLOOD, V79, P981; BOS JL, 1989, CANCER RES, V49, P4682; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Chen CY, 1998, SCIENCE, V280, P1945, DOI 10.1126/science.280.5371.1945; Chen G, 2000, J BIOL CHEM, V275, P38973, DOI 10.1074/jbc.M002856200; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Danial NN, 1998, MOL CELL BIOL, V18, P6795, DOI 10.1128/MCB.18.11.6795; Darley RL, 2002, BLOOD, V100, P4185, DOI 10.1182/blood-2002-05-1358; Darley RL, 1999, EXP HEMATOL, V27, P1599, DOI 10.1016/S0301-472X(99)00100-9; Darley RL, 1997, J EXP MED, V185, P1337, DOI 10.1084/jem.185.7.1337; DUNBAR CE, 1991, ONCOGENE RES, V6, P39; DURONIO V, 1992, P NATL ACAD SCI USA, V89, P1587, DOI 10.1073/pnas.89.5.1587; Ehrhardt A, 2004, MOL CELL BIOL, V24, P6311, DOI 10.1128/MCB.24.14.6311-6323.2004; Ehrhardt A, 2002, EXP HEMATOL, V30, P1089, DOI 10.1016/S0301-472X(02)00904-9; Ehrhardt GRA, 1999, BLOOD, V94, P2433, DOI 10.1182/blood.V94.7.2433.419k31_2433_2444; Ehrhardt GRA, 2001, ONCOGENE, V20, P188, DOI 10.1038/sj.onc.1204053; Foltz IN, 1997, BLOOD, V89, P3092, DOI 10.1182/blood.V89.9.3092; Foltz IN, 1997, J BIOL CHEM, V272, P3296, DOI 10.1074/jbc.272.6.3296; Gao XL, 2001, J BIOL CHEM, V276, P42219, DOI 10.1074/jbc.M105760200; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; GOLD MR, 1994, J BIOL CHEM, V269, P5403; Grill B, 2002, BLOOD, V100, P3183, DOI 10.1182/blood-2002-01-0154; Guo XC, 2003, J BIOL CHEM, V278, P22237, DOI 10.1074/jbc.M300847200; Gupta AK, 2003, CANCER BIOL THER, V2, P73; GURISH MF, 1995, IMMUNITY, V3, P175, DOI 10.1016/1074-7613(95)90087-X; Hamad NM, 2002, ONCOGENE, V21, P7121, DOI 10.1038/sj.onc.1205860; HAWLEY RG, 1995, ONCOGENE, V11, P1113; HIBI S, 1993, BLOOD, V81, P1841; Ingram DA, 2000, J EXP MED, V191, P181, DOI 10.1084/jem.191.1.181; Ingram DA, 2001, J EXP MED, V194, P57, DOI 10.1084/jem.194.1.57; JIN DI, 1995, MOL CELL BIOL, V15, P693; Karlsson R, 2003, J LEUKOCYTE BIOL, V74, P923, DOI 10.1189/jlb.0403142; Kimmelman A, 1997, ONCOGENE, V15, P2675, DOI 10.1038/sj.onc.1201674; Kimmelman AC, 2000, ONCOGENE, V19, P2014, DOI 10.1038/sj.onc.1203530; Levings MK, 1999, BLOOD, V93, P3694, DOI 10.1182/blood.V93.11.3694.411a33_3694_3702; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Louahed J, 1999, BLOOD, V94, P1701, DOI 10.1182/blood.V94.5.1701.417k29_1701_1710; MacKenzie KL, 1999, BLOOD, V93, P2043, DOI 10.1182/blood.V93.6.2043.406k17_2043_2056; MACLEOD AR, 1995, J BIOL CHEM, V270, P11327, DOI 10.1074/jbc.270.19.11327; MAHER J, 1994, EXP HEMATOL, V22, P8; Matsuguchi T, 1998, ONCOGENE, V17, P2701, DOI 10.1038/sj.onc.1202201; Matsumoto K, 1997, ONCOGENE, V15, P2409, DOI 10.1038/sj.onc.1201416; McFall A, 2001, MOL CELL BIOL, V21, P5488, DOI 10.1128/MCB.21.16.5488-5499.2001; Ming XF, 1998, EMBO J, V17, P6039, DOI 10.1093/emboj/17.20.6039; Ming XF, 2001, MOL CELL BIOL, V21, P5778, DOI 10.1128/MCB.21.17.5778-5789.2001; NAIR APK, 1992, ONCOGENE, V7, P1963; NAIR APK, 1989, MOL CELL BIOL, V9, P1183, DOI 10.1128/MCB.9.3.1183; Ohba Y, 2000, J BIOL CHEM, V275, P20020, DOI 10.1074/jbc.M000981200; Oki S, 2002, BLOOD, V100, P966, DOI 10.1182/blood.V100.3.966; OKUDA K, 1994, J BIOL CHEM, V269, P24602; Pacold ME, 2000, CELL, V103, P931, DOI 10.1016/S0092-8674(00)00196-3; PIERCE JH, 1982, J EXP MED, V156, P873, DOI 10.1084/jem.156.3.873; PIERCE JH, 1985, MOL CELL BIOL, V5, P667, DOI 10.1128/MCB.5.4.667; Pruitt K, 2002, J BIOL CHEM, V277, P31808, DOI 10.1074/jbc.M203964200; Quilliam LA, 1999, J BIOL CHEM, V274, P23850, DOI 10.1074/jbc.274.34.23850; Rausch O, 1999, J BIOL CHEM, V274, P4096, DOI 10.1074/jbc.274.7.4096; Rausch O, 1997, MOL CELL BIOL, V17, P1170, DOI 10.1128/MCB.17.3.1170; Rebhun JF, 2000, J BIOL CHEM, V275, P34901, DOI 10.1074/jbc.M005327200; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; Sheng HM, 2001, J BIOL CHEM, V276, P14498, DOI 10.1074/jbc.M010093200; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; SKORSKI T, 1992, J EXP MED, V175, P743, DOI 10.1084/jem.175.3.743; Terada K, 1997, J BIOL CHEM, V272, P4544, DOI 10.1074/jbc.272.7.4544; TERADA K, 1995, J BIOL CHEM, V270, P27880, DOI 10.1074/jbc.270.46.27880; Tuveson DA, 2004, CANCER CELL, V5, P375, DOI 10.1016/S1535-6108(04)00085-6; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Varnum-Finney B, 2000, NAT MED, V6, P1278, DOI 10.1038/81390; VONRUDEN T, 1992, BLOOD, V79, P3145; Ward KR, 2004, ONCOGENE, V23, P1187, DOI 10.1038/sj.onc.1207226; Weijzen S, 2002, NAT MED, V8, P979, DOI 10.1038/nm754; WELHAM MJ, 1992, J IMMUNOL, V149, P1683; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Wolthuis RMF, 1999, CURR OPIN GENET DEV, V9, P112, DOI 10.1016/S0959-437X(99)80016-1; Wolthuis RMF, 1997, EMBO J, V16, P6748, DOI 10.1093/emboj/16.22.6748; Zhang KX, 2004, MOL CANCER RES, V2, P242; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	80	17	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 31	2005	24	14					2330	2342		10.1038/sj.onc.1208441	http://dx.doi.org/10.1038/sj.onc.1208441			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909RC	15735740				2022-12-17	WOS:000227877400006
J	Grabocka, E; Wedegaertner, PB				Grabocka, E; Wedegaertner, PB			Functional consequences of G alpha(13) mutations that disrupt interaction with p115RhoGEF	ONCOGENE			English	Article						signal transduction; heterotrimeric G protein; Rho GTPase; RGS protein; guanine nucleotide; exchange factor	STRESS FIBER FORMATION; PROTEIN ALPHA-SUBUNIT; SERUM RESPONSE FACTOR; PLASMA-MEMBRANE RECRUITMENT; RHO-FAMILY GTPASES; G-BETA-GAMMA; EXCHANGE FACTOR; P115 RHOGEF; LYSOPHOSPHATIDIC ACID; NEURITE RETRACTION	The G-protein alpha subunit, alpha(13), regulates cell growth and differentiation through the monomeric Rho GTPase. alpha(13) activates Rho through direct stimulation of the guanine nucleotide exchange factor p115RhoGEF, which contains a regulator of G-protein signaling homology domain ( RH) in its N-terminus. Through its RH domain, p115RhoGEF also functions as a GAP for G alpha(13). The mechanism for the G alpha(13)/p115RhoGEF interaction is not well understood. Here, we determined specific alpha(13) residues important for its interaction with p115RhoGEF. GST-pulldowns and co-immunoprecipitation assays revealed that individually mutating alpha(13) residues Lys204, Glu229, or Arg232 to opposite charge residues disrupts the interaction of activated alpha(13) with the RH domain of p115RhoGEF or full-length p115RhoGEF. We further demonstrate that mutation of Glu229, and to a lesser extent Lys204 or Arg232, disrupts the ability of activated alpha(13) to induce the recruitment of p115RhoGEF to the plasma membrane (PM) and to activate Rho-mediated serum response element-luciferase gene transcription. Interestingly, an alpha(13) mutant where a conserved Gly was mutated to a Ser (G205S) retained its ability to bind to p115RhoGEF, induce p115RhoGEF recruitment to the PM, and activate Rho-dependent signaling, even though identical Gly to Ser mutations in other a disrupt their interaction with regulator of G-protein signaling (RGS) proteins. These results demonstrate that, whereas several features of a typical alpha/RGS interaction are preserved in the alpha(13)/p115RhoGEF interaction, there are also significant differences.	Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Jefferson University	Wedegaertner, PB (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, 233 S 10th St,839 BLSB, Philadelphia, PA 19107 USA.	P_Wedegaertner@mail.jci.tju.edu		Grabocka, E/0000-0001-7196-8498; Grabocka, Elda/0000-0002-8768-0955	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062884] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM062884, GM62884] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Althoefer H, 1997, J BIOL CHEM, V272, P24380, DOI 10.1074/jbc.272.39.24380; Berestetskaya YV, 1998, J BIOL CHEM, V273, P27816, DOI 10.1074/jbc.273.43.27816; Bhattacharyya R, 2003, BIOCHEM J, V371, P709, DOI 10.1042/BJ20021897; Bhattacharyya R, 2003, FEBS LETT, V540, P211, DOI 10.1016/S0014-5793(03)00267-9; Bhattacharyya R, 2000, J BIOL CHEM, V275, P14992, DOI 10.1074/jbc.M000415200; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Chen Z, 2003, J BIOL CHEM, V278, P9912, DOI 10.1074/jbc.M212695200; Chen Z, 2001, NAT STRUCT BIOL, V8, P805, DOI 10.1038/nsb0901-805; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; DiBello PR, 1998, J BIOL CHEM, V273, P5780, DOI 10.1074/jbc.273.10.5780; Evanko DS, 2000, J BIOL CHEM, V275, P1327, DOI 10.1074/jbc.275.2.1327; Fleming IN, 1996, J BIOL CHEM, V271, P33067, DOI 10.1074/jbc.271.51.33067; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Gohla A, 1999, J BIOL CHEM, V274, P17901, DOI 10.1074/jbc.274.25.17901; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hollinger S, 2002, PHARMACOL REV, V54, P527, DOI 10.1124/pr.54.3.527; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; Katoh H, 1998, J BIOL CHEM, V273, P28700, DOI 10.1074/jbc.273.44.28700; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Kranenburg O, 1997, J CELL SCI, V110, P2417; Kranenburg O, 1999, MOL BIOL CELL, V10, P1851, DOI 10.1091/mbc.10.6.1851; Lan KL, 1998, J BIOL CHEM, V273, P12794, DOI 10.1074/jbc.273.21.12794; Mao JH, 1998, P NATL ACAD SCI USA, V95, P12973, DOI 10.1073/pnas.95.22.12973; Mao JH, 1998, EMBO J, V17, P5638, DOI 10.1093/emboj/17.19.5638; Mao JH, 1998, J BIOL CHEM, V273, P27118, DOI 10.1074/jbc.273.42.27118; Meigs TE, 2002, J BIOL CHEM, V277, P24594, DOI 10.1074/jbc.M201984200; Meigs TE, 2001, P NATL ACAD SCI USA, V98, P519, DOI 10.1073/pnas.021350998; Nakamura S, 2004, MOL PHARMACOL, V66, P1029, DOI 10.1124/mol.104.002287; NEUBIG RR, 1994, FASEB J, V8, P939, DOI 10.1096/fasebj.8.12.8088459; Offermanns S, 2000, REV PHYSIOL BIOCH P, V140, P63; PARKS S, 1991, CELL, V64, P447, DOI 10.1016/0092-8674(91)90652-F; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; Shi CS, 2000, J BIOL CHEM, V275, P24470, DOI 10.1074/jbc.M908449199; Sterne-Marr R, 2003, J BIOL CHEM, V278, P6050, DOI 10.1074/jbc.M208787200; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; Takida S, 2003, J BIOL CHEM, V278, P17284, DOI 10.1074/jbc.M213239200; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Vaiskunaite R, 2000, J BIOL CHEM, V275, P26206, DOI 10.1074/jbc.M001863200; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; VoynoYasenetskaya TA, 1996, J BIOL CHEM, V271, P21081, DOI 10.1074/jbc.271.35.21081; Wells C, 2002, METHOD ENZYMOL, V345, P371; Wells CD, 2002, J BIOL CHEM, V277, P1174, DOI 10.1074/jbc.M105274200; Wells CD, 2001, J BIOL CHEM, V276, P28897, DOI 10.1074/jbc.M102913200; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; Yamaguchi Y, 2003, J BIOL CHEM, V278, P14936, DOI 10.1074/jbc.M301409200; Yamaguchi Y, 2002, CURR BIOL, V12, P1353, DOI 10.1016/S0960-9822(02)01034-5	48	17	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 24	2005	24	13					2155	2165		10.1038/sj.onc.1208414	http://dx.doi.org/10.1038/sj.onc.1208414			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909KD	15735747	Green Accepted			2022-12-17	WOS:000227857900003
J	Wiemann, SU; Satyanarayana, A; Buer, J; Kamino, K; Manns, MP; Rudolph, KL				Wiemann, SU; Satyanarayana, A; Buer, J; Kamino, K; Manns, MP; Rudolph, KL			Contrasting effects of telomere shortening on organ homeostasis, tumor suppression, and survival during chronic liver damage	ONCOGENE			English	Article						telomere shortening; tumor suppression; regeneration; aging; chronic disease	HEPATOCYTE PROLIFERATIVE ACTIVITY; DYSFUNCTION; MICE; CARCINOMA; REGENERATION; CIRRHOSIS; CANCER	Telomere shortening limits the regenerative capacity of cells during aging and chronic disease but at the same time inhibits tumor progression, and it has yet to be determined which of these mechanisms is dominantly affecting organismal survival. Here we show that telomere shortening in telomerase knockout (mTERC(-/-)) mice in combination with chronic liver damage significantly reduced organismal survival even though telomere shortening strongly inhibited liver tumor formation. Decreased survival induced by telomere shortening correlated with an imbalance between liver cell proliferation and liver cell apoptosis. Specific changes in gene expression were associated with telomere shortening and chronic liver damage and these gene expression changes were partially reversed by adenovirus mediated telomerase gene delivery. This study gives experimental evidence that the negative impact of telomere shortening on organ homeostasis and organismal survival can surpass the beneficial effects of telomere shortening on suppression of tumor growth in the setting of chronic organ damage.	Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, D-3000 Hannover, Germany; Hannover Med Sch, Inst Med Microbiol, D-3000 Hannover, Germany; Hannover Med Sch, Inst Cell & Mol Pathol, D-3000 Hannover, Germany	Hannover Medical School; Hannover Medical School; Hannover Medical School	Rudolph, KL (corresponding author), Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, Carl Neuberg Str 1, D-3000 Hannover, Germany.	rudolph.lenhard@mh-hannover.de		Rudolph, Karl Lenhard/0000-0002-4839-2862; Buer, Jan/0000-0002-7602-1698				Albrecht JH, 1997, HEPATOLOGY, V25, P557, DOI 10.1002/hep.510250311; ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; Artandi SE, 2000, NATURE, V406, P641, DOI 10.1038/35020592; Blasco MA, 1998, CIBA F SYMP, V211, P160; BRISCIOLI V, 1995, AM J MED GENET, V58, P21, DOI 10.1002/ajmg.1320580106; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; CHISARI FV, 1989, CELL, V59, P1145, DOI 10.1016/0092-8674(89)90770-8; CHISARI FV, 1987, P NATL ACAD SCI USA, V84, P6909, DOI 10.1073/pnas.84.19.6909; Delhaye M, 1996, HEPATOLOGY, V23, P1003, DOI 10.1002/hep.510230510; Delhaye M, 1999, J HEPATOL, V30, P461, DOI 10.1016/S0168-8278(99)80106-8; Djojosubroto MW, 2003, MOL CELLS, V15, P164; Edwards JE, 1942, J NATL CANCER I, V3, P19; ESCHENBRENNER AB, 1946, J NATL CANCER I, V6, P325; Farazi PA, 2003, CANCER RES, V63, P5021; Gonzalez-Suarez E, 2000, NAT GENET, V26, P114, DOI 10.1038/79089; Greenberg RA, 1999, CELL, V97, P515, DOI 10.1016/S0092-8674(00)80761-8; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Herrera E, 1999, EMBO J, V18, P2950, DOI 10.1093/emboj/18.11.2950; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Ly DH, 2000, SCIENCE, V287, P2486, DOI 10.1126/science.287.5462.2486; Minamishima YA, 2002, CANCER RES, V62, P995; Plentz RR, 2004, HEPATOLOGY, V40, P80, DOI 10.1002/hep.20271; Plentz RR, 2003, GUT, V52, P1304, DOI 10.1136/gut.52.9.1304; Ramirez R, 2003, J BIOL CHEM, V278, P836, DOI 10.1074/jbc.M206818200; Rudolph KL, 2000, SCIENCE, V287, P1253, DOI 10.1126/science.287.5456.1253; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; Rudolph KL, 2001, NAT GENET, V28, P155, DOI 10.1038/88871; Satyanarayana A, 2004, HEPATOLOGY, V40, P276, DOI 10.1002/hep.20308; Satyanarayana A, 2003, EMBO J, V22, P4003, DOI 10.1093/emboj/cdg367; Stewart SA, 2000, SEMIN CANCER BIOL, V10, P399, DOI 10.1006/scbi.2000.0339; Wiemann SU, 2002, FASEB J, V16, P935, DOI 10.1096/fj.01-0977com; Wong KK, 2000, NAT GENET, V26, P85, DOI 10.1038/79232; Wright WE, 1996, DEV GENET, V18, P173	33	17	19	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 24	2005	24	9					1501	1509		10.1038/sj.onc.1208308	http://dx.doi.org/10.1038/sj.onc.1208308			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	900ME	15608677				2022-12-17	WOS:000227218200003
J	Zaffaroni, D; Spinola, M; Galvan, A; Falvella, FS; Pazzaglia, S; Saran, A; Mancuso, MT; Galbiati, F; Pignatiello, C; Cabrera, W; Ibanez, O; Manenti, G; Dragani, TA				Zaffaroni, D; Spinola, M; Galvan, A; Falvella, FS; Pazzaglia, S; Saran, A; Mancuso, MT; Galbiati, F; Pignatiello, C; Cabrera, W; Ibanez, O; Manenti, G; Dragani, TA			Met proto-oncogene juxtamembrane rare variations in mouse and humans: differential effects of Arg and Cys alleles on mouse lung tumorigenesis	ONCOGENE			English	Article						polygenic inheritance; susceptibility to disease; cancer modifier loci	CANCER MODIFIER LOCI; SUSCEPTIBILITY LOCUS; MICE; RECEPTOR; RESISTANCE; MUTATIONS; STRAINS; PREDISPOSITION; CARCINOGENESIS; KINASE	Analysis of seven candidate genes mapping in the 1-Mb region of the mouse pulmonary adenoma resistance 4 (Par4) locus revealed a single amino-acid change, consisting in a nonconservative Arg968Cys variation in the juxtamembrane domain of the Met proto-oncogene-encoded protein. The BALB/c strain ( resistant allele) carried the Arg allele, whereas the SWR/J mouse strain (Par4-susceptible allele) carried the Cys variation, recently proven to functionally modulate tumorigenesis. Seven genetic linkage crosses herein analysed and six crosses reported in the literature pointed to the candidacy of the Met gene for Par4. Analysis of genomic DNA of 126 lung adenocarcinoma patients for the Met juxtamembrane domain revealed the same Arg/Cys variation at the mouse homologous position in one patient; two other patients carried additional variants in the same domain, suggesting a potential role for rare MET juxtamembrane variants in human lung cancer.	Ist Nazl Tumori, Dept Expt Oncol, I-20133 Milan, Italy; ENEA, CR Casaccia, Rome, Italy; Inst Butantan, Sao Paulo, Brazil	Fondazione IRCCS Istituto Nazionale Tumori Milan; Italian National Agency New Technical Energy & Sustainable Economics Development; Instituto Butantan	Dragani, TA (corresponding author), Ist Nazl Tumori, Dept Expt Oncol, Via G Venezian 1, I-20133 Milan, Italy.	dragani@istitutotumori.mi.it	Zaffaroni, Daniela/I-8731-2017; Dragani, Tommaso A./K-4493-2016; Manenti, Giacomo/J-3339-2017; Ibañez, Olga CM/B-9627-2015; Cabrera, Wafa HK/F-7189-2016	Zaffaroni, Daniela/0000-0002-6995-2216; Dragani, Tommaso A./0000-0001-5915-4598; Manenti, Giacomo/0000-0002-4887-4482; Ibañez, Olga CM/0000-0002-2672-4758; Saran, Anna/0000-0002-5587-064X				Biozzi G, 1998, CARCINOGENESIS, V19, P337, DOI 10.1093/carcin/19.2.337; De Gregorio L, 1998, INT J CANCER, V79, P269, DOI 10.1002/(SICI)1097-0215(19980619)79:3<269::AID-IJC10>3.3.CO;2-J; DEVEREUX TR, 1994, MAMM GENOME, V5, P749, DOI 10.1007/BF00292007; Dragani TA, 2003, CANCER RES, V63, P3011; Festing MFW, 1998, GENOMICS, V53, P129, DOI 10.1006/geno.1998.5450; GANDINO L, 1994, J BIOL CHEM, V269, P1815; Gariboldi M, 2003, CARCINOGENESIS, V24, P1819, DOI 10.1093/carcin/bgg133; GARIBOLDI M, 1993, NAT GENET, V3, P132, DOI 10.1038/ng0293-132; Lee JH, 2000, ONCOGENE, V19, P4947, DOI 10.1038/sj.onc.1203874; LINCOLN S, 1992, MAPPING GENES CONTRO; Longati P, 2001, CURR DRUG TARGETS, V2, P41, DOI 10.2174/1389450013348920; Ma PC, 2003, CANCER RES, V63, P6272; Manenti G, 1997, MAMM GENOME, V8, P801, DOI 10.1007/s003359900582; MANENTI G, 1995, GENOMICS, V29, P438, DOI 10.1006/geno.1995.9984; Manenti G, 2002, INT J CANCER, V99, P555, DOI 10.1002/ijc.10386; Manenti G, 1997, CANCER RES, V57, P4164; Manenti G, 2000, TOXICOL LETT, V112, P257, DOI 10.1016/S0378-4274(99)00232-5; Maria DA, 2003, ONCOGENE, V22, P426, DOI 10.1038/sj.onc.1206157; Obata M, 1996, ONCOGENE, V13, P1599; Peschard P, 2001, MOL CELL, V8, P995, DOI 10.1016/S1097-2765(01)00378-1; Saran A, 2000, INT J CANCER, V88, P424, DOI 10.1002/1097-0215(20001101)88:3<424::AID-IJC15>3.0.CO;2-D; Saran A, 2002, INT J CANCER, V97, P580, DOI 10.1002/ijc.10104; Shultz KL, 2003, J BONE MINER RES, V18, P175, DOI 10.1359/jbmr.2003.18.2.175; WEIDNER KM, 1995, P NATL ACAD SCI USA, V92, P2597, DOI 10.1073/pnas.92.7.2597; Zhang ZQ, 2000, EXP LUNG RES, V26, P627, DOI 10.1080/01902140150216710	25	17	18	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 3	2005	24	6					1084	1090		10.1038/sj.onc.1208324	http://dx.doi.org/10.1038/sj.onc.1208324			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	893VS	15592501				2022-12-17	WOS:000226749200014
J	Bocchetta, M; Carbone, M				Bocchetta, M; Carbone, M			Epidemiology and molecular pathology at crossroads to establish causation: molecular mechanisms of malignant transformation	ONCOGENE			English	Article						tumor suppressor genes; senoscence; cell cycle checkpoints; cell immortalization; inflammation	TUMOR-SUPPRESSOR GENE; NECROSIS-FACTOR-ALPHA; TELOMERE DYSFUNCTION; DROSOPHILA NOTCH; MYELOID-LEUKEMIA; MICE DEFICIENT; HUMAN HOMOLOG; HUMAN CANCER; CELL-GROWTH; IN-VIVO	Epidemiology is a very reliable science for the identification of carcinogens. Epidemiological studies require that the effect, cancer in this case, has already occurred, when of course it would be more desirable to identify potential carcinogenic substances at an earlier stage before they have caused a large number of malignancies and thus become identifiable by epidemiological studies. In the past 30 years, molecular pathology (which includes chemistry, biochemistry, molecular biology, molecular virology, molecular genetics, epigenetics, genomics, proteomics, and other molecular-based approaches) has identified some key alterations that are required for cellular transformation and malignancy. Agents that specifically interfere with some of these mechanisms are suspected human carcinogens. It can be stated that tumor formation requires the following steps: (1) inactivation of Rb and p53 cellular pathways; (2) activation of Ras and/or other growth promoting pathways; (3) inactivation of phosphatase 2A that causes changes in the phosphorylation and activity of several cellular proteins; (4) evasion of apoptosis; (5) telomerase activation or alternative mechanisms of cellular immortalization; (6) angiogenic activity; and (7) the ability to invade surrounding tissues and to metastasize. Here, we review the molecular mechanisms of cellular transformation. The integration of this knowledge with classical epidemiology and animal studies should permit a more rapid and accurate identification of human carcinogens.	Loyola Univ, Cardinal Bernardin Canc Ctr, Maywood, IL 60153 USA	Loyola University Chicago	Bocchetta, M (corresponding author), Loyola Univ, Cardinal Bernardin Canc Ctr, 2160 South 1st Ave, Maywood, IL 60153 USA.	mbocche@lumc.edu			NCI NIH HHS [R01CA92657] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA092657] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Al-Zoubi AM, 2001, J BIOL CHEM, V276, P47202, DOI 10.1074/jbc.M104835200; Ali SH, 2001, SEMIN CANCER BIOL, V11, P15, DOI 10.1006/scbi.2000.0342; ASTER J, 1994, COLD SPRING HARB SYM, V59, P125, DOI 10.1101/SQB.1994.059.01.016; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Basu S, 2001, IMMUNITY, V14, P303, DOI 10.1016/S1074-7613(01)00111-X; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BRYAN TM, 1994, CRIT REV ONCOGENESIS, V5, P331, DOI 10.1615/CritRevOncog.v5.i4.10; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Butel JS, 2000, CARCINOGENESIS, V21, P405, DOI 10.1093/carcin/21.3.405; CARBONE M, IN PRESS CANC RES; Chene P, 2003, NAT REV CANCER, V3, P102, DOI 10.1038/nrc991; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; CLARK WH, 1989, JNCI-J NATL CANCER I, V81, P1893, DOI 10.1093/jnci/81.24.1893; COLLINS S, 1982, NATURE, V298, P679, DOI 10.1038/298679a0; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Dammann R, 2001, CANCER RES, V61, P3105; DEFEO D, 1981, P NATL ACAD SCI-BIOL, V78, P3328, DOI 10.1073/pnas.78.6.3328; Diefenbach A, 2003, CURR OPIN IMMUNOL, V15, P37, DOI 10.1016/S0952-7915(02)00007-9; Efimova E, 2003, CANCER RES, V63, P8768; Efimova EV, 2004, ONCOGENE, V23, P1076, DOI 10.1038/sj.onc.1207210; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Foddis R, 2002, ONCOGENE, V21, P1434, DOI 10.1038/sj.onc.1205203; Goytisolo FA, 2002, ONCOGENE, V21, P584, DOI 10.1038/sj.onc.1205085; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; HARIHARAN IK, 1987, EMBO J, V6, P115, DOI 10.1002/j.1460-2075.1987.tb04727.x; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Hermeking H, 2003, NAT REV CANCER, V3, P931, DOI 10.1038/nrc1230; HILBERT DM, 1995, J EXP MED, V182, P243, DOI 10.1084/jem.182.1.243; Horner SM, 2004, J VIROL, V78, P4063, DOI 10.1128/JVI.78.8.4063-4073.2004; Hudson JD, 1999, J EXP MED, V190, P1375, DOI 10.1084/jem.190.10.1375; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Karre K, 2002, SCAND J IMMUNOL, V55, P221, DOI 10.1046/j.1365-3083.2002.01053.x; Kwabi-Addo B, 2001, P NATL ACAD SCI USA, V98, P11563, DOI 10.1073/pnas.201167798; LAX I, 1985, EMBO J, V4, P3179, DOI 10.1002/j.1460-2075.1985.tb04062.x; LEE JH, 1991, ONCOGENE, V6, P665; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Lin EY, 2001, J EXP MED, V193, P727, DOI 10.1084/jem.193.6.727; Macip S, 2003, MOL CELL BIOL, V23, P8576, DOI 10.1128/MCB.23.23.8576-8585.2003; Maeda H, 1998, BIOCHEMISTRY-MOSCOW+, V63, P854; Magee JA, 2003, CANCER CELL, V3, P273, DOI 10.1016/S1535-6108(03)00047-3; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; McLaughlin ME, 2002, CANCER CELL, V1, P408, DOI 10.1016/S1535-6108(02)00078-8; Moore RJ, 1999, NAT MED, V5, P828, DOI 10.1038/10552; MOYZIS RK, 1988, P NATL ACAD SCI USA, V85, P6622, DOI 10.1073/pnas.85.18.6622; Myohanen SK, 1998, CANCER RES, V58, P591; Naito Y, 1998, CANCER RES, V58, P3491; Nauts H, 1953, ACTA MED SCAND, V144, pS1; Neumann AA, 2002, NAT REV CANCER, V2, P879, DOI 10.1038/nrc929; Parkin D, 1999, INFECT HUMAN CANC; Rangarajan A, 2003, NAT REV CANCER, V3, P952, DOI 10.1038/nrc1235; Reddel RR, 2000, CARCINOGENESIS, V21, P477, DOI 10.1093/carcin/21.3.477; Rodriguez LAG, 2001, EPIDEMIOLOGY, V12, P88, DOI 10.1097/00001648-200101000-00015; Ruggero D, 2003, SCIENCE, V299, P259, DOI 10.1126/science.1079447; Rundell K, 2001, SEMIN CANCER BIOL, V11, P5, DOI 10.1006/scbi.2000.0341; Schoppmann SF, 2002, AM J PATHOL, V161, P947, DOI 10.1016/S0002-9440(10)64255-1; SCHREIBER H, IN PRESS SEMIN CANC; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shankaran V, 2001, NATURE, V410, P1107, DOI 10.1038/35074122; Sharpe AH, 2002, NAT REV IMMUNOL, V2, P116, DOI 10.1038/nri727; SHAY JW, 1991, BIOCHIM BIOPHYS ACTA, V1072, P1, DOI 10.1016/0304-419X(91)90003-4; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Smyth MJ, 2000, J IMMUNOL, V165, P2665, DOI 10.4049/jimmunol.165.5.2665; Torisu H, 2000, INT J CANCER, V85, P182, DOI 10.1002/(SICI)1097-0215(20000115)85:2<182::AID-IJC6>3.0.CO;2-M; Voronov E, 2003, P NATL ACAD SCI USA, V100, P2645, DOI 10.1073/pnas.0437939100; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; Wei WY, 2001, MOL CELL BIOL, V21, P6748, DOI 10.1128/MCB.21.20.6748-6757.2001; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984; WOGAN GN, IN PRESS SEM CANC BI	74	17	20	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 23	2004	23	38					6484	6491		10.1038/sj.onc.1207855	http://dx.doi.org/10.1038/sj.onc.1207855			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	848LJ	15322519				2022-12-17	WOS:000223468800013
J	Abadie, A; Besancon, F; Wietzerbin, J				Abadie, A; Besancon, F; Wietzerbin, J			Type I interferon and TNF alpha cooperate with type II interferon for TRAIL induction and triggering of apoptosis in SK-N-MC EWING tumor cells	ONCOGENE			English	Article						Ewing's sarcoma; TRAIL; apoptosis; IFN alpha; IFN gamma; TNF alpha	NECROSIS-FACTOR-ALPHA; KAPPA-B ACTIVITY; LIGAND TRAIL; SARCOMA FAMILY; TRANSCRIPTIONAL ACTIVATION; TUMORICIDAL ACTIVITY; RETINOIC ACID; APO2 LIGAND; IFN-GAMMA; T-CELLS	Ewing's sarcoma is the second most common human bone tumor in childhood. Here, we investigated the sensitivity of the Ewing tumor cell line, SK-N-MC, to the apoptotic effect of type I (IFNalpha) and type II (IFNgamma) interferons and TNFalpha. We demonstrate that although IFNalpha and TNFalpha alone are unable to induce cell death, they act in synergy with IFNgamma to induce SK-N-MC cell apoptosis. The synergistic induction of apoptosis correlated with the synergistic induction of TNFalpha-related apoptosis-inducing ligand ( TRAIL) mRNA and TRAIL protein synthesis as well as of TRAIL secretion. Preparations of inducer-free supernatants from SK-N-MC cells stimulated with combinations of cytokines were shown to be cytotoxic for untreated SK-N-MC cells. This cytotoxicity was partially inhibited by addition of TRAILR2/Fc fusion protein, indicating that the secreted TRAIL mediates, at least in part, the apoptotic effect displayed by the supernatants of stimulated SK-N-MC cells. We have shown that the presence of IFNgamma is required to allow the sustained expression of IRF1 in SK-N-MC cells stimulated by addition of IFNalpha or TNFalpha suggesting that IRF1 plays a role in the synergistic induction of apoptosis by combinations of cytokines. Furthermore, we have shown that inhibition of NF-kappaB activation contributes to the IFNgamma-mediated sensitization to the apoptotic effect of TNFalpha. To our knowledge, this is the first report showing that interferon/cytokine combinations are able to induce TRAIL gene expression and TRAIL protein synthesis and secretion in Ewing sarcoma-derived cells. We believe that the observations reported here might contribute to the development of alternative new approaches to the treatment of Ewing tumors resistant to conventional therapy.	Inst Curie, INSERM, U365, Sect Rech, F-75248 Paris 05, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Wietzerbin, J (corresponding author), Inst Curie, INSERM, U365, Sect Rech, 26 Rue Ulm, F-75248 Paris 05, France.	jeanne.wietzerbin@curie.fr						Altucci L, 2001, NAT MED, V7, P680, DOI 10.1038/89050; Arvand A, 2001, ONCOGENE, V20, P5747, DOI 10.1038/sj.onc.1204598; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; AURIAS A, 1983, NEW ENGL J MED, V309, P496; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Borden, 1998, Oncologist, V3, P198; Borden EC, 2000, SEMIN CANCER BIOL, V10, P125, DOI 10.1006/scbi.2000.0315; Chawla-Sarkar M, 2003, APOPTOSIS, V8, P237, DOI 10.1023/A:1023668705040; Cheshire JL, 1997, MOL CELL BIOL, V17, P6746, DOI 10.1128/MCB.17.11.6746; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; de Alava E, 2000, J CLIN ONCOL, V18, P204, DOI 10.1200/JCO.2000.18.1.204; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Fanger NA, 1999, J EXP MED, V190, P1155, DOI 10.1084/jem.190.8.1155; Fizazi K, 1998, J CLIN ONCOL, V16, P3736, DOI 10.1200/JCO.1998.16.12.3736; Griffith TS, 1998, J IMMUNOL, V161, P2833; Griffith TS, 1999, J EXP MED, V189, P1343, DOI 10.1084/jem.189.8.1343; Horowitz Marc E., 1997, P831; Javelaud D, 2002, INT J CANCER, V98, P193, DOI 10.1002/ijc.10192; Javelaud D, 2000, ONCOGENE, V19, P61, DOI 10.1038/sj.onc.1203246; Javelaud D, 2001, ONCOGENE, V20, P4365, DOI 10.1038/sj.onc.1204570; Kayagaki N, 1999, J EXP MED, V189, P1451, DOI 10.1084/jem.189.9.1451; Kontny HU, 2001, CELL DEATH DIFFER, V8, P506, DOI 10.1038/sj.cdd.4400836; Kovar H, 1996, CELL GROWTH DIFFER, V7, P429; Kretz-Remy C, 2001, J BIOL CHEM, V276, P43723, DOI 10.1074/jbc.M010821200; Kumar A, 2001, ONCOGENE, V20, P1010, DOI 10.1038/sj.onc.1204154; Langaas V, 2001, ANTICANCER RES, V21, P3733; LAWRENCE D, 2001, NATURE, V7, P382; Lejeune FJ, 2002, J CLIN INVEST, V110, P433, DOI 10.1172/JCI200216493; LIENARD D, 1992, J CLIN ONCOL, V10, P52, DOI 10.1200/JCO.1992.10.1.52; Linder RE, 1997, REPROD TOXICOL, V11, P681, DOI 10.1016/S0890-6238(97)00031-2; Lindner DJ, 1997, CLIN CANCER RES, V3, P931; LIU SQ, 1995, NAT MED, V1, P267, DOI 10.1038/nm0395-267; Martinez-Lorenzo MJ, 1998, EUR J IMMUNOL, V28, P2714, DOI 10.1002/(SICI)1521-4141(199809)28:09<2714::AID-IMMU2714>3.0.CO;2-9; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; Mitsiades N, 2001, CANCER RES, V61, P2704; MUNOZ E, 1994, J VIROL, V68, P8035; Nesterov A, 2002, ONCOGENE, V21, P1135, DOI 10.1038/sj.onc.1205151; Oshima K, 2001, CYTOKINE, V14, P193, DOI 10.1006/cyto.2001.0873; Pfeffer LM, 1998, CANCER RES, V58, P2489; Pinkerton CR, 2001, EUR J CANCER, V37, P1338, DOI 10.1016/S0959-8049(01)00131-9; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Rodriguez-Galindo C, 2003, MED PEDIATR ONCOL, V40, P276, DOI 10.1002/mpo.10240; Sanceau J, 2000, ONCOGENE, V19, P3372, DOI 10.1038/sj.onc.1203670; Sanceau J, 2002, ONCOGENE, V21, P7700, DOI 10.1038/sj.onc.1205881; Shankar AG, 2003, MED PEDIATR ONCOL, V40, P141, DOI 10.1002/mpo.10248; Shin EC, 2001, INT J CANCER, V93, P262, DOI 10.1002/ijc.1310; SINGH RK, 1995, P NATL ACAD SCI USA, V92, P4562, DOI 10.1073/pnas.92.10.4562; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Suk K, 2001, FEBS LETT, V495, P66, DOI 10.1016/S0014-5793(01)02335-3; Suk K, 2001, J BIOL CHEM, V276, P13153, DOI 10.1074/jbc.M007646200; Toomey NL, 2001, ONCOGENE, V20, P7029, DOI 10.1038/sj.onc.1204895; TRACEY KJ, 1994, ANNU REV MED, V45, P491, DOI 10.1146/annurev.med.45.1.491; Van Valen F, 2000, INT J CANCER, V88, P252, DOI 10.1002/1097-0215(20001015)88:2<252::AID-IJC17>3.0.CO;2-U; VANVALEN F, 1993, J CANCER RES CLIN, V119, P615, DOI 10.1007/BF01372725; Wadler, 1997, Oncologist, V2, P254; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wandinger KP, 2003, LANCET, V361, P2036, DOI 10.1016/S0140-6736(03)13641-0; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Zhang CH, 1996, J IMMUNOL, V157, P3980; [No title captured]	62	17	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2004	23	28					4911	4920		10.1038/sj.onc.1207614	http://dx.doi.org/10.1038/sj.onc.1207614			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	830EK	15077162				2022-12-17	WOS:000222104200012
J	Sasaki, H; Hirai, K; Yamamoto, H; Tanooka, H; Sakamoto, H; Iwamoto, T; Takahashi, T; Terada, M; Ochiya, T				Sasaki, H; Hirai, K; Yamamoto, H; Tanooka, H; Sakamoto, H; Iwamoto, T; Takahashi, T; Terada, M; Ochiya, T			HST-1/FGF-4 plays a critical role in crypt cell survival and facilitates epithelial cell restitution and proliferation	ONCOGENE			English	Article						HST-1/FGF-4; intestinal damage; crypt survival; apoptosis; radiation	ADENOVIRUS-MEDIATED TRANSFER; KERATINOCYTE GROWTH-FACTOR; INTESTINAL STEM-CELLS; IN-VIVO; RADIATION-DAMAGE; PROTECTS MICE; SMALL-BOWEL; FACTOR-BETA; IRRADIATION; MIGRATION	The fibroblast growth factor-4 (HST-1/FGF-4) is a heparin-binding growth factor that influences on epithelial and many other cells through interaction with FGF receptors. It has been demonstrated that the HST-1/FGF-4 gene protects mice from lethal irradiation by preventing bone marrow damage and intestinal tract damage. However, the radioprotective mechanism is unknown. In this study, we have investigated the expression of Hst-1/Fgf-4 in mouse small intestine after irradiation, and determined the role of HST-1/FGF-4 in mouse intestinal crypt cell survival and epithelial cell proliferation and restitution. We found the induction of endogenous Hst-1/Fgf-4 expression in intestine when mice are exposed to 9.0 Gy irradiation. Laser-captured microdissection (LCM) coupled with RT-PCR analysis revealed that expression of Hst-1/Fgf-4 was found in epithelial cell of the villi and crypt cells. Pretreatment of HST-1/FGF-4 caused an increase in the number of surviving crypt cells, and clearly suppresses the radiation-induced apoptosis of the crypt cells. Moreover, exogenous HST-1/FGF-4 enhances epithelial cell restitution and proliferation in an in vitro model. These data suggest that HST-1/FGF-4 is induced by irradiation injury, and that HST-1/FGF-4 will find a therapeutic role in the prevention of intestinal cell toxicity following intensive chemotherapy and radiation therapy protocols, and in allogenic cell transplantation.	Natl Canc Ctr, Res Inst, Sect Studies Metastasis, Chuo Ku, Tokyo 1040045, Japan; Natl Inst Radiol Sci, Inage Ku, Chiba 2638555, Japan; Natl Inst Canc Res, Div Genet, Chuo Ku, Tokyo 1040045, Japan; St Marianna Univ, Sch Med, Dept Urol, Miyamae Ku, Kanagawa 2168511, Japan	National Cancer Center - Japan; National Institutes for Quantum Science & Technology; National Cancer Center - Japan; Saint Marianna University	Ochiya, T (corresponding author), Natl Canc Ctr, Res Inst, Sect Studies Metastasis, Chuo Ku, 1-1 Tsukiji,5 Chome, Tokyo 1040045, Japan.	tochiya@ncc.go.jp	Ochiya, Takahiro/AAH-7585-2019					Arman E, 1998, P NATL ACAD SCI USA, V95, P5082, DOI 10.1073/pnas.95.9.5082; Aviezer D, 1999, BIOCHEM BIOPH RES CO, V263, P621, DOI 10.1006/bbrc.1999.1434; Bach SP, 2000, CARCINOGENESIS, V21, P469, DOI 10.1093/carcin/21.3.469; CIACCI C, 1993, GASTROENTEROLOGY, V105, P93, DOI 10.1016/0016-5085(93)90014-4; COHN SM, 1992, J CELL BIOL, V119, P27, DOI 10.1083/jcb.119.1.27; Cohn SM, 1997, J CLIN INVEST, V99, P1367, DOI 10.1172/JCI119296; Cutler NS, 2003, CANCER RES, V63, P1748; Deroanne CF, 1997, CANCER RES, V57, P5590; DIGNASS AU, 1993, GASTROENTEROLOGY, V105, P1323, DOI 10.1016/0016-5085(93)90136-Z; DIGNASS AU, 1994, GASTROENTEROLOGY, V106, P1254, DOI 10.1016/0016-5085(94)90017-5; Farrell CL, 1998, CANCER RES, V58, P933; FEIL W, 1987, GASTROENTEROLOGY, V92, P1973, DOI 10.1016/0016-5085(87)90632-9; FELDMAN B, 1995, SCIENCE, V267, P246, DOI 10.1126/science.7809630; Houchen CW, 1999, AM J PHYSIOL-GASTR L, V276, pG249, DOI 10.1152/ajpgi.1999.276.1.G249; HUGHES SE, 1993, LAB INVEST, V69, P173; Khan WB, 1997, RADIAT RES, V148, P248, DOI 10.2307/3579609; LACY ER, 1988, J CLIN GASTROENTEROL, V10, P72; LEIGH BR, 1995, RADIAT RES, V142, P12, DOI 10.2307/3578961; LI YQ, 1992, CARCINOGENESIS, V13, P361, DOI 10.1093/carcin/13.3.361; MCCORMACK SA, 1992, AM J PHYSIOL-GASTR L, V263, P426; NUSRAT A, 1992, J CLIN INVEST, V89, P1501, DOI 10.1172/JCI115741; OCHIYA T, 1997, J TOXICOL PATHOL, V10, P129; Okunieff P, 1998, RADIAT RES, V150, P204, DOI 10.2307/3579856; Paris F, 2001, SCIENCE, V293, P293, DOI 10.1126/science.1060191; POTTEN CS, 1990, INT J RADIAT BIOL, V58, P925, DOI 10.1080/09553009014552281; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; Potten CS, 1997, BRIT J CANCER, V75, P1454, DOI 10.1038/bjc.1997.249; POTTEN CS, 1981, INT J RADIAT BIOL, V40, P321, DOI 10.1080/09553008114551251; POTTEN CS, 1992, CARCINOGENESIS, V13, P2305, DOI 10.1093/carcin/13.12.2305; ROBERTS DB, 1993, RADIAT RES, V135, P56, DOI 10.2307/3578396; SAKAMOTO H, 1994, P NATL ACAD SCI USA, V91, P12368, DOI 10.1073/pnas.91.26.12368; Santos MF, 1997, J CLIN INVEST, V100, P216, DOI 10.1172/JCI119515; Takahama Y, 1999, ONCOGENE, V18, P5943, DOI 10.1038/sj.onc.1203171; Wambersie A, 1996, Rev Med Brux, V17, P75; WINTON DJ, 1990, P ROY SOC B-BIOL SCI, V241, P13, DOI 10.1098/rspb.1990.0059; WITHERS HR, 1970, INT J RADIAT BIOL RE, V17, P261, DOI 10.1080/09553007014550291; Wright JA, 1996, HISTOL HISTOPATHOL, V11, P521; YOSHIDA T, 1994, CANCER LETT, V83, P261, DOI 10.1016/0304-3835(94)90328-X	38	17	18	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3681	3688		10.1038/sj.onc.1207348	http://dx.doi.org/10.1038/sj.onc.1207348			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15116099				2022-12-17	WOS:000221101700020
J	Connor, MK; Seth, A				Connor, MK; Seth, A			A central role for the ring finger protein RNF11 in ubiquitin-mediated proteolysis via interactions with E2s and E3s	ONCOGENE			English	Review						RNF11; ubiquitination; Smurf2; TGF-beta; breast cancer; signaling; EGFR	GROWTH-FACTOR-BETA; KINASE INHIBITOR P27(KIP1); U-BOX PROTEINS; TGF-BETA; BREAST-CANCER; NEGATIVE REGULATION; PROGNOSTIC-FACTOR; LIGASE; BRCA1; PHOSPHORYLATION	The identification of novel tumor-associated genes represents an important area of cancer research. To that end, we have discovered a number of genes whose expression is altered in breast tumors. One of these genes has been identified as the ring finger protein 11 ( RNF11) and its expression is elevated in breast and prostate cancer. The RNF11 gene encodes a 154 amino-acid protein that contains a ring finger and a PY motif. RNF11 is capable of binding numerous proteins, which encompass a wide variety of cellular pathways and mechanisms. This gives RNF11 a corresponding breadth of functions, including involvement in TGF-beta and epidermal growth factor receptor ( EGFR) signaling. In addition, RNF11 has the potential to mediate the ubiquitination and subsequent proteolysis of many cellular proteins. Thus, it may represent an important target of novel cancer therapies.	Sunnybrook & Womens Coll Hlth Sci Ctr, Lab Mol Pathol, Toronto, ON M4N 3M5, Canada; Univ Toronto, Dept Lab Med & Pathobiol, CIHR Grp Matrix Dynam, Toronto, ON M4N 3M5, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto	Seth, A (corresponding author), Sunnybrook & Womens Coll Hlth Sci Ctr, Lab Mol Pathol, Rm E-423B,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	arun.seth@utoronto.ca						Aravind L, 2000, CURR BIOL, V10, pR132, DOI 10.1016/S0960-9822(00)00398-5; Asao H, 1997, J BIOL CHEM, V272, P32785, DOI 10.1074/jbc.272.52.32785; Bache KG, 2003, J BIOL CHEM, V278, P12513, DOI 10.1074/jbc.M210843200; Ben-Izhak O, 2003, J UROLOGY, V170, P241, DOI 10.1097/01.ju.0000072113.34524.a7; Boehmer C, 2003, BIOCHEM BIOPH RES CO, V306, P156, DOI 10.1016/S0006-291X(03)00921-5; Bres V, 2003, NAT CELL BIOL, V5, P754, DOI 10.1038/ncb1023; Burger AM, 1998, EUR J CANCER PREV, V7, pS29, DOI 10.1097/00008469-199802001-00007; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Catzavelos C, 1999, CANCER RES, V59, P684; Confalonieri S, 2000, J CELL BIOL, V150, P905, DOI 10.1083/jcb.150.4.905; Coopman PJP, 2000, NATURE, V406, P742, DOI 10.1038/35021086; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Donovan J, 2000, BREAST CANCER RES, V2, P116, DOI 10.1186/bcr43; Fang S, 2003, SEMIN CANCER BIOL, V13, P5, DOI 10.1016/S1044-579X(02)00095-0; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Fukuchi M, 2002, CANCER RES, V62, P7162; Gillessen S, 2002, ONKOLOGIE, V25, P534, DOI 10.1159/000068624; Gilmore PM, 2003, BIOCHEM SOC T, V31, P257, DOI 10.1042/bst0310257; Gstaiger M, 2001, P NATL ACAD SCI USA, V98, P5043, DOI 10.1073/pnas.081474898; Hatakeyama S, 2001, J BIOL CHEM, V276, P33111, DOI 10.1074/jbc.M102755200; Hatakeyama S, 2003, BIOCHEM BIOPH RES CO, V302, P635, DOI 10.1016/S0006-291X(03)00245-6; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Itoh F, 2001, EMBO J, V20, P4132, DOI 10.1093/emboj/20.15.4132; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Jolliffe CN, 2000, BIOCHEM J, V351, P557, DOI 10.1042/0264-6021:3510557; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Kitching R, 2003, BBA-MOL BASIS DIS, V1639, P104, DOI 10.1016/j.bbadis.2003.07.001; Kretzschmar M, 2000, BREAST CANCER RES, V2, P107, DOI 10.1186/bcr42; LI HX, 2003, IN PRESS ONCOGENE; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Liu XD, 2001, CYTOKINE GROWTH F R, V12, P1, DOI 10.1016/S1359-6101(00)00031-9; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Medrano EE, 2003, ONCOGENE, V22, P3123, DOI 10.1038/sj.onc.1206452; Mehra A, 2002, BIOCHEM CELL BIOL, V80, P605, DOI 10.1139/O02-161; Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8; Miyazono K, 2003, CANCER SCI, V94, P230, DOI 10.1111/j.1349-7006.2003.tb01425.x; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; Monteleone G, 2001, J CLIN INVEST, V108, P601, DOI 10.1172/JCI200112821; Mori N, 2003, INT J CANCER, V105, P661, DOI 10.1002/ijc.11146; Moynahan ME, 2002, ONCOGENE, V21, P8994, DOI 10.1038/sj.onc.1206177; Mustelin T, 2003, BIOCHEM J, V371, P15, DOI 10.1042/BJ20021637; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nalepa G, 2003, CANCER TREAT REV, V29, P49, DOI 10.1016/S0305-7372(03)00083-5; Peng HZ, 2002, CANCER RES, V62, P3773; Pray TR, 2002, DRUG RESIST UPDATE, V5, P249, DOI 10.1016/S1368-7646(02)00121-8; Rosen EM, 2003, J CELL PHYSIOL, V196, P19, DOI 10.1002/jcp.10257; Sakamoto KM, 2002, MOL GENET METAB, V77, P44, DOI 10.1016/S1096-7192(02)00146-4; Seki N, 1999, BBA-GENE STRUCT EXPR, V1489, P421, DOI 10.1016/S0167-4781(99)00190-6; Shigemasa K, 2003, CLIN CANCER RES, V9, P1756; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Subramaniam V, 2003, BRIT J CANCER, V89, P1538, DOI 10.1038/sj.bjc.6601301; Sun Y, 1999, P NATL ACAD SCI USA, V96, P12442, DOI 10.1073/pnas.96.22.12442; Tanaka N, 1999, J BIOL CHEM, V274, P19129, DOI 10.1074/jbc.274.27.19129; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Winberg G, 2000, MOL CELL BIOL, V20, P8526, DOI 10.1128/MCB.20.22.8526-8535.2000; Xu J, 2000, P NATL ACAD SCI USA, V97, P4820, DOI 10.1073/pnas.97.9.4820; Yanagi S, 2001, BIOCHEM BIOPH RES CO, V288, P495, DOI 10.1006/bbrc.2001.5788; Zheng L, 2000, MOL CELL, V6, P757, DOI 10.1016/S1097-2765(00)00075-7	60	17	18	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 15	2004	23	11					2089	2095		10.1038/sj.onc.1207380	http://dx.doi.org/10.1038/sj.onc.1207380			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	803EC	15021896				2022-12-17	WOS:000220213400013
J	Gu, J; Zhang, LD; Swisher, SG; Liu, JS; Roth, JA; Fang, BL				Gu, J; Zhang, LD; Swisher, SG; Liu, JS; Roth, JA; Fang, BL			Induction of p53-regulated genes in lung cancer cells: implications of the mechanism for adenoviral p53-mediated apoptosis	ONCOGENE			English	Article						lung cancer; real-time PCR; p53; apoptosis; siRNA	P53-DEPENDENT APOPTOSIS; P53-INDUCED APOPTOSIS; BINDING PROTEIN; BCL-2 FAMILY; P53 PROTEIN; BAX; TRANSCRIPTION; SEQUENCE; DEATH; PUMA	The p53 gene is the most frequently mutated gene in human cancers. Loss of functional p53 leads to impaired responses of cancer cells to apoptosis induction and to poor prognosis in patients with certain types of cancer. Cancer gene therapies using ectopic expression of wildtype p53 to force cancer cells through the apoptotic pathway have been tested extensively preclinically and clinically, and genes in various cell lines have been reported to be regulated upon ectopic p53 overexpression. However, the effect of p53 on many other p53-dependent and apoptosis-related genes remains unclear, as does the mechanism of p53-induced apoptosis in human cancers. In this study, we used real-time reverse transcription polymerase chain reaction to evaluate the changes in expression of various p53-dependent and apoptosis-related genes in five human non-small-cell lung cancer cell lines with varying p53 statuses after adenoviral p53 treatment. We found that Ad/p53 induced the expression of the proapoptotic genes PUMA, Bak, Bax, and Fas in a cell type- and time-dependent manner. Among these genes, PUMA was upregulated the most dramatically and broadly. However, when a specific siRNA construct against PUMA was employed, we observed no attenuation of apoptosis in H1299 cells. Our data suggest that Ad-p53 induces the expression of a variety of proapoptotic genes and that lack of induction in one of these genes does not block Ad/p53-mediated cell killing in human lung cancer cells.	Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Fang, BL (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, 1515 Holcombe Blvd, Houston, TX 77030 USA.	bfang@mdanderson.org	Gu, Jian/Q-4780-2018	Gu, Jian/0000-0003-3499-0973	NATIONAL CANCER INSTITUTE [R01CA092487, R01CA098582, P01CA078778] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 098582-01A1, R01 CA 092487-01A1, 2P50-CA70970-04, P01 CA78778-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Clayman GL, 1998, J CLIN ONCOL, V16, P2221, DOI 10.1200/JCO.1998.16.6.2221; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; EL DW, 1993, CELL, V75, P817; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; HARPER JW, 1993, CELL, V75, P805; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lane DP, 2002, TRENDS MOL MED, V8, pS38, DOI 10.1016/S1471-4914(02)02309-2; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lin YP, 2000, NAT GENET, V26, P122, DOI 10.1038/79102; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MIYASHITA T, 1995, CELL, V80, P293; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nemunaitis J, 2000, J CLIN ONCOL, V18, P609, DOI 10.1200/JCO.2000.18.3.609; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; QUINLAN DC, 1992, CANCER RES, V52, P4828; Reinke V, 1997, ONCOGENE, V15, P1527, DOI 10.1038/sj.onc.1201316; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; Swisher SG, 1999, J NATL CANCER I, V91, P763, DOI 10.1093/jnci/91.9.763; THOR AD, 1992, JNCI-J NATL CANCER I, V84, P845, DOI 10.1093/jnci/84.11.845; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang LQ, 2001, J BIOL CHEM, V276, P43604, DOI 10.1074/jbc.M106570200; Xiang H, 1998, J NEUROSCI, V18, P1363; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100; ZHANG WW, 1993, BIOTECHNIQUES, V15, P868; Zhao RB, 2000, GENE DEV, V14, P981	39	17	23	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2004	23	6					1300	1307		10.1038/sj.onc.1207239	http://dx.doi.org/10.1038/sj.onc.1207239			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	773HH	14676844				2022-12-17	WOS:000188892200015
J	Puccetti, E; Beissert, T; Guller, S; Li, JE; Hoelzer, D; Ottmann, OG; Ruthardt, M				Puccetti, E; Beissert, T; Guller, S; Li, JE; Hoelzer, D; Ottmann, OG; Ruthardt, M			Leukemia-associated translocation products able to activate RAS modify PML and render cells sensitive to arsenic-induced apoptosis	ONCOGENE			English	Article						PML; arsenic; RAS; CML; APL; AML	ACUTE PROMYELOCYTIC LEUKEMIA; NF-KAPPA-B; TRIOXIDE-INDUCED APOPTOSIS; ALPHA FUSION PROTEIN; RETINOIC ACID; PREMATURE SENESCENCE; NUCLEAR-BODIES; MYELOID-LEUKEMIA; ONCOGENIC RAS; BCR-ABL	Since the 19th century, arsenic (As2O3) has been used in the treatment of chronic myelogenous leukemia (CML) characterized by the t(9;22) translocation. As2O3 induces complete remissions in patients with acute promyelocytic leukemia. The response to As2O3 is genetically determined by the t(15;17)- or the t(9;22)-specific fusion proteins PML/RARalpha or BCR/ABL. The PML portion of PML/RARalpha is crucial for the sensitivity to As2O3. PML is nearly entirely contained in PML/RARalpha. PML is upregulated by oncogenic RAS in primary fibroblasts. The aberrant kinase activity of BCR/ABL leads to constitutive activation of RAS. Therefore, we hypothesized that BCR/ABL could increase sensitivity to As2O2-induced apoptosis by modifying PML expression. To disclose the mechanism of As2O3-induced apoptosis in PML/RARalpha- and BCR/ABL-expressing cells, we focused on the role of PML for As2O3-induced cell death. Here we report that (i) sensitivity to As2O3-induced apoptosis of U937 cells can be increased either by overexpression of PML, or by conditional expression of activated RAS; (ii) also the expression of the t(8;21)-related AML-1/ETO increased sensitivity to As2O3-induced apoptosis; (iii) both BCR/ABL and AML-1/ETO activated RAS and modified the PML expression pattern; (iv) the expression of either BCR/ABL or AML-1/ETO rendered U937 cells sensitive to interferon alpha-induced apoptosis. In summary, these data suggest a crucial role of factors able to upregulate PML for As2O2-induced cell death.	Univ Frankfurt, Med Klin 3, Hamatol Abt, D-60590 Frankfurt, Germany	Goethe University Frankfurt	Ruthardt, M (corresponding author), Univ Frankfurt Klinikum, Med Klin 3, Hamatol Abt, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.		Ottmann, Oliver G/D-5007-2016	Ottmann, Oliver G/0000-0001-9559-1330; Ruthardt, Martin/0000-0003-1021-3811				Bischof O, 2002, EMBO J, V21, P3358, DOI 10.1093/emboj/cdf341; ChelbiAlix MK, 1995, LEUKEMIA, V9, P2027; Chen F, 2001, ONCOGENE, V20, P3585, DOI 10.1038/sj.onc.1204442; Chen F, 2001, J BIOL CHEM, V276, P11414, DOI 10.1074/jbc.M011682200; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; El-Sabban ME, 2000, BLOOD, V96, P2849; Faderl S, 1999, NEW ENGL J MED, V341, P164, DOI 10.1056/NEJM199907153410306; Ferbeyre G, 2000, GENE DEV, V14, P2015; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Forkner CE, 1931, J AMER MED ASSOC, V97, P0003, DOI 10.1001/jama.1931.02730010007002; Gianni M, 1998, BLOOD, V91, P4300, DOI 10.1182/blood.V91.11.4300.411k41_4300_4310; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Jensen K, 2001, ONCOGENE, V20, P7223, DOI 10.1038/sj.onc.1204765; Koken MHM, 1999, ONCOGENE, V18, P1113, DOI 10.1038/sj.onc.1202414; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; Lee RK, 1999, CANCER RES, V59, P5514; LISSAUER H, 1865, KLIN WOCHENSCHR, V2, P403; Mahieux R, 2001, BLOOD, V98, P3762, DOI 10.1182/blood.V98.13.3762; McNeil S, 2000, J CELL BIOCHEM, V79, P103, DOI 10.1002/1097-4644(2000)79:1<103::AID-JCB100>3.0.CO;2-B; Miller WH, 2002, CANCER RES, V62, P3893; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Perkins C, 2000, BLOOD, V95, P1014, DOI 10.1182/blood.V95.3.1014.003k04_1014_1022; Puccetti E, 2000, CANCER RES, V60, P3409; Puccetti E, 2002, CANCER RES, V62, P7050; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Ruthardt M, 1997, MOL CELL BIOL, V17, P4859, DOI 10.1128/MCB.17.8.4859; SEARS DA, 1988, AM J MED SCI, V296, P85, DOI 10.1097/00000441-198808000-00001; Stadler M, 1995, ONCOGENE, V11, P2565; Sternsdorf T, 1999, MOL CELL BIOL, V19, P5170; STUURMAN N, 1992, J CELL SCI, V101, P773; VALENTINER W, 1865, BERL KLIN WOCHENSCHR, V2, P320; Villa E, 2001, AM J GASTROENTEROL, V96, P2973; Visani G, 2000, LEUKEMIA, V14, P22, DOI 10.1038/sj.leu.2401641; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Zhu J, 1997, P NATL ACAD SCI USA, V94, P3978, DOI 10.1073/pnas.94.8.3978	37	17	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 9	2003	22	44					6900	6908		10.1038/sj.onc.1206747	http://dx.doi.org/10.1038/sj.onc.1206747			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	730RH	14534537				2022-12-17	WOS:000185843400011
J	Russo, G; Claudio, PP; Fu, Y; Stiegler, P; Yu, ZL; Macaluso, M; Giordano, A				Russo, G; Claudio, PP; Fu, Y; Stiegler, P; Yu, ZL; Macaluso, M; Giordano, A			pRB(2)/p130 target genes in non-small lung cancer cells identified by microarray analysis	ONCOGENE			English	Article						lung cancer; Rb2/p130; microarray analysis	NF-KAPPA-B; POLO-LIKE KINASE; NUCLEAR ANTIGEN; CYCLIN D1; DIFFERENTIAL EXPRESSION; IN-VIVO; GROWTH; PROTEIN; CARCINOMA; MYB	The retinoblastoma gene family consisting of RB/p105, p107, and RB2/p130 cooperate to regulate cell-cycle progression through the G1 phase of the cell cycle. Previous data demonstrated an independent role for the reduction or loss of pRb2/p130 expression in the formation and/or progression of lung carcinoma. Rb2/p130 is mutated in a human cell line of lung small cell carcinoma as well as in primary lung tumors. To identify potential pRb2/p130 target genes in an unbiased manner, we have utilized an adenovirus-mediated expression system of pRb2/p130 in a non-small lung cancer cell line to identify specific genes that are regulated by pRb2/p130. Using oligonucleotide arrays, a number of Rb2/p130 downregulated genes were identified and their regulation was confirmed by semiquantitative reverse transcription polymerase chain reaction (RT-PCR) and Western blot analysis. As a result, 40 genes showed greater than 2.0-fold modi. cation in their expression level after the RB2/p130 viral transduction. In conclusion, coupling adenoviral overexpression with microarray and semiquantitative RT-PCR analyses proved to be a versatile strategy for identifying pRb2/p130 target genes and for better understanding the expression profiles of these genes. Our results may also contribute to identifying novel therapeutic biomarkers in lung carcinoma.	Temple Univ, Coll Sci & Technol, Dept Biotechnol, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA; Univ Siena, Inst Human Pathol & Oncol, I-53100 Siena, Italy; Univ Naples Federico II, Dipartimento Sci Odontostomatol & Maxillofacciali, Naples, Italy; Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Jefferson Med Coll, Philadelphia, PA 19107 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Siena; University of Naples Federico II; Jefferson University; Jefferson University	Giordano, A (corresponding author), Temple Univ, Coll Sci & Technol, Dept Biotechnol, Sbarro Inst Canc Res & Mol Med, 1900 N 12th St,Room 333, Philadelphia, PA 19122 USA.	giordano@temple.edu	Giordano, Antonio/F-1927-2010; Claudio, Pier Paolo/AAW-7282-2021	Giordano, Antonio/0000-0002-5959-016X; Claudio, Pier Paolo/0000-0001-7790-1622				Baldi A, 1996, CLIN CANCER RES, V2, P1239; Baldi A, 1997, CLIN CANCER RES, V3, P1691; Bhattacharya N, 2002, CHROMOSOMA, V111, P80, DOI 10.1007/s00412-002-0192-6; Caputi M, 1999, AM J RESP CELL MOL, V20, P746, DOI 10.1165/ajrcmb.20.4.3366; Claudio PP, 2000, CANCER RES, V60, P372; Claudio PP, 1999, CIRC RES, V85, P1032; Claudio PP, 1996, CANCER RES, V56, P2003; CLAUDIO PP, 1994, CANCER RES, V54, P5556; Cunningham MD, 2003, BIOCHEM BIOPH RES CO, V300, P403, DOI 10.1016/S0006-291X(02)02863-2; Davis AR, 1998, GENE THER, V5, P1148, DOI 10.1038/sj.gt.3300705; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; Fathi Z, 1996, J CELL BIOCHEM, P237; Forgacs Eva, 2001, Pathology and Oncology Research, V7, P6; Forslund KO, 2001, EXP CELL RES, V265, P185, DOI 10.1006/excr.2001.5173; GILLETT C, 1994, CANCER RES, V54, P1812; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; Gorgoulis VG, 2002, J PATHOL, V198, P142, DOI 10.1002/path.1121; Greenberg AK, 2002, AM J RESP CELL MOL, V26, P558, DOI 10.1165/ajrcmb.26.5.4689; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Helin K, 1997, P NATL ACAD SCI USA, V94, P6933, DOI 10.1073/pnas.94.13.6933; Hibi K, 1998, CANCER RES, V58, P5690; HOYT RF, 1993, ANAT REC, V236, P15, DOI 10.1002/ar.1092360106; Jiang YX, 2001, ONCOGENE, V20, P2254, DOI 10.1038/sj.onc.1204293; KAWAI T, 1994, CANCER, V74, P2468, DOI 10.1002/1097-0142(19941101)74:9<2468::AID-CNCR2820740913>3.0.CO;2-X; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; Lane S, 1997, ONCOGENE, V14, P2445, DOI 10.1038/sj.onc.1201086; LYON J, 1994, CRIT REV ONCOGENESIS, V5, P373, DOI 10.1615/CritRevOncog.v5.i4.30; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Markey MP, 2002, CANCER RES, V62, P6587; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; Masuda A, 2002, ONCOGENE, V21, P6884, DOI 10.1038/sj.onc.1205566; MATHEWS MB, 1984, NATURE, V309, P374, DOI 10.1038/309374a0; Milligan SA, 2001, ANTICANCER RES, V21, P39; Minimo C, 1999, PATHOL RES PRACT, V195, P67, DOI 10.1016/S0344-0338(99)80072-7; MOTOKURA T, 1993, BIOCHIM BIOPHYS ACTA, V1155, P63, DOI 10.1016/0304-419X(93)90022-5; MUKHOPADHYAY T, 1995, ONCOGENE, V11, P999; Muller D, 1997, EUR J CANCER, V33, P2203, DOI 10.1016/S0959-8049(97)00198-6; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; Paggi MG, 1996, J CELL BIOCHEM, V62, P418; Ramakrishna G, 2002, TOXICOL APPL PHARM, V179, P21, DOI 10.1006/taap.2001.9344; Raschella G, 1996, EXP CELL RES, V222, P395, DOI 10.1006/excr.1996.0049; Raschella G, 1997, J CELL BIOCHEM, V67, P297, DOI 10.1002/(SICI)1097-4644(19971201)67:3<297::AID-JCB2>3.0.CO;2-R; Reissmann PT, 1999, J CANCER RES CLIN, V125, P61, DOI 10.1007/s004320050243; ROZENGURT E, 1988, ANN NY ACAD SCI, V547, P277, DOI 10.1111/j.1749-6632.1988.tb23896.x; Sala A, 1996, J BIOL CHEM, V271, P9363, DOI 10.1074/jbc.271.16.9363; Sala A, 1997, P NATL ACAD SCI USA, V94, P532, DOI 10.1073/pnas.94.2.532; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; SCHAUER IE, 1994, P NATL ACAD SCI USA, V91, P7827, DOI 10.1073/pnas.91.16.7827; Siegfried JM, 1999, PULM PHARMACOL THER, V12, P291, DOI 10.1006/pupt.1999.0210; Smith MR, 1997, BIOCHEM BIOPH RES CO, V234, P397, DOI 10.1006/bbrc.1997.6633; Sugita M, 2002, CANCER RES, V62, P3971; Teng DHF, 2001, GENOMICS, V74, P352, DOI 10.1006/geno.2001.6551; VandenEynde BJ, 1997, CURR OPIN IMMUNOL, V9, P684, DOI 10.1016/S0952-7915(97)80050-7; Volm M, 2000, BRIT J CANCER, V82, P1747; Wiest JS, 1997, J CELL BIOCHEM, P64; Wolf G, 1997, ONCOGENE, V14, P543, DOI 10.1038/sj.onc.1200862; Yano T, 1998, LIFE SCI, V64, P229, DOI 10.1016/S0024-3205(98)00558-X; Yuan JP, 2002, CANCER RES, V62, P4186; Yuan JP, 1997, AM J PATHOL, V150, P1165; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595	60	17	21	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	2003	22	44					6959	6969		10.1038/sj.onc.1206866	http://dx.doi.org/10.1038/sj.onc.1206866			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	730RH	14534545				2022-12-17	WOS:000185843400019
J	Krutilina, RI; Smirnova, AN; Mudrak, OS; Pleskach, NM; Svetlova, MP; Oei, SL; Yau, PM; Bradbury, EM; Zalensky, AO; Tomilin, NV				Krutilina, RI; Smirnova, AN; Mudrak, OS; Pleskach, NM; Svetlova, MP; Oei, SL; Yau, PM; Bradbury, EM; Zalensky, AO; Tomilin, NV			Protection of internal (TTAGGG)n repeats in Chinese hamster cells by telomeric protein TRF1	ONCOGENE			English	Article						internal telomeric repeats; instability; TRF1; wortmannin; tankyrase 1	DOUBLE-STRAND BREAK; ATM-DEPENDENT PHOSPHORYLATION; ATAXIA-TELANGIECTASIA CELLS; DNA-DAMAGE RESPONSE; END-JOINING FACTORS; OVARY CELLS; CHROMOSOMAL INSTABILITY; L1 ENDONUCLEASE; MAMMALIAN-CELLS; TTAGGG REPEATS	Chinese hamster cells have large interstitial ( TTAGGG) bands (ITs) which are unstable and should be protected by an unknown mechanism. Here, we expressed in Chinese hamster V79 cells green fluorescent protein (GFP)-tagged human TRF1, and found that a major fraction of GFP-TRF1 bound to ITs is diffusionally mobile. This fraction strongly decreases after treatment of cells with wortmannin, a protein kinase inhibitor, and this drug also increases the frequency of chromosome aberrations. Ionizing radiation does not induce detectable translocation of GFP-TRF1 to the sites of random double-strand breaks visualized using antibodies against histone gamma-H2AX. TRF1 is known to be eliminated from telomeres by overexpression of tankyrase 1 which induces TRF1 poly(ADP-ribosyl) ation. We transfected V79 cells by plasmid encoding tankyrase 1 and found that the frequency of chromosome rearrangements is increased in these cells independently of their treatment by IR. Taken together, our results suggest that TRF1 is involved in sequence-specific protection of internal nontelomeric (TTAGGG) n repeats.	Russian Acad Sci, Inst Cytol, Lab Chromosome Stabil, St Petersburg 194064, Russia; Free Univ Berlin, Inst Biochem, D-14195 Berlin, Germany; Univ Calif Davis, Sch Med, Dept Biol Chem, Davis, CA 95616 USA; Los Alamos Natl Lab, Biosci Div, Los Alamos, NM 87545 USA	Russian Academy of Sciences; St. Petersburg Scientific Centre of the Russian Academy of Sciences; Institute of Cytology RAS; Free University of Berlin; University of California System; University of California Davis; United States Department of Energy (DOE); Los Alamos National Laboratory	Tomilin, NV (corresponding author), Russian Acad Sci, Inst Cytol, Lab Chromosome Stabil, St Petersburg 194064, Russia.		Smirnova, Alexandra/Y-9941-2019; Pleskach, Nadezhda/AAE-9290-2021	Smirnova, Alexandra/0000-0002-8911-8827; Yau, Peter/0000-0002-1984-185X; Krutilina, Raisa/0000-0002-2118-4019	NICHD NIH HHS [5R01-HD39830-02] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD039830] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Allen C, 2002, P NATL ACAD SCI USA, V99, P3758, DOI 10.1073/pnas.052545899; Allio T, 2000, MUTAT RES-FUND MOL M, V453, P5, DOI 10.1016/S0027-5107(00)00030-0; ALVAREZ L, 1993, GENE CHROMOSOME CANC, V8, P8, DOI 10.1002/gcc.2870080103; Azzalin CM, 2001, CHROMOSOMA, V110, P75, DOI 10.1007/s004120100135; Bailey SM, 1999, P NATL ACAD SCI USA, V96, P14899, DOI 10.1073/pnas.96.26.14899; Baumann P, 2001, SCIENCE, V292, P1171, DOI 10.1126/science.1060036; Bertoni L, 1996, MAMM GENOME, V7, P853, DOI 10.1007/s003359900250; Boulton S, 1996, CARCINOGENESIS, V17, P2285, DOI 10.1093/carcin/17.11.2285; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Chernikova SB, 1999, RADIAT RES, V151, P159, DOI 10.2307/3579766; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Cost GJ, 1998, BIOCHEMISTRY-US, V37, P18081, DOI 10.1021/bi981858s; Cost GJ, 2001, NUCLEIC ACIDS RES, V29, P573, DOI 10.1093/nar/29.2.573; Day JP, 1998, CARCINOGENESIS, V19, P259, DOI 10.1093/carcin/19.2.259; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; di Fagagna FD, 2001, CURR BIOL, V11, P1192, DOI 10.1016/S0960-9822(01)00328-1; Faravelli M, 2002, GENE, V283, P11, DOI 10.1016/S0378-1119(01)00877-0; Ferguson DO, 2001, ONCOGENE, V20, P5572, DOI 10.1038/sj.onc.1204767; Fernandez JL, 1998, CYTOGENET CELL GENET, V82, P195, DOI 10.1159/000015098; FERNANDEZ JL, 1995, CHROMOSOME RES, V3, P281, DOI 10.1007/BF00713065; FLINT J, 1994, AM J HUM GENET, V55, P505; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Gilley D, 2001, P NATL ACAD SCI USA, V98, P15084, DOI 10.1073/pnas.261574698; Gineitis AA, 2000, J CELL BIOL, V151, P1591, DOI 10.1083/jcb.151.7.1591; Goytisolo FA, 2002, ONCOGENE, V21, P584, DOI 10.1038/sj.onc.1205085; Griffith J, 1998, J MOL BIOL, V278, P79, DOI 10.1006/jmbi.1998.1686; Hande MP, 2001, HUM MOL GENET, V10, P519, DOI 10.1093/hmg/10.5.519; Hsu HL, 2000, GENE DEV, V14, P2807, DOI 10.1101/gad.844000; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P12454, DOI 10.1073/pnas.96.22.12454; Jeggo PA, 1998, TRENDS GENET, V14, P312, DOI 10.1016/S0168-9525(98)01511-X; Jurka J, 1997, P NATL ACAD SCI USA, V94, P1872, DOI 10.1073/pnas.94.5.1872; Kilburn AE, 2001, MOL CELL BIOL, V21, P126, DOI 10.1128/MCB.21.1.126-135.2001; Kim SH, 1999, NAT GENET, V23, P405, DOI 10.1038/70508; Kishi S, 2002, J BIOL CHEM, V277, P7420, DOI 10.1074/jbc.M111365200; Kishi S, 2001, J BIOL CHEM, V276, P29282, DOI 10.1074/jbc.M011534200; Krutilina RI, 2001, BIOCHEM BIOPH RES CO, V280, P471, DOI 10.1006/bbrc.2000.4143; Lippincott-Schwartz J, 2001, NAT REV MOL CELL BIO, V2, P444, DOI 10.1038/35073068; MEYNE J, 1990, CHROMOSOMA, V99, P3, DOI 10.1007/BF01737283; Misteli T, 2000, NATURE, V408, P877, DOI 10.1038/35048610; Morgan WF, 2002, MUTAT RES-FUND MOL M, V504, P91, DOI 10.1016/S0027-5107(02)00083-0; Okabe J, 2000, HUM MOL GENET, V9, P2639, DOI 10.1093/hmg/9.18.2639; PANDITA TK, 1995, CYTOGENET CELL GENET, V71, P86, DOI 10.1159/000134069; PANDITA TK, 1995, CYTOGENET CELL GENET, V68, P95, DOI 10.1159/000133899; Pandita TK, 2002, ONCOGENE, V21, P611, DOI 10.1038/sj.onc.1205060; Pandita TK, 2001, RADIAT RES, V156, P642, DOI 10.1667/0033-7587(2001)156[0642:TROAIT]2.0.CO;2; RADMAN M, 1991, BIOCHIMIE, V73, P357, DOI 10.1016/0300-9084(91)90101-6; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Samper E, 2000, EMBO REP, V1, P244, DOI 10.1093/embo-reports/kvd051; Sarkaria JN, 1998, CANCER RES, V58, P4375; Sekiguchi J, 2001, P NATL ACAD SCI USA, V98, P3243, DOI 10.1073/pnas.051632098; Shen MH, 1997, P NATL ACAD SCI USA, V94, P13618, DOI 10.1073/pnas.94.25.13618; Simi S, 1998, MUTAT RES-FUND MOL M, V397, P229, DOI 10.1016/S0027-5107(97)00217-0; SLIJEPCEVIC P, 1995, CYTOGENET CELL GENET, V69, P87, DOI 10.1159/000133944; Slijepcevic P, 1996, CHROMOSOMA, V104, P596, DOI 10.1007/s004120050152; Smilenov LB, 1998, ONCOGENE, V17, P2137, DOI 10.1038/sj.onc.1202138; SMITH GP, 1976, SCIENCE, V191, P528, DOI 10.1126/science.1251186; Smith S, 2000, CURR BIOL, V10, P1299, DOI 10.1016/S0960-9822(00)00752-1; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Smogorzewska A, 2000, MOL CELL BIOL, V20, P1659, DOI 10.1128/MCB.20.5.1659-1668.2000; Song K, 2000, FEBS LETT, V481, P81, DOI 10.1016/S0014-5793(00)01958-X; Sprung CN, 1999, P NATL ACAD SCI USA, V96, P6781, DOI 10.1073/pnas.96.12.6781; Taylor AMR, 1996, BLOOD, V87, P423, DOI 10.1182/blood.V87.2.423.bloodjournal872423; Tomilin NV, 2001, RADIAT RES, V156, P347, DOI 10.1667/0033-7587(2001)156[0347:VOFNSO]2.0.CO;2; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; Zalensky AO, 1997, EXP CELL RES, V232, P29, DOI 10.1006/excr.1997.3482; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083; ZHONG Z, 1992, MOL CELL BIOL, V12, P4834, DOI 10.1128/MCB.12.11.4834	69	17	17	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 2	2003	22	43					6690	6698		10.1038/sj.onc.1206745	http://dx.doi.org/10.1038/sj.onc.1206745			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	729XA	14555982				2022-12-17	WOS:000185799300004
J	Chen, SJ; Paul, P; Price, BD				Chen, SJ; Paul, P; Price, BD			ATM's leucine-rich domain and adjacent sequences are essential for ATM to regulate the DNA damage response	ONCOGENE			English	Article						leucine zipper; ATM; kinase; radiosensitivity; ataxia telangiectasia	ATAXIA-TELANGIECTASIA GENE; S-PHASE CHECKPOINT; FUNCTIONAL-LINK; BREAST-CANCER; DEPENDENT PHOSPHORYLATION; TRANSCRIPTIONAL ACTIVITY; MISSENSE MUTATIONS; ALLELIC VARIANTS; P53; RADIATION	The ATM protein kinase regulates the DNA damage response by phosphorylating proteins involved in cell cycle checkpoints and DNA repair. We report here on the function of the predicted leucine zipper (LZ) motif, and sequences adjacent to this, in regulating ATM activity. The predicted LZ sequence was deleted from ATM, generating ATMDeltaLZ, and expressed in an ATM-negative AT cell line. ATM increased cell survival following exposure to ionizing radiation, whereas expression of ATMDeltaLZ failed to increase cell survival. ATMDeltaLZ retained in vitro kinase activity, but was unable to phosphorylate p53 in vivo. Leucine zippers mediate homo- and heterodimerization of proteins. However, the predicted LZ of ATM did not mediate the formation of ATM dimers. We examined if the predicted LZ of ATM was a dominant-negative inhibitor of ATM function in SW480 cells. Expression of amino acids 769-1436 of ATM, including the predicted LZ, sensitized SW480 cells to ionizing radiation, but did not inhibit ATM's kinase activity or its ability to phosphorylate Brca1. Further, this dominant-negative activity was not dependent on the predicted LZ domain. The central region of the ATM protein therefore contains multiple sequences which regulate cell survival following DNA damage.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Price, BD (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Radiat Oncol, 44 Binney St,JF513, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [R01CA093602, R01CA064585] Funding Source: NIH RePORTER; NCI NIH HHS [CA93602, CA64585] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Beamish H, 2002, J BIOL CHEM, V277, P30515, DOI 10.1074/jbc.M203801200; Beamish H, 1996, J BIOL CHEM, V271, P20486, DOI 10.1074/jbc.271.34.20486; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Bosotti R, 2000, TRENDS BIOCHEM SCI, V25, P225, DOI 10.1016/S0968-0004(00)01563-2; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chenevix-Trench G, 2002, JNCI-J NATL CANCER I, V94, P205, DOI 10.1093/jnci/94.3.205; CORNFORTH MN, 1985, SCIENCE, V227, P1589, DOI 10.1126/science.3975628; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Gatei M, 2000, CANCER RES, V60, P3299; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Groves MR, 1999, CURR OPIN STRUC BIOL, V9, P383, DOI 10.1016/S0959-440X(99)80052-9; Hess RD, 1997, ONCOGENE, V15, P2501, DOI 10.1038/sj.onc.1201404; Izatt L, 1999, GENE CHROMOSOME CANC, V26, P286, DOI 10.1002/(SICI)1098-2264(199912)26:4<286::AID-GCC2>3.0.CO;2-X; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kastan MB, 2001, ACTA ONCOL, V40, P686; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Kim ST, 2002, GENE DEV, V16, P560, DOI 10.1101/gad.970602; Kishi S, 2001, J BIOL CHEM, V276, P29282, DOI 10.1074/jbc.M011534200; Kohli M, 1999, BIOCHEM BIOPH RES CO, V257, P168, DOI 10.1006/bbrc.1999.0389; Li S, 2000, NATURE, V406, P210, DOI 10.1038/35018134; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Luo CM, 1996, J BIOL CHEM, V271, P4497; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Meyn MS, 1999, CLIN GENET, V55, P289, DOI 10.1034/j.1399-0004.1999.550501.x; MEYN MS, 1993, SCIENCE, V260, P1327, DOI 10.1126/science.8493577; Morgan SE, 1997, MOL CELL BIOL, V17, P2020, DOI 10.1128/MCB.17.4.2020; Pecker I, 1996, GENOMICS, V35, P39, DOI 10.1006/geno.1996.0320; Price BD, 1996, CANCER RES, V56, P246; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; Scott SP, 2002, P NATL ACAD SCI USA, V99, P925, DOI 10.1073/pnas.012329699; Taniguchi T, 2002, CELL, V109, P459, DOI 10.1016/S0092-8674(02)00747-X; TAYLOR AMR, 1975, NATURE, V258, P427, DOI 10.1038/258427a0; Turenne GA, 2001, ONCOGENE, V20, P5100, DOI 10.1038/sj.onc.1204665; Turenne GA, 2001, BMC CELL BIOL, V2, DOI 10.1186/1471-2121-2-12; Wang Y, 2000, GENE DEV, V14, P927; Yavuzer U, 1998, GENE DEV, V12, P2188, DOI 10.1101/gad.12.14.2188; Yazdi PT, 2002, GENE DEV, V16, P571, DOI 10.1101/gad.970702; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083	39	17	18	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 25	2003	22	41					6332	6339		10.1038/sj.onc.1206760	http://dx.doi.org/10.1038/sj.onc.1206760			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	725GK	14508513				2022-12-17	WOS:000185535300003
J	Xu, QY; Karouji, Y; Kobayashi, M; Ihara, S; Konishi, H; Fukui, Y				Xu, QY; Karouji, Y; Kobayashi, M; Ihara, S; Konishi, H; Fukui, Y			The PI 3-kinase-Rac-p38 MAP kinase pathway is involved in the formation of signet-ring cell carcinoma	ONCOGENE			English	Article						PI3-kinase; signet-ring cell carcinoma; cell-cell contact; p38 MAP kinase; MUC1	ACTIVATED PROTEIN-KINASE; SIGNALING PATHWAY; EXPRESSION; ADHESION; STRESS; FAMILY; PHOSPHORYLATION; IDENTIFICATION; DOWNSTREAM; DYNAMICS	Signet-ring cell carcinoma is classified in poorly differentiated adenocarcinoma with an aggressive nature and a poor prognosis. We have shown that the activation of PI 3-kinase in highly differentiated adenocarcinomas induces loss of cell-cell contact and formation of vacuoles, giving phenotypes similar to those of signet-ring cell lines. SB203580, a potent p38 MAP kinase inhibitor, blocked this transition, and expression of an active form of MKK6 (MKK6DA), an activator of p38 MAP kinase, gave effects similar to those induced by expression of the active form of PI 3-kinase (BD110), although formation of large vacuoles was not induced. Activation of MKK3, another activator of p38 MAP kinase, was activated in native signet-ring carcinoma cell lines. Anchorage-independent growth of signet-ring cell lines was inhibited by LY294002 or SB203580. These results suggest that p38 MAP kinase is functioning downstream of PI 3-kinase in signaling of the malignant phenotype. Secretion of mucins was enhanced in BD110-expressing cells, but not in MKK6DA-expressing cells, suggesting that secretion of mucins is independent of the MKK6-p38 MAP kinase cascade. Thus, there may be at least two pathways, p38 MAP kinase-dependent and -independent, which are involved in regulation of cell-cell contact and the protein secretion system, respectively.	Univ Tokyo, Fac Agr & Life Sci, Grad Sch Agr & Life Sci, Dept Appl Biol Chem,Lab Biol Chem,Bunkyo Ku, Tokyo 1138657, Japan	University of Tokyo	Fukui, Y (corresponding author), Univ Tokyo, Fac Agr & Life Sci, Grad Sch Agr & Life Sci, Dept Appl Biol Chem,Lab Biol Chem,Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1138657, Japan.	ayfukui@mail.ecc.u-tokyo.ac.jp	Fukui, Yasuhisa/E-8806-2010					AKIYAMA S, 1988, JPN J SURG, V18, P438, DOI 10.1007/BF02471470; Braga V, 2000, EXP CELL RES, V261, P83, DOI 10.1006/excr.2000.5050; Cassimeris L, 2002, CURR OPIN CELL BIOL, V14, P18, DOI 10.1016/S0955-0674(01)00289-7; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Desprez PY, 1998, MOL CELL BIOL, V18, P4577, DOI 10.1128/MCB.18.8.4577; DUANE GB, 1985, ACTA CYTOL, V29, P211; Fronsdal K, 2000, PROSTATE, V43, P111, DOI 10.1002/(SICI)1097-0045(20000501)43:2<111::AID-PROS5>3.0.CO;2-4; Gavet O, 1998, J CELL SCI, V111, P3333; Gimmi CD, 1996, NAT MED, V2, P1367, DOI 10.1038/nm1296-1367; Guay J, 1997, J CELL SCI, V110, P357; Hilkens J, 1995, BIOCHEM SOC T, V23, P822, DOI 10.1042/bst0230822; Jamora C, 2002, NAT CELL BIOL, V4, pE101, DOI 10.1038/ncb0402-e101; Kameda H, 2001, MOL CELL BIOL, V21, P6895, DOI 10.1128/MCB.21.20.6895-6905.2001; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; Kita Y, 1998, J CELL SCI, V111, P907; Kobayashi M, 1999, P NATL ACAD SCI USA, V96, P4874, DOI 10.1073/pnas.96.9.4874; Kobayashi M, 2003, ONCOGENE, V22, P1294, DOI 10.1038/sj.onc.1206256; KUFE D, 1984, HYBRIDOMA, V3, P223, DOI 10.1089/hyb.1984.3.223; Kuroda S, 1996, J BIOL CHEM, V271, P23363, DOI 10.1074/jbc.271.38.23363; Laffargue M, 1999, J BIOL CHEM, V274, P32835, DOI 10.1074/jbc.274.46.32835; Landry J, 1995, BIOCHEM CELL BIOL, V73, P703, DOI 10.1139/o95-078; Maeno Y, 1999, AM J PATHOL, V154, P1323, DOI 10.1016/S0002-9440(10)65385-0; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; ODA T, 1994, P NATL ACAD SCI USA, V91, P1858, DOI 10.1073/pnas.91.5.1858; Parker CG, 1998, BIOCHEM BIOPH RES CO, V249, P791, DOI 10.1006/bbrc.1998.9250; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Tahara E, 1989, Gan To Kagaku Ryoho, V16, P2149; vom Dahl S, 2001, BIOCHEM J, V354, P31, DOI 10.1042/0264-6021:3540031; Yamada KM, 1997, CURR OPIN CELL BIOL, V9, P76, DOI 10.1016/S0955-0674(97)80155-X; YAMAMOTO R, 1990, VIRCHOWS ARCH B, V59, P26, DOI 10.1007/BF02899383; Yonezawa S, 1997, PATHOL INT, V47, P813, DOI 10.1111/j.1440-1827.1997.tb03713.x; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	36	17	18	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2003	22	36					5537	5544		10.1038/sj.onc.1206796	http://dx.doi.org/10.1038/sj.onc.1206796			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	713NY	12944900				2022-12-17	WOS:000184865900001
J	Gutmann, DH; Winkeler, E; Kabbarah, O; Hedrick, N; Dudley, S; Goodfellow, PJ; Liskay, RM				Gutmann, DH; Winkeler, E; Kabbarah, O; Hedrick, N; Dudley, S; Goodfellow, PJ; Liskay, RM			Mlh1 deficiency accelerates myeloid leukemogenesis in neurofibromatosis 1 (Nf1) heterozygous mice	ONCOGENE			English	Article						tumor suppressor gene; mismatch repair; leukemia; neurofibromin	DNA MISMATCH REPAIR; JUVENILE MYELOMONOCYTIC LEUKEMIA; ENDOMETRIAL TUMORIGENESIS; HEMATOLOGICAL MALIGNANCY; BONE-MARROW; GENE; TYPE-1; CHILDREN; CELL; MUTATION	Defects in DNA mismatch repair (MMR) have been implicated in the genesis of a diverse set of human cancers. Recent studies have suggested that one of the targets of MMR is the neurofibromatosis 1 (NF1) gene. To evaluate the contribution of Mlh1 MMR deficiency to Nf1 tumorigenesis, Mlh1 - / -; Nfl + / - mice were generated. All Mlh1 - / -; Nfl +/- mice (n = 21) were dead by 260 days compared to none of the Nf1 + / - mice. In all, 50% of the Mlh1 - / -; Nfl +/- mice were dead at 150 days compared to 252 days for Mlh1 - / - mice. Nine of the Mlh1 - / -; Nf1 + / - mice were found to harbor intrathoracic NOS2-immunoreactive myeloid leukemias similar to the hematopoietic malignancies observed in older Nfl + / - mice. As expected, significant microsatellite instability was observed in six of six tumors and neurofibromin expression was lost in all tumors analysed. These results suggest that MMR deficiency can accelerate myeloid leukemogenesis in Nfl + / - mice, presumably by inactivating Nf1 gene expression.	Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA; Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA	Washington University (WUSTL); Washington University (WUSTL); Oregon Health & Science University	Gutmann, DH (corresponding author), Washington Univ, Sch Med, Dept Neurol, Box 8111,660 S Euclid Ave, St Louis, MO 63110 USA.		Dudley, Samuel C/A-7085-2009	Gutmann, David/0000-0002-3127-5045	NIGMS NIH HHS [R37 GM32741] Funding Source: Medline; NINDS NIH HHS [NS36996] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM032741] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036996] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Birnbaum RA, 2000, MOL CELL, V5, P189, DOI 10.1016/S1097-2765(00)80415-3; Boland CR, 1998, CANCER RES, V58, P5248; Buermeyer AB, 1999, CANCER RES, V59, P538; Cohn DE, 2001, GENE CHROMOSOME CANC, V32, P295, DOI 10.1002/gcc.1194; Cooper LJN, 2000, BLOOD, V96, P2310; Edelmann W, 1999, CANCER RES, V59, P1301; Gutmann DH, 1997, JAMA-J AM MED ASSOC, V278, P51, DOI 10.1001/jama.278.1.51; Gutmann DH, 2000, NEUROPATH APPL NEURO, V26, P361, DOI 10.1046/j.1365-2990.2000.00258.x; Heinen CD, 2002, CANCER BIOL THER, V1, P477, DOI 10.4161/cbt.1.5.160; Ingram DA, 2002, BLOOD, V100, P3656, DOI 10.1182/blood-2002-03-0734; Ingram DA, 2001, J EXP MED, V194, P57, DOI 10.1084/jem.194.1.57; JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794-353; Kim TJ, 2002, MOL IMMUNOL, V38, P701, DOI 10.1016/S0161-5890(01)00101-8; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; Kowalski LD, 1997, GENE CHROMOSOME CANC, V18, P219, DOI 10.1002/(SICI)1098-2264(199703)18:3<219::AID-GCC8>3.0.CO;2-4; Li Y, 1996, CANCER RES, V56, P2872; Mahgoub N, 1999, BLOOD, V93, P3617, DOI 10.1182/blood.V93.11.3617.411a49_3617_3623; Maris JM, 1997, CANCER-AM CANCER SOC, V79, P1438, DOI 10.1002/(SICI)1097-0142(19970401)79:7<1438::AID-CNCR22>3.3.CO;2-A; Prolla TA, 1998, NAT GENET, V18, P276, DOI 10.1038/ng0398-276; Ricciardone MD, 1999, CANCER RES, V59, P290; Shannon KM, 2001, SEMIN CANCER BIOL, V11, P191, DOI 10.1006/scbi.2001.0372; SHANNON KM, 1994, NEW ENGL J MED, V330, P597, DOI 10.1056/NEJM199403033300903; Shoemaker AR, 2000, ONCOGENE, V19, P2774, DOI 10.1038/sj.onc.1203574; Side L, 1997, NEW ENGL J MED, V336, P1713, DOI 10.1056/NEJM199706123362404; Side LE, 1998, BLOOD, V92, P267, DOI 10.1182/blood.V92.1.267.413a31_267_272; STILLER CA, 1994, BRIT J CANCER, V70, P969, DOI 10.1038/bjc.1994.431; Wang H, 2002, AM J PATHOL, V160, P1481, DOI 10.1016/S0002-9440(10)62573-4; Wang Q, 1999, CANCER RES, V59, P294; Wang Q, 2003, HUM GENET, V112, P117, DOI 10.1007/s00439-002-0858-4; Whiteside D, 2002, CANCER RES, V62, P359; Yao X, 1999, P NATL ACAD SCI USA, V96, P6850, DOI 10.1073/pnas.96.12.6850	31	17	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 17	2003	22	29					4581	4585		10.1038/sj.onc.1206768	http://dx.doi.org/10.1038/sj.onc.1206768			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	699JX	12881715				2022-12-17	WOS:000184054700014
J	Chinwalla, V; Chien, A; Odero, M; Neilly, MB; Zeleznik-Le, NJ; Rowley, JD				Chinwalla, V; Chien, A; Odero, M; Neilly, MB; Zeleznik-Le, NJ; Rowley, JD			A t(11;15) fuses MLL to two different genes, AF15q14 and a novel gene MPFYVE on chromosome 15	ONCOGENE			English	Article						t(11;15)(q23;ql5); MLL; AF15q14; MPFYVE; FYVE domain; leukemia	ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOID LEUKEMIAS; DROSOPHILA-TRITHORAX; 11Q23 TRANSLOCATIONS; FYVE-FINGER; REARRANGEMENTS; TRANSCRIPTS; BINDING; LEUKEMOGENESIS; DUPLICATION	The mixed lineage leukemia gene (MLL, also known as HRX, ALL-1 and Htrx) located at 11q23 is involved in translocations with over 40 different chromosomal bands in a variety of leukemia subtypes. Here we report our analysis of a rare but recurring translocation, t(11;15)(q23;q14). This translocation has been described in a small subset of cases with both acute myeloblastic leukemia and ALL. Recent studies have shown that MLL is fused to AF15q14 in the t(11;15). Here we analyse a sample from another patient with this translocation and confirm the presence of an MLL-AF15q14 fusion. However, we have also identified and cloned another fusion transcript from the same patient sample. In this fusion transcript, MLL is fused to a novel gene, MLL partner containing FYVE domain (MPFYVE). Both MLL-AF15q14 and MLL-MPFYVE are in-frame fusion transcripts with the potential to code for novel fusion proteins. MPFYVE is also located on chromosome 15, approximately 170kb telomeric to AF15q14. MPFYVE contains a highly conserved motif, the FYVE domain which, in other proteins, has been shown to bind to phosphotidyl-inositol-3 phosphate (PtdIns(3)P). The MLL-MPFYVE fusion may be functionally important in the leukemia process in at least some patients containing this translocation.	Univ Chicago, Dept Med, Hematol Oncol Sect, Chicago, IL 60637 USA	University of Chicago	Rowley, JD (corresponding author), Univ Chicago, Dept Med, Hematol Oncol Sect, Chicago, IL 60637 USA.		Odero/ABG-9860-2020	Odero/0000-0002-8858-2054	NCI NIH HHS [CA 84405, CA42557, CA78438, CA40046, T32 CA09595] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA084405, R29CA078438, R35CA042557, T32CA009595] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; Ayton PM, 2001, ONCOGENE, V20, P5695, DOI 10.1038/sj.onc.1204639; BERNARD OA, 1995, GENE CHROMOSOME CANC, V13, P75, DOI 10.1002/gcc.2870130202; BREEN TR, 1993, DEVELOPMENT, V117, P119; Burd CG, 1998, MOL CELL, V2, P157, DOI 10.1016/S1097-2765(00)80125-2; Caldas C, 1998, GENE, V208, P167, DOI 10.1016/S0378-1119(97)00640-9; DiMartino JF, 1999, BRIT J HAEMATOL, V106, P614, DOI 10.1046/j.1365-2141.1999.01439.x; Divoky V, 2000, GENE, V247, P111, DOI 10.1016/S0378-1119(00)00111-6; Gaullier JM, 1998, NATURE, V394, P432, DOI 10.1038/28767; GIBBONS B, 1990, BRIT J HAEMATOL, V74, P264, DOI 10.1111/j.1365-2141.1990.tb02581.x; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Hanson RD, 1999, P NATL ACAD SCI USA, V96, P14372, DOI 10.1073/pnas.96.25.14372; Hayette S, 2000, ONCOGENE, V19, P4446, DOI 10.1038/sj.onc.1203789; HERNANDEZ JM, 1995, LEUKEMIA, V9, P1162; Hillion J, 1997, BLOOD, V90, P3714, DOI 10.1182/blood.V90.9.3714; HUNGER SP, 1993, BLOOD, V81, P3197; KANEKO Y, 1988, LEUKEMIA, V2, P672; KUEFER MU, 1997, BLOOD S, V90, P1235; Lavau C, 2000, P NATL ACAD SCI USA, V97, P10984, DOI 10.1073/pnas.190167297; Lavau C, 2000, EMBO J, V19, P4655, DOI 10.1093/emboj/19.17.4655; Lavau C, 1997, EMBO J, V16, P4226, DOI 10.1093/emboj/16.14.4226; MARTINEZCLIMENT JA, 1995, LEUKEMIA, V9, P1299; Nilson I, 1996, BRIT J HAEMATOL, V93, P966, DOI 10.1046/j.1365-2141.1996.d01-1748.x; NUCIFORA G, 1994, P NATL ACAD SCI USA, V91, P4004, DOI 10.1073/pnas.91.9.4004; Patki V, 1998, NATURE, V394, P433, DOI 10.1038/28771; RAIMONDI SC, 1989, BLOOD, V73, P1627; Rowley JD, 1999, SEMIN HEMATOL, V36, P59; ROWLEY JD, 1993, SEMIN CANCER BIOL, V4, P377; RUBNITZ JE, 1994, BLOOD, V84, P570; SCHWABE JWR, 1994, NAT STRUCT BIOL, V1, P345, DOI 10.1038/nsb0694-345; Stenmark H, 1999, J CELL SCI, V112, P4175; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; THIRMAN MJ, 1993, NEW ENGL J MED, V329, P909, DOI 10.1056/NEJM199309233291302; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; Waring PM, 1997, CURR TOP MICROBIOL, V220, P1; Whitman SP, 2001, CANCER RES, V61, P59; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0; ZELEZNIKLE NJ, 1994, P NATL ACAD SCI USA, V91, P10610, DOI 10.1073/pnas.91.22.10610	38	17	21	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 6	2003	22	9					1400	1410		10.1038/sj.onc.1206273	http://dx.doi.org/10.1038/sj.onc.1206273			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652CA	12618766	Green Published			2022-12-17	WOS:000181360900015
J	Mac Partlin, M; Homer, E; Robinson, H; McCormick, CJ; Crouch, DH; Durant, ST; Matheson, EC; Hall, AG; Gillespie, DAF; Brown, R				Mac Partlin, M; Homer, E; Robinson, H; McCormick, CJ; Crouch, DH; Durant, ST; Matheson, EC; Hall, AG; Gillespie, DAF; Brown, R			Interactions of the DNA mismatch repair proteins MLH1 and MSH2 with c-MYC and MAX	ONCOGENE			English	Article						DNA mismatch repair; MYC; MAX; mutator phenotype; protein interactions	CELL-CYCLE; GENOMIC INSTABILITY; NUCLEAR EXTRACTS; APOPTOSIS; BINDING; DAMAGE; LINES; ALPHA; PCNA; DIFFERENTIATION	MSH2 and MLH1 have a central role in correcting mismatches in DNA occurring during DNA replication and have been implicated in the engagement of apoptosis induced by a number of cytotoxic anticancer agents. The function of MLH1 is not clearly defined, although it is required for mismatch repair (MMR) and engagement of apoptosis after certain types of DNA damage. In order to identify other partners of MLH1 that may be involved in signalling MMR or apoptosis, we used human MLH1 in yeast two-hybrid screens of normal human breast and ovarian cDNA libraries. As well as known partners of MLH1 such as PMS1, MLH3 and MBD4, we identified the carboxy terminus of the human c-MYC protooncogene as an interacting sequence. We demonstrate, both in vitro by yeast two-hybrid and GST-fusion pull-down experiments, as well as in vivo by coimmunoprecipitation from human tumour cell extracts, that MLH1 interacts with the c-MYC protein. We further demonstrate that the heterodimeric partner of c-MYC, MAX, interacts with a different MMR protein, MSH2, both in vitro and in vivo. Using an inducible c-MYC-ER(TM) fusion gene, we show that elevated c-MYC expression leads to an increased HGPRT mutation rate of Rat1 cells and an increase in the number of frameshift mutants at the HGPRT locus. The effect on HGPRT mutation rate is small (2-3-fold), but is consistent with deregulated c-MYC expression partially inhibiting MMR activity.	Univ Glasgow, Dept Med Oncol, Canc Res UK, Beatson Labs, Glasgow G61 1BD, Lanark, Scotland; Univ Newcastle Upon Tyne, Sch Med, Leukaemia Res Grp, Canc Res Unit, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Dundee DD1 9SY, Scotland	Beatson Institute; Cancer Research UK; University of Glasgow; Newcastle University - UK; University of Dundee	Brown, R (corresponding author), Univ Glasgow, Dept Med Oncol, Canc Res UK, Beatson Labs, Garscube Estate,Swichback Rd, Glasgow G61 1BD, Lanark, Scotland.		Gillespie, David/R-4771-2019; Hall, Andy/AAD-8622-2020; Hall, Andrew G/B-3485-2009	Gillespie, David/0000-0002-6338-0544; Brown, Robert/0000-0001-7960-5755				Adachi S, 2001, MOL CELL BIOL, V21, P4929, DOI 10.1128/MCB.21.15.4929-4937.2001; Bellacosa A, 1999, P NATL ACAD SCI USA, V96, P3969, DOI 10.1073/pnas.96.7.3969; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; Blackwood EM, 1992, CURR OPIN GENET DEV, V2, P227, DOI 10.1016/S0959-437X(05)80278-3; Bowers J, 2001, J MOL BIOL, V306, P957, DOI 10.1006/jmbi.2001.4467; Claij N, 2002, ONCOGENE, V21, P2873, DOI 10.1038/sj.onc.1205395; Cole MD, 1999, ONCOGENE, V18, P2916, DOI 10.1038/sj.onc.1202748; Colussi C, 2002, CURR BIOL, V12, P912, DOI 10.1016/S0960-9822(02)00863-1; CROUCH DH, 1993, ONCOGENE, V8, P1849; Drummond JT, 1996, J BIOL CHEM, V271, P19645, DOI 10.1074/jbc.271.33.19645; Duckett DR, 1996, P NATL ACAD SCI USA, V93, P6443, DOI 10.1073/pnas.93.13.6443; Duckett DR, 1999, P NATL ACAD SCI USA, V96, P12384, DOI 10.1073/pnas.96.22.12384; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; Gu LY, 1998, NUCLEIC ACIDS RES, V26, P1173, DOI 10.1093/nar/26.5.1173; Guerrette S, 1999, J BIOL CHEM, V274, P6336, DOI 10.1074/jbc.274.10.6336; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; Hardman RA, 2001, CANCER RES, V61, P1392; HAWN MT, 1995, CANCER RES, V55, P3721; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; Jiricny J, 1998, EMBO J, V17, P6427, DOI 10.1093/emboj/17.22.6427; Karran P, 1996, CANCER SURV, V28, P69; Kondo E, 2001, NUCLEIC ACIDS RES, V29, P1695, DOI 10.1093/nar/29.8.1695; Kuismanen SA, 2000, AM J PATHOL, V156, P1773, DOI 10.1016/S0002-9440(10)65048-1; LAROCCA SA, 1994, ONCOGENE, V9, P3499; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Luria SE, 1943, GENETICS, V28, P491; Mai S, 1996, ONCOGENE, V12, P277; Matton N, 2000, J BIOL CHEM, V275, P17808, DOI 10.1074/jbc.M909794199; Modrich P, 1997, J BIOL CHEM, V272, P24727, DOI 10.1074/jbc.272.40.24727; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Moreland NJ, 1999, CANCER RES, V59, P2102; Obaya AJ, 1999, ONCOGENE, V18, P2934, DOI 10.1038/sj.onc.1202749; Oliver S, 2000, NATURE, V403, P601, DOI 10.1038/35001165; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; Raschle M, 1999, J BIOL CHEM, V274, P32368, DOI 10.1074/jbc.274.45.32368; Rockwood LD, 2002, ONCOGENE, V21, P7235, DOI 10.1038/sj.onc.1205697; Schreiber-Agus N, 1998, BIOESSAYS, V20, P808, DOI 10.1002/(SICI)1521-1878(199810)20:10<808::AID-BIES6>3.0.CO;2-U; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Strathdee G, 2001, ONCOGENE, V20, P1923, DOI 10.1038/sj.onc.1204276; Toft NJ, 1999, P NATL ACAD SCI USA, V96, P3911, DOI 10.1073/pnas.96.7.3911; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; Yamada M, 1997, NUCLEIC ACIDS RES, V25, P491, DOI 10.1093/nar/25.3.491	45	17	19	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 13	2003	22	6					819	825		10.1038/sj.onc.1206252	http://dx.doi.org/10.1038/sj.onc.1206252			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	643MD	12584560				2022-12-17	WOS:000180864300003
J	Heisterkamp, N; Groffen, J				Heisterkamp, N; Groffen, J			Philadelphia-positive leukemia: a personal perspective	ONCOGENE			English	Article						BCR/ABL; leukemia; BCR; ABL; Crkl; somatic cell hybrids	CHRONIC MYELOGENOUS LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; C-ABL ONCOGENE; CHRONIC MYELOCYTIC-LEUKEMIA; TRANSFERASE INHIBITOR SCH66336; CHRONIC MYELOID-LEUKEMIA; ALTERED TRANSCRIPTION; TRANSGENIC MICE; KINASE-ACTIVITY; GENE-PRODUCT		Childrens Hosp Los Angeles, Res Inst, Div Hematol Oncol, Sect Mol Cacinogenesis, Los Angeles, CA 90027 USA; Univ So Calif, Keck Sch Med, Los Angeles, CA 90027 USA	Children's Hospital Los Angeles; University of Southern California	Heisterkamp, N (corresponding author), Childrens Hosp Los Angeles, Res Inst, Div Hematol Oncol, Sect Mol Cacinogenesis, Ms 54, Los Angeles, CA 90027 USA.		Heisterkamp, Nora/C-1698-2012	Heisterkamp, Nora/0000-0003-2769-2273	NCI NIH HHS [CA50248, CA90321] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090321, R01CA050248] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARTRAM CR, 1983, NATURE, V306, P277, DOI 10.1038/306277a0; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; CANAANI E, 1984, LANCET, V1, P593; CHAN LC, 1987, NATURE, V325, P635, DOI 10.1038/325635a0; CHISSOE SL, 1995, GENOMICS, V27, P67, DOI 10.1006/geno.1995.1008; COLLINS SJ, 1984, SCIENCE, V225, P72, DOI 10.1126/science.6587568; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; DEKLEIN A, 1986, BLOOD, V68, P1369; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; ERIKSON J, 1986, P NATL ACAD SCI USA, V83, P1807, DOI 10.1073/pnas.83.6.1807; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; FREED E, 1992, MOL CELL BIOL, V12, P1312, DOI 10.1128/MCB.12.3.1312; GALE RP, 1984, P NATL ACAD SCI-BIOL, V81, P5648, DOI 10.1073/pnas.81.18.5648; Goldman J, 2001, SEMIN HEMATOL, V38, P28, DOI 10.1053/shem.2001.27081; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; GROFFEN J, 1982, SCIENCE, V216, P1136, DOI 10.1126/science.6281890; GROFFEN J, 1983, NATURE, V304, P167, DOI 10.1038/304167a0; HARIHARAN IK, 1989, MOL CELL BIOL, V9, P2798, DOI 10.1128/MCB.9.7.2798; HEISTERKAMP N, 1982, NATURE, V299, P747, DOI 10.1038/299747a0; HEISTERKAMP N, 1983, Journal of Molecular and Applied Genetics, V2, P57; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; HEISTERKAMP N, 1983, VIROLOGY, V126, P248, DOI 10.1016/0042-6822(83)90476-2; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; HEISTERKAMP N, 1988, NUCLEIC ACIDS RES, V16, P10069, DOI 10.1093/nar/16.21.10069; Hemmeryckx B, 2002, ONCOGENE, V21, P3225, DOI 10.1038/sj.onc.1205452; HERMANS A, 1987, CELL, V51, P33, DOI 10.1016/0092-8674(87)90007-9; Kardinal C, 2000, FASEB J, V14, P1529, DOI 10.1096/fj.14.11.1529; KLOETZER W, 1985, VIROLOGY, V140, P230, DOI 10.1016/0042-6822(85)90361-7; KOH EY, 2001, CHRONIC MYELOID LEUK, P55; KONOPKA JB, 1985, P NATL ACAD SCI USA, V82, P1810, DOI 10.1073/pnas.82.6.1810; Mauro MJ, 2002, J CLIN ONCOL, V20, P325, DOI 10.1200/JCO.20.1.325; MESMASSON AM, 1986, P NATL ACAD SCI USA, V83, P9768, DOI 10.1073/pnas.83.24.9768; NOWELL PC, 1960, SCIENCE, V132, P1497; PENDERGAST AM, 1993, MOL CELL BIOL, V13, P1728, DOI 10.1128/MCB.13.3.1728; Peters DG, 2001, BLOOD, V97, P1404, DOI 10.1182/blood.V97.5.1404; Reichert A, 2001, BLOOD, V97, P1399, DOI 10.1182/blood.V97.5.1399; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; STAM K, 1987, MOL CELL BIOL, V7, P1955, DOI 10.1128/MCB.7.5.1955; STAM K, 1985, NEW ENGL J MED, V313, P1429, DOI 10.1056/NEJM198512053132301; Tari AM, 1997, BIOCHEM BIOPH RES CO, V235, P383, DOI 10.1006/bbrc.1997.6791; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837	43	17	18	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 9	2002	21	56					8536	8540		10.1038/sj.onc.1206080	http://dx.doi.org/10.1038/sj.onc.1206080			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZF	12476299				2022-12-17	WOS:000179734300002
J	Bild, AH; Mendoza, FJ; Gibson, EM; Huang, M; Villanueva, J; Garrington, TP; Jove, R; Johnson, GL; Gibson, SB				Bild, AH; Mendoza, FJ; Gibson, EM; Huang, M; Villanueva, J; Garrington, TP; Jove, R; Johnson, GL; Gibson, SB			MEKK1-induced apoptosis requires TRAIL death receptor activation and is inhibited by AKT/PKB through inhibition of MEKK1 cleavage	ONCOGENE			English	Article						apoptosis; serine threonine kinases; signal transduction; death receptors; caspases; MAPK	FAS LIGAND EXPRESSION; DECOY RECEPTORS; PROTEIN-KINASE; CANCER-CELLS; MUTATIONS; GENES; INVOLVEMENT; RESISTANCE; INDUCTION; CASPASES	MEK kinase 1 (MEKK1) induces apoptosis through the activation of caspases. The mechanism for MEKK1-induced apoptosis involves caspase-mediated cleavage of MEKK1, releasing a pro-apoptotic 91 kDa kinase fragment that serves to further amplify caspase activation in a feedback loop. Both cleavage of MEKK1 and increased expression of death receptor 4 (DR4, TRAILR1) and death receptor 5 (DR5, TRAILR2) occur following exposure of cells to genotoxins. Overexpression of kinase inactive MEKK1 inhibits MEKK1-mediated apoptosis and effectively blocks death receptor upregulation following etoposide treatment. Herein, we investigate the role of death receptor activation and the ability of AKT/PKB (AKT) to inhibit cell death in MEKK1-induced apoptosis. We show that by preventing DR4 and DR5 activation through expression of decoy receptor 1 (DcR1) and dominant negative FADD, we inhibit MEKK1-induced apoptosis. Furthermore, expression of 91 kDa MEKK1 increased DR4 and FAS mRNA and protein levels. MEKK1-induced apoptosis is amplified by blocking PI-3 kinase activation and overexpression of AKT blocked both MEKK1-induced apoptosis and caspase activation. AKT overexpression also prevented the cleavage of endogenous MEKK1 by genotoxins. AKT did not, however, block MEKK1-induced JNK activation, showing that regulation of the JNK pathway by MEKK1 is independent of its role in regulation of apoptosis. Thus, MEKK1-induced apoptosis requires TRAIL death receptor activation and is blocked by AKT through inhibition of MEKK1 cleavage.	Univ Manitoba, Manitoba Inst Cell Biol, Winnipeg, MB R3E 0V9, Canada; Univ Colorado, Dept Pharmacol, Denver, CO 80262 USA; H Lee Moffit Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA	University of Manitoba; University of Colorado System; University of Colorado Denver	Gibson, SB (corresponding author), Univ Manitoba, Manitoba Inst Cell Biol, 675 McDermot Ave, Winnipeg, MB R3E 0V9, Canada.			Gibson, Spencer/0000-0003-0119-732X				Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Asselin E, 2001, CANCER RES, V61, P1862; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Deak JC, 1998, P NATL ACAD SCI USA, V95, P5595, DOI 10.1073/pnas.95.10.5595; Di Cristofano A, 1999, SCIENCE, V285, P2122, DOI 10.1126/science.285.5436.2122; Faris M, 1998, J IMMUNOL, V160, P134; Faris M, 1998, MOL CELL BIOL, V18, P5414, DOI 10.1128/MCB.18.9.5414; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Gebauer G, 2000, INT J ONCOL, V16, P321; Gibson S, 1999, J BIOL CHEM, V274, P10916, DOI 10.1074/jbc.274.16.10916; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; GOLSTEIN P, 1997, CURR BIOL, V7, P750; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Griffith TS, 1998, CURR OPIN IMMUNOL, V10, P559, DOI 10.1016/S0952-7915(98)80224-0; Gura T, 1997, SCIENCE, V277, P768, DOI 10.1126/science.277.5327.768; Khwaja A, 1999, NATURE, V401, P33, DOI 10.1038/43354; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Lee SH, 2001, ONCOGENE, V20, P399, DOI 10.1038/sj.onc.1204103; Lin H, 2001, BIOCHEM J, V353, P299, DOI 10.1042/0264-6021:3530299; Mullauer L, 2001, MUTAT RES-REV MUTAT, V488, P211, DOI 10.1016/S1383-5742(01)00057-6; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Panka DJ, 2001, J BIOL CHEM, V276, P6893, DOI 10.1074/jbc.C000569200; Schlesinger Thomas K., 1998, Frontiers in Bioscience, V3, pD1181; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Shin MS, 2001, CANCER RES, V61, P4942; Soh JW, 2001, J BIOL CHEM, V276, P16406, DOI 10.1074/jbc.C100079200; Straus SE, 2001, BLOOD, V98, P194, DOI 10.1182/blood.V98.1.194; Tran J, 1999, BIOCHEM BIOPH RES CO, V264, P781, DOI 10.1006/bbrc.1999.1589; Tschopp J, 1998, CURR OPIN IMMUNOL, V10, P552, DOI 10.1016/S0952-7915(98)80223-9; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Widmann C, 1997, ONCOGENE, V15, P2439, DOI 10.1038/sj.onc.1201421; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911	36	17	18	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 26	2002	21	43					6649	6656		10.1038/sj.onc.1205819	http://dx.doi.org/10.1038/sj.onc.1205819			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	597BM	12242663				2022-12-17	WOS:000178202300011
J	Pucci, B; Claudio, PP; Masciullo, V; Bellincampi, L; Terrinoni, A; Khalili, K; Melino, G; Giordano, A				Pucci, B; Claudio, PP; Masciullo, V; Bellincampi, L; Terrinoni, A; Khalili, K; Melino, G; Giordano, A			pRb2/p130 promotes radiation-induced cell death in the glioblastoma cell line HJC12 by p73 upregulation and Bcl-2 downregulation	ONCOGENE			English	Article						apoptosis; gamma-radiation; pRb2/p130; glioblastoma; p73; Bcl-2; cell cycle	RETINOBLASTOMA GENE-PRODUCT; HUMAN NEUROBLASTOMA-CELLS; GROWTH IN-VIVO; KINASE C-ABL; INDUCED APOPTOSIS; DNA-DAMAGE; TISSUE TRANSGLUTAMINASE; TUMOR-CELLS; PROTEIN; CYCLE	This study shows that in the glioblastoma hamster cell line HJC12 the retinoblastoma family member pRb2/p130 enhances gamma-radiation-induced cell death. In HJC12 cells the tetracycline-regulated expression of pRb2/p130 increased the percentage of gamma-radiation-induced apoptotic cells from 27 to 47%. pRb2/p130 overexpression was associated with the downregulation of the anti-apoptotic factor Bcl-2 and the upregulation of the steady-state protein levels of the pro-apoptotic transcription factor p73. In particular, RT-PCR showed a significant increase in the expression of the p73delta isoform when pRb2/p130 was overexpressed. The ability of pRb2/p130 to modulate apoptosis was not associated with its role in mediating G0/G1 arrest during cell cycle progression. Our data suggest a role for pRb2/p130 in glioblastoma gamma-radiation-induced cell death, indicating that the antitumoral action of pRb2/p130 can regulate both inhibition of cell cycle progression and induction of cell death.	Temple Univ, Sbarro Inst Canc Res & Mol Med, Coll Sci & Technol, Philadelphia, PA 19122 USA; Jefferson Med Coll, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Univ Naples Federico II, Dipartimento Sci Odontostomatol & Maxillo Faccial, I-80131 Naples, Italy; Univ Roma Tor Vergata, Dipartimento Med Interna, I-00133 Rome, Italy; Univ Roma Tor Vergata, Biochim Lab, IDI, IRCCS,Dipartimento Med Sperimentale & Sci Biochim, I-00133 Rome, Italy; Temple Univ, Ctr Neuro Virol & Canc Biol, Philadelphia, PA 19122 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Jefferson University; University of Naples Federico II; University of Rome Tor Vergata; IRCCS Istituto Dermopatico dell'Immacolata (IDI); University of Rome Tor Vergata; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Giordano, A (corresponding author), Temple Univ, Sbarro Inst Canc Res & Mol Med, Coll Sci & Technol, BioLife Sci Bldg,Suite 333,1900 N 12th St, Philadelphia, PA 19122 USA.		TERRINONI, Alessandro/J-1533-2012; Claudio, Pier Paolo/AAW-7282-2021; Giordano, Antonio/F-1927-2010	TERRINONI, Alessandro/0000-0002-7442-2252; Claudio, Pier Paolo/0000-0001-7790-1622; Giordano, Antonio/0000-0002-5959-016X	NCI NIH HHS [5 T32 CA09137, P01-CA56309, R01 CA60999/01A1] Funding Source: Medline; NINDS NIH HHS [P01 NS36466] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA056309, R01CA060999, T32CA009137] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS036466] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Agami R, 1999, NATURE, V399, P809; An B, 1996, CANCER RES, V56, P438; BALDI A, 1995, J CELL BIOCHEM, V59, P402, DOI 10.1002/jcb.240590311; Berry DE, 1996, ONCOGENE, V12, P1809; Bowen C, 1998, CANCER RES, V58, P3275; CHOISYROSSI C, 1999, CELL DEATH DIFFER, V5, P1162; Claudio PP, 2000, CANCER RES, V60, P372; CLAUDIO PP, 1994, CANCER RES, V54, P5555; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; De Laurenzi V, 2000, BIOCHEM BIOPH RES CO, V273, P342, DOI 10.1006/bbrc.2000.2932; De Laurenzi V, 1999, CELL DEATH DIFFER, V6, P389, DOI 10.1038/sj.cdd.4400521; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Debatin KM, 1997, BIOCHEM SOC T, V25, P405, DOI 10.1042/bst0250405; DeLuca A, 1997, J BIOL CHEM, V272, P20971, DOI 10.1074/jbc.272.34.20971; Ding Y, 1999, DNA Res, V6, P347, DOI 10.1093/dnares/6.5.347; Dou QP, 1997, J CELL BIOCHEM, V64, P586; Fan GS, 1996, ONCOGENE, V12, P1909; Gil-Gomez G, 1998, EMBO J, V17, P7209, DOI 10.1093/emboj/17.24.7209; Gong JG, 1999, NATURE, V399, P806; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; Harvey KJ, 1998, MOL CELL BIOL, V18, P2912, DOI 10.1128/MCB.18.5.2912; Howard CM, 1998, J NATL CANCER I, V90, P1451, DOI 10.1093/jnci/90.19.1451; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; JOST C, 1997, NATURE, V38, P191; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kasten MM, 1998, CELL DEATH DIFFER, V5, P132, DOI 10.1038/sj.cdd.4400323; Knudsen KE, 1999, ONCOGENE, V18, P5239, DOI 10.1038/sj.onc.1202910; LeCouter JE, 1998, DEVELOPMENT, V125, P4669; Levrero M, 1999, CELL DEATH DIFFER, V6, P1146, DOI 10.1038/sj.cdd.4400624; MACLACHLAN TK, 1995, CRIT REV EUKAR GENE, V5, P127, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.20; MELINO G, 1994, MOL CELL BIOL, V14, P6584, DOI 10.1128/MCB.14.10.6584; Mo YY, 1999, MOL PHARMACOL, V55, P216, DOI 10.1124/mol.55.2.216; Muschel RJ, 1998, ONCOGENE, V17, P3359, DOI 10.1038/sj.onc.1202580; NEGRINI M, 1987, CELL, V49, P455, DOI 10.1016/0092-8674(87)90448-X; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; PIACENTINI M, 1992, INT J CANCER, V52, P271, DOI 10.1002/ijc.2910520220; RAY GV, 1995, INT J ONCOL, V7, P801; Sheard MA, 1999, BRIT J CANCER, V80, P1689, DOI 10.1038/sj.bjc.6690585; Stiegler P, 1998, Prog Mol Subcell Biol, V20, P25; Strasser-Wozak EMC, 1998, CELL DEATH DIFFER, V5, P687, DOI 10.1038/sj.cdd.4400402; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zhivotovsky B, 1997, J CELL BIOCHEM, V64, P43, DOI 10.1002/(SICI)1097-4644(199701)64:1<43::AID-JCB7>3.3.CO;2-S	47	17	18	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 29	2002	21	38					5897	5905		10.1038/sj.onc.1205750	http://dx.doi.org/10.1038/sj.onc.1205750			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	585JD	12185589				2022-12-17	WOS:000177520900009
J	Blons, H; Laccourreye, O; Houllier, AM; Carnot, F; Brasnu, D; Beaune, P; Zucman-Rossi, J; Laurent-Puig, P				Blons, H; Laccourreye, O; Houllier, AM; Carnot, F; Brasnu, D; Beaune, P; Zucman-Rossi, J; Laurent-Puig, P			Delineation and candidate gene mutation screening of the 18q22 minimal region of deletion in head and neck squamous cell carcinoma	ONCOGENE			English	Article						head and neck neoplasm; chromosome 18; tumor suppressor gene; allelic losses; mutations; dHPLC	TUMOR-SUPPRESSOR GENE; HOMOZYGOUS DELETIONS; CHROMOSOME 18Q; ALLELIC LOSS; TUMORIGENICITY; IDENTIFICATION; HETEROZYGOSITY; CHEMOTHERAPY; METHYLATION; PROGRESSION	The 18q chromosome arm is frequently lost in advanced head and neck squamous cell carcinoma. Twenty-four microsatellite markers located on chromosome 18q were genotyped in 145 primary tumors and 10 cell lines in order. to identify putative tumor suppressor genes implicated in tumor progression. Two different minimal common regions of loss (MCRL) were identified at 18q22 and l8q23 respectively. To refine and delineate boundaries of an homozygous deletion found in one cell line, 44 extra markers located at 18q22 were analysed and the homozygous deletion was precisely defined within a critical region of 4.9 Mb. Four known genes (CDH7, CDH19, DNAM-1, FLJ23594) located in this critical region and two EST clusters (Hs.96900, Hs.98628) were selected for further investigations. For these six genes, genomic structures were established, somatic mutations were screened in 20 HNSCC and 10 cell lines and transcription levels were determined in eight cell lines. No somatic mutations were found in any of the candidate genes analysed (57 coding exons). However, differential transcription levels were observed for CDH19 and Hs.96900 in head and neck cancer cell lines supporting their putative involvement through down regulation mechanisms in head and neck cancer progression.	INSERM, U490, Unite Toxicol Mol, Mol Toxicol Lab, F-75006 Paris, France; Assistance Publ Hop Paris, Hop Europeen Georges Pompidou, Serv Otorhinolaryngol & Chirurg Cervicofaciale, F-75015 Paris, France; Assistance Publ Hop Paris, Hop Europeen Georges Pompidou, Lab Anatomopathol, F-75015 Paris, France; Ctr Etud Polymorphisme Humain, INSERM, U434, F-75010 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm)	Laurent-Puig, P (corresponding author), INSERM, U490, Unite Toxicol Mol, Mol Toxicol Lab, 45 Rue Sts Peres, F-75006 Paris, France.	Pierre.Laurent-Puig@biomedicale.univ-paris5.fr	j, zucman-rossi/AAV-3594-2021; Laurent-Puig, Pierre/K-3641-2019; zucman-rossi, Jessica/B-5098-2009; laurent-puig, pierre/B-2226-2013	j, zucman-rossi/0000-0002-5687-0334; Laurent-Puig, Pierre/0000-0001-8475-5459; zucman-rossi, Jessica/0000-0002-5687-0334; laurent-puig, pierre/0000-0001-8475-5459; Beaune, Philippe/0000-0002-6569-9014; Blons, Helene/0000-0002-0572-8426				Adeyinka A, 1999, INT J CANCER, V84, P370, DOI 10.1002/(SICI)1097-0215(19990820)84:4<370::AID-IJC7>3.0.CO;2-7; Blons H, 1999, MOL CARCINOGEN, V26, P254; Blons H, 1999, INT J CANCER, V84, P410; Bluteau O, 1999, GASTROEN CLIN BIOL, V23, P1225; Cabelguenne A, 2000, J CLIN ONCOL, V18, P1465, DOI 10.1200/JCO.2000.18.7.1465; Califano J, 1996, CANCER RES, V56, P2488; ElNaggar AK, 1997, AM J PATHOL, V151, P1767; GARRIGUEANTAR L, 1995, CANCER RES, V55, P3982; Hidaka E, 1999, J CANCER RES CLIN, V125, P439, DOI 10.1007/s004320050300; Hilgers W, 1999, GENE CHROMOSOME CANC, V25, P370, DOI 10.1002/(SICI)1098-2264(199908)25:4<370::AID-GCC9>3.0.CO;2-S; JEN J, 1994, NEW ENGL J MED, V331, P213, DOI 10.1056/NEJM199407283310401; Kim SK, 1996, CANCER RES, V56, P2519; Kisielewski AE, 1998, ONCOGENE, V17, P83, DOI 10.1038/sj.onc.1201910; KOMURO H, 1999, NEOPLASIA, V3, P253; Kools P, 2000, GENOMICS, V68, P283, DOI 10.1006/geno.2000.6305; Kremmidiotis G, 1998, GENOMICS, V49, P467, DOI 10.1006/geno.1998.5281; Lassus H, 2001, AM J PATHOL, V159, P35, DOI 10.1016/S0002-9440(10)61670-7; Mao L, 1996, CANCER RES, V56, P5128; Nagase T, 2001, DNA RES, V8, P85, DOI 10.1093/dnares/8.2.85; NAWROZ H, 1994, CANCER RES, V54, P1152; Padalecki SS, 2000, INT J CANCER, V85, P654, DOI 10.1002/(SICI)1097-0215(20000301)85:5<654::AID-IJC10>3.0.CO;2-D; Padalecki SS, 2001, GENE CHROMOSOME CANC, V30, P221, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1093>3.0.CO;2-L; Pearlstein RP, 1998, GENE CHROMOSOME CANC, V21, P333, DOI 10.1002/(SICI)1098-2264(199804)21:4<333::AID-GCC7>3.0.CO;2-#; Riggins GJ, 1997, CANCER RES, V57, P2578; Shiseki M, 1996, GENE CHROMOSOME CANC, V17, P71, DOI 10.1002/(SICI)1098-2264(199610)17:2<71::AID-GCC1>3.0.CO;2-Y; SOBIN LH, 1988, CANCER, V61, P2310, DOI 10.1002/1097-0142(19880601)61:11<2310::AID-CNCR2820611127>3.0.CO;2-X; Takebayashi S, 2000, CANCER RES, V60, P3397; TANAKA K, 1991, NATURE, V349, P340, DOI 10.1038/349340a0; Ueda T, 1997, GENE CHROMOSOME CANC, V20, P140, DOI 10.1002/(SICI)1098-2264(199710)20:2<140::AID-GCC4>3.0.CO;2-3; Worm J, 2000, ONCOGENE, V19, P5111, DOI 10.1038/sj.onc.1203891; Yakicier MC, 2001, ONCOGENE, V20, P5232, DOI 10.1038/sj.onc.1204674; YAMADA H, 1995, GENE CHROMOSOME CANC, V13, P18, DOI 10.1002/gcc.2870130104	32	17	17	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 25	2002	21	32					5016	5023		10.1038/sj.onc.1205626	http://dx.doi.org/10.1038/sj.onc.1205626			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	574EE	12118382				2022-12-17	WOS:000176874800018
J	King, D; Yang, GY; Thompson, MA; Hiebert, SW				King, D; Yang, GY; Thompson, MA; Hiebert, SW			Loss of neurofibromatosis-1 and p19(ARF) cooperate to induce a multiple tumor phenotype	ONCOGENE			English	Article						NF1; p19(ARF); cell cycle; oncogenesis; sarcoma; lymphoma	NF1 GENE; IN-VIVO; TYPE-1; SUPPRESSOR; MICE; PATHWAY; RAS; HAPLOINSUFFICIENCY; INACTIVATION; DISRUPTION	Inactivation of the neurofibromatosis-1 (NF1) gene deregulates RAS and cooperates with mutation or loss of the p(53) tumor suppressor to induce tumorigenesis. p19(ARF) acts upstream of p53 in an oncogene checkpoint to induce apoptosis in response to activated RAS and other factors that stimulate proliferation. Therefore, we bred p19(ARF-/-) to NF1(+/-) -mice to determine if loss of these genes collaborates in tumorigenesis. As expected from the embryonic lethality of NF1 null mice, no mice lacking both p19(ARF) and NF1 were born. Unexpectedly, the loss of one allele of NF1 did not greatly shorten the time to tumor formation in a p19(ARF) null background. The tumor types observed were characteristic of p19(ARF) null animals, not those associated with neurofibromatosis or those observed with NF1(+/-)/p53(+/-) mice. However, seven out of 12 animals developed multiple tumors, some With metastases. This multiple tumor phenotype was not previously observed with p19(ARF)-null mice and suggests a distinct form of cooperation between the loss of these tumor suppressors.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Vanderbilt Ingram Ctr, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Hiebert, SW (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, PRB 512,23rd & Pierce, Nashville, TN 37232 USA.				NCI NIH HHS [R01-CA87549, CA68485] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA087549, P30CA068485] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRANNAN CI, 1994, GENE DEV, V8, P1019, DOI 10.1101/gad.8.9.1019; Cichowski K, 1999, SCIENCE, V286, P2172, DOI 10.1126/science.286.5447.2172; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Gutmann DH, 1999, ONCOGENE, V18, P4450, DOI 10.1038/sj.onc.1202829; Hiatt KK, 2001, J BIOL CHEM, V276, P7240, DOI 10.1074/jbc.M009202200; Ingram DA, 2000, J EXP MED, V191, P181, DOI 10.1084/jem.191.1.181; JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794-353; Kamijo T, 1999, CANCER RES, V59, P2217; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Largaespada DA, 1996, NAT GENET, V12, P137, DOI 10.1038/ng0296-137; Lin AW, 2001, P NATL ACAD SCI USA, V98, P5025, DOI 10.1073/pnas.091100298; Nip J, 2001, ONCOGENE, V20, P910, DOI 10.1038/sj.onc.1204171; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Side L, 1997, NEW ENGL J MED, V336, P1713, DOI 10.1056/NEJM199706123362404; Side LE, 1998, BLOOD, V92, P267, DOI 10.1182/blood.V92.1.267.413a31_267_272; Vogel KS, 1999, SCIENCE, V286, P2176, DOI 10.1126/science.286.5447.2176; Zhang YY, 2001, J CLIN INVEST, V108, P709, DOI 10.1172/JCI12758; Zhu Y, 2001, EXP CELL RES, V264, P19, DOI 10.1006/excr.2000.5138	22	17	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 25	2002	21	32					4978	4982		10.1038/sj.onc.1205632	http://dx.doi.org/10.1038/sj.onc.1205632			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	574EE	12118376				2022-12-17	WOS:000176874800012
J	Ding, ZH; Zhou, JY; Wei, WZ; Baker, VV; Wu, GS				Ding, ZH; Zhou, JY; Wei, WZ; Baker, VV; Wu, GS			Induction of apoptosis by the new anticancer drug XK469 in human ovarian cancer cell lines	ONCOGENE			English	Article						XK469; apoptosis; caspases; DN-caspase 9; Bcl2; Bax	CYTOCHROME-C RELEASE; P53-DEPENDENT APOPTOSIS; BCL-2 PROTEIN; MITOCHONDRIA; BAX; CLEAVAGE; DEATH; CASPASE; FAMILY; CHEMOSENSITIVITY	XK469, a synthetic quinoxaline phenoxypropionic acid derivative, has been found to have selective activity against a broad panel of solid tumors including several drug-resistant cell lines and has been approved for phase I clinical evaluation. Recent studies suggested that XK469 is a selective topoisomerase IIbeta inhibitor, but the mechanism of XK469-induced cell death remains unknown. Here we investigate the ability of XK469 to induce apoptosis of human cancer cells. In the human ovarian cancer cell line PA1, XK469 caused the release of cytochrome e, activation of caspases including caspases 9, 7 and 3, cleavage of PARP, and subsequently cell death. Moreover, 1362 and Bax were cleaved in XK469 treated cells. PA1 cells expressing the dominant negative-caspase 9 were less sensitive to XK469. Importantly, in these PA1 cells expressing DN-casp 9, the activation of caspases including caspases 3, 7 and 9, and cleavage of Bax and Bcl2 were inhibited, suggesting that the activation of the mitochondrial pathway is required for XK469-induced anticancer activity. These results indicate that the induction of apoptosis by XK469 may account for its anti-tumor activity and such activity is required for the activation of the mitochondrial pathway. Thus, our study defines a possible mechanism, at least in part, underlying XK469-induced anti-cancer activity.	Wayne State Univ, Sch Med, Karmanos Canc Inst, Dept Pathol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Karmanos Canc Inst, Dept Immunol Microbiol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Karmanos Canc Inst, Dept Obstet & Gynecol, Detroit, MI 48201 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University; Barbara Ann Karmanos Cancer Institute; Wayne State University; Barbara Ann Karmanos Cancer Institute; Wayne State University	Wu, GS (corresponding author), Wayne State Univ, Sch Med, Karmanos Canc Inst, Dept Pathol, Detroit, MI 48201 USA.	wug@karmanos.org						Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Blagosklonny MV, 1999, LEUKEMIA, V13, P1028, DOI 10.1038/sj.leu.2401449; Blagosklonny MV, 1996, CANCER RES, V56, P1851; Chen Q, 2001, BLOOD, V98, P2183, DOI 10.1182/blood.V98.7.2183; Chen Q, 2000, CELL DEATH DIFFER, V7, P227, DOI 10.1038/sj.cdd.4400629; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Corbett TH, 1998, INVEST NEW DRUG, V16, P129, DOI 10.1023/A:1006174622061; Costantini P, 2000, J NATL CANCER I, V92, P1042, DOI 10.1093/jnci/92.13.1042; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Ding ZH, 2001, CLIN CANCER RES, V7, P3336; Gao G, 2000, J CELL BIOCHEM, V80, P53; Gao HL, 1999, P NATL ACAD SCI USA, V96, P12168, DOI 10.1073/pnas.96.21.12168; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; Kirsch DG, 1999, J BIOL CHEM, V274, P21155, DOI 10.1074/jbc.274.30.21155; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Korsmeyer SJ, 1999, CANCER RES, V59, p1693S; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LoRusso PM, 1999, INVEST NEW DRUG, V16, P287; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Snapka RM, 2001, BIOCHEM BIOPH RES CO, V280, P1155, DOI 10.1006/bbrc.2001.4249; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Sun SY, 2001, BIOCHEM BIOPH RES CO, V280, P788, DOI 10.1006/bbrc.2000.4218; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Wood DE, 2000, EXP CELL RES, V256, P375, DOI 10.1006/excr.2000.4859; Wu GS, 1999, ONCOGENE, V18, P6411, DOI 10.1038/sj.onc.1203025; Wu GS, 1996, CLIN CANCER RES, V2, P623; Wu GS, 2002, ONCOGENE, V21, P1, DOI 10.1038/sj.onc.1205020; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	35	17	17	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	2002	21	29					4530	4538		10.1038/sj.onc.1205545	http://dx.doi.org/10.1038/sj.onc.1205545			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	567GH	12085231				2022-12-17	WOS:000176476700007
J	Peng, YF; Mandai, K; Nakanishi, H; Ikeda, W; Asada, M; Momose, Y; Shibamoto, S; Yanagihara, K; Shiozaki, H; Monden, M; Takeichi, M; Takai, Y				Peng, YF; Mandai, K; Nakanishi, H; Ikeda, W; Asada, M; Momose, Y; Shibamoto, S; Yanagihara, K; Shiozaki, H; Monden, M; Takeichi, M; Takai, Y			Restoration of E-cadherin-based cell-cell adhesion by overexpression of nectin in HSC-39 cells, a human signet ring cell gastric cancer cell line	ONCOGENE			English	Article						nectin; afadin; cadherin; catenin; cell-cell adhesion	SIMPLEX VIRUS TYPE-1; POLIOVIRUS RECEPTOR GENE; ALPHA-CATENIN; JUNCTIONAL COMPLEX; ADHERENS JUNCTION; EPITHELIAL-CELLS; MOLECULE UVOMORULIN; CYTOPLASMIC DOMAIN; ARMADILLO PROTEIN; STRUCTURAL BASIS	Nectin is an immunoglobulin-like adhesion molecule that comprises a family consisting of four members, nectin-1, -2, -3, and -4. Nectin is associated with the actin cytoskeleton through afadin, a nectin- and actin filament-binding protein. The nectin-afadin and cadherin-catenin systems are associated with each other and cooperatively form cell-cell adherens junctions in intact epithelial cells. HSC-39 cells, a human signet ring cell gastric cancer cell line, express E-cadherin but do not form cell-cell adhesion. The beta-catenin gene has been shown to be truncated at the N-terminal region including the alpha-catenin-binding domain in HSC-39 cells, but overexpression of normal beta-catenin failed to form cell-cell adhesion. HSC-39 cells expressed nectin-1, -2, and afadin, but not nectin-3. Overexpression of nectin-3 or -2 formed cell-cell adhesion and accumulation of E-cadherin, but not actin filaments, at the cell-cell adhesion sites. Overexpression of a truncated form of nectin-2 incapable of interacting with afadin failed to form cell-cell adhesion. However, the nectin-formed cell-cell adhesion was not so strong as that observed in epithelial cells, such as CaCo-2 cells. Co-expression of nectin-2 and normal beta-catenin did not form strong cell-cell adhesion. These results suggest that an unidentified mechanism, by which nectin and E-cadherin form the actin cytoskeleton-associated adherens junctions to form strong cell-cell adhesion, is impaired in HSC-39 cells.	Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Fac Med, Dept Surg & Clin Oncol, Suita, Osaka 5650871, Japan; Setsunan Univ, Fac Pharmaceut Sci, Dept Biochem, Hirakata, Osaka 5730101, Japan; Natl Canc Ctr, Res Inst, Cent Anim Lab, Tokyo 1040045, Japan; Kyoto Univ, Grad Sch Biostudies, Dept Cell & Dev Biol, Kyoto 6068502, Japan	Osaka University; Osaka University; Setsunan University; National Cancer Center - Japan; Kyoto University	Takai, Y (corresponding author), Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		Takeichi, Masatoshi/G-5903-2012; Ikeda, Wataru/V-8531-2019	Takeichi, Masatoshi/0000-0002-9931-3378; Ikeda, Wataru/0000-0002-6907-9058; Mandai, Kenji/0000-0002-0115-6635; Nakanishi, Hiroyuki/0000-0002-9765-0266				Adams CL, 1998, J CELL BIOL, V142, P1105, DOI 10.1083/jcb.142.4.1105; ADAMSON ED, 1990, DEV BIOL, V138, P338, DOI 10.1016/0012-1606(90)90201-S; Ando-Akatsuka Y, 1999, J CELL PHYSIOL, V179, P115, DOI 10.1002/(SICI)1097-4652(199905)179:2<115::AID-JCP1>3.0.CO;2-T; Aoki J, 1997, EXP CELL RES, V235, P374, DOI 10.1006/excr.1997.3685; AOKI J, 1994, J BIOL CHEM, V269, P8431; Asakura T, 1999, GENES CELLS, V4, P573, DOI 10.1046/j.1365-2443.1999.00283.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cocchi F, 1998, J VIROL, V72, P9992, DOI 10.1128/JVI.72.12.9992-10002.1998; Cocchi F, 2000, J VIROL, V74, P3909, DOI 10.1128/JVI.74.8.3909-3917.2000; EBERLE F, 1995, GENE, V159, P267, DOI 10.1016/0378-1119(95)00180-E; Geraghty RJ, 1998, SCIENCE, V280, P1618, DOI 10.1126/science.280.5369.1618; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; GUMBINER B, 1986, J CELL BIOL, V102, P457, DOI 10.1083/jcb.102.2.457; Ikeda W, 1999, J CELL BIOL, V146, P1117, DOI 10.1083/jcb.146.5.1117; Imamura Y, 1999, J CELL BIOL, V144, P1311, DOI 10.1083/jcb.144.6.1311; KAWANISHI J, 1995, MOL CELL BIOL, V15, P1175; Kemler R, 1992, Semin Cell Biol, V3, P149; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lambert M, 2000, J CELL SCI, V113, P2207; Lopez M, 1998, BLOOD, V92, P4602, DOI 10.1182/blood.V92.12.4602.424k21_4602_4611; Lopez M, 2000, J VIROL, V74, P1267, DOI 10.1128/JVI.74.3.1267-1274.2000; LOPEZ M, 1995, GENE, V155, P261, DOI 10.1016/0378-1119(94)00842-G; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; Marrs JA, 1996, INT REV CYTOL, V165, P159, DOI 10.1016/S0074-7696(08)62222-6; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; Miyahara M, 2000, J BIOL CHEM, V275, P613, DOI 10.1074/jbc.275.1.613; Mizoguchi A, 2002, J CELL BIOL, V156, P555, DOI 10.1083/jcb.200103113; MORRISON ME, 1992, J VIROL, V66, P2807, DOI 10.1128/JVI.66.5.2807-2813.1992; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; Nagar B, 1996, NATURE, V380, P360, DOI 10.1038/380360a0; Nishioka H, 2000, J COMP NEUROL, V424, P297, DOI 10.1002/1096-9861(20000821)424:2<297::AID-CNE8>3.0.CO;2-J; ODA H, 1993, J CELL BIOL, V121, P1133, DOI 10.1083/jcb.121.5.1133; OYAMA T, 1994, CANCER RES, V54, P6282; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; Pertz O, 1999, EMBO J, V18, P1738, DOI 10.1093/emboj/18.7.1738; PRASAD R, 1993, CANCER RES, V53, P5624; Reymond N, 2001, J BIOL CHEM, V276, P43205, DOI 10.1074/jbc.M103810200; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; Sakisaka T, 1999, ONCOGENE, V18, P1609, DOI 10.1038/sj.onc.1202451; Sakisaka T, 2001, J VIROL, V75, P4734, DOI 10.1128/JVI.75.10.4734-4743.2001; Satoh-Horikawa K, 2000, J BIOL CHEM, V275, P10291, DOI 10.1074/jbc.275.14.10291; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; SHIOZAKI H, 1991, AM J PATHOL, V139, P17; Suzuki K, 2000, NAT GENET, V25, P427, DOI 10.1038/78119; Tachibana K, 2000, J CELL BIOL, V150, P1161, DOI 10.1083/jcb.150.5.1161; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Tamura K, 1998, NEURON, V20, P1153, DOI 10.1016/S0896-6273(00)80496-1; Tomschy A, 1996, EMBO J, V15, P3507, DOI 10.1002/j.1460-2075.1996.tb00719.x; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; Warner MS, 1998, VIROLOGY, V246, P179, DOI 10.1006/viro.1998.9218; WATABE M, 1994, J CELL BIOL, V127, P247, DOI 10.1083/jcb.127.1.247; Watabe-Uchida M, 1998, J CELL BIOL, V142, P847, DOI 10.1083/jcb.142.3.847; Weiss EE, 1998, J CELL BIOL, V141, P755, DOI 10.1083/jcb.141.3.755; YANAGIHARA K, 1991, CANCER RES, V51, P381; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119; YONEMURA S, 1995, J CELL SCI, V108, P127	58	17	17	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 13	2002	21	26					4108	4119		10.1038/sj.onc.1205517	http://dx.doi.org/10.1038/sj.onc.1205517			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562FD	12037667	Bronze			2022-12-17	WOS:000176186000005
J	Jacobsen, K; Groth, A; Willumsen, BM				Jacobsen, K; Groth, A; Willumsen, BM			Ras-inducible immortalized fibroblasts: focus formation without cell cycle deregulation	ONCOGENE			English	Article						oncogene; inducible ras; saturation density; reversible transformation	NIH 3T3 CELLS; MAMMALIAN-CELLS; RETINOBLASTOMA PROTEIN; TUMOR SUPPRESSION; GENE-EXPRESSION; ONCOGENIC RAS; LAC OPERATOR; INK4A LOCUS; C-RASH; ACTIVATION	The Ras oncogene transforms cultured murine fibroblasts into malignant, focus-forming cells, whose lack of contact inhibition is evidenced by high saturation densities. In order to investigate the reversibility of Ras transformation, as well as the kinetics of Ras-induced changes, cell lines that conditionally express oncogenic Ras were constructed. Both focus formation and increased saturation density were inducible and fully reversible. In exponentially growing cells, oncogenic Ras-expression had no effect on proliferation rates, Erk phosphorylation, or the level of cyclin D1, and Ras-induction did not confer serum-independent growth. As expected, growth to high density in uninduced cells led to quiescence with a low level of cyclin D1 and no active Erk; in this setting, Ras induction prevented full downregulation of cyclin D1 and inactivation of Erk. Our results show that Ras expression to a level sufficient for transformation leads to relatively subtle effects on known downstream targets, and that the focus formation and increased saturation density growth induced by Ras is not a result of growth factor independence.	Univ Copenhagen, Dept Mol Cell Biol, DK-1353 Copenhagen, Denmark	University of Copenhagen	Willumsen, BM (corresponding author), Univ Copenhagen, Dept Mol Cell Biol, DK-1353 Copenhagen, Denmark.	bmw@biobase.dk	Willumsen, Berthe M/H-1903-2012; Groth, Anja/AAH-5386-2019	Willumsen, Berthe M/0000-0002-2277-6999; Groth, Anja/0000-0003-0577-1771				ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; BALMAIN A, 1984, NATURE, V307, P658, DOI 10.1038/307658a0; BROWN M, 1987, CELL, V49, P603, DOI 10.1016/0092-8674(87)90536-8; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; CHUNG HH, 1992, BIOCHIM BIOPHYS ACTA, V1129, P278, DOI 10.1016/0167-4781(92)90504-S; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; DONZE O, 1995, EMBO J, V14, P3828, DOI 10.1002/j.1460-2075.1995.tb00052.x; DURKIN JP, 1986, MOL CELL BIOL, V6, P1386, DOI 10.1128/MCB.6.5.1386; ELLIS RW, 1980, J VIROL, V36, P408, DOI 10.1128/JVI.36.2.408-420.1980; FILMUS J, 1994, ONCOGENE, V9, P3627; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; Gjoerup O, 1998, J BIOL CHEM, V273, P18812, DOI 10.1074/jbc.273.30.18812; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HARTMAN SC, 1988, P NATL ACAD SCI USA, V85, P8047, DOI 10.1073/pnas.85.21.8047; Harvey J J, 1971, Int Rev Exp Pathol, V10, P265; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; Hitomi M, 1999, MOL CELL BIOL, V19, P4623; HOLLEY RW, 1975, NATURE, V258, P487, DOI 10.1038/258487a0; HU MCT, 1987, CELL, V48, P555, DOI 10.1016/0092-8674(87)90234-0; JACOBSEN KD, 1995, J MOL BIOL, V252, P289, DOI 10.1006/jmbi.1995.0496; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; KAPLAN PL, 1982, P NATL ACAD SCI-BIOL, V79, P485, DOI 10.1073/pnas.79.2.485; KUMAR R, 1990, SCIENCE, V248, P1101, DOI 10.1126/science.2188364; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Mittnacht S, 1997, CURR BIOL, V7, P219, DOI 10.1016/S0960-9822(97)70094-0; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; PARDEE AB, 1978, ANNU REV BIOCHEM, V47, P715, DOI 10.1146/annurev.bi.47.070178.003435; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; PIRONIN M, 1992, INT J CANCER, V51, P980, DOI 10.1002/ijc.2910510624; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; QUELLE DE, 1995, ONCOGENE, V11, P635; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SHIH TY, 1982, J BIOL CHEM, V257, P1767; SIMONS A, 1984, P NATL ACAD SCI-BIOL, V81, P1624, DOI 10.1073/pnas.81.6.1624; SIMONS PJ, 1967, NATURE, V214, P897, DOI 10.1038/214897a0; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; ULSH LS, 1984, MOL CELL BIOL, V4, P1647, DOI 10.1128/MCB.4.8.1647; Villalonga P, 2000, ONCOGENE, V19, P690, DOI 10.1038/sj.onc.1203341; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WILLUMSEN BM, 1991, MOL CELL BIOL, V11, P6026, DOI 10.1128/MCB.11.12.6026; WILLUMSEN BM, 1995, METHOD ENZYMOL, V250, P269; Winston JT, 1996, ONCOGENE, V12, P127; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; ZAVADA J, 1970, NATURE, V225, P24, DOI 10.1038/225024a0; ZHAN X, 1986, MOL CELL BIOL, V6, P3541, DOI 10.1128/MCB.6.10.3541	54	17	17	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2002	21	19					3058	3067		10.1038/sj.onc.1205423	http://dx.doi.org/10.1038/sj.onc.1205423			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546FM	12082537				2022-12-17	WOS:000175262700014
J	Shao, CS; Yin, MY; Deng, L; Stambrook, PJ; Doetschman, T; Tischfield, JA				Shao, CS; Yin, MY; Deng, L; Stambrook, PJ; Doetschman, T; Tischfield, JA			Loss of heterozygosity and point mutation at Aprt locus in T cells and fibroblasts of Pms2(-/-) mice	ONCOGENE			English	Article						mismatch repair; PMS2; APRT; mouse model; somatic mutation; loss of heterozygosity	DNA MISMATCH REPAIR; MITOTIC RECOMBINATION; DEFICIENT; GENE; APOPTOSIS; TRANSITIONS; MLH1	Mice null for the Pms2 mismatch repair (MMR) gene exhibit a predisposition to lymphoma, microsatellite repeat instability, and failure of spermatogenesis. To study the role of Pms2 in the maintenance of in vivo genomic integrity in somatic cells, we characterized Aprt mutations in T cells and fibroblasts of 129 x C3H Pms2(-/-)Aprt(+/-) mice. The spontaneous frequency of DAP-resistant T lymphocytes, as a consequence of APRT-deficiency, was increased threefold. Point mutation, which accounted for less than 20% of the DAP(r) mutant clones in Pms2(+/+) mice, was predominant in the mutant T cell clones from Pms2(-/-) mice. These point mutations were predominantly TA to CG transitions. Fibroblasts of Pms2(-/-) mice exhibited only a modest increase in the frequency of clones with point mutations, such that mitotic recombination was still the primary cause of APRT deficiency. Thus, the mutator phenotype as a consequence of PMS2 deficiency is tissue-dependent, which may be related to the tissue-specific tumor proneness of Pms2(-/-)Aprt(+/-) mice.	Rutgers State Univ, Dept Genet, Piscataway, NJ 08854 USA; Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Cell Biol Neurobiol & Anat, Cincinnati, OH 45267 USA	Rutgers State University New Brunswick; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Tischfield, JA (corresponding author), Rutgers State Univ, Dept Genet, Piscataway, NJ 08854 USA.		Shao, Changshun/AAD-8977-2022	Shao, Changshun/0000-0003-2618-9342; Tischfield, Jay/0000-0003-3217-8287	NIDDK NIH HHS [R01DK38185] Funding Source: Medline; NIEHS NIH HHS [P01ES05652, P30ES05022] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038185] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES005652, P30ES005022] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Andrew SE, 2000, CARCINOGENESIS, V21, P1291, DOI 10.1093/carcin/21.7.1291; Andrew SE, 1997, ONCOGENE, V15, P123, DOI 10.1038/sj.onc.1201180; BAKER SM, 1995, CELL, V82, P309, DOI 10.1016/0092-8674(95)90318-6; Baross-Francis A, 2001, ONCOGENE, V20, P619, DOI 10.1038/sj.onc.1204138; Bielas JH, 2000, P NATL ACAD SCI USA, V97, P11391, DOI 10.1073/pnas.190330997; Buermeyer AB, 1999, ANNU REV GENET, V33, P533, DOI 10.1146/annurev.genet.33.1.533; DUSH MK, 1985, P NATL ACAD SCI USA, V82, P2731, DOI 10.1073/pnas.82.9.2731; Engle SJ, 1996, P NATL ACAD SCI USA, V93, P5307, DOI 10.1073/pnas.93.11.5307; Gong JG, 1999, NATURE, V399, P806; Harfe BD, 2000, ANNU REV GENET, V34, P359, DOI 10.1146/annurev.genet.34.1.359; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; MELTON DW, 1984, P NATL ACAD SCI-BIOL, V81, P2147, DOI 10.1073/pnas.81.7.2147; Meng QX, 1998, ENVIRON MOL MUTAGEN, V32, P236, DOI 10.1002/(SICI)1098-2280(1998)32:3<236::AID-EM6>3.3.CO;2-P; MIRSALIS JC, 1995, ANNU REV PHARMACOL, V35, P145; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Narayanan L, 1997, P NATL ACAD SCI USA, V94, P3122, DOI 10.1073/pnas.94.7.3122; Prolla TA, 1998, NAT GENET, V18, P276, DOI 10.1038/ng0398-276; Rose JA, 2000, CANCER RES, V60, P3404; Shaddock J. G., 2001, Environmental and Molecular Mutagenesis, V37, P68; Shao CS, 2000, P NATL ACAD SCI USA, V97, P7405, DOI 10.1073/pnas.97.13.7405; Shao CS, 1999, P NATL ACAD SCI USA, V96, P9230, DOI 10.1073/pnas.96.16.9230; Shao CS, 2001, NAT GENET, V28, P169, DOI 10.1038/88897; Toft NJ, 1999, P NATL ACAD SCI USA, V96, P3911, DOI 10.1073/pnas.96.7.3911; Yao X, 1999, P NATL ACAD SCI USA, V96, P6850, DOI 10.1073/pnas.96.12.6850; Zeng M, 2000, CANCER RES, V60, P4889; Zhang H, 1999, CANCER RES, V59, P3021	26	17	17	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2002	21	18					2840	2845		10.1038/sj.onc.1205358	http://dx.doi.org/10.1038/sj.onc.1205358			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	542UY	11973643				2022-12-17	WOS:000175063700008
J	Chua, SS; Ma, ZQ; Gong, L; Lin, SH; DeMayo, FJ; Tsai, SY				Chua, SS; Ma, ZQ; Gong, L; Lin, SH; DeMayo, FJ; Tsai, SY			Ectopic expression of FGF-3 results in abnormal prostate and Wolffian duct development	ONCOGENE			English	Article						FGF-3; transgenic mice; prostate; Wolffian duct derivatives; hyperplasia	FIBROBLAST-GROWTH-FACTOR; MAMMARY-TUMOR VIRUS; PROTO-ONCOGENE INT-2; TRANSGENIC MICE; EPITHELIAL-CELLS; GENE-EXPRESSION; NUCLEAR-LOCALIZATION; SEMINAL-VESICLE; TRAMP MODEL; MOUSE	To evaluate the effects of FGF-3 expression in the prostate and male reproductive tract, we employed a bitransgenic system to target FGF-3 to these organs. We present a first study that ectopic FGF-3 expression resulted in exuberant hyperplasia of all bigenic prostatic lobes typified by epithelial stratification, cribiform structures and papillary tufts. These cells displayed increased nuclear-to-cytoplasmic ratios and bromodeoxyuridine (BrdU) proliferative index but retained relatively uniform nuclear androgen receptor (AR) and the tumor suppressor C-CAM1 staining. Furthermore, the dysmorphogenic prostatic cells also resembled PIN (prostatic intraepithelial neoplasia)-like lesions but did not appear to have invaded the basal lamina. In addition to these phenotypes, profound disorders of the bigenic Wolffian duct derivatives were observed. The bigenic ampullary glands and vas deferens were extremely cystic, hypertrophic and hyperplastic; the enlarged epididymi showed a reduction of spermatozoa and the seminal vesicles exhibited a dramatic reduction of seminal secretions. Because of these severe abnormalities, these infertile males presented with diaphragmatic hernias, hemoperitoneum and many secondary abnormalities at sacrifice. Taken together, we show that ectopic FGF-3 expression severely perturbs normal prostate development and our system should be useful for the analyses of early changes in prostatic hyperplasia.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol & Genitourinary Med Oncol, Houston, TX 77030 USA	Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center	Tsai, SY (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza, Houston, TX 77030 USA.		DeMayo, Francesco/C-6255-2019	DeMayo, Francesco/0000-0002-9480-7336				Antoine M, 1997, J BIOL CHEM, V272, P29475, DOI 10.1074/jbc.272.47.29475; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; Callahan R, 1996, BREAST CANCER RES TR, V39, P33, DOI 10.1007/BF01806076; CHUNG JH, 1993, CELL, V74, P505, DOI 10.1016/0092-8674(93)80052-G; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COX KH, 1984, DEV BIOL, V101, P485, DOI 10.1016/0012-1606(84)90162-3; DARBRE P, 1986, MOL CELL BIOL, V6, P2847, DOI 10.1128/MCB.6.8.2847; DICKSON C, 1987, NATURE, V326, P833, DOI 10.1038/326833a0; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; Donjacour AA, 1998, DIFFERENTIATION, V62, P227, DOI 10.1046/j.1432-0436.1998.6250227.x; Feng SJ, 1997, CANCER RES, V57, P5369; Foster BA, 1999, PROSTATE CANCER P D, V2, P76; Gingrich JR, 1999, PROSTATE CANCER P D, V2, P70, DOI 10.1038/sj/pcan/4500296; GOSPODAROWICZ D, 1978, IN VITRO CELL DEV B, V14, P85; GUNZBURG WH, 1992, BIOCHEM J, V283, P625; HAM J, 1988, NUCLEIC ACIDS RES, V16, P5263, DOI 10.1093/nar/16.12.5263; Ittman M, 1997, J UROLOGY, V157, P351, DOI 10.1016/S0022-5347(01)65376-X; JAKOBOVITS A, 1986, P NATL ACAD SCI USA, V83, P7806, DOI 10.1073/pnas.83.20.7806; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KIEFER P, 1995, MOL CELL BIOL, V15, P4364; KIEFER P, 1994, EMBO J, V13, P4126, DOI 10.1002/j.1460-2075.1994.tb06730.x; Ma ZQ, 1999, ONCOGENE, V18, P4564, DOI 10.1038/sj.onc.1202809; MANSOUR SL, 1993, DEVELOPMENT, V117, P13; MATHIEU M, 1995, J BIOL CHEM, V270, P24197, DOI 10.1074/jbc.270.41.24197; MULLER WJ, 1990, EMBO J, V9, P907, DOI 10.1002/j.1460-2075.1990.tb08188.x; ORNITZ DM, 1991, P NATL ACAD SCI USA, V88, P698, DOI 10.1073/pnas.88.3.698; PETERS G, 1983, CELL, V33, P369, DOI 10.1016/0092-8674(83)90418-X; PRINS GS, 1995, ENDOCRINOLOGY, V136, P1303, DOI 10.1210/en.136.3.1303; Pu YS, 1999, J UROLOGY, V162, P892, DOI 10.1097/00005392-199909010-00085; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; Robinson ML, 1998, DEV BIOL, V198, P13, DOI 10.1016/S0012-1606(98)80026-2; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; STAMP G, 1992, CELL GROWTH DIFFER, V3, P929; Tekmal Rajeshwar Rao, 1997, Frontiers in Bioscience, V2, pD519; Thomson AA, 1999, DEVELOPMENT, V126, P3693; Thomson AA, 1997, DEVELOPMENT, V124, P2431; Thomson AA, 2001, REPRODUCTION, V121, P187, DOI 10.1530/rep.0.1210187; Wang Y, 1997, GENE THER, V4, P432, DOI 10.1038/sj.gt.3300402; Wang YL, 1997, NAT BIOTECHNOL, V15, P239, DOI 10.1038/nbt0397-239; WANG YL, 1994, P NATL ACAD SCI USA, V91, P8180, DOI 10.1073/pnas.91.17.8180; WILKINSON DG, 1989, DEVELOPMENT, V105, P131; WILKINSON DG, 1988, EMBO J, V7, P691, DOI 10.1002/j.1460-2075.1988.tb02864.x; Xue LX, 1997, CARCINOGENESIS, V18, P995, DOI 10.1093/carcin/18.5.995; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; Yamashita T, 2000, BIOCHEM BIOPH RES CO, V277, P494, DOI 10.1006/bbrc.2000.3696; YAN GC, 1993, MOL CELL BIOL, V13, P4513, DOI 10.1128/MCB.13.8.4513; Zhao BH, 2001, P NATL ACAD SCI USA, V98, P5898, DOI 10.1073/pnas.101116598	48	17	18	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 14	2002	21	12					1899	1908		10.1038/sj.onc.1205096	http://dx.doi.org/10.1038/sj.onc.1205096			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	529DJ	11896623				2022-12-17	WOS:000174284500013
J	Beneke, R; Moroy, T				Beneke, R; Moroy, T			Inhibition of poly(ADO-ribose) polymerase activity accelerates T-cell lymphomagenesis in p53 deficient mice	ONCOGENE			English	Article						PARP-1; apoptosis; DNA repair; p53; T-cell lymphoma	DNA-BINDING DOMAIN; POLY(ADP-RIBOSE) POLYMERASE; TRANSDOMINANT INHIBITION; TRANSGENIC MICE; EXCISION-REPAIR; CD95 APO-1/FAS; APOPTOSIS; DAMAGE; EXPRESSION; RECOVERY	Cells that lack PARP-1 activity are limited in their ability to repair DNA single strand breaks and respond to DNA damage with a strong accumulation of p53 and enhanced rates of apoptotic cell death. We have generated combinatorial mutant mice that both lack p53 and PARP-1 activity due to the expression of a dominant negative PARP-1 allele targeted to T-cells by the lck promoter. Here we report that these double mutant mice develop T-cell lymphoma at a significantly reduced latency period compared to single p53 null mice that are already cancer prone. We demonstrate that the absence of p53 does not only protect T-cells from lck-PARP-DBD transgenic mice from apoptosis but also abrogates the DNA damage induced cell cycle arrest in the G1 phase. T-cells from double mutant mice continue to proliferate after the induction of DNA strand breaks, are limited in their DNA repair capacity and cannot be eliminated by apoptosis. These results indicate that PARP-1 and p53 cooperate in the suppression of tumorigenesis by maintaining genomic integrity after DNA damage through the activation of a G1/S cell cycle checkpoint the initiation of DNA repair and the induction of cell death.	Univ Essen Gesamthsch Klinikum, Inst Zellbiol Tumorforsch, D-45122 Essen, Germany	University of Duisburg Essen	Moroy, T (corresponding author), Univ Essen Gesamthsch Klinikum, Inst Zellbiol Tumorforsch, 1FZ,Virchowstr 173, D-45122 Essen, Germany.	moeroey@uni-essen.de	Moroy, Tarik/D-9923-2011					ALTHAUS FR, 1994, MOL CELL BIOCHEM, V138, P53, DOI 10.1007/BF00928443; Beneke R, 2000, MOL CELL BIOL, V20, P6695, DOI 10.1128/MCB.20.18.6695-6703.2000; Conde C, 2001, EMBO J, V20, P3535, DOI 10.1093/emboj/20.13.3535; Dantzer F, 2000, BIOCHEMISTRY-US, V39, P7559, DOI 10.1021/bi0003442; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; DEPPERT W, 1994, SEMIN CANCER BIOL, V5, P187; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ENOCH T, 1995, TRENDS BIOCHEM SCI, V20, P426, DOI 10.1016/S0968-0004(00)89093-3; Hassa PO, 1999, BIOL CHEM, V380, P953, DOI 10.1515/BC.1999.118; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jackson SP, 1996, CURR OPIN GENET DEV, V6, P19, DOI 10.1016/S0959-437X(96)90005-2; Jeggo PA, 1998, CURR BIOL, V8, pR49, DOI 10.1016/S0960-9822(98)70032-6; JOSHI VV, 1970, J NATL CANCER I, V44, P185; Karsunky H, 1999, ONCOGENE, V18, P7816, DOI 10.1038/sj.onc.1203205; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Kupper JH, 1996, CANCER RES, V56, P2715; KUPPER JH, 1990, J BIOL CHEM, V265, P18721; KUPPER JH, 1995, MOL CELL BIOL, V15, P3154; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LINDAHL T, 1995, TRENDS BIOCHEM SCI, V20, P405, DOI 10.1016/S0968-0004(00)89089-1; LIU LL, 1994, CANCER RES, V54, P4648; MOLINETE M, 1993, EMBO J, V12, P2109, DOI 10.1002/j.1460-2075.1993.tb05859.x; MOROY T, 1993, P NATL ACAD SCI USA, V90, P10734, DOI 10.1073/pnas.90.22.10734; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Newton K, 2000, J EXP MED, V191, P195, DOI 10.1084/jem.191.1.195; Oliver FJ, 1999, EMBO J, V18, P4446, DOI 10.1093/emboj/18.16.4446; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; PANZETER PL, 1993, J BIOL CHEM, V268, P17662; Samper E, 2001, J CELL BIOL, V154, P49, DOI 10.1083/jcb.200103049; SCHREIBER V, 1995, P NATL ACAD SCI USA, V92, P4753, DOI 10.1073/pnas.92.11.4753; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SoferLevi Y, 1996, ONCOGENE, V13, P2431; Tong WM, 2001, MOL CELL BIOL, V21, P4046, DOI 10.1128/MCB.21.12.4046-4054.2001; Trucco C, 1998, NUCLEIC ACIDS RES, V26, P2644, DOI 10.1093/nar/26.11.2644; Tsutsumi M, 2001, CARCINOGENESIS, V22, P1, DOI 10.1093/carcin/22.1.1; Van Meyel DJ, 1998, INT J ONCOL, V13, P917; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509	41	17	18	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 6	2001	20	56					8136	8141		10.1038/sj.onc.1205056	http://dx.doi.org/10.1038/sj.onc.1205056			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	496LJ	11781827				2022-12-17	WOS:000172396800011
J	De Rienzo, A; Balsara, BR; Apostolou, S; Jhanwar, SC; Testa, JR				De Rienzo, A; Balsara, BR; Apostolou, S; Jhanwar, SC; Testa, JR			Loss of heterozygosity analysis defines a 3-cM region of 15q commonly deleted in human malignant mesothelioma	ONCOGENE			English	Article						malignant mesothelioma; LOH; chromosome arm 15q; tumor suppressor gene	TUMOR-SUPPRESSOR GENE; COMPARATIVE GENOMIC HYBRIDIZATION; ALLELIC LOSS; DELETIONS; CANCER; CARCINOMAS; MUTATIONS; NF2; 14Q; 6Q	Previous comparative genomic hybridization and allelic loss analyses demonstrated frequent deletions from 15q11.1-15 in malignant mesothelioma. Recurrent losses of 15q11-22 have also been reported in several other tumor types such as breast and colorectal cancers. To more precisely map the commonly deleted region, we have performed a high density loss of heterozygosity analysis of 46 malignant mesotheliomas, using 26 polymorphic microsatellite markers spanning the entire long arm of chromsome 15. Allelic loss from 15q was observed in 22 of 46 (48%) cases. These analyses have defined a minimally deleted region of similar to3-cM, which was confirmed to reside at 15q15 by fluorescence in situ hybridization analysis with yeast artificial chromosome probes. No tumor suppressor genes have been reported to map to this site. The minimally deleted region identified in this investigation overlaps those observed in other kinds of cancer, and is the smallest site of recurrent 15q loss identified to date in human tumors. The identification of this commonly deleted site implicates a putative tumor suppressor gene(s) at 15q15 involved in diverse forms of human neoplasia.	Fox Chase Canc Ctr, Human Genet Program, Philadelphia, PA 19111 USA; Mem Sloan Kettering Canc Ctr, Dept Human Genet, New York, NY 10021 USA	Fox Chase Cancer Center; Memorial Sloan Kettering Cancer Center	Testa, JR (corresponding author), Fox Chase Canc Ctr, Human Genet Program, 7701 Burholme Ave, Philadelphia, PA 19111 USA.				NCI NIH HHS [CA-45745, CA-06927] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altomare DA, 1996, CYTOGENET CELL GENET, V74, P248, DOI 10.1159/000134426; ANTMAN KH, 1981, SEMIN ONCOL, V8, P313; ANTMAN KH, 1989, MESOTHELIOMA; Attanoos RL, 1997, HISTOPATHOLOGY, V30, P403, DOI 10.1046/j.1365-2559.1997.5460776.x; Balsara BR, 1999, CANCER RES, V59, P450; Bell DW, 1997, CANCER RES, V57, P4057; BIANCHI AB, 1995, P NATL ACAD SCI USA, V92, P10854, DOI 10.1073/pnas.92.24.10854; Bisconti M, 2000, RESPIRATION, V67, P223, DOI 10.1159/000029493; Bjorkqvist AM, 1997, BRIT J CANCER, V75, P523, DOI 10.1038/bjc.1997.91; Bjorkqvist AM, 1999, BRIT J CANCER, V81, P1111, DOI 10.1038/sj.bjc.6690816; Broman KW, 1998, AM J HUM GENET, V63, P861, DOI 10.1086/302011; Carbone M, 1999, J CELL PHYSIOL, V180, P167, DOI 10.1002/(SICI)1097-4652(199908)180:2<167::AID-JCP4>3.0.CO;2-Q; Cheng JQ, 1999, GENE CHROMOSOME CANC, V24, P238, DOI 10.1002/(SICI)1098-2264(199903)24:3<238::AID-GCC9>3.0.CO;2-M; CHENG JQ, 1994, CANCER RES, V54, P5547; Collins A, 1996, GENOMICS, V36, P157, DOI 10.1006/geno.1996.0436; CRAIGHEAD JE, 1982, NEW ENGL J MED, V306, P1446, DOI 10.1056/NEJM198206173062403; De Rienzo A, 2000, GENE CHROMOSOME CANC, V28, P337, DOI 10.1002/1098-2264(200007)28:3<337::AID-GCC12>3.0.CO;2-B; DODSON MK, 1993, CANCER RES, V53, P4456; Kersemaekers AMF, 1998, INT J CANCER, V79, P411, DOI 10.1002/(SICI)1097-0215(19980821)79:4<411::AID-IJC17>3.3.CO;2-Z; KNUDSON AG, 1989, CANCER, V63, P1888, DOI 10.1002/1097-0142(19890515)63:10<1888::AID-CNCR2820631004>3.0.CO;2-L; LYNCH HT, 1985, CANCER GENET CYTOGEN, V15, P25, DOI 10.1016/0165-4608(85)90128-1; Mossman BT, 1996, CANCER INVEST, V14, P466, DOI 10.3109/07357909609018904; Olson TM, 1998, SCIENCE, V280, P750, DOI 10.1126/science.280.5364.750; Pache JC, 1998, AM J PATHOL, V152, P333; Park WS, 2000, CANCER RES, V60, P70; POPESCU NC, 1988, CANCER RES, V48, P142; Schmutte C, 1999, CANCER RES, V59, P4564; SEEMAYER TA, 1989, LAB INVEST, V60, P585; SEKIDO Y, 1995, CANCER RES, V55, P1227; Shivapurkar N, 1999, CLIN CANCER RES, V5, P17; Stanton SE, 2000, GENE CHROMOSOME CANC, V27, P323, DOI 10.1002/(SICI)1098-2264(200003)27:3<323::AID-GCC14>3.0.CO;2-P; TAGUCHI T, 1993, CANCER RES, V53, P4349; Tahara H, 1996, CANCER RES, V56, P599; Testa JR, 1998, CANCER RES, V58, P4505; Tomlinson I, 1999, GASTROENTEROLOGY, V116, P789, DOI 10.1016/S0016-5085(99)70061-2; WEINBERG R, 1993, NEURON, V11, P191, DOI 10.1016/0896-6273(93)90177-S; Wick W, 1996, ONCOGENE, V12, P973	37	17	17	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 27	2001	20	43					6245	6249		10.1038/sj.onc.1204828	http://dx.doi.org/10.1038/sj.onc.1204828			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476BL	11593434				2022-12-17	WOS:000171206300017
J	Yokoyama, N; Miller, WT				Yokoyama, N; Miller, WT			Protein phosphatase 2A interacts with the Src kinase substrate p130(CAS)	ONCOGENE			English	Article						Src; PP2A; Cas; serine dephosphorylation	POLYOMAVIRUS MIDDLE-T; ROUS-SARCOMA VIRUS; TYROSINE PHOSPHORYLATION; V-SRC; SACCHAROMYCES-CEREVISIAE; CELL-TRANSFORMATION; COMPLEX-FORMATION; STABLE COMPLEXES; OKADAIC ACID; ANTIGEN	In this study, we report that the Src substrate Cas (p130 Crk-associated substrate) associates with protein phosphatase 2A (PP2A), a serine/threonine phosphatase. We investigated this interaction in cells expressing a temperature-sensitive mutant form of v-Src. v-Src activation (by shifting cells from the nonpermissive to the permissive temperature) led to an increase in the tyrosine phosphorylation of v-Src and Cas, as well as in the association between v-Src and Cas. v-Src has previously been shown to bind to PP2A and to phosphorylate the catalytic subunit of PP2A, resulting in inhibition of phosphatase activity. We found that the association between v-Src and PP2A decreased as cells were shifted to the permissive temperature. In contrast, the levels of PP2A that co-immunoprecipitated with Cas increased when v-Src was activated. We obtained similar results in pull-down experiments with immobilized Microcystin, a PP2A inhibitor. Serine/threonine phosphorylation of Cas has previously been shown to occur in a cell cycle regulated matter. Treatment of NIH3T3 cells with okadaic acid, a PP2A inhibitor, augments the serine/threonine phosphorylation of Cas that occurs at mitosis. Furthermore, PP2A dephosphorylates serine residues on Cas in vitro. Taken together, our results suggest that PP2A may be involved in the cell cycle-specific dephosphorylation of Cas.	SUNY Stony Brook, Sch Med, Dept Physiol & Biophys, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Miller, WT (corresponding author), SUNY Stony Brook, Sch Med, Dept Physiol & Biophys, Stony Brook, NY 11794 USA.	miller@physiology.pnb.sunysb.edu			NCI NIH HHS [CA 58530, CA 28146] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058530, P01CA028146, R29CA058530] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CAMPBELL KS, 1995, J VIROL, V69, P3721, DOI 10.1128/JVI.69.6.3721-3728.1995; CAYLA X, 1990, BIOCHEMISTRY-US, V29, P658, DOI 10.1021/bi00455a010; Chaudhuri Sadhan K., 1997, Indian Journal of Experimental Biology, V35, P1044; CHEN J, 1994, J BIOL CHEM, V269, P7957; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; Chung HY, 1999, CELL SIGNAL, V11, P575, DOI 10.1016/S0898-6568(99)00033-9; Evans DRH, 2000, MOL GEN GENET, V264, P425; Favre B, 1997, J BIOL CHEM, V272, P13856, DOI 10.1074/jbc.272.21.13856; GARCIA P, 1993, J BIOL CHEM, V268, P25146; Garcia-Guzman M, 1999, J BIOL CHEM, V274, P5762, DOI 10.1074/jbc.274.9.5762; GLENN GM, 1993, J VIROL, V67, P1945, DOI 10.1128/JVI.67.4.1945-1952.1993; Glover HR, 1999, ONCOGENE, V18, P4364, DOI 10.1038/sj.onc.1202816; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; Goldberg Y, 1999, BIOCHEM PHARMACOL, V57, P321, DOI 10.1016/S0006-2952(98)00245-7; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; JOVE R, 1986, J VIROL, V60, P840, DOI 10.1128/JVI.60.3.840-848.1986; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; LIN FC, 1995, EMBO J, V14, P2745, DOI 10.1002/j.1460-2075.1995.tb07275.x; MAYER BJ, 1986, J VIROL, V60, P858, DOI 10.1128/JVI.60.3.858-867.1986; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; O'Neill GM, 2000, TRENDS CELL BIOL, V10, P111, DOI 10.1016/S0962-8924(99)01714-6; Ogris E, 1999, J VIROL, V73, P7390, DOI 10.1128/JVI.73.9.7390-7398.1999; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; SAKAI R, 1994, J BIOL CHEM, V269, P32740; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; SEFTON BM, 1980, J VIROL, V33, P220, DOI 10.1128/JVI.33.1.220-229.1980; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; Sheppeck JE, 1997, BIOORGAN MED CHEM, V5, P1739, DOI 10.1016/S0968-0896(97)00146-6; TUROWSKI P, 1995, J CELL BIOL, V129, P397, DOI 10.1083/jcb.129.2.397; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Yamakita Y, 1999, J CELL BIOL, V144, P315, DOI 10.1083/jcb.144.2.315; YANAGIDA M, 1992, CIBA F SYMP, V170, P130; YOKOYAMA N, 1995, MOL CELL BIOCHEM, V148, P123, DOI 10.1007/BF00928149; Yokoyama N, 1999, FEBS LETT, V456, P403, DOI 10.1016/S0014-5793(99)00992-8; ZHENG B, 1991, J BIOL CHEM, V266, P10031	39	17	17	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2001	20	42					6057	6065		10.1038/sj.onc.1204735	http://dx.doi.org/10.1038/sj.onc.1204735			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473QF	11593413				2022-12-17	WOS:000171056300013
J	Persengiev, SP; Li, JQ; Poulin, ML; Kilpatrick, DL				Persengiev, SP; Li, JQ; Poulin, ML; Kilpatrick, DL			E2F2 converts reversibly differentiated PC12 cells to an irreversible, neurotrophin-dependent state	ONCOGENE			English	Article						terminal differentiation; neuron; apoptosis; growth arrest	NERVE GROWTH-FACTOR; ACTIVE TRANSCRIPTIONAL REPRESSION; RETINOBLASTOMA PROTEIN FAMILY; SUBCELLULAR-LOCALIZATION; PHEOCHROMOCYTOMA CELLS; MICE LACKING; CYCLIN D1; DEATH; NEURONS; PROLIFERATION	E2Fs play a central role in cell proliferation and growth arrest through their ability to regulate genes involved in cell cycle progression, arrest and apoptosis. Recent studies further indicate that this family of transcriptional regulators participate in cell fate/differentiation events. They are thus likely to have a prominent role in controlling the terminal differentiation process and its irreversibility. Here we have specifically examined the role of E2F2 in neuronal differentiation using a gain-of-function approach. Endogenous E2F2 increased in PC12 cells in response to nerve growth factor (NGF) and was also expressed in cerebellar granule neurons undergoing terminal differentiation. While PC12 cells normally undergo reversible dedifferentiation and cell cycle reentry upon NGF removal, forced expression of E2F2 inhibited these events and induced apoptosis. Thus, E2F2 converted PC12-derived neurons from a reversible to a 'terminally' differentiated, NGF-dependent state, analogous to postmitotic sympathetic neurons. This contrasts with the effects of E2F4, which enhances the differentiation state of PC12 cells without affecting cell cycle parameters or survival. These results indicate that E2F2 may have a unique role in maintaining the postmitotic state of terminally differentiated neurons, and may participate in apoptosis in neurons attempting to reenter the cell cycle. It may also be potentially useful in promoting the terminally arrested/differentiated state of tumor cells.	Univ Massachusetts, Sch Med, Dept Cellular & Mol Physiol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester	Kilpatrick, DL (corresponding author), Univ Massachusetts, Sch Med, Dept Cellular & Mol Physiol, 55 Lake Ave N, Worcester, MA 01655 USA.				NATIONAL CANCER INSTITUTE [R01CA079999] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036468] Funding Source: NIH RePORTER; NCI NIH HHS [CA-79999] Funding Source: Medline; NIDDK NIH HHS [DK36468] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; BREWER GJ, 1995, J NEUROSCI RES, V42, P674, DOI 10.1002/jnr.490420510; Brook A, 1996, EMBO J, V15, P3676, DOI 10.1002/j.1460-2075.1996.tb00737.x; BUCHKOVICH KJ, 1994, MOL BIOL CELL, V5, P1225, DOI 10.1091/mbc.5.11.1225; Callaghan DA, 1999, DEV BIOL, V207, P257, DOI 10.1006/dbio.1998.9162; CAMBRAYDEAKIN MA, 1995, NEURAL CELL CULTURE, P3; Cartwright P, 1998, ONCOGENE, V17, P611, DOI 10.1038/sj.onc.1201975; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Cui H, 1998, DEV BRAIN RES, V106, P129, DOI 10.1016/S0165-3806(97)00204-6; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; Dirks PB, 1998, ONCOGENE, V17, P867, DOI 10.1038/sj.onc.1202008; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; Frade JM, 2000, J CELL SCI, V113, P1139; Francesconi CM, 2000, INVEST OPHTH VIS SCI, V41, P1054; Gaubatz S, 1998, P NATL ACAD SCI USA, V95, P9190, DOI 10.1073/pnas.95.16.9190; Gill RM, 2000, J CELL BIOL, V148, P1187, DOI 10.1083/jcb.148.6.1187; Giovanni A, 2000, J BIOL CHEM, V275, P11553, DOI 10.1074/jbc.275.16.11553; Gollapudi L, 1999, J NEUROSCI RES, V56, P99, DOI 10.1002/(SICI)1097-4547(19990401)56:1<99::AID-JNR13>3.0.CO;2-G; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Hansen LA, 2000, CARCINOGENESIS, V21, P1271, DOI 10.1093/carcin/21.7.1271; Heibein JA, 1999, J IMMUNOL, V163, P4683; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; Kastner A, 1998, CELL GROWTH DIFFER, V9, P857; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Lindeman GJ, 1997, P NATL ACAD SCI USA, V94, P5095, DOI 10.1073/pnas.94.10.5095; Lukas J, 1996, MOL CELL BIOL, V16, P1047; MacManus JP, 1999, NEUROREPORT, V10, P2711, DOI 10.1097/00001756-199909090-00004; Magae J, 1996, J CELL SCI, V109, P1717; MESNER PW, 1992, J CELL BIOL, V119, P1669, DOI 10.1083/jcb.119.6.1669; Muller H, 2000, BBA-REV CANCER, V1470, pM1, DOI 10.1016/S0304-419X(99)00030-X; Myster DL, 2000, DEVELOPMENT, V127, P3249; Nagy Z, 1999, J NEURAL TRANSM-SUPP, P233; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; O'Hare MJ, 2000, J BIOL CHEM, V275, P25358, DOI 10.1074/jbc.M001725200; OKANO HJ, 1993, J NEUROSCI, V13, P2930; Park DS, 2000, J NEUROSCI, V20, P3104, DOI 10.1523/JNEUROSCI.20-09-03104.2000; PERSENGIEV SP, 1993, INT J BIOCHEM, V25, P441, DOI 10.1016/0020-711X(93)90637-T; Persengiev SP, 1999, MOL CELL BIOL, V19, P6048; Raina AK, 2000, J NEUROSCI RES, V61, P128, DOI 10.1002/1097-4547(20000715)61:2<128::AID-JNR2>3.3.CO;2-8; Ross ME, 1996, TRENDS NEUROSCI, V19, P62, DOI 10.1016/0166-2236(96)89622-6; Slack RS, 1998, J CELL BIOL, V140, P1497, DOI 10.1083/jcb.140.6.1497; Suzuki A, 2000, MOL CELL, V5, P217, DOI 10.1016/S1097-2765(00)80418-9; Takahashi Y, 2000, GENE DEV, V14, P804; Trimarchi JM, 1998, P NATL ACAD SCI USA, V95, P2850, DOI 10.1073/pnas.95.6.2850; vanGrunsven LA, 1996, ONCOGENE, V12, P855; Verona R, 1997, MOL CELL BIOL, V17, P7268, DOI 10.1128/MCB.17.12.7268; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; YAN GZ, 1995, J NEUROSCI, V15, P6200; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X	52	17	19	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 23	2001	20	37					5124	5131		10.1038/sj.onc.1204663	http://dx.doi.org/10.1038/sj.onc.1204663			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	463EN	11526501				2022-12-17	WOS:000170464000006
J	Parreno, M; Garriga, J; Limon, A; Albrecht, JH; Grana, X				Parreno, M; Garriga, J; Limon, A; Albrecht, JH; Grana, X			E1A modulates phosphorylation of p130 and p107 by differentially regulating the activity of G1/S cyclin/CDK complexes	ONCOGENE			English	Article						large T antigen (TAg); cyclins; cyclin dependent kinase (CDK); adenovirus; retinoblastoma protein	CELL-CYCLE CONTROL; CDC2-RELATED KINASE PITALRE; LARGE T-ANTIGEN; RETINOBLASTOMA PROTEIN; GENE-EXPRESSION; ADENOVIRUS E1A; PRB; INHIBITOR; CDK2; GROWTH	We have previously shown that the adenoviral 12S E1A protein modulates the phosphorylation status of p130 and p107 without apparent changes in the cell cycle dependent phosphorylation of the retinoblastoma protein. Here we report on the mechanisms by which E1A modifies differentially the phosphorylation status of pocket proteins. In human U-2 OS osteosarcoma cells transiently expressing E1A, ectopic expression of D-type cyclins alone or combined, but not cyclins E and/or A, fully rescues EIA-mediated block in hyperphosphorylation of p130 to form 3. However, cyclins E and A, individually or together, induce hyperphosphorylation of p130 to species with intermediate mobility. Phosphopeptide maps indicate that E1A inhibits phosphorylation of sites phosphorylatable by CDKs. One of these sites is Ser-1044. The effects of blocking the activities of endogenous and exogenous cyclins with p16 and dominant negative CDK2 in E1A expressing cells further indicate that p130 is phosphorylated by both D-type cyclin and cyclin E/CDK complexes and that E1A modulates the activity of these G1/S CDKs by independent mechanisms. Stable expression of E1A in MC3T3-E1 cells leads to downregulation of D-type cyclins, and upregulation of cyclins E and A. This is accompanied by increased CDK2 kinase activity. Downregulation of D-type cyclins in these cells correlates with a block on both p130 hyperphosphorylation to form 3 and hyperphosphorylation of p107. This is rescued by D-type cyclins but not by cyclin E. In addition, we show that the upregulation of cyclins E and A is at least partially dependent on an intact pocket protein/E2F pathway, but downregulation of D-type cyclins is not. Moreover, we provide evidence that while the lack of a functional pRB pathway also results in a block on hyperphosphorylation of p130 to form 3, this is not sufficient to induce constitutive expression of p130 form 2b.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Dept Biochem, Philadelphia, PA 19140 USA; Hennepin Cty Med Ctr, Dept Med, Minneapolis, MN 55415 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Hennepin County Medical Center	Grana, X (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Dept Biochem, 3307 N Broad St, Philadelphia, PA 19140 USA.	xavier@unix.temple.edu			NIAID NIH HHS [R01 AI45450, K02 AI01823] Funding Source: Medline; NIGMS NIH HHS [R29 GM54894] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K02AI001823, R01AI045450] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM054894] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albanese C, 1999, J BIOL CHEM, V274, P34186, DOI 10.1074/jbc.274.48.34186; Albrecht JH, 1999, CELL GROWTH DIFFER, V10, P397; Alevizopoulos K, 1998, EMBO J, V17, P5987, DOI 10.1093/emboj/17.20.5987; Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; Beck GR, 1998, J CELL BIOCHEM, V68, P269, DOI 10.1002/(SICI)1097-4644(19980201)68:2<269::AID-JCB13>3.0.CO;2-A; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Canhoto AJ, 2000, ONCOGENE, V19, P5116, DOI 10.1038/sj.onc.1203893; Castano E, 1998, MOL CELL BIOL, V18, P5380, DOI 10.1128/MCB.18.9.5380; Cenciarelli C, 1999, MOL CELL BIOL, V19, P5203; Cheng LY, 2000, J BIOL CHEM, V275, P30317, DOI 10.1074/jbc.M005707200; Coats S, 1999, CURR BIOL, V9, P163, DOI 10.1016/S0960-9822(99)80086-4; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; DeLuca A, 1997, J BIOL CHEM, V272, P20971, DOI 10.1074/jbc.272.34.20971; Garriga J, 1996, BIOCHEM J, V319, P293, DOI 10.1042/bj3190293; Garriga J, 1996, BIOCHEM J, V320, P983, DOI 10.1042/bj3200983; Garriga J, 1998, BIOCHEM J, V333, P645, DOI 10.1042/bj3330645; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; Hansen K, 2001, EMBO J, V20, P422, DOI 10.1093/emboj/20.3.422; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LUDLOW JW, 1995, SEMIN CANCER BIOL, V6, P195, DOI 10.1006/scbi.1995.0026; Mayol X, 1996, ONCOGENE, V13, P237; MAYOL X, 1995, ONCOGENE, V11, P801; MAYOL X, 1998, FRONT BIOSCI, V3, P11; MAYOL X, 1997, PROGR CELL CYCLE RES, P157; McConnell BB, 1999, MOL CELL BIOL, V19, P1981; Mitra J, 1999, MOL CELL BIOL, V19, P3916; MORAN E, 1993, FASEB J, V7, P880, DOI 10.1096/fasebj.7.10.8344487; Parreno M, 2000, J VIROL, V74, P3166, DOI 10.1128/JVI.74.7.3166-3176.2000; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; Raghunath M, 2000, MOL BRAIN RES, V77, P151, DOI 10.1016/S0169-328X(00)00048-6; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Smith EJ, 1998, CELL GROWTH DIFFER, V9, P297; SPITKOVSKY D, 1995, ONCOGENE, V10, P2421; SPITKOVSKY D, 1994, J VIROL, V68, P2206, DOI 10.1128/JVI.68.4.2206-2214.1994; Stubdal H, 1996, J VIROL, V70, P2781, DOI 10.1128/JVI.70.5.2781-2788.1996; Stubdal H, 1997, MOL CELL BIOL, V17, P4979, DOI 10.1128/MCB.17.9.4979; TAM SW, 1994, CANCER RES, V54, P5816; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Woo MSA, 1997, MOL CELL BIOL, V17, P3566, DOI 10.1128/MCB.17.7.3566; YEAGER T, 1995, CANCER RES, V55, P493; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740	50	17	17	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 9	2001	20	35					4793	4806		10.1038/sj.onc.1204644	http://dx.doi.org/10.1038/sj.onc.1204644			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	459VH	11521191				2022-12-17	WOS:000170271800004
J	Weil, MM; Kittrell, FS; Yu, YJ; McCarthy, M; Zabriskie, RC; Ullrich, RL				Weil, MM; Kittrell, FS; Yu, YJ; McCarthy, M; Zabriskie, RC; Ullrich, RL			Radiation induces genomic instability and mammary ductal dysplasia in Atm heterozygous mice	ONCOGENE			English	Article						radiation effects; breast cancer; ataxia-telangiectasia; genomic instability	ATAXIA-TELANGIECTASIA; DEFICIENT MICE; CANCER; SENSITIVITY; BALB/C	Ataxia-telangiectasia (AT) is a genetic syndrome resulting from the inheritance of two defective copies of the ATM gene that includes among its stigmata radiosensitivity and cancer susceptibility. Epidemiological studies have demonstrated that although women with a single defective copy of ATM (AT heterozygotes) appear clinically normal, they may never the less have an increased relative risk of developing breast cancer. Whether they are at increased risk for radiation-induced breast cancer from medical exposures to ionizing radiation is unknown. We have used a murine model of AT to investigate the effect of a single defective Atm allele, the murine homologue of ATM, on the susceptibility of mammary epithelial cells to radiation-induced transformation. Here we report that mammary epithelial cells from irradiated mice with one copy of Atm truncated in the PI-3 kinase domain were susceptible to radiation-induced genomic instability and generated a 10% incidence of dysplastic mammary ducts when transplanted into syngenic recipients, whereas cells from Atm(+/+) mice were stable and formed only normal ducts. Since radiation-induced ductal dysplasia is a precursor to mammary cancer, the results indicate that AT heterozygosity increases susceptibility to radiogenic breast cancer in this murine model system.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Univ Texas, Med Branch, Dept Radiat Oncol, Div Biol, Galveston, TX 77555 USA; Colorado State Univ, Dept Radiol Hlth Sci, Ft Collins, CO 80523 USA	University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; University of Texas System; University of Texas Medical Branch Galveston; Colorado State University	Weil, MM (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [R01CA073929, P01CA006294, R01CA043322] Funding Source: NIH RePORTER; NCI NIH HHS [CA43322, CA06294, CA73929] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS LM, 1987, CANCER RES, V47, P4425; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Barlow C, 1999, NAT GENET, V21, P359, DOI 10.1038/7684; BICEHOUSE HJ, 1975, 7 ANN NATL C RAD CON, P136; BOICE JD, 1992, NEW ENGL J MED, V326, P1357; BRIDGES BA, 1992, NEW ENGL J MED, V326, P1357; CONWAY BJ, 1994, RADIOLOGY, V191, P323, DOI 10.1148/radiology.191.2.8153301; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; HALL EJ, 1992, NEW ENGL J MED, V326, P1358; KULLER LH, 1992, NEW ENGL J MED, V326, P1357; LAND CE, 1992, NEW ENGL J MED, V326, P1359; Ponnaiya B, 1997, RADIAT RES, V147, P121, DOI 10.2307/3579411; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; SWIFT M, 1986, AM J HUM GENET, V39, P573; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; Ullrich RL, 1996, RADIAT RES, V146, P353, DOI 10.2307/3579468; UPTON AC, 1977, J NATL CANCER I, V59, P480; WAGNER LK, 1992, NEW ENGL J MED, V326, P1358	18	17	17	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 19	2001	20	32					4409	4411		10.1038/sj.onc.1204589	http://dx.doi.org/10.1038/sj.onc.1204589			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	453JK	11466622				2022-12-17	WOS:000169912600015
J	Kim, H; You, S; Farris, J; Foster, LK; Foster, DN				Kim, H; You, S; Farris, J; Foster, LK; Foster, DN			Post-transcriptional inactivation of p53 in immortalized murine embryo fibroblast cells	ONCOGENE			English	Article						p53 mRNA; immortal MEF; half-life; cycloheximide; emetine; actinomycin D	MYC MESSENGER-RNA; DEGRADATION; PROMOTES; DECAY; MDM2	The steady-state levels of p53 mRNA and protein were barely detectable by Northern and Western blot analysis in spontaneously immortalized (10)3 and (10)7 murine embryo fibroblast (MEF) cells, But when cells were treated with cycloheximide (CHX) or emetine, expression levels were restored to those observed in primary and immortal (10)10 MEF cells. However, levels of p53 mRNA were not changed in primary or (10)10 MEF cells by CHX treatment. De novo p53 mRNA synthetic rates were similar in primary, (10)10, (10)3, and (10)7 MEF cells treated with or without CHX. Treatment with actinomycin D (ActD) showed that p53 mRNA in primary and (10)10 MEF cells had a relatively long half-life of 22 h, compared to less than 2 h for (10)3 and (10)7 MEF cells. Pulse-chase analysis of p53 mRNA turnover using CHX and ActD showed that the rapid destabilization of p53 mRNA in (10)3 and (10)7 MEF cells could be regulated at the transcriptional and translational levels. In addition, the destabilization of p53 mRNA appeared to occur in the nucleus for (10)3 and (10)7 cells, but not for primary and (10)10 MEF cells. Taken together, the present study demonstrates: that inactivation of the p53 gene occurs at the posttranscriptional level by rapid destabilization of its mRNA in the nucleus of spontaneously immortalized (10)3 and (10)7 MEF cells.	Univ Minnesota, Dept Anim Sci, St Paul, MN 55108 USA; Seoul Natl Univ, Sch Agr Biotechnol, Suwon 441744, South Korea	University of Minnesota System; University of Minnesota Twin Cities; Seoul National University (SNU)	Foster, DN (corresponding author), Univ Minnesota, Dept Anim Sci, St Paul, MN 55108 USA.		Kang, Phil Jun/F-4716-2013; Kim, Hyunggee/F-2673-2013; You, Seungkwon/H-3067-2015	Kim, Hyunggee/0000-0002-4738-0990; 				Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HERRICK DJ, 1994, MOL CELL BIOL, V14, P2119, DOI 10.1128/MCB.14.3.2119; Jackson DA, 2000, FASEB J, V14, P242, DOI 10.1096/fasebj.14.2.242; Jarzembowski J A, 1997, Prog Mol Subcell Biol, V18, P141; JIANG D, 1993, ONCOGENE, V8, P2805; Kim H, 2001, ONCOGENE, V20, P2671, DOI 10.1038/sj.onc.1204378; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; Madisen L, 1998, MOL CELL BIOL, V18, P6281, DOI 10.1128/MCB.18.11.6281; Maquat LE, 2001, CELL, V104, P173, DOI 10.1016/S0092-8674(01)00202-1; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; Yeilding NM, 1998, J BIOL CHEM, V273, P15749, DOI 10.1074/jbc.273.25.15749	16	17	21	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 31	2001	20	25					3306	3310		10.1038/sj.onc.1204423	http://dx.doi.org/10.1038/sj.onc.1204423			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	440ET	11423980				2022-12-17	WOS:000169163500014
J	Park, SH; Kim, YS; Park, BK; Hougaard, S; Kim, SJ				Park, SH; Kim, YS; Park, BK; Hougaard, S; Kim, SJ			Sequence-specific enhancer binding protein is responsible for the differential expression of ERT/ESX/ELF-3/ESE-1/jen gene in human gastric cancer cell lines: Implication for the loss of TCF-beta type II receptor expression	ONCOGENE			English	Article						TGF-beta type II receptor; ets transcription factor; promoter; enhancer; gastric cancer	GROWTH-FACTOR-BETA; ETS TRANSCRIPTION FACTOR; TGF-BETA; MICROSATELLITE INSTABILITY; GENOMIC ORGANIZATION; FAMILY; MEMBER; INACTIVATION; REPRESSION; RESISTANCE	Transcriptional repression of the TGF-beta type II receptor (RII) is one of the mechanisms leading to TGF-beta resistance. The newly identified epithelium-specific ets transcription factor ERT/ESX/ELF-3/ESE-1/jen binds to the TGF-beta RII promoter and induces promoter activity. The human gastric cancer cell lines, which show undetectable level of TGF-beta RII mRNA, do not express ERT mRNA, To study the molecular mechanisms of loss of ERT expression, we have cloned and characterized the human ERT promoter, DNA transfection experiments and electrophoretic mobility shift assays have revealed the existence of a distinct enhancer element (-186 to -177) which we named ESE ((E) under bar RT promoter Specific element). Deletion of the ESE markedly decreased expression of the target gene. ESE interacts with two distinct nuclear protein complexes, at least one of which appears to be inactivated in a cell line which does not express the ERT mRNA, compared to a cell line expressing the ERT mRNA, These results suggest the possibility that inactivation of the sequence-specific DNA binding protein to the region from -186 to -177 contributes to the loss of ERT expression, leading to the loss of TGF-beta type II receptor mRNA in human gastric cancer cell lines.	NCI, Lab Cell Regulat & Carcinogenesis, Bethesda, MD 20892 USA; Gyeongsang Natl Univ, Coll Med, Dept Pediat, Chinju 660702, South Korea	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Gyeongsang National University	Kim, SJ (corresponding author), NCI, Lab Cell Regulat & Carcinogenesis, Bethesda, MD 20892 USA.							Andreoli JM, 1997, NUCLEIC ACIDS RES, V25, P4287, DOI 10.1093/nar/25.21.4287; BAE HW, 1995, J BIOL CHEM, V270, P29460, DOI 10.1074/jbc.270.49.29460; Chang CH, 1997, ONCOGENE, V14, P1617, DOI 10.1038/sj.onc.1200978; Chang J, 1997, CANCER RES, V57, P2856; Chang J, 2000, ONCOGENE, V19, P151, DOI 10.1038/sj.onc.1203252; Choi SG, 1998, J BIOL CHEM, V273, P110, DOI 10.1074/jbc.273.1.110; HAGAN KW, 1995, MOL CELL BIOL, V15, P809; Hahm KB, 1999, NAT GENET, V23, P222, DOI 10.1038/13854; Horie K, 1998, J CELL PHYSIOL, V175, P305, DOI 10.1002/(SICI)1097-4652(199806)175:3<305::AID-JCP8>3.0.CO;2-S; Hougaard S, 1999, BRIT J CANCER, V79, P1005, DOI 10.1038/sj.bjc.6690161; KADIN M, 1994, P NATL ACAD SCI USA, V9, P6002; Kim David H., 1996, Journal of Biomedical Science, V3, P143, DOI 10.1007/BF02253095; Kim DH, 1997, J BIOL CHEM, V272, P688; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Markowitz Sanford D., 1996, Cytokine and Growth Factor Reviews, V7, P93, DOI 10.1016/1359-6101(96)00001-9; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MISSERO C, 1991, P NATL ACAD SCI USA, V88, P3489, DOI 10.1073/pnas.88.8.3489; MYEROFF LL, 1995, CANCER RES, V55, P5545; Neve R, 1998, FASEB J, V12, P1541, DOI 10.1096/fasebj.12.14.1541; Oettgen P, 1997, MOL CELL BIOL, V17, P4419, DOI 10.1128/MCB.17.8.4419; Oettgen P, 1999, GENOMICS, V55, P358, DOI 10.1006/geno.1998.5681; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11576, DOI 10.1073/pnas.91.24.11576; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; Reiss M, 1997, ONCOL RES, V9, P447; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; Tymms MJ, 1997, ONCOGENE, V15, P2449, DOI 10.1038/sj.onc.1201427; WATSON DK, 1992, CELL GROWTH DIFFER, V3, P705; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Yang HK, 1999, ONCOGENE, V18, P2213, DOI 10.1038/sj.onc.1202535	32	17	18	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 8	2001	20	10					1235	1245		10.1038/sj.onc.1204227	http://dx.doi.org/10.1038/sj.onc.1204227			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	412TH	11313868				2022-12-17	WOS:000167570100011
J	Rudolph, B; Hueber, AO; Evan, GI				Rudolph, B; Hueber, AO; Evan, GI			Expression of Mad1 in T cells leads to reduced thymic cellularity and impaired mitogen-induced proliferation	ONCOGENE			English	Article						Myc; Mad; oncogene; cell cycle; lymphocyte; tumor suppressor	MYC-MEDIATED APOPTOSIS; WILD-TYPE P53; C-MYC; CYCLE PROGRESSION; GENE-EXPRESSION; TRANSCRIPTIONAL REPRESSORS; MAX; ACTIVATION; MICE; DIFFERENTIATION	To investigate Mad1 function in vivo, transgenic mice were:generated that express a Mad1 transgene in T lineage cells under the control of the proximal lck promoter. Thymus size in lck-Mad1 transgenic mice is drastically reduced although representation of the various thymocyte sub populations appears normal. To investigate more closely any effects of Mad1 expression on thymocytes, we examined thymic selection using MHC class I-restricted H-Y-TCR transgenic mice. Mad1 expression in vivo reduces the efficiency of positive selection. Furthermore, thymocytes and splenic T cells from lck-Mad1 transgenic mice display a profound proliferative defect in response to activation with either PMA/lonomycin or immobilized anti-CD3/CD28 antibody. This proliferative defect is not reversed by addition of exogenous IL-2 and is p53-independent. The growth inhibition caused by Mad1 is overcome by expression of active c-Myc.	Imperial Canc Res Fund, London WC2A 3PX, England	Cancer Research UK	Evan, GI (corresponding author), Univ Calif San Francisco, Ctr Canc, 2340 Sutter St, San Francisco, CA 94143 USA.		Anne-Odile, Hueber/P-9860-2019; Anne-Odile, Hueber/G-4352-2013	Anne-Odile, Hueber/0000-0003-3816-2446; Anne-Odile, Hueber/0000-0003-3816-2446				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Albrecht JH, 1998, ONCOGENE, V16, P2141, DOI 10.1038/sj.onc.1201728; AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BACKWOOD EM, 1992, GENE DEV, V6, P71; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLUTHMANN H, 1988, NATURE, V334, P156, DOI 10.1038/334156a0; Boonen GJJC, 1999, EUR J IMMUNOL, V29, P789; Boothby MR, 1997, J EXP MED, V185, P1897, DOI 10.1084/jem.185.11.1897; BRINSTER RL, 1985, P NATL ACAD SCI USA, V82, P4438, DOI 10.1073/pnas.82.13.4438; BroussardDiehl C, 1996, J IMMUNOL, V156, P3141; CARDING S, 1987, THYMUS, V10, P219; CHAFFIN KE, 1990, EMBO J, V9, P3821, DOI 10.1002/j.1460-2075.1990.tb07600.x; CHEN J, 1995, NAT MED, V1, P638, DOI 10.1038/nm0795-638; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; EDELHOFF S, 1994, ONCOGENE, V9, P665; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; ELSON A, 1995, ONCOGENE, V11, P181; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Foley KP, 1998, EMBO J, V17, P774, DOI 10.1093/emboj/17.3.774; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HSU B, 1995, ONCOGENE, V11, P175; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; KEATH EJ, 1984, CELL, V39, P339, DOI 10.1016/0092-8674(84)90012-6; Kiermaier A, 1997, CURR BIOL, V7, pR505, DOI 10.1016/S0960-9822(06)00249-1; LAHOZ EG, 1994, P NATL ACAD SCI USA, V91, P5503, DOI 10.1073/pnas.91.12.5503; LARSSON LG, 1994, ONCOGENE, V9, P1247; LINDEMAN GJ, 1995, ONCOGENE, V10, P1013; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; LYONS AB, 1994, J IMMUNOL METHODS, V171, P131, DOI 10.1016/0022-1759(94)90236-4; MOORE JP, 1987, ONCOGENE RES, V2, P65; Queva C, 1998, ONCOGENE, V16, P967, DOI 10.1038/sj.onc.1201611; Roussel MF, 1996, MOL CELL BIOL, V16, P2796; Rudolph B, 1996, EMBO J, V15, P3065, DOI 10.1002/j.1460-2075.1996.tb00669.x; Rudolph B, 2000, ONCOGENE, V19, P1891, DOI 10.1038/sj.onc.1203508; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; Schreiber-Agus N, 1998, NATURE, V393, P483, DOI 10.1038/31008; Schwartz D, 1998, SEMIN CANCER BIOL, V8, P325, DOI 10.1006/scbi.1998.0095; SPANOPOULOU E, 1989, NATURE, V342, P185, DOI 10.1038/342185a0; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; STEWART M, 1993, INT J CANCER, V53, P1023; TEH HS, 1989, J EXP MED, V169, P795, DOI 10.1084/jem.169.3.795; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Wells AD, 1997, J CLIN INVEST, V100, P3173, DOI 10.1172/JCI119873; WILDIN RS, 1991, J EXP MED, V173, P383, DOI 10.1084/jem.173.2.383; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; Zornig M, 1998, CURR BIOL, V8, P467, DOI 10.1016/S0960-9822(98)70182-4	56	17	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 8	2001	20	10					1164	1175		10.1038/sj.onc.1204196	http://dx.doi.org/10.1038/sj.onc.1204196			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	412TH	11313860				2022-12-17	WOS:000167570100003
J	Forgacs, E; Wren, JD; Kamibayashi, C; Kondo, M; Xu, XL; Markowitz, S; Tomlinson, GE; Muller, CY; Gazdar, AF; Garner, HR; Minna, JD				Forgacs, E; Wren, JD; Kamibayashi, C; Kondo, M; Xu, XL; Markowitz, S; Tomlinson, GE; Muller, CY; Gazdar, AF; Garner, HR; Minna, JD			Searching for microsatellite mutations in coding regions in lung, breast, ovarian and colorectal cancers	ONCOGENE			English	Article						microsatellite instability; mutation; repetitive DNA sequences	NONPOLYPOSIS COLON-CANCER; GENETIC INSTABILITY; MUTATOR PHENOTYPE; REPEAT EXPANSION; CELL-LINES; PROTEIN; HMLH1; IDENTIFICATION; TRANSCRIPTION; CONSEQUENCES	RepX represents a new informatics approach to probe the UniGene database for potentially polymorphic repeat sequences in the open reading frame (ORF) of genes, 56% of which were found to be actually polymorphic. We now have performed mutational analysis of 17 such sites in genes not found to be polymorphic (<0.03 frequency) in a large panel of human cancer genomic DNAs derived from 31 lung, 21 breast, seven ovarian, 21 (13 microsatellite instability (MSI)+ and eight MS-) colorectal cancer cell lines. In the lung, breast and ovarian tumor DNAs we found no mutations (<0.03-0.04 rate of tumor associated open reading frame mutations) in these sequences, BS contrast, 18 MSI+ colorectal cancers (13 cancer cell lines and five primary tumors) with mismatch repair defects exhibited six mutations in three of the 17 genes (SREBP-2, TAN-1, GR6) (P<0.000003 compared to all other cancers tested). We conclude that coding region microsatellite alterations are rare in lung, breast, ovarian carcinomas and MSI(-) colorectal cancers, but are relatively frequent in MSI (+) colorectal cancers with mismatch repair deficits.	Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Program Genet & Dev, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, McDermott Ctr Human Growth & Dev, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Ctr Biomed Invent, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Case Western Reserve Univ, Howard Hughes Med Inst, Cleveland, OH 44106 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Case Western Reserve University; Howard Hughes Medical Institute	Minna, JD (corresponding author), Univ Texas, Med Ctr, Hamon Ctr Therapeut Oncol, 6000 Harry Hines Blvd,NB 8-206, Dallas, TX 75390 USA.		Kondo, Masashi/I-7378-2014; Wren, Jonathan D/E-5611-2011	Wren, Jonathan D/0000-0003-2776-3545	NCI NIH HHS [P50 CA70907, CA 67409] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA067409, P50CA070907] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREW SE, 1993, NAT GENET, V4, P398, DOI 10.1038/ng0893-398; Bidichandani SI, 1998, AM J HUM GENET, V62, P111, DOI 10.1086/301680; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Fondon JW, 1998, P NATL ACAD SCI USA, V95, P7514, DOI 10.1073/pnas.95.13.7514; Girard L, 1996, GENE DEV, V10, P1930, DOI 10.1101/gad.10.15.1930; Gurin CC, 1999, CANCER RES, V59, P462; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; Jakupciak JP, 1999, J BIOL CHEM, V274, P23468, DOI 10.1074/jbc.274.33.23468; King BL, 1997, CANCER RES, V57, P209; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; Liu T, 1999, HUM GENET, V105, P437, DOI 10.1007/s004390051127; Malkhosyan S, 1996, NATURE, V382, P499, DOI 10.1038/382499a0; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Matuoka K, 1997, BIOCHEM BIOPH RES CO, V239, P488, DOI 10.1006/bbrc.1997.7492; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; ORTH K, 1994, P NATL ACAD SCI USA, V91, P9495, DOI 10.1073/pnas.91.20.9495; PARSONS R, 1995, CANCER RES, V55, P5548; Pekarsky Y, 1997, CANCER RES, V57, P3914; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Satijn DPE, 1997, MOL CELL BIOL, V17, P6076, DOI 10.1128/MCB.17.10.6076; Wells RD, 1996, J BIOL CHEM, V271, P2875, DOI 10.1074/jbc.271.6.2875; Wren JD, 2000, AM J HUM GENET, V67, P345, DOI 10.1086/303013; Yamamoto H, 1997, CANCER RES, V57, P4420	26	17	21	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 22	2001	20	8					1005	1009		10.1038/sj.onc.1204211	http://dx.doi.org/10.1038/sj.onc.1204211			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	404KP	11314036				2022-12-17	WOS:000167097000012
J	Sonneveld, E; Vrieling, H; Mullenders, LHF; van Hoffen, A				Sonneveld, E; Vrieling, H; Mullenders, LHF; van Hoffen, A			Mouse mismatch repair gene Msh2 is not essential for transcription-coupled repair of UV-induced cyclobutane pyrimidine dimers	ONCOGENE			English	Article						mismatch repair; transcription-coupled repair; UV-damage; mouse fibroblasts	NUCLEOTIDE-EXCISION-REPAIR; INDUCED DNA-DAMAGE; CANCER; PREDISPOSITION; FIBROBLASTS; DEFICIENCY; CELLS	The human mutS homolog gene MSH2 is essential for DNA mismatch repair (MMR) and defects in this gene can result in increased mutagenesis, genomic instability and hereditary nonpolyposis colorectal cancer (HNPCC). Besides correcting mismatch errors arising from DNA replication, it mas shown that deficiencies in bacterial and human MMR genes including MSH2 resulted in defective transcription-coupled repair (TCR) of UV-induced photolesions. Here we show that MMR-deficient fibroblasts derived from two independent isogenic mouse strains,vith defined Msh2 deficiencies are as proficient in TCR of UV-induced cyclobutane pyrimidine dimers (CPD) as wildtype fibroblasts. Our results indicate that in mouse cells Msh2 is not essential for TCR of UV-induced CPD in contrast to bacteria and human cells and suggest that the biological effects of UV in mouse Msh2(-/-) cells and mice are not due to defective TCR.	Leiden Univ, Med Ctr, Dept Radiat Genet & Chem Mutagenesis MGC, NL-2300 RA Leiden, Netherlands; Erasmus Univ, Dept Cell Biol & Genet MGC, NL-3000 DR Rotterdam, Netherlands; Interuniv Res Inst Radiopathol & Radiat Protect, JA Cohen Inst, Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Erasmus University Rotterdam	Mullenders, LHF (corresponding author), Leiden Univ, Med Ctr, Dept Radiat Genet & Chem Mutagenesis MGC, POB 9503, NL-2300 RA Leiden, Netherlands.		Vrieling, Harry/ABC-8068-2020	Vrieling, Harry/0000-0002-3034-2664				Berg RJW, 2000, CANCER RES, V60, P2858; Berry SE, 2000, CANCER RES, V60, P5773; Bertrand P, 1998, P NATL ACAD SCI USA, V95, P14278, DOI 10.1073/pnas.95.24.14278; Bootsma D., 1998, GENETIC BASIS HUMAN, P245; Buermeyer AB, 1999, ANNU REV GENET, V33, P533, DOI 10.1146/annurev.genet.33.1.533; CHEO DL, 1997, MUTAT RES, V4, P1; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; de Wind N, 1998, CANCER RES, V58, P248; de Wind N, 1999, NAT GENET, V23, P359, DOI 10.1038/15544; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; Friedberg E.C., 2016, DNA REPAIR MUTAGENES, V33, P35; Friedberg EC, 2000, MUTAT RES-DNA REPAIR, V459, P99, DOI 10.1016/S0921-8777(99)00068-3; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Leadon SA, 1998, MUTAT RES-DNA REPAIR, V407, P177, DOI 10.1016/S0921-8777(98)00007-X; Leadon SA, 1997, CANCER RES, V57, P3784; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; Lynch HT, 1997, CANCER GENET CYTOGEN, V93, P84, DOI 10.1016/S0165-4608(96)00290-7; Mellon I, 1996, SCIENCE, V272, P557, DOI 10.1126/science.272.5261.557; Mellon I, 1996, P NATL ACAD SCI USA, V93, P1292, DOI 10.1073/pnas.93.3.1292; Reitmair AH, 1997, CANCER RES, V57, P3765; Rey O, 1999, ONCOGENE, V18, P6997, DOI 10.1038/sj.onc.1203180; Smits R, 2000, GENE CHROMOSOME CANC, V29, P229, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1033>3.0.CO;2-R; Sweder KS, 1996, GENETICS, V143, P1127; van Oosten M, 2000, P NATL ACAD SCI USA, V97, P11268, DOI 10.1073/pnas.200226697; Van Sloun PPH, 1999, NUCLEIC ACIDS RES, V27, P3276, DOI 10.1093/nar/27.16.3276; VANHOFFEN A, 1995, EMBO J, V14, P360, DOI 10.1002/j.1460-2075.1995.tb07010.x; VANHOFFEN A, 1993, NUCLEIC ACIDS RES, V21, P5890, DOI 10.1093/nar/21.25.5890; Wu JX, 1999, MOL CELL BIOL, V19, P8292	28	17	17	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 25	2001	20	4					538	541		10.1038/sj.onc.1204125	http://dx.doi.org/10.1038/sj.onc.1204125			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395DB	11313985				2022-12-17	WOS:000166562500014
J	Wang, XP; Zhang, YJ; Deng, JH; Pan, HY; Zhou, FC; Montalvo, EA; Gao, SJ				Wang, XP; Zhang, YJ; Deng, JH; Pan, HY; Zhou, FC; Montalvo, EA; Gao, SJ			Characterization of the promoter region of the viral interferon regulatory factor encoded by Kaposi's sarcoma-associated herpesvirus	ONCOGENE			English	Article						Kaposi's sarcoma-associated herpesvirus; viral interferon regulatory factor; oncogene; promoter; TPA induction	MULTICENTRIC CASTLEMANS DISEASE; CAVITY-BASED LYMPHOMA; DNA-SEQUENCES; NUCLEOTIDE-SEQUENCE; TRANSCRIPTION; GENES; KSHV; IRF-1; IDENTIFICATION; PATHWAY	Viral interferon regulatory factor (vIRF) encoded by Kaposi's sarcoma-associated herpesvirus (KSHV) inhibits the expression of interferon-responsive genes, causes cellular transformation and transactivates KSHV genes. In the present study, we characterized the mRNA expression pattern of the vIRF gene and its promoter, A vIRF transcript of 1.7 kb in size was detected in low level in uninduced KSHV-infected cells and its expression was inducible by 12-O-tetradecanoylphorbol-13-acetate (TPA), sensitive to cycloheximide and resistant to phosphonoacetic acid. The transcription start site was mapped to 79 nt upstream of the ATG initiation site by 5'-RACE. Mutagenesis analysis identified a region between -56 and the transcription start site (+1) as the minimal promoter region that contains a functional TATA box at -27. A region between -337 and -125 contains a repressor domain negated by sequence from -991 to -499 in BCBL-1 cells, a region which was also identified to be responsive to TPA induction. These results demonstrate vIRF as st KSHV early gene, identify its promoter and define the promoter regions that contain regulatory elements controlling vIRF transcription.	Univ Texas, Hlth Sci Ctr, Dept Pediat, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Microbiol, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Gao, SJ (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Pediat, San Antonio, TX 78229 USA.		Gao, Shou-Jiang/B-8641-2012	Gao, Shou-Jiang/0000-0001-6194-1742	NHLBI NIH HHS [HL60604-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060604] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASUBEL FM, 1995, CURRENT PROTOCOLS MO; BOSHOFF C, 1995, LANCET, V345, P1043; Burysek L, 1999, J VIROL, V73, P7334; Carbone A, 1996, BRIT J HAEMATOL, V94, P533, DOI 10.1046/j.1365-2141.1996.d01-1826.x; CESARMAN E, 1995, BLOOD, V86, P2708, DOI 10.1182/blood.V86.7.2708.bloodjournal8672708; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHADBURN A, 1996, LAB INVEST, V74, pA109; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chang Y, 1996, ARCH INTERN MED, V156, P202, DOI 10.1001/archinte.156.2.202; Chen JG, 2000, J VIROL, V74, P8623, DOI 10.1128/JVI.74.18.8623-8634.2000; DUPIN N, 1995, LANCET, V345, P761, DOI 10.1016/S0140-6736(95)90642-8; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; Gao SJ, 1997, ONCOGENE, V15, P1979, DOI 10.1038/sj.onc.1201571; Gessain A, 1996, BLOOD, V87, P414; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; IMAM AMA, 1990, NUCLEIC ACIDS RES, V18, P6573, DOI 10.1093/nar/18.22.6573; Inagi R, 1999, J HUMAN VIROL, V2, P63; KARCHER DS, 1995, NEW ENGL J MED, V333, P797; LEBBE C, 1995, LANCET, V345, P1180, DOI 10.1016/S0140-6736(95)91011-5; Li MT, 1998, J VIROL, V72, P5433, DOI 10.1128/JVI.72.7.5433-5440.1998; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; Moore PS, 1996, SCIENCE, V274, P1739, DOI 10.1126/science.274.5293.1739; NADOR RG, 1995, NEW ENGL J MED, V333, P943, DOI 10.1056/NEJM199510053331417; PASTORE C, 1995, BRIT J HAEMATOL, V91, P918, DOI 10.1111/j.1365-2141.1995.tb05410.x; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Renne R, 1996, NAT MED, V2, P342, DOI 10.1038/nm0396-342; Roan F, 1999, J GEN VIROL, V80, P2205, DOI 10.1099/0022-1317-80-8-2205; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; Sarid R, 1998, J VIROL, V72, P1005, DOI 10.1128/JVI.72.2.1005-1012.1998; SCHALLING M, 1995, NAT MED, V1, P707, DOI 10.1038/nm0795-707; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; Sun R, 1999, J VIROL, V73, P2232, DOI 10.1128/JVI.73.3.2232-2242.1999; Zimring JC, 1998, J VIROL, V72, P701, DOI 10.1128/JVI.72.1.701-707.1998	35	17	19	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 25	2001	20	4					523	530		10.1038/sj.onc.1204115	http://dx.doi.org/10.1038/sj.onc.1204115			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395DB	11313983				2022-12-17	WOS:000166562500012
J	Zarich, N; Oliva, JL; Jorge, R; Santos, E; Rojas, JM				Zarich, N; Oliva, JL; Jorge, R; Santos, E; Rojas, JM			The isoform-specific stretch of hSos1 defines a new Grb2-binding domain	ONCOGENE			English	Article						hSos1; isoforms; Grb2; SH3 domains	NUCLEOTIDE EXCHANGE FACTOR; RECEPTOR TYROSINE KINASES; ACTIVATED PROTEIN-KINASE; SRC HOMOLOGY-3 DOMAINS; RAS SIGNALING PATHWAY; SH3 DOMAINS; FACTOR SON; SH3-LIGAND INTERACTIONS; STRUCTURAL BASIS; ADAPTER PROTEIN	hSos1 isoform II, defined by the presence of a 15 amino acid stretch in its carboxy-terminal region, exhibits higher Grb2 affinity than hSos1 isoform I. In this study, we investigated the cause for this difference and observed that, in addition to the four currently accepted Grb2-binding motifs, a number of additional, putative SH3-minimal binding sites (SH3-MBS) could be identified. The isoform II-specific 15 amino acid stretch contained one of them, Indeed, me demonstrated by site-directed mutagenesis that these SH3-MBS were responsible for the Grb2 interaction, and we found that C-terminal fragments of the two hSos1 isoforms (lacking the four cannonical Grb2-binding motifs, but containing the SH3-minimal binding sites) were able to bind Grb2, with the isoform II fragment showing higher Grb2 affinity than the corresponding isoform I fragment. Furthermore, we provide evidence that C-terminal truncated mutants of either hSos1 isoform, containing only the SH3-minimal binding sites, were able to originate in vivo stable complexes with Grb2, Although, Grb2-binding remains higher in both full-length isoforms, compared to the C-terminal truncated mutants, these mutants were also able to activate Ras, supporting a potential role of this C-terminal region as negative modulator of Sos1 activity. These findings document the existence of a new, functional, SH3-minimal binding site located in the specific stretch of hSos1 isoform II which may be responsible for the increased Grb2 affinity of this isoform in comparison to isoform I, and for the physiological properties differences between both isoforms, Moreover, these SH3-minimal binding sites may be sufficient to attain stable and functional hSos1-Grb2 complexes.	Inst Salud Carlos III, Ctr Nacl Biol Fundamental, Unidad Biol Celular, Madrid 28220, Spain; NCI, Cellular & Mol Biol Lab, NIH, Bethesda, MD 20892 USA	Instituto de Salud Carlos III; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Rojas, JM (corresponding author), Inst Salud Carlos III, Ctr Nacl Biol Fundamental, Unidad Biol Celular, Madrid 28220, Spain.		Rojas, José M./AAA-3354-2021; Rojas, José M/D-3718-2018	Rojas, José M./0000-0002-7547-2825; Rojas, José M/0000-0002-5383-3482; Zarich, Natasha/0000-0003-1058-6191				ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; Byrne JL, 1996, ONCOGENE, V13, P2055; CHARDIN P, 1995, FEBS LETT, V369, P47, DOI 10.1016/0014-5793(95)00578-W; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHERNIACK AD, 1994, J BIOL CHEM, V269, P4717; Corbalan-Garcia S, 1998, MOL CELL BIOL, V18, P880, DOI 10.1128/MCB.18.2.880; CorbalanGarcia S, 1996, MOL CELL BIOL, V16, P5674; Cussac D, 1999, FASEB J, V13, P31, DOI 10.1096/fasebj.13.1.31; CUSSAC D, 1994, EMBO J, V13, P4011, DOI 10.1002/j.1460-2075.1994.tb06717.x; DENHERTOG J, 1994, EMBO J, V13, P3020, DOI 10.1002/j.1460-2075.1994.tb06601.x; Douville E, 1997, ONCOGENE, V15, P373, DOI 10.1038/sj.onc.1201214; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FEIG LA, 1994, CURR OPIN CELL BIOL, V6, P204, DOI 10.1016/0955-0674(94)90137-6; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Guerrero C, 1998, ONCOGENE, V16, P613, DOI 10.1038/sj.onc.1201569; HOLSINGER LJ, 1995, P NATL ACAD SCI USA, V92, P9810, DOI 10.1073/pnas.92.21.9810; Joneson T, 1997, J MOL MED-JMM, V75, P587, DOI 10.1007/s001090050143; KARLOVICH CA, 1995, SCIENCE, V268, P576, DOI 10.1126/science.7725106; Kim JH, 1998, ONCOGENE, V16, P2597, DOI 10.1038/sj.onc.1201822; Koshiba S, 1997, J MOL BIOL, V269, P579, DOI 10.1006/jmbi.1997.1041; LI BQ, 1995, BIOCHEM BIOPH RES CO, V216, P110, DOI 10.1006/bbrc.1995.2598; LI BQ, 1993, P NATL ACAD SCI USA, V90, P8504, DOI 10.1073/pnas.90.18.8504; Li BQ, 1996, P NATL ACAD SCI USA, V93, P1001, DOI 10.1073/pnas.93.3.1001; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIM WA, 1994, NAT STRUCT BIOL, V1, P221, DOI 10.1038/nsb0494-221; Marinissen MJ, 1999, MOL CELL BIOL, V19, P4289; MAYER BJ, 1995, CURR BIOL, V5, P364, DOI 10.1016/S0960-9822(95)00073-X; MCCOLLAM L, 1995, J BIOL CHEM, V270, P15954, DOI 10.1074/jbc.270.27.15954; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; Mendelsohn Andrew R., 1994, Current Opinion in Biotechnology, V5, P482, DOI 10.1016/0958-1669(94)90061-2; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Rojas JM, 1996, ONCOGENE, V12, P2291; Rojas JM, 1999, ONCOGENE, V18, P1651, DOI 10.1038/sj.onc.1202483; ROZAKISADCOCK M, 1995, ONCOGENE, V11, P1417; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SIMON JA, 1995, CHEM BIOL, V2, P53, DOI 10.1016/1074-5521(95)90080-2; Soisson SM, 1998, CELL, V95, P259, DOI 10.1016/S0092-8674(00)81756-0; Sudol M, 1998, ONCOGENE, V17, P1469, DOI 10.1038/sj.onc.1202182; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; Tong XK, 2000, EMBO J, V19, P1263, DOI 10.1093/emboj/19.6.1263; WANG W, 1995, NAT GENET, V10, P294, DOI 10.1038/ng0795-294; YE ZS, 1994, P NATL ACAD SCI USA, V91, P12629, DOI 10.1073/pnas.91.26.12629; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; Zohar M, 1998, ONCOGENE, V17, P991, DOI 10.1038/sj.onc.1202022	57	17	18	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 30	2000	19	51					5872	5883		10.1038/sj.onc.1203955	http://dx.doi.org/10.1038/sj.onc.1203955			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	378CA	11127818				2022-12-17	WOS:000165563100006
J	Siegert, JL; Rushton, JJ; Sellers, WR; Kaelin, WG; Robbins, PD				Siegert, JL; Rushton, JJ; Sellers, WR; Kaelin, WG; Robbins, PD			Cyclin D1 suppresses retinoblastoma protein-mediated inhibition of TAF(II)250 kinase activity	ONCOGENE			English	Article						cyclin D1; Rb; TAF(II)250; kinase	RNA-POLYMERASE-II; SUSCEPTIBILITY GENE-PRODUCT; CELL-CYCLE; HISTONE DEACETYLASE; SP1-MEDIATED TRANSCRIPTION; REPRESSES TRANSCRIPTION; DIFFERENTIAL REGULATION; ESTROGEN-RECEPTOR; INITIATION-FACTOR; RB INTERACTS	The retinoblastoma tumor suppressor protein has been shown to bind directly and inhibit a transcriptionally-important amino-terminal kinase domain of TATA-binding protein-associated factor TAF(II)250. Cyclin D1 also is able to associate! with the amino terminus of TAF(II)250 in a region, cry similar to or overlapping the Rb-binding site. In this study, we ha,le examined whether cyclin D1 affects the functional interaction between Rb and TAF(II)250. We observed that when cyclin D1 is coincubated with Rb and TAF(II)250, the ability of Rb to inhibit TAF(II)250 kinase activity is effectively blocked, However, cyclin D1 by itself has no apparent effect on TAF(II)250 kinase activity. We further found that the Rb-related protein p107 can inhibit TAF(II)250 kinase activity, and this inhibition is likewise alleviated by cyclin D1, Cyclin D1 prevents the kinase-inhibitory effect of an Rb mutant unable to bind to D-type cyclins, indicating that it is acting through its association with TAF(II)250 and not with Rb, However, we found no evidence of TAF(II)250-binding competition between Rb and cyclin D1 in vitro. The adenovirus ELA protein, which also binds to both Rb and TAF(II)250, exhibited a suppressive effect on Rb-mediated kinase inhibition similar to that seen with cyclin D1, Our results suggest a novel means by which cyclin D1 may be able to independently regulate the activity of Rb.	Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA; Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Robbins, PD (corresponding author), Univ New Mexico, Dept Mol Genet & Microbiol, Canc Res Ctr 125, Sch Med, Albuquerque, NM 87131 USA.				PHS HHS [55227] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Adnane J, 1999, ONCOGENE, V18, P239, DOI 10.1038/sj.onc.1202297; ADNANE J, 1995, J BIOL CHEM, V270, P8837, DOI 10.1074/jbc.270.15.8837; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; Castano E, 1998, MOL CELL BIOL, V18, P5380, DOI 10.1128/MCB.18.9.5380; CHEN PL, 1995, CELL GROWTH DIFFER, V6, P199; Dikstein R, 1996, CELL, V84, P781, DOI 10.1016/S0092-8674(00)81055-7; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FINKELSTEIN A, 1992, NATURE, V355, P464, DOI 10.1038/355464a0; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; GEISBERG JV, 1995, MOL CELL BIOL, V15, P6283; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; Hahn S, 1998, CELL, V95, P579, DOI 10.1016/S0092-8674(00)81625-6; Harlow E LD, 1988, ANTIBODIES LAB MANUA; HAYASHIDA T, 1994, GENE, V141, P267; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Inoue K, 1998, MOL CELL BIOL, V18, P1590, DOI 10.1128/MCB.18.3.1590; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KITAJIMA S, 1994, J BIOL CHEM, V269, P29970; Lei L, 1998, MOL CELL BIOL, V18, P2130, DOI 10.1128/MCB.18.4.2130; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; O'Brien T, 2000, P NATL ACAD SCI USA, V97, P2456, DOI 10.1073/pnas.97.6.2456; O'Brien T, 1998, MOL CELL, V1, P905, DOI 10.1016/S1097-2765(00)80089-1; Ross JF, 1999, MOL CELL, V3, P195, DOI 10.1016/S1097-2765(00)80310-X; RUPPERT S, 1995, GENE DEV, V9, P2747, DOI 10.1101/gad.9.22.2747; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; Rushton JJ, 1997, CELL GROWTH DIFFER, V8, P1099; Sanchez I, 1996, CURR OPIN CELL BIOL, V8, P318, DOI 10.1016/S0955-0674(96)80004-4; Sekiguchi T, 1999, ONCOGENE, V18, P1797, DOI 10.1038/sj.onc.1202508; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; SHAO ZH, 1995, P NATL ACAD SCI USA, V92, P3115, DOI 10.1073/pnas.92.8.3115; Shao ZH, 1997, ONCOGENE, V15, P385, DOI 10.1038/sj.onc.1201204; SHAO ZH, 1995, ONCOGENE, V10, P221; Siegert JL, 1999, MOL CELL BIOL, V19, P846; SuzukiYagawa Y, 1997, MOL CELL BIOL, V17, P3284, DOI 10.1128/MCB.17.6.3284; Tansey WP, 1997, CELL, V88, P729, DOI 10.1016/S0092-8674(00)81916-9; WANG EH, 1994, SCIENCE, V263, P811, DOI 10.1126/science.8303298; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; WEINZIERL ROJ, 1993, NATURE, V362, P511, DOI 10.1038/362511a0; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; Woo MSA, 1997, MOL CELL BIOL, V17, P3566, DOI 10.1128/MCB.17.7.3566; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	51	17	17	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 23	2000	19	50					5703	5711		10.1038/sj.onc.1203966	http://dx.doi.org/10.1038/sj.onc.1203966			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	376VP	11126356				2022-12-17	WOS:000165477700001
J	Knight, EL; Warner, AJ; Maxwell, A; Prigent, SA				Knight, EL; Warner, AJ; Maxwell, A; Prigent, SA			Chimeric VEGFRs are activated by a small-molecule dimerizer and mediate downstream signalling cascades in endothelial cells	ONCOGENE			English	Article						VEGF; receptor; angiogenesis; signalling	RECEPTOR TYROSINE KINASE; GROWTH-FACTOR VEGF; PHOSPHATIDYLINOSITOL 3-KINASE; VASCULAR ENDOTHELIUM; FUNCTIONAL-ANALYSIS; BINDING-SITES; PLC-GAMMA; FLT-1; KDR; TRANSDUCTION	Despite much interest in vascular endothelial growth factor (VEGF) and its receptors (VEGFRs -1 and -2), VEGF-induced signalling cascades remain incompletely defined. Attempts to assign individual responses to a particular receptor have used either transfected cell lines, receptor-specific growth factors or antisense oligonucleotides. Such studies have attributed the majority of VEGF-induced responses to activation of VEGFR-2. As a consequence of poor growth factor-induced VEGFR-1 autophosphorylation however, observations from these studies may instead reflect the relative activation of the two receptors. We have generated novel chimeric VEGF receptors in which the dimerization domain of the B subunit of DNA gyrase is fused to the cytoplasmic domain of VEGFRs -1 and -2. When expressed in porcine aortic endothelial cells, both chimeric VEGFR-1 and -2 autophosphorylate in response to addition of the small-molecule dimerizing agent, coumermycin. Once activated, both receptors induce downstream signalling cascades, exemplified here by the activation of MAPK, PLC gamma and PKB/Akt. Furthermore, we demonstrate that the Y1175 residue of VEGFR-2 is essential for the activation of PLC gamma mediated by this chimeric receptor. In contrast to previous reports which show a limited ability of VEGFR-1 to mediate signalling cascades, we show that once sufficiently activated, VEGFR-1 signals in a similar manner to VEGFR-2 in endothelial cells.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England	University of Leicester	Prigent, SA (corresponding author), Univ Leicester, Dept Biochem, Univ Rd, Leicester LE1 7RH, Leics, England.			Maxwell, Anthony/0000-0002-5756-6430				Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; Bernatchez PN, 1999, J BIOL CHEM, V274, P31047, DOI 10.1074/jbc.274.43.31047; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; CUNNINGHAM SA, 1995, J BIOL CHEM, V270, P20254, DOI 10.1074/jbc.270.35.20254; Cunningham SA, 1997, BIOCHEM BIOPH RES CO, V240, P635, DOI 10.1006/bbrc.1997.7719; DANGELO G, 1995, P NATL ACAD SCI USA, V92, P6374, DOI 10.1073/pnas.92.14.6374; Dougher M, 1999, ONCOGENE, V18, P1619, DOI 10.1038/sj.onc.1202478; Esser S, 1998, J CELL SCI, V111, P1853; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; GILBERT EJ, 1994, MOL MICROBIOL, V12, P365, DOI 10.1111/j.1365-2958.1994.tb01026.x; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; Huang LW, 1999, J BIOL CHEM, V274, P38183, DOI 10.1074/jbc.274.53.38183; Igarashi K, 1998, BIOCHEM BIOPH RES CO, V251, P77, DOI 10.1006/bbrc.1998.9442; Katso RM, 1999, MOL CELL BIOL, V19, P6427; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; Kume A, 1999, BIOCHEM BIOPH RES CO, V260, P9, DOI 10.1006/bbrc.1999.0859; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Meyer M, 1999, EMBO J, V18, P363, DOI 10.1093/emboj/18.2.363; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; Mohi MG, 1998, MOL BIOL CELL, V9, P3299, DOI 10.1091/mbc.9.12.3299; Mukhopadhyay D, 1998, CANCER RES, V58, P1278; PELLMAN D, 1985, NATURE, V314, P374, DOI 10.1038/314374a0; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; Sawano A, 1997, BIOCHEM BIOPH RES CO, V238, P487, DOI 10.1006/bbrc.1997.7327; Schratzberger P, 2000, NAT MED, V6, P405, DOI 10.1038/74664; SEETHARAM L, 1995, ONCOGENE, V10, P135; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Sierke SL, 1997, BIOCHEM J, V322, P757, DOI 10.1042/bj3220757; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Takahashi T, 1999, ONCOGENE, V18, P2221, DOI 10.1038/sj.onc.1202527; Takahashi T, 1997, ONCOGENE, V14, P2079, DOI 10.1038/sj.onc.1201047; Thakker GD, 1999, J BIOL CHEM, V274, P10002, DOI 10.1074/jbc.274.15.10002; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Warner AJ, 2000, BIOCHEM J, V347, P501, DOI 10.1042/0264-6021:3470501; Wu LW, 2000, J BIOL CHEM, V275, P6059, DOI 10.1074/jbc.275.9.6059; Wu LW, 2000, J BIOL CHEM, V275, P5096, DOI 10.1074/jbc.275.7.5096; Yang JX, 1998, CURR BIOL, V8, P11, DOI 10.1016/S0960-9822(98)70015-6; Yu Y, 1999, J CELL PHYSIOL, V178, P235, DOI 10.1002/(SICI)1097-4652(199902)178:2<235::AID-JCP13>3.3.CO;2-J	45	17	18	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 9	2000	19	47					5398	5405		10.1038/sj.onc.1203915	http://dx.doi.org/10.1038/sj.onc.1203915			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	373RH	11103941				2022-12-17	WOS:000165302300011
J	Gregory, MA; Xiao, QR; Cornwall, GA; Lutterbach, B; Hann, SR				Gregory, MA; Xiao, QR; Cornwall, GA; Lutterbach, B; Hann, SR			B-Myc is preferentially expressed in hormonally-controlled tissues and inhibits cellular proliferation	ONCOGENE			English	Article						B-Myc protein; tissue-specific expression; phosphorylation; ubiquitin; growth inhibition	C-MYC; DIFFERENTIAL EXPRESSION; NEOPLASTIC-CELLS; ONCOGENE FAMILY; TARGET GENES; IN-VIVO; PROTEINS; MOUSE; PHOSPHORYLATION; TRANSFORMATION	The myc family of genes plays an important role in several cellular processes including proliferation, apoptosis, differentiation, and transformation. B-myc, a relatively new and largely unstudied member of the myc family, encodes a protein that is highly homologous to the N-terminal transcriptional regulatory domain of c-Myc, Here, we show that high level B-myc expression is restricted to specific mouse tissues, primarily hormonally-controlled tissues, with the highest level of expression in the epididymis, We also report the identification of the endogenous B-Myc protein from mouse tissues. Like other Myc family proteins, B-Myc is a short-lived nuclear protein which is phosphorylated on residues Ser-60 and Ser-68, Rapid proteolysis of B-Myc occurs via the ubiquitin-proteasome pathway. Finally, we found that overexpression of B-Myc significantly slows the growth of Rat la fibroblasts and COS cells suggesting B-Myc functions as an inhibitor of cellular proliferation.	Vanderbilt Univ, Sch Med, Dept Cell Biol, Nashville, TN 37232 USA; Texas Tech Univ, Hlth Sci Ctr, Dept Cell Biol & Biochem, Lubbock, TX 79430 USA	Vanderbilt University; Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center	Hann, SR (corresponding author), Vanderbilt Univ, Sch Med, Dept Cell Biol, MCN C-2310, Nashville, TN 37232 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD033903, R01HD033903] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA078888, R01CA047399] Funding Source: NIH RePORTER; NCI NIH HHS [CA47399, CA78888] Funding Source: Medline; NICHD NIH HHS [HD33903] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ASKER C, 1989, ONCOGENE, V4, P1523; ASKER CE, 1995, ONCOGENE, V11, P1963; Chang DW, 2000, MOL CELL BIOL, V20, P4309, DOI 10.1128/MCB.20.12.4309-4319.2000; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; Domashenko AD, 1997, MOL REPROD DEV, V47, P57, DOI 10.1002/(SICI)1098-2795(199705)47:1&lt;57::AID-MRD8&gt;3.0.CO;2-P; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; Gross-Mesilaty S, 1998, P NATL ACAD SCI USA, V95, P8058, DOI 10.1073/pnas.95.14.8058; HANN SR, 1983, CELL, V34, P789, DOI 10.1016/0092-8674(83)90535-4; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; INGVARSSON S, 1988, ONCOGENE, V3, P679; INGVARSSON S, 1988, MOL CELL BIOL, V8, P3168, DOI 10.1128/MCB.8.8.3168; Kjerfve, 1988, HYDRODYNAMICS ESTUAR, P31; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LUTTERBACH B, 1994, MOL CELL BIOL, V14, P5510, DOI 10.1128/MCB.14.8.5510; Lutterbach B, 1997, ONCOGENE, V14, P967, DOI 10.1038/sj.onc.1200920; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; Noguchi K, 1999, J BIOL CHEM, V274, P32580, DOI 10.1074/jbc.274.46.32580; OHagan RC, 1996, ONCOGENE, V13, P1323; PANNO JP, 1993, COMP BIOCHEM PHYS B, V104, P649, DOI 10.1016/0305-0491(93)90191-7; PULVERER BJ, 1994, ONCOGENE, V9, P59; RESAR LMS, 1993, MOL CELL BIOL, V13, P1130, DOI 10.1128/MCB.13.2.1130; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; SCHMID P, 1989, SCIENCE, V243, P226, DOI 10.1126/science.2911736; SEMSEI I, 1989, ONCOGENE, V4, P465; Spotts GD, 1997, MOL CELL BIOL, V17, P1459, DOI 10.1128/MCB.17.3.1459; TASHJIAN AH, 1970, J CELL BIOL, V47, P61, DOI 10.1083/jcb.47.1.61; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Turgeon JL, 1996, MOL ENDOCRINOL, V10, P439, DOI 10.1210/me.10.4.439; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	40	17	20	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	2000	19	42					4886	4895		10.1038/sj.onc.1203851	http://dx.doi.org/10.1038/sj.onc.1203851			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	362BB	11039906				2022-12-17	WOS:000089757800011
J	Zhang, CL; Tada, M; Kobayashi, H; Nozaki, M; Moriuchi, T; Abe, H				Zhang, CL; Tada, M; Kobayashi, H; Nozaki, M; Moriuchi, T; Abe, H			Detection of PTEN nonsense mutation and psi PTEN expression in central nervous system high-grade astrocytic tumors by a yeast-based stop codon assay	ONCOGENE			English	Article						astrocytoma; glioblastoma; PTEN/MMAC1; psi PTEN; pseudogene	P53 FUNCTIONAL ASSAY; BANNAYAN-ZONANA-SYNDROME; SUPPRESSOR GENE; GLIOBLASTOMA-MULTIFORME; HUMAN GLIOMAS; CELL-LINES; PTEN/MMAC1 MUTATIONS; GERMLINE MUTATIONS; MALIGNANT GLIOMAS; COWDEN-DISEASE	We have developed a new yeast-based assay for the detection of PTEN nonsense mutation, and applied it to a total of 42 astrocytic tumors, The assay utilizes homologous recombination of PCR-amplified PTEN cDNA samples to a yeast vector which expresses an in-frame PTEN::ADE2 chimera protein. An allele of nonsense mutation in the sample PTEN mRNA gives a truncated chimera protein in a yeast cell, resulting in the formation of a red colony, The assay and subsequent sequence analysis demonstrated nonsense mutations as red colonies of more than 10% in one of 10 anaplastic astrocytomas and six of 18 glioblastomas, but none in six pilocytic astrocytomas or in eight astrocytomas, Sequence analysis of white colonies showed one missense mutation in a glioblastoma. Interestingly, four of seven nonsense mutations were frame-shifts due to exon skipping, In addition, pink colonies were found in one of six pilocytic astrocytomas, three of eight astrocytomas, two of 10 anaplastic astrocytomas, and 10 of 18 glioblastomas, Sequence analysis of the pink colonies revealed a sequence similar to those reported as psi PTEN/PTH2. By testing mRNA and genomic DNA, it was found to be a processed pseudogene which was transcribed, The psi PTEN expression was complementary to PTEN mutation, for 14 of 18 glioblastomas showed either PTEN mutation or psi PTEN expression and only one case showed both PTEN mutation and psi PTEN expression (P<0.046), suggesting a pathological role of psi PTEN expression as an alternative to PTEN mutation in glioblastomas.	Hokkaido Univ, Grad Sch Med, Inst Canc, Div Cell Biol, Sapporo, Hokkaido 0608638, Japan; Hokkaido Univ, Grad Sch Med, Neurosurg Sect, Dept Neuropathophysiol, Sapporo, Hokkaido 0608638, Japan	Hokkaido University; Hokkaido University	Tada, M (corresponding author), Hokkaido Univ, Grad Sch Med, Inst Canc, Div Cell Biol, Sapporo, Hokkaido 0608638, Japan.		KOBAYASHI, Hiroyuki/G-8990-2012					AndreuttiZaugg C, 1997, CANCER RES, V57, P3288; AYALA FJ, 1995, SCIENCE, V270, P1930, DOI 10.1126/science.270.5244.1930; BELLO MJ, 1994, INT J CANCER, V57, P172, DOI 10.1002/ijc.2910570207; Bostrom J, 1998, CANCER RES, V58, P29; Cheney IW, 1998, CANCER RES, V58, P2331; Chiariello E, 1998, ONCOGENE, V16, P541, DOI 10.1038/sj.onc.1201689; Dahia PLM, 1998, ONCOGENE, V16, P2403, DOI 10.1038/sj.onc.1201762; Davies MA, 1999, CANCER RES, V59, P2551; Davies MA, 1998, CANCER RES, V58, P5285; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Haas-Kogan D, 1998, CURR BIOL, V8, P1195, DOI 10.1016/S0960-9822(07)00493-9; Hayashi Y, 1997, BRAIN PATHOL, V7, P871, DOI 10.1111/j.1750-3639.1997.tb00890.x; Ishii N, 1998, INT J CANCER, V76, P797, DOI 10.1002/(SICI)1097-0215(19980610)76:6<797::AID-IJC5>3.3.CO;2-1; Kim SK, 1998, ONCOGENE, V16, P89, DOI 10.1038/sj.onc.1201512; Kleihues P, 1993, HISTOLOGICAL TYPING; Kon H, 1998, ONCOGENE, V16, P257, DOI 10.1038/sj.onc.1201488; Kong DH, 1997, NAT GENET, V17, P143, DOI 10.1038/ng1097-143; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; LI WH, 1981, NATURE, V292, P237, DOI 10.1038/292237a0; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Liu WG, 1997, CANCER RES, V57, P5254; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; MAQUAT LE, 1995, RNA, V1, P453; Marsh DJ, 1998, HUM MOL GENET, V7, P507, DOI 10.1093/hmg/7.3.507; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Matsumoto R, 1998, CANCER RES, V58, P609; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Nakamura H, 1998, ONCOGENE, V16, P1009, DOI 10.1038/sj.onc.1201618; Olschwang S, 1998, NAT GENET, V18, P12, DOI 10.1038/ng0198-12; Rasheed BKA, 1997, CANCER RES, V57, P4187; REIFENBERGER G, 1994, CANCER RES, V54, P4299; Scala S, 1998, INT J ONCOL, V13, P665; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Tada M, 1997, NEUROSURGERY, V40, P393, DOI 10.1097/00006123-199702000-00034; Tada M, 1997, MOL CARCINOGEN, V18, P171, DOI 10.1002/(SICI)1098-2744(199703)18:3<171::AID-MC6>3.3.CO;2-2; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Teng DHF, 1997, CANCER RES, V57, P5221; Tohma Y, 1998, J NEUROPATH EXP NEUR, V57, P684, DOI 10.1097/00005072-199807000-00005; Tsou HC, 1998, HUM GENET, V102, P467, DOI 10.1007/s004390050723; VONDEIMLING A, 1992, J NEUROSURG, V77, P295, DOI 10.3171/jns.1992.77.2.0295; VONDEIMLING A, 1994, INT J CANCER, V57, P676, DOI 10.1002/ijc.2910570511; Wang SI, 1997, CANCER RES, V57, P4183; WEISMAN LS, 1987, J CELL BIOL, V105, P1539, DOI 10.1083/jcb.105.4.1539	48	17	18	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 7	2000	19	38					4346	4353		10.1038/sj.onc.1203795	http://dx.doi.org/10.1038/sj.onc.1203795			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	353JW	10980610				2022-12-17	WOS:000089271900005
J	Reddy, TR				Reddy, TR			A single point mutation in the nuclear localization domain of Sam68 blocks the Rev/RRE-mediated transactivation	ONCOGENE			English	Article						Sam68; nuclear localization signal; RRE-mediated transactivation; HIV-1 inhibition	RNA-BINDING PROTEIN; KH DOMAIN; HIV-1 REV; SRC; MITOSIS; REPLICATION; GENE	We have previously demonstrated that overexpression of Sam68 functionally substitutes for, as well as synergizes with, HIV-1 Rev in RRE-mediated gene expression and virus replication. In addition, we have shown that the C-terminal deletion mutants of Sam68 act with a transdominant negative phenotype in HIV replication, Previously, an Arginine429 mutation within the C-terminal domain of Sam68 has been reported to be critical for the localization of Sam68 in the nucleus. However, these studies were done in the context of truncated protein in which C-terminal amino acids 420-443 of Sam68 were fused to GFP. In contrast, we now report that the full length Sam68 protein having the same mutation (Arginine429 --> Alanine) is completely localized in the nucleus while another Sam68 (Proline439-->Arginine) mutant is found in the cytoplasm. The localization of these Sam68 mutant proteins also correlates,vith their function in RRE-mediated reporter gene expression, i.e. Sam68 mutant protein that is localized in the cytoplasm failed to enhance RRE-mediated transactivation. Furthermore, we demonstrate that Sam68 P439-->R inhibited the transactivation of RRE-mediated gene expression by both wild type Sam68 and Rev. These results indicate that the proline residue at position 439 unlike arginine at position 429, mag play a critical role in targeting Sam68 protein to nucleus. We propose that these negative dominant mutants of Sam68 may have potential as anti-viral agents to combat AIDS.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Reddy, TR (corresponding author), Univ Calif San Diego, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.				NCRR NIH HHS [RR04050] Funding Source: Medline; NIAID NIH HHS [P30AI36214-06] Funding Source: Medline; NIGMS NIH HHS [GM56089] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR004050] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI036214] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Barlat I, 1997, J BIOL CHEM, V272, P3129, DOI 10.1074/jbc.272.6.3129; Chen TP, 1997, MOL CELL BIOL, V17, P5707, DOI 10.1128/MCB.17.10.5707; CRUZALVAREZ M, 1987, J BIOL CHEM, V262, P13377; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; Ishidate T, 1997, FEBS LETT, V409, P237, DOI 10.1016/S0014-5793(97)00455-9; JONES AR, 1995, GENE DEV, V9, P1491, DOI 10.1101/gad.9.12.1491; Lin Q, 1997, J BIOL CHEM, V272, P27274, DOI 10.1074/jbc.272.43.27274; MALIM MH, 1992, J EXP MED, V176, P1197, DOI 10.1084/jem.176.4.1197; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; McBride AE, 1998, EXP CELL RES, V241, P84, DOI 10.1006/excr.1998.4047; Reddy TR, 1999, NAT MED, V5, P635, DOI 10.1038/9479; Resnick RJ, 1997, ONCOGENE, V15, P1247, DOI 10.1038/sj.onc.1201289; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; SIOMI H, 1993, NUCLEIC ACIDS RES, V21, P1193, DOI 10.1093/nar/21.5.1193; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0	15	17	17	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 22	2000	19	27					3110	3114		10.1038/sj.onc.1203637	http://dx.doi.org/10.1038/sj.onc.1203637			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329JM	10871864				2022-12-17	WOS:000087903900009
J	Itano, O; Ueda, M; Kikuchi, K; Shimazu, M; Kitagawa, Y; Aiura, K; Kitajima, M				Itano, O; Ueda, M; Kikuchi, K; Shimazu, M; Kitagawa, Y; Aiura, K; Kitajima, M			A new predictive factor for hepatocellular carcinoma based on two-dimensional electrophoresis of genomic DNA	ONCOGENE			English	Article						RLGS; HCC; postoperative recurrence; disease-free survival; genetic marker	INTRAHEPATIC RECURRENCE; CLONING METHOD; AMPLIFICATION; CANCER; HEPATECTOMY; RESECTION; CIRRHOSIS; SEQUENCES	Molecular genetic analyses have clarified that accumulation of genomic changes provides important steps in carcinogenesis and have identified a number of valuable genetic markers for certain cancers. To date, however, no prognostic markers have been identified for hepatocellular carcinoma (HCC). In this study, we used restriction landmark genomic scanning (RLGS), a new high-speed screening method for multiple genomic changes, to detect unknown genetic alterations in HCC. Thirty-one HCC samples and their normal counterparts were examined by RLGS. Eight spot changes were common in several cases, and all were seen only on the HCC profile. Five of these spots were detected in more than 12 of 31 cases (38.7%). Viral infection had no influence on changes in the RLGS spots. The disease-free survival rate for patients,vith greater than or equal to 16 changed RLGS spots was significantly lower than that for patients with fewer changed RLGS spots (less than or equal to 15 spots) (P < 0.001). In multivariate analysis, the number of changed spots,vas proven to retain an independent prognostic value (relative risk 1.095: P = 0.0031). These results suggest that the number of changed RLGS spots may be a useful biological marker for recurrence of HCC.	Keio Univ, Sch Med, Dept Surg, Shinjuku Ku, Tokyo 1608582, Japan; Tokyo Denryoku Hosp, Dept Surg, Shinjuku Ku, Tokyo 1600016, Japan	Keio University	Ueda, M (corresponding author), Keio Univ, Sch Med, Dept Surg, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.							ARII S, 1992, CANCER, V69, P913, DOI 10.1002/1097-0142(19920215)69:4<913::AID-CNCR2820690413>3.0.CO;2-T; BELGHITI J, 1991, ANN SURG, V214, P114, DOI 10.1097/00000658-199108000-00004; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; Costello JF, 1997, CANCER RES, V57, P1250; HATADA I, 1991, P NATL ACAD SCI USA, V88, P9523, DOI 10.1073/pnas.88.21.9523; HIMENO Y, 1988, LIVER, V8, P208; HIROTSUNE S, 1992, CANCER RES, V52, P3642; HIROTSUNE S, 1993, BIOCHEM BIOPH RES CO, V194, P1406, DOI 10.1006/bbrc.1993.1981; HSU HC, 1988, CANCER, V61, P2095, DOI 10.1002/1097-0142(19880515)61:10<2095::AID-CNCR2820611027>3.0.CO;2-H; HSU HC, 1991, HEPATOLOGY, V13, P923, DOI 10.1002/hep.1840130520; JOW SC, 1992, HEPATOLOGY, V16, P1367; KEW MC, 1984, SEMIN LIVER DIS, V4, P136, DOI 10.1055/s-2008-1040653; KINOSHITA T, 1995, CANCER, V76, P2504, DOI 10.1002/1097-0142(19951215)76:12<2504::AID-CNCR2820761215>3.0.CO;2-I; Kitagawa Y, 1996, CLIN CANCER RES, V2, P909; Kubo S, 1998, JPN J CANCER RES, V89, P419, DOI 10.1111/j.1349-7006.1998.tb00580.x; LINDSAY S, 1987, NATURE, V327, P336, DOI 10.1038/327336a0; Lise M, 1998, CANCER, V82, P1028, DOI 10.1002/(SICI)1097-0142(19980315)82:6<1028::AID-CNCR4>3.0.CO;2-A; *LIV CANC STUD GRO, 1997, CLASS PRIM LIV CANC, P1; Miwa W, 1996, BIOCHEM BIOPH RES CO, V225, P968, DOI 10.1006/bbrc.1996.1280; MIWA W, 1995, ELECTROPHORESIS, V16, P227, DOI 10.1002/elps.1150160138; OHSUMI T, 1995, BIOCHEM BIOPH RES CO, V212, P632, DOI 10.1006/bbrc.1995.2016; OHSUMI T, 1995, ELECTROPHORESIS, V16, P203, DOI 10.1002/elps.1150160135; SIRABE K, 1991, HEPATOLOGY, V14, P913; TAKAYAMA T, 1990, LANCET, V336, P1150, DOI 10.1016/0140-6736(90)92768-D; TSUDA H, 1988, GASTROENTEROLOGY, V95, P1664, DOI 10.1016/S0016-5085(88)80093-3; Yamanaka N, 1997, CANCER-AM CANCER SOC, V79, P1509, DOI 10.1002/(SICI)1097-0142(19970415)79:8<1509::AID-CNCR10>3.0.CO;2-1; ZHANG XS, 1987, J BEIJING I CIVIL EN, V2, P2	27	17	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 23	2000	19	13					1676	1683		10.1038/sj.onc.1203459	http://dx.doi.org/10.1038/sj.onc.1203459			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	297LG	10763824				2022-12-17	WOS:000086083800007
J	McCormack, MP; Gonda, TJ				McCormack, MP; Gonda, TJ			Myeloproliferative disorder and leukaemia in mice induced by different classes of constitutive mutants of the human IL-3/IL-5/GM-CSF receptor common beta subunit	ONCOGENE			English	Article						cytokine receptor; leukaemia; myeloproliferative disorder; mice	COLONY-STIMULATING FACTOR; HUMAN GM-CSF; ACUTE MYELOBLASTIC-LEUKEMIA; GROWTH SIGNAL-TRANSDUCTION; HEMATOPOIETIC STEM-CELLS; TRANSGENIC MICE; ALPHA-CHAIN; FACTOR GENE; TYROSINE PHOSPHORYLATION; CYTOKINE RECEPTORS	Several constitutively active mutant forms of the common beta subunit of the human IL-3, IL-5 and GMCSF receptors (hpc), which enable it to signal in the absence of ligand, have recently been described. Two of these, V449E and I374N, are amino acid substitutions in the transmembrane and extracellular regions of h beta c, respectively, A third, FI Delta, contains a 37 amino acid duplication in the extracellular domain. We have shown previously that when expressed in primary murine haemopoietic cells, the extracellular mutants confer factor-independence on cells of the neutrophil and monocyte lineages only, whereas V449E does so on all cell types of the myeloid and erythroid compartments. To study the in vivo effects and leukaemic potential of these mutants, we have expressed all three in mice by bone marrow reconstitution using retrovirally infected donor cells, Expression of the extracellular mutants leads to an early onset, chronic myeloproliferative disorder marked by elevations in the neutrophil, monocyte, erythrocyte and platelet lineages, In contrast, expression of V449E leads to an acute leukaemia-like syndrome of anaemia, thrombocytopaenia and blast cell expansion, These data support the possibility that activating mutations in h beta c are involved in haemopoietic disorders in man.	Hanson Ctr Canc Res, Inst Med & Vet Sci, Adelaide, SA 5000, Australia	Institute Medical & Veterinary Science Australia	Gonda, TJ (corresponding author), Hanson Ctr Canc Res, Inst Med & Vet Sci, Frome Rd, Adelaide, SA 5000, Australia.		Gonda, Thomas J/A-3620-2012	McCormack, Matthew/0000-0003-1536-5611				BARRY SC, 1994, J BIOL CHEM, V269, P8488; Barry SC, 1997, BLOOD, V89, P842, DOI 10.1182/blood.V89.3.842; CHANG JM, 1989, J CLIN INVEST, V84, P1488, DOI 10.1172/JCI114324; CHANG JM, 1989, BLOOD, V73, P1487; D'Andrea RJ, 1998, J CLIN INVEST, V102, P1951, DOI 10.1172/JCI3729; DANDREA R, 1994, BLOOD, V83, P2802, DOI 10.1182/blood.V83.10.2802.2802; DeJong MO, 1997, STEM CELLS, V15, P275, DOI 10.1002/stem.150275; Doi H, 1997, P NATL ACAD SCI USA, V94, P2513, DOI 10.1073/pnas.94.6.2513; FREEDMAN MH, 1993, BLOOD, V81, P3068; Gonda TJ, 1997, BLOOD, V89, P355, DOI 10.1182/blood.V89.2.355; GUALTIERI RJ, 1989, BLOOD, V74, P2360; Ihle JN, 1995, ADV IMMUNOL, V60, P1, DOI 10.1016/S0065-2776(08)60582-9; Jenkins BJ, 1998, BLOOD, V92, P1989, DOI 10.1182/blood.V92.6.1989; Jenkins BJ, 1999, J BIOL CHEM, V274, P8669, DOI 10.1074/jbc.274.13.8669; JENKINS BJ, 1995, EMBO J, V14, P4276, DOI 10.1002/j.1460-2075.1995.tb00102.x; JOHNSON GR, 1989, EMBO J, V8, P441, DOI 10.1002/j.1460-2075.1989.tb03396.x; KAUFMAN DC, 1988, BLOOD, V72, P1329; LANG RA, 1987, CELL, V51, P675, DOI 10.1016/0092-8674(87)90136-X; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; McCormack MP, 1997, BLOOD, V90, P1471, DOI 10.1182/blood.V90.4.1471.1471_1471_1481; METCALF D, 1987, EXP HEMATOL, V15, P1; METCALF D, 1986, BLOOD, V67, P37; METCALF D, 1986, J CELL PHYSIOL, V128, P421, DOI 10.1002/jcp.1041280311; Metcalf D, 1995, HEMOPOIETIC COLONY S; Metcalf D, 1984, CLONAL CULTURE HEMOP; MIYAJIMA A, 1993, BLOOD, V82, P1960; Nishijima I, 1997, BLOOD, V90, P1031, DOI 10.1182/blood.V90.3.1031.1031_1031_1038; OKADA S, 1992, BLOOD, V80, P3044; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; POLOTSKAYA A, 1993, CELL GROWTH DIFFER, V4, P523; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; TAKAKI S, 1994, MOL CELL BIOL, V14, P7404, DOI 10.1128/MCB.14.11.7404; UCHIDA N, 1992, J EXP MED, V175, P175, DOI 10.1084/jem.175.1.175; YOUNG DC, 1987, J CLIN INVEST, V79, P100, DOI 10.1172/JCI112769; YOUNG DC, 1986, BLOOD, V68, P1178	35	17	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	1999	18	51					7190	7199		10.1038/sj.onc.1203226	http://dx.doi.org/10.1038/sj.onc.1203226			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602472				2022-12-17	WOS:000084119400002
J	Knecht, H; Berger, C; McQuain, C; Rothenberger, S; Bachmann, E; Martin, J; Esslinger, C; Drexler, HG; Cai, YC; Quesenberry, PJ; Odermatt, BF				Knecht, H; Berger, C; McQuain, C; Rothenberger, S; Bachmann, E; Martin, J; Esslinger, C; Drexler, HG; Cai, YC; Quesenberry, PJ; Odermatt, BF			Latent membrane protein 1 associated signaling pathways are important in tumor cells of Epstein-Barr virus negative Hodgkin's disease	ONCOGENE			English	Article						LMP1; Reed-Sternberg cells; TRAF2; JNK pathway	NF-KAPPA-B; NECROSIS-FACTOR RECEPTOR; REED-STERNBERG CELLS; TERMINAL KINASE; MEDIATED TRANSCRIPTION; TRANSFORMING PROTEIN; CYTOPLASMIC DOMAIN; GENE-EXPRESSION; LMP1 ONCOGENE; ACTIVATION	The latent membrane protein 1 (LMP1) oncogene of Epstein-Barr virus (EBV) is selectively expressed in the Reed-Sternberg (RS) cells of EBV-associated Hodgkin's disease (HD). However, no differences in clinical presentation and course are found between EBV positive and EBV negative forms of HD suggesting a common pathogenetic mechanism. We have studied the LMP1 associated signaling pathways and their dominant negative inhibition in the myelomonocytic HD-MyZ and the B-lymphoid L-428 HD cell lines. In both EBV negative cell lines expression of LMP1 is associated with the formation of multinuclear RS cells. Dominant negative inhibition of NF-kappa B mediated signaling at the step of I kappa B-alpha phosphorylation results in increased cell death with only a few typical RS cells resistant to overexpression of the dominant negative inhibitor I kappa B-alpha-N Delta 54. However, dominant negative inhibition of NF-kappa B mediated signaling at the early step of TRAF2 interaction results in the formation of multinuclear cells in both cell lines and, in addition, in clusters of small mononuclear cells in the HD-MyZ cell line. In HD-MyZ cells overexpression of the powerful JBD-inhibitor of the JNK signal transduction pathway is restricted to small cells and never observed in RS cells. These small cells undergo apoptosis as shown by the TUNEL technique. Apoptosis of small cells is still observed after cotransfection of JBD and LMP1 but in addition a few apoptotic HD-MyZ cells with large fused nuclear masses are identified suggesting that specific inhibition of JNK leads also to apoptosis of LMP1. induced RS cells. Thus, activation of the JNK signaling pathway is also important in the formation of Reed-Sternberg cells. Our findings are consistent with a model where all three LMP1 associated functions, i.e. NF-kappa B mediated transcription, TRAF2 dependent signaling, and c-Jun activation act as a common pathogenetic denominator of both EBV negative and EBV positive HD.	Univ Massachusetts, Ctr Canc, LIMK Labs, Worcester, MA 01605 USA; Univ Lausanne, Inst Pharmacol & Toxicol, CH-1015 Lausanne, Switzerland; Univ Colorado, MCD Biol, Boulder, CO 80309 USA; LICR, Lausanne, Switzerland; DSMZ, Braunschweig, Germany; Univ Zurich Hosp, Lab Immunohistochem, CH-8091 Zurich, Switzerland	University of Massachusetts System; University of Massachusetts Worcester; University of Lausanne; University of Colorado System; University of Colorado Boulder; Leibniz Institut fur Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); University of Zurich; University Zurich Hospital	Knecht, H (corresponding author), Viollier Inst, Div Hematol, Spalenring 145, CH-4002 Basel, Switzerland.			Rothenberger, Sylvia/0000-0001-8633-2994				Baeuerle PA, 1998, CURR BIOL, V8, pR19, DOI 10.1016/S0960-9822(98)70010-7; BAICHWAL VR, 1988, ONCOGENE, V2, P461; Baker SJ, 1996, ONCOGENE, V12, P1; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; BARGOU RC, 1993, J EXP MED, V177, P1257, DOI 10.1084/jem.177.5.1257; Bargou RC, 1996, BLOOD, V87, P4340, DOI 10.1182/blood.V87.10.4340.bloodjournal87104340; Brodeur SR, 1997, J BIOL CHEM, V272, P19777, DOI 10.1074/jbc.272.32.19777; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; CARBONE A, 1995, BLOOD, V85, P780, DOI 10.1182/blood.V85.3.780.bloodjournal853780; Devergne O, 1996, MOL CELL BIOL, V16, P7098; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; DREXLER HG, 1994, LEUKEMIA LYMPHOMA, V3, P201; Duckett CS, 1997, MOL CELL BIOL, V17, P1535, DOI 10.1128/MCB.17.3.1535; DURKOP H, 1992, CELL, V68, P421, DOI 10.1016/0092-8674(92)90180-K; Eliopoulos AG, 1996, ONCOGENE, V13, P2243; Eliopoulos AG, 1998, ONCOGENE, V16, P1731, DOI 10.1038/sj.onc.1201694; Floettmann JE, 1997, ONCOGENE, V15, P1851, DOI 10.1038/sj.onc.1201359; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gires O, 1997, EMBO J, V16, P6131, DOI 10.1093/emboj/16.20.6131; Glaser SL, 1997, INT J CANCER, V70, P375, DOI 10.1002/(SICI)1097-0215(19970207)70:4&lt;375::AID-IJC1&gt;3.0.CO;2-T; HALUSKA FG, 1994, BLOOD, V84, P1005, DOI 10.1182/blood.V84.4.1005.bloodjournal8441005; HAMMARSKJOLD ML, 1992, J VIROL, V66, P6496; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HERBST H, 1991, P NATL ACAD SCI USA, V88, P4766, DOI 10.1073/pnas.88.11.4766; HERRERO JA, 1995, J VIROL, V69, P2168, DOI 10.1128/JVI.69.4.2168-2174.1995; HUEN DS, 1995, ONCOGENE, V10, P549; Izumi KM, 1999, MOL CELL BIOL, V19, P5759; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P12592, DOI 10.1073/pnas.94.23.12592; JOSKE DJL, 1992, BLOOD, V80, P2610; Kadin Marshall E., 1994, Current Opinion in Oncology, V6, P456, DOI 10.1097/00001622-199409000-00002; Kanzler H, 1996, J EXP MED, V184, P1495, DOI 10.1084/jem.184.4.1495; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kaye KM, 1996, P NATL ACAD SCI USA, V93, P11085, DOI 10.1073/pnas.93.20.11085; Kieser A, 1999, EMBO J, V18, P2511, DOI 10.1093/emboj/18.9.2511; Kieser A, 1997, EMBO J, V16, P6478, DOI 10.1093/emboj/16.21.6478; Kilger E, 1998, EMBO J, V17, P1700, DOI 10.1093/emboj/17.6.1700; KNECHT H, 1993, BLOOD, V82, P2937; Knecht H, 1996, ONCOGENE, V13, P947; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MARTIN JM, 1993, J VIROL, V67, P5269, DOI 10.1128/JVI.67.9.5269-5278.1993; Messineo C, 1998, BLOOD, V91, P2443, DOI 10.1182/blood.V91.7.2443.2443_2443_2451; MITCHELL T, 1995, J VIROL, V69, P2968, DOI 10.1128/JVI.69.5.2968-2976.1995; MOORTHY RK, 1993, J VIROL, V67, P1638, DOI 10.1128/JVI.67.3.1638-1646.1993; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; PALLESEN G, 1991, LANCET, V337, P320, DOI 10.1016/0140-6736(91)90943-J; REGNIER CH, 1995, J BIOL CHEM, V270, P25715, DOI 10.1074/jbc.270.43.25715; Reinhard C, 1997, EMBO J, V16, P1080, DOI 10.1093/emboj/16.5.1080; Rothe M, 1996, P NATL ACAD SCI USA, V93, P8241, DOI 10.1073/pnas.93.16.8241; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Rothenberger S, 1997, ONCOGENE, V14, P2123, DOI 10.1038/sj.onc.1201032; Sandberg M, 1997, J VIROL, V71, P4649, DOI 10.1128/JVI.71.6.4649-4656.1997; SCHAADT M, 1979, BLUT, V38, P185, DOI 10.1007/BF01007965; STEIN H, 1985, BLOOD, V66, P848; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; URBA WJ, 1992, NEW ENGL J MED, V326, P678, DOI 10.1056/NEJM199203053261006; Van Antwerp DJ, 1998, TRENDS CELL BIOL, V8, P107, DOI 10.1016/S0962-8924(97)01215-4; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063	60	17	19	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 25	1999	18	50					7161	7167		10.1038/sj.onc.1203177	http://dx.doi.org/10.1038/sj.onc.1203177			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597317				2022-12-17	WOS:000083901900023
J	Konishi, Y; Tominaga, M; Watanabe, Y; Imamura, F; Goldfarb, A; Maki, R; Blum, H; De Robertis, EM; Tominaga, A				Konishi, Y; Tominaga, M; Watanabe, Y; Imamura, F; Goldfarb, A; Maki, R; Blum, H; De Robertis, EM; Tominaga, A			GOOSECOID inhibits erythrocyte differentiation by competing with Rb for PU.1 binding in murine cells	ONCOGENE			English	Article						goosecoid; PU.1; Rb	TRANSCRIPTION FACTOR PU.1; RETINOBLASTOMA PROTEIN; ERYTHROLEUKEMIA-CELLS; POSITIVE REGULATOR; GENE-PRODUCT; ETS ONCOGENE; LEUKEMIA; EXPRESSION; SCL; HEMATOPOIESIS	Misexpression of the dorsal mesodermal patterning factor goosecoid on the ventral side of amphibian embryos results in inhibition of blood formation in early embryogenesis, To investigate the mechanism of this inhibition, we ectopically expressed goosecoid in erythroleukemia cells. While erythroid differentiation of these cells can be induced by activin, goosecoid expressing cells were unresponsive to activin, We demonstrate an in vitro interaction between the oncogene PU.1, an ets family transcription factor thought to play a role in erythropoiesis, and the goosecoid protein (GSC). Interaction with PU.1 was specific as GSC did not bind to the ets family members, Fli-1 or Ets-2, The ability of goosecoid expressing erythroleukemia cells to differentiate in response to activin was rescued by coexpression of the GSC-binding N-terminal portion of PU.1. The N-terminal portion of PU.1 was coimmunoprecipitated with anti-GSC antibodies as well. The N-terminal domain of PU.1 is the region recognized by the retinoblastoma protein (Rb), a tumor suppressor gene presumably involved in erythroid differentiation. We show that GSC competitively inhibits binding of Rb to PU.1, Our data suggest that the suppression of blood formation by GSC could, at least in part, be mediated by binding to PU.1.	Kochi Med Sch, Med Res Ctr, Nankoku, Kochi 7838505, Japan; Kumamoto City Hosp, Div Pulm Dis, Kumamoto 8620808, Japan; Univ Virginia, Dept Pathol, Charlottesville, VA 22908 USA; Burnham Inst, La Jolla, CA 92037 USA; Forschungszentrum Karlsruhe, Inst Genet, D-76021 Karlsruhe, Germany; Univ Calif Los Angeles, Sch Med, HHMI, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA	Kochi University; University of Virginia; Sanford Burnham Prebys Medical Discovery Institute; Helmholtz Association; Karlsruhe Institute of Technology; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Tominaga, A (corresponding author), Kochi Med Sch, Med Res Ctr, Okoh Cho, Nankoku, Kochi 7838505, Japan.							APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BLUM M, 1992, CELL, V69, P1097, DOI 10.1016/0092-8674(92)90632-M; BLUMBERG B, 1991, SCIENCE, V253, P194, DOI 10.1126/science.1677215; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; DEROBERTIS EM, 1992, DEVELOPMENT, P167; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; ETO Y, 1987, BIOCHEM BIOPH RES CO, V142, P1095, DOI 10.1016/0006-291X(87)91528-2; GOLDFARB AN, 1992, BLOOD, V80, P2858; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HROMAS R, 1993, BLOOD, V82, P2998; IKAWA Y, 1976, GANN, V67, P767; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; Klemsz MJ, 1996, MOL CELL BIOL, V16, P390; KULESSA H, 1995, GENE DEV, V9, P1250, DOI 10.1101/gad.9.10.1250; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; NIEHRS C, 1994, SCIENCE, V263, P817, DOI 10.1126/science.7905664; NIEHRS C, 1993, CELL, V72, P491, DOI 10.1016/0092-8674(93)90069-3; Rao G, 1997, ONCOGENE, V14, P123, DOI 10.1038/sj.onc.1200807; SCHUETZE S, 1992, MOL CELL BIOL, V12, P2967, DOI 10.1128/MCB.12.7.2967; SCHUETZE S, 1993, MOL CELL BIOL, V13, P5670, DOI 10.1128/MCB.13.9.5670; Scott EW, 1997, IMMUNITY, V6, P437, DOI 10.1016/S1074-7613(00)80287-3; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; Spemann H., 1924, FDN EXPT EMBRYOLOGY, P144; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; TSAI SF, 1991, GENE DEV, V5, P919, DOI 10.1101/gad.5.6.919; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; Yamada T, 1997, BLOOD, V89, P1383, DOI 10.1182/blood.V89.4.1383; YU J, 1987, NATURE, V330, P765, DOI 10.1038/330765a0	42	17	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	1999	18	48					6795	6805		10.1038/sj.onc.1203118	http://dx.doi.org/10.1038/sj.onc.1203118			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597288				2022-12-17	WOS:000083792000022
J	Coutte, L; Monte, D; Imai, K; Pouilly, L; Dewitte, F; Vidaud, M; Adamski, J; Baert, JL; de Launoit, Y				Coutte, L; Monte, D; Imai, K; Pouilly, L; Dewitte, F; Vidaud, M; Adamski, J; Baert, JL; de Launoit, Y			Characterization of the human and mouse ETV1/ER81 transcription factor genes: role of the two alternatively spliced isoforms in the human	ONCOGENE			English	Article						Ets; transcription factor; ER81; ETV1; gene structure	ETS ONCOGENE FAMILY; GENOMIC ORGANIZATION; MOLECULAR-CLONING; PEA3 GROUP; CHROMOSOMAL TRANSLOCATION; HOMEOBOX GENE; CANCER-CELLS; MEMBER ERM; DOMAIN; FUSION	The Ets transcription factors of the PEA3 group-E1AF/PEA3, ETV1/ER81 and ERM-are almost identical in the ETS DNA-binding and the transcriptional acidic domains. To accelerate our understanding of the molecular basis of putative diseases linked to ETV1 such as Ewing's sarcoma we characterized the human ETV1 and the mouse ER81 genes. We showed that these genes are both encoded by 13 exons in more than 90 kbp genomic DNA, and that the classical acceptor and donor splicing sites are present in each junction except for the 5' donor site of intron 9 where GT is replaced by TT. The genomic organization of the ETS and acidic domains in the human ETV1 and mouse ER81 (localized to chromosome 12) genes is similar to that observed in human ERM and human E1AF/PEA3 genes. Moreover, as in human ERM and human E1AF/PEA3 genes, a first untranslated exon is upstream from the first methionine, and the mouse ER81 gene transcription is regulated by a 1.8 kbp of genomic DNA upstream from this exon. In human, the alternative splicing of the ETV1 gene leads to the presence (ETV1 alpha) or the absence (ETV1 beta) of exon 5 encoding the C-terminal part of the transcriptional acidic domain, but without affecting the alpha helix previously described as crucial for transactivation. We demonstrated here that the truncated isoform (human ETV1 beta) and the full-length isoform (human ETV1 alpha) bind similarly specific DNA Ets binding sites. Moreover, they both activate transcription similarly through the PKA-transduction pathway, so suggesting that this alternative splicing is not crucial for the function of this protein as a transcription factor. The comparison of human ETV1 A and human ETV1 beta expression in the same tissues, such as the adrenal gland or the bladder, showed no clear-cut differences. Altogether, these data open a new avenue of investigation leading to a better understanding of the functional role of this transcription factor.	Inst Biol Lille, Inst Pasteur Lille, CNRS, UMR 8526, F-59021 Lille, France; GSF Forschungszentrum Umwelt & Gesundheit GMBH, Inst Saugetiergenet, D-85758 Neuherberg, Germany; Univ Paris 05, Fac Sci Pharmaceut & Biol Paris, Genet Mol Lab, F-75006 Paris, France; Free Univ Brussels, Fac Med, Mol Virol Lab, B-1070 Brussels, Belgium	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; UDICE-French Research Universities; Universite Paris Cite; Universite Libre de Bruxelles; Vrije Universiteit Brussel	de Launoit, Y (corresponding author), Inst Biol Lille, Inst Pasteur Lille, CNRS, UMR 8526, BP 447,1 Rue Calmette, F-59021 Lille, France.		Vidaud, Michel/O-7346-2017	monte, didier/0000-0002-0613-6203; coutte, laurent/0000-0002-0031-4742; Adamski, Jerzy/0000-0001-9259-0199				Baens M, 1996, GENOME RES, V6, P404, DOI 10.1101/gr.6.5.404; Baert JL, 1997, INT J CANCER, V70, P590, DOI 10.1002/(SICI)1097-0215(19970304)70:5<590::AID-IJC17>3.0.CO;2-H; BEN DY, 1991, GENE DEV, V5, P908; Brown LA, 1998, ONCOGENE, V17, P93, DOI 10.1038/sj.onc.1201911; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; CANDIA AF, 1992, DEVELOPMENT, V116, P1123; ChotteauLelievre A, 1997, ONCOGENE, V15, P937, DOI 10.1038/sj.onc.1201261; de Launoit Y, 1998, ONCOGENE, V16, P2065, DOI 10.1038/sj.onc.1201726; Defossez PA, 1997, NUCLEIC ACIDS RES, V25, P4455, DOI 10.1093/nar/25.22.4455; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; deLaunoit Y, 1997, BIOCHEM MOL MED, V61, P127, DOI 10.1006/bmme.1997.2605; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; FRIEDMAN LS, 1994, CANCER RES, V54, P6374; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GORSKI DH, 1993, MOL CELL BIOL, V13, P3722, DOI 10.1128/MCB.13.6.3722; HIGASHINO F, 1995, ONCOGENE, V10, P1461; HIGASHINO F, 1993, NUCLEIC ACIDS RES, V21, P547, DOI 10.1093/nar/21.3.547; Janknecht R, 1996, ONCOGENE, V13, P1745; JANKNECHT R, 1996, MOL CELL BIOL, V16, P1551; Jeon In-Sang, 1998, Journal of Korean Medical Science, V13, P355; JEON IS, 1995, ONCOGENE, V10, P1229; Kaneko Y, 1996, GENE CHROMOSOME CANC, V15, P115, DOI 10.1002/(SICI)1098-2264(199602)15:2<115::AID-GCC6>3.0.CO;2-6; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; Kaya M, 1996, ONCOGENE, V12, P221; Laget MP, 1996, ONCOGENE, V12, P1325; LAZAR V, 1995, CANCER RES, V55, P3735; Liu DR, 1997, ONCOGENE, V14, P1445, DOI 10.1038/sj.onc.1200965; Lunetta KL, 1996, AM J HUM GENET, V59, P717; MONTE D, 1995, ONCOGENE, V11, P771; MONTE D, 1994, ONCOGENE, V9, P1397; Monte D, 1996, GENOMICS, V35, P236, DOI 10.1006/geno.1996.0345; MONTE D, UNPUB; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; NAKAE K, 1995, J BIOL CHEM, V270, P23795, DOI 10.1074/jbc.270.40.23795; Peter M, 1997, ONCOGENE, V14, P1159, DOI 10.1038/sj.onc.1200933; Sharrocks AD, 1997, INT J BIOCHEM CELL B, V29, P1371, DOI 10.1016/S1357-2725(97)00086-1; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; TRIMBLE MS, 1993, ONCOGENE, V8, P3037; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	40	17	18	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 4	1999	18	46					6278	6286		10.1038/sj.onc.1203020	http://dx.doi.org/10.1038/sj.onc.1203020			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	260DK	10597226	Bronze			2022-12-17	WOS:000083934100011
J	Koritschoner, NP; Bartunek, P; Knespel, S; Blendinger, G; Zenke, M				Koritschoner, NP; Bartunek, P; Knespel, S; Blendinger, G; Zenke, M			The fibroblast growth factor receptor FGFR-4 acts as a ligand dependent modulator of erythroid cell proliferation	ONCOGENE			English	Article						fibroblast growth factor; FGFR-4; bFGF; tyrosine kinase; erythroid cells; hematopoiesis	PROTEIN-TYROSINE KINASE; POLYMERASE CHAIN-REACTION; HUMAN LEUKEMIA-CELLS; PROGENITOR CELLS; SIGNAL-TRANSDUCTION; SELF-RENEWAL; MITOGENIC POTENTIALS; HEMATOPOIETIC-CELLS; MOLECULAR-CLONING; ADAPTER PROTEINS	Receptor and non-receptor tyrosine kinases constitute a large family of proteins that play a pivotal role in hematopoiesis. Here we conducted a comprehensive survey of tyrosine kinase gene expression in primary erythroid progenitor cells from bone marrow by employing a PCR-based strategy that targets the conserved kinase encoding region. We demonstrate that erythroid progenitor cells express several receptor and nonreceptor tyrosine kinases, like c-kit, Jak1, Ryk, FAK, Syk, Arg, Csk and members of the insulin receptor family, Specific changes in the expression profile of tyrosine kinases were observed following differentiation induction. We also report on the identification of a new ligand dependent modulator of erythropoiesis, fibroblast growth factor receptor-4 (FGFR-4), FGFR-4 is effectively expressed in erythroid progenitors and downregulated when cells differentiate. Furthermore, the FGFR-4 ligand, basic fibroblast growth factor (bFGF), enhanced erythroid cell proliferation induced by SCF or insulin, and thus modulated both erythroid proliferation and differentiation in vitro.	Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine	Zenke, M (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13092 Berlin, Germany.		Bartunek, Petr/J-3897-2014	Bartunek, Petr/0000-0002-6202-7650				ARMSTRONG E, 1992, CANCER RES, V52, P2004; Bartunek P, 1996, CYTOKINE, V8, P14, DOI 10.1006/cyto.1996.0003; Bartunek P, 1997, ONCOGENE, V15, P2939, DOI 10.1038/sj.onc.1201457; BEUG H, 1995, METHOD ENZYMOL, V254, P41; Briegel K, 1996, DEVELOPMENT, V122, P3839; BRIEGEL K, 1993, GENE DEV, V7, P1097, DOI 10.1101/gad.7.6.1097; Broudy VC, 1997, BLOOD, V90, P1345, DOI 10.1182/blood.V90.4.1345.1345_1345_1364; CHOI KG, 1993, P NATL ACAD SCI USA, V90, P5747, DOI 10.1073/pnas.90.12.5747; CHOI KH, 1994, ONCOGENE, V9, P1261; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Coulier F, 1997, J MOL EVOL, V44, P43, DOI 10.1007/PL00006120; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; DeBerry C, 1997, BIOCHEM J, V327, P73, DOI 10.1042/bj3270073; DISELA C, 1991, GENE DEV, V5, P2033, DOI 10.1101/gad.5.11.2033; DOLZNIG H, 1995, CELL GROWTH DIFFER, V6, P1341; GABBIANELLI M, 1990, SCIENCE, V249, P1561, DOI 10.1126/science.2218497; GABRILOVE JL, 1994, BLOOD, V83, P907; GARRIDO C, 1993, VIROLOGY, V192, P578, DOI 10.1006/viro.1993.1074; HALEVY O, 1994, EXP CELL RES, V212, P278, DOI 10.1006/excr.1994.1144; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARRISON ML, 1994, J BIOL CHEM, V269, P955; HAYMAN MJ, 1993, CELL, V74, P157, DOI 10.1016/0092-8674(93)90303-8; Hoehn GT, 1996, ONCOGENE, V12, P903; Holzenberger M, 1996, DEV BRAIN RES, V97, P76, DOI 10.1016/S0165-3806(96)00133-2; HOVENS CM, 1992, P NATL ACAD SCI USA, V89, P11818, DOI 10.1073/pnas.89.24.11818; Huber TL, 1998, BLOOD, V92, P4128, DOI 10.1182/blood.V92.11.4128.423k46_4128_4137; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; JIA R, 1994, J BIOL CHEM, V269, P1839; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; LEUTZ A, 1984, EMBO J, V3, P3191, DOI 10.1002/j.1460-2075.1984.tb02278.x; Madruga J, 1997, ADV EXP MED BIOL, V417, P461; MARCELLE C, 1995, DEV BIOL, V172, P100, DOI 10.1006/dbio.1995.0008; MARCELLE C, 1992, ONCOGENE, V7, P2479; MARCELLE C, 1994, DEVELOPMENT, V120, P683; Mellitzer G, 1996, P NATL ACAD SCI USA, V93, P9600, DOI 10.1073/pnas.93.18.9600; MUTA K, 1994, J CLIN INVEST, V94, P34, DOI 10.1172/JCI117327; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; Panzenbock B, 1998, BLOOD, V92, P3658, DOI 10.1182/blood.V92.10.3658.422k18_3658_3668; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; Robinson D, 1998, J BIOMED SCI, V5, P93, DOI 10.1159/000025318; SABE H, 1992, P NATL ACAD SCI USA, V89, P2190, DOI 10.1073/pnas.89.6.2190; SASAKI E, 1993, GENE, V128, P257, DOI 10.1016/0378-1119(93)90571-J; SAWADA K, 1989, J CLIN INVEST, V83, P1701, DOI 10.1172/JCI114070; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHROEDER C, 1993, EMBO J, V12, P951, DOI 10.1002/j.1460-2075.1993.tb05736.x; SIMONEAUX DK, 1995, J IMMUNOL, V154, P1157; STARK KL, 1991, DEVELOPMENT, V113, P641; STEINLEIN P, 1995, CURR BIOL, V5, P191, DOI 10.1016/S0960-9822(95)00040-6; TAMAGNONE L, 1993, ONCOGENE, V8, P2009; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VAINIKKA S, 1994, J BIOL CHEM, V269, P18320; Vainikka S, 1996, J BIOL CHEM, V271, P1270, DOI 10.1074/jbc.271.3.1270; VAINIKKA S, 1992, EMBO J, V11, P4273, DOI 10.1002/j.1460-2075.1992.tb05526.x; Wang JK, 1997, ONCOGENE, V14, P1767, DOI 10.1038/sj.onc.1201021; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; Wessely O, 1997, EMBO J, V16, P267, DOI 10.1093/emboj/16.2.267; WILKS AF, 1989, GENE, V85, P67, DOI 10.1016/0378-1119(89)90465-4; WILKS AF, 1991, METHOD ENZYMOL, V200, P533; Xu H, 1998, J BIOL CHEM, V273, P17987, DOI 10.1074/jbc.273.29.17987; YEE K, 1993, BLOOD, V82, P1335; Yuen D, 1998, BLOOD, V91, P3202, DOI 10.1182/blood.V91.9.3202.3202_3202_3209; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1	70	17	18	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	1999	18	43					5904	5914		10.1038/sj.onc.1202979	http://dx.doi.org/10.1038/sj.onc.1202979			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248JE	10557077				2022-12-17	WOS:000083270700007
J	Sacristan, MP; de Diego, JG; Bonilla, M; Martin-Zanca, D				Sacristan, MP; de Diego, JG; Bonilla, M; Martin-Zanca, D			Molecular cloning and characterization of the 5 ' region of the mouse trkA proto-oncogene	ONCOGENE			English	Article						trkA; proto-oncogene; promoter; NGF receptor; CpG island; IRR	RECEPTOR-RELATED RECEPTOR; NERVE GROWTH-FACTOR; IN-SITU HYBRIDIZATION; TYROSINE KINASE; EXPRESSION; CELLS; GENE; NEURONS; NEUROTROPHINS; TRANSCRIPTION	The trkA proto-oncogene encodes a high-affinity NGF receptor that is essential for the survival, differentiation and maintenance of many neural and non-neural cell types. Altered expression of the trkA gene or trkA receptor malfunction have been implicated in neurodegeneration, tumor progression and oncogenesis. We have cloned and characterized the 5' region of the mouse trkA gene and have identified its promoter, trkA promoter sequences are GC-rich, lack genuine TATA or CAAT boxes, and are contained within a CpG island which extends over the entire first coding exon, The mouse trkA transcription start site is located 70/71 bp upstream to the AUG translation initiation codon, Sequence analysis showed that the gene encoding the insulin receptor-related receptor, IRR, is located just 1.6 kbp upstream to the trkA gene and is transcribed in the opposite direction, We have used trkA-CAT transcriptional fusions to study trkA promoter function in transient transfection experiments. RNase protection assays and CAT protein ELISA analyses showed that a 150 bp long DNA segment, immediately upstream to the start site, is sufficient to direct accurate transcription in trkA-expressing cells, Dissection of this fragment allowed us to identify a 13 bp cis-regulatory element essential for both promoter activity and cell-type specific expression, Deletion of this 13 bp segment as well as modification of its sequence by site-directed mutagenesis led to a dramatic decline in promoter activity, Gel mobility shift assays carried out with double-stranded oligonucleotides containing the 13 bp element revealed several specific DIVA-protein complexes when nuclear extracts from trkA-expressing cells were used. Supershift experiments showed that the Sp1 transcription factor was a component of one of these complexes, Our results identify a minimal trkA gene promoter, located very close to the transcription start site, and define a 13 bp enhancer within this promoter sequence.	Univ Salamanca, CSIC, Inst Microbiol Bioquim, Salamanca 37007, Spain; Univ Salamanca, Dept Bioquim & Biol Mol, Salamanca 37007, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Funcional y Genomica (IBFG); University of Salamanca; University of Salamanca	Martin-Zanca, D (corresponding author), Univ Salamanca, CSIC, Inst Microbiol Bioquim, Avda Campo Charro S-N, Salamanca 37007, Spain.		Sacristan, Maria/Y-4923-2019; Sacristán, María P/A-9587-2016	Sacristan, Maria/0000-0003-2314-8430; Sacristán, María P/0000-0003-2314-8430				AUSUBEL FM, 1995, CURR PROTO MOL BIOL; BARBACID M, 1995, CURR OPIN CELL BIOL, V7, P148, DOI 10.1016/0955-0674(95)80022-0; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; Boissiere F, 1997, EXP NEUROL, V145, P245, DOI 10.1006/exnr.1997.6443; Brodeur GM, 1997, J NEURO-ONCOL, V31, P49, DOI 10.1023/A:1005729329526; Chang BB, 1998, J BIOL CHEM, V273, P39, DOI 10.1074/jbc.273.1.39; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Dalal R, 1997, MOL CELL ENDOCRINOL, V134, P15, DOI 10.1016/S0303-7207(97)00165-2; DAVIES AM, 1994, J NEUROBIOL, V25, P1334, DOI 10.1002/neu.480251103; ERNFORS P, 1992, EUR J NEUROSCI, V4, P1140, DOI 10.1111/j.1460-9568.1992.tb00141.x; Fagan AM, 1996, J NEUROSCI, V16, P6208; Greco A, 1997, GENE CHROMOSOME CANC, V19, P112, DOI 10.1002/(SICI)1098-2264(199706)19:2<112::AID-GCC7>3.0.CO;2-1; HOLTZMAN DM, 1995, J NEUROSCI, V15, P1567; Indo Y, 1996, NAT GENET, V13, P485, DOI 10.1038/ng0896-485; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; LOMENHOERTH C, 1995, J NEUROCHEM, V64, P1780; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MARTINZANCA D, 1990, GENE DEV, V4, P683, DOI 10.1101/gad.4.5.683; Mayerhofer A, 1996, ENDOCRINOLOGY, V137, P5662, DOI 10.1210/en.137.12.5662; Miralles F, 1998, J ENDOCRINOL, V156, P431, DOI 10.1677/joe.0.1560431; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; Parks CL, 1996, J BIOL CHEM, V271, P4417; REINHARDT RR, 1994, J NEUROSCI, V14, P4674; SHIER P, 1992, MOL ENDOCRINOL, V6, P723, DOI 10.1210/me.6.5.723; SHIER P, 1990, CYTOGENET CELL GENET, V54, P80, DOI 10.1159/000132963; Tam SY, 1997, BLOOD, V90, P1807, DOI 10.1182/blood.V90.5.1807; Torcia M, 1996, CELL, V85, P345, DOI 10.1016/S0092-8674(00)81113-7; Tsuji N, 1996, MOL BRAIN RES, V41, P250, DOI 10.1016/0169-328X(96)00102-7; Valent A, 1997, EUR J HUM GENET, V5, P102, DOI 10.1159/000484742; Wheeler EF, 1998, J COMP NEUROL, V391, P407; YAAR M, 1994, J CLIN INVEST, V94, P1550, DOI 10.1172/JCI117496	32	17	17	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 14	1999	18	42					5836	5842		10.1038/sj.onc.1202963	http://dx.doi.org/10.1038/sj.onc.1202963			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	245FG	10523865				2022-12-17	WOS:000083095100013
J	Melendez, B; Santos, J; Fernandez-Piqueras, J				Melendez, B; Santos, J; Fernandez-Piqueras, J			Loss of heterozygosity at the proximal-mid part of mouse chromosome 4 defines two novel tumor suppressor gene loci in T-cell lymphomas	ONCOGENE			English	Article						mouse T-cell lymphomas; gamma-irradiation; LOH; proximal-mid chromosome 4; tumor suppressor loci	MAMMARY-TUMORS; ALLELIC LOSSES; ALLELOTYPE ANALYSIS; HIGH-FREQUENCY; LUNG-TUMORS; LONG ARM; P15(INK4B); DELETION; CANCER; CARCINOMAS	Recent studies in our laboratory reported frequent loss of heterozygosity (LOH) on mouse chromosome 4 in T-cell lymphomas, identifying three candidate tumor suppressor regions (TLSR1-3), To determine the possible existence of other tumor suppressor gene loci on the proximal-mid part of chromosome 4 and to clarify whether the p16(INK4a) (alpha and beta) and p15(INK4b) genes are the inactivation targets of deletion at TLSR1, we have tested 73 gamma-radiation-induced T-cell lymphomas of F1 hybrid mice by LOH analysis, Frequent LOH was found at the INK4a and INK4b loci and the surrounding markers D4Mit77, D4Mit245 and D4Wsm1. In addition, we identified two distinct regions of significant allelic losses in the proximal-mid part of chromosome 4, defined by the markers D4Mit16 (TLSR4) and D4Mit21 (TLSR5). Taken together, this evidence and our previous data indicate the existence of at least five different candidate sites for tumor suppressor genes on chromosome 4, thus revealing a main role for this chromosome in the development of mouse T-cell lymphomas.	Univ Autonoma Madrid, Fac Ciencias, Dept Biol, Lab Genet Mol Humana, E-28049 Madrid, Spain	Autonomous University of Madrid	Fernandez-Piqueras, J (corresponding author), Univ Autonoma Madrid, Fac Ciencias, Dept Biol, Lab Genet Mol Humana, E-28049 Madrid, Spain.		Melendez, Barbara/E-1216-2017; Santos, Javier/ABF-5755-2021	Melendez, Barbara/0000-0001-5004-8895; Santos, Javier/0000-0002-4168-6251				Aldaz CM, 1996, MOL CARCINOGEN, V17, P126, DOI 10.1002/(SICI)1098-2744(199611)17:3<126::AID-MC4>3.0.CO;2-D; Bell DW, 1997, CANCER RES, V57, P4057; Cairns P, 1997, CANCER RES, V57, P5356; Cayuela JM, 1997, BLOOD, V90, P3720, DOI 10.1182/blood.V90.9.3720; Farrell WE, 1997, CANCER RES, V57, P2703; Gardie B, 1998, BLOOD, V91, P1016, DOI 10.1182/blood.V91.3.1016.1016_1016_1020; Gupta PK, 1997, CANCER RES, V57, P1188; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HEGI ME, 1994, CANCER RES, V54, P6257; Herman JG, 1996, CANCER RES, V56, P722; Herzog CR, 1996, ONCOGENE, V13, P1885; HERZOG CR, 1994, CANCER RES, V54, P4007; Herzog CR, 1997, MAMM GENOME, V8, P65, DOI 10.1007/s003359900352; HERZOG CR, 1995, ONCOGENE, V11, P1811; HOLLAND EA, 1994, ONCOGENE, V9, P1361; Holmberg E, 1996, BRIT J CANCER, V74, P246, DOI 10.1038/bjc.1996.345; JOHNSON DW, 1995, GENOMICS, V28, P356, DOI 10.1006/geno.1995.1157; KAMB A, 1994, SCIENCE, V264, P440; Kim SK, 1997, CANCER RES, V57, P400; Kuan J, 1998, MAMM GENOME, V9, P95, DOI 10.1007/s003359900695; Lee GH, 1995, ONCOGENE, V11, P2281; Malumbres M, 1999, ONCOGENE, V18, P385, DOI 10.1038/sj.onc.1202299; Malumbres M, 1997, ONCOGENE, V14, P1361, DOI 10.1038/sj.onc.1200969; Malumbres M, 1998, MAMM GENOME, V9, P183, DOI 10.1007/s003359900722; MIURA K, 1995, CANCER RES, V55, P1828; MIYASAKA K, 1995, MOL CARCINOGEN, V13, P37, DOI 10.1002/mc.2940130107; Mock BA, 1998, MAMM GENOME, V8, pS68, DOI 10.1007/s003359900649; NEVILLE EM, 1995, ONCOGENE, V11, P581; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; Pasche B, 1998, CANCER RES, V58, P2727; QUELLE DE, 1995, ONCOGENE, V11, P635; Radany EH, 1997, P NATL ACAD SCI USA, V94, P8664, DOI 10.1073/pnas.94.16.8664; Richards FM, 1997, HUM GENET, V101, P317, DOI 10.1007/s004390050635; Ritland SR, 1997, CANCER RES, V57, P3520; Santos J, 1998, ONCOGENE, V17, P925, DOI 10.1038/sj.onc.1202009; Santos J, 1996, ONCOGENE, V12, P669; SANTOS J, 1995, CYTOGENET CELL GENET, V71, P223, DOI 10.1159/000134114; SCHULTZ DC, 1995, CANCER RES, V55, P2150; SHANLEY SM, 1995, HUM MOL GENET, V4, P129; Simoneau AR, 1996, CANCER RES, V56, P5039; Simoneau M, 1999, ONCOGENE, V18, P157, DOI 10.1038/sj.onc.1202277; Takita J, 1997, CANCER RES, V57, P907; Waber P, 1997, ONCOGENE, V15, P1699, DOI 10.1038/sj.onc.1201336; Zhang SL, 1998, P NATL ACAD SCI USA, V95, P2429, DOI 10.1073/pnas.95.5.2429; Zhuang SM, 1996, CANCER RES, V56, P3338	45	17	17	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 15	1999	18	28					4166	4169		10.1038/sj.onc.1202826	http://dx.doi.org/10.1038/sj.onc.1202826			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	216FP	10435599				2022-12-17	WOS:000081431000015
J	Picon, A; Bertagna, X; de Keyzer, Y				Picon, A; Bertagna, X; de Keyzer, Y			Analysis of the human proopiomelanocortin gene promoter in a small cell lung carcinoma cell line reveals an unusual role for E2F transcription factors	ONCOGENE			English	Article						ectopic ACTH syndrome; SCLC; proopiomelanocortin; gene expression regulation; E2F; DNA binding proteins	RETINOBLASTOMA GENE; TRANSGENIC MICE; EXPRESSION; RECEPTOR; PROTEIN; ABNORMALITIES; CANCER; NUR77; SITE; DP	The small cell lung carcinoma (SCLC) cell line DMS-79 has been used as a model for studying the molecular mechanism underlying the ectopic ACTH syndrome, We previously showed that two domains of the human Proopiomelanocortin (POMC) gene promoter were specifically active in DMS-79 cells. The present study focuses on the more distal one, Domain IV (-376/-417), DNaseI footprinting experiments identified a single binding site for DMS-79 cell proteins in this domain, Gel-shift and sequence analysis indicated that E2F proteins might bind this site. Indeed, proteins from DMS-79 cells which bind this site (i) have in vitro DNA binding properties indistinguishable from those of E2F proteins (ii) form, like E2F proteins, multiprotein complexes which can be dissociated by sodium deoxycholate and (iii) are recognized by antibodies directed against E2F proteins. Further, we show that the rat POMC distal promoter domain contains a homologous sequence which constitutes a natural mutant of the human POMC E2F binding site, since it does not bind E2F. We show by transient transfection that this natural mutant, in the context of the rat POMC promoter, is not active in DMS-79 cells by contrast to the human POMC E2F binding site. We conclude that E2F binding is required for the activity of Domain IV in DMS-79 cells and contributes to the expression of the POMC gene in SCLC, Further studies are required to elucidate the role of E2F factors in POMC gene transcription in SCLC cells, but our results have identified mechanisms different from those in pituitary corticotroph cells that are used by these SCLC tumor cells.	CHU Cochin Port Royal, Inst Cochin Genet Mol, CNRS, F-75014 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	de Keyzer, Y (corresponding author), CHU Cochin Port Royal, Inst Cochin Genet Mol, CNRS, UPR 1524,3eme Etage,24 Rue Faubourg St Jacques, F-75014 Paris, France.							ABE K, 1984, ENDOCRINE LUNG HLTH, P549; Baylin S B, 1980, Endocr Rev, V1, P45; BECKER KL, 1984, ENDOCRINE LUNG HLTH; BERTAGNA XY, 1978, P NATL ACAD SCI USA, V75, P5160, DOI 10.1073/pnas.75.10.5160; DEKEYZER Y, 1985, J CLIN INVEST, V76, P1892, DOI 10.1172/JCI112184; deKeyzer Y, 1996, ENDOCR-RELAT CANCER, V3, P99, DOI 10.1677/erc.0.0030099; GAITAN D, 1995, MOL ENDOCRINOL, V9, P1193, DOI 10.1210/me.9.9.1193; Gould VE, 1984, ENDOCRINE LUNG HLTH, P406; HAMMER GD, 1990, MOL ENDOCRINOL, V4, P1689, DOI 10.1210/mend-4-11-1689; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HEDVAT CV, 1995, MOL ENDOCRINOL, V9, P1692, DOI 10.1210/me.9.12.1692; Helin K, 1997, P NATL ACAD SCI USA, V94, P6933, DOI 10.1073/pnas.94.13.6933; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; JEANNOTTE L, 1987, MOL CELL BIOL, V7, P4058, DOI 10.1128/MCB.7.11.4058; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; Lamonerie T, 1996, GENE DEV, V10, P1284, DOI 10.1101/gad.10.10.1284; Loiseau L, 1997, GENE EXPRESSION, V6, P259; Maxam A M, 1980, Methods Enzymol, V65, P499; Murphy EP, 1997, MOL ENDOCRINOL, V11, P39, DOI 10.1210/me.11.1.39; Okabe T, 1998, J ENDOCRINOL, V156, P169, DOI 10.1677/joe.0.1560169; ORTH DN, 1995, NEW ENGL J MED, V332, P791, DOI 10.1056/NEJM199503233321207; Phillips A, 1997, MOL CELL BIOL, V17, P5946, DOI 10.1128/MCB.17.10.5946; PICON A, 1995, J MOL ENDOCRINOL, V15, P187, DOI 10.1677/jme.0.0150187; Poulin G, 1997, MOL CELL BIOL, V17, P6673, DOI 10.1128/MCB.17.11.6673; RAYMONDJEAN M, 1988, P NATL ACAD SCI USA, V85, P757, DOI 10.1073/pnas.85.3.757; RYGAARD K, 1990, CANCER RES, V50, P5312; Sambrook J, 1989, MOL CLONING LAB MANU; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; SORENSON GD, 1981, CANCER, V47, P1289, DOI 10.1002/1097-0142(19810315)47:6<1289::AID-CNCR2820470610>3.0.CO;2-B; THERRIEN M, 1991, MOL CELL BIOL, V11, P3492, DOI 10.1128/MCB.11.7.3492; THERRIEN M, 1993, MOL CELL BIOL, V13, P2342, DOI 10.1128/MCB.13.4.2342; TREMBLAY Y, 1988, P NATL ACAD SCI USA, V85, P8890, DOI 10.1073/pnas.85.23.8890; WAJCHENBERG BL, 1994, ENDOCR REV, V15, P752, DOI 10.1210/er.15.6.752; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; WONG KK, 1995, MOL CELL BIOL, V15, P6535; YEE AS, 1987, EMBO J, V6, P2061, DOI 10.1002/j.1460-2075.1987.tb02471.x	37	17	17	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 22	1999	18	16					2627	2633		10.1038/sj.onc.1202635	http://dx.doi.org/10.1038/sj.onc.1202635			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	189LU	10353606				2022-12-17	WOS:000079907100010
J	Sawamoto, K; Yamada, C; Kishida, S; Hirota, Y; Taguchi, A; Kikuchi, A; Okano, H				Sawamoto, K; Yamada, C; Kishida, S; Hirota, Y; Taguchi, A; Kikuchi, A; Okano, H			Ectopic expression of constitutively activated Ral GTPase inhibits cell shape changes during Drosophila eye development	ONCOGENE			English	Article						actin; cell shape; Drosophila; Ra1	NUCLEOTIDE DISSOCIATION STIMULATOR; PROTEIN TYROSINE KINASE; C-FOS PROMOTER; PUTATIVE EFFECTOR; FATE; MEMBRANE; GROWTH; IDENTIFICATION; TRANSFORMATION; MELANOGASTER	The small GTP-binding protein Ral is activated by RalGDS, one of the effector molecules for Ras. Active Ral binds to a GTPase activating protein for CDC42 and Rac. Although previous studies suggest a role for Ral in the regulation of CDC42 and Rac, which are involved in arranging the cytoskeleton, its in vivo function is largely unknown. To examine the effect of overexpressing Ral on development, transgenic Drosophila were generated that overexpress wild-type or mutated Ral during eye development. While wild-type Ral caused no developmental defects, expression of a constitutively activated protein resulted in a rough eye phenotype, Activated Ral did not affect cell fate determination in the larval eye discs but caused severe disruption of the ommatidial organization later in pupal development. Phalloidin staining showed that activated Ral perturbed the cytoskeletal structure and cell shape changes during pupal development. This phenotype is similar to that caused by RhoA overexpression. In addition, the phenotype was synergistically enhanced by the coexpression of RhoA, These results suggest that Ral functions to control the cytoskeletal structure required for cell shape changes during Drosophila development.	Osaka Univ, Sch Med, Biomed Res Ctr, Dept Neuroanat, Suita, Osaka 5650871, Japan; Hiroshima Univ, Sch Med, Dept Biochem, Minami Ku, Hiroshima 7340037, Japan; JST, CREST, Minato Ku, Tokyo 1050011, Japan	Osaka University; Hiroshima University; Japan Science & Technology Agency (JST)	Okano, H (corresponding author), Osaka Univ, Sch Med, Biomed Res Ctr, Dept Neuroanat, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		Okano, Hideyuki/I-7584-2019; Hirota, Yuki/A-9736-2015	Hirota, Yuki/0000-0001-9629-0038; Sawamoto, Kazunobu/0000-0003-1984-5129; kishida, shosei/0000-0003-0405-851X				Aelst L, 1997, GENE DEV, V11, P2295; ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; Barrett K, 1997, CELL, V91, P905, DOI 10.1016/S0092-8674(00)80482-1; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BLOCHLINGER K, 1993, DEVELOPMENT, V117, P441; Bos JL, 1997, BBA-REV CANCER, V1333, pM19, DOI 10.1016/S0304-419X(97)00015-2; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; CHANG EC, 1994, CELL, V79, P131, DOI 10.1016/0092-8674(94)90406-5; DENOOIJ JC, 1995, SCIENCE, V270, P983, DOI 10.1126/science.270.5238.983; Eaton S, 1996, J CELL BIOL, V135, P1277, DOI 10.1083/jcb.135.5.1277; Feig LA, 1996, TRENDS BIOCHEM SCI, V21, P438, DOI 10.1016/S0968-0004(96)10058-X; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; FRECH M, 1990, J BIOL CHEM, V265, P6353; HARDEN N, 1995, DEVELOPMENT, V121, P903; HARIHARAN IK, 1995, EMBO J, V14, P292, DOI 10.1002/j.1460-2075.1995.tb07003.x; HAY BA, 1994, DEVELOPMENT, V120, P2121; HIGASHIJIMA SI, 1992, GENE DEV, V6, P50, DOI 10.1101/gad.6.1.50; Hinoi T, 1996, J BIOL CHEM, V271, P19710, DOI 10.1074/jbc.271.33.19710; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; JULLIENFLORES V, 1995, J BIOL CHEM, V270, P22473, DOI 10.1074/jbc.270.38.22473; Karim FD, 1998, DEVELOPMENT, V125, P1; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; Kishida S, 1997, ONCOGENE, V15, P2899, DOI 10.1038/sj.onc.1201473; Lee T, 1996, DEVELOPMENT, V122, P409; Leevers SJ, 1996, EMBO J, V15, P6584, DOI 10.1002/j.1460-2075.1996.tb01049.x; LONGLEY RL, 1995, DEV BIOL, V171, P415, DOI 10.1006/dbio.1995.1292; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Matsuo T, 1997, DEVELOPMENT, V124, P2671; Miller DT, 1998, DEVELOPMENT, V125, P2327; Miller MJ, 1997, J BIOL CHEM, V272, P5600, DOI 10.1074/jbc.272.9.5600; MIYAMOTO H, 1995, GENE DEV, V9, P612, DOI 10.1101/gad.9.5.612; Murai H, 1997, J BIOL CHEM, V272, P10483; Okazaki M, 1997, ONCOGENE, V14, P515, DOI 10.1038/sj.onc.1200860; Park SH, 1995, ONCOGENE, V11, P2349; REICHMANFRIED M, 1994, GENE DEV, V8, P428, DOI 10.1101/gad.8.4.428; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROBINOW S, 1988, DEV BIOL, V126, P294, DOI 10.1016/0012-1606(88)90139-X; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Sawamoto K, 1998, CELL DEATH DIFFER, V5, P262, DOI 10.1038/sj.cdd.4400342; SAWAMOTO K, 1994, DEV BIOL, V164, P267, DOI 10.1006/dbio.1994.1197; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; Strutt DI, 1997, NATURE, V387, P292, DOI 10.1038/387292a0; TOMLINSON A, 1987, DEV BIOL, V123, P264, DOI 10.1016/0012-1606(87)90448-9; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Warrick JM, 1998, CELL, V93, P939, DOI 10.1016/S0092-8674(00)81200-3; WASSARMAN DA, 1997, ADV DEV BIO, V5, P1; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WOLFF T, 1991, DEVELOPMENT, V113, P825; Wolff T, 1993, DEV DROSOPHILA MELAN; Wolthuis RMF, 1998, CURR BIOL, V8, P471, DOI 10.1016/S0960-9822(98)70183-6; Wolthuis RMF, 1997, EMBO J, V16, P6748, DOI 10.1093/emboj/16.22.6748; Wolthuis RMF, 1996, ONCOGENE, V13, P353; ZIPURSKY SL, 1994, ANNU REV NEUROSCI, V17, P373, DOI 10.1146/annurev.neuro.17.1.373	58	17	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 18	1999	18	11					1967	1974		10.1038/sj.onc.1202522	http://dx.doi.org/10.1038/sj.onc.1202522			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177DC	10208418				2022-12-17	WOS:000079191300006
J	Philips, A; Huet, X; Plet, A; Rech, J; Vie, A; Blanchard, JM				Philips, A; Huet, X; Plet, A; Rech, J; Vie, A; Blanchard, JM			Anchorage-dependent expression of cyclin A in primary cells requires a negative DNA regulatory element and a functional Rb	ONCOGENE			English	Article						cyclin A; Rb; adhesion; primary cells	CCAAT-BINDING PROTEIN; A GENE-EXPRESSION; RETINOBLASTOMA PROTEIN; TRANSCRIPTIONAL REPRESSION; INDEPENDENT GROWTH; DOWN-REGULATION; NUDE MICE; RAS; PROGRESSION; TUMORIGENICITY	Many cells, when cultured in suspension, fail to express cyclin A, a regulatory component of cell cycle kinases cdc2 and cdk2 and as a consequence, do not enter S phase, However, many cell type-specific differences are disclosed between not only normal and transformed cells, but also between cell lines whose proliferation is strictly anchorage-dependent, These apparent discrepancies are seen in established cell lines most probably because of adaptative events that have occurred during cell culture, We have therefore used primary cells to understand how cyclin A transcription is controlled by cell anchorage properties, To this aim, we have used embryonic fibroblasts from either wild type, Rb(-/-) or p107(-/-)/p130(-/-) mice and tested the effect of an ectopic expression of Rb mutants. In the experiments reported here, we show that anchorage-dependent expression of cyclin A (i) is reflected by the irt vivo occupancy of a negative DNA regulatory element previously shown to be instrumental in the down regulation of cyclin A transcription in quiescent cells (Cell Cycle Responsive Element: CCRE) (ii) requires a functional Rb but neither p107 nor p130 (iii) mutation of the CCRE abolishes both adhesion-dependent regulation and response to Rb.	Inst Mol Genet, CNRS, UMR 5535, F-34293 Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier	Blanchard, JM (corresponding author), Inst Mol Genet, CNRS, UMR 5535, 1919 Route Mende, F-34293 Montpellier 5, France.		PHILIPS, Alexandre/AAB-6047-2020					Assoian RK, 1997, CURR OPIN CELL BIOL, V9, P93, DOI 10.1016/S0955-0674(97)80157-3; BARLAT I, 1995, ONCOGENE, V11, P1309; BARLAT I, 1993, CELL GROWTH DIFFER, V4, P105; BOS JL, 1989, CANCER RES, V49, P4682; Carstens CP, 1996, EXP CELL RES, V229, P86, DOI 10.1006/excr.1996.0346; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; COLBURN NH, 1978, CANCER RES, V38, P624; DESDOUETS C, 1995, MOL CELL BIOL, V15, P3301; Downward J, 1997, CURR BIOL, V7, P258; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; GIRARD F, 1991, CELL, V67, P1; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; Huet X, 1996, MOL CELL BIOL, V16, P3789; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kang JS, 1996, MOL CELL BIOL, V16, P3370; Kramer A, 1996, J BIOL CHEM, V271, P6579; Kramer A, 1997, CANCER RES, V57, P5117; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Liu NS, 1997, NUCLEIC ACIDS RES, V25, P4915, DOI 10.1093/nar/25.24.4915; Liu NS, 1998, ONCOGENE, V16, P2957, DOI 10.1038/sj.onc.1201838; Mittnacht S, 1997, CURR BIOL, V7, P219, DOI 10.1016/S0960-9822(97)70094-0; NAKAMURA T, 1995, EXP CELL RES, V216, P422, DOI 10.1006/excr.1995.1053; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; PAGANO M, 1992, EMBO J, V88, P1039; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; Philips A, 1998, ONCOGENE, V16, P1373, DOI 10.1038/sj.onc.1201655; Plet A, 1997, ONCOGENE, V14, P2575, DOI 10.1038/sj.onc.1201103; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; SARDET C, 1997, ONCOGENES TRANSCRIPT, V2, P1; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; Schulze A, 1996, MOL CELL BIOL, V16, P4632; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHIN SI, 1975, P NATL ACAD SCI USA, V72, P4435, DOI 10.1073/pnas.72.11.4435; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Yang WN, 1997, J BIOL CHEM, V272, P24819, DOI 10.1074/jbc.272.40.24819; YOSHIZUMI M, 1995, MOL CELL BIOL, V15, P3266; ZerfassThome K, 1997, MOL CELL BIOL, V17, P407, DOI 10.1128/MCB.17.1.407; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G; Zwicker J, 1997, TRENDS GENET, V13, P3, DOI 10.1016/S0168-9525(96)30112-1; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	50	17	17	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 11	1999	18	10					1819	1825		10.1038/sj.onc.1202530	http://dx.doi.org/10.1038/sj.onc.1202530			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175JM	10086336				2022-12-17	WOS:000079090000005
J	Abraham, J; Spaner, D; Benchimol, S				Abraham, J; Spaner, D; Benchimol, S			Phosphorylation of p53 protein in response to ionizing radiation occurs at multiple sites in both normal and DNA-PK deficient cells	ONCOGENE			English	Article						p53; phosphorylation; DNA-PK; scid; ionizing radiation	PHOSPHATIDYLINOSITOL 3-KINASE; MOUSE CELLS; KINASE; DAMAGE; MICE; APOPTOSIS; INDUCTION; MUTATION; TRANSACTIVATION; ACTIVATION	The tumour suppressor gene product, p53, is involved in mediating cellular responses to DNA damage including growth arrest and/or apoptosis, The mechanism by which p53 protein senses the presence of damaged DNA is not understood. The possibility that p53 may be posttranslationally modified by enzymes that are activated in response to DNA damage including DNA-dependent protein kinase (DNA-PK), poly(ADP-ribose) polymerase and stress activated protein kinase has received considerable attention. Recent studies have indicated that DNA-PK is not required for the transactivation or apoptosis-promoting activities of p53 protein. However, the possibility that other functions of p53 may be dependent on phosphorylation by DNA-PK has not been explored. Here we describe a series of experiments that compares the expression, function and phosphorylation status of p53 protein in normal and DNA-PK-deficient scid cells. While several novel p53 phosphoforms are generated in response to DNA damage in normal cells, the same phosphoforms are observed in scid cells.	Univ Toronto, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Benchimol, S (corresponding author), Univ Toronto, Ontario Canc Inst, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.			Benchimol, Samuel/0000-0003-3433-890X				ADAMS LD, 1995, CURRENT PROTOCOLS MO, V2; Anderson Carl W., 1994, Seminars in Cell Biology, V5, P427, DOI 10.1006/scel.1994.1050; ANDERSON CW, 1993, TRENDS BIOCHEM SCI, V18, P433, DOI 10.1016/0968-0004(93)90144-C; Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; Bogue MA, 1996, GENE DEV, V10, P553, DOI 10.1101/gad.10.5.553; BOSMA MJ, 1991, ANNU REV IMMUNOL, V9, P323, DOI 10.1146/annurev.iy.09.040191.001543; Chernov MV, 1997, ONCOGENE, V14, P2503, DOI 10.1038/sj.onc.1201104; Chernov MV, 1998, P NATL ACAD SCI USA, V95, P2284, DOI 10.1073/pnas.95.5.2284; Di JA, 1996, J EXP MED, V183, P1923, DOI 10.1084/jem.183.4.1923; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DOVER R, 1994, J CELL SCI, V107, P1181; FISCELLA M, 1994, ONCOGENE, V9, P3249; FISCELLA M, 1993, ONCOGENE, V8, P1519; Fried LM, 1996, P NATL ACAD SCI USA, V93, P13825, DOI 10.1073/pnas.93.24.13825; Fu LN, 1997, EMBO J, V16, P4117, DOI 10.1093/emboj/16.13.4117; FUCHS B, 1995, ONCOGENE, V10, P789; FULOP GM, 1990, NATURE, V347, P479, DOI 10.1038/347479a0; Guidos CJ, 1996, GENE DEV, V10, P2038, DOI 10.1101/gad.10.16.2038; Hall SR, 1996, NUCLEIC ACIDS RES, V24, P1119, DOI 10.1093/nar/24.6.1119; Hao MM, 1996, J BIOL CHEM, V271, P29380, DOI 10.1074/jbc.271.46.29380; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; Huang LC, 1996, CANCER RES, V56, P2940; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; KHANNA KK, 1993, ONCOGENE, V8, P3307; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; Mayo LD, 1997, CANCER RES, V57, P5013; MAYR GA, 1995, CANCER RES, V55, P2410; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; Nacht M, 1996, GENE DEV, V10, P2055, DOI 10.1101/gad.10.16.2055; Price BD, 1996, CANCER RES, V56, P246; Rathmell WK, 1997, CANCER RES, V57, P68; ROTTER V, 1993, P NATL ACAD SCI USA, V90, P9075, DOI 10.1073/pnas.90.19.9075; Sakaguchi K, 1997, BIOCHEMISTRY-US, V36, P10117, DOI 10.1021/bi970759w; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; SHIMONKEVITZ R, 1984, J IMMUNOL, V133, P2067; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; SPANER D, 1994, RES IMMUNOL, V145, P337, DOI 10.1016/S0923-2494(94)80196-7; Steegenga WT, 1996, J MOL BIOL, V263, P103, DOI 10.1006/jmbi.1996.0560; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WU JM, 1993, BIOCHEM BIOPH RES CO, V193, P13, DOI 10.1006/bbrc.1993.1583; YEARGIN J, 1995, CURR BIOL, V5, P423, DOI 10.1016/S0960-9822(95)00083-2	48	17	18	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	1999	18	8					1521	1527		10.1038/sj.onc.1202454	http://dx.doi.org/10.1038/sj.onc.1202454			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169VX	10102621				2022-12-17	WOS:000078770700001
J	Grossi, M; La Rocca, SA; Pierluigi, G; Vannucchi, S; Ruaro, EM; Schneider, C; Tato, F				Grossi, M; La Rocca, SA; Pierluigi, G; Vannucchi, S; Ruaro, EM; Schneider, C; Tato, F			Role of Gas1 down-regulation in mitogenic stimulation of quiescent NIH3T3 cells by v-Src	ONCOGENE			English	Article						v-Src; proliferation; gas1; PI 3-kinase	PHOSPHATIDYLINOSITOL KINASE-ACTIVITY; MAP KINASE; SIGNAL-TRANSDUCTION; TYROSINE KINASES; TRANSFORMATION; PROTEINS; ACTIVATION; INHIBITOR; 3-KINASE; GENES	Quiescent mammalian fibroblasts can be induced to reenter the cell cycle by growth factors and oncoproteins, We studied the pathway(s) through which v-Src, the oncogenic tyrosine kinase encoded by the v-src oncogene of Rous sarcoma virus, forces serum-starved NIH3T3 cells to enter S-phase, To this purpose, we isolated and characterized a polyclonal population of NIH3T3 cells transformed by the MR31 retroviral vector, encoding G418 resistance and the v-src temperature-sensitive allele from the mutant ts LA31 PR-A, NIH(MR31! cells displayed a temperature-conditional transformed phenotype and could be made quiescent by serum deprivation at the restrictive temperature, Serum stimulation or thermolabile v-Src reactivation induced entry into S-phase to a comparable extent, although with different kinetics. The data suggest that v-Src mitogenic activity involves early activation of the Erk1/Erk2 MAP kinases with very little tyrosine phosphorylation of the Shc adaptor proteins at least during the early stages of v-Src reactivation and that v-Src-induced S-phase entry was strongly inhibited by drugs affecting MEK or PI 3-kinase, Our results also suggest that down-regulation of gas1 gene expression plays an important role in regulating the efficiency of entry into S-phase triggered by reactivated v-Src and that Gas1 down-regulation does not require PI 3-kinase dependent signals.	Univ Rome La Sapienza, Fdn Cenci Bolognetti, Inst Pasteur, Dipartimento Biol Cellulare & Sviluppo, I-00185 Rome, Italy; Lab Nazl Consorzio Interuni Biotecnol, I-34012 Trieste, Italy	Fondazione Cenci Bolognetti; Sapienza University Rome	Tato, F (corresponding author), Univ Rome La Sapienza, Fdn Cenci Bolognetti, Inst Pasteur, Dipartimento Biol Cellulare & Sviluppo, Vie Apuli, I-00185 Rome, Italy.		la rocca, severina anna/D-8028-2011; Grossi, Milena/D-2955-2009					ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; CATLING AD, 1993, ONCOGENE, V8, P1875; CHAN TO, 1990, MOL CELL BIOL, V10, P3280, DOI 10.1128/MCB.10.6.3280; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Dahl J, 1996, MOL CELL BIOL, V16, P2728; DELSAL G, 1992, CELL, V70, P595, DOI 10.1016/0092-8674(92)90429-G; DELSAL G, 1995, MOL CELL BIOL, V15, P7152; DOTTO GP, 1989, J CELL BIOL, V109, P3115, DOI 10.1083/jcb.109.6.3115; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FINCHAM VJ, 1986, J VIROL, V58, P694, DOI 10.1128/JVI.58.2.694-699.1986; Fincham VJ, 1996, J CELL BIOL, V135, P1551, DOI 10.1083/jcb.135.6.1551; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; Haefner B, 1997, BIOCHEM J, V328, P649, DOI 10.1042/bj3280649; HAEFNER B, 1995, J BIOL CHEM, V270, P7937, DOI 10.1074/jbc.270.14.7937; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KAZLAUSKAS A, 1994, CURR OPIN GENET DEV, V4, P5, DOI 10.1016/0959-437X(94)90085-X; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MCCLADE J, 1992, P NATL ACAD SCI USA, V89, P8869; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; RODRIGUES CA, 1994, CURR OPIN GENET DEV, V4, P15, DOI 10.1016/0959-437X(94)90086-8; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; VERDERAME MF, 1995, MOL BIOL CELL, V6, P953, DOI 10.1091/mbc.6.8.953; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WELHAM MJ, 1990, ONCOGENE, V5, P161; YU CL, 1993, MOL CELL BIOL, V13, P2011, DOI 10.1128/MCB.13.4.2011	33	17	18	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 1	1998	17	13					1629	1638		10.1038/sj.onc.1202090	http://dx.doi.org/10.1038/sj.onc.1202090			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124UH	9796692				2022-12-17	WOS:000076200100001
J	de Lau, WBM; Hurenkamp, J; Berendes, P; Touw, IP; Clevers, HC; van Dijk, MA				de Lau, WBM; Hurenkamp, J; Berendes, P; Touw, IP; Clevers, HC; van Dijk, MA			The gene encoding the granulocyte colony-stimulating factor receptor is a target for deregulation in pre-B ALL by the t(1;19)-specific oncoprotein E2A-Pbx1	ONCOGENE			English	Article						G-CSF receptor; cDNA subtraction; leukemia; chromosomal translocation	ACUTE LYMPHOBLASTIC-LEUKEMIA; REPRESENTATIONAL DIFFERENCE ANALYSIS; CHROMOSOMAL TRANSLOCATIONS; TRANSCRIPTIONAL ACTIVATOR; HOMEODOMAIN PROTEIN; MAMMALIAN-CELLS; MESSENGER-RNA; FUSION; PBX1; E2A	Approximately 25-30% of childhood pre-B cell acute lymphoblastic leukemias (pre-B ALL) is characterized by the presence of a (1;19)(q23;p13.3) translocation, The presence of this translocation is generally accompanied by a poor prognosis. The chimeric gene resulting from this chromosomal rearrangement encodes a hybrid transcription factor, E2A-Pbx1, In an attempt to delineate the genetic cascade initiated by E2A-Pbx1, we sought to identify genes that are deregulated by this transcription factor in t(1;19) pre-B ALL, We show here that the gene encoding the granulocyte colony-stimulating factor receptor (G-CSFr) is specifically upregulated in pre-B cells expressing E2A-Pbx1. G-CSFr is also expressed in cell lines established from t(1;19) pre-B cell leukemia and on primary t(1;19) tumor cells, but not on control cells. These data indicate that G-CSFr gene is a target for deregulation by E2A-Pbx1.	Acad Hosp Utrecht, Dept Immunol F03 821, NL-3508 GA Utrecht, Netherlands; Erasmus Univ, Dept Immunol, NL-3000 DR Rotterdam, Netherlands; Erasmus Univ, Dept Hematol, NL-3000 DR Rotterdam, Netherlands	Utrecht University; Utrecht University Medical Center; Erasmus University Rotterdam; Erasmus University Rotterdam	van Dijk, MA (corresponding author), Acad Hosp Utrecht, Dept Immunol F03 821, POB 85500, NL-3508 GA Utrecht, Netherlands.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AVALOS BR, 1990, BLOOD, V75, P851; Avalos BR, 1996, BLOOD, V88, P761, DOI 10.1182/blood.V88.3.761.bloodjournal883761; BERENDES P, 1995, LEUKEMIA, V9, P1321; BRADSTOCK K, 1993, BLOOD, V82, P3437; BRADSTOCK KF, 1995, LEUKEMIA LYMPHOMA, V18, P1, DOI 10.3109/10428199509064917; BURROWS PD, 1993, CURR OPIN IMMUNOL, V5, P201, DOI 10.1016/0952-7915(93)90005-D; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; DEDERA DA, 1993, CELL, V74, P833, DOI 10.1016/0092-8674(93)90463-Z; DONG F, 1995, NEW ENGL J MED, V333, P487, DOI 10.1056/NEJM199508243330804; DONG F, 1993, MOL CELL BIOL, V13, P7774, DOI 10.1128/MCB.13.12.7774; DREXLER HG, 1995, LEUKEMIA, V9, P480; Fu XY, 1997, MOL CELL BIOL, V17, P1503, DOI 10.1128/MCB.17.3.1503; FUKUNAGA R, 1990, P NATL ACAD SCI USA, V87, P8702, DOI 10.1073/pnas.87.22.8702; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; JACK I, 1986, CANCER GENET CYTOGEN, V19, P261, DOI 10.1016/0165-4608(86)90055-5; KAMPS MP, 1991, GENE DEV, V5, P358, DOI 10.1101/gad.5.3.358; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KAMPS MP, 1994, ONCOGENE, V9, P3159; KHWAJA A, 1993, BRIT J HAEMATOL, V85, P254, DOI 10.1111/j.1365-2141.1993.tb03164.x; LEBRUN DP, 1994, ONCOGENE, V9, P1641; LIESCHKE GJ, 1994, BLOOD, V84, P1737; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; LOWENBERG B, 1993, BLOOD, V81, P281; LU Q, 1994, MOL CELL BIOL, V14, P3938, DOI 10.1128/MCB.14.6.3938; MADSEN M, 1980, J IMMUNOL METHODS, V33, P323, DOI 10.1016/0022-1759(80)90003-4; Massari ME, 1996, MOL CELL BIOL, V16, P121; Matsushita K, 1997, BRIT J HAEMATOL, V96, P715, DOI 10.1046/j.1365-2141.1997.d01-2102.x; McWhirter JR, 1997, DEVELOPMENT, V124, P3221; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; QUONG MW, 1993, MOL CELL BIOL, V13, P792, DOI 10.1128/MCB.13.2.792; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; ROSENFELD C, 1977, NATURE, V267, P841, DOI 10.1038/267841a0; SCHUTTE M, 1995, NUCLEIC ACIDS RES, V23, P4127, DOI 10.1093/nar/23.20.4127; SETO Y, 1992, J IMMUNOL, V148, P259; TACHIBANA M, 1995, CANCER RES, V55, P3438; VANDIJK MA, 1993, P NATL ACAD SCI USA, V90, P6061, DOI 10.1073/pnas.90.13.6061; WILLIAMS DL, 1984, CELL, V36, P101, DOI 10.1016/0092-8674(84)90078-3; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0	41	17	17	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 30	1998	17	4					503	510		10.1038/sj.onc.1201967	http://dx.doi.org/10.1038/sj.onc.1201967			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	104XY	9696044				2022-12-17	WOS:000075043000013
J	Huang, JH; Logsdon, N; Schmieg, FI; Simmons, DT				Huang, JH; Logsdon, N; Schmieg, FI; Simmons, DT			p53-mediated transcription induces resistance of DNA to UV inactivation	ONCOGENE			English	Article						p53; DNA repair; transcriptional activation; genetic reactivation	WILD-TYPE P53; CYCLIN-DEPENDENT KINASES; RNA-POLYMERASE-II; NUCLEOTIDE EXCISION-REPAIR; CELL NUCLEAR ANTIGEN; LI-FRAUMENI SYNDROME; TUMOR-SUPPRESSOR; PYRIMIDINE DIMER; GENE-PRODUCT; HOMOLOGOUS RECOMBINATION	A possible role of p53-dependent transcription in the induction of DIVA repair was explored by transfecting a UV-irradiated chloramphenicol acetyl transferase (CAT) reporter plasmid (pRGC.FOS.CAT), containing a minimal FOS promoter driven by a consensus p53 binding site, into a p53 negative-mouse cell line [(10)1], When a p53-expressing plasmid (pSV.p53) was cotransfected into these cells, CAT expression levels persisted even after prolonged UV irradiation. In comparison, CAT expression from pSV2.CAT, which lacks a p53-responsive element in its SV40 promoter, dropped off much more precipitously after UV irradiation in the absence or presence of WT p53 expression. A similar sharp drop was observed with three other constructs when the reporter gene was under the control of the ras, beta-actin or fos promoter. Mouse cells (A1-5) that constitutively express a temperature-sensitive mutant (135 AV) of mouse p53 also generated, at 32 degrees C, higher levels of enzyme expressed from UV-irradiated pRGC,FOS,CAT than from UV-irradiated pSV2.CAT. The frequency of cyclobutane pyrimidine dimers in UV-irradiated pRGC,FOS,CAT was determined with T4 endo V, and the probability of having an undamaged CAT coding strand was calculated by the Poisson distribution for various times of UV-irradiation, The observed relative CAT expression levels from irradiated pSV2,CAT and pRGC,FOS,CAT in the absence of p53 were consistent with those numbers. These results show that WT p53-mediated transcription directs a resistance of the transcribed DNA to UV inactivation and reactivates the reporter gene. Furthermore, some single point substitution mutants of p53 that maintain a near normal ability to activate transcription had lost their ability to extend CAT gene expression after UV irradiation. Conversely, other mutants with reduced transcriptional activity retained this ability. This indicates that although resistance to UV inactivation is transcriptionally-dependent, these two activities are genetically distinct. These data, taken together, suggest that the transcription of UV-damaged DNA by a p53-dependent process promotes its repair.	Univ Delaware, Dept Biol Sci, Newark, DE 19716 USA	University of Delaware	Simmons, DT (corresponding author), Univ Delaware, Dept Biol Sci, Newark, DE 19716 USA.				NATIONAL CANCER INSTITUTE [R55CA055234] Funding Source: NIH RePORTER; NCI NIH HHS [CA55234] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTON NK, 1979, NATURE, V282, P864, DOI 10.1038/282864a0; Bertrand P, 1997, ONCOGENE, V14, P1117, DOI 10.1038/sj.onc.1200931; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; BOHR VA, 1991, CARCINOGENESIS, V12, P1983, DOI 10.1093/carcin/12.11.1983; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; DEFFIE A, 1993, MOL CELL BIOL, V13, P3415, DOI 10.1128/MCB.13.6.3415; DONAHUE BA, 1994, P NATL ACAD SCI USA, V91, P8502, DOI 10.1073/pnas.91.18.8502; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; DRAPKIN R, 1994, CELL, V77, P9, DOI 10.1016/0092-8674(94)90228-3; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GRAFSTROM RH, 1982, J BIOL CHEM, V257, P13465; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; HARPER JW, 1993, CELL, V75, P805; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HAVRE PA, 1995, CANCER RES, V55, P4420; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; HUMBERT S, 1994, EMBO J, V13, P2393, DOI 10.1002/j.1460-2075.1994.tb06523.x; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; ISHII S, 1985, SCIENCE, V230, P1378, DOI 10.1126/science.2999983; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KERN SE, 1991, SCIENCE, V252, P1707; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Li G, 1997, AM J PATHOL, V150, P1457; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LINK CJ, 1991, CANCER CELL-MON REV, V3, P427; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Lu H, 1997, MOL CELL BIOL, V17, P5923, DOI 10.1128/MCB.17.10.5923; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; McKay BC, 1997, CARCINOGENESIS, V18, P245, DOI 10.1093/carcin/18.2.245; MCKEEL KL, 1997, ONCOGENE, V14, P1847; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MIRZAYANS R, 1995, ONCOGENE, V11, P1597; Mirzayans R, 1996, CARCINOGENESIS, V17, P691, DOI 10.1093/carcin/17.4.691; NAKABEPPU Y, 1982, J BIOL CHEM, V257, P2556; PARK CH, 1995, J BIOL CHEM, V270, P4896, DOI 10.1074/jbc.270.9.4896; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; PIETENPOL JA, 1993, NATURE, V365, P17, DOI 10.1038/365017a0; PROTIC M, 1988, SOMAT CELL MOLEC GEN, V14, P351, DOI 10.1007/BF01534643; PROTICSABLJIC M, 1985, P NATL ACAD SCI USA, V82, P6622, DOI 10.1073/pnas.82.19.6622; QUITSCHKE WW, 1989, J BIOL CHEM, V264, P9539; RADANY EH, 1980, NATURE, V286, P182, DOI 10.1038/286182a0; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; SAUERBIER W, 1978, ANNU REV GENET, V12, P329, DOI 10.1146/annurev.ge.12.120178.001553; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHAEFFER L, 1994, EMBO J, V13, P2388, DOI 10.1002/j.1460-2075.1994.tb06522.x; SCHMIEG FI, 1993, ONCOGENE, V8, P2043; SELBY CP, 1994, MICROBIOL REV, V58, P317, DOI 10.1128/MMBR.58.3.317-329.1994; SELBY CP, 1990, J BIOL CHEM, V265, P21330; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SMITH ML, 1995, ONCOGENE, V10, P1053; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Smith ML, 1996, ONCOGENE, V13, P2255; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; SVEJSTRUP JQ, 1995, CELL, V80, P21, DOI 10.1016/0092-8674(95)90447-6; TAN TH, 1986, J VIROL, V59, P574, DOI 10.1128/JVI.59.3.574-583.1986; TOKINO T, 1994, HUM MOL GENET, V3, P1537, DOI 10.1093/hmg/3.9.1537; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VANVUUREN AJ, 1994, EMBO J, V13, P1645, DOI 10.1002/j.1460-2075.1994.tb06428.x; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; Wiesmuller L, 1996, J VIROL, V70, P737; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; YUAN JL, 1995, CARCINOGENESIS, V16, P2295, DOI 10.1093/carcin/16.10.2295; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZHAO JQ, 1994, MOL CELL BIOL, V14, P8483, DOI 10.1128/MCB.14.12.8483	94	17	17	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 30	1998	17	4					401	411		10.1038/sj.onc.1201951	http://dx.doi.org/10.1038/sj.onc.1201951			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	104XY	9696032				2022-12-17	WOS:000075043000001
J	Ojaniemi, M; Langdon, WY; Vuori, K				Ojaniemi, M; Langdon, WY; Vuori, K			Oncogenic forms of Cbl abrogate the anchorage requirement but not the growth factor requirement for proliferation	ONCOGENE			English	Article						anchorage-independent growth; integrin signaling; oncogene	MEDIATED CELL-ADHESION; PRODUCT C-CBL; TYROSINE PHOSPHORYLATION; PROTOONCOGENE PRODUCT; PROTEIN PRODUCT; PHOSPHATIDYLINOSITOL 3-KINASE; ANTIGEN RECEPTOR; EGF STIMULATION; SH3 DOMAIN; EXTRACELLULAR-MATRIX	Recent studies have demonstrated that Chi, the 120 kDa protein product of the c-cbl proto-oncogene, becomes tyrosine phosphorylated in response to stimulation of growth factor receptors and upon integrin-mediated cell adhesion. As a result, Cbl forms complexes with SH2 and SH3 domain-containing proteins, pointing to its role in signal transduction. The cellular form of CM can be rendered into transforming by naturally occurring or engineered mutations to its amino acid sequence. To gain insight into the mechanisms how oncogenic forms of Cbl render cells tumorigenic and what the function of the cellular CM might be, we have undertaken an analysis of NIH3T3 cells transfected with mild-type and oncogenic forms of Chi. We demonstrate that unlike cellular Cbl, the mutant forms of Cbl are tyrosine phosphorylated in an adhesion-independent manner and interact with and activate SH2-containing signaling molecules in both suspended and adherent cells. Our data further show that oncogenic forms of Cbl induce anchorage-independent but serum-dependent growth. These results support the view that transformation by oncogenic forms of Cbl results from constitutive activation of integrin-dependent, rather than growth factor-dependent signaling events and, as a corollary, suggest that cellular Chi might be a functionally important mediator of integrin signaling.	Burnham Inst, La Jolla Canc Res Ctr, La Jolla, CA 92037 USA; Univ Western Australia, Dept Pathol, Nedlands, WA 6009, Australia	Sanford Burnham Prebys Medical Discovery Institute; University of Western Australia	Vuori, K (corresponding author), Burnham Inst, La Jolla Canc Res Ctr, La Jolla, CA 92037 USA.				NCI NIH HHS [CA72560, CA76037] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA072560, R01CA076037] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; Barber DL, 1997, BLOOD, V89, P3166, DOI 10.1182/blood.V89.9.3166; BLAKE TJ, 1992, ONCOGENE, V7, P757; BLAKE TJ, 1991, ONCOGENE, V6, P653; Bonita DP, 1997, MOL CELL BIOL, V17, P4597, DOI 10.1128/MCB.17.8.4597; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; BOWTELL DDL, 1995, ONCOGENE, V11, P1561; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CORY GOC, 1995, J EXP MED, V182, P611, DOI 10.1084/jem.182.2.611; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; JONGEWARD GD, 1995, GENETICS, V139, P1553; KIM TJ, 1995, J BIOL CHEM, V270, P27504, DOI 10.1074/jbc.270.46.27504; Kontani K, 1996, J BIOL CHEM, V271, P1534; Langdon WY, 1995, AUST NZ J MED, V25, P859, DOI 10.1111/j.1445-5994.1995.tb02892.x; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; MEISNER H, 1995, J BIOL CHEM, V270, P25332, DOI 10.1074/jbc.270.43.25332; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; Ojaniemi M, 1997, J BIOL CHEM, V272, P3780, DOI 10.1074/jbc.272.6.3780; Oldham SM, 1996, P NATL ACAD SCI USA, V93, P6924, DOI 10.1073/pnas.93.14.6924; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; REEDQUIST KA, 1994, P NATL ACAD SCI USA, V91, P4135, DOI 10.1073/pnas.91.10.4135; RENSHAW MW, 1995, MOL CELL BIOL, V15, P1286; SASAKI K, 1995, BIOCHEM BIOPH RES CO, V216, P338, DOI 10.1006/bbrc.1995.2629; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Schwartz MA, 1996, EMBO J, V15, P6525, DOI 10.1002/j.1460-2075.1996.tb01043.x; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; Thien CBF, 1997, ONCOGENE, V14, P2239, DOI 10.1038/sj.onc.1201193; TUCKER R W, 1981, Journal of Supramolecular Structure and Cellular Biochemistry, V15, P29, DOI 10.1002/jsscb.1981.380150104; Verfaillie CM, 1997, ACTA HAEMATOL-BASEL, V97, P40; Vuori K, 1996, MOL CELL BIOL, V16, P2606; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; Wang Y, 1996, J BIOL CHEM, V271, P17, DOI 10.1074/jbc.271.1.17; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0	45	17	17	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 18	1998	16	24					3159	3167		10.1038/sj.onc.1201859	http://dx.doi.org/10.1038/sj.onc.1201859			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV030	9671395				2022-12-17	WOS:000074261300009
J	Zachos, G; Spandidos, DA				Zachos, G; Spandidos, DA			Transcriptional regulation of the c-H-ras1 gene by the P53 protein is implicated in the development of human endometrial and ovarian tumours	ONCOGENE			English	Article						H-ras proto-oncogene; P53 protein; DNA binding; endometrial tumours; ovarian tumours	H-RAS PROTOONCOGENE; WILD-TYPE P53; ESTROGEN-RECEPTORS; CARCINOMA; EXPRESSION; SEQUENCE; ONCOGENE; CELLS; OVEREXPRESSION; SUPPRESSOR	The human c-H-ras1 gene contains within the first intron a p53 element, which functions as a transcriptional enhancer. Using nuclear extracts from human endometrial and ovarian tumours in gel retardation assays, we examined the binding levels of the P53 protein to the H-ras element in tumour versus the adjacent normal tissue. Elevated P53 binding in the tumour tissue was found in 5/12 (42%) endometrial and in 2/5 (40%) ovarian specimens and these cases were found to overexpress wild-type P53, Loss of P53 binding to the H-l as element due to p53 mutations, was observed in 3/12 (25%) endometrial and in 1/5 (20%) ovarian cases, Similar P53 binding levels to the H-uas element were found in 4/12 (33%) endometrial and in 2/5 (40%) ovarian pairs showing normal expression of wild-type P53, Overexpression of the Ras p21 protein correlated with elevated binding and increased nuclear levels of wildtype P53. Our results suggest that P53 protein alterations, participate in the development of human gynecological neoplasias through aberrant transcriptional regulation of the H-ras proto-oncogene.	Univ Crete, Sch Med, Div Virol, Heraklion 71409, Greece; Natl Hellen Res Fdn, Inst Biol Res & Biotechnol, Athens 11635, Greece	University of Crete; National Hellenic Research Foundation	Spandidos, DA (corresponding author), Univ Crete, Sch Med, Div Virol, Heraklion 71409, Greece.			Spandidos, Demetrios/0000-0002-1146-931X				Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; EGAN SE, 1987, MOL CELL BIOL, V7, P830, DOI 10.1128/MCB.7.2.830; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; Hurd C, 1997, ONCOGENE, V15, P991, DOI 10.1038/sj.onc.1201233; Hwang DY, 1997, J VIROL, V71, P6416, DOI 10.1128/JVI.71.9.6416-6426.1997; JUVEN T, 1993, ONCOGENE, V8, P3411; KIHANA T, 1995, CANCER, V76, P72, DOI 10.1002/1097-0142(19950701)76:1<72::AID-CNCR2820760110>3.0.CO;2-3; KLEMI PJ, 1995, CANCER, V76, P1201, DOI 10.1002/1097-0142(19951001)76:7<1201::AID-CNCR2820760716>3.0.CO;2-L; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEVESQUE MA, 1995, CANCER-AM CANCER SOC, V75, P1327, DOI 10.1002/1097-0142(19950315)75:6<1327::AID-CNCR2820750615>3.0.CO;2-P; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Liloglou T, 1997, BRIT J CANCER, V75, P1119, DOI 10.1038/bjc.1997.193; LONG CA, 1988, AM J OBSTET GYNECOL, V159, P1512, DOI 10.1016/0002-9378(88)90586-8; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Maniatis T., 1989, MOL CLONING LAB MANU; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; Miturski R, 1996, ACTA HISTOCHEM, V98, P411, DOI 10.1016/S0065-1281(96)80008-0; Scambia G, 1997, BRIT J CANCER, V75, P1547, DOI 10.1038/bjc.1997.264; SCAMBIA G, 1993, AM J OBSTET GYNECOL, V168, P71, DOI 10.1016/S0002-9378(12)90888-1; Soong R, 1996, BRIT J CANCER, V74, P562, DOI 10.1038/bjc.1996.401; SPANDIDOS DA, 1995, INT J ONCOL, V7, P1029; Varras MN, 1996, ONCOLOGY-BASEL, V53, P505; Zachos G, 1997, CRIT REV ONCOL HEMAT, V26, P65, DOI 10.1016/S1040-8428(97)00013-9; Zachos G, 1996, J Exp Ther Oncol, V1, P335; Zachos G, 1996, JPN J CANCER RES, V87, P916, DOI 10.1111/j.1349-7006.1996.tb02120.x; ZACHOS G, 1995, INT J ONCOL, V6, P595; ZOUMPOURLIS V, 1995, INT J ONCOL, V7, P1035	29	17	17	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 11	1998	16	23					3013	3017		10.1038/sj.onc.1201836	http://dx.doi.org/10.1038/sj.onc.1201836			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZT782	9662334				2022-12-17	WOS:000074125300008
J	Latil, A; Bieche, I; Fournier, G; Cussenot, O; Pesche, S; Lidereau, R				Latil, A; Bieche, I; Fournier, G; Cussenot, O; Pesche, S; Lidereau, R			Molecular analysis of the FHIT gene in human prostate cancer	ONCOGENE			English	Article						FHIT; tumor suppressor gene; prostate cancer; reverse transcription; single stage PCR; nested PCR	TUMOR-SUPPRESSOR GENE; ALLELIC LOSS; CELL-LINES; MICROSATELLITE INSTABILITY; HOMOZYGOUS DELETIONS; LUNG-CANCER; 3P14.2; CARCINOMAS; HETEROZYGOSITY; ADENOCARCINOMA	A variety of studies suggest that the FHIT gene, which encompasses the fragile site at 3p14.2, is a candidate tumor suppressor gene in several forms of human cancer. To determine whether the FHIT gene is altered in prostate carcinomas, we examined 15 prostate tumors, four normal prostate tissue specimens and RNA from a pool of 62 normal human prostate tissues (Clontech) for the integrity of FHIT transcripts, using a robust single-stage PCR and a nested PCR method. In each case a major FHIT-specific full-length product was observed, Additional aberrantly sized products, which were more numerous in the nested PCR strategy, were present at a far lower level than the full-length transcripts in 14 of 15 tumors, three of four normal human prostate tissues and in the pooled normal prostate RNA. Sequence analysis revealed that these aberrant products corresponded to alternatively spliced FHIT transcripts, which were neither more numerous nor more prominent in the tumors than in the normal prostate specimens. Deletion at the FHIT locus was also evaluated by using three intragenic polymorphic markers (D13S1481, D3S1300, and D3S1234). Allelic loss was observed in two tumors, but these genomic alterations did not correspond to the aberrant FHIT transcripts. DNA analysis, furthermore, suggested that the tumor heterogeneity was not a likely explanation for presence of normal and alternatively spliced FHIT transcripts in the prostate tumors. In conclusion, we detected neither frequent loss of heterozygosity nor tumor specific transcripts of the FHIT gene in human prostate cancer.	Ctr Rene Huguenin, Lab Oncogenet, F-92211 St Cloud, France; Hop Cavale Blanche, Dept Urol, F-29609 Brest, France; CHU St Louis, Dept Urol, F-75010 Paris, France	Rene Huguenin Hospital; CHU Brest; Universite de Bretagne Occidentale; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	Lidereau, R (corresponding author), Ctr Rene Huguenin, Lab Oncogenet, F-92211 St Cloud, France.		Bièche, Ivan/O-7399-2017	Bièche, Ivan/0000-0002-2430-5429; cussenot, olivier/0000-0002-9912-0533				Barnes LD, 1996, BIOCHEMISTRY-US, V35, P11529, DOI 10.1021/bi961415t; Boldog F, 1997, HUM MOL GENET, V6, P193, DOI 10.1093/hmg/6.2.193; BOVA GS, 1993, CANCER RES, V53, P3869; CAIRNS P, 1994, CANCER RES, V54, P1422; CARTER BS, 1990, P NATL ACAD SCI USA, V87, P8751, DOI 10.1073/pnas.87.22.8751; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Cooney KA, 1996, CANCER RES, V56, P1142; Cunningham JM, 1996, CANCER RES, V56, P4475; Dahiya R, 1997, INT J CANCER, V71, P20, DOI 10.1002/(SICI)1097-0215(19970328)71:1<20::AID-IJC5>3.3.CO;2-G; Druck T, 1997, CANCER RES, V57, P504; Fong KM, 1997, CANCER RES, V57, P2256; GAO X, 1995, CANCER RES, V55, P1002; GAO X, 1993, CANCER RES, V53, P2723; Hayashi S, 1997, CANCER RES, V57, P1981; Hendricks DT, 1997, CANCER RES, V57, P2112; HUDSON TJ, 1992, GENOMICS, V13, P622, DOI 10.1016/0888-7543(92)90133-D; Ittmann M, 1996, CANCER RES, V56, P2143; Kastury K, 1996, CANCER RES, V56, P978; LATIL A, 1994, GENE CHROMOSOME CANC, V11, P119, DOI 10.1002/gcc.2870110208; Luan XD, 1997, ONCOGENE, V15, P79, DOI 10.1038/sj.onc.1201164; Mao L, 1996, CANCER RES, V56, P5128; MCGROGAN D, 1994, GENE CHROMOSOME CANC, V10, P151; Negrini M, 1996, CANCER RES, V56, P3173; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Panagopoulos I, 1996, CANCER RES, V56, P4871; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; Sozzi G, 1996, CANCER RES, V56, P2472; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; Thiagalingam S, 1996, CANCER RES, V56, P2936; UMBAS R, 1992, CANCER RES, V52, P5104; Virgilio L, 1996, P NATL ACAD SCI USA, V93, P9770, DOI 10.1073/pnas.93.18.9770; WATANABE M, 1995, BRIT J CANCER, V72, P562, DOI 10.1038/bjc.1995.374; Yanagisawa K, 1996, CANCER RES, V56, P5579; ZENKLUSEN JC, 1994, CANCER RES, V54, P6370; Zou TT, 1997, ONCOGENE, V15, P101, DOI 10.1038/sj.onc.1201169	35	17	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 9	1998	16	14					1863	1868		10.1038/sj.onc.1201703	http://dx.doi.org/10.1038/sj.onc.1201703			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZG368	9583683				2022-12-17	WOS:000072994600009
J	Wark, G; Heyworth, CM; Spooncer, E; Czaplewski, L; Francis, JM; Dexter, TM; Whetton, AD				Wark, G; Heyworth, CM; Spooncer, E; Czaplewski, L; Francis, JM; Dexter, TM; Whetton, AD			Abl protein kinase abrogates the response of multipotent haemopoietic cells to the growth inhibitor macrophage inflammatory protein-1 alpha	ONCOGENE			English	Article						chronic myeloid leukaemia (CML); MIP-1 alpha; abl	CHRONIC MYELOID-LEUKEMIA; CHRONIC MYELOGENOUS LEUKEMIA; COLONY FORMATION INVITRO; TYROSINE KINASE; HEMATOPOIETIC-CELLS; BCR-ABL; FUNCTIONAL EXPRESSION; PROGENITOR CELLS; SELF-RENEWAL; PROLIFERATION	The clonogenic cells of chronic myeloid leukaemia (CML), unlike normal haemopoietic progenitor cells, are resistant to the growth inhibitory effects of the chemokine macrophage inflammatory protein-1 alpha (MIP-1 alpha). CML is also relatively resistant to chemotherapy and the disease is difficult to cure using conventional therapeutic routes, CML is associated with increased abl oncogene protein tyrosine kinase (PTK) activity. Here, we have tested the hypothesis that these aberrant responses to MIP-1 alpha and the relative resistance to chemotherapy are directly related to this increased abl PTK activity in primitive haemopoietic cells. to do this we have expressed a temperature sensitive abl PTK in a growth factor dependent, multipotent stem cell line (FDCP-Mix) in which growth is normally suppressed by MIB-1 alpha. In FDCP-Mix cells expressing the ts v-abl PTK and grown at the restrictive temperature for PTK activity the cells were relatively sensitive to cytotoxic agents such as cytosine arabinoside and 5-fluorouracil but MTP-1 alpha could induce growth inhibition and confer some degree of protection from these agents. At the permissive temperature for abl PTK, the cells were relatively resistant to cytotoxic drugs and MIP-1 alpha treatment neither induced growth inhibition nor protected the cells from cytotoxic drug induced cell death. This lack of response to MIP-1 alpha was not due to receptor down modulation as neither the affinity nor the number of I-125-MIP-1 alpha binding sites was altered by activating Abl PTK. However, MIP-1 alpha mediated increases in cytosolic Ca2+ levels were abrogated by switching cells to the permissive temperature for Abl PTK activity. These data suggest that the relative resistance of CML progenitor cells to therapeutic drugs and the lack of response to MIP-1 alpha occurs as a direct consequence of abl PTK activity and involves desensitisation of signal transduction events stimulated by MIP-1 alpha receptors. Thus one contributory mechanism to transformation of primitive haemopoietic cells is abrogation of response to a growth inhibitor.	Christie Hosp NHS Trust, Paterson Inst Canc Res, Dept Expt Hematol, Canc Res Campaign, Manchester M20 9BX, Lancs, England; British Biotech, Oxford OX4 5LY, England	Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research	Dexter, TM (corresponding author), Christie Hosp NHS Trust, Paterson Inst Canc Res, Dept Expt Hematol, Canc Res Campaign, Wilmslow Rd, Manchester M20 9BX, Lancs, England.			WHETTON, ANTHONY D/0000-0002-1098-3878				BEDI A, 1994, BLOOD, V83, P2038; BEDI A, 1995, BLOOD, V86, P1148, DOI 10.1182/blood.V86.3.1148.bloodjournal8631148; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; BHATIA R, 1995, J CLIN INVEST, V96, P931, DOI 10.1172/JCI118141; BROXMEYER HE, 1990, BLOOD, V76, P1110; BROXMEYER HE, 1989, J EXP MED, V170, P1583, DOI 10.1084/jem.170.5.1583; Broxmeyer HE, 1996, ANN HEMATOL, V73, P1, DOI 10.1007/s002770050192; CHAMPLIN RE, 1985, BLOOD, V65, P1039; CHAPMAN RS, 1994, CANCER RES, V54, P5131; CHASTY RC, 1995, BLOOD, V86, P4270, DOI 10.1182/blood.V86.11.4270.bloodjournal86114270; CLEMENTS JM, 1992, CYTOKINE, V4, P76, DOI 10.1016/1043-4666(92)90040-X; COUTINHO LH, 1993, HAEMOPOIESIS PRACTIC, P75; DALEY GQ, 1991, ADV CANCER RES, V57, P151; DEXTER TM, 1994, BLOOD, V84, P673; DUNLOP DJ, 1992, BLOOD, V79, P2221; EAVES AC, 1986, P NATL ACAD SCI USA, V83, P5306, DOI 10.1073/pnas.83.14.5306; EAVES CJ, 1993, P NATL ACAD SCI USA, V90, P12015, DOI 10.1073/pnas.90.24.12015; EVANS CA, 1993, CANCER RES, V53, P1735; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; GRAHAM GJ, 1990, NATURE, V344, P442, DOI 10.1038/344442a0; Heyworth CM, 1990, GROWTH FACTORS, V2, P197, DOI 10.3109/08977199009071506; HEYWORTH CM, 1995, GROWTH FACTORS, V12, P165, DOI 10.3109/08977199509036876; HOLYOAKE TL, 1993, STEM CELLS, V11, P122, DOI 10.1002/stem.5530110925; KABAROWSKI JHS, 1994, EMBO J, V13, P5887, DOI 10.1002/j.1460-2075.1994.tb06934.x; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; LORD BI, 1992, BLOOD, V79, P2605; MAJOR PP, 1981, BIOCHEM PHARMACOL, V30, P2221, DOI 10.1016/0006-2952(81)90091-5; METCALF D, 1989, CANCER RES, V49, P2305; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PARKER WB, 1990, PHARMACOL THERAPEUT, V48, P381, DOI 10.1016/0163-7258(90)90056-8; PARKINSON EK, 1993, J INVEST DERMATOL, V101, P113, DOI 10.1111/1523-1747.ep12363603; SPOONCER E, 1994, LEUKEMIA, V8, P620; SPOONCER E, 1986, DIFFERENTIATION, V31, P111, DOI 10.1111/j.1432-0436.1986.tb00391.x; WHETTON AD, 1986, EMBO J, V5, P3281, DOI 10.1002/j.1460-2075.1986.tb04640.x; WOLPE SD, 1989, FASEB J, V3, P2565, DOI 10.1096/fasebj.3.14.2687068	36	17	17	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 12	1998	16	10					1319	1324		10.1038/sj.onc.1201914	http://dx.doi.org/10.1038/sj.onc.1201914			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA978	9546433				2022-12-17	WOS:000072422000010
J	Gagnebin, J; Kovar, H; Kajava, AV; Estreicher, A; Jug, G; Monnier, P; Iggo, R				Gagnebin, J; Kovar, H; Kajava, AV; Estreicher, A; Jug, G; Monnier, P; Iggo, R			Use of transcription reporters with novel p53 binding sites to target tumour cells expressing endogenous or virally transduced p53 mutants with altered sequence-specificity	ONCOGENE			English	Article						p53; gene therapy; transcription	DNA-BINDING; PROTEIN; MUTATIONS; GENE	p53 triple mutants (120N/121G/277H, 120H/121G/277H, 120S/121G/277H and 120H/121G/277Y) have altered sequence specificity in bandshift assays in vitro and transcription assays in vivo. These mutants activate transcription from the site TTT CATG AAA but not from wild type sites. The triple mutants activate more strongly than p53 with a single 277Y mutation. The TTT site matches the wild type p53 consensus at only 4/10 positions and is not recognised by wild type p53. 277Y mutations have been described in human tumours, and Ewing tumour cells expressing this mutant from the endogenous p53 locus selectively activate transcription from transfected luciferase reporters regulated by TTT-mutant p53 binding sites. p53 mutants with altered sequence specificity have potential advantages for cancer gene therapy: if used to activate transcription of conditionally toxic genes they would allow tumour-targeting by p53, which acts as a sensor for the malignant state, but place control over cell killing in the hands of the clinician. Rare tumours expressing such mutants from the endogenous p53 locus could be targeted directly with p53-regulated suicide vectors, but for most tumours both the p53 mutant and the reporter would need to be encoded by the virus.	Swiss Inst Expt Canc Res, CH-1066 Epalinges, Switzerland; CHU Vaudois, Univ Hosp, Serv Otorhinolaryngol, CH-1011 Lausanne, Switzerland; St Anna Kinderspital, CCRI, A-1090 Vienna, Austria	Swiss Institute Experimental Cancer Research; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Saint Anna Children's Hospital	Iggo, R (corresponding author), Swiss Inst Expt Canc Res, CH-1066 Epalinges, Switzerland.		Kajava, Andrey V/E-1107-2014; Iggo, Richard/G-3546-2014	Kajava, Andrey V/0000-0002-2342-6886; Kovar, Heinrich/0000-0001-6873-9109; Estreicher, Anne/0000-0001-6828-2508				ABARZUA P, 1996, ONCOGENE, V13, P2447; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CULVER KW, 1992, SCIENCE, V256, P1500; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; EZZEDDINE ZD, 1991, NEW BIOL, V3, P608; FLAMAN JM, 1994, NUCLEIC ACIDS RES, V22, P3259, DOI 10.1093/nar/22.15.3259; FREEMAN J, 1994, EMBO J, V13, P5393, DOI 10.1002/j.1460-2075.1994.tb06874.x; FREIDLANDER P, 1996, MOL CELL BIOL, V16, P4961; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KOVAR H, 1993, ONCOGENE, V8, P2683; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; Roth JA, 1996, NAT MED, V2, P985, DOI 10.1038/nm0996-985; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P77; Sandig V, 1997, NAT MED, V3, P313, DOI 10.1038/nm0397-313; THUKRAL SK, 1995, MOL CELL BIOL, V15, P5196	22	17	18	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 5	1998	16	5					685	690		10.1038/sj.onc.1201568	http://dx.doi.org/10.1038/sj.onc.1201568			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YV376	9482117				2022-12-17	WOS:000071816600016
J	Masutani, H; MagnaghiJaulin, L; Ali, SAS; Groisman, R; Robin, P; HarelBellan, A				Masutani, H; MagnaghiJaulin, L; Ali, SAS; Groisman, R; Robin, P; HarelBellan, A			Activation of the c-fos SRE through SAP-1a	ONCOGENE			English	Article						c-fos; SAP-1; serum response element (SRE); serum response factor (SRF); ternary complex factor (TCF)	SERUM RESPONSE FACTOR; FACTOR-DEPENDENT TRANSCRIPTION; DNA-BINDING SPECIFICITIES; TERNARY COMPLEX-FORMATION; FACTORS ELK-1; MAP KINASE; PROTEIN ELK-1; FACTOR P62TCF; GROWTH-FACTOR; ETS FAMILY	TCFs, which are members of the Ets family of transcription factors, are recruited to the Serum Response Element (SRE) in the c-fos promoter by SRF. These Ets proteins, which are substrates for the MAP kinases, are direct targets of the Ras/MAP kinase signal transduction pathway, In this paper, we demonstrate that one of the TCFs, SAP-la, displays a significant level of autonomous binding to the SRE Ets box, in contrast to previous observations, deletion of the SRF binding domain did not modulate the autonomous binding of SAP-la. Also, the autonomous binding was not modulated by the phosphorylation of SAP-la by MAP kinases, The autonomous binding was also detected in live cells: transfected SAP-la was able to restore the response of a CArG-less SRE in PC12 cells. The response occurred in the absence of SRF recruitment since a mutant of SAP-la in which the B-box, a domain required for interaction with SRF, had been deleted was still able to transactivate the CArG-less SRE. The transactivation was repressed by a Ras transdominant negative mutant, indicating the involvement of the Ras/MAP kinase pathway. Taken together, these data demonstrate that SAP-la is capable of binding to the c-fos SRE in the absence of SRF.	INST GUSTAVE ROUSSY,LAB BIOL TUMEURS HUMAINES,CNRS,URA 1156,F-94805 VILLEJUIF,FRANCE	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy			Harel-Bellan, Annick/M-9795-2015; Masutani, Hiroshi/B-5114-2014	Groisman, Sonia/0000-0003-1153-3841; Harel-Bellan, Annick/0000-0002-2339-153X; Groisman, Regina/0000-0003-3990-7622; Masutani, Hiroshi/0000-0001-7633-2827				BONNI A, 1995, MOL CELL NEUROSCI, V6, P168, DOI 10.1006/mcne.1995.1015; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; Gille H, 1996, MOL CELL BIOL, V16, P1094; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HIPSKIND RA, 1994, GENE DEV, V8, P1803, DOI 10.1101/gad.8.15.1803; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; JANKNECHT R, 1995, ONCOGENE, V10, P1209; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LOPEZ M, 1994, MOL CELL BIOL, V14, P3292, DOI 10.1128/MCB.14.5.3292; MagnaghiJaulin L, 1996, NUCLEIC ACIDS RES, V24, P1052, DOI 10.1093/nar/24.6.1052; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; MIRANTI CK, 1995, MOL CELL BIOL, V15, P3672; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SHORE P, 1994, MOL CELL BIOL, V14, P3283, DOI 10.1128/MCB.14.5.3283; SHORE P, 1995, NUCLEIC ACIDS RES, V23, P4698, DOI 10.1093/nar/23.22.4698; TREISMAN R, 1992, EMBO J, V11, P4631, DOI 10.1002/j.1460-2075.1992.tb05565.x; Treisman R, 1990, Semin Cancer Biol, V1, P47; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; TROUCHE D, 1991, BLOOD, V77, P55; TROUCHE D, 1993, BIOCHEM BIOPH RES CO, V196, P611, DOI 10.1006/bbrc.1993.2293; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; ZHANG LQ, 1993, ONCOGENE, V8, P1621; ZINCK R, 1993, EMBO J, V12, P2377, DOI 10.1002/j.1460-2075.1993.tb05892.x	34	17	17	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 2	1997	15	14					1661	1669		10.1038/sj.onc.1201328	http://dx.doi.org/10.1038/sj.onc.1201328			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XY631	9349499				2022-12-17	WOS:A1997XY63100005
J	Kirkpatrick, H; Waber, P; HoaThai, T; Barnes, R; OsborneLawrence, S; Truelson, J; Nisen, P; Bowcock, A				Kirkpatrick, H; Waber, P; HoaThai, T; Barnes, R; OsborneLawrence, S; Truelson, J; Nisen, P; Bowcock, A			Infrequency of BRCA2 alterations in head and neck squamous cell carcinoma	ONCOGENE			English	Article						head and neck squamous cell carcinoma; chromosome 13; BRCA2; mutational analysis	CANCER SUSCEPTIBILITY GENE; FREQUENT LOSS; MUTATIONS; RETINOBLASTOMA; POLYMORPHISMS; ALLELOTYPE; DELETION; TUMORS; P53; 13Q	Alterations of BRCA2 result in increased susceptibility to breast cancer in both men and women (relative lifetime risks of 0.06 and 0.8 respectively). BRCA2 maps to 13q12-q13 and encodes a transcript of 10157 bp. Other cancers that have been described in BRCA2 mutation carriers include those of the larynx. Human chromosome 13q has been shown previously by LOH studies to harbor several tumor suppressor genes for head and neck squamous cell carcinoma (HNSCCs). We therefore examined the role of BRCA2 in the development of these cancers. Only 6/22 (27%) of the laryngeal cancers we examined demonstrated LOH of the BRCA2-containing region. These and 10 other HNSCCs of different origins that were demonstrated by LOH studies to have lost the region of chromosome 13 containing BRCA2 were examined for alterations in this gene. SSCP analysis failed to reveal any alterations leading us to conclude that BRCA2 alterations are not frequently involved in the pathogenesis of HNSCCs and that the observed LOH of chromosome 13 loci is due to other, as yet, unidentified tumor suppressor gene(s). Interestingly tumors with LOH in this region (proximal to D13S118) were far more likely to be derived from women than men. This is unusual since HNSCCs are usually fourfold more common in men than in women.	UNIV TEXAS, SW MED CTR, DEPT PEDIAT, DIV HEMATOL ONCOL, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT OTOLARYNGOL, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Bowcock, Anne/0000-0001-8691-9090	NCI NIH HHS [CA60650] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060650] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHSEE KW, 1994, CANCER RES, V54, P1617; BORING CC, 1992, CA-CANCER J CLIN, V42, P19, DOI 10.3322/canjclin.42.1.19; BOWCOCK A, 1993, GENOMICS, V15, P376, DOI 10.1006/geno.1993.1071; Couch FJ, 1996, NAT GENET, V13, P123, DOI 10.1038/ng0596-123; COWAN JM, 1992, J NATL CANCER I, V84, P793, DOI 10.1093/jnci/84.10.793; HOSKING L, 1995, NAT GENET, V9, P343, DOI 10.1038/ng0495-343; JIN YS, 1993, CANCER RES, V53, P2140; Lancaster JM, 1996, NAT GENET, V13, P238, DOI 10.1038/ng0696-238; LEE NK, 1992, HEAD NECK-J SCI SPEC, V14, P235, DOI 10.1002/hed.2880140312; LEE NK, 1992, HEAD NECK-J SCI SPEC, V14, P407, DOI 10.1002/hed.2880140513; LEE NK, 1993, ARCH OTOLARYNGOL, V119, P1125; LI XH, 1994, J NATL CANCER I, V86, P1524, DOI 10.1093/jnci/86.20.1524; Maestro R, 1996, CANCER RES, V56, P1146; MAESTRO R, 1993, CANCER RES, V53, P5775; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; Miki Y, 1996, NAT GENET, V13, P245, DOI 10.1038/ng0696-245; NAWROZ H, 1994, CANCER RES, V54, P1152; Nylander K, 1996, BRIT J CANCER, V73, P1381, DOI 10.1038/bjc.1996.262; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PARKIN DM, 1988, INT J CANCER, V41, P184, DOI 10.1002/ijc.2910410205; Phelan CM, 1996, NAT GENET, V13, P120, DOI 10.1038/ng0596-120; PONDER B, 1988, NATURE, V335, P400, DOI 10.1038/335400a0; Reed AL, 1996, CANCER RES, V56, P3630; Rowley H, 1996, ARCH OTOLARYNGOL, V122, P497; SOMERS KD, 1992, CANCER RES, V52, P5997; Stratton MR, 1996, HUM MOL GENET, V5, P1515, DOI 10.1093/hmg/5.Supplement_1.1515; VANDERRIET P, 1994, CANCER RES, V54, P1156; Weber BHF, 1996, AM J HUM GENET, V59, P962; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; WU CL, 1994, CANCER RES, V54, P6484; YOO GH, 1994, CANCER RES, V54, P4603	33	17	17	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 8	1997	14	18					2189	2193		10.1038/sj.onc.1201060	http://dx.doi.org/10.1038/sj.onc.1201060			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WX938	9174054				2022-12-17	WOS:A1997WX93800007
J	Alemi, M; Lucas, SD; Sallstrom, JF; Bergholm, U; Akerstrom, G; Wilander, E				Alemi, M; Lucas, SD; Sallstrom, JF; Bergholm, U; Akerstrom, G; Wilander, E			A complex nine base pair deletion in RET exon 11 common in sporadic medullary thyroid carcinoma	ONCOGENE			English	Article						RET proto-oncogene; deletion; medullary thyroid carcinoma	MULTIPLE ENDOCRINE NEOPLASIA; PROTOONCOGENE MUTATIONS; TYROSINE KINASE; MEN 2A; FMTC; ACTIVATION; CANCER; GENE	Genetic alteration of the RET proto-oncogene is associated with multiple endocrine neoplasia type 2A and 2B (MEN 2A and MEN 2B), familial medullary thyroid carcinoma (FMTC) and Hirschprung's disease. Oncogenically activated RET has also been demonstrated in sporadic medullary thyroid tumors, which in some cases show somatic missense mutations, We have recently described a complex 9 bp deletion in RET exon 11 in a single case of sporadic MTC, In order to determine the prevalence of this mutation among sporadic MTC tumors, we have now analysed 15 cases and five normal controls by PCR-based nonradioactive single-strand conformational polymorphism analysis (PCR-SSCP) and fragment size analysis of exon 11, DNA was extracted from microdissected tumor tissue or normal cells and subjected to nested PCR prior to analysis, A markedly divergent SSCP pattern and a PCR fragment 9 bp shorter than normal were demonstrated in 14 of the 15 MTC tumors. Sequencing revealed the deletion of nine bases encompassing a key cysteine at codon 634, often altered in MEN 2A, Four lymphocyte controls and normal thyroid tissue from one patient failed to show the deletion, Several factors in the DNA sequence environment immediately surrounding the deletions, including an extended inverted repeat, several direct repeats and a so-called symmetric element suggest that the deletional events may be non-random.	UNIV UPPSALA HOSP,DEPT SURG,S-75185 UPPSALA,SWEDEN	Uppsala University; Uppsala University Hospital	Alemi, M (corresponding author), UNIV UPPSALA HOSP,DEPT PATHOL,S-75185 UPPSALA,SWEDEN.			Lucas, Steven/0000-0002-3409-2033				ALBERTINI AM, 1982, CELL, V29, P3189; Alemi M, 1996, ANTICANCER RES, V16, P2619; BOLINO A, 1995, ONCOGENE, V10, P2415; BRUNIER D, 1988, CELL, V52, P883, DOI 10.1016/0092-8674(88)90430-8; CARNEY JA, 1976, ORAL SURG ORAL MED O, V41, P739, DOI 10.1016/0030-4220(76)90187-0; DASGUPTA U, 1987, GENETICS, V115, P41; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; DONISKELLER H, 1995, J INTERN MED, V238, P319, DOI 10.1111/j.1365-2796.1995.tb01205.x; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; ENG C, 1995, ONCOGENE, V10, P509; FARNDON JR, 1986, BRIT J SURG, V73, P278, DOI 10.1002/bjs.1800730411; GALAS DJ, 1978, J MOL BIOL, V126, P858, DOI 10.1016/0022-2836(78)90024-4; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; Jackson C E, 1989, Henry Ford Hosp Med J, V37, P116; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; KIMURA T, 1995, ENDOCR J, V42, P517, DOI 10.1507/endocrj.42.517; KRAWCZAK M, 1991, HUM GENET, V86, P425; LAIRMORE TC, 1993, BRIT J SURG, V80, P1092, DOI 10.1002/bjs.1800800904; LLOYD RV, 1995, AM J PATHOL, V147, P1539; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHAAPER RM, 1986, J MOL BIOL, V189, P272; SCHIMKE RN, 1968, NEW ENGL J MED, V279, P1, DOI 10.1056/NEJM196807042790101; SCHUFFENECKER I, 1994, HUM MOL GENET, V3, P1939, DOI 10.1093/hmg/3.11.1939; SINGER BS, 1988, J MOL BIOL, V202, P233, DOI 10.1016/0022-2836(88)90454-8; SIPPLE JH, 1961, AM J MED, V31, P163, DOI 10.1016/0002-9343(61)90234-0; TAKAHASHI M, 1995, CRIT REV ONCOGENESIS, V6, P35, DOI 10.1615/CritRevOncog.v6.i1.30; TAKAHASHI M, 1988, ONCOGENE, V3, P571; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; YAMAKAWAKOBAYASHI K, 1994, HUM GENET, V93, P625	30	17	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 1	1997	14	17					2041	2045		10.1038/sj.onc.1201042	http://dx.doi.org/10.1038/sj.onc.1201042			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WW809	9160884				2022-12-17	WOS:A1997WW80900006
J	Higuchi, O; Amano, T; Yang, N; Mizuno, K				Higuchi, O; Amano, T; Yang, N; Mizuno, K			Inhibition of activated Ras-induced neuronal differentiation of PC12 cells by the LIM domain of LIM-kinase 1	ONCOGENE			English	Article						LIM protein; LIM motif; protein kinase; MAP kinase; neurite outgrowth	ZINC-FINGER MOTIF; PROTEIN-KINASE; SIGNAL-TRANSDUCTION; MAP KINASE; TRANSFORMATION; IDENTIFICATION; THREONINE; INDUCTION; PAXILLIN; LEUKEMIA	LIM-kinase 1 and 2 (LIMK1 and LIMK2) are members of a novel class of protein kinases with structures composed of two LIM motifs at the N-terminus and an unusual protein kinase domain at the C-terminus. The cellular functions of the LIMK family proteins have remained unknown, In the present study, we examined effects of LIMKs on neuronal differentiation of PC12 pheochromocytoma cells. Transient expression analyses revealed that LIMK1, in itself, had no apparent effect on PC12 cells, but the oncogenic Ras-induced differentiation of PC12 cells was notably inhibited by co-expression with LIMK1 or LIMK2. A mutant of LIMK1 lacking a protein kinase domain (Delta K) similarly inhibited Ras-induced differentiation of PC12 cells, but a mutant lacking a LIM domain (Delta LIM) failed to do so, indicating that a LIM domain but not a protein kinase domain is required for the inhibitory activity. This notion was further supported by the finding that mutation, changing conserved cysteines involved in zinc coordination to glycines in both of two LIM motifs, abolished the inhibitory activity of Delta K. Additionally, we also found that the constitutively activated MAP kinase kinase (MAPKK)-induced differentiation of PC12 cells was inhibited by co-expression with Delta K. Furthermore, Delta K did not inhibit the kinase activity of MAP kinase (MAPK) stimulated by MAPKK, when co-expressed in COS7 cells. These findings suggest that LIMK1 inhibits neuronal differentiation of PC12 cells, through its LIM domain and by interfering with events downstream of MAPK activation.	KYUSHU UNIV,FAC SCI,DEPT BIOL,HAKOZAKI,FUKUOKA 81281,JAPAN; JAPAN SCI & TECHNOL CORP,PRESTO,INHERITANCE & VARIAT GRP,KYOTO 61902,JAPAN	Kyushu University; Japan Science & Technology Agency (JST)			Mizuno, Kensaku/G-8631-2015					BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BERNARD O, 1994, CELL GROWTH DIFFER, V5, P1159; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; Blobe GC, 1996, J BIOL CHEM, V271, P15823, DOI 10.1074/jbc.271.26.15823; CHENG AK, 1995, MECH DEVELOP, V52, P187, DOI 10.1016/0925-4773(95)00400-U; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CRAWFORD AW, 1992, J CELL BIOL, V116, P1381, DOI 10.1083/jcb.116.6.1381; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAWID IB, 1995, CR ACAD SCI III-VIE, V318, P295; Durick K, 1996, J BIOL CHEM, V271, P12691, DOI 10.1074/jbc.271.22.12691; FEUERSTEIN R, 1994, P NATL ACAD SCI USA, V91, P10655, DOI 10.1073/pnas.91.22.10655; Frangiskakis JM, 1996, CELL, V86, P59, DOI 10.1016/S0092-8674(00)80077-X; FUKUDA M, 1995, ONCOGENE, V11, P239; GOTOH Y, 1995, J BIOL CHEM, V270, P25898, DOI 10.1074/jbc.270.43.25898; HATTORI S, 1985, MOL CELL BIOL, V5, P1449, DOI 10.1128/MCB.5.6.1449; Higuchi O, 1996, FEBS LETT, V396, P81, DOI 10.1016/0014-5793(96)01072-1; ITO A, 1990, BIOCHEM INT, V22, P235; Kuroda S, 1996, J BIOL CHEM, V271, P31029, DOI 10.1074/jbc.271.49.31029; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MIZUNO K, 1994, ONCOGENE, V9, P1605; MORI T, 1996, IN PRESS MOL BRAIN R; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; NUNOUE K, 1995, ONCOGENE, V11, P701; OHASHI K, 1994, J BIOCH, V111, P636; Okano I, 1995, J BIOL CHEM, V270, P31321, DOI 10.1074/jbc.270.52.31321; PEREZALVARADO GC, 1994, NAT STRUCT BIOL, V1, P388, DOI 10.1038/nsb0694-388; PROSCHEL C, 1995, ONCOGENE, V11, P1271; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; TAIRA M, 1994, NATURE, V372, P677, DOI 10.1038/372677a0; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TENG KK, 1995, J BIOL CHEM, V270, P20677, DOI 10.1074/jbc.270.35.20677; Toshima J, 1995, J BIOL CHEM, V270, P31331, DOI 10.1074/jbc.270.52.31331; TURNER CE, 1994, J CELL SCI, V107, P1583; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; WOOD KW, 1993, P NATL ACAD SCI USA, V90, P5016, DOI 10.1073/pnas.90.11.5016; WU RY, 1994, J BIOL CHEM, V269, P25085	42	17	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 17	1997	14	15					1819	1825		10.1038/sj.onc.1201020	http://dx.doi.org/10.1038/sj.onc.1201020			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WW166	9150388				2022-12-17	WOS:A1997WW16600008
J	Liu, DR; Pavlopoulos, E; Modi, W; Moschonas, N; Mavrothalassitis, G				Liu, DR; Pavlopoulos, E; Modi, W; Moschonas, N; Mavrothalassitis, G			ERF: Genomic organization, chromosomal localization and promoter analysis of the human and mouse genes	ONCOGENE			English	Article						ets; transcriptional repressor; genomic organization; promoter	ETS DOMAIN PROTEIN; EWINGS-SARCOMA TRANSLOCATION; CHRONIC LYMPHOCYTIC-LEUKEMIA; TRANSCRIPTION FACTORS; SIGNAL-TRANSDUCTION; THYROID ADENOMAS; MYELOID-LEUKEMIA; ONCOGENE FAMILY; DROSOPHILA EYE; TEL GENE	ERF (Ets2 Repressor Factor) is a ubiquitously expressed ets-domain protein that exhibits strong transcriptional repressor activity, has been shown to suppress ets-induced transformation and has been suggested to be regulated by MAPK phosphorylation. We report here the sequence of the mouse gene, the genomic organization of the human and the mouse genes, their chromosomal position and the analysis of the promoter region. Genomic clones encompassing either the human ERI; or the mouse Erf gene were isolated and utilized to define their molecular organization. The gene in both species consists of 4 exons over a 10 kb region. Utilizing FISH, somatic cell hybrids and linkage analysis, we identified the chromosomal position of ERP on human chromosome 19q13.1 and on its syntenic region in the mouse, on chromosome 7. Sequence analysis of the mouse gene indicated a 90% identity to the human gene within the coding and promoter regions. The predicted Erf protein is 98% identical to the human protein and all of the identifiable motifs are conserved between the two proteins. However, the mouse protein is three amino acids longer (551 versus 548 aa). The area surrounding the region that is homologous to the 5' end of the human cDNA can serve as a promoter in transfection into eukaryotic cells. This region is highly conserved between the mouse and the human genes. A number of conserved transcription factor binding sites can be identified in the region including an ets binding site (EBS). Interestingly, removal of a small segment that includes the :EBS, seriously hampers promoter function, suggesting the ERF transcription may be regulated by ets-domain proteins.	NCI,FREDERICK CANC RES & DEV CTR,MOL ONCOL LAB,FREDERICK,MD 21702; NCI,FREDERICK CANC RES & DEV CTR,SAIC,FREDERICK,MD 21702; FORTH,INST MOL BIOL & BIOTECHNOL,IRAKLION 71110,GREECE; UNIV CRETE,DEPT BIOL,IRAKLION 71110,GREECE	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Foundation for Research & Technology - Hellas (FORTH); University of Crete				Moschonas, Nicholas/0000-0002-2556-537X				BARTNITZKE S, 1989, CANCER GENET CYTOGEN, V39, P65, DOI 10.1016/0165-4608(89)90230-6; BELGE G, 1992, CANCER GENET CYTOGEN, V60, P23, DOI 10.1016/0165-4608(92)90227-Y; BISTER K, 1982, P NATL ACAD SCI-BIOL, V79, P3677, DOI 10.1073/pnas.79.12.3677; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; BUIJS A, 1995, ONCOGENE, V10, P1511; DEGNAN BM, 1993, NUCLEIC ACIDS RES, V21, P3479, DOI 10.1093/nar/21.15.3479; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; GILLE H, 1992, NATURE, V358, P415; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HROMAS R, 1994, INT J HEMATOL, V59, P257; HROMAS R, 1993, BIOCHIM BIOPHYS ACTA, V1172, P155, DOI 10.1016/0167-4781(93)90283-J; Janknecht R, 1996, MOL CELL BIOL, V16, P1550; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; JEON IS, 1995, ONCOGENE, V10, P1229; JOHANSSON B, 1994, CANCER GENET CYTOGEN, V74, P62, DOI 10.1016/0165-4608(94)90031-0; JORCYK CL, 1991, ONCOGENE, V6, P523; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KLEMSZ M, 1994, GENOMICS, V20, P291, DOI 10.1006/geno.1994.1169; Kodandapani R, 1996, NATURE, V380, P456, DOI 10.1038/380456a0; LAUDET V, 1993, BIOCHEM BIOPH RES CO, V190, P8, DOI 10.1006/bbrc.1993.1002; LAUTENBERGER JA, 1992, ONCOGENE, V7, P1713; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MAVROTHALASSITIS GJ, 1990, P NATL ACAD SCI USA, V87, P1047, DOI 10.1073/pnas.87.3.1047; MAVROTHALASSITIS GJ, 1990, ONCOGENE, V5, P1337; MAVROTHALASSITIS GJ, 1991, CELL GROWTH DIFFER, V2, P215; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; NUNN M, 1984, VIROLOGY, V133, P330; OHNO H, 1993, LEUKEMIA, V7, P2057; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; PAIETTA E, 1988, CANCER GENET CYTOGEN, V34, P19, DOI 10.1016/0165-4608(88)90162-8; PANAGOPOULOS I, 1994, GENE CHROMOSOME CANC, V11, P256, DOI 10.1002/gcc.2870110408; RAO VN, 1994, ONCOGENE, V9, P1855; ROUSSEL MF, 1994, ONCOGENE, V9, P405; Sambrook J, 1989, MOL CLONING LAB MANU; SAVOYSKY E, 1994, ONCOGENE, V9, P1839; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SGOURAS DN, 1995, EMBO J, V14, P4781, DOI 10.1002/j.1460-2075.1995.tb00160.x; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; Sieweke MH, 1996, CELL, V85, P49, DOI 10.1016/S0092-8674(00)81081-8; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; STARK B, 1995, LEUKEMIA RES, V19, P367, DOI 10.1016/0145-2126(94)00150-9; Sumarsono SH, 1996, NATURE, V379, P534, DOI 10.1038/379534a0; TANAKA S, 1990, CANCER GENET CYTOGEN, V49, P219, DOI 10.1016/0165-4608(90)90144-Y; TORY K, 1992, GENOMICS, V13, P275, DOI 10.1016/0888-7543(92)90243-L; TREIER M, 1995, CELL, V83, P753, DOI 10.1016/0092-8674(95)90188-4; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WERNER MH, 1995, CELL, V83, P761, DOI 10.1016/0092-8674(95)90189-2; WLODARSKA I, 1995, BLOOD, V85, P2848, DOI 10.1182/blood.V85.10.2848.bloodjournal85102848; YABUMOTO K, 1994, INT J HEMATOL, V59, P211; Yang BS, 1996, MOL CELL BIOL, V16, P538; 1995, GENOME NEWS, V19, P21	56	17	18	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 27	1997	14	12					1445	1451		10.1038/sj.onc.1200965	http://dx.doi.org/10.1038/sj.onc.1200965			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WT584	9136988				2022-12-17	WOS:A1997WT58400007
J	Kuroda, H; White, PS; Sulman, EP; Manohar, CF; Reiter, JL; Cohn, SL; Brodeur, GM				Kuroda, H; White, PS; Sulman, EP; Manohar, CF; Reiter, JL; Cohn, SL; Brodeur, GM			Physical mapping of the DDX1 gene to 340 kb 5' of MYCN	ONCOGENE			English	Article						DDX1; DEAD box protein; MYCN; neuroblastoma; amplification	DEAD BOX PROTEIN; N-MYC; HUMAN NEUROBLASTOMAS; CELL-LINES; AMPLIFICATION; EXPRESSION; DNA; COAMPLIFICATION; ASSOCIATION; HOMOLOGY	One of the most important prognostic factors in neuroblastoma is amplification of the MYCN gene, which is strongly associated with advanced stages of disease and a poor prognosis. Although the MYCN amplicon sometimes spans more than 1 Mb, no other consistently expressed sequences from the MYCN amplicon have been reported. However, DDX1, a gene encoding a DEAD box protein, was recently mapped to chromosome 2p24 and is frequently co-amplified with MYCN. Therefore, we performed genomic mapping with YACs to determine the physical relationship between DDX1 and MYCN, and whether DDX1 was contained within the core region of amplification, Based on YAC restriction mapping and content analysis, DDX1 maps 340 kb 5' of MYCN, outside the core domain of consistent amplification. Interestingly, we also determined by sequence analysis and detailed restriction mapping that G21, previously isolated as a 'neuroblastoma-specific' cDNA clone from an MYCN amplicon, is a partial cDNA of DDX1. Our data confirm that DDX1 is amplified in some but not all MYCN-amplified tumors, and that it is rearranged in other cases. This suggests that the co-amplification of DDX1 is due to its proximity to MYCN.	CHILDRENS HOSP PHILADELPHIA, DIV ONCOL, PHILADELPHIA, PA 19104 USA; NORTHWESTERN UNIV, DEPT PEDIAT, CHICAGO, IL 60611 USA; NORTHWESTERN UNIV, ROBERT H LURIE CANC CTR, CHICAGO, IL 60611 USA; MAYO CLIN, DEPT BIOCHEM & MOL BIOL, ROCHESTER, MN USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Northwestern University; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Mayo Clinic			Reiter, Jill/AGZ-7331-2022; Cohn, Susan/AAB-6010-2021; Reiter, Jill L/J-3335-2013	Reiter, Jill/0000-0001-5460-2355; Reiter, Jill L/0000-0001-5460-2355; Sulman, Erik/0000-0003-4933-9120; Cohn, Susan/0000-0001-5749-7650	NATIONAL CANCER INSTITUTE [R01CA039771] Funding Source: NIH RePORTER; NCI NIH HHS [CA-39771] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA K, 1991, NUCLEIC ACIDS RES, V19, P6887, DOI 10.1093/nar/19.24.6887; AMLER LC, 1989, MOL CELL BIOL, V9, P4903, DOI 10.1128/MCB.9.11.4903; Amler LC, 1996, GENE CHROMOSOME CANC, V15, P134, DOI 10.1002/(SICI)1098-2264(199602)15:2<134::AID-GCC9>3.0.CO;2-4; BRODEUR GM, 1994, SEMIN DIAGN PATHOL, V11, P118; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BRODEUR GM, 1977, CANCER-AM CANCER SOC, V40, P2256, DOI 10.1002/1097-0142(197711)40:5<2256::AID-CNCR2820400536>3.0.CO;2-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CHU G, 1986, SCIENCE, V234, P1582, DOI 10.1126/science.3538420; DEVALOIR T, 1991, P NATL ACAD SCI USA, V88, P2113, DOI 10.1073/pnas.88.6.2113; George RE, 1996, ONCOGENE, V12, P1583; GODBOUT R, 1993, P NATL ACAD SCI USA, V90, P7578, DOI 10.1073/pnas.90.16.7578; GODBOUT R, 1994, GENE, V138, P243, DOI 10.1016/0378-1119(94)90816-8; IOST I, 1994, NATURE, V372, P193, DOI 10.1038/372193a0; KOHL NE, 1984, SCIENCE, V226, P1335, DOI 10.1126/science.6505694; MANOHAR CF, 1995, GENE CHROMOSOME CANC, V14, P196, DOI 10.1002/gcc.2870140307; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; Noguchi T, 1996, GENE CHROMOSOME CANC, V15, P129, DOI 10.1002/(SICI)1098-2264(199602)15:2<129::AID-GCC8>3.3.CO;2-M; Reiter JL, 1996, GENOMICS, V32, P97, DOI 10.1006/geno.1996.0081; REITER JL, 1996, UNPUB GENOMICS; Reynolds C P, 1988, Prog Clin Biol Res, V271, P291; Sambrook J., MOL CLONING LAB MANU; SCHNEIDER SS, 1992, MOL CELL BIOL, V12, P5563, DOI 10.1128/MCB.12.12.5563; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SCHWAB M, 1990, GENE CHROMOSOME CANC, V1, P181, DOI 10.1002/gcc.2870010302; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SQUIRE JA, 1995, ONCOGENE, V10, P1417	26	17	17	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	1996	13	7					1561	1565						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875996				2022-12-17	WOS:A1996VL38400023
J	Ording, E; Bergholtz, S; Brendeford, EM; Jamin, N; Gabrielsen, OS				Ording, E; Bergholtz, S; Brendeford, EM; Jamin, N; Gabrielsen, OS			Flexibility in the second half-site sequence recognised by the c-Myb R(2) domain - In vitro and in vivo analysis	ONCOGENE			English	Article						c-Myb; DNA-binding; flexibility; yeast	DNA-BINDING DOMAIN; HELIX-RELATED MOTIF; V-MYB; TRANSCRIPTIONAL ACTIVATOR; PROTOONCOGENE PRODUCT; ONCOGENE PRODUCT; SACCHAROMYCES-CEREVISIAE; ONCOPROTEIN; PROTEIN; YEAST	The oncoprotein c-Myb is a transcription factor that recognises its specific target sequences through two subdomains. The R(3)-domain binds the first half-site, YAAC, and plays a dominant role in sequence recognition, while the homologous R(2)-domain interacts with a more loosely defined sequence in the second half-site, The difficulty in precisely defining a preferred second half-site sequence might reflect the flexible nature of R(2) which only attains its fully folded structure upon binding to DNA, a process that might allow the protein to adapt to different half-site sequences, Here we report that shifting the most conserved base in the second half-site, the G6, into position 5 resulted only in a minor reduction of complex stability in vitro. From an analysis of a series of second half-site variants by EMSA and DMS-interference, we conclude that the preferred recognition sequence should be revised to read [YAACNG or YAACGN], Modeling the structure of c-Myb R(2)R(3) in complex with a GT half-site variant revealed specific interactions with G5, When second half-site variants were tested in vivo using a sensitive yeast effector-reporter system, both the TG and GT half-site variants were functional mediating c-Myb-dependent transactivation, Unexpectedly, we observed large differences between the best second half-site variants at low levels of c-Myb-effector, the GG variant being five- to fifteen-fold more active in vivo than the single-G half-sites, the GH or HG variants.	UNIV OSLO,DEPT BIOCHEM,N-0316 OSLO,NORWAY; CEA SACLAY,DIEP,F-91191 GIF SUR YVETTE,FRANCE	University of Oslo; CEA; UDICE-French Research Universities; Universite Paris Saclay			Jamin, Nadege/AAA-7067-2021					BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BONNER JJ, 1991, GENE, V104, P113, DOI 10.1016/0378-1119(91)90475-Q; BRUNELLE A, 1987, P NATL ACAD SCI USA, V84, P6673, DOI 10.1073/pnas.84.19.6673; CHEN DC, 1992, CURR GENET, V21, P83, DOI 10.1007/BF00318659; CHEN RH, 1993, MOL CELL BIOL, V13, P4423, DOI 10.1128/MCB.13.7.4423; DASGUPTA P, 1992, J VIROL, V66, P270, DOI 10.1128/JVI.66.1.270-276.1992; EKKER SC, 1992, EMBO J, V11, P4059, DOI 10.1002/j.1460-2075.1992.tb05499.x; ESS KC, 1995, MOL CELL BIOL, V15, P5705; FRAMPTON J, 1991, PROTEIN ENG, V4, P891, DOI 10.1093/protein/4.8.891; FRIED MG, 1989, ELECTROPHORESIS, V10, P366, DOI 10.1002/elps.1150100515; GABRIELSEN OS, 1991, SCIENCE, V253, P1140, DOI 10.1126/science.1887237; GRASSER FA, 1992, ONCOGENE, V7, P1005; GUARENTE L, 1981, P NATL ACAD SCI-BIOL, V78, P2199, DOI 10.1073/pnas.78.4.2199; GUEHMANN S, 1992, NUCLEIC ACIDS RES, V20, P2279, DOI 10.1093/nar/20.9.2279; HOVERING PI, 1994, J BIOL CHEM, V269, P17663; HOWE KM, 1991, NUCLEIC ACIDS RES, V19, P3913, DOI 10.1093/nar/19.14.3913; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; INTRONA M, 1994, SEMIN CANCER BIOL, V5, P113; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; JAMIN N, 1993, EUR J BIOCHEM, V216, P147, DOI 10.1111/j.1432-1033.1993.tb18126.x; KANEIISHII C, 1990, J BIOL CHEM, V265, P19990; KNEGTEL RMA, 1994, J MOL BIOL, V235, P318, DOI 10.1016/S0022-2836(05)80035-X; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; Miller JH, 1972, EXPT MOL GENETICS; MYRSET AH, 1993, EMBO J, V12, P4625, DOI 10.1002/j.1460-2075.1993.tb06151.x; NAKAGOSHI H, 1990, J BIOL CHEM, V265, P3479; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; OGATA K, 1994, CELL, V79, P639, DOI 10.1016/0092-8674(94)90549-5; OGATA K, 1992, P NATL ACAD SCI USA, V89, P6428, DOI 10.1073/pnas.89.14.6428; ORDING E, 1994, EUR J BIOCHEM, V222, P113, DOI 10.1111/j.1432-1033.1994.tb18848.x; PLAZA S, 1995, ONCOGENE, V10, P329; PUNYAMMALEE B, 1991, ONCOGENE, V6, P11; SAIKUMAR P, 1994, ONCOGENE, V9, P1279; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SOLANO R, 1995, EMBO J, V14, P1773, DOI 10.1002/j.1460-2075.1995.tb07166.x; STOBERGRASSER U, 1992, ONCOGENE, V7, P589; Struhl K, 1996, CELL, V84, P179, DOI 10.1016/S0092-8674(00)80970-8; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TANIKAWA J, 1993, P NATL ACAD SCI USA, V90, P9320, DOI 10.1073/pnas.90.20.9320; THOMPSON MA, 1995, BIOESSAYS, V17, P341, DOI 10.1002/bies.950170410; WESTON K, 1992, NUCLEIC ACIDS RES, V20, P3043, DOI 10.1093/nar/20.12.3043; WILLIAMSON JR, 1990, NUCLEIC ACIDS RES, V18, P379, DOI 10.1093/nar/18.2.379	42	17	18	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 5	1996	13	5					1043	1051						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VG766	8806694				2022-12-17	WOS:A1996VG76600018
J	Li, HM; Lahti, JM; Kidd, VJ				Li, HM; Lahti, JM; Kidd, VJ			Alternatively spliced cyclin C mRNA is widely expressed, cell cycle regulated, and encodes a truncated cyclin box	ONCOGENE			English	Article						cyclin C; alternative splicing; cell cycle	ACUTE LYMPHOBLASTIC-LEUKEMIA; RNA-POLYMERASE-II; PROTEIN-KINASE; CLN FUNCTION; GENE; CHILDHOOD; YEAST; IDENTIFICATION; ARREST	The cyclin C protein has recently been shown to associate with a unique cyclin dependent protein kinase (cdk8) and it has been proposed that this complex may regulate RNA transcription during the cell cycle. In addition, the human cyclin C gene has been localized to human chromosome 6q21 and it was found to be frequently deleted in a subset of acute lymphoblastic leukemias (ALL's). Screening of an avian T-cell cDNA library resulted in the isolation of a cyclin C homologue as well as an abundant, yet distinct, cyclin C-related cDNA. The predicted open reading frame (ORF) of the cyclin C cDNA predicted a 283 amino acid protein that was >99% identical to the human protein and 72% identical to the Drosophila melanogaster protein. However, the predicted ORF of the cyclin C-related cDNA predicted a much smaller 105 amino acid protein that was identical to cyclin C well into the cyclin-box region (amino acid residue 98), where it abruptly diverges and then terminates. Using PCR analysis of cDNA derived from a range of cell lines and tissues, alternative splicing of the avian cyclin C gene has been demonstrated. Furthermore, a smaller similar to 19 kDa protein that co-migrates with the in vitro transcribed and translated truncated cyclin C protein was detected in normal and virally-transformed avian cells with a cyclin C-specific antibody, Expression of alternatively spliced cyclin C mRNA and protein is regulated in a cell cycle-dependent manner reminiscent of cyclin B2. The function of this truncated cyclin C protein is not known, but its expression in avian cells suggest that this truncated cyclin C protein may participate as an early endogenously encoded cyclin C inhibitor.	ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, MEMPHIS, TN 38101 USA	St Jude Children's Research Hospital					NATIONAL CANCER INSTITUTE [P30CA021765, R01CA067938] Funding Source: NIH RePORTER; NCI NIH HHS [CA 67938, CA 21765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKOULITCHEV S, 1995, NATURE, V377, P557, DOI 10.1038/377557a0; BETTICHER DC, 1995, ONCOGENE, V11, P1005; BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; BUNNELL BA, 1990, P NATL ACAD SCI USA, V87, P7467, DOI 10.1073/pnas.87.19.7467; CROSS FR, 1990, MOL CELL BIOL, V10, P6482, DOI 10.1128/MCB.10.12.6482; DEMETRICK DJ, 1995, CYTOGENET CELL GENET, V69, P190, DOI 10.1159/000133960; DOLZNIG H, 1995, CELL GROWTH DIFFER, V6, P1341; EIPERS PG, 1992, GENOMICS, V13, P613, DOI 10.1016/0888-7543(92)90132-C; GALLANT P, 1992, J CELL BIOL, V117, P213, DOI 10.1083/jcb.117.1.213; KEYOMARSI K, 1995, ONCOGENE, V15, P2612; KIDD VJ, 1991, CELL GROWTH DIFFER, V2, P85; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KOWALCZYK JR, 1985, CANCER GENET CYTOGEN, V15, P47, DOI 10.1016/0165-4608(85)90130-X; LAHTI JM, 1994, NAT GENET, V7, P370, DOI 10.1038/ng0794-370; LAHTI JM, 1991, P NATL ACAD SCI USA, V88, P10595; LAHUE EE, 1991, GENE DEV, V5, P2166, DOI 10.1101/gad.5.12a.2166; Leclerc V, 1996, MOL BIOL CELL, V7, P505, DOI 10.1091/mbc.7.4.505; LEOPOLD P, 1991, CELL, V66, P1207, DOI 10.1016/0092-8674(91)90043-X; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; Li HM, 1996, GENOMICS, V32, P253, DOI 10.1006/geno.1996.0112; LI HM, 1995, GENE, V153, P237, DOI 10.1016/0378-1119(94)00801-X; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; ONEILL EM, 1995, NATURE, V374, P121, DOI 10.1038/374121a0; PIETENPOL JA, 1995, CANCER RES, V55, P1206; PRIGOGINA EL, 1988, CANCER GENET CYTOGEN, V32, P183, DOI 10.1016/0165-4608(88)90281-6; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; TASSAN JP, 1995, P NATL ACAD SCI USA, V92, P8871, DOI 10.1073/pnas.92.19.8871; XIANG JL, 1994, J BIOL CHEM, V269, P15786	29	17	20	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 15	1996	13	4					705	712						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VD433	8761291				2022-12-17	WOS:A1996VD43300005
J	Schryver, B; Hinck, L; Papkoff, J				Schryver, B; Hinck, L; Papkoff, J			Properties of Wnt-1 protein that enable cell surface association	ONCOGENE			English	Article						Wnt-1; basic sequence motif; proteoglycan	FIBROBLAST GROWTH-FACTOR; MAMMARY ONCOGENE INT-1; HEPARAN-SULFATE; EXTRACELLULAR-MATRIX; EPITHELIAL-CELLS; WINGLESS PROTEIN; EXPRESSION; DROSOPHILA; BINDING; TRANSFORMATION	Members of the highly conserved Wnt gene family serve key functions in cellular growth and differentiation. Regulated expression of the murine Wnt-1 protooncogene is essential for normal development of the embryonic nervous system and when misexpressed in the mammary gland leads to hyperplasias and tumorigenic progression. Wnt-1 encodes a cysteine rich glycoprotein that is secreted and tightly associated with the cell surface and/or extracellular matrix. This restricted diffusion of Wnt-1 protein is important for specifying a spatially defined pattern of Wnt-activity necessary for cell to cell signaling in cell growth and differentiation. Since the receptors and cell surface molecules that bind Wnt proteins are as yet unknown we have sought to define the sequences within Wnt-1 protein that enable cell surface association and to define the nature of the cell surface structures with which Wnt-1 protein associates. First, site directed mutagenesis was used to identify a basic amino acid sequence motif within Wnt-1 protein that is required for this protein to accumulate on the cell surface. Second, wild type Wnt-1 protein was expressed in a series of proteoglycan-deficient CHO cell lines to show that, contrary to expectations, cellular glycosaminoglycans are not required for processing, secretion, cell surface association and accumulation of Wnt-1 protein.	STANFORD UNIV,CANC BIOL PROGRAM,STANFORD,CA 94305; SUGEN INC,REDWOOD CITY,CA 94063	Stanford University				Hinck, Lindsay/0000-0002-4009-3913				BAME KJ, 1989, J BIOL CHEM, V264, P8059; BLASBAND A, 1992, ONCOGENE, V7, P153; BRADLEY RS, 1995, MOL CELL BIOL, V15, P4616; BRADLEY RS, 1993, J CELL BIOL, V123, P1857, DOI 10.1083/jcb.123.6.1857; BRADLEY RS, 1990, EMBO J, V9, P1569, DOI 10.1002/j.1460-2075.1990.tb08276.x; BROWN AMC, 1987, MOL CELL BIOL, V7, P3971, DOI 10.1128/MCB.7.11.3971; BROWN AMC, 1986, CELL, V46, P1001, DOI 10.1016/0092-8674(86)90699-9; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; ESCO JD, 1987, J BIOL CHEM, V262, P12189; ESCO JD, 1986, J BIOL CHEM, V261, P15725; ESCO JD, 1985, P NATL ACAD SCI USA, V82, P3197; FUNG YKT, 1985, MOL CELL BIOL, V5, P3337, DOI 10.1128/MCB.5.12.3337; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; HINCK L, 1994, J CELL BIOL, V124, P729, DOI 10.1083/jcb.124.5.729; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KELLY JL, 1993, J CELL BIOL, V121, P1153, DOI 10.1083/jcb.121.5.1153; KITAJEWSKI J, 1992, MOL CELL BIOL, V12, P784, DOI 10.1128/MCB.12.2.784; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; KLINGENSMITH J, 1994, DEV BIOL, V166, P396, DOI 10.1006/dbio.1994.1325; LAROCHELLE WJ, 1991, GENE DEV, V5, P1191, DOI 10.1101/gad.5.7.1191; MASON JO, 1992, MOL BIOL CELL, V3, P521, DOI 10.1091/mbc.3.5.521; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; NUSSE R, 1984, NATURE, V307, P131, DOI 10.1038/307131a0; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; OLSON DJ, 1991, SCIENCE, V252, P1173, DOI 10.1126/science.252.5009.1173; OLWIN BB, 1992, J CELL BIOL, V118, P631, DOI 10.1083/jcb.118.3.631; OSTMAN A, 1991, CELL REGUL, V2, P503, DOI 10.1091/mbc.2.7.503; PAPKOFF J, 1989, MOL CELL BIOL, V9, P3377, DOI 10.1128/MCB.9.8.3377; PAPKOFF J, 1990, MOL CELL BIOL, V10, P2723, DOI 10.1128/MCB.10.6.2723; PAPKOFF J, 1987, MOL CELL BIOL, V7, P3978, DOI 10.1128/MCB.7.11.3978; Papkoff J, 1996, MOL CELL BIOL, V16, P2128; PEIFER M, 1995, TRENDS CELL BIOL, V5, P224, DOI 10.1016/S0962-8924(00)89015-7; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; RIGGLEMAN B, 1990, CELL, V63, P549, DOI 10.1016/0092-8674(90)90451-J; RIJSEWIJK F, 1987, EMBO J, V6, P127, DOI 10.1002/j.1460-2075.1987.tb04729.x; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; SHACKLEFORD GM, 1987, CELL, V50, P89, DOI 10.1016/0092-8674(87)90665-9; SIEGFRIED E, 1994, BIOESSAYS, V16, P395, DOI 10.1002/bies.950160607; SMOLICH BD, 1993, MOL BIOL CELL, V4, P1267, DOI 10.1091/mbc.4.12.1267; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; VANDENHEUVEL M, 1993, EMBO J, V12, P5293, DOI 10.1002/j.1460-2075.1993.tb06225.x; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; VANLEEUWEN F, 1994, NATURE, V368, P342, DOI 10.1038/368342a0; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; WILLIAMS LT, 1984, J BIOL CHEM, V259, P5287; WOLLNER DA, 1992, J CELL BIOL, V116, P889, DOI 10.1083/jcb.116.4.889; WONG GT, 1994, MOL CELL BIOL, V14, P6278, DOI 10.1128/MCB.14.9.6278; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	52	17	17	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 18	1996	13	2					333	342						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VA252	8710372				2022-12-17	WOS:A1996VA25200012
J	Velasco, JA; Zimonjic, DB; Popescu, NC; Cansado, J; DiPaolo, JA; Albor, A; Notario, V				Velasco, JA; Zimonjic, DB; Popescu, NC; Cansado, J; DiPaolo, JA; Albor, A; Notario, V			Tissue-specific expression, evolutionary conservation and localization of the cph proto-oncogene on Syrian hamster chromosome X	ONCOGENE			English	Article						cph oncogene; evolution; FISH; gene expression; gene mapping; Syrian hamster	BANDING PATTERNS; GENES; SEQUENCES; CELLS	Treatment of Syrian hamster embryo fibroblasts with a single dose of 3-methylcholanthrene caused the activation of the transforming potential of cellular sequences (Notario et al,, Oncogene 5: 1425-1430, 1990), which were subsequently isolated by cosmid rescue techniques, and further identified as a novel oncogene, termed cph because of its involvement in the carcinogenic progression of hamster embryo cells (Velasco ed al., Oncogene 9: 2065-2069, 1994), We have analysed the expression of the cph proto-oncogene in adult Syrian hamster tissues by northern hybridization using cph-specific genomic probes, The three cph transcripts expressed in normal and neoplastic Syrian hamster embryo cells in culture (5.0, 3.5 and 2.0 kb) were also present in most adult tissues, although different mRNA species, most likely resulting from alternative splicing events, were expressed in testes, The highest steady-state level of cph mRNA was found in kidney, whereas cph expression was nearly undetectable in skin and skeletal muscle, Southern blot analyses of DNAs from other eucaryotic organisms were performed under moderate stringency conditions with a Syrian hamster-specific cph probe, Discrete cpk-hybridizing sequences were present in genomes from yeast to mammalian species, including humans, thus demonstrating that cph is a highly conserved gene in eucaryotic evolution, Using fluorescence in situ hybridization (FISH), we have determined also the chromosomal Idealization of the cph proto-oncogene in the hamster genome, FISH experiments demonstrated that cph is a single copy gene, localized on the euchromatic short arm of the X chromosome, at region Xpa7, Because chromosome X is frequently involved in structural alterations in neoplastic Syrian hamster cells transformed by chemical carcinogens and oncogenic viruses, the localization of the cph locus on this chromosome supports the notion that the cph oncogene plays a role in the malignant conversion of chemically transformed hamster fibroblasts, The wide range of tissue-specific expression and species-specific distribution of cph strongly suggest that the normal function of the cph protein product(s) may be essential for metabolic processes involved in the regulation of cell proliferation and survival.	GEORGETOWN UNIV,MED CTR,DEPT RADIAT MED,WASHINGTON,DC 20007; NCI,BIOL LAB,NIH,BETHESDA,MD	Georgetown University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			/AFP-0764-2022; Cansado, Jose/ABC-6872-2020; /AAB-6461-2022; Cansado, Jose/K-5212-2014; Zimonjic, Drazen/AAX-7513-2020	Cansado, Jose/0000-0002-2342-8152; 	NCI NIH HHS [CA64472] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064472] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBOR A, 1994, CANCER RES, V54, P4502; AVILA MA, 1995, ONCOGENE, V10, P963; AVILA MA, 1994, YEAST, V10, P1003, DOI 10.1002/yea.320100803; BARRETT JC, 1984, PHARMACOL REV, V36, P535; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DiPaolo J A, 1979, Prog Exp Tumor Res, V24, P2; DIPAOLO JA, 1973, CANCER RES, V33, P3250; HAMEISTER H, 1986, HUM GENET, V72, P242; HUEBNER K, 1986, P NATL ACAD SCI USA, V83, P3934, DOI 10.1073/pnas.83.11.3934; LI S, 1982, CYTOGENET CELL GENET, V33, P295, DOI 10.1159/000131775; MIYOSHI J, 1984, NUCLEIC ACIDS RES, V12, P1821, DOI 10.1093/nar/12.4.1821; MORTON CC, 1989, GENOMICS, V4, P367, DOI 10.1016/0888-7543(89)90344-3; NOGUCHI T, 1987, EMBO J, V6, P1301, DOI 10.1002/j.1460-2075.1987.tb02368.x; NOTARIO V, 1990, ONCOGENE, V5, P1425; OBRIEN SJ, 1983, NATURE, V302, P839, DOI 10.1038/302839a0; OSHIMURA M, 1985, NATURE, V316, P636, DOI 10.1038/316636a0; PATHAK S, 1974, GENETICS, V78, P703; PATHAK S, 1981, GENES CHROMOSOMES NE, P405; POPESCU NC, 1980, CYTOGENET CELL GENET, V28, P10, DOI 10.1159/000131507; POPESCU NC, 1988, CANCER RES, V48, P7246; POPESCU NC, 1995, CYTOGENET CELL GENET, V68, P71, DOI 10.1159/000133893; POPESCU NC, 1989, ONCOGENE, V4, P517; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; SATOH H, 1994, CYTOGENET CELL GENET, V65, P127, DOI 10.1159/000133617; TARUSCIO D, 1991, CHROMOSOMA, V101, P141, DOI 10.1007/BF00355364; TRONICK SR, 1989, GENOMICS, V5, P546, DOI 10.1016/0888-7543(89)90022-0; VELASCO JA, 1993, GENE, V137, P179, DOI 10.1016/0378-1119(93)90004-M; VELASCO JA, 1994, ONCOGENE, V9, P2065; VELASCO JA, 1995, ONCOGENE, V10, P2253; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; ZIMONJIC DB, 1994, CYTOGENET CELL GENET, V65, P184, DOI 10.1159/000133628	31	17	17	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 20	1996	12	12					2713	2717						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700531				2022-12-17	WOS:A1996UW48700026
J	Ohta, Y; Haire, RN; Amemiya, CT; Litman, RT; Trager, T; Riess, O; Litman, GW				Ohta, Y; Haire, RN; Amemiya, CT; Litman, RT; Trager, T; Riess, O; Litman, GW			Human Txk: Genomic organization, structure and contiguous physical linkage with the Tec gene	ONCOGENE			English	Article						protein tyrosine kinase; gene linkage; Tec gene family; P1 artificial chromosome; DNA sequencing	X-LINKED AGAMMAGLOBULINEMIA; PROTEIN-TYROSINE KINASE; EXPRESSION; SEQUENCE	Txk is a Tec-family tyrosine kinase expressed in mouse and human T lymphocytes. Among the Tec kinases, Txk is unique in that its amino terminal region does not include a pleckstrin homology domain or other known extended functional region. Txk is encoded at human chromosome 4p12 and at a recognized region of conserved synteny on mouse chromosome 5. The genomic organization of Txk consists of 15 exons with strong exon-intron organizational homology to Btk, the only other Tee-family kinase for which the genomic structure is fully known. The human Tec gene also maps to 4p12 and, based on limited studies reported here, possesses organizational homology with Btk and Txk. We have sequenced a continuous region of DNA that contains 3' Tec and 5' Txk exons separated by only a similar to 1.5 kb intergenic region containing the putative promoter region of Txk. The close physical linkage of these Tee-family tyrosine kinases, which are expressed in different hematopoetic cell lineages, suggests their potential for coordinate cis-regulation.	UNIV S FLORIDA,ALL CHILDRENS HOSP,DEPT PEDIAT,ST PETERSBURG,FL 33701; BOSTON UNIV,CTR HUMAN GENET,BOSTON,MA 02118; RUHR UNIV BOCHUM,DEPT HUMAN MOLEC GENET,W-4470 BOCHUM,GERMANY	State University System of Florida; University of South Florida; Boston University; Ruhr University Bochum								BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; CONLEY ME, 1994, HUM MOL GENET, V3, P1751, DOI 10.1093/hmg/3.10.1751; DHALLAN RS, 1992, J NEUROSCI, V12, P3248, DOI 10.1523/JNEUROSCI.12-08-03248.1992; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; GIBSON S, 1993, BLOOD, V82, P1561; GREGORY RJ, 1987, MOL CELL BIOL, V7, P2119, DOI 10.1128/MCB.7.6.2119; HAGEMANN TL, 1994, HUM MOL GENET, V3, P1743, DOI 10.1093/hmg/3.10.1743; HAIRE RN, 1995, MAMM GENOME, V6, P476, DOI 10.1007/BF00360659; HAIRE RN, 1994, HUM MOL GENET, V3, P897, DOI 10.1093/hmg/3.6.897; HEYECK SD, 1993, P NATL ACAD SCI USA, V90, P669, DOI 10.1073/pnas.90.2.669; HU Q, 1995, J BIOL CHEM, V270, P1928, DOI 10.1074/jbc.270.4.1928; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; LEE ST, 1993, ONCOGENE, V8, P3403; MANO H, 1990, ONCOGENE, V5, P1781; MANO H, 1993, ONCOGENE, V8, P417; MAZZARELLA R, 1995, GENOMICS, V26, P629, DOI 10.1016/0888-7543(95)80190-W; Nadeau J H, 1991, Mamm Genome, V1 Spec No, pS461, DOI 10.1007/BF00656504; NAGLE DL, 1995, HUM MOL GENET, V4, P2073, DOI 10.1093/hmg/4.11.2073; OELTJEN JC, 1995, MAMM GENOME, V6, P334, DOI 10.1007/BF00364796; OHTA Y, 1994, P NATL ACAD SCI USA, V91, P9062, DOI 10.1073/pnas.91.19.9062; OLSEN AS, 1993, BIOTECHNIQUES, V14, P116; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; RIESS O, 1994, CYTOGENET CELL GENET, V65, P238, DOI 10.1159/000133638; ROBERTS WM, 1988, CELL, V55, P655, DOI 10.1016/0092-8674(88)90224-3; ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1; SATO K, 1994, LEUKEMIA, V8, P1663; SIDERAS P, 1994, J IMMUNOL, V153, P5607; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; SOMMERS CL, 1995, ONCOGENE, V11, P245; TAMAGNONE L, 1994, ONCOGENE, V9, P3683; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VETRIE D, 1993, NATURE, V361, P266	33	17	20	2	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 15	1996	12	4					937	942						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TW686	8632917				2022-12-17	WOS:A1996TW68600026
J	KWON, TK; BUCHHOLZ, MA; GABRIELSON, EW; NORDIN, AA				KWON, TK; BUCHHOLZ, MA; GABRIELSON, EW; NORDIN, AA			A NOVEL CYTOPLASMIC SUBSTRATE FOR CDK4 AND CDK6 IN NORMAL AND MALIGNANT EPITHELIAL DERIVED CELLS	ONCOGENE			English	Article						CYCLIN-DEPENDENT KINASE; G1 CYCLINS; CELL CYCLE; BREAST CELL CARCINOMA; LUNG CELL CARCINOMA	RETINOBLASTOMA SUSCEPTIBILITY GENE; BREAST-CANCER; PROTEIN; EXPRESSION; CYCLINS; IDENTIFICATION; AMPLIFICATION	Cyclins and cyclin-dependent kinases (cdk) have been identified as important regulators of cell replication. Molecular alteration in the cdk pathways appear to be important in cancer with some cyclins (eg cyclin D and E) proposed to be oncogenes and some inhibitors of cdk (eg p16) proposed to be tumor suppressor genes, In human breast carcinoma cell line MDA361 both cyclin D and E are overexpressed and cdk 4 and 6 are the predominate kinases which phosphorylate retinoblastoma protein and to a greater extent a novel 88 kDa protein. This 88 kDa protein was detected as a significant substrate in five of seven breast carcinoma cell lines, three lung carcinoma cell lines as well as in primary breast and lung epithelium. Normal human and murine T lymphocytes and established lymphoid cell lines are devoid of this protein and minimal amounts were detected in normal human fibroblast. In contrast to retinoblastoma protein, the 88 kDa protein appears to be more prevalent in the cytosolic than the nuclear subfraction. The phosphorylation of this 88 kDa protein by the G(1) associated cdks suggest that this protein may represent another targeted substrate regulating the G(1) phase of the cell cycle.	NIA,GERONTOL RES CTR,CLIN IMMUNOL SECT,BALTIMORE,MD 21224; JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,BALTIMORE,MD 21224	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Johns Hopkins University					NCI NIH HHS [P20 CA-ES 66204] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P20CA066204] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; Dunphy William G., 1994, Trends in Cell Biology, V4, P202; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GOODRICH DW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P43, DOI 10.1016/0304-419X(93)90021-4; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HAMMOND SL, 1984, P NATL ACAD SCI-BIOL, V81, P5435, DOI 10.1073/pnas.81.17.5435; HANNA Z, 1993, ONCOGENE, V8, P1661; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; KAMB A, 1994, SCIENCE, V246, P436; KEYOMARSI K, 1994, CANCER RES, V54, P380; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KIM YH, 1992, J IMMUNOL, V149, P17; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LAN S, 1981, J SURG ONCOL, V18, P317, DOI 10.1002/jso.2930180313; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; MARTELLI AM, 1992, NATURE, V358, P242, DOI 10.1038/358242a0; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; NOBORI T, 1994, SCIENCE, V264, P753; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PETERS G, 1994, J CELL SCI S, V18, P89; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHERR CJ, 1993, CELL, V73, P1053	33	17	17	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 16	1995	11	10					2077	2083						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478527				2022-12-17	WOS:A1995TF29700018
J	XU, L; MENG, Y; WALLEN, R; DEPINHO, RA				XU, L; MENG, Y; WALLEN, R; DEPINHO, RA			LOSS OF TRANSCRIPTIONAL ATTENUATION IN N-MYC IS ASSOCIATED WITH PROGRESSION TOWARDS A MORE MALIGNANT PHENOTYPE	ONCOGENE			English	Article						N-MYC PROTOONCOGENE; TRANSCRIPTIONAL ATTENUATION; MALIGNANT PROGRESSION	ZINC-FINGER PROTEIN; C-MYC; SEQUENCE REQUIREMENTS; GENE-EXPRESSION; 1ST EXON; CELLS; ELONGATION; FAMILY; BLOCK; PROMOTER	The modulation of RNA polymerase II processivity through the untranslated N-myc first exon represents an important mechanism governing N-myc mRNA levels during normal development. In this study, we employed the rat embryo fibroblast (REF) cooperation assay as a functional means to (i) map N-myc first exon sequences involved in the regulation of N-myc gene expression and specifically their contribution to controlling a block to transcriptional elongation and (ii) determine whether this transcriptional control mechanism plays a role in governing the oncogenic activity of N-myc. Transfection of N-myc expression constructs harboring various deletions within the untranslated first exon revealed that a region encoding a potential stem-loop structure followed by a thymine stretch (stem-loop/T region) was required for efficient transcriptional attenuation. The increase in transcriptional read-through associated with all deletions involving the stem-loop/T region also resulted in a more aggressive malignant phenotype as evidenced by a significant enhancement in the subcloning efficiency of N-myc/ras transformed foci. Most significantly, when cell lines generated from overexpression of the intact N-myc expression construct were selected for anchorage-independent growth, a strong block to transcriptional elongation was completely eliminated in all cases examined. Since the subcloning efficiency of transformed foci and the capacity of permanently established cell lines for anchorage-independent growth are direct correlates of more advanced stages of malignant transformation, our findings suggest that loss of transcriptional attenuation represents an important genetic event in the progression of N-myc-induced cellular transformation.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MICROBIOL & IMMUNOL, BRONX, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine				DePinho, Ronald/0000-0002-5625-577X	NICHD NIH HHS [HD283117 2P30CA13330-20] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BOSSONE SA, 1992, P NATL ACAD SCI USA, V89, P7452, DOI 10.1073/pnas.89.16.7452; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; EICK D, 1987, ONCOGENE, V2, P61; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; EICK D, 1989, EMBO J, V8, P1965, DOI 10.1002/j.1460-2075.1989.tb03602.x; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; GREENBLATT J, 1993, NATURE, V364, P401, DOI 10.1038/364401a0; KRUMM A, 1995, GENE DEV, V9, P559, DOI 10.1101/gad.9.5.559; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; KRYSTAL G, 1988, MOL CELL BIOL, V8, P3373, DOI 10.1128/MCB.8.8.3373; LIN X, 1991, MOL CELL BIOL, V11, P6007, DOI 10.1128/MCB.11.12.6007; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MECHTI N, 1991, MOL CELL BIOL, V11, P2832, DOI 10.1128/MCB.11.5.2832; MECHTI N, 1986, NUCLEIC ACIDS RES, V14, P9653, DOI 10.1093/nar/14.24.9653; MORROW MA, 1992, GENE DEV, V6, P61, DOI 10.1101/gad.6.1.61; MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480; NEPVEU A, 1987, GENE DEV, V1, P938, DOI 10.1101/gad.1.9.938; PLATT T, 1986, ANNU REV BIOCHEM, V55, P339, DOI 10.1146/annurev.bi.55.070186.002011; PYRC JJ, 1992, BIOCHEMISTRY-US, V31, P4102, DOI 10.1021/bi00131a029; RAMAMURTHY V, 1990, MOL CELL BIOL, V10, P1484, DOI 10.1128/MCB.10.4.1484; SCHREIBERAGUS N, 1993, MOL CELL BIOL, V13, P2456, DOI 10.1128/MCB.13.4.2456; SCHWEIGERER L, 1990, CANCER RES, V50, P4411; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SPENCER CA, 1990, ONCOGENE, V5, P777; SPENCER CA, 1990, GENE DEV, V4, P75, DOI 10.1101/gad.4.1.75; STANTON LW, 1986, P NATL ACAD SCI USA, V83, P1772, DOI 10.1073/pnas.83.6.1772; STROBL LJ, 1992, EMBO J, V11, P3307, DOI 10.1002/j.1460-2075.1992.tb05409.x; XU L, 1993, ONCOGENE, V8, P2547; YANKULOV K, 1994, CELL, V77, P749, DOI 10.1016/0092-8674(94)90058-2	31	17	17	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 2	1995	11	9					1865	1872						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478616				2022-12-17	WOS:A1995TD09400023
J	QUANG, CT; PIRONIN, M; VONLINDERN, M; BEUG, H; GHYSDAEL, J				QUANG, CT; PIRONIN, M; VONLINDERN, M; BEUG, H; GHYSDAEL, J			SPI-1 AND MUTANT P53 REGULATE DIFFERENT ASPECTS OF THE PROLIFERATION AND DIFFERENTIATION CONTROL OF PRIMARY ERYTHROID PROGENITORS	ONCOGENE			English	Article						LEUKEMIA; SPI-1; ETS PROTEINS; P53; ERYTHROID PROGENITORS	WILD-TYPE P53; VIRUS-INDUCED ERYTHROLEUKEMIA; AVIAN ERYTHROBLASTOSIS VIRUS; RAT EMBRYO FIBROBLASTS; GROWTH-FACTOR RECEPTOR; SEA ONCOGENE PRODUCT; ETS DOMAIN PROTEIN; V-ERBA; FRIEND-VIRUS; TRANSCRIPTIONAL ACTIVATION	The emergence of leukemic cells in Friend virus complex-induced erythroleukemia is associated with two recurrent genetic alterations, namely the inactivation of the p53 tumor suppressor gene and the overexpression of Spi-1, a member of the Ets family of transcriptional regulators. In order to determine the role of these genetic alterations on the proliferation and differentiation control of erythroblasts, we expressed Spi-1 and the temperature sensitive mutant p53(V135A) in avian primary erythroid progenitors. We show that enforced expression of Spi-1 in erythroblasts obtained from bone marrow cells by expression of the ts-Sea tyrosine kinase inhibits the execution of the differentiation program normally induced in these cells in response to Epo and insulin and following inactivation of ts-Sea function. In contrast, overexpression of p53(V135A) is without effect on the ability of these cells to differentiate into erythrocytes. However, expression of p53(V135A) in erythroid progenitors obtained from bone marrow cells in the presence of SCF, TGF alpha and estradiol, was found to relieve these cells from their absolute TGF alpha requirement for long term proliferation. This phenotype is dependent upon the expression of the mutant form of p53(V135A) as it is not observed at a temperature at which p53(V135A) regains wild type p53 function. Our results show that each of the genetic alterations which characterize Friend erythroleukemic cells affect in a distinct manner the proliferation and differentiation control of primary erythroid progenitors.	CTR UNIV ORSAY,INST CURIE,ONCOL VIRALE & CELLULAIRE LAB,CNRS,UMR 146,F-91405 ORSAY,FRANCE; INST MOLEC PATHOL,A-1030 VIENNA,AUSTRIA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)			QUANG, christine TRAN/G-7508-2016; von Lindern, Marieke/AAH-2350-2020; GHYSDAEL, Jacques/F-3377-2013					Andrews N C, 1994, Curr Opin Hematol, V1, P119; BEN-DAVID Y, 1990, New Biologist, V2, P1015; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BEUG H, 1982, CELL, V28, P907, DOI 10.1016/0092-8674(82)90070-8; BEUG H, 1985, VIROLOGY, V145, P141, DOI 10.1016/0042-6822(85)90209-0; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; BEUG H, 1994, CURR OPIN CELL BIOL, V6, P816, DOI 10.1016/0955-0674(94)90050-7; BEUG H, 1992, NUCLEAR PROCESSES ON, P53; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHOW V, 1987, J VIROL, V61, P2777, DOI 10.1128/JVI.61.9.2777-2781.1987; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CROWE AJ, 1993, ONCOGENE, V8, P181; CROWE AJ, 1991, J VIROL, V65, P2533, DOI 10.1128/JVI.65.5.2533-2538.1991; CROWE AJ, 1993, CELL GROWTH DIFFER, V4, P403; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; ELIYAHU D, 1988, ONCOGENE, V3, P313; FRYKBERG L, 1983, CELL, V32, P227, DOI 10.1016/0092-8674(83)90513-5; FUERSTENBERG S, 1992, EMBO J, V11, P3355, DOI 10.1002/j.1460-2075.1992.tb05414.x; FUHRMANN U, 1989, GENE DEV, V3, P2072, DOI 10.1101/gad.3.12b.2072; GANDRILLON O, 1994, ONCOGENE, V9, P749; GAUTHIER JM, 1993, EMBO J, V12, P5089, DOI 10.1002/j.1460-2075.1993.tb06203.x; GEGONNE A, 1992, NEW BIOL, V4, P512; GHYSDAEL J, 1992, CANCER SURV, V14, P169; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GLINEUR C, 1990, GENE DEV, V4, P1663, DOI 10.1101/gad.4.10.1663; GOLDBERG Y, 1988, EMBO J, V7, P2425, DOI 10.1002/j.1460-2075.1988.tb03088.x; GOTTLIEB E, 1994, EMBO J, V13, P1368, DOI 10.1002/j.1460-2075.1994.tb06390.x; HAYMAN MJ, 1993, CELL, V74, P157, DOI 10.1016/0092-8674(93)90303-8; HAYMAN MJ, 1982, J CELL BIOCHEM, V18, P351, DOI 10.1002/jcb.1982.240180308; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HOATLIN ME, 1990, P NATL ACAD SCI USA, V87, P9985, DOI 10.1073/pnas.87.24.9985; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KELLEY LL, 1994, MOL CELL BIOL, V14, P4183, DOI 10.1128/MCB.14.6.4183; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KNIGHT J, 1988, GENE DEV, V2, P247, DOI 10.1101/gad.2.2.247; KNIGHT J, 1988, ONCOGENE, V2, P317; KORNFELD S, 1983, EXP CELL RES, V143, P383, DOI 10.1016/0014-4827(83)90065-4; Kowenz E, 1987, Haematol Blood Transfus, V31, P199; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; LAVIGUEUR A, 1991, ONCOGENE, V6, P2197; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOTEM J, 1993, BLOOD, V82, P1092, DOI 10.1182/blood.V82.4.1092.bloodjournal8241092; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MORIMOTO AM, 1994, J VIROL, V68, P1837, DOI 10.1128/JVI.68.3.1837-1842.1994; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; MUNROE DG, 1990, MOL CELL BIOL, V10, P3307, DOI 10.1128/MCB.10.7.3307; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; PAIN B, 1991, CELL, V65, P37, DOI 10.1016/0092-8674(91)90405-N; PAUL R, 1991, J VIROL, V65, P464, DOI 10.1128/JVI.65.1.464-467.1991; PEACOCK JW, 1990, ONCOGENE, V5, P1769; POGNONEC P, 1988, EMBO J, V7, P977, DOI 10.1002/j.1460-2075.1988.tb02904.x; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; RABAULT B, 1994, J BIOL CHEM, V269, P28143; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; ROVINSKI B, 1988, ONCOGENE, V2, P445; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SCHMIDT JA, 1986, LEUKEMIA RES, V10, P257, DOI 10.1016/0145-2126(86)90023-8; SCHROEDER C, 1993, EMBO J, V12, P951, DOI 10.1002/j.1460-2075.1993.tb05736.x; SCHROEDER C, 1992, ONCOGENE, V7, P217; SCHUETZE S, 1992, MOL CELL BIOL, V12, P2967, DOI 10.1128/MCB.12.7.2967; SCHUETZE S, 1993, MOL CELL BIOL, V13, P5670, DOI 10.1128/MCB.13.9.5670; SHAULIAN E, 1993, EMBO J, V12, P2789, DOI 10.1002/j.1460-2075.1993.tb05940.x; STEINLEIN P, 1994, GROWTH FACTORS, V10, P1, DOI 10.3109/08977199409019599; STEINLEIN P, 1995, CURR BIOL, V5, P191, DOI 10.1016/S0960-9822(95)00040-6; TEI H, 1992, P NATL ACAD SCI USA, V89, P6856, DOI 10.1073/pnas.89.15.6856; WILLIAMS BP, 1988, ONCOGENE, V3, P345; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1	80	17	17	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 5	1995	11	7					1229	1239						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478542				2022-12-17	WOS:A1995RY96700002
J	TAKAHASHI, H; IKEDA, T				TAKAHASHI, H; IKEDA, T			MOLECULAR-CLONING AND EXPRESSION OF RAT AND MOUSE B61 GENE - IMPLICATIONS ON ORGANOGENESIS	ONCOGENE			English	Article						B61; ECK; IN SITU HYBRIDIZATION; ORGANOGENESIS	RECEPTOR TYROSINE KINASES; PROTEIN; FAMILY	ECK is a member of EPH receptor protein-tyrosine kinase subfamily and human B61 has been identified as the ligand for ECK recently, In order to better understand the roles of B61-ECK signalling pathway in mammalian development, me have cloned rat and mouse B61 cDNA and examined the expression pattern during rat development, Sequence analysis has revealed that there is a considerable degree of identity among rat, mouse and human B61 (98.0% between rat and mouse, 86.3% between rat and human in amino acid level), Examination of B61 mRNA expression by in situ hybridization analysis revealed tight association of B61 with endothelial cells at an early stage and epithelial cells in various tissues including lung, kidney, intestine, skin at later stage of organogenesis. In the developing skeletal system, B61 is expressed in periosteum, perichondrium and hypertrophic chondrocytes and osteoblasts, In the developing nervous system, expression of B61 is restricted in the neurons of dorsal root ganglia, These expression profiles of B61 in epithelial cells of various organs, developing skeletal system and dorsal. root ganglia match those of ECK, Our data suggest that B61 plays pivotal roles in organogenesis, especially vasculogenesis/angiogenesis and epithelial cell proliferation/differentiation.	SHOWA UNIV,SCH DENT,DEPT ORAL PATHOL,SHINAGAWA KU,TOKYO 142,JAPAN	Showa University	TAKAHASHI, H (corresponding author), MITSUBISHI KASEI INST LIFE SCI,HISTOCHEM LAB,11 MINAMIOOYA,MACHIDA,TOKYO 194,JAPAN.							BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BECKMANN MP, 1994, EMBO J, V13, P3757, DOI 10.1002/j.1460-2075.1994.tb06685.x; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; GANJU P, 1994, ONCOGENE, V9, P1613; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HOLZMAN LB, 1990, MOL CELL BIOL, V10, P5830, DOI 10.1128/MCB.10.11.5830; IKEDA T, 1992, J CLIN INVEST, V92, P2814; KARPERIEN M, 1994, MECH DEVELOP, V47, P29, DOI 10.1016/0925-4773(94)90093-0; KORHONEN J, 1994, ONCOGENE, V9, P395; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; RUIZ JC, 1994, MECH DEVELOP, V46, P87; SAJJADI FG, 1993, ONCOGENE, V8, P1807; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHNURCH H, 1993, DEVELOPMENT, V119, P957	15	17	21	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 7	1995	11	5					879	883						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RU798	7675446				2022-12-17	WOS:A1995RU79800008
J	BALSALOBRE, A; JOLICOEUR, P				BALSALOBRE, A; JOLICOEUR, P			FOS PROTEINS CAN ACT AS NEGATIVE REGULATORS OF CELL-GROWTH INDEPENDENTLY OF THE FOS TRANSFORMING PATHWAY	ONCOGENE			English	Article						FOS; CELL CYCLE; CELL GROWTH	D-TYPE CYCLINS; RETINOBLASTOMA GENE-PRODUCT; C-FOS; DIFFERENTIAL EXPRESSION; G0-TO-G1 TRANSITION; MOUSE FIBROBLASTS; ANTISENSE RNA; V-FOS; PHOSPHORYLATION; JUN	The proto-oncogene c-fos is known to be an important positive regulator of cell growth and notably of the G0/G1 transition. However, we observed that v-fos or c-fos-transformed rat-1 fibroblasts paradoxically had a low growth rate as compared to control untransformed rat-1 cells. We determined that this slow growth mainly reflects an increase of the G1 phase of the cell cycle (up to fourfold). In addition, the G0-->S progression of serum-starved fos-expressing rat-1 cells refed with serum was found to be also delayed as compared to rat-1 cells. The delayed G0-->S progression in fos-expressing cells was accompanied by the inappropriate levels or kinetics of expression of several cell cycle-regulated genes (cyclin D1, cdc2, cdk2, cdk4 and rb). Furthermore, a clear uncoupling of the pRb hyperphosphorylation with the entry into S phase was found in these fos-expressing rat-1 cells. Interestingly, the effect of the Fos proteins on the cell cycle was independent of the fos transforming pathway, indicating that the effector genes for Fos proteins are likely to be different for each process. In conclusion, our results indicate that Fos proteins may act as negative regulators of cell growth in some cell types, independently of the fos transforming pathway.	CLIN RES INST MONTREAL,MOLEC BIOL LAB,MONTREAL,PQ H2W 1R7,CANADA; UNIV MONTREAL,DEPT MICROBIOL & IMMUNOL,MONTREAL,PQ H3C 3J7,CANADA; MCGILL UNIV,DEPT EXPTL MED,MONTREAL,PQ H3G 1A4,CANADA	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite de Montreal; McGill University								ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BAIM SB, 1991, P NATL ACAD SCI USA, V88, P5072, DOI 10.1073/pnas.88.12.5072; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BASSETSEGUIN N, 1994, ONCOGENE, V9, P765; BISHOP JM, 1983, ANNU REV BIOCHEM, V52, P301, DOI 10.1146/annurev.bi.52.070183.001505; BRAVO R, 1986, EMBO J, V5, P695, DOI 10.1002/j.1460-2075.1986.tb04269.x; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CURRAN T, 1982, VIROLOGY, V116, P221, DOI 10.1016/0042-6822(82)90415-9; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FILED SJ, 1992, P NATL ACAD SCI USA, V89, P9306; FISHER C, 1991, DEVELOPMENT, V111, P253; GARRIDO C, 1993, ONCOGENE, V8, P2713; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Holt J, 1992, Cancer Treat Res, V63, P301; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; HU ED, 1994, EMBO J, V13, P3094, DOI 10.1002/j.1460-2075.1994.tb06608.x; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; IBA H, 1988, ONCOGENE RES, V2, P121; JIANG X, 1994, MAMM GENOME, V5, P142, DOI 10.1007/BF00352344; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; JOLICOEUR P, 1992, J VIROL, V66, P3904, DOI 10.1128/JVI.66.6.3904-3908.1992; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; LEE MG, 1988, NATURE, V333, P676, DOI 10.1038/333676a0; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MIAO GG, 1994, MOL CELL BIOL, V14, P4295, DOI 10.1128/MCB.14.6.4295; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MILLER AD, 1984, CELL, V36, P51; MITCHELL RL, 1986, CELL, V45, P497, DOI 10.1016/0092-8674(86)90281-3; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MULLER R, 1982, NATURE, V299, P640, DOI 10.1038/299640a0; MULLER R, 1984, EMBO J, V3, P1887, DOI 10.1002/j.1460-2075.1984.tb02063.x; MULLER R, 1983, EMBO J, V2, P679, DOI 10.1002/j.1460-2075.1983.tb01484.x; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; OGRYZKO VV, 1994, J VIROL, V68, P3724, DOI 10.1128/JVI.68.6.3724-3732.1994; PARDEE A B, 1992, Current Opinion in Cell Biology, V4, P186, DOI 10.1016/0955-0674(92)90031-7; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PEAR WS, 1993, P NATL ACAD SCI USA, V98, P8392; QUADE K, 1979, VIROLOGY, V98, P461, DOI 10.1016/0042-6822(79)90569-5; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; RIABOWOL KT, 1988, MOL CELL BIOL, V8, P1670, DOI 10.1128/MCB.8.4.1670; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; VANBEVEREN C, 1983, CELL, V32, P124; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; ZARBL H, 1987, CELL, V51, P357, DOI 10.1016/0092-8674(87)90632-5	57	17	17	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 3	1995	11	3					455	465						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN530	7630629				2022-12-17	WOS:A1995RN53000005
J	BEUG, H; DAHL, R; STEINLEIN, P; MEYER, S; DEINER, EM; HAYMAN, MJ				BEUG, H; DAHL, R; STEINLEIN, P; MEYER, S; DEINER, EM; HAYMAN, MJ			IN-VITRO GROWTH OF FACTOR-DEPENDENT MULTIPOTENTIAL HEMATOPOIETIC-CELLS IS INDUCED BY THE NUCLEAR ONCOPROTEIN V-SKI	ONCOGENE			English	Article						SKI; C-KIT; MULTIPOTENT PROGENITORS; HEMATOPOIESIS; CYTOKINES; STEROID HORMONES	AVIAN ERYTHROBLASTOSIS VIRUS; CHICKEN-EMBRYO FIBROBLASTS; PROGENITOR CELLS; STEM-CELLS; MONOCLONAL-ANTIBODIES; SELF-RENEWAL; ERYTHROID-DIFFERENTIATION; ONCOGENE; INVITRO; TRANSFORMATION	Understanding how self renewal, commitment and differentiation are regulated in normal, multipotent hematopoietic progenitors is important for our understanding of underlying mechanisms involved in leukemogenesis, In addition, knowledge of progenitor cell biology is critical if these cells are to be used far gene therapy, In this communication, we demonstrate that the oncogenic transcription factor v-Ski, together with the ligand activated receptor tyrosine kinase c-Kit, induces the continuous in vitro self renewal of primary avian multipotent progenitors, These cells have an in vitro life span of >100 generations, In addition they spontaneously differentiate into cells of the erythroid, monocytic and granulocytic lineages, If clonal strains of these multipotent progenitors are exposed to specific mixtures of growth factors and hormones, they develop into committed cells of either the erythroid or myeloid Lineages, These committed cells underwent efficient terminal differentiation when they were treated with the relevant lineage-specific growth/differentiation factors, but underwent apoptosis when exposed to the incorrect factors for the respective lineage, While the committed tells coexpress marker proteins from different lineages, expression of the 'wrong' lineage marker is repressed during terminal differentiation, Our results indicate that a combination of v-Ski and activated c-Kit induces long-term self renewal in primary multipotent progenitors, which can be induced to commit and differentiate along specific lineages under different, defined conditions, Our data also suggest that growth factors and steroid hormones control terminal differentiation by a combined induction of commitment, growth and apoptosis, a process likely to be affected in stem cell leukemias.	SUNY STONY BROOK,DEPT MICROBIOL,STONY BROOK,NY 11794; INST MOLEC PATHOL,A-1030 VIENNA,AUSTRIA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)				Dahl, Richard/0000-0002-6341-5604				BARKA T, 1962, J HISTOCHEM CYTOCHEM, V10, P741, DOI 10.1177/10.6.741; BEUG H, 1981, VIROLOGY, V115, P295, DOI 10.1016/0042-6822(81)90112-4; BEUG H, 1982, CELL, V28, P907, DOI 10.1016/0092-8674(82)90070-8; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; BEUG H, 1977, EXP CELL RES, V107, P417, DOI 10.1016/0014-4827(77)90363-9; BEUG H, 1994, IN PRESS METHODS ENZ; BROXMEYER HE, 1991, BLOOD, V77, P2142; CROWE AJ, 1991, J VIROL, V65, P2533, DOI 10.1128/JVI.65.5.2533-2538.1991; DALYOT N, 1993, NUCLEIC ACIDS RES, V21, P4031, DOI 10.1093/nar/21.17.4031; FAIRBAIRN LJ, 1993, CELL, V74, P823, DOI 10.1016/0092-8674(93)90462-Y; GISHIZKY ML, 1992, SCIENCE, V256, P836, DOI 10.1126/science.1375394; GRAF T, 1992, CELL, V70, P201, DOI 10.1016/0092-8674(92)90096-U; GRAF T, 1978, NATURE, V275, P496, DOI 10.1038/275496a0; HAYMAN MJ, 1993, CELL, V74, P157, DOI 10.1016/0092-8674(93)90303-8; HAYMAN MJ, 1982, J CELL BIOCHEM, V18, P351, DOI 10.1002/jcb.1982.240180308; HEBERLEIN C, 1992, MOL CELL BIOL, V12, P1815, DOI 10.1128/MCB.12.4.1815; KAMPS MP, 1988, ONCOGENE, V2, P305; KORNFELD S, 1983, EXP CELL RES, V143, P383, DOI 10.1016/0014-4827(83)90065-4; KOWENZ E, 1987, MODERN TRENDS HUMA 7, V31, P199; KRAUT N, 1994, GENE DEV, V8, P33, DOI 10.1101/gad.8.1.33; LARSEN J, 1992, ONCOGENE, V7, P1903; LARSEN J, 1993, ONCOGENE, V8, P3221; LEUTZ A, 1989, EMBO J, V8, P175, DOI 10.1002/j.1460-2075.1989.tb03362.x; LEUTZ A, 1984, EMBO J, V3, P3191, DOI 10.1002/j.1460-2075.1984.tb02278.x; MCNAGNY KM, 1992, LEUKEMIA, V6, P975; MCNIECE IK, 1991, EXP HEMATOL, V19, P226; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; NAMCIU S, 1994, ONCOGENE, V9, P1407; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SCHMIDT JA, 1986, LEUKEMIA RES, V10, P257, DOI 10.1016/0145-2126(86)90023-8; SCHROEDER C, 1990, ONCOGENE, V5, P1445; SCHROEDER C, 1993, EMBO J, V12, P951, DOI 10.1002/j.1460-2075.1993.tb05736.x; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; SPANGRUDE GJ, 1991, BLOOD, V78, P1395; SPOONCER E, 1986, DIFFERENTIATION, V31, P111, DOI 10.1111/j.1432-0436.1986.tb00391.x; SPOONCER E, 1984, NATURE, V310, P228, DOI 10.1038/310228a0; STAVNEZER E, 1986, J VIROL, V57, P1073, DOI 10.1128/JVI.57.3.1073-1083.1986; ULRICH E, 1992, GENE DEV, V6, P876, DOI 10.1101/gad.6.5.876; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1	40	17	17	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 6	1995	11	1					59	72						14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RJ295	7624132				2022-12-17	WOS:A1995RJ29500008
J	DESAINTES, C; HALLEZ, S; DETREMMERIE, O; BURNY, A				DESAINTES, C; HALLEZ, S; DETREMMERIE, O; BURNY, A			WILD-TYPE P53 DOWN-REGULATES TRANSCRIPTION FROM ONCOGENIC HUMAN PAPILLOMAVIRUS PROMOTERS THROUGH THE EPITHELIAL SPECIFIC ENHANCER	ONCOGENE			English	Article						HPV; P53; TBP; TRANSCRIPTION; EPITHELIAL ENHANCER	CARCINOMA CELL-LINES; OPEN READING FRAMES; NUCLEAR FACTOR-I; HUMAN KERATINOCYTES; GENE-EXPRESSION; SV40-TRANSFORMED CELLS; RESPONSIVE ELEMENT; BINDING PROTEIN; E6 ONCOPROTEIN; TUMOR-ANTIGEN	High-risk Human Papillomavirus (HPV) E6 and E7 immortalizing oncoproteins are expressed from promoter tightly regulated by an epithelial specific enhancer. To determine if the p53 tumour suppressor protein can modulate the transcription of these genes, we performed co-transfection experiments with plasmids containing the HPV type 16 or 18 long control regions linked to the chloramphenicol acetyl transferase gene, along with p53 expression vectors. Wild-type, but not mutant, murine or human p53 expression vectors reduced the activity of reporter constructs when co-transfected into HeLa or C33 cell lines. Mutations within the HPV TATA boxes did not significantly alter the levels of p53 repression, suggesting a TATA-independent mechanism. Deletion analyses mapped the p53-responsive domain to the constitutive 230 base pair epithelial specific enhancer. In addition, the enhancer could confer p53-mediated repression when placed upstream of a heterologous promoter.	FREE UNIV BRUSSELS,CHIM BIOL LAB,B-1640 RHODE ST GENESE,BELGIUM									AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; AOYAMA N, 1992, P NATL ACAD SCI USA, V89, P5403, DOI 10.1073/pnas.89.12.5403; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAND V, 1993, EMBO J, V12, P1847, DOI 10.1002/j.1460-2075.1993.tb05833.x; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BLANTON RA, 1992, CELL GROWTH DIFFER, V3, P791; CHONG T, 1990, NUCLEIC ACIDS RES, V18, P465, DOI 10.1093/nar/18.3.465; CRIPE T P, 1990, New Biologist, V2, P450; CROOK T, 1992, EMBO J, V11, P3935, DOI 10.1002/j.1460-2075.1992.tb05487.x; CRUM CP, 1988, J VIROL, V62, P84, DOI 10.1128/JVI.62.1.84-90.1988; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; DESAINTES C, 1992, J VIROL, V66, P325, DOI 10.1128/JVI.66.1.325-333.1992; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; DURST M, 1992, VIROLOGY, V189, P132, DOI 10.1016/0042-6822(92)90688-L; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GARCIACARRANCA A, 1988, J VIROL, V62, P4321, DOI 10.1128/JVI.62.11.4321-4330.1988; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GLOSS B, 1989, NUCLEIC ACIDS RES, V17, P3519, DOI 10.1093/nar/17.9.3519; GUSTERSON BA, 1991, ONCOGENE, V6, P1785; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HOPPESEYLER F, 1991, J VIROL, V65, P5613, DOI 10.1128/JVI.65.10.5613-5618.1991; HUBBERT NL, 1992, J VIROL, V66, P6237, DOI 10.1128/JVI.66.10.6237-6241.1992; HUDSON JB, 1990, J VIROL, V64, P519, DOI 10.1128/JVI.64.2.519-526.1990; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KLEY N, 1992, NUCLEIC ACIDS RES, V20, P4083, DOI 10.1093/nar/20.15.4083; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MACK DH, 1991, P NATL ACAD SCI USA, V88, P9102, DOI 10.1073/pnas.88.20.9102; MAY M, 1994, EMBO J, V13, P1460, DOI 10.1002/j.1460-2075.1994.tb06400.x; MCCANCE DJ, 1988, P NATL ACAD SCI USA, V85, P7169, DOI 10.1073/pnas.85.19.7169; MOMMAND J, 1992, CELL, V69, P1237; MUNGER K, 1989, J VIROL, V63, P4417; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PEACOCK JW, 1994, EMBO J, V13, P1084, DOI 10.1002/j.1460-2075.1994.tb06357.x; PFISTER H, 1984, REV PHYSIOL BIOCH P, V99, P111, DOI 10.1007/BFb0027716; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; SANG BC, 1994, ONCOGENE, V9, P853; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SCHNEIDERGADICK.A, 1986, EMBO J, V5, P2285; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SEDMAN SA, 1992, J VIROL, V66, P4201, DOI 10.1128/JVI.66.7.4201-4208.1992; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; THIERRY F, 1992, J VIROL, V66, P3740, DOI 10.1128/JVI.66.6.3740-3748.1992; THIERRY F, 1991, NEW BIOL, V3, P90; THIERRY F, 1990, MOL CELL BIOL, V10, P4431, DOI 10.1128/MCB.10.8.4431; THIERRY F, 1987, CANCER CELL, V5, P23; TRUANT R, 1993, J BIOL CHEM, V268, P2284; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; YANG YC, 1985, NATURE, V318, P575, DOI 10.1038/318575a0; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	64	17	17	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 1	1995	10	11					2155	2161						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7784059				2022-12-17	WOS:A1995RB70300010
J	MARTEL, C; LALLEMAND, D; CREMISI, C				MARTEL, C; LALLEMAND, D; CREMISI, C			SPECIFIC C-MYC AND MAX REGULATION IN EPITHELIAL-CELLS	ONCOGENE			English	Article						C-MYC; MAX; C-FOS; EPITHELIAL CELLS	DENSITY-DEPENDENT REGULATION; MESSENGER-RNA; GROWTH-FACTOR; TRANSCRIPTIONAL ACTIVATION; RAS COTRANSFORMATION; TRANSGENIC MICE; PROTO-ONCOGENE; DNA-BINDING; BSC-1 CELLS; 3T3 CELLS	We have investigated c-myc, max and c-fos mRNA and protein expression in proliferating, quiescent and stimulated immortalized, SV40 T antigen (LT) transformed and tumor-derived epithelial cells as well in human primary keratinocytes and have compared them to their expression in fibroblasts. In proliferating immortalized and tumor-derived epithelial cells, the levels of c-myc, max and c-fos expression were comparable and much higher than in transformed fibroblasts, c-myc and c-fos mRNA and protein levels remained high even during quiescence, when cells stopped dividing. In contrast, whereas max mRNA was constitutively expressed, max protein levels decreased in both fibroblasts and epithelial cells at high cell density. Changing the medium to serum-free medium of confluent epithelial cells induced a complete proliferative response which started with a transient increase in c-fos and c-myc mRNA, followed by the expression of max, Addition of serum to the medium did not induce additional effects. In fibroblasts, similar treatment induced the arrest of c-myc expression and growth, but max expression was also induced in these cells by serum. Our results therefore show that max expression is growth regulated in both immortalized and transformed epithelial as well as fibroblast cells, In contrast, in epithelial cells, c-myc displayed two contrasting behaviors.	INST PASTEUR, UNITE TECHNOL CELLULAIRE, F-75724 PARIS 15, FRANCE; INST PASTEUR, UNITE VIRUS ONCOGENES, F-75724 PARIS 15, FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			lallemand, dominique/O-7445-2017	lallemand, dominique/0000-0002-0212-7342				AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BERBERICH S, 1992, ONCOGENE, V7, P775; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; COOK PW, 1991, J CELL PHYSIOL, V146, P277, DOI 10.1002/jcp.1041460213; CREMISI C, 1989, MECH B CELL NEOPLASI, P314; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; DEAN M, 1986, J BIOL CHEM, V261, P9161; DOTTO GP, 1986, EMBO J, V5, P2853, DOI 10.1002/j.1460-2075.1986.tb04579.x; DULBECCO R, 1973, NATURE, V246, P197, DOI 10.1038/246197a0; DULBECCO R, 1970, NATURE, V227, P802, DOI 10.1038/227802a0; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREENHALGH DA, 1993, ONCOGENE, V8, P2145; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; HANN SR, 1983, CELL, V34, P789, DOI 10.1016/0092-8674(83)90535-4; HANN SR, 1992, GENE DEV, V6, P1229, DOI 10.1101/gad.6.7.1229; HANN SR, 1994, GENE DEV, V8, P2441, DOI 10.1101/gad.8.20.2441; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; HOLLEY RW, 1977, P NATL ACAD SCI USA, V74, P5046, DOI 10.1073/pnas.74.11.5046; HOLLEY RW, 1978, P NATL ACAD SCI USA, V75, P339, DOI 10.1073/pnas.75.1.339; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; MAHESWARAN S, 1994, MOL CELL BIOL, V14, P1147, DOI 10.1128/MCB.14.2.1147; MAKELA TP, 1992, SCIENCE, V256, P373, DOI 10.1126/science.256.5055.373; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; MORELLO D, 1989, ONCOGENE, V4, P955; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; ONCLERCQ R, 1989, NUCLEIC ACIDS RES, V17, P735, DOI 10.1093/nar/17.2.735; ONCLERCQ R, 1989, ONCOGENE RES, V4, P293; ONCLERCQ R, 1988, J VIROL, V62, P4533, DOI 10.1128/JVI.62.12.4533-4537.1988; PARDEE AB, 1978, ANNU REV BIOCHEM, V47, P715, DOI 10.1146/annurev.bi.47.070178.003435; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; PIECHACZYK M, 1994, CRIT REV ONCOL HEMAT, V17, P93, DOI 10.1016/1040-8428(94)90021-3; PIENTENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758; PLEDGER WJ, 1977, P NATL ACAD SCI USA, V74, P4481, DOI 10.1073/pnas.74.10.4481; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; SAMBROOK J, 1989, COLD SPR HARB LAB PR; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; SPENCER CA, 1991, ADV CANCER RES, V56, P1; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; THOMPSON CB, 1985, NATURE, V314, P363, DOI 10.1038/314363a0; WAGNER AJ, 1992, P NATL ACAD SCI USA, V89, P3111, DOI 10.1073/pnas.89.7.3111; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WATERS CM, 1991, ONCOGENE, V6, P797; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	63	17	17	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	1995	10	11					2195	2205						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7784064				2022-12-17	WOS:A1995RB70300015
J	WOODRUFF, KA; ROSENBLATT, JD; MOORE, TB; MEDZOYAN, RH; PAI, DSM; NOLAND, JL; YAMASHIRO, JM; WADA, RK				WOODRUFF, KA; ROSENBLATT, JD; MOORE, TB; MEDZOYAN, RH; PAI, DSM; NOLAND, JL; YAMASHIRO, JM; WADA, RK			CELL-TYPE-SPECIFIC ACTIVITY OF THE N-MYC PROMOTER IN HUMAN NEUROBLASTOMA-CELLS IS MEDIATED BY A DOWNSTREAM SILENCER	ONCOGENE			English	Article						N-MYC; DOWNSTREAM SILENCER; NEUROBLASTOMA	HUMAN NEURO-BLASTOMA; EMBRYONAL CARCINOMA-CELLS; C-MYC; TRANSCRIPTIONAL REGULATION; DEPENDENT SILENCER; ENHANCER ELEMENT; GENE-EXPRESSION; RETINOIC ACID; AMPLIFICATION; DIFFERENTIATION	The N-myc oncogene is actively transcribed in many neuroblastoma tumors, but is not expressed in mature, normal tissue of any type. Chloramphenicol acetyl transferase (CAT) assays of constructs containing N-myc sequence transfected into N-myc expressing LA-N-5 neuroblastoma cells or non-expressing HeLa carcinoma cells have revealed a 201 base pair (bp) regulatory region mediating the cell type-specific activity of the promoter. While located downstream from 5' mRNA cap sites, the region appears to function by preventing transcriptional initiation. This downstream region is capable of suppressing promoter activity independently of position, and contains an element having 100% homology with the 9 bp consensus sequence of a transcriptional silencer found in the upstream region of the lysozyme gene. DNA gel retardation assays have shown that this sequence is involved in a specific DNA-protein interaction with nuclear extract from HeLa cells that is distinct from that occurring with extract from LA-NB cells. These results suggest that the N-myc promoter's cell type-specific activity is regulated by a downstream silencer, and that differential binding of regulatory protein from that present in non-expressing cells may result in the constitutive N-myc expression seen in neuroblastoma.	UNIV CALIF LOS ANGELES, SCH MED,JONSSON COMPREHENS CANC CTR,DEPT PEDIAT, DIV HEMATOL ONCOL, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, GWYNNE HAZEN CHERRY MEM LABS, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, DIV HEMATOL ONCOL, LOS ANGELES, CA 90024 USA	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					PHS HHS [P01] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AKESON R, 1990, MOL CELL BIOL, V10, P2012, DOI 10.1128/MCB.10.5.2012; BABISS LE, 1990, MOL CELL BIOL, V10, P6700, DOI 10.1128/MCB.10.12.6700; BANIAHMAD A, 1987, EMBO J, V6, P2297, DOI 10.1002/j.1460-2075.1987.tb02504.x; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BERNARDS R, 1986, CELL, V47, P667, DOI 10.1016/0092-8674(86)90509-X; BERNARDS R, 1991, EMBO J, V10, P1119, DOI 10.1002/j.1460-2075.1991.tb08052.x; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CANNIO R, 1991, NUCLEIC ACIDS RES, V19, P2303, DOI 10.1093/nar/19.9.2303; CAO SX, 1989, P NATL ACAD SCI USA, V86, P5306, DOI 10.1073/pnas.86.14.5306; CESARMAN E, 1987, SCIENCE, V238, P1272, DOI 10.1126/science.3685977; CHODOSH LA, 1988, CURRENT PROTOCOLS MO; COHN SL, 1990, ONCOGENE, V5, P1821; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; EICK D, 1987, ONCOGENE, V2, P61; GRADY EF, 1987, CANCER RES, V47, P2931; HARA E, 1993, ONCOGENE, V8, P1023; HEN R, 1983, NUCLEIC ACIDS RES, V11, P8747, DOI 10.1093/nar/11.24.8747; HILLER S, 1991, ONCOGENE, V6, P969; HIYAMA E, 1991, J PEDIATR SURG, V26, P838, DOI 10.1016/0022-3468(91)90151-I; IBSON JM, 1988, ONCOGENE, V2, P399; IMAMURA Y, 1992, BIOCHIM BIOPHYS ACTA, V1132, P177, DOI 10.1016/0167-4781(92)90009-O; KRYSTAL G, 1988, MOL CELL BIOL, V8, P3373, DOI 10.1128/MCB.8.8.3373; LARSEN PR, 1986, P NATL ACAD SCI USA, V83, P8283, DOI 10.1073/pnas.83.21.8283; LI LA, 1993, P NATL ACAD SCI USA, V90, P1460, DOI 10.1073/pnas.90.4.1460; Locker J, 1990, DNA Seq, V1, P3, DOI 10.3109/10425179009041342; MARZLUFF WF, 1985, TRANSCRIPTION TRANSL, P89; MASTRANGELO IA, 1991, P NATL ACAD SCI USA, V88, P5670, DOI 10.1073/pnas.88.13.5670; MORROW MA, 1992, GENE DEV, V6, P61, DOI 10.1101/gad.6.1.61; MUGRAUER G, 1988, J CELL BIOL, V107, P1325, DOI 10.1083/jcb.107.4.1325; NAKABAYASHI H, 1991, MOL CELL BIOL, V11, P5885, DOI 10.1128/MCB.11.12.5885; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; OVERDIER DG, 1992, P NATL ACAD SCI USA, V89, P3140, DOI 10.1073/pnas.89.7.3140; PONTE P, 1983, MOL CELL BIOL, V3, P1783, DOI 10.1128/MCB.3.10.1783; REYNOLDS CP, 1990, PROG CLIN BIOL RES, V366, P203; ROSEN N, 1986, CANCER RES, V46, P4139; ROUET P, 1992, BIOTECHNIQUES, V13, P700; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; Seeger R C, 1988, Prog Clin Biol Res, V271, P41; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SMITH RK, 1992, MOL CELL BIOL, V12, P1578, DOI 10.1128/MCB.12.4.1578; SPENCER CA, 1990, GENE DEV, V4, P75, DOI 10.1101/gad.4.1.75; STANTON LW, 1986, P NATL ACAD SCI USA, V83, P1772, DOI 10.1073/pnas.83.6.1772; TAKEHANA K, 1991, GENE, V103, P219, DOI 10.1016/0378-1119(91)90276-H; TAKIMOTO M, 1989, J BIOL CHEM, V264, P8992; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; THIELE CJ, 1988, EXP CELL BIOL, V56, P321; TOURMENTE S, 1993, INSECT BIOCHEM MOLEC, V23, P137, DOI 10.1016/0965-1748(93)90092-7; Wada R K, 1988, Prog Clin Biol Res, V271, P57; WADA RK, 1992, ONCOGENE, V7, P711; WADAKIYAMA Y, 1992, J BIOL CHEM, V267, P1152; ZIMMERMAN K, 1990, MOL CELL BIOL, V10, P2096, DOI 10.1128/MCB.10.5.2096; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	53	17	17	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1335	1341						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731684				2022-12-17	WOS:A1995QR65100010
J	MORRIS, C; BENJES, S; HAATAJA, L; LEDBETTER, DH; HEISTERKAMP, N; GROFFEN, J				MORRIS, C; BENJES, S; HAATAJA, L; LEDBETTER, DH; HEISTERKAMP, N; GROFFEN, J			SPATIAL-ORGANIZATION OF ABR AND CRK GENES ON HUMAN-CHROMOSOME BAND 17P13.3	ONCOGENE			English	Note						ABR GENE; CRK GENE; CHROMOSOME; 17P13.3; D17S34	GUANINE-NUCLEOTIDE EXCHANGE; INTERPHASE CELL-NUCLEI; MILLER-DIEKER SYNDROME; HYPERVARIABLE RFLP; DNA-SEQUENCES; ONCOGENE; PROTEIN; P53; LOCALIZATION; HOMOLOGY	Deletion of part or all of chromosome 17p is among the most frequent chromosome abnormalities in human cancer. We show that the CRK and ABR genes are close to a marker on chromosome 17p13.3, D17S34, which is frequently deleted in different tumours, and demonstrate that CRK is centromeric to ABR. CRK and ABR may be involved in cancer themselves, or otherwise may function as points of reference for further experiments to clone genes from chromosome 17p which may play a role in cancer.	CHILDRENS HOSP LOS ANGELES,DEPT PATHOL,MOLEC DIAGNOSIS SECT,LOS ANGELES,CA 90027; CHRISTCHURCH HOSP,CYTOGENET & MOLEC ONCOL UNIT,CHRISTCHURCH,NEW ZEALAND; NIH,NATL CTR HUMAN GENOME RES,BETHESDA,MD 20892	Children's Hospital Los Angeles; Christchurch Hospital New Zealand; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)			Morris, Christine/G-1690-2011; Heisterkamp, Nora/C-1698-2012	Heisterkamp, Nora/0000-0003-2769-2273	NATIONAL CANCER INSTITUTE [R55CA047456, R01CA047456] Funding Source: NIH RePORTER; NCI NIH HHS [CA47456] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1992, ONCOGENE, V7, P611; BIEGEL JA, 1992, CANCER RES, V52, P3391; CHAN AML, 1994, ONCOGENE, V9, P1057; DISILVESTRE D, 1990, NUCLEIC ACIDS RES, V18, P5925, DOI 10.1093/nar/18.19.5925; DISILVESTRE D, 1990, NUCLEIC ACIDS RES, V18, P5924, DOI 10.1093/nar/18.19.5924; FIORETOS T, 1993, ONCOGENE, V8, P2853; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HEISTERKAMP N, 1989, NUCLEIC ACIDS RES, V17, P8821, DOI 10.1093/nar/17.21.8821; HEISTERKAMP N, 1993, J BIOL CHEM, V268, P16903; HEISTERKAMP N, 1993, CAUSES CONSEQUENCES, P359; ISOMURA M, 1994, GENE CHROMOSOME CANC, V9, P173, DOI 10.1002/gcc.2870090305; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; KWIATKOWSKI DJ, 1990, AM J HUM GENET, V46, P559; LAWRENCE JB, 1990, SCIENCE, V249, P928, DOI 10.1126/science.2203143; LEDBETTER SA, 1990, GENOMICS, V7, P264, DOI 10.1016/0888-7543(90)90549-A; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MAYER BJ, 1990, J VIROL, V64, P3581, DOI 10.1128/JVI.64.8.3581-3589.1990; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MCBRIDE OW, 1986, P NATL ACAD SCI USA, V83, P130, DOI 10.1073/pnas.83.1.130; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MORRIS C, 1993, HUM GENET, V91, P31, DOI 10.1007/BF00230218; NISHIDA N, 1993, CANCER RES, V53, P368; PRESTI JC, 1991, CANCER RES, V51, P5405; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; REINER O, 1993, NATURE, V364, P717, DOI 10.1038/364717a0; RON D, 1991, NEW BIOL, V3, P372; SAXENA A, 1992, CANCER RES, V52, P6716; TAN EC, 1993, J BIOL CHEM, V268, P27291; TENHOEVE J, 1993, ONCOGENE, V8, P2469; TRASK B, 1989, GENOMICS, V5, P710, DOI 10.1016/0888-7543(89)90112-2; TRASK BJ, 1991, AM J HUM GENET, V48, P1; TSAO SW, 1991, ANTICANCER RES, V11, P1975; UMBRICHT CB, 1994, GENOMICS, V20, P249, DOI 10.1006/geno.1994.1161; VANTUINEN P, 1988, AM J HUM GENET, V43, P587; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0	36	17	20	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 2	1995	10	5					1009	1011						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7898918				2022-12-17	WOS:A1995QL03800023
J	KOTANI, S; ENDO, T; KITAGAWA, M; HIGASHI, H; ONAYA, T				KOTANI, S; ENDO, T; KITAGAWA, M; HIGASHI, H; ONAYA, T			A VARIANT FORM OF CYCLIN-DEPENDENT KINASE-2 (CDK2) IN A MALIGNANTLY TRANSFORMED RAT-THYROID (FRTL-TC) CELL-LINE	ONCOGENE			English	Article						CDK2-BETA, FRTL-TC; CELL CYCLE; CYCLINS	RETINOBLASTOMA GENE-PRODUCT; PROTEIN-KINASE; MAMMALIAN-CELLS; S-PHASE; EPITHELIAL-CELLS; G1 PHASE; CDC2; YEAST; PHOSPHORYLATION; ACID	Cyclin-dependent kinase 2 (Cdk2) controls the transition from the G1 to the S phase in the mammalian cell cycle. We found by immunoblotting that anti-Cdk2 antibodies recognize three Cdk2 proteins (of 33, 34 and 39 kDa) in FRTL-5 and FRTL-Tc cells (malignantly transformed FRTL cells). Although 33 kDa protein is a phosphorylated form of 34 kDa protein previously reported, the nature of 39 kDa protein is unknown. In order to determine the nature of this protein, we screened a FRTL-5 cDNA library. Two cDNA clones of the rat homologue (rat Cdk2-alpha and -beta) of human Cdk2 were isolated. The open reading frame of rat Cdk2-alpha cDNA encoded a protein with 428 amino acids and has a high degree of conservation with human Cdk2. The calculated molecular weight of Cdk2-alpha protein is 33892 Da. The rat Cdk2-beta cDNA was identical to Cdk2-alpha cDNA except that it had extra 144 bp; this coincided with insertion of 48 amino acids into Cdk2-alpha protein between Met 196 and Val 197. The calculated molecular weight of Cdk2-beta protein is 39087 Da. Northern blot analysis indicated that the sizes of rat Cdk2-alpha and -beta mRNAs are approximately 2.5 kb and 3.0 kb, respectively. Partial proteolytic mapping showed that Cdk2-beta gene product is 39 kDa Cdk2 in the immunoblotting. We also found that Cdk2-beta protein binds to cyclin A and suc1 proteins. During G1-S phase in FRTL-Tc cells, Cdk2-alpha protein level is constant, but is gradually phosphorylated. In contrast, the level of Cdk2-beta protein increases through the S phase and decreases at the early G2 phase. These results suggest that a variant form of Cdk2 protein might be required for entry into the S phase of the cell cycle in FRTL-Tc cells.	UNIV YAMANASHI, SCH MED, DEPT INTERNAL MED 3, YAMANASHI 40938, JAPAN; BANYU PHARMACEUT CO LTD, TSUKUBA RES INST, TSUKUBA 30033, IBARAKI, JAPAN	University of Yamanashi; Merck & Company; Novartis			Higashi, Hideaki/F-6872-2012					AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; BANKS L, 1990, ONCOGENE, V5, P833; BROEK D, 1991, NATURE, V349, P388, DOI 10.1038/349388a0; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; ENDO T, 1990, ENDOCRINOLOGY, V126, P1492; ENDO T, 1991, MOL ENDOCRINOL, V5, P905, DOI 10.1210/mend-5-7-905; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HARLOW E, 1988, ANTIBODIES LABORATOR; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; IKEDA M, 1991, ENDOCRINOLOGY, V128, P2540, DOI 10.1210/endo-128-5-2540; KITAGAWA M, 1992, ONCOGENE, V7, P1067; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; NOGUCHI E, 1993, BIOCHEM BIOPH RES CO, V197, P1524, DOI 10.1006/bbrc.1993.2650; OHTA K, 1994, J MOL ENDOCRINOL, V12, P85, DOI 10.1677/jme.0.0120085; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SANGER F, 1981, SCIENCE, V214, P1205, DOI 10.1126/science.7302589; TAMURA K, 1993, ONCOGENE, V8, P2113; TSAI LH, 1993, ONCOGENE, V8, P1593; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	47	17	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 16	1995	10	4					663	669						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QH612	7862443				2022-12-17	WOS:A1995QH61200005
J	KOIKE, M; ISHINO, K; IKUTA, T; HUH, NH; KUROKI, T				KOIKE, M; ISHINO, K; IKUTA, T; HUH, NH; KUROKI, T			GROWTH ENHANCEMENT OF NORMAL HUMAN KERATINOCYTES BY THE ANTISENSE OLIGONUCLEOTIDE OF RETINOBLASTOMA SUSCEPTIBILITY GENE	ONCOGENE			English	Article						RB; P53; ANTISENSE; KERATINOCYTES	HUMAN PAPILLOMAVIRUS TYPE-16; CARCINOMA CELL-LINES; LARGE T-ANTIGEN; LARGE TUMOR-ANTIGEN; P53 GENE; SIMIAN VIRUS-40; SV40-TRANSFORMED CELLS; CYCLE PROGRESSION; BREAST-CANCER; FACTOR BETA-1	We have found that the growth of normal human keratinocytes, grown in serum-free medium, was significantly stimulated by the antisense oligonucleotide of retinoblastoma susceptibility gene (Rb). Normal human keratinocytes were exposed to phosphorothionate oligonucleotides which were complementary to translation initiation codon of Rb gene. The growth of keratinocytes was enhanced by the antisense, but not the sense, oligonucleotide of Rb gene in a dose-dependent manner from 1 to 10 mu M. The Rb antisense oligonucleotide, however, did not result in any appreciable change in transcription of the gene when examined by reverse-transcription polymerase chain reaction (RT-PCR) analysis or in the protein expression and the phosphorylation pattern when examined by immunoprecipitation and Western blotting.	UNIV TOKYO,INST MED SCI,DEPT CANC CELL RES,MINATO KU,TOKYO 108,JAPAN	University of Tokyo			Kuroki, Toshio/A-9500-2011; HUH, Nam-ho/B-1613-2011; Koike, Manabu/AAP-3107-2021	Kuroki, Toshio/0000-0001-6369-4351; 				ALBERTS AS, 1993, P NATL ACAD SCI USA, V90, P388, DOI 10.1073/pnas.90.2.388; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CALABRETTA B, 1991, CANCER RES, V51, P4505; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CROOK T, 1991, ONCOGENE, V6, P873; Crouch R. J., 1982, NUCLEASES, P211; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HELENE C, 1990, BIOCHIM BIOPHYS ACTA, V1049, P99, DOI 10.1016/0167-4781(90)90031-V; HELENE C, 1991, EUR J CANCER, V27, P1466, DOI 10.1016/0277-5379(91)90033-A; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUDSON JB, 1990, J VIROL, V64, P519, DOI 10.1128/JVI.64.2.519-526.1990; KOIKE M, 1994, BIOCHEM BIOPH RES CO, V201, P673, DOI 10.1006/bbrc.1994.1753; KUROKI T, 1993, JPN J CANCER RES, V84, P1091, DOI 10.1111/j.1349-7006.1993.tb02806.x; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEAVITT J, 1984, MOL CELL BIOL, V4, P1961, DOI 10.1128/MCB.4.10.1961; LEE EYHP, 1988, P NATL ACAD SCI USA, V85, P6017, DOI 10.1073/pnas.85.16.6017; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LIN JY, 1991, J VIROL, V65, P6447, DOI 10.1128/JVI.65.12.6447-6453.1991; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MATSUKURA M, 1987, P NATL ACAD SCI USA, V84, P7706, DOI 10.1073/pnas.84.21.7706; MATSUSHIME H, 1991, COLD SH Q B, V56, P69; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MILLER CW, 1990, CANCER RES, V50, P7950; MOLES JP, 1993, ONCOGENE, V8, P583; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; MUNGER K, 1989, J VIROL, V63, P4417; MUNGER K, 1992, CELL GROWTH DIFFER, V3, P291; MURAKAMI Y, 1991, ONCOGENE, V6, P37; MURPHREE AL, 1984, SCIENCE, V223, P1028, DOI 10.1126/science.6320372; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PIETENPOL JA, 1991, P NATL ACAD SCI USA, V88, P10227, DOI 10.1073/pnas.88.22.10227; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; POTTER BVL, 1983, BIOCHEMISTRY-US, V22, P1369, DOI 10.1021/bi00275a008; RINA ZH, 1985, EMBO J, V4, P1251; RUNNEBAUM IB, 1991, P NATL ACAD SCI USA, V88, P10657, DOI 10.1073/pnas.88.23.10657; SAKAI T, 1991, NATURE, V353, P83, DOI 10.1038/353083a0; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STEELE C, 1993, CANCER RES, V53, P2330; STOREY A, 1991, NUCLEIC ACIDS RES, V19, P4109, DOI 10.1093/nar/19.15.4109; STRAUSS M, 1992, ONCOGENE, V7, P769; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TSUNENAGA M, 1994, JPN J CANCER RES, V85, P238, DOI 10.1111/j.1349-7006.1994.tb02088.x; WALDER RY, 1988, P NATL ACAD SCI USA, V85, P5011, DOI 10.1073/pnas.85.14.5011; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WREDE D, 1991, MOL CARCINOGEN, V4, P171, DOI 10.1002/mc.2940040302; YASUMOTO S, 1992, MOL PATHWAYS KINASES, P35; ZHU JY, 1992, J VIROL, V66, P2780, DOI 10.1128/JVI.66.5.2780-2791.1992; ZHU JY, 1991, J VIROL, V65, P6872, DOI 10.1128/JVI.65.12.6872-6880.1991	68	17	17	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 5	1995	10	1					117	122						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA980	7824264				2022-12-17	WOS:A1995QA98000014
J	MARSHALLHEYMAN, H; ENGEL, G; LJUNGDAHL, S; SHOSHAN, MC; SVENSSON, C; WASYLYK, B; LINDER, S				MARSHALLHEYMAN, H; ENGEL, G; LJUNGDAHL, S; SHOSHAN, MC; SVENSSON, C; WASYLYK, B; LINDER, S			TUMORIGENIC AND METASTATIC PROPERTIES OF 2 RAS-ONCOGENE TRANSFECTED RAT FIBROSARCOMA CELL-LINES DEFECTIVE IN C-JUN	ONCOGENE			English	Article							EMBRYO FIBROBLASTS; TRANSCRIPTIONAL ACTIVATION; MOUSE FIBROBLASTS; MAMMALIAN-CELLS; PHORBOL ESTERS; GENE PROMOTER; GROWTH ARREST; FOS PROTEINS; TRANSFORMATION; AP-1	We here report the spontaneous loss of both homologues of the c-jun gene in two cell lines, isolated after transfection of rat embryo fibroblasts with single ras-oncogenes. These cells lines (designated A14 and B25) grow rapidly in vitro, have transformed morphologies and are invasive through reconstituted basal membranes. Both c-jun defective cell lines were found to be tumorigenic and metastatic in athymic mice. Loss of c-jun was paralleled by a dramatic decrease in interstitial collagenase expression, whereas stromelysin mRNA expression in c-jun(-) A14 and B25 cells was similar to that observed in c-jun(+) transformed cell lines. Transient transfection experiments using reporter plasmids showed that stromelysin promoter activity in A14 cells was severely impaired by a point mutation in the -71 to -65 AP-1 motif, and was inhibited by a Jun dominant negative mutant. Gel mobility shift studies demonstrated the presence of a factor in A14 nuclear extracts capable of binding the stromelysin TRE. This factor bound JunB, JunD and Fos antibodies. Our findings suggest that c-Jun is not required for the tumorigenic and metastatic potential of vas-transformed fibrosarcoma cells, and that AP-1 protein(s) lacking c-Jun are capable of activating the stromelysin gene promoter.	KAROLINSKA HOSP & INST, RADIUM HEMMET, DEPT GEN ONCOL, DIV EXPTL ONCOL, S-17176 STOCKHOLM, SWEDEN; KAROLINSKA INST, DEPT MICROBIAL GENET, S-17176 STOCKHOLM, SWEDEN; FAC MED STRASBOURG, INST CHIM BIOL,CNRS,U184 BIOL MOLEC,INSERM, GENET MOLEC EUCARYOTES LAB, F-67085 STRASBOURG, FRANCE	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Wasylyk, Bohdan/ABG-6778-2020	Wasylyk, Bohdan/0000-0002-1718-1237				ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; ALBINI A, 1987, CANCER RES, V47, P3239; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BOSSYWETZEL E, 1992, GENE DEV, V6, P2340, DOI 10.1101/gad.6.12a.2340; CHAMBERS AF, 1993, CRIT REV ONCOGENESIS, V4, P95; CHIU R, 1987, NATURE, V329, P648, DOI 10.1038/329648a0; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CLASSON M, 1987, NATURE, V330, P272, DOI 10.1038/330272a0; DELALUNA S, 1992, METHOD ENZYMOL, V216, P376; DEMCZUK S, 1993, P NATL ACAD SCI USA, V90, P2574, DOI 10.1073/pnas.90.7.2574; EDMONDS M, 1969, J BIOL CHEM, V244, P1314; ENGEL G, 1993, INT J ONCOL, V3, P457; GINSBERG D, 1991, ONCOGENE, V6, P669; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HICKS GG, 1991, MOL CELL BIOL, V11, P1344, DOI 10.1128/MCB.11.3.1344; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V85, P1519, DOI 10.1073/pnas.85.5.1519; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; LINDER S, 1992, ONCOGENE, V7, P439; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MARSHALL H, 1993, ONCOGENE, V8, P1303; MARSHALL H, 1991, EXP CELL RES, V194, P35, DOI 10.1016/0014-4827(91)90126-F; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; PIETTE J, 1988, P NATL ACAD SCI USA, V85, P3401, DOI 10.1073/pnas.85.10.3401; QUINN CO, 1990, J BIOL CHEM, V265, P22342; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; RULEY HE, 1990, CANCER CELL-MON REV, V2, P258; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; RYSECK RP, 1991, ONCOGENE, V6, P533; Sambrook J., 1989, MOL CLONING LAB MANU; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; THIERRY F, 1992, J VIROL, V66, P3740, DOI 10.1128/JVI.66.6.3740-3748.1992; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WISDOM R, 1993, MOL CELL BIOL, V13, P7429, DOI 10.1128/MCB.13.12.7429; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	53	17	17	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1994	9	12					3655	3663						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970724				2022-12-17	WOS:A1994PT39200029
J	KOZUTSUMI, H; TOYOSHIMA, H; HAGIWARA, K; YAZAKI, Y; HIRAI, H				KOZUTSUMI, H; TOYOSHIMA, H; HAGIWARA, K; YAZAKI, Y; HIRAI, H			HUMAN LTK RECEPTOR TYROSINE KINASE BINDS TO PLC-GAMMA-1, PI3-K, GAP AND RAF-1 IN-VIVO	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; PHOSPHOLIPASE-C-GAMMA; GUANINE-NUCLEOTIDE EXCHANGE; SIGNAL TRANSDUCTION; EGF RECEPTOR; PDGF RECEPTOR; PROTEIN; RAS; ASSOCIATION; GRB2	Leukocyte tyrosine kinase (ltk) is a receptor-type tyrosine kinase which is suggested to be expressed in hematopoietic cells and neuronal cells in human. Recently we have cloned a full sized human ltk cDNA which has a 423 amino acid extracellular domain which may bind to unknown ligand(s), and a 415 amino acid cytoplasmic domain which contains a tyrosine kinase domain. To identify the cellular signal transducer proteins binding to the ltk protein, we have analysed the recombinant ltk protein transiently expressed in COS cells. By an in vitro immune complex kinase assay, a major 140 kDa phosphoprotein and other cellular phosphoproteins were co-immunoprecipitated with the 100 kDa ltk protein using anti-ltk monoclonal antibodies. Western blot analysis revealed that the wild-type ltk protein was tyrosine-phosphorylated in vivo and associated with SH2 containing proteins, PLC-gamma 1, p85 subunit of PI3-K and GAP, in vivo. Furthermore, the wild-type ltk protein also binds to a serine/threonine kinase, Raf-1, in vivo. In contrast, none of these signal transducer proteins were associated with a kinase-negative ltk mutant (K544M-ltk) in which methionine at the putative ATP binding site was replaced with lysine. These results suggest that the associations of the ltk protein with those signaling molecules depend on the tyrosine kinase activity of the ltk protein. This is the first detection of cytoplasmic signal transducers that bind to the ltk protein in vivo.	UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,TOKYO 113,JAPAN	University of Tokyo								BACCARINI M, 1990, EMBO J, V9, P3649, DOI 10.1002/j.1460-2075.1990.tb07576.x; BAUSKIN AR, 1991, CELL, V66, P685, DOI 10.1016/0092-8674(91)90114-E; BEN-NERIAH Y, 1988, NATURE, V333, P672, DOI 10.1038/333672a0; COUGHLIN SR, 1989, SCIENCE, V243, P1191; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FUKUI Y, 1991, MOL CELL BIOL, V11, P1972, DOI 10.1128/MCB.11.4.1972; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KOZUTSUMI H, 1993, BIOCHEM BIOPH RES CO, V190, P674, DOI 10.1006/bbrc.1993.1101; KROLEWSKI JJ, 1991, EMBO J, V10, P2911, DOI 10.1002/j.1460-2075.1991.tb07841.x; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MARGOLIS B, 1990, MOL CELL BIOL, V10, P435, DOI 10.1128/MCB.10.2.435; MARU Y, 1990, ONCOGENE RES, V5, P199; MATSUSHIME H, 1986, MOL CELL BIOL, V6, P3000, DOI 10.1128/MCB.6.8.3000; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SPAARGAREN M, 1991, J BIOL CHEM, V266, P1773; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TOYOSHIMA H, 1993, P NATL ACAD SCI USA, V90, P5404, DOI 10.1073/pnas.90.12.5404; TWAMLEY GM, 1992, ONCOGENE, V7, P1893; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	39	17	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					2991	2998						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084603				2022-12-17	WOS:A1994PG82200026
J	RAKOTOMAHANINA, CK; HILGER, C; FINK, T; ZENTGRAF, H; SCHRODER, CH				RAKOTOMAHANINA, CK; HILGER, C; FINK, T; ZENTGRAF, H; SCHRODER, CH			BIOLOGICAL-ACTIVITIES OF A PUTATIVE TRUNCATED HEPATITIS-B VIRUS-X GENE-PRODUCT FUSED TO A POLYLYSIN STRETCH	ONCOGENE			English	Article							SURFACE-ANTIGEN GENE; HEPATOCELLULAR-CARCINOMA; DNA-SEQUENCES; MAMMALIAN-CELLS; PLASMID DNA; MOUSE CELLS; VIRAL-DNA; PROTEIN; TRANSFORMATION; TRANSFECTION	Truncated transcripts terminating within the HBx frame have been recognized previously in tumor and liver tissue of HCC patients. In this study biological activities of a predicted truncated HBx fused to a polysin stretch (HBtx-polylysin) and of full length HBx were compared in NIH3T3 cells transfected with respective cDNA plasmids. Transactivation of a co-transfecting reporter gene and influence on neo' DNA mediated transformation to G418 resistance were determined. In comparison to full length HBx the data indicate for HBtx-polylysin a lower transactivating capacity and as judged by the yield of colonies on a solid surface, a lower capacity to stimulate neo(r) DNA mediated transformation. In soft agar the outgrowth into G418 resistant colonies was dependent on co-transfecting HBx cDNA. In providing this condition HBtx-polylysin had a much higher relative activity than full length HBx. Large cointegrants consisting of the plasmids carrying truncated HBx cDNA and neo(r) DNA respectively were identified by chromosomal in situ hybridization. Based on Southern blot analyses extended concatemeres of the HBx cDNA plasmid constituted a main part of the cointegrants. Expression of truncated HBx cDNA was followed on the RNA and the protein level. The presence of this cDNA could be correlated to a compact spindle like cell appearance, its loss after prolonged passaging in the absence of G418 to a concomitant reversion to the phenotype of the NIH3T3 cell. Interspersed selection for G418 resistance stabilized the morphologically transformed phenotype. These results provide a basis to manipulate expression of truncated HBx and to recognize thereby processes leading to transformation.	DEUTSCH KREBSFORSCHUNGSZENTRUM,DEPT VIRUS WECHSELWIRKUNGEN,D-69009 HEIDELBERG,GERMANY; DEUTSCH KREBSFORSCHUNGSZENTRUM,DEPT ORG KOMPLEXER GENOME,D-69009 HEIDELBERG,GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)				Hilger, Christiane/0000-0001-9455-5442				ARTELT P, 1988, GENE, V68, P213, DOI 10.1016/0378-1119(88)90023-6; BEASLEY RP, 1988, CANCER, V61, P1942, DOI 10.1002/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO;2-J; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRECHOT C, 1981, LANCET, V2, P765; CATTANEO R, 1983, NATURE, V305, P336, DOI 10.1038/305336a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; GRUMMT F, 1989, CELL, V56, P143, DOI 10.1016/0092-8674(89)90886-6; HARNES BD, 1984, TRANSCRIPTION TRANSL; HILGER C, 1991, J VIROL, V65, P4284, DOI 10.1128/JVI.65.8.4284-4291.1991; HOHNE M, 1990, EMBO J, V9, P1137, DOI 10.1002/j.1460-2075.1990.tb08220.x; HOLST A, 1988, CELL, V52, P355; IMAZEKI F, 1987, HEPATOLOGY, V7, P753, DOI 10.1002/hep.1840070423; KESSLER C, 1990, BIOL CHEM H-S, V371, P917, DOI 10.1515/bchm3.1990.371.2.917; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; KLEIN R, 1991, VIRUS GENES, V5, P157, DOI 10.1007/BF00571930; KRIEG UC, 1989, J CELL BIOL, V109, P2033, DOI 10.1083/jcb.109.5.2033; KUPPER H, 1984, EXPRESSION FOOT MOUT, P222; LEARY JJ, 1983, P NATL ACAD SCI-BIOL, V80, P4045, DOI 10.1073/pnas.80.13.4045; LEVRERO M, 1990, J VIROL, V64, P3082, DOI 10.1128/JVI.64.6.3082-3086.1990; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; LICHTER P, 1992, HUMAN CYTOGENETICS P, V1, P157; NAGAYA T, 1987, GENE DEV, V1, P773, DOI 10.1101/gad.1.8.773; POURCEL C, 1982, J VIROL, V42, P100, DOI 10.1128/JVI.42.1.100-105.1982; PULM W, 1985, MOL CELL BIOL, V5, P295; RADZIWILL G, 1990, J VIROL, V64, P613, DOI 10.1128/JVI.64.2.613-620.1990; RAIMONDO G, 1988, VIROLOGY, V166, P103, DOI 10.1016/0042-6822(88)90151-1; SCHEK N, 1991, ONCOGENE, V6, P1735; SHAFRITZ DA, 1981, HEPATOLOGY, V1, P1, DOI 10.1002/hep.1840010102; SHIRAKATA Y, 1989, JPN J CANCER RES, V80, P617, DOI 10.1111/j.1349-7006.1989.tb01686.x; SIMONSEN CC, 1983, MOL CELL BIOL, V3, P2250, DOI 10.1128/MCB.3.12.2250; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TAKADA S, 1990, J VIROL, V64, P822, DOI 10.1128/JVI.64.2.822-828.1990; THOMAS JO, 1975, P NATL ACAD SCI USA, V72, P2626, DOI 10.1073/pnas.72.7.2626; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TWU JS, 1987, J VIROL, V61, P3448, DOI 10.1128/JVI.61.11.3448-3453.1987; WOLLERSHEIM M, 1988, ONCOGENE, V3, P545; ZASTROW G, 1989, NUCLEIC ACIDS RES, V17, P1867, DOI 10.1093/nar/17.5.1867	40	17	18	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2613	2621						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058325				2022-12-17	WOS:A1994PC05400021
J	MATIN, A; HUNG, MC				MATIN, A; HUNG, MC			THE RETINOBLASTOMA GENE-PRODUCT, RB, REPRESSES NEU EXPRESSION THROUGH 2 REGIONS WITHIN THE NEU REGULATORY SEQUENCE	ONCOGENE			English	Article							TRANSCRIPTION FACTOR E2F; LARGE T-ANTIGEN; CELL-CYCLE; SUSCEPTIBILITY GENE; OVARIAN-CANCER; DNA-BINDING; ENCODED PROTEIN; MAMMALIAN-CELLS; POINT MUTATION; C-ERBB-2 GENE	The neu oncogene is frequently overexpressed in breast, ovarian and lung cancers, and its overexpression correlates with poor disease prognosis. The exact mechanism of deregulation of neu expression is not well understood. Our previous studies indicate that the tumor suppressor retinoblastoma gene product, Rb, represses transcription of neu through the GTG enhancer (-243 to -234 relative to initiation of translation site of rat neu). We carried out further deletion analysis of the regulatory sequences of neu and found that Rb also represses neu close to transcription initiation sites (-172 to -79). Bal 31 deletions downstream of nucleotide -172 show that the sequence TCGAGGAA (-172 to -165) is important for efficient transcription from the neu promoter and also for repression by Rb. Rb mutants with mutations in the large T/E1a binding domain repress transcription from transcription initiation sites but not the GTG enhancer, suggesting that Rb modulates different regions of the regulatory sequence of neu by different pathways. The net effect of the Rb mutants is to repress not only transcription but also the transforming activity of activated neu in focus-forming assays. Thus, one mechanism whereby Rb may act as a tumor suppressor is to repress transcription of the strongly transforming nea oncogene.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT TUMOR BIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center			Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740	NCI NIH HHS [NCI CA58880, NCI CA16672, NCI CA60856] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060856, P30CA016672, R01CA058880] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BERCHUCK A, 1990, CANCER RES, V50, P4087; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DAHMUS ME, 1992, TRANSCRIPTIONAL REGU, P109; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEMILIA J, 1989, ONCOGENE, V4, P1233; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FUKUSHIGE S, 1986, MOL CELL BIOL, V6, P955, DOI 10.1128/MCB.6.3.955; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; HUDSON LG, 1990, J BIOL CHEM, V265, P4389; HUNG MC, 1989, P NATL ACAD SCI USA, V86, P2545, DOI 10.1073/pnas.86.8.2545; HUNG MC, 1992, CANCER LETT, V61, P95, DOI 10.1016/0304-3835(92)90166-S; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KERN JA, 1990, CANCER RES, V50, P5184; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MILLER SJ, 1994, IN PRESS INT J ONCOL; NORTON PA, 1985, MOL CELL BIOL, V5, P281, DOI 10.1128/MCB.5.2.281; PARK JB, 1989, CANCER RES, V49, P6005; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; RUSSELL KS, 1992, CANCER RES, V52, P6624; SCHNEIDER PM, 1989, CANCER RES, V49, P4968; SHEW JY, 1990, CELL GROWTH DIFFER, V1, P17; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SHI DR, 1992, MOL CARCINOGEN, V5, P213, DOI 10.1002/mc.2940050308; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SUEN TC, 1990, MOL CELL BIOL, V10, P6306, DOI 10.1128/MCB.10.12.6306; SUMEGI J, 1990, CELL GROWTH DIFFER, V1, P247; VIJVER M, 1987, MOL CELL BIOL, V7, P2019; WANG NP, 1993, ONCOGENE, V8, P279; WATANABE H, 1988, MOL CELL BIOL, V8, P1290, DOI 10.1128/MCB.8.3.1290; WEINER DB, 1990, CANCER RES, V50, P421; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WHITE MRA, 1992, ONCOGENE, V7, P677; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YOKOTA J, 1988, ONCOGENE, V2, P283; YU DH, 1992, J BIOL CHEM, V267, P10203; YU DH, 1991, ONCOGENE, V6, P1991; ZHANG X, 1989, ONCOGENE, V4, P985; ZHAO XY, 1992, MOL CELL BIOL, V12, P2739, DOI 10.1128/MCB.12.6.2739	68	17	17	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1994	9	5					1333	1339						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	7908732				2022-12-17	WOS:A1994NH40100004
J	GALIEN, R; EMANOILRAVIER, R; MERCIER, G				GALIEN, R; EMANOILRAVIER, R; MERCIER, G			DIFFERENTIAL-EFFECTS OF C-JUN AND CREB ON CAMP RESPONSE ELEMENT ACTIVATION BY HA-RAS	ONCOGENE			English	Article							LEUCINE ZIPPER STRUCTURE; DNA-BINDING PROTEIN; ATF CDNA CLONES; CYCLIC-AMP; TRANSCRIPTION FACTOR; GROWTH-FACTOR; SIGNAL TRANSDUCTION; GENE-TRANSCRIPTION; CROSS-TALK; FOS-JUN	We have previously shown that a Long Terminal Repeat (LTR) of the Intracisternal A-type Particle (IAP) element was activated by ras oncogenes. Here we show that, like the somatostatin CRE (som CRE) and the collagenase TPA Response Element (coll TRE), the IAP CRE is activated by c-jun and that Val 12 Ha-ras cooperates with c-jun to activate these motifs. Neither jun-B nor jun-D activated the IAP CRE, although they were able to act on the som CRE and the coll TRE and to synergize with ras. The CREB factor activated both CREs and modestly inhibited the coll TRE, but diminished the effect of ras on the coll TRE. Finally, forskolin was shown to cooperate with Ha-ras to activate the CRE and the coll TRE. Taken together, these results show that CREB is not involved in ras activation of the CRE and suggest that c-jun is at least one of the elements implicated in this phenomenon.	HOP ST LOUIS,RETROVIRUS & RETROTRANSPOSONS VERTEBRES LAB,CNRS,UPR 0043,1 AVE CLAUDE VELLEFAUX,F-75010 PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite								ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AUWERX J, 1992, ONCOGENE, V7, P2271; BAICHWAL VR, 1991, NATURE, V352, P165, DOI 10.1038/352165a0; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOS TJ, 1988, CELL, V52, P705, DOI 10.1016/0092-8674(88)90408-4; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; DEGROOT RP, 1990, NUCLEIC ACIDS RES, V18, P3195, DOI 10.1093/nar/18.11.3195; DEGROOT RP, 1992, ONCOGENE, V7, P2281; DEGROOT RP, 1992, ONCOGENE, V7, P841; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; DEUTSCH PJ, 1988, J BIOL CHEM, V263, P18466; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FLINT KJ, 1991, ONCOGENE, V6, P2019; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FUKUMOTO Y, 1990, J BIOL CHEM, V265, P774; GAIRE M, 1990, NUCLEIC ACIDS RES, V18, P3467, DOI 10.1093/nar/18.12.3467; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GALIEN R, 1991, ONCOGENE, V6, P849; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HIRAI S-I, 1989, New Biologist, V1, P181; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; IMLER JL, 1988, NATURE, V332, P275, DOI 10.1038/332275a0; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; KARPINSKI BA, 1992, P NATL ACAD SCI USA, V89, P4820, DOI 10.1073/pnas.89.11.4820; KEDAR PS, 1990, MOL CELL BIOL, V10, P3852, DOI 10.1128/MCB.10.7.3852; LAMPH WW, 1990, P NATL ACAD SCI USA, V87, P4320, DOI 10.1073/pnas.87.11.4320; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MAEKAWA T, 1991, ONCOGENE, V6, P627; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MARSHALL CJ, 1991, TRENDS GENET, V7, P91, DOI 10.1016/0168-9525(91)90063-V; MASQUILIER D, 1992, J BIOL CHEM, V267, P22460; MATSUDA S, 1991, J BIOL CHEM, V266, P18188; MATSUI M, 1990, ONCOGENE, V5, P249; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NICHOLS M, 1992, EMBO J, V11, P3337, DOI 10.1002/j.1460-2075.1992.tb05412.x; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; NOMURA N, 1993, J BIOL CHEM, V268, P4259; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; RUPPERT S, 1992, EMBO J, V11, P1503, DOI 10.1002/j.1460-2075.1992.tb05195.x; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1991, ONCOGENE, V6, P533; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; SASSONECORSI P, 1990, ONCOGENE, V5, P427; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1992, J BIOL CHEM, V267, P24149; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SCHONTAL A, 1989, CELL, V54, P325; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SEAMON KB, 1981, P NATL ACAD SCI-BIOL, V78, P3363, DOI 10.1073/pnas.78.6.3363; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; VALLEJO M, 1993, P NATL ACAD SCI USA, V90, P4679, DOI 10.1073/pnas.90.10.4679; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; XU YL, 1990, J BIOL CHEM, V265, P20285; YOSHIMURA T, 1990, EMBO J, V9, P2537, DOI 10.1002/j.1460-2075.1990.tb07434.x; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	83	17	17	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1101	1108						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	7907782				2022-12-17	WOS:A1994NC04800012
J	HODIVALA, KJ; PEI, XF; LIU, QY; JONES, PH; RYTINA, ERC; GILBERT, C; SINGER, A; WATT, FM				HODIVALA, KJ; PEI, XF; LIU, QY; JONES, PH; RYTINA, ERC; GILBERT, C; SINGER, A; WATT, FM			INTEGRIN EXPRESSION AND FUNCTION IN HPV16-IMMORTALIZED HUMAN KERATINOCYTES IN THE PRESENCE OR ABSENCE OF V-HA-RAS - COMPARISON WITH CERVICAL INTRAEPITHELIAL NEOPLASIA	ONCOGENE			English	Note							PAPILLOMAVIRUS TYPE-16 DNA; HUMAN EPIDERMAL-KERATINOCYTES; SQUAMOUS-CELL CARCINOMA; TERMINAL DIFFERENTIATION; MONOCLONAL-ANTIBODIES; FIBRONECTIN; ADHESION; GROWTH; TRANSFORMATION; TRANSFECTION	Keratinocytes express several receptors of the integrin family which regulate both adhesion and differentiation. We have investigated whether HPV immortalisation, which changes the growth and differentiation properties of keratinocytes, is associated with altered integrin expression or function. We compared two HPV 16-immortalised lines of human keratinocytes, up and vp, with the normal keratinocyte strains, u and v, from which they were derived and with upr, obtained by transfection of up with viral Harvey ras. Immunofluorescence, immunoprecipitation and flow cytometry demonstrated that up and vp had lower levels of integrins than u and v, the reduction in up being greater than in vp. Up and vp also had reduced levels of mRNA encoding the beta(1) integrin subunit. Reduced expression of the alpha(5) beta(1) and alpha(2) beta(1) integrins was correlated with reduced adhesion to fibronectin and collagen in up but not in vp and there were no significant differences between the normal and immortalised cells in adhesion to laminin. Reduced integrin expression was correlated with decreased motility, up showing a greater reduction in motility than vp. Introduction of activated ras into up had no effect on integrin levels, cell motility or tumorigenicity in nude mice; the only difference between up and upr was that upr showed increased adhesion to fibronectin. Examination of eight biopsies of cervical intraepithelial neoplasias with evidence of HPV infection revealed reduced, or discontinuous integrin expression in the most severe lesions. We conclude that both in vivo and in cultured keratinocytes the impaired differentiation that is associated with the presence of HPV is correlated with reduced integrin expression.	IMPERIAL CANC RES FUND, KERATINOCYTE LAB, LONDON WC2A 3PX, ENGLAND; IMPERIAL CANC RES FUND, APPL MICROSCOPY LAB, LONDON WC2A 3PX, ENGLAND; WHITTINGTON HOSP, DEPT GYNAECOL, LONDON N19 5NF, ENGLAND	Cancer Research UK; Cancer Research UK; University of London; University College London			Jones, Philip/D-2464-2009; Watt, Fiona/AHB-0226-2022	Jones, Philip/0000-0002-5904-795X; Watt, Fiona/0000-0001-9151-5154; Hodivala-Dilke, Kairbaan/0000-0002-2859-749X				ADAMS JC, 1993, DEVELOPMENT, V117, P1183; ADAMS JC, 1991, J CELL BIOL, V115, P829, DOI 10.1083/jcb.115.3.829; ADAMS JC, 1990, CELL, V63, P425, DOI 10.1016/0092-8674(90)90175-E; AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; ALITALO K, 1982, J CELL BIOL, V94, P497, DOI 10.1083/jcb.94.3.497; BRISSETTE JL, 1993, MOL CARCINOGEN, V7, P21, DOI 10.1002/mc.2940070105; CUZICK J, 1992, LANCET, V339, P959, DOI 10.1016/0140-6736(92)91532-D; DIPAOLO JA, 1989, ONCOGENE, V4, P395; DOWNER CS, 1993, J PATHOL, V171, P183, DOI 10.1002/path.1711710306; DURST M, 1987, ONCOGENE, V1, P251; DURST M, 1989, VIROLOGY, V173, P767, DOI 10.1016/0042-6822(89)90595-3; EDWARDS DR, 1987, EMBO J, V6, P1899, DOI 10.1002/j.1460-2075.1987.tb02449.x; FINNEY RE, 1993, SCIENCE, V260, P1524, DOI 10.1126/science.8502998; FURTH ME, 1987, ONCOGENE, V1, P47; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; HAUSEN HZ, 1988, MOL CARCINOGEN, V1, P147, DOI 10.1002/mc.2940010302; HERTLE MD, 1991, DEVELOPMENT, V112, P193; HERTLE MD, 1992, J CLIN INVEST, V89, P1892, DOI 10.1172/JCI115794; HOTCHIN NA, 1992, J BIOL CHEM, V267, P14852; HOTCHIN NA, 1993, IN PRESS J CELL SCI; Howley P M, 1987, Important Adv Oncol, P55; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JONES J, 1993, J PATHOL, V169, P235, DOI 10.1002/path.1711690210; JONES PH, 1993, CELL, V73, P713, DOI 10.1016/0092-8674(93)90251-K; KAUFMANN R, 1989, J CELL BIOL, V109, P1807, DOI 10.1083/jcb.109.4.1807; KENNEL SJ, 1989, J BIOL CHEM, V264, P15515; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCCANCE DJ, 1988, P NATL ACAD SCI USA, V85, P7169, DOI 10.1073/pnas.85.19.7169; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NICHOLSON LJ, 1991, J CELL SCI, V98, P225; PEI X F, 1991, Carcinogenesis (Oxford), V12, P277, DOI 10.1093/carcin/12.2.277; Pei X F, 1992, Epithelial Cell Biol, V1, P84; PELTONEN J, 1989, J CLIN INVEST, V84, P1916, DOI 10.1172/JCI114379; PIRISI L, 1988, CARCINOGENESIS, V9, P1573, DOI 10.1093/carcin/9.9.1573; PIRISI L, 1987, J VIROL, V61, P1061, DOI 10.1128/JVI.61.4.1061-1066.1987; RALFKIAER E, 1991, BRIT J DERMATOL, V124, P527, DOI 10.1111/j.1365-2133.1991.tb04944.x; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; RHIM JS, 1989, ONCOGENE, V4, P1403; RIDDLE PN, 1990, METHOD MOL BIOL, P415; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SONNENBERG A, 1986, J HISTOCHEM CYTOCHEM, V34, P1037, DOI 10.1177/34.8.2426332; SOSNOWSKI RG, 1993, J CELL BIOL, V121, P113, DOI 10.1083/jcb.121.1.113; SUGIYAMA M, 1993, CARCINOGENESIS, V14, P2171, DOI 10.1093/carcin/14.10.2171; TENCHINI ML, 1993, CELL ADHES COMMUN, V1, P55, DOI 10.3109/15419069309095681; TERRY G, 1993, ARCH VIROL, V128, P123, DOI 10.1007/BF01309793; WATT FM, 1984, J CELL BIOL, V98, P16, DOI 10.1083/jcb.98.1.16; WATT FM, 1993, KERATINOCYTE HDB, P153; WATT FM, 1993, IN PRESS DEV SUPPLEM; WOLF GT, 1990, JNCI-J NATL CANCER I, V82, P1566, DOI 10.1093/jnci/82.19.1566; WOODWORTH CD, 1988, CANCER RES, V48, P4620	52	17	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1994	9	3					943	948						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108139				2022-12-17	WOS:A1994MW55100032
J	SOLLENBERGER, KG; KAO, TL; TAPAROWSKY, EJ				SOLLENBERGER, KG; KAO, TL; TAPAROWSKY, EJ			STRUCTURAL-ANALYSIS OF THE CHICKEN MAX GENE	ONCOGENE			English	Note							DNA-BINDING; C-MYC; RAS COTRANSFORMATION; ENHANCERS; PROTEIN; DOMAINS; FORMS	The recent identification of Max, a nuclear phosphoprotein that dimerizes with members of the Myc protein family, has provided an additional tool to examine the role of the Myc oncoprotein as a sequence-specific DNA binding protein and a potential regulator of gene transcription. Here we report the nucleotide sequence of an avian max gene isolated from a lambda EMBL3 genomic library prepared from size-selected chicken embryo fibroblast DNA. The complete transcription unit encoding chicken Max is contained on a 5.7kbp BglII DNA fragment which expresses an appropriately sized max mRNA of 1.5 kb following transfection of C3H10T1/2 mouse fibroblasts. The coding region of the chicken max gene is organized into five exons and the overall identity between the human and chicken max coding sequences is 85% at the nucleotide level and 96% at the amino acid level. The basic helix - loop - helix/leucine zipper region, the casein kinase II phosphorylation sites and the nuclear localization signal sequence are 100% conserved in all vertebrate Max proteins characterized to date. DNA sequence analysis of the 5' flanking region of the chicken max coding sequence reveals the absence of consensus TATA or CAAT motifs, but the presence of numerous GC-rich sequences that are typical in eukaryotic genes which are expressed constitutively in different tissues and under different growth conditions.	PURDUE UNIV,DEPT BIOL SCI,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus					NCI NIH HHS [CA42835] Funding Source: Medline; NIDDK NIH HHS [DK07532] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R23CA042835, R01CA042835] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007532] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CHURCH GM, 1985, NATURE, V313, P798, DOI 10.1038/313798a0; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P381; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KING MW, 1993, CELL GROWTH DIFFER, V4, P85; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; MAKELA TP, 1992, SCIENCE, V256, P373, DOI 10.1126/science.256.5055.373; MEICHLE A, 1992, BIOCHIM BIOPHYS ACTA, V1114, P129, DOI 10.1016/0304-419X(92)90011-M; MIN SY, 1992, ONCOGENE, V7, P1531; MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PRENDERGAST GC, 1992, GENE DEV, V6, P2429, DOI 10.1101/gad.6.12a.2429; SCHREIBERAGUS N, 1993, MOL CELL BIOL, V13, P2765, DOI 10.1128/MCB.13.5.2765; VAIDYA TB, 1992, GENE, V116, P223, DOI 10.1016/0378-1119(92)90519-U; VASTRIK I, 1993, ONCOGENE, V8, P503	22	17	19	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					661	664						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290277				2022-12-17	WOS:A1994MW24800035
J	TSUCHIYA, H; FUJII, M; TANAKA, Y; TOZAWA, H; SEIKI, M				TSUCHIYA, H; FUJII, M; TANAKA, Y; TOZAWA, H; SEIKI, M			2 DISTINCT REGIONS FORM A FUNCTIONAL ACTIVATION DOMAIN OF THE HTLV-1 TRANSACTIVATOR TAX1	ONCOGENE			English	Note							VIRUS TYPE-I; TRANSCRIPTIONAL ACTIVATION; ADENOVIRUS-E1A PROTEIN; BINDING; EXPRESSION; GENES; PROMOTERS; MECHANISM; SEQUENCES; ENHANCER	Taxi of human T-cell leukemia virus type 1 (HTLV-1) is an enigmatic viral transactivator that regulates expression of the viral gene and also several cellular genes normally controlled by various mitogenic signals. However, previous studies have failed to define the functional domains of Taxi for enhancer specificities and for transcriptional activation (95% of the protein portion was indispensable for the activation function). This complexity has hampered understanding of the molecular basis of Taxi action. In this study, we analysed the activation function of a Taxi fused to the heterologous DNA-binding domain of the yeast transcription factor GAL4 and dissected the domain required for the activation function by using derivatives of a Taxi mutant with an insertion between amino acids (a.a.) 170 and 171. Analysis of the derivatives of the mutant fusion protein having various partial overlaps encompassing the interrupted site suggested that two contiguous stretches, AD-I (2-255 a.a.) and AD-II (227-337 a.a.), should be both intact for the activation function of Taxi and that they form a functional activation domain.	KANAZAWA UNIV,CANC RES INST,DEPT MOLEC VIROL & ONCOL,KANAZAWA,ISHIKAWA 920,JAPAN; KITASATO UNIV,SCH HYG SCI,DEPT IMMUNOL,SAGAMIHARA,KANAGAWA 228,JAPAN	Kanazawa University; Kitasato University			Seiki, Motoharu/K-9443-2015					ALEXANDRE C, 1991, ONCOGENE, V6, P1851; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJII M, 1991, ONCOGENE, V6, P2349; FUJII M, 1991, ONCOGENE, V6, P1023; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; FUJISAWA JI, 1991, J VIROL, V65, P4525, DOI 10.1128/JVI.65.8.4525-4528.1991; GITLIN SD, 1991, J VIROL, V65, P2612, DOI 10.1128/JVI.65.5.2612-2621.1991; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HIRAI H, 1992, ONCOGENE, V7, P1737; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; KATOH I, 1989, EMBO J, V8, P497, DOI 10.1002/j.1460-2075.1989.tb03403.x; KELLY K, 1992, ONCOGENE, V7, P1463; LEE B, 1989, TOHOKU J EXP MED, V157, P1, DOI 10.1620/tjem.157.1; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; PASKALIS H, 1986, P NATL ACAD SCI USA, V83, P6558, DOI 10.1073/pnas.83.17.6558; SEIKI M, 1985, SCIENCE, V228, P1532, DOI 10.1126/science.2990031; SEMMES OJ, 1992, J VIROL, V66, P7183, DOI 10.1128/JVI.66.12.7183-7192.1992; SEMMES OJ, 1992, VIROLOGY, V188, P754, DOI 10.1016/0042-6822(92)90530-3; SHIMOTOHNO K, 1986, P NATL ACAD SCI USA, V83, P8112, DOI 10.1073/pnas.83.21.8112; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; SODROSKI J, 1992, BIOCHIM BIOPHYS ACTA, V1114, P19, DOI 10.1016/0304-419X(92)90003-H; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; YOSHIDA M, 1987, ANNU REV IMMUNOL, V5, P541, DOI 10.1146/annurev.iy.05.040187.002545; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070	34	17	17	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					337	340						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302601				2022-12-17	WOS:A1994MW24700043
J	KODURU, PRK; GOH, JC; PERGOLIZZI, RG; LICHTMAN, SM; BROOME, JD				KODURU, PRK; GOH, JC; PERGOLIZZI, RG; LICHTMAN, SM; BROOME, JD			MOLECULAR CHARACTERIZATION OF A VARIANT PH(1) TRANSLOCATION T(92211) (Q34Q11Q13) IN CHRONIC MYELOGENOUS LEUKEMIA (CML) REVEALS THE TRANSLOCATION OF THE 3'-PART OF BCR GENE TO THE CHROMOSOME BAND 11Q13	ONCOGENE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; CHRONIC MYELOCYTIC-LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; TRANSFERASE-PI-GENE; B-CELL LYMPHOMAS; C-ABL ONCOGENE; PHILADELPHIA-CHROMOSOME; FRAGILE SITES; CLUSTER REGION; PROTO-ONCOGENE	We performed cloning and sequence analysis of translocation junctions at 11q- and 22q- (Ph(1)) chromosomes and the corresponding germline DNAs of a variant Ph(1)-positive CML with t(9;22;11)(q34;q11;q13). Southern blot analysis using probes for different regions of bcr mapped the translocation break near the 5'-side of bcr exon 4. Cloning, Southern blot analysis and restriction map analysis of both bcr fragments showed that the part of bcr 3'- to the translocation break moved to 11q13. Sequence analysis of the translocation junction on the Ph(1) chromosome showed that the translocation break occurred 63 bp upstream of exon 4. Compared to the germline sequence, bcr sequence from the translocated partners showed deletion of seven basepairs at the site of translocation. A probe derived from the 5'-region of the clone isolated from the 11q- chromosome identified clonal rearrangements in the leukemic DNA. Restriction map and sequence analysis showed that this clone consisted of the 3'-half of the glutathione S-transferase Pi (GST-Pi) gene and the 3'-part of bcr. We identified two point mutations in the GST-Pi allele involved in translocation. Northern blot analysis showed that the GST-Pi gene was expressed in the leukemic cells at blast crisis but not at chronic phase; however, no fusion mRNA between GST-Pi and bcr was identified. We did not find any sequence homology between 11q13 DNA and 22q11 DNA around the translocation breakpoints; however, sequences homologous to ALU repeats were identified close to the sites of translocation breaks at 22q11 and 11q13. This study supports our hypothesis that variant Ph(1) translocations may occur as primary cytogenetic changes similar to the classical Ph(1) translocations.	N SHORE UNIV HOSP,CORNELL UNIV MED COLL,DEPT LABS,MANHASSET,NY 11030; N SHORE UNIV HOSP,CORNELL UNIV MED COLL,DEPT RES,MANHASSET,NY 11030; N SHORE UNIV HOSP,CORNELL UNIV MED COLL,DEPT MED,DON MONTI DIV HEMATOL & ONCOL,MANHASSET,NY 11030; CORNELL UNIV,COLL MED,DEPT PATHOL,NEW YORK,NY; CORNELL UNIV,COLL MED,DEPT MED,NEW YORK,NY	Cornell University; Northwell Health; North Shore University Hospital; Cornell University; Northwell Health; North Shore University Hospital; Cornell University; Northwell Health; North Shore University Hospital; Cornell University; Cornell University					NCRR NIH HHS [S07 RR05924] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005924] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ADELAIDE J, 1988, ONCOGENE, V2, P413; BAKSHI A, 1988, P NATL ACAD SCI USA, V84, P2396; BLENNERHASSETT GT, 1988, LEUKEMIA, V2, P648; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; CASEY G, 1986, MOL CELL BIOL, V6, P502, DOI 10.1128/MCB.6.2.502; CHAGANTI RSK, 1987, CYTOGENET CELL GENET, V45, P93, DOI 10.1159/000132436; CHEN SJ, 1989, ONCOGENE, V4, P195; COLES B, 1990, CRIT REV BIOCHEM MOL, V25, P47, DOI 10.3109/10409239009090605; COLLINS SJ, 1987, BLOOD, V69, P893; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DEBRAEKELEER M, 1987, CYTOGENET CELL GENET, V44, P215, DOI 10.1159/000132374; DEKLEIN A, 1986, NUCLEIC ACIDS RES, V14, P7071, DOI 10.1093/nar/14.17.7071; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GAO JZ, 1991, P NATL ACAD SCI USA, V88, P4882, DOI 10.1073/pnas.88.11.4882; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; GROFFEN J, 1987, ADV VIRAL ONCOL, V7, P77; HALUSKA FG, 1987, TRENDS GENET, V3, P11, DOI 10.1016/0168-9525(87)90155-7; HARTL P, 1987, MOL CELL BIOL, V7, P2037, DOI 10.1128/MCB.7.6.2037; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; HOLMES J, 1990, BRIT J CANCER, V62, P209, DOI 10.1038/bjc.1990.262; ISHIHARA T, 1988, CANCER GENET CYTOGEN, V32, P75, DOI 10.1016/0165-4608(88)90314-7; ISLAM MQ, 1989, HUM GENET, V82, P338; JURKA J, 1988, P NATL ACAD SCI USA, V85, P4774; KODURU P, 1988, CYTOGENET CELL GENET, V49, P269, DOI 10.1159/000132675; KODURU P, 1991, HEMATOL PATHOL, V5, P57; KODURU PRK, 1989, ONCOGENE, V4, P929; KORSMEYER SJ, 1992, BLOOD, V80, P879; LAMMIE GA, 1991, ONCOGENE, V6, P439; LEBEAU MM, 1984, NATURE, V308, P607, DOI 10.1038/308607a0; LEBEAU MM, 1986, BLOOD, V67, P849; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MCKEITHAN TW, 1992, P NATL ACAD SCI USA, V89, P4923, DOI 10.1073/pnas.89.11.4923; MCQUAID S, 1989, BRIT J CANCER, V59, P540, DOI 10.1038/bjc.1989.110; MELO JV, 1993, BLOOD, V81, P158; MORROW CS, 1989, GENE, V75, P3, DOI 10.1016/0378-1119(89)90377-6; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; PAPADOPOULOS PC, 1990, GENE CHROMOSOME CANC, V1, P233, DOI 10.1002/gcc.2870010308; PEAR WS, 1988, ONCOGENE, V2, P499; RABBITTS PH, 1988, ONCOGENE, V3, P99; ROSENBERG CL, 1991, ONCOGENE, V6, P449; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; STAM K, 1985, NEW ENGL J MED, V313, P1429, DOI 10.1056/NEJM198512053132301; TSUJIMOTO Y, 1988, ONCOGENE, V2, P347; TSUJIMOTO Y, 1984, SCIENCE, V224, P1403, DOI 10.1126/science.6610211; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; VANDERFELTZ MJM, 1989, NUCLEIC ACIDS RES, V17, P1, DOI 10.1093/nar/17.1.1; WILLIAMS BP, 1988, ONCOGENE, V3, P345; YUNIS JJ, 1987, ONCOGENE, V1, P59	53	17	17	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1993	8	12					3239	3247						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247527				2022-12-17	WOS:A1993MG78200006
J	LANGGUT, W; REISSER, T; KERSTEN, H; NISHIMURA, S				LANGGUT, W; REISSER, T; KERSTEN, H; NISHIMURA, S			MODULATION OF EPIDERMAL GROWTH-FACTOR RECEPTOR ACTIVITY AND RELATED RESPONSES BY THE 7-DEAZAGUANINE DERIVATIVE, QUEUINE	ONCOGENE			English	Article							TRANSFER-RNA; PROTO-ONCOGENES; TYROSINE KINASE; C-FOS; PHOSPHORYLATION; ACTIVATION; PROTEINS; ENZYME; CELLS; BASE	Epidermal growth factor (EGF) induces autophosphorylation of its cognate receptor at tyrosine residues. Here we show that queuine (q), a widely distributed modified guanine analogue occurring free or as a tRNA wobble base, modulates this EGF receptor activity in vitro and in intact cells. Autophosphorylation of the immunopurified receptor from human A431 epidermoid carcinoma cells was enhanced three to fourfold in the presence of physiological concentrations of q. Using a membrane fraction of A431 cells, a twofold increase in autophosphorylation activity in the presence of q was observed, however, only when the receptor was activated by the ligand. In intact A431 cells, q enhanced the initial ligand-induced autophosphorylation of the EGF receptor three to fourfold. However, upon longer treatment of the cells with EGF in the presence of q, significantly less autophosphorylated receptor was detectable compared with stimulation of cells in the absence of q. A similar q-dependent modulation of EGF receptor autophosphorylation was observed also in human cervical carcinoma cells HeLa-S3. Treatment of q-deficient HeLa cells with EGF induced the c-fos gene expression, transiently increased the activity of the anoxic stress protein LDH k, and stimulated proliferation. Treatment of HeLa cells with EGF in the presence of q resulted in a delayed c-fos gene expression and an accelerated increase and decrease of LDH k activity. The stimulatory effect of low doses of EGF on HeLa cell proliferation was completely antagonized in the presence of q. The results suggest that the mitogenic signalling initiated by the EGF receptor is modulated by q.	NATL CANC CTR,RES INST,DIV BIOL,TOKYO 104,JAPAN	National Cancer Center - Japan	LANGGUT, W (corresponding author), UNIV ERLANGEN NURNBERG,FAK MED,INST BIOCHEM,FAHRSTR 17,W-8520 ERLANGEN,GERMANY.							ANDERSON GR, 1981, J BIOL CHEM, V256, P583; BERTICS PJ, 1988, J BIOL CHEM, V263, P3610; BRAVO R, 1985, EMBO J, V4, P1193, DOI 10.1002/j.1460-2075.1985.tb03759.x; DIETZ AA, 1967, ANAL BIOCHEM, V20, P246, DOI 10.1016/0003-2697(67)90030-9; EMMERICH B, 1985, CANCER RES, V45, P4308; FRENCH BT, 1991, P NATL ACAD SCI USA, V88, P370, DOI 10.1073/pnas.88.2.370; FUJITAYAMAGUCHI Y, 1989, BIOCHEM J, V263, P813, DOI 10.1042/bj2630813; GOGH NM, 1988, ANAL BIOCHEM, V173, P93; HELIN K, 1991, J BIOL CHEM, V266, P8363; HUBLER L, 1992, BIOCHEM J, V281, P107, DOI 10.1042/bj2810107; KASAI H, 1975, BIOCHEMISTRY-US, V14, P4198, DOI 10.1021/bi00690a008; KATZE JR, 1982, SCIENCE, V216, P55; KATZE JR, 1979, P NATL ACAD SCI USA, V76, P3271, DOI 10.1073/pnas.76.7.3271; KERSTEN H, 1988, Biofactors, V1, P27; Kersten H., 1990, CHROMATOGRAPHY MODIF, V45, pB69; LANGGUT W, 1990, FEBS LETT, V265, P33, DOI 10.1016/0014-5793(90)80877-L; LANGGUT W, 1993, BIOFACTORS, V4, P117; LANGGUT W, 1990, Biofactors, V2, P245; LANGGUT W, 1989, CHEM BIOL PTERIDINES, P356; MAHR U, 1990, Biofactors, V2, P185; NISHIMURA S, 1983, PROG NUCLEIC ACID RE, V28, P49, DOI 10.1016/S0079-6603(08)60082-3; OKADA N, 1978, P NATL ACAD SCI USA, V75, P4247, DOI 10.1073/pnas.75.9.4247; OKADA N, 1979, EUR J BIOCHEM, V254, P3062; SZABO L, 1988, BIOFACTORS, V1, P242; TODDERUD G, 1989, Biofactors, V2, P11; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDEVIJVER MJ, 1991, J BIOL CHEM, V266, P7503; WHITAKER JR, 1980, ANAL BIOCHEM, V109, P156, DOI 10.1016/0003-2697(80)90024-X; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	29	17	17	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					3141	3147						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414516				2022-12-17	WOS:A1993MC09300031
J	XU, L; WALLEN, R; PATEL, V; DEPINHO, RA				XU, L; WALLEN, R; PATEL, V; DEPINHO, RA			ROLE OF 1ST EXON-INTRON SEQUENCES IN THE REGULATION OF MYC FAMILY ONCOGENIC POTENCY	ONCOGENE			English	Article							BURKITT-LYMPHOMA CELLS; C-MYC; N-MYC; MESSENGER-RNA; EMBRYO FIBROBLASTS; GENE FAMILY; LUNG-CANCER; EXPRESSION; TRANSCRIPTION; ELONGATION	cis-Acting sequence elements that participate in the regulation of myc family gene expression in normal tissues and that serve as potential targets for the deregulation of expression in tumors have been localized to the first exon/intron region of all three myc family genes. To test directly the importance of these cis elements in the tumor-associated deregulation of myc family gene expression, we have compared the oncogenic activities of complete (exons 1, 2 and 3) and truncated (exons 2 and 3 only) c-, N- and L-myc expression constructs in the rat embryo fibroblast (REF) cooperation assay. Removal of the first exon/intron region from each construct was associated with a dramatic increase in oncogenic potency by several criteria. Analysis of N-myc/ras-transformed cell lines demonstrated (i) fewer transfected N-myc gene copies and an overall higher level of steady-state N-myc mRNA with the truncated N-myc expression construct and (ii) the presence of a significant block to transcriptional elongation in the first exon of the complete N-myc expression construct. These results indicate that the first exon of N-myc plays an important role in governing oncogenic potency, possibly through transcriptional control mechanisms.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MICROBIOL & IMMUNOL, 1300 MORRIS PK AVE, BRONX, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine				DePinho, Ronald/0000-0002-5625-577X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028317] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY009300] Funding Source: NIH RePORTER; NCI NIH HHS [2P30CA13330-20] Funding Source: Medline; NEI NIH HHS [R01 EY09300-01] Funding Source: Medline; NICHD NIH HHS [R01 HD28317-01] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; AUSUBEL FM, 1991, CURR PROTOCOLS MOL B, V1; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BERNSTEIN PL, 1992, GENE DEV, V6, P642, DOI 10.1101/gad.6.4.642; BIRRER MJ, 1988, MOL CELL BIOL, V8, P2668, DOI 10.1128/MCB.8.6.2668; BONNIEU A, 1990, ONCOGENE, V5, P1585; Cleveland J L, 1988, Oncogene Res, V3, P357; DEPINHO R, 1984, MOL CELL BIOL, V4, P2905, DOI 10.1128/MCB.4.12.2905; DEPINHO RA, 1986, P NATL ACAD SCI USA, V83, P1827, DOI 10.1073/pnas.83.6.1827; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; DEPINHO RA, 1987, GENE DEV, V1, P1311, DOI 10.1101/gad.1.10.1311; EICK D, 1987, ONCOGENE, V2, P61; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; EICK D, 1989, EMBO J, V8, P1965, DOI 10.1002/j.1460-2075.1989.tb03602.x; EICK D, 1985, EMBO J, V4, P3717, DOI 10.1002/j.1460-2075.1985.tb04140.x; FASANO O, 1983, Journal of Molecular and Applied Genetics, V2, P173; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; KRYSTAL G, 1988, MOL CELL BIOL, V8, P3373, DOI 10.1128/MCB.8.8.3373; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEGOUY E, 1987, EMBO J, V6, P3359, DOI 10.1002/j.1460-2075.1987.tb02657.x; LIN X, 1991, MOL CELL BIOL, V11, P6007, DOI 10.1128/MCB.11.12.6007; Maniatis T, 1989, MOL CLONING; MARCU KB, 1987, BIOESSAYS, V6, P28, DOI 10.1002/bies.950060108; MORROW MA, 1992, GENE DEV, V6, P61, DOI 10.1101/gad.6.1.61; MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480; NAU MM, 1984, CURR TOP MICROBIOL, V113, P172; NILSEN TW, 1984, MOL CELL BIOL, V4, P2235, DOI 10.1128/MCB.4.10.2235; PARKIN N, 1988, MOL CELL BIOL, V8, P2875, DOI 10.1128/MCB.8.7.2875; SCHWAB M, 1985, NATURE, V316, P160, DOI 10.1038/316160a0; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SEJERSEN T, 1987, EXP CELL RES, V172, P304, DOI 10.1016/0014-4827(87)90389-2; SHOWE LC, 1987, ANNU REV IMMUNOL, V5, P253, DOI 10.1146/annurev.iy.05.040187.001345; SPENCER CA, 1990, ONCOGENE, V5, P777; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; TORRES R, 1992, Current Opinion in Cell Biology, V4, P468, DOI 10.1016/0955-0674(92)90013-3; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; WISDOM R, 1990, J BIOL CHEM, V265, P19015; YANCOPOULOS GD, 1985, P NATL ACAD SCI USA, V82, P5455, DOI 10.1073/pnas.82.16.5455	39	17	17	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1993	8	9					2547	2553						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8361763				2022-12-17	WOS:A1993LT36800027
J	LUCIBELLO, FC; BRUSSELBACH, S; SEWING, A; MULLER, R				LUCIBELLO, FC; BRUSSELBACH, S; SEWING, A; MULLER, R			SUPPRESSION OF THE GROWTH FACTOR-MEDIATED INDUCTION OF C-FOS AND DOWN-MODULATION OF AP-1-BINDING ACTIVITY ARE NOT REQUIRED FOR CELLULAR SENESCENCE	ONCOGENE			English	Note							HUMAN-FIBROBLASTS; PROTO-ONCOGENE; GENE; JUN; CELLS; PHOSPHORYLATE; FAILURE; PRODUCT; RNA	It has been suggested that the impaired response of the c-fos gene to serum growth factors and the concomitant loss of AP-1 activity may be a crucial step in the process of cellular senescence. In the present study, we provide evidence arguing against such a conclusion. Data obtained in five independent experiments showed that both c-fos RNA and protein expression were similar in 'young' and in senescent serum-stimulated WI-38 cells, suggesting that the previously reported suppression of c-fos induction is not an obligatory event in the process of cellular senescence. Likewise, expression of fra-1, c-jun and junB continued to be high in serum-stimulated senescent cells, while induction of fosB was reduced approximately fivefold. Among all genes tested fosB thus seems to be the most suitable marker for the detection of senescent cells. Stimulated senescent cells showed only a approximately twofold reduction of AP-1-binding activity, and senescent cells continuously exposed to serum exhibited normal AP-1-binding activity. These observations support the conclusion that a down-modulation of AP-1 is not crucial for human fibroblasts to enter the senescent state.	UNIV MARBURG,INST MOLEK BIOL & TUMORFORSCH,EMIL MANNKOPFF STR 2,W-3550 MARBURG,GERMANY	Philipps University Marburg			Müller, Rolf/L-4997-2016	Müller, Rolf/0000-0003-3339-4248				BELL E, 1978, SCIENCE, V202, P1158, DOI 10.1126/science.725592; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; FUTREAL PA, 1991, ONCOGENE, V6, P1109; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4784; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; McCormick A, 1991, CURR OPIN CELL BIOL, V3, P230, DOI 10.1016/0955-0674(91)90144-N; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; PAULSSON Y, 1986, EMBO J, V5, P2157, DOI 10.1002/j.1460-2075.1986.tb04479.x; RIABOWOL K, 1992, P NATL ACAD SCI USA, V89, P157, DOI 10.1073/pnas.89.1.157; RIABOWOL KT, 1988, MOL CELL BIOL, V8, P1670, DOI 10.1128/MCB.8.4.1670; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SESHADRI T, 1990, SCIENCE, V247, P205, DOI 10.1126/science.2104680; STEIN GH, 1990, SCIENCE, V249, P666, DOI 10.1126/science.2166342; STEIN GH, 1991, P NATL ACAD SCI USA, V88, P11012, DOI 10.1073/pnas.88.24.11012; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VERRIER B, 1986, EMBO J, V5, P913, DOI 10.1002/j.1460-2075.1986.tb04303.x; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	24	17	17	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1667	1672						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	7684831				2022-12-17	WOS:A1993LE06400031
J	PICKSLEY, SM; MEEK, DW; LANE, DP				PICKSLEY, SM; MEEK, DW; LANE, DP			THE CONFORMATIONAL CHANGE OF A MURINE TEMPERATURE-SENSITIVE P53 PROTEIN IS INDEPENDENT OF A CHANGE IN PHOSPHORYLATION STATUS	ONCOGENE			English	Note							LARGE T-ANTIGEN; MONOCLONAL-ANTIBODY; SIMIAN VIRUS-40; CELL-CYCLE; ACTIVATING MUTATIONS; GENE-PRODUCT; MUTANT P53; 3T3 CELLS; TRANSFORMATION; ONCOGENE	Wild-type and mutant p53 proteins exhibit opposing activities in respectively suppressing and promoting tumour development. In a rat embryo fibroblast cell line transformed with a murine temperature-sensitive p53 gene, p53 functions as a oncogene at 37-degrees-C and as a tumour suppressor at 32-degrees-C [Michalovitz, D., Halevy, O. & Oren, M. (1990). Cell, 62, 671-6801. We have used this cell line to investigate whether this temperature-dependent switching of function involves changes in the phosphorylation of p53 protein. Monoclonal antibodies PAb246 and PAb240 were used to immunoprecipitate metabolically P-32-labelled p53 protein in the `wild-type' or mutant conformation from cells grown at 32-degrees-C or 37-degrees-C. Tryptic phosphopeptide maps were prepared from the isolated `wild-type' and mutant p53 proteins. At 32-degrees-C and 37-degrees-C phosphopeptide maps of the `wild-type' and mutant protein were identical. This demonstrates that the temperature-dependent conformation change, and associated functional change, in the p53 protein does not involve a change in the state of phosphorylation.	UNIV DUNDEE,CANC RES CAMPAIGN,CELL TRANSFORMAT GRP,DUNDEE DD1 4HN,SCOTLAND; UNIV DUNDEE,MRC,PHOSPHORYLAT GRP,DUNDEE DD1 4HN,SCOTLAND	University of Dundee; University of Dundee			Lane, David P/C-4920-2008	Lane, David/0000-0003-0551-3545				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BALL RK, 1984, EMBO J, V3, P1485, DOI 10.1002/j.1460-2075.1984.tb02000.x; BARTEK J, 1990, ONCOGENE, V5, P893; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; MEEK DW, 1988, MOL CELL BIOL, V8, P461, DOI 10.1128/MCB.8.1.461; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; MILNER J, 1984, NATURE, V310, P143, DOI 10.1038/310143a0; MILNER J, 1987, ONCOGENE, V1, P453; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PATCHINSKY T, 1990, ONCOGENE, V5, P1071; SAMAD A, 1986, P NATL ACAD SCI USA, V83, P897, DOI 10.1073/pnas.83.4.897; SCHEIDTMANN KH, 1990, J VIROL, V64, P672, DOI 10.1128/JVI.64.2.672-679.1990; SOUSSI T, 1987, ONCOGENE, V1, P71; STURZBECHER HW, 1987, VIROLOGY, V160, P445; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	25	17	17	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1992	7	8					1649	1651						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1630825				2022-12-17	WOS:A1992JE81300023
J	BRUSTLE, O; AGUZZI, A; TALARICO, D; BASILICO, C; KLEIHUES, P; WIESTLER, OD				BRUSTLE, O; AGUZZI, A; TALARICO, D; BASILICO, C; KLEIHUES, P; WIESTLER, OD			ANGIOGENIC ACTIVITY OF THE K-FGF/HST ONCOGENE IN NEURAL TRANSPLANTS	ONCOGENE			English	Article							FIBROBLAST GROWTH-FACTOR; FACTOR GENE FAMILY; NIH 3T3 CELLS; ENDOTHELIAL-CELLS; TRANSFORMING GENE; FACTOR RECEPTOR; MESODERM INDUCTION; STOMACH CANCERS; DOWN-REGULATION; MESSENGER-RNA	Using retrovirus-mediated gene transfer into neural transplants, we have expressed the human K-fgf/hst oncogene in the central nervous system. Single-cell suspensions of fetal rat brains were removed at embryonic days 13 and 14, exposed to a retroviral vector encoding the K-fgf oncogene and stereotaxically implanted into the caudate putamen of syngenic adult Fisher rats. Recipient animals were sacrificed at intervals of 6-16 months without evidence of neurological impairment. Mock-infected grafts showed the characteristic histopathological appearance of organotypically differentiated neural transplants. In contrast, grafts exposed to the K-fgf gene exhibited abundant capillary proliferation and capillary angiomas. By in situ hybridization analysis and immunohistochemistry, expression of K-fgf was detected in neural cells adjacent to vascular proliferations. Neurons and glia with abundant K-fgf transcripts were morphologically unaffected. In order to examine the transforming potential of the K-fgf gene in the nervous system, we combined retrovirus-mediated transfer of the K-fgf oncogene with a single transplacental exposure of the donor animals to the neurotropic carcinogen N-ethyl-N-nitrosourea (NEU). However, this combination of transforming agents did not result in tumor formation in the grafts. These results provide evidence for a powerful angiogenic effect of K-fgf on the developing brain in vivo.	UNIV ZURICH, DEPT PATHOL, NEUROPATHOL LAB, CH-8091 ZURICH, SWITZERLAND; RES INST MOLEC PATHOL, A-1030 VIENNA, AUSTRIA; NYU HOSP, DEPT MICROBIOL, NEW YORK, NY 10016 USA	University of Zurich; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); New York University			Talarico, Daniela/AAN-5608-2020; Aguzzi, Adriano/A-3351-2008	Talarico, Daniela/0000-0001-5814-9244; Aguzzi, Adriano/0000-0002-0344-6708				ADELAIDE J, 1988, ONCOGENE, V2, P413; AGUZZI A, 1991, ONCOGENE, V6, P113; AGUZZI A, 1990, New Biologist, V2, P533; BAIRD A, 1989, BRIT MED BULL, V45, P438, DOI 10.1093/oxfordjournals.bmb.a072333; BENHARROCH D, 1990, ISRAEL J MED SCI, V26, P212; BOVI PD, 1987, P NATL ACAD SCI USA, V84, P5660, DOI 10.1073/pnas.84.16.5660; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BURGER PC, 1988, CANCER RES, V48, P2871; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CONNOLLY DT, 1987, BIOCHEM BIOPH RES CO, V144, P705, DOI 10.1016/S0006-291X(87)80022-0; DELLIBOVI P, 1988, MOL CELL BIOL, V8, P2933, DOI 10.1128/MCB.8.7.2933; DICKSON C, 1987, NATURE, V326, P833, DOI 10.1038/326833a0; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; DRUCKREY H, 1966, NATURE, V210, P1378, DOI 10.1038/2101378a0; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1987, NATURE, V329, P671, DOI 10.1038/329671a0; FRIESEL R, 1991, MOL CELL BIOL, V11, P2481, DOI 10.1128/MCB.11.5.2481; GOSPODAROWICZ D, 1974, P NATL ACAD SCI USA, V71, P2295, DOI 10.1073/pnas.71.6.2295; Hannan RL, 1988, GROWTH FACTORS, V1, P7, DOI 10.3109/08977198809000242; HAYEK A, 1987, BIOCHEM BIOPH RES CO, V147, P876, DOI 10.1016/0006-291X(87)91011-4; HEBERT JM, 1990, DEV BIOL, V138, P454, DOI 10.1016/0012-1606(90)90211-Z; HERBERT JM, 1988, INT J TISSUE REACT, V10, P133; HOLLAND PWH, 1987, J CELL BIOL, V105, P473, DOI 10.1083/jcb.105.1.473; HUEBNER K, 1988, ONCOGENE RES, V3, P263; KLEIHUES P, 1990, TOXICOL PATHOL, V18, P193, DOI 10.1177/019262339001800125; KLEIHUES P, 1989, IARC SCI PUBLIC, V96, P121; KNIGHTON DR, 1990, J TRAUMA, V30, pS134; KODA T, 1987, JPN J CANCER RES, V78, P325; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; LAFAGE M, 1990, GENE CHROMOSOME CANC, V2, P171, DOI 10.1002/gcc.2870020302; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MARICS I, 1989, ONCOGENE, V4, P335; MILLER WH, 1990, ONCOGENE, V5, P511; MIYAGAWA K, 1988, ONCOGENE, V3, P383; MOSCATELLI D, 1989, J CELL BIOL, V109, P2519, DOI 10.1083/jcb.109.5.2519; NAKAGAMA H, 1987, JPN J CANCER RES, V78, P651; NEUFELD G, 1988, J CELL PHYSIOL, V136, P537, DOI 10.1002/jcp.1041360321; NEUFELD G, 1987, J CELL PHYSIOL, V131, P131, DOI 10.1002/jcp.1041310119; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PATERNO GD, 1989, DEVELOPMENT, V106, P79; REID HH, 1990, P NATL ACAD SCI USA, V87, P1596, DOI 10.1073/pnas.87.4.1596; SAFRAN A, 1990, ONCOGENE, V5, P635; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; SATO Y, 1988, J CELL BIOL, V107, P1199, DOI 10.1083/jcb.107.3.1199; SCHWEIGERER L, 1987, NATURE, V325, P257, DOI 10.1038/325257a0; Singer B., 1983, MOL BIOL MUTAGENS CA; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; SMITH JC, 1989, DEVELOPMENT, V105, P665; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; TALARICO D, 1991, MOL CELL BIOL, V11, P1138, DOI 10.1128/MCB.11.2.1138; THEILLET C, 1989, ONCOGENE, V4, P915; THOMAS KA, 1980, J BIOL CHEM, V255, P5517; TIESMAN J, 1989, IN VITRO CELL DEV B, V25, P1193; TOGARI A, 1985, J NEUROSCI, V5, P307; TSUDA T, 1989, CANCER RES, V49, P5505; TSUTSUMI M, 1988, JPN J CANCER RES, V79, P428, DOI 10.1111/j.1349-7006.1988.tb01609.x; VELCICH A, 1989, ONCOGENE RES, V5, P31; WALICKE P, 1986, P NATL ACAD SCI USA, V83, P3012, DOI 10.1073/pnas.83.9.3012; WIESTLER OD, 1989, IARC SCI PUBL, V96, P267; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487; ZHOU DJ, 1988, ONCOGENE, V2, P279	66	17	18	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1992	7	6					1177	1183						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU642	1375717				2022-12-17	WOS:A1992HU64200015
J	GILLADOGA, AD; EDELHOFF, S; BLACKWOOD, EM; EISENMAN, RN; DISTECHE, CM				GILLADOGA, AD; EDELHOFF, S; BLACKWOOD, EM; EISENMAN, RN; DISTECHE, CM			MAPPING OF MAX TO HUMAN CHROMOSOME-14 AND MOUSE CHROMOSOME-12 BY INSITU HYBRIDIZATION	ONCOGENE			English	Note							GENE; ABNORMALITIES; LOCALIZATION	The protein encoded by the MAX gene is a member of the class of basic region-helix-loop-helix-zipper proteins and has been demonstrated to associate with N-, L-, and c-Myc proteins both in vitro and in vivo. Heterodimers formed between c-Myc and Max proteins have been shown to possess sequence-specific DNA-binding activity. Here we report the mapping of the MAX gene to a single region on human chromosome 14 (bands q22-q24) and to mouse chromosome 12 (region D). Chromosome abnormalities linked to several neoplasms have been previously associated with this region on human chromosome 14. The mapping results also confirm a region of homology between human chromosome 14q22-24 and mouse chromosome 12 region D.	FRED HUTCHINSON CANC RES CTR,DIV BASIC SCI,1124 COLUMBIA ST,SEATTLE,WA 98104; UNIV WASHINGTON,SCH MED,DEPT PATHOL,SEATTLE,WA 98195	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle					NATIONAL CANCER INSTITUTE [R01CA057138, T32CA009437] Funding Source: NIH RePORTER; NCI NIH HHS [T32CA09437, R01CA57138] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERBERICH SJ, IN PRESS ONCOGENE; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BLACKWOOD EM, 1992, IN PRESS CURR OPIN G; BLOOMFIELD CD, 1983, CANCER RES, V43, P2975; COLE MD, 1991, CELL, V65, P715, DOI 10.1016/0092-8674(91)90377-B; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; EISEMAN RN, ONCOGENES MOL ORIGIN, P175; GAHRTON G, 1980, BLOOD, V56, P640; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; MAGRATH I, 1990, ADV CANCER RES, V55, P137; MARTH JD, 1986, P NATL ACAD SCI USA, V83, P7400, DOI 10.1073/pnas.83.19.7400; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; TEDDER TF, 1988, J IMMUNOL, V141, P4388; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x; 1990, CYTOGENET CELL GENET, V55, P1	16	17	17	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1992	7	6					1249	1251						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU642	1594250				2022-12-17	WOS:A1992HU64200024
J	WATSON, DK; MAVROTHALASSITIS, GJ; JORCYK, CL; SMYTH, FE; PAPAS, TS				WATSON, DK; MAVROTHALASSITIS, GJ; JORCYK, CL; SMYTH, FE; PAPAS, TS			MOLECULAR-ORGANIZATION AND DIFFERENTIAL POLYADENYLATION SITES OF THE HUMAN ETS2 GENE	ONCOGENE			English	Article									PROGRAM RESOURCES INC,NUCLEIC ACID & PROT SYNTH LAB,FREDERICK,MD 21701		WATSON, DK (corresponding author), NCI,MOLEC ONCOL LAB,FREDERICK,MD 21701, USA.							BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BERGET SM, 1984, NATURE, V309, P179, DOI 10.1038/309179a0; BHAT NK, 1989, J IMMUNOL, V142, P672; BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; BISHOP JM, 1983, ANNU REV BIOCHEM, V52, P301, DOI 10.1146/annurev.bi.52.070183.001505; BOND BJ, 1986, MOL CELL BIOL, V6, P2080, DOI 10.1128/MCB.6.6.2080; CAPETANAKI YG, 1983, CELL, V35, P411, DOI 10.1016/0092-8674(83)90174-5; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHISHOLM D, 1989, BIOTECHNIQUES, V7, P21; FUJIWARA S, 1988, ONCOGENE, V2, P99; FUJIWARA S, 1990, MOL CELL BIOL, V10, P1249, DOI 10.1128/MCB.10.3.1249; FUJIWARA S, 1988, MOL CELL BIOL, V8, P4700, DOI 10.1128/MCB.8.11.4700; KAUFMAN RJ, 1983, MOL CELL BIOL, V3, P1598, DOI 10.1128/MCB.3.9.1598; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; MANIATIS T, 1975, P NATL ACAD SCI USA, V72, P1184, DOI 10.1073/pnas.72.3.1184; Maniatis T., 1982, MOL CLONING; MAVROTHALASSITIS GJ, 1990, P NATL ACAD SCI USA, V87, P1047, DOI 10.1073/pnas.87.3.1047; Maxam A M, 1980, Methods Enzymol, V65, P499; MCLAUCHLAN J, 1985, NUCLEIC ACIDS RES, V13, P1347, DOI 10.1093/nar/13.4.1347; NUNN M, 1984, VIROLOGY, V139, P330, DOI 10.1016/0042-6822(84)90378-7; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; ROBERTSON DL, 1979, J VIROL, V30, P576, DOI 10.1128/JVI.30.2.576-589.1979; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SETH A, 1989, P NATL ACAD SCI USA, V86, P7833, DOI 10.1073/pnas.86.20.7833; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; URANO Y, 1986, J BIOL CHEM, V261, P3244; WATSON DK, 1988, VIROLOGY, V164, P99, DOI 10.1016/0042-6822(88)90624-1; WATSON DK, 1983, P NATL ACAD SCI-BIOL, V80, P2146, DOI 10.1073/pnas.80.8.2146; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WATSON DK, 1985, P NATL ACAD SCI USA, V82, P7294, DOI 10.1073/pnas.82.21.7294; WICKENS M, 1984, SCIENCE, V226, P1045, DOI 10.1126/science.6208611	34	17	18	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1990	5	10					1521	1527						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK502	2250910				2022-12-17	WOS:A1990EK50200011
J	PETERS, DJ; MCGREW, BR; PERRON, DC; LIPTAK, LM; LAUDANO, AP				PETERS, DJ; MCGREW, BR; PERRON, DC; LIPTAK, LM; LAUDANO, AP			INVIVO PHOSPHORYLATION AND MEMBRANE ASSOCIATION OF THE FYN PROTOONCOGENE PRODUCT IN IM-9 HUMAN LYMPHOBLASTS	ONCOGENE			English	Article									UNIV NEW HAMPSHIRE,DEPT BIOCHEM,DURHAM,NH 03824	University System Of New Hampshire; University of New Hampshire								AMES GFL, 1974, J BIOL CHEM, V249, P634; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; BOLEN JB, 1984, CELL, V38, P767, DOI 10.1016/0092-8674(84)90272-1; CARTWRIGHT CA, 1985, MOL CELL BIOL, V5, P2647, DOI 10.1128/MCB.5.10.2647; CARTWRIGHT CA, 1986, MOL CELL BIOL, V6, P1562, DOI 10.1128/MCB.6.5.1562; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CHENG SH, 1988, MOL CELL BIOL, V8, P1736, DOI 10.1128/MCB.8.4.1736; CHENG SH, 1988, EMBO J, V7, P3845, DOI 10.1002/j.1460-2075.1988.tb03270.x; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; COOPER JA, 1988, PEPTIDES PROTEIN PHO; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; COURTNEIDGE SA, 1984, EMBO J, V3, P585, DOI 10.1002/j.1460-2075.1984.tb01852.x; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; GOULD KL, 1985, CELL, V42, P849, DOI 10.1016/0092-8674(85)90281-8; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; HORAK ID, 1989, J VIROL, V63, P2343, DOI 10.1128/JVI.63.5.2343-2347.1989; IBA H, 1985, MOL CELL BIOL, V5, P1058, DOI 10.1128/MCB.5.5.1058; INOUE K, 1987, ONCOGENE, V1, P301; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KARESS RE, 1981, CELL, V24, P155, DOI 10.1016/0092-8674(81)90511-0; KATAGIRI T, 1989, MOL CELL BIOL, V9, P4914, DOI 10.1128/MCB.9.11.4914; KAWAKAMI T, 1986, MOL CELL BIOL, V6, P4195, DOI 10.1128/MCB.6.12.4195; KAWAKAMI T, 1988, P NATL ACAD SCI USA, V85, P3870, DOI 10.1073/pnas.85.11.3870; KAWAKAMI Y, 1989, ONCOGENE, V4, P389; KITAGAWA T, 1976, J BIOCHEM-TOKYO, V79, P233, DOI 10.1093/oxfordjournals.jbchem.a131053; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KORNBLUTH S, 1987, NATURE, V325, P171, DOI 10.1038/325171a0; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; LAUDANO AP, 1986, P NATL ACAD SCI USA, V83, P892, DOI 10.1073/pnas.83.4.892; LINDER ME, 1988, J VIROL, V62, P2665, DOI 10.1128/JVI.62.8.2665-2673.1988; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LIU FT, 1979, BIOCHEMISTRY-US, V18, P690, DOI 10.1021/bi00571a022; MACAULEY A, 1988, MOL CELL BIOL, V8, P3560, DOI 10.1128/MCB.8.8.3560; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; OSHIMA RG, 1981, J BIOL CHEM, V256, P8124; PANTAZIS P, 1981, J BIOL CHEM, V256, P4669; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; RESH MD, 1985, J CELL BIOL, V100, P409, DOI 10.1083/jcb.100.2.409; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; SEMBA K, 1986, P NATL ACAD SCI USA, V83, P5459, DOI 10.1073/pnas.83.15.5459; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; STEWARTJM, 1984, SOLID PHASE PEPTIDE; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; YONEMOTO W, 1985, P NATL ACAD SCI USA, V82, P4568, DOI 10.1073/pnas.82.14.4568	49	17	22	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1990	5	9					1313	1319						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EC241	1699196				2022-12-17	WOS:A1990EC24100006
J	HENRARD, DR; THORNLEY, AT; BROWN, ML; RHEINWALD, JG				HENRARD, DR; THORNLEY, AT; BROWN, ML; RHEINWALD, JG			SPECIFIC EFFECTS OF RAS ONCOGENE EXPRESSION ON THE GROWTH AND HISTOGENESIS OF HUMAN EPIDERMAL-KERATINOCYTES	ONCOGENE			English	Article									HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CELL GROWTH & REGULAT,44 BINNEY ST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT CELLULAR & MOLEC PHYSIOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School								ALLENHOFFMANN BL, 1984, P NATL ACAD SCI-BIOL, V81, P7802, DOI 10.1073/pnas.81.24.7802; BADER BL, 1986, EMBO J, V5, P1865, DOI 10.1002/j.1460-2075.1986.tb04438.x; BANKSSCHLEGEL SP, 1982, J CELL BIOL, V93, P551, DOI 10.1083/jcb.93.3.551; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARRANDON Y, 1987, CELL, V50, P1131, DOI 10.1016/0092-8674(87)90179-6; BARRANDON Y, 1988, J INVEST DERMATOL, V91, P415; BARTEK J, 1986, HISTOCHEM J, V18, P565, DOI 10.1007/BF01675198; BOSCH FX, 1988, J CELL BIOL, V106, P1635, DOI 10.1083/jcb.106.5.1635; BOUKAMP P, 1985, CANCER RES, V45, P5582; Boyce S.T., 1983, J INVEST DERMATOL S, V81, P33; BROWN K, 1986, CELL, V46, P447, DOI 10.1016/0092-8674(86)90665-3; CARTER RL, 1984, PRECANCEROUS STATES; COMPERE SJ, 1989, MOL CELL BIOL, V9, P6, DOI 10.1128/MCB.9.1.6; CONNELL ND, 1983, CELL, V34, P245, DOI 10.1016/0092-8674(83)90155-1; COROMINAS M, 1989, P NATL ACAD SCI USA, V86, P6372, DOI 10.1073/pnas.86.16.6372; DALE BA, 1985, J CELL BIOL, V101, P1257, DOI 10.1083/jcb.101.4.1257; DALE BA, 1979, J INVEST DERMATOL, V72, P257, DOI 10.1111/1523-1747.ep12531715; DELLIBOVI P, 1988, MOL CELL BIOL, V8, P2933, DOI 10.1128/MCB.8.7.2933; Dixon I S, 1984, Mol Biol Med, V2, P37; ECKERT RL, 1988, P NATL ACAD SCI USA, V85, P1114, DOI 10.1073/pnas.85.4.1114; FALCO JP, 1988, ONCOGENE, V2, P573; FALLER DV, 1988, J CELL PHYSIOL, V134, P47, DOI 10.1002/jcp.1041340106; FEIG LA, 1987, MOL ENDOCRINOL, V1, P127, DOI 10.1210/mend-1-2-127; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; KAPLAN PL, 1987, J VIROL, V61, P1731, DOI 10.1128/JVI.61.5.1731-1734.1987; KARSTEN U, 1985, EUR J CANCER CLIN ON, V21, P733, DOI 10.1016/0277-5379(85)90271-8; LINDBERG K, 1989, AM J PATHOL, V134, P89; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; MOLL R, 1982, DIFFERENTIATION, V23, P170, DOI 10.1111/j.1432-0436.1982.tb01280.x; MORGAN JR, 1987, SCIENCE, V237, P1476; MORGAN PR, 1987, EPITHELIA, V1, P31; NEUFELD G, 1987, J CELL PHYSIOL, V131, P131, DOI 10.1002/jcp.1041310119; PARKINSON EK, 1985, BRIT J CANCER, V52, P479, DOI 10.1038/bjc.1985.219; PEEHL DM, 1980, IN VITRO CELL DEV B, V16, P526; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; RHEINWALD JG, 1977, NATURE, V265, P421, DOI 10.1038/265421a0; RHEINWALD JG, 1980, CELL, V22, P629, DOI 10.1016/0092-8674(80)90373-6; RHEINWALD JG, 1981, CANCER RES, V41, P1657; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; ROLLINS BJ, 1989, J CELL PHYSIOL, V139, P455, DOI 10.1002/jcp.1041390302; ROOP DR, 1986, NATURE, V323, P822, DOI 10.1038/323822a0; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; RYLE CM, 1989, DIFFERENTIATION, V40, P42, DOI 10.1111/j.1432-0436.1989.tb00812.x; SAGER R, 1983, P NATL ACAD SCI-BIOL, V80, P7601, DOI 10.1073/pnas.80.24.7601; SATO Y, 1988, J CELL BIOL, V107, P1199, DOI 10.1083/jcb.107.3.1199; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; TUBO RA, 1987, ONCOGENE RES, V1, P407; WAGNER JA, 1986, J CELL BIOL, V103, P1363, DOI 10.1083/jcb.103.4.1363; WEISSMAN BE, 1983, CELL, V32, P599, DOI 10.1016/0092-8674(83)90479-8; WORST PKM, 1974, JNCI-J NATL CANCER I, V53, P1061, DOI 10.1093/jnci/53.4.1061; YOAKUM GH, 1985, SCIENCE, V227, P1174, DOI 10.1126/science.3975607; YUSPA SH, 1985, NATURE, V314, P459, DOI 10.1038/314459a0; ZHAN X, 1987, ONCOGENE, V1, P369; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487	56	17	17	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1990	5	4					475	481						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DB853	2183155				2022-12-17	WOS:A1990DB85300004
J	DUDEK, H; REDDY, EP				DUDEK, H; REDDY, EP			MURINE MYELOID LEUKEMIAS WITH ABERRANT MYB LOCI SHOW HETEROGENEOUS EXPRESSION OF NOVEL MYB PROTEINS	ONCOGENE			English	Article											DUDEK, H (corresponding author), WISTAR INST,3601 SPRUCE ST,PHILADELPHIA,PA 19104, USA.		Reddy, E. Premkumar/F-6233-2011		NATIONAL CANCER INSTITUTE [R01CA044463] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007229] Funding Source: NIH RePORTER; NCI NIH HHS [1R01 CA 44463] Funding Source: Medline; NIGMS NIH HHS [5T32 GM 07229] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; BADING H, 1987, ONCOGENE, V1, P395; BENDER TP, 1986, P NATL ACAD SCI USA, V83, P3204, DOI 10.1073/pnas.83.10.3204; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BOYLE WJ, 1983, P NATL ACAD SCI-BIOL, V80, P2834, DOI 10.1073/pnas.80.10.2834; BOYLE WJ, 1986, P NATL ACAD SCI USA, V83, P4685, DOI 10.1073/pnas.83.13.4685; CHALLBERG MD, 1979, P NATL ACAD SCI USA, V76, P655, DOI 10.1073/pnas.76.2.655; DUDEK H, 1989, ONCOGENE, V4, P1061; DUPREY SP, 1985, P NATL ACAD SCI USA, V82, P6937, DOI 10.1073/pnas.82.20.6937; GONDA TJ, 1989, EMBO J, V8, P1777, DOI 10.1002/j.1460-2075.1989.tb03571.x; HOLLENBERG SM, 1987, CELL, V49, P39, DOI 10.1016/0092-8674(87)90753-7; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KLEMPNAUER KH, 1986, EMBO J, V5, P1903, DOI 10.1002/j.1460-2075.1986.tb04443.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVU S, 1986, NUCLEIC ACIDS RES, V14, P5309, DOI 10.1093/nar/14.13.5309; MOELLING K, 1985, CELL, V40, P983, DOI 10.1016/0092-8674(85)90358-7; MOSCOVICI MG, 1980, IN VIVO IN VITRO ERY, P503; MUSHINSKI JF, 1983, SCIENCE, V220, P795, DOI 10.1126/science.6687762; PAIGE CJ, 1978, J IMMUNOL, V121, P641; PETERS CWB, 1987, EMBO J, V6, P3085, DOI 10.1002/j.1460-2075.1987.tb02616.x; POTTER M, 1978, NATL CANCER I MONOGR, V48, P311; RAMSAY RG, 1986, P NATL ACAD SCI USA, V83, P6849, DOI 10.1073/pnas.83.18.6849; REDDY EP, 1988, ONCOGENE HDB, P327; ROSSON D, 1987, P NATL ACAD SCI USA, V84, P3171, DOI 10.1073/pnas.84.10.3171; ROSSON D, 1986, NATURE, V319, P604, DOI 10.1038/319604a0; RUSHLOW KE, 1982, SCIENCE, V216, P1421, DOI 10.1126/science.6283631; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SHENONG GLC, 1987, EMBO J, V6, P4035, DOI 10.1002/j.1460-2075.1987.tb02748.x; SHENONG GLC, 1984, SCIENCE, V226, P1077, DOI 10.1126/science.6093260; SHENONG GLC, 1986, MOL CELL BIOL, V6, P380, DOI 10.1128/MCB.6.2.380; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; WEINSTEIN Y, 1986, P NATL ACAD SCI USA, V83, P5010, DOI 10.1073/pnas.83.14.5010; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	35	17	17	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1989	4	12					1489	1495						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB659	2480562				2022-12-17	WOS:A1989CB65900011
J	MUSER, J; KAECH, S; MORONI, C; BALLMERHOFER, K				MUSER, J; KAECH, S; MORONI, C; BALLMERHOFER, K			STIMULATION OF PP60C-SRC KINASE-ACTIVITY IN FDC-P1 CELLS BY POLYOMA MIDDLE-T ANTIGEN AND HEMATOPOIETIC GROWTH-FACTORS	ONCOGENE			English	Article									FRIEDRICH MIESCHER INST,POSTFACH 2543,CH-4002 BASEL,SWITZERLAND	Friedrich Miescher Institute for Biomedical Research				Kaech Petrie, Stefanie/0000-0002-6246-6434; Ballmer-Hofer, Kurt/0000-0002-3800-9129				BALLMERHOFER K, 1987, VIRUS RES, V6, P345, DOI 10.1016/0168-1702(87)90066-9; BOLEN JB, 1984, CELL, V38, P767, DOI 10.1016/0092-8674(84)90272-1; BROWDER TM, 1989, MOL CELL BIOL, V9, P204, DOI 10.1128/MCB.9.1.204; CARMICHAEL GG, 1982, P NATL ACAD SCI-BIOL, V79, P3579, DOI 10.1073/pnas.79.11.3579; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CHENG SH, 1988, MOL CELL BIOL, V8, P1736, DOI 10.1128/MCB.8.4.1736; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; COLLETT MS, 1979, J VIROL, V29, P770, DOI 10.1128/JVI.29.2.770-781.1979; COOK WD, 1985, CELL, V41, P677, DOI 10.1016/S0092-8674(85)80048-9; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COOPER JA, 1984, J BIOL CHEM, V259, P7835; COOPER JA, 1988, BIO ESSDAYS, V4, P9; COURTNEIDGE SA, 1986, CANCER SURV, V5, P173; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; COURTNEIDGE SA, 1984, EMBO J, V3, P585, DOI 10.1002/j.1460-2075.1984.tb01852.x; DAWE CJ, 1987, AM J PATHOL, V127, P243; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; FUNG MC, 1984, NATURE, V307, P233, DOI 10.1038/307233a0; GOUGH NM, 1985, EMBO J, V4, P645, DOI 10.1002/j.1460-2075.1985.tb03678.x; GUALTIERI RJ, 1987, EXP HEMATOL, V15, P883; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HUANG SS, 1988, J BIOL CHEM, V263, P12608; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; ISFORT RJ, 1988, P NATL ACAD SCI USA, V85, P7982, DOI 10.1073/pnas.85.21.7982; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KIPREOS ET, 1988, ONCOGENE RES, V2, P277; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOYASU S, 1987, EMBO J, V6, P3979, DOI 10.1002/j.1460-2075.1987.tb02740.x; LANG RA, 1985, CELL, V43, P531, DOI 10.1016/0092-8674(85)90182-5; LEE JC, 1982, J IMMUNOL, V128, P2393; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; MATHEYPREVOT B, 1986, MOL CELL BIOL, V6, P4133, DOI 10.1128/MCB.6.11.4133; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; METCALF D, 1987, EMBO J, V6, P3703, DOI 10.1002/j.1460-2075.1987.tb02704.x; METCALF D, 1984, HEMOPOIETIC GROWTH F; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; NICOLA NA, 1987, IMMUNOL TODAY, V8, P134, DOI 10.1016/0167-5699(87)90140-X; PALLAS DC, 1986, J VIROL, V60, P1075, DOI 10.1128/JVI.60.3.1075-1084.1986; PARK LS, 1986, J BIOL CHEM, V261, P205; PIERCE JH, 1985, CELL, V41, P685, DOI 10.1016/S0092-8674(85)80049-0; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; RAPTIS L, 1985, MOL CELL BIOL, V5, P2476, DOI 10.1128/MCB.5.9.2476; SCHAFFHAUSEN B, 1981, J VIROL, V40, P184, DOI 10.1128/JVI.40.1.184-196.1981; SEFTON BM, 1986, CANCER SURV, V5, P159; STOCKING C, 1988, CELL, V53, P869, DOI 10.1016/S0092-8674(88)90329-7; VONRUDEN T, 1988, EMBO J, V7, P2749, DOI 10.1002/j.1460-2075.1988.tb03129.x; WATSON JD, 1987, J IMMUNOL, V139, P123; WHEELER EF, 1987, MOL CELL BIOL, V7, P1673, DOI 10.1128/MCB.7.5.1673; WHETTON AD, 1986, TRENDS BIOCHEM SCI, V11, P207, DOI 10.1016/0968-0004(86)90008-3; WHETTON AD, 1988, P NATL ACAD SCI USA, V85, P3284, DOI 10.1073/pnas.85.10.3284; YONEMOTO W, 1985, P NATL ACAD SCI USA, V82, P4568, DOI 10.1073/pnas.82.14.4568	54	17	17	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1989	4	12					1433	1439						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB659	2480561				2022-12-17	WOS:A1989CB65900003
J	AZARNIA, R; MITCHO, M; SHALLOWAY, D; LOEWENSTEIN, WR				AZARNIA, R; MITCHO, M; SHALLOWAY, D; LOEWENSTEIN, WR			JUNCTIONAL INTERCELLULAR COMMUNICATION IS COOPERATIVELY INHIBITED BY ONCOGENES IN TRANSFORMATION	ONCOGENE			English	Article									PENN STATE UNIV, DEPT MOLEC & CELL BIOL, UNIVERSITY PK, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	AZARNIA, R (corresponding author), UNIV MIAMI, SCH MED, DEPT PHYSIOL & BIOPHYS, MIAMI, FL 33101 USA.				NCI NIH HHS [CA01139, CA14464, CA47333] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047333] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATKINSON MM, 1981, J CELL BIOL, V91, P573, DOI 10.1083/jcb.91.2.573; ATKINSON MM, 1988, AM J PHYSIOL, V255, pC674, DOI 10.1152/ajpcell.1988.255.5.C674; AZARNIA R, 1987, MOL CELL BIOL, V7, P946, DOI 10.1128/MCB.7.2.946; AZARNIA R, 1988, SCIENCE, V239, P398, DOI 10.1126/science.2447651; AZARNIA R, 1984, J MEMBRANE BIOL, V82, P191, DOI 10.1007/BF01871629; AZARNIA R, 1984, J MEMBRANE BIOL, V82, P213, DOI 10.1007/BF01871631; AZARNIA R, 1984, J MEMBRANE BIOL, V82, P207, DOI 10.1007/BF01871630; AZARNIA R, 1988, 4TH INT C CELL BIOL, P233; BEYER EC, 1989, J CELL BIOL, V108, P595, DOI 10.1083/jcb.108.2.595; BEYER EC, 1987, J CELL BIOL, V105, P2621, DOI 10.1083/jcb.105.6.2621; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CHANG CC, 1985, P NATL ACAD SCI USA, V82, P5360, DOI 10.1073/pnas.82.16.5360; CHEN MJ, 1987, NATURE, V330, P581, DOI 10.1038/330581a0; COOK JL, 1986, P NATL ACAD SCI USA, V83, P6965, DOI 10.1073/pnas.83.18.6965; COOK JL, 1989, J IMMUNOL, V142, P4527; DOTTO GP, 1988, P NATL ACAD SCI USA, V85, P6389, DOI 10.1073/pnas.85.17.6389; EPSTEIN ML, 1977, J CELL BIOL, V75, P769, DOI 10.1083/jcb.75.3.769; FLAGGNEWTON J, 1979, SCIENCE, V205, P404, DOI 10.1126/science.377490; FLAGGNEWTON JL, 1981, J MEMBRANE BIOL, V63, P105, DOI 10.1007/BF01969452; FLETCHER WH, 1987, J IMMUNOL, V139, P956; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; HUNTER GK, 1981, J CELL SCI, V49, P163; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.bi.54.070185.004341; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; KINGSTON RE, 1985, CELL, V41, P3, DOI 10.1016/0092-8674(85)90049-2; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LOEWENST.WR, 1966, ANN NY ACAD SCI, V137, P441, DOI 10.1111/j.1749-6632.1966.tb50175.x; LOEWENSTEIN WR, 1988, ANN NY ACAD SCI, V551, P337, DOI 10.1111/j.1749-6632.1988.tb22359.x; LOEWENSTEIN WR, 1981, PHYSIOL REV, V61, P829, DOI 10.1152/physrev.1981.61.4.829; LOEWENSTEIN WR, 1987, CELL, V48, P725, DOI 10.1016/0092-8674(87)90067-5; LOEWENSTEIN WR, 1979, BIOCHIM BIOPHYS ACTA, V560, P1, DOI 10.1016/0304-419X(79)90002-7; LOEWENSTEIN WR, 1964, J CELL BIOL, V22, P565, DOI 10.1083/jcb.22.3.565; MACAULEY A, 1988, J VIROL, V62, P4712, DOI 10.1128/JVI.62.12.4712-4721.1988; MADHUKAR BV, 1989, CARCINOGENESIS, V10, P13, DOI 10.1093/carcin/10.1.13; MALDONADO PE, 1988, J MEMBRANE BIOL, V106, P203, DOI 10.1007/BF01872158; MANJUNATH CK, 1987, BIOCHEM BIOPH RES CO, V142, P228, DOI 10.1016/0006-291X(87)90475-X; MEHTA PP, 1989, J CELL BIOL, V108, P1053, DOI 10.1083/jcb.108.3.1053; MEHTA PP, 1986, CELL, V44, P187, DOI 10.1016/0092-8674(86)90497-6; MICHALKE W, 1971, NATURE, V232, P121, DOI 10.1038/232121b0; NICHOLSON BJ, 1985, J BIOL CHEM, V260, P6514; NONNER WF, 1989, J CELL BIOL, V108, P1063; PERRICAUDET M, 1980, NATURE, V288, P174, DOI 10.1038/288174a0; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; REDDY S, 1988, MOL CELL BIOL, V8, P704, DOI 10.1128/MCB.8.2.704; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; ROSE B, 1986, J MEMBRANE BIOL, V94, P129, DOI 10.1007/BF01871193; ROSEN A, 1988, CANCER RES, V48, P3485; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SHALLOWAY D, 1987, MOL CELL BIOL, V7, P3582, DOI 10.1128/MCB.7.10.3582; SHALLOWAY D, 1984, P NATL ACAD SCI-BIOL, V81, P7071, DOI 10.1073/pnas.81.22.7071; Socolar S J, 1979, METHODS MEMBRANE BIO, V10, P123; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPECTOR DJ, 1986, VIROLOGY, V151, P329, DOI 10.1016/0042-6822(86)90053-X; TAKEYA T, 1982, J VIROL, V44, P12, DOI 10.1128/JVI.44.1.12-18.1982; YADA T, 1985, J MEMBRANE BIOL, V88, P217, DOI 10.1007/BF01871087	58	17	18	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1989	4	10					1161	1168						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AU508	2477782				2022-12-17	WOS:A1989AU50800001
J	HEWLETT, IK; RUTA, M; CRISTIANO, K; HAWTHORNE, CA; EPSTEIN, JS				HEWLETT, IK; RUTA, M; CRISTIANO, K; HAWTHORNE, CA; EPSTEIN, JS			CO-AMPLIFICATION OF MULTIPLE REGIONS OF THE HIV-1 GENOME BY THE POLYMERASE CHAIN-REACTION - POTENTIAL USE IN MULTIPLE DIAGNOSIS	ONCOGENE			English	Article											HEWLETT, IK (corresponding author), US FDA,CTR BIOL EVALUAT & RES,DIV BLOOD & BLOOD PROD,RETROVIROL LAB,BETHESDA,MD 20892, USA.			Epstein, Jay/0000-0003-2293-9062				CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; HEWLETT IK, 1989, IN PRESS J CLIN IMMU; IMPRAIM CC, 1987, BIOCHEM BIOPH RES CO, V142, P710, DOI 10.1016/0006-291X(87)91472-0; KWOK S, 1987, J VIROL, V61, P1690, DOI 10.1128/JVI.61.5.1690-1694.1987; KWOK S, 1989, IN PRESS; Maniatis T., 1984, MOL CLONING; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; MURAKAWA GJ, 1988, DNA-J MOLEC CELL BIO, V7, P287, DOI 10.1089/dna.1988.7.287; OSTE C, 1988, BIOTECHNIQUES, V6, P162; OU CY, 1988, SCIENCE, V239, P295, DOI 10.1126/science.3336784; PETRICCIANI JC, 1985, ANN INTERN MED, V103, P726, DOI 10.7326/0003-4819-103-5-726; SAIKI RK, 1985, BIO-TECHNOL, V3, P1008, DOI 10.1038/nbt1185-1008; SCHARF SJ, 1986, SCIENCE, V233, P1076, DOI 10.1126/science.3461561; SCHARF SJ, 1986, SCIENCE, V223, P1076; WOLINSKY S, 1988, 4TH INT AIDS M STOCK, P137	15	17	22	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1989	4	9					1149	1151						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AM531	2571115				2022-12-17	WOS:A1989AM53100016
J	VELCICH, A; ZIFF, EB				VELCICH, A; ZIFF, EB			THE ADENOVIRUS-5 12S E1A PROTEIN, BUT NOT THE 13S INDUCES EXPRESSION OF THE ENDOA DIFFERENTIATION MARKER IN F9 CELLS	ONCOGENE			English	Article									NYU, DEPT BIOCHEM, NEW YORK, NY 10016 USA; NYU, KAPLAN CANC CTR, NEW YORK, NY 10016 USA	New York University; New York University				Ziff, Edward/0000-0001-7389-8649	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030760] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 30760] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMATI P, 1985, CELL, V43, P561, DOI 10.1016/0092-8674(85)90225-9; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BERK AJ, 1986, CANCER SURV, V5, P367; BOCCARA M, 1978, ANN INST PASTEUR MIC, VA129, P227; BORRELLI E, 1986, P NATL ACAD SCI USA, V83, P2846, DOI 10.1073/pnas.83.9.2846; BORRELLI E, 1984, NATURE, V312, P608, DOI 10.1038/312608a0; BRANTON PE, 1984, BIOCHIM BIOPHYS ACTA, V780, P67, DOI 10.1016/0304-419X(84)90007-6; BRULET P, 1982, P NATL ACAD SCI-BIOL, V79, P2328, DOI 10.1073/pnas.79.7.2328; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; CREMISI C, 1987, NUCLEIC ACIDS RES, V15, P6105, DOI 10.1093/nar/15.15.6105; CURRAN T, 1987, BIOESSAYS, V7, P255, DOI 10.1002/bies.950070606; DUPREY P, 1985, P NATL ACAD SCI USA, V82, P8535, DOI 10.1073/pnas.82.24.8535; GORMAN CM, 1985, CELL, V42, P519, DOI 10.1016/0092-8674(85)90109-6; HEN R, 1985, SCIENCE, V230, P1391, DOI 10.1126/science.2999984; HEN R, 1986, NATURE, V321, P249, DOI 10.1038/321249a0; HOGAN BLM, 1981, NATURE, V291, P235, DOI 10.1038/291235a0; IMLER JL, 1987, MOL CELL BIOL, V7, P2558, DOI 10.1128/MCB.7.7.2558; IMLER JL, 1988, NATURE, V332, P275, DOI 10.1038/332275a0; IMPERIALE MJ, 1984, MOL CELL BIOL, V4, P867, DOI 10.1128/MCB.4.5.867; KRYSZKE MH, 1987, NATURE, V328, P254, DOI 10.1038/328254a0; KURKINEN M, 1983, COLD SPRING HARBOR C, V10, P389; LATHANGUE NB, 1987, CELL, V49, P507, DOI 10.1016/0092-8674(87)90453-3; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; LINNEY E, 1983, CELL, V35, P693, DOI 10.1016/0092-8674(83)90102-2; MARTIN GR, 1980, SCIENCE, V209, P768, DOI 10.1126/science.6250214; MARUYAMA K, 1987, ONCOGENE, V1, P361; MONTANO X, 1987, MOL CELL BIOL, V7, P1782, DOI 10.1128/MCB.7.5.1782; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; MULLER R, 1986, TRENDS BIOCHEM SCI, V11, P129, DOI 10.1016/0968-0004(86)90066-6; MULLER R, 1984, NATURE, V311, P438, DOI 10.1038/311438a0; PERRICAUDET M, 1979, NATURE, V281, P694, DOI 10.1038/281694a0; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SASSONECORSI P, 1987, P NATL ACAD SCI USA, V84, P6430, DOI 10.1073/pnas.84.18.6430; SERFLING E, 1985, TRENDS GENET, V1, P224, DOI 10.1016/0168-9525(85)90088-5; SLEIGH MJ, 1985, EMBO J, V4, P3831, DOI 10.1002/j.1460-2075.1985.tb04155.x; SMITH DH, 1985, MOL CELL BIOL, V5, P2684, DOI 10.1128/MCB.5.10.2684; STEIN RW, 1987, MOL CELL BIOL, V7, P1164, DOI 10.1128/MCB.7.3.1164; STRICKLAND S, 1980, CELL, V21, P347, DOI 10.1016/0092-8674(80)90471-7; STRICKLAND S, 1981, CELL, V24, P277, DOI 10.1016/0092-8674(81)90313-5; SUEMORI H, 1988, MOL CELL BIOL, V8, P3553, DOI 10.1128/MCB.8.8.3553; VELCICH A, 1986, MOL CELL BIOL, V6, P4019, DOI 10.1128/MCB.6.11.4019; VELCICH A, 1985, CELL, V40, P705, DOI 10.1016/0092-8674(85)90219-3; VELCICH A, 1988, MOL CELL BIOL, V8, P2177, DOI 10.1128/MCB.8.5.2177; VELCICH A, 1988, IN PRESS; WASYLYK B, 1988, P NATL ACAD SCI USA, V85, P7952, DOI 10.1073/pnas.85.21.7952; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; ZERLER B, 1987, MOL CELL BIOL, V7, P821, DOI 10.1128/MCB.7.2.821; ZERLER B, 1986, MOL CELL BIOL, V6, P887, DOI 10.1128/MCB.6.3.887; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	51	17	17	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1989	4	6					707	713						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA660	2543941				2022-12-17	WOS:A1989AA66000006
J	INGVARSSON, S; SUNDARESAN, S; JIN, P; FRANCKE, U; ASKER, C; SUMEGI, J; KLEIN, G; SEJERSEN, T				INGVARSSON, S; SUNDARESAN, S; JIN, P; FRANCKE, U; ASKER, C; SUMEGI, J; KLEIN, G; SEJERSEN, T			CHROMOSOME LOCALIZATION AND EXPRESSION PATTERN OF LMYC AND BMYC IN MURINE EMBRYONAL CARCINOMA-CELLS	ONCOGENE			English	Article									KAROLINSKA INST, DEPT MED CELL GENET, S-10401 STOCKHOLM 60, SWEDEN; YALE UNIV, SCH MED, DEPT HUMAN GENET, NEW HAVEN, CT 06510 USA	Karolinska Institutet; Yale University	INGVARSSON, S (corresponding author), KAROLINSKA INST, DEPT TUMOR BIOL, S-10401 STOCKHOLM 60, SWEDEN.		Ingvarsson, Sigurdur/E-7448-2011	Ingvarsson, Sigurdur/0000-0003-4125-1714	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026105] Funding Source: NIH RePORTER; NCI NIH HHS [3R01CA140554] Funding Source: Medline; NIGMS NIH HHS [GM26105] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ASKER C, 1988, LEUKEMIA RES, V12, P523, DOI 10.1016/0145-2126(88)90120-8; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BARTON DE, 1986, HUM GENET, V72, P221, DOI 10.1007/BF00291881; BIRRER MJ, 1988, MOL CELL BIOL, V8, P2668, DOI 10.1128/MCB.8.6.2668; BROOKS BJ, 1987, ADV VIRAL ONCOL, V7, P155; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CAVALIERI F, 1988, ONCOGENE, V2, P289; CLASSON M, 1987, NATURE, V330, P272, DOI 10.1038/330272a0; CLEVELAND JL, 1987, VIRAL CARCINOG, V24, P339; DALLAFAVERA R, 1982, NATURE, V299, P61; DEAN M, 1987, ONCOGENE RES, V1, P279; DELLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P6497, DOI 10.1073/pnas.79.21.6497; DEPINHO R, 1987, J CELL BIOCHEM, V33, P257, DOI 10.1002/jcb.240330404; DEPINHO RA, 1986, P NATL ACAD SCI USA, V83, P1827, DOI 10.1073/pnas.83.6.1827; DEPINHO RA, 1987, J CELL BIOCHEM, V1, P1311; EDMONDS M, 1969, J BIOL CHEM, V244, P1314; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; EICK D, 1985, EMBO J, V4, P3717, DOI 10.1002/j.1460-2075.1985.tb04140.x; EVANS G, 1988, IN PRESS CURR TOP MI, V138; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRANCKE U, 1977, CYTOGENET CELL GENET, V19, P57, DOI 10.1159/000130799; FRANCKE U, 1979, P NATL ACAD SCI USA, V76, P5230, DOI 10.1073/pnas.76.10.5230; HAYATA I, 1983, CANCER RES, V43, P367; HENRIKSSON M, 1988, IN PRESS ONCOGENE, V3; IGUCHIARIGA SMM, 1988, EMBO J, V7, P3135, DOI 10.1002/j.1460-2075.1988.tb03180.x; INGVARSSON S, 1988, MOL CELL BIOL, V8, P3168, DOI 10.1128/MCB.8.8.3168; INGVARSSON S, 1987, SOMAT CELL MOLEC GEN, V13, P335, DOI 10.1007/BF01534927; JAKOBOVITS A, 1985, NATURE, V318, P188, DOI 10.1038/318188a0; KOHL NE, 1986, NATURE, V319, P73, DOI 10.1038/319073a0; KRYSTAL G, 1988, MOL CELL BIOL, V8, P3373, DOI 10.1128/MCB.8.8.3373; LALLEY PA, 1987, CYTOGENET CELL GENET, V46, P367, DOI 10.1159/000132486; LECH K, 1988, CELL, V52, P179, DOI 10.1016/0092-8674(88)90506-5; LEGOUY E, 1987, EMBO J, V6, P3359, DOI 10.1002/j.1460-2075.1987.tb02657.x; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; NESBITT MN, 1974, CHROMOSOMA, V46, P217, DOI 10.1007/BF00332519; RABBITTS PH, 1985, EMBO J, V4, P3727, DOI 10.1002/j.1460-2075.1985.tb04141.x; RAMSAY G, 1986, MOL CELL BIOL, V6, P4450, DOI 10.1128/MCB.6.12.4450; RIZZINO A, 1980, P NATL ACAD SCI-BIOL, V77, P457, DOI 10.1073/pnas.77.1.457; ROSENBAUM H, 1989, IN PRESS EMBO J; SCHWAB M, 1985, NATURE, V315, P345, DOI 10.1038/315345a0; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SEJERSEN T, 1987, EXP CELL RES, V172, P304, DOI 10.1016/0014-4827(87)90389-2; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; SUMEGI J, 1985, INT J CANCER, V36, P367; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; YANCOPOULOS GD, 1985, P NATL ACAD SCI USA, V82, P5455, DOI 10.1073/pnas.82.16.5455; YOSHIDA MC, 1978, CYTOGENET CELL GENET, V22, P606, DOI 10.1159/000131034; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	51	17	18	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1988	3	6					679	685						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	R6460	2577870				2022-12-17	WOS:A1988R646000009
J	CARROLL, RB; SAMAD, A; MANN, A; HARPER, J; ANDERSON, CW				CARROLL, RB; SAMAD, A; MANN, A; HARPER, J; ANDERSON, CW			RNA IS COVALENTLY LINKED TO SV40 LARGE T-ANTIGEN	ONCOGENE			English	Article									NYU, RITA & STANLEY H KAPLAN CANC CTR, SCH MED, NEW YORK, NY 10016 USA; BROOKHAVEN NATL LAB, DEPT BIOL, UPTON, NY 11973 USA	New York University; United States Department of Energy (DOE); Brookhaven National Laboratory	CARROLL, RB (corresponding author), NYU, SCH MED, DEPT PATHOL, 550 1ST AVE, NEW YORK, NY 10016 USA.				NATIONAL CANCER INSTITUTE [R01CA020802, P01CA016239] Funding Source: NIH RePORTER; NCI NIH HHS [CA9161, CA20802, CA16239] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON CW, 1986, CANCER CELL, V1, P395; ANDERSON KP, 1984, P NATL ACAD SCI-BIOL, V81, P4023, DOI 10.1073/pnas.81.13.4023; BOCK RM, 1967, METHODS ENZYMOLOGY A, V12, P638; CARROLL RB, 1982, J VIROL, V44, P565, DOI 10.1128/JVI.44.2.565-573.1982; CHALLBERG MD, 1980, P NATL ACAD SCI-BIOL, V77, P5105, DOI 10.1073/pnas.77.9.5105; CRAWFORD LV, 1979, COLD SPRING HARB SYM, V44, P179; FLANEGAN JB, 1977, P NATL ACAD SCI USA, V74, P961, DOI 10.1073/pnas.74.3.961; GLUZMAN Y, 1982, VIROLOGY, V123, P78, DOI 10.1016/0042-6822(82)90296-3; GREENSPAN DS, 1981, P NATL ACAD SCI-BIOL, V78, P105, DOI 10.1073/pnas.78.1.105; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HOUMARD J, 1972, P NATL ACAD SCI USA, V69, P3506, DOI 10.1073/pnas.69.12.3506; JEKEL PA, 1983, ANAL BIOCHEM, V134, P347, DOI 10.1016/0003-2697(83)90308-1; KALDERON D, 1984, VIROLOGY, V139, P109, DOI 10.1016/0042-6822(84)90334-9; KHANDJIAN EW, 1982, P NATL ACAD SCI-BIOL, V79, P1139, DOI 10.1073/pnas.79.4.1139; KLEIN G, 1982, ADV VIRAL ONCOL, V2, P53; KLEIN H, 1979, J BIOL CHEM, V254, P1051; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEE YF, 1977, P NATL ACAD SCI USA, V74, P59, DOI 10.1073/pnas.74.1.59; MANOS MM, 1985, J VIROL, V53, P120, DOI 10.1128/JVI.53.1.120-127.1985; MARTENSEN TM, 1984, METHOD ENZYMOL, V107, P3; PAUCHA E, 1986, J VIROL, V57, P50, DOI 10.1128/JVI.57.1.50-64.1986; ROTHBERG PG, 1978, P NATL ACAD SCI USA, V75, P4868, DOI 10.1073/pnas.75.10.4868; SAMAD A, 1986, P NATL ACAD SCI USA, V83, P897, DOI 10.1073/pnas.83.4.897; SCHEIDTMANN KH, 1982, J VIROL, V44, P116, DOI 10.1128/JVI.44.1.116-133.1982; SCHEIDTMANN KH, 1981, J VIROL, V38, P59, DOI 10.1128/JVI.38.1.59-69.1981; Tooze J., 1981, COLD SPRING HARB MON, Vsecond; TORNOW J, 1983, J VIROL, V47, P487, DOI 10.1128/JVI.47.3.487-494.1983	27	17	18	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1988	2	5					437	444						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	N4348	2836778				2022-12-17	WOS:A1988N434800004
J	JULIUS, MA; STREET, AJ; FAHRLANDER, PD; YANG, JQ; EISENMAN, RN; MARCU, KB				JULIUS, MA; STREET, AJ; FAHRLANDER, PD; YANG, JQ; EISENMAN, RN; MARCU, KB			TRANSLOCATED C-MYC GENES PRODUCE CHIMERIC TRANSCRIPTS CONTAINING ANTISENSE SEQUENCES OF THE IMMUNOGLOBULIN HEAVY-CHAIN LOCUS IN MOUSE PLASMACYTOMAS	ONCOGENE			English	Article									SUNY STONY BROOK,DEPT MICROBIOL & PATHOL,STONY BROOK,NY 11794; FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Fred Hutchinson Cancer Center	JULIUS, MA (corresponding author), SUNY STONY BROOK,DEPT BIOCHEM,STONY BROOK,NY 11794, USA.				NCI NIH HHS [CA09176, CA36246] Funding Source: Medline; NIGMS NIH HHS [GM26939] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA036246, T32CA009176] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026939] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS JM, 1983, P NATL ACAD SCI-BIOL, V80, P1982, DOI 10.1073/pnas.80.7.1982; ALEXANDER WS, 1987, MOL CELL BIOL, V7, P1436, DOI 10.1128/MCB.7.4.1436; BANERJI J, 1983, CELL, V33, P729, DOI 10.1016/0092-8674(83)90015-6; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BRAUN J, 1983, J IMMUNOL, V130, P2113; CALABI F, 1985, EMBO J, V4, P667, DOI 10.1002/j.1460-2075.1985.tb03681.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CORCORAN LM, 1985, CELL, V40, P71, DOI 10.1016/0092-8674(85)90310-1; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; CROCE CM, 1984, P NATL ACAD SCI-BIOL, V81, P3170, DOI 10.1073/pnas.81.10.3170; DUNNICK W, 1983, P NATL ACAD SCI-BIOL, V80, P7269, DOI 10.1073/pnas.80.23.7269; EICK D, 1985, EMBO J, V4, P3717, DOI 10.1002/j.1460-2075.1985.tb04140.x; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; FAHRLANDER PD, 1985, P NATL ACAD SCI USA, V82, P3746, DOI 10.1073/pnas.82.11.3746; FAHRLANDER PD, 1985, EMBO J, V4, P3195, DOI 10.1002/j.1460-2075.1985.tb04065.x; FAHRLANDER PD, 1986, ONCOGENES GROWTH CON, P264; FALKNER FG, 1984, NATURE, V310, P71, DOI 10.1038/310071a0; FALKNER FG, 1986, NUCLEIC ACIDS RES, V14, P8819, DOI 10.1093/nar/14.22.8819; GERONDAKIS S, 1984, CELL, V36, P973, DOI 10.1016/0092-8674(84)90047-3; GILLIES SD, 1983, CELL, V33, P717, DOI 10.1016/0092-8674(83)90014-4; GROSSCHEDL R, 1985, CELL, V41, P479; HANN SR, 1983, CELL, V34, P789, DOI 10.1016/0092-8674(83)90535-4; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; KAKKIS E, 1986, MOL CELL BIOL, V6, P1357, DOI 10.1128/MCB.6.4.1357; KEATH EJ, 1984, CELL, V37, P521, DOI 10.1016/0092-8674(84)90382-9; KING MW, 1986, MOL CELL BIOL, V6, P4499, DOI 10.1128/MCB.6.12.4499; KLEIN G, 1983, CELL, V32, P311, DOI 10.1016/0092-8674(83)90449-X; Klein G, 1981, NATURE, V294, P313, DOI 10.1038/294313a0; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LASKOV R, 1970, Journal of Experimental Medicine, V131, P515, DOI 10.1084/jem.131.3.515; MANIATIS T, 1982, MOL CLONING LABORATO; MARCU KB, 1987, BIOESSAYS, V6, P28, DOI 10.1002/bies.950060108; MARCU KB, 1986, CURRENT TOPICS MICRO, V132, P320; MASON JO, 1985, CELL, V41, P479, DOI 10.1016/S0092-8674(85)80021-0; MESSING J, 1983, METHODS ENZYMOLOGY C, V101; NEUBERGER MS, 1983, NATURE, V305, P240, DOI 10.1038/305240a0; OI VT, 1983, P NATL ACAD SCI-BIOL, V80, P825, DOI 10.1073/pnas.80.3.825; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; OLLO R, 1981, P NATL ACAD SCI-BIOL, V78, P2442, DOI 10.1073/pnas.78.4.2442; PARSLOW TG, 1987, SCIENCE, V235, P1498, DOI 10.1126/science.3029871; PARSLOW TG, 1984, P NATL ACAD SCI-BIOL, V81, P2650, DOI 10.1073/pnas.81.9.2650; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; PERRY RP, 1983, CELL, V33, P647, DOI 10.1016/0092-8674(83)90006-5; PONCZ M, 1982, P NATL ACAD SCI-BIOL, V79, P4298, DOI 10.1073/pnas.79.14.4298; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHENONG GLC, 1982, CELL, V31, P443, DOI 10.1016/0092-8674(82)90137-4; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; STANTON LW, 1984, NATURE, V310, P423, DOI 10.1038/310423a0; STANTON LW, 1984, P NATL ACAD SCI-BIOL, V81, P829, DOI 10.1073/pnas.81.3.829; WIRTH T, 1987, NATURE, V329, P174, DOI 10.1038/329174a0; YAMAWAKIKATAOKA Y, 1981, NUCLEIC ACIDS RES, V9, P1365, DOI 10.1093/nar/9.6.1365; YANG JQ, 1985, EMBO J, V4, P1441, DOI 10.1002/j.1460-2075.1985.tb03800.x	57	17	17	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1988	2	5					469	476						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	N4348	2453828				2022-12-17	WOS:A1988N434800008
J	NISHIKURA, K; MURRAY, JM				NISHIKURA, K; MURRAY, JM			THE MECHANISM OF INACTIVATION OF THE NORMAL C-MYC GENE LOCUS IN HUMAN BURKITT-LYMPHOMA CELLS	ONCOGENE			English	Article									UNIV PENN,SCH MED,DEPT ANAT,PHILADELPHIA,PA 19104	University of Pennsylvania	NISHIKURA, K (corresponding author), WISTAR INST ANAT & BIOL,36TH ST SPRUCE,PHILADELPHIA,PA 19104, USA.							ABRAMS HD, 1982, CELL, V29, P427, DOI 10.1016/0092-8674(82)90159-3; BENTLEY DL, 1986, MOL CELL BIOL, V6, P3481, DOI 10.1128/MCB.6.10.3481; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BERK AJ, 1978, P NATL ACAD SCI USA, V75, P1274, DOI 10.1073/pnas.75.3.1274; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BLANCHARD JM, 1985, NATURE, V317, P443, DOI 10.1038/317443a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CROCE CM, 1983, P NATL ACAD SCI-BIOL, V80, P6922, DOI 10.1073/pnas.80.22.6922; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; DONY C, 1985, NATURE, V317, P636, DOI 10.1038/317636a0; DUNNICK W, 1985, GENE, V39, P287, DOI 10.1016/0378-1119(85)90325-7; DYSON PJ, 1985, P NATL ACAD SCI USA, V82, P1984, DOI 10.1073/pnas.82.7.1984; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; EICK D, 1985, EMBO J, V4, P3717, DOI 10.1002/j.1460-2075.1985.tb04140.x; ERIKSON J, 1983, P NATL ACAD SCI-BIOL, V80, P7581, DOI 10.1073/pnas.80.24.7581; FAHRLANDER PD, 1985, EMBO J, V4, P3195, DOI 10.1002/j.1460-2075.1985.tb04065.x; GAZIN C, 1986, EMBO J, V5, P2241, DOI 10.1002/j.1460-2075.1986.tb04491.x; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; LEDER P, 1983, SCIENCE, V222, P765, DOI 10.1126/science.6356357; LEY TJ, 1982, P NATL ACAD SCI-BIOL, V79, P4775, DOI 10.1073/pnas.79.15.4775; MANIATIS T, 1975, BIOCHEMISTRY-US, V14, P3787, DOI 10.1021/bi00688a010; Maxam A M, 1980, Methods Enzymol, V65, P499; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; NISHIKURA K, 1984, SCIENCE, V224, P399, DOI 10.1126/science.6424234; NISHIKURA K, 1985, MOL CELL BIOL, V5, P1434, DOI 10.1128/MCB.5.6.1434; NISHIKURA K, 1985, P NATL ACAD SCI USA, V82, P2900, DOI 10.1073/pnas.82.9.2900; NISHIKURA K, 1983, P NATL ACAD SCI-BIOL, V80, P4822, DOI 10.1073/pnas.80.15.4822; PIECHACZYK M, 1985, CELL, V42, P589, DOI 10.1016/0092-8674(85)90116-3; RABBITTS PH, 1985, EMBO J, V4, P3727, DOI 10.1002/j.1460-2075.1985.tb04141.x; RABBITTS TH, 1984, NATURE, V309, P592, DOI 10.1038/309592a0; RABBITTS TH, 1983, NATURE, V306, P760, DOI 10.1038/306760a0; SIEBENLIST U, 1984, CELL, V37, P381, DOI 10.1016/0092-8674(84)90368-4; SWARTWOUT SG, 1987, MOL CELL BIOL, V7, P2052, DOI 10.1128/MCB.7.6.2052; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837	36	17	17	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1988	2	5					493	498						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	N4348	3131718				2022-12-17	WOS:A1988N434800011
J	JORDANO, J; PERUCHO, M				JORDANO, J; PERUCHO, M			INITIAL CHARACTERIZATION OF A POTENTIAL TRANSCRIPTIONAL ENHANCER FOR THE HUMAN C-K-RAS GENE	ONCOGENE			English	Article											JORDANO, J (corresponding author), SUNY STONY BROOK,DEPT BIOCHEM,STONY BROOK,NY 11794, USA.		Jordano, Juan/J-5829-2012	Jordano, Juan/0000-0002-2583-4453; Perucho, Manuel/0000-0002-2169-2662	NCI NIH HHS [CA33021] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA033021] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BIENZ M, 1986, CELL, V45, P753, DOI 10.1016/0092-8674(86)90789-0; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BORGMEYER U, 1984, NUCLEIC ACIDS RES, V12, P4295, DOI 10.1093/nar/12.10.4295; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BUETTI E, 1986, J MOL BIOL, V190, P379, DOI 10.1016/0022-2836(86)90009-4; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CHARNAY P, 1984, CELL, V38, P251, DOI 10.1016/0092-8674(84)90547-6; CORDINGLEY MG, 1987, CELL, V48, P262; DIERKS P, 1983, CELL, V32, P695, DOI 10.1016/0092-8674(83)90055-7; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; FUJIMURA FK, 1986, NUCLEIC ACIDS RES, V14, P2845, DOI 10.1093/nar/14.7.2845; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GOODBOURN S, 1985, CELL, V41, P509, DOI 10.1016/S0092-8674(85)80024-6; GOYETTE M, 1984, MOL CELL BIOL, V4, P1493, DOI 10.1128/MCB.4.8.1493; GRONOSTAJSKI RM, 1985, MOL CELL BIOL, V5, P964, DOI 10.1128/MCB.5.5.964; GRONOSTAJSKI RM, 1986, NUCLEIC ACIDS RES, V14, P9117, DOI 10.1093/nar/14.22.9117; HALL A, 1985, NUCLEIC ACIDS RES, V13, P5255, DOI 10.1093/nar/13.14.5255; HENNINGHAUSEN L, 1985, NATURE, V314, P284; HERR W, 1985, NATURE, V313, P711, DOI 10.1038/313711a0; HERR W, 1986, CELL, V45, P461, DOI 10.1016/0092-8674(86)90332-6; HOFFMAN EK, 1987, MOL CELL BIOL, V7, P2592, DOI 10.1128/MCB.7.7.2592; HONKAWA H, 1987, MOL CELL BIOL, V7, P2933, DOI 10.1128/MCB.7.8.2933; ISHII S, 1985, SCIENCE, V230, P1378, DOI 10.1126/science.2999983; ISHII S, 1986, SCIENCE, V232, P1410, DOI 10.1126/science.3012774; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; JORDANO J, 1986, NUCLEIC ACIDS RES, V14, P7361, DOI 10.1093/nar/14.18.7361; KHOURY G, 1983, CELL, V33, P313, DOI 10.1016/0092-8674(83)90410-5; LAWN RM, 1980, CELL, V21, P647, DOI 10.1016/0092-8674(80)90428-6; LEEGWATER PAJ, 1986, EMBO J, V5, P381, DOI 10.1002/j.1460-2075.1986.tb04223.x; LEON J, 1987, MOL CELL BIOL, V7, P1535, DOI 10.1128/MCB.7.4.1535; MANIATIS T, 1982, MOL CLONING LABORATO; Maxam A M, 1980, Methods Enzymol, V65, P499; MIKSICEK R, 1987, EMBO J, V6, P1355, DOI 10.1002/j.1460-2075.1987.tb02375.x; MULLER R, 1983, MOL CELL BIOL, V3, P1062; MYERS RM, 1986, SCIENCE, V232, P613, DOI 10.1126/science.3457470; NAGATA K, 1982, P NATL ACAD SCI-BIOL, V79, P6438, DOI 10.1073/pnas.79.21.6438; NAKANO H, 1984, P NATL ACAD SCI-BIOL, V81, P71, DOI 10.1073/pnas.81.1.71; NOWOCK J, 1982, CELL, V30, P607, DOI 10.1016/0092-8674(82)90257-4; NOWOCK J, 1985, NUCLEIC ACIDS RES, V13, P2045, DOI 10.1093/nar/13.6.2045; ONDEK B, 1987, EMBO J, V6, P1017, DOI 10.1002/j.1460-2075.1987.tb04854.x; OSTAPCHUK P, 1986, P NATL ACAD SCI USA, V83, P8550, DOI 10.1073/pnas.83.22.8550; ROSENFELD PJ, 1986, J BIOL CHEM, V261, P1398; ROSENFELD PJ, 1987, MOL CELL BIOL, V7, P875, DOI 10.1128/MCB.7.2.875; SERFLING E, 1985, TRENDS GENET, V1, P224, DOI 10.1016/0168-9525(85)90088-5; SERGEANT A, 1984, J MOL BIOL, V180, P577, DOI 10.1016/0022-2836(84)90028-7; SIEBENLIST U, 1984, CELL, V37, P381, DOI 10.1016/0092-8674(84)90368-4; SPANDIDOS DA, 1986, FEBS LETT, V203, P169, DOI 10.1016/0014-5793(86)80736-0; THEISEN M, 1986, EMBO J, V5, P719, DOI 10.1002/j.1460-2075.1986.tb04273.x; VANDYKE MW, 1987, MOL CELL BIOL, V7, P1021, DOI 10.1128/MCB.7.3.1021; WEIHER H, 1983, SCIENCE, V219, P626, DOI 10.1126/science.6297005; WILDEMAN AG, 1986, MOL CELL BIOL, V6, P2098, DOI 10.1128/MCB.6.6.2098; WINTER E, 1985, P NATL ACAD SCI USA, V82, P7575, DOI 10.1073/pnas.82.22.7575; YASWEN P, 1985, MOL CELL BIOL, V5, P780, DOI 10.1128/MCB.5.4.780	56	17	17	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1988	2	4					359	366						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M9472	3283654				2022-12-17	WOS:A1988M947200008
J	TAVASSOLI, M; SHALL, S				TAVASSOLI, M; SHALL, S			TRANSCRIPTION OF THE C-MYC ONCOGENE IS ALTERED IN SPONTANEOUSLY IMMORTALIZED RODENT FIBROBLASTS	ONCOGENE			English	Article											TAVASSOLI, M (corresponding author), UNIV SUSSEX, CELL & MOLEC BIOL LAB, BIOL BLDG, BRIGHTON BN1 9QG, E SUSSEX, ENGLAND.							ALITALO K, 1986, ADV CANCER RES, V47, P235, DOI 10.1016/S0065-230X(08)60201-8; BERK AJ, 1977, CELL, V12, P721, DOI 10.1016/0092-8674(77)90272-0; BISTER K, 1986, ADV CANCER RES, V47, P99, DOI 10.1016/S0065-230X(08)60199-2; BISTER K, 1977, VIROLOGY, V82, P431, DOI 10.1016/0042-6822(77)90017-4; BLANCHARD JM, 1985, NATURE, V317, P443, DOI 10.1038/317443a0; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; CURRAN T, 1982, VIROLOGY, V116, P221, DOI 10.1016/0042-6822(82)90415-9; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; DELLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P6497, DOI 10.1073/pnas.79.21.6497; DONNER P, 1982, NATURE, V296, P262, DOI 10.1038/296262a0; DUESBERG PH, 1977, P NATL ACAD SCI USA, V74, P4320, DOI 10.1073/pnas.74.10.4320; EISENMAN RN, 1986, CANCER SURV, V5, P309; ELLIS RW, 1981, NATURE, V292, P506, DOI 10.1038/292506a0; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; IGUCHIARIGA SMM, 1987, EMBO J, V6, P2365, DOI 10.1002/j.1460-2075.1987.tb02513.x; KARATZA C, 1984, J CELL SCI, V65, P163; KARATZA C, 1984, J CELL SCI, V66, P401; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KRAEMER PM, 1986, J NATL CANCER I, V76, P703, DOI 10.1093/jnci/76.4.703; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEE WMF, 1985, MOL CELL BIOL, V5, P3345, DOI 10.1128/MCB.5.12.3345; LEY TJ, 1982, P NATL ACAD SCI-BIOL, V79, P4775, DOI 10.1073/pnas.79.15.4775; MANIATIS T, 1982, MOL CLONING LABORATO; MILES MF, 1981, J BIOL CHEM, V256, P2545; MOUGNEAU E, 1984, P NATL ACAD SCI-BIOL, V81, P5758, DOI 10.1073/pnas.81.18.5758; NEUBERGER MS, 1983, NATURE, V305, P240, DOI 10.1038/305240a0; NICOLAIEW N, 1986, EXP CELL RES, V166, P357, DOI 10.1016/0014-4827(86)90482-9; PERSSON H, 1984, SCIENCE, V225, P718, DOI 10.1126/science.6463648; PIECHACZYK M, 1985, CELL, V42, P589, DOI 10.1016/0092-8674(85)90116-3; PONTEN J, 1983, J CELL PHYSIOL, V117, P342, DOI 10.1002/jcp.1041170309; PONTEN J, 1971, SPONTANEOUS VIRUS IN; RABBITTS PH, 1985, EMBO J, V4, P3727, DOI 10.1002/j.1460-2075.1985.tb04141.x; RABBITTS TH, 1985, TRENDS GENET, V1, P327, DOI 10.1016/0168-9525(85)90127-1; RALSTON R, 1983, NATURE, V306, P803, DOI 10.1038/306803a0; RASSOULZADEGAN M, 1983, P NATL ACAD SCI-BIOL, V80, P4354, DOI 10.1073/pnas.80.14.4354; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SCHIBLER U, 1983, CELL, V33, P501, DOI 10.1016/0092-8674(83)90431-2; SHALL S, 1979, J THEOR BIOL, V76, P219, DOI 10.1016/0022-5193(79)90371-0; SHALL S, 1987, PERSPECTIVES MAMMALI, P184; SMITH JR, 1984, P NATL ACAD SCI USA, V83, P8167; STANTON LW, 1984, NATURE, V310, P423, DOI 10.1038/310423a0; STEIN WD, 1978, CELL REPRODUCTION, P147; STUDZINSKI GP, 1986, SCIENCE, V234, P467, DOI 10.1126/science.3532322; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; VARMUS HE, 1984, ANNU REV GENET, V18, P553; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917	52	17	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1988	2	4					337	345						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M9472	3283652				2022-12-17	WOS:A1988M947200005
J	HUME, CR; NOCKA, KH; SORRENTINO, V; LEE, JS; FLEISSNER, E				HUME, CR; NOCKA, KH; SORRENTINO, V; LEE, JS; FLEISSNER, E			CONSTITUTIVE C-MYC EXPRESSION ENHANCES THE RESPONSE OF MURINE MAST-CELLS TO IL-3, BUT DOES NOT ELIMINATE THEIR REQUIREMENT FOR GROWTH-FACTORS	ONCOGENE			English	Article									CORNELL UNIV,GRAD SCH MED SCI,SLOAN KETTERING DIV,NEW YORK,NY 10021	Cornell University; Memorial Sloan Kettering Cancer Center			Sorrentino, Vincenzo/A-4793-2014	Sorrentino, Vincenzo/0000-0002-8573-8631				ALEXANDER WS, 1987, MOL CELL BIOL, V7, P1436, DOI 10.1128/MCB.7.4.1436; ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; CONSCIENCE JF, 1986, EMBO J, V5, P317, DOI 10.1002/j.1460-2075.1986.tb04215.x; CORY S, 1987, ONCOGENE RES, V1, P61; DEAN M, 1987, ONCOGENE RES, V1, P279; DUNNICK W, 1983, P NATL ACAD SCI-BIOL, V80, P7269, DOI 10.1073/pnas.80.23.7269; Favaloro J, 1980, Methods Enzymol, V65, P718; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAHN SR, 1985, NATURE, V314, P366; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; LEDER P, 1983, SCIENCE, V222, P765, DOI 10.1126/science.6356357; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; METCALF D, 1985, BLOOD, V65, P357; RALPH P, 1976, J EXP MED, V143, P1528, DOI 10.1084/jem.143.6.1528; RAPP UR, 1985, NATURE, V317, P434, DOI 10.1038/317434a0; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SORRENTINO V, 1986, P NATL ACAD SCI USA, V83, P8167, DOI 10.1073/pnas.83.21.8167; SORRENTINO V, IN PRESS ANN NY ACAD; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; STERN DF, 1986, MOL CELL BIOL, V6, P870, DOI 10.1128/MCB.6.3.870; THOMPSON CB, 1985, NATURE, V314, P363, DOI 10.1038/314363a0; YUNG YP, 1981, J IMMUNOL, V127, P794; ZERLIN M, 1987, ONCOGENE, V1, P19	26	17	17	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1988	2	3					223	226						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M5931	3281092				2022-12-17	WOS:A1988M593100003
J	POPESCU, NC; KAWAKAMI, T; MATSUI, T; ROBBINS, KC				POPESCU, NC; KAWAKAMI, T; MATSUI, T; ROBBINS, KC			CHROMOSOMAL LOCALIZATION OF THE HUMAN FYN-GENE	ONCOGENE			English	Note									NCI,BIOL LAB,CELLULAR & MOLEC BIOL LAB,BLDG 37,ROOM 1E24,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Kawakami, Toshiaki/O-1616-2015; Matsui, Toshimitsu/E-8065-2010	Matsui, Toshimitsu/0000-0002-2536-7584				BALABAN GB, 1986, CANCER GENET CYTOGEN, V19, P113, DOI 10.1016/0165-4608(86)90378-X; BECHER R, 1981, CANCER GENET CYTOGEN, V5, P173; BENEDICT WF, 1983, CANCER GENET CYTOGEN, V10, P311, DOI 10.1016/0165-4608(83)90090-0; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; CHANDLER ME, 1978, CYTOGENET CELL GENET, V22, P352, DOI 10.1159/000130970; GIBAS Z, 1986, CANCER GENET CYTOGEN, V20, P191, DOI 10.1016/0165-4608(86)90074-9; HARPER ME, 1983, NATURE, V304, P169, DOI 10.1038/304169a0; HARPER ME, 1981, CHROMOSOMA, V83, P431, DOI 10.1007/BF00327364; HEIM S, 1987, HUM GENET, V75, P70; JANSSEN JWG, 1986, CYTOGENET CELL GENET, V41, P129, DOI 10.1159/000132217; KAWAKAMI T, 1986, MOL CELL BIOL, V6, P4195, DOI 10.1128/MCB.6.12.4195; NAGARAJAN L, 1986, P NATL ACAD SCI USA, V83, P6568, DOI 10.1073/pnas.83.17.6568; NAGARAJAN L, 1986, P NATL ACAD SCI USA, V83, P2556, DOI 10.1073/pnas.83.8.2556; NOWELL PC, 1982, J INVEST DERMATOL, V78, P69, DOI 10.1111/1523-1747.ep12497947; OSHIMURA M, 1976, LANCET, V2, P1045; PATHAK S, 1983, CYTOGENET CELL GENET, V36, P573, DOI 10.1159/000131975; POPESCU NC, 1985, CYTOGENET CELL GENET, V39, P73, DOI 10.1159/000132107; POPESCU NC, 1985, SOMAT CELL MOLEC GEN, V11, P149, DOI 10.1007/BF01534703; SAKAGUCHI AY, 1983, PROG NUCLEIC ACID RE, V29, P279, DOI 10.1016/S0079-6603(08)60460-2; SEMBA K, 1985, SCIENCE, V227, P1038, DOI 10.1126/science.2983418; SEMBA K, 1986, P NATL ACAD SCI USA, V83, P5459, DOI 10.1073/pnas.83.15.5459; SQUIRE J, 1984, HUM GENET, V66, P46, DOI 10.1007/BF00275185; STENMAN G, 1986, CANCER GENET CYTOGEN, V22, P283, DOI 10.1016/0165-4608(86)90021-X; TRENT JM, 1981, CANCER GENET CYTOGEN, V3, P279, DOI 10.1016/0165-4608(81)90037-6; TRONICK SR, 1985, P NATL ACAD SCI USA, V82, P6595, DOI 10.1073/pnas.82.19.6595; WAKE N, 1980, CANCER RES, V40, P4512; WHANGPENG J, 1985, J NATL CANCER I, V74, P357; Yunis J J, 1986, Important Adv Oncol, P93	28	17	18	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene		1987	1	4					449	451						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	K7483	3330788				2022-12-17	WOS:A1987K748300016
J	Zhao, SL; Guan, BJ; Mi, YS; Shi, DB; Wei, P; Gu, YZ; Cai, SJ; Xu, Y; Li, XX; Yan, DW; Huang, MZ; Li, DW				Zhao, Senlin; Guan, Bingjie; Mi, Yushuai; Shi, Debing; Wei, Ping; Gu, Yanzi; Cai, Sanjun; Xu, Ye; Li, Xinxiang; Yan, Dongwang; Huang, Mingzhu; Li, Dawei			LncRNA MIR17HG promotes colorectal cancer liver metastasis by mediating a glycolysis-associated positive feedback circuit	ONCOGENE			English	Article								Glycolysis plays a crucial role in reprogramming the metastatic tumor microenvironment. A series of lncRNAs have been identified to function as oncogenic molecules by regulating glycolysis. However, the roles of glycolysis-related lncRNAs in regulating colorectal cancer liver metastasis (CRLM) remain poorly understood. In the present study, the expression of the glycolysis-related lncRNA MIR17HG gradually increased from adjacent normal to CRC to the paired liver metastatic tissues, and high MIR17HG expression predicted poor survival, especially in patients with liver metastasis. Functionally, MIR17HG promoted glycolysis in CRC cells and enhanced their invasion and liver metastasis in vitro and in vivo. Mechanistically, MIR17HG functioned as a ceRNA to regulate HK1 expression by sponging miR-138-5p, resulting in glycolysis in CRC cells and leading to their invasion and liver metastasis. More interestingly, lactate accumulated via glycolysis activated the p38/Elk-1 signaling pathway to promote the transcriptional expression of MIR17HG in CRC cells, forming a positive feedback loop, which eventually resulted in persistent glycolysis and the invasion and liver metastasis of CRC cells. In conclusion, the present study indicates that the lactate-responsive lncRNA MIR17HG, acting as a ceRNA, promotes CRLM through a glycolysis-mediated positive feedback circuit and might be a novel biomarker and therapeutic target for CRLM.	[Zhao, Senlin; Shi, Debing; Cai, Sanjun; Xu, Ye; Li, Xinxiang; Li, Dawei] Fudan Univ, Shanghai Canc Ctr, Dept Colorectal Surg, Shanghai, Peoples R China; [Zhao, Senlin; Shi, Debing; Wei, Ping; Cai, Sanjun; Xu, Ye; Li, Xinxiang; Huang, Mingzhu; Li, Dawei] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China; [Guan, Bingjie; Yan, Dongwang] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Sch Med, Dept Gen Surg, Shanghai, Peoples R China; [Mi, Yushuai] Shandong Univ, Hosp 2, Cheeloo Coll Med, Dept Gastrointestinal Surg, Jinan, Peoples R China; [Wei, Ping] Fudan Univ, Canc Inst, Shanghai Canc Ctr, Shanghai, Peoples R China; [Wei, Ping] Fudan Univ, Shanghai Canc Ctr, Dept Pathol, Shanghai, Peoples R China; [Gu, Yanzi] Fudan Univ, Shanghai Canc Ctr, Dept Biobank, Shanghai, Peoples R China; [Huang, Mingzhu] Fudan Univ, Shanghai Canc Ctr, Dept Med Oncol, Shanghai, Peoples R China	Fudan University; Fudan University; Shanghai Jiao Tong University; Shandong University; Fudan University; Fudan University; Fudan University; Fudan University	Li, DW (corresponding author), Fudan Univ, Shanghai Canc Ctr, Dept Colorectal Surg, Shanghai, Peoples R China.; Huang, MZ; Li, DW (corresponding author), Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China.; Yan, DW (corresponding author), Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Sch Med, Dept Gen Surg, Shanghai, Peoples R China.; Huang, MZ (corresponding author), Fudan Univ, Shanghai Canc Ctr, Dept Med Oncol, Shanghai, Peoples R China.	yandw70@163.com; mingzhuhuang0718@163.com; li_dawei@fudan.edu.cn	xu, ye/GQO-8972-2022		National Nature Science Foundation of China [81772583, 81871931, 81802420, 81972293, 82003088]; Shanghai Sailing Program [19YF1409600]; Nature Science Foundation of Shandong Province [ZR2019PH008]	National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Sailing Program; Nature Science Foundation of Shandong Province(Natural Science Foundation of Shandong Province)	This research was supported by grants from the National Nature Science Foundation of China (81772583, 81871931, 81802420, 81972293, 82003088), Shanghai Sailing Program (19YF1409600), the Nature Science Foundation of Shandong Province (ZR2019PH008).	Alspach E, 2014, CANCER DISCOV, V4, P716, DOI 10.1158/2159-8290.CD-13-0743; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chen C, 2019, ONCOGENE, V38, P4527, DOI 10.1038/s41388-019-0735-4; Chen F, 2019, NAT CELL BIOL, V21, P498, DOI 10.1038/s41556-019-0299-0; Chen JA, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0947-9; Dekker E, 2019, LANCET, V394, P1467, DOI 10.1016/S0140-6736(19)32319-0; Fakih MG, 2015, J CLIN ONCOL, V33, P1809, DOI 10.1200/JCO.2014.59.7633; Ganesh K, 2019, NAT REV GASTRO HEPAT, V16, P361, DOI 10.1038/s41575-019-0126-x; Graziano F, 2017, PHARMACOGENOMICS J, V17, P258, DOI 10.1038/tpj.2016.13; He D, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13911-x; Hu QS, 2019, NAT IMMUNOL, V20, P835, DOI 10.1038/s41590-019-0400-7; Huarte M, 2015, NAT MED, V21, P1253, DOI 10.1038/nm.3981; Ippolito L, 2019, TRENDS BIOCHEM SCI, V44, P153, DOI 10.1016/j.tibs.2018.10.011; Jiao Lin, 2018, Autophagy, V14, P671, DOI 10.1080/15548627.2017.1381804; Koutsioumpa M, 2019, GUT, V68, P1271, DOI 10.1136/gutjnl-2017-315690; Kumar S, 1999, BIOCHEM BIOPH RES CO, V263, P825, DOI 10.1006/bbrc.1999.1454; Lee DC, 2015, CELL, V161, P595, DOI 10.1016/j.cell.2015.03.011; Lee HJ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10374-y; Lee YS, 2018, CELL HOST MICROBE, V24, P833, DOI 10.1016/j.chom.2018.11.002; Li Q, 2019, HEPATOLOGY, V70, P1298, DOI 10.1002/hep.30671; Liberti MV, 2016, TRENDS BIOCHEM SCI, V41, P211, DOI 10.1016/j.tibs.2015.12.001; Liu QH, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-020-01021-x; Miranda-Goncalves V, 2013, NEURO-ONCOLOGY, V15, P172, DOI 10.1093/neuonc/nos298; Olivero CE, 2020, MOL CELL, V77, P761, DOI 10.1016/j.molcel.2019.12.014; Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006; Puccini A, 2018, NAT REV CLIN ONCOL, V15, P77, DOI 10.1038/nrclinonc.2017.185; Qu L, 2016, CANCER CELL, V29, P653, DOI 10.1016/j.ccell.2016.03.004; Quinn JJ, 2016, NAT REV GENET, V17, P47, DOI 10.1038/nrg.2015.10; Rapino F, 2018, NATURE, V558, P605, DOI 10.1038/s41586-018-0243-7; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Sonveaux P, 2008, J CLIN INVEST, V118, P3930, DOI 10.1172/JCI36843; Vegran F, 2011, CANCER RES, V71, P2550, DOI 10.1158/0008-5472.CAN-10-2828; Wei S, 2020, BMC PULM MED, V20, DOI 10.1186/s12890-020-1112-3; Wiel C, 2019, CELL, V178, P330, DOI 10.1016/j.cell.2019.06.005; Xiao GA, 2019, EUR UROL, V76, P315, DOI 10.1016/j.eururo.2018.11.012; Xie LYJ, 2019, CELL CYCLE, V18, P2110, DOI 10.1080/15384101.2019.1641388; Xu J, 2019, CANCER RES, V79, P4882, DOI 10.1158/0008-5472.CAN-18-3880; Zhao X, 2020, AUTOPHAGY, V16, P70, DOI 10.1080/15548627.2019.1598750; Zhuang M, 2019, EBIOMEDICINE, V41, P286, DOI 10.1016/j.ebiom.2018.12.049; Zhuo W, 2019, GASTROENTEROLOGY, V156, P676, DOI 10.1053/j.gastro.2018.10.054	40	16	16	7	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2021	40	28					4709	4724		10.1038/s41388-021-01859-6	http://dx.doi.org/10.1038/s41388-021-01859-6		JUN 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK8LG	34145399	Green Published, hybrid			2022-12-17	WOS:000663295300004
J	Zhang, Y; Wang, Y; Zhou, D; Wang, K; Wang, X; Wang, X; Jiang, Y; Zhao, M; Yu, RT; Zhou, XP				Zhang, Yu; Wang, Yan; Zhou, Ding; Wang, Kai; Wang, Xu; Wang, Xiang; Jiang, Yang; Zhao, Min; Yu, Rutong; Zhou, Xiuping			Radiation-induced YAP activation confers glioma radioresistance via promoting FGF2 transcription and DNA damage repair	ONCOGENE			English	Article							FIBROBLAST-GROWTH-FACTOR; GLIOBLASTOMA RADIORESISTANCE; HIPPO PATHWAY; CELLS; INVASION; PROTEIN; EXPRESSION; MIGRATION; AKT	Although radiotherapy is a well-known effective non-surgical treatment for malignant gliomas, the therapeutic efficacy is severely limited due to the radioresistance of tumor cells. Previously, we demonstrated that Yes-associated protein (YAP) promotes glioma malignant progression. However, whether YAP plays a role in radioresistance and its potential value in cancer treatment are still unclear. In this study, we found that high YAP expression is associated with poor prognosis in malignant glioma patients undergoing radiotherapy. Research in immortalized cell lines and primary cells from GBM patients revealed that YAP exhibited a radioresistant effect on gliomas via promoting DNA damage repair. Mechanistically, after radiation, YAP was translocated into the nucleus, where it promoted the expression and secretion of FGF2, leading to MAPK-ERK pathway activation. FGF2 is a novel target gene of YAP. Inhibition of YAP-FGF2-MAPK signaling sensitizes gliomas to radiotherapy and prolongs the survival of intracranial cell-derived and patient-derived xenograft models. These results suggest that YAP-FGF2-MAPK is a key mechanism of radioresistance and is an actionable target for improving radiotherapy efficacy.	[Zhang, Yu; Wang, Yan; Zhou, Ding; Wang, Kai; Wang, Xu; Wang, Xiang; Jiang, Yang; Zhao, Min; Yu, Rutong; Zhou, Xiuping] Xuzhou Med Univ, Inst Nervous Syst Dis, Xuzhou, Jiangsu, Peoples R China; [Zhang, Yu; Wang, Yan; Zhou, Ding; Wang, Kai; Wang, Xu; Wang, Xiang; Jiang, Yang; Zhao, Min; Yu, Rutong; Zhou, Xiuping] Xuzhou Med Univ, Affiliated Hosp, Dept Neurosurg, Xuzhou, Jiangsu, Peoples R China; [Zhang, Yu; Wang, Yan; Zhou, Ding; Wang, Kai; Wang, Xu; Wang, Xiang; Jiang, Yang; Zhao, Min; Yu, Rutong; Zhou, Xiuping] Xuzhou Med Univ, Grad Sch, Xuzhou, Jiangsu, Peoples R China	Xuzhou Medical University; Xuzhou Medical University; Xuzhou Medical University	Yu, RT; Zhou, XP (corresponding author), Xuzhou Med Univ, Inst Nervous Syst Dis, Xuzhou, Jiangsu, Peoples R China.; Yu, RT; Zhou, XP (corresponding author), Xuzhou Med Univ, Affiliated Hosp, Dept Neurosurg, Xuzhou, Jiangsu, Peoples R China.; Yu, RT; Zhou, XP (corresponding author), Xuzhou Med Univ, Grad Sch, Xuzhou, Jiangsu, Peoples R China.	yu.rutong@163.com; xpzhou@xzhmu.edu.cn			National Natural Science Foundation of China [81872053, 81902526, 82072770]; Natural Science Foundation of Jiangsu province [BK20201458]; Postgraduate Research & Practice Innovation Program of Jiangsu Province [KYCX19_2225]; Social Development Project of XuZhou [KC20125]; Youth Science and Technology Innovation Team Cultivation Program of Xuzhou Medical University [TD2020002]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Jiangsu province(Natural Science Foundation of Jiangsu Province); Postgraduate Research & Practice Innovation Program of Jiangsu Province; Social Development Project of XuZhou; Youth Science and Technology Innovation Team Cultivation Program of Xuzhou Medical University	We thank the supports from Professor Longzhen Zhang and Professor Lingyu Zeng at the Affiliated Hospital of Xuzhou Medical University. This work was supported by the National Natural Science Foundation of China (numbers 81872053, 81902526, and 82072770); Natural Science Foundation of Jiangsu province (number BK20201458); the Postgraduate Research & Practice Innovation Program of Jiangsu Province (number KYCX19_2225), Social Development Project of XuZhou (number KC20125), and Youth Science and Technology Innovation Team Cultivation Program of Xuzhou Medical University (number TD2020002).	Ader I, 2002, ONCOGENE, V21, P6471, DOI 10.1038/sj.onc.1205838; Ader I, 2014, EUR J CANCER, V50, P2351, DOI 10.1016/j.ejca.2014.05.012; Beenken A, 2009, NAT REV DRUG DISCOV, V8, P235, DOI 10.1038/nrd2792; Ciamporcero E, 2016, ONCOGENE, V35, P1541, DOI 10.1038/onc.2015.219; CohenJonathan E, 1997, CANCER RES, V57, P1364; Edgar BA, 2006, CELL, V124, P267, DOI 10.1016/j.cell.2006.01.005; Fernandez A, 2012, ONCOGENE, V31, P1923, DOI 10.1038/onc.2011.379; Georgiou V, 2019, REV NEUROSCIENCE, V30, P543, DOI 10.1515/revneuro-2018-0051; Golding SE, 2009, CANCER BIOL THER, V8, P730, DOI 10.4161/cbt.8.8.7927; Gouaze-Andersson V, 2016, CANCER RES, V76, P3036, DOI 10.1158/0008-5472.CAN-15-2058; Gulston M, 2002, NUCLEIC ACIDS RES, V30, P3464, DOI 10.1093/nar/gkf467; Han D, 2020, STEM CELLS DEV, V29, P1240, DOI 10.1089/scd.2019.0281; Han XT, 2017, ONCOTARGET, V8, P100931, DOI 10.18632/oncotarget.21753; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; Hu HM, 2018, CELL, V175, P1665, DOI 10.1016/j.cell.2018.09.038; Hua G, 2016, ONCOGENE, V35, P2247, DOI 10.1038/onc.2015.288; Ibrahimi OA, 2004, BIOCHEMISTRY-US, V43, P4724, DOI 10.1021/bi0352320; Jiang T, 2021, CANCER LETT, V499, P60, DOI 10.1016/j.canlet.2020.10.050; Katoh M, 2014, MED RES REV, V34, P280, DOI 10.1002/med.21288; Kim MH, 2017, CELL MOL LIFE SCI, V74, P1457, DOI 10.1007/s00018-016-2412-x; Liu XJ, 2015, J NEURO-ONCOL, V125, P113, DOI 10.1007/s11060-015-1901-3; Liu YP, 2016, CELL MOL NEUROBIOL, V36, P737, DOI 10.1007/s10571-015-0254-y; Ma JH, 2019, CANCER CELL, V35, P504, DOI [10.1016/j.ccell.2019.01.020, 10.1016/j.ccell.2019.04.011]; Marampon F, 2014, INT J ONCOL, V44, P2121, DOI 10.3892/ijo.2014.2358; Miao FA, 2019, J NEURO-ONCOL, V143, P221, DOI 10.1007/s11060-019-03163-6; Morgenroth A, 2014, ONCOTARGET, V5, P5483, DOI 10.18632/oncotarget.2123; Steinhardt AA, 2008, HUM PATHOL, V39, P1582, DOI 10.1016/j.humpath.2008.04.012; Sudol M, 2012, SEMIN CELL DEV BIOL, V23, P827, DOI 10.1016/j.semcdb.2012.05.002; Toyoda K, 2013, CELL MOL NEUROBIOL, V33, P489, DOI 10.1007/s10571-013-9913-z; Turner N, 2010, NAT REV CANCER, V10, P116, DOI 10.1038/nrc2780; Wang X, 2019, CELL PROLIFERAT, V52, DOI 10.1111/cpr.12636; Wang Y, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0606-1; Yan JF, 2019, J CELL PHYSIOL, V234, P13014, DOI 10.1002/jcp.27971; Yu FX, 2015, CELL, V163, P811, DOI 10.1016/j.cell.2015.10.044; Zhang L, 2019, ONCOGENE, V38, P2788, DOI 10.1038/s41388-018-0626-0; Zhang Y, 2018, J MOL NEUROSCI, V64, P262, DOI 10.1007/s12031-017-1018-6; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408; Zhou XP, 2017, NEURO-ONCOLOGY, V19, P1628, DOI 10.1093/neuonc/nox104; Zhou Z, 2011, HEPATO-GASTROENTEROL, V58, P2156, DOI 10.5754/hge11234	39	16	16	2	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2021	40	27					4580	4591		10.1038/s41388-021-01878-3	http://dx.doi.org/10.1038/s41388-021-01878-3		JUN 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TG4PV	34127812	Green Published, hybrid			2022-12-17	WOS:000661408100004
J	Fukasawa, K; Kadota, T; Horie, T; Tokumura, K; Terada, R; Kitaguchi, Y; Park, G; Ochiai, S; Iwahashi, S; Okayama, Y; Hiraiwa, M; Yamada, T; Iezaki, T; Kaneda, K; Yamamoto, M; Kitao, T; Shirahase, H; Hazawa, M; Wong, RW; Todo, T; Hirao, A; Hinoi, E				Fukasawa, Kazuya; Kadota, Takuya; Horie, Tetsuhiro; Tokumura, Kazuya; Terada, Ryuichi; Kitaguchi, Yuka; Park, Gyujin; Ochiai, Shinsuke; Iwahashi, Sayuki; Okayama, Yasuka; Hiraiwa, Manami; Yamada, Takanori; Iezaki, Takashi; Kaneda, Katsuyuki; Yamamoto, Megumi; Kitao, Tatsuya; Shirahase, Hiroaki; Hazawa, Masaharu; Wong, Richard W.; Todo, Tomoki; Hirao, Atsushi; Hinoi, Eiichi			CDK8 maintains stemness and tumorigenicity of glioma stem cells by regulating the c-MYC pathway	ONCOGENE			English	Article								Glioblastoma (GBM) is the most malignant form of glioma. Glioma stem cells (GSCs) contribute to the initiation, progression, and recurrence of GBM as a result of their self-renewal potential and tumorigenicity. Cyclin-dependent kinase 8 (CDK8) belongs to the transcription-related CDK family. Although CDK8 has been shown to be implicated in the malignancy of several types of cancer, its functional role and mechanism in gliomagenesis remain largely unknown. Here, we demonstrate how CDK8 plays an essential role in maintaining stemness and tumorigenicity in GSCs. The genetic inhibition of CDK8 by shRNA or CRISPR interference resulted in an abrogation of the self-renewal potential and tumorigenicity of patient-derived GSCs, which could be significantly rescued by the ectopic expression of c-MYC, a stem cell transcription factor. Moreover, we demonstrated that the pharmacological inhibition of CDK8 significantly attenuated the self-renewal potential and tumorigenicity of GSCs. CDK8 expression was significantly higher in human GBM tissues than in normal brain tissues, and its expression was positively correlated with stem cell markers including c-MYC and SOX2 in human GBM specimens. Additionally, CDK8 expression is associated with poor survival in GBM patients. Collectively, these findings highlight the importance of the CDK8-c-MYC axis in maintaining stemness and tumorigenicity in GSCs; these findings also identify the CDK8-c-MYC axis as a potential target for GSC-directed therapy.	[Fukasawa, Kazuya; Kadota, Takuya; Horie, Tetsuhiro; Tokumura, Kazuya; Terada, Ryuichi; Kitaguchi, Yuka; Park, Gyujin; Ochiai, Shinsuke; Iwahashi, Sayuki; Okayama, Yasuka; Hiraiwa, Manami; Yamada, Takanori; Iezaki, Takashi; Hinoi, Eiichi] Gifu Pharmaceut Univ, Dept Bioact Mol, Lab Pharmacol, Gifu, Japan; [Kadota, Takuya; Yamamoto, Megumi; Kitao, Tatsuya; Shirahase, Hiroaki] Kyoto Pharmaceut Ind Co Ltd, Drug Discovery Res Dept, Kyoto, Japan; [Kitaguchi, Yuka; Kaneda, Katsuyuki] Kanazawa Univ, Grad Sch, Div Pharmaceut Sci, Lab Mol Pharmacol, Kanazawa, Ishikawa, Japan; [Hazawa, Masaharu; Wong, Richard W.] Kanazawa Univ, Inst Frontier Sci Initiat, Cell Bion Res Unit, Kanazawa, Ishikawa, Japan; [Wong, Richard W.; Hirao, Atsushi] Kanazawa Univ, WPI Nano Life Sci Inst WPI Nano LSI, Kanazawa, Ishikawa, Japan; [Todo, Tomoki] Univ Tokyo, Inst Med Sci, Div Innovat Canc Therapy, Tokyo, Japan; [Hirao, Atsushi] Kanazawa Univ, Canc Res Inst, Div Mol Genet, Canc & Stem Cell Res Program, Kanazawa, Ishikawa, Japan; [Hinoi, Eiichi] Gifu Univ, United Grad Sch Drug Discovery & Med Informat Sci, Gifu, Japan	Gifu Pharmaceutical University; Kyoto Pharmaceutical Industries Co., Ltd.; Kanazawa University; Kanazawa University; Kanazawa University; University of Tokyo; Kanazawa University; Gifu University	Hinoi, E (corresponding author), Gifu Pharmaceut Univ, Dept Bioact Mol, Lab Pharmacol, Gifu, Japan.	hinoi-e@gifu-pu.ac.jp	Wong, Richard W./E-9155-2011	Horie, Tetsuhiro/0000-0002-2095-9425; Fukasawa, Kazuya/0000-0002-1845-0275; Wong, Richard/0000-0002-2131-6595	Japan Society for the Promotion of Science [20H03407]; Extramural Collaborative Research Grant of Cancer Research Institute, Kanazawa University	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Extramural Collaborative Research Grant of Cancer Research Institute, Kanazawa University	We wish to thank Dr. H. Hojo (University of Tokyo) for technical training in RNA-seq data analysis. RNA-seq data and survival analysis were performed using the super-computing resource provided by Human Genome Center, the Institute of Medical Science, the University of Tokyo. This work was supported in part by the Japan Society for the Promotion of Science (20H03407 to EH), and the Extramural Collaborative Research Grant of Cancer Research Institute, Kanazawa University.	Adler AS, 2012, CANCER RES, V72, P2129, DOI 10.1158/0008-5472.CAN-11-3886; Alarcon C, 2009, CELL, V139, P757, DOI 10.1016/j.cell.2009.09.035; [Anonymous], 2018, N Engl J Med, V379, P2582, DOI 10.1056/NEJMx180043; Bancerek J, 2013, IMMUNITY, V38, P250, DOI 10.1016/j.immuni.2012.10.017; Bhat KPL, 2013, CANCER CELL, V24, P331, DOI 10.1016/j.ccr.2013.08.001; Bragelmann J, 2017, CLIN CANCER RES, V23, P1829, DOI 10.1158/1078-0432.CCR-16-0094; Broude EV, 2015, CURR CANCER DRUG TAR, V15, P739, DOI 10.2174/156800961508151001105814; Chen MQ, 2017, P NATL ACAD SCI USA, V114, P10208, DOI 10.1073/pnas.1710467114; Cheng L, 2013, CELL, V153, P139, DOI 10.1016/j.cell.2013.02.021; Conaway RC, 2011, CURR OPIN GENET DEV, V21, P225, DOI 10.1016/j.gde.2011.01.013; Dang CV, 2009, CLIN CANCER RES, V15, P6479, DOI 10.1158/1078-0432.CCR-09-0889; Finn RS, 2016, NEW ENGL J MED, V375, P1925, DOI 10.1056/NEJMoa1607303; Firestein R, 2008, NATURE, V455, P547, DOI 10.1038/nature07179; Galbraith MD, 2013, CELL, V153, P1327, DOI 10.1016/j.cell.2013.04.048; Gu WT, 2013, CELL CYCLE, V12, P987, DOI 10.4161/cc.24003; Ikushima H, 2009, CELL STEM CELL, V5, P504, DOI 10.1016/j.stem.2009.08.018; Kapoor A, 2010, NATURE, V468, P1105, DOI 10.1038/nature09590; Kitao T, 2019, YAKUGAKU ZASSHI, V139, P19, DOI 10.1248/yakushi.18-00154-2; Knuesel MT, 2009, MOL CELL BIOL, V29, P650, DOI 10.1128/MCB.00993-08; Kumar SK, 2015, BLOOD, V125, P443, DOI 10.1182/blood-2014-05-573741; Laderian B, 2017, SEMIN ONCOL, V44, P395, DOI 10.1053/j.seminoncol.2018.03.006; Lathia JD, 2015, GENE DEV, V29, P1203, DOI 10.1101/gad.261982.115; Lim SH, 2013, DEVELOPMENT, V140, P3079, DOI 10.1242/dev.091744; Malumbres M, 2014, GENOME BIOL, V15, DOI 10.1186/gb4184; Malumbres M, 2009, NAT CELL BIOL, V11, P1275, DOI 10.1038/ncb1109-1275; Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602; Martinez-Fabregas J, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108545; McCleland ML, 2015, J PATHOL, V237, P508, DOI 10.1002/path.4596; Meyer M, 2015, P NATL ACAD SCI USA, V112, P851, DOI 10.1073/pnas.1320611111; Ostrom QT, 2019, J NEURO-ONCOL, V142, P27, DOI 10.1007/s11060-018-03073-z; Patel AP, 2014, SCIENCE, V344, P1396, DOI 10.1126/science.1254257; Pelish HE, 2015, NATURE, V526, P273, DOI 10.1038/nature14904; Putz EM, 2013, CELL REP, V4, P437, DOI 10.1016/j.celrep.2013.07.012; Quevedo M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10502-8; Ramana CV, 2000, EMBO J, V19, P263, DOI 10.1093/emboj/19.2.263; Rinkenbaugh AL, 2016, ONCOTARGET, V7, P69173, DOI 10.18632/oncotarget.12507; Sachdeva R, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51270-1; Serrao A, 2018, ONCOGENE, V37, P4792, DOI 10.1038/s41388-018-0316-y; Shi Y, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aah6816; Sledge GW, 2017, J CLIN ONCOL, V35, P2875, DOI 10.1200/JCO.2017.73.7585; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Taatjes DJ, 2010, TRENDS BIOCHEM SCI, V35, P315, DOI 10.1016/j.tibs.2010.02.004; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Venere M, 2011, GLIA, V59, P1148, DOI 10.1002/glia.21185; Waghmare I, 2014, STEM CELL TRANSL MED, V3, P1262, DOI 10.5966/sctm.2014-0086; Wang JL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003769; Wasylishen Amanda R, 2010, Genes Cancer, V1, P532, DOI 10.1177/1947601910378024; Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126; Westerling T, 2007, MOL CELL BIOL, V27, P6177, DOI 10.1128/MCB.01302-06; Witalisz-Siepracka A, 2018, CANCER IMMUNOL RES, V6, P458, DOI 10.1158/2326-6066.CIR-17-0183; Xu DZ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7641; Xu W, 2015, CANCER LETT, V356, P613, DOI 10.1016/j.canlet.2014.10.008; Zhang JF, 2018, CANCER CELL INT, V18, DOI 10.1186/s12935-018-0694-9; Zhang N, 2011, CANCER CELL, V20, P427, DOI 10.1016/j.ccr.2011.08.016; Zheng H, 2008, COLD SH Q B, V73, P427, DOI 10.1101/sqb.2008.73.047; Zhou WC, 2015, NAT CELL BIOL, V17, P170, DOI 10.1038/ncb3090	56	16	16	1	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2021	40	15					2803	2815		10.1038/s41388-021-01745-1	http://dx.doi.org/10.1038/s41388-021-01745-1		MAR 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN8NW	33727660				2022-12-17	WOS:000629505700001
J	Eagen, KP; French, CA				Eagen, Kyle P.; French, Christopher A.			Supercharging BRD4 with NUT in carcinoma	ONCOGENE			English	Review							BROMODOMAIN PROTEIN BRD4; CELL-CYCLE PROGRESSION; MIDLINE CARCINOMA; C-MYC; TRANSCRIPTION FACTORS; GENE-EXPRESSION; SELECTIVE-INHIBITION; REVEALS PRINCIPLES; SUPER-ENHANCERS; P-TEFB	NUT carcinoma (NC) is an extremely aggressive squamous cancer with no effective therapy. NC is driven, most commonly, by the BRD4-NUT fusion oncoprotein. BRD4-NUT combines the chromatin-binding bromo- and extraterminal domain-containing (BET) protein, BRD4, with an unstructured, poorly understood protein, NUT, which recruits and activates the histone acetyltransferase p300. Recruitment of p300 to chromatin by BRD4 is believed to lead to the formation of hyperacetylated nuclear foci, as seen by immunofluorescence. BRD4-NUT nuclear foci correspond with massive contiguous regions of chromatin co-enriched with BRD4-NUT, p300, and acetylated histones, termed "megadomains" (MD). Megadomains stretch for as long as 2 MB. Proteomics has defined a BRD4-NUT chromatin complex in which members that associate with BRD4 also exist as rare NUT-fusion partners. This suggests that the common pathogenic denominator is the presence of both BRD4 and NUT, and that the function of BRD4-NUT may mimic that of wild-type BRD4. If so, then MDs may function as massive super-enhancers, activating transcription in a BET-dependent manner. Common targets of MDs across multiple NCs and tissues are three stem cell-related transcription factors frequently implicated in cancer: MYC, SOX2, and TP63. Recently, MDs were found to form a novel nuclear sub-compartment, called subcompartment M (subM), where MD-MD interactions occur both intra- and inter-chromosomally. Included in subM are MYC, SOX2, and TP63. Here we explore the possibility that if MDs are simply large super-enhancers, subM may exist in other cell systems, with broad implications for how 3D organization of the genome may function in gene regulation and maintenance of cell identity. Finally, we discuss how our knowledge of BRD4-NUT function has been leveraged for the therapeutic development of first-in-class BET inhibitors and other targeted strategies.	[Eagen, Kyle P.] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Dept Biochem & Mol Genet,Simpson Querrey Inst Epi, Chicago, IL 60611 USA; [French, Christopher A.] Brigham & Womens Hosp, Harvard Med Sch, Dept Pathol, Boston, MA 02115 USA	Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Eagen, KP (corresponding author), Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Dept Biochem & Mol Genet,Simpson Querrey Inst Epi, Chicago, IL 60611 USA.; French, CA (corresponding author), Brigham & Womens Hosp, Harvard Med Sch, Dept Pathol, Boston, MA 02115 USA.	eagen@northwestern.edu; Cfrench@bwh.harvard.edu		Eagen, Kyle/0000-0002-2610-8664; French, Christopher/0000-0002-7434-4987				Abbas HA, 2018, CANCER RES, V78, P451, DOI 10.1158/0008-5472.CAN-17-1803; Alekseyenko Artyom A, 2015, Curr Protoc Mol Biol, V109, DOI 10.1002/0471142727.mb2130s109; Alekseyenko AA, 2017, P NATL ACAD SCI USA, V114, pE4184, DOI 10.1073/pnas.1702086114; Alekseyenko AA, 2015, GENE DEV, V29, P1507, DOI 10.1101/gad.267583.115; Alexandrova EM, 2013, CELL DEATH DIFFER, V20, P1698, DOI 10.1038/cdd.2013.122; aniakas A, 2020, JAMA ONCOL; Asangani IA, 2014, NATURE, V510, P278, DOI 10.1038/nature13229; Bass AJ, 2009, NAT GENET, V41, P1238, DOI 10.1038/ng.465; Bauer DE, 2012, CLIN CANCER RES, V18, P5773, DOI 10.1158/1078-0432.CCR-12-1153; Beesley AH, 2014, BRIT J CANCER, V110, P1189, DOI 10.1038/bjc.2014.54; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Bragelmann J, 2017, CELL REP, V20, P2833, DOI 10.1016/j.celrep.2017.08.082; Cabrita R, 2020, NATURE, V577, P561, DOI 10.1038/s41586-019-1914-8; Chapuy B, 2013, CANCER CELL, V24, P777, DOI 10.1016/j.ccr.2013.11.003; Chau NG, 2020, JNCI CANCER SPECT, V4, DOI 10.1093/jncics/pkz094; Chen YL, 2018, CELL DEATH DIFFER, V25, P2118, DOI 10.1038/s41418-018-0132-5; Chiang CT, 2009, J CELL PHYSIOL, V219, P117, DOI 10.1002/jcp.21656; Coude MM, 2015, ONCOTARGET, V6, P17698, DOI 10.18632/oncotarget.4131; DAKSIS JI, 1994, ONCOGENE, V9, P3635; Dawson MA, 2011, NATURE, V478, P529, DOI 10.1038/nature10509; de Marval PLM, 2004, MOL CELL BIOL, V24, P7538, DOI 10.1128/MCB.24.17.7538-7547.2004; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Dey A, 2000, MOL CELL BIOL, V20, P6537, DOI 10.1128/MCB.20.17.6537-6549.2000; Dey A, 2003, P NATL ACAD SCI USA, V100, P8758, DOI 10.1073/pnas.1433065100; Di Micco R, 2014, CELL REP, V9, P234, DOI 10.1016/j.celrep.2014.08.055; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Faivre EJ, 2020, NATURE, V578, P306, DOI 10.1038/s41586-020-1930-8; Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; Fong CY, 2015, NATURE, V525, P538, DOI 10.1038/nature14888; French CA, 2008, ONCOGENE, V27, P2237, DOI 10.1038/sj.onc.1210852; French CA, 2004, J CLIN ONCOL, V22, P4135, DOI 10.1200/JCO.2004.02.107; French CA, 2003, CANCER RES, V63, P304; French CA, 2017, WHO CLASSIFICATION H; French CA, 2018, PATHOL INT, V68, P583, DOI 10.1111/pin.12727; French CA, 2014, CANCER DISCOV, V4, P928, DOI 10.1158/2159-8290.CD-14-0014; Giacobbe A, 2016, ONCOGENE, V35, P1602, DOI 10.1038/onc.2015.230; Gillespie MA, 2020, MOL CELL, V78, P960, DOI 10.1016/j.molcel.2020.03.031; Grayson AR, 2014, ONCOGENE, V33, P1736, DOI 10.1038/onc.2013.126; Guo LD, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17350-x; Haack H, 2009, AM J SURG PATHOL, V33, P984, DOI 10.1097/PAS.0b013e318198d666; Hamdan FH, 2018, P NATL ACAD SCI USA, V115, pE12343, DOI 10.1073/pnas.1812915116; Helmink BA, 2020, NATURE, V577, P549, DOI 10.1038/s41586-019-1922-8; Henssen A, 2013, ONCOTARGET, V4, DOI 10.18632/oncotarget.1534; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; Herranz D, 2014, NAT MED, V20, P1130, DOI 10.1038/nm.3665; Hinze L, 2019, CANCER CELL, V35, P664, DOI 10.1016/j.ccell.2019.03.004; Hnisz D, 2013, CELL, V155, P934, DOI 10.1016/j.cell.2013.09.053; Hussenet T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008960; Jang MK, 2005, MOL CELL, V19, P523, DOI 10.1016/j.molcel.2005.06.027; Janicki SM, 2004, CELL, V116, P683, DOI 10.1016/S0092-8674(04)00171-0; Konermann S, 2018, CELL, V173, P665, DOI 10.1016/j.cell.2018.02.033; Lanza M, 2006, CELL CYCLE, V5, P1996, DOI 10.4161/cc.5.17.3188; Lasko LM, 2017, NATURE, V550, P128, DOI 10.1038/nature24028; Latina A, 2016, ONCOGENE, V35, P1493, DOI 10.1038/onc.2015.222; Lee JK, 2017, ANN ONCOL, V28, P890, DOI 10.1093/annonc/mdw686; Lewin J, 2018, J CLIN ONCOL, V36, P3007, DOI 10.1200/JCO.2018.78.2292; Li N, 2016, MOL CELL, V63, P470, DOI 10.1016/j.molcel.2016.06.035; Liao SD, 2018, GENE DEV, V32, P1188, DOI 10.1101/gad.315648.118; Lieberman-Aiden E, 2009, SCIENCE, V326, P289, DOI 10.1126/science.1181369; Loven J, 2013, CELL, V153, P320, DOI 10.1016/j.cell.2013.03.036; Maher OM, 2015, PEDIATR BLOOD CANCER, V62, P715, DOI 10.1002/pbc.25350; Malovannaya A, 2011, CELL, V145, P787, DOI 10.1016/j.cell.2011.05.006; Mateyak MK, 1999, MOL CELL BIOL, V19, P4672; Matzuk MM, 2012, CELL, V150, P673, DOI 10.1016/j.cell.2012.06.045; McCleland ML, 2016, J CLIN INVEST, V126, P639, DOI 10.1172/JCI83265; Mertz JA, 2011, P NATL ACAD SCI USA, V108, P16669, DOI 10.1073/pnas.1108190108; Morrison-Smiths CD, 2020, MOL CANCER THER, V19, P1406, DOI 10.1158/1535-7163.MCT-20-0087; Mukhopadhyay A, 2014, CELL REP, V8, P40, DOI 10.1016/j.celrep.2014.05.036; Nicodeme E, 2010, NATURE, V468, P1119, DOI 10.1038/nature09589; Ortega E, 2018, NATURE, V562, P538, DOI 10.1038/s41586-018-0621-1; Palmer AC, 2017, CELL, V171, P1678, DOI 10.1016/j.cell.2017.11.009; Piha-Paul SA, 2020, JNCI CANCER SPECT, V4, DOI 10.1093/jncics/pkz093; Puissant A, 2013, CANCER DISCOV, V3, P308, DOI 10.1158/2159-8290.CD-12-0418; Qiu HF, 2015, ONCOTARGET, V6, P6915, DOI 10.18632/oncotarget.3126; Rahman S, 2011, MOL CELL BIOL, V31, P2641, DOI 10.1128/MCB.01341-10; Rao SSP, 2017, CELL, V171, P305, DOI 10.1016/j.cell.2017.09.026; Rao SSP, 2014, CELL, V159, P1665, DOI 10.1016/j.cell.2014.11.021; Reynoird N, 2010, EMBO J, V29, P2943, DOI 10.1038/emboj.2010.176; Riquelme E, 2014, J THORAC ONCOL, V9, P998, DOI 10.1097/JTO.0000000000000202; Rizk M, 2019, DRUG TODAY, V55, P315, DOI 10.1358/dot.2019.55.5.2958475; Roe JS, 2015, MOL CELL, V58, P1028, DOI 10.1016/j.molcel.2015.04.011; Romero FA, 2017, J MED CHEM, V60, P9162, DOI 10.1021/acs.jmedchem.7b00796; Rosencrance CD, 2020, MOL CELL, V78, P112, DOI 10.1016/j.molcel.2020.03.018; Saint-Andre V, 2016, GENOME RES, V26, P385, DOI 10.1101/gr.197590.115; Schwartz BE, 2011, CANCER RES, V71, P2686, DOI 10.1158/0008-5472.CAN-10-3513; Sheppard GS, 2020, J MED CHEM, V63, P5585, DOI 10.1021/acs.jmedchem.0c00628; Shiota H, 2018, CELL REP, V24, P3477, DOI 10.1016/j.celrep.2018.08.069; Shiota H, 2018, MOL CANCER RES, V16, P1826, DOI 10.1158/1541-7786.MCR-18-0474; Spruijt CG, 2016, CELL REP, V17, P783, DOI 10.1016/j.celrep.2016.09.037; Stathis A, 2016, CANCER DISCOV, V6, P492, DOI 10.1158/2159-8290.CD-15-1335; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; Stirnweiss A, 2017, ONCOTARGET, V8, P112313, DOI 10.18632/oncotarget.22862; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; TALBOT D, 1989, NATURE, V338, P352, DOI 10.1038/338352a0; Tilson MP, 2014, HEAD NECK PATHOL, V8, P141, DOI 10.1007/s12105-013-0496-2; Tseng YY, 2014, NATURE, V512, P82, DOI 10.1038/nature13311; Vito D, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2019.100785; Wang D, 2011, NATURE, V474, P390, DOI 10.1038/nature10006; Wang HF, 2014, P NATL ACAD SCI USA, V111, P705, DOI 10.1073/pnas.1315023111; Wang RR, 2015, J BIOL CHEM, V290, P2744, DOI 10.1074/jbc.M114.600759; Wang RR, 2014, CANCER RES, V74, P3332, DOI 10.1158/0008-5472.CAN-13-2658; Warner BJ, 1999, MOL CELL BIOL, V19, P5913; Watanabe H, 2014, J CLIN INVEST, V124, P1636, DOI 10.1172/JCI71545; Westcott JM, 2020, CANCER RES, V80, P3933, DOI 10.1158/0008-5472.CAN-20-0014; Whyte WA, 2013, CELL, V153, P307, DOI 10.1016/j.cell.2013.03.035; Wu T, 2018, CELL REP, V25, P1756, DOI 10.1016/j.celrep.2018.10.003; Wyce A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072967; Xiang JF, 2014, CELL RES, V24, P513, DOI 10.1038/cr.2014.35; Yan YQ, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201910659; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yang ZY, 2008, MOL CELL BIOL, V28, P967, DOI 10.1128/MCB.01020-07; Yang ZY, 2005, MOL CELL, V19, P535, DOI 10.1016/j.molcel.2005.06.029; Zhang X, 2020, ONCOGENE, V39, P4770, DOI 10.1038/s41388-020-1301-9	114	16	16	0	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2021	40	8					1396	1408		10.1038/s41388-020-01625-0	http://dx.doi.org/10.1038/s41388-020-01625-0		JAN 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QM6NM	33452461	Green Accepted			2022-12-17	WOS:000607998600003
J	Xiao, YN; Jin, L; Deng, CL; Guan, Y; Kalogera, E; Ray, U; Thirusangu, P; Staub, J; Bhattacharya, SS; Xu, HT; Fang, XL; Shridhar, V				Xiao, Yinan; Jin, Ling; Deng, Chaolin; Guan, Ye; Kalogera, Eleftheria; Ray, Upasana; Thirusangu, Prabhu; Staub, Julie; Bhattacharya, Sayantani Sarkar; Xu, Haotian; Fang, Xiaoling; Shridhar, Viji			Inhibition of PFKFB3 induces cell death and synergistically enhances chemosensitivity in endometrial cancer	ONCOGENE			English	Article							PHASE-II; THERAPEUTIC TARGET; OVARIAN-CANCER; TUMOR-GROWTH; AUTOPHAGY; GLYCOLYSIS; COMBINATION; METASTASIS; EXPRESSION; INDUCTION	The advanced or recurrent endometrial cancer (EC) has a poor prognosis because of chemoresistance. 6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3), a glycolytic enzyme, is overexpressed in a variety of human cancers and plays important roles in promoting tumor cell growth. Here, we showed that high expression of PFKFB3 in EC cell lines is associated with chemoresistance. Pharmacological inhibition of PFKFB3 with PFK158 and or genetic downregulation of PFKFB3 dramatically suppressed cell proliferation and enhanced the sensitivity of EC cells to carboplatin (CBPt) and cisplatin (Cis). Moreover, PFKFB3 inhibition resulted in reduced glucose uptake, ATP production, and lactate release. Notably, we found that PFK158 with CBPt or Cis exerted strong synergistic antitumor activity in chemoresistant EC cell lines, HEC-1B and ARK-2 cells. We also found that the combination of PFK158 and CBPt/Cis induced apoptosis- and autophagy-mediated cell death through inhibition of the Akt/mTOR signaling pathway. Mechanistically, we found that PFK158 downregulated the CBPt/Cis-induced upregulation of RAD51 expression and enhanced CBPt/Cis-induced DNA damage as demonstrated by an increase in gamma-H2AX levels in HEC-1B and ARK-2 cells, potentially revealing a means to enhance PFK158-induced chemosensitivity. More importantly, PFK158 treatment, either as monotherapy or in combination with CBPt, led to a marked reduction in tumor growth in two chemoresistant EC mouse xenograft models. These data suggest that PFKFB3 inhibition alone or in combination with standard chemotherapy may be used as a novel therapeutic strategy for improved therapeutic efficacy and outcomes of advanced and recurrent EC patients.	[Xiao, Yinan; Jin, Ling; Ray, Upasana; Thirusangu, Prabhu; Staub, Julie; Bhattacharya, Sayantani Sarkar; Shridhar, Viji] Mayo Clin, Dept Expt Pathol, Rochester, MN 55905 USA; [Xiao, Yinan; Fang, Xiaoling] Cent South Univ, Xiangya Hosp 2, Dept Obstet & Gynecol, Changsha, Hunan, Peoples R China; [Deng, Chaolin] Mayo Clin, Dept Gastroenterol & Hepatol, Rochester, MN USA; [Guan, Ye] Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA; [Kalogera, Eleftheria] Mayo Clin, Div Gynecol Oncol, Rochester, MN USA; [Xu, Haotian] Wayne State Univ, Dept Comp Sci, Detroit, MI 48202 USA	Mayo Clinic; Central South University; Mayo Clinic; University of Michigan System; University of Michigan; Mayo Clinic; Wayne State University	Shridhar, V (corresponding author), Mayo Clin, Dept Expt Pathol, Rochester, MN 55905 USA.	shridhar.vijayalakshmi@mayo.edu	Sarkar Bhattacharya, Sayantani/AAG-6222-2020	Sarkar Bhattacharya, Sayantani/0000-0001-8971-7566; Ray, Upasana/0000-0002-9804-6888; Xiao, Yinan/0000-0003-3873-9444	National Institutes of Health [P50CA136393]; Department of Experimental Pathology and Laboratory Medicine; Mayo Clinic; China Scholarship Council (CSC)	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Experimental Pathology and Laboratory Medicine; Mayo Clinic; China Scholarship Council (CSC)(China Scholarship Council)	We would like to thank Dr. Gottfried E. Konecny (UCLA Medical Center, Santa Monica), who provided the EC cell lines used in this study; Dr. Daniel Billadeau (Mayo Clinic, Rochester, MN) for providing the RFP-GFP-LC3B plasmid; Dr. Scott Kaufmann (Mayo Clinic, Rochester, MN) for providing the DR-GFP and I-SceI plasmids; the contributions of the Pathology Research Core laboratory, the Microscopy Core laboratory, and the Flow Cytometry Facility, Mayo Clinic, Rochester, MN. This work is supported in part by the National Institutes of Health P50CA136393 and the Department of Experimental Pathology and Laboratory Medicine and the Mayo Clinic (VS). The support provided by China Scholarship Council (CSC) during a visit of YX to Mayo Clinic is acknowledged.	Arend RC, 2018, GYNECOL ONCOL, V150, P569, DOI 10.1016/j.ygyno.2018.05.015; Atsumi T, 2002, CANCER RES, V62, P5881; Bhattacharya SS, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1916-3; Bobarykina AY, 2006, ACTA BIOCHIM POL, V53, P789, DOI 10.18388/abp.2006_3308; Cantelmo AR, 2016, CANCER CELL, V30, P968, DOI 10.1016/j.ccell.2016.10.006; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; Clem BF, 2013, MOL CANCER THER, V12, P1461, DOI 10.1158/1535-7163.MCT-13-0097; Cortez MA, 2015, MOL THER-NUCL ACIDS, V4, DOI 10.1038/mtna.2015.47; De Bock K, 2013, CELL, V154, P651, DOI 10.1016/j.cell.2013.06.037; Emons G, 2016, GYNECOL ONCOL, V140, P450, DOI 10.1016/j.ygyno.2015.12.025; Farkas T, 2009, AUTOPHAGY, V5, P1018, DOI 10.4161/auto.5.7.9443; Galluzzi L, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.428; Galluzzi L, 2012, ONCOGENE, V31, P1869, DOI 10.1038/onc.2011.384; Guan Y, 2018, ELIFE, V7, DOI 10.7554/eLife.33549; Gustafsson NMS, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06287-x; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Ngo H, 2015, MOL BIOL REP, V42, P825, DOI 10.1007/s11033-014-3764-7; Hong KJ, 2015, AM J CANCER RES, V5, P2422; Huang Z, 2016, INT J CANCER, V139, P23, DOI 10.1002/ijc.29990; Ji MM, 2015, AUTOPHAGY, V11, P2160, DOI 10.1080/15548627.2015.1082024; Jia WZ, 2018, ONCOGENE, V37, P1685, DOI 10.1038/s41388-017-0072-4; Jones NL, 2017, INT J CANCER, V140, P1396, DOI 10.1002/ijc.30537; Jung DB, 2015, ONCOTARGET, V6, P4992, DOI 10.18632/oncotarget.3214; Kessler R, 2008, J NEURO-ONCOL, V86, P257, DOI 10.1007/s11060-007-9471-7; Khurana A, 2015, ONCOTARGET, V6, P36354, DOI 10.18632/oncotarget.5632; Kim YC, 2015, J CLIN INVEST, V125, P25, DOI 10.1172/JCI73939; Li HM, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-016-0481-1; Liu Y, 2020, ONCOGENE, V39, P6190, DOI 10.1038/s41388-020-01422-9; Marino G, 2014, NAT REV MOL CELL BIO, V15, P81, DOI 10.1038/nrm3735; Minchenko OH, 2005, BIOCHIMIE, V87, P1005, DOI 10.1016/j.biochi.2005.04.007; Mondal S, 2019, INT J CANCER, V144, P178, DOI 10.1002/ijc.31868; Morice P, 2016, LANCET, V387, P1094, DOI 10.1016/S0140-6736(15)00130-0; Moxley KM, 2010, ONCOLOGIST, V15, P1026, DOI 10.1634/theoncologist.2010-0087; Myers AP, 2020, INT J CANCER, V147, P413, DOI 10.1002/ijc.32783; Nagathihalli NS, 2011, BBA-REV CANCER, V1816, P209, DOI 10.1016/j.bbcan.2011.07.004; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Ray-Coquard I, 2013, BRIT J CANCER, V108, P1771, DOI 10.1038/bjc.2013.183; Roncolato F, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012160.pub2; ROY D, 2017, SCI REP UK, V7; Rozengurt E, 2014, MOL CANCER THER, V13, P2477, DOI 10.1158/1535-7163.MCT-14-0330; Schoors S, 2014, CELL METAB, V19, P37, DOI 10.1016/j.cmet.2013.11.008; Shafer A, 2010, INT J CANCER, V126, P1144, DOI 10.1002/ijc.24837; Shi LL, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.44; Shi WK, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0435-y; Shteingauz A, 2015, CANCER RES, V75, P3946, DOI 10.1158/0008-5472.CAN-15-0037; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Slomovitz BM, 2012, CLIN CANCER RES, V18, P5856, DOI 10.1158/1078-0432.CCR-12-0662; Tsoref D, 2014, GYNECOL ONCOL, V135, P184, DOI 10.1016/j.ygyno.2014.06.033; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Ward A, 2015, CANCER TREAT REV, V41, P35, DOI 10.1016/j.ctrv.2014.10.006; White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023; Yan SY, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20215415; Zhao Y, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.60	53	16	16	3	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2021	40	8					1409	1424		10.1038/s41388-020-01621-4	http://dx.doi.org/10.1038/s41388-020-01621-4		JAN 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QM6NM	33420377	hybrid, Green Published			2022-12-17	WOS:000607346000014
J	Fan, KJ; Spassova, I; Gravemeyer, J; Ritter, C; Horny, K; Lange, A; Gambichler, T; Odum, N; Schrama, D; Schadendorf, D; Ugurel, S; Becker, JC				Fan, Kaiji; Spassova, Ivelina; Gravemeyer, Jan; Ritter, Cathrin; Horny, Kai; Lange, Anja; Gambichler, Thilo; Odum, Niels; Schrama, David; Schadendorf, Dirk; Ugurel, Selma; Becker, Juergen C.			Merkel cell carcinoma-derived exosome-shuttle miR-375 induces fibroblast polarization by inhibition of RBPJ and p53	ONCOGENE			English	Article							DOWN-REGULATION; EXPRESSION; MICRORNAS; MELANOMA; GENE; ANGIOGENESIS; RELEVANCE; YAP1; CSL	Merkel cell carcinoma (MCC) is a highly invasive and metastatic skin cancer. While high expression of miR-375 is a characteristic of MCC, it seems not to contribute to the malignant phenotype of MCC cells. miR-375 enrichment in MCC-derived extracellular vesicles suggests its intercellular signaling function. Here, we demonstrate that horizontally transferred miR-375 causes fibroblast polarization toward cancer-associated fibroblasts (CAFs). The polarization is evidenced by phenotypic changes and induction of alpha-SMA, CXCL2, and IL-1 beta. Fibroblast polarization is inhibited by specific antagomirs and mimicked by experimental miR-375 expression. Mechanistically, miR-375 downregulates RBPJ and p53, two key players regulating fibroblast polarization. In clinical MCC samples, in situ hybridization located miR-375 in CAFs, which correlated with high alpha-SMA protein and low RBPJ and TP53 expression; single-cell RNAseq revealed a disparate fibroblast polarization negatively correlating with p53 pathway-related gene expression. Thus, the functional role of miR-375 in MCC is to generate a pro-tumorigenic microenvironment by inducing fibroblast polarization.	[Fan, Kaiji; Spassova, Ivelina; Gravemeyer, Jan; Ritter, Cathrin; Horny, Kai; Becker, Juergen C.] Univ Hosp Essen, Dept Translat Skin Canc Res, Essen, Germany; [Fan, Kaiji; Spassova, Ivelina; Gravemeyer, Jan; Ritter, Cathrin; Horny, Kai; Schadendorf, Dirk; Becker, Juergen C.] German Canc Consortium DKTK, Essen, Germany; [Fan, Kaiji; Spassova, Ivelina; Gravemeyer, Jan; Ritter, Cathrin; Horny, Kai; Becker, Juergen C.] German Canc Res Ctr, Heidelberg, Germany; [Fan, Kaiji] Med Univ Graz, Dept Dermatol, Graz, Austria; [Lange, Anja] Univ Duisburg Essen, Fac Biol, Res Grp Bioinformat, Essen, Germany; [Gambichler, Thilo] Ruhr Univ Bochum, Dept Dermatol, Skin Canc Ctr, Bochum, Germany; [Odum, Niels] Univ Copenhagen, Dept Immunol & Microbiol, LEO Fdn, Skin Immunol Res Ctr, Copenhagen, Denmark; [Schrama, David] Univ Hosp Wurzburg, Dept Dermatol, Wurzburg, Germany; [Schadendorf, Dirk; Ugurel, Selma; Becker, Juergen C.] Univ Hosp Essen, Dept Dermatol, Essen, Germany	University of Duisburg Essen; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Medical University of Graz; University of Duisburg Essen; Ruhr University Bochum; University of Copenhagen; University of Wurzburg; University of Duisburg Essen	Becker, JC (corresponding author), Univ Hosp Essen, Dept Translat Skin Canc Res, Essen, Germany.; Becker, JC (corresponding author), German Canc Consortium DKTK, Essen, Germany.; Becker, JC (corresponding author), German Canc Res Ctr, Heidelberg, Germany.; Becker, JC (corresponding author), Univ Hosp Essen, Dept Dermatol, Essen, Germany.	j.becker@dkfz.de		Schrama, David/0000-0002-6931-8194; Fan, Kaiji/0000-0003-4310-4515; Schadendorf, Dirk/0000-0003-3524-7858	Deutsches Krebsforschungszentrum (DKFZ) [DKTK ED03]; Projekt DEAL	Deutsches Krebsforschungszentrum (DKFZ)(Helmholtz Association); Projekt DEAL	This work was funded by DKTK ED03 from Deutsches Krebsforschungszentrum (DKFZ) including funding for KF. Open Access funding enabled and organized by Projekt DEAL.	Abraham KJ, 2016, AM J PATHOL, V186, P1025, DOI 10.1016/j.ajpath.2015.11.020; Arandkar S, 2018, P NATL ACAD SCI USA, V115, P6410, DOI 10.1073/pnas.1719076115; Becker JC, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.77; Bhome R, 2018, CANCER LETT, V420, P228, DOI 10.1016/j.canlet.2018.02.002; Bussard KM, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0740-2; Butler A, 2018, NAT BIOTECHNOL, V36, P411, DOI 10.1038/nbt.4096; Chen XM, 2019, NAT REV DRUG DISCOV, V18, P99, DOI 10.1038/s41573-018-0004-1; Colombo M, 2014, ANNU REV CELL DEV BI, V30, P255, DOI 10.1146/annurev-cellbio-101512-122326; Cui H, 2015, ONCOGENE, V34, P3640, DOI 10.1038/onc.2014.300; Dror S, 2016, NAT CELL BIOL, V18, P1006, DOI 10.1038/ncb3399; Erez N, 2010, CANCER CELL, V17, P135, DOI 10.1016/j.ccr.2009.12.041; Fan KJ, 2020, CANCERS, V12, DOI 10.3390/cancers12030529; Fan KJ, 2020, J INVEST DERMATOL, V140, P56, DOI 10.1016/j.jid.2019.06.135; Fan K, 2018, CLIN CANCER RES, V24, P5873, DOI 10.1158/1078-0432.CCR-18-1184; Fang T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02583-0; Frank AC, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08989-2; Goruppi S, 2017, CELL REP, V20, P2468, DOI 10.1016/j.celrep.2017.08.048; Hood JL, 2011, CANCER RES, V71, P3792, DOI 10.1158/0008-5472.CAN-10-4455; Hudson J, 2013, EXP MOL PATHOL, V95, P62, DOI 10.1016/j.yexmp.2013.05.001; Ishii G, 2016, ADV DRUG DELIVER REV, V99, P186, DOI 10.1016/j.addr.2015.07.007; Kalluri R, 2016, NAT REV CANCER, V16, P582, DOI 10.1038/nrc.2016.73; Khare D, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03053; Kogure T, 2011, HEPATOLOGY, V54, p1278A; Konstantinell A, 2016, PROTEOMICS, V16, P2587, DOI 10.1002/pmic.201600223; Korsunsky I, 2019, NAT METHODS, V16, P1289, DOI 10.1038/s41592-019-0619-0; Kourembanas S, 2015, ANNU REV PHYSIOL, V77, P13, DOI 10.1146/annurev-physiol-021014-071641; La Manno G, 2018, NATURE, V560, P494, DOI 10.1038/s41586-018-0414-6; Liang XL, 2016, J CELL SCI, V129, P2182, DOI 10.1242/jcs.170373; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Lindahl LM, 2016, ONCOTARGET, V7, P45730, DOI 10.18632/oncotarget.10160; Liu JT, 2019, HEPATOLOGY, V70, P241, DOI 10.1002/hep.30607; Liu Y, 2016, CANCER LETT, V370, P125, DOI 10.1016/j.canlet.2015.10.011; Liu YX, 2013, DNA REPAIR, V12, P741, DOI 10.1016/j.dnarep.2013.06.002; Mitra AK, 2012, CANCER DISCOV, V2, P1100, DOI 10.1158/2159-8290.CD-12-0206; Nagarsheth N, 2017, NAT REV IMMUNOL, V17, P559, DOI 10.1038/nri.2017.49; Nishikawa E, 2011, CANCER RES, V71, P6165, DOI 10.1158/0008-5472.CAN-11-1020; Pang WJ, 2015, CANCER SCI, V106, P1362, DOI 10.1111/cas.12747; Paulson KG, 2014, AM J CLIN PATHOL, V142, P452, DOI 10.1309/AJCPIKDZM39CRPNC; Popp S, 2002, INT J CANCER, V99, P352, DOI 10.1002/ijc.10321; Poy MN, 2009, P NATL ACAD SCI USA, V106, P5813, DOI 10.1073/pnas.0810550106; Prager-Khoutorsky M, 2011, NAT CELL BIOL, V13, P1457, DOI 10.1038/ncb2370; Procopio MG, 2015, NAT CELL BIOL, V17, P1193, DOI 10.1038/ncb3228; Renwick N, 2013, J CLIN INVEST, V123, P2694, DOI 10.1172/JCI68760; Serini G, 1999, EXP CELL RES, V250, P273, DOI 10.1006/excr.1999.4543; Seto AG, 2018, BRIT J HAEMATOL, V183, P428, DOI 10.1111/bjh.15547; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Szczyrba J, 2011, MOL CANCER RES, V9, P791, DOI 10.1158/1541-7786.MCR-10-0573; Thayanithy V, 2014, TRANSL RES, V164, P359, DOI 10.1016/j.trsl.2014.05.011; Tirosh I, 2016, SCIENCE, V352, P189, DOI 10.1126/science.aad0501; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; van der Pol E, 2012, PHARMACOL REV, V64, P676, DOI 10.1124/pr.112.005983; Walsh NM, 2016, HUM PATHOL, V52, P190, DOI 10.1016/j.humpath.2016.02.002; Wardhani LO, 2019, HUM PATHOL, V84, P52, DOI 10.1016/j.humpath.2018.09.003; Wheat R, 2014, CANCERS, V6, P1047, DOI 10.3390/cancers6021047; Xie H, 2014, J INVEST DERMATOL, V134, P507, DOI 10.1038/jid.2013.355; Xu R, 2018, NAT REV CLIN ONCOL, V15, P617, DOI 10.1038/s41571-018-0036-9; Yan JW, 2014, INT J CANCER, V135, P1011, DOI 10.1002/ijc.28563; Yan W, 2018, NAT CELL BIOL, V20, P597, DOI 10.1038/s41556-018-0083-6; Zheng GXY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14049; Zhou WY, 2014, CANCER CELL, V25, P501, DOI 10.1016/j.ccr.2014.03.007	60	16	16	1	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2021	40	5					980	996		10.1038/s41388-020-01576-6	http://dx.doi.org/10.1038/s41388-020-01576-6		DEC 2020	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC5NB	33311552	Green Published, hybrid			2022-12-17	WOS:000598100200001
J	Tan, IL; Arifa, RDN; Rallapalli, H; Kana, V; Lao, ZM; Sanghrajka, RM; Bayin, NS; Tanne, A; Wojcinski, A; Korshunov, A; Bhardwaj, N; Merad, M; Turnbull, DH; Lafaille, JJ; Joyner, AL				Tan, I-Li; Arifa, Raquel Duque Nascimento; Rallapalli, Harikrishna; Kana, Veronika; Lao, Zhimin; Sanghrajka, Reeti Mayur; Sumru Bayin, N.; Tanne, Antoine; Wojcinski, Alexandre; Korshunov, Andrey; Bhardwaj, Nina; Merad, Miriam; Turnbull, Daniel H.; Lafaille, Juan J.; Joyner, Alexandra L.			CSF1R inhibition depletes tumor-associated macrophages and attenuates tumor progression in a mouse sonic Hedgehog-Medulloblastoma model	ONCOGENE			English	Article							MICROGLIA; EXPRESSION; LANDSCAPE; SYSTEM; GROWTH; BETA	The immune microenvironment of tumors can play a critical role in promoting or inhibiting tumor progression depending on the context. We present evidence that tumor-associated macrophages/microglia (TAMs) can promote tumor progression in the sonic hedgehog subgroup of medulloblastoma (SHH-MB). By combining longitudinal manganese-enhanced magnetic resonance imaging (MEMRI) and immune profiling of a sporadic mouse model of SHH-MB, we found the density of TAMs is higher in the similar to 50% of tumors that progress to lethal disease. Furthermore, reducing regulatory T cells or eliminating B and T cells in Rag1 mutants does not alter SHH-MB tumor progression. As TAMs are a dominant immune component in tumors and are normally dependent on colony-stimulating factor 1 receptor (CSF1R), we treated mice with a CSF1R inhibitor, PLX5622. Significantly, PLX5622 reduces a subset of TAMs, prolongs mouse survival, and reduces the volume of most tumors within 4 weeks of treatment. Moreover, concomitant with a reduction in TAMs the percentage of infiltrating cytotoxic T cells is increased, indicating a change in the tumor environment. Our studies in an immunocompetent preclinical mouse model demonstrate TAMs can have a functional role in promoting SHH-MB progression. Thus, CSF1R inhibition could have therapeutic potential for a subset of SHH-MB patients.	[Tan, I-Li; Lao, Zhimin; Sanghrajka, Reeti Mayur; Sumru Bayin, N.; Wojcinski, Alexandre; Joyner, Alexandra L.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA; [Tan, I-Li; Sanghrajka, Reeti Mayur; Joyner, Alexandra L.] Cornell Univ, Weill Grad Sch Med Sci, Biochem Cell & Mol Biol Program, New York, NY 10021 USA; [Arifa, Raquel Duque Nascimento; Rallapalli, Harikrishna; Turnbull, Daniel H.; Lafaille, Juan J.] NYU, Sch Med, Skirball Inst Biomol Med, New York, NY USA; [Kana, Veronika; Tanne, Antoine; Bhardwaj, Nina; Merad, Miriam] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA; [Tanne, Antoine] Agenus Inc, Lexington, MA USA; [Korshunov, Andrey] German Canc Res Ctr, Clin Cooperat Unit Neuropathol, Heidelberg, Germany; [Korshunov, Andrey] Univ Hosp, Dept Neuropathol, Heidelberg, Germany	Memorial Sloan Kettering Cancer Center; Cornell University; New York University; Icahn School of Medicine at Mount Sinai; Agenus Inc; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg	Joyner, AL (corresponding author), Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.; Joyner, AL (corresponding author), Cornell Univ, Weill Grad Sch Med Sci, Biochem Cell & Mol Biol Program, New York, NY 10021 USA.	joynera@mskcc.org		Bhardwaj, Nina/0000-0003-1865-4187; Kana, Veronika/0000-0002-9362-3156; Turnbull, Daniel/0000-0003-0889-5155	MSKCC Brain Tumor Center fellowship; National Cancer Institute Cancer Center Support Grant [P30 CA008748-48];  [R01CA192176]	MSKCC Brain Tumor Center fellowship; National Cancer Institute Cancer Center Support Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); 	We thank the Joyner lab members for helpful discussions and comments on the manuscript. We are grateful to Andrey Rymar and Parmveer Singh at Plexxikon for providing the PLX5622 used in these studies. We appreciate the technical assistance from Daniel Stephen, and Yu-Jung Chen. We also thank the Center for comparative medicine and pathology and the Integrated Genomics Operation (IGO) core facilities of MSKCC for outstanding technical support. This work was supported by the following grants: R01CA192176 (ALJ), MSKCC Brain Tumor Center fellowship (AW), and a National Cancer Institute Cancer Center Support Grant [P30 CA008748-48].	Archer TC, 2018, CANCER CELL, V34, P396, DOI 10.1016/j.ccell.2018.08.004; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Bennett ML, 2016, P NATL ACAD SCI USA, V113, pE1738, DOI 10.1073/pnas.1525528113; Bockmayr M, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1462430; Carbon S, 2019, NUCLEIC ACIDS RES, V47, pD330, DOI 10.1093/nar/gky1055; Cavalli FMG, 2017, CANCER CELL, V31, P737, DOI 10.1016/j.ccell.2017.05.005; CELADA A, 1989, EUR J IMMUNOL, V19, P1103, DOI 10.1002/eji.1830190621; Corcoran RB, 2008, CANCER RES, V68, P8788, DOI 10.1158/0008-5472.CAN-08-2135; Gate D, 2014, P NATL ACAD SCI USA, V111, pE3458, DOI 10.1073/pnas.1412489111; Greter M, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00249; Gyori D, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.120631; Hahn H, 2000, J BIOL CHEM, V275, P28341, DOI 10.1074/jbc.C000352200; Huang YB, 2018, NAT NEUROSCI, V21, P530, DOI 10.1038/s41593-018-0090-8; Kana V, 2019, J EXP MED, V216, P2265, DOI 10.1084/jem.20182037; Kool M, 2014, CANCER CELL, V25, P393, DOI 10.1016/j.ccr.2014.02.004; Lee C, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4457-8; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1; Machold R, 2005, NEURON, V48, P17, DOI 10.1016/j.neuron.2005.08.028; Mantovani A, 2006, CANCER METAST REV, V25, P315, DOI 10.1007/s10555-006-9001-7; Mao J, 2006, CANCER RES, V66, P10171, DOI 10.1158/0008-5472.CAN-06-0657; Margol AS, 2015, CLIN CANCER RES, V21, P1457, DOI 10.1158/1078-0432.CCR-14-1144; Martin Allison M, 2018, Oncotarget, V9, P19177, DOI 10.18632/oncotarget.24951; Maximov V, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10458-9; McNeill KA, 2016, NEUROL CLIN, V34, P981, DOI 10.1016/j.ncl.2016.06.014; Mi HY, 2019, NUCLEIC ACIDS RES, V47, pD419, DOI 10.1093/nar/gky1038; Mizutani M, 2012, J IMMUNOL, V188, P29, DOI 10.4049/jimmunol.1100421; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Murata D, 2018, J NEUROSURG, V128, P710, DOI 10.3171/2016.11.JNS16991; Northcott PA, 2017, NATURE, V547, P311, DOI 10.1038/nature22973; Northcott PA, 2012, NAT REV CANCER, V12, P818, DOI 10.1038/nrc3410; Peranzoni E, 2018, P NATL ACAD SCI USA, V115, pE4041, DOI 10.1073/pnas.1720948115; Pham CD, 2016, CLIN CANCER RES, V22, P582, DOI 10.1158/1078-0432.CCR-15-0713; Pyonteck SM, 2013, NAT MED, V19, P1264, DOI 10.1038/nm.3337; Quail DF, 2017, CANCER CELL, V31, P326, DOI 10.1016/j.ccell.2017.02.009; Quail DF, 2016, SCIENCE, V352, DOI 10.1126/science.aad3018; Rallapalli H, 2020, MAGN RESON MED, V83, P214, DOI 10.1002/mrm.27904; Ramaswamy V, 2017, J CLIN ONCOL, V35, P2355, DOI 10.1200/JCO.2017.72.7842; Rao G, 2004, ONCOGENE, V23, P6156, DOI 10.1038/sj.onc.1207818; Ries CH, 2014, CANCER CELL, V25, P846, DOI 10.1016/j.ccr.2014.05.016; Schmidt A, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00051; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tan IL, 2018, P NATL ACAD SCI USA, V115, P3392, DOI 10.1073/pnas.1717815115; Tanori M, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-53; Taylor MD, 2012, ACTA NEUROPATHOL, V123, P465, DOI 10.1007/s00401-011-0922-z; Togashi Y, 2019, NAT REV CLIN ONCOL, V16, P356, DOI 10.1038/s41571-019-0175-7; Tsou CL, 2007, J CLIN INVEST, V117, P902, DOI 10.1172/JCI29919; Vermeulen JF, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1398877; Wang JY, 2001, ONCOGENE, V20, P3857, DOI 10.1038/sj.onc.1204532; Yang M, 2018, CANCER RES, V78, P5492, DOI 10.1158/0008-5472.CAN-18-1367; Yao MJ, 2020, CELL, V180, P502, DOI 10.1016/j.cell.2019.12.024; Zhu Y, 2014, CANCER RES, V74, P5057, DOI 10.1158/0008-5472.CAN-13-3723	52	16	16	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2021	40	2					396	407		10.1038/s41388-020-01536-0	http://dx.doi.org/10.1038/s41388-020-01536-0		NOV 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PS4WP	33159168	Green Accepted			2022-12-17	WOS:000587081500001
J	Kung, CP; Cottrell, KA; Ryu, S; Bramel, ER; Kladney, RD; Bao, EA; Freeman, EC; Sabloak, T; Maggi, L; Weber, JD				Kung, Che-Pei; Cottrell, Kyle A.; Ryu, Sua; Bramel, Emily R.; Kladney, Raleigh D.; Bao, Emily A.; Freeman, Eric C.; Sabloak, Thwisha; Maggi Jr., Leonard; Weber, Jason D.			Evaluating the therapeutic potential of ADAR1 inhibition for triple-negative breast cancer	ONCOGENE			English	Article							GENOMIC LANDSCAPE; RNA; INTERFERON; STRESS; SUPPRESSES; EXPRESSION; DIVERSITY; APOPTOSIS	Triple-negative breast cancer (TNBC) is the deadliest form of breast cancer. Unlike other types of breast cancer that can be effectively treated by targeted therapies, no such targeted therapy exists for all TNBC patients. The ADAR1 enzyme carries out A-to-I editing of RNA to prevent sensing of endogenous double-stranded RNAs. ADAR1 is highly expressed in breast cancer including TNBC. Here, we demonstrate that expression of ADAR1, specifically its p150 isoform, is required for the survival of TNBC cell lines. In TNBC cells, knockdown of ADAR1 attenuates proliferation and tumorigenesis. Moreover, ADAR1 knockdown leads to robust translational repression. ADAR1-dependent TNBC cell lines also exhibit elevated IFN stimulated gene expression. IFNAR1 reduction significantly rescued the proliferative defects of ADAR1 loss. These findings establish ADAR1 as a novel therapeutic target for TNBC tumors.	[Kung, Che-Pei; Cottrell, Kyle A.; Ryu, Sua; Bramel, Emily R.; Kladney, Raleigh D.; Bao, Emily A.; Freeman, Eric C.; Sabloak, Thwisha; Maggi Jr., Leonard; Weber, Jason D.] Washington Univ, Sch Med, Dept Med, Div Mol Oncol, St Louis, MO 63110 USA; [Weber, Jason D.] Washington Univ, Sch Med, Dept Cell Biol & Physiol, Siteman Canc Ctr, St Louis, MO 63110 USA	Washington University (WUSTL); Siteman Cancer Center; Washington University (WUSTL)	Weber, JD (corresponding author), Washington Univ, Sch Med, Dept Med, Div Mol Oncol, St Louis, MO 63110 USA.; Weber, JD (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, Siteman Canc Ctr, St Louis, MO 63110 USA.	jweber@wustl.edu	Kung, Che-Pei/I-6276-2019	Kung, Che-Pei/0000-0002-1150-4998; Weber, Jason/0000-0002-1069-6983; Maggi, Leonard/0000-0003-0138-0984	National Institute of Health [R01CA190986, F32GM131514, TL1TR002344]; Department of Defense [W81XWH-18-1-0025]; Longer Life Foundation: A RGA/Washington University partnership	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense); Longer Life Foundation: A RGA/Washington University partnership	This work was supported by R01CA190986 (JDW), F32GM131514 (KAC), and TL1TR002344 (C-PK) from the National Institute of Health, and W81XWH-18-1-0025 from the Department of Defense (JDW). This work was supported by the Longer Life Foundation: A RGA/Washington University partnership. We thank Kazuko Nishikura (The Wistar Institute) for providing ADAR1 expressing constructs. The results shown here are in whole or part based upon data generated by the TCGA Research Network: https://www.cancer.gov/tcga.	Ademuyiwa F, 2017, BREAST CANCER RES TR, V161, P491, DOI 10.1007/s10549-016-4062-y; Anantharaman A, 2017, FEBS LETT, V591, P2890, DOI 10.1002/1873-3468.12795; Anders Carey K, 2016, Am Soc Clin Oncol Educ Book, V35, P34, DOI 10.14694/EDBK_159135; Apicelli AJ, 2008, MOL CELL BIOL, V28, P1068, DOI 10.1128/MCB.00484-07; Binothman N, 2017, EBIOMEDICINE, V21, P65, DOI 10.1016/j.ebiom.2017.06.023; Brenot A, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389-018-0042-x; Chen LL, 2013, NAT MED, V19, P209, DOI 10.1038/nm.3043; Chung HC, 2018, CELL, V172, P811, DOI 10.1016/j.cell.2017.12.038; Crews LA, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-014-0370-3; Dar AC, 2005, CELL, V122, P887, DOI 10.1016/j.cell.2005.06.044; Dave B, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw292; Doherty MR, 2019, BREAST CANCER RES, V21, DOI 10.1186/s13058-019-1136-x; Doherty MR, 2017, P NATL ACAD SCI USA, V114, P13792, DOI 10.1073/pnas.1713728114; Forys JT, 2014, CELL REP, V7, P514, DOI 10.1016/j.celrep.2014.03.026; Fumagalli D, 2015, CELL REP, V13, P277, DOI 10.1016/j.celrep.2015.09.032; Gannon HS, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07824-4; Garrido-Castro AC, 2019, CANCER DISCOV, V9, P176, DOI 10.1158/2159-8290.CD-18-1177; George CX, 2016, J BIOL CHEM, V291, P6158, DOI 10.1074/jbc.M115.709014; Gumireddy K, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10715; Han L, 2015, CANCER CELL, V28, DOI 10.1016/j.ccell.2015.08.013; Holcik M, 2005, NAT REV MOL CELL BIO, V6, P318, DOI 10.1038/nrm1618; Holcik M, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00264; Ishizuka JJ, 2019, NATURE, V565, P43, DOI 10.1038/s41586-018-0768-9; Kung CP, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00762; Lan Q, 2019, ONCOGENE, V38, P2814, DOI 10.1038/s41388-018-0624-2; Lehmann BD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157368; Li Y, 2017, ELIFE, V6, DOI [10.7554/eLife.29914, 10.7554/eLife.25687]; Li ZQ, 2012, J VIROL, V86, P3787, DOI 10.1128/JVI.06307-11; Liddicoat BJ, 2015, SCIENCE, V349, P1115, DOI 10.1126/science.aac7049; Liu HY, 2019, NAT MED, V25, P95, DOI 10.1038/s41591-018-0302-5; Liu HY, 2017, DEV CELL, V41, P392, DOI 10.1016/j.devcel.2017.04.024; Lo PK, 2018, ELIFE, V7, DOI 10.7554/eLife.31334; Mannion NM, 2014, CELL REP, V9, P1482, DOI 10.1016/j.celrep.2014.10.041; Marcotte R, 2016, CELL, V164, P293, DOI 10.1016/j.cell.2015.11.062; McFarland JM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06916-5; Meyers RM, 2017, NAT GENET, V49, P1779, DOI 10.1038/ng.3984; Nakano M, 2017, J BIOL CHEM, V292, P4873, DOI 10.1074/jbc.M117.775684; Paz-Yaacov N, 2015, CELL REP, V13, P267, DOI 10.1016/j.celrep.2015.08.080; Peng XX, 2018, CANCER CELL, V33, P817, DOI 10.1016/j.ccell.2018.03.026; Perou CM, 2011, ONCOLOGIST, V16, P61, DOI 10.1634/theoncologist.2011-S1-61; Pestal K, 2015, IMMUNITY, V43, P933, DOI 10.1016/j.immuni.2015.11.001; Pujantell M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13580-0; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Sagredo EA, 2018, BIOL RES, V51, DOI 10.1186/s40659-018-0185-4; Sakurai M, 2017, NAT STRUCT MOL BIOL, V24, P534, DOI 10.1038/nsmb.3403; Shigeyasu K, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.99976; Sidrauski C, 2015, ELIFE, V4, DOI 10.7554/eLife.07314; SILVERMAN RH, 1983, J VIROL, V46, P1051, DOI 10.1128/JVI.46.3.1051-1055.1983; Snell LM, 2017, TRENDS IMMUNOL, V38, P542, DOI 10.1016/j.it.2017.05.005; Song In Hye, 2017, Tumour Biol, V39, p1010428317734816, DOI 10.1177/1010428317734816; Waks AG, 2019, JAMA-J AM MED ASSOC, V321, P288, DOI 10.1001/jama.2018.19323; Wang QD, 2004, J BIOL CHEM, V279, P4952, DOI 10.1074/jbc.M310162200	52	16	17	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2021	40	1					189	202		10.1038/s41388-020-01515-5	http://dx.doi.org/10.1038/s41388-020-01515-5		OCT 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PR5VS	33110236	Green Accepted			2022-12-17	WOS:000582768100002
J	Liu, CD; Zhou, XH; Long, Q; Zeng, HY; Sun, QC; Chen, YT; Wu, DH; Liu, L				Liu, Chengdong; Zhou, Xiaohan; Long, Qian; Zeng, Hanyi; Sun, Qingcan; Chen, Yuting; Wu, Dehua; Liu, Li			Small extracellular vesicles containing miR-30a-3p attenuate the migration and invasion of hepatocellular carcinoma by targeting SNAP23 gene	ONCOGENE			English	Article							THERAPEUTIC STRATEGY; EXOSOMES; CELLS; PROLIFERATION; METASTASIS; SECRETION; RELEASE; STRESS	Cancer cells under hypoxic, endoplasmic reticulum, and reactive oxygen species stress secrete copious amounts of small extracellular vesicles (sEVs) to promote tumor metastasis. The effects of blocking stress-induced sEV release on tumor metastasis remain unknown. We found that miR-30a-3p was selectively sorted into sEVs by hepatocellular carcinoma (HCC) cells under the influence of multiple stressors. miR-30a-3p removal from cancer cells through sEVs promoted HCC cell migration and invasion, whereas exogenous overexpression of miR-30a-3p could inhibit migration, invasion, and sEV release by directly targeting SNAP23. HCC cells efficiently absorbed hepatic stellate cell (HSC) sEVs, providing an advantage in the treatment of HCC using HSC sEVs. Treatment with HSC sEVs rich in miR-30a-3p cargo effectively attenuated HCC migration, invasion, and metastasis. Overall, sEVs containing miR-30a-3p decreased sEV secretion as well as the migration, invasion, and metastasis of HCC by directly targeting SNAP23, thereby providing an effective strategy to attenuate metastasis of HCC.	[Liu, Chengdong; Long, Qian; Zeng, Hanyi; Sun, Qingcan; Liu, Li] Southern Med Univ, Nanfang Hosp, Dept Infect Dis, Guangzhou 510515, Guangdong, Peoples R China; [Zhou, Xiaohan; Chen, Yuting; Wu, Dehua] Southern Med Univ, Nanfang Hosp, Dept Radiat Oncol, Guangzhou 510515, Guangdong, Peoples R China	Southern Medical University - China; Southern Medical University - China	Liu, L (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Infect Dis, Guangzhou 510515, Guangdong, Peoples R China.; Wu, DH (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Radiat Oncol, Guangzhou 510515, Guangdong, Peoples R China.	18602062748@163.com; liuli@i.smu.edu.cn		Wu, De-Hua/0000-0003-0560-0016	National Nature Science Foundation of China [81773008, 81672756, 81872399, 81972897]; Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme; Natural Science Foundation of Guangdong Province [2017A030311023]; Local Innovative and Research Teams Project of Guangdong Pearl River Talents Program [2017BT01S131]; Guangzhou Technology Project [201804010044]	National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme; Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Local Innovative and Research Teams Project of Guangdong Pearl River Talents Program; Guangzhou Technology Project	This work was supported by the National Nature Science Foundation of China [grant numbers 81773008, 81672756, 81872399, 81972897], the Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme (2015), the Natural Science Foundation of Guangdong Province [grant number 2017A030311023], the Local Innovative and Research Teams Project of Guangdong Pearl River Talents Program: 2017BT01S131 and the Guangzhou Technology Project [grant number 201804010044].	An TX, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.27522; Atienzar-Aroca S, 2016, J CELL MOL MED, V20, P1457, DOI 10.1111/jcmm.12834; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Costa-Silva B, 2015, NAT CELL BIOL, V17, P816, DOI 10.1038/ncb3169; Fang T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02583-0; Gross JC, 2012, NAT CELL BIOL, V14, P1036, DOI 10.1038/ncb2574; Hoshino A, 2015, NATURE, V527, P329, DOI 10.1038/nature15756; Hou J, 2018, J ORAL PATHOL MED, V47, P144, DOI 10.1111/jop.12654; Hu JL, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1019-x; Huang TT, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0967-5; Im EJ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09387-4; Johnsen KB, 2014, BBA-REV CANCER, V1846, P75, DOI 10.1016/j.bbcan.2014.04.005; Kamerkar S, 2017, NATURE, V546, P498, DOI 10.1038/nature22341; Kanlikilicer P, 2016, CANCER RES, V76, P7194, DOI 10.1158/0008-5472.CAN-16-0714; Keklikoglou I, 2019, NAT CELL BIOL, V21, P190, DOI 10.1038/s41556-018-0256-3; Kowal J, 2014, CURR OPIN CELL BIOL, V29, P116, DOI 10.1016/j.ceb.2014.05.004; Li L, 2017, HEPATOLOGY, V65, P501, DOI 10.1002/hep.28735; Liu JT, 2019, HEPATOLOGY, V70, P241, DOI 10.1002/hep.30607; Lucchetti D, 2020, CANCERS, V12, DOI 10.3390/cancers12020260; Meng WR, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0982-6; Merchant ML, 2017, NAT REV NEPHROL, V13, P731, DOI 10.1038/nrneph.2017.148; Nishida-Aoki N, 2017, MOL THER, V25, P181, DOI 10.1016/j.ymthe.2016.10.009; O'Neill CP, 2019, CANCERS, V11, DOI 10.3390/cancers11020136; Pavlyukov MS, 2018, CANCER CELL, V34, P119, DOI 10.1016/j.ccell.2018.05.012; Peng DY, 2018, LEUKEMIA, V32, P1180, DOI 10.1038/s41375-018-0015-2; Poggio M, 2019, CELL, V177, P414, DOI 10.1016/j.cell.2019.02.016; Qiao Y, 2018, ONCOGENE, V37, P873, DOI 10.1038/onc.2017.387; Spychalski P, 2019, RADIOTHER ONCOL, V132, P127, DOI 10.1016/j.radonc.2018.12.012; Teng Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14448; Trajkovic K, 2008, SCIENCE, V319, P1244, DOI 10.1126/science.1153124; Vader P, 2016, ADV DRUG DELIVER REV, V106, P148, DOI 10.1016/j.addr.2016.02.006; Wang F, 2018, HEPATOLOGY, V67, P940, DOI 10.1002/hep.29586; Wang W, 2014, EJSO-EUR J SURG ONC, V40, P1586, DOI 10.1016/j.ejso.2013.11.008; Wang XF, 2018, CANCER RES, V78, P4586, DOI 10.1158/0008-5472.CAN-17-3841; Wang XH, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0468-y; Wei Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14041; Wu XG, 2019, ANGIOGENESIS, V22, P397, DOI 10.1007/s10456-019-09665-1; Xie Y, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0984-4; Yang L, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0990-6; Zeng ZC, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07810-w; Zhan CN, 2020, ORAL DIS, V26, P865, DOI 10.1111/odi.13172; Zhang X, 2019, CANCER MANAG RES, V11, P1653, DOI 10.2147/CMAR.S188248; Zhang XN, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0959-5; Zhang ZC, 2017, CANCER LETT, V397, P33, DOI 10.1016/j.canlet.2017.03.004	44	16	16	2	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2021	40	2					233	245		10.1038/s41388-020-01521-7	http://dx.doi.org/10.1038/s41388-020-01521-7		OCT 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PS4WP	33110233				2022-12-17	WOS:000582768100001
J	Kwon, OJ; Zhang, L; Jia, DY; Zhou, ZC; Li, ZYH; Haffner, M; Lee, JK; True, L; Morrissey, C; Xin, L				Kwon, Oh-Joon; Zhang, Li; Jia, Deyong; Zhou, Zhicheng; Li, Zhouyihan; Haffner, Michael; Lee, John K.; True, Lawrence; Morrissey, Colm; Xin, Li			De novo induction of lineage plasticity from human prostate luminal epithelial cells by activated AKT1 and c-Myc	ONCOGENE			English	Article							NEUROENDOCRINE PHENOTYPE; PROGENITOR CELLS; CANCER; IDENTIFICATION; DIFFERENTIATION; ORIGIN; MOUSE; BASAL; RESISTANCE; MECHANISM	Neuroendocrine prostate cancer (NEPC) is an aggressive variant of prostate cancer that either develops de novo or arises from prostate adenocarcinoma as a result of treatment resistance. Although the prostate basal cells have been shown to directly generate tumor cells with neuroendocrine features when transduced with oncogenic signaling, the identity of the cell-of-origin for de novo NEPC remains unclear. We show that the TACSTD2(high)human prostate luminal epithelia cells highly express SOX2 and are relatively enriched in the transition zone prostate. Both TACSTD2(high)and TACSTD2(low)luminal cells transduced by constitutively activated AKT1 (caAKT1), and c-Myc can form organoids containing versatile clinically relevant tumor cell lineages with regard to the expression of AR and the neuroendocrine cell markers Synaptophysin and Chromogranin A. Tumor organoid cells derived from the TACSTD2(high)luminal cells are more predisposed to neuroendocrine differentiation along passaging and are relatively more castration-resistant. Knocking downTACSTD2andSOX2both attenuate neuroendocrine differentiation of tumor organoid cells. This study demonstrates de novo neuroendocrine differentiation of the human prostate luminal epithelial cells induced by caAKT1 and c-Myc and reveals an impact of cellular status on initiation of lineage plasticity.	[Kwon, Oh-Joon; Zhang, Li; Jia, Deyong; Zhou, Zhicheng; Morrissey, Colm; Xin, Li] Univ Washington, Dept Urol, Seattle, WA 98109 USA; [Li, Zhouyihan] Univ Washington, Dept Chem & Biochem, Seattle, WA 98109 USA; [Haffner, Michael; Lee, John K.] Fred Hutch Canc Res Ctr, Human Biol Div, Seattle, WA 98109 USA; [True, Lawrence] Univ Washington, Dept Pathol, Seattle, WA 98109 USA; [Xin, Li] Univ Washington, Inst Stem Cell & Regenerat Med, Seattle, WA 98109 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Xin, L (corresponding author), Univ Washington, Dept Urol, Seattle, WA 98109 USA.; Xin, L (corresponding author), Univ Washington, Inst Stem Cell & Regenerat Med, Seattle, WA 98109 USA.	xin18@uw.edu	Jia, Deyong/GSJ-0327-2022; Zhou, Zhicheng/AAM-8685-2020; Jia, Deyong/GQP-9611-2022	Jia, Deyong/0000-0003-2034-0363; Kwon, Oh-Joon/0000-0001-9067-0240; Xin, Li/0000-0002-7138-0042	 [R01CA190378];  [R01DK092202];  [R01DK107436]	; ; 	This work was supported by R01CA190378, R01DK092202, and R01DK107436 (L.X.).	Beltran H, 2019, CLIN CANCER RES, V25, P43, DOI 10.1158/1078-0432.CCR-18-1912; Beltran H, 2016, NAT MED, V22, P298, DOI 10.1038/nm.4045; Beltran H, 2011, CANCER DISCOV, V1, P487, DOI 10.1158/2159-8290.CD-11-0130; Bishop JL, 2017, CANCER DISCOV, V7, P54, DOI 10.1158/2159-8290.CD-15-1263; Choi N, 2012, CANCER CELL, V21, P253, DOI 10.1016/j.ccr.2012.01.005; Collins AT, 2001, J CELL SCI, V114, P3865; Conteduca V, 2019, EUR J CANCER, V121, P7, DOI 10.1016/j.ejca.2019.08.011; Crowell PD, 2019, CELL REP, V28, P1499, DOI 10.1016/j.celrep.2019.07.007; Dardenne E, 2016, CANCER CELL, V30, P563, DOI 10.1016/j.ccell.2016.09.005; Davies AH, 2018, NAT REV UROL, V15, P271, DOI 10.1038/nrurol.2018.22; Fine SW, 2012, ADV ANAT PATHOL, V19, P204, DOI 10.1097/PAP.0b013e31825c6b92; Goldstein AS, 2010, SCIENCE, V329, P568, DOI 10.1126/science.1189992; Guo HY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08133-6; Hsu EC, 2020, P NATL ACAD SCI USA, V117, P2032, DOI 10.1073/pnas.1905384117; Joseph DB, 2020, PROSTATE, V80, P872, DOI 10.1002/pros.24020; Karthaus WR, 2020, SCIENCE, V368, P497, DOI 10.1126/science.aay0267; Karthaus WR, 2014, CELL, V159, P163, DOI 10.1016/j.cell.2014.08.017; Ku SY, 2017, SCIENCE, V355, P78, DOI 10.1126/science.aah4199; Kwon OJ, 2020, STEM CELLS, V38, P1479, DOI 10.1002/stem.3253; Kwon OJ, 2016, STEM CELLS, V34, P191, DOI 10.1002/stem.2217; Labrecque MP, 2019, J CLIN INVEST, V129, P4492, DOI 10.1172/JCI128212; Lapuk AV, 2012, J PATHOL, V227, P286, DOI 10.1002/path.4047; Lawson DA, 2007, P NATL ACAD SCI USA, V104, P181, DOI 10.1073/pnas.0609684104; Lee JK, 2016, CANCER CELL, V29, P536, DOI 10.1016/j.ccell.2016.03.001; Leong KG, 2008, NATURE, V456, P804, DOI 10.1038/nature07427; Lin D, 2014, CANCER RES, V74, P1272, DOI 10.1158/0008-5472.CAN-13-2921-T; Liu J, 2011, MOL ENDOCRINOL, V25, P1849, DOI 10.1210/me.2011-1081; Lu TL, 2013, AM J PATHOL, V182, P975, DOI 10.1016/j.ajpath.2012.11.025; MCNEAL JE, 1988, AM J SURG PATHOL, V12, P897, DOI 10.1097/00000478-198812000-00001; Mu P, 2017, SCIENCE, V355, P84, DOI 10.1126/science.aah4307; Park JW, 2018, SCIENCE, V362, P91, DOI 10.1126/science.aat5749; Park JW, 2016, P NATL ACAD SCI USA, V113, P4482, DOI 10.1073/pnas.1603645113; Rotinen M, 2018, NAT MED, V24, P1887, DOI 10.1038/s41591-018-0241-1; Wang ZA, 2013, NAT CELL BIOL, V15, P274, DOI 10.1038/ncb2697; Xin L, 2006, P NATL ACAD SCI USA, V103, P7789, DOI 10.1073/pnas.0602567103; Yao JL, 2006, AM J SURG PATHOL, V30, P705, DOI 10.1097/00000478-200606000-00005; Zou M, 2017, CANCER DISCOV, V7, P736, DOI 10.1158/2159-8290.CD-16-1174	37	16	17	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 26	2020	39	48					7142	7151		10.1038/s41388-020-01487-6	http://dx.doi.org/10.1038/s41388-020-01487-6		OCT 2020	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PE1YE	33009488	Green Accepted			2022-12-17	WOS:000574731000001
J	Santoni, MJ; Kashyap, R; Camoin, L; Borg, JP				Santoni, Marie-Josee; Kashyap, Rudra; Camoin, Luc; Borg, Jean-Paul			The Scribble family in cancer: twentieth anniversary	ONCOGENE			English	Review							UBIQUITIN-MEDIATED DEGRADATION; PROMOTES MAMMARY TUMORIGENESIS; TUMOR-SUPPRESSOR SCRIBBLE; BASOLATERAL PDZ PROTEIN; CELL-CELL JUNCTIONS; LEUCINE-RICH REPEAT; RISK HPV E6; INTERACTING PROTEIN; S-PALMITOYLATION; DOWN-REGULATION	Among the more than 160 PDZ containing proteins described in humans, the cytoplasmic scaffold Scribble stands out because of its essential role in many steps of cancer development and dissemination. Its fame has somehow blurred the importance of homologous proteins, Erbin and Lano, all belonging to the LRR and PDZ (LAP) protein family first described twenty years ago. In this review, we will retrace the history of LAP family protein research and draw attention to their contribution in cancer by detailing the features of its members at the structural and functional levels, and highlighting their shared-but also different-implication in the tumoral process.	[Santoni, Marie-Josee; Kashyap, Rudra; Borg, Jean-Paul] Aix Marseille Univ, Ctr Rech Cancerol Marseille, Equipe Labellisee Ligue Cell Polar Cell Signaling, CRCM,INSERM,CNRS,Inst Paoli Calmettes, F-13009 Marseille, France; [Kashyap, Rudra] Katholisch Univ Leuven, Cellular & Mol Med, Leuven, Belgium; [Camoin, Luc; Borg, Jean-Paul] Aix Marseille Univ, CNRS, Inst Paoli Calmettes, INSERM,CRCM,Marseille Proteom, Marseille, France; [Borg, Jean-Paul] Inst Univ France IUF, Paris, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UNICANCER; Institut Paoli-Calmette (IPC); Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UNICANCER; Institut Paoli-Calmette (IPC); Institut Universitaire de France	Santoni, MJ; Borg, JP (corresponding author), Aix Marseille Univ, Ctr Rech Cancerol Marseille, Equipe Labellisee Ligue Cell Polar Cell Signaling, CRCM,INSERM,CNRS,Inst Paoli Calmettes, F-13009 Marseille, France.; Borg, JP (corresponding author), Aix Marseille Univ, CNRS, Inst Paoli Calmettes, INSERM,CRCM,Marseille Proteom, Marseille, France.; Borg, JP (corresponding author), Inst Univ France IUF, Paris, France.	marie-josee.santoni@inserm.fr; jean-paul.borg@inserm.fr	Kashyap, Rudra/ABD-3316-2020; Borg, Jean-Paul/AAX-8096-2020	Borg, Jean-Paul/0000-0001-8418-3382; Camoin, Luc/0000-0002-1230-4787; Santoni, Marie-Josee/0000-0002-2619-7257	La Ligue Nationale Contre le Cancer (Label Ligue Equipe labellisee 2019); Fondation de France; European PDZnet consortium (EU Horizon 2020 RIA under the Marie Skodowska-Curie grant) [675341]; Excellence Initiative of Aix-Marseille University-A*Midex, "Investissement d'avenir" (CapoStromEx)	La Ligue Nationale Contre le Cancer (Label Ligue Equipe labellisee 2019); Fondation de France(Fondation de France); European PDZnet consortium (EU Horizon 2020 RIA under the Marie Skodowska-Curie grant); Excellence Initiative of Aix-Marseille University-A*Midex, "Investissement d'avenir" (CapoStromEx)(French National Research Agency (ANR))	We thank Philippe Roche and the Phyre2 web portal for the generation of images, and Valerie Depraetere for careful reading of the manuscript. J-PB's lab is funded by La Ligue Nationale Contre le Cancer (Label Ligue Equipe labellisee 2019), Fondation de France (fellowship to RK), the European PDZnet consortium (EU Horizon 2020 RIA under the Marie Skodowska-Curie grant agreement no. 675341), and by Excellence Initiative of Aix-Marseille University-A*Midex, "Investissement d'avenir" (CapoStromEx). J-PB is a scholar of Institut Universitaire de France.	Almeida LL, 2018, STEM CELL REP, V11, P1040, DOI 10.1016/j.stemcr.2018.09.008; Althoff M, BLOOD, DOI [10.1182/blood.2019004113, DOI 10.1182/BL00D.2019004113]; Anastas JN, 2012, ONCOGENE, V31, P3696, DOI 10.1038/onc.2011.528; Apperson ML, 1996, J NEUROSCI, V16, P6839; Appleton BA, 2006, J BIOL CHEM, V281, P22312, DOI 10.1074/jbc.M602901200; Arnaud C, 2009, FEBS LETT, V583, P2326, DOI 10.1016/j.febslet.2009.06.034; Aster JC, 2017, ANNU REV PATHOL-MECH, V12, P245, DOI 10.1146/annurev-pathol-052016-100127; Audebert S, 2004, CURR BIOL, V14, P987, DOI 10.1016/j.cub.2004.05.051; Awadia S, 2019, J CELL BIOL, V218, P2699, DOI 10.1083/jcb.201811114; Baker L, 2016, J CELL SCI, V129, P2307, DOI 10.1242/jcs.185413; Bilder D, 2000, NAT CELL BIOL, V2, pE114, DOI 10.1038/35017119; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Birrane G, 2003, J BIOL CHEM, V278, P1399, DOI 10.1074/jbc.C200571200; Boisguerin P, 2004, CHEM BIOL, V11, P449, DOI 10.1016/j.chembiol.2004.03.010; Bonello TT, 2019, J CELL BIOL, V218, P742, DOI 10.1083/jcb.201810103; Borg JP, 2000, NAT CELL BIOL, V2, P407, DOI 10.1038/35017038; Chastney M, 2020, PREPRINT, DOI [10.1101/2020.01.24.918458v1.full, DOI 10.1101/2020.01.24.918458V1.FULL]; Chen BE, 2016, NAT CHEM BIOL, V12, P686, DOI 10.1038/nchembio.2119; Choi J, 2019, J CELL BIOL, V218, P2277, DOI 10.1083/jcb.201804201; Chong CH, 2019, TRANSL PSYCHIAT, V9, DOI 10.1038/s41398-019-0580-9; Cordenonsi M, 2011, CELL, V147, P759, DOI 10.1016/j.cell.2011.09.048; Dai FY, 2007, MOL CELL BIOL, V27, P6183, DOI 10.1128/MCB.00132-07; Dai PG, 2006, J BIOL CHEM, V281, P927, DOI 10.1074/jbc.M507360200; Daulat AM, 2019, PROTEOMICS, V19, DOI 10.1002/pmic.201800487; Daulat AM, 2017, TRENDS CANCER, V3, P113, DOI 10.1016/j.trecan.2017.01.001; Dow LE, 2007, ONCOGENE, V26, P2272, DOI 10.1038/sj.onc.1210016; Dow LE, 2003, ONCOGENE, V22, P9225, DOI 10.1038/sj.onc.1207154; Elsum IA, 2014, ONCOGENE, V33, P5523, DOI 10.1038/onc.2013.498; Elsum IA, 2013, J CELL SCI, V126, P3990, DOI 10.1242/jcs.129387; Favre B, 2001, J BIOL CHEM, V276, P32427, DOI 10.1074/jbc.M011005200; Feigin ME, 2014, CANCER RES, V74, P3180, DOI 10.1158/0008-5472.CAN-13-3415; Godde NJ, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004323; Harmon RM, 2013, J CLIN INVEST, V123, P1556, DOI 10.1172/JCI65220; Hawkins ED, 2016, ONCOGENE, V35, P1193, DOI 10.1038/onc.2015.167; Hernandez JL, 2017, CELL CHEM BIOL, V24, P87, DOI 10.1016/j.chembiol.2016.12.007; Horton ER, 2015, NAT CELL BIOL, V17, P1577, DOI 10.1038/ncb3257; How JY, 2019, FEBS LETT, V593, P533, DOI 10.1002/1873-3468.13329; HRDLICKOVA R, 1995, J VIROL, V69, P403; Hu Y, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.18; Hua SN, 2020, AGING-US, V12, P5439, DOI 10.18632/aging.102969; Huang H, 2015, BIOCHEM BIOPH RES CO, V463, P370, DOI 10.1016/j.bbrc.2015.05.071; Huang YZ, 2003, J BIOL CHEM, V278, P1108, DOI 10.1074/jbc.M205413200; Huang YZ, 2001, J BIOL CHEM, V276, P19318, DOI 10.1074/jbc.M100494200; Ivanov AI, 2010, AM J PATHOL, V176, P134, DOI 10.2353/ajpath.2010.090220; Ivarsson Y, 2014, P NATL ACAD SCI USA, V111, P2542, DOI 10.1073/pnas.1312296111; Izawa I, 2002, GENES CELLS, V7, P475, DOI 10.1046/j.1365-2443.2002.00533.x; Izawa I, 2008, GENES CELLS, V13, P691, DOI 10.1111/j.1365-2443.2008.01198.x; Jarjour AA, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002107; Jaulin-Bastard F, 2002, J BIOL CHEM, V277, P2869, DOI 10.1074/jbc.M109652200; Jaulin-Bastard F, 2001, J BIOL CHEM, V276, P15256, DOI 10.1074/jbc.M010032200; Kallay LM, 2006, J CELL BIOCHEM, V99, P647, DOI 10.1002/jcb.20992; Kelley LA, 2015, NAT PROTOC, V10, P845, DOI 10.1038/nprot.2015.053; Khoury MJ, 2020, P NATL ACAD SCI USA, V117, P11531, DOI 10.1073/pnas.1918462117; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; Kranjec C, 2016, PAPILLOMAVIRUS RES, V2, P70, DOI 10.1016/j.pvr.2016.04.001; Laura RP, 2002, J BIOL CHEM, V277, P12906, DOI 10.1074/jbc.M200818200; Lebeau S, 2005, BRIT J DERMATOL, V152, P1248, DOI 10.1111/j.1365-2133.2005.06687.x; Legouis R, 2000, NAT CELL BIOL, V2, P415, DOI 10.1038/35017046; Legouis R, 2003, EMBO REP, V4, P1096, DOI 10.1038/sj.embor.7400006; Li H, 2017, NEOPLASIA, V19, P509, DOI 10.1016/j.neo.2017.04.003; Li X, 2011, EMBO REP, V12, P818, DOI 10.1038/embor.2011.106; Li YD, 2013, MOL BIOL REP, V40, P4543, DOI 10.1007/s11033-013-2549-8; Lim KYB, 2017, J BIOL CHEM, V292, P20425, DOI 10.1074/jbc.M117.799452; Liu D, 2013, MOL IMMUNOL, V56, P104, DOI 10.1016/j.molimm.2013.04.007; Liu H, 2018, J CELL BIOL, V217, P299, DOI 10.1083/jcb.201705136; Liu HB, 2010, J VIROL, V84, P11164, DOI 10.1128/JVI.01278-10; Liu N, 2008, J BIOCHEM, V143, P793, DOI 10.1093/jb/mvn032; Liu X, 2019, INT REV CEL MOL BIO, V343, P129, DOI 10.1016/bs.ircmb.2018.05.013; Ludford-Menting MJ, 2005, IMMUNITY, V22, P737, DOI 10.1016/j.immuni.2005.04.009; Lyons JJ, 2017, J EXP MED, V214, P669, DOI 10.1084/jem.20161435; McDonald C, 2005, J BIOL CHEM, V280, P40301, DOI 10.1074/jbc.M508538200; Metais JY, 2005, FEBS LETT, V579, P3725, DOI 10.1016/j.febslet.2005.05.062; Montcouquiol M, 2006, J NEUROSCI, V26, P5265, DOI 10.1523/JNEUROSCI.4680-05.2006; Moreau MM, 2010, J NEUROSCI, V30, P9738, DOI 10.1523/JNEUROSCI.6007-09.2010; Murdoch JN, 2001, GENOMICS, V78, P55, DOI 10.1006/geno.2001.6638; Nagasaka K, 2010, ONCOGENE, V29, P5311, DOI 10.1038/onc.2010.265; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; Nakagawa S, 2004, BRIT J CANCER, V90, P194, DOI 10.1038/sj.bjc.6601465; Navarro C, 2005, ONCOGENE, V24, P4330, DOI 10.1038/sj.onc.1208632; Nola S, 2008, HUM MOL GENET, V17, P3552, DOI 10.1093/hmg/ddn248; Nolan ME, 2008, CANCER RES, V68, P8201, DOI 10.1158/0008-5472.CAN-07-6567; Nourry Claire, 2003, Sci STKE, V2003, pRE7; Okajima M, 2008, VIRUS GENES, V37, P231, DOI 10.1007/s11262-008-0259-4; Ono Y, 2015, CELL REP, V10, P1135, DOI 10.1016/j.celrep.2015.01.045; Osmani N, 2006, CURR BIOL, V16, P2395, DOI 10.1016/j.cub.2006.10.026; Pearson HB, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0440-z; Pearson HB, 2011, J CLIN INVEST, V121, P4257, DOI 10.1172/JCI58509; Peres E, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006933; Phua DCY, 2009, MOL BIOL CELL, V20, P2841, DOI 10.1091/mbc.E08-02-0199; PRINTEN JA, 1994, GENETICS, V138, P609; Rachmin I, 2014, P NATL ACAD SCI USA, V111, P5902, DOI 10.1073/pnas.1320350111; Rangwala R, 2005, J BIOL CHEM, V280, P11790, DOI 10.1074/jbc.M414154200; Ress A, 2008, EUR SURG RES, V41, P284, DOI 10.1159/000148241; Ress A, 2006, PROTEIN PEPTIDE LETT, V13, P877, DOI 10.2174/092986606778256126; Robertson J, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7265; Rubin I, 2001, ANN ONCOL, V12, P3, DOI 10.1023/A:1011195320446; Saito H, 2001, J BIOL CHEM, V276, P32051, DOI 10.1074/jbc.C100330200; Santoni MJ, 2002, TRENDS GENET, V18, P494, DOI 10.1016/S0168-9525(02)02738-5; Schurmann C, 2019, CARDIOVASC RES, V115, P1963, DOI 10.1093/cvr/cvz093; Sflomos G, 2011, J CELL SCI, V124, P3209, DOI 10.1242/jcs.062307; Shen LB, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389-018-0034-x; Simeone L, 2010, J NEUROSCI, V30, P6620, DOI 10.1523/JNEUROSCI.5778-09.2010; Skouloudaki K, 2009, P NATL ACAD SCI USA, V106, P8579, DOI 10.1073/pnas.0811691106; Song CJ, 2009, IUBMB LIFE, V61, P685, DOI 10.1002/iub.221; Stephens R, 2018, J MOL BIOL, V430, P3585, DOI 10.1016/j.jmb.2018.01.011; Stevens PD, 2018, CANCER RES, V78, P4839, DOI 10.1158/0008-5472.CAN-17-3629; Strassburger K, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0198149; Sundell GN, 2018, MOL SYST BIOL, V14, DOI 10.15252/msb.20178129; Takizawa S, 2006, GENES CELLS, V11, P453, DOI 10.1111/j.1365-2443.2006.00954.x; Tao YM, 2014, P NATL ACAD SCI USA, V111, pE4429, DOI 10.1073/pnas.1407139111; Tao YM, 2009, P NATL ACAD SCI USA, V106, P9477, DOI 10.1073/pnas.0901844106; Thomas M, 2005, ONCOGENE, V24, P6222, DOI 10.1038/sj.onc.1208757; Thomas M, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005766; Tran E, 2014, SCIENCE, V344, P641, DOI 10.1126/science.1251102; Valenzuela-Iglesias A, 2019, MOL CANCER RES, V17, P1195, DOI 10.1158/1541-7786.MCR-18-0048; Wan S, 2018, HEPATOLOGY, V67, P1842, DOI 10.1002/hep.29669; Warner DR, 2003, FEBS LETT, V539, P167, DOI 10.1016/S0014-5793(03)00155-8; Wilkes MC, 2009, DEV CELL, V16, P433, DOI 10.1016/j.devcel.2009.01.009; Wu H, 2017, J HEPATOL, V66, P1193, DOI 10.1016/j.jhep.2017.01.030; Yao S, 2015, J PATHOL, V236, P65, DOI 10.1002/path.4502; Yoshihara K, 2011, EXP CELL RES, V317, P413, DOI 10.1016/j.yexcr.2010.12.004; Young LC, 2013, MOL CELL, V52, P679, DOI 10.1016/j.molcel.2013.10.004; Yuan J, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13489-4; Zeitler J, 2004, J CELL BIOL, V167, P1137, DOI 10.1083/jcb.200407158; Zhan LX, 2008, CELL, V135, P865, DOI 10.1016/j.cell.2008.09.045; Zheng WY, 2016, NAT CELL BIOL, V18, P1244, DOI 10.1038/ncb3413; Zheng ZJ, 2019, MOL THER, V27, P542, DOI 10.1016/j.ymthe.2019.01.016	127	16	16	1	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 19	2020	39	47					7019	7033		10.1038/s41388-020-01478-7	http://dx.doi.org/10.1038/s41388-020-01478-7		SEP 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OT7KA	32999444	Green Submitted, Green Published, Bronze			2022-12-17	WOS:000574076200001
J	Shi, X; Liu, TT; Yu, XN; Balakrishnan, A; Zhu, HR; Guo, HY; Zhang, GC; Bilegsaikhan, E; Sun, JL; Song, GQ; Weng, SQ; Dong, L; Ott, M; Zhu, JM; Shen, XZ				Shi, Xuan; Liu, Tao-Tao; Yu, Xiang-Nan; Balakrishnan, Asha; Zhu, Hai-Rong; Guo, Hong-Ying; Zhang, Guang-Cong; Bilegsaikhan, Enkhnaran; Sun, Jia-Lei; Song, Guang-Qi; Weng, Shu-Qiang; Dong, Ling; Ott, Michael; Zhu, Ji-Min; Shen, Xi-Zhong			microRNA-93-5p promotes hepatocellular carcinoma progression via a microRNA-93-5p/MAP3K2/c-Jun positive feedback circuit	ONCOGENE			English	Article							C-JUN; PATHWAY; JNK; PROLIFERATION; PATHOGENESIS; EXPRESSION; REPRESSION; APOPTOSIS; DATABASE; MAP3K2	Cumulative evidence suggests that microRNAs (miRNAs) promote gene expression in cancers. However, the pathophysiologic relevance of miRNA-mediated RNA activation in hepatocellular carcinoma (HCC) remains to be established. Our previous miRNA expression profiling in seven-paired HCC specimens revealed miR-93-5p as an HCC-related miRNA. In this study, miR-93-5p expression was assessed in HCC tissues and cell lines by quantitative real-time PCR and fluorescence in situ hybridization. The correlation of miR-93-5p expression with survival and clinicopathological features of HCC was determined by statistical analysis. The function and potential mechanism of miR-93-5p in HCC were further investigated by a series of gain- or loss-of-function experiments in vitro and in vivo. We identified that miR-93-5p, overexpressed in HCC specimens and cell lines, leads to poor outcomes in HCC cases and promotes proliferation, migration, and invasion in HCC cell lines. Mechanistically, rather than decreasing target mRNA levels as expected, miR-93-5p binds to the 3 '-untranslated region (UTR) of mitogen-activated protein kinase kinase kinase 2 (MAP3K2) to directly upregulate its expression and downstream p38 and c-Jun N-terminal kinase (JNK) pathway, thereby leading to cell cycle progression in HCC. Notably, we also demonstrated that c-Jun, a downstream effector of the JNK pathway, enhances miR-93-5p transcription by targeting its promoter region. Besides, downregulation of miR-93-5p significantly retarded tumor growth, while overexpression of miR-93-5p accelerated tumor growth in the HCC xenograft mouse model. Altogether, we revealed a miR-93-5p/MAP3K2/c-Jun positive feedback loop to promote HCC progression in vivo and in vitro, representing an RNA-activating role of miR-93-5p in HCC development.	[Shi, Xuan; Liu, Tao-Tao; Yu, Xiang-Nan; Zhu, Hai-Rong; Guo, Hong-Ying; Zhang, Guang-Cong; Bilegsaikhan, Enkhnaran; Sun, Jia-Lei; Song, Guang-Qi; Weng, Shu-Qiang; Dong, Ling; Zhu, Ji-Min; Shen, Xi-Zhong] Fudan Univ, Dept Gastroenterol & Hepatol, Zhongshan Hosp, 180 Fenglin Rd, Shanghai 200032, Peoples R China; [Shi, Xuan; Liu, Tao-Tao; Yu, Xiang-Nan; Zhu, Hai-Rong; Guo, Hong-Ying; Zhang, Guang-Cong; Bilegsaikhan, Enkhnaran; Sun, Jia-Lei; Song, Guang-Qi; Weng, Shu-Qiang; Dong, Ling; Zhu, Ji-Min; Shen, Xi-Zhong] Fudan Univ, Shanghai Inst Liver Dis, 180 Fenglin Rd, Shanghai 200032, Peoples R China; [Balakrishnan, Asha; Ott, Michael] Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, Carl Neuberg Str 1, D-30625 Hannover, Germany; [Balakrishnan, Asha; Ott, Michael] TWINCORE, Ctr Expt & Clin Infect Res, Feodor Lynen Str 7, D-30625 Hannover, Germany; [Shen, Xi-Zhong] Fudan Univ, Shanghai Med Coll, Key Lab Med Mol Virol, 130 Dongan Rd, Shanghai 200032, Peoples R China	Fudan University; Fudan University; Hannover Medical School; Helmholtz Association; Helmholtz-Center for Infection Research; Fudan University	Zhu, JM; Shen, XZ (corresponding author), Fudan Univ, Dept Gastroenterol & Hepatol, Zhongshan Hosp, 180 Fenglin Rd, Shanghai 200032, Peoples R China.; Zhu, JM; Shen, XZ (corresponding author), Fudan Univ, Shanghai Inst Liver Dis, 180 Fenglin Rd, Shanghai 200032, Peoples R China.; Shen, XZ (corresponding author), Fudan Univ, Shanghai Med Coll, Key Lab Med Mol Virol, 130 Dongan Rd, Shanghai 200032, Peoples R China.	zhu.jimin@zs-hospital.sh.cn; shen.xizhong@zs-hospital.sh.cn	zhu, jimin/HDN-1451-2022; liu, taotao/GSI-7460-2022	Zhu, Ji-Min/0000-0002-2150-473X; Song, Guangqi/0000-0002-2409-0771	National Natural Science Foundation of China [81402273, 81672720, 81672334, 81700550]; National Clinical Key Special Subject of China	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Clinical Key Special Subject of China	This work was partly supported by the National Natural Science Foundation of China (grant numbers 81402273, 81672720, 81672334, and 81700550), and by the National Clinical Key Special Subject of China.	Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chaluvally-Raghavan P, 2016, CELL REP, V15, P1493, DOI 10.1016/j.celrep.2016.04.034; Chen CY, 2019, CLIN RES HEPATOL GAS, V43, P436, DOI 10.1016/j.clinre.2018.11.008; Chen X, 2015, MOL CANCER, V14, P11; Das M, 2007, P NATL ACAD SCI USA, V104, P15759, DOI 10.1073/pnas.0707782104; Delire B, 2015, EUR J CLIN INVEST, V45, P609, DOI 10.1111/eci.12441; Du L, 2014, ONCOGENE, V33, P4307, DOI 10.1038/onc.2013.381; Fallmann J, 2016, NUCLEIC ACIDS RES, V44, pD90, DOI 10.1093/nar/gkv1238; Fang L, 2011, ONCOGENE, V30, P806, DOI 10.1038/onc.2010.465; Gong C, 2015, ONCOGENE, V34, P84, DOI 10.1038/onc.2013.525; Guarnieri AL, 2018, ONCOGENE, V37, P3879, DOI 10.1038/s41388-018-0239-7; He Y, 2017, EXP THER MED, V13, P2003, DOI 10.3892/etm.2017.4204; Huang V, 2012, NUCLEIC ACIDS RES, V40, P1695, DOI 10.1093/nar/gkr934; Ji CM, 2017, BIOTECHNOL LETT, V39, P1621, DOI 10.1007/s10529-017-2403-5; Johnson JM, 2005, TRENDS GENET, V21, P93, DOI 10.1016/j.tig.2004.12.009; Kim EK, 2010, BBA-MOL BASIS DIS, V1802, P396, DOI 10.1016/j.bbadis.2009.12.009; Lee SY, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-53561-z; Li JH, 2014, NUCLEIC ACIDS RES, V42, pD92, DOI 10.1093/nar/gkt1248; Li N, 2017, CELL DEATH DIS, V8; Li Y, 2009, CANCER SCI, V100, P1234, DOI 10.1111/j.1349-7006.2009.01164.x; Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30; Nahand JS, 2019, J CELL PHYSIOL, V234, P12188, DOI 10.1002/jcp.27956; Niu Y, 2018, ONCOGENE, V37, P1743, DOI 10.1038/s41388-017-0082-2; Ohta K, 2015, ONCOTARGET, V6, P3211, DOI 10.18632/oncotarget.3085; Orom UA, 2008, MOL CELL, V30, P460, DOI 10.1016/j.molcel.2008.05.001; Petrocca F, 2008, CANCER CELL, V13, P272, DOI 10.1016/j.ccr.2008.02.013; Pichon X, 2012, CURR PROTEIN PEPT SC, V13, P294, DOI 10.2174/138920312801619475; POLISENO L, 2010, SCI SIGNAL, V3, P29, DOI DOI 10.1126/SCISIGNAL.2000594; Schwabe RF, 2003, HEPATOLOGY, V37, P824, DOI 10.1053/jhep.2003.50135; Seki E, 2012, GASTROENTEROLOGY, V143, P307, DOI 10.1053/j.gastro.2012.06.004; Sun Q, 2019, CELL DEATH DIS, V10; Vasaikar SV, 2018, NUCLEIC ACIDS RES, V46, pD956, DOI 10.1093/nar/gkx1090; Vasudevan S, 2007, SCIENCE, V318, P1931, DOI 10.1126/science.1149460; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Wang C., 2016, UROL ONCOL, V34, pe23; Wang CH, 2000, BIOCHEM BIOPH RES CO, V270, P303, DOI 10.1006/bbrc.2000.2422; Wong CCL, 2011, GASTROENTEROLOGY, V140, P322, DOI 10.1053/j.gastro.2010.10.006; Wu J, 2017, BIOCHEM BIOPH RES CO, V483, P10, DOI 10.1016/j.bbrc.2017.01.023; Xiao M, 2017, RNA BIOL, V14, P1326, DOI 10.1080/15476286.2015.1112487; Xue XF, 2018, BIOCHEM BIOPH RES CO, V502, P515, DOI 10.1016/j.bbrc.2018.05.208; Yang JH, 2011, NUCLEIC ACIDS RES, V39, pD202, DOI 10.1093/nar/gkq1056; Yang Z, 2019, AUTOPHAGY, V15, P668, DOI 10.1080/15548627.2018.1539590; Yu J, 2015, AM J CANCER RES, V5, P802; Yu XN, 2020, ACS APPL MATER INTER, V12, P17193, DOI 10.1021/acsami.0c00375; Yu XN, 2020, ANN SURG ONCOL, V27, P1546, DOI 10.1245/s10434-020-08263-6; Zhu HR, 2018, TOHOKU J EXP MED, V245, P89, DOI 10.1620/tjem.245.89	46	16	17	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 27	2020	39	35					5768	5781		10.1038/s41388-020-01401-0	http://dx.doi.org/10.1038/s41388-020-01401-0		JUL 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NF2QB	32719439				2022-12-17	WOS:000552933000001
J	Samsa, WE; Mamidi, MK; Bashur, LA; Elliott, R; Miron, A; Chen, YQ; Lees, B; Greenfield, EM; Chan, R; Danielpour, D; Zhou, G				Samsa, William E.; Mamidi, Murali K.; Bashur, Lindsay A.; Elliott, Robin; Miron, Alexander; Chen, Yuqing; Lees, Brendan; Greenfield, Edward M.; Chan, Ricky; Danielpour, David; Zhou, Guang			The crucial p53-dependent oncogenic role of JAB1 in osteosarcoma in vivo	ONCOGENE			English	Article							NEDD8-ACTIVATING ENZYME; COP9 SIGNALOSOME; CELL-LINES; P53; RB; INACTIVATION; ACTIVATION; INHIBITOR; CARCINOMA; TOOLS	Osteosarcoma (OS) is the most common primary bone cancer and ranks amongst the leading causes of cancer mortality in young adults. Jun activation domain-binding protein 1 (JAB1) is overexpressed in many cancers and has recently emerged as a novel target for cancer treatment. However, the role of JAB1 in osteosarcoma was virtually unknown. In this study, we demonstrate that JAB1-knockdown in malignant osteosarcoma cell lines significantly reduced their oncogenic properties, including proliferation, colony formation, and motility. We also performed RNA-sequencing analysis in JAB1-knockdown OS cells and identified 4110 genes that are significantly differentially expressed. This demonstrated for the first time that JAB1 regulates a large and specific transcriptome in cancer. We also found that JAB1 is overexpressed in human OS and correlates with a poor prognosis. Moreover, we generated a novel mouse model that overexpresses Jab1 specifically in osteoblasts upon a TP53 heterozygous sensitizing background. Interestingly, by 13 months of age, a significant proportion of these mice spontaneously developed conventional OS. Finally, we demonstrate that a novel, highly specific small molecule inhibitor of JAB1, CSN5i-3, reduces osteosarcoma cell viability, and has specific effects on the ubiquitin-proteasome system in OS. Thus, we show for the first time that the overexpression of JAB1 in vivo can result in accelerated spontaneous tumor formation in a p53-dependent manner. In summary, JAB1 might be a unique target for the treatment of osteosarcoma and other cancers.	[Samsa, William E.; Mamidi, Murali K.; Bashur, Lindsay A.; Zhou, Guang] Case Western Reserve Univ, Dept Orthopaed, Cleveland, OH 44106 USA; [Samsa, William E.; Mamidi, Murali K.; Miron, Alexander; Danielpour, David; Zhou, Guang] Case Comprehens Canc Ctr, Cleveland, OH 44106 USA; [Elliott, Robin] Dept Pathol, Cleveland, OH USA; [Miron, Alexander; Zhou, Guang] Dept Genet & Genome Sci, Cleveland, OH 44106 USA; [Chen, Yuqing; Lees, Brendan] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; [Greenfield, Edward M.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA; [Chan, Ricky] Case Comprehens Canc Ctr, Inst Computat Biol, Cleveland, OH USA; [Danielpour, David] Div Gen Med Sci, Cleveland, OH USA	Case Western Reserve University; Case Western Reserve University; Baylor College of Medicine; Indiana University System; Indiana University Bloomington; Case Western Reserve University	Zhou, G (corresponding author), Case Western Reserve Univ, Dept Orthopaed, Cleveland, OH 44106 USA.; Zhou, G (corresponding author), Case Comprehens Canc Ctr, Cleveland, OH 44106 USA.; Zhou, G (corresponding author), Dept Genet & Genome Sci, Cleveland, OH 44106 USA.	gxz27@case.edu	Mamidi, Murali/ABD-1676-2021		NCI [R03 CA175874]; NIAMS [R01 AR068361, T32 AR7505-30]; Rally Foundation for Childhood Cancer Research and Open Hands Overflowing Hearts Fellowship [CON221575]; ACS [119999-IRG-91-022-18IRG]	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Rally Foundation for Childhood Cancer Research and Open Hands Overflowing Hearts Fellowship; ACS(American Cancer Society)	NCI R03 CA175874 to GZ, ACS #119999-IRG-91-022-18IRG to GZ, NIAMS R01 AR068361 to GZ, NIAMS T32 AR7505-30 to WES and LAB, and the Rally Foundation for Childhood Cancer Research and Open Hands Overflowing Hearts Fellowship CON221575 to WES.	Ballatori SE, 2016, SIGNAL TRANSDUCT TAR, V1, DOI 10.1038/sigtrans.2016.1; Bashur LA, 2014, J CELL PHYSIOL, V229, P1607, DOI 10.1002/jcp.24602; Behjati S, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15936; Berman SD, 2008, P NATL ACAD SCI USA, V105, P11851, DOI 10.1073/pnas.0805462105; Chen DX, 2013, J CELL SCI, V126, P234, DOI 10.1242/jcs.113795; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; Collier CD, 2018, CLIN ORTHOP RELAT R, V476, P1400, DOI 10.1007/s11999.0000000000000059; Crone SG, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-71; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Enchev RI, 2015, NAT REV MOL CELL BIO, V16, P30, DOI 10.1038/nrm3919; Gavet O, 2010, DEV CELL, V18, P533, DOI 10.1016/j.devcel.2010.02.013; Gianferante DM, 2017, NAT REV ENDOCRINOL, V13, P480, DOI 10.1038/nrendo.2017.16; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Johmura Y, 2018, J CLIN INVEST, V128, P5603, DOI 10.1172/JCI121679; Kato JY, 2009, GENES CELLS, V14, P1209, DOI 10.1111/j.1365-2443.2009.01349.x; Lauvrak SU, 2013, BRIT J CANCER, V109, P2228, DOI 10.1038/bjc.2013.549; Lee YH, 2011, ONCOGENE, V30, P4175, DOI 10.1038/onc.2011.126; Liang BJ, 2012, CALCIFIED TISSUE INT, V90, P76, DOI 10.1007/s00223-011-9550-9; Lin PP, 2009, CARCINOGENESIS, V30, P1789, DOI 10.1093/carcin/bgp180; Liu GH, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00135; Loukil Abdelhalim, 2015, World J Biol Chem, V6, P346, DOI 10.4331/wjbc.v6.i4.346; Lu RQ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12044; Malhab LJB, 2016, SCI REP-UK, V6, DOI 10.1038/srep37775; Manasanch EE, 2017, NAT REV CLIN ONCOL, V14, P417, DOI [10.1038/nrclinonc.2016.206, 10.1007/s12079-011-0121-7]; Mirabello L, 2009, CANCER-AM CANCER SOC, V115, P1531, DOI 10.1002/cncr.24121; Mori M, 2008, J BIOL CHEM, V283, P29011, DOI 10.1074/jbc.M804539200; Oh W, 2006, J BIOL CHEM, V281, P17457, DOI 10.1074/jbc.M601857200; Ottaviano L, 2010, GENE CHROMOSOME CANC, V49, P40, DOI 10.1002/gcc.20717; Pan Y, 2017, ONCOGENE, V36, P1069, DOI 10.1038/onc.2016.271; Pan Y, 2013, ONCOGENE, V32, P2756, DOI 10.1038/onc.2012.294; Panattoni M, 2008, J EXP MED, V205, P465, DOI 10.1084/jem.20070725; Perry JA, 2014, P NATL ACAD SCI USA, V111, pE5564, DOI 10.1073/pnas.1419260111; Schlierf A, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13166; Sitte S, 2012, J IMMUNOL, V188, P2677, DOI 10.4049/jimmunol.1101455; Soucy TA, 2009, NATURE, V458, P732, DOI 10.1038/nature07884; Sun R, 2018, CANCER RES, V78, P5274, DOI 10.1158/0008-5472.CAN-17-3647; Swords RT, 2017, BLOOD CANCER J, V7, DOI 10.1038/bcj.2017.1; Tao JN, 2014, CANCER CELL, V26, P390, DOI 10.1016/j.ccr.2014.07.023; Tian L, 2010, ONCOGENE, V29, P6125, DOI 10.1038/onc.2010.345; Walkley CR, 2008, GENE DEV, V22, P1662, DOI 10.1101/gad.1656808; Wang ZW, 2014, NAT REV CANCER, V14, P233, DOI 10.1038/nrc3700; Wei N, 2008, TRENDS BIOCHEM SCI, V33, P592, DOI 10.1016/j.tibs.2008.09.004; Zhang F, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0791-6; Zhang YD, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32428-9; Zhou G, 2006, P NATL ACAD SCI USA, V103, P19004, DOI 10.1073/pnas.0605170103; Zhou LS, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0979-1	48	16	16	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2020	39	23					4581	4591		10.1038/s41388-020-1320-6	http://dx.doi.org/10.1038/s41388-020-1320-6		MAY 2020	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LU5ZF	32390003	Green Accepted, Green Submitted			2022-12-17	WOS:000531697700001
J	Yadav, S; Anbalagan, M; Baddoo, M; Chellamuthu, VK; Mukhopadhyay, S; Woods, C; Jiang, W; Moroz, K; Flemington, EK; Makridakis, N				Yadav, Santosh; Anbalagan, Muralidharan; Baddoo, Melody; Chellamuthu, Vinodh K.; Mukhopadhyay, Sudurika; Woods, Carol; Jiang, Wei; Moroz, Krzysztof; Flemington, Erik K.; Makridakis, Nick			Somatic mutations in the DNA repairome in prostate cancers in African Americans and Caucasians	ONCOGENE			English	Article							GENE-MUTATIONS; HUMAN BREAST; PATTERNS; DEFECTS; ORIGINS; CELLS; RISK	Most hereditary tumors show aberrations in DNA repair genes or their regulators. In contrast, only a minority of sporadic tumors show alterations in these genes. As a result, genomic instability is currently considered an enhancer of tumorigenesis rather than an obligatory event in this process. However, tumor heterogeneity presents a significant technical challenge for most cancer genomics studies performed at less than 100x mean resolution depth. To address the importance of genomic instability in prostate carcinogenesis and tumor progression, we performed ultrahigh depth exome sequencing of 124 DNA damage repair/response (repairome) genes in 63 tumors and matched normal tissue samples in African Americans and Caucasians. The average sequence depth was 712-fold for DNA isolated from normal tissue and 368-fold for FFPE tumors. We identified 671 somatic mutations in tumors from African Americans and 762 somatic mutations in tumors in Caucasians. The most frequently mutated DNA repairome genes were EXO1, ATR, POLQ, NEIL3, ERCC6, BRCA2, BRCA1, XPC, JAG1, RPA1, POLE, ATM, and LIG1 in African American men, and POLQ, NEIL3, POLB, BRCA2, EXO1, ERCC6, ATR, RBBP8, BRCA1, ATM, JAG1, XPC, and POLE in Caucasians. We found that 89% of tumors had at least one mutation in nucleotide excision repair pathway genes in African Americans, whereas >40% of tumors had mutations in base excision repair pathway genes in Caucasians. We further identified a marginal increase in mutation rate in tumors in African Americans with increasing age. Tumors in Caucasians did not show a correlation with age, but a progressive increase in the mutation rate was observed at higher Gleason scores. Our data reveal significant differences in the molecular signatures in the DNA repairome in prostate cancer between African Americans and Caucasians. These data also have substantial implications regarding the well-known health disparities in prostate cancer, such as the higher mortality in African Americans than Caucasians.	[Yadav, Santosh; Anbalagan, Muralidharan; Baddoo, Melody; Mukhopadhyay, Sudurika; Woods, Carol; Jiang, Wei; Flemington, Erik K.; Makridakis, Nick] Louisiana Canc Res Ctr, New Orleans, LA 70112 USA; [Yadav, Santosh] Tulane Univ, Dept Med, Tulane Ctr Aging, New Orleans, LA 70118 USA; [Anbalagan, Muralidharan] Tulane Univ, Dept Struct & Cellular Biol, New Orleans, LA 70118 USA; [Baddoo, Melody; Moroz, Krzysztof; Flemington, Erik K.] Tulane Univ, Dept Pathol, New Orleans, LA 70118 USA; [Chellamuthu, Vinodh K.] Dixie State Univ, Dept Math, St George, UT 84770 USA; [Makridakis, Nick] 1Globe Hlth Inst, Boston, MA 02062 USA	Tulane University; Tulane University; Tulane University; Utah System of Higher Education; Dixie State University	Yadav, S; Makridakis, N (corresponding author), Louisiana Canc Res Ctr, New Orleans, LA 70112 USA.; Yadav, S (corresponding author), Tulane Univ, Dept Med, Tulane Ctr Aging, New Orleans, LA 70118 USA.; Makridakis, N (corresponding author), 1Globe Hlth Inst, Boston, MA 02062 USA.	Syadav1@tulane.edu; NMakridakis@1Globe-USA.com	Yadav, Santosh/GQZ-7569-2022; Chellamuthu, Vinodh Kumar/AAS-6906-2020	Anbalagan, Muralidharan/0000-0001-5797-7558	NCI NIH HHS [R01 CA243793] Funding Source: Medline; NIGMS NIH HHS [P20 GM103518] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akalu A, 1999, GENET ANAL-BIOMOL E, V15, P229, DOI 10.1016/S1050-3862(99)00050-9; An CL, 2011, HUM MUTAT, V32, P415, DOI 10.1002/humu.21465; Athie A, 2019, CURR ONCOL REP, V21, DOI 10.1007/s11912-019-0790-6; Barbieri CE, 2012, NAT GENET, V44, P685, DOI 10.1038/ng.2279; Bostwick DG, 2004, CANCER-AM CANCER SOC, V101, P2371, DOI 10.1002/cncr.20408; Brown JS, 2017, CANCER DISCOV, V7, P20, DOI 10.1158/2159-8290.CD-16-0860; Burgers PMJ, 2017, ANNU REV BIOCHEM, V86, P417, DOI 10.1146/annurev-biochem-061516-044709; Caglayan M, 2015, DNA REPAIR, V35, P85, DOI 10.1016/j.dnarep.2015.09.010; Caronia D, 2009, PHARMACOGENOMICS J, V9, P347, DOI 10.1038/tpj.2009.19; Choi Y, 2015, BIOINFORMATICS, V31, P2745, DOI 10.1093/bioinformatics/btv195; Christenson ES, 2018, EXPERT OPIN EMERG DR, V23, P123, DOI 10.1080/14728214.2018.1459563; DeSantis CE, 2019, CA-CANCER J CLIN, V69, P211, DOI 10.3322/caac.21555; Dong XQ, 2009, J CLIN ONCOL, V27, P1592, DOI 10.1200/JCO.2008.20.1111; Eyler CE, 2008, J CLIN ONCOL, V26, P2839, DOI 10.1200/JCO.2007.15.1829; Fox EJ, 2013, CANCER METAST REV, V32, P353, DOI 10.1007/s10555-013-9426-8; Gaines AR, 2014, CANCER CAUSE CONTROL, V25, P1029, DOI 10.1007/s10552-014-0402-6; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Gronberg H, 2003, LANCET, V361, P859, DOI 10.1016/S0140-6736(03)12713-4; Hoeijmakers JHJ, 2009, NEW ENGL J MED, V361, P1475, DOI 10.1056/NEJMra0804615; Koboldt Daniel C, 2013, Curr Protoc Bioinformatics, V44, DOI 10.1002/0471250953.bi1504s44; Kumar P, 2009, NAT PROTOC, V4, P1073, DOI 10.1038/nprot.2009.86; Lin PC, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40571-0; Loeb LA, 2003, P NATL ACAD SCI USA, V100, P776, DOI 10.1073/pnas.0334858100; Makridakis NM, 2009, HUM MUTAT, V30, P39, DOI 10.1002/humu.20810; Marx J, 2002, SCIENCE, V297, P544, DOI 10.1126/science.297.5581.544; Mateo J, 2015, NEW ENGL J MED, V373, P1697, DOI 10.1056/NEJMoa1506859; Nelson WG, 2003, NEW ENGL J MED, V349, P366, DOI 10.1056/NEJMra021562; Nelson WG, 2014, CANCER TREAT RES, V159, P51, DOI 10.1007/978-3-642-38007-5_4; Nogueira Guilherme Augusto Silva, 2018, Oncotarget, V9, P29538, DOI 10.18632/oncotarget.25268; Powell IJ, 2007, J UROLOGY, V177, P444, DOI 10.1016/j.juro.2006.09.024; Pritchard CC, 2016, NEW ENGL J MED, V375, P443, DOI 10.1056/NEJMoa1603144; Ross CA, 2017, NATURE, V541, P34, DOI 10.1038/nature21107; Schweizer MT, 2017, CLIN ADV HEMATOL ONC, V15, P785; Shi WW, 2018, CELL REP, V25, P1446, DOI 10.1016/j.celrep.2018.10.046; Stephens P, 2005, NAT GENET, V37, P590, DOI 10.1038/ng1571; Stratton MR, 2009, NATURE, V458, P719, DOI 10.1038/nature07943; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603; Wedge DC, 2018, NAT GENET, V50, P682, DOI 10.1038/s41588-018-0086-z; Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720; Yadav S, 2015, HUM MUTAT, V36, P873, DOI 10.1002/humu.22820	41	16	17	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	21					4299	4311		10.1038/s41388-020-1280-x	http://dx.doi.org/10.1038/s41388-020-1280-x			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LQ2DH	32300177	hybrid, Green Published			2022-12-17	WOS:000534819000011
J	Adamski, V; Hattermann, K; Kubelt, C; Cohrs, G; Lucius, R; Synowitz, M; Sebens, S; Held-Feindt, J				Adamski, Vivian; Hattermann, Kirsten; Kubelt, Carolin; Cohrs, Gesa; Lucius, Ralph; Synowitz, Michael; Sebens, Susanne; Held-Feindt, Janka			Entry and exit of chemotherapeutically-promoted cellular dormancy in glioblastoma cells is differentially affected by the chemokines CXCL12, CXCL16, and CX3CL1	ONCOGENE			English	Article							MONOCYTE CHEMOATTRACTANT PROTEIN-1; INTRATUMOR HETEROGENEITY; ANGIOGENIC SWITCH; TUMOR DORMANCY; RECEPTOR CXCR7; TEMOZOLOMIDE; MECHANISMS; EXPRESSION; ESCAPE; PROLIFERATION	Glioblastoma multiforme (GBM) is a malignant brain tumor that evades therapy regimens. Since cellular dormancy is one strategy for surviving, and since chemokines determine the environmental conditions in which dormancy occurs, we investigated how chemokines affect temozolomide (TMZ)-promoted cellular dormancy entry and exit in GBM cells. TMZ administration over ten days promoted cellular dormancy entry, whereas discontinuing TMZ for a further 15 days resulted in resumption of proliferation. Co-administration of a chemokine cocktail containing CXCL12, CXCL16, and CX3CL1 resulted in both delayed entry and exit from cellular dormancy. A microarray-based transcriptome analysis in LN229 GBM cells revealed that cellular dormancy entry was characterized by an increased expression of CCL2 and SAA2, while THSD4, FSTL3, and VEGFC were upregulated during dormancy exit. Co-stimulation with the chemokine cocktail reduced upregulation of identified genes. After verifying the appearance of identified genes in human GBM primary cultures and ex vivo samples, we clarified whether each chemokine alone impacts cellular dormancy mechanisms using specific antagonists and selective CRISPR/Cas9 clones. While expression of CCL2 and SAA2 in LN229 cells was altered by the CXCL12-CXCR4-CXCR7 axis, CXCL16 and CX3CL1 contributed to reduced upregulation of THSD4 and, to a weaker extent, of VEGFC. The influence on FSTL3 expression depended on the entire chemokine cocktail. Effects of chemokines on dormancy entry and exit-associated genes were detectable in human GBM primary cells, too, even if in a more complex, cell-specific manner. Thus, chemokines play a significant role in the regulation of TMZ-promoted cellular dormancy in GBMs.	[Adamski, Vivian; Kubelt, Carolin; Cohrs, Gesa; Synowitz, Michael; Held-Feindt, Janka] Univ Med Ctr Schleswig Holstein UKSH, Dept Neurosurg, Campus Kiel, D-24105 Kiel, Germany; [Hattermann, Kirsten; Lucius, Ralph] Univ Kiel, Dept Anat, D-24118 Kiel, Germany; [Sebens, Susanne] Univ Kiel, Inst Expt Canc Res, Campus Kiel, D-24105 Kiel, Germany; [Sebens, Susanne] Univ Med Ctr Schleswig Holstein UKSH, Campus Kiel, D-24105 Kiel, Germany	University of Kiel; Schleswig Holstein University Hospital; University of Kiel; University of Kiel; University of Kiel; Schleswig Holstein University Hospital	Held-Feindt, J (corresponding author), Univ Med Ctr Schleswig Holstein UKSH, Dept Neurosurg, Campus Kiel, D-24105 Kiel, Germany.	Janka.Held-Feindt@uksh.de	Sebens, Susanne/C-1222-2010; Hattermann, Kirsten/E-8043-2010		German Research Foundation (DFG) as part of the Research Training Group "Materials4Brain" [RTG2154]; University Medical Center Schleswig-Holstein, UKSH ("Anschubforderung 2020"); Projekt DEAL	German Research Foundation (DFG) as part of the Research Training Group "Materials4Brain"(German Research Foundation (DFG)); University Medical Center Schleswig-Holstein, UKSH ("Anschubforderung 2020"); Projekt DEAL	We thank Fereshteh Ebrahim, Brigitte Rehmke, and Judith Becker for expert technical assistance. This work was funded by the German Research Foundation (DFG) as part of the Research Training Group "Materials4Brain" (RTG2154; P8) and a sponsorship of the University Medical Center Schleswig-Holstein, UKSH ("Anschubforderung 2020" given to JHF). Open access funding was provided by Projekt DEAL.	Adamski V, 2017, ONCOTARGET, V8, P108064, DOI 10.18632/oncotarget.22514; Adamski V, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071468; Aguirre-Ghiso JA, 2007, NAT REV CANCER, V7, P834, DOI 10.1038/nrc2256; Almog N, 2010, CANCER LETT, V294, P139, DOI 10.1016/j.canlet.2010.03.004; Almog N, 2009, CANCER RES, V69, P836, DOI 10.1158/0008-5472.CAN-08-2590; Ammerpohl O., 2017, ECOLOGY EVOLUTION CA, P235, DOI [10.1016/B978-0-12-804310-3.00020-X, DOI 10.1016/B978-0-12-804310-3.00020-X]; Bai D, 2009, INT J CANCER, V125, P2863, DOI 10.1002/ijc.24748; Bartholin L, 2007, GENE, V393, P153, DOI 10.1016/j.gene.2007.02.007; Bonavia R, 2011, CANCER RES, V71, P4055, DOI 10.1158/0008-5472.CAN-11-0153; Bowman RL, 2014, IMMUNOTHERAPY-UK, V6, P663, DOI [10.2217/IMT.14.48, 10.2217/imt.14.48]; Bruyere C, 2011, INT J ONCOL, V38, P1453, DOI 10.3892/ijo.2011.964; Chen L, 2018, INT J OPHTHALMOL-CHI, V11, P216, DOI 10.18240/ijo.2018.02.06; Christofides A, 2015, CYTOKINE, V71, P377, DOI 10.1016/j.cyto.2014.09.008; Clark AM, 2017, LAB CHIP, V17, P156, DOI 10.1039/c6lc01171c; Cohen H, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0464-0; Coppola D, 2014, J GERIATR ONCOL, V5, P389, DOI 10.1016/j.jgo.2014.08.003; De Cock JM, 2016, CANCER RES, V76, P6778, DOI 10.1158/0008-5472.CAN-16-0608; DESBAILLETS I, 1994, INT J CANCER, V58, P240, DOI 10.1002/ijc.2910580216; Ehtesham M, 2013, J NEURO-ONCOL, V113, P153, DOI 10.1007/s11060-013-1108-4; Endaya BB, 2016, MOL ONCOL, V10, P126, DOI 10.1016/j.molonc.2015.09.001; Facci L, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1205-6; Goffart N, 2017, NEURO-ONCOLOGY, V19, P66, DOI 10.1093/neuonc/now136; Guo YC, 2017, AM J PATHOL, V187, P1736, DOI 10.1016/j.ajpath.2017.04.007; Hasan T, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1387-6; Hattermann K, 2008, MOL CELL NEUROSCI, V39, P133, DOI 10.1016/j.mcn.2008.03.009; Hattermann K, 2016, CELL COMMUN SIGNAL, V14, DOI 10.1186/s12964-016-0149-7; Hattermann K, 2016, ELIFE, V5, DOI 10.7554/eLife.10820; Hattermann K, 2013, J NEUROIMMUNOL, V260, P47, DOI 10.1016/j.jneuroim.2013.04.006; Hattermann K, 2012, ONCOL REP, V27, P1348, DOI 10.3892/or.2012.1674; Hattermann K, 2010, CANCER RES, V70, P3299, DOI 10.1158/0008-5472.CAN-09-3642; Held-Feindt J, 2006, INT J CANCER, V118, P55, DOI 10.1002/ijc.21258; Held-Feindt J, 2010, EXP CELL RES, V316, P1553, DOI 10.1016/j.yexcr.2010.02.018; Hirose Y, 2001, CANCER RES, V61, P1957; Jin X, 2017, CELL PHYSIOL BIOCHEM, V44, P1616, DOI 10.1159/000485759; Johnson BE, 2014, SCIENCE, V343, P189, DOI 10.1126/science.1239947; Khazali AS, 2018, BRIT J CANCER, V118, P566, DOI 10.1038/bjc.2017.414; Lacalle RA, 2017, INT REV CEL MOL BIO, V331, P181, DOI 10.1016/bs.ircmb.2016.09.011; Lee SY, 2016, GENES DIS, V3, P198, DOI 10.1016/j.gendis.2016.04.007; Li JH, 2017, CYTOKINE, V94, P45, DOI 10.1016/j.cyto.2017.04.010; Liu Y, 2015, ANTICANCER RES, V35, P53; Magnus N, 2013, J THROMB HAEMOST, V11, P1197, DOI 10.1111/jth.12242; Magnus N, 2014, THROMB RES, V133, pS1, DOI 10.1016/S0049-3848(14)50001-1; Magnus N, 2014, P NATL ACAD SCI USA, V111, P3544, DOI 10.1073/pnas.1314118111; Malle E, 2009, CELL MOL LIFE SCI, V66, P9, DOI 10.1007/s00018-008-8321-x; Nagarsheth N, 2017, NAT REV IMMUNOL, V17, P559, DOI 10.1038/nri.2017.49; Naumov GN, 2006, JNCI-J NATL CANCER I, V98, P316, DOI 10.1093/jnci/djj068; Nie E, 2019, ONCOGENE, V38, P2706, DOI 10.1038/s41388-018-0596-2; Nobutani K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130032; Oh JW, 2001, J IMMUNOL, V166, P2695, DOI 10.4049/jimmunol.166.4.2695; Perazzoli G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140131; Quail DF, 2017, CANCER CELL, V31, P326, DOI 10.1016/j.ccell.2017.02.009; Ray A, 2002, MOL CELL BIOL, V22, P1027, DOI 10.1128/MCB.22.4.1027-1035.2002; Resende R. R., 2013, TRENDS STEM CELL PRO, P339; Satchi-Fainaro R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044395; Schols D, 1997, J EXP MED, V186, P1383, DOI 10.1084/jem.186.8.1383; Senft D, 2016, PIGM CELL MELANOMA R, V29, P27, DOI 10.1111/pcmr.12432; Song YR, 2013, P NATL ACAD SCI USA, V110, P17933, DOI 10.1073/pnas.1317026110; Sosa MS, 2011, CLIN CANCER RES, V17, P5850, DOI 10.1158/1078-0432.CCR-10-2574; Sottoriva A, 2013, P NATL ACAD SCI USA, V110, P4009, DOI 10.1073/pnas.1219747110; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Tabouret E, 2015, ONCOTARGET, V6, P11664, DOI 10.18632/oncotarget.3256; Tiram G, 2018, FASEB J, V1, pfj201701568R; Tivari S, 2018, CELL COMMUN SIGNAL, V16, DOI 10.1186/s12964-018-0259-5; Tong LQ, 2018, ONCOL REP, V40, P463, DOI 10.3892/or.2018.6425; Vakilian A, 2017, NEUROCHEM INT, V103, P1, DOI 10.1016/j.neuint.2016.12.013; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Yao M, 2016, ADV CANCER RES, V132, P265, DOI 10.1016/bs.acr.2016.05.005; Yeh AC, 2015, CANCER RES, V75, P5014, DOI 10.1158/0008-5472.CAN-15-1370; Zeng LC, 2016, ONCOL LETT, V12, P815, DOI 10.3892/ol.2016.4690; Zhang ZJ, 2012, CELL MOL NEUROBIOL, V32, P1003, DOI 10.1007/s10571-012-9816-4	70	16	16	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	22					4421	4435		10.1038/s41388-020-1302-8	http://dx.doi.org/10.1038/s41388-020-1302-8		APR 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LR9IT	32346064	Green Published, hybrid			2022-12-17	WOS:000529462400001
J	Li, JN; Alvero, AB; Nuti, S; Tedja, R; Roberts, CM; Pitruzzello, M; Li, YM; Xiao, Q; Zhang, S; Gan, YQ; Wu, XY; Mor, G; Yin, G				Li, Juanni; Alvero, Ayesha B.; Nuti, Sudhakar; Tedja, Roslyn; Roberts, Cai M.; Pitruzzello, Mary; Li, Yimin; Xiao, Qing; Zhang, Sai; Gan, Yaqi; Wu, Xiaoying; Mor, Gil; Yin, Gang			CBX7 binds the E-box to inhibit TWIST-1 function and inhibit tumorigenicity and metastatic potential	ONCOGENE			English	Article							CANCER STEM-CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; OVARIAN-CANCER; TUMOR-SUPPRESSOR; E-CADHERIN; POLYCOMB; CARCINOMA; GROWTH; CHEMORESISTANCE; EXPRESSION	Deaths from ovarian cancer usually occur when patients succumb to overwhelmingly numerous and widespread micrometastasis. Whereas epithelial-mesenchymal transition is required for epithelial ovarian cancer cells to acquire metastatic potential, the cellular phenotype at secondary sites and the mechanisms required for the establishment of metastatic tumors are not fully determined. Using in vitro and in vivo models we show that secondary epithelial ovarian cancer cells (sEOC) do not fully reacquire the molecular signature of the primary epithelial ovarian cancer cells from which they are derived. Despite displaying an epithelial morphology, sEOC maintains a high expression of the mesenchymal effector, TWIST-1. TWIST-1 is however transcriptionally nonfunctional in these cells as it is precluded from binding its E-box by the PcG protein, CBX7. Deletion of CBX7 in sEOC was sufficient to reactivate TWIST-1-induced transcription, prompt mesenchymal transformation, and enhanced tumorigenicity in vivo. This regulation allows secondary tumors to achieve an epithelial morphology while conferring the advantage of prompt reversal to a mesenchymal phenotype upon perturbation of CBX7. We also describe a subclassification of ovarian tumors based on CBX7 and TWIST-1 expression, which predicts clinical outcomes and patient prognosis.	[Li, Juanni; Li, Yimin; Xiao, Qing; Zhang, Sai; Gan, Yaqi; Wu, Xiaoying; Yin, Gang] Cent South Univ, Sch Basic Med Sci, Xiangya Hosp, Dept Pathol, Changsha, Hunan, Peoples R China; [Alvero, Ayesha B.; Nuti, Sudhakar; Tedja, Roslyn; Roberts, Cai M.; Pitruzzello, Mary; Mor, Gil] Yale Sch Med, Div Reprod Sci, Dept Obstet Gynecol & Reprod Sci, New Haven, CT USA; [Mor, Gil] Wayne State Univ, Dept Obstet & Gynecol, CS Mott Ctr Human Growth & Dev, Detroit, MI USA	Central South University; Yale University; Wayne State University	Yin, G (corresponding author), Cent South Univ, Sch Basic Med Sci, Xiangya Hosp, Dept Pathol, Changsha, Hunan, Peoples R China.; Mor, G (corresponding author), Yale Sch Med, Div Reprod Sci, Dept Obstet Gynecol & Reprod Sci, New Haven, CT USA.	gmor@med.wayne.edu; gang.yin@csu.edu.cn		Alvero, Ayesha/0000-0002-6593-3595; Gan, Yaqi/0000-0001-8097-4603	NIH NCI [R01CA199004]; National Natural Science Foundation of China [81572900]; National Key R&D Program of China; Stem Cell and Translation Research [2016YFA0102000]; Hunan Provincial Natural Science Foundation of China [2018JJ3820]	NIH NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key R&D Program of China; Stem Cell and Translation Research; Hunan Provincial Natural Science Foundation of China(Natural Science Foundation of Hunan Province)	This study is supported in part by grants from NIH NCI R01CA199004 (GM), The National Natural Science Foundation of China No. 81572900 (GY), The National Key R&D Program of China, Stem Cell and Translation Research No. 2016YFA0102000 (GY), and Hunan Provincial Natural Science Foundation of China No. 2018JJ3820 (JL).	Alvero AB, 2006, CANCER-AM CANCER SOC, V106, P599, DOI 10.1002/cncr.21633; Alvero AB, 2017, SCI REP-UK, V7, DOI 10.1038/srep40989; Alvero AB, 2016, MOL CANCER THER, V15, P1279, DOI 10.1158/1535-7163.MCT-16-0005; Alvero AB, 2014, ONCOTARGET, V5, P8703, DOI 10.18632/oncotarget.2367; Alvero AB, 2009, CANCER-AM CANCER SOC, V115, P3204, DOI 10.1002/cncr.24397; Alvero AB, 2009, CELL CYCLE, V8, P158, DOI 10.4161/cc.8.1.7533; Ansieau S, 2008, CANCER CELL, V14, P79, DOI 10.1016/j.ccr.2008.06.005; Armstrong DK, 2002, ONCOLOGIST, V7, P20, DOI 10.1634/theoncologist.7-suppl_5-20; Bao ZY, 2017, ONCOTARGET, V8, P39048, DOI 10.18632/oncotarget.16587; Baylies MK, 1996, SCIENCE, V272, P1481, DOI 10.1126/science.272.5267.1481; Bernard D, 2005, ONCOGENE, V24, P5543, DOI 10.1038/sj.onc.1208735; Bialek P, 2004, DEV CELL, V6, P423, DOI 10.1016/S1534-5807(04)00058-9; Cardenas C, 2017, APOPTOSIS, V22, P558, DOI 10.1007/s10495-016-1339-x; Carmona-Fontaine C, 2011, DEV CELL, V21, P1026, DOI 10.1016/j.devcel.2011.10.012; Chen R, 2008, ONCOGENE, V27, P4712, DOI 10.1038/onc.2008.112; Chen R, 2008, ONCOGENE, V27, P225, DOI 10.1038/sj.onc.1210907; Cheng GZ, 2008, J BIOL CHEM, V283, P14665, DOI 10.1074/jbc.M707429200; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Craveiro V, 2013, CANCER MED-US, V2, P751, DOI 10.1002/cam4.115; Duan RS, 2018, CELL DEATH DIFFER, V25, P1598, DOI 10.1038/s41418-018-0064-0; Fabregat I, 2016, J CLIN MED, V5, DOI 10.3390/jcm5030037; Federico A, 2019, BBA-GENE REGUL MECH, V1862, P509, DOI 10.1016/j.bbagrm.2019.02.006; Forzati F, 2014, BIOL OPEN, V3, P871, DOI 10.1242/bio.20147872; Forzati F, 2012, CELL CYCLE, V11, P1888, DOI 10.4161/cc.20022; Forzati F, 2012, J CLIN INVEST, V122, P612, DOI 10.1172/JCI58620; GLACKIN CA, 1992, BIOCHEM INT, V28, P67; Glackin CA, 2014, MATURITAS, V79, P48, DOI 10.1016/j.maturitas.2014.06.015; Glackin Carlotta A., 1994, Molecular and Cellular Differentiation, V2, P309; Goff Barbara A, 2013, Gynecol Oncol, V130, P9; Heintz APM, 2006, INT J GYNECOL OBSTET, V95, pS161, DOI 10.1016/S0020-7292(06)60033-7; HILDRETH NG, 1981, AM J EPIDEMIOL, V114, P398, DOI 10.1093/oxfordjournals.aje.a113207; Howard TD, 1997, NAT GENET, V15, P36, DOI 10.1038/ng0197-36; Jarboe EA, 2008, HISTOPATHOLOGY, V53, P127, DOI 10.1111/j.1365-2559.2007.02938.x; Jelovac D, 2011, CA-CANCER J CLIN, V61, P183, DOI 10.3322/caac.20113; Jolly MK, 2017, MOL ONCOL, V11, P755, DOI 10.1002/1878-0261.12083; Jordan NV, 2011, CELL CYCLE, V10, P2865, DOI 10.4161/cc.10.17.17188; Kamsteeg M, 2003, ONCOGENE, V22, P2611, DOI 10.1038/sj.onc.1206422; Kelly MG, 2006, CANCER RES, V66, P3859, DOI 10.1158/0008-5472.CAN-05-3948; Kian W, 2018, TRANSL LUNG CANCER R, V7, pS334, DOI 10.21037/tlcr.2018.12.01; Kurman RJ, 2010, AM J SURG PATHOL, V34, P433, DOI 10.1097/PAS.0b013e3181cf3d79; Lee YB, 2009, NUCLEIC ACIDS RES, V37, P123, DOI 10.1093/nar/gkn920; Leeb M, 2010, CELL CYCLE, V9, P2692, DOI 10.4161/cc.9.14.12455; Leeb M, 2010, GENE DEV, V24, P265, DOI 10.1101/gad.544410; Lovisa S, 2015, NAT MED, V21, P998, DOI 10.1038/nm.3902; Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784; Mas G, 2016, CURR OPIN CELL BIOL, V43, P87, DOI 10.1016/j.ceb.2016.09.006; Morey L, 2010, TRENDS BIOCHEM SCI, V35, P323, DOI 10.1016/j.tibs.2010.02.009; Naora H, 2005, NAT REV CANCER, V5, P355, DOI 10.1038/nrc1611; Pallante P, 2015, AM J CANCER RES, V5, P1594; Pallante P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098295; Pizzonia J, 2012, AM J REPROD IMMUNOL, V67, P84, DOI 10.1111/j.1600-0897.2011.01070.x; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Scott CL, 2007, P NATL ACAD SCI USA, V104, P5389, DOI 10.1073/pnas.0608721104; Seto ML, 2001, AM J MED GENET, V104, P323, DOI 10.1002/ajmg.10065; Shen CH, 2011, J BUON, V16, P733; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Tan TZ, 2014, EMBO MOL MED, V6, P1279, DOI 10.15252/emmm.201404208; Tedja R, 2019, J BIOL CHEM, V294, P5082, DOI 10.1074/jbc.RA118.005921; Thrall MM, 2011, GYNECOL ONCOL, V122, P100, DOI 10.1016/j.ygyno.2011.03.022; Tsai JH, 2012, CANCER CELL, V22, P725, DOI 10.1016/j.ccr.2012.09.022; Vergara D, 2010, CANCER LETT, V291, P59, DOI 10.1016/j.canlet.2009.09.017; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611; Wu WN, 2017, AM J CANCER RES, V7, P64; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yang MH, 2008, NAT CELL BIOL, V10, P295, DOI 10.1038/ncb1691; Yang MH, 2010, NAT CELL BIOL, V12, P982, DOI 10.1038/ncb2099; Yang-Hartwich Y, 2015, ONCOGENE, V34, P3605, DOI 10.1038/onc.2014.296; Yang-Hartwich Y, 2019, MOL CANCER RES, V17, P153, DOI 10.1158/1541-7786.MCR-18-0238; Yao DB, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-432; Yao DB, 2011, MOL CANCER RES, V9, P1608, DOI 10.1158/1541-7786.MCR-10-0568; Ye X, 2015, TRENDS CELL BIOL, V25, P675, DOI 10.1016/j.tcb.2015.07.012; Yin G, 2013, ONCOGENE, V32, P39, DOI 10.1038/onc.2012.33; Yin G, 2010, ONCOGENE, V29, P3545, DOI 10.1038/onc.2010.111; Yuen HF, 2007, J CLIN PATHOL, V60, P510, DOI 10.1136/jcp.2006.039099; Zanudo JGT, 2019, PHYS BIOL, V16, DOI 10.1088/1478-3975/aaffa1; Zeisberg M, 2009, J CLIN INVEST, V119, P1429, DOI 10.1172/JCI36183; Zhang YY, 2018, ONCOL RES, V26, P1327, DOI 10.3727/096504018X15165493852990; Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064	78	16	16	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	20					3965	3979		10.1038/s41388-020-1269-5	http://dx.doi.org/10.1038/s41388-020-1269-5		MAR 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LN3GC	32205869	Green Accepted			2022-12-17	WOS:000521527500001
J	Francart, ME; Vanwynsberghe, AM; Lambert, J; Bourcy, M; Genna, A; Ancel, J; Perez-Boza, J; Noel, A; Birembaut, P; Struman, I; Polette, M; Gilles, C				Francart, Marie-Emilie; Vanwynsberghe, Aline M.; Lambert, Justine; Bourcy, Morgane; Genna, Anthony; Ancel, Julien; Perez-Boza, Jennifer; Noel, Agnes; Birembaut, Philippe; Struman, Ingrid; Polette, Myriam; Gilles, Christine			Vimentin prevents a miR-dependent negative regulation of tissue factor mRNA during epithelial-mesenchymal transitions and facilitates early metastasis	ONCOGENE			English	Article							CIRCULATING TUMOR-CELLS; FACTOR EXPRESSION; CANCER-CELLS; COAGULATION; PATHWAY; BINDING; IDENTIFICATION; CONTRIBUTES; ACTIVATION; MECHANISMS	Epithelial-mesenchymal transitions (EMTs) are high-profile in the field of circulating tumor cells (CTCs). EMT-shifted CTCs are considered to encompass pre-metastatic subpopulations though underlying molecular mechanisms remain elusive. Our previous work identified tissue factor (TF) as an EMT-induced gene providing tumor cells with coagulant properties and supporting metastatic colonization by CTCs. We here report that vimentin, the type III intermediate filament considered a canonical EMT marker, contributes to TF regulation and positively supports coagulant properties and early metastasis. Different evidence further pointed to a new post-transcriptional regulatory mechanism of TF mRNA by vimentin: (1) vimentin silencing accelerated TF mRNA decay after actinomycin D treatment, reflecting TF mRNA stabilization, (2) RNA immunoprecipitation revealed enriched levels of TF mRNA in vimentin immunoprecipitate, (3) TF 3 '-UTR-luciferase reporter vector assays implicated the 3 '-UTR of TF mRNA in vimentin-dependent TF regulation, and (4) using different TF 3 ' UTR-luciferase reporter vectors mutated for potential miR binding sites and specific Target Site Blockers identified a key miR binding site in vimentin-dependent TF mRNA regulation. All together, these data support a novel mechanism by which vimentin interferes with a miR-dependent negative regulation of TF mRNA, thereby promoting coagulant activity and early metastasis of vimentin-expressing CTCs.	[Francart, Marie-Emilie; Vanwynsberghe, Aline M.; Lambert, Justine; Bourcy, Morgane; Genna, Anthony; Noel, Agnes; Gilles, Christine] Univ Liege, GIGA Canc, Lab Tumor & Dev Biol, Liege, Belgium; [Ancel, Julien] CHU Reims, Hop Maison Blanche, Serv Pneumol, F-51092 Reims, France; [Ancel, Julien; Birembaut, Philippe; Polette, Myriam] Univ Reims, INSERM, P3Cell UMRS 1250, SFR CAP SANTE, F-51097 Reims, France; [Perez-Boza, Jennifer; Struman, Ingrid] Univ Liege, GIGA Canc, Mol Angiogenesis Lab, Liege, Belgium; [Polette, Myriam] CHU Reims, Hop Maison Blanche, Lab Pathol, F-51092 Reims, France	University of Liege; CHU de Reims; Universite de Reims Champagne-Ardenne; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Reims Champagne-Ardenne; University of Liege; CHU de Reims; Universite de Reims Champagne-Ardenne	Gilles, C (corresponding author), Univ Liege, GIGA Canc, Lab Tumor & Dev Biol, Liege, Belgium.	cgilles@uliege.be	ancel, julien/AAM-8908-2020; ANCEL, Julien/AAD-7228-2022; Boza, Jennifer Perez/AAA-7061-2021	ancel, julien/0000-0003-3128-9348; Boza, Jennifer Perez/0000-0003-3843-494X; struman, ingrid/0000-0003-2550-3707	"Fonds de la Recherche Scientifique" FNRS (F.R.S.-FNRS, Belgium); "Fonds Speciaux de la Recherche" (University of Liege, Belgium); "Fondation contre le Cancer" (foundation of public interest, Belgium); Fondation Hospitalo Universitaire Leon Fredericq (FHULF, University of Liege); Programme Hubert-Curien (WBI); Televie grants	"Fonds de la Recherche Scientifique" FNRS (F.R.S.-FNRS, Belgium)(Fonds de la Recherche Scientifique - FNRS); "Fonds Speciaux de la Recherche" (University of Liege, Belgium); "Fondation contre le Cancer" (foundation of public interest, Belgium); Fondation Hospitalo Universitaire Leon Fredericq (FHULF, University of Liege); Programme Hubert-Curien (WBI); Televie grants	We thank Erika Konradowski, Nathalie Lefin, Emilie Feyereisen, Isabelle Dasoul, Laetitia Montero-Ruiz, and Marie Dehuy for technical assistance. We thank Pr. Silvia Blacher and Thomas Louis for their help with statistical analyses. We thank the following technical platforms from the University of Liege (Belgium): the GIGA-imaging and flow cytometry platform for providing access to FACSCanto II (BD), and the GIGA-Animal Facility. This work was supported by grants from the "Fonds de la Recherche Scientifique" FNRS (F.R.S.-FNRS, Belgium), the "Fonds Speciaux de la Recherche" (University of Liege, Belgium), the "Fondation contre le Cancer" (foundation of public interest, Belgium), the Fondation Hospitalo Universitaire Leon Fredericq (FHULF, University of Liege), and the "Programme Hubert-Curien (WBI)". CG and IS are Senior Research Associates at the F.R.S-FNRS. M-EF, AMV, JL, AG, MB, JP-B are/were supported by Televie grants.	Aberg M, 2013, J THROMB HAEMOST, V11, P817, DOI 10.1111/jth.12156; Ackland ML, 2003, LAB INVEST, V83, P435, DOI 10.1097/01.LAB.0000059927.97515.FD; Agarwal V, 2015, ELIFE, V4, DOI 10.7554/eLife.05005; Alix-Panabieres C, 2017, J MOL MED, V95, P133, DOI 10.1007/s00109-016-1500-6; Alix-Panabieres C, 2016, CANCER DISCOV, V6, P479, DOI 10.1158/2159-8290.CD-15-1483; Beinse G, 2017, J THROMB HAEMOST, V15, P1981, DOI 10.1111/jth.13792; Biggerstaff JP, 2008, CLIN APPL THROMB-HEM, V14, P193, DOI 10.1177/1076029607305619; Bonnomet A, 2012, ONCOGENE, V31, P3741, DOI 10.1038/onc.2011.540; Bourcy M, 2016, CANCER RES, V76, P4270, DOI 10.1158/0008-5472.CAN-15-2263; Breij ECW, 2014, CANCER RES, V74, P1214, DOI 10.1158/0008-5472.CAN-13-2440; Bystricky B, 2017, CRIT REV ONCOL HEMAT, V114, P33, DOI 10.1016/j.critrevonc.2017.04.003; Cabel L, 2017, INT J CLIN ONCOL, V22, P421, DOI 10.1007/s10147-017-1105-2; Challa AA, 2011, MOL CELL BIOL, V31, P3773, DOI 10.1128/MCB.05263-11; Chatterjee S, 2013, FEBS LETT, V587, P474, DOI 10.1016/j.febslet.2013.01.013; D'Asti E, 2016, THROMB RES, V140, pS37, DOI 10.1016/S0049-3848(16)30096-2; D'Asti E, 2016, AM J PATHOL, V186, P446, DOI 10.1016/j.ajpath.2015.10.020; Dauphin M, 2013, LUNG CANCER, V81, P117, DOI 10.1016/j.lungcan.2013.03.011; de Bono JS, 2019, LANCET ONCOL, V20, P383, DOI 10.1016/S1470-2045(18)30859-3; Dmello C, 2016, INT J BIOCHEM CELL B, V70, P161, DOI 10.1016/j.biocel.2015.11.015; Eisenreich A, 2014, TRENDS CARDIOVAS MED, V24, P128, DOI 10.1016/j.tcm.2013.09.005; Francart ME, 2018, DEV DYNAM, V247, P432, DOI 10.1002/dvdy.24506; Garnier D, 2010, THROMB RES, V125, pS44, DOI 10.1016/S0049-3848(10)70012-8; Gil-Bernabe AM, 2013, BRIT J HAEMATOL, V162, P433, DOI 10.1111/bjh.12381; Gilles C, 1999, J CELL SCI, V112, P4615; Hisada Y, 2019, SEMIN THROMB HEMOST, V45, P385, DOI 10.1055/s-0039-1687894; Hu ZW, 2017, ONCOTARGET, V8, P1481, DOI 10.18632/oncotarget.13644; Ivaska Johanna, 2011, Small GTPases, V2, P51; Jolly MK, 2019, PHARMACOL THERAPEUT, V194, P161, DOI 10.1016/j.pharmthera.2018.09.007; Li SF, 2014, ATHEROSCLEROSIS, V237, P514, DOI 10.1016/j.atherosclerosis.2014.09.033; Liu SL, 2019, NANO LETT, V19, P4721, DOI 10.1021/acs.nanolett.9b01785; Lowery J, 2015, J BIOL CHEM, V290, P17145, DOI 10.1074/jbc.R115.640359; Magnus N, 2014, THROMB RES, V133, pS1, DOI 10.1016/S0049-3848(14)50001-1; Markiewicz A, 2017, PATHOBIOLOGY, V84, P264, DOI 10.1159/000477812; Matrone MA, 2010, CANCER RES, V70, P7737, DOI 10.1158/0008-5472.CAN-10-1569; Mego M, 2009, BRIT J CANCER, V101, P1813, DOI 10.1038/sj.bjc.6605413; Milsom C, 2009, ARTERIOSCL THROM VAS, V29, P2005, DOI 10.1161/ATVBAHA.108.177444; Milsom CC, 2008, CANCER RES, V68, P10068, DOI 10.1158/0008-5472.CAN-08-2067; Mitrugno A, 2016, BLOOD REV, V30, P11, DOI 10.1016/j.blre.2015.07.001; Palumbo JS, 2008, SEMIN THROMB HEMOST, V34, P154, DOI 10.1055/s-2008-1079255; Palumbo JS, 2007, BLOOD, V110, P133, DOI 10.1182/blood-2007-01-065995; Pastushenko I, 2019, TRENDS CELL BIOL, V29, P212, DOI 10.1016/j.tcb.2018.12.001; Perlson E, 2006, J MOL BIOL, V364, P938, DOI 10.1016/j.jmb.2006.09.056; Phua DCY, 2009, MOL BIOL CELL, V20, P2841, DOI 10.1091/mbc.E08-02-0199; Provencal M, 2009, CARCINOGENESIS, V30, P1089, DOI 10.1093/carcin/bgp085; Rothmeier AS, 2018, BLOOD, V131, P674, DOI 10.1182/blood-2017-02-768218; Ruf W.R.M., 2013, MADAME CURIE BIOSCIE; Ruf W, 2016, THROMB RES, V140, pS1, DOI 10.1016/S0049-3848(16)30090-1; Sarrio D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017; Satelli A, 2016, J CANCER, V7, P1824, DOI 10.7150/jca.15622; Satelli A, 2016, SCI REP-UK, V6, DOI 10.1038/srep28910; Satelli A, 2011, CELL MOL LIFE SCI, V68, P3033, DOI 10.1007/s00018-011-0735-1; Schmidt Y, 2015, BIOL CHEM, V396, P253, DOI 10.1515/hsz-2014-0274; Song KY, 2013, RNA BIOL, V10, P256, DOI 10.4161/rna.23022; Sun B, 2015, BIOMED REP, V3, P603, DOI 10.3892/br.2015.494; Teruel R, 2011, J THROMB HAEMOST, V9, P1985, DOI 10.1111/j.1538-7836.2011.04451.x; Theunissen JW, 2018, MOL CANCER THER, V17, P2412, DOI 10.1158/1535-7163.MCT-18-0471; Ueno T, 2000, BRIT J CANCER, V83, P164; Unlu B, 2018, RES PRACT THROMB HAE, V2, P622, DOI 10.1002/rth2.12143; Virtakoivu R, 2015, CANCER RES, V75, P2349, DOI 10.1158/0008-5472.CAN-14-2842; Wang HX, 2017, ONCOTARGET, V8, P1884, DOI 10.18632/oncotarget.12242; Wang W, 2018, MOL CELL BIOCHEM, V438, P47, DOI 10.1007/s11010-017-3112-z; Witkowski M, 2018, CARDIOVASC DIABETOL, V17, DOI 10.1186/s12933-018-0678-z; Witkowski M, 2016, ARTERIOSCL THROM VAS, V36, P1263, DOI 10.1161/ATVBAHA.115.306094; Wong N, 2015, NUCLEIC ACIDS RES, V43, pD146, DOI 10.1093/nar/gku1104; Yamashita N, 2013, J CANCER RES CLIN, V139, P739, DOI 10.1007/s00432-013-1376-6; Yoneyama MS, 2014, EUR J CELL BIOL, V93, P157, DOI 10.1016/j.ejcb.2014.03.002; Yu G, 2013, MOL CELL BIOCHEM, V380, P239, DOI 10.1007/s11010-013-1679-6; Yu M, 2013, SCIENCE, V339, P580, DOI 10.1126/science.1228522; Yu YH, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt332; Zhang XX, 2011, J BIOL CHEM, V286, P1429, DOI 10.1074/jbc.M110.146530; Zhang XS, 2017, ONCOTARGET, V8, P59086, DOI 10.18632/oncotarget.19175; Zhao XT, 2018, EXP THER MED, V16, P4075, DOI 10.3892/etm.2018.6723	72	16	17	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	18					3680	3692		10.1038/s41388-020-1244-1	http://dx.doi.org/10.1038/s41388-020-1244-1		MAR 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LI5XR	32152404	Green Published, hybrid			2022-12-17	WOS:000518734100001
J	Tamura, R; Yoshihara, K; Nakaoka, H; Yachida, N; Yamaguchi, M; Suda, K; Ishiguro, T; Nishino, K; Ichikawa, H; Homma, K; Kikuchi, A; Ueda, Y; Takei, Y; Fujiwara, H; Motoyama, T; Okuda, S; Wakai, T; Inoue, I; Enomoto, T				Tamura, Ryo; Yoshihara, Kosuke; Nakaoka, Hirofumi; Yachida, Nozomi; Yamaguchi, Manako; Suda, Kazuaki; Ishiguro, Tatsuya; Nishino, Koji; Ichikawa, Hiroshi; Homma, Keiichi; Kikuchi, Akira; Ueda, Yutaka; Takei, Yuji; Fujiwara, Hiroyuki; Motoyama, Teiichi; Okuda, Shujiro; Wakai, Toshifumi; Inoue, Ituro; Enomoto, Takayuki			XCL1 expression correlates with CD8-positive T cells infiltration and PD-L1 expression in squamous cell carcinoma arising from mature cystic teratoma of the ovary	ONCOGENE			English	Article							GENOMIC CHARACTERIZATION; HEAD; LYMPHOTACTIN; NIVOLUMAB; RECEPTOR; NUMBER; XCR1	Molecular characteristics of carcinoma arising from mature cystic teratoma of the ovary (MCT) remain unclear due to its rarity. We analyzed RNA-sequencing data of 2322 pan-cancer [1378 squamous cell carcinomas (SCC), 6 adenosquamous carcinomas (ASC), and 938 adenocarcinomas (AC)] including six carcinomas arising from MCT (four SCCs, one ASC, and one AC). Hierarchical clustering and principal component analysis showed that gene expression profiles of carcinomas arising from MCT were different between each histological type and that gene expression profiles of SCCs arising MCT (MCT-SCCs) was apparently similar to those of lung SCCs. By epidermis-associated pathways activity based on gene set enrichment analysis, 1030 SCCs were divided into two groups: epidermis-signature high (head and neck, esophagus, and skin) and low (cervix, lung, and MCT). In addition to pan-SCC transcriptome analysis, cytokeratin profiling based on immunohistochemistry in the independent samples of 21 MCT-SCCs clarified that MCT-SCC dominantly expressed CK18, suggesting the origin of MCT-SCC was columnar epithelium. Subsequently, we investigated differentially expressed genes in MCT-SCCs compared with different SCCs and identified XCL1 was specifically overexpressed in MCT-SCCs. Through immunohistochemistry analysis, we identified XCL1 expression on tumor cells in 13/24 (54%) of MCT-SCCs but not in MCTs. XCL1 expression was also significantly associated with the number of tumor-infiltrating CD8-positive T cells and PD-L1 expression on tumor cells. XCL1 produced by tumor cells may induce PD1/PD-L1 interaction and dysfunction of CD8-positive T cells in tumor microenvironment. XCL1 expression may be a novel biomarker for malignant transformation of MCT into SCC and a biomarker candidate for therapeutic response to an anti-PD1/PD-L1 therapy.	[Tamura, Ryo; Yoshihara, Kosuke; Yachida, Nozomi; Yamaguchi, Manako; Suda, Kazuaki; Ishiguro, Tatsuya; Nishino, Koji; Enomoto, Takayuki] Niigata Univ, Dept Obstet & Gynecol, Grad Sch Med & Dent Sci, Niigata 9518510, Japan; [Nakaoka, Hirofumi; Inoue, Ituro] Natl Inst Genet, Human Genet Lab, Mishima, Shizuoka 4118540, Japan; [Ichikawa, Hiroshi; Wakai, Toshifumi] Niigata Univ, Div Digest & Gen Surg, Grad Sch Med & Dent Sci, Niigata 9518510, Japan; [Homma, Keiichi] Niigata Canc Ctr Hosp, Dept Pathol, Niigata 9518133, Japan; [Kikuchi, Akira] Niigata Canc Ctr Hosp, Dept Gynecol, Niigata 9518133, Japan; [Ueda, Yutaka] Osaka Univ, Dept Obstet & Gynecol, Sch Med, Suita, Osaka 5650871, Japan; [Takei, Yuji; Fujiwara, Hiroyuki] Jichi Med Univ, Dept Obstet & Gynecol, Shimotsuke, Tochigi 3290498, Japan; [Motoyama, Teiichi] Niigata Univ, Dept Mol & Diagnost Pathol, Grad Sch Med & Dent Sci, Niigata 9518510, Japan; [Okuda, Shujiro] Niigata Univ, Div Bioinformat, Grad Sch Med & Dent Sci, Niigata 9518510, Japan	Niigata University; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Niigata University; Osaka University; Jichi Medical University; Niigata University; Niigata University	Yoshihara, K (corresponding author), Niigata Univ, Dept Obstet & Gynecol, Grad Sch Med & Dent Sci, Niigata 9518510, Japan.	yoshikou@med.niigata-u.ac.jp	Takei, Yuji/ABD-2485-2020; Yoshihara, Kosuke/AAU-9874-2020	Yoshihara, Kosuke/0000-0002-2254-3378; Enomoto, Takayuki/0000-0003-4538-5541; Nakaoka, Hirofumi/0000-0002-8454-1159; Ueda, Yutaka/0000-0001-8760-6379; Ishiguro, Tatsuya/0000-0002-6445-4066	JSPS KAKENHI [18K16760, JP16H06267, JP16H06279]; Mochida Grant; Tsukada Grant for Niigata University Medical Research; ROIS (Research Organization of Information and Systems)	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Mochida Grant; Tsukada Grant for Niigata University Medical Research; ROIS (Research Organization of Information and Systems)	We are grateful to Anna Ishida, Junko Kajiwara, Junko Kitayama, and Yumiko Sato for their technical assistance. We also grateful to Yusuke Tanaka, Reisa Kakubari, Mariko Kayamori, and Taeko Hyuga for sample collections. This work was supported in part by JSPS KAKENHI grant number 18K16760 (Grant-in-Aid for Young Scientists for RT), JP16H06267 (Grant-in-Aid for Young Scientists A for KY), JP16H06279 (Grant-in-Aid for Scientific Research on Innovative Areas-Platforms for Advanced Technologies and Research Resources for HN and KY), the Mochida Grant for KY, the Tsukada Grant for Niigata University Medical Research for RT, and "Challenging Exploratory Research Projects for the Future" grant from ROIS (Research Organization of Information and Systems) for HN.	Akazawa M, 2018, INT J GYNECOL CANCER, V28, P1650, DOI 10.1097/IGC.0000000000001375; AMERIGO J, 1979, GYNECOL ONCOL, V8, P277, DOI 10.1016/0090-8258(79)90035-0; Bray NL, 2016, NAT BIOTECHNOL, V34, P888, DOI 10.1038/nbt0816-888d; Burk RD, 2017, NATURE, V543, P378, DOI 10.1038/nature21386; Calinski T., 1974, COMMUN STAT, V3, P1, DOI [10.1080/03610927408827101, DOI 10.1080/03610927408827101]; Campbell JD, 2018, CELL REP, V23, P194, DOI 10.1016/j.celrep.2018.03.063; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chakravarty D, 2017, JCO PRECIS ONCOL, V1; Chiang AJ, 2017, J GYNECOL ONCOL, V28, DOI 10.3802/jgo.2017.28.e69; Chitsazzadeh V, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12601; Chung HC, 2019, J CLIN ONCOL, V37, P1470, DOI 10.1200/JCO.18.01265; Cooke SL, 2017, CLIN CANCER RES, V23, P7633, DOI 10.1158/1078-0432.CCR-17-1789; Cristescu R, 2018, SCIENCE, V362, P197, DOI 10.1126/science.aar3593; Ding HY, 2019, CELL REP, V27, P3331, DOI 10.1016/j.celrep.2019.05.043; Dorner BG, 2009, IMMUNITY, V31, P823, DOI 10.1016/j.immuni.2009.08.027; Eifert C, 2017, PERS MED, V14, P309, DOI 10.2217/pme-2017-0011; Ferris RL, 2016, NEW ENGL J MED, V375, P1856, DOI 10.1056/NEJMoa1602252; Forbes SA, 2015, NUCLEIC ACIDS RES, V43, pD805, DOI 10.1093/nar/gku1075; Fruman DA, 2017, CELL, V170, P605, DOI 10.1016/j.cell.2017.07.029; Hackethal A, 2008, LANCET ONCOL, V9, P1173, DOI 10.1016/S1470-2045(08)70306-1; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; HIRAKAWA T, 1989, AM J SURG PATHOL, V13, P397, DOI 10.1097/00000478-198905000-00007; Hoadley KA, 2018, CELL, V173, P291, DOI 10.1016/j.cell.2018.03.022; Ichikawa H, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0484-3; Iwasa A, 2007, HISTOPATHOLOGY, V51, P98, DOI 10.1111/j.1365-2559.2007.02727.x; John T, 2009, ONCOGENE, V28, pS14, DOI 10.1038/onc.2009.197; Keck MK, 2015, CLIN CANCER RES, V21, P870, DOI 10.1158/1078-0432.CCR-14-2481; KELNER GS, 1994, SCIENCE, V266, P1395, DOI 10.1126/science.7973732; Khurram SA, 2010, J PATHOL, V221, P153, DOI 10.1002/path.2695; Kim J, 2017, NATURE, V541, P169, DOI 10.1038/nature20805; Kim M, 2012, MOL CANCER RES, V10, P1419, DOI 10.1158/1541-7786.MCR-12-0361; KRZANOWSKI WJ, 1988, BIOMETRICS, V44, P23, DOI 10.2307/2531893; Kudo T, 2017, LANCET ONCOL, V18, P631, DOI 10.1016/S1470-2045(17)30181-X; Lawrence MS, 2015, NATURE, V517, P576, DOI 10.1038/nature14129; Lei Y, 2012, MICROBES INFECT, V14, P262, DOI 10.1016/j.micinf.2011.10.003; Li BL, 2019, CLIN CANCER RES, V25, P3528, DOI 10.1158/1078-0432.CCR-18-4085; Li F, 2013, CELL, V153, P590, DOI 10.1016/j.cell.2013.03.025; MARCIALROJAS RA, 1958, ARCH PATHOL, V66, P577; Migden MR, 2018, NEW ENGL J MED, V379, P341, DOI 10.1056/NEJMoa1805131; Mori Y, 2003, GYNECOL ONCOL, V90, P338, DOI 10.1016/S0090-8258(03)00259-2; Murumagi A, 2014, BIORXIV, DOI [10.1101/011650, DOI 10.1101/011650V1]; Nishiwaki M, 2008, J CLIN MICROBIOL, V46, P1161, DOI 10.1128/JCM.00793-07; O'Malley DP, 2019, MODERN PATHOL, V32, P929, DOI 10.1038/s41379-019-0210-3; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Suda K, 2018, CELL REP, V24, P1777, DOI 10.1016/j.celrep.2018.07.037; Sun JQ, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-219; Tamura R, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389-017-0018-2; Teng MWL, 2015, CANCER RES, V75, P2139, DOI 10.1158/0008-5472.CAN-15-0255; Torres-Garcia W, 2014, BIOINFORMATICS, V30, P2224, DOI 10.1093/bioinformatics/btu169; Yarchoan M, 2017, NEW ENGL J MED, V377, P2500, DOI 10.1056/NEJMc1713444; Zhang L, 2003, NEW ENGL J MED, V348, P203, DOI 10.1056/NEJMoa020177	51	16	17	8	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	17					3541	3554		10.1038/s41388-020-1237-0	http://dx.doi.org/10.1038/s41388-020-1237-0		MAR 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LH1YK	32115573	Green Published, hybrid			2022-12-17	WOS:000517359700002
J	Green, AL; DeSisto, J; Flannery, P; Lemma, R; Knox, A; Lemieux, M; Sanford, B; O'Rourke, R; Ramkissoon, S; Jones, K; Perry, J; Hui, X; Moroze, E; Balakrishnan, I; O'Neill, AF; Dunn, K; DeRyckere, D; Danis, E; Safadi, A; Gilani, A; Hubbell-Engler, B; Nuss, Z; Levy, JMM; Serkova, N; Venkataraman, S; Graham, DK; Foreman, N; Ligon, K; Jones, K; Kung, AL; Vibhakar, R				Green, Adam L.; DeSisto, John; Flannery, Patrick; Lemma, Rakeb; Knox, Aaron; Lemieux, Madeleine; Sanford, Bridget; O'Rourke, Rebecca; Ramkissoon, Shakti; Jones, Kristen; Perry, Jennifer; Hui, Xu; Moroze, Erin; Balakrishnan, Ilango; O'Neill, Allison F.; Dunn, Katherine; DeRyckere, Deborah; Danis, Etienne; Safadi, Aaron; Gilani, Ahmed; Hubbell-Engler, Benjamin; Nuss, Zachary; Levy, Jean M. Mulcahy; Serkova, Natalie; Venkataraman, Sujatha; Graham, Douglas K.; Foreman, Nicholas; Ligon, Keith; Jones, Ken; Kung, Andrew L.; Vibhakar, Rajeev			BPTF regulates growth of adult and pediatric high-grade glioma through the MYC pathway	ONCOGENE			English	Article							HISTONE DEACETYLASE INHIBITORS; SELF-RENEWAL; PHD-FINGER; GLIOBLASTOMA; CANCER; RNA; MUTATIONS; PROGNOSIS; FAMILY; CELLS	High-grade gliomas (HGG) afflict both children and adults and respond poorly to current therapies. Epigenetic regulators have a role in gliomagenesis, but a broad, functional investigation of the impact and role of specific epigenetic targets has not been undertaken. Using a two-step, in vitro/in vivo epigenomic shRNA inhibition screen, we determine the chromatin remodeler BPTF to be a key regulator of adult HGG growth. We then demonstrate that BPTF knockdown decreases HGG growth in multiple pediatric HGG models as well. BPTF appears to regulate tumor growth through cell self-renewal maintenance, and BPTF knockdown leads these glial tumors toward more neuronal characteristics. BPTF's impact on growth is mediated through positive effects on expression of MYC and MYC pathway targets. HDAC inhibitors synergize with BPTF knockdown against HGG growth. BPTF inhibition is a promising strategy to combat HGG through epigenetic regulation of the MYC oncogenic pathway.	[Green, Adam L.; DeSisto, John; Flannery, Patrick; Lemma, Rakeb; Knox, Aaron; Sanford, Bridget; O'Rourke, Rebecca; Moroze, Erin; Balakrishnan, Ilango; Danis, Etienne; Nuss, Zachary; Levy, Jean M. Mulcahy; Venkataraman, Sujatha; Foreman, Nicholas; Jones, Ken; Vibhakar, Rajeev] Univ Colorado, Morgan Adams Fdn Pediat Brain Tumor Res Program, Dept Pediat, Sch Med, Anschutz Med Campus,RC1-N,Mail Stop 8302, Aurora, CO 80045 USA; [Green, Adam L.; Levy, Jean M. Mulcahy; Foreman, Nicholas; Vibhakar, Rajeev] Childrens Hosp Colorado, Ctr Canc & Blood Disorders, Aurora, CO 80045 USA; [Lemieux, Madeleine] Bioinfo, Ottawa, ON, Canada; [Ramkissoon, Shakti; Jones, Kristen; Perry, Jennifer; O'Neill, Allison F.; Dunn, Katherine; Hubbell-Engler, Benjamin; Ligon, Keith] Dana Farber Canc Inst, Boston, MA 02115 USA; [Hui, Xu] Mem Sloan Kettering Canc Ctr, Dept Pediat, 1275 York Ave, New York, NY 10021 USA; [DeRyckere, Deborah; Graham, Douglas K.] Emory Univ, Aflac Canc & Blood Disorders Ctr, Childrens Healthcare Atlanta, Atlanta, GA 30322 USA; [Safadi, Aaron; Serkova, Natalie] Univ Colorado, Dept Radiol, Sch Med, Aurora, CO USA; [Gilani, Ahmed] Univ Colorado, Dept Pathol, Sch Med, Aurora, CO USA; [Kung, Andrew L.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; Children's Hospital Colorado; Harvard University; Dana-Farber Cancer Institute; Memorial Sloan Kettering Cancer Center; Children's Healthcare of Atlanta (CHOA); Emory University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; Memorial Sloan Kettering Cancer Center	Green, AL (corresponding author), Univ Colorado, Morgan Adams Fdn Pediat Brain Tumor Res Program, Dept Pediat, Sch Med, Anschutz Med Campus,RC1-N,Mail Stop 8302, Aurora, CO 80045 USA.; Green, AL (corresponding author), Childrens Hosp Colorado, Ctr Canc & Blood Disorders, Aurora, CO 80045 USA.	adam.green@cuanschutz.edu	Gilani, Ahmed/GYJ-5201-2022; Kung, Andrew/AAL-2384-2020; Kung, Andrew L/AEU-0826-2022	Kung, Andrew L/0000-0002-9091-488X; Knox, Aaron/0000-0002-2179-9961; Lemieux, Madeleine/0000-0001-6355-8691	NCI NIH HHS [P30 CA008748, P30 CA046934] Funding Source: Medline; NICHD NIH HHS [K12 HD068372] Funding Source: Medline; NINDS NIH HHS [P30 NS048154, R01 NS086839, L40 NS098453] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Andrade JM, 2014, ANAL CHIM ACTA, V838, P1, DOI 10.1016/j.aca.2014.04.057; Arrigoni L, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkv1495; Baird NL, 2014, J VIROL, V88, P5877, DOI 10.1128/JVI.00476-14; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Bekpen C, 2012, GENOME RES, V22, P1050, DOI 10.1101/gr.134098.111; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; Bramanti Vincenzo, 2010, Front Biosci (Schol Ed), V2, P558; Broad D, 2019, DEPMAP ACHILLES 19Q1; Buganim Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009657; Clarke J, 2013, EPIGENETICS-US, V8, P785, DOI 10.4161/epi.25440; Dai M, 2015, ONCOTARGET, V6, P33878, DOI 10.18632/oncotarget.5302; Dar AA, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv034; Fangusaro J, 2009, J CHILD NEUROL, V24, P1409, DOI 10.1177/0883073809338960; Frey WD, 2017, STEM CELL REP, V9, P23, DOI 10.1016/j.stemcr.2017.04.031; Ghandi M, 2019, NATURE, V569, P503, DOI 10.1038/s41586-019-1186-3; Ghantous A, 2015, MUTAGENESIS, V30, P733, DOI 10.1093/mutage/gev010; Gong YC, 2017, EUR REV MED PHARMACO, V21, P102; Grasso CS, 2015, NAT MED, V21, P827, DOI 10.1038/nm0715-827a; Green AL, 2015, NEURO-ONCOLOGY, V17, P697, DOI 10.1093/neuonc/nou303; Herms JW, 1999, SURG NEUROL, V51, P536, DOI 10.1016/S0090-3019(98)00028-7; Kerosuo L, 2008, J CELL SCI, V121, P3941, DOI 10.1242/jcs.024802; Kim J, 2003, NEURON, V38, P17, DOI 10.1016/S0896-6273(03)00163-6; Landry J, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000241; Lapin DH, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00057; Lee JH, 2016, APMIS, V124, P425, DOI 10.1111/apm.12512; Lee P, 2015, ANTICANCER RES, V35, P615; Li HT, 2006, NATURE, V442, P91, DOI 10.1038/nature04802; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Lulla RR, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1501354; Ma YQ, 2015, J NEUROSCI, V35, P8493, DOI 10.1523/JNEUROSCI.0377-15.2015; Maleszewska Marta, 2013, Cancers (Basel), V5, P1120, DOI 10.3390/cancers5031120; Meyers RM, 2017, NAT GENET, V49, P1779, DOI 10.1038/ng.3984; Miozzo M, 2015, FUTURE ONCOL, V11, P333, DOI [10.2217/FON.14.237, 10.2217/fon.14.237]; La Madrid AM, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00148; Mottamal M, 2015, MOLECULES, V20, P3898, DOI 10.3390/molecules20033898; Nebbioso A, 2017, CLIN CANCER RES, V23, P2542, DOI 10.1158/1078-0432.CCR-15-2388; Person F, 2017, TUMOR BIOL, V39, DOI [DOI 10.1177/1010428317712166, 10.1177/1010428317712166]; Ramirez F, 2016, NUCLEIC ACIDS RES, V44, pW160, DOI 10.1093/nar/gkw257; Richart L, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10153; Rodriguez-Paredes M, 2011, NAT MED, V17, P330, DOI 10.1038/nm.2305; Ross-Innes CS, 2012, NATURE, V481, P389, DOI 10.1038/nature10730; Schwartzentruber J, 2012, NATURE, V482, P226, DOI [10.1038/nature10833, 10.1007/s13311-012-0137-6]; Ferreira WAS, 2016, EPIGENOMICS-UK, V8, P1289, DOI 10.2217/epi-2016-0040; Stankiewicz P, 2017, AM J HUM GENET, V101, P503, DOI 10.1016/j.ajhg.2017.08.014; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Su ZD, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4338; Touat M, 2017, ANN ONCOL, V28, P1457, DOI 10.1093/annonc/mdx106; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Urick AK, 2015, ACS CHEM BIOL, V10, P2246, DOI 10.1021/acschembio.5b00483; Wang JL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003769; Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126; Wu TD, 2005, BIOINFORMATICS, V21, P1859, DOI 10.1093/bioinformatics/bti310; Wu TD, 2010, BIOINFORMATICS, V26, P873, DOI 10.1093/bioinformatics/btq057; Xiao SA, 2015, J CANCER RES CLIN, V141, P1465, DOI 10.1007/s00432-015-1937-y; Xiao S, 2015, DIGEST DIS SCI, V60, P910, DOI 10.1007/s10620-014-3411-0; Xie Q, 2016, J CLIN INVEST, V126, P2757, DOI 10.1172/JCI86114	58	16	17	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	11					2305	2327		10.1038/s41388-019-1125-7	http://dx.doi.org/10.1038/s41388-019-1125-7			23	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KU0ZS	31844250	Green Accepted			2022-12-17	WOS:000519440400006
J	Chobrutskiy, BI; Yeagley, M; Tipping, P; Zaman, S; Diviney, A; Patel, DN; Falasiri, S; Uversky, VN; Blanck, G				Chobrutskiy, Boris, I; Yeagley, Michelle; Tipping, Price; Zaman, Saif; Diviney, Andrea; Patel, Dhruv N.; Falasiri, Shayan; Uversky, Vladimir N.; Blanck, George			Chemical complementarity between immune receptor CDR3s and IDH1 mutants correlates with increased survival for lower grade glioma	ONCOGENE			English	Article							PERIPHERAL-BLOOD; DISTINCT; SEQUENCE; IDENTIFICATION; LYMPHOCYTES; MECHANISMS; MELANOMA; DATASETS; GENES	Focusing on highly specific aspects of the immune response is likely to answer a number of basic questions, and in some cases even resolve basic contradictions, in cancer immunology. For example, there are many cases, where chronic inflammation is associated with cancer development, and many other cases where an immune response represents an anticancer process. In this study, using bioinformatics algorithms, we examined the chemical relationships between the amino acid sequences of the complementarity-determining region-3 (CDR3) represented by immune receptors associated with lower grade glioma and isocitrate dehydrogenase-1 (IDH1) mutants. In particular, we developed a chemical complementarity scoring approach to classify tumors based on the complementarity of CDR3s and mutant IDH1 amino acids, relying on net charge per residue and hydropathy parameters. There was a strong correlation between the increased survival in low-grade glioma (LGG) and complementarity of IDH1 mutants to the CDR3 domain of the T-cell receptor beta chain (TRB). Similar results were obtained for TRB CDR3s and NRAS mutants in melanoma. Furthermore, the clear connection between increased survival rates and immune receptor-IDH1 mutant complementarities may also, partially, explain the better LGG prognosis for patients with IDH1 mutants.	[Chobrutskiy, Boris, I; Yeagley, Michelle; Tipping, Price; Zaman, Saif; Diviney, Andrea; Patel, Dhruv N.; Falasiri, Shayan; Uversky, Vladimir N.; Blanck, George] Univ S Florida, Morsani Coll Med, Dept Mol Med, Tampa, FL 33612 USA; [Zaman, Saif; Blanck, George] H Lee Moffitt Canc Ctr & Res Inst, Immunol Program, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute	Blanck, G (corresponding author), Univ S Florida, Morsani Coll Med, Dept Mol Med, Tampa, FL 33612 USA.; Blanck, G (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Immunol Program, Tampa, FL 33612 USA.	gblanck@health.usf.edu	Uversky, Vladimir N./F-4515-2011	Uversky, Vladimir N./0000-0002-4037-5857; Falasiri, Seyed Shayan/0000-0002-8701-5146; Patel, Dhruv/0000-0002-9888-7783	USF Morsani College of Medicine RISE fellowships	USF Morsani College of Medicine RISE fellowships	Authors thank USF research computing and the taxpayers of the State of Florida. BIC, SZ, SF, MY and AD were recipients of USF Morsani College of Medicine RISE fellowships.	[Anonymous], 2014, Cancer Discov, V4, pOF13, DOI 10.1158/2159-8290.CD-RW2014-145; Berghoff AS, 2017, NEURO-ONCOLOGY, V19, P1460, DOI 10.1093/neuonc/nox054; Chen G, 2017, CELL REP, V19, P569, DOI 10.1016/j.celrep.2017.03.072; Chen WW, 2013, MOL THER-NUCL ACIDS, V2, DOI 10.1038/mtna.2013.28; Chobrutskiy BI, 2019, J CANCER RES CLIN, V145, P615, DOI 10.1007/s00432-018-2815-1; Chobrutskiy BI, 2018, J NEURO-ONCOL, V140, P697, DOI 10.1007/s11060-018-03001-1; Cohen AL, 2013, CURR NEUROL NEUROSCI, V13, DOI 10.1007/s11910-013-0345-4; Davidson TB, 2019, CLIN CANCER RES, V25, P1913, DOI 10.1158/1078-0432.CCR-18-1176; Dutoit V, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1391972; Fisler DA, 2018, ONCOL LETT, V16, P2757, DOI 10.3892/ol.2018.8957; Gros A, 2016, NAT MED, V22, P433, DOI 10.1038/nm.4051; Han S, 2014, BRIT J CANCER, V110, P2560, DOI 10.1038/bjc.2014.162; Holehouse AS, 2017, BIOPHYS J, V112, P16, DOI 10.1016/j.bpj.2016.11.3200; KIMURA H, 1988, J IMMUNOL, V140, P1212; Kiviniemi A, 2015, J NEURO-ONCOL, V124, P237, DOI 10.1007/s11060-015-1829-7; Leu S, 2013, NEURO-ONCOLOGY, V15, P469, DOI 10.1093/neuonc/nos317; Mauro JA, 2017, GENE, V614, P37, DOI 10.1016/j.gene.2017.02.026; Mauro JA, 2015, GENE, V554, P50, DOI 10.1016/j.gene.2014.10.021; Mauro JA, 2014, GENE, V536, P398, DOI 10.1016/j.gene.2013.11.013; Metellus P, 2010, ACTA NEUROPATHOL, V120, P719, DOI 10.1007/s00401-010-0777-8; Roca AM, 2019, HUM IMMUNOL, V80, P237, DOI 10.1016/j.humimm.2019.01.005; Schumacher T, 2014, NATURE, V512, P324, DOI 10.1038/nature13387; Sikaria D, 2018, J CANCER RES CLIN, V144, P459, DOI 10.1007/s00432-017-2569-1; Syed P, 2015, SCI REP-UK, V5, DOI 10.1038/srep13895; Thorsson V, 2018, IMMUNITY, V48, P812, DOI 10.1016/j.immuni.2018.03.023; Tong WL, 2019, BREAST CANCER RES TR, V173, P167, DOI 10.1007/s10549-018-4961-1; Tsuchiya Y, 2018, IMMUNOLOGY, V153, P466, DOI 10.1111/imm.12849; Yin QS, 2010, HEMATOLOGY, V15, P48, DOI 10.1179/102453310X12583347009694; You ZB, 2006, CANCER RES, V66, P175, DOI 10.1158/0008-5472.CAN-05-1130; Zaman S, 2019, ONCOL REP, V41, P1359, DOI 10.3892/or.2018.6896; Zaman S, 2019, CLIN BIOCHEM, V63, P85, DOI 10.1016/j.clinbiochem.2018.11.004; Zaman S, 2018, BIOCHEM BIOPH RES CO, V503, P2218, DOI 10.1016/j.bbrc.2018.06.141; Zhang J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099255; Zhou CY, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00983	34	16	16	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	8					1773	1783		10.1038/s41388-019-1101-2	http://dx.doi.org/10.1038/s41388-019-1101-2			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN6CG	31740784				2022-12-17	WOS:000514923000011
J	Hillert, LK; Ivanisenko, NV; Espe, J; Konig, C; Ivanisenko, VA; Kahne, T; Lavrik, IN				Hillert, Laura K.; Ivanisenko, Nikita, V; Espe, Johannes; Koenig, Corinna; Ivanisenko, Vladimir A.; Kaehne, Thilo; Lavrik, Inna N.			Long and short isoforms of c-FLIP act as control checkpoints of DED filament assembly	ONCOGENE			English	Article							KAPPA-B ACTIVATION; CELL-DEATH; CASPASE-8; REVEALS; PROCASPASE-8; MECHANISM; QUANTIFICATION; REGULATOR; APOPTOSIS; SKYLINE	The assembly of the death-inducing signaling complex (DISC) and death effector domain (DED) filaments at CD95/Fas initiates extrinsic apoptosis. Procaspase-8 activation at the DED filaments is controlled by short and long c-FLIP isoforms. Despite apparent progress in understanding the assembly of CD95-activated platforms and DED filaments, the detailed molecular mechanism of c-FLIP action remains elusive. Here, we further addressed the mechanisms of c-FLIP action at the DISC using biochemical assays, quantitative mass spectrometry, and structural modeling. Our data strongly indicate that c-FLIP can bind to both FADD and procaspase-8 at the DED filament. Moreover, the constructed in silico model shows that c-FLIP proteins can lead to the formation of the DISCs comprising short DED filaments as well as serve as bridging motifs for building a cooperative DISC network, in which adjacent CD95 DISCs are connected by DED filaments. This network is based on selective interactions of FADD with both c-FLIP and procaspase-8. Hence, c-FLIP proteins at the DISC control initiation, elongation, and composition of DED filaments, playing the role of control checkpoints. These findings provide new insights into DISC and DED filament regulation and open innovative possibilities for targeting the extrinsic apoptosis pathway.	[Hillert, Laura K.; Espe, Johannes; Koenig, Corinna; Lavrik, Inna N.] Otto von Guericke Univ, Ctr Dynam Syst, Med Fac, Translat Inflammat Res, D-39106 Magdeburg, Germany; [Ivanisenko, Nikita, V; Ivanisenko, Vladimir A.] SB RAS, Inst Cytol & Genet, Fed Res Ctr, Novosibirsk 630090, Russia; [Kaehne, Thilo] Otto von Guericke Univ, Med Fac, Inst Internal Expt Med, D-39120 Magdeburg, Germany	Otto von Guericke University; Russian Academy of Sciences; Institute of Cytology & Genetics ICG SB RAS; Otto von Guericke University	Lavrik, IN (corresponding author), Otto von Guericke Univ, Ctr Dynam Syst, Med Fac, Translat Inflammat Res, D-39106 Magdeburg, Germany.	inna.lavrik@med.ovgu.de	Lavrik, Inna N/C-1700-2009; Ivanisenko, Vladimir/J-7832-2018; Ivanisenko, Nikita/AAO-1621-2020	Lavrik, Inna N/0000-0002-9324-309X; Ivanisenko, Vladimir/0000-0002-1859-4631	Volkswagen Foundation [VW 90315]; Wilhelm Sander-Stiftung [2017.008.01]; Center of dynamic systems (CDS) - EU-program ERDF (European Regional Development Fund); DFG [LA 2386]	Volkswagen Foundation(Volkswagen); Wilhelm Sander-Stiftung; Center of dynamic systems (CDS) - EU-program ERDF (European Regional Development Fund); DFG(German Research Foundation (DFG))	We acknowledge Volkswagen Foundation (VW 90315), Wilhelm Sander-Stiftung (2017.008.01), Center of dynamic systems (CDS), funded by the EU-program ERDF (European Regional Development Fund) and DFG (LA 2386) for supporting our work.	Algeciras-Schimnich A, 2002, MOL CELL BIOL, V22, P207, DOI 10.1128/MCB.22.1.207-220.2002; Algeciras-Schimnich A, 2003, FEBS LETT, V546, P185, DOI 10.1016/S0014-5793(03)00558-1; Bentele M, 2004, J CELL BIOL, V166, P839, DOI 10.1083/jcb.200404158; Chang DW, 2002, EMBO J, V21, P3704, DOI 10.1093/emboj/cdf356; Chaudhury S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022477; Dickens LS, 2012, MOL CELL, V47, P291, DOI 10.1016/j.molcel.2012.05.004; Fricker N, 2010, J CELL BIOL, V190, P377, DOI 10.1083/jcb.201002060; Fu TM, 2016, MOL CELL, V64, P236, DOI 10.1016/j.molcel.2016.09.009; Golks A, 2006, CELL DEATH DIFFER, V13, P489, DOI 10.1038/sj.cdd.4401766; Golks A, 2005, J BIOL CHEM, V280, P14507, DOI 10.1074/jbc.M414425200; Hoffmann JC, 2009, MOL CELL BIOL, V29, P4431, DOI 10.1128/MCB.02261-07; Horn S, 2017, CELL REP, V19, P785, DOI 10.1016/j.celrep.2017.04.010; Hughes MA, 2016, MOL CELL, V61, P834, DOI 10.1016/j.molcel.2016.02.023; Hwang EY, 2014, BMB REP, V47, P488, DOI 10.5483/BMBRep.2014.47.9.239; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Krammer PH, 2007, NAT REV IMMUNOL, V7, P532, DOI 10.1038/nri2115; Lavrik I, 2005, J CELL SCI, V118, P265, DOI 10.1242/jcs.01610; Lavrik IN, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.160; Lavrik IN, 2012, CELL DEATH DIFFER, V19, P36, DOI 10.1038/cdd.2011.155; MacLean B, 2010, BIOINFORMATICS, V26, P966, DOI 10.1093/bioinformatics/btq054; Majkut J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4350; Micheau O, 2002, J BIOL CHEM, V277, P45162, DOI 10.1074/jbc.M206882200; Neumann L, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.6; Ozturk S, 2012, EXP CELL RES, V318, P1324, DOI 10.1016/j.yexcr.2012.01.019; Peter Marcus E, 2004, Biochem J, V382, pe1; Pietkiewicz S, 2015, EXP CELL RES, V339, P1, DOI 10.1016/j.yexcr.2015.10.005; Pietkiewicz S, 2015, J IMMUNOL METHODS, V423, P99, DOI 10.1016/j.jim.2015.04.025; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Schilling B, 2012, MOL CELL PROTEOMICS, V11, P202, DOI 10.1074/mcp.M112.017707; Schleich K, 2016, CELL DEATH DIFFER, V23, P681, DOI 10.1038/cdd.2015.137; Schleich K, 2012, MOL CELL, V47, P306, DOI 10.1016/j.molcel.2012.05.006; Schmidt JH, 2015, J IMMUNOL METHODS, V423, P12, DOI 10.1016/j.jim.2015.04.026; Sprick MR, 2002, EMBO J, V21, P4520, DOI 10.1093/emboj/cdf441; Thome M, 2001, NAT REV IMMUNOL, V1, P50, DOI 10.1038/35095508; Ueffing N, 2008, CELL DEATH DIFFER, V15, P773, DOI 10.1038/sj.cdd.4402314; Warnken Uwe, 2013, Cells, V2, P476, DOI 10.3390/cells2030476; Yu JW, 2009, P NATL ACAD SCI USA, V106, P8169, DOI 10.1073/pnas.0812453106	37	16	18	2	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	8					1756	1772		10.1038/s41388-019-1100-3	http://dx.doi.org/10.1038/s41388-019-1100-3			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN6CG	31740779				2022-12-17	WOS:000514923000010
J	Lopez-Guerra, M; Xargay-Torrent, S; Fuentes, P; Roldan, J; Gonzalez-Farre, B; Rosich, L; Silkenstedt, E; Garcia-Leon, MJ; Lee-Verges, E; Gimenez, N; Giro, A; Aymerich, M; Villamor, N; Delgado, J; Lopez-Guillermo, A; Puente, XS; Campo, E; Toribio, ML; Colomer, D				Lopez-Guerra, Monica; Xargay-Torrent, Silvia; Fuentes, Patricia; Roldan, Jocabed; Gonzalez-Farre, Blanca; Rosich, Laia; Silkenstedt, Elisabeth; Garcia-Leon, Maria J.; Lee-Verges, Eriong; Gimenez, Neus; Giro, Ariadna; Aymerich, Marta; Villamor, Neus; Delgado, Julio; Lopez-Guillermo, Armando; Puente, Xose S.; Campo, Elias; Toribio, Maria L.; Colomer, Dolors			Specific NOTCH1 antibody targets DLL4-induced proliferation, migration, and angiogenesis in NOTCH1-mutated CLL cells	ONCOGENE			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; RECURRENT MUTATIONS; ACTIVATION; PROMOTES; SURVIVAL; LIGAND; OVEREXPRESSION; TRANSFORMATION; MECHANISMS; INHIBITION	Targeting Notch signaling has emerged as a promising therapeutic strategy for chronic lymphocytic leukemia (CLL), particularly in NOTCH1-mutated patients. We provide first evidence that the Notch ligand DLL4 is a potent stimulator of Notch signaling in NOTCH1-mutated CLL cells while increases cell proliferation. Importantly, DLL4 is expressed in histiocytes from the lymph node, both in NOTCH1-mutated and -unmutated cases. We also show that the DLL4-induced activation of the Notch signaling pathway can be efficiently blocked with the specific anti-Notch1 antibody OMP-52M51. Accordingly, OMP-52M51 also reverses Notch-induced MYC, CCND1, and NPM1 gene expression as well as cell proliferation in NOTCH1-mutated CLL cells. In addition, DLL4 stimulation triggers the expression of protumor target genes, such as CXCR4, NRARP, and VEGFA, together with an increase in cell migration and angiogenesis. All these events can be antagonized by OMP-52M51. Collectively, our results emphasize the role of DLL4 stimulation in NOTCH1-mutated CLL and confirm the specific therapeutic targeting of Notch1 as a promising approach for this group of poor prognosis CLL patients.	[Lopez-Guerra, Monica; Xargay-Torrent, Silvia; Roldan, Jocabed; Rosich, Laia; Silkenstedt, Elisabeth; Lee-Verges, Eriong; Gimenez, Neus; Giro, Ariadna; Aymerich, Marta; Colomer, Dolors] IDIBAPS, Expt Therapeut Lymphoid Malignancies Grp, Barcelona, Spain; [Lopez-Guerra, Monica; Roldan, Jocabed; Gonzalez-Farre, Blanca; Aymerich, Marta; Villamor, Neus; Campo, Elias; Colomer, Dolors] IDIBAPS, Hosp Clin, Hematopathol Sect, Barcelona, Spain; [Lopez-Guerra, Monica; Roldan, Jocabed; Gonzalez-Farre, Blanca; Rosich, Laia; Lee-Verges, Eriong; Gimenez, Neus; Giro, Ariadna; Aymerich, Marta; Villamor, Neus; Delgado, Julio; Lopez-Guillermo, Armando; Puente, Xose S.; Campo, Elias; Colomer, Dolors] Ctr Invest Biomed Red Canc CIBERONC, Barcelona, Spain; [Fuentes, Patricia; Toribio, Maria L.] Univ Autonoma Madrid, Consejo Super Invest Cient, Ctr Biol Mol Severo Ochoa, Madrid, Spain; [Gonzalez-Farre, Blanca; Lopez-Guillermo, Armando; Campo, Elias; Colomer, Dolors] Univ Barcelona, Barcelona, Spain; [Silkenstedt, Elisabeth] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Internal Med 3, Munich, Germany; [Garcia-Leon, Maria J.] INSERM U1109, Inst Hematol Immunol, Strasbourg, France; [Delgado, Julio; Lopez-Guillermo, Armando] IDIBAPS, Hematol Dept, Hosp Clin, Barcelona, Spain; [Puente, Xose S.] Univ Oviedo, Dept Bioquim & Biol, Mol Inst Univ Oncol, Oviedo, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); University of Barcelona; University of Munich; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Oviedo	Colomer, D (corresponding author), IDIBAPS, Expt Therapeut Lymphoid Malignancies Grp, Barcelona, Spain.; Colomer, D (corresponding author), IDIBAPS, Hosp Clin, Hematopathol Sect, Barcelona, Spain.; Colomer, D (corresponding author), Ctr Invest Biomed Red Canc CIBERONC, Barcelona, Spain.; Colomer, D (corresponding author), Univ Barcelona, Barcelona, Spain.	dcolomer@clinic.cat	COLOMER, DOLORS/ABG-6894-2020; Puente, Xosé S./ADB-0672-2022; Gonzalez-Farre, Blanca/AAD-9467-2019; Toribio, Maria L/C-2039-2017	Puente, Xosé S./0000-0001-9525-1483; Gonzalez-Farre, Blanca/0000-0002-1796-7248; Toribio, Maria L/0000-0002-8637-0373; Fuentes, Patricia/0000-0003-4597-1022; Garcia-Leon, Maria Jesus/0000-0001-9790-808X	Ministerio de Ciencia e Innovacion [SAF2015-31242-R, RTI2018-094584-B-I00, SAF2016-75442-R]; Departament de Salut [SLT002-16-00350]; ISCII-Sub-Directorate General for Evaluation [PM15/00007]; European Regional Development Fund (FEDER-"Una manera de hacer Europa"); Generalitat de Catalunya [2014SGR967, 2017SGR1009]; CIBERONC [CB16/12/00334, CB16/12/00225, CB16/12/00236]; Ministerio de Ciencia e Innovacion (FPI program); Agaur, Generalitat de Catalunya	Ministerio de Ciencia e Innovacion(Ministry of Science and Innovation, Spain (MICINN)Instituto de Salud Carlos IIISpanish Government); Departament de Salut; ISCII-Sub-Directorate General for Evaluation; European Regional Development Fund (FEDER-"Una manera de hacer Europa"); Generalitat de Catalunya(Generalitat de Catalunya); CIBERONC; Ministerio de Ciencia e Innovacion (FPI program); Agaur, Generalitat de Catalunya(Agencia de Gestio D'Ajuts Universitaris de Recerca Agaur (AGAUR)Generalitat de Catalunya)	The authors would like to thank Sandra Cabezas and Laura Jimenez for their technical support. We also thank Dr Maria C Cid for providing HUVEC cells. We are very grateful to the CLL Genome Consortium and all CLL patients who have participated in this study. This work was carried out at the Centre Esther Koplowitz, Barcelona. This study was supported by research funding from Ministerio de Ciencia e Innovacion (SAF2015-31242-R and RTI2018-094584-B-I00 to DC and SAF2016-75442-R to MLT), Departament de Salut (SLT002-16-00350) to DC, the ISCII-Sub-Directorate General for Evaluation (PM15/00007), which are part of Plan Nacional de I+D+I and are co-financed by and the European Regional Development Fund (FEDER-"Una manera de hacer Europa"), Generalitat de Catalunya (2014SGR967 and 2017SGR1009) and CIBERONC (CB16/12/00334, CB16/12/00225 and CB16/12/00236). ELV and NG are recipients of predoctoral fellowships from Ministerio de Ciencia e Innovacion (FPI program), and from Agaur, Generalitat de Catalunya, respectively.	Agnusdei V, 2014, LEUKEMIA, V28, P278, DOI 10.1038/leu.2013.183; Andersson ER, 2014, NAT REV DRUG DISCOV, V13, P359, DOI 10.1038/nrd4252; Andrawes MB, 2013, J BIOL CHEM, V288, P25477, DOI 10.1074/jbc.M113.454850; Arruga F, 2017, LEUKEMIA, V31, P1882, DOI 10.1038/leu.2016.383; Arruga F, 2014, LEUKEMIA, V28, P1060, DOI 10.1038/leu.2013.319; Arruga F, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00550; Aste-Amezaga M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009094; Ayllon V, 2015, LEUKEMIA, V29, P1741, DOI 10.1038/leu.2015.74; Beckstead BL, 2006, J BIOMED MATER RES A, V79A, P94, DOI 10.1002/jbm.a.30760; Belver L, 2016, NAT REV CANCER, V16, P494, DOI 10.1038/nrc.2016.63; Bray SJ, 2006, NAT REV MOL CELL BIO, V7, P678, DOI 10.1038/nrm2009; Burkle A, 2007, BLOOD, V110, P3316, DOI 10.1182/blood-2007-05-089409; Calissano C, 2009, BLOOD, V114, P4832, DOI 10.1182/blood-2009-05-219634; Fabbri G, 2017, P NATL ACAD SCI USA, V114, pE2911, DOI 10.1073/pnas.1702564114; Fabbri G, 2013, J EXP MED, V210, P2273, DOI 10.1084/jem.20131448; Fabbri G, 2011, J EXP MED, V208, P1389, DOI 10.1084/jem.20110921; Galletti G, 2016, LEUKEMIA, V30, P2293, DOI 10.1038/leu.2016.261; Galletti G, 2016, CELL REP, V14, P1748, DOI 10.1016/j.celrep.2016.01.042; Guo DM, 2009, LEUKEMIA RES, V33, P678, DOI 10.1016/j.leukres.2008.10.026; Hanna BS, 2016, LEUKEMIA, V30, P570, DOI 10.1038/leu.2015.305; Herishanu Y, 2011, BLOOD, V117, P563, DOI 10.1182/blood-2010-05-284984; Kangsamaksin T, 2015, CANCER DISCOV, V5, P182, DOI 10.1158/2159-8290.CD-14-0650; Krebs LT, 2001, DEV BIOL, V238, P110, DOI 10.1006/dbio.2001.0408; Lamar E, 2001, GENE DEV, V15, P1885, DOI 10.1101/gad.908101; Lopez-Guerra M, 2015, LEUKEMIA, V29, P96, DOI 10.1038/leu.2014.143; Mirandola L, 2013, LEUKEMIA, V27, P1558, DOI 10.1038/leu.2013.27; Mongini PKA, 2015, J IMMUNOL, V195, P901, DOI 10.4049/jimmunol.1403189; Palomero T, 2006, P NATL ACAD SCI USA, V103, P18261, DOI 10.1073/pnas.0606108103; Patel NS, 2005, CANCER RES, V65, P8690, DOI 10.1158/0008-5472.CAN-05-1208; Phng LK, 2009, DEV CELL, V16, P196, DOI 10.1016/j.devcel.2009.01.015; Pozzo F, 2017, LEUKEMIA, V31, P2407, DOI 10.1038/leu.2017.90; Puente XS, 2015, NATURE, V526, P519, DOI 10.1038/nature14666; Puente XS, 2011, NATURE, V475, P101, DOI 10.1038/nature10113; Quesada V, 2012, NAT GENET, V44, P47, DOI 10.1038/ng.1032; Rosati E, 2009, BLOOD, V113, P856, DOI 10.1182/blood-2008-02-139725; Rosich L, 2014, ONCOTARGET, V5, P6788, DOI 10.18632/oncotarget.2253; Rossi D, 2012, BLOOD, V119, P521, DOI 10.1182/blood-2011-09-379966; Scehnet JS, 2007, BLOOD, V109, P4753, DOI 10.1182/blood-2006-12-063933; Thurston G, 2008, BRIT J CANCER, V99, P1204, DOI 10.1038/sj.bjc.6604484; Varnum-Finney B, 2000, J CELL SCI, V113, P4313; Villamor N, 2013, LEUKEMIA, V27, P1100, DOI 10.1038/leu.2012.357; Wu Y, 2010, NATURE, V464, P1052, DOI 10.1038/nature08878; Xargay-Torrent S, 2015, ONCOTARGET, V6, P22734, DOI 10.18632/oncotarget.4212; Zhang JR, 2013, CARCINOGENESIS, V34, P667, DOI 10.1093/carcin/bgs386	44	16	16	4	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	6					1185	1197		10.1038/s41388-019-1053-6	http://dx.doi.org/10.1038/s41388-019-1053-6			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE4UH	31616059	Green Published, hybrid			2022-12-17	WOS:000526714600002
J	Cebria-Costa, JP; Pascual-Reguant, L; Gonzalez-Perez, A; Serra-Bardenys, G; Querol, J; Cosin, M; Verde, G; Cigliano, RA; Sanseverino, W; Segura-Bayona, S; Iturbide, A; Andreu, D; Nuciforo, P; Bernado-Morales, C; Rodilla, V; Arribas, J; Yelamos, J; de Herreros, AG; Stracker, TH; Peiro, S				Cebria-Costa, J. P.; Pascual-Reguant, L.; Gonzalez-Perez, A.; Serra-Bardenys, G.; Querol, J.; Cosin, M.; Verde, G.; Cigliano, R. A.; Sanseverino, W.; Segura-Bayona, S.; Iturbide, A.; Andreu, D.; Nuciforo, P.; Bernado-Morales, C.; Rodilla, V.; Arribas, J.; Yelamos, J.; Garcia de Herreros, A.; Stracker, T. H.; Peiro, S.			LOXL2-mediated H3K4 oxidation reduces chromatin accessibility in triple-negative breast cancer cells	ONCOGENE			English	Article							OXIDASE-LIKE 2; DOUBLE-STRAND BREAKS; TO-MESENCHYMAL TRANSITION; DNA-DAMAGE RESPONSE; LYSYL OXIDASE; GENOMIC INSTABILITY; E-CADHERIN; LOXL2; EXPRESSION; TRANSCRIPTION	Oxidation of H3 at lysine 4 (H3K4ox) by lysyl oxidase-like 2 (LOXL2) generates an H3 modification with an unknown physiological function. We find that LOXL2 and H3K4ox are higher in triple-negative breast cancer (TNBC) cell lines and patient-derived xenografts (PDXs) than those from other breast cancer subtypes. ChIP-seq revealed that H3K4ox is located primarily in heterochromatin, where it is involved in chromatin compaction. Knocking down LOXL2 reduces H3K4ox levels and causes chromatin decompaction, resulting in a sustained activation of the DNA damage response (DDR) and increased susceptibility to anticancer agents. This critical role that LOXL2 and oxidized H3 play in chromatin compaction and DDR suggests that functionally targeting LOXL2 could be a way to sensitize TNBC cells to conventional therapy.	[Cebria-Costa, J. P.; Pascual-Reguant, L.; Serra-Bardenys, G.; Querol, J.; Cosin, M.; Verde, G.; Nuciforo, P.; Bernado-Morales, C.; Rodilla, V.; Arribas, J.; Peiro, S.] Vall dHebron Inst Oncol VHIO, Barcelona 08035, Spain; [Gonzalez-Perez, A.; Segura-Bayona, S.; Stracker, T. H.] Barcelona Inst Sci & Technol, Inst Res Biomed IRB Barcelona, Barcelona 08028, Spain; [Verde, G.] Univ Int Catalunya, Fac Med & Hlth Sci, Barcelona, Spain; [Cigliano, R. A.; Sanseverino, W.] Sequentia Biotech SL, Comte Urgell 240, Barcelona, Spain; [Iturbide, A.] Helmoholtz Zentrum Munchen, Inst Epigenet & Stem Cells, D-81377 Munich, Germany; [Andreu, D.; Garcia de Herreros, A.] Univ Pompeu Fabra, Dept Ciencies Expt & Salut, Barcelona, Spain; [Bernado-Morales, C.; Arribas, J.] Ctr Invest Biomed Red Oncol CIBERONC, Barcelona 08035, Spain; [Arribas, J.] ICREA, Barcelona, Spain; [Arribas, J.] Univ Autonoma Barcelona, Dept Bioquim & Biol Mol, Bellaterra, Spain; [Yelamos, J.; Garcia de Herreros, A.] Inst Hosp del Mar Invest Med IMIM, Programa Recerca Canc, Barcelona, Spain	Vall d'Hebron Institut d'Oncologia (VHIO); Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; Universitat Internacional de Catalunya (UIC); Pompeu Fabra University; CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; ICREA; Autonomous University of Barcelona; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar	Peiro, S (corresponding author), Vall dHebron Inst Oncol VHIO, Barcelona 08035, Spain.	speiro@vhio.net	Yelamos, Jose/N-2842-2016; Sanseverino, Walter/AAX-5254-2021; Segura-Bayona, Sandra/W-8156-2019; Benito, Verónica Rodilla/A-5171-2018; Reguant, Laura Pascual/AAB-6274-2019; Arribas, Joaquin/M-4482-2014; Verde, Gaetano/U-2749-2017	Sanseverino, Walter/0000-0003-3324-5912; Segura-Bayona, Sandra/0000-0001-7788-9889; Benito, Verónica Rodilla/0000-0003-0512-4179; Reguant, Laura Pascual/0000-0003-2361-1392; Cebria Costa, Joan Pau/0000-0002-3628-2973; Arribas, Joaquin/0000-0002-0504-0664; Gonzalez-Perez, Abel/0000-0002-8582-4660; Verde, Gaetano/0000-0003-4768-0165; Yelamos, Jose/0000-0003-1195-1496; Peiro, Sandra/0000-0001-9519-3877; Bernado Morales, Cristina/0000-0003-1376-0407	Instituto de Salud Carlos III (ISCIII) FIS/FEDER [PI12/01250, CP08/00223, PI16/00253, CB16/12/00449]; MINECO [SAF201348849-C2-1-R]; Breast Cancer Research Foundation [BCRF-17-008]; Worldwide Cancer Research; Red Tematica de Investigacion Cooperativa en Cancer [RD012/0036/005]; Fundacion Cientifica de la Asociacion Espanola contra el Cancer; Fundacio La Marato TV3; institutional funding (MINECO) through the Centres of Excellence Severo Ochoa award; CERCA Programme of the Catalan Government; Fundacio La Caixa fellowship; MINECO ("Juan de la Cierva Incorporation" fellowship) [IJCI-2014-20723]; Miguel Servet contract (ISCIII/FIS); Fundacio FERO; FI Fellowship from the Generalitat de Catalunya;  [BFU2015-68354];  [AGL2014-52395-C2-2-R]	Instituto de Salud Carlos III (ISCIII) FIS/FEDER; MINECO(Spanish Government); Breast Cancer Research Foundation; Worldwide Cancer Research; Red Tematica de Investigacion Cooperativa en Cancer; Fundacion Cientifica de la Asociacion Espanola contra el Cancer; Fundacio La Marato TV3; institutional funding (MINECO) through the Centres of Excellence Severo Ochoa award; CERCA Programme of the Catalan Government; Fundacio La Caixa fellowship; MINECO ("Juan de la Cierva Incorporation" fellowship); Miguel Servet contract (ISCIII/FIS); Fundacio FERO; FI Fellowship from the Generalitat de Catalunya(Generalitat de Catalunya); ; 	We would like to thank R. Pena and J. Valle for technical assistance, V.A. Raker for manuscript editing, G. Gil for manuscript reading and advice, A. Jordan for H1-GFP constructs, T. Jenuwein for SUV-39 constructs, and H. Galvez-Garcia for ATAC protocol implementation. This work was supported by grants from Instituto de Salud Carlos III (ISCIII) FIS/FEDER (PI12/01250; CP08/00223; PI16/00253; and CB16/12/00449), MINECO (SAF201348849-C2-1-R) to SP, BFU2015-68354 to THS, Breast Cancer Research Foundation (BCRF-17-008) to JA, AGL2014-52395-C2-2-R to DA, Worldwide Cancer Research, Red Tematica de Investigacion Cooperativa en Cancer (RD012/0036/005), Fundacion Cientifica de la Asociacion Espanola contra el Cancer, and Fundacio La Marato TV3. THS was supported by institutional funding (MINECO) through the Centres of Excellence Severo Ochoa award and the CERCA Programme of the Catalan Government, and SS-B, by a Fundacio La Caixa fellowship. We thank La Caixa Foundation and Cellex Foundation for provide research facilities and equipment. GV has received funding from the MINECO (a "Juan de la Cierva Incorporation" fellowship; IJCI-2014-20723). SP was a recipient of a Miguel Servet contract (ISCIII/FIS), and AI, JPC-C, LP-G, and GS-B are supported by contracts from Worldwide Cancer Research, Fundacio La Marato TV3, Fundacio FERO, and a FI Fellowship from the Generalitat de Catalunya, respectively.	Ahn SG, 2013, BREAST CANCER RES TR, V141, P89, DOI 10.1007/s10549-013-2662-3; Almendro V, 2014, CELL REP, V6, P514, DOI 10.1016/j.celrep.2013.12.041; Ayrapetov MK, 2014, P NATL ACAD SCI USA, V111, P9169, DOI 10.1073/pnas.1403565111; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Baldeyron C, 2011, J CELL BIOL, V193, P81, DOI 10.1083/jcb.201101030; Bannister AJ, 2011, CELL RES, V21, P381, DOI 10.1038/cr.2011.22; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Barker HE, 2012, NAT REV CANCER, V12, P540, DOI 10.1038/nrc3319; Bayona-Feliu A, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00338-5; Bekker-Jensen S, 2006, J CELL BIOL, V173, P195, DOI 10.1083/jcb.200510130; Bonilla CY, 2008, MOL CELL, V30, P267, DOI 10.1016/j.molcel.2008.03.023; Buenrostro JD, 2013, NAT METHODS, V10, P1213, DOI [10.1038/NMETH.2688, 10.1038/nmeth.2688]; Burgess RC, 2015, CELL, V162, P944, DOI 10.1016/j.cell.2015.08.006; Burgess RC, 2014, CELL REP, V9, P1703, DOI 10.1016/j.celrep.2014.10.060; Cano A, 2012, FUTURE ONCOL, V8, P1095, DOI [10.2217/FON.12.105, 10.2217/fon.12.105]; De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447; Ernst J, 2012, NAT METHODS, V9, P215, DOI 10.1038/nmeth.1906; Escriva M, 2008, MOL CELL BIOL, V28, P1528, DOI 10.1128/MCB.02061-07; Fischer KR, 2015, NATURE, V527, P472, DOI 10.1038/nature15748; Fong SFT, 2007, GENE CHROMOSOME CANC, V46, P644, DOI 10.1002/gcc.20444; Gan WJ, 2011, GENE DEV, V25, P2041, DOI 10.1101/gad.17010011; Garcia-Rubio ML, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005674; Goodarzi AA, 2008, MOL CELL, V31, P167, DOI 10.1016/j.molcel.2008.05.017; Guelen L, 2008, NATURE, V453, P948, DOI 10.1038/nature06947; Gursoy-Yuzugullu O, 2016, J MOL BIOL, V428, P1846, DOI 10.1016/j.jmb.2015.11.021; Herranz N, 2008, MOL CELL BIOL, V28, P4772, DOI 10.1128/MCB.00323-08; Herranz N, 2016, FEBS J, V283, P4263, DOI 10.1111/febs.13922; Holliday DL, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2889; Iturbide A, 2015, MOL CELL, V58, P755, DOI 10.1016/j.molcel.2015.04.012; Iturbide A, 2015, FEBS J, V282, P1768, DOI 10.1111/febs.12961; Kaidi A, 2013, NATURE, V498, DOI 10.1038/nature12201; Khurana S, 2014, CELL REP, V8, P1049, DOI 10.1016/j.celrep.2014.07.024; Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Lerat E, 2017, NUCLEIC ACIDS RES, V45, DOI 10.1093/nar/gkw953; Martin A, 2015, EMBO J, V34, P1090, DOI 10.15252/embj.201489975; McDonald OG, 2011, NAT STRUCT MOL BIOL, V18, P867, DOI 10.1038/nsmb.2084; Millanes-Romero A, 2013, MOL CELL, V52, P746, DOI 10.1016/j.molcel.2013.10.015; Moreno-Bueno G, 2011, EMBO MOL MED, V3, P528, DOI 10.1002/emmm.201100156; Murga M, 2007, J CELL BIOL, V178, P1101, DOI 10.1083/jcb.200704140; Peinado H, 2005, EMBO J, V24, P3446, DOI 10.1038/sj.emboj.7600781; Peinado H, 2008, CANCER RES, V68, P4541, DOI 10.1158/0008-5472.CAN-07-6345; Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033; Schietke R, 2010, J BIOL CHEM, V285, P6658, DOI 10.1074/jbc.M109.042424; Soria G, 2012, MOL CELL, V46, P722, DOI 10.1016/j.molcel.2012.06.002; Soutoglou E, 2008, SCIENCE, V320, P1507, DOI [10.1126/science.1159051, 10.1126/science.ll59051]; Tarazona S, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv711; Torres S, 2015, CLIN CANCER RES, V21, P4892, DOI 10.1158/1078-0432.CCR-14-3096; Toth KF, 2004, J CELL SCI, V117, P4277, DOI 10.1242/jcs.01293; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; Tsompana M, 2014, EPIGENET CHROMATIN, V7, DOI 10.1186/1756-8935-7-33; Tuduri S, 2009, NAT CELL BIOL, V11, P1315, DOI 10.1038/ncb1984; Vega S, 2004, GENE DEV, V18, P1131, DOI 10.1101/gad.294104; Voloshenyuk TG, 2011, CYTOKINE, V55, P90, DOI 10.1016/j.cyto.2011.03.024; WILLIAMSON PR, 1986, J BIOL CHEM, V261, P9477; Wong CCL, 2014, HEPATOLOGY, V60, P1645, DOI 10.1002/hep.27320; Wu M, 2008, MOL CELL BIOL, V28, P7337, DOI 10.1128/MCB.00976-08; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137; Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064; Ziv Y, 2006, NAT CELL BIOL, V8, P870, DOI 10.1038/ncb1446	61	16	16	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	1					79	121		10.1038/s41388-019-0969-1	http://dx.doi.org/10.1038/s41388-019-0969-1			43	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KG3NM	31462706	hybrid, Green Published			2022-12-17	WOS:000509849200007
J	Nicolai, S; Mahen, R; Raschella, G; Marini, A; Pieraccioli, M; Malewicz, M; Venkitaraman, AR; Melino, G				Nicolai, Sara; Mahen, Robert; Raschella, Giuseppe; Marini, Alberto; Pieraccioli, Marco; Malewicz, Michal; Venkitaraman, Ashok R.; Melino, Gerry			ZNF281 is recruited on DNA breaks to facilitate DNA repair by non-homologous end joining	ONCOGENE			English	Article							DOUBLE-STRAND BREAKS; DAMAGE RESPONSE; HOMOLOGOUS-RECOMBINATION; ATM; PLURIPOTENCY; KU	Efficient repair of DNA double-strand breaks (DSBs) is of critical importance for cell survival. Although non-homologous end joining (NHEJ) is the most used DSBs repair pathway in the cells, how NHEJ factors are sequentially recruited to damaged chromatin remains unclear. Here, we identify a novel role for the zinc-finger protein ZNF281 in participating in the ordered recruitment of the NHEJ repair factor XRCC4 at damage sites. ZNF281 is recruited to DNA lesions within seconds after DNA damage through a mechanism dependent on its DNA binding domain and, at least in part, on poly-ADP ribose polymerase (PARP) activity. ZNF281 binds XRCC4 through its zinc-finger domain and facilitates its recruitment to damaged sites. Consequently, depletion of ZNF281 impairs the efficiency of the NHEJ repair pathway and decreases cell viability upon DNA damage. Survival analyses from datasets of commonly occurring human cancers show that higher levels of ZNF281 correlate with poor prognosis of patients treated with DNA-damaging therapies. Thus, our results define a late ZNF281-dependent regulatory step of NHEJ complex assembly at DNA lesions and suggest additional possibilities for cancer patients' stratification and for the development of personalised therapeutic strategies.	[Nicolai, Sara; Marini, Alberto; Malewicz, Michal; Melino, Gerry] Univ Cambridge, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England; [Mahen, Robert; Venkitaraman, Ashok R.] Univ Cambridge, MRC, Canc Unit, Cambridge CB2 0XZ, England; [Raschella, Giuseppe] ENEA, Lab Biosafety & Risk Assessment, I-00123 Rome, Italy; [Pieraccioli, Marco; Melino, Gerry] Univ Roma Tor Vergata, Dept Expt Med, I-00133 Rome, Italy	University of Cambridge; University of Leicester; University of Cambridge; Italian National Agency New Technical Energy & Sustainable Economics Development; University of Rome Tor Vergata	Melino, G (corresponding author), Univ Cambridge, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England.	gm614@mrc-tox.cam.ac.uk	Marini, Alberto/AIA-5808-2022; Pieraccioli, Marco/K-4294-2018; Marini, Alberto/AAA-7802-2022	Marini, Alberto/0000-0001-7222-9056; Pieraccioli, Marco/0000-0003-3995-535X; Nicolai, Sara/0000-0001-8776-1440; Mahen, Robert/0000-0002-4748-3690; MELINO, GERRY/0000-0001-9428-5972	Medical Research Council, UK; Associazione Italiana per la Ricerca contro il Cancro (AIRC) [20473]; EMBO Fellowship [ASTF 572-2015]; Wellcome Trust Henry Wellcome Fellowship [100090/12/Z]; MRC [MC_UU_00025/2, MC_U132670600, MC_UU_12022/1] Funding Source: UKRI	Medical Research Council, UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Associazione Italiana per la Ricerca contro il Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); EMBO Fellowship(European Molecular Biology Organization (EMBO)); Wellcome Trust Henry Wellcome Fellowship; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We wish to thank D.J. Read for his expert assistance in confocal microscopy and G. Legube and M. Bushell for providing the DIvA and the NHEJ and HR reporter cell lines, respectively. This work was supported by the Medical Research Council, UK; grants from Associazione Italiana per la Ricerca contro il Cancro (AIRC) to GM IG#20473 (2018-2022). SN was supported by an EMBO Fellowship (ASTF 572-2015). RM was supported by a Wellcome Trust Henry Wellcome Fellowship (grant number 100090/12/Z).	Aymard F, 2014, NAT STRUCT MOL BIOL, V21, P366, DOI 10.1038/nsmb.2796; Ayoub N, 2008, NATURE, V453, P682, DOI 10.1038/nature06875; Begg AC, 2011, NAT REV CANCER, V11, P239, DOI 10.1038/nrc3007; Berkovich E, 2008, NAT PROTOC, V3, P915, DOI 10.1038/nprot.2008.54; Berkovich E, 2007, NAT CELL BIOL, V9, P683, DOI 10.1038/ncb1599; Britton S, 2013, J CELL BIOL, V202, P579, DOI 10.1083/jcb.201303073; Chapman JR, 2012, MOL CELL, V47, P497, DOI 10.1016/j.molcel.2012.07.029; Chen G, 2018, NUCLEIC ACIDS RES, V46, P1266, DOI 10.1093/nar/gkx1258; Chou DM, 2010, P NATL ACAD SCI USA, V107, P18475, DOI 10.1073/pnas.1012946107; Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019; Cohen S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-02894-w; Craxton A, 2015, CELL DEATH DIFFER, V22, P890, DOI 10.1038/cdd.2015.22; Fidalgo M, 2016, CELL STEM CELL, V19, P355, DOI 10.1016/j.stem.2016.05.025; Fidalgo M, 2012, P NATL ACAD SCI USA, V109, P16202, DOI 10.1073/pnas.1208533109; Fidalgo M, 2011, STEM CELLS, V29, P1705, DOI 10.1002/stem.736; Goldstein M, 2015, ANNU REV MED, V66, P129, DOI 10.1146/annurev-med-081313-121208; Goldstein M, 2013, P NATL ACAD SCI USA, V110, P16874, DOI 10.1073/pnas.1306160110; Hahn S, 2013, EMBO J, V32, P3079, DOI 10.1038/emboj.2013.236; Izhar L, 2015, CELL REP, V11, P1486, DOI 10.1016/j.celrep.2015.04.053; Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467; Jungmichel S, 2013, MOL CELL, V52, P272, DOI 10.1016/j.molcel.2013.08.026; Law DJ, 1999, BIOCHEM BIOPH RES CO, V262, P113, DOI 10.1006/bbrc.1999.1180; Liu C, 2017, NUCLEIC ACIDS RES, V45, P8129, DOI 10.1093/nar/gkx565; Lord CJ, 2012, NATURE, V481, P287, DOI 10.1038/nature10760; Lukas J, 2011, NAT CELL BIOL, V13, P1161, DOI 10.1038/ncb2344; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; Miller KM, 2010, NAT STRUCT MOL BIOL, V17, P1144, DOI 10.1038/nsmb.1899; Nowsheen S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05161-0; O'Connor MJ, 2015, MOL CELL, V60, P547, DOI 10.1016/j.molcel.2015.10.040; Ochi T, 2015, SCIENCE, V347, P185, DOI 10.1126/science.1261971; Pieraccioli M, 2016, ONCOGENE, V35, P2592, DOI 10.1038/onc.2015.320; Pieraccioli M, 2018, P NATL ACAD SCI USA, V115, P7356, DOI 10.1073/pnas.1801435115; Raschell G, 2017, ONCOGENE, V36, P4673, DOI 10.1038/onc.2017.60; Srivastava M, 2015, CHEM BIOL, V22, P17, DOI 10.1016/j.chembiol.2014.11.013; Wang JL, 2006, NATURE, V444, P364, DOI 10.1038/nature05284; Wei HT, 2016, GENOM PROTEOM BIOINF, V14, P131, DOI 10.1016/j.gpb.2016.05.001; Xiao X, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06771-4; Ziv Y, 2006, NAT CELL BIOL, V8, P870, DOI 10.1038/ncb1446	38	16	16	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	4					754	766		10.1038/s41388-019-1028-7	http://dx.doi.org/10.1038/s41388-019-1028-7			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KF4EJ	31570788	Green Published, hybrid			2022-12-17	WOS:000509197200002
J	Park, SH; Jeong, S; Kim, BR; Jeong, YA; Kim, JL; Na, YJ; Jo, MJ; Yun, HK; Kim, DY; Kim, BG; Lee, DH; Oh, SC				Park, Seong Hye; Jeong, Soyeon; Kim, Bo Ram; Jeong, Yoon A.; Kim, Jung Lim; Na, Yoo Jin; Jo, Min Jee; Yun, Hye Kyeong; Kim, Dae Yeong; Kim, Bu Gyeom; Lee, Dae-Hee; Oh, Sang Cheul			Activating CCT2 triggers Gli-1 activation during hypoxic condition in colorectal cancer	ONCOGENE			English	Article							ER STRESS; CHAPERONIN; CELLS; INHIBITOR; PROTEINS; TRIC/CCT; SURVIVAL; COMPLEX; GROWTH; HSP90	Hypoxia, or the deficiency of oxygen, in solid tumors is majorly responsible for the progression of cancer and remains unaffected by chemotherapy, but still requires definitive definition of the hypoxia signaling. Hypoxia disrupts the complete folding of mitochondrial proteins, leading to several diseases. The present study confirms that hypoxia activates the Hedgehog pathway in colorectal cancer (CRC), considering its role in cancer epithelial to mesenchymal transition, migration, and invasion. The activity of hypoxia-mediated Gli-1, a Hedgehog signaling factor in hypoxia, was confirmed by in vitro western blotting, immunofluorescence staining, wound-healing assay, and matrigel invasion assay, as well as by in vivo xenograft models (n = 5 per group). The Gli-1 mechanism in hypoxia was analyzed via mass spectrometry. Hypoxia enhanced the interaction of Gli-1 and T-complex protein 1 subunit beta (CCT2), as observed in the mass spectrometric analysis. We observed that reduction in CCT2 inhibits tumor induction by Gli-1. Ubiquitination-mediated Gli-1 degradation by beta-TrCP occurs during incomplete folding of Gli-1 in hypoxia. The human CRC tissues revealed greater CCT2 expression than did the normal colon tissues, indicating that higher CCT2 expression in tumor tissues from CRC patients reduced their survival rate. Moreover, we suggest that CCT2 correlates with Gli-1 expression and is an important determinant of survival in the CRC patients. The results reveal that CCT2 can regulate the folding of Gli-1 in relation to hypoxia in CRC.	[Park, Seong Hye; Jeong, Yoon A.; Na, Yoo Jin; Jo, Min Jee; Yun, Hye Kyeong; Kim, Dae Yeong; Kim, Bu Gyeom; Lee, Dae-Hee; Oh, Sang Cheul] Korea Univ, Coll Med, Grad Sch Med, Seoul, South Korea; [Jeong, Soyeon; Kim, Bo Ram; Kim, Jung Lim; Lee, Dae-Hee; Oh, Sang Cheul] Korea Univ, Guro Hosp, Dept Oncol, Seoul 152703, South Korea	Korea University; Korea University Medicine (KU Medicine); Korea University; Korea University Medicine (KU Medicine)	Lee, DH; Oh, SC (corresponding author), Korea Univ, Coll Med, Grad Sch Med, Seoul, South Korea.; Lee, DH; Oh, SC (corresponding author), Korea Univ, Guro Hosp, Dept Oncol, Seoul 152703, South Korea.	neogene@korea.ac.kr; sachoh@korea.ac.kr			National Research Foundation (NRF) of Korea - Korean government (MSIP) [NRF-2017R1A2B2011684, NRF-2018M3A9G1075561]	National Research Foundation (NRF) of Korea - Korean government (MSIP)	This work was supported by grant from the National Research Foundation (NRF) of Korea and funded by the Korean government (MSIP) (NRF-2017R1A2B2011684, NRF-2018M3A9G1075561).	Altaba ARI, 1999, TRENDS GENET, V15, P418, DOI 10.1016/S0168-9525(99)01840-5; Boudiaf-Benmammar C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060895; Briscoe J, 2013, NAT REV MOL CELL BIO, V14, P416, DOI 10.1038/nrm3598; Calderwood SK, 2006, TRENDS BIOCHEM SCI, V31, P164, DOI 10.1016/j.tibs.2006.01.006; Carr AC, 2017, ONCOTARGET, V8, P110273, DOI 10.18632/oncotarget.22681; Feldman DE, 2005, MOL CANCER RES, V3, P597, DOI 10.1158/1541-7786.MCR-05-0221; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Flamment M, 2012, TRENDS ENDOCRIN MET, V23, P381, DOI 10.1016/j.tem.2012.06.003; Gao Q, 2015, ONCOL LETT, V9, P2381, DOI 10.3892/ol.2015.2988; Guest ST, 2015, EXP CELL RES, V332, P223, DOI 10.1016/j.yexcr.2015.02.005; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Huntzicker EG, 2006, GENE DEV, V20, P276, DOI 10.1101/gad.1380906; Kalisman N, 2012, P NATL ACAD SCI USA, V109, P2884, DOI 10.1073/pnas.1119472109; Kasembeli M, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001844; Kim BR, 2017, ONCOTARGET, V8, P101952, DOI 10.18632/oncotarget.21882; Koumenis C, 2006, CURR MOL MED, V6, P55, DOI 10.2174/156652406775574604; Koumenis C, 2002, MOL CELL BIOL, V22, P7405, DOI 10.1128/MCB.22.21.7405-7416.2002; KUBOTA H, 1994, CURR BIOL, V4, P89, DOI 10.1016/S0960-9822(94)00024-2; Lei JJ, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-66; Leitner A, 2012, STRUCTURE, V20, P814, DOI 10.1016/j.str.2012.03.007; Leu JIJ, 2009, MOL CELL, V36, P15, DOI 10.1016/j.molcel.2009.09.023; Melki R, 1997, BIOCHEMISTRY-US, V36, P5817, DOI 10.1021/bi962830o; Michieli P, 2009, CELL CYCLE, V8, P3291, DOI 10.4161/cc.8.20.9741; Morimoto RI, 2008, GENE DEV, V22, P1427, DOI 10.1101/gad.1657108; Pandolfi S, 2015, EXPERT REV MOL MED, V17, DOI 10.1017/erm.2015.3; Pennacchietti S, 2003, CANCER CELL, V3, P347, DOI 10.1016/S1535-6108(03)00085-0; Qualtrough D, 2015, CANCERS, V7, P1885, DOI 10.3390/cancers7030867; Roh SH, 2015, INT J MOL SCI, V16, P26706, DOI 10.3390/ijms161125975; Sergeeva OA, 2013, J BIOL CHEM M, VM112, P443929; SHUIN T, 1994, CANCER RES, V54, P2852; Teglund S, 2010, BBA-REV CANCER, V1805, P181, DOI 10.1016/j.bbcan.2010.01.003; Trinidad AG, 2013, MOL CELL, V50, P805, DOI 10.1016/j.molcel.2013.05.002; Tu BP, 2004, J CELL BIOL, V164, P341, DOI 10.1083/jcb.200311055; Varnat F, 2009, EMBO MOL MED, V1, P338, DOI 10.1002/emmm.200900039; Whitesell L, 2005, NAT REV CANCER, V5, P761, DOI 10.1038/nrc1716; Won KA, 1998, MOL CELL BIOL, V18, P7584, DOI 10.1128/MCB.18.12.7584; Workman P, 2007, NAT CHEM BIOL, V3, P455, DOI 10.1038/nchembio0807-455; Zhang K, 2015, MED ONCOL, V32, DOI 10.1007/s12032-014-0368-y	38	16	16	2	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	1					136	150		10.1038/s41388-019-0972-6	http://dx.doi.org/10.1038/s41388-019-0972-6			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KG3NM	31462707				2022-12-17	WOS:000509849200009
J	Sun, J; Yan, J; Qiao, HY; Zhao, FY; Li, C; Jiang, JY; Liu, BQ; Meng, XN; Wang, HQ				Sun, Jia; Yan, Jing; Qiao, Huai-Yu; Zhao, Fu-Ying; Li, Chao; Jiang, Jing-Yi; Liu, Bao-Qin; Meng, Xiao-Na; Wang, Hua-Qin			Loss of TRIM29 suppresses cancer stem cell-like characteristics of PDACs via accelerating ISG15 degradation	ONCOGENE			English	Article							BREAST-CANCER; PROMOTES PROLIFERATION; ONCOGENIC FUNCTION; PANCREATIC-CANCER; TUMOR-SUPPRESSOR; INTERFERON; GROWTH; IDENTIFICATION; METASTASIS; AUTOPHAGY	TRIM family proteins are defined as E3 ubiquitin ligases because of their RING-finger domains. The ubiquitin-like protein interferon-stimulated gene 15 (ISG15) encodes a 15-kDa protein, that is implicated in the posttranslational modification of diverse proteins. Both TRIM29 and ISG15 play both pro-tumoral and anti-tumoral functions in cancer cells derived from different histology. In the current study, we demonstrated that correlation expression of TRIM29 and ISG15 in pancreatic ductal adenocarcinomas (PDACs). The current study demonstrated that TRIM29 knockdown destabilized ISG15 protein via promoting its processing by calpain 3 (CAPN3). Importantly, the current study found that TRIM29 knockdown suppressed cancer stem cell-like features of PDACs, which can be rescued by ISG15 independent of its conjugation function. In addition, the current study demonstrated that extracellular free ISG15 played an important role in maintenance of cancer stem cell-like features of PDACs. Thereby, the current study displayed a novel mechanism by which TRIM29 modulates ISG15 stability via CAPN3-mediated processing, and subsequently extracellular ISG15 maintains the cancer stem cell-like features of PDAC via autocrine mode of action.	[Sun, Jia; Yan, Jing; Qiao, Huai-Yu; Zhao, Fu-Ying; Li, Chao; Jiang, Jing-Yi; Liu, Bao-Qin; Meng, Xiao-Na; Wang, Hua-Qin] China Med Univ, Dept Biochem & Mol Biol, Shenyang 110122, Peoples R China; [Sun, Jia; Wang, Hua-Qin] China Med Univ, Minist Publ Hlth, Key Lab Cell Biol, Shenyang 110122, Peoples R China; [Sun, Jia; Wang, Hua-Qin] China Med Univ, Minist Educ, Key Lab Med Cell Biol, Shenyang 110122, Peoples R China	China Medical University; China Medical University; China Medical University	Wang, HQ (corresponding author), China Med Univ, Dept Biochem & Mol Biol, Shenyang 110122, Peoples R China.; Wang, HQ (corresponding author), China Med Univ, Minist Publ Hlth, Key Lab Cell Biol, Shenyang 110122, Peoples R China.; Wang, HQ (corresponding author), China Med Univ, Minist Educ, Key Lab Med Cell Biol, Shenyang 110122, Peoples R China.	hqwang@cmu.edu.cn			National Natural Science Foundation of China [81572828, 81602510, 81602439]; China Postdoctoral Science Foundation [2017M611286]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	This work was partly supported by National Natural Science Foundation of China (81572828, 81602510, and 81602439) and China Postdoctoral Science Foundation (2017M611286).	Ai LB, 2014, CANCER RES, V74, P4875, DOI 10.1158/0008-5472.CAN-13-3579; Balic A, 2012, EXP CELL RES, V318, P691, DOI 10.1016/j.yexcr.2011.11.007; Burks J, 2014, ONCOGENE, V33, P794, DOI 10.1038/onc.2012.633; Burks J, 2015, ONCOTARGET, V6, P7221, DOI 10.18632/oncotarget.3372; Charton K, 2015, HUM MOL GENET, V24, P3718, DOI 10.1093/hmg/ddv116; Chen RH, 2016, ONCOTARGET, V7, P16910, DOI 10.18632/oncotarget.7626; Chronopoulos A, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12630; Desai SD, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1052935; Desai SD, 2012, EXP BIOL MED, V237, P38, DOI 10.1258/ebm.2011.011236; Du ZY, 2017, BIOCHEM BIOPH RES CO, V491, P343, DOI 10.1016/j.bbrc.2017.07.098; Dukel M, 2016, J BIOL CHEM, V291, P21541, DOI 10.1074/jbc.M116.730960; Feng Q, 2008, MOL CANCER THER, V7, P3780, DOI 10.1158/1535-7163.MCT-08-0753; Giannakopoulos NV, 2009, J VIROL, V83, P1602, DOI 10.1128/JVI.01590-08; HAAS AL, 1987, J BIOL CHEM, V262, P11315; Hatakeyama S, 2017, TRENDS BIOCHEM SCI, V42, P297, DOI 10.1016/j.tibs.2017.01.002; Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002; Jeon YJ, 2012, J CLIN INVEST, V122, P2622, DOI 10.1172/JCI61762; Jiang T, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0715-4; KAPP LN, 1992, AM J HUM GENET, V51, P45; Kosaka Y, 2007, ANN SURG ONCOL, V14, P2543, DOI 10.1245/s10434-007-9461-1; Lenschow DJ, 2005, J VIROL, V79, P13974, DOI 10.1128/JVI.79.22.13974-13983.2005; Liu J, 2012, AM J PATHOL, V180, P839, DOI 10.1016/j.ajpath.2011.10.020; LOEB KR, 1992, J BIOL CHEM, V267, P7806; Mao HW, 2016, ONCOTARGET, V7, P70143, DOI 10.18632/oncotarget.12160; Mizushima N, 2010, NAT CELL BIOL, V12, P823, DOI 10.1038/ncb0910-823; Mustachio LM, 2018, CANCER RES, V78, P587, DOI 10.1158/0008-5472.CAN-17-1752; Mutter GL, 2001, GYNECOL ONCOL, V83, P177, DOI 10.1006/gyno.2001.6352; Paget S., 1889, 1889 CANC METASTASIS, V1, P571, DOI DOI 10.1016/S0140-6736(00)49915-0; Pattyn E, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002427; Reymond A, 2001, EMBO J, V20, P2140, DOI 10.1093/emboj/20.9.2140; Sainz B, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/9012369; Sainz B, 2014, CANCER RES, V74, P7309, DOI 10.1158/0008-5472.CAN-14-1354; Sho T, 2011, BBA-MOL CELL RES, V1813, P1245, DOI 10.1016/j.bbamcr.2011.03.018; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Singh SK, 2003, CANCER RES, V63, P5821; Song XM, 2015, ONCOL LETT, V10, P2283, DOI 10.3892/ol.2015.3623; Tait SWG, 2010, NAT REV MOL CELL BIO, V11, P621, DOI 10.1038/nrm2952; Tan ST, 2016, CANCER RES TREAT, V48, P1302, DOI 10.4143/crt.2015.381; Tanaka K, 2009, P JPN ACAD B-PHYS, V85, P12, DOI [10.2183/pjab.85.12, 10.2183/pjab/85.12]; Valle S, 2018, CANCERS, V10, DOI 10.3390/cancers10020033; Vlashi E, 2015, SEMIN CANCER BIOL, V31, P28, DOI 10.1016/j.semcancer.2014.07.001; Vries RGJ, 2010, MOL ONCOL, V4, P373, DOI 10.1016/j.molonc.2010.05.001; Wang LD, 2015, GENE DEV, V29, P171, DOI 10.1101/gad.253591.114; Wang LD, 2009, CANCER CELL, V15, P207, DOI 10.1016/j.ccr.2009.01.018; Wang T, 2015, ONCOTARGET, V6, P44191, DOI 10.18632/oncotarget.6176; Xu R, 2016, ONCOTARGET, V7, P28579, DOI 10.18632/oncotarget.8686; Yanagi T, 2018, CANCER RES, V78, P6795, DOI 10.1158/0008-5472.CAN-18-1495; Yoo L, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0138-9; Yuan HY, 2018, EXP CELL RES, V367, P47, DOI 10.1016/j.yexcr.2018.03.017; Yuan ZG, 2010, MOL CELL BIOL, V30, P3004, DOI 10.1128/MCB.01023-09; Zhang QM, 2017, EXP THER MED, V14, P2329, DOI 10.3892/etm.2017.4720; Zhou MJ, 2017, INT J MOL MED, V39, P446, DOI 10.3892/ijmm.2016.2845; Zhou XM, 2016, ONCOTARGET, V7, P13634, DOI 10.18632/oncotarget.7215	53	16	16	1	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	3					546	559		10.1038/s41388-019-0992-2	http://dx.doi.org/10.1038/s41388-019-0992-2			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KG1RJ	31501523				2022-12-17	WOS:000509718300005
J	Han, X; Ren, CN; Yang, TT; Qiao, PY; Wang, L; Jiang, AF; Meng, YH; Liu, ZJ; Du, Y; Yu, ZH				Han, Xue; Ren, Chune; Yang, Tingting; Qiao, Pengyun; Wang, Li; Jiang, Aifang; Meng, Yuhan; Liu, Zhijun; Du, Yu; Yu, Zhenhai			Negative regulation of AMPK alpha 1 by PIM2 promotes aerobic glycolysis and tumorigenesis in endometrial cancer	ONCOGENE			English	Article							ACTIVATED PROTEIN-KINASE; TUMOR-GROWTH; AMPK; PHOSPHORYLATION; INHIBITION; METABOLISM; PATHWAY; FAMILY; PKM2; AKT	Endometrial cancer (EC) is one of the most common gynecologic malignancies. However, the molecular mechanisms underlying the development and progression of EC remain unclear. Here, we demonstrated that the protein proviral insertion in murine lymphomas 2 (PIM2) was necessary for maintaining EC tumorigenesis in vivo and in vitro, and could inhibit AMPK alpha 1 kinase activity in EC cells. Specifically, we found that PIM2 bound to AMPK alpha 1, and directly phosphorylated it on Thr467. Phosphorylation of AMPK alpha 1 by PIM2 led to decreasing AMPK alpha 1 kinase activity, which in turn promoted aerobic glycolysis and tumor growth. In addition, PIM2 expression positively correlated with AMPK alpha 1 Thr467 phosphorylation in EC tissues. Further, treatment with a combination of the PIM2 inhibitor SMI-4a and the AMPK alpha 1 activator AICAR could effectively inhibit tumor growth. Thus, our findings provide insight into the role of PIM2 and AMPK alpha 1 in EC and suggest that combination targeting of these proteins may represent a new strategy for EC treatment.	[Han, Xue; Ren, Chune; Yang, Tingting; Qiao, Pengyun; Wang, Li; Jiang, Aifang; Meng, Yuhan; Yu, Zhenhai] Weifang Med Univ, Dept Reprod Med, Affiliated Hosp, Weifang, Shandong, Peoples R China; [Liu, Zhijun; Du, Yu] Weifang Med Univ, Dept Med Microbiol, Weifang, Shandong, Peoples R China	Weifang Medical University; Weifang Medical University	Yu, ZH (corresponding author), Weifang Med Univ, Dept Reprod Med, Affiliated Hosp, Weifang, Shandong, Peoples R China.	tomsyu@163.com			Innovation fund of National Natural Science Foundation of China [81602440, 81602301, 81501275, 81471048]; Shandong Province College Science and Technology Plan Project [J16LL08, J17KA254]; Projects of medical and health technology development program in Shandong province [2016WS0688, 2017WS398]	Innovation fund of National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shandong Province College Science and Technology Plan Project; Projects of medical and health technology development program in Shandong province	The study was supported by research grants from Innovation fund of National Natural Science Foundation of China (Grant no. 81602440, 81602301, 81501275 and 81471048), Shandong Province College Science and Technology Plan Project (Grant no. J16LL08 and J17KA254), Projects of medical and health technology development program in Shandong province (Grant no. 2016WS0688 and 2017WS398).	Beharry Z, 2011, P NATL ACAD SCI USA, V108, P528, DOI 10.1073/pnas.1013214108; Bungard D, 2010, SCIENCE, V329, P1201, DOI 10.1126/science.1191241; Daenthanasanmak A, 2018, J CLIN INVEST, V128, P2787, DOI 10.1172/JCI95407; Dagon Y, 2012, CELL METAB, V16, P104, DOI 10.1016/j.cmet.2012.05.010; Faubert B, 2013, CELL METAB, V17, P113, DOI 10.1016/j.cmet.2012.12.001; Garcia D, 2017, MOL CELL, V66, P789, DOI 10.1016/j.molcel.2017.05.032; Hall DT, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201708307; Hardie DG, 2016, TRENDS CELL BIOL, V26, P190, DOI 10.1016/j.tcb.2015.10.013; Hawley SA, 1996, J BIOL CHEM, V271, P27879, DOI 10.1074/jbc.271.44.27879; Hawley SA, 2014, BIOCHEM J, V459, P275, DOI 10.1042/BJ20131344; Herzig S, 2018, NAT REV MOL CELL BIO, V19, P121, DOI 10.1038/nrm.2017.95; Hospital MA, 2018, LEUKEMIA, V32, P597, DOI 10.1038/leu.2017.284; Jansen M, 2009, PHYSIOL REV, V89, P777, DOI 10.1152/physrev.00026.2008; Kreuz S, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0477-z; Lin SC, 2018, CELL METAB, V27, P299, DOI 10.1016/j.cmet.2017.10.009; Lu J, 2013, BLOOD, V122, P1610, DOI 10.1182/blood-2013-01-481457; Morishita D, 2008, CANCER RES, V68, P5076, DOI 10.1158/0008-5472.CAN-08-0634; Nair JR, 2017, LEUKEMIA, V31, P1715, DOI 10.1038/leu.2016.379; Narlik-Grassow M, 2014, MED RES REV, V34, P136, DOI 10.1002/med.21284; Onstad MA, 2016, J CLIN ONCOL, V34, P4225, DOI 10.1200/JCO.2016.69.4638; Ren CN, 2018, MOL ONCOL, V12, P690, DOI 10.1002/1878-0261.12192; Shukla K, 2017, CANCER LETT, V411, P57, DOI 10.1016/j.canlet.2017.09.031; Suzuki T, 2013, MOL CELL, V50, P407, DOI 10.1016/j.molcel.2013.03.022; Wang ZP, 2010, INT J BIOCHEM CELL B, V42, P1030, DOI 10.1016/j.biocel.2010.03.012; Warfel NA, 2015, PHARMACOL THERAPEUT, V151, P41, DOI 10.1016/j.pharmthera.2015.03.001; Yang TT, 2018, ONCOGENE, V37, P5997, DOI 10.1038/s41388-018-0386-x; Ye S, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2230-4; Yu ZH, 2016, BIOCHEM BIOPH RES CO, V473, P953, DOI 10.1016/j.bbrc.2016.03.160; Yu ZH, 2014, CELL SIGNAL, V26, P1560, DOI 10.1016/j.cellsig.2014.03.016; Yu ZH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088301; Yu ZH, 2013, J BIOL CHEM, V288, P35406, DOI 10.1074/jbc.M113.508226; Yuan JM, 2018, J BIOL CHEM, V293, P14276, DOI 10.1074/jbc.RA118.004597; Zhao YQ, 2016, ACTA PHARMACOL SIN, V37, P1237, DOI 10.1038/aps.2016.60; Zhou XK, 2017, CANCER LETT, V411, P1, DOI 10.1016/j.canlet.2017.09.027	34	16	16	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	2019	38	38					6537	6549		10.1038/s41388-019-0898-z	http://dx.doi.org/10.1038/s41388-019-0898-z			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IY7XR	31358902				2022-12-17	WOS:000486609000005
J	Berg, KCG; Sveen, A; Holand, M; Alagaratnam, S; Berg, M; Danielsen, SA; Nesbakken, A; Soreide, K; Lothel, RA				Berg, Kaja C. G.; Sveen, Anita; Holand, Maren; Alagaratnam, Sharmini; Berg, Marianne; Danielsen, Stine A.; Nesbakken, Arild; Soreide, Kjetil; Lothel, Ragnhild A.			Gene expression profiles of CMS2-epithelial/canonical colorectal cancers are largely driven by DNA copy number gains	ONCOGENE			English	Article							CONSENSUS MOLECULAR SUBTYPES; ANNEXIN A11	About 80% of colorectal cancers (CRCs) have chromosomal instability, which is an integral part of aggressive malignancy development, but the importance of specific copy number aberrations (CNAs) in modulating gene expression, particularly within the framework of clinically relevant molecular subtypes, remains mostly elusive. We performed DNA copy number profiling of 257 stage I-IV primary CRCs and integrative gene expression analysis in 151 microsatellite stable (MSS) tumors, focusing on high-level amplifications and the effect of CNAs on the characteristics of the gene expression-based consensus molecular subtypes (CMS). The results were validated in 323 MSS tumors from TCGA. Novel recurrent high-level amplifications (>= 15 additional copies) with a major impact on gene expression were found for TOX3 (16q) at 1.5% frequency, as well as for CCND2 (12p) and ANXA11 (10q) at 1% frequency, in addition to the well-known targets ERBB2 (17q) and MYC (8q). Focal amplifications with >= 15 or >= 5 additional copies of at least one of these regions were associated with a poor overall survival among patients with stage I-III MSS CRCs (multivariable hazard ratio >= 3.2, p <= 0.01). All highlevel amplifications were focal and had a more consistent relationship with gene expression than lower amplitude and/or broad-range amplifications, suggesting specific targeting during carcinogenesis. Genome-wide, copy number driven gene expression was enriched for pathways characteristic of the CMS2-epithelial/canonical subtype, including DNA repair and cell cycle progression. Furthermore, 50% of upregulated genes in CMS2-epithelial/canonical MSS CRCs were driven by CNAs, an enrichment compared with the other CMS groups, and associated with the stronger correspondence between CNAs and gene expression in malignant epithelial cells than in the cells of the tumor microenvironment (fibroblasts, endothelial cells, leukocytes). In conclusion, we identify novel recurrent amplifications with impact on gene expression in CRC and provide the first evidence that CMS2 may have a stronger copy-number related genetic basis than subtypes more heavily influenced by gene expression signals from the tumor microenvironment.	[Berg, Kaja C. G.; Sveen, Anita; Holand, Maren; Alagaratnam, Sharmini; Berg, Marianne; Danielsen, Stine A.; Lothel, Ragnhild A.] Oslo Univ Hosp, Inst Canc Res, Dept Mol Oncol, POB 4953, NO-0424 Oslo, Norway; [Berg, Kaja C. G.; Sveen, Anita; Holand, Maren; Alagaratnam, Sharmini; Danielsen, Stine A.; Nesbakken, Arild; Lothel, Ragnhild A.] Oslo Univ Hosp, KG Jebsen Colorectal Canc Res Ctr, POB 4953, NO-0424 Oslo, Norway; [Berg, Kaja C. G.; Sveen, Anita; Holand, Maren; Nesbakken, Arild; Lothel, Ragnhild A.] Univ Oslo, Fac Med, Inst Clin Med, POB 4950, NO-0424 Oslo, Norway; [Nesbakken, Arild] Oslo Univ Hosp, Dept Gastrointestinal Surg, POB 4950, NO-0424 Oslo, Norway; [Berg, Marianne; Soreide, Kjetil] Stavanger Univ Hosp, Gastrointestinal Translat Res Unit, Lab Mol Biol, POB 8100, NO-4011 Stavanger, Norway; [Soreide, Kjetil] Stavanger Univ Hosp, Dept Gastrointestinal Surg, POB 8100, NO-4011 Stavanger, Norway; [Soreide, Kjetil] Univ Bergen, Dept Clin Med, POB 7804, NO-5020 Bergen, Norway	University of Oslo; University of Oslo; University of Oslo; University of Oslo; Stavanger University Hospital; Stavanger University Hospital; University of Bergen	Lothel, RA (corresponding author), Oslo Univ Hosp, Inst Canc Res, Dept Mol Oncol, POB 4953, NO-0424 Oslo, Norway.; Lothel, RA (corresponding author), Oslo Univ Hosp, KG Jebsen Colorectal Canc Res Ctr, POB 4953, NO-0424 Oslo, Norway.; Lothel, RA (corresponding author), Univ Oslo, Fac Med, Inst Clin Med, POB 4950, NO-0424 Oslo, Norway.	rlothe@rr-research.no		Sveen, Anita/0000-0001-8219-6251; Lothe, Ragnhild A./0000-0002-1693-1032	Norwegian Cancer Society [6824048-2016, 72190-PR-2006-0442/182759-2016]; Southern and Eastern Norway Regional Health Authority; foundation "Stiftelsen Kristian Gerhard Jebsen"; Research Council of Norway ("Toppforsk" project) [250993]	Norwegian Cancer Society(Norwegian Cancer Society); Southern and Eastern Norway Regional Health Authority; foundation "Stiftelsen Kristian Gerhard Jebsen"; Research Council of Norway ("Toppforsk" project)(Research Council of Norway)	The authors are grateful to Dr Oddmund Nordgard, Dept of Haematology and Oncology, Stavanger University Hospital, for providing the DNA from the Stavanger series. The study was supported by the Norwegian Cancer Society (project number 6824048-2016 to A. Sveen and project numbers 72190-PR-2006-0442/182759-2016 to R.A. Lothe), the Southern and Eastern Norway Regional Health Authority, the foundation "Stiftelsen Kristian Gerhard Jebsen", the Research Council of Norway ("Toppforsk" project number 250993).	Agesen TH, 2012, GUT, V61, P1560, DOI 10.1136/gutjnl-2011-301179; Ahmed D, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.35; Berg KCG, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0691-y; Calon A, 2012, CANCER CELL, V22, P571, DOI 10.1016/j.ccr.2012.08.013; Carter JH, 2017, COLD SPRING HARB MOL, V3, P1; Cha Y, 2018, MOL ONCOL, V12, P993, DOI 10.1002/1878-0261.12194; Crockford A, 2017, ANN ONCOL, V28, P149, DOI 10.1093/annonc/mdw612; Danielsen HE, 2016, NAT REV CLIN ONCOL, V13, P291, DOI 10.1038/nrclinonc.2015.208; Dittmer S, 2011, J CELL SCI, V124, P252, DOI 10.1242/jcs.068759; Domingo E, 2016, LANCET GASTROENTEROL, V1, P207, DOI 10.1016/S2468-1253(16)30014-0; Duncan R, 2008, BRIT J CANCER, V98, P426, DOI 10.1038/sj.bjc.6604128; Fehrmann RSN, 2015, NAT GENET, V47, P115, DOI 10.1038/ng.3173; Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967; Alonso MH, 2017, BRIT J CANCER, V117, P421, DOI 10.1038/bjc.2017.208; Hua KL, 2018, MED SCI MONITOR, V24, P149, DOI 10.12659/MSM.905372; HUGO gene Nomenclature Committee, MULT CHECK; Lee AJX, 2011, CANCER RES, V71, P1858, DOI 10.1158/0008-5472.CAN-10-3604; Mi HY, 2017, NUCLEIC ACIDS RES, V45, pD183, DOI 10.1093/nar/gkw1138; Nilsen G, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-591; Sartore-Bianchi A, 2016, LANCET ONCOL, V17, P738, DOI 10.1016/S1470-2045(16)00150-9; Shan JX, 2013, CANCER RES, V73, P2840, DOI 10.1158/0008-5472.CAN-12-4313; Sveen A, 2018, CLIN CANCER RES, V24, P794, DOI 10.1158/1078-0432.CCR-17-1234; Sveen A, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006225; Valtorta E, 2013, INT J CANCER, V133, P1259, DOI 10.1002/ijc.28106; Van Loo P, 2010, P NATL ACAD SCI USA, V107, P16910, DOI 10.1073/pnas.1009843107; Wang H, 2016, ONCOGENE, V35, P2011, DOI 10.1038/onc.2015.304; Wang JS, 2014, CLIN CHIM ACTA, V431, P164, DOI 10.1016/j.cca.2014.01.031	27	16	16	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	2019	38	33					6109	6122		10.1038/s41388-019-0868-5	http://dx.doi.org/10.1038/s41388-019-0868-5			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IR6TP	31308487	Green Published, hybrid			2022-12-17	WOS:000481572400003
J	Delespaul, L; Merle, C; Lesluyes, T; Lagarde, P; Le Guellec, S; Perot, G; Baud, J; Carlotti, M; Danet, C; Fevre, M; Rousseau, B; Durrieu, S; Teichmann, M; Coindre, JM; Lartigue, L; Chibon, F				Delespaul, Lucile; Merle, Candice; Lesluyes, Tom; Lagarde, Pauline; Le Guellec, Sophie; Perot, Gaelle; Baud, Jessica; Carlotti, Martina; Danet, Coralie; Fevre, Murielle; Rousseau, Benoit; Durrieu, Stephanie; Teichmann, Martin; Coindre, Jean-Michel; Lartigue, Lydia; Chibon, Frederic			Fusion-mediated chromosomal instability promotes aneuploidy patterns that resemble human tumors	ONCOGENE			English	Article							MARROW-DERIVED CELLS; SOFT-TISSUE SARCOMAS; PURKINJE NEURONS; LARGE SERIES; CANCER; BONE; DNA; METASTASIS; MUSCLE; CONDENSATION	Oncogenesis is considered to result from chromosomal instability, in addition to oncogene and tumor-suppressor alterations. Intermediate to aneuploidy and chromosomal instability, genome doubling is a frequent event in tumor development but the mechanisms driving tetraploidization and its impact remain unexplored. Cell fusion, one of the pathways to tetraploidy, is a physiological process involved in mesenchymal cell differentiation. Besides simple genome doubling, cell fusion results in the merging of two different genomes that can be destabilized upon proliferation. By testing whether cell fusion is involved in mesenchymal oncogenesis, we provide evidence that it induces genomic instability and mediates tumor initiation. After a latency period, the tumor emerges with the cells most suited for its development. Furthermore, hybrid tumor genomes were stabilized after this selection process and were very close to those of human pleomorphic mesenchymal tumors. Thus genome restructuring triggered by cell fusion may account for the chromosomal instability involved in oncogenesis.	[Delespaul, Lucile; Merle, Candice; Lesluyes, Tom; Le Guellec, Sophie; Perot, Gaelle; Chibon, Frederic] CRCT, INSERM U1037, F-31037 Toulouse, France; [Delespaul, Lucile; Lesluyes, Tom; Lagarde, Pauline; Baud, Jessica; Lartigue, Lydia] INSERM U1218, 229 Cours Argonne, F-33076 Bordeaux, France; [Delespaul, Lucile; Lesluyes, Tom; Coindre, Jean-Michel; Lartigue, Lydia] Univ Bordeaux, 146 Rue Leo Saignat, F-33000 Bordeaux, France; [Merle, Candice] Univ Toulouse, 3 Paul Sabatier,118 Route Narbonne, F-31062 Toulouse 9, France; [Merle, Candice; Lesluyes, Tom] IUCT Oncopole, Inst Claudius Regaud, Toulouse, France; [Lagarde, Pauline; Baud, Jessica; Coindre, Jean-Michel] Bergonie Inst, Dept Biopathol, 229 Cours Argonne, F-33076 Bordeaux, France; [Le Guellec, Sophie; Perot, Gaelle; Chibon, Frederic] IUCT Oncopole, Inst Claudius Regaud, Dept Pathol, Toulouse, France; [Carlotti, Martina] INSERM U1053, 146 Rue Leo Saignat, F-33000 Bordeaux, France; [Danet, Coralie; Fevre, Murielle; Rousseau, Benoit] Bordeaux Univ, Anim Facil A2, 146 Rue Leo Saignat, F-33000 Bordeaux, France; [Durrieu, Stephanie; Teichmann, Martin] ARNA Lab, CNRS UMR 5320, INSERM U1212, F-33000 Bordeaux, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; UDICE-French Research Universities; Universite de Bordeaux; UNICANCER; Institut Claudius Regaud; UNICANCER; Institut Bergonie; UNICANCER; Institut Claudius Regaud; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux	Chibon, F (corresponding author), CRCT, INSERM U1037, F-31037 Toulouse, France.; Chibon, F (corresponding author), IUCT Oncopole, Inst Claudius Regaud, Dept Pathol, Toulouse, France.	frederic.chibon@inserm.fr	Pérot, Gaëlle/W-8038-2019; Lesluyes, Tom/AAB-6229-2019; Delespaul, Lucile/AAZ-1073-2021; Lesluyes, Tom/GSD-4621-2022; Teichmann, Martin/M-7407-2014	Lesluyes, Tom/0000-0003-2251-5884; Lesluyes, Tom/0000-0003-2251-5884; Delespaul, Lucile/0000-0002-9509-6425; chibon, Frederic/0000-0002-6548-2181; Teichmann, Martin/0000-0002-5257-0510	Fondation ARC pour la Recherche Contre le Cancer; Fondation Recherche Medicale	Fondation ARC pour la Recherche Contre le Cancer; Fondation Recherche Medicale	This work was supported by the Fondation ARC pour la Recherche Contre le Cancer (to T.L.) and the Fondation Recherche Medicale (to L.L. and L.D.). We acknowledge personnel of CREFRE US006 for technical assistance.	Aichel O., 1911, VORTRAGE AUFSATZE EN, P92; Alvarez-Dolado M, 2003, NATURE, V425, P968, DOI 10.1038/nature02069; Bakhoum SF, 2018, NATURE, V553, P467, DOI 10.1038/nature25432; Bielski CM, 2018, NAT GENET, V50, P1189, DOI 10.1038/s41588-018-0165-1; Camargo FD, 2003, NAT MED, V9, P1520, DOI 10.1038/nm963; Chakraborty A, 2004, BONE MARROW TRANSPL, V34, P183, DOI 10.1038/sj.bmt.1704547; Chen EH, 2005, SCIENCE, V308, P369, DOI 10.1126/science.1104799; Chibon F, 2000, CANCER RES, V60, P6339; Clawson GA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184451; Clawson GA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134320; Clawson GA, 2013, SCIENCE, V342, P699, DOI 10.1126/science.1244270; Clawson GA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041052; Commo F, 2016, BIOINFORMATICS, V32, P1402, DOI 10.1093/bioinformatics/btv718; Davoli T, 2017, SCIENCE, V355, DOI 10.1126/science.aaf8399; Davoli T, 2013, CELL, V155, P948, DOI 10.1016/j.cell.2013.10.011; Davoli T, 2011, ANNU REV CELL DEV BI, V27, P585, DOI 10.1146/annurev-cellbio-092910-154234; Davoli T, 2010, CELL, V141, P81, DOI 10.1016/j.cell.2010.01.031; Ding JX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041942; Dittmar T, 2015, INT J MOL SCI, V16, P30362, DOI 10.3390/ijms161226240; Dodd RD, 2010, DIS MODEL MECH, V3, P557, DOI 10.1242/dmm.005223; Duelli D, 2003, CANCER CELL, V3, P445, DOI 10.1016/S1535-6108(03)00114-4; Duelli D, 2007, NAT REV CANCER, V7, P968, DOI 10.1038/nrc2272; Duelli DM, 2007, CURR BIOL, V17, P431, DOI 10.1016/j.cub.2007.01.049; Durrieu-Gaillard S, 2018, CELL CYCLE, V17, P605, DOI 10.1080/15384101.2017.1405881; Elinav E, 2013, NAT REV CANCER, V13, P759, DOI 10.1038/nrc3611; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; Fletcher CD, 2012, WHO CLASSIFICATION T; Fujiwara T, 2005, NATURE, V437, P1043, DOI 10.1038/nature04217; Ganem NJ, 2007, CURR OPIN GENET DEV, V17, P157, DOI 10.1016/j.gde.2007.02.011; Gast CE, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aat7828; Gibault L, 2011, J PATHOL, V223, P64, DOI 10.1002/path.2787; Giroux V, 2017, NAT REV CANCER, V17, P594, DOI 10.1038/nrc.2017.68; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Johansson CB, 2008, NAT CELL BIOL, V10, P575, DOI 10.1038/ncb1720; JOHNSON RT, 1970, NATURE, V226, P717, DOI 10.1038/226717a0; Kemeny LV, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17060826; Kirsch DG, 2007, NAT MED, V13, P992, DOI 10.1038/nm1602; KOVACS G, 1985, LANCET, V1, P350; KOVACS G, 1985, INT J CANCER, V36, P637, DOI 10.1002/ijc.2910360602; Kurgyis Z, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17060980; Kwon M, 2008, GENE DEV, V22, P2189, DOI 10.1101/gad.1700908; LaBerge GS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0168581; Lazar AJ, 2017, CELL, V171, P950, DOI 10.1016/j.cell.2017.10.014; Lazebnik Y, 2014, CELL CYCLE, V13, P2323, DOI 10.4161/cc.29704; Lazova R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066731; Li GH, 2013, STEM CELLS, V31, P2304, DOI 10.1002/stem.1491; Lu X, 2009, P NATL ACAD SCI USA, V106, P9385, DOI 10.1073/pnas.0900108106; Luo F, 2016, ONCOTARGET, V7, P30924, DOI 10.18632/oncotarget.9045; Margolis RL, 2005, CANCER CELL, V8, P353, DOI 10.1016/j.ccr.2005.10.017; Martincorena I, 2018, SCIENCE, V362, P911, DOI 10.1126/science.aau3879; Martincorena I, 2015, SCIENCE, V348, P880, DOI 10.1126/science.aaa6806; MUKHOPADHYAY KD, 2011, PLOS ONE, V0006; Nygren JM, 2008, NAT CELL BIOL, V10, P584, DOI 10.1038/ncb1721; Ogle BM, 2005, NAT REV MOL CELL BIO, V6, P567, DOI 10.1038/nrm1678; Pawelek JM, 2005, LANCET ONCOL, V6, P988, DOI 10.1016/S1470-2045(05)70466-6; Pawelek JM, 2008, NAT REV CANCER, V8, P377, DOI 10.1038/nrc2371; Perot G, 2010, AM J PATHOL, V177, P2080, DOI 10.2353/ajpath.2010.100104; Perot G, 2009, CANCER RES, V69, P2269, DOI 10.1158/0008-5472.CAN-08-1443; Powell AE, 2011, CANCER RES, V71, P1497, DOI 10.1158/0008-5472.CAN-10-3223; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; Rizvi AZ, 2006, P NATL ACAD SCI USA, V103, P6321, DOI 10.1073/pnas.0508593103; Santaguida S, 2015, NAT REV MOL CELL BIO, V16, P473, DOI 10.1038/nrm4025; Targa A, 2018, CURR OPIN CELL BIOL, V52, P136, DOI 10.1016/j.ceb.2018.03.007; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; Turajlic S, 2018, CELL, V173, P581, DOI 10.1016/j.cell.2018.03.057; Van Mater D, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.123687; Vignery A, 2005, J EXP MED, V202, P337, DOI 10.1084/jem.20051123; Vitale I, 2011, CELL DEATH DIFFER, V18, P1403, DOI 10.1038/cdd.2010.145; Vitale I, 2011, NAT REV MOL CELL BIO, V12, P384, DOI 10.1038/nrm3115; Walsh S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027500; Weimann JM, 2003, NAT CELL BIOL, V5, P959, DOI 10.1038/ncb1053; Yano T, 2010, INT J MOL MED, V25, P153, DOI 10.3892/ijmm_00000325; Zack TI, 2013, NAT GENET, V45, P1134, DOI 10.1038/ng.2760; Zhou XF, 2015, AM J PATHOL, V185, P2049, DOI 10.1016/j.ajpath.2015.03.014	75	16	16	0	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	2019	38	33					6083	6094		10.1038/s41388-019-0859-6	http://dx.doi.org/10.1038/s41388-019-0859-6			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IR6TP	31270395				2022-12-17	WOS:000481572400001
J	Saigi, M; Alburquerque-Bejar, JJ; Sanchez-Cespedes, M				Saigi, Maria; Alburquerque-Bejar, Juan J.; Sanchez-Cespedes, Montse			Determinants of immunological evasion and immunocheckpoint inhibition response in non-small cell lung cancer: the genetic front	ONCOGENE			English	Review							TUMOR MUTATIONAL BURDEN; PD-1 BLOCKADE; IFN-GAMMA; CHECKPOINT INHIBITORS; ACQUIRED-RESISTANCE; OPEN-LABEL; NIVOLUMAB; PEMBROLIZUMAB; MECHANISM; IMMUNITY	The incorporation into clinical practice of immune-checkpoint inhibitors (ICIs), such as those targeting the cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and the programmed cell death 1 (PD-1) and its ligand (PD-L1), has represented a major breakthrough in non-small cell lung cancer (NSCLC) treatment, especially in cases where the cancer has no druggable genetic alterations. Despite becoming the standard of care in certain clinical settings, either alone or in combination with chemotherapy, a proportion of patients do not respond while others actually progress during treatment. Therefore, there is a clinical need to identify accurate predictive biomarkers and to develop novel therapeutic strategies based on ICIs. Although they have limitations, the current markers evaluated to select which patients will undergo ICI treatment are the levels of PD-Ll and the tumor mutational burden. In this paper we describe what is currently known about the dynamic interaction between the cancer cell and the immune system during carcinogenesis, with a particular focus on the description of the functions and gene alterations that preclude the host immunoresponse in NSCLC. We emphasize the deleterious gene alterations in components of the major histocompatibility complex (HLA-I or B2M) and of the response to IFN gamma (such as JAK2) which are mutually exclusive and can affect up to one fifth of the NSCLCs. The participation of other gene alterations, such as those of common oncogenes and tumor suppressors, and of the epigenetic alterations will also be discussed, in detail. Finally, we discuss the potential use of the tumor's genetic profile to predict sensitivity to ICIs.	[Saigi, Maria; Alburquerque-Bejar, Juan J.; Sanchez-Cespedes, Montse] Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Program PEBC, Genes & Canc Grp, Barcelona, Spain; [Saigi, Maria] Catalan Inst Oncol ICO, Dept Med Oncol, Avda Gran Via 199-203, Barcelona 08908, Spain; [Sanchez-Cespedes, Montse] Josep Carreras Leukemia Res Inst, Canc Genom Grp, IJC Bldg, Barcelona 08916, Spain	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Catalan Institute of Oncology; Institut de Recerca Contra la Leucemia Josep Carreras (IJC)	Sanchez-Cespedes, M (corresponding author), Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Program PEBC, Genes & Canc Grp, Barcelona, Spain.; Sanchez-Cespedes, M (corresponding author), Josep Carreras Leukemia Res Inst, Canc Genom Grp, IJC Bldg, Barcelona 08916, Spain.	mscespedes@carrerasresearch.org	Sanchez-Cespedes, Montse/H-8485-2012; Alburquerque-Bejar, Juan/AAA-7666-2020	Sanchez-Cespedes, Montse/0000-0002-6045-5627; 	MINECO [SAF2014-54571-R]; Fundacion Cientifica Asociacion Espanola Contra el Cancer [GCB14142170MONT]; CERCA program;  [CM17/00180]	MINECO(Spanish Government); Fundacion Cientifica Asociacion Espanola Contra el Cancer; CERCA program; 	This work was supported by Spanish grant SAF2014-54571-R (to MSC) from the MINECO and a grant from the Fundacion Cientifica Asociacion Espanola Contra el CancerGCB14142170MONT. Saigi is supported by a Rio Hortega (CM17/00180) contract. We also thank the CERCA program for support.	Adeegbe DO, 2017, CANCER DISCOV, V7, P852, DOI 10.1158/2159-8290.CD-16-1020; Antonia SJ, 2018, NEW ENGL J MED, V379, P2342, DOI 10.1056/NEJMoa1809697; Ayers M, 2017, J CLIN INVEST, V127, P2930, DOI 10.1172/JCI91190; Best SA, 2018, CELL METAB, V27, P935, DOI 10.1016/j.cmet.2018.02.006; Brahmer J, 2015, NEW ENGL J MED, V373, P123, DOI 10.1056/NEJMoa1504627; Brambilla E, 2016, J CLIN ONCOL, V34, P1223, DOI 10.1200/JCO.2015.63.0970; BURNET M, 1957, BMJ-BRIT MED J, V1, P841, DOI 10.1136/bmj.1.5023.841; Canadas I, 2018, NAT MED, V24, P1143, DOI 10.1038/s41591-018-0116-5; Carbone DP, 2017, NEW ENGL J MED, V376, P2415, DOI 10.1056/NEJMoa1613493; Champiat S, 2017, CLIN CANCER RES, V23, P1920, DOI 10.1158/1078-0432.CCR-16-1741; Cristescu R, 2018, SCIENCE, V362, P197, DOI 10.1126/science.aar3593; Donnem T, 2015, CLIN CANCER RES, V21, P2635, DOI 10.1158/1078-0432.CCR-14-1905; Dunn GP, 2006, NAT REV IMMUNOL, V6, P836, DOI 10.1038/nri1961; Dunn GP, 2004, ANNU REV IMMUNOL, V22, P329, DOI 10.1146/annurev.immunol.22.012703.104803; Duruisseaux M, 2018, LANCET RESP MED, V6, P771, DOI 10.1016/S2213-2600(18)30284-4; Fabrizio DA, 2018, ANN ONCOL, V29, P16; Frampton GM, 2015, CANCER DISCOV, V5, P850, DOI 10.1158/2159-8290.CD-15-0285; Gainor JF, 2016, CLIN CANCER RES, V22, P4585, DOI 10.1158/1078-0432.CCR-15-3101; Galon J, 2019, NAT REV DRUG DISCOV, V18, P197, DOI 10.1038/s41573-018-0007-y; Gandhi L, 2018, NEW ENGL J MED, V378, P2078, DOI 10.1056/NEJMoa1801005; Gao JJ, 2016, CELL, V167, P397, DOI 10.1016/j.cell.2016.08.069; Gettinger S, 2017, CANCER DISCOV, V7, P1420, DOI 10.1158/2159-8290.CD-17-0593; Goodman AM, 2018, JAMA ONCOL, V4, P1237, DOI 10.1001/jamaoncol.2018.1701; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; He YY, 2018, ONCOTARGETS THER, V11, P7005, DOI 10.2147/OTT.S170385; Hellmann MD, 2018, NEW ENGL J MED, V378, P2093, DOI 10.1056/NEJMoa1801946; Hellmann MD, 2018, CANCER CELL, V33, P843, DOI 10.1016/j.ccell.2018.03.018; Hellmann MD, 2017, LANCET ONCOL, V18, P31, DOI [10.1016/S1470-2045(16)30624-6, 10.1016/s1470-2045(16)30624-6]; Herbst RS, 2016, LANCET, V387, P1540, DOI 10.1016/S0140-6736(15)01281-7; IASLC, 2017, J THORAC ONCOL; Ihara S, 2012, CANCER RES, V72, P2990, DOI 10.1158/0008-5472.CAN-11-4062; Ikeda H, 2002, CYTOKINE GROWTH F R, V13, P95, DOI 10.1016/S1359-6101(01)00038-7; Ikeda S, 2016, J THORAC ONCOL, V11, P62, DOI 10.1016/j.jtho.2015.09.010; Johnston CJC, 2016, CELL IMMUNOL, V299, P14, DOI 10.1016/j.cellimm.2015.10.006; Jordan EJ, 2017, CANCER DISCOV, V7, P596, DOI 10.1158/2159-8290.CD-16-1337; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Kataoka K, 2016, NATURE, V534, P402, DOI 10.1038/nature18294; Kato S, 2017, CLIN CANCER RES, V23, P4242, DOI 10.1158/1078-0432.CCR-16-3133; Kerdidani D, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09370-z; Kitapma S, 2019, CANCER DISCOV, V9, P34, DOI 10.1158/2159-8290.CD-18-0689; Koyama S, 2016, CANCER RES, V76, P999, DOI 10.1158/0008-5472.CAN-15-1439; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; Lee CK, 2017, J THORAC ONCOL, V12, P403, DOI 10.1016/j.jtho.2016.10.007; Motzer RJ, 2015, NEW ENGL J MED, V373, P1803, DOI 10.1056/NEJMoa1510665; O'Donnell JS, 2019, NAT REV CLIN ONCOL, V16, P151, DOI 10.1038/s41571-018-0142-8; Palomero T, 2014, NAT GENET, V46, P166, DOI 10.1038/ng.2873; Pan D, 2018, SCIENCE, V359, P770, DOI 10.1126/science.aao1710; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Paz-Ares L, 2018, NEW ENGL J MED, V379, P2040, DOI 10.1056/NEJMoa1810865; Peng WY, 2016, CANCER DISCOV, V6, P202, DOI 10.1158/2159-8290.CD-15-0283; Pereira C, 2017, CLIN CANCER RES, V23, P3203, DOI 10.1158/1078-0432.CCR-16-1946; Planchard D, 2018, ANN ONCOL, V29, P192, DOI 10.1093/annonc/mdy275; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Ribas A, 2015, NEW ENGL J MED, V373, P1490, DOI 10.1056/NEJMp1510079; Rittmeyer A, 2017, LANCET, V389, P255, DOI 10.1016/S0140-6736(16)32517-X; Rizvi H, 2018, J CLIN ONCOL, V36, P633, DOI 10.1200/JCO.2017.75.3384; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Roach C, 2016, APPL IMMUNOHISTO M M, V24, P392, DOI 10.1097/PAI.0000000000000408; Robert C, 2015, NEW ENGL J MED, V372, P2521, DOI 10.1056/NEJMoa1503093; Romero OA, 2014, ONCOGENE, V33, P2681, DOI 10.1038/onc.2013.227; Sabari JK, 2018, ANN ONCOL, V29, P2085, DOI 10.1093/annonc/mdy334; Saigi M, 2018, CLIN CANCER RES, V24, P4579, DOI 10.1158/1078-0432.CCR-18-0267; Samstein RM, 2019, NAT GENET, V51, P202, DOI 10.1038/s41588-018-0312-8; Sanchez-Cespedes M, 2007, ONCOGENE, V26, P7825, DOI 10.1038/sj.onc.1210594; Sanchez-Cespedes M, 2002, CANCER RES, V62, P3659; Shin DS, 2017, CANCER DISCOV, V7, P188, DOI 10.1158/2159-8290.CD-16-1223; Shukla SA, 2015, NAT BIOTECHNOL, V33, P1152, DOI 10.1038/nbt.3344; Skoulidis F, 2018, CANCER DISCOV, V8, P822, DOI 10.1158/2159-8290.CD-18-0099; Skoulidis F, 2015, CANCER DISCOV, V5, P860, DOI 10.1158/2159-8290.CD-14-1236; Socinski MA, 2018, NEW ENGL J MED, V378, P2288, DOI 10.1056/NEJMoa1716948; Springer S, 2015, CURR OPIN IMMUNOL, V34, P83, DOI 10.1016/j.coi.2015.02.009; Swanton C, 2015, CANCER DISCOV, V5, P704, DOI 10.1158/2159-8290.CD-15-0344; Topalian SL, 2016, NAT REV CANCER, V16, P275, DOI 10.1038/nrc.2016.36; Vendetti FP, 2015, ONCOTARGET, V6, P56, DOI 10.18632/oncotarget.2695; Voron T, 2015, J EXP MED, V212, P139, DOI 10.1084/jem.20140559; Wang SX, 2018, ONCOGENE, V37, P3924, DOI 10.1038/s41388-018-0245-9; Wei SC, 2018, CANCER DISCOV, V8, P1069, DOI 10.1158/2159-8290.CD-18-0367; Yarchoan M, 2017, NEW ENGL J MED, V377, P2500, DOI 10.1056/NEJMc1713444; Zaretsky JM, 2016, NEW ENGL J MED, V375, P819, DOI 10.1056/NEJMoa1604958; Zingg D, 2017, CELL REP, V20, P854, DOI 10.1016/j.celrep.2017.07.007	81	16	16	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 1	2019	38	31					5921	5932		10.1038/s41388-019-0855-x	http://dx.doi.org/10.1038/s41388-019-0855-x			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IT3GE	31253869				2022-12-17	WOS:000482740000001
J	Maric, G; Annis, MG; MacDonald, PA; Russo, C; Perkins, D; Siwak, DR; Mills, GB; Siegel, PM				Maric, Gordana; Annis, Matthew G.; MacDonald, Patricia A.; Russo, Caterina; Perkins, Dru; Siwak, Doris R.; Mills, Gordon B.; Siegel, Peter M.			GPNMB augments Wnt-1 mediated breast tumor initiation and growth by enhancing PI3K/AKT/mTOR pathway signaling and beta-catenin activity	ONCOGENE			English	Article							GLYCOPROTEIN NONMETASTATIC B; WNT/BETA-CATENIN; TRANSGENIC MICE; MAMMARY-TUMORS; BASAL-LIKE; GLEMBATUMUMAB VEDOTIN; THERAPEUTIC TARGET; CANCER; EXPRESSION; PROMOTES	Glycoprotein Nmb (GPNMB) is overexpressed in triple-negative and basal-like breast cancers and its expression is predictive of poor prognosis within this aggressive breast cancer subtype. GPNMB promotes breast cancer growth, invasion, and metastasis; however, its role in mammary tumor initiation remains unknown. To address this question, we overexpressed GPNMB in the mammary epithelium to generate MMTV/GPNMB transgenic mice and crossed these animals to the MMTV/Wnt-1 mouse model, which is known to recapitulate features of human basal breast cancers. We show that GPNMB alone does not display oncogenic properties; however, its expression dramatically accelerates tumor onset in MMTV/Wnt-1 mice. MMTV/Wnt-1 x MMTV/GPNMB bigenic mice also exhibit a significant increase in the growth rate of established primary tumors, which is attributable to increased proliferation and decreased apoptosis. To elucidate molecular mechanisms underpinning the tumor-promoting effects of GPNMB in this context, we interrogated activated pathways in tumors derived from the MMTV/Wnt-1 and MMTV/Wnt-1 x MMTV/GPNMB mice using RPPA analysis. These data revealed that MMTV/Wnt-1 x MMTV/GPNMB bigenic tumors exhibit a pro-growth signature characterized by elevated PI3K/AKT/mTOR signaling and increased beta-catenin activity. Furthermore, we extended these observations to an independent Wnt-1 expressing model of aggressive breast cancer, and confirmed that GPNMB enhances canonical Wnt pathway activation, as evidenced by increased beta-catenin transcriptional activity, in breast cancer cells and tumors co-expressing Wnt-1 and GPNMB. GPNMB-dependent engagement of beta-catenin occurred, in part, through AKT activation. Taken together, these data ascribe a novel, pro-growth role for GPNMB in Wnt-1 expressing basal breast cancers.	[Maric, Gordana; Annis, Matthew G.; MacDonald, Patricia A.; Russo, Caterina; Perkins, Dru; Siegel, Peter M.] McGill Univ, Goodman Canc Res Ctr, Montreal, PQ, Canada; [Maric, Gordana; Annis, Matthew G.; MacDonald, Patricia A.; Russo, Caterina; Siegel, Peter M.] McGill Univ, Dept Med, Montreal, PQ, Canada; [Siwak, Doris R.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA; [Mills, Gordon B.] Oregon Hlth & Sci Univ, Knight Canc Inst, Dept Cell Dev & Canc Biol, Portland, OR 97201 USA; [Siegel, Peter M.] McGill Univ, Dept Biochem, Montreal, PQ, Canada	McGill University; McGill University; University of Texas System; UTMD Anderson Cancer Center; Oregon Health & Science University; McGill University	Siegel, PM (corresponding author), McGill Univ, Goodman Canc Res Ctr, Montreal, PQ, Canada.; Siegel, PM (corresponding author), McGill Univ, Dept Med, Montreal, PQ, Canada.; Siegel, PM (corresponding author), McGill Univ, Dept Biochem, Montreal, PQ, Canada.	peter.siegel@mcgill.ca		Mills, Gordon/0000-0002-0144-9614; Annis, Matthew/0000-0002-8776-004X	Canadian Institutes for Health Research (CIHR); CIHR [MOP-119401, PJT-153327]	Canadian Institutes for Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); CIHR(Canadian Institutes of Health Research (CIHR))	We acknowledge the Goodman Cancer Research Centre (GCRC) transgenic facility (McGill University) for generation of the MMTV/GPNMB mice, the GCRC histology core facility (McGill University) for routine histological services and Zhifeng Dong for some Immunohistochemical staining. We thank members of the Siegel laboratory for thoughtful discussions and critical reading of the manuscript. GM acknowledges studentship support from the Canadian Institutes for Health Research (CIHR). PMS is currently a McGill University William Dawson Scholar. This research was supported solely by grants from the CIHR (MOP-119401; PJT-153327).	Bankfalvi A, 2004, MODERN PATHOL, V17, P1051, DOI 10.1038/modpathol.3800082; Bao G, 2016, EXP BIOL MED, V241, P1968, DOI 10.1177/1535370216654224; Bianchini G, 2016, NAT REV CLIN ONCOL, V13, P674, DOI 10.1038/nrclinonc.2016.66; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Bocker W, 2002, LAB INVEST, V82, P737, DOI 10.1097/01.LAB.0000017371.72714.C5; Cadigan KM, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007906; Chen C, 2018, CANCER RES, V78, P6424, DOI 10.1158/0008-5472.CAN-18-0599; Conacci-Sorrell M, 2003, J CELL BIOL, V163, P847, DOI 10.1083/jcb.200308162; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Davies BR, 2012, MOL CANCER THER, V11, P873, DOI 10.1158/1535-7163.MCT-11-0824-T; Ding VW, 2000, J BIOL CHEM, V275, P32475, DOI 10.1074/jbc.M005342200; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; Failor KL, 2007, MOL ENDOCRINOL, V21, P2403, DOI 10.1210/me.2007-0143; Geyer FC, 2011, MODERN PATHOL, V24, P209, DOI 10.1038/modpathol.2010.205; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Howe LR, 2004, CANCER BIOL THER, V3, P36, DOI 10.4161/cbt.3.1.561; Hu TH, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-236; Huang S, 2005, GENOME BIOL, V6, P1; Huang SX, 2008, NEOPLASIA, V10, P118, DOI 10.1593/neo.07637; Iadevaia S, 2010, CANCER RES, V70, P6704, DOI 10.1158/0008-5472.CAN-10-0460; Jin R, 2018, ONCOL REP, V39, P3034, DOI 10.3892/or.2018.6346; Kanematsu M, 2015, CANCER MED-US, V4, P1344, DOI 10.1002/cam4.480; Kapoun AM, 1997, ONCOGENE, V14, P2985, DOI 10.1038/sj.onc.1201146; Khramtsov AI, 2010, AM J PATHOL, V176, P2911, DOI 10.2353/ajpath.2010.091125; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Korkaya H, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000121; KWAN H, 1992, MOL CELL BIOL, V12, P147, DOI 10.1128/MCB.12.1.147; Li SG, 2014, TUMOR BIOL, V35, P7693, DOI 10.1007/s13277-014-1975-0; Li Y, 2000, ONCOGENE, V19, P1002, DOI 10.1038/sj.onc.1203273; Li Y, 2003, P NATL ACAD SCI USA, V100, P15853, DOI 10.1073/pnas.2136825100; Li Y, 2001, BMC Mol Biol, V2, P2, DOI 10.1186/1471-2199-2-2; Lim E, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2560; Lin AF, 2016, NAT CELL BIOL, V18, P213, DOI 10.1038/ncb3295; Lin J, 2013, CLIN CANCER RES, V19, P1760, DOI 10.1158/1078-0432.CCR-12-3072; Lopez-Knowles E, 2010, INT J CANCER, V126, P1121, DOI 10.1002/ijc.24831; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Maric G, 2015, ONCOGENE, V34, P5494, DOI 10.1038/onc.2015.8; Maric G, 2013, ONCOTARGETS THER, V6, P839, DOI 10.2147/OTT.S44906; Marusyk A, 2012, NAT REV CANCER, V12, P323, DOI 10.1038/nrc3261; Maubant S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122333; Mulholland DJ, 2006, ONCOGENE, V25, P329, DOI 10.1038/sj.onc.1209020; Musgrove EA, 2004, BREAST CANCER RES, V6, P65, DOI 10.1186/bcr737; Nagahara Y, 2017, J NEUROSCI RES, V95, P1647, DOI 10.1002/jnr.23999; Nieto AI, 2003, COMPARATIVE MED, V53, P433; Northey JJ, 2008, MOL CELL BIOL, V28, P3162, DOI 10.1128/MCB.01734-07; Nusse R, 2017, CELL, V169, P985, DOI 10.1016/j.cell.2017.05.016; Okita Y, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aak9397; Ono Y, 2016, BIOCHEM BIOPH RES CO, V481, P7, DOI 10.1016/j.bbrc.2016.11.034; Perry JM, 2011, GENE DEV, V25, P1928, DOI 10.1101/gad.17421911; Pfefferle AD, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-11-r125; Podsypanina K, 2004, BMC MED, V2, DOI 10.1186/1741-7015-2-24; Prat A, 2013, ONCOLOGIST, V18, P123, DOI 10.1634/theoncologist.2012-0397; Prat A, 2011, MOL ONCOL, V5, P5, DOI 10.1016/j.molonc.2010.11.003; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Robles AI, 2008, CHEM-BIOL INTERACT, V171, P159, DOI 10.1016/j.cbi.2007.01.014; Rose AAN, 2007, MOL CANCER RES, V5, P1001, DOI 10.1158/1541-7786.MCR-07-0119; Rose AAN, 2017, PHARMACOL THERAPEUT, V179, P127, DOI 10.1016/j.pharmthera.2017.05.010; Rose AAN, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012093; Rose AAN, 2010, CLIN CANCER RES, V16, P2147, DOI 10.1158/1078-0432.CCR-09-1611; Schroeder JA, 2000, ONCOGENE, V19, P3193, DOI 10.1038/sj.onc.1203652; Schroeder JA, 2002, J BIOL CHEM, V277, P22692, DOI 10.1074/jbc.M201975200; SHACKLEFORD GM, 1993, P NATL ACAD SCI USA, V90, P740, DOI 10.1073/pnas.90.2.740; Sharma P, 2016, ONCOLOGIST, V21, P1050, DOI 10.1634/theoncologist.2016-0067; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Taelman VF, 2010, CELL, V143, P1136, DOI 10.1016/j.cell.2010.11.034; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Vargo-Gogola T, 2007, NAT REV CANCER, V7, P659, DOI 10.1038/nrc2193; Wakefield LM, 2003, COMPARATIVE MED, V53, P424; Watanabe K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092317; Xu JH, 2016, MOL CARCINOGEN, V55, P431, DOI 10.1002/mc.22292; Yardley DA, 2015, J CLIN ONCOL, V33, P1609, DOI 10.1200/JCO.2014.56.2959; Yu B, 2016, J CELL BIOCHEM, V117, P1511, DOI 10.1002/jcb.25394; Yuan HD, 1999, J BIOL CHEM, V274, P30419, DOI 10.1074/jbc.274.43.30419; Zhang YX, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317699119	75	16	16	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 27	2019	38	26					5294	5307		10.1038/s41388-019-0793-7	http://dx.doi.org/10.1038/s41388-019-0793-7			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IF4AX	30914799				2022-12-17	WOS:000473025300013
J	Murugan, AK; Liu, RY; Xing, MZ				Murugan, Avaniyapuram Kannan; Liu, Rengyun; Xing, Mingzhao			Identification and characterization of two novel oncogenic mTOR mutations	ONCOGENE			English	Article							SOMATIC MUTATIONS; MAMMALIAN TARGET; GENETIC ALTERATIONS; POINT MUTATIONS; THYROID-CANCER; PATHWAY; ACTIVATION; KINASE; RAPAMYCIN; CONFER	Mammalian target of rapamycin (mTOR) signaling is often aberrantly activated, particularly when genetically altered, in human cancers. mTOR inhibitors targeting the activated mTOR signaling are highly promising anti-cancer drugs. Knowing the activating genetic change in mTOR can help guide the use of mTOR inhibitors for cancer treatment. This study was conducted to identify and characterize novel oncogenic mTOR mutations that can potentially be therapeutic targets in human cancer. We sequenced 30 exons of the mTOR gene in 12 thyroid cancer cell lines, 3 melanoma cell lines, 20 anaplastic thyroid cancer (ATC) tumors, and 23 melanoma tumors and functionally characterized the identified novel mTOR mutations in vitro and in vivo. We identified a novel point mutation A1256G in ATC cell line and G7076A in melanoma tumor in exon 9 and exon 51 of the mTOR gene, respectively. Over-expression of the corresponding mTOR mutants H419R and G2359E created through induced mutagenesis showed markedly elevated protein kinase activities associated with the activation of mTOR/p70S6K signaling in HEK293T cells. Stable expression of the two mTOR mutants in NIH3T3 cells strongly activated the mTOR/p70S6K signaling pathway and induced morphologic transformation, cell focus formation, anchorage-independent cell growth, and invasion. Inoculation of these mutant-expressing cells in athymic nude mice induced rapid tumor development, showing their driving oncogenicity. We also demonstrated that transfection with the novel mutants conferred cells high sensitivities to the mTOR inhibitor temsirolimus. We speculate that human cancers harboring these mTOR mutations, such as ATC and melanoma, may be effectively treated with inhibitors targeting mTOR.	[Murugan, Avaniyapuram Kannan; Liu, Rengyun; Xing, Mingzhao] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Lab Cellular & Mol Thyroid Res, Sch Med,Dept Med,Div Endocrinol Diabet & Metab, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins Medicine	Xing, MZ (corresponding author), Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Lab Cellular & Mol Thyroid Res, Sch Med,Dept Med,Div Endocrinol Diabet & Metab, Baltimore, MD 21287 USA.	mxing1@jhmi.edu	Murugan, Avaniyapuram Kannan/AAI-8222-2020; Liu, Rengyun/O-4039-2018	Murugan, Avaniyapuram Kannan/0000-0002-3096-6100; Liu, Rengyun/0000-0002-1408-2372	U.S.A. National Institutes of Health (NIH) [R01CA215142, R01CA189224]; NATIONAL CANCER INSTITUTE [R01CA215142, R01CA189224] Funding Source: NIH RePORTER	U.S.A. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by U.S.A. National Institutes of Health (NIH) grants R01CA215142 and R01CA189224 to M. Xing.	Agrawal N, 2014, CELL, V159, P676, DOI 10.1016/j.cell.2014.09.050; Berven LA, 2000, IMMUNOL CELL BIOL, V78, P447, DOI 10.1046/j.1440-1711.2000.00928.x; Davies H, 2005, CANCER RES, V65, P7591, DOI 10.1158/0008-5472.CAN-05-1855; Edinger AL, 2004, ONCOGENE, V23, P5654, DOI 10.1038/sj.onc.1207738; Fukui Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014180; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Ghosh AP, 2015, ONCOTARGET, V6, P17895, DOI 10.18632/oncotarget.4963; Grabiner BC, 2014, CANCER DISCOV, V4, P554, DOI 10.1158/2159-8290.CD-13-0929; Hardt M, 2011, GENES CELLS, V16, P141, DOI 10.1111/j.1365-2443.2010.01482.x; Janku F, 2018, NAT REV CLIN ONCOL, V15, P273, DOI 10.1038/nrclinonc.2018.28; Jiao QL, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0801-5; Kang SY, 2005, P NATL ACAD SCI USA, V102, P802, DOI 10.1073/pnas.0408864102; Karbowniczek M, 2008, J INVEST DERMATOL, V128, P980, DOI 10.1038/sj.jid.5701074; Kong Y, 2016, CLIN CANCER RES, V22, P1018, DOI 10.1158/1078-0432.CCR-15-1110; Kunstman JW, 2015, HUM MOL GENET, V24, P2318, DOI 10.1093/hmg/ddu749; Lancia I, 2016, J CLIN INVEST, V126, P1052, DOI 10.1172/JCI85271; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Li YY, 2015, CLIN CANCER RES, V21, P1447, DOI 10.1158/1078-0432.CCR-14-1773; de Souza ECL, 2011, EXPERT OPIN THER TAR, V15, P1099, DOI 10.1517/14728222.2011.594044; Liu DX, 2009, CANCER RES, V69, P7311, DOI 10.1158/0008-5472.CAN-09-1077; Liu J, 2010, ANN CLIN LAB SCI, V40, P211; Liu Z, 2008, J CLIN ENDOCR METAB, V93, P3106, DOI 10.1210/jc.2008-0273; Lochhead PA, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.254pe4; Murugan AK, 2015, META GENE, V6, P69, DOI 10.1016/j.mgene.2015.08.005; Murugan AK, 2013, J BIOL CHEM, V288, P6511, DOI 10.1074/jbc.M112.399485; Murugan AK, 2011, CANCER RES, V71, P4403, DOI 10.1158/0008-5472.CAN-10-4041; Murugan AK, 2009, CELL CYCLE, V8, P2122, DOI 10.4161/cc.8.13.8710; Neff RL, 2008, ENDOCRIN METAB CLIN, V37, P525, DOI 10.1016/j.ecl.2008.02.003; Ohne Y, 2008, J BIOL CHEM, V283, P31861, DOI 10.1074/jbc.M801546200; Paquette M, 2018, CANCERS, V10, DOI 10.3390/cancers10010018; Prete A, 2018, CLIN CANCER RES, V24, P6078, DOI 10.1158/1078-0432.CCR-18-0693; Sadow PM, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju182; Saji M, 2010, MOL CELL ENDOCRINOL, V321, P20, DOI 10.1016/j.mce.2009.10.016; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sato T, 2010, ONCOGENE, V29, P2746, DOI 10.1038/onc.2010.28; Schweppe RE, 2008, J CLIN ENDOCR METAB, V93, P4331, DOI 10.1210/jc.2008-1102; Sekulic A, 2000, CANCER RES, V60, P3504; Sturgill TW, 2009, ACS CHEM BIOL, V4, P999, DOI 10.1021/cb900193e; Urano J, 2007, P NATL ACAD SCI USA, V104, P3514, DOI 10.1073/pnas.0608510104; Volkers M, 2013, P NATL ACAD SCI USA, V110, P12661, DOI 10.1073/pnas.1301455110; Wagle N, 2014, NEW ENGL J MED, V371, P1426, DOI 10.1056/NEJMoa1403352; Xing MZ, 2010, THYROID, V20, P697, DOI 10.1089/thy.2010.1646; Xu JN, 2016, J CLIN INVEST, V126, P3526, DOI 10.1172/JCI86120; Yamaguchi H, 2015, CANCER SCI, V106, P1687, DOI 10.1111/cas.12828	45	16	17	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 27	2019	38	26					5211	5226		10.1038/s41388-019-0787-5	http://dx.doi.org/10.1038/s41388-019-0787-5			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IF4AX	30918329	Green Accepted			2022-12-17	WOS:000473025300007
J	Bernat-Peguera, A; Simon-Extremera, P; da Silva-Diz, V; de Munain, ML; Diaz-Gil, L; Penin, RM; Gonzalez-Suarez, E; Sidelnikova, DP; Bermejo, O; Vinals, JM; Vinals, F; Munoz, P				Bernat-Peguera, Adria; Simon-Extremera, Pilar; da Silva-Diz, Victoria; Lopez de Munain, Mikel; Diaz-Gil, Laura; Penin, Rosa M.; Gonzalez-Suarez, Eva; Sidelnikova, Diana Perez; Bermejo, Oriol; Vinals, Joan Maria; Vinals, Francesc; Munoz, Purificacion			PDGFR-induced autocrine SDF-1 signaling in cancer cells promotes metastasis in advanced skin carcinoma	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; BREAST-CANCER; TUMOR-GROWTH; CHEMOKINE RECEPTOR; FACTOR-I; SDF-1/CXCR4 AXIS; CXCR4; EXPRESSION; PROGRESSION; SURVIVAL	Advanced and undifferentiated skin squamous cell carcinomas (SCCs) exhibit aggressive growth and enhanced metastasis capability, which is associated in mice with an expansion of the cancer stem-like cell (CSC) population and with changes in the regulatory mechanisms that control the proliferation and invasion of these cells. Indeed, autocrine activation of PDGFR alpha induces CSC invasion and promotes distant metastasis in advanced SCCs. However, the mechanisms involved in this process were unclear. Here, we show that CSCs of mouse advanced SCCs (L-CSCs) express CXCR4 and CXCR7, both receptors of SDF-1. PDGFR alpha signaling induces SDF-1 expression and secretion, and the autocrine activation of this pathway in L-CSCs. Autocrine SDF-1/CXCR4 signaling induces L-CSC proliferation and survival, and mediates PDGFR alpha-induced invasion, promoting in vivo lung metastasis. Validation of these findings in patient samples of skin SCCs shows a strong correlation between the expression of SDF1, PDGFRA, and PDGFRB, which is upregulated, along CXCR4 in tumor cells of advanced SCCs. Furthermore, PDGFR regulates SDF-1 expression and inhibition of SDF-1/CXCR4 and PDGFR pathways blocks distant metastasis of human PD/S-SCCs. Our results indicate that functional crosstalk between PDGFR/ SDF-1 signaling regulates tumor cell invasion and metastasis in human and mouse advanced SCCs, and suggest that CXCR4 and/or PDGFR inhibitors could be used to block metastasis of these aggressive tumors.	[Bernat-Peguera, Adria; Simon-Extremera, Pilar; da Silva-Diz, Victoria; Lopez de Munain, Mikel; Diaz-Gil, Laura; Gonzalez-Suarez, Eva; Munoz, Purificacion] Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Program PEBC, Barcelona, Spain; [Penin, Rosa M.] Hosp Univ Bellvitge, Pathol Serv, IDIBELL, Barcelona, Spain; [Sidelnikova, Diana Perez; Bermejo, Oriol; Vinals, Joan Maria] Hosp Univ Bellvitge, Plast Surg Unit, IDIBELL, Barcelona, Spain; [Vinals, Francesc] Catalan Inst Oncol ICO, Lab Translat Res, IDIBELL, Barcelona, Spain; [Vinals, Francesc] Univ Barcelona, Dept Ciencies Fisiol, Unitat Bioquim & Biol Mol, IDIBELL, Barcelona, Spain; [da Silva-Diz, Victoria] Rutgers State Univ, Rutgers Canc Inst New Jersey, New Brunswick, NJ USA	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; University of Barcelona; Catalan Institute of Oncology; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey	Munoz, P (corresponding author), Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Program PEBC, Barcelona, Spain.	p.munoz@idibell.cat	Gonzalez-Suarez, Eva/L-6298-2014; Viñals, Francesc/F-5928-2016	Gonzalez-Suarez, Eva/0000-0003-0858-8171; Viñals, Francesc/0000-0002-9918-6751; Bernat Peguera, Adria/0000-0002-3108-0571; Simon, Pilar/0000-0002-0702-2443	IDIBELL Fellowship; Spanish Ministry of Science and Innovation Fellowships; Spanish Ministry of Economy and Competitiveness MINECO [SAF2014-55944R, SAF2017-84976R]; FEDER funds/European Regional Development Fund (ERDF); Catalan Department of Health (Generalitat de Catalunya) [2017SGR595]	IDIBELL Fellowship; Spanish Ministry of Science and Innovation Fellowships; Spanish Ministry of Economy and Competitiveness MINECO(Spanish Government); FEDER funds/European Regional Development Fund (ERDF); Catalan Department of Health (Generalitat de Catalunya)	AB-P received an IDIBELL Fellowship, VdS-D and PS-E are funded by Spanish Ministry of Science and Innovation Fellowships; the research of PM's group is supported by the Spanish Ministry of Economy and Competitiveness MINECO (SAF2014-55944R; SAF2017-84976R, co-funded by FEDER funds/European Regional Development Fund (ERDF)-a way to build Europa) and by the Catalan Department of Health (Generalitat de Catalunya; 2017SGR595). We thank J. Comas (Universitat de Barcelona-SCT) for technical support with flow cytometry; the patients enrolled in this study for their participation; the Hospital Universitario Ramon y Cajal, Hospital Virgen de la Salud, Biobanco del Principado de Asturias and Fundacion Instituto Valenciano de Oncologia, which are members of the Spanish Hospital Platform Biobanks Network; Y. Perez (Tumor Bank, Hospital de Bellvitge) for help with human tumor sample collection; and the IDIBELL animal facility service for mouse care.	ARBEIT JM, 1994, J VIROL, V68, P4358, DOI 10.1128/JVI.68.7.4358-4368.1994; Balabanian K, 2005, J BIOL CHEM, V280, P35760, DOI 10.1074/jbc.M508234200; Basile J, 2008, J CUTAN PATHOL, V35, P623, DOI 10.1111/j.1600-0560.2007.00879.x; Bertolini G, 2009, P NATL ACAD SCI USA, V106, P16281, DOI 10.1073/pnas.0905653106; Boumahdi S, 2014, NATURE, V511, P246, DOI 10.1038/nature13305; Burns JM, 2006, J EXP MED, V203, P2201, DOI 10.1084/jem.20052144; Chen SJ, 2009, BRIT J DERMATOL, V160, P710, DOI 10.1111/j.1365-2133.2008.08996.x; Cherpelis BS, 2002, DERMATOL SURG, V28, P268, DOI 10.1046/j.1524-4725.2002.01169.x; Coussens LM, 1996, AM J PATHOL, V149, P1899; da Silva-Diz V, 2018, SEMIN CANCER BIOL, V53, P48, DOI 10.1016/j.semcancer.2018.08.009; da Silva-Diz V, 2016, CANCER RES, V76, P1245, DOI 10.1158/0008-5472.CAN-15-1631; Darash-Yahana M, 2004, FASEB J, V18, P1240, DOI 10.1096/fj.03-0935fje; Ehtesham M, 2009, CANCER LETT, V274, P305, DOI 10.1016/j.canlet.2008.09.034; Folkins C, 2009, CANCER RES, V69, P7243, DOI 10.1158/0008-5472.CAN-09-0167; Franco R, 2013, EXPERT OPIN BIOL TH, V13, P51, DOI 10.1517/14712598.2012.725720; Gatti M, 2013, TOXICOLOGY, V314, P209, DOI 10.1016/j.tox.2013.10.003; Gellmini S, 2008, J ENDOCRINOL INVEST, V31, P809, DOI 10.1007/BF03349262; Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002; Hu SCS, 2014, EXP DERMATOL, V23, P902, DOI 10.1111/exd.12557; Hu TH, 2014, CANCER LETT, V354, P417, DOI 10.1016/j.canlet.2014.08.012; Kang H, 2005, BREAST CANCER RES, V7, pR402, DOI 10.1186/bcr1022; Kong LX, 2016, INT J ONCOL, V48, P1085, DOI 10.3892/ijo.2016.3343; Kryczek I, 2007, AM J PHYSIOL-CELL PH, V292, pC987, DOI 10.1152/ajpcell.00406.2006; Lapouge G, 2012, EMBO J, V31, P4563, DOI 10.1038/emboj.2012.312; Li XQ, 2014, MOL CELL BIOCHEM, V392, P77, DOI 10.1007/s11010-014-2020-8; Liang ZX, 2004, CANCER RES, V64, P4302, DOI 10.1158/0008-5472.CAN-03-3958; Matthys P, 2001, J IMMUNOL, V167, P4686, DOI 10.4049/jimmunol.167.8.4686; Miao Z, 2007, P NATL ACAD SCI USA, V104, P15735, DOI 10.1073/pnas.0610444104; Miki J, 2007, CANCER RES, V67, P3153, DOI 10.1158/0008-5472.CAN-06-4429; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Nassar D, 2016, ANNU REV PATHOL-MECH, V11, P47, DOI 10.1146/annurev-pathol-012615-044438; Naumann U, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009175; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Pablos JL, 1999, AM J PATHOL, V155, P1577, DOI 10.1016/S0002-9440(10)65474-0; PONTEN F, 1994, J INVEST DERMATOL, V102, P304, DOI 10.1111/1523-1747.ep12371787; Quan CJ, 2015, PROTEIN CELL, V6, P890, DOI 10.1007/s13238-015-0198-5; Rogers HW, 2010, ARCH DERMATOL, V146, P283, DOI 10.1001/archdermatol.2010.19; Sciaccaluga M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073426; Smith MCP, 2004, CANCER RES, V64, P8604, DOI 10.1158/0008-5472.CAN-04-1844; Stratigos A, 2015, EUR J CANCER, V51, P1989, DOI 10.1016/j.ejca.2015.06.110; Sun XQ, 2010, CANCER METAST REV, V29, P709, DOI 10.1007/s10555-010-9256-x; Tang X, 2016, TUMOR BIOL, V37, P13425, DOI 10.1007/s13277-016-5180-1; Uchida D, 2007, MOL CANCER RES, V5, P685, DOI 10.1158/1541-7786.MCR-06-0368; Uchida DE, 2004, LAB INVEST, V84, P1538, DOI 10.1038/labinvest.3700190; Uemae Y, 2014, J NEURO-ONCOL, V117, P43, DOI 10.1007/s11060-014-1364-y; Wang JF, 2004, BBA-MOL CELL RES, V1691, P129, DOI 10.1016/j.bbamcr.2004.01.002; Wang X, 2016, ONCOTARGET, V8, P36149; White RA, 2013, J CLIN INVEST, V123, P4390, DOI 10.1172/JCI65856; Wong CE, 2013, GENE DEV, V27, P670, DOI 10.1101/gad.210427.112; Wu YC, 2016, ONCOGENE, V35, P2123, DOI 10.1038/onc.2015.274; Yang P, 2014, CURR MOL MED, V14, P174, DOI 10.2174/1566524013666131121115656; Yuan LP, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-18	52	16	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2019	38	25					5021	5037		10.1038/s41388-019-0773-y	http://dx.doi.org/10.1038/s41388-019-0773-y			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IE1KY	30874597	Green Published, hybrid, Green Accepted			2022-12-17	WOS:000472145900010
J	Cao, ZY; Xue, JH; Cheng, YN; Wang, JY; Liu, YJ; Li, H; Jiang, W; Li, G; Gui, YT; Zhang, XW				Cao, Zhengyi .; Xue, Junhui; Cheng, Yuning; Wang, Jiyin; Liu, Yujuan; Li, Hui; Jiang, Wei; Li, Gang; Gui, Yaoting; Zhang, Xiaowei			MDM2 promotes genome instability by ubiquitinating the transcription factor HBP1	ONCOGENE			English	Article							TUMOR-SUPPRESSOR PROTEIN; DNA-DAMAGE; CELL-CYCLE; EXPRESSION; DEGRADATION; GENE; OVEREXPRESSION; CANCER; APOPTOSIS; PATHWAY	Genome instability is a common feature of tumor cells, and the persistent presence of genome instability is a potential mechanism of tumorigenesis. The E3 ubiquitin ligase MDM2 is intimately involved in genome instability, but its mechanisms are unclear. Our data demonstrated that the transcription factor HBP1 is a target of MDM2. MDM2 facilitates HBP1 proteasomal degradation by ubiquitinating HBP1, regardless of p53 status, thus attenuating the transcriptional inhibition of HBP1 in the expression of its target genes, such as the DNA methyltransferase DNMT1 and histone methyltransferase EZH2, which results in global DNA hypermethylation and histone hypermethylation and ultimately genome instability. The repression of HBP1 by MDM2 finally promotes cell growth and tumorigenesis. Next, we thoroughly explored the regulatory mechanism of the MDM2/HBP1 axis in DNA damage repair following ionizing radiation. Our data indicated that MDM2 overexpression-mediated repression of HBP1 delays DNA damage repair and causes cell death in a p53-independent manner. This investigation elucidated the mechanism of how MDM2 promotes genome instability and enhances tumorigenesis in the absence of p53, thus providing a theoretical and experimental basis for targeting MDM2 as a cancer therapy.	[Cao, Zhengyi .; Xue, Junhui; Cheng, Yuning; Wang, Jiyin; Liu, Yujuan; Li, Hui; Jiang, Wei; Li, Gang; Zhang, Xiaowei] Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol,Sch Basic Med Sci, Beijing Key Lab Prot Posttranslat Modificat & Cel, Beijing 100191, Peoples R China; [Gui, Yaoting] Hong Kong Univ Sci & Technol, Shenzhen Peking Univ, Peking Univ Shenzhen Hosp,Inst Urol,Med Ctr, Guangdong & Shenzhen Key Lab Male Reprod Med & Ge, Shenzhen 518000, Peoples R China	Peking University; Hong Kong University of Science & Technology; Peking University	Zhang, XW (corresponding author), Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol,Sch Basic Med Sci, Beijing Key Lab Prot Posttranslat Modificat & Cel, Beijing 100191, Peoples R China.	xiaoweizhang@bjmu.edu.cn	Cheng, Yuning/GSE-2360-2022; gui, yaoting/GLT-3684-2022	Cheng, Yuning/0000-0002-8171-8748; 	National Natural Science Foundation of China [81672717, 31471292, 81874141, 81572705]; Beijing Natural Science Foundation [5162013]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Beijing Natural Science Foundation(Beijing Natural Science Foundation)	This work was supported by grants of the National Natural Science Foundation of China (No. 81672717, 31471292, 81874141, and 81572705) and Beijing Natural Science Foundation Grant (No. 5162013).	Alt JR, 2005, J BIOL CHEM, V280, P18771, DOI 10.1074/jbc.M413387200; Bartel F, 2002, CANCER CELL, V2, P9, DOI 10.1016/S1535-6108(02)00091-0; Berasi SP, 2004, MOL CELL BIOL, V24, P3011, DOI 10.1128/MCB.24.7.3011-3024.2004; Bond GL, 2004, CELL, V119, P591, DOI 10.1016/j.cell.2004.11.022; Carroll PE, 1999, ONCOGENE, V18, P1935, DOI 10.1038/sj.onc.1202515; Chen YF, 2016, J BIOL CHEM, V291, P12688, DOI 10.1074/jbc.M116.714147; Chene P, 2004, MOL CANCER RES, V2, P20; Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019; CORDONCARDO C, 1994, CANCER RES, V54, P794; Deb Swati Palit, 2014, Subcell Biochem, V85, P215, DOI 10.1007/978-94-017-9211-0_12; Eischen CM, 2017, J MOL CELL BIOL, V9, P69, DOI 10.1093/jmcb/mjw052; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Escamilla-Powers JR, 2010, J BIOL CHEM, V285, P4847, DOI 10.1074/jbc.M109.074856; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; Ganguli G, 2003, MOL CANCER RES, V1, P1027; Gartel AL, 1998, ONCOGENE, V17, P3463, DOI 10.1038/sj.onc.1202240; Iwasa H, 2013, J BIOL CHEM, V288, P30320, DOI 10.1074/jbc.M113.507384; Jazayeri A, 2006, NAT CELL BIOL, V8, P37, DOI 10.1038/ncb1337; Jones SN, 1998, P NATL ACAD SCI USA, V95, P15608, DOI 10.1073/pnas.95.26.15608; Legube G, 2002, EMBO J, V21, P1704, DOI 10.1093/emboj/21.7.1704; Lehmann C, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0280-3; Lemercier C, 2000, MOL CELL BIOL, V20, P6627, DOI 10.1128/MCB.20.18.6627-6637.2000; Li H, 2010, ONCOGENE, V29, P5083, DOI 10.1038/onc.2010.252; Li Q, 2013, CLIN CANCER RES, V19, P34, DOI 10.1158/1078-0432.CCR-12-0053; Li YL, 2014, CANCER CELL, V26, P262, DOI 10.1016/j.ccr.2014.06.014; Lin HK, 2002, EMBO J, V21, P4037, DOI 10.1093/emboj/cdf406; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; Mendrysa SM, 2006, GENE DEV, V20, P16, DOI 10.1101/gad.1378506; Meulmeester E, 2005, MOL CELL, V18, P565, DOI 10.1016/j.molcel.2005.04.024; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; Pan KW, 2013, MOL CELL BIOL, V33, P887, DOI 10.1128/MCB.00637-12; Pan Y, 2003, MOL CELL BIOL, V23, P5113, DOI 10.1128/MCB.23.15.5113-5121.2003; Rayburn E, 2005, CURR CANCER DRUG TAR, V5, P27, DOI 10.2174/1568009053332636; Riley MF, 2016, ONCOGENE, V35, P358, DOI 10.1038/onc.2015.88; Saadatzadeh MR, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18102216; Slack A, 2005, P NATL ACAD SCI USA, V102, P731, DOI 10.1073/pnas.0405495102; Stommel JM, 2004, EMBO J, V23, P1547, DOI 10.1038/sj.emboj.7600145; Wang P, 2008, ONCOGENE, V27, P1590, DOI 10.1038/sj.onc.1210788; Wang P, 2006, ONCOGENE, V25, P3708, DOI 10.1038/sj.onc.1209411; Wang SP, 2009, NAT CELL BIOL, V11, P694, DOI 10.1038/ncb1875; Wang SY, 2017, J BIOL CHEM, V292, P8207, DOI 10.1074/jbc.M116.768101; Watanabe T, 1996, LEUKEMIA LYMPHOMA, V21, P391, DOI 10.3109/10428199609093436; Wen W, 2014, ONCOGENE, V33, P421, DOI 10.1038/onc.2012.605; Wienken M, 2016, MOL CELL, V61, P68, DOI 10.1016/j.molcel.2015.12.008; Xiu M, 2003, MOL CELL BIOL, V23, P8890, DOI 10.1128/MCB.23.23.8890-8901.2003; Yang JY, 2008, NAT CELL BIOL, V10, P138, DOI 10.1038/ncb1676; Yang JY, 2006, MOL CELL BIOL, V26, P7269, DOI 10.1128/MCB.00172-06; Yao CJ, 2005, LEUKEMIA, V19, P1958, DOI 10.1038/sj.leu.2403918; Yu JW, 2016, CELL PROLIFERAT, V49, P79, DOI 10.1111/cpr.12238; Zhang XW, 2006, MOL CELL BIOL, V26, P8252, DOI 10.1128/MCB.00604-06; Zhao YJ, 2015, J MED CHEM, V58, P1038, DOI 10.1021/jm501092z; Zhou YL, 2018, CANCER BIOL THER, V19, P465, DOI 10.1080/15384047.2018.1433500	53	16	21	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 13	2019	38	24					4835	4855		10.1038/s41388-019-0761-2	http://dx.doi.org/10.1038/s41388-019-0761-2			21	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IC7ND	30816344	hybrid, Green Published			2022-12-17	WOS:000471160500013
J	Zhou, F; Gao, S; Han, D; Han, WT; Chen, SJ; Patalano, S; Macoska, JA; He, HSHS; Cai, CM				Zhou, Feng; Gao, Shuai; Han, Dong; Han, Wanting; Chen, Sujun; Patalano, Susan; Macoska, Jill A.; He, Housheng Hansen; Cai, Changmeng			TMPRSS2-ERG activates NO-cGMP signaling in prostate cancer cells	ONCOGENE			English	Article							SOLUBLE GUANYLATE-CYCLASE; ANDROGEN RECEPTOR; NITRIC-OXIDE; GENE FUSIONS; 5 INHIBITORS; PATHWAY; MIGRATION; EXPRESSION; ANGIOGENESIS; PERMEABILITY	The aberrant activation of the ERG oncogenic pathway due to the TMPRSS2-ERG gene fusion is the major event that contributes to prostate cancer (PCa) development. However, the critical downstream effectors that can be therapeutically targeted remain to be identified. In this study, we have found that the expression of the alpha 1 and beta 1 subunits of soluble guanylyl cyclase (sGC) was directly and specifically regulated by ERG in vitro and in vivo and was significantly associated with TMPRSS2-ERG fusion in clinical PCa cohorts. sGC is the major mediator of nitric oxide (NO)-cGMP signaling in cells that, upon NO binding, catalyzes the synthesis of cGMP and subsequently activates protein kinase G (PKG). We showed that cGMP synthesis was significantly elevated by ERG in PCa cells, leading to increased PKG activity and cell proliferation. Importantly, we also demonstrated that sGC inhibitor treatment repressed tumor growth in TMPRSS2-ERG-positive PCa xenograft models and can act in synergy with a potent AR antagonist, enzalutamide. This study strongly suggests that targeting NO-cGMP signaling pathways may be a novel therapeutic strategy to treat PCa with TMPRSS2-ERG gene fusion.	[Zhou, Feng] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Urol, Hangzhou 310003, Zhejiang, Peoples R China; [Zhou, Feng; Gao, Shuai; Han, Dong; Han, Wanting; Patalano, Susan; Macoska, Jill A.; Cai, Changmeng] Univ Massachusetts, Ctr Personalized Canc Therapy, Boston, MA 02125 USA; [Zhou, Feng; Gao, Shuai; Han, Dong; Han, Wanting; Patalano, Susan; Macoska, Jill A.; Cai, Changmeng] Dana Farber Harvard Canc Ctr, Boston, MA 02215 USA; [Chen, Sujun; He, Housheng Hansen] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON M5G 1L7, Canada	Zhejiang University; University of Massachusetts System; University of Massachusetts Boston; Harvard University; Dana-Farber Cancer Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Cai, CM (corresponding author), Dana Farber Harvard Canc Ctr, Boston, MA 02215 USA.	changmeng.cai@umb.edu	He, Hansen/ABD-8439-2020; Han, Dong/AAG-9502-2021; Han, Wanting/AEX-5349-2022; Cai, Changmeng/AAE-6835-2020; Han, Wanting/GQA-5728-2022	He, Hansen/0000-0003-2898-3363; Han, Dong/0000-0002-6224-855X; Han, Wanting/0000-0002-2173-3647; Macoska, Jill/0000-0001-8471-2221; Gao, Shuai/0000-0002-7304-8801	NIH [R00 CA166507, R01 CA211350, U54 CA156734-06A1]; DOD [W81XWH-15-1-0554, W81XWH-16-1-0445]; Zhejiang Provincial Natural Science Foundation of China [LH19H05001]; NATIONAL CANCER INSTITUTE [R01CA211350, R00CA166507, U54CA156734] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD(United States Department of Defense); Zhejiang Provincial Natural Science Foundation of China(Natural Science Foundation of Zhejiang Province); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work is supported by grants from NIH (R00 CA166507 and R01 CA211350 to CC, and U54 CA156734-06A1 to JAM), DOD (W81XWH-15-1-0554 to SG, and W81XWH-16-1-0445 to CC), and the research grant from Zhejiang Provincial Natural Science Foundation of China (LH19H05001 to FZ). We thank Drs. Sen Chen, Steven P. Balk (Beth Israel Deaconess Medical Center), and Eva Corey (Fred Hutchinson Cancer Center) for the support of animal study and Dr. Lirim Shemshedini (University of Toledo) for the advice on manuscript writing.	Birdsey GM, 2008, BLOOD, V111, P3498, DOI 10.1182/blood-2007-08-105346; Birdsey GM, 2012, BLOOD, V119, P894, DOI 10.1182/blood-2011-04-350025; Brenner JC, 2011, CANCER CELL, V19, P664, DOI 10.1016/j.ccr.2011.04.010; Cai C, 2007, ONCOGENE, V26, P1606, DOI 10.1038/sj.onc.1209956; Cai CM, 2007, MOL ENDOCRINOL, V21, P1835, DOI 10.1210/me.2006-0480; Cai CM, 2013, J CLIN INVEST, V123, P1109, DOI 10.1172/JCI66666; Cai CM, 2012, MOL ENDOCRINOL, V26, P292, DOI 10.1210/me.2010-0394; Cai CM, 2009, CANCER RES, V69, P6027, DOI 10.1158/0008-5472.CAN-09-0395; Carvajal JA, 2000, J CELL PHYSIOL, V184, P409, DOI 10.1002/1097-4652(200009)184:3<409::AID-JCP16>3.3.CO;2-B; Carver BS, 2009, NAT GENET, V41, P619, DOI 10.1038/ng.370; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chavez AH, 2013, ASIAN J ANDROL, V15, P246, DOI 10.1038/aja.2012.162; Chen Y, 2013, NAT MED, V19, P1023, DOI 10.1038/nm.3216; Chinnaiyan AM, 2008, NEOPLASIA, V10, P177, DOI 10.1593/neo.07822; Ciani E, 2002, J NEUROCHEM, V81, P218, DOI 10.1046/j.1471-4159.2002.00857.x; Corey E, 2003, PROSTATE, V55, P239, DOI 10.1002/pros.10198; Dhayade S, 2016, CELL REP, V14, P2599, DOI 10.1016/j.celrep.2016.02.028; DRAIJER R, 1995, CIRC RES, V76, P199, DOI 10.1161/01.RES.76.2.199; Fajardo AM, 2014, CANCERS, V6, P436, DOI 10.3390/cancers6010436; Fraser M, 2017, NATURE, V541, P359, DOI 10.1038/nature20788; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gao S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064189; Hollenhorst PC, 2011, GENE DEV, V25, P2147, DOI 10.1101/gad.17546311; Kawasaki K, 2003, MOL CELL BIOL, V23, P5726, DOI 10.1128/MCB.23.16.5726-5737.2003; King JC, 2009, NAT GENET, V41, P524, DOI 10.1038/ng.371; Klinger James R, 2017, Am J Cardiol, V120, pS71, DOI 10.1016/j.amjcard.2017.06.012; Kron KJ, 2017, NAT GENET, V49, P1336, DOI 10.1038/ng.3930; Li WQ, 2014, JAMA INTERN MED, V174, P964, DOI 10.1001/jamainternmed.2014.594; Loberg RD, 2006, NEOPLASIA, V8, P578, DOI 10.1593/neo.06280; Michl U, 2015, J UROLOGY, V193, P479, DOI 10.1016/j.juro.2014.08.111; Mittendorf J, 2009, CHEMMEDCHEM, V4, P853, DOI 10.1002/cmdc.200900014; Monica FZ, 2018, NAT REV UROL, V15, P42, DOI 10.1038/nrurol.2017.181; Morbidelli L, 2010, AM J PHYSIOL-REG I, V298, pR824, DOI 10.1152/ajpregu.00222.2009; Mosquera JM, 2008, CLIN CANCER RES, V14, P3380, DOI 10.1158/1078-0432.CCR-07-5194; Nguyen HM, 2017, PROSTATE, V77, P654, DOI 10.1002/pros.23313; Nikolova-Krstevski V, 2009, BMC DEV BIOL, V9, DOI 10.1186/1471-213X-9-72; Olesen SP, 1998, BRIT J PHARMACOL, V123, P299, DOI 10.1038/sj.bjp.0701603; Pyriochou A, 2006, J PHARMACOL EXP THER, V319, P663, DOI 10.1124/jpet.106.108878; Reffelmann T, 2006, CURR PHARM DESIGN, V12, P3485, DOI 10.2174/138161206778343073; Schwappacher R, 2013, J CELL SCI, V126, P1626, DOI 10.1242/jcs.118190; Stojanovic A, 2006, J BIOL CHEM, V281, P16333, DOI 10.1074/jbc.M512378200; Sun C, 2008, ONCOGENE, V27, P5348, DOI 10.1038/onc.2008.183; Surapisitchat J, 2007, CIRC RES, V101, P811, DOI 10.1161/CIRCRESAHA.107.154229; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Tomlins SA, 2006, CANCER RES, V66, P3396, DOI 10.1158/0008-5472.CAN-06-0168; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Tomlins SA, 2007, NATURE, V448, P595, DOI 10.1038/nature06024; Wang L, 2005, J CEREBR BLOOD F MET, V25, P1150, DOI 10.1038/sj.jcbfm.9600112; Wang XJ, 2017, CANCER CELL, V31, P532, DOI 10.1016/j.ccell.2017.02.017; Wu LT, 2013, CANCER RES, V73, P6068, DOI 10.1158/0008-5472.CAN-13-0882; Yu JD, 2010, CANCER CELL, V17, P443, DOI 10.1016/j.ccr.2010.03.018; Yuan X, 2014, ONCOGENE, V33, P2815, DOI 10.1038/onc.2013.235; Zhou J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184088	53	16	16	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 30	2019	38	22					4397	4411		10.1038/s41388-019-0730-9	http://dx.doi.org/10.1038/s41388-019-0730-9			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IA1RB	30718921	Green Accepted, hybrid, Green Published			2022-12-17	WOS:000469339100014
J	El Kharbili, M; Agaesse, G; Barbollat-Boutrand, L; Pommier, RM; de la Fouchardiere, A; Larue, L; Caramel, J; Puisieux, A; Berthier-Vergnes, O; Masse, I				El Kharbili, Manale; Agaesse, Gweltaz; Barbollat-Boutrand, Laetitia; Pommier, Roxane M.; de la Fouchardiere, Arnaud; Larue, Lionel; Caramel, Julie; Puisieux, Alain; Berthier-Vergnes, Odile; Masse, Ingrid			Tspan8-beta-catenin positive feedback loop promotes melanoma invasion	ONCOGENE			English	Article							BETA-CATENIN EXPRESSION; TETRASPANIN CO-029; CELL MOTILITY; METASTASIS; TUMORS; OVEREXPRESSION; ASSOCIATION; PROGRESSION; CADHERIN; PATHWAY	Due to its high proclivity to metastasize, and despite the recent development of targeted and immune therapy strategies, melanoma is still the deadliest form of skin cancer. Therefore, understanding the molecular mechanisms underlying melanoma invasion remains crucial. We previously characterized Tspan8 for its ability to prompt melanoma cell detachment from their microenvironment and trigger melanoma cell invasiveness, but the signaling events by which Tspan8 regulates the invasion process still remain unknown. Here, we demonstrated that beta-catenin stabilization is a molecular signal subsequent to the onset of Tspan8 expression, and that, in turn, beta-catenin triggers the direct transcriptional activation of Tspan8 expression, leading to melanoma invasion. Moreover, we showed that beta-catenin activation systematically correlates with a high expression of Tspan8 protein in melanoma lesions from transgenic Nras; bcat* mice, as well as in deep penetrating naevi, a type of human pre-melanoma neoplasm characterized by a combined activation of beta-catenin and MAP kinase signaling. Overall, our data suggest that beta-catenin and Tspan8 are part of a positive feedback loop, which sustains a high Tspan8 expression level, conferring to melanoma cells the invasive properties required for tumor progression and dissemination.	[El Kharbili, Manale; Agaesse, Gweltaz; Barbollat-Boutrand, Laetitia; Berthier-Vergnes, Odile; Masse, Ingrid] Univ Lyon, F-69003 Lyon, France; [El Kharbili, Manale; Agaesse, Gweltaz; Barbollat-Boutrand, Laetitia; Berthier-Vergnes, Odile; Masse, Ingrid] Univ Lyon 1, F-69003 Lyon, France; [El Kharbili, Manale; Agaesse, Gweltaz; Barbollat-Boutrand, Laetitia; Berthier-Vergnes, Odile; Masse, Ingrid] CNRS, UMR5534, Ctr Genet & Physiol Mol & Cellulaires, F-69622 Villeurbanne, France; [Pommier, Roxane M.; de la Fouchardiere, Arnaud; Caramel, Julie; Puisieux, Alain] Univ Lyon 1, Univ Lyon, Ctr Rech Cancerol Lyon, CNRS,UMR5286,Inserm,U1052, F-69000 Lyon, France; [de la Fouchardiere, Arnaud] Ctr Leon Berard, Dept Biopathol, Lyon, France; [Larue, Lionel] PSL Res Univ, Normal & Pathol Dev Melanocytes, Inst Curie, INSERM,U1021, Orsay, France; [Larue, Lionel] Univ Paris Saclay, Univ Paris Sud, CNRS, UMR 3347, Orsay, France; [Larue, Lionel] Equipe Labellisee Ligue Canc, Orsay, France; [El Kharbili, Manale] Univ Colorado, Dept Dermatol, Anschutz Med Campus,12800 E 19th Ave,P18-8132, Aurora, CO 80045 USA; [Barbollat-Boutrand, Laetitia; Masse, Ingrid] Univ Lyon 1, Univ Lyon, Ctr Rech Cancerol Lyon, CNRS,UMR5286,Inserm,U1052, F-69000 Lyon, France	UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; UNICANCER; Centre Leon Berard; UNICANCER; Centre Leon Berard; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Saclay; University of Colorado System; University of Colorado Anschutz Medical Campus; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; UNICANCER; Centre Leon Berard	Masse, I (corresponding author), Univ Lyon, F-69003 Lyon, France.; Masse, I (corresponding author), Univ Lyon 1, F-69003 Lyon, France.; Masse, I (corresponding author), CNRS, UMR5534, Ctr Genet & Physiol Mol & Cellulaires, F-69622 Villeurbanne, France.; Masse, I (corresponding author), Univ Lyon 1, Univ Lyon, Ctr Rech Cancerol Lyon, CNRS,UMR5286,Inserm,U1052, F-69000 Lyon, France.	ingrid.masse@univ-lyon1.fr		Caramel, Julie/0000-0002-8883-918X; POMMIER, Roxane/0000-0002-5351-7367; MASSE, Ingrid/0000-0003-3193-970X; PUISIEUX, Alain/0000-0002-9938-3798	French Society for Dermatological Research (SRD); La Ligue Contre le Cancer (Comite Ardeche); association "Vaincre le Melanome"	French Society for Dermatological Research (SRD); La Ligue Contre le Cancer (Comite Ardeche); association "Vaincre le Melanome"	This work was supported by a grant from the French Society for Dermatological Research (SRD), a grant from La Ligue Contre le Cancer (Comite Ardeche) and a grant from the association "Vaincre le Melanome".	Abe M, 2008, CANCER LETT, V266, P163, DOI 10.1016/j.canlet.2008.02.058; Agaesse G, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.11; Agaesse G, 2017, ONCOGENE, V36, P446, DOI 10.1038/onc.2016.219; Ailane N, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00364; Aktary Z, 2016, PIGM CELL MELANOMA R, V29, P524, DOI 10.1111/pcmr.12501; Arozarena I, 2011, ONCOGENE, V30, P4531, DOI 10.1038/onc.2011.162; Bachmann IM, 2005, CLIN CANCER RES, V11, P8606, DOI 10.1158/1078-0432.CCR-05-0011; Berthier-Vergnes O, 2011, BRIT J CANCER, V104, P155, DOI 10.1038/sj.bjc.6605994; Bhansali M, 2016, MOL ENDOCRINOL, V30, P13, DOI 10.1210/me.2015-1075; Cavard C, 2006, ONCOGENE, V25, P599, DOI 10.1038/sj.onc.1208860; Chien AJ, 2009, P NATL ACAD SCI USA, V106, P1193, DOI 10.1073/pnas.0811902106; Claas C, 1998, J CELL BIOL, V141, P267, DOI 10.1083/jcb.141.1.267; Conde-Perez A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9093; Damsky WE, 2011, CANCER CELL, V20, P741, DOI 10.1016/j.ccr.2011.10.030; Delmas V, 2003, GENESIS, V36, P73, DOI 10.1002/gene.10197; Delmas V, 2007, GENE DEV, V21, P2923, DOI 10.1101/gad.450107; Eichhoff OM, 2011, PIGM CELL MELANOMA R, V24, P631, DOI 10.1111/j.1755-148X.2011.00871.x; El Kharbili M, 2017, ONCOTARGET, V8, P17140, DOI 10.18632/oncotarget.15084; Gallagher SJ, 2013, ONCOGENE, V32, P2230, DOI 10.1038/onc.2012.229; Gesierich S, 2005, CLIN CANCER RES, V11, P2840, DOI 10.1158/1078-0432.CCR-04-1935; Gesierich S, 2006, CANCER RES, V66, P7083, DOI 10.1158/0008-5472.CAN-06-0391; Greco C, 2010, CANCER RES, V70, P7674, DOI 10.1158/0008-5472.CAN-09-4482; Grossmann AH, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003398; Guo Q, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0053523; Hemler ME, 2014, NAT REV CANCER, V14, P49, DOI 10.1038/nrc3640; Herlevsen M, 2003, J CELL SCI, V116, P4373, DOI 10.1242/jcs.00760; Kageshita T, 2001, BRIT J DERMATOL, V145, P210, DOI 10.1046/j.1365-2133.2001.04336.x; Kanetaka K, 2003, J GASTROEN HEPATOL, V18, P1309, DOI 10.1046/j.1440-1746.2003.03182.x; Kanetaka K, 2001, J HEPATOL, V35, P637, DOI 10.1016/S0168-8278(01)00183-0; Larue L, 2006, FRONT BIOSCI-LANDMRK, V11, P733, DOI 10.2741/1831; Le Naour F, 2006, MOL CELL PROTEOMICS, V5, P845, DOI 10.1074/mcp.M500330-MCP200; Li L, 2018, INT J ONCOL, V52, P473, DOI 10.3892/ijo.2017.4231; Luke JJ, 2017, NAT REV CLIN ONCOL, V14, P463, DOI 10.1038/nrclinonc.2017.43; Maelandsmo GM, 2003, CLIN CANCER RES, V9, P3383; Maisonial-Besset A, 2017, ONCOTARGET, V8, P22034, DOI 10.18632/oncotarget.15787; Masse I, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.62; Murakami T, 2001, BIOCHEM BIOPH RES CO, V288, P8, DOI 10.1006/bbrc.2001.5719; Nazarenko I, 2010, CANCER RES, V70, P1668, DOI 10.1158/0008-5472.CAN-09-2470; Pan SJ, 2015, INT J MOL SCI, V16, P5363, DOI 10.3390/ijms16035363; Pan SJ, 2015, BIOCHEM BIOPH RES CO, V458, P476, DOI 10.1016/j.bbrc.2015.01.128; Park CS, 2016, ONCOGENE, V35, P4540, DOI 10.1038/onc.2015.520; Rodia MT, 2016, ONCOTARGET, V7, P30295, DOI 10.18632/oncotarget.8108; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Seubert B, 2015, INT J CANCER, V136, P2304, DOI 10.1002/ijc.29296; Shain AH, 2016, NEW ENGL J MED, V374, P995, DOI 10.1056/NEJMc1515834; Sinnberg T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023429; SZALA S, 1990, P NATL ACAD SCI USA, V87, P3542, DOI 10.1073/pnas.87.9.3542; Yeh I, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00758-3; Yue SJ, 2015, ONCOTARGET, V6, P2366, DOI 10.18632/oncotarget.2958; Zhou Z, 2008, CLIN EXP METASTAS, V25, P537, DOI 10.1007/s10585-008-9168-0; Zoller M, 2009, NAT REV CANCER, V9, P40, DOI 10.1038/nrc2543	51	16	16	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2019	38	20					3781	3793		10.1038/s41388-019-0691-z	http://dx.doi.org/10.1038/s41388-019-0691-z			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HY3OI	30679790				2022-12-17	WOS:000468035600002
J	Sloot, YJE; Rabold, K; Netea, MG; Smit, JWA; Hoogerbrugge, N; Netea-Maier, RT				Sloot, Yvette J. E.; Rabold, Katrin; Netea, Mihai G.; Smit, Johannes W. A.; Hoogerbrugge, Nicoline; Netea-Maier, Romana T.			Effect of PTEN inactivating germline mutations on innate immune cell function and thyroid cancer-induced macrophages in patients with PTEN hamartoma tumor syndrome	ONCOGENE			English	Article							HEMATOPOIETIC STEM-CELLS; COWDEN SYNDROME; METFORMIN; MTOR; MYELOPOIESIS; REINFECTION; EXPRESSION; PROTECTION; MONOCYTES; KINASE	PTEN hamartoma tumor syndrome (PHTS) is caused by inactivating germline PTEN mutations with subsequent activation of Akt-mTOR signaling, leading to an increased risk of developing thyroid carcinoma (TC). Activation of Akt-mTOR signaling is essential for innate immune cell activation and reprogramming of TC-induced macrophages. Here, we aim to assess the effect of PTEN mutations on innate immune cell function in PHTS patients, especially in the context of TC, using a unique ex vivo model. Monocyte-derived cytokine responses were assessed in 29 PHTS patients and 29 controls. To assess the functional profile of TC-induced-macrophages, a co-culture model with two TC cell lines was performed. Rapamycin, a lactate transport blocker and metformin were used as modulators of the Akt-mTOR pathway and cell metabolism. Monocytes from PHTS patients showed increased production of IL-6, TNF-alpha, IL-8 and MCP-1, and higher lactate production. After co-culture with TC cell lines, TC-induced macrophages showed significantly increased production of cytokines in both patients and controls, especially after co-culture with a PTEN-deficient TC cell line; these effects were abolished after use of rapamycin or a lactate transport blocker. Metformin blocked the production of anti-inflammatory cytokines. In conclusion, innate immune cells from PHTS patients have increased lactate production and a more proinflammatory phenotype, especially after co-culture with PTEN-deficient TC. Metformin promotes a proinflammatory phenotype by blocking anti-inflammatory cytokine response, whereas rapamycin reduces production of proinflammatory cytokines. This indicates that PHTS patients may benefit from treatment with mTOR blocking agents to limit the inflammatory response in the tumor microenvironment.	[Sloot, Yvette J. E.; Rabold, Katrin; Smit, Johannes W. A.; Netea-Maier, Romana T.] Radboud Univ Nijmegen, Med Ctr, Div Endocrinol, Dept Internal Med, Nijmegen, Netherlands; [Rabold, Katrin] Radboud Univ Nijmegen, Med Ctr, Dept Radiat Oncol, Radiotherapy & OncoImmunol Lab, Nijmegen, Netherlands; [Netea, Mihai G.] Radboud Univ Nijmegen, Med Ctr, Dept Internal Med, Nijmegen, Netherlands; [Netea, Mihai G.] Radboud Univ Nijmegen, Med Ctr, Radboud Ctr Infect Dis RCI, Nijmegen, Netherlands; [Hoogerbrugge, Nicoline] Radboud Univ Nijmegen, Med Ctr, Dept Human Genet, Nijmegen, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen	Netea-Maier, RT (corresponding author), Radboud Univ Nijmegen, Med Ctr, Div Endocrinol, Dept Internal Med, Nijmegen, Netherlands.	romana.netea-maier@radboudumc.nl	Netea, Mihai/N-5155-2014; Rabold, Katrin/R-9495-2017	Netea, Mihai/0000-0003-2421-6052	Netherlands Cancer Foundation (KWF) [10559]; Spinoza grant of the Netherlands Organization for Scientific Research	Netherlands Cancer Foundation (KWF); Spinoza grant of the Netherlands Organization for Scientific Research	This work was supported by a grant from the Netherlands Cancer Foundation (KWF) [grant number #10559, 2017]. MGN was supported by a Spinoza grant of the Netherlands Organization for Scientific Research.	Aguirre-Gamboa R, 2016, CELL REP, V17, P2474, DOI 10.1016/j.celrep.2016.10.053; Amer M, 2011, INT J DERMATOL, V50, P516, DOI 10.1111/j.1365-4632.2010.04669.x; Arts RJW, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1229725; Arts RJW, 2016, CELL REP, V17, P2562, DOI 10.1016/j.celrep.2016.11.011; Bekkering S, 2016, CLIN VACCINE IMMUNOL, V23, P926, DOI 10.1128/CVI.00349-16; Bridges HR, 2014, BIOCHEM J, V462, P475, DOI 10.1042/BJ20140620; Caillou B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022567; Chen HH, 2017, J ALLERGY CLIN IMMUN, V139, P607, DOI 10.1016/j.jaci.2016.03.059; Cheng SC, 2014, SCIENCE, V345, P1579, DOI 10.1126/science.1250684; Colegio OR, 2014, NATURE, V513, P559, DOI 10.1038/nature13490; Delgoffe GM, 2009, IMMUNITY, V30, P832, DOI 10.1016/j.immuni.2009.04.014; Dinarello CA, 2011, BLOOD, V117, P3720, DOI 10.1182/blood-2010-07-273417; Fu YC, 2004, BLOOD CELL MOL DIS, V32, P182, DOI 10.1016/j.bcmd.2003.09.002; Han BY, 2015, TUMOR BIOL, V36, P6295, DOI 10.1007/s13277-015-3315-4; Heindl M, 2012, GASTROENTEROLOGY, V142, P1093, DOI 10.1053/j.gastro.2012.01.011; Hou P, 2007, CLIN CANCER RES, V13, P1161, DOI 10.1158/1078-0432.CCR-06-1125; Jang EK, 2015, EUR THYROID J, V4, P181, DOI 10.1159/000437365; Kleinnijenhuis J, 2012, P NATL ACAD SCI USA, V109, P17537, DOI 10.1073/pnas.1202870109; Klubo-Gwiezdzinska J, 2013, J CLIN ENDOCR METAB, V98, P3269, DOI 10.1210/jc.2012-3799; Kozicky LK, 2015, SEMIN IMMUNOL, V27, P276, DOI 10.1016/j.smim.2015.07.001; Landsberg J, 2012, NATURE, V490, P412, DOI 10.1038/nature11538; Mehta A, 2018, CANCER DISCOV, V8, P935, DOI 10.1158/2159-8290.CD-17-1178; Mitroulis I, 2018, CELL, V172, P147, DOI 10.1016/j.cell.2017.11.034; Molnarfi N, 2007, J IMMUNOL, V178, P446, DOI 10.4049/jimmunol.178.1.446; Morani F, 2014, J MOL ENDOCRINOL, V53, P247, DOI 10.1530/JME-14-0118; Murdoch C, 2008, NAT REV CANCER, V8, P618, DOI 10.1038/nrc2444; Netea MG, 2017, J LEUKOCYTE BIOL, V102, P1323, DOI 10.1189/jlb.5RI0217-064RR; Netea MG, 2016, SCIENCE, V352, DOI 10.1126/science.aaf1098; Newton RH, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00151; Nieuwenhuis MH, 2014, FAM CANCER, V13, P57, DOI 10.1007/s10689-013-9674-3; Noy R, 2014, IMMUNITY, V41, P49, DOI 10.1016/j.immuni.2014.06.010; Peng WY, 2016, CANCER DISCOV, V6, P202, DOI 10.1158/2159-8290.CD-15-0283; Phadngam S, 2016, ONCOTARGET, V7, P84999, DOI 10.18632/oncotarget.13113; Pilarski R, 2013, JNCI-J NATL CANCER I, V105, P1607, DOI 10.1093/jnci/djt277; Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014; Quintin J, 2012, CELL HOST MICROBE, V12, P223, DOI 10.1016/j.chom.2012.06.006; Ryder M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054302; Saccardi A, 1994, Minerva Stomatol, V43, P417; Sarrazy V, 2016, CIRC RES, V118, P1062, DOI 10.1161/CIRCRESAHA.115.307599; Schweppe RE, 2008, J CLIN ENDOCR METAB, V93, P4331, DOI 10.1210/jc.2008-1102; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; STARINK TM, 1986, CLIN GENET, V29, P222; Xie SB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094496; Xu J, 2012, CRIT REV FOOD SCI, V52, P373, DOI 10.1080/10408398.2010.500245; Zhang JW, 2006, NATURE, V441, P518, DOI 10.1038/nature04747; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI13505; 1989, OBSTET GYNECOL 2, V73, P890	47	16	17	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 9	2019	38	19					3743	3755		10.1038/s41388-019-0685-x	http://dx.doi.org/10.1038/s41388-019-0685-x			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HX4OU	30670777				2022-12-17	WOS:000467379600013
J	Zhou, HY; Yu, CL; Kong, LM; Xu, XL; Yan, JM; Li, YC; An, T; Gong, L; Gong, YX; Zhu, HF; Zhang, HB; Yang, XD; Li, Y				Zhou, Hongyu; Yu, Chunlei; Kong, Lingmei; Xu, Xiaoliang; Yan, Juming; Li, Yingchao; An, Tao; Gong, Liang; Gong, Yaxiao; Zhu, Huifang; Zhang, Hongbin; Yang, Xiaodong; Li, Yan			B591, a novel specific pan-PI3K inhibitor, preferentially targets cancer stem cells	ONCOGENE			English	Article							ACUTE MYELOID-LEUKEMIA; IN-VITRO PROPAGATION; MTOR; ACTIVATION; PATHWAY; IDENTIFICATION; EXPRESSION; VIABILITY; RECEPTOR; GROWTH	Cancer stem cells (CSCs) have been implicated in metastasis, relapse, and therapeutic resistance of cancer, so successful cancer therapy may therefore require the development of drugs against CSCs or combining anti-CSCs drugs with conventional therapies. The phosphoinositide 3-kinase (PI3K) signaling pathway is one of the most frequently activated signaling pathways in human cancer, playing a central role in tumorigenesis as well as the maintenance of CSCs. Here, we designed and identified B591, a dihydrobenzofuran-imidazolium salt, as a novel specific pan-PI3K inhibitor with potent inhibitory activity against class I PI3K isoforms, which showed effective inhibition of cellular PI3K/mTOR signaling pathway and robust antitumor activity in a set of cancer cell lines. Notably, compared with bulk tumor cell populations, B591 exhibited more potency in suppressing CSCs survival and inducing CSCs apoptosis, and presence of B591 effectively eliminated paclitaxel-enriched CSCs. B591 diminished self-renewal capacity and decreased the expression of epithelial-mesenchymal transition (EMT) markers of CSCs. In vivo, B591 preferentially decreased CSCs levels in mouse xenograft model of human breast cancer as evidenced especially by remarkable reduction of tumor-initiating ability. Consistent with the preferential targeting of CSCs, B591 effectively inhibited breast tumor metastasis and delayed tumor regrowth following paclitaxel treatment. Taken together, our findings establish B591, a novel PI3K inhibitor, as a strong candidate for clinical evaluation as a CSCs targeting agent.	[Zhou, Hongyu; Yu, Chunlei; Kong, Lingmei; Yan, Juming; An, Tao; Gong, Liang; Gong, Yaxiao; Zhu, Huifang; Li, Yan] Chinese Acad Sci, Kunming Inst Bot, State Key Lab Phytochem & Plant Resources West Ch, Kunming, Yunnan, Peoples R China; [Yu, Chunlei] North Sichuan Med Coll, Sch Pharm, Inst Mat Med, Nanchong, Peoples R China; [Xu, Xiaoliang; Li, Yingchao; Zhang, Hongbin; Yang, Xiaodong] Yunnan Univ, Sch Chem Sci & Technol, Minist Educ & Yunnan Prov, Key Lab Med Chem Nat Resource, Kunming, Yunnan, Peoples R China; [Yan, Juming; Gong, Liang; Gong, Yaxiao; Zhu, Huifang] Univ Chinese Acad Sci, Beijing, Peoples R China; [An, Tao; Li, Yan] Chinese Acad Sci, Kunming Inst Bot, Yunnan Key Lab Nat Med Chem, Kunming, Yunnan, Peoples R China	Chinese Academy of Sciences; Kunming Institute of Botany, CAS; North Sichuan Medical University; Yunnan University; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Chinese Academy of Sciences; Kunming Institute of Botany, CAS	Li, Y (corresponding author), Chinese Acad Sci, Kunming Inst Bot, State Key Lab Phytochem & Plant Resources West Ch, Kunming, Yunnan, Peoples R China.; Zhang, HB; Yang, XD (corresponding author), Yunnan Univ, Sch Chem Sci & Technol, Minist Educ & Yunnan Prov, Key Lab Med Chem Nat Resource, Kunming, Yunnan, Peoples R China.; Li, Y (corresponding author), Chinese Acad Sci, Kunming Inst Bot, Yunnan Key Lab Nat Med Chem, Kunming, Yunnan, Peoples R China.	zhanghb@ynu.edu.cn; xdyang@ynu.edu.cn; liyanb@mail.kib.ac.cn	Yu, Chunlei/I-9383-2016	Yu, Chunlei/0000-0002-2934-2122; Yan, Juming/0000-0003-0857-8870; Yang, Xiaodong/0000-0002-8466-5418; Zhou, Hongyu/0000-0001-5852-3953	National Natural Science Foundation of China [U1402227, 21662043, 81302807]; Yunnan Province [U1402227]; Program for Changjiang Scholars and Innovative Research Team in University [IRT17R94]; Exploitation and Utilization of Abundant Natural Products from Plants from Kunming Institute of Botany [KIB2017009]; West Light Foundation of The Chinese Academy of Sciences	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Yunnan Province; Program for Changjiang Scholars and Innovative Research Team in University(Program for Changjiang Scholars & Innovative Research Team in University (PCSIRT)); Exploitation and Utilization of Abundant Natural Products from Plants from Kunming Institute of Botany; West Light Foundation of The Chinese Academy of Sciences(Chinese Academy of Sciences)	This work was supported by the Joint Funds of the National Natural Science Foundation of China and Yunnan Province (U1402227), the Program for Changjiang Scholars and Innovative Research Team in University (IRT17R94), the Exploitation and Utilization of Abundant Natural Products from Plants from Kunming Institute of Botany (KIB2017009), the National Natural Science Foundation of China (No. 21662043, 81302807), and the West Light Foundation of The Chinese Academy of Sciences (H.Z.).	Ahmed D, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.35; Akbari-Birgani S, 2016, DRUG DISCOV TODAY, V21, P836, DOI 10.1016/j.drudis.2016.03.004; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Carracedo A, 2008, J CLIN INVEST, V118, P3065, DOI [10.1172/jCI34739, 10.1172/JCI34739]; Chang L, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.407; Chen K, 2013, ACTA PHARMACOL SIN, V34, P732, DOI 10.1038/aps.2013.27; Chen XS, 2013, MOL CANCER RES, V11, P1269, DOI 10.1158/1541-7786.MCR-13-0212; Culjkovic B, 2008, J CELL BIOL, V181, P51, DOI 10.1083/jcb.200707018; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; Djuzenova CS, 2016, ONCOTARGET, V7, P38191, DOI 10.18632/oncotarget.9501; Dolgikh N, 2018, CANCER RES, V78, P2000, DOI 10.1158/0008-5472.CAN-17-1737; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Dubrovska A, 2009, P NATL ACAD SCI USA, V106, P268, DOI 10.1073/pnas.0810956106; Efeyan A, 2010, CURR OPIN CELL BIOL, V22, P169, DOI 10.1016/j.ceb.2009.10.007; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Fillmore CM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1982; Gedaly R, 2010, ANTICANCER RES, V30, P4951; Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; Hu YP, 2012, AM J CANCER RES, V2, P340; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Ilagan E, 2016, TRENDS CANCER, V2, P241, DOI 10.1016/j.trecan.2016.03.008; Korkaya H, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000121; Kwitkowski VE, 2010, ONCOLOGIST, V15, P428, DOI 10.1634/theoncologist.2009-0178; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Leung ELH, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0065-9; Liu PD, 2015, CANCER DISCOV, V5, P1194, DOI 10.1158/2159-8290.CD-15-0460; Liu SL, 2010, J CLIN ONCOL, V28, P4006, DOI 10.1200/JCO.2009.27.5388; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Markham A, 2017, DRUGS, V77, P1247, DOI 10.1007/s40265-017-0771-8; Marone R, 2008, BBA-PROTEINS PROTEOM, V1784, P159, DOI 10.1016/j.bbapap.2007.10.003; Medema JP, 2013, NAT CELL BIOL, V15, P338, DOI 10.1038/ncb2717; Miller BW, 2015, CLIN CANCER RES, V21, P1525, DOI 10.1158/1078-0432.CCR-14-2522; Morales GA, 2013, J MED CHEM, V56, P1922, DOI 10.1021/jm301522m; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Pattabiraman DR, 2014, NAT REV DRUG DISCOV, V13, P497, DOI 10.1038/nrd4253; Peitzsch C, 2017, SEMIN CANCER BIOL, V44, P10, DOI 10.1016/j.semcancer.2017.02.011; Ponti D, 2005, CANCER RES, V65, P5506, DOI 10.1158/0008-5472.CAN-05-0626; Pulaski BA, 2000, CANCER RES, V60, P2710; Rahman M, 2011, NEUROSURGERY, V68, P531, DOI 10.1227/NEU.0b013e3181ff9eb5; Riaz N, 2018, TRANSL ONCOL, V11, P920, DOI 10.1016/j.tranon.2018.05.002; Ricardo S, 2011, J CLIN PATHOL, V64, P937, DOI 10.1136/jcp.2011.090456; Rong L, 2008, RNA, V14, P1318, DOI 10.1261/rna.950608; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Smith AL, 2012, J MED CHEM, V55, P5188, DOI 10.1021/jm300184s; Steeg PS, 2016, NAT REV CANCER, V16, P201, DOI 10.1038/nrc.2016.25; Thorpe LM, 2015, NAT REV CANCER, V15, P7, DOI 10.1038/nrc3860; Wan X, 2007, ONCOGENE, V26, P1932, DOI 10.1038/sj.onc.1209990; Weng LP, 2001, HUM MOL GENET, V10, P599, DOI 10.1093/hmg/10.6.599; WEXLER H, 1966, JNCI-J NATL CANCER I, V36, P641, DOI 10.1093/jnci/36.4.641; Xia P, 2015, AM J CANCER RES, V5, P1602; Zhou JB, 2007, P NATL ACAD SCI USA, V104, P16158, DOI 10.1073/pnas.0702596104; Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025	55	16	17	3	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2019	38	18					3371	3386		10.1038/s41388-018-0674-5	http://dx.doi.org/10.1038/s41388-018-0674-5			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HW3RI	30635656	Green Published, hybrid			2022-12-17	WOS:000466610000004
J	Witten, LW; Cheng, CJ; Slac, FJ				Witten, Lisa W.; Cheng, Christopher J.; Slac, Frank J.			miR-155 drives oncogenesis by promoting and cooperating with mutations in the c-Kit oncogene	ONCOGENE			English	Article							KINASE-ACTIVITY; MICRORNA-155; EXPRESSION; INHIBITION; ACTIVATION; CANCER; CELLS; MODEL; OVEREXPRESSION; PROLIFERATION	MicroRNAs (miRNAs) have emerged as crucial players in the development and maintenance of disease. miR-155 is an inflammation-associated, oncogenic miRNA, frequently overexpressed in hematological malignancies and solid tumors. However, the mechanism of oncogenesis by miR-155 is not well characterized, and research has focused primarily on individual, direct targets, which does not recapitulate the complexities of cancer. Using a powerful, inducible transgenic mouse model that overexpresses miR-155 and develops miR-155-addicted hematological malignancy, we describe here a multi-step process of oncogenesis by miR-155, which involves cooperation between miR-155, its direct targets, and other oncogenes. miR-155 is known to target DNA-repair proteins, leading to a mutator phenotype, and we find that over 93% of tumors in our miR-155 overexpressing mice contain activating mutations in a single oncogene, c-Kit. Treating mice with dasatinib or imatinib, which target c-Kit, resulted in complete tumor regression, indicating that c-Kit activity is crucial in the oncogenic process. Interestingly, c-Kit expression is high when miR-155 is overexpressed, indicating further cooperation between miR-155 and c-Kit. Our findings support a multi-step model of oncogenesis by miR-155 in which miR-155 promotes both a mutator phenotype and a cellular environment particularly susceptible to mutations in a given oncogene.	[Witten, Lisa W.; Slac, Frank J.] Beth Israel Deaconess Med Ctr, Dept Pathol, HMS Initiat RNA Med, 330 Brookline Ave, Boston, MA 02115 USA; [Cheng, Christopher J.] Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06511 USA; [Cheng, Christopher J.] Casebia Therapeut, 610 Main St, Cambridge, MA 02139 USA	Harvard University; Beth Israel Deaconess Medical Center; Yale University	Slac, FJ (corresponding author), Beth Israel Deaconess Med Ctr, Dept Pathol, HMS Initiat RNA Med, 330 Brookline Ave, Boston, MA 02115 USA.	fslack@bidmc.harvard.edu		Slack, Frank/0000-0001-8263-0409	Ludwig Center at Harvard	Ludwig Center at Harvard	We wish to thank Bohyung Yoon and Eleni Anastasiadou for assistance with animal care and Jacob Witten for critical reading of the manuscript. The work was supported by the Ludwig Center at Harvard.	Babar IA, 2012, P NATL ACAD SCI USA, V109, pE1695, DOI 10.1073/pnas.1201516109; Cheng CJ, 2015, NATURE, V518, P107, DOI 10.1038/nature13905; Costinean S, 2006, P NATL ACAD SCI USA, V103, P7024, DOI 10.1073/pnas.0602266103; Costinean S, 2009, BLOOD, V114, P1374, DOI 10.1182/blood-2009-05-220814; Czochor JR, 2016, MOL CANCER RES, V14, P363, DOI 10.1158/1541-7786.MCR-15-0399; Dorsett Y, 2008, IMMUNITY, V28, P630, DOI 10.1016/j.immuni.2008.04.002; Eis PS, 2005, P NATL ACAD SCI USA, V102, P3627, DOI 10.1073/pnas.0500613102; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Faraoni I, 2009, BBA-MOL BASIS DIS, V1792, P497, DOI 10.1016/j.bbadis.2009.02.013; Fulci V, 2007, BLOOD, V109, P4944, DOI 10.1182/blood-2006-12-062398; Gironella M, 2007, P NATL ACAD SCI USA, V104, P16170, DOI 10.1073/pnas.0703942104; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Heinrich MC, 2000, BLOOD, V96, P925, DOI 10.1182/blood.V96.3.925.015k50_925_932; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Kastner P, 2008, INT J BIOCHEM CELL B, V40, P22, DOI 10.1016/j.biocel.2007.01.026; Klimenko OV, 2013, CANCER GENE THER, V20, P237, DOI 10.1038/cgt.2013.11; Kosmider O, 2005, CANCER CELL, V8, P467, DOI 10.1016/j.ccr.2005.11.009; Kosmider O, 2006, CELL CYCLE, V5, P569, DOI 10.4161/cc.5.6.2577; Larizza L, 2005, LEUKEMIA LYMPHOMA, V46, P247, DOI 10.1080/10428190400007565; Lennartsson J, 2012, PHYSIOL REV, V92, P1619, DOI 10.1152/physrev.00046.2011; Mol CD, 2004, J BIOL CHEM, V279, P31655, DOI 10.1074/jbc.M403319200; Ning ZQ, 2001, BLOOD, V97, P3559, DOI 10.1182/blood.V97.11.3559; O'Connell RM, 2008, J EXP MED, V205, P585, DOI 10.1084/jem.20072108; O'Connell RM, 2009, P NATL ACAD SCI USA, V106, P7113, DOI 10.1073/pnas.0902636106; Pedersen IM, 2009, EMBO MOL MED, V1, P288, DOI 10.1002/emmm.200900028; Ratajczak MZ, 1998, BLOOD, V91, P1934, DOI 10.1182/blood.V91.6.1934.1934_1934_1946; Rupaimoole R, 2017, NAT REV DRUG DISCOV, V16, P203, DOI 10.1038/nrd.2016.246; Schittenhelm MM, 2006, CANCER RES, V66, P473, DOI 10.1158/0008-5472.CAN-05-2050; Thai TH, 2007, SCIENCE, V316, P604, DOI 10.1126/science.1141229; Tili E, 2011, P NATL ACAD SCI USA, V108, P4908, DOI 10.1073/pnas.1101795108; Valeri N, 2010, P NATL ACAD SCI USA, V107, P21098, DOI 10.1073/pnas.1015541107; Valeri N, 2010, P NATL ACAD SCI USA, V107, P6982, DOI 10.1073/pnas.1002472107; Vandenbark GR, 1996, CELL GROWTH DIFFER, V7, P1383; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Wallace JA, 2017, BLOOD, V129, P3074, DOI 10.1182/blood-2016-09-740209	36	16	16	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2019	38	12					2151	2161		10.1038/s41388-018-0571-y	http://dx.doi.org/10.1038/s41388-018-0571-y			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP6UR	30459357				2022-12-17	WOS:000461822600011
J	Toshiyama, R; Konno, M; Eguchi, H; Takemoto, H; Noda, T; Asai, A; Koseki, J; Haraguchi, N; Ueda, Y; Matsushita, K; Asukai, K; Ohashi, T; Iwagami, Y; Yamada, D; Sakai, D; Asaoka, T; Kudo, T; Kawamoto, K; Gotoh, K; Kobayashi, S; Satoh, T; Doki, Y; Nishiyama, N; Mori, M; Ishii, H				Toshiyama, Reishi; Konno, Masamitsu; Eguchi, Hidetoshi; Takemoto, Hiroyasu; Noda, Takehiro; Asai, Ayumu; Koseki, Jun; Haraguchi, Naotsugu; Ueda, Yuji; Matsushita, Katsunori; Asukai, Kei; Ohashi, Tomofumi; Iwagami, Yoshifumi; Yamada, Daisaku; Sakai, Daisuke; Asaoka, Tadafumi; Kudo, Toshihiro; Kawamoto, Koichi; Gotoh, Kunihito; Kobayashi, Shogo; Satoh, Taroh; Doki, Yuichiro; Nishiyama, Nobuhiro; Mori, Masaki; Ishii, Hideshi			Poly(ethylene glycol)-poly(lysine) block copolymer-ubenimex conjugate targets aminopeptidase N and exerts an antitumor effect in hepatocellular carcinoma stem cells	ONCOGENE			English	Article							CANCER; BESTATIN; THERAPY; DRUG; CD13; INHIBITOR; APOPTOSIS; BIOLOGY	Previous studies highlighted that aminopeptidase N (APN)/CD13 acts as a scavenger in the survival of hepatocellular carcinoma (HCC) stem cells by reducing reactive oxygen species (ROS) levels. Hence, it has been proposed that APN/CD13 inhibition can increase cellular ROS levels and sensitize cells to chemotherapeutic agents. Although ubenimex, also known as bestatin, competitively inhibits proteases such as APN/CD13 on the cellular membrane and it is clinically used for patients with acute myeloid leukemia and lymphedema, research has demonstrated that higher concentrations of the agent induce the death of APN/CD13(+) HCC stem cells. In this study, we developed a poly(ethylene glycol)-poly(lysine) block copolymer-ubenimex conjugate (PEG-b-PLys(Ube)) to increase the efficacy of reagents in APN/CD13(+) cancer stem cells. Exposure to PEG-b-PLys(Ube) increased the intracellular ROS concentration by inhibiting APN enzyme activity, permitting the induction of apoptosis and attenuation of HCC cell proliferation. In addition, PEG-b-PLys(Ube) exhibited a relatively stronger antitumor effect in mice than PEG-b-PLys alone or phosphate-buffered saline. Moreover, an isobologram analysis revealed that combinations of fluorouracil, cisplatin, or doxorubicin with PEG-b-PLys(Ube) exhibited synergistic effects. This study demonstrated that PEG-b-PLys(Ube) does not impair the properties of ubenimex and exerts a potent antitumor effect.	[Toshiyama, Reishi; Eguchi, Hidetoshi; Noda, Takehiro; Haraguchi, Naotsugu; Ueda, Yuji; Matsushita, Katsunori; Asukai, Kei; Ohashi, Tomofumi; Iwagami, Yoshifumi; Yamada, Daisaku; Asaoka, Tadafumi; Kawamoto, Koichi; Gotoh, Kunihito; Kobayashi, Shogo; Doki, Yuichiro; Mori, Masaki] Osaka Univ, Grad Sch Med, Dept Gastroenterol Surg, Suita, Osaka 5650871, Japan; [Toshiyama, Reishi; Konno, Masamitsu; Asai, Ayumu; Ueda, Yuji; Matsushita, Katsunori; Asukai, Kei; Ohashi, Tomofumi; Sakai, Daisuke; Kudo, Toshihiro; Kawamoto, Koichi; Satoh, Taroh] Osaka Univ, Grad Sch Med, Dept Frontier Sci Canc, Suita, Osaka 5650871, Japan; [Toshiyama, Reishi; Konno, Masamitsu; Asai, Ayumu; Ueda, Yuji; Matsushita, Katsunori; Asukai, Kei; Ohashi, Tomofumi; Sakai, Daisuke; Kudo, Toshihiro; Kawamoto, Koichi; Satoh, Taroh] Osaka Univ, Grad Sch Med, Dept Chemotherapy, Suita, Osaka 5650871, Japan; [Toshiyama, Reishi; Asai, Ayumu; Koseki, Jun; Ueda, Yuji; Matsushita, Katsunori; Asukai, Kei; Ohashi, Tomofumi; Ishii, Hideshi] Osaka Univ, Grad Sch Med, Dept Med Data Sci, Suita, Osaka 5650871, Japan; [Takemoto, Hiroyasu; Nishiyama, Nobuhiro] Tokyo Inst Technol, Lab Chem & Life Sci, Inst Innovat Res, Midori Ku, Nagatsuta Cho, Yokohama, Kanagawa, Japan	Osaka University; Osaka University; Osaka University; Osaka University; Tokyo Institute of Technology	Mori, M (corresponding author), Osaka Univ, Grad Sch Med, Dept Gastroenterol Surg, Suita, Osaka 5650871, Japan.; Ishii, H (corresponding author), Osaka Univ, Grad Sch Med, Dept Med Data Sci, Suita, Osaka 5650871, Japan.	mmori@gesurg.med.osaka-u.ac.jp; hishii@cfs.med.osaka-u.ac.jp	Koseki, Jun/ABH-7420-2020; Takemoto, Hiroyasu/F-1886-2014; Satoh, Taroh/AAF-7913-2020; Satoh, Taroh/AAF-5193-2021; Ishii, Hideshi/AAV-5317-2020; Iwagami, Yoshifumi/AAJ-3184-2021	Takemoto, Hiroyasu/0000-0002-0264-8746; Satoh, Taroh/0000-0002-4615-2638; Noda, Takehiro/0000-0002-6768-5783	Ministry of Education, Culture, Sports, Science, and Technology [17H04282, 17K19698, 16K15615, 15H05791]; Ministry of Education, Culture, Sports, Science, and Technology (P-DIRECT); Ministry of Education, Culture, Sports, Science, and Technology (P-CREATE); Ministry of Education, Culture, Sports, Science, and Technology (AMED-Japan Cancer Research Project)	Ministry of Education, Culture, Sports, Science, and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Ministry of Education, Culture, Sports, Science, and Technology (P-DIRECT); Ministry of Education, Culture, Sports, Science, and Technology (P-CREATE); Ministry of Education, Culture, Sports, Science, and Technology (AMED-Japan Cancer Research Project)	This work received financial support from grants-in-aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology (grant no. 17H04282; 17K19698; 16K15615; 15H05791; P-DIRECT; P-CREATE; AMED-Japan Cancer Research Project).	Abou-Alfa GK, 2006, SEMIN ONCOL, V33, pS79, DOI 10.1053/j.seminoncol.2006.10.015; [Anonymous], 1980, RECENT RESULTS CANC, V75, P126; Bao Bin, 2013, Curr Protoc Pharmacol, VChapter 14, DOI 10.1002/0471141755.ph1425s61; Bijnsdorp IV, 2011, METHODS MOL BIOL, V731, P421, DOI 10.1007/978-1-61779-080-5_34; BRULEYROSSET M, 1979, IMMUNOLOGY, V38, P75; Chen MW, 2010, CANCER RES, V70, P7830, DOI 10.1158/0008-5472.CAN-10-0833; Colvin H, 2017, ANN GASTROENT SURG, V1, P5, DOI 10.1002/ags3.12008; Dando I, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/425708; Ding M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035153; Fischer D, 2003, BIOMATERIALS, V24, P1121, DOI 10.1016/S0142-9612(02)00445-3; Haraguchi N, 2010, J CLIN INVEST, V120, P3326, DOI 10.1172/JCI42550; Hitzerd SM, 2014, AMINO ACIDS, V46, P793, DOI 10.1007/s00726-013-1648-0; Hu YP, 2012, AM J CANCER RES, V2, P340; Ishii H, 2008, CANCER SCI, V99, P1871, DOI 10.1111/j.1349-7006.2008.00914.x; Jhaveri AM, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00077; Ji JF, 2012, SEMIN ONCOL, V39, P461, DOI 10.1053/j.seminoncol.2012.05.011; Karsten U, 2013, SPRINGERPLUS, V2, DOI 10.1186/2193-1801-2-301; Kumamoto Y, 1985, Hinyokika Kiyo, V31, P1861; Lee H, 2002, J CONTROL RELEASE, V79, P283, DOI 10.1016/S0168-3659(02)00002-0; Liu SP, 2013, GASTROENTEROLOGY, V144, P1031, DOI 10.1053/j.gastro.2013.01.046; LOOK AT, 1989, J CLIN INVEST, V83, P1299, DOI 10.1172/JCI114015; Luan YP, 2007, CURR MED CHEM, V14, P639, DOI 10.2174/092986707780059571; Ma S, 2008, MOL CANCER RES, V6, P1146, DOI 10.1158/1541-7786.MCR-08-0035; Ma S, 2007, GASTROENTEROLOGY, V132, P2542, DOI 10.1053/j.gastro.2007.04.025; Mi P, 2017, J CONTROL RELEASE, V254, P1, DOI 10.1016/j.jconrel.2017.03.036; Mishra P, 2016, ASIAN J PHARM SCI, V11, P337, DOI 10.1016/j.ajps.2015.08.011; NIIMOTO M, 1990, JPN J SURG, V20, P186, DOI 10.1007/BF02470767; Oikawa T, 2013, HEPATOLOGY, V57, P1469, DOI 10.1002/hep.26159; Osada K, 2009, J R SOC INTERFACE, V6, pS325, DOI 10.1098/rsif.2008.0547.focus; Ribas A, 2017, CELL, V170, P1109, DOI 10.1016/j.cell.2017.08.027; Rusznyak LFM, 1967, PHYSL PATHOLOGY, P475; Schwabe RF, 2006, AM J PHYSIOL-GASTR L, V290, pG583, DOI 10.1152/ajpgi.00422.2005; Sekine K, 1999, LEUKEMIA, V13, P729, DOI 10.1038/sj.leu.2401388; Stange T, 1996, ACTA HISTOCHEM, V98, P323, DOI 10.1016/S0065-1281(96)80025-0; Sun JH, 2016, WORLD J GASTROENTERO, V22, P3547, DOI 10.3748/wjg.v22.i13.3547; Takada M, 2009, ACTA ONCOL MADR, V29, P821; TALMADGE JE, 1986, CANCER RES, V46, P4505; Tanjaya J, 2016, BIORESEARCH OPEN ACC, V5, P159, DOI 10.1089/biores.2016.0018; Terauchi M, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-140; Tomimaru Y, 2015, SURG TODAY, V45, P1112, DOI 10.1007/s00595-014-1028-8; UMEZAWA H, 1976, J ANTIBIOT, V29, P97, DOI 10.7164/antibiotics.29.97; Vinogradov S, 2012, NANOMEDICINE-UK, V7, P597, DOI [10.2217/NNM.12.22, 10.2217/nnm.12.22]; Wada H, 2018, SURG TODAY, V48, P73, DOI 10.1007/s00595-017-1553-3; Webster R, 2007, DRUG METAB DISPOS, V35, P9, DOI 10.1124/dmd.106.012419; Wickstrom M, 2011, CANCER SCI, V102, P501, DOI 10.1111/j.1349-7006.2010.01826.x; Yamada N, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06438-y; Yamamoto T, 2004, CLIN CANCER RES, V10, P7884, DOI 10.1158/1078-0432.CCR-04-0794; Yamashita M, 2016, INT J ONCOL, V49, P89, DOI 10.3892/ijo.2016.3496; Yang W, 2008, CANCER RES, V68, P4287, DOI 10.1158/0008-5472.CAN-07-6691; Yang ZF, 2008, CANCER CELL, V13, P153, DOI 10.1016/j.ccr.2008.01.013; Yasunaga M, 2017, BMC BIOTECHNOL, V17, DOI 10.1186/s12896-017-0374-1; Zhao W, 2013, CANCER CELL, V23, P541, DOI 10.1016/j.ccr.2013.02.025; Zhu Z, 2010, INT J CANCER, V126, P2067, DOI 10.1002/ijc.24868	53	16	16	1	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2019	38	2					244	260		10.1038/s41388-018-0406-x	http://dx.doi.org/10.1038/s41388-018-0406-x			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG9XX	30089817				2022-12-17	WOS:000455366700007
J	Stratikopoulos, EE; Kiess, N; Szabolcs, M; Pegno, S; Kakit, C; Wu, XW; Poulikakos, PI; Cheung, P; Schmidt, H; Parsons, R				Stratikopoulos, Elias E.; Kiess, Nicole; Szabolcs, Matthias; Pegno, Sarah; Kakit, Cheung; Wu, Xuewei; Poulikakos, Poulikos, I; Cheung, Pamela; Schmidt, Hank; Parsons, Ramon			Mouse ER+/PIK3CAH1047R breast cancers caused by exogenous estrogen are heterogeneously dependent on estrogen and undergo BIM-dependent apoptosis with BH3 and PI3K agents	ONCOGENE			English	Article							BCL-2 FAMILY; TRANSCRIPTIONAL REGULATION; AROMATASE INHIBITORS; RECEPTOR; RESISTANT; TAMOXIFEN; MUTATIONS; THERAPY; PATHWAY; PIK3CA	Estrogen dependence is major driver of ER + breast cancer, which is associated with PI3K mutation. PI3K inhibition (PI3Ki) can restore dependence on ER signaling for some hormone therapy-resistant ER + breast cancers, but is ineffective in others. Here we show that short-term supplementation with estrogen strongly enhanced Pik3caH1047R-induced mammary tumorigenesis in mice that resulted exclusively in ER + tumors, demonstrating the cooperation of the hormone and the oncogene in tumor development. Similar to human ER + breast cancers that are endocrine-dependent or endocrine-independent at diagnosis, tumor lines from this model retained ER expression but were sensitive or resistant to hormonal therapies. PI3Ki did not induce cell death but did cause upregulation of the pro-apoptotic gene BIM. BH3 mimetics or PI3Ki were unable to restore hormone sensitivity in several resistant mouse and human tumor lines. Importantly however, combination of PI3Ki and BH3 mimetics had a profound, BIM-dependent cytotoxic effect in PIK3CA-mutant cancer cells while sparing normal cells. We propose that addition of BH3 mimetics offers a therapeutic strategy to markedly improve the cytotoxic activity of PI3Ki in hormonal therapy-resistant and ER-independent PIK3CA-mutant breast cancer.	[Stratikopoulos, Elias E.; Kiess, Nicole; Pegno, Sarah; Kakit, Cheung; Wu, Xuewei; Poulikakos, Poulikos, I; Cheung, Pamela; Parsons, Ramon] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Dept Oncol Sci, New York, NY 10029 USA; [Szabolcs, Matthias] Columbia Univ, Dept Pathol, Med Ctr, New York, NY 10032 USA; [Schmidt, Hank] Icahn Sch Med Mt Sinai, Dept Surg, Tisch Canc Inst, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Columbia University; Icahn School of Medicine at Mount Sinai	Parsons, R (corresponding author), Icahn Sch Med Mt Sinai, Tisch Canc Inst, Dept Oncol Sci, New York, NY 10029 USA.	ramon.parsons@mssm.edu		Parsons, Ramon/0000-0002-6656-3514	Komen Foundation Scholar Award [SAC110028]; NCI [R01 CA129432]; Department of Defense Breast Cancer Research Program Era of Hope Award [BC087596]; NATIONAL CANCER INSTITUTE [R35CA220491] Funding Source: NIH RePORTER	Komen Foundation Scholar Award; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Department of Defense Breast Cancer Research Program Era of Hope Award(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We would like to thank Stuart Aaronson and Jerry Chipuk for providing reagents and helpful discussions, Xi Sun for technical assistance and all members of the Parsons laboratory for critical reading of the manuscript. We also thank the Stand Up To Cancer (SU2C) PI3K Dream Team for providing BYL719. This work was supported by the Komen Foundation Scholar Award SAC110028 and NCI R01 CA129432 to R. Parsons. Additional support was given to E. Stratikopoulos from the Department of Defense Breast Cancer Research Program Era of Hope Award BC087596.	Adams JR, 2011, CANCER RES, V71, P2706, DOI 10.1158/0008-5472.CAN-10-0738; Bachelot T, 2012, J CLIN ONCOL, V30, P2718, DOI 10.1200/JCO.2011.39.0708; Baird RD, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.2520; Baselga J, 2016, CANCER RES, V76, DOI 10.1158/1538-7445.SABCS15-OT1-03-14; Baselga J, 2012, NEW ENGL J MED, V366, P520, DOI 10.1056/NEJMoa1109653; Bosch A, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa4442; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Creighton CJ, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2594; Crowder RJ, 2009, CANCER RES, V69, P3955, DOI 10.1158/0008-5472.CAN-08-4450; Dowsett M, 2015, LANCET, V386, P1341, DOI 10.1016/S0140-6736(15)61074-1; Ebi H, 2013, P NATL ACAD SCI USA, V110, P21124, DOI 10.1073/pnas.1314124110; Essafi A, 2005, ONCOGENE, V24, P2317, DOI 10.1038/sj.onc.1208421; Faber AC, 2015, P NATL ACAD SCI USA, V112, pE1288, DOI 10.1073/pnas.1411848112; Gandhi L, 2011, J CLIN ONCOL, V29, P909, DOI 10.1200/JCO.2010.31.6208; Gutierrez MC, 2005, J CLIN ONCOL, V23, P2469, DOI 10.1200/JCO.2005.01.172; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hata AN, 2014, CANCER RES, V74, P3146, DOI 10.1158/0008-5472.CAN-13-3728; Juric D, 2014, ANN ONCOL         S4, V25, piv150, DOI DOI 10.1093/ANNONC/MDU331.11; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Krop IE, 2016, LANCET ONCOL, V17, P811, DOI 10.1016/S1470-2045(16)00106-6; Ludwig T, 2001, ONCOGENE, V20, P3937, DOI 10.1038/sj.onc.1204512; Mayer IA, 2017, CLIN CANCER RES, V23, P26, DOI 10.1158/1078-0432.CCR-16-0134; Mayer IA, 2016, ANNU REV MED, V67, P11, DOI 10.1146/annurev-med-062913-051343; Meyer DS, 2011, CANCER RES, V71, P4344, DOI 10.1158/0008-5472.CAN-10-3827; Miller TW, 2010, J CLIN INVEST, V120, P2406, DOI 10.1172/JCI41680; Mohibi Shakur, 2011, J Carcinog, V10, P35, DOI 10.4103/1477-3163.91116; Mouridsen H, 2003, J CLIN ONCOL, V21, P2101, DOI 10.1200/JCO.2003.04.194; Muranen T, 2012, CANCER CELL, V21, P227, DOI 10.1016/j.ccr.2011.12.024; Ndubaku CO, 2013, J MED CHEM, V56, P4597, DOI 10.1021/jm4003632; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Osborne CK, 2011, ANNU REV MED, V62, P233, DOI 10.1146/annurev-med-070909-182917; Perez K, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.3530; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; Roberts AW, 2016, NEW ENGL J MED, V374, P311, DOI 10.1056/NEJMoa1513257; Roberts AW, 2012, J CLIN ONCOL, V30, P488, DOI 10.1200/JCO.2011.34.7898; Robinson DR, 2013, NAT GENET, V45, P1446, DOI 10.1038/ng.2823; Saal LH, 2005, CANCER RES, V65, P2554, DOI 10.1158/0008-5472-CAN-04-3913; Sabnis G, 2007, CLIN CANCER RES, V13, P2751, DOI 10.1158/1078-0432.CCR-06-2466; Sanchez CG, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2833; Saura C, 2015, CANCER RES, V75; Shamas-Din A, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008714; Stratikopoulos EE, 2015, CANCER CELL, V27, P837, DOI 10.1016/j.ccell.2015.05.006; Sunters A, 2003, J BIOL CHEM, V278, P49795, DOI 10.1074/jbc.M309523200; Tikoo A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036924; Toska E, 2017, SCIENCE, V355, P1324, DOI 10.1126/science.aah6893; Toy W, 2013, NAT GENET, V45, P1439, DOI 10.1038/ng.2822; Vaillant F, 2013, CANCER CELL, V24, P120, DOI 10.1016/j.ccr.2013.06.002; Wilson WH, 2010, LANCET ONCOL, V11, P1149, DOI 10.1016/S1470-2045(10)70261-8; Yu M, 2014, SCIENCE, V345, P216, DOI 10.1126/science.1253533; Yuan W, 2013, ONCOGENE, V32, P318, DOI 10.1038/onc.2012.53	50	16	16	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2019	38	1					47	59		10.1038/s41388-018-0436-4	http://dx.doi.org/10.1038/s41388-018-0436-4			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG2EL	30076411	Green Accepted			2022-12-17	WOS:000454775900004
J	Zhou, YS; Xu, ZJ; Quan, D; Zhang, F; Zhang, H; Xiao, TQ; Hou, SL; Qiao, H; Harismendy, O; Wang, JYJ; Suo, GL				Zhou, Yuanshuai; Xu, Zhongjuan; Quan, Daniel; Zhang, Fan; Zhang, Hai; Xiao, Tongqian; Hou, Shulan; Qiao, Hong; Harismendy, Olivier; Wang, Jean Y. J.; Suo, Guangli			Nuclear respiratory factor 1 promotes spheroid survival and mesenchymal transition in mammary epithelial cells	ONCOGENE			English	Article							MITOCHONDRIAL CALCIUM UNIPORTER; BREAST-CANCER CELLS; PANCREATIC-CANCER; FACTOR-I; BIOGENESIS; EXPRESSION; TRANSCRIPTION; DETACHMENT; REGULATOR; CCDC90A	Epithelial cells aggregate into spheroids when deprived of matrix, and the proclivity for spheroid formation and survival is a hallmark of normal and tumorigenic mammary stem cells. We show here that Nuclear Respiratory Factor 1 (NRF1) is a spheroid promoter by in silico identification of this transcription factor as highly connected to top shRNA-hits deduced from re-iterative selections for shRNAs enriched in MCF10A spheroids. NRF1-promoted spheroid survival is linked to its stimulation of mitochondrial OXPHOS, cell migration, invasion, and mesenchymal transition. Conversely, NRF1 knockdown in breast cancer MDA-MB-231 cells reduced spheroids, migration, invasion, and mesenchymal marker expression. NRF1 knockdown also reduced tumor burden in mammary fat pads and lungs of orthotopic-or tail vein-transplanted mice. With the Luminal A subtype of breast cancer, higher NRF1 expression is associated with lower survival. These results show that NRF1, an activator of mitochondrial metabolism, supports mammary spheroid survival and tumor development.	[Zhou, Yuanshuai; Xu, Zhongjuan; Zhang, Hai; Xiao, Tongqian; Hou, Shulan; Suo, Guangli] Chinese Acad Sci, CAS Key Lab Nanobio Interface, Suzhou Inst Nanotech & Nanobion, Nanjing 215123, Jiangsu, Peoples R China; [Zhou, Yuanshuai; Xiao, Tongqian] Univ Chinese Acad Sci, Beijing 100049, Peoples R China; [Quan, Daniel; Harismendy, Olivier; Wang, Jean Y. J.] Univ Calif San Diego, Sch Med, Dept Med, Div Hematol Oncol,Moores Canc Ctr, La Jolla, CA 92093 USA; [Zhang, Fan; Qiao, Hong] Univ Texas Austin, Dept Mol Biosci, Austin, TX 78712 USA	Chinese Academy of Sciences; Suzhou Institute of Nano-Tech & Nano-Bionics, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; University of California System; University of California San Diego; University of Texas System; University of Texas Austin	Suo, GL (corresponding author), Chinese Acad Sci, CAS Key Lab Nanobio Interface, Suzhou Inst Nanotech & Nanobion, Nanjing 215123, Jiangsu, Peoples R China.	glsuo2013@sinano.ac.cn	Harismendy, Olivier/AAM-2072-2021	Harismendy, Olivier/0000-0002-8098-9888; Quan, Daniel/0000-0003-1752-0080; Wang, Jean Yin Jen/0000-0002-8217-0868	pilot project in the San Diego Systems Biology Center [NIH P50GM085764]; National Natural Science Foundation of China [31471307]; Ministry of Science and Technology (MOST) [2014CB965003, 2017YFA0104301]; Hundred Talent Program of Chinese Academy of Sciences; CAS/SAFEA International Innovation Teams program; NIH [R01CA043054]; NATIONAL CANCER INSTITUTE [R01CA043054] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM085764] Funding Source: NIH RePORTER	pilot project in the San Diego Systems Biology Center; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Science and Technology (MOST)(Ministry of Science and Technology, China); Hundred Talent Program of Chinese Academy of Sciences(Chinese Academy of Sciences); CAS/SAFEA International Innovation Teams program; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank J. Dai, Q. Wang, Z. Zhang, and G. Cheng for insightful comments on the study, and X. He for technical assistance. Nano-Bio-Chem Centre in Suzhou Institute of Nano-Tech and Nano-Bionics (SINANO) is acknowledged for professional assistance of cell imaging and FACS assay. This study was initiated as a pilot project in the San Diego Systems Biology Center (NIH P50GM085764) that supported G.S., D.Q., O.H., and J.Y.J.W.; D.Q. was also supported by a grant to J.Y.J.W. (NIH R01CA043054). The study of NFR1 was supported by National Natural Science Foundation of China (Grant No. 31471307), Ministry of Science and Technology (MOST) (Grant No. 2014CB965003, and 2017YFA0104301) to G.S., who is also supported by Hundred Talent Program of Chinese Academy of Sciences. The study was also supported by the CAS/SAFEA International Innovation Teams program.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Au SH, 2016, P NATL ACAD SCI USA, V113, P4947, DOI 10.1073/pnas.1524448113; Birsoy K, 2015, CELL, V162, P540, DOI 10.1016/j.cell.2015.07.016; Dey D, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005329; Dey P, 2017, NATURE, V542, P119, DOI 10.1038/nature21052; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Grassian AR, 2011, J BIOL CHEM, V286, P79, DOI 10.1074/jbc.M110.169821; Grimshaw MJ, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2106; Hindupur SK, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0420-z; Ivanova MM, 2011, FASEB J, V25, P1402, DOI 10.1096/fj.10-169029; Jeon SM, 2012, NATURE, V485, P661, DOI 10.1038/nature11066; Kelly DP, 2004, GENE DEV, V18, P357, DOI 10.1101/gad.1177604; Kim YN, 2012, INT J CELL BIOL, V2012, DOI DOI 10.1155/2012/306879; Koike-Yusa H, 2014, NAT BIOTECHNOL, V32, P267, DOI 10.1038/nbt.2800; LeBleu VS, 2014, NAT CELL BIOL, V16, P992, DOI 10.1038/ncb3039; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mason JA, 2017, TRENDS CANCER, V3, P475, DOI 10.1016/j.trecan.2017.04.009; Mattingly KA, 2008, MOL ENDOCRINOL, V22, P609, DOI 10.1210/me.2007-0029; Mattingly KA, 2012, ARCH TOXICOL, V86, P633, DOI 10.1007/s00204-011-0778-y; Ng TL, 2012, CELL DEATH DIFFER, V19, P501, DOI 10.1038/cdd.2011.119; Oliver D, 2017, SCI REP-UK, V7, DOI 10.1038/srep43023; Paoli P, 2013, BBA-MOL CELL RES, V1833, P3481, DOI 10.1016/j.bbamcr.2013.06.026; Paupe V, 2015, CELL METAB, V21, P109, DOI 10.1016/j.cmet.2014.12.004; Qu Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131285; Rayavarapu RR, 2015, J BIOL CHEM, V290, P8722, DOI 10.1074/jbc.M114.612754; Rosenbloom KR, 2013, NUCLEIC ACIDS RES, V41, pD56, DOI 10.1093/nar/gks1172; Scarpulla RC, 2006, J CELL BIOCHEM, V97, P673, DOI 10.1002/jcb.20743; Scarpulla RC, 2008, ANN NY ACAD SCI, V1147, P321, DOI 10.1196/annals.1427.006; Schafer ZT, 2009, NATURE, V461, P109, DOI 10.1038/nature08268; Sims D, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-10-r104; Sullivan LB, 2015, CELL, V162, P552, DOI 10.1016/j.cell.2015.07.017; Tan AS, 2015, CELL METAB, V21, P81, DOI 10.1016/j.cmet.2014.12.003; Vais H, 2015, CELL METAB, V22, P533, DOI 10.1016/j.cmet.2015.09.015; Viale A, 2014, NATURE, V514, P628, DOI 10.1038/nature13611; Vlahakis A, 2017, J MOL BIOL, V429, P515, DOI 10.1016/j.jmb.2016.11.027; Zhou YX, 2014, NATURE, V509, P487, DOI 10.1038/nature13166	37	16	17	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 22	2018	37	47					6152	6165		10.1038/s41388-018-0349-2	http://dx.doi.org/10.1038/s41388-018-0349-2			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HB2PG	29995872	Green Accepted			2022-12-17	WOS:000450883000004
J	Kim, JM; Shin, Y; Lee, S; Kim, MY; Punj, V; Shin, HI; Kim, K; Koh, JM; Jeong, D; An, W				Kim, Jin-Man; Shin, Yonghwan; Lee, Sunyoung; Kim, Mi Yeong; Punj, Vasu; Shin, Hong-In; Kim, Kyunghwan; Koh, Jung-Min; Jeong, Daewon; An, Woojin			MacroH2A1.2 inhibits prostate cancer-induced osteoclastogenesis through cooperation with HP1 alpha and H1.2	ONCOGENE			English	Article							NF-KAPPA-B; LYMPHOTOXIN-ALPHA; HISTONE VARIANTS; EXPRESSION; METASTASIS; CELLS; TUMOR; PHOSPHORYLATION; DIFFERENTIATION; TRANSCRIPTION	Osteoclasts are multinuclear bone-resorbing cells that differentiate from hematopoietic precursor cells. Prostate cancer cells frequently spread to bone and secrete soluble signaling factors to accelerate osteoclast differentiation and bone resorption. However, processes and mechanisms that govern the expression of osteoclastogenic soluble factors secreted by prostate cancer cells are largely unknown. MacroH2A (mH2A) is a histone variant that replaces canonical H2A at designated genomic loci and establishes functionally distinct chromatin regions. Here, we report that mH2A1.2, one of the mH2A isoforms, attenuates prostate cancer-induced osteoclastogenesis by maintaining the inactive state of genes encoding soluble factors in prostate cancer cells. Our functional analyses of soluble factors identify lymphotoxin beta (LT beta) as a major stimulator of osteoclastogenesis and an essential mH2A1.2 target for its anti-osteoclastogenic activity. Mechanistically, mH2A1.2 directly interacts with HP1 alpha and H1.2 and requires them to inactivate LT beta gene in prostate cancer cells. Consistently, HP1 alpha and H1.2 have an intrinsic ability to inhibit osteoclast differentiation in a mH2A1.2-dependent manner. Together, our data uncover a new and specific role for mH2A1.2 in modulating osteoclastogenic potential of prostate cancer cells and demonstrate how this signaling pathway can be exploited to treat osteolytic bone metastases at the molecular level.	[Kim, Jin-Man; Shin, Yonghwan; Lee, Sunyoung; Kim, Kyunghwan; An, Woojin] Univ Southern Calif, Dept Biochem & Mol Biol, Norris Comprehens Canc Ctr, Los Angeles, CA 90033 USA; [Kim, Mi Yeong; Jeong, Daewon] Yeungnam Univ, Dept Microbiol, Coll Med, Daegu 705717, South Korea; [Punj, Vasu] Univ Southern Calif, Dept Med, Norris Comprehens Canc Ctr, Los Angeles, CA 90033 USA; [Shin, Hong-In] Kyungpook Natl Univ, Sch Dent, Dept Oral Pathol, Daegu 700412, South Korea; [Kim, Kyunghwan] Chungbuk Natl Univ, Dept Biol, Coll Nat Sci, Cheongju 361763, Chungbuk, South Korea; [Koh, Jung-Min] Univ Ulsan, Div Endocrinol & Metab, Asan Med Ctr, Coll Med, Seoul 138736, South Korea	University of Southern California; Yeungnam University; University of Southern California; Kyungpook National University; Chungbuk National University; University of Ulsan; Asan Medical Center	An, W (corresponding author), Univ Southern Calif, Dept Biochem & Mol Biol, Norris Comprehens Canc Ctr, Los Angeles, CA 90033 USA.	woojinan@usc.edu			NIH [CA201561]; Keck School of Medicine of USC; NATIONAL CANCER INSTITUTE [R01CA201561] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Keck School of Medicine of USC; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NIH Grant CA201561 awarded to W.A. The study was also funded in part by pilot project grants from Keck School of Medicine of USC.	Armstrong AP, 2008, PROSTATE, V68, P92, DOI 10.1002/pros.20678; Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150; ASH P, 1980, NATURE, V283, P669, DOI 10.1038/283669a0; Baron R, 2004, NAT MED, V10, P458, DOI 10.1038/nm0504-458; Boyce BF, 2010, ANN NY ACAD SCI, V1192, P367, DOI 10.1111/j.1749-6632.2009.05315.x; Chen HS, 2014, NAT STRUCT MOL BIOL, V21, P981, DOI 10.1038/nsmb.2903; Dell'Orso S, 2016, CELL REP, V14, P1156, DOI 10.1016/j.celrep.2015.12.103; Edwards Claire M, 2008, Int J Med Sci, V5, P263; Gamble MJ, 2010, GENE DEV, V24, P21, DOI 10.1101/gad.1876110; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; Heo K, 2008, MOL CELL, V30, P86, DOI 10.1016/j.molcel.2008.02.029; Hideshima T, 2001, CANCER RES, V61, P3071; Jimi E, 2005, IMMUNOL REV, V208, P80, DOI 10.1111/j.0105-2896.2005.00329.x; Jimi E, 2004, NAT MED, V10, P617, DOI 10.1038/nm1054; Kapoor A, 2010, NATURE, V468, P1105, DOI 10.1038/nature09590; Kim JM, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.40; Kim JM, 2015, NUCLEIC ACIDS RES, V43, P8868, DOI 10.1093/nar/gkv874; Kim K, 2016, GENE DEV, V30, P208, DOI 10.1101/gad.268714.115; Kim K, 2013, CELL REP, V5, P1690, DOI 10.1016/j.celrep.2013.11.038; Koni PA, 1997, IMMUNITY, V6, P491, DOI 10.1016/S1074-7613(00)80292-7; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; Liepinsh DJ, 2006, MOL CELL BIOL, V26, P4214, DOI 10.1128/MCB.01751-05; Madge LA, 2008, J IMMUNOL, V180, P3467, DOI 10.4049/jimmunol.180.5.3467; Matsuo K, 2008, ARCH BIOCHEM BIOPHYS, V473, P201, DOI 10.1016/j.abb.2008.03.027; Maze I, 2014, NAT REV GENET, V15, P259, DOI 10.1038/nrg3673; Melters DP, 2015, GENES-BASEL, V6, P751, DOI 10.3390/genes6030751; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Mori K, 2007, BONE, V40, P981, DOI 10.1016/j.bone.2006.11.006; Novack DV, 2008, ANNU REV PATHOL-MECH, V3, P457, DOI 10.1146/annurev.pathmechdis.3.121806.151431; PEHRSON JR, 1992, SCIENCE, V257, P1398; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Punj V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037498; Rasmussen TP, 1999, NUCLEIC ACIDS RES, V27, P3685, DOI 10.1093/nar/27.18.3685; Richart AN, 2012, J BIOL CHEM, V287, P18730, DOI 10.1074/jbc.M111.337204; Smothers JF, 2000, CURR BIOL, V10, P27, DOI 10.1016/S0960-9822(99)00260-2; Sporn JC, 2009, ONCOGENE, V28, P3423, DOI 10.1038/onc.2009.26; Talbert PB, 2010, NAT REV MOL CELL BIO, V11, P264, DOI 10.1038/nrm2861; Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; Timinszky G, 2009, NAT STRUCT MOL BIOL, V16, P923, DOI 10.1038/nsmb.1664; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; Yin JJ, 2005, CELL RES, V15, P57, DOI 10.1038/sj.cr.7290266; Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593; Zelzer E, 2003, NATURE, V423, P343, DOI 10.1038/nature01659; Zhang J, 2001, J CLIN INVEST, V107, P1235, DOI 10.1172/JCI11685	46	16	16	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 25	2018	37	43					5749	5765		10.1038/s41388-018-0356-3	http://dx.doi.org/10.1038/s41388-018-0356-3			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GY1KL	29925860	Green Accepted			2022-12-17	WOS:000448288200004
J	Zhang, YY; Tabataba, H; Liu, XY; Wang, JY; Yan, XG; Farrelly, M; Jiang, CC; Guo, ST; Liu, T; Kao, HY; Thorne, RF; Zhang, XD; Jin, L				Zhang, Yuan Yuan; Tabataba, Hessam; Liu, Xiao Ying; Wang, Jia Yu; Yan, Xu Guang; Farrelly, Margaret; Jiang, Chen Chen; Guo, Su Tang; Liu, Tao; Kao, Hung-Ying; Thorne, Rick F.; Zhang, Xu Dong; Jin, Lei			ACTN4 regulates the stability of RIPK1 in melanoma	ONCOGENE			English	Article							ALPHA-ACTININ 4; NF-KAPPA-B; COPY NUMBER INCREASE; GENE AMPLIFICATION; CELL MOTILITY; STAGE-I; CANCER; KINASE; CROSSROADS; ALPHA-ACTININ-4	The actin crosslinking protein alpha-actinin-4 (ACTN4) is emerging as an important contributor to the pathogenesis of cancer. This has largely been attributed to its role in regulating cytoskeleton organization and its involvement in transcriptional regulation of gene expression. Here we report a novel function of ACTN4 as a scaffold necessary for stabilization of receptor-interacting protein kinase 1 (RIPK1) that we have recently found to be an oncogenic driver in melanoma. ACTN4 bound to RIPK1 and cellular inhibitor of apoptosis protein 1 (cIAP1) with its actin-binding domain at the N-terminus and the CaM-like domain at the C-terminus, respectively. This facilitated the physical association between RIPK1 and cIAP1 and was critical for stabilization of RIPK1 that in turn activated NF-kappa B. Functional investigations showed that silencing of ACTN4 suppressed melanoma cell proliferation and retarded melanoma xenograft growth. In contrast, overexpression of ACTN4 promoted melanocyte and melanoma cell proliferation and moreover, prompted melanocyte anchorage-independent growth. Of note, the expression of ACTN4 was transcriptionally activated by NF-kappa B. Taken together, our findings identify ACTN4 as an oncogenic regulator through driving a feedforward signaling axis of ACTN4-RIPK1-NF-kappa B, with potential implications for targeting ACTN4 in the treatment of melanoma.	[Zhang, Yuan Yuan; Liu, Xiao Ying; Jiang, Chen Chen; Jin, Lei] Univ Newcastle, Sch Med & Publ Hlth, Callaghan, NSW 2308, Australia; [Tabataba, Hessam; Wang, Jia Yu; Yan, Xu Guang; Farrelly, Margaret; Guo, Su Tang; Zhang, Xu Dong] Univ Newcastle, Sch Biomed Sci & Pharm, Callaghan, NSW 2308, Australia; [Liu, Xiao Ying] Anhui Med Univ, Sch Life Sci, Hefei 230000, Anhui, Peoples R China; [Jiang, Chen Chen; Zhang, Xu Dong; Jin, Lei] Hunter Med Res Inst, Canc Res Program, New Lambton, NSW 2305, Australia; [Guo, Su Tang] Shanxi Canc Hosp & Inst, Dept Mol Biol, Taiyuan 030013, Shanxi, Peoples R China; [Liu, Tao] Univ New South Wales, Childrens Canc Inst Australia Med Res, Sydney, NSW 2750, Australia; [Kao, Hung-Ying] Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA; [Thorne, Rick F.] Univ Newcastle, Sch Environm & Life Sci, Callaghan, NSW 2308, Australia	University of Newcastle; University of Newcastle; Anhui Medical University; Hunter Medical Research Institute; University of Newcastle; Children's Cancer Institute; Children's Medical Research Institute - Australia; University of New South Wales Sydney; Case Western Reserve University; University of Newcastle	Jin, L (corresponding author), Univ Newcastle, Sch Med & Publ Hlth, Callaghan, NSW 2308, Australia.; Zhang, XD (corresponding author), Univ Newcastle, Sch Biomed Sci & Pharm, Callaghan, NSW 2308, Australia.; Zhang, XD; Jin, L (corresponding author), Hunter Med Res Inst, Canc Res Program, New Lambton, NSW 2305, Australia.	Xu.Zhang@newcastle.edu.au; Lei.Jin@newcastle.edu.au	ZHANG, YUANYUAN/Q-3332-2019; Jin, Lei/J-1896-2019; Liu, Tao/A-3922-2015; Wang, jiayu/ABB-6772-2020; Jin, Lei/K-2315-2019; zhang, xian/GYA-0290-2022; Zhang, xiaoyu/GXA-3206-2022; zhang, xu/GRX-9733-2022; zhang, xu/GYE-3558-2022	ZHANG, YUANYUAN/0000-0001-5851-5128; Jin, Lei/0000-0001-7187-9671; Tabatabaee, Hessam/0000-0001-8912-1746; Zhang, Xu Dong/0000-0001-9457-8003; Liu, Tao/0000-0001-6244-7316; Thorne, Rick/0000-0001-7882-7081	National Health and Medical Research Council (NHMRC) [APP1083496, APP1099947]; Natural Science Foundation of China (NSFC) [81772908]; Cancer Institute NSW Fellowships	National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Cancer Institute NSW Fellowships	This work was supported by the National Health and Medical Research Council (NHMRC) (APP1083496 and APP1099947) and the Natural Science Foundation of China (NSFC) (81772908). L.J. and C.C.J. are recipients of Cancer Institute NSW Fellowships.	Agarwal N, 2013, ONCOGENE, V32, P462, DOI 10.1038/onc.2012.69; Aksenova V, 2013, ONCOTARGET, V4, P362, DOI 10.18632/oncotarget.901; Babakov V N, 2004, Tsitologiia, V46, P1064; Babakov VN, 2008, EXP CELL RES, V314, P1030, DOI 10.1016/j.yexcr.2007.12.001; Bertrand MJM, 2008, MOL CELL, V30, P689, DOI 10.1016/j.molcel.2008.05.014; Blackwell K, 2013, MOL CELL BIOL, V33, P1901, DOI 10.1128/MCB.01416-12; Broderick MJF, 2002, J STRUCT BIOL, V137, P184, DOI 10.1006/jsbi.2002.4465; Carragher NO, 2001, J BIOL CHEM, V276, P4270, DOI 10.1074/jbc.M008972200; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Christofferson DE, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.64; Ding ZY, 2006, P NATL ACAD SCI USA, V103, P15014, DOI 10.1073/pnas.0606917103; Djinovic-Carugo K, 2002, FEBS LETT, V513, P119, DOI 10.1016/S0014-5793(01)03304-X; Dong L, 2014, ONCOGENE, V33, P4756, DOI 10.1038/onc.2013.420; Dong L, 2011, ONCOGENE, V30, P3716, DOI 10.1038/onc.2011.87; Fagerlund R, 2005, J BIOL CHEM, V280, P15942, DOI 10.1074/jbc.M500814200; Festjens N, 2007, CELL DEATH DIFFER, V14, P400, DOI 10.1038/sj.cdd.4402085; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gao YF, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1295-9; Honda K, 1998, J CELL BIOL, V140, P1383, DOI 10.1083/jcb.140.6.1383; Honda K, 2015, CELL BIOSCI, V5, DOI 10.1186/s13578-015-0031-0; Hsu KS, 2013, VITAM HORM, V93, P323, DOI 10.1016/B978-0-12-416673-8.00005-8; Hu W, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.441; Jin L, 2016, MOL CELL ONCOL, V3, DOI 10.1080/23723556.2015.1035690; Jin L, 2011, P NATL ACAD SCI USA, V108, P15840, DOI 10.1073/pnas.1019312108; Kakuya T, 2017, INT J ORAL MAX SURG, V46, P968, DOI 10.1016/j.ijom.2017.03.001; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Khurana S, 2011, J BIOL CHEM, V286, P1850, DOI 10.1074/jbc.M110.162107; Kumeta M, 2010, J CELL SCI, V123, P1020, DOI 10.1242/jcs.059568; Liu XY, 2015, CANCER RES, V75, P1736, DOI 10.1158/0008-5472.CAN-14-2199; Luan Q, 2015, AUTOPHAGY, V11, P975, DOI 10.1080/15548627.2015.1049800; Moquin DM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076841; Noro R, 2013, ANN ONCOL, V24, P2594, DOI 10.1093/annonc/mdt293; Ofengeim D, 2013, NAT REV MOL CELL BIO, V14, P727, DOI 10.1038/nrm3683; Oikonomou KG, 2011, AUTOIMMUN REV, V10, P389, DOI 10.1016/j.autrev.2010.12.009; Shao HS, 2014, J BIOL CHEM, V289, DOI 10.1074/jbc.M114.579185; Shao HS, 2013, INT J BIOCHEM CELL B, V45, P1051, DOI 10.1016/j.biocel.2013.02.015; Shao HS, 2010, J BIOL CHEM, V285, P2591, DOI 10.1074/jbc.M109.035790; Sjoblom B, 2008, CELL MOL LIFE SCI, V65, P2688, DOI 10.1007/s00018-008-8080-8; Tay KH, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.79; Vince JE, 2007, CELL, V131, P682, DOI 10.1016/j.cell.2007.10.037; Wang L, 2008, CELL, V133, P693, DOI 10.1016/j.cell.2008.03.036; Watabe Y, 2014, CANCER MED-US, V3, P613, DOI 10.1002/cam4.214; Watanabe T, 2015, BRIT J CANCER, V112, P704, DOI 10.1038/bjc.2014.623; Yamamoto S, 2012, HISTOPATHOLOGY, V60, P1073, DOI 10.1111/j.1365-2559.2011.04163.x; Yamamoto S, 2009, MODERN PATHOL, V22, P499, DOI 10.1038/modpathol.2008.234; Ye Y, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2489; Zhao X, 2015, J BIOL CHEM, V290, P338, DOI 10.1074/jbc.M114.597260	48	16	16	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 19	2018	37	29					4033	4045		10.1038/s41388-018-0260-x	http://dx.doi.org/10.1038/s41388-018-0260-x			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GN5LP	29706658				2022-12-17	WOS:000439101300009
J	Zhu, Y; Lu, L; Qiao, C; Shan, Y; Li, HP; Qian, SX; Hong, M; Zhao, HH; Li, JY; Yang, ZF; Chen, YY				Zhu, Yu; Lu, Luo; Qiao, Chun; Shan, Yi; Li, Huapeng; Qian, Sixuan; Hong, Ming; Zhao, Huihui; Li, Jianyong; Yang, Zhongfa; Chen, Yaoyu			Targeting PFKFB3 sensitizes chronic myelogenous leukemia cells to tyrosine kinase inhibitor	ONCOGENE			English	Article							CHRONIC MYELOID-LEUKEMIA; 6-PHOSPHOFRUCTO-2-KINASE PFKFB3; IMATINIB-RESISTANCE; STEM-CELLS; IN-VITRO; THERAPY; GLYCOLYSIS; EXPRESSION; CANCER; PU.1	Resistance to the BCR-ABL tyrosine kinase inhibitor (TKI) remains a challenge for curing the disease in chronic myeloid leukemia (CML) patients as leukemia cells may survive through BCR-ABL kinase activity-independent signal pathways. To gain insight into BCR-ABL kinase activity-independent mechanisms, we performed an initial bioinformatics screen and followed by a quantitative PCR screen of genes that were elevated in CML samples. A total of 33 candidate genes were identified to be highly expressed in TKIs resistant patients. Among those genes, 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3), controlling the limiting step of glycolysis, was found to be strongly associated with TKIs resistance. PFKFB3 knockdown or pharmacological inhibition of its kinase activity markedly enhanced the sensitivity of CML cells to TKIs. Furthermore, pharmacological inhibition of PFKFB3 inhibited CML cells growth and significantly prolonged the survival of both allograft and xenograft CML mice. ChIP-seq data analysis combined with subsequent knockdown experiment showed that the Ets transcription factor PU.1 regulated the elevated expression of PFKFB3 in TKIs-resistant CML cells. Therefore, our results showed that targeting PFKFB3 sensitizes CML cells to TKIs and PFKFB3 may be a potential BCR-ABL kinase activity-independent mechanism in CML.	[Zhu, Yu; Lu, Luo; Qiao, Chun; Qian, Sixuan; Hong, Ming; Zhao, Huihui; Li, Jianyong; Chen, Yaoyu] Nanjing Med Univ, Affiliated Hosp 1, Dept Hematol, Jiangsu Prov Hosp, Nanjing, Jiangsu, Peoples R China; [Zhu, Yu; Lu, Luo; Qiao, Chun; Qian, Sixuan; Hong, Ming; Zhao, Huihui; Li, Jianyong; Chen, Yaoyu] Nanjing Med Univ, Key Lab Hematol, Jiangsu Prov Hosp, Nanjing 210029, Jiangsu, Peoples R China; [Zhu, Yu; Lu, Luo; Qiao, Chun; Qian, Sixuan; Hong, Ming; Zhao, Huihui; Li, Jianyong; Chen, Yaoyu] Jiangsu Prov Hosp, Collaborat Innovat Ctr Canc Personalized Med, Nanjing 210029, Jiangsu, Peoples R China; [Zhu, Yu; Shan, Yi; Li, Huapeng; Yang, Zhongfa] Univ Massachusetts, Sch Med, Dept Med, Div Hematol Oncol, Worcester, MA 01655 USA	Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; University of Massachusetts System; University of Massachusetts Worcester	Zhu, Y; Chen, YY (corresponding author), Nanjing Med Univ, Affiliated Hosp 1, Dept Hematol, Jiangsu Prov Hosp, Nanjing, Jiangsu, Peoples R China.; Zhu, Y; Chen, YY (corresponding author), Nanjing Med Univ, Key Lab Hematol, Jiangsu Prov Hosp, Nanjing 210029, Jiangsu, Peoples R China.; Zhu, Y; Chen, YY (corresponding author), Jiangsu Prov Hosp, Collaborat Innovat Ctr Canc Personalized Med, Nanjing 210029, Jiangsu, Peoples R China.; Zhu, Y (corresponding author), Univ Massachusetts, Sch Med, Dept Med, Div Hematol Oncol, Worcester, MA 01655 USA.	zhuyu@jsph.org.cn; Yaoyu.chen@njmu.edu.cn	Li, Jing/GYU-5036-2022; LI, JIAN/GRY-2197-2022; li, jian/GSE-0245-2022		National Natural Science Foundation of the People's Republic of China [81070437, 81270614, 81300379, 81570134, 81570141, 81522001, 81200362]; National Public Health Grand Research Foundation [201202017]; Priority Academic Program Development of Jiangsu Higher Education Institute [JX10231801]; Key Project of Jiangsu Province Health Agency [K201107]	National Natural Science Foundation of the People's Republic of China(National Natural Science Foundation of China (NSFC)); National Public Health Grand Research Foundation; Priority Academic Program Development of Jiangsu Higher Education Institute; Key Project of Jiangsu Province Health Agency	This work was supported by the National Natural Science Foundation of the People's Republic of China (Nos. 81070437, 81270614, 81300379, 81570134, 81570141, 81522001, 81200362), National Public Health Grand Research Foundation (No. 201202017), A Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institute (No. JX10231801) and Key Project of Jiangsu Province Health Agency (K201107).	Antony-Debre I, 2017, J CLIN INVEST, V127, P4297, DOI 10.1172/JCI92504; Bar-Natan Michal, 2012, JAKSTAT, V1, P55, DOI 10.4161/jkst.20006; Bibi S, 2014, HAEMATOLOGICA, V99, P417, DOI 10.3324/haematol.2013.098442; Cang SD, 2008, J HEMATOL ONCOL, V1, DOI 10.1186/1756-8722-1-15; Cantelmo AR, 2016, CANCER CELL, V30, P968, DOI 10.1016/j.ccell.2016.10.006; Chen YY, 2014, J CLIN INVEST, V124, P3847, DOI 10.1172/JCI66129; Chen YY, 2009, NAT GENET, V41, P783, DOI 10.1038/ng.389; Chen Z, 2017, LEUKEMIA, V31, P585, DOI 10.1038/leu.2016.231; Clem B, 2008, MOL CANCER THER, V7, P110, DOI 10.1158/1535-7163.MCT-07-0482; Clem BF, 2013, MOL CANCER THER, V12, P1461, DOI 10.1158/1535-7163.MCT-13-0097; Coller HA, 2014, AM J PATHOL, V184, P4, DOI 10.1016/j.ajpath.2013.07.035; Cruys B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12240; De Bock K, 2013, CELL, V154, P651, DOI 10.1016/j.cell.2013.06.037; DeKoter RP, 2000, SCIENCE, V288, P1439, DOI 10.1126/science.288.5470.1439; Domenech E, 2015, NAT CELL BIOL, V17, P1304, DOI 10.1038/ncb3231; Eadie LN, 2017, LEUKEMIA, V31, P75, DOI 10.1038/leu.2016.179; Ganapathy-Kanniappan S, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-152; Gotlib J, 2017, BLOOD, V129, P838, DOI 10.1182/blood-2016-08-693630; Haferlach T, 2010, J CLIN ONCOL, V28, P2529, DOI 10.1200/JCO.2009.23.4732; Han SH, 2017, LEUKEMIA, V31, P1532, DOI 10.1038/leu.2017.72; Holyoake TL, 2017, BLOOD, V129, P1595, DOI 10.1182/blood-2016-09-696013; Lee CR, 2016, FEBS LETT, V590, P358, DOI 10.1002/1873-3468.12057; Li TY, 2012, CELL, V149, P1269, DOI 10.1016/j.cell.2012.04.026; Moon SH, 2013, CELL CYCLE, V12, P867, DOI 10.4161/cc.23911; Oaxaca DM, 2016, TUMOR BIOL, V37, P12643, DOI 10.1007/s13277-016-5179-7; Ohzono T, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4735; Okabe S, 2008, CLIN CANCER RES, V14, P6181, DOI 10.1158/1078-0432.CCR-08-0461; Pene-Dumitrescu T, 2010, J BIOL CHEM, V285, P21446, DOI 10.1074/jbc.M109.090043; Qian SX, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0360-4; Quentmeier H, 2011, J HEMATOL ONCOL, V4, DOI 10.1186/1756-8722-4-6; RAY D, 1990, ONCOGENE, V5, P663; Rodriguez OC, 2012, CELL CYCLE, V11, P4436, DOI 10.4161/cc.22778; Rosti G, 2017, NAT REV CLIN ONCOL, V14, P141, DOI 10.1038/nrclinonc.2016.139; Schutz C, 2017, LEUKEMIA, V31, P829, DOI 10.1038/leu.2017.9; Shultz LD, 2005, J IMMUNOL, V174, P6477, DOI 10.4049/jimmunol.174.10.6477; Steelman LS, 2011, LEUKEMIA, V25, P1080, DOI 10.1038/leu.2011.66; Sweet K, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-54; Wagle M, 2016, LEUKEMIA, V30, P1493, DOI 10.1038/leu.2016.51; Yalcin A, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.292; Yalcin A, 2017, BIOCHEM BIOPH RES CO, V484, P687, DOI 10.1016/j.bbrc.2017.01.178; Yamada Osamu, 2013, JAKSTAT, V2, pe25256, DOI 10.4161/jkst.25256; Yang Z, 2014, AUTOPHAGY, V10, P382, DOI 10.4161/auto.27345; Zhang P, 1999, P NATL ACAD SCI USA, V96, P8705, DOI 10.1073/pnas.96.15.8705; Zhou H, 2017, LEUKEMIA, V31, P2065, DOI 10.1038/leu.2017.87	44	16	16	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	21					2837	2849		10.1038/s41388-018-0157-8	http://dx.doi.org/10.1038/s41388-018-0157-8			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GG8EE	29511345				2022-12-17	WOS:000432929800006
J	di Martino, S; Amoreo, CA; Nuvoli, B; Galati, R; Strano, S; Facciolo, F; Alessandrini, G; Pass, HI; Ciliberto, G; Blandino, G; De Maria, R; Cioce, M				di Martino, Simona; Amoreo, Carla Azzurra; Nuvoli, Barbara; Galati, Rossella; Strano, Sabrina; Facciolo, Francesco; Alessandrini, Gabriele; Pass, Harvey I.; Ciliberto, Gennaro; Blandino, Giovanni; De Maria, Ruggero; Cioce, Mario			HSP90 inhibition alters the chemotherapy-driven rearrangement of the oncogenic secretome	ONCOGENE			English	Article							MALIGNANT PLEURAL MESOTHELIOMA; CELL LUNG-CANCER; POTENT ANTITUMOR-ACTIVITY; ADVANCED SOLID TUMORS; IN-VITRO; SENESCENT CELLS; STEM-CELLS; INTRATUMORAL HETEROGENEITY; ACQUIRED-RESISTANCE; DRUG-RESISTANCE	Adaptive resistance to therapy is a hallmark of cancer progression. To date, it is not entirely clear how microenvironmental stimuli would mediate emergence of therapy-resistant cell subpopulations, although a rearrangement of the cancer cell secretome following therapy-induced stress can be pivotal for such a process. Here, by using the highly chemoresistant malignant pleural mesothelioma (MPM) as an experimental model, we unveiled a key contribution of the chaperone HSP90 at assisting a chemotherapy-instigated Senescence-Associated-Secretory-Phenotype (SASP). Thus, administration of a clinical trial grade, HSP90, inhibitor blunted the release of several cytokines by the chemotherapy-treated MPM cells, including interleukin (IL)-8. Reduction of IL-8 levels hampered the FAK-AKT signaling and inhibited 3D growth and migration. This correlated with downregulation of key EMT and chemoresistance genes and affected the survival of chemoresistant ALDH(bright) cell subpopulations. Altogether, inhibition of HSP90 provoked a switch from a pro-tumorigenic SASP to a pro-apoptotic senescence status, thus resulting in chemosensitizing effects. In mouse xenografts treated with firstline agents, inhibiting HSP90 blunted FAK activation and reduced the expression of ALDH1A3 and the levels of circulating human IL-8, these latter strongly correlating with the effect on tumor growth. We validated the above findings in primary mesothelioma cultures, a more clinically relevant model. We unveiled here a key contribution of the chaperone HSP90 at assisting the secretory stress in chemotherapy-treated cells, which may warrant further investigation in combinatorial therapeutic settings.	[di Martino, Simona; Blandino, Giovanni; Cioce, Mario] Regina Elena Inst Canc Res, Oncogen & Epigenet Unit, Rome, Italy; [Amoreo, Carla Azzurra] Regina Elena Inst Canc Res, Dept Pathol, Rome, Italy; [Nuvoli, Barbara; Galati, Rossella] Regina Elena Inst Canc Res, Preclin Models & New Therapeut Agents Unit, Rome, Italy; [Strano, Sabrina] Regina Elena Inst Canc Res, Mol Chemoprevent Unit, Rome, Italy; [Facciolo, Francesco; Alessandrini, Gabriele] Regina Elena Inst Canc Res, Dept Thorac Surg, Rome, Italy; [Pass, Harvey I.] NYU, Sch Med, Dept Cardiothorac Surg, New York, NY USA; [Ciliberto, Gennaro; De Maria, Ruggero] Regina Elena Inst Canc Res, Sci Direct, Rome, Italy; [De Maria, Ruggero] Catholic Univ, Inst Gen Pathol, Rome, Italy; [De Maria, Ruggero] Gemelli Polyclin, Rome, Italy; [Strano, Sabrina; Blandino, Giovanni] McMaster Univ, Dept Oncol, Hamilton, ON, Canada	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; New York University; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; McMaster University	Cioce, M (corresponding author), Regina Elena Inst Canc Res, Oncogen & Epigenet Unit, Rome, Italy.; De Maria, R (corresponding author), Regina Elena Inst Canc Res, Sci Direct, Rome, Italy.; De Maria, R (corresponding author), Catholic Univ, Inst Gen Pathol, Rome, Italy.; De Maria, R (corresponding author), Gemelli Polyclin, Rome, Italy.	demariaruggero@gmail.com; mariocioce@gmail.com	di Martino, Simona SdM/K-9304-2016; De Maria, Ruggero/S-6385-2019; Strano, Sabrina/K-9654-2016; Galati, Rossella/ABH-6437-2020; Galati, Rossella Maria/H-8867-2017; Cioce, Mario/R-9734-2017; AMOREO, CARLA AZZURRA/K-5375-2018; Ciliberto, Gennaro/J-4131-2017	di Martino, Simona SdM/0000-0003-4533-3776; De Maria, Ruggero/0000-0003-2255-0583; Galati, Rossella/0000-0003-2646-8384; Galati, Rossella Maria/0000-0003-2646-8384; Cioce, Mario/0000-0001-8129-6664; AMOREO, CARLA AZZURRA/0000-0003-3817-1967; Ciliberto, Gennaro/0000-0003-2851-8605; strano, sabrina/0000-0002-6341-4230; Facciolo, Francesco/0000-0002-7137-8946; Alessandrini, Gabriele/0000-0002-4380-7627; Pass, Harvey/0000-0003-3222-3471	Fundacio' La Marato' de TV3 [432/C/2013]; AIRC; Marie Curie Actions-People-COFUND fellowship; Italian Ministry of Health (Progetto Nazionale Amianto)	Fundacio' La Marato' de TV3; AIRC(Fondazione AIRC per la ricerca sul cancro); Marie Curie Actions-People-COFUND fellowship; Italian Ministry of Health (Progetto Nazionale Amianto)	The funding for this study was provided by the Fundacio' La Marato' de TV3 (grant 432/C/2013) to RDM. M.C. was supported by an AIRC and Marie Curie Actions-People-COFUND fellowship. We thankfully acknowledge the support of the Italian Ministry of Health (Progetto Nazionale Amianto) to R.D.M. We thankfully acknowledge the helpful advice of Dr. Paola Nistico, Dr. Maria Lucia Dell' Anna, and Dr. Valeria Catena (Regina Elena National Cancer Institute, Rome, Italy).	Acosta JC, 2013, NAT CELL BIOL, V15, P978, DOI 10.1038/ncb2784; Aird Katherine M, 2013, Methods Mol Biol, V965, P185, DOI 10.1007/978-1-62703-239-1_12; Alimbetov D, 2016, BIOGERONTOLOGY, V17, P305, DOI 10.1007/s10522-015-9610-z; Araki S, 2007, CANCER RES, V67, P6854, DOI 10.1158/0008-5472.CAN-07-1162; Basu D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052188; Benoy IH, 2004, CLIN CANCER RES, V10, P7157, DOI 10.1158/1078-0432.CCR-04-0812; Bussing I, 2008, TRENDS MOL MED, V14, P400, DOI 10.1016/j.molmed.2008.07.001; Busacca S, 2016, ONCOGENE, V35, P1483, DOI 10.1038/onc.2015.213; Cahu J, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.183; Campisi J, 2011, SEMIN CANCER BIOL, V21, P354, DOI 10.1016/j.semcancer.2011.09.001; Canino C, 2012, ONCOGENE, V31, P3148, DOI 10.1038/onc.2011.485; Canino C, 2016, METHODS MOL BIOL, V1379, P139, DOI 10.1007/978-1-4939-3191-0_13; Canino C, 2015, ONCOTARGET, V6, P12637, DOI 10.18632/oncotarget.3703; Carbone M, 2012, J CELL PHYSIOL, V227, P44, DOI 10.1002/jcp.22724; Chatterjee S, 2017, MOL CANCER THER, V16, P793, DOI 10.1158/1535-7163.MCT-16-0677; Chernova T, 2016, CELL DEATH DIFFER, V23, P1152, DOI 10.1038/cdd.2015.165; Cioce M, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.136; Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301; Corpet A, 2014, CHROMOSOMA, V123, P423, DOI 10.1007/s00412-014-0469-6; Cortes-Dericks L, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-304; Cortes-Dericks L, 2010, INT J ONCOL, V37, P437, DOI 10.3892/ijo_00000692; Davalos AR, 2010, CANCER METAST REV, V29, P273, DOI 10.1007/s10555-010-9220-9; Debacq-Chainiaux F, 2009, NAT PROTOC, V4, P1798, DOI 10.1038/nprot.2009.191; Demaria M, 2017, CANCER DISCOV, V7, P165, DOI 10.1158/2159-8290.CD-16-0241; Freund A, 2011, EMBO J, V30, P1536, DOI 10.1038/emboj.2011.69; Galffy G, 1999, CANCER RES, V59, P367; Galffy G, 1999, ONCOL RES, V11, P187; Garon EB, 2013, MOL CANCER THER, V12, P890, DOI 10.1158/1535-7163.MCT-12-0998; Genovese G, 2017, NATURE, V542, P362, DOI 10.1038/nature21064; Ginestier C, 2010, J CLIN INVEST, V120, P485, DOI 10.1172/JCI39397; Gomez-Casal R, 2015, CANCERS, V7, P876, DOI 10.3390/cancers7020814; He SQ, 2014, INVEST NEW DRUG, V32, P577, DOI 10.1007/s10637-014-0095-4; Hillegass JM, 2010, ANN NY ACAD SCI, V1203, P7, DOI 10.1111/j.1749-6632.2010.05554.x; Jones SF, 2015, INVEST NEW DRUG, V33, P1100, DOI 10.1007/s10637-015-0282-y; Kang C, 2015, SCIENCE, V349, DOI 10.1126/science.aaa5612; Kim KL, 2005, AM J RESP CELL MOL, V33, P541, DOI 10.1165/rcmb.2004-0355OC; Laberge RM, 2015, NAT CELL BIOL, V17, P1049, DOI 10.1038/ncb3195; Lai CH, 2014, ONCOGENE, V33, P4867, DOI 10.1038/onc.2013.439; Liu X, 2016, ANTI-CANCER DRUG, V27, P417, DOI 10.1097/CAD.0000000000000347; Lundgren K, 2009, MOL CANCER THER, V8, P921, DOI 10.1158/1535-7163.MCT-08-0758; Marcato P, 2011, CELL CYCLE, V10, P1378, DOI 10.4161/cc.10.9.15486; Mathias RA, 2009, J PROTEOME RES, V8, P2827, DOI 10.1021/pr8010974; Mujoomdar AA, 2010, J THORAC CARDIOV SUR, V140, P352, DOI 10.1016/j.jtcvs.2009.11.072; Ning Y, 2011, INT J CANCER, V128, P2038, DOI 10.1002/ijc.25562; Obenauf AC, 2015, NATURE, V520, P368, DOI 10.1038/nature14336; Ohanna M, 2011, GENE DEV, V25, P1245, DOI 10.1101/gad.625811; Ohanna M, 2013, ONCOTARGET, V4, P2212, DOI 10.18632/oncotarget.1143; Ohkubo S, 2015, MOL CANCER THER, V14, P14, DOI 10.1158/1535-7163.MCT-14-0219; Park SY, 2014, EUR J CANCER, V50, P341, DOI 10.1016/j.ejca.2013.09.021; Patel S, 2014, ADV EXP MED BIOL, V806, P409, DOI 10.1007/978-3-319-06068-2_20; Piper PW, 2011, PHARMACEUTICALS, V4, P1400, DOI 10.3390/ph4111400; Pribluda A, 2015, CLIN CANCER RES, V21, P2916, DOI 10.1158/1078-0432.CCR-14-1213; Sarker D, 2015, CLIN CANCER RES, V21, P77, DOI 10.1158/1078-0432.CCR-14-0947; Saunders NA, 2012, EMBO MOL MED, V4, P675, DOI 10.1002/emmm.201101131; Shapiro IM, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008639; Shimamura T, 2012, CLIN CANCER RES, V18, P4973, DOI 10.1158/1078-0432.CCR-11-2967; Shimizu T, 2016, CANCER CHEMOTH PHARM, V77, P997, DOI 10.1007/s00280-016-3010-1; Singh JK, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3436; Socinski MA, 2013, CLIN CANCER RES, V19, P3068, DOI 10.1158/1078-0432.CCR-12-3381; Taipale M, 2012, CELL, V150, P987, DOI 10.1016/j.cell.2012.06.047; Thakur MK, 2016, INVEST NEW DRUG, V34, P112, DOI 10.1007/s10637-015-0307-6; Trepel J, 2010, NAT REV CANCER, V10, P537, DOI 10.1038/nrc2887; Vogelzang NJ, 2003, J CLIN ONCOL, V21, P2636, DOI 10.1200/JCO.2003.11.136; Wang Y, 2011, CYTOKINE, V56, P365, DOI 10.1016/j.cyto.2011.06.005; Ying WW, 2012, MOL CANCER THER, V11, P475, DOI 10.1158/1535-7163.MCT-11-0755	65	16	17	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	10					1369	1385		10.1038/s41388-017-0044-8	http://dx.doi.org/10.1038/s41388-017-0044-8			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ0RI	29311642				2022-12-17	WOS:000427279300008
J	Hsieh, HY; Jou, YC; Tung, CL; Tsai, YS; Wang, YH; Chi, CL; Lin, RI; Hung, SK; Chuang, YM; Wu, SF; Li, C; Shen, CH; Chan, MWY; Hsu, CD				Hsieh, H-Y; Jou, Y-C; Tung, C-L; Tsai, Y-S; Wang, Y-H; Chi, C-L; Lin, R-I; Hung, S-K; Chuang, Y-M; Wu, S-F; Li, C.; Shen, C-H; Chan, M. W. Y.; Hsu, C-D			Epigenetic silencing of the dual-role signal mediator, ANGPTL4 in tumor tissues and its overexpression in the urothelial carcinoma microenvironment	ONCOGENE			English	Article							ANGIOPOIETIN-LIKE 4; PROMOTES VENOUS INVASION; LARGE GENE LISTS; BLADDER-CANCER; VASCULAR-PERMEABILITY; KAPOSIS-SARCOMA; ANGIOGENESIS; EXPRESSION; PROTEIN; METASTASIS	Urothelial carcinoma (UC) carcinogenesis has been hypothesized to occur through epigenetic repression of tumor-suppressor genes (TSGs). By quantitative real-time polymerase chain reaction array, we found that one potential TSG, angiopoietin-like 4 (ANGPTL4), was expressed at very low levels in all bladder cancer cell lines we examined. Previous studies had demonstrated that ANGPTL4 is highly expressed in some cancers, but downregulated, by DNA methylation, in others. Consequently, owing to these seemingly conflicting functions in distinct cancers, the precise role of ANGPTL4 in the etiology of UC remains unclear. In this study, using methylation-specific PCR and bisulfite pyrosequencing, we show that ANGPTL4 is transcriptionally repressed by DNA methylation in UC cell lines and primary tumor samples, as compared with adjacent noncancerous bladder epithelium. Functional studies further demonstrated that ectopic expression of ANGPTL4 potently suppressed UC cell proliferation, monolayer colony formation in vitro, and invasion, migration, and xenograft formation in vivo. Surprisingly, circulating ANGPTL4 was significantly higher in plasma samples from UC patients than normal control, suggesting it might be secreted from other cell types. Interestingly, our data also indicated that exogenous cANGPTL4 could promote cell proliferation and cell migration via activation of signaling through the Erk/focal adhesion kinase axis. We further confirmed that mouse xenograft tumor growth could be promoted by administration of exogenous cANGPTL4. Finally, immunohistochemistry demonstrated that ANGPTL4 was downregulated in tumor cells but overexpressed in tumor adjacent stromal tissues of muscle-invasive UC tissue samples. In conclusion, our data support dual roles for ANGPTL4 in UC progression, either as a tumor suppressor or oncogene, in response to microenvironmental context.	[Hsieh, H-Y; Hsu, C-D] Ditmanson Med Fountain Chiayi Christian Hosp, Dept Med Res, Chiayi, Taiwan; [Hsieh, H-Y; Jou, Y-C; Shen, C-H; Hsu, C-D] Ditmanson Med Fdn Chiayi Christian Hosp, Dept Urol, 539 Zhongxiao Rd, Chiayi 600, Taiwan; [Hsieh, H-Y; Chuang, Y-M; Wu, S-F; Li, C.; Chan, M. W. Y.; Hsu, C-D] Natl Chung Cheng Univ, Dept Life Sci, 168 Univ Rd, Chiayi 62102, Taiwan; [Hsieh, H-Y] Natl Museum Nat Sci, Dept Biol, Taichung, Taiwan; [Tung, C-L] Ditmanson Med Fdn Chiayi Christian Hosp, Dept Pathol, Chiayi, Taiwan; [Tsai, Y-S] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Dept Urol, Coll Med, Tainan, Taiwan; [Wang, Y-H] Taipei Med Univ, Grad Inst Clin Med, Coll Med, Taipei, Taiwan; [Wang, Y-H] Taipei Med Univ, Shuang Ho Hosp, Div Gen Surg, Dept Urol, New Taipei, Taiwan; [Chi, C-L] Buddhist Dalin Tzu Chi Gen Hosp, Dept Pathol, Chiayi, Taiwan; [Lin, R-I; Hung, S-K] Buddhist Dalin Tzu Chi Gen Hosp, Dept Radiat Oncol, Chiayi, Taiwan; [Hung, S-K] Tzu Chi Univ, Sch Med, Hualien, Taiwan; [Chuang, Y-M; Wu, S-F; Li, C.; Chan, M. W. Y.] Natl Chung Cheng Univ, Inst Mol Biol, Chiayi, Taiwan	Chia-Yi Christian Hospital; National Chung Cheng University; Chia-Yi Christian Hospital; National Cheng Kung University; National Cheng Kung University Hospital; Taipei Medical University; Taipei Medical University; Shuang Ho Hospital; Buddhist Tzu Chi General Hospital; Dalin Tzu Chi Hospital; Buddhist Tzu Chi General Hospital; Dalin Tzu Chi Hospital; Tzu Chi University; National Chung Cheng University	Hsu, CD (corresponding author), Ditmanson Med Fdn Chiayi Christian Hosp, Dept Urol, 539 Zhongxiao Rd, Chiayi 600, Taiwan.; Chan, MWY (corresponding author), Natl Chung Cheng Univ, Dept Life Sci, 168 Univ Rd, Chiayi 62102, Taiwan.	biowyc@ccu.edu.tw; cdh199712@gmail.com	Chan, Michael/F-9615-2018; Chuang, Yu-Ming/AAE-4901-2021	Chan, Michael/0000-0003-1431-322X; Hung, Shih-Kai/0000-0002-4945-528X; Chan, Michael/0000-0003-0314-2437	Ditmanson Medical Foundation Chiayi Christian Hospital, Taiwan [R101-9]; Ministry of Science and Technology, Taiwan [MOST 104-2314-B-194-001-MY3]	Ditmanson Medical Foundation Chiayi Christian Hospital, Taiwan; Ministry of Science and Technology, Taiwan(Ministry of Science and Technology, Taiwan)	This study was supported by grants from the Ditmanson Medical Foundation Chiayi Christian Hospital, Taiwan (grant no. R101-9) and the Ministry of Science and Technology, Taiwan (MOST 104-2314-B-194-001-MY3). The authors would like to thank Dr Curt Balch for English editing.	Arnold SA, 2009, J CELL COMMUN SIGNAL, V3, P255, DOI 10.1007/s12079-009-0072-4; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Cazes A, 2006, CIRC RES, V99, P1207, DOI 10.1161/01.RES.0000250758.63358.91; Chiodoni C, 2010, CANCER METAST REV, V29, P295, DOI 10.1007/s10555-010-9221-8; Chomel C, 2009, FASEB J, V23, P940, DOI 10.1096/fj.08-115170; Chong HC, 2012, J ONCOL, V2012, DOI 10.1155/2012/351089; Clement LC, 2014, NAT MED, V20, P37, DOI 10.1038/nm.3396; Costa VL, 2010, EPIGENETICS-US, V5, P343, DOI 10.4161/epi.5.4.11749; Feng S, 2010, ENDOCR-RELAT CANCER, V17, P1021, DOI 10.1677/ERC-10-0073; Foreman JE, 2010, CANCER LETT, V288, P219, DOI 10.1016/j.canlet.2009.07.006; Galaup A, 2006, P NATL ACAD SCI USA, V103, P18721, DOI 10.1073/pnas.0609025103; Ge HF, 2004, J BIOL CHEM, V279, P2038, DOI 10.1074/jbc.M307583200; Girroir EE, 2008, TOXICOLOGY, V243, P236, DOI 10.1016/j.tox.2007.10.023; Goh YY, 2010, AM J PATHOL, V177, P2791, DOI 10.2353/ajpath.2010.100129; Goh YY, 2010, J BIOL CHEM, V285, P32999, DOI 10.1074/jbc.M110.108175; Hato T, 2008, TRENDS CARDIOVAS MED, V18, P6, DOI 10.1016/j.tcm.2007.10.003; Hattori N, 2011, CANCER SCI, V102, P1337, DOI 10.1111/j.1349-7006.2011.01955.x; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hsieh HY, 2016, CANCER LETT, V370, P56, DOI 10.1016/j.canlet.2015.09.018; Hu J, 2011, ORAL ONCOL, V47, P371, DOI 10.1016/j.oraloncology.2011.02.018; Huang C, 2004, J CELL SCI, V117, P4619, DOI 10.1242/jcs.01481; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Huang RL, 2011, BLOOD, V118, P3990, DOI 10.1182/blood-2011-01-328716; Ito Y, 2003, CANCER RES, V63, P6651; Kakizoe T, 2006, CANCER SCI, V97, P821, DOI 10.1111/j.1349-7006.2006.00264.x; Kaneda A, 2002, CANCER RES, V62, P6645; Kastritis E, 2009, INT J CANCER, V124, P103, DOI 10.1002/ijc.23917; Katoh Y, 2006, INT J MOL MED, V17, P1145; Kersten S, 2005, BIOCHEM SOC T, V33, P1059, DOI 10.1042/BST0331059; Khandekar MJ, 2011, NAT REV CANCER, V11, P886, DOI 10.1038/nrc3174; Kim I, 2000, BIOCHEM J, V346, P603, DOI 10.1042/0264-6021:3460603; Kim SH, 2011, CANCER RES, V71, P7010, DOI 10.1158/0008-5472.CAN-11-1262; Kim WJ, 2008, CANCER SCI, V99, P646, DOI 10.1111/j.1349-7006.2008.00735.x; Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038; Lei X, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.217638; Levine AJ, 2010, SCIENCE, V330, P1340, DOI 10.1126/science.1193494; Lin HY, 2015, ONCOTARGET, V6, P915, DOI 10.18632/oncotarget.2821; Ma T, 2010, P NATL ACAD SCI USA, V107, P14363, DOI 10.1073/pnas.1001065107; Muendlein A, 2014, ATHEROSCLEROSIS, V237, P632, DOI 10.1016/j.atherosclerosis.2014.10.028; Nakayama T, 2011, ONCOL REP, V25, P929, DOI 10.3892/or.2011.1176; Nakayama T, 2010, ONCOL REP, V24, P599, DOI 10.3892/or_00000897; Ng KTP, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-196; Oike Y, 2005, TRENDS MOL MED, V11, P473, DOI 10.1016/j.molmed.2005.08.002; Okochi-Takada E, 2014, ONCOGENE, V33, P2273, DOI 10.1038/onc.2013.174; Padua D, 2008, CELL, V133, P66, DOI 10.1016/j.cell.2008.01.046; Pasin Erik, 2008, Rev Urol, V10, P31; Roupret M, 2011, EUR UROL, V59, P584, DOI 10.1016/j.eururo.2010.12.042; Schulz WA, 2006, INT J CANCER, V119, P1513, DOI 10.1002/ijc.21852; Shibata K, 2010, J CLIN PATHOL, V63, P1054, DOI 10.1136/jcp.2010.078600; Shiina H, 2002, J UROLOGY, V168, P2220, DOI 10.1016/S0022-5347(05)64359-5; STUDER UE, 1994, J UROLOGY, V152, P81, DOI 10.1016/S0022-5347(17)32822-7; Swales C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109524; Tan MJ, 2012, MOL CANCER RES, V10, P677, DOI 10.1158/1541-7786.MCR-11-0519; Tjeerdema N, 2014, BMJ OPEN DIAB RES CA, V2, DOI 10.1136/bmjdrc-2014-000034; Urakami S, 2006, CLIN CANCER RES, V12, P383, DOI 10.1158/1078-0432.CCR-05-1344; Verine J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010421; Wang YH, 2009, TOXICOL APPL PHARM, V241, P111, DOI 10.1016/j.taap.2009.08.008; Wang YH, 2009, UROLOGY, V73, P670, DOI 10.1016/j.urology.2008.09.048; Wang ZM, 2010, BIOMARKERS, V15, P39, DOI 10.3109/13547500903261362; Wu YQ, 2016, EUR REV MED PHARMACO, V20, P44; Yang YH, 2008, ARTERIOSCL THROM VAS, V28, P835, DOI 10.1161/ATVBAHA.107.157776; Yeh CM, 2014, INT J ONCOL, V45, P2101, DOI 10.3892/ijo.2014.2627; Yoon JC, 2000, MOL CELL BIOL, V20, P5343, DOI 10.1128/MCB.20.14.5343-5349.2000; Zhang H, 2012, ONCOGENE, V31, P1757, DOI 10.1038/onc.2011.365; Zhang H, 2013, EXP THER MED, V5, P119, DOI 10.3892/etm.2012.750; Zhu PC, 2011, CANCER CELL, V19, P401, DOI 10.1016/j.ccr.2011.01.018; Zordan MD, 2011, CYTOM PART A, V79A, P227, DOI 10.1002/cyto.a.21029	68	16	17	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 1	2018	37	5					673	686		10.1038/onc.2017.375	http://dx.doi.org/10.1038/onc.2017.375			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FU4GT	29035390				2022-12-17	WOS:000423812200012
J	Liu, Q; Kulak, MV; Borcherding, N; Maina, PK; Zhang, W; Weigel, RJ; Qi, HH				Liu, Q.; Kulak, M. V.; Borcherding, N.; Maina, P. K.; Zhang, W.; Weigel, R. J.; Qi, H. H.			A novel HER2 gene body enhancer contributes to HER2 expression	ONCOGENE			English	Article							BREAST-CANCER CELLS; NEGATIVE REGULATORY ELEMENTS; HUMAN ERBB-2 GENE; TRANSCRIPTION FACTOR; DNA METHYLATION; ACTIVATOR PROTEIN-2; PROMOTER; OVEREXPRESSION; IDENTIFICATION; RECEPTOR	The transcriptional regulation of the human epidermal growth factor receptor-2 (HER2) contributes to an enhanced HER2 expression in HER2-positive breast cancers with HER2 gene amplification and HER2-low or HER2-negative breast cancers following radiotherapy or endocrine therapy, and this drives tumorigenesis and the resistance to therapy. Epigenetic mechanisms are critical for transcription regulation, however, such mechanisms in the transcription regulation of HER2 are limited to the involvement of trimethylated histone 3 lysine 4 (H3K4me3) and acetylated histone 3 lysine 9 (H3K9ac) at the HER2 promoter region. Here, we report the identification of a novel enhancer in the HER2 3' gene body, which we have termed HER2 gene body enhancer (HGE). The HGE starts from the 3' end of intron 19 and extends into intron 22, possesses enhancer histone modification marks in specific cells and enhances the transcriptional activity of the HER2 promoters. We also found that TFAP2C, a known regulator of HER2, binds to HGE and is required for its enhancer function and that DNA methylation in the HGE region inhibits the histone modifications characterizing enhancer and is inversely correlated with HER2 expression in breast cancer samples. The identification of this novel enhancer sheds a light on the roles of epigenetic mechanisms in HER2 transcription, in both HER2-positive breast cancer samples and individuals with HER2-low or HER2-negative breast cancers undergoing radiotherapy or endocrine therapy.	[Liu, Q.; Maina, P. K.; Qi, H. H.] Univ Iowa, Dept Anat & Cell Biol, Carver Coll Med, 1-632 BSB,51 Newton Rd, Iowa City, IA 52243 USA; [Kulak, M. V.; Weigel, R. J.] Univ Iowa, Dept Surg, Carver Coll Med, Iowa City, IA 52243 USA; [Borcherding, N.; Zhang, W.] Univ Iowa, Dept Pathol, Carver Coll Med, Iowa City, IA 52243 USA; [Weigel, R. J.] Univ Iowa, Dept Biochem, Carver Coll Med, Iowa City, IA 52243 USA	University of Iowa; University of Iowa; University of Iowa; University of Iowa	Qi, HH (corresponding author), Univ Iowa, Dept Anat & Cell Biol, Carver Coll Med, 1-632 BSB,51 Newton Rd, Iowa City, IA 52243 USA.	hank-qi@uiowa.edu		Kulak, Mikhail/0000-0002-4307-5868; Weigel, Ronald/0000-0002-9249-0793; Qi, Hank/0000-0002-3401-4940; Borcherding, Nicholas/0000-0003-1427-6342; Maina, Peterson/0000-0002-5909-190X	Department of Anatomy and Cell Biology, the Carver College of Medicine, University of Iowa; Carver Trust Young Investigator Award from the Roy J Carver Charitable Trust [01-224]; Breast Cancer Research Award by the Holden Comprehensive Cancer Center at University of Iowa; NIH [P30 CA086862, R01CA183702, CA200673, CA203834]; NIH MD/PhD fellowship [F30 CA206255]; V Scholar award from Holden Comprehensive Cancer Center at the University of Iowa; Breast Cancer Research Award from Holden Comprehensive Cancer Center at the University of Iowa; Oberley Award (National Cancer Institute Award) from Holden Comprehensive Cancer Center at the University of Iowa [P30 CA086862]; NATIONAL CANCER INSTITUTE [R01CA183702, R01CA203834, R00CA158055, F30CA206255, P30CA086862, R01CA200673] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007337] Funding Source: NIH RePORTER	Department of Anatomy and Cell Biology, the Carver College of Medicine, University of Iowa; Carver Trust Young Investigator Award from the Roy J Carver Charitable Trust; Breast Cancer Research Award by the Holden Comprehensive Cancer Center at University of Iowa; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH MD/PhD fellowship; V Scholar award from Holden Comprehensive Cancer Center at the University of Iowa; Breast Cancer Research Award from Holden Comprehensive Cancer Center at the University of Iowa; Oberley Award (National Cancer Institute Award) from Holden Comprehensive Cancer Center at the University of Iowa; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Dr Brad Amendt and his lab for helpful discussions, and the ENCODE Consortium and the ENCODE production laboratories for generating the relevant data sets. The results of the bioinformatical analysis are based, in whole or part, upon data generated by The Cancer Genome Atlas Research Network (http://cancergenome.nih.gov/). The K562 cell line was a kind gift from Dr Fenghuang Zhan. We also thank Drs Christine Blaumueller and Marie Gaine for editorial consultation. This work was supported by to HHQ start-up funds from the Department of Anatomy and Cell Biology, the Carver College of Medicine, University of Iowa; Carver Trust Young Investigator Award (01-224 to HHQ) from the Roy J Carver Charitable Trust; a Breast Cancer Research Award (to HHQ) by the Holden Comprehensive Cancer Center at University of Iowa; The NIH grant (P30 CA086862) to the Genomics and Flow Cytometry core facilities at the University of Iowa. NIH grants R01CA183702 (PI: RJW) and by a generous gift from the Kristen Olewine Milke Breast Cancer Research Fund (PI: RJW). NB was supported by NIH MD/PhD fellowship (F30 CA206255); WZ was supported by NIH grants CA200673, and CA203834, the V Scholar award, a Breast Cancer Research Award and an Oberley Award (National Cancer Institute Award P30 CA086862) from Holden Comprehensive Cancer Center at the University of Iowa.	Allouche A, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1851; Anido J, 2006, EMBO J, V25, P3234, DOI 10.1038/sj.emboj.7601191; Baselga J, 2009, NAT REV CANCER, V9, P463, DOI 10.1038/nrc2656; Begon DY, 2005, J BIOL CHEM, V280, P24428, DOI 10.1074/jbc.M503790200; Benz CC, 2006, GENE CHROMOSOME CANC, V45, P983, DOI 10.1002/gcc.20364; Bofin AM, 2004, AM J CLIN PATHOL, V122, P110, DOI 10.1309/8A2DJFT07NE6EWHE; Bosher JM, 1996, ONCOGENE, V13, P1701; Cao N, 2009, RADIAT RES, V171, P9, DOI 10.1667/RR1472.1; Chen YY, 1997, J BIOL CHEM, V272, P14110, DOI 10.1074/jbc.272.22.14110; Chen YY, 1996, J BIOL CHEM, V271, P5183; CHEN YY, 1994, ONCOGENE, V9, P2269; Choudhury A, 2004, INT J CANCER, V108, P71, DOI 10.1002/ijc.11497; Contino F, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-81; Crawford GE, 2006, GENOME RES, V16, P123, DOI 10.1101/gr.4074106; Creyghton MP, 2010, P NATL ACAD SCI USA, V107, P21931, DOI 10.1073/pnas.1016071107; Deblois G, 2010, CANCER RES, V70, P10277, DOI 10.1158/0008-5472.CAN-10-2840; Delacroix L, 2005, DNA CELL BIOL, V24, P582, DOI 10.1089/dna.2005.24.582; Dillon RL, 2007, MOL CELL BIOL, V27, P8648, DOI 10.1128/MCB.00866-07; Dittrich A, 2014, J MAMMARY GLAND BIOL, V19, P253, DOI 10.1007/s10911-014-9329-5; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Duru N, 2012, CLIN CANCER RES, V18, P6634, DOI 10.1158/1078-0432.CCR-12-1436; Greer EL, 2012, NAT REV GENET, V13, P343, DOI 10.1038/nrg3173; GROOTECLAES M, 1994, CANCER RES, V54, P4193; Hua GQ, 2009, MOL CANCER RES, V7, P402, DOI 10.1158/1541-7786.MCR-08-0175; Huang WY, 2015, NUCLEIC ACIDS RES, V43, pD856, DOI 10.1093/nar/gku1151; Hurtado A, 2008, NATURE, V456, P663, DOI 10.1038/nature07483; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; Kulak MV, 2013, ONCOGENE, V32, P4043, DOI 10.1038/onc.2012.400; Malik S, 2010, NAT REV GENET, V11, P761, DOI 10.1038/nrg2901; MIZUGUCHI G, 1995, J BIOL CHEM, V270, P9384, DOI 10.1074/jbc.270.16.9384; Moarii M, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1994-2; Mungamuri SK, 2013, CELL REP, V5, P302, DOI 10.1016/j.celrep.2013.09.009; Nezu M, 1999, BIOCHEM BIOPH RES CO, V258, P499, DOI 10.1006/bbrc.1999.0634; Ong CT, 2011, NAT REV GENET, V12, P283, DOI 10.1038/nrg2957; PASLEAU F, 1993, ONCOGENE, V8, P849; Perissi V, 2000, ONCOGENE, V19, P280, DOI 10.1038/sj.onc.1203303; Rada-Iglesias A, 2011, NATURE, V470, P279, DOI 10.1038/nature09692; RENBAUM P, 1990, NUCLEIC ACIDS RES, V18, P1145, DOI 10.1093/nar/18.5.1145; Rose NR, 2014, BBA-GENE REGUL MECH, V1839, P1362, DOI 10.1016/j.bbagrm.2014.02.007; Roskoski R, 2014, PHARMACOL RES, V79, P34, DOI 10.1016/j.phrs.2013.11.002; Schaefer KA, 2017, NAT METHODS, V14, P547, DOI 10.1038/nmeth.4293; Scott GK, 2000, ONCOGENE, V19, P6490, DOI 10.1038/sj.onc.1204041; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; TAL M, 1987, MOL CELL BIOL, V7, P2597, DOI 10.1128/MCB.7.7.2597; Tata PR, 2011, NUCLEIC ACIDS RES, V39, P3574, DOI 10.1093/nar/gkq1344; Vernimmen D, 2003, BIOCHEM J, V370, P323, DOI 10.1042/BJ20021238; Vojta A, 2016, NUCLEIC ACIDS RES, V44, P5615, DOI 10.1093/nar/gkw159; Wang H, 2017, CANCER LETT, V385, P137, DOI 10.1016/j.canlet.2016.10.033; Woodfield GW, 2010, GENE CHROMOSOME CANC, V49, P948, DOI 10.1002/gcc.20807; Woodfield GW, 2009, CLIN CANCER RES, V15, P3672, DOI 10.1158/1078-0432.CCR-08-2343; Wu J, 2006, CANCER RES, V66, P4872, DOI 10.1158/0008-5472.CAN-05-3561; Xing XM, 2000, NAT MED, V6, P189, DOI 10.1038/72294; Zuo T, 2007, CELL, V129, P1275, DOI 10.1016/j.cell.2007.04.034	53	16	16	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 1	2018	37	5					687	694		10.1038/onc.2017.382	http://dx.doi.org/10.1038/onc.2017.382			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FU4GT	29035388	Green Published, Green Accepted, hybrid			2022-12-17	WOS:000423812200013
J	Xia, L; Xiao, X; Liu, WL; Song, Y; Liu, TJJ; Li, YJ; Zacksenhaus, E; Hao, XJ; Ben-David, Y				Xia, L.; Xiao, X.; Liu, W. L.; Song, Y.; Liu, T. J. J.; Li, Y. J.; Zacksenhaus, E.; Hao, X. J.; Ben-David, Y.			Coactosin-like protein CLP/Cot11 suppresses breast cancer growth through activation of IL-24/PERP and inhibition of non-canonical TGF beta signaling	ONCOGENE			English	Article							ANCHORAGE-INDEPENDENT GROWTH; MAMMARY-TUMOR CELLS; EXPRESSION; MDA-7/IL-24; APOPTOSIS; 5-LIPOXYGENASE; MEDIATOR; COTL1; SMAD4; LINES	Coactosin-like protein (CLP, or Cotl1), is an F-actin-binding protein, whose role in cancer is largely unknown. Here we show that CLP/Cotl1 is highly expressed in a rat epithelial breast cancer cell line (FE1.3) compared with its mesenchymal counterpart (FE1.2). Knockdown of CLP/Cotl1 in FE1.3 cells increased cell proliferation, whereas its overexpression in FE1.2 cells inhibited proliferation in culture and reduced tumor growth in xenograft assays in mice. Mechanistically, we identified two major pathways through which CLP/Cotl1 exerts its suppressive effects. First, CLP/Cotl1 re-expression in FE1.2 and in human MCF7 breast cancer cells induced expression of the growth-suppressor gene interleukin-24 (IL-24), which independently of p53 upregulates the tumor-suppressor genes p53 apoptosis effector related to PMP-22 (PERP) and p21(cip1). Second, overexpression of CLP/Cotl1 potentiated the growthsuppressive effect of transforming growth factor-beta 1 (TGF beta 1), leading to downregulation of TGF beta-responsive genes vascular growth factor A/B (VEGFA/VEGFB), hypoxia inducing factor 1 alpha (HIF-1 alpha) and trombospondin 1 (TSP1), which mediate various hallmarks of cancer progression including angiogenesis, invasion and metastasis. CLP/Cotl1 inhibited TGF beta signaling via a non-canonical signaling involving IL-24-instigated inhibition of mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) phosphorylation and subsequent post-transcriptional downregulation of SMAD2 and SMAD4. We also showed that CLP/ COTL1 expression sensitizes breast cancer cells to chemotherapeutic drugs, and this was further enhanced by addition of exogenous TGF beta 1. CLP/Cotl1 expression is lost in many human malignancies including prostate, uterine and breast cancers. Thus, our results uncover a novel tumor-suppressor role for CLP/Cotl1 and identify the downstream effectors interleukin 24 (IL-24)/PERP and IL-24/MAPK/ERK/TGF beta as potential targets for precision therapy.	[Xia, L.; Xiao, X.; Liu, W. L.; Song, Y.; Liu, T. J. J.; Hao, X. J.; Ben-David, Y.] Guizhou Med Univ, State Key Lab Funct & Applicat Med Plants, Guiyang, Guizhou, Peoples R China; [Xia, L.; Xiao, X.; Liu, W. L.; Song, Y.; Liu, T. J. J.; Hao, X. J.; Ben-David, Y.] Key Lab Chem Nat Prod Guizhou Prov, Guiyang, Guizhou, Peoples R China; [Xia, L.; Xiao, X.; Liu, W. L.; Song, Y.; Liu, T. J. J.; Hao, X. J.; Ben-David, Y.] Chinese Acad Sci, Guiyang, Guizhou, Peoples R China; [Xia, L.; Hao, X. J.] Guizhou Univ, Sch Pharmaceut Sci, Guiyang, Guizhou, Peoples R China; [Li, Y. J.] Jilin Univ, Dept Anat, Norman Bethune Coll Med, Changchun, Jilin, Peoples R China; [Zacksenhaus, E.] Univ Toronto, Dept Med, Toronto, ON, Canada; [Zacksenhaus, E.] Univ Hlth Network, Toronto Gen Res Inst, Div Adv Diagnost, Toronto, ON, Canada	Guizhou Medical University; Chinese Academy of Sciences; Guizhou University; Jilin University; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital	Ben-David, Y (corresponding author), State Key Lab Funct & Applicat Med Plants, Guiyang 550014, Guizhou, Peoples R China.	yaacovbendavid@hotmail.com	Zacksenhaus, Eldad/AAD-3584-2020		National Natural Science Foundation of China [81472609]; Science and Technology Department of Guizhou Province Innovation and Project Grant [2013-6012]; Thousand Talent Program of China [WQ20135200171]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Department of Guizhou Province Innovation and Project Grant; Thousand Talent Program of China	This work was supported by research grants from the National Natural Science Foundation of China (81472609), the Science and Technology Department of Guizhou Province Innovation and Project Grant (2013-6012) and Thousand Talent Program of China (WQ20135200171) and to YBD.	Bhola NE, 2013, J CLIN INVEST, V123, P1348, DOI 10.1172/JCI65416; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Dai HM, 2006, BBA-PROTEINS PROTEOM, V1764, P1688, DOI 10.1016/j.bbapap.2006.06.017; Dai HM, 2004, J BIOMOL NMR, V29, P455, DOI 10.1023/B:JNMR.0000032550.18424.aa; de Caestecker MP, 2000, JNCI-J NATL CANCER I, V92, P1388, DOI 10.1093/jnci/92.17.1388; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gevaert K, 2003, NAT BIOTECHNOL, V21, P566, DOI 10.1038/nbt810; Gubin MM, 2014, CELL CYCLE, V9, P3357; Guo SQ, 2017, ONCOTARGET, V8, P644, DOI 10.18632/oncotarget.13501; Ihrie RA, 2003, CURR BIOL, V13, P1985, DOI 10.1016/j.cub.2003.10.055; Kim JA, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0085445, 10.1371/journal.pone.0091940]; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; Li XM, 2004, ACTA CRYSTALLOGR D, V60, P2387, DOI [10.1107/S0907444904028112, 10.1107/S097444904028112]; Li XM, 2004, PROTEIN SCI, V13, P2845, DOI 10.1110/ps.04937304; Li YJ, 2003, ONCOGENE, V22, P3452, DOI 10.1038/sj.onc.1206411; Li YJ, 2015, ONCOTARGET, V6, P36943, DOI 10.18632/oncotarget.6046; Liu L, 2004, ACTA CRYSTALLOGR D, V60, P1651, DOI 10.1107/S0907444904016701; Luo K, 2017, COLD SPRING HARB PER, V9; Menezes ME, 2015, ONCOTARGET, V6, P36928, DOI 10.18632/oncotarget.6047; Menezes ME, 2014, ADV EXP MED BIOL, V818, P127, DOI 10.1007/978-1-4471-6458-6_6; Nakagawa T, 2004, KIDNEY INT, V66, P605, DOI 10.1111/j.1523-1755.2004.00780.x; Nakatsura T, 2002, EUR J IMMUNOL, V32, P826, DOI 10.1002/1521-4141(200203)32:3<826::AID-IMMU826>3.0.CO;2-Y; Provost P, 1999, P NATL ACAD SCI USA, V96, P1881, DOI 10.1073/pnas.96.5.1881; Provost P, 2001, J BIOL CHEM, V276, P16520, DOI 10.1074/jbc.M011205200; Provost P, 2001, BIOCHEM J, V359, P255, DOI 10.1042/0264-6021:3590255; Rakonjac M, 2006, P NATL ACAD SCI USA, V103, P13150, DOI 10.1073/pnas.0605150103; Sainz-Perez A, 2008, J IMMUNOL, V181, P6051, DOI 10.4049/jimmunol.181.9.6051; Su ZZ, 2003, ONCOGENE, V22, P1164, DOI 10.1038/sj.onc.1206062; Sun WJ, 2012, J INVEST MED, V60, P689, DOI 10.2310/JIM.0b013e31824963b6; Tian MZ, 2011, CELL SIGNAL, V23, P951, DOI 10.1016/j.cellsig.2010.10.015; Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419; Uhlen M, 2010, NAT BIOTECHNOL, V28, P1248, DOI 10.1038/nbt1210-1248; Wang CJ, 2010, ONCOL RES, V18, P561, DOI 10.3727/096504010X12767359113929; Wurthner JU, 2001, J BIOL CHEM, V276, P19495, DOI 10.1074/jbc.M006473200; Wylie-Sears J, 2014, BIOCHEM BIOPH RES CO, V446, P870, DOI 10.1016/j.bbrc.2014.03.014; Xia L, 2016, MOL CLIN ONCOL, V5, P717, DOI 10.3892/mco.2016.1059; Xuan WL, 2009, MOL CANCER RES, V7, P433, DOI 10.1158/1541-7786.MCR-08-0252; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1	38	16	18	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	2018	37	3					323	331		10.1038/onc.2017.342	http://dx.doi.org/10.1038/onc.2017.342			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS9QS	28925397				2022-12-17	WOS:000422753900005
J	Zhang, F; Virshup, DM; Cheong, JK				Zhang, F.; Virshup, D. M.; Cheong, J. K.			Oncogenic RAS-induced CK1 alpha drives nuclear FOXO proteolysis	ONCOGENE			English	Article							FORKHEAD TRANSCRIPTION FACTORS; SYNTHETIC LETHAL INTERACTIONS; CANCER-CELLS; SELECTIVE INHIBITORS; MULTIPLE-MYELOMA; HUMAN COLON; FACTOR AFX; E3 LIGASE; PHASE-I; KINASE	Evasion of forkhead box O (FOXO) family of longevity-related transcription factors-mediated growth suppression is necessary to promote cancer development. Since somatic alterations or mutations and transcriptional dysregulation of the FOXO genes are infrequent in human cancers, it remains unclear how these tumour suppressors are eliminated from cancer cells. The protein stability of FOXO3A is regulated by Casein Kinase 1 alpha (CK1 alpha) in an oncogenic RAS-specific manner, but whether this mode of regulation extends to related FOXO family members is unknown. Here we report that CK1 alpha similarly destabilizes FOXO4 in RASmutant cells by phosphorylation at serines 265/268. The CK1 alpha-dependent phosphoregulation of FOXO4 is primed, in part, by the PI3K/AKT effector axis of oncogenic RAS signalling. In addition, mutant RAS coordinately elevates proteasome subunit expression and proteolytic activity to eradicate nuclear FOXO4 proteins from RAS-mutant cancer cells. Importantly, dual inhibition of CK1 alpha and the proteasome synergistically inhibited the growth of multiple RAS-mutant human cancer cell lines of diverse tissue origin by blockade of nuclear FOXO4 degradation and induction of caspase-dependent apoptosis. Our findings challenge the current paradigm that nuclear export regulates the proteolysis of FOXO3A/4 tumour suppressors in the context of cancer and illustrates how oncogenic RAS-mediated degradation of FOXOs, via post-translational mechanisms, blocks these important tumour suppressors.	[Zhang, F.; Virshup, D. M.; Cheong, J. K.] Duke NUS Med Sch, Programme Canc & Stem Cell Biol, 8 Coll Rd, Singapore 169857, Singapore; [Virshup, D. M.] Natl Univ Singapore, Dept Biochem, Singapore, Singapore; [Virshup, D. M.] Duke Univ, Dept Pediat, Sch Med, Durham, NC 27706 USA	National University of Singapore; National University of Singapore; Duke University	Virshup, DM; Cheong, JK (corresponding author), Duke NUS Med Sch, Programme Canc & Stem Cell Biol, 8 Coll Rd, Singapore 169857, Singapore.	david.virshup@duke-nus.edu.sg; jitkong.cheong@duke-nus.edu.sg	Virshup, David M/C-1449-2009	Virshup, David M/0000-0001-6976-850X	Singapore Ministry of Health's National Medical Research Council under its NMRC-CBRG New Investigator Grant [NMRC/BNIG/1078/2012]; Duke-NUS-St. Baldrick's Foundation Pediatric Cancer Research Fund [Duke-NUSSBF/2015/0004]; Singapore Ministry of Education Academic Research Fund (AcRF) Tier 2 grant [MOE2016-T2-2-052]; Singapore Agency for Science, Technology and Research (A*STAR); Singapore Ministry of Health (MOH) under its Duke-NUS Signature Research Program; National Research Foundation under its Singapore Translational Research (STaR) Investigator Award; Singapore Ministry of Health's National Medical Research Council [NMRC/STaR/0017/2013]	Singapore Ministry of Health's National Medical Research Council under its NMRC-CBRG New Investigator Grant(Ministry of Health-SingaporeNational Medical Research Council, Singapore); Duke-NUS-St. Baldrick's Foundation Pediatric Cancer Research Fund; Singapore Ministry of Education Academic Research Fund (AcRF) Tier 2 grant(Ministry of Education, Singapore); Singapore Agency for Science, Technology and Research (A*STAR)(Agency for Science Technology & Research (A*STAR)); Singapore Ministry of Health (MOH) under its Duke-NUS Signature Research Program(Ministry of Education, SingaporeMinistry of Health-SingaporeNational University of Singapore); National Research Foundation under its Singapore Translational Research (STaR) Investigator Award(National Research Foundation, Singapore); Singapore Ministry of Health's National Medical Research Council(National Medical Research Council, Singapore)	We thank Chun Wei Chan, Edison and Yun Ka Wong (Duke-NUS) for their excellent technical support. We are greatly indebted to Christopher Counter (Duke), William Kaelin (Harvard), Koji Itahana (Duke-NUS), Sujoy Ghosh (Duke-NUS) and John Chua (NUS) for reagents and helpful discussions. This research is supported by the Singapore Ministry of Health's National Medical Research Council under its NMRC-CBRG New Investigator Grant (NMRC/BNIG/1078/2012), a Duke-NUS-St. Baldrick's Foundation Pediatric Cancer Research Fund (Duke-NUSSBF/2015/0004) and the Singapore Ministry of Education Academic Research Fund (AcRF) Tier 2 grant (MOE2016-T2-2-052) awarded to JKC. DMV is supported by the Singapore Agency for Science, Technology and Research (A*STAR) and the Singapore Ministry of Health (MOH) under its Duke-NUS Signature Research Program Grant, as well as the National Research Foundation under its Singapore Translational Research (STaR) Investigator Award and administered by the Singapore Ministry of Health's National Medical Research Council (NMRC/STaR/0017/2013).	Alexander TB, 2016, J CLIN ONCOL, V34, P4094, DOI 10.1200/JCO.2016.67.5066; Arlt A, 2013, ONCOGENE, V32, P4825, DOI 10.1038/onc.2012.493; Asada S, 2007, CELL SIGNAL, V19, P519, DOI 10.1016/j.cellsig.2006.08.015; Azmi AS, 2013, HAEMATOLOGICA, V98, P1098, DOI 10.3324/haematol.2012.074781; Bailey P, 2016, NATURE, V531, P47, DOI 10.1038/nature16965; Bain J, 2007, BIOCHEM J, V408, P297, DOI 10.1042/BJ20070797; Barbie DA, 2009, NATURE, V462, P108, DOI 10.1038/nature08460; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Brenkman AB, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002819; Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Castrillon DH, 2003, SCIENCE, V301, P215, DOI 10.1126/science.1086336; Cheong JK, 2011, ONCOGENE, V30, P2558, DOI 10.1038/onc.2010.627; Cheong JK, 2015, J CLIN INVEST, V125, P1401, DOI 10.1172/JCI78018; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189; De Ruiter ND, 2001, MOL CELL BIOL, V21, P8225, DOI 10.1128/MCB.21.23.8225-8235.2001; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Dobson M, 2011, BBA-MOL CELL RES, V1813, P1453, DOI 10.1016/j.bbamcr.2011.05.001; Essers MAG, 2004, EMBO J, V23, P4802, DOI 10.1038/sj.emboj.7600476; Feoktistova Maria, 2016, Cold Spring Harb Protoc, V2016, DOI 10.1101/pdb.prot087379; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Fu W, 2009, J BIOL CHEM, V284, P13987, DOI 10.1074/jbc.M901758200; Furuyama T, 2004, J BIOL CHEM, V279, P34741, DOI 10.1074/jbc.M314214200; Gounder MM, 2016, J CLIN ONCOL, V34, P3166, DOI 10.1200/JCO.2016.67.6346; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harper JW, 2016, NATURE, V537, P328, DOI 10.1038/nature19947; Hietanen S, 2000, P NATL ACAD SCI USA, V97, P8501, DOI 10.1073/pnas.97.15.8501; Hoang B, 2010, BLOOD, V116, P4560, DOI 10.1182/blood-2010-05-285726; Honaker Y, 2010, ONCOGENE, V29, P3324, DOI 10.1038/onc.2010.96; Hosaka T, 2004, P NATL ACAD SCI USA, V101, P2975, DOI 10.1073/pnas.0400093101; Huang HJ, 2011, BBA-MOL CELL RES, V1813, P1961, DOI 10.1016/j.bbamcr.2011.01.007; Huart AS, 2009, J BIOL CHEM, V284, P32384, DOI 10.1074/jbc.M109.052647; Jaras M, 2014, J EXP MED, V211, P605, DOI 10.1084/jem.20131033; Kato S, 2008, J BIOL CHEM, V283, P35464, DOI 10.1074/jbc.M801011200; Kattapuram T, 2005, J BIOL CHEM, V280, P15340, DOI 10.1074/jbc.M500214200; Kitamura T, 2007, J CLIN INVEST, V117, P2477, DOI 10.1172/JCI32054; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kops GJPL, 1999, J MOL MED-JMM, V77, P656, DOI 10.1007/s001099900050; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kumar MS, 2012, CELL, V149, P642, DOI 10.1016/j.cell.2012.02.059; Lantermann AB, 2015, CANCER RES, V75, P1; Lapalombella R, 2012, BLOOD, V120, P4621, DOI 10.1182/blood-2012-05-429506; Li J, 2016, ONCOTARGET, V7, P25585, DOI 10.18632/oncotarget.8339; Lin LH, 2014, INT J ONCOL, V44, P557, DOI 10.3892/ijo.2013.2205; Luo J, 2009, CELL, V137, P835, DOI 10.1016/j.cell.2009.05.006; Matsuzaki H, 2003, P NATL ACAD SCI USA, V100, P11285, DOI 10.1073/pnas.1934283100; Modur V, 2002, J BIOL CHEM, V277, P47928, DOI 10.1074/jbc.M207509200; Morin RD, 2011, NATURE, V476, P298, DOI 10.1038/nature10351; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Nalepa G, 2006, NAT REV DRUG DISCOV, V5, P596, DOI 10.1038/nrd2056; Oerlemans R, 2008, BLOOD, V112, P2489, DOI 10.1182/blood-2007-08-104950; Paik JH, 2007, CELL, V128, P309, DOI 10.1016/j.cell.2006.12.029; Pereira B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11479; Radhakrishnan SK, 2010, MOL CELL, V38, P17, DOI 10.1016/j.molcel.2010.02.029; Razak ARA, 2016, J CLIN ONCOL, V34, P4142, DOI 10.1200/JCO.2015.65.3949; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Rena G, 2004, EMBO REP, V5, P60, DOI 10.1038/sj.embor.7400048; Rena G, 2002, EMBO J, V21, P2263, DOI 10.1093/emboj/21.9.2263; Riccardi C, 2006, NAT PROTOC, V1, P1458, DOI 10.1038/nprot.2006.238; Schmidt M, 2002, MOL CELL BIOL, V22, P7842, DOI 10.1128/MCB.22.22.7842-7852.2002; Sengupta A, 2009, J BIOL CHEM, V284, P28319, DOI 10.1074/jbc.M109.024406; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; Steckel M, 2012, CELL RES, V22, P1227, DOI 10.1038/cr.2012.82; Su LN, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-378; Sun QX, 2013, P NATL ACAD SCI USA, V110, P1303, DOI 10.1073/pnas.1217203110; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; Trinh DL, 2013, BLOOD, V121, P3666, DOI 10.1182/blood-2013-01-479865; Tzivion G, 2011, BBA-MOL CELL RES, V1813, P1938, DOI 10.1016/j.bbamcr.2011.06.002; van der Vos KE, 2012, NAT CELL BIOL, V14, P829, DOI 10.1038/ncb2536; Walton KM, 2009, J PHARMACOL EXP THER, V330, P430, DOI 10.1124/jpet.109.151415; Wang GJ, 2015, BIOCHEM BIOPH RES CO, V459, P629, DOI 10.1016/j.bbrc.2015.02.160; Warr MR, 2013, NATURE, V494, P323, DOI 10.1038/nature11895; Yang JY, 2008, NAT CELL BIOL, V10, P138, DOI 10.1038/ncb1676; Yu WJ, 2017, LEUKEMIA LYMPHOMA, V58, P428, DOI 10.1080/10428194.2016.1190968; Zhang W, 2016, CELL REP, V15, P349, DOI 10.1016/j.celrep.2016.03.021; Zhang WW, 2006, J BIOL CHEM, V281, P10105, DOI 10.1074/jbc.M600272200; Zhang YN, 2014, NATURE, V513, P440, DOI 10.1038/nature13492; Zhou W, 2009, GASTROENTEROLOGY, V137, P1403, DOI 10.1053/j.gastro.2009.06.049; Zhu JY, 1998, CELL, V93, P851, DOI 10.1016/S0092-8674(00)81445-2	81	16	17	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	2018	37	3					363	376		10.1038/onc.2017.334	http://dx.doi.org/10.1038/onc.2017.334			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS9QS	28945225	Green Published, hybrid			2022-12-17	WOS:000422753900009
J	Lustig, LC; Dingar, D; Tu, WB; Lourenco, C; Kalkat, M; Inamoto, I; Ponzielli, R; Chan, WCW; Shin, JA; Penn, LZ				Lustig, L. C.; Dingar, D.; Tu, W. B.; Lourenco, C.; Kalkat, M.; Inamoto, I.; Ponzielli, R.; Chan, W. C. W.; Shin, J. A.; Penn, L. Z.			Inhibiting MYC binding to the E-box DNA motif by ME47 decreases tumour xenograft growth	ONCOGENE			English	Article							C-MYC; TRANSCRIPTIONAL REGULATION; PROTEIN-INTERACTION; INDUCED APOPTOSIS; BET BROMODOMAINS; IN-VIVO; CANCER; MAX; RESISTANCE; OMOMYC	Developing therapeutics to effectively inhibit the MYC oncoprotein would mark a key advance towards cancer patient care as MYC is deregulated in over 50% of human cancers. MYC deregulation is correlated with aggressive disease and poor patient outcome. Despite strong evidence in mouse models that inhibiting MYC would significantly impact tumour cell growth and patient survival, traditional approaches have not yet yielded the urgently needed therapeutic agents that directly target MYC. MYC functions through its interaction with MAX to regulate gene transcription by binding to E-box DNA response elements of MYC target genes. Here we used a structure-based strategy to design ME47, a small minimalist hybrid protein (MHP) able to disrupt the MAX: E-box interaction/binding and block transcriptional MYC activity. We show that inducing ME47 expression in established tumour xenografts inhibits tumour growth and decreases cellular proliferation. Mechanistically, we show by chromatin immunoprecipitation that ME47 binds to E-box binding sites of MYC target genes. Moreover, ME47 occupancy decreases MYC: DNA interaction at its cognate E-box binding sites. Taken together, ME47 is a prototypic MHP inhibitor that antagonizes tumour cell growth in vitro and in vivo and inhibits the interaction of MYC with DNA E-box elements. These results support ME47's role as a MYC inhibitor and suggest that MHPs provide an alternative therapeutic targeting system that can be used to target transcription factors important in human diseases, including cancer.	[Lustig, L. C.; Dingar, D.; Tu, W. B.; Lourenco, C.; Kalkat, M.; Ponzielli, R.; Penn, L. Z.] Univ Hlth Network, Princess Margaret Canc Ctr, Princess Margaret Canc Res Tower 13-706, Toronto, ON M5G 1L7, Canada; [Tu, W. B.; Lourenco, C.; Kalkat, M.; Penn, L. Z.] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; [Inamoto, I.; Shin, J. A.] Univ Toronto, Dept Chem, Toronto, ON, Canada; [Chan, W. C. W.] Univ Toronto, Inst Biomat & Biomed Engn, Donnelly Ctr Cellular & Biomol Res, Dept Mat Sci & Engn,Dept Chem Engn, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University of Toronto; University of Toronto	Penn, LZ (corresponding author), Univ Hlth Network, Princess Margaret Canc Ctr, Princess Margaret Canc Res Tower 13-706, Toronto, ON M5G 1L7, Canada.	lpenn@uhnres.utoronto.ca		Tu, William/0000-0002-2365-1995; Penn, Linda/0000-0001-8133-5459; Kalkat, Manpreet/0000-0002-4843-9755	Collaborative Health Research Program; Canadian Research Chairs Program; Natural Sciences and Engineering Research Council; Canadian Breast Cancer Foundation Ontario Region Doctoral Fellowship	Collaborative Health Research Program; Canadian Research Chairs Program(Canada Research Chairs); Natural Sciences and Engineering Research Council(Natural Sciences and Engineering Research Council of Canada (NSERC)); Canadian Breast Cancer Foundation Ontario Region Doctoral Fellowship	We would like to thank the Penn, Shin, and Chen labs for their helpful reviews and contributions to this manuscript. Special thanks to Dr Peter Mullen, Dr Sam Sathiamoorthy and Peter Tang. Funding was provided by way of Operating grant support from the Collaborative Health Research Program (JS, WC, LZP). Salary and stipend support from the Canadian Research Chairs Program (LZP), Natural Sciences and Engineering Research Council (LCL), Canadian Breast Cancer Foundation Ontario Region Doctoral Fellowship (WBT and MK).	Ahmadpour F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032136; Beaulieu ME, 2012, J MOL RECOGNIT, V25, P414, DOI 10.1002/jmr.2203; Berg T, 2011, CURR TOP MICROBIOL, V348, P139, DOI 10.1007/82_2010_90; Bhagwat AS, 2015, TRENDS CANCER, V1, P53, DOI 10.1016/j.trecan.2015.07.001; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Callus BA, 2008, CELL DEATH DIFFER, V15, P213, DOI 10.1038/sj.cdd.4402245; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Felsher Dean W, 2010, Genes Cancer, V1, P597, DOI 10.1177/1947601910377798; Follis AV, 2009, BIOORG MED CHEM LETT, V19, P807, DOI 10.1016/j.bmcl.2008.12.025; Fong CY, 2015, NATURE, V525, P538, DOI 10.1038/nature14888; Fu LL, 2015, ONCOTARGET, V6, P5501, DOI 10.18632/oncotarget.3551; Jain M, 2002, SCIENCE, V297, P102, DOI 10.1126/science.1071489; Jung KY, 2015, J MED CHEM, V58, P3002, DOI 10.1021/jm501440q; Kalkat M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115337; Lee TI, 2013, CELL, V152, P1237, DOI 10.1016/j.cell.2013.02.014; Lin CY, 2012, CELL, V151, P56, DOI 10.1016/j.cell.2012.08.026; Meyer N, 2008, NAT REV CANCER, V8, P976, DOI 10.1038/nrc2231; Mongiardi MP, 2015, SCI REP-UK, V5, DOI 10.1038/srep15494; Montagne M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032172; Oster SK, 2003, ONCOGENE, V22, P1998, DOI 10.1038/sj.onc.1206228; Picaud S, 2013, CANCER RES, V73, P3336, DOI 10.1158/0008-5472.CAN-12-3292; Ponzielli R, 2005, EUR J CANCER, V41, P2485, DOI 10.1016/j.ejca.2005.08.017; Ponzielli R, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkn735; Posternak V., 2016, F1000RESEARCH, V5, DOI [DOI 10.12688/F1000RESEARCH.7879.1, 10.12688/f1000research.7879.1]; Rathert P, 2015, NATURE, V525, P543, DOI 10.1038/nature14898; Sabo A, 2014, NATURE, V511, P488, DOI 10.1038/nature13537; Savino M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022284; Shi XR, 2016, P NATL ACAD SCI USA, V113, pE4558, DOI 10.1073/pnas.1608319113; Soodgupta D, 2015, MOL CANCER THER, V14, P1286, DOI 10.1158/1535-7163.MCT-14-0774-T; Soucek L, 2004, CELL DEATH DIFFER, V11, P1038, DOI 10.1038/sj.cdd.4401443; Soucek L, 2002, CANCER RES, V62, P3507; Soucek L, 1998, ONCOGENE, V17, P2463, DOI 10.1038/sj.onc.1202199; Soucek L, 2008, NATURE, V455, P679, DOI 10.1038/nature07260; Soucek L, 2013, GENE DEV, V27, P504, DOI 10.1101/gad.205542.112; Stojanova A, 2016, CELL CYCLE, V15, P1693, DOI 10.1080/15384101.2016.1146836; Vince JE, 2007, CELL, V131, P682, DOI 10.1016/j.cell.2007.10.037; Wasylishen AR, 2014, ONCOGENE, V33, P1066, DOI 10.1038/onc.2013.36; Wasylishen AR, 2011, ONCOGENE, V30, P3727, DOI 10.1038/onc.2011.88; Wasylishen AR, 2013, CANCER RES, V73, P6504, DOI 10.1158/0008-5472.CAN-12-4063; Wilson CH, 2014, ONCOGENE, V33, P4877, DOI 10.1038/onc.2014.78; Xu J, 2009, J AM CHEM SOC, V131, P7839, DOI 10.1021/ja901306q; Yin XY, 2003, ONCOGENE, V22, P6151, DOI 10.1038/sj.onc.1206641	43	16	16	2	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	2017	36	49					6830	6837		10.1038/onc.2017.275	http://dx.doi.org/10.1038/onc.2017.275			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FP0IK	28806396				2022-12-17	WOS:000417282500009
J	Park, JL; Lee, YS; Song, MJ; Hong, SH; Ahn, JH; Seo, EH; Shin, SP; Lee, SJ; Johnson, BH; Stampfer, MR; Kim, HP; Kim, SY; Lee, YS				Park, J-L; Lee, Y-S; Song, M-J; Hong, S-H; Ahn, J-H; Seo, E-H; Shin, S-P; Lee, S-J; Johnson, B. H.; Stampfer, M. R.; Kim, H-P; Kim, S-Y; Lee, Y. S.			Epigenetic regulation of RNA polymerase III transcription in early breast tumorigenesis	ONCOGENE			English	Article							MAMMARY EPITHELIAL-CELLS; DNA METHYLATION; NONCODING RNA; C-MYC; GENOMIC BINDING; P53 FUNCTION; POL II; CANCER; ACTIVATION; CHROMATIN	RNA polymerase III (Pol III) transcribes medium-sized non-coding RNAs (collectively termed Pol III genes). Emerging diverse roles of Pol III genes suggest that individual Pol III genes are exquisitely regulated by transcription and epigenetic factors. Here we report global Pol III expression/methylation profiles and molecular mechanisms of Pol III regulation that have not been as extensively studied, using nc886 as a representative Pol III gene. In a human mammary epithelial cell system that recapitulates early breast tumorigenesis, the fraction of actively transcribed Pol III genes increases reaching a plateau during immortalization. Hyper-methylation of Pol III genes inhibits Pol III binding to DNA via inducing repressed chromatin and is a determinant for the Pol III repertoire. When Pol III genes are hypo-methylated, MYC amplifies their transcription, regardless of its recognition DNA motif. Thus, Pol III expression during tumorigenesis is delineated by methylation and magnified by MYC.	[Park, J-L; Seo, E-H; Kim, S-Y] KRIBB, Personalized Genom Med Res Ctr, Daejeon, South Korea; [Park, J-L; Seo, E-H; Kim, S-Y] Univ Sci & Technol, Dept Funct Genom, Daejeon, South Korea; [Lee, Y-S; Hong, S-H] Natl Canc Ctr, Res Inst, Rare Canc Branch, Goyang Si, South Korea; [Song, M-J; Kim, H-P] Yonsei Univ, Dept Environm Med Biol, Coll Med, Seoul, South Korea; [Ahn, J-H] Kyung Hee Univ, Dept Life & Nanopharmaceut Sci, Seoul, South Korea; [Ahn, J-H] Kyung Hee Univ, Dept Oriental Pharm, Seoul, South Korea; [Shin, S-P; Lee, S-J] Natl Canc Ctr, Res Inst, Immunotherapeut Branch, Goyang Si, South Korea; [Johnson, B. H.; Lee, Y. S.] Univ Texas Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77555 USA; [Stampfer, M. R.] Lawrence Berkeley Natl Lab, Biol Syst & Engn Div, Berkeley, CA USA; [Kim, H-P] Yonsei Univ, Inst Trop Med, Coll Med, Seoul, South Korea; [Kim, H-P] Yonsei Univ, Brain Korea Plus Project Med Sci 21, Coll Med, Seoul, South Korea; [Lee, Y. S.] Natl Canc Ctr, Grad Sch Canc Sci & Policy, Dept Canc Biomed Sci, 323 Ilsan Ro, Goyang 10408, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB); University of Science & Technology (UST); National Cancer Center - Korea (NCC); Yonsei University; Yonsei University Health System; Kyung Hee University; Kyung Hee University; National Cancer Center - Korea (NCC); University of Texas System; University of Texas Medical Branch Galveston; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; National Cancer Center - Korea (NCC)	Kim, HP; Kim, SY; Lee, YS (corresponding author), Natl Canc Ctr, Grad Sch Canc Sci & Policy, Dept Canc Biomed Sci, 323 Ilsan Ro, Goyang 10408, South Korea.	kimhp@yuhs.ac; kimsy@kribb.re.kr; yslee@ncc.re.kr		Kim, Hyoung-Pyo/0000-0003-1441-8822; Shin, Seung-Phil/0000-0003-4290-3067	American Cancer Society [RSG-12-187-01-RMC]; Ministry of Science, ICT and Future Planning [NRF-2012M3A9D1054670, NRF-2014M3C9A3068554]; KRIBB Research Initiative; National Research Foundation of Korea [2016R1A2B4014183, 2017M3C9A5029978]; National Cancer Center (Korea) [1610090]; US Department of Energy [DE-AC02-05CH11231]	American Cancer Society(American Cancer Society); Ministry of Science, ICT and Future Planning(Ministry of Science, ICT & Future Planning, Republic of Korea); KRIBB Research Initiative; National Research Foundation of Korea(National Research Foundation of Korea); National Cancer Center (Korea); US Department of Energy(United States Department of Energy (DOE))	This work was supported by a Research Scholar Grant, RSG-12-187-01-RMC from the American Cancer Society to YSL; grants NRF-2012M3A9D1054670 and NRF-2014M3C9A3068554 funded by the Ministry of Science, ICT and Future Planning and KRIBB Research Initiative to S-YK; a grant 2016R1A2B4014183 and 2017M3C9A5029978 funded by National Research Foundation of Korea to H-PK; National Cancer Center (Korea) intramural project # 1610090 to Y-SL; and US Department of Energy under Contract No. DE-AC02-05CH11231 to MRS.	Alla RK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085648; Banati F, 2008, FEBS LETT, V582, P705, DOI 10.1016/j.febslet.2008.01.042; Barski A, 2010, NAT STRUCT MOL BIOL, V17, P629, DOI 10.1038/nsmb.1806; Bartke T, 2010, CELL, V143, P470, DOI 10.1016/j.cell.2010.10.012; BESSER D, 1990, FEBS LETT, V269, P358, DOI 10.1016/0014-5793(90)81193-R; Bhargava P, 2013, BBA-GENE REGUL MECH, V1829, P1015, DOI 10.1016/j.bbagrm.2013.05.005; Canella D, 2012, GENOME RES, V22, P666, DOI 10.1101/gr.130286.111; Canella D, 2010, GENOME RES, V20, P710, DOI 10.1101/gr.101337.109; Cao JZ, 2013, CANCER RES, V73, P3326, DOI 10.1158/0008-5472.CAN-12-3055; Carriere L, 2012, NUCLEIC ACIDS RES, V40, P270, DOI 10.1093/nar/gkr737; Chen W, 1997, J PATHOL, V183, P345, DOI 10.1002/(SICI)1096-9896(199711)183:3<345::AID-PATH930>3.0.CO;2-8; Chen W, 1997, EUR J CANCER, V33, P288, DOI 10.1016/S0959-8049(96)00453-4; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; Deaton AM, 2011, GENE DEV, V25, P1010, DOI 10.1101/gad.2037511; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; Felton-Edkins ZA, 2002, J BIOL CHEM, V277, P48182, DOI 10.1074/jbc.M201333200; Felton-Edkins ZA, 2003, CELL CYCLE, V2, P181, DOI 10.4161/cc.2.3.375; Fu Yu, 2015, Genomics & Informatics, V13, P94, DOI 10.5808/GI.2015.13.4.94; Fuks F, 2005, CURR OPIN GENET DEV, V15, P490, DOI 10.1016/j.gde.2005.08.002; Garbe JC, 2007, CELL CYCLE, V6, P1927, DOI 10.4161/cc.6.15.4519; Garbe JC, 2014, CELL CYCLE, V13, P3423, DOI 10.4161/15384101.2014.954456; Garbe JC, 2009, CANCER RES, V69, P7557, DOI 10.1158/0008-5472.CAN-09-0270; Gomez-Roman N, 2003, NATURE, V421, P290, DOI 10.1038/nature01327; Guccione E, 2006, NAT CELL BIOL, V8, P764, DOI 10.1038/ncb1434; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Hines WC, 2016, BREAST CANCER RES TR, V155, P37, DOI 10.1007/s10549-015-3649-z; Hu SS, 2012, INT J BIOCHEM CELL B, V44, P1847, DOI 10.1016/j.biocel.2012.07.013; JUTTERMANN R, 1991, J VIROL, V65, P1735; Kadauke S, 2009, BBA-GENE REGUL MECH, V1789, P17, DOI 10.1016/j.bbagrm.2008.07.002; Kenneth NS, 2007, P NATL ACAD SCI USA, V104, P14917, DOI 10.1073/pnas.0702909104; Klose RJ, 2006, TRENDS BIOCHEM SCI, V31, P89, DOI 10.1016/j.tibs.2005.12.008; LaBarge MA, 2013, JOVE-J VIS EXP, DOI 10.3791/50011; Lee EK, 2016, ONCOTARGET, V7, P75000, DOI 10.18632/oncotarget.11852; Lee HS, 2014, ONCOTARGET, V5, P3472, DOI 10.18632/oncotarget.1927; Lee JK, 2015, FRONT CELL DEV BIOL, V3, DOI 10.3389/fcell.2015.00013; Lee K, 2011, RNA, V17, P1076, DOI 10.1261/rna.2701111; Lee KS, 2014, ONCOTARGET, V5, P3944, DOI 10.18632/oncotarget.2047; Li H, 2009, BIOINFORMATICS, V25, P2078, DOI 10.1093/bioinformatics/btp352; Lin CY, 2012, CELL, V151, P56, DOI 10.1016/j.cell.2012.08.026; LIU WM, 1994, NUCLEIC ACIDS RES, V22, P1087, DOI 10.1093/nar/22.6.1087; LIU WM, 1993, NUCLEIC ACIDS RES, V21, P1351, DOI 10.1093/nar/21.6.1351; Messeguer X, 2002, BIOINFORMATICS, V18, P333, DOI 10.1093/bioinformatics/18.2.333; Moqtaderi Z, 2010, NAT STRUCT MOL BIOL, V17, P635, DOI 10.1038/nsmb.1794; Novak P, 2009, CANCER RES, V69, P5251, DOI 10.1158/0008-5472.CAN-08-4977; Oler AJ, 2010, NAT STRUCT MOL BIOL, V17, P620, DOI 10.1038/nsmb.1801; Ong CT, 2014, NAT REV GENET, V15, P234, DOI 10.1038/nrg3663; Park JL, 2017, EPIGENOMICS-UK, V9, P171, DOI 10.2217/epi-2016-0108; Park K, 2012, J LEUKOCYTE BIOL, V91, P245, DOI 10.1189/jlb.0111020; Romanelli V, 2014, EPIGENETICS-US, V9, P783, DOI 10.4161/epi.28323; Schramm L, 2002, GENE DEV, V16, P2593, DOI 10.1101/gad.1018902; Selvakumar T, 2012, J BIOL CHEM, V287, P7039, DOI 10.1074/jbc.M111.285601; Silver MJ, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0660-y; Stampfer MR, 2003, ONCOGENE, V22, P5238, DOI 10.1038/sj.onc.1206667; STAMPFER MR, 1985, P NATL ACAD SCI USA, V82, P2394, DOI 10.1073/pnas.82.8.2394; Stampfer MR, 2013, CELL MOL BIOL BREAST, P323, DOI [10.1007/978-1-62703-634-4_15, DOI 10.1007/978-1-62703-634-4_15]; Treppendahl MB, 2012, BLOOD, V119, P206, DOI 10.1182/blood-2011-06-362541; Varshney D, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7569; White RJ, 2004, ONCOGENE, V23, P3208, DOI 10.1038/sj.onc.1207547; Winter AG, 2000, P NATL ACAD SCI USA, V97, P12619, DOI 10.1073/pnas.230224097; Xie HH, 2010, P NATL ACAD SCI USA, V107, P6952, DOI 10.1073/pnas.0913836107	60	16	16	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	2017	36	49					6793	6804		10.1038/onc.2017.285	http://dx.doi.org/10.1038/onc.2017.285			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FP0IK	28846112	Green Published			2022-12-17	WOS:000417282500005
J	D'Abundo, L; Callegari, E; Bresin, A; Chillemi, A; Elamin, BK; Guerriero, P; Huang, X; Saccenti, E; Hussein, EMAA; Casciano, F; Secchiero, P; Zauli, G; Calin, GA; Russo, G; Lee, LJ; Croce, CM; Marcucci, G; Sabbioni, S; Malavasi, F; Negrini, M				D'Abundo, L.; Callegari, E.; Bresin, A.; Chillemi, A.; Elamin, B. K.; Guerriero, P.; Huang, X.; Saccenti, E.; Hussein, E. M. A. A.; Casciano, F.; Secchiero, P.; Zauli, G.; Calin, G. A.; Russo, G.; Lee, L. J.; Croce, C. M.; Marcucci, G.; Sabbioni, S.; Malavasi, F.; Negrini, M.			Anti-leukemic activity of microRNA-26a in a chronic lymphocytic leukemia mouse model	ONCOGENE			English	Article							INHIBITS CELL-PROLIFERATION; IN-VIVO; MONOCLONAL-ANTIBODIES; CD38 EXPRESSION; CANCER; DELIVERY; PATHOGENESIS; MIR-130A; SURVIVAL; DISEASE	Dysregulation of microRNAs (miRNAs) plays an important role in the pathogenesis of chronic lymphocytic leukemia (CLL). The E mu-TCL1 transgenic mouse develops a form of leukemia that is similar to the aggressive type of human B-CLL, and this valuable model has been widely used for testing novel therapeutic approaches. Here, we adopted this model to investigate the potential effects of miR-26a, miR-130an and antimiR-155 in CLL therapy. Improved delivery of miRNA molecules into CLL cells was obtained by developing a novel system based on lipid nanoparticles conjugated with an anti-CD38 monoclonal antibody. This methodology has proven to be highly effective in delivering miRNA molecules into leukemic cells. Short-and long-term experiments showed that miR-26a, miR-130a and anti-miR-155 increased apoptosis after in vitro and in vivo treatment. Of this miRNA panel, miR-26a was the most effective in reducing leukemic cell expansion. Following long-term treatment, apoptosis was readily detectable by analyzing cleavage of PARP and caspase-7. These effects could be directly attributed to miR-26a, as confirmed by significant downregulation of its proven targets, namely cyclin-dependent kinase 6 and Mcl1. The results of this study are relevant to two distinct areas. The first is related to the design of a technical strategy and to the selection of CD38 as a molecular target on CLL cells, both consenting efficient and specific intracellular transfer of miRNA. The original scientific finding inferred from the above approach is that miR-26a can elicit in vivo anti-leukemic activities mediated by increased apoptosis.	[D'Abundo, L.; Callegari, E.; Bresin, A.; Guerriero, P.; Hussein, E. M. A. A.; Negrini, M.] Univ Ferrara, Dept Morphol Surg & Expt Med, Via Luigi Borsari 46, I-44121 Ferrara, Italy; [Bresin, A.; Russo, G.] IRCCS, IDI, Lab Oncol Mol, Rome, Italy; [Chillemi, A.; Malavasi, F.] Univ Turin, Dept Med Sci, Lab Immunogenet, Turin, Italy; [Chillemi, A.; Malavasi, F.] Lab Immunol Trapianti Citta Salute & Sci, Turin, Italy; [Elamin, B. K.] Univ Khartoum, Fac Med Lab Sci, Microbiol Dept, Khartoum, Sudan; [Elamin, B. K.] Univ Bisha, Coll Med, Microbiol Dept, Bisha, Saudi Arabia; [Huang, X.; Lee, L. J.] Ohio State Univ, Nanoscale Sci & Engn Ctr Affordable Nanoengn Poly, Columbus, OH 43210 USA; [Huang, X.; Lee, L. J.] Ohio State Univ, Dept Chem & Biomol Engn, Columbus, OH 43210 USA; [Huang, X.; Croce, C. M.] Ohio State Univ, Comprehens Canc Ctr, Columbus, OH 43210 USA; [Saccenti, E.] Univ Ferrara, Univ Hosp Arcispedale S Anna, Dept Med Sci, Hematol Sect, Ferrara, Italy; [Hussein, E. M. A. A.] Univ Khartoum, Fac Med Lab Sci, Hematol & Immunohematol Dept, Khartoum, Sudan; [Casciano, F.; Secchiero, P.; Zauli, G.] Univ Ferrara, Surg Expt Med & LTTA Ctr, Dept Morphol, Ferrara, Italy; [Calin, G. A.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Div Canc Med, Houston, TX 77030 USA; [Marcucci, G.] City Hope Natl Med Ctr, Gehr Family Ctr Leukemia Res Hematol Malignancies, Duarte, CA USA; [Sabbioni, S.] Univ Ferrara, Dept Life Sci & Biotechnol, Ferrara, Italy	University of Ferrara; IRCCS Istituto Dermopatico dell'Immacolata (IDI); University of Turin; A.O.U. Citta della Salute e della Scienza di Torino; University of Khartoum; University of Bisha; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University of Ferrara; Arcispedale Sant'Anna; University of Khartoum; University of Ferrara; University of Texas System; UTMD Anderson Cancer Center; City of Hope; University of Ferrara	D'Abundo, L; Negrini, M (corresponding author), Univ Ferrara, Dept Morphol Surg & Expt Med, Via Luigi Borsari 46, I-44121 Ferrara, Italy.	dbnlll@unife.it; ngm@unife.it	Young, Richard A/F-6495-2012; Russo, Giandomenico/K-9566-2016; Casciano, Fabio FC/H-3219-2015; Calin, George/E-9390-2011; bresin, antonella/AAG-7189-2020; Zauli, Giorgio/ABE-8001-2020; Callegari, Elisa/Q-6135-2019; Negrini, Matteo/C-8906-2014; D'ABUNDO, LUCILLA/AAB-9816-2019; NEGRINI, Massimo/J-2377-2016	Young, Richard A/0000-0001-8855-8647; Russo, Giandomenico/0000-0002-7718-9687; Casciano, Fabio FC/0000-0002-6431-3335; Callegari, Elisa/0000-0002-4969-5400; Negrini, Matteo/0000-0003-0101-6963; BRESIN, antonella/0000-0003-3954-5481; D'Abundo, Lucilla/0000-0003-4196-0203; Calin, George/0000-0001-6704-5615; NEGRINI, Massimo/0000-0002-0007-1920; GUERRIERO, Paola/0000-0003-3724-7472; Calin, George/0000-0002-7427-0578; Elamin, Bahaeldin K./0000-0002-1136-4980	Italian Association for Cancer Research (AIRC) [9980]; University of Ferrara; US National Cancer Institute [CA19-7706]; FIRB Programme of the Ministry of University and Research (Rome, Italy); Fondazione Cassa di Risparmio di Torino; Fondazione Ricerca Molinette Torino	Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro); University of Ferrara; US National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); FIRB Programme of the Ministry of University and Research (Rome, Italy); Fondazione Cassa di Risparmio di Torino(Fondazione CRT); Fondazione Ricerca Molinette Torino	This work was supported by funds from the Italian Association for Cancer Research (AIRC Special program 5xmille n.9980) and the University of Ferrara to MN, from the US National Cancer Institute grant CA19-7706 to CMC, from FIRB Programme of the Ministry of University and Research (Rome, Italy), Fondazione Cassa di Risparmio di Torino and Fondazione Ricerca Molinette Torino to FM.	Acunzo M, 2012, ONCOGENE, V31, P634, DOI 10.1038/onc.2011.260; Amendola M, 2009, MOL THER, V17, P1039, DOI 10.1038/mt.2009.48; Ansari MQ, 1996, AM J CLIN PATHOL, V105, P221; Bende RJ, 2003, AM J PATHOL, V162, P105, DOI 10.1016/S0002-9440(10)63802-3; Bichi R, 2002, P NATL ACAD SCI USA, V99, P6955, DOI 10.1073/pnas.102181599; BINET JL, 1981, CANCER-AM CANCER SOC, V48, P198, DOI 10.1002/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V; Boll K, 2013, ONCOGENE, V32, P277, DOI 10.1038/onc.2012.55; Bresin A, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2015.419; Bresin A, 2015, ONCOTARGET, V6, P19807, DOI 10.18632/oncotarget.4415; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Calin GA, 2005, NEW ENGL J MED, V353, P1793, DOI 10.1056/NEJMoa050995; Calin GA, 2007, BEST PRACT RES CL HA, V20, P425, DOI 10.1016/j.beha.2007.02.003; Callegari E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073964; Chen JS, 2016, ONCOL REP, V35, P3285, DOI 10.3892/or.2016.4719; Chen YC, 2015, ADV DRUG DELIVER REV, V81, P128, DOI 10.1016/j.addr.2014.05.009; Chillemi A, 2013, MOL MED, V19, P99, DOI 10.2119/molmed.2013.00009; Chiorazzi N, 2005, ANN NY ACAD SCI, V1062, P1, DOI 10.1196/annals.1358.002; Chiorazzi N, 2005, NEW ENGL J MED, V352, P804, DOI 10.1056/NEJMra041720; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; Colomo L, 2004, AM J SURG PATHOL, V28, P736, DOI 10.1097/01.pas.0000126781.87158.e3; Costinean S, 2006, P NATL ACAD SCI USA, V103, P7024, DOI 10.1073/pnas.0602266103; Cui B, 2014, BLOOD, V124, P546, DOI 10.1182/blood-2014-03-559690; Cuneo A, 2014, CANCER MED-US, V3, P555, DOI 10.1002/cam4.226; Damle RN, 1999, BLOOD, V94, P1840, DOI 10.1182/blood.V94.6.1840; Di Martino MT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090005; Dohner H, 2000, NEW ENGL J MED, V343, P1910, DOI 10.1056/NEJM200012283432602; Dorrance AM, 2015, LEUKEMIA, V29, P2143, DOI 10.1038/leu.2015.139; Efanov A, 2010, LEUKEMIA, V24, P970, DOI 10.1038/leu.2010.46; Elmen J, 2008, NATURE, V452, P896, DOI 10.1038/nature06783; Fabbri M, 2011, JAMA-J AM MED ASSOC, V305, P59, DOI 10.1001/jama.2010.1919; Fujita Y, 2015, PROSTATE, V75, P1568, DOI 10.1002/pros.23031; Gao J, 2013, J CHEM-NY, V2013, DOI 10.1155/2013/719179; Garzon R, 2008, CURR OPIN HEMATOL, V15, P352, DOI 10.1097/MOH.0b013e328303e15d; Ghosh R, 2013, BIOMATERIALS, V34, P807, DOI 10.1016/j.biomaterials.2012.10.023; Grever MR, 2007, J CLIN ONCOL, V25, P799, DOI 10.1200/JCO.2006.08.3089; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Horenstein Alberto L., 2005, V308, P191; Huang XM, 2013, CLIN CANCER RES, V19, P2355, DOI 10.1158/1078-0432.CCR-12-3191; Huse JT, 2009, GENE DEV, V23, P1327, DOI 10.1101/gad.1777409; Ibrahim S, 2001, BLOOD, V98, P181, DOI 10.1182/blood.V98.1.181; Ji JF, 2009, NEW ENGL J MED, V361, P1437, DOI 10.1056/NEJMoa0901282; Jia XQ, 2012, CELL BIOCHEM BIOPHYS, V62, P237, DOI 10.1007/s12013-011-9263-8; Jiang H, 2015, ONCOL REP, V34, P1153, DOI 10.3892/or.2015.4099; Johnson AJ, 2006, BLOOD, V108, P1334, DOI 10.1182/blood-2005-12-011213; Kim H, 2010, P NATL ACAD SCI USA, V107, P2183, DOI 10.1073/pnas.0909896107; Klein U, 2010, CANCER CELL, V17, P28, DOI 10.1016/j.ccr.2009.11.019; Kota J, 2009, CELL, V137, P1005, DOI 10.1016/j.cell.2009.04.021; Kovaleva V, 2012, CANCER RES, V72, P1763, DOI 10.1158/0008-5472.CAN-11-3671; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; Landau DA, 2015, NATURE, V526, P525, DOI 10.1038/nature15395; Lee SH, 2015, ONCOTARGET, V6, P33269, DOI 10.18632/oncotarget.5037; Li BK, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0230-2; Li YH, 2015, ONCOTARGET, V6, P1101, DOI 10.18632/oncotarget.2728; Li ZH, 2014, NAT REV DRUG DISCOV, V13, P622, DOI 10.1038/nrd4359; Liu L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055532; Malavasi F, 2008, PHYSIOL REV, V88, P841, DOI 10.1152/physrev.00035.2007; Malavasi F, 2011, BLOOD, V118, P3470, DOI 10.1182/blood-2011-06-275610; Masotti A, 2016, NANOMED-NANOTECHNOL, V12, P1511, DOI 10.1016/j.nano.2016.02.017; Mattiske S, 2012, CANCER EPIDEM BIOMAR, V21, P1236, DOI 10.1158/1055-9965.EPI-12-0173; Miotto E, 2014, CANCER EPIDEM BIOMAR, V23, P2638, DOI 10.1158/1055-9965.EPI-14-0503; Negrini M, 2007, J CELL SCI, V120, P1833, DOI 10.1242/jcs.03450; Negrini M, 2014, CLIN CANCER RES, V20, P4141, DOI 10.1158/1078-0432.CCR-13-2497; O'Connell RM, 2008, J EXP MED, V205, P585, DOI 10.1084/jem.20072108; Pan YQ, 2015, INT J CLIN EXP PATHO, V8, P384; Perez-Galan P, 2011, BLOOD, V117, P26, DOI 10.1182/blood-2010-04-189977; Roberts AW, 2016, NEW ENGL J MED, V374, P311, DOI 10.1056/NEJMoa1513257; Rossi D, 2011, BLOOD, V118, P6904, DOI 10.1182/blood-2011-08-373159; Rossi S, 2010, BLOOD, V116, P945, DOI 10.1182/blood-2010-01-263889; Sander S, 2008, BLOOD, V112, P4202, DOI 10.1182/blood-2008-03-147645; Scognamiglio I, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/217365; Shen SY, 2015, CELL RES, V25, P997, DOI 10.1038/cr.2015.98; Simonetti G, 2014, BLOOD, V124, P1010, DOI 10.1182/blood-2014-05-577122; Taccioli C, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv220; Tagawa H, 2013, CANCER SCI, V104, P801, DOI 10.1111/cas.12160; Vaisitti T, 2015, LEUKEMIA, V29, P356, DOI 10.1038/leu.2014.207; van de Donk NWCJ, 2016, BLOOD, V127, P681, DOI 10.1182/blood-2015-10-646810; Vargova K, 2011, BLOOD, V117, P3816, DOI 10.1182/blood-2010-05-285064; Visone R, 2011, BLOOD, V118, P3072, DOI 10.1182/blood-2011-01-333484; Visone R, 2009, BLOOD, V114, P3872, DOI 10.1182/blood-2009-06-229211; Wiestner A, 2003, BLOOD, V101, P4944, DOI 10.1182/blood-2002-10-3306; Yan XJ, 2006, P NATL ACAD SCI USA, V103, P11713, DOI 10.1073/pnas.0604564103; Yang X, 2013, HEPATOLOGY, V58, P158, DOI 10.1002/hep.26305; Zanesi Nicola, 2010, J Nucleic Acids Investig, V1, P36; Zenz T, 2010, NAT REV CANCER, V10, P37, DOI 10.1038/nrc2764; Zhang Y, 2012, BLOOD, V120, P1678, DOI 10.1182/blood-2012-02-410647; Zhang Y, 2013, J CONTROL RELEASE, V172, P962, DOI 10.1016/j.jconrel.2013.09.015; Zhu X, 2015, CANCER GENE THER, V22, P573, DOI 10.1038/cgt.2015.50; Zhu Y, 2012, NUCLEIC ACIDS RES, V40, P4615, DOI 10.1093/nar/gkr1278	88	16	16	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 23	2017	36	47					6617	6626		10.1038/onc.2017.269	http://dx.doi.org/10.1038/onc.2017.269			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FN5LN	28783166	Green Submitted			2022-12-17	WOS:000416049200010
J	Umeda, Y; Hasegawa, Y; Otsuka, M; Ariki, S; Takamiya, R; Saito, A; Uehara, Y; Saijo, H; Kuronuma, K; Chiba, H; Ohnishi, H; Sakuma, Y; Takahashi, H; Kuroki, Y; Takahashi, M				Umeda, Y.; Hasegawa, Y.; Otsuka, M.; Ariki, S.; Takamiya, R.; Saito, A.; Uehara, Y.; Saijo, H.; Kuronuma, K.; Chiba, H.; Ohnishi, H.; Sakuma, Y.; Takahashi, H.; Kuroki, Y.; Takahashi, M.			Surfactant protein D inhibits activation of non-small cell lung cancer-associated mutant EGFR and affects clinical outcomes of patients	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; TYROSINE KINASE INHIBITORS; ACQUIRED-RESISTANCE; PULMONARY COLLECTINS; INNATE IMMUNITY; MECHANISM; BINDING; DISEASE; DOMAIN; LIPOPOLYSACCHARIDE	Tyrosine kinase inhibitor (TKI)-sensitive and TKI-resistant mutations of epidermal growth factor receptor (EGFR) are associated with lung adenocarcinoma. EGFR mutants were previously shown to exhibit ligand-independent activation. We have previously demonstrated that pulmonary surfactant protein D (SP-D, SFTPD) suppressed wild-type EGFR signaling by blocking ligand binding to EGFR. We herein demonstrate that SFTPD downregulates ligand-independent signaling in cells harboring EGFR mutations such as TKI-sensitive exon 19 deletion (Ex19del) and L858R mutation as well as TKI-resistant T790M mutation, subsequently suppressing cellular growth and motility. Lectin blotting and ligand blotting in lung cancer cell lines suggested that EGFR mutants express oligomannose-type N-glycans and interact with SFTPD directly. Cross-linking assay indicated that SFTPD inhibits ligand-independent dimerization of EGFR mutants. We also demonstrated that SFTPD reduced dimerization-independent phosphorylation of Ex19del and T790M EGFR mutants using point mutations that disrupted the asymmetric dimer interface. It was confirmed that SFTPD augmented the viability-suppressing effects of EGFR-TKIs. Furthermore, retrospective analysis of 121 patients with lung adenocarcinoma to examine associations between serum SFTPD levels and clinical outcome indicated that in TKI-treated patients with lung cancer harboring EGFR mutations, including Ex19del or L858R, high serum SFTPD levels correlated with a lower number of distant metastases and prolonged overall survival and progression-free survival. These findings suggest that SFTPD downregulates both TKI-sensitive and -resistant EGFR mutant signaling, and SFTPD level is correlated with clinical outcome. These findings illustrate the use of serum SFTPD level as a potential marker to estimate the efficacy of EGFR-TKIs.	[Umeda, Y.; Hasegawa, Y.; Otsuka, M.; Saito, A.; Uehara, Y.; Saijo, H.; Kuronuma, K.; Chiba, H.; Takahashi, H.] Sapporo Med Univ, Res Inst Frontier Med, Dept Resp Med & Allergol, Sch Med, Sapporo, Hokkaido, Japan; [Hasegawa, Y.; Ariki, S.; Takamiya, R.; Saito, A.; Uehara, Y.; Kuroki, Y.; Takahashi, M.] Sapporo Med Univ, Res Inst Frontier Med, Dept Biochem, Sch Med, Sapporo, Hokkaido, Japan; [Ohnishi, H.] Sapporo Med Univ, Res Inst Frontier Med, Dept Publ Hlth, Sch Med, Sapporo, Hokkaido, Japan; [Sakuma, Y.] Sapporo Med Univ, Res Inst Frontier Med, Dept Mol Med, Sch Med, Sapporo, Hokkaido, Japan	Sapporo Medical University; Sapporo Medical University; Sapporo Medical University; Sapporo Medical University	Takahashi, M (corresponding author), Sapporo Med Univ, Res Inst Frontier Med, Dept Biochem, Sch Med,Chuo Ku, South 1 West 17, Sapporo, Hokkaido 0608556, Japan.	takam@sapmed.ac.jp	Ariki, Shigeru/E-3861-2014; Sakuma, Yuji/HGC-0692-2022; Saito, Atsushi/M-7382-2018; Takahashi, Motoko/I-3154-2013	Ariki, Shigeru/0000-0001-5838-499X; Sakuma, Yuji/0000-0003-2298-1359; Saito, Atsushi/0000-0003-3430-884X; Uehara, Yasuaki/0000-0002-6439-2715; Ohnishi, Hirofumi/0000-0002-5873-6438; Takahashi, Motoko/0000-0002-2112-6142; UMEDA, YASUAKI/0000-0001-9577-3353	Japan Society for the Promotion of Science [26860611]; Northern Advancement Center for Science Technology [H26 T-1-35]; Ito Foundation [H26-23]	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Northern Advancement Center for Science Technology; Ito Foundation	This study was supported by a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (26860611), grants from the Northern Advancement Center for Science & Technology (H26 T-1-35) and grants from the Ito Foundation (H26-23).	Arteaga CL, 2014, CANCER CELL, V25, P282, DOI 10.1016/j.ccr.2014.02.025; BETZ C, 1995, CANCER RES, V55, P4283; Bianco R, 2008, CLIN CANCER RES, V14, P5069, DOI 10.1158/1078-0432.CCR-07-4905; Cho J, 2013, CANCER RES, V73, P6770, DOI 10.1158/0008-5472.CAN-13-1145; Crouch E, 2000, IMMUNOL REV, V173, P52, DOI 10.1034/j.1600-065X.2000.917311.x; Dokala A, 2017, ONCOGENE, V36, P2337, DOI 10.1038/onc.2016.393; Engelman JA, 2008, CLIN CANCER RES, V14, P2895, DOI 10.1158/1078-0432.CCR-07-2248; Ferguson KM, 2008, ANNU REV BIOPHYS, V37, P353, DOI 10.1146/annurev.biophys.37.032807.125829; Gazdar AF, 2009, ONCOGENE, V28, pS24, DOI 10.1038/onc.2009.198; Goldstraw Peter, 2007, J Thorac Oncol, V2, P706, DOI 10.1097/JTO.0b013e31812f3c1a; Guix M, 2008, J CLIN INVEST, V118, P2609, DOI 10.1172/JCI34588; Hase T, 2011, CANCER SCI, V102, P1493, DOI 10.1111/j.1349-7006.2011.01973.x; Hasegawa Y, 2015, ONCOGENE, V34, P838, DOI [10.1038/onc.2014.20, 10.1038/onc.2015.266]; Ishii T, 2012, COPD, V9, P409, DOI 10.3109/15412555.2012.676110; Kovacs E, 2015, ANNU REV BIOCHEM, V84, P739, DOI 10.1146/annurev-biochem-060614-034402; KUROKI Y, 1994, J BIOL CHEM, V269, P25943; Kuroki Y, 2007, CELL MICROBIOL, V9, P1871, DOI 10.1111/j.1462-5822.2007.00953.x; Li SQ, 2005, CANCER CELL, V7, P301, DOI 10.1016/j.ccr.2005.03.003; Maemondo M, 2010, NEW ENGL J MED, V362, P2380, DOI 10.1056/NEJMoa0909530; Mitsudomi T, 2010, LANCET ONCOL, V11, P121, DOI 10.1016/S1470-2045(09)70364-X; Nagae H, 1997, CLIN CHIM ACTA, V266, P157, DOI 10.1016/S0009-8981(97)00124-1; Nagai Y, 2005, CANCER RES, V65, P7276, DOI 10.1158/0008-5472.CAN-05-0331; Ohya M, 2006, BIOCHEMISTRY-US, V45, P8657, DOI 10.1021/bi060176z; Okabe T, 2007, CANCER RES, V67, P2046, DOI 10.1158/0008-5472.CAN-06-3339; Pan JB, 2014, CLIN LAB, V60, P1439, DOI 10.7754/Clin.Lab.2013.131002; Red Brewer M, 2013, P NATL ACAD SCI USA, V110, pE3595, DOI 10.1073/pnas.1220050110; RENNARD SI, 1986, J APPL PHYSIOL, V60, P532, DOI 10.1152/jappl.1986.60.2.532; Sawada K, 2010, J BIOL CHEM, V285, P8434, DOI 10.1074/jbc.M109.074765; Sharma SV, 2007, NAT REV CANCER, V7, P169, DOI 10.1038/nrc2088; Shaykhiev R, 2013, P NATL ACAD SCI USA, V110, P12102, DOI 10.1073/pnas.1303058110; Takahashi H, 2000, AM J RESP CRIT CARE, V162, P1109, DOI 10.1164/ajrccm.162.3.9910080; Takahashi H, 2000, AM J RESP CRIT CARE, V162, P258, DOI 10.1164/ajrccm.162.1.9903014; Takahashi H, 1996, RESPIRATION, V63, P390; Takahashi M, 2013, J BIOL CHEM, V288, P32910, DOI 10.1074/jbc.M113.491902; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Thiel KW, 2007, P NATL ACAD SCI USA, V104, P19238, DOI 10.1073/pnas.0703854104; VANDEGRAAF EA, 1992, J LAB CLIN MED, V120, P252; Voynow JA, 2005, AM J RESP CRIT CARE, V172, P1013, DOI 10.1164/rccm.200410-1398OC; Whitsett JA, 2002, NEW ENGL J MED, V347, P2141, DOI 10.1056/NEJMra022387; Wright JR, 2005, NAT REV IMMUNOL, V5, P58, DOI 10.1038/nri1528; Wright JR, 1997, PHYSIOL REV, V77, P931, DOI 10.1152/physrev.1997.77.4.931; Romero-Ventosa EY, 2015, SPRINGERPLUS, V4, DOI 10.1186/s40064-015-0891-0; Yamaguchi H, 2011, CANCER CHEMOTH PHARM, V67, P331, DOI 10.1007/s00280-010-1325-x; Yamazoe M, 2008, J BIOL CHEM, V283, P35878, DOI 10.1074/jbc.M807268200; Yatabe Y, 2006, J MOL DIAGN, V8, P335, DOI 10.2353/jmoldx.2006.050104; Yu HA, 2014, CLIN CANCER RES, V20, P5898, DOI 10.1158/1078-0432.CCR-13-2437; Zhang F, 2004, CHEST, V125, p109S, DOI 10.1378/chest.125.5_suppl.109S; Zhang XW, 2006, CELL, V125, P1137, DOI 10.1016/j.cell.2006.05.013; Zhang XW, 2007, NATURE, V450, P741, DOI 10.1038/nature05998	49	16	16	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 16	2017	36	46					6432	6445		10.1038/onc.2017.253	http://dx.doi.org/10.1038/onc.2017.253			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FM9WN	28745320				2022-12-17	WOS:000415622900007
J	Ivanov, AA; Gonzalez-Pecchi, V; Khuri, LF; Niu, Q; Wang, Y; Xu, Y; Bai, Y; Mo, X; Prochownik, EV; Johns, MA; Du, Y; Khuri, FR; Fu, H				Ivanov, A. A.; Gonzalez-Pecchi, V.; Khuri, L. F.; Niu, Q.; Wang, Y.; Xu, Y.; Bai, Y.; Mo, X.; Prochownik, E. V.; Johns, M. A.; Du, Y.; Khuri, F. R.; Fu, H.			OncoPPi-informed discovery of mitogen-activated protein kinase kinase 3 as a novel binding partner of c-Myc	ONCOGENE			English	Article							GENE-EXPRESSION; TUMOR-CELLS; CANCER; MAX; PHOSPHORYLATION; TRANSFORMATION; INTERACTORS; PATHWAYS; NETWORK; COMPLEX	Mitogen-activated protein kinase kinase 3 (MKK3) is a dual threonine/ tyrosine protein kinase that regulates inflammation, proliferation and apoptosis through specific phosphorylation and activation of the p38 mitogen-activated protein kinase. However, the role of MKK3 beyond p38-signaling remains elusive. Recently, we reported a protein-protein interaction (PPI) network of cancer-associated genes, termed OncoPPi, as a resource for the scientific community to generate new biological models. Analysis of the OncoPPi connectivity identified MKK3 as one of the major hub proteins in the network. Here, we show that MKK3 interacts with a large number of proteins critical for cell growth and metabolism, including the major oncogenic driver MYC. Multiple complementary approaches were used to demonstrate the direct interaction of MKK3 with MYC in vitro and in vivo. Computational modeling and experimental studies mapped the interaction interface to the MYC helix-loop-helix domain and a novel 15-residue MYC-binding motif in MKK3 (MBM). The MBM in MKK3 is distinct from the known binding sites for p38 or upstream kinases. Functionally, MKK3 stabilized MYC protein, enhanced its transcriptional activity and increased expression of MYC-regulated genes. The defined MBM peptide mimicked the MKK3 effect in promoting MYC activity. Together, the exploration of OncoPPi led to a new biological model in which MKK3 operates by two distinct mechanisms in cellular regulation through its phosphorylation of p38 and its activation of MYC through PPI.	[Ivanov, A. A.; Gonzalez-Pecchi, V.; Khuri, L. F.; Niu, Q.; Wang, Y.; Xu, Y.; Bai, Y.; Mo, X.; Johns, M. A.; Du, Y.; Khuri, F. R.; Fu, H.] Emory Univ, Dept Pharmacol, Atlanta, GA USA; [Ivanov, A. A.; Gonzalez-Pecchi, V.; Khuri, L. F.; Niu, Q.; Wang, Y.; Xu, Y.; Bai, Y.; Mo, X.; Johns, M. A.; Du, Y.; Khuri, F. R.; Fu, H.] Emory Univ, Emory Chem Biol Discovery Ctr, Atlanta, GA USA; [Prochownik, E. V.] UPMC, Childrens Hosp Pittsburgh, Sect Hematol Oncol, Pittsburgh, PA USA; [Prochownik, E. V.] Univ Pittsburgh, Canc Inst, Pittsburgh, PA USA; [Du, Y.; Khuri, F. R.; Fu, H.] Emory Univ, Winship Canc Inst, Atlanta, GA USA	Emory University; Emory University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Emory University	Ivanov, AA; Fu, H (corresponding author), Emory Univ, Sch Med, Dept Pharmacol, 1510 Clifton Rd, Atlanta, GA 30322 USA.	andrey.ivanov@emory.edu; hfu@emory.edu	Khuri, Fadlo R./AAU-4942-2020	Khuri, Fadlo R./0000-0002-8638-7618; Gonzalez, Valentina/0000-0002-9163-4118; Ivanov, Andrei A/0000-0001-7476-1329	NIH [U01CA168449]; Winship Cancer Institute [NIH 5P30CA138292]; Emory University Research Committee award; NATIONAL CANCER INSTITUTE [R01CA174713, U01CA168449, P30CA138292, U54CA199092] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Winship Cancer Institute; Emory University Research Committee award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Min Qui for technical assistance. We thank Lauren Rusnak for editing the manuscript. This research was supported in part by NIH U01CA168449 (HF) and Winship Cancer Institute (NIH 5P30CA138292) and by Emory University Research Committee 2015 award (AAI). The results published here are in part based upon data generated by the TCGA Research Network: http://cancergenome.nih.gov/.	Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703; Babur O, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0612-6; Baldari S, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.591; Banerjee A, 2006, BIOCHEMISTRY-US, V45, P2333, DOI 10.1021/bi0522551; Ben-Levy R, 1998, CURR BIOL, V8, P1049, DOI 10.1016/S0960-9822(98)70442-7; Bretones G, 2015, BBA-GENE REGUL MECH, V1849, P506, DOI 10.1016/j.bbagrm.2014.03.013; Bunkoczi G, 2007, STRUCTURE, V15, P1215, DOI 10.1016/j.str.2007.08.011; Chymkowitch P, 2012, P NATL ACAD SCI USA, V109, P10450, DOI 10.1073/pnas.1200067109; Cuadrado A, 2010, BIOCHEM J, V429, P403, DOI 10.1042/BJ20100323; Forbes SA, 2015, NUCLEIC ACIDS RES, V43, pD805, DOI 10.1093/nar/gku1075; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; Hudson TJ, 2010, NATURE, V464, P993, DOI 10.1038/nature08987; Jung KY, 2015, J MED CHEM, V58, P3002, DOI 10.1021/jm501440q; Kodama Y, 2012, BIOTECHNIQUES, V53, P285, DOI [10.2144/0000113943, 10.2144/000113943]; Kragelj J, 2015, P NATL ACAD SCI USA, V112, P3409, DOI 10.1073/pnas.1419528112; Li S, 2015, CELL DEATH DIFFER, V22, P1000, DOI 10.1038/cdd.2014.188; Li ZG, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14356; Lin CY, 2012, CELL, V151, P56, DOI 10.1016/j.cell.2012.08.026; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Nair SK, 2003, CELL, V112, P193, DOI 10.1016/S0092-8674(02)01284-9; Pan J, 2015, ONCOGENE, V34, P3957, DOI 10.1038/onc.2014.327; Parajuli P, 2015, CELL PROLIFERAT, V48, P421, DOI 10.1111/cpr.12196; Ponzielli R, 2013, METHODS MOL BIOL, V1012, P51, DOI 10.1007/978-1-62703-429-6_4; Ruzinova MB, 2010, AM J SURG PATHOL, V34, P882, DOI 10.1097/PAS.0b013e3181db83af; Schreiber SL, 2010, NAT BIOTECHNOL, V28, P904, DOI 10.1038/nbt0910-904; Sultana A., 2015, CURR PROTOC PROTEIN, V79, P19, DOI [10.1002/0471140864.ps1925s79, DOI 10.1002/0471140864.PS1925S79, DOI 10.1002/0471140864.ps1925s79]; Sun XX, 2015, P NATL ACAD SCI USA, V112, P3734, DOI 10.1073/pnas.1411713112; Takekawa M, 2005, MOL CELL, V18, P295, DOI 10.1016/j.molcel.2005.04.001; Thomas LR, 2011, ADV CANCER RES, V110, P77, DOI 10.1016/B978-0-12-386469-7.00004-9; Tomczak Katarzyna, 2015, Contemp Oncol (Pozn), V19, pA68, DOI 10.5114/wo.2014.47136; Tu WB, 2015, BBA-GENE REGUL MECH, V1849, P469, DOI 10.1016/j.bbagrm.2014.06.002; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Yin XY, 2003, ONCOGENE, V22, P6151, DOI 10.1038/sj.onc.1206641; Zarubin T, 2005, CELL RES, V15, P11, DOI 10.1038/sj.cr.7290257; Zippo A, 2007, NAT CELL BIOL, V9, P932, DOI 10.1038/ncb1618	36	16	16	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	2017	36	42					5852	5860		10.1038/onc.2017.180	http://dx.doi.org/10.1038/onc.2017.180			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FK2DN	28628118	Green Accepted			2022-12-17	WOS:000413292900007
J	Kang, SM; Rosales, JL; Meier-Stephenson, V; Kim, S; Lee, KY; Narendran, A				Kang, S. M.; Rosales, J. L.; Meier-Stephenson, V.; Kim, S.; Lee, K. Y.; Narendran, A.			Genome-wide loss-of-function genetic screening identifies opioid receptor mu 1 as a key regulator of L-asparaginase resistance in pediatric acute lymphoblastic leukemia	ONCOGENE			English	Article							DOWN-REGULATION; CELLS; SYNTHETASE; SENSITIVITY; ACTIVATION; EXPRESSION	L-asparaginase is a critical chemotherapeutic agent for acute lymphoblastic leukemia (ALL). It hydrolyzes plasma asparagine into aspartate and NH3, causing asparagine deficit and inhibition of protein synthesis and eventually, leukemic cell death. However, patient relapse often occurs due to development of resistance. The molecular mechanism by which ALL cells acquire resistance to L-asparaginase is unknown. Therefore, we sought to identify genes that are involved in L-asparaginase resistance in primary leukemic cells. By unbiased genome-wide RNAi screening, we found that among 10 resistant ALL clones, six hits were for opioid receptor mu 1 (oprm1), two hits were for carbonic anhydrase 1 (ca1) and another two hits were for ubiquitin-conjugating enzyme E2C (ube2c). We also found that OPRM1 is expressed in all leukemic cells tested. Specific knockdown of OPRM1 confers L-asparaginase resistance, validating our genome-wide retroviral shRNA library screening data. Methadone, an agonist of OPRM1, enhances the sensitivity of parental leukemic cells, but not OPRM1-depleted cells, to L-asparaginase treatment, indicating that OPRM1 is required for the synergistic action of L-asparaginase and methadone, and that OPRM1 loss promotes leukemic cell survival likely through downregulation of the OPRM1-mediated apoptotic pathway. Consistent with this premise, patient leukemic cells with relatively high levels of OPRM1 are more sensitive to L-asparaginase treatment compared to OPRM1-depleted leukemic cells, further indicating that OPRM1 loss has a crucial role in L-asparaginase resistance in leukemic patients. Thus, our study demonstrates for the first time, a novel OPRM1-mediated mechanism for L-asparaginase resistance in ALL, and identifies OPRM1 as a functional biomarker for defining high-risk subpopulations and for the detection of evolving resistant clones. Oprm1 may also be utilized for effective treatment of L-asparaginase-resistant ALL.	[Kang, S. M.; Lee, K. Y.] Univ Calgary, Arnie Charbonneau Canc Inst, Dept Cell Biol & Anat, Calgary, AB T2N 4N1, Canada; [Kang, S. M.; Meier-Stephenson, V.; Narendran, A.] Univ Calgary, Div Pediat Oncol, Alberta Childrens Hosp, Calgary, AB, Canada; [Kang, S. M.; Meier-Stephenson, V.; Narendran, A.] Univ Calgary, POETIC Lab Preclin & Drug Discovery Studies, Arnie Charbonneau Canc Inst, Calgary, AB, Canada; [Rosales, J. L.] Univ Calgary, Snyder Inst Chron Dis, Dept Biochem & Mol Biol, Calgary, AB, Canada; [Kim, S.] Univ Calgary, Arnie Charbonneau Canc Inst, Dept Biochem & Mol Biol, Calgary, AB, Canada	University of Calgary; Alberta Childrens Hospital; University of Calgary; University of Calgary; University of Calgary; University of Calgary	Lee, KY (corresponding author), Univ Calgary, Arnie Charbonneau Canc Inst, Dept Cell Biol & Anat, Calgary, AB T2N 4N1, Canada.	kylee@ucalgary.ca		Rosales, Jesusa/0000-0002-2543-3801	CIHR [MOP-123400]; NSERC [RGPIN/312985-2011]	CIHR(Canadian Institutes of Health Research (CIHR)); NSERC(Natural Sciences and Engineering Research Council of Canada (NSERC))	This work was supported in part by grants from the CIHR (MOP-123400) and NSERC (RGPIN/312985-2011) to KYL.	Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen SH, 2015, PEDIATR NEONATOL, V56, P287, DOI 10.1016/j.pedneo.2014.10.006; Friesen C, 2008, CANCER RES, V68, P6059, DOI 10.1158/0008-5472.CAN-08-1227; Friesen C, 2014, CELL CYCLE, V13, P1560, DOI 10.4161/cc.28493; Friesen C, 2013, ONCOTARGET, V4, P677, DOI 10.18632/oncotarget.952; Howlader N, 2016, SEER CANC STAT REV; KILLANDER D, 1976, CANCER, V37, P220, DOI 10.1002/1097-0142(197601)37:1<220::AID-CNCR2820370132>3.0.CO;2-W; Krejci O, 2004, LEUKEMIA, V18, P434, DOI 10.1038/sj.leu.2403259; Li BS, 2006, LEUKEMIA, V20, P2199, DOI 10.1038/sj.leu.2404423; Stams WAG, 2003, BLOOD, V101, P2743, DOI 10.1182/blood-2002-08-2446; Su N, 2008, PEDIATR BLOOD CANCER, V50, P274, DOI 10.1002/pbc.21213; Supuran CT, 2017, EXPERT OPIN DRUG DIS, V12, P61, DOI 10.1080/17460441.2017.1253677; Xie CL, 2014, INT J BIOCHEM CELL B, V47, P113, DOI 10.1016/j.biocel.2013.11.023	14	16	16	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	2017	36	42					5910	5913		10.1038/onc.2017.211	http://dx.doi.org/10.1038/onc.2017.211			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FK2DN	28650467	hybrid, Green Published			2022-12-17	WOS:000413292900012
J	Huhn, SC; Liu, J; Ye, C; Lu, H; Jiang, X; Feng, X; Ganesan, S; White, E; Shen, Z				Huhn, S. C.; Liu, J.; Ye, C.; Lu, H.; Jiang, X.; Feng, X.; Ganesan, S.; White, E.; Shen, Z.			Regulation of spindle integrity and mitotic fidelity by BCCIP	ONCOGENE			English	Article							XENOPUS EGG EXTRACTS; MICROTUBULE ATTACHMENT; CHROMOSOME INSTABILITY; SELF-ORGANIZATION; MOTHER CENTRIOLE; TUMOR-SUPPRESSOR; DNA-DAMAGE; CENTROSOMES; PROTEIN; CANCER	Centrosomes together with the mitotic spindle ensure the faithful distribution of chromosomes between daughter cells, and spindle orientation is a major determinant of cell fate during tissue regeneration. Spindle defects are not only an impetus of chromosome instability but are also a cause of developmental disorders involving defective asymmetric cell division. In this work, we demonstrate BCCIP, especially BCCIP alpha, as a previously unidentified component of the mitotic spindle pole and the centrosome. We demonstrate that BCCIP localizes proximal to the mother centriole and participates in microtubule organization and then redistributes to the spindle pole to ensure faithful spindle architecture. We find that BCCIP depletion leads to morphological defects, disoriented mitotic spindles, chromosome congression defects and delayed mitotic progression. Our study identifies BCCIP as a novel factor critical for microtubule regulation and explicates a mechanism utilized by BCCIP in tumor suppression.	[Huhn, S. C.; Liu, J.; Ye, C.; Lu, H.; Jiang, X.; Feng, X.; Ganesan, S.; White, E.; Shen, Z.] Rutgers Canc Inst New Jersey, 195 Little Albany St, New Brunswick, NJ 08903 USA; [Huhn, S. C.; Liu, J.; Ye, C.; Lu, H.; Jiang, X.; Feng, X.; Shen, Z.] Rutgers Robert Wood Johnson Med Sch, Dept Radiat Oncol, New Brunswick, NJ USA; [Ganesan, S.] Rutgers Robert Wood Johnson Med Sch, Dept Med, New Brunswick, NJ USA; [White, E.] Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ USA; [Jiang, X.] Jilin Univ, Hosp 1, Changchun, Jilin, Peoples R China	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Jilin University	Shen, Z (corresponding author), Rutgers State Univ, Rutgers Canc Inst New Jersey, Dept Radiat Oncol, 195 Little Albany St, New Brunswick, NJ USA.	shenzh@cinj.rutgers.edu	White, Eileen/ABD-6745-2021	White, Eileen/0000-0003-2961-3065; Shen, Zhiyuan/0000-0003-2834-0309; feng, xing/0000-0001-8226-3389; Feng, Xing/0000-0002-2253-4180	NIH [R01CA156706, R01CA195612-01]; New Jersey Commission on Cancer Research Pre-Doctoral fellowship [DFHS15PPC042]; Histopathology and Imaging shared resources of The Cancer Institute of New Jersey [P30CA072720]; NATIONAL CANCER INSTITUTE [R01CA156706, R01CA115488, R01CA195612] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); New Jersey Commission on Cancer Research Pre-Doctoral fellowship; Histopathology and Imaging shared resources of The Cancer Institute of New Jersey; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This research was supported by NIH R01CA156706 and R01CA195612-01 to ZS, by New Jersey Commission on Cancer Research Pre-Doctoral fellowship (DFHS15PPC042) to SH and by the Histopathology and Imaging shared resources of The Cancer Institute of New Jersey (P30CA072720).	Audhya A, 2003, EMBO J, V22, P4223, DOI 10.1093/emboj/cdg397; Basto R, 2006, CELL, V125, P1375, DOI 10.1016/j.cell.2006.05.025; Bornens M, 2002, CURR OPIN CELL BIOL, V14, P25, DOI 10.1016/S0955-0674(01)00290-3; Chandhok NS, 2009, CURR OPIN GENET DEV, V19, P74, DOI 10.1016/j.gde.2008.12.004; Cimini D, 2005, TRENDS CELL BIOL, V15, P442, DOI 10.1016/j.tcb.2005.06.008; Delgehyr N, 2005, J CELL SCI, V118, P1565, DOI 10.1242/jcs.02302; DeLuca JG, 2005, MOL BIOL CELL, V16, P519, DOI 10.1091/mbc.E04-09-0852; Fan JJ, 2009, CELL CYCLE, V8, P3019; Fukasawa K, 2007, NAT REV CANCER, V7, P911, DOI 10.1038/nrc2249; Godin JD, 2010, NEURON, V67, P392, DOI 10.1016/j.neuron.2010.06.027; Green RA, 2003, J CELL BIOL, V163, P949, DOI 10.1083/jcb.200307070; Gruber R, 2011, NAT CELL BIOL, V13, P1325, DOI 10.1038/ncb2342; Guo J, 2006, MOL BIOL CELL, V17, P680, DOI 10.1091/mbc.E05-04-0360; Haren Laurence, 2009, BMC Res Notes, V2, P64, DOI 10.1186/1756-0500-2-64; Heald R, 1997, J CELL BIOL, V138, P615, DOI 10.1083/jcb.138.3.615; Heald R, 1996, NATURE, V382, P420, DOI 10.1038/382420a0; Heckman KL, 2007, NAT PROTOC, V2, P924, DOI 10.1038/nprot.2007.132; Hernandez P, 2010, DIS MODEL MECH, V3, P304, DOI 10.1242/dmm.004507; Hori A, 2014, EMBO REP, V15, P175, DOI 10.1002/embr.201337929; Howell BJ, 2001, J CELL BIOL, V155, P1159, DOI 10.1083/jcb.200105093; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; Huang YY, 2013, CANCER RES, V73, P7122, DOI 10.1158/0008-5472.CAN-13-1766; Huang YY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030638; Ivanova N, 2006, NATURE, V442, P533, DOI 10.1038/nature04915; Jackman M, 2003, NAT CELL BIOL, V5, P143, DOI 10.1038/ncb918; Keryer G, 2003, MOL BIOL CELL, V14, P4260, DOI 10.1091/mbc.E02-11-0773; Khodjakov A, 2000, CURR BIOL, V10, P59, DOI 10.1016/S0960-9822(99)00276-6; Kim DJ, 2013, BLOOD, V121, P3521, DOI 10.1182/blood-2012-11-470179; King JM, 2000, J CELL SCI, V113, P3815; Kline-Smith SL, 2004, MOL CELL, V15, P317, DOI 10.1016/j.molcel.2004.07.012; Kops GJPL, 2005, NAT REV CANCER, V5, P773, DOI 10.1038/nrc1714; Lara-Gonzalez P, 2012, CURR BIOL, V22, pR966, DOI 10.1016/j.cub.2012.10.006; Liu JM, 2001, ONCOGENE, V20, P336, DOI 10.1038/sj.onc.1204098; Louie RK, 2004, J CELL SCI, V117, P1117, DOI 10.1242/jcs.00939; Lu HM, 2005, MOL CELL BIOL, V25, P1949, DOI 10.1128/MCB.25.5.1949-1957.2005; Lu HM, 2007, NUCLEIC ACIDS RES, V35, P7160, DOI 10.1093/nar/gkm732; Lu HM, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002291; Mao NH, 2007, DNA REPAIR, V6, P1651, DOI 10.1016/j.dnarep.2007.05.012; Meng XB, 2003, GENE, V302, P139, DOI 10.1016/S0378-1119(02)01098-3; Meng XB, 2007, J BIOL CHEM, V282, P1570, DOI 10.1074/jbc.M607520200; Merdes A, 1997, J CELL BIOL, V138, P953, DOI 10.1083/jcb.138.5.953; MITCHISON TJ, 1986, METHOD ENZYMOL, V134, P261; Mogensen MM, 2000, J CELL SCI, V113, P3013; Namba M, 1996, CRIT REV ONCOGENESIS, V7, P19, DOI 10.1615/CritRevOncog.v7.i1-2.20; Nigg EA, 2011, NAT CELL BIOL, V13, P1154, DOI 10.1038/ncb2345; Pellman D, 2007, NATURE, V446, P38, DOI 10.1038/446038a; Quintyne NJ, 2002, J CELL BIOL, V159, P245, DOI 10.1083/jcb.200203089; Raaijmakers JA, 2013, J CELL BIOL, V201, P201, DOI 10.1083/jcb.201208098; Ried T, 2012, BBA-GENE REGUL MECH, V1819, P784, DOI 10.1016/j.bbagrm.2012.02.020; Salisbury JL, 2003, CURR BIOL, V13, pR88, DOI 10.1016/S0960-9822(03)00033-2; Sehrawat S, 2011, BLOOD, V117, P708, DOI 10.1182/blood-2010-02-268870; Shida T, 2010, P NATL ACAD SCI USA, V107, P21517, DOI 10.1073/pnas.1013728107; Skop AR, 2004, SCIENCE, V305, P61, DOI 10.1126/science.1097931; Song YY, 2015, TRENDS CELL BIOL, V25, P125, DOI 10.1016/j.tcb.2014.10.004; Thoma CR, 2009, NAT CELL BIOL, V11, P994, DOI 10.1038/ncb1912; Thornton GK, 2009, TRENDS GENET, V25, P501, DOI 10.1016/j.tig.2009.09.011; Vos MD, 2004, CANCER RES, V64, P4244, DOI 10.1158/0008-5472.CAN-04-0339; Wang HF, 2011, CANCER RES, V71, P68, DOI 10.1158/0008-5472.CAN-10-0030; Waters JC, 1998, J CELL BIOL, V141, P1181, DOI 10.1083/jcb.141.5.1181; Waters JC, 1996, J CELL SCI, V109, P2823; Wyler E, 2014, FEBS LETT, V588, P3685, DOI 10.1016/j.febslet.2014.08.013; Yang YF, 2014, P NATL ACAD SCI USA, V111, P2158, DOI 10.1073/pnas.1319341111; Young A, 2000, MOL BIOL CELL, V11, P2047, DOI 10.1091/mbc.11.6.2047; Zhou ZW, 2013, DNA REPAIR, V12, P645, DOI 10.1016/j.dnarep.2013.04.017	64	16	19	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2017	36	33					4750	4766		10.1038/onc.2017.92	http://dx.doi.org/10.1038/onc.2017.92			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FD7JM	28394342	Green Accepted, Green Published, hybrid			2022-12-17	WOS:000407702400008
J	Noto, A; De Vitis, C; Pisanu, ME; Roscilli, G; Ricci, G; Catizone, A; Sorrentino, G; Chianese, G; Taglialatela-Scafati, O; Trisciuoglio, D; Del Bufalo, D; Di Martile, M; Di Napoli, A; Ruco, L; Costantini, S; Jakopin, Z; Budillon, A; Melino, G; Del Sal, G; Ciliberto, G; Mancini, R				Noto, A.; De Vitis, C.; Pisanu, M. E.; Roscilli, G.; Ricci, G.; Catizone, A.; Sorrentino, G.; Chianese, G.; Taglialatela-Scafati, O.; Trisciuoglio, D.; Del Bufalo, D.; Di Martile, M.; Di Napoli, A.; Ruco, L.; Costantini, S.; Jakopin, Z.; Budillon, A.; Melino, G.; Del Sal, G.; Ciliberto, G.; Mancini, R.			Stearoyl-CoA-desaturase 1 regulates lung cancer stemness via stabilization and nuclear localization of YAP/TAZ (vol 36, pg 4573, 2017)	ONCOGENE			English	Correction													Del Bufalo, Donatella/K-8673-2016; Jakopin, Žiga/B-7089-2019; Budillon, Alfredo/K-4763-2016; Pisanu, Maria Elena/AAC-9143-2019; Ciliberto, Gennaro/J-4131-2017; Di Napoli, Arianna/AAB-3210-2022; Del Bufalo, Donatella/AAC-1594-2021; trisciuoglio, daniela/AAL-4002-2021	Del Bufalo, Donatella/0000-0002-3148-6096; Jakopin, Žiga/0000-0001-9384-0858; Budillon, Alfredo/0000-0002-6330-6053; Ciliberto, Gennaro/0000-0003-2851-8605; Di Napoli, Arianna/0000-0002-3159-5380; Del Bufalo, Donatella/0000-0002-3148-6096; 	Medical Research Council [MC_U132670600] Funding Source: researchfish; MRC [MC_U132670600] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Noto A, 2017, ONCOGENE, V36, P4573, DOI [10.1038/onc.2017.75, 10.1038/onc.2017.212]	1	16	17	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 10	2017	36	32					4671	4672		10.1038/onc.2017.212	http://dx.doi.org/10.1038/onc.2017.212			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FD0RK		Bronze			2022-12-17	WOS:000407246200015
J	Tao, T; Sondalle, SB; Shi, H; Zhu, S; Perez-Atayde, AR; Peng, J; Baserga, SJ; Look, AT				Tao, T.; Sondalle, S. B.; Shi, H.; Zhu, S.; Perez-Atayde, A. R.; Peng, J.; Baserga, S. J.; Look, A. T.			The pre-rRNA processing factor DEF is rate limiting for the pathogenesis of MYCN-driven neuroblastoma	ONCOGENE			English	Article							POLYMERASE I TRANSCRIPTION; SMALL-SUBUNIT PROCESSOME; NUCLEOLAR RNA; C-MYC; GRANULOCYTE DIFFERENTIATION; SACCHAROMYCES-CEREVISIAE; PROMINENT NUCLEOLI; RDNA TRANSCRIPTION; TUMOR INITIATION; CANCER	The nucleolar factor, digestive organ expansion factor (DEF), has a key role in ribosome biogenesis, functioning in pre-ribosomal RNA (pre-rRNA) processing as a component of the small ribosomal subunit (SSU) processome. Here we show that the peripheral sympathetic nervous system (PSNS) is very underdeveloped in def-deficient zebrafish, and that def haploinsufficiency significantly decreases disease penetrance and tumor growth rate in a MYCN-driven transgenic zebrafish model of neuroblastoma that arises in the PSNS. Consistent with these findings, DEF is highly expressed in human neuroblastoma, and its depletion in human neuroblastoma cell lines induces apoptosis. Interestingly, overexpression of MYCN in zebrafish and in human neuroblastoma cells results in the appearance of intermediate pre-rRNAs species that reflect the processing of pre-rRNAs through Pathway 2, a pathway that processes pre-rRNAs in a different temporal order than the more often used Pathway 1. Our results indicate that DEF and possibly other components of the SSU processome provide a novel site of vulnerability in neuroblastoma cells that could be exploited for targeted therapy.	[Tao, T.; Shi, H.; Look, A. T.] Harvard Med Sch, Dana Farber Canc Inst, Dept Pediat Oncol, 450 Brookline Ave,Mayer 630, Boston, MA 02115 USA; [Sondalle, S. B.] Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA; [Shi, H.; Peng, J.] Zhejiang Univ, Coll Anim Sci, Hangzhou, Zhejiang, Peoples R China; [Zhu, S.] Mayo Clin, Canc Ctr, Coll Med, Dept Biochem & Mol Biol, Rochester, MN USA; [Zhu, S.] Mayo Clin, Ctr Individualized Med, Rochester, MN USA; [Zhu, S.] Mayo Clin, Ctr Canc, Coll Med, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN USA; [Perez-Atayde, A. R.] Harvard Med Sch, Childrens Hosp Boston, Dept Pathol, Boston, MA 02115 USA; [Baserga, S. J.] Yale Univ, Dept Mol Biophys & Biochem, 333 Cedar St, New Haven, CT 06520 USA; [Baserga, S. J.] Yale Univ, Dept Genet, 333 Cedar St, New Haven, CT 06520 USA; [Baserga, S. J.] Yale Univ, Dept Therapeut Radiol, 333 Cedar St, New Haven, CT 06520 USA; [Baserga, S. J.] Yale Univ, Sch Med, 333 Cedar St, New Haven, CT 06520 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Yale University; Zhejiang University; Mayo Clinic; Mayo Clinic; Mayo Clinic; Harvard University; Boston Children's Hospital; Harvard Medical School; Yale University; Yale University; Yale University; Yale University	Look, AT (corresponding author), Harvard Med Sch, Dana Farber Canc Inst, Dept Pediat Oncol, 450 Brookline Ave,Mayer 630, Boston, MA 02115 USA.; Baserga, SJ (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, 333 Cedar St, New Haven, CT 06520 USA.; Baserga, SJ (corresponding author), Yale Univ, Dept Genet, 333 Cedar St, New Haven, CT 06520 USA.; Baserga, SJ (corresponding author), Yale Univ, Dept Therapeut Radiol, 333 Cedar St, New Haven, CT 06520 USA.; Baserga, SJ (corresponding author), Yale Univ, Sch Med, 333 Cedar St, New Haven, CT 06520 USA.	susan.baserga@yale.edu; thomas_look@dfci.harvard.edu	Sondalle, Samuel/C-1283-2014	Sondalle, Samuel/0000-0002-4144-9897; Tao, Ting/0000-0003-1260-2351	Innovation Award from Alex's Lemonade Stand Foundation; NIH [CA180692, GM115710, GM07205, HD007149, F30DK109582]; National Natural Science Foundation of China [31330050]; Young Investigator Award from Alex's Lemonade Stand Foundation; David Abraham Fellowship; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD007149] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F30DK109582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007205, R01GM115710] Funding Source: NIH RePORTER	Innovation Award from Alex's Lemonade Stand Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Young Investigator Award from Alex's Lemonade Stand Foundation; David Abraham Fellowship; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank John R Gilbert for editorial review of the manuscript and critical comments, and Hillary Layden and Shawna Chamberlin for their excellent care of the zebrafish. This work was supported by an Innovation Award from Alex's Lemonade Stand Foundation (ATL), NIH grant CA180692 (ATL), NIH grant GM115710 (SJB), a National Natural Science Foundation of China (No. 31330050; JP), a Young Investigator Award from Alex's Lemonade Stand Foundation (TT), NIH grants GM07205, HD007149 and F30DK109582 (SBS), and David Abraham Fellowship (HS).	An M, 2002, J COMP NEUROL, V446, P267, DOI 10.1002/cne.10214; Azuma M, 2006, J BIOL CHEM, V281, P13309, DOI 10.1074/jbc.M601892200; Barna M, 2008, NATURE, V456, P971, DOI 10.1038/nature07449; Berghmans S, 2005, P NATL ACAD SCI USA, V102, P407, DOI 10.1073/pnas.0406252102; Bernstein KA, 2004, EUKARYOT CELL, V3, P1619, DOI 10.1128/EC.3.6.1619-1626.2004; Boglev Y, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003279; Boisvert FM, 2007, NAT REV MOL CELL BIO, V8, P574, DOI 10.1038/nrm2184; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; Borovjagin AV, 1999, J MOL BIOL, V286, P1347, DOI 10.1006/jmbi.1999.2527; Bywater MJ, 2013, NAT REV CANCER, V13, P299, DOI 10.1038/nrc3496; Bywater MJ, 2012, CANCER CELL, V22, P51, DOI 10.1016/j.ccr.2012.05.019; Chan JC, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001754; Charette JM, 2010, RNA, V16, P2156, DOI 10.1261/rna.2359810; Chen J, 2005, GENE DEV, V19, P2900, DOI 10.1101/gad.1366405; Cheung NKV, 2013, NAT REV CANCER, V13, P397, DOI 10.1038/nrc3526; Dai MS, 2004, J BIOL CHEM, V279, P44475, DOI 10.1074/jbc.M403722200; Dave B, 2014, P NATL ACAD SCI USA, V111, P8838, DOI 10.1073/pnas.1320769111; Derenzini M, 2009, HISTOPATHOLOGY, V54, P753, DOI 10.1111/j.1365-2559.2008.03168.x; Dragon F, 2002, NATURE, V417, P967, DOI 10.1038/nature00769; Dutton KA, 2001, DEVELOPMENT, V128, P4113; Essers PB, 2014, DEV BIOL, V385, P304, DOI 10.1016/j.ydbio.2013.10.029; Etchin J, 2011, METHOD CELL BIOL, V105, P309, DOI 10.1016/B978-0-12-381320-6.00013-8; Fleurie A, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004275; Fumagalli S, 2012, GENE DEV, V26, P1028, DOI 10.1101/gad.189951.112; Gandin V, 2008, NATURE, V455, P684, DOI 10.1038/nature07267; George RE, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000255; Goldfeder MB, 2010, FEBS J, V277, P2838, DOI 10.1111/j.1742-4658.2010.07701.x; Grewal SS, 2005, NAT CELL BIOL, V7, P295, DOI 10.1038/ncb1223; Griffin JN, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005018; Hannan KM, 2013, BBA-GENE REGUL MECH, V1829, P342, DOI 10.1016/j.bbagrm.2012.10.014; Harscoet E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012829; Hein N, 2013, TRENDS MOL MED, V19, P643, DOI 10.1016/j.molmed.2013.07.005; Henras AK, 2015, WIRES RNA, V6, P225, DOI 10.1002/wrna.1269; Huang M, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a014415; Kang J, 2016, ONCOTARGET, V7, P48887, DOI 10.18632/oncotarget.10346; Kim CH, 1996, NEUROSCI LETT, V216, P109, DOI 10.1016/0304-3940(96)13021-4; Kobayashi C, 2005, CANCER-AM CANCER SOC, V103, P174, DOI 10.1002/cncr.20717; Kocak H, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.84; Langenau DM, 2008, ONCOGENE, V27, P4242, DOI 10.1038/onc.2008.56; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; Maris JM, 1999, J CLIN ONCOL, V17, P2264, DOI 10.1200/JCO.1999.17.7.2264; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; Maris JM, 2010, NEW ENGL J MED, V362, P2202, DOI 10.1056/NEJMra0804577; Mitchell NC, 2015, CELL SIGNAL, V27, P2045, DOI 10.1016/j.cellsig.2015.07.018; Montanaro L, 2008, AM J PATHOL, V173, P301, DOI 10.2353/ajpath.2008.070752; Montanaro L, 2013, ONCOTARGETS THER, V6, P909, DOI 10.2147/OTT.S36627; Murphy DM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008154; Nakaguro M, 2015, CANCER SCI, V106, P237, DOI 10.1111/cas.12598; Nakamura Y, 2007, BIOCHEM BIOPH RES CO, V354, P892, DOI 10.1016/j.bbrc.2007.01.057; Pei DS, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003533; Peltonen K, 2014, CANCER CELL, V25, P77, DOI 10.1016/j.ccr.2013.12.009; Pestov Dimitri G, 2008, Curr Protoc Cell Biol, VChapter 22, DOI 10.1002/0471143030.cb2211s39; Pezzolo A, 2009, NEURO-ONCOLOGY, V11, P192, DOI 10.1215/15228517-2008-086; Phipps KR, 2011, WIRES RNA, V2, P1, DOI 10.1002/wrna.57; Poortinga G, 2004, EMBO J, V23, P3325, DOI 10.1038/sj.emboj.7600335; Poortinga G, 2015, ONCOGENE, V34, P403, DOI 10.1038/onc.2014.13; Poortinga G, 2011, NUCLEIC ACIDS RES, V39, P3267, DOI 10.1093/nar/gkq1205; Preti M, 2013, NUCLEIC ACIDS RES, V41, P4709, DOI 10.1093/nar/gkt160; Quin JE, 2014, BBA-MOL BASIS DIS, V1842, P802, DOI 10.1016/j.bbadis.2013.12.009; SAVINO R, 1990, EMBO J, V9, P2299, DOI 10.1002/j.1460-2075.1990.tb07401.x; Sloan KE, 2013, J CELL BIOL, V200, P577, DOI 10.1083/jcb.201207131; Stanke M, 1999, DEVELOPMENT, V126, P4087; Stewart RA, 2006, DEV BIOL, V292, P174, DOI 10.1016/j.ydbio.2005.12.035; Tafforeau L, 2013, MOL CELL, V51, P539, DOI 10.1016/j.molcel.2013.08.011; Tao T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058858; Tao T, 2013, CELL RES, V23, P620, DOI 10.1038/cr.2013.16; Tornoczky T, 2007, PATHOL ONCOL RES, V13, P269, DOI 10.1007/BF02940304; Wang HZ, 2009, CELL RES, V19, P1150, DOI 10.1038/cr.2009.99; Wang LL, 2013, CANCER-AM CANCER SOC, V119, P3718, DOI 10.1002/cncr.28251; Wang MS, 2014, NUCLEIC ACIDS RES, V42, P11180, DOI 10.1093/nar/gku787; Wang Y, 2012, INT J ANTENN PROPAG, V2012, DOI 10.1155/2012/636349; Warner JR, 1999, TRENDS BIOCHEM SCI, V24, P437, DOI 10.1016/S0968-0004(99)01460-7; WEINBERG RA, 1970, J MOL BIOL, V47, P169, DOI 10.1016/0022-2836(70)90337-2; WEINBERG RA, 1967, P NATL ACAD SCI USA, V58, P1088, DOI 10.1073/pnas.58.3.1088; Wilkins BJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077670; Woolford JL, 2013, GENETICS, V195, P643, DOI 10.1534/genetics.113.153197; Zhu SZ, 2012, CANCER CELL, V21, P362, DOI 10.1016/j.ccr.2012.02.010; Zhu ZH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096576	78	16	16	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 6	2017	36	27					3852	3867		10.1038/onc.2016.527	http://dx.doi.org/10.1038/onc.2016.527			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EZ6SM	28263972	Green Published, Green Accepted, hybrid			2022-12-17	WOS:000404848200006
J	Liu, Z; Yanagisawa, K; Griesing, S; Iwai, M; Kano, K; Hotta, N; Kajino, T; Suzuki, M; Takahashi, T				Liu, Z.; Yanagisawa, K.; Griesing, S.; Iwai, M.; Kano, K.; Hotta, N.; Kajino, T.; Suzuki, M.; Takahashi, T.			TTF-1/NKX2-1 binds to DDB1 and confers replication stress resistance to lung adenocarcinomas	ONCOGENE			English	Article							DNA-DAMAGE; THYROID TRANSCRIPTION; CHK1; ONCOGENE; EXPRESSION; CANCER; GENE; ACTIVATION; SURVIVAL; TARGETS	TTF-1, also known as NKX2-1, is a transcription factor that has indispensable roles in both lung development and physiology. We and others have reported that TTF-1 frequently exhibits high expression with increased copy number in lung adenocarcinomas, and also has a role as a lineage-survival oncogene through transcriptional activation of crucial target genes including ROR1 and LMO3. In the present study, we employed a global proteomic search for proteins that interact with TTF-1 in order to provide a more comprehensive picture of this still enigmatic lineage-survival oncogene. Our results unexpectedly revealed a function independent of its transcriptional activity, as TTF-1 was found to interact with DDB1 and block its binding to CHK1, which in turn attenuated ubiquitylation and subsequent degradation of CHK1. Furthermore, TTF-1 overexpression conferred resistance to cellular conditions under DNA replication stress (RS) and prevented an increase in consequential DNA double-strand breaks, as reflected by attenuated induction of pCHK2 and gamma H2AX. Our findings suggest that the novel non-transcriptional function of TTF-1 identified in this study may contribute to lung adenocarcinoma development by conferring tolerance to DNA RS, which is known to be inherently elicited by activation of various oncogenes.	[Liu, Z.; Yanagisawa, K.; Griesing, S.; Iwai, M.; Kano, K.; Hotta, N.; Kajino, T.; Suzuki, M.; Takahashi, T.] Nagoya Univ, Grad Sch Med, Ctr Neurol Dis & Canc, Div Mol Carcinogenesis, Nagoya, Aichi, Japan	Nagoya University	Takahashi, T (corresponding author), Nagoya Univ, Grad Sch Med, Ctr Neurol Dis & Canc, Div Mol Carcinogenesis,Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	tak@med.nagoya-u.ac.jp	Takahashi, Takashi/I-7262-2014	Takahashi, Takashi/0000-0003-0615-7001; Liu, Zhuoran/0000-0002-6679-4136	Japan Society for the Promotion of Science (JSPS); Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan; China Scholarship Council; Grants-in-Aid for Scientific Research [16H06277, 25293191, 15H05910, 25640076] Funding Source: KAKEN	Japan Society for the Promotion of Science (JSPS)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); China Scholarship Council(China Scholarship Council); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported in part by a Grant-in-Aid for Scientific Research (A) from the Japan Society for the Promotion of Science (JSPS) and by a Grant-in-Aid for Scientific Research on Innovative Areas from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan. Zhuoran Liu was supported by a fellowship from the China Scholarship Council.	Bartek J, 2004, NAT REV MOL CELL BIO, V5, P792, DOI 10.1038/nrm1493; Bartkova J, 2007, ONCOGENE, V26, P7414, DOI 10.1038/sj.onc.1210553; Cardnell RJG, 2015, CLIN CANCER RES, V21, P3480, DOI 10.1158/1078-0432.CCR-14-3286; Gaillard H, 2015, NAT REV CANCER, V15, P276, DOI 10.1038/nrc3916; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Guo TN, 2015, NAT MED, V21, P407, DOI 10.1038/nm.3807; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Hills SA, 2014, CURR BIOL, V24, pR435, DOI 10.1016/j.cub.2014.04.012; Hosono Y, 2012, EMBO J, V31, P481, DOI 10.1038/emboj.2011.416; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Isogaya K, 2014, CELL RES, V24, P994, DOI 10.1038/cr.2014.97; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Kamitani T, 1997, J BIOL CHEM, V272, P28557, DOI 10.1074/jbc.272.45.28557; Kendall J, 2007, P NATL ACAD SCI USA, V104, P16663, DOI 10.1073/pnas.0708286104; Kimura S, 1996, GENE DEV, V10, P60, DOI 10.1101/gad.10.1.60; Kwei KA, 2008, ONCOGENE, V27, P3635, DOI 10.1038/sj.onc.1211012; Lee MN, 2007, CLIN CANCER RES, V13, P832, DOI 10.1158/1078-0432.CCR-05-2694; Leung-Pineda V, 2009, CANCER RES, V69, P2630, DOI 10.1158/0008-5472.CAN-08-3382; Lopez-Contreras AJ, 2012, J EXP MED, V209, P455, DOI 10.1084/jem.20112147; Maeda Y, 2006, J BIOL CHEM, V281, P9600, DOI 10.1074/jbc.M510435200; Maeda Y, 2012, J CLIN INVEST, V122, P4388, DOI 10.1172/JCI64048; Meuth M, 2010, CELL DIV, V5, DOI 10.1186/1747-1028-5-21; Missero C, 2001, J BIOL CHEM, V276, P33569, DOI 10.1074/jbc.M104963200; Mizuno K, 2002, ONCOGENE, V21, P2328, DOI 10.1038/sj.onc.1205402; Osada H, 2002, ONCOGENE, V21, P2418, DOI 10.1038/sj.onc.1205303; Petermann E, 2006, MOL CELL BIOL, V26, P3319, DOI 10.1128/MCB.26.8.3319-3326.2006; Snyder EL, 2013, MOL CELL, V50, P185, DOI 10.1016/j.molcel.2013.02.018; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; Takeuchi T, 2006, J CLIN ONCOL, V24, P1679, DOI 10.1200/JCO.2005.03.8224; Tanaka H, 2007, CANCER RES, V67, P6007, DOI 10.1158/0008-5472.CAN-06-4774; Tell G, 2002, J BIOL CHEM, V277, P14564, DOI 10.1074/jbc.M200582200; Verlinden L, 2007, CANCER RES, V67, P6574, DOI 10.1158/0008-5472.CAN-06-3545; Watanabe H, 2013, GENE DEV, V27, P197, DOI 10.1101/gad.203208.112; Weir BA, 2007, NATURE, V450, P893, DOI 10.1038/nature06358; Yamaguchi T, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10060; Yamaguchi T, 2013, CANCER CELL, V23, P718, DOI 10.1016/j.ccr.2013.04.002; Yamaguchi T, 2012, CANCER CELL, V21, P348, DOI 10.1016/j.ccr.2012.02.008; Yatabe Y, 2002, AM J SURG PATHOL, V26, P767, DOI 10.1097/00000478-200206000-00010; Zeman MK, 2014, NAT CELL BIOL, V16, P2, DOI 10.1038/ncb2897; Zhang YW, 2005, MOL CELL, V19, P607, DOI 10.1016/j.molcel.2005.07.019	41	16	17	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 29	2017	36	26					3740	3748		10.1038/onc.2016.524	http://dx.doi.org/10.1038/onc.2016.524			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY9WM	28192407				2022-12-17	WOS:000404349700009
J	Dunnill, CJ; Ibraheem, K; Mohamed, A; Southgate, J; Georgopoulos, NT				Dunnill, C. J.; Ibraheem, K.; Mohamed, A.; Southgate, J.; Georgopoulos, N. T.			A redox state-dictated signalling pathway deciphers the malignant cell specificity of CD40-mediated apoptosis	ONCOGENE			English	Article							HUMAN UROTHELIAL CELLS; IN-VITRO; C-JUN; ANTIOXIDANT PATHWAYS; EPITHELIAL-CELLS; CARCINOMA-CELLS; CD40 PATHWAY; CANCER-CELLS; JNK; ACTIVATION	CD40, a member of the tumour necrosis factor receptor (TNFR) superfamily, has the capacity to cause extensive apoptosis in carcinoma cells, while sparing normal epithelial cells. Yet, apoptosis is only achieved by membrane-presented CD40 ligand (mCD40L), as soluble receptor agonists are but weakly pro-apoptotic. Here, for the first time we have identified the precise signalling cascade underpinning mCD40L-mediated death as involving sequential TRAF3 stabilisation, ASK1 phosphorylation, MKK4 (but not MKK7) activation and JNK/AP-1 induction, leading to a Bak-and Bax-dependent mitochondrial apoptosis pathway. TRAF3 is central in the activation of the NADPH oxidase(Nox)-2 component p40phox and the elevation of reactive oxygen species (ROS) is essential in apoptosis. Strikingly, CD40 activation resulted in down-regulation of Thioredoxin (Trx)-1 to permit ASK1 activation and apoptosis. Although soluble receptor agonist alone could not induce death, combinatorial treatment incorporating soluble CD40 agonist and pharmacological inhibition of Trx-1 was functionally equivalent to the signal triggered by mCD40L. Finally, we demonstrate using normal, 'para-malignant' and tumour-derived cells that progression to malignant transformation is associated with increase in oxidative stress in epithelial cells, which coincides with increased susceptibility to CD40 killing, while in normal cells CD40 signalling is cytoprotective. Our studies have revealed the molecular nature of the tumour specificity of CD40 signalling and explained the differences in pro-apoptotic potential between soluble and membrane-bound CD40 agonists. Equally importantly, by exploiting a unique epithelial culture system that allowed us to monitor alterations in the redox-state of epithelial cells at different stages of malignant transformation, our study reveals how pro-apoptotic signals can elevate ROS past a previously hypothesised 'lethal pro-apoptotic threshold' to induce death; an observation that is both of fundamental importance and carries implications for cancer therapy.	[Dunnill, C. J.; Ibraheem, K.; Mohamed, A.; Georgopoulos, N. T.] Univ Huddersfield, Sch Appl Sci, Dept Biol Sci, Huddersfield HD1 3DH, W Yorkshire, England; [Southgate, J.] Univ York, Dept Biol, Jack Birch Unit Mol Carcinogenesis, York, N Yorkshire, England	University of Huddersfield; University of York - UK	Georgopoulos, NT (corresponding author), Univ Huddersfield, Sch Appl Sci, Dept Biol Sci, Huddersfield HD1 3DH, W Yorkshire, England.	N.Georgopoulos@hud.ac.uk	Southgate, Jennifer/AAJ-9089-2021	Southgate, Jennifer/0000-0002-0135-480X	York Against Cancer	York Against Cancer	The authors are grateful to all clinical colleagues for the supply of normal urothelial tissue, and would like to thank Prof Alan Melcher and Dr Liz Illett (Targeted & Biological Therapies Group, Leeds Institute of Cancer and Pathology, University of Leeds, UK) for the provision of the G28-5 antibody and fruitful discussions. JS holds a research chair supported by York Against Cancer.	Al-Tameemi W, 2014, TOXICOL IN VITRO, V28, P1366, DOI 10.1016/j.tiv.2014.07.011; Albarbar B, 2015, CYTOKINE GROWTH F R, V26, P659, DOI 10.1016/j.cytogfr.2015.05.001; Altenburg A, 1999, J IMMUNOL, V162, P4140; Baker AF, 2006, J LAB CLIN MED, V147, P83, DOI 10.1016/j.lab.2005.09.001; Baxendale AJ, 2005, ONCOGENE, V24, P7913, DOI 10.1038/sj.onc.1208929; Benhar M, 2001, MOL CELL BIOL, V21, P6913, DOI 10.1128/MCB.21.20.6913-6926.2001; Bhogal RH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030867; Bishop GA, 2007, ADV EXP MED BIOL, V597, P131; Booth C, 1997, LAB INVEST, V76, P843; Bugajska U, 2002, J NATL CANCER I, V94, P1381; Cargnello M, 2011, MICROBIOL MOL BIOL R, V75, P50, DOI 10.1128/MMBR.00031-10; Chonghaile TN, 2011, SCIENCE, V334, P1129, DOI 10.1126/science.1206727; Crallan RA, 2006, CARCINOGENESIS, V27, P374, DOI 10.1093/carcin/bgi266; Dadgostar H, 2000, J BIOL CHEM, V275, P2539, DOI 10.1074/jbc.275.4.2539; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dhanasekaran DN, 2008, ONCOGENE, V27, P6245, DOI 10.1038/onc.2008.301; Duffy CL, 2003, VIROLOGY, V314, P196, DOI 10.1016/S0042-6822(03)00390-8; Elgueta R, 2009, IMMUNOL REV, V229, P152, DOI 10.1111/j.1600-065X.2009.00782.x; Eliopoulos AG, 2004, CURR OPIN PHARMACOL, V4, P360, DOI 10.1016/j.coph.2004.02.008; Eliopoulos AG, 1996, ONCOGENE, V13, P2243; Elmetwali T, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-52; Elmetwali T, 2010, J IMMUNOL, V184, P1111, DOI 10.4049/jimmunol.0900528; Galluzzi L, 2009, CELL DEATH DIFFER, V16, P1093, DOI 10.1038/cdd.2009.44; Georgopoulos NT, 2007, INT J CANCER, V121, P1373, DOI 10.1002/ijc.22846; Georgopoulos NT, 2011, EUR UROL, V60, P141, DOI 10.1016/j.eururo.2011.02.022; Grewal IS, 1998, ANNU REV IMMUNOL, V16, P111, DOI 10.1146/annurev.immunol.16.1.111; Gupta SC, 2012, ANTIOXID REDOX SIGN, V16, P1295, DOI 10.1089/ars.2011.4414; Ha YJ, 2004, J IMMUNOL, V172, P231, DOI 10.4049/jimmunol.172.1.231; Harris IS, 2015, CANCER CELL, V27, P211, DOI 10.1016/j.ccell.2014.11.019; Hess S, 1996, J EXP MED, V183, P159, DOI 10.1084/jem.183.1.159; Hill KS, 2008, J IMMUNOL, V181, P3108, DOI 10.4049/jimmunol.181.5.3108; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Jiang F, 2011, PHARMACOL REV, V63, P218, DOI 10.1124/pr.110.002980; Jin HO, 2006, J CELL PHYSIOL, V206, P477, DOI 10.1002/jcp.20488; JOHNSON PWM, 1993, BLOOD, V82, P1848, DOI 10.1182/blood.V82.6.1848.bloodjournal8261848; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Kim SD, 2005, BIOCHEM BIOPH RES CO, V328, P326, DOI 10.1016/j.bbrc.2004.11.173; Kyriakis JM, 2012, PHYSIOL REV, V92, P689, DOI 10.1152/physrev.00028.2011; Lei K, 2002, MOL CELL BIOL, V22, P4929, DOI 10.1128/MCB.22.13.4929-4942.2002; Liu J, 2005, CELL RES, V15, P36, DOI 10.1038/sj.cr.7290262; Nishiyama A, 1999, IMMUNOL LETT, V68, P155, DOI 10.1016/S0165-2478(99)00045-0; Piskounova E, 2015, NATURE, V527, P186, DOI 10.1038/nature15726; Pound JD, 1999, INT IMMUNOL, V11, P11, DOI 10.1093/intimm/11.1.11; Ramanathan RK, 2012, INVEST NEW DRUG, V30, P1591, DOI 10.1007/s10637-011-9739-9; Reznikoff CA, 1996, CANCER RES, V56, P2886; Saretzki G, 2009, EXP GERONTOL, V44, P485, DOI 10.1016/j.exger.2009.05.004; Schattner E, 1996, IMMUNOL RES, V15, P246, DOI 10.1007/BF02918252; Schumacker PT, 2006, CANCER CELL, V10, P175, DOI 10.1016/j.ccr.2006.08.015; Shaw NJ, 2005, INT J CANCER, V116, P634, DOI 10.1002/ijc.21114; Simic T, 2009, NAT REV UROL, V6, P281, DOI 10.1038/nrurol.2009.49; Soga Mayumi, 2012, Int J Cell Biol, V2012, P439587, DOI 10.1155/2012/439587; SOUTHGATE J, 1994, LAB INVEST, V71, P583; Southgate J, 2012, CULT EPITHEL CELLS, P381; Stewart R, 2007, J IMMUNOL, V179, P2705, DOI 10.4049/jimmunol.179.5.2705; T Georgopoulos N, 2006, CELL DEATH DIFFER, V13, P1789, DOI 10.1038/sj.cdd.4401859; Tournier C, 2001, GENE DEV, V15, P1419, DOI 10.1101/gad.888501; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; Vardouli L, 2009, CANCER GENE THER, V16, P848, DOI 10.1038/cgt.2009.31; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Wang HCR, 2011, NAT REV UROL, V8, P608, DOI 10.1038/nrurol.2011.135; Whitmarsh AJ, 2007, ONCOGENE, V26, P3172, DOI 10.1038/sj.onc.1210410; Xie Ping, 2013, J Mol Signal, V8, P7, DOI 10.1186/1750-2187-8-7; Yodoi J, 2001, BIOFACTORS, V15, P107, DOI 10.1002/biof.5520150212; Young TW, 2004, CANCER RES, V64, P4577, DOI 10.1158/0008-5472.CAN-04-0222	64	16	19	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2017	36	18					2515	2528		10.1038/onc.2016.401	http://dx.doi.org/10.1038/onc.2016.401			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ET9AN	27869172	Green Accepted, Green Published, hybrid			2022-12-17	WOS:000400597300003
J	Bogoevska, V; Wolters-Eisfeld, G; Hofmann, BT; El Gammal, AT; Mercanoglu, B; Gebauer, F; Vashist, YK; Bogoevski, D; Perez, D; Gagliani, N; Izbicki, JR; Bockhorn, M; Gungor, C				Bogoevska, V.; Wolters-Eisfeld, G.; Hofmann, B. T.; El Gammal, A. T.; Mercanoglu, B.; Gebauer, F.; Vashist, Y. K.; Bogoevski, D.; Perez, D.; Gagliani, N.; Izbicki, J. R.; Bockhorn, M.; Guengoer, C.			HRG/HER2/HER3 signaling promotes AhR-mediated Memo-1 expression and migration in colorectal cancer	ONCOGENE			English	Article							ARYL-HYDROCARBON RECEPTOR; EPITHELIAL-MESENCHYMAL TRANSITION; N-WASP; PROTEIN; GROWTH; TRANSCRIPTION; NETWORK; TARGETS	Colorectal cancer (CRC) is a complex disease with still unsatisfactory prognosis even in western societies, although substantial progress has been made in pre-screening programs, surgical techniques and targeted therapy options. Mediator of motility-1 (Memo-1) was previously recognized as an important effector of cell migration downstream of receptor tyrosine kinase signaling in breast cancer. This study identified Memo-1 as frequently overexpressed in CRC and established a close link between extracellular HER2 activation, AhR/ARNT transcriptional activity and Memo-1 expression. Dissection of the hMemo-1 gene promoter using reporter assays and chromatin IP techniques revealed recruitment of Aryl hydrocarbon receptor (AhR)/Aryl hydrocarbon receptor nuclear-translocator (ARNT) complex, which positively influenced Memo-1 expression in cancer cells. We found that Memo-1 depletion negatively influenced the cellular actin network and that its expression is required for HER2-mediated cell migration and invasion. Moreover, analyses of Memo-1 expression in primary CRC revealed correlation with clinical parameters that point to Memo-1 as a new prognostic factor of aggressive disease in CRC patients. Altogether, these observations demonstrate that Memo-1 is an important downstream regulator of HER2-driven CRC cell migration and invasion through connecting extracellular signals from membrane to the cytoskeletal actin network.	[Bogoevska, V.] Cardiologicum Hamburg Res & Study Ctr, Hamburg, Germany; [Bogoevska, V.; Wolters-Eisfeld, G.; Hofmann, B. T.; El Gammal, A. T.; Mercanoglu, B.; Gebauer, F.; Vashist, Y. K.; Bogoevski, D.; Perez, D.; Gagliani, N.; Izbicki, J. R.; Bockhorn, M.; Guengoer, C.] Univ Med Ctr Hamburg Eppendorf, Dept Gen Visceral & Thorac Surg, Expt Oncol, Martinistr 52, D-20246 Hamburg, Germany; [Vashist, Y. K.] Kantonsspital Aarau AG, Sect Visceral Surg, Dept Surg, Aarau, Switzerland; [Gagliani, N.] Univ Med Ctr, Dept Med, Hamburg, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf; Kantonsspital Aarau AG (KSA); University of Hamburg; University Medical Center Hamburg-Eppendorf	Gungor, C (corresponding author), Univ Med Ctr Hamburg Eppendorf, Dept Gen Visceral & Thorac Surg, Expt Oncol, Martinistr 52, D-20246 Hamburg, Germany.	c.guengoer@uke.de	Vashist, Yogesh/AFH-9205-2022; Vashist, Yogesh/AAF-3529-2022; Wolters-Eisfeld, Gerrit/H-8333-2019; Vashist, Yogesh/ABE-4001-2020	Wolters-Eisfeld, Gerrit/0000-0002-2984-6515; Perez, Daniel/0000-0002-3154-7311; Gagliani, Nicola/0000-0001-8514-1395	'Roggenbuck Foundation', Hamburg, Germany	'Roggenbuck Foundation', Hamburg, Germany	We thank A Heinecke, P Merkert and P Schroder for excellent technical assistance and Dr M Linnebacher for providing primary CRC cells. This work (CG) was partially funded by the 'Roggenbuck Foundation', Hamburg, Germany.	Applewhite DA, 2007, MOL BIOL CELL, V18, P2579, DOI 10.1091/mbc.E06-11-0990; Atlas E, 2003, MOL CANCER RES, V1, P165; Baselga J, 2009, NAT REV CANCER, V9, P463, DOI 10.1038/nrc2656; Carvajal-Gonzalez JM, 2009, MOL BIOL CELL, V20, P1715, DOI 10.1091/mbc.E08-05-0451; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Feng SL, 2013, BBA-REV CANCER, V1836, P197, DOI 10.1016/j.bbcan.2013.05.001; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Gramatzki D, 2009, ONCOGENE, V28, P2593, DOI 10.1038/onc.2009.104; Gungor C, 2007, P NATL ACAD SCI USA, V104, P15000, DOI 10.1073/pnas.0703738104; Hannafon BN, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2839; Heppner BI, 2014, BRIT J CANCER, V111, P1977, DOI 10.1038/bjc.2014.483; Iwatsuki M, 2010, CANCER SCI, V101, P293, DOI 10.1111/j.1349-7006.2009.01419.x; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Jiang K, 2013, J BIOL CHEM, V288, P24590, DOI 10.1074/jbc.M113.467837; Johnsen SA, 2009, CANCER RES, V69, P128, DOI 10.1158/0008-5472.CAN-08-1630; Kovacs EM, 2011, NAT CELL BIOL, V13, P934, DOI 10.1038/ncb2290; Lai DW, 2014, ONCOTARGET, V5, P7788, DOI 10.18632/oncotarget.2307; Lemmon MA, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a020768; MacDonald G, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2004870; Maletzki C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052485; Marone R, 2004, NAT CELL BIOL, V6, P515, DOI 10.1038/ncb1134; Momeny M, 2015, ONCOTARGET, V6, P3932, DOI 10.18632/oncotarget.2846; Oberlander M, 2013, LANGENBECK ARCH SURG, V398, P251, DOI 10.1007/s00423-012-1043-4; Opitz CA, 2011, NATURE, V478, P197, DOI 10.1038/nature10491; Qiu C, 2008, J BIOL CHEM, V283, P2734, DOI 10.1074/jbc.M703523200; Rawnaq T, 2014, MOL CANCER RES, V12, P670, DOI 10.1158/1541-7786.MCR-13-0467; Rodriguez OC, 2003, NAT CELL BIOL, V5, P599, DOI 10.1038/ncb0703-599; Romiti A, 2015, MED ONCOL, V32, DOI 10.1007/s12032-015-0496-z; Roskoski R, 2014, PHARMACOL RES, V79, P34, DOI 10.1016/j.phrs.2013.11.002; Ross JS, 2001, CANCER INVEST, V19, P554, DOI 10.1081/CNV-100103852; Rotty JD, 2013, NAT REV MOL CELL BIO, V14, P7, DOI 10.1038/nrm3492; Sorokin AV, 2013, ONCOGENE, V32, P3130, DOI 10.1038/onc.2012.327; Stier S, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/271246; Suetsugu S, 2002, DEV CELL, V3, P645, DOI 10.1016/S1534-5807(02)00324-6; Takenawa T, 2007, NAT REV MOL CELL BIO, V8, P37, DOI 10.1038/nrm2069; Yang MH, 2011, LEUKEMIA LYMPHOMA, V52, P298, DOI 10.3109/10428194.2010.538776; Zaoui K, 2008, J CELL BIOL, V183, P401, DOI 10.1083/jcb.200805107; Zegers Mirjam M, 2014, Small GTPases, V5, pe28997, DOI 10.4161/sgtp.28997; Zhao S, 2013, CANCER LETT, V330, P41, DOI 10.1016/j.canlet.2012.11.021	39	16	17	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 27	2017	36	17					2394	2404		10.1038/onc.2016.390	http://dx.doi.org/10.1038/onc.2016.390			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ET4QE	27941874				2022-12-17	WOS:000400268900006
J	Hiken, JF; McDonald, JI; Decker, KF; Sanchez, C; Hoog, J; VanderKraats, ND; Jung, KL; Akinhanmi, M; Rois, LE; Ellis, MJ; Edwards, JR				Hiken, J. F.; McDonald, J. I.; Decker, K. F.; Sanchez, C.; Hoog, J.; VanderKraats, N. D.; Jung, K. L.; Akinhanmi, M.; Rois, L. E.; Ellis, M. J.; Edwards, J. R.			Epigenetic activation of the prostaglandin receptor EP4 promotes resistance to endocrine therapy for breast cancer	ONCOGENE			English	Article							HISTONE DEACETYLASE INHIBITION; HUMAN ESTROGEN-RECEPTOR; DNA METHYLATION; GENE-EXPRESSION; PROTEIN-KINASE; SYNERGISTIC ACTIVATION; AROMATASE INHIBITORS; CELLS; ALPHA; PHOSPHORYLATION	Approximately 75% of breast cancers express estrogen receptor a (ER alpha) and depend on estrogen signals for continued growth. Aromatase inhibitors (AIs) prevent estrogen production and inhibit ER signaling, resulting in decreased cancer recurrence and mortality. Advanced tumors treated with AIs almost always develop resistance to these drugs via the upregulation of alternative growth signals. The mechanisms that drive this resistance-especially epigenetic events that alter gene expression-are, however, not well understood. Genome-wide DNA methylation and expression analysis of cell line models of acquired AI resistance indicated that prostaglandin E2 receptor 4 (PTGER4) is upregulated after demethylation in resistant cells. Knockdown and inhibitor studies demonstrate that PTGER4 is essential for estrogen-independent growth. Our exploratory analysis of downstream signaling indicates that PTGER4 likely promotes AI resistance via ligand-independent activation of the ER alpha-cofactor CARM1. We believe that we have discovered a novel epigenetic mechanism for altering cell signaling and acquiring endocrine therapy resistance. Our findings indicate that PTGER4 is a potential drug target in AI-resistant cancers. In addition, the epigenetic component of PTGER4 regulation suggests that further study of PTGER4 may yield valuable insights into how DNA methylation-targeted diagnoses and treatments can improve AI-resistant breast cancer treatment.	[Hiken, J. F.; McDonald, J. I.; Decker, K. F.; VanderKraats, N. D.; Jung, K. L.; Akinhanmi, M.; Rois, L. E.; Edwards, J. R.] Washington Univ, Sch Med, Ctr Pharmacogen, Dept Med, 660S Euclid Ave,Campus Box 8220, St Louis, MO 63110 USA; [Sanchez, C.] Pontificia Univ Catolica Chile, Haematol Oncol, Dept Canc Programme, Sch Med, Santiago, Chile; [Hoog, J.] Washington Univ, Sch Med, Dept Med, Div Oncol, St Louis, MO 63110 USA; [Ellis, M. J.] Baylor Coll Med, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA	Washington University (WUSTL); Pontificia Universidad Catolica de Chile; Washington University (WUSTL); Baylor College of Medicine	Edwards, JR (corresponding author), Washington Univ, Sch Med, Ctr Pharmacogen, Dept Med, 660S Euclid Ave,Campus Box 8220, St Louis, MO 63110 USA.	jedwards@dom.wustl.edu		Jung, Kyle/0000-0002-6694-4333	NIH [R00 CA127360, R21 LM011199, 2T32GM007067-37, P30 CA91842, UL1 TR000448]; Department of Defense [W81XWH-11-1-0401]; Siteman Cancer Center Breast Cancer Program career development award; NATIONAL CANCER INSTITUTE [R00CA127360, P30CA091842] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000448] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM108811] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [R21LM011199] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense); Siteman Cancer Center Breast Cancer Program career development award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))	We thank C de Guzman-Strong and S Matkovich for their comments on the manuscript. This work was supported by grants NIH R00 CA127360, NIH R21 LM011199, NIH 2T32GM007067-37, Department of Defense W81XWH-11-1-0401 and a Siteman Cancer Center Breast Cancer Program career development award to JRE. We also thank the Genome Technology Access Center at the Washington University School of Medicine for help with genomic analysis (partially supported by NIH P30 CA91842 and NIH UL1 TR000448).	Aguilar H, 2010, ONCOGENE, V29, P6071, DOI 10.1038/onc.2010.333; Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Carascossa S, 2010, GENE DEV, V24, P708, DOI 10.1101/gad.568410; Chan CMW, 2002, J STEROID BIOCHEM, V81, P333, DOI 10.1016/S0960-0760(02)00074-2; Chen DS, 1999, MOL CELL BIOL, V19, P1002; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; Crowder RJ, 2009, CANCER RES, V69, P3955, DOI 10.1158/0008-5472.CAN-08-4450; Dowsett M, 2010, J CLIN ONCOL, V28, P509, DOI 10.1200/JCO.2009.23.1274; Edwards JR, 2010, GENOME RES, V20, P972, DOI 10.1101/gr.101535.109; Ellis MJ, 2008, J NATL CANCER I, V100, P1380, DOI 10.1093/jnci/djn309; Ellis MJ, 2012, NATURE, V486, P353, DOI 10.1038/nature11143; Ellis MJ, 2011, J CLIN ONCOL, V29, P2342, DOI 10.1200/JCO.2010.31.6950; Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748; FERGUSON AT, 1995, CANCER RES, V55, P2279; Forbes SA, 2015, NUCLEIC ACIDS RES, V43, pD805, DOI 10.1093/nar/gku1075; Fritah A, 2008, MOL CELL BIOL, V28, P1114, DOI 10.1128/MCB.01335-07; Giacinti L, 2012, J CELL PHYSIOL, V227, P3426, DOI 10.1002/jcp.24043; Harvey JM, 1999, J CLIN ONCOL, V17, P1474, DOI 10.1200/JCO.1999.17.5.1474; Holemon H, 2007, BIOTECHNIQUES, V43, P683, DOI 10.2144/000112597; Iorns E, 2008, CANCER CELL, V13, P91, DOI 10.1016/j.ccr.2008.01.001; Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298; Johnston SRD, 2003, NAT REV CANCER, V3, P821, DOI 10.1038/nrc1211; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Keen JC, 2003, BREAST CANCER RES TR, V81, P177, DOI 10.1023/A:1026146524737; Kim JH, 2012, MOL CELLS, V33, P127, DOI 10.1007/s10059-012-2182-8; Kulis M, 2010, ADV GENET, V70, P27, DOI [10.1016/B978-0-12-380866-0.60002-2, 10.1016/S0065-2660(10)70002-X]; Lazennec G, 2001, J STEROID BIOCHEM, V77, P193, DOI 10.1016/S0960-0760(01)00060-7; LEGOFF P, 1994, J BIOL CHEM, V269, P4458; Li SQ, 2013, CELL REP, V4, P1116, DOI 10.1016/j.celrep.2013.08.022; Ma CX, 2015, NAT REV CANCER, V15, P261, DOI 10.1038/nrc3920; Ma XR, 2006, CANCER RES, V66, P2923, DOI 10.1158/0008-5472.CAN-05-4348; Merenbakh-Lamin K, 2013, CANCER RES, V73, P6856, DOI 10.1158/0008-5472.CAN-13-1197; Miller TW, 2011, CLIN CANCER RES, V17, P2024, DOI 10.1158/1078-0432.CCR-10-2567; Musgrove EA, 2009, NAT REV CANCER, V9, P631, DOI 10.1038/nrc2713; Nguyen VTM, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10044; Olson JA, 2009, J AM COLL SURGEONS, V208, P906, DOI 10.1016/j.jamcollsurg.2009.01.035; OTTAVIANO YL, 1994, CANCER RES, V54, P2552; Robinson DR, 2013, NAT GENET, V45, P1446, DOI 10.1038/ng.2823; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Sabnis GJ, 2011, CANCER RES, V71, P1893, DOI 10.1158/0008-5472.CAN-10-2458; Sanchez CG, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2833; Stone A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8758; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Terada N, 2010, CANCER RES, V70, P1606, DOI 10.1158/0008-5472.CAN-09-2984; Tharakan R, 2008, MOL CELL ENDOCRINOL, V295, P70, DOI 10.1016/j.mce.2008.07.018; Toy W, 2013, NAT GENET, V45, P1439, DOI 10.1038/ng.2822; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; VANAGTHOVEN T, 1994, MOL ENDOCRINOL, V8, P1474, DOI 10.1210/me.8.11.1474; VanderKraats ND, 2013, NUCLEIC ACIDS RES, V41, P6816, DOI 10.1093/nar/gkt482; Yang XW, 2001, CANCER RES, V61, P7025; Yang XW, 2000, CANCER RES, V60, P6890; Yokoyama U, 2013, PHARMACOL REV, V65, P1010, DOI 10.1124/pr.112.007195; Zhang QX, 1997, CANCER RES, V57, P1244; Zhou Q, 2009, BREAST CANCER RES TR, V117, P443, DOI 10.1007/s10549-008-0148-5; Zilli M, 2009, BBA-REV CANCER, V1795, P62, DOI 10.1016/j.bbcan.2008.08.003	55	16	17	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 20	2017	36	16					2319	2327		10.1038/onc.2016.397	http://dx.doi.org/10.1038/onc.2016.397			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ES8DM	27869171	Green Accepted, Green Submitted			2022-12-17	WOS:000399782700012
J	Wu, J; Liu, W; Williams, JP; Ratner, N				Wu, J.; Liu, W.; Williams, J. P.; Ratner, N.			EGFR-Stat3 signalling in nerve glial cells modifies neurofibroma initiation	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; SCHWANN-CELLS; SHEATH TUMORS; TYPE-1 NF1; EGFR; INHIBITION; EXPRESSION; PHENOTYPE; PLEXIFORM; ORIGIN	Neurofibromatosis type 1 (NF1) is an inherited disease in which affected patients are predisposed to develop benign Schwann cell (SC) tumours called neurofibromas. In the mouse, loss of Nf1 in the SC lineage causes neurofibroma formation. The tyrosine kinase receptor EGFR is expressed in Schwann cell precursors (SCP), which have been implicated in plexiform neurofibroma initiation. To test if EGFR activity affects neurofibroma initiation, size, and/or number, we studied mice expressing human EGFR in SCs and SCP in the context of mice that form neurofibromas. Neurofibroma number increased in homozygous CNP-hEGFR mice versus heterozygous littermates, and neurofibroma number and size increased when CNP-hEGFR was crossed to Nf1(fl/fl); DhhCre mice. Conversely, diminished EGFR signalling in Nf1(fl/fl); DhhCre; Wa2/+ mice decreased neurofibroma number. In vivo transplantation verified the correlation between EGFR activity and neurofibroma formation. Mechanistically, expression of CNP-hEGFR increased SCP/neurofibroma-initiating cell self-renewal, a surrogate for tumour initiation, and activated P-Stat3. Further, Il-6 reinforced Jak2/ Stat3 activation in SCPs and SCs. These gain-and loss-of function assays show that levels of tyrosine kinase expression in SCPs modify neurofibroma initiation.	[Wu, J.; Liu, W.; Williams, J. P.; Ratner, N.] Univ Cincinnati, Cincinnati Childrens Hosp, Cincinnati Childrens Hosp Res Fdn, Canc & Blood Dis Inst,Div Expt Hematol & Canc Bio, 3333 Burnet Ave, Cincinnati, OH 45229 USA; [Liu, W.] Shandong Univ, Dept Pediat Surg, Prov Hosp Affiliated, Jinan, Peoples R China; [Williams, J. P.] San Antonio Mil Med Ctr Neurol, JBSA, 3551 Roger Brooke Dr, Ft Sam Houston, TX 78234 USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University of Cincinnati; Shandong University; San Antonio Military Medical Center	Ratner, N (corresponding author), Univ Cincinnati, Cincinnati Childrens Hosp, Cincinnati Childrens Hosp Res Fdn, Canc & Blood Dis Inst,Div Expt Hematol & Canc Bio, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	nancy.ratner@cchmc.org	Williams, Jon/AAP-2761-2020	RATNER, NANCY/0000-0001-5030-9354	DAMD New Investigator Award [W81XWH-11-1-0259]; NIH [R01 NS28840]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028840, R01NS086219] Funding Source: NIH RePORTER	DAMD New Investigator Award; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Dr Luis F Parada (Memorial Sloan Kettering, NY) for Nf1<SUP>fl/fl</SUP> mice and Dr Anat O Stemmer-Rachamimov (Massachusetts General Hospital) for assistance with mouse pathology. We thank Dr Adam Lane (CCHMC) for consultation on statistical analysis. This work was supported by a DAMD New Investigator Award (W81XWH-11-1-0259) (Jianqiang Wu) and NIH R01 NS28840 (Nancy Ratner).	Battle T. E., 2002, Current Molecular Medicine (Hilversum), V2, P381, DOI 10.2174/1566524023362456; Bos JL, 2007, CELL, V129, P865, DOI 10.1016/j.cell.2007.05.018; Boyd KP, 2009, J AM ACAD DERMATOL, V61, P1, DOI 10.1016/j.jaad.2008.12.051; Carroll SL, 2008, GLIA, V56, P1590, DOI 10.1002/glia.20776; Chen SZ, 2003, NAT NEUROSCI, V6, P1186, DOI 10.1038/nn1139; Chen ZG, 2014, CANCER CELL, V26, P695, DOI 10.1016/j.ccell.2014.09.009; Corcoran RB, 2011, CANCER RES, V71, P5020, DOI 10.1158/0008-5472.CAN-11-0908; de Bruin EC, 2014, CANCER DISCOV, V4, P606, DOI 10.1158/2159-8290.CD-13-0741; DeClue JE, 2000, J CLIN INVEST, V105, P1233, DOI 10.1172/JCI7610; EASTON DF, 1993, AM J HUM GENET, V53, P305; Gomez-Sanchez JA, 2009, J NEUROSCI, V29, P11304, DOI 10.1523/JNEUROSCI.1753-09.2009; HARVEY M, 1993, FASEB J, V7, P938, DOI 10.1096/fasebj.7.10.8344491; Holtkamp N, 2008, NEURO-ONCOLOGY, V10, P946, DOI 10.1215/15228517-2008-053; Huijbregts RPH, 2003, J NEUROSCI, V23, P7269; Jessen WJ, 2013, J CLIN INVEST, V123, P340, DOI 10.1172/JCI60578; Joseph NM, 2008, CANCER CELL, V13, P129, DOI 10.1016/j.ccr.2008.01.003; Kazmi SJ, 2013, AM J PATHOL, V182, P646, DOI 10.1016/j.ajpath.2012.11.017; Le LQ, 2011, CANCER RES, V71, P4686, DOI 10.1158/0008-5472.CAN-10-4577; Leppig KA, 1997, AM J MED GENET, V73, P197, DOI 10.1002/(SICI)1096-8628(1997)73:2<197::AID-AJMG17>3.0.CO;2-P; Lesina M, 2011, CANCER CELL, V19, P456, DOI 10.1016/j.ccr.2011.03.009; Li H, 2016, ONCOGENE, V35, P1468, DOI 10.1038/onc.2015.207; Li HZ, 2002, CANCER RES, V62, P4507; Ling BC, 2005, CANCER CELL, V7, P65, DOI 10.1016/j.ccr.2004.10.016; LUETTEKE NC, 1994, GENE DEV, V8, P399, DOI 10.1101/gad.8.4.399; Mautner VF, 2010, J MED GENET, V47, P623, DOI 10.1136/jmg.2009.075937; Mayes DA, 2011, CANCER RES, V71, P4675, DOI 10.1158/0008-5472.CAN-10-4558; Ratner N, 2006, METHOD ENZYMOL, V407, P22, DOI 10.1016/S0076-6879(05)07003-5; Ribeiro S, 2013, CELL REP, V5, P126, DOI 10.1016/j.celrep.2013.08.033; Rieley MB, 2011, AM J MED GENET A, V155A, P478, DOI 10.1002/ajmg.a.33851; Rizvi TA, 2002, J NEUROSCI, V22, P9831; Ryan MA, 2010, NAT MED, V16, P1141, DOI 10.1038/nm.2217; Stemmer-Rachamimov AO, 2004, CANCER RES, V64, P3718, DOI 10.1158/0008-5472.CAN-03-4079; Upadhyaya M, 2007, AM J HUM GENET, V80, P140, DOI 10.1086/510781; Vogel KS, 1999, SCIENCE, V286, P2176, DOI 10.1126/science.286.5447.2176; Walrath JC, 2009, MAMM GENOME, V20, P214, DOI 10.1007/s00335-009-9179-4; Wang L, 2009, NEUROREPORT, V20, P663, DOI 10.1097/WNR.0b013e32832a09f8; Williams JP, 2008, CELL STEM CELL, V3, P658, DOI 10.1016/j.stem.2008.10.003; Wu J, 2014, ONCOGENE, V33, P173, DOI 10.1038/onc.2012.579; Wu JQ, 2008, CANCER CELL, V13, P105, DOI 10.1016/j.ccr.2007.12.027; Wu JQ, 2016, CELL REP, V14, P1979, DOI 10.1016/j.celrep.2016.01.074; Wu JQ, 2006, AM J PATHOL, V168, P1686, DOI 10.2353/ajpath.2006.050859; Yarden Y, 2001, EUR J CANCER, V37, pS3; Zheng H, 2008, CANCER CELL, V13, P117, DOI 10.1016/j.ccr.2008.01.002; Zhu Y, 2002, SCIENCE, V296, P920, DOI 10.1126/science.1068452	44	16	16	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	12					1669	1677		10.1038/onc.2016.386	http://dx.doi.org/10.1038/onc.2016.386			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EP6AP	27748759	Green Accepted			2022-12-17	WOS:000397460600006
J	Zhong, H; Fazenbaker, C; Chen, C; Breen, S; Huang, J; Yao, X; Ren, P; Yao, Y; Herbst, R; Hollingsworth, RE				Zhong, H.; Fazenbaker, C.; Chen, C.; Breen, S.; Huang, J.; Yao, X.; Ren, P.; Yao, Y.; Herbst, R.; Hollingsworth, R. E.			Overproduction of IGF-2 drives a subset of colorectal cancer cells, which specifically respond to an anti-IGF therapeutic antibody and combination therapies	ONCOGENE			English	Article							GROWTH-FACTOR-I; FACTOR RECEPTOR; ANTITUMOR-ACTIVITY; FACTOR (IGF)-I; INSULIN; GENE; EXPRESSION; INHIBITOR; RISK; MECHANISMS	Colorectal cancer (CRC) is a heterogeneous disease with a broad spectrum of genetic and epigenetic changes. A comprehensive molecular characterization of CRC by The Cancer Genome Atlas Network detected the overexpression of the insulin-like growth factor 2 (IGF2) gene, encoding a ligand for the insulin-like growth factor 1 receptor (IGF-1R), in a subset of CRC tumors. In this study, we investigated the oncogenic potential of IGF-2 in IGF2-overexpressing CRC models and the efficacy of MEDI-573, an IGF-1/2-neutralizing antibody. We found that a subset of CRC cell lines express high IGF-2 levels owing to an increased DNA copy number and hypermethylation in the H19 promoter of the IGF2 gene. MEDI-573 efficiently neutralized IGF-2 and induced apoptosis, which resulted in significant tumor growth inhibition in CRC mouse models that express high levels of IGF-2. These effects were specific to CRCs overexpressing IGF-2, as MEDI-573 did not affect the growth CRC cell lines with normal levels. Moreover, blockade of IGF-2 by MEDI-573 modulated other signaling pathways, suggesting combination therapies with inhibitors of these pathways. Indeed, in vivo efficacy was significantly enhanced when MEDI-573 was used in combination with trastuzumab, AZD2014 (dual mTORC1/2i), AZD5363 (AKTi) and selumetinib (AZD6244/ARRY-142886, MEK1/2i) or cetuximab. These results demonstrate that overexpressed IGF-2 is the major tumorigenic driver in a subset of CRCs and encourage testing of MEDI-573, alone and in combinations, in IGF2-overexpressing CRC patients.	[Zhong, H.; Fazenbaker, C.; Chen, C.; Breen, S.; Herbst, R.; Hollingsworth, R. E.] MedImmune, Oncol Res, One MedImmune Way, Gaithersburg, MD 20878 USA; [Huang, J.; Yao, X.; Yao, Y.] MedImmune, Translat Sci, Gaithersburg, MD USA; [Ren, P.] MedImmune, Biostat, Gaithersburg, MD USA	AstraZeneca; Medimmune; AstraZeneca; Medimmune; AstraZeneca; Medimmune	Hollingsworth, RE (corresponding author), MedImmune, Oncol Res, One MedImmune Way, Gaithersburg, MD 20878 USA.	hollingsworthr@medimmune.com			MedImmune	MedImmune(AstraZenecaMedimmune)	We thank Mohammed Dar, Parthiv Mahadevia, Dirk Mendel, Robert Sikorski, Teresa Klinowska, Sabina Cosulich, Barry Davies and Stephen Green for scientific input and manuscript review. This work was supported by MedImmune.	Abraham J, 2011, MOL CANCER THER, V10, P697, DOI 10.1158/1535-7163.MCT-10-0695; Baserga R, 2005, EXPERT OPIN THER TAR, V9, P753, DOI 10.1517/14728222.9.4.753; Belfiore A, 2009, ENDOCR REV, V30, P586, DOI 10.1210/er.2008-0047; Cheng YW, 2010, INT J CANCER, V127, P568, DOI 10.1002/ijc.25086; Cui HM, 1998, NAT MED, V4, P1276, DOI 10.1038/3260; Cui HM, 2003, SCIENCE, V299, P1753, DOI 10.1126/science.1080902; Davies BR, 2007, MOL CANCER THER, V6, P2209, DOI 10.1158/1535-7163.MCT-07-0231; Davies BR, 2012, MOL CANCER THER, V11, P873, DOI 10.1158/1535-7163.MCT-11-0824-T; Faubert B, 2015, CANCER LETT, V356, P165, DOI 10.1016/j.canlet.2014.01.018; Fearon ER, 2011, ANNU REV PATHOL-MECH, V6, P479, DOI 10.1146/annurev-pathol-011110-130235; Fidler MJ, 2012, THER ADV MED ONCOL, V4, P51, DOI 10.1177/1758834011427576; Gao J, 2011, CANCER RES, V71, P1029, DOI 10.1158/0008-5472.CAN-10-2274; Gazdar AF, 2009, ONCOGENE, V28, pS24, DOI 10.1038/onc.2009.198; Ghosh JC, 2008, J BIOL CHEM, V283, P5188, DOI 10.1074/jbc.M705904200; Giovannucci E, 2001, J NUTR, V131, p3109S, DOI 10.1093/jn/131.11.3109S; Gualberto A, 2009, CURR DRUG TARGETS, V10, P923, DOI 10.2174/138945009789577945; Guichard SM, 2015, MOL CANCER THER, V14, P2508, DOI 10.1158/1535-7163.MCT-15-0365; Haluska P, 2014, CLIN CANCER RES, V20, P4747, DOI 10.1158/1078-0432.CCR-14-0114; Huang F, 2009, CANCER RES, V69, P161, DOI 10.1158/0008-5472.CAN-08-0835; LAHM H, 1994, INT J CANCER, V58, P452, DOI 10.1002/ijc.2910580325; LAHM H, 1992, BRIT J CANCER, V65, P341, DOI 10.1038/bjc.1992.69; Ma J, 1999, J NATL CANCER I, V91, P620, DOI 10.1093/jnci/91.7.620; Mazzoletti M, 2011, CANCER RES, V71, P4573, DOI 10.1158/0008-5472.CAN-10-4322; Misale S, 2014, CANCER DISCOV, V4, P1269, DOI 10.1158/2159-8290.CD-14-0462; Morgillo F, 2006, CANCER RES, V66, P10100, DOI 10.1158/0008-5472.CAN-06-1684; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Nakagawa H, 2001, P NATL ACAD SCI USA, V98, P591, DOI 10.1073/pnas.011528698; Ou DL, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-2; Ravenel JD, 2001, JNCI-J NATL CANCER I, V93, P1698, DOI 10.1093/jnci/93.22.1698; REMACLEBONNET M, 1992, INT J CANCER, V52, P910, DOI 10.1002/ijc.2910520614; Renehan AG, 2004, LANCET, V363, P1346, DOI 10.1016/S0140-6736(04)16044-3; Sachdev D, 2007, MOL CANCER THER, V6, P1, DOI 10.1158/1535-7163.MCT-06-0080; Saltz LB, 2004, J CLIN ONCOL, V22, P1201, DOI 10.1200/JCO.2004.10.182; Sciacca L, 1999, ONCOGENE, V18, P2471, DOI 10.1038/sj.onc.1202600; Seshagiri S, 2012, NATURE, V488, P660, DOI 10.1038/nature11282; Shin DH, 2011, MOL CANCER THER, V10, P2437, DOI 10.1158/1535-7163.MCT-11-0235; Shiratsuchi I, 2011, ANTICANCER RES, V31, P2541; Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI 10.3322/caac.21220; Tran TN, 2014, J CLIN PATHOL, V67, P985, DOI 10.1136/jclinpath-2014-202347; Van Cutsem E, 2007, J CLIN ONCOL, V25, P1658, DOI 10.1200/JCO.2006.08.1620; Wang Y, 2005, MOL CANCER THER, V4, P1214, DOI 10.1158/1535-7163.MCT-05-0048; Weroha S, 2008, J MAMMARY GLAND BIOL, V13, P471, DOI 10.1007/s10911-008-9104-6; Yuen JSP, 2008, EXPERT OPIN THER TAR, V12, P589, DOI 10.1517/14728222.12.5.589 ; Zanella ER, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010445; Zhang HT, 2007, J CLIN INVEST, V117, P2051, DOI 10.1172/JCI32278; Zhao RH, 2008, CURR COLORECT CANC R, V4, P65, DOI 10.1007/s11888-008-0012-3; Zhong HH, 2014, MOL CANCER THER, V13, P2662, DOI 10.1158/1535-7163.MCT-14-0144	47	16	16	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 9	2017	36	6					797	806		10.1038/onc.2016.248	http://dx.doi.org/10.1038/onc.2016.248			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IX	27399333				2022-12-17	WOS:000394168200007
J	Kim, JE; Shin, JS; Moon, JH; Hong, SW; Jung, DJ; Kim, JH; Hwang, IY; Shin, YJ; Gong, EY; Lee, DH; Kim, SM; Lee, EY; Kim, YS; Kim, D; Hur, D; Kim, TW; Kim, KP; Jin, DH; Lee, WJ				Kim, J-E; Shin, J-S; Moon, J-H; Hong, S-W; Jung, D-J; Kim, J. H.; Hwang, I-Y; Shin, Y. J.; Gong, E-Y; Lee, D. H.; Kim, S-M; Lee, E. Y.; Kim, Y. S.; Kim, D.; Hur, D.; Kim, T. W.; Kim, K-p; Jin, D-H; Lee, W-J			Foxp3 is a key downstream regulator of p53-mediated cellular senescence	ONCOGENE			English	Article							HUMAN-DIPLOID CELLS; DNA-DAMAGE; REPLICATIVE SENESCENCE; TRANSCRIPTION FACTOR; OXIDATIVE STRESS; ONCOGENIC RAS; MUTANT P53; LIFE-SPAN; CANCER; EXPRESSION	The downstream events and target genes of p53 in the process of senescence are not fully understood. Here, we report a novel function of the forkhead transcription factor Foxp3, which is a key player in mediating T-cell inhibitory functions, in p53-mediated cellular senescence. The overexpression of Foxp3 in mouse embryonic fibroblasts (MEFs) accelerates senescence, whereas Foxp3 knockdown leads to escape from p53-mediated senescence in p53-expressing MEFs. Consistent with these results, Foxp3 expression resulted in the induction of senescence in epithelial cancer cells, including MCF7 and HCT116 cells. Foxp3 overexpression also increased the intracellular levels of reactive oxygen species (ROS). The ROS inhibitor N-acetyl-L-cysteine rescued cells from Foxp3-expression-induced senescence. Furthermore, the elevated ROS levels that accompanied Foxp3 overexpression were paralleled by an increase in p21 expression. Knockdown of p21 in Foxp3-expressing MEFs abrogated the Foxp3-dependent increase in ROS levels, indicating that Foxp3 acts through the induction of p21 and the subsequent ROS elevation to trigger senescence. Collectively, these results suggest that Foxp3 is a downstream target of p53 that is sufficient to induce p21 expression, ROS production and p53-mediated senescence.	[Kim, J-E; Jung, D-J; Lee, W-J] Seoul Natl Univ, Coll Med, Dept Anat, Seoul, South Korea; [Kim, J-E; Jung, D-J; Lee, W-J] Seoul Natl Univ, Coll Med, Tumor Immun Med Res Ctr, Seoul, South Korea; [Shin, J-S; Moon, J-H; Hong, S-W; Kim, J. H.; Hwang, I-Y; Shin, Y. J.; Gong, E-Y; Lee, D. H.; Kim, S-M; Lee, E. Y.; Kim, T. W.; Kim, K-p; Jin, D-H] Asan Inst Life Sci, Asan Med Ctr, Innovat Canc Res, Seoul, South Korea; [Shin, J-S; Moon, J-H; Hong, S-W; Kim, J. H.; Hwang, I-Y; Shin, Y. J.; Gong, E-Y; Lee, D. H.; Kim, S-M; Lee, E. Y.; Kim, T. W.; Kim, K-p; Jin, D-H] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, 88 Olymp Ro 43 Gil, Seoul 138736, South Korea; [Kim, Y. S.; Kim, D.; Hur, D.] Inje Univ, Coll Med, Dept Anat, Busan, South Korea; [Kim, Y. S.; Kim, D.; Hur, D.] Inje Univ, Coll Med, Res Ctr Tumor Immunol, Busan, South Korea; [Jin, D-H] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Convergence Med, 88 Olymp Ro 43 Gil, Seoul 138736, South Korea	Seoul National University (SNU); Seoul National University (SNU); University of Ulsan; Asan Medical Center; University of Ulsan; Asan Medical Center; Inje University; Inje University; University of Ulsan; Asan Medical Center	Kim, KP (corresponding author), Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, 88 Olymp Ro 43 Gil, Seoul 138736, South Korea.; Jin, DH (corresponding author), Univ Ulsan, Coll Med, Asan Med Ctr, Dept Convergence Med, 88 Olymp Ro 43 Gil, Seoul 138736, South Korea.	kkp1122@amc.seoul.kr; inno183@amc.seoul.kr			Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education [NRF-2013R1A1A2013233]; National Research Foundation of Korea (NRF) grant - Korean government (MEST), Seoul, Republic of Korea [NRF-2013R1A2A2A01067394]; Korea Government (Ministry of Education, Science and Technology) [NRF-2010355-000062]	Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education(National Research Foundation of KoreaMinistry of Education (MOE), Republic of KoreaNational Research Council for Economics, Humanities & Social Sciences, Republic of Korea); National Research Foundation of Korea (NRF) grant - Korean government (MEST), Seoul, Republic of Korea(National Research Foundation of KoreaMinistry of Education, Science & Technology (MEST), Republic of Korea); Korea Government (Ministry of Education, Science and Technology)(Ministry of Education, Science & Technology (MEST), Republic of KoreaKorean Government)	This study was supported by grants from Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2013R1A1A2013233), and the National Research Foundation of Korea (NRF) grant funded by the Korean government (MEST) (NRF-2013R1A2A2A01067394), Seoul, Republic of Korea. The National Research Foundation of Korea Grant funded by the Korea Government (Ministry of Education, Science and Technology) (NRF-2010355-000062).	Bacchetta R, 2006, J CLIN INVEST, V116, P1713, DOI 10.1172/JCI25112; BOND JA, 1994, ONCOGENE, V9, P1885; BOND JA, 1995, CANCER RES, V55, P2404; CHEN Q, 1995, P NATL ACAD SCI USA, V92, P4337, DOI 10.1073/pnas.92.10.4337; Das S, 2007, CELL, V130, P624, DOI 10.1016/j.cell.2007.06.013; Feng LJ, 2006, CELL CYCLE, V5, P2812, DOI 10.4161/cc.5.23.3526; Ferbeyre G, 2002, MOL CELL BIOL, V22, P3497, DOI 10.1128/MCB.22.10.3497-3508.2002; Grimmig T, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.24521; Hagen TM, 1997, P NATL ACAD SCI USA, V94, P3064, DOI 10.1073/pnas.94.7.3064; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; Inoue T, 2009, CANCER SCI, V100, P1275, DOI 10.1111/j.1349-7006.2009.01166.x; Jung DJ, 2010, J BIOL CHEM, V285, P7995, DOI 10.1074/jbc.M109.047985; Jung MS, 2004, J BIOL CHEM, V279, P17765, DOI 10.1074/jbc.M305015200; Jung MS, 2001, ONCOGENE, V20, P5818, DOI 10.1038/sj.onc.1204748; Kim HJ, 2009, CELLS TISSUES ORGANS, V190, P1, DOI 10.1159/000153041; Ladoire S, 2011, BREAST CANCER RES TR, V125, P65, DOI 10.1007/s10549-010-0831-1; Le Bras S, 2006, J CLIN INVEST, V116, P1473, DOI 10.1172/JCI28880; Lee AC, 1999, J BIOL CHEM, V274, P7936, DOI 10.1074/jbc.274.12.7936; Liu RH, 2009, CANCER RES, V69, P2252, DOI 10.1158/0008-5472.CAN-08-3717; Ma GF, 2014, BRIT J CANCER, V110, P1552, DOI 10.1038/bjc.2014.47; Macip S, 2002, EMBO J, V21, P2180, DOI 10.1093/emboj/21.9.2180; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730; PACKER L, 1977, NATURE, V267, P423, DOI 10.1038/267423a0; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Sreeramaneni R, 2005, MOL CELL BIOL, V25, P220, DOI 10.1128/MCB.25.1.220-232.2005; Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648; Thaler S, 2009, CANCER RES, V69, P1748, DOI 10.1158/0008-5472.CAN-08-1377; VONZGLINICKI T, 1995, EXP CELL RES, V220, P186, DOI 10.1006/excr.1995.1305; Wang CF, 2009, AGING CELL, V8, P311, DOI 10.1111/j.1474-9726.2009.00481.x; Winerdal ME, 2011, BJU INT, V108, P1672, DOI 10.1111/j.1464-410X.2010.10020.x; Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514; Zhu QB, 2006, MOL CELL BIOL, V26, P9279, DOI 10.1128/MCB.00724-06; Zuo T, 2007, J CLIN INVEST, V117, P3765, DOI 10.1172/JCI32538; Zuo T, 2007, CELL, V129, P1275, DOI 10.1016/j.cell.2007.04.034	36	16	16	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 12	2017	36	2					219	230		10.1038/onc.2016.193	http://dx.doi.org/10.1038/onc.2016.193			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK5AA	27238838				2022-12-17	WOS:000393938100007
J	Mendoza-Villanueva, D; Balamurugan, K; Ali, HR; Kim, SR; Sharan, S; Johnson, RC; Merchant, AS; Caldas, C; Landberg, G; Sterneck, E				Mendoza-Villanueva, D.; Balamurugan, K.; Ali, H. R.; Kim, S-R; Sharan, S.; Johnson, R. C.; Merchant, A. S.; Caldas, C.; Landberg, G.; Sterneck, E.			The C/EBP delta protein is stabilized by estrogen receptor alpha activity, inhibits SNAI2 expression and associates with good prognosis in breast cancer	ONCOGENE			English	Article							CCAAT/ENHANCER-BINDING PROTEINS; MAMMARY-GLAND INVOLUTION; GENE-EXPRESSION; TUMOR PROGRESSION; CELL-STATE; CYCLIN D1; SLUG; PATHWAY; BETA; IDENTIFICATION	Hypoxia and inflammatory cytokines like interleukin-6 (IL-6, IL6) are strongly linked to cancer progression, and signal in part through the transcription factor Ccaat/enhancer-binding protein d (C/EBPd, CEBPD), which has been shown to promote mesenchymal features and malignant progression of glioblastoma. Here we report a different role for C/EBPd in breast cancer. We found that the C/EBPd protein is expressed in normal breast epithelial cells and in low-grade cancers. C/EBPd protein (but not mRNA) expression correlates with estrogen receptor (ER+) and progesterone receptor (PGR) expression and longer progression-free survival of breast cancer patients. Specifically in ER+ breast cancers, CEBPD-but not the related CEBPB-mRNA in combination with IL6 correlated with lower risk of progression. Functional studies in cell lines showed that ERa promotes C/EBPd expression at the level of protein stability by inhibition of the FBXW7 pathway. Furthermore, we found that C/EBPd attenuates cell growth, motility and invasiveness by inhibiting expression of the SNAI2 (Slug) transcriptional repressor, which leads to expression of the cyclin-dependent kinase inhibitor CDKN1A (p21(CIP1/WAF1)). These findings identify a molecular mechanism by which ERa signaling reduces the aggressiveness of cancer cells, and demonstrate that C/EBPd can have different functions in different types of cancer. Furthermore, our results support a potentially beneficial role for the IL-6 pathway specifically in ER+ breast cancer and call for further evaluation of the role of intra-tumoral IL-6 expression and of which cancers might benefit from current attempts to target the IL-6 pathway as a therapeutic strategy.	[Mendoza-Villanueva, D.; Balamurugan, K.; Kim, S-R; Sharan, S.; Sterneck, E.] NCI, Lab Cell & Dev Signaling, Ctr Canc Res, POB B, Frederick, MD 21702 USA; [Ali, H. R.; Caldas, C.] Univ Cambridge, Cambridge Inst, Dept Oncol, Canc Res UK,Li Ka Shing Ctr, Cambridge, England; [Johnson, R. C.; Merchant, A. S.] Frederick Natl Lab, CCR Collaborat Bioinformat Resource, Adv Biomed Comp Ctr, Leidos Biomed, Frederick, MD USA; [Landberg, G.] Univ Manchester, Breakthrough Breast Canc Unit, Inst Canc Sci, Paterson Inst Canc Res, Manchester, Lancs, England; [Kim, S-R] US FDA, Div Biotechnol Review & Res 4, Off Biotechnol Prod, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA; [Landberg, G.] Gothenburg Univ, Dept Pathol, Sahlgrenska Canc Ctr, Medicinaregatan 1F, S-40530 Gothenburg, Sweden	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Cancer Research UK; CRUK Cambridge Institute; University of Cambridge; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Paterson Institute for Cancer Research; University of Manchester; US Food & Drug Administration (FDA); University of Gothenburg	Sterneck, E (corresponding author), NCI, Lab Cell & Dev Signaling, Ctr Canc Res, POB B, Frederick, MD 21702 USA.	sternecg@mail.nih.gov	Johnson, Randall C/B-1517-2014; Kuppusamy, Balamurugan/AAC-6020-2022; Caldas, Carlos/U-7250-2019	Johnson, Randall C/0000-0001-7754-0847; Caldas, Carlos/0000-0003-3547-1489; Sterneck, Esta/0000-0001-7716-8766	Intramural Research Program of the NIH, National Cancer Institute; Frederick National Laboratory (NIH) [HHSN261200800001E]; National Council on Science and Technology (CONACYT), Mexico; MRC [MR/M008975/1] Funding Source: UKRI; Academy of Medical Sciences (AMS) [AMS-SGCL11-Ali] Funding Source: researchfish; Cancer Research UK [16942] Funding Source: researchfish; Medical Research Council [MR/M008975/1] Funding Source: researchfish; National Institute for Health Research [CL-2013-14-006, NF-SI-0611-10154, NF-SI-0515-10090] Funding Source: researchfish; NATIONAL CANCER INSTITUTE [ZIABC010307] Funding Source: NIH RePORTER	Intramural Research Program of the NIH, National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Frederick National Laboratory (NIH); National Council on Science and Technology (CONACYT), Mexico(Consejo Nacional de Ciencia y Tecnologia (CONACyT)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Academy of Medical Sciences (AMS)(Academy of Medical Sciences (AMS)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are thankful to the Laboratory Animal Sciences Program (Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research) for excellent support, especially Donna Butcher and Glenn Summers for superb services, and Bao Tran and Jyoti Shetty (Leidos Biomedical Research, Inc.) for mRNA-Seq data. We also thank Elise Nilsson for excellent technical assistance. We thank student interns Katherine L Zhou and Yasmin Y Lachir for their valuable contributions, Linda Miller for preparation of plasmids, and Allen Kane and Joseph Meyer (Leidos Biomedical Research, Inc.) for preparing the figures for publication. This research was supported by the Intramural Research Program of the NIH, National Cancer Institute and in part with Federal Funds from the Frederick National Laboratory (NIH) under contract no. HHSN261200800001E. DM-V was supported in part by a scholarship from the National Council on Science and Technology (CONACYT), Mexico. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products or organizations imply endorsement by the US Government.	Alves CC, 2009, FRONT BIOSCI-LANDMRK, V14, P3041, DOI 10.2741/3433; Bailey CK, 2012, J BIOL CHEM, V287, P19472, DOI 10.1074/jbc.M112.345728; Balamurugan K, 2013, INT J BIOL SCI, V9, P917, DOI 10.7150/ijbs.7224; Balamurugan K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2677; Balamurugan K, 2010, EMBO J, V29, P4106, DOI 10.1038/emboj.2010.280; Baranda-Avila N, 2013, STEROIDS, V78, P717, DOI 10.1016/j.steroids.2013.03.003; Begay V, 2015, J MOL MED, V93, P39, DOI 10.1007/s00109-014-1215-5; Bermejo-Rodriguez C, 2006, GENOMICS, V87, P113, DOI 10.1016/j.ygeno.2005.09.014; Cardona-Gomez P, 2004, MOL CELL NEUROSCI, V25, P363, DOI 10.1016/j.mcn.2003.10.008; Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901; Chaudary Naz, 2006, Breast Dis, V26, P55; Chen JC, 2014, CELL, V159, P402, DOI 10.1016/j.cell.2014.09.021; Chin SF, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-10-r215; Cicenas J, 2011, J CANCER RES CLIN, V137, P1409, DOI 10.1007/s00432-011-1039-4; Cobaleda C, 2007, ANNU REV GENET, V41, P41, DOI 10.1146/annurev.genet.41.110306.130146; Davis RJ, 2014, CANCER CELL, V26, P455, DOI 10.1016/j.ccell.2014.09.013; Dethlefsen C, 2013, BREAST CANCER RES TR, V138, P657, DOI 10.1007/s10549-013-2488-z; Dhasarathy A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026514; Eroles P, 2012, CANCER TREAT REV, V38, P698, DOI 10.1016/j.ctrv.2011.11.005; Grisouard J, 2007, MOL ENDOCRINOL, V21, P2427, DOI 10.1210/me.2007-0129; Guo WJ, 2012, CELL, V148, P1015, DOI 10.1016/j.cell.2012.02.008; Hagedorn M, 2007, CELL DIV, V2, DOI 10.1186/1747-1028-2-9; Hefti MM, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3462; Hutt JA, 2002, MOL CANCER THER, V1, P601; Ikezoe T, 2005, CANCER RES, V65, P4762, DOI 10.1158/0008-5472.CAN-03-3619; Jones SA, 2011, J CLIN INVEST, V121, P3375, DOI 10.1172/JCI57158; Knupfer H, 2007, BREAST CANCER RES TR, V102, P129, DOI 10.1007/s10549-006-9328-3; Korkaya H, 2011, J CLIN INVEST, V121, P3804, DOI 10.1172/JCI57099; Liao XH, 2014, FEBS J, V281, P927, DOI 10.1111/febs.12658; Liu J, 2015, TUMOR BIOL, V36, P1849, DOI 10.1007/s13277-014-2787-y; Lyng MB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054078; Madden SF, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3444; Martinson HA, 2015, INT J CANCER, V136, P1803, DOI 10.1002/ijc.29181; Milde-Langosch K, 2003, BREAST CANCER RES TR, V79, P175, DOI 10.1023/A:1023929504884; Naderi A, 2007, ONCOGENE, V26, P1507, DOI 10.1038/sj.onc.1209920; Pawar SA, 2010, P NATL ACAD SCI USA, V107, P9210, DOI 10.1073/pnas.0913813107; Phillips S, 2014, STEM CELL REP, V2, P633, DOI 10.1016/j.stemcr.2014.03.008; Porter DA, 2001, CANCER RES, V61, P5697; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/BJ20020508; Ranger JJ, 2009, CANCER RES, V69, P6823, DOI 10.1158/0008-5472.CAN-09-1684; Reed W, 1999, VIRCHOWS ARCH, V435, P116, DOI 10.1007/s004280050408; Resemann HK, 2014, MOL CELL ENDOCRINOL, V382, P603, DOI 10.1016/j.mce.2013.06.029; Ringner M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017911; Ryden L, 2005, EUR J CANCER, V41, P256, DOI 10.1016/j.ejca.2004.06.030; Sanchez-Garcia F, 2014, CELL, V159, P1461, DOI 10.1016/j.cell.2014.10.048; Sanford DC, 2005, PROSTATE, V63, P143, DOI 10.1002/pros.20159; Sarkar TR, 2012, MOL CELL BIOL, V32, P320, DOI 10.1128/MCB.05790-11; Stamos JL, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a007898; Taniguchi K, 2014, SEMIN IMMUNOL, V26, P54, DOI 10.1016/j.smim.2014.01.001; Thangaraju M, 2005, DEVELOPMENT, V132, P4675, DOI 10.1242/dev.02050; van Roosmalen W, 2015, J CLIN INVEST, V125, P1648, DOI 10.1172/JCI74440; Wang Y, 2015, BIOMED RES INT, V2015, P6, DOI DOI 10.1128/MBI0.01280-15; Wang ZW, 2012, FEBS LETT, V586, P1409, DOI 10.1016/j.febslet.2012.03.017; Wei Guangwei, 2012, J Cancer Sci Ther, V4, P299; Ye Y, 2010, ONCOGENE, V29, P1451, DOI 10.1038/onc.2009.433; Yu XY, 2010, CANCER CELL INT, V10, DOI 10.1186/1475-2867-10-48; Zahnow CA, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409001033; Zhang F, 2003, J BIOL CHEM, V278, P33067, DOI 10.1074/jbc.M212635200	58	16	16	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 1	2016	35	48					6166	6176		10.1038/onc.2016.156	http://dx.doi.org/10.1038/onc.2016.156			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ED4YH	27181204	Green Accepted			2022-12-17	WOS:000388857700002
J	Groves, IJ; Knight, ELA; Ang, QY; Scarpini, CG; Coleman, N				Groves, I. J.; Knight, E. L. A.; Ang, Q. Y.; Scarpini, C. G.; Coleman, N.			HPV16 oncogene expression levels during early cervical carcinogenesis are determined by the balance of epigenetic chromatin modifications at the integrated virus genome	ONCOGENE			English	Article							HUMAN-PAPILLOMAVIRUS TYPE-16; TRANSCRIPTION FACTOR-BINDING; GENE-EXPRESSION; IN-VITRO; HISTONE MODIFICATIONS; REGULATORY ELEMENTS; CELL-LINE; P-TEFB; KERATINOCYTES; METHYLATION	In cervical squamous cell carcinomas, high-risk human papillomavirus (HRHPV) DNA is usually integrated into host chromosomes. Multiple integration events are thought to be present within the cells of a polyclonal premalignant lesion and the features that underpin clonal selection of one particular integrant remain poorly understood. We previously used the W12 model system to generate a panel of cervical keratinocyte clones, derived from cells of a low-grade premalignant lesion naturally infected with the major HRHPV type, HPV16. The cells were isolated regardless of their selective advantage and differed only by the site of HPV16 integration into the host genome. We used this resource to test the hypothesis that levels of HPV16 E6/E7 oncogene expression in premalignant cells are regulated epigenetically. We performed a comprehensive analysis of the epigenetic landscape of the integrated HPV16 DNA in selected clones, in which levels of virus oncogene expression per DNA template varied similar to 6.6-fold. Across the cells examined, higher levels of virus expression per template were associated with more open chromatin at the HPV16 long control region, together with greater loading of chromatin remodelling enzymes and lower nucleosome occupancy. There were higher levels of histone post-translational modification hallmarks of transcriptionally active chromatin and lower levels of repressive hallmarks. There was greater abundance of the active/elongating form of the RNA polymerase-II enzyme (RNAPII-Ser2P), together with CDK9, the component of positive transcription elongation factor b complex responsible for Ser2 phosphorylation. The changes observed were functionally significant, as cells with higher HPV16 expression per template showed greater sensitivity to depletion and/or inhibition of histone acetyltransferases and CDK9 and less sensitivity to histone deacetylase inhibition. We conclude that virus gene expression per template following HPV16 integration is determined through multiple layers of epigenetic regulation, which are likely to contribute to selection of individual cells during cervical carcinogenesis.	[Groves, I. J.; Knight, E. L. A.; Ang, Q. Y.; Scarpini, C. G.; Coleman, N.] Univ Cambridge, Dept Pathol, Tennis Court Rd, Cambridge CB2 1QP, England	University of Cambridge	Coleman, N (corresponding author), Univ Cambridge, Dept Pathol, Tennis Court Rd, Cambridge CB2 1QP, England.	nc109@cam.ac.uk	Groves, Ian John/HGU-5954-2022	Groves, Ian John/0000-0001-8882-6701; Scarpini, Cinzia G./0000-0003-4730-5197; Ang, Qi Yan/0000-0002-9788-1283	Cancer Research UK [A13080]; Medical Research Council; Pathological Society of Great Britain and Ireland; Agency for Science, Technology and Research, Singapore; Cancer Research UK [13080] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Pathological Society of Great Britain and Ireland; Agency for Science, Technology and Research, Singapore(Agency for Science Technology & Research (A*STAR)); Cancer Research UK(Cancer Research UK)	This work was supported by Cancer Research UK (Programme Grant A13080); the Medical Research Council; The Pathological Society of Great Britain and Ireland (ELAK); and the Agency for Science, Technology and Research, Singapore (QYA). Funding for open access charge: Cancer Research UK and the Medical Research Council.	Arce JD, 2012, HUM MOL GENET, V21, P1693, DOI 10.1093/hmg/ddr604; Bannister AJ, 2011, CELL RES, V21, P381, DOI 10.1038/cr.2011.22; BEDELL MA, 1991, J VIROL, V65, P2254, DOI 10.1128/JVI.65.5.2254-2260.1991; Bernard HU, 2013, VIROLOGY, V445, P197, DOI 10.1016/j.virol.2013.04.035; Bogdanovic O, 2012, GENOME RES, V22, P2043, DOI 10.1101/gr.134833.111; Carson A, 2006, J VIROL, V80, P4356, DOI 10.1128/JVI.80.9.4356-4362.2006; Chao SH, 2000, J BIOL CHEM, V275, P28345, DOI 10.1074/jbc.C000446200; COLEMAN N, 1994, HUM PATHOL, V25, P73, DOI 10.1016/0046-8177(94)90174-0; COLEMAN N, 1993, AM J PATHOL, V143, P355; Dall KL, 2008, CANCER RES, V68, P8249, DOI 10.1158/0008-5472.CAN-08-1741; Dou YL, 2006, NAT STRUCT MOL BIOL, V13, P713, DOI 10.1038/nsmb1128; Euskirchen GM, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002008; Forman D, 2012, VACCINE, V30, pF12, DOI 10.1016/j.vaccine.2012.07.055; FRIEDL F, 1970, P SOC EXP BIOL MED, V135, P543; Gray E, 2010, CANCER RES, V70, P4081, DOI 10.1158/0008-5472.CAN-09-3335; Groves IJ, 2015, J PATHOL, V235, P527, DOI 10.1002/path.4496; Groves IJ, 2009, J GEN VIROL, V90, P2364, DOI 10.1099/vir.0.012526-0; Hanning JE, 2013, BRIT J CANCER, V108, P450, DOI 10.1038/bjc.2012.564; Hanning JE, 2013, J PATHOL, V231, P354, DOI 10.1002/path.4244; Hanning JE, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-159; Hazzalin CA, 2005, PLOS BIOL, V3, P2111, DOI 10.1371/journal.pbio.0030393; He HP, 2012, CELL CYCLE, V11, P617, DOI 10.4161/cc.11.3.19115; Herdman MT, 2006, CARCINOGENESIS, V27, P2341, DOI 10.1093/carcin/bgl172; Hyland PL, 2011, J VIROL, V85, P10999, DOI 10.1128/JVI.00160-11; JEON S, 1995, J VIROL, V69, P2989, DOI 10.1128/JVI.69.5.2989-2997.1995; Jeong KW, 2011, NAT STRUCT MOL BIOL, V18, P1358, DOI 10.1038/nsmb.2153; Jha S, 2010, MOL CELL, V38, P700, DOI 10.1016/j.molcel.2010.05.020; Johannsen E, 2013, VIROLOGY, V445, P205, DOI 10.1016/j.virol.2013.07.016; Johansson C, 2015, VIROLOGY, V482, P244, DOI 10.1016/j.virol.2015.02.053; Kelly TK, 2012, GENOME RES, V22, P2497, DOI 10.1101/gr.143008.112; Kim CH, 2015, BIOSCI BIOTECH BIOCH, V79, P532, DOI 10.1080/09168451.2014.993914; Kruppel U, 2008, VIROLOGY, V377, P151, DOI 10.1016/j.virol.2008.04.006; Li GL, 2012, CELL, V148, P84, DOI 10.1016/j.cell.2011.12.014; McLaughlin-Drubin ME, 2011, P NATL ACAD SCI USA, V108, P2130, DOI 10.1073/pnas.1009933108; Palermo RD, 2008, BIOCHEM SOC T, V36, P625, DOI 10.1042/BST0360625; Pena LD, 2001, J VIROL, V75, P10005, DOI 10.1128/JVI.75.20.10005-10013.2001; Pett M, 2007, J PATHOL, V212, P356, DOI 10.1002/path.2192; Pett MR, 2004, CANCER RES, V64, P1359, DOI 10.1158/0008-5472.CAN-03-3214; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Scarpini CG, 2014, J PATHOL, V233, P281, DOI 10.1002/path.4358; Simon JM, 2012, NAT PROTOC, V7, P256, DOI 10.1038/nprot.2011.444; Smith JA, 2014, VIROLOGY, V468, P311, DOI 10.1016/j.virol.2014.08.022; STANLEY MA, 1989, INT J CANCER, V43, P672, DOI 10.1002/ijc.2910430422; STOLER MH, 1992, HUM PATHOL, V23, P117, DOI 10.1016/0046-8177(92)90232-R; Stunkel W, 1999, J VIROL, V73, P1918; Sun YL, 2009, NAT CELL BIOL, V11, P1376, DOI 10.1038/ncb1982; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Wang S, 2008, TRENDS PHARMACOL SCI, V29, P302, DOI 10.1016/j.tips.2008.03.003; Wang WM, 2011, J BIOL CHEM, V286, P40974, DOI 10.1074/jbc.M111.290874; Wang ZB, 2009, CELL, V138, P1019, DOI 10.1016/j.cell.2009.06.049; Wentzensen N, 2004, CANCER RES, V64, P3878, DOI 10.1158/0008-5472.CAN-04-0009; Wentzensen N, 2012, JNCI-J NATL CANCER I, V104, P1738, DOI 10.1093/jnci/djs425; Wooldridge TR, 2008, VIROLOGY, V374, P371, DOI 10.1016/j.virol.2007.12.011; Xu M, 2013, VIROLOGY, V446, P17, DOI 10.1016/j.virol.2013.07.014; Yew CW, 2011, CANCER RES, V71, P6696, DOI 10.1158/0008-5472.CAN-11-1271; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	56	16	17	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 8	2016	35	36					4773	4786		10.1038/onc.2016.8	http://dx.doi.org/10.1038/onc.2016.8			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW0IS	26876196	Green Published, hybrid			2022-12-17	WOS:000383324700010
J	Wang, G; Yu, Y; Sun, C; Liu, T; Liang, T; Zhan, L; Lin, X; Feng, XH				Wang, G.; Yu, Y.; Sun, C.; Liu, T.; Liang, T.; Zhan, L.; Lin, X.; Feng, X-H			STAT3 selectively interacts with Smad3 to antagonize TGF-beta signalling (vol 35, pg 4388, 2016)	ONCOGENE			English	Correction																		Wang G, 2016, ONCOGENE, V35, P4388, DOI 10.1038/onc.2015.446	1	16	16	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	33					4422	4422		10.1038/onc.2016.145	http://dx.doi.org/10.1038/onc.2016.145			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU3ZU	27345395	Bronze			2022-12-17	WOS:000382152100014
J	Joly, AL; Deepti, A; Seignez, A; Goloudina, A; Hebrard, S; Schmitt, E; Richaud, S; Fourmaux, E; Hammann, A; Collura, A; Svrcek, M; Jego, G; Robinet, E; Solary, E; Demidov, O; Kohli, E; Garrido, C				Joly, A-L; Deepti, A.; Seignez, A.; Goloudina, A.; Hebrard, S.; Schmitt, E.; Richaud, S.; Fourmaux, E.; Hammann, A.; Collura, A.; Svrcek, M.; Jego, G.; Robinet, E.; Solary, E.; Demidov, O.; Kohli, E.; Garrido, C.			The HSP90 inhibitor, 17AAG, protects the intestinal stem cell niche and inhibits graft versus host disease development	ONCOGENE			English	Article							NEURAL PROGENITOR CELLS; ER STRESS; T-CELLS; SENSITIVITY; MOLECULES; THERAPY; TARGET; HSP70; RISK	Graft versus host disease (GvHD), which is the primary complication of allogeneic bone marrow transplantation, can alter the intestinal barrier targeted by activated donor T-cells. Chemical inhibition of the stress protein HSP90 was demonstrated in vitro to inhibit T-cell activation and to modulate endoplasmic reticulum (ER) stress to which intestinal cells are highly susceptible. Since the HSP90 inhibitor 17-allylamino-demethoxygeldanamycin (17AAG) is developed in clinics, we explored here its ability to control intestinal acute GvHD in vivo in two mouse GvHD models (C57BL/6 -> BALB/c and FVB/N -> Lgr5-eGFP), ex vivo in intestine organoids and in vitro in intestinal epithelial cultures. We show that 17AAG decreases GvHD-associated mortality without impairing graft versus leukemia effect. While 17AAG effect in T-cell activation is just moderate at the dose used in vivo, we observe a striking intestinal integrity protection. At the intestine level, the drug promotes the splicing of the transcription factor X-box binding protein 1 (XBP1), which is a key component of the ER stress. This effect is associated with a decrease in intestinal damage and an increase in Lgr5(+) stem cells, Paneth cells and defensins production. The importance of XBP1 splicing control is further confirmed in cultured cells and organoids of primary intestinal epithelium where XBP1 is either shRNA depleted or inhibited with toyocamycin. In conclusion, 17AAG has a protective effect on the epithelial intestinal barrier in mouse models of acute GvHD. This compound deserves to be tested in the therapeutic control of acute GvHD.	[Joly, A-L; Deepti, A.; Seignez, A.; Goloudina, A.; Hebrard, S.; Schmitt, E.; Richaud, S.; Fourmaux, E.; Hammann, A.; Jego, G.; Demidov, O.; Kohli, E.; Garrido, C.] INSERM, UMR 866, Equipe Labellisee Ligue Natl Canc, F-21079 Dijon, France; [Joly, A-L; Deepti, A.; Seignez, A.; Goloudina, A.; Hebrard, S.; Schmitt, E.; Richaud, S.; Fourmaux, E.; Hammann, A.; Jego, G.; Demidov, O.; Kohli, E.; Garrido, C.] Lab Excellence LipSTIC, Dijon, France; [Joly, A-L; Deepti, A.; Seignez, A.; Goloudina, A.; Hebrard, S.; Schmitt, E.; Richaud, S.; Fourmaux, E.; Hammann, A.; Jego, G.; Demidov, O.; Kohli, E.; Garrido, C.] Univ Bourgogne, Dijon, France; [Seignez, A.] CHU, Dijon, France; [Collura, A.; Svrcek, M.] INSERM, UMR S938, Ctr Rech St Antoine, Paris, France; [Robinet, E.] INSERM, U748, Inst Virol, Strasbourg, France; [Robinet, E.] Inst Hosp Univ Strasbourg, Strasbourg, France; [Solary, E.] Inst Gustave Roussy, INSERM, UMR1009, F-94805 Villejuif, France; [Solary, E.] Univ Paris 11, Villejuif, France; [Garrido, C.] Anticanc Ctr George Francois Leclerc, Dijon, France	Institut Agro; AgroSup Dijon; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Universite de Bourgogne; CHU Dijon Bourgogne; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay	Garrido, C (corresponding author), INSERM, Fac Med & Pharm, UMR866, 7 Blvd Jeanne dArc, F-21079 Dijon, France.	cgarrido@u-bourgogne.fr	Garrido, Carolina/GWM-5557-2022; Garrido, carmen/G-1633-2018; Demidov, Oleg/AAC-4462-2021; Demidov, Oleg/U-2050-2017; Goloudina, Anastasia/T-4989-2019; jego, gaetan/N-7226-2018	Garrido, carmen/0000-0003-1368-1493; Demidov, Oleg/0000-0003-4323-7174; Demidov, Oleg/0000-0003-4323-7174; jego, gaetan/0000-0003-0376-9299; Solary, Eric/0000-0002-8629-1341; deepti, ayswaria/0000-0001-7159-6911	Institut National du Cancer; Agence Nationale de la Recherche; Ligue Nationale Contre le Cancer; Association pour la Recherche sur le Cancer; FEDER; La Ligue Nationale Contre le Cancer; Conseil Regional de Bourgogne	Institut National du Cancer(Institut National du Cancer (INCA) France); Agence Nationale de la Recherche(French National Research Agency (ANR)); Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); FEDER(European Commission); La Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer); Conseil Regional de Bourgogne(Region Bourgogne-Franche-Comte)	We thank J Haiech (University of Strasbourg), P Saas and B Gaugler (INSERM U1098, Besancon, France), for helpful discussions. We thank P Saas, H Clevers (Hubrecht Institute, The Netherlands) and A Jevnikar (Ontario, CA) for providing A20-luc cells, Lgr5-eGFP mice and IEC 4-1, respectively, and A Bouchot and JF Merlin (INSERM U866, Dijon, France) for excellent technical assistance. This work was supported by grants from the Institut National du Cancer, Agence Nationale de la Recherche, Ligue Nationale Contre le Cancer ('Labeled teams' to CG and ES), the Association pour la Recherche sur le Cancer (labeled team to CG and OD), and FEDER. CG team belongs to the LabEx LipSTIC and GR-Ex. ALJ has a doctoral fellowship from La Ligue Nationale Contre le Cancer and AD by the 'Conseil Regional de Bourgogne'.	Aucagne R, 2011, J CLIN INVEST, V121, P2361, DOI 10.1172/JCI45213; Bertolotti A, 2001, J CLIN INVEST, V107, P585, DOI 10.1172/JCI11476; Biamonte MA, 2010, J MED CHEM, V53, P3, DOI 10.1021/jm9004708; Bradley E, 2014, J CELL COMMUN SIGNAL, V8, P353, DOI 10.1007/s12079-014-0247-5; Cawley K, 2011, METHOD ENZYMOL, V490, P31, DOI 10.1016/B978-0-12-385114-7.00002-7; Choi SW, 2014, NAT REV CLIN ONCOL, V11, P536, DOI 10.1038/nrclinonc.2014.102; Collins CB, 2013, MUCOSAL IMMUNOL, V6, P960, DOI 10.1038/mi.2012.134; Contassot E, 1998, TRANSPLANTATION, V65, P1365, DOI 10.1097/00007890-199805270-00014; Cooke KR, 1998, J CLIN INVEST, V102, P1882, DOI 10.1172/JCI4285; Cooke KR, 1996, BLOOD, V88, P3230, DOI 10.1182/blood.V88.8.3230.bloodjournal8883230; Couturier M, 2013, LEUKEMIA, V27, P1527, DOI 10.1038/leu.2013.39; Davenport EL, 2007, BLOOD, V110, P2641, DOI 10.1182/blood-2006-11-053728; Didelot C, 2008, CELL DEATH DIFFER, V15, P859, DOI 10.1038/sj.cdd.4402320; Elo MA, 2005, BBA-MOL CELL RES, V1743, P115, DOI 10.1016/j.bbamcr.2004.09.004; Eriguchi Y, 2012, BLOOD, V120, P223, DOI 10.1182/blood-2011-12-401166; Ferrara JLM, 2009, LANCET, V373, P1550, DOI 10.1016/S0140-6736(09)60237-3; Hanash AM, 2012, IMMUNITY, V37, P339, DOI 10.1016/j.immuni.2012.05.028; Hill GR, 2000, BLOOD, V95, P2754, DOI 10.1182/blood.V95.9.2754.009k25_2754_2759; Jego G, 2013, CANCER LETT, V332, P275, DOI 10.1016/j.canlet.2010.10.014; Kabiri Z, 2014, DEVELOPMENT, V141, P2206, DOI 10.1242/dev.104976; Kaser A, 2008, CELL, V134, P743, DOI 10.1016/j.cell.2008.07.021; Kaser A, 2010, CURR OPIN GASTROEN, V26, P318, DOI 10.1097/MOG.0b013e32833a9ff1; Levine JE, 2013, BLOOD, V122, P1505, DOI 10.1182/blood-2013-02-485813; Li XC, 1997, CELL IMMUNOL, V175, P58, DOI 10.1006/cimm.1996.1050; Marcu MG, 2002, MOL CELL BIOL, V22, P8506, DOI 10.1128/MCB.22.24.8506-8513.2002; Mimura N, 2012, BLOOD, V119, P5772, DOI 10.1182/blood-2011-07-366633; Mjahed H, 2012, EXP CELL RES, V318, P1946, DOI 10.1016/j.yexcr.2012.05.012; Moser C, 2009, ANTICANCER RES, V29, P2031; Murphy S, 2011, LEUKEMIA LYMPHOMA, V52, P1844, DOI 10.3109/10428194.2011.580476; Neckers L, 2012, CLIN CANCER RES, V18, P64, DOI 10.1158/1078-0432.CCR-11-1000; Pelicano H, 2006, LEUKEMIA, V20, P610, DOI 10.1038/sj.leu.2404140; Penack O, 2010, BLOOD, V115, P1865, DOI 10.1182/blood-2009-09-242784; Rerole AL, 2011, CANCER RES, V71, P484, DOI 10.1158/0008-5472.CAN-10-1443; Ri M, 2012, BLOOD CANCER J, V2, DOI 10.1038/bcj.2012.26; Salzman NH, 2010, NAT IMMUNOL, V11, P76, DOI 10.1038/ni.1825; Sato T, 2013, SCIENCE, V340, P1190, DOI 10.1126/science.1234852; Sato T, 2011, NATURE, V469, P415, DOI 10.1038/nature09637; Sato T, 2009, NATURE, V459, P262, DOI 10.1038/nature07935; Stuehler C, 2009, BLOOD, V114, P2829, DOI 10.1182/blood-2009-06-224600; Takashima S, 2011, J EXP MED, V208, P285, DOI 10.1084/jem.20101559; Tirosh B, 2006, J BIOL CHEM, V281, P5852, DOI 10.1074/jbc.M509061200; Wang GH, 2011, J NEUROCHEM, V117, P703, DOI 10.1111/j.1471-4159.2011.07239.x; Werner T, 2011, GUT, V60, P325, DOI 10.1136/gut.2010.216929	43	16	17	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2016	35	22					2842	2851		10.1038/onc.2015.242	http://dx.doi.org/10.1038/onc.2015.242			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0MT	26364610				2022-12-17	WOS:000377473700004
J	Hsu, PY; Hsu, HK; Hsiao, TH; Ye, Z; Wang, E; Profit, AL; Jatoi, I; Chen, Y; Kirma, NB; Jin, VX; Sharp, ZD; Huang, THM				Hsu, P-Y; Hsu, H-K; Hsiao, T-H; Ye, Z.; Wang, E.; Profit, A. L.; Jatoi, I.; Chen, Y.; Kirma, N. B.; Jin, V. X.; Sharp, Z. D.; Huang, T. H-M			Spatiotemporal control of estrogen-responsive transcription in ER alpha-positive breast cancer cells	ONCOGENE			English	Article							GENE-EXPRESSION; RECEPTOR-ALPHA; CERVICAL-CANCER; CHROMATIN; HETEROCHROMATIN; FACTORIES; BINDING; GROWTH; MECHANISMS; EVOLUTION	Recruitment of transcription machinery to target promoters for aberrant gene expression has been well studied, but underlying control directed by distant-acting enhancers remains unclear in cancer development. Our previous study demonstrated that distant estrogen response elements (DEREs) located on chromosome 20q13 are frequently amplified and translocated to other chromosomes in ER alpha-positive breast cancer cells. In this study, we used three-dimensional interphase fluorescence in situ hybridization to decipher spatiotemporal gathering of multiple DEREs in the nucleus. Upon estrogen stimulation, scattered 20q13 DEREs were mobilized to form regulatory depots for synchronized gene expression of target loci. A chromosome conformation capture assay coupled with chromatin immunoprecipitation further uncovered that ER alpha-bound regulatory depots are tethered to heterochromatin protein 1 (HP1) for coordinated chromatin movement and histone modifications of target loci, resulting in transcription repression. Neutralizing HP1 function dysregulated the formation of DERE-involved regulatory depots and transcription inactivation of candidate tumor-suppressor genes. Deletion of amplified DEREs using the CRISPR/Cas9 genomic-editing system profoundly altered transcriptional profiles of proliferation-associated signaling networks, resulting in reduction of cancer cell growth. These findings reveal a formerly uncharacterized feature wherein multiple copies of the amplicon congregate as transcriptional units in the nucleus for synchronous regulation of function-related loci in tumorigenesis. Disruption of their assembly can be a new strategy for treating breast cancers and other malignancies.	[Hsu, P-Y; Hsu, H-K; Ye, Z.; Kirma, N. B.; Jin, V. X.; Sharp, Z. D.; Huang, T. H-M] Univ Texas Hlth Sci Ctr San Antonio, Inst Biotechnol, Dept Mol Med, STRF 300-31,8403 Floyd Curl Dr, San Antonio, TX 78229 USA; [Hsiao, T-H; Chen, Y.] Univ Texas Hlth Sci Ctr San Antonio, Greehey Childrens Canc Res Inst, San Antonio, TX 78229 USA; [Hsiao, T-H; Profit, A. L.; Jatoi, I.; Chen, Y.; Sharp, Z. D.; Huang, T. H-M] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA; [Hsiao, T-H] Taichung Vet Gen Hosp, Dept Med Res, Taichung, Taiwan; [Wang, E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA; [Profit, A. L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA; [Jatoi, I.] Univ Texas Hlth Sci Ctr San Antonio, Dept Surg, San Antonio, TX 78229 USA; [Chen, Y.; Jin, V. X.] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; Cancer Therapy & Research Center; University of Texas System; University of Texas Health San Antonio; Taichung Veterans General Hospital; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Huang, THM (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Inst Biotechnol, Dept Mol Med, STRF 300-31,8403 Floyd Curl Dr, San Antonio, TX 78229 USA.	huangt3@uthscsa.edu			National Institutes of Health (NIH) [R01 CA069065, R01 ES017594, U01 ES015986, U54 CA113001]; NCI CCSG [P30 CA054174]; University of Texas System STARS award; UTHSCSA; NIH-NCI [P30 CA54174]; NATIONAL CANCER INSTITUTE [R01CA069065, P30CA054174, U54CA113001] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [U01ES015986, R01ES017594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM114142] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI CCSG; University of Texas System STARS award; UTHSCSA; NIH-NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank staff at the Optical Imaging Facility of the Cancer Therapy and Research Center (CTRC) for technical assistance of FISH analyses. This work was supported by National Institutes of Health (NIH) grants (R01 CA069065, R01 ES017594, U01 ES015986, U54 CA113001; Integrative Cancer Biology Program) and NCI CCSG (P30 CA054174) and the University of Texas System STARS award and by generous gifts from the CTRC Foundation and the Voelcker Fund. Confocal images were generated in the Optical Imaging Core Facility, which is supported by UTHSCSA and NIH-NCI grant (P30 CA54174).	Beisel C, 2011, NAT REV GENET, V12, P123, DOI 10.1038/nrg2932; Brisken C, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a003178; Cai ST, 2006, NAT GENET, V38, P1278, DOI 10.1038/ng1913; Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901; Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009; Cicatiello L, 2010, AM J PATHOL, V176, P2113, DOI 10.2353/ajpath.2010.090837; Cong L, 2013, SCIENCE, V339, P819, DOI 10.1126/science.1231143; Deng BW, 2013, SEMIN CANCER BIOL, V23, P65, DOI 10.1016/j.semcancer.2012.01.003; Fahrner JA, 2003, GENE DEV, V17, P1805, DOI 10.1101/gad.1123303; Feng XS, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-633; Fullwood MJ, 2009, NATURE, V462, P58, DOI 10.1038/nature08497; Gaszner M, 2006, NAT REV GENET, V7, P703, DOI 10.1038/nrg1925; Ginestier C, 2006, CLIN CANCER RES, V12, P4533, DOI 10.1158/1078-0432.CCR-05-2339; Gu F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060980; Harmston N, 2013, NUCLEIC ACIDS RES, V41, P7185, DOI 10.1093/nar/gkt499; Hoffman B, 2008, ONCOGENE, V27, P6462, DOI 10.1038/onc.2008.312; Hsu PD, 2014, CELL, V157, P1262, DOI 10.1016/j.cell.2014.05.010; Hsu PY, 2013, CANCER CELL, V24, P197, DOI 10.1016/j.ccr.2013.07.007; Hsu PY, 2010, GENOME RES, V20, P733, DOI 10.1101/gr.101923.109; Joseph R, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.109; Karla N, 2004, J BIOL CHEM, V279, P25313, DOI 10.1074/jbc.M400932200; Kim J, 2004, GENOMICS, V84, P47, DOI 10.1016/j.ygeno.2004.02.007; Kwak HI, 2007, CARCINOGENESIS, V28, P259, DOI 10.1093/carcin/bgl122; Ma DD, 2013, GYNECOL ONCOL, V131, P445, DOI 10.1016/j.ygyno.2013.07.113; Michell JA, 2008, GENE DEV, V22, P20; Misteli T, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000794; Ong CT, 2012, EMBO REP, V13, P423, DOI 10.1038/embor.2012.52; Osborne CS, 2007, PLOS BIOL, V5, P1763, DOI 10.1371/journal.pbio.0050192; Papantonis A, 2013, CHEM REV, V113, P8683, DOI 10.1021/cr300513p; Papantonis A, 2012, EMBO J, V31, P4404, DOI 10.1038/emboj.2012.288; Protty MB, 2009, BIOCHEM J, V417, P391, DOI 10.1042/BJ20081126; Qi JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098052; Santarius T, 2010, NAT REV CANCER, V10, P59, DOI 10.1038/nrc2771; Sciacovelli M, 2013, CELL METAB, V17, P988, DOI 10.1016/j.cmet.2013.04.019; Sharma RP, 2012, PHARMACOGENOMICS J, V12, P361, DOI 10.1038/tpj.2011.64; Sleeman JE, 2014, CURR OPIN CELL BIOL, V28, P76, DOI 10.1016/j.ceb.2014.03.004; Springuel L, 2014, BLOOD, V124, P3924, DOI 10.1182/blood-2014-05-576652; Sutherland H, 2009, NAT REV GENET, V10, P457, DOI 10.1038/nrg2592; Symmans WF, 2010, J CLIN ONCOL, V28, P4111, DOI 10.1200/JCO.2010.28.4273; Thomas C, 2011, NAT REV CANCER, V11, P597, DOI 10.1038/nrc3093; Ulbricht T, 2012, J CELL BIOL, V199, P49, DOI 10.1083/jcb.201112015; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Xue W, 2014, NATURE, V514, P380, DOI 10.1038/nature13589; Yamada T, 1999, J BIOCHEM, V125, P832, DOI 10.1093/oxfordjournals.jbchem.a022356; Zhang CZ, 2013, GENE DEV, V27, P2513, DOI 10.1101/gad.229559.113; Zhang XP, 2007, CANCER RES, V67, P9425, DOI 10.1158/0008-5472.CAN-07-1310; Zhen S, 2014, BIOCHEM BIOPH RES CO, V450, P1422, DOI 10.1016/j.bbrc.2014.07.014	47	16	17	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 5	2016	35	18					2379	2389		10.1038/onc.2015.298	http://dx.doi.org/10.1038/onc.2015.298			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GL	26300005	Green Published, hybrid			2022-12-17	WOS:000376165000010
J	Li, HJ; Yu, PN; Huang, KY; Su, HY; Hsiao, TH; Chang, CP; Yu, MH; Lin, YW				Li, H-J; Yu, P-N; Huang, K-Y; Su, H-Y; Hsiao, T-H; Chang, C-P; Yu, M-H; Lin, Y-W			NKX6.1 functions as a metastatic suppressor through epigenetic regulation of the epithelial-mesenchymal transition	ONCOGENE			English	Article							PANCREATIC BETA-CELLS; E-CADHERIN REPRESSION; VENTRAL NEURAL-TUBE; CANCER STEM-CELLS; CERVICAL-CANCER; HEPATOCELLULAR-CARCINOMA; SIGNALING PATHWAY; TUMOR-SUPPRESSOR; NEURONAL FATE; COMPLEX	The transcription factor NKX6.1 (NK6 homeobox 1) is important in the development of pancreatic beta-cells and neurons. Although recent publications show that NKX6.1 is hypermethylated and downregulated during tumorigenesis, the function of NKX6.1 in carcinogenesis remains elusive. Here, we address the metastasis suppressor function of human NKX6.1 using cell, animal and clinical analyses. Our data show that NKX6.1 represses tumor formation and metastatic ability both in vitro and in vivo. Mechanistically, NKX6.1 suppresses cell invasion by inhibiting the epithelial-to-mesenchymal transition (EMT). NKX6.1 directly enhances the mRNA level of E-cadherin by recruiting BAF155 coactivator and represses that of vimentin and N-cadherin by recruiting RBBP7 (retinoblastoma binding protein 7) corepressor. Clinical cancer tumors with metastasis show low NKX6.1 protein expression coinciding with low E-cadherin and high vimentin expression. Our results demonstrate that NKX6.1 functions as an EMT suppressor by interacting with different epigenetic modifiers, making it a potential novel therapeutic option.	[Li, H-J; Huang, K-Y; Lin, Y-W] Natl Def Med Ctr, Grad Inst Life Sci, 161,Sect 6,Min Chuan East Rd, Taipei, Taiwan; [Yu, P-N; Chang, C-P; Lin, Y-W] Natl Def Med Ctr, Dept & Grad Inst Microbiol & Immunol, 161,Sect 6,Min Chuan East Rd, Taipei, Taiwan; [Su, H-Y; Yu, M-H] Natl Def Med Ctr, Dept Obstet & Gynecol, Triserv Gen Hosp, Taipei, Taiwan; [Hsiao, T-H] Taichung Vet Gen Hosp, Dept Med Res, Taipei, Taiwan	National Defense Medical Center; National Defense Medical Center; National Defense Medical Center; Tri-Service General Hospital; Taichung Veterans General Hospital	Lin, YW (corresponding author), Natl Def Med Ctr, Grad Inst Life Sci, 161,Sect 6,Min Chuan East Rd, Taipei, Taiwan.; Lin, YW (corresponding author), Natl Def Med Ctr, Dept & Grad Inst Microbiol & Immunol, 161,Sect 6,Min Chuan East Rd, Taipei, Taiwan.	ndmc.yawen@msa.hinet.net	Huang, Kuo-Yen/AAC-9247-2019		National Research Program for Genomic Medicine Grants of NSC [NSC 97-3112-B-001-016]; Ministry of Science and Technology, Taiwan, Republic of China [NSC 100-2314-B-016-021, NSC 102-2320-B-016-016-MY3, MOST 103-2314-B-016-008, MOST 103-2321-B-016-007]; Liver Disease Prevention and Treatment Research Foundation, Taiwan, Republic of China	National Research Program for Genomic Medicine Grants of NSC; Ministry of Science and Technology, Taiwan, Republic of China; Liver Disease Prevention and Treatment Research Foundation, Taiwan, Republic of China	We thank Yong-Jang Chen for technical assistance. RNA interference reagents were obtained from the National RNAi Core Facility located at the Institute of Molecular Biology/Genomic Research Center, Academia Sinica, supported by the National Research Program for Genomic Medicine Grants of NSC (NSC 97-3112-B-001-016). This work was supported by the following grants: NSC 100-2314-B-016-021, NSC 102-2320-B-016-016-MY3, MOST 103-2314-B-016-008 and MOST 103-2321-B-016-007 from the Ministry of Science and Technology, Taiwan, Republic of China, and the Liver Disease Prevention and Treatment Research Foundation, Taiwan, Republic of China.	Briscoe J, 2000, CELL, V101, P435, DOI 10.1016/S0092-8674(00)80853-3; Dave B, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr2938; De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447; DelBove J, 2011, EPIGENETICS-US, V6, P1444, DOI 10.4161/epi.6.12.18492; Donelan W, 2010, J BIOL CHEM, V285, P12181, DOI 10.1074/jbc.M109.064238; Dong C, 2013, ONCOGENE, V32, P1351, DOI 10.1038/onc.2012.169; Dong CF, 2012, J CLIN INVEST, V122, P1469, DOI 10.1172/JCI57349; Duffield JS, 2013, ANNU REV PATHOL-MECH, V8, P241, DOI 10.1146/annurev-pathol-020712-163930; Fan F, 2012, CANCER MED-US, V1, P5, DOI 10.1002/cam4.4; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; Fu JJ, 2011, CELL RES, V21, P275, DOI 10.1038/cr.2010.118; Gao DC, 2012, CANCER RES, V72, P4883, DOI 10.1158/0008-5472.CAN-12-1223; Herranz N, 2008, MOL CELL BIOL, V28, P4772, DOI 10.1128/MCB.00323-08; Hsu TI, 2012, ONCOGENE, V31, P3973, DOI 10.1038/onc.2011.568; Iype T, 2004, MOL ENDOCRINOL, V18, P1363, DOI 10.1210/me.2004-0006; Jorgensen MC, 1999, FEBS LETT, V461, P287, DOI 10.1016/S0014-5793(99)01436-2; Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902; Lai HC, 2008, INT J CANCER, V123, P161, DOI 10.1002/ijc.23519; Lai HC, 2010, CANCER-AM CANCER SOC, V116, P4266, DOI 10.1002/cncr.25252; Lin WC, 2013, BBA-MOL CELL RES, V1833, P3206, DOI 10.1016/j.bbamcr.2013.08.020; Lin YW, 2013, GYNECOL ONCOL, V131, P174, DOI 10.1016/j.ygyno.2013.07.111; Liu CY, 2009, J PATHOL, V219, P222, DOI 10.1002/path.2589; Massague J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434; Matsuno Y, 2012, INT J BIOCHEM CELL B, V44, P776, DOI 10.1016/j.biocel.2012.01.021; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Mi HY, 2013, NUCLEIC ACIDS RES, V41, pD377, DOI 10.1093/nar/gks1118; Micalizzi DS, 2009, FUTURE ONCOL, V5, P1129, DOI [10.2217/fon.09.94, 10.2217/FON.09.94]; Muhr J, 2001, CELL, V104, P861, DOI 10.1016/S0092-8674(01)00283-5; Ohta H, 2009, BRIT J CANCER, V100, P389, DOI 10.1038/sj.bjc.6604846; PECORARO G, 1991, AM J PATHOL, V138, P1; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; RUDNICK A, 1994, P NATL ACAD SCI USA, V91, P12203, DOI 10.1073/pnas.91.25.12203; Scheel C, 2012, SEMIN CANCER BIOL, V22, P396, DOI 10.1016/j.semcancer.2012.04.001; Su HY, 2010, INT J CANCER, V127, P555, DOI 10.1002/ijc.25083; Syu LJ, 2009, BRAIN RES, V1266, P8, DOI 10.1016/j.brainres.2009.01.068; Taylor KH, 2007, CANCER RES, V67, P2617, DOI 10.1158/0008-5472.CAN-06-3993; Tsao CM, 2012, HEPATOLOGY, V56, P2277, DOI 10.1002/hep.25933; Wang YT, 2008, J MOL BIOL, V380, P869, DOI 10.1016/j.jmb.2008.05.043; Wilson BG, 2011, NAT REV CANCER, V11, P481, DOI 10.1038/nrc3068; Wu MZ, 2011, MOL CELL, V43, P811, DOI 10.1016/j.molcel.2011.07.012; Yang MH, 2010, NAT CELL BIOL, V12, P982, DOI 10.1038/ncb2099; Yue P, 2012, ONCOGENE, V31, P2309, DOI 10.1038/onc.2011.409; Zhang L, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-108	43	16	16	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 28	2016	35	17					2266	2278		10.1038/onc.2015.289	http://dx.doi.org/10.1038/onc.2015.289			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DK5UK	26257059	Green Published, hybrid			2022-12-17	WOS:000374986000011
J	Dodd, RD; Sachdeva, M; Mito, JK; Eward, WC; Brigman, BE; Ma, Y; Dodd, L; Kim, Y; Lev, D; Kirsch, DG				Dodd, R. D.; Sachdeva, M.; Mito, J. K.; Eward, W. C.; Brigman, B. E.; Ma, Y.; Dodd, L.; Kim, Y.; Lev, D.; Kirsch, D. G.			Myogenic transcription factors regulate pro-metastatic miR-182	ONCOGENE			English	Article							MOUSE MODEL; SARCOMA; PAX7; NETWORKS; DISTINCT; GENES	Approximately 30% of patients with soft-tissue sarcoma die from pulmonary metastases. The mechanisms that drive sarcoma metastasis are not well understood. Recently, we identified miR-182 as a driver of sarcoma metastasis in a primary mouse model of soft-tissue sarcoma. We also observed elevated miR-182 in a subset of primary human sarcomas that metastasized to the lungs. Here, we show that myogenic differentiation factors regulate miR-182 levels to contribute to metastasis in mouse models. We find that MyoD directly binds the miR-182 promoter to increase miR-182 expression. Furthermore, mechanistic studies revealed that Pax7 can promote sarcoma metastasis in vivo through MyoD-dependent regulation of pro-metastatic miR-182. Taken together, these results suggest that sarcoma metastasis can be partially controlled through Pax7/MyoD-dependent activation of miR-182 and provide insight into the role that myogenic transcription factors have in sarcoma progression.	[Dodd, R. D.; Sachdeva, M.; Ma, Y.; Kirsch, D. G.] Duke Univ, Med Ctr, Dept Radiat Oncol, Box 91006, Durham, NC 27708 USA; [Mito, J. K.; Kirsch, D. G.] Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27708 USA; [Eward, W. C.; Brigman, B. E.] Duke Univ, Med Ctr, Dept Orthopaed Surg, Durham, NC 27708 USA; [Dodd, L.] Univ N Carolina, Dept Pathol, Chapel Hill, NC USA; [Kim, Y.] Seoul Natl Univ, Coll Vet Med, Dept Clin Pathol, Seoul, South Korea; [Lev, D.] Univ Texas MD Anderson Canc Ctr, Sarcoma Res Ctr, Houston, TX 77030 USA	Duke University; Duke University; Duke University; University of North Carolina; University of North Carolina Chapel Hill; Seoul National University (SNU); University of Texas System; UTMD Anderson Cancer Center	Kirsch, DG (corresponding author), Duke Univ, Med Ctr, Dept Radiat Oncol, Box 91006, Durham, NC 27708 USA.	david.kirsch@duke.edu		Dodd, Rebecca/0000-0001-7295-1882	American Cancer Society/Canary Foundation; Children's Tumor Foundation; QuadW/AACR; SARC SPORE pilot project [5U54 CA 168512-02];  [RO1 CA 138265]; NATIONAL CANCER INSTITUTE [R01CA138265] Funding Source: NIH RePORTER	American Cancer Society/Canary Foundation(American Cancer Society); Children's Tumor Foundation; QuadW/AACR; SARC SPORE pilot project; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Ron Dephino (MD Anderson) for providing the Ink4a/Arf flox mice, Tyler Jacks (MIT) for the LSL-Kras mice, and Anton Berns (Netherlands Cancer Institute) for the p53 flox mice. We thank Michael Rudnicki for the Pax7-FLAG tagged vectors. We thank Laura Jeffords, Rafaela Rodrigues, and Loretta Woodleif for assistance with mouse work. RDD is supported by postdoctoral fellowships from the American Cancer Society/Canary Foundation and the Children's Tumor Foundation. MS is supported by a postdoctoral fellowship from the QuadW/AACR. This work is supported by RO1 CA 138265 (DGK) and a SARC SPORE pilot project 5U54 CA 168512-02 (DKG and RDD).	Blum JM, 2013, CELL REP, V5, P933, DOI 10.1016/j.celrep.2013.10.020; Borden EC, 2003, CLIN CANCER RES, V9, P1941; Buckingham M, 2007, ANNU REV CELL DEV BI, V23, P645, DOI 10.1146/annurev.cellbio.23.090506.123438; Buckingham M, 2014, DEV CELL, V28, P225, DOI 10.1016/j.devcel.2013.12.020; Canter RJ, 2007, CANCER, V110, P2050, DOI 10.1002/cncr.23023; Cheung TH, 2012, NATURE, V482, P524, DOI 10.1038/nature10834; Dodd RD, 2010, DIS MODEL MECH, V3, P557, DOI 10.1242/dmm.005223; Eisinger-Mathason TSK, 2013, CANCER DISCOV, V3, P1190, DOI 10.1158/2159-8290.CD-13-0118; Fletcher CDM, 2001, J CLIN ONCOL, V19, P3045, DOI 10.1200/JCO.2001.19.12.3045; Gibbons DL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005401; Heitzer E, 2013, GENOME MED, V5, DOI 10.1186/gm434; Hu P, 2008, DEV CELL, V15, P534, DOI 10.1016/j.devcel.2008.08.018; Kassar-Duchossoy L, 2005, GENE DEV, V19, P1426, DOI 10.1101/gad.345505; Kimmelman AC, 2008, P NATL ACAD SCI USA, V105, P19372, DOI 10.1073/pnas.0809966105; Kirsch DG, 2007, NAT MED, V13, P992, DOI 10.1038/nm1602; Liu WN, 2009, NAT MED, V15, P559, DOI 10.1038/nm.1944; McKinnell IW, 2008, NAT CELL BIOL, V10, P77, DOI 10.1038/ncb1671; Mito JK, 2013, J PATHOL, V229, P132, DOI 10.1002/path.4099; Mito JK, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008075; Nguyen DX, 2007, NAT REV GENET, V8, P341, DOI 10.1038/nrg2101; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Relaix F, 2006, J CELL BIOL, V172, P91, DOI 10.1083/jcb.200508044; Rubin BP, 2011, CANCER CELL, V19, P177, DOI 10.1016/j.ccr.2010.12.023; Sachdeva M, 2014, J CLIN INVEST, V124, P4305, DOI 10.1172/JCI77116; Salazar R, 2011, J CLIN ONCOL, V29, P17, DOI 10.1200/JCO.2010.30.1077; Soleimani VD, 2012, DEV CELL, V22, P1208, DOI 10.1016/j.devcel.2012.03.014; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Yachida S, 2010, NATURE, V467, P1114, DOI 10.1038/nature09515	29	16	16	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2016	35	14					1868	1875		10.1038/onc.2015.252	http://dx.doi.org/10.1038/onc.2015.252			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DI6LM	26234681	Green Accepted, Green Submitted			2022-12-17	WOS:000373610400012
J	Friedmann-Morvinski, D; Bhargava, V; Gupta, S; Verma, IM; Subramaniam, S				Friedmann-Morvinski, D.; Bhargava, V.; Gupta, S.; Verma, I. M.; Subramaniam, S.			Identification of therapeutic targets for glioblastoma by network analysis	ONCOGENE			English	Article							PLURIPOTENT STEM-CELLS; GENE-EXPRESSION; TUMOR-GROWTH; OSTEOPONTIN; CANCER; MICE; DEDIFFERENTIATION; PROGNOSIS; SURVIVAL; TISSUE	Glioblastoma can originate from terminally differentiated astrocytes and neurons, which can dedifferentiate to a stem cell-like state upon transformation. In this study, we confirmed that transformed dedifferentiated astrocytes and neurons acquired a stem/progenitor cell state, although they still retained gene expression memory from their parental cell. Transcriptional network analysis on these cells identified upregulated genes in three main pathways: Wnt signaling, cell cycle and focal adhesion with the gene Spp1, also known as osteopontin (OPN) serving as a key common node connecting these three pathways. Inhibition of OPN blocked the formation of neurospheres, affected the proliferative capacity of transformed neurons and reduced the expression levels of neural stem cell markers. Specific inhibition of OPN in both murine and human glioma tumors prolonged mice survival. We conclude that OPN is an important player in dedifferentiation of cells during tumor formation, hence its inhibition can be a therapeutic target for glioblastoma.	[Friedmann-Morvinski, D.; Verma, I. M.] Salk Inst Biol Studies, Genet Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA; [Friedmann-Morvinski, D.] Tel Aviv Univ, George S Wise Fac Life Sci, Dept Biochem & Mol Biol, IL-69978 Tel Aviv, Israel; [Bhargava, V.; Subramaniam, S.] Univ Calif San Diego, Bioinformat & Syst Biol Grad Program, San Diego, CA 92103 USA; [Gupta, S.; Subramaniam, S.] Univ Calif San Diego, Dept Bioengn, San Diego, CA 92103 USA; [Subramaniam, S.] Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; [Subramaniam, S.] Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	Salk Institute; Tel Aviv University; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Verma, IM (corresponding author), Salk Inst Biol Studies, Genet Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.; Subramaniam, S (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA.; Subramaniam, S (corresponding author), Univ Calif San Diego, Dept Cellular & Mol Med, Dept Bioengn, La Jolla, CA 92093 USA.	verma@salk.edu; shankar@ucsd.edu			NIH [HL053670]; Cancer Center Core Grant [P30 CA014195-38]; H.N. and Frances C. Berger Foundation; Leona M. and Harry B. Helmsley Charitable Trust grant [2012-PG-MED002]; National Institutes of Health (NIH) National Heart, Lung and Blood Institute [HL087375, HL106579, HL108735]; National Science Foundation (NSF) [DBI-0835541, STC-0939370]; California Institute for Regenerative Medicine (CIRM) Graduate Fellowship [T1-00003, TG2-01154]; NATIONAL CANCER INSTITUTE [P30CA023100, P30CA014195] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL108735, R01HL106579, R01HL053670, R33HL087375] Funding Source: NIH RePORTER; Direct For Biological Sciences [0835541] Funding Source: National Science Foundation	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Center Core Grant; H.N. and Frances C. Berger Foundation; Leona M. and Harry B. Helmsley Charitable Trust grant; National Institutes of Health (NIH) National Heart, Lung and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Science Foundation (NSF)(National Science Foundation (NSF)); California Institute for Regenerative Medicine (CIRM) Graduate Fellowship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Direct For Biological Sciences(National Science Foundation (NSF)NSF - Directorate for Biological Sciences (BIO))	We thank Gabriela Estepa for her technical help and Ruben Alvarez Rodriguez for designing the inducible miRNA lentivector. IMV is an American Cancer Society Professor of Molecular Biology, and holds the Irwin and Joan Jacobs Chair in Exemplary Life Science. This work was supported in part by grants from the NIH (HL053670) (to IM Verma and D Friedmann-Morvinski), Cancer Center Core Grant (P30 CA014195-38), the H.N. and Frances C. Berger Foundation, and the Leona M. and Harry B. Helmsley Charitable Trust grant #2012-PG-MED002 (to IM Verma). S Subramaniam is supported by National Institutes of Health (NIH) National Heart, Lung and Blood Institute Grant HL087375, HL106579, HL108735, the National Science Foundation (NSF) grants DBI-0835541 and STC-0939370. V Bhargava was the recipient of a California Institute for Regenerative Medicine (CIRM) Graduate Fellowship (T1-00003 and TG2-01154, Interdisciplinary Stem Cell Training Program at UCSD). Accession Code. Gene Expression Omnibus: GSE64411 (sequencing read data).	Atai NA, 2011, IMMUNOLOGY, V132, P39, DOI 10.1111/j.1365-2567.2010.03335.x; Bache M, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-132; Bachoo RM, 2002, CANCER CELL, V1, P269, DOI 10.1016/S1535-6108(02)00046-6; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Bhargava V, 2014, SCI REP-UK, V4, DOI 10.1038/srep03678; Bhargava V, 2013, SCI REP-UK, V3, DOI 10.1038/srep01740; Cahoy JD, 2008, J NEUROSCI, V28, P264, DOI 10.1523/JNEUROSCI.4178-07.2008; Chaffer CL, 2013, CELL, V154, P61, DOI 10.1016/j.cell.2013.06.005; Chatr-aryamontri A, 2013, NUCLEIC ACIDS RES, V41, pD816, DOI 10.1093/nar/gks1158; Chin MH, 2009, CELL STEM CELL, V5, P111, DOI 10.1016/j.stem.2009.06.008; Denhardt DT, 2001, J CLIN INVEST, V107, P1055, DOI 10.1172/JCI12980; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; Friedmann-Morvinski D, 2014, EMBO REP, V15, P244, DOI 10.1002/embr.201338254; Friedmann-Morvinski D, 2012, SCIENCE, V338, P1080, DOI 10.1126/science.1226929; Ghosh Z, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008975; Holland JD, 2013, CURR OPIN CELL BIOL, V25, P254, DOI 10.1016/j.ceb.2013.01.004; Ikawa M, 2003, MOL THER, V8, P666, DOI 10.1016/S1525-0016(03)00240-5; Ischenko I, 2013, P NATL ACAD SCI USA, V110, P3937, DOI 10.1073/pnas.1219592110; Jain N, 2003, BIOINFORMATICS, V19, P1945, DOI 10.1093/bioinformatics/btg264; Jan HJ, 2010, NEURO-ONCOLOGY, V12, P58, DOI 10.1093/neuonc/nop013; Katagiri YU, 1999, CANCER RES, V59, P219; Lamour V, 2010, INT J CANCER, V126, P1797, DOI 10.1002/ijc.24751; Langmead Ben, 2010, Curr Protoc Bioinformatics, VChapter 11, DOI 10.1002/0471250953.bi1107s32; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602; Marchetto MCN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007076; Mason CK, 2008, MOL CANCER THER, V7, P548, DOI 10.1158/1535-7163.MCT-07-2251; Matys V, 2003, NUCLEIC ACIDS RES, V31, P374, DOI 10.1093/nar/gkg108; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MEYERFRANKE A, 1995, NEURON, V15, P805, DOI 10.1016/0896-6273(95)90172-8; Ohi Y, 2011, NAT CELL BIOL, V13, P541, DOI 10.1038/ncb2239; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Pietras A, 2014, CELL STEM CELL, V14, P357, DOI 10.1016/j.stem.2014.01.005; Polakis P, 2000, GENE DEV, V14, P1837; Polakis P, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008052; Rangaswami H, 2006, TRENDS CELL BIOL, V16, P79, DOI 10.1016/j.tcb.2005.12.005; Schwitalla S, 2013, CELL, V152, P25, DOI 10.1016/j.cell.2012.12.012; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Sreekanthreddy P, 2010, CANCER EPIDEM BIOMAR, V19, P1409, DOI 10.1158/1055-9965.EPI-09-1077; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Wai PY, 2004, J SURG RES, V121, P228, DOI 10.1016/j.jss.2004.03.028; Wang DD, 2008, PROG NEUROBIOL, V86, P342, DOI 10.1016/j.pneurobio.2008.09.015; Weber GF, 2001, BBA-REV CANCER, V1552, P61, DOI 10.1016/S0304-419X(01)00037-3; Weber GF, 1996, SCIENCE, V271, P509, DOI 10.1126/science.271.5248.509; Yamaguchi Y, 2013, J BIOL CHEM, V288, P3097, DOI 10.1074/jbc.M112.362954; Zhao WX, 2012, MOLECULES, V17, P6196, DOI 10.3390/molecules17066196; Zuber J, 2011, NAT BIOTECHNOL, V29, P79, DOI 10.1038/nbt.1720	48	16	16	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2016	35	5					608	620		10.1038/onc.2015.119	http://dx.doi.org/10.1038/onc.2015.119			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC9NR	25961929	Green Accepted			2022-12-17	WOS:000369548800008
J	Park, JM; Wu, T; Cyr, AR; Woodfield, GW; De Andrade, JP; Spanheimer, PM; Li, T; Sugg, SL; Lal, G; Domann, FE; Zhang, W; Weigel, RJ				Park, J. M.; Wu, T.; Cyr, A. R.; Woodfield, G. W.; De Andrade, J. P.; Spanheimer, P. M.; Li, T.; Sugg, S. L.; Lal, G.; Domann, F. E.; Zhang, W.; Weigel, R. J.			The role of Tcfap2c in tumorigenesis and cancer growth in an activated Neu model of mammary carcinogenesis	ONCOGENE			English	Article							TRANSCRIPTION FACTOR AP-2-GAMMA; PATHOLOGICAL COMPLETE RESPONSE; NEGATIVE BREAST-CANCER; FACTOR RECEPTOR; EXPRESSION PATTERNS; CELL-LINES; GENE; TUMORS; AP-2; OVEREXPRESSION	TFAP2C/AP-2 gamma influences development of the mammary gland and regulates patterns of gene expression in luminal and HER2-amplified breast cancer. The roles of TFAP2C in mammary gland tumorigenesis and in pathways critical to cancer progression remain poorly understood. To gain greater insight into oncogenic mechanisms regulated by TFAP2C, we examined mammary tumorigenesis in MMTV-Neu transgenic female mice with or without conditional knockout (KO) of Tcfap2c, the mouse homolog of TFAP2C. Loss of Tcfap2c increased the latency of tumorigenesis and tumors that formed demonstrated reduced proliferative index and increased apoptosis. In addition, tumors formed in Tcfap2c KO animals had a significant reduction in Egfr levels without a change in the expression of the Neu oncogene. The MMneu-flAP2C cell line was established from tumor tissue derived from MMTV-Neu/Tcfap2c(L/L) control animals and parallel cell lines with and without expression of Tcfap2c were created by transduction with adenovirus-empty and adenovirus-Cre, respectively. KO of Tcfap2c in vitro reduced activated phosphorylated-Erk, decreased cell viability, repressed tumor growth and was associated with attenuation of Egfr expression. Chromatin immunoprecipitation and direct sequencing and expression analysis confirmed that Egfr was a Tcfap2c target gene in murine, as well as human, mammary carcinoma cells. Furthermore, decreased viability of mammary cancer cells was directly related to Egfr functional blockade. We conclude that TFAP2C regulates tumorigenesis, cell growth and survival in HER2-amplified breast cancer through transcriptional regulation of EGFR. The findings have important implications for targeting the EGFR pathway in breast cancer.	[Park, J. M.; Wu, T.; Cyr, A. R.; Woodfield, G. W.; De Andrade, J. P.; Spanheimer, P. M.; Sugg, S. L.; Lal, G.; Domann, F. E.; Weigel, R. J.] Univ Iowa, Dept Surg, Iowa City, IA 52242 USA; [Park, J. M.; Weigel, R. J.] Univ Iowa, Dept Anat & Cell Biol, Iowa City, IA 52242 USA; [Li, T.] Washington Univ, Genome Inst, St Louis, MO USA; [Domann, F. E.] Univ Iowa, Dept Radiat Oncol, Iowa City, IA 52242 USA; [Domann, F. E.; Zhang, W.] Univ Iowa, Dept Pathol, Iowa City, IA 52242 USA; [Weigel, R. J.] Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; Washington University (WUSTL); University of Iowa; University of Iowa; University of Iowa	Weigel, RJ (corresponding author), Univ Iowa, Dept Surg, 200 Hawkins Dr,1516 JCP, Iowa City, IA 52242 USA.	Ronald-Weigel@uiowa.edu	Li, Tiandao/F-4039-2012	Li, Tiandao/0000-0003-1650-0555; Lal, Geeta/0000-0001-6471-6479; De Andrade, James/0000-0001-7357-9322; Sugg, Sonia/0000-0001-7530-8526; Weigel, Ronald/0000-0002-9249-0793; Domann, Frederick/0000-0002-0489-2179	National Institutes of Health [R01CA109294, T32CA148062]; NATIONAL CANCER INSTITUTE [R01CA109294, T32CA078586, R01CA115438, T32CA148062, K08CA151658, R00CA158055] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007337] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Alicia Olivier from University of Iowa Pathology Core Lab for her assistance in IHC. This work was supported by the National Institutes of Health grants R01CA109294 (PI: RJW), T32CA148062 (PI: RJW) and by a generous gift from the Kristen Olewine Milke Breast Cancer Research Fund.	Allouche A, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1851; Auman HJ, 2002, DEVELOPMENT, V129, P2733; Balko JM, 2012, P NATL ACAD SCI USA, V109, P221, DOI 10.1073/pnas.1115802109; Bertucci F, 2012, CURR MOL MED, V12, P96, DOI 10.2174/156652412798376134; Bogachek MV, 2014, CANCER CELL, V25, P748, DOI 10.1016/j.ccr.2014.04.008; Bos M, 1997, CLIN CANCER RES, V3, P2099; Bosher JM, 1996, ONCOGENE, V13, P1701; Bria E, 2014, CANCER TREAT REV, V40, P847, DOI 10.1016/j.ctrv.2014.05.001; Carey LA, 2006, JAMA-J AM MED ASSOC, V295, P2492, DOI 10.1001/jama.295.21.2492; Corkery B, 2009, ANN ONCOL, V20, P862, DOI 10.1093/annonc/mdn710; Cyr AR, 2015, ONCOGENE, V34, P436, DOI 10.1038/onc.2013.569; DeFazio-Eli L, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2866; Delacroix L, 2005, DNA CELL BIOL, V24, P582, DOI 10.1089/dna.2005.24.582; Friedrichs N, 2007, HISTOPATHOLOGY, V51, P814, DOI 10.1111/j.1365-2559.2007.02887.x; He AL, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-279; Huang SX, 2008, NEOPLASIA, V10, P118, DOI 10.1593/neo.07637; Jager R, 2010, DEV DYNAM, V239, P1027, DOI 10.1002/dvdy.22239; Jager R, 2005, BREAST CANCER RES TR, V90, P273, DOI 10.1007/s10549-004-4815-x; Jager R, 2003, MOL CANCER RES, V1, P921; Kao J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006146; Kulak MV, 2013, ONCOGENE, V32, P4043, DOI 10.1038/onc.2012.400; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; Linggi B, 2006, TRENDS CELL BIOL, V16, P649, DOI 10.1016/j.tcb.2006.10.008; Masuda H, 2012, BREAST CANCER RES TR, V136, P331, DOI 10.1007/s10549-012-2289-9; MELLENTINMICHELOTTI J, 1994, J BIOL CHEM, V269, P31983; Molyneux G, 2010, CELL STEM CELL, V7, P403, DOI 10.1016/j.stem.2010.07.010; Nieto Y, 2007, J CLIN ONCOL, V25, P4405, DOI 10.1200/JCO.2006.09.8822; Pegram MD, 1998, BREAST CANCER RES TR, V52, P65, DOI 10.1023/A:1006111117877; Pellikainen J, 2004, EUR J CANCER, V40, P1485, DOI 10.1016/j.ejca.2004.02.020; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Sale S, 2013, NAT CELL BIOL, V15, P451, DOI 10.1038/ncb2725; Shiu KK, 2014, ONCOGENE, V33, P619, DOI 10.1038/onc.2012.625; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Spanheimer PM, 2013, J SURG RES, V184, P519, DOI 10.1016/j.jss.2013.04.042; Turner BC, 1998, CANCER RES, V58, P5466; Visvader JE, 2009, GENE DEV, V23, P2563, DOI 10.1101/gad.1849509; Wagner KU, 2013, ONCOGENE, V32, P1338, DOI 10.1038/onc.2012.452; Wang X, 2006, J CELL BIOL, V172, P409, DOI 10.1083/jcb.200510002; Wood ER, 2004, CANCER RES, V64, P6652, DOI 10.1158/0008-5472.CAN-04-1168; Woodfield GW, 2007, CANCER RES, V67, P8439, DOI 10.1158/0008-5472.CAN-07-2293; Woodfield GW, 2010, GENE CHROMOSOME CANC, V49, P948, DOI 10.1002/gcc.20807; Zhang J, 2003, DEV BIOL, V256, P127, DOI 10.1016/S0012-1606(02)00119-7	42	16	17	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 10	2015	34	50					6105	6114		10.1038/onc.2015.59	http://dx.doi.org/10.1038/onc.2015.59			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CY0RQ	25772240	Green Accepted			2022-12-17	WOS:000366113800007
J	Zhang, H; Hu, L; Qiu, W; Deng, T; Zhang, Y; Bergholz, J; Xiao, ZX				Zhang, H.; Hu, L.; Qiu, W.; Deng, T.; Zhang, Y.; Bergholz, J.; Xiao, Z-X			MDMX exerts its oncogenic activity via suppression of retinoblastoma protein	ONCOGENE			English	Article							TUMOR-SUPPRESSOR; MOLECULAR-BASIS; P53 ACTIVITY; DOMAIN; INACTIVATION; CANCER; PHOSPHORYLATION; UBIQUITINATION; MECHANISMS; CELLS	Inactivation of the retinoblastoma protein (RB) has a major role in the development of human malignancies. We have previously shown that MDM2, an ubiquitin E3 ligase and major negative regulator of p53, binds to and promotes proteasome-mediated degradation of RB. MDMX, a homolog of MDM2, also binds to and inhibits p53 transactivation activity, yet it does not possess intrinsic ubiquitin ligase activity. Here, we show that MDMX binds to and promotes RB degradation in an MDM2-dependent manner. Specifically, the MDMX C-terminal ring domain binds to the RB C-pocket and enhances MDM2-RB interaction. Silencing MDMX induces RB accumulation, cell cycle arrest and senescence-like phenotypes, which are reverted by simultaneous RB knockdown. Furthermore, MDMX ablation leads to significant retardation of xenograft tumor growth, concomitant with RB accumulation. These results demonstrate that MDMX exerts oncogenic activity via suppression of RB, and suggest that both MDM2 and MDMX could be chemotherapeutic targets.	[Zhang, H.; Hu, L.; Deng, T.; Zhang, Y.; Bergholz, J.; Xiao, Z-X] Sichuan Univ, Ctr Growth Metab & Aging, Key Lab Bioresource & Ecoenvironm, Minist Educ,Coll Life Sci, Chengdu 610014, Peoples R China; [Zhang, H.; Hu, L.; Deng, T.; Zhang, Y.; Bergholz, J.; Xiao, Z-X] Sichuan Univ, State Key Lab Biotherapy, Chengdu 610014, Peoples R China; [Qiu, W.; Xiao, Z-X] Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA	Sichuan University; Sichuan University; Boston University	Xiao, ZX (corresponding author), Sichuan Univ, Ctr Growth Metab & Aging, Key Lab Bioresource & Ecoenvironm, Minist Educ,Coll Life Sci, Chengdu 610014, Peoples R China.	jimzx@scu.edu.cn	zhang, haibo/K-5146-2019		National Key Basic Research Program (973 Program) of China [2012CB910700]; National Natural Science Foundation of China (NSFC) [81330054, 31171362]; NSFC [31350110216]	National Key Basic Research Program (973 Program) of China(National Basic Research Program of China); National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); NSFC(National Natural Science Foundation of China (NSFC))	We thank Dr Scott Lowe (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA) for kindly providing short hairpin RNA plasmids against human RB. This work was supported by the National Key Basic Research Program (973 Program) of China (2012CB910700) and National Natural Science Foundation of China (NSFC) grant (81330054 and 31171362) to Z-XX, and NSFC grant (31350110216) to JB.	Avni D, 2003, MOL CELL, V12, P735, DOI 10.1016/S1097-2765(03)00355-1; Bottger V, 1999, ONCOGENE, V18, P189, DOI 10.1038/sj.onc.1202281; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Burkhart DL, 2008, NAT REV CANCER, V8, P671, DOI 10.1038/nrc2399; Cicchillitti L, 2003, J BIOL CHEM, V278, P19509, DOI 10.1074/jbc.M300511200; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; CORDONCARDO C, 1994, CANCER RES, V54, P794; Di Fiore R, 2013, J CELL PHYSIOL, V228, P1676, DOI 10.1002/jcp.24329; Dick FA, 2013, NAT REV MOL CELL BIO, V14, P297, DOI 10.1038/nrm3567; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Giacinti C, 2006, ONCOGENE, V25, P5220, DOI 10.1038/sj.onc.1209615; Gu JJ, 2002, J BIOL CHEM, V277, P19251, DOI 10.1074/jbc.C200150200; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Henley SA, 2012, CELL DIV, V7, DOI 10.1186/1747-1028-7-10; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Huang L, 2011, P NATL ACAD SCI USA, V108, P12001, DOI 10.1073/pnas.1102309108; Jin Y, 2008, MOL CELL BIOL, V28, P1218, DOI 10.1128/MCB.01198-07; Kato MV, 1996, CANCER LETT, V106, P75, DOI 10.1016/0304-3835(96)04305-4; Kawai H, 2007, CANCER RES, V67, P6026, DOI 10.1158/0008-5472.CAN-07-1313; Kruse JP, 2009, CELL, V137, P609, DOI 10.1016/j.cell.2009.04.050; Laurie NA, 2006, NATURE, V444, P61, DOI 10.1038/nature05194; Lee C, 2002, GENE DEV, V16, P3199, DOI 10.1101/gad.1046102; Linares LK, 2003, P NATL ACAD SCI USA, V100, P12009, DOI 10.1073/pnas.2030930100; Linke K, 2008, CELL DEATH DIFFER, V15, P841, DOI 10.1038/sj.cdd.4402309; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; Marine JC, 2006, CELL DEATH DIFFER, V13, P927, DOI 10.1038/sj.cdd.4401912; Marine JC, 2010, CELL DEATH DIFFER, V17, P93, DOI 10.1038/cdd.2009.68; Okamoto K, 2009, FEBS LETT, V583, P2710, DOI 10.1016/j.febslet.2009.07.021; Pant V, 2011, P NATL ACAD SCI USA, V108, P11995, DOI 10.1073/pnas.1102241108; Reinke V, 1997, RADIAT RES, V148, P115, DOI 10.2307/3579567; Sdek P, 2005, MOL CELL, V20, P699, DOI 10.1016/j.molcel.2005.10.017; Sdek P, 2004, J BIOL CHEM, V279, P53317, DOI 10.1074/jbc.M406062200; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sharp DA, 1999, J BIOL CHEM, V274, P38189, DOI 10.1074/jbc.274.53.38189; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Suda T, 2011, ONCOL REP, V26, P49, DOI 10.3892/or.2011.1270; Tanimura S, 1999, FEBS LETT, V447, P5, DOI 10.1016/S0014-5793(99)00254-9; Thomas DM, 2003, CANCER BIOL THER, V2, P124, DOI 10.4161/cbt.2.2.235; Uchida C, 2006, FEBS LETT, V580, P1753, DOI 10.1016/j.febslet.2006.02.029; Wade M, 2013, NAT REV CANCER, V13, P83, DOI 10.1038/nrc3430; Wade M, 2009, MOL CANCER RES, V7, P1, DOI 10.1158/1541-7786.MCR-08-0423; WATANABE T, 1994, BLOOD, V84, P3158; Wu L, 1997, MOL MED, V3, P441, DOI 10.1007/BF03401691; Wunderlich M, 2004, CELL CYCLE, V3, P472; Xiao B, 2003, P NATL ACAD SCI USA, V100, P2363, DOI 10.1073/pnas.0436813100; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738	47	16	17	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 29	2015	34	44					5560	5569		10.1038/onc.2015.11	http://dx.doi.org/10.1038/onc.2015.11			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CV9FX	25703327				2022-12-17	WOS:000364594000005
J	Lecointre, C; Desrues, L; Joubert, JE; Perzo, N; Guichet, PO; Le Joncour, V; Brule, C; Chabbert, M; Leduc, R; Prezeau, L; Laquerriere, A; Proust, F; Gandolfo, P; Morin, F; Castel, H				Lecointre, C.; Desrues, L.; Joubert, J. E.; Perzo, N.; Guichet, P-O; Le Joncour, V.; Brule, C.; Chabbert, M.; Leduc, R.; Prezeau, L.; Laquerriere, A.; Proust, F.; Gandolfo, P.; Morin, F.; Castel, H.			Signaling switch of the urotensin II vasosactive peptide GPCR: prototypic chemotaxic mechanism in glioma	ONCOGENE			English	Article							PROTEIN-COUPLED RECEPTORS; CANCER CELL-MIGRATION; EXTRACELLULAR-MATRIX; CEREBROSPINAL-FLUID; ENDOTHELIAL-CELLS; MALIGNANT GLIOMAS; ORPHAN RECEPTOR; IN-VITRO; EXPRESSION; ACTIVATION	Multiform glioblastomas (GBM) are the most frequent and aggressive primary brain tumors in adults. The poor prognosis is due to neo-angiogenesis and cellular invasion, processes that require complex chemotaxic mechanisms involving motility, migration and adhesion. Understanding these different cellular events implies identifying receptors and transduction pathways that lead to and promote either migration or adhesion. Here we establish that glioma express the vasoactive peptide urotensin II (UII) and its receptor UT and that UT-mediated signaling cascades are involved in glioma cell migration and adhesion. Components of the urotensinergic systems, UII and UT, are widely expressed in patient-derived GBM tissue sections, glioma cell lines and fresh biopsy explants. Interestingly, gradient concentrations of UII produced chemoattracting migratory/motility effects in glioma as well as HEK293 cells expressing human UT. These effects mainly involved the G(13)/Rho/rho kinase pathway while partially requiring G(i/o)/PI3K components. In contrast, we observed that homogeneous concentrations of UII drastically blocked cell motility and stimulated cell-matrix adhesions through a UT/G(i/o) signaling cascade, partially involving phosphatidylinositol-3 kinase. Finally, we provide evidence that, in glioma cells, homogeneous concentration of UII allowed translocation of G(alpha 13) to the UT receptor at the plasma membrane and increased actin stress fibers, lamellipodia formation and vinculin-stained focal adhesions. UII also provoked a re-localization of UT precoupled to G(alpha i) in filipodia and initiated integrin-stained focal points. Altogether, these findings suggest that UT behaves as a chemotaxic receptor, relaying a signaling switch between directional migration and cell adhesion under gradient or homogeneous concentrations, thereby redefining sequential mechanisms affecting tumor cells during glioma invasion. Taken together, our results allow us to propose a model in order to improve the design of compounds that demonstrate signaling bias for therapies that target specifically the G(i/o) signaling pathway.	[Lecointre, C.; Desrues, L.; Joubert, J. E.; Perzo, N.; Guichet, P-O; Le Joncour, V.; Proust, F.; Gandolfo, P.; Morin, F.; Castel, H.] Univ Rouen, Lab Neuronal & Neuroendocrine Commun & Differenti, Biomed Res Inst IRIB, Inserm,U982,DC2N,Astrocyte & Vasc Niche,Network T, F-76821 Mont St Aignan, France; [Perzo, N.; Brule, C.; Leduc, R.] Univ Sherbrooke, Fac Med & Sci Sante, Inst Pharmacol, Dept Pharmacol, Sherbrooke, PQ J1K 2R1, Canada; [Brule, C.; Prezeau, L.] Univ Montpellier 1 & 2, Inst Funct Genom, IGF, CNRS,UMR 5203,Inserm,U661, Montpellier, France; [Chabbert, M.] Fac Med 3, UMR CNRS 6214, Inserm 1083, Angers, France; [Laquerriere, A.] CHU Rouen, Serv Anatomocytopathol, INSERM, ERI28, Rouen, France; [Proust, F.] CHU Rouen, Serv Neurosurg, Rouen, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rouen Normandie; University of Sherbrooke; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite d'Angers; CHU de Rouen; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Rouen	Castel, H (corresponding author), Univ Rouen, Lab Neuronal & Neuroendocrine Commun & Differenti, Biomed Res Inst IRIB, Inserm,U982,DC2N,Astrocyte & Vasc Niche,Network T, F-76821 Mont St Aignan, France.	helene.castel@univ-rouen.fr	castel, helene/B-8675-2009; Le Joncour, Vadim/X-6274-2019	castel, helene/0000-0002-8972-5555; Le Joncour, Vadim/0000-0001-8153-8563; Guichet, Pierre-Olivier/0000-0003-0115-2199; Morin, Fabrice/0000-0001-6785-1967	CIHR (Canadian Institutes of Health Research); Inserm; Gefluc; TC2N network; LARC Neuroscience; Institute on Innovative and Biomedical Research (IRIB), The University of Rouen; Haute-Normandy or French ministry	CIHR (Canadian Institutes of Health Research)(Canadian Institutes of Health Research (CIHR)); Inserm(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Gefluc; TC2N network; LARC Neuroscience; Institute on Innovative and Biomedical Research (IRIB), The University of Rouen; Haute-Normandy or French ministry	We thank Mme Marie-Therese Schouft for her expertise in cytometry, the PRIMACEN platform (University of Rouen, France) for imaging equipments and Mr Arnaud Arabo and Mrs Huguette Lemonnier for skillful technical assistance. This work was supported by a CIHR (Canadian Institutes of Health Research) grant to RL and by Inserm, Gefluc, TC2N network, LARC Neuroscience and Institute on Innovative and Biomedical Research (IRIB), The University of Rouen. CL, VL, J-EJ and P-OG were recipients of a fellowship from the Haute-Normandy or French ministry.	Ames RS, 1999, NATURE, V401, P282, DOI 10.1038/45809; Ayoub MA, 2007, MOL PHARMACOL, V71, P1329, DOI 10.1124/mol.106.030304; Baneres JL, 2003, J MOL BIOL, V329, P801, DOI 10.1016/S0022-2836(03)00438-8; Bartolome RA, 2008, CANCER RES, V68, P8221, DOI 10.1158/0008-5472.CAN-08-0561; Bian D, 2006, ONCOGENE, V25, P2234, DOI 10.1038/sj.onc.1209261; BOCCHINI V, 1991, CELL TISSUE RES, V265, P73, DOI 10.1007/BF00318141; Brat DJ, 2004, CANCER RES, V64, P920, DOI 10.1158/0008-5472.CAN-03-2073; Brule C, 2014, FASEB J, V28, P5148, DOI 10.1096/fj.14-249771; Castel H, 2006, J NEUROCHEM, V99, P582, DOI 10.1111/j.1471-4159.2006.04130.x; Cirillo P, 2008, J THROMB HAEMOST, V6, P726, DOI 10.1111/j.1538-7836.2008.02923.x; Coulouarn Y, 1998, P NATL ACAD SCI USA, V95, P15803, DOI 10.1073/pnas.95.26.15803; Cowley E, 2005, BRIT J ANAESTH, V95, P495, DOI 10.1093/bja/aei222; Daher Z, 2008, CELL SIGNAL, V20, P2256, DOI 10.1016/j.cellsig.2008.08.021; Desrues L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036319; Dorsam RT, 2007, NAT REV CANCER, V7, P79, DOI 10.1038/nrc2069; Federico A, 2014, EUR J CLIN INVEST, V44, P285, DOI 10.1111/eci.12231; Filipeanu CM, 2002, J NEUROCHEM, V83, P879, DOI 10.1046/j.1471-4159.2002.01196.x; Franco R, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/1756-9966-33-48; Giese A, 2003, J CLIN ONCOL, V21, P1624, DOI 10.1200/JCO.2003.05.063; Glodek AM, 2003, J EXP MED, V197, P461, DOI 10.1084/jem.20021477; Gould PS, 2010, HYPERTENSION, V56, P172, DOI 10.1161/HYPERTENSIONAHA.110.152074; Grieco P, 2011, J CELL BIOCHEM, V112, P341, DOI 10.1002/jcb.22933; Hotchin NA, 1995, J CELL BIOL, V131, P1857, DOI 10.1083/jcb.131.6.1857; Jarjour AA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025408; Jarry M, 2010, BIOCHEM J, V428, P113, DOI 10.1042/BJ20090867; Johnston ALM, 2007, PLOS BIOL, V5, P1723, DOI 10.1371/journal.pbio.0050212; Kenakin T, 1997, TRENDS PHARMACOL SCI, V18, P456, DOI 10.1016/S0165-6147(97)90683-0; Kirui JK, 2010, J PHARMACOL EXP THER, V333, P393, DOI 10.1124/jpet.109.164814; Lachance M, 1999, CELL SIGNAL, V11, P523, DOI 10.1016/S0898-6568(99)00024-8; Lin YZ, 2003, HYPERTENS RES, V26, P839, DOI 10.1291/hypres.26.839; Lu DY, 2010, J CELL BIOCHEM, V110, P141, DOI 10.1002/jcb.22520; Manes S, 1999, EMBO J, V18, P6211, DOI 10.1093/emboj/18.22.6211; Matsusaka S, 2006, N-S ARCH PHARMACOL, V373, P381, DOI 10.1007/s00210-006-0086-x; Medeiros PJ, 2012, INT J CANCER, V131, P276, DOI 10.1002/ijc.26350; Mitra P, 2001, CELL SIGNAL, V13, P311, DOI 10.1016/S0898-6568(01)00156-5; Monterrubio M, 2009, BIOCHEM BIOPH RES CO, V388, P199, DOI 10.1016/j.bbrc.2009.07.153; Mori M, 1999, BIOCHEM BIOPH RES CO, V265, P123, DOI 10.1006/bbrc.1999.1640; Mugabe BE, 2010, J PHARMACOL EXP THER, V332, P116, DOI 10.1124/jpet.109.157552; MUNSHI R, 1991, J BIOL CHEM, V266, P22285; Nishikawa K, 2011, NEUROCHEM INT, V58, P261, DOI 10.1016/j.neuint.2010.11.013; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Nobles M, 2005, P NATL ACAD SCI USA, V102, P18706, DOI 10.1073/pnas.0504778102; Nothacker HP, 1999, NAT CELL BIOL, V1, P383, DOI 10.1038/14081; Panetti TS, 2000, ARTERIOSCL THROM VAS, V20, P1013, DOI 10.1161/01.ATV.20.4.1013; Perzelova A, 1998, NEOPLASMA, V45, P25; Proulx CD, 2008, MOL PHARMACOL, V74, P552, DOI 10.1124/mol.108.045054; Rempel SA, 2000, CLIN CANCER RES, V6, P102; Rossowski WJ, 2002, EUR J PHARMACOL, V438, P159, DOI 10.1016/S0014-2999(02)01341-9; Sauzeau V, 2001, CIRC RES, V88, P1102, DOI 10.1161/hh1101.092034; Segain JP, 2007, J IMMUNOL, V179, P901, DOI 10.4049/jimmunol.179.2.901; Shyu KG, 2012, EUR J CLIN INVEST, V42, P17, DOI 10.1111/j.1365-2362.2011.02549.x; Song W, 2006, N-S ARCH PHARMACOL, V373, P148, DOI 10.1007/s00210-006-0057-2; Stupp R, 2005, ANN ONCOL, V16, P64, DOI 10.1093/annonc/mdi834; Sugo T, 2003, BIOCHEM BIOPH RES CO, V310, P860, DOI 10.1016/j.bbrc.2003.09.102; Takahashi K, 2003, PEPTIDES, V24, P301, DOI 10.1016/S0196-9781(03)00039-1; Takahashi K, 2001, PEPTIDES, V22, P1175, DOI 10.1016/S0196-9781(01)00441-7; Tan WF, 2006, J BIOL CHEM, V281, P39542, DOI 10.1074/jbc.M609062200; Teicher BA, 2010, CLIN CANCER RES, V16, P2927, DOI 10.1158/1078-0432.CCR-09-2329; Thompson JP, 2003, ANESTH ANALG, V97, P1501, DOI 10.1213/01.ANE.0000086723.97421.BC; Totsune K, 2001, LANCET, V358, P810, DOI 10.1016/S0140-6736(01)06002-0; Tzanidis A, 2003, CIRC RES, V93, P246, DOI 10.1161/01.RES.0000084382.64418.BC; Wang SC, 2012, LAB INVEST, V92, P151, DOI 10.1038/labinvest.2011.128; Watson AMD, 2013, DIABETOLOGIA, V56, P1155, DOI 10.1007/s00125-013-2837-9; Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126; Wu YQ, 2010, ONCOL REP, V24, P1179, DOI 10.3892/or_00000970; Xie Y, 2013, BIOCHEM PHARMACOL, V85, P1454, DOI 10.1016/j.bcp.2013.03.001; Xu SK, 2009, TOHOKU J EXP MED, V219, P283, DOI 10.1620/tjem.219.283; Yagi H, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2002221; Yamazaki F, 2005, BIOCHEM BIOPH RES CO, V332, P782, DOI 10.1016/j.bbrc.2005.05.023; Yi KH, 2012, PEPTIDES, V33, P87, DOI 10.1016/j.peptides.2011.11.016; Zagzag D, 2008, AM J PATHOL, V173, P545, DOI 10.2353/ajpath.2008.071197; Zagzag D, 2006, LAB INVEST, V86, P1221, DOI 10.1038/labinvest.3700482; Zhang YG, 2008, J HYPERTENS, V26, P1119, DOI 10.1097/HJH.0b013e3282fa1412; Zhang YG, 2011, PEPTIDES, V32, P2452, DOI 10.1016/j.peptides.2011.10.018; Zhou CH, 2012, ONCOL LETT, V4, P1259, DOI 10.3892/ol.2012.932; Ziltener P, 2002, J RECEPT SIGNAL TR R, V22, P155, DOI 10.1081/RRS-120014593	76	16	17	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	2015	34	39					5080	5094		10.1038/onc.2014.433	http://dx.doi.org/10.1038/onc.2014.433			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CR9RC	25597409				2022-12-17	WOS:000361693300008
J	Gerez, J; Tedesco, L; Bonfiglio, JJ; Fuertes, M; Barontini, M; Silberstein, S; Wu, Y; Renner, U; Paez-Pereda, M; Holsboer, F; Stalla, GK; Arzt, E				Gerez, J.; Tedesco, L.; Bonfiglio, J. J.; Fuertes, M.; Barontini, M.; Silberstein, S.; Wu, Y.; Renner, U.; Paez-Pereda, M.; Holsboer, F.; Stalla, G. K.; Arzt, E.			RSUME inhibits VHL and regulates its tumor suppressor function	ONCOGENE			English	Article							HYPOXIA-INDUCIBLE FACTOR; SUMO CONJUGATION; GENE-MUTATIONS; PROTEIN; SUMOYLATION; GROWTH; HIF; REQUIRES; BINDING; DEGRADATION	Somatic mutations or loss of von Hippel-Lindau (pVHL) happen in the majority of VHL disease tumors, which present a constitutively active Hypoxia Inducible Factor (HIF), essential for tumor growth. Recently described mechanisms for pVHL modulation shed light on the open question of the HIF/pVHL pathway regulation. The aim of the present study was to determine the molecular mechanism by which RSUME stabilizes HIFs, by studying RSUME effect on pVHL function and to determine the role of RSUME on pVHL-related tumor progression. We determined that RSUME sumoylates and physically interacts with pVHL and negatively regulates the assembly of the complex between pVHL, Elongins and Cullins (ECV), inhibiting HIF-1 and 2 alpha ubiquitination and degradation. We found that RSUME is expressed in human VHL tumors (renal clear-cell carcinoma (RCC), pheochromocytoma and hemangioblastoma) and by overexpressing or silencing RSUME in a pVHL-HIF-oxygen-dependent degradation stability reporter assay, we determined that RSUME is necessary for the loss of function of type 2 pVHL mutants. The functional RSUME/pVHL interaction in VHL-related tumor progression was further confirmed using a xenograft assay in nude mice. RCC clones, in which RSUME was knocked down and express either pVHL wt or type 2 mutation, have an impaired tumor growth, as well as HIF-2 alpha, vascular endothelial growth factor A and tumor vascularization diminution. This work shows a novel mechanism for VHL tumor progression and presents a new mechanism and factor for targeting tumor-related pathologies with pVHL/HIF altered function.	[Gerez, J.; Tedesco, L.; Bonfiglio, J. J.; Fuertes, M.; Silberstein, S.; Arzt, E.] Max Planck Gesell, Partner Inst, CONICET, Inst Invest Biomed Buenos Aires IBioBA, RA-2390 Buenos Aires, DF, Argentina; [Gerez, J.; Bonfiglio, J. J.; Silberstein, S.; Arzt, E.] Univ Buenos Aires, Fac Ciencias Exactas & Nat, Dept Fisiol & Biol Mol & Celular, Buenos Aires, DF, Argentina; [Barontini, M.] Hosp Ninos Dr Ricardo Gutierrez, Ctr Endocrinol Invest CEDIE, Buenos Aires, DF, Argentina; [Wu, Y.; Renner, U.; Paez-Pereda, M.; Holsboer, F.; Stalla, G. K.] Max Planck Inst Psychiat, Dept Clin Res, D-80804 Munich, Germany	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Max Planck Society; University of Buenos Aires; Hospital de Ninos Doctor Ricardo Gutierrez; University of Buenos Aires; Max Planck Society	Arzt, E (corresponding author), Max Planck Gesell, Partner Inst, CONICET, Inst Invest Biomed Buenos Aires IBioBA, C1425FQD, RA-2390 Buenos Aires, DF, Argentina.	earzt@ibioba-mpsp-conicet.gov.ar	Wu, Yonghe/N-2269-2019; Bonfiglio, Juan José/B-5853-2013	Wu, Yonghe/0000-0001-9667-8198; Bonfiglio, Juan José/0000-0001-7767-0799; Paez-Pereda, Marcelo/0000-0001-6029-0706	Argentinian Instituto Nacional del Cancer (INC); BungeBorn Foundation; Max Planck Society, Germany; University of Buenos Aires; CONICET; Agencia Nacional de Promocion Cientifica y Tecnologica, Argentina; FOCEM-Mercosur [COF 03/11]	Argentinian Instituto Nacional del Cancer (INC); BungeBorn Foundation; Max Planck Society, Germany(Max Planck Society); University of Buenos Aires(University of Buenos Aires); CONICET(Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)); Agencia Nacional de Promocion Cientifica y Tecnologica, Argentina(ANPCyT); FOCEM-Mercosur	We thank Sergio Senin, Maria Antunica Noguerol, Jimena Druker and Mariana Haedo for technical help. We also thank the Argentinian Instituto Nacional del Cancer (INC) and Bunge&Born Foundation for financial support to Lucas Tedesco and Juan Jose Bonfiglio, respectively. This work was supported by grants from the Max Planck Society, Germany; the University of Buenos Aires; CONICET; the Agencia Nacional de Promocion Cientifica y Tecnologica, Argentina and FOCEM-Mercosur (COF 03/11).	Bae SH, 2004, BIOCHEM BIOPH RES CO, V324, P394, DOI 10.1016/j.bbrc.2004.09.068; Bergmann TK, 2013, ACTA ONCOL, V52, P871, DOI 10.3109/0284186X.2012.707787; Berra E, 2007, METHOD ENZYMOL, V435, P107, DOI 10.1016/S0076-6879(07)35006-4; Brahimi-Horn MC, 2009, J CELL SCI, V122, P1055, DOI 10.1242/jcs.035022; Brooks SA, 2014, EUR UROL, V66, P77, DOI 10.1016/j.eururo.2014.02.035; Cai QL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009720; Carbia-Nagashima A, 2007, CELL, V131, P309, DOI 10.1016/j.cell.2007.07.044; Castro CP, 2003, ENDOCRINOLOGY, V144, P693, DOI 10.1210/en.2002-220891; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Cheng J, 2007, CELL, V131, P584, DOI 10.1016/j.cell.2007.08.045; Chien W, 2013, BRIT J CANCER, V109, P1795, DOI 10.1038/bjc.2013.531; Cimarosti H, 2008, NEUROPHARMACOLOGY, V54, P280, DOI 10.1016/j.neuropharm.2007.09.010; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Cowey CL, 2009, CURR ONCOL REP, V11, P94, DOI 10.1007/s11912-009-0015-5; Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Druker J, 2013, MOL CELL BIOL, V33, P2116, DOI 10.1128/MCB.01470-12; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Geiss-Friedlander R, 2007, NAT REV MOL CELL BIO, V8, P947, DOI 10.1038/nrm2293; Gerez J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057795; Gnarra JR, 1996, P NATL ACAD SCI USA, V93, P10589, DOI 10.1073/pnas.93.20.10589; Greer SN, 2012, EMBO J, V31, P2448, DOI 10.1038/emboj.2012.125; Groulx I, 2002, MOL CELL BIOL, V22, P5319, DOI 10.1128/MCB.22.15.5319-5336.2002; Hacker KE, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003801; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Hoffman MA, 2001, HUM MOL GENET, V10, P1019, DOI 10.1093/hmg/10.10.1019; Huang C, 2009, EMBO J, V28, P2748, DOI 10.1038/emboj.2009.210; Huang CC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076421; Huang JH, 2002, J BIOL CHEM, V277, P39792, DOI 10.1074/jbc.M206955200; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Jonasch E, 2012, MOL CANCER RES, V10, P859, DOI 10.1158/1541-7786.MCR-12-0117; Juengel E, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-161; Kaelin WG, 2002, NAT REV CANCER, V2, P673, DOI 10.1038/nrc885; Kaelin WG, 2008, NAT REV CANCER, V8, P865, DOI 10.1038/nrc2502; Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009; Kang X, 2010, ONCOGENE, V29, P5568, DOI 10.1038/onc.2010.297; Keefe SM, 2013, SEMIN ONCOL, V40, P421, DOI 10.1053/j.seminoncol.2013.05.006; Keith B, 2012, NAT REV CANCER, V12, P9, DOI 10.1038/nrc3183; Kim WY, 2006, EMBO J, V25, P4650, DOI 10.1038/sj.emboj.7601300; Kim WY, 2004, J CLIN ONCOL, V22, P4991, DOI 10.1200/JCO.2004.05.061; Knauth K, 2006, ONCOGENE, V25, P370, DOI 10.1038/sj.onc.1209062; Knauth K, 2009, J BIOL CHEM, V284, P10514, DOI 10.1074/jbc.M809056200; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; Lolkema MP, 2005, J BIOL CHEM, V280, P22205, DOI 10.1074/jbc.M503220200; Maher ER, 1997, MEDICINE, V76, P381, DOI 10.1097/00005792-199711000-00001; Maranchie JK, 2002, CANCER CELL, V1, P247, DOI 10.1016/S1535-6108(02)00044-2; Nunez-O'Mara A, 2013, BIOL CHEM, V394, P459, DOI 10.1515/hsz-2012-0319; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Paez-Pereda M, 2003, P NATL ACAD SCI USA, V100, P1034, DOI 10.1073/pnas.0237312100; Post DE, 2001, GENE THER, V8, P1801, DOI 10.1038/sj.gt.3301605; Pugh CW, 1997, J BIOL CHEM, V272, P11205; Rathmell WK, 2010, CURR OPIN ONCOL, V22, P250, DOI 10.1097/CCO.0b013e328337a5d2; Rathmell WK, 2004, CANCER RES, V64, P8595, DOI 10.1158/0008-5472.CAN-04-1430; Rechsteiner MP, 2011, CANCER RES, V71, P5500, DOI 10.1158/0008-5472.CAN-11-0757; Richard DE, 2000, J BIOL CHEM, V275, P26765; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; Rojewska E, 2014, MOL PAIN, V10, DOI 10.1186/1744-8069-10-47; Safran M, 2006, P NATL ACAD SCI USA, V103, P105, DOI 10.1073/pnas.0509459103; Schneider BP, 2011, J CLIN ONCOL, V29, DOI 10.1200/jco.2011.29.15_suppl.1000; Schoenfeld AR, 2000, P NATL ACAD SCI USA, V97, P8507, DOI 10.1073/pnas.97.15.8507; Schwartz AL, 2009, ANNU REV PHARMACOL, V49, P73, DOI 10.1146/annurev.pharmtox.051208.165340; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Semenza GL, 2011, NEW ENGL J MED, V365, P537, DOI [10.1056/NEJMra1011165, 10.1056/NEJMc1110602]; Semenza GL, 2013, J CLIN INVEST, V123, P3664, DOI 10.1172/JCI67230; Shan B, 2012, ENDOCR-RELAT CANCER, V19, P13, DOI 10.1530/ERC-11-0211; Skuli N, 2012, J CLIN INVEST, V122, P1427, DOI 10.1172/JCI57322; Tanos T, 2005, J BIOL CHEM, V280, P18842, DOI 10.1074/jbc.M500620200; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; van Hagen M, 2010, NUCLEIC ACIDS RES, V38, P1922, DOI 10.1093/nar/gkp1157; Willi-Monnerat S, 2008, MOL CELL NEUROSCI, V37, P845, DOI 10.1016/j.mcn.2008.01.009; Yang W, 2008, J CEREBR BLOOD F MET, V28, P892, DOI 10.1038/sj.jcbfm.9600601; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498; Zimmer M, 2004, MOL CANCER RES, V2, P89	73	16	16	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2015	34	37					4855	4866		10.1038/onc.2014.407	http://dx.doi.org/10.1038/onc.2014.407			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CR0YP	25500545				2022-12-17	WOS:000361050000006
J	Sangrar, W; Shi, C; Mullins, G; LeBrun, D; Ingalls, B; Greer, PA				Sangrar, W.; Shi, C.; Mullins, G.; LeBrun, D.; Ingalls, B.; Greer, P. A.			Amplified Ras-MAPK signal states correlate with accelerated EGFR internalization, cytostasis and delayed HER2 tumor onset in Fer-deficient model systems	ONCOGENE			English	Article							EPIDERMAL-GROWTH-FACTOR; TYROSINE KINASE FER; HUMAN-BREAST-CANCER; CELL-ADHESION; CORTACTIN PHOSPHORYLATION; MEMBRANE INVAGINATION; MEDIATED ENDOCYTOSIS; RECEPTOR ENDOCYTOSIS; ERBB RECEPTORS; NEU ONCOGENE	The non-receptor tyrosine kinase Fer belongs to a distinct subfamily of F-BAR domain containing kinases implicated in vesicular trafficking and signaling downstream of adhesion and growth factor receptors. Targeted inactivation of the fer gene in a transgenic mouse model of HER2(+), breast cancer was associated with delayed tumor onset and reduced proliferative rates in tumor cells. Fer deficiency was associated with increased rates of epidermal growth factor (EGF)-induced epidermal growth factor receptor (EGFR) internalization and amplified Ras-Raf-Mek-Erk (Ras-MAPK) signaling in primary mammary tumor epithelial cells, as well as increased cytotoxic and anti-proliferative sensitivity to the dual EGFR/HER2 inhibitor Lapatinib (LPN). These observations suggest a model in which accelerated ligand-induced EGFR internalization in Fer-deficient cells hypersensitizes the Ras-MAPK pathway to EGF, resulting in MAPK signal amplification to levels that induce cytostasis, rather than proliferation. Thus, Ras-MAPK cytostatic signaling delays HER2 tumor initiation and increases LPN cytotoxicity in Fer-deficient model systems. Taken together, these data suggest that targeting Fer alone, or in combination with LPN, may be of therapeutic benefit in HER2(+) breast cancer.	[Sangrar, W.; Shi, C.; Mullins, G.; LeBrun, D.; Greer, P. A.] Queens Canc Res Inst, Div Canc Biol & Genet, Kingston, ON, Canada; [Sangrar, W.; Mullins, G.; LeBrun, D.; Greer, P. A.] Queens Univ, Queens Canc Res Inst, Dept Pathol & Mol Med, Kingston, ON, Canada; [Sangrar, W.] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada; [Ingalls, B.] Univ Waterloo, Dept Appl Math, Waterloo, ON N2L 3G1, Canada	McMaster University; Queens University - Canada; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Waterloo	Sangrar, W (corresponding author), Queens Univ, Queens Canc Res Inst, Dept Pathol & Mol Med, Botterell Hall,Room A309, Kingston, ON K7L 3N6, Canada.	ws4@queensu.ca; greerp@queensu.ca			Canadian Breast Cancer Foundation; Canadian Institutes for Health Research; Canadian Cancer Society Research Institute	Canadian Breast Cancer Foundation(Canadian Cancer Society (CCS)); Canadian Institutes for Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Cancer Society Research Institute(Canadian Cancer Society (CCS))	We are grateful to Lee Boudreau, Christine Hall and Yan Gao for technical assistance. This work was funded by operating grants from the Canadian Breast Cancer Foundation, the Canadian Institutes for Health Research, and the Canadian Cancer Society Research Institute to PAG.	Amin DN, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000389; Aspenstrom P, 1997, CURR BIOL, V7, P479, DOI 10.1016/S0960-9822(06)00219-3; Blagosklonny MV, 2003, EMBO REP, V4, P358, DOI 10.1038/sj.embor.embor806; Citri A, 2006, NAT REV MOL CELL BIO, V7, P505, DOI 10.1038/nrm1962; Craig AWB, 1999, J BIOL CHEM, V274, P19934, DOI 10.1074/jbc.274.28.19934; Craig AWB, 2001, MOL CELL BIOL, V21, P603, DOI 10.1128/MCB.21.2.603-613.2001; Dankort D, 2001, MOL CELL BIOL, V21, P1540, DOI 10.1128/MCB.21.5.1540-1551.2001; Das Thakur M, 2013, NATURE, V494, P251, DOI 10.1038/nature11814; de Wit R, 2000, J BIOMOL SCREEN, V5, P133, DOI 10.1177/108705710000500305; Disanza A, 2009, MOL ONCOL, V3, P280, DOI 10.1016/j.molonc.2009.05.008; Ebisuya M, 2005, J CELL SCI, V118, P2997, DOI 10.1242/jcs.02505; Frost A, 2008, CELL, V132, P807, DOI 10.1016/j.cell.2007.12.041; GILL GN, 1981, NATURE, V293, P305, DOI 10.1038/293305a0; Greer P, 2002, NAT REV MOL CELL BIO, V3, P278, DOI 10.1038/nrm783; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; IMAI Y, 1982, CANCER RES, V42, P4394; Itoh T, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000393; Ivanova IA, 2013, ONCOGENE, V32, P5582, DOI 10.1038/onc.2013.277; Iwanishi M, 2000, J BIOL CHEM, V275, P38995, DOI 10.1074/jbc.M006665200; Jiang XJ, 2003, MOL BIOL CELL, V14, P858, DOI 10.1091/mbc.E02-08-0532; Jones RB, 2006, NATURE, V439, P168, DOI 10.1038/nature04177; KAWAMOTO T, 1984, J BIOL CHEM, V259, P7761; KIM L, 1995, MOL CELL BIOL, V15, P4553; Kogata N, 2003, MOL BIOL CELL, V14, P3553, DOI 10.1091/mbc.E03-02-0080; Kumar N, 2008, MOL PHARMACOL, V73, P1668, DOI 10.1124/mol.107.043794; Laurent CE, 2004, MOL CELL BIOL, V24, P9351, DOI 10.1128/MCB.24.21.9351-9358.2004; Lee CS, 2009, BBA-MOL CELL BIOL L, V1791, P862, DOI 10.1016/j.bbalip.2009.04.007; Lenferink AEG, 1998, EMBO J, V17, P3385, DOI 10.1093/emboj/17.12.3385; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Martinez-Quiles N, 2004, MOL CELL BIOL, V24, P5269, DOI 10.1128/MCB.24.12.5269-5280.2004; Mayor S, 2007, NAT REV MOL CELL BIO, V8, P603, DOI 10.1038/nrm2216; Milde-Langosch K, 2005, BRIT J CANCER, V92, P2206, DOI 10.1038/sj.bjc.6602655; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; PHONPHOK Y, 1991, FEBS LETT, V281, P188, DOI 10.1016/0014-5793(91)80390-O; Piccart-Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659, DOI 10.1056/NEJMoa052306; Sangrar W, 2005, CANCER RES, V65, P3518, DOI 10.1158/0008-5472.CAN-04-3468; Sangrar W, 2009, POMBE CDC15 HOMOLOGY, P78; Sangrar W, 2007, MOL CELL BIOL, V27, P6140, DOI 10.1128/MCB.01744-06; Schmidt-Glenewinkel H, 2008, BMC SYST BIOL, V2, DOI 10.1186/1752-0509-2-32; Sebolt-Leopold JS, 2004, NAT REV CANCER, V4, P937, DOI 10.1038/nrc1503; Shimada A, 2007, CELL, V129, P761, DOI 10.1016/j.cell.2007.03.040; Sigismund S, 2008, DEV CELL, V15, P209, DOI 10.1016/j.devcel.2008.06.012; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Sorkin A, 2010, CURRENT PROTOCOLS CE, pChapter 15, DOI DOI 10.1002/0471143030.CB1514S46; Sorkin A, 2009, EXP CELL RES, V315, P683, DOI [10.1016/j.yexcr.2008.07.029, 10.1016/j.yexcr.2008.08.013]; Sousa LP, 2012, P NATL ACAD SCI USA, V109, P4419, DOI 10.1073/pnas.1200164109; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Wang ZX, 1996, SCIENCE, V272, P1935, DOI 10.1126/science.272.5270.1935; WILEY HS, 1982, J BIOL CHEM, V257, P4222; Wilson TR, 2012, NATURE, V487, P505, DOI 10.1038/nature11249; Yu QY, 2006, CANCER CELL, V9, P23, DOI 10.1016/j.ccr.2005.12.012; Zhang Y, 2009, BMC CELL BIOL, V10, DOI 10.1186/1471-2121-10-78	53	16	18	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	31					4109	4117		10.1038/onc.2014.340	http://dx.doi.org/10.1038/onc.2014.340			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CN9PE	25347743				2022-12-17	WOS:000358780500009
J	Mungamuri, S; Wang, S; Manfredi, JJ; Gu, W; Aaronson, SA				Mungamuri, S. K.; Wang, S.; Manfredi, J. J.; Gu, W.; Aaronson, S. A.			Ash2L enables P53-dependent apoptosis by favoring stable transcription pre-initiation complex formation on its pro-apoptotic target promoters	ONCOGENE			English	Article							RNA-POLYMERASE-II; HISTONE H3; STRUCTURAL BASIS; P53; METHYLATION; ACTIVATION; CHROMATIN; TFIIB; SET1; DNA	Chromatin conformation has a major role in all cellular decisions. We showed previously that P53 pro-apoptotic target promoters are enriched with H3K9me3 mark and induction of P53 abrogates this repressive chromatin conformation by downregulating SUV39H1, the writer of this mark present on these promoters. In the present study, we demonstrate that in response to P53 stabilization, its pro-apoptotic target promoters become enriched with the H3K4me3 epigenetic mark as well as its readers, Wdr5, RbBP5 and Ash2L, which were not observed in response to SUV39H1 downregulation alone. Overexpression of Ash2L enhanced P53-dependent apoptosis in response to chemotherapy, associated with increased P53 pro-apoptotic gene promoter occupancy and target gene expression. In contrast, pre-silencing of Ash2L abrogated P53's ability to induce the expression of these transcriptional targets, without affecting P53 or RNAP II recruitment. However, Ash2L pre-silencing, under the same conditions, resulted in reduced RNAP II ser5-CTD phosphorylation on these same pro-apoptotic target promoters, which correlated with reduced promoter occupancy of TFIIB as well as TFIIF (RAP74). Based on these findings, we propose that Ash2L acts in concert with P53 promoter occupancy to activate RNAP II by aiding formation of a stable transcription pre-initiation complex required for its activation.	[Mungamuri, S. K.; Manfredi, J. J.; Aaronson, S. A.] Icahn Sch Med Mt Sinai, Dept Oncol Sci, New York, NY 10029 USA; [Wang, S.] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; [Gu, W.] Columbia Univ, Dept Pathol & Cell Biol, Coll Phys & Surg, Inst Canc Genet, New York, NY USA	Icahn School of Medicine at Mount Sinai; University of Michigan System; University of Michigan; Columbia University	Aaronson, SA (corresponding author), Icahn Sch Med Mt Sinai, Dept Oncol Sci, One Gustave L Levy Pl,Box 1130, New York, NY 10029 USA.	stuart.aaronson@mssm.edu		Manfredi, James/0000-0003-2234-9097; Mungamuri, Sathish Kumar/0000-0002-0012-5298; Wang, Shaomeng/0000-0002-8782-6950	National Cancer Institute [P01CA080058]; Breast Cancer Research Foundation; NATIONAL CANCER INSTITUTE [P01CA080058] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Breast Cancer Research Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank SW Lee (MGH, Harvard) for helpful discussions. This research was supported by grants from the National Cancer Institute (P01CA080058) and Breast Cancer Research Foundation (SAA). The content of this paper is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the US National Institutes of Health.	Ardehali MB, 2011, EMBO J, V30, P2817, DOI 10.1038/emboj.2011.194; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; Bartkowiak B, 2011, TRANSCR-AUSTIN, V2, P115, DOI 10.4161/trns.2.3.15004; Beckerman R, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000935; Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001; Bernstein BE, 2002, P NATL ACAD SCI USA, V99, P8695, DOI 10.1073/pnas.082249499; Bieging KT, 2012, TRENDS CELL BIOL, V22, P97, DOI 10.1016/j.tcb.2011.10.006; Bosch-Presegue L, 2011, MOL CELL, V42, P210, DOI 10.1016/j.molcel.2011.02.034; Buratowski S, 2003, NAT STRUCT BIOL, V10, P679, DOI 10.1038/nsb0903-679; Cabart P, 2011, P NATL ACAD SCI USA, V108, P15786, DOI 10.1073/pnas.1104591108; Deng WS, 2007, CHROMOSOMA, V116, P417, DOI 10.1007/s00412-007-0113-9; Dou YL, 2006, NAT STRUCT MOL BIOL, V13, P713, DOI 10.1038/nsmb1128; Egloff S, 2008, TRENDS GENET, V24, P280, DOI 10.1016/j.tig.2008.03.008; Egloff S, 2012, TRENDS GENET, V28, P333, DOI 10.1016/j.tig.2012.03.007; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fu Y, 2009, CURR MED CHEM, V16, P3966, DOI 10.2174/092986709789352277; Gomes NP, 2010, GENE DEV, V24, P111, DOI 10.1101/gad.1893610; Goodman RH, 2000, GENE DEV, V14, P1553; Grewal SIS, 2007, NATURE, V447, P399, DOI 10.1038/nature05914; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Han ZF, 2006, MOL CELL, V22, P137, DOI 10.1016/j.molcel.2006.03.018; Hosoda H, 2011, CYTOTECHNOLOGY, V63, P211, DOI 10.1007/s10616-011-9335-z; Jaskelioff M, 2003, NAT CELL BIOL, V5, P395, DOI 10.1038/ncb0503-395; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kasper LH, 2010, EMBO J, V29, P3660, DOI 10.1038/emboj.2010.235; Kim TH, 2005, NATURE, V436, P876, DOI 10.1038/nature03877; Laptenko O, 2006, CELL DEATH DIFFER, V13, P951, DOI 10.1038/sj.cdd.4401916; Lauberth SM, 2013, CELL, V152, P1021, DOI 10.1016/j.cell.2013.01.052; Lee J, 2009, P NATL ACAD SCI USA, V106, P8513, DOI 10.1073/pnas.0902873106; Levine AJ, 2009, NAT REV CANCER, V9, P749, DOI 10.1038/nrc2723; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Mandinova A, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001366; Mungamuri SK, 2006, CANCER RES, V66, P4715, DOI 10.1158/0008-5472.CAN-05-3830; Mungamuri SK, 2012, NAT STRUCT MOL BIOL, V19, P478, DOI 10.1038/nsmb.2271; Murray-Zmijewski F, 2008, NAT REV MOL CELL BIO, V9, P702, DOI 10.1038/nrm2451; Ng HH, 2003, MOL CELL, V11, P709, DOI 10.1016/S1097-2765(03)00092-3; Patel A, 2009, J BIOL CHEM, V284, P24242, DOI 10.1074/jbc.M109.014498; Pekowska A, 2011, EMBO J, V30, P4198, DOI 10.1038/emboj.2011.295; Pommier Y, 2010, CHEM BIOL, V17, P421, DOI 10.1016/j.chembiol.2010.04.012; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Roh TY, 2006, P NATL ACAD SCI USA, V103, P15782, DOI 10.1073/pnas.0607617103; Roh TY, 2005, GENE DEV, V19, P542, DOI 10.1101/gad.1272505; Schmid CD, 2007, CELL, V131, P831, DOI 10.1016/j.cell.2007.11.017; Shandilya J, 2012, P NATL ACAD SCI USA, V109, P18797, DOI 10.1073/pnas.1207483109; Shangary S, 2008, P NATL ACAD SCI USA, V105, P3933, DOI 10.1073/pnas.0708917105; Shilatifard A, 2012, ANNU REV BIOCHEM, V81, P65, DOI 10.1146/annurev-biochem-051710-134100; Sims RJ, 2011, SCIENCE, V332, P99, DOI 10.1126/science.1202663; Southall SM, 2009, MOL CELL, V33, P181, DOI 10.1016/j.molcel.2008.12.029; Steward MM, 2006, NAT STRUCT MOL BIOL, V13, P852, DOI 10.1038/nsmb1131; Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648; Tang ZY, 2013, CELL, V154, P297, DOI 10.1016/j.cell.2013.06.027; Thomas A, 1998, GENE DEV, V12, P1975, DOI 10.1101/gad.12.13.1975; Thomas MC, 2006, CRIT REV BIOCHEM MOL, V41, P105, DOI 10.1080/10409230600648736; Trievel RC, 2009, NAT STRUCT MOL BIOL, V16, P678, DOI 10.1038/nsmb0709-678; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vermeulen M, 2010, EPIGENOMICS-UK, V2, P395, DOI 10.2217/EPI.10.11; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Wang YM, 2010, CURR BIOL, V20, P548, DOI 10.1016/j.cub.2010.01.052; Zhang DW, 2012, GENET RES INT, V2012, DOI 10.1155/2012/347214; Zheng H, 2014, ONCOGENE, V33, P734, DOI 10.1038/onc.2013.6	61	16	16	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 7	2015	34	19					2461	2470		10.1038/onc.2014.198	http://dx.doi.org/10.1038/onc.2014.198			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CH7BK	25023704	Green Accepted			2022-12-17	WOS:000354190400005
J	Dahmani, R; Just, PA; Delay, A; Canal, F; Finzi, L; Prip-Buus, C; Lambert, M; Sujobert, P; Buchet-Poyau, K; Miller, E; Cavard, C; Marmier, S; Terris, B; Billaud, M; Perret, C				Dahmani, R.; Just, P-A; Delay, A.; Canal, F.; Finzi, L.; Prip-Buus, C.; Lambert, M.; Sujobert, P.; Buchet-Poyau, K.; Miller, E.; Cavard, C.; Marmier, S.; Terris, B.; Billaud, M.; Perret, C.			A novel LKB1 isoform enhances AMPK metabolic activity and displays oncogenic properties	ONCOGENE			English	Article							ACTIVATED PROTEIN-KINASE; TUMOR-SUPPRESSOR LKB1; SPLICE VARIANT; CANCER; MUSCLE; INACTIVATION; REVEALS; PATHWAY; LINK	The LKB1 tumor suppressor gene encodes a master kinase that coordinates the regulation of energetic metabolism and cell polarity. We now report the identification of a novel isoform of LKB1 (named Delta N-LKB1) that is generated through alternative transcription and internal initiation of translation of the LKB1 mRNA. The Delta N-LKB1 protein lacks the N-terminal region and a portion of the kinase domain. Although Delta N-LKB1 is catalytically inactive, it potentiates the stimulating effect of LKB1 on the AMP-activated protein kinase (AMPK) metabolic sensor through a direct interaction with the regulatory autoinhibitory domain of AMPK. In contrast, Delta N-LKB1 negatively interferes with the LKB1 polarizing activity. Finally, combining in vitro and in vivo approaches, we showed that Delta N-LKB1 has an intrinsic oncogenic property. Delta N-LKB1 is expressed solely in the lung cancer cell line, NCI-H460. Silencing of Delta N-LKB1 decreased the survival of NCI-H460 cells and inhibited their tumorigenicity when engrafted in nude mice. In conclusion, we have identified a novel LKB1 isoform that enhances the LKB1-controlled AMPK metabolic activity but inhibits LKB1-induced polarizing activity. Both the LKB1 tumor suppressor gene and the oncogene Delta N-LKB1 are expressed from the same locus and this may account for some of the paradoxical effects of LKB1 during tumorigenesis.	[Dahmani, R.; Just, P-A; Canal, F.; Finzi, L.; Prip-Buus, C.; Lambert, M.; Sujobert, P.; Cavard, C.; Marmier, S.; Terris, B.; Perret, C.] Inst Cochin Genet Mol, INSERM, U1016, F-75014 Paris, France; [Dahmani, R.; Just, P-A; Canal, F.; Finzi, L.; Prip-Buus, C.; Lambert, M.; Sujobert, P.; Cavard, C.; Marmier, S.; Terris, B.; Perret, C.] CNRS, UMR8104, Paris, France; [Dahmani, R.; Just, P-A; Canal, F.; Finzi, L.; Prip-Buus, C.; Lambert, M.; Sujobert, P.; Cavard, C.; Marmier, S.; Terris, B.; Perret, C.] Univ Paris 05, Paris, France; [Dahmani, R.; Just, P-A; Canal, F.; Finzi, L.; Cavard, C.; Marmier, S.; Terris, B.; Perret, C.] LNCC, Equipe Labellisee, Paris, France; [Delay, A.; Buchet-Poyau, K.; Billaud, M.] UJF, INSERM, Inst Albert Bonniot, CRI,U823, F-38706 La Tronche, France; [Miller, E.] Boston Univ, Sch Med, Cardiol Sect, Boston, MA 02118 USA; [Terris, B.] Hop Cochin, Pathol Unit, F-75674 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Boston University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite	Billaud, M (corresponding author), UJF, INSERM, Inst Albert Bonniot, CRI,U823, F-38706 La Tronche, France.	Marc.Billaud@ujf-grenoble.fr; christine.perret@inserm.fr	Perret-Mayeux, Christine/L-3297-2017; sujobert, pierre/N-8149-2017; Terris, Benoit/P-1497-2017; JUST, Pierre-Alexandre/P-1972-2017; PRIP-BUUS, Carina/P-9084-2017	Miller, Edward/0000-0002-2156-5962; perret, christine/0000-0003-4710-7051; Prip-Buus, Carina/0000-0002-2153-7857	INSERM; LNCC (France) 'Equipe labelisee Ligue Nationale Contre le Cancer'; INCA grants; LABEX Who amI?; LNCC fellowship	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); LNCC (France) 'Equipe labelisee Ligue Nationale Contre le Cancer'; INCA grants; LABEX Who amI?; LNCC fellowship	We thank Graham Hardie and Simon Hawley (University of Dundee, Dundee, UK) for their helpful comments and valuable scientific input into our work and also for their kindness in providing us with different antibodies and reagents to measure the LKB1-controlled AMPK activity and to test the role of Delta N-LKB1 on different ARKs. We are also grateful to Christelle Forcet, Nicolas Aznar and Maya Ghawitian from Billaud's laboratory for their help with the analysis of LKB1-induced polarizing activity. We are indebted to Benoit Viollet and Marc Foretz for providing us with AMPK plasmids and helpful discussions. We thank Pascal Maire (from Inserm U1016, Paris, France) and all people of the team for helpful discussions, suggestions and critical reading of the manuscript. We are grateful to Helene Blons (HEGP, Paris, France) and Sylvie Grazzeri (Inserm U823, Grenoble, France) for providing the lung cancer cell lines and some lung tumors, respectively. We also thank Veronique Lenoir and Catherine Esnous for technical help in fatty acid oxidation experiments, and animal facility of Institut Cochin for maintenance of mouse colonies. Core fundings came from INSERM, grants from LNCC (France) 'Equipe labelisee Ligue Nationale Contre le Cancer', INCA grants and LABEX Who amI?. RD was funded by an LNCC fellowship.	Alessi DR, 2006, ANNU REV BIOCHEM, V75, P137, DOI 10.1146/annurev.biochem.75.103004.142702; Baas AF, 2004, CELL, V116, P457, DOI 10.1016/S0092-8674(04)00114-X; Bardeesy N, 2002, NATURE, V419, P162, DOI 10.1038/nature01045; Carling D, 2011, NAT CHEM BIOL, V7, P512, DOI [10.1038/NCHEMBIO.610, 10.1038/nchembio.610]; Denison FC, 2009, J BIOL CHEM, V284, P67, DOI 10.1074/jbc.M806153200; Forcet C, 2005, HUM MOL GENET, V14, P1283, DOI 10.1093/hmg/ddi139; Friedrichsen M, 2013, MOL CELL ENDOCRINOL, V366, P204, DOI 10.1016/j.mce.2012.06.013; Giardiello FM, 2000, GASTROENTEROLOGY, V119, P1447, DOI 10.1053/gast.2000.20228; Hardie DG, 2013, BMC BIOL, V11, DOI 10.1186/1741-7007-11-36; Hardie DG, 2012, NAT REV MOL CELL BIO, V13, P251, DOI 10.1038/nrm3311; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hong SP, 2003, P NATL ACAD SCI USA, V100, P8839, DOI 10.1073/pnas.1533136100; Ikeda Y, 2009, J BIOL CHEM, V284, P35839, DOI 10.1074/jbc.M109.057273; Jansen M, 2009, PHYSIOL REV, V89, P777, DOI 10.1152/physrev.00026.2008; Jeon SM, 2012, NATURE, V485, P661, DOI 10.1038/nature11066; Kottakis F, 2012, CELL RES, V22, P1617, DOI 10.1038/cr.2012.108; Liang JY, 2013, CANCER RES, V73, P2929, DOI 10.1158/0008-5472.CAN-12-3876; Matsumoto S, 2007, ONCOGENE, V26, P5911, DOI 10.1038/sj.onc.1210418; Neu-Yilik G, 2011, RNA, V17, P843, DOI 10.1261/rna.2401811; Partanen JI, 2012, P NATL ACAD SCI USA, V109, pE388, DOI 10.1073/pnas.1120421109; Richter EA, 2009, BIOCHEM J, V418, P261, DOI 10.1042/BJ20082055; Rose AJ, 2009, J PHYSIOL-LONDON, V587, P1547, DOI 10.1113/jphysiol.2008.167528; Sanchez-Cespedes M, 2007, ONCOGENE, V26, P7825, DOI 10.1038/sj.onc.1210594; Shackelford DB, 2013, CANCER CELL, V23, P143, DOI 10.1016/j.ccr.2012.12.008; Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Towler MC, 2008, BIOCHEM J, V416, P1, DOI 10.1042/BJ20081447; Vaahtomeri K, 2011, FEBS LETT, V585, P944, DOI 10.1016/j.febslet.2010.12.034; Winder WW, 1996, AM J PHYSIOL-ENDOC M, V270, pE299, DOI 10.1152/ajpendo.1996.270.2.E299; Wingo SN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005137; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Zeqiraj E, 2009, SCIENCE, V326, P1707, DOI 10.1126/science.1178377; Zeqiraj E, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000126	33	16	16	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 30	2015	34	18					2337	2346		10.1038/onc.2014.182	http://dx.doi.org/10.1038/onc.2014.182			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CH2AH	24998845				2022-12-17	WOS:000353824800007
J	Ding, LW; Sun, QY; Lin, DC; Chien, W; Hattori, N; Dong, XM; Gery, S; Garg, M; Doan, NB; Said, JW; Xiao, JF; Yang, H; Liu, LZ; Meng, X; Huang, RYJ; Tang, K; Koeffler, H				Ding, L-W; Sun, Q-Y; Lin, D-C; Chien, W.; Hattori, N.; Dong, X-M; Gery, S.; Garg, M.; Doan, N. B.; Said, J. W.; Xiao, J-F; Yang, H.; Liu, L-Z; Meng, X.; Huang, R. Y-J; Tang, K.; Koeffler, H. P.			LNK (SH2B3): paradoxical effects in ovarian cancer	ONCOGENE			English	Article							ADAPTER PROTEIN LNK; ACUTE LYMPHOBLASTIC-LEUKEMIA; MYELOPROLIFERATIVE NEOPLASMS; HEMATOPOIETIC STEM; PLECKSTRIN HOMOLOGY; ENDOTHELIAL-CELLS; PROGENITOR CELLS; ACTIVATION; EXPRESSION; MUTATIONS	LNK (SH2B3) is an adaptor protein studied extensively in normal and malignant hematopoietic cells. In these cells, it downregulates activated tyrosine kinases at the cell surface resulting in an antiproliferative effect. To date, no studies have examined activities of LNK in solid tumors. In this study, we found by in silico analysis and staining tissue arrays that the levels of LNK expression were elevated in high-grade ovarian cancer. To test the functional importance of this observation, LNK was either overexpressed or silenced in several ovarian cancer cell lines. Remarkably, overexpression of LNK rendered the cells resistant to death induced by either serum starvation or nutrient deprivation, and generated larger tumors using a murine xenograft model. In contrast, silencing of LNK decreased ovarian cancer cell growth in vitro and in vivo. Western blot studies indicated that overexpression of LNK upregulated and extended the transduction of the mitogenic signal, whereas silencing of LNK produced the opposite effects. Furthermore, forced expression of LNK reduced cell size, inhibited cell migration and markedly enhanced cell adhesion. Liquid chromatography-mass spectroscopy identified 14-3-3 as one of the LNK-binding partners. Our results suggest that in contrast to the findings in hematologic malignancies, the adaptor protein LNK acts as a positive signal transduction modulator in ovarian cancers.	[Ding, L-W; Sun, Q-Y; Lin, D-C; Chien, W.; Hattori, N.; Garg, M.; Xiao, J-F; Yang, H.; Liu, L-Z; Meng, X.; Huang, R. Y-J; Koeffler, H. P.] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore 117599, Singapore; [Lin, D-C; Gery, S.; Koeffler, H. P.] Univ Calif Los Angeles, Sch Med, Cedar Sinai Med Ctr, Div Hematol Oncol, Los Angeles, CA USA; [Dong, X-M; Tang, K.] Nanyang Technol Univ, Sch Biol Sci, Singapore 639798, Singapore; [Doan, N. B.; Said, J. W.] Santa Monica Univ Calif, Los Angeles Med Ctr, Los Angeles, CA USA; [Koeffler, H. P.] Natl Univ Singapore Hosp, Natl Univ Canc Inst, Singapore 117548, Singapore	National University of Singapore; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; National University of Singapore	Ding, LW (corresponding author), Natl Univ Singapore, Canc Sci Inst Singapore, 13 North,MD6,14 Med Dr, Singapore 117599, Singapore.	csidlw@nus.edu.sg	Huang, Ruby Yun-Ju/AAE-8854-2019; Sun, Qiao-Yang/ABA-6813-2020; Ding, Ling-Wen/H-6916-2019; Garg, Manoj/C-4076-2019; Tang, Kai/A-2194-2011	Huang, Ruby Yun-Ju/0000-0001-6376-3185; Ding, Ling-Wen/0000-0003-0022-1551; Garg, Manoj/0000-0002-3492-2957; Sun, Qiao-Yang/0000-0002-9855-5586	National Research Foundation Singapore; Singapore Ministry of Education under the Research Centres of Excellence initiative; National Institutes of Health of the USA [R01CA026038-33]; Singapore Ministry of Health's National Medical Research Council under its Singapore Translational Research Investigator Award; NATIONAL CANCER INSTITUTE [R01CA026038] Funding Source: NIH RePORTER	National Research Foundation Singapore(National Research Foundation, Singapore); Singapore Ministry of Education under the Research Centres of Excellence initiative(Ministry of Education, Singapore); National Institutes of Health of the USA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Singapore Ministry of Health's National Medical Research Council under its Singapore Translational Research Investigator Award(Ministry of Health-SingaporeNational Medical Research Council, Singapore); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This research is supported by the National Research Foundation Singapore and the Singapore Ministry of Education under the Research Centres of Excellence initiative, and by the National Institutes of Health of the USA (R01CA026038-33) and the Singapore Ministry of Health's National Medical Research Council under its Singapore Translational Research Investigator Award to HPK.	Ahmed Z, 2003, BIOCHEM J, V371, P405, DOI 10.1042/BJ20021589; Almudi I, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478-811X-11-26; Baran-Marszak F, 2010, BLOOD, V116, P5961, DOI 10.1182/blood-2009-12-256768; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Bersenev A, 2010, J CLIN INVEST, V120, P2058, DOI 10.1172/JCI42032; Buza-Vidas N, 2006, GENE DEV, V20, P2018, DOI 10.1101/gad.385606; Chatelais M, 2011, XENOTRANSPLANTATION, V18, P108, DOI 10.1111/j.1399-3089.2011.00629.x; Dawson MR, 2009, NATURE, V461, pE4, DOI 10.1038/nature08254; Devalliere J, 2012, FASEB J, V26, P2592, DOI 10.1096/fj.11-193383; Devalliere J, 2011, BIOCHEM PHARMACOL, V82, P1391, DOI 10.1016/j.bcp.2011.06.023; Fitau J, 2006, J BIOL CHEM, V281, P20148, DOI 10.1074/jbc.M510997200; Gery S, 2013, ONCOGENE, V32, P3111, DOI 10.1038/onc.2012.435; Gery S, 2007, BLOOD, V110, P3360, DOI 10.1182/blood-2007-05-089326; Gery S, 2009, J LEUKOCYTE BIOL, V85, P957, DOI 10.1189/jlb.0908575; Gery S, 2009, EXP HEMATOL, V37, P585, DOI 10.1016/j.exphem.2009.01.009; Gueller S, 2008, BIOCHEM J, V415, P241, DOI 10.1042/BJ20080102; Gueller S, 2011, EXP HEMATOL, V39, P591, DOI 10.1016/j.exphem.2011.02.001; Gueller S, 2010, J LEUKOCYTE BIOL, V88, P699, DOI 10.1189/jlb.0309185; Ha JS, 2011, AM J HEMATOL, V86, P866, DOI 10.1002/ajh.22107; Hurtado C, 2011, LEUKEMIA RES, V35, P1537, DOI 10.1016/j.leukres.2011.07.009; Jiang J, 2012, J CLIN INVEST, V122, P2079, DOI 10.1172/JCI59719; Lanning NJ, 2011, J CELL SCI, V124, P3095, DOI 10.1242/jcs.081547; Lasho TL, 2010, NEW ENGL J MED, V363, P1189, DOI 10.1056/NEJMc1006966; Lee JI, 2008, PHYSIOL GENOMICS, V33, P218, DOI 10.1152/physiolgenomics.00263.2007; Li YJ, 2000, J IMMUNOL, V164, P5199, DOI 10.4049/jimmunol.164.10.5199; Lin DC, 2012, BLOOD, V120, P3310, DOI 10.1182/blood-2011-10-388611; Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239; Maures TJ, 2009, MOL ENDOCRINOL, V23, P1077, DOI 10.1210/me.2009-0011; Nishi M, 2005, MOL CELL BIOL, V25, P2607, DOI 10.1128/MCB.25.7.2607-2621.2005; Oh ST, 2011, THER ADV HEMATOL, V2, P11, DOI 10.1177/2040620710393391; Oh ST, 2010, BLOOD, V116, P988, DOI 10.1182/blood-2010-02-270108; Pellinen T, 2008, DEV CELL, V15, P371, DOI 10.1016/j.devcel.2008.08.001; Perez-Garcia A, 2013, BLOOD, V122, P2425, DOI 10.1182/blood-2013-05-500850; Qian XZ, 2001, MOL CELL BIOL, V21, P1613, DOI 10.1128/MCB.21.5.1613-1620.2001; Roberts KG, 2012, CANCER CELL, V22, P153, DOI 10.1016/j.ccr.2012.06.005; Rudd C E, 2001, Sci STKE, V2001, ppe1; Seita J, 2007, P NATL ACAD SCI USA, V104, P2349, DOI 10.1073/pnas.0606238104; Simon C, 2008, BLOOD, V112, P1039, DOI 10.1182/blood-2008-05-154849; Takaki S, 2002, J EXP MED, V195, P151, DOI 10.1084/jem.20011170; Tan TZ, 2013, EMBO MOL MED, V5, P1051, DOI 10.1002/emmm.201201823; Tong W, 2005, BLOOD, V105, P4604, DOI 10.1182/blood-2004-10-4093; Tong W, 2004, J EXP MED, V200, P569, DOI 10.1084/jem.20040762; Velazquez L, 2002, J EXP MED, V195, P1599, DOI 10.1084/jem.20011883; Werz C, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000596; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Yoshida K, 2013, NAT GENET, V45, P1293, DOI 10.1038/ng.2759; Zhang JH, 2012, NATURE, V481, P157, DOI 10.1038/nature10725	47	16	18	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 12	2015	34	11					1463	1474		10.1038/onc.2014.34	http://dx.doi.org/10.1038/onc.2014.34			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CD1AR	24704825	Green Accepted, Green Submitted			2022-12-17	WOS:000350806500012
J	Marivin, A; Berthelet, J; Cartier, J; Paul, C; Gemble, S; Morizot, A; Boireau, W; Saleh, M; Bertoglio, J; Solary, E; Dubrez, L				Marivin, A.; Berthelet, J.; Cartier, J.; Paul, C.; Gemble, S.; Morizot, A.; Boireau, W.; Saleh, M.; Bertoglio, J.; Solary, E.; Dubrez, L.			cIAP1 regulates TNF-mediated cdc42 activation and filopodia formation	ONCOGENE			English	Article						IAPs; TNF; RhoGTPases; cdc42; metastasis; Ras	NF-KAPPA-B; INDUCED ACTIN REORGANIZATION; ALPHA-DEPENDENT APOPTOSIS; SIGNALING PATHWAY; CELL-SURVIVAL; CANCER-CELLS; RHO GTPASES; E3 LIGASE; MIGRATION; IAPS	Tumour necrosis factor-alpha (TNF) is a cytokine endowed with multiple functions, depending on the cellular and environmental context. TNF receptor engagement induces the formation of a multimolecular complex including the TNFR-associated factor TRAF2, the receptor-interaction protein kinase RIP1 and the cellular inhibitor of apoptosis cIAP1, the latter being essential for NF-kappa B activation. Here, we show that cIAP1 also regulates TNF-induced actin cytoskeleton reorganization through a cdc42-dependent, NF-kappa B-independent pathway. Deletion of cIAP1 prevents TNF-induced filopodia and cdc42 activation. The expression of cIAP1 or its E3-ubiquitin ligase-defective mutant restores the ability of cIAP1(-/-) MEFs to produce filopodia, whereas a cIAP1 mutant unable to bind TRAF2 does not. Accordingly, the silencing of TRAF2 inhibits TNF-mediated filopodia formation, whereas silencing of RIP1 does not. cIAP1 directly binds cdc42 and promotes its RhoGDI alpha-mediated stabilization. TNF decreases cIAP1-cdc42 interaction, suggesting that TNF-induced recruitment of cIAP1/TRAF2 to the receptor releases cdc42, which in turn triggers actin remodeling. cIAP1 also regulates cdc42 activation in response to EGF and HRas-V12 expression. A downregulation of cIAP1 altered the cell polarization, the cell adhesion to endothelial cells and cell intercalation, which are cdc42-dependent processes. Finally, we demonstrated that the deletion of cIAP1 regulated the HRas-V12-mediated transformation process, including anchorage-dependent cell growth, tumour growth in a xenograft model and the development of experimental metastasis in the lung.	[Marivin, A.; Berthelet, J.; Cartier, J.; Gemble, S.; Dubrez, L.] Fac Med, INSERM, UMR866, 7 Blvd Jeanne Arc, F-21079 Dijon, France; [Marivin, A.; Berthelet, J.; Cartier, J.; Paul, C.; Gemble, S.; Dubrez, L.] Univ Bourgogne, IFR 100, Dijon, France; [Paul, C.] EPHE, Dijon, France; [Morizot, A.; Saleh, M.] McGill Univ, Dept Med, Montreal, PQ, Canada; [Boireau, W.] Univ Franche Comte, Inst FEMTO ST, CLIPP, F-25030 Besancon, France; [Bertoglio, J.] IFR 54, Inserm UMR749, Villejuif, France; [Bertoglio, J.; Solary, E.] IFR 54, Inst Gustave Roussy, Villejuif, France; [Solary, E.] IFR 54, UMR1009, Villejuif, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Universite de Bourgogne; UDICE-French Research Universities; PSL Research University Paris; Ecole Pratique des Hautes Etudes (EPHE); McGill University; Universite de Franche-Comte; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay	Dubrez, L (corresponding author), Fac Med, INSERM, UMR866, 7 Blvd Jeanne Arc, F-21079 Dijon, France.	ldubrez@u-bourgogne.fr	Laurence, Dubrez/P-9472-2019; Dubrez, Laurence/I-4971-2016	Laurence, Dubrez/0000-0002-7030-2181; Dubrez, Laurence/0000-0002-7030-2181; Paul, Catherine/0000-0002-7657-5535; Solary, Eric/0000-0002-8629-1341; CARTIER, Jessy/0000-0002-0366-8546; Berthelet, Jean/0000-0003-2562-0575	Comite de Cote d'Or of the Ligue Contre le Cancer; 'Association pour la Recherche sur le Cancer' (ARC); Association 'Cent pour sang la Vie'; European Union; Conseil Regional de Bourgogne'; French National Research Agency under the program [ANR-11-LABX-0021]; 'Ministere de l'Enseignement Superieur et de la Recherche' of France; Societe Francaise d'Hematologie	Comite de Cote d'Or of the Ligue Contre le Cancer; 'Association pour la Recherche sur le Cancer' (ARC)(Fondation ARC pour la Recherche sur le Cancer); Association 'Cent pour sang la Vie'; European Union(European Commission); Conseil Regional de Bourgogne'(Region Bourgogne-Franche-Comte); French National Research Agency under the program(French National Research Agency (ANR)); 'Ministere de l'Enseignement Superieur et de la Recherche' of France; Societe Francaise d'Hematologie	We thank Dr J Silke, Dr E Lemichez, Dr S Gasman, Dr CL Day, Dr S Ansieu, Dr R Weil and S Monier for kindly providing plasmids and cell lines. We are grateful to Lydie Desoche, Aziza Aznague, Cedric Seignez and Benoit Simon (FEMTO-ST, CLIPP platform) for their technical assistance. We thank A Bouchot and B Gasquet (CellImaP Imagery Facility), A Hammann (Cytometry platform), V Saint-Giorgio (Animal Facility), A Oudot and B Collin (Precilinal imagery platform, Georges-Francois Leclerc Center) for the use of the imagery, cytometry and animal facilities. We thank P Meier, K Rajalingam, J Breard, M David and S Ansieu for helpful discussions. This work was supported by grants from the 'Comite de Cote d'Or of the Ligue Contre le Cancer' (LD), the 'Association pour la Recherche sur le Cancer' (ARC to LD), the Association 'Cent pour sang la Vie' (LD), the European Union and the 'Conseil Regional de Bourgogne', a French Government grant managed by the French National Research Agency under the program 'Investissements d'Avenir with reference ANR-11-LABX-0021', and fellowships from the 'Ministere de l'Enseignement Superieur et de la Recherche' of France (to AM, JB, JC), ARC (JC) and the 'Societe Francaise d'Hematologie' (AM).	Allen WE, 1997, J CELL SCI, V110, P707; Bertrand MJM, 2008, MOL CELL, V30, P689, DOI 10.1016/j.molcel.2008.05.014; Boulter E, 2012, FASEB J, V26, P469, DOI 10.1096/fj.11-192252; Boulter E, 2010, NAT CELL BIOL, V12, P477, DOI 10.1038/ncb2049; Cartier J, 2011, J BIOL CHEM, V286, P26406, DOI 10.1074/jbc.M110.191239; Cheng CM, 2011, MOL CELL BIOL, V31, P983, DOI 10.1128/MCB.00137-10; Dogan T, 2008, NAT CELL BIOL, V10, P1447, DOI 10.1038/ncb1804; Dynek JN, 2010, EMBO J, V29, P4198, DOI 10.1038/emboj.2010.300; Etienne-Manneville S, 2004, J CELL SCI, V117, P1291, DOI 10.1242/jcs.01115; Feoktistova M, 2011, MOL CELL, V43, P449, DOI 10.1016/j.molcel.2011.06.011; Fortin SP, 2012, MOL CANCER RES, V10, P958, DOI 10.1158/1541-7786.MCR-11-0616; Gadea G, 2004, J CELL SCI, V117, P6355, DOI 10.1242/jcs.01566; Garcia-Mata R, 2011, NAT REV MOL CELL BIO, V12, P493, DOI 10.1038/nrm3153; Geisbrecht ER, 2004, CELL, V118, P111, DOI 10.1016/j.cell.2004.06.020; Grandclement C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020444; Gyrd-Hansen M, 2008, NAT CELL BIOL, V10, P1309, DOI 10.1038/ncb1789; Gyrd-Hansen M, 2010, NAT REV CANCER, V10, P561, DOI 10.1038/nrc2889; Haas TL, 2009, MOL CELL, V36, P831, DOI 10.1016/j.molcel.2009.10.013; Haubert D, 2007, EMBO J, V26, P3308, DOI 10.1038/sj.emboj.7601778; Hehnly H, 2010, TRAFFIC, V11, P1067, DOI 10.1111/j.1600-0854.2010.01082.x; Iden S, 2008, NAT REV MOL CELL BIO, V9, P846, DOI 10.1038/nrm2521; Kant S, 2011, GENE DEV, V25, P2069, DOI 10.1101/gad.17224711; Liu JY, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.176982; Lopez J, 2011, MOL CELL, V42, P569, DOI 10.1016/j.molcel.2011.04.008; Mace PD, 2010, J MOL BIOL, V400, P8, DOI 10.1016/j.jmb.2010.04.055; Makrodouli E, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-118; Mathew SJ, 2009, J CELL SCI, V122, P1939, DOI 10.1242/jcs.044487; Mckenzie JAG, 2007, J CELL PHYSIOL, V213, P221, DOI 10.1002/jcp.21114; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Oberoi TK, 2012, EMBO J, V31, P14, DOI 10.1038/emboj.2011.423; Parameswaran N, 2010, CRIT REV EUKAR GENE, V20, P87, DOI 10.1615/CritRevEukarGeneExpr.v20.i2.10; Peppelenbosch M, 1999, J IMMUNOL, V162, P837; Puls A, 1999, J CELL SCI, V112, P2983; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; Reymond N, 2012, J CELL BIOL, V199, P653, DOI 10.1083/jcb.201205169; Silke J, 2011, CURR OPIN IMMUNOL, V23, P620, DOI 10.1016/j.coi.2011.08.002; Stengel K, 2011, CELL SIGNAL, V23, P1415, DOI 10.1016/j.cellsig.2011.04.001; Stengel KR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037317; Vallabhapurapu S, 2008, NAT IMMUNOL, V9, P1364, DOI 10.1038/ni.1678; Van Troys M, 2008, EUR J CELL BIOL, V87, P649, DOI 10.1016/j.ejcb.2008.04.001; Vanlangenakker N, 2011, CELL DEATH DIFFER, V18, P656, DOI 10.1038/cdd.2010.138; Varfolomeev E, 2008, J BIOL CHEM, V283, P24295, DOI 10.1074/jbc.C800128200; Varfolomeev E, 2007, CELL, V131, P669, DOI 10.1016/j.cell.2007.10.030; Vince JE, 2007, CELL, V131, P682, DOI 10.1016/j.cell.2007.10.037; Wang L, 2008, CELL, V133, P693, DOI 10.1016/j.cell.2008.03.036; Xu L, 2007, MOL CELL, V28, P914, DOI 10.1016/j.molcel.2007.10.027; Yang L, 2006, MOL BIOL CELL, V17, P4675, DOI 10.1091/mbc.E06-05-0466; Zarnegar BJ, 2008, NAT IMMUNOL, V9, P1371, DOI 10.1038/ni.1676; Zhuang M, 2013, MOL CELL, V49, P273, DOI 10.1016/j.molcel.2012.10.022	49	16	16	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 27	2014	33	48					5534	5545		10.1038/onc.2013.499	http://dx.doi.org/10.1038/onc.2013.499			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AW1ZO	24276241				2022-12-17	WOS:000346087900006
J	Buck, MJ; Raaijmakers, LM; Ramakrishnan, S; Wang, D; Valiyaparambil, S; Liu, S; Nowak, NJ; Pili, R				Buck, M. J.; Raaijmakers, L. M.; Ramakrishnan, S.; Wang, D.; Valiyaparambil, S.; Liu, S.; Nowak, N. J.; Pili, R.			Alterations in chromatin accessibility and DNA methylation in clear cell renal cell carcinoma	ONCOGENE			English	Article						Epigenetics; epigenome; FAIRE; FAIRE-seq; renal cell carcinoma	REGULATORY ELEMENTS; FAIRE	Recent studies have demonstrated that in clear cell renal cell carcinoma (ccRCC) several chromatin remodeling enzymes are genetically inactivated. Although, growing evidence in cancer models has demonstrated the importance of epigenetic changes, currently only changes in DNA methylation can be accurately determined from clinical samples. To address this limitation, we have applied formaldehyde-assisted isolation of regulatory elements (FAIREs) combined with next-generation sequencing (FAIRE-seq) to identify specific changes in chromatin accessibility in clinical samples of ccRCC. We modified the FAIRE procedure to allow us to examine chromatin accessibility for small samples of solid tumors. Our FAIRE results were compared with DNA-methylation analysis and show how chromatin accessibility decreases at many sites where DNA-methylation remains unchanged. In addition, our FAIRE-seq analysis allowed us to identify regulatory elements associated with both normal and tumor tissue. We have identified decreases in chromatin accessibility at key ccRCC-linked genes, including PBRM1, SETD2 and MLL2. Overall, our results demonstrate the power of examining multiple aspects of the epigenome.	[Buck, M. J.; Valiyaparambil, S.; Nowak, N. J.] SUNY Buffalo, State Ctr Excellence Bioinformat & Life Sci, Dept Biochem, Buffalo, NY 14214 USA; [Buck, M. J.; Wang, D.; Liu, S.; Nowak, N. J.] Roswell Pk Canc Inst, Buffalo, NY 14263 USA; [Raaijmakers, L. M.] Roswell Pk Canc Inst, CanSys Program, Buffalo, NY 14263 USA; [Ramakrishnan, S.; Pili, R.] Roswell Pk Canc Inst, Dept Med, Buffalo, NY 14263 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Roswell Park Cancer Institute; Roswell Park Cancer Institute; Roswell Park Cancer Institute	Buck, MJ (corresponding author), SUNY Buffalo, State Ctr Excellence Bioinformat & Life Sci, Dept Biochem, Buffalo, NY 14214 USA.	mjbuck@buffalo.edu; njnowak@buffalo.edu; Roberto.Pili@RoswellPark.org			National Cancer Institute at the National Institutes of Health [P30CA016056]; RPCI -Alliance Foundation; Bruce Cuvelier Family Trust; NATIONAL CANCER INSTITUTE [P30CA016056] Funding Source: NIH RePORTER	National Cancer Institute at the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); RPCI -Alliance Foundation; Bruce Cuvelier Family Trust; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This research was supported in part by the National Cancer Institute at the National Institutes of Health (P30CA016056; to RP), a grant from the RPCI -Alliance Foundation (to RP) and a donation from the, The Bruce Cuvelier Family Trust (to RP).	[Anonymous], 2013, NATURE, V499, P43, DOI [10.1038/nature12222, DOI 10.1038/NATURE12222, DOI 10.1038/nature12222]; Bibikova M, 2011, GENOMICS, V98, P288, DOI 10.1016/j.ygeno.2011.07.007; Cairns P, 2011, CANCER BIOMARK, V9, P461, DOI 10.3233/CBM-2011-0176; Dalgliesh GL, 2010, NATURE, V463, P360, DOI 10.1038/nature08672; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Ernst J, 2011, NATURE, V473, P43, DOI 10.1038/nature09906; Gaulton KJ, 2010, NAT GENET, V42, P255, DOI 10.1038/ng.530; Giresi PG, 2007, GENOME RES, V17, P877, DOI 10.1101/gr.5533506; Henrique Rui, 2012, Frontiers in Genetics, V3, P94, DOI 10.3389/fgene.2012.00094; Lai WKM, 2012, BIOINFORMATICS, V28, P1021, DOI 10.1093/bioinformatics/bts063; O'Rourke CJ, 2013, PHARMACOL THERAPEUT, V138, P185, DOI 10.1016/j.pharmthera.2013.01.007; Pena-LlopiS S, 2012, NAT GENET, V44, P751, DOI 10.1038/ng.2323; Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033; Rizzo JM, 2012, CANCER PREV RES, V5, P887, DOI 10.1158/1940-6207.CAPR-11-0432; Simon JM, 2012, NAT PROTOC, V7, P256, DOI 10.1038/nprot.2011.444; Sonpavde G, 2012, CURR ONCOL REP, V14, P295, DOI 10.1007/s11912-012-0237-9; van Haaften G, 2009, NAT GENET, V41, P521, DOI 10.1038/ng.349; Varela I, 2011, NATURE, V469, P539, DOI 10.1038/nature09639; Ververis K, 2013, BIOL-TARGETS THER, V7, P47, DOI 10.2147/BTT.S29965; Wang H, 2012, GENOME RES, V22, P1680, DOI 10.1101/gr.136101.111; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137	21	16	16	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	2014	33	41					4961	4965		10.1038/onc.2013.455	http://dx.doi.org/10.1038/onc.2013.455			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR7OA	24186201				2022-12-17	WOS:000343767900009
J	He, L; Guo, L; Vathipadiekal, V; Sergent, PA; Growdon, WB; Engler, DA; Rueda, BR; Birrer, MJ; Orsulic, S; Mohapatra, G				He, L.; Guo, L.; Vathipadiekal, V.; Sergent, P. A.; Growdon, W. B.; Engler, D. A.; Rueda, B. R.; Birrer, M. J.; Orsulic, S.; Mohapatra, G.			Identification of LMX1B as a novel oncogene in human ovarian cancer	ONCOGENE			English	Article						ovarian cancer; aCGH; LMX1B; tumor progression; transcription factor	NAIL-PATELLA-SYNDROME; COMPARATIVE GENOMIC HYBRIDIZATION; MOUSE MODEL; MOLECULAR CHARACTERIZATION; HOMEODOMAIN PROTEINS; TRANSCRIPTION FACTOR; GENETIC CHANGES; BREAST CANCERS; KAPPA-B; INFLAMMATION	Ovarian cancers are thought to result from the accumulation of multiple genetic aberrations that transform ovarian and/or fallopian tube surface epithelial cells, allowing for their abnormal growth, proliferation and metastasis. In the report presented here, we carried out genome-wide copy-number analysis using comparative genomic hybridization on a panel of mouse ovarian cancer (OVCA) cell lines previously established in our laboratory. We identified a recurrent focal amplification on mouse chromosomal region 2qB, which contains the LIM-homeodomain-containing transcription factor 1B (Lmx1b) gene. LMX1B is not expressed in normal human ovary, but is expressed in many human OVCA cell lines and primary tumors. High expression of LMX1B correlates with poor outcome. To clarify the role of LMX1B in ovarian carcinogenesis, we transduced LMX1B into a panel of mouse and human OVCA cell lines and demonstrated that LMX1B strongly promotes migration of cancer cells in culture and promotes xenograft growth in nude mice. Conversely, knockdown of LMX1B in a human cell line with endogenous high expression of LMX1B inhibits cell migration in vitro and tumor growth in vivo. Microarray analysis of cells overexpressing LMX1B identified the nuclear factor (NF)-kappa B pathway as a potential mediator of tumor progression and subsequent treatment of NF kappa B inhibitor decreased the migratory capacity of these cells. Thus, our data demonstrate that LMX1B is a novel oncogene in OVCA pathogenesis.	[He, L.; Mohapatra, G.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; [He, L.; Vathipadiekal, V.; Growdon, W. B.; Rueda, B. R.; Birrer, M. J.; Mohapatra, G.] Harvard Univ, Sch Med, Boston, MA USA; [Guo, L.; Sergent, P. A.; Growdon, W. B.; Rueda, B. R.] Massachusetts Gen Hosp, Dept Vincent Obstet & Gynecol, Vincent Ctr Reprod Biol, Boston, MA 02114 USA; [Vathipadiekal, V.; Birrer, M. J.] Massachusetts Gen Hosp, Div Hematol Oncol, Boston, MA 02114 USA; [Vathipadiekal, V.; Birrer, M. J.] Massachusetts Gen Hosp, Ctr Canc Res, Boston, MA 02114 USA; [Engler, D. A.] Brigham Young Univ, Dept Stat, Provo, UT 84602 USA; [Orsulic, S.] Cedars Sinai Med Ctr, Womens Canc Res Inst, Los Angeles, CA 90048 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Brigham Young University; Cedars Sinai Medical Center	Mohapatra, G (corresponding author), Massachusetts Gen Hosp, Dept Pathol, 70 Blossom St, Boston, MA 02114 USA.	gmohapatra@partners.org		Sergent, Petra/0000-0002-8244-8209; /0000-0002-8181-6890	American Cancer Society [118900-RSG-10-252-01-TBG]; Advanced Medical Research Foundation; Vincent Memorial Research Funds; Michael Wall Gynecologic Oncology Research Fund	American Cancer Society(American Cancer Society); Advanced Medical Research Foundation; Vincent Memorial Research Funds; Michael Wall Gynecologic Oncology Research Fund	We thank Jinsong Liu (MD Anderson Cancer Center) for the T29-immortalized human ovarian surface epithelial cell line. This work was supported by the American Cancer Society Grant 118900-RSG-10-252-01-TBG (SO), Advanced Medical Research Foundation (BRR) and Vincent Memorial Research Funds (BRR) and the Michael Wall Gynecologic Oncology Research Fund (GM).	Bach I, 2000, MECH DEVELOP, V91, P5, DOI 10.1016/S0925-4773(99)00314-7; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Bongers EMHF, 2002, PEDIATR NEPHROL, V17, P703, DOI 10.1007/s00467-002-0911-5; Burbach JPH, 2003, ANN NY ACAD SCI, V991, P61; Cannistra SA, 2004, NEW ENGL J MED, V351, P2519, DOI 10.1056/NEJMra041842; Chen H, 1998, NAT GENET, V19, P51, DOI 10.1038/ng0598-51; Cheng KW, 2004, NAT MED, V10, P1251, DOI 10.1038/nm1125; Dreyer SD, 1998, NAT GENET, V19, P47, DOI 10.1038/ng0598-47; Fishman A, 2005, INT J GYNECOL CANCER, V15, P261, DOI 10.1111/j.1525-1438.2005.15213.x; Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299; Gabeau-Lacet D, 2009, J NEUROPATH EXP NEUR, V68, P1155, DOI 10.1097/NEN.0b013e3181ba3952; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Grivennikov SI, 2010, CYTOKINE GROWTH F R, V21, P11, DOI 10.1016/j.cytogfr.2009.11.005; Guo C, 2007, DEVELOPMENT, V134, P317, DOI 10.1242/dev.02745; Hernandez L, 2010, CANCER RES, V70, P4005, DOI 10.1158/0008-5472.CAN-09-3912; Hunter C, 2005, MOL BIOL REP, V32, P67, DOI 10.1007/s11033-004-7657-z; Israeli O, 2004, CANCER GENET CYTOGEN, V154, P16, DOI 10.1016/j.cancergencyto.2004.02.006; Ivan C, 2013, GYNECOL ONCOL, V128, P506, DOI 10.1016/j.ygyno.2012.11.029; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Johnson JD, 1997, MOL CELL BIOL, V17, P3488, DOI 10.1128/MCB.17.7.3488; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Kim M, 2006, CELL, V125, P1269, DOI 10.1016/j.cell.2006.06.008; Lee TI, 2013, CELL, V152, P1237, DOI 10.1016/j.cell.2013.02.014; Liu GZ, 2010, JNCI-J NATL CANCER I, V102, P812, DOI 10.1093/jnci/djq127; Liu JS, 2004, CANCER RES, V64, P1655, DOI 10.1158/0008-5472.CAN-03-3380; Mani SA, 2007, P NATL ACAD SCI USA, V104, P10069, DOI 10.1073/pnas.0703900104; Mantovani A, 2010, ANN MED, V42, P161, DOI 10.3109/07853890903405753; Mayr D, 2006, AM J CLIN PATHOL, V126, P101, DOI 10.1309/N6X5MB24BP42KP20; McCann CK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028077; McIntosh I, 2005, ANN HUM GENET, V69, P349, DOI 10.1111/j.1529-8817.2005.00191.x; Miao J, 2007, P NATL ACAD SCI USA, V104, P17093, DOI 10.1073/pnas.0707938104; MOHAPATRA G, 1995, GENE CHROMOSOME CANC, V13, P86, DOI 10.1002/gcc.2870130203; Mok SC, 2009, CANCER CELL, V16, P521, DOI 10.1016/j.ccr.2009.10.018; Nanjundan M, 2007, CANCER RES, V67, P3074, DOI 10.1158/0008-5472.CAN-06-2366; Orsulic S, 2002, CANCER CELL, V1, P53, DOI 10.1016/S1535-6108(01)00002-2; Ozols RF, 2004, CANCER CELL, V5, P19, DOI 10.1016/S1535-6108(04)00002-9; Pinkel D, 2005, NAT GENET, V37, pS11, DOI 10.1038/ng1569; Pressman CL, 2000, GENESIS, V26, P15, DOI 10.1002/(SICI)1526-968X(200001)26:1<15::AID-GENE5>3.0.CO;2-V; Rascle A, 2009, EXP CELL RES, V315, P76, DOI 10.1016/j.yexcr.2008.10.012; Sato U, 2005, PEDIATR RES, V57, P783, DOI 10.1203/01.PDR.0000157674.63621.2C; Stratton MR, 2011, SCIENCE, V331, P1553, DOI 10.1126/science.1204040; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; White KL, 2011, CANCER CAUSE CONTROL, V22, P785, DOI 10.1007/s10552-011-9745-4; Xing DY, 2006, CANCER RES, V66, P8949, DOI 10.1158/0008-5472.CAN-06-1495; Xing DY, 2005, P NATL ACAD SCI USA, V102, P6936, DOI 10.1073/pnas.0502256102; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734; Zender L, 2006, CELL, V125, P1253, DOI 10.1016/j.cell.2006.05.030	49	16	16	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 14	2014	33	33					4226	4235		10.1038/onc.2013.375	http://dx.doi.org/10.1038/onc.2013.375			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AO2MB	24056967				2022-12-17	WOS:000341155800004
J	Wallace, MD; Southard, TL; Schimenti, KJ; Schimenti, JC				Wallace, M. D.; Southard, T. L.; Schimenti, K. J.; Schimenti, J. C.			Role of DNA damage response pathways in preventing carcinogenesis caused by intrinsic replication stress	ONCOGENE			English	Article						DNA replication; DNA damage checkpoints; minichromosome maintenance proteins; 9-1-1; MCM2-7 helicase; replication stress	ATAXIA-TELANGIECTASIA; BREAST-CANCER; TUMOR SUSCEPTIBILITY; GENOMIC INSTABILITY; IONIZING-RADIATION; MOUSE MODEL; ATM; MICE; CHK2; PHOSPHORYLATION	Defective DNA replication can result in genomic instability, cancer and developmental defects. To understand the roles of DNA damage response (DDR) genes on carcinogenesis in mutants defective for core DNA replication components, we utilized the Mcm4Chaos3/Chaos3 ('Chaos3') mouse model that, by virtue of an amino-acid alteration in MCM4 that destabilizes the MCM2-7 DNA replicative helicase, has fewer dormant replication origins and an increased number of stalled replication forks. This leads to genomic instability and cancer in most Chaos3 mice. We found that animals doubly mutant for Chaos3 and components of the ataxia telangiectasia-mutated (ATM) double-strand break response pathway (Atm, p21/Cdkn1a and Chk2/Chek2) had decreased tumor latency and/or increased tumor susceptibility. Tumor latency and susceptibility differed between genetic backgrounds and genders, with females demonstrating an overall greater cancer susceptibility to Atm and p21 deficiency than males. Atm deficiency was semilethal in the Chaos3 background and impaired embryonic fibroblast proliferation, suggesting that ATM drug inhibitors might be useful against tumors with DNA replication defects. Hypomorphism for the 9-1-1 component Hus1 did not affect tumor latency or susceptibility in Chaos3 animals, and tumors in these mice did not exhibit impaired ATR pathway signaling. These and other data indicate that under conditions of systemic replication stress, the ATM pathway is particularly important both for cancer suppression and viability during development.	[Wallace, M. D.; Southard, T. L.; Schimenti, K. J.; Schimenti, J. C.] Cornell Univ, Dept Biomed Sci, Coll Vet Med, Ithaca, NY 14853 USA; [Wallace, M. D.; Schimenti, J. C.] Dept Mol Biol & Genet, Ithaca, NY USA; [Southard, T. L.] Sect Anat Pathol, Ithaca, NY USA; [Schimenti, J. C.] Cornell Univ, Ctr Vertebrate Genom, Ithaca, NY 14853 USA	Cornell University; Cornell University	Schimenti, JC (corresponding author), Cornell Univ, Dept Biomed Sci, Coll Vet Med, VRT 9014A, Ithaca, NY 14853 USA.	jcs92@cornell.edu		Wallace, Marsha/0000-0001-8588-9512	NIH Training [IT32HDO57854, 5T32GM007617]; Empire State Stem Cell Fund [C026442, C024174]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD057854] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007617] Funding Source: NIH RePORTER	NIH Training(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Empire State Stem Cell Fund; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank RS Weiss and T Mak for providing mice. We also thank RS Weiss and G Balmus for critical feedback on the manuscript. This study was supported by NIH Training Grants IT32HDO57854 and 5T32GM007617, and Empire State Stem Cell Fund Contract Numbers C026442 and C024174 to JCS.	Albertson TM, 2009, P NATL ACAD SCI USA, V106, P17101, DOI 10.1073/pnas.0907147106; Arana ME, 2010, SEMIN CANCER BIOL, V20, P304, DOI 10.1016/j.semcancer.2010.10.003; Bagley BN, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1003034; Balmus G, 2012, HUM MOL GENET, V21, P3408, DOI 10.1093/hmg/dds173; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Barlow C, 1999, NAT GENET, V21, P359, DOI 10.1038/7684; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Berger AH, 2011, NATURE, V476, P163, DOI 10.1038/nature10275; Bhatti S, 2011, CELL MOL LIFE SCI, V68, P2977, DOI 10.1007/s00018-011-0683-9; Cazzalini O, 2010, MUTAT RES-REV MUTAT, V704, P12, DOI 10.1016/j.mrrev.2010.01.009; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Chuang CH, 2012, NUCLEIC ACIDS RES, V40, P4914, DOI 10.1093/nar/gks176; Chuang CH, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001110; Cimprich KA, 2008, NAT REV MOL CELL BIO, V9, P616, DOI 10.1038/nrm2450; Cortez D, 2004, P NATL ACAD SCI USA, V101, P10078, DOI 10.1073/pnas.0403410101; Curtin NJ, 2012, NAT REV CANCER, V12, P801, DOI 10.1038/nrc3399; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Dorak M. Tevfik, 2012, Frontiers in Genetics, V3, P268, DOI 10.3389/fgene.2012.00268; El GS, 2011, PLOS GENET, V7; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; Errico A, 2012, CRIT REV BIOCHEM MOL, V47, P222, DOI 10.3109/10409238.2012.655374; Gatei M, 2003, J BIOL CHEM, V278, P14806, DOI 10.1074/jbc.M210862200; Goldsby RE, 2001, NAT MED, V7, P638, DOI 10.1038/88963; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hirao A, 2002, MOL CELL BIOL, V22, P6521, DOI 10.1128/MCB.22.18.6521-6532.2002; Honeycutt KA, 2006, ONCOGENE, V25, P4027, DOI 10.1038/sj.onc.1209435; Ilves I, 2010, MOL CELL, V37, P247, DOI 10.1016/j.molcel.2009.12.030; Jones RM, 2012, BIOCHEM J, V443, P13, DOI 10.1042/BJ20112100; Karabinis ME, 2001, CARCINOGENESIS, V22, P343, DOI 10.1093/carcin/22.2.343; Kawabata T, 2011, MAMM GENOME, V22, P506, DOI 10.1007/s00335-011-9333-7; Kawabata T, 2011, MOL CELL, V41, P543, DOI 10.1016/j.molcel.2011.02.006; Kemp M, 2009, CURR BIOL, V19, pR733, DOI 10.1016/j.cub.2009.07.026; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kunnev D, 2010, ONCOGENE, V29, P3630, DOI 10.1038/onc.2010.125; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Levitt PS, 2007, MOL CELL BIOL, V27, P2189, DOI 10.1128/MCB.01763-06; Levitt PS, 2005, GENOMICS, V86, P212, DOI 10.1016/j.ygeno.2005.04.007; Li XCL, 2011, GENETICS, V187, P1031, DOI 10.1534/genetics.110.125450; Lieberman HB, 2011, J MOL CELL BIOL, V3, P39, DOI 10.1093/jmcb/mjq039; Lopez-Contreras AJ, 2010, DNA REPAIR, V9, P1249, DOI 10.1016/j.dnarep.2010.09.012; Lu S, 2006, CARCINOGENESIS, V27, P848, DOI 10.1093/carcin/bgi302; Mao JH, 2008, ONCOGENE, V27, P6596, DOI 10.1038/onc.2008.280; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Meijers-Heijboer H, 2002, NAT GENET, V31, P55, DOI 10.1038/ng879; Mokrani-Benhelli H, 2013, HUM MUTAT, V34, P374, DOI 10.1002/humu.22245; Moyer SE, 2006, P NATL ACAD SCI USA, V103, P10236, DOI 10.1073/pnas.0602400103; Moynahan ME, 2010, NAT REV MOL CELL BIO, V11, P196, DOI 10.1038/nrm2851; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Murga M, 2011, NAT STRUCT MOL BIOL, V18, P1331, DOI 10.1038/nsmb.2189; Murga M, 2009, NAT GENET, V41, P891, DOI 10.1038/ng.420; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Niida H, 2010, EMBO J, V29, P3558, DOI 10.1038/emboj.2010.218; Pabla N, 2008, J BIOL CHEM, V283, P6572, DOI 10.1074/jbc.M707568200; Petermann E, 2010, NAT REV MOL CELL BIO, V11, P683, DOI 10.1038/nrm2974; Preston BD, 2010, SEMIN CANCER BIOL, V20, P281, DOI 10.1016/j.semcancer.2010.10.009; Pruitt SC, 2007, STEM CELLS, V25, P3121, DOI 10.1634/stemcells.2007-0483; Reiman A, 2011, BRIT J CANCER, V105, P586, DOI 10.1038/bjc.2011.266; Schoppy DW, 2012, J CLIN INVEST, V122, P241, DOI 10.1172/JCI58928; Sclafani RA, 2007, ANNU REV GENET, V41, P237, DOI 10.1146/annurev.genet.41.110306.130308; Shechter D, 2004, P NATL ACAD SCI USA, V101, P10845, DOI 10.1073/pnas.0404143101; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shima N, 2007, NAT GENET, V39, P93, DOI 10.1038/ng1936; Spring K, 2002, NAT GENET, V32, P185, DOI 10.1038/ng958; Stracker TH, 2008, MOL CELL, V31, P21, DOI 10.1016/j.molcel.2008.04.028; Takai H, 2002, EMBO J, V21, P5195, DOI 10.1093/emboj/cdf506; Thompson D, 2005, JNCI-J NATL CANCER I, V97, P813, DOI 10.1093/jnci/dji141; Vijayraghavan Sriram, 2012, Subcell Biochem, V62, P113, DOI 10.1007/978-94-007-4572-8_7; Wallace MD, 2012, GENETICS, V192, P385, DOI 10.1534/genetics.112.142802; Warmerdam DO, 2009, MUTAT RES, V704, P2; Weiss RS, 2000, GENE DEV, V14, P1886; Weiss RS, 2002, CURR BIOL, V12, P73, DOI 10.1016/S0960-9822(01)00626-1; Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zheng YL, 2010, INT J CANCER, V126, P2199, DOI 10.1002/ijc.24771	78	16	17	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 10	2014	33	28					3688	3695		10.1038/onc.2013.339	http://dx.doi.org/10.1038/onc.2013.339			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL2GC	23975433	Green Accepted			2022-12-17	WOS:000338942900008
J	Iguchi, M; Osanai, M; Hayashi, Y; Koentgen, F; Lee, GH				Iguchi, M.; Osanai, M.; Hayashi, Y.; Koentgen, F.; Lee, G-H			The error-prone DNA polymerase iota provides quantitative resistance to lung tumorigenesis and mutagenesis in mice	ONCOGENE			English	Article						lung tumor susceptibility; quantitative trait locus; causative gene; DNA polymerase iota; mutagenesis	INDUCED PULMONARY ADENOMAS; TUMOR SUSCEPTIBILITY; POL-IOTA; URETHANE-INDUCTION; MAJOR MODIFIER; BALB/CBYJ MICE; LOCUS; CANCER; GENES; ETA	Opposite undamaged nucleotide T, DNA polymerase iota (Poli) preferentially incorporates G rather than A, violating the Watson-Crick rule. Although the actual biological role of Poli remains enigmatic, we have identified its coding gene as a candidate for pulmonary adenoma resistance 2 (Par2), a mouse quantitative trait locus modulating chemically induced lung tumor susceptibility. Notably, the most tumor-sensitive Par2 allele possessed by the 129X1/SvJ mouse is associated with a loss-of-function mutation in Poli. To determine whether the nonfunctional Poli is responsible for the 129X1/SvJ-specific Par2 phenotype, we knocked out Poli in a C57BL/6J mouse carrying a less tumor-sensitive Par2 allele. Disruption of the C57BL/6J Poli conferred 129X1/SvJ-like sensitivity on the C57BL/6J Par2 locus and increased the in vivo mutation frequency in the lung, providing definitive proof that Poli causes the Par2 effect and inhibits tumorigenesis and mutagenesis, despite its extreme replication infidelity.	[Iguchi, M.; Osanai, M.; Hayashi, Y.; Lee, G-H] Kochi Univ, Sch Med, Dept Pathol, Kochi 7838505, Japan; [Koentgen, F.] Ozgene Pty Ltd, Bentley Dc, WA, Australia	Kochi University	Lee, GH (corresponding author), Kochi Univ, Sch Med, Dept Pathol, Nanko Ku, Oko Cho, Kochi 7838505, Japan.	ghlee@kochi-u.ac.jp			Ministry of Education, Culture, Sports, Science and Technology; Smoking Research Foundation of Japan	Ministry of Education, Culture, Sports, Science and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Smoking Research Foundation of Japan	We are grateful to Dr Yukari Totsuka and Dr Hitoshi Nakagama for their helpful advice on the gpt delta mouse assay. This work was supported in part by grants from the Ministry of Education, Culture, Sports, Science and Technology, and the Smoking Research Foundation of Japan.	Albertella MR, 2005, DNA REPAIR, V4, P583, DOI 10.1016/j.dnarep.2005.01.005; DEVEREUX TR, 1994, MAMM GENOME, V5, P749, DOI 10.1007/BF00292007; Dragani TA, 1995, ADV CANCER RES, V67, P83, DOI 10.1016/S0065-230X(08)60711-3; Dumstorf CA, 2006, P NATL ACAD SCI USA, V103, P18083, DOI 10.1073/pnas.0605247103; Dwyer-Nield LD, 2010, INT J CANCER, V126, P125, DOI 10.1002/ijc.24743; Faili A, 2002, NATURE, V419, P944, DOI 10.1038/nature01117; FESTING MFW, 1994, GENET RES, V64, P99, DOI 10.1017/S0016672300032705; Frank EG, 2001, EMBO J, V20, P2914, DOI 10.1093/emboj/20.11.2914; GARIBOLDI M, 1993, NAT GENET, V3, P132, DOI 10.1038/ng0293-132; Gueranger Q, 2008, DNA REPAIR, V7, P1551, DOI 10.1016/j.dnarep.2008.05.012; Hayashi Y, 2011, CANCER SCI, V102, P1228, DOI 10.1111/j.1349-7006.2011.01910.x; Kannouche P, 2003, EMBO J, V22, P1223, DOI 10.1093/emboj/7595006; Karasaki H, 1997, ONCOGENE, V15, P1833, DOI 10.1038/sj.onc.1201357; Kirouac KN, 2011, P NATL ACAD SCI USA, V108, P3210, DOI 10.1073/pnas.1013909108; Lee GH, 2005, CANCER SCI, V96, P256, DOI 10.1111/j.1349-7006.2005.00042.x; Lee GH, 2003, ONCOGENE, V22, P2374, DOI 10.1038/sj.onc.1206387; Lee GH, 2001, ONCOGENE, V20, P3979, DOI 10.1038/sj.onc.1204562; Liu PY, 2009, CANCER RES, V69, P6290, DOI 10.1158/0008-5472.CAN-09-0782; Liu PY, 2006, NAT GENET, V38, P888, DOI 10.1038/ng1849; MALKINSON AM, 1985, J NATL CANCER I, V75, P971, DOI 10.1093/jnci/75.5.971; Malkinson AM, 2001, LUNG CANCER, V32, P265, DOI 10.1016/S0169-5002(00)00232-4; Manenti G, 2004, ONCOGENE, V23, P4495, DOI 10.1038/sj.onc.1207584; Manenti G, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000331; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; McDonald JP, 2003, J EXP MED, V198, P635, DOI 10.1084/jem.20030767; McDonald JP, 1999, GENOMICS, V60, P20, DOI 10.1006/geno.1999.5906; Nohmi T, 1996, ENVIRON MOL MUTAGEN, V28, P465, DOI 10.1002/(SICI)1098-2280(1996)28:4<465::AID-EM24>3.0.CO;2-C; Obata M, 1996, ONCOGENE, V13, P1599; Ohkumo T, 2006, MOL CELL BIOL, V26, P7696, DOI 10.1128/MCB.01076-06; Petta TB, 2008, EMBO J, V27, P2883, DOI 10.1038/emboj.2008.210; Reif AE, 1999, ADV CANCER RES, V76, P161; Sakiyama T, 2005, INT J CANCER, V114, P730, DOI 10.1002/ijc.20790; Skovlund E, 2001, J CLIN EPIDEMIOL, V54, P86, DOI 10.1016/S0895-4356(00)00264-X; Vaisman A, 2002, MUTAT RES-FUND MOL M, V510, P9, DOI 10.1016/S0027-5107(02)00248-8; Vidal AE, 2009, DNA REPAIR, V8, P420, DOI 10.1016/j.dnarep.2008.12.007; Wang HB, 2010, NEURO-ONCOLOGY, V12, P679, DOI 10.1093/neuonc/nop074; Wang M, 2004, CANCER RES, V64, P1924, DOI 10.1158/0008-5472.CAN-03-3080; Wang WYS, 2005, NAT REV GENET, V6, P109, DOI 10.1038/nrg1522; Wong ML, 2005, BIOTECHNIQUES, V39, P75, DOI 10.2144/05391RV01; Yang J, 2004, CANCER RES, V64, P5597, DOI 10.1158/0008-5472.CAN-04-0603; Yokota J, 2010, ADV CANCER RES, V109, P51, DOI 10.1016/B978-0-12-380890-5.00002-8; Yuan BF, 2011, J BIOL CHEM, V286, P17503, DOI 10.1074/jbc.M111.232835; Zhou JD, 2012, CANCER SCI, V103, P1574, DOI 10.1111/j.1349-7006.2012.02309.x	43	16	17	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	2014	33	27					3612	3617		10.1038/onc.2013.331	http://dx.doi.org/10.1038/onc.2013.331			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL2FK	23955086				2022-12-17	WOS:000338941100013
J	Li, ZJ; Mack, SC; Mak, TH; Angers, S; Taylor, MD; Hui, CC				Li, Z. J.; Mack, S. C.; Mak, T. H.; Angers, S.; Taylor, M. D.; Hui, C-C			Evasion of p53 and G(2)/M checkpoints are characteristic of Hh-driven basal cell carcinoma	ONCOGENE			English	Article						Sufu; Ptc1; Hedgehog; basal cell carcinoma; cell cycle; p53	CYCLE PROGRESSION; SIGNALING PATHWAY; SMAD PROTEINS; HEDGEHOG; SKIN; MICE; EXPRESSION; TUMORIGENESIS; SUPPRESSOR; PROLIFERATION	Basal cell carcinoma (BCC), the most common type of cancer, is characterized by aberrant Hedgehog (Hh) pathway activity. Mutations in pathway components, such as PATCHED1 (PTCH1), are commonly found in BCC. While the tumor suppressor role of PTCH1 in BCC is well established, how Hh pathway activation disrupts normal skin homeostasis to promote BCC formation remains poorly understood. Like Ptc1, Sufu is a major negative regulator of the Hh pathway. Previously, we showed that inactivation of Sufu in the skin does not result in BCC formation. Why loss of Ptc1, but not Sufu, in the epidermis induces BCC formation is unclear. In this report, we utilized gene expression profiling to identify biological pathways and processes that distinguish Sufu from Ptc1 mutants, and discovered a novel role for Sufu in cell cycle regulation. We demonstrated that the Hh pathway activation in Sufu and Ptc1 mutant skin is associated with abnormal cell cycle entry, ectopic expression of D-type cyclins and increased DNA damage. However, despite the presence of DNA damage, p53 stabilization was impaired in the mutant skin. Alternative mechanism to halt genomic instability is the activation of G2/M cell cycle checkpoint, which can occur independent of p53. We found that while Ptc1 mutant cells continue to cycle, which would favor genomic instability, loss of Sufu results in G2/M cell cycle arrest. This finding may explain why inactivation of Sufu is not sufficient to drive BCC formation. Taken together, these studies revealed a unique role for Sufu in G2/M phase progression, and uncovered the molecular and cellular features associated with Hh-driven BCC.	[Li, Z. J.; Mack, S. C.; Mak, T. H.; Taylor, M. D.; Hui, C-C] Hosp Sick Children, Program Dev & Stem Cell Biol, Toronto, ON M5G 1L7, Canada; [Li, Z. J.; Hui, C-C] Univ Toronto, Dept Mol Genet, Toronto, ON, Canada; [Mack, S. C.; Taylor, M. D.] Hosp Sick Children, Arthur & Sonia Labatt Brain Tumor Res Ctr, Div Neurosurg, Toronto, ON M5G 1X8, Canada; [Mack, S. C.; Taylor, M. D.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; [Angers, S.] Univ Toronto, Leslie Dan Fac Pharm, Toronto, ON, Canada; [Angers, S.] Univ Toronto, Dept Biochem, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University of Toronto	Hui, CC (corresponding author), Hosp Sick Children, Program Dev & Stem Cell Biol, 101 Coll St,TMDT East Tower,Room 13-314, Toronto, ON M5G 1L7, Canada.	cchui@sickkids.ca	Angers, Stephane/E-1432-2014	Angers, Stephane/0000-0001-7241-9044; Mack, Stephen C./0000-0001-9620-4742; Taylor, Michael/0000-0001-7009-3466	Canadian Cancer Society Research Institute [2011-700774]	Canadian Cancer Society Research Institute(Canadian Cancer Society (CCS))	We thank E Nieuwenhuis and W Nien for initial characterization of the Sufu and Ptc1 mutants, and T Satkunendran for technical help. This research is funded by the Canadian Cancer Society Research Institute (2011-700774) to CCH.	Abe Y, 2008, P NATL ACAD SCI USA, V105, P4838, DOI 10.1073/pnas.0712216105; Adolphe C, 2006, CANCER RES, V66, P2081, DOI 10.1158/0008-5472.CAN-05-2146; Aszterbaum M, 1999, NAT MED, V5, P1285, DOI 10.1038/15242; Barnes EA, 2001, EMBO J, V20, P2214, DOI 10.1093/emboj/20.9.2214; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Cooper AF, 2005, DEVELOPMENT, V132, P4407, DOI 10.1242/dev.02021; Cwinn MA, 2011, J NEUROSCI, V31, P5169, DOI 10.1523/JNEUROSCI.5495-10.2011; Epstein EH, 2008, NAT REV CANCER, V8, P743, DOI 10.1038/nrc2503; Fan HR, 1999, J CELL BIOL, V147, P71, DOI 10.1083/jcb.147.1.71; Gambichler T, 2007, EUR J MED RES, V12, P509; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Grachtchouk M, 2000, NAT GENET, V24, P216, DOI 10.1038/73417; Grachtchouk V, 2003, EMBO J, V22, P2741, DOI 10.1093/emboj/cdg271; Howell BG, 2005, J DERMATOL SCI, V39, P39, DOI 10.1016/j.jdermsci.2005.02.004; Humke EW, 2010, GENE DEV, V24, P670, DOI 10.1101/gad.1902910; Hutchin ME, 2005, GENE DEV, V19, P214, DOI 10.1101/gad.1258705; Kasper M, 2011, P NATL ACAD SCI USA, V108, P4099, DOI 10.1073/pnas.1014489108; Kenney AM, 2003, DEVELOPMENT, V130, P15, DOI 10.1242/dev.00182; Kenney AM, 2000, MOL CELL BIOL, V20, P9055, DOI 10.1128/MCB.20.23.9055-9067.2000; Lange D, 1999, INT J ONCOL, V14, P1049; Li ZJ, 2012, DEVELOPMENT, V139, P4152, DOI 10.1242/dev.081190; Mancuso M, 2004, CANCER RES, V64, P934, DOI 10.1158/0008-5472.CAN-03-2460; Merico D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013984; Mill P, 2003, GENE DEV, V17, P282, DOI 10.1101/gad.1038103; Mill P, 2005, DEV CELL, V9, P293, DOI 10.1016/j.devcel.2005.05.009; Ng D, 2005, AM J MED GENET A, V134A, P399, DOI 10.1002/ajmg.a.30653; Nieuwenhuis E, 2006, MOL CELL BIOL, V26, P6609, DOI 10.1128/MCB.00295-06; Nilsson M, 2000, P NATL ACAD SCI USA, V97, P3438, DOI 10.1073/pnas.050467397; O'Driscoll L, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-74; Oro AE, 2003, DEV BIOL, V255, P238, DOI 10.1016/S0012-1606(02)00042-8; Reifenberger J, 2005, BRIT J DERMATOL, V152, P43, DOI 10.1111/J.1365-2133.2005.06353.X; Ribeiro GRH, 2004, J DERMATOL SCI, V36, P79, DOI 10.1016/j.jdermsci.2004.08.003; Sardi I, 2000, ONCOL REP, V7, P1119; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Svard J, 2006, DEV CELL, V10, P187, DOI 10.1016/j.devcel.2005.12.013; Takizawa CG, 2000, CURR OPIN CELL BIOL, V12, P658, DOI 10.1016/S0955-0674(00)00149-6; Tukachinsky H, 2010, J CELL BIOL, V191, P415, DOI 10.1083/jcb.201004108; Van Haren R, 2009, BRIT J DERMATOL, V161, P1278, DOI 10.1111/j.1365-2133.2009.09338.x; Villani RM, 2010, CANCER PREV RES, V3, P1222, DOI 10.1158/1940-6207.CAPR-10-0082; Welss T, 2003, INT J CANCER, V104, P66, DOI 10.1002/ijc.10912	41	16	17	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2014	33	20					2674	2680		10.1038/onc.2013.212	http://dx.doi.org/10.1038/onc.2013.212			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AH9YT	23752195				2022-12-17	WOS:000336502700013
J	Harrison, W; Cochrane, B; Neill, G; Philpott, M				Harrison, W.; Cochrane, B.; Neill, G.; Philpott, M.			The oncogenic GLI transcription factors facilitate keratinocyte survival and transformation upon exposure to genotoxic agents	ONCOGENE			English	Article						Hedgehog; GLI; Genotoxic; Transformation; Keratinocyte	BASAL-CELL CARCINOMAS; EPITHELIAL-MESENCHYMAL TRANSITIONS; GENE-EXPRESSION; HUMAN HOMOLOG; E-CADHERIN; FACTOR SNAIL; DNA-DAMAGE; STEM-CELLS; ACTIVATION; APOPTOSIS	Ultraviolet B (UVB) light is the principal aetiological factor associated with non-melanoma skin cancer, the most prevalent group of malignancies in the Caucasian population. Exposure to environmental chemicals has also been shown to promote skin carcinogenesis and, as for UVB, this is associated with the acquisition of genomic DNA damage. Cells respond to DNA damage by inducing cell cycle arrest to facilitate DNA repair, although apoptosis will occur if the damage is excessive. Oncogenes may drive carcinogenesis by disrupting the balanced control of cell cycle progression, DNA repair and apoptosis, allowing for the propagation of cells with damaged DNA. The transcription factors GLI1 and GLI2 have been implicated in both the initiation and progression of several cancers, including basal cell carcinoma. Here we show that GLI1 and an active mutant of GLI2 (Delta NGLI2) promote apoptotic resistance in N/TERT human keratinocytes upon exposure to UVB and the DNA-alkylating chemicals such as methyl methanesulphonate (MMS) and N-ethyl-N-nitrosurea. Compared with control and untreated N/TERT-GLI1 and -GLI2 cells, those that survived genotoxic insult formed significantly more colonies in soft agar and were significantly more invasive when grown in three-dimensional organotypic collagen gel cultures. Indeed, surviving N/TERT-GLI1 and -GLI2 cells expressed higher levels of the epithelial-to-mesenchymal transition markers Snail and vimentin, and a subpopulation of MMS-treated cells displayed an elongated fibroblast-like morphology with decreased levels of E-cadherin. Finally, whereas Bcl2 was strongly increased in N/TERT-GLI2 cells, the level of induction was weak in N/TERT-GLI1 cells, indicating that GLI1 may activate anti-apoptotic mechanisms(s) independently of Bcl2. In summary, our results show that GLI1 and GLI2 facilitate the propagation of cells with damaged DNA, and thus their expression may be naturally higher in cells that form the earliest precursor tumour lesions.	[Harrison, W.; Neill, G.; Philpott, M.] Queen Mary Univ London, Blizard Inst, Barts & London Sch Med & Dent, Ctr Cutaneous Res, London E1 2AT, England; [Cochrane, B.] Unilever, Safety & Environm Assurance Ctr, Bedford, England	University of London; Queen Mary University London; Unilever	Philpott, M (corresponding author), Queen Mary Univ London, Blizard Inst, Barts & London Sch Med & Dent, Ctr Cutaneous Res, 4 Newark St, London E1 2AT, England.	m.p.philpott@qmul.ac.uk		Philpott, Michael/0000-0002-1255-4612	Dr Hadwen Trust for Humane Research and Unilever Research	Dr Hadwen Trust for Humane Research and Unilever Research(Unilever)	This work was funded by a basic science grants from the Dr Hadwen Trust for Humane Research and Unilever Research to Professor Mike Philpott and Dr Graham Neill.	Ahmadian A, 1998, ONCOGENE, V17, P1837, DOI 10.1038/sj.onc.1202080; Alexaki VI, 2010, JNCI-J NATL CANCER I, V102, P1148, DOI 10.1093/jnci/djq257; Almahroos Mona, 2004, Skinmed, V3, P132; Armstrong BK, 2001, J PHOTOCH PHOTOBIO B, V63, P8, DOI 10.1016/S1011-1344(01)00198-1; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Biddle A, 2011, CANCER RES, V71, P5317, DOI 10.1158/0008-5472.CAN-11-1059; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Chen XL, 2010, ARCH MED RES, V41, P315, DOI 10.1016/j.arcmed.2010.06.003; Dahmane N, 1997, NATURE, V389, P876, DOI 10.1038/39918; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; Fan L, 2004, ENDOCRINOLOGY, V145, P3961, DOI 10.1210/en.2004-0079; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; Grachtchouk M, 2011, J CLIN INVEST, V121, P1768, DOI 10.1172/JCI46307; Han G, 2005, J CLIN INVEST, V115, P1714, DOI 10.1172/JCI24399; Hoot KE, 2008, J CLIN INVEST, V118, P2722, DOI 10.1172/JCI33713; Hudson LG, 2009, J DERMATOL SCI, V56, P19, DOI 10.1016/j.jdermsci.2009.06.009; Ikram MS, 2004, J INVEST DERMATOL, V122, P1503, DOI 10.1111/j.0022-202X.2004.22612.x; Javelaud D, 2011, CANCER RES, V71, P5606, DOI 10.1158/0008-5472.CAN-11-1194; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Kaina B, 1998, MUTAT RES-FUND MOL M, V404, P119, DOI 10.1016/S0027-5107(98)00103-1; Kandala PK, 2012, J BIOL CHEM, V287, P28745, DOI 10.1074/jbc.M112.351379; Kump E, 2008, ONCOGENE, V27, P3856, DOI 10.1038/onc.2008.5; Lear W, 2007, J CUTAN MED SURG, V11, P19, DOI 10.2310/7750.2007.00011; Leonard JM, 2008, J CELL BIOL, V183, P385, DOI 10.1083/jcb.200804042; Li X, 2007, ONCOGENE, V26, P4489, DOI 10.1038/sj.onc.1210241; Li X, 2006, ONCOGENE, V25, P609, DOI 10.1038/sj.onc.1209077; Louro ID, 2002, CANCER RES, V62, P5867; Mah LJ, 2010, LEUKEMIA, V24, P679, DOI 10.1038/leu.2010.6; Mazumdar T, 2011, CANCER RES, V71, P5904, DOI 10.1158/0008-5472.CAN-10-4173; McCalla-Martin AC, 2010, TRANSGENIC RES, V19, P869, DOI 10.1007/s11248-010-9362-0; Nakamura M, 2011, J DERMATOL SCI, V61, P7, DOI 10.1016/j.jdermsci.2010.11.015; Neill GW, 2008, CARCINOGENESIS, V29, P738, DOI 10.1093/carcin/bgn037; Newkirk KM, 2007, AM J PATHOL, V171, P1629, DOI 10.2353/ajpath.2007.070221; Nilsson M, 2000, P NATL ACAD SCI USA, V97, P3438, DOI 10.1073/pnas.050467397; Nystrom ML, 2005, J PATHOL, V205, P468, DOI 10.1002/path.1716; Papanikolaou S, 2010, HISTOPATHOLOGY, V56, P799, DOI 10.1111/j.1365-2559.2010.03556.x; Patil MA, 2006, CANCER BIOL THER, V5, P111, DOI 10.4161/cbt.5.1.2379; Perrot CY, 2013, PHARMACOL THERAPEUT, V137, P183, DOI 10.1016/j.pharmthera.2012.10.002; Ping XL, 2001, J INVEST DERMATOL, V116, P614, DOI 10.1046/j.1523-1747.2001.01301.x; Raj D, 2006, J INVEST DERMATOL, V126, P243, DOI 10.1038/sj.jid.5700008; Regl G, 2004, CANCER RES, V64, P7724, DOI 10.1158/0008-5472.CAN-04-1085; Regl G, 2002, ONCOGENE, V21, P5529, DOI 10.1038/sj.onc.1205748; Reichrath J, 2006, MED INTELL UNIT, P10, DOI 10.1007/0-387-35098-5_2; Rittie L, 2009, AGING CELL, V8, P738, DOI 10.1111/j.1474-9726.2009.00526.x; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Sarasin A, 1999, MUTAT RES-FUND MOL M, V428, P5, DOI 10.1016/S1383-5742(99)00025-3; Savagner P, 2005, J CELL PHYSIOL, V202, P858, DOI 10.1002/jcp.20188; Schnidar H, 2009, CANCER RES, V69, P1284, DOI 10.1158/0008-5472.CAN-08-2331; Sheng H, 2002, CANCER RES, V62, P5308; Teh MT, 2002, CANCER RES, V62, P4773; Teh MT, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-45; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thomas ZI, 2011, BRIT J CANCER, V104, P1575, DOI 10.1038/bjc.2011.133; Varnat F, 2009, EMBO MOL MED, V1, P338, DOI 10.1002/emmm.200900039; Vorechovsky I, 1997, ONCOGENE, V15, P361, DOI 10.1038/sj.onc.1201340; Wong CSM, 2003, BMJ-BRIT MED J, V327, P794, DOI 10.1136/bmj.327.7418.794; Yoon JW, 2002, J BIOL CHEM, V277, P5548, DOI 10.1074/jbc.M105708200; Yu M, 2008, J INVEST DERMATOL, V128, P1797, DOI 10.1038/sj.jid.5701243; Yuan JS, 2010, FEBS LETT, V584, P3717, DOI 10.1016/j.febslet.2010.05.021; Zheng X, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049581	60	16	16	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 8	2014	33	19					2432	2440		10.1038/onc.2013.199	http://dx.doi.org/10.1038/onc.2013.199			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AH3OK	23792444				2022-12-17	WOS:000336033600003
J	Lee, M; Dworkin, AM; Gildea, D; Trivedi, NS; Moorhead, GB; Crawford, NPS				Lee, M.; Dworkin, A. M.; Gildea, D.; Trivedi, N. S.; Moorhead, G. B.; Crawford, N. P. S.		NISC Comparative Sequencing Progra	RRP1B is a metastasis modifier that regulates the expression of alternative mRNA isoforms through interactions with SRSF1	ONCOGENE			English	Article						Metastasis; RRP1B; germline modifiers; RNA-seq; alternative splicing; breast cancer	SPLICE-SITE SELECTION; CANCER; PROTEINS; IDENTIFICATION; PATTERNS; SEQUENCE	RRP1B (ribosomal RNA processing 1 homolog B) was first identified as a metastasis susceptibility gene in breast cancer through its ability to modulate gene expression in a manner that can be used to accurately predict prognosis in breast cancer. However, the mechanism(s) by which RRP1B modulates gene expression is currently unclear. Many RRP1B binding candidates are involved in alternative splicing, a mechanism of gene expression regulation that is increasingly recognized to be involved in cancer progression and metastasis. One such target is SRSF1 (serine/arginine-rich splicing factor 1) (SF2/ASF, splicing factor 2/alternative splicing factor), an essential splicing regulator that also functions as an oncoprotein. Earlier studies demonstrated that splicing and transcription occur concurrently and are coupled processes. Given that RRP1B regulates transcriptional activity, we hypothesized that RRP1B also regulates the expression of alternative mRNA isoforms through its interaction with SRSF1. Interaction between RRP1B and SRSF1 was verified by coimmunoprecipitation and coimmunofluorescence. Treatment of cells with transcriptional inhibitors significantly increased this interaction, demonstrating that the association of these two proteins is transcriptionally regulated. To assess the role of RRP1B in the regulation of alternative isoform expression, RNA-sequencing data were generated from control and Rrp1b-knockdown cells. Knockdown of Rrp1b induced a significant change in isoform expression in over 600 genes compared with control cell lines. This was verified by quantitative reverse-transcription PCR using isoform-specific primers. Pathway enrichment analyses identified cell cycle and checkpoint regulation to be those most affected by Rrp1b knockdown. These data suggest that RRP1B suppresses metastatic progression by altering the transcriptome through its interaction with splicing regulators such as SRSF1.	[Lee, M.; Dworkin, A. M.; Crawford, N. P. S.] NHGRI, Canc Genet Branch, NIH, Bethesda, MD 20892 USA; [Gildea, D.; Trivedi, N. S.; NISC Comparative Sequencing Progra] NHGRI, Genome Technol Branch, NIH, Bethesda, MD 20892 USA; [Moorhead, G. B.] Univ Calgary, Dept Biol Sci, Calgary, AB, Canada	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of Calgary	Crawford, NPS (corresponding author), NHGRI, Canc Genet Branch, NIH, MSC 8000,50 South Dr,Bldg 50,Room 5154, Bethesda, MD 20892 USA.	crawforn@mail.nih.gov			Intramural Research Program of the National Human Genome Research Institute; National Institutes of Health, USA; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [ZIBHG000196, ZIAHG200380] Funding Source: NIH RePORTER	Intramural Research Program of the National Human Genome Research Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); National Institutes of Health, USA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	This work was supported by the Intramural Research Program of the National Human Genome Research Institute, National Institutes of Health, USA. We thank Stephen Wincovitch and Sujata Bupp for technical assistance, and Drs Kent Hunter, Tom Misteli and Larry Brody for critical review of the manuscript.	Albulescu LO, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002530; Alexander RD, 2010, MOL CELL, V40, P582, DOI 10.1016/j.molcel.2010.11.005; Arhin GK, 2002, NUCLEIC ACIDS RES, V30, P1842, DOI 10.1093/nar/30.8.1842; ASLAKSON CJ, 1992, CANCER RES, V52, P1399; BAGGA PS, 1995, NUCLEIC ACIDS RES, V23, P1625, DOI 10.1093/nar/23.9.1625; Baumli S, 2010, CHEM BIOL, V17, P931, DOI 10.1016/j.chembiol.2010.07.012; Bensaude O, 2011, TRANSCR-AUSTIN, V2, P103, DOI 10.4161/trns.2.3.16172; Chamousset D, 2010, MOL BIOL CELL, V21, P4212, DOI 10.1091/mbc.E10-04-0287; Crawford NPS, 2007, PLOS GENET, V3, P2296, DOI 10.1371/journal.pgen.0030214; Crawford NPS, 2009, J BIOL CHEM, V284, P28660, DOI 10.1074/jbc.M109.023457; Du KY, 1998, J BIOL CHEM, V273, P35208, DOI 10.1074/jbc.273.52.35208; Grosso AR, 2008, EMBO REP, V9, P1087, DOI 10.1038/embor.2008.189; Hsieh SM, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2412; Hui LJ, 2004, ONCOGENE, V23, P3013, DOI 10.1038/sj.onc.1207362; Ip JY, 2011, GENOME RES, V21, P390, DOI 10.1101/gr.111070.110; Karni R, 2007, NAT STRUCT MOL BIOL, V14, P185, DOI 10.1038/nsmb1209; Kim E, 2008, TRENDS GENET, V24, P7, DOI 10.1016/j.tig.2007.10.001; KRAINER AR, 1990, CELL, V62, P35, DOI 10.1016/0092-8674(90)90237-9; Lee JH, 2008, CANCER RES, V68, P639, DOI 10.1158/0008-5472.CAN-07-2632; Lemischka IR, 2006, CELL CYCLE, V5, P347, DOI 10.4161/cc.5.4.2424; Luco RF, 2010, SCIENCE, V327, P996, DOI 10.1126/science.1184208; Nurtdinov RN, 2003, HUM MOL GENET, V12, P1313, DOI 10.1093/hmg/ddg137; Oesterreich FC, 2010, MOL CELL, V40, P571, DOI 10.1016/j.molcel.2010.11.004; Pei XF, 2004, IN VITRO CELL DEV-AN, V40, P14; Piva F, 2009, BIOINFORMATICS, V25, P1211, DOI 10.1093/bioinformatics/btp124; Puig O, 2007, NUCLEIC ACIDS RES, V35, P5874, DOI 10.1093/nar/gkm505; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Roberts A, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-3-r22; Thorsen K, 2008, MOL CELL PROTEOMICS, V7, P1214, DOI 10.1074/mcp.M700590-MCP200; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; TRASK DK, 1988, P NATL ACAD SCI USA, V85, P1417, DOI 10.1073/pnas.85.5.1417; Umehara H, 2003, BIOCHEM BIOPH RES CO, V301, P324, DOI 10.1016/S0006-291X(02)03017-6; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; Vargas DY, 2011, CELL, V147, P1054, DOI 10.1016/j.cell.2011.10.024; Venables JP, 2004, CANCER RES, V64, P7647, DOI 10.1158/0008-5472.CAN-04-1910; Venables JP, 2006, BIOESSAYS, V28, P378, DOI 10.1002/bies.20390; Venables JP, 2009, NAT STRUCT MOL BIOL, V16, P670, DOI 10.1038/nsmb.1608; Wang ET, 2008, NATURE, V456, P470, DOI 10.1038/nature07509; Wang GS, 2007, NAT REV GENET, V8, P749, DOI 10.1038/nrg2164; Wang ZN, 2003, CANCER RES, V63, P655; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; Xu Q, 2003, NUCLEIC ACIDS RES, V31, P5635, DOI 10.1093/nar/gkg786; Yeo G, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r74; Yeo GW, 2005, P NATL ACAD SCI USA, V102, P2850, DOI 10.1073/pnas.0409742102; ZAHLER AM, 1993, SCIENCE, V260, P219, DOI 10.1126/science.8385799; ZUO P, 1993, EMBO J, V12, P4727, DOI 10.1002/j.1460-2075.1993.tb06161.x	47	16	18	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 3	2014	33	14					1818	1827		10.1038/onc.2013.133	http://dx.doi.org/10.1038/onc.2013.133			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9RE	23604122	Green Accepted			2022-12-17	WOS:000334345500008
J	Saito, K; Sakaguchi, M; Iioka, H; Matsui, M; Nakanishi, H; Huh, NH; Kondo, E				Saito, K.; Sakaguchi, M.; Iioka, H.; Matsui, M.; Nakanishi, H.; Huh, N. H.; Kondo, E.			Coxsackie and adenovirus receptor is a critical regulator for the survival and growth of oral squamous carcinoma cells	ONCOGENE			English	Article						CAR; ROCK; anoikis; SCC	RHO-KINASE; BLADDER-CANCER; TIGHT JUNCTION; E-CADHERIN; CAR; EXPRESSION; ANOIKIS; DOMAIN; KERATINOCYTES; ACTIVATION	Coxsackie and adenovirus receptor (CAR) is essential for adenovirus infection to target cells, and its constitutive expression in various cancerous and normal tissues has been reported. Recently, the biological role of CAR in human cancers of several different origins has been investigated with respect to tumor progression, metastasis and tumorigenesis. However, its biological function in tumor cells remains controversial. Here we report the critical role of CAR in growth regulation of oral squamous cell carcinomas (SCCs) in vitro and in vivo via the specific interaction with Rho-associated protein kinase (ROCK). Loss of endogenous CAR expression by knockdown using specific small interfering RNA (siRNA) against CAR facilitates growth suppression of SCC cells due to cell dissociation, followed by apoptosis. The consequent morphological reaction was reminiscent of anoikis, rather than epithelial-mesenchymal transition, and the dissociation of oral SCC cells was triggered not by lack of contact with extracellular matrix, but by loss of cell-to-cell contact caused by abnormal translocation of E-cadherin from surface membrane to cytoplasm. Immunoprecipitation assays of the CAR-transfected oral SCC cell line, HSC-2, with or without ROCK inhibitor (Y-27632) revealed that CAR directly associates with ROCK! and ROCKII, which results in inhibition of ROCK activity and contributes to maintenance of cell-to-cell adhesion for their growth and survival. Based on these findings, in vivo behavior of CAR-downregulated HSC-2 cells from siRNA knockdown was compared with that of normally CAR-expressing cells in intraperitoneally xenografted mouse models. The mice engrafted with CAR siRNA-pretreated HSC-2 cells showed poor formation of metastatic foci in contrast to those implanted with the control siRNA-pretreated cells. Thus, CAR substantially has an impact on growth and survival of oral SCC cells as a negative regulator of ROCK in vitro and in vivo.	[Saito, K.; Iioka, H.; Matsui, M.; Nakanishi, H.; Kondo, E.] Aichi Canc Ctr, Res Inst, Div Oncol Pathol, Nagoya, Aichi 4648681, Japan; [Sakaguchi, M.; Huh, N. H.] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Cell Biol, Okayama 7008530, Japan; [Iioka, H.] Aichi Med Univ, Adv Med Res Ctr, Div Translat Res, Nagakute, Aichi 48011, Japan; [Kondo, E.] Nagoya Univ, Grad Sch Med, Dept Epidemiol, Program Hlth & Community Med, Nagoya, Aichi 4648601, Japan	Aichi Cancer Center; Okayama University; Aichi Medical University; Nagoya University	Kondo, E (corresponding author), Aichi Canc Ctr, Res Inst, Div Oncol Pathol, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.	ekondo@aichi-cc.jp	Sakaguchi, Masakiyo/B-2280-2011; Iioka, Hidekazu/AAB-1424-2021	Iioka, Hidekazu/0000-0002-2639-8315	Grants-in-Aid for Scientific Research [23650625] Funding Source: KAKEN	Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))		Anders M, 2009, CANCER GENE THER, V16, P508, DOI 10.1038/cgt.2008.103; Anders M, 2009, BRIT J CANCER, V100, P352, DOI 10.1038/sj.bjc.6604876; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; Bruning A, 2005, CLIN CANCER RES, V11, P4316, DOI 10.1158/1078-0432.CCR-04-2370; Cheng HL, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-126; Cohen CJ, 2001, P NATL ACAD SCI USA, V98, P15191, DOI 10.1073/pnas.261452898; Coyne CB, 2004, J BIOL CHEM, V279, P48079, DOI 10.1074/jbc.M409061200; Dorner AA, 2005, J CELL SCI, V118, P3509, DOI 10.1242/jcs.02476; Excoffon KJDA, 2004, J CELL SCI, V117, P4401, DOI 10.1242/jcs.01300; Fok PT, 2007, J BIOL CHEM, V282, P7512, DOI 10.1074/jbc.M607230200; Fouquet S, 2004, J BIOL CHEM, V279, P43061, DOI 10.1074/jbc.M405095200; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Giaginis C, 2010, APMIS, V118, P210, DOI 10.1111/j.1600-0463.2009.02582.x; HERMISTON ML, 1995, J CELL BIOL, V129, P489, DOI 10.1083/jcb.129.2.489; Huang KC, 2005, INT J CANCER, V113, P738, DOI 10.1002/ijc.20623; Lai JM, 2003, J CELL SCI, V116, P3491, DOI 10.1242/jcs.00660; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; Marconi A, 2004, J CELL SCI, V117, P5815, DOI 10.1242/jcs.01490; Maseki S, 2012, BRIT J CANCER, V106, P1196, DOI 10.1038/bjc.2012.24; Matsumoto K, 2005, UROLOGY, V66, P441, DOI 10.1016/j.urology.2005.02.033; Mayr GA, 1997, J VIROL, V71, P412, DOI 10.1128/JVI.71.1.412-418.1997; Mege RM, 2006, CURR OPIN CELL BIOL, V18, P541, DOI 10.1016/j.ceb.2006.08.004; Okegawa T, 2000, CANCER RES, V60, P5031; Okegawa T, 2001, CANCER RES, V61, P6592; Qin M, 2004, CANCER RES, V64, P6377, DOI 10.1158/0008-5472.CAN-04-1490; Sakaguchi M, 2003, J CELL BIOL, V163, P825, DOI 10.1083/jcb.200304017; Sakaguchi M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023132; Schackmann RCJ, 2011, J CLIN INVEST, V121, P3176, DOI 10.1172/JCI41695; Shewan AM, 2005, MOL BIOL CELL, V16, P4531, DOI 10.1091/mbc.E05-04-0330; Shi JJ, 2007, ARCH IMMUNOL THER EX, V55, P61, DOI 10.1007/s00005-007-0009-7; Sollerbrant K, 2003, J BIOL CHEM, V278, P7439, DOI 10.1074/jbc.M205927200; Stecker K, 2011, BRIT J CANCER, V104, P1426, DOI 10.1038/bjc.2011.116; Stoff A, 2006, WOUND REPAIR REGEN, V14, P608, DOI 10.1111/j.1743-6109.2006.00168.x; Street CA, 2011, ANTICANCER RES, V31, P3645; Tomko RP, 1997, P NATL ACAD SCI USA, V94, P3352, DOI 10.1073/pnas.94.7.3352; Valentijn AJ, 2004, J BIOL CHEM, V279, P32848, DOI 10.1074/jbc.M313375200; Verdino P, 2010, SCIENCE, V329, P1210, DOI 10.1126/science.1187996; Vigl B, 2009, EXP CELL RES, V315, P336, DOI 10.1016/j.yexcr.2008.10.020; Walters RW, 2002, CELL, V110, P789, DOI 10.1016/S0092-8674(02)00912-1; Xiao LQ, 2009, J BIOL CHEM, V284, P29365, DOI 10.1074/jbc.M109.007971; Yamashita M, 2007, INT J CANCER, V121, P1690, DOI 10.1002/ijc.22852; Yonemura S, 2011, CURR OPIN CELL BIOL, V23, P515, DOI 10.1016/j.ceb.2011.07.001	42	16	18	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 6	2014	33	10					1274	1286		10.1038/onc.2013.66	http://dx.doi.org/10.1038/onc.2013.66			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AC6KI	23503462				2022-12-17	WOS:000332631100008
J	Solga, AC; Gianino, SM; Gutmann, DH				Solga, A. C.; Gianino, S. M.; Gutmann, D. H.			NG2-cells are not the cell of origin for murine neurofibromatosis-1 (Nf1) optic glioma	ONCOGENE			English	Article						genetically-engineered mice; NG2+; optic glioma; neurofibromatosis type 1	CENTRAL-NERVOUS-SYSTEM; GLIAL PROGENITORS; NG2 PROTEOGLYCAN; GROWTH-FACTOR; OLIGODENDROCYTE PRECURSORS; MALIGNANT GLIOMAS; PATHWAY GLIOMAS; CLONAL ANALYSIS; WHITE-MATTER; CHILDREN	Low-grade glial neoplasms (astrocytomas) represent one of the most common brain tumors in the pediatric population. These tumors frequently form in the optic pathway (optic pathway gliomas, OPGs), especially in children with the neurofibromatosis type 1 (NF1)-inherited tumor predisposition syndrome. To model these tumors in mice, we have previously developed several Nf1 genetically-engineered mouse strains that form optic gliomas. However, there are three distinct macroglial cell populations in the optic nerve (astrocytes, NG2 + (nerve/glial antigen 2) cells and oligodendrocytes). The presence of NG2 + cells in the optic nerve raises the intriguing possibility that these cells could be the tumor-initiating cells, as has been suggested for adult glioma. In this report, we used a combination of complementary in vitro and novel genetically-engineered mouse strains in vivo to determine whether NG2 + cells could give rise to Nf1 optic glioma. First, we show that Nf1 inactivation results in a cell-autonomous increase in glial fibrillary acidic protein + (GFAP + ), but not in NG2 + , cell proliferation in vitro. Second, similar to the GFAP-Cre transgenic strain that drives Nf1 optic gliomagenesis, NG2-expressing cells also give rise to all three macroglial lineages in vivo. Third, in contrast to the GFAP-Cre strain, Nf1 gene inactivation in NG2 + cells is not sufficient for optic gliomagenesis in vivo. Collectively, these data demonstrate that NG2 + cells are not the cell of origin for mouse optic glioma, and support a model in which gliomagenesis requires Nf1 loss in specific neuroglial progenitors during embryogenesis.	[Solga, A. C.; Gianino, S. M.; Gutmann, D. H.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA	Washington University (WUSTL)	Gutmann, DH (corresponding author), Washington Univ, Sch Med, Dept Neurol, Box 8111,660 South Euclid Ave, St Louis, MO 63110 USA.	gutmannd@neuro.wustl.edu		Gutmann, David/0000-0002-3127-5045	National Cancer Institute [U01-CA141549]; National Eye Institute [EY02687]; NATIONAL CANCER INSTITUTE [U01CA141549] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [P30EY002687] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Eye Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	We appreciate the excellent technical assistance of Angela Petti and Belinda McMahan in the Ophthalmology Core Facility for preparing the optic nerve sections. This work was funded by a grant from the National Cancer Institute (U01-CA141549 to DHG), whereas the Ophthalmology Core Facility is funded by a grant from the National Eye Institute EY02687).	Abel TW, 2009, MOL CANCER RES, V7, P645, DOI 10.1158/1541-7786.MCR-08-0477; Al-Mayhani MTF, 2011, NEURO-ONCOLOGY, V13, P830, DOI 10.1093/neuonc/nor088; Assanah M, 2006, J NEUROSCI, V26, P6781, DOI 10.1523/JNEUROSCI.0514-06.2006; Bajenaru ML, 2002, MOL CELL BIOL, V22, P5100, DOI 10.1128/MCB.22.14.5100-5113.2002; Bajenaru ML, 2003, CANCER RES, V63, P8573; Baracskay KL, 2007, GLIA, V55, P1001, DOI 10.1002/glia.20519; Blazo MA, 2004, AM J MED GENET A, V127A, P224, DOI 10.1002/ajmg.a.20650; BRANNAN CI, 1994, GENE DEV, V8, P1019, DOI 10.1101/gad.8.9.1019; Czyzyk E, 2003, J CHILD NEUROL, V18, P471, DOI 10.1177/08830738030180070401; Dahiya S, 2011, J NEUROPATH EXP NEUR, V70, P622, DOI 10.1097/NEN.0b013e31822200aa; Dawson MRL, 2003, MOL CELL NEUROSCI, V24, P476, DOI 10.1016/S1044-7431(03)00210-0; Doetsch F, 1999, P NATL ACAD SCI USA, V96, P11619, DOI 10.1073/pnas.96.20.11619; Ellis JA, 2012, NEUROSURGERY, V70, P198, DOI 10.1227/NEU.0b013e31822ce963; Gao LM, 2006, J NEUROSCI, V26, P7619, DOI 10.1523/JNEUROSCI.0855-06.2006; Hegedus B, 2008, CANCER RES, V68, P1520, DOI 10.1158/0008-5472.CAN-07-5916; Ju PJ, 2012, CYTOTHERAPY, V14, P608, DOI 10.3109/14653249.2011.651528; Kwon CH, 2008, CANCER RES, V68, P3286, DOI 10.1158/0008-5472.CAN-07-6867; Lee DY, 2012, CANCER CELL, V22, P131, DOI 10.1016/j.ccr.2012.05.036; Levine JM, 2001, TRENDS NEUROSCI, V24, P39, DOI 10.1016/S0166-2236(00)01691-X; Listernick R, 1997, ANN NEUROL, V41, P143, DOI 10.1002/ana.410410204; LISTERNICK R, 1995, J PEDIATR-US, V127, P718, DOI 10.1016/S0022-3476(95)70159-1; Liu C, 2011, CELL, V146, P209, DOI 10.1016/j.cell.2011.06.014; Llaguno SA, 2009, CANCER CELL, V15, P45, DOI 10.1016/j.ccr.2008.12.006; LUND AM, 1991, EUR J PEDIATR, V150, P835, DOI 10.1007/BF01955002; Madisen L, 2010, NAT NEUROSCI, V13, P133, DOI 10.1038/nn.2467; Masui K, 2010, GLIA, V58, P1050, DOI 10.1002/glia.20986; MILLER RH, 1985, DEV BIOL, V111, P35, DOI 10.1016/0012-1606(85)90432-4; Mokry J, 2008, STEM CELLS DEV, V17, P333, DOI 10.1089/scd.2007.0091; Neymeyer V, 1997, BRAIN RES, V766, P195, DOI 10.1016/S0006-8993(97)00528-3; Ogden AT, 2008, NEUROSURGERY, V62, P505, DOI 10.1227/01.neu.0000316019.28421.95; Ono K, 1997, NEURON, V19, P283, DOI 10.1016/S0896-6273(00)80939-3; Ozerdem U, 2001, DEV DYNAM, V222, P218, DOI 10.1002/dvdy.1200; RAFF MC, 1984, DEV BIOL, V106, P53, DOI 10.1016/0012-1606(84)90060-5; RAFF MC, 1983, J NEUROSCI, V3, P1289; SCHRAPPE M, 1991, CANCER RES, V51, P4986; Silber J, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-14; STALLCUP WB, 1987, J NEUROSCI, V7, P2737; Tchoghandjian A, 2010, BRAIN PATHOL, V20, P211, DOI 10.1111/j.1750-3639.2009.00269.x; Tchoghandjian A, 2009, BRAIN, V132, P1523, DOI 10.1093/brain/awp048; Wang J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023062; Winkler EA, 2011, NAT NEUROSCI, V14, P1398, DOI 10.1038/nn.2946; Wiranowska M, 2006, BRAIN CELL BIOL, V35, P159, DOI 10.1007/s11068-007-9009-0; Yeh TH, 2009, GLIA, V57, P1239, DOI 10.1002/glia.20845; Yoo S, 2007, DEV NEUROBIOL, V67, P860, DOI 10.1002/dneu.20369; Zhu XQ, 2008, DEVELOPMENT, V135, P145, DOI 10.1242/dev.004895; Zhu Y, 2005, DEVELOPMENT, V132, P5577, DOI 10.1242/dev.02162; Zhu Y, 2001, GENE DEV, V15, P859, DOI 10.1101/gad.862101	47	16	16	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 16	2014	33	3					289	299		10.1038/onc.2012.580	http://dx.doi.org/10.1038/onc.2012.580			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	296VR	23318450	Green Accepted			2022-12-17	WOS:000330214000003
J	Ichim, G; Mola, M; Finkbeiner, MG; Cros, MP; Herceg, Z; Hernandez-Vargas, H				Ichim, G.; Mola, M.; Finkbeiner, M. G.; Cros, M-P; Herceg, Z.; Hernandez-Vargas, H.			The histone acetyltransferase component TRRAP is targeted for destruction during the cell cycle	ONCOGENE			English	Article						APC; Cdc20; Cdh1; TRRAP; mitosis; cell cycle	ANAPHASE-PROMOTING COMPLEX/CYCLOSOME; EARLY MITOTIC DEGRADATION; HAT COFACTOR TRRAP; CHROMATIN; MITOSIS; PROGRESSION; COMPLEX; ACETYLATION; TRANSCRIPTION; CHECKPOINT	Chromosomes are dynamic structures that must be reversibly condensed and unfolded to accommodate mitotic division and chromosome segregation. Histone modifications are involved in the striking chromatin reconfiguration taking place during mitosis. However, the mechanisms that regulate activity and function of histone-modifying factors as cells enter and exit mitosis are poorly understood. Here, we show that the anaphase-promoting complex or cyclosome (APC/C) is involved in the mitotic turnover of TRRAP (TRansformation/tRanscription domain-Associated Protein), a common component of histone acetyltransferase (HAT) complexes, and that the pre-mitotic degradation of TRRAP is mediated by the APC/C ubiquitin ligase activators Cdc20 and Cdh1. Ectopic expression of both Cdh1 and Cdc20 reduced the levels of coexpressed TRRAP protein and induced its ubiquitination. TRRAP overexpression or stabilization induces multiple mitotic defects, including lagging chromosomes, chromosome bridges and multipolar spindles. In addition, lack of sister chromatid cohesion and impaired chromosome condensation were found after TRRAP overexpression or stabilization. By using a truncated form of TRRAP, we show that mitotic delay is associated with a global histone H4 hyperacetylation induced by TRRAP overexpression. These results demonstrate that the chromatin modifier TRRAP is targeted for destruction in a cell cycle-dependent fashion. They also suggest that degradation of TRRAP by the APC/C is necessary for a proper condensation of chromatin and proper chromosome segregation. Chromatin compaction mediated by histone modifiers may represent a fundamental arm for APC/C orchestration of the mitotic machinery.	[Ichim, G.; Mola, M.; Finkbeiner, M. G.; Cros, M-P; Herceg, Z.; Hernandez-Vargas, H.] Int Agcy Res Canc IARC, Epigenet Grp, F-69008 Lyon, Rhone Alpes, France	World Health Organization; International Agency for Research on Cancer (IARC)	Herceg, Z (corresponding author), Int Agcy Res Canc IARC, Epigenet Grp, 150 Rue Albert Thomas, F-69008 Lyon, Rhone Alpes, France.	herceg@iarc.fr; vargash@iarc.fr	Ichim, Gabriel/AAJ-5822-2021	Ichim, Gabriel/0000-0002-8386-7405; Hernandez-Vargas, Hector/0000-0001-6045-2103	Association pour la Recherche sur le Cancer (ARC), France; la Ligue Nationale (Francaise) Contre le Cancer (France); Institut National du Cancer (INCA, France); Association for International Cancer Research (AICR), UK	Association pour la Recherche sur le Cancer (ARC), France(Fondation ARC pour la Recherche sur le Cancer); la Ligue Nationale (Francaise) Contre le Cancer (France)(Ligue nationale contre le cancer); Institut National du Cancer (INCA, France)(Institut National du Cancer (INCA) France); Association for International Cancer Research (AICR), UK	We thank Michael Cole for generous gift of the TRRAP expression vector. This work was supported by the Association pour la Recherche sur le Cancer (ARC), France, la Ligue Nationale (Francaise) Contre le Cancer (France), the Institut National du Cancer (INCA, France) and the Association for International Cancer Research (AICR), UK.	Amador V, 2007, MOL CELL, V27, P462, DOI 10.1016/j.molcel.2007.06.013; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Cummings WJ, 2007, PLOS BIOL, V5, P2145, DOI 10.1371/journal.pbio.0050246; Deran M, 2008, MOL CELL BIOL, V28, P435, DOI 10.1128/MCB.00607-07; Eot-Houllier G, 2008, GENE DEV, V22, P2639, DOI 10.1101/gad.484108; Fu GS, 2007, CELL RES, V17, P608, DOI 10.1038/cr.2007.55; Gabellini D, 2003, EMBO J, V22, P3715, DOI 10.1093/emboj/cdg340; Geley S, 2001, J CELL BIOL, V153, P137, DOI 10.1083/jcb.153.1.137; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hayes MJ, 2006, NAT CELL BIOL, V8, P607, DOI 10.1038/ncb1410; Herceg Z, 2001, NAT GENET, V29, P206, DOI 10.1038/ng725; Herceg Z, 2005, CELL CYCLE, V4, P383, DOI 10.4161/cc.4.3.1546; Herceg Z, 2003, NUCLEIC ACIDS RES, V31, P7011, DOI 10.1093/nar/gkg902; Hernandez-Vargas H, 2007, ONCOGENE, V26, P2902, DOI 10.1038/sj.onc.1210102; Kruhlak MJ, 2001, J BIOL CHEM, V276, P38307; Li H, 2004, EMBO J, V23, P4824, DOI 10.1038/sj.emboj.7600479; Murr R, 2007, ONCOGENE, V26, P5358, DOI 10.1038/sj.onc.1210605; Murr R, 2006, NAT CELL BIOL, V8, P91, DOI 10.1038/ncb1343; Ono T, 2004, MOL BIOL CELL, V15, P3296, DOI 10.1091/mbc.E04-03-0242; Peters JM, 2006, NAT REV MOL CELL BIO, V7, P644, DOI 10.1038/nrm1988; Pfleger CM, 2001, GENE DEV, V15, P2396, DOI 10.1101/gad.918201; Ramaswamy V, 2003, MOL CELL BIOL, V23, P9136, DOI 10.1128/MCB.23.24.9136-9149.2003; Robert F, 2006, MOL CELL BIOL, V26, P402, DOI 10.1128/MCB.26.2.402-412.2006; Sapountzi V, 2006, INT J BIOCHEM CELL B, V38, P1496, DOI 10.1016/j.biocel.2006.03.003; Schueler MG, 2006, ANNU REV GENOM HUM G, V7, P301, DOI 10.1146/annurev.genom.7.080505.115613; Song L, 2011, CELL CYCLE, V10, P52, DOI 10.4161/cc.10.1.14387; Turnell AS, 2005, NATURE, V438, P690, DOI 10.1038/nature04151; Valls E, 2005, J BIOL CHEM, V280, P42592, DOI 10.1074/jbc.M507407200; Vernarecci S, 2008, MOL CELL BIOL, V28, P988, DOI 10.1128/MCB.01366-07; Wu SM, 2010, GENE DEV, V24, P2531, DOI 10.1101/gad.1984210	30	16	18	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 9	2014	33	2					181	192		10.1038/onc.2012.570	http://dx.doi.org/10.1038/onc.2012.570			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	286BY	23318449				2022-12-17	WOS:000329440700006
J	Wang, Y; Balan, V; Kho, D; Hogan, V; Nangia-Makker, P; Raz, A				Wang, Y.; Balan, V.; Kho, D.; Hogan, V.; Nangia-Makker, P.; Raz, A.			Galectin-3 regulates p21 stability in human prostate cancer cells	ONCOGENE			English	Article						galectin-3; p21; stability; CRD	BREAST-CARCINOMA; UBIQUITIN LIGASE; CYCLE ARREST; S-PHASE; EXPRESSION; APOPTOSIS; INHIBITION; PROTEIN; P53; DEGRADATION	Galectin-3 (Gal-3) is a multifunctional protein involved in cancer through regulation of cell adhesion, cell growth, apoptosis and metastasis, while p21 (Cip1/WAF1) is a negative regulator of the cell cycle, involved in apoptosis, transcription, DNA repair and metastasis. The results presented here demonstrate for the first time that the level of Gal-3 protein is associated with the level of p21 protein expression in human prostate cancer cells and the effects of Gal-3 on cell growth and apoptosis were reversed by modulating p21 expression level. Furthermore, Gal-3 regulates p21 expression at the post-translational level by stabilizing p21 protein via the carbohydrate-recognition domain. This is the first report suggesting a molecular function not yet described for Gal-3 as the regulator of p21 protein stability. This study provides a unique insight into the relationship of these two molecules during prostate cancer progression, and may provide a novel therapeutic target.	[Wang, Y.; Balan, V.; Kho, D.; Hogan, V.; Nangia-Makker, P.; Raz, A.] Wayne State Univ, Sch Med, Karmanos Canc Inst, Dept Oncol Tumor Progress & Metastasis, Detroit, MI 48201 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University	Nangia-Makker, P (corresponding author), Wayne State Univ, Sch Med, Karmanos Canc Inst, Dept Oncol Tumor Progress & Metastasis, 110 E Warren Ave, Detroit, MI 48201 USA.	makkerp@karmanos.org; raza@karmanos.org		Nangia-Makker, Pratima/0000-0002-1917-169X	National Institutes of Health [R37CA46120-19]; American Cancer Society [11-053-01-IRG]; NATIONAL CANCER INSTITUTE [R37CA046120] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Reuben Lotan for providing Gal-3-transfected LNCaP clones. This study was supported by the National Institutes of Health grant R37CA46120-19 (A Raz) and the American Cancer Society grant 11-053-01-IRG (V Balan).	Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Amador V, 2007, MOL CELL, V27, P462, DOI 10.1016/j.molcel.2007.06.013; Anttila MA, 1999, BRIT J CANCER, V79, P1870, DOI 10.1038/sj.bjc.6690298; Balan V, 2012, J BIOL CHEM, V287, P5192, DOI 10.1074/jbc.C111.331686; Baretton GB, 1999, BRIT J CANCER, V80, P546, DOI 10.1038/sj.bjc.6690390; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; Bartolazzi A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003768; Beck SE, 2007, CELL SIGNAL, V19, P1465, DOI 10.1016/j.cellsig.2007.01.017; Blagosklonny MV, 2002, CELL CYCLE, V1, P391, DOI 10.4161/cc.1.6.262; Bornstein G, 2003, J BIOL CHEM, V278, P25752, DOI 10.1074/jbc.M301774200; Brugarolas J, 1999, P NATL ACAD SCI USA, V96, P1002, DOI 10.1073/pnas.96.3.1002; Brustmann H, 2008, INT J GYNECOL PATHOL, V27, P380, DOI 10.1097/PGP.0b013e31815d060d; Caffo O, 1996, CLIN CANCER RES, V2, P1591; Califice S, 2004, INT J ONCOL, V25, P983; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Ellerhorst JA, 2002, PROSTATE, V50, P64, DOI 10.1002/pros.10033; Feilchenfeldt J, 2003, MODERN PATHOL, V16, P1117, DOI 10.1097/01.MP.0000096047.99202.31; Gan L, 2011, PROSTATE, V71, P1158, DOI 10.1002/pros.21331; Garner E, 2008, CELL CYCLE, V7, P277, DOI 10.4161/cc.7.3.5328; Gong JG, 2003, CANCER RES, V63, P3340; HARPER JW, 1993, CELL, V75, P805; Iacovazzi PA, 2010, IMMUNOPHARM IMMUNOT, V32, P160, DOI [10.3109/08923970902936880, 10.1080/08923970902936880]; Idikio H, 1998, INT J ONCOL, V12, P1287; Kim HRC, 1999, CANCER RES, V59, P4148; Kim Y, 2008, GENE DEV, V22, P2507, DOI 10.1101/gad.1703708; Lee EW, 2009, EMBO J, V28, P2100, DOI 10.1038/emboj.2009.164; Lin HM, 2000, CARCINOGENESIS, V21, P1941, DOI 10.1093/carcin/21.11.1941; Mashiach E, 2008, NUCLEIC ACIDS RES, V36, pW229, DOI 10.1093/nar/gkn186; Merseburger AS, 2008, PROSTATE, V68, P72, DOI 10.1002/pros.20688; Nangia-Makker P, 1998, BREAST CANCER RES TR, V49, P171, DOI 10.1023/A:1005913810250; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Ogawa M, 2001, INT J MOL MED, V7, P479; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Pavelic SK, 2008, CANCER GENE THER, V15, P576, DOI 10.1038/cgt.2008.28; PODUST VN, 1995, BIOCHEMISTRY-US, V34, P8869, DOI 10.1021/bi00027a039; Puglisi F, 2004, CANCER LETT, V212, P233, DOI 10.1016/j.canlet.2004.03.006; Roy A, 2010, NAT PROTOC, V5, P725, DOI 10.1038/nprot.2010.5; Schneidman-Duhovny D, 2005, NUCLEIC ACIDS RES, V33, pW363, DOI 10.1093/nar/gki481; Seetharaman J, 1998, J BIOL CHEM, V273, P13047, DOI 10.1074/jbc.273.21.13047; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; Stivala LA, 2012, CURR CANCER DRUG TAR, V12, P85; Streetly MJ, 2010, BLOOD, V115, P3939, DOI 10.1182/blood-2009-10-251660; Suzuki A, 1999, ONCOGENE, V18, P1239, DOI 10.1038/sj.onc.1202409; Touitou R, 2001, EMBO J, V20, P2367, DOI 10.1093/emboj/20.10.2367; Van Le H, 2005, J BIOL CHEM, V280, P32018, DOI 10.1074/jbc.M504689200; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang Y, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.79; Wang Y, 2009, AM J PATHOL, V174, P1515, DOI 10.2353/ajpath.2009.080816; Yang LP, HEPATO-GASTROENTEROL, DOI DOI 10.5754/HGE12129)	50	16	18	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	2013	32	42					5058	5065		10.1038/onc.2012.528	http://dx.doi.org/10.1038/onc.2012.528			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	238IB	23160381	Green Accepted			2022-12-17	WOS:000325937900007
J	Wen, J; Cerosaletti, K; Schultz, KJ; Wright, JA; Concannon, P				Wen, J.; Cerosaletti, K.; Schultz, K. J.; Wright, J. A.; Concannon, P.			NBN Phosphorylation regulates the accumulation of MRN and ATM at sites of DNA double-strand breaks	ONCOGENE			English	Article						MRN; ATM; nibrin (NBN); I-PpoI and DNA double-strand breaks	DISTINCT FUNCTIONAL DOMAINS; CELL-PENETRATING PEPTIDES; S-PHASE CHECKPOINT; ATAXIA-TELANGIECTASIA; IONIZING-RADIATION; DEPENDENT PHOSPHORYLATION; CHROMOSOMAL INSTABILITY; SYNDROME PROTEIN; DAMAGE RESPONSE; REPAIR	In response to ionizing radiation, the MRE11/RAD50/NBN complex re-distributes to the sites of DNA double-strand breaks (DSBs) where each of its individual components is phosphorylated by the serine-threonine kinase, ATM. ATM phosphorylation of NBN is required for the activation of the S-phase checkpoint, but the mechanism whereby these phosphorylation events signal the checkpoint machinery remains unexplained. Here, we describe the use of direct protein transduction of the homing endonuclease, I-PpoI, into human cells to generate site-specific DSBs. Direct transduction of I-PpoI protein results in rapid accumulation and turnover of the endonuclease in live cells, facilitating comparisons across multiple cell lines. We demonstrate the utility of this system by introducing I-PpoI into isogenic cell lines carrying mutations at the ATM phosphorylation sites in NBN and assaying the effects of these mutations on the spatial distribution and temporal accumulation of NBN and ATM at DSBs by chromatin immunoprecipitation, as well as timing and extent of DSB repair. Although the spatial distribution of NBN and ATM recruited to the sites of DSBs was comparable between control cells and those expressing phosphorylation mutants of NBN, the timing of accumulation of NBN and ATM was altered. Serine-to-alanine mutations that blocked phosphorylation resulted in delayed recruitment of both NBN and ATM to DSBs. Serine-to-glutamic acid substitutions that mimicked the phosphorylation event resulted in both increased and prolonged accumulation of both NBN and ATM at DSBs. The repair of DSBs in cells lacking full-length NBN was significantly delayed compared with control cells, whereas blocking phosphorylation of NBN resulted in a more modest delay in repair. These data indicate that following the induction of DSBs, phosphorylation of NBN regulates its accumulation, and that of ATM, at sites of DNA DSB as well as the timing of the repair of these sites.	[Wen, J.; Wright, J. A.; Concannon, P.] Univ Virginia, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA; [Cerosaletti, K.] Benaroya Res Inst, Translat Res Program, Seattle, WA USA; [Schultz, K. J.] Univ New Mexico, Sch Med, Albuquerque, NM 87131 USA; [Concannon, P.] Univ Virginia, Ctr Publ Hlth Genom, Charlottesville, VA 22908 USA	University of Virginia; Benaroya Research Institute; University of New Mexico; University of Virginia	Concannon, P (corresponding author), Univ Virginia, Ctr Publ Hlth Genom, Dept Biochem & Mol Genet, POB 800717, Charlottesville, VA 22908 USA.	pjc6n@virginia.edu		Concannon, Patrick/0000-0002-5801-1859	NCI [CA57569]; NATIONAL CANCER INSTITUTE [R01CA057569] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by a grant from the NCI (CA57569).	Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bekker-Jensen S, 2006, J CELL BIOL, V173, P195, DOI 10.1083/jcb.200510130; Berkovich E, 2007, NAT CELL BIOL, V9, P683, DOI 10.1038/ncb1599; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Carson CT, 2003, EMBO J, V22, P6610, DOI 10.1093/emboj/cdg630; Cerosaletti K, 2004, J BIOL CHEM, V279, P38813, DOI 10.1074/jbc.M404294200; Cerosaletti K, 2006, MOL CELL BIOL, V26, P1691, DOI 10.1128/MCB.26.5.1691-1699.2006; de Jager M, 2001, MOL CELL, V8, P1129, DOI 10.1016/S1097-2765(01)00381-1; DERZWET MK, 1999, MUTAT RES, V434, P17; Desai-Mehta A, 2001, MOL CELL BIOL, V21, P2184, DOI 10.1128/MCB.21.6.2184-2191.2001; Di VM, 2009, DNA REPAIR, V8, P1311; Difilippantonio S, 2005, NAT CELL BIOL, V7, P675, DOI 10.1038/ncb1270; Dong ZW, 1999, J BIOL CHEM, V274, P19513, DOI 10.1074/jbc.274.28.19513; Falck J, 2002, NAT GENET, V30, P290, DOI 10.1038/ng845; Falck J, 2005, NATURE, V434, P605, DOI 10.1038/nature03442; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Gatei M, 2011, J BIOL CHEM, V286, P31542, DOI 10.1074/jbc.M111.258152; Horejsi Z, 2004, ONCOGENE, V23, P3122, DOI 10.1038/sj.onc.1207447; JASPERS NGJ, 1988, AM J HUM GENET, V42, P66; Kitagawa R, 2004, GENE DEV, V18, P1423, DOI 10.1101/gad.1200304; Lee JH, 2003, J BIOL CHEM, V278, P45171, DOI 10.1074/jbc.M308705200; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Lindgren M, 2011, METHODS MOL BIOL, V683, P3, DOI 10.1007/978-1-60761-919-2_1; Lins S, 2009, GENE, V447, P12, DOI 10.1016/j.gene.2009.07.013; Lukas C, 2003, NAT CELL BIOL, V5, P255, DOI 10.1038/ncb945; Lukas C, 2004, EMBO J, V23, P2674, DOI 10.1038/sj.emboj.7600269; Luo GB, 1999, P NATL ACAD SCI USA, V96, P7376, DOI 10.1073/pnas.96.13.7376; Maser RS, 2001, NAT GENET, V27, P417, DOI 10.1038/86920; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; Matsuura S, 1998, NAT GENET, V19, P179, DOI 10.1038/549; Milletti F, 2012, DRUG DISCOV TODAY, V17, P850, DOI 10.1016/j.drudis.2012.03.002; Nelms BE, 1998, SCIENCE, V280, P590, DOI 10.1126/science.280.5363.590; O'Driscoll M, 2001, MOL CELL, V8, P1175, DOI 10.1016/S1097-2765(01)00408-7; Paull TT, 1999, GENE DEV, V13, P1276, DOI 10.1101/gad.13.10.1276; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; ROUET P, 1994, MOL CELL BIOL, V14, P8096, DOI 10.1128/MCB.14.12.8096; ROUET P, 1994, P NATL ACAD SCI USA, V91, P6064, DOI 10.1073/pnas.91.13.6064; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; TAALMAN RDFM, 1983, MUTAT RES, V112, P23, DOI 10.1016/0167-8817(83)90021-4; TAALMAN RDFM, 1989, AM J MED GENET, V32, P425, DOI 10.1002/ajmg.1320320332; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; Vissinga CS, 2009, MOL CELL BIOL, V29, P1000, DOI 10.1128/MCB.01131-08; WEEMAES CMR, 1981, ACTA PAEDIATR SCAND, V70, P557, DOI 10.1111/j.1651-2227.1981.tb05740.x; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; Xiao YH, 1997, NUCLEIC ACIDS RES, V25, P2985, DOI 10.1093/nar/25.15.2985; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083; Zhu J, 2001, CURR BIOL, V11, P105, DOI 10.1016/S0960-9822(01)00019-7	50	16	17	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 12	2013	32	37					4448	4456		10.1038/onc.2012.443	http://dx.doi.org/10.1038/onc.2012.443			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	218AF	23146902	Green Accepted			2022-12-17	WOS:000324404200013
J	De Menna, M; D'Amato, V; Ferraro, A; Fusco, A; Di Lauro, R; Garbi, C; De Vita, G				De Menna, M.; D'Amato, V.; Ferraro, A.; Fusco, A.; Di Lauro, R.; Garbi, C.; De Vita, G.			Wnt4 inhibits cell motility induced by oncogenic Ras	ONCOGENE			English	Article						cancer; cell motility; miR-24; Ras; Wnt4	UP-REGULATION; EXPRESSION; MIGRATION; DIFFERENTIATION; ACTIVATION; PATHWAY; BETA	Aberrant motility and invasive ability are relevant hallmarks of malignant tumor cells. Pathways regulating the movement of cancer cells from the site of primary tumor toward adjacent and/or distant tissues are not entirely defined. By using a model of malignant transformation induced by Ras, we identified Wnt4 as an early target of Ras oncogenic signaling. Here we show that Wnt4 is repressed by Ras and that forced Wnt4 expression inhibits Ras-induced cell motility. Accordingly, we found that Wnt4 is downregulated in human anaplastic thyroid carcinomas, the most malignant and metastatic thyroid cancer histotype. Wnt4 interferes with Ras-induced actin cytoskeleton reorganization through non-canonical pathways, by altering the balance between the activation of different Rho-family small guanosine triphosphatases (GTPases). Finally, we demonstrate that Wnt4 is post-transcriptionally repressed by miR-24, a Ras-induced micro RNA (miRNA) targeting the 3'-untranslated region (UTR) of Wnt4. Taken together our data highlight a novel Ras-regulated miRNA-dependent circuitry regulating the motile phenotype of cancer cells.	[De Menna, M.; D'Amato, V.; Ferraro, A.; Fusco, A.; Di Lauro, R.; Garbi, C.; De Vita, G.] Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, I-580131 Naples, Italy; [Fusco, A.] CNR, Ist Endocrinol Oncol Sperimentale, I-80125 Naples, Italy	University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR)	De Vita, G (corresponding author), Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, I-580131 Naples, Italy.	gdevita@unina.it	Ferraro, Angelo/H-3193-2019; De Vita, Gabriella/H-4422-2011; Di Lauro, Roberto/A-2746-2012; Ferraro, Angelo/A-4172-2014	Ferraro, Angelo/0000-0002-2044-7569; De Vita, Gabriella/0000-0002-7302-1174; Di Lauro, Roberto/0000-0001-9493-3036; Ferraro, Angelo/0000-0002-2044-7569; Fusco, Alfredo/0000-0003-3332-5197; De Menna, Marta/0000-0002-6306-3485	Associazione Italiana per la Ricerca sul Cancro (AIRC)	Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro)	This work was supported by Associazione Italiana per la Ricerca sul Cancro (AIRC).	Abreu MTH, 2011, MOL BIOL CELL, V22, P105, DOI 10.1091/mbc.E10-03-0185; Arthur WT, 2001, MOL BIOL CELL, V12, P2711, DOI 10.1091/mbc.12.9.2711; Baratta MG, 2009, MOL ENDOCRINOL, V23, P838, DOI 10.1210/me.2008-0353; Benhaj K, 2006, ONCOL REP, V15, P701; Bhushan L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022484; Braga VMM, 2000, MOL BIOL CELL, V11, P3703, DOI 10.1091/mbc.11.11.3703; Bui TD, 1997, BRIT J CANCER, V75, P1131, DOI 10.1038/bjc.1997.195; Cully M, 2006, NAT REV CANCER, V6, P184, DOI 10.1038/nrc1819; De Vita G, 2005, MOL ENDOCRINOL, V19, P76, DOI 10.1210/me.2004-0172; Drosten M, 2010, EMBO J, V29, P1091, DOI 10.1038/emboj.2010.7; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Frezzetti D, 2011, ONCOGENE, V30, P275, DOI 10.1038/onc.2010.416; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hatziapostolou M, 2011, CELL, V147, P1233, DOI 10.1016/j.cell.2011.10.043; Hingorani SR, 2003, CURR OPIN GENET DEV, V13, P6, DOI 10.1016/S0959-437X(02)00017-5; HUGUET EL, 1994, CANCER RES, V54, P2615; Jeays-Ward K, 2003, DEVELOPMENT, V130, P3663, DOI 10.1242/dev.00591; Kimura T, 2001, ENDOCR REV, V22, P631, DOI 10.1210/er.22.5.631; Kondo T, 2006, NAT REV CANCER, V6, P292, DOI 10.1038/nrc1836; Landgraf P, 2007, CELL, V129, P1401, DOI 10.1016/j.cell.2007.04.040; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Miyakoshi T, 2008, ENDOCR PATHOL, V19, P261, DOI 10.1007/s12022-008-9048-9; Papadimitriou E, 2012, ONCOGENE, V31, P2862, DOI 10.1038/onc.2011.457; Parri M, 2010, CELL COMMUN SIGNAL, V8, DOI 10.1186/1478-811X-8-23; Qin WM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009429; Quinlan MP, 1999, ONCOGENE, V18, P6434, DOI 10.1038/sj.onc.1203026; Roger PP, 2010, MOL CELL ENDOCRINOL, V321, P3, DOI 10.1016/j.mce.2009.11.015; Schlessinger K, 2009, GENE DEV, V23, P265, DOI 10.1101/gad.1760809; Schubbert S, 2007, NAT REV CANCER, V7, P295, DOI 10.1038/nrc2109; STARK K, 1994, NATURE, V372, P679, DOI 10.1038/372679a0; Taki M, 2003, CANCER SCI, V94, P593, DOI 10.1111/j.1349-7006.2003.tb01488.x; Tanigawa S, 2011, DEV BIOL, V352, P58, DOI 10.1016/j.ydbio.2011.01.012; Vainio S, 1999, NATURE, V397, P405, DOI 10.1038/17068; Vainio SJ, 2003, J NEPHROL, V16, P279; Vincent JP, 2011, EMBO J, V30, P3665, DOI 10.1038/emboj.2011.311; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Xie L, 2011, CLIN BIOCHEM, V44, P216, DOI 10.1016/j.clinbiochem.2010.11.002	38	16	16	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 29	2013	32	35					4110	4119		10.1038/onc.2012.419	http://dx.doi.org/10.1038/onc.2012.419			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209IG	23027131				2022-12-17	WOS:000323748500006
J	Salm, F; Cwiek, P; Ghosal, A; Buccarello, AL; Largey, F; Wotzkow, C; Holand, K; Styp-Rekowska, B; Djonov, V; Zlobec, I; Bodmer, N; Gross, N; Westermann, F; Schafer, SC; Arcaro, A				Salm, F.; Cwiek, P.; Ghosal, A.; Buccarello, A. Lucia; Largey, F.; Wotzkow, C.; Hoeland, K.; Styp-Rekowska, B.; Djonov, V.; Zlobec, I.; Bodmer, N.; Gross, N.; Westermann, F.; Schaefer, S. C.; Arcaro, A.			RNA interference screening identifies a novel role for autocrine fibroblast growth factor signaling in neuroblastoma chemoresistance	ONCOGENE			English	Article						neuroblastoma; RNAi screen; FGFR2; BCL2; chemoresistance; cisplatin	NF-KAPPA-B; DEPENDENT PATHWAY; EXPRESSION; APOPTOSIS; BCL-2; RESISTANCE; AMPLIFICATION; ENZASTAURIN; INHIBITOR; CISPLATIN	Chemotherapeutic drug resistance is one of the major causes for treatment failure in high-risk neuroblastoma (NB), the most common extra cranial solid tumor in children. Poor prognosis is typically associated with MYCN amplification. Here, we utilized a loss-of-function kinome-wide RNA interference screen to identify genes that cause cisplatin sensitization. We identified fibroblast growth factor receptor 2 (FGFR2) as an important determinant of cisplatin resistance. Pharmacological inhibition of FGFR2 confirmed the importance of this kinase in NB chemoresistance. Silencing of FGFR2 sensitized NB cells to cisplatin-induced apoptosis, which was regulated by the downregulation of the anti-apoptotic proteins BCL2 and BCLXL. Mechanistically, FGFR2 was shown to activate protein kinase C-delta to induce BCL2 expression. FGFR2, as well as the ligand fibroblast growth factor-2, were consistently expressed in primary NB and NB cell lines, indicating the presence of an autocrine loop. Expression analysis revealed that FGFR2 correlates with MYCN amplification and with advanced stage disease, demonstrating the clinical relevance of FGFR2 in NB. These findings suggest a novel role for FGFR2 in chemoresistance and provide a rational to combine pharmacological inhibitors against FGFR2 with chemotherapeutic agents for the treatment of NB.	[Salm, F.; Cwiek, P.; Wotzkow, C.; Hoeland, K.; Arcaro, A.] Univ Bern, Dept Clin Res, CH-3004 Bern, Switzerland; [Ghosal, A.; Buccarello, A. Lucia; Largey, F.; Bodmer, N.] Univ Childrens Hosp Zurich, Dept Oncol, Zurich, Switzerland; [Styp-Rekowska, B.; Djonov, V.] Univ Bern, Inst Anat, CH-3004 Bern, Switzerland; [Zlobec, I.; Schaefer, S. C.] Univ Bern, Inst Pathol, CH-3004 Bern, Switzerland; [Gross, N.] CHU Vaudois, Univ Lausanne Hosp, Dept Paediat, CH-1011 Lausanne, Switzerland; [Westermann, F.] German Canc Res Ctr, Dept Tumor Genet, Heidelberg, Dkfz, Germany	University of Bern; University Children's Hospital Zurich; University of Bern; University of Bern; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Helmholtz Association; German Cancer Research Center (DKFZ)	Arcaro, A (corresponding author), Univ Bern, Dept Clin Res, Div Pediat Hematol Oncol, Tiefenaustr 120C, CH-3004 Bern, Switzerland.	alexandre.arcaro@dkf.unibe.ch	buccarello, lucia/AAO-1407-2020; Arcaro, Alexandre/G-1711-2010; Westermann, Frank/F-7509-2013	buccarello, lucia/0000-0002-3393-653X; Arcaro, Alexandre/0000-0001-9107-2947; Djonov, Valentin/0000-0002-5062-1169; Zlobec, Inti/0000-0001-6741-3000; Cwiek, Paulina/0000-0002-0964-6364	Gottfried und Julia Bangerter-Rhyner-Stiftung; Jubilaumsstiftung Swiss Life; European Union [259348]	Gottfried und Julia Bangerter-Rhyner-Stiftung; Jubilaumsstiftung Swiss Life; European Union(European Commission)	This work was supported by grants from the Gottfried und Julia Bangerter-Rhyner-Stiftung and Jubilaumsstiftung Swiss Life. The research leading to these results has received funding from the European Union's Seventh Framework Programme (FP7/2007-2013) under grant agreement no. 259348.	Arcaro A, 2002, EMBO J, V21, P5097, DOI 10.1093/emboj/cdf512; Boller D, 2008, CLIN CANCER RES, V14, P1172, DOI 10.1158/1078-0432.CCR-07-0737; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; Byron SA, 2009, FUTURE ONCOL, V5, P27, DOI 10.2217/14796694.5.1.27; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; Cole C, 2010, CANCER BIOL THER, V10, DOI 10.4161/cbt.10.5.12585; Cole KA, 2011, P NATL ACAD SCI USA, V108, P3336, DOI 10.1073/pnas.1012351108; Diep CH, 2011, CLIN CANCER RES, V17, P2744, DOI 10.1158/1078-0432.CCR-10-2214; Eggert A, 2000, CLIN CANCER RES, V6, P1900; Erovic BM, 2005, CLIN CANCER RES, V11, P8632, DOI 10.1158/1078-0432.CCR-05-1170; Fanale D, 2012, ONCOGENE, V31, P2121, DOI 10.1038/onc.2011.408; Fang H, 2011, CLIN CANCER RES, V17, P7093, DOI 10.1158/1078-0432.CCR-11-0578; Flahaut M, 2006, GENE CHROMOSOME CANC, V45, P495, DOI 10.1002/gcc.20312; Galanski M, 2006, RECENT PAT ANTI-CANC, V1, P285, DOI 10.2174/157489206777442287; Ghobrial IM, 2011, AM J HEMATOL, V86, P573, DOI 10.1002/ajh.22048; Giulietti A, 2001, METHODS, V25, P386, DOI 10.1006/meth.2001.1261; Goldsmith KC, 2010, CELL DEATH DIFFER, V17, P872, DOI 10.1038/cdd.2009.171; Goldsmith KC, 2005, CANCER LETT, V228, P133, DOI 10.1016/j.canlet.2005.01.048; Guo BC, 2004, CURR OPIN IMMUNOL, V16, P367, DOI 10.1016/j.coi.2004.03.012; Herbst RS, 2007, CLIN CANCER RES, V13, p4641S, DOI 10.1158/1078-0432.CCR-07-0538; Holzel M, 2010, CELL, V142, P218, DOI 10.1016/j.cell.2010.06.004; Iorns E, 2008, CANCER CELL, V13, P91, DOI 10.1016/j.ccr.2008.01.001; Katoh M, 2008, INT J ONCOL, V33, P233, DOI 10.3892/ijo_00000001; Kelland L, 2007, NAT REV CANCER, V7, P573, DOI 10.1038/nrc2167; Lee CH, 2008, MOL IMMUNOL, V45, P3693, DOI 10.1016/j.molimm.2008.06.007; Lucas PC, 2004, J CELL SCI, V117, P31, DOI 10.1242/jcs.00904; Ma S, 2007, CURR OPIN ONCOL, V19, P590, DOI 10.1097/CCO.0b013e3282f10a00; MacKeigan JP, 2005, NAT CELL BIOL, V7, P591, DOI 10.1038/ncb1258; Maris JM, 2010, NEW ENGL J MED, V362, P2202, DOI 10.1056/NEJMra0804577; Mattson MP, 2006, CELL DEATH DIFFER, V13, P852, DOI 10.1038/sj.cdd.4401837; Michaud WA, 2009, CLIN CANCER RES, V15, P1645, DOI 10.1158/1078-0432.CCR-08-2581; Muth D, CANC RES, V70, P3791; Nikolova Z, 1998, J CELL SCI, V111, P2741; Oberthuer A, 2006, J CLIN ONCOL, V24, P5070, DOI 10.1200/JCO.2006.06.1879; Otto T, 2009, CANCER CELL, V15, P67, DOI 10.1016/j.ccr.2008.12.005; Pardo OE, 2002, J BIOL CHEM, V277, P12040, DOI 10.1074/jbc.M109006200; Pardo OE, 2006, EMBO J, V25, P3078, DOI 10.1038/sj.emboj.7601198; Sagulenko V, 2008, CARCINOGENESIS, V29, P1869, DOI 10.1093/carcin/bgn147; Sheridan C, 2010, ONCOGENE, V29, P6428, DOI 10.1038/onc.2010.380; Shukla N, 2012, CLIN CANCER RES, V18, P748, DOI 10.1158/1078-0432.CCR-11-2056; Siddik ZH, 2003, ONCOGENE, V22, P7265, DOI 10.1038/sj.onc.1206933; SORENSON CM, 1990, JNCI-J NATL CANCER I, V82, P749, DOI 10.1093/jnci/82.9.749; Terrile M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028356; Turner N, 2010, ONCOGENE, V29, P2013, DOI 10.1038/onc.2009.489; Turner N, 2010, NAT REV CANCER, V10, P116, DOI 10.1038/nrc2780; Wilson TR, 2006, ANN ONCOL, V17, pX315, DOI 10.1093/annonc/mdl280; Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206	47	16	16	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 22	2013	32	34					3944	3953		10.1038/onc.2012.416	http://dx.doi.org/10.1038/onc.2012.416			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209IC	23027129				2022-12-17	WOS:000323748100003
J	Longoni, N; Kunderfranco, P; Pellini, S; Albino, D; Mello-Grand, M; Pinton, S; D'Ambrosio, G; Sarti, M; Sessa, F; Chiorino, G; Catapano, CV; Carbone, GM				Longoni, N.; Kunderfranco, P.; Pellini, S.; Albino, D.; Mello-Grand, M.; Pinton, S.; D'Ambrosio, G.; Sarti, M.; Sessa, F.; Chiorino, G.; Catapano, C. V.; Carbone, G. M.			Aberrant expression of the neuronal-specific protein DCDC2 promotes malignant phenotypes and is associated with prostate cancer progression	ONCOGENE			English	Article						prostate cancer; DCDC2; doublecortin domain containing 2 protein; ESE3/EHF; ETS; cell migration; taxol resistance	MICROTUBULE-ASSOCIATED PROTEIN; PACLITAXEL SENSITIVITY; TRANSCRIPTION FACTORS; DOUBLECORTIN GENE; DCX SUPERFAMILY; MARKER; DISEASE; FAMILY; AGENTS; ROLES	By integrating gene profiling and immunohistochemical data with functional experiments in cell lines in this study we show for the first time that doublecortin (DCX) domain containing 2 (DCDC2), a protein belonging to the DCX family and involved in neuronal cell migration, is aberrantly expressed in prostate tumors whereas absent in normal prostate. Furthermore, in patients treated with radical prostatectomy, high levels of DCDC2 RNA were significantly associated with increased biochemical relapse (LogRank Mantel-Cox 0.012). Mechanistically, we found that the ETS transcription factor ESE3/EHF, which is expressed in normal prostate and frequently lost in prostate tumors, maintained DCDC2 repressed by binding to a novel identified ETS binding site in the gene promoter. Consistently, in prostate tumors and in cellular models of gain and loss of ESE3/EHF, the expression of DCDC2 and ESE3/EHF were inversely correlated. In prostate cancer cells, DCDC2 colocalized with microtubules and promoted cell migration and resistance to the microtubule-targeting drug taxol. Collectively, this study establishes DCDC2 as a novel ESE3/EHF oncogenic target in prostate cancer. These findings may be relevant for the clinical management of prostate cancer as DCDC2 may signal tumors more prone to relapse and resistant to taxol treatment.	[Longoni, N.; Kunderfranco, P.; Pellini, S.; Albino, D.; Pinton, S.; Sarti, M.; Catapano, C. V.; Carbone, G. M.] IOR, Bellinzona, Switzerland; [Longoni, N.; Kunderfranco, P.; Pellini, S.; Albino, D.; Pinton, S.; Sarti, M.; Catapano, C. V.; Carbone, G. M.] Oncol Inst Sourthern Switzerland IOSI, CH-6500 Bellinzona, Switzerland; [Mello-Grand, M.; Chiorino, G.] Fdn Edo & Elvo Tempia Valenta, Lab Canc Genom, Biella, Italy; [Sessa, F.] IRCCS Multimed, Milan, Italy; [Sessa, F.] Univ Insubria, Dept Pathol, Varese, Italy	Institute of Oncology Research (IOR); Universita della Svizzera Italiana; Institute of Oncology Research (IOR); IRCCS Multimedica; University of Insubria	Carbone, GM (corresponding author), Oncol Inst Sourthern Switzerland IOSI, IOR, Via Vela 6, CH-6500 Bellinzona, Switzerland.	pina.carbone@ior.iosi.ch	Kunderfranco, Paolo/GUQ-8968-2022; Kunderfranco, Paolo/J-7636-2016; Chiorino, Giovanna/K-5037-2016; Kunderfranco, Paolo/ABH-9294-2020	Kunderfranco, Paolo/0000-0001-7477-8710; Kunderfranco, Paolo/0000-0003-3636-3391; Chiorino, Giovanna/0000-0002-9502-6400; Kunderfranco, Paolo/0000-0001-7477-8710; Catapano, Carlo V./0000-0002-7079-557X	Oncosuisse [KFS-01913-08, KFS-02573-02-2010]; Swiss National Science Foundation [FNS-31003A-118113]; Ticino Foundation for Cancer Research; Compagnia di San Paolo, Torino, Italy	Oncosuisse; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Ticino Foundation for Cancer Research; Compagnia di San Paolo, Torino, Italy(Compagnia di San Paolo)	This work was supported by grants from Oncosuisse (KFS-01913-08 and KFS-02573-02-2010), Swiss National Science Foundation (FNS-31003A-118113) and Ticino Foundation for Cancer Research to GMC. MMG and GC were supported by Compagnia di San Paolo, Torino, Italy.	Albertini V, 2006, NUCLEIC ACIDS RES, V34, P1721, DOI 10.1093/nar/gkl063; Bowen C, 2000, CANCER RES, V60, P6111; Burbridge TJ, 2008, NEUROSCIENCE, V152, P723, DOI 10.1016/j.neuroscience.2008.01.020; Cangemi R, 2008, ONCOGENE, V27, P2877, DOI 10.1038/sj.onc.1210953; Carver BS, 2009, NAT GENET, V41, P619, DOI 10.1038/ng.370; Chinnaiyan AM, 2008, NEOPLASIA, V10, P177, DOI 10.1593/neo.07822; Coquelle FM, 2006, CELL CYCLE, V5, P976, DOI 10.4161/cc.5.9.2715; Daou MC, 2005, ACTA NEUROPATHOL, V110, P472, DOI 10.1007/s00401-005-1070-0; DeMarzo AM, 2003, LANCET, V361, P955, DOI 10.1016/S0140-6736(03)12779-1; Dijkmans Thomas Frederik, 2010, Central Nervous System Agents in Medicinal Chemistry, V10, P32; Dobyns WB, 1999, NEUROLOGY, V53, P270, DOI 10.1212/WNL.53.2.270; Dumontet C, 2010, NAT REV DRUG DISCOV, V9, P790, DOI 10.1038/nrd3253; Gleeson JG, 1999, NEURON, V23, P257, DOI 10.1016/S0896-6273(00)80778-3; Horesh D, 1999, HUM MOL GENET, V8, P1599, DOI 10.1093/hmg/8.9.1599; Kim MH, 2003, NAT STRUCT BIOL, V10, P324, DOI 10.1038/nsb918; King JC, 2009, NAT GENET, V41, P524, DOI 10.1038/ng.371; Klezovitch O, 2008, P NATL ACAD SCI USA, V105, P2105, DOI 10.1073/pnas.0711711105; Koizumi H, 2006, NAT NEUROSCI, V9, P779, DOI 10.1038/nn1704; Kumar-Sinha C, 2008, NAT REV CANCER, V8, P497, DOI 10.1038/nrc2402; Kunderfranco P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010547; Massinen S, PLOS ONE, V6; Meng HY, 2011, BEHAV GENET, V41, P58, DOI 10.1007/s10519-010-9408-3; Meng HY, 2005, P NATL ACAD SCI USA, V102, P17053, DOI 10.1073/pnas.0508591102; Mollinedo F, 2003, APOPTOSIS, V8, P413, DOI 10.1023/A:1025513106330; Oltra S, 2005, DIAGN MOL PATHOL, V14, P53, DOI 10.1097/01.pas.0000149876.32376.c0; Reiner O, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-188; Rouzier R, 2005, P NATL ACAD SCI USA, V102, P8315, DOI 10.1073/pnas.0408974102; Sapir T, 2000, HUM MOL GENET, V9, P703, DOI 10.1093/hmg/9.5.703; Seth A, 2005, EUR J CANCER, V41, P2462, DOI 10.1016/j.ejca.2005.08.013; Soltani MH, 2005, AM J PATHOL, V166, P1841, DOI 10.1016/S0002-9440(10)62493-5; Tint I, 2009, J NEUROSCI, V29, P10995, DOI 10.1523/JNEUROSCI.3399-09.2009; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Viprey VF, 2008, J PATHOL, V216, P245, DOI 10.1002/path.2406; Wagner P, 2005, CELL CYCLE, V4, P1149, DOI 10.4161/cc.4.9.2038; Zong Y, 2009, P NATL ACAD SCI USA, V106, P12465, DOI 10.1073/pnas.0905931106	35	16	17	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2013	32	18					2315	2324		10.1038/onc.2012.245	http://dx.doi.org/10.1038/onc.2012.245			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	140VF	22733135				2022-12-17	WOS:000318683600008
J	Jagan, I; Fatehullah, A; Deevi, RK; Bingham, V; Campbell, FC				Jagan, I.; Fatehullah, A.; Deevi, R. K.; Bingham, V.; Campbell, F. C.			Rescue of glandular dysmorphogenesis in PTEN-deficient colorectal cancer epithelium by PPAR gamma-targeted therapy	ONCOGENE			English	Article						PTEN; cdc42; epithelium; morphogenesis	PLECKSTRIN HOMOLOGY DOMAIN; POLARITY PROTEIN PAR6; SPINDLE ORIENTATION; GLYCOGEN-SYNTHASE; TUMOR-SUPPRESSOR; CELL-POLARITY; RHO-GTPASES; CDC42 GEF; DUAL ROLE; KINASE B	Disruption of glandular architecture associates with poor clinical outcome in high-grade colorectal cancer (CRC). Phosphatase and tensin homolog deleted on chromosome ten (PTEN) regulates morphogenic growth of benign MDCK (Madin Darby Canine Kidney) cells through effects on the Rho-like GTPase cdc42 (cell division cycle 42). This study investigates PTEN-dependent morphogenesis in a CRC model. Stable short hairpin RNA knockdown of PTEN in Caco-2 cells influenced expression or localization of cdc42 guanine nucleotide exchange factors and inhibited cdc42 activation. Parental Caco-2 cells formed regular hollow gland-like structures (glands) with a single central lumen, in three-dimensional (3D) cultures. Conversely, PTEN-deficient Caco-2 ShPTEN cells formed irregular glands with multiple abnormal lumens as well as intra-and/or intercellular vacuoles evocative of the high-grade CRC phenotype. Effects of targeted treatment were investigated. Phosphatidinylinositol 3-kinase (PI3K) modulating treatment did not affect gland morphogenesis but did influence gland number, gland size and/or cell size within glands. As PTEN may be regulated by the nuclear receptor peroxisome proliferator-activated receptor-gamma (PPAR gamma), cultures were treated with the PPAR gamma ligand rosiglitazone. This treatment enhanced PTEN expression, cdc42 activation and rescued dysmorphogenesis by restoring single lumen formation in Caco-2 ShPTEN glands. Rosiglitazone effects on cdc42 activation and Caco-2 ShPTEN gland development were attenuated by cotreatment with GW9662, a PPAR gamma antagonist. Taken together, these studies show PTEN-cdc42 regulation of lumen formation in a 3D model of human CRC glandular morphogenesis. Treatment by the PPAR gamma ligand rosiglitazone, but not PI3K modulators, rescued colorectal glandular dysmorphogenesis of PTEN deficiency. Oncogene (2013) 32, 1305-1315; doi:10.1038/onc.2012.140; published online 30 April 2012	[Jagan, I.; Fatehullah, A.; Deevi, R. K.; Bingham, V.; Campbell, F. C.] Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast BT9 7BL, Antrim, North Ireland	Queens University Belfast	Campbell, FC (corresponding author), Queens Univ Belfast, Ctr Canc Res & Cell Biol, Lisburn Rd, Belfast BT9 7BL, Antrim, North Ireland.	f.c.campbell@qub.ac.uk		Campbell, Frederick/0000-0002-0363-9964	Wellcome Trust [WT081232MA]; Department for Education and Learning, Northern Ireland	Wellcome Trust(Wellcome TrustEuropean Commission); Department for Education and Learning, Northern Ireland	We gratefully acknowledge the support of the Wellcome Trust (WT081232MA) and the Department for Education and Learning, Northern Ireland for financial support. We are greatly indebted to Dr T Waldman, Georgetown University, USA, for supply of PTEN<SUP>+/+</SUP> HCT116 and PTEN <SUP>-/-</SUP> HCT116 cells, to Dr Pietro DiCamilli, Howard Hughes Medical Institute, Yale, for his generous provision of anti-human Tuba antibody, to Dr Estelle McLean for technical help, to Dr James Murray for the gift of PI-103 and to S Church for assistance with all imaging.	Al-Khouri AM, 2005, J BIOL CHEM, V280, P35195, DOI 10.1074/jbc.M503045200; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Aoki K, 2005, MOL BIOL CELL, V16, P2207, DOI 10.1091/mbc.e04-10-0904; Backman SA, 2002, CURR OPIN NEUROBIOL, V12, P516, DOI 10.1016/S0959-4388(02)00354-9; Balciunaite E, 2001, BIOCHEM J, V358, P281, DOI 10.1042/0264-6021:3580281; Boehm JS, 2005, MOL CELL BIOL, V25, P6464, DOI 10.1128/MCB.25.15.6464-6474.2005; Carracedo A, 2011, CANCER RES, V71, P629, DOI 10.1158/0008-5472.CAN-10-2488; Cho YB, 2009, HEPATO-GASTROENTEROL, V56, P1335; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; De Sarno P, 2002, NEUROPHARMACOLOGY, V43, P1158, DOI 10.1016/S0028-3908(02)00215-0; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Deevi R, 2011, BRIT J CANCER, V105, P1313, DOI 10.1038/bjc.2011.384; Donev IS, 2011, CLIN CANCER RES, V17, P2260, DOI 10.1158/1078-0432.CCR-10-1993; Durgan J, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.174235; Etienne-Manneville S, 2003, CURR OPIN CELL BIOL, V15, P67, DOI 10.1016/S0955-0674(02)00005-4; Etienne-Manneville S, 2004, J CELL SCI, V117, P1291, DOI 10.1242/jcs.01115; Etienne-Manneville S, 2003, NATURE, V421, P753, DOI 10.1038/nature01423; Etienne-Manneville S, 2001, CELL, V106, P489, DOI 10.1016/S0092-8674(01)00471-8; Fuentes EJ, 2003, J BIOL CHEM, V278, P21188, DOI 10.1074/jbc.M211792200; Goberdhan DCI, 1999, GENE DEV, V13, P3244, DOI 10.1101/gad.13.24.3244; Grant S, 2008, J CLIN INVEST, V118, P3003, DOI 10.1172/JCI36898; Gunaratne J, 2011, J BIOL CHEM, V286, P18093, DOI 10.1074/jbc.M111.221184; Guruswamy S, 2008, INT J CANCER, V122, P25, DOI 10.1002/ijc.23031; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Hussain NK, 2001, NAT CELL BIOL, V3, P927, DOI 10.1038/ncb1001-927; Itoh T, 2006, BBA-MOL CELL BIOL L, V1761, P897, DOI 10.1016/j.bbalip.2006.06.015; Jaffe AB, 2008, J CELL BIOL, V183, P625, DOI 10.1083/jcb.200807121; Joberty G, 2000, NAT CELL BIOL, V2, P531, DOI 10.1038/35019573; Johnson K, 2003, NAT CELL BIOL, V5, P12, DOI 10.1038/ncb0103-12; Kong M, 2000, J BIOL CHEM, V275, P36035, DOI 10.1074/jbc.M005621200; Lee C, 2004, CANCER RES, V64, P6906, DOI 10.1158/0008-5472.CAN-04-1767; Lemmon MA, 2008, NAT REV MOL CELL BIO, V9, P99, DOI 10.1038/nrm2328; Liliental J, 2000, CURR BIOL, V10, P401, DOI 10.1016/S0960-9822(00)00417-6; Maccario H, 2007, BIOCHEM J, V405, P439, DOI 10.1042/BJ20061837; Martin-Belmonte F, 2007, CELL, V128, P383, DOI 10.1016/j.cell.2006.11.051; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; Mitsushima M, 2009, MOL CELL BIOL, V29, P2816, DOI 10.1128/MCB.01713-08; Nassif NT, 2004, ONCOGENE, V23, P617, DOI 10.1038/sj.onc.1207059; Noda Y, 2001, GENES CELLS, V6, P107, DOI 10.1046/j.1365-2443.2001.00404.x; Orena SJ, 2000, J BIOL CHEM, V275, P15765, DOI 10.1074/jbc.M910002199; Patel L, 2001, CURR BIOL, V11, P764, DOI 10.1016/S0960-9822(01)00225-1; PELZ C, 1989, J CELL BIOCHEM, V39, P197, DOI 10.1002/jcb.240390211; Pertz O, 2010, J CELL SCI, V123, P1841, DOI 10.1242/jcs.064345; Poliseno L, 2010, NATURE, V465, P1033, DOI 10.1038/nature09144; Pruitt WM, 2003, BBA-MOL CELL RES, V1640, P61, DOI 10.1016/S0167-4889(03)00002-8; Qin Y, 2010, J CELL BIOL, V189, P661, DOI 10.1083/jcb.201002097; Raynaud FI, 2009, MOL CANCER THER, V8, P1725, DOI 10.1158/1535-7163.MCT-08-1200; Rodriguez-Fraticelli AE, 2010, J CELL BIOL, V189, P725, DOI 10.1083/jcb.201002047; Salazar MA, 2003, J BIOL CHEM, V278, P49031, DOI 10.1074/jbc.M308104200; Sawai H, 2008, BMC GASTROENTEROL, V8, DOI 10.1186/1471-230X-8-56; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Seargent JM, 2004, BRIT J PHARMACOL, V143, P933, DOI 10.1038/sj.bjp.0705973; Shao J, 2007, CARCINOGENESIS, V28, P2476, DOI 10.1093/carcin/bgm186; Sinha S, 2008, CELL SIGNAL, V20, P1927, DOI 10.1016/j.cellsig.2008.05.002; Song MS, 2011, CELL, V144, P187, DOI 10.1016/j.cell.2010.12.020; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Summers SA, 1999, J BIOL CHEM, V274, P17934, DOI 10.1074/jbc.274.25.17934; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Tan I, 2008, CELL, V135, P123, DOI 10.1016/j.cell.2008.09.018; ter Haar E, 2001, NAT STRUCT BIOL, V8, P593, DOI 10.1038/89624; Teresi RE, 2008, HUM MOL GENET, V17, P919, DOI 10.1093/hmg/ddm364; Trotman LC, 2003, PLOS BIOL, V1, P385, DOI 10.1371/journal.pbio.0000059; Wang H, 2010, P NATL ACAD SCI USA, V107, P5142, DOI 10.1073/pnas.0912524107; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Wong KK, 2010, CURR OPIN GENET DEV, V20, P87, DOI 10.1016/j.gde.2009.11.002	65	16	19	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2013	32	10					1305	1315		10.1038/onc.2012.140	http://dx.doi.org/10.1038/onc.2012.140			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110OP	22543585	Green Accepted			2022-12-17	WOS:000316454500011
J	Reilly, PT; Teo, WL; Low, MJ; Amoyo-Brion, AA; Dominguez-Brauer, C; Elia, AJ; Berger, T; Greicius, G; Pettersson, S; Mak, TW				Reilly, P. T.; Teo, W. L.; Low, M. J.; Amoyo-Brion, A. A.; Dominguez-Brauer, C.; Elia, A. J.; Berger, T.; Greicius, G.; Pettersson, S.; Mak, T. W.			Lipocalin 2 performs contrasting, location-dependent roles in APCmin tumor initiation and progression	ONCOGENE			English	Article						NGAL; 24p3; iron; intestinal cancer	GELATINASE-ASSOCIATED LIPOCALIN; INTESTINAL TUMORIGENESIS; BREAST-CANCER; NEUTROPHIL LIPOCALIN; APC(MIN/+) MOUSE; GASTRIC-CANCER; BETA-CATENIN; IRON; NGAL; MICE	Evidence that lipocalin 2 (LCN2) is oncogenic has grown in recent years and comes from both animal models and expression analysis from a variety of human cancers. In the intestine, LCN2 is overexpressed in colitis patients and its overexpression is a negative prognostic indicator in colorectal cancer. Functionally, LCN2 has a number of different activities that may contribute to its oncogenic potential, including increasing matrix metalloproteinase activity, control of iron availability and stimulating inflammation. In this report, we examined APCmin intestinal tumorigenesis in an LCN2-deficient background. We found that the loss of LCN2 increased tumor multiplicity specifically in the duodenum, suggesting a potential tumor-suppressive activity. Concurrently, however, LCN2 increased the average small intestinal tumor size particularly in the distal small intestine. We found that this increase was correlated to tumor iron(II) content, suggesting that an iron-scavenging role is important for LCN2 oncogenic activity in the intestine. Oncogene (2013) 32, 1233-1239; doi:10.1038/onc.2012.159; published online 21 May 2012	[Reilly, P. T.; Teo, W. L.; Amoyo-Brion, A. A.; Greicius, G.; Pettersson, S.; Mak, T. W.] Natl Canc Ctr Singapore, Div Cellular & Mol Res, Singapore, Singapore; [Dominguez-Brauer, C.; Elia, A. J.; Berger, T.; Mak, T. W.] Univ Hlth Network, Campbell Family Canc Res Inst, Toronto, ON M5G 2C1+, Canada	National Cancer Centre Singapore (NCCS); University of Toronto; University Toronto Affiliates; University Health Network Toronto	Mak, TW (corresponding author), Univ Hlth Network, Campbell Family Canc Res Inst, 620 Univ Ave,Suite 706, Toronto, ON M5G 2C1+, Canada.	tmak@uhnres.utoronto.ca	Berger, Thorsten/J-7632-2012; Pettersson, Sven/F-9511-2015	Greicius, Gediminas/0000-0001-8333-787X	National Cancer Centre Research Foundation, Singapore	National Cancer Centre Research Foundation, Singapore	We would like to acknowledge the National Cancer Centre Research Foundation, Singapore for financial support. We also thank Dr Ralph Bunte for helpful discussion as well as Dr Keith Rogers, Dr Seow Shih Wee, Mr Wong Jieshun, and Dr Annie-Gale Cambel for technical assistance.	Alpizar-Alpizar W, 2009, VIRCHOWS ARCH, V455, P225, DOI 10.1007/s00428-009-0825-8; Bachman MA, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000622; Baltgalvis KA, 2008, J APPL PHYSIOL, V104, P1137, DOI 10.1152/japplphysiol.00955.2007; Bao GH, 2010, NAT CHEM BIOL, V6, P602, DOI [10.1038/nchembio.402, 10.1038/NCHEMBIO.402]; Barresi V, 2010, CLIN NEUROPATHOL, V29, P317; Barresi V, 2011, PATHOL RES PRACT, V207, P479, DOI 10.1016/j.prp.2011.05.012; Barresi V, 2010, ONCOL REP, V24, P305, DOI 10.3892/or_00000860; Bauer M, 2008, BREAST CANCER RES TR, V108, P389, DOI 10.1007/s10549-007-9619-3; Berger T, 2006, P NATL ACAD SCI USA, V103, P1834, DOI 10.1073/pnas.0510847103; Berger T, 2010, P NATL ACAD SCI USA, V107, P2995, DOI 10.1073/pnas.1000101107; Carlson M, 2002, GUT, V50, P501, DOI 10.1136/gut.50.4.501; Dale JC, 2002, AM J CLIN PATHOL, V117, P802, DOI 10.1309/2YT4-CMP3-KYW7-9RK1; de  Haar C, 2012, CARCINOGENESIS; Devireddy LR, 2010, CELL, V141, P1006, DOI 10.1016/j.cell.2010.04.040; Devireddy LR, 2005, CELL, V123, P1293, DOI 10.1016/j.cell.2005.10.027; Dove WF, 1997, CANCER RES, V57, P812; Fernandez CA, 2005, CLIN CANCER RES, V11, P5390, DOI 10.1158/1078-0432.CCR-04-2391; Fischbach MA, 2006, P NATL ACAD SCI USA, V103, P16502, DOI 10.1073/pnas.0604636103; Flo TH, 2004, NATURE, V432, P917, DOI 10.1038/nature03104; Forbes A, 2009, GASTROENTEROLOGY, V137, pS47, DOI 10.1053/j.gastro.2009.08.013; Friedl A, 1999, HISTOCHEM J, V31, P433, DOI 10.1023/A:1003708808934; Goetz DH, 2002, MOL CELL, V10, P1033, DOI 10.1016/S1097-2765(02)00708-6; Hata K, 2006, CANCER LETT, V239, P123, DOI 10.1016/j.canlet.2005.07.033; Hvidberg V, 2005, FEBS LETT, V579, P773, DOI 10.1016/j.febslet.2004.12.031; Kubben FJGM, 2007, EUR J CANCER, V43, P1869, DOI 10.1016/j.ejca.2007.05.013; Leng XH, 2009, CANCER RES, V69, P8579, DOI 10.1158/0008-5472.CAN-09-1934; Mori K, 2007, KIDNEY INT, V71, P967, DOI 10.1038/sj.ki.5002165; MOSER AR, 1995, EUR J CANCER, V31A, P1061, DOI 10.1016/0959-8049(95)00181-H; Murphy EA, 2011, J INTERF CYTOK RES, V31, P219, DOI 10.1089/jir.2010.0051; Mutanen M, 2000, CARCINOGENESIS, V21, P1167, DOI 10.1093/carcin/21.6.1167; Nielsen BS, 1996, GUT, V38, P414, DOI 10.1136/gut.38.3.414; Nuntagowat C, 2010, CLIN EXP METASTAS, V27, P295, DOI 10.1007/s10585-010-9327-y; Rakoff-Nahoum S, 2007, SCIENCE, V317, P124, DOI 10.1126/science.1140488; Rao CV, 2005, P NATL ACAD SCI USA, V102, P4365, DOI 10.1073/pnas.0407822102; Rodvold JJ, 2012, CANCER LETT, V316, P132, DOI 10.1016/j.canlet.2011.11.002; Ryon J, 2002, BIOCHEM J, V367, P271, DOI 10.1042/BJ20020026; Shen Zhe-zhu, 2003, Zhonghua Wai Ke Za Zhi, V41, P817; Sinnamon MJ, 2008, INT J EXP PATHOL, V89, P466, DOI 10.1111/j.1365-2613.2008.00621.x; Stoesz SP, 1998, INT J CANCER, V79, P565, DOI 10.1002/(SICI)1097-0215(19981218)79:6<565::AID-IJC3>3.3.CO;2-6; Vinuesa E, 2008, AM J PHYSIOL-RENAL, V295, pF1554, DOI 10.1152/ajprenal.90250.2008; Wang DZ, 2004, CANCER CELL, V6, P285, DOI 10.1016/j.ccr.2004.08.011; Wang HJ, 2010, ANAT REC, V293, P1855, DOI 10.1002/ar.21230; Wilson CL, 1997, P NATL ACAD SCI USA, V94, P1402, DOI 10.1073/pnas.94.4.1402; Xiao H, 2010, GASTROENTEROLOGY, V139, P574, DOI 10.1053/j.gastro.2010.04.043; Xu G, 2012, J BIOL CHEM, V287, P4808, DOI 10.1074/jbc.M111.275719; Yan L, 2001, J BIOL CHEM, V276, P37258, DOI 10.1074/jbc.M106089200; Yang J, 2002, MOL CELL, V10, P1045, DOI 10.1016/S1097-2765(02)00710-4; Yang J, 2009, P NATL ACAD SCI USA, V106, P3913, DOI 10.1073/pnas.0810617106; Zhang HH, 2007, J CLIN PATHOL, V60, P555, DOI 10.1136/jcp.2006.039297; Zhang JH, 2008, MOL ENDOCRINOL, V22, P1416, DOI 10.1210/me.2007-0420	50	16	16	2	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2013	32	10					1233	1239		10.1038/onc.2012.159	http://dx.doi.org/10.1038/onc.2012.159			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110OP	22614012	Green Published			2022-12-17	WOS:000316454500004
J	Thaler, S; Schmidt, M; Schad, A; Sleeman, JP				Thaler, S.; Schmidt, M.; Schad, A.; Sleeman, J. P.			RASSF1A inhibits estrogen receptor alpha expression and estrogen-independent signalling: implications for breast cancer development	ONCOGENE			English	Article						RASSF1A; estrogen receptor alpha; senescence; breast cancer inhibition	ONCOGENE-INDUCED SENESCENCE; C-MYC; ACTIVATION; BCL-2; DNA; CELLS; MICE; TRANSFORMATION; PROLIFERATION; METHYLATION	The Ras association domain family 1 isoform A (RASSF1A) is a tumor suppressor whose inactivation is implicated in the development of many human cancers, including breast carcinomas. Little is known about the tumor-suppressive function of RASSF1A in breast tissue and whether its inactivation is mechanistically involved in the initiation and progression of breast tumors. Here, we show that RASSF1A inhibits breast cancer growth in vivo, and suppresses estrogen receptor (ER alpha) expression and function. Reconstitution of RASSF1A in MCF7 cells led to decreased ER alpha levels and reduced sensitivity to estrogen (E2). Concomitantly, we observed decreased expression of Id1 as well as the E2-responsive genes Bcl-2 and c-Myc that cooperatively contribute to the immortalization and transformation of breast epithelial cells. This downregulation was associated with induction of cell-cycle arrest and senescence that constitute early barriers to cancer initiation and progression. Knockdown of ER alpha showed that downregulation of ER alpha suffices to increase senescence and inhibit expression of Bcl-2, c-Myc and Id1. However, enforced expression of ER alpha only partially rescued RASSF1A-mediated growth inhibition and senescence, suggesting that suppression of ER alpha expression and activity is not the only mechanism by which RASSF1A inhibits growth and survival of breast cancer cells. Ectopic expression of Bcl-2, c-Myc and Id1 had little or no effect on RASSF1A-mediated growth arrest, indicating that RASSF1A acts dominantly over these oncogenes. Mechanistically, RASSF1A was found to suppress ER alpha expression through Akt1. It also transiently inhibited ER alpha-induced Ras-MAPK activity after exposure of cells to E2. Together, our data show that RASSF1A acts as a tumor suppressor in ER alpha+ mammary epithelial cells, in part through inhibiting ER alpha expression and activity. These findings suggest that RASSF1A has a key role in suppressing the transformation of human breast epithelial cells and ER alpha+ breast cancer initiation.	[Thaler, S.] Heidelberg Univ, Univ Med Mannheim, Ctr Biomed & Med Technol Mannheim CBTM, Med Fac Mannheim, D-68167 Mannheim, Germany; [Schmidt, M.] Johannes Gutenberg Univ Mainz, Dept Obstet & Gynecol, Mainz, Germany; [Schad, A.] Johannes Gutenberg Univ Mainz, Dept Pathol, D-6500 Mainz, Germany; [Sleeman, J. P.] Kernforschungszentrum Karlsruhe GmbH, Inst Genet & Toxikol, D-7500 Karlsruhe, Germany	Ruprecht Karls University Heidelberg; Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz; Helmholtz Association; Karlsruhe Institute of Technology	Thaler, S (corresponding author), Heidelberg Univ, Univ Med Mannheim, Ctr Biomed & Med Technol Mannheim CBTM, Med Fac Mannheim, TRIDOMUS Gebaude Haus C,Ludolf Krehl Str 13-17, D-68167 Mannheim, Germany.	Sonja.Thaler@medma.uni-heidelberg.de	Thaler, Sonja/AAC-4784-2020; Schmidt, Marcus/H-3383-2013; Sleeman, Jonathan P/H-2515-2013	Schmidt, Marcus/0000-0003-1365-2414; Sleeman, Jonathan P/0000-0003-1718-7687	Deutsche Forschungsgemeinschaft [TH1523/1-2]; MAIFOR	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); MAIFOR	We are grateful to Selma Huber and workers in the KIT rodent facility and Gitta Flaig for excellent technical assistance. We thank Robert Weinberg for kindly providing pBabe-neo; William Hahn for providing pBabe-Neo-Myr-Flag-AKT1 and pWZL Blast myc and Jean Zhao for pWZL Neo Myr Flag AKT3. pMIG Bcl-2 was created in the laboratory of Stanley Korsmeyer and was kindly provided from Dana Farber Cancer Institute. This study was supported by Deutsche Forschungsgemeinschaft grant TH1523/1-2 to ST and MAIFOR (ST and MS).	Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Blanco-Aparicio C, 2007, CARCINOGENESIS, V28, P584, DOI 10.1093/carcin/bgl190; Boehm JS, 2007, CELL, V129, P1065, DOI 10.1016/j.cell.2007.03.052; Boehm JS, 2005, MOL CELL BIOL, V25, P6464, DOI 10.1128/MCB.25.15.6464-6474.2005; Campbell RA, 2001, J BIOL CHEM, V276, P9817, DOI 10.1074/jbc.M010840200; Castoria G, 2001, EMBO J, V20, P6050, DOI 10.1093/emboj/20.21.6050; Chen L, 2009, CANCER LETT, V278, P210, DOI 10.1016/j.canlet.2009.01.008; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Clarke RB, 1997, CANCER RES, V57, P4987; Dahlman-Wright K, 2006, PHARMACOL REV, V58, P773, DOI 10.1124/pr.58.4.8; Dammann R, 2005, HISTOL HISTOPATHOL, V20, P645, DOI 10.14670/HH-20.645; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; DUBIK D, 1992, ONCOGENE, V7, P1587; Faridi J, 2003, CLIN CANCER RES, V9, P2933; Feng W, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1762; Fowler AM, 2006, MOL ENDOCRINOL, V20, P291, DOI 10.1210/me.2005-0288; Gartel AL, 2001, P NATL ACAD SCI USA, V98, P4510, DOI 10.1073/pnas.081074898; Holst F, 2007, NAT GENET, V39, P655, DOI 10.1038/ng2006; KASID A, 1985, SCIENCE, V228, P725, DOI 10.1126/science.4039465; Keshamouni VG, 2002, J BIOL CHEM, V277, P22558, DOI 10.1074/jbc.M202351200; Khan SA, 1998, J NATL CANCER I, V90, P37, DOI 10.1093/jnci/90.1.37; Kondo N, 2008, CANCER RES, V68, P5004, DOI 10.1158/0008-5472.CAN-08-0180; Lawson JS, 1999, LANCET, V354, P1787, DOI 10.1016/S0140-6736(99)04936-3; Levin ER, 2005, MOL ENDOCRINOL, V19, P1951, DOI 10.1210/me.2004-0390; Li TH, 2006, AM J PATHOL, V168, P1998, DOI 10.2353/ajpath.2006.051089; Lin CQ, 2000, CANCER RES, V60, P1332; Magro G, 2000, HISTOPATHOLOGY, V36, P515, DOI 10.1046/j.1365-2559.2000.00907.x; Migliaccio A, 2002, ANN NY ACAD SCI, V963, P185; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Moelling K, 2002, J BIOL CHEM, V277, P31099, DOI 10.1074/jbc.M111974200; Mueller SO, 2002, ENDOCRINOLOGY, V143, P2357, DOI 10.1210/en.143.6.2357; Norton JD, 1998, MOL CELL BIOL, V18, P2371, DOI 10.1128/MCB.18.4.2371; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Perillo B, 2000, MOL CELL BIOL, V20, P2890, DOI 10.1128/MCB.20.8.2890-2901.2000; PEVERALI FA, 1994, EMBO J, V13, P4291, DOI 10.1002/j.1460-2075.1994.tb06749.x; Planas-Silva MD, 2007, EXP MOL PATHOL, V82, P85, DOI 10.1016/j.yexmp.2006.09.001; Prabhu S, 1997, MOL CELL BIOL, V17, P5888, DOI 10.1128/MCB.17.10.5888; Razandi M, 2002, MOL ENDOCRINOL, V16, P100, DOI 10.1210/me.16.1.100; Razandi M, 2003, J BIOL CHEM, V278, P2701, DOI 10.1074/jbc.M205692200; REED JC, 1990, MOL CELL BIOL, V10, P4370, DOI 10.1128/MCB.10.8.4370; Shaaban AM, 2002, AM J PATHOL, V160, P597, DOI 10.1016/S0002-9440(10)64879-1; Shinozaki M, 2005, CLIN CANCER RES, V11, P2156, DOI 10.1158/1078-0432.CCR-04-1810; Shoker BS, 2000, J CLIN PATHOL, V53, P778, DOI 10.1136/jcp.53.10.778; Shoker BS, 1999, J PATHOL, V188, P237; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Strunnikova M, 2005, MOL CELL BIOL, V25, P3923, DOI 10.1128/MCB.25.10.3923-3933.2005; Sunami E, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2098; Swarbrick A, 2008, P NATL ACAD SCI USA, V105, P5402, DOI 10.1073/pnas.0801505105; Thaler S, 2009, CANCER RES, V69, P1748, DOI 10.1158/0008-5472.CAN-08-1377; Urlinger S, 2000, P NATL ACAD SCI USA, V97, P7963, DOI 10.1073/pnas.130192197; Yang QF, 1999, PATHOL INT, V49, P775, DOI 10.1046/j.1440-1827.1999.00942.x; Zhao JJ, 2003, CANCER CELL, V3, P483, DOI 10.1016/S1535-6108(03)00088-6	53	16	17	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2012	31	47					4912	4922		10.1038/onc.2011.658	http://dx.doi.org/10.1038/onc.2011.658			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	041VU	22266866				2022-12-17	WOS:000311430200003
J	Dart, DA; Brooke, GN; Sita-Lumsden, A; Waxman, J; Bevan, CL				Dart, D. A.; Brooke, G. N.; Sita-Lumsden, A.; Waxman, J.; Bevan, C. L.			Reducing prohibitin increases histone acetylation, and promotes androgen independence in prostate tumours by increasing androgen receptor activation by adrenal androgens	ONCOGENE			English	Article						prohibitin; androgen receptor; prostate; androgens; castrate-resistant prostate cancer; corepressor	TRANSCRIPTIONAL REPRESSION; CANCER CELLS; NUCLEUS; PROTEIN; RAT; SUPERFAMILY; RECRUITMENT; SUPPRESSION; PROGRESSION; SENESCENCE	Prostate cancers (PCs), initially responsive to anti-androgen therapies, often advance to a hormone-refractory 'castrate-resistant' PC (CRPC) stage. However, the androgen receptor (AR) pathway remains active and key for cell growth and gene expression within tumours, even in the apparent absence of hormone. Proposed mechanisms to explain progression, including AR amplification/mutation, are insufficient to completely explain CRPC and possible roles of AR cofactors such as prohibitin (PHB) are poorly understood. We investigated whether PHB loss could sensitise PC cells and tumours to adrenal gland-derived androgens, which persist even after androgen ablation, hence contribute to development of CRPC. Using a pair of PC cell lines, inducibly expressing ectopic cDNA or RNAi for PHB, responses to different androgens and hormone concentrations were studied both in vitro and in vivo. PHB was found at the promoters of several genes, both AR and non-AR-regulated, and knockdown increased histone acetylation at these promoters. Further, PHB knockdown increased the rate of AR ligand-induced chromatin binding, and binding rate and occupancy of AR upon the PSA promoter. This resulted in increased cell growth and AR activity in response to all androgens, including promoting a response to the weaker adrenal androgens previously absent at physiological concentrations. In vivo this had functional consequences such that PHB knockdown resulted in androstenedione being sufficient to promote tumour growth, under conditions mimicking those in patients undergoing androgen ablation therapy. We conclude that reduction in PHB levels is sufficient to lower the threshold of AR activity in vitro and in vivo; this may be via a general increase in histone acetylation that could potentially affect signalling by other transcription factors. PHB loss may provide a mechanism for progression to CRPC by sensitising PC cells to 'castrate' conditions-that is, low levels of testicular androgens in the continued presence of weak adrenal and dietary androgens.	[Dart, D. A.; Brooke, G. N.; Sita-Lumsden, A.; Bevan, C. L.] Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, Androgen Signalling Lab, London W12 0NN, England; Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, London W12 0NN, England	Imperial College London; Imperial College London	Bevan, CL (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, Androgen Signalling Lab, Hammersmith Hosp Campus,Du Cane Rd, London W12 0NN, England.	charlotte.bevan@imperial.ac.uk	Brooke, Greg/ABF-4859-2020; Bevan, Charlotte/T-7769-2019; Brooke, Greg/C-9426-2013; Bevan, Charlotte L/K-2276-2012	Bevan, Charlotte L/0000-0002-7533-0552; Brooke, Greg/0000-0003-4501-4134	Hammersmith Hospital; Medical Research Council of the UK; Cancer Research UK; Prostate Cancer Charity; Medical Research Council [G0700915] Funding Source: researchfish; Prostate Cancer UK [PG10-25] Funding Source: researchfish; MRC [G0700915] Funding Source: UKRI	Hammersmith Hospital; Medical Research Council of the UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); Prostate Cancer Charity; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Prostate Cancer UK; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We are grateful to members of the Androgen Signalling Laboratory for advice and technical help, to Ana Costa Pereira for the kind gift of TAP1 primers and interferon, and to Malcolm Parker for advice and critical reading of the manuscript. This work was supported by grants from the Hammersmith Hospital Special Trustees, the Medical Research Council of the UK, Cancer Research UK and The Prostate Cancer Charity.	Brinkmann AO, 2000, NAT MED, V6, P628, DOI 10.1038/76194; Brinkmann AO, 2001, MOL CELL ENDOCRINOL, V179, P105, DOI 10.1016/S0303-7207(01)00466-X; Brooke GN, 2009, CURR GENOMICS, V10, P18, DOI 10.2174/138920209787581307; Chen F, 2004, J STEROID BIOCHEM, V91, P247, DOI 10.1016/j.jsbmb.2004.04.009; Choi D, 2008, ONCOGENE, V27, P1716, DOI 10.1038/sj.onc.1210806; Coates PJ, 1997, CURR BIOL, V7, P607, DOI 10.1016/S0960-9822(06)00261-2; Dai Y, 2008, CARCINOGENESIS, V29, P1725, DOI 10.1093/carcin/bgn117; Dart DA, 2009, ENDOCR-RELAT CANCER, V16, P1157, DOI 10.1677/ERC-09-0028; DELATORRE B, 1976, ACTA ENDOCRINOL-COP, V81, P170, DOI 10.1530/acta.0.0810170; Eissenberg JC, 2000, CURR OPIN GENET DEV, V10, P204, DOI 10.1016/S0959-437X(00)00058-7; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FEEK CM, 1989, J STEROID BIOCHEM, V32, P573, DOI 10.1016/0022-4731(89)90392-0; Ferlay J, 2007, ANN ONCOL, V18, P581, DOI 10.1093/annonc/mdl498; Fusaro G, 2003, J BIOL CHEM, V278, P47853, DOI 10.1074/jbc.M305171200; Gamble SC, 2007, ONCOGENE, V26, P1757, DOI 10.1038/sj.onc.1209967; Gamble SC, 2004, ONCOGENE, V23, P2996, DOI 10.1038/sj.onc.1207444; He B, 2008, MOL ENDOCRINOL, V22, P344, DOI 10.1210/me.2007-0400; Isaacs JT, 2004, NAT MED, V10, P26, DOI 10.1038/nm0104-26; Jenster G, 1999, SEMIN ONCOL, V26, P407; Jia L, 2005, CANCER RES, V65, P8003, DOI 10.1158/0008-5472.CAN-04-3679; Joshi B, 2007, BIOCHEM J, V401, P155, DOI 10.1042/BJ20060364; Kang ZG, 2004, MOL ENDOCRINOL, V18, P2633, DOI 10.1210/me.2004-0245; Kang ZG, 2002, J BIOL CHEM, V277, P48366, DOI 10.1074/jbc.M209074200; Kokontis JM, 1999, VITAM HORM, V55, P219; MCCLUNG JK, 1995, EXP GERONTOL, V30, P99, DOI 10.1016/0531-5565(94)00069-7; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Min W, 1996, J IMMUNOL, V156, P3174; Mullins LJ, 2009, J BIOL CHEM, V284, P3925, DOI 10.1074/jbc.M805081200; Nijtmans LGJ, 2002, CELL MOL LIFE SCI, V59, P143, DOI 10.1007/s00018-002-8411-0; Pignatelli D, 2006, J ENDOCRINOL, V191, P301, DOI 10.1677/joe.1.06972; Rajalingam K, 2005, NAT CELL BIOL, V7, P837, DOI 10.1038/ncb1283; Rastogi S, 2006, MOL CELL BIOL, V26, P4161, DOI 10.1128/MCB.02142-05; Shi SL, 2009, J CELL BIOCHEM, V108, P926, DOI 10.1002/jcb.22324; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; VANWEERDEN WM, 1992, LIFE SCI, V50, P857, DOI 10.1016/0024-3205(92)90204-3; Wang S, 2004, EMBO J, V23, P2293, DOI 10.1038/sj.emboj.7600231; Wang S, 2002, ONCOGENE, V21, P8388, DOI 10.1038/sj.onc.1205944; Zhang LQ, 2003, CANCER RES, V63, P4552	38	16	18	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2012	31	43					4588	4598		10.1038/onc.2011.591	http://dx.doi.org/10.1038/onc.2011.591			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	029WP	22179832	Green Submitted, Green Accepted			2022-12-17	WOS:000310528200002
J	Sekine, Y; Ikeda, O; Mizushima, A; Ueno, Y; Muromoto, R; Yoshimura, A; Kanakura, Y; Oritani, K; Matsuda, T				Sekine, Y.; Ikeda, O.; Mizushima, A.; Ueno, Y.; Muromoto, R.; Yoshimura, A.; Kanakura, Y.; Oritani, K.; Matsuda, T.			STAP-2 interacts with and modulates BCR-ABL-mediated tumorigenesis	ONCOGENE			English	Article						chronic myeloid leukemia; BCR-ABL; signal-transducing adaptor protein-2; chemokine; tumorigenesis	CHRONIC MYELOID-LEUKEMIA; CHRONIC MYELOGENOUS LEUKEMIA; KINASE DOMAIN MUTATIONS; TRANSDUCING ADAPTER PROTEIN-2; TYROSINE KINASE; CHEMOTACTIC RESPONSE; IMATINIB THERAPY; INHIBITOR STI571; CELL-SURVIVAL; RESISTANCE	In chronic myeloid leukemia (CML), the BCR-ABL fusion oncoprotein activates multiple pathways involved in cell survival, growth promotion and disease progression. In this report, we show that the signal-transducing adaptor protein-2 (STAP-2) is involved in BCR-ABL activity. We demonstrate that STAP-2 bound to BCR-ABL, and BCR and ABL proteins, depending on the STAP-2 Src homology 2-like domain. BCR-ABL phosphorylates STAP-2 Tyr250 and the phosphorylated STAP-2 in turn upregulated BCR-ABL phosphorylation, leading to enhanced activation of downstream signaling molecules including ERK (extracellular-signal-regulated kinase), STAT5 (signal transducer and activator of transcription 5), BCL-xL (B-cell lymphoma-extra large) and BCL-2(B-cell lymphoma 2). In addition, STAP-2 interacts with BCR-ABL to alter chemokine receptor expression leading to downregulation of CXCR4 and upregulation of CCR7. The interaction between STAP-2 and BCR-ABL plays a crucial role in conferring a growth advantage and resistance to imatinib, a BCR-ABL inhibitor, as well as tumor progression. Notably, mice injected with BCRABL/STAP-2-expressing Ba/F3 cells developed lymph node enlargement and hepatosplenomegaly. Moreover, suppression of STAP-2 in K562 CML cells resulted in no tumor formation in mice. Our results demonstrate a critical contribution of STAP-2 in BCR-ABL activity, and suggest that STAP-2 might be an important candidate for drug development for patients with CML. Furthermore, the expression of STAP-2 provides useful information for estimating the characteristics of individual CML clones. Oncogene (2012) 31, 4384-4396; doi:10.1038/onc.2011.604; published online 9 January 2012	[Matsuda, T.] Hokkaido Univ, Dept Immunol, Grad Sch Pharmaceut Sci, Kita Ku, Sapporo, Hokkaido 0600812, Japan; [Yoshimura, A.] Keio Univ, Sch Med, Dept Microbiol & Immunol, Shinjuku Ku, Tokyo, Japan; [Kanakura, Y.; Oritani, K.] Osaka Univ, Grad Sch Med, Dept Hematol & Oncol, Suita, Osaka, Japan	Hokkaido University; Keio University; Osaka University	Matsuda, T (corresponding author), Hokkaido Univ, Dept Immunol, Grad Sch Pharmaceut Sci, Kita Ku, Kita 12 Nishi 6, Sapporo, Hokkaido 0600812, Japan.	tmatsuda@pharm.hokudai.ac.jp	Matsuda, Tadashi/A-3835-2012; Sekine, Yuichi/S-8813-2019; Muromoto, Ryuta/E-4203-2012; Yoshimura, Akihiko/K-5515-2013	Matsuda, Tadashi/0000-0002-3089-3757; Sekine, Yuichi/0000-0002-2861-603X; Muromoto, Ryuta/0000-0002-7474-493X; 	Ministry of Education, Culture, Sports, Science and Technology of Japan; Grants-in-Aid for Scientific Research [21591202] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This study was supported in part by the Grant-in-Aid for scientific research from Ministry of Education, Culture, Sports, Science and Technology of Japan.	Brehme M, 2009, P NATL ACAD SCI USA, V106, P7414, DOI 10.1073/pnas.0900653106; Bruennert D, 2009, LEUKEMIA, V23, P983, DOI 10.1038/leu.2008.337; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Chang YC, 2009, ONCOGENE, V28, P4105, DOI 10.1038/onc.2009.260; Chu S, 2007, CANCER RES, V67, P7045, DOI 10.1158/0008-5472.CAN-06-4312; Corbin AS, 2003, BLOOD, V101, P4611, DOI 10.1182/blood-2002-12-3659; Cortes J, 2007, BLOOD, V110, P4005, DOI 10.1182/blood-2007-03-080838; Crossman LC, 2005, BLOOD, V106, P1133, DOI 10.1182/blood-2005-02-0694; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; Donato NJ, 2003, BLOOD, V101, P690, DOI 10.1182/blood.V101.2.690; Gambacorti-Passerini C, 2003, CLIN CANCER RES, V9, P625; Gambacorti-Passerini CB, 2003, LANCET ONCOL, V4, P75, DOI 10.1016/S1470-2045(03)00979-3; Geay JF, 2005, CANCER RES, V65, P2676, DOI 10.1158/0008-5472.CAN-04-2152; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Hochhaus A, 2004, LEUKEMIA, V18, P1321, DOI 10.1038/sj.leu.2403426; Hoelbl A, 2006, BLOOD, V107, P4898, DOI 10.1182/blood-2005-09-3596; Hughes T, 2006, BLOOD, V108, P28, DOI 10.1182/blood-2006-01-0092; Ikeda O, 2011, CANCER SCI, V102, P756, DOI 10.1111/j.1349-7006.2010.01842.x; Jin LH, 2008, MOL CANCER THER, V7, P48, DOI 10.1158/1535-7163.MCT-07-0042; le Coutre P, 2000, BLOOD, V95, P1758, DOI 10.1182/blood.V95.5.1758.005a41_1758_1766; Lowenberg B, 2003, NEW ENGL J MED, V349, P1399, DOI 10.1056/NEJMp038130; Ma Q, 1999, IMMUNITY, V10, P463, DOI 10.1016/S1074-7613(00)80046-1; Mahon FX, 2010, LANCET ONCOL, V11, P1029, DOI 10.1016/S1470-2045(10)70233-3; Mahon FX, 2000, BLOOD, V96, P1070, DOI 10.1182/blood.V96.3.1070.015k17_1070_1079; Mburu YK, 2006, IMMUNOL RES, V36, P61, DOI 10.1385/IR:36:1:61; Minoguchi M, 2003, J BIOL CHEM, V278, P11182, DOI 10.1074/jbc.M211230200; Mitchell PJ, 2000, ONCOGENE, V19, P4273, DOI 10.1038/sj.onc.1203775; O'Hare T, 2007, BLOOD, V110, P2242, DOI 10.1182/blood-2007-03-066936; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Peled A, 1999, SCIENCE, V283, P845, DOI 10.1126/science.283.5403.845; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; Ptasznik A, 2004, NAT MED, V10, P1187, DOI 10.1038/nm1127; Quintas-Cardama A, 2009, BLOOD, V113, P1619, DOI 10.1182/blood-2008-03-144790; Ren R, 2005, NAT REV CANCER, V5, P172, DOI 10.1038/nrc1567; Salgia R, 1999, BLOOD, V94, P4233; Sattler M, 1996, ONCOGENE, V12, P839; Sekine Y, 2006, J IMMUNOL, V176, P380, DOI 10.4049/jimmunol.176.1.380; Sekine Y, 2005, J BIOL CHEM, V280, P8188, DOI 10.1074/jbc.M411692200; Sekine Y, 2007, J IMMUNOL, V179, P2397, DOI 10.4049/jimmunol.179.4.2397; Sekine Y, 2007, BIOCHEM BIOPH RES CO, V356, P517, DOI 10.1016/j.bbrc.2007.03.031; Sekine Y, 2009, J IMMUNOL, V183, P7966, DOI 10.4049/jimmunol.0902096; Sekine Y, 2009, BIOCHEM BIOPH RES CO, V384, P187, DOI 10.1016/j.bbrc.2009.04.109; Shah NP, 2002, CANCER CELL, V2, P117, DOI 10.1016/S1535-6108(02)00096-X; Tokunaga M, 2010, J BIOL CHEM, V285, P31774, DOI 10.1074/jbc.M110.118653; Toyofuku T, 2004, NAT CELL BIOL, V6, P1204, DOI 10.1038/ncb1193; Wang L, 2008, CLIN PHARMACOL THER, V83, P258, DOI 10.1038/sj.clpt.6100268; Weisberg E, 2000, BLOOD, V95, P3498, DOI 10.1182/blood.V95.11.3498.011k27_3498_3505; Xie SH, 2001, ONCOGENE, V20, P6188, DOI 10.1038/sj.onc.1204834; Yamamoto T, 2003, BIOCHEM BIOPH RES CO, V306, P767, DOI 10.1016/S0006-291X(03)01042-8	50	16	16	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2012	31	40					4384	4396		10.1038/onc.2011.604	http://dx.doi.org/10.1038/onc.2011.604			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	017LL	22231445	Green Submitted			2022-12-17	WOS:000309591300005
J	Church, DN; Phillips, BR; Stuckey, DJ; Barnes, DJ; Buffa, FM; Manek, S; Clarke, K; Harris, AL; Carter, EJ; Hassan, AB				Church, D. N.; Phillips, B. R.; Stuckey, D. J.; Barnes, D. J.; Buffa, F. M.; Manek, S.; Clarke, K.; Harris, A. L.; Carter, E. J.; Hassan, A. B.			Igf2 ligand dependency of Pten(+/-) developmental and tumour phenotypes in the mouse	ONCOGENE			English	Article						PTEN; IGF2; Cowden syndrome; imprinting; placenta; mammary gland	GROWTH-FACTOR-II; INSULIN-RECEPTOR SUBSTRATE-1; BREAST-CANCER; INTESTINAL ADENOMA; COLORECTAL-CANCER; HETEROZYGOUS MICE; MURINE PLACENTA; GLYCOGEN CELLS; H19 GENE; PTEN	The tumour suppressor PTEN is a key negative regulator of the PI3K-Akt pathway, and is frequently either reduced or lost in human tumours. Murine genetic studies have confirmed that reduction of Pten promotes tumourigenesis in multiple organs, and demonstrated dependency of tumour development on the activation of downstream components such as Akt. Insulin-like growth factors (IGFs) act via IGF1R to activate the PI3K-Akt pathway, and are commonly upregulated in cancer. A context-dependent interplay between IGFs and PTEN exists in normal tissue and tumours; increased IGF2 ligand supply induces Pten expression creating an autoregulatory negative feedback loop, whereas complete loss of PTEN may either cooperate with IGF overexpression in tumour promotion, or result in desensitisation to IGF ligand. However, it remains unknown whether neoplasia associated with Pten loss is dependent on upstream IGF ligand supply in vivo. We evaluated this by generation of Pten(+/-) mice with differing allelic dosage of Igf2, an imprinted gene encoding the potent embryonic and tumour growth factor Igf2. We show that biallelic Igf2 supply potentiates a previously unreported Pten(+/-) placental phenotype and results in strain-dependent cardiac hyperplasia and neonatal lethality. Importantly, we also show that the effects of Pten loss in vivo are modified by Igf2 supply, as lack of Igf2 results in extended survival and delayed tumour development while biallelic supply is associated with reduced lifespan and accelerated neoplasia in females. Furthermore, we demonstrate that reduction of PTEN protein to heterozygote levels in human MCF7 cells is associated with increased proliferation in response to IGF2, and does not result in desensitisation to IGF2 signalling. These data indicate that the effects of Pten loss at heterozygote levels commonly observed in human tumours are modified by Igf2 ligand, and emphasise the importance of the evaluation of upstream pathways in tumours with Pten loss. Oncogene (2012) 31, 3635-3646; doi:10.1038/onc.2011.526; published online 28 November 2011	[Church, D. N.; Barnes, D. J.; Carter, E. J.; Hassan, A. B.] Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; [Phillips, B. R.; Manek, S.] John Radcliffe Hosp, Dept Histopathol, Oxford OX3 9DU, England; [Stuckey, D. J.; Clarke, K.] Univ Oxford, Dept Physiol Anat & Genet, Oxford OX1 3RE, England; [Buffa, F. M.; Harris, A. L.] Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, Oxford OX1 3RE, England	University of Oxford; University of Oxford; University of Oxford; University of Oxford	Hassan, AB (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, S Parks Rd, Oxford OX1 3RE, England.	bass.hassan@path.ox.ac.uk	Harris, Adrian L/ABA-3343-2020; Buffa, Francesca/D-2574-2013	Harris, Adrian L/0000-0003-1376-8409; Buffa, Francesca/0000-0003-0409-406X; Carter, Emma/0000-0002-0825-2793; Church, David/0000-0002-4617-962X; stuckey, daniel/0000-0001-8888-627X; Hassan, Andrew/0000-0002-2517-6681; Barnes, David/0000-0002-7937-2004	Cancer Research UK (CRUK) Clinical Research Training Fellowship (DC); CRUK Programme Grant [C429]; British Heart Foundation [PS/02/002/14893, RG/07/004/22659] Funding Source: researchfish; National Institute for Health Research [CL-2010-13-007] Funding Source: researchfish	Cancer Research UK (CRUK) Clinical Research Training Fellowship (DC); CRUK Programme Grant; British Heart Foundation(British Heart Foundation); National Institute for Health Research(National Institute for Health Research (NIHR))	Igf2 knockout mice were a kind gift from Argiris Efstratidiadis, H19/ICR knockout mice from Shirley Tilghman and Pten knockout mice from Ramon Parsons. PTEN shRNA sequences were generously provided by Nick Leslie. We also thank Richard Stillion (histology), Miguel Constancia, Ionel Sandovici, Elisabeth Robertson, Yoichi Sekita and Shuomo Bhattacharya for their helpful discussions. This work was funded by a Cancer Research UK (CRUK) Clinical Research Training Fellowship (DC) and CRUK Programme Grant C429 (ABH).	Alimonti A, 2010, NAT GENET, V42, P454, DOI 10.1038/ng.556; BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0; BATES P, 1995, BRIT J CANCER, V72, P1189, DOI 10.1038/bjc.1995.484; Bayascas JR, 2005, CURR BIOL, V15, P1839, DOI 10.1016/j.cub.2005.08.066; Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100; Burns JL, 2001, DEVELOPMENT, V128, P3819; Camps C, 2008, CLIN CANCER RES, V14, P1340, DOI 10.1158/1078-0432.CCR-07-1755; Carracedo A, 2008, ONCOGENE, V27, P5527, DOI 10.1038/onc.2008.247; Carter AM, 2006, PLACENTA, V27, P278, DOI 10.1016/j.placenta.2005.01.014; Chen ML, 2006, GENE DEV, V20, P1569, DOI 10.1101/gad.1395006; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; Coan PM, 2006, DEV DYNAM, V235, P3280, DOI 10.1002/dvdy.20981; Corcoran RB, 2008, CANCER RES, V68, P8788, DOI 10.1158/0008-5472.CAN-08-2135; Crackower MA, 2002, CELL, V110, P737, DOI 10.1016/S0092-8674(02)00969-8; Cui HM, 2002, CANCER RES, V62, P6442; Cully M, 2004, P NATL ACAD SCI USA, V101, P15358, DOI 10.1073/pnas.0406613101; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Di Cristofano A, 2001, NAT GENET, V27, P222, DOI 10.1038/84879; Esquiliano DR, 2009, PLACENTA, V30, P693, DOI 10.1016/j.placenta.2009.05.004; Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764; Foulstone E, 2005, J PATHOL, V205, P145, DOI 10.1002/path.1712; Frank D, 2002, P NATL ACAD SCI USA, V99, P7490, DOI 10.1073/pnas.122039999; Gabory A, 2009, DEVELOPMENT, V136, P3413, DOI 10.1242/dev.036061; Guertin DA, 2009, CANCER CELL, V15, P148, DOI 10.1016/j.ccr.2008.12.017; Harper J, 2006, CANCER RES, V66, P1940, DOI 10.1158/0008-5472.CAN-05-2036; Hassan AB, 2000, CANCER RES, V60, P1070; Lackey J, 2007, ONCOGENE, V26, P7132, DOI 10.1038/sj.onc.1210520; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; Li P, 2011, DEVELOPMENT, V138, P1795, DOI 10.1242/dev.054338; Liu YF, 2001, J BIOL CHEM, V276, P14459, DOI 10.1074/jbc.M007281200; Lopez MF, 1996, ENDOCRINOLOGY, V137, P2100, DOI 10.1210/en.137.5.2100; Ma L, 2005, GENE DEV, V19, P1779, DOI 10.1101/gad.1314405; Manning BD, 2005, GENE DEV, V19, P1773, DOI 10.1101/gad.1314605; Moorehead RA, 2003, J BIOL CHEM, V278, P50422, DOI 10.1074/jbc.M306894200; Perks CM, 2007, ONCOGENE, V26, P5966, DOI 10.1038/sj.onc.1210397; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Ravichandran LV, 2001, J BIOL CHEM, V276, P3543, DOI 10.1074/jbc.M007231200; Reardon W, 2001, J MED GENET, V38, P820, DOI 10.1136/jmg.38.12.820; Sakatani T, 2005, SCIENCE, V307, P1976, DOI 10.1126/science.1108080; SINGER C, 1995, CANCER RES, V55, P2448; Soroceanu L, 2007, P NATL ACAD SCI USA, V104, P3466, DOI 10.1073/pnas.0611271104; Trimboli AJ, 2009, NATURE, V461, P1084, DOI 10.1038/nature08486; Trotman LC, 2006, NATURE, V441, P523, DOI 10.1038/nature04809; Tsang WP, 2010, CARCINOGENESIS, V31, P350, DOI 10.1093/carcin/bgp181; van Roozendaal CEP, 1998, FEBS LETT, V437, P107, DOI 10.1016/S0014-5793(98)01211-3; Veronese A, 2010, CANCER RES, V70, P3140, DOI 10.1158/0008-5472.CAN-09-4456; Wang H, 2010, P NATL ACAD SCI USA, V107, P5142, DOI 10.1073/pnas.0912524107; Yang ZZ, 2003, J BIOL CHEM, V278, P32124, DOI 10.1074/jbc.M302847200; Yoshimizu T, 2008, P NATL ACAD SCI USA, V105, P12417, DOI 10.1073/pnas.0801540105	51	16	17	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2012	31	31					3635	3646		10.1038/onc.2011.526	http://dx.doi.org/10.1038/onc.2011.526			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	985EG	22120709	Green Published, hybrid			2022-12-17	WOS:000307245600006
J	Zwolinska, AK; Whiting, AH; Beekman, C; Sedivy, JM; Marine, JC				Zwolinska, A. K.; Whiting, A. Heagle; Beekman, C.; Sedivy, J. M.; Marine, J-C			Suppression of Myc oncogenic activity by nucleostemin haploinsufficiency	ONCOGENE			English	Article						nucleostemin; c-Myc; p53; lymphoma; transgenic mice	TARGETED HOMOLOGOUS RECOMBINATION; RIBOSOMAL-PROTEIN L23; CELL-CYCLE ARREST; C-MYC; STEM-CELLS; IN-VIVO; GENE-EXPRESSION; DNA-DAMAGE; TRANSCRIPTIONAL REGULATION; INDUCED LYMPHOMAGENESIS	Nucleostemin (NS), a nucleolar GTPase, is highly expressed in stem/progenitor cells and in most cancer cells. However, little is known about the regulation of its expression. Here, we identify the NS gene as a novel direct transcriptional target of the c-Myc oncoprotein. We show that Myc overexpression enhances NS transcription in cultured cells and in pre-neoplastic B cells from El-myc transgenic mice. Consistent with NS being downstream of Myc, NS expression parallels that of Myc in a large panel of human cancer cell lines. Using chromatin immunoprecipitation we show that c-Myc binds to a well-conserved E-box in the NS promoter. Critically, we show NS haploinsufficiency profoundly delays Myc-induced cancer formation in vivo. NS+/- El-myc transgenic mice have much slower rates of B-cell lymphoma development, with life spans twice that of their wild-type littermates. Moreover, we demonstrate that NS is essential for the proliferation of Myc-overexpressing cells in cultured cells and in vivo: impaired lymphoma development was associated with a drastic decrease of c-Myc-induced proliferation of pre-tumoural B cells. Finally, we provide evidence that in cell culture NS controls cell proliferation independently of p53 and that NS haploinsufficiency significantly delays lymphomagenesis in p53-deficient mice. Together these data indicate that NS functions downstream of Myc as a rate-limiting regulator of cell proliferation and transformation, independently from its putative role within the p53 pathway. Targeting NS is therefore expected to compromise early tumour development irrespectively of the p53 status. Oncogene (2012) 31, 3311-3321; doi: 10.1038/onc.2011.507; published online 14 November 2011	[Zwolinska, A. K.; Marine, J-C] VIB KULeuven, Lab Mol Canc Biol, Dept Mol & Dev Genet, B-3000 Louvain, Belgium; [Zwolinska, A. K.; Beekman, C.; Marine, J-C] VIB UGent, Lab Mol Canc Biol, Dept Biomed Mol Biol, Ghent, Belgium; [Whiting, A. Heagle; Sedivy, J. M.] Brown Univ, Dept Mol Biol Cell Biol & Biochem, Providence, RI 02912 USA	Flanders Institute for Biotechnology (VIB); KU Leuven; Flanders Institute for Biotechnology (VIB); Ghent University; Brown University	Marine, JC (corresponding author), VIB KULeuven, Lab Mol Canc Biol, Dept Mol & Dev Genet, Campus Gasthuisberg,Herestr 49,Box 602, B-3000 Louvain, Belgium.	JeanChristophe.Marine@cme.vib-kuleuven.be	Marine, Jean-Christophe/K-3292-2016; Marine, Jean Christophe/J-2237-2015	Marine, Jean-Christophe/0000-0003-2433-9837; Heagle Whiting, Amy/0000-0003-4392-1451	NIH [R01 GM041690]; COBRE [P20 RR015578];  [T32 GM007601]; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015578] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007601, R01GM041690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG016694] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); COBRE; ; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported in part by the Geconcerteerde Onderzoeksacties (GOA, University Ghent, Belgium). A K Zwolinska is a recipient of a FWO fellowship. Work in the Sedivy lab was supported by grant R01 GM041690 from the NIH. A Whiting was supported in part by training grant T32 GM007601. The Genomics Core Facility at Brown University was supported in part by the COBRE grant P20 RR015578.	ADAMS JM, 1986, CURR TOP MICROBIOL, V132, P1; Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703; ASKEW DS, 1991, ONCOGENE, V6, P1915; Barna M, 2008, NATURE, V456, P971, DOI 10.1038/nature07449; Beekman C, 2006, MOL CELL BIOL, V26, P9291, DOI 10.1128/MCB.01183-06; Bernardi R, 2003, NAT MED, V9, P24, DOI 10.1038/nm0103-24; Bouchard C, 1998, TRENDS CELL BIOL, V8, P202, DOI 10.1016/S0962-8924(98)01251-3; Brodsky AS, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-8-r64; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Chao C, 2000, P NATL ACAD SCI USA, V97, P11936, DOI 10.1073/pnas.220252297; Chen YH, 2008, EXPERT REV ANTICANC, V8, P1689, DOI 10.1586/14737140.8.10.1689; Dai MS, 2004, J BIOL CHEM, V279, P44475, DOI 10.1074/jbc.M403722200; Dai MS, 2004, MOL CELL BIOL, V24, P7654, DOI 10.1128/MCB.24.17.7654-7668.2004; Dai MS, 2008, MOL CELL BIOL, V28, P4365, DOI 10.1128/MCB.01662-07; Dang CV, 2006, SEMIN CANCER BIOL, V16, P253, DOI 10.1016/j.semcancer.2006.07.014; Dave SS, 2006, NEW ENGL J MED, V354, P2431, DOI 10.1056/NEJMoa055759; De Clercq S, 2010, MOL CELL BIOL, V30, P5394, DOI 10.1128/MCB.00330-10; Dominguez-Sola D, 2007, NATURE, V448, P445, DOI 10.1038/nature05953; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Eilers M, 2008, GENE DEV, V22, P2755, DOI 10.1101/gad.1712408; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Eischen CM, 2001, MOL CELL BIOL, V21, P5063, DOI 10.1128/MCB.21.15.5063-5070.2001; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Han CX, 2005, INT J MOL MED, V16, P205; Huang M, 2009, CANCER RES, V69, P3004, DOI 10.1158/0008-5472.CAN-08-3413; HURSTING SD, 1994, P NATL ACAD SCI USA, V91, P7036, DOI 10.1073/pnas.91.15.7036; Izumi H, 2001, J CELL SCI, V114, P1533; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jafarnejad SM, 2008, CELL PROLIFERAT, V41, P28, DOI 10.1111/j.1365-2184.2007.00505.x; Jin A, 2004, MOL CELL BIOL, V24, P7669, DOI 10.1128/MCB.24.17.7669-7680.2004; Kidder BL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003932; Kim J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001798; Li ZR, 2003, P NATL ACAD SCI USA, V100, P8164, DOI 10.1073/pnas.1332764100; Lin T, 2010, CANCER RES, V70, P9444, DOI 10.1158/0008-5472.CAN-10-2159; Liu SJ, 2004, WORLD J GASTROENTERO, V10, P1246; Lo D, 2010, CELL CYCLE, V9, P3227, DOI 10.4161/cc.9.16.12605; Mai S, 1996, CHROMOSOME RES, V4, P365, DOI 10.1007/BF02257272; Malakootian M, 2010, MOL CARCINOGEN, V49, P818, DOI 10.1002/mc.20658; Mao DYL, 2003, CURR BIOL, V13, P882, DOI 10.1016/S0960-9822(03)00297-5; Marine JC, 2010, CANCER CELL, V18, P399, DOI 10.1016/j.ccr.2010.10.026; Mateyak MK, 1999, MOL CELL BIOL, V19, P4672; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; Meyer N, 2006, SEMIN CANCER BIOL, V16, P275, DOI 10.1016/j.semcancer.2006.07.011; O'Connell BC, 2003, J BIOL CHEM, V278, P12563, DOI 10.1074/jbc.M210462200; Perna D, 2012, ONCOGENE, V31, P1695, DOI 10.1038/onc.2011.359; PROUTY SM, 1993, ONCOGENE, V8, P899; Qi Y, 2004, NATURE, V431, P712, DOI 10.1038/nature02958; Ray S, 2006, CANCER RES, V66, P6598, DOI 10.1158/0008-5472.CAN-05-3115; Romanova L, 2009, J BIOL CHEM, V284, P4968, DOI 10.1074/jbc.M804594200; Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914; Schorl C, 2003, MOL BIOL CELL, V14, P823, DOI 10.1091/mbc.E02-10-0649; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Shaffer AL, 2006, IMMUNOL REV, V210, P67, DOI 10.1111/j.0105-2896.2006.00373.x; Sijin L, 2004, J EXP CLIN CANC RES, V23, P529; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Toledo F, 2007, INT J BIOCHEM CELL B, V39, P1476, DOI 10.1016/j.biocel.2007.03.022; Tsai RYL, 2002, GENE DEV, V16, P2991, DOI 10.1101/gad.55671; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; van Riggelen J, 2010, GENE DEV, V24, P1281, DOI 10.1101/gad.585710; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Vita M, 2006, SEMIN CANCER BIOL, V16, P318, DOI 10.1016/j.semcancer.2006.07.015; Wang JH, 2008, J EXP MED, V205, P3079, DOI 10.1084/jem.20082271; Wei WY, 2003, MOL CELL BIOL, V23, P2859, DOI 10.1128/MCB.23.8.2859-2870.2003; Ye F, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-108; Zeller KI, 2006, P NATL ACAD SCI USA, V103, P17834, DOI 10.1073/pnas.0604129103; Zhang JY, 2010, BMC MUSCULOSKEL DIS, V11, DOI 10.1186/1471-2474-11-10; Zhang X, 2005, PNAS, V102, P13969; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	70	16	18	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2012	31	28					3311	3321		10.1038/onc.2011.507	http://dx.doi.org/10.1038/onc.2011.507			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	973NT	22081066	Green Accepted			2022-12-17	WOS:000306367600001
J	Wang, LY; Kung, HJ				Wang, L-Y; Kung, H-J			Male germ cell-associated kinase is overexpressed in prostate cancer cells and causes mitotic defects via deregulation of APC/C-CDH1	ONCOGENE			English	Article						APC/C complex; CDH1/FZR1; MAK; mitosis; prostate cancer	ANAPHASE-PROMOTING COMPLEX; CHROMOSOMAL INSTABILITY; CENTROSOME AMPLIFICATION; PHOSPHORYLATION SITES; GENOMIC INSTABILITY; ANDROGEN RECEPTOR; PHOSPHATASE CDC14; ACTIVATING KINASE; MECHANISM; CDH1	Male germ cell-associated kinase (MAK), a direct transcriptional target of androgen receptor (AR), is a co-activator of AR. In this study, we determined the activating mechanism of MAK and identified a previously unknown AR-independent role of MAK in mitosis. We found that MAK kinase activity requires dual phosphorylation of the conserved TDY motif and that the phosphorylation is dynamic during cell cycle. MAK associates with CDH1 (FZR1, fizzy/cell division cycle 20 related 1) and phosphorylates CDH1 at sites phosphorylated by cyclin-dependent kinases. When MAK is overexpressed, the binding of CDH1 to anaphase promoting complex/cyclosome decreased, resulting in an attenuation of anaphase-promoting complex/C ubiquitin ligase activity and the consequential stabilization of the CDH1 targets such as Aurora kinase A and Polo-like kinase 1. As such, overexpression of MAK leads to mitotic defects such as centrosome amplification and lagging chromosomes. Our immunohistochemistry result showed that MAK is overexpressed in prostate tumor tissues, suggesting a role of MAK in prostate carcinogenesis. Taken with our previous results, our data implicate MAK in both AR activation and chromosomal instability, acting in both early and late prostate cancer development.	[Kung, H-J] Univ Calif Davis, Ctr Canc, Dept Biochem & Mol Med, Sch Med, Sacramento, CA 95817 USA	University of California System; University of California Davis	Kung, HJ (corresponding author), Univ Calif Davis, Ctr Canc, Dept Biochem & Mol Med, Sch Med, UCDMC Res 3,95 Room 2400B,4645 2nd Ave, Sacramento, CA 95817 USA.	hkung@ucdavis.edu	Kung, Hsing-Jien/C-7651-2013	Wang, Ling-Yu/0000-0002-1413-817X	NATIONAL CANCER INSTITUTE [R01CA150197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052659, R01DK078243] Funding Source: NIH RePORTER; NCI NIH HHS [CA150197, R01 CA150197] Funding Source: Medline; NIDDK NIH HHS [R01 DK078243, DK526529, DK078243, R01 DK052659] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Beheshti B, 2001, NEOPLASIA, V3, P62, DOI 10.1038/sj.neo.7900125; Bolte M, 2002, P NATL ACAD SCI USA, V99, P4385, DOI 10.1073/pnas.072385099; Brown NR, 1999, J BIOL CHEM, V274, P8746, DOI 10.1074/jbc.274.13.8746; Buschhorn HM, 2005, PROSTATE, V64, P341, DOI 10.1002/pros.20247; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Clark JP, 2009, NAT REV UROL, V6, P429, DOI 10.1038/nrurol.2009.127; Engelbert D, 2008, ONCOGENE, V27, P907, DOI 10.1038/sj.onc.1210703; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Fu Z, 2005, MOL CELL BIOL, V25, P6047, DOI 10.1128/MCB.25.14.6047-6064.2005; Fu Z, 2006, MOL CELL BIOL, V26, P8639, DOI 10.1128/MCB.00816-06; Ganem NJ, 2009, NATURE, V460, P278, DOI 10.1038/nature08136; Garcia-Higuera I, 2008, NAT CELL BIOL, V10, P802, DOI 10.1038/ncb1742; GIBAS Z, 1984, CANCER GENET CYTOGEN, V11, P399, DOI 10.1016/0165-4608(84)90020-7; Gregory CW, 2001, CANCER RES, V61, P4315; Holt LJ, 2007, MOL CELL, V25, P689, DOI 10.1016/j.molcel.2007.02.012; Honigberg SM, 2004, J CELL BIOCHEM, V92, P1025, DOI 10.1002/jcb.20131; Jaspersen SL, 1999, CURR BIOL, V9, P227, DOI 10.1016/S0960-9822(99)80111-0; KOJI T, 1992, CELL BIOCHEM FUNCT, V10, P273, DOI 10.1002/cbf.290100411; Kraft C, 2005, MOL CELL, V18, P543, DOI 10.1016/j.molcel.2005.04.023; Kramer ER, 2000, MOL BIOL CELL, V11, P1555, DOI 10.1091/mbc.11.5.1555; Lukas C, 1999, NATURE, V401, P815, DOI 10.1038/44611; Ma AH, 2006, CANCER RES, V66, P8439, DOI 10.1158/0008-5472.CAN-06-1636; MATSUSHIME H, 1990, MOL CELL BIOL, V10, P2261, DOI 10.1128/MCB.10.5.2261; Mendiratta P, 2009, J CLIN ONCOL, V27, P2022, DOI 10.1200/JCO.2008.17.2882; Ouyang XS, 2001, BBA-MOL CELL RES, V1541, P212, DOI 10.1016/S0167-4889(01)00157-4; Pan Y, 1999, CYTOGENET CELL GENET, V87, P225, DOI 10.1159/000015432; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; Pfleger CM, 2001, GENE DEV, V15, P1759, DOI 10.1101/gad.897901; Pihan GA, 2001, CANCER RES, V61, P2212; Reimann JDR, 2001, GENE DEV, V15, P3278, DOI 10.1101/gad.945701; Robinson D, 1996, P NATL ACAD SCI USA, V93, P5958, DOI 10.1073/pnas.93.12.5958; Roh M, 2003, CANCER RES, V63, P8079; Ross KE, 2003, GENETICS, V165, P489; Shand RL, 2006, CURR OPIN UROL, V16, P123, DOI 10.1097/01.mou.0000193384.39351.64; TRIBUKAIT B, 1991, ACTA ONCOL, V30, P187, DOI 10.3109/02841869109092348; Wang X, 2008, ONCOGENE, V27, P4456, DOI 10.1038/onc.2008.87; Wasch R, 2005, ONCOGENE, V24, P1, DOI 10.1038/sj.onc.1208017; Weichert W, 2004, PROSTATE, V60, P240, DOI 10.1002/pros.20050; Wohlbold L, 2006, CELL CYCLE, V5, P546, DOI 10.4161/cc.5.5.2541; Xia L, 2002, J BIOL CHEM, V277, P35422, DOI 10.1074/jbc.M203940200; Zachariae W, 1998, SCIENCE, V282, P1721, DOI 10.1126/science.282.5394.1721; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496; Zhou Y, 2003, J BIOL CHEM, V278, P12530, DOI 10.1074/jbc.M212853200	43	16	19	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2012	31	24					2907	2918		10.1038/onc.2011.464	http://dx.doi.org/10.1038/onc.2011.464			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960LD	21986944	Green Accepted			2022-12-17	WOS:000305388400001
J	Fischer, JM; Miller, AJ; Shibata, D; Liskay, RM				Fischer, J. M.; Miller, A. J.; Shibata, D.; Liskay, R. M.			Different phenotypic consequences of simultaneous versus stepwise Apc loss	ONCOGENE			English	Article						APC; cancer; simultaneous; stepwise intestine	FAMILIAL ADENOMATOUS POLYPOSIS; MULTIPLE INTESTINAL NEOPLASIA; SOMATIC MUTATIONS; MOUSE MODEL; STEM-CELLS; CANCER; SUPPRESSION; PROTEOME; SEQUENCE; CATALOG	APC is considered a gatekeeper for colorectal cancer (CRC). Cells with heterozygous APC mutations have altered expression profiles suggesting that the first APC hit may help set the stage for subsequent transformation. Therefore, we measured transformation efficiency following what we have designated as 'simultaneous' versus 'stepwise' Apc loss. We combined a conditional Apc allele (Apc(CKO)) with a Cre reporter gene and an out-of-frame Cre allele (Pms2(cre)) that stochastically becomes functional by a frameshift mutation in single cells. Loss of one Apc allele (Apc(CKO/+)) had little consequence, whereas simultaneous loss of both Apc alleles (Apc(CKO/CKO)) resulted in increased clonal expansion (crypt fission), consistent with the gatekeeper function of Apc. Interestingly, our analyses showed that most of the Apc-deficient crypts in Apc(CKO/CKO) mice appeared normal, with morphological transformation, including beta-catenin deregulation, occurring in only 17% of such crypts. To determine whether transformation efficiency was different following stepwise Apc loss, we combined Apc(CKO) with a germline mutant allele, either Apc(Min) or Apc(1638N). Transformation efficiency following stepwise Apc loss (Apc(Min/CKO) or Apc(1638N/CKO)) was increased five-fold and essentially all of the Apc-deficient cells were dysplastic. In summary, our data suggest that the gatekeeper function of Apc consists of two roles, clonal expansion and morphological transformation, because simultaneous Apc loss frequently leads to occult clonal expansion without morphological transformation, whereas stepwise Apc loss more often results in visible neoplasia. Finally, that Apc-deficient cells in certain scenarios can retain a normal phenotype is unexpected and may have clinical implications for surveillance strategies to prevent CRC. Oncogene (2012) 31, 2028-2038; doi: 10.1038/onc.2011.385; published online 5 September 2011	[Fischer, J. M.; Miller, A. J.; Liskay, R. M.] Oregon Hlth & Sci Univ, Portland, OR 97239 USA; [Shibata, D.] Univ So Calif, Sch Med, Dept Pathol, Norris Canc Ctr, Los Angeles, CA 90033 USA	Oregon Health & Science University; University of Southern California	Liskay, RM (corresponding author), Oregon Hlth & Sci Univ, 3181 Sam Jackson Pk Rd, Portland, OR 97239 USA.	liskaym@ohsu.edu	Fischer, Jared/HCH-8013-2022	Fischer, Jared/0000-0002-0062-0870	NIH [2R01GM032741-28, 5T32HD046420-05]; ACS [PF-11-067-01-TBE]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD046420] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032741] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ACS(American Cancer Society); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Drs James Stringer and Melissa Wong for critical reading of the manuscript. We also thank Drs Raju Kucherlapati and Winfried Edelmann for the Apc<SUP>CKO</SUP> and Apc<SUP>1638N</SUP> mice, respectively; John Swain and Dr Melissa Wong for Apc<SUP>Min</SUP> mice and Apc<SUP>580S</SUP> intestinal material; and Dan Lioy and Drs Gail Mandel and Paul Brehm for assistance with confocal microscopy. RML and DS were funded by NIH Grant 2R01GM032741-28. JMF was funded by NIH training Grant 5T32HD046420-05 and ACS postdoctoral fellow PF-11-067-01-TBE.	Akyol A, 2008, NAT METHODS, V5, P231, DOI 10.1038/NMETH.1182; Attolini CSO, 2010, P NATL ACAD SCI USA, V107, P17604, DOI 10.1073/pnas.1009117107; Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602; Buchert M, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000816; Chan MF, 2001, MOL CELL BIOL, V21, P7587, DOI 10.1128/MCB.21.22.7587-7600.2001; Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779; Cruz-Correa M, 2002, GASTROENTEROLOGY, V122, P641, DOI 10.1053/gast.2002.31890; Eads CA, 2002, CANCER RES, V62, P1296; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FODDE R, 1994, P NATL ACAD SCI USA, V91, P8969, DOI 10.1073/pnas.91.19.8969; Forbes SA, 2010, NUCLEIC ACIDS RES, V38, pD652, DOI 10.1093/nar/gkp995; Hung KE, 2010, P NATL ACAD SCI USA, V107, P1565, DOI 10.1073/pnas.0908682107; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kuraguchi M, 2006, PLOS GENET, V2, P1362, DOI 10.1371/journal.pgen.0020146; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; Lopez-Garcia C, 2010, SCIENCE, V330, P822, DOI 10.1126/science.1196236; Lynch PM, 2010, EXPERT OPIN PHARMACO, V11, P1101, DOI 10.1517/14656561003698123; Miller AJ, 2008, NAT METHODS, V5, P227, DOI 10.1038/NMETH.1183; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; OSHIMA M, 1995, P NATL ACAD SCI USA, V92, P4482, DOI 10.1073/pnas.92.10.4482; Patel BB, 2011, ONCOTARGET, V2, P197, DOI 10.18632/oncotarget.241; Pleasance ED, 2010, NATURE, V463, P191, DOI 10.1038/nature08658; Quante M, 2011, CANCER CELL, V19, P257, DOI 10.1016/j.ccr.2011.01.020; Quintana E, 2010, CANCER CELL, V18, P510, DOI 10.1016/j.ccr.2010.10.012; Quyn AJ, 2010, CELL STEM CELL, V6, P175, DOI 10.1016/j.stem.2009.12.007; Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404; Sasai H, 2000, CARCINOGENESIS, V21, P953, DOI 10.1093/carcin/21.5.953; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Smits R, 1998, GASTROENTEROLOGY, V114, P275, DOI 10.1016/S0016-5085(98)70478-0; Snippert HJ, 2010, CELL, V143, P134, DOI 10.1016/j.cell.2010.09.016; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048; Wang DH, 2010, CANCER RES, V70, P5348, DOI 10.1158/0008-5472.CAN-09-4593; Yeung AT, 2008, CANCER RES, V68, P7579, DOI 10.1158/0008-5472.CAN-08-0856	35	16	16	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2012	31	16					2028	2038		10.1038/onc.2011.385	http://dx.doi.org/10.1038/onc.2011.385			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	928TP	21892206	Green Accepted			2022-12-17	WOS:000303008600004
J	Chaudhuri, L; Nicholson, AM; Kalen, AL; Goswami, PC				Chaudhuri, L.; Nicholson, A. M.; Kalen, A. L.; Goswami, P. C.			Preferential selection of MnSOD transcripts in proliferating normal and cancer cells	ONCOGENE			English	Article						MnSOD; 3 '-untranslated region; radiation; polyadenylation; quiescence	MANGANESE SUPEROXIDE-DISMUTASE; MESSENGER-RNA DEGRADATION; IRON-RESPONSIVE ELEMENT; 3' UNTRANSLATED REGION; MALIGNANT PHENOTYPE; 3'-UNTRANSLATED REGION; HUMAN FIBROBLASTS; BINDING; POLYADENYLATION; OVEREXPRESSION	Manganese superoxide dismutase (MnSOD) is a nuclear encoded and mitochondrial matrix-localized redox enzyme that is known to regulate the cellular redox environment. Cellular redox environment changes during transitions between quiescent and proliferative cycles. Human MnSOD has two poly(A) sites resulting in two transcripts: 1.5 and 4.2 kb. The present study investigates if the 3'-untranslated region (UTR) of MnSOD regulates its expression during transitions between quiescent and proliferating cycles, and in response to radiation. A preferential increase in the levels of the 1.5-kb MnSOD transcript was observed in quiescent cells, whereas the abundance of the longer transcript showed a direct correlation with the percentage of S-phase cells. The log-transformed expression ratio of the longer to the shorter transcript was also higher in proliferating normal and cancer cells. Deletion and reporter assays showed a significant decrease in reporter activity in constructs carrying multiple AU-rich sequence that are present in the 3'-UTR of the longer MnSOD transcript. Overexpression of the MnSOD 3'-UTR representing the longer transcript enhanced endogenous MnSOD mRNA levels, which was associated with an increase in MnSOD protein levels and a decrease in the percentage of S-phase cells. Irradiation increases the mRNA levels of the 1.5-kb MnSOD transcript, which was consistent with a significant increase in the reporter activity of the construct carrying the 3'-UTR of the shorter transcript. We conclude that the 3'-UTR of MnSOD regulates MnSOD expression in response to different growth states and radiation. Oncogene (2012) 31, 1207-1216; doi: 10.1038/onc.2011.325; published online 1 August 2011	[Chaudhuri, L.] Mayo Clin, Div Hematol Oncol, Scottsdale, AZ USA; [Goswami, P. C.] Univ Iowa, Dept Radiat Oncol, Free Rad & Radiat Biol Div, Med Labs B180, Iowa City, IA 52242 USA	Mayo Clinic; Mayo Clinic Phoenix; University of Iowa	Goswami, PC (corresponding author), Univ Iowa, Dept Radiat Oncol, Free Rad & Radiat Biol Div, Med Labs B180, Iowa City, IA 52242 USA.	prabhat-goswami@uiowa.edu	Kalen, Amanda/AAJ-7531-2020	Goswami, Prabhat/0000-0002-5700-2096	NIH [CA111365]; NIEHS [P42 ES 013661]; NATIONAL CANCER INSTITUTE [R01CA111365, P30CA086862] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES013661] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank Dr Ehab H Sarsour and Maneesh G Kumar at the Free Radical and Radiation Biology Division, and Amy Dubinsky and Dr Beverly L Davidson at the Department of Internal Medicine, for technical assistance with the UTR cloning and luciferase reporter assay; Drs Ann Simons and Melissa Fath for human oral squamous and lung cancer cells; Mr Gareth Smith with editorial assistance and the staff at the Flow Cytometry and Radiation and Free Radical Research Core Facilities. Funding from NIH CA111365 and NIEHS P42 ES 013661 supported this work.	AKASHI M, 1995, J BIOL CHEM, V270, P15864, DOI 10.1074/jbc.270.26.15864; Chaudhuri L, 2010, ENVIRON INT, V36, P924, DOI 10.1016/j.envint.2010.01.001; Chaudhuri L, 2010, FREE RADICAL BIO MED, V49, P40, DOI 10.1016/j.freeradbiomed.2010.03.012; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Chivukula RR, 2008, TRENDS BIOCHEM SCI, V33, P474, DOI 10.1016/j.tibs.2008.06.008; CHURCH SL, 1990, BIOCHIM BIOPHYS ACTA, V1087, P250, DOI 10.1016/0167-4781(90)90213-L; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3113, DOI 10.1073/pnas.90.7.3113; Clerch LB, 2000, ANN NY ACAD SCI, V899, P103; EdwaldsGilbert G, 1997, NUCLEIC ACIDS RES, V25, P2547, DOI 10.1093/nar/25.13.2547; Goswami PC, 2000, J BIOL CHEM, V275, P38384, DOI 10.1074/jbc.M005298200; GUO B, 1994, J BIOL CHEM, V269, P24252; Jupe ER, 1996, EXP CELL RES, V224, P128, DOI 10.1006/excr.1996.0120; Jupe ER, 1996, CELL GROWTH DIFFER, V7, P871; Lal A, 2004, EMBO J, V23, P3092, DOI 10.1038/sj.emboj.7600305; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Lutz CS, 2008, ACS CHEM BIOL, V3, P609, DOI 10.1021/cb800138w; Martincic K, 1998, P NATL ACAD SCI USA, V95, P11095, DOI 10.1073/pnas.95.19.11095; Mayr C, 2009, CELL, V138, P673, DOI 10.1016/j.cell.2009.06.016; Mazumder B, 2003, TRENDS BIOCHEM SCI, V28, P91, DOI 10.1016/S0968-0004(03)00002-1; McCord J, 1969, J BIOL CHEM, V244, P6049; Menon SG, 2005, ANTIOXID REDOX SIGN, V7, P711, DOI 10.1089/ars.2005.7.711; Oberley LW, 2001, ANTIOXID REDOX SIGN, V3, P461, DOI 10.1089/15230860152409095; OBERLEY LW, 1989, FREE RADICAL BIO MED, V6, P379, DOI 10.1016/0891-5849(89)90083-X; OBERLEY TD, 1995, FREE RADICAL BIO MED, V19, P53, DOI 10.1016/0891-5849(95)00012-M; ROUAULT TA, 1988, SCIENCE, V241, P1207, DOI 10.1126/science.3413484; Sandberg R, 2008, SCIENCE, V320, P1643, DOI 10.1126/science.1155390; Sarsour EH, 2005, J BIOL CHEM, V280, P18033, DOI 10.1074/jbc.M501939200; Sarsour EH, 2008, AGING CELL, V7, P405, DOI 10.1111/j.1474-9726.2008.00384.x; Sarsour EH, 2010, MITOCHONDRION, V10, P342, DOI 10.1016/j.mito.2010.02.004; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SPITZ DR, 1989, ANAL BIOCHEM, V179, P8, DOI 10.1016/0003-2697(89)90192-9; STCLAIR DK, 1991, FREE RADICAL RES COM, V12-3, P771; Tian B, 2005, NUCLEIC ACIDS RES, V33, P201, DOI 10.1093/nar/gki158; WAN XS, 1994, DNA CELL BIOL, V13, P1127, DOI 10.1089/dna.1994.13.1127; Wang YM, 2009, CANCER RES, V69, P4093, DOI 10.1158/0008-5472.CAN-09-0309; Weydert C, 2003, MOL CANCER THER, V2, P361; Xu Y, 1999, DNA CELL BIOL, V18, P709, DOI 10.1089/104454999314999; Zhong WX, 1997, ONCOGENE, V14, P481, DOI 10.1038/sj.onc.1200852	38	16	17	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2012	31	10					1207	1216		10.1038/onc.2011.325	http://dx.doi.org/10.1038/onc.2011.325			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906KS	21804600	Green Accepted			2022-12-17	WOS:000301344600001
J	Zoppoli, G; Solier, S; Reinhold, WC; Liu, H; Connelly, JW; Monks, A; Shoemaker, RH; Abaan, OD; Davis, SR; Meltzer, PS; Doroshow, JH; Pommier, Y				Zoppoli, G.; Solier, S.; Reinhold, W. C.; Liu, H.; Connelly, J. W., Jr.; Monks, A.; Shoemaker, R. H.; Abaan, O. D.; Davis, S. R.; Meltzer, P. S.; Doroshow, J. H.; Pommier, Y.			CHEK2 genomic and proteomic analyses reveal genetic inactivation or endogenous activation across the 60 cell lines of the US National Cancer Institute	ONCOGENE			English	Article						Chk2; centrosome; H2AX; p53; BRCA1; Fanconi anemia	DNA-DAMAGE RESPONSE; CHK2 PROTEIN-KINASE; LI-FRAUMENI-SYNDROME; TUMOR-SUPPRESSOR; BREAST-CANCER; THREONINE-68 PHOSPHORYLATION; CHECKPOINT PATHWAY; LUNG-CANCER; IN-VITRO; EXPRESSION	CHEK2 encodes a serine/threonine kinase (Chk2) activated by ATM in response to DNA double-strand breaks. On the one hand, CHEK2 has been described as a tumor suppressor with proapoptotic, cell-cycle checkpoint and mitotic functions. On the other hand, Chk2 is also commonly activated (phosphorylated at T68) in cancers and precancerous lesions. Here, we report an extensive characterization of CHEK2 across the panel of 60 established cancer cell lines from the NCI Anticancer Screen (the NCI-60) using genomic and proteomic analyses, including exon-specific mRNA expression, DNA copy-number variation (CNV) by aCGH, exome sequencing, as well as western blot analyses for total and activated (pT68-Chk2) Chk2. We show that the high heterogeneity of Chk2 levels in cancer cells is primarily due to its inactivation (owing to low gene expression, alternative splicing, point mutations, copy-number alterations and premature truncation) or reduction of protein levels. Moreover, we observe that a significant percentage of cancer cells (12% of the NCI-60 and HeLa cells) show high endogenous Chk2 activation, which is always associated with p53 inactivation, and which is accompanied by downregulation of the Fanconi anemia and homologous recombination pathways. We also report the presence of activated Chk2 (pT68-Chk2) along with histone gamma-H2AX in centrosomes. Oncogene (2012) 31, 403-418; doi: 10.1038/onc.2011.283; published online 18 July 2011	[Zoppoli, G.] Univ Genoa, Dept Internal Med DiMI, I-16132 Genoa, Italy; [Zoppoli, G.; Solier, S.; Reinhold, W. C.; Liu, H.; Doroshow, J. H.; Pommier, Y.] NCI, Mol Pharmacol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Liu, H.] Mayo Clin, Div Biomed Stat & Informat, Rochester, MN USA; [Connelly, J. W., Jr.; Monks, A.] SAIC Frederick Inc, Lab Funct Genom, NCI Frederick, Frederick, MD USA; [Shoemaker, R. H.] NCI, Screening Technol Branch, Dev Therapeut Program, Div Canc Treatment & Diag,NIH, Frederick, MD 21701 USA; [Abaan, O. D.; Davis, S. R.; Meltzer, P. S.] NCI, Genet Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Doroshow, J. H.] NCI, Div Canc Treatment & Diag, NIH, Bethesda, MD 20892 USA	University of Genoa; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Mayo Clinic; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Zoppoli, G (corresponding author), Univ Genoa, Dept Internal Med DiMI, Avancorpo 2 Piano,Vle Benedetto XV,Room 223,6, I-16132 Genoa, Italy.	gabriele.zoppoli@unige.it; pommier@nih.gov	Shoemaker, Robert/GPK-1314-2022; Zoppoli, Gabriele/B-6935-2016; SOLIER, STEPHANIE/AAA-6851-2020; Davis, Sean/AAD-1801-2021; Reinhold, William/J-6704-2017; Zoppoli, Gabriele/B-6935-2016	Zoppoli, Gabriele/0000-0003-3890-5588; Davis, Sean/0000-0002-8991-6458; Reinhold, William/0000-0001-5513-9323; Zoppoli, Gabriele/0000-0002-1619-1708; SOLIER, Stephanie/0000-0003-3867-4644	Center for Cancer Research; National Cancer Institute; Division of Cancer Treatment and Diagnosis; National Cancer Institute (National Institutes of Health); AIRC MFAG [10570]; University of Genova (Genova, Italy); NATIONAL CANCER INSTITUTE [ZIABC011091, ZIABC011078, ZIABC006150] Funding Source: NIH RePORTER	Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Division of Cancer Treatment and Diagnosis(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Treatment & Diagnosis); National Cancer Institute (National Institutes of Health)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); AIRC MFAG(Fondazione AIRC per la ricerca sul cancro); University of Genova (Genova, Italy); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the Center for Cancer Research, Intramural Program of the National Cancer Institute, and by the Division of Cancer Treatment and Diagnosis, Extramural Program of the National Cancer Institute (National Institutes of Health), and by AIRC MFAG grant no. 10570 (GZ). GZ was also supported by a PhD fellowship grant (XXIII Ciclo) from the University of Genova (Genova, Italy).	Abdelmohsen K, 2007, MOL CELL, V25, P543, DOI 10.1016/j.molcel.2007.01.011; Ahn J, 2004, DNA REPAIR, V3, P1039, DOI 10.1016/j.dnarep.2004.03.033; Ahn J, 2002, J BIOL CHEM, V277, P48418, DOI 10.1074/jbc.M208321200; Ahn JY, 2002, J BIOL CHEM, V277, P19389, DOI 10.1074/jbc.M200822200; Ahn JY, 2000, CANCER RES, V60, P5934; Albert JM, 2007, CLIN CANCER RES, V13, P3033, DOI 10.1158/1078-0432.CCR-06-2872; Antoni L, 2007, NAT REV CANCER, V7, P925, DOI 10.1038/nrc2251; Bahassi EM, 2008, ONCOGENE, V27, P3977, DOI 10.1038/onc.2008.17; Bartek J, 2001, NAT REV MOL CELL BIO, V2, P877, DOI 10.1038/35103059; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bartkova J, 2004, ONCOGENE, V23, P8545, DOI 10.1038/sj.onc.1207878; Bartkova J, 2010, ONCOGENE, V29, P5095, DOI 10.1038/onc.2010.249; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bartkova J, 2001, ONCOGENE, V20, P5897, DOI 10.1038/sj.onc.1204746; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Berge EO, 2010, BBA-MOL CELL RES, V1803, P386, DOI 10.1016/j.bbamcr.2010.01.005; Bonner WM, 2008, NAT REV CANCER, V8, P957, DOI 10.1038/nrc2523; Bussey KJ, 2006, MOL CANCER THER, V5, P853, DOI 10.1158/1535-7163.MCT-05-0155; Cao L, 2006, EMBO J, V25, P2167, DOI 10.1038/sj.emboj.7601115; Castedo M, 2004, ONCOGENE, V23, P4353, DOI 10.1038/sj.onc.1207573; Chehab NH, 2000, GENE DEV, V14, P278; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Eymin B, 2006, MOL CELL BIOL, V26, P4339, DOI 10.1128/MCB.02240-05; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Fan C, 2006, BBA-MOL CELL RES, V1763, P1090, DOI 10.1016/j.bbamcr.2006.08.026; Ghosh JC, 2006, CANCER RES, V66, P11576, DOI 10.1158/0008-5472.CAN-06-3095; Gire W, 2004, EMBO J, V23, P2554, DOI 10.1038/sj.emboj.7600259; Gmeiner WH, 2010, MOL CANCER THER, V9, P3105, DOI 10.1158/1535-7163.MCT-10-0674; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Harper JW, 2007, MOL CELL, V28, P739, DOI 10.1016/j.molcel.2007.11.015; Hattori H, 2004, PATHOL INT, V54, P26, DOI 10.1111/j.1440-1827.2004.01585.x; Hickson I, 2004, CANCER RES, V64, P9152, DOI 10.1158/0008-5472.CAN-04-2727; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hirao A, 2002, MOL CELL BIOL, V22, P6521, DOI 10.1128/MCB.22.18.6521-6532.2002; Holbeck SL, 2010, MOL CANCER THER, V9, P1451, DOI 10.1158/1535-7163.MCT-10-0106; Ikediobi ON, 2006, MOL CANCER THER, V5, P2606, DOI 10.1158/1535-7163.MCT-06-0433; Jobson AG, 2009, J PHARMACOL EXP THER, V331, P816, DOI 10.1124/jpet.109.154997; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; Kim DS, 2009, LUNG CANCER, V65, P247, DOI 10.1016/j.lungcan.2009.03.011; Leahy JJJ, 2004, BIOORG MED CHEM LETT, V14, P6083, DOI 10.1016/j.bmcl.2004.09.060; Lee SB, 2001, CANCER RES, V61, P8062; Li J, 2005, J BIOL CHEM, V280, P12041, DOI 10.1074/jbc.M412445200; Li J, 2008, J BIOL CHEM, V283, P36019, DOI 10.1074/jbc.M804075200; Lukas C, 2001, CANCER RES, V61, P4990; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Matys V, 2006, NUCLEIC ACIDS RES, V34, pD108, DOI 10.1093/nar/gkj143; Meijers-Heijboer H, 2002, NAT GENET, V31, P55, DOI 10.1038/ng879; Nevanlinna H, 2006, ONCOGENE, V25, P5912, DOI 10.1038/sj.onc.1209877; Ng PC, 2003, NUCLEIC ACIDS RES, V31, P3812, DOI 10.1093/nar/gkg509; Niida H, 2010, EMBO J, V29, P3558, DOI 10.1038/emboj.2010.218; Nishizuka S, 2003, P NATL ACAD SCI USA, V100, P14229, DOI 10.1073/pnas.2331323100; Nuciforo PG, 2007, CARCINOGENESIS, V28, P2082, DOI 10.1093/carcin/bgm108; Ou YH, 2005, MOL BIOL CELL, V16, P1684, DOI 10.1091/mbc.E04-08-0689; Pfister TD, 2009, MOL CANCER THER, V8, P1878, DOI 10.1158/1535-7163.MCT-09-0016; Pommier Y, 2006, CLIN CANCER RES, V12, P2657, DOI 10.1158/1078-0432.CCR-06-0743; Pommier Y, 2005, CURR PHARM DESIGN, V11, P2855, DOI 10.2174/1381612054546716; Powers JT, 2004, MOL CANCER RES, V2, P203; Reinhold WC, 2010, CANCER RES, V70, P2191, DOI 10.1158/0008-5472.CAN-09-3528; Ribeiro-Silva A, 2006, HISTOL HISTOPATHOL, V21, P373, DOI 10.14670/HH-21.373; Rogoff HA, 2004, MOL CELL BIOL, V24, P2968, DOI 10.1128/MCB.24.7.2968-2977.2004; Roschke AV, 2003, CANCER RES, V63, P8634; Sarbia M, 2007, BRIT J CANCER, V97, P1404, DOI 10.1038/sj.bjc.6604037; Scherf U, 2000, NAT GENET, V24, P236, DOI 10.1038/73439; Schwarz JK, 2003, MOL CANCER RES, V1, P598; Sedelnikova OA, 2006, CELL CYCLE, V5, P2909, DOI 10.4161/cc.5.24.3569; Shankavaram UT, 2007, MOL CANCER THER, V6, P820, DOI 10.1158/1535-7163.MCT-06-0650; Shoemaker RH, 2006, NAT REV CANCER, V6, P813, DOI 10.1038/nrc1951; Solier S, 2009, CELL CYCLE, V8, P1853, DOI 10.4161/cc.8.12.8865; Solier S, 2009, MOL CELL BIOL, V29, P68, DOI 10.1128/MCB.00581-08; Staalesen V, 2004, ONCOGENE, V23, P8535, DOI 10.1038/sj.onc.1207928; Stevens C, 2003, NAT CELL BIOL, V5, P401, DOI 10.1038/ncb974; Stolz A, 2010, NAT CELL BIOL, V12, P492, DOI 10.1038/ncb2051; Sullivan A, 2002, ONCOGENE, V21, P1316, DOI 10.1038/sj.onc.1205207; Sun YL, 2005, P NATL ACAD SCI USA, V102, P13182, DOI 10.1073/pnas.0504211102; Takai H, 2002, EMBO J, V21, P5195, DOI 10.1093/emboj/cdf506; Tsvetkov L, 2003, J BIOL CHEM, V278, P8468, DOI 10.1074/jbc.M211202200; Yang ST, 2006, J BIOL CHEM, V281, P26645, DOI 10.1074/jbc.M604391200; YEE C, 1985, AM J PATHOL, V119, P361; Yu Q, 2001, FEBS LETT, V505, P7, DOI 10.1016/S0014-5793(01)02756-9; Zhang SS, 2007, J CELL BIOCHEM, V101, P451, DOI 10.1002/jcb.21195; Zhao H, 2008, CYTOM PART A, V73A, P480, DOI 10.1002/cyto.a.20574; Zhao H, 2007, CYTOM PART A, V71A, P905, DOI 10.1002/cyto.a.20469; Zhou M, 2007, ANAL CHEM, V79, P7603, DOI 10.1021/ac071584r	84	16	16	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2012	31	4					403	418		10.1038/onc.2011.283	http://dx.doi.org/10.1038/onc.2011.283			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891LU	21765476	Green Accepted			2022-12-17	WOS:000300219300001
J	Yu, YP; Luo, JH				Yu, Y-P; Luo, J-H			Phosphorylation and interaction of myopodin by integrin-link kinase lead to suppression of cell growth and motility in prostate cancer cells	ONCOGENE			English	Article						myopodin; ILK; phosphorylation; tumor suppression; prostate cancer	LIVER-SPECIFIC ABLATION; BLADDER-CANCER; EXPRESSION; ILK; PROLIFERATION; ADHESION; PROTEIN; PARVIN; PINCH	Myopodin is a tumor-suppressor gene that suppresses growth of prostate and urothelial carcinomas. However, the mechanism of myopodin tumor-suppressor activity or signaling that leads to activation of myopodin remains unclear. In this report, we showed that the N-terminus of myopodin binds integrin-linked kinase (ILK) both in vivo and in vitro. An ILK interaction motif of 78 amino acids (amino acids 82-157) was identified in the N-terminus region of myopodin. Induction of ILK-dependent kinase activity by integrin alpha 7 led to phosphorylation of myopodin both in vivo and in vitro. Knocking down ILK dramatically reduced the inhibition of cell growth and motility mediated by myopodin. A mutant of myopodin lacking the ILK interaction motif is inactive in suppressing the growth and motility of PC3 cells. As a result, this study showed a novel and critical signaling pathway that leads to activation of myopodin. Oncogene (2011) 30, 4855-4863; doi:10.1038/onc.2011.200; published online 6 June 2011	[Yu, Y-P; Luo, J-H] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Yu, YP (corresponding author), Univ Pittsburgh, Sch Med, Dept Pathol, BST S-416,3550 Terrace St, Pittsburgh, PA 15261 USA.	ypyu@pitt.edu			National Cancer Institute [R56 CA098249, RO1 CA098249]; American Cancer Society [RSG-08-137-01-CNE]; NATIONAL CANCER INSTITUTE [R56CA098249, R01CA098249] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants from National Cancer Institute (R56 CA098249 and RO1 CA098249 to JHL) and American Cancer Society (RSG-08-137-01-CNE to YPY).	Acconcia F, 2007, P NATL ACAD SCI USA, V104, P6782, DOI 10.1073/pnas.0701999104; Apte U, 2009, HEPATOLOGY, V50, P844, DOI 10.1002/hep.23059; Cebrian V, 2008, J PATHOL, V216, P111, DOI 10.1002/path.2390; Deng JT, 2001, J BIOL CHEM, V276, P16365, DOI 10.1074/jbc.M011634200; Donthamsetty S, 2010, TOXICOL SCI, V113, P358, DOI 10.1093/toxsci/kfp281; Gkretsi V, 2008, HEPATOLOGY, V48, P1932, DOI 10.1002/hep.22537; Han YC, 2010, CANCER RES, V70, P4375, DOI 10.1158/0008-5472.CAN-09-4403; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Jing L, 2004, AM J PATHOL, V164, P1799, DOI 10.1016/S0002-9440(10)63738-8; Legate KR, 2006, NAT REV MOL CELL BIO, V7, P20, DOI 10.1038/nrm1789; Lin F, 2001, AM J PATHOL, V159, P1603, DOI 10.1016/S0002-9440(10)63006-4; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Ren BG, 2007, J NATL CANCER I, V99, P868, DOI 10.1093/jnci/djk199; Sakai T, 2003, GENE DEV, V17, P926, DOI 10.1101/gad.255603; Sanchez-Carbayo M, 2003, ONCOGENE, V22, P5298, DOI 10.1038/sj.onc.1206616; Wu CY, 2004, BBA-MOL CELL RES, V1692, P55, DOI 10.1016/j.bbamcr.2004.01.006; Yamaji S, 2001, J CELL BIOL, V153, P1251, DOI 10.1083/jcb.153.6.1251; Yu YP, 2006, UROLOGY, V68, P578, DOI 10.1016/j.urology.2006.03.027; Yu YP, 2006, CANCER RES, V66, P7414, DOI 10.1158/0008-5472.CAN-06-0227	19	16	18	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC	2011	30	49					4855	4863		10.1038/onc.2011.200	http://dx.doi.org/10.1038/onc.2011.200			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865YI	21643011	Green Accepted			2022-12-17	WOS:000298346400002
J	Tauchi, T; Okabe, S; Ashihara, E; Kimura, S; Maekawa, T; Ohyashiki, K				Tauchi, T.; Okabe, S.; Ashihara, E.; Kimura, S.; Maekawa, T.; Ohyashiki, K.			Combined effects of novel heat shock protein 90 inhibitor NVP-AUY922 and nilotinib in a random mutagenesis screen	ONCOGENE			English	Article						BCR-ABL; tyrosine kinase inhibitor; nilotinib; HSP90; T315I	CHRONIC MYELOID-LEUKEMIA; ABL KINASE INHIBITORS; BCR-ABL; IMATINIB; RESISTANCE; DASATINIB; HEAT-SHOCK-PROTEIN-90; IDENTIFICATION; ACTIVATION; MECHANISMS	To overcome imatinib resistance, more potent ABL tyrosine kinase inhibitors (TKIs), such as nilotinib and dasatinib have been developed, with demonstrable preclinical activity against most imatinib-resistant BCR-ABL kinase domain mutations, with the exception of T315I. However, imatinib-resistant patients already harboring mutations have a higher likelihood of developing further mutations under the selective pressure of potent ABL TKIs. NVP-AUY922 (Novartis) is a novel 4,5-diaryloxazole adenosine triphosphate-binding site heat shock protein 90 (HSP90) inhibitor, which has been shown to inhibit the chaperone function of HSP90 and deplete the levels of HSP90 client protein including BCR-ABL. In this study, we investigated the combined effects of AUY922 and nilotinib on random mutagenesis for BCR-ABL mutation (Blood, 109; 5011, 2007). Compared with single agents, combination with AUY922 and nilotinib was more effective at reducing the outgrowth of resistant cell clones. No outgrowth was observed in the presence of 2 mu M of nilotinib and 20 nM of AUY922. The observed data from the isobologram indicated the synergistic effect of simultaneous exposure to AUY922 and nilotinib even in BaF3 cells expressing BCR-ABL mutants including T315I. In vivo studies also demonstrated that the combination of AUY922 and nilotinib prolonged the survival of mice transplanted with mixture of BaF3 cells expressing wild-type BCR-ABL and mutant forms. Taken together, this study shows that the combination of AUY922 and nilotinib exhibits a desirable therapeutic index that can reduce the in vivo growth of mutant forms of BCR-ABL-expressing cells. Oncogene (2011) 30, 2789-2797; doi: 10.1038/onc.2011.3; published online 31 January 2011	[Tauchi, T.; Okabe, S.; Ohyashiki, K.] Tokyo Med Univ, Dept Internal Med 1, Shinjuku Ku, Tokyo 1600023, Japan; [Ashihara, E.] Kyoto Prefectural Univ Med, Dept Mol Cell Physiol, Kyoto, Japan; [Kimura, S.] Saga Univ, Dept Internal Med, Fac Med, Div Hematol Resp Med & Oncol, Saga 840, Japan; [Maekawa, T.] Kyoto Univ, Fac Med, Dept Transfus Med & Cell Therapy, Kyoto, Japan	Tokyo Medical University; Kyoto Prefectural University of Medicine; Saga University; Kyoto University	Tauchi, T (corresponding author), Tokyo Med Univ, Dept Internal Med 1, Shinjuku Ku, 6-7-1 Nishishinjuku, Tokyo 1600023, Japan.	tauchi@tokyo-med.ac.jp			MEXT (Ministry of Education, Culture, Sports, Science and Technology)	MEXT (Ministry of Education, Culture, Sports, Science and Technology)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This work was supported by a 'High-Tech Research Center' Project for private universities: matching fund subsidy from the MEXT (Ministry of Education, Culture, Sports, Science and Technology), and by the 'University-Industry Joint Research Project' for private universities: matching fund subsidy from the MEXT.	Azam M, 2003, CELL, V112, P831, DOI 10.1016/S0092-8674(03)00190-9; Bantscheff M, 2007, NAT BIOTECHNOL, V25, P1035, DOI 10.1038/nbt1328; Branford S, 2009, BLOOD, V114, P5426, DOI 10.1182/blood-2009-08-215939; Brough PA, 2008, J MED CHEM, V51, P196, DOI 10.1021/jm701018h; Deguchi Y, 2008, LEUKEMIA RES, V32, P980, DOI 10.1016/j.leukres.2007.11.008; Eccles SA, 2008, CANCER RES, V68, P2850, DOI 10.1158/0008-5472.CAN-07-5256; Garg RJ, 2009, BLOOD, V114, P4361, DOI 10.1182/blood-2009-05-221531; Gorre ME, 2002, BLOOD, V100, P3041, DOI 10.1182/blood-2002-05-1361; Jabbour E, 2008, BLOOD, V112, P53, DOI 10.1182/blood-2007-11-123950; Kano Y, 2001, BLOOD, V97, P1999, DOI 10.1182/blood.V97.7.1999; Kantarjian H, 2007, BLOOD, V109, P5143, DOI 10.1182/blood-2006-11-056028; Kantarjian H, 2006, NEW ENGL J MED, V354, P2542, DOI 10.1056/NEJMoa055104; Kantarjian H, 2009, BLOOD, V113, P6322, DOI 10.1182/blood-2008-11-186817; Matsuyama W, 2004, J IMMUNOL, V172, P2332, DOI 10.4049/jimmunol.172.4.2332; Nunoda K, 2007, ONCOGENE, V26, P4179, DOI 10.1038/sj.onc.1210179; O'Hare T, 2007, BLOOD, V110, P2242, DOI 10.1182/blood-2007-03-066936; Ottmann O, 2007, BLOOD, V110, P2309, DOI 10.1182/blood-2007-02-073528; Ray A, 2007, BLOOD, V109, P5011, DOI 10.1182/blood-2006-01-015347; Rix U, 2007, BLOOD, V110, P4055, DOI 10.1182/blood-2007-07-102061; Shah NP, 2004, SCIENCE, V305, P399, DOI 10.1126/science.1099480; Stuhmer T, 2008, LEUKEMIA, V22, P1604, DOI 10.1038/leu.2008.111; TAUCHI T, 1994, J EXP MED, V179, P167, DOI 10.1084/jem.179.1.167; Weisberg E, 2005, CANCER CELL, V7, P129, DOI 10.1016/j.ccr.2005.01.007	23	16	16	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2011	30	24					2789	2797		10.1038/onc.2011.3	http://dx.doi.org/10.1038/onc.2011.3			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778DB	21278787				2022-12-17	WOS:000291678500009
J	Das, SK; Bhutia, SK; Sokhi, UK; Dash, R; Azab, B; Sarkar, D; Fisher, PB				Das, S. K.; Bhutia, S. K.; Sokhi, U. K.; Dash, R.; Azab, B.; Sarkar, D.; Fisher, P. B.			Human polynucleotide phosphorylase (hPNPaseold(35)): an evolutionary conserved gene with an expanding repertoire of RNA degradation functions	ONCOGENE			English	Review						hPNPase(old-35); senescence; RNA degradation; c-myc; miRNA	HUMAN-MELANOMA CELLS; DOUBLE-STRANDED-RNA; MESSENGER-RNA; POSTTRANSCRIPTIONAL REGULATION; POLY(A) POLYMERASE; TRANSCRIPTION FACTOR; MITOCHONDRIAL RNA; OXIDATIVE STRESS; KAPPA-B; C-MYC	Human polynucleotide phosphorylase (hPNPase(old-35)) is an evolutionary conserved RNA-processing enzyme with expanding roles in regulating cellular physiology. hPNPase(old-35) was cloned using an innovative 'overlapping pathway screening' strategy designed to identify genes coordinately regulated during the processes of cellular differentiation and senescence. Although hPNPase(old-35) structurally and biochemically resembles PNPase of other species, overexpression and inhibition studies reveal that hPNPase(old-35) has evolved to serve more specialized and diversified functions in humans. Targeting specific mRNA or non-coding small microRNA, hPNPase(old-35) modulates gene expression that in turn has a pivotal role in regulating normal physiological and pathological processes. In these contexts, targeted overexpression of hPNPase(old-35) represents a novel strategy to selectively downregulate RNA expression and consequently intervene in a variety of pathophysiological conditions. Oncogene (2011) 30, 1733-1743; doi:10.1038/onc.2010.572; published online 13 December 2010	[Sarkar, D.; Fisher, P. B.] Virginia Commonwealth Univ, Sch Med, VCU Massey Canc Ctr, VCU Inst Mol Med,Dept Human & Mol Genet, Richmond, VA 23298 USA	Virginia Commonwealth University	Fisher, PB (corresponding author), Virginia Commonwealth Univ, Sch Med, VCU Massey Canc Ctr, VCU Inst Mol Med,Dept Human & Mol Genet, 1101 E Marshall St,Sanger Hall Bldg,Room 11-015, Richmond, VA 23298 USA.	pbfisher@vcu.edu	Azab, Belal/AAJ-5652-2021	Azab, Belal/0000-0003-0293-6489; dash, rupesh/0000-0001-5740-7053; SOKHI, UPNEET/0000-0001-5907-5646; Bhutia, Sujit Kumar/0000-0003-0962-3354	NIH [R01 CA097318, R01 CA127641, CA134721, P01 CA104177, R01 CA134721]; Samuel Waxman Cancer Research Foundation; National Foundation for Cancer Research; NATIONAL CANCER INSTITUTE [R01CA097318, P01CA104177, R01CA127641, R01CA134721] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Samuel Waxman Cancer Research Foundation; National Foundation for Cancer Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported in part by NIH grants R01 CA097318, R01 CA127641, CA134721, and P01 CA104177, the Samuel Waxman Cancer Research Foundation and the National Foundation for Cancer Research (PBF) and NIH grant R01 CA134721 (DS). DS is the Harrison Endowed Scholar in Cancer Research. PBF holds the Thelma Newmeyer Corman Chair in Cancer Research and is a SWCRF Investigator.	Allmang C, 1999, GENE DEV, V13, P2148, DOI 10.1101/gad.13.16.2148; Almeida FC, 2008, EVOL BIOINFORM, V4, P109; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BARNES PJ, 1997, NEW ENGL J MED, V336, P1; Bueno MJ, 2008, CANCER CELL, V13, P496, DOI 10.1016/j.ccr.2008.04.018; Buttner K, 2006, MOL MICROBIOL, V61, P1372, DOI 10.1111/j.1365-2958.2006.05331.x; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Calin GA, 2006, CANCER RES, V66, P7390, DOI 10.1158/0008-5472.CAN-06-0800; CAMPISI J, 1992, ANN NY ACAD SCI, V663, P195, DOI 10.1111/j.1749-6632.1992.tb38663.x; Cao D, 2003, CELL, V113, P533, DOI 10.1016/S0092-8674(03)00353-2; Chan I, 2008, J CELL PHYSIOL, V215, P401, DOI 10.1002/jcp.21320; CHANG DD, 1987, SCIENCE, V235, P1178, DOI 10.1126/science.2434997; Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30; Chen HW, 2007, TRENDS CELL BIOL, V17, P600, DOI 10.1016/j.tcb.2007.09.006; Chen HW, 2006, MOL CELL BIOL, V26, P8475, DOI 10.1128/MCB.01002-06; Chen JF, 2006, NAT GENET, V38, P228, DOI 10.1038/ng1725; Chen QM, 2000, ANN NY ACAD SCI, V908, P111; Colavitti R, 2005, IUBMB LIFE, V57, P277, DOI 10.1080/15216540500091890; Das SK, 2010, P NATL ACAD SCI USA, V107, P11948, DOI 10.1073/pnas.0914143107; Deutscher MP, 2001, PROG NUCLEIC ACID RE, V66, P67; DEUTSCHER MP, 1993, J BACTERIOL, V175, P4577, DOI 10.1128/JB.175.15.4577-4583.1993; DEUTSCHER MP, 1993, J BIOL CHEM, V268, P13011; Dodson RE, 2002, PROG NUCLEIC ACID RE, V72, P129, DOI 10.1016/S0079-6603(02)72069-2; Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; FISHER PB, 1985, J INTERFERON RES, V5, P11, DOI 10.1089/jir.1985.5.11; FISHER PB, 1985, PHARMACOL THERAPEUT, V27, P143, DOI 10.1016/0163-7258(85)90067-1; FISHER PB, 1986, ANTICANCER RES, V6, P765; Fornari F, 2008, ONCOGENE, V27, P5651, DOI 10.1038/onc.2008.178; Frischmeyer PA, 2002, SCIENCE, V295, P2258, DOI 10.1126/science.1067338; Fukuhara N, 2006, CANCER SCI, V97, P499, DOI 10.1111/j.1349-7006.2006.00209.x; Gewartowski K, 2006, ACTA BIOCHIM POL, V53, P179; GUARINI L, 1992, PIGM CELL RES, P123; GUARINI L, 1989, CANCER IMMUNOL IMMUN, V30, P262, DOI 10.1007/BF01744892; Hagen TM, 1997, P NATL ACAD SCI USA, V94, P3064, DOI 10.1073/pnas.94.7.3064; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; Hayakawa H, 2006, BIOCHEMISTRY-US, V45, P6749, DOI 10.1021/bi052585l; HAYFLICK L, 1976, NEW ENGL J MED, V295, P1302, DOI 10.1056/NEJM197612022952308; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; He L, 2007, NAT REV CANCER, V7, P819, DOI 10.1038/nrc2232; HOOF A, 1999, CELL, V99, P347; Jarrige AC, 2002, J MOL BIOL, V321, P397, DOI 10.1016/S0022-2836(02)00645-9; Jarrige AC, 2001, EMBO J, V20, P6845, DOI 10.1093/emboj/20.23.6845; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P41; JIANG HP, 1995, ONCOGENE, V11, P1179; Kennedy S, 2004, NATURE, V427, P645, DOI 10.1038/nature02302; Khidr L, 2008, J BIOL CHEM, V283, P27064, DOI 10.1074/jbc.M802991200; Kiecolt-Glaser JK, 2003, P NATL ACAD SCI USA, V100, P9090, DOI 10.1073/pnas.1531903100; Kim VN, 2005, NAT REV MOL CELL BIO, V6, P376, DOI 10.1038/nrm1644; Kirschner LS, 1999, GENOMICS, V62, P21, DOI 10.1006/geno.1999.5957; Landgraf P, 2007, CELL, V129, P1401, DOI 10.1016/j.cell.2007.04.040; Leszczyniecka M, 2003, GENE, V316, P143, DOI 10.1016/S0378-1119(03)00752-2; Leszczyniecka M, 2004, MOL PHYLOGENET EVOL, V31, P123, DOI 10.1016/j.ympev.2003.07.012; Leszczyniecka M, 2002, P NATL ACAD SCI USA, V99, P16636, DOI 10.1073/pnas.252643699; LITTAUER UZ, 1999, ENCY MOL BIOL, V3, P1911; Mitchell P, 2000, NAT STRUCT BIOL, V7, P843, DOI 10.1038/82817; Mitchell P, 1997, CELL, V91, P457, DOI 10.1016/S0092-8674(00)80432-8; Mohanty BK, 2000, P NATL ACAD SCI USA, V97, P11966, DOI 10.1073/pnas.220295997; Nagaike T, 2005, J BIOL CHEM, V280, P19721, DOI 10.1074/jbc.M500804200; O'Hagan RC, 2000, GENE DEV, V14, P2185, DOI 10.1101/gad.827200; Obaya AJ, 1999, ONCOGENE, V18, P2934, DOI 10.1038/sj.onc.1202749; Parker R, 2004, NAT STRUCT MOL BIOL, V11, P121, DOI 10.1038/nsmb724; Passos JF, 2006, REJUV RES, V9, P64, DOI 10.1089/rej.2006.9.64; Piwowarski J, 2003, J MOL BIOL, V329, P853, DOI 10.1016/S0022-2836(03)00528-X; Portnoy V, 2005, EMBO REP, V6, P1188, DOI 10.1038/sj.embor.7400571; Raijmakers R, 2004, EUR J CELL BIOL, V83, P175, DOI 10.1078/0171-9335-00385; Raijmakers R, 2002, J MOL BIOL, V323, P653, DOI 10.1016/S0022-2836(02)00947-6; Ramachandran V, 2008, SCIENCE, V321, P1490, DOI 10.1126/science.1163728; Rao PK, 2006, P NATL ACAD SCI USA, V103, P8721, DOI 10.1073/pnas.0602831103; Regonesi ME, 2004, NUCLEIC ACIDS RES, V32, P1006, DOI 10.1093/nar/gkh268; Sarkar D, 2004, CANCER RES, V64, P7473, DOI 10.1158/0008-5472.CAN-04-1772; Sarkar D, 2006, CELL DEATH DIFFER, V13, P1541, DOI 10.1038/sj.cdd.4401829; Sarkar D, 2005, MOL CELL BIOL, V25, P7333, DOI 10.1128/MCB.25.16.7333-7343.2005; Sarkar D, 2003, J BIOL CHEM, V278, P24542, DOI 10.1074/jbc.M302421200; Sarkar D, 2007, CANCER RES, V67, P7948, DOI 10.1158/0008-5472.CAN-07-0872; Sarkar D, 2006, CANCER LETT, V236, P13, DOI 10.1016/j.canlet.2005.04.009; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SEE YP, 1972, BIOCHEM J, V130, P343, DOI 10.1042/bj1300343; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Slomovic S, 2005, MOL CELL BIOL, V25, P6427, DOI 10.1128/MCB.25.15.6427-6435.2005; Stickney LM, 2005, J BACTERIOL, V187, P7214, DOI 10.1128/JB.187.21.7214-7221.2005; Suh MR, 2004, DEV BIOL, V270, P488, DOI 10.1016/j.ydbio.2004.02.019; Symmons MF, 2002, TRENDS BIOCHEM SCI, V27, P11, DOI 10.1016/S0968-0004(01)01999-5; Symmons MF, 2000, STRUCTURE, V8, P1215, DOI 10.1016/S0969-2126(00)00521-9; Temperley RJ, 2003, HUM MOL GENET, V12, P2341, DOI 10.1093/hmg/ddg238; Thomson JM, 2006, GENE DEV, V20, P2202, DOI 10.1101/gad.1444406; Tsuchiya S, 2006, J PHARMACOL SCI, V101, P267, DOI 10.1254/jphs.CPJ06013X; Tucker M, 2000, ANNU REV BIOCHEM, V69, P571, DOI 10.1146/annurev.biochem.69.1.571; Van Maerken T, 2009, J CELL PHYSIOL, V219, P707, DOI 10.1002/jcp.21719; Wang DDH, 2009, J BIOL CHEM, V284, P20812, DOI 10.1074/jbc.M109.009605; Wang G, 2010, CELL, V142, P456, DOI 10.1016/j.cell.2010.06.035; Wang ZR, 2001, CELL, V107, P751, DOI 10.1016/S0092-8674(01)00592-X; Wu JH, 2008, BIOCHEM BIOPH RES CO, V372, P288, DOI 10.1016/j.bbrc.2008.05.058; Wulczyn FG, 2007, FASEB J, V21, P415, DOI 10.1096/fj.06-6130com; Yamanaka K, 2001, J BACTERIOL, V183, P2808, DOI 10.1128/JB.183.9.2808-2816.2001; Yehudai-Resheff S, 2003, PLANT CELL, V15, P2003, DOI 10.1105/tpc.013326; Yehudai-Resheff S, 2001, MOL CELL BIOL, V21, P5408, DOI 10.1128/MCB.21.16.5408-5416.2001	98	16	19	1	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2011	30	15					1733	1743		10.1038/onc.2010.572	http://dx.doi.org/10.1038/onc.2010.572			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	749ZM	21151174	Green Accepted			2022-12-17	WOS:000289512200001
J	Czeh, M; Loddenkemper, C; Shalapour, S; Schon, C; Robine, S; Goldscheid, E; Stein, H; Schuler, T; Willimsky, G; Blankenstein, T				Czeh, M.; Loddenkemper, C.; Shalapour, S.; Schoen, C.; Robine, S.; Goldscheid, E.; Stein, H.; Schueler, T.; Willimsky, G.; Blankenstein, T.			The immune response to sporadic colorectal cancer in a novel mouse model	ONCOGENE			English	Article						colorectal cancer; sporadic cancer; mouse model; antitumor immune response	SV40 T-ANTIGEN; ONCOGENIC K-RAS; TRANSGENIC MICE; GENE-EXPRESSION; TUMOR-ANTIGEN; VILLIN GENE; JC VIRUS; INTESTINAL EPITHELIUM; CELL TOLERANCE; DEVELOP TUMORS	Current mouse models do not reflect the sporadic nature of colon cancer and do not allow the analysis of antitumor immune response because of the lack of known tumor-specific antigens. Two transgenic mouse models with spontaneous tumor development were generated, directing the expression of SV40T antigen (Tag) either constitutively (Vil-Cre x LoxP-Tag-transgenic mice) or stochastically (Vil-Cre-ERT2 x LoxP-Tag-transgenic mice) into the putative stem cell region of the crypt of Lieberkuhn. Tumor development and antitumor immune response were monitored. Vil-Cre x LoxP-Tag mice developed multiple adenocarcinomas of the small intestine and colon at an average age of 6 months. During the tumor development, Tag-specific immunoglobulin G (IgG) antibodies were induced in half of the mice, although they had developed neonatal cytotoxic T lymphocyte (CTL) tolerance. This model shows similarity to hereditary colon cancer but not to the sporadic tumor development. Therefore, the conditional Vil-Cre-ERT2 x LoxP-Tag mice were established, in which expression of the dormant Tag was induced by stochastic, tissue-specific activation of Cre recombinase. These mice spontaneously developed highly invasive, metastasizing colon carcinomas at an average age of 20 months. Colon carcinomas expressed epithelial and/or neuroendocrine markers depending on the grade of differentiation. Young Vil-Cre-ERT2 x LoxP-Tag mice had retained CTL responses against epitope IV of Tag. The tumors induced strong anti-Tag IgG responses. We report, for the first time, a mouse model based on stochastic, tissue-specific activation of a dormant oncogene in the colon allowing the analysis of antitumor immune response against primary colorectal cancer. Oncogene (2010) 29, 6591-6602; doi:10.1038/onc.2010.388; published online 6 September 2010	[Goldscheid, E.; Willimsky, G.; Blankenstein, T.] Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany; [Czeh, M.; Shalapour, S.; Schoen, C.; Schueler, T.; Willimsky, G.; Blankenstein, T.] Charite Campus Benjamin Franklin, Inst Immunol, Berlin, Germany; [Loddenkemper, C.; Stein, H.] Charite Campus Benjamin Franklin, Inst Pathol, Berlin, Germany; [Loddenkemper, C.] Charite Campus Benjamin Franklin, Res Ctr ImmunoSci, Berlin, Germany; [Robine, S.] Inst Curie, CNRS, Dept Morphogenesis & Intracellular Signali, F-75231 Paris, France	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Cite	Blankenstein, T (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13092 Berlin, Germany.	tblanke@mdc-berlin.de	Willimsky, Gerald/AAA-2445-2021	Willimsky, Gerald/0000-0002-9693-948X	Sonderforschungsbereich [SFB 633, TR 36]	Sonderforschungsbereich(German Research Foundation (DFG))	We thank S Spieckermann, M Rosch, C Westen and S Horn for excellent technical assistance and JC Schmollinger for reading the paper. This study was supported by the Research grants Sonderforschungsbereich SFB 633 and TR 36.	Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602; Boivin GP, 2003, GASTROENTEROLOGY, V124, P762, DOI 10.1053/gast.2003.50094; Bos R, 2008, CANCER RES, V68, P8446, DOI 10.1158/0008-5472.CAN-08-1864; Boyle P, 2005, ANN ONCOL, V16, P481, DOI 10.1093/annonc/mdi098; BRINSTER RL, 1984, CELL, V37, P367, DOI 10.1016/0092-8674(84)90367-2; BURKE AB, 1991, AM J CLIN PATHOL, V95, P315, DOI 10.1093/ajcp/95.3.315; Calcagno SR, 2008, INT J CANCER, V122, P2462, DOI 10.1002/ijc.23383; CHENG H, 1974, AM J ANAT, V141, P537, DOI 10.1002/aja.1001410407; CORBETT TH, 1975, CANCER RES, V35, P2434; Derbinski J, 2001, NAT IMMUNOL, V2, P1032, DOI 10.1038/ni723; El Marjou F, 2004, GENESIS, V39, P186, DOI 10.1002/gene.20042; Enam S, 2002, CANCER RES, V62, P7093; FAAS SJ, 1987, J EXP MED, V165, P417, DOI 10.1084/jem.165.2.417; Gum JR, 2004, MOL CANCER RES, V2, P504; Gum JR, 2001, CANCER RES, V61, P3472; HAUFT SM, 1992, J CELL BIOL, V117, P825, DOI 10.1083/jcb.117.4.825; Heyer J, 1999, ONCOGENE, V18, P5325, DOI 10.1038/sj.onc.1203036; HORI R, 2005, VIRCHOWS ARCH, V14, P1; Janssen KP, 2002, GASTROENTEROLOGY, V123, P492, DOI 10.1053/gast.2002.34786; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kinzler KW, 1998, SCIENCE, V280, P1036, DOI 10.1126/science.280.5366.1036; Laghi L, 1999, P NATL ACAD SCI USA, V96, P7484, DOI 10.1073/pnas.96.13.7484; Lauwen MM, 2008, CANCER RES, V68, P893, DOI 10.1158/0008-5472.CAN-07-3166; LUDLOW JW, 1993, FASEB J, V7, P866, DOI 10.1096/fasebj.7.10.8344486; Madison BB, 2002, J BIOL CHEM, V277, P33275, DOI 10.1074/jbc.M204935200; MAUNOURY R, 1992, DEVELOPMENT, V115, P717; Nagy A, 2000, GENESIS, V26, P99, DOI 10.1002/(SICI)1526-968X(200002)26:2<99::AID-GENE1>3.0.CO;2-B; Newcomb PA, 2004, CANCER EPIDEM BIOMAR, V13, P662; Otahal P, 2006, J IMMUNOL, V177, P3089, DOI 10.4049/jimmunol.177.5.3089; Pages F, 2010, ONCOGENE, V29, P1093, DOI 10.1038/onc.2009.416; PALMITER RD, 1985, NATURE, V316, P457, DOI 10.1038/316457a0; Pinto D, 1999, J BIOL CHEM, V274, P6476, DOI 10.1074/jbc.274.10.6476; Saam JR, 1999, J BIOL CHEM, V274, P38071, DOI 10.1074/jbc.274.53.38071; SARSFIELD P, 1990, HISTOPATHOLOGY, V16, P357, DOI 10.1111/j.1365-2559.1990.tb01139.x; Sauer B, 1998, METHODS, V14, P381, DOI 10.1006/meth.1998.0593; Schell TD, 2000, CANCER RES, V60, P3002; Smith KM, 1997, INT IMMUNOL, V9, P1355, DOI 10.1093/intimm/9.9.1355; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Syder AJ, 2004, P NATL ACAD SCI USA, V101, P4471, DOI 10.1073/pnas.0307983101; Weinreb D, 2006, VIRCHOWS ARCH, V448, P239, DOI 10.1007/s00428-005-0128-7; Willimsky G, 2005, NATURE, V437, P141, DOI 10.1038/nature03954; Willimsky G, 2008, J EXP MED, V205, P1687, DOI 10.1084/jem.20072016; Yen TH, 2006, STEM CELL REV, V2, P203, DOI 10.1007/s12015-006-0048-1	45	16	17	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2010	29	50					6591	6602		10.1038/onc.2010.388	http://dx.doi.org/10.1038/onc.2010.388			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	695OA	20818425				2022-12-17	WOS:000285380200008
J	Qian, T; Lee, JY; Park, JH; Kim, HJ; Kong, G				Qian, T.; Lee, J-Y; Park, J-H; Kim, H-J; Kong, G.			Id1 enhances RING1b E3 ubiquitin ligase activity through the Mel-18/Bmi-1 polycomb group complex	ONCOGENE			English	Article						Id1; polycomb group proteins; E3 ubiquitin ligase	CELL-CYCLE PROGRESSION; ESOPHAGEAL CANCER-CELLS; NF-KAPPA-B; BREAST-CANCER; PROTEASOME PATHWAY; STEM-CELLS; TRANSCRIPTIONAL REPRESSION; H2A UBIQUITYLATION; SIGNALING PATHWAY; DEPENDENT MANNER	The helix-loop-helix inhibitor of differentiation and DNA binding (Id1) is well known as an oncogene in various tumors. Although it has been reported that Id1 promotes several oncogenic processes, it is still unclear whether Id1 functions through epigenetic transcriptional regulation. In this study, we examined the effect of Id1 on polycomb group (PcG) proteins, which are crucial epigenetic gene silencers, and found that Id1 regulated the expression of Mel-18 and Bmi-1, both of which belong to polycomb repressive complex 1. We also confirmed that Id1 induced Mel-18 downregulation, which was mediated by the Akt pathway, and consequently upregulated the transcription of its target gene, c-Myc. Using a promoter-reporter, we demonstrated that Id1 regulated Bmi-1 transcription through c-Myc binding to its E-box in the promoter. Finally, we examined the activity of E3 ligase RING1b, whose catalytic activity is increased by binding with the RING finger protein Bmi-1, and found that Id1 overexpression enhanced RING1b E3 ligase activity leading to accumulation of H2A ubiquitination and ubiquitin/proteasome-mediated degradation of geminin. Taken together, our study provided a novel link between Id1 and PcG proteins and suggested that Id1 may contribute to tumor development through PcG-mediated epigenetic regulation. Oncogene (2010) 29, 5818-5827; doi: 10.1038/onc.2010.317; published online 9 August 2010	[Qian, T.; Park, J-H; Kim, H-J; Kong, G.] Hanyang Univ, Dept Pathol, Coll Med, Seoul 133791, South Korea; [Lee, J-Y; Kong, G.] Hanyang Univ, Inst Bioengn & Biopharmaceut Res, Seoul 133791, South Korea	Hanyang University; Hanyang University	Kong, G (corresponding author), Hanyang Univ, Dept Pathol, Coll Med, 17 Haengdang Dong, Seoul 133791, South Korea.	gkong@hanyang.ac.kr			Korean Government (MOEHRD) [KRF-2007-314-E00041]; Korean government (MEST) [20090081874]	Korean Government (MOEHRD)(Ministry of Education & Human Resources Development (MOEHRD), Republic of KoreaKorean Government); Korean government (MEST)(Ministry of Education, Science & Technology (MEST), Republic of KoreaKorean Government)	This work was supported by a Korea Research Foundation Grant (KRF-2007-314-E00041) funded by the Korean Government (MOEHRD, Basic Research Promotion Fund) and a Korea Science and Engineering Foundation grant funded by the Korean government (MEST) (No. 20090081874).	Bernardi R, 2000, ONCOGENE, V19, P2447, DOI 10.1038/sj.onc.1203564; Buchwald G, 2006, EMBO J, V25, P2465, DOI 10.1038/sj.emboj.7601144; Calses C, 2008, MOL CELL BIOL, V28, P1018, DOI 10.1128/MCB.01136-07; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Cao R, 2005, MOL CELL, V20, P845, DOI 10.1016/j.molcel.2005.12.002; Choi YS, 2005, MOL CELLS, V20, P241; Elderkin S, 2007, MOL CELL, V28, P107, DOI 10.1016/j.molcel.2007.08.009; Gao HD, 2007, MOL CELL BIOCHEM, V305, P35, DOI 10.1007/s11010-007-9525-3; Geng H, 2010, CANCER RES, V70, P3239, DOI 10.1158/0008-5472.CAN-09-3186; Guo WJ, 2007, MOL BIOL CELL, V18, P536, DOI 10.1091/mbc.E06-05-0447; Hattori T, 2003, GENES CELLS, V8, P889, DOI 10.1046/j.1365-2443.2003.00684.x; Jang KS, 2006, CANCER LETT, V244, P203, DOI 10.1016/j.canlet.2005.12.016; KANNO M, 1995, EMBO J, V14, P5672, DOI 10.1002/j.1460-2075.1995.tb00254.x; Kim H, 2008, BREAST CANCER RES TR, V112, P287, DOI 10.1007/s10549-007-9871-6; Kim HJ, 2007, MOL CANCER RES, V5, P321, DOI 10.1158/1541-7786.MCR-06-0218; Kroll KL, 2007, FRONT BIOSCI, V12, P1395, DOI 10.2741/2156; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Lee JY, 2009, ONCOGENE, V28, P824, DOI 10.1038/onc.2008.451; Lee JY, 2008, CANCER RES, V68, P4201, DOI 10.1158/0008-5472.CAN-07-2570; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Levine SS, 2004, TRENDS BIOCHEM SCI, V29, P478, DOI 10.1016/j.tibs.2004.07.007; Li B, 2007, CARCINOGENESIS, V28, P2313, DOI 10.1093/carcin/bgm152; Li B, 2009, INT J CANCER, V125, P2576, DOI 10.1002/ijc.24675; Li ZZ, 2006, J BIOL CHEM, V281, P20643, DOI 10.1074/jbc.M602461200; Lin JZ, 2010, CLIN CANCER RES, V16, P77, DOI 10.1158/1078-0432.CCR-08-2362; Ling MT, 2006, DIFFERENTIATION, V74, P481, DOI 10.1111/j.1432-0436.2006.00083.x; Liu SL, 2006, CANCER RES, V66, P6063, DOI 10.1158/0008-5472.CAN-06-0054; Lund AH, 2004, CURR OPIN CELL BIOL, V16, P239, DOI 10.1016/j.ceb.2004.03.010; Matsuo Fumie, 2002, Breast Cancer, V9, P33, DOI 10.1007/BF02967544; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; Ohtsubo M, 2008, P NATL ACAD SCI USA, V105, P10396, DOI 10.1073/pnas.0800672105; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Saxena S, 2005, MUTAT RES-FUND MOL M, V569, P111, DOI 10.1016/j.mrfmmm.2004.05.026; Seo S, 2005, GENE DEV, V19, P1723, DOI 10.1101/gad.1319105; Singh J, 2002, ONCOGENE, V21, P1812, DOI 10.1038/sj.onc.1205252; Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991; Swarbrick A, 2005, ONCOGENE, V24, P381, DOI 10.1038/sj.onc.1208188; Tang XL, 2007, NAT CELL BIOL, V9, P1199, DOI 10.1038/ncb1641; Van Damme N, 2008, CELL HOST MICROBE, V3, P245, DOI 10.1016/j.chom.2008.03.001; Voncken JW, 2003, P NATL ACAD SCI USA, V100, P2468, DOI 10.1073/pnas.0434312100; Wang HB, 2004, NATURE, V431, P873, DOI 10.1038/nature02985; Wei JH, 2006, J BIOL CHEM, V281, P22537, DOI 10.1074/jbc.M600826200; Zaaroor-Regev D, 2010, P NATL ACAD SCI USA, V107, P6788, DOI 10.1073/pnas.1003108107; Zeller KI, 2006, P NATL ACAD SCI USA, V103, P17834, DOI 10.1073/pnas.0604129103; Zhao J, 2000, J CELL SCI, V113, P4363; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973	46	16	16	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2010	29	43					5818	5827		10.1038/onc.2010.317	http://dx.doi.org/10.1038/onc.2010.317			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	672LY	20697353				2022-12-17	WOS:000283586200007
J	Cantelmo, AR; Cammarota, R; Noonan, DM; Focaccetti, C; Comoglio, PM; Prat, M; Albini, A				Cantelmo, A. R.; Cammarota, R.; Noonan, D. M.; Focaccetti, C.; Comoglio, P. M.; Prat, M.; Albini, A.			Cell delivery of Met docking site peptides inhibit angiogenesis and vascular tumor growth	ONCOGENE			English	Article						Met; cell-penetrating peptides; Antennapedia; Tat; angiogenesis; cancer	FACTOR SCATTER FACTOR; SMALL-MOLECULE INHIBITOR; FACTOR/SCATTER FACTOR; C-MET; PENETRATING PEPTIDES; IN-VIVO; TYROSINE KINASE; INVASIVE GROWTH; FACTOR-RECEPTOR; HGF RECEPTOR	Hepatocyte growth factor (HGF) and its receptor Met are responsible for a wide variety of cellular responses, both physiologically during embryo development and tissue homeostasis, and pathologically, particularly during tumor growth and dissemination. In cancer, Met can act as an oncogene on tumor cells, as well as a pro-angiogenic factor activating endothelial cells and inducing new vessel formation. Molecules interfering with Met activity could be valuable therapeutic agents. Here we have investigated the antiangiogenic properties of a synthetic peptide mimicking the docking site of the Met carboxyl-terminal tail, which was delivered into the cells by fusion with the internalization sequences from Antennapedia or HIV-Tat. We showed that these peptides inhibit ligand-dependent endothelial cell proliferation, motility, invasiveness and morphogenesis in vitro to an even greater extent and with much less toxicity than the Met inhibitor PHA-665752, which correlated with interference of HGF-dependent downstream signaling. In vivo, the peptides inhibited HGF-induced angiogenesis in the matrigel sponge assay and impaired xenograft tumor growth and vascularization in Kaposi's sarcoma. These data show that interference with the Met receptor intracellular sequence impairs HGF-induced angiogenesis, suggesting the use of antidocking site compounds as a therapeutic strategy to counteract angiogenesis in cancer as well as in other diseases. Oncogene (2010) 29, 5286-5298; doi:10.1038/onc.2010.267; published online 5 July 2010	[Cantelmo, A. R.; Cammarota, R.; Noonan, D. M.; Focaccetti, C.; Albini, A.] Casa Cura MultiMed IRCCS, I-20138 Milan, Italy; [Noonan, D. M.] Univ Insubria, Dept Expt Med, Varese, Italy; [Comoglio, P. M.] Univ Turin, Sch Med, Inst Canc Res & Treatment IRCC, Candiolo, Italy; [Prat, M.] Univ Piemonte Orientale, Dept Med Sci, Novara, Italy	IRCCS Multimedica; University of Insubria; IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; University of Eastern Piedmont Amedeo Avogadro	Albini, A (corresponding author), MultiMed Castellanza, Via Piemonte 70, I-21053 Castellanza, VA, Italy.	adriana.albini@multimedica.it	Noonan, Douglas M/A-8620-2010; Focaccetti, Chiara/AAD-9378-2019; Cantelmo, Anna Rita/G-6766-2018	Noonan, Douglas M/0000-0001-8058-0719; Focaccetti, Chiara/0000-0002-7334-3966; Cantelmo, Anna Rita/0000-0002-2748-264X; Comoglio, Paolo/0000-0002-7056-5328; Albini, Adriana/0000-0002-9624-5103	AIRC (Associazione Italiana per la Ricerca sul Cancro); ISS; Compagnia San Paolo; MIUR	AIRC (Associazione Italiana per la Ricerca sul Cancro)(Fondazione AIRC per la ricerca sul cancro); ISS; Compagnia San Paolo(Compagnia di San Paolo); MIUR(Ministry of Education, Universities and Research (MIUR))	These studies were supported by AIRC (Associazione Italiana per la Ricerca sul Cancro), ISS, Compagnia San Paolo and the MIUR. We thank Drs Monica Morini and Raffaella Dell'Eva (Istituto Nazionale per la Ricerca sul Cancro, Genova) for preliminary observations. We are indebted to Dr Paola Corradino (CBA, Genova) for literature searches and Alessandra Panvini-Rosati (Multimedica, Milan) for assistance. ARC is a PhD student at the Department of Structural and Functional Biology, Via Dunant 5, Varese, CF is a MIUR 'Grande Progetto Strategico' fellow.	Albini A, 1997, AIDS, V11, P713, DOI 10.1097/00002030-199706000-00003; Albini A, 2001, CANCER RES, V61, P8171; ALBINI A, 1994, AIDS, V8, P1237, DOI 10.1097/00002030-199409000-00004; ALBINI A, 1987, CANCER RES, V47, P3239; Albini A, 2007, NAT PROTOC, V2, P504, DOI 10.1038/nprot.2006.466; Anastasi S, 1997, J CELL BIOL, V137, P1057, DOI 10.1083/jcb.137.5.1057; Bardelli A, 1999, J BIOL CHEM, V274, P29274, DOI 10.1074/jbc.274.41.29274; Bardelli C, 2005, BIOCHEM BIOPH RES CO, V334, P1172, DOI 10.1016/j.bbrc.2005.07.020; Berthou S, 2004, ONCOGENE, V23, P5387, DOI 10.1038/sj.onc.1207691; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; Boccaccio C, 2006, NAT REV CANCER, V6, P637, DOI 10.1038/nrc1912; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; Cao B, 2001, P NATL ACAD SCI USA, V98, P7443, DOI 10.1073/pnas.131200498; Cao RH, 2006, BLOOD, V107, P3531, DOI 10.1182/blood-2005-06-2538; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; CHAN AML, 1991, SCIENCE, V254, P1382, DOI 10.1126/science.1720571; Christensen JG, 2003, CANCER RES, V63, P7345; Chu SH, 2009, J NEURO-ONCOL, V93, P183, DOI 10.1007/s11060-008-9772-5; Comoglio PM, 2008, NAT REV DRUG DISCOV, V7, P504, DOI 10.1038/nrd2530; Corso S, 2008, ONCOGENE, V27, P684, DOI 10.1038/sj.onc.1210697; Deregibus MC, 2003, J BIOL CHEM, V278, P18008, DOI 10.1074/jbc.M300711200; Deshayes S, 2005, CELL MOL LIFE SCI, V62, P1839, DOI 10.1007/s00018-005-5109-0; DIRENZO MF, 1991, ONCOGENE, V6, P1997; Dong G, 2001, CANCER RES, V61, P5911; Dong QG, 1997, ARTERIOSCL THROM VAS, V17, P1599, DOI 10.1161/01.ATV.17.8.1599; Ebens A, 1996, NEURON, V17, P1157, DOI 10.1016/S0896-6273(00)80247-0; Ebos JML, 2009, CANCER CELL, V15, P232, DOI 10.1016/j.ccr.2009.01.021; Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027; Fischer C, 2008, NAT REV CANCER, V8, P942, DOI 10.1038/nrc2524; Foged C, 2008, EXPERT OPIN DRUG DEL, V5, P105, DOI 10.1517/17425247.5.1.105; FOLKMAN J, 1985, ADV CANCER RES, V43, P175, DOI 10.1016/S0065-230X(08)60946-X; Gherardi E, 2006, P NATL ACAD SCI USA, V103, P4046, DOI 10.1073/pnas.0509040103; Giordano S, 2000, FASEB J, V14, P399, DOI 10.1096/fasebj.14.2.399; Goh PP, 2007, CURR CANCER DRUG TAR, V7, P743, DOI 10.2174/156800907783220462; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; GRANT DS, 1989, CELL, V58, P933, DOI 10.1016/0092-8674(89)90945-8; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; Gupta B, 2005, ADV DRUG DELIVER REV, V57, P637, DOI 10.1016/j.addr.2004.10.007; Jun HT, 2007, CLIN CANCER RES, V13, P6735, DOI 10.1158/1078-0432.CCR-06-2969; Khwaja A, 1998, J BIOL CHEM, V273, P18793, DOI 10.1074/jbc.273.30.18793; Kim KJ, 2006, CLIN CANCER RES, V12, P1292, DOI 10.1158/1078-0432.CCR-05-1793; KLEINMAN HK, 1986, BIOCHEMISTRY-US, V25, P312, DOI 10.1021/bi00350a005; Lock LS, 2003, J BIOL CHEM, V278, P30083, DOI 10.1074/jbc.M302675200; Loges S, 2009, CANCER CELL, V15, P167, DOI 10.1016/j.ccr.2009.02.007; LONGATI P, 1994, ONCOGENE, V9, P49; Lou XQ, 2009, MOL CANCER THER, V8, P1126, DOI 10.1158/1535-7163.MCT-08-0904; Matsumoto K, 2003, CANCER SCI, V94, P321, DOI 10.1111/j.1349-7006.2003.tb01440.x; Mazzone M, 2004, J CLIN INVEST, V114, P1418, DOI 10.1172/JCI200422235; Michieli P, 2004, CANCER CELL, V6, P61, DOI 10.1016/j.ccr.2004.05.032; Morotti A, 2002, ONCOGENE, V21, P4885, DOI 10.1038/sj.onc.1205622; Morris MC, 2008, BIOL CELL, V100, P201, DOI 10.1042/BC20070116; NISHINO T, 1995, BLOOD, V85, P3093, DOI 10.1182/blood.V85.11.3093.bloodjournal85113093; Paez-Ribes M, 2009, CANCER CELL, V15, P220, DOI 10.1016/j.ccr.2009.01.027; Paranjpe S, 2007, HEPATOLOGY, V45, P1471, DOI 10.1002/hep.21570; Pennacchietti S, 2003, CANCER CELL, V3, P347, DOI 10.1016/S1535-6108(03)00085-0; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; Prat M, 1998, J CELL SCI, V111, P237; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Sengupta S, 2003, ARTERIOSCL THROM VAS, V23, P69, DOI 10.1161/01.ATV.0000048701.86621.D0; SILVAGNO F, 1995, ARTERIOSCL THROM VAS, V15, P1857, DOI 10.1161/01.ATV.15.11.1857; Stewart KM, 2008, ORG BIOMOL CHEM, V6, P2242, DOI 10.1039/b719950c; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; Vigna E, 2008, CANCER RES, V68, P9176, DOI 10.1158/0008-5472.CAN-08-1688; You WK, 2008, BMB REP, V41, P833, DOI 10.5483/BMBRep.2008.41.12.833; Zhang YW, 2003, P NATL ACAD SCI USA, V100, P12718, DOI 10.1073/pnas.2135113100; Zou HY, 2007, CANCER RES, V67, P4408, DOI 10.1158/0008-5472.CAN-06-4443	69	16	18	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2010	29	38					5286	5298		10.1038/onc.2010.267	http://dx.doi.org/10.1038/onc.2010.267			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	653KE	20603611	Green Submitted, Green Published, hybrid			2022-12-17	WOS:000282089100007
J	Hatton, BA; Villavicencio, EH; Pritchard, J; LeBlanc, M; Hansen, S; Ulrich, M; Ditzler, S; Pullar, B; Stroud, MR; Olson, JM				Hatton, B. A.; Villavicencio, E. H.; Pritchard, J.; LeBlanc, M.; Hansen, S.; Ulrich, M.; Ditzler, S.; Pullar, B.; Stroud, M. R.; Olson, J. M.			Notch signaling is not essential in sonic hedgehog-activated medulloblastoma	ONCOGENE			English	Article						medulloblastoma; notch; sonic hedgehog; gamma secretase inhibitor	GAMMA-SECRETASE INHIBITORS; EMBRYONAL BRAIN-TUMORS; PATHWAY; CELLS; GROWTH; MODEL; CORE; MICE	Dysregulated signal transduction through the notch pathway has been noted in human and mouse medulloblastoma studies. Gamma secretase inhibitors (GSIs) impair notch signaling by preventing the cleavage of transmembrane notch proteins into their active intracellular domain fragments. Previous studies have shown that GSI treatment caused apoptosis and impaired medulloblastoma cell engraftment in xenograft systems. In this study, we used in vivo genetic and pharmacologic approaches to quantify the contribution of notch signaling to sonic hedgehog (shh)-activated mouse medulloblastoma models. In contrast to prior in vitro studies, pharmacologic inhibition of notch pathways did not reduce the efficiency of medulloblastoma xenotransplantation nor did systemic therapy impact tumor size, proliferation, or apoptosis in genetically engineered mouse medulloblastoma models. The incidence and pathology of medulloblastomas driven by the SmoA1 transgene was unchanged by the bi-allelic absence of Notch1, Notch2, or Hes5 genes. These data show that notch signaling is not essential for the initiation, engraftment, or maintenance of sonic hedgehog pathway-driven medulloblastomas. Oncogene (2010) 29, 3865-3872; doi: 10.1038/onc.2010.142; published online 3 May 2010	[Hatton, B. A.; Villavicencio, E. H.; Pritchard, J.; LeBlanc, M.; Hansen, S.; Ulrich, M.; Ditzler, S.; Pullar, B.; Stroud, M. R.; Olson, J. M.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center	Olson, JM (corresponding author), Fred Hutchinson Canc Res Ctr, Div Clin Res, 1100 Fairview Ave N,Mailstop D4-100, Seattle, WA 98109 USA.	jolson@fhcrc.org			NIH [5R01CA112350-04, 5R01CA114567-04, 5T32CA009351, 5K12CA076930]; NATIONAL CANCER INSTITUTE [R01CA114567, T32CA009351, K12CA076930, R01CA112350] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to Dr Francois Guillemot for providing the Hes5-null mice, to Freddy Radtke for the notch1 conditional knockout mice, to Thomas Gridley for the notch2 conditional knockout mice, and to Dr Irwin Bernstein for providing the 18G anti-Notch antibody and advice. The gamma secretase inhibitor MRK-003 was provided by Merck Research Laboratories, which also provided partial funding for the studies. This work was supported by NIH Grants 5R01CA112350-04, 5R01CA114567-04, 5T32CA009351, and 5K12CA076930.	Cau E, 2000, DEVELOPMENT, V127, P2323; Eberhart CG, 2007, NEUROSURG CLIN N AM, V18, P59, DOI 10.1016/j.nec.2006.10.005; Fan X, 2004, CANCER RES, V64, P7787, DOI 10.1158/0008-5472.CAN-04-1446; Fan X, 2006, CANCER RES, V66, P7445, DOI 10.1158/0008-5472.CAN-06-0858; Fortini ME, 2009, DEV CELL, V16, P633, DOI 10.1016/j.devcel.2009.03.010; Gilbertson RJ, 2008, ANNU REV PATHOL-MECH, V3, P341, DOI 10.1146/annurev.pathmechdis.3.121806.151518; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Hallahan AR, 2004, CANCER RES, V64, P7794, DOI 10.1158/0008-5472.CAN-04-1813; Hatton BA, 2008, CANCER RES, V68, P1768, DOI 10.1158/0008-5472.CAN-07-5092; Ingram WJ, 2008, ONCOGENE, V27, P1489, DOI 10.1038/sj.onc.1210767; Julian E, 2010, ONCOGENE, V29, P3465, DOI 10.1038/onc.2010.101; Lewis SJ, 2005, BIOORG MED CHEM LETT, V15, P373, DOI 10.1016/j.bmcl.2004.10.062; McCright B, 2006, GENESIS, V44, P29, DOI 10.1002/gene.20181; Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a; Radtke F, 1999, IMMUNITY, V10, P547, DOI 10.1016/S1074-7613(00)80054-0; Sasai K, 2006, CANCER RES, V66, P4215, DOI 10.1158/0008-5472.CAN-05-4505; Schouwey K, 2008, HISTOL HISTOPATHOL, V23, P609, DOI 10.14670/HH-23.609; Solecki DJ, 2001, NEURON, V31, P557, DOI 10.1016/S0896-6273(01)00395-6; Sparey T, 2005, BIOORG MED CHEM LETT, V15, P4212, DOI 10.1016/j.bmcl.2005.06.084; Wall DS, 2009, J CELL BIOL, V184, P101, DOI 10.1083/jcb.200805155; Weiner HL, 2002, CANCER RES, V62, P6385; Zeltzer PM, 1999, J CLIN ONCOL, V17, P832, DOI 10.1200/JCO.1999.17.3.832	22	16	16	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 1	2010	29	26					3865	3872		10.1038/onc.2010.142	http://dx.doi.org/10.1038/onc.2010.142			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	618VW	20440271	Green Accepted			2022-12-17	WOS:000279385200014
J	Li, Z; Zhang, Q; Mao, JH; Weise, A; Mrasek, K; Fan, X; Zhang, X; Liehr, T; Lu, KH; Balmain, A; Cai, WW				Li, Z.; Zhang, Q.; Mao, J-H; Weise, A.; Mrasek, K.; Fan, X.; Zhang, X.; Liehr, T.; Lu, K. H.; Balmain, A.; Cai, W-W			An HDAC1-binding domain within FATS bridges p21 turnover to radiation-induced tumorigenesis	ONCOGENE			English	Article						radiation; p21; acetylation; carcinogenesis	HISTONE-DEACETYLASE INHIBITORS; FRAGILE SITE FRA16D; REPEAT INSTABILITY; IONIZING-RADIATION; BREAST-CANCER; DEGRADATION; EXPRESSION; COMMON; ATM; P53	There is a gap between the initial formation of cells carrying radiation-induced genetic damage and their contribution to cancer development. Herein, we reveal a previously uncharacterized gene FATS through a genome-wide approach and demonstrate its essential role in regulating the abundance of p21 in surveillance of genome integrity. A large exon coding the NH2-terminal domain of FATS, deleted in spontaneous mouse lymphomas, is much more frequently deleted in radiation-induced mouse lymphomas. Its human counterpart is a fragile site gene at a previously identified loss of heterozygosity site. FATS is essential for maintaining steady-state level of p21 protein and sustaining DNA damage checkpoint. Furthermore, the NH2-terminal FATS physically interacts with histone deacetylase 1 (HDAC1) to enhance the acetylation of endogenous p21, leading to the stabilization of p21. Our results reveal a molecular linkage between p21 abundance and radiation-induced carcinogenesis. Oncogene (2010) 29, 2659-2671; doi:10.1038/onc.2010.19; published online 15 February 2010	[Li, Z.; Fan, X.; Zhang, X.; Liehr, T.] Tianjin Med Univ, Canc Inst & Hosp, Dept Biochem & Mol Biol, Key Lab,Minist Educ Breast Canc Prevent & Treatme, Tianjin 300030, Peoples R China; [Zhang, Q.; Lu, K. H.] Univ Texas Houston, MD Anderson Canc Ctr, Dept Gynecol Oncol, Houston, TX 77030 USA; [Mao, J-H; Balmain, A.] Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94143 USA; [Weise, A.; Mrasek, K.; Liehr, T.] Inst Human Genet & Anthropol, Jena, Germany; [Cai, W-W] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA	Tianjin Medical University; University of Texas System; University of Texas Health Science Center Houston; UTMD Anderson Cancer Center; University of California System; University of California San Francisco; Baylor College of Medicine	Li, Z (corresponding author), Tianjin Med Univ, Canc Inst & Hosp, Dept Biochem & Mol Biol, Key Lab,Minist Educ Breast Canc Prevent & Treatme, Huan Hu Xi Rd, Tianjin 300030, Peoples R China.	zhengli@tijmu.edu.cn	Weise, Anja/H-6669-2019; Mao, Jian-Hua/EIZ-8595-2022; Liehr, Thomas/H-2852-2019	Weise, Anja/0000-0003-3988-8919; Mao, Jian-Hua/0000-0001-9320-6021; Liehr, Thomas/0000-0003-1672-3054	Tianjin Medical University Cancer Institute and Hospital [08Y01]; Ministry of Science and Technology of China 973 [2009CB526407]; Tianjin Municipal Science and Technology Foundation; Department of defense of United States [FG02-03ER63630]; IZKF Jena Start-up S16	Tianjin Medical University Cancer Institute and Hospital; Ministry of Science and Technology of China 973(Ministry of Science and Technology, ChinaNational Basic Research Program of China); Tianjin Municipal Science and Technology Foundation; Department of defense of United States(United States Department of Defense); IZKF Jena Start-up S16	We are grateful to Mien-Chi Hung for critical discussions. We thank Xiangwei He and Qi Gao for assistance in microscopic imaging; Tao Jiang and Qian Li for technical assistance. This study was supported in part by the following grants: Tianjin Medical University Cancer Institute and Hospital Start-up 08Y01 (to Z Li); Ministry of Science and Technology of China 973-program Concept Award 2009CB526407 (to Z Li); Tianjin Municipal Science and Technology Foundation ( to Z Li); Department of defense of United States FG02-03ER63630 (to A Balmain); IZKF Jena Start-up S16 (to T Liehr).	Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Barboza JA, 2006, P NATL ACAD SCI USA, V103, P19842, DOI 10.1073/pnas.0606343104; Bendjennat M, 2003, CELL, V114, P599, DOI 10.1016/j.cell.2003.08.001; Bichara M, 2006, MUTAT RES-FUND MOL M, V598, P144, DOI 10.1016/j.mrfmmm.2006.01.020; Bloom J, 2003, CELL, V115, P71, DOI 10.1016/S0092-8674(03)00755-4; Brenner DJ, 2003, P NATL ACAD SCI USA, V100, P13761, DOI 10.1073/pnas.2235592100; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Buttel I, 2004, ANN NY ACAD SCI, V1028, P14, DOI 10.1196/annals.1322.002; Cai WW, 2002, NAT BIOTECHNOL, V20, P393, DOI 10.1038/nbt0402-393; Casper AM, 2002, CELL, V111, P779, DOI 10.1016/S0092-8674(02)01113-3; Cen B, 2008, CANCER RES, V68, P5355, DOI 10.1158/0008-5472.CAN-07-6869; Chen XY, 2007, MOL CELL, V26, P843, DOI 10.1016/j.molcel.2007.05.022; Chen XY, 2004, MOL CELL, V16, P839, DOI 10.1016/j.molcel.2004.11.011; Coulombe P, 2004, MOL CELL BIOL, V24, P6140, DOI 10.1128/MCB.24.14.6140-6150.2004; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Dokmanovic M, 2007, MOL CANCER RES, V5, P981, DOI 10.1158/1541-7786.MCR-07-0324; Durkin SG, 2007, ANNU REV GENET, V41, P169, DOI 10.1146/annurev.genet.41.042007.165900; Efeyan A, 2007, ONCOGENE, V26, P1645, DOI 10.1038/sj.onc.1209972; Glover TW, 2005, HUM MOL GENET, V14, pR197, DOI 10.1093/hmg/ddi265; HOLM LE, 1990, INT J RADIAT ONCOL, V19, P1303, DOI 10.1016/0360-3016(90)90249-J; HOPPESEYLER F, 1993, J VIROL, V67, P3111, DOI 10.1128/JVI.67.6.3111-3117.1993; Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; KEMP CJ, 1994, NAT GENET, V8, P66, DOI 10.1038/ng0994-66; Kim GD, 1999, J BIOL CHEM, V274, P31127, DOI 10.1074/jbc.274.44.31127; Lagger G, 2002, EMBO J, V21, P2672, DOI 10.1093/emboj/21.11.2672; Li XT, 2007, MOL CELL, V26, P831, DOI 10.1016/j.molcel.2007.05.028; Li Z, 2004, CANCER RES, V64, P9080, DOI 10.1158/0008-5472.CAN-04-2419; Liehr Thomas, 2002, Expert Rev Mol Diagn, V2, P217, DOI 10.1586/14737159.2.3.217; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Magrath IT, 1997, ANN ONCOL, V8, P7, DOI 10.1023/A:1008225127815; Maier D, 1997, ONCOGENE, V15, P997, DOI 10.1038/sj.onc.1201209; Mangelsdorf M, 2000, CANCER RES, V60, P1683; Mao JH, 2005, ONCOGENE, V24, P7924, DOI 10.1038/sj.onc.1208926; Martin-Caballero J, 2001, CANCER RES, V61, P6234; Maser RS, 2002, SCIENCE, V297, P565, DOI 10.1126/science.297.5581.565; Nagase S, 1997, CANCER RES, V57, P1630; Ohi R, 1999, CURR OPIN CELL BIOL, V11, P267, DOI 10.1016/S0955-0674(99)80036-2; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Pearson CE, 2005, NAT REV GENET, V6, P729, DOI 10.1038/nrg1689; Rouse J, 2002, SCIENCE, V297, P547, DOI 10.1126/science.1074740; Schellong G, 1998, ANN ONCOL, V9, P115, DOI 10.1023/A:1008482728545; Schwartz M, 2006, CANCER LETT, V232, P13, DOI 10.1016/j.canlet.2005.07.039; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Touitou R, 2001, EMBO J, V20, P2367, DOI 10.1093/emboj/20.10.2367; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; Varshavsky A, 2000, BIOL CHEM, V381, P779, DOI 10.1515/BC.2000.101; Wei Q, 2003, MOL CELL BIOL, V23, P4035, DOI 10.1128/MCB.23.12.4035-4045.2003; Winters ZE, 2003, BREAST CANCER RES, V5, pR242, DOI 10.1186/bcr654; Xia WY, 2004, CLIN CANCER RES, V10, P3815, DOI 10.1158/1078-0432.CCR-03-0527; Zhang H, 2007, MOL CELL, V27, P367, DOI 10.1016/j.molcel.2007.06.012; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032; Zupkovitz G, 2006, MOL CELL BIOL, V26, P7913, DOI 10.1128/MCB.01220-06	58	16	22	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2010	29	18					2659	2671		10.1038/onc.2010.19	http://dx.doi.org/10.1038/onc.2010.19			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	592DC	20154723				2022-12-17	WOS:000277354600006
J	Meunier, C; Cai, J; Fortin, A; Kwan, T; Marquis, JF; Turbide, C; Van der Kraak, L; Jothy, S; Beauchemin, N; Gros, P				Meunier, C.; Cai, J.; Fortin, A.; Kwan, T.; Marquis, J-F; Turbide, C.; Van der Kraak, L.; Jothy, S.; Beauchemin, N.; Gros, P.			Characterization of a major colon cancer susceptibility locus (Ccs3) on mouse chromosome 3	ONCOGENE			English	Article						colon cancer; Ccs3; genetics; azoxymethane; gene mapping	GENOME-WIDE ASSOCIATION; COPY NUMBER ANALYSIS; NF-KAPPA-B; COLORECTAL-CANCER; TUMOR SUSCEPTIBILITY; GENETIC-CONTROL; MICE; CARCINOGENESIS; AZOXYMETHANE; COMPLEX	Treatment of mice with the carcinogen azoxymethane (AOM) induces a number of lesions in the colon, including hyperplastic lesions, as well adenomas and carcinomas in situ. Inbred strains of mice show different responses to AOM-induced carcinogenesis. A/J mice are highly susceptible and develop a greater number of hyperplastic lesions and tumors (15-70 tumors per mouse) than resistant C57BL/6J mice (0-6 tumors per mouse). Susceptibility to AOM-induced tumors segregates as a co-dominant trait in (A x B6)F1 hybrids. Using a set of 23 AcB and BcA recombinant congenic mouse strains derived from A/J (susceptible) and B6 (resistant) parents, we observed that the number of hyperplastic lesions and tumors induced by AOM was under different genetic controls in AcB/BcA strains. The multiplicity of AOM-induced tumors is controlled by a major locus that we have mapped on the distal portion of chromosome 3, to which we have given the temporary designation colon cancer susceptibility locus 3 (Ccs3). B6 and A/J alleles at Ccs3 are associated with resistance and susceptibility, respectively. Haplotype analysis in key informative AcB/BcA strains restricts the size of the Ccs3 locus to a 14Mb segment that contains 94 annotated genes. The expression level of all these genes in normal colon has been established by transcript profiling with microarrays, and has led to the identification of a subset of positional candidates that are expressed at high levels in this tissue. The 4q and 1p human chromosomal segments sharing syntenic homology with the mouse Ccs3 segment are known to be associated with inflammatory bowel diseases and colorectal tumors in humans, suggesting that the study of the mouse Ccs3 locus may help further the pathogenesis of these human conditions. Oncogene (2010) 29, 647-661; doi: 10.1038/onc.2009.369; published online 16 November 2009	[Meunier, C.; Cai, J.; Fortin, A.; Marquis, J-F; Van der Kraak, L.; Beauchemin, N.; Gros, P.] McGill Univ, Dept Biochem, Quebec City, PQ H3G 0B1, Canada; [Fortin, A.] Dafra Pharma Int, Turnhout, Belgium; [Kwan, T.] McGill Univ, Genome Quebec Innovat Ctr, Quebec City, PQ H3G 0B1, Canada; [Turbide, C.; Beauchemin, N.; Gros, P.] McGill Univ, Goodman Canc Ctr, Quebec City, PQ H3G 0B1, Canada; [Jothy, S.] St Michaels Hosp, Dept Lab Med & Pathobiol, Toronto, ON M5B 1W8, Canada; [Jothy, S.] Univ Toronto, Toronto, ON M5B 1W8, Canada	McGill University; McGill University; McGill University; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto	Gros, P (corresponding author), McGill Univ, Dept Biochem, McGill Life Sci Complex,Bellini Pavil,Room 366,36, Quebec City, PQ H3G 0B1, Canada.	philippe.gros@mcgill.ca			National Cancer Institute of Canada; Goodman Cancer Centre	National Cancer Institute of Canada(Canadian Cancer Society (CCS)); Goodman Cancer Centre	We thank George Chountalos for his work in the haplotype mapping of the genetic interval of Ccs3 in common mouse strains. This work was supported by research grants to PG and NB from the National Cancer Institute of Canada and the Canderel Initiative Program of the Goodman Cancer Centre. PG is a James McGill professor of biochemistry.	AKAGI K, 2004, NUCLEIC ACIDS RES, V32, pD253; Angel JM, 2000, MOL CARCINOGEN, V27, P47, DOI 10.1002/(SICI)1098-2744(200001)27:1<47::AID-MC7>3.0.CO;2-7; Barrett JC, 2008, NAT GENET, V40, P955, DOI 10.1038/ng.175; Cho JH, 1998, P NATL ACAD SCI USA, V95, P7502, DOI 10.1073/pnas.95.13.7502; Cianciulli A, 2004, CANCER GENET CYTOGEN, V151, P52, DOI 10.1016/j.cancergencyto.2003.09.013; Couturier-Turpin MH, 2001, CANCER GENET CYTOGEN, V124, P47, DOI 10.1016/S0165-4608(00)00325-3; de la Chapelle A, 2004, NAT REV CANCER, V4, P769, DOI 10.1038/nrc1453; Demant P, 2003, NAT REV GENET, V4, P721, DOI 10.1038/nrg1157; DESCHNER EE, 1988, CANCER, V61, P478, DOI 10.1002/1097-0142(19880201)61:3<478::AID-CNCR2820610312>3.0.CO;2-A; Dragani TA, 2003, CANCER RES, V63, P3011; EVANS JT, 1977, CANCER RES, V37, P134; FIJNEMAN RJA, 1995, CANCER RES, V55, P3179; Fortin A, 2001, GENOMICS, V74, P21, DOI 10.1006/geno.2001.6528; Fortin Anny, 2007, Novartis Found Symp, V281, P141; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Gross O, 2008, BLOOD, V112, P2421, DOI 10.1182/blood-2007-11-123513; Herath NI, 2006, J GASTROEN HEPATOL, V21, P15, DOI 10.1111/j.1440-1746.2005.04043.x; Houlston RS, 2008, NAT GENET, V40, P1426, DOI 10.1038/ng.262; JACOBY RF, 1994, GENOMICS, V22, P381, DOI 10.1006/geno.1994.1399; Jaeger E, 2008, NAT GENET, V40, P26, DOI 10.1038/ng.2007.41; Karin M, 2008, CELL RES, V18, P334, DOI 10.1038/cr.2008.30; Kurashina K, 2008, CANCER SCI, V99, P1835, DOI 10.1111/j.1349-7006.2008.00881.x; LOTHE RA, 1995, GENE CHROMOSOME CANC, V14, P182, DOI 10.1002/gcc.2870140305; MALO D, 1994, GENOMICS, V23, P51, DOI 10.1006/geno.1994.1458; Manly KF, 2001, MAMM GENOME, V12, P930, DOI 10.1007/s00335-001-1016-3; Min-Oo G, 2003, NAT GENET, V35, P357, DOI 10.1038/ng1260; Min-Oo G, 2007, J EXP MED, V204, P511, DOI 10.1084/jem.20061252; Moen CJA, 1996, P NATL ACAD SCI USA, V93, P1082, DOI 10.1073/pnas.93.3.1082; Nambiar PR, 2003, INT J ONCOL, V22, P145; Nancarrow DJ, 2008, CANCER RES, V68, P4163, DOI 10.1158/0008-5472.CAN-07-6710; Pacifico F, 2006, BIOCHEM PHARMACOL, V72, P1142, DOI 10.1016/j.bcp.2006.07.032; Papanikolaou A, 1998, CANCER LETT, V130, P29, DOI 10.1016/S0304-3835(98)00101-3; Rajagopalan H, 2003, NAT REV CANCER, V3, P695, DOI 10.1038/nrc1165; Ruivenkamp C, 2003, ONCOGENE, V22, P3472, DOI 10.1038/sj.onc.1206246; Shih IM, 2001, CANCER RES, V61, P818; Stork PJS, 2005, BLOOD, V106, P2952, DOI 10.1182/blood-2005-03-1062; Stork PJS, 2003, TRENDS BIOCHEM SCI, V28, P267, DOI 10.1016/S0968-0004(03)00087-2; Suzui M, 2002, CANCER LETT, V183, P31, DOI 10.1016/S0304-3835(02)00114-3; Takahashi M, 2004, CANCER SCI, V95, P475, DOI 10.1111/j.1349-7006.2004.tb03235.x; Tenesa A, 2008, NAT GENET, V40, P631, DOI 10.1038/ng.133; Thome M, 2004, NAT REV IMMUNOL, V4, P348, DOI 10.1038/nri1352; Tomlinson I, 2007, NAT GENET, V39, P984, DOI 10.1038/ng2085; Tomlinson IPM, 2008, NAT GENET, V40, P623, DOI 10.1038/ng.111; Tuite A, 2005, GENES IMMUN, V6, P672, DOI 10.1038/sj.gene.6364254; vanWezel T, 1996, NAT GENET, V14, P468, DOI 10.1038/ng1296-468; Willis TG, 1999, CELL, V96, P35, DOI 10.1016/S0092-8674(00)80957-5; Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720; Xue LQ, 2003, NAT IMMUNOL, V4, P857, DOI 10.1038/ni963; Zanke BW, 2007, NAT GENET, V39, P989, DOI 10.1038/ng2089	49	16	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2010	29	5					647	661		10.1038/onc.2009.369	http://dx.doi.org/10.1038/onc.2009.369			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	551QI	19915610				2022-12-17	WOS:000274223700003
J	Sowalsky, AG; Alt-Holland, A; Shamis, Y; Garlick, JA; Feig, LA				Sowalsky, A. G.; Alt-Holland, A.; Shamis, Y.; Garlick, J. A.; Feig, L. A.			RalA suppresses early stages of Ras-induced squamous cell carcinoma progression	ONCOGENE			English	Article						Ral; Ras; squamous cell carcinoma; E-cadherin; tumor progression	EXOCYST COMPLEX; CANCER; GTPASES; RAIA; SKIN; ACTIVATION; EXPRESSION; GROWTH; IDENTIFICATION; PROLIFERATION	Ras proteins activate Raf and PI-3 kinases, as well as exchange factors for RalA and RalB GTPases. Many previous studies have reported that the Ral-signaling cascade contributes positively to Ras-mediated oncogenesis. Here, using a bioengineered tissue model of early steps in Ras-induced human squamous cell carcinoma of the skin, we found the opposite. Conversion of Ras-expressing keratinocytes from a premalignant to malignant state induced by decreasing E-cadherin function was associated with and required an approximately two to threefold decrease in RalA expression. Moreover, direct knockdown of RalA to a similar degree by shRNA expression in these cells reduced E-cadherin levels and also induced progression to a malignant phenotype. Knockdown of the Ral effector, Exo84, mimicked the effects of decreasing RalA levels in these engineered tissues. These phenomena can be explained by our finding that the stability of E-cadherin in Ras-expressing keratinocytes depends upon this RalA signaling cascade. These results imply that an important component of the early stages in squamous carcinoma progression may be a modest decrease in RalA gene expression that magnifies the effects of decreased E-cadherin expression by promoting its degradation.	[Sowalsky, A. G.; Feig, L. A.] Tufts Univ, Dept Biochem, Sch Med, Boston, MA 02111 USA; [Sowalsky, A. G.; Shamis, Y.; Feig, L. A.] Tufts Univ, Sackler Sch Grad Biomed Sci, Sch Med, Boston, MA 02111 USA; [Alt-Holland, A.] Tufts Univ, Dept Endodont, Sch Dent Med, Boston, MA 02111 USA; [Garlick, J. A.] Tufts Univ, Dept Oral & Maxillofacial Pathol, Sch Dent Med, Boston, MA 02111 USA	Tufts University; Tufts University; Tufts University; Tufts University	Feig, LA (corresponding author), Tufts Univ, Dept Biochem, Sch Med, 136 Harrison Ave, Boston, MA 02111 USA.	larry.feig@tufts.edu	Sowalsky, Adam/K-1485-2013	Sowalsky, Adam/0000-0003-2760-1853	NIGMS; NIDCR; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047717, R56GM047717] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH083324] Funding Source: NIH RePORTER	NIGMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDCR(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	We thank MW Carlson, Y Szwec-Levin, S Ezell, T DesRochers and S Dong for excellent technical assistance. This work was supported by grants to LAF from NIGMS and to JAG from NIDCR. We thank N Fusenig for HaCaT cells and their derivatives and F Watt for the H-2K<SUP>d</SUP>-Ecad vectors.	BAILLEUL B, 1990, CELL, V62, P697, DOI 10.1016/0092-8674(90)90115-U; Bodemann BO, 2008, NAT REV CANCER, V8, P133, DOI 10.1038/nrc2296; Brymora A, 2001, J BIOL CHEM, V276, P29792, DOI 10.1074/jbc.C100320200; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; Carlson Mark W, 2008, Curr Protoc Cell Biol, VChapter 19, DOI 10.1002/0471143030.cb1909s41; Cascone I, 2008, EMBO J, V27, P2375, DOI 10.1038/emboj.2008.166; Chen XW, 2006, J BIOL CHEM, V281, P38609, DOI 10.1074/jbc.M512847200; Chien YC, 2003, EMBO REP, V4, P800, DOI 10.1038/sj.embor.embor899; Chien YC, 2006, CELL, V127, P157, DOI 10.1016/j.cell.2006.08.034; Dajee M, 2003, NATURE, V421, P639, DOI 10.1038/nature01283; Dlugosz A, 2002, J INVEST DERM SYMP P, V7, P17, DOI 10.1046/j.1523-1747.2002.19631.x; Feig LA, 2003, TRENDS CELL BIOL, V13, P419, DOI 10.1016/S0962-8924(03)00152-1; FENWICK R, 2009, BIOCHEMISTRY; Frankel P, 2005, EMBO J, V24, P54, DOI 10.1038/sj.emboj.7600497; Garlick JA, 2007, ADV BIOCHEM ENG BIOT, V103, P207; Ginos MA, 2004, CANCER RES, V64, P55, DOI 10.1158/0008-5472.CAN-03-2144; Gonzalez-Garcia A, 2005, CANCER CELL, V7, P219, DOI 10.1016/j.ccr.2005.01.029; Greenberg S, 2004, METH MOL B, V289, P425; Hamad NM, 2002, GENE DEV, V16, P2045, DOI 10.1101/gad.993902; Hao YS, 2008, MOL CELL BIOL, V28, P2851, DOI 10.1128/MCB.01917-07; Hsu SC, 2004, INT REV CYTOL, V233, P243, DOI 10.1016/S0074-7696(04)33006-8; Jeanes A, 2008, ONCOGENE, V27, P6920, DOI 10.1038/onc.2008.343; JULLIENFLORES V, 1995, J BIOL CHEM, V270, P22473, DOI 10.1074/jbc.270.38.22473; Kudo Y, 2003, ORAL ONCOL, V39, P515, DOI 10.1016/S1368-8375(03)00015-0; Lim KH, 2005, CANCER CELL, V7, P533, DOI 10.1016/j.ccr.2005.04.030; Lim KH, 2006, CURR BIOL, V16, P2385, DOI 10.1016/j.cub.2006.10.023; Margulis A, 2004, METH MOL B, V289, P61; Margulis A, 2005, CANCER RES, V65, P1783, DOI 10.1158/0008-5472.CAN-04-3399; Moskalenko S, 2003, J BIOL CHEM, V278, P51743, DOI 10.1074/jbc.M308702200; Moskalenko S, 2002, NAT CELL BIOL, V4, P66, DOI 10.1038/ncb728; Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938; Oxford G, 2005, CANCER RES, V65, P7111, DOI 10.1158/0008-5472.CAN-04-1957; Panner A, 2006, MOL CELL BIOL, V26, P7345, DOI 10.1128/MCB.00126-06; PIERCEALL WE, 1991, MOL CARCINOGEN, V4, P196, DOI 10.1002/mc.2940040306; Polzin A, 2002, MOL CELL BIOL, V22, P1714, DOI 10.1128/MCB.22.6.1714-1722.2002; Pons M, 2006, Clin Transl Oncol, V8, P466, DOI 10.1007/s12094-006-0046-4; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Rosse C, 2006, MOL CELL BIOL, V26, P727, DOI 10.1128/MCB.26.2.727-734.2006; Sablina AA, 2007, CELL, V129, P969, DOI 10.1016/j.cell.2007.03.047; Shipitsin M, 2004, MOL CELL BIOL, V24, P5746, DOI 10.1128/MCB.24.13.5746-5756.2004; Singhal SS, 2005, BIOCHEM PHARMACOL, V70, P481, DOI 10.1016/j.bcp.2005.05.005; Smith SC, 2007, CLIN CANCER RES, V13, P3803, DOI 10.1158/1078-0432.CCR-06-2419; Sugihara K, 2002, NAT CELL BIOL, V4, P73, DOI 10.1038/ncb720; Sugita S, 2008, ACTA PHYSIOL, V192, P185, DOI 10.1111/j.1748-1716.2007.01803.x; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Zhu AJ, 1996, J CELL SCI, V109, P3013	47	16	17	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2010	29	1					45	55		10.1038/onc.2009.307	http://dx.doi.org/10.1038/onc.2009.307			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540XE	19802010	Green Accepted			2022-12-17	WOS:000273373500005
J	Mira, A; Isella, C; Renzulli, T; Cantarella, D; Martelli, ML; Medico, E				Mira, A.; Isella, C.; Renzulli, T.; Cantarella, D.; Martelli, M. L.; Medico, E.			The GAB2 signaling scaffold promotes anchorage independence and drives a transcriptional response associated with metastatic progression of breast cancer	ONCOGENE			English	Article						Gab2; anchorage independence; metastasis; microarray; breast cancer	RECEPTOR TYROSINE KINASE; PROGNOSTIC SIGNATURE; EXPRESSION SIGNATURE; HEMATOPOIETIC-CELLS; HISTOLOGIC GRADE; PROTEIN GAB2; GROWTH; SRC; ACTIVATION; INTEGRINS	Acquisition of independence from anchorage to the extracellular matrix is a critical event for onset and progression of solid cancers. To identify and characterize new genes conferring anchorage independence, we transduced MCF10A human normal breast cells with a retroviral cDNA expression library and selected them by growth in suspension. Microarray analysis targeted on library-derived transcripts revealed robust and reproducible enrichment, after selection, of cDNAs encoding the scaffolding adaptor Gab2. Gab2 was confirmed to strongly promote anchorage-independent growth when overexpressed. Interestingly, downregulation by RNA interference of endogenous Gab2 in neoplastic cells did not affect their adherent growth, but abrogated their growth in soft agar. Gab2-driven anchorage independence was found to specifically involve activation of the Src-Stat3 signaling axis. A transcriptional 'signature' of 205 genes was obtained from GAB2-transduced, anchorage-independent MCF10A cells, and found to contain two main functional modules, controlling proliferation and cell adhesion/migration/invasion, respectively. Extensive validation on breast cancer data sets showed that the GAB2 signature provides a robust prognostic classifier for breast cancer metastatic relapse, largely independent from existing clinical and genomic indicators and from estrogen receptor status. This work highlights a pivotal role for GAB2 and its transcriptional targets in anchorage-independent growth and breast cancer metastatic progression. Oncogene (2009) 28, 4444-4455; doi:10.1038/onc.2009.296; published online 19 October 2009	[Medico, E.] Univ Torino, Dept Oncol Sci, Inst Canc Res & Treatment, Sch Med, I-10060 Turin, Italy; Univ Torino, Lab Funct Genom, Inst Canc Res & Treatment, Sch Med, I-10060 Turin, Italy	University of Turin; University of Turin	Medico, E (corresponding author), Univ Torino, Dept Oncol Sci, Inst Canc Res & Treatment, Sch Med, Str Prov 142,Km 3,95, I-10060 Turin, Italy.	enzo.medico@ircc.it	Medico, Enzo/AAC-3185-2021; Isella, Claudio/F-7327-2012	Medico, Enzo/0000-0002-3917-2438; Isella, Claudio/0000-0003-0679-4756; CANTARELLA, DANIELA/0000-0001-6135-2032; Mira, Alessia/0000-0002-8456-8159	AIRC; EC [503438]; CNR-MIUR; FIRB-MIUR; Ministero della Salute, Regione Piemonte; Foundations CRT and 'Compagnia di San Paolo'	AIRC(Fondazione AIRC per la ricerca sul cancro); EC(European CommissionEuropean Commission Joint Research Centre); CNR-MIUR(Ministry of Education, Universities and Research (MIUR)Consiglio Nazionale delle Ricerche (CNR)); FIRB-MIUR(Ministry of Education, Universities and Research (MIUR)Fund for Investment in Basic Research (FIRB)); Ministero della Salute, Regione Piemonte(Regione PiemonteMinistry of Health, Italy); Foundations CRT and 'Compagnia di San Paolo'(Compagnia di San Paolo)	We thank Barbara Martinoglio and Roberta Porporato for technical assistance. We thank Simona Destefanis, Antonella Cignetto and Michela Bruno for secretarial assistance. This research was supported by grants from AIRC, the EC (contract no. 503438 'TRANSFOG'), CNR-MIUR, FIRB-MIUR, Ministero della Salute, Regione Piemonte and the Foundations CRT and 'Compagnia di San Paolo.'	Ariga N, 2001, INT J CANCER, V95, P67, DOI 10.1002/1097-0215(20010120)95:1<67::AID-IJC1012>3.0.CO;2-U; Bennett HL, 2008, ONCOGENE, V27, P2693, DOI 10.1038/sj.onc.1210928; Berrier AL, 2007, J CELL PHYSIOL, V213, P565, DOI 10.1002/jcp.21237; Bouscary D, 2001, ONCOGENE, V20, P2197, DOI 10.1038/sj.onc.1204317; Brummer T, 2006, J BIOL CHEM, V281, P626, DOI 10.1074/jbc.M509567200; Buyse M, 2006, JNCI-J NATL CANCER I, V98, P1183, DOI 10.1093/jnci/djj329; Cooley J, 2001, BIOCHEMISTRY-US, V40, P15762, DOI 10.1021/bi0113925; Daly RJ, 2002, ONCOGENE, V21, P5175, DOI 10.1038/sj.onc.1205522; Danen EHJ, 2001, J CELL PHYSIOL, V189, P1, DOI 10.1002/jcp.1137; Debnath J, 2005, NAT REV CANCER, V5, P675, DOI 10.1038/nrc1695; DerMardirossian C, 2005, TRENDS CELL BIOL, V15, P356, DOI 10.1016/j.tcb.2005.05.001; Desmedt C, 2007, CLIN CANCER RES, V13, P3207, DOI 10.1158/1078-0432.CCR-06-2765; ffrench-Constant C, 2004, TRENDS CELL BIOL, V14, P678, DOI 10.1016/j.tcb.2004.10.005; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; Geiger TR, 2007, CANCER RES, V67, P6221, DOI 10.1158/0008-5472.CAN-07-0121; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Hess Viviane, 2008, Ther Umsch, V65, P201, DOI 10.1024/0040-5930.65.4.201; Horst B, 2009, AM J PATHOL, V174, P1524, DOI 10.2353/ajpath.2009.080543; Ivshina AV, 2006, CANCER RES, V66, P10292, DOI 10.1158/0008-5472.CAN-05-4414; Ke Y, 2007, ONCOGENE, V26, P4951, DOI 10.1038/sj.onc.1210315; Kitamura T, 2003, EXP HEMATOL, V31, P1007, DOI 10.1016/j.exphem.2003.07.005; Kong M, 2003, J BIOL CHEM, V278, P5837, DOI 10.1074/jbc.M208286200; Laird AD, 2003, MOL CANCER THER, V2, P461; Liu Y, 2001, MOL CELL BIOL, V21, P3047, DOI 10.1128/MCB.21.9.3047-3056.2001; Martelli ML, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-254; Mason JM, 2006, TRENDS CELL BIOL, V16, P45, DOI 10.1016/j.tcb.2005.11.004; Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102; Miranti CK, 2002, NAT CELL BIOL, V4, pE83, DOI 10.1038/ncb0402-e83; Ni S, 2007, MOL CELL BIOL, V27, P3708, DOI 10.1128/MCB.01838-06; Nishida K, 1999, BLOOD, V93, P1809, DOI 10.1182/blood.V93.6.1809.406k35_1809_1816; Playford MP, 2004, ONCOGENE, V23, P7928, DOI 10.1038/sj.onc.1208080; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; Roux KJ, 2005, MOL BIOL CELL, V16, P1142, DOI 10.1091/mbc.E04-07-0551; Sattler M, 2002, CANCER CELL, V1, P479, DOI 10.1016/S1535-6108(02)00074-0; Schwartz MA, 1999, CURR OPIN CELL BIOL, V11, P197, DOI 10.1016/S0955-0674(99)80026-X; Sotiriou C, 2006, JNCI-J NATL CANCER I, V98, P262, DOI 10.1093/jnci/djj052; SOULE HD, 1990, CANCER RES, V50, P6075; TIRESALJ M, 2006, NAT MED, V12, P114; Tsatsanis C, 2004, ANN NY ACAD SCI, V1028, P168, DOI 10.1196/annals.1322.019; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Wessels LFA, 2005, BIOINFORMATICS, V21, P3755, DOI 10.1093/bioinformatics/bti429; Wirapati P, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2124; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Yu M, 2006, J BIOL CHEM, V281, P28615, DOI 10.1074/jbc.M603742200; Yuan K, 2008, PATHOL ONCOL RES, V14, P145, DOI 10.1007/s12253-008-9036-x; Zatkova A, 2006, GENE CHROMOSOME CANC, V45, P798, DOI 10.1002/gcc.20344; Zhang SQ, 2004, MOL CELL, V13, P341, DOI 10.1016/S1097-2765(04)00050-4; Zhang X, 2006, J COSMOL ASTROPART P, DOI 10.1088/1475-7516/2005/01/003	51	16	17	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 17	2009	28	50					4444	4455		10.1038/onc.2009.296	http://dx.doi.org/10.1038/onc.2009.296			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	534DU	19838208	Green Submitted			2022-12-17	WOS:000272876500004
J	Chang, YC; Tien, SC; Tien, HF; Zhang, H; Bokoch, GM; Chang, ZF				Chang, Y-C; Tien, S-C; Tien, H-F; Zhang, H.; Bokoch, G. M.; Chang, Z-F			p210(Bcr-Abl) desensitizes Cdc42 GTPase signaling for SDF-1 alpha-directed migration in chronic myeloid leukemia cells	ONCOGENE			English	Article						chronic myeloid leukemia (CML); p210(Bcr-Abl); Cdc42, chemotaxis; stromal-derived factor-1 alpha (SDF-1 alpha)	CHRONIC MYELOGENOUS LEUKEMIA; TYROSINE PHOSPHORYLATION; CHEMOTACTIC RESPONSE; BCR-ABL; PHILADELPHIA-CHROMOSOME; PROTOONCOGENE VAV; STRUCTURAL BASIS; ACTIVATION; INDUCTION; BCR/ABL	Chronic myeloid leukemia (CML) is a lethal hematological disorder caused by the p210(Bcr-Abl) oncogene. Previous studies have suggested that p210(Bcr-Abl) transformation contributes to homing and retention defects, typical of immature myeloid cells in CML, by attenuating chemotactic response to stromal-derived factor-1 alpha (SDF-1 alpha). As Rho family GTPases are key regulators of the cytoskeleton and have been previously found to interact with p210(Bcr-Abl), this study aimed to determine whether p210(Bcr-Abl) signaling affects SDF-1 alpha chemotaxis through Rho GTPase signaling. We found that SDF-1 alpha stimulated Cdc42 GTPase activation in myeloid progenitor 32D, but not in p210(BcrAbl)-transformed (32Dp210) cells. In fact, the basal level of active Cdc42 was elevated in 32Dp210 cells and mononuclear cells isolated from bone marrow of CML patients. Inhibition of p210(Bcr-Abl) kinase activity decreased basal Cdc42 activity and restored SDF-1 alpha-induced Cdc42 and migration responses. Transduction of active Tat-Cdc42V12 abolished this reconstituted chemotactic response. As Cdc42 is particularly important in cytoskeletal remodeling and directional sensing, these results suggest that sustained activation of Cdc42 GTPase through p210(Bcr-Abl) tyrosine kinase signaling in CML cells contributes to defects in SDF-1 alpha-chemotactic response due to desensitization of the actin polarization signal required for directional migration. Oncogene (2009) 28, 4105-4115; doi:10.1038/onc.2009.260; published online 31 August 2009	[Chang, Y-C; Tien, S-C; Chang, Z-F] Natl Taiwan Univ, Coll Med, Inst Biochem & Mol Biol, Taipei, Taiwan; [Tien, H-F] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan; [Zhang, H.; Bokoch, G. M.] Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; [Zhang, H.; Bokoch, G. M.] Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA	National Taiwan University; National Taiwan University; National Taiwan University Hospital; Scripps Research Institute; Scripps Research Institute	Chang, ZF (corresponding author), Natl Taiwan Univ, Coll Med, Inst Biochem & Mol Biol, 1 Sect,1 Jen Ai Rd, Taipei, Taiwan.	zfchang@ntu.edu.tw		TIEN, HWEI-FANG/0000-0002-1384-5593	National Science Council, Taiwan [NSC 96-3112-B-002-006, NSC 97-3112-B-002-026]	National Science Council, Taiwan(Ministry of Science and Technology, Taiwan)	We are grateful to Dr RB Arlinghaus (Department of Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA) for providing 32Dp210 and WEHI cells. We thank the staff of the Second Core Lab, Department of Medical Research, National Taiwan University Hospital for technical support during this study. This study is supported by grant NSC 96-3112-B-002-006 and NSC 97-3112-B-002-026 from the National Science Council, Taiwan.	Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; Bassermann F, 2002, J BIOL CHEM, V277, P12437, DOI 10.1074/jbc.M112397200; Burger JA, 2007, BRIT J HAEMATOL, V137, P288, DOI 10.1111/j.1365-2141.2007.06590.x; Chang YC, 2006, CELL DEATH DIFFER, V13, P2023, DOI 10.1038/sj.cdd.4401901; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Daubon T, 2008, ONCOGENE, V27, P2673, DOI 10.1038/sj.onc.1210933; Deininger M, 2005, BLOOD, V105, P2640, DOI 10.1182/blood-2004-08-3097; Deininger MWN, 2000, BLOOD, V96, P3343, DOI 10.1182/blood.V96.10.3343; Geay JF, 2005, CANCER RES, V65, P2676, DOI 10.1158/0008-5472.CAN-04-2152; Genth H, 1996, BIOCHEM BIOPH RES CO, V229, P370, DOI 10.1006/bbrc.1996.1812; Gottig S, 2006, EUR J IMMUNOL, V36, P180, DOI 10.1002/eji.200525607; Haddad E, 2001, BLOOD, V97, P33, DOI 10.1182/blood.V97.1.33; Harnois T, 2003, ONCOGENE, V22, P6445, DOI 10.1038/sj.onc.1206626; Hornstein I, 2004, CELL SIGNAL, V16, P1, DOI 10.1016/S0898-6568(03)00110-4; Li Z, 2003, CELL, V114, P215, DOI 10.1016/S0092-8674(03)00559-2; Lopez-Lago M, 2000, MOL CELL BIOL, V20, P1678, DOI 10.1128/MCB.20.5.1678-1691.2000; Macara IG, 2004, NAT REV MOL CELL BIO, V5, P220, DOI 10.1038/nrm1332; MATSUGUCHI T, 1995, EMBO J, V14, P257, DOI 10.1002/j.1460-2075.1995.tb06999.x; Miletic AV, 2003, CURR OPIN IMMUNOL, V15, P261, DOI 10.1016/S0952-7915(03)00054-2; Nagar B, 2003, CELL, V112, P859, DOI 10.1016/S0092-8674(03)00194-6; Niggli V, 2003, INT J BIOCHEM CELL B, V35, P1619, DOI 10.1016/S1357-2725(03)00144-4; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; Ramaraj P, 2004, CANCER RES, V64, P5322, DOI 10.1158/0008-5472.CAN-03-3656; Ren R, 2005, NAT REV CANCER, V5, P172, DOI 10.1038/nrc1567; ROWLEY JD, 1990, CANCER, V65, P2178, DOI 10.1002/1097-0142(19900515)65:10<2178::AID-CNCR2820651004>3.0.CO;2-#; Salesse S, 2002, ONCOGENE, V21, P8547, DOI 10.1038/sj.onc.1206082; Salgia R, 1999, BLOOD, V94, P4233; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; Stofega Mary, 2006, V332, P269; Van Haastert PJM, 2004, NAT REV MOL CELL BIO, V5, P626, DOI 10.1038/nrm1435; Vicente-Manzanares M, 2004, NAT REV IMMUNOL, V4, P110, DOI 10.1038/nri1268; Vicente-Manzanares M, 2005, BLOOD, V105, P3026, DOI 10.1182/blood-2004-07-2925; Volinsky N, 2006, BIOCHEM J, V397, P213, DOI 10.1042/BJ20051655; Wertheim JA, 2002, ONCOGENE, V21, P8612, DOI 10.1038/sj.onc.1206089; Wilkinson B, 2006, J BIOL CHEM, V281, P20842, DOI 10.1074/jbc.M600627200	36	16	16	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 19	2009	28	46					4105	4115		10.1038/onc.2009.260	http://dx.doi.org/10.1038/onc.2009.260			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	530AE	19718053				2022-12-17	WOS:000272560500006
J	Farina, AR; Tacconelli, A; Cappabianca, L; Cea, G; Chioda, A; Romanelli, A; Pensato, S; Pedone, C; Gulino, A; Mackay, AR				Farina, A. R.; Tacconelli, A.; Cappabianca, L.; Cea, G.; Chioda, A.; Romanelli, A.; Pensato, S.; Pedone, C.; Gulino, A.; Mackay, A. R.			The neuroblastoma tumour-suppressor TrkAI and its oncogenic alternative TrkAIII splice variant exhibit geldanamycin-sensitive interactions with Hsp90 in human neuroblastoma cells	ONCOGENE			English	Article						neuroblastoma; TrkAI; TrkAIII; Hsp90; geldanamycin	ENDOPLASMIC-RETICULUM STRESS; NERVE GROWTH-FACTOR; CANCER CHEMOTHERAPEUTIC-AGENTS; PHASE-I; SOLID TUMORS; INHIBITOR GELDANAMYCIN; PEDIATRIC-PATIENTS; ADULT PATIENTS; CHAPERONE; RECEPTOR	Hsp90 chaperones stabilize many tyrosine kinases including several oncogenes, which are inhibited or induced to degrade by the Hsp90 inhibitor geldanamycin (GA). As a consequence, GA has been developed for future chemotherapeutic use in several tumour types including neuroblastoma (NB). Alternative splicing of the neurotrophin receptor tyrosine kinase TrkA may have a pivotal function in regulating NB behaviour, with reports suggesting that tumour-suppressing signals from TrkA may be converted to oncogenic signals by stress-regulated alternative TrkAIII splicing. Within this context, it is important to know whether Hsp90 interacts with TrkA variants in NB cells and how GA influences this. Here, we report that both TrkAI and TrkAIII are Hsp90 clients in human NB cells. TrkAI exhibits GA-sensitive interaction with Hsp90 required for receptor endoplasmic reticulum export, maturation, cell surface stabilization and ligand-mediated activation, whereas TrkAIII exhibits GA-sensitive interactions with Hsp90 required for spontaneous activity and to a lesser extent stability. We show that GA inhibits proliferation and induces apoptosis of TrkAI expressing NB cells, whereas TrkAIII reduces the sensitivity of NB cells to GA-induced elimination. Our data suggest that GA-sensitive interactions with Hsp90 are critical for both TrkAI tumour suppressor and TrkAIII oncogenic function in NB and that TrkAIII expression exerts a negative impact on GA-induced NB cell eradication, which can be counteracted by a novel TrkAIII-specific peptide nucleic acid inhibitor. Oncogene (2009) 28, 4075-4094; doi:10.1038/onc.2009.256; published online 7 September 2009	[Mackay, A. R.] Univ Aquila, Dept Expt Med, Sect Mol Pathol, I-67100 Laquila, AQ, Italy; [Romanelli, A.; Pensato, S.; Pedone, C.] Univ Naples Federico 2, Dept Biol Sci, Naples, Italy; [Gulino, A.] Univ Roma La Sapienza, Dept Expt Med, I-00185 Rome, Italy	University of L'Aquila; University of Naples Federico II; Sapienza University Rome	Mackay, AR (corresponding author), Univ Aquila, Dept Expt Med, Sect Mol Pathol, Coppito 2,Via Vetoio, I-67100 Laquila, AQ, Italy.	andrewreay.mackay@univaq.it		ROMANELLI, Alessandra/0000-0002-7609-4061; cappabianca, lucia/0000-0002-9112-1750; FARINA, Antonietta Rosella/0000-0003-0962-6088; Mackay, Andrew Reay/0000-0001-7096-3759	AIRC; Progetto Speciale Ministero Della Sanita; MURST-Cofin; MIUR-CNR-Oncology; Center of Excellence BEMM	AIRC(Fondazione AIRC per la ricerca sul cancro); Progetto Speciale Ministero Della Sanita; MURST-Cofin(Ministry of Education, Universities and Research (MIUR)Research Projects of National Relevance (PRIN)); MIUR-CNR-Oncology(Ministry of Education, Universities and Research (MIUR)); Center of Excellence BEMM	We thank Dr Pyrwes (University of Michigan) for providing the 5xATF6GL3 reporter gene construct, Drs B Cinque, N Di Ianni and M Zani and post-graduate students Paolo Ciufici, Stefania Merolle and Marzia Ragone for technical assistance. This work was supported by AIRC, Progetto Speciale Ministero Della Sanita, MURST-Cofin, MIUR-CNR-Oncology project and Center of Excellence BEMM. We dedicate this work to all the students of L'Aquila University who lost their lives in the earthquake of L'Aquila, 6 April 2009.	Arevalo JC, 2000, MOL CELL BIOL, V20, P5908, DOI 10.1128/MCB.20.16.5908-5916.2000; Bagatell R, 2007, CLIN CANCER RES, V13, P1783, DOI 10.1158/1078-0432.CCR-06-1892; Becker B, 2004, EXP DERMATOL, V13, P27, DOI 10.1111/j.0906-6705.2004.00114.x; Bijlmakers MJJE, 2000, MOL BIOL CELL, V11, P1585, DOI 10.1091/mbc.11.5.1585; Citri A, 2006, J BIOL CHEM, V281, P14361, DOI 10.1074/jbc.M512613200; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; Crevecoeur J, 2008, BIOCHEM PHARMACOL, V75, P2183, DOI 10.1016/j.bcp.2008.03.009; Dai Chengkai, 2005, Future Oncol, V1, P529; Eggert A, 2002, CANCER RES, V62, P1802; Erdmann F, 2007, FEBS LETT, V581, P5709, DOI 10.1016/j.febslet.2007.11.037; Escobar MA, 2005, J PEDIATR SURG, V40, P349, DOI 10.1016/j.jpedsurg.2004.10.032; Frey S, 2007, J BIOL CHEM, V282, P35612, DOI 10.1074/jbc.M704647200; Geetha T, 2008, TRAFFIC, V9, P1146, DOI 10.1111/j.1600-0854.2008.00751.x; Graner MW, 2005, NEURO-ONCOLOGY, V7, P260, DOI 10.1215/S1152851704001188; Grem JL, 2005, J CLIN ONCOL, V23, P1885, DOI 10.1200/JCO.2005.12.085; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; Grenert JP, 1999, J BIOL CHEM, V274, P17525, DOI 10.1074/jbc.274.25.17525; JAKOB U, 1995, J BIOL CHEM, V270, P7288, DOI 10.1074/jbc.270.13.7288; Jullien J, 2002, J BIOL CHEM, V277, P38700, DOI 10.1074/jbc.M202348200; Kim S, 2003, INT J CANCER, V103, P352, DOI 10.1002/ijc.10820; LAVENIUS E, 1995, CELL GROWTH DIFFER, V6, P727; Lavictoire SJ, 2003, J BIOL CHEM, V278, P5292, DOI 10.1074/jbc.M209494200; Lopez-Maderuelo MD, 2001, FEBS LETT, V490, P23, DOI 10.1016/S0014-5793(01)02130-5; Lucarelli E, 1997, EUR J CANCER, V33, P2068, DOI 10.1016/S0959-8049(97)00266-9; Marcu MG, 2002, MOL CELL BIOL, V22, P8506, DOI 10.1128/MCB.22.24.8506-8513.2002; MARCZIN N, 1993, AM J PHYSIOL, V265, P34; Marques C, 2004, FASEB J, V18, P1424, DOI 10.1096/fj.04-1743fje; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; Matei D, 2007, J BIOL CHEM, V282, P445, DOI 10.1074/jbc.M607012200; MATSUSHIMA H, 1990, MOL CELL BIOL, V10, P5015, DOI 10.1128/MCB.10.9.5015; Miyata Y, 2005, CURR PHARM DESIGN, V11, P1131, DOI 10.2174/1381612053507585; NAKAGAWARA A, 1992, CANCER RES, V52, P1364; Nakagawara A, 2001, CANCER LETT, V169, P107, DOI 10.1016/S0304-3835(01)00530-4; Neckers L, 2002, TRENDS MOL MED, V8, pS55, DOI 10.1016/S1471-4914(02)02316-X; Nimmanapalli R, 2003, BLOOD, V102, P269, DOI 10.1182/blood-2002-12-3718; Onuoha SC, 2007, J MOL BIOL, V372, P287, DOI 10.1016/j.jmb.2007.06.065; Orike N, 2001, J CELL BIOL, V154, P995, DOI 10.1083/jcb.200101068; Pahlman S, 2000, NEUROBLASTOMA, P9; Peng XY, 2005, J BIOL CHEM, V280, P13148, DOI 10.1074/jbc.M410838200; Puyo S, 2008, MOL DIAGN THER, V12, P225, DOI 10.1007/BF03256288; Ramanathan RK, 2007, CLIN CANCER RES, V13, P1769, DOI 10.1158/1078-0432.CCR-06-2233; Rao RV, 2002, FEBS LETT, V514, P122, DOI 10.1016/S0014-5793(02)02289-5; Richter K, 2001, J BIOL CHEM, V276, P33689, DOI 10.1074/jbc.M103832200; Rosser MFN, 2004, BIOCHEMISTRY-US, V43, P8835, DOI 10.1021/bi049539q; Scheibel T, 1998, P NATL ACAD SCI USA, V95, P1495, DOI 10.1073/pnas.95.4.1495; Schneider C, 1996, P NATL ACAD SCI USA, V93, P14536, DOI 10.1073/pnas.93.25.14536; Schroder M, 2008, CELL MOL LIFE SCI, V65, P862, DOI 10.1007/s00018-007-7383-5; SHANKOVICH R, 1992, MOL CELL BIOL, V12, P5059; Shen JH, 2007, NEUROSCI LETT, V414, P110, DOI 10.1016/j.neulet.2006.06.050; Sidera K, 2004, J BIOL CHEM, V279, P45379, DOI 10.1074/jbc.M405486200; Sidera K, 2008, J BIOL CHEM, V283, P2031, DOI 10.1074/jbc.M701803200; Solit DB, 2007, CLIN CANCER RES, V13, P1775, DOI 10.1158/1078-0432.CCR-06-1863; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Tacconelli A, 2004, CANCER CELL, V6, P347, DOI 10.1016/j.ccr.2004.09.011; TACCONELLI A, 2006, ALTERNATIVE SPLICING, P67; Tacconelli Antonella, 2005, Future Oncol, V1, P689, DOI 10.2217/14796694.1.5.689; Theodoraki MA, 2007, EXP CELL RES, V313, P3851, DOI 10.1016/j.yexcr.2007.06.022; Vega VL, 2003, MOL BIOL CELL, V14, P764, DOI 10.1091/mbc.E02-08-0498; Wang Y, 2000, J BIOL CHEM, V275, P27013; Watson FL, 1999, J NEUROBIOL, V39, P323, DOI 10.1002/(SICI)1097-4695(199905)39:2<323::AID-NEU15>3.0.CO;2-4; Weigel BJ, 2007, CLIN CANCER RES, V13, P1789, DOI 10.1158/1078-0432.CCR-06-2270; Xu WP, 2007, CLIN CANCER RES, V13, P1625, DOI 10.1158/1078-0432.CCR-06-2966; Xu WP, 2002, P NATL ACAD SCI USA, V99, P12847, DOI 10.1073/pnas.202365899; Xu WP, 2001, J BIOL CHEM, V276, P3702, DOI 10.1074/jbc.M006864200; Yoshimura S, 2001, J CELL SCI, V114, P4105; Zhout PC, 2003, J BIOL CHEM, V278, P13829, DOI 10.1074/jbc.M209640200	66	16	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 19	2009	28	46					4075	4094		10.1038/onc.2009.256	http://dx.doi.org/10.1038/onc.2009.256			20	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	530AE	19734938				2022-12-17	WOS:000272560500004
J	Komlodi-Pasztor, E; Trostel, S; Sackett, D; Poruchynsky, M; Fojo, T				Komlodi-Pasztor, E.; Trostel, S.; Sackett, D.; Poruchynsky, M.; Fojo, T.			Impaired p53 binding to importin: a novel mechanism of cytoplasmic sequestration identified in oxaliplatin-resistant cells	ONCOGENE			English	Article						nuclear localization; mutant p53; platinum resistance	WILD-TYPE P53; NUCLEAR-LOCALIZATION SIGNALS; COLORECTAL ADENOCARCINOMA; SUBCELLULAR-LOCALIZATION; N-MYC; PROTEIN; ACCUMULATION; GENE; NEUROBLASTOMA; AMPLIFICATION	Previous studies have described one nuclear localization signal (NLSI) in p53 and speculated on two additional sites termed NLSII and NLSIII. Drug-resistant KB cells selected with cisplatin or oxaliplatin were found to have increased p53 levels and in oxaliplatin-selected cells, a larger p53 predominantly in the cytoplasm. In oxaliplatin-selected cells a single nucleotide deletion in the sequence-encoding amino acid 382, part of NLSIII, resulted in a frame shift and a 420 amino acid protein (p53(420)). We investigated explanations for the cytoplasmic sequestration of p53(420) while assessing the role, if any, of NLSII and NLSIII in p53 nuclear import. We found that neither NLSII nor NLSIII are essential for p53 nuclear localization. Furthermore, we confirmed p53(420) is able to tetramerize, transactivate a p21 promoter, bind dynein and that the reduced nuclear accumulation is not a consequence of increased p53 nuclear export. However, the association of p53(420) with importin-beta, essential for nuclear import, was significantly impaired. We conclude that despite sequence similarity to consensus NLSs neither NLSII nor NLSIII have roles in p53 nuclear transport. We also identified impaired association with importin as a novel mechanism of p53 cytoplasmic sequestration that impairs nuclear transport rendering cells functionally deficient in p53. Oncogene (2009) 28, 3111-3120; doi: 10.1038/onc.2009.166; published online 6 July 2009	[Komlodi-Pasztor, E.; Trostel, S.; Poruchynsky, M.; Fojo, T.] NCI, Med Oncol Branch, NIH, Bethesda, MD 20892 USA; [Sackett, D.] NICHHD, Lab Integrat & Med Biophys, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Komlodi-Pasztor, E (corresponding author), NCI, Med Oncol Branch, NIH, 9000 Rockville Pike,B10 R13N260, Bethesda, MD 20892 USA.	komlodie@mail.nih.gov			NATIONAL CANCER INSTITUTE [ZIABC010626, ZIABC010625, ZIASC006732] Funding Source: NIH RePORTER; Intramural NIH HHS [Z99 CA999999] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Becker K, 2007, CELL DEATH DIFFER, V14, P1350, DOI 10.1038/sj.cdd.4402126; BOSARI S, 1995, AM J PATHOL, V147, P790; BOSARI S, 1994, JNCI-J NATL CANCER I, V86, P681, DOI 10.1093/jnci/86.9.681; Bristow RG, 2003, ONCOGENE, V22, P2960, DOI 10.1038/sj.onc.1206405; DANG CV, 1989, J BIOL CHEM, V264, P18019; DINGWALL C, 1987, EMBO J, V6, P69, DOI 10.1002/j.1460-2075.1987.tb04720.x; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Giannakakou P, 2000, NAT CELL BIOL, V2, P709, DOI 10.1038/35036335; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; IMAMURA J, 1993, CANCER RES, V53, P4053; Kim IS, 2000, J BIOL CHEM, V275, P23139, DOI 10.1074/jbc.M909256199; LANE DP, 1992, NATURE, V358, P16; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Li Q, 2007, ONCOGENE, V26, P7885, DOI 10.1038/sj.onc.1210597; Liang SH, 1999, J BIOL CHEM, V274, P32699, DOI 10.1074/jbc.274.46.32699; Lilling G, 2002, CANCER INVEST, V20, P509, DOI 10.1081/CNV-120002151; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; O'Brate A, 2003, DRUG RESIST UPDATE, V6, P313, DOI 10.1016/j.drup.2003.10.004; Oggionni M, 2005, ONCOLOGY-BASEL, V69, P154, DOI 10.1159/000087839; Ottaggio L, 2000, CARCINOGENESIS, V21, P1631, DOI 10.1093/carcin/21.9.1631; Qu LK, 2004, GENE DEV, V18, P261, DOI 10.1101/gad.1165804; Riddick G, 2005, J CELL BIOL, V168, P1027, DOI 10.1083/jcb.200409024; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Scata KA, 2007, ADV EXP MED BIOL, V608, P70; Sembritzki O, 2002, NEURO-ONCOLOGY, V4, P171, DOI 10.1093/neuonc/4.3.171; SHAULSKY G, 1991, ONCOGENE, V6, P2055; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; SMITH AE, 1985, PROC R SOC SER B-BIO, V226, P43, DOI 10.1098/rspb.1985.0078; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; SUN XF, 1992, LANCET, V340, P1369, DOI 10.1016/0140-6736(92)92558-W; Trostel SY, 2006, CELL CYCLE, V5, P2253, DOI 10.4161/cc.5.19.3291; Utama B, 2006, J CELL SCI, V119, P2457, DOI 10.1242/jcs.02974; WEISS J, 1995, BRIT J DERMATOL, V133, P23; Woods DB, 2001, EXP CELL RES, V264, P56, DOI 10.1006/excr.2000.5141	37	16	16	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2009	28	35					3111	3120		10.1038/onc.2009.166	http://dx.doi.org/10.1038/onc.2009.166			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	490QC	19581934	Green Accepted			2022-12-17	WOS:000269515100003
J	Seng, S; Avraham, HK; Birrane, G; Jiang, S; Li, H; Katz, G; Bass, CE; Zagozdzon, R; Avraham, S				Seng, S.; Avraham, H. K.; Birrane, G.; Jiang, S.; Li, H.; Katz, G.; Bass, C. E.; Zagozdzon, R.; Avraham, S.			NRP/B mutations impair Nrf2-dependent NQO1 induction in human primary brain tumors	ONCOGENE			English	Article						NRP/B mutation; Nrf2; NQO1; primary brain tumors	NUCLEAR-MATRIX PROTEINS; ANTIOXIDANT RESPONSIVE ELEMENTS; DT-DIAPHORASE; CANCER CELLS; GENE; NRF2; EXPRESSION; ENC-1; OXIDOREDUCTASE-1; DIFFERENTIATION	Brain tumors are associated with genetic alterations of oncogenes and tumor suppressor genes. Accumulation of reactive oxygen species (ROS) in cells leads to oxidative stress-induced damage, resulting in tumorigenesis. Here, we showed that the nuclear matrix protein nuclear restricted protein in brain (NRP/B) was colocalized and interacted with NF-E2-related factor 2 (Nrf2). During oxidative stress response, NRP/B expression and its interaction with Nrf2 were upregulated in SH-SY5Y cells. Association of NRP/B with Nrf2 was crucial for NAD(P)H:quinone oxidoreductase 1 (NQO1) expression. NRP/B was localized predominantly in the nucleus of normal brain cells, whereas in primary brain tumors NRP/B was almost exclusively contained in the cytoplasm. In addition, unlike wild-type NRP/B, the expression of NRP/B mutants isolated from primary brain tumors was found in the cytoplasm, and these mutants failed to induce Nrf2-dependent NQO1 transcription. Thus, NRP/B mutations and their altered localization resulted in changes in NRP/B function and deregulation of Nrf2-dependent NQO1 activation in brain tumors. This study provides insights into the mechanism by which the NRP/B modulates Nrf2-dependent NQO1 induction in cellular protection against ROS in brain tumors.	[Seng, S.; Avraham, H. K.; Birrane, G.; Jiang, S.; Li, H.; Katz, G.; Bass, C. E.; Zagozdzon, R.; Avraham, S.] Harvard Univ, Sch Med, Harvard Inst Med, Beth Israel Deaconess Med Ctr,Div Expt Med, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Avraham, S (corresponding author), Harvard Univ, Sch Med, Harvard Inst Med, Beth Israel Deaconess Med Ctr,Div Expt Med, 4 Blackfan Circle, Boston, MA 02115 USA.	savraham@bidmc.harvard.edu	Zagozdzon, Radoslaw/AAC-4298-2019; Zagozdzon, Radoslaw/K-2141-2012	Zagozdzon, Radoslaw/0000-0002-7957-2372; Birrane, Gabriel/0000-0002-1759-5499; Katz, Gabrielle/0000-0002-9233-5654; Avraham, Hava/0000-0002-7545-3640; Bass, Caroline/0000-0002-5856-6387	NIH [HL80699, CA096805]; Department of Defense Cancer Concept Award; NATIONAL CANCER INSTITUTE [R01CA096805] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL080699] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense Cancer Concept Award(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank Janet Delahanty and Makara Men for editing the paper. This study was supported by NIH grants HL80699 (SA), CA096805 (HKA) and the Department of Defense Cancer Concept Award (SA).	Alberti I, 2000, J CELL BIOCHEM, V79, P471, DOI 10.1002/1097-4644(20001201)79:3<471::AID-JCB120>3.3.CO;2-F; Andreassi MG, 2003, MUTAT RES-REV MUTAT, V543, P67, DOI 10.1016/S1383-5742(02)00089-3; Asher G, 2002, P NATL ACAD SCI USA, V99, P3099, DOI 10.1073/pnas.052706799; Asher G, 2001, P NATL ACAD SCI USA, V98, P1188, DOI 10.1073/pnas.021558898; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Begleiter A, 1997, ONCOL RES, V9, P371; Berezney R, 1995, INT REV CYTOL, V162A, P1; Bode J, 2000, J CELL BIOCHEM, P3; Dalton TD, 1999, ANNU REV PHARMACOL, V39, P67, DOI 10.1146/annurev.pharmtox.39.1.67; FEY EG, 1984, P NATL ACAD SCI-BIOL, V81, P4409, DOI 10.1073/pnas.81.14.4409; Fujita M, 2001, CANCER RES, V61, P7722; Furukawa M, 2005, MOL CELL BIOL, V25, P162, DOI 10.1128/MCB.25.1.162-171.2005; Getzenberg RH, 1996, CANCER RES, V56, P1690; Hammarsund M, 2004, HUM MOL GENET, V13, P2925, DOI 10.1093/hmg/ddh315; He D, 1995, INT REV CYTOL, V162B, P1; Hernandez MC, 1998, EXP CELL RES, V242, P470, DOI 10.1006/excr.1998.4109; Hernandez MC, 1997, J NEUROSCI, V17, P3038; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Kim TA, 2000, GENE, V255, P105, DOI 10.1016/S0378-1119(00)00297-3; Kim TA, 1998, J CELL BIOL, V141, P553, DOI 10.1083/jcb.141.3.553; Konety BR, 1999, J CELL BIOCHEM, P183; Lee JM, 2004, J BIOCHEM MOL BIOL, V37, P139; Liang XQ, 2004, ONCOGENE, V23, P5890, DOI 10.1038/sj.onc.1207776; Loidl P, 1995, INT REV CYTOL, V162B, P377; Long DJ, 2002, CANCER RES, V62, P3030; Louis DN, 2002, CANCER CELL, V1, P125, DOI 10.1016/S1535-6108(02)00040-5; Maher EA, 2001, GENE DEV, V15, P1311, DOI 10.1101/gad.891601; Nguyen T, 2003, J BIOL CHEM, V278, P4536, DOI 10.1074/jbc.M207293200; Nioi P, 2004, MUTAT RES-FUND MOL M, V555, P149, DOI 10.1016/j.mrfmmm.2004.05.023; RILEY RJ, 1992, BIOCHEM PHARMACOL, V43, P1657, DOI 10.1016/0006-2952(92)90694-E; Saunders WS, 2000, P NATL ACAD SCI USA, V97, P303, DOI 10.1073/pnas.97.1.303; Seng S, 2007, CANCER RES, V67, P8596, DOI 10.1158/0008-5472.CAN-06-3785; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; Wakabayashi N, 2004, P NATL ACAD SCI USA, V101, P2040, DOI 10.1073/pnas.0307301101; Wasserman WW, 1997, P NATL ACAD SCI USA, V94, P5361, DOI 10.1073/pnas.94.10.5361; Wechsler-Reya R, 2001, ANNU REV NEUROSCI, V24, P385, DOI 10.1146/annurev.neuro.24.1.385; Zipper LM, 2002, J BIOL CHEM, V277, P36544, DOI 10.1074/jbc.M206530200	37	16	17	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2009	28	3					378	389		10.1038/onc.2008.396	http://dx.doi.org/10.1038/onc.2008.396			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395UZ	18981988				2022-12-17	WOS:000262550300006
J	Chan, YW; Chen, Y; Poon, RYC				Chan, Y. W.; Chen, Y.; Poon, R. Y. C.			Generation of an indestructible cyclin B1 by caspase-6-dependent cleavage during mitotic catastrophe	ONCOGENE			English	Article						apoptosis; cell cycle; checkpoint; cyclin; DNA damage; mitotic catastrophe	CELL-CYCLE; DNA-DAMAGE; CHECKPOINT PATHWAY; DEPENDENT KINASES; APOPTOSIS; DEATH; CHK1; PHOSPHORYLATION; ACTIVATION; DISTINCT	Overriding the G(2) DNA damage checkpoint permits precocious entry into mitosis that ultimately leads to mitotic catastrophe. Mitotic catastrophe is manifested by an unscheduled activation of CDK1, caspase activation and apoptotic cell death. We found that although cyclin B1 was required for mitotic catastrophe, it was cleaved into a similar to 35kDa protein by a caspase-dependent mechanism during the process. Cyclin B1 cleavage occurred after Asp123 in the motif ILVD123 down arrow, and mutation of this motif attenuated the cleavage. Cleavage was abolished by a pan-caspase inhibitor as well as by specific inhibitors for the effector caspase-6 and the initiator caspase-8. Cleavage created a truncated cyclin B1 lacking part of the NH2-terminal regulatory domain that included the destruction box sequence. Although cleavage of cyclin B1 itself was not absolutely required for mitotic catastrophe, expression of the truncated product enhanced cell death. In support of this, ectopic expression of this truncated cyclin B1 was not only sufficient to induce mitotic block and apoptosis but also enhanced mitotic catastrophe induced by ionizing radiation and caffeine. These data underscore a possible linkage between mitotic and apoptotic functions by caspase-dependent processing of mitotic activators.	[Chan, Y. W.; Chen, Y.; Poon, R. Y. C.] Hong Kong Univ Sci & Technol, Dept Biochem, Hong Kong, Hong Kong, Peoples R China	Hong Kong University of Science & Technology	Poon, RYC (corresponding author), Hong Kong Univ Sci & Technol, Dept Biochem, Hong Kong, Hong Kong, Peoples R China.	rycpoon@ust.hk	Chan, Gary/P-7347-2019	Chan, Gary/0000-0002-6196-7675; Poon, Randy/0000-0001-5571-6231	Hong Kong Research Grants Council [66207, HKUST6439/06M]	Hong Kong Research Grants Council(Hong Kong Research Grants Council)	Many thanks are due to members of the Poon Lab for constructive criticism on the manuscript. We thank Julian Gannon, Tim Hunt and Katsumi Yamashita for generous gifts of reagents. We also thank Talha Arooz and Wai Yi Siu for technical assistance and Jeremy PK Chow for the original observation of cyclin B1 cleavage. This work was supported in part by the Hong Kong Research Grants Council Grants 66207 and HKUST6439/06M to RYCP.	Arooz T, 2000, BIOCHEMISTRY-US, V39, P9494, DOI 10.1021/bi0009643; Baek KH, 2005, ONCOL RES, V15, P161, DOI 10.3727/096504005776367906; Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Castedo M, 2002, CELL DEATH DIFFER, V9, P1287, DOI 10.1038/sj.cdd.4401130; Castedo M, 2004, ONCOGENE, V23, P4362, DOI 10.1038/sj.onc.1207572; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chan YW, 2008, J BIOL CHEM, V283, P15716, DOI 10.1074/jbc.M800629200; Chan YW, 2008, CELL CYCLE, V7, P1449, DOI 10.4161/cc.7.10.5880; Chow JPH, 2003, MOL BIOL CELL, V14, P3989, DOI 10.1091/mbc.E03-03-0168; Chow JPH, 2003, J BIOL CHEM, V278, P40815, DOI 10.1074/jbc.M306683200; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Fung TK, 2005, CELL CYCLE, V4, P1411, DOI 10.4161/cc.4.10.2046; Fung TK, 2002, J BIOL CHEM, V277, P35140, DOI 10.1074/jbc.M205503200; Fung TK, 2007, MOL BIOL CELL, V18, P1861, DOI 10.1091/mbc.E06-12-1092; Furnari B, 1999, MOL BIOL CELL, V10, P833, DOI 10.1091/mbc.10.4.833; Giles N, 2003, J BIOL CHEM, V278, P28580, DOI 10.1074/jbc.M304027200; Graham RK, 2006, CELL, V125, P1179, DOI 10.1016/j.cell.2006.04.026; Hall-Jackson CA, 1999, ONCOGENE, V18, P6707, DOI 10.1038/sj.onc.1203077; Ho CC, 2006, CANCER RES, V66, P2233, DOI 10.1158/0008-5472.CAN-05-1790; Ho CC, 2005, EXP CELL RES, V304, P1, DOI 10.1016/j.yexcr.2004.10.016; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Kim M, 2005, MOL CELL BIOL, V25, P9232, DOI 10.1128/MCB.25.21.9232-9248.2005; Konishi Y, 2002, MOL CELL, V9, P1005, DOI 10.1016/S1097-2765(02)00524-5; Kramer A, 2004, NAT CELL BIOL, V6, P884, DOI 10.1038/ncb1165; Lee J, 2001, MOL BIOL CELL, V12, P551, DOI 10.1091/mbc.12.3.551; Li KKW, 2002, LIVER, V22, P259, DOI 10.1046/j.0106-9543.2002.01629.x; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Mansilla S, 2006, CELL CYCLE, V5, P53, DOI 10.4161/cc.5.1.2267; Niida H, 2005, J BIOL CHEM, V280, P39246, DOI 10.1074/jbc.M505009200; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; POON RYC, 1995, SCIENCE, V270, P90, DOI 10.1126/science.270.5233.90; Rothblum-Oviatt CJ, 2001, CELL GROWTH DIFFER, V12, P581; Ruchaud S, 2002, EMBO J, V21, P1967, DOI 10.1093/emboj/21.8.1967; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Schmitt E, 2006, J CELL SCI, V119, P4269, DOI 10.1242/jcs.03200; Siu WY, 2004, MOL CANCER THER, V3, P621; Siu WY, 1999, EXP CELL RES, V250, P131, DOI 10.1006/excr.1999.4551; Slee EA, 2001, J BIOL CHEM, V276, P7320, DOI 10.1074/jbc.M008363200; Stack JH, 1997, DEVELOPMENT, V124, P3185; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; Vogel C, 2007, CANCER RES, V67, P339, DOI 10.1158/0008-5472.CAN-06-2548; Yam CH, 1999, CANCER RES, V59, P5075; Yam CH, 1999, MOL CELL BIOL, V19, P635; Yam CH, 2000, J BIOL CHEM, V275, P3158, DOI 10.1074/jbc.275.5.3158; Yanagida M, 2005, PHILOS T R SOC B, V360, P609, DOI 10.1098/rstb.2004.1615; Yang J, 1998, GENE DEV, V12, P2131, DOI 10.1101/gad.12.14.2131; Yim H, 2003, MOL BIOL CELL, V14, P4250, DOI 10.1091/mbc.E03-01-0029; Yim H, 2006, J CELL BIOL, V174, P77, DOI 10.1083/jcb.200509141	52	16	17	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2009	28	2					170	183		10.1038/onc.2008.369	http://dx.doi.org/10.1038/onc.2008.369			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395CY	18820706				2022-12-17	WOS:000262501100002
J	Matsushita, H; Nakajima, H; Nakamura, Y; Tsukamoto, H; Tanaka, Y; Jin, G; Yabe, M; Asai, S; Ono, R; Nosaka, T; Sugita, K; Morimoto, A; Hayashi, Y; Hotta, T; Ando, K; Miyachi, H				Matsushita, H.; Nakajima, H.; Nakamura, Y.; Tsukamoto, H.; Tanaka, Y.; Jin, G.; Yabe, M.; Asai, S.; Ono, R.; Nosaka, T.; Sugita, K.; Morimoto, A.; Hayashi, Y.; Hotta, T.; Ando, K.; Miyachi, H.			C/EBP alpha and C/EBP epsilon induce the monocytic differentiation of myelomonocytic cells with the MLL-chimeric fusion gene	ONCOGENE			English	Article						acute myeloid leukemia; mixed lineage leukemia gene; monocytic differentiation; CCAAT/enhancer binding protein-alpha; CCAAT/enhancer binding protein-epsilon	COLONY-STIMULATING FACTOR; ACUTE MYELOID-LEUKEMIA; BINDING-PROTEIN-ALPHA; TRANS-RETINOIC ACID; GRANULOCYTIC DIFFERENTIATION; DEFICIENT MICE; PU.1 GENE; EXPRESSION; PROGENITORS; MACROPHAGE	CCAAT/enhancer binding proteins (C/EBPs) have an important function in granulocytic differentiation, and are also involved in the leukemogenesis of acute myeloid leukemia (AML). Their involvement in myelomonocytic leukemia, however, is still unclear. Therefore, the expression and function of C/EBPs in myelomonocytic cells with MLL-fusion genes were investigated. Retinoic acid (RA) induced monocytic differentiation in the myelomonocytic cell lines with MLL-fusion genes, THP-1, MOLM-14 and HF-6 cells, accompanied by monocytic differentiation with the upregulation of C/EBP alpha and C/EBP epsilon. Monocytic differentiation by RA treatment was confirmed in primary AML cells using a clonogenic assay. When the activity of C/EBP alpha or C/EBP epsilon was introduced into HF-6 cells, their cellular growth was arrested through differentiation into monocytes with the concomitant marked downregulation of Myc. Cebpe mRNA was upregulated by the induction of C/EBP alpha-ER, but not vice versa, thus suggesting that C/EBP epsilon may have an important function in the differentiation process. Introduction of Myc isoforms into HF-6 cells partially antagonized the C/EBP alpha effects. These findings suggest that the ectopic expression of C/EBP epsilon, as well as C/EBP alpha, can induce the monocytic differentiation of myelomonocytic leukemic cells with MLL-fusion gene through the downregulation of Myc, thus providing insight into the development of novel therapeutic approaches.	[Matsushita, H.; Tanaka, Y.; Jin, G.; Yabe, M.; Asai, S.; Miyachi, H.] Tokai Univ, Sch Med, Dept Lab Med, Kanagawa 2591193, Japan; [Nakajima, H.] Univ Tokyo, Inst Med Sci, Ctr Excellence, Tokyo, Japan; [Nakamura, Y.; Tsukamoto, H.] Tokai Univ, Sch Med, Teaching & Res Support Ctr, Kanagawa 2591193, Japan; [Ono, R.; Nosaka, T.] Mie Univ, Grad Sch Med, Dept Microbiol, Tsu, Mie, Japan; [Sugita, K.] Univ Yamanashi, Sch Med, Dept Pediat, Yamanashi, Japan; [Morimoto, A.] Kyoto Prefectural Univ Med, Dept Pediat, Kyoto 602, Japan; [Hayashi, Y.] Gunma Childrens Med Ctr, Dept Hematol Oncol, Gunma, Japan; [Hotta, T.; Ando, K.] Tokai Univ, Sch Med, Dept Hematol, Kanagawa 2591193, Japan	Tokai University; University of Tokyo; Tokai University; Mie University; University of Yamanashi; Kyoto Prefectural University of Medicine; Gunma Children's Medical Centre; Tokai University	Matsushita, H (corresponding author), Tokai Univ, Sch Med, Dept Lab Med, 143 Shimokasuya, Kanagawa 2591193, Japan.	hmatsu@is.icc.u-tokai.ac.jp	松下, 弘道/AEX-6164-2022	松下, 弘道/0000-0002-1629-6630	Ministry of Education, Culture, Sports, Science and Technology of Japan [19591139]	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	We thank Dr Toshio Kitamura (Institute of Medical Science, University of Tokyo, Tokyo, Japan) for providing PLAT-E cells. This study was supported in part by Research and Study Program of Tokai University Educational System General Research Organization and a Grant-in Aid for Scientific Research (C) No. 19591139 from the Ministry of Education, Culture, Sports, Science and Technology of Japan.	Ayton PM, 2003, GENE DEV, V17, P2298, DOI 10.1101/gad.1111603; Cozzio A, 2003, GENE DEV, V17, P3029, DOI 10.1101/gad.1143403; Dahl R, 2003, NAT IMMUNOL, V4, P1029, DOI 10.1038/ni973; De Braekeleer M, 2005, ANTICANCER RES, V25, P1931; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; Fukuchi Y, 2006, EMBO J, V25, P3398, DOI 10.1038/sj.emboj.7601199; Gery S, 2004, BLOOD, V103, P828, DOI 10.1182/blood-2003-01-0159; Gombart AF, 2002, BLOOD, V99, P1332, DOI 10.1182/blood.V99.4.1332; Gombart AF, 2003, BLOOD, V101, P3265, DOI 10.1182/blood-2002-04-1039; HEMMI H, 1985, JPN J CANCER RES, V76, P345; Iijima K, 2004, LEUKEMIA LYMPHOMA, V45, P1017, DOI 10.1080/1042819031000163887; Johansen LM, 2001, MOL CELL BIOL, V21, P3789, DOI 10.1128/MCB.21.11.3789-3806.2001; Kawada H, 1999, EXP HEMATOL, V27, P904, DOI 10.1016/S0301-472X(99)00012-0; Kitamura T, 2003, EXP HEMATOL, V31, P1007, DOI 10.1016/j.exphem.2003.07.005; Kubota T, 2000, BLOOD, V96, P3953, DOI 10.1182/blood.V96.12.3953.h8003953_3953_3957; Kummalue T, 2003, J LEUKOCYTE BIOL, V74, P464, DOI 10.1189/jlb.1202622; Lee IH, 2002, BIOCHEM BIOPH RES CO, V294, P956, DOI 10.1016/S0006-291X(02)00581-8; Lee YJ, 2006, BLOOD, V108, P2416, DOI 10.1182/blood-2006-02-003582; Li ZY, 2005, LEUKEMIA, V19, P183, DOI 10.1038/sj.leu.2403602; Mueller BU, 2006, BLOOD, V107, P3330, DOI 10.1182/blood-2005-07-3068; Nakajima H, 2001, BLOOD, V98, P897, DOI 10.1182/blood.V98.4.897; Nakajima H, 2006, J BIOL CHEM, V281, P14494, DOI 10.1074/jbc.M600575200; Oelgeschlager M, 1996, MOL CELL BIOL, V16, P4717; Ono R, 2005, J CLIN INVEST, V115, P919, DOI 10.1172/JCI200522725; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; Pabst T, 2001, NAT MED, V7, P444, DOI 10.1038/86515; Pan Z, 1999, J BIOL CHEM, V274, P23242, DOI 10.1074/jbc.274.33.23242; Radomska HS, 2006, J EXP MED, V203, P371, DOI 10.1084/jem.20052242; Schoch C, 2003, BLOOD, V102, P2395, DOI 10.1182/blood-2003-02-0434; Schreiner S, 2001, CANCER RES, V61, P6480; Schuster MB, 2006, BBA-REV CANCER, V1766, P88, DOI 10.1016/j.bbcan.2006.02.003; Tavor S, 2002, BLOOD, V99, P1794, DOI 10.1182/blood.V99.5.1794; Truong BTH, 2003, BLOOD, V101, P1141, DOI 10.1182/blood-2002-05-1374; Walkley CR, 2004, BLOOD, V103, P1286, DOI 10.1182/blood-2003-07-2391; Wang D, 2006, BLOOD, V108, P1223, DOI 10.1182/blood-2005-12-008763; Wang XP, 1999, BLOOD, V94, P560, DOI 10.1182/blood.V94.2.560.414k41_560_571; Williams SC, 1998, J BIOL CHEM, V273, P13493, DOI 10.1074/jbc.273.22.13493; Yamanaka R, 1997, P NATL ACAD SCI USA, V94, P13187, DOI 10.1073/pnas.94.24.13187; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; Zhang P, 2004, IMMUNITY, V21, P853, DOI 10.1016/j.immuni.2004.11.006; Zheng R, 2004, BLOOD, V103, P1883, DOI 10.1182/blood-2003-06-1978	41	16	16	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 13	2008	27	53					6749	6760		10.1038/onc.2008.285	http://dx.doi.org/10.1038/onc.2008.285			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	371XO	18776924	Bronze			2022-12-17	WOS:000260866200005
J	Sobczak, I; Galabova-Kovacs, G; Sadzak, I; Kren, A; Christofori, G; Baccarini, M				Sobczak, I.; Galabova-Kovacs, G.; Sadzak, I.; Kren, A.; Christofori, G.; Baccarini, M.			B-Raf is required for ERK activation and tumor progression in a mouse model of pancreatic beta-cell carcinogenesis	ONCOGENE			English	Article						Raf kinases; ERK pathway; angiogenesis; tumor progression	MULTISTAGE CARCINOGENESIS; ANGIOGENIC SWITCH; REGULATED KINASE; GROWTH; MICE; GENE; EXPRESSION; PATHWAY; CANCER; P53	Activation of the Raf/MEK/ERK pathway, often by gain-of-function mutations of RAS or RAF, is observed in many human cancers. The extracellular signal-regulated kinase (ERK) pathway is required for the proliferation of cancer cell lines harboring activating BRAF or, to a lesser extent, activating RAS mutations. It is still unclear, however, whether the pathway is required in vivo for tumor development, particularly in tumors in which B-Raf is not mutationally activated. During embryonic development, B-Raf is essential for angiogenesis in the placenta. To address the question of whether B-Raf contributed to tumor angiogenesis in vivo we conditionally ablated B-Raf in a model of pancreatic islet carcinoma driven by the functional inactivation of tumor suppressors (RIP1Tag2), which critically depends on angiogenesis for growth. We find that B-Raf is dispensable for the proliferation of tumor cells in culture, but necessary for ERK activation and for the expression of angiogenic factors by tumor cells in vivo and in vitro. In vivo, these defects result in the formation of hollow tumors with decreased vessel density and strongly reduced proliferation. The progression from adenoma to carcinoma is also significantly impaired. Thus, endogenous B-Raf contributes to the development of RIP1Tag2 tumors by supporting the stromal response and tumor progression.	[Sobczak, I.; Galabova-Kovacs, G.; Sadzak, I.; Baccarini, M.] Univ Vienna, Dept Microbiol & Immunol, Max F Perutz Labs, A-1030 Vienna, Austria; [Kren, A.; Christofori, G.] Univ Basel, Ctr Biomed, Inst Biochem & Genet, Dept Clin Biol Sci, Basel, Switzerland	Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL); University of Basel	Baccarini, M (corresponding author), Univ Vienna, Dept Microbiol & Immunol, Max F Perutz Labs, Dr Bohr Gasse 9, A-1030 Vienna, Austria.	manuela.baccarini@univie.ac.at	Baccarini, Manuela/B-6481-2014	Baccarini, Manuela/0000-0002-3033-391X				Abdulkadir SA, 2001, NAT MED, V7, P101, DOI 10.1038/83231; Ahlgren U, 1998, GENE DEV, V12, P1763, DOI 10.1101/gad.12.12.1763; Baron V, 2006, CANCER GENE THER, V13, P115, DOI 10.1038/sj.cgt.7700896; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Bergers G, 1999, SCIENCE, V284, P808, DOI 10.1126/science.284.5415.808; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Casanovas O, 2005, CANCER CELL, V8, P299, DOI 10.1016/j.ccr.2005.09.005; Cavallaro U, 2001, BBA-REV CANCER, V1552, P39, DOI 10.1016/S0304-419X(01)00038-5; Chen AP, 2006, J NEUROSCI RES, V83, P28, DOI 10.1002/jnr.20703; Compagni A, 2000, CANCER RES, V60, P7163; De Benedetti A, 2004, ONCOGENE, V23, P3189, DOI 10.1038/sj.onc.1207545; Downward J, 2006, NATURE, V439, P274, DOI 10.1038/439274a; Dumaz N, 2006, CANCER RES, V66, P9483, DOI 10.1158/0008-5472.CAN-05-4227; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; Eid MA, 1998, CANCER RES, V58, P2461; Emuss V, 2005, CANCER RES, V65, P9719, DOI 10.1158/0008-5472.CAN-05-1683; Galabova-Kovacs G, 2006, P NATL ACAD SCI USA, V103, P1325, DOI 10.1073/pnas.0507399103; Galabova-Kovacs G, 2006, CELL CYCLE, V5, P1514, DOI 10.4161/cc.5.14.2981; Garnett MJ, 2004, CANCER CELL, V6, P313, DOI 10.1016/j.ccr.2004.09.022; Gavert N, 2005, J CELL BIOL, V168, P633, DOI 10.1083/jcb.200408051; Gomez E, 2002, J BIOL CHEM, V277, P48146, DOI 10.1074/jbc.M209165200; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; Hashizume H, 2000, AM J PATHOL, V156, P1363, DOI 10.1016/S0002-9440(10)65006-7; Herbert TP, 2002, J BIOL CHEM, V277, P11591, DOI 10.1074/jbc.M110367200; Herzig M, 1999, BIOL CHEM, V380, P203, DOI 10.1515/BC.1999.028; Inoue M, 2002, CANCER CELL, V1, P193, DOI 10.1016/S1535-6108(02)00031-4; Krones-Herzig A, 2005, CANCER RES, V65, P5133, DOI 10.1158/0008-5472.CAN-04-3742; Krones-Herzig A, 2003, P NATL ACAD SCI USA, V100, P3233, DOI 10.1073/pnas.2628034100; Lee CG, 2004, J EXP MED, V200, P377, DOI 10.1084/jem.20040104; Lim KH, 2005, CANCER CELL, V8, P381, DOI 10.1016/j.ccr.2005.10.014; Mikula M, 2001, EMBO J, V20, P1952, DOI 10.1093/emboj/20.8.1952; Morrison TB, 1998, BIOTECHNIQUES, V24, P954; Nozawa H, 2006, P NATL ACAD SCI USA, V103, P12493, DOI 10.1073/pnas.0601807103; Pannu J, 2007, J BIOL CHEM, V282, P10405, DOI 10.1074/jbc.M611742200; Perl AK, 1999, NAT MED, V5, P286, DOI 10.1038/6502; Rolli-Derkinderen M, 2003, J BIOL CHEM, V278, P18859, DOI 10.1074/jbc.M211696200; Roux PP, 2004, P NATL ACAD SCI USA, V101, P13489, DOI 10.1073/pnas.0405659101; Solit DB, 2006, NATURE, V439, P358, DOI 10.1038/nature04304; Sugimoto H, 2006, CANCER BIOL THER, V5, P1640, DOI 10.4161/cbt.5.12.3354; Ueda T, 2004, MOL CELL BIOL, V24, P6539, DOI 10.1128/MCB.24.15.6539-6549.2004; Wang XM, 2007, METHOD ENZYMOL, V431, P113, DOI 10.1016/S0076-6879(07)31007-0; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498; Xian XJ, 2006, J CLIN INVEST, V116, P642, DOI 10.1172/JCI25705	44	16	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 14	2008	27	35					4779	4787		10.1038/onc.2008.128	http://dx.doi.org/10.1038/onc.2008.128			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	337OJ	18490924				2022-12-17	WOS:000258445100003
J	Fumoto, K; Lee, PC; Saya, H; Kikuchi, A				Fumoto, K.; Lee, P-C; Saya, H.; Kikuchi, A.			AIP regulates stability of Aurora-A at early mitotic phase coordinately with GSK-3 beta	ONCOGENE			English	Article						AIP; GSK-3 beta; Aurora; cell cycle; mitosis	GLYCOGEN-SYNTHASE KINASE-3; ADENOMATOUS POLYPOSIS-COLI; BETA-CATENIN; BICAUDAL-D; NEGATIVE REGULATOR; SIGNALING PATHWAY; PROTEIN-KINASE; CELL-DIVISION; SPINDLE; DYNEIN	Glycogen synthase kinase-3 (GSK-3 beta) regulates microtubule dynamics and cellular polarity through phosphorylating various microtubule associating proteins and plus-end tracking proteins. Although it was also reported that GSK-3 beta is inactivated by protein kinase B at the spindle poles, functions and targets of GSK-3 beta in the mitotic phase are unknown. Here, we identified Aurora-A-interacting protein (AIP), a negative regulator of Aurora-A, as a binding partner of GSK-3 beta. AIP was colocalized with Aurora-A and GSK-3 beta to the spindle poles in metaphase, and its depletion in cells stabilized and activated Aurora-A in early mitotic phase and caused mitotic cell arrest. Treatment of the cells with a GSK-3 beta inhibitor reduced the protein level of Aurora-A and this reduction was suppressed by AIP knockdown. AIP was phosphorylated by GSK-3 beta, and an AIP mutant in which the GSK-3 beta phosphorylation site was mutated could bind and downregulate Aurora-A more efficiently. These results suggest that GSK-3 beta modulates the early mitotic Aurora-A level through binding and phosphorylating AIP.	[Fumoto, K.; Lee, P-C; Kikuchi, A.] Hiroshima Univ, Grad Sch Biomed Sci, Dept Biochem, Minami Ku, Hiroshima 7348551, Japan; [Saya, H.] Keio Univ, Sch Med, Inst Adv Med Res, Div Gene Regulat, Tokyo, Japan	Hiroshima University; Keio University	Kikuchi, A (corresponding author), Hiroshima Univ, Grad Sch Biomed Sci, Dept Biochem, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.	akikuchi@hiroshima-u.ac.jp	Saya, Hideyuki/J-4325-2013; Lee, Ping Chin/AGV-4612-2022	Lee, Ping Chin/0000-0002-4280-0829				Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Etienne-Manneville S, 2003, NATURE, V421, P753, DOI 10.1038/nature01423; Fumoto K, 2006, EMBO J, V25, P5670, DOI 10.1038/sj.emboj.7601459; Gruss OJ, 2002, NAT CELL BIOL, V4, P871, DOI 10.1038/ncb870; Hino S, 2003, J BIOL CHEM, V278, P14066, DOI 10.1074/jbc.M213265200; Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1; Hoogenraad CC, 2001, EMBO J, V20, P4041, DOI 10.1093/emboj/20.15.4041; Hoogenraad CC, 2003, EMBO J, V22, P6004, DOI 10.1093/emboj/cdg592; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Kiat LS, 2002, J BIOL CHEM, V277, P45558, DOI 10.1074/jbc.M206820200; Kimura M, 1997, J BIOL CHEM, V272, P13766, DOI 10.1074/jbc.272.21.13766; Kobayashi T, 2006, MOL CELL BIOL, V26, P898, DOI 10.1128/MCB.26.3.898-911.2006; Kufer TA, 2002, J CELL BIOL, V158, P617, DOI 10.1083/jcb.200204155; Kunitoku N, 2003, DEV CELL, V5, P853, DOI 10.1016/S1534-5807(03)00364-2; Lim SK, 2007, BIOCHEM J, V403, P119, DOI 10.1042/BJ20061272; Marumoto T, 2005, NAT REV CANCER, V5, P42, DOI 10.1038/nrc1526; Matanis T, 2002, NAT CELL BIOL, V4, P986, DOI 10.1038/ncb891; Meraldi P, 2004, CURR OPIN GENET DEV, V14, P29, DOI 10.1016/j.gde.2003.11.006; PLYTE SE, 1992, BIOCHIM BIOPHYS ACTA, V1114, P147, DOI 10.1016/0304-419X(92)90012-N; Sarkissian M, 2004, GENE DEV, V18, P48, DOI 10.1101/gad.1136004; Stenoien DL, 2003, CELL MOTIL CYTOSKEL, V55, P134, DOI 10.1002/cm.10120; SUTER B, 1989, GENE DEV, V3, P1957, DOI 10.1101/gad.3.12a.1957; Tanji C, 2002, J BIOL CHEM, V277, P36955, DOI 10.1074/jbc.M206210200; Tighe A, 2007, BMC CELL BIOL, V8, DOI 10.1186/1471-2121-8-34; Tsai MY, 2003, NAT CELL BIOL, V5, P242, DOI 10.1038/ncb936; Wakefield JG, 2003, J CELL SCI, V116, P637, DOI 10.1242/jcs.00273; Yamamoto H, 2003, EMBO J, V22, P2047, DOI 10.1093/emboj/cdg204; Yamamoto H, 1998, MOL CELL BIOL, V18, P2867, DOI 10.1128/MCB.18.5.2867; Zachariae W, 1999, GENE DEV, V13, P2039, DOI 10.1101/gad.13.16.2039; Zumbrunn J, 2001, CURR BIOL, V11, P44, DOI 10.1016/S0960-9822(01)00002-1	32	16	16	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 24	2008	27	32					4478	4487		10.1038/onc.2008.92	http://dx.doi.org/10.1038/onc.2008.92			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329PU	18391981				2022-12-17	WOS:000257881700010
J	Dong, W; Arpin, C; Accardi, R; Gissmann, L; Sylla, BS; Marvel, J; Tommasino, M				Dong, W.; Arpin, C.; Accardi, R.; Gissmann, L.; Sylla, B. S.; Marvel, J.; Tommasino, M.			Loss of p53 or p73 in human papillomavirus type 38 E6 and E7 transgenic mice partially restores the UV-activated cell cycle checkpoints	ONCOGENE			English	Article						HPV38; transgenic mice; Delta Np73; UV irradiation; cell cycle checkpoints	SPONTANEOUS TUMORS; SKIN; PROTEINS; CANCER	We have previously shown that human keratinocytes expressing E6 and E7 from the cutaneous human papillomavirus (HPV) type 38 have high levels of a specific form of p53, which in turn activate the transcription of Delta Np73 gene. Expression of HPV38 E6 and E7 in mouse skin also promotes p53 and Delta Np73 accumulation. Interestingly, keratinocytes of these mice do not undergo cell cycle arrest after skin ultraviolet (UV) irradiation. Here, we provide several lines of evidence that Delta Np73 expression and lack of the UV response are directly linked. Loss of p53 gene in HPV38E6/E7 transgenic mice abolished Delta Np73 expression and partially restored the UV-activated cell cycle checkpoints. Similarly, loss of p73, and consequently Delta Np73, led to restoration of the p53 pathways. In fact, keratinocytes of p73(-/-) HPV38 E6/E7 transgenic mice upon UV irradiation express high levels of p21(WAF1) and are cell cycle arrested. Thus, HPV38 E6 and E7, via Delta Np73 accumulation, are able to alter the regulation of cell cycle checkpoints activated by UV radiation. These data suggest that UV and HPV may cooperate in skin carcinogenesis.	[Dong, W.; Accardi, R.; Sylla, B. S.; Tommasino, M.] WHO, Int Agcy Res Canc, Infect & Canc Biol Grp, F-69008 Lyon, France; [Arpin, C.; Marvel, J.] INSERM, U851, Lyon, France; [Arpin, C.; Marvel, J.] BioSci Lyon Gerland, IFR128, Lyon, France; [Arpin, C.; Marvel, J.] Univ Lyon 1, F-69622 Villeurbanne, France; [Gissmann, L.] Deutsch Krebsforschungszentrum, D-6900 Heidelberg, Germany	World Health Organization; International Agency for Research on Cancer (IARC); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Helmholtz Association; German Cancer Research Center (DKFZ)	Tommasino, M (corresponding author), WHO, Int Agcy Res Canc, Infect & Canc Biol Grp, F-69008 Lyon, France.	tommasino@iarc.fr	marvel, jacqueline/H-8638-2014; Gissmann, Lutz/H-4688-2011; Arpin, Christophe/M-3862-2014	marvel, jacqueline/0000-0001-6241-459X; Arpin, Christophe/0000-0003-0915-5554				Accardi R, 2006, EMBO REP, V7, P334, DOI 10.1038/sj.embor.7400615; Akgul B, 2005, CANCER RES, V65, P2216, DOI 10.1158/0008-5472.CAN-04-1952; Caldeira S, 2003, J VIROL, V77, P2195, DOI 10.1128/JVI.77.3.2195-2206.2003; de Villiers EM, 2004, VIROLOGY, V324, P17, DOI 10.1016/j.virol.2004.03.033; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Dong W, 2005, J VIROL, V79, P14899, DOI 10.1128/JVI.79.23.14899-14908.2005; Jackson S, 2000, GENE DEV, V14, P3065, DOI 10.1101/gad.182100; Michel A, 2006, J VIROL, V80, P11153, DOI 10.1128/JVI.00954-06; Pfister Herbert, 2003, J Natl Cancer Inst Monogr, P52; Schaper ID, 2005, CANCER RES, V65, P1394, DOI 10.1158/0008-5472.CAN-04-3263; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798	12	16	17	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 1	2008	27	20					2923	2928		10.1038/sj.onc.1210944	http://dx.doi.org/10.1038/sj.onc.1210944			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	295VR	18026133				2022-12-17	WOS:000255502500013
J	Shi, L; Itoh, F; Itoh, S; Takahashi, S; Yamamoto, M; Kato, M				Shi, L.; Itoh, F.; Itoh, S.; Takahashi, S.; Yamamoto, M.; Kato, M.			Ephrin-A1 promotes the malignant progression of intestinal tumors in Apc(min/+) mice	ONCOGENE			English	Article						ephrin-A1; intestinal adenoma; invasion Apc(min/+) mice	EPHA2 OVEREXPRESSION; COLORECTAL-CANCER; GENE-EXPRESSION; RECEPTOR; CARCINOMA; CELLS; TUMORIGENESIS; ANGIOGENESIS; METASTASIS; REGULATOR	The ephrin-A1 and EphA receptors are frequently highly expressed in different human cancers, suggesting that they may promote tumor development and progression. We generated transgenic mice carrying Fabpl(4xat-132) ephrin-A1, which express ephrin-A1 in the intestinal epithelial cells. Those mice were then mated with Apc(min/+) mice to produce the compound mice, which overexpress ephrin-A1 in the intestinal tumors of Apc(min/+) mice. We compared the number, size and histopathological features of the intestinal tumors in the Fabpl(4xat-132) ephrin-A1/Apc(min/+) compound mice with those of the Apc(min/+) mice. The compound mice showed an increased number of intestinal tumors, significantly in the large intestine, and developed more invasive tumors. Among the 20 mice of each type examined, 5 Apc(min/+) mice developed 5 invasive tumors, 1 invasive tumor in each mouse, in the proximal or middle portions of the small intestine. On the other hand, 14 out of 20 compound mice developed 29 invasive tumors and 16 of them were in the distal small intestine and the large intestine, where transgenic ephrin-A1 was highly expressed. These results suggested that the increased expression of ephrin-A1 accelerated the malignant progression of the intestinal adenoma to invasive tumors.	[Shi, L.; Itoh, F.; Itoh, S.; Kato, M.] Univ Tsukuba, Grad Sch Comprehens Human Sci, Dept Expt Pathol, Tsukuba, Ibaraki 3058575, Japan; [Takahashi, S.] Univ Tsukuba, Grad Sch Comprehens Human Sci, Dept Anat, Tsukuba, Ibaraki 3058575, Japan; [Takahashi, S.] Univ Tsukuba, Grad Sch Comprehens Human Sci, Dept Embryol, Tsukuba, Ibaraki 3058575, Japan; [Yamamoto, M.] Tohoku Univ, Grad Sch Med, Dept Med Biochem, Sendai, Miyagi 980, Japan; [Yamamoto, M.] Japan Sci & Technol Corp, ERATO Environm Response Project, Tsukuba, Ibaraki, Japan	University of Tsukuba; University of Tsukuba; University of Tsukuba; Tohoku University; Japan Science & Technology Agency (JST)	Kato, M (corresponding author), Univ Tsukuba, Grad Sch Comprehens Human Sci, Dept Expt Pathol, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan.	mit-kato@md.tsukuba.ac.jp		Itoh, Susumu/0000-0002-7967-0730; Itoh, Fumiko/0000-0002-6134-5331				Abraham S, 2006, CLIN CANCER RES, V12, P353, DOI 10.1158/1078-0432.CCR-05-1505; Batlle E, 2005, NATURE, V435, P1126, DOI 10.1038/nature03626; Brantley-Sieders DM, 2006, CANCER RES, V66, P10315, DOI 10.1158/0008-5472.CAN-06-1560; Brantley-Sieders DM, 2005, FASEB J, V19, P1884, DOI 10.1096/fj.05-4038fje; Coffman KT, 2003, CANCER RES, V63, P7907; DEBRUINE AP, 1993, INT J CANCER, V54, P765, DOI 10.1002/ijc.2910540510; Dobrzanski P, 2004, CANCER RES, V64, P910, DOI 10.1158/0008-5472.CAN-3430-2; Flanagan JG, 1997, CELL, V90, P403; Hamamoto T, 2002, CANCER RES, V62, P5955; Herath NI, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-144; Huusko P, 2004, NAT GENET, V36, P979, DOI 10.1038/ng1408; Kataoka H, 2004, CANCER SCI, V95, P136, DOI 10.1111/j.1349-7006.2004.tb03194.x; Kullander K, 2002, NAT REV MOL CELL BIO, V3, P475, DOI 10.1038/nrm856; Liu DP, 2007, INT J ONCOL, V30, P865; LUONGO C, 1994, CANCER RES, V54, P5947; Mellitzer G, 1999, NATURE, V400, P77, DOI 10.1038/21907; Murai KK, 2003, J CELL SCI, V116, P2823, DOI 10.1242/jcs.00625; Nakamura R, 2005, CANCER SCI, V96, P42, DOI 10.1111/j.1349-7006.2005.00007.x; Noren NK, 2006, NAT CELL BIOL, V8, P815, DOI 10.1038/ncb1438; Ogawa K, 2000, ONCOGENE, V19, P6043, DOI 10.1038/sj.onc.1204004; Parri M, 2005, J BIOL CHEM, V280, P34008, DOI 10.1074/jbc.M502879200; Pasquale EB, 2005, NAT REV MOL CELL BIO, V6, P462, DOI 10.1038/nrm1662; Potla L, 2002, CANCER LETT, V175, P187, DOI 10.1016/S0304-3835(01)00613-9; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; Saam JR, 1999, J BIOL CHEM, V274, P38071, DOI 10.1074/jbc.274.53.38071; Simon TC, 1997, J BIOL CHEM, V272, P10652; Straume O, 2005, BRIT J CANCER, V93, P933, DOI 10.1038/sj.bjc.6602792; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Surawska H, 2004, CYTOKINE GROWTH F R, V15, P419, DOI 10.1016/j.cytogfr.2004.09.002; Swatek Jaroslaw, 2000, Polish Journal of Pathology, V51, P127; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0; Wang YJ, 2002, BIOCHEM BIOPH RES CO, V296, P214, DOI 10.1016/S0006-291X(02)00806-9; Wu D, 2004, GYNECOL ONCOL, V94, P312, DOI 10.1016/j.ygyno.2004.05.019; Xu F, 2005, ANTICANCER RES, V25, P2943; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Zelinski DP, 2001, CANCER RES, V61, P2301	37	16	17	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2008	27	23					3265	3273		10.1038/sj.onc.1210992	http://dx.doi.org/10.1038/sj.onc.1210992			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	304LQ	18246128				2022-12-17	WOS:000256111400005
J	Balakrishnan, SK; Gross, DS				Balakrishnan, S. K.; Gross, D. S.			The tumor suppressor p53 associates with gene coding regions and co-traverses with elongating RNA polymerase II in an in vivo model	ONCOGENE			English	Article						p53; transcription elongation; RNA polymerase II; chromatin; acidic activator; yeast genetics	TRANSCRIPTIONAL ACTIVATION DOMAINS; FACTOR-BINDING-SITES; HEAT-SHOCK FACTOR; SACCHAROMYCES-CEREVISIAE; TARGET GENES; DNA-DAMAGE; YEAST; INITIATION; PROMOTER; COMPLEX	Sequence-specific transcriptional regulators function by stably binding cognate DNA sequences followed by recruitment of both general and specialized factors to target gene promoters. The tumor suppressor p53 mediates its antioncogenic effect on cells by functioning as a sequence specific regulator. p53 employs a secondary mechanism to suppress tumor formation by permeabilizing the outer mitochondrial membrane, thereby releasing pro-apoptotic factors. Here, we report a potential third biological function of p53: as a transcriptional elongation factor. Using chromatin immunoprecipitation, we demonstrate that human p53 robustly associates with RNA polymerase II (Pol II), but neither Pol I- nor Pol III-transcribed regions in the budding yeast, Saccharomyces cerevisiae. p53's association with open reading frames is mediated by its physical interaction with elongating Pol II, with which p53 travels in vivo and co-immunoprecipitates in vitro. When similarly expressed, the potent acidic activator VP16 cannot be crosslinked to Pol II coding regions. p53 levels comparable to those found in induced mammalian cells confer synthetic sickness or lethality in combination with deletions in genes encoding transcription elongation factors; p53 likewise confers hypersensitivity to the anti-elongation drug 6-azauracil. Collectively, our results indicate that p53 can physically interact with the transcription elongation complex and influence transcription elongation, and open up new avenues of investigation in mammalian cells.	[Balakrishnan, S. K.; Gross, D. S.] Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA; [Balakrishnan, S. K.; Gross, D. S.] Feist Weiller Canc Ctr, Shreveport, LA USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Gross, DS (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, 1501 Kings Hwy, Shreveport, LA 71130 USA.	dgross@lsuhsc.edu						Blau J, 1996, MOL CELL BIOL, V16, P2044; Brown SA, 1998, EMBO J, V17, P3146, DOI 10.1093/emboj/17.11.3146; Candau R, 1997, ONCOGENE, V15, P807, DOI 10.1038/sj.onc.1201244; Cawley S, 2004, CELL, V116, P499, DOI 10.1016/S0092-8674(04)00127-8; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DAMMANN R, 1993, NUCLEIC ACIDS RES, V21, P2331, DOI 10.1093/nar/21.10.2331; Di Lello P, 2006, MOL CELL, V22, P731, DOI 10.1016/j.molcel.2006.05.007; Donner AJ, 2007, MOL CELL, V27, P121, DOI 10.1016/j.molcel.2007.05.026; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Espinosa JM, 2003, MOL CELL, V12, P1015, DOI 10.1016/S1097-2765(03)00359-9; EXINGER F, 1992, CURR GENET, V22, P9, DOI 10.1007/BF00351735; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Gomes NP, 2006, GENE DEV, V20, P601, DOI 10.1101/gad.1398206; GROSS DS, 1993, EMBO J, V12, P3931, DOI 10.1002/j.1460-2075.1993.tb06071.x; Hampsey M, 1998, MICROBIOL MOL BIOL R, V62, P465, DOI 10.1128/MMBR.62.2.465-503.1998; Ho J, 2003, CELL DEATH DIFFER, V10, P404, DOI 10.1038/sj.cdd.4401191; Kaeser MD, 2004, ONCOGENE, V23, P4007, DOI 10.1038/sj.onc.1207536; Kennedy BK, 2002, NAT REV MOL CELL BIO, V3, P41, DOI 10.1038/nrm704; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; Laptenko O, 2006, CELL DEATH DIFFER, V13, P951, DOI 10.1038/sj.cdd.4401916; LEE SW, 1993, MOL CELL BIOL, V13, P727, DOI 10.1128/MCB.13.2.727; LIS J, 1993, CELL, V74, P1, DOI 10.1016/0092-8674(93)90286-Y; Mason PB, 2005, MOL CELL, V17, P831, DOI 10.1016/j.molcel.2005.02.017; Mattia M, 2007, MOL CELL BIOL, V27, P1309, DOI 10.1128/MCB.01520-06; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Nourani A, 2003, J BIOL CHEM, V278, P19171, DOI 10.1074/jbc.C300036200; Pokholok DK, 2006, SCIENCE, V313, P533, DOI 10.1126/science.1127677; Proft M, 2006, MOL CELL, V23, P241, DOI 10.1016/j.molcel.2006.05.031; Saunders A, 2006, NAT REV MOL CELL BIO, V7, P557, DOI 10.1038/nrm1981; Schwabish MA, 2004, MOL CELL BIOL, V24, P10111, DOI 10.1128/MCB.24.23.10111-10117.2004; Shinobu N, 1999, J BIOL CHEM, V274, P17003, DOI 10.1074/jbc.274.24.17003; Sim RJ, 2004, GENE DEV, V18, P2437, DOI 10.1101/gad.1235904; THIAGALINGAM S, 1995, P NATL ACAD SCI USA, V92, P6062, DOI 10.1073/pnas.92.13.6062; THUKRAL SK, 1995, MOL CELL BIOL, V15, P5196; Venturi CB, 2000, MOL CELL BIOL, V20, P6435, DOI 10.1128/MCB.20.17.6435-6448.2000; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wei CL, 2006, CELL, V124, P207, DOI 10.1016/j.cell.2005.10.043; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; Zhao J, 2005, MOL CELL BIOL, V25, P8985, DOI 10.1128/MCB.25.20.8985-8999.2005	42	16	16	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	2008	27	19					2661	2672		10.1038/sj.onc.1210935	http://dx.doi.org/10.1038/sj.onc.1210935			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	292IK	18026140				2022-12-17	WOS:000255259500001
J	Daubon, T; Chasseriau, J; El Ali, A; Rivet, J; Kitzis, A; Constantin, B; Bourmeyster, N				Daubon, T.; Chasseriau, J.; El Ali, A.; Rivet, J.; Kitzis, A.; Constantin, B.; Bourmeyster, N.			Differential motility of p190(bcr-abl)- and p210(bcr-abl)-expressing cells: respective roles of Vav and Bcr-Abl GEFs	ONCOGENE			English	Article						amoeboid; Bcr-Abl; motility; Rho; Vav	CHRONIC MYELOGENOUS LEUKEMIA; GTP-BINDING PROTEIN; TYROSINE PHOSPHORYLATION; ACTIVATION; MIGRATION; TRANSFORMATION; ASSOCIATION; EXPRESSION; ONCOGENE; ADHESION	The chimeric oncogene Bcr-Abl is known to induce autonomous motility of leukemicc ells. We show here that p210(bcr-abl) responsible for chronic myelogenous leukemia induces an amoeboid type of motility while p190(bcr-abl), associated with acute lymphoid leukemia, induces a rolling type of motility. We previously reported that p210(bcr-abl) activates RhoA and Rac1, while p190(bcr-abl) although devoid of a Dbl-homology (DH) domain activates Rac1, but not RhoA. We investigated the regulation of GDP/GTP exchange factor (GEF) activities in the Bcr-Abl complex. For that purpose, different GEF activity mutants of Vav and of Bcr-Abl were constructed and stably transfected in Ba/F3 cells. Using these mutants, we demonstrate that RhoA is exclusively activated by the DH domain of p210(bcr-abl), while Rac1 activation is mostly due to Vav. Inhibition of Rac1 by Vav GEF mutant leads to immobilization of cells. Vav depletion using shRNA also induces immobilization of cells and suppression of GTP-bound Rac1. RhoA inactivation induces the specific loss of amoeboid movements. These results suggest that Rac1 activation by Vav triggers the motility of Bcr-Abl-expressing Ba/F3 cells, while the specific amoeboid mode of motility induced by p210(bcr-abl) is a consequence of RhoA activation.	[Daubon, T.; Chasseriau, J.; El Ali, A.; Kitzis, A.; Constantin, B.; Bourmeyster, N.] Univ Poitiers, CNRS, Inst Phys & Biol Cellulaires, UMR 6187,Fac Sci, F-86021 Poitiers, France; [Rivet, J.; Kitzis, A.; Bourmeyster, N.] CHU Poitiers, LGCM, Poitiers, France	Centre National de la Recherche Scientifique (CNRS); Universite de Poitiers; CHU Poitiers; Universite de Poitiers	Bourmeyster, N (corresponding author), Univ Poitiers, CNRS, Inst Phys & Biol Cellulaires, UMR 6187,Fac Sci, 40 Ave Recteur Pineau,BP 577, F-86021 Poitiers, France.	n.bourmeyster@chu-poitiers.fr	Constantin, Bruno/AAH-6463-2021	ElAli, Ayman/0000-0002-4048-6039; Bourmeyster, Nicolas/0000-0002-9563-5142; DAUBON, Thomas/0000-0002-0319-7617; Constantin, Bruno/0000-0003-1668-581X				Bassermann F, 2002, J BIOL CHEM, V277, P12437, DOI 10.1074/jbc.M112397200; Bhatia R, 1999, EXP HEMATOL, V27, P1384, DOI 10.1016/S0301-472X(99)00084-3; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; CHUANG TH, 1995, P NATL ACAD SCI USA, V92, P10282, DOI 10.1073/pnas.92.22.10282; CLARK SS, 1988, SCIENCE, V239, P775, DOI 10.1126/science.3422516; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Deininger MWN, 2000, BLOOD, V96, P3343, DOI 10.1182/blood.V96.10.3343; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Harnois T, 2003, ONCOGENE, V22, P6445, DOI 10.1038/sj.onc.1206626; Hernandez SE, 2004, TRENDS CELL BIOL, V14, P36, DOI 10.1016/j.tcb.2003.11.003; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; Marvaud JC, 2002, J BIOL CHEM, V277, P43659, DOI 10.1074/jbc.M207828200; MATSUGUCHI T, 1995, EMBO J, V14, P257, DOI 10.1002/j.1460-2075.1995.tb06999.x; Nakashima S, 1999, CHEM PHYS LIPIDS, V98, P153, DOI 10.1016/S0009-3084(99)00027-4; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; Salgia R, 1997, J CLIN INVEST, V100, P46, DOI 10.1172/JCI119520; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; STASIA MJ, 1991, BIOCHEM BIOPH RES CO, V180, P615, DOI 10.1016/S0006-291X(05)81110-6; Unwin RD, 2005, J BIOL CHEM, V280, P6316, DOI 10.1074/jbc.M410598200; Van Etten RA, 1999, TRENDS CELL BIOL, V9, P179, DOI 10.1016/S0962-8924(99)01549-4; Wertheim JA, 2002, BLOOD, V99, P4122, DOI 10.1182/blood.V99.11.4122; Yamazaki D, 2005, CANCER SCI, V96, P379, DOI 10.1111/j.1349-7006.2005.00062.x; Zheng J, 1997, J BIOL CHEM, V272, P30340, DOI 10.1074/jbc.272.48.30340	27	16	17	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	2008	27	19					2673	2685		10.1038/sj.onc.1210933	http://dx.doi.org/10.1038/sj.onc.1210933			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	292IK	18059343				2022-12-17	WOS:000255259500002
J	Datta, A; Nicot, C				Datta, A.; Nicot, C.			Telomere attrition induces a DNA double-strand break damage signal that reactivates p53 transcription in HTLV-I leukemic cells	ONCOGENE			English	Article						telomere; p53; MDMX; HTLV-I; ATM; senescence	HOMOLOGOUS RECOMBINATION; INTERFERON-ALFA; MDMX; PHOSPHORYLATION; ZIDOVUDINE; LYMPHOMA; TAX; ATM; INACTIVATION; COMBINATION	Persistent inhibition of telomerase induces a severe telomere shortening in human T-cell leukemia virus type-1-infected cells which signals a DNA double-strand break damage response, formation of telomere dysfunction-induced foci and activates the ATM pathway. In turn, activation of ATM and its downstream effectors led to an increased phosphorylation and acetylation on specific residues of p53 known to be involved in transcriptional activation. Disruption of Mdm2-p53 complexes coupled with increased proteasomal degradation of MDMX further enhanced reactivation of p53 transcription, ultimately leading to senescence of tumor cells. Induction of senescence in these T-cells was associated with an increased expression of p21, p16 and activation of GSK3 beta. Our results support the cancer - aging model and demonstrate that the halt of aging in cancer cells can be reversed through reactivation of p53.	[Datta, A.; Nicot, C.] Univ Kansas, Med Ctr, Dept Microbiol Mol Genet & Immunol, Kansas City, KS 66103 USA	University of Kansas; University of Kansas Medical Center	Nicot, C (corresponding author), Univ Kansas, Med Ctr, Dept Microbiol Mol Genet & Immunol, 3025 Wahl Hall W,3901 Rainbow Blvd, Kansas City, KS 66103 USA.	cnicot@kumc.edu		Datta, Abhik/0000-0002-3442-5774	NCI NIH HHS [R01 CA106258, R01CA106258] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA106258] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bellon M, 2006, INT J CANCER, V119, P2090, DOI 10.1002/ijc.22026; Celli GB, 2005, NAT CELL BIOL, V7, P712, DOI 10.1038/ncb1275; Celli GB, 2006, NAT CELL BIOL, V8, P885, DOI 10.1038/ncb1444; Chehab NH, 2000, GENE DEV, V14, P278; Datta A, 2006, BLOOD, V108, P1021, DOI 10.1182/blood-2006-01-0067; GILL PS, 1995, NEW ENGL J MED, V332, P1744, DOI 10.1056/NEJM199506293322603; Grassmann R, 2005, ONCOGENE, V24, P5976, DOI 10.1038/sj.onc.1208978; Gu JJ, 2002, J BIOL CHEM, V277, P19251, DOI 10.1074/jbc.C200150200; Haoudi A, 2003, J BIOL CHEM, V278, P37736, DOI 10.1074/jbc.M301649200; He H, 2006, EMBO J, V25, P5180, DOI 10.1038/sj.emboj.7601294; HERMINE O, 1995, NEW ENGL J MED, V332, P1749, DOI 10.1056/NEJM199506293322604; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Li CG, 2002, MOL CELL BIOL, V22, P7562, DOI 10.1128/MCB.22.21.7562-7571.2002; Liu L, 1999, MOL CELL BIOL, V19, P1202; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Matutes E, 2001, BRIT J HAEMATOL, V113, P779, DOI 10.1046/j.1365-2141.2001.02794.x; Pan Y, 2003, MOL CELL BIOL, V23, P5113, DOI 10.1128/MCB.23.15.5113-5121.2003; Park HU, 2006, ONCOGENE, V25, P438, DOI 10.1038/sj.onc.1209059; Park HU, 2004, ONCOGENE, V23, P4966, DOI 10.1038/sj.onc.1207644; Pise-Masison CA, 1998, J VIROL, V72, P6348, DOI 10.1128/JVI.72.8.6348-6355.1998; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Ramos YFM, 2001, CANCER RES, V61, P1839; Sabbatini P, 2002, DNA CELL BIOL, V21, P519, DOI 10.1089/104454902320219077; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Sinha-Datta U, 2004, BLOOD, V104, P2523, DOI 10.1182/blood-2003-12-4251; White JD, 2001, LEUKEMIA LYMPHOMA, V40, P287, DOI 10.3109/10428190109057927	29	16	16	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 14	2008	27	8					1135	1141		10.1038/sj.onc.1210718	http://dx.doi.org/10.1038/sj.onc.1210718			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	262GJ	17704807				2022-12-17	WOS:000253136700013
J	Radhakrishnan, SK; Halasi, M; Bhat, UG; Kurmasheva, RT; Houghton, PJ; Gartel, AL				Radhakrishnan, S. K.; Halasi, M.; Bhat, U. G.; Kurmasheva, R. T.; Houghton, P. J.; Gartel, A. L.			Proapoptotic compound ARC targets Akt and N-myc in neuroblastoma cells	ONCOGENE			English	Article						ARC; neuroblastoma; survivin; Mcl-1; Akt; N-myc	HIGH-RISK NEUROBLASTOMA; APOPTOSIS; TRANSPLANTATION; CHEMOTHERAPY; INHIBITOR; SURVIVAL; PROTEIN; EXPRESSION; REPRESSION; IRINOTECAN	We have previously described the identification of a nucleoside analog transcriptional inhibitor ARC (4-amino- 6-hydrazino-7-beta-D-ribofuranosyl-7H-pyrrolo[ 2,3-d]- pyrimidine-5-carboxamide) that was able to induce apoptosis in cancer cell lines of different origin. Here, we report the characterization of ARC on a panel of neuroblastoma cell lines. We found that these cell lines were more than 10-fold sensitive to ARC than to the well-known nucleoside analog DRB (5,6-dichloro-1-beta-Dribofuranosylbenzimidazole), and that ARC-induced apoptosis proceeds through mitochondrial injury. Also, we observed that ARC-mediated cell death was accompanied by caspase-3 cleavage and repression of antiapoptotic proteins such as Mcl-1 and survivin. Conversely, we found that overexpression of Mcl-1-protected neuroblastoma cell line NB-1691 from ARC-induced apoptosis. Furthermore, we found that while ARC inhibited the phosphorylation of Akt Ser-473 in multiple cancer cell lines, forced expression of myristoylated Akt promoted resistance to ARC-induced apoptosis in neuroblastoma cells. In addition, we observed that ARC was able to downregulate the protein levels of N-myc, a commonly amplified oncogene in neuroblastomas, and Akt protected N-myc from ARC-induced downregulation. These data suggest that ARC may antagonize different antiapoptotic pathways and induce apoptosis in neuroblastoma cells via multiple mechanisms. Overall, ARC could represent an attractive candidate for anticancer drug development against neuroblastomas.	[Radhakrishnan, S. K.; Bhat, U. G.; Gartel, A. L.] Univ Illinois, Dept Med, Chicago, IL 60612 USA; [Radhakrishnan, S. K.; Gartel, A. L.] Univ Illinois, Dept Microbiol & Immunol, Chicago, IL 60680 USA; [Halasi, M.] Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL 60680 USA; [Kurmasheva, R. T.; Houghton, P. J.] St Jude Childrens Hosp, Dept Mol Pharmacol, Memphis, TN 38105 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; St Jude Children's Research Hospital	Gartel, AL (corresponding author), Univ Illinois, Dept Med, 840 S Wood St,Room 1041, Chicago, IL 60612 USA.	agartel@uic.edu	Houghton, Peter/E-3265-2011	Radhakrishnan, Senthil/0000-0002-5211-9498	NCI NIH HHS [CA96696, CA23099] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA096696, P01CA023099] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Castel V, 2001, MED PEDIATR ONCOL, V37, P537, DOI 10.1002/mpo.1248; Castel V, 2000, MED PEDIATR ONCOL, V35, P724, DOI 10.1002/1096-911X(20001201)35:6<724::AID-MPO53>3.0.CO;2-U; Castillo S, 2004, ATHEROSCLEROSIS SUPP, V5, P80, DOI 10.1016/S1567-5688(04)90347-4; Chesler L, 2006, CANCER RES, V66, P8139, DOI 10.1158/0008-5472.CAN-05-2769; Donfrancesco A, 2004, ACTA PAEDIATR, V93, P6, DOI 10.0180/08035320310021165; DuBois SG, 1999, J PEDIAT HEMATOL ONC, V21, P181, DOI 10.1097/00043426-199905000-00005; Furman WL, 1999, J CLIN ONCOL, V17, P1815, DOI 10.1200/JCO.1999.17.6.1815; Gojo I, 2002, CLIN CANCER RES, V8, P3527; Goldsby Robert E, 2004, Paediatr Drugs, V6, P107, DOI 10.2165/00148581-200406020-00004; Houghton PJ, 2002, J PEDIAT HEMATOL ONC, V24, P84, DOI 10.1097/00043426-200202000-00002; Imaizumi M, 2001, TOHOKU J EXP MED, V195, P73, DOI 10.1620/tjem.195.73; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Kaneko M, 2002, J PEDIAT HEMATOL ONC, V24, P613, DOI 10.1097/00043426-200211000-00004; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Ma YH, 2003, MOL CANCER THER, V2, P73; MARSHALL NF, 1992, MOL CELL BIOL, V12, P2078, DOI 10.1128/MCB.12.5.2078; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Matthay KK, 1999, NEW ENGL J MED, V341, P1165, DOI 10.1056/NEJM199910143411601; Newcomb EW, 2003, CELL CYCLE, V2, P243, DOI 10.4161/cc.2.3.357; Norris MD, 1996, NEW ENGL J MED, V334, P231, DOI 10.1056/NEJM199601253340405; Peng J, 1998, COLD SPRING HARB SYM, V63, P365, DOI 10.1101/sqb.1998.63.365; Radhakrishnan SK, 2006, CANCER RES, V66, P9731, DOI 10.1158/0008-5472.CAN-06-1576; Radhakrishnan SK, 2006, CELL CYCLE, V5, P519, DOI 10.4161/cc.5.5.2514; Radhakrishnan SK, 2006, CANCER RES, V66, P3264, DOI 10.1158/0008-5472.CAN-05-3940; Radhakrishnan SK, 2005, CELL CYCLE, V4, P582, DOI 10.4161/cc.4.4.1583; Radhakrishnan SK, 2004, ONCOGENE, V23, P4173, DOI 10.1038/sj.onc.1207571; Thompson J, 1999, CLIN CANCER RES, V5, P3617; Thompson J, 2001, CANCER CHEMOTH PHARM, V47, P211, DOI 10.1007/s002800000235; Valteau-Couanet D, 2000, BONE MARROW TRANSPL, V25, P937, DOI 10.1038/sj.bmt.1702376; van Noesel MM, 2004, GENE, V325, P1, DOI 10.1016/j.gene.2003.09.042	31	16	18	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 24	2008	27	5					694	699		10.1038/sj.onc.1210692	http://dx.doi.org/10.1038/sj.onc.1210692			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	255RK	17724478				2022-12-17	WOS:000252674900013
J	Fadloun, A; Kobi, D; Delacroix, L; Dembele, D; Michel, I; Lardenois, A; Tisserand, J; Losson, R; Mengus, G; Davidson, I				Fadloun, A.; Kobi, D.; Delacroix, L.; Dembele, D.; Michel, I.; Lardenois, A.; Tisserand, J.; Losson, R.; Mengus, G.; Davidson, I.			Retinoic acid induces TGF beta-dependent autocrine fibroblast growth	ONCOGENE			English	Article						TAF4; transcription regulation; CTGF; MBD1; ENPP1/PC-1	LIVER STELLATE CELLS; TREATED HL-60 CELLS; TFIID COMPLEX; INCREASES SUSCEPTIBILITY; EMBRYONAL CARCINOMA; TARGET GENES; EXPRESSION; DIFFERENTIATION; PROTEIN; TRANSCRIPTION	To evaluate the role of murine TFIID subunit TAF4 in activation of cellular genes by all-trans retinoic acid (T-RA), we have characterized the T-RA response of taf4(lox/-) and taf4(-/-) embryonic fibroblasts. T-RA regulates almost 1000 genes in taf4(lox/-) cells, but less than 300 in taf4(-/-) cells showing that TAF4 is required for T-RA regulation of most, but not all cellular genes. We further show that T-RA-treated taf4(lox/-) cells exhibit transforming growth factor (TGF) beta-dependent autocrine growth and identify a set of genes regulated by loss of TAF4 and by T-RA corresponding to key mediators of the TGF beta signalling pathway. T-RA rapidly and potently induces expression of connective tissue growth factor (CTGF) via a conserved DR2 type response element in its proximal promoter leading to serum-free autocrine growth. These results highlight the role of TAF4 as a cofactor in the cellular response to T-RA and identify the genetic programme of a novel cross talk between the T-RA and TGFb pathways that leads to deregulated cell growth.	[Fadloun, A.; Kobi, D.; Delacroix, L.; Dembele, D.; Michel, I.; Lardenois, A.; Tisserand, J.; Losson, R.; Mengus, G.; Davidson, I.] Inst Genet & Biol Mol & Cellulaire, CNRS, INSERM, ULP,UMR7104, F-67404 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Davidson, I (corresponding author), Inst Genet & Biol Mol & Cellulaire, CNRS, INSERM, ULP,UMR7104, 1 Rue Laurent Fries, F-67404 Illkirch Graffenstaden, France.	irwin@titus.u-strasbg.fr	Dembélé, Doulaye/O-6513-2017; Lardenois, Aurélie/AAA-8961-2020	Dembélé, Doulaye/0000-0003-3879-6940; Delacroix, Laurence/0000-0003-3440-5359; Davidson, Irwin/0000-0001-5533-1171; MENGUS, Gabrielle/0000-0002-2844-1778				Abreu JG, 2002, NAT CELL BIOL, V4, P599, DOI 10.1038/ncb826; Annes JP, 2003, J CELL SCI, V116, P217, DOI 10.1242/jcs.00229; Bastien J, 2004, GENE, V328, P1, DOI 10.1016/j.gene.2003.12.005; Benetti R, 2001, EMBO J, V20, P2702, DOI 10.1093/emboj/20.11.2702; Bohnsack BL, 2004, GENE DEV, V18, P1345, DOI 10.1101/gad.1184904; Brand M, 1999, J BIOL CHEM, V274, P18285, DOI 10.1074/jbc.274.26.18285; Brigstock DR, 2003, J ENDOCRINOL, V178, P169, DOI 10.1677/joe.0.1780169; Cao ZH, 2003, BLOOD, V101, P498, DOI 10.1182/blood-2002-05-1549; Cerignoli F, 2002, CANCER RES, V62, P1196; Chen F, 2002, CELL, V110, P713, DOI 10.1016/S0092-8674(02)00932-7; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; Eifert C, 2006, MOL REPROD DEV, V73, P796, DOI 10.1002/mrd.20444; Falender AE, 2005, GENE DEV, V19, P794, DOI 10.1101/gad.1290105; FALK LA, 1991, BLOOD, V77, P1248; Freemantle SJ, 2002, ONCOGENE, V21, P2880, DOI 10.1038/sj.onc.1205408; Freiman RN, 2001, SCIENCE, V293, P2084, DOI 10.1126/science.1061935; Gangloff YG, 2000, MOL CELL BIOL, V20, P340, DOI 10.1128/MCB.20.1.340-351.2000; GLICK AB, 1991, DEVELOPMENT, V111, P1081; GLICK AB, 1989, CELL REGUL, V1, P87, DOI 10.1091/mbc.1.1.87; Grob P, 2006, STRUCTURE, V14, P511, DOI 10.1016/j.str.2005.11.020; Grotendorst GR, 1996, CELL GROWTH DIFFER, V7, P469; Harris Thomas M, 2002, Funct Integr Genomics, V2, P105, DOI 10.1007/s10142-002-0062-6; Inman GJ, 2002, MOL CELL, V10, P283, DOI 10.1016/S1097-2765(02)00585-3; Jacquemin P, 1996, J BIOL CHEM, V271, P21775, DOI 10.1074/jbc.271.36.21775; Kizawa H, 2005, NAT GENET, V37, P138, DOI 10.1038/ng1496; Koda H, 1996, BIOCHEM BIOPH RES CO, V221, P565, DOI 10.1006/bbrc.1996.0636; Krig SR, 2002, TOXICOL SCI, V68, P102, DOI 10.1093/toxsci/68.1.102; Laping NJ, 2002, MOL PHARMACOL, V62, P58, DOI 10.1124/mol.62.1.58; Leask A, 2003, J BIOL CHEM, V278, P13008, DOI 10.1074/jbc.M210366200; Leask A, 2003, BIOCHEM CELL BIOL, V81, P355, DOI 10.1139/O03-069; Lee YJ, 2000, FEBS LETT, V472, P230, DOI 10.1016/S0014-5793(00)01461-7; Leurent C, 2004, EMBO J, V23, P719, DOI 10.1038/sj.emboj.7600111; MADDUX BA, 1995, NATURE, V373, P448, DOI 10.1038/373448a0; Matangkasombut O, 2004, ADV PROTEIN CHEM, V67, P67; Mengus G, 2005, EMBO J, V24, P2753, DOI 10.1038/sj.emboj.7600748; Mengus G, 1997, GENE DEV, V11, P1381, DOI 10.1101/gad.11.11.1381; Meyre D, 2005, NAT GENET, V37, P863, DOI 10.1038/ng1604; Nagpal S, 1999, J BIOL CHEM, V274, P22563, DOI 10.1074/jbc.274.32.22563; Nugent P, 1998, J CELL PHYSIOL, V177, P36, DOI 10.1002/(SICI)1097-4652(199810)177:1<36::AID-JCP4>3.0.CO;2-F; Nunes I, 1996, CANCER RES, V56, P495; Okuno M, 1997, HEPATOLOGY, V26, P913, DOI 10.1053/jhep.1997.v26.pm0009328313; Okuno M, 2002, FRONT BIOSCI-LANDMRK, V7, pD204, DOI 10.2741/okuno; Pendaries V, 2003, ONCOGENE, V22, P8212, DOI 10.1038/sj.onc.1206913; ROBERTS AB, 1992, CANCER SURV, V14, P205; Sanders SL, 2000, J BIOL CHEM, V275, P13895, DOI 10.1074/jbc.275.18.13895; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Tanese N, 1996, P NATL ACAD SCI USA, V93, P13611, DOI 10.1073/pnas.93.24.13611; Thuault S, 2002, J BIOL CHEM, V277, P45510, DOI 10.1074/jbc.M206556200; Tora L, 2002, GENE DEV, V16, P673, DOI 10.1101/gad.976402; Villa R, 2006, P NATL ACAD SCI USA, V103, P1400, DOI 10.1073/pnas.0509343103; Walker AK, 2001, EMBO J, V20, P5269, DOI 10.1093/emboj/20.18.5269; Wei Y, 2002, DIFFERENTIATION, V70, P204, DOI 10.1046/j.1432-0436.2002.700409.x; Yu Q, 2000, GENE DEV, V14, P163	53	16	17	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2008	27	4					477	489		10.1038/sj.onc.1210657	http://dx.doi.org/10.1038/sj.onc.1210657			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	252DU	17637747				2022-12-17	WOS:000252426100008
J	Okuyama, T; Kurata, S; Tomimori, Y; Fukunishi, N; Sato, S; Osada, M; Tsukinoki, K; Jin, HF; Yamashita, A; Ito, M; Kobayashi, S; Hata, RI; Ikawa, Y; Katoh, I				Okuyama, T.; Kurata, S.; Tomimori, Y.; Fukunishi, N.; Sato, S.; Osada, M.; Tsukinoki, K.; Jin, H-F; Yamashita, A.; Ito, M.; Kobayashi, S.; Hata, R-I; Ikawa, Y.; Katoh, I.			p63(TP63) elicits strong trans-activation of the MFG-E8/lactadherin/BA46 gene through interactions between the TA and Delta N isoforms	ONCOGENE			English	Article						p63; MFG-E8; lactadherin; BA46; P53	MILK-FAT GLOBULE; SQUAMOUS-CELL CARCINOMA; P53 HOMOLOG P63; PROTEIN STABILITY; APOPTOTIC CELLS; STEM-CELLS; EXPRESSION; GLYCOPROTEIN; BINDING; CANCER	We report here that human MFGE8 encoding milk fat globule-EGF factor 8 protein (MFG-E8), also termed 46 kDa breast epithelial antigen and lactadherin, is transcriptionally activated by p63, or TP63, a p53 (TP53) family protein frequently overexpressed in head-and-neck squamous cell carcinomas, mammary carcinomas and so on. Despite that human MFG-E8 was originally identified as a breast cancer marker, and has recently been reported to provide peptides for cancer immunotherapy, its transcriptional control remains an open question. Observations in immunohistochemical analyses, a tetracycline-induced p63 expression system and keratinocyte cultures suggested a physiological link between p63 and MFGE8. By reporter assays with immediately upstream regions of MFGE8, we determined that the trans-activator (TA) isoforms of p63 activate MFGE8 transcription though a p53/p63 motif at -370, which was confirmed by a chromatin immunoprecipitation experiment. Upon siRNA-mediated p63 silencing in a squamous cell carinoma line, MFG-E8 production decreased to diminish Saos-2 cell adhesion. Interestingly, the Delta N-p63 isoform lacking the TA domain enhanced the MFGE8-activating function of TA-p63, if Delta N-p63 was dominant over TA-p63 as typically observed in undifferentiated keratinocytes and squamous cell carcinomas, implying a self-regulatory mechanism of p63 by the TA: Delta N association. MFG-E8 may provide a novel pathway of epithelial-nonepithelial cell interactions inducible by p63, probably in pathological processes.	[Jin, H-F; Yamashita, A.; Ito, M.; Katoh, I.] Univ Yamanashi, Interdisciplinary Grad Sch Med & Engn, Dept Microbiol, Yamanashi 4063898, Japan; [Okuyama, T.; Tomimori, Y.; Ikawa, Y.; Katoh, I.] RIKEN, Ikawa Lab, Wako, Saitama 35101, Japan; [Okuyama, T.; Kobayashi, S.] Kyoritsu Univ Pharm, Dept Mol Physiol, Tokyo, Japan; [Kurata, S.] Tokyo Med & Dent Univ, Inst Med Res, Dept Redox Response Cell Biol, Tokyo, Japan; [Kurata, S.; Tsukinoki, K.; Hata, R-I] Kanagawa Dent Coll, Oral Hlth Sci Res Ctr, Yokosuka, Kanagawa 238, Japan; [Sato, S.] Tokyo Med & Dent Univ, Dept Immune Regulat, Tokyo, Japan; [Osada, M.] Tokyo Med & Dent Univ, Human Gene Sci Ctr, Tokyo, Japan; [Jin, H-F; Ito, M.; Katoh, I.] Univ Yamanashi, Interdisciplinary Grad Sch Med & Engn, Dept Microbiol, Yamanashi, Japan; [Jin, H-F; Yamashita, A.; Katoh, I.] Tokyo Med & Dent Univ, Dept Hematol, Tokyo, Japan	University of Yamanashi; RIKEN; Keio University; Tokyo Medical & Dental University (TMDU); Kanagawa Dental College; Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); University of Yamanashi; Tokyo Medical & Dental University (TMDU)	Katoh, I (corresponding author), Univ Yamanashi, Interdisciplinary Grad Sch Med & Engn, Dept Microbiol, Yamanashi 4063898, Japan.	iyoko@yamanashi.ac.jp						Brunner HG, 2002, J MED GENET, V39, P377, DOI 10.1136/jmg.39.6.377; Carmon L, 2002, J CLIN INVEST, V110, P453, DOI 10.1172/JCI200214071; Carroll DK, 2006, NAT CELL BIOL, V8, P551, DOI 10.1038/ncb1420; Celli J, 1999, CELL, V99, P143, DOI 10.1016/S0092-8674(00)81646-3; DiRenzo J, 2002, CANCER RES, V62, P89; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Ensslin MA, 2003, CELL, V114, P405, DOI 10.1016/S0092-8674(03)00643-3; Gailit J, 1997, EXP CELL RES, V232, P118, DOI 10.1006/excr.1997.3512; Hanayama R, 2002, NATURE, V417, P182, DOI 10.1038/417182a; Hanayama R, 2005, P NATL ACAD SCI USA, V102, P16886, DOI 10.1073/pnas.0508599102; Hanayama R, 2004, SCIENCE, V304, P1147, DOI 10.1126/science.1094359; Helton ES, 2006, J BIOL CHEM, V281, P2533, DOI 10.1074/jbc.M507964200; Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462; Hoffmann Stephan, 2005, BMC Ophthalmol, V5, P16, DOI 10.1186/1471-2415-5-16; Hvarregaard J, 1996, EUR J BIOCHEM, V240, P628, DOI 10.1111/j.1432-1033.1996.0628h.x; Ihrie RA, 2005, CELL, V120, P843, DOI 10.1016/j.cell.2005.01.008; Koga F, 2003, BRIT J CANCER, V88, P740, DOI 10.1038/sj.bjc.6600764; Koistinen P, 1999, MATRIX BIOL, V18, P239, DOI 10.1016/S0945-053X(99)00022-0; Kojima T, 2001, BIOCHEM BIOPH RES CO, V281, P1170, DOI 10.1006/bbrc.2001.4486; Kruger W, 2000, BRIT J CANCER, V83, P874, DOI 10.1054/bjoc.2000.1404; Kurata S, 2004, J BIOL CHEM, V279, P50069, DOI 10.1074/jbc.M406322200; LAROCCA D, 1991, CANCER RES, V51, P4994; Li ER, 2000, EXP DERMATOL, V9, P431, DOI 10.1034/j.1600-0625.2000.009006431.x; Liu Y, 2005, CANCER GENE THER, V12, P304, DOI 10.1038/sj.cgt.7700785; Massion PP, 2003, CANCER RES, V63, P7113; MATHER IH, 1993, BIOCHEM MOL BIOL INT, V29, P545; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Okada Y, 2002, EXP CELL RES, V276, P194, DOI 10.1006/excr.2002.5535; Osada M, 2005, MOL CELL BIOL, V25, P6077, DOI 10.1128/MCB.25.14.6077-6089.2005; Osada M, 2005, J INVEST DERMATOL, V125, P52, DOI 10.1111/j.0022-202X.2005.23801.x; Osada M, 2001, BIOCHEM BIOPH RES CO, V283, P1135, DOI 10.1006/bbrc.2001.4905; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Oshima K, 2002, EUR J BIOCHEM, V269, P1209, DOI 10.1046/j.1432-1033.2002.02758.x; Pellegrini G, 2001, P NATL ACAD SCI USA, V98, P3156, DOI 10.1073/pnas.061032098; PETERSON JA, 1990, HYBRIDOMA, V9, P221, DOI 10.1089/hyb.1990.9.221; Quade BJ, 2001, GYNECOL ONCOL, V80, P24, DOI 10.1006/gyno.2000.5953; Rossi M, 2006, P NATL ACAD SCI USA, V103, P12753, DOI 10.1073/pnas.0603449103; Shi JL, 2003, BLOOD, V101, P2628, DOI 10.1182/blood-2002-07-1951; Silvestre JS, 2005, NAT MED, V11, P499, DOI 10.1038/nm1233; Smith RA, 2004, ANN BIOMED ENG, V32, P635, DOI 10.1023/B:ABME.0000030230.81832.99; Taylor MR, 1997, DNA CELL BIOL, V16, P861, DOI 10.1089/dna.1997.16.861; Watanabe T, 2005, CELL TISSUE RES, V321, P185, DOI 10.1007/s00441-005-1148-y; Wu GJ, 2005, CANCER RES, V65, P758; Yamaguchi K, 2000, INT J CANCER, V86, P684, DOI 10.1002/(SICI)1097-0215(20000601)86:5<684::AID-IJC13>3.0.CO;2-M; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0	46	16	16	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2008	27	3					308	317		10.1038/sj.onc.1210646	http://dx.doi.org/10.1038/sj.onc.1210646			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249UR	17637751				2022-12-17	WOS:000252256000006
J	Spaner, DE; Foley, R; Galipeau, J; Bramson, J				Spaner, D. E.; Foley, R.; Galipeau, J.; Bramson, J.			Obstacles to effective Toll-like receptor agonist therapy for hematologic malignancies	ONCOGENE			English	Review						cancer immunotherapy; Toll-like receptors; hypoxia; glycolysis; adenosine; microenvironment	CHRONIC LYMPHOCYTIC-LEUKEMIA; REGULATORY T-CELLS; CANCER-THERAPY; B-CELLS; ADENOSINE RECEPTORS; MULTIPLE-MYELOMA; CYCLOOXYGENASE INHIBITORS; HEXOSAMINE BIOSYNTHESIS; NUCLEOSIDE TRANSPORTERS; DENDRITIC CELLS	It has long been noted that products of microorganisms have clinical activity against hematologic malignancies. Recent advances suggest that Toll-like receptors (TLRs) activated by ligands in the microbial preparations might account for some of this activity, and that defined TLR agonists might improve the clinical efficacy of this approach. A potentially important mechanism of action of TLR agonists is their ability to cause tumor cells to differentiate into a 'tolerized' state in which they become highly sensitive to cytotoxic effector cells and chemotherapeutic drugs. TLR agonists as single agents have strong activity against cutaneous leukemias and lymphomas but are not as effective against systemic disease. A possible reason for this discrepancy is the hypoxic internal tumor microenvironment, which promotes glycolytic metabolism, and the presence of suppressive cytokines, prostaglandins and nucleosides that prevent strong TLR signaling in cancer cells. Accordingly, concomitant use of agents to counter this intrinsic microenvironmental inhibition, together with TLR agonists, may prove to be an effective treatment strategy for the hematologic malignancies.	[Spaner, D. E.] Sunnybrook & Womens Coll Hlth Sci Ctr, Div Mol & Cellular Biol, Res Inst, Toronto, ON M4N 3M5, Canada; [Spaner, D. E.] Sunnybrook Reg Canc Ctr, Toronto, ON, Canada; [Spaner, D. E.] Univ Toronto, Dept Med, Toronto, ON, Canada; [Spaner, D. E.] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; [Foley, R.; Bramson, J.] McMaster Univ, Ctr Gene Therapeut, Dept Pathol & Mol Med, Hamilton, ON, Canada; [Galipeau, J.] McGill Univ, Dept Med & Oncol, Sir Mortimer B Davis Jewish Gen Hosp, Montreal, PQ, Canada; [Galipeau, J.] McGill Univ, Dept Med & Oncol, Lady Davis Inst Med Res, Montreal, PQ, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Toronto; McMaster University; McGill University; Lady Davis Institute; McGill University	Spaner, DE (corresponding author), Sunnybrook & Womens Coll Hlth Sci Ctr, Div Mol & Cellular Biol, Res Inst, S-116A,Res Bldg,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	david.spaner@swri.ca	Galipeau, Jacques/R-9909-2019	Galipeau, Jacques/0000-0002-9374-1996; Bramson, Jonathan/0000-0003-2874-6886				Al-Waili NS, 2005, MED SCI MONITOR, V11, pRA279; Bernasconi NL, 2003, BLOOD, V101, P4500, DOI 10.1182/blood-2002-11-3569; Blagosklonny MV, 2002, NAT REV CANCER, V2, P221, DOI 10.1038/nrc743; Blay J, 1997, CANCER RES, V57, P2602; Bogner C, 2003, EXP HEMATOL, V31, P218, DOI 10.1016/S0301-472X(02)01076-7; Bohle A, 2003, J UROLOGY, V170, P964, DOI 10.1097/01.ju.0000073852.24341.4a; Bohnhorst J, 2006, LEUKEMIA, V20, P1138, DOI 10.1038/sj.leu.2404225; Bouche C, 2004, ENDOCR REV, V25, P807, DOI 10.1210/er.2003-0026; Brown JM, 2004, NAT REV CANCER, V4, P437, DOI 10.1038/nrc1367; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Cairns R, 2006, MOL CANCER RES, V4, P61, DOI 10.1158/1541-7786.MCR-06-0002; Cann SAH, 2003, POSTGRAD MED J, V79, P672; Casale TB, 2006, ANN ALLERG ASTHMA IM, V97, P454, DOI 10.1016/S1081-1206(10)60934-9; Coors EA, 2006, EUR J DERMATOL, V16, P391; Corthals SL, 2006, BRIT J HAEMATOL, V132, P452, DOI 10.1111/j.1365-2141.2005.05893.x; Curiel TJ, 2007, J CLIN INVEST, V117, P1167, DOI 10.1172/JCI31202; Diebold SS, 2006, EUR J IMMUNOL, V36, P3256, DOI 10.1002/eji.200636617; Dudley ME, 2005, J CLIN ONCOL, V23, P2346, DOI 10.1200/JCO.2005.00.240; Fan HK, 2004, J ENDOTOXIN RES, V10, P71, DOI 10.1179/096805104225003997; Gambhir SS, 2002, NAT REV CANCER, V2, P683, DOI 10.1038/nrc882; Garriga-Canut M, 2006, NAT NEUROSCI, V9, P1382, DOI 10.1038/nn1791; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Godaly G, 2005, CELL MICROBIOL, V7, P591, DOI 10.1111/j.1462-5822.2004.00489.x; Gomez G, 2003, INT J BIOCHEM CELL B, V35, P410, DOI 10.1016/S1357-2725(02)00177-2; GOODMAN MG, 1994, BLOOD, V84, P3457; GREEN H, 1973, SCIENCE, V182, P836, DOI 10.1126/science.182.4114.836; Gross BJ, 2005, J AM CHEM SOC, V127, P14588, DOI 10.1021/ja0555217; Harrison LI, 2007, J CLIN PHARMACOL, V47, P962, DOI 10.1177/0091270007303766; Hart GW, 2007, NATURE, V446, P1017, DOI 10.1038/nature05815; Hemmi H, 2002, NAT IMMUNOL, V3, P196, DOI 10.1038/ni758; Heyen JRR, 2000, MOL BRAIN RES, V77, P138, DOI 10.1016/S0169-328X(00)00042-5; Huang JB, 2007, CELL IMMUNOL, V245, P1, DOI 10.1016/j.cellimm.2007.03.006; IMAMURA J, 1994, BLOOD, V84, P2412, DOI 10.1182/blood.V84.8.2412.bloodjournal8482412; Jacobson KA, 2006, NAT REV DRUG DISCOV, V5, P247, DOI 10.1038/nrd1983; Jager Dirk, 2007, Methods Mol Biol, V360, P319; Jahrsdorfer B, 2005, CLIN CANCER RES, V11, P1490, DOI 10.1158/1078-0432.CCR-04-1890; Jego G, 2006, LEUKEMIA, V20, P1130, DOI 10.1038/sj.leu.2404226; Kabelitz D, 2007, CURR OPIN IMMUNOL, V19, P39, DOI 10.1016/j.coi.2006.11.007; Kindzelskii AL, 2002, J CLIN INVEST, V110, P1801, DOI 10.1172/JCI200215973; King AE, 2006, TRENDS PHARMACOL SCI, V27, P416, DOI 10.1016/j.tips.2006.06.004; Kleef R, 2001, NEUROIMMUNOMODULAT, V9, P55, DOI 10.1159/000049008; Kloor D, 2004, TRENDS PHARMACOL SCI, V25, P294, DOI 10.1016/j.tips.2004.04.004; Kolm-Litty V, 1998, J CLIN INVEST, V101, P160, DOI 10.1172/JCI119875; Komarova EA, 2005, FASEB J, V19, P1030, DOI 10.1096/fj.04-3213fje; Krieg AM, 2007, J CLIN INVEST, V117, P1184, DOI 10.1172/JCI31414; Lasley RD, 1999, BASIC RES CARDIOL, V94, P199, DOI 10.1007/s003950050143; Le YY, 2004, J IMMUNOL, V173, P962, DOI 10.4049/jimmunol.173.2.962; Lee J, 2006, P NATL ACAD SCI USA, V103, P1828, DOI 10.1073/pnas.0510801103; Lee J, 2003, P NATL ACAD SCI USA, V100, P6646, DOI 10.1073/pnas.0631696100; LEVENTHAL BG, 1970, CANCER CHEMOTH REP 1, V54, P47; Levy O, 2006, J IMMUNOL, V177, P1956, DOI 10.4049/jimmunol.177.3.1956; Link BK, 2006, J IMMUNOTHER, V29, P558, DOI 10.1097/01.cji.0000211304.60126.8f; Llorente L, 2000, ARTHRITIS RHEUM, V43, P1790, DOI 10.1002/1529-0131(200008)43:8<1790::AID-ANR15>3.0.CO;2-2; Malissen B, 2005, NAT IMMUNOL, V6, P749, DOI 10.1038/ni0805-749; Mantovani A, 2006, LEUKEMIA, V20, P937, DOI 10.1038/sj.leu.2404229; Maratheftis CI, 2007, CLIN CANCER RES, V13, P1154, DOI 10.1158/1078-0432.CCR-06-2108; MARSHALL S, 1991, J BIOL CHEM, V266, P4706; Mathe G, 2001, BIOMED PHARMACOTHER, V55, P531, DOI 10.1016/S0753-3322(01)00138-X; Melillo G, 2006, MOL CANCER RES, V4, P601, DOI 10.1158/1541-7786.MCR-06-0235; Miggin SM, 2006, J LEUKOCYTE BIOL, V80, P220, DOI 10.1189/jlb.1105672; Napolitani G, 2005, NAT IMMUNOL, V6, P769, DOI 10.1038/ni1223; Ohm JE, 2001, IMMUNOL RES, V23, P263, DOI 10.1385/IR:23:2-3:263; Olah Mark E, 2003, Mol Interv, V3, P370, DOI 10.1124/mi.3.7.370; Pascoe J, 2006, CURR OPIN ONCOL, V18, P325, DOI 10.1097/01.cco.0000228736.39885.e5; Peng SL, 2005, CURR OPIN IMMUNOL, V17, P230, DOI 10.1016/j.coi.2005.03.003; PETTIPHER ER, 1994, CYTOKINE, V6, P500, DOI 10.1016/1043-4666(94)90077-9; Pinhal-Enfield G, 2003, AM J PATHOL, V163, P711, DOI 10.1016/S0002-9440(10)63698-X; Podar K, 2007, CELL CYCLE, V6, P538, DOI 10.4161/cc.6.5.3922; RANDOW F, 1995, J EXP MED, V181, P1887, DOI 10.1084/jem.181.5.1887; Richardson MA, 1999, ALTERN THER HEALTH M, V5, P42; Sala-Newby GB, 1999, J BIOL CHEM, V274, P17789, DOI 10.1074/jbc.274.25.17789; Sato A, 2004, P NATL ACAD SCI USA, V101, P16274, DOI 10.1073/pnas.0406268101; Sato S, 2002, INT IMMUNOL, V14, P783, DOI 10.1093/intimm/dxf046; Saunier EF, 2006, CURR CANCER DRUG TAR, V6, P565, DOI 10.2174/156800906778742460; Shi YH, 2007, CANCER RES, V67, P1823, DOI 10.1158/0008-5472.CAN-06-2381; Sitkovsky M, 2005, NAT REV IMMUNOL, V5, P712, DOI 10.1038/nri1685; Spaner DE, 2007, LEUKEMIA, V21, P53, DOI 10.1038/sj.leu.2404456; Spaner DE, 2006, LEUKEMIA, V20, P286, DOI 10.1038/sj.leu.2404061; Spaner DE, 2005, LEUKEMIA LYMPHOMA, V46, P935, DOI 10.1080/10428190500054426; Sprangers B, 2007, NAT CLIN PRACT ONCOL, V4, P404, DOI 10.1038/ncponc0848; STARNES CO, 1992, NATURE, V357, P11, DOI 10.1038/357011a0; Suleyman H, 2007, PHARMACOL REP, V59, P247; Sun WT, 2005, J BIOCHEM MOL BIOL, V38, P314; Sutinen J, 2007, ANTIVIR THER, V12, P97; Sutmuller RPM, 2006, TRENDS IMMUNOL, V27, P387, DOI 10.1016/j.it.2006.06.005; Takahashi HK, 2005, EUR J PHARMACOL, V512, P223, DOI 10.1016/j.ejphar.2005.01.046; Tergaonkar V, 2007, MOL CELL, V26, P158, DOI 10.1016/j.molcel.2007.04.006; Thompson KA, 1996, EUR J CLIN MICROBIOL, V15, P580, DOI 10.1007/BF01709367; Tiberio L, 2004, VACCINE, V22, P1515, DOI 10.1016/j.vaccine.2003.10.019; Tomic J, 2006, J IMMUNOL, V176, P3830, DOI 10.4049/jimmunol.176.6.3830; Tsung K, 2006, SURG ONCOL, V15, P25, DOI 10.1016/j.suronc.2006.05.002; von Ardenne M, 1970, Acta Biol Med Ger, V25, P671; Waldmann TA, 2006, NAT REV IMMUNOL, V6, P595, DOI 10.1038/nri1901; Waltz E, 2007, NAT MED, V13, P516, DOI 10.1038/nm0507-516b; Wang HY, 2007, CURR OPIN IMMUNOL, V19, P217, DOI 10.1016/j.coi.2007.02.004; WICE BM, 1983, J BIOL CHEM, V258, P3134; Wolf NA, 2007, J NEUROIMMUNOL, V185, P115, DOI 10.1016/j.jneuroim.2007.02.001; Zeytin HE, 2004, CANCER RES, V64, P3668, DOI 10.1158/0008-5472.CAN-03-3878; ZINKERNAGEL RMG, 1996, SCIENCE, V272, P634; 2006, BLOOD, V108, pB3	100	16	17	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 7	2008	27	2					208	217		10.1038/sj.onc.1210905	http://dx.doi.org/10.1038/sj.onc.1210905			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248OO	18176602				2022-12-17	WOS:000252163600007
J	Donatello, S; Fiorino, A; Degl'Innocenti, D; Alberti, L; Miranda, C; Gorla, L; Bongarzone, I; Rizzetti, MG; Pierotti, MA; Borrello, MG				Donatello, S.; Fiorino, A.; Degl'Innocenti, D.; Alberti, L.; Miranda, C.; Gorla, L.; Bongarzone, I.; Rizzetti, M. G.; Pierotti, M. A.; Borrello, M. G.			SH2B1 beta adaptor is a key enhancer of RET tyrosine kinase signaling	ONCOGENE			English	Article						RET; SH2B1; signaling	INSULIN-RECEPTOR KINASE; SH2 DOMAIN; CELLULAR-TRANSFORMATION; REGULATED KINASE; ACTIVATION LOOP; DOCKING SITE; PROTEIN; SH2-B-BETA; IDENTIFICATION; JAK2	The RET gene encodes two main isoforms of a receptor tyrosine kinase (RTK) implicated in various human diseases. Activating germ-line point mutations are responsible for multiple endocrine neoplasia type 2-associated medullary thyroid carcinomas, inactivating germ-line mutations for Hirschsprung's disease, while somatic rearrangements (RET/PTCs) are specific to papillary thyroid carcinomas. SH2B1 beta, a member of the SH2B adaptors family, and binding partner for several RTKs, has been recently described to interact with proto-RET. Here, we show that both RET isoforms and its oncogenic derivatives bind to SH2B1 beta through the SRC homology 2 (SH2) domain and a kinase activity-dependent mechanism. As a result, RET phosphorylates SH2B1 beta, which in turn enhances its autophosphorylation, kinase activity, and downstream signaling. RET tyrosine residues 905 and 981 are important determinants for functional binding of the adaptor, as removal of both autophosphorylation sites displaces its recruitment. Binding of SH2B1 beta appears to protect RET from dephosphorylation by protein tyrosine phosphatases, and might represent a likely mechanism contributing to its upregulation. Thus, overexpression of SH2B1 beta, by enhancing phosphorylation/activation of RET transducers, potentiates the cellular differentiation and the neoplastic transformation thereby induced, and counteracts the action of RET inhibitors. Overall, our results identify SH2B1 beta as a key enhancer of RET physiologic and pathologic activities.	Ist Nazl Tumori, IRCCS, Dept Expt Oncol, UO3, I-20133 Milan, Italy; Dept Expt Oncol, Res Unit 3, Milan, Italy; Dept Expt Oncol, Res Unit 4, Milan, Italy; FIRC Inst Mol Oncol Fdn, Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; IFOM - FIRC Institute of Molecular Oncology	Borrello, MG (corresponding author), Ist Nazl Tumori, IRCCS, Dept Expt Oncol, UO3, Via Venezian 1, I-20133 Milan, Italy.	mariagrazia.borrello@istitutotumori.mi.it	Pierotti, Marco Alessandro/AAC-4728-2022; Borrello, Maria Grazia/C-3161-2017; Bongarzone, Italia/B-9544-2017; Fiorino, Antonio/D-5828-2017	Pierotti, Marco Alessandro/0000-0002-7431-8332; Borrello, Maria Grazia/0000-0002-6854-2848; Bongarzone, Italia/0000-0003-2530-9170; Fiorino, Antonio/0000-0002-2621-9276				Ahmed Z, 2003, BIOCHEM J, V371, P405, DOI 10.1042/BJ20021589; Ahmed Z, 2001, BIOCHEM SOC T, V29, P529, DOI 10.1042/BST0290529; Airaksinen MS, 2002, NAT REV NEUROSCI, V3, P383, DOI 10.1038/nrn812; Albert L, 2003, J CELL PHYSIOL, V195, P168, DOI 10.1002/jcp.10252; Arighi E, 2005, CYTOKINE GROWTH F R, V16, P441, DOI 10.1016/j.cytogfr.2005.05.010; Arighi E, 1997, ONCOGENE, V14, P773, DOI 10.1038/sj.onc.1200896; Besser D, 1999, MOL CELL BIOL, V19, P1401; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; Borrello MG, 1995, ONCOGENE, V11, P2419; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Canu N, 1997, J NEUROCHEM, V68, P1390; Carlomagno F, 2002, CANCER RES, V62, P1077; Cuccuru G, 2004, JNCI-J NATL CANCER I, V96, P1006, DOI 10.1093/jnci/djh184; de Graaff E, 2001, GENE DEV, V15, P2433, DOI 10.1101/gad.205001; Dhe-Sirano D, 2004, NAT STRUCT MOL BIOL, V11, P968, DOI 10.1038/nsmb829; DONATELLO S, 2004, TUMORI, V4, P122; Duan CJ, 2004, MOL CELL BIOL, V24, P7435, DOI 10.1128/MCB.24.17.7435-7443.2004; Gorla L, 2006, CELL SIGNAL, V18, P2272, DOI 10.1016/j.cellsig.2006.05.016; Gryz EA, 2000, ONCOGENE, V19, P417, DOI 10.1038/sj.onc.1203330; Hennige AM, 2001, ENDOCRINOLOGY, V142, P4441, DOI 10.1210/en.142.10.4441; Hu JJ, 2003, MOL CELL, V12, P1379, DOI 10.1016/S1097-2765(03)00487-8; Ichihara M, 2004, CANCER LETT, V204, P197, DOI 10.1016/S0304-3835(03)00456-7; Kawamoto Y, 2004, J BIOL CHEM, V279, P14213, DOI 10.1074/jbc.M312600200; Kong M, 2002, J BIOL CHEM, V277, P15962, DOI 10.1074/jbc.M102777200; Kotani K, 1998, BIOCHEM J, V335, P103, DOI 10.1042/bj3350103; Kurzer JH, 2004, MOL CELL BIOL, V24, P4557, DOI 10.1128/MCB.24.10.4557-4570.2004; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; Lorenzo MJ, 1997, ONCOGENE, V14, P763, DOI 10.1038/sj.onc.1200894; Nelms K, 1999, MAMM GENOME, V10, P1160, DOI 10.1007/s003359901183; O'Brien KB, 2003, J BIOL CHEM, V278, P11970, DOI 10.1074/jbc.M210765200; Ohtsuka S, 2002, MOL CELL BIOL, V22, P3066, DOI 10.1128/MCB.22.9.3066-3077.2002; OSBORNE MA, 1995, BIO-TECHNOL, V13, P1474, DOI 10.1038/nbt1295-1474; Qian XZ, 2001, MOL CELL BIOL, V21, P1613, DOI 10.1128/MCB.21.5.1613-1620.2001; Qian XZ, 1998, NEURON, V21, P1017, DOI 10.1016/S0896-6273(00)80620-0; Ravichandran KS, 2001, ONCOGENE, V20, P6322, DOI 10.1038/sj.onc.1204776; Ren DC, 2005, CELL METAB, V2, P95, DOI 10.1016/j.cmet.2005.07.004; Riedel H, 1997, J BIOCHEM-TOKYO, V122, P1105; Roccato E, 2005, J BIOL CHEM, V280, P3382, DOI 10.1074/jbc.M407522200; Rui LY, 2000, MOL CELL BIOL, V20, P3168, DOI 10.1128/MCB.20.9.3168-3177.2000; Rui LY, 1998, J BIOL CHEM, V273, P21239, DOI 10.1074/jbc.273.33.21239; Rui LY, 1999, P NATL ACAD SCI USA, V96, P7172, DOI 10.1073/pnas.96.13.7172; Rui LY, 1997, MOL CELL BIOL, V17, P6633, DOI 10.1128/MCB.17.11.6633; Takahashi M, 2001, CYTOKINE GROWTH F R, V12, P361, DOI 10.1016/S1359-6101(01)00012-0; Wang CC, 1998, J ELECTROCERAM, V2, P273, DOI 10.1023/A:1009978607621; Yousaf N, 2001, J BIOL CHEM, V276, P40940, DOI 10.1074/jbc.M104191200; Zhang Y, 2006, J CELL SCI, V119, P1666, DOI 10.1242/jcs.02845	47	16	18	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2007	26	45					6546	6559		10.1038/sj.onc.1210480	http://dx.doi.org/10.1038/sj.onc.1210480			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	217AF	17471236				2022-12-17	WOS:000249919800008
J	Matskova, LV; Helmstetter, C; Ingham, RJ; Gish, G; Lindholm, CK; Ernberg, I; Pawson, T; Winberg, G				Matskova, L. V.; Helmstetter, C.; Ingham, R. J.; Gish, G.; Lindholm, C. K.; Ernberg, I.; Pawson, T.; Winberg, G.			The Shb signalling scaffold binds to and regulates constitutive signals from the Epstein-Barr virus LMP2A membrane protein	ONCOGENE			English	Article						Epstein-Barr virus; latency-associated membrane protein 2A (LMP2A); Syk; Shb; AIP4; Akt	SYK TYROSINE KINASE; T-CELL-RECEPTOR; EPITHELIAL-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; NEGATIVE REGULATION; DOMAIN-PROTEIN; IN-VIVO; CBL; 2A; LYMPHOCYTES	The Epstein-Barr virus latency-associated membrane protein LMP2A has been shown to activate the survival kinase Akt in epithelial and B cells in a phosphoinositide 3-kinase-dependent fashion. In this study, we demonstrate that the signalling scaffold Shb associates through SH2 and PTB domain interactions with phosphorylated tyrosine motifs in the LMP2A N-terminal tail. Additionally, we show that mutation of tyrosines in these motifs as well as shRNA-mediated downregulation of Shb leads to a loss of constitutive Akt-activation in LMP2A-expressing cells. Furthermore, utilization by Shb of the LMP2A ITAM motif regulates stability of the Syk tyrosine kinase in LMP2A-expressing cells. Our data set the precedent for viral utilization of the Shb signalling scaffold and implicate Shb as a regulator of LMP2A-dependent Akt activation.	Karolinska Inst, MTC, SE-17177 Stockholm, Sweden; Univ Victoria, Dept Biol, Victoria, BC V8W 2Y2, Canada; Mt Sinai Hosp, Samuel Res Inst, Toronto, ON M5G 1X5, Canada; Univ Lausanne, Lausanne Branch, Ludwig Inst Canc Res, CH-1066 Epalinges, Switzerland	Karolinska Institutet; University of Victoria; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Ludwig Institute for Cancer Research; University of Lausanne	Matskova, LV (corresponding author), Karolinska Inst, MTC, Nobels Vag 16,Box 280, SE-17177 Stockholm, Sweden.	ludmat@ki.se	Pawson, Tony J/E-4578-2013; Matskova, Liudmila/AAF-4201-2020; Winberg, Gosta/I-5686-2013; Gish, Gerald D/C-7228-2017; Matskova, Liudmila/J-3843-2017	Matskova, Liudmila/0000-0002-3174-1560; Matskova, Liudmila/0000-0002-3174-1560; Peine, Caroline/0000-0001-6267-3452; Winberg, Gosta/0000-0002-3371-4056				Abdallah B, 1996, HUM GENE THER, V7, P1947, DOI 10.1089/hum.1996.7.16-1947; BEAUFILS P, 1993, EMBO J, V12, P5105, DOI 10.1002/j.1460-2075.1993.tb06205.x; Caldwell RG, 1998, IMMUNITY, V9, P405, DOI 10.1016/S1074-7613(00)80623-8; Casola S, 2004, NAT IMMUNOL, V5, P317, DOI 10.1038/ni1036; Coligan JE, 2001, CURRENT PROTOCOLS PR; Coopman PJP, 2000, NATURE, V406, P742, DOI 10.1038/35021086; Courbard JR, 2002, J BIOL CHEM, V277, P45267, DOI 10.1074/jbc.M206460200; DIANZANI U, 1994, J IMMUNOL, V153, P952; Engels N, 2001, J EXP MED, V194, P255, DOI 10.1084/jem.194.3.255; Ettenberg SA, 2001, J BIOL CHEM, V276, P27677, DOI 10.1074/jbc.M102641200; Fodor S, 2006, IMMUNOL LETT, V104, P29, DOI 10.1016/j.imlet.2005.11.001; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Fruehling S, 1996, J VIROL, V70, P6216, DOI 10.1128/JVI.70.9.6216-6226.1996; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Grande Shannon M, 2006, Future Oncol, V2, P301, DOI 10.2217/14796694.2.2.301; HARLOWE E, 1988, ANTIBODIES LAB MANUA; Holmqvist K, 2004, J BIOL CHEM, V279, P22267, DOI 10.1074/jbc.M312729200; Ikeda M, 2000, VIROLOGY, V268, P178, DOI 10.1006/viro.1999.0166; Ikeda M, 2002, VIROLOGY, V300, P153, DOI 10.1006/viro.2002.1562; Ingham RJ, 2005, J BIOL CHEM, V280, P34133, DOI 10.1074/jbc.M507831200; KARLSSON T, 1995, ONCOGENE, V10, P1475; Katz E, 2005, J EXP MED, V201, P431, DOI 10.1084/jem.20041471; Koretzky GA, 2006, NAT REV IMMUNOL, V6, P67, DOI 10.1038/nri1750; Kunath T, 2003, NAT BIOTECHNOL, V21, P559, DOI 10.1038/nbt813; LAUX G, 1988, EMBO J, V7, P769, DOI 10.1002/j.1460-2075.1988.tb02874.x; Lindholm CK, 2002, EUR J BIOCHEM, V269, P3279, DOI 10.1046/j.1432-1033.2002.03008.x; LONGNECKER R, 1991, J VIROL, V65, P3681, DOI 10.1128/JVI.65.7.3681-3692.1991; Lu J, 2006, J BIOL CHEM, V281, P8806, DOI 10.1074/jbc.M507305200; Lupher ML, 1998, J BIOL CHEM, V273, P35273, DOI 10.1074/jbc.273.52.35273; Magnifico A, 2003, J BIOL CHEM, V278, P43169, DOI 10.1074/jbc.M308009200; Matskova L, 2001, J VIROL, V75, P10941, DOI 10.1128/JVI.75.22.10941-10949.2001; Merchant M, 2000, J VIROL, V74, P9115, DOI 10.1128/JVI.74.19.9115-9124.2000; Morrison JA, 2005, J VIROL, V79, P2375, DOI 10.1128/JVI.79.4.2375-2382.2005; Ota S, 2000, J BIOL CHEM, V275, P414, DOI 10.1074/jbc.275.1.414; Rao N, 2001, EMBO J, V20, P7085, DOI 10.1093/emboj/20.24.7085; Scholle F, 2000, J VIROL, V74, P10681, DOI 10.1128/JVI.74.22.10681-10689.2000; Scholle F, 2001, VIROLOGY, V291, P208, DOI 10.1006/viro.2001.1197; Shaw G, 2002, FASEB J, V16, P869, DOI 10.1096/fj.01-0995fje; Silvennoinen O, 1996, J IMMUNOL, V156, P100; Swart R, 2000, J VIROL, V74, P10838, DOI 10.1128/JVI.74.22.10838-10845.2000; Swart R, 1999, VIROLOGY, V263, P485, DOI 10.1006/viro.1999.9964; Tomlinson CC, 2004, J VIROL, V78, P1918, DOI 10.1128/JVI.78.4.1918-1927.2004; WELSH M, 1994, ONCOGENE, V9, P19; Welsh M, 1998, ONCOGENE, V16, P891, DOI 10.1038/sj.onc.1201607; Welsh N, 2002, MOL MED, V8, P695, DOI 10.1007/BF03402033; Winberg G, 2000, MOL CELL BIOL, V20, P8526, DOI 10.1128/MCB.20.22.8526-8535.2000; Zubiaur M, 1997, J IMMUNOL, V159, P193	47	16	18	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2007	26	34					4908	4917		10.1038/sj.onc.1210298	http://dx.doi.org/10.1038/sj.onc.1210298			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	194CV	17311000				2022-12-17	WOS:000248322500003
J	Caporali, A; Wark, L; Vermolen, BJ; Garini, Y; Mai, S				Caporali, A.; Wark, L.; Vermolen, B. J.; Garini, Y.; Mai, S.			Telomeric aggregates and end-to-end chromosomal fusions require myc box II	ONCOGENE			English	Article						three-dimensional nuclear organization; telomere aggregates; c-Myc; genomic instability; telomeric fusions	C-MYC; CELL-CYCLE; NUCLEAR ARCHITECTURE; GENOMIC INSTABILITY; GENE; DYNAMICS; ORGANIZATION; ACTIVATION; MITOSIS; DOMAIN	Telomeres of tumor cells form telomeric aggregates (TAs) within the three-dimensional (3D) interphase nucleus. Some of these TAs represent end-to-end chromosomal fusions and may subsequently initiate breakage-bridge fusion cycles. Wild-type (wt) and myc box II mutant (mt) Myc induce different types of genomic instability when conditionally expressed in mouse proB cells (Ba/F3). Only wt Myc overexpressing Ba/F3 cells are capable of tumor formation in severe combined immunodeficient mice. In this study, we investigated whether telomere dysfunction leading to TA formation is linked to the genetic changes that permit wt c-Myc-dependent transformation of Ba/F3 cells. To this end, we examined the 3D organization of telomeres after the deregulated expression of deletion myc box II mutant (D106) or wt Myc. D106-Myc overexpression did not induce TAs, whereas wt-Myc deregulation did. Instead, D106-Myc remodelled the 3D telomeric organization such that telomeres aligned in the center of the 3D interphase nucleus forming a telomeric disk owing to a D106-induced G1/S cell cycle arrest. In contrast, wt-Myc overexpression led to distorted telomere distribution and TA formation. Analysis of chromosomal alterations using spectral karyotyping confirmed D106-Myc and wt-Myc-associated genomic instability. A significant number of chromosomal end-to-end fusions indicative of telomere dysfunction were noted in wt-Myc-expressing cells only. This study suggests that TAs may play a fundamental role in Myc-induced tumorigenesis and provides a novel way to dissect tumor initiation.	Univ Parma, Dipartimento Med Sperimentale, Sez Biochim Biochim Clin & Biochim Esercizio Fis, I-43100 Parma, Italy; Univ Manitoba, Manitoba Inst Cell Biol, Winnipeg, MB, Canada; Univ Manitoba, Genom Ctr Canc Res & Diag, Winnipeg, MB, Canada; Delft Univ Technol, Fac Sci Appl, Dept Imaging Sci & Technol, Delft, Netherlands	University of Parma; University of Manitoba; University of Manitoba; Delft University of Technology	Mai, S (corresponding author), Manitoba Inst Cell Biol Physiol Biochem & Med Gen, 675 McDermot, Winnipeg, MB R3E 0V9, Canada.	smai@cc.umanitoba.ca	Mai, Sabine/E-5667-2017; Vermolen, Bart/C-4739-2008	Mai, Sabine/0000-0002-5797-2201; Garini, Yuval/0000-0002-8783-2015				Bahram F, 2000, BLOOD, V95, P2104, DOI 10.1182/blood.V95.6.2104; Barber CB, 1996, ACM T MATH SOFTWARE, V22, P469, DOI 10.1145/235815.235821; Chuang TCY, 2004, BMC BIOL, V2, DOI 10.1186/1741-7007-2-12; Cremer M, 2003, J CELL BIOL, V162, P809, DOI 10.1083/jcb.200304096; Cremer T, 2001, NAT REV GENET, V2, P292, DOI 10.1038/35066075; de Lange T, 2005, GENE DEV, V19, P2100, DOI 10.1101/gad.1346005; Deb-Basu D, 2006, CELL CYCLE, V5, P1348, DOI 10.4161/cc.5.12.2860; DePinho RA, 2004, NAT GENET, V36, P932, DOI 10.1038/ng0904-932; Ermler S, 2004, EUR J CELL BIOL, V83, P681, DOI 10.1078/0171-9335-00430; Essers J, 2005, MOL BIOL CELL, V16, P769, DOI 10.1091/mbc.e04-10-0876; Feldser DM, 2003, NAT REV CANCER, V3, P623, DOI 10.1038/nrc1142; Fest T, 2005, ONCOGENE, V24, P2944, DOI 10.1038/sj.onc.1208467; Fest T, 2002, ONCOGENE, V21, P2981, DOI 10.1038/sj/onc/1205274; Frye M, 2003, DEVELOPMENT, V130, P2793, DOI 10.1242/dev.00462; Fukatsu K, 1997, SEN-I GAKKAISHI, V53, P15, DOI 10.2115/fiber.53.15; Gasser SM, 2002, SCIENCE, V296, P1412, DOI 10.1126/science.1067703; Gerlich D, 2003, CELL, V112, P751, DOI 10.1016/S0092-8674(03)00189-2; Kozubek S, 1999, CHROMOSOMA, V108, P426, DOI 10.1007/s004120050394; Kuschak TI, 2002, ONCOGENE, V21, P909, DOI 10.1038/sj.onc.1205145; Kuschak TI, 1999, GENE, V238, P351, DOI 10.1016/S0378-1119(99)00341-8; KUTTLER F, 2005, GENOME DIS GENOME DY, V1, P171; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Louis SF, 2005, P NATL ACAD SCI USA, V102, P9613, DOI 10.1073/pnas.0407512102; Mai S, 2006, J CELL BIOCHEM, V97, P904, DOI 10.1002/jcb.20760; Mai S, 2005, CELL CYCLE, V4, P1327, DOI 10.4161/cc.4.10.2082; Mai Sabine, 2003, Journal of Environmental Pathology Toxicology and Oncology, V22, P179; Mai Sabine, 1999, Neoplasia (New York), V1, P241, DOI 10.1038/sj.neo.7900030; McClintock B, 1941, GENETICS, V26, P234; Molenaar C, 2003, EMBO J, V22, P6631, DOI 10.1093/emboj/cdg633; Neves H, 1999, BLOOD, V93, P1197, DOI 10.1182/blood.V93.4.1197.404k33_1197_1207; Nikiforov MA, 2002, MOL CELL BIOL, V22, P5054, DOI 10.1128/MCB.22.14.5054-5063.2002; Oster SK, 2003, ONCOGENE, V22, P1998, DOI 10.1038/sj.onc.1206228; Parada LA, 2002, CURR BIOL, V12, P1692, DOI 10.1016/S0960-9822(02)01166-1; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; Poon SSS, 1999, CYTOMETRY, V36, P267, DOI 10.1002/(SICI)1097-0320(19990801)36:4<267::AID-CYTO1>3.0.CO;2-O; Schaefer LH, 2001, J MICROSC-OXFORD, V204, P99, DOI 10.1046/j.1365-2818.2001.00949.x; Solovei I, 2002, EXP CELL RES, V276, P10, DOI 10.1006/excr.2002.5513; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; Trumpp A, 2001, NATURE, V414, P768, DOI 10.1038/414768a; Vermolen BJ, 2005, CYTOM PART A, V67A, P144, DOI 10.1002/cyto.a.20159; Walter J, 2003, J CELL BIOL, V160, P685, DOI 10.1083/jcb.200211103	41	16	16	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 1	2007	26	10					1398	1406		10.1038/sj.onc.1209928	http://dx.doi.org/10.1038/sj.onc.1209928			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141DV	16953226				2022-12-17	WOS:000244558800004
J	Yang, G; Rosen, DG; Colacino, JA; Mercado-Uribe, I; Liu, J				Yang, G.; Rosen, D. G.; Colacino, J. A.; Mercado-Uribe, I.; Liu, J.			Disruption of the retinoblastoma pathway by small interfering RNA and ectopic expression of the catalytic subunit of telomerase lead to immortalization of human ovarian surface epithelial cells	ONCOGENE			English	Article						human ovarian surface epithelial cells; immortalization; siRNA; pRb; hTERT	HUMAN-PAPILLOMAVIRUS TYPE-16; GENOMIC INSTABILITY; GENE-EXPRESSION; CANCER; GROWTH; PROTEIN; P53; TRANSFORMATION; RETROVIRUS; BREAST	The risk of developing ovarian cancer is about 1% over a lifetime, but it is the most deadly gynecologic cancer, in part due to lack of diagnostic markers for early-stage disease and cell model system for studying early neoplastic changes. Most existing immortal human ovarian surface epithelial cells were achieved by using viral protein such as SV40 T/t antigen or E6/E7, which inactivate multiple cellular pathways. In the current study, we used a small interfering RNA ( siRNA) against the retinoblastoma gene (pRb) and ectopic expression of human telomerase reverse transcriptase ( hTERT) to immortalize the primary ovarian epithelial cell line OSE137 and two additional human ovarian surface epithelial cells. The immortalized OSE137 showed increased telomerase activity, lengthened telomeres, increased G(2)/M phase, altered cell-cycle regulatory proteins but nontumorigenic. As both Rb and hTERT pathways are commonly altered in human ovarian cancer and these genetic changes are faithfully modeled in these cells without using viral protein, these immortal cells represent an authentic in vitro model system with which to study the initiation and progression of human ovarian cancer.	Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Unit 85, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Liu, J (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Unit 85, 1515 Holcombe Blvd, Houston, TX 77030 USA.	jliu@mdanderson.org			NCI NIH HHS [CA016672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aprelikova ON, 1999, P NATL ACAD SCI USA, V96, P11866, DOI 10.1073/pnas.96.21.11866; Baege AC, 2002, AM J PATHOL, V160, P1251, DOI 10.1016/S0002-9440(10)62552-7; Band V, 1998, INT J ONCOL, V12, P499; Bantounas I, 2004, J MOL ENDOCRINOL, V33, P545, DOI 10.1677/jme.1.01582; BERNUES J, 1991, GENE, V108, P269, DOI 10.1016/0378-1119(91)90444-G; Chun YM, 2002, ANN OTO RHINOL LARYN, V111, P507, DOI 10.1177/000348940211100606; D'Andrilli G, 2004, CLIN CANCER RES, V10, P8132, DOI 10.1158/1078-0432.CCR-04-0886; Davies BR, 2003, EXP CELL RES, V288, P390, DOI 10.1016/S0014-4827(03)00218-0; Duensing S, 2002, ONCOGENE, V21, P6241, DOI 10.1038/sj.onc.1205709; Ferrandina G, 2000, INT J ONCOL, V17, P1231; Gao QS, 2001, J VIROL, V75, P4459, DOI 10.1128/JVI.75.9.4459-4466.2001; Hashiguchi Y, 2001, HUM PATHOL, V32, P988, DOI 10.1053/hupa.2001.27115; Hayflick L, 1973, TISSUE CULTURE METHO, P220, DOI DOI 10.1016/B978-0-12-427150-0.50060-7; Hu YM, 2005, J BIOL CHEM, V280, P39485, DOI 10.1074/jbc.M503296200; Iftner T, 2002, EMBO J, V21, P4741, DOI 10.1093/emboj/cdf443; Jarrard DF, 1999, CANCER RES, V59, P2957; Kauff ND, 2005, JNCI-J NATL CANCER I, V97, P1382, DOI 10.1093/jnci/dji281; Kusakari T, 2003, BRIT J CANCER, V89, P2293, DOI 10.1038/sj.bjc.6601423; Kusume T, 1999, CLIN CANCER RES, V5, P4152; Lenferink AEG, 2000, P NATL ACAD SCI USA, V97, P9609, DOI 10.1073/pnas.160564197; Liu J, 2001, CANCER CYTOPATHOL, V93, P390, DOI 10.1002/cncr.10141; Liu JS, 2004, CANCER RES, V64, P1655, DOI 10.1158/0008-5472.CAN-03-3380; Lundberg AS, 2002, ONCOGENE, V21, P4577, DOI 10.1038/sj.onc.1205550; McDougall J K, 2001, Dev Biol (Basel), V106, P267; McDougall JK, 2001, DEV BIOL BASEL, V106; MCDOUGALL JK, 2001, DEV BIOL BASEL, V106, P272; Noble JR, 2004, ONCOGENE, V23, P3116, DOI 10.1038/sj.onc.1207440; Ouellette MM, 2000, HUM MOL GENET, V9, P403, DOI 10.1093/hmg/9.3.403; Ozols RF, 2004, CANCER CELL, V5, P19, DOI 10.1016/S1535-6108(04)00002-9; Plug-Demaggio AW, 2002, ONCOGENE, V21, P7507, DOI 10.1038/sj.onc.1205903; Prowse A, 2003, ACS A CLIN ONCOL SER, P49; Rosen DG, 2005, CLIN CANCER RES, V11, P632; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; SANKARANARAYANA.R, 2006, BEST PRACT RES CLIN, V20, P1; Takebayashi T, 2003, J BIOL CHEM, V278, P14897, DOI 10.1074/jbc.M210849200; Tammela J, 2004, Minerva Ginecol, V56, P495; Terasawa K, 1999, CANCER LETT, V142, P207, DOI 10.1016/S0304-3835(99)00170-6; Vasey PA, 2003, BRIT J CANCER, V89, pS23, DOI 10.1038/sj.bjc.6601497; Xiang H, 2002, ONCOGENE, V21, P3784, DOI 10.1038/sj.onc.1205455; Yang G, 2004, J BIOL CHEM, V279, P4339, DOI 10.1074/jbc.M311153200; Zou GM, 2005, BIOL CELL, V97, P211	41	16	20	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 1	2007	26	10					1492	1498		10.1038/sj.onc.1209905	http://dx.doi.org/10.1038/sj.onc.1209905			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141DV	16953228				2022-12-17	WOS:000244558800014
J	Baluchamy, S; Sankar, N; Navaraj, A; Moran, E; Thimmapaya, B				Baluchamy, S.; Sankar, N.; Navaraj, A.; Moran, E.; Thimmapaya, B.			Relationship between E1A binding to cellular proteins, c-myc activation and S-phase induction	ONCOGENE			English	Article						E1A; p300; c-myc repression; cell cycle	ACETYLTRANSFERASE COMPLEX; G(1) EXIT; P300; TRANSFORMATION; ACETYLATION; EXPRESSION; DEPLETION; PRB	We recently showed that p300/CREB-binding protein (CBP) plays an important role in maintaining cells in G0/G1 phase by keeping c-myc in a repressed state. Consistent with this, adenovirus E1A oncoprotein induces c-myc in a p300-dependent manner, and the c-myc induction is linked to S-phase induction. The induction of S phase by E1A is dependent on its binding to and inactivating several host proteins including p300/CBP. To determine whether there is a correlation between the host proteins binding to the N-terminal region of E1A, activation of c-myc and induction of S phase, we assayed the c-myc and S-phase induction in quiescent human cells by infecting them with Ad N-terminal E1A mutants with mutations that specifically affect binding to different chromatin-associated proteins including pRb, p300, p400 and p300/CBP-associated factor (PCAF). We show that the mutants that failed to bind to p300 or pRb were severely defective for c-myc and S-phase induction. The induction of c-myc and S phase was only moderately affected when E1A failed to bind to p400. Furthermore, analysis of the E1A mutants that fail to bind to p300, and both p300 and PCAF suggests that PCAF may also play a role in c-myc repression, and that the two chromatin-associated proteins may repress c-myc independently. In summary, these results suggest that c-myc deregulation by E1A through its interaction with these chromatin-associated proteins is an important step in the E1A-mediated cell cycle deregulation and possibly in cell transformation.	Northwestern Univ, Feinberg Sch Med, Dept Microbiol Immunol, Chicago, IL 60611 USA; Temple Univ, Sch Med, Inst Canc Res & Mol Biol, Philadelphia, PA 19122 USA	Northwestern University; Feinberg School of Medicine; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Thimmapaya, B (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Microbiol Immunol, 303 E Chicago Ave,Olson 8452, Chicago, IL 60611 USA.	b-thimmapaya@northwestern.edu	Natesan, Sankar/C-9866-2015		NCI NIH HHS [CA74403, R01 CA074403] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA074403] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baluchamy S, 2003, P NATL ACAD SCI USA, V100, P9524, DOI 10.1073/pnas.1633700100; BARBEAU D, 1994, ONCOGENE, V9, P359; Buchmann AM, 1998, MOL CELL BIOL, V18, P4565, DOI 10.1128/MCB.18.8.4565; Chen CR, 2002, CELL, V110, P19, DOI 10.1016/S0092-8674(02)00801-2; Doyon Y, 2004, MOL CELL BIOL, V24, P1884, DOI 10.1128/MCB.24.5.1884-1896.2004; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; Fuchs M, 2001, CELL, V106, P297, DOI 10.1016/S0092-8674(01)00450-0; Goodman RH, 2000, GENE DEV, V14, P1553; GRISCH SM, 2002, NAT REV MOL CELL BIO, V6, P441; Harbour JW, 2001, ARCH OPHTHALMOL-CHIC, V119, P1699; Kolli S, 2001, P NATL ACAD SCI USA, V98, P4646, DOI 10.1073/pnas.081141998; Lang SE, 2003, ONCOGENE, V22, P2836, DOI 10.1038/sj.onc.1206376; Mitchell KO, 1999, CELL GROWTH DIFFER, V10, P223; MORAN E, 1993, FASEB J, V7, P880, DOI 10.1096/fasebj.7.10.8344487; Nees M, 2000, CANCER RES, V60, P4289; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Rajabi HN, 2005, J BIOL CHEM, V280, P361, DOI 10.1074/jbc.M408633200; Reid JL, 1998, EMBO J, V17, P4469, DOI 10.1093/emboj/17.15.4469; Santoso BY, 2006, NAT STRUCT MOL BIOL, V13, P131, DOI 10.1038/nsmb1048; SOULE HD, 1990, CANCER RES, V50, P6075; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Taubert S, 2004, MOL CELL BIOL, V24, P4546, DOI 10.1128/MCB.24.10.4546-4556.2004; WANG HGH, 1995, J VIROL, V69, P7917, DOI 10.1128/JVI.69.12.7917-7924.1995; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993	24	16	17	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2007	26	5					781	787		10.1038/sj.onc.1209825	http://dx.doi.org/10.1038/sj.onc.1209825			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	131WM	16862175				2022-12-17	WOS:000243902200015
J	Baert, JL; Beaudoin, C; Monte, D; Degerny, C; Mauen, S; de Launoit, Y				Baert, J-L; Beaudoin, C.; Monte, D.; Degerny, C.; Mauen, S.; de Launoit, Y.			The 26S proteasome system degrades the ERM transcription factor and regulates its transcription-enhancing activity	ONCOGENE			English	Article						ETS; ERM; transcription factor; 26S proteasome; degradation; ubiquitin; regulation of transcription	UBIQUITIN-MEDIATED PROTEOLYSIS; FAMILY MEMBER ERM; ACTIVATION DOMAIN; TARGET GENES; ETS-DOMAIN; PEA3 GROUP; ORNITHINE-DECARBOXYLASE; EXPRESSION PATTERNS; DNA-BINDING; DEGRADATION	ERM is a member of the ETS transcription factor family. High levels of the corresponding mRNA are detected in a variety of human breast cancer cell lines, as well as in aggressive human breast tumors. As ERM protein is almost undetectable in these cells, high degradation of this transcription factor has been postulated. Here we have investigated whether ERM degradation might depend on the proteasome pathway. We show that endogenous and ectopically expressed ERM protein is short-lived protein and undergoes proteasome- dependent degradation. Deletion mutagenesis studies indicate that the 61 C-terminal amino acids of ERM are critical for its proteolysis and serve as a degradation signal. Although ERM conjugates with ubiquitin, this post-translational modi. cation does not depend on the C-terminaldomain. We have used an Ets-responsive ICAM-1 reporter plasmid to show that the ubiquitin - proteasome pathway can affect transcriptional function of ERM. Thus, ERM is subject to degradation via the 26S proteasome pathway, and this pathway probably plays an important	Univ Lille 1, Inst Pasteur Lille, CNRS, Inst Biol Lille,UMR 8161,Univ Lille 2,IFR 142, F-59021 Lille, France; Univ Libre Bruxelles, Fac Med, Mol Virol Lab, Brussels, Belgium	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille; Universite Libre de Bruxelles	de Launoit, Y (corresponding author), Univ Lille 1, Inst Pasteur Lille, CNRS, Inst Biol Lille,UMR 8161,Univ Lille 2,IFR 142, 1 Rue Prof Calmette, F-59021 Lille, France.	yvan.delaunoit@ibl.fr		monte, didier/0000-0002-0613-6203				Alvarez-Castelao B, 2005, FEBS LETT, V579, P4797, DOI 10.1016/j.febslet.2005.07.060; Baert JL, 2002, J BIOL CHEM, V277, P1002, DOI 10.1074/jbc.M107139200; Baert JL, 1997, INT J CANCER, V70, P590, DOI 10.1002/(SICI)1097-0215(19970304)70:5<590::AID-IJC17>3.0.CO;2-H; Blanquart C, 2002, J BIOL CHEM, V277, P37254, DOI 10.1074/jbc.M110598200; Bres V, 2003, NAT CELL BIOL, V5, P754, DOI 10.1038/ncb1023; Chotteau-Lelievre A, 2001, MECH DEVELOP, V108, P191, DOI 10.1016/S0925-4773(01)00480-4; Chotteau-Lelievre A, 2003, DEV BIOL, V259, P241, DOI 10.1016/S0012-1606(03)00182-9; ChotteauLelievre A, 1997, ONCOGENE, V15, P937, DOI 10.1038/sj.onc.1201261; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; Conaway RC, 2002, SCIENCE, V296, P1254, DOI 10.1126/science.1067466; Dalton WS, 2004, SEMIN ONCOL, V31, P3, DOI 10.1053/j.seminoncol.2004.10.012; de Launoit Y, 1998, ONCOGENE, V16, P2065, DOI 10.1038/sj.onc.1201726; Defossez PA, 1997, NUCLEIC ACIDS RES, V25, P4455, DOI 10.1093/nar/25.22.4455; Degerny C, 2005, J BIOL CHEM, V280, P24330, DOI 10.1074/jbc.M411250200; Deroo BJ, 2002, MOL CELL BIOL, V22, P4113, DOI 10.1128/MCB.22.12.4113-4123.2002; Galang CK, 2004, J BIOL CHEM, V279, P11281, DOI 10.1074/jbc.M311887200; Goel A, 2003, MOL CELL BIOL, V23, P6243, DOI 10.1128/MCB.23.17.6243-6254.2003; Greer SF, 2003, NAT IMMUNOL, V4, P1074, DOI 10.1038/ni985; Janknecht R, 1996, ONCOGENE, V13, P1745; Kurosu T, 2004, CURR BIOL, V14, P1112, DOI 10.1016/j.cub.2004.06.020; Laget MP, 1996, ONCOGENE, V12, P1325; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; LELIEVRE AC, 2004, CLIN CANCER RES, V19, P7297; Lipford JR, 2003, NAT CELL BIOL, V5, P845, DOI 10.1038/ncb1003-845; Maurer P, 2003, ONCOGENE, V22, P3319, DOI 10.1038/sj.onc.1206572; Molinari E, 1999, EMBO J, V18, P6439, DOI 10.1093/emboj/18.22.6439; Murakami Y, 1999, MOL CELL BIOL, V19, P7216; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; Muratani M, 2005, CELL, V120, P887, DOI 10.1016/j.cell.2004.12.025; Peloponese JM, 2004, J VIROL, V78, P11686, DOI 10.1128/JVI.78.21.11686-11695.2004; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Pickart CM, 2004, CELL, V116, P181, DOI 10.1016/S0092-8674(03)01074-2; Pollenz RS, 2002, CHEM-BIOL INTERACT, V141, P41, DOI 10.1016/S0009-2797(02)00065-0; Prakash S, 2004, NAT STRUCT MOL BIOL, V11, P830, DOI 10.1038/nsmb814; Salghetti SE, 2001, SCIENCE, V293, P1651, DOI 10.1126/science.1062079; Salghetti SE, 2000, P NATL ACAD SCI USA, V97, P3118, DOI 10.1073/pnas.050007597; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; Shepherd TG, 2001, CURR BIOL, V11, P1739, DOI 10.1016/S0960-9822(01)00536-X; Takahashi A, 2005, BIOCHEM BIOPH RES CO, V327, P575, DOI 10.1016/j.bbrc.2004.12.045; Touitou R, 2001, EMBO J, V20, P2367, DOI 10.1093/emboj/20.10.2367; Tworkowski KA, 2002, ONCOGENE, V21, P8515, DOI 10.1038/sj.onc.1205976; Zhang MS, 2003, EMBO J, V22, P1488, DOI 10.1093/emboj/cdg158	42	16	17	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2007	26	3					415	424		10.1038/sj.onc.1209801	http://dx.doi.org/10.1038/sj.onc.1209801			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126VQ	16832340				2022-12-17	WOS:000243544000010
J	Sasai, K; Kakumoto, K; Hanafusa, H; Akagi, T				Sasai, K.; Kakumoto, K.; Hanafusa, H.; Akagi, T.			The Ras-MAPK pathway downregulates Caveolin-1 in rodent fibroblast but not in human fibroblasts: implications in the resistance to oncogene-mediated transformation	ONCOGENE			English	Article						caveolin-1; hTERT; normal human diploid fibroblast; oncogenic transformation; Ras-MAPK pathway	HUMAN-DIPLOID FIBROBLASTS; CANCER; CELLS; INVASIVENESS; EXPRESSION; KINASE	Normal human diploid fibroblasts (HDFs) are refractory to oncogene-mediated transformations in vitro, compared with rodent fibroblasts. As successful oncogene-mediated transformations of normal HDFs have been reported using the human telomerase catalytic subunit, it has been considered that telomerase activity contributes to the species-specific transformability. However, these transformed HDFs are much less malignant compared with those of rodent cells, suggesting the existence of undetermined mechanisms that render HDFs resistant to malignant transformation. Here, cDNA microarray analysis identified caveolin-1 as one of the possible cellular factors involved in such mechanisms. The mitogen-activated protein kinases ( MAPK) pathway downregulates Caveolin-1 in rodent fibroblasts, transformed by coexpression of the SV40 early region and activated H-Ras. In contrast, the coexpression of these two oncogenes in HDFs failed to reduce the expression level of Caveolin-1. These results strongly suggest the presence of critical differences in events following the phosphorylation of ERK during the activation process of the MAPK signaling pathway between human and rodent cells, as the ERK protein was similarly phosphorylated in both systems. Furthermore, the small interfering RNA-mediated suppression of Caveolin-1 facilitated the oncogene-mediated transformation of normal HDFs, clearly indicating that the differences in the transformability between human and rodent cells are due, at least in part, to the mechanism responsible for the resistance to Ras-induced Caveolin-1 downregulation in HDFs.	Osaka Biosci Inst, Oncol Mol Lab, Ibaraki, Osaka 5670085, Japan		Akagi, T (corresponding author), Osaka Biosci Inst, Oncol Mol Lab, Saito Boincubator Rm204,7-7-15 Saito Asagi, Ibaraki, Osaka 5670085, Japan.	takagi@obi.or.jp						Accili D, 2004, CELL, V117, P421, DOI 10.1016/S0092-8674(04)00452-0; Akagi T, 2004, TRENDS MOL MED, V10, P542, DOI 10.1016/j.molmed.2004.09.001; Akagi T, 2003, P NATL ACAD SCI USA, V100, P13567, DOI 10.1073/pnas.1834876100; Akagi T, 2002, MOL CELL BIOL, V22, P7015, DOI 10.1128/MCB.22.20.7015-7023.2002; Chi JT, 2003, P NATL ACAD SCI USA, V100, P6343, DOI 10.1073/pnas.1037853100; Cho KA, 2003, J BIOL CHEM, V278, P27789, DOI 10.1074/jbc.M208105200; Fiucci G, 2002, ONCOGENE, V21, P2365, DOI 10.1038/sj.onc.1205300; Galbiati F, 2001, MOL BIOL CELL, V12, P2229, DOI 10.1091/mbc.12.8.2229; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; Ge SJ, 2004, J BIOL CHEM, V279, P6688, DOI 10.1074/jbc.M311769200; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Kakumoto K, 2006, P NATL ACAD SCI USA, V103, P5490, DOI 10.1073/pnas.0601222103; Razani B, 2001, J BIOL CHEM, V276, P38121; Sasai K, 2003, J BIOL CHEM, V278, P25295, DOI 10.1074/jbc.M301913200; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Sukezane T, 2005, ONCOGENE, V24, P5648, DOI 10.1038/sj.onc.1208724; Tang W, 2004, MOL BIOL CELL, V15, P4043, DOI 10.1091/mbc.E04-05-0402; van den Heuvel APJ, 2005, BIOCHEM J, V385, P795, DOI 10.1042/BJ20041449; Volonte D, 2002, MOL BIOL CELL, V13, P2502, DOI 10.1091/mbc.01-11-0529; Williams TM, 2004, J BIOL CHEM, V279, P24745, DOI 10.1074/jbc.M402064200; Zhao JJ, 2004, TRENDS MOL MED, V10, P344, DOI 10.1016/j.molmed.2004.05.005	22	16	18	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2007	26	3					449	455		10.1038/sj.onc.1209792	http://dx.doi.org/10.1038/sj.onc.1209792			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126VQ	16832346				2022-12-17	WOS:000243544000013
J	Kikuchi, H; Ozaki, T; Furuya, K; Hanamoto, T; Nakanishi, M; Yamamoto, H; Yoshida, K; Todo, S; Nakagawara, A				Kikuchi, H.; Ozaki, T.; Furuya, K.; Hanamoto, T.; Nakanishi, M.; Yamamoto, H.; Yoshida, K.; Todo, S.; Nakagawara, A.			NF-kappa B regulates the stability and activity of p73 by inducing its proteolytic degradation through a ubiquitin-dependent proteasome pathway	ONCOGENE			English	Article						apoptosis; NF-B; p53; p73; ubiquitination	KINASE C-ABL; DNA-DAMAGE; TYROSINE KINASE; P53-RELATED PROTEIN; APOPTOTIC RESPONSE; CELL-SURVIVAL; P53; ACTIVATION; DEATH; INHIBITION	Nuclear factor kappa B (NF-kappa B), which exists as heterodimeric complexes composed of p50 and p65, has been shown to play an important role in cell survival processes. In the present study, we found for the first time that NF-kappa B has an ability to induce the ubiquitin-dependent proteasomal degradation of proapoptotic p73 alpha. The activation of NF-kappa B in tumor necrosis factor a (TNF-alpha)-stimulated H1299 cells resulted in a significant reduction in the amounts of the endogenous p73 alpha. Consistent with these results, TNF-alpha-mediated down-regulation of p73 alpha was observed in wild-type (WT) mouse embryonic fibroblasts (MEFs) but not in p65-deficient MEFs. Ectopic expression of NF-kappa B decreased a half-life of p73a by increasing its ubiquitination levels, and thereby inhibiting the transcriptional activity as well as proapoptotic function of p73a, whereas NF-kappa B had undetectable effects on p53. Immunoprecipitation experiments demonstrated that, under our experimental conditions, NF-kappa B does not bind to p73a in mammalian cultured cells. In contrast to WT p65, the COOH-terminal deletion mutant of p65 (p65 Delta C) failed to reduce the expression levels of p73a, suggesting that NF-kappa B-mediated proteolytic degradation of p73a requires the transcriptional activity of NF-kappa B. Taken together, our present results imply that NF-kappa B-mediated degradation of proapoptotic p73 is a novel inhibitory mechanism of p73 that regulates cell survival and death.	Chiba Canc Ctr Res Inst, Div Biochem, Chuoh Ku, Chiba 2608717, Japan; Hokkaido Univ, Dept Gen Surg, Sch Med, Kita Ku, Sapporo, Hokkaido, Japan	Chiba Cancer Center; Hokkaido University	Nakagawara, A (corresponding author), Chiba Canc Ctr Res Inst, Div Biochem, Chuoh Ku, 666-2 Nitona, Chiba 2608717, Japan.	akiranak@chiba-cc.jp						Agami R, 1999, NATURE, V399, P809; Balint E, 1999, ONCOGENE, V18, P3923, DOI 10.1038/sj.onc.1202781; Bayon Y, 2003, MOL CELL BIOL, V23, P1061, DOI 10.1128/MCB.23.3.1061-1074.2003; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bernassola F, 2004, J EXP MED, V199, P1545, DOI 10.1084/jem.20031943; Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905; Chang LF, 2006, CELL, V124, P601, DOI 10.1016/j.cell.2006.01.021; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Fontemaggi G, 2001, MOL CELL BIOL, V21, P8461, DOI 10.1128/MCB.21.24.8461-8470.2001; Gong JG, 1999, NATURE, V399, P806; Gressner O, 2005, EMBO J, V24, P2458, DOI 10.1038/sj.emboj.7600708; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; Huang TT, 2000, J BIOL CHEM, V275, P9501, DOI 10.1074/jbc.275.13.9501; Ikawa S, 1999, CELL DEATH DIFFER, V6, P1154, DOI 10.1038/sj.cdd.4400631; Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kawai H, 2002, MOL CELL BIOL, V22, P6079, DOI 10.1128/MCB.22.17.6079-6088.2002; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kim JS, 2004, BIOCHEM PHARMACOL, V67, P1459, DOI 10.1016/j.bcp.2003.12.013; Kramer S, 2005, ONCOGENE, V24, P938, DOI 10.1038/sj.onc.1208257; Lee CW, 1999, ONCOGENE, V18, P4171, DOI 10.1038/sj.onc.1202793; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; Mantovani F, 2004, MOL CELL, V14, P625, DOI 10.1016/j.molcel.2004.05.007; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Muta T, 2001, EUR J BIOCHEM, V268, P4580, DOI 10.1046/j.1432-1327.2001.02385.x; Nakagawa T, 2002, MOL CELL BIOL, V22, P2575, DOI 10.1128/MCB.22.8.2575-2585.2002; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Rossi M, 2005, EMBO J, V24, P836, DOI 10.1038/sj.emboj.7600444; Stiewe T, 2002, CELL DEATH DIFFER, V9, P237, DOI 10.1038/sj.cdd.4400995; Stiewe T, 2002, CANCER RES, V62, P3598; Strano S, 2005, MOL CELL, V18, P447, DOI 10.1016/j.molcel.2005.04.008; VAN AD, 1996, SCIENCE, V274, P787; Wan YSY, 2003, IMMUNITY, V18, P331, DOI 10.1016/S1074-7613(03)00053-0; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Yamagishi N, 1997, INT J RADIAT BIOL, V72, P157, DOI 10.1080/095530097143374; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zaika AI, 2002, J EXP MED, V196, P765, DOI 10.1084/jem.20020179; Zeng XY, 1999, MOL CELL BIOL, V19, P3257	45	16	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	2006	25	58					7608	7617		10.1038/sj.onc.1209748	http://dx.doi.org/10.1038/sj.onc.1209748			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114GU	16953234				2022-12-17	WOS:000242655500006
J	Masuda, K; Richter, M; Song, X; Berezov, A; Masuda, K; Murali, R; Greene, MI; Zhang, H				Masuda, K.; Richter, M.; Song, X.; Berezov, A.; Masuda, K.; Murali, R.; Greene, M. I.; Zhang, H.			AHNP-streptavidin: a tetrameric bacterially produced antibody surrogate fusion protein against p185(her2/neu)	ONCOGENE			English	Article						AHNP; P185(her2/neu); streptavidin; tetramer	ESCHERICHIA-COLI; EXPRESSION; ONCOGENE; TUMOR; PHARMACOKINETICS; BIODISTRIBUTION; ADENOCARCINOMAS; PEPTIDES; C-ERBB-2; P185NEU	The anti-p185(her2/neu) peptidomimetic (AHNP) is a small exo-cyclic peptide derived from the anti-p185(her2/neu) rhumAb 4D5 (h4D5). AHNP mimics many but not all of the antitumor characteristics exhibited by h4D5. However, the pharmacokinetic profiles of AHNP are less than optimal for therapeutic or diagnostic purposes. To improve the binding affinity to p185(her2/neu) and the antitumor efficacy, we have engineered a fusion protein containing AHNP and a nonimmunoglobulin protein scaffold, streptavidin (SA). The recombinant protein, AHNP-SA (ASA) bound to p185(her2/neu) with high affinity, inhibited the proliferation of p185(her2/neu)-overexpressing cells, and reduced tumor growth induced by p185(her2/neu)-transformed cells. These data suggest that the bacterially produced tetrameric ASA can be used as an antibody-surrogate molecule. This class of molecule will play a role in the diagnosis and treatment of p185(her2/neu)-related tumors. Our studies establish a general principle by which a small biologically active synthetic exo-cyclic peptide can be engineered to enhance functional aspects by structured oligomerization and can be produced recombinantly using bacterial expression.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Greene, MI (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, 252 John Morgan Bldg,36th Hamilton Walk, Philadelphia, PA 19104 USA.	greene@reo.med.upenn.edu		Zhang, Hongtao/0000-0001-9173-0049; Murali, Ramachandran/0000-0002-8384-2793	NCI NIH HHS [5P01 CA 89480] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA089480] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Berezov A, 2002, J BIOL CHEM, V277, P28330, DOI 10.1074/jbc.M202880200; Berezov A, 2001, J MED CHEM, V44, P2565, DOI 10.1021/jm000527m; BRUCK C, 1986, P NATL ACAD SCI USA, V83, P6578, DOI 10.1073/pnas.83.17.6578; Chinol M, 1998, BRIT J CANCER, V78, P189, DOI 10.1038/bjc.1998.463; COHEN JA, 1989, ONCOGENE, V4, P81; DI FP, 1987, CELL, V51, P1063; DREBIN JA, 1985, CELL, V41, P695, DOI 10.1016/S0092-8674(85)80050-7; DREBIN JA, 1984, NATURE, V312, P545, DOI 10.1038/312545a0; DREBIN JA, 1988, ONCOGENE, V2, P387; DREBIN JA, 1986, S FUND CANC RES, V381, P277; Farlow SJ, 2002, FEBS LETT, V516, P197, DOI 10.1016/S0014-5793(02)02565-6; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Hudson PJ, 2003, NAT MED, V9, P129, DOI 10.1038/nm0103-129; Jurado P, 2002, J MOL BIOL, V320, P1, DOI 10.1016/S0022-2836(02)00405-9; KALOFONOS HP, 1990, J NUCL MED, V31, P1791; KERN JA, 1990, CANCER RES, V50, P5184; Kobayashi T, 1999, EMBO J, V18, P1192, DOI 10.1093/emboj/18.5.1192; KOKAI Y, 1988, PRINC TAK S, V191, P45; LODATO RF, 1990, MODERN PATHOL, V3, P449; Maynard J, 2000, ANNU REV BIOMED ENG, V2, P339, DOI 10.1146/annurev.bioeng.2.1.339; Meyer DL, 2001, PROTEIN SCI, V10, P491, DOI 10.1110/ps.19901; Murali R, 1998, IMMUNOL RES, V17, P163, DOI 10.1007/BF02786441; Park BW, 2000, NAT BIOTECHNOL, V18, P194, DOI 10.1038/72651; Proba K, 1997, J MOL BIOL, V265, P161, DOI 10.1006/jmbi.1996.0726; ROSEBROUGH SF, 1993, NUCL MED BIOL, V20, P663, DOI 10.1016/0969-8051(93)90037-U; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Sliwkowski MX, 1999, SEMIN ONCOL, V26, P60; WILLIAMS TM, 1991, PATHOBIOLOGY, V59, P46, DOI 10.1159/000163614; WILLIAMS WV, 1989, P NATL ACAD SCI USA, V86, P5537, DOI 10.1073/pnas.86.14.5537; Zhang HT, 2006, NAT MED, V12, P473, DOI 10.1038/nm1378	30	16	19	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2006	25	59					7740	7746		10.1038/sj.onc.1209745	http://dx.doi.org/10.1038/sj.onc.1209745			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	116VE	16785990				2022-12-17	WOS:000242830800008
J	Piltti, K; Kerosuo, L; Hakanen, J; Eriksson, M; Angers-Loustau, A; Leppa, S; Salminen, M; Sariola, H; Wartiovaara, K				Piltti, K.; Kerosuo, L.; Hakanen, J.; Eriksson, M.; Angers-Loustau, A.; Leppa, S.; Salminen, M.; Sariola, H.; Wartiovaara, K.			E6/E7 oncogenes increase and tumor suppressors decrease the proportion of self-renewing neural progenitor cells	ONCOGENE			English	Article						oncogene; tumor suppressor; progenitor; self-renewal	HUMAN-PAPILLOMAVIRUS TYPE-16; STEM-CELL; E7 GENE; RETINOBLASTOMA PROTEIN; SIGNALING PATHWAY; EPITHELIAL-CELLS; PRECURSOR CELLS; LARGE-T; PROMOTES; KINASE	Many if not most tissues need a controlled number of stem cells to maintain normal function. Cancer can be seen as a process of disturbed tissue homeostasis, in which too many cells have or acquire too primitive identity. Here we measured how oncogenes and tumour suppressors affect the differentiation capacity, proportion and characteristics of progenitor cells in a model tissue. Neural progenitor cells (NPCs) were exposed to human papilloma virus E6, E7 or E6/E7 oncogenes, which degrade tumour suppressors p53 and pRb family members, respectively. E6/E7-expressing or p53(-/-) NPCs were able to differentiate, but simultaneously retained high capacity for self-renewal, proliferation, ability to remain multi-potent in conditions promoting differentiation and showed delayed cell cycle exit. These functions were mediated through p53 and pRb family, and involved MEK-ERK signalling. Decreased amount of p53 increased self-renewal and proliferation, whereas pRb affected only proliferation. Our results suggest that the oncogenes increase whereas p53 and pRb family tumour suppressors decrease the number and proportion of progenitor cells. These findings provide one explanation how oncogenes and tumour suppressors control tissue homeostasis and highlight their importance in stem cell self-renewal, linked both to cancer and life-long tissue turnover.	Univ Helsinki, Dept Biol, Inst Biomed, FIN-00014 Helsinki, Finland; Univ Helsinki, Inst Biotechnol, FIN-00014 Helsinki, Finland; Univ Helsinki, Cent Hosp, HUCH Lab Diagnost, Helsinki, Finland	University of Helsinki; University of Helsinki; University of Helsinki; Helsinki University Central Hospital	Wartiovaara, K (corresponding author), Univ Helsinki, Dept Biol, Inst Biomed, POB 63, FIN-00014 Helsinki, Finland.	kirmo.wartiovaara@helsinki.fi	Hakanen, Janne/O-2166-2016	Hakanen, Janne/0000-0002-7501-2917; Salminen, Marjo/0000-0003-0696-6845; Piltti, Katja/0000-0002-9773-0442; Leppa, Sirpa/0000-0002-8265-511X; Angers-Loustau, Alexandre/0000-0003-1425-4143				Antinore MJ, 1996, EMBO J, V15, P1950, DOI 10.1002/j.1460-2075.1996.tb00546.x; ARMSTRONG JF, 1995, CURR BIOL, V5, P931, DOI 10.1016/S0960-9822(95)00183-7; Bach S, 2005, J BIOL CHEM, V280, P31208, DOI 10.1074/jbc.M500806200; Boyer SN, 1996, CANCER RES, V56, P4620; Bruggeman SWM, 2005, GENE DEV, V19, P1438, DOI 10.1101/gad.1299305; Callaghan DA, 1999, DEV BIOL, V207, P257, DOI 10.1006/dbio.1998.9162; Chakrabarti O, 2004, J VIROL, V78, P5934, DOI 10.1128/JVI.78.11.5934-5945.2004; CHENG S, 1995, GENE DEV, V9, P2335, DOI 10.1101/gad.9.19.2335; Choi J, 1999, CELL MOL LIFE SCI, V55, P38, DOI 10.1007/s000180050268; Coursen JD, 1997, EXP CELL RES, V235, P245, DOI 10.1006/excr.1997.3670; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; Dazy S, 2003, ONCOGENE, V22, P9205, DOI 10.1038/sj.onc.1207049; DeCaprio JA, 1999, BIOLOGICALS, V27, P23, DOI 10.1006/biol.1998.0173; DYSON N, 1993, J VIROL, V67, P7641, DOI 10.1128/JVI.67.12.7641-7647.1993; Farah MH, 2000, DEVELOPMENT, V127, P693; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fehrmann F, 2003, ONCOGENE, V22, P5201, DOI 10.1038/sj.onc.1206554; Ferguson KL, 2000, J BIOL CHEM, V275, P33593, DOI 10.1074/jbc.M004879200; Grewal SS, 1999, CURR OPIN NEUROBIOL, V9, P544, DOI 10.1016/S0959-4388(99)00010-0; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; Harris KF, 1998, MOL CELL BIOL, V18, P1746, DOI 10.1128/MCB.18.3.1746; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; Herdegen T, 1997, TRENDS NEUROSCI, V20, P227, DOI 10.1016/S0166-2236(96)01000-4; Liu HP, 2004, CURR OPIN GENET DEV, V14, P55, DOI 10.1016/j.gde.2003.11.005; Macleod KF, 1996, EMBO J, V15, P6178, DOI 10.1002/j.1460-2075.1996.tb01006.x; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Miller MW, 2003, BRAIN RES, V965, P57, DOI 10.1016/S0006-8993(02)04119-7; Molofsky AV, 2005, GENE DEV, V19, P1432, DOI 10.1101/gad.1299505; Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060; Munger K, 2004, J VIROL, V78, P11451, DOI 10.1128/JVI.78.21.11451-11460.2004; Pardal R, 2003, NAT REV CANCER, V3, P895, DOI 10.1038/nrc1232; Popsueva A, 2003, J CELL BIOL, V161, P119, DOI 10.1083/jcb.200212174; Ross SE, 2003, NEURON, V39, P13, DOI 10.1016/S0896-6273(03)00365-9; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Singh SK, 2003, CANCER RES, V63, P5821; SLACK RS, 1993, ONCOGENE, V8, P1585; Slack RS, 1998, J CELL BIOL, V140, P1497, DOI 10.1083/jcb.140.6.1497; TeKippe M, 2003, EXP HEMATOL, V31, P521, DOI 10.1016/S0301-472X(03)00072-9; Toma JG, 2001, NAT CELL BIOL, V3, P778, DOI 10.1038/ncb0901-778; Toma JG, 2000, J NEUROSCI, V20, P7648; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; van Houten VMM, 2001, INT J CANCER, V93, P232, DOI 10.1002/ijc.1313; Vanderluit JL, 2004, J CELL BIOL, V166, P853, DOI 10.1083/jcb.200403156; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0	45	16	17	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 10	2006	25	35					4880	4889		10.1038/sj.onc.1209492	http://dx.doi.org/10.1038/sj.onc.1209492			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	072QE	16532024				2022-12-17	WOS:000239687100006
J	Wang, L; Tam, JP; Liu, DX				Wang, L.; Tam, J. P.; Liu, D. X.			Biochemical and functional characterization of Epstein-Barr virus-encoded BARF1 protein: interaction with human hTid1 protein facilitates its maturation and secretion	ONCOGENE			English	Article						Epstein-Barr virus; BARF1; human hTid1; interaction; maturation and secretion	HUMAN DNAJ PROTEIN; DROSOPHILA TUMOR-SUPPRESSOR; MALIGNANT-TRANSFORMATION; NASOPHARYNGEAL CARCINOMA; HUMAN HOMOLOG; CELL-LINE; GENE; EXPRESSION; HSP70; ABSENCE	EBV BARF1 gene encodes a secretory protein with transforming and mitogenic activities. In this report, the post-translational modification, folding, maturation and secretion of BARF1 are systematically studied by site-directed mutagenesis and overexpression of the protein in mammalian cells using the vaccinia/T7 system. The protein was shown to be post-translationally modified by N-linked glycosylation on the asparagine 95 residue. This modi. cation was confirmed to be essential for the maturation and secretion of the protein. Analysis of the four cysteine residues by site-directed mutagenesis demonstrated that cysteine 146 and 201 were essential for proper folding and secretion of the protein. To search for human proteins involved in the maturation process of the protein, a yeast two-hybrid screening was carried out using the BARF1 sequence from amino acids 21 - 221 (BARF1 Delta) as bait, leading to the identification of human hTid1 protein as a potential interacting protein. This interaction was subsequently confirmed by coimmunoprecipitation and dual immunofluorescent labeling of cells coexpressing BARF1 and hTid1, and the interaction domain in hTid1 was mapped to amino acids 149 - 320. Interestingly, coexpression of BARF1 with hTid1 demonstrated that hTid1 could promote secretion of BARF1, suggesting that hTid1 may act as a chaperone to facilitate the folding, processing and maturation of BARF1.	Inst Mol & Cell Biol, Singapore 138673, Singapore; Nanyang Technol Univ, Sch Biol Sci, Singapore, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University	Liu, DX (corresponding author), Inst Mol & Cell Biol, 61 Biopolis Dr, Singapore 138673, Singapore.	dxliu@imcb.a-star.edu.sg	Tam, James P/A-2176-2011; Liu, Ding Xiang/A-2226-2011	Tam, James P/0000-0003-4433-198X; 				BORK P, 1992, P NATL ACAD SCI USA, V89, P7290, DOI 10.1073/pnas.89.16.7290; Cheetham ME, 1998, CELL STRESS CHAPERON, V3, P28, DOI 10.1379/1466-1268(1998)003<0028:SFAEOD>2.3.CO;2; Cheng H, 2002, J BIOL CHEM, V277, P20605, DOI 10.1074/jbc.M201204200; Cheng H, 2001, CURR BIOL, V11, P1771, DOI 10.1016/S0960-9822(01)00540-1; Cohen JI, 1999, J VIROL, V73, P7627, DOI 10.1128/JVI.73.9.7627-7632.1999; Danve C, 2001, VIROLOGY, V288, P223, DOI 10.1006/viro.2001.1072; de Turenne-Tessier M, 2005, VIRUS RES, V109, P9, DOI 10.1016/j.virusres.2004.10.003; Decaussin G, 2000, CANCER RES, V60, P5584; Eom CY, 2002, P NATL ACAD SCI USA, V99, P1894, DOI 10.1073/pnas.042689499; KIEFF E, 1996, FIELDS VIROLOGY, V3, P2343; Kim SW, 2004, CANCER RES, V64, P7732, DOI 10.1158/0008-5472.CAN-04-1323; Liu DX, 1997, J VIROL, V71, P1814, DOI 10.1128/JVI.71.3.1814-1820.1997; Mayer MP, 2005, REV PHYSIOL BIOCH P, V153, P1, DOI 10.1007/s10254-004-0025-5; Nishikawa J, 1999, J VIROL, V73, P1286, DOI 10.1128/JVI.73.2.1286-1292.1999; Sall A, 2004, ONCOGENE, V23, P4938, DOI 10.1038/sj.onc.1207607; Sarkar S, 2001, J BIOL CHEM, V276, P49034, DOI 10.1074/jbc.M103683200; Schaaf CP, 2004, FASEB J, V18, P267, DOI 10.1096/fj.04-1558fje; Schilling B, 1998, VIROLOGY, V247, P74, DOI 10.1006/viro.1998.9220; Seto E, 2005, J MED VIROL, V76, P82, DOI 10.1002/jmv.20327; Sheng W, 2003, J VIROL, V77, P3859, DOI 10.1128/JVI.77.6.3859-3865.2003; Sheng W, 2001, ONCOGENE, V20, P1176, DOI 10.1038/sj.onc.1204217; Strockbine LD, 1998, J VIROL, V72, P4015, DOI 10.1128/JVI.72.5.4015-4021.1998; Syken J, 1999, P NATL ACAD SCI USA, V96, P8499, DOI 10.1073/pnas.96.15.8499; Wang CC, 2004, DEV CELL, V7, P359, DOI 10.1016/j.devcel.2004.08.002; WEI MX, 1989, EMBO J, V8, P2897, DOI 10.1002/j.1460-2075.1989.tb08438.x; Wei MX, 1997, ONCOGENE, V14, P3073, DOI 10.1038/sj.onc.1201128; WEI MX, 1994, CANCER RES, V54, P1843; ZHANG CX, 1988, J VIROL, V62, P1862, DOI 10.1128/JVI.62.6.1862-1869.1988	28	16	17	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	2006	25	31					4320	4331		10.1038/sj.onc.1209458	http://dx.doi.org/10.1038/sj.onc.1209458			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	066OU	16518412				2022-12-17	WOS:000239240100007
J	Mantoni, TS; Reid, G; Garrett, MD				Mantoni, T. S.; Reid, G.; Garrett, M. D.			Androgen receptor activity is inhibited in response to genotoxic agents in a p53-independent manner	ONCOGENE			English	Article						androgen receptor; genotoxic agents; p53; chemotherapeutics	PROSTATE-SPECIFIC ANTIGEN; RNA-POLYMERASE-II; TRANSCRIPTIONAL REGULATION; PIFITHRIN-ALPHA; HEAT-SHOCK; IN-VIVO; CANCER; PHOSPHORYLATION; CISPLATIN; CELLS	The androgen receptor (AR) is fundamental to androgen signalling within the prostate gland, and deregulation of its activity is frequently linked to the development of prostate cancer. Advanced prostate cancer is often treated with chemotherapy and most of these drugs exert their function by generating genotoxic stress such as DNA damage. We have investigated here the effects of genotoxic agents used in chemotherapeutic regimens on AR function and expression. We have discovered that endogenous AR activity in LNCaP cells is inhibited in response to the chemotherapeutic agents etoposide and cisplatin. This loss of AR activity is not caused by a change in cell cycle distribution, a change in subcellular localisation of the AR nor by induction of apoptosis. In addition, we found that inhibition of AR activity in response to genotoxic stress is independent of p53 function. Interestingly, our studies revealed that genotoxic stress inhibits the hormone-stimulated recruitment of AR to androgen response elements. Thus, we report for the first time a mechanism by which the AR activity is inhibited in response to different chemotherapeutic agents.	Inst Canc Res, Haddow Labs, Canc Res UK Ctr Canc Therapeut, Sutton SM2 5NG, Surrey, England; European Mol Biol Lab, Heidelberg, Germany	Cancer Research UK; University of London; Institute of Cancer Research - UK; European Molecular Biology Laboratory (EMBL)	Garrett, MD (corresponding author), Inst Canc Res, Haddow Labs, Canc Res UK Ctr Canc Therapeut, 15 Cotswold Rd, Sutton SM2 5NG, Surrey, England.	michelle.garrett@icr.ac.uk		Reid, George/0000-0002-0298-693X				Black BE, 2004, MOL ENDOCRINOL, V18, P834, DOI 10.1210/me.2003-0145; BRUCHOVSKY N, 1968, J BIOL CHEM, V243, P2012; Chen L, 2004, NEW ASTRON, V10, P39, DOI 10.1016/j.newast.2004.04.008; Cleutjens KBJM, 1997, MOL ENDOCRINOL, V11, P148, DOI 10.1210/me.11.2.148; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Cronauer MV, 2004, ONCOGENE, V23, P3541, DOI 10.1038/sj.onc.1207346; Denmeade SR, 2004, PROSTATE, V58, P211, DOI 10.1002/pros.10360; Edwards J, 2003, BRIT J CANCER, V89, P552, DOI 10.1038/sj.bjc.6601127; Espinosa E, 2003, CANCER TREAT REV, V29, P515, DOI 10.1016/S0305-7372(03)00116-6; Fang YF, 1996, J BIOL CHEM, V271, P28697, DOI 10.1074/jbc.271.45.28697; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Georget V, 2002, BIOCHEMISTRY-US, V41, P11824, DOI 10.1021/bi0259150; Gioeli D, 2002, J BIOL CHEM, V277, P29304, DOI 10.1074/jbc.M204131200; Gregory CW, 2001, CANCER RES, V61, P2892; Gudmundsdottir K, 2004, EMBO REP, V5, P989, DOI 10.1038/sj.embor.7400255; Hande KR, 1998, EUR J CANCER, V34, P1514, DOI 10.1016/S0959-8049(98)00228-7; Hoshi Senji, 2003, Int J Clin Oncol, V8, P118, DOI 10.1007/s101470300021; Jordan P, 2000, CELL MOL LIFE SCI, V57, P1229, DOI 10.1007/PL00000762; Kang ZG, 2004, MOL ENDOCRINOL, V18, P2633, DOI 10.1210/me.2004-0245; Kang ZG, 2002, J BIOL CHEM, V277, P48366, DOI 10.1074/jbc.M209074200; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Komarova EA, 2003, J BIOL CHEM, V278, P15465, DOI 10.1074/jbc.C300011200; Lin HK, 2001, P NATL ACAD SCI USA, V98, P7200, DOI 10.1073/pnas.121173298; Linton KD, 2003, CANCER TREAT REV, V29, P151, DOI 10.1016/S0305-7372(03)00096-3; Litvinov IV, 2003, J CLIN ENDOCR METAB, V88, P2972, DOI 10.1210/jc.2002-022038; Louie MC, 2003, P NATL ACAD SCI USA, V100, P2226, DOI 10.1073/pnas.0437824100; Marcelli M, 2000, CANCER RES, V60, P944; Martinez ED, 2002, J BIOL CHEM, V277, P29719, DOI 10.1074/jbc.M112134200; Meek DW, 2004, DNA REPAIR, V3, P1049, DOI 10.1016/j.dnarep.2004.03.027; Nelson PS, 2002, P NATL ACAD SCI USA, V99, P11890, DOI 10.1073/pnas.182376299; Nissen RM, 2000, GENE DEV, V14, P2314, DOI 10.1101/gad.827900; Parker CC, 2003, CANCER TREAT REV, V29, P161, DOI 10.1016/S0305-7372(03)00070-7; Pilat MJP, 1998, CANCER METAST REV, V17, P373, DOI 10.1023/A:1006166511344; RENNIE PS, 1993, MOL ENDOCRINOL, V7, P23, DOI 10.1210/me.7.1.23; RIEGMAN PHJ, 1991, MOL ENDOCRINOL, V5, P1921, DOI 10.1210/mend-5-12-1921; Rocha S, 2003, BMC MOL BIOL, V4, DOI 10.1186/1471-2199-4-9; Rosenfeld MG, 2001, J BIOL CHEM, V276, P36865, DOI 10.1074/jbc.R100041200; Rosenhagen MC, 2003, MOL ENDOCRINOL, V17, P1991, DOI 10.1210/me.2003-0141; Sack JS, 2001, P NATL ACAD SCI USA, V98, P4904, DOI 10.1073/pnas.081565498; Sciuto R, 2002, J NUCL MED, V43, P79; Shenk JL, 2001, J BIOL CHEM, V276, P38472, DOI 10.1074/jbc.M103652200; Solit DB, 2002, CLIN CANCER RES, V8, P986; Steineck G, 2002, ACTA ONCOL, V41, P668, DOI 10.1080/028418602321028292; Tyagi RK, 2000, MOL ENDOCRINOL, V14, P1162, DOI 10.1210/me.14.8.1162; Vaishampayan U, 2004, AM J CLIN ONCOL-CANC, V27, P550, DOI 10.1097/01.coc.0000135922.12198.e4; VELDSCHOLTE J, 1990, BIOCHEM BIOPH RES CO, V173, P534, DOI 10.1016/S0006-291X(05)80067-1; Whitesell L, 2005, NAT REV CANCER, V5, P761, DOI 10.1038/nrc1716; Wong HY, 2004, BIOCHEM J, V383, P267, DOI 10.1042/BJ20040683; Yang J, 2003, CARCINOGENESIS, V24, P1571, DOI 10.1093/carcin/bgg137	49	16	16	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 25	2006	25	22					3139	3149		10.1038/sj.onc.1209347	http://dx.doi.org/10.1038/sj.onc.1209347			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MK	16434973				2022-12-17	WOS:000237951000005
J	Chen, J; Kremer, CS; Bender, TP				Chen, J; Kremer, CS; Bender, TP			The carbonic anhydrase I locus contains a c-Myb target promoter and modulates differentiation of murine erythroleukemia cells	ONCOGENE			English	Article						c-Myb; B-Myb; carbonic anhydrase; erythroleukemia; transcription factor; differentiation	HUMAN HEMATOPOIETIC-CELLS; INDUCED TRANSCRIPTION ACTIVATION; NEUTROPHIL ELASTASE PROMOTER; NEGATIVE REGULATORY DOMAIN; ERYTHROID-DIFFERENTIATION; B-MYB; A-MYB; PHOSPHORYLATION SITE; GENE-EXPRESSION; BINDING-SITES	The Myb proto-oncogene encodes a transcription factor (c-Myb) that is essential for normal hematopoiesis and is thought to regulate hematopoietic cell proliferation and differentiation by regulating expression of specific target genes. We identify the mouse erythroid-specific carbonic anhydrase I promoter (CAIe) as a target of c-Myb activity and demonstrate that Myb activity is critical for carbonic anhydrase I (CAI) expression in C19 MEL cells. CAI expression is downregulated when MEL cells differentiate in response to MEnT or treatment with N, N-hexamethylene bisacetamide (HMBA). Coexpression of GATA-1 with c-Myb results in synergistic activation of transcription from the CAIe promoter and both transcription factors interact with the CAIe promoter in vivo. We identify a novel 20 bp sequence in the CAIe promoter that is sufficient to mediate synergistic activation of the CAIe promoter by c-Myb and GATA-1. c-Myb and GATA-1 interact with this DNA sequence suggesting that c-Myb and GATA-1 may be contained in a complex that interacts with this region of the CAIe promoter. Forced expression of CAI delayed HMBA-induced differentiation of MEL cells and maintained them in a proliferating state. These data strongly suggest that CAI is a c-Myb target and is involved in regulating MEL cell proliferation and differentiation.	Univ Virginia Hlth Syst, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia Hlth Syst, Dept Mol Physiol & Biol Phys, Charlottesville, VA USA	University of Virginia; University of Virginia	Bender, TP (corresponding author), Univ Virginia Hlth Syst, Dept Microbiol, POB 800734,1300 Jefferson Pk Ave, Charlottesville, VA 22908 USA.	tpb3e@virginia.edu			NATIONAL CANCER INSTITUTE [R01CA085842] Funding Source: NIH RePORTER; NCI NIH HHS [CA85842] Funding Source: Medline; NIGMS NIH HHS [GM55985] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen RD, 1999, GENE DEV, V13, P1073, DOI 10.1101/gad.13.9.1073; AZIZ N, 1995, P NATL ACAD SCI USA, V92, P6429, DOI 10.1073/pnas.92.14.6429; BADIANI P, 1994, GENE DEV, V8, P770, DOI 10.1101/gad.8.7.770; Bender TP, 2004, NAT IMMUNOL, V5, P721, DOI 10.1038/ni1085; BENDER TP, 1986, P NATL ACAD SCI USA, V83, P3204, DOI 10.1073/pnas.83.10.3204; Beug H, 1996, BBA-REV CANCER, V1288, pM35, DOI 10.1016/S0304-419X(96)00032-7; BRADY HJM, 1991, BIOCHEM J, V277, P903, DOI 10.1042/bj2770903; BRADY HJM, 1989, FEBS LETT, V257, P451, DOI 10.1016/0014-5793(89)81594-7; Burk O, 1997, EMBO J, V16, P1371, DOI 10.1093/emboj/16.6.1371; BUSFIELD SJ, 1995, EUR J BIOCHEM, V230, P475; Cardone RA, 2005, NAT REV CANCER, V5, P786, DOI 10.1038/nrc1713; Chen J, 2002, ONCOGENE, V21, P1859, DOI 10.1038/sj.onc.1205003; Ciana P, 1998, EMBO J, V17, P7382, DOI 10.1093/emboj/17.24.7382; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; CUDDIHY AE, 1993, MOL CELL BIOL, V13, P3505, DOI 10.1128/MCB.13.6.3505; DISELA C, 1991, GENE DEV, V5, P2033, DOI 10.1101/gad.5.11.2033; Emambokus N, 2003, EMBO J, V22, P4478, DOI 10.1093/emboj/cdg434; ENDO T, 1994, LEUKEMIA RES, V18, P49, DOI 10.1016/0145-2126(94)90008-6; EVANS JL, 1990, MOL CELL BIOL, V10, P5747, DOI 10.1128/MCB.10.11.5747; FRASER P, 1989, MOL CELL BIOL, V9, P3308, DOI 10.1128/MCB.9.8.3308; FRASER PJ, 1986, J MOL EVOL, V23, P294, DOI 10.1007/BF02100637; FRASER PJ, 1987, GENE DEV, V1, P855, DOI 10.1101/gad.1.8.855; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; FUERSTENBERG S, 1992, EMBO J, V11, P3355, DOI 10.1002/j.1460-2075.1992.tb05414.x; Ganter B, 1997, ONCOGENE, V15, P193, DOI 10.1038/sj.onc.1201173; GOLAY J, 1991, BLOOD, V77, P149; Golay J, 1996, BLOOD, V87, P1900; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; Henry RP, 1996, ANNU REV PHYSIOL, V58, P523, DOI 10.1146/annurev.physiol.58.1.523; INOUE T, 1994, J BIOL CHEM, V269, P32451; KaneiIshii C, 1997, SCIENCE, V277, P246, DOI 10.1126/science.277.5323.246; KIRSCH IR, 1986, J CELL BIOCHEM, V32, P11, DOI 10.1002/jcb.240320103; Lang G, 2005, ONCOGENE, V24, P1375, DOI 10.1038/sj.onc.1208301; Latchman D. S., 1993, TRANSCRIPTION FACTOR; Leverson JD, 1998, MOL CELL, V2, P417, DOI 10.1016/S1097-2765(00)80141-0; Liao SY, 1997, CANCER RES, V57, P2827; Lipsick JS, 1996, ONCOGENE, V13, P223; LOWE N, 1990, GENE, V93, P277, DOI 10.1016/0378-1119(90)90236-K; Marks P A, 1987, Prog Clin Biol Res, V251, P253; MARKS PA, 1978, ANNU REV BIOCHEM, V47, P419, DOI 10.1146/annurev.bi.47.070178.002223; MartinezZaguilan R, 1996, CLIN EXP METASTAS, V14, P176, DOI 10.1007/BF00121214; McAdams TA, 1998, BRIT J HAEMATOL, V103, P317, DOI 10.1046/j.1365-2141.1998.00975.x; MCCLINTON D, 1990, MOL CELL BIOL, V10, P705, DOI 10.1128/MCB.10.2.705; MELOTTI P, 1994, J BIOL CHEM, V269, P25303; MELOTTI P, 1994, J EXP MED, V179, P1023, DOI 10.1084/jem.179.3.1023; Miglarese MR, 1996, J BIOL CHEM, V271, P22697, DOI 10.1074/jbc.271.37.22697; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; Ness SA, 1999, ONCOGENE, V18, P3039, DOI 10.1038/sj.onc.1202726; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; Nuchprayoon I, 1997, BLOOD, V89, P4546, DOI 10.1182/blood.V89.12.4546; Oelgeschlager M, 1996, MOL CELL BIOL, V16, P4717; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; Parkkila S, 2000, P NATL ACAD SCI USA, V97, P2220, DOI 10.1073/pnas.040554897; Pastorekova S, 2004, J ENZYM INHIB MED CH, V19, P199, DOI 10.1080/14756360410001689540; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; Ratajczak MZ, 1998, BLOOD, V91, P1934, DOI 10.1182/blood.V91.6.1934.1934_1934_1946; REISS K, 1991, J CELL PHYSIOL, V148, P338, DOI 10.1002/jcp.1041480303; Rushton JJ, 2003, ONCOGENE, V22, P308, DOI 10.1038/sj.onc.1206131; SCHER W, 1977, CELL DIFFER DEV, V6, P285, DOI 10.1016/0045-6039(77)90003-3; Schmidt M, 2000, MOL CELL BIOL, V20, P1970, DOI 10.1128/MCB.20.6.1970-1981.2000; SHAPIRO LH, 1995, J BIOL CHEM, V270, P8763, DOI 10.1074/jbc.270.15.8763; SIU G, 1992, MOL CELL BIOL, V12, P1592, DOI 10.1128/MCB.12.4.1592; SOWDEN J, 1993, DIFFERENTIATION, V53, P67, DOI 10.1111/j.1432-0436.1993.tb00647.x; Takahashi T, 2000, ONCOGENE, V19, P134, DOI 10.1038/sj.onc.1203228; TASHIAN RE, 1989, BIOESSAYS, V10, P186, DOI 10.1002/bies.950100603; Tureci O, 1998, P NATL ACAD SCI USA, V95, P7608, DOI 10.1073/pnas.95.13.7608; Webb SD, 1999, J THEOR BIOL, V196, P237, DOI 10.1006/jtbi.1998.0836; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1	72	16	16	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2006	25	19					2758	2772		10.1038/sj.onc.1209295	http://dx.doi.org/10.1038/sj.onc.1209295			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	039AW	16407849				2022-12-17	WOS:000237272900007
J	Belka, C				Belka, C			The fate of irradiated tumor cells	ONCOGENE			English	Editorial Material						apoptosis; cell cycle arrest; radiation P21(CIP/WAF1); cell death	MITOTIC CATASTROPHE; DNA-DAMAGE; SUPPRESSION; CARCINOMA; APOPTOSIS; P53	Radiotherapy remains a key component of modern multimodal anticancer treatment approaches. Although most clinically relevant improvements in radiation oncology are based on optimized radiation technology, it now becomes obvious that biology-based approaches will further boost the efficacy of modern radiation oncology. Of relevance to this is the question of the ultimate fate of an irradiated cell and the mechanistic basis of the induced cell death or inactivation observed. Research bearing on this question is reported in this issue of Oncogene by Wendt et al. (2005), who show that the levels of p21(CIP/WAF1) play a key role in determining whether an irradiated tumour cell is arrested in the G2 phase of the cell cycle, rather than apoptosing. The demonstration that caffeine treatment can abrogate this G2 arrest, and that the cells go on to die, has implications for overcoming treatment resistance imposed by radiation- induced upregulation of p21(CIP/WAF1).	Univ Tubingen, Dept Radiat Oncol, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen	Belka, C (corresponding author), Univ Tubingen, Dept Radiat Oncol, Hoppe Seyler Str 3, D-72076 Tubingen, Germany.	claus.belka@uni-tuebingen.de						Belka C, 2004, INT J RADIAT ONCOL, V58, P542, DOI 10.1016/j.ijrobp.2003.09.067; Castedo M, 2004, ONCOGENE, V23, P4362, DOI 10.1038/sj.onc.1207572; Castedo M, 2004, ONCOGENE, V23, P4353, DOI 10.1038/sj.onc.1207573; El-Deiry WS, 2003, ONCOGENE, V22, P7486, DOI 10.1038/sj.onc.1206949; Iliakis G, 2003, ONCOGENE, V22, P5834, DOI 10.1038/sj.onc.1206682; Rau B, 2003, J CLIN ONCOL, V21, P3391, DOI 10.1200/JCO.2003.07.077; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Sturm I, 2001, J CLIN ONCOL, V19, P2272, DOI 10.1200/JCO.2001.19.8.2272; WENDT J, 2005, IN PRESS ONCOGENE	9	16	16	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2006	25	7					969	971		10.1038/sj.onc.1209175	http://dx.doi.org/10.1038/sj.onc.1209175			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	012SX	16247448	Bronze			2022-12-17	WOS:000235361000001
J	Grandinetti, KB; Spengler, BA; Biedler, JL; Ross, RA				Grandinetti, KB; Spengler, BA; Biedler, JL; Ross, RA			Loss of one HuD allele on chromosome # 1p selects for amplification of the N-myc proto-oncogene in human neuroblastoma cells	ONCOGENE			English	Article						HuD; N-myc; human neuroblastoma; RNA-binding protein; chromosome 1p deletion; gene amplification	PARANEOPLASTIC ENCEPHALOMYELITIS ANTIGEN; RESISTANT CHINESE-HAMSTER; RNA-BINDING PROTEIN; GENE AMPLIFICATION; SHORT ARM; EXPRESSION; ELAV; LINES; HETEROZYGOSITY; HYBRIDIZATION	In human neuroblastoma tumors, amplification of the N-myc proto-oncogene and loss of all or part of the short arm of chromosome #1 are both associated with a poor prognosis. Accruing evidence indicates that it is the absence of one allele of the HuD (ELAVL4) gene, encoding the neuronal-specific RNA-binding protein HuD and localized to 1p34, that is linked to amplification. In 12 human neuroblastoma cell lines, N-myc amplification correlates with loss of one HuD allele and decreased HuD expression. Transfection experiments demonstrate that modulating HuD expression affects N-myc gene copy number as well as expression. Introduction of a sense HuD construct into two N-myc amplified cell lines considerably increases N-myc expression whereas gene copy number decreases. Conversely, expression of antisense HuD in N-myc nonamplified SH-SY5Y cells reduces HuD and N-myc mRNA levels even as cells show amplification of the N-myc gene. Thus, N-myc gene copy number is modulated by alteration of HuD expression. We propose that haploinsufficiency of HuD due to chromosome #1p deletion in neuroblastoma selects for cells that amplify N-myc genes. Application of these findings could lead to more effective therapies in the treatment of those patients with the worst prognosis.	Fordham Univ, Dept Biol Sci, Neurobiol Lab, Bronx, NY 10458 USA	Fordham University	Ross, RA (corresponding author), Fordham Univ, Dept Biol Sci, Neurobiol Lab, 441 E Fordham Rd, Bronx, NY 10458 USA.	rross@fordham.edu			NCI NIH HHS [CA77593] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077593] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER BS, 1989, GENOME, V31, P638, DOI 10.1139/g89-117; Ball NS, 1997, CLIN CANCER RES, V3, P1859; BELLO MJ, 1995, CANCER GENET CYTOGEN, V83, P160, DOI 10.1016/0165-4608(95)00064-V; BIEDLER JL, 1976, J NATL CANCER I, V57, P683, DOI 10.1093/jnci/57.3.683; BIEDLER JL, 1979, PROGR CANC RES THERP, V12, P881; BIEDLER JL, 1983, RATIONAL BASIS CHEMO, P71; Bown N, 1999, NEW ENGL J MED, V340, P1954, DOI 10.1056/NEJM199906243402504; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; BRODEUR GM, 1986, CANCER GENET CYTOGEN, V19, P101, DOI 10.1016/0165-4608(86)90377-8; CARON H, 1995, HUM MOL GENET, V4, P535, DOI 10.1093/hmg/4.4.535; Caron H, 1996, NEW ENGL J MED, V334, P225, DOI 10.1056/NEJM199601253340404; Chagnovich D, 1996, J BIOL CHEM, V271, P33580, DOI 10.1074/jbc.271.52.33580; CHAMBERLAIN JS, 1988, NUCLEIC ACIDS RES, V16, P11141, DOI 10.1093/nar/16.23.11141; CHARRON J, 1992, GENE DEV, V6, P2248, DOI 10.1101/gad.6.12a.2248; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; Cole MD, 1999, ONCOGENE, V18, P2916, DOI 10.1038/sj.onc.1202748; FOLEY J, 1991, CANCER RES, V51, P6338; FONG CT, 1989, P NATL ACAD SCI USA, V86, P3753, DOI 10.1073/pnas.86.10.3753; Han J, 1996, GENOMICS, V36, P189, DOI 10.1006/geno.1996.0444; Henegariu O, 1997, BIOTECHNIQUES, V23, P504, DOI 10.2144/97233rr01; IKEGAKI N, 1986, P NATL ACAD SCI USA, V83, P5929, DOI 10.1073/pnas.83.16.5929; ISCN, 1995, INT SYST HUM CYT NOM; Izbicki T, 2003, ANTICANCER RES, V23, P755; KING PH, 1994, J NEUROSCI, V14, P1943; Koushika SP, 1996, CURR BIOL, V6, P1634, DOI 10.1016/S0960-9822(02)70787-2; Lazarova DL, 1999, ONCOGENE, V18, P2703, DOI 10.1038/sj.onc.1202621; LOOK AT, 1991, J CLIN ONCOL, V9, P581, DOI 10.1200/JCO.1991.9.4.581; Lutz W, 1996, ONCOGENE, V13, P803; Manohar CF, 2002, J BIOL CHEM, V277, P1967, DOI 10.1074/jbc.M106966200; Maris JM, 1999, J CLIN ONCOL, V17, P2264, DOI 10.1200/JCO.1999.17.7.2264; MARIS JM, 1995, CANCER RES, V55, P4664; MEYERS MB, 1985, J CELL BIOL, V100, P588, DOI 10.1083/jcb.100.2.588; Mora J, 2001, ONCOLOGIST, V6, P263, DOI 10.1634/theoncologist.6-3-263; MUGRAUER G, 1988, J CELL BIOL, V107, P1325, DOI 10.1083/jcb.107.4.1325; MURESU R, 1994, CYTOGENET CELL GENET, V65, P177, DOI 10.1159/000133626; Reynolds C P, 1988, Prog Clin Biol Res, V271, P291; REYNOLDS CP, 1986, J NATL CANCER I, V76, P375; ROSS RA, 1983, J NATL CANCER I, V71, P741; SCHLEIERMACHER G, 1994, GENE CHROMOSOME CANC, V10, P275, DOI 10.1002/gcc.2870100409; Sivak LE, 1999, MOL CELL BIOL, V19, P155; Spengler BA, 1997, ONCOL RES, V9, P467; SZABO A, 1991, CELL, V67, P325, DOI 10.1016/0092-8674(91)90184-Z; TAKEDA O, 1994, GENE CHROMOSOME CANC, V10, P30, DOI 10.1002/gcc.2870100106; Valent A, 2001, AM J PATHOL, V158, P1579, DOI 10.1016/S0002-9440(10)64112-0; WADA RK, 1993, CANCER, V72, P3346, DOI 10.1002/1097-0142(19931201)72:11<3346::AID-CNCR2820721134>3.0.CO;2-E; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985	47	16	17	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	5					706	712		10.1038/sj.onc.1209095	http://dx.doi.org/10.1038/sj.onc.1209095			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	008VM	16278682				2022-12-17	WOS:000235068800006
J	Piu, F; Gauthier, NK; Wang, F				Piu, F; Gauthier, NK; Wang, F			beta-arrestin 2 modulates the activity of nuclear receptor RAR beta 2 through activation of ERK2 kinase	ONCOGENE			English	Article						nuclear receptor; arrestin; MAP kinase; activation	LIGAND-BINDING DOMAIN; RETINOID-X-RECEPTOR; EPIDERMAL GROWTH-FACTOR; PROTEIN-KINASE; BETA-ARRESTIN; CRYSTAL-STRUCTURE; RXR-ALPHA; DOWN-REGULATION; ACID; PATHWAY	The activity of retinoid receptors activity can be regulated by various extracellular stimuli. In an effort to understand the molecular basis for this phenomenon, the role of beta-arrestins was investigated. beta-Arrestins constitute a class of proteins involved in the internalization of agonist-activated receptors. They have also been linked to MAPK activation suggesting a direct involvement in signaling cascades. Here, we report that beta-arrestin 2 stimulates the transcriptional activation of the retinoid RAR and RXR receptors. Of all the retinoid receptors, the RAR beta 2 subtype showed the strongest sensitivity to beta-arrestin 2 action. Interestingly, this event requires the presence of the MAP kinase ERK2, but not that of JNK or P38. Site-directed mutagenesis showed that Ser 22 and Leu 217 are critical residues of the RAR b2 receptor through which b-arrestin 2 effects are mediated. More importantly, we demonstrate that the induction of PC12 growth inhibition by Nerve Growth Factor is indeed dependent upon RAR b2 transcriptional activation in a beta-arrestin 2- and ERK2-dependent manner.	ACADIA Pharmaceut Inc, San Diego, CA 92121 USA		Piu, F (corresponding author), ACADIA Pharmaceut Inc, 3911 Sorrento Valley Blvd, San Diego, CA 92121 USA.	fpiu@acadia-pharm.com						Adam-Stitah S, 1999, J BIOL CHEM, V274, P18932, DOI 10.1074/jbc.274.27.18932; Ahuja HS, 2003, J BIOL REG HOMEOS AG, V17, P29; ANDREATTAVANLEYEN S, 1994, J CELL PHYSIOL, V160, P265, DOI 10.1002/jcp.1041600208; Avruch J, 2001, RECENT PROG HORM RES, V56, P127, DOI 10.1210/rp.56.1.127; Barlic J, 2000, NAT IMMUNOL, V1, P227, DOI 10.1038/79767; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bourguet W, 2000, MOL CELL, V5, P289, DOI 10.1016/S1097-2765(00)80424-4; Brauner-Osborne H, 1996, EUR J PHARMACOL, V295, P93, DOI 10.1016/0014-2999(95)00639-7; Burstein ES, 1998, ONCOGENE, V17, P1617, DOI 10.1038/sj.onc.1202067; Corcoran J, 1999, NAT NEUROSCI, V2, P307, DOI 10.1038/7214; Cosgaya JM, 2001, J NEUROCHEM, V76, P661, DOI 10.1046/j.1471-4159.2001.00078.x; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Dalle S, 2001, J BIOL CHEM, V276, P15688, DOI 10.1074/jbc.M010884200; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; DeFea KA, 2000, P NATL ACAD SCI USA, V97, P11086, DOI 10.1073/pnas.190276697; Delmotte MH, 1999, J BIOL CHEM, V274, P38225, DOI 10.1074/jbc.274.53.38225; Demary K, 2001, ENDOCRINOLOGY, V142, P2600, DOI 10.1210/en.142.6.2600; Egea PF, 2000, EMBO J, V19, P2592, DOI 10.1093/emboj/19.11.2592; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fox T, 1998, PROTEIN SCI, V7, P2249, DOI 10.1002/pro.5560071102; Harish S, 2000, BIOCHEM BIOPH RES CO, V279, P853, DOI 10.1006/bbrc.2000.4043; Holland PM, 1999, CURR BIOL, V9, pR329, DOI 10.1016/S0960-9822(99)80205-X; Ishaq M, 2000, J IMMUNOL, V165, P4217, DOI 10.4049/jimmunol.165.8.4217; Klaholz BP, 1998, NAT STRUCT BIOL, V5, P199, DOI 10.1038/nsb0398-199; Klaholz BP, 2000, J MOL BIOL, V302, P155, DOI 10.1006/jmbi.2000.4032; Kolch W, 2000, BIOCHEM J, V351, P289, DOI 10.1042/0264-6021:3510289; Koutsilieris M, 1997, ANTICANCER RES, V17, P1461; Krupnick JG, 1997, J BIOL CHEM, V272, P15011, DOI 10.1074/jbc.272.23.15011; KYRIAKIS JM, 2000, SCI STKE 2000, pE1; Lee HY, 2000, J BIOL CHEM, V275, P32193, DOI 10.1074/jbc.M005490200; Lefebvre P, 2005, VITAM HORM, V70, P199, DOI 10.1016/S0083-6729(05)70007-8; Lin FT, 1998, J BIOL CHEM, V273, P31640, DOI 10.1074/jbc.273.48.31640; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; MILLER LA, 1993, CANCER RES, V53, P2527; Miller WE, 2001, J BIOL CHEM, V276, P27770, DOI 10.1074/jbc.M102264200; Ostrowski J, 1998, J BIOL CHEM, V273, P3490, DOI 10.1074/jbc.273.6.3490; Piu F, 2002, ONCOGENE, V21, P3579, DOI 10.1038/sj.onc.1205444; Rakhit S, 2001, MOL PHARMACOL, V60, P63, DOI 10.1124/mol.60.1.63; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; ROCHETTEEGLY C, 1995, MOL ENDOCRINOL, V9, P860, DOI 10.1210/me.9.7.860; Schmidt P, 2001, MOL ENDOCRINOL, V15, P553, DOI 10.1210/me.15.4.553; Sharrocks AD, 2000, TRENDS BIOCHEM SCI, V25, P448, DOI 10.1016/S0968-0004(00)01627-3; TAHAYATO A, 1993, MOL ENDOCRINOL, V7, P1642, DOI 10.1210/me.7.12.1642; Vo HP, 1998, INT J ONCOL, V13, P1127; Wang ZQ, 1999, NAT MED, V5, P418, DOI 10.1038/7417; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87	47	16	20	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	2					218	229		10.1038/sj.onc.1209024	http://dx.doi.org/10.1038/sj.onc.1209024			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	002AK	16170358				2022-12-17	WOS:000234583600006
J	Zou, GM; Chen, JJ; Ni, J				Zou, GM; Chen, JJ; Ni, J			LIGHT induces differentiation of mouse embryonic stem cells associated with activation of ERK5	ONCOGENE			English	Article						LIGHT; ES cells; ERK5; MKP-3; differentiation	TNF SUPERFAMILY; DENDRITIC CELLS; SIGNAL; ALPHA; PROLIFERATION; PHOSPHORYLATION; PLURIPOTENCY; ANGIOGENESIS; EXPRESSION; MATURATION	LT-related inducible ligand that competes for glycoprotein D binding to herpesvirus entry mediator on T cells ( LIGHT) is a recently cloned type II transmembrane protein belonging to the TNF family that was originally identified as a weak inducer of apoptosis. This cytokine has been extensively defined in its role on T-cell regulation and dendritic cell maturation. However, whether this cytokine regulates stem cell proliferation and/or differentiation remains unknown. In this study, we transduced exogenous LIGHT into embryonic stem cells (ES cells) and found it induced their differentiation. The expression of phospho-STAT3, Nanog and Oct-4 was reduced in LIGHT-transduced ES cells compared with wild-type ES cells. LIGHT-transduced ES cells exhibit a low level of SSEA-1 surface antigen and alkaline phosphatase staining compared with wild-type cells. Introduction of LIGHT into ES cells results in the dephosphorylation of MKP-3 and activation of extracellular signal-regulated kinase (ERK)5. When ERK5 was inhibited by the specific inhibitor PD184352 or knocked down by ERK5 siRNA, reduction of Oct-4 and SSEA-1 expression was rescued. We conclude that LIGHT overrides leukemia inhibitory factor to induce ES cell differentiation associated with activation of ERK5.	Univ Iowa, Sch Med, Dept Internal Med, Iowa City, IA 52242 USA; Univ Chicago, Med Ctr, Dept Med, Chicago, IL 60637 USA; Shanghai Fuchun Zhongnan Biotech Co Ltd, Shanghai, Peoples R China	University of Iowa; University of Chicago; University of Chicago Medical Center	Zou, GM (corresponding author), Indiana Univ, Sch Med, Herman B Wells Ctr Pediat Res, 1044 W Walnut St,Rm402, Indianapolis, IN 46202 USA.	gzou@iupui.edu	Zou, Gang-Ming/F-1085-2016					Bode JG, 2003, J IMMUNOL, V171, P257, DOI 10.4049/jimmunol.171.1.257; Boeuf H, 2001, J BIOL CHEM, V276, P46204, DOI 10.1074/jbc.M106718200; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Chen Y, 2003, FASEB J, V17, P2231, DOI 10.1096/fj.03-0030com; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; Fandrich F, 2002, NAT MED, V8, P171, DOI 10.1038/nm0202-171; Harrop JA, 1998, J BIOL CHEM, V273, P27548, DOI 10.1074/jbc.273.42.27548; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; Kato Y, 1998, NATURE, V395, P713, DOI 10.1038/27234; Lynch CN, 1999, J BIOL CHEM, V274, P8455, DOI 10.1074/jbc.274.13.8455; Mauri DN, 1998, IMMUNITY, V8, P21, DOI 10.1016/S1074-7613(00)80455-0; Mody N, 2003, BIOCHEM J, V372, P567, DOI 10.1042/BJ20030193; Morel Y, 2001, J IMMUNOL, V167, P2479, DOI 10.4049/jimmunol.167.5.2479; Nakaoka Y, 2003, CIRC RES, V93, P221, DOI 10.1161/01.RES.0000085562.48906.4A; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; Pan GJ, 2002, CELL RES, V12, P321, DOI 10.1038/sj.cr.7290134; Sato M, 2001, INTERNAL MED, V40, P195, DOI 10.2169/internalmedicine.40.195; Smith AG, 2001, ANNU REV CELL DEV BI, V17, P435, DOI 10.1146/annurev.cellbio.17.1.435; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; Tamada K, 2000, NAT MED, V6, P283; Wang YC, 2004, DEV DYNAM, V231, P72, DOI 10.1002/dvdy.20114; Wiley SR, 2001, IMMUNITY, V15, P837, DOI 10.1016/S1074-7613(01)00232-1; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0; Wu DY, 2005, CELL RES, V15, P317, DOI 10.1038/sj.cr.7290300; Wuu YD, 1998, BIOL REPROD, V58, P1416, DOI 10.1095/biolreprod58.6.1416; Zou GM, 2005, J CELL PHYSIOL, V205, P437, DOI 10.1002/jcp.20420; Zou GM, 2000, AM J REPROD IMMUNOL, V43, P240, DOI 10.1111/j.8755-8920.2000.430409.x; Zou GM, 2004, CANCER IMMUNOL IMMUN, V53, P681, DOI 10.1007/s00262-004-0518-8; Zou GM, 2003, TRANSPL P, V35, P2827, DOI 10.1016/j.transproceed.2003.09.044; Zou GM, 2003, BIOL CELL, V95, P365, DOI 10.1016/S0248-4900(03)00079-0	32	16	16	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	3					463	469		10.1038/sj.onc.1208987	http://dx.doi.org/10.1038/sj.onc.1208987			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	003WY	16247486				2022-12-17	WOS:000234714100014
J	Yang, WL; Roland, IH; Godwin, AK; Xu, XX				Yang, WL; Roland, IH; Godwin, AK; Xu, XX			Loss of TNF-alpha-regulated COX-2 expression in ovarian cancer cells	ONCOGENE			English	Article						cyclooxygenases; ovarian epithelial cells; ovarian carcinomas; TNF-alpha	TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; CYCLOOXYGENASE-2 EXPRESSION; SIGNAL-TRANSDUCTION; PROSTAGLANDIN E-2; UP-REGULATION; IN-VITRO; INHIBITOR; OVULATION; APOPTOSIS	Cyclooxygenase 2 (COX-2) is often found overexpressed in cancer and is thought to have a role in carcinogenic promotion, and thus is a target for therapeutic intervention. Here, we investigated the regulation of COX-2 expression in normal and cancer ovarian surface epithelial cells. Tumor necrosis factor alpha (TNF-alpha) is a potent inducer of COX-2 expression in the ovarian surface epithelium and this regulation is a critical step in ovulation. We observed that TNF-alpha stimulated COX-2 expression in human primary and immortalized epithelial (HIO) cell lines. The stimulation was suppressed by inhibitors of several signaling pathways, indicating the collaboration of TNF-alpha-activated signaling pathways mediates the regulation of COX-2 expression. In five ovarian cancer cell lines analysed, four did not express detectable COX-2 and TNF-alpha failed to elicit COX-2 expression. In NIH:OVCAR-5, the only ovarian cancer cell line expressing COX-2, signal pathway inhibitors no longer affected TNF-alpha-induced COX-2 expression. Thus, we conclude that TNF-a mediated signaling is uncoupled from the modulation of COX-2 expression in ovarian cancer. The loss of COX-2 expression was also observed to associate closely with epithelial neoplastic morphological transformation. The frequent loss of COX-2 expression suggests in ovarian cancer, unlike in other epithelial cancers, COX-2 expression does not contribute to ovarian cancer malignancy.	Fox Chase Canc Ctr, Ovarian Canc Program, Philadelphia, PA 19111 USA; Fox Chase Canc Ctr, Tumor Cell Biol Program, Philadelphia, PA 19111 USA	Fox Chase Cancer Center; Fox Chase Cancer Center	Xu, XX (corresponding author), Fox Chase Canc Ctr, Ovarian Canc Program, 333 Cottman Ave, Philadelphia, PA 19111 USA.	x_xu@fccc.edu			NCI NIH HHS [R01 CA75389, P50 CA83638, R01 CA79716] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA083638, R01CA079716, R01CA075389] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKHMEDKHANOV AA, 2001, SOC GYNECOL ONCOL, V80, P286; Arnott CH, 2004, ONCOGENE, V23, P1902, DOI 10.1038/sj.onc.1207317; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barnes MN, 2002, CA-CANCER J CLIN, V52, P216, DOI 10.3322/canjclin.52.4.216; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRANNSTROM M, 1995, REPROD FERT DEVELOP, V7, P67, DOI 10.1071/RD9950067; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Chun KS, 2004, BIOCHEM PHARMACOL, V68, P1089, DOI 10.1016/j.bcp.2004.05.031; Cramer DW, 1998, LANCET, V351, P104, DOI 10.1016/S0140-6736(97)08064-1; Davis BJ, 1999, ENDOCRINOLOGY, V140, P2685, DOI 10.1210/en.140.6.2685; Denkert C, 2002, AM J PATHOL, V160, P893, DOI 10.1016/S0002-9440(10)64912-7; Dore M, 1998, J HISTOCHEM CYTOCHEM, V46, P77, DOI 10.1177/002215549804600110; DOWNS SM, 1982, AM J ANAT, V164, P265, DOI 10.1002/aja.1001640307; Duffy DM, 2001, MOL HUM REPROD, V7, P731, DOI 10.1093/molehr/7.8.731; ESPEY LL, 1994, BIOL REPROD, V50, P233, DOI 10.1095/biolreprod50.2.233; Ferrandina G, 2002, GYNECOL ONCOL, V85, P305, DOI 10.1006/gyno.2002.6620; Fong CY, 2000, AM J PHYSIOL-LUNG C, V279, pL201, DOI 10.1152/ajplung.2000.279.1.L201; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; Gupta RA, 2003, CANCER RES, V63, P906; HAMILTON TC, 1984, CANCER RES, V44, P5286; Howe LR, 2002, SEMIN ONCOL, V29, P111, DOI 10.1053/sonc.2002.34063; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Klimp AH, 2001, CANCER RES, V61, P7305; KOMORI A, 1993, CANCER RES, V53, P1982; Lal G, 2001, CANCER RES, V61, P6131; Leahy KM, 2002, CANCER RES, V62, P625; Lim H, 1997, CELL, V91, P197, DOI 10.1016/S0092-8674(00)80402-X; Liu CH, 2001, J BIOL CHEM, V276, P18563, DOI 10.1074/jbc.M010787200; MALIK STA, 1990, EUR J CANCER, V26, P1031, DOI 10.1016/0277-5379(90)90044-T; MALIK STA, 1989, INT J CANCER, V44, P918, DOI 10.1002/ijc.2910440529; Masferrer J, 2001, CANCER J, V7, pS144; Masferrer JL, 2000, CANCER RES, V60, P1306; Matsumoto Y, 2001, INT J MOL MED, V8, P31; Moore BC, 2000, CURR MED CHEM, V7, P1131, DOI 10.2174/0929867003374273; Moore RJ, 1999, NAT MED, V5, P828, DOI 10.1038/10552; Munkarah AR, 2002, J SOC GYNECOL INVEST, V9, P168, DOI 10.1016/S1071-5576(02)00141-7; Murdoch WJ, 1997, J ANIM SCI, V75, P1601; Nabors LLB, 2003, CANCER RES, V63, P4181; Nasi ML, 2002, ANN ONCOL, V13, P1169, DOI 10.1093/annonc/mdf312; Ness RB, 1999, JNCI-J NATL CANCER I, V91, P1459, DOI 10.1093/jnci/91.17.1459; Ness RB, 2000, JNCI-J NATL CANCER I, V92, P163, DOI 10.1093/jnci/92.2.163; Norman RJ, 2001, LANCET, V358, P1287, DOI 10.1016/S0140-6736(01)06455-8; Okamura H, 1985, Adv Prostaglandin Thromboxane Leukot Res, V15, P597; OLD LJ, 1985, SCIENCE, V230, P630, DOI 10.1126/science.2413547; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Pall M, 2001, HUM REPROD, V16, P1323, DOI 10.1093/humrep/16.7.1323; PRESCOTT SM, 2000, BIOCHIM BIOPHYS ACTA, V1470, P69, DOI [10.1016/s0304-419x(00)00006-8), DOI 10.1016/S0304-419X(00)00006-8]; Richards JS, 2002, ANNU REV PHYSIOL, V64, P69, DOI 10.1146/annurev.physiol.64.081501.131029; Rodriguez-Burford C, 2002, CLIN CANCER RES, V8, P202; Roland IH, 2003, CANCER-AM CANCER SOC, V98, P2607, DOI 10.1002/cncr.11847; SCHILDER RJ, 1990, INT J CANCER, V45, P416, DOI 10.1002/ijc.2910450306; Shigemasa K, 2003, INT J ONCOL, V22, P99; SIEMENS CH, 1988, J CELL PHYSIOL, V134, P347, DOI 10.1002/jcp.1041340305; Singer CA, 2003, AM J PHYSIOL-LUNG C, V285, pL1087, DOI 10.1152/ajplung.00409.2002; Smith ER, 2004, CANCER EPIDEM BIOMAR, V13, P144, DOI 10.1158/1055-9965.EPI-461-2; Sorensen HT, 2003, BRIT J CANCER, V88, P1687, DOI 10.1038/sj.bjc.6600945; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; Subbaramaiah K, 2003, TRENDS PHARMACOL SCI, V24, P96, DOI 10.1016/S0165-6147(02)00043-3; Suganuma M, 1999, CANCER RES, V59, P4516; Terranova PF, 1997, AM J REPROD IMMUNOL, V37, P50; Tiano HF, 2002, CANCER RES, V62, P3395; Tokuyama O, 2001, INT J MOL MED, V8, P603; Trifan OC, 2003, J CELL MOL MED, V7, P207, DOI 10.1111/j.1582-4934.2003.tb00222.x; Tsafriri A, 1999, EXP CLIN ENDOCR DIAB, V107, P1, DOI 10.1055/s-0029-1212066; Wang HB, 2004, J BIOL CHEM, V279, P10649, DOI 10.1074/jbc.M312203200; Wang SL, 2003, ONCOGENE, V22, P8628, DOI 10.1038/sj.onc.1207232; Williams CS, 2000, CANCER RES, V60, P6045; Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286; Yang DH, 2002, CANCER-AM CANCER SOC, V94, P2380, DOI 10.1002/cncr.10497; Yang WL, 2004, CANCER RES, V64, P1534, DOI 10.1158/0008-5472.CAN-03-2928	72	16	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 1	2005	24	54					7991	8002		10.1038/sj.onc.1208943	http://dx.doi.org/10.1038/sj.onc.1208943			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	989EV	16044148				2022-12-17	WOS:000233656600006
J	Caterina, C; Marcella, M; Giordano, A				Caterina, C; Marcella, M; Giordano, A			Tumor-specific exon 1 mutations could be the 'hit event' predisposing Rb2/p130 gene to epigenetic silencing in lung cancer	ONCOGENE			English	Article						methylation; Rb2/p130 silencing; tumor markers; lung tumors; Rb2/p130 mutations	DNA METHYLATION; PROTEIN; FAMILY; TRANSCRIPTION; PROGRESSION; EXPRESSION; COMPLEXES; MEMBER; CELLS; P130	Genetic alterations in Rb2/p130 gene have been reported in several tumors, but till now there are insufficient and conflicting data linking the loss of pRb2/p130 expression with the mutational status of this gene in lung cancer. We recently reported that loss or lowering of pRb2/p130 expression is mainly due to aberrant Rb2/p130 promoter methylation, in retinoblastoma tumors, and indicated that epigenetic silencing of Rb2/p130 can impair its function to negatively regulate cell cycle progression as well as apoptotic response. In order to clarify Rb2/p130 gene inactivation in lung cancer, we investigated whether epigenetic events could impair the expression of this gene in NSLC. Here, we show that specific Rb2-exon 1 homozygous mutations, occurring in an Rb2/p130, region, rich in CpG dinucleotides, could be the 'hit event' that predispose this gene to epigenetic changes, leading to Rb2/p130 gene silencing in lung cancer. Moreover, these homozygous mutations, found in different tumor histotypes, could represent tumor-specific markers.	Temple Univ, Sbarro Inst Canc Res & Mol Med, Ctr Biotechnol, Coll Sci & Technol, Philadelphia, PA 19122 USA; Univ Siena, CNR, Inst Clin Physiol, I-53100 Siena, Italy; Univ Siena, Dept Human Pathol & Oncol, I-53100 Siena, Italy	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Consiglio Nazionale delle Ricerche (CNR); Istituto di Fisiologia Clinica (IFC-CNR); University of Siena; University of Siena	Giordano, A (corresponding author), Temple Univ, Sbarro Inst Canc Res & Mol Med, Ctr Biotechnol, Coll Sci & Technol, Biolife Sci Bldg,1900 N 12th St,Suite 333, Philadelphia, PA 19122 USA.	giordano@temple.edu	Giordano, Antonio/F-1927-2010	Giordano, Antonio/0000-0002-5959-016X; Cinti, Caterina/0000-0001-8049-0369	NATIONAL CANCER INSTITUTE [R01CA066999] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA066999-09A2] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baldi A, 1997, CLIN CANCER RES, V3, P1691; Belinsky SA, 2004, NAT REV CANCER, V4, P707, DOI 10.1038/nrc1432; Cinti C, 2000, CANCER RES, V60, P383; Claudio PP, 2000, CANCER RES, V60, P372; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; Helin K, 1997, P NATL ACAD SCI USA, V94, P6933, DOI 10.1073/pnas.94.13.6933; Jun HX, 2003, MOL CARCINOGEN, V38, P124, DOI 10.1002/mc.10152; KALEBIC T, 2003, ANN ACAD SCI, V293, P278; La Sala D, 2003, ONCOGENE, V22, P3518, DOI 10.1038/sj.onc.1206487; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; Macaluso M, 2005, ANN ONCOL, V16, P20, DOI 10.1093/annonc/mdi903; Macaluso M, 2004, TUMORI J, V90, P367, DOI 10.1177/030089160409000401; Macaluso M, 2003, ONCOGENE, V22, P6472, DOI 10.1038/sj.onc.1206955; Macaluso M, 2003, ONCOGENE, V22, P3511, DOI 10.1038/sj.onc.1206578; MACALUSO M, 2005, IN PRESS SEMIN ONCOL; MAYOL X, 1993, ONCOGENE, V8, P2561; Modi S, 2000, ONCOGENE, V19, P4632, DOI 10.1038/sj.onc.1203815; Nephew KP, 2003, CANCER LETT, V190, P125, DOI 10.1016/S0304-3835(02)00511-6; Russo G, 2003, ONCOGENE, V22, P6959, DOI 10.1038/sj.onc.1206866; Scarano MI, 2005, J CELL PHYSIOL, V204, P21, DOI 10.1002/jcp.20280; Suzuki M, 2005, LUNG CANCER, V47, P309, DOI 10.1016/j.lungcan.2004.08.006; TOSI GM, 2005, IN PRESS ONCOGENE; Yokota J, 2004, CANCER SCI, V95, P197, DOI 10.1111/j.1349-7006.2004.tb02203.x; Zochbauer-Muller S, 2002, ONCOLOGIST, V7, P451, DOI 10.1634/theoncologist.7-5-451	24	16	16	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	38					5821	5826		10.1038/sj.onc.1208880	http://dx.doi.org/10.1038/sj.onc.1208880			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960KW	16044156				2022-12-17	WOS:000231590400004
J	Burr, KLA; Smith, AG; Dubrova, YE				Burr, KLA; Smith, AG; Dubrova, YE			p53 deficiency does not affect mutation rate in the mouse germline	ONCOGENE			English	Article						p53; mutagenesis; mouse; germlines	HOMOLOGOUS RECOMBINATION; DNA-REPAIR; MICE; RADIATION; INSTABILITY; CELLS; HETEROZYGOSITY; FREQUENCY	Although the influence of p53 deficiency on somatic genetic stability is well established, its effect in the germline is poorly understood. Mutation rates at two expanded simple tandem repeat ( ESTR) loci were studied in the germline of nonexposed and irradiated p53-deficient mice. Spontaneous mutation rates in the homozygous and heterozygous p53-deficient males did not significantly differ from that in the isogenic wild-type mice. Acute exposure to 1 Gy of X rays resulted in a similar increase in mutation rates across males with different p53 genotypes. ESTR mutation spectra did not significantly differ across males with different p53 genotypes. Taken together, these results suggest that p53-deficiency does not affect spontaneous and radiation-induced mutation in the mouse germline.	Univ Leicester, Dept Genet, Leicester LE1 7RH, Leics, England; Univ Leicester, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England	University of Leicester; University of Leicester	Dubrova, YE (corresponding author), Univ Leicester, Dept Genet, Adrian Bldg,Univ Rd, Leicester LE1 7RH, Leics, England.	yed2@le.ac.uk	Dubrova, Yuri/ABA-7148-2020	Dubrova, Yuri/0000-0001-5281-7539	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Barber RC, 2004, MUTAT RES-FUND MOL M, V554, P287, DOI 10.1016/j.mrfmmm.2004.05.003; Beumer TL, 1998, CELL DEATH DIFFER, V5, P669, DOI 10.1038/sj.cdd.4400396; Bishop AJR, 2003, CANCER RES, V63, P5335; BOUE A, 1985, ADV HUM GENET, V14, P1; Chang PY, 2001, MUTAGENESIS, V16, P7, DOI 10.1093/mutage/16.1.7; Chuang YYE, 1999, CANCER RES, V59, P3073; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Dubrova YE, 1998, P NATL ACAD SCI USA, V95, P6251, DOI 10.1073/pnas.95.11.6251; Liang L, 2002, MUTAT RES-FUND MOL M, V502, P69, DOI 10.1016/S0027-5107(02)00029-5; Lu XB, 2003, MUTAT RES-FUND MOL M, V522, P69, DOI 10.1016/S0027-5107(02)00261-0; Morris SM, 2002, MUTAT RES-REV MUTAT, V511, P45, DOI 10.1016/S1383-5742(01)00075-8; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; SANDS AT, 1995, P NATL ACAD SCI USA, V92, P8517, DOI 10.1073/pnas.92.18.8517; SEARLE AG, 1974, ADV RADIAT BIOL, V4, P131; Shao CS, 2000, P NATL ACAD SCI USA, V97, P7405, DOI 10.1073/pnas.97.13.7405; SOUTHERN EM, 1979, ANAL BIOCHEM, V100, P319, DOI 10.1016/0003-2697(79)90235-5; van Buul PPW, 2002, MUTAT RES-FUND MOL M, V508, P29, DOI 10.1016/S0027-5107(02)00137-9; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Yatagai F, 2004, MUTAT RES-GEN TOX EN, V560, P133, DOI 10.1016/j.mrgentox.2004.02.012; Zhivotovsky B, 2004, NAT REV MOL CELL BIO, V5, P752, DOI 10.1038/nrm1443	20	16	16	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 16	2005	24	26					4315	4318		10.1038/sj.onc.1208604	http://dx.doi.org/10.1038/sj.onc.1208604			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	935WY	15806156				2022-12-17	WOS:000229815300015
J	Lo, SS; Lo, SH; Hao, S				Lo, SS; Lo, SH; Hao, S			Cleavage of cten by caspase-3 during apoptosis	ONCOGENE			English	Article						cten; tensin; focal adhesion; apoptosis caspase	PROSTATE-CANCER; SIGNALING PATHWAY; ACTIVATION; BINDING; MATRIX; CELLS	Normal endothelial and epithelial cells undergo apoptosis when cell adhesion and spreading are disrupted, implying a critical role of focal adhesions in cell survival. Cten is a focal adhesion molecule of the tensin family. In contrast to other tensins, cten expression is limited to very few tissues, such as the prostate, and only in epithelial cells. Here, we have explored the potential roles of cten in apoptosis. We found cten was cleaved during apoptosis induced by staurosporine in normal prostate epithelial cells. By using recombinant caspases and site-directed mutagenesis, we have identified caspase-3 as the major protease to digest cten at the DSTD570 down arrow S site. The biological relevance of cten-cleaved fragments was demonstrated by cells ectopically expressing these fragments. Cten fragment ( residues 571 - 715) containing the phosphotyrosine- binding domain significantly reduced the growth rate. Detection of cleaved poly( ADP-ribose) polymerase and annexin binding in cells expressing cten ( 571 - 715) indicated that a fraction of cells underwent apoptosis. These results demonstrate that cten is a target of caspase-3 and the resultant fragments could further promote apoptosis.	Univ Calif Davis, Dept Orthopaed Surg, 4635 2nd Ave,Room 2000, Sacramento, CA 95817 USA; Natl Yang Ming Univ, Taipei Vet Gen Hosp, Div Gen Surg, Taipei 112, Taiwan; Tao Yuan Gen Hosp, Div Endocrinol & Metab, Tao Yuan, Taiwan; Univ Calif Davis, Ctr Canc, Ctr Tissue Regenerat & Repair, Sacramento, CA 95817 USA	University of California System; University of California Davis; National Yang Ming Chiao Tung University; Taipei Veterans General Hospital; University of California System; University of California Davis	Hao, S (corresponding author), Univ Calif Davis, Dept Orthopaed Surg, 4635 2nd Ave,Room 2000, Sacramento, CA 95817 USA.	shlo@ucdavis.edu		Lo, Su Hao/0000-0002-2675-9387	NCI NIH HHS [CA102537] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R56CA102537, R01CA102537] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; Bowen C, 1999, CELL DEATH DIFFER, V6, P394, DOI 10.1038/sj.cdd.4400502; Calderwood DA, 2003, P NATL ACAD SCI USA, V100, P2272, DOI 10.1073/pnas.262791999; Chen HY, 2003, BIOCHEM J, V370, P1039, DOI 10.1042/BJ20021308; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Guo YP, 1999, CANCER RES, V59, P1366; Henkels KM, 1999, CANCER RES, V59, P3077; Kyprianou N, 1996, HUM PATHOL, V27, P668, DOI 10.1016/S0046-8177(96)90396-2; Lo SH, 2004, INT J BIOCHEM CELL B, V36, P31, DOI 10.1016/S1357-2725(03)00171-7; Lo SH, 2002, CANCER RES, V62, P4217; Marcelli M, 1999, CANCER RES, V59, P382; Marcelli M, 1998, CANCER RES, V58, P76; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Motwani M, 1999, CLIN CANCER RES, V5, P1876; RE F, 1994, J CELL BIOL, V127, P537, DOI 10.1083/jcb.127.2.537; Simbulan-Rosenthal CM, 1999, CANCER RES, V59, P2190	17	16	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 16	2005	24	26					4311	4314		10.1038/sj.onc.1208571	http://dx.doi.org/10.1038/sj.onc.1208571			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	935WY	15806167				2022-12-17	WOS:000229815300014
J	Wang, JY; Ho, T; Trojanek, J; Chintapalli, J; Grabacka, M; Stoklosa, T; Garcia, FU; Skorski, T; Reiss, K				Wang, JY; Ho, T; Trojanek, J; Chintapalli, J; Grabacka, M; Stoklosa, T; Garcia, FU; Skorski, T; Reiss, K			Impaired homologous recombination DNA repair and enhanced sensitivity to DNA damage in prostate cancer cells exposed to anchorage-independence	ONCOGENE			English	Article						prostate cancer; anchorage-independence; Rad51; homologous recombination; DNA repair	HUMAN RAD51 PROTEIN; FACTOR-I RECEPTOR; STRAND BREAK REPAIR; MAMMALIAN-CELLS; BIOCHEMICAL-CHARACTERIZATION; GENOMIC INSTABILITY; MISMATCH REPAIR; DOWN-REGULATION; TUMOR-GROWTH; APOPTOSIS	During metastases, cancer cells are temporarily exposed to the condition in which interactions with extracellular environment can be restricted (anchorage-independence). We demonstrate that the sensitivity of prostate cancer cell lines, DU145 and PC-3, to genotoxic treatment ( cisplatin and gamma-irradiation) increased several folds when cells were forced to grow in anchorage-independence. This enhanced drug sensitivity was associated with a severe impairment of homologous recombination-directed DNA repair (HRR). The mechanism involves Rad51, which is the major enzymatic component of HRR. The protein level of Rad51 and its recruitment to DNA double-strand breaks (DSBs) were both attenuated. Rad51 deficiency in anchorage-independence was not associated with Rad51 promoter activity, and was not compensated by a constitutive overexpression of Rad51 cDNA. Instead, Rad51 protein level and its ability to colocalize with DSBs were restored in the presence of proteosome inhibitors, or when cells from the suspension cultures were allowed reattachment. Presented results indicate that anchorage-independence sensitizes prostate cancer cells to genotoxic agents; however, it also attenuates faithful component of DNA repair by targeting stability of Rad51. This temporal attenuation of HRR may contribute to the accumulation mutations after DNA damage, and possibly the selection of new adaptations in cells, which survived genotoxic treatment.	Temple Univ, Ctr Neurovirol & Canc Biol, Coll Sci & Technol, Philadelphia, PA 19122 USA; Temple Univ, Ctr Biotechnol, Coll Sci & Technol, Philadelphia, PA 19122 USA; Drexel Univ, Coll Med, Dept Pathol & Lab Med, Philadelphia, PA 19146 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Drexel University	Reiss, K (corresponding author), Temple Univ, Ctr Neurovirol & Canc Biol, Coll Sci & Technol, Biol Life Sci Bldg,Room 230,1900 N 12th St, Philadelphia, PA 19122 USA.	kreiss@temple.edu	Grabacka, Maja/ABE-5286-2021; Stoklosa, Tomasz A/I-8825-2017	Grabacka, Maja/0000-0003-4407-8814; Trojanek, Joanna/0000-0002-3200-735X; Stoklosa, Tomasz/0000-0001-6918-5056				Baumann P, 1998, TRENDS BIOCHEM SCI, V23, P247, DOI 10.1016/S0968-0004(98)01232-8; Bindra RS, 2004, MOL CELL BIOL, V24, P8504, DOI 10.1128/MCB.24.19.8504-8518.2004; Bondar VM, 2002, PROSTATE, V51, P42, DOI 10.1002/pros.10070; Chen G, 1999, J BIOL CHEM, V274, P12748, DOI 10.1074/jbc.274.18.12748; Chen Y, 2003, INT J ONCOL, V22, P1033; Chen Y, 2001, CANCER RES, V61, P4112; Chendil D, 2004, ONCOGENE, V23, P1599, DOI 10.1038/sj.onc.1207284; Collis SJ, 2001, NUCLEIC ACIDS RES, V29, P1534, DOI 10.1093/nar/29.7.1534; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; Del Valle L, 2002, CLIN CANCER RES, V8, P1822; Essers J, 2002, EMBO J, V21, P2030, DOI 10.1093/emboj/21.8.2030; Flygare J, 2001, EXP CELL RES, V268, P61, DOI 10.1006/excr.2001.5265; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Huang YY, 1999, MOL CELL BIOL, V19, P2986; Karan D, 2003, INT J CANCER, V103, P285, DOI 10.1002/ijc.10813; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kovalenko OV, 1996, P NATL ACAD SCI USA, V93, P2958, DOI 10.1073/pnas.93.7.2958; Labhart P, 1999, EUR J BIOCHEM, V265, P849, DOI 10.1046/j.1432-1327.1999.00805.x; Lim DS, 1996, MOL CELL BIOL, V16, P7133; Ludwig T, 1996, DEV BIOL, V177, P517, DOI 10.1006/dbio.1996.0182; Lundin C, 2002, MOL CELL BIOL, V22, P5869, DOI 10.1128/MCB.22.16.5869-5878.2002; Mills KD, 2003, IMMUNOL REV, V194, P77, DOI 10.1034/j.1600-065X.2003.00060.x; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Petrini JHJ, 2000, CURR OPIN CELL BIOL, V12, P293, DOI 10.1016/S0955-0674(00)00091-0; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Pierce AJ, 2001, MOL CELL, V8, P1160, DOI 10.1016/S1097-2765(01)00424-5; Raderschall E, 2002, CANCER RES, V62, P219; Reiss K, 1999, J CELL PHYSIOL, V181, P124, DOI 10.1002/(SICI)1097-4652(199910)181:1<124::AID-JCP13>3.0.CO;2-0; Reiss K, 2000, ONCOGENE, V19, P2687, DOI 10.1038/sj.onc.1203587; Reiss K, 1998, CLIN CANCER RES, V4, P2647; Reiss K, 1998, EXP CELL RES, V242, P361, DOI 10.1006/excr.1998.4113; Richardson C, 2004, ONCOGENE, V23, P546, DOI 10.1038/sj.onc.1207098; Richardson C, 2000, MOL CELL BIOL, V20, P9068, DOI 10.1128/MCB.20.23.9068-9075.2000; Rodgers KJ, 2003, INT J BIOCHEM CELL B, V35, P716, DOI 10.1016/S1357-2725(02)00391-6; Schindewolf C, 2000, MAMM GENOME, V11, P552, DOI 10.1007/s003350010106; Schmutte C, 1999, CANCER RES, V59, P4564; Sieber OM, 2003, NAT REV CANCER, V3, P701, DOI 10.1038/nrc1170; Sigurdsson S, 2002, J BIOL CHEM, V277, P42790, DOI 10.1074/jbc.M208004200; SKORSKI T, 1995, J EXP MED, V182, P1645, DOI 10.1084/jem.182.6.1645; Slupianek A, 2001, MOL CELL, V8, P795, DOI 10.1016/S1097-2765(01)00357-4; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Tombline G, 2002, J BIOL CHEM, V277, P14426, DOI 10.1074/jbc.M109916200; Tombline G, 2002, J BIOL CHEM, V277, P14417, DOI 10.1074/jbc.M109915200; Trojanek J, 2003, MOL CELL BIOL, V23, P7510, DOI 10.1128/MCB.23.21.7510-7524.2003; Valentinis B, 1998, J CELL PHYSIOL, V176, P648, DOI 10.1002/(SICI)1097-4652(199809)176:3<648::AID-JCP22>3.3.CO;2-6; Valerie K, 2003, ONCOGENE, V22, P5792, DOI 10.1038/sj.onc.1206679; Van Komen S, 2002, J BIOL CHEM, V277, P43578, DOI 10.1074/jbc.M205864200; Wang JY, 2001, ONCOGENE, V20, P3857, DOI 10.1038/sj.onc.1204532; Wozniak K, 2002, ACTA BIOCHIM POL, V49, P583; Xia SJJ, 1997, MOL CELL BIOL, V17, P7151, DOI 10.1128/MCB.17.12.7151; Yeh CC, 2001, BIOCHEM BIOPH RES CO, V285, P409, DOI 10.1006/bbrc.2001.5187; Zhu XD, 2000, NAT GENET, V25, P347, DOI 10.1038/77139	52	16	16	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 26	2005	24	23					3748	3758		10.1038/sj.onc.1208537	http://dx.doi.org/10.1038/sj.onc.1208537			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	929KZ	15782124				2022-12-17	WOS:000229346300006
J	Chun, KH; Pfahl, M; Lotan, R				Chun, KH; Pfahl, M; Lotan, R			Induction of apoptosis by the synthetic retinoid MX3350-1 through extrinsic and intrinsic pathways in head and neck squamous carcinoma cells	ONCOGENE			English	Article						retinoid; apoptosis; mitochondrial pathway; death receptor-related pathway; HNSCC	BCL-2 FAMILY PROTEINS; RECEPTOR-INDEPENDENT INDUCTION; STRESS-INDUCED APOPTOSIS; CYTOCHROME-C RELEASE; LUNG-CANCER CELLS; MEDIATED APOPTOSIS; SIGNAL-TRANSDUCTION; CHEMOPREVENTIVE AGENTS; SELECTIVE RETINOIDS; CARBOXYLIC-ACID	Retinoids have shown promise in cancer prevention and therapy. As some retinoids exhibit undesirable side effects, new retinoid analogs have been synthesized. In this study, we examined the effects of the retinoid MX3350-1 on human head and neck squamous cell carcinoma (HNSCC) cell lines. MX3350-1 suppressed the growth of 7/8 HNSCC cell lines by >65%. This inhibition appeared to be due to induction of apoptosis as revealed by the terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling assay. Studies with cell line UMSCC17B indicated that apoptosis was induced within 1-2 days and involved activation of caspase-8, -9, and -3. Inhibitors of these caspases suppressed MX3350-1-induced apoptosis. MX3350-1 decreased the levels of antiapoptotic Bcl-2 and Bcl-XL, increased proapoptotic Bax, induced mitochondrial membrane permeabilization (MMP), and cytochrome c release from mitochondria to cytosol. The antioxidant butylated hydroxyanisol and the MMP inhibitor cyclosporin A (Cs A) blocked apoptosis induced by MX3350-1. In contrast, retinoid receptor antagonists failed to inhibit apoptosis. MX3350-1 increased the levels of Fas-ligand, Fas, and Fas-associated death domain, and enhanced activation of procaspase-8 and cleavage of its substrate Bid. Soluble Fas rescued the cells from MX3350-1-induced apoptosis. These results demonstrate that MX3350-1 induces apoptosis by activating both extrinsic and intrinsic apoptosis pathways and suggest that further studies on the potential of this retinoid for prevention and therapy of HNSCCs are warranted.	Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Unit 432, Houston, TX 77030 USA; Maxocore Pharmaceut Inc, San Diego, CA USA	University of Texas System; UTMD Anderson Cancer Center	Lotan, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Unit 432, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rlotan@mdanderson.org			NCI NIH HHS [P30 CA16672-30, P50 CA907007] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bang S, 2000, J BIOL CHEM, V275, P36217, DOI 10.1074/jbc.M006620200; Bayon Y, 2003, MOL CELL BIOL, V23, P1061, DOI 10.1128/MCB.23.3.1061-1074.2003; Cao XF, 2003, BLOOD, V102, P2605, DOI 10.1182/blood-2003-01-0211; CHAKRAVARTI N, 2003, INT J CANCER, V91, P27; Chun KH, 2003, CANCER RES, V63, P4796; Chun KH, 2003, CANCER RES, V63, P3826; D'Ambrosio SM, 2000, ANTICANCER RES, V20, P2273; Daniel PT, 2003, ESSAYS BIOCHEM, V39, P73, DOI 10.1042/bse0390073; DiSepio D, 1999, Mol Cell Biol Res Commun, V1, P7, DOI 10.1006/mcbr.1999.0101; Dragovich T, 1998, ONCOGENE, V17, P3207, DOI 10.1038/sj.onc.1202587; Garattini E, 2004, CURR PHARM DESIGN, V10, P433, DOI 10.2174/1381612043453351; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Guruswamy S, 2001, JNCI-J NATL CANCER I, V93, P516, DOI 10.1093/jnci/93.7.516; HSU CK, 1997, EXP CELL RES, V232, P7; Krilleke D, 2003, INT J CANCER, V107, P520, DOI 10.1002/ijc.11331; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Lee JJ, 2000, CLIN CANCER RES, V6, P1702; Lippman SC, 2000, J NUTR, V130, p479S, DOI 10.1093/jn/130.2.479S; Lotan R, 2003, J BIOL REG HOMEOS AG, V17, P13; LOTAN R, 1995, CANCER RES, V55, P232; Lotan R, 1996, ANTICANCER RES, V16, P2415; Lu XP, 1997, NAT MED, V3, P686, DOI 10.1038/nm0697-686; Marchetti P, 1999, CANCER RES, V59, P6257; Mologni L, 1999, BLOOD, V93, P1045, DOI 10.1182/blood.V93.3.1045.403k22_1045_1061; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NAGY L, 1995, MOL CELL BIOL, V15, P3540; Ortiz MA, 2001, CANCER RES, V61, P8504; Pfahl M, 2003, ONCOGENE, V22, P9058, DOI 10.1038/sj.onc.1207109; Schmitz I, 2000, INT J BIOCHEM CELL B, V32, P1123, DOI 10.1016/S1357-2725(00)00048-0; Shi Y, 2003, BIOCHEM BIOPH RES CO, V305, P989, DOI 10.1016/S0006-291X(03)00871-4; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Strasser A, 1999, INT J BIOCHEM CELL B, V31, P533, DOI 10.1016/S1357-2725(99)00003-5; Sun SY, 2000, CANCER RES, V60, P6537; Sun SY, 1999, ONCOGENE, V18, P2357, DOI 10.1038/sj.onc.1202543; Sun SY, 2000, MOL PHARMACOL, V58, P508, DOI 10.1124/mol.58.3.508; Sun SY, 2000, CLIN CANCER RES, V6, P1563; Tang DM, 2000, J BIOL CHEM, V275, P9303, DOI 10.1074/jbc.275.13.9303; Ulukaya E, 1999, CANCER TREAT REV, V25, P229, DOI 10.1053/ctrv.1999.0127; Yanase N, 2000, J INTERF CYTOK RES, V20, P1121, DOI 10.1089/107999000750053799; Yin XM, 2000, CELL RES, V10, P161, DOI 10.1038/sj.cr.7290045	40	16	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2005	24	22					3669	3677		10.1038/sj.onc.1208339	http://dx.doi.org/10.1038/sj.onc.1208339			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	927SW	15782141				2022-12-17	WOS:000229221800014
J	Lemaire, C; Godefroy, N; Costina-Parvu, I; Rincheval, V; Renaud, F; Trotot, P; Bouleau, S; Mignotte, B; Vayssiere, JL				Lemaire, C; Godefroy, N; Costina-Parvu, I; Rincheval, V; Renaud, F; Trotot, P; Bouleau, S; Mignotte, B; Vayssiere, JL			Caspase-9 can antagonize p53-induced apoptosis by generating a p76Rb truncated form of Rb	ONCOGENE			English	Article						apoptosis; caspase-9; fibroblasts; p53; Rb	RETINOBLASTOMA PROTEIN; MEDIATED CLEAVAGE; P53-DEPENDENT APOPTOSIS; CYTOCHROME-C; ACTIVATION; P53; INHIBITION; INDUCTION; CELLS; GROWTH	The tumor suppressor Rb ( retinoblastoma protein) is known to regulate p53-dependent apoptosis, but the mechanisms involved are unclear. In a rat fibroblast model, we previously observed that caspase inhibition potentiates p53-dependent apoptosis and prevents the Rb cleavage associated with p53 activation. These results suggested that a caspase(s) can antagonize p53-mediated apoptosis via the production of a protective Rb truncated form. Here, we identify caspase-9 as the caspase that interferes, upstream of the mitochondrion, with p53-induced apoptosis in both immortalized and primary fibroblasts. This caspase can be detected as a p38 processed form in living cells, in the absence of apoptosome formation and apoptotic signal. We also provide evidence that the involvement of caspase-9 in a premitochondrial protective pathway results from the previously undescribed cleavage of Rb, at a LExD site, into a p76(Rb) form, which antagonizes p53-induced apoptosis. These results establish that a truncated form of Rb can display an antiapoptotic activity, rather than just being a by-product of Rb degradation.	Univ Versailles, Lab Genet & Biol Cellulaire, CNRS, FRE 2445, F-78035 Versailles, France; Ecole Prat Hautes Etud, Lab Genet Mol & Physiol, F-78035 Versailles, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Vayssiere, JL (corresponding author), Univ Versailles, Lab Genet & Biol Cellulaire, CNRS, FRE 2445, 45 Ave Etatsunis, F-78035 Versailles, France.	vayssiere@genetique.uvsq.fr	Godefroy, Nelly/AAG-2052-2020; Mignotte, Bernard/A-3499-2009; Ferecatu, Ioana/AAW-5055-2021	Mignotte, Bernard/0000-0002-8512-8518; Ferecatu, Ioana/0000-0001-6842-9506; Lemaire, Christophe/0000-0001-6316-8781; Krejbich Trotot, Pascale/0000-0001-7329-1716				Alam A, 1999, J EXP MED, V190, P1879, DOI 10.1084/jem.190.12.1879; An B, 1996, CANCER RES, V56, P438; Angelastro JM, 2001, J BIOL CHEM, V276, P12190, DOI 10.1074/jbc.M009523200; Bitzer M, 2002, J BIOL CHEM, V277, P29817, DOI 10.1074/jbc.M111898200; Boutillier AL, 2000, ONCOGENE, V19, P2171, DOI 10.1038/sj.onc.1203532; Bowen C, 1998, CANCER RES, V58, P3275; Chandler JM, 1997, BIOCHEM J, V322, P19, DOI 10.1042/bj3220019; Chen WD, 1997, ONCOGENE, V14, P1243, DOI 10.1038/sj.onc.1201096; Cregan SP, 1999, J NEUROSCI, V19, P7860; De Maria R, 1999, NATURE, V401, P489, DOI 10.1038/46809; Ding HF, 2000, J BIOL CHEM, V275, P38905, DOI 10.1074/jbc.M004714200; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Eymin B, 1999, ONCOGENE, V18, P4839, DOI 10.1038/sj.onc.1202860; Fattman CL, 2001, ONCOGENE, V20, P2918, DOI 10.1038/sj.onc.1204414; Fearnhead HO, 1998, P NATL ACAD SCI USA, V95, P13664, DOI 10.1073/pnas.95.23.13664; Forcet C, 2001, P NATL ACAD SCI USA, V98, P3416, DOI 10.1073/pnas.051378298; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Fujita E, 2001, CELL DEATH DIFFER, V8, P335, DOI 10.1038/sj.cdd.4400824; Gao CF, 2001, EXP CELL RES, V265, P145; Godefroy N, 2004, CELL DEATH DIFFER, V11, P785, DOI 10.1038/sj.cdd.4401398; Gottlieb E, 1998, EMBO J, V17, P3587, DOI 10.1093/emboj/17.13.3587; Guenal I, 1997, ONCOGENE, V15, P347, DOI 10.1038/sj.onc.1201182; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; Kaufmann SH, 2001, TRENDS CELL BIOL, V11, P526, DOI 10.1016/S0962-8924(01)02173-0; Kennedy NJ, 1999, J EXP MED, V190, P1891, DOI 10.1084/jem.190.12.1891; Knudsen KE, 1999, ONCOGENE, V18, P5239, DOI 10.1038/sj.onc.1202910; Lemaire C, 1999, CELL DEATH DIFFER, V6, P813, DOI 10.1038/sj.cdd.4400556; Lopez-Hernandez FJ, 2004, CELL DEATH DIFFER, V11, P154, DOI 10.1038/sj.cdd.4401329; Macleod K, 1999, CURR OPIN GENET DEV, V9, P31, DOI 10.1016/S0959-437X(99)80005-7; MALCOMSON RDG, 1995, BRIT J CANCER, V72, P952, DOI 10.1038/bjc.1995.440; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; Mashima T, 1999, ONCOGENE, V18, P2423, DOI 10.1038/sj.onc.1202558; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; PETIT CA, 1983, VIROLOGY, V127, P74, DOI 10.1016/0042-6822(83)90372-0; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Rincheval V, 1999, FEBS LETT, V460, P203, DOI 10.1016/S0014-5793(99)01345-9; Ritter PM, 2000, EUR J CELL BIOL, V79, P358, DOI 10.1078/S0171-9335(04)70040-0; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Seol DW, 1999, J BIOL CHEM, V274, P2072, DOI 10.1074/jbc.274.4.2072; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Slinskey A, 1999, J VIROL, V73, P6791, DOI 10.1128/JVI.73.8.6791-6799.1999; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Srinivasula SM, 1999, CANCER RES, V59, P999; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Yang JY, 2001, MOL CELL BIOL, V21, P5346, DOI 10.1128/MCB.21.16.5346-5358.2001; Zhang YK, 1999, ONCOGENE, V18, P1131, DOI 10.1038/sj.onc.1202426; ZHENG DQ, 1994, ONCOGENE, V9, P3345; Zheng TS, 1999, CELL DEATH DIFFER, V6, P1043, DOI 10.1038/sj.cdd.4400593	58	16	20	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 5	2005	24	20					3297	3308		10.1038/sj.onc.1208493	http://dx.doi.org/10.1038/sj.onc.1208493			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	923AU	15735701				2022-12-17	WOS:000228881800008
J	Kuznetsov, NV; Andersson, P; Gradin, K; von Stein, P; Dieckmann, A; Pettersson, S; Hanberg, A; Poellinger, L				Kuznetsov, NV; Andersson, P; Gradin, K; von Stein, P; Dieckmann, A; Pettersson, S; Hanberg, A; Poellinger, L			The dioxin/aryl hydrocarbon receptor mediates downregulation of osteopontin gene expression in a mouse model of gastric tumourigenesis	ONCOGENE			English	Article						osteopontin; dioxin/aryl hydrocarbon receptor; gastric cancer; gene expression profiling; suppression subtractive hybridization	IMMUNOGLOBULIN-M; INFLUENZA-VIRUS; AH RECEPTOR; IDENTIFICATION; 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN; INHIBITION; INDUCTION; AP-1; TRANSCRIPTION; PROGRESSION	The dioxin/aryl hydrocarbon receptor functions as a ligand-activated transcription factor regulating transcription of a battery of genes encoding primarily drug-metabolizing enzymes. Expression of a constitutively active mutant of the aryl hydrocarbon receptor (CA-AhR) in transgenic mice results in development of stomach tumours, correlating with increased mortality. We have used suppression subtractive hybridization techniques followed by macroarray analysis to elucidate which genes are differentially expressed during this process. In the glandular stomach of CA-AhR mice, we observed decreased mRNA expression of osteopontin (OPN), a noncollagenous protein of bone matrix that is also involved in several important functions including regulation of cytokine production, macrophage accumulation, cell motility and adhesion. Downregulated expression of OPN during tumour development was confirmed by RT-PCR and RNA blot analysis. Immunohistochemical analysis showed that this decrease was confined to the corpus region, correlating with the restricted localization of the tumours. Decreased OPN mRNA expression was also observed in other organs of CA-AhR mice. Taken together, these results show that OPN is negatively regulated by the dioxin receptor, and that downregulation of its expression correlates with development of stomach tumours in mice expressing a constitutively active mutant of dioxin receptor.	Karolinska Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden; InDex Pharmaceut AB, S-17177 Stockholm, Sweden; Karolinska Inst, Inst Environm Med, S-17177 Stockholm, Sweden; Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet	Poellinger, L (corresponding author), Karolinska Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden.	lorenz.poellinger@cmb.ki.se	Pettersson, Sven/F-9511-2015; Kuznetsov, Nikolai V/I-7622-2013; Kuznetsov, Nikolay/AAB-2354-2021; Кузнецов, Николай Юрьевич/GZM-2865-2022	Kuznetsov, Nikolay/0000-0002-0131-6387; Hanberg, Annika/0000-0001-7255-9856; Kuznetsov, Nikolai/0000-0003-3010-3927				Agrawal D, 2002, J NATL CANCER I, V94, P513; Andersson P, 2003, BIOCHEM BIOPH RES CO, V302, P336, DOI 10.1016/S0006-291X(03)00185-2; Andersson P, 2002, P NATL ACAD SCI USA, V99, P9990, DOI 10.1073/pnas.152706299; Ashkar S, 2000, SCIENCE, V287, P860, DOI 10.1126/science.287.5454.860; Baumgarth N, 1999, P NATL ACAD SCI USA, V96, P2250, DOI 10.1073/pnas.96.5.2250; Baumgarth N, 2000, J EXP MED, V192, P271, DOI 10.1084/jem.192.2.271; Bidder M, 2002, J BIOL CHEM, V277, P44485, DOI 10.1074/jbc.M206235200; Boes M, 1998, J EXP MED, V188, P2381, DOI 10.1084/jem.188.12.2381; BROWN LF, 1994, AM J PATHOL, V145, P610; BROWN LF, 1992, MOL BIOL CELL, V3, P1169, DOI 10.1091/mbc.3.10.1169; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CRAIG AM, 1991, GENE, V100, P163, DOI 10.1016/0378-1119(91)90362-F; Crawford HC, 1998, CANCER RES, V58, P5206; Denhardt D T, 1998, J Cell Biochem Suppl, V30-31, P92; Denhardt DT, 2003, CLIN EXP METASTAS, V20, P77, DOI 10.1023/A:1022550721404; Denhardt DT, 2001, ANNU REV PHARMACOL, V41, P723, DOI 10.1146/annurev.pharmtox.41.1.723; Denhardt DT, 2001, J CLIN INVEST, V107, P1055, DOI 10.1172/JCI12980; FERNANDEZSALGUERO P, 1995, SCIENCE, V268, P722, DOI 10.1126/science.7732381; FernandezSalguero PM, 1997, VET PATHOL, V34, P605, DOI 10.1177/030098589703400609; Frueh FW, 2001, TOXICOL LETT, V122, P189, DOI 10.1016/S0378-4274(01)00364-2; Furger Kara A., 2001, Current Molecular Medicine (Hilversum), V1, P621, DOI 10.2174/1566524013363339; Gillesby BE, 1997, BIOCHEMISTRY-US, V36, P6080, DOI 10.1021/bi962131b; Gu YZ, 2000, ANNU REV PHARMACOL, V40, P519, DOI 10.1146/annurev.pharmtox.40.1.519; Iizuka J, 1998, LAB INVEST, V78, P1523; KLEMAN MI, 1994, J BIOL CHEM, V269, P5137; Kolluri SK, 2001, CANCER RES, V61, P8534; Kolluri SK, 1999, GENE DEV, V13, P1742, DOI 10.1101/gad.13.13.1742; Kurachi M, 2002, BIOCHEM BIOPH RES CO, V292, P368, DOI 10.1006/bbrc.2002.6669; Lahvis GP, 2000, P NATL ACAD SCI USA, V97, P10442, DOI 10.1073/pnas.190256997; McGuire J, 2001, J BIOL CHEM, V276, P41841, DOI 10.1074/jbc.M105607200; Mimura J, 1999, GENE DEV, V13, P20, DOI 10.1101/gad.13.1.20; Mimura J, 1997, GENES CELLS, V2, P645, DOI 10.1046/j.1365-2443.1997.1490345.x; MIYAZAKI Y, 1990, J BIOL CHEM, V265, P14432; Morimoto I, 2002, GENE CHROMOSOME CANC, V33, P270, DOI 10.1002/gcc.10020; Nemir M, 2000, J BIOL CHEM, V275, P969, DOI 10.1074/jbc.275.2.969; Ochsenbein AF, 1999, SCIENCE, V286, P2156, DOI 10.1126/science.286.5447.2156; Ohbayashi T, 2001, FEBS LETT, V508, P341, DOI 10.1016/S0014-5793(01)03039-3; Oikawa K, 2002, BIOCHEM BIOPH RES CO, V290, P984, DOI 10.1006/bbrc.2001.6302; Paciorkowski N, 2000, J EXP MED, V191, P731, DOI 10.1084/jem.191.4.731; POHJANVIRTA R, 1994, PHARMACOL REV, V46, P483; Puga A, 2000, BIOCHEM PHARMACOL, V60, P1129, DOI 10.1016/S0006-2952(00)00403-2; QuHong, 1997, J HISTOCHEM CYTOCHEM, V45, P21; Renault MA, 2003, CIRC RES, V93, P674, DOI 10.1161/01.RES.0000094747.05021.62; Rittling SR, 2004, BRIT J CANCER, V90, P1877, DOI 10.1038/sj.bjc.6601839; Rivera SP, 2002, MOL PHARMACOL, V61, P255, DOI 10.1124/mol.61.2.255; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; Schmidt JV, 1996, P NATL ACAD SCI USA, V93, P6731, DOI 10.1073/pnas.93.13.6731; Suh J, 2002, TOXICOL APPL PHARM, V181, P116, DOI 10.1006/taap.2002.9403; Svensson C, 2001, MOL PHARMACOL, V60, P135, DOI 10.1124/mol.60.1.135; Thomas RS, 2001, MOL PHARMACOL, V60, P1189, DOI 10.1124/mol.60.6.1189; Ue T, 1998, INT J CANCER, V79, P127, DOI 10.1002/(SICI)1097-0215(19980417)79:2<127::AID-IJC5>3.0.CO;2-V; von Stein OD, 2001, METH MOL B, V175, P263; Yumoto K, 2002, P NATL ACAD SCI USA, V99, P4556, DOI 10.1073/pnas.052523599	53	16	19	1	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 28	2005	24	19					3216	3222		10.1038/sj.onc.1208529	http://dx.doi.org/10.1038/sj.onc.1208529			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	920XF	15735673				2022-12-17	WOS:000228728100015
J	Zancai, P; Dal Col, J; Piccinin, S; Guidoboni, M; Cariati, R; Rizzo, S; Boiocchi, M; Maestro, R; Dolcetti, R				Zancai, P; Dal Col, J; Piccinin, S; Guidoboni, M; Cariati, R; Rizzo, S; Boiocchi, M; Maestro, R; Dolcetti, R			Retinoic acid stabilizes p27(Kip1) in EBV-immortalized lymphoblastoid B cell lines through enhanced proteasome-dependent degradation of the p45(Skp2) and Cks1 proteins	ONCOGENE			English	Article						retinoic acid; p27(Kip1); p45(Skp2); Cks1; EBV; B lymphocytes; proteasome	CDK INHIBITOR P27; MEDIATED GROWTH ARREST; S-PHASE KINASE; NUCLEAR EXPORT; CYCLIN D1; UP-REGULATION; LEPTOMYCIN B; LUNG-CANCER; HUMAN CUL-1; C-MYC	Retinoic acid (RA) arrests the growth of EBV-immortalized lymphoblastoid B cell lines (LCLs) by upregulating the cyclin-dependent kinase inhibitor p27(Kip1). Here, we show that in LCLs, RA inhibits ubiquitination and proteasomedependent degradation of p27Kip1, a phenomenon that is associated with downregulation of Thr187 phosphorylation of the protein, whereas the phosphorylation on Ser10 is unaffected. Furthermore, we demonstrate that RA downregulates the expression of the p45(Skp2) and Cks1 proteins, two essential components of the SCFSkp2 ubiquitin ligase complex that target p27(Kip1) for degradation. Downregulation of p45(Skp2) and Cks1 occurs before the onset of growth arrest and is due to enhanced proteasome-mediated proteolysis of these proteins. Moreover, overexpression of p45(Skp2) in DG75 cells prevents p27(Kip1) protein accumulation and promotes resistance to the antiproliferative effects of RA. Treatment with Leptomycin B (LMB) blocked the translocation of p27(Kip1) to the cytoplasm and prevented its degradation, indicating that CRM1-dependent nuclear export is required for p27(Kip1) degradation. The shuttle protein p38(Jab1), however, does not accumulate in the nucleus upon LMB treatment, nor does it interact with p27(Kip1). Conversely, p45(Skp2) is associated with p27(Kip1) both in the nucleus and in the cytoplasm, accumulating within the nuclei after exposure to LMB and co-localizing with the exportin CRM1, suggesting a possible involvement of p45(Skp2) in CRM1-dependent nuclear export of p27(Kip1). These results indicate that downregulation of p45(Skp2) is a key element underlying RA-induced p27(Kip1) stabilization in B cells, resulting in an impaired targeting of the protein to the ubiquitin-proteasome pathway and probably contributing to the nuclear accumulation of p27(Kip1).	Natl Canc Inst, IRCCS, Ctr Riferimento Oncol, Dept Preclin & Epidemiol Res,Immunovirol & Biothe, I-33081 Aviano, PN, Italy; Natl Canc Inst, IRCCS, Ctr Riferimento Oncol, Mechanisms Neoplast Progress Unit, I-33081 Aviano, PN, Italy	IRCCS Aviano (CRO); IRCCS Aviano (CRO)	Dolcetti, R (corresponding author), Natl Canc Inst, IRCCS, Ctr Riferimento Oncol, Dept Preclin & Epidemiol Res,Immunovirol & Biothe, Via Pedemontana Occidentale 12, I-33081 Aviano, PN, Italy.	rdolcetti@cro.it	, Dal Col Jessica/AAC-4852-2020; Dal Col, Jessica/ABD-9479-2020; PICCININ, SARA/AAZ-2679-2020; Dolcetti, Riccardo/O-3832-2015; Maestro, Roberta/P-9748-2019; Guidoboni, Massimo/A-5322-2010; Maestro, Roberta/M-1846-2015; Rizzo, Silvana/AAW-1132-2020	Dal Col, Jessica/0000-0002-0042-2161; PICCININ, SARA/0000-0002-7987-4020; Dolcetti, Riccardo/0000-0003-1625-9853; Maestro, Roberta/0000-0002-6642-5592; Maestro, Roberta/0000-0002-6642-5592; Rizzo, Silvana/0000-0002-7156-1783; Guidoboni, Massimo/0000-0001-7703-790X				Baldassarre G, 2000, CELL GROWTH DIFFER, V11, P517; Bloom J, 2003, SEMIN CANCER BIOL, V13, P41, DOI 10.1016/S1044-579X(02)00098-6; Boyle JO, 1999, J NATL CANCER I, V91, P373, DOI 10.1093/jnci/91.4.373; Cariati R, 2000, INT J CANCER, V86, P375, DOI 10.1002/(SICI)1097-0215(20000501)86:3<375::AID-IJC12>3.0.CO;2-Z; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Chiarle R, 2002, AM J PATHOL, V160, P1457, DOI 10.1016/S0002-9440(10)62571-0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; de Vos S, 2003, DIAGN MOL PATHOL, V12, P35, DOI 10.1097/00019606-200303000-00005; Delmas C, 2003, J BIOL CHEM, V278, P12443, DOI 10.1074/jbc.M209523200; Dimberg A, 2002, BLOOD, V99, P2199, DOI 10.1182/blood.V99.6.2199; Dow R, 2001, J BIOL CHEM, V276, P45945, DOI 10.1074/jbc.M103593200; Esposito V, 1997, CANCER RES, V57, P3381; Ganoth D, 2001, NAT CELL BIOL, V3, P321, DOI 10.1038/35060126; Hannon GJ, 1999, SCIENCE, V283, P1129, DOI 10.1126/science.283.5405.1129; Hattori T, 2003, GENES CELLS, V8, P889, DOI 10.1046/j.1365-2443.2003.00684.x; Hsu SL, 2000, EXP CELL RES, V258, P322, DOI 10.1006/excr.2000.4933; Ishida N, 2002, J BIOL CHEM, V277, P14355, DOI 10.1074/jbc.C100762200; Ishida N, 2000, J BIOL CHEM, V275, P25146, DOI 10.1074/jbc.M001144200; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Langenfeld J, 1997, P NATL ACAD SCI USA, V94, P12070, DOI 10.1073/pnas.94.22.12070; Latres E, 2001, P NATL ACAD SCI USA, V98, P2515, DOI 10.1073/pnas.041475098; Li Y, 1998, MOL CELL BIOL, V18, P4719, DOI 10.1128/MCB.18.8.4719; Lim MS, 2002, BLOOD, V100, P2950, DOI 10.1182/blood.V100.8.2950; Lisztwan J, 1998, EMBO J, V17, P368, DOI 10.1093/emboj/17.2.368; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Michel JJ, 1998, CELL GROWTH DIFFER, V9, P435; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Muller D, 1997, ONCOGENE, V15, P2561, DOI 10.1038/sj.onc.1201440; Nakamura M, 2003, CELL DEATH DIFFER, V10, P230, DOI 10.1038/sj.cdd.4401125; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; Pomponi F, 1996, BLOOD, V88, P3147, DOI 10.1182/blood.V88.8.3147.bloodjournal8883147; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; RICHARDSON HE, 1990, GENE DEV, V4, P1332, DOI 10.1101/gad.4.8.1332; Seger YR, 2002, CANCER CELL, V2, P401, DOI 10.1016/S1535-6108(02)00183-6; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Spinella MJ, 1999, J BIOL CHEM, V274, P22013, DOI 10.1074/jbc.274.31.22013; Spruck C, 2001, MOL CELL, V7, P639, DOI 10.1016/S1097-2765(01)00210-6; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Suzui M, 2002, CANCER RES, V62, P3997; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Tomoda K, 2002, J BIOL CHEM, V277, P2302, DOI 10.1074/jbc.M104431200; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Wirbelauer C, 2000, EMBO J, V19, P5362, DOI 10.1093/emboj/19.20.5362; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; Zancai P, 1998, ONCOGENE, V17, P1827, DOI 10.1038/sj.onc.1202089; Zhang DM, 2001, ONCOGENE, V20, P7935, DOI 10.1038/sj.onc.1204971; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6	51	16	20	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2005	24	15					2483	2494		10.1038/sj.onc.1208458	http://dx.doi.org/10.1038/sj.onc.1208458			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	913UV	15735731				2022-12-17	WOS:000228180600006
J	Xin, BZ; Platzer, P; Fink, SP; Reese, L; Nosrati, A; Willson, JKV; Wilson, K; Markowitz, S				Xin, BZ; Platzer, P; Fink, SP; Reese, L; Nosrati, A; Willson, JKV; Wilson, K; Markowitz, S			Colon cancer secreted protein-2 (CCSP-2), a novel candidate serological marker of colon neoplasia	ONCOGENE			English	Article						colon cancer; secreted proteins; serum markers	CLINICAL-PRACTICE GUIDELINES; COLORECTAL-CANCER; TUMOR-MARKERS; FECAL DNA; PREVENTION; EXPRESSION; UPDATE; BREAST; STOOL; SERUM	Cancers of the colon and rectum are the second leading cause of cancer death among adult Americans. When detected at early stages, colon cancer is highly curable. Colonoscopy, an effective but invasive screening test, has been limited in its public acceptance. The goal of this study was to identify novel serum markers of colon cancers and precancerous colon adenomas as potential candidates for noninvasive detection of early colon neoplasms. Employing expression microarrays, we identified colon cancer secreted protein-2 (CCSP-2) as a novel transcript whose expression is generally absent in normal colon and other normal body tissues, but that is induced an average of 78-fold in Stage II, III, and IV colon cancers, as well as in colon adenomas and colon cancer cell lines. These findings were validated by real-time PCR analysis in an independent panel of colon cancer cases. Moreover, CCSP-2 was shown to encode a secreted protein that circulates stably and is detectable in the blood of mice bearing human cancer xenografts transfected with epitope-tagged CCSP-2. As a novel secreted protein that is markedly induced in colon adenomas and cancers, CCSP-2 is a novel candidate for development as a diagnostic serum marker of early stage colon cancer.	Case Western Reserve Univ, Howard Hughes Med Inst, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA; Case Western Reserve Univ, Ireland Comprehens Canc Ctr, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA; Prot Design Labs, Fremont, CA 94555 USA	Case Western Reserve University; Howard Hughes Medical Institute; Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland	Markowitz, S (corresponding author), Case Western Reserve Univ, Howard Hughes Med Inst, Wolstein Res Bldg,3rd Floor,Mailstop 7285,10900 E, Cleveland, OH 44106 USA.	sxm10@cwru.edu		Fink, Stephen/0000-0003-4107-7912	NATIONAL CANCER INSTITUTE [U01CA088130, P30CA043703] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA43703, U01CA88130] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahlquist DA, 2000, GASTROENTEROLOGY, V119, P1219, DOI 10.1053/gast.2000.19580; Bast RC, 1996, J CLIN ONCOL, V14, P2843; Bast RC, 2001, J CLIN ONCOL, V19, P1865, DOI 10.1200/JCO.2001.19.6.1865; Bond JH, 2000, MED CLIN N AM, V84, P1163, DOI 10.1016/S0025-7125(05)70281-9; Brunschwig EB, 2003, CANCER RES, V63, P1568; Dong SM, 2001, J NATL CANCER I, V93, P858, DOI 10.1093/jnci/93.11.858; Grady WM, 2001, CANCER RES, V61, P900; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Hibi K, 1998, CANCER RES, V58, P1405; Lipshutz RJ, 1999, NAT GENET, V21, P20, DOI 10.1038/4447; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Nielsen H, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P122; Pignone M, 2002, ANN INTERN MED, V137, P132, DOI 10.7326/0003-4819-137-2-200207160-00015; Platzer P, 2002, CANCER RES, V62, P1134; Schoen RE, 2002, NAT REV CANCER, V2, P65, DOI 10.1038/nrc705; Sengle G, 2003, J BIOL CHEM, V278, P50240, DOI 10.1074/jbc.M307794200; Smith RA, 2002, CA-CANCER J CLIN, V52, P8, DOI 10.3322/canjclin.52.1.8; Traverso G, 2002, NEW ENGL J MED, V346, P311, DOI 10.1056/NEJMoa012294; Traverso G, 2002, LANCET, V359, P403, DOI 10.1016/S0140-6736(02)07591-8; Vernon SW, 1997, JNCI-J NATL CANCER I, V89, P1406, DOI 10.1093/jnci/89.19.1406; WINAWER SJ, 1993, NEW ENGL J MED, V329, P1977, DOI 10.1056/NEJM199312303292701	21	16	24	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 20	2005	24	4					724	731		10.1038/sj.onc.1208134	http://dx.doi.org/10.1038/sj.onc.1208134			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	889CF	15580307				2022-12-17	WOS:000226420400020
J	Althaus, FR				Althaus, FR			Poly(ADP-ribose): a co-regulator of DNA methylation?	ONCOGENE			English	Editorial Material						PARP inhibitors; ADP-ribosylation; polymer-binding proteins; CpG islands	DOMAINS; BINDS; PARP	The formation of multiprotein complexes is l'ordre du jour in regulatory pathways. In this issue of Oncogene, Reale et al. report the formation of a particularly sophisticated complex of two important regulatory enzymes, DNMT1 (DNA methyltransferase-1) and PARP-1 (poly(ADP-ribose) polymerase-1). The former evolved with a specific sequence motif binding the enzymatic product of the latter. The product, poly(ADP-ribose), bonds the two partners into a heterodimeric complex and, as a consequence, the catalytic function of DNMT1 is silenced. Thus, PARP-1 becomes a conditional negative regulator of DNMT1. In a larger perspective, Reale et al. highlight the potential role of PARP-1 as a co-regulator of DNA methylation leading to epigenetic reprogramming of cancer cells.	Univ Zurich, Inst Pharmacol & Toxicol, CH-8057 Zurich, Switzerland	University of Zurich	Althaus, FR (corresponding author), Univ Zurich, Inst Pharmacol & Toxicol, Winterthurerstr 260, CH-8057 Zurich, Switzerland.	fra@vetpharm.unizh.ch						El-Khamisy SF, 2003, NUCLEIC ACIDS RES, V31, P5526, DOI 10.1093/nar/gkg761; Feltus FA, 2003, P NATL ACAD SCI USA, V100, P12253, DOI 10.1073/pnas.2037852100; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Kraus WL, 2003, CELL, V113, P677, DOI 10.1016/S0092-8674(03)00433-1; Malanga M, 1998, J BIOL CHEM, V273, P11839, DOI 10.1074/jbc.273.19.11839; Malanga M, 2004, J BIOL CHEM, V279, P5244, DOI 10.1074/jbc.C300437200; Okano S, 2003, MOL CELL BIOL, V23, P3974, DOI 10.1128/MCB.23.11.3974-3981.2003; Pleschke JM, 2000, J BIOL CHEM, V275, P40974, DOI 10.1074/jbc.M006520200; Reale A, 2005, ONCOGENE, V24, P13, DOI 10.1038/sj.onc.1208005; Rouleau M, 2004, J CELL SCI, V117, P815, DOI 10.1242/jcs.01080; Tulin A, 2003, SCIENCE, V299, P560, DOI 10.1126/science.1078764; Zardo G, 1998, J BIOL CHEM, V273, P16517, DOI 10.1074/jbc.273.26.16517; Zardo G, 1997, BIOCHEMISTRY-US, V36, P7937, DOI 10.1021/bi970241s	13	16	17	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 6	2005	24	1					11	12		10.1038/sj.onc.1208382	http://dx.doi.org/10.1038/sj.onc.1208382			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	884ZS	15637586	Green Accepted			2022-12-17	WOS:000226125800002
J	Saleh-Gohari, N; Helleday, T				Saleh-Gohari, N; Helleday, T			Strand invasion involving short tract gene conversion is specifically suppressed in BRCA2-deficient hamster cells	ONCOGENE			English	Article						homologous recombination; BRCA2; strand invasion; sister chromatid exchange; gene conversion; DNA double-strand break	HOMOLOGY-DIRECTED REPAIR; DNA-REPAIR; CHROMOSOMAL TRANSLOCATIONS; CANCER SUSCEPTIBILITY; MAMMALIAN-CELLS; RAD51 PROTEIN; BREAK REPAIR; BRCA2 LEADS; RECOMBINATION; DEFICIENCY	The BRCA2 tumour suppressor protein is involved in maintaining genetic stability through its role in homologous recombination (HR), where it mediates RAD51-dependent strand invasion. Here, we show that BRCA2-defective cells are not completely impaired in HR by strand invasion although the spontaneous HR rate is 10-fold lower than that in wild-type cells. Furthermore, a DNA double-strand break (DSB) triggers HR repair by strand invasion also in BRCA2-defective cells, but less efficiently. Thus, either the strand invasion pathway(s) in which BRCA2 operates is still operative in the absence of a functional BRCA2, albeit at a reduced frequency, or there is a separate pathway for strand invasion still functional in BRCA2-deficient cells. Consistent with the latter hypothesis, we show that HR events occurring in BRCA2-defective cells differ from HR events in wild-type cells. These data suggest that BRCA2-defective hamster cells are impaired in short tract gene conversion but maintain proficiency in sister chromatid exchange.	Univ Sheffield, Sch Med, Inst Canc Studies, Sheffield S10 2RX, S Yorkshire, England; Univ Stockholm, Arrhenius Lab, Dept Genet Microbiol & Toxicol, S-10691 Stockholm, Sweden	University of Sheffield; Stockholm University	Helleday, T (corresponding author), Univ Sheffield, Sch Med, Inst Canc Studies, Beech Hill Rd, Sheffield S10 2RX, S Yorkshire, England.	t.helleday@sheffield.ac.uk	Helleday, Thomas/D-5224-2013; Gohari, Nasrollah Saleh/ABB-4209-2020	Gohari, Nasrollah Saleh/0000-0003-1256-0323; Helleday, Thomas/0000-0002-7384-092X				Arnaudeau C, 2001, J MOL BIOL, V307, P1235, DOI 10.1006/jmbi.2001.4564; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; Friedman LS, 1998, CANCER RES, V58, P1338; Johnson RD, 2000, EMBO J, V19, P3398, DOI 10.1093/emboj/19.13.3398; Johnson RD, 1999, NATURE, V401, P397, DOI 10.1038/43935; Kraakman-van der Zwet M, 2002, MOL CELL BIOL, V22, P669, DOI 10.1128/MCB.22.2.669-679.2002; Larminat F, 2002, ONCOGENE, V21, P5188, DOI 10.1038/sj.onc.1205659; Marmorstein LY, 1998, P NATL ACAD SCI USA, V95, P13869, DOI 10.1073/pnas.95.23.13869; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Pellegrini L, 2002, NATURE, V420, P287, DOI 10.1038/nature01230; Richardson C, 2000, NATURE, V405, P697, DOI 10.1038/35015097; Richardson C, 1998, GENE DEV, V12, P3831, DOI 10.1101/gad.12.24.3831; Schultz N, 2003, NUCLEIC ACIDS RES, V31, P4959, DOI 10.1093/nar/gkg703; Shin DS, 2003, EMBO J, V22, P4566, DOI 10.1093/emboj/cdg429; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Suzuki A, 1997, GENE DEV, V11, P1242, DOI 10.1101/gad.11.10.1242; Tarsounas M, 2003, ONCOGENE, V22, P1115, DOI 10.1038/sj.onc.1206263; Tutt A, 1999, CURR BIOL, V9, P1107, DOI 10.1016/S0960-9822(99)80479-5; Tutt A, 2001, EMBO J, V20, P4704, DOI 10.1093/emboj/20.17.4704; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; Xia F, 2001, P NATL ACAD SCI USA, V98, P8644, DOI 10.1073/pnas.151253498; Yu VPCC, 2000, GENE DEV, V14, P1400	28	16	16	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2004	23	56					9136	9141		10.1038/sj.onc.1208178	http://dx.doi.org/10.1038/sj.onc.1208178			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	876JN	15480413				2022-12-17	WOS:000225492800015
J	McCubrey, JA; Shelton, JG; Steelman, LS; Franklin, RA; Sreevalsan, T; McMahon, M				McCubrey, JA; Shelton, JG; Steelman, LS; Franklin, RA; Sreevalsan, T; McMahon, M			Effects of a conditionally active v-ErbB and an EGF-R inhibitor on transformation of NIH-3T3 cells and abrogation of cytokine dependency of hematopoietic cells	ONCOGENE			English	Article						ErbB; EGF-R; Raf/MEK/ERK; PI3K/Akt; signal transduction; apoptosis	CYCLE PROGRESSION; SIGNAL-TRANSDUCTION; PREVENT APOPTOSIS; PROTEIN-KINASE; GM-CSF; RAS/RAF/MEK/ERK PATHWAY; DIFFERENTIAL ABILITIES; PI3K/AKT PATHWAY; PRECURSOR CELLS; BETA-SUBUNIT	Epidermal growth factor (EGF) and its cognate receptor (EGF-R) are often dysregulated in human neoplasia. Moreover, EGF-R-transformed cell lines have constitutive EGF-R activity, which makes elucidation of its effects difficult to determine. In the following studies, the effects of a novel conditionally activated form of EGF-R, v-ErbB:ER, on the morphological transformation of NIH-3T3 cells and the abrogation of hematopoietic cell cytokine dependence were investigated. The v-ErbB ES-4 oncogene was fused to the hormone binding domain of the estrogen receptor (ER). This construct, v-ErbB:ER, requires beta-estradiol or 4-OH tamoxifen for activation. v-ErbB:ER conditionally transformed NIH-3T3 cells and abrogated cytokine dependence of hematopoietic cells. Stimulation of v-ErbB:ER activity resulted in the activation of the phosphatidylinositol 3-kinase (PI3K)/Akt and Raf/MEK/ERK kinase cascades. To determine the importance of these signal transduction pathways, the conditionally transformed hematopoietic cells were treated with EGF-R, PI3K and MEK inhibitors. The EGF-R inhibitor AG1478 effectively inhibited MEK, ERK and Akt activation, and induced apoptosis when the cells were grown in response to v-ErbB:ER. Apoptosis was observed at 100- to 1000-fold lower concentrations of AG1478 when the cells were grown in response to v-ErbB:ER as opposed to IL-3. Furthermore, the parental, BCR-ABL- and Raf-transformed cells were only susceptible to the apoptosis-inducing effects of AG1478 at the highest concentrations demonstrating the specificity of these inhibitors. MEK or PI3K inhibitors suppressed ERK or Akt activation, respectively, and induced apoptosis in the v-ErbB:ER-responsive cells. However, MEK and PI3K inhibitors only induced apoptosis at 1000-fold higher concentrations than the EGFR inhibitor. This novel v-ErbB:ER construct and these conditionally transformed cell lines will be useful to further elucidate ErbB-mediated signal transduction and to determine the effectiveness of various inhibitors in targeting different aspects of EGFR-mediated signal transduction and malignant transformation.	E Carolina Univ, Brody Sch Med, Dept Microbiol & Immunol, Greenville, NC 27858 USA; E Carolina Univ, Brody Sch Med, Leo Jenkins Canc Ctr, Greenville, NC 27858 USA; Georgetown Univ, Sch Med, Dept Microbiol & Immunol, Washington, DC 20057 USA; UCSF Mt Zion Canc Ctr, San Francisco, CA 94115 USA	University of North Carolina; East Carolina University; University of North Carolina; East Carolina University; Georgetown University; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Medical Center at Mount Zion	McCubrey, JA (corresponding author), E Carolina Univ, Brody Sch Med, Dept Microbiol & Immunol, Brody Bldg 5N98C, Greenville, NC 27858 USA.	mccubreyj@mail.ecu.edu	McMahon, Martin/L-3303-2013	McMahon, Martin/0000-0003-2812-1042; Franklin, Richard A./0000-0003-0299-9578; McCubrey, James/0000-0001-6027-3156	NCI NIH HHS [R01CA98185, R01CA51025] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA098185, R01CA051025] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn NG, 2001, METHOD ENZYMOL, V332, P417; Blalock WL, 1999, LEUKEMIA, V13, P1109, DOI 10.1038/sj.leu.2401493; Blalock WL, 2003, LEUKEMIA, V17, P1058, DOI 10.1038/sj.leu.2402925; Blalock WL, 2001, LEUKEMIA, V15, P794, DOI 10.1038/sj.leu.2402109; Blalock WL, 2000, LEUKEMIA, V14, P1080, DOI 10.1038/sj.leu.2401793; Blalock WL, 2000, ONCOGENE, V19, P526, DOI 10.1038/sj.onc.1203337; Bosch E, 1997, ONCOGENE, V15, P1021, DOI 10.1038/sj.onc.1201270; BRUSKIN A, 1990, ONCOGENE, V5, P15; Chang F, 2003, LEUKEMIA, V17, P590, DOI 10.1038/sj.leu.2402824; Chang F, 2003, LEUKEMIA, V17, P1263, DOI 10.1038/sj.leu.2402945; Chang FM, 2003, INT J ONCOL, V22, P469; Chang FM, 2002, CELL CYCLE, V1, P220, DOI 10.4161/cc.1.3.128; CLARK SS, 1988, SCIENCE, V239, P775, DOI 10.1126/science.3422516; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; Fan QW, 2002, CURR BIOL, V12, P1386, DOI 10.1016/S0960-9822(02)01070-9; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Hoyle PE, 2000, LEUKEMIA, V14, P642, DOI 10.1038/sj.leu.2401720; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; KUAN CT, 2001, BRAIN TUMOR PATHOL, V17, P71; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; Larson RA, 2003, LEUKEMIA, V17, P2358, DOI 10.1038/sj.leu.2403156; Lee JT, 2002, LEUKEMIA, V16, P486, DOI 10.1038/sj/leu/2402460; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; MCCUBREY J, 1989, ONCOGENE RES, V4, P97; MCCUBREY JA, 1993, ONCOGENE, V8, P2905; McCubrey JA, 1998, LEUKEMIA, V12, P1903, DOI 10.1038/sj.leu.2401215; MCCUBREY JA, 1995, INT J ONCOL, V7, P573; McCubrey JA, 2000, LEUKEMIA, V14, P9, DOI 10.1038/sj.leu.2401657; MCKEARN JP, 1985, P NATL ACAD SCI USA, V82, P7414, DOI 10.1073/pnas.82.21.7414; MCMAHON M, 1991, MOL CELL BIOL, V11, P4760, DOI 10.1128/MCB.11.9.4760; McMahon M, 2001, METHOD ENZYMOL, V332, P401; MILLER M, 1990, ONCOGENE, V5, P1125; Muthuswamy SK, 1999, MOL CELL BIOL, V19, P6845; Navolanic PM, 2003, INT J ONCOL, V22, P237; PRITCHARD CA, 1995, MOL CELL BIOL, V15, P6430; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; Shelton JG, 2004, CELL CYCLE, V3, P189; Shelton JG, 2004, CELL CYCLE, V3, P372; Shelton JG, 2004, CELL CYCLE, V3, P503; Shelton JG, 2003, ONCOGENE, V22, P2478, DOI 10.1038/sj.onc.1206321; Steelman LS, 1996, LEUKEMIA, V10, P528; Steelman LS, 2004, LEUKEMIA, V18, P189, DOI 10.1038/sj.leu.2403241; von Lindern M, 2001, ONCOGENE, V20, P3651, DOI 10.1038/sj.onc.1204494; WEISS R, 1984, RNA TUMOR VIRUSES	50	16	18	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	2004	23	47					7810	7820		10.1038/sj.onc.1208055	http://dx.doi.org/10.1038/sj.onc.1208055			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	860GX	15361836				2022-12-17	WOS:000224331600007
J	Chen, CM; Chang, JL; Behringer, RR				Chen, CM; Chang, JL; Behringer, RR			Tumor formation in p53 mutant ovaries transplanted into wild-type female hosts	ONCOGENE			English	Article						ovarian cancer; tumor suppressor; p53; ovary transplantation; hemangiosarcoma	MICE; ANGIOSARCOMA; INDUCTION; SPECTRUM; CANCER; MODEL; GENE	p53 gene alterations correlate highly with advanced ovarian carcinoma in women. In mice, p53 deficiency predominantly results in the formation of lymphomas and sarcomas. However, ovarian epithelial tumors have not been documented in p53 homozygous mutant (p53(-/-)) mice, probably because they die before other tumors can form. To determine whether p53(-/-) ovaries can develop epithelial tumors, they were transplanted into the ovarian bursae of histocompatible wild-type recipient females. The p53(-/-) ovarian grafts formed tumors similar to1 year posttransplantation. The tumor type was angiosarcoma, suggesting that vascular tissues are predisposed to tumor formation in p53(-/-) ovaries. These findings suggest that p53 deficiency alone is not sufficient for ovarian epithelial tumorigenesis in mice. Thus, other genetic lesions are likely required to develop mouse models of human ovarian cancer.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA; Armed Forced Taoyuan Gen Hosp, Dept Pathol, Taoyuan, Taiwan	University of Texas System; UTMD Anderson Cancer Center	Behringer, RR (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rrb@notes.mdacc.tmc.edu		Chen, Chun-Ming/0000-0001-8873-7602	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD030284] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA016672, P50CA083639] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672, CA83639] Funding Source: Medline; NICHD NIH HHS [HD30284] Funding Source: Medline; ONCHIT HHS [OC20187] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); ONCHIT HHS		Auersperg N, 2001, ENDOCR REV, V22, P255, DOI 10.1210/er.22.2.255; Bast RC, 2000, METH MOLEC MED, V39, P37; Blackburn AC, 2003, CANCER RES, V63, P2364; Capen CC, 2001, INT CLASSIFICATION R, P269; Chen CM, 2004, GENE DEV, V18, P320, DOI 10.1101/gad.1162204; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Flesken-Nikitin A, 2003, CANCER RES, V63, P3459; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Jylling A M, 1999, Pathol Oncol Res, V5, P318, DOI 10.1053/paor.1999.0213; Kuperwasser C, 2000, AM J PATHOL, V157, P2151, DOI 10.1016/S0002-9440(10)64853-5; Nagy A., 2003, MANIPULATING MOUSE E; Naka N, 1997, INT J CANCER, V71, P952, DOI 10.1002/(SICI)1097-0215(19970611)71:6<952::AID-IJC7>3.3.CO;2-N; Nucci MR, 1998, AM J SURG PATHOL, V22, P620, DOI 10.1097/00000478-199805000-00014; Orsulic S, 2002, CANCER CELL, V1, P53, DOI 10.1016/S1535-6108(01)00002-2; Platt JS, 1999, GYNECOL ONCOL, V73, P443, DOI 10.1006/gyno.1998.5335; PURDIE CA, 1994, ONCOGENE, V9, P603; Schuijer M, 2003, HUM MUTAT, V21, P285, DOI 10.1002/humu.10181; SHELLING AN, 1995, BRIT J CANCER, V72, P521, DOI 10.1038/bjc.1995.367; TURUSOV V, 1994, IARC SCI PUBLICATION, V111; Venkatachalam Sundaresan, 2002, P247; Zietz C, 1998, AM J PATHOL, V153, P1425, DOI 10.1016/S0002-9440(10)65729-X	22	16	16	2	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2004	23	46					7722	7725		10.1038/sj.onc.1208037	http://dx.doi.org/10.1038/sj.onc.1208037			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	859ZK	15334065				2022-12-17	WOS:000224306700013
J	Iwakuma, T; Parant, JM; Fasulo, M; Zwart, E; Jacks, T; de Vries, A; Lozano, G				Iwakuma, T; Parant, JM; Fasulo, M; Zwart, E; Jacks, T; de Vries, A; Lozano, G			Mutation at p53 serine 389 does not rescue the embryonic lethality in mdm2 or mdm4 null mice	ONCOGENE			English	Article						p53; phosphorylation; mdm2; mdm4; embryogenesis	DNA-BINDING FUNCTION; PHOSPHORYLATION SITE; MDM2-DEFICIENT MICE; P53-BINDING PROTEIN; CRYSTAL-STRUCTURE; MDM4-NULL MICE; GROWTH ARREST; MURINE P53; CELL-DEATH; ACTIVATION	Mdm2 and its homolog Mdm4 inhibit the function of the tumor suppressor p53. Targeted disruption of either mdm2 or mdm4 genes in mice results in embryonic lethality that is completely rescued by concomitant deletion of p53, suggesting that deletion of negative regulators of p53 results in a constitutively active p53. Thus, these mouse models offer a unique in vivo system to assay the functional significance of different p53 modi. cations. Phosphorylation of serine 389 in murine p53 occurs specifically after ultraviolet-light-induced DNA damage, and phosphorylation of this site enhances p53 activity both in vitro and in vivo. Recently, mice with a serine to alanine substitution at serine 389 (p53(S389A)) in the endogenous p53 locus were generated. To examine the in vivo significance of serine 389 phosphorylation during embryogenesis, we crossed these mutant mice to mice lacking mdm2 or mdm4. The p53S389A allele did not alter the embryonic lethality of mdm2 or mdm4. Additional crosses to assay the effect of one p53S389A allele with a p53 null allele also did not rescue the lethal phenotypes. In conclusion, the phenotypes due to loss of mdm2 or mdm4 were not even partially rescued by p53S389A, suggesting that p53S389A is functionally wild type during embryogenesis.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Sect Canc Genet, Houston, TX 77030 USA; Natl Inst Publ Hlth & Environm, Lab Toxicol Pathol & Genet, NL-3720 BA Bilthoven, Netherlands; MIT, Ctr Canc Res, Cambridge, MA 02139 USA	University of Texas System; UTMD Anderson Cancer Center; Netherlands National Institute for Public Health & the Environment; Massachusetts Institute of Technology (MIT)	Lozano, G (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Sect Canc Genet, Houston, TX 77030 USA.	gglozano@mdanderson.org			NATIONAL CANCER INSTITUTE [R01CA047296, R29CA047296] Funding Source: NIH RePORTER; NCI NIH HHS [CA47296] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Achison M, 2003, ONCOGENE, V22, P3431, DOI 10.1038/sj.onc.1206434; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Blattner C, 1999, ONCOGENE, V18, P1723, DOI 10.1038/sj.onc.1202480; Bottger V, 1999, ONCOGENE, V18, P189, DOI 10.1038/sj.onc.1202281; BRUINS W, 2004, IN PRESS MOL CELL BI; Chao C, 2000, P NATL ACAD SCI USA, V97, P11936, DOI 10.1073/pnas.220252297; Chavez-Reyes A, 2003, CANCER RES, V63, P8664; Chen JD, 1996, MOL CELL BIOL, V16, P2445; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; de Rozieres S, 2000, ONCOGENE, V19, P1691, DOI 10.1038/sj.onc.1203468; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Finch RA, 2002, CANCER RES, V62, P3221; FISCELLA M, 1994, ONCOGENE, V9, P3249; Furihata M, 2002, J PATHOL, V197, P82, DOI 10.1002/path.1082; Hao MM, 1996, J BIOL CHEM, V271, P29380, DOI 10.1074/jbc.271.46.29380; HARVEY M, 1993, ONCOGENE, V8, P2457; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; HUPP TR, 1994, COLD SPRING HARB SYM, V59, P195, DOI 10.1101/SQB.1994.059.01.024; Itahana K, 2002, J BIOL CHEM, V277, P18206, DOI 10.1074/jbc.M201028200; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kapoor M, 1998, P NATL ACAD SCI USA, V95, P2834, DOI 10.1073/pnas.95.6.2834; Keller DM, 2001, MOL CELL, V7, P283, DOI 10.1016/S1097-2765(01)00176-9; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Lee CW, 1998, ONCOGENE, V16, P2695, DOI 10.1038/sj.onc.1201818; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Lowe SW, 1999, ENDOCR-RELAT CANCER, V6, P45, DOI 10.1677/erc.0.0060045; Lu H, 1998, P NATL ACAD SCI USA, V95, P6399, DOI 10.1073/pnas.95.11.6399; LUNA RMD, 1995, NATURE, V378, P203; Migliorini D, 2002, MOL CELL BIOL, V22, P5527, DOI 10.1128/MCB.22.15.5527-5538.2002; Miller M, 1996, FEBS LETT, V399, P166, DOI 10.1016/S0014-5793(96)01231-8; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; Parant JM, 2003, HUM MUTAT, V21, P321, DOI 10.1002/humu.10186; PELLEGATA NS, 1995, ONCOGENE, V11, P337; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; ROLLEY N, 1994, ONCOGENE, V9, P3067; Sakaguchi K, 1997, BIOCHEMISTRY-US, V36, P10117, DOI 10.1021/bi970759w; Sayed M, 2000, J BIOL CHEM, V275, P16569, DOI 10.1074/jbc.M000312200; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Shikama N, 1999, MOL CELL, V4, P365, DOI 10.1016/S1097-2765(00)80338-X; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Shvarts A, 1997, GENOMICS, V43, P34, DOI 10.1006/geno.1997.4775; Sluss HK, 2004, MOL CELL BIOL, V24, P976, DOI 10.1128/MCB.24.3.976-984.2004; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; Wiederschain D, 2001, J BIOL CHEM, V276, P27999, DOI 10.1074/jbc.M102400200; Wu ZQ, 2002, MOL CELL BIOL, V22, P2441, DOI 10.1128/MCB.22.8.2441-2449.2002	54	16	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2004	23	46					7644	7650		10.1038/sj.onc.1207793	http://dx.doi.org/10.1038/sj.onc.1207793			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	859ZK	15361844				2022-12-17	WOS:000224306700005
J	Faubert, A; Lessard, J; Sauvageau, G				Faubert, A; Lessard, J; Sauvageau, G			Are genetic determinants of asymmetric stem cell division active in hematopoietic stem cells?	ONCOGENE			English	Review						asymmetric division; hematopoiesis; phylogenic search; self-renewal; stem cell	CENTRAL-NERVOUS-SYSTEM; TUMOR-SUPPRESSOR; DROSOPHILA NEUROBLASTS; MAMMALIAN NUMB; CORTICAL NEUROGENESIS; INTRACELLULAR DOMAIN; MITOTIC NEUROBLASTS; ENDOCYTIC PROTEIN; EPITHELIAL-CELLS; PROGENITOR CELLS	Stem cells have acquired a golden glow in the past few years as they represent possible tools for reversing the damage wreak on organs. These cells are found not only in major regenerative tissues, such as the epithelia, blood and testes, but also in 'static tissues', such as the nervous system and liver, where they play a central role in tissue growth and maintenance. The mechanism by which stem cells maintain populations of highly differentiated, short-lived cells seems to involve a critical balance between alternate fates: daughter cells either maintain stem cell identity or initiate differentiation. Recent studies in lower organisms have unveiled the regulatory mechanisms of asymmetric stem cell divisions. In these models, the surrounding environment likely provides key instructive signals for the cells to choose one fate over another. Our understanding now extends to the intrinsic mechanisms of cell polarity that influence asymmetrical stem cell divisions. This article focuses on the genetic determinants of asymmetric stem cell divisions in lower organisms as a model for studying the process of self-renewal of mammalian hematopoietic stem cells.	Univ Montreal, IRIC Inst Res Immunol & Canc, Lab Mol Genet Hematopoiet Stem Cells, Montreal, PQ H3C 3J7, Canada; McGill Univ, Dept Expt Med, Montreal, PQ, Canada; Stanford Univ, Dept Dev Biol, Stanford, CA 94305 USA; Hosp Maisonneuve Rosemont, Dept Med, Montreal, PQ, Canada; Hosp Maisonneuve Rosemont, Div Hematol, Montreal, PQ, Canada	Universite de Montreal; McGill University; Stanford University; Universite de Montreal; Universite de Montreal	Sauvageau, G (corresponding author), Univ Montreal, IRIC Inst Res Immunol & Canc, Lab Mol Genet Hematopoiet Stem Cells, CP 6128,Downtown Stn, Montreal, PQ H3C 3J7, Canada.	guy.sauvageau@umontreal.ca		Sauvageau, Guy/0000-0002-4333-7266				Allman D, 2002, IMMUNOL REV, V187, P75, DOI 10.1034/j.1600-065X.2002.18707.x; Armstrong SA, 2002, NAT GENET, V30, P41, DOI 10.1038/ng765; Baker NE, 2000, BIOESSAYS, V22, P264, DOI 10.1002/(SICI)1521-1878(200003)22:3<264::AID-BIES8>3.0.CO;2-M; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Beatus P, 1999, DEVELOPMENT, V126, P3925; Berdnik D, 2002, DEV CELL, V3, P221, DOI 10.1016/S1534-5807(02)00215-0; Bernstein E, 2003, NAT GENET, V35, P215, DOI 10.1038/ng1253; Berthet C, 2003, CURR BIOL, V13, P1775, DOI 10.1016/j.cub.2003.09.024; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; Broadus J, 1998, NATURE, V391, P792, DOI 10.1038/35861; Brummendorf TH, 1998, J EXP MED, V188, P1117, DOI 10.1084/jem.188.6.1117; Bu W, 2001, ONCOGENE, V20, P3185, DOI 10.1038/sj.onc.1204429; Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040; Cayouette M, 2003, DEVELOPMENT, V130, P2329, DOI 10.1242/dev.00446; Cayouette M, 2002, NAT NEUROSCI, V5, P1265, DOI 10.1038/nn1202-1265; Cayouette M, 2001, J NEUROSCI, V21, P5643, DOI 10.1523/JNEUROSCI.21-15-05643.2001; Chant T, 1999, ANNU REV CELL DEV BI, V15, P365, DOI 10.1146/annurev.cellbio.15.1.365; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; CHENN A, 1995, CELL, V82, P631, DOI 10.1016/0092-8674(95)90035-7; Darzacq X, 2003, CURR OPIN MICROBIOL, V6, P614, DOI 10.1016/j.mib.2003.10.005; DELABIE J, 1993, LEUKEMIA LYMPHOMA, V12, P21, DOI 10.3109/10428199309059567; Dho SE, 1999, J BIOL CHEM, V274, P33097, DOI 10.1074/jbc.274.46.33097; DOE CQ, 1991, CELL, V65, P451, DOI 10.1016/0092-8674(91)90463-9; Doe CQ, 2001, CURR OPIN CELL BIOL, V13, P68, DOI 10.1016/S0955-0674(00)00176-9; Fuchs E, 2004, CELL, V116, P769, DOI 10.1016/S0092-8674(04)00255-7; Fukata M, 2002, CELL, V109, P873, DOI 10.1016/S0092-8674(02)00800-0; Furukawa T, 2000, NEURON, V26, P383, DOI 10.1016/S0896-6273(00)81171-X; Gaiano N, 2000, NEURON, V26, P395, DOI 10.1016/S0896-6273(00)81172-1; Gonczy P, 1996, DEVELOPMENT, V122, P2437; GONZALEZ C, 2002, SCI STKE, pE48; Greenwald I, 1998, GENE DEV, V12, P1751, DOI 10.1101/gad.12.12.1751; Grunicke HH, 2003, ADV ENZYME REGUL, V43, P213, DOI 10.1016/S0065-2571(02)00032-8; HARDY RW, 1979, J ULTRA MOL STRUCT R, V69, P180, DOI 10.1016/S0022-5320(79)90108-4; Hawkins N, 1998, GENE DEV, V12, P3625, DOI 10.1101/gad.12.23.3625; HIRATA J, 1995, NATURE, V377, P627, DOI 10.1038/377627a0; Hirokawa N, 2000, TRAFFIC, V1, P29, DOI 10.1034/j.1600-0854.2000.010105.x; Ho SM, 2003, ONCOGENE, V22, P4243, DOI 10.1038/sj.onc.1206437; IkeshimaKataoka H, 1997, NATURE, V390, P625, DOI 10.1038/37641; Jablonka S, 2004, J NEUROBIOL, V58, P272, DOI 10.1002/neu.10313; Jan YN, 1998, NATURE, V392, P775, DOI 10.1038/33854; Jimbo T, 2002, NAT CELL BIOL, V4, P323, DOI 10.1038/ncb779; Kaltschmidt JA, 2002, J CELL SCI, V115, P2257; Katayama Hiroshi, 2003, Cancer and Metastasis Reviews, V22, P451, DOI 10.1023/A:1023789416385; Katoh M, 2003, INT J MOL MED, V11, P111; Kiger AA, 2001, SCIENCE, V294, P2542, DOI 10.1126/science.1066707; KNOBLICH JA, 1995, NATURE, V377, P624, DOI 10.1038/377624a0; Knoblich JA, 2001, NAT REV MOL CELL BIO, V2, P11, DOI 10.1038/35048085; Knoblich JA, 1999, CURR BIOL, V9, P155, DOI 10.1016/S0960-9822(99)80070-0; Knust E, 2001, CELL, V107, P125, DOI 10.1016/S0092-8674(01)00534-7; KONDO S, 1994, J CELL BIOL, V125, P1095, DOI 10.1083/jcb.125.5.1095; Kraut R, 1996, NATURE, V383, P50, DOI 10.1038/383050a0; Kraut R, 1996, DEV BIOL, V174, P65, DOI 10.1006/dbio.1996.0052; Lardelli M, 1996, MECH DEVELOP, V59, P177, DOI 10.1016/0925-4773(96)00589-8; Li P, 1997, CELL, V90, P437, DOI 10.1016/S0092-8674(00)80504-8; Liakopoulos D, 2003, CELL, V112, P561, DOI 10.1016/S0092-8674(03)00119-3; Lin HF, 2002, NAT REV GENET, V3, P931, DOI 10.1038/nrg952; Lin HJ, 2001, J CELL BIOL, V155, P1173, DOI 10.1083/jcb.200108119; Lu BW, 1998, CELL, V95, P225, DOI 10.1016/S0092-8674(00)81753-5; Marszalek JR, 2000, CELL, V102, P175, DOI 10.1016/S0092-8674(00)00023-4; Matsuzaki F, 1998, DEVELOPMENT, V125, P4089; Morrison SJ, 2000, CELL, V101, P499, DOI 10.1016/S0092-8674(00)80860-0; Mumm JS, 2000, DEV BIOL, V228, P151, DOI 10.1006/dbio.2000.9960; Nagai H, 2003, GENE CHROMOSOME CANC, V38, P13, DOI 10.1002/gcc.10248; Nance J, 2003, DEVELOPMENT, V130, P5339, DOI 10.1242/dev.00735; O'Connor-Giles KM, 2003, DEV CELL, V5, P231, DOI 10.1016/S1534-5807(03)00226-0; Ohno S, 2001, CURR OPIN CELL BIOL, V13, P641, DOI 10.1016/S0955-0674(00)00264-7; Ohshiro T, 2000, NATURE, V408, P593, DOI 10.1038/35046087; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; Parmentier ML, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-14-j0003.2000; Peng CY, 2000, NATURE, V408, P596, DOI 10.1038/35046094; Petersen PH, 2002, NATURE, V419, P929, DOI 10.1038/nature01124; Petritsch C, 2003, DEV CELL, V4, P273, DOI 10.1016/S1534-5807(03)00020-0; Plant PJ, 2003, NAT CELL BIOL, V5, P301, DOI 10.1038/ncb948; Qiu RG, 2000, CURR BIOL, V10, P697, DOI 10.1016/S0960-9822(00)00535-2; Radtke F, 2002, IMMUNOL REV, V187, P65, DOI 10.1034/j.1600-065X.2002.18706.x; RHYU MS, 1994, CELL, V76, P477, DOI 10.1016/0092-8674(94)90112-0; Roegiers F, 2001, P NATL ACAD SCI USA, V98, P14469, DOI 10.1073/pnas.261555598; Sahin U, 2002, BLOOD, V100, P4139, DOI 10.1182/blood.V100.12.4139; Santolini E, 2000, J CELL BIOL, V151, P1345, DOI 10.1083/jcb.151.6.1345; Schaefer M, 2000, CURR BIOL, V10, P353, DOI 10.1016/S0960-9822(00)00401-2; Schaner CE, 2003, DEV CELL, V5, P747, DOI 10.1016/S1534-5807(03)00327-7; Schober M, 1999, NATURE, V402, P548, DOI 10.1038/990135; Schuldt AJ, 1998, GENE DEV, V12, P1847, DOI 10.1101/gad.12.12.1847; Schweisguth F, 2000, CURR BIOL, V10, pR265, DOI 10.1016/S0960-9822(00)00402-4; Segal M, 2001, TRENDS CELL BIOL, V11, P160, DOI 10.1016/S0962-8924(01)01954-7; Selzer E, 2002, MELANOMA RES, V12, P201, DOI 10.1097/00008390-200206000-00003; Shen CP, 1997, CELL, V90, P449, DOI 10.1016/S0092-8674(00)80505-X; Shen Q, 2002, DEVELOPMENT, V129, P4843; SHEN Q, 2002, SCI STKE, pE52; Shi SH, 2003, CELL, V112, P63, DOI 10.1016/S0092-8674(02)01249-7; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; Song XQ, 2002, P NATL ACAD SCI USA, V99, P14813, DOI 10.1073/pnas.232389399; SPANA EP, 1995, DEVELOPMENT, V121, P3187; Tio M, 1999, J CELL SCI, V112, P1541; Torii MA, 1999, DEVELOPMENT, V126, P443; Tulina N, 2001, SCIENCE, V294, P2546, DOI 10.1126/science.1066700; VAESSIN H, 1991, CELL, V67, P941, DOI 10.1016/0092-8674(91)90367-8; Verdi J, 1996, CURR BIOL, V6, P1134, DOI 10.1016/S0960-9822(02)70680-5; Verdi JM, 1999, P NATL ACAD SCI USA, V96, P10472, DOI 10.1073/pnas.96.18.10472; Wai P, 1999, DEVELOPMENT, V126, P2759; Wakamatsu Y, 2000, DEVELOPMENT, V127, P2811; Wakamatsu Y, 1999, NEURON, V23, P71, DOI 10.1016/S0896-6273(00)80754-0; Wang SL, 2000, NEURON, V27, P197, DOI 10.1016/S0896-6273(00)00028-3; Wigle JT, 1999, NAT GENET, V21, P318, DOI 10.1038/6844; Wigle JT, 1999, CELL, V98, P769, DOI 10.1016/S0092-8674(00)81511-1; Wodarz A, 1999, NATURE, V402, P544, DOI 10.1038/990128; Wodarz A, 2002, NAT CELL BIOL, V4, pE39, DOI 10.1038/ncb0202-e39; Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469; Yamashita YM, 2003, SCIENCE, V301, P1547, DOI 10.1126/science.1087795; Yu FW, 2000, CELL, V100, P399, DOI 10.1016/S0092-8674(00)80676-5; Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041; Zhong WM, 1996, NEURON, V17, P43, DOI 10.1016/S0896-6273(00)80279-2; Zhong WM, 2000, P NATL ACAD SCI USA, V97, P6844, DOI 10.1073/pnas.97.12.6844; Zhu CH, 2003, DEVELOPMENT, V130, P2579, DOI 10.1242/dev.00499	114	16	18	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2004	23	43					7247	7255		10.1038/sj.onc.1207944	http://dx.doi.org/10.1038/sj.onc.1207944			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	855TZ	15378084				2022-12-17	WOS:000223998800010
J	Opdam, FJM; Kamp, M; de Bruijn, R; Roos, E				Opdam, FJM; Kamp, M; de Bruijn, R; Roos, E			Jak kinase activity is required for lymphoma invasion and metastasis	ONCOGENE			English	Article						integrin; adhesion; G-protein; CXCR4 migration	ZAP-70 TYROSINE KINASE; JAK/STAT PATHWAY; ACTIVATION; PHOSPHORYLATION; MIGRATION; CXCR4; LFA-1; CELLS; DISSEMINATION; INVASIVENESS	Jak tyrosine kinases are activated by interleukins and other growth factors, and promote survival and proliferation of cells in multiple tissues. These kinases are constitutively active in many hematopoietic malignancies and certain carcinomas. We have investigated whether Jak kinases play a role in lymphoma invasion and metastasis. Proliferation and survival of a highly metastatic T-lymphoma was made independent of its constitutively active Jak by expression of active forms of both STAT3 and PI3-kinase. Jak activity was then blocked by the isolated JH2 'pseudokinase' domain of Jak2. In vitro invasion was blocked by the JH2 domain, and the metastatic capacity of the JH2-expressing cells was much reduced. The Jak inhibitor AG490 inhibited invasion as well. Invasion and metastasis of these cells requires activation of the integrin LFA-1 by the CXCR4 chemokine receptor. We show that Jak kinases act downstream of LFA-1. We conclude that Jak kinase activity is essential for lymphoma invasion and metastasis, independent of its role in survival and proliferation, and independent of STAT and PI3K signaling. This indicates that Jak kinases contribute in multiple ways to the induction of malignant behavior.	Netherlands Canc Inst, Div Cell Biol, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Roos, E (corresponding author), Netherlands Canc Inst, Div Cell Biol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	E.ROOS@NKI.NL						Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Carron C, 2000, BLOOD, V95, P3891; Chan AC, 1996, CURR OPIN IMMUNOL, V8, P394, DOI 10.1016/S0952-7915(96)80130-0; Didichenko SA, 1996, CURR BIOL, V6, P1271, DOI 10.1016/S0960-9822(02)70713-6; Dobbeling U, 1998, BLOOD, V92, P252, DOI 10.1182/blood.V92.1.252.413k08_252_258; Galm O, 2003, BLOOD, V101, P2784, DOI 10.1182/blood-2002-06-1735; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; Hou SX, 2002, DEV CELL, V3, P765, DOI 10.1016/S1534-5807(02)00376-3; LARIVIERE G, 1988, CANCER RES, V48, P3405; LARIVIERE G, 1993, J LEUKOCYTE BIOL, V53, P381, DOI 10.1002/jlb.53.4.381; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Luo H, 1997, MOL CELL BIOL, V17, P1562, DOI 10.1128/MCB.17.3.1562; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Michiels F, 2000, METHOD ENZYMOL, V325, P295; Nguyen MHH, 2001, J BIOL CHEM, V276, P32704, DOI 10.1074/jbc.M103100200; Peeters P, 1997, BLOOD, V90, P2535, DOI 10.1182/blood.V90.7.2535.2535_2535_2540; Roland J, 2003, BLOOD, V101, P399, DOI 10.1182/blood-2002-03-0978; ROOSSIEN FF, 1989, J CELL BIOL, V108, P1979, DOI 10.1083/jcb.108.5.1979; Saharinen P, 2000, MOL CELL BIOL, V20, P3387, DOI 10.1128/MCB.20.10.3387-3395.2000; Saharinen P, 2002, J BIOL CHEM, V277, P47954, DOI 10.1074/jbc.M205156200; Schuringa JJ, 2000, BLOOD, V95, P3765, DOI 10.1182/blood.V95.12.3765; Silver DL, 2001, CELL, V107, P831, DOI 10.1016/S0092-8674(01)00607-9; Soede RDM, 1998, J CELL BIOL, V142, P1371, DOI 10.1083/jcb.142.5.1371; Soede RDM, 2001, J IMMUNOL, V166, P4293, DOI 10.4049/jimmunol.166.7.4293; Soede RDM, 1999, J IMMUNOL, V163, P4253; Soriano SF, 2003, EUR J IMMUNOL, V33, P1328, DOI 10.1002/eji.200323897; Takeshita T, 1997, IMMUNITY, V6, P449, DOI 10.1016/S1074-7613(00)80288-5; Tibbles HE, 2001, J BIOL CHEM, V276, P17815, DOI 10.1074/jbc.M011405200; Vila-Coro AJ, 1999, FASEB J, V13, P1699, DOI 10.1096/fasebj.13.13.1699; Xie SH, 2001, ONCOGENE, V20, P6188, DOI 10.1038/sj.onc.1204834; Zeelenberg IS, 2001, J CLIN INVEST, V108, P269, DOI 10.1172/JCI200111330; Zhang XF, 2001, BLOOD, V97, P3342, DOI 10.1182/blood.V97.11.3342	33	16	23	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2004	23	39					6647	6653		10.1038/sj.onc.1207887	http://dx.doi.org/10.1038/sj.onc.1207887			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	849IB	15235585				2022-12-17	WOS:000223530800012
J	You, FL; Chiba, N; Ishioka, C; Parvin, JD				You, FL; Chiba, N; Ishioka, C; Parvin, JD			Expression of an amino-terminal BRCA1 deletion mutant causes a dominant growth inhibition in MCF10A cells	ONCOGENE			English	Article						BRCA1; apoptosis; centrosomes	POLYMERASE-II HOLOENZYME; DNA-DAMAGE RESPONSE; UBIQUITIN LIGASE; OVARIAN-CANCER; BREAST-CANCER; RNA HELICASE; PROTEIN; COMPLEX; TRANSCRIPTION; GENE	Expression of deletion mutants of the breast and ovarian cancer-specific tumor suppressor protein, BRCA1, in the mammary epithelial cell line MCF10A revealed a powerful growth suppressive effect by a mutant that has the amino-terminal 302 amino acids deleted (DeltaN-BRCA1). The growth suppression is associated with an increase in apoptosis and amplification in centrosome number. The growth inhibitory effect of DeltaN-BRCA1 was not observed in cervical epithelial HeLa cells, suggesting that the phenotypes of BRCA1 mutant proteins differ depending on the cell line being tested. An internal domain, including BRCA1 residues 303-1292, caused the suppression of MCF10A cell growth, and the amino terminus of BRCA1 autoinhibited the growth suppression. Single point mutations that disrupted the amino-terminal RING domain of BRCA1 caused significant suppression of growth in MCF10A cells. These results suggest that the proper function of the RING domain, likely to be ubiquitin ligase function, is important in regulating the growth of the mammary epithelial cell line and in autoregulating the powerful internal growth-inhibiting domain of the BRCA1 tumor suppressor.	Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Tohoku Univ, Dept Clin Oncol, Inst Dev Aging & Canc, Aoba Ku, Sendai, Miyagi 9808575, Japan	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Tohoku University	Parvin, JD (corresponding author), Brigham & Womens Hosp, Dept Pathol, NRB 630,77 Ave Louis Pasteur, Boston, MA 02115 USA.	jparvin@rics.bwh.harvard.edu	Parvin, Jeffrey D/C-8955-2009	Ishioka, Chikashi/0000-0002-3023-1227	NCI NIH HHS [CA90281] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090281] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; Andrews HN, 2002, J BIOL CHEM, V277, P26225, DOI 10.1074/jbc.M201316200; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; Chen A, 2002, J BIOL CHEM, V277, P22085, DOI 10.1074/jbc.M201252200; Chiba N, 2002, CANCER RES, V62, P4222; Chiba N, 2001, J BIOL CHEM, V276, P38549, DOI 10.1074/jbc.M105227200; Dong YS, 2003, MOL CELL, V12, P1087, DOI 10.1016/S1097-2765(03)00424-6; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; Haile DT, 1999, J BIOL CHEM, V274, P2113, DOI 10.1074/jbc.274.4.2113; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Hsu LC, 2001, CANCER RES, V61, P7713; Hu YF, 1999, GENE DEV, V13, P637, DOI 10.1101/gad.13.6.637; Kleiman FE, 2001, CELL, V104, P743, DOI 10.1016/S0092-8674(01)00270-7; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; MacLachlan TK, 2000, J BIOL CHEM, V275, P2777, DOI 10.1074/jbc.275.4.2777; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Narita T, 2003, MOL CELL BIOL, V23, P1863, DOI 10.1128/MCB.23.6.1863-1873.2003; Neish AS, 1998, NUCLEIC ACIDS RES, V26, P847, DOI 10.1093/nar/26.3.847; Paull TT, 2001, P NATL ACAD SCI USA, V98, P6086, DOI 10.1073/pnas.111125998; Schlegel BP, 2000, P NATL ACAD SCI USA, V97, P3148, DOI 10.1073/pnas.070452397; Schlegel BP, 2003, ONCOGENE, V22, P983, DOI 10.1038/sj.onc.1206195; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Snouwaert JN, 1999, ONCOGENE, V18, P7900, DOI 10.1038/sj.onc.1203334; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Starita LM, 2003, CURR OPIN CELL BIOL, V15, P345, DOI 10.1016/S0955-0674(03)00042-5; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Wu-Baer F, 2003, J BIOL CHEM, V278, P34743, DOI 10.1074/jbc.C300249200; Xia Y, 2003, J BIOL CHEM, V278, P5255, DOI 10.1074/jbc.M204591200; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	33	16	17	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2004	23	34					5792	5798		10.1038/sj.onc.1207739	http://dx.doi.org/10.1038/sj.onc.1207739			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KW	15122325				2022-12-17	WOS:000222629800008
J	Penninkhof, F; Grootegoed, JA; Blok, LJ				Penninkhof, F; Grootegoed, JA; Blok, LJ			Identification of REPS2 as a putative modulator of NF-kappa B activity in prostate cancer cells	ONCOGENE			English	Article						REPS2; p65; NF-kappa B/p65; prostate cancer; apoptosis; cell survival	TYROSINE KINASE SUBSTRATE; INTERLEUKIN-6 EXPRESSION; CONSTITUTIVE ACTIVATION; CRYSTAL-STRUCTURE; EH DOMAINS; PROTEIN; YEAST; EPS15; TRANSFORMATION; SPECIFICITY	The protein REPS2 is implicated in growth factor receptor-mediated endocytosis and signalling, and its expression is downregulated in androgen-independent prostate cancer cells. Herein, the NF-kappaB subunit p65 is identified as a human REPS2 protein partner, interacting with the EH domain of REPS2. Using crystal structure data from literature and experimental data from yeast and mammalian two-hybrid analysis, the results indicate that the NPF-motif in p65 acts as binding site for the EH domain in REPS2. However, in cultured prostate cancer cells, the REPS2-p65 interaction is triggered upon stimulation with phorbol ester (PMA). This indicates that PMA-sensitive signalling pathways can affect the interaction between REPS2 and p65. During prostate cancer progression from androgen-dependent to androgen-independent growth, downregulation of REPS2 is accompanied by upregulation of NF-kappaB activity. This might involve loss of REPS2-p65 interaction, which would lead to increased NF-kappaB activity. Androgen-deprivation causes apoptosis of prostate cancer cells, and activated NF-kappaB is a known inhibitor of apoptosis. Hence, decreased expression of REPS2 might be a key factor, causing prostate cancer cells to become resistant to induction of apoptosis by androgen deprivation.	Erasmus Univ, Med Ctr, Dept Reprod & Dev, NL-3000 DR Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC	Blok, LJ (corresponding author), Erasmus Univ, Med Ctr, Dept Reprod & Dev, POB 1738, NL-3000 DR Rotterdam, Netherlands.	l.blok@erasmusmc.nl						Chang GTG, 1997, CANCER RES, V57, P4075; Chen CD, 2002, MOL CELL BIOL, V22, P2862, DOI 10.1128/MCB.22.8.2862-2870.2002; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; de Beer T, 2000, NAT STRUCT BIOL, V7, P1018, DOI 10.1038/80924; de Beer T, 1998, SCIENCE, V281, P1357, DOI 10.1126/science.281.5381.1357; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; Garg A, 2002, LEUKEMIA, V16, P1053, DOI 10.1038/sj.leu.2402482; Gietz RD, 2002, METHOD ENZYMOL, V350, P87; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; Huxford T, 1998, CELL, V95, P759, DOI 10.1016/S0092-8674(00)81699-2; Ikeda M, 1998, J BIOL CHEM, V273, P814, DOI 10.1074/jbc.273.2.814; Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092-8674(00)81698-0; Kimura K, 2002, CELL DEATH DIFFER, V9, P972, DOI 10.1038/sj.cdd.4401049; Ling MT, 2003, ONCOGENE, V22, P4498, DOI 10.1038/sj.onc.1206693; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Nakashima S, 1999, EMBO J, V18, P3629, DOI 10.1093/emboj/18.13.3629; Oosterhoff JK, 2003, ONCOGENE, V22, P2920, DOI 10.1038/sj.onc.1206397; Palayoor ST, 1999, ONCOGENE, V18, P7389, DOI 10.1038/sj.onc.1203160; Paoluzi S, 1998, EMBO J, V17, P6541, DOI 10.1093/emboj/17.22.6541; Park JI, 2003, ONCOGENE, V22, P4314, DOI 10.1038/sj.onc.1206478; Salcini AE, 1997, GENE DEV, V11, P2239, DOI 10.1101/gad.11.17.2239; Santolini E, 1999, EXP CELL RES, V253, P186, DOI 10.1006/excr.1999.4694; Steiner H, 2003, AM J PATHOL, V162, P655, DOI 10.1016/S0002-9440(10)63859-X; Sumitomo M, 1999, J UROLOGY, V161, P674, DOI 10.1016/S0022-5347(01)61993-1; VAN AD, 1996, SCIENCE, V274, P787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WONG WT, 1995, P NATL ACAD SCI USA, V92, P9530, DOI 10.1073/pnas.92.21.9530; Zerbini LF, 2003, CANCER RES, V63, P2206	28	16	17	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2004	23	33					5607	5615		10.1038/sj.onc.1207750	http://dx.doi.org/10.1038/sj.onc.1207750			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KT	15184881	Green Published			2022-12-17	WOS:000222629500005
J	Pinte, S; Guerardel, C; Deltour-Balerdi, S; Godwin, AK; Leprince, D				Pinte, S; Guerardel, C; Deltour-Balerdi, S; Godwin, AK; Leprince, D			Identification of a second G-C-rich promoter conserved in the human, murine and rat tumor suppressor genes HIC1	ONCOGENE			English	Article						HIC1; 17p13.3; MDS; BTB/POZ; promoter; CpG island; 5 '-UTR	MILLER-DIEKER-SYNDROME; DNA METHYLATION; CHROMOSOME 17P13.3; BREAST-CANCER; EXPRESSION; HYPERMETHYLATION; REGION; MOUSE; MICE; P53	The BTB/POZ transcriptional repressor HIC1 (Hypermethylated in Cancer 1) is a tumor suppressor gene located at chromosome 17p13.3, a region frequently hypermethylated or deleted in human tumors and in a contiguous-gene syndrome, the Miller-Dieker syndrome. The human and murine HIC1 genes are composed of two alternative 5' exons, 1a and 1b fused to a large second coding exon 2. Exon 1a is a noncoding exon associated with a major G-C-rich promoter whereas exon 1b is a downstream coding exon associated with a minor TATA box promoter. By human-mouse genome comparison, we have identified a short upstream conserved sequence containing G-C boxes which were shown to be functional. Transcripts initiating from this new promoter were detected in various human and mouse tissues and contained a long 5'-UTR sequence, called 1c which encompass the G-C-rich promoter associated with exon 1a and uses the same splice donor site. RT-PCR analyses of two primary breast epithelial cell lines identified two other 5'-UTRs generated by alternative splicing within exon 1c. Our results thus highlight the existence of an unexpected complex transcriptional regulation of HIC1.	Inst Pasteur, Inst Biol Lille, CNRS, UMR 8526, F-59017 Lille, France; Fox Chase Canc Ctr, Dept Med Oncol, Philadelphia, PA 19111 USA	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Fox Chase Cancer Center	Leprince, D (corresponding author), Inst Pasteur, Inst Biol Lille, CNRS, UMR 8526, 1 Rue Calmette, F-59017 Lille, France.	dominique.leprince@ibl.fr		Leprince, Dominique/0000-0002-1999-0775	NCI NIH HHS [P50 CA83638] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA083638] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; Baylin SB, 1998, ADV CANCER RES, V72, P141; Bruening W, 1999, CANCER RES, V59, P4973; Carter MG, 2000, HUM MOL GENET, V9, P413, DOI 10.1093/hmg/9.3.413; Chen WY, 2003, NAT GENET, V33, P197, DOI 10.1038/ng1077; Deltour S, 1999, P NATL ACAD SCI USA, V96, P14831, DOI 10.1073/pnas.96.26.14831; Feltus FA, 2003, P NATL ACAD SCI USA, V100, P12253, DOI 10.1073/pnas.2037852100; Fujii H, 1998, ONCOGENE, V16, P2159, DOI 10.1038/sj.onc.1201976; Grimm C, 1999, HUM MOL GENET, V8, P697, DOI 10.1093/hmg/8.4.697; Guerardel C, 2001, J BIOL CHEM, V276, P3078, DOI 10.1074/jbc.M008690200; Han BG, 2003, ONCOGENE, V22, P5325, DOI 10.1038/sj.onc.1206783; Kanai Y, 1999, HEPATOLOGY, V29, P703, DOI 10.1002/hep.510290338; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Liscia DS, 1999, BRIT J CANCER, V80, P821, DOI 10.1038/sj.bjc.6690427; MAKOSWALES M, 1995, NAT MED, V1, P570; Melki JR, 1999, LEUKEMIA, V13, P877, DOI 10.1038/sj.leu.2401401; Phillips NJ, 1996, CANCER LETT, V102, P85, DOI 10.1016/0304-3835(96)04169-9; Rood BR, 2002, CANCER RES, V62, P3794; Schultz DC, 1996, CANCER RES, V56, P1997; Yingling J, 2003, AM J HUM GENET, V73, P475, DOI 10.1086/378096; Yuasa Y, 2002, MECH AGEING DEV, V123, P1649, DOI 10.1016/S0047-6374(02)00100-8	22	16	16	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2004	23	22					4023	4031		10.1038/sj.onc.1207504	http://dx.doi.org/10.1038/sj.onc.1207504			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	820IQ	15007385				2022-12-17	WOS:000221382000015
J	Matsubara, S; Ozawa, M				Matsubara, S; Ozawa, M			Expression of alpha-catenin in alpha-catenin-deficient cells results in a reduced proliferation in three-dimensional multicellular spheroids but not in two-dimensional monolayer cultures	ONCOGENE			English	Article						alpha-catenin; cadherin; proliferation; compaction; multicellular spheroids	ANCHORAGE-INDEPENDENT GROWTH; E-CADHERIN FUNCTION; BETA-CATENIN; CONTACT INHIBITION; ALKYLATING-AGENTS; ADHESION COMPLEX; EPITHELIAL-CELLS; DEPENDENT KINASE; CARCINOMA-CELLS; PROSTATE-CANCER	alpha-Catenin is an intracellular protein that associates with the carboxy-terminal region of cadherin, a cell adhesion molecule, via beta-catenin or gamma-catenin (plakoglobin). Linkage of cadherin to the cytoskeleton by catenins is required for full cadherin activity. Following transfection of an alpha-catenin-deficient colon carcinoma cell line with a series of alpha-catenin constructs, we discovered that the restoration of alpha-catenin expression results in reduced proliferation in three-dimensional multicellular spheroids, but not in two-dimensional monolayer cultures. The cellular function of alpha-catenin has not been compared between cells in three- and two-dimensional culture; this is the first evidence that growth regulation in three- dimensional cultures requires signaling mediated by alpha-catenin. Two classes of constructs, containing deletions in either the central segment or the COOH terminus of the molecule, both induced morphological changes, including cell compaction, and suppressed cell growth in three- dimensional cultures. In alpha-catenin-expressing cells, inhibition of cadherin cell adhesion by treatment with anti-E-cadherin antibodies resulted in a similar phenotype as that observed following the loss of alpha-catenin. Therefore, both the homophilic interaction of the cadherin extracellular domain and the linkage of the cadherin cytoplasmic domain to the actin cytoskeleton by alpha-catenin are necessary for growth control in three- dimensional culture.	Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Biochem & Mol Biol, Kagoshima 8908544, Japan	Kagoshima University	Matsubara, S (corresponding author), Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Biochem & Mol Biol, Kagoshima 8908544, Japan.	shmlmcbd@m.kufm.kagoshima-u.ac.jp						ALLEY MC, 1988, CANCER RES, V48, P589; Anttila M, 1998, J CLIN ONCOL, V16, P2591, DOI 10.1200/JCO.1998.16.8.2591; Bracke ME, 1997, EUR J CELL BIOL, V74, P342; Bullions LC, 1997, MOL CELL BIOL, V17, P4501, DOI 10.1128/MCB.17.8.4501; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Che XM, 1999, ONCOLOGY-BASEL, V57, P131, DOI 10.1159/000012020; Espada J, 1999, J CELL BIOL, V146, P967, DOI 10.1083/jcb.146.5.967; EWING CM, 1995, CANCER RES, V55, P4813; FUKAZAWA H, 1995, ANAL BIOCHEM, V228, P83, DOI 10.1006/abio.1995.1318; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; HYAFIL F, 1980, CELL, V21, P927, DOI 10.1016/0092-8674(80)90456-0; Kantak SS, 1998, J BIOL CHEM, V273, P16953, DOI 10.1074/jbc.273.27.16953; Kato A, 1997, J BIOL CHEM, V272, P8065, DOI 10.1074/jbc.272.12.8065; KEMLER R, 1977, P NATL ACAD SCI USA, V74, P4449, DOI 10.1073/pnas.74.10.4449; KOBAYASHI H, 1993, P NATL ACAD SCI USA, V90, P3294, DOI 10.1073/pnas.90.8.3294; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lampugnani MG, 2003, J CELL BIOL, V161, P793, DOI 10.1083/jcb.200209019; Maeno Y, 1999, AM J PATHOL, V154, P1323, DOI 10.1016/S0002-9440(10)65385-0; Matsubara S, 2001, J CELL BIOL, V154, P573, DOI 10.1083/jcb.200103097; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Nakopoulou L, 2002, HISTOPATHOLOGY, V40, P536, DOI 10.1046/j.1365-2559.2002.01392.x; Obama H, 1997, J BIOL CHEM, V272, P11017; Ohkubo T, 1999, J BIOL CHEM, V274, P21409, DOI 10.1074/jbc.274.30.21409; Ozawa M, 1998, J BIOL CHEM, V273, P29524, DOI 10.1074/jbc.273.45.29524; Pece S, 1999, J BIOL CHEM, V274, P19347, DOI 10.1074/jbc.274.27.19347; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Raftopoulos I, 1998, J SURG ONCOL, V68, P92, DOI 10.1002/(SICI)1096-9098(199806)68:2<92::AID-JSO4>3.0.CO;2-F; Roe S, 1998, CELL ADHES COMMUN, V5, P283, DOI 10.3109/15419069809040298; Ropponen KM, 1999, J CLIN PATHOL, V52, P10, DOI 10.1136/jcp.52.1.10; Shimazui T, 1997, INT J CANCER, V74, P523, DOI 10.1002/(SICI)1097-0215(19971021)74:5<523::AID-IJC8>3.0.CO;2-5; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; St Croix B, 1998, J CELL BIOL, V142, P557, DOI 10.1083/jcb.142.2.557; SURANI MAH, 1980, EXP CELL RES, V125, P275, DOI 10.1016/0014-4827(80)90123-8; SUTHERLAND RM, 1988, SCIENCE, V240, P177, DOI 10.1126/science.2451290; TAKEICHI M, 1977, J CELL BIOL, V75, P464, DOI 10.1083/jcb.75.2.464; TEICHER BA, 1990, SCIENCE, V247, P1457, DOI 10.1126/science.2108497; Tran NL, 2002, J BIOL CHEM, V277, P32905, DOI 10.1074/jbc.M200300200; Umbas R, 1997, INT J CANCER, V74, P374, DOI 10.1002/(SICI)1097-0215(19970822)74:4<374::AID-IJC2>3.0.CO;2-S; Vasioukhin V, 2001, CELL, V104, P605, DOI 10.1016/S0092-8674(01)00246-X; VERMEULEN SJ, 1995, CANCER RES, V55, P4722; VESTWEBER D, 1985, EMBO J, V4, P3393, DOI 10.1002/j.1460-2075.1985.tb04095.x; WATABE M, 1994, J CELL BIOL, V127, P247, DOI 10.1083/jcb.127.1.247; Watabe-Uchida M, 1998, J CELL BIOL, V142, P847, DOI 10.1083/jcb.142.3.847; Winston J, 1996, J BIOL CHEM, V271, P11253, DOI 10.1074/jbc.271.19.11253; Woodfield RJ, 2001, BIOCHEM J, V360, P335, DOI 10.1042/0264-6021:3600335	47	16	16	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2004	23	15					2694	2702		10.1038/sj.onc.1207423	http://dx.doi.org/10.1038/sj.onc.1207423			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	810OZ	14755240				2022-12-17	WOS:000220714900011
J	Farhana, L; Dawson, MI; Huang, Y; Zhang, YX; Rishi, AK; Reddy, KB; Freeman, RS; Fontana, JA				Farhana, L; Dawson, MI; Huang, Y; Zhang, YX; Rishi, AK; Reddy, KB; Freeman, RS; Fontana, JA			Apoptosis signaling by the novel compound 3-Cl-AHPC involves increased EGFR proteolysis and accompanying decreased phosphatidylinositol 3-kinase and AKT kinase activities	ONCOGENE			English	Article						3-Cl-AHPC; CD437/AHPN; PI3-K; AKT; EGFR	PROSTATE CARCINOMA-CELLS; GROWTH-FACTOR RECEPTOR; SYNTHETIC RETINOID CD437; INTEGRIN-LINKED KINASE; NF-KAPPA-B; PROTEIN-KINASE; CANCER CELLS; PHOSPHOINOSITIDE 3-KINASE; CELLULAR-SURVIVAL; ACTIVATION	The threonine and serine protein kinase AKT plays a major role in inhibiting apoptosis in a number of malignant cell types including prostate and breast carcinoma. Activation of AKT is a complex process involving translocation to the plasma membrane and phosphorylation of serine and threonine amino-acid residues. We now report that the novel compound 4-[3(1-adamantyl)-4-hydroxyphenyl]-3-chlorocinnamic acid (3-Cl-AHPC), induces apoptosis in breast and prostate carcinoma cells and inhibits AKT activity in these cells. Overexpression of a constitutively activated AKT inhibits 3-Cl-AHPC-mediated apoptosis. Decrease in AKT activity occurs through 3-Cl-AHPC inhibition of phosphatidylinositol 3 kinase (PI3-K) activity. 3-Cl-AHPC inhibits PI3-K activity by enhancing epidermal growth factor receptor ( EGFR) proteolysis and thus inhibiting EGFR association with the p85 subunit of PI3-K. 3-Cl-AHPC-mediated decrease in PI3-K activity results in the reduced synthesis of phosphatidylinositol 3,4 bisphosphate and phosphatidylinositol 3,4,5 triphosphate with the subsequent inhibition of integrin-linked kinase activity and serine-473 phosphorylation of AKT. Overexpression of EGFR results in increased AKT activity and inhibition of 3-Cl-AHPC-mediated decrease in AKT activation, AKT activity and 3-Cl-AHPC-mediated apoptosis. Inhibition of AKT activity by this compound results in the inability of AKT to phosphorylate and inactivate the proapoptotic forkhead transcription factor.	Wayne State Univ, John D Dingell VA Med Ctr, Karmanos Canc Inst, Dept Internal Med, Detroit, MI 48201 USA; Burnham Inst, La Jolla, CA 92037 USA; SUNY, Upstate Med Univ, Dept Pharmacol, Syracuse, NY 13210 USA; Wayne State Univ, Dept Pathol, Detroit, MI 48201 USA; Univ Rochester, Dept Physiol & Pharmacol, Rochester, NY 14642 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University; Sanford Burnham Prebys Medical Discovery Institute; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; SUNY Maritime College; Wayne State University; University of Rochester	Fontana, JA (corresponding author), Wayne State Univ, John D Dingell VA Med Ctr, Karmanos Canc Inst, Dept Internal Med, Room C3687,4646 John R, Detroit, MI 48201 USA.	Joseph.Fontana@Med.VA.Gov		Fontana, Joseph/0000-0003-3829-3358	NATIONAL CANCER INSTITUTE [P01CA051993] Funding Source: NIH RePORTER; NCI NIH HHS [P0 CA51993] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agarwal R, 2000, BIOCHEM PHARMACOL, V60, P1051, DOI 10.1016/S0006-2952(00)00385-3; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; AUGER KR, 1990, METHODS INOSITIDE RE; Ayllon V, 2000, MOL MEMBR BIOL, V17, P65; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Balmer LA, 2001, MOL CELL BIOL, V21, P2070, DOI 10.1128/MCB.21.6.2070-2084.2001; Brognard J, 2001, CANCER RES, V61, P3986; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Charpentier B, 1995, J MED CHEM, V38, P4993, DOI 10.1021/jm00026a006; Chen RH, 1998, ONCOGENE, V17, P1959, DOI 10.1038/sj.onc.1202111; Crowder RJ, 1998, J NEUROSCI, V18, P2933; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Davies MA, 1999, CANCER RES, V59, P2551; de Medina SGD, 1998, HUM PATHOL, V29, P1005, DOI 10.1016/S0046-8177(98)90208-8; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Domin J, 1997, FEBS LETT, V410, P91, DOI 10.1016/S0014-5793(97)00617-0; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Ettenberg S A, 1999, Mol Cell Biol Res Commun, V2, P111, DOI 10.1006/mcbr.1999.0157; Farhana L, 2002, CANCER RES, V62, P3842; Ghosh AK, 1999, GENE, V235, P85, DOI 10.1016/S0378-1119(99)00206-1; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Hausler P, 1998, EUR J IMMUNOL, V28, P57, DOI 10.1002/(SICI)1521-4141(199801)28:01<57::AID-IMMU57>3.0.CO;2-8; Holmes WF, 2000, J CELL PHYSIOL, V185, P61, DOI 10.1002/1097-4652(200010)185:1<61::AID-JCP5>3.0.CO;2-0; Hsu AL, 2000, J BIOL CHEM, V275, P11397, DOI 10.1074/jbc.275.15.11397; Inukai I, 2001, FEBS LETT, V490, P32, DOI 10.1016/S0014-5793(01)02132-9; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KAPELLER R, 1994, J BIOL CHEM, V269, P1927; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Khwaja A, 1999, NATURE, V401, P33, DOI 10.1038/43354; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; LAZEBNIK Y, 2000, SCIENCE, V287, pA1363; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; LEVYTOLEDANO R, 1994, J BIOL CHEM, V269, P31178; Li XS, 1996, CANCER RES, V56, P5055; Liang JY, 1999, PROSTATE, V38, P228; Lin JQ, 1999, CANCER RES, V59, P2891; Pacold ME, 2000, CELL, V103, P931, DOI 10.1016/S0092-8674(00)00196-3; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Philpott KL, 1997, J CELL BIOL, V139, P809, DOI 10.1083/jcb.139.3.809; Ponzanelli I, 2000, BLOOD, V95, P2672; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Rong R, 2002, ONCOGENE, V21, P1062, DOI 10.1038/sj.onc.1205154; Rubiol I, 1999, EUR J BIOCHEM, V266, P70, DOI 10.1046/j.1432-1327.1999.00815.x; Schwartz S, 1999, INT J ONCOL, V14, P367; SHAO ZM, 1995, ONCOGENE, V11, P493; SJOLANDER A, 1991, P NATL ACAD SCI USA, V88, P7908, DOI 10.1073/pnas.88.18.7908; SOLER C, 1994, J BIOL CHEM, V269, P12320; SOOK E, 2002, EMBO J, V21, P4796; Sun SY, 2000, MOL PHARMACOL, V58, P508, DOI 10.1124/mol.58.3.508; Sun SY, 2000, ONCOGENE, V19, P4513, DOI 10.1038/sj.onc.1203810; Tang D, 2001, J BIOL CHEM, V276, P30461, DOI 10.1074/jbc.M102045200; Tiganis T, 1999, J BIOL CHEM, V274, P27768, DOI 10.1074/jbc.274.39.27768; Toker A, 2000, MOL PHARMACOL, V57, P652, DOI 10.1124/mol.57.4.652; Wan XL, 2001, J MOL MED, V79, P143, DOI 10.1007/s001090100201; YAMAMOTO K, 1992, ENDOCRINOLOGY, V130, P1490, DOI 10.1210/en.130.3.1490; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang YX, 2002, BLOOD, V100, P2917, DOI 10.1182/blood.V100.8.2917; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X; ZHENG Y, 1994, J BIOL CHEM, V269, P18727	70	16	16	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 11	2004	23	10					1874	1884		10.1038/sj.onc.1207311	http://dx.doi.org/10.1038/sj.onc.1207311			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	801XV	14981538				2022-12-17	WOS:000220129500009
J	Cencig, S; Nanbru, C; Le, SY; Gueydan, C; Huez, G; Kruys, V				Cencig, S; Nanbru, C; Le, SY; Gueydan, C; Huez, G; Kruys, V			Mapping and characterization of the minimal internal ribosome entry segment in the human c-myc mRNA 5 ' untranslated region	ONCOGENE			English	Article						translation; IRES; proto-oncogene; c-myc	SITE-MEDIATED TRANSLATION; 5' UNTRANSLATED REGION; GROWTH-FACTOR; CELL-CYCLE; ALTERNATIVE TRANSLATION; PROTEIN-SYNTHESIS; INITIATION; TRANSCRIPTION; BINDING; IDENTIFICATION	The human c-myc proto-oncogene is transcribed from four alternative promoters generating transcripts with 5' untranslated regions of various lengths. These transcripts encode two proteins, c-Myc1 and c-Myc2, from two initiation codons, CUG and AUG, respectively. We and others have previously demonstrated that the region of c-myc transcripts between nucleotides (nt) -363 and -94 upstream from the CUG start codon contained an internal ribosome entry site leading to the cap-independent translation of c-myc open reading frames (ORFs). Here, we mapped a 50-nt sequence (-143 -94), which is sufficient to promote internal translation initiation of c-myc ORFs. Interestingly, this 50-nt element can be further dissected into two segments of 14 nt, each capable of activating internal translation initiation. We also demonstrate that this 50-nt element acts as the ribosome landing site from which the preinitiation ribosomal complex scans the mRNA until the CUG or AUG start codons.	Free Univ Brussels, Inst Biol & Med Mol, Chim Biol Lab, B-6041 Gosselies, Belgium; NCI, Lab Expt & Computat Biol, Ctr Canc Res, NIH, Frederick, MD 21701 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kruys, V (corresponding author), Free Univ Brussels, Inst Biol & Med Mol, Chim Biol Lab, Rue Profs Jeener & Brachet 12, B-6041 Gosselies, Belgium.	vkruys@ulb.ac.be	Kruys, Veronique I/N-6613-2018	Kruys, Veronique/0000-0002-3144-5403; Gueydan, Cyril/0000-0003-3097-7667				Akiri G, 1998, ONCOGENE, V17, P227, DOI 10.1038/sj.onc.1202019; BENTLEY DL, 1986, MOL CELL BIOL, V6, P3481, DOI 10.1128/MCB.6.10.3481; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; Bernstein J, 1997, J BIOL CHEM, V272, P9356; BLACKWOOD EM, 1994, MOL BIOL CELL, V5, P597, DOI 10.1091/mbc.5.5.597; Chappell SA, 2000, P NATL ACAD SCI USA, V97, P1536, DOI 10.1073/pnas.97.4.1536; Cornelis S, 2000, MOL CELL, V5, P597, DOI 10.1016/S1097-2765(00)80239-7; Creancier L, 2001, MOL CELL BIOL, V21, P1833, DOI 10.1128/MCB.21.5.1833-1840.2001; Galy B, 2001, ONCOGENE, V20, P4613, DOI 10.1038/sj.onc.1204630; HANN SR, 1992, GENE DEV, V6, P1229, DOI 10.1101/gad.6.7.1229; HANN SR, 1994, GENE DEV, V8, P2441, DOI 10.1101/gad.8.20.2441; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; Henis-Korenblit S, 2000, MOL CELL BIOL, V20, P496, DOI 10.1128/MCB.20.2.496-506.2000; Holcik M, 2003, MOL CELL BIOL, V23, P280, DOI 10.1128/MCB.23.1.280-288.2003; Holcik M, 2000, MOL CELL BIOL, V20, P4648, DOI 10.1128/MCB.20.13.4648-4657.2000; Holcik M, 1999, NAT CELL BIOL, V1, P190, DOI 10.1038/11109; Hu MCY, 1999, P NATL ACAD SCI USA, V96, P1339, DOI 10.1073/pnas.96.4.1339; Huez I, 1998, MOL CELL BIOL, V18, P6178, DOI 10.1128/MCB.18.11.6178; JACKSON RJ, 1988, NATURE, V334, P292, DOI 10.1038/334292a0; Jackson RJ, 1995, RNA, V1, P985; Johannes G, 1999, P NATL ACAD SCI USA, V96, P13118, DOI 10.1073/pnas.96.23.13118; Johannes G, 1998, RNA, V4, P1500, DOI 10.1017/S1355838298981080; KAMINSKI A, 1990, EMBO J, V9, P3753, DOI 10.1002/j.1460-2075.1990.tb07588.x; Kim JH, 2003, MOL CELL BIOL, V23, P708, DOI 10.1128/MCB.23.2.708-720.2003; KRUYS V, 1993, J EXP MED, V177, P1383, DOI 10.1084/jem.177.5.1383; Le Quesne JPC, 2001, J MOL BIOL, V310, P111, DOI 10.1006/jmbi.2001.4745; Le SY, 1996, VIRUS GENES, V12, P135, DOI 10.1007/BF00572952; Le SY, 1997, NUCLEIC ACIDS RES, V25, P362, DOI 10.1093/nar/25.2.362; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; Mitchell SA, 2003, MOL CELL, V11, P757, DOI 10.1016/S1097-2765(03)00093-5; Mitchell SA, 2001, MOL CELL BIOL, V21, P3364, DOI 10.1128/MCB.21.10.3364-3374.2001; Nanbru C, 2001, ONCOGENE, V20, P4270, DOI 10.1038/sj.onc.1204548; Nanbru C, 1997, J BIOL CHEM, V272, P32061, DOI 10.1074/jbc.272.51.32061; Obaya AJ, 1999, ONCOGENE, V18, P2934, DOI 10.1038/sj.onc.1202749; Owens GC, 2001, P NATL ACAD SCI USA, V98, P1471, DOI 10.1073/pnas.98.4.1471; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; PRATS AC, 1992, MOL CELL BIOL, V12, P4796, DOI 10.1128/MCB.12.10.4796; Pyronnet S, 2000, MOL CELL, V5, P607, DOI 10.1016/S1097-2765(00)80240-3; Ryan KM, 1996, BIOCHEM J, V314, P713, DOI 10.1042/bj3140713; Sella O, 1999, MOL CELL BIOL, V19, P5429; SPENCER CA, 1990, GENE DEV, V4, P75, DOI 10.1101/gad.4.1.75; Stoneley M, 2000, MOL CELL BIOL, V20, P1162, DOI 10.1128/MCB.20.4.1162-1169.2000; Stoneley M, 1998, ONCOGENE, V16, P423, DOI 10.1038/sj.onc.1201763; Subkhankulova T, 2001, BIOCHEM J, V359, P183, DOI 10.1042/0264-6021:3590183; Teerink H, 1995, BBA-GENE STRUCT EXPR, V1264, P403, DOI 10.1016/0167-4781(95)00185-9; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; Willis AE, 1999, INT J BIOCHEM CELL B, V31, P73, DOI 10.1016/S1357-2725(98)00133-2	48	16	18	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	2004	23	1					267	277		10.1038/sj.onc.1207017	http://dx.doi.org/10.1038/sj.onc.1207017			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712232				2022-12-17	WOS:000187895300028
J	Takahashi, M; Mutoh, M; Shoji, Y; Kamanaka, Y; Naka, M; Maruyama, T; Sugimura, T; Wakabayashi, K				Takahashi, M; Mutoh, M; Shoji, Y; Kamanaka, Y; Naka, M; Maruyama, T; Sugimura, T; Wakabayashi, K			Transfection of K-ras(Asp12) cDNA markedly elevates IL-1 beta- and lipopolysaccharide-mediated inducible nitric oxide synthase expression in rat intestinal epithelial cells	ONCOGENE			English	Article						inducible nitric oxide synthase; K-ras; rat; IL-1 beta; lipopolysaccharide	FACTOR-KAPPA-B; ACTIVATED PROTEIN-KINASE; ABERRANT CRYPT FOCI; ELEMENT-BINDING PROTEIN; ONCOGENIC RAS; PRIMARY ASTROCYTES; TUMOR-GROWTH; CYCLIN D1; COLON; CANCER	Activating mutations of K-ras are frequent in colon tumors and aberrant crypt foci, and may play important roles in colon carcinogenesis. Here, we investigated the effects of a K-ras codon 12 mutation on inducible nitric oxide synthase ( iNOS) expression. When rat intestinal epithelial cells (IEC-6) were transfected with K-ras(Asp12) cDNA, the iNOS expression linked to interleukin-1beta (IL-1beta) or lipopolysaccharide (LPS) treatment was markedly increased and prolonged. In contrast, it was only very faint and transient in cells transfected with the control vector or K-ras(WT). Electrophoretic mobility-shift assays demonstrated that NF-kappaB binding activity induced by IL-1beta or LPS was also increased in K-ras(Asp12)-transfected cells, along with the bindingof CREB-1, CREM-1, ATF-1, ATF-2, and Jun D to a cAMP-responsive element (CRE)-like site and the bindingof C/EBPbeta to a C/EBP-binding consensus site. Furthermore, the anchorage-independent growth of K-ras(Asp12)-transfected cells was markedly increased by IL-1beta or LPS treatment, and decreased by ONO-1714, an iNOS inhibitor. In addition, tumor growth in nude mice injected with K-ras(Asp12)-transfected cells was significantly suppressed by NOS inhibition with 50 p. p. m. ONO-1714 or 100 p. p. m. L-N-G-nitroarginine methyl ester. These results suggest that an activating mutation of K-ras can markedly enhance the iNOS expression mediated by IL-1beta or LPS, through the activation of promoters on NF-kappaB, C/EBP, and CRE-like sites, and that nitric oxide contributes to the colony formation and tumor growth of K-ras-transformed cells.	Natl Canc Ctr, Res Inst, Canc Prevent Basic Res Project, Chuo Ku, Tokyo 1040045, Japan; Ono Pharmaceut Co Ltd, Minase Res Inst, Shimamoto, Osaka 6188585, Japan	National Cancer Center - Japan; Ono Pharmaceutical Co Ltd	Takahashi, M (corresponding author), Natl Canc Ctr, Res Inst, Canc Prevent Basic Res Project, Chuo Ku, 1-1 Tsukiji 5 Chome, Tokyo 1040045, Japan.		Mutoh, Michihiro/AAB-1868-2022	Takahashi, Mami/0000-0001-5062-811X				Adjei AA, 2001, JNCI-J NATL CANCER I, V93, P1062, DOI 10.1093/jnci/93.14.1062; Ambs S, 1998, CANCER RES, V58, P334; Arsura M, 2000, MOL CELL BIOL, V20, P5381, DOI 10.1128/MCB.20.15.5381-5391.2000; Bhat NR, 2002, J BIOL CHEM, V277, P29584, DOI 10.1074/jbc.M204994200; Bissonnette M, 2000, CANCER RES, V60, P4602; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Cirillo G, 1999, MOL CELL BIOL, V19, P6240; D'Amico M, 2000, J BIOL CHEM, V275, P32649, DOI 10.1074/jbc.M000643200; Eberhardt W, 1998, J IMMUNOL, V160, P4961; HIGINBOTHAM KG, 1994, ONCOGENE, V9, P2455; ICHII S, 1993, ONCOGENE, V8, P2399; INOUE Y, 1991, JPN J CANCER RES, V82, P90, DOI 10.1111/j.1349-7006.1991.tb01751.x; IRITANI A, 1986, Bulletin of Tokyo Medical and Dental University, V33, P35; JENKINS DC, 1995, P NATL ACAD SCI USA, V92, P4392, DOI 10.1073/pnas.92.10.4392; Jiang BB, 2001, ARTERIOSCL THROM VAS, V21, P1915, DOI 10.1161/hq1201.099424; Kawamori T, 2000, CANCER LETT, V148, P33, DOI 10.1016/S0304-3835(99)00310-9; Kawasaki H, 2000, NATURE, V405, P195, DOI 10.1038/35012097; Keinanen R, 1999, GENE, V234, P297, DOI 10.1016/S0378-1119(99)00196-1; Kiechle FL, 1996, ANN CLIN LAB SCI, V26, P501; Kojima M, 2000, ONCOGENE, V19, P1225, DOI 10.1038/sj.onc.1203427; Liu CY, 1998, BRIT J CANCER, V78, P534, DOI 10.1038/bjc.1998.528; Mifflin RC, 2002, AM J PHYSIOL-CELL PH, V282, pC824, DOI 10.1152/ajpcell.00388.2001; Naka M, 2000, BIOCHEM BIOPH RES CO, V270, P663, DOI 10.1006/bbrc.2000.2474; Norris JL, 1999, J BIOL CHEM, V274, P13841, DOI 10.1074/jbc.274.20.13841; Pahan K, 1997, J CLIN INVEST, V100, P2671, DOI 10.1172/JCI119812; Pahan K, 2000, J NEUROCHEM, V74, P2288, DOI 10.1046/j.1471-4159.2000.0742288.x; QUARONI A, 1979, J CELL BIOL, V80, P248, DOI 10.1083/jcb.80.2.248; Rahmani M, 2001, ONCOGENE, V20, P5132, DOI 10.1038/sj.onc.1204678; Rao CV, 1999, CARCINOGENESIS, V20, P641, DOI 10.1093/carcin/20.4.641; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shao JY, 2000, J BIOL CHEM, V275, P33951, DOI 10.1074/jbc.M002324200; Sheng HM, 2001, CANCER RES, V61, P2670; Singh K, 1996, J BIOL CHEM, V271, P1111, DOI 10.1074/jbc.271.2.1111; Slice LW, 2000, BIOCHEM BIOPH RES CO, V276, P406, DOI 10.1006/bbrc.2000.3487; Takahashi M, 2000, CARCINOGENESIS, V21, P1319, DOI 10.1093/carcin/21.7.1319; Takahashi M, 1997, CANCER RES, V57, P1233; Tannous M, 2001, BIOCHEM PHARMACOL, V62, P1459, DOI 10.1016/S0006-2952(01)00818-8; Thomsen LL, 1997, CANCER RES, V57, P3300; Vickers SM, 1999, ARCH SURG-CHICAGO, V134, P245, DOI 10.1001/archsurg.134.3.245; YAMASHITA N, 1995, GASTROENTEROLOGY, V108, P434, DOI 10.1016/0016-5085(95)90071-3	40	16	16	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 23	2003	22	48					7667	7676		10.1038/sj.onc.1207051	http://dx.doi.org/10.1038/sj.onc.1207051			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	735KQ	14576830				2022-12-17	WOS:000186113000015
J	Takeuchi, S; Seriu, T; van Dongen, JJM; Szczepanski, T; Tsukasaki, K; Takeuchi, N; Fermin, AC; Seo, H; Bartram, CR; Koeffler, HP				Takeuchi, S; Seriu, T; van Dongen, JJM; Szczepanski, T; Tsukasaki, K; Takeuchi, N; Fermin, AC; Seo, H; Bartram, CR; Koeffler, HP			Allelotype analysis in relapsed childhood acute lymphoblastic leukemia	ONCOGENE			English	Article						LOH; ALL; 9p; 12p	2 DISTINCT REGIONS; INITIAL DIAGNOSIS; FREQUENT LOSS; LONG ARM; DELETION; ABNORMALITIES; HETEROZYGOSITY; IDENTIFICATION; CHILDREN; TEL	We performed for the first time the allelotype of relapsed childhood acute lymphoblastic leukemia ( ALL). A total of 38 cases were screened for loss of heterozygosity (LOH) using 71 markers. In all, 26 (68%) patients showed LOH on at least one chromosomal arm, indicating that LOH is a frequent event at relapse. The most frequent loss was found on chromosomal arm 9p at the p16/INK4a locus (39%). LOH at the TEL gene locus on chromosomal arm 12p also occurred often (25%). Frequent loss was observed on chromosome arms 4q (20%), 6q (21%), and 17q (20%). Sequential analysis (i.e. samples obtained from both initial diagnosis and relapse) shows that some patients (63%) have the identical LOH status at both phases, suggesting the presence of the same clone. Other samples (37%) showed distinct LOH alterations, indicating clonal evolution at relapse. Despite the heterogeneous and complex changes, some shared LOH loci occurred in these matched samples, suggesting that many of the same tumor-suppressor genes are aberrant at both phases. In summary, novel tumor-suppressor genes on chromosome arms 4q, 6q, and 17q, as well as the p16 and TEL genes, have an important role in the relapse of childhood ALL.	Kochi Med Sch, Dept Med, Nanko Ku, Kochi 7838505, Japan; Heidelberg Univ, Inst Human Genet, D-69120 Heidelberg, Germany; Erasmus Univ, Dept Immunol, NL-3000 DR Rotterdam, Netherlands; L Warynski Silesian Med Acad, Dept Pediat Hematol & Chemotherapy, Zabrze, Poland; Univ Calif Los Angeles, Sch Med, Cedars Sinai Res Inst, Div Hematol Oncol, Los Angeles, CA 90048 USA	Kochi University; Ruprecht Karls University Heidelberg; Erasmus University Rotterdam; Medical University Silesia; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Takeuchi, S (corresponding author), Kochi Med Sch, Dept Med, Nanko Ku, Kochi 7838505, Japan.	takeuti@kochi-ms.ac.jp	van Dongen, Jacques J.M./F-8537-2015	van Dongen, Jacques J.M./0000-0001-7686-0021; Szczepanski, Tomasz/0000-0001-5336-261X; van Dongen, Jacques J.M./0000-0002-3650-7087				CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; Carter TL, 2001, BRIT J HAEMATOL, V113, P323, DOI 10.1046/j.1365-2141.2001.02729.x; Gaynon PS, 1998, CANCER, V82, P1387, DOI 10.1002/(SICI)1097-0142(19980401)82:7<1387::AID-CNCR24>3.0.CO;2-1; Gerard B, 1997, LEUKEMIA, V11, P228, DOI 10.1038/sj.leu.2400566; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; Harrison CJ, 2001, BLOOD REV, V15, P49, DOI 10.1054/blre.2001.0150; HEEREMA NA, 1992, LEUKEMIA, V6, P185; Heerema NA, 1999, BLOOD, V94, P1537; Heerema NA, 2000, CANCER-AM CANCER SOC, V88, P1945, DOI 10.1002/(SICI)1097-0142(20000415)88:8<1945::AID-CNCR25>3.0.CO;2-6; HEIM S, 1988, CANCER RES, V48, P5911; KAMELREID S, 1991, BLOOD, V78, P2973; Kamps WA, 2002, LEUKEMIA, V16, P1099, DOI 10.1038/sj.leu.2402489; Maloney KW, 1999, BLOOD, V93, P2380, DOI 10.1182/blood.V93.7.2380.407k27_2380_2385; McLean TW, 1996, BLOOD, V88, P4252; OKUDA T, 1995, BLOOD, V85, P2321, DOI 10.1182/blood.V85.9.2321.bloodjournal8592321; RAIMONDI SC, 1993, BLOOD, V81, P2237; Schrappe M, 2000, BLOOD, V95, P3310; SHIKANO T, 1990, LEUKEMIA, V4, P419; Shurtleff SA, 1995, LEUKEMIA, V9, P1985; STEGMAIER K, 1995, BLOOD, V86, P38, DOI 10.1182/blood.V86.1.38.bloodjournal86138; Szczepanski T, 2002, BLOOD, V99, P2315, DOI 10.1182/blood.V99.7.2315; Takeuchi S, 1997, LEUKEMIA, V11, P1220, DOI 10.1038/sj.leu.2400743; Takeuchi S, 1996, BLOOD, V87, P3368, DOI 10.1182/blood.V87.8.3368.bloodjournal8783368; Takeuchi S, 1998, CANCER RES, V58, P2618; Takeuchi S, 2003, LEUKEMIA, V17, P149, DOI 10.1038/sj.leu.2402727; Takeuchi S, 1997, LEUKEMIA, V11, P1636, DOI 10.1038/sj.leu.2400817; TAKEUCHI S, 1995, CANCER RES, V55, P5377; Takeuchi S, 1999, ONCOGENE, V18, P7387, DOI 10.1038/sj.onc.1203145; TAKEUCHI S, 1995, BLOOD, V86, P755, DOI 10.1182/blood.V86.2.755.bloodjournal862755	29	16	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	2003	22	44					6970	6976		10.1038/sj.onc.1206974	http://dx.doi.org/10.1038/sj.onc.1206974			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	730RH	14534546				2022-12-17	WOS:000185843400020
J	Sirri, V; Leibovitch, MP; Leibovitch, SA				Sirri, V; Leibovitch, MP; Leibovitch, SA			Muscle regulatory factor MRF4 activates differentiation in rhabdomyosarcoma RD cells through a positive-acting C-terminal protein domain	ONCOGENE			English	Article						MRF4; rhabdomyosarcoma; transactivation domain; differentiation	KINASE-ACTIVITY; GENE; EXPRESSION; TRANSCRIPTION; INHIBITION; P38	Rhabdomyosarcoma (RMS) has deregulated proliferation and is blocked in the differentiation program despite Myf-5, MyoD and myogenin expression. Here we show that ectopic expression of MRF4, which is not subject to an autoregulatory pathway but regulated by the other MRFs protein family, induces growth arrest and terminal differentiation in RD cells. Deletion mapping identified a positive-acting C-terminal domain in MRF4 as the mediator of transcriptional activity, revealing a conserved motif with helix III in MyoD previously found to initiate expression of endogenous skeletal muscle genes. By using chimeric MyoD/MRF4 proteins, we observe that the G terminal motif of MRF4 rescues MyoD activity in RD cells. Moreover, comparative induction of muscle-specific genes following activation of MyoD, through the expression of a constitutively activated MKK6 either in the absence or presence of MRF4, shows that MyoD and MRF4 can differently regulate muscle genes expression. Together, these results demonstrate that the MRF4 G terminus functions as specification as well as activation domain in tumor cells. They provide a basis to identify gene products necessary for b-HLH-mediated differentiation versus tumor progression.	Inst Gustave Roussy, CNRS, UMR 8125, Lab Genet Oncol, F-94800 Villejuif, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Leibovitch, SA (corresponding author), Inst Gustave Roussy, CNRS, UMR 8125, Lab Genet Oncol, 39 Rue Camille Desmoulins, F-94800 Villejuif, France.	leibovit@igr.fr						Bergstrom DA, 2001, MOL CELL BIOL, V21, P2404, DOI 10.1128/MCB.21.7.2404-2412.2001; BLACK BL, 1995, J BIOL CHEM, V270, P2889, DOI 10.1074/jbc.270.7.2889; BOBER E, 1991, J CELL BIOL, V113, P1255, DOI 10.1083/jcb.113.6.1255; BUCKINGHAM M, 1994, CURR BIOL, V4, P61, DOI 10.1016/S0960-9822(00)00014-2; DIAZ P, 1992, CANCER RES, V52, P6431; EDMONDSON DG, 1993, J BIOL CHEM, V268, P755; FUJISAWASEHARA A, 1990, J BIOL CHEM, V265, P15219; HINTERBERGER TJ, 1991, DEV BIOL, V147, P144, DOI 10.1016/S0012-1606(05)80014-4; Knudsen ES, 1998, CANCER RES, V58, P2042; MAK KL, 1992, MOL CELL BIOL, V12, P4334, DOI 10.1128/MCB.12.10.4334; Meedel TH, 1997, DEVELOPMENT, V124, P1711; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; Otten AD, 1997, CELL GROWTH DIFFER, V8, P1151; Puri PL, 2000, GENE DEV, V14, P574; RAO SS, 1994, MOL CELL BIOL, V14, P5259, DOI 10.1128/MCB.14.8.5259; Rawls A, 1998, DEVELOPMENT, V125, P2349; Reynaud EG, 1999, MOL CELL BIOL, V19, P7621; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; Tajbakhsh S, 1997, CELL, V89, P127, DOI 10.1016/S0092-8674(00)80189-0; TAPSCOTT SJ, 1993, SCIENCE, V259, P1450, DOI 10.1126/science.8383879; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; Wu ZG, 2000, MOL CELL BIOL, V20, P3951, DOI 10.1128/MCB.20.11.3951-3964.2000; Zhang JM, 1999, EMBO J, V18, P6983, DOI 10.1093/emboj/18.24.6983	25	16	17	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2003	22	36					5658	5666		10.1038/sj.onc.1206690	http://dx.doi.org/10.1038/sj.onc.1206690			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	713NY	12944914				2022-12-17	WOS:000184865900015
J	Hoare, K; Hoare, S; Smith, OM; Kalmaz, G; Small, D; May, WS				Hoare, K; Hoare, S; Smith, OM; Kalmaz, G; Small, D; May, WS			Kos1, a nonreceptor tyrosine kinase that suppresses Ras signaling	ONCOGENE			English	Article						embryonic stem (ES) cells; nonreceptor protein tyrosine kinase (NRPTK); apoptosis; Ras; green fluorescent protein (GFP)	EMBRYONIC STEM-CELLS; HEMATOPOIETIC-CELLS; GTPASE ACTIVITY; GROWTH-FACTOR; PROTEIN-KINASES; MOUSE EMBRYOS; SH2 DOMAINS; IN-VITRO; BINDING; TRANSDUCTION	Kinase of embryonic stem cells (Kos1), a nonreceptor protein tyrosine kinase (NRPTK), was identified and cloned from differentiating murine embryonic stem cells. Kos1 is localized on mouse chromosome 11 that corresponds to human chromosome 17p13.1 and is homologous to Tnk1, Ack1 and Ack2, making it a new member of the Ack family of NRPTKs. Kos1 is a ubiquitously expressed 47-kDa protein with autotyrosine kinase activity that is developmentally regulated during embryogenesis. Kos1 is also upregulated following IL3 withdrawal from factor-dependent murine NSF/N1.H7 cells that undergo apoptosis, suggesting a role in growth inhibition. Stable overexpression of Kos1 inhibits growth of NIH 3T3 cells, while the kinase-dead Kos1(CN) promotes cell growth in both liquid culture and soft agar. In addition, forced expression of Kos1 inhibits Ras activity in an indirect mechanism that results in the downregulation of the Ras-Raf1-MAPK growth pathway. Furthermore, overexpression of Kos1 in NCI-H82 lung cancer cells that express oncogenic Ha-Ras(G12V) inhibits cell growth under reduced serum (0.5%) conditions in close association with the upregulation of the Ras inhibitor, Rap1A. Collectively, these data support a negative regulatory role for Kos1 in regulating the Ras-Raf1-MAPK growth pathway by a mechanism that requires its autotyrosine kinase activity.	Univ Florida, Shands Canc Ctr, Gainesville, FL 32610 USA; Univ Texas, Med Branch, Sealy Ctr Oncol & Hematol, Galveston, TX 77555 USA; Johns Hopkins Univ, Sch Med, Dept Oncol & Pediat, Baltimore, MD 21287 USA	State University System of Florida; University of Florida; University of Texas System; University of Texas Medical Branch Galveston; Johns Hopkins University	May, WS (corresponding author), Univ Florida, Shands Canc Ctr, 1600 SW Archer Rd, Gainesville, FL 32610 USA.			Small, Donald/0000-0002-3072-243X	NCI NIH HHS [CA44649] Funding Source: Medline; NHLBI NIH HHS [HL5408] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044649] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMREIN KE, 1992, P NATL ACAD SCI USA, V89, P3343, DOI 10.1073/pnas.89.8.3343; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; Avraham H, 2000, J HEMATOTH STEM CELL, V9, P425, DOI 10.1089/152581600419080; Barradas M, 1999, EMBO J, V18, P6362, DOI 10.1093/emboj/18.22.6362; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Ernst M, 1996, J BIOL CHEM, V271, P30136, DOI 10.1074/jbc.271.47.30136; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P5704, DOI 10.1073/pnas.81.18.5704; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Haucke V, 1999, SCIENCE, V285, P1268, DOI 10.1126/science.285.5431.1268; Higuchi R., 1989, PCR TECHNOLOGY, P61; Hoehn GT, 1996, ONCOGENE, V12, P903; Hole N, 1996, BLOOD, V88, P1266, DOI 10.1182/blood.V88.4.1266.bloodjournal8841266; Hopper NA, 2000, MOL CELL, V6, P65, DOI 10.1016/S1097-2765(00)00008-3; ISAKOV N, 1995, J EXP MED, V181, P375, DOI 10.1084/jem.181.1.375; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Laminet AA, 1996, J BIOL CHEM, V271, P264, DOI 10.1074/jbc.271.1.264; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Lin Q, 2002, J BIOL CHEM, V277, P10134, DOI 10.1074/jbc.M110329200; LLOYD AC, 1989, EMBO J, V8, P1099, DOI 10.1002/j.1460-2075.1989.tb03479.x; MANNE V, 1985, P NATL ACAD SCI USA, V82, P376, DOI 10.1073/pnas.82.2.376; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; Nakano T, 1996, SCIENCE, V272, P722, DOI 10.1126/science.272.5262.722; Neet K, 1996, GENES CELLS, V1, P147, DOI 10.1046/j.1365-2443.1996.d01-234.x; Neubauer H, 1998, CELL, V93, P397, DOI 10.1016/S0092-8674(00)81168-X; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Okada S, 1998, EMBO J, V17, P2554, DOI 10.1093/emboj/17.9.2554; OKUDA K, 1994, J BIOL CHEM, V269, P24602; Pandey A, 2000, J BIOL CHEM, V275, P38633, DOI 10.1074/jbc.M007849200; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; Sada K, 2001, J BIOCHEM-TOKYO, V130, P177, DOI 10.1093/oxfordjournals.jbchem.a002970; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Sambrook J., 1989, MOL CLONING, pA1; SATOH T, 1995, METHOD ENZYMOL, V255, P149; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schmitt JM, 2001, MOL CELL BIOL, V21, P3671, DOI 10.1128/MCB.21.11.3671-3683.2001; SCHMITT RM, 1991, GENE DEV, V5, P728, DOI 10.1101/gad.5.5.728; Sem KP, 2002, MOL CELL BIOL, V22, P3685, DOI 10.1128/MCB.22.11.3685-3697.2002; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; STAHL N, 1995, SCIENCE, V267, P1701; Sun HY, 2000, CURR BIOL, V10, P281, DOI 10.1016/S0960-9822(00)00359-6; Teo M, 2001, J BIOL CHEM, V276, P18392, DOI 10.1074/jbc.M008795200; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WILES MV, 1991, DEVELOPMENT, V111, P259; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0; Yamane T, 1997, BLOOD, V90, P3516, DOI 10.1182/blood.V90.9.3516; YANG JJ, 1998, MOL CELL BIOL, V17, P3850; Yang WN, 1997, J BIOL CHEM, V272, P24819, DOI 10.1074/jbc.272.40.24819; Yang WN, 2001, J BIOL CHEM, V276, P43987, DOI 10.1074/jbc.M104819200; Yang WN, 2001, J BIOL CHEM, V276, P17468, DOI 10.1074/jbc.M010893200	68	16	17	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 5	2003	22	23					3562	3577		10.1038/sj.onc.1206480	http://dx.doi.org/10.1038/sj.onc.1206480			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	687WD	12789265				2022-12-17	WOS:000183399200007
J	Bristow, RG; Peacock, J; Jang, A; Kim, J; Hill, RP; Benchimol, S				Bristow, RG; Peacock, J; Jang, A; Kim, J; Hill, RP; Benchimol, S			Resistance to DNA-damaging agents is discordant from experimental metastatic capacity in MEF ras-transformants-expressing gain of function MTp53	ONCOGENE			English	Article						p53; sensitivity; MEF; gain of function; metastasis; transformation	OF-FUNCTION MUTATIONS; P53 TUMOR-SUPPRESSOR; WILD-TYPE P53; REPAIR PATHWAYS; CELL-SURVIVAL; MUTANT FORMS; CORE DOMAIN; IN-VITRO; GENE; CHECKPOINT	Tumor cells can acquire aggressive phenotypes secondary to the loss of expression of the wild-type p53 (WTp53) protein or by the gain of function for selected mutant p53 (MTp53) proteins. However, it is unclear as to whether the development of aggressive phenotypes is inter-related. Herein we report the radiosensitivity, chemosensitivity, and in vivo growth characteristics of isogenic p53(-/-) MEF ras-transformants that variably express an MTp53 protein. Initial experiments revealed significant clonal heterogeneity with respect to cellular sensitivity to DNA-damaging agents (i.e. ionizing radiation, ultraviolet radiation, cis-platinum, and methotrexate) within subclones of a pre-existing p53(-/-) MEF cell population. Moreover, this differential sensitivity was also observed within suliclones of p53(-/-) MEF cells transformed with an activated ras allele, suggesting that secondary genetic events and clonal selection, but not cellular transformation per se, may drive the resistance patterns for certain null-p53 tumors. In contrast, uniform resistance was observed following the additional transfection of an MTp53 allele (MTp53pro193) into p53(-/-) MEF transformants and p53(-/-) DP-16 Friend erythroleukemia cells, consistent with a gain of MTp53 function for this allele. Relative tumor growth rate and experimental metastatic ability was not enhanced by MTp53pro193 expression. Our results support the concept that gain of MTp53pro193 function leads to the selection of dominant clones, which may exhibit cellular resistance following cancer therapy.	Univ Toronto, Princess Margaret Hosp, Univ Hlth Network,Ontario Canc Inst, Dept Radiat Oncol, Toronto, ON M5G 2M9, Canada; Univ Toronto, Princess Margaret Hosp, Univ Hlth Network,Ontario Canc Inst, Dept Med Biophys, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Bristow, RG (corresponding author), Univ Toronto, Princess Margaret Hosp, Univ Hlth Network,Ontario Canc Inst, Dept Radiat Oncol, 610 Univ Ave,Room 5-923, Toronto, ON M5G 2M9, Canada.			Hill, Richard Peter/0000-0001-5331-8045; Benchimol, Samuel/0000-0003-3433-890X; Bristow, Robert/0000-0002-8553-9544				Albor A, 1998, CANCER RES, V58, P2091; Bernstein C, 2002, MUTAT RES-REV MUTAT, V511, P145, DOI 10.1016/S1383-5742(02)00009-1; Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; Bristow RG, 1996, RADIOTHER ONCOL, V40, P197, DOI 10.1016/0167-8140(96)01806-3; Bristow RG, 1998, ONCOGENE, V16, P1789, DOI 10.1038/sj.onc.1201935; Bullock AN, 2000, ONCOGENE, V19, P1245, DOI 10.1038/sj.onc.1203434; Cadwell C, 2001, GENE, V277, P15, DOI 10.1016/S0378-1119(01)00696-5; Chang BD, 1999, ONCOGENE, V18, P4808, DOI 10.1038/sj.onc.1203078; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Gangopadhyay S, 2002, EXP CELL RES, V275, P122, DOI 10.1006/excr.2002.5493; Grant SW, 1998, CANCER DETECT PREV, V22, P185, DOI 10.1046/j.1525-1500.1998.0oa18.x; Gualberto A, 1998, P NATL ACAD SCI USA, V95, P5166, DOI 10.1073/pnas.95.9.5166; HARVEY M, 1993, ONCOGENE, V8, P2457; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; HSIAO M, 1994, AM J PATHOL, V145, P702; Illidge TM, 2000, CELL BIOL INT, V24, P621, DOI 10.1006/cbir.2000.0557; Iwamoto KS, 1996, CANCER RES, V56, P3862; Iwanaga Y, 2002, CANCER RES, V62, P2618; KIESER A, 1994, ONCOGENE, V9, P963; Kirsch DG, 1998, J CLIN ONCOL, V16, P3158, DOI 10.1200/JCO.1998.16.9.3158; Li RZ, 1998, ONCOGENE, V16, P3269, DOI 10.1038/sj.onc.1201867; LIN YP, 1995, MOL CELL BIOL, V15, P6045; Liu G, 2000, P NATL ACAD SCI USA, V97, P4174, DOI 10.1073/pnas.97.8.4174; Liu MC, 2002, SEMIN ONCOL, V29, P246, DOI 10.1053/sonc.2002.32900; Melchior F, 2002, CELL CYCLE, V1, P243, DOI 10.4161/cc.1.4.131; Monti P, 2002, ONCOGENE, V21, P1641, DOI 10.1038/sj.onc.1205250; Morris SM, 2002, MUTAT RES-REV MUTAT, V511, P45, DOI 10.1016/S1383-5742(01)00075-8; Offer H, 2001, ONCOGENE, V20, P581, DOI 10.1038/sj.onc.1204120; PEACOCK JW, 1995, MOL CELL BIOL, V15, P1446; POWELL SN, 1995, CANCER RES, V55, P1643; Pugacheva EN, 2002, ONCOGENE, V21, P4595, DOI 10.1038/sj.onc.1205704; Roth JA, 2001, ACTA ONCOL, V40, P739; Selivanova G, 2001, Curr Opin Investig Drugs, V2, P1136; Sharpless NE, 2002, CELL, V110, P9, DOI 10.1016/S0092-8674(02)00818-8; Sigal A, 2000, CANCER RES, V60, P6788; SLICHENMYER WJ, 1993, CANCER RES, V53, P4164; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; Smith ML, 2002, MUTAGENESIS, V17, P149, DOI 10.1093/mutage/17.2.149; Soussi T, 2001, NAT REV CANCER, V1, P233, DOI 10.1038/35106009; STRANO S, 2002, J BIOL CHEM, V13, P13; Takimoto R, 2002, CANCER BIOL THER, V1, P47, DOI 10.4161/cbt.1.1.41; Tang W, 1999, CANCER RES, V59, P2562; Tannock IF, 2001, BRIT J CANCER, V84, P100, DOI 10.1054/bjoc.2000.1538; van Oijen MGCT, 2000, CLIN CANCER RES, V6, P2138; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; Wiesmueller Lisa, 2001, Journal of Biomedicine and Biotechnology, V1, P7, DOI 10.1155/S1110724301000043	49	16	16	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 15	2003	22	19					2960	2966		10.1038/sj.onc.1206405	http://dx.doi.org/10.1038/sj.onc.1206405			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	677TY	12771947				2022-12-17	WOS:000182824800011
J	Merle, P; Barraud, L; Lefrancois, L; Chevallier, M; Guerret, S; Maisonnas, M; Bordes, I; Savre-Train, I; Trepo, C; Vitvitski-Trepo, L				Merle, P; Barraud, L; Lefrancois, L; Chevallier, M; Guerret, S; Maisonnas, M; Bordes, I; Savre-Train, I; Trepo, C; Vitvitski-Trepo, L			Long-term high-dose interferon-alpha therapy delays Hepadnavirus-related hepatocarcinogenesis in X/myc transgenic mice	ONCOGENE			English	Article						hepatocellular carcinoma; interferon; c-myc; proliferation	HEPATITIS-B-VIRUS; TELOMERASE REVERSE-TRANSCRIPTASE; C-MYC; HEPATOCELLULAR-CARCINOMA; NUCLEOTIDE-SEQUENCE; EXPRESSION; GENE; ACTIVATION; GROWTH; CANCER	The role of interferon-alpha (IFN-alpha) remains unclear in prevention of virus-induced hepatocellular carcinoma in humans. We have investigated it herewith in the X/myc transgenic mouse model of Hepadnavirus-related hepatocarcinogenesis because of upregulation of c-myc oncogene in the liver. We have demonstrated that IFN-alpha can downregulate dose-dependently hepatocyte proliferation and c-myc overexpression at early premalignant stages, while it does not affect either hepatocyte apoptosis or telomerase activity at these steps. However, continuous and long-term administration of IFN-alpha dose-dependently delays tumor onset in dysplastic livers and increases overall survival of animals, more efficiently whether started before the onset of dysplasia. The present study therefore highlights that early preventive administration of IFN-alpha can slow down evolution towards hepatocellular carcinoma via repression of c-myc and hepatocyte proliferation at premalignant steps in experimental c-myc-induced hepatocarcinogenesis. However, the transient effect observed in this study emphasizes a need to clarify the possible mechanisms of acquired resistance and subsequent therapeutic escape. Our experimental model may be a pertinent toot to explore antioncogenic properties of IFN-alpha in human cirrhotic livers showing c-myc upregulation.	INSERM, U271, F-69424 Lyon 03, France; Labs Marcel Merieux, Dept Anat Pathol, F-69365 Lyon 07, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Trepo, C (corresponding author), INSERM, U271, 151 Cours Albert Thomas, F-69003 Lyon, France.	trepo@lyon151.inserm.fr						BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; Blasco MA, 1996, NAT GENET, V12, P200, DOI 10.1038/ng0296-200; Buendia MA, 2000, SEMIN CANCER BIOL, V10, P185; CHAOUCHI N, 1994, CLIN IMMUNOL IMMUNOP, V73, P197, DOI 10.1006/clin.1994.1188; Cheng J, 2000, CANCER GENE THER, V7, P407, DOI 10.1038/sj.cgt.7700127; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Ebinuma H, 1999, INT J ONCOL, V15, P991; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; Einhorn S, 1996, J INTERF CYTOK RES, V16, P275, DOI 10.1089/jir.1996.16.275; ETIEMBLE J, 1994, ONCOGENE, V9, P727; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; FARSHID M, 1993, J MED VIROL, V39, P177; Fausto N, 1999, SEMIN LIVER DIS, V19, P243, DOI 10.1055/s-2007-1007114; FERRANTINI M, 1994, J IMMUNOL, V153, P4604; GALIBERT F, 1979, NATURE, V281, P646, DOI 10.1038/281646a0; GALIBERT F, 1982, J VIROL, V41, P51, DOI 10.1128/JVI.41.1.51-65.1982; Greenberg RA, 1998, ONCOGENE, V16, P1723, DOI 10.1038/sj.onc.1201933; HIMENO Y, 1988, LIVER, V8, P208; HOHNE M, 1990, EMBO J, V9, P1137, DOI 10.1002/j.1460-2075.1990.tb08220.x; HSU TY, 1988, CELL, V55, P627, DOI 10.1016/0092-8674(88)90221-8; IKEDA K, 1993, HEPATOLOGY, V18, P47, DOI 10.1002/hep.1840180109; Ikeda K, 1998, CANCER-AM CANCER SOC, V82, P827, DOI 10.1002/(SICI)1097-0142(19980301)82:5<827::AID-CNCR5>3.0.CO;2-G; Kawate S, 1999, ONCOLOGY-BASEL, V57, P157, DOI 10.1159/000012024; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kojima H, 1997, GASTROENTEROLOGY, V112, P493, DOI 10.1053/gast.1997.v112.pm9024303; Komine F, 2000, J HEPATOL, V32, P235, DOI 10.1016/S0168-8278(00)80068-9; Kondoh N, 2001, INT J ONCOL, V18, P1271; Kumada T, 1997, HEPATOLOGY, V25, P87, DOI 10.1053/jhep.1997.v25.pm0008985270; Liu P, 1997, HEPATOLOGY, V25, P874, DOI 10.1002/hep.510250415; Llovet JM, 2000, HEPATOLOGY, V31, P54, DOI 10.1002/hep.510310111; Lundberg AS, 1999, EUR J CANCER, V35, P1886, DOI 10.1016/S0959-8049(99)00292-0; Merle P, 2001, J HEPATOL, V34, P562, DOI 10.1016/S0168-8278(00)00054-4; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; Nishiguchi S, 2001, LANCET, V357, P196, DOI 10.1016/S0140-6736(00)03595-9; Qin XQ, 1998, P NATL ACAD SCI USA, V95, P14411, DOI 10.1073/pnas.95.24.14411; Shen LL, 1998, HEPATO-GASTROENTEROL, V45, P1753; SHOUVAL D, 1983, J CLIN INVEST, V72, P707, DOI 10.1172/JCI111020; SU TS, 1985, BIOCHEM BIOPH RES CO, V132, P264, DOI 10.1016/0006-291X(85)91017-4; Terradillos O, 1997, ONCOGENE, V14, P395, DOI 10.1038/sj.onc.1200850; VORAVUD N, 1989, HUM PATHOL, V20, P1163, DOI 10.1016/S0046-8177(89)80006-1; WADLER S, 1990, CANCER RES, V50, P3473; Wang L, 2000, HEPATOLOGY, V32, P43, DOI 10.1053/jhep.2000.8525; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Xu DW, 2000, BLOOD, V96, P4313, DOI 10.1182/blood.V96.13.4313.h8004313_4313_4318; Yano H, 1999, HEPATOLOGY, V29, P1708, DOI 10.1002/hep.510290624; Yuen MF, 2001, CANCER, V91, P106, DOI 10.1002/1097-0142(20010101)91:1<106::AID-CNCR14>3.0.CO;2-2; ZHANG XK, 1990, ONCOGENE, V5, P909	47	16	18	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 8	2003	22	18					2762	2771		10.1038/sj.onc.1206375	http://dx.doi.org/10.1038/sj.onc.1206375			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FJ	12743599				2022-12-17	WOS:000182569300007
J	Graveel, CR; Harkins-Perry, SR; Acevedo, LG; Farnham, PJ				Graveel, CR; Harkins-Perry, SR; Acevedo, LG; Farnham, PJ			Identification and characterization of CRG-L2, a new marker for liver tumor development	ONCOGENE			English	Article						hepatocellular carcinoma; cancer testis antigen; olfactomedin domain; tumor marker; rapid amplification of cDNA ends	EXPRESSION; PROTEIN; GENE; DIETHYLNITROSAMINE; C57BL/6J; LESIONS; FAMILY; TESTIS; MEMBER; FOCI	Liver cancer is very common worldwide and the rates of hepatocellular carcinoma (HCC) have increased by over 70% in the last 2 decades in the US. Late diagnosis, because of the lack of clinical symptoms, and decreased hepatic function, because of underlying hepatic disease, lead to the extremely high mortality rates associated with HCC. Clearly, the identification of markers that are expressed early in the development of HCC and that are easily detected in high-risk patients would aid in early diagnosis and increased survival. We present the cloning and characterization of a novel gene, CRG-L2 (Cancer related gene-Liver 2), which displays high expression in murine and human hepatocellular carcinomas. Using in situ hybridization, we show that CRG-L2 mRNA levels are increased early during the development of liver tumors in C3H/HeJ mice, and that in normal tissues CRG-L2 mRNA is restricted to the murine testis and human placenta. Its restricted expression in normal tissues and unique early upregulation during tumor development make CRG-L2 an excellent candidate as a new clinical marker of HCC.	Univ Wisconsin, McArdle Lab Canc Res, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Farnham, PJ (corresponding author), Univ Wisconsin, McArdle Lab Canc Res, 1400 Univ Ave, Madison, WI 53706 USA.	farnham@oncology.wisc.edu		Farnham, Peggy/0000-0003-4469-7914	NCI NIH HHS [CA22484, CA14520] Funding Source: Medline; NIGMS NIH HHS [GM08349] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA022484, P30CA014520] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		*AM CANC SOC, 2002, CANC FACTS FIG 2002, P1; Borscheri N, 2001, AM J SURG PATHOL, V25, P1297, DOI 10.1097/00000478-200110000-00011; Bosch FX, 1999, SEMIN LIVER DIS, V19, P271, DOI 10.1055/s-2007-1007117; Brinkmann U, 1998, P NATL ACAD SCI USA, V95, P10757, DOI 10.1073/pnas.95.18.10757; El-Serag HB, 1999, NEW ENGL J MED, V340, P745, DOI 10.1056/NEJM199903113401001; Gilboa E, 1999, IMMUNITY, V11, P263, DOI 10.1016/S1074-7613(00)80101-6; Graveel CR, 2001, ONCOGENE, V20, P2704, DOI 10.1038/sj.onc.1204391; HANIGAN MH, 1988, CARCINOGENESIS, V9, P885, DOI 10.1093/carcin/9.6.885; KOEN H, 1983, CANCER RES, V43, P702; Kulkarni NH, 2000, GENET RES, V76, P41, DOI 10.1017/S0016672300004584; Lukas ER, 1999, MOL CARCINOGEN, V25, P295, DOI 10.1002/(SICI)1098-2744(199908)25:4<295::AID-MC8>3.0.CO;2-9; Micales BK, 2001, METHODS, V23, P313, DOI 10.1006/meth.2000.1143; MOORE MR, 1981, CANCER RES, V41, P1585; Ono T, 2001, P NATL ACAD SCI USA, V98, P3282, DOI 10.1073/pnas.041625098; Rainov NG, 1995, CLIN CANCER RES, V1, P775; Richards JE, 1998, OPHTHALMOLOGY, V105, P1698, DOI 10.1016/S0161-6420(98)99041-8; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; Scanlan MJ, 2000, CANCER LETT, V150, P155, DOI 10.1016/S0304-3835(99)00385-7; Scanlan MJ, 2002, INT J CANCER, V98, P485, DOI 10.1002/ijc.10276; Song BC, 2002, CANCER-AM CANCER SOC, V94, P175, DOI 10.1002/cncr.10170; Struss AK, 2001, ONCOGENE, V20, P4107, DOI 10.1038/sj.onc.1204552; Tureci O, 1998, P NATL ACAD SCI USA, V95, P5211, DOI 10.1073/pnas.95.9.5211; VESSELINOVITCH SD, 1985, CANCER RES, V45, P2774; Zhang JC, 2002, GENE, V283, P83, DOI 10.1016/S0378-1119(01)00763-6	24	16	19	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 20	2003	22	11					1730	1736		10.1038/sj.onc.1206309	http://dx.doi.org/10.1038/sj.onc.1206309			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	655YH	12642876				2022-12-17	WOS:000181580500015
J	Shimizu, Y; Yamamichi, N; Saitoh, K; Watanabe, A; Ito, T; Yamamichi-Nishina, M; Mizutani, M; Yahagi, N; Suzuki, T; Sasakawa, C; Yasugi, S; Ichinose, M; Iba, H				Shimizu, Y; Yamamichi, N; Saitoh, K; Watanabe, A; Ito, T; Yamamichi-Nishina, M; Mizutani, M; Yahagi, N; Suzuki, T; Sasakawa, C; Yasugi, S; Ichinose, M; Iba, H			Kinetics of v-src-induced epithelial-mesenchymal transition in developing glandular stomach	ONCOGENE			English	Article						RSV; epithelial-mesenchymal transition; MAP kinase; apoptosis; v-src	HIGH-LEVEL EXPRESSION; CHICKEN-EMBRYO FIBROBLASTS; RETROVIRUS VECTORS; CELLULAR-TRANSFORMATION; PHOSPHORYLATION SITES; PROTEIN CAUSES; DEVELOPING GUT; GENE-TRANSFER; FOS GENE; C-JUN	The oncogene function in primary epithelial cells is largely unclear. Recombination organ cultures in combination with the stable and transient gene transfer techniques by retrovirus and electroporation, respectively, enable us to transfer oncogenes specifically into primary epithelial cells of the developing avian glandular stomach (proventriculns). In this system, the epithelium and mesenchyme are mutually dependent on each other for their growth and differentiation. We report here that either stable or transient expression of v-src in the epithelium causes budding and migration of epithelial cells into mesenchyme. In response to the transient expression of v-Src or a constitutive active mutant of MEK, we observed immediate downregulation of the Sonic hedgehog gene and subsequent elimination of E-cadherine expression in migrating cells, suggesting the involvement of MAP kinase signaling pathway in these processes. v-src-expressing cells that were retained in the epithelium underwent apoptosis (anoikis) and detached from the culture. Continuous expression of v-src by, for example, Rous sarcoma virus (RSV) was required for the epithetial cells to acquire the ability to express type I collagen and fihronectin genes (mesenchymal markers), and finally to establish the epithelial-mesenchymal transition. These observations would partly explain why RSV does not apparently cause carcinoma formation, but induces sarcomas exclusively.	Univ Tokyo, Inst Med Sci, Dept Microbiol & Immunol, Div Host Parasite Interact,Minato Ku, Tokyo 1088639, Japan; Univ Tokyo, Inst Med Sci, Div Bacterial Infect, Dept Microbiol & Immunol,Minato Ku, Tokyo 1088639, Japan; Nippon Inst Biol Sci, Lab Anim Res Stn, Yamanashi 4080041, Japan; Univ Tokyo, Dept Gastroenterol, Fac Internal Med, Bunkyo Ku, Tokyo 1138655, Japan; Tokyo Metropolitan Univ, Fac Sci, Dept Biol, Hachioji, Tokyo 1920397, Japan; Wakayama Med Coll, Dept Internal Med 2, Wakayama 6400012, Japan	University of Tokyo; University of Tokyo; University of Tokyo; Tokyo Metropolitan University; Wakayama Medical University	Iba, H (corresponding author), Univ Tokyo, Inst Med Sci, Dept Microbiol & Immunol, Div Host Parasite Interact,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.							BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; BIRCHMEIER W, 1994, BIOESSAYS, V16, P305, DOI 10.1002/bies.950160503; Boyer B, 2000, BIOCHEM PHARMACOL, V60, P1091, DOI 10.1016/S0006-2952(00)00427-5; Daigo Y, 1999, CANCER RES, V59, P4222; Fialka I, 1996, J CELL BIOL, V132, P1115, DOI 10.1083/jcb.132.6.1115; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; FUJIWARA KT, 1987, J VIROL, V61, P4012, DOI 10.1128/JVI.61.12.4012-4018.1987; Fukuda K, 2000, DEV GROWTH DIFFER, V42, P207; Gailani MR, 1997, JNCI-J NATL CANCER I, V89, P1103, DOI 10.1093/jnci/89.15.1103; Hay E.D., 1990, Seminars in Developmental Biology, V1, P347; HAY ED, 1995, AM J KIDNEY DIS, V26, P678, DOI 10.1016/0272-6386(95)90610-X; HUANG WD, 1995, MOL BIOL CELL, V6, P237, DOI 10.1091/mbc.6.3.237; HUANG WD, 1994, P NATL ACAD SCI USA, V91, P8960, DOI 10.1073/pnas.91.19.8960; IBA H, 1988, ONCOGENE RES, V2, P121; Iba H, 2000, DEV GROWTH DIFFER, V42, P213; IBA H, 1984, P NATL ACAD SCI-BIOL, V81, P4424, DOI 10.1073/pnas.81.14.4424; IBA H, 1985, MOL CELL BIOL, V5, P1058, DOI 10.1128/MCB.5.5.1058; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; Kameda T, 1997, CELL GROWTH DIFFER, V8, P495; Koike T, 1999, DIFFERENTIATION, V65, P13, DOI 10.1046/j.1432-0436.1999.6510013.x; Matsumoto K, 1998, ONCOGENE, V16, P1611, DOI 10.1038/sj.onc.1201675; Murakami M, 1999, CELL GROWTH DIFFER, V10, P333; Murakami M, 1997, GENE, V202, P23, DOI 10.1016/S0378-1119(97)00468-X; Murakami M, 1997, ONCOGENE, V14, P2435, DOI 10.1038/sj.onc.1201077; Narita T, 2000, DEVELOPMENT, V127, P981; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; REICHMANN E, 1992, CELL, V71, P1103, DOI 10.1016/S0092-8674(05)80060-1; Roberts DJ, 1998, DEVELOPMENT, V125, P2791; Rosenberg N., 1997, P475; SORKIN BC, 1988, P NATL ACAD SCI USA, V85, P7617, DOI 10.1073/pnas.85.20.7617; STOKER AW, 1990, J CELL BIOL, V111, P217, DOI 10.1083/jcb.111.1.217; Sukegawa A, 2000, DEVELOPMENT, V127, P1971; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; SUZUKI T, 1991, JPN J CANCER RES, V82, P58, DOI 10.1111/j.1349-7006.1991.tb01746.x; Tabata H, 1998, DEV GROWTH DIFFER, V40, P519; TAKIGUCHI K, 1988, DEV GROWTH DIFFER, V30, P241; Watanabe H, 1997, P NATL ACAD SCI USA, V94, P3994, DOI 10.1073/pnas.94.8.3994; WEBSTER MA, 1995, P NATL ACAD SCI USA, V92, P7849, DOI 10.1073/pnas.92.17.7849; YASUGI S, 1993, DEV GROWTH DIFFER, V35, P1; Zhang Y, 2000, J BIOL CHEM, V275, P24935, DOI 10.1074/jbc.M002383200	40	16	18	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 13	2003	22	6					884	893		10.1038/sj.onc.1206174	http://dx.doi.org/10.1038/sj.onc.1206174			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	643MD	12584568				2022-12-17	WOS:000180864300011
J	Schuster, R; Hildt, E; Chang, SF; Terradillos, O; Pollicino, T; Lanford, R; Gerlich, WH; Will, H; Schaefer, S				Schuster, R; Hildt, E; Chang, SF; Terradillos, O; Pollicino, T; Lanford, R; Gerlich, WH; Will, H; Schaefer, S			Conserved transactivating and pro-apoptotic functions of hepadnaviral X protein in ortho- and avihepadnaviruses	ONCOGENE			English	Article						HBx; DHBV; avihepadnavirus; HCC; apoptosis; transactivation	HEPATITIS-B VIRUS; PROGRAMMED CELL-DEATH; OPEN READING FRAME; HEPATOCELLULAR-CARCINOMA; HBX PROTEIN; TRANSGENIC MICE; GROUND-SQUIRRELS; P53-INDUCED APOPTOSIS; MEDIATED APOPTOSIS; EMBRYO FIBROBLASTS	Two established activities of the multifunctional human hepatitis B virus X-protein are its transactivating and pro-apoptotic potential. We analysed whether X-proteins from other orthohepadnaviruses and the newly discovered avihepadnaviral X-proteins have similar functions as HBx. Previously, we have shown that HBx suppresses oncogenic transformation of primary rat embryo fibroblasts (REF) by induction of apoptosis. Using this system, we found that the wildtype X-proteins of woodchuck, ground squirrel, arctic squirrel and woolly monkey hepatitis B virus exhibit similar levels of proapoptotic activity as HBx, whereas mutants with carboxyterminal deletions were severely impaired in this activity. A strong correlation between the pro-apoptotic and transactivating abilities of the mammalian X-proteins was found. The newly discovered avihepadnaviral X-like proteins showed similar and Raf-MAPK pathway-dependent transactivating abilities and induced apoptosis in the REF-assay. Our data indicate that the transactivating and pro-apoptotic activities reside in the carboxyterminal half of orthohepadnaviral X and are conserved in avihepadnaviral X-proteins.	JLU Giessen, Inst Med Virol, Giessen, Germany; Robert Koch Inst, D-1000 Berlin, Germany; Heinrich Pette Inst, Hamburg, Germany; Inst Pasteur, Paris, France; SW Fdn Biomed Res, San Antonio, TX 78284 USA	Justus Liebig University Giessen; Robert Koch Institute; Heinrich Pette Institute; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Texas Biomedical Research Institute	Schaefer, S (corresponding author), Univ Rostock, Dept Virol, Schillingallee 70, D-18055 Rostock, Germany.		Pollicino, Teresa/HDN-3708-2022; Hildt, Eberhard/A-1040-2015; Pollicino, Teresa/K-5790-2016	Pollicino, Teresa/0000-0001-6602-3035				Andrisani OM, 1999, INT J ONCOL, V15, P373; AUSUBEL FM, 1998, CURRENT PROTOCOLS MO, P974; BEASLEY RP, 1981, LANCET, V2, P1129; Becker SA, 1998, J VIROL, V72, P266, DOI 10.1128/JVI.72.1.266-272.1998; Bergametti F, 1999, ONCOGENE, V18, P2860, DOI 10.1038/sj.onc.1202643; Bouchard MJ, 2001, SCIENCE, V294, P2376, DOI 10.1126/science.294.5550.2376; BUENDIA MA, 1998, VIRAL HEPATITIS, P179; Chang SF, 2001, J VIROL, V75, P161, DOI 10.1128/JVI.75.1.161-170.2001; Chang SF, 1999, VIROLOGY, V262, P39, DOI 10.1006/viro.1999.9844; CHEN HS, 1993, J VIROL, V67, P1218, DOI 10.1128/JVI.67.3.1218-1226.1993; Chirillo P, 1997, P NATL ACAD SCI USA, V94, P8162, DOI 10.1073/pnas.94.15.8162; COLGROVE R, 1989, J VIROL, V63, P4019, DOI 10.1128/JVI.63.9.4019-4026.1989; CUENDE E, 1993, EMBO J, V12, P1555, DOI 10.1002/j.1460-2075.1993.tb05799.x; DANE DS, 1970, LANCET, V1, P695; Diao JY, 2001, J BIOL CHEM, V276, P8328, DOI 10.1074/jbc.M006026200; Elmore LW, 1997, P NATL ACAD SCI USA, V94, P14707, DOI 10.1073/pnas.94.26.14707; FEITELSON MA, 1988, P NATL ACAD SCI USA, V85, P6162, DOI 10.1073/pnas.85.16.6162; Gottlob K, 1998, CANCER RES, V58, P3566; Gottlob K, 1998, J BIOL CHEM, V273, P33347, DOI 10.1074/jbc.273.50.33347; Grethe S, 2000, J VIROL, V74, P5377, DOI 10.1128/JVI.74.11.5377-5381.2000; Hu XL, 2000, P NATL ACAD SCI USA, V97, P1661, DOI 10.1073/pnas.97.4.1661; Huo TI, 2001, ONCOGENE, V20, P3620, DOI 10.1038/sj.onc.1204495; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Kim H, 1998, J BIOL CHEM, V273, P381, DOI 10.1074/jbc.273.1.381; Kim YC, 2001, ONCOGENE, V20, P16, DOI 10.1038/sj.onc.1203840; LAND H, 1995, METHOD ENZYMOL, V254, P37; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lanford RE, 2000, J VIROL, V74, P2955, DOI 10.1128/JVI.74.6.2955-2959.2000; Lanford RE, 1998, P NATL ACAD SCI USA, V95, P5757, DOI 10.1073/pnas.95.10.5757; LEE TH, 1995, J VIROL, V69, P1107, DOI 10.1128/JVI.69.2.1107-1114.1995; Lin B, 2000, INTERVIROLOGY, V43, P185, DOI 10.1159/000025037; MacDonald DM, 2000, J VIROL, V74, P4253, DOI 10.1128/JVI.74.9.4253-4257.2000; MARION PL, 1980, P NATL ACAD SCI-BIOL, V77, P2941, DOI 10.1073/pnas.77.5.2941; MARION PL, 1986, P NATL ACAD SCI USA, V83, P4543, DOI 10.1073/pnas.83.12.4543; MARION PL, 1984, P NATL ACAD SCI-BIOL, V81, P898, DOI 10.1073/pnas.81.3.898; MASON WS, 1980, J VIROL, V36, P829, DOI 10.1128/JVI.36.3.829-836.1980; Murakami S, 1999, INTERVIROLOGY, V42, P81, DOI 10.1159/000024969; Netter HJ, 1997, J GEN VIROL, V78, P1707, DOI 10.1099/0022-1317-78-7-1707; Norder H, 1996, VIROLOGY, V218, P214, DOI 10.1006/viro.1996.0181; Oguey D, 1996, HEPATOLOGY, V24, P1024, DOI 10.1002/hep.510240508; POPPER H, 1987, P NATL ACAD SCI USA, V84, P866, DOI 10.1073/pnas.84.3.866; Poussin K, 1999, INT J CANCER, V80, P497, DOI 10.1002/(SICI)1097-0215(19990209)80:4<497::AID-IJC3>3.0.CO;2-8; Pult I, 2001, VIROLOGY, V289, P114, DOI 10.1006/viro.2001.1115; RUNKEL L, 1993, VIROLOGY, V197, P529, DOI 10.1006/viro.1993.1626; Schuster R, 2000, ONCOGENE, V19, P1173, DOI 10.1038/sj.onc.1203417; SEEGER C, 1984, J VIROL, V51, P367, DOI 10.1128/JVI.51.2.367-375.1984; SEIFER M, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P586; Shih WL, 2000, J BIOL CHEM, V275, P25858, DOI 10.1074/jbc.M003578200; Shintani Y, 1999, J GEN VIROL, V80, P3257, DOI 10.1099/0022-1317-80-12-3257; SHIRAKATA Y, 1989, JPN J CANCER RES, V80, P617, DOI 10.1111/j.1349-7006.1989.tb01686.x; Sirma H, 1999, ONCOGENE, V18, P4848, DOI 10.1038/sj.onc.1202867; Sitterlin D, 2000, ONCOGENE, V19, P4427, DOI 10.1038/sj.onc.1203770; Sitterlin D, 2000, ONCOGENE, V19, P4417, DOI 10.1038/sj.onc.1203771; Sitterlin D, 1997, J VIROL, V71, P6194, DOI 10.1128/JVI.71.8.6194-6199.1997; Slagle BL, 1996, MOL CARCINOGEN, V15, P261, DOI 10.1002/(SICI)1098-2744(199604)15:4<261::AID-MC3>3.0.CO;2-J; SPRENGEL R, 1988, J VIROL, V62, P3832, DOI 10.1128/JVI.62.10.3832-3839.1988; Su F, 1997, P NATL ACAD SCI USA, V94, P8744, DOI 10.1073/pnas.94.16.8744; SUMMERS J, 1978, P NATL ACAD SCI USA, V75, P4533, DOI 10.1073/pnas.75.9.4533; Takada S, 1999, ONCOGENE, V18, P6965, DOI 10.1038/sj.onc.1203188; Takahashi K, 2000, VIROLOGY, V267, P58, DOI 10.1006/viro.1999.0102; Terradillos O, 1997, ONCOGENE, V14, P395, DOI 10.1038/sj.onc.1200850; Terradillos O, 1998, ONCOGENE, V17, P2115, DOI 10.1038/sj.onc.1202432; Testut P, 1996, J VIROL, V70, P4210, DOI 10.1128/JVI.70.7.4210-4219.1996; Tu H, 2001, CANCER RES, V61, P7803; WANG XW, 1995, CANCER RES, V55, P6012; Warren KS, 1999, J VIROL, V73, P7860, DOI 10.1128/JVI.73.9.7860-7865.1999; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; Yu DY, 1999, J HEPATOL, V31, P123, DOI 10.1016/S0168-8278(99)80172-X; ZOULIM F, 1994, J VIROL, V68, P2026, DOI 10.1128/JVI.68.3.2026-2030.1994	69	16	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 26	2002	21	43					6606	6613		10.1038/sj.onc.1205916	http://dx.doi.org/10.1038/sj.onc.1205916			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	597BM	12242658				2022-12-17	WOS:000178202300006
J	Brun, S; Rincheval, V; Gaumer, S; Mignotte, B; Guenal, I				Brun, S; Rincheval, V; Gaumer, S; Mignotte, B; Guenal, I			reaper and bax initiate two different apoptotic pathways affecting mitochondria and antagonized by bcl-2 in Drosophila	ONCOGENE			English	Article						apoptosis; Drosophila; bcl-2; reaper; bax; mitochondria	PROGRAMMED CELL-DEATH; NF-KAPPA-B; IMMUNE-DEFICIENCY IMD; CYTOCHROME-C; CASPASE; HOMOLOG; PROTEIN; FAMILY; GENES; HID	bcl-2 was the first regulator of apoptosis shown to be involved in oncogenesis. Subsequent studies in mammals, in the nematode and in Drosophila revealed wide evolutionary conservation of the regulation of apoptosis. Although dbok/debcl, a member of the bcl-2 gene family described in Drosophila, shows pro-apoptotic activities, no anti-apoptotic bcl-2 family gene has been studied in Drosophila. We have previously reported that the human anti-apoptotic gene bcl-2 is functional in Drosophila, suggesting that the fruit fly shares regulatory mechanisms with vertebrates and the nematode, involving antiapoptotic members of the bcl-2 family. We now report that bcl-2 suppresses rpr-induced apoptosis in Drosophila. Additionally, we have compared features of bax- and rpr-induced apoptosis. Flow cytometry analysis of wing disc cells demonstrate that both killers trigger mitochondrial defects. Interestingly, bcl-2 suppresses both bax- and rpr-induced mitochondrial defects while the caspase-inhibitor p35 is specific to the rpr pathway. Finally, we show that the inhibition of apoptosis by bcl-2 is associated with the down-regulation of rpr expression.	Univ Versailles, Lab Genet & Biol Cellulaire, CNRS, UPRESA 8087, F-78035 Versailles, France; Univ Versailles, Lab Genet Mol & Physiol, EPHE, F-78035 Versailles, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; PSL Research University Paris; Ecole Pratique des Hautes Etudes (EPHE); Universite Paris Saclay	Guenal, I (corresponding author), Univ Versailles, Lab Genet & Biol Cellulaire, CNRS, UPRESA 8087, 45 Ave Etats Unis, F-78035 Versailles, France.	guenal@genetique.uvsq.fr	Mignotte, Bernard/A-3499-2009; Guenal, Isabelle/F-3415-2019	Mignotte, Bernard/0000-0002-8512-8518; Guenal, Isabelle/0000-0003-1186-1458; Brun, Sylvain/0000-0002-6714-4012				Baehrecke EH, 2000, CELL DEATH DIFFER, V7, P1057, DOI 10.1038/sj.cdd.4400753; Brachmann CB, 2000, CURR BIOL, V10, P547, DOI 10.1016/S0960-9822(00)00474-7; Brodsky MH, 2000, CELL, V101, P103, DOI 10.1016/S0092-8674(00)80627-3; CAMPOSORTEGA JA, 1995, EMBRYONIC DEV DROSOP; Chen P, 2000, J CELL BIOL, V148, P625, DOI 10.1083/jcb.148.4.625; Chen P, 1998, DEV BIOL, V201, P202, DOI 10.1006/dbio.1998.9000; Claveria C, 1998, EMBO J, V17, P7199, DOI 10.1093/emboj/17.24.7199; Cohen SM., 1993, DEV DROSOPHILA MELAN; Colussi PA, 2000, J CELL BIOL, V148, P703, DOI 10.1083/jcb.148.4.703; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; de Moissac D, 1998, J BIOL CHEM, V273, P23946, DOI 10.1074/jbc.273.37.23946; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Dorstyn L, 2002, J CELL BIOL, V156, P1089, DOI 10.1083/jcb.200111107; Dorstyn L, 1999, P NATL ACAD SCI USA, V96, P4307, DOI 10.1073/pnas.96.8.4307; Dorstyn L, 1999, J BIOL CHEM, V274, P30778, DOI 10.1074/jbc.274.43.30778; Doumanis J, 2001, CELL DEATH DIFFER, V8, P387, DOI 10.1038/sj.cdd.4400864; Evans EK, 1997, EMBO J, V16, P7372, DOI 10.1093/emboj/16.24.7372; Fraser AG, 1997, EMBO J, V16, P2805, DOI 10.1093/emboj/16.10.2805; Gaumer S, 2000, CELL DEATH DIFFER, V7, P804, DOI 10.1038/sj.cdd.4400714; Georgel P, 2001, DEV CELL, V1, P503, DOI 10.1016/S1534-5807(01)00059-4; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Haining WN, 1999, P NATL ACAD SCI USA, V96, P4936, DOI 10.1073/pnas.96.9.4936; Harvey NL, 2001, J BIOL CHEM, V276, P25342, DOI 10.1074/jbc.M009444200; Hawkins CJ, 2000, J BIOL CHEM, V275, P27084; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; Hour TC, 2000, EUR J CELL BIOL, V79, P121, DOI 10.1078/S0171-9335(04)70014-X; Hu SM, 2000, J BIOL CHEM, V275, P30761, DOI 10.1074/jbc.C000341200; Igaki T, 2000, P NATL ACAD SCI USA, V97, P662, DOI 10.1073/pnas.97.2.662; Kanuka H, 1999, MOL CELL, V4, P757, DOI 10.1016/S1097-2765(00)80386-X; LEMAITRE B, 1995, P NATL ACAD SCI USA, V92, P9465, DOI 10.1073/pnas.92.21.9465; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Milan M, 1997, P NATL ACAD SCI USA, V94, P5691, DOI 10.1073/pnas.94.11.5691; Nordstrom W, 1996, DEV BIOL, V180, P213, DOI 10.1006/dbio.1996.0296; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; Okuno S, 1998, J BIOL CHEM, V273, P34272, DOI 10.1074/jbc.273.51.34272; PETIT PX, 1990, EUR J BIOCHEM, V194, P389, DOI 10.1111/j.1432-1033.1990.tb15632.x; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Rodriguez A, 1999, NAT CELL BIOL, V1, P272, DOI 10.1038/12984; Song ZW, 1997, SCIENCE, V275, P536, DOI 10.1126/science.275.5299.536; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thress K, 1999, EMBO J, V18, P5486, DOI 10.1093/emboj/18.20.5486; Tzou P, 2002, METHOD MICROBIOL, V31, P507, DOI 10.1016/S0580-9517(02)31028-6; Varkey J, 1999, J CELL BIOL, V144, P701, DOI 10.1083/jcb.144.4.701; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; VAYSSIERE JL, 1994, P NATL ACAD SCI USA, V91, P11752, DOI 10.1073/pnas.91.24.11752; Vekrellis K, 1997, DEVELOPMENT, V124, P1239; WILCOXON F, 1945, BIOMETRICS BULL, V1, P80, DOI 10.1093/jee/39.2.269; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989; Zhang H, 2000, J BIOL CHEM, V275, P27303; Zhou L, 1999, MOL CELL, V4, P745, DOI 10.1016/S1097-2765(00)80385-8; Zhou L, 1997, P NATL ACAD SCI USA, V94, P5131, DOI 10.1073/pnas.94.10.5131; Zimmermann KC, 2002, J CELL BIOL, V156, P1077, DOI 10.1083/jcb.20112068	54	16	16	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	2002	21	42					6458	6470		10.1038/sj.onc.1205839	http://dx.doi.org/10.1038/sj.onc.1205839			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	592FD	12226749	Green Submitted			2022-12-17	WOS:000177925300006
J	Nathrath, MH; Kuosaite, V; Rosemann, M; Kremer, M; Poremba, C; Wakana, S; Yanagi, M; Nathrath, WBJ; Hofler, H; Imai, K; Atkinson, MJ				Nathrath, MH; Kuosaite, V; Rosemann, M; Kremer, M; Poremba, C; Wakana, S; Yanagi, M; Nathrath, WBJ; Hofler, H; Imai, K; Atkinson, MJ			Two novel tumor suppressor gene loci on chromosome 6q and 15q in human osteosarcoma identified through comparative study of allelic imbalances in mouse and man	ONCOGENE			English	Article						osteosarcoma; allelic imbalance; LOH; synteny relationship; inbred mouse strains	REPRESENTATIONAL DIFFERENCE ANALYSIS; COMPARATIVE GENOMIC HYBRIDIZATION; RADIATION HYBRID MAP; MUTATION SPECTRUM; OSTEO-SARCOMA; DNA-SEQUENCES; CDK4 GENE; RETINOBLASTOMA; P53; HETEROZYGOSITY	We have performed a comparative study of allelic imbalances in human and murine osteosarcomas to identify genetic changes critical for osteosarcomagenesis. Two adjacent but discrete loci on mouse chromosome 9 were found to show high levels of allelic imbalance in radiation-induced osteosarcomas arising in (BALB/c x CBA/CA) F1 hybrid mice. The syntenic human chromosomal regions were investigated in 42 sporadic human osteosarcomas. For the distal locus (OSS1) on mouse chromosome 9 the syntenic human locus was identified on chromosome 6q14 and showed allelic imbalance in 77% of the cases. Comparison between the human and mouse syntenic regions narrowed the locus down to a 4 Mbp fragment flanked by the marker genes ME1 and SCL35A1 For the proximal locus (OSS2) on mouse chromosome 9, a candidate human locus was mapped to chromosome 15q21 in a region showing allelic imbalance in 58% of human osteosarcomas. We have used a combination of synteny and microsatellite mapping to identify two potential osteosarcoma suppressor gene loci. This strategy represents a powerful tool for the identification of new genes important for the formation of human tumors.	GFS Natl Res Ctr Environm & Hlth, Inst Pathol, D-85764 Neuherberg, Germany; Tech Univ Munich, Dept Pediat, D-80804 Munich, Germany; Tech Univ Munich, Inst Pathol, D-81675 Munich, Germany; Univ Dusseldorf, Inst Pathol, D-40225 Dusseldorf, Germany; RIKEN, Genomics Sci Ctr, Mouse Funct Genomics Res Grp, Yokohama, Kanagawa 2240804, Japan; Municipal Hosp Munchen Harlaching, Inst Pathol, D-81545 Munich, Germany; GSF Natl Res Ctr Environm & Hlth, Inst Mammalian Genet, D-85764 Neuherberg, Germany	Technical University of Munich; Technical University of Munich; Heinrich Heine University Dusseldorf; RIKEN; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Nathrath, MH (corresponding author), GFS Natl Res Ctr Environm & Hlth, Inst Pathol, Ingolstaedter Landstr 1, D-85764 Neuherberg, Germany.		Rosemann, Michael/AAX-8082-2020; Atkinson, Michael/AAU-5127-2020; Atkinson, Michael J/E-5537-2011; Rosemann, Michael/O-2449-2015	Rosemann, Michael/0000-0002-5855-065X; Atkinson, Michael/0000-0003-3358-2089; Atkinson, Michael J/0000-0003-3358-2089; Rosemann, Michael/0000-0002-5855-065X				Balmain A, 2000, CARCINOGENESIS, V21, P371, DOI 10.1093/carcin/21.3.371; Balsara BR, 1999, CANCER RES, V59, P450; Belchis DA, 1996, DIAGN MOL PATHOL, V5, P214, DOI 10.1097/00019606-199609000-00011; Bernues M, 1999, CANCER GENET CYTOGEN, V112, P42, DOI 10.1016/S0165-4608(98)00248-9; BIEGEL JA, 1989, CANCER GENET CYTOGEN, V38, P89, DOI 10.1016/0165-4608(89)90169-6; BOEHNKE M, 1991, AM J HUM GENET, V49, P1174; Bridge JA, 1997, CANCER GENET CYTOGEN, V95, P74, DOI 10.1016/S0165-4608(96)00306-8; Brinkschmidt C, 1998, Verh Dtsch Ges Pathol, V82, P184; Chen JR, 2001, MOL CELL ENDOCRINOL, V177, P43, DOI 10.1016/S0303-7207(01)00456-7; DAVIS LM, 1994, CARCINOGENESIS, V15, P1637; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; DRAPER GJ, 1986, BRIT J CANCER, V53, P661, DOI 10.1038/bjc.1986.110; FLETCHER JA, 1994, CANCER GENET CYTOGEN, V77, P81, DOI 10.1016/0165-4608(94)90154-6; Fuchs N, 1998, ANN ONCOL, V9, P893, DOI 10.1023/A:1008391103132; Gamberi G, 1998, ONCOLOGY-BASEL, V55, P556, DOI 10.1159/000011912; GOSSNER W, 1976, RECENT RES CANCER, V54, P36; Goto A, 1998, JPN J CANCER RES, V89, P539, DOI 10.1111/j.1349-7006.1998.tb03295.x; HANSEN MF, 1985, P NATL ACAD SCI USA, V82, P6216, DOI 10.1073/pnas.82.18.6216; Hatcher CJ, 2001, DEV BIOL, V230, P177, DOI 10.1006/dbio.2000.0134; Kanoe H, 1998, ANTICANCER RES, V18, P2317; Kraus F, 2001, MECH DEVELOP, V100, P83, DOI 10.1016/S0925-4773(00)00494-9; Kruzelock RP, 1997, CANCER RES, V57, P106; LADANYI M, 1993, CANCER RES, V53, P16; Lonardo F, 1997, CANCER, V79, P1541, DOI 10.1002/(SICI)1097-0142(19970415)79:8<1541::AID-CNCR15>3.0.CO;2-Y; LUZ A, 1991, RADIAT ENVIRON BIOPH, V30, P225, DOI 10.1007/BF01226625; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; McCarthy LC, 1997, GENOME RES, V7, P1153, DOI 10.1101/gr.7.12.1153; MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5863, DOI 10.1073/pnas.87.15.5863; Nellissery MJ, 1998, AM J HUM GENET, V63, P817, DOI 10.1086/302019; Park WS, 2000, CANCER RES, V60, P70; Pompetti F, 1996, J CELL BIOCHEM, V63, P37; Provisor AJ, 1997, J CLIN ONCOL, V15, P76, DOI 10.1200/JCO.1997.15.1.76; Reardon DA, 1999, GENE CHROMOSOME CANC, V24, P230, DOI 10.1002/(SICI)1098-2264(199903)24:3<230::AID-GCC8>3.0.CO;2-C; Simons A, 1999, GENE CHROMOSOME CANC, V26, P115, DOI 10.1002/(SICI)1098-2264(199910)26:2<115::AID-GCC3>3.0.CO;2-E; Simons A, 1997, GENE CHROMOSOME CANC, V20, P196, DOI 10.1002/(SICI)1098-2264(199710)20:2<196::AID-GCC10>3.0.CO;2-P; Stock C, 2000, GENE CHROMOSOME CANC, V28, P329, DOI 10.1002/1098-2264(200007)28:3<329::AID-GCC11>3.0.CO;2-F; TARKKANEN M, 1995, CANCER RES, V55, P1334; TOGUCHIDA J, 1988, CANCER RES, V48, P3939; TOGUCHIDA J, 1992, CANCER RES, V52, P6194; Van Etten WJ, 1999, NAT GENET, V22, P384, DOI 10.1038/11962; WADAYAMA B, 1994, CANCER RES, V54, P3042; Wei G, 1999, INT J CANCER, V80, P199, DOI 10.1002/(SICI)1097-0215(19990118)80:2<199::AID-IJC7>3.0.CO;2-4; YAMAGUCHI T, 1992, CANCER RES, V52, P2419	43	16	16	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 29	2002	21	38					5975	5980		10.1038/sj.onc.1205764	http://dx.doi.org/10.1038/sj.onc.1205764			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	585JD	12185601				2022-12-17	WOS:000177520900021
